<!doctype html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1, viewport-fit=cover" />
  <meta name="color-scheme" content="light" />
  <meta http-equiv="Cache-Control" content="no-cache, no-store, must-revalidate" />
  <meta http-equiv="Pragma" content="no-cache" />
  <meta http-equiv="Expires" content="0" />
  <meta name="apple-mobile-web-app-capable" content="yes" />
  <meta name="apple-mobile-web-app-status-bar-style" content="default" />
  <meta name="apple-mobile-web-app-title" content="PCP Learning" />
  <link rel="manifest" href="manifest.json" />
  <title>Primary Care Provider Learning Program</title>
  <meta name="description" content="Primary care learning program: clinical microlearning, quizzes, and rapid review." />
  <style>
    html, body {
      height: 100%;
      margin: 0;
      padding: 0;
      background: #f8fafc;
      font-family: system-ui, -apple-system, Segoe UI, Roboto, Helvetica, Arial, "Apple Color Emoji", "Segoe UI Emoji";
    }
    #root {
      min-height: 100%;
    }
    button, a, [role="button"] {
      -webkit-tap-highlight-color: transparent;
      touch-action: manipulation;
    }
      details:not([open]) > :not(summary) { display: none !important; }
</style>
</head>
<body>
  <noscript>This app requires JavaScript to run.</noscript>
  <div id="root"></div>

  <!-- React 18/19 (bundled inline â€” no external requests needed) -->
  <script>
(()=>{var Ft=(l,t)=>()=>(t||l((t={exports:{}}).exports,t),t.exports);var We=Ft(O=>{"use strict";var Le=Symbol.for("react.transitional.element"),om=Symbol.for("react.portal"),sm=Symbol.for("react.fragment"),bm=Symbol.for("react.strict_mode"),zm=Symbol.for("react.profiler"),Tm=Symbol.for("react.consumer"),Em=Symbol.for("react.context"),Am=Symbol.for("react.forward_ref"),Mm=Symbol.for("react.suspense"),Om=Symbol.for("react.memo"),Ri=Symbol.for("react.lazy"),_m=Symbol.for("react.activity"),Ni=Symbol.iterator;function Dm(l){return l===null||typeof l!="object"?null:(l=Ni&&l[Ni]||l["@@iterator"],typeof l=="function"?l:null)}var pi={isMounted:function(){return!1},enqueueForceUpdate:function(){},enqueueReplaceState:function(){},enqueueSetState:function(){}},Ci=Object.assign,Gi={};function bu(l,t,u){this.props=l,this.context=t,this.refs=Gi,this.updater=u||pi}bu.prototype.isReactComponent={};bu.prototype.setState=function(l,t){if(typeof l!="object"&&typeof l!="function"&&l!=null)throw Error("takes an object of state variables to update or a function which returns an object of state variables.");this.updater.enqueueSetState(this,l,t,"setState")};bu.prototype.forceUpdate=function(l){this.updater.enqueueForceUpdate(this,l,"forceUpdate")};function Xi(){}Xi.prototype=bu.prototype;function Ke(l,t,u){this.props=l,this.context=t,this.refs=Gi,this.updater=u||pi}var Je=Ke.prototype=new Xi;Je.constructor=Ke;Ci(Je,bu.prototype);Je.isPureReactComponent=!0;var qi=Array.isArray;function xe(){}var L={H:null,A:null,T:null,S:null},Qi=Object.prototype.hasOwnProperty;function re(l,t,u){var a=u.ref;return{$$typeof:Le,type:l,key:t,ref:a!==void 0?a:null,props:u}}function Um(l,t){return re(l.type,t,l.props)}function we(l){return typeof l=="object"&&l!==null&&l.$$typeof===Le}function Hm(l){var t={"=":"=0",":":"=2"};return"$"+l.replace(/[=:]/g,function(u){return t[u]})}var Yi=/\/+/g;function Ve(l,t){return typeof l=="object"&&l!==null&&l.key!=null?Hm(""+l.key):t.toString(36)}function Nm(l){switch(l.status){case"fulfilled":return l.value;case"rejected":throw l.reason;default:switch(typeof l.status=="string"?l.then(xe,xe):(l.status="pending",l.then(function(t){l.status==="pending"&&(l.status="fulfilled",l.value=t)},function(t){l.status==="pending"&&(l.status="rejected",l.reason=t)})),l.status){case"fulfilled":return l.value;case"rejected":throw l.reason}}throw l}function su(l,t,u,a,n){var e=typeof l;(e==="undefined"||e==="boolean")&&(l=null);var f=!1;if(l===null)f=!0;else switch(e){case"bigint":case"string":case"number":f=!0;break;case"object":switch(l.$$typeof){case Le:case om:f=!0;break;case Ri:return f=l._init,su(f(l._payload),t,u,a,n)}}if(f)return n=n(l),f=a===""?"."+Ve(l,0):a,qi(n)?(u="",f!=null&&(u=f.replace(Yi,"$&/")+"/"),su(n,t,u,"",function(m){return m})):n!=null&&(we(n)&&(n=Um(n,u+(n.key==null||l&&l.key===n.key?"":(""+n.key).replace(Yi,"$&/")+"/")+f)),t.push(n)),1;f=0;var c=a===""?".":a+":";if(qi(l))for(var i=0;i<l.length;i++)a=l[i],e=c+Ve(a,i),f+=su(a,t,u,e,n);else if(i=Dm(l),typeof i=="function")for(l=i.call(l),i=0;!(a=l.next()).done;)a=a.value,e=c+Ve(a,i++),f+=su(a,t,u,e,n);else if(e==="object"){if(typeof l.then=="function")return su(Nm(l),t,u,a,n);throw t=String(l),Error("Objects are not valid as a React child (found: "+(t==="[object Object]"?"object with keys {"+Object.keys(l).join(", ")+"}":t)+"). If you meant to render a collection of children, use an array instead.")}return f}function mn(l,t,u){if(l==null)return l;var a=[],n=0;return su(l,a,"","",function(e){return t.call(u,e,n++)}),a}function qm(l){if(l._status===-1){var t=l._result;t=t(),t.then(function(u){(l._status===0||l._status===-1)&&(l._status=1,l._result=u)},function(u){(l._status===0||l._status===-1)&&(l._status=2,l._result=u)}),l._status===-1&&(l._status=0,l._result=t)}if(l._status===1)return l._result.default;throw l._result}var Bi=typeof reportError=="function"?reportError:function(l){if(typeof window=="object"&&typeof window.ErrorEvent=="function"){var t=new window.ErrorEvent("error",{bubbles:!0,cancelable:!0,message:typeof l=="object"&&l!==null&&typeof l.message=="string"?String(l.message):String(l),error:l});if(!window.dispatchEvent(t))return}else if(typeof process=="object"&&typeof process.emit=="function"){process.emit("uncaughtException",l);return}console.error(l)},Ym={map:mn,forEach:function(l,t,u){mn(l,function(){t.apply(this,arguments)},u)},count:function(l){var t=0;return mn(l,function(){t++}),t},toArray:function(l){return mn(l,function(t){return t})||[]},only:function(l){if(!we(l))throw Error("React.Children.only expected to receive a single React element child.");return l}};O.Activity=_m;O.Children=Ym;O.Component=bu;O.Fragment=sm;O.Profiler=zm;O.PureComponent=Ke;O.StrictMode=bm;O.Suspense=Mm;O.__CLIENT_INTERNALS_DO_NOT_USE_OR_WARN_USERS_THEY_CANNOT_UPGRADE=L;O.__COMPILER_RUNTIME={__proto__:null,c:function(l){return L.H.useMemoCache(l)}};O.cache=function(l){return function(){return l.apply(null,arguments)}};O.cacheSignal=function(){return null};O.cloneElement=function(l,t,u){if(l==null)throw Error("The argument must be a React element, but you passed "+l+".");var a=Ci({},l.props),n=l.key;if(t!=null)for(e in t.key!==void 0&&(n=""+t.key),t)!Qi.call(t,e)||e==="key"||e==="__self"||e==="__source"||e==="ref"&&t.ref===void 0||(a[e]=t[e]);var e=arguments.length-2;if(e===1)a.children=u;else if(1<e){for(var f=Array(e),c=0;c<e;c++)f[c]=arguments[c+2];a.children=f}return re(l.type,n,a)};O.createContext=function(l){return l={$$typeof:Em,_currentValue:l,_currentValue2:l,_threadCount:0,Provider:null,Consumer:null},l.Provider=l,l.Consumer={$$typeof:Tm,_context:l},l};O.createElement=function(l,t,u){var a,n={},e=null;if(t!=null)for(a in t.key!==void 0&&(e=""+t.key),t)Qi.call(t,a)&&a!=="key"&&a!=="__self"&&a!=="__source"&&(n[a]=t[a]);var f=arguments.length-2;if(f===1)n.children=u;else if(1<f){for(var c=Array(f),i=0;i<f;i++)c[i]=arguments[i+2];n.children=c}if(l&&l.defaultProps)for(a in f=l.defaultProps,f)n[a]===void 0&&(n[a]=f[a]);return re(l,e,n)};O.createRef=function(){return{current:null}};O.forwardRef=function(l){return{$$typeof:Am,render:l}};O.isValidElement=we;O.lazy=function(l){return{$$typeof:Ri,_payload:{_status:-1,_result:l},_init:qm}};O.memo=function(l,t){return{$$typeof:Om,type:l,compare:t===void 0?null:t}};O.startTransition=function(l){var t=L.T,u={};L.T=u;try{var a=l(),n=L.S;n!==null&&n(u,a),typeof a=="object"&&a!==null&&typeof a.then=="function"&&a.then(xe,Bi)}catch(e){Bi(e)}finally{t!==null&&u.types!==null&&(t.types=u.types),L.T=t}};O.unstable_useCacheRefresh=function(){return L.H.useCacheRefresh()};O.use=function(l){return L.H.use(l)};O.useActionState=function(l,t,u){return L.H.useActionState(l,t,u)};O.useCallback=function(l,t){return L.H.useCallback(l,t)};O.useContext=function(l){return L.H.useContext(l)};O.useDebugValue=function(){};O.useDeferredValue=function(l,t){return L.H.useDeferredValue(l,t)};O.useEffect=function(l,t){return L.H.useEffect(l,t)};O.useEffectEvent=function(l){return L.H.useEffectEvent(l)};O.useId=function(){return L.H.useId()};O.useImperativeHandle=function(l,t,u){return L.H.useImperativeHandle(l,t,u)};O.useInsertionEffect=function(l,t){return L.H.useInsertionEffect(l,t)};O.useLayoutEffect=function(l,t){return L.H.useLayoutEffect(l,t)};O.useMemo=function(l,t){return L.H.useMemo(l,t)};O.useOptimistic=function(l,t){return L.H.useOptimistic(l,t)};O.useReducer=function(l,t,u){return L.H.useReducer(l,t,u)};O.useRef=function(l){return L.H.useRef(l)};O.useState=function(l){return L.H.useState(l)};O.useSyncExternalStore=function(l,t,u){return L.H.useSyncExternalStore(l,t,u)};O.useTransition=function(){return L.H.useTransition()};O.version="19.2.0"});var Wi=Ft(w=>{"use strict";function Ie(l,t){var u=l.length;l.push(t);l:for(;0<u;){var a=u-1>>>1,n=l[a];if(0<dn(n,t))l[a]=t,l[u]=n,u=a;else break l}}function Wl(l){return l.length===0?null:l[0]}function Sn(l){if(l.length===0)return null;var t=l[0],u=l.pop();if(u!==t){l[0]=u;l:for(var a=0,n=l.length,e=n>>>1;a<e;){var f=2*(a+1)-1,c=l[f],i=f+1,m=l[i];if(0>dn(c,u))i<n&&0>dn(m,c)?(l[a]=m,l[i]=u,a=i):(l[a]=c,l[f]=u,a=f);else if(i<n&&0>dn(m,u))l[a]=m,l[i]=u,a=i;else break l}}return t}function dn(l,t){var u=l.sortIndex-t.sortIndex;return u!==0?u:l.id-t.id}w.unstable_now=void 0;typeof performance=="object"&&typeof performance.now=="function"?(Zi=performance,w.unstable_now=function(){return Zi.now()}):($e=Date,ji=$e.now(),w.unstable_now=function(){return $e.now()-ji});var Zi,$e,ji,tt=[],At=[],Bm=1,pl=null,hl=3,Pe=!1,ya=!1,va=!1,lf=!1,Li=typeof setTimeout=="function"?setTimeout:null,Ki=typeof clearTimeout=="function"?clearTimeout:null,Vi=typeof setImmediate<"u"?setImmediate:null;function hn(l){for(var t=Wl(At);t!==null;){if(t.callback===null)Sn(At);else if(t.startTime<=l)Sn(At),t.sortIndex=t.expirationTime,Ie(tt,t);else break;t=Wl(At)}}function tf(l){if(va=!1,hn(l),!ya)if(Wl(tt)!==null)ya=!0,Tu||(Tu=!0,zu());else{var t=Wl(At);t!==null&&uf(tf,t.startTime-l)}}var Tu=!1,ma=-1,Ji=5,ri=-1;function wi(){return lf?!0:!(w.unstable_now()-ri<Ji)}function Fe(){if(lf=!1,Tu){var l=w.unstable_now();ri=l;var t=!0;try{l:{ya=!1,va&&(va=!1,Ki(ma),ma=-1),Pe=!0;var u=hl;try{t:{for(hn(l),pl=Wl(tt);pl!==null&&!(pl.expirationTime>l&&wi());){var a=pl.callback;if(typeof a=="function"){pl.callback=null,hl=pl.priorityLevel;var n=a(pl.expirationTime<=l);if(l=w.unstable_now(),typeof n=="function"){pl.callback=n,hn(l),t=!0;break t}pl===Wl(tt)&&Sn(tt),hn(l)}else Sn(tt);pl=Wl(tt)}if(pl!==null)t=!0;else{var e=Wl(At);e!==null&&uf(tf,e.startTime-l),t=!1}}break l}finally{pl=null,hl=u,Pe=!1}t=void 0}}finally{t?zu():Tu=!1}}}var zu;typeof Vi=="function"?zu=function(){Vi(Fe)}:typeof MessageChannel<"u"?(ke=new MessageChannel,xi=ke.port2,ke.port1.onmessage=Fe,zu=function(){xi.postMessage(null)}):zu=function(){Li(Fe,0)};var ke,xi;function uf(l,t){ma=Li(function(){l(w.unstable_now())},t)}w.unstable_IdlePriority=5;w.unstable_ImmediatePriority=1;w.unstable_LowPriority=4;w.unstable_NormalPriority=3;w.unstable_Profiling=null;w.unstable_UserBlockingPriority=2;w.unstable_cancelCallback=function(l){l.callback=null};w.unstable_forceFrameRate=function(l){0>l||125<l?console.error("forceFrameRate takes a positive int between 0 and 125, forcing frame rates higher than 125 fps is not supported"):Ji=0<l?Math.floor(1e3/l):5};w.unstable_getCurrentPriorityLevel=function(){return hl};w.unstable_next=function(l){switch(hl){case 1:case 2:case 3:var t=3;break;default:t=hl}var u=hl;hl=t;try{return l()}finally{hl=u}};w.unstable_requestPaint=function(){lf=!0};w.unstable_runWithPriority=function(l,t){switch(l){case 1:case 2:case 3:case 4:case 5:break;default:l=3}var u=hl;hl=l;try{return t()}finally{hl=u}};w.unstable_scheduleCallback=function(l,t,u){var a=w.unstable_now();switch(typeof u=="object"&&u!==null?(u=u.delay,u=typeof u=="number"&&0<u?a+u:a):u=a,l){case 1:var n=-1;break;case 2:n=250;break;case 5:n=1073741823;break;case 4:n=1e4;break;default:n=5e3}return n=u+n,l={id:Bm++,callback:t,priorityLevel:l,startTime:u,expirationTime:n,sortIndex:-1},u>a?(l.sortIndex=u,Ie(At,l),Wl(tt)===null&&l===Wl(At)&&(va?(Ki(ma),ma=-1):va=!0,uf(tf,u-a))):(l.sortIndex=n,Ie(tt,l),ya||Pe||(ya=!0,Tu||(Tu=!0,zu()))),l};w.unstable_shouldYield=wi;w.unstable_wrapCallback=function(l){var t=hl;return function(){var u=hl;hl=t;try{return l.apply(this,arguments)}finally{hl=u}}}});var Fi=Ft((d2,$i)=>{"use strict";$i.exports=Wi()});var af=Ft((h2,ki)=>{"use strict";ki.exports=We()});var Pi=Ft(gl=>{"use strict";var Rm=af();function Ii(l){var t="https://react.dev/errors/"+l;if(1<arguments.length){t+="?args[]="+encodeURIComponent(arguments[1]);for(var u=2;u<arguments.length;u++)t+="&args[]="+encodeURIComponent(arguments[u])}return"Minified React error #"+l+"; visit "+t+" for the full message or use the non-minified dev environment for full errors and additional helpful warnings."}function Mt(){}var Sl={d:{f:Mt,r:function(){throw Error(Ii(522))},D:Mt,C:Mt,L:Mt,m:Mt,X:Mt,S:Mt,M:Mt},p:0,findDOMNode:null},pm=Symbol.for("react.portal");function Cm(l,t,u){var a=3<arguments.length&&arguments[3]!==void 0?arguments[3]:null;return{$$typeof:pm,key:a==null?null:""+a,children:l,containerInfo:t,implementation:u}}var da=Rm.__CLIENT_INTERNALS_DO_NOT_USE_OR_WARN_USERS_THEY_CANNOT_UPGRADE;function gn(l,t){if(l==="font")return"";if(typeof t=="string")return t==="use-credentials"?t:""}gl.__DOM_INTERNALS_DO_NOT_USE_OR_WARN_USERS_THEY_CANNOT_UPGRADE=Sl;gl.createPortal=function(l,t){var u=2<arguments.length&&arguments[2]!==void 0?arguments[2]:null;if(!t||t.nodeType!==1&&t.nodeType!==9&&t.nodeType!==11)throw Error(Ii(299));return Cm(l,t,null,u)};gl.flushSync=function(l){var t=da.T,u=Sl.p;try{if(da.T=null,Sl.p=2,l)return l()}finally{da.T=t,Sl.p=u,Sl.d.f()}};gl.preconnect=function(l,t){typeof l=="string"&&(t?(t=t.crossOrigin,t=typeof t=="string"?t==="use-credentials"?t:"":void 0):t=null,Sl.d.C(l,t))};gl.prefetchDNS=function(l){typeof l=="string"&&Sl.d.D(l)};gl.preinit=function(l,t){if(typeof l=="string"&&t&&typeof t.as=="string"){var u=t.as,a=gn(u,t.crossOrigin),n=typeof t.integrity=="string"?t.integrity:void 0,e=typeof t.fetchPriority=="string"?t.fetchPriority:void 0;u==="style"?Sl.d.S(l,typeof t.precedence=="string"?t.precedence:void 0,{crossOrigin:a,integrity:n,fetchPriority:e}):u==="script"&&Sl.d.X(l,{crossOrigin:a,integrity:n,fetchPriority:e,nonce:typeof t.nonce=="string"?t.nonce:void 0})}};gl.preinitModule=function(l,t){if(typeof l=="string")if(typeof t=="object"&&t!==null){if(t.as==null||t.as==="script"){var u=gn(t.as,t.crossOrigin);Sl.d.M(l,{crossOrigin:u,integrity:typeof t.integrity=="string"?t.integrity:void 0,nonce:typeof t.nonce=="string"?t.nonce:void 0})}}else t==null&&Sl.d.M(l)};gl.preload=function(l,t){if(typeof l=="string"&&typeof t=="object"&&t!==null&&typeof t.as=="string"){var u=t.as,a=gn(u,t.crossOrigin);Sl.d.L(l,u,{crossOrigin:a,integrity:typeof t.integrity=="string"?t.integrity:void 0,nonce:typeof t.nonce=="string"?t.nonce:void 0,type:typeof t.type=="string"?t.type:void 0,fetchPriority:typeof t.fetchPriority=="string"?t.fetchPriority:void 0,referrerPolicy:typeof t.referrerPolicy=="string"?t.referrerPolicy:void 0,imageSrcSet:typeof t.imageSrcSet=="string"?t.imageSrcSet:void 0,imageSizes:typeof t.imageSizes=="string"?t.imageSizes:void 0,media:typeof t.media=="string"?t.media:void 0})}};gl.preloadModule=function(l,t){if(typeof l=="string")if(t){var u=gn(t.as,t.crossOrigin);Sl.d.m(l,{as:typeof t.as=="string"&&t.as!=="script"?t.as:void 0,crossOrigin:u,integrity:typeof t.integrity=="string"?t.integrity:void 0})}else Sl.d.m(l)};gl.requestFormReset=function(l){Sl.d.r(l)};gl.unstable_batchedUpdates=function(l,t){return l(t)};gl.useFormState=function(l,t,u){return da.H.useFormState(l,t,u)};gl.useFormStatus=function(){return da.H.useHostTransitionStatus()};gl.version="19.2.0"});var u0=Ft((g2,t0)=>{"use strict";function l0(){if(!(typeof __REACT_DEVTOOLS_GLOBAL_HOOK__>"u"||typeof __REACT_DEVTOOLS_GLOBAL_HOOK__.checkDCE!="function"))try{__REACT_DEVTOOLS_GLOBAL_HOOK__.checkDCE(l0)}catch(l){console.error(l)}}l0(),t0.exports=Pi()});var Sm=Ft(je=>{"use strict";var nl=Fi(),H1=af(),Gm=u0();function b(l){var t="https://react.dev/errors/"+l;if(1<arguments.length){t+="?args[]="+encodeURIComponent(arguments[1]);for(var u=2;u<arguments.length;u++)t+="&args[]="+encodeURIComponent(arguments[u])}return"Minified React error #"+l+"; visit "+t+" for the full message or use the non-minified dev environment for full errors and additional helpful warnings."}function N1(l){return!(!l||l.nodeType!==1&&l.nodeType!==9&&l.nodeType!==11)}function Ia(l){var t=l,u=l;if(l.alternate)for(;t.return;)t=t.return;else{l=t;do t=l,(t.flags&4098)!==0&&(u=t.return),l=t.return;while(l)}return t.tag===3?u:null}function q1(l){if(l.tag===13){var t=l.memoizedState;if(t===null&&(l=l.alternate,l!==null&&(t=l.memoizedState)),t!==null)return t.dehydrated}return null}function Y1(l){if(l.tag===31){var t=l.memoizedState;if(t===null&&(l=l.alternate,l!==null&&(t=l.memoizedState)),t!==null)return t.dehydrated}return null}function a0(l){if(Ia(l)!==l)throw Error(b(188))}function Xm(l){var t=l.alternate;if(!t){if(t=Ia(l),t===null)throw Error(b(188));return t!==l?null:l}for(var u=l,a=t;;){var n=u.return;if(n===null)break;var e=n.alternate;if(e===null){if(a=n.return,a!==null){u=a;continue}break}if(n.child===e.child){for(e=n.child;e;){if(e===u)return a0(n),l;if(e===a)return a0(n),t;e=e.sibling}throw Error(b(188))}if(u.return!==a.return)u=n,a=e;else{for(var f=!1,c=n.child;c;){if(c===u){f=!0,u=n,a=e;break}if(c===a){f=!0,a=n,u=e;break}c=c.sibling}if(!f){for(c=e.child;c;){if(c===u){f=!0,u=e,a=n;break}if(c===a){f=!0,a=e,u=n;break}c=c.sibling}if(!f)throw Error(b(189))}}if(u.alternate!==a)throw Error(b(190))}if(u.tag!==3)throw Error(b(188));return u.stateNode.current===u?l:t}function B1(l){var t=l.tag;if(t===5||t===26||t===27||t===6)return l;for(l=l.child;l!==null;){if(t=B1(l),t!==null)return t;l=l.sibling}return null}var r=Object.assign,Qm=Symbol.for("react.element"),on=Symbol.for("react.transitional.element"),Ta=Symbol.for("react.portal"),Du=Symbol.for("react.fragment"),R1=Symbol.for("react.strict_mode"),Qf=Symbol.for("react.profiler"),p1=Symbol.for("react.consumer"),yt=Symbol.for("react.context"),Rc=Symbol.for("react.forward_ref"),Zf=Symbol.for("react.suspense"),jf=Symbol.for("react.suspense_list"),pc=Symbol.for("react.memo"),Ot=Symbol.for("react.lazy");Symbol.for("react.scope");var Vf=Symbol.for("react.activity");Symbol.for("react.legacy_hidden");Symbol.for("react.tracing_marker");var Zm=Symbol.for("react.memo_cache_sentinel");Symbol.for("react.view_transition");var n0=Symbol.iterator;function ha(l){return l===null||typeof l!="object"?null:(l=n0&&l[n0]||l["@@iterator"],typeof l=="function"?l:null)}var jm=Symbol.for("react.client.reference");function xf(l){if(l==null)return null;if(typeof l=="function")return l.$$typeof===jm?null:l.displayName||l.name||null;if(typeof l=="string")return l;switch(l){case Du:return"Fragment";case Qf:return"Profiler";case R1:return"StrictMode";case Zf:return"Suspense";case jf:return"SuspenseList";case Vf:return"Activity"}if(typeof l=="object")switch(l.$$typeof){case Ta:return"Portal";case yt:return l.displayName||"Context";case p1:return(l._context.displayName||"Context")+".Consumer";case Rc:var t=l.render;return l=l.displayName,l||(l=t.displayName||t.name||"",l=l!==""?"ForwardRef("+l+")":"ForwardRef"),l;case pc:return t=l.displayName||null,t!==null?t:xf(l.type)||"Memo";case Ot:t=l._payload,l=l._init;try{return xf(l(t))}catch{}}return null}var Ea=Array.isArray,M=H1.__CLIENT_INTERNALS_DO_NOT_USE_OR_WARN_USERS_THEY_CANNOT_UPGRADE,C=Gm.__DOM_INTERNALS_DO_NOT_USE_OR_WARN_USERS_THEY_CANNOT_UPGRADE,uu={pending:!1,data:null,method:null,action:null},Lf=[],Uu=-1;function Pl(l){return{current:l}}function cl(l){0>Uu||(l.current=Lf[Uu],Lf[Uu]=null,Uu--)}function x(l,t){Uu++,Lf[Uu]=l.current,l.current=t}var Il=Pl(null),Qa=Pl(null),Ct=Pl(null),$n=Pl(null);function Fn(l,t){switch(x(Ct,t),x(Qa,l),x(Il,null),t.nodeType){case 9:case 11:l=(l=t.documentElement)&&(l=l.namespaceURI)?m1(l):0;break;default:if(l=t.tagName,t=t.namespaceURI)t=m1(t),l=lm(t,l);else switch(l){case"svg":l=1;break;case"math":l=2;break;default:l=0}}cl(Il),x(Il,l)}function Ju(){cl(Il),cl(Qa),cl(Ct)}function Kf(l){l.memoizedState!==null&&x($n,l);var t=Il.current,u=lm(t,l.type);t!==u&&(x(Qa,l),x(Il,u))}function kn(l){Qa.current===l&&(cl(Il),cl(Qa)),$n.current===l&&(cl($n),$a._currentValue=uu)}var nf,e0;function It(l){if(nf===void 0)try{throw Error()}catch(u){var t=u.stack.trim().match(/\n( *(at )?)/);nf=t&&t[1]||"",e0=-1<u.stack.indexOf(`
    at`)?" (<anonymous>)":-1<u.stack.indexOf("@")?"@unknown:0:0":""}return`
`+nf+l+e0}var ef=!1;function ff(l,t){if(!l||ef)return"";ef=!0;var u=Error.prepareStackTrace;Error.prepareStackTrace=void 0;try{var a={DetermineComponentFrameRoot:function(){try{if(t){var s=function(){throw Error()};if(Object.defineProperty(s.prototype,"props",{set:function(){throw Error()}}),typeof Reflect=="object"&&Reflect.construct){try{Reflect.construct(s,[])}catch(S){var h=S}Reflect.construct(l,[],s)}else{try{s.call()}catch(S){h=S}l.call(s.prototype)}}else{try{throw Error()}catch(S){h=S}(s=l())&&typeof s.catch=="function"&&s.catch(function(){})}}catch(S){if(S&&h&&typeof S.stack=="string")return[S.stack,h.stack]}return[null,null]}};a.DetermineComponentFrameRoot.displayName="DetermineComponentFrameRoot";var n=Object.getOwnPropertyDescriptor(a.DetermineComponentFrameRoot,"name");n&&n.configurable&&Object.defineProperty(a.DetermineComponentFrameRoot,"name",{value:"DetermineComponentFrameRoot"});var e=a.DetermineComponentFrameRoot(),f=e[0],c=e[1];if(f&&c){var i=f.split(`
`),m=c.split(`
`);for(n=a=0;a<i.length&&!i[a].includes("DetermineComponentFrameRoot");)a++;for(;n<m.length&&!m[n].includes("DetermineComponentFrameRoot");)n++;if(a===i.length||n===m.length)for(a=i.length-1,n=m.length-1;1<=a&&0<=n&&i[a]!==m[n];)n--;for(;1<=a&&0<=n;a--,n--)if(i[a]!==m[n]){if(a!==1||n!==1)do if(a--,n--,0>n||i[a]!==m[n]){var g=`
`+i[a].replace(" at new "," at ");return l.displayName&&g.includes("<anonymous>")&&(g=g.replace("<anonymous>",l.displayName)),g}while(1<=a&&0<=n);break}}}finally{ef=!1,Error.prepareStackTrace=u}return(u=l?l.displayName||l.name:"")?It(u):""}function Vm(l,t){switch(l.tag){case 26:case 27:case 5:return It(l.type);case 16:return It("Lazy");case 13:return l.child!==t&&t!==null?It("Suspense Fallback"):It("Suspense");case 19:return It("SuspenseList");case 0:case 15:return ff(l.type,!1);case 11:return ff(l.type.render,!1);case 1:return ff(l.type,!0);case 31:return It("Activity");default:return""}}function f0(l){try{var t="",u=null;do t+=Vm(l,u),u=l,l=l.return;while(l);return t}catch(a){return`
Error generating stack: `+a.message+`
`+a.stack}}var Jf=Object.prototype.hasOwnProperty,Cc=nl.unstable_scheduleCallback,cf=nl.unstable_cancelCallback,xm=nl.unstable_shouldYield,Lm=nl.unstable_requestPaint,Hl=nl.unstable_now,Km=nl.unstable_getCurrentPriorityLevel,C1=nl.unstable_ImmediatePriority,G1=nl.unstable_UserBlockingPriority,In=nl.unstable_NormalPriority,Jm=nl.unstable_LowPriority,X1=nl.unstable_IdlePriority,rm=nl.log,wm=nl.unstable_setDisableYieldValue,Pa=null,Nl=null;function qt(l){if(typeof rm=="function"&&wm(l),Nl&&typeof Nl.setStrictMode=="function")try{Nl.setStrictMode(Pa,l)}catch{}}var ql=Math.clz32?Math.clz32:Fm,Wm=Math.log,$m=Math.LN2;function Fm(l){return l>>>=0,l===0?32:31-(Wm(l)/$m|0)|0}var sn=256,bn=262144,zn=4194304;function Pt(l){var t=l&42;if(t!==0)return t;switch(l&-l){case 1:return 1;case 2:return 2;case 4:return 4;case 8:return 8;case 16:return 16;case 32:return 32;case 64:return 64;case 128:return 128;case 256:case 512:case 1024:case 2048:case 4096:case 8192:case 16384:case 32768:case 65536:case 131072:return l&261888;case 262144:case 524288:case 1048576:case 2097152:return l&3932160;case 4194304:case 8388608:case 16777216:case 33554432:return l&62914560;case 67108864:return 67108864;case 134217728:return 134217728;case 268435456:return 268435456;case 536870912:return 536870912;case 1073741824:return 0;default:return l}}function Oe(l,t,u){var a=l.pendingLanes;if(a===0)return 0;var n=0,e=l.suspendedLanes,f=l.pingedLanes;l=l.warmLanes;var c=a&134217727;return c!==0?(a=c&~e,a!==0?n=Pt(a):(f&=c,f!==0?n=Pt(f):u||(u=c&~l,u!==0&&(n=Pt(u))))):(c=a&~e,c!==0?n=Pt(c):f!==0?n=Pt(f):u||(u=a&~l,u!==0&&(n=Pt(u)))),n===0?0:t!==0&&t!==n&&(t&e)===0&&(e=n&-n,u=t&-t,e>=u||e===32&&(u&4194048)!==0)?t:n}function ln(l,t){return(l.pendingLanes&~(l.suspendedLanes&~l.pingedLanes)&t)===0}function km(l,t){switch(l){case 1:case 2:case 4:case 8:case 64:return t+250;case 16:case 32:case 128:case 256:case 512:case 1024:case 2048:case 4096:case 8192:case 16384:case 32768:case 65536:case 131072:case 262144:case 524288:case 1048576:case 2097152:return t+5e3;case 4194304:case 8388608:case 16777216:case 33554432:return-1;case 67108864:case 134217728:case 268435456:case 536870912:case 1073741824:return-1;default:return-1}}function Q1(){var l=zn;return zn<<=1,(zn&62914560)===0&&(zn=4194304),l}function yf(l){for(var t=[],u=0;31>u;u++)t.push(l);return t}function tn(l,t){l.pendingLanes|=t,t!==268435456&&(l.suspendedLanes=0,l.pingedLanes=0,l.warmLanes=0)}function Im(l,t,u,a,n,e){var f=l.pendingLanes;l.pendingLanes=u,l.suspendedLanes=0,l.pingedLanes=0,l.warmLanes=0,l.expiredLanes&=u,l.entangledLanes&=u,l.errorRecoveryDisabledLanes&=u,l.shellSuspendCounter=0;var c=l.entanglements,i=l.expirationTimes,m=l.hiddenUpdates;for(u=f&~u;0<u;){var g=31-ql(u),s=1<<g;c[g]=0,i[g]=-1;var h=m[g];if(h!==null)for(m[g]=null,g=0;g<h.length;g++){var S=h[g];S!==null&&(S.lane&=-536870913)}u&=~s}a!==0&&Z1(l,a,0),e!==0&&n===0&&l.tag!==0&&(l.suspendedLanes|=e&~(f&~t))}function Z1(l,t,u){l.pendingLanes|=t,l.suspendedLanes&=~t;var a=31-ql(t);l.entangledLanes|=t,l.entanglements[a]=l.entanglements[a]|1073741824|u&261930}function j1(l,t){var u=l.entangledLanes|=t;for(l=l.entanglements;u;){var a=31-ql(u),n=1<<a;n&t|l[a]&t&&(l[a]|=t),u&=~n}}function V1(l,t){var u=t&-t;return u=(u&42)!==0?1:Gc(u),(u&(l.suspendedLanes|t))!==0?0:u}function Gc(l){switch(l){case 2:l=1;break;case 8:l=4;break;case 32:l=16;break;case 256:case 512:case 1024:case 2048:case 4096:case 8192:case 16384:case 32768:case 65536:case 131072:case 262144:case 524288:case 1048576:case 2097152:case 4194304:case 8388608:case 16777216:case 33554432:l=128;break;case 268435456:l=134217728;break;default:l=0}return l}function Xc(l){return l&=-l,2<l?8<l?(l&134217727)!==0?32:268435456:8:2}function x1(){var l=C.p;return l!==0?l:(l=window.event,l===void 0?32:mm(l.type))}function c0(l,t){var u=C.p;try{return C.p=l,t()}finally{C.p=u}}var Wt=Math.random().toString(36).slice(2),yl="__reactFiber$"+Wt,Al="__reactProps$"+Wt,ua="__reactContainer$"+Wt,rf="__reactEvents$"+Wt,Pm="__reactListeners$"+Wt,ld="__reactHandles$"+Wt,i0="__reactResources$"+Wt,un="__reactMarker$"+Wt;function Qc(l){delete l[yl],delete l[Al],delete l[rf],delete l[Pm],delete l[ld]}function Hu(l){var t=l[yl];if(t)return t;for(var u=l.parentNode;u;){if(t=u[ua]||u[yl]){if(u=t.alternate,t.child!==null||u!==null&&u.child!==null)for(l=o1(l);l!==null;){if(u=l[yl])return u;l=o1(l)}return t}l=u,u=l.parentNode}return null}function aa(l){if(l=l[yl]||l[ua]){var t=l.tag;if(t===5||t===6||t===13||t===31||t===26||t===27||t===3)return l}return null}function Aa(l){var t=l.tag;if(t===5||t===26||t===27||t===6)return l.stateNode;throw Error(b(33))}function Qu(l){var t=l[i0];return t||(t=l[i0]={hoistableStyles:new Map,hoistableScripts:new Map}),t}function fl(l){l[un]=!0}var L1=new Set,K1={};function du(l,t){ru(l,t),ru(l+"Capture",t)}function ru(l,t){for(K1[l]=t,l=0;l<t.length;l++)L1.add(t[l])}var td=RegExp("^[:A-Z_a-z\\u00C0-\\u00D6\\u00D8-\\u00F6\\u00F8-\\u02FF\\u0370-\\u037D\\u037F-\\u1FFF\\u200C-\\u200D\\u2070-\\u218F\\u2C00-\\u2FEF\\u3001-\\uD7FF\\uF900-\\uFDCF\\uFDF0-\\uFFFD][:A-Z_a-z\\u00C0-\\u00D6\\u00D8-\\u00F6\\u00F8-\\u02FF\\u0370-\\u037D\\u037F-\\u1FFF\\u200C-\\u200D\\u2070-\\u218F\\u2C00-\\u2FEF\\u3001-\\uD7FF\\uF900-\\uFDCF\\uFDF0-\\uFFFD\\-.0-9\\u00B7\\u0300-\\u036F\\u203F-\\u2040]*$"),y0={},v0={};function ud(l){return Jf.call(v0,l)?!0:Jf.call(y0,l)?!1:td.test(l)?v0[l]=!0:(y0[l]=!0,!1)}function pn(l,t,u){if(ud(t))if(u===null)l.removeAttribute(t);else{switch(typeof u){case"undefined":case"function":case"symbol":l.removeAttribute(t);return;case"boolean":var a=t.toLowerCase().slice(0,5);if(a!=="data-"&&a!=="aria-"){l.removeAttribute(t);return}}l.setAttribute(t,""+u)}}function Tn(l,t,u){if(u===null)l.removeAttribute(t);else{switch(typeof u){case"undefined":case"function":case"symbol":case"boolean":l.removeAttribute(t);return}l.setAttribute(t,""+u)}}function ut(l,t,u,a){if(a===null)l.removeAttribute(u);else{switch(typeof a){case"undefined":case"function":case"symbol":case"boolean":l.removeAttribute(u);return}l.setAttributeNS(t,u,""+a)}}function Gl(l){switch(typeof l){case"bigint":case"boolean":case"number":case"string":case"undefined":return l;case"object":return l;default:return""}}function J1(l){var t=l.type;return(l=l.nodeName)&&l.toLowerCase()==="input"&&(t==="checkbox"||t==="radio")}function ad(l,t,u){var a=Object.getOwnPropertyDescriptor(l.constructor.prototype,t);if(!l.hasOwnProperty(t)&&typeof a<"u"&&typeof a.get=="function"&&typeof a.set=="function"){var n=a.get,e=a.set;return Object.defineProperty(l,t,{configurable:!0,get:function(){return n.call(this)},set:function(f){u=""+f,e.call(this,f)}}),Object.defineProperty(l,t,{enumerable:a.enumerable}),{getValue:function(){return u},setValue:function(f){u=""+f},stopTracking:function(){l._valueTracker=null,delete l[t]}}}}function wf(l){if(!l._valueTracker){var t=J1(l)?"checked":"value";l._valueTracker=ad(l,t,""+l[t])}}function r1(l){if(!l)return!1;var t=l._valueTracker;if(!t)return!0;var u=t.getValue(),a="";return l&&(a=J1(l)?l.checked?"true":"false":l.value),l=a,l!==u?(t.setValue(l),!0):!1}function Pn(l){if(l=l||(typeof document<"u"?document:void 0),typeof l>"u")return null;try{return l.activeElement||l.body}catch{return l.body}}var nd=/[\n"\\]/g;function Zl(l){return l.replace(nd,function(t){return"\\"+t.charCodeAt(0).toString(16)+" "})}function Wf(l,t,u,a,n,e,f,c){l.name="",f!=null&&typeof f!="function"&&typeof f!="symbol"&&typeof f!="boolean"?l.type=f:l.removeAttribute("type"),t!=null?f==="number"?(t===0&&l.value===""||l.value!=t)&&(l.value=""+Gl(t)):l.value!==""+Gl(t)&&(l.value=""+Gl(t)):f!=="submit"&&f!=="reset"||l.removeAttribute("value"),t!=null?$f(l,f,Gl(t)):u!=null?$f(l,f,Gl(u)):a!=null&&l.removeAttribute("value"),n==null&&e!=null&&(l.defaultChecked=!!e),n!=null&&(l.checked=n&&typeof n!="function"&&typeof n!="symbol"),c!=null&&typeof c!="function"&&typeof c!="symbol"&&typeof c!="boolean"?l.name=""+Gl(c):l.removeAttribute("name")}function w1(l,t,u,a,n,e,f,c){if(e!=null&&typeof e!="function"&&typeof e!="symbol"&&typeof e!="boolean"&&(l.type=e),t!=null||u!=null){if(!(e!=="submit"&&e!=="reset"||t!=null)){wf(l);return}u=u!=null?""+Gl(u):"",t=t!=null?""+Gl(t):u,c||t===l.value||(l.value=t),l.defaultValue=t}a=a??n,a=typeof a!="function"&&typeof a!="symbol"&&!!a,l.checked=c?l.checked:!!a,l.defaultChecked=!!a,f!=null&&typeof f!="function"&&typeof f!="symbol"&&typeof f!="boolean"&&(l.name=f),wf(l)}function $f(l,t,u){t==="number"&&Pn(l.ownerDocument)===l||l.defaultValue===""+u||(l.defaultValue=""+u)}function Zu(l,t,u,a){if(l=l.options,t){t={};for(var n=0;n<u.length;n++)t["$"+u[n]]=!0;for(u=0;u<l.length;u++)n=t.hasOwnProperty("$"+l[u].value),l[u].selected!==n&&(l[u].selected=n),n&&a&&(l[u].defaultSelected=!0)}else{for(u=""+Gl(u),t=null,n=0;n<l.length;n++){if(l[n].value===u){l[n].selected=!0,a&&(l[n].defaultSelected=!0);return}t!==null||l[n].disabled||(t=l[n])}t!==null&&(t.selected=!0)}}function W1(l,t,u){if(t!=null&&(t=""+Gl(t),t!==l.value&&(l.value=t),u==null)){l.defaultValue!==t&&(l.defaultValue=t);return}l.defaultValue=u!=null?""+Gl(u):""}function $1(l,t,u,a){if(t==null){if(a!=null){if(u!=null)throw Error(b(92));if(Ea(a)){if(1<a.length)throw Error(b(93));a=a[0]}u=a}u==null&&(u=""),t=u}u=Gl(t),l.defaultValue=u,a=l.textContent,a===u&&a!==""&&a!==null&&(l.value=a),wf(l)}function wu(l,t){if(t){var u=l.firstChild;if(u&&u===l.lastChild&&u.nodeType===3){u.nodeValue=t;return}}l.textContent=t}var ed=new Set("animationIterationCount aspectRatio borderImageOutset borderImageSlice borderImageWidth boxFlex boxFlexGroup boxOrdinalGroup columnCount columns flex flexGrow flexPositive flexShrink flexNegative flexOrder gridArea gridRow gridRowEnd gridRowSpan gridRowStart gridColumn gridColumnEnd gridColumnSpan gridColumnStart fontWeight lineClamp lineHeight opacity order orphans scale tabSize widows zIndex zoom fillOpacity floodOpacity stopOpacity strokeDasharray strokeDashoffset strokeMiterlimit strokeOpacity strokeWidth MozAnimationIterationCount MozBoxFlex MozBoxFlexGroup MozLineClamp msAnimationIterationCount msFlex msZoom msFlexGrow msFlexNegative msFlexOrder msFlexPositive msFlexShrink msGridColumn msGridColumnSpan msGridRow msGridRowSpan WebkitAnimationIterationCount WebkitBoxFlex WebKitBoxFlexGroup WebkitBoxOrdinalGroup WebkitColumnCount WebkitColumns WebkitFlex WebkitFlexGrow WebkitFlexPositive WebkitFlexShrink WebkitLineClamp".split(" "));function m0(l,t,u){var a=t.indexOf("--")===0;u==null||typeof u=="boolean"||u===""?a?l.setProperty(t,""):t==="float"?l.cssFloat="":l[t]="":a?l.setProperty(t,u):typeof u!="number"||u===0||ed.has(t)?t==="float"?l.cssFloat=u:l[t]=(""+u).trim():l[t]=u+"px"}function F1(l,t,u){if(t!=null&&typeof t!="object")throw Error(b(62));if(l=l.style,u!=null){for(var a in u)!u.hasOwnProperty(a)||t!=null&&t.hasOwnProperty(a)||(a.indexOf("--")===0?l.setProperty(a,""):a==="float"?l.cssFloat="":l[a]="");for(var n in t)a=t[n],t.hasOwnProperty(n)&&u[n]!==a&&m0(l,n,a)}else for(var e in t)t.hasOwnProperty(e)&&m0(l,e,t[e])}function Zc(l){if(l.indexOf("-")===-1)return!1;switch(l){case"annotation-xml":case"color-profile":case"font-face":case"font-face-src":case"font-face-uri":case"font-face-format":case"font-face-name":case"missing-glyph":return!1;default:return!0}}var fd=new Map([["acceptCharset","accept-charset"],["htmlFor","for"],["httpEquiv","http-equiv"],["crossOrigin","crossorigin"],["accentHeight","accent-height"],["alignmentBaseline","alignment-baseline"],["arabicForm","arabic-form"],["baselineShift","baseline-shift"],["capHeight","cap-height"],["clipPath","clip-path"],["clipRule","clip-rule"],["colorInterpolation","color-interpolation"],["colorInterpolationFilters","color-interpolation-filters"],["colorProfile","color-profile"],["colorRendering","color-rendering"],["dominantBaseline","dominant-baseline"],["enableBackground","enable-background"],["fillOpacity","fill-opacity"],["fillRule","fill-rule"],["floodColor","flood-color"],["floodOpacity","flood-opacity"],["fontFamily","font-family"],["fontSize","font-size"],["fontSizeAdjust","font-size-adjust"],["fontStretch","font-stretch"],["fontStyle","font-style"],["fontVariant","font-variant"],["fontWeight","font-weight"],["glyphName","glyph-name"],["glyphOrientationHorizontal","glyph-orientation-horizontal"],["glyphOrientationVertical","glyph-orientation-vertical"],["horizAdvX","horiz-adv-x"],["horizOriginX","horiz-origin-x"],["imageRendering","image-rendering"],["letterSpacing","letter-spacing"],["lightingColor","lighting-color"],["markerEnd","marker-end"],["markerMid","marker-mid"],["markerStart","marker-start"],["overlinePosition","overline-position"],["overlineThickness","overline-thickness"],["paintOrder","paint-order"],["panose-1","panose-1"],["pointerEvents","pointer-events"],["renderingIntent","rendering-intent"],["shapeRendering","shape-rendering"],["stopColor","stop-color"],["stopOpacity","stop-opacity"],["strikethroughPosition","strikethrough-position"],["strikethroughThickness","strikethrough-thickness"],["strokeDasharray","stroke-dasharray"],["strokeDashoffset","stroke-dashoffset"],["strokeLinecap","stroke-linecap"],["strokeLinejoin","stroke-linejoin"],["strokeMiterlimit","stroke-miterlimit"],["strokeOpacity","stroke-opacity"],["strokeWidth","stroke-width"],["textAnchor","text-anchor"],["textDecoration","text-decoration"],["textRendering","text-rendering"],["transformOrigin","transform-origin"],["underlinePosition","underline-position"],["underlineThickness","underline-thickness"],["unicodeBidi","unicode-bidi"],["unicodeRange","unicode-range"],["unitsPerEm","units-per-em"],["vAlphabetic","v-alphabetic"],["vHanging","v-hanging"],["vIdeographic","v-ideographic"],["vMathematical","v-mathematical"],["vectorEffect","vector-effect"],["vertAdvY","vert-adv-y"],["vertOriginX","vert-origin-x"],["vertOriginY","vert-origin-y"],["wordSpacing","word-spacing"],["writingMode","writing-mode"],["xmlnsXlink","xmlns:xlink"],["xHeight","x-height"]]),cd=/^[\u0000-\u001F ]*j[\r\n\t]*a[\r\n\t]*v[\r\n\t]*a[\r\n\t]*s[\r\n\t]*c[\r\n\t]*r[\r\n\t]*i[\r\n\t]*p[\r\n\t]*t[\r\n\t]*:/i;function Cn(l){return cd.test(""+l)?"javascript:throw new Error('React has blocked a javascript: URL as a security precaution.')":l}function vt(){}var Ff=null;function jc(l){return l=l.target||l.srcElement||window,l.correspondingUseElement&&(l=l.correspondingUseElement),l.nodeType===3?l.parentNode:l}var Nu=null,ju=null;function d0(l){var t=aa(l);if(t&&(l=t.stateNode)){var u=l[Al]||null;l:switch(l=t.stateNode,t.type){case"input":if(Wf(l,u.value,u.defaultValue,u.defaultValue,u.checked,u.defaultChecked,u.type,u.name),t=u.name,u.type==="radio"&&t!=null){for(u=l;u.parentNode;)u=u.parentNode;for(u=u.querySelectorAll('input[name="'+Zl(""+t)+'"][type="radio"]'),t=0;t<u.length;t++){var a=u[t];if(a!==l&&a.form===l.form){var n=a[Al]||null;if(!n)throw Error(b(90));Wf(a,n.value,n.defaultValue,n.defaultValue,n.checked,n.defaultChecked,n.type,n.name)}}for(t=0;t<u.length;t++)a=u[t],a.form===l.form&&r1(a)}break l;case"textarea":W1(l,u.value,u.defaultValue);break l;case"select":t=u.value,t!=null&&Zu(l,!!u.multiple,t,!1)}}}var vf=!1;function k1(l,t,u){if(vf)return l(t,u);vf=!0;try{var a=l(t);return a}finally{if(vf=!1,(Nu!==null||ju!==null)&&(Ge(),Nu&&(t=Nu,l=ju,ju=Nu=null,d0(t),l)))for(t=0;t<l.length;t++)d0(l[t])}}function Za(l,t){var u=l.stateNode;if(u===null)return null;var a=u[Al]||null;if(a===null)return null;u=a[t];l:switch(t){case"onClick":case"onClickCapture":case"onDoubleClick":case"onDoubleClickCapture":case"onMouseDown":case"onMouseDownCapture":case"onMouseMove":case"onMouseMoveCapture":case"onMouseUp":case"onMouseUpCapture":case"onMouseEnter":(a=!a.disabled)||(l=l.type,a=!(l==="button"||l==="input"||l==="select"||l==="textarea")),l=!a;break l;default:l=!1}if(l)return null;if(u&&typeof u!="function")throw Error(b(231,t,typeof u));return u}var gt=!(typeof window>"u"||typeof window.document>"u"||typeof window.document.createElement>"u"),kf=!1;if(gt)try{Eu={},Object.defineProperty(Eu,"passive",{get:function(){kf=!0}}),window.addEventListener("test",Eu,Eu),window.removeEventListener("test",Eu,Eu)}catch{kf=!1}var Eu,Yt=null,Vc=null,Gn=null;function I1(){if(Gn)return Gn;var l,t=Vc,u=t.length,a,n="value"in Yt?Yt.value:Yt.textContent,e=n.length;for(l=0;l<u&&t[l]===n[l];l++);var f=u-l;for(a=1;a<=f&&t[u-a]===n[e-a];a++);return Gn=n.slice(l,1<a?1-a:void 0)}function Xn(l){var t=l.keyCode;return"charCode"in l?(l=l.charCode,l===0&&t===13&&(l=13)):l=t,l===10&&(l=13),32<=l||l===13?l:0}function En(){return!0}function h0(){return!1}function Ml(l){function t(u,a,n,e,f){this._reactName=u,this._targetInst=n,this.type=a,this.nativeEvent=e,this.target=f,this.currentTarget=null;for(var c in l)l.hasOwnProperty(c)&&(u=l[c],this[c]=u?u(e):e[c]);return this.isDefaultPrevented=(e.defaultPrevented!=null?e.defaultPrevented:e.returnValue===!1)?En:h0,this.isPropagationStopped=h0,this}return r(t.prototype,{preventDefault:function(){this.defaultPrevented=!0;var u=this.nativeEvent;u&&(u.preventDefault?u.preventDefault():typeof u.returnValue!="unknown"&&(u.returnValue=!1),this.isDefaultPrevented=En)},stopPropagation:function(){var u=this.nativeEvent;u&&(u.stopPropagation?u.stopPropagation():typeof u.cancelBubble!="unknown"&&(u.cancelBubble=!0),this.isPropagationStopped=En)},persist:function(){},isPersistent:En}),t}var hu={eventPhase:0,bubbles:0,cancelable:0,timeStamp:function(l){return l.timeStamp||Date.now()},defaultPrevented:0,isTrusted:0},_e=Ml(hu),an=r({},hu,{view:0,detail:0}),id=Ml(an),mf,df,Sa,De=r({},an,{screenX:0,screenY:0,clientX:0,clientY:0,pageX:0,pageY:0,ctrlKey:0,shiftKey:0,altKey:0,metaKey:0,getModifierState:xc,button:0,buttons:0,relatedTarget:function(l){return l.relatedTarget===void 0?l.fromElement===l.srcElement?l.toElement:l.fromElement:l.relatedTarget},movementX:function(l){return"movementX"in l?l.movementX:(l!==Sa&&(Sa&&l.type==="mousemove"?(mf=l.screenX-Sa.screenX,df=l.screenY-Sa.screenY):df=mf=0,Sa=l),mf)},movementY:function(l){return"movementY"in l?l.movementY:df}}),S0=Ml(De),yd=r({},De,{dataTransfer:0}),vd=Ml(yd),md=r({},an,{relatedTarget:0}),hf=Ml(md),dd=r({},hu,{animationName:0,elapsedTime:0,pseudoElement:0}),hd=Ml(dd),Sd=r({},hu,{clipboardData:function(l){return"clipboardData"in l?l.clipboardData:window.clipboardData}}),gd=Ml(Sd),od=r({},hu,{data:0}),g0=Ml(od),sd={Esc:"Escape",Spacebar:" ",Left:"ArrowLeft",Up:"ArrowUp",Right:"ArrowRight",Down:"ArrowDown",Del:"Delete",Win:"OS",Menu:"ContextMenu",Apps:"ContextMenu",Scroll:"ScrollLock",MozPrintableKey:"Unidentified"},bd={8:"Backspace",9:"Tab",12:"Clear",13:"Enter",16:"Shift",17:"Control",18:"Alt",19:"Pause",20:"CapsLock",27:"Escape",32:" ",33:"PageUp",34:"PageDown",35:"End",36:"Home",37:"ArrowLeft",38:"ArrowUp",39:"ArrowRight",40:"ArrowDown",45:"Insert",46:"Delete",112:"F1",113:"F2",114:"F3",115:"F4",116:"F5",117:"F6",118:"F7",119:"F8",120:"F9",121:"F10",122:"F11",123:"F12",144:"NumLock",145:"ScrollLock",224:"Meta"},zd={Alt:"altKey",Control:"ctrlKey",Meta:"metaKey",Shift:"shiftKey"};function Td(l){var t=this.nativeEvent;return t.getModifierState?t.getModifierState(l):(l=zd[l])?!!t[l]:!1}function xc(){return Td}var Ed=r({},an,{key:function(l){if(l.key){var t=sd[l.key]||l.key;if(t!=="Unidentified")return t}return l.type==="keypress"?(l=Xn(l),l===13?"Enter":String.fromCharCode(l)):l.type==="keydown"||l.type==="keyup"?bd[l.keyCode]||"Unidentified":""},code:0,location:0,ctrlKey:0,shiftKey:0,altKey:0,metaKey:0,repeat:0,locale:0,getModifierState:xc,charCode:function(l){return l.type==="keypress"?Xn(l):0},keyCode:function(l){return l.type==="keydown"||l.type==="keyup"?l.keyCode:0},which:function(l){return l.type==="keypress"?Xn(l):l.type==="keydown"||l.type==="keyup"?l.keyCode:0}}),Ad=Ml(Ed),Md=r({},De,{pointerId:0,width:0,height:0,pressure:0,tangentialPressure:0,tiltX:0,tiltY:0,twist:0,pointerType:0,isPrimary:0}),o0=Ml(Md),Od=r({},an,{touches:0,targetTouches:0,changedTouches:0,altKey:0,metaKey:0,ctrlKey:0,shiftKey:0,getModifierState:xc}),_d=Ml(Od),Dd=r({},hu,{propertyName:0,elapsedTime:0,pseudoElement:0}),Ud=Ml(Dd),Hd=r({},De,{deltaX:function(l){return"deltaX"in l?l.deltaX:"wheelDeltaX"in l?-l.wheelDeltaX:0},deltaY:function(l){return"deltaY"in l?l.deltaY:"wheelDeltaY"in l?-l.wheelDeltaY:"wheelDelta"in l?-l.wheelDelta:0},deltaZ:0,deltaMode:0}),Nd=Ml(Hd),qd=r({},hu,{newState:0,oldState:0}),Yd=Ml(qd),Bd=[9,13,27,32],Lc=gt&&"CompositionEvent"in window,_a=null;gt&&"documentMode"in document&&(_a=document.documentMode);var Rd=gt&&"TextEvent"in window&&!_a,P1=gt&&(!Lc||_a&&8<_a&&11>=_a),s0=" ",b0=!1;function ly(l,t){switch(l){case"keyup":return Bd.indexOf(t.keyCode)!==-1;case"keydown":return t.keyCode!==229;case"keypress":case"mousedown":case"focusout":return!0;default:return!1}}function ty(l){return l=l.detail,typeof l=="object"&&"data"in l?l.data:null}var qu=!1;function pd(l,t){switch(l){case"compositionend":return ty(t);case"keypress":return t.which!==32?null:(b0=!0,s0);case"textInput":return l=t.data,l===s0&&b0?null:l;default:return null}}function Cd(l,t){if(qu)return l==="compositionend"||!Lc&&ly(l,t)?(l=I1(),Gn=Vc=Yt=null,qu=!1,l):null;switch(l){case"paste":return null;case"keypress":if(!(t.ctrlKey||t.altKey||t.metaKey)||t.ctrlKey&&t.altKey){if(t.char&&1<t.char.length)return t.char;if(t.which)return String.fromCharCode(t.which)}return null;case"compositionend":return P1&&t.locale!=="ko"?null:t.data;default:return null}}var Gd={color:!0,date:!0,datetime:!0,"datetime-local":!0,email:!0,month:!0,number:!0,password:!0,range:!0,search:!0,tel:!0,text:!0,time:!0,url:!0,week:!0};function z0(l){var t=l&&l.nodeName&&l.nodeName.toLowerCase();return t==="input"?!!Gd[l.type]:t==="textarea"}function uy(l,t,u,a){Nu?ju?ju.push(a):ju=[a]:Nu=a,t=se(t,"onChange"),0<t.length&&(u=new _e("onChange","change",null,u,a),l.push({event:u,listeners:t}))}var Da=null,ja=null;function Xd(l){kv(l,0)}function Ue(l){var t=Aa(l);if(r1(t))return l}function T0(l,t){if(l==="change")return t}var ay=!1;gt&&(gt?(Mn="oninput"in document,Mn||(Sf=document.createElement("div"),Sf.setAttribute("oninput","return;"),Mn=typeof Sf.oninput=="function"),An=Mn):An=!1,ay=An&&(!document.documentMode||9<document.documentMode));var An,Mn,Sf;function E0(){Da&&(Da.detachEvent("onpropertychange",ny),ja=Da=null)}function ny(l){if(l.propertyName==="value"&&Ue(ja)){var t=[];uy(t,ja,l,jc(l)),k1(Xd,t)}}function Qd(l,t,u){l==="focusin"?(E0(),Da=t,ja=u,Da.attachEvent("onpropertychange",ny)):l==="focusout"&&E0()}function Zd(l){if(l==="selectionchange"||l==="keyup"||l==="keydown")return Ue(ja)}function jd(l,t){if(l==="click")return Ue(t)}function Vd(l,t){if(l==="input"||l==="change")return Ue(t)}function xd(l,t){return l===t&&(l!==0||1/l===1/t)||l!==l&&t!==t}var Bl=typeof Object.is=="function"?Object.is:xd;function Va(l,t){if(Bl(l,t))return!0;if(typeof l!="object"||l===null||typeof t!="object"||t===null)return!1;var u=Object.keys(l),a=Object.keys(t);if(u.length!==a.length)return!1;for(a=0;a<u.length;a++){var n=u[a];if(!Jf.call(t,n)||!Bl(l[n],t[n]))return!1}return!0}function A0(l){for(;l&&l.firstChild;)l=l.firstChild;return l}function M0(l,t){var u=A0(l);l=0;for(var a;u;){if(u.nodeType===3){if(a=l+u.textContent.length,l<=t&&a>=t)return{node:u,offset:t-l};l=a}l:{for(;u;){if(u.nextSibling){u=u.nextSibling;break l}u=u.parentNode}u=void 0}u=A0(u)}}function ey(l,t){return l&&t?l===t?!0:l&&l.nodeType===3?!1:t&&t.nodeType===3?ey(l,t.parentNode):"contains"in l?l.contains(t):l.compareDocumentPosition?!!(l.compareDocumentPosition(t)&16):!1:!1}function fy(l){l=l!=null&&l.ownerDocument!=null&&l.ownerDocument.defaultView!=null?l.ownerDocument.defaultView:window;for(var t=Pn(l.document);t instanceof l.HTMLIFrameElement;){try{var u=typeof t.contentWindow.location.href=="string"}catch{u=!1}if(u)l=t.contentWindow;else break;t=Pn(l.document)}return t}function Kc(l){var t=l&&l.nodeName&&l.nodeName.toLowerCase();return t&&(t==="input"&&(l.type==="text"||l.type==="search"||l.type==="tel"||l.type==="url"||l.type==="password")||t==="textarea"||l.contentEditable==="true")}var Ld=gt&&"documentMode"in document&&11>=document.documentMode,Yu=null,If=null,Ua=null,Pf=!1;function O0(l,t,u){var a=u.window===u?u.document:u.nodeType===9?u:u.ownerDocument;Pf||Yu==null||Yu!==Pn(a)||(a=Yu,"selectionStart"in a&&Kc(a)?a={start:a.selectionStart,end:a.selectionEnd}:(a=(a.ownerDocument&&a.ownerDocument.defaultView||window).getSelection(),a={anchorNode:a.anchorNode,anchorOffset:a.anchorOffset,focusNode:a.focusNode,focusOffset:a.focusOffset}),Ua&&Va(Ua,a)||(Ua=a,a=se(If,"onSelect"),0<a.length&&(t=new _e("onSelect","select",null,t,u),l.push({event:t,listeners:a}),t.target=Yu)))}function kt(l,t){var u={};return u[l.toLowerCase()]=t.toLowerCase(),u["Webkit"+l]="webkit"+t,u["Moz"+l]="moz"+t,u}var Bu={animationend:kt("Animation","AnimationEnd"),animationiteration:kt("Animation","AnimationIteration"),animationstart:kt("Animation","AnimationStart"),transitionrun:kt("Transition","TransitionRun"),transitionstart:kt("Transition","TransitionStart"),transitioncancel:kt("Transition","TransitionCancel"),transitionend:kt("Transition","TransitionEnd")},gf={},cy={};gt&&(cy=document.createElement("div").style,"AnimationEvent"in window||(delete Bu.animationend.animation,delete Bu.animationiteration.animation,delete Bu.animationstart.animation),"TransitionEvent"in window||delete Bu.transitionend.transition);function Su(l){if(gf[l])return gf[l];if(!Bu[l])return l;var t=Bu[l],u;for(u in t)if(t.hasOwnProperty(u)&&u in cy)return gf[l]=t[u];return l}var iy=Su("animationend"),yy=Su("animationiteration"),vy=Su("animationstart"),Kd=Su("transitionrun"),Jd=Su("transitionstart"),rd=Su("transitioncancel"),my=Su("transitionend"),dy=new Map,lc="abort auxClick beforeToggle cancel canPlay canPlayThrough click close contextMenu copy cut drag dragEnd dragEnter dragExit dragLeave dragOver dragStart drop durationChange emptied encrypted ended error gotPointerCapture input invalid keyDown keyPress keyUp load loadedData loadedMetadata loadStart lostPointerCapture mouseDown mouseMove mouseOut mouseOver mouseUp paste pause play playing pointerCancel pointerDown pointerMove pointerOut pointerOver pointerUp progress rateChange reset resize seeked seeking stalled submit suspend timeUpdate touchCancel touchEnd touchStart volumeChange scroll toggle touchMove waiting wheel".split(" ");lc.push("scrollEnd");function wl(l,t){dy.set(l,t),du(t,[l])}var le=typeof reportError=="function"?reportError:function(l){if(typeof window=="object"&&typeof window.ErrorEvent=="function"){var t=new window.ErrorEvent("error",{bubbles:!0,cancelable:!0,message:typeof l=="object"&&l!==null&&typeof l.message=="string"?String(l.message):String(l),error:l});if(!window.dispatchEvent(t))return}else if(typeof process=="object"&&typeof process.emit=="function"){process.emit("uncaughtException",l);return}console.error(l)},Cl=[],Ru=0,Jc=0;function He(){for(var l=Ru,t=Jc=Ru=0;t<l;){var u=Cl[t];Cl[t++]=null;var a=Cl[t];Cl[t++]=null;var n=Cl[t];Cl[t++]=null;var e=Cl[t];if(Cl[t++]=null,a!==null&&n!==null){var f=a.pending;f===null?n.next=n:(n.next=f.next,f.next=n),a.pending=n}e!==0&&hy(u,n,e)}}function Ne(l,t,u,a){Cl[Ru++]=l,Cl[Ru++]=t,Cl[Ru++]=u,Cl[Ru++]=a,Jc|=a,l.lanes|=a,l=l.alternate,l!==null&&(l.lanes|=a)}function rc(l,t,u,a){return Ne(l,t,u,a),te(l)}function gu(l,t){return Ne(l,null,null,t),te(l)}function hy(l,t,u){l.lanes|=u;var a=l.alternate;a!==null&&(a.lanes|=u);for(var n=!1,e=l.return;e!==null;)e.childLanes|=u,a=e.alternate,a!==null&&(a.childLanes|=u),e.tag===22&&(l=e.stateNode,l===null||l._visibility&1||(n=!0)),l=e,e=e.return;return l.tag===3?(e=l.stateNode,n&&t!==null&&(n=31-ql(u),l=e.hiddenUpdates,a=l[n],a===null?l[n]=[t]:a.push(t),t.lane=u|536870912),e):null}function te(l){if(50<Ga)throw Ga=0,Ec=null,Error(b(185));for(var t=l.return;t!==null;)l=t,t=l.return;return l.tag===3?l.stateNode:null}var pu={};function wd(l,t,u,a){this.tag=l,this.key=u,this.sibling=this.child=this.return=this.stateNode=this.type=this.elementType=null,this.index=0,this.refCleanup=this.ref=null,this.pendingProps=t,this.dependencies=this.memoizedState=this.updateQueue=this.memoizedProps=null,this.mode=a,this.subtreeFlags=this.flags=0,this.deletions=null,this.childLanes=this.lanes=0,this.alternate=null}function Dl(l,t,u,a){return new wd(l,t,u,a)}function wc(l){return l=l.prototype,!(!l||!l.isReactComponent)}function dt(l,t){var u=l.alternate;return u===null?(u=Dl(l.tag,t,l.key,l.mode),u.elementType=l.elementType,u.type=l.type,u.stateNode=l.stateNode,u.alternate=l,l.alternate=u):(u.pendingProps=t,u.type=l.type,u.flags=0,u.subtreeFlags=0,u.deletions=null),u.flags=l.flags&65011712,u.childLanes=l.childLanes,u.lanes=l.lanes,u.child=l.child,u.memoizedProps=l.memoizedProps,u.memoizedState=l.memoizedState,u.updateQueue=l.updateQueue,t=l.dependencies,u.dependencies=t===null?null:{lanes:t.lanes,firstContext:t.firstContext},u.sibling=l.sibling,u.index=l.index,u.ref=l.ref,u.refCleanup=l.refCleanup,u}function Sy(l,t){l.flags&=65011714;var u=l.alternate;return u===null?(l.childLanes=0,l.lanes=t,l.child=null,l.subtreeFlags=0,l.memoizedProps=null,l.memoizedState=null,l.updateQueue=null,l.dependencies=null,l.stateNode=null):(l.childLanes=u.childLanes,l.lanes=u.lanes,l.child=u.child,l.subtreeFlags=0,l.deletions=null,l.memoizedProps=u.memoizedProps,l.memoizedState=u.memoizedState,l.updateQueue=u.updateQueue,l.type=u.type,t=u.dependencies,l.dependencies=t===null?null:{lanes:t.lanes,firstContext:t.firstContext}),l}function Qn(l,t,u,a,n,e){var f=0;if(a=l,typeof l=="function")wc(l)&&(f=1);else if(typeof l=="string")f=Fh(l,u,Il.current)?26:l==="html"||l==="head"||l==="body"?27:5;else l:switch(l){case Vf:return l=Dl(31,u,t,n),l.elementType=Vf,l.lanes=e,l;case Du:return au(u.children,n,e,t);case R1:f=8,n|=24;break;case Qf:return l=Dl(12,u,t,n|2),l.elementType=Qf,l.lanes=e,l;case Zf:return l=Dl(13,u,t,n),l.elementType=Zf,l.lanes=e,l;case jf:return l=Dl(19,u,t,n),l.elementType=jf,l.lanes=e,l;default:if(typeof l=="object"&&l!==null)switch(l.$$typeof){case yt:f=10;break l;case p1:f=9;break l;case Rc:f=11;break l;case pc:f=14;break l;case Ot:f=16,a=null;break l}f=29,u=Error(b(130,l===null?"null":typeof l,"")),a=null}return t=Dl(f,u,t,n),t.elementType=l,t.type=a,t.lanes=e,t}function au(l,t,u,a){return l=Dl(7,l,a,t),l.lanes=u,l}function of(l,t,u){return l=Dl(6,l,null,t),l.lanes=u,l}function gy(l){var t=Dl(18,null,null,0);return t.stateNode=l,t}function sf(l,t,u){return t=Dl(4,l.children!==null?l.children:[],l.key,t),t.lanes=u,t.stateNode={containerInfo:l.containerInfo,pendingChildren:null,implementation:l.implementation},t}var _0=new WeakMap;function jl(l,t){if(typeof l=="object"&&l!==null){var u=_0.get(l);return u!==void 0?u:(t={value:l,source:t,stack:f0(t)},_0.set(l,t),t)}return{value:l,source:t,stack:f0(t)}}var Cu=[],Gu=0,ue=null,xa=0,Xl=[],Ql=0,Kt=null,$l=1,Fl="";function ct(l,t){Cu[Gu++]=xa,Cu[Gu++]=ue,ue=l,xa=t}function oy(l,t,u){Xl[Ql++]=$l,Xl[Ql++]=Fl,Xl[Ql++]=Kt,Kt=l;var a=$l;l=Fl;var n=32-ql(a)-1;a&=~(1<<n),u+=1;var e=32-ql(t)+n;if(30<e){var f=n-n%5;e=(a&(1<<f)-1).toString(32),a>>=f,n-=f,$l=1<<32-ql(t)+n|u<<n|a,Fl=e+l}else $l=1<<e|u<<n|a,Fl=l}function Wc(l){l.return!==null&&(ct(l,1),oy(l,1,0))}function $c(l){for(;l===ue;)ue=Cu[--Gu],Cu[Gu]=null,xa=Cu[--Gu],Cu[Gu]=null;for(;l===Kt;)Kt=Xl[--Ql],Xl[Ql]=null,Fl=Xl[--Ql],Xl[Ql]=null,$l=Xl[--Ql],Xl[Ql]=null}function sy(l,t){Xl[Ql++]=$l,Xl[Ql++]=Fl,Xl[Ql++]=Kt,$l=t.id,Fl=t.overflow,Kt=l}var vl=null,J=null,Y=!1,Gt=null,Vl=!1,tc=Error(b(519));function Jt(l){var t=Error(b(418,1<arguments.length&&arguments[1]!==void 0&&arguments[1]?"text":"HTML",""));throw La(jl(t,l)),tc}function D0(l){var t=l.stateNode,u=l.type,a=l.memoizedProps;switch(t[yl]=l,t[Al]=a,u){case"dialog":U("cancel",t),U("close",t);break;case"iframe":case"object":case"embed":U("load",t);break;case"video":case"audio":for(u=0;u<wa.length;u++)U(wa[u],t);break;case"source":U("error",t);break;case"img":case"image":case"link":U("error",t),U("load",t);break;case"details":U("toggle",t);break;case"input":U("invalid",t),w1(t,a.value,a.defaultValue,a.checked,a.defaultChecked,a.type,a.name,!0);break;case"select":U("invalid",t);break;case"textarea":U("invalid",t),$1(t,a.value,a.defaultValue,a.children)}u=a.children,typeof u!="string"&&typeof u!="number"&&typeof u!="bigint"||t.textContent===""+u||a.suppressHydrationWarning===!0||Pv(t.textContent,u)?(a.popover!=null&&(U("beforetoggle",t),U("toggle",t)),a.onScroll!=null&&U("scroll",t),a.onScrollEnd!=null&&U("scrollend",t),a.onClick!=null&&(t.onclick=vt),t=!0):t=!1,t||Jt(l,!0)}function U0(l){for(vl=l.return;vl;)switch(vl.tag){case 5:case 31:case 13:Vl=!1;return;case 27:case 3:Vl=!0;return;default:vl=vl.return}}function Au(l){if(l!==vl)return!1;if(!Y)return U0(l),Y=!0,!1;var t=l.tag,u;if((u=t!==3&&t!==27)&&((u=t===5)&&(u=l.type,u=!(u!=="form"&&u!=="button")||Dc(l.type,l.memoizedProps)),u=!u),u&&J&&Jt(l),U0(l),t===13){if(l=l.memoizedState,l=l!==null?l.dehydrated:null,!l)throw Error(b(317));J=g1(l)}else if(t===31){if(l=l.memoizedState,l=l!==null?l.dehydrated:null,!l)throw Error(b(317));J=g1(l)}else t===27?(t=J,$t(l.type)?(l=qc,qc=null,J=l):J=t):J=vl?Ll(l.stateNode.nextSibling):null;return!0}function cu(){J=vl=null,Y=!1}function bf(){var l=Gt;return l!==null&&(Tl===null?Tl=l:Tl.push.apply(Tl,l),Gt=null),l}function La(l){Gt===null?Gt=[l]:Gt.push(l)}var uc=Pl(null),ou=null,mt=null;function Dt(l,t,u){x(uc,t._currentValue),t._currentValue=u}function ht(l){l._currentValue=uc.current,cl(uc)}function ac(l,t,u){for(;l!==null;){var a=l.alternate;if((l.childLanes&t)!==t?(l.childLanes|=t,a!==null&&(a.childLanes|=t)):a!==null&&(a.childLanes&t)!==t&&(a.childLanes|=t),l===u)break;l=l.return}}function nc(l,t,u,a){var n=l.child;for(n!==null&&(n.return=l);n!==null;){var e=n.dependencies;if(e!==null){var f=n.child;e=e.firstContext;l:for(;e!==null;){var c=e;e=n;for(var i=0;i<t.length;i++)if(c.context===t[i]){e.lanes|=u,c=e.alternate,c!==null&&(c.lanes|=u),ac(e.return,u,l),a||(f=null);break l}e=c.next}}else if(n.tag===18){if(f=n.return,f===null)throw Error(b(341));f.lanes|=u,e=f.alternate,e!==null&&(e.lanes|=u),ac(f,u,l),f=null}else f=n.child;if(f!==null)f.return=n;else for(f=n;f!==null;){if(f===l){f=null;break}if(n=f.sibling,n!==null){n.return=f.return,f=n;break}f=f.return}n=f}}function na(l,t,u,a){l=null;for(var n=t,e=!1;n!==null;){if(!e){if((n.flags&524288)!==0)e=!0;else if((n.flags&262144)!==0)break}if(n.tag===10){var f=n.alternate;if(f===null)throw Error(b(387));if(f=f.memoizedProps,f!==null){var c=n.type;Bl(n.pendingProps.value,f.value)||(l!==null?l.push(c):l=[c])}}else if(n===$n.current){if(f=n.alternate,f===null)throw Error(b(387));f.memoizedState.memoizedState!==n.memoizedState.memoizedState&&(l!==null?l.push($a):l=[$a])}n=n.return}l!==null&&nc(t,l,u,a),t.flags|=262144}function ae(l){for(l=l.firstContext;l!==null;){if(!Bl(l.context._currentValue,l.memoizedValue))return!0;l=l.next}return!1}function iu(l){ou=l,mt=null,l=l.dependencies,l!==null&&(l.firstContext=null)}function ml(l){return by(ou,l)}function On(l,t){return ou===null&&iu(l),by(l,t)}function by(l,t){var u=t._currentValue;if(t={context:t,memoizedValue:u,next:null},mt===null){if(l===null)throw Error(b(308));mt=t,l.dependencies={lanes:0,firstContext:t},l.flags|=524288}else mt=mt.next=t;return u}var Wd=typeof AbortController<"u"?AbortController:function(){var l=[],t=this.signal={aborted:!1,addEventListener:function(u,a){l.push(a)}};this.abort=function(){t.aborted=!0,l.forEach(function(u){return u()})}},$d=nl.unstable_scheduleCallback,Fd=nl.unstable_NormalPriority,tl={$$typeof:yt,Consumer:null,Provider:null,_currentValue:null,_currentValue2:null,_threadCount:0};function Fc(){return{controller:new Wd,data:new Map,refCount:0}}function nn(l){l.refCount--,l.refCount===0&&$d(Fd,function(){l.controller.abort()})}var Ha=null,ec=0,Wu=0,Vu=null;function kd(l,t){if(Ha===null){var u=Ha=[];ec=0,Wu=Ei(),Vu={status:"pending",value:void 0,then:function(a){u.push(a)}}}return ec++,t.then(H0,H0),t}function H0(){if(--ec===0&&Ha!==null){Vu!==null&&(Vu.status="fulfilled");var l=Ha;Ha=null,Wu=0,Vu=null;for(var t=0;t<l.length;t++)(0,l[t])()}}function Id(l,t){var u=[],a={status:"pending",value:null,reason:null,then:function(n){u.push(n)}};return l.then(function(){a.status="fulfilled",a.value=t;for(var n=0;n<u.length;n++)(0,u[n])(t)},function(n){for(a.status="rejected",a.reason=n,n=0;n<u.length;n++)(0,u[n])(void 0)}),a}var N0=M.S;M.S=function(l,t){Bv=Hl(),typeof t=="object"&&t!==null&&typeof t.then=="function"&&kd(l,t),N0!==null&&N0(l,t)};var nu=Pl(null);function kc(){var l=nu.current;return l!==null?l:V.pooledCache}function Zn(l,t){t===null?x(nu,nu.current):x(nu,t.pool)}function zy(){var l=kc();return l===null?null:{parent:tl._currentValue,pool:l}}var ea=Error(b(460)),Ic=Error(b(474)),qe=Error(b(542)),ne={then:function(){}};function q0(l){return l=l.status,l==="fulfilled"||l==="rejected"}function Ty(l,t,u){switch(u=l[u],u===void 0?l.push(t):u!==t&&(t.then(vt,vt),t=u),t.status){case"fulfilled":return t.value;case"rejected":throw l=t.reason,B0(l),l;default:if(typeof t.status=="string")t.then(vt,vt);else{if(l=V,l!==null&&100<l.shellSuspendCounter)throw Error(b(482));l=t,l.status="pending",l.then(function(a){if(t.status==="pending"){var n=t;n.status="fulfilled",n.value=a}},function(a){if(t.status==="pending"){var n=t;n.status="rejected",n.reason=a}})}switch(t.status){case"fulfilled":return t.value;case"rejected":throw l=t.reason,B0(l),l}throw eu=t,ea}}function lu(l){try{var t=l._init;return t(l._payload)}catch(u){throw u!==null&&typeof u=="object"&&typeof u.then=="function"?(eu=u,ea):u}}var eu=null;function Y0(){if(eu===null)throw Error(b(459));var l=eu;return eu=null,l}function B0(l){if(l===ea||l===qe)throw Error(b(483))}var xu=null,Ka=0;function _n(l){var t=Ka;return Ka+=1,xu===null&&(xu=[]),Ty(xu,l,t)}function ga(l,t){t=t.props.ref,l.ref=t!==void 0?t:null}function Dn(l,t){throw t.$$typeof===Qm?Error(b(525)):(l=Object.prototype.toString.call(t),Error(b(31,l==="[object Object]"?"object with keys {"+Object.keys(t).join(", ")+"}":l)))}function Ey(l){function t(v,y){if(l){var d=v.deletions;d===null?(v.deletions=[y],v.flags|=16):d.push(y)}}function u(v,y){if(!l)return null;for(;y!==null;)t(v,y),y=y.sibling;return null}function a(v){for(var y=new Map;v!==null;)v.key!==null?y.set(v.key,v):y.set(v.index,v),v=v.sibling;return y}function n(v,y){return v=dt(v,y),v.index=0,v.sibling=null,v}function e(v,y,d){return v.index=d,l?(d=v.alternate,d!==null?(d=d.index,d<y?(v.flags|=67108866,y):d):(v.flags|=67108866,y)):(v.flags|=1048576,y)}function f(v){return l&&v.alternate===null&&(v.flags|=67108866),v}function c(v,y,d,o){return y===null||y.tag!==6?(y=of(d,v.mode,o),y.return=v,y):(y=n(y,d),y.return=v,y)}function i(v,y,d,o){var E=d.type;return E===Du?g(v,y,d.props.children,o,d.key):y!==null&&(y.elementType===E||typeof E=="object"&&E!==null&&E.$$typeof===Ot&&lu(E)===y.type)?(y=n(y,d.props),ga(y,d),y.return=v,y):(y=Qn(d.type,d.key,d.props,null,v.mode,o),ga(y,d),y.return=v,y)}function m(v,y,d,o){return y===null||y.tag!==4||y.stateNode.containerInfo!==d.containerInfo||y.stateNode.implementation!==d.implementation?(y=sf(d,v.mode,o),y.return=v,y):(y=n(y,d.children||[]),y.return=v,y)}function g(v,y,d,o,E){return y===null||y.tag!==7?(y=au(d,v.mode,o,E),y.return=v,y):(y=n(y,d),y.return=v,y)}function s(v,y,d){if(typeof y=="string"&&y!==""||typeof y=="number"||typeof y=="bigint")return y=of(""+y,v.mode,d),y.return=v,y;if(typeof y=="object"&&y!==null){switch(y.$$typeof){case on:return d=Qn(y.type,y.key,y.props,null,v.mode,d),ga(d,y),d.return=v,d;case Ta:return y=sf(y,v.mode,d),y.return=v,y;case Ot:return y=lu(y),s(v,y,d)}if(Ea(y)||ha(y))return y=au(y,v.mode,d,null),y.return=v,y;if(typeof y.then=="function")return s(v,_n(y),d);if(y.$$typeof===yt)return s(v,On(v,y),d);Dn(v,y)}return null}function h(v,y,d,o){var E=y!==null?y.key:null;if(typeof d=="string"&&d!==""||typeof d=="number"||typeof d=="bigint")return E!==null?null:c(v,y,""+d,o);if(typeof d=="object"&&d!==null){switch(d.$$typeof){case on:return d.key===E?i(v,y,d,o):null;case Ta:return d.key===E?m(v,y,d,o):null;case Ot:return d=lu(d),h(v,y,d,o)}if(Ea(d)||ha(d))return E!==null?null:g(v,y,d,o,null);if(typeof d.then=="function")return h(v,y,_n(d),o);if(d.$$typeof===yt)return h(v,y,On(v,d),o);Dn(v,d)}return null}function S(v,y,d,o,E){if(typeof o=="string"&&o!==""||typeof o=="number"||typeof o=="bigint")return v=v.get(d)||null,c(y,v,""+o,E);if(typeof o=="object"&&o!==null){switch(o.$$typeof){case on:return v=v.get(o.key===null?d:o.key)||null,i(y,v,o,E);case Ta:return v=v.get(o.key===null?d:o.key)||null,m(y,v,o,E);case Ot:return o=lu(o),S(v,y,d,o,E)}if(Ea(o)||ha(o))return v=v.get(d)||null,g(y,v,o,E,null);if(typeof o.then=="function")return S(v,y,d,_n(o),E);if(o.$$typeof===yt)return S(v,y,d,On(y,o),E);Dn(y,o)}return null}function z(v,y,d,o){for(var E=null,B=null,T=y,D=y=0,N=null;T!==null&&D<d.length;D++){T.index>D?(N=T,T=null):N=T.sibling;var R=h(v,T,d[D],o);if(R===null){T===null&&(T=N);break}l&&T&&R.alternate===null&&t(v,T),y=e(R,y,D),B===null?E=R:B.sibling=R,B=R,T=N}if(D===d.length)return u(v,T),Y&&ct(v,D),E;if(T===null){for(;D<d.length;D++)T=s(v,d[D],o),T!==null&&(y=e(T,y,D),B===null?E=T:B.sibling=T,B=T);return Y&&ct(v,D),E}for(T=a(T);D<d.length;D++)N=S(T,v,D,d[D],o),N!==null&&(l&&N.alternate!==null&&T.delete(N.key===null?D:N.key),y=e(N,y,D),B===null?E=N:B.sibling=N,B=N);return l&&T.forEach(function(Et){return t(v,Et)}),Y&&ct(v,D),E}function A(v,y,d,o){if(d==null)throw Error(b(151));for(var E=null,B=null,T=y,D=y=0,N=null,R=d.next();T!==null&&!R.done;D++,R=d.next()){T.index>D?(N=T,T=null):N=T.sibling;var Et=h(v,T,R.value,o);if(Et===null){T===null&&(T=N);break}l&&T&&Et.alternate===null&&t(v,T),y=e(Et,y,D),B===null?E=Et:B.sibling=Et,B=Et,T=N}if(R.done)return u(v,T),Y&&ct(v,D),E;if(T===null){for(;!R.done;D++,R=d.next())R=s(v,R.value,o),R!==null&&(y=e(R,y,D),B===null?E=R:B.sibling=R,B=R);return Y&&ct(v,D),E}for(T=a(T);!R.done;D++,R=d.next())R=S(T,v,D,R.value,o),R!==null&&(l&&R.alternate!==null&&T.delete(R.key===null?D:R.key),y=e(R,y,D),B===null?E=R:B.sibling=R,B=R);return l&&T.forEach(function(gm){return t(v,gm)}),Y&&ct(v,D),E}function Q(v,y,d,o){if(typeof d=="object"&&d!==null&&d.type===Du&&d.key===null&&(d=d.props.children),typeof d=="object"&&d!==null){switch(d.$$typeof){case on:l:{for(var E=d.key;y!==null;){if(y.key===E){if(E=d.type,E===Du){if(y.tag===7){u(v,y.sibling),o=n(y,d.props.children),o.return=v,v=o;break l}}else if(y.elementType===E||typeof E=="object"&&E!==null&&E.$$typeof===Ot&&lu(E)===y.type){u(v,y.sibling),o=n(y,d.props),ga(o,d),o.return=v,v=o;break l}u(v,y);break}else t(v,y);y=y.sibling}d.type===Du?(o=au(d.props.children,v.mode,o,d.key),o.return=v,v=o):(o=Qn(d.type,d.key,d.props,null,v.mode,o),ga(o,d),o.return=v,v=o)}return f(v);case Ta:l:{for(E=d.key;y!==null;){if(y.key===E)if(y.tag===4&&y.stateNode.containerInfo===d.containerInfo&&y.stateNode.implementation===d.implementation){u(v,y.sibling),o=n(y,d.children||[]),o.return=v,v=o;break l}else{u(v,y);break}else t(v,y);y=y.sibling}o=sf(d,v.mode,o),o.return=v,v=o}return f(v);case Ot:return d=lu(d),Q(v,y,d,o)}if(Ea(d))return z(v,y,d,o);if(ha(d)){if(E=ha(d),typeof E!="function")throw Error(b(150));return d=E.call(d),A(v,y,d,o)}if(typeof d.then=="function")return Q(v,y,_n(d),o);if(d.$$typeof===yt)return Q(v,y,On(v,d),o);Dn(v,d)}return typeof d=="string"&&d!==""||typeof d=="number"||typeof d=="bigint"?(d=""+d,y!==null&&y.tag===6?(u(v,y.sibling),o=n(y,d),o.return=v,v=o):(u(v,y),o=of(d,v.mode,o),o.return=v,v=o),f(v)):u(v,y)}return function(v,y,d,o){try{Ka=0;var E=Q(v,y,d,o);return xu=null,E}catch(T){if(T===ea||T===qe)throw T;var B=Dl(29,T,null,v.mode);return B.lanes=o,B.return=v,B}finally{}}}var yu=Ey(!0),Ay=Ey(!1),_t=!1;function Pc(l){l.updateQueue={baseState:l.memoizedState,firstBaseUpdate:null,lastBaseUpdate:null,shared:{pending:null,lanes:0,hiddenCallbacks:null},callbacks:null}}function fc(l,t){l=l.updateQueue,t.updateQueue===l&&(t.updateQueue={baseState:l.baseState,firstBaseUpdate:l.firstBaseUpdate,lastBaseUpdate:l.lastBaseUpdate,shared:l.shared,callbacks:null})}function Xt(l){return{lane:l,tag:0,payload:null,callback:null,next:null}}function Qt(l,t,u){var a=l.updateQueue;if(a===null)return null;if(a=a.shared,(p&2)!==0){var n=a.pending;return n===null?t.next=t:(t.next=n.next,n.next=t),a.pending=t,t=te(l),hy(l,null,u),t}return Ne(l,a,t,u),te(l)}function Na(l,t,u){if(t=t.updateQueue,t!==null&&(t=t.shared,(u&4194048)!==0)){var a=t.lanes;a&=l.pendingLanes,u|=a,t.lanes=u,j1(l,u)}}function zf(l,t){var u=l.updateQueue,a=l.alternate;if(a!==null&&(a=a.updateQueue,u===a)){var n=null,e=null;if(u=u.firstBaseUpdate,u!==null){do{var f={lane:u.lane,tag:u.tag,payload:u.payload,callback:null,next:null};e===null?n=e=f:e=e.next=f,u=u.next}while(u!==null);e===null?n=e=t:e=e.next=t}else n=e=t;u={baseState:a.baseState,firstBaseUpdate:n,lastBaseUpdate:e,shared:a.shared,callbacks:a.callbacks},l.updateQueue=u;return}l=u.lastBaseUpdate,l===null?u.firstBaseUpdate=t:l.next=t,u.lastBaseUpdate=t}var cc=!1;function qa(){if(cc){var l=Vu;if(l!==null)throw l}}function Ya(l,t,u,a){cc=!1;var n=l.updateQueue;_t=!1;var e=n.firstBaseUpdate,f=n.lastBaseUpdate,c=n.shared.pending;if(c!==null){n.shared.pending=null;var i=c,m=i.next;i.next=null,f===null?e=m:f.next=m,f=i;var g=l.alternate;g!==null&&(g=g.updateQueue,c=g.lastBaseUpdate,c!==f&&(c===null?g.firstBaseUpdate=m:c.next=m,g.lastBaseUpdate=i))}if(e!==null){var s=n.baseState;f=0,g=m=i=null,c=e;do{var h=c.lane&-536870913,S=h!==c.lane;if(S?(q&h)===h:(a&h)===h){h!==0&&h===Wu&&(cc=!0),g!==null&&(g=g.next={lane:0,tag:c.tag,payload:c.payload,callback:null,next:null});l:{var z=l,A=c;h=t;var Q=u;switch(A.tag){case 1:if(z=A.payload,typeof z=="function"){s=z.call(Q,s,h);break l}s=z;break l;case 3:z.flags=z.flags&-65537|128;case 0:if(z=A.payload,h=typeof z=="function"?z.call(Q,s,h):z,h==null)break l;s=r({},s,h);break l;case 2:_t=!0}}h=c.callback,h!==null&&(l.flags|=64,S&&(l.flags|=8192),S=n.callbacks,S===null?n.callbacks=[h]:S.push(h))}else S={lane:h,tag:c.tag,payload:c.payload,callback:c.callback,next:null},g===null?(m=g=S,i=s):g=g.next=S,f|=h;if(c=c.next,c===null){if(c=n.shared.pending,c===null)break;S=c,c=S.next,S.next=null,n.lastBaseUpdate=S,n.shared.pending=null}}while(!0);g===null&&(i=s),n.baseState=i,n.firstBaseUpdate=m,n.lastBaseUpdate=g,e===null&&(n.shared.lanes=0),wt|=f,l.lanes=f,l.memoizedState=s}}function My(l,t){if(typeof l!="function")throw Error(b(191,l));l.call(t)}function Oy(l,t){var u=l.callbacks;if(u!==null)for(l.callbacks=null,l=0;l<u.length;l++)My(u[l],t)}var $u=Pl(null),ee=Pl(0);function R0(l,t){l=zt,x(ee,l),x($u,t),zt=l|t.baseLanes}function ic(){x(ee,zt),x($u,$u.current)}function li(){zt=ee.current,cl($u),cl(ee)}var Rl=Pl(null),xl=null;function Ut(l){var t=l.alternate;x(k,k.current&1),x(Rl,l),xl===null&&(t===null||$u.current!==null||t.memoizedState!==null)&&(xl=l)}function yc(l){x(k,k.current),x(Rl,l),xl===null&&(xl=l)}function _y(l){l.tag===22?(x(k,k.current),x(Rl,l),xl===null&&(xl=l)):Ht(l)}function Ht(){x(k,k.current),x(Rl,Rl.current)}function _l(l){cl(Rl),xl===l&&(xl=null),cl(k)}var k=Pl(0);function fe(l){for(var t=l;t!==null;){if(t.tag===13){var u=t.memoizedState;if(u!==null&&(u=u.dehydrated,u===null||Hc(u)||Nc(u)))return t}else if(t.tag===19&&(t.memoizedProps.revealOrder==="forwards"||t.memoizedProps.revealOrder==="backwards"||t.memoizedProps.revealOrder==="unstable_legacy-backwards"||t.memoizedProps.revealOrder==="together")){if((t.flags&128)!==0)return t}else if(t.child!==null){t.child.return=t,t=t.child;continue}if(t===l)break;for(;t.sibling===null;){if(t.return===null||t.return===l)return null;t=t.return}t.sibling.return=t.return,t=t.sibling}return null}var ot=0,_=null,j=null,P=null,ce=!1,Lu=!1,vu=!1,ie=0,Ja=0,Ku=null,Pd=0;function $(){throw Error(b(321))}function ti(l,t){if(t===null)return!1;for(var u=0;u<t.length&&u<l.length;u++)if(!Bl(l[u],t[u]))return!1;return!0}function ui(l,t,u,a,n,e){return ot=e,_=t,t.memoizedState=null,t.updateQueue=null,t.lanes=0,M.H=l===null||l.memoizedState===null?uv:hi,vu=!1,e=u(a,n),vu=!1,Lu&&(e=Uy(t,u,a,n)),Dy(l),e}function Dy(l){M.H=ra;var t=j!==null&&j.next!==null;if(ot=0,P=j=_=null,ce=!1,Ja=0,Ku=null,t)throw Error(b(300));l===null||ul||(l=l.dependencies,l!==null&&ae(l)&&(ul=!0))}function Uy(l,t,u,a){_=l;var n=0;do{if(Lu&&(Ku=null),Ja=0,Lu=!1,25<=n)throw Error(b(301));if(n+=1,P=j=null,l.updateQueue!=null){var e=l.updateQueue;e.lastEffect=null,e.events=null,e.stores=null,e.memoCache!=null&&(e.memoCache.index=0)}M.H=av,e=t(u,a)}while(Lu);return e}function lh(){var l=M.H,t=l.useState()[0];return t=typeof t.then=="function"?en(t):t,l=l.useState()[0],(j!==null?j.memoizedState:null)!==l&&(_.flags|=1024),t}function ai(){var l=ie!==0;return ie=0,l}function ni(l,t,u){t.updateQueue=l.updateQueue,t.flags&=-2053,l.lanes&=~u}function ei(l){if(ce){for(l=l.memoizedState;l!==null;){var t=l.queue;t!==null&&(t.pending=null),l=l.next}ce=!1}ot=0,P=j=_=null,Lu=!1,Ja=ie=0,Ku=null}function ol(){var l={memoizedState:null,baseState:null,baseQueue:null,queue:null,next:null};return P===null?_.memoizedState=P=l:P=P.next=l,P}function I(){if(j===null){var l=_.alternate;l=l!==null?l.memoizedState:null}else l=j.next;var t=P===null?_.memoizedState:P.next;if(t!==null)P=t,j=l;else{if(l===null)throw _.alternate===null?Error(b(467)):Error(b(310));j=l,l={memoizedState:j.memoizedState,baseState:j.baseState,baseQueue:j.baseQueue,queue:j.queue,next:null},P===null?_.memoizedState=P=l:P=P.next=l}return P}function Ye(){return{lastEffect:null,events:null,stores:null,memoCache:null}}function en(l){var t=Ja;return Ja+=1,Ku===null&&(Ku=[]),l=Ty(Ku,l,t),t=_,(P===null?t.memoizedState:P.next)===null&&(t=t.alternate,M.H=t===null||t.memoizedState===null?uv:hi),l}function Be(l){if(l!==null&&typeof l=="object"){if(typeof l.then=="function")return en(l);if(l.$$typeof===yt)return ml(l)}throw Error(b(438,String(l)))}function fi(l){var t=null,u=_.updateQueue;if(u!==null&&(t=u.memoCache),t==null){var a=_.alternate;a!==null&&(a=a.updateQueue,a!==null&&(a=a.memoCache,a!=null&&(t={data:a.data.map(function(n){return n.slice()}),index:0})))}if(t==null&&(t={data:[],index:0}),u===null&&(u=Ye(),_.updateQueue=u),u.memoCache=t,u=t.data[t.index],u===void 0)for(u=t.data[t.index]=Array(l),a=0;a<l;a++)u[a]=Zm;return t.index++,u}function st(l,t){return typeof t=="function"?t(l):t}function jn(l){var t=I();return ci(t,j,l)}function ci(l,t,u){var a=l.queue;if(a===null)throw Error(b(311));a.lastRenderedReducer=u;var n=l.baseQueue,e=a.pending;if(e!==null){if(n!==null){var f=n.next;n.next=e.next,e.next=f}t.baseQueue=n=e,a.pending=null}if(e=l.baseState,n===null)l.memoizedState=e;else{t=n.next;var c=f=null,i=null,m=t,g=!1;do{var s=m.lane&-536870913;if(s!==m.lane?(q&s)===s:(ot&s)===s){var h=m.revertLane;if(h===0)i!==null&&(i=i.next={lane:0,revertLane:0,gesture:null,action:m.action,hasEagerState:m.hasEagerState,eagerState:m.eagerState,next:null}),s===Wu&&(g=!0);else if((ot&h)===h){m=m.next,h===Wu&&(g=!0);continue}else s={lane:0,revertLane:m.revertLane,gesture:null,action:m.action,hasEagerState:m.hasEagerState,eagerState:m.eagerState,next:null},i===null?(c=i=s,f=e):i=i.next=s,_.lanes|=h,wt|=h;s=m.action,vu&&u(e,s),e=m.hasEagerState?m.eagerState:u(e,s)}else h={lane:s,revertLane:m.revertLane,gesture:m.gesture,action:m.action,hasEagerState:m.hasEagerState,eagerState:m.eagerState,next:null},i===null?(c=i=h,f=e):i=i.next=h,_.lanes|=s,wt|=s;m=m.next}while(m!==null&&m!==t);if(i===null?f=e:i.next=c,!Bl(e,l.memoizedState)&&(ul=!0,g&&(u=Vu,u!==null)))throw u;l.memoizedState=e,l.baseState=f,l.baseQueue=i,a.lastRenderedState=e}return n===null&&(a.lanes=0),[l.memoizedState,a.dispatch]}function Tf(l){var t=I(),u=t.queue;if(u===null)throw Error(b(311));u.lastRenderedReducer=l;var a=u.dispatch,n=u.pending,e=t.memoizedState;if(n!==null){u.pending=null;var f=n=n.next;do e=l(e,f.action),f=f.next;while(f!==n);Bl(e,t.memoizedState)||(ul=!0),t.memoizedState=e,t.baseQueue===null&&(t.baseState=e),u.lastRenderedState=e}return[e,a]}function Hy(l,t,u){var a=_,n=I(),e=Y;if(e){if(u===void 0)throw Error(b(407));u=u()}else u=t();var f=!Bl((j||n).memoizedState,u);if(f&&(n.memoizedState=u,ul=!0),n=n.queue,ii(Yy.bind(null,a,n,l),[l]),n.getSnapshot!==t||f||P!==null&&P.memoizedState.tag&1){if(a.flags|=2048,Fu(9,{destroy:void 0},qy.bind(null,a,n,u,t),null),V===null)throw Error(b(349));e||(ot&127)!==0||Ny(a,t,u)}return u}function Ny(l,t,u){l.flags|=16384,l={getSnapshot:t,value:u},t=_.updateQueue,t===null?(t=Ye(),_.updateQueue=t,t.stores=[l]):(u=t.stores,u===null?t.stores=[l]:u.push(l))}function qy(l,t,u,a){t.value=u,t.getSnapshot=a,By(t)&&Ry(l)}function Yy(l,t,u){return u(function(){By(t)&&Ry(l)})}function By(l){var t=l.getSnapshot;l=l.value;try{var u=t();return!Bl(l,u)}catch{return!0}}function Ry(l){var t=gu(l,2);t!==null&&El(t,l,2)}function vc(l){var t=ol();if(typeof l=="function"){var u=l;if(l=u(),vu){qt(!0);try{u()}finally{qt(!1)}}}return t.memoizedState=t.baseState=l,t.queue={pending:null,lanes:0,dispatch:null,lastRenderedReducer:st,lastRenderedState:l},t}function py(l,t,u,a){return l.baseState=u,ci(l,j,typeof a=="function"?a:st)}function th(l,t,u,a,n){if(pe(l))throw Error(b(485));if(l=t.action,l!==null){var e={payload:n,action:l,next:null,isTransition:!0,status:"pending",value:null,reason:null,listeners:[],then:function(f){e.listeners.push(f)}};M.T!==null?u(!0):e.isTransition=!1,a(e),u=t.pending,u===null?(e.next=t.pending=e,Cy(t,e)):(e.next=u.next,t.pending=u.next=e)}}function Cy(l,t){var u=t.action,a=t.payload,n=l.state;if(t.isTransition){var e=M.T,f={};M.T=f;try{var c=u(n,a),i=M.S;i!==null&&i(f,c),p0(l,t,c)}catch(m){mc(l,t,m)}finally{e!==null&&f.types!==null&&(e.types=f.types),M.T=e}}else try{e=u(n,a),p0(l,t,e)}catch(m){mc(l,t,m)}}function p0(l,t,u){u!==null&&typeof u=="object"&&typeof u.then=="function"?u.then(function(a){C0(l,t,a)},function(a){return mc(l,t,a)}):C0(l,t,u)}function C0(l,t,u){t.status="fulfilled",t.value=u,Gy(t),l.state=u,t=l.pending,t!==null&&(u=t.next,u===t?l.pending=null:(u=u.next,t.next=u,Cy(l,u)))}function mc(l,t,u){var a=l.pending;if(l.pending=null,a!==null){a=a.next;do t.status="rejected",t.reason=u,Gy(t),t=t.next;while(t!==a)}l.action=null}function Gy(l){l=l.listeners;for(var t=0;t<l.length;t++)(0,l[t])()}function Xy(l,t){return t}function G0(l,t){if(Y){var u=V.formState;if(u!==null){l:{var a=_;if(Y){if(J){t:{for(var n=J,e=Vl;n.nodeType!==8;){if(!e){n=null;break t}if(n=Ll(n.nextSibling),n===null){n=null;break t}}e=n.data,n=e==="F!"||e==="F"?n:null}if(n){J=Ll(n.nextSibling),a=n.data==="F!";break l}}Jt(a)}a=!1}a&&(t=u[0])}}return u=ol(),u.memoizedState=u.baseState=t,a={pending:null,lanes:0,dispatch:null,lastRenderedReducer:Xy,lastRenderedState:t},u.queue=a,u=Py.bind(null,_,a),a.dispatch=u,a=vc(!1),e=di.bind(null,_,!1,a.queue),a=ol(),n={state:t,dispatch:null,action:l,pending:null},a.queue=n,u=th.bind(null,_,n,e,u),n.dispatch=u,a.memoizedState=l,[t,u,!1]}function X0(l){var t=I();return Qy(t,j,l)}function Qy(l,t,u){if(t=ci(l,t,Xy)[0],l=jn(st)[0],typeof t=="object"&&t!==null&&typeof t.then=="function")try{var a=en(t)}catch(f){throw f===ea?qe:f}else a=t;t=I();var n=t.queue,e=n.dispatch;return u!==t.memoizedState&&(_.flags|=2048,Fu(9,{destroy:void 0},uh.bind(null,n,u),null)),[a,e,l]}function uh(l,t){l.action=t}function Q0(l){var t=I(),u=j;if(u!==null)return Qy(t,u,l);I(),t=t.memoizedState,u=I();var a=u.queue.dispatch;return u.memoizedState=l,[t,a,!1]}function Fu(l,t,u,a){return l={tag:l,create:u,deps:a,inst:t,next:null},t=_.updateQueue,t===null&&(t=Ye(),_.updateQueue=t),u=t.lastEffect,u===null?t.lastEffect=l.next=l:(a=u.next,u.next=l,l.next=a,t.lastEffect=l),l}function Zy(){return I().memoizedState}function Vn(l,t,u,a){var n=ol();_.flags|=l,n.memoizedState=Fu(1|t,{destroy:void 0},u,a===void 0?null:a)}function Re(l,t,u,a){var n=I();a=a===void 0?null:a;var e=n.memoizedState.inst;j!==null&&a!==null&&ti(a,j.memoizedState.deps)?n.memoizedState=Fu(t,e,u,a):(_.flags|=l,n.memoizedState=Fu(1|t,e,u,a))}function Z0(l,t){Vn(8390656,8,l,t)}function ii(l,t){Re(2048,8,l,t)}function ah(l){_.flags|=4;var t=_.updateQueue;if(t===null)t=Ye(),_.updateQueue=t,t.events=[l];else{var u=t.events;u===null?t.events=[l]:u.push(l)}}function jy(l){var t=I().memoizedState;return ah({ref:t,nextImpl:l}),function(){if((p&2)!==0)throw Error(b(440));return t.impl.apply(void 0,arguments)}}function Vy(l,t){return Re(4,2,l,t)}function xy(l,t){return Re(4,4,l,t)}function Ly(l,t){if(typeof t=="function"){l=l();var u=t(l);return function(){typeof u=="function"?u():t(null)}}if(t!=null)return l=l(),t.current=l,function(){t.current=null}}function Ky(l,t,u){u=u!=null?u.concat([l]):null,Re(4,4,Ly.bind(null,t,l),u)}function yi(){}function Jy(l,t){var u=I();t=t===void 0?null:t;var a=u.memoizedState;return t!==null&&ti(t,a[1])?a[0]:(u.memoizedState=[l,t],l)}function ry(l,t){var u=I();t=t===void 0?null:t;var a=u.memoizedState;if(t!==null&&ti(t,a[1]))return a[0];if(a=l(),vu){qt(!0);try{l()}finally{qt(!1)}}return u.memoizedState=[a,t],a}function vi(l,t,u){return u===void 0||(ot&1073741824)!==0&&(q&261930)===0?l.memoizedState=t:(l.memoizedState=u,l=pv(),_.lanes|=l,wt|=l,u)}function wy(l,t,u,a){return Bl(u,t)?u:$u.current!==null?(l=vi(l,u,a),Bl(l,t)||(ul=!0),l):(ot&42)===0||(ot&1073741824)!==0&&(q&261930)===0?(ul=!0,l.memoizedState=u):(l=pv(),_.lanes|=l,wt|=l,t)}function Wy(l,t,u,a,n){var e=C.p;C.p=e!==0&&8>e?e:8;var f=M.T,c={};M.T=c,di(l,!1,t,u);try{var i=n(),m=M.S;if(m!==null&&m(c,i),i!==null&&typeof i=="object"&&typeof i.then=="function"){var g=Id(i,a);Ba(l,t,g,Yl(l))}else Ba(l,t,a,Yl(l))}catch(s){Ba(l,t,{then:function(){},status:"rejected",reason:s},Yl())}finally{C.p=e,f!==null&&c.types!==null&&(f.types=c.types),M.T=f}}function nh(){}function dc(l,t,u,a){if(l.tag!==5)throw Error(b(476));var n=$y(l).queue;Wy(l,n,t,uu,u===null?nh:function(){return Fy(l),u(a)})}function $y(l){var t=l.memoizedState;if(t!==null)return t;t={memoizedState:uu,baseState:uu,baseQueue:null,queue:{pending:null,lanes:0,dispatch:null,lastRenderedReducer:st,lastRenderedState:uu},next:null};var u={};return t.next={memoizedState:u,baseState:u,baseQueue:null,queue:{pending:null,lanes:0,dispatch:null,lastRenderedReducer:st,lastRenderedState:u},next:null},l.memoizedState=t,l=l.alternate,l!==null&&(l.memoizedState=t),t}function Fy(l){var t=$y(l);t.next===null&&(t=l.alternate.memoizedState),Ba(l,t.next.queue,{},Yl())}function mi(){return ml($a)}function ky(){return I().memoizedState}function Iy(){return I().memoizedState}function eh(l){for(var t=l.return;t!==null;){switch(t.tag){case 24:case 3:var u=Yl();l=Xt(u);var a=Qt(t,l,u);a!==null&&(El(a,t,u),Na(a,t,u)),t={cache:Fc()},l.payload=t;return}t=t.return}}function fh(l,t,u){var a=Yl();u={lane:a,revertLane:0,gesture:null,action:u,hasEagerState:!1,eagerState:null,next:null},pe(l)?lv(t,u):(u=rc(l,t,u,a),u!==null&&(El(u,l,a),tv(u,t,a)))}function Py(l,t,u){var a=Yl();Ba(l,t,u,a)}function Ba(l,t,u,a){var n={lane:a,revertLane:0,gesture:null,action:u,hasEagerState:!1,eagerState:null,next:null};if(pe(l))lv(t,n);else{var e=l.alternate;if(l.lanes===0&&(e===null||e.lanes===0)&&(e=t.lastRenderedReducer,e!==null))try{var f=t.lastRenderedState,c=e(f,u);if(n.hasEagerState=!0,n.eagerState=c,Bl(c,f))return Ne(l,t,n,0),V===null&&He(),!1}catch{}finally{}if(u=rc(l,t,n,a),u!==null)return El(u,l,a),tv(u,t,a),!0}return!1}function di(l,t,u,a){if(a={lane:2,revertLane:Ei(),gesture:null,action:a,hasEagerState:!1,eagerState:null,next:null},pe(l)){if(t)throw Error(b(479))}else t=rc(l,u,a,2),t!==null&&El(t,l,2)}function pe(l){var t=l.alternate;return l===_||t!==null&&t===_}function lv(l,t){Lu=ce=!0;var u=l.pending;u===null?t.next=t:(t.next=u.next,u.next=t),l.pending=t}function tv(l,t,u){if((u&4194048)!==0){var a=t.lanes;a&=l.pendingLanes,u|=a,t.lanes=u,j1(l,u)}}var ra={readContext:ml,use:Be,useCallback:$,useContext:$,useEffect:$,useImperativeHandle:$,useLayoutEffect:$,useInsertionEffect:$,useMemo:$,useReducer:$,useRef:$,useState:$,useDebugValue:$,useDeferredValue:$,useTransition:$,useSyncExternalStore:$,useId:$,useHostTransitionStatus:$,useFormState:$,useActionState:$,useOptimistic:$,useMemoCache:$,useCacheRefresh:$};ra.useEffectEvent=$;var uv={readContext:ml,use:Be,useCallback:function(l,t){return ol().memoizedState=[l,t===void 0?null:t],l},useContext:ml,useEffect:Z0,useImperativeHandle:function(l,t,u){u=u!=null?u.concat([l]):null,Vn(4194308,4,Ly.bind(null,t,l),u)},useLayoutEffect:function(l,t){return Vn(4194308,4,l,t)},useInsertionEffect:function(l,t){Vn(4,2,l,t)},useMemo:function(l,t){var u=ol();t=t===void 0?null:t;var a=l();if(vu){qt(!0);try{l()}finally{qt(!1)}}return u.memoizedState=[a,t],a},useReducer:function(l,t,u){var a=ol();if(u!==void 0){var n=u(t);if(vu){qt(!0);try{u(t)}finally{qt(!1)}}}else n=t;return a.memoizedState=a.baseState=n,l={pending:null,lanes:0,dispatch:null,lastRenderedReducer:l,lastRenderedState:n},a.queue=l,l=l.dispatch=fh.bind(null,_,l),[a.memoizedState,l]},useRef:function(l){var t=ol();return l={current:l},t.memoizedState=l},useState:function(l){l=vc(l);var t=l.queue,u=Py.bind(null,_,t);return t.dispatch=u,[l.memoizedState,u]},useDebugValue:yi,useDeferredValue:function(l,t){var u=ol();return vi(u,l,t)},useTransition:function(){var l=vc(!1);return l=Wy.bind(null,_,l.queue,!0,!1),ol().memoizedState=l,[!1,l]},useSyncExternalStore:function(l,t,u){var a=_,n=ol();if(Y){if(u===void 0)throw Error(b(407));u=u()}else{if(u=t(),V===null)throw Error(b(349));(q&127)!==0||Ny(a,t,u)}n.memoizedState=u;var e={value:u,getSnapshot:t};return n.queue=e,Z0(Yy.bind(null,a,e,l),[l]),a.flags|=2048,Fu(9,{destroy:void 0},qy.bind(null,a,e,u,t),null),u},useId:function(){var l=ol(),t=V.identifierPrefix;if(Y){var u=Fl,a=$l;u=(a&~(1<<32-ql(a)-1)).toString(32)+u,t="_"+t+"R_"+u,u=ie++,0<u&&(t+="H"+u.toString(32)),t+="_"}else u=Pd++,t="_"+t+"r_"+u.toString(32)+"_";return l.memoizedState=t},useHostTransitionStatus:mi,useFormState:G0,useActionState:G0,useOptimistic:function(l){var t=ol();t.memoizedState=t.baseState=l;var u={pending:null,lanes:0,dispatch:null,lastRenderedReducer:null,lastRenderedState:null};return t.queue=u,t=di.bind(null,_,!0,u),u.dispatch=t,[l,t]},useMemoCache:fi,useCacheRefresh:function(){return ol().memoizedState=eh.bind(null,_)},useEffectEvent:function(l){var t=ol(),u={impl:l};return t.memoizedState=u,function(){if((p&2)!==0)throw Error(b(440));return u.impl.apply(void 0,arguments)}}},hi={readContext:ml,use:Be,useCallback:Jy,useContext:ml,useEffect:ii,useImperativeHandle:Ky,useInsertionEffect:Vy,useLayoutEffect:xy,useMemo:ry,useReducer:jn,useRef:Zy,useState:function(){return jn(st)},useDebugValue:yi,useDeferredValue:function(l,t){var u=I();return wy(u,j.memoizedState,l,t)},useTransition:function(){var l=jn(st)[0],t=I().memoizedState;return[typeof l=="boolean"?l:en(l),t]},useSyncExternalStore:Hy,useId:ky,useHostTransitionStatus:mi,useFormState:X0,useActionState:X0,useOptimistic:function(l,t){var u=I();return py(u,j,l,t)},useMemoCache:fi,useCacheRefresh:Iy};hi.useEffectEvent=jy;var av={readContext:ml,use:Be,useCallback:Jy,useContext:ml,useEffect:ii,useImperativeHandle:Ky,useInsertionEffect:Vy,useLayoutEffect:xy,useMemo:ry,useReducer:Tf,useRef:Zy,useState:function(){return Tf(st)},useDebugValue:yi,useDeferredValue:function(l,t){var u=I();return j===null?vi(u,l,t):wy(u,j.memoizedState,l,t)},useTransition:function(){var l=Tf(st)[0],t=I().memoizedState;return[typeof l=="boolean"?l:en(l),t]},useSyncExternalStore:Hy,useId:ky,useHostTransitionStatus:mi,useFormState:Q0,useActionState:Q0,useOptimistic:function(l,t){var u=I();return j!==null?py(u,j,l,t):(u.baseState=l,[l,u.queue.dispatch])},useMemoCache:fi,useCacheRefresh:Iy};av.useEffectEvent=jy;function Ef(l,t,u,a){t=l.memoizedState,u=u(a,t),u=u==null?t:r({},t,u),l.memoizedState=u,l.lanes===0&&(l.updateQueue.baseState=u)}var hc={enqueueSetState:function(l,t,u){l=l._reactInternals;var a=Yl(),n=Xt(a);n.payload=t,u!=null&&(n.callback=u),t=Qt(l,n,a),t!==null&&(El(t,l,a),Na(t,l,a))},enqueueReplaceState:function(l,t,u){l=l._reactInternals;var a=Yl(),n=Xt(a);n.tag=1,n.payload=t,u!=null&&(n.callback=u),t=Qt(l,n,a),t!==null&&(El(t,l,a),Na(t,l,a))},enqueueForceUpdate:function(l,t){l=l._reactInternals;var u=Yl(),a=Xt(u);a.tag=2,t!=null&&(a.callback=t),t=Qt(l,a,u),t!==null&&(El(t,l,u),Na(t,l,u))}};function j0(l,t,u,a,n,e,f){return l=l.stateNode,typeof l.shouldComponentUpdate=="function"?l.shouldComponentUpdate(a,e,f):t.prototype&&t.prototype.isPureReactComponent?!Va(u,a)||!Va(n,e):!0}function V0(l,t,u,a){l=t.state,typeof t.componentWillReceiveProps=="function"&&t.componentWillReceiveProps(u,a),typeof t.UNSAFE_componentWillReceiveProps=="function"&&t.UNSAFE_componentWillReceiveProps(u,a),t.state!==l&&hc.enqueueReplaceState(t,t.state,null)}function mu(l,t){var u=t;if("ref"in t){u={};for(var a in t)a!=="ref"&&(u[a]=t[a])}if(l=l.defaultProps){u===t&&(u=r({},u));for(var n in l)u[n]===void 0&&(u[n]=l[n])}return u}function nv(l){le(l)}function ev(l){console.error(l)}function fv(l){le(l)}function ye(l,t){try{var u=l.onUncaughtError;u(t.value,{componentStack:t.stack})}catch(a){setTimeout(function(){throw a})}}function x0(l,t,u){try{var a=l.onCaughtError;a(u.value,{componentStack:u.stack,errorBoundary:t.tag===1?t.stateNode:null})}catch(n){setTimeout(function(){throw n})}}function Sc(l,t,u){return u=Xt(u),u.tag=3,u.payload={element:null},u.callback=function(){ye(l,t)},u}function cv(l){return l=Xt(l),l.tag=3,l}function iv(l,t,u,a){var n=u.type.getDerivedStateFromError;if(typeof n=="function"){var e=a.value;l.payload=function(){return n(e)},l.callback=function(){x0(t,u,a)}}var f=u.stateNode;f!==null&&typeof f.componentDidCatch=="function"&&(l.callback=function(){x0(t,u,a),typeof n!="function"&&(Zt===null?Zt=new Set([this]):Zt.add(this));var c=a.stack;this.componentDidCatch(a.value,{componentStack:c!==null?c:""})})}function ch(l,t,u,a,n){if(u.flags|=32768,a!==null&&typeof a=="object"&&typeof a.then=="function"){if(t=u.alternate,t!==null&&na(t,u,n,!0),u=Rl.current,u!==null){switch(u.tag){case 31:case 13:return xl===null?Se():u.alternate===null&&F===0&&(F=3),u.flags&=-257,u.flags|=65536,u.lanes=n,a===ne?u.flags|=16384:(t=u.updateQueue,t===null?u.updateQueue=new Set([a]):t.add(a),Bf(l,a,n)),!1;case 22:return u.flags|=65536,a===ne?u.flags|=16384:(t=u.updateQueue,t===null?(t={transitions:null,markerInstances:null,retryQueue:new Set([a])},u.updateQueue=t):(u=t.retryQueue,u===null?t.retryQueue=new Set([a]):u.add(a)),Bf(l,a,n)),!1}throw Error(b(435,u.tag))}return Bf(l,a,n),Se(),!1}if(Y)return t=Rl.current,t!==null?((t.flags&65536)===0&&(t.flags|=256),t.flags|=65536,t.lanes=n,a!==tc&&(l=Error(b(422),{cause:a}),La(jl(l,u)))):(a!==tc&&(t=Error(b(423),{cause:a}),La(jl(t,u))),l=l.current.alternate,l.flags|=65536,n&=-n,l.lanes|=n,a=jl(a,u),n=Sc(l.stateNode,a,n),zf(l,n),F!==4&&(F=2)),!1;var e=Error(b(520),{cause:a});if(e=jl(e,u),Ca===null?Ca=[e]:Ca.push(e),F!==4&&(F=2),t===null)return!0;a=jl(a,u),u=t;do{switch(u.tag){case 3:return u.flags|=65536,l=n&-n,u.lanes|=l,l=Sc(u.stateNode,a,l),zf(u,l),!1;case 1:if(t=u.type,e=u.stateNode,(u.flags&128)===0&&(typeof t.getDerivedStateFromError=="function"||e!==null&&typeof e.componentDidCatch=="function"&&(Zt===null||!Zt.has(e))))return u.flags|=65536,n&=-n,u.lanes|=n,n=cv(n),iv(n,l,u,a),zf(u,n),!1}u=u.return}while(u!==null);return!1}var Si=Error(b(461)),ul=!1;function il(l,t,u,a){t.child=l===null?Ay(t,null,u,a):yu(t,l.child,u,a)}function L0(l,t,u,a,n){u=u.render;var e=t.ref;if("ref"in a){var f={};for(var c in a)c!=="ref"&&(f[c]=a[c])}else f=a;return iu(t),a=ui(l,t,u,f,e,n),c=ai(),l!==null&&!ul?(ni(l,t,n),bt(l,t,n)):(Y&&c&&Wc(t),t.flags|=1,il(l,t,a,n),t.child)}function K0(l,t,u,a,n){if(l===null){var e=u.type;return typeof e=="function"&&!wc(e)&&e.defaultProps===void 0&&u.compare===null?(t.tag=15,t.type=e,yv(l,t,e,a,n)):(l=Qn(u.type,null,a,t,t.mode,n),l.ref=t.ref,l.return=t,t.child=l)}if(e=l.child,!gi(l,n)){var f=e.memoizedProps;if(u=u.compare,u=u!==null?u:Va,u(f,a)&&l.ref===t.ref)return bt(l,t,n)}return t.flags|=1,l=dt(e,a),l.ref=t.ref,l.return=t,t.child=l}function yv(l,t,u,a,n){if(l!==null){var e=l.memoizedProps;if(Va(e,a)&&l.ref===t.ref)if(ul=!1,t.pendingProps=a=e,gi(l,n))(l.flags&131072)!==0&&(ul=!0);else return t.lanes=l.lanes,bt(l,t,n)}return gc(l,t,u,a,n)}function vv(l,t,u,a){var n=a.children,e=l!==null?l.memoizedState:null;if(l===null&&t.stateNode===null&&(t.stateNode={_visibility:1,_pendingMarkers:null,_retryCache:null,_transitions:null}),a.mode==="hidden"){if((t.flags&128)!==0){if(e=e!==null?e.baseLanes|u:u,l!==null){for(a=t.child=l.child,n=0;a!==null;)n=n|a.lanes|a.childLanes,a=a.sibling;a=n&~e}else a=0,t.child=null;return J0(l,t,e,u,a)}if((u&536870912)!==0)t.memoizedState={baseLanes:0,cachePool:null},l!==null&&Zn(t,e!==null?e.cachePool:null),e!==null?R0(t,e):ic(),_y(t);else return a=t.lanes=536870912,J0(l,t,e!==null?e.baseLanes|u:u,u,a)}else e!==null?(Zn(t,e.cachePool),R0(t,e),Ht(t),t.memoizedState=null):(l!==null&&Zn(t,null),ic(),Ht(t));return il(l,t,n,u),t.child}function Ma(l,t){return l!==null&&l.tag===22||t.stateNode!==null||(t.stateNode={_visibility:1,_pendingMarkers:null,_retryCache:null,_transitions:null}),t.sibling}function J0(l,t,u,a,n){var e=kc();return e=e===null?null:{parent:tl._currentValue,pool:e},t.memoizedState={baseLanes:u,cachePool:e},l!==null&&Zn(t,null),ic(),_y(t),l!==null&&na(l,t,a,!0),t.childLanes=n,null}function xn(l,t){return t=ve({mode:t.mode,children:t.children},l.mode),t.ref=l.ref,l.child=t,t.return=l,t}function r0(l,t,u){return yu(t,l.child,null,u),l=xn(t,t.pendingProps),l.flags|=2,_l(t),t.memoizedState=null,l}function ih(l,t,u){var a=t.pendingProps,n=(t.flags&128)!==0;if(t.flags&=-129,l===null){if(Y){if(a.mode==="hidden")return l=xn(t,a),t.lanes=536870912,Ma(null,l);if(yc(t),(l=J)?(l=um(l,Vl),l=l!==null&&l.data==="&"?l:null,l!==null&&(t.memoizedState={dehydrated:l,treeContext:Kt!==null?{id:$l,overflow:Fl}:null,retryLane:536870912,hydrationErrors:null},u=gy(l),u.return=t,t.child=u,vl=t,J=null)):l=null,l===null)throw Jt(t);return t.lanes=536870912,null}return xn(t,a)}var e=l.memoizedState;if(e!==null){var f=e.dehydrated;if(yc(t),n)if(t.flags&256)t.flags&=-257,t=r0(l,t,u);else if(t.memoizedState!==null)t.child=l.child,t.flags|=128,t=null;else throw Error(b(558));else if(ul||na(l,t,u,!1),n=(u&l.childLanes)!==0,ul||n){if(a=V,a!==null&&(f=V1(a,u),f!==0&&f!==e.retryLane))throw e.retryLane=f,gu(l,f),El(a,l,f),Si;Se(),t=r0(l,t,u)}else l=e.treeContext,J=Ll(f.nextSibling),vl=t,Y=!0,Gt=null,Vl=!1,l!==null&&sy(t,l),t=xn(t,a),t.flags|=4096;return t}return l=dt(l.child,{mode:a.mode,children:a.children}),l.ref=t.ref,t.child=l,l.return=t,l}function Ln(l,t){var u=t.ref;if(u===null)l!==null&&l.ref!==null&&(t.flags|=4194816);else{if(typeof u!="function"&&typeof u!="object")throw Error(b(284));(l===null||l.ref!==u)&&(t.flags|=4194816)}}function gc(l,t,u,a,n){return iu(t),u=ui(l,t,u,a,void 0,n),a=ai(),l!==null&&!ul?(ni(l,t,n),bt(l,t,n)):(Y&&a&&Wc(t),t.flags|=1,il(l,t,u,n),t.child)}function w0(l,t,u,a,n,e){return iu(t),t.updateQueue=null,u=Uy(t,a,u,n),Dy(l),a=ai(),l!==null&&!ul?(ni(l,t,e),bt(l,t,e)):(Y&&a&&Wc(t),t.flags|=1,il(l,t,u,e),t.child)}function W0(l,t,u,a,n){if(iu(t),t.stateNode===null){var e=pu,f=u.contextType;typeof f=="object"&&f!==null&&(e=ml(f)),e=new u(a,e),t.memoizedState=e.state!==null&&e.state!==void 0?e.state:null,e.updater=hc,t.stateNode=e,e._reactInternals=t,e=t.stateNode,e.props=a,e.state=t.memoizedState,e.refs={},Pc(t),f=u.contextType,e.context=typeof f=="object"&&f!==null?ml(f):pu,e.state=t.memoizedState,f=u.getDerivedStateFromProps,typeof f=="function"&&(Ef(t,u,f,a),e.state=t.memoizedState),typeof u.getDerivedStateFromProps=="function"||typeof e.getSnapshotBeforeUpdate=="function"||typeof e.UNSAFE_componentWillMount!="function"&&typeof e.componentWillMount!="function"||(f=e.state,typeof e.componentWillMount=="function"&&e.componentWillMount(),typeof e.UNSAFE_componentWillMount=="function"&&e.UNSAFE_componentWillMount(),f!==e.state&&hc.enqueueReplaceState(e,e.state,null),Ya(t,a,e,n),qa(),e.state=t.memoizedState),typeof e.componentDidMount=="function"&&(t.flags|=4194308),a=!0}else if(l===null){e=t.stateNode;var c=t.memoizedProps,i=mu(u,c);e.props=i;var m=e.context,g=u.contextType;f=pu,typeof g=="object"&&g!==null&&(f=ml(g));var s=u.getDerivedStateFromProps;g=typeof s=="function"||typeof e.getSnapshotBeforeUpdate=="function",c=t.pendingProps!==c,g||typeof e.UNSAFE_componentWillReceiveProps!="function"&&typeof e.componentWillReceiveProps!="function"||(c||m!==f)&&V0(t,e,a,f),_t=!1;var h=t.memoizedState;e.state=h,Ya(t,a,e,n),qa(),m=t.memoizedState,c||h!==m||_t?(typeof s=="function"&&(Ef(t,u,s,a),m=t.memoizedState),(i=_t||j0(t,u,i,a,h,m,f))?(g||typeof e.UNSAFE_componentWillMount!="function"&&typeof e.componentWillMount!="function"||(typeof e.componentWillMount=="function"&&e.componentWillMount(),typeof e.UNSAFE_componentWillMount=="function"&&e.UNSAFE_componentWillMount()),typeof e.componentDidMount=="function"&&(t.flags|=4194308)):(typeof e.componentDidMount=="function"&&(t.flags|=4194308),t.memoizedProps=a,t.memoizedState=m),e.props=a,e.state=m,e.context=f,a=i):(typeof e.componentDidMount=="function"&&(t.flags|=4194308),a=!1)}else{e=t.stateNode,fc(l,t),f=t.memoizedProps,g=mu(u,f),e.props=g,s=t.pendingProps,h=e.context,m=u.contextType,i=pu,typeof m=="object"&&m!==null&&(i=ml(m)),c=u.getDerivedStateFromProps,(m=typeof c=="function"||typeof e.getSnapshotBeforeUpdate=="function")||typeof e.UNSAFE_componentWillReceiveProps!="function"&&typeof e.componentWillReceiveProps!="function"||(f!==s||h!==i)&&V0(t,e,a,i),_t=!1,h=t.memoizedState,e.state=h,Ya(t,a,e,n),qa();var S=t.memoizedState;f!==s||h!==S||_t||l!==null&&l.dependencies!==null&&ae(l.dependencies)?(typeof c=="function"&&(Ef(t,u,c,a),S=t.memoizedState),(g=_t||j0(t,u,g,a,h,S,i)||l!==null&&l.dependencies!==null&&ae(l.dependencies))?(m||typeof e.UNSAFE_componentWillUpdate!="function"&&typeof e.componentWillUpdate!="function"||(typeof e.componentWillUpdate=="function"&&e.componentWillUpdate(a,S,i),typeof e.UNSAFE_componentWillUpdate=="function"&&e.UNSAFE_componentWillUpdate(a,S,i)),typeof e.componentDidUpdate=="function"&&(t.flags|=4),typeof e.getSnapshotBeforeUpdate=="function"&&(t.flags|=1024)):(typeof e.componentDidUpdate!="function"||f===l.memoizedProps&&h===l.memoizedState||(t.flags|=4),typeof e.getSnapshotBeforeUpdate!="function"||f===l.memoizedProps&&h===l.memoizedState||(t.flags|=1024),t.memoizedProps=a,t.memoizedState=S),e.props=a,e.state=S,e.context=i,a=g):(typeof e.componentDidUpdate!="function"||f===l.memoizedProps&&h===l.memoizedState||(t.flags|=4),typeof e.getSnapshotBeforeUpdate!="function"||f===l.memoizedProps&&h===l.memoizedState||(t.flags|=1024),a=!1)}return e=a,Ln(l,t),a=(t.flags&128)!==0,e||a?(e=t.stateNode,u=a&&typeof u.getDerivedStateFromError!="function"?null:e.render(),t.flags|=1,l!==null&&a?(t.child=yu(t,l.child,null,n),t.child=yu(t,null,u,n)):il(l,t,u,n),t.memoizedState=e.state,l=t.child):l=bt(l,t,n),l}function $0(l,t,u,a){return cu(),t.flags|=256,il(l,t,u,a),t.child}var Af={dehydrated:null,treeContext:null,retryLane:0,hydrationErrors:null};function Mf(l){return{baseLanes:l,cachePool:zy()}}function Of(l,t,u){return l=l!==null?l.childLanes&~u:0,t&&(l|=Ul),l}function mv(l,t,u){var a=t.pendingProps,n=!1,e=(t.flags&128)!==0,f;if((f=e)||(f=l!==null&&l.memoizedState===null?!1:(k.current&2)!==0),f&&(n=!0,t.flags&=-129),f=(t.flags&32)!==0,t.flags&=-33,l===null){if(Y){if(n?Ut(t):Ht(t),(l=J)?(l=um(l,Vl),l=l!==null&&l.data!=="&"?l:null,l!==null&&(t.memoizedState={dehydrated:l,treeContext:Kt!==null?{id:$l,overflow:Fl}:null,retryLane:536870912,hydrationErrors:null},u=gy(l),u.return=t,t.child=u,vl=t,J=null)):l=null,l===null)throw Jt(t);return Nc(l)?t.lanes=32:t.lanes=536870912,null}var c=a.children;return a=a.fallback,n?(Ht(t),n=t.mode,c=ve({mode:"hidden",children:c},n),a=au(a,n,u,null),c.return=t,a.return=t,c.sibling=a,t.child=c,a=t.child,a.memoizedState=Mf(u),a.childLanes=Of(l,f,u),t.memoizedState=Af,Ma(null,a)):(Ut(t),oc(t,c))}var i=l.memoizedState;if(i!==null&&(c=i.dehydrated,c!==null)){if(e)t.flags&256?(Ut(t),t.flags&=-257,t=_f(l,t,u)):t.memoizedState!==null?(Ht(t),t.child=l.child,t.flags|=128,t=null):(Ht(t),c=a.fallback,n=t.mode,a=ve({mode:"visible",children:a.children},n),c=au(c,n,u,null),c.flags|=2,a.return=t,c.return=t,a.sibling=c,t.child=a,yu(t,l.child,null,u),a=t.child,a.memoizedState=Mf(u),a.childLanes=Of(l,f,u),t.memoizedState=Af,t=Ma(null,a));else if(Ut(t),Nc(c)){if(f=c.nextSibling&&c.nextSibling.dataset,f)var m=f.dgst;f=m,a=Error(b(419)),a.stack="",a.digest=f,La({value:a,source:null,stack:null}),t=_f(l,t,u)}else if(ul||na(l,t,u,!1),f=(u&l.childLanes)!==0,ul||f){if(f=V,f!==null&&(a=V1(f,u),a!==0&&a!==i.retryLane))throw i.retryLane=a,gu(l,a),El(f,l,a),Si;Hc(c)||Se(),t=_f(l,t,u)}else Hc(c)?(t.flags|=192,t.child=l.child,t=null):(l=i.treeContext,J=Ll(c.nextSibling),vl=t,Y=!0,Gt=null,Vl=!1,l!==null&&sy(t,l),t=oc(t,a.children),t.flags|=4096);return t}return n?(Ht(t),c=a.fallback,n=t.mode,i=l.child,m=i.sibling,a=dt(i,{mode:"hidden",children:a.children}),a.subtreeFlags=i.subtreeFlags&65011712,m!==null?c=dt(m,c):(c=au(c,n,u,null),c.flags|=2),c.return=t,a.return=t,a.sibling=c,t.child=a,Ma(null,a),a=t.child,c=l.child.memoizedState,c===null?c=Mf(u):(n=c.cachePool,n!==null?(i=tl._currentValue,n=n.parent!==i?{parent:i,pool:i}:n):n=zy(),c={baseLanes:c.baseLanes|u,cachePool:n}),a.memoizedState=c,a.childLanes=Of(l,f,u),t.memoizedState=Af,Ma(l.child,a)):(Ut(t),u=l.child,l=u.sibling,u=dt(u,{mode:"visible",children:a.children}),u.return=t,u.sibling=null,l!==null&&(f=t.deletions,f===null?(t.deletions=[l],t.flags|=16):f.push(l)),t.child=u,t.memoizedState=null,u)}function oc(l,t){return t=ve({mode:"visible",children:t},l.mode),t.return=l,l.child=t}function ve(l,t){return l=Dl(22,l,null,t),l.lanes=0,l}function _f(l,t,u){return yu(t,l.child,null,u),l=oc(t,t.pendingProps.children),l.flags|=2,t.memoizedState=null,l}function F0(l,t,u){l.lanes|=t;var a=l.alternate;a!==null&&(a.lanes|=t),ac(l.return,t,u)}function Df(l,t,u,a,n,e){var f=l.memoizedState;f===null?l.memoizedState={isBackwards:t,rendering:null,renderingStartTime:0,last:a,tail:u,tailMode:n,treeForkCount:e}:(f.isBackwards=t,f.rendering=null,f.renderingStartTime=0,f.last=a,f.tail=u,f.tailMode=n,f.treeForkCount=e)}function dv(l,t,u){var a=t.pendingProps,n=a.revealOrder,e=a.tail;a=a.children;var f=k.current,c=(f&2)!==0;if(c?(f=f&1|2,t.flags|=128):f&=1,x(k,f),il(l,t,a,u),a=Y?xa:0,!c&&l!==null&&(l.flags&128)!==0)l:for(l=t.child;l!==null;){if(l.tag===13)l.memoizedState!==null&&F0(l,u,t);else if(l.tag===19)F0(l,u,t);else if(l.child!==null){l.child.return=l,l=l.child;continue}if(l===t)break l;for(;l.sibling===null;){if(l.return===null||l.return===t)break l;l=l.return}l.sibling.return=l.return,l=l.sibling}switch(n){case"forwards":for(u=t.child,n=null;u!==null;)l=u.alternate,l!==null&&fe(l)===null&&(n=u),u=u.sibling;u=n,u===null?(n=t.child,t.child=null):(n=u.sibling,u.sibling=null),Df(t,!1,n,u,e,a);break;case"backwards":case"unstable_legacy-backwards":for(u=null,n=t.child,t.child=null;n!==null;){if(l=n.alternate,l!==null&&fe(l)===null){t.child=n;break}l=n.sibling,n.sibling=u,u=n,n=l}Df(t,!0,u,null,e,a);break;case"together":Df(t,!1,null,null,void 0,a);break;default:t.memoizedState=null}return t.child}function bt(l,t,u){if(l!==null&&(t.dependencies=l.dependencies),wt|=t.lanes,(u&t.childLanes)===0)if(l!==null){if(na(l,t,u,!1),(u&t.childLanes)===0)return null}else return null;if(l!==null&&t.child!==l.child)throw Error(b(153));if(t.child!==null){for(l=t.child,u=dt(l,l.pendingProps),t.child=u,u.return=t;l.sibling!==null;)l=l.sibling,u=u.sibling=dt(l,l.pendingProps),u.return=t;u.sibling=null}return t.child}function gi(l,t){return(l.lanes&t)!==0?!0:(l=l.dependencies,!!(l!==null&&ae(l)))}function yh(l,t,u){switch(t.tag){case 3:Fn(t,t.stateNode.containerInfo),Dt(t,tl,l.memoizedState.cache),cu();break;case 27:case 5:Kf(t);break;case 4:Fn(t,t.stateNode.containerInfo);break;case 10:Dt(t,t.type,t.memoizedProps.value);break;case 31:if(t.memoizedState!==null)return t.flags|=128,yc(t),null;break;case 13:var a=t.memoizedState;if(a!==null)return a.dehydrated!==null?(Ut(t),t.flags|=128,null):(u&t.child.childLanes)!==0?mv(l,t,u):(Ut(t),l=bt(l,t,u),l!==null?l.sibling:null);Ut(t);break;case 19:var n=(l.flags&128)!==0;if(a=(u&t.childLanes)!==0,a||(na(l,t,u,!1),a=(u&t.childLanes)!==0),n){if(a)return dv(l,t,u);t.flags|=128}if(n=t.memoizedState,n!==null&&(n.rendering=null,n.tail=null,n.lastEffect=null),x(k,k.current),a)break;return null;case 22:return t.lanes=0,vv(l,t,u,t.pendingProps);case 24:Dt(t,tl,l.memoizedState.cache)}return bt(l,t,u)}function hv(l,t,u){if(l!==null)if(l.memoizedProps!==t.pendingProps)ul=!0;else{if(!gi(l,u)&&(t.flags&128)===0)return ul=!1,yh(l,t,u);ul=(l.flags&131072)!==0}else ul=!1,Y&&(t.flags&1048576)!==0&&oy(t,xa,t.index);switch(t.lanes=0,t.tag){case 16:l:{var a=t.pendingProps;if(l=lu(t.elementType),t.type=l,typeof l=="function")wc(l)?(a=mu(l,a),t.tag=1,t=W0(null,t,l,a,u)):(t.tag=0,t=gc(null,t,l,a,u));else{if(l!=null){var n=l.$$typeof;if(n===Rc){t.tag=11,t=L0(null,t,l,a,u);break l}else if(n===pc){t.tag=14,t=K0(null,t,l,a,u);break l}}throw t=xf(l)||l,Error(b(306,t,""))}}return t;case 0:return gc(l,t,t.type,t.pendingProps,u);case 1:return a=t.type,n=mu(a,t.pendingProps),W0(l,t,a,n,u);case 3:l:{if(Fn(t,t.stateNode.containerInfo),l===null)throw Error(b(387));a=t.pendingProps;var e=t.memoizedState;n=e.element,fc(l,t),Ya(t,a,null,u);var f=t.memoizedState;if(a=f.cache,Dt(t,tl,a),a!==e.cache&&nc(t,[tl],u,!0),qa(),a=f.element,e.isDehydrated)if(e={element:a,isDehydrated:!1,cache:f.cache},t.updateQueue.baseState=e,t.memoizedState=e,t.flags&256){t=$0(l,t,a,u);break l}else if(a!==n){n=jl(Error(b(424)),t),La(n),t=$0(l,t,a,u);break l}else{switch(l=t.stateNode.containerInfo,l.nodeType){case 9:l=l.body;break;default:l=l.nodeName==="HTML"?l.ownerDocument.body:l}for(J=Ll(l.firstChild),vl=t,Y=!0,Gt=null,Vl=!0,u=Ay(t,null,a,u),t.child=u;u;)u.flags=u.flags&-3|4096,u=u.sibling}else{if(cu(),a===n){t=bt(l,t,u);break l}il(l,t,a,u)}t=t.child}return t;case 26:return Ln(l,t),l===null?(u=b1(t.type,null,t.pendingProps,null))?t.memoizedState=u:Y||(u=t.type,l=t.pendingProps,a=be(Ct.current).createElement(u),a[yl]=t,a[Al]=l,dl(a,u,l),fl(a),t.stateNode=a):t.memoizedState=b1(t.type,l.memoizedProps,t.pendingProps,l.memoizedState),null;case 27:return Kf(t),l===null&&Y&&(a=t.stateNode=am(t.type,t.pendingProps,Ct.current),vl=t,Vl=!0,n=J,$t(t.type)?(qc=n,J=Ll(a.firstChild)):J=n),il(l,t,t.pendingProps.children,u),Ln(l,t),l===null&&(t.flags|=4194304),t.child;case 5:return l===null&&Y&&((n=a=J)&&(a=Xh(a,t.type,t.pendingProps,Vl),a!==null?(t.stateNode=a,vl=t,J=Ll(a.firstChild),Vl=!1,n=!0):n=!1),n||Jt(t)),Kf(t),n=t.type,e=t.pendingProps,f=l!==null?l.memoizedProps:null,a=e.children,Dc(n,e)?a=null:f!==null&&Dc(n,f)&&(t.flags|=32),t.memoizedState!==null&&(n=ui(l,t,lh,null,null,u),$a._currentValue=n),Ln(l,t),il(l,t,a,u),t.child;case 6:return l===null&&Y&&((l=u=J)&&(u=Qh(u,t.pendingProps,Vl),u!==null?(t.stateNode=u,vl=t,J=null,l=!0):l=!1),l||Jt(t)),null;case 13:return mv(l,t,u);case 4:return Fn(t,t.stateNode.containerInfo),a=t.pendingProps,l===null?t.child=yu(t,null,a,u):il(l,t,a,u),t.child;case 11:return L0(l,t,t.type,t.pendingProps,u);case 7:return il(l,t,t.pendingProps,u),t.child;case 8:return il(l,t,t.pendingProps.children,u),t.child;case 12:return il(l,t,t.pendingProps.children,u),t.child;case 10:return a=t.pendingProps,Dt(t,t.type,a.value),il(l,t,a.children,u),t.child;case 9:return n=t.type._context,a=t.pendingProps.children,iu(t),n=ml(n),a=a(n),t.flags|=1,il(l,t,a,u),t.child;case 14:return K0(l,t,t.type,t.pendingProps,u);case 15:return yv(l,t,t.type,t.pendingProps,u);case 19:return dv(l,t,u);case 31:return ih(l,t,u);case 22:return vv(l,t,u,t.pendingProps);case 24:return iu(t),a=ml(tl),l===null?(n=kc(),n===null&&(n=V,e=Fc(),n.pooledCache=e,e.refCount++,e!==null&&(n.pooledCacheLanes|=u),n=e),t.memoizedState={parent:a,cache:n},Pc(t),Dt(t,tl,n)):((l.lanes&u)!==0&&(fc(l,t),Ya(t,null,null,u),qa()),n=l.memoizedState,e=t.memoizedState,n.parent!==a?(n={parent:a,cache:a},t.memoizedState=n,t.lanes===0&&(t.memoizedState=t.updateQueue.baseState=n),Dt(t,tl,a)):(a=e.cache,Dt(t,tl,a),a!==n.cache&&nc(t,[tl],u,!0))),il(l,t,t.pendingProps.children,u),t.child;case 29:throw t.pendingProps}throw Error(b(156,t.tag))}function at(l){l.flags|=4}function Uf(l,t,u,a,n){if((t=(l.mode&32)!==0)&&(t=!1),t){if(l.flags|=16777216,(n&335544128)===n)if(l.stateNode.complete)l.flags|=8192;else if(Xv())l.flags|=8192;else throw eu=ne,Ic}else l.flags&=-16777217}function k0(l,t){if(t.type!=="stylesheet"||(t.state.loading&4)!==0)l.flags&=-16777217;else if(l.flags|=16777216,!fm(t))if(Xv())l.flags|=8192;else throw eu=ne,Ic}function Un(l,t){t!==null&&(l.flags|=4),l.flags&16384&&(t=l.tag!==22?Q1():536870912,l.lanes|=t,ku|=t)}function oa(l,t){if(!Y)switch(l.tailMode){case"hidden":t=l.tail;for(var u=null;t!==null;)t.alternate!==null&&(u=t),t=t.sibling;u===null?l.tail=null:u.sibling=null;break;case"collapsed":u=l.tail;for(var a=null;u!==null;)u.alternate!==null&&(a=u),u=u.sibling;a===null?t||l.tail===null?l.tail=null:l.tail.sibling=null:a.sibling=null}}function K(l){var t=l.alternate!==null&&l.alternate.child===l.child,u=0,a=0;if(t)for(var n=l.child;n!==null;)u|=n.lanes|n.childLanes,a|=n.subtreeFlags&65011712,a|=n.flags&65011712,n.return=l,n=n.sibling;else for(n=l.child;n!==null;)u|=n.lanes|n.childLanes,a|=n.subtreeFlags,a|=n.flags,n.return=l,n=n.sibling;return l.subtreeFlags|=a,l.childLanes=u,t}function vh(l,t,u){var a=t.pendingProps;switch($c(t),t.tag){case 16:case 15:case 0:case 11:case 7:case 8:case 12:case 9:case 14:return K(t),null;case 1:return K(t),null;case 3:return u=t.stateNode,a=null,l!==null&&(a=l.memoizedState.cache),t.memoizedState.cache!==a&&(t.flags|=2048),ht(tl),Ju(),u.pendingContext&&(u.context=u.pendingContext,u.pendingContext=null),(l===null||l.child===null)&&(Au(t)?at(t):l===null||l.memoizedState.isDehydrated&&(t.flags&256)===0||(t.flags|=1024,bf())),K(t),null;case 26:var n=t.type,e=t.memoizedState;return l===null?(at(t),e!==null?(K(t),k0(t,e)):(K(t),Uf(t,n,null,a,u))):e?e!==l.memoizedState?(at(t),K(t),k0(t,e)):(K(t),t.flags&=-16777217):(l=l.memoizedProps,l!==a&&at(t),K(t),Uf(t,n,l,a,u)),null;case 27:if(kn(t),u=Ct.current,n=t.type,l!==null&&t.stateNode!=null)l.memoizedProps!==a&&at(t);else{if(!a){if(t.stateNode===null)throw Error(b(166));return K(t),null}l=Il.current,Au(t)?D0(t,l):(l=am(n,a,u),t.stateNode=l,at(t))}return K(t),null;case 5:if(kn(t),n=t.type,l!==null&&t.stateNode!=null)l.memoizedProps!==a&&at(t);else{if(!a){if(t.stateNode===null)throw Error(b(166));return K(t),null}if(e=Il.current,Au(t))D0(t,e);else{var f=be(Ct.current);switch(e){case 1:e=f.createElementNS("http://www.w3.org/2000/svg",n);break;case 2:e=f.createElementNS("http://www.w3.org/1998/Math/MathML",n);break;default:switch(n){case"svg":e=f.createElementNS("http://www.w3.org/2000/svg",n);break;case"math":e=f.createElementNS("http://www.w3.org/1998/Math/MathML",n);break;case"script":e=f.createElement("div"),e.innerHTML="<script><\/script>",e=e.removeChild(e.firstChild);break;case"select":e=typeof a.is=="string"?f.createElement("select",{is:a.is}):f.createElement("select"),a.multiple?e.multiple=!0:a.size&&(e.size=a.size);break;default:e=typeof a.is=="string"?f.createElement(n,{is:a.is}):f.createElement(n)}}e[yl]=t,e[Al]=a;l:for(f=t.child;f!==null;){if(f.tag===5||f.tag===6)e.appendChild(f.stateNode);else if(f.tag!==4&&f.tag!==27&&f.child!==null){f.child.return=f,f=f.child;continue}if(f===t)break l;for(;f.sibling===null;){if(f.return===null||f.return===t)break l;f=f.return}f.sibling.return=f.return,f=f.sibling}t.stateNode=e;l:switch(dl(e,n,a),n){case"button":case"input":case"select":case"textarea":a=!!a.autoFocus;break l;case"img":a=!0;break l;default:a=!1}a&&at(t)}}return K(t),Uf(t,t.type,l===null?null:l.memoizedProps,t.pendingProps,u),null;case 6:if(l&&t.stateNode!=null)l.memoizedProps!==a&&at(t);else{if(typeof a!="string"&&t.stateNode===null)throw Error(b(166));if(l=Ct.current,Au(t)){if(l=t.stateNode,u=t.memoizedProps,a=null,n=vl,n!==null)switch(n.tag){case 27:case 5:a=n.memoizedProps}l[yl]=t,l=!!(l.nodeValue===u||a!==null&&a.suppressHydrationWarning===!0||Pv(l.nodeValue,u)),l||Jt(t,!0)}else l=be(l).createTextNode(a),l[yl]=t,t.stateNode=l}return K(t),null;case 31:if(u=t.memoizedState,l===null||l.memoizedState!==null){if(a=Au(t),u!==null){if(l===null){if(!a)throw Error(b(318));if(l=t.memoizedState,l=l!==null?l.dehydrated:null,!l)throw Error(b(557));l[yl]=t}else cu(),(t.flags&128)===0&&(t.memoizedState=null),t.flags|=4;K(t),l=!1}else u=bf(),l!==null&&l.memoizedState!==null&&(l.memoizedState.hydrationErrors=u),l=!0;if(!l)return t.flags&256?(_l(t),t):(_l(t),null);if((t.flags&128)!==0)throw Error(b(558))}return K(t),null;case 13:if(a=t.memoizedState,l===null||l.memoizedState!==null&&l.memoizedState.dehydrated!==null){if(n=Au(t),a!==null&&a.dehydrated!==null){if(l===null){if(!n)throw Error(b(318));if(n=t.memoizedState,n=n!==null?n.dehydrated:null,!n)throw Error(b(317));n[yl]=t}else cu(),(t.flags&128)===0&&(t.memoizedState=null),t.flags|=4;K(t),n=!1}else n=bf(),l!==null&&l.memoizedState!==null&&(l.memoizedState.hydrationErrors=n),n=!0;if(!n)return t.flags&256?(_l(t),t):(_l(t),null)}return _l(t),(t.flags&128)!==0?(t.lanes=u,t):(u=a!==null,l=l!==null&&l.memoizedState!==null,u&&(a=t.child,n=null,a.alternate!==null&&a.alternate.memoizedState!==null&&a.alternate.memoizedState.cachePool!==null&&(n=a.alternate.memoizedState.cachePool.pool),e=null,a.memoizedState!==null&&a.memoizedState.cachePool!==null&&(e=a.memoizedState.cachePool.pool),e!==n&&(a.flags|=2048)),u!==l&&u&&(t.child.flags|=8192),Un(t,t.updateQueue),K(t),null);case 4:return Ju(),l===null&&Ai(t.stateNode.containerInfo),K(t),null;case 10:return ht(t.type),K(t),null;case 19:if(cl(k),a=t.memoizedState,a===null)return K(t),null;if(n=(t.flags&128)!==0,e=a.rendering,e===null)if(n)oa(a,!1);else{if(F!==0||l!==null&&(l.flags&128)!==0)for(l=t.child;l!==null;){if(e=fe(l),e!==null){for(t.flags|=128,oa(a,!1),l=e.updateQueue,t.updateQueue=l,Un(t,l),t.subtreeFlags=0,l=u,u=t.child;u!==null;)Sy(u,l),u=u.sibling;return x(k,k.current&1|2),Y&&ct(t,a.treeForkCount),t.child}l=l.sibling}a.tail!==null&&Hl()>de&&(t.flags|=128,n=!0,oa(a,!1),t.lanes=4194304)}else{if(!n)if(l=fe(e),l!==null){if(t.flags|=128,n=!0,l=l.updateQueue,t.updateQueue=l,Un(t,l),oa(a,!0),a.tail===null&&a.tailMode==="hidden"&&!e.alternate&&!Y)return K(t),null}else 2*Hl()-a.renderingStartTime>de&&u!==536870912&&(t.flags|=128,n=!0,oa(a,!1),t.lanes=4194304);a.isBackwards?(e.sibling=t.child,t.child=e):(l=a.last,l!==null?l.sibling=e:t.child=e,a.last=e)}return a.tail!==null?(l=a.tail,a.rendering=l,a.tail=l.sibling,a.renderingStartTime=Hl(),l.sibling=null,u=k.current,x(k,n?u&1|2:u&1),Y&&ct(t,a.treeForkCount),l):(K(t),null);case 22:case 23:return _l(t),li(),a=t.memoizedState!==null,l!==null?l.memoizedState!==null!==a&&(t.flags|=8192):a&&(t.flags|=8192),a?(u&536870912)!==0&&(t.flags&128)===0&&(K(t),t.subtreeFlags&6&&(t.flags|=8192)):K(t),u=t.updateQueue,u!==null&&Un(t,u.retryQueue),u=null,l!==null&&l.memoizedState!==null&&l.memoizedState.cachePool!==null&&(u=l.memoizedState.cachePool.pool),a=null,t.memoizedState!==null&&t.memoizedState.cachePool!==null&&(a=t.memoizedState.cachePool.pool),a!==u&&(t.flags|=2048),l!==null&&cl(nu),null;case 24:return u=null,l!==null&&(u=l.memoizedState.cache),t.memoizedState.cache!==u&&(t.flags|=2048),ht(tl),K(t),null;case 25:return null;case 30:return null}throw Error(b(156,t.tag))}function mh(l,t){switch($c(t),t.tag){case 1:return l=t.flags,l&65536?(t.flags=l&-65537|128,t):null;case 3:return ht(tl),Ju(),l=t.flags,(l&65536)!==0&&(l&128)===0?(t.flags=l&-65537|128,t):null;case 26:case 27:case 5:return kn(t),null;case 31:if(t.memoizedState!==null){if(_l(t),t.alternate===null)throw Error(b(340));cu()}return l=t.flags,l&65536?(t.flags=l&-65537|128,t):null;case 13:if(_l(t),l=t.memoizedState,l!==null&&l.dehydrated!==null){if(t.alternate===null)throw Error(b(340));cu()}return l=t.flags,l&65536?(t.flags=l&-65537|128,t):null;case 19:return cl(k),null;case 4:return Ju(),null;case 10:return ht(t.type),null;case 22:case 23:return _l(t),li(),l!==null&&cl(nu),l=t.flags,l&65536?(t.flags=l&-65537|128,t):null;case 24:return ht(tl),null;case 25:return null;default:return null}}function Sv(l,t){switch($c(t),t.tag){case 3:ht(tl),Ju();break;case 26:case 27:case 5:kn(t);break;case 4:Ju();break;case 31:t.memoizedState!==null&&_l(t);break;case 13:_l(t);break;case 19:cl(k);break;case 10:ht(t.type);break;case 22:case 23:_l(t),li(),l!==null&&cl(nu);break;case 24:ht(tl)}}function fn(l,t){try{var u=t.updateQueue,a=u!==null?u.lastEffect:null;if(a!==null){var n=a.next;u=n;do{if((u.tag&l)===l){a=void 0;var e=u.create,f=u.inst;a=e(),f.destroy=a}u=u.next}while(u!==n)}}catch(c){X(t,t.return,c)}}function rt(l,t,u){try{var a=t.updateQueue,n=a!==null?a.lastEffect:null;if(n!==null){var e=n.next;a=e;do{if((a.tag&l)===l){var f=a.inst,c=f.destroy;if(c!==void 0){f.destroy=void 0,n=t;var i=u,m=c;try{m()}catch(g){X(n,i,g)}}}a=a.next}while(a!==e)}}catch(g){X(t,t.return,g)}}function gv(l){var t=l.updateQueue;if(t!==null){var u=l.stateNode;try{Oy(t,u)}catch(a){X(l,l.return,a)}}}function ov(l,t,u){u.props=mu(l.type,l.memoizedProps),u.state=l.memoizedState;try{u.componentWillUnmount()}catch(a){X(l,t,a)}}function Ra(l,t){try{var u=l.ref;if(u!==null){switch(l.tag){case 26:case 27:case 5:var a=l.stateNode;break;case 30:a=l.stateNode;break;default:a=l.stateNode}typeof u=="function"?l.refCleanup=u(a):u.current=a}}catch(n){X(l,t,n)}}function kl(l,t){var u=l.ref,a=l.refCleanup;if(u!==null)if(typeof a=="function")try{a()}catch(n){X(l,t,n)}finally{l.refCleanup=null,l=l.alternate,l!=null&&(l.refCleanup=null)}else if(typeof u=="function")try{u(null)}catch(n){X(l,t,n)}else u.current=null}function sv(l){var t=l.type,u=l.memoizedProps,a=l.stateNode;try{l:switch(t){case"button":case"input":case"select":case"textarea":u.autoFocus&&a.focus();break l;case"img":u.src?a.src=u.src:u.srcSet&&(a.srcset=u.srcSet)}}catch(n){X(l,l.return,n)}}function Hf(l,t,u){try{var a=l.stateNode;Yh(a,l.type,u,t),a[Al]=t}catch(n){X(l,l.return,n)}}function bv(l){return l.tag===5||l.tag===3||l.tag===26||l.tag===27&&$t(l.type)||l.tag===4}function Nf(l){l:for(;;){for(;l.sibling===null;){if(l.return===null||bv(l.return))return null;l=l.return}for(l.sibling.return=l.return,l=l.sibling;l.tag!==5&&l.tag!==6&&l.tag!==18;){if(l.tag===27&&$t(l.type)||l.flags&2||l.child===null||l.tag===4)continue l;l.child.return=l,l=l.child}if(!(l.flags&2))return l.stateNode}}function sc(l,t,u){var a=l.tag;if(a===5||a===6)l=l.stateNode,t?(u.nodeType===9?u.body:u.nodeName==="HTML"?u.ownerDocument.body:u).insertBefore(l,t):(t=u.nodeType===9?u.body:u.nodeName==="HTML"?u.ownerDocument.body:u,t.appendChild(l),u=u._reactRootContainer,u!=null||t.onclick!==null||(t.onclick=vt));else if(a!==4&&(a===27&&$t(l.type)&&(u=l.stateNode,t=null),l=l.child,l!==null))for(sc(l,t,u),l=l.sibling;l!==null;)sc(l,t,u),l=l.sibling}function me(l,t,u){var a=l.tag;if(a===5||a===6)l=l.stateNode,t?u.insertBefore(l,t):u.appendChild(l);else if(a!==4&&(a===27&&$t(l.type)&&(u=l.stateNode),l=l.child,l!==null))for(me(l,t,u),l=l.sibling;l!==null;)me(l,t,u),l=l.sibling}function zv(l){var t=l.stateNode,u=l.memoizedProps;try{for(var a=l.type,n=t.attributes;n.length;)t.removeAttributeNode(n[0]);dl(t,a,u),t[yl]=l,t[Al]=u}catch(e){X(l,l.return,e)}}var it=!1,ll=!1,qf=!1,I0=typeof WeakSet=="function"?WeakSet:Set,el=null;function dh(l,t){if(l=l.containerInfo,Oc=Ae,l=fy(l),Kc(l)){if("selectionStart"in l)var u={start:l.selectionStart,end:l.selectionEnd};else l:{u=(u=l.ownerDocument)&&u.defaultView||window;var a=u.getSelection&&u.getSelection();if(a&&a.rangeCount!==0){u=a.anchorNode;var n=a.anchorOffset,e=a.focusNode;a=a.focusOffset;try{u.nodeType,e.nodeType}catch{u=null;break l}var f=0,c=-1,i=-1,m=0,g=0,s=l,h=null;t:for(;;){for(var S;s!==u||n!==0&&s.nodeType!==3||(c=f+n),s!==e||a!==0&&s.nodeType!==3||(i=f+a),s.nodeType===3&&(f+=s.nodeValue.length),(S=s.firstChild)!==null;)h=s,s=S;for(;;){if(s===l)break t;if(h===u&&++m===n&&(c=f),h===e&&++g===a&&(i=f),(S=s.nextSibling)!==null)break;s=h,h=s.parentNode}s=S}u=c===-1||i===-1?null:{start:c,end:i}}else u=null}u=u||{start:0,end:0}}else u=null;for(_c={focusedElem:l,selectionRange:u},Ae=!1,el=t;el!==null;)if(t=el,l=t.child,(t.subtreeFlags&1028)!==0&&l!==null)l.return=t,el=l;else for(;el!==null;){switch(t=el,e=t.alternate,l=t.flags,t.tag){case 0:if((l&4)!==0&&(l=t.updateQueue,l=l!==null?l.events:null,l!==null))for(u=0;u<l.length;u++)n=l[u],n.ref.impl=n.nextImpl;break;case 11:case 15:break;case 1:if((l&1024)!==0&&e!==null){l=void 0,u=t,n=e.memoizedProps,e=e.memoizedState,a=u.stateNode;try{var z=mu(u.type,n);l=a.getSnapshotBeforeUpdate(z,e),a.__reactInternalSnapshotBeforeUpdate=l}catch(A){X(u,u.return,A)}}break;case 3:if((l&1024)!==0){if(l=t.stateNode.containerInfo,u=l.nodeType,u===9)Uc(l);else if(u===1)switch(l.nodeName){case"HEAD":case"HTML":case"BODY":Uc(l);break;default:l.textContent=""}}break;case 5:case 26:case 27:case 6:case 4:case 17:break;default:if((l&1024)!==0)throw Error(b(163))}if(l=t.sibling,l!==null){l.return=t.return,el=l;break}el=t.return}}function Tv(l,t,u){var a=u.flags;switch(u.tag){case 0:case 11:case 15:et(l,u),a&4&&fn(5,u);break;case 1:if(et(l,u),a&4)if(l=u.stateNode,t===null)try{l.componentDidMount()}catch(f){X(u,u.return,f)}else{var n=mu(u.type,t.memoizedProps);t=t.memoizedState;try{l.componentDidUpdate(n,t,l.__reactInternalSnapshotBeforeUpdate)}catch(f){X(u,u.return,f)}}a&64&&gv(u),a&512&&Ra(u,u.return);break;case 3:if(et(l,u),a&64&&(l=u.updateQueue,l!==null)){if(t=null,u.child!==null)switch(u.child.tag){case 27:case 5:t=u.child.stateNode;break;case 1:t=u.child.stateNode}try{Oy(l,t)}catch(f){X(u,u.return,f)}}break;case 27:t===null&&a&4&&zv(u);case 26:case 5:et(l,u),t===null&&a&4&&sv(u),a&512&&Ra(u,u.return);break;case 12:et(l,u);break;case 31:et(l,u),a&4&&Mv(l,u);break;case 13:et(l,u),a&4&&Ov(l,u),a&64&&(l=u.memoizedState,l!==null&&(l=l.dehydrated,l!==null&&(u=Eh.bind(null,u),Zh(l,u))));break;case 22:if(a=u.memoizedState!==null||it,!a){t=t!==null&&t.memoizedState!==null||ll,n=it;var e=ll;it=a,(ll=t)&&!e?ft(l,u,(u.subtreeFlags&8772)!==0):et(l,u),it=n,ll=e}break;case 30:break;default:et(l,u)}}function Ev(l){var t=l.alternate;t!==null&&(l.alternate=null,Ev(t)),l.child=null,l.deletions=null,l.sibling=null,l.tag===5&&(t=l.stateNode,t!==null&&Qc(t)),l.stateNode=null,l.return=null,l.dependencies=null,l.memoizedProps=null,l.memoizedState=null,l.pendingProps=null,l.stateNode=null,l.updateQueue=null}var W=null,zl=!1;function nt(l,t,u){for(u=u.child;u!==null;)Av(l,t,u),u=u.sibling}function Av(l,t,u){if(Nl&&typeof Nl.onCommitFiberUnmount=="function")try{Nl.onCommitFiberUnmount(Pa,u)}catch{}switch(u.tag){case 26:ll||kl(u,t),nt(l,t,u),u.memoizedState?u.memoizedState.count--:u.stateNode&&(u=u.stateNode,u.parentNode.removeChild(u));break;case 27:ll||kl(u,t);var a=W,n=zl;$t(u.type)&&(W=u.stateNode,zl=!1),nt(l,t,u),Xa(u.stateNode),W=a,zl=n;break;case 5:ll||kl(u,t);case 6:if(a=W,n=zl,W=null,nt(l,t,u),W=a,zl=n,W!==null)if(zl)try{(W.nodeType===9?W.body:W.nodeName==="HTML"?W.ownerDocument.body:W).removeChild(u.stateNode)}catch(e){X(u,t,e)}else try{W.removeChild(u.stateNode)}catch(e){X(u,t,e)}break;case 18:W!==null&&(zl?(l=W,h1(l.nodeType===9?l.body:l.nodeName==="HTML"?l.ownerDocument.body:l,u.stateNode),ta(l)):h1(W,u.stateNode));break;case 4:a=W,n=zl,W=u.stateNode.containerInfo,zl=!0,nt(l,t,u),W=a,zl=n;break;case 0:case 11:case 14:case 15:rt(2,u,t),ll||rt(4,u,t),nt(l,t,u);break;case 1:ll||(kl(u,t),a=u.stateNode,typeof a.componentWillUnmount=="function"&&ov(u,t,a)),nt(l,t,u);break;case 21:nt(l,t,u);break;case 22:ll=(a=ll)||u.memoizedState!==null,nt(l,t,u),ll=a;break;default:nt(l,t,u)}}function Mv(l,t){if(t.memoizedState===null&&(l=t.alternate,l!==null&&(l=l.memoizedState,l!==null))){l=l.dehydrated;try{ta(l)}catch(u){X(t,t.return,u)}}}function Ov(l,t){if(t.memoizedState===null&&(l=t.alternate,l!==null&&(l=l.memoizedState,l!==null&&(l=l.dehydrated,l!==null))))try{ta(l)}catch(u){X(t,t.return,u)}}function hh(l){switch(l.tag){case 31:case 13:case 19:var t=l.stateNode;return t===null&&(t=l.stateNode=new I0),t;case 22:return l=l.stateNode,t=l._retryCache,t===null&&(t=l._retryCache=new I0),t;default:throw Error(b(435,l.tag))}}function Hn(l,t){var u=hh(l);t.forEach(function(a){if(!u.has(a)){u.add(a);var n=Ah.bind(null,l,a);a.then(n,n)}})}function sl(l,t){var u=t.deletions;if(u!==null)for(var a=0;a<u.length;a++){var n=u[a],e=l,f=t,c=f;l:for(;c!==null;){switch(c.tag){case 27:if($t(c.type)){W=c.stateNode,zl=!1;break l}break;case 5:W=c.stateNode,zl=!1;break l;case 3:case 4:W=c.stateNode.containerInfo,zl=!0;break l}c=c.return}if(W===null)throw Error(b(160));Av(e,f,n),W=null,zl=!1,e=n.alternate,e!==null&&(e.return=null),n.return=null}if(t.subtreeFlags&13886)for(t=t.child;t!==null;)_v(t,l),t=t.sibling}var rl=null;function _v(l,t){var u=l.alternate,a=l.flags;switch(l.tag){case 0:case 11:case 14:case 15:sl(t,l),bl(l),a&4&&(rt(3,l,l.return),fn(3,l),rt(5,l,l.return));break;case 1:sl(t,l),bl(l),a&512&&(ll||u===null||kl(u,u.return)),a&64&&it&&(l=l.updateQueue,l!==null&&(a=l.callbacks,a!==null&&(u=l.shared.hiddenCallbacks,l.shared.hiddenCallbacks=u===null?a:u.concat(a))));break;case 26:var n=rl;if(sl(t,l),bl(l),a&512&&(ll||u===null||kl(u,u.return)),a&4){var e=u!==null?u.memoizedState:null;if(a=l.memoizedState,u===null)if(a===null)if(l.stateNode===null){l:{a=l.type,u=l.memoizedProps,n=n.ownerDocument||n;t:switch(a){case"title":e=n.getElementsByTagName("title")[0],(!e||e[un]||e[yl]||e.namespaceURI==="http://www.w3.org/2000/svg"||e.hasAttribute("itemprop"))&&(e=n.createElement(a),n.head.insertBefore(e,n.querySelector("head > title"))),dl(e,a,u),e[yl]=l,fl(e),a=e;break l;case"link":var f=T1("link","href",n).get(a+(u.href||""));if(f){for(var c=0;c<f.length;c++)if(e=f[c],e.getAttribute("href")===(u.href==null||u.href===""?null:u.href)&&e.getAttribute("rel")===(u.rel==null?null:u.rel)&&e.getAttribute("title")===(u.title==null?null:u.title)&&e.getAttribute("crossorigin")===(u.crossOrigin==null?null:u.crossOrigin)){f.splice(c,1);break t}}e=n.createElement(a),dl(e,a,u),n.head.appendChild(e);break;case"meta":if(f=T1("meta","content",n).get(a+(u.content||""))){for(c=0;c<f.length;c++)if(e=f[c],e.getAttribute("content")===(u.content==null?null:""+u.content)&&e.getAttribute("name")===(u.name==null?null:u.name)&&e.getAttribute("property")===(u.property==null?null:u.property)&&e.getAttribute("http-equiv")===(u.httpEquiv==null?null:u.httpEquiv)&&e.getAttribute("charset")===(u.charSet==null?null:u.charSet)){f.splice(c,1);break t}}e=n.createElement(a),dl(e,a,u),n.head.appendChild(e);break;default:throw Error(b(468,a))}e[yl]=l,fl(e),a=e}l.stateNode=a}else E1(n,l.type,l.stateNode);else l.stateNode=z1(n,a,l.memoizedProps);else e!==a?(e===null?u.stateNode!==null&&(u=u.stateNode,u.parentNode.removeChild(u)):e.count--,a===null?E1(n,l.type,l.stateNode):z1(n,a,l.memoizedProps)):a===null&&l.stateNode!==null&&Hf(l,l.memoizedProps,u.memoizedProps)}break;case 27:sl(t,l),bl(l),a&512&&(ll||u===null||kl(u,u.return)),u!==null&&a&4&&Hf(l,l.memoizedProps,u.memoizedProps);break;case 5:if(sl(t,l),bl(l),a&512&&(ll||u===null||kl(u,u.return)),l.flags&32){n=l.stateNode;try{wu(n,"")}catch(z){X(l,l.return,z)}}a&4&&l.stateNode!=null&&(n=l.memoizedProps,Hf(l,n,u!==null?u.memoizedProps:n)),a&1024&&(qf=!0);break;case 6:if(sl(t,l),bl(l),a&4){if(l.stateNode===null)throw Error(b(162));a=l.memoizedProps,u=l.stateNode;try{u.nodeValue=a}catch(z){X(l,l.return,z)}}break;case 3:if(rn=null,n=rl,rl=ze(t.containerInfo),sl(t,l),rl=n,bl(l),a&4&&u!==null&&u.memoizedState.isDehydrated)try{ta(t.containerInfo)}catch(z){X(l,l.return,z)}qf&&(qf=!1,Dv(l));break;case 4:a=rl,rl=ze(l.stateNode.containerInfo),sl(t,l),bl(l),rl=a;break;case 12:sl(t,l),bl(l);break;case 31:sl(t,l),bl(l),a&4&&(a=l.updateQueue,a!==null&&(l.updateQueue=null,Hn(l,a)));break;case 13:sl(t,l),bl(l),l.child.flags&8192&&l.memoizedState!==null!=(u!==null&&u.memoizedState!==null)&&(Ce=Hl()),a&4&&(a=l.updateQueue,a!==null&&(l.updateQueue=null,Hn(l,a)));break;case 22:n=l.memoizedState!==null;var i=u!==null&&u.memoizedState!==null,m=it,g=ll;if(it=m||n,ll=g||i,sl(t,l),ll=g,it=m,bl(l),a&8192)l:for(t=l.stateNode,t._visibility=n?t._visibility&-2:t._visibility|1,n&&(u===null||i||it||ll||tu(l)),u=null,t=l;;){if(t.tag===5||t.tag===26){if(u===null){i=u=t;try{if(e=i.stateNode,n)f=e.style,typeof f.setProperty=="function"?f.setProperty("display","none","important"):f.display="none";else{c=i.stateNode;var s=i.memoizedProps.style,h=s!=null&&s.hasOwnProperty("display")?s.display:null;c.style.display=h==null||typeof h=="boolean"?"":(""+h).trim()}}catch(z){X(i,i.return,z)}}}else if(t.tag===6){if(u===null){i=t;try{i.stateNode.nodeValue=n?"":i.memoizedProps}catch(z){X(i,i.return,z)}}}else if(t.tag===18){if(u===null){i=t;try{var S=i.stateNode;n?S1(S,!0):S1(i.stateNode,!1)}catch(z){X(i,i.return,z)}}}else if((t.tag!==22&&t.tag!==23||t.memoizedState===null||t===l)&&t.child!==null){t.child.return=t,t=t.child;continue}if(t===l)break l;for(;t.sibling===null;){if(t.return===null||t.return===l)break l;u===t&&(u=null),t=t.return}u===t&&(u=null),t.sibling.return=t.return,t=t.sibling}a&4&&(a=l.updateQueue,a!==null&&(u=a.retryQueue,u!==null&&(a.retryQueue=null,Hn(l,u))));break;case 19:sl(t,l),bl(l),a&4&&(a=l.updateQueue,a!==null&&(l.updateQueue=null,Hn(l,a)));break;case 30:break;case 21:break;default:sl(t,l),bl(l)}}function bl(l){var t=l.flags;if(t&2){try{for(var u,a=l.return;a!==null;){if(bv(a)){u=a;break}a=a.return}if(u==null)throw Error(b(160));switch(u.tag){case 27:var n=u.stateNode,e=Nf(l);me(l,e,n);break;case 5:var f=u.stateNode;u.flags&32&&(wu(f,""),u.flags&=-33);var c=Nf(l);me(l,c,f);break;case 3:case 4:var i=u.stateNode.containerInfo,m=Nf(l);sc(l,m,i);break;default:throw Error(b(161))}}catch(g){X(l,l.return,g)}l.flags&=-3}t&4096&&(l.flags&=-4097)}function Dv(l){if(l.subtreeFlags&1024)for(l=l.child;l!==null;){var t=l;Dv(t),t.tag===5&&t.flags&1024&&t.stateNode.reset(),l=l.sibling}}function et(l,t){if(t.subtreeFlags&8772)for(t=t.child;t!==null;)Tv(l,t.alternate,t),t=t.sibling}function tu(l){for(l=l.child;l!==null;){var t=l;switch(t.tag){case 0:case 11:case 14:case 15:rt(4,t,t.return),tu(t);break;case 1:kl(t,t.return);var u=t.stateNode;typeof u.componentWillUnmount=="function"&&ov(t,t.return,u),tu(t);break;case 27:Xa(t.stateNode);case 26:case 5:kl(t,t.return),tu(t);break;case 22:t.memoizedState===null&&tu(t);break;case 30:tu(t);break;default:tu(t)}l=l.sibling}}function ft(l,t,u){for(u=u&&(t.subtreeFlags&8772)!==0,t=t.child;t!==null;){var a=t.alternate,n=l,e=t,f=e.flags;switch(e.tag){case 0:case 11:case 15:ft(n,e,u),fn(4,e);break;case 1:if(ft(n,e,u),a=e,n=a.stateNode,typeof n.componentDidMount=="function")try{n.componentDidMount()}catch(m){X(a,a.return,m)}if(a=e,n=a.updateQueue,n!==null){var c=a.stateNode;try{var i=n.shared.hiddenCallbacks;if(i!==null)for(n.shared.hiddenCallbacks=null,n=0;n<i.length;n++)My(i[n],c)}catch(m){X(a,a.return,m)}}u&&f&64&&gv(e),Ra(e,e.return);break;case 27:zv(e);case 26:case 5:ft(n,e,u),u&&a===null&&f&4&&sv(e),Ra(e,e.return);break;case 12:ft(n,e,u);break;case 31:ft(n,e,u),u&&f&4&&Mv(n,e);break;case 13:ft(n,e,u),u&&f&4&&Ov(n,e);break;case 22:e.memoizedState===null&&ft(n,e,u),Ra(e,e.return);break;case 30:break;default:ft(n,e,u)}t=t.sibling}}function oi(l,t){var u=null;l!==null&&l.memoizedState!==null&&l.memoizedState.cachePool!==null&&(u=l.memoizedState.cachePool.pool),l=null,t.memoizedState!==null&&t.memoizedState.cachePool!==null&&(l=t.memoizedState.cachePool.pool),l!==u&&(l!=null&&l.refCount++,u!=null&&nn(u))}function si(l,t){l=null,t.alternate!==null&&(l=t.alternate.memoizedState.cache),t=t.memoizedState.cache,t!==l&&(t.refCount++,l!=null&&nn(l))}function Jl(l,t,u,a){if(t.subtreeFlags&10256)for(t=t.child;t!==null;)Uv(l,t,u,a),t=t.sibling}function Uv(l,t,u,a){var n=t.flags;switch(t.tag){case 0:case 11:case 15:Jl(l,t,u,a),n&2048&&fn(9,t);break;case 1:Jl(l,t,u,a);break;case 3:Jl(l,t,u,a),n&2048&&(l=null,t.alternate!==null&&(l=t.alternate.memoizedState.cache),t=t.memoizedState.cache,t!==l&&(t.refCount++,l!=null&&nn(l)));break;case 12:if(n&2048){Jl(l,t,u,a),l=t.stateNode;try{var e=t.memoizedProps,f=e.id,c=e.onPostCommit;typeof c=="function"&&c(f,t.alternate===null?"mount":"update",l.passiveEffectDuration,-0)}catch(i){X(t,t.return,i)}}else Jl(l,t,u,a);break;case 31:Jl(l,t,u,a);break;case 13:Jl(l,t,u,a);break;case 23:break;case 22:e=t.stateNode,f=t.alternate,t.memoizedState!==null?e._visibility&2?Jl(l,t,u,a):pa(l,t):e._visibility&2?Jl(l,t,u,a):(e._visibility|=2,Ou(l,t,u,a,(t.subtreeFlags&10256)!==0||!1)),n&2048&&oi(f,t);break;case 24:Jl(l,t,u,a),n&2048&&si(t.alternate,t);break;default:Jl(l,t,u,a)}}function Ou(l,t,u,a,n){for(n=n&&((t.subtreeFlags&10256)!==0||!1),t=t.child;t!==null;){var e=l,f=t,c=u,i=a,m=f.flags;switch(f.tag){case 0:case 11:case 15:Ou(e,f,c,i,n),fn(8,f);break;case 23:break;case 22:var g=f.stateNode;f.memoizedState!==null?g._visibility&2?Ou(e,f,c,i,n):pa(e,f):(g._visibility|=2,Ou(e,f,c,i,n)),n&&m&2048&&oi(f.alternate,f);break;case 24:Ou(e,f,c,i,n),n&&m&2048&&si(f.alternate,f);break;default:Ou(e,f,c,i,n)}t=t.sibling}}function pa(l,t){if(t.subtreeFlags&10256)for(t=t.child;t!==null;){var u=l,a=t,n=a.flags;switch(a.tag){case 22:pa(u,a),n&2048&&oi(a.alternate,a);break;case 24:pa(u,a),n&2048&&si(a.alternate,a);break;default:pa(u,a)}t=t.sibling}}var Oa=8192;function Mu(l,t,u){if(l.subtreeFlags&Oa)for(l=l.child;l!==null;)Hv(l,t,u),l=l.sibling}function Hv(l,t,u){switch(l.tag){case 26:Mu(l,t,u),l.flags&Oa&&l.memoizedState!==null&&kh(u,rl,l.memoizedState,l.memoizedProps);break;case 5:Mu(l,t,u);break;case 3:case 4:var a=rl;rl=ze(l.stateNode.containerInfo),Mu(l,t,u),rl=a;break;case 22:l.memoizedState===null&&(a=l.alternate,a!==null&&a.memoizedState!==null?(a=Oa,Oa=16777216,Mu(l,t,u),Oa=a):Mu(l,t,u));break;default:Mu(l,t,u)}}function Nv(l){var t=l.alternate;if(t!==null&&(l=t.child,l!==null)){t.child=null;do t=l.sibling,l.sibling=null,l=t;while(l!==null)}}function sa(l){var t=l.deletions;if((l.flags&16)!==0){if(t!==null)for(var u=0;u<t.length;u++){var a=t[u];el=a,Yv(a,l)}Nv(l)}if(l.subtreeFlags&10256)for(l=l.child;l!==null;)qv(l),l=l.sibling}function qv(l){switch(l.tag){case 0:case 11:case 15:sa(l),l.flags&2048&&rt(9,l,l.return);break;case 3:sa(l);break;case 12:sa(l);break;case 22:var t=l.stateNode;l.memoizedState!==null&&t._visibility&2&&(l.return===null||l.return.tag!==13)?(t._visibility&=-3,Kn(l)):sa(l);break;default:sa(l)}}function Kn(l){var t=l.deletions;if((l.flags&16)!==0){if(t!==null)for(var u=0;u<t.length;u++){var a=t[u];el=a,Yv(a,l)}Nv(l)}for(l=l.child;l!==null;){switch(t=l,t.tag){case 0:case 11:case 15:rt(8,t,t.return),Kn(t);break;case 22:u=t.stateNode,u._visibility&2&&(u._visibility&=-3,Kn(t));break;default:Kn(t)}l=l.sibling}}function Yv(l,t){for(;el!==null;){var u=el;switch(u.tag){case 0:case 11:case 15:rt(8,u,t);break;case 23:case 22:if(u.memoizedState!==null&&u.memoizedState.cachePool!==null){var a=u.memoizedState.cachePool.pool;a!=null&&a.refCount++}break;case 24:nn(u.memoizedState.cache)}if(a=u.child,a!==null)a.return=u,el=a;else l:for(u=l;el!==null;){a=el;var n=a.sibling,e=a.return;if(Ev(a),a===u){el=null;break l}if(n!==null){n.return=e,el=n;break l}el=e}}}var Sh={getCacheForType:function(l){var t=ml(tl),u=t.data.get(l);return u===void 0&&(u=l(),t.data.set(l,u)),u},cacheSignal:function(){return ml(tl).controller.signal}},gh=typeof WeakMap=="function"?WeakMap:Map,p=0,V=null,H=null,q=0,G=0,Ol=null,Bt=!1,fa=!1,bi=!1,zt=0,F=0,wt=0,fu=0,zi=0,Ul=0,ku=0,Ca=null,Tl=null,bc=!1,Ce=0,Bv=0,de=1/0,he=null,Zt=null,al=0,jt=null,Iu=null,St=0,zc=0,Tc=null,Rv=null,Ga=0,Ec=null;function Yl(){return(p&2)!==0&&q!==0?q&-q:M.T!==null?Ei():x1()}function pv(){if(Ul===0)if((q&536870912)===0||Y){var l=bn;bn<<=1,(bn&3932160)===0&&(bn=262144),Ul=l}else Ul=536870912;return l=Rl.current,l!==null&&(l.flags|=32),Ul}function El(l,t,u){(l===V&&(G===2||G===9)||l.cancelPendingCommit!==null)&&(Pu(l,0),Rt(l,q,Ul,!1)),tn(l,u),((p&2)===0||l!==V)&&(l===V&&((p&2)===0&&(fu|=u),F===4&&Rt(l,q,Ul,!1)),lt(l))}function Cv(l,t,u){if((p&6)!==0)throw Error(b(327));var a=!u&&(t&127)===0&&(t&l.expiredLanes)===0||ln(l,t),n=a?bh(l,t):Yf(l,t,!0),e=a;do{if(n===0){fa&&!a&&Rt(l,t,0,!1);break}else{if(u=l.current.alternate,e&&!oh(u)){n=Yf(l,t,!1),e=!1;continue}if(n===2){if(e=t,l.errorRecoveryDisabledLanes&e)var f=0;else f=l.pendingLanes&-536870913,f=f!==0?f:f&536870912?536870912:0;if(f!==0){t=f;l:{var c=l;n=Ca;var i=c.current.memoizedState.isDehydrated;if(i&&(Pu(c,f).flags|=256),f=Yf(c,f,!1),f!==2){if(bi&&!i){c.errorRecoveryDisabledLanes|=e,fu|=e,n=4;break l}e=Tl,Tl=n,e!==null&&(Tl===null?Tl=e:Tl.push.apply(Tl,e))}n=f}if(e=!1,n!==2)continue}}if(n===1){Pu(l,0),Rt(l,t,0,!0);break}l:{switch(a=l,e=n,e){case 0:case 1:throw Error(b(345));case 4:if((t&4194048)!==t)break;case 6:Rt(a,t,Ul,!Bt);break l;case 2:Tl=null;break;case 3:case 5:break;default:throw Error(b(329))}if((t&62914560)===t&&(n=Ce+300-Hl(),10<n)){if(Rt(a,t,Ul,!Bt),Oe(a,0,!0)!==0)break l;St=t,a.timeoutHandle=tm(P0.bind(null,a,u,Tl,he,bc,t,Ul,fu,ku,Bt,e,"Throttled",-0,0),n);break l}P0(a,u,Tl,he,bc,t,Ul,fu,ku,Bt,e,null,-0,0)}}break}while(!0);lt(l)}function P0(l,t,u,a,n,e,f,c,i,m,g,s,h,S){if(l.timeoutHandle=-1,s=t.subtreeFlags,s&8192||(s&16785408)===16785408){s={stylesheets:null,count:0,imgCount:0,imgBytes:0,suspenseyImages:[],waitingForImages:!0,waitingForViewTransition:!1,unsuspend:vt},Hv(t,e,s);var z=(e&62914560)===e?Ce-Hl():(e&4194048)===e?Bv-Hl():0;if(z=Ih(s,z),z!==null){St=e,l.cancelPendingCommit=z(t1.bind(null,l,t,e,u,a,n,f,c,i,g,s,null,h,S)),Rt(l,e,f,!m);return}}t1(l,t,e,u,a,n,f,c,i)}function oh(l){for(var t=l;;){var u=t.tag;if((u===0||u===11||u===15)&&t.flags&16384&&(u=t.updateQueue,u!==null&&(u=u.stores,u!==null)))for(var a=0;a<u.length;a++){var n=u[a],e=n.getSnapshot;n=n.value;try{if(!Bl(e(),n))return!1}catch{return!1}}if(u=t.child,t.subtreeFlags&16384&&u!==null)u.return=t,t=u;else{if(t===l)break;for(;t.sibling===null;){if(t.return===null||t.return===l)return!0;t=t.return}t.sibling.return=t.return,t=t.sibling}}return!0}function Rt(l,t,u,a){t&=~zi,t&=~fu,l.suspendedLanes|=t,l.pingedLanes&=~t,a&&(l.warmLanes|=t),a=l.expirationTimes;for(var n=t;0<n;){var e=31-ql(n),f=1<<e;a[e]=-1,n&=~f}u!==0&&Z1(l,u,t)}function Ge(){return(p&6)===0?(cn(0,!1),!1):!0}function Ti(){if(H!==null){if(G===0)var l=H.return;else l=H,mt=ou=null,ei(l),xu=null,Ka=0,l=H;for(;l!==null;)Sv(l.alternate,l),l=l.return;H=null}}function Pu(l,t){var u=l.timeoutHandle;u!==-1&&(l.timeoutHandle=-1,ph(u)),u=l.cancelPendingCommit,u!==null&&(l.cancelPendingCommit=null,u()),St=0,Ti(),V=l,H=u=dt(l.current,null),q=t,G=0,Ol=null,Bt=!1,fa=ln(l,t),bi=!1,ku=Ul=zi=fu=wt=F=0,Tl=Ca=null,bc=!1,(t&8)!==0&&(t|=t&32);var a=l.entangledLanes;if(a!==0)for(l=l.entanglements,a&=t;0<a;){var n=31-ql(a),e=1<<n;t|=l[n],a&=~e}return zt=t,He(),u}function Gv(l,t){_=null,M.H=ra,t===ea||t===qe?(t=Y0(),G=3):t===Ic?(t=Y0(),G=4):G=t===Si?8:t!==null&&typeof t=="object"&&typeof t.then=="function"?6:1,Ol=t,H===null&&(F=1,ye(l,jl(t,l.current)))}function Xv(){var l=Rl.current;return l===null?!0:(q&4194048)===q?xl===null:(q&62914560)===q||(q&536870912)!==0?l===xl:!1}function Qv(){var l=M.H;return M.H=ra,l===null?ra:l}function Zv(){var l=M.A;return M.A=Sh,l}function Se(){F=4,Bt||(q&4194048)!==q&&Rl.current!==null||(fa=!0),(wt&134217727)===0&&(fu&134217727)===0||V===null||Rt(V,q,Ul,!1)}function Yf(l,t,u){var a=p;p|=2;var n=Qv(),e=Zv();(V!==l||q!==t)&&(he=null,Pu(l,t)),t=!1;var f=F;l:do try{if(G!==0&&H!==null){var c=H,i=Ol;switch(G){case 8:Ti(),f=6;break l;case 3:case 2:case 9:case 6:Rl.current===null&&(t=!0);var m=G;if(G=0,Ol=null,Xu(l,c,i,m),u&&fa){f=0;break l}break;default:m=G,G=0,Ol=null,Xu(l,c,i,m)}}sh(),f=F;break}catch(g){Gv(l,g)}while(!0);return t&&l.shellSuspendCounter++,mt=ou=null,p=a,M.H=n,M.A=e,H===null&&(V=null,q=0,He()),f}function sh(){for(;H!==null;)jv(H)}function bh(l,t){var u=p;p|=2;var a=Qv(),n=Zv();V!==l||q!==t?(he=null,de=Hl()+500,Pu(l,t)):fa=ln(l,t);l:do try{if(G!==0&&H!==null){t=H;var e=Ol;t:switch(G){case 1:G=0,Ol=null,Xu(l,t,e,1);break;case 2:case 9:if(q0(e)){G=0,Ol=null,l1(t);break}t=function(){G!==2&&G!==9||V!==l||(G=7),lt(l)},e.then(t,t);break l;case 3:G=7;break l;case 4:G=5;break l;case 7:q0(e)?(G=0,Ol=null,l1(t)):(G=0,Ol=null,Xu(l,t,e,7));break;case 5:var f=null;switch(H.tag){case 26:f=H.memoizedState;case 5:case 27:var c=H;if(f?fm(f):c.stateNode.complete){G=0,Ol=null;var i=c.sibling;if(i!==null)H=i;else{var m=c.return;m!==null?(H=m,Xe(m)):H=null}break t}}G=0,Ol=null,Xu(l,t,e,5);break;case 6:G=0,Ol=null,Xu(l,t,e,6);break;case 8:Ti(),F=6;break l;default:throw Error(b(462))}}zh();break}catch(g){Gv(l,g)}while(!0);return mt=ou=null,M.H=a,M.A=n,p=u,H!==null?0:(V=null,q=0,He(),F)}function zh(){for(;H!==null&&!xm();)jv(H)}function jv(l){var t=hv(l.alternate,l,zt);l.memoizedProps=l.pendingProps,t===null?Xe(l):H=t}function l1(l){var t=l,u=t.alternate;switch(t.tag){case 15:case 0:t=w0(u,t,t.pendingProps,t.type,void 0,q);break;case 11:t=w0(u,t,t.pendingProps,t.type.render,t.ref,q);break;case 5:ei(t);default:Sv(u,t),t=H=Sy(t,zt),t=hv(u,t,zt)}l.memoizedProps=l.pendingProps,t===null?Xe(l):H=t}function Xu(l,t,u,a){mt=ou=null,ei(t),xu=null,Ka=0;var n=t.return;try{if(ch(l,n,t,u,q)){F=1,ye(l,jl(u,l.current)),H=null;return}}catch(e){if(n!==null)throw H=n,e;F=1,ye(l,jl(u,l.current)),H=null;return}t.flags&32768?(Y||a===1?l=!0:fa||(q&536870912)!==0?l=!1:(Bt=l=!0,(a===2||a===9||a===3||a===6)&&(a=Rl.current,a!==null&&a.tag===13&&(a.flags|=16384))),Vv(t,l)):Xe(t)}function Xe(l){var t=l;do{if((t.flags&32768)!==0){Vv(t,Bt);return}l=t.return;var u=vh(t.alternate,t,zt);if(u!==null){H=u;return}if(t=t.sibling,t!==null){H=t;return}H=t=l}while(t!==null);F===0&&(F=5)}function Vv(l,t){do{var u=mh(l.alternate,l);if(u!==null){u.flags&=32767,H=u;return}if(u=l.return,u!==null&&(u.flags|=32768,u.subtreeFlags=0,u.deletions=null),!t&&(l=l.sibling,l!==null)){H=l;return}H=l=u}while(l!==null);F=6,H=null}function t1(l,t,u,a,n,e,f,c,i){l.cancelPendingCommit=null;do Qe();while(al!==0);if((p&6)!==0)throw Error(b(327));if(t!==null){if(t===l.current)throw Error(b(177));if(e=t.lanes|t.childLanes,e|=Jc,Im(l,u,e,f,c,i),l===V&&(H=V=null,q=0),Iu=t,jt=l,St=u,zc=e,Tc=n,Rv=a,(t.subtreeFlags&10256)!==0||(t.flags&10256)!==0?(l.callbackNode=null,l.callbackPriority=0,Mh(In,function(){return rv(),null})):(l.callbackNode=null,l.callbackPriority=0),a=(t.flags&13878)!==0,(t.subtreeFlags&13878)!==0||a){a=M.T,M.T=null,n=C.p,C.p=2,f=p,p|=4;try{dh(l,t,u)}finally{p=f,C.p=n,M.T=a}}al=1,xv(),Lv(),Kv()}}function xv(){if(al===1){al=0;var l=jt,t=Iu,u=(t.flags&13878)!==0;if((t.subtreeFlags&13878)!==0||u){u=M.T,M.T=null;var a=C.p;C.p=2;var n=p;p|=4;try{_v(t,l);var e=_c,f=fy(l.containerInfo),c=e.focusedElem,i=e.selectionRange;if(f!==c&&c&&c.ownerDocument&&ey(c.ownerDocument.documentElement,c)){if(i!==null&&Kc(c)){var m=i.start,g=i.end;if(g===void 0&&(g=m),"selectionStart"in c)c.selectionStart=m,c.selectionEnd=Math.min(g,c.value.length);else{var s=c.ownerDocument||document,h=s&&s.defaultView||window;if(h.getSelection){var S=h.getSelection(),z=c.textContent.length,A=Math.min(i.start,z),Q=i.end===void 0?A:Math.min(i.end,z);!S.extend&&A>Q&&(f=Q,Q=A,A=f);var v=M0(c,A),y=M0(c,Q);if(v&&y&&(S.rangeCount!==1||S.anchorNode!==v.node||S.anchorOffset!==v.offset||S.focusNode!==y.node||S.focusOffset!==y.offset)){var d=s.createRange();d.setStart(v.node,v.offset),S.removeAllRanges(),A>Q?(S.addRange(d),S.extend(y.node,y.offset)):(d.setEnd(y.node,y.offset),S.addRange(d))}}}}for(s=[],S=c;S=S.parentNode;)S.nodeType===1&&s.push({element:S,left:S.scrollLeft,top:S.scrollTop});for(typeof c.focus=="function"&&c.focus(),c=0;c<s.length;c++){var o=s[c];o.element.scrollLeft=o.left,o.element.scrollTop=o.top}}Ae=!!Oc,_c=Oc=null}finally{p=n,C.p=a,M.T=u}}l.current=t,al=2}}function Lv(){if(al===2){al=0;var l=jt,t=Iu,u=(t.flags&8772)!==0;if((t.subtreeFlags&8772)!==0||u){u=M.T,M.T=null;var a=C.p;C.p=2;var n=p;p|=4;try{Tv(l,t.alternate,t)}finally{p=n,C.p=a,M.T=u}}al=3}}function Kv(){if(al===4||al===3){al=0,Lm();var l=jt,t=Iu,u=St,a=Rv;(t.subtreeFlags&10256)!==0||(t.flags&10256)!==0?al=5:(al=0,Iu=jt=null,Jv(l,l.pendingLanes));var n=l.pendingLanes;if(n===0&&(Zt=null),Xc(u),t=t.stateNode,Nl&&typeof Nl.onCommitFiberRoot=="function")try{Nl.onCommitFiberRoot(Pa,t,void 0,(t.current.flags&128)===128)}catch{}if(a!==null){t=M.T,n=C.p,C.p=2,M.T=null;try{for(var e=l.onRecoverableError,f=0;f<a.length;f++){var c=a[f];e(c.value,{componentStack:c.stack})}}finally{M.T=t,C.p=n}}(St&3)!==0&&Qe(),lt(l),n=l.pendingLanes,(u&261930)!==0&&(n&42)!==0?l===Ec?Ga++:(Ga=0,Ec=l):Ga=0,cn(0,!1)}}function Jv(l,t){(l.pooledCacheLanes&=t)===0&&(t=l.pooledCache,t!=null&&(l.pooledCache=null,nn(t)))}function Qe(){return xv(),Lv(),Kv(),rv()}function rv(){if(al!==5)return!1;var l=jt,t=zc;zc=0;var u=Xc(St),a=M.T,n=C.p;try{C.p=32>u?32:u,M.T=null,u=Tc,Tc=null;var e=jt,f=St;if(al=0,Iu=jt=null,St=0,(p&6)!==0)throw Error(b(331));var c=p;if(p|=4,qv(e.current),Uv(e,e.current,f,u),p=c,cn(0,!1),Nl&&typeof Nl.onPostCommitFiberRoot=="function")try{Nl.onPostCommitFiberRoot(Pa,e)}catch{}return!0}finally{C.p=n,M.T=a,Jv(l,t)}}function u1(l,t,u){t=jl(u,t),t=Sc(l.stateNode,t,2),l=Qt(l,t,2),l!==null&&(tn(l,2),lt(l))}function X(l,t,u){if(l.tag===3)u1(l,l,u);else for(;t!==null;){if(t.tag===3){u1(t,l,u);break}else if(t.tag===1){var a=t.stateNode;if(typeof t.type.getDerivedStateFromError=="function"||typeof a.componentDidCatch=="function"&&(Zt===null||!Zt.has(a))){l=jl(u,l),u=cv(2),a=Qt(t,u,2),a!==null&&(iv(u,a,t,l),tn(a,2),lt(a));break}}t=t.return}}function Bf(l,t,u){var a=l.pingCache;if(a===null){a=l.pingCache=new gh;var n=new Set;a.set(t,n)}else n=a.get(t),n===void 0&&(n=new Set,a.set(t,n));n.has(u)||(bi=!0,n.add(u),l=Th.bind(null,l,t,u),t.then(l,l))}function Th(l,t,u){var a=l.pingCache;a!==null&&a.delete(t),l.pingedLanes|=l.suspendedLanes&u,l.warmLanes&=~u,V===l&&(q&u)===u&&(F===4||F===3&&(q&62914560)===q&&300>Hl()-Ce?(p&2)===0&&Pu(l,0):zi|=u,ku===q&&(ku=0)),lt(l)}function wv(l,t){t===0&&(t=Q1()),l=gu(l,t),l!==null&&(tn(l,t),lt(l))}function Eh(l){var t=l.memoizedState,u=0;t!==null&&(u=t.retryLane),wv(l,u)}function Ah(l,t){var u=0;switch(l.tag){case 31:case 13:var a=l.stateNode,n=l.memoizedState;n!==null&&(u=n.retryLane);break;case 19:a=l.stateNode;break;case 22:a=l.stateNode._retryCache;break;default:throw Error(b(314))}a!==null&&a.delete(t),wv(l,u)}function Mh(l,t){return Cc(l,t)}var ge=null,_u=null,Ac=!1,oe=!1,Rf=!1,pt=0;function lt(l){l!==_u&&l.next===null&&(_u===null?ge=_u=l:_u=_u.next=l),oe=!0,Ac||(Ac=!0,_h())}function cn(l,t){if(!Rf&&oe){Rf=!0;do for(var u=!1,a=ge;a!==null;){if(!t)if(l!==0){var n=a.pendingLanes;if(n===0)var e=0;else{var f=a.suspendedLanes,c=a.pingedLanes;e=(1<<31-ql(42|l)+1)-1,e&=n&~(f&~c),e=e&201326741?e&201326741|1:e?e|2:0}e!==0&&(u=!0,a1(a,e))}else e=q,e=Oe(a,a===V?e:0,a.cancelPendingCommit!==null||a.timeoutHandle!==-1),(e&3)===0||ln(a,e)||(u=!0,a1(a,e));a=a.next}while(u);Rf=!1}}function Oh(){Wv()}function Wv(){oe=Ac=!1;var l=0;pt!==0&&Rh()&&(l=pt);for(var t=Hl(),u=null,a=ge;a!==null;){var n=a.next,e=$v(a,t);e===0?(a.next=null,u===null?ge=n:u.next=n,n===null&&(_u=u)):(u=a,(l!==0||(e&3)!==0)&&(oe=!0)),a=n}al!==0&&al!==5||cn(l,!1),pt!==0&&(pt=0)}function $v(l,t){for(var u=l.suspendedLanes,a=l.pingedLanes,n=l.expirationTimes,e=l.pendingLanes&-62914561;0<e;){var f=31-ql(e),c=1<<f,i=n[f];i===-1?((c&u)===0||(c&a)!==0)&&(n[f]=km(c,t)):i<=t&&(l.expiredLanes|=c),e&=~c}if(t=V,u=q,u=Oe(l,l===t?u:0,l.cancelPendingCommit!==null||l.timeoutHandle!==-1),a=l.callbackNode,u===0||l===t&&(G===2||G===9)||l.cancelPendingCommit!==null)return a!==null&&a!==null&&cf(a),l.callbackNode=null,l.callbackPriority=0;if((u&3)===0||ln(l,u)){if(t=u&-u,t===l.callbackPriority)return t;switch(a!==null&&cf(a),Xc(u)){case 2:case 8:u=G1;break;case 32:u=In;break;case 268435456:u=X1;break;default:u=In}return a=Fv.bind(null,l),u=Cc(u,a),l.callbackPriority=t,l.callbackNode=u,t}return a!==null&&a!==null&&cf(a),l.callbackPriority=2,l.callbackNode=null,2}function Fv(l,t){if(al!==0&&al!==5)return l.callbackNode=null,l.callbackPriority=0,null;var u=l.callbackNode;if(Qe()&&l.callbackNode!==u)return null;var a=q;return a=Oe(l,l===V?a:0,l.cancelPendingCommit!==null||l.timeoutHandle!==-1),a===0?null:(Cv(l,a,t),$v(l,Hl()),l.callbackNode!=null&&l.callbackNode===u?Fv.bind(null,l):null)}function a1(l,t){if(Qe())return null;Cv(l,t,!0)}function _h(){Ch(function(){(p&6)!==0?Cc(C1,Oh):Wv()})}function Ei(){if(pt===0){var l=Wu;l===0&&(l=sn,sn<<=1,(sn&261888)===0&&(sn=256)),pt=l}return pt}function n1(l){return l==null||typeof l=="symbol"||typeof l=="boolean"?null:typeof l=="function"?l:Cn(""+l)}function e1(l,t){var u=t.ownerDocument.createElement("input");return u.name=t.name,u.value=t.value,l.id&&u.setAttribute("form",l.id),t.parentNode.insertBefore(u,t),l=new FormData(l),u.parentNode.removeChild(u),l}function Dh(l,t,u,a,n){if(t==="submit"&&u&&u.stateNode===n){var e=n1((n[Al]||null).action),f=a.submitter;f&&(t=(t=f[Al]||null)?n1(t.formAction):f.getAttribute("formAction"),t!==null&&(e=t,f=null));var c=new _e("action","action",null,a,n);l.push({event:c,listeners:[{instance:null,listener:function(){if(a.defaultPrevented){if(pt!==0){var i=f?e1(n,f):new FormData(n);dc(u,{pending:!0,data:i,method:n.method,action:e},null,i)}}else typeof e=="function"&&(c.preventDefault(),i=f?e1(n,f):new FormData(n),dc(u,{pending:!0,data:i,method:n.method,action:e},e,i))},currentTarget:n}]})}}for(Nn=0;Nn<lc.length;Nn++)qn=lc[Nn],f1=qn.toLowerCase(),c1=qn[0].toUpperCase()+qn.slice(1),wl(f1,"on"+c1);var qn,f1,c1,Nn;wl(iy,"onAnimationEnd");wl(yy,"onAnimationIteration");wl(vy,"onAnimationStart");wl("dblclick","onDoubleClick");wl("focusin","onFocus");wl("focusout","onBlur");wl(Kd,"onTransitionRun");wl(Jd,"onTransitionStart");wl(rd,"onTransitionCancel");wl(my,"onTransitionEnd");ru("onMouseEnter",["mouseout","mouseover"]);ru("onMouseLeave",["mouseout","mouseover"]);ru("onPointerEnter",["pointerout","pointerover"]);ru("onPointerLeave",["pointerout","pointerover"]);du("onChange","change click focusin focusout input keydown keyup selectionchange".split(" "));du("onSelect","focusout contextmenu dragend focusin keydown keyup mousedown mouseup selectionchange".split(" "));du("onBeforeInput",["compositionend","keypress","textInput","paste"]);du("onCompositionEnd","compositionend focusout keydown keypress keyup mousedown".split(" "));du("onCompositionStart","compositionstart focusout keydown keypress keyup mousedown".split(" "));du("onCompositionUpdate","compositionupdate focusout keydown keypress keyup mousedown".split(" "));var wa="abort canplay canplaythrough durationchange emptied encrypted ended error loadeddata loadedmetadata loadstart pause play playing progress ratechange resize seeked seeking stalled suspend timeupdate volumechange waiting".split(" "),Uh=new Set("beforetoggle cancel close invalid load scroll scrollend toggle".split(" ").concat(wa));function kv(l,t){t=(t&4)!==0;for(var u=0;u<l.length;u++){var a=l[u],n=a.event;a=a.listeners;l:{var e=void 0;if(t)for(var f=a.length-1;0<=f;f--){var c=a[f],i=c.instance,m=c.currentTarget;if(c=c.listener,i!==e&&n.isPropagationStopped())break l;e=c,n.currentTarget=m;try{e(n)}catch(g){le(g)}n.currentTarget=null,e=i}else for(f=0;f<a.length;f++){if(c=a[f],i=c.instance,m=c.currentTarget,c=c.listener,i!==e&&n.isPropagationStopped())break l;e=c,n.currentTarget=m;try{e(n)}catch(g){le(g)}n.currentTarget=null,e=i}}}}function U(l,t){var u=t[rf];u===void 0&&(u=t[rf]=new Set);var a=l+"__bubble";u.has(a)||(Iv(t,l,2,!1),u.add(a))}function pf(l,t,u){var a=0;t&&(a|=4),Iv(u,l,a,t)}var Yn="_reactListening"+Math.random().toString(36).slice(2);function Ai(l){if(!l[Yn]){l[Yn]=!0,L1.forEach(function(u){u!=="selectionchange"&&(Uh.has(u)||pf(u,!1,l),pf(u,!0,l))});var t=l.nodeType===9?l:l.ownerDocument;t===null||t[Yn]||(t[Yn]=!0,pf("selectionchange",!1,t))}}function Iv(l,t,u,a){switch(mm(t)){case 2:var n=t2;break;case 8:n=u2;break;default:n=Di}u=n.bind(null,t,u,l),n=void 0,!kf||t!=="touchstart"&&t!=="touchmove"&&t!=="wheel"||(n=!0),a?n!==void 0?l.addEventListener(t,u,{capture:!0,passive:n}):l.addEventListener(t,u,!0):n!==void 0?l.addEventListener(t,u,{passive:n}):l.addEventListener(t,u,!1)}function Cf(l,t,u,a,n){var e=a;if((t&1)===0&&(t&2)===0&&a!==null)l:for(;;){if(a===null)return;var f=a.tag;if(f===3||f===4){var c=a.stateNode.containerInfo;if(c===n)break;if(f===4)for(f=a.return;f!==null;){var i=f.tag;if((i===3||i===4)&&f.stateNode.containerInfo===n)return;f=f.return}for(;c!==null;){if(f=Hu(c),f===null)return;if(i=f.tag,i===5||i===6||i===26||i===27){a=e=f;continue l}c=c.parentNode}}a=a.return}k1(function(){var m=e,g=jc(u),s=[];l:{var h=dy.get(l);if(h!==void 0){var S=_e,z=l;switch(l){case"keypress":if(Xn(u)===0)break l;case"keydown":case"keyup":S=Ad;break;case"focusin":z="focus",S=hf;break;case"focusout":z="blur",S=hf;break;case"beforeblur":case"afterblur":S=hf;break;case"click":if(u.button===2)break l;case"auxclick":case"dblclick":case"mousedown":case"mousemove":case"mouseup":case"mouseout":case"mouseover":case"contextmenu":S=S0;break;case"drag":case"dragend":case"dragenter":case"dragexit":case"dragleave":case"dragover":case"dragstart":case"drop":S=vd;break;case"touchcancel":case"touchend":case"touchmove":case"touchstart":S=_d;break;case iy:case yy:case vy:S=hd;break;case my:S=Ud;break;case"scroll":case"scrollend":S=id;break;case"wheel":S=Nd;break;case"copy":case"cut":case"paste":S=gd;break;case"gotpointercapture":case"lostpointercapture":case"pointercancel":case"pointerdown":case"pointermove":case"pointerout":case"pointerover":case"pointerup":S=o0;break;case"toggle":case"beforetoggle":S=Yd}var A=(t&4)!==0,Q=!A&&(l==="scroll"||l==="scrollend"),v=A?h!==null?h+"Capture":null:h;A=[];for(var y=m,d;y!==null;){var o=y;if(d=o.stateNode,o=o.tag,o!==5&&o!==26&&o!==27||d===null||v===null||(o=Za(y,v),o!=null&&A.push(Wa(y,o,d))),Q)break;y=y.return}0<A.length&&(h=new S(h,z,null,u,g),s.push({event:h,listeners:A}))}}if((t&7)===0){l:{if(h=l==="mouseover"||l==="pointerover",S=l==="mouseout"||l==="pointerout",h&&u!==Ff&&(z=u.relatedTarget||u.fromElement)&&(Hu(z)||z[ua]))break l;if((S||h)&&(h=g.window===g?g:(h=g.ownerDocument)?h.defaultView||h.parentWindow:window,S?(z=u.relatedTarget||u.toElement,S=m,z=z?Hu(z):null,z!==null&&(Q=Ia(z),A=z.tag,z!==Q||A!==5&&A!==27&&A!==6)&&(z=null)):(S=null,z=m),S!==z)){if(A=S0,o="onMouseLeave",v="onMouseEnter",y="mouse",(l==="pointerout"||l==="pointerover")&&(A=o0,o="onPointerLeave",v="onPointerEnter",y="pointer"),Q=S==null?h:Aa(S),d=z==null?h:Aa(z),h=new A(o,y+"leave",S,u,g),h.target=Q,h.relatedTarget=d,o=null,Hu(g)===m&&(A=new A(v,y+"enter",z,u,g),A.target=d,A.relatedTarget=Q,o=A),Q=o,S&&z)t:{for(A=Hh,v=S,y=z,d=0,o=v;o;o=A(o))d++;o=0;for(var E=y;E;E=A(E))o++;for(;0<d-o;)v=A(v),d--;for(;0<o-d;)y=A(y),o--;for(;d--;){if(v===y||y!==null&&v===y.alternate){A=v;break t}v=A(v),y=A(y)}A=null}else A=null;S!==null&&i1(s,h,S,A,!1),z!==null&&Q!==null&&i1(s,Q,z,A,!0)}}l:{if(h=m?Aa(m):window,S=h.nodeName&&h.nodeName.toLowerCase(),S==="select"||S==="input"&&h.type==="file")var B=T0;else if(z0(h))if(ay)B=Vd;else{B=Zd;var T=Qd}else S=h.nodeName,!S||S.toLowerCase()!=="input"||h.type!=="checkbox"&&h.type!=="radio"?m&&Zc(m.elementType)&&(B=T0):B=jd;if(B&&(B=B(l,m))){uy(s,B,u,g);break l}T&&T(l,h,m),l==="focusout"&&m&&h.type==="number"&&m.memoizedProps.value!=null&&$f(h,"number",h.value)}switch(T=m?Aa(m):window,l){case"focusin":(z0(T)||T.contentEditable==="true")&&(Yu=T,If=m,Ua=null);break;case"focusout":Ua=If=Yu=null;break;case"mousedown":Pf=!0;break;case"contextmenu":case"mouseup":case"dragend":Pf=!1,O0(s,u,g);break;case"selectionchange":if(Ld)break;case"keydown":case"keyup":O0(s,u,g)}var D;if(Lc)l:{switch(l){case"compositionstart":var N="onCompositionStart";break l;case"compositionend":N="onCompositionEnd";break l;case"compositionupdate":N="onCompositionUpdate";break l}N=void 0}else qu?ly(l,u)&&(N="onCompositionEnd"):l==="keydown"&&u.keyCode===229&&(N="onCompositionStart");N&&(P1&&u.locale!=="ko"&&(qu||N!=="onCompositionStart"?N==="onCompositionEnd"&&qu&&(D=I1()):(Yt=g,Vc="value"in Yt?Yt.value:Yt.textContent,qu=!0)),T=se(m,N),0<T.length&&(N=new g0(N,l,null,u,g),s.push({event:N,listeners:T}),D?N.data=D:(D=ty(u),D!==null&&(N.data=D)))),(D=Rd?pd(l,u):Cd(l,u))&&(N=se(m,"onBeforeInput"),0<N.length&&(T=new g0("onBeforeInput","beforeinput",null,u,g),s.push({event:T,listeners:N}),T.data=D)),Dh(s,l,m,u,g)}kv(s,t)})}function Wa(l,t,u){return{instance:l,listener:t,currentTarget:u}}function se(l,t){for(var u=t+"Capture",a=[];l!==null;){var n=l,e=n.stateNode;if(n=n.tag,n!==5&&n!==26&&n!==27||e===null||(n=Za(l,u),n!=null&&a.unshift(Wa(l,n,e)),n=Za(l,t),n!=null&&a.push(Wa(l,n,e))),l.tag===3)return a;l=l.return}return[]}function Hh(l){if(l===null)return null;do l=l.return;while(l&&l.tag!==5&&l.tag!==27);return l||null}function i1(l,t,u,a,n){for(var e=t._reactName,f=[];u!==null&&u!==a;){var c=u,i=c.alternate,m=c.stateNode;if(c=c.tag,i!==null&&i===a)break;c!==5&&c!==26&&c!==27||m===null||(i=m,n?(m=Za(u,e),m!=null&&f.unshift(Wa(u,m,i))):n||(m=Za(u,e),m!=null&&f.push(Wa(u,m,i)))),u=u.return}f.length!==0&&l.push({event:t,listeners:f})}var Nh=/\r\n?/g,qh=/\u0000|\uFFFD/g;function y1(l){return(typeof l=="string"?l:""+l).replace(Nh,`
`).replace(qh,"")}function Pv(l,t){return t=y1(t),y1(l)===t}function Z(l,t,u,a,n,e){switch(u){case"children":typeof a=="string"?t==="body"||t==="textarea"&&a===""||wu(l,a):(typeof a=="number"||typeof a=="bigint")&&t!=="body"&&wu(l,""+a);break;case"className":Tn(l,"class",a);break;case"tabIndex":Tn(l,"tabindex",a);break;case"dir":case"role":case"viewBox":case"width":case"height":Tn(l,u,a);break;case"style":F1(l,a,e);break;case"data":if(t!=="object"){Tn(l,"data",a);break}case"src":case"href":if(a===""&&(t!=="a"||u!=="href")){l.removeAttribute(u);break}if(a==null||typeof a=="function"||typeof a=="symbol"||typeof a=="boolean"){l.removeAttribute(u);break}a=Cn(""+a),l.setAttribute(u,a);break;case"action":case"formAction":if(typeof a=="function"){l.setAttribute(u,"javascript:throw new Error('A React form was unexpectedly submitted. If you called form.submit() manually, consider using form.requestSubmit() instead. If you\\'re trying to use event.stopPropagation() in a submit event handler, consider also calling event.preventDefault().')");break}else typeof e=="function"&&(u==="formAction"?(t!=="input"&&Z(l,t,"name",n.name,n,null),Z(l,t,"formEncType",n.formEncType,n,null),Z(l,t,"formMethod",n.formMethod,n,null),Z(l,t,"formTarget",n.formTarget,n,null)):(Z(l,t,"encType",n.encType,n,null),Z(l,t,"method",n.method,n,null),Z(l,t,"target",n.target,n,null)));if(a==null||typeof a=="symbol"||typeof a=="boolean"){l.removeAttribute(u);break}a=Cn(""+a),l.setAttribute(u,a);break;case"onClick":a!=null&&(l.onclick=vt);break;case"onScroll":a!=null&&U("scroll",l);break;case"onScrollEnd":a!=null&&U("scrollend",l);break;case"dangerouslySetInnerHTML":if(a!=null){if(typeof a!="object"||!("__html"in a))throw Error(b(61));if(u=a.__html,u!=null){if(n.children!=null)throw Error(b(60));l.innerHTML=u}}break;case"multiple":l.multiple=a&&typeof a!="function"&&typeof a!="symbol";break;case"muted":l.muted=a&&typeof a!="function"&&typeof a!="symbol";break;case"suppressContentEditableWarning":case"suppressHydrationWarning":case"defaultValue":case"defaultChecked":case"innerHTML":case"ref":break;case"autoFocus":break;case"xlinkHref":if(a==null||typeof a=="function"||typeof a=="boolean"||typeof a=="symbol"){l.removeAttribute("xlink:href");break}u=Cn(""+a),l.setAttributeNS("http://www.w3.org/1999/xlink","xlink:href",u);break;case"contentEditable":case"spellCheck":case"draggable":case"value":case"autoReverse":case"externalResourcesRequired":case"focusable":case"preserveAlpha":a!=null&&typeof a!="function"&&typeof a!="symbol"?l.setAttribute(u,""+a):l.removeAttribute(u);break;case"inert":case"allowFullScreen":case"async":case"autoPlay":case"controls":case"default":case"defer":case"disabled":case"disablePictureInPicture":case"disableRemotePlayback":case"formNoValidate":case"hidden":case"loop":case"noModule":case"noValidate":case"open":case"playsInline":case"readOnly":case"required":case"reversed":case"scoped":case"seamless":case"itemScope":a&&typeof a!="function"&&typeof a!="symbol"?l.setAttribute(u,""):l.removeAttribute(u);break;case"capture":case"download":a===!0?l.setAttribute(u,""):a!==!1&&a!=null&&typeof a!="function"&&typeof a!="symbol"?l.setAttribute(u,a):l.removeAttribute(u);break;case"cols":case"rows":case"size":case"span":a!=null&&typeof a!="function"&&typeof a!="symbol"&&!isNaN(a)&&1<=a?l.setAttribute(u,a):l.removeAttribute(u);break;case"rowSpan":case"start":a==null||typeof a=="function"||typeof a=="symbol"||isNaN(a)?l.removeAttribute(u):l.setAttribute(u,a);break;case"popover":U("beforetoggle",l),U("toggle",l),pn(l,"popover",a);break;case"xlinkActuate":ut(l,"http://www.w3.org/1999/xlink","xlink:actuate",a);break;case"xlinkArcrole":ut(l,"http://www.w3.org/1999/xlink","xlink:arcrole",a);break;case"xlinkRole":ut(l,"http://www.w3.org/1999/xlink","xlink:role",a);break;case"xlinkShow":ut(l,"http://www.w3.org/1999/xlink","xlink:show",a);break;case"xlinkTitle":ut(l,"http://www.w3.org/1999/xlink","xlink:title",a);break;case"xlinkType":ut(l,"http://www.w3.org/1999/xlink","xlink:type",a);break;case"xmlBase":ut(l,"http://www.w3.org/XML/1998/namespace","xml:base",a);break;case"xmlLang":ut(l,"http://www.w3.org/XML/1998/namespace","xml:lang",a);break;case"xmlSpace":ut(l,"http://www.w3.org/XML/1998/namespace","xml:space",a);break;case"is":pn(l,"is",a);break;case"innerText":case"textContent":break;default:(!(2<u.length)||u[0]!=="o"&&u[0]!=="O"||u[1]!=="n"&&u[1]!=="N")&&(u=fd.get(u)||u,pn(l,u,a))}}function Mc(l,t,u,a,n,e){switch(u){case"style":F1(l,a,e);break;case"dangerouslySetInnerHTML":if(a!=null){if(typeof a!="object"||!("__html"in a))throw Error(b(61));if(u=a.__html,u!=null){if(n.children!=null)throw Error(b(60));l.innerHTML=u}}break;case"children":typeof a=="string"?wu(l,a):(typeof a=="number"||typeof a=="bigint")&&wu(l,""+a);break;case"onScroll":a!=null&&U("scroll",l);break;case"onScrollEnd":a!=null&&U("scrollend",l);break;case"onClick":a!=null&&(l.onclick=vt);break;case"suppressContentEditableWarning":case"suppressHydrationWarning":case"innerHTML":case"ref":break;case"innerText":case"textContent":break;default:if(!K1.hasOwnProperty(u))l:{if(u[0]==="o"&&u[1]==="n"&&(n=u.endsWith("Capture"),t=u.slice(2,n?u.length-7:void 0),e=l[Al]||null,e=e!=null?e[u]:null,typeof e=="function"&&l.removeEventListener(t,e,n),typeof a=="function")){typeof e!="function"&&e!==null&&(u in l?l[u]=null:l.hasAttribute(u)&&l.removeAttribute(u)),l.addEventListener(t,a,n);break l}u in l?l[u]=a:a===!0?l.setAttribute(u,""):pn(l,u,a)}}}function dl(l,t,u){switch(t){case"div":case"span":case"svg":case"path":case"a":case"g":case"p":case"li":break;case"img":U("error",l),U("load",l);var a=!1,n=!1,e;for(e in u)if(u.hasOwnProperty(e)){var f=u[e];if(f!=null)switch(e){case"src":a=!0;break;case"srcSet":n=!0;break;case"children":case"dangerouslySetInnerHTML":throw Error(b(137,t));default:Z(l,t,e,f,u,null)}}n&&Z(l,t,"srcSet",u.srcSet,u,null),a&&Z(l,t,"src",u.src,u,null);return;case"input":U("invalid",l);var c=e=f=n=null,i=null,m=null;for(a in u)if(u.hasOwnProperty(a)){var g=u[a];if(g!=null)switch(a){case"name":n=g;break;case"type":f=g;break;case"checked":i=g;break;case"defaultChecked":m=g;break;case"value":e=g;break;case"defaultValue":c=g;break;case"children":case"dangerouslySetInnerHTML":if(g!=null)throw Error(b(137,t));break;default:Z(l,t,a,g,u,null)}}w1(l,e,c,i,m,f,n,!1);return;case"select":U("invalid",l),a=f=e=null;for(n in u)if(u.hasOwnProperty(n)&&(c=u[n],c!=null))switch(n){case"value":e=c;break;case"defaultValue":f=c;break;case"multiple":a=c;default:Z(l,t,n,c,u,null)}t=e,u=f,l.multiple=!!a,t!=null?Zu(l,!!a,t,!1):u!=null&&Zu(l,!!a,u,!0);return;case"textarea":U("invalid",l),e=n=a=null;for(f in u)if(u.hasOwnProperty(f)&&(c=u[f],c!=null))switch(f){case"value":a=c;break;case"defaultValue":n=c;break;case"children":e=c;break;case"dangerouslySetInnerHTML":if(c!=null)throw Error(b(91));break;default:Z(l,t,f,c,u,null)}$1(l,a,n,e);return;case"option":for(i in u)if(u.hasOwnProperty(i)&&(a=u[i],a!=null))switch(i){case"selected":l.selected=a&&typeof a!="function"&&typeof a!="symbol";break;default:Z(l,t,i,a,u,null)}return;case"dialog":U("beforetoggle",l),U("toggle",l),U("cancel",l),U("close",l);break;case"iframe":case"object":U("load",l);break;case"video":case"audio":for(a=0;a<wa.length;a++)U(wa[a],l);break;case"image":U("error",l),U("load",l);break;case"details":U("toggle",l);break;case"embed":case"source":case"link":U("error",l),U("load",l);case"area":case"base":case"br":case"col":case"hr":case"keygen":case"meta":case"param":case"track":case"wbr":case"menuitem":for(m in u)if(u.hasOwnProperty(m)&&(a=u[m],a!=null))switch(m){case"children":case"dangerouslySetInnerHTML":throw Error(b(137,t));default:Z(l,t,m,a,u,null)}return;default:if(Zc(t)){for(g in u)u.hasOwnProperty(g)&&(a=u[g],a!==void 0&&Mc(l,t,g,a,u,void 0));return}}for(c in u)u.hasOwnProperty(c)&&(a=u[c],a!=null&&Z(l,t,c,a,u,null))}function Yh(l,t,u,a){switch(t){case"div":case"span":case"svg":case"path":case"a":case"g":case"p":case"li":break;case"input":var n=null,e=null,f=null,c=null,i=null,m=null,g=null;for(S in u){var s=u[S];if(u.hasOwnProperty(S)&&s!=null)switch(S){case"checked":break;case"value":break;case"defaultValue":i=s;default:a.hasOwnProperty(S)||Z(l,t,S,null,a,s)}}for(var h in a){var S=a[h];if(s=u[h],a.hasOwnProperty(h)&&(S!=null||s!=null))switch(h){case"type":e=S;break;case"name":n=S;break;case"checked":m=S;break;case"defaultChecked":g=S;break;case"value":f=S;break;case"defaultValue":c=S;break;case"children":case"dangerouslySetInnerHTML":if(S!=null)throw Error(b(137,t));break;default:S!==s&&Z(l,t,h,S,a,s)}}Wf(l,f,c,i,m,g,e,n);return;case"select":S=f=c=h=null;for(e in u)if(i=u[e],u.hasOwnProperty(e)&&i!=null)switch(e){case"value":break;case"multiple":S=i;default:a.hasOwnProperty(e)||Z(l,t,e,null,a,i)}for(n in a)if(e=a[n],i=u[n],a.hasOwnProperty(n)&&(e!=null||i!=null))switch(n){case"value":h=e;break;case"defaultValue":c=e;break;case"multiple":f=e;default:e!==i&&Z(l,t,n,e,a,i)}t=c,u=f,a=S,h!=null?Zu(l,!!u,h,!1):!!a!=!!u&&(t!=null?Zu(l,!!u,t,!0):Zu(l,!!u,u?[]:"",!1));return;case"textarea":S=h=null;for(c in u)if(n=u[c],u.hasOwnProperty(c)&&n!=null&&!a.hasOwnProperty(c))switch(c){case"value":break;case"children":break;default:Z(l,t,c,null,a,n)}for(f in a)if(n=a[f],e=u[f],a.hasOwnProperty(f)&&(n!=null||e!=null))switch(f){case"value":h=n;break;case"defaultValue":S=n;break;case"children":break;case"dangerouslySetInnerHTML":if(n!=null)throw Error(b(91));break;default:n!==e&&Z(l,t,f,n,a,e)}W1(l,h,S);return;case"option":for(var z in u)if(h=u[z],u.hasOwnProperty(z)&&h!=null&&!a.hasOwnProperty(z))switch(z){case"selected":l.selected=!1;break;default:Z(l,t,z,null,a,h)}for(i in a)if(h=a[i],S=u[i],a.hasOwnProperty(i)&&h!==S&&(h!=null||S!=null))switch(i){case"selected":l.selected=h&&typeof h!="function"&&typeof h!="symbol";break;default:Z(l,t,i,h,a,S)}return;case"img":case"link":case"area":case"base":case"br":case"col":case"embed":case"hr":case"keygen":case"meta":case"param":case"source":case"track":case"wbr":case"menuitem":for(var A in u)h=u[A],u.hasOwnProperty(A)&&h!=null&&!a.hasOwnProperty(A)&&Z(l,t,A,null,a,h);for(m in a)if(h=a[m],S=u[m],a.hasOwnProperty(m)&&h!==S&&(h!=null||S!=null))switch(m){case"children":case"dangerouslySetInnerHTML":if(h!=null)throw Error(b(137,t));break;default:Z(l,t,m,h,a,S)}return;default:if(Zc(t)){for(var Q in u)h=u[Q],u.hasOwnProperty(Q)&&h!==void 0&&!a.hasOwnProperty(Q)&&Mc(l,t,Q,void 0,a,h);for(g in a)h=a[g],S=u[g],!a.hasOwnProperty(g)||h===S||h===void 0&&S===void 0||Mc(l,t,g,h,a,S);return}}for(var v in u)h=u[v],u.hasOwnProperty(v)&&h!=null&&!a.hasOwnProperty(v)&&Z(l,t,v,null,a,h);for(s in a)h=a[s],S=u[s],!a.hasOwnProperty(s)||h===S||h==null&&S==null||Z(l,t,s,h,a,S)}function v1(l){switch(l){case"css":case"script":case"font":case"img":case"image":case"input":case"link":return!0;default:return!1}}function Bh(){if(typeof performance.getEntriesByType=="function"){for(var l=0,t=0,u=performance.getEntriesByType("resource"),a=0;a<u.length;a++){var n=u[a],e=n.transferSize,f=n.initiatorType,c=n.duration;if(e&&c&&v1(f)){for(f=0,c=n.responseEnd,a+=1;a<u.length;a++){var i=u[a],m=i.startTime;if(m>c)break;var g=i.transferSize,s=i.initiatorType;g&&v1(s)&&(i=i.responseEnd,f+=g*(i<c?1:(c-m)/(i-m)))}if(--a,t+=8*(e+f)/(n.duration/1e3),l++,10<l)break}}if(0<l)return t/l/1e6}return navigator.connection&&(l=navigator.connection.downlink,typeof l=="number")?l:5}var Oc=null,_c=null;function be(l){return l.nodeType===9?l:l.ownerDocument}function m1(l){switch(l){case"http://www.w3.org/2000/svg":return 1;case"http://www.w3.org/1998/Math/MathML":return 2;default:return 0}}function lm(l,t){if(l===0)switch(t){case"svg":return 1;case"math":return 2;default:return 0}return l===1&&t==="foreignObject"?0:l}function Dc(l,t){return l==="textarea"||l==="noscript"||typeof t.children=="string"||typeof t.children=="number"||typeof t.children=="bigint"||typeof t.dangerouslySetInnerHTML=="object"&&t.dangerouslySetInnerHTML!==null&&t.dangerouslySetInnerHTML.__html!=null}var Gf=null;function Rh(){var l=window.event;return l&&l.type==="popstate"?l===Gf?!1:(Gf=l,!0):(Gf=null,!1)}var tm=typeof setTimeout=="function"?setTimeout:void 0,ph=typeof clearTimeout=="function"?clearTimeout:void 0,d1=typeof Promise=="function"?Promise:void 0,Ch=typeof queueMicrotask=="function"?queueMicrotask:typeof d1<"u"?function(l){return d1.resolve(null).then(l).catch(Gh)}:tm;function Gh(l){setTimeout(function(){throw l})}function $t(l){return l==="head"}function h1(l,t){var u=t,a=0;do{var n=u.nextSibling;if(l.removeChild(u),n&&n.nodeType===8)if(u=n.data,u==="/$"||u==="/&"){if(a===0){l.removeChild(n),ta(t);return}a--}else if(u==="$"||u==="$?"||u==="$~"||u==="$!"||u==="&")a++;else if(u==="html")Xa(l.ownerDocument.documentElement);else if(u==="head"){u=l.ownerDocument.head,Xa(u);for(var e=u.firstChild;e;){var f=e.nextSibling,c=e.nodeName;e[un]||c==="SCRIPT"||c==="STYLE"||c==="LINK"&&e.rel.toLowerCase()==="stylesheet"||u.removeChild(e),e=f}}else u==="body"&&Xa(l.ownerDocument.body);u=n}while(u);ta(t)}function S1(l,t){var u=l;l=0;do{var a=u.nextSibling;if(u.nodeType===1?t?(u._stashedDisplay=u.style.display,u.style.display="none"):(u.style.display=u._stashedDisplay||"",u.getAttribute("style")===""&&u.removeAttribute("style")):u.nodeType===3&&(t?(u._stashedText=u.nodeValue,u.nodeValue=""):u.nodeValue=u._stashedText||""),a&&a.nodeType===8)if(u=a.data,u==="/$"){if(l===0)break;l--}else u!=="$"&&u!=="$?"&&u!=="$~"&&u!=="$!"||l++;u=a}while(u)}function Uc(l){var t=l.firstChild;for(t&&t.nodeType===10&&(t=t.nextSibling);t;){var u=t;switch(t=t.nextSibling,u.nodeName){case"HTML":case"HEAD":case"BODY":Uc(u),Qc(u);continue;case"SCRIPT":case"STYLE":continue;case"LINK":if(u.rel.toLowerCase()==="stylesheet")continue}l.removeChild(u)}}function Xh(l,t,u,a){for(;l.nodeType===1;){var n=u;if(l.nodeName.toLowerCase()!==t.toLowerCase()){if(!a&&(l.nodeName!=="INPUT"||l.type!=="hidden"))break}else if(a){if(!l[un])switch(t){case"meta":if(!l.hasAttribute("itemprop"))break;return l;case"link":if(e=l.getAttribute("rel"),e==="stylesheet"&&l.hasAttribute("data-precedence"))break;if(e!==n.rel||l.getAttribute("href")!==(n.href==null||n.href===""?null:n.href)||l.getAttribute("crossorigin")!==(n.crossOrigin==null?null:n.crossOrigin)||l.getAttribute("title")!==(n.title==null?null:n.title))break;return l;case"style":if(l.hasAttribute("data-precedence"))break;return l;case"script":if(e=l.getAttribute("src"),(e!==(n.src==null?null:n.src)||l.getAttribute("type")!==(n.type==null?null:n.type)||l.getAttribute("crossorigin")!==(n.crossOrigin==null?null:n.crossOrigin))&&e&&l.hasAttribute("async")&&!l.hasAttribute("itemprop"))break;return l;default:return l}}else if(t==="input"&&l.type==="hidden"){var e=n.name==null?null:""+n.name;if(n.type==="hidden"&&l.getAttribute("name")===e)return l}else return l;if(l=Ll(l.nextSibling),l===null)break}return null}function Qh(l,t,u){if(t==="")return null;for(;l.nodeType!==3;)if((l.nodeType!==1||l.nodeName!=="INPUT"||l.type!=="hidden")&&!u||(l=Ll(l.nextSibling),l===null))return null;return l}function um(l,t){for(;l.nodeType!==8;)if((l.nodeType!==1||l.nodeName!=="INPUT"||l.type!=="hidden")&&!t||(l=Ll(l.nextSibling),l===null))return null;return l}function Hc(l){return l.data==="$?"||l.data==="$~"}function Nc(l){return l.data==="$!"||l.data==="$?"&&l.ownerDocument.readyState!=="loading"}function Zh(l,t){var u=l.ownerDocument;if(l.data==="$~")l._reactRetry=t;else if(l.data!=="$?"||u.readyState!=="loading")t();else{var a=function(){t(),u.removeEventListener("DOMContentLoaded",a)};u.addEventListener("DOMContentLoaded",a),l._reactRetry=a}}function Ll(l){for(;l!=null;l=l.nextSibling){var t=l.nodeType;if(t===1||t===3)break;if(t===8){if(t=l.data,t==="$"||t==="$!"||t==="$?"||t==="$~"||t==="&"||t==="F!"||t==="F")break;if(t==="/$"||t==="/&")return null}}return l}var qc=null;function g1(l){l=l.nextSibling;for(var t=0;l;){if(l.nodeType===8){var u=l.data;if(u==="/$"||u==="/&"){if(t===0)return Ll(l.nextSibling);t--}else u!=="$"&&u!=="$!"&&u!=="$?"&&u!=="$~"&&u!=="&"||t++}l=l.nextSibling}return null}function o1(l){l=l.previousSibling;for(var t=0;l;){if(l.nodeType===8){var u=l.data;if(u==="$"||u==="$!"||u==="$?"||u==="$~"||u==="&"){if(t===0)return l;t--}else u!=="/$"&&u!=="/&"||t++}l=l.previousSibling}return null}function am(l,t,u){switch(t=be(u),l){case"html":if(l=t.documentElement,!l)throw Error(b(452));return l;case"head":if(l=t.head,!l)throw Error(b(453));return l;case"body":if(l=t.body,!l)throw Error(b(454));return l;default:throw Error(b(451))}}function Xa(l){for(var t=l.attributes;t.length;)l.removeAttributeNode(t[0]);Qc(l)}var Kl=new Map,s1=new Set;function ze(l){return typeof l.getRootNode=="function"?l.getRootNode():l.nodeType===9?l:l.ownerDocument}var Tt=C.d;C.d={f:jh,r:Vh,D:xh,C:Lh,L:Kh,m:Jh,X:wh,S:rh,M:Wh};function jh(){var l=Tt.f(),t=Ge();return l||t}function Vh(l){var t=aa(l);t!==null&&t.tag===5&&t.type==="form"?Fy(t):Tt.r(l)}var ca=typeof document>"u"?null:document;function nm(l,t,u){var a=ca;if(a&&typeof t=="string"&&t){var n=Zl(t);n='link[rel="'+l+'"][href="'+n+'"]',typeof u=="string"&&(n+='[crossorigin="'+u+'"]'),s1.has(n)||(s1.add(n),l={rel:l,crossOrigin:u,href:t},a.querySelector(n)===null&&(t=a.createElement("link"),dl(t,"link",l),fl(t),a.head.appendChild(t)))}}function xh(l){Tt.D(l),nm("dns-prefetch",l,null)}function Lh(l,t){Tt.C(l,t),nm("preconnect",l,t)}function Kh(l,t,u){Tt.L(l,t,u);var a=ca;if(a&&l&&t){var n='link[rel="preload"][as="'+Zl(t)+'"]';t==="image"&&u&&u.imageSrcSet?(n+='[imagesrcset="'+Zl(u.imageSrcSet)+'"]',typeof u.imageSizes=="string"&&(n+='[imagesizes="'+Zl(u.imageSizes)+'"]')):n+='[href="'+Zl(l)+'"]';var e=n;switch(t){case"style":e=la(l);break;case"script":e=ia(l)}Kl.has(e)||(l=r({rel:"preload",href:t==="image"&&u&&u.imageSrcSet?void 0:l,as:t},u),Kl.set(e,l),a.querySelector(n)!==null||t==="style"&&a.querySelector(yn(e))||t==="script"&&a.querySelector(vn(e))||(t=a.createElement("link"),dl(t,"link",l),fl(t),a.head.appendChild(t)))}}function Jh(l,t){Tt.m(l,t);var u=ca;if(u&&l){var a=t&&typeof t.as=="string"?t.as:"script",n='link[rel="modulepreload"][as="'+Zl(a)+'"][href="'+Zl(l)+'"]',e=n;switch(a){case"audioworklet":case"paintworklet":case"serviceworker":case"sharedworker":case"worker":case"script":e=ia(l)}if(!Kl.has(e)&&(l=r({rel:"modulepreload",href:l},t),Kl.set(e,l),u.querySelector(n)===null)){switch(a){case"audioworklet":case"paintworklet":case"serviceworker":case"sharedworker":case"worker":case"script":if(u.querySelector(vn(e)))return}a=u.createElement("link"),dl(a,"link",l),fl(a),u.head.appendChild(a)}}}function rh(l,t,u){Tt.S(l,t,u);var a=ca;if(a&&l){var n=Qu(a).hoistableStyles,e=la(l);t=t||"default";var f=n.get(e);if(!f){var c={loading:0,preload:null};if(f=a.querySelector(yn(e)))c.loading=5;else{l=r({rel:"stylesheet",href:l,"data-precedence":t},u),(u=Kl.get(e))&&Mi(l,u);var i=f=a.createElement("link");fl(i),dl(i,"link",l),i._p=new Promise(function(m,g){i.onload=m,i.onerror=g}),i.addEventListener("load",function(){c.loading|=1}),i.addEventListener("error",function(){c.loading|=2}),c.loading|=4,Jn(f,t,a)}f={type:"stylesheet",instance:f,count:1,state:c},n.set(e,f)}}}function wh(l,t){Tt.X(l,t);var u=ca;if(u&&l){var a=Qu(u).hoistableScripts,n=ia(l),e=a.get(n);e||(e=u.querySelector(vn(n)),e||(l=r({src:l,async:!0},t),(t=Kl.get(n))&&Oi(l,t),e=u.createElement("script"),fl(e),dl(e,"link",l),u.head.appendChild(e)),e={type:"script",instance:e,count:1,state:null},a.set(n,e))}}function Wh(l,t){Tt.M(l,t);var u=ca;if(u&&l){var a=Qu(u).hoistableScripts,n=ia(l),e=a.get(n);e||(e=u.querySelector(vn(n)),e||(l=r({src:l,async:!0,type:"module"},t),(t=Kl.get(n))&&Oi(l,t),e=u.createElement("script"),fl(e),dl(e,"link",l),u.head.appendChild(e)),e={type:"script",instance:e,count:1,state:null},a.set(n,e))}}function b1(l,t,u,a){var n=(n=Ct.current)?ze(n):null;if(!n)throw Error(b(446));switch(l){case"meta":case"title":return null;case"style":return typeof u.precedence=="string"&&typeof u.href=="string"?(t=la(u.href),u=Qu(n).hoistableStyles,a=u.get(t),a||(a={type:"style",instance:null,count:0,state:null},u.set(t,a)),a):{type:"void",instance:null,count:0,state:null};case"link":if(u.rel==="stylesheet"&&typeof u.href=="string"&&typeof u.precedence=="string"){l=la(u.href);var e=Qu(n).hoistableStyles,f=e.get(l);if(f||(n=n.ownerDocument||n,f={type:"stylesheet",instance:null,count:0,state:{loading:0,preload:null}},e.set(l,f),(e=n.querySelector(yn(l)))&&!e._p&&(f.instance=e,f.state.loading=5),Kl.has(l)||(u={rel:"preload",as:"style",href:u.href,crossOrigin:u.crossOrigin,integrity:u.integrity,media:u.media,hrefLang:u.hrefLang,referrerPolicy:u.referrerPolicy},Kl.set(l,u),e||$h(n,l,u,f.state))),t&&a===null)throw Error(b(528,""));return f}if(t&&a!==null)throw Error(b(529,""));return null;case"script":return t=u.async,u=u.src,typeof u=="string"&&t&&typeof t!="function"&&typeof t!="symbol"?(t=ia(u),u=Qu(n).hoistableScripts,a=u.get(t),a||(a={type:"script",instance:null,count:0,state:null},u.set(t,a)),a):{type:"void",instance:null,count:0,state:null};default:throw Error(b(444,l))}}function la(l){return'href="'+Zl(l)+'"'}function yn(l){return'link[rel="stylesheet"]['+l+"]"}function em(l){return r({},l,{"data-precedence":l.precedence,precedence:null})}function $h(l,t,u,a){l.querySelector('link[rel="preload"][as="style"]['+t+"]")?a.loading=1:(t=l.createElement("link"),a.preload=t,t.addEventListener("load",function(){return a.loading|=1}),t.addEventListener("error",function(){return a.loading|=2}),dl(t,"link",u),fl(t),l.head.appendChild(t))}function ia(l){return'[src="'+Zl(l)+'"]'}function vn(l){return"script[async]"+l}function z1(l,t,u){if(t.count++,t.instance===null)switch(t.type){case"style":var a=l.querySelector('style[data-href~="'+Zl(u.href)+'"]');if(a)return t.instance=a,fl(a),a;var n=r({},u,{"data-href":u.href,"data-precedence":u.precedence,href:null,precedence:null});return a=(l.ownerDocument||l).createElement("style"),fl(a),dl(a,"style",n),Jn(a,u.precedence,l),t.instance=a;case"stylesheet":n=la(u.href);var e=l.querySelector(yn(n));if(e)return t.state.loading|=4,t.instance=e,fl(e),e;a=em(u),(n=Kl.get(n))&&Mi(a,n),e=(l.ownerDocument||l).createElement("link"),fl(e);var f=e;return f._p=new Promise(function(c,i){f.onload=c,f.onerror=i}),dl(e,"link",a),t.state.loading|=4,Jn(e,u.precedence,l),t.instance=e;case"script":return e=ia(u.src),(n=l.querySelector(vn(e)))?(t.instance=n,fl(n),n):(a=u,(n=Kl.get(e))&&(a=r({},u),Oi(a,n)),l=l.ownerDocument||l,n=l.createElement("script"),fl(n),dl(n,"link",a),l.head.appendChild(n),t.instance=n);case"void":return null;default:throw Error(b(443,t.type))}else t.type==="stylesheet"&&(t.state.loading&4)===0&&(a=t.instance,t.state.loading|=4,Jn(a,u.precedence,l));return t.instance}function Jn(l,t,u){for(var a=u.querySelectorAll('link[rel="stylesheet"][data-precedence],style[data-precedence]'),n=a.length?a[a.length-1]:null,e=n,f=0;f<a.length;f++){var c=a[f];if(c.dataset.precedence===t)e=c;else if(e!==n)break}e?e.parentNode.insertBefore(l,e.nextSibling):(t=u.nodeType===9?u.head:u,t.insertBefore(l,t.firstChild))}function Mi(l,t){l.crossOrigin==null&&(l.crossOrigin=t.crossOrigin),l.referrerPolicy==null&&(l.referrerPolicy=t.referrerPolicy),l.title==null&&(l.title=t.title)}function Oi(l,t){l.crossOrigin==null&&(l.crossOrigin=t.crossOrigin),l.referrerPolicy==null&&(l.referrerPolicy=t.referrerPolicy),l.integrity==null&&(l.integrity=t.integrity)}var rn=null;function T1(l,t,u){if(rn===null){var a=new Map,n=rn=new Map;n.set(u,a)}else n=rn,a=n.get(u),a||(a=new Map,n.set(u,a));if(a.has(l))return a;for(a.set(l,null),u=u.getElementsByTagName(l),n=0;n<u.length;n++){var e=u[n];if(!(e[un]||e[yl]||l==="link"&&e.getAttribute("rel")==="stylesheet")&&e.namespaceURI!=="http://www.w3.org/2000/svg"){var f=e.getAttribute(t)||"";f=l+f;var c=a.get(f);c?c.push(e):a.set(f,[e])}}return a}function E1(l,t,u){l=l.ownerDocument||l,l.head.insertBefore(u,t==="title"?l.querySelector("head > title"):null)}function Fh(l,t,u){if(u===1||t.itemProp!=null)return!1;switch(l){case"meta":case"title":return!0;case"style":if(typeof t.precedence!="string"||typeof t.href!="string"||t.href==="")break;return!0;case"link":if(typeof t.rel!="string"||typeof t.href!="string"||t.href===""||t.onLoad||t.onError)break;switch(t.rel){case"stylesheet":return l=t.disabled,typeof t.precedence=="string"&&l==null;default:return!0}case"script":if(t.async&&typeof t.async!="function"&&typeof t.async!="symbol"&&!t.onLoad&&!t.onError&&t.src&&typeof t.src=="string")return!0}return!1}function fm(l){return!(l.type==="stylesheet"&&(l.state.loading&3)===0)}function kh(l,t,u,a){if(u.type==="stylesheet"&&(typeof a.media!="string"||matchMedia(a.media).matches!==!1)&&(u.state.loading&4)===0){if(u.instance===null){var n=la(a.href),e=t.querySelector(yn(n));if(e){t=e._p,t!==null&&typeof t=="object"&&typeof t.then=="function"&&(l.count++,l=Te.bind(l),t.then(l,l)),u.state.loading|=4,u.instance=e,fl(e);return}e=t.ownerDocument||t,a=em(a),(n=Kl.get(n))&&Mi(a,n),e=e.createElement("link"),fl(e);var f=e;f._p=new Promise(function(c,i){f.onload=c,f.onerror=i}),dl(e,"link",a),u.instance=e}l.stylesheets===null&&(l.stylesheets=new Map),l.stylesheets.set(u,t),(t=u.state.preload)&&(u.state.loading&3)===0&&(l.count++,u=Te.bind(l),t.addEventListener("load",u),t.addEventListener("error",u))}}var Xf=0;function Ih(l,t){return l.stylesheets&&l.count===0&&wn(l,l.stylesheets),0<l.count||0<l.imgCount?function(u){var a=setTimeout(function(){if(l.stylesheets&&wn(l,l.stylesheets),l.unsuspend){var e=l.unsuspend;l.unsuspend=null,e()}},6e4+t);0<l.imgBytes&&Xf===0&&(Xf=62500*Bh());var n=setTimeout(function(){if(l.waitingForImages=!1,l.count===0&&(l.stylesheets&&wn(l,l.stylesheets),l.unsuspend)){var e=l.unsuspend;l.unsuspend=null,e()}},(l.imgBytes>Xf?50:800)+t);return l.unsuspend=u,function(){l.unsuspend=null,clearTimeout(a),clearTimeout(n)}}:null}function Te(){if(this.count--,this.count===0&&(this.imgCount===0||!this.waitingForImages)){if(this.stylesheets)wn(this,this.stylesheets);else if(this.unsuspend){var l=this.unsuspend;this.unsuspend=null,l()}}}var Ee=null;function wn(l,t){l.stylesheets=null,l.unsuspend!==null&&(l.count++,Ee=new Map,t.forEach(Ph,l),Ee=null,Te.call(l))}function Ph(l,t){if(!(t.state.loading&4)){var u=Ee.get(l);if(u)var a=u.get(null);else{u=new Map,Ee.set(l,u);for(var n=l.querySelectorAll("link[data-precedence],style[data-precedence]"),e=0;e<n.length;e++){var f=n[e];(f.nodeName==="LINK"||f.getAttribute("media")!=="not all")&&(u.set(f.dataset.precedence,f),a=f)}a&&u.set(null,a)}n=t.instance,f=n.getAttribute("data-precedence"),e=u.get(f)||a,e===a&&u.set(null,n),u.set(f,n),this.count++,a=Te.bind(this),n.addEventListener("load",a),n.addEventListener("error",a),e?e.parentNode.insertBefore(n,e.nextSibling):(l=l.nodeType===9?l.head:l,l.insertBefore(n,l.firstChild)),t.state.loading|=4}}var $a={$$typeof:yt,Provider:null,Consumer:null,_currentValue:uu,_currentValue2:uu,_threadCount:0};function l2(l,t,u,a,n,e,f,c,i){this.tag=1,this.containerInfo=l,this.pingCache=this.current=this.pendingChildren=null,this.timeoutHandle=-1,this.callbackNode=this.next=this.pendingContext=this.context=this.cancelPendingCommit=null,this.callbackPriority=0,this.expirationTimes=yf(-1),this.entangledLanes=this.shellSuspendCounter=this.errorRecoveryDisabledLanes=this.expiredLanes=this.warmLanes=this.pingedLanes=this.suspendedLanes=this.pendingLanes=0,this.entanglements=yf(0),this.hiddenUpdates=yf(null),this.identifierPrefix=a,this.onUncaughtError=n,this.onCaughtError=e,this.onRecoverableError=f,this.pooledCache=null,this.pooledCacheLanes=0,this.formState=i,this.incompleteTransitions=new Map}function cm(l,t,u,a,n,e,f,c,i,m,g,s){return l=new l2(l,t,u,f,i,m,g,s,c),t=1,e===!0&&(t|=24),e=Dl(3,null,null,t),l.current=e,e.stateNode=l,t=Fc(),t.refCount++,l.pooledCache=t,t.refCount++,e.memoizedState={element:a,isDehydrated:u,cache:t},Pc(e),l}function im(l){return l?(l=pu,l):pu}function ym(l,t,u,a,n,e){n=im(n),a.context===null?a.context=n:a.pendingContext=n,a=Xt(t),a.payload={element:u},e=e===void 0?null:e,e!==null&&(a.callback=e),u=Qt(l,a,t),u!==null&&(El(u,l,t),Na(u,l,t))}function A1(l,t){if(l=l.memoizedState,l!==null&&l.dehydrated!==null){var u=l.retryLane;l.retryLane=u!==0&&u<t?u:t}}function _i(l,t){A1(l,t),(l=l.alternate)&&A1(l,t)}function vm(l){if(l.tag===13||l.tag===31){var t=gu(l,67108864);t!==null&&El(t,l,67108864),_i(l,67108864)}}function M1(l){if(l.tag===13||l.tag===31){var t=Yl();t=Gc(t);var u=gu(l,t);u!==null&&El(u,l,t),_i(l,t)}}var Ae=!0;function t2(l,t,u,a){var n=M.T;M.T=null;var e=C.p;try{C.p=2,Di(l,t,u,a)}finally{C.p=e,M.T=n}}function u2(l,t,u,a){var n=M.T;M.T=null;var e=C.p;try{C.p=8,Di(l,t,u,a)}finally{C.p=e,M.T=n}}function Di(l,t,u,a){if(Ae){var n=Yc(a);if(n===null)Cf(l,t,a,Me,u),O1(l,a);else if(n2(n,l,t,u,a))a.stopPropagation();else if(O1(l,a),t&4&&-1<a2.indexOf(l)){for(;n!==null;){var e=aa(n);if(e!==null)switch(e.tag){case 3:if(e=e.stateNode,e.current.memoizedState.isDehydrated){var f=Pt(e.pendingLanes);if(f!==0){var c=e;for(c.pendingLanes|=2,c.entangledLanes|=2;f;){var i=1<<31-ql(f);c.entanglements[1]|=i,f&=~i}lt(e),(p&6)===0&&(de=Hl()+500,cn(0,!1))}}break;case 31:case 13:c=gu(e,2),c!==null&&El(c,e,2),Ge(),_i(e,2)}if(e=Yc(a),e===null&&Cf(l,t,a,Me,u),e===n)break;n=e}n!==null&&a.stopPropagation()}else Cf(l,t,a,null,u)}}function Yc(l){return l=jc(l),Ui(l)}var Me=null;function Ui(l){if(Me=null,l=Hu(l),l!==null){var t=Ia(l);if(t===null)l=null;else{var u=t.tag;if(u===13){if(l=q1(t),l!==null)return l;l=null}else if(u===31){if(l=Y1(t),l!==null)return l;l=null}else if(u===3){if(t.stateNode.current.memoizedState.isDehydrated)return t.tag===3?t.stateNode.containerInfo:null;l=null}else t!==l&&(l=null)}}return Me=l,null}function mm(l){switch(l){case"beforetoggle":case"cancel":case"click":case"close":case"contextmenu":case"copy":case"cut":case"auxclick":case"dblclick":case"dragend":case"dragstart":case"drop":case"focusin":case"focusout":case"input":case"invalid":case"keydown":case"keypress":case"keyup":case"mousedown":case"mouseup":case"paste":case"pause":case"play":case"pointercancel":case"pointerdown":case"pointerup":case"ratechange":case"reset":case"resize":case"seeked":case"submit":case"toggle":case"touchcancel":case"touchend":case"touchstart":case"volumechange":case"change":case"selectionchange":case"textInput":case"compositionstart":case"compositionend":case"compositionupdate":case"beforeblur":case"afterblur":case"beforeinput":case"blur":case"fullscreenchange":case"focus":case"hashchange":case"popstate":case"select":case"selectstart":return 2;case"drag":case"dragenter":case"dragexit":case"dragleave":case"dragover":case"mousemove":case"mouseout":case"mouseover":case"pointermove":case"pointerout":case"pointerover":case"scroll":case"touchmove":case"wheel":case"mouseenter":case"mouseleave":case"pointerenter":case"pointerleave":return 8;case"message":switch(Km()){case C1:return 2;case G1:return 8;case In:case Jm:return 32;case X1:return 268435456;default:return 32}default:return 32}}var Bc=!1,Vt=null,xt=null,Lt=null,Fa=new Map,ka=new Map,Nt=[],a2="mousedown mouseup touchcancel touchend touchstart auxclick dblclick pointercancel pointerdown pointerup dragend dragstart drop compositionend compositionstart keydown keypress keyup input textInput copy cut paste click change contextmenu reset".split(" ");function O1(l,t){switch(l){case"focusin":case"focusout":Vt=null;break;case"dragenter":case"dragleave":xt=null;break;case"mouseover":case"mouseout":Lt=null;break;case"pointerover":case"pointerout":Fa.delete(t.pointerId);break;case"gotpointercapture":case"lostpointercapture":ka.delete(t.pointerId)}}function ba(l,t,u,a,n,e){return l===null||l.nativeEvent!==e?(l={blockedOn:t,domEventName:u,eventSystemFlags:a,nativeEvent:e,targetContainers:[n]},t!==null&&(t=aa(t),t!==null&&vm(t)),l):(l.eventSystemFlags|=a,t=l.targetContainers,n!==null&&t.indexOf(n)===-1&&t.push(n),l)}function n2(l,t,u,a,n){switch(t){case"focusin":return Vt=ba(Vt,l,t,u,a,n),!0;case"dragenter":return xt=ba(xt,l,t,u,a,n),!0;case"mouseover":return Lt=ba(Lt,l,t,u,a,n),!0;case"pointerover":var e=n.pointerId;return Fa.set(e,ba(Fa.get(e)||null,l,t,u,a,n)),!0;case"gotpointercapture":return e=n.pointerId,ka.set(e,ba(ka.get(e)||null,l,t,u,a,n)),!0}return!1}function dm(l){var t=Hu(l.target);if(t!==null){var u=Ia(t);if(u!==null){if(t=u.tag,t===13){if(t=q1(u),t!==null){l.blockedOn=t,c0(l.priority,function(){M1(u)});return}}else if(t===31){if(t=Y1(u),t!==null){l.blockedOn=t,c0(l.priority,function(){M1(u)});return}}else if(t===3&&u.stateNode.current.memoizedState.isDehydrated){l.blockedOn=u.tag===3?u.stateNode.containerInfo:null;return}}}l.blockedOn=null}function Wn(l){if(l.blockedOn!==null)return!1;for(var t=l.targetContainers;0<t.length;){var u=Yc(l.nativeEvent);if(u===null){u=l.nativeEvent;var a=new u.constructor(u.type,u);Ff=a,u.target.dispatchEvent(a),Ff=null}else return t=aa(u),t!==null&&vm(t),l.blockedOn=u,!1;t.shift()}return!0}function _1(l,t,u){Wn(l)&&u.delete(t)}function e2(){Bc=!1,Vt!==null&&Wn(Vt)&&(Vt=null),xt!==null&&Wn(xt)&&(xt=null),Lt!==null&&Wn(Lt)&&(Lt=null),Fa.forEach(_1),ka.forEach(_1)}function Bn(l,t){l.blockedOn===t&&(l.blockedOn=null,Bc||(Bc=!0,nl.unstable_scheduleCallback(nl.unstable_NormalPriority,e2)))}var Rn=null;function D1(l){Rn!==l&&(Rn=l,nl.unstable_scheduleCallback(nl.unstable_NormalPriority,function(){Rn===l&&(Rn=null);for(var t=0;t<l.length;t+=3){var u=l[t],a=l[t+1],n=l[t+2];if(typeof a!="function"){if(Ui(a||u)===null)continue;break}var e=aa(u);e!==null&&(l.splice(t,3),t-=3,dc(e,{pending:!0,data:n,method:u.method,action:a},a,n))}}))}function ta(l){function t(i){return Bn(i,l)}Vt!==null&&Bn(Vt,l),xt!==null&&Bn(xt,l),Lt!==null&&Bn(Lt,l),Fa.forEach(t),ka.forEach(t);for(var u=0;u<Nt.length;u++){var a=Nt[u];a.blockedOn===l&&(a.blockedOn=null)}for(;0<Nt.length&&(u=Nt[0],u.blockedOn===null);)dm(u),u.blockedOn===null&&Nt.shift();if(u=(l.ownerDocument||l).$$reactFormReplay,u!=null)for(a=0;a<u.length;a+=3){var n=u[a],e=u[a+1],f=n[Al]||null;if(typeof e=="function")f||D1(u);else if(f){var c=null;if(e&&e.hasAttribute("formAction")){if(n=e,f=e[Al]||null)c=f.formAction;else if(Ui(n)!==null)continue}else c=f.action;typeof c=="function"?u[a+1]=c:(u.splice(a,3),a-=3),D1(u)}}}function hm(){function l(e){e.canIntercept&&e.info==="react-transition"&&e.intercept({handler:function(){return new Promise(function(f){return n=f})},focusReset:"manual",scroll:"manual"})}function t(){n!==null&&(n(),n=null),a||setTimeout(u,20)}function u(){if(!a&&!navigation.transition){var e=navigation.currentEntry;e&&e.url!=null&&navigation.navigate(e.url,{state:e.getState(),info:"react-transition",history:"replace"})}}if(typeof navigation=="object"){var a=!1,n=null;return navigation.addEventListener("navigate",l),navigation.addEventListener("navigatesuccess",t),navigation.addEventListener("navigateerror",t),setTimeout(u,100),function(){a=!0,navigation.removeEventListener("navigate",l),navigation.removeEventListener("navigatesuccess",t),navigation.removeEventListener("navigateerror",t),n!==null&&(n(),n=null)}}}function Hi(l){this._internalRoot=l}Ze.prototype.render=Hi.prototype.render=function(l){var t=this._internalRoot;if(t===null)throw Error(b(409));var u=t.current,a=Yl();ym(u,a,l,t,null,null)};Ze.prototype.unmount=Hi.prototype.unmount=function(){var l=this._internalRoot;if(l!==null){this._internalRoot=null;var t=l.containerInfo;ym(l.current,2,null,l,null,null),Ge(),t[ua]=null}};function Ze(l){this._internalRoot=l}Ze.prototype.unstable_scheduleHydration=function(l){if(l){var t=x1();l={blockedOn:null,target:l,priority:t};for(var u=0;u<Nt.length&&t!==0&&t<Nt[u].priority;u++);Nt.splice(u,0,l),u===0&&dm(l)}};var U1=H1.version;if(U1!=="19.2.0")throw Error(b(527,U1,"19.2.0"));C.findDOMNode=function(l){var t=l._reactInternals;if(t===void 0)throw typeof l.render=="function"?Error(b(188)):(l=Object.keys(l).join(","),Error(b(268,l)));return l=Xm(t),l=l!==null?B1(l):null,l=l===null?null:l.stateNode,l};var f2={bundleType:0,version:"19.2.0",rendererPackageName:"react-dom",currentDispatcherRef:M,reconcilerVersion:"19.2.0"};if(typeof __REACT_DEVTOOLS_GLOBAL_HOOK__<"u"&&(za=__REACT_DEVTOOLS_GLOBAL_HOOK__,!za.isDisabled&&za.supportsFiber))try{Pa=za.inject(f2),Nl=za}catch{}var za;je.createRoot=function(l,t){if(!N1(l))throw Error(b(299));var u=!1,a="",n=nv,e=ev,f=fv;return t!=null&&(t.unstable_strictMode===!0&&(u=!0),t.identifierPrefix!==void 0&&(a=t.identifierPrefix),t.onUncaughtError!==void 0&&(n=t.onUncaughtError),t.onCaughtError!==void 0&&(e=t.onCaughtError),t.onRecoverableError!==void 0&&(f=t.onRecoverableError)),t=cm(l,1,!1,null,null,u,a,null,n,e,f,hm),l[ua]=t.current,Ai(l),new Hi(t)};je.hydrateRoot=function(l,t,u){if(!N1(l))throw Error(b(299));var a=!1,n="",e=nv,f=ev,c=fv,i=null;return u!=null&&(u.unstable_strictMode===!0&&(a=!0),u.identifierPrefix!==void 0&&(n=u.identifierPrefix),u.onUncaughtError!==void 0&&(e=u.onUncaughtError),u.onCaughtError!==void 0&&(f=u.onCaughtError),u.onRecoverableError!==void 0&&(c=u.onRecoverableError),u.formState!==void 0&&(i=u.formState)),t=cm(l,1,!0,t,u??null,a,n,i,e,f,c,hm),t.context=im(null),u=t.current,a=Yl(),a=Gc(a),n=Xt(a),n.callback=null,Qt(u,n,a),u=a,t.current.lanes=u,tn(t,u),lt(t),l[ua]=t.current,Ai(l),new Ze(t)};je.version="19.2.0"});var c2=We();window.React=c2;var i2=Sm();window.ReactDOM=i2;})();
/*! Bundled license information:

react/cjs/react.production.js:
  (**
   * @license React
   * react.production.js
   *
   * Copyright (c) Meta Platforms, Inc. and affiliates.
   *
   * This source code is licensed under the MIT license found in the
   * LICENSE file in the root directory of this source tree.
   *)

scheduler/cjs/scheduler.production.js:
  (**
   * @license React
   * scheduler.production.js
   *
   * Copyright (c) Meta Platforms, Inc. and affiliates.
   *
   * This source code is licensed under the MIT license found in the
   * LICENSE file in the root directory of this source tree.
   *)

react-dom/cjs/react-dom.production.js:
  (**
   * @license React
   * react-dom.production.js
   *
   * Copyright (c) Meta Platforms, Inc. and affiliates.
   *
   * This source code is licensed under the MIT license found in the
   * LICENSE file in the root directory of this source tree.
   *)

react-dom/cjs/react-dom-client.production.js:
  (**
   * @license React
   * react-dom-client.production.js
   *
   * Copyright (c) Meta Platforms, Inc. and affiliates.
   *
   * This source code is licensed under the MIT license found in the
   * LICENSE file in the root directory of this source tree.
   *)
*/
  </script>

  <!-- App (pre-compiled, no Babel needed) -->
  <script>
const { useState, useEffect, useCallback, useRef, useMemo } = React;
if (!window.storage) {
  const mem = {};
  const localOk = (() => {
    try {
      const testKey = "__pcp_storage_test__";
      window.localStorage.setItem(testKey, "1");
      window.localStorage.removeItem(testKey);
      return true;
    } catch (e) {
      return false;
    }
  })();
  window.storage = {
    get: async (key) => {
      if (localOk) {
        return { value: window.localStorage.getItem(key) };
      }
      return { value: mem[key] ?? null };
    },
    set: async (key, value) => {
      if (localOk) {
        window.localStorage.setItem(key, value);
        return;
      }
      mem[key] = value;
    },
    remove: async (key) => {
      if (localOk) {
        window.localStorage.removeItem(key);
        return;
      }
      delete mem[key];
    }
  };
}
const FemaleIcon = ({ size = 24 }) => {
  const s = size > 20 ? size * 1.1 : size;
  return /* @__PURE__ */ React.createElement("svg", { width: s, height: s, viewBox: "0 0 64 64", fill: "none", xmlns: "http://www.w3.org/2000/svg" },
    /* @__PURE__ */ React.createElement("circle", { cx: "32", cy: "24", r: "14", stroke: "#1a1a2e", strokeWidth: "2.5", fill: "none" }),
    /* @__PURE__ */ React.createElement("line", { x1: "32", y1: "38", x2: "32", y2: "58", stroke: "#1a1a2e", strokeWidth: "2.5", strokeLinecap: "round" }),
    /* @__PURE__ */ React.createElement("line", { x1: "24", y1: "49", x2: "40", y2: "49", stroke: "#1a1a2e", strokeWidth: "2.5", strokeLinecap: "round" })
  );
};
const PancreasIcon = ({ size = 24 }) => /* @__PURE__ */ React.createElement(
  "img",
  {
    src: "data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAA5cAAAQACAYAAAB1Ua2QAAEAAElEQVR42uz9eZQlyX3fh34iIjPvUlvvPVtPT8+K2TFYZgDMACAIgAQJkBJlyrKeNpuS7eNnS/Jyzjvv+R372M9Psq1jy9bTStJcxEUUQZEECRIECIAgQJAABgQG28xg9n3p6e7p7truzcyI+L0/Iu+tW9W3tq6qXqp/nzk1VX3XzMjIyN83f5uJMbISY8zwbxFhs2z1/Zth8Pmj37mZ79/q+7eKMTJ2m8Zt13js2P0Zty9rHavB+zb+vedu67jP3sjnrNxfY8zwMWvtBZk/q47uyPefz1wQkeEYDPZrdJ+3vn9xzeO+3jZv9Dif//xe+1xabb5tdKyNcRd1fqw3fpt9/2bP38Hx3ykG14fVtmO97YsxrvqadG64Da/FG53TF/L4DvZvtXPcWrvsOzZ6fMc9Pu5zxr3uwl6/44bHd/zxdetuy1rXl52+Pm913dvM/NrqsRp3Pd7I9X/ltX+9940+F6Nf87ivf32zF/X83fr6uT3X753a//XeZ22249u/2pq3kfN3u87/87WLV+qj1a5Nm7NZRs95sy3rzIW2e5ZeF1a1+zMuc1a7CG9m0HfawL7Q43GhL7grL6TnO54bFaOX4/wct6Dutn3djvHZrounnr87s75uds6ud06vdT7shvNjp47lpSysLqXju9WbP5facb9c1iu9tunx2e3r9mZ1xpU0v0Rk94jLlTt4PncRLtYkXu3u8/leoLb63vMd/7Xu6lzp4mmnjcPLWbRu9/y/HI7/5SIc1vOsbdRzMO4u724QF2vdvd7pea1r7KV1fmzUs7zTBvF2zLHNnJ87EVFwsW8ObPz7L18b+WILkIu1DRuJUtx8BJGufysjILLdtJPbtbhf6BNhLYF5vgvHZvZ7K/s7GPetGlIXy2txMRaNtcZsO0Xl5bIgjhuLS0UoX6iw4cvhYrZT2zRunbjczv/NGuPnG861G67NF/L4XsjxG03nuFzO1ZU3Q1baUJuNALtYUVNq3F/aIu9i2ncbtY/Gnb+73f7YyZsHGcolZ2CfzyJwvgvHdiw2WzUeVr5/t3itzkdUXG7G23bN+9VCK64U4+FSnfPbKb7O1wi4XMTFZm6SXGlGsaYDXB4ieqvr0G67dq+/L+ayPQ+vxLVns+vvxfb6Xs5ku3URWC+X60IZIusXhFjb63c+uaOb2Y+VovZ8xmMrwmCl0XG+YbmXgnF5PnN064bWxQ832UmjfKe371LMb9zMndP1Nn+r+7+eINhqQR9r176zvNMFlbbbcFmrgNd2iaoLW3Bu6/Nv7eN7aa9Pm72WbreQvhjze7MRR2sZ7pd6WOl2F2S71K4v23Hjf7vO/+20GXbSPltvm1VobmyOZ7t1x3bK6N2pfTjfsNitXhy2up9rhSLrSbh8nMZ5Z7fT4LwcPQOrVQPdLd6N8zFOLsW7y+c7ty52zuXFMuC2a53VohFXrv2xHevqRm4erRYxtZkbxDt1vVcb4sLNhYu9Pl6obdiIUNQ19/zs2tGx2zXicruLyVwpi9p2GS9bydXYjOG9GwWGXvzMJXUxVLZvvdiIx3Mn725fyp6FnRSll7r4vlRyLncyj1jZfdcm5coYTz3uW1tfjTGYcX0uVxvkcV6q9foYXe5hBTtvvMTz/o702XZL23qxw6rW6iN0sebH+YZAnK8o2kobjnF9Us/3/FvrtdsRdr4z2Et6zRidEytvhI0zure7z+XFDvsaCKPV+vGN63O4nSFI57P955NKcb7n8OV//ZMtjdV29nlbq9rjauO9/vzcvlZJF+Om2U6vz+P63G1ufpuLus+r9enb+Pnrdtz+29n1fWe3fzv6uO5kn9utXh+2fvPKcimzleNvL8QJrCg6pxSd30bPAUW5wOfaQDzquaUoinJh2JJs1sVahZsKyyvTWNO5tPVtuxLyPcZ5a7RqqHKh5t64SJiVPzo/FUVRtpd1cy4170lF5cXYPr2wXzrH53Jsp3C55G1eTn0ut4peS5SLNac2cj7p/FQURdkerA6BooJY2ezx0GO0+TFca8x0PBVFURRF2Q2cV7VYNYQuf3Zzw3blypvHl0PvrMHv1Xof7sYquesXZNA5fKkfv3Vm+CW9zaPn2rj92emCIYqiKFeiDrAX88sVFZYqLC8/I/NSPFaX2zq11vbutnNhrYq5irKT5/24asyjPzo/FUVRLoK4VIGpKIqiKMrlKjDHNftWFEVRdoZ1+1ye14duax+YjV1YLtadxovVpPlSurCv1QNM7wBf3vN65/ukqadA56zu005dky72dl/p10e9fl4+5+duWr+upOvqlVB1/VJbt0fHeLXXakEfRVEURVEURVEUZdMidGV0iIpLRVEURdkl6B17RVEU5WKJTDjParGKoiiKoqjAVJRL2ejVc0FRLpyoHITKqudSURRFURRF2ZUGsBZzUpQLi3oud8HCuRZ6105RFGV3r/+6zivK+ueKnieKsn2MtnFa2a5OPZeKoiiKsgtEpqIoep4oysUQmaN/q7hUFEVRFEVRVGAqinJeonLZv9frc7mZnpU7vfHjFohLPczhYi9kmxmfcdt6ofocXoj9u9jbN27ObjWseSfev9kxXavP1Hp93LZ6fM93HdhMH6ftGqvzef/lHva+mfNnNMRmq/u31vdu5DPPZ35cquO7k+ffTu/LVs+Pnd6X8z0/tzo/L5f5u5nxGVccxFp7UY7PpbL+rtfD8VK0Hy4H/bBbrq8X4vxcz75bDc25VBRFURRFUS4J1jNcL+YNBUVR1kfDYhVFURRF2dViRdFjpijKhUE9l4qiF0vlIqH5P8punr8Xe83TNVfXP0VRLjzquVQURVEURVEURVG2jHouFWUH2WpBG0W52PN3LdQzpFzO81rn76WHHhNFufxRz6WiKIqiKFeUsFT0WCiKsjOo51JRFEVRFEW5KAJzp7yVGnmhKBeHsX0uN9ObZqsn71ZP7nE90bajT9pan7+Z/V/3AFyExW07eoOt/IzLdZHeTHjUToRSDT5ztfG8FPt4XqyxuljHXdlZ4229Xm46vqtf33SsLu01Zb20iCu9j95W7A8R2XIfTGVn1ve1enrrWrV7zs+15kS2XR+kKMr5nT8DI2Pl4qvnlqIoiqKo7akolxM7Li53S0z9blrItqtBsbL9AlMvnIqiKIqiKMoVKy6vBMN/N++XikydZ4qiKIpyOV0v1XZRlEsXDVhXFEVRFEVRLinWEpB6Q1ZRLl2ynTz5r9RF71LcTl2IL6/jo8dNURRF0Wuk6HVQUS4z1HN5hQhqDSG5tI/L6PFZrYKsoiiKoiiKoqi4VBRlQwJThaWiKIqi6HVQUS5XzKhBe86TFyBp+nIPd9DwRWWnLqA6py5940aPkaLzT7mU58+V3GdTz0+1j5ULM9dXop5LRVEURVEURVEUZctoKxJFuciMixDQO32Koii7G/V8KYqi4lJRlB0XmGpQKIqia4GiKIqi4lJRFDUkFUVRFF3zFUW5ItGcS0VRFEVRFEVRFEXFpaIoiqIoiqIoinLx0bBYRVEURVGUC4wW9FEUZTdiYoxrLmjn0+fyQi6IujgriqIoiqIoinKxuXyKM8Y1tdR6WlBk9f1Tz6WiKIqiKIqiKIqyIdYSz5pzqSiKoiiKoiiKomwZFZeKoiiKoiiKoijKltGwWEVRFEVRFEVRFGVDrFXzRj2XiqIoiqIoiqIoypZRz6WiKIqiKIqiKIqyIbSgj6IoiqIoiqIoirKjbNlzuV4/l53uQ7mdfWQun940iqIoiqIoinLxUft5Z3TJhThm5/u8MWbV19jtGMSVA7neBimKoiiKoiiKoii7iy17LgfCcqWgVIGpKIqiKIqiKIpy5bBtOZfjvJcqMBVFURRFURRFUVRcKoqiKIqiKIqiKMqG2LZWJCu9lJrUqyiKoiiKoiiKouLyvEXlSnGpobGKoiiKoiiKoii7ny2HxY7LrVSvpaIoiqIoiqIoypWFidGf++CIOFy/z4m7pHdwp/tsKpc32ptJUfS83837uVYPal33FD0/FeVKJa4Zfbp+5Kk9j2cURVEURVEURVEUZYOouFQURVEURVEURVG2zI4V9BmgYQ2KoiiKoiiKoii7H/VcKoqiKIqiKIqiKCouFUVRFEVRFEVRFBWXiqIoiqIoiqIoiopLRVEURVEURVEURVmlz+WyF6zb89Ju+P2KoiiKoiiKolyaaJ/RK4OB/hs9zmv1Rd6M/lPPpaIoiqIoiqIoyhXETt1AUHGpKIqiKIqiKIqiwnLLZDq8iqIoiqIoiqIoVy6j4a9bEZ/quVQURVEURVEURVG2jHouFUVRFEVRFEVRrhDWL9h6/qjnUlEURVEURVEURdmy2FRxqSiKoiiKoiiKosJyy58xNix2M67S80n43EzC6E58/7jP1X4+iqIoiqIoypWM2sNXCnbkmC9TSINHR/SS2dTcUc+loiiKoiiKoiiKsmW2XNDnfDyLxphtTx5VFEVRFEVRFEVRLmNxeb6o211RFEVRFEVRFGX3oGGxiqIoiqIoiqIoyqUvLkVEQ2AVRVEURVEURVF2OVsOi91otVcR0VBYRVEURVEURVGUXYqGxSqKoiiKoiiKoihbxsToz31wFQ/juPBWY9yqYa876akcfKd6QxVFURRFURRFUXZOc20U9VwqiqIoiqIoiqIoWya72BtwPn0yFUVRFEVRFEVRlEsL9VwqiqIoiqIoiqIoKi4VRVEURVEURVEUFZeKoiiKoiiKoijKLuCi51xqTqWiKIqiKIqiKMrlj3ouFUVRFEVRFEVRlC1jVlZrXdk/crO9Tc75gvPwTI5+p3o2FUVRFEVRlCsJ7aag7CxxzXk3Or/Gz8XV/ZPZZibyBVO8mxC2evIpiqIoiqIoiqJcfOzFFpZrfa8KQ0VRFEVRFEVRlMtIXF5sj6WIXDJeU0VRFEVRFEVRFGXzZKOiTkQuO2+hejcVRVEURVEURVEuMXGpAlFRFEVRFEVRlJ1Ea6bsYnE57mBfyAO61ndtZFt0ciqKoiiKoiiKolyC4vJSQPMvFUVRFEVRFEVRLjNxuZpnb70+J+OePx+hOO79m/E2qmdSUS4eV3rkwMXoA6woun7o/im7H50fyuViy5wjLrcy6dXDqCiKosaBouj5oee/oijKlsSlLpyKougaoCiKoiiKomxYXKp3UlEURVEURVEURVkPq0OgKIqiKIqiKIqibJXzCotdrcjP5Ygm3CuKnh+Kzg9FURRFUS6AuLzQfS8VRVFxoSiKoiiKouxCcakCU1EURcW3ouj5ofunKIqyHibGuLNfoIunosaBoiiKrp8qHvX4Kjp+ymU3FzeLFvRRFEVRFEVRFEVRVFwqiqIoiqIoiqIoKi4VRVEURVEURVEUFZeKoiiKoiiKoiiKouJSURRFURRFURRFUXGpKIqiKIqiKIqiqLhUFEVRFEVRFEVRdgXZei8Y7bOz3X1QtoPBNu1UPyDt03Vl91m60vdf+7jJqvu41nOKoue/rp96fbyyzw8dP10/r9Tjr55LRVEURVEURVEURcWloiiKoiiKoiiKcvHJdAiubDQsQ9H5oSiKnv86PorOD0WP/3agnktFURRFURRFURRly6jnch30zpOiKIqiKIqiKMr6qOdSURRFURRFURRFUXGpKIqiKIqiKIqiXHxMjHH7P/QyCiXdaJ+itXrd7ZaxUPT4Kjq/r4T5vdH+yFd6Hztd/67s8dE+jnp+6Phcucdt9PiMO5ajj608luq5VBRFURRFURRFUbaMiktFURRFURRFURRly1zx1WK3Ghalbv0re34oiqLnv6LzQ/dPj7+i46Mk1HOpKIqiKIqiKIqiqLhUFEVRFEVRFEVRVFwqiqIoiqIoiqIoKi4VRVEURVEURVEUZQN9Li92Qq6IrNljUhOGFUVRFEVRFEVRNq6vNqr/xr3WGIOInPOcMUarxSqKoiiKoiiKolwpbNU5t5Y4zbby5u3YOEVRFEVRFEVRFGUXCNf1wmIvtjJWFEVRFEVRFEVRLjzrORoHzw80n4bFKoqiKIqiKIqiqGBcJhTXev/gNStfay+3gVhvMBRFURRFURRFUZQLK1BFZH3P5UaUq6IoiqIoiqIoinLps5Npi9rnUlEURVEURVEURTkvoToqVi/5gj5arVZRtn7+6HmiY6UoiqIoinK+NtKoJlvLVlLPpaIoiqIoiqIoirJlVFwqiqIoiqIoiqIo57DZyC5tRaIoiqIoiqIoiqKsyUYEpnouFUVRFEVRFEVRlGWcT1eQLXsutfiFoiiKoiiKoijKlSsqB6jnUlEURVEURVEURVmTlW1HVFwqiqIoiqIoiqIoOyNAx/W5XE2RbsVFupHPVxRFURRFURRFUS4826H11HOpKIqiKIqiKIqiqLhUFEVRFEVRFEVRVFwqiqIoiqIoiqIoKi4VRVEURVEURVEURcWloiiKoiiKoiiKouJSURRFURRFURRFUXGpKIqiKIqiKIqi7AqycQ9uVz9LWL+n5bjv0j6YiqIoinJps56tsNPX8ov9/YqiKLt1LR9dPzerC9VzqSiKoiiKoiiKomyZTIdAURRFUZTLDfVMKoqiqLhUFEVRFEXFnaIoirIL0bBYRVEURVEURVEUZcts2XOpdy4VRVEURVEURVEUDYtVFEVRFOWyQ6vFKoqiXHpoWKyiKIqiKIqiKIqyZUyM8eJugN5ZVBRFURRFUa5QBl54tYl1LC7lY7JSv60WPaKeS0VRFEVRFEVRFGXLqLhUFEVRFEVRFEVRtowW9FGUNdCCEYqiKIqiKIqyMdRzqSiKoiiKoiiKoqi4VBRFURRFURRFUVRcKoqiKIqiKIqiKCouFUVRFEVRFEVRFEX7XCrKkCupt9J6hYq26/xc73tEZPgdo991pRyLwfprjBm7r6v1lrqE9mCL88xe4deHrV1/g4wfLyMrzqfVjg+hOQrnO856f3on10e1jxRFuRTWn43ajAO0WqyiKIqiXMby1K5iOCwXmHKOpFVpqCiKomw3Ki4V5Qpjs3eglJ1lNe+EHidlI9g15tFgDokZ/54l4dl8hg6nolywa+1u90yrZ16vS4qiXAEXOhUsKix3k3GirD+P1jrvh+JzTOCsjr2iKIpyPqjnUlHUSFcuIXGgx2r83NW73OcyyJVcOWPi4BGzfBxHczIH7xt9XJZerIOrKNu4ruv+KyouFUXZ1aLxQhX0Uc5/jFfmzOlc1/HY7Lk9+rcxZkmojwmAHfVemlXWiXPepYdDURRFUXGpKGp8Kpe+sFRUYJ7vuT0o2BOaasR2ZK4ZY4iD+bVKYswgR9PISgGq2lJRFEVRcakoiooWRQXmrmPUGzlgtLnJoNWNGIMdHbcVUbM6popy4a+3WtBH15xde21aK9l/3IXrfC5+inKlirHtnP8rQ9xWPjeamzZ4PoQw9j0X6ry80s//7Zo/K9fpwTG++BfvuOb828j+r/Uaa9erOWcv6+O72T6hK8/hYZ9qazAYAkKQSAiBGKOEEIbvscaQGWuMMcM+mEEiOItzDosdjmaUiIgMx9/I+Y3/lW4879b1UdMqLoy4utzF2Vo3rTYyh1Q/XL5rnXouFWUXnPArxcY4MaJcnsd3t1f5XUuIjntM5/Jywy0iIEI0AGkd8BLFB5/GT8BhEGPAIk5MEphAQDAxCUnnHMZYDAZrLJjxVWQVRVEURcWlouxyA3PU8B4VJOMMcTXOLx9iY/iPHutL7fiNq+a60W0ddwNkPSG9/D1XzlwYO5bGgAhhKAKFKnipfE1d18NjEDFkxqZ1wdqhwMRAjFGacTXiHJnNzu2DuUoOpqIoiqKouFSUXWRcjguPXctAV2F5+d08uJSP3VpCcDvy+MYJ1ytxDq8aWkbyWIqAj4EQgpR1RVlXVN6TO4cxBmcskYhzDiKIMeLEINaM3sAQa62JRAxG8zAVRVEUFZeKcqWJjpWeylGPkRqGu09UjB7X7ciJv5zE6pUoLNfLV5Lha4QQgvTK/lBYSop7TZ5LE3GmyZ80ghhDNIbom2qy1mJM480khcsKQraiHqys2Bz1ZCqKoigqLhVlFzIs7DFGhKxmtG+HZ0IF7M6ysqDNpTzemynis56YXOsztEiIDIVeQIgxUgUv/aqkX5WUdU1kkI8ZG3FpEZtuPkVjyYzFAN57sixLBX2sTSKz+S/pSlWPl8Nc0HNFURQVl4qibAuj1WDHicrRx7UNyeXH5VINcLW8360ayTHG4eeNitcl7+2VLSbquqaqa1lsPJY+BoIIYmgK/DTFfIhgLWKan6bwT+YcWZaR57lxzqXvSM/qyacoiqKouFSU3WhMrhUaNzC+jTGD0LZlz416vlRgKpcacWXDRYAoy+b4asLy8heXEcxIxIHYsTcX4oj3cPTsjQbK4GWh7jO7OE/tS4zNMJlBxBJDOv8jpGI+QZL30ggRg8PQ7XTI89y0sjxVk42RgGANWGPVb6koiqJsv7hcL7RuI8bxRj9fUS41LoX5eU6T9DjsY0eWZau+bj0xuV37djkWD1pZKGa1Po0XQmCsnVe33nbsbJ+09d/feLvk3O0yJolHa+yIOJLRV8CggilhSUiKIBJGt0EQa4Zhm9ZA870X+twbKxA3OKbnfJaJgGAQwI4kMFoigohpkirTvgYiQiQaCLGWqqp5c3GWU7NnEAOdTpvKB0Qi1mWE4CFA7hzWZCBQ14FoLJ1Wl4lOl4l22xhjsIOtsA43Oqt2ubocVzBqO68PO30zb6fXqbUqjuuNyp2//u0G+3grNojqh0v32G1ZXCqKcukwqOw48FTqAruzhpr2Ct25MU1VTlMIZ9OOcfi4XV6t1MQow7ziJP7ZJaGbcUTKLd1MsDiiSQGqS8IyiWrBM7e4wKmzZygJ9EKFc47oK7z3zYVdkBho5S1ijJR1icPQzlq02226nS6topX6XTZfa5vv0lmuKIqibAUVl4pymRjoA2G5Ulyq8Dl/VvNcaEuXHRhrllc0HlY4TgNNqnkaaYqfjnqVBSQJUNltA59CT83QS21SzmMjnoPEJL4bz2JNkIVygZNnTnPizCmCMwQCOTm2Dnjvl9aFEAnOQ4jYaCjygk6nw0R3gomiZdyweA9r3lRRFEVRFBWXinKZiZvNvF5EsNbinCOEsKw1hbI5Bjmro+M32tZlVExq37/tEZajAjM24tKsEPRmzPmxMq94I+fPJX28xA5zLpdCoJfPMe89WZ4jGPrSlzOzpzk1e5qzc7Mshj5VHXB5RrRgosc0ojzGCDFS9fq0ixZT3Qkmul0mWxO08sI4YzFRxq4dy46DzndFUS4Suv6ouFQUZYfE53q9DnUR3h5xv/JvNa63f6xHw7qHYy4QGYisOBCjAuCDT6LSOJxzJrMu+dokvfayPz7DIj6CDMq7GgNWwBjy3BGIlFLLmdnTvH76JKfOnqb0NeKEvq/IbKCONdZa2nkBWLyvMCFiyei02uzbu4du0cZijGuEZ/ouqxNTURRFUXGpKFcKKwsnrCUqV/YZ1D6WG9+/cwQPjG2xoWxyfJswz5Vey5WCflDoRxIMMjAHnnnj7LJjsruiNm0KC25yUCOSKuZaAWPp1Qvyxpk3OTV/hjPzc8zXi1TB430ghECGxeDIncM5B5VgAmTWMTU1yczUFJNF12RYYkjezUFxpEGi6/L2LmZsi5nxNwx0jiuKoigqLhXlsmLUGB/Ns7ySROCOmfXWjq2yO25MdYy3Zy4vE5eE0ceb3ErBNx7MOoQUCkv6HU1sQmNhtADOZS0sMWAbwWwiiBAJ+CiUsZQ3Tp/itVNvcKY3Sy/U9GJFHTyRJC7FZhjxWHK89/g6YKNhujPBnulpuu1OU6wnYhGctTibvjeuknOsc11RFEVRcakou9woH3gSVnrYlPNnyRN2sVqRXJk3SYZ/LxvmFDIbJGIaD94glNabiA1BjAkmHzkPLv9TwCx1+7ApGNgTiCJ4E+T1U8c5NXeG04tnma8W6UVP+k+wzlDXnizaprpuRHzAVxVFdLiOodvuUFiHRZAYya0btoaRGJq8z/E9RBVFURTlvMTlOAN1q70tlcvT4FvN+N5t+3op7dNq59pKobPa61brQbZd+7mR+XG5zJFx4nG0n6IZae63Xcve+mOz/vHfyfNzp8//0U93ziXvY4x47wkhCI5GUPqlKrIWoo/UMWBtEl+RiJeAk0DEjLSXXLsdz3rXt+08fuuN88pzOMYIxhEQnDVEoA4em1l69aK8euJ1Xjn+Ogu+x3x/gb5UqTqsAR8jofJMtlv05heYmpjGWcvi/AJ1r0/WmeKGIzcw2ZowTZYqmc0YOnwZ3Kyyy47RZq/35jLP2dzptWu39yncjbbQZo/ZWq+/0m/WXO77fynajJeCfbohcanySlEuvQu4ehD0+O/2i5YxxoQYUoalCAEBiaSI2OS5jIPqyI0YiqbJF2xEpci5XufVBN3FPrYr83rFpHo6MQaqEAUrRCcslgu8fuI4L7/+Mmf7iwQTqIynip6qigQr5HlOuyjwZZ/JyS42QivLOTl7hkwcb33HvUx3JrCAY1gfKPW0HBHGss3zVo1rRVEURcWlosbDJTi+Gvqqx39X7B8ytp3I4LHa1007kpjEJJEogiH1d4wSmrYaSUzmIYjPosmNG37eyjzOcXm0F2t9HLS6Ge1VOzoWQsRYgwHjidIPFcfPvMEzx5/n5JmTeCNEB8GQvLtN+GuMBkIGUcgwtPOC119+FcrIHXfcw/7pPUxkXWMaYWkxjbCMQ2GpKIqiKCouFWWXigutSnpliccr5fivFsJtrSWSIjQDQpQkKiORGOOwcE80SaDGkMKXM+Ow1gq5NZlJZWqGfR05t7rypbD/K/OkRx9b6C9Kq902BstivcAbZ0/y/PGXeWP2FJUNBANVrJP3NnMUeUZmMmLt6fUX2TPRJcNw6sRJTr7+Bu+4+23cc/udUAkOi4kRa0zKrbQCOGhCwcUAeu9KUS7a+q/XekXFpXJFooufoijbsY6YgbfMLM8ljiESYhjmVtYxICbiDEl0xoiEVJCmj8U5h3M5OLtpY+6i7PdaOVm5ISAssCgvHn+Rl0+8ymtnTjJf9XHdPInvmPIzMyCSUWAxxuKso2Uz6l7Jq8+/yM1Hb+Rt99xLh8JkhYMQsCZrBKRJatJEBJuq0ur1QVEURVFxqSi7X7xr1UY9/rvl+I8tOMWSsEweTMGHANYQiASJBAkEhBAChEgMgk0pmTjnyLOW5C43EcGwFAq70jN4sUltU8Z7pQOBwhVmNszLsy89xzOvvsCphbPMhz61S47G6Joen9EQfKQsS7AZnbyg3eoQq4qXnnueQ/v288773sa+zh4DgsFgbXauZ1IsxkQiFmi8mmugYfmKsr3rn6KouFQU5YJcfFYacWrU6fHfDcaJWSW3byj+nEUk4L1PvR4zg4+RKIEgkbquMQIShOgDHg8iFC4jzzIcDmfsUFyGEC7o2G30O1Ye3xiTgPYuyFNPPcH3X3iWed+jygTvoHYRkYCRVOvVAYaYChlJgCiYEDn+8qtkxvKu+x/gyNXXESRI27RM1S9pt7rNl7MsxTJ5iIGm++VWRknD/hRFURQVl4oaD5eoyDifVhTKFsddhipomfE9/NuMee0yRkMzY/PvDYYcmth8cdOCA0m5caQqqOn4r/z83TT4MYVpNr0tRUCiJZpAHQJECDE9HyXgQ00/gDeRvMwxmZOJomsGfRtHhbqR5Ydm2XFcNo5baaWxseMx9KiamI62gUggSJAXX3+VR597gpeOv0Zn3zSuXeBjwIsQYqSVZwQfkCi0jKOTFxRiofIslj1eeuYl/sKPfoybrj9Gm5axxhFDoN1uI7XHuGy5ejSDfQ5pvmlhH0VRFOVCiMvtDsvaTA+yiymiVhr0V4JhfyWJl0t9Xy/Foi6X/vyIa4i9wbk9almPnOcY8LHp0WAaO7vZX5seiyy91gyKy8SIJYV01j7inG16ZLr0XWYpRDOz6fNCU5DG2PR+07SGEOPFGMGYzBgyMEIIqf+gtSkM1DSFV0KIGCtY65b2Wwwy9hht7OaEmOXexShxWVipjKn4Mvr68+4CKZA1HkeXO6gNIdaECJ5AJTWlr4fbUocakYBI5MyZMyzWC9zQvYG27SCxJrcZSCRzGUE882fnZWb/HiMMPHUyMl/icLu2PLsHfVJlRLiNtkMh9a50ziAGQqgEZ00tpbwxe5rf+8JneGPhNMVkF99yzPYXqIyn6HawBqIP5MbSKXJyMbQlY0+ny/ypMzz6ncf54AMf4L5b7mOv22MWeosy1ZkwxmWEENK4ysqDkfbdDXyWcu4R3tw6pOL0Uma9nsjb9R61DxSdE7t/DVk5NmtpOKvTRyeSouzelZG1K2IOhOWqprMZiq7BvzObhCVA5sySLh1oUgzOQGYNPlT4UIGJWDdoxWFwzmKdwVpjhEhd9yWECkFwztB8PCIQ45JAlsEDIwLycr9wxRjxvqJfV5R1n8rXVMFTx0Ada/p1n9KXSXDGijJUnOnN8uJrL7FQ98TY1K8xxkhVljhrmdm3xywu9ORcub1Tk2z53YyhtzJGnEtzzCDMlwvUoS/z5QJf/LMv8fjzT2G6LSb2zxANkDnyop0q5vqAMwYJkUwMYaFPNyuYPzPLk489zi3XH+O+O+7lwNR+43C0XcuY5pI+uJkx8A4nL3lcJgn1aqesZgepLaQoylbQsFgVmIqyi0/o1Z5oXIJ2ydIWQBoRKY2QtANxSSSG0KwPkRghhJqi1Uqvj7Fp7SBL3kBjyJxb/p1AjJ46RrEWnLPGGofNMwM2fQ5LMZ2DoixiBOdSvdClKAvT6OLtk00rc0BXrodmmyXJaP/HqqoIJhCtoZZUQdaLp6qq4et9XeEl0F+smD09y/7pfUwfmKAKfXIsRbsghoA1lqLIzMqpYMeI2y1dD0wzeYwddZEPPYLJUy2IEfp1T3CW2d4C3/jmN/nKn3+Nzv5ppmamCDEy11sg7xQ45+hVPRwG17JEX2Gdod2eoOpVvPjMC0Qv3P/2d3LttdeawX4M8k5jjMObH4qy1jxeK0pNbSFFUVRcnie7vYm5oijDs/2cR4JdCg0VkjC0oxohNqGojX4YhM46Y3A2I4RyuF5Y4xoPkTR5giJlWVJVFVVV4b1v+jFGiqJNUWSEEKTVKsjzQqzNcCYzKexVCN7jshQOK0CWZUuCZhCCuUVduZZYHBUpO7UeZjYzWZaJtRkxRupYE60hGPB4fAyU0afxFeiHOo1NDCzMz/HYE99n39Re6RQtU1a15C4z1loINVmeD8NVl2fCbnzc1k3dGOR7DmbXCoFpMPhQS5BIv+7T6rZ4/Jnn+cwffZZSAjcfPUJwlrIqoQkzqssKYiQrCmJZY3ykpmKyPcFzTzzNm8eP86H3/gC33nILAGVZYowhy7KhyFytUNR2XR+XaWvlshOV446x2jyKoqi43EZxqQ3sFeVKEpZL3klvzNBPmHRIJCCkGp1mmfEswSfj3RkwqRl9ckyKgBDx9Ho9zsyeZe7sLP2q5MSJk5w6dYpXX3+dN998k36/jxDJs4KiKJjZu4drr76Go0ePcvjgQSY6k9LpdJjodHFZZiBgTBJTPkSsy0cqfRowskqhoa2viwMv2GgO+soMva16Mh2GPMsoXIYV8N4TDAQneIlUEvCNuIwx0qur5A0uHKbleOzJx5jpTvLO+94mWZGZ0pe0ssabLL6pszqUlIz6Lg2RuAXPpZjBrLKYpv1HEpSAhFS4RyLOOeNjkKxV8Mobr/Plr3+Vk7NnuP72m6iIzC/O0+l2me5OsdCbp65q2q2cHEtvboGZzgSx53n+hWd57bmXuf2mW3jwne9mwraNwxKz1PtzcENgsM3e++Hjq2PH3nJY64aMoiiKoqi43KDAVGGpKLuduOyvQbkeWfFcqn0yUk2H5KQyAzcYQrBRzs6eZm5xjtnZWd48c5pXXnmF5557jpdffpnTs2c5/voJFvs9+v0+WEOe5+R5jnMOaxyzs7N472m3Wtxw/VHuu+se3nrP3dx07Eb279snBw8cwjpnCpcBliABMUlYRgG3zUvWwIM7ECoDgWWtPadn49axKcfUZhRFC2szghcqqfE2EiyUscaH0Hg1A7UE6hDT+HVbZO2cL3/tT9m3Z5rbj90OJkhVlyazWaq8a+M5AsrIoPJv6vm4tdnUVPttZtHoN1mJLPR60u52jA+eMlR89RsP8+3Hv8sNt9/M5MF99KwhxFS7tfI10Qe67Q6t3LFwdhYThBxLf26OZ598iiMHr+GHfvCDHJzch49BnDXGuaVvvRDeZmV32DwbuYGiKIqi4nILwlJRlMuZTeaYmdj4/mTofTM0IbEiyQNlBF/VkuV5qrDTfIWPlZw+M8vJs6d48bUXefzp7/PII4/wzDPPMDs7S94qOHzoavYfOsjt112LmBTS2u50aLXa6TO8x0uk30shs4uzZzn+yqv8xu/9Np/63Kd44G3v4P63v4Obj93MNddcI1dfdZ0xJsMZh2s2xEdpojLXEkhuQ8MhI+MwWBcHP6Pr47YLTBFyl5miKCTPc0QkjY2NVFaooycaKEON9x4xlhA84gNd5zh4zVU89sojfOXhr3Bg3345NHOAuqrEOExetJoo1SWBacSMmTfnLzAFIWJxMvjsOLDYk1Q3htKXMre4wGPPPMEjj36XrNtm/zWH6RNxRUaXDO8rqsWS3GW08hx8DT4y056kd3aB1194hQPT+/jAQ+/ntmO3YjDGihWROGxXM/BaDo6Zc0775SrnLSzVNlIURcWloijKKhIgEYfCclR6LbWlaErLCsMelFmrMGAIUstir8ep2Td54eWX+O6j3+P7Tz/Jl7/+Z3iEbrfLoWuu5pb77mVmZobJ6T1MTEzQ7nYJIRAHuXBZPvQEOucIEaqyJJYlb+n3OP7KKzz/5JN89ZGH+erDX+GD7/tB3v62t/HOtyGHDl1F7tpmkOfn1i2Fu3GBtBoxRrHWmp0SKRIN1mXkeYvM5VjcMBxXTCNwraGOgYCQOUuInqqqyUxBkWUcvu5qnnjmaab/5I/50Q99hOnOFL6upez3KNptM+gduhM3NAZNTVLvSobln4yk7W91CnP87Ek5O3+Wr33jYU6eOcUNt9/KXLmAtHPOzM0zvW8fLreE2tPJU55l3e+xb2KKibzD08+8yEvPPs9f+OGP8sDb30GoPLbIMNaagZgc5FoORKb3filHV1HOU3wqiqKcl7hcrVfJVu5abfR9l8JdsfVzUhRFuVgGznasEYPPCCEm746VxsOT+iJWZV8AsiwzRoRoIs4m2VnWPTk9N8urr7/G4089yZ9/+xs8/sT3OX32LFI4jt55OzP797F//37a7TZZq0i/8wKAyjpitPg41CMYA84Zsszi64i0M4puTiFdju2d4urrr+H4Sy/xynPP8cnPforHn3yCs2fmePCBd3Pd1UelPTltiEkMxxhTDihQ+xpn82HV0LSPYemLV1l3V+ZNDsRvI1TMaP7lYM0cvEfWEamr5WQOHIiZy+hVfekUbbN3zx55+firhBDI2hlnzr6J67TwMSAmpuI+ZcA4C7ljtrdAEMfha6/h5PE3+Oo3vs5Vhw/z4DveTZEXppJaYowgYFxTSTUIWZb2ra48LrfDvRi95o1WsV3tmiUIdfDSyvJUXslADJG6Lul0WpRlT7wJ5EXBw9/8Bk8+9wyHjl7DngP7mKsW8RIpum0Wy0U6RYt20aLul0hZ07IFNlrOvnGa5554hnfccx/vuf8B2q5FYXJTV14yVxixMiwiNLqtA6/lelVj4yo3GwbnnzV21RsRIrKs+NX5XevjFtcBu+Prx05+5sVgve1Xb6WiqP211dforU1FUXYt3jeVRm0SdOlmkgwN07rfl6JVABZf9aT0Nd2JCVPHwOsn3pCnnn+aR77zbb781a/w3Msv4k1g7759HHnLzUwf2MeB666lPTlBq9UihICXSG0t3lhCjDhAXIbJDKl5ZRK1tQDekxc5IUCIAbzHmkixZ5JrW8fYu38fM3v38cR3Hufnf/lf8+qrr/GXfuwnuO3m2wQyg3MY05RDTeKYQZ/DrYa0DXLQB96vwb/XEiuj+ZobvogBzuXG4egULSY6Xc4unqHn+xgrVGWP2gh104JlWJ3VObJ2i2q+z5sLs9x7/zv43O99ij/47B9y9Mj13HDVUVpFbmofECJODMY4zIgayosMH/yIAB9vYC8TlCMXVEGwg3pKIiz2e9Jp5abdabFYLkoVKmo8Tz7/NN/8ziO0Jrpcdd21VDFg8wKXWWrxOGOoqopWy1FYRxBP22XEXslTjz7ODVcf4e33vJWrD1yFM5mRAJkrTAqHdWs2rFwpjs/ZT5udt8Awxmy66q4KF0VRlN2PiktFUXbvAte0ZwihTi1FrEUkeTCRIHmrgFjjq4BtOSZaXU4vnJWvPfIN/vThr/JnD3+N10++weziAnsO7Oem227nyLEbmJmZwRYZPREqZ4liEOOSsZ65FAIrQuV9ElDWJo8bFpFUKyhGjw81Bsgzi1hH8BFrLNnEJG1juX16DwcPX81Xv/Bl/uBzn6HT6WCNcP2110urO2kwS2J5EJK5UgRtTOQt5VemKrQMQ3dXe/1AUK4UmKPPr8zlXPacCBKEPEvfkec5+/bs4fibr7E4P08x1cZHj0RPjEI0EA0EH4hYLJHcWaJA31e87V3388l/+5t88U++xIEf/0syUXSNzQxJX0UE2xx/hm1OzaBP5Sriaqmn6Hjh5ZxL7WqMIYSAsW0ikdnFBbpTXc6cOcOXvvpnHD/zJrfcfQetiUnmZs8QM4s1yXNb1zW5sVgMVVkx1WozYXOeevJZTp84yQc++iBvf+vbmenuMTH6dFvEZfg64LINCMA1iBKHNyTS69f5PAzLh2OT82zFTQ8NwVQURVFxqSiKcsFY3/iUNY3cZMhGrANjkrCEiHMGgzOh6otzjqxTcGbuLA9/5xH++M++zNe//QjPvfISJs+Y2DfNnffczpEbjrHv4AGyIicg1CKQ54jNIcuwA6PZGDyCDwHTFMAJAuIj1gjGWqxLujD6gLEGmxdAhhehjEIVamofqBYWOHLLzbwLy5/+0R/z8d/+OD6U/PW/8te4aqItGGOiLFUJtcZtSFSME5YrRcSqjdc3IChGRea414sIiMXaVLm1jDXWGbN3Zo9MdLq8cfoNYp1hXER8QKIgziRxGQJ1SAGR3W6Xcn6B2cUF9u7dw7vf+xC/+8lPcu3V1/EDD75XMgqDjdTB4xxYMsSY5FU2FmNNMy9k7NwZ9fyt7B0pBKxxVFUleZ6bicmOgUgZypTMm8H3vv8o3/zutzlyyzGuvv46js+eRjKLl0hucpwzlIs9OpPTSB2IZU23O838qTO88PTzvOXYLbztnnvZP7OfEGqxOGNsuklR+xK7xbSOGNP5sTIceGQqbxvqtVQURVFxqSiKcomzdk6Z91XT9sMOJeiwCqoVbFGYuXJeHv/+k/zh5z/HH/zRH/HyyeNMH9jHVbcc4+iNN9GamWR6Zoa81aYMgcWqIs9zWp0uiGBt1mzHiCCLEYsjc3aYAxkkYkSSoDLJsG+12qngTxAwIC6FS7p2B5O3qQWefu1lrr7mMO/+wffy+//uN/nEp36XG28+yod+8IeZnthPCrUd5F824zFsfrn9Bv164a+rPTdOwFkgePA+SNZxZk932uzbs1defO1FTp96k850lyAVIQqQ4zJHtBaHgRgpQ8TmOdZknDh5irfccTtPPvY4P/+LP8ctNx7jumuux5KBjVS+xmQOOxgTa5qbDUvietSztnJ7V4Z2GgGRiAUjoca6nDKU1LGW1kSLp196jj/84h9B4bj6yHVEa6h9oN3tEINvvJ6BIsshRvq9HvtmZih7fR779qO0spwPvPd9HLvuekyIVP2abrcASfPJuXzdmy/rhcUOwoyXcnQHv9Mc3apjcav5fVv1bK4VHq7VUBVFUS6GZaYoinIZ45xLxjJC7avUosE6nDXU3sv3X3xKfv7f/DL//T/8n/il3/x1TvbnuemeO7jvfe/hbe9/D4duPsrU4QNIp02VGWy7RWtqkmJyApsVKby19viyIlQ14gMOQzsvmOy2KbKMdlHQabVoZ6nNRMs5cmPJIuADUnui943AtJBlmKyFbbeZPnSQkGXMi+fqm27gPR96HydmT/JLH/8Vnnv5WUpfiSHlRq40lKNsrYejrPGfaf4b99rVDPnRn+HjMeXFWsFkWByWg/v2s2dqmtmzp6nLEiNQuAxjkoA2zYVLRKiDR6xjsS6xecbxUyd5z0MPcfyNN/in/+Kf89LrrwhEMmNxzhJiTSAVCBIJjdA3wxYrq+VarvZYZh3tIsdZiATqupYsdyxWJV/5+td45oXnuOPeuwkWTp89w/SemeF768oTQmCi06Xs9aEO7Jmc5pXnX+TF557n/vvezl133Ek76yyby0EiPgp5UZwzrquN81ribuVPenxw3Mb/bEbcXezQ19UKFiqKoig7g3ouFUXZtQzCRaOk36Zpev/CSy/IY08+wc/+m1/kqRefpR8CR99yC9fefIzJffuwE22kKDCdLj546tqn/EBrKKyDIARqZianVvgGY7OwCg5HBLImvDLGgBFLbh3GOkIGZa/EhIDJcjCWWiJl5altaidRl4u0p6c5O3eWuu7zlrfew0svPc83v/UtvvDlL3Jw7zUc2HtYirxtBiJ6WUjrJqt5LgtnXcvr03zPSjE5Lj9xnMAQkeG4iQh5nhMlEkxg7569XH/kCM+9/Cyzs7N09kxSFC18qKmrCsks1qSWLkVRMHvmLPu7UwRfkWXQbXX4wQ9/iN/5zd/iqquu4kd/9GNy+423m8xkBAnDbYkIzthNjc9KrBFEkvCr6koCqQjRdx79Hn/+yDe55rprOXztNZyam6XvPe28he8tDvNAc2tS25vomZrscuL4cZ568kmuu/ZaHnz3uzmwdx/B1+SuMDZ31N5jjEseyQ1ExK5XDT3Kucdu4LkcnD8r93/0+fUcf6Me4fHjeGFE3loeaUVRFEXFpaIou5WB0Tpq9K6wR2UVgza9J46IvYhEj3EZzli81MxXi/LEU0/y8Y//W37jd36beRs4cvON3HvPPRy45ipi7qDIcJ0O3loWq5K8VTDRbiMhQgBnLK28oMhzevOLFNaR53lTWTXFEhpjsNKINR8JdU1d1lhrKbKcVKE2adGy8gQLQSKVD+AsrTyjnWV0ui3ePHEcNzlBv7eItApuuutOnvj+9/nk7/0eH3jwg0x0uhR5AURCAOeyRiTadfMjR58/p/DOquIyDj97NUN9nJgY91jKhU1VfEtf0Q+ldNsdc+TwETm09zDfe+JRMlfQyjoQBF/XOJNj2wbrcrx42t0W3gh5YfFlxLYLjt5yE+988N38wi/9a/bs28s111wjk+1JIwKZTa0vnckIITTbZoiEc8THoDruyCMYWcrl9SFQ1X1ptdumioEgntdPnOQbj3yTl195hfd/5MPMLyySFwWtzLDY72GcxdmCLAMTPfVin07e4uCefXztm1/mxEuv88M/+R9w7MgN5LTNQjknxUSXKJ6q8tLptEwdAlXlcZnDrOGhXltI2Q179ZYLz41Xfh17U2HZ+wxrtSPRsFVFUZTLUFyudfE53zt8o+/b6YuDljhXlMtYS8qYqqOD9aNJ/DKyJCgHzeqXyvgY6hgojCEzEH2NjRHjDEQvWWaQUFJL5IXXX+HTn/sM//if/f84PT/Pbffew90338z0oUPsP3iArJ16KtYSqcuaaAx5UUDdiFRjsNbgEEKsqarAxGSnyb0TYvRpL2LqTxEI5E0+YKvTpsg7LC4ucubsPB0fmd67h6xr6MVFFusSnMVkySvleyWmcEBkYnqGs/NnKUvLiV7Jvquu55bb7uFrn/8Cn//sH/Cf/6f/OVH6EoMhyzomeMHZLI2dGRHaQy9SEhYD296sKIo0rARrhPHVZ5eOgIgBsWOOa/NKGQiIpQS+4eElEoFWJ0vf6S2dvGMsOV03wUNvfx/PP/ECvTfmycjZf81hqjMnWej32bd3htNzZ7HWkruMiFBn4KLhVH+OAsfbH3o3b5w8yf/4D/6/ZFnG3/r3/yaRWpAIESLRRLFkeYsYoa59ExpqwSbB6xvxaYaeOtuE5ALGMN9fkM5E25QmpkI9lfDEs0/zla8/zI233sb0nr2UEqhjAJuBtWluIoTgyWOkYy2FZDz/+NM8++iT3Hf73Xzsh36UPd29pq48rbxjyipijKPIC1MHITMpTFgkIuedV7vUxmaj4m7lv8O6kdd2+D4z5hRfb8tjHMzFOPI5ZsVcHLfd564xK82ZQa/btfZ5vNAefa32yb6o1w21+xRl29mOKA/1XCqKcgmsZqwbITcQlivNypZ1eF+TZ47oawnBI/2a1nQXqWsWQ58/+/Ov8i9/7mf51Bc+x2133829t7ybvddcQ7H3ALRbVNbQK/tEhCzLsHlOZu0wF89ZS2bS35YkPCyGfr+XvJY2g6aojjOWbqdDp9Umz1uIAYmGfl0hxuIX5pmdX+TM/AJ79u/DdVq0Wo5+VRFDGEgxfJVyA/uhpO8DtTUEl9Oa6LD/4FXsmdnHd7/7XV5+5QWO3XBrY/Q2BvOgB6FZ+0ahSDgntnFlKOMKc39ErI5v47GZHLcoHiiQZkzFgMXSaXXNgSkjH3zoB/m9z3wKY+foTkzRzdu0piY4c+ZNslZOCGnMK+NxQLBCZpvyShJ58AffT1VV/Jtf+zU6rbZ87Id/hKl2l/neAp3OhMSI6fVKxKbiSgaoo8d7L3UMOOdMkkh2qCwCYMUSMbgso19XUtYl0RoWqj5/+PnPIZnlttvfQhBJI2YN2DSHU7/ORtzUFcZY9kxN8s3v/xlS1vzFj/4FDszsh2AwYhuB1rSwsem4plDjpsqr2TnP30ojfivGxupFgixreS/HbdNm9mvU27pd46IoiqKouFQU5RJkNMR1NE3QSPPbxLGa05BSzhyOquxRZMn4z9uFgQwkk7n5WZ5/6UU+/cef5Z/+zL/CtHMe+qEPc+y225jevxdTFPTJCM4ipJ6DLs9S/p9Znm/mSKLSGosztvltoGidY3hba1MFWevwMQwlmcstk/kUtsjxp9/k9OxZ8oUFulOTtFot+r6mrgJFlkE0VFWFmEiv6i99jghFp8U1117LoasO881vfpOnnnqKYzfcirWW4H3yvDXGPKsKvYGX8lyBuMJxfI4Q2Ey0y3pCM4RAbWoYVNSNsamEapjoTJg77rhDnnnxOb71+Hcopjvsve4Qc1WP3FgkCCZIymVtGlcaDNEZfEh7Nr1vLx/48Af5+X/1M/zrX/lljl1/lNtuupl2lqr0WpsTJJJZh0gceipzlxkfA3YYph1HhFAS5ULEWGkEk9Dvl3zjkW/w/aee5K633cOeg/s5NXeWYJPHM3kak1/YYXDG0s4LnA+8/vIrPPfMszz41vt51wMPkIklc47K+1WEP6zXhmej93Q2IuRWa9WyWUG4+tSxK25ebE70bkZgqrBUFEVRcakoypUgNEcEp5jx4mY0ANMIGDxSlWKLCVP1FqTotExZLsrZhTm++o2H+b9+6Rf5k4f/jNvuvYtb7rmb/VcfxhQFIUtVWes6Dguy5K2CVquFtZYqpEqezjkyY8msI7MOa5OozGyq3JkVOb6qiU1IZbvdJncZCCwuLlKWZRMKaclbBe3uJBNTk1QSqGJgfmEByR22aNpKWNO0LRF8DEQTqYLHWEc0jip4IrDv4CEOHLqKbz3zFM888wz1D9S0igkT/EieoCwPmFwrP3KjBvfSZww8eXbdz1/rOWNMyntc8pZKXdeIWJNnOd1Ox7z3PQ/Kq28c541XXqM1NUHWyWi7gsW6jzUOiU22pLVEYzHWEjAQhEVfETLLv/dX/wq/+Wu/zj/76X/Jf/2f/z1uPnYzWd6i1+tJ3mqbLMtSAaWqkqLdNoXLkhCMS5Vr0hgtF1pFlpvF/qKICLPzc3zqM59m78ED3HDbzZxZnKeWSDQWsSn42MRBGxxDhmGyNYHEPl97+MtMtLr8+//eX6br2sbXQWKMI9+51rjKNpx1bOrYrSY41xN3K2/EbGTepdfI2Lm63jasV/1XURRFUXGpKMouI7LcgzKs5WlkWS6mbR43I+IS72kXGYjH2ciZM6fk+JmT/MFn/5B/8fM/S3CG9/zQh9h37VVMHdhP+8BeTp45y9TEHmYXe0zNzBBCJMZIHQOxKoehsFmWkVuHMymvL3fpb9uEyFpr8U3SWZZlFEVBp93GOUeoYiMQIyKROkSMr1gMNVmRUwUP1lAHz+z8HK5VYFzK9SurGnwghBQW62PA5QVkliCRflWyd2oq5YlmGc899xxnz57l0MGuWGvNMgNezhURo4LE2PUM7pXi0WxYVG4kPNa5lGMaRbCZI8OaGOOwF2XL5BzYv5+H3vVufvczv8uLTz/LrffcTqwrCpMRgbopLBRFiE0UaUTwIsQo5FNdZpzjgz/yw3z8l36VgwcP8p/8rb/DtVddSwiCqYxYxFhraRe5sRYkRiSEpRYdwz2PYFL4rTHJa1nVfXpln+88+h2eePZp3vWB92FbbRa8b0oEGYw1w7xNJ2AFMgHrIydeP8nrL7/CRz7wQ9x7293GNKK16ldiXW4Gwiiapdzkwf93uvLpauGkGxWH5/bPXD4Px8jWkVVh9POXPJvLazqsl/O4dkEpmiOkKIqiqLhUFGWXMhrsJ4y2rGiE5fAF0qxgxsyfPimtyQ7fffx7/Mtf/Dl+81Of5O53vo23Pfguamu45thRYpHzwisvs/fgIRYl0pmZIWKxGIxdyqmLMSZPpnUYAWsMrsm1zIxtwmMbwRGFVquVwhudAxG890QhiaUip5JAqDxlVRL7i2AMdUw9GskdZV1jiOStFgCVr5CyxhiDJ1BLKrozyN1brGoOzkyxZ/8+ut0uL730EqdPn2bf3oM4m6rQprRLM0ZUjjf+NyoutktUjj4eBq1BmrYx1qYxRgwYaLvC3H37HXLq9Ek++6XP88zjT3DstlvIM8NCqMBYfCNGYtOIUZq7D56IuIzWRJvD11/Hx/7SX+Rf/+qvsGdmHx/7yEe55/a7iT5S1X3Js5Zpt9tUVUVVeWm1WkYGRaVWFpJptnlhbk46nQ6vnDjOZz//ObrTU1xz/RGChWgsdUy9NC0pz9I28zdrOon053o88pU/58DUPn7yL/ylwWykLmvJssJEMSl0fDUNabbYy/QCtOVYS2BekPVklVBt9WQqiqKouFQUZZeRxNtoQ4K4rHuiaR5NbT0GobCDZyP4UkKomS8X+fjvf4L/4X/9h1QOPvhjH+XqY9dT7JnmwMGDvHLqBMXkJHuvvhaXZ/R7i/Tm5um02xhJnsc8z7GSvFYDMeEwZDblWWbGYgciUwxiDK2iwA6a24dAXQfquiaEQDQQYqD2niqkn9LX+BiQphopjZcsisVK8srUIWBEsMYQSR65OgZAMHmGLwNYQ2eiS7vb4fTp01RVtWQwD3pWGkMc5gqON7BF7JiCPku/h6J76YiNhGie20ZiszmXMaaCQiIioenh6Jwzg/zE2pfSabWMa1nz4DsfkJMn3+Ar3/waZ2b2MHNwP4U1VBYMFo8QELyEoTAVCfjKY/M2+646RG9+gY/+xF/gZ3/x5wHodrscueo6XO4oq764zJgoQZBAnlmCl5GQ2KaoVIzpm2KgX/fJjOMbjzzCc88/zx3vejv5RIfSROoQ8I2wzBrZaIlYwEVwIrz2wkucOfUmf/nHfoIbr7nRxBCEmLy3rVZGWfl05IYx4qMevbVyGNmQgLpQOm/zwtKeM2+Xec6H+7cxYbla/1VFURRFxaWiKLtQYBqz3JwcCE070rLAjOYQpgQ25usez73wLD/ziz/PL/zqL3PnO97O4aNH2H/9tcxcdRV1Zjhbley/+moWygqX58zNz4OzTM5MY6IQQ0jtP7wfithBOGwry8iso3AZeZalSrEsebKChbqu6fV6pBw5h5f0WVVdA1AFj5eY8u4M1DFgsLgsQxovqTjXtDNJwtZmKb8TiUhcKlBjswLfXyRI8rbmeY73PuWGDvpsAsYycP2uYnCbdcXfThjfKz/TWpvCiEVM5Wtp+k6KdSm8d6I1YXr9BVzhmO5Mmffc/245deoUj377Me58x72090wiAr7J0Y0SiTYVKjLG0J7o8uYbJ2jlBQunT7H38EEmJiZYWOjxv/7j/41Op8NP/Nhf5Mbrj1HWNT56KfLCGEkFhgYh0oNcWEGIJiJRiIh0Jyd44pkn+eKffIn21ARHb7qRMwtzhFaGtxCdaSrggo2SCvk0nss8wotPPcex647y0Y98FItBxBrnMrKsbcqyjySfJxEZaYdycYTROKG63nas5RmX8RWjdmy+je/VqeuvoijKBRGXm0mYv+iGqV4dFOWSZd0QtCjJO9ZUv6yqkizLyJwhRMFZBwjBe2yWQQhUVV+stZw8e4ovff1P+Wc/+8/47uPf523vf5C33HMPnX17kE6bhVhTFJNgHYtVqkha1zXtopM8UE3/yoHAsdYm499aCuOGLUcyl5FnOa2iILMO1+S6BQRrHcFUSBSq2lPXJSGmHM6ANO1TJAnOkAr05K0siRYL1mYESa8FwThLVuTYmIxyG0B8hSAUWUa/KpnOc3wMeBH6/T4Hp2YGniwTvMdlBb3FPp1u+9y2FUPjOj2e59nQTyzD8FRBYhJnSxVz3SrHde31eJwQGvdvEYPFEUlCX6yjyFwS+i5DQsBaw21HbzFnHnhQThw/yRPfSQIz5Ia8VWBzi/dVKryU5/TriiCRiZnplPuaOxZDzZ59e7j3nW9HRPgH/+h/YW5ujr/3d/8uM5MznD09y76Zgn5ZSqvdNhJSRVtnk1oXiWQ2I8RI5WuqusfXv/Ewz770HPc9+C7ydovZ/jySO1y7nTyzMYnSwuWEchFTBQ4dOsTDX/wyzz31NP/j/+u/58DefWleGUvdL6XoZCbPWviYPNdmECU8PJ7NDZd1cg5jWDr/xp2Da10+B+L6fG46DL7LWrvma6Ks3IDlnvBhzrWJY0vbxvUKEplzd1ZG5+kmCgKdj5hda/8VtfsU5XI4z9YqyLfyujC41qjnUlGUi7d4WYt4TxAhy3NarVbjcYs4LL6uMMZQ17UE8WTOGZNnPPrYY/z6J36Dn/61X2D60F7e96Mf4dhtt1AhLEikW2RMdKepoiC2KQ9jAEmhrUOaCrCjwjJr2o1ktqkSa1JbiMHrMAYbhWiEsqyofE1d19TeE5rCQCIyrHjrJabw1qb1JCtCVxFSsRaT8jtpciWXWptkVLGmrD02QidrESJUdU0dAkVRNF7PICKpQo9zboURZsYaZVUzvoOf0XYqSWjGVUSJGXpaN3pxGr0IDS9EtqmemgokGWcGUaCCryO+Lul2ukBgsb8grpOZt919H3NzC/z27/8233r4z3nPD76PxaoktwXGp3BU8YFWu5XCiUXw0IQgC30Cew4d4L4H3snCwhy/+Gu/xOTeKf7qT/4HXLX/ahZ7PZmZmTIxBCQaXJ4BqbCScY6ApwyliIFXXn+NR773HfYePMDBa66ijJ6s3SLkWcqpbQSMJbWJKYxjcqLDyVdf56VnnuPB+9/D9ddeTzfvmCUllFzc3tdgHTKIGx8cG2EkD3ljN383mm+7WnXV5UV0Nn7zef1qrjt/c2stj+t2f/3ofFcBpCjKlXrTR8WloigXnCXjzmCyjCzUEH1qJ1FWRPGStVrGAjbLcJk1VajltVMn5I+/9AU+8cnf5Utf+wrX3nYzR95yE0duvAnaHayFqU4Xspxe7XGtAtv0ZhwITCuksilNuOMg9NE1AjOzDmcdmXM4l/4eiKlBv0kJES+RxbKkDBFfVSn8NQZiI55CIzADQhRPbHyE0pQedeOMeWsQMUiwjQfPkOU5tQ/0e32MQHQF0TDM79yzZ08KrR0xaJ1zyIoyvKOey8ET1gjWLgnLgUdT8Mtabxizss/jxrxY6xnYA08cZiBojRm0APHBD78PY2gXLdPv9aXVafPQA+9mdv4s//Z3Ps43v/owb33H2ynLmpZzOAsLVUXW7dLr9TACzjqKdgsThDIEgoHpw/t434c/wOmzp/lH//h/Z2bPPv7yX/j3mOlM0yv70mm1TRU8rpk/aV8DPvjUtkQqHn3yMb77xGO87d3vYt+hgxyfnyWbnsC2CqqyTB5xEyEIoaxoFS3aLueJp59h4cw8P/TXfogbjhzDklqhDKoRhxBSlWDrlo2lYSAylx+PzQrMcXebz0c8rifkNi8ul/e7HL5fRjyYy75gvf1fyks9Zy6uUgxpOwr+qLBUFOVKsePGrXkqLhVFuWgLkg8+5QpmDnwAAdvKsJIZzMCgj/TrUl4+/gqf+sPP8DO/8HO8duIN7n3gHVx1241MHNqHtDqU1uCKFrVpvD5ZjrHZUFiKSPL6GJNErV3KqUvFeuyw7Ugxkms5FJbeN0VmkrjwEikD6d8hFfEJcRDimkL2QtMiQwYBfM4Ov1OMQZq+hzLG+I8xEiRgrEGMo/I1WbRIx+DrwMLCAmVZcuDAgWF/zkb7Yq0diraVxv+4wihLrwnEOOqBWSkcZM0LykaM7WV/D0REFKQR+gFBJEiQSMtlpq48eZFhbU6oe/TjIhMTk+bDH/igvHn2JL/2Wx8ndxl3v/0+OkXGmXKRLIKUdSrQRPIe5yYjb+dUi316/R59AwevPcRP/NWf5Nd+6d/wv/2T/529e/bwIx/6CJ1W25R1hbEO7z3GWWyW0a974iUgRjj+xgke+e53cO2Ca264nmgjdazJncUYN6x664zDhBobDDkZZ0+c4sVnnuMtt93GPXfdRafVMakYVC02bxucHR7DUV21UpRDaiUjGzzXxgnLlZ62jVRWXcsTuLIy7GbWghXPbGh+bebmxnjxu7JI0sY/e7w4VhRFUVRcKoqyo4zzhAzCRk2W4RGIgczZoaFHU1wl67TN7NwZeeyZJ/mVj/8bfvNTn6Q11eEHfuyHOHT99ZzsL9LHQuOZyloder0eQQwz01OUdZUE0rBqasQYm0JQrU1eTGOaarCO3Dlyl6U8yyZkdmDqxhgJIVA2YbA+BqpgCBLxPuKb3MYUDpvCYAc9HAdVi8yKthYhDHIMk9QSaTyWsakc6wM2T56sJF6T6OxXJW+ePUO/32f//v1kWbZcAFggjtbdPdcoFwn4UIsxxgz3cyg8008cGORNgZtRj1nKKVv72C/lbJqxIsU0r5GmJ6UxFgwYnDEGKctSMuvIi8yI93Q6HZPljjp4uq2u+Ys/+jE5ffpNPvH7n2Rqaoob33IrtvRMdtr0+iWtPENMKqrUK/vEmPqFuk4La+DN+Vn2HdrHX/+pv8m//Kf/gn/0f/5jpiZn+MEHfwCcIcdSlqV0shS2Wtc1YtNxe+qZJ/nO49/jpttvYWLPFGfm58haKURZYsQZCwEyl0Rmt2iBDzz79DP05ub54E/+ADPTewGDr1PhJoPDNt5r6wwBMyxeNRRI53nurTz+q+VhjvNwnq+4O/+w2MF8XOmpNGNF6Eb3f70CQ1vJsdzM+CuKouxmW0+zzRVFuaCMCswA9EMt0SZPXl1XVIuLQmbJ2m1z5swp+fo3/pz/zz/8n/hXv/BzHL7hWh768A/S2jsNEy0O33CU7sxe+j4w3085apNTeynaXcqyJsbm+yR5C621WGewmcXaRlSSciuLLEvCMssoXDYs8jP0NNrUyF6anwj4GKhjWMqrbNphBCQV9hEZthMZGPPDCqSNuFzpQRr1FjnnRoq22KaXpqUsS+bm5rA248CBA8sKhwTvlwTmqJAb81MUhUleQTvy0xybEFY1oFfmT672syQcl/+Wph9las9hzskhbMbJWOcQg0mFnDxZngOWhfl5cQL7Z/byU3/9b/L+d72H3/13v8VLzzxHt2ixpzuJC4LUHiPQKVq4IqcfaoJEXLsgaxeETFgMfaYOzPA3/qP/kFdee5n/45/8n3z1zx8WZ3MCgjHGJJEcm3DnyJnZ03z7e9/l1NkzHLv1ZqKBXlXS7naG+2ElhU+bYMhdTisvmJ+d441XX+PIVddx31vfSpZlJkgaZ2tTvqxpWtAshSoLAZHRPMHR8V3rZ3Q+jTMC1hKYqwnQ0eO73vm92rwbzfFd62e71pqNbv9mv3OntltRFOVyseVWCksRUc+loigX5k7WOWGfBiqppY6BwmXJJ2YNRbdrQDj+2qvy6c99hv/pH/3PvDH3Jh/+6I9w9c3XI90CCkdlBRcCJs9pdbqpZUcdiXmqPlqWZePRS17DQYVWY1MbD2sMLhgKm9p45I2gzK1L/SwHBvBwo5dCXcNANMZIbPpTCul7Y0xhsFEEY2UYWxoNZEOjOi4JOLskOgc5jyaJDTJjUhuTZb0hI/1+zdzcHHv27OHw4cNDcZny9ZZeOwiPPTe8MXkmjUntO2QYhjgQvpEQopjhG+IyD6YxGwtbHFctc1iVdlAFtSnokz7KNcOVQpazVsvUVcXi4qI454zUqV/ooIrvYn+eg9P7+Ts/9bf5zve+x9e/8lXeKvdz9Jab6WQFC3VJoCbPc7JOwcLCAh7BGojBM713D35xkV5Vcs3RI/y1v/U3+ZWf/xV+5Vd+hW6rI7fdeCvdbtf0ylKMA5M5fNXnpZde4nuPPcrhaw8zvW8vi2U/Vfm1Fg84a5EYsdZBiDhriSFw8vXjGIH3PvgQVx08hMMRguBs1ojBxmMcU16oYIipDShpikWzItp5zXvEy3uSrvx7dSG0XpXTjRYI2glxuNr6st5nbHTbtpJzqZ5KRVGuNIE5bt1TcakoyhZWlnEW1rlPmUagJEM4YsRgTaRtjLG5wRHxvkRClDzLzPce/Z78zP/10/zTf/bTXH/XjXz0r/xl9l57FWUWqaxQSWTf1BSuNYFEA01uZU3EhgpjGBa5ASEbVIM1BmsN1oLFUjRtR3Kb4ZpCPnbEW5PapKRWIrVE6iDUwVP6QBU8EYbtRgaCc5BhGSXiGF+NU5YkG2BxA++o+KGQS44sRxUCZRUp60Buk4dMen0WFubYv38/+/fvp3BZ+nQriA8gddPrsSlOSxxWoU3bAYIwO39WYkzFe7Iso9XqmNxmqbCSs8Z73xy9gMEhI2IZsRtqtbDypsJKobzkyUobZmUpmDfGSJZlzC3MUxSFGOeMyzKm2m3z5plTMjXZpSx7HL3mCP/rP/if+ehP/DiLvR5TU1Psu/oQ1lpOL8xR2T4t18WajOQV7yB1Rd8HWq0uNhjOzi9y77seYHGxzy/+q59jamqK/8d/+V8zNdGl7vcofcXk9BR1XfLaa6/x0isvc/+HHkrFoxYW6U5NU/nURiXL0nzMjSEs9skko14sOXPiFDPdae5/5zspTMtEHBJDMx9s8lg2wjvl6lqRZfLREkl9UtcTlqPju27V1BVhyyt/rzyGKx/fGW9d3OG1yyLpDG6iA5bWpxT2Hcc+vvQbxuWGbl5gRjSITFGU3US20SR+Rdmpux461y4tbZgeH4TgrW40GgDffMgwTS8OQ0ejSWGfmcsIdY0hUuRtYvCIF7J2BqEvLnpMnhuXWRbqHh//xO/If/Ff/X1OvPomH/prP87RW29lz7WHmfMl/ejp7plmutum70MKezRu+P0mBIykqpvOJYFpYsSaZJA7ST9GBBuFtsvITI5r/stMhs0cMUZq70HAh0C/rppcy0AVKnwUfBRCXadiP42gFCupyIoAzhKCJzTtQjJj8d5TtFsIhtkz89QltNuDfpQ1xkSsixiBIBYxLYJxzNWRSiwFkHVynn/se8yeOcW77ruffTN7aRUZxEqINdYIWDEmhiax1eDrktnZWd588ySvvP4azz71NM+/9CKnzpxmbm6OGCMH9u/nyJEjctOxG7nzLXdy4403UuQ5BGFusUe3M2mwEANkeU6vX+JsPvbu5UBEWpstP9dHiiultiy26TyTRFA0fvT+BKWvJTPWdKemTQhB5qtKTC20Wi2zZ88BU/cXpFwIzOyd4J6b7+Ln/vlP83f/m/+SL3/uj3j/hz/A9IEDdLIMZ3MWZheh1SJvTTC/0GdyYoLQK6lIHuR+FF47+yZve/+D4OBnf+ZnOXBgiv/sp/5jaRUF0zMzzPcWef21V/j2tx+h0+lw0623U1aB9sQ0wWSItUQDZVmSW0u1uMhkltGxhuMn3+CZJ5/iP/sP/zbXHLiWGAyVT/M3SKqcXNUB6tAUfnLEGI0VxGCHgyuGobiMZj39ZEZl4bnnsFl+K8gJa4pFc8773fBmxbh1fFgNeJWbDdi46k0IaDyoJq5x/bAbvn6Mu9bE5vwwzW9W/JYgKby8WeMMS8+bVB0MiCtym8056+iqa+ggn3bVPnJOL1KKolxUVurEceGwozaA9rlUFOU8ae62G7PMcF1ZbyNzGQYhz13TNiAVOonGQ1WK+BLTadGfPStn5uf4t7/1m/xX/83/m6N3HuPHPvJhrrv1FuxUh0UiVWYpiklsu02No5aAbfo5DjyEQmw8j01xmNB45YwhbzxKqcVIqtyZi6UwGS5PeYc0FT6l8aaVVUUZPFUd6DdCsYpJjAwauKeKsJFgwDQep6HtPCKqBotujJHS1yzWJdbn+BAxTXitxYMJWJMjxhAMlLWhDBFXtIi+pOr3iKGiXJjn2sOHOLh3HxPtDsRU8MdlGRAkhIr53iLf//73+eY3/5zvPvo9Hn38MV544Tm890xMT9Kra9rdDhOdLv6xitOn3qTbavPuB97D+x56Px943we48eZbmGi3wApzs7Mys2evmZ2dlYmJCTNsXbLCIzkMfY3jxcOScb+iYmnzkoFocs4ZhqHJFmtck/eIVD6a3LXNVNdy6sSbcujwQT70vg/yP/y3/x3/xX/99+l223z4oz/Cvslp3jh7hmKiS9bqMr/YJy9azC/0yANIZinaHVrW4INQETly0zE+9hM/zm//zm9z20038SMf+iHOnD5JFSMnThznm9/+Fje95RbAEowQcUkoG9eERwsSIu0io2Us1fwCr730IjceOcpNx25memLKeA9WLNIkxwaiDDtupPEcdM9ZcVbZdUXlVm72ba4ViZxjYGzo7tUGjJn0R9zwdo99/wb2MXkwZckbLKO/JRVaanrkDnrljv2cEUE50OxmvfJLJizfT1EPpqIol5fYHLe2qrhUFOUc42h97LJfQ/s3xWAuhZthCT559zKXqp6m3pUOBBOdEakrXjlxgv/s7/9dPvuHf8IDH3o3N999F295690sxshs3acfamzRwrU6WJsqgLbzYphfaAd9G5vwUjtSDTYbVIC1DmdNCo/FpRBZY3GZJc9zjDGpN+VIoZSyLJO49DWlr5NHk1TZMyJYCcln2RT0MdEsK4GZ9IElRHCSRGu/8sz3e8wv9GgbsDHHRYuJsjSW1hKMo46GxbqkV5dMFhm5gWpxgXpujjaGG687wv49eyDPwNcQIv1Q8errb/C9xx/jd37vkzz6+GO89OorTM5McvV113LvQ++iOznBxPQUew8cTFVoa0+/1+PMqTd57cWX+dNHvskffP7z/NhHPsZ/8O//FR588H24KJLnOcHXFLlrBLMZW4xoNaN/o0VUZIxIMAmBphBSiII1JsYgk9PTzM0v4NqWn/yJv8SJ0yf5R//4fwfjeP9HPsxUd4KzvT4mL8hdRpAAUbDWNR5WS14UlAuLLPQWmd6/l3c99BCvP/civ/yrv8rM1DQPvuvdzJ46xbe+823m52e55rprhzcYrLVI02YmxtDk4qaCPlmRc/LMGV5/9TU++J4PcOPRGzCkdjkGt2ZhHNnh6jCDzx/k1ibRmooRnY+oW/VAriL84kg12PGCcPPVaFczfNYTzWtF0axs1bJcTJ/7PtmgqtZ4HUVRdqPAVHGpKMqqBtFaRpLQ5CQO/x0GJmPjsQNrIEiklRcAhOip61LyPDciQc72ejzy3W/xl37yLxMzy8f++l/klrvv4uobj/LC668Tc0dpBFO0yDotcJayrlPhnVZBCNWwb6WVJG6dsTgLmbFkWepVmVmXPJLB42MgGE8wholWd7j9oRGVPqa2H3XwVHVNHTy1r/HBEyT1sRQG3qaRKpHNaMUR4zzEFDLnpKkgK0Kv7HN2bo753iLZRIvYVCFFJGXT2ZxoHJ6MhRg4szhPWde0bKBdFPhTZzn9ysvcdO01vPWOu7BB8Gdnce2CM3NzfPM73+Yzn/s8f/L1r3J2dpap/Xt5+/sf5LobjnLVNVfTnerinEset0G7lSg4DJ2iRehXPPvkUzzxvcf4wz/5Y1587RX+xokT/OgP/QgH9h1i9vRZmd6zx4TKY7JUvXXgkV1puI96Ls8JmVzj4tS0pxzrkRoUQqpjRKwR5xzWQFn1mCja9Hol//F/9Hd4+eWX+a3f/yTkjg9+5CPsm57hxOwsxdQUYMiLHIujrmvK2uMyC5mjioHcG/JWwY/8+Mf4d7/8b/j13/g4111/hOMnTvK1hx/myLEbmJyZRExMnkc7kqdLREJEYiDWHpO3OP7a63RaXe6+8y4muhPG1yFVkm087yIiY4T4ugplu1phrBSZG/n8JlZhTTF3vmkPQ/G2vUL63M9f57FxvUCHrxmExq4hTtc9PqwX9itrylLNJlEUZcdswvO8vmi1WEW54onrisiEXeWdcaQcRSoYMwgFNaQfZyGEihijxBhpdQrqupbjJ0/wy7/xb/lv/5//HdfcdD3v//AHufMd9+HzjGdffw3TblESyboT5N02GEfla2IYVNX0GIlJWBqTqsBKam2RDXtXNmLT2CZktVG9IsNeHQHBiE9FeWLAe0/tU1VS7z1h4ImKg3I9QtMcYlh8ZRDOGJqRlKYPpBGDGYZLWoJEFnslC70+QSLRGoyziB1UbxWMzfE4FkPgzcVF3uzNN7lpholWzvzsWU6++CLvfej9XHPgAOSOWFW8+NwrfPIPPs0nPvV7PPvaq3T3THPn/e/g+ptv5NpjR3Gtgp6vKE0SNWLg7MIiWZGTGUusPVldMZG3OHL7bRy56Sb2HT7Mtx/+Bv/4n/4T9u7dzwff+37a7QLf74lxmRGRpalhDRKbsOCm9YsQxxrqxrh0c8LEtQXMykq3ZnlbFY+hqismOl1mZvYyN3+GrJXRX+jz9/7vf5fgI5/6wueYnprhAx/7CFVVMd/r0ZqaoI5h2PIjSCoy5YoWTiJ1VeN9xcTMNA+87yG+8/Vv8DM//3NMTE3y8vFXeff7HmJqZprFpkXNaNEdEwWJaY4VWU65MM+rL77Encdu4+Ybb8JhqX2VPKgjwnJ0PzfqsNxqrvoYT1zyDC+d9eZcQbmcgIht2m+eI6yWesyMFWlLoxbHFgoaPr9OeOxaRs5Y0boJz+W447L8c1YWPxp97zprb1OB+XxuBY6KTEVRlEtJjKq4VJQreTFANmR0ri1N0++m5TvS1EBFAqGpRBpiFKzQygvmFuf5wpe+yCc//Sn+r3/9i7zzh9/Pez/wg0zu28Oihfn+ImaqSz7RIYaILXLEOuoQCCKp1yONGMqbMNgmPNOaVBHWGUPWCEpiap3hTAp/Hb7W2iTsGu+qD4HQCMt+XVH5miokT6ZvciyH4nFQGTbEpd6WTb97AWIMqUiNQFEURGcICFVds9Dv0a88zuUYB9HK0NspJgOT0feR+Tpwcv4svbpisp3TLXJcDMydfAPpL3LPbbeyZ3oSQuDb3/0OH//Eb/GJT32ahVBxx9vfxlsfeIBrjh2lslAaCKEmOEPEJvEsgazbZa7XwwhMTXQw1rFY1bStYWbvNA/94A/Q6XT4g0/8Hv/yp/8F+6ZnePc77sdmLfrzi0JujM3MsGrsaA/LtfLgVib/r1V1dFnl0qVczBSCaqBcLJmwjiDC4kKPa2euYbFv6My0+dv/4d9msezzpw8/zPT+vbz1/vux/UV8DJRVjcta5HkLsYYgPoU3pymT2oqIcMfdd/H666/z+T/5It2pSYqJDhMz05g8I9rkxY6DIx9i8gILZGLoFAWvPP80i2fnuP2WW9k7M9P09Wz6lwrDtjTj8h3XO/+2K2p2rX5la77PLl9ANtqOZHi82WiO59oevC2I6TWF50phufI1y1I3x6yZa1dTtiBRL0KKolw2rNVebhQVl4pyxRPHGGAbu5tuh+9vAkUbMTcwHGOMkuXOZNaZhaqSJ59/ls//8ef53d/7JF/91rf42F/7v3H7vXczsXcPkjvePH2K1p4Z5udnacWIKQpqiQRfpQXLuOS1ioJxLuVvmlSExzWFfNygeI9LobCuKdWRGUvmXAqRtSmUMcaAGMFHn3Iq60Dpa/pVSa8s8Y0nzhsZhsMGs+T8DHFQJdYQByMRkwc0hICJBpel3pohRHpVzfxCj35ZMzXdiE4bm5Dc1H4kiGEhCGf7febrCpOn/puddkHv1Elmjx/n2NVXcedtt2It/MkXv8hP/8Iv8JVvfJ3Ovn188IM/zo133kExPUVPPCUGcRbJHR6h8jXiLC4vEJOq6UqI9GOkX3lC2adlHDEIXeu45c7bOXv6DJ/5xCf54y9/kdtuuZkDBw5jLdQhCNaZpVzXDCEQZanFyOhMOXeeLff2DH83z1vrRkQrxNj0xARwBoPQnuhy4s1TFM5y7TVHmT17GmuE7mSXW47cyN/5mz/F/EKP7/75tzlw4ACHjl7Hoq/ISX1FjTFEEeoYEImpL2X0tJ2lOzXB4ptnue2O23nj5Aleee1lbrntNiamuvjowRWEVP42ebajgShkYsiNJVY1Lz/3Atcevoq33HobjqypetX0I7VmTVG1VfG47s2hxuVulxkMI9/f5LgOPJOrfk5Tc2mQFDuIFl0qzNMUb1qxO6mysowRiXH5+2VtD+ZGPJTblXM57nNW++ytV0GPq54/iqIoO8lmbxaO/lvFpaKoqDwvY9YSl7cqafLrkq2devdluTNlXcmJM2/yncce5bc++dv8/mc+zczePfyN//inOHjjjdTA6bJPXQl2coLjs6fZc+gAVQxgDT6kqou5yzDREMsaYwx5lgOpl6RtqrwaI2Qm9Y10xtLK8tRJUmJ6TfNjBg0gG1HoQ8DHQB09fV/Tryp6dUmQVLgnNq1VxNB4KIVoBE9ofFbp8yKpSImPAQlCDJ5MCogGL5F+WbNYVtR1ncJITeP5lIghVdQNGPo+sFBXRIRWq4WLNW1rmX/zNL3Zs9x99Bg3HLme7zz2OL/xyd/lS1/9M646dpQH3vtern/LbYQ8x2eOfu0xRQF5TkCIFrKiNTSURYRuN6eua0Jd0e50mJmZgbJmbnYW2+7S7rS58ZabOXDVYb716Hc5Mz/L9MQ0xcQE9UK1LEwVSXmWG+l/Oe7O5yAsUxjfE3NQidc513jEAz5CpztJhjA3t0DuCnJnKOd7FBNt7rjldv7WX/0b/Mwv/zxf/7Ov8gOTH2Lq4D4klpRRCFVNTSTaiMsyxIRGdFrmypI6eg5cew3X3XCUN868STHRweQZpsiIdmkcTYwYsc0ND8jF4Bd6zL55mofueyc3Hb0Blwa+Gf/VL+TjPJnnaxxspxGxjpA1m922ldVUl7Z3Y5ETmynosxlDaVPVZtd4z/o5l4qiKJe/wFy55mXr5btsNSxnuwoOXM4HRvf/yt3/Sx0zIg9H78KPNhgxTbBr3VR9LZriPAbThHUJEgLGZUhdU9WlFBNdU/YWpaz7vPT6q/zupz/Fr/zGr/PG2ZO8/V338/Z3voP2nj2ELKeMgV7wVN4jFib27KUMkTpGQkjZXw4DsSaTpp2ISZVgnbUYI1gDDrCNxzJ32bD1iDWGbFA9djDfYlMR1tAU7mn6WPpAGWrqKARjqUIkpno3jcdSkLiUW2mynNLXqXrpoLCNSCrkE8G5jKoOWJNRljWnTp2iqiq63S5ZlmEyh9gmRNfmBDHM90vm+ov0yzKJaAMTRUY1e5awuMiZE6d4x0d/nO898QS//olP8bk/+TL3PPAO7n/f++jM7CWbnqbvPQt1BUULb9PxE2tSASZnh2Glvl/SbrcxHUPV6+HrkqqqyIyh6LSpQ6BTdGhNTHDzW97CM889y+tvvMGxI0dTtVNjhr5hiU048GiPwib3lDFicWUFzlGBMug+sjJcdlR8xRAwWYYzASRQ+6aQjgGiwbkc6khmHO9/8CHm+vP8H//8n/DYt77Dgz/wXtpYfExhycF7WhMtTJ7RLz0WqCSQuxyynBgjew4dIFrD5Mye5HGOkSpEenXN9HQKd636Jc5YqGp87Tn+wov4xT533XE3E51JU1DgK6Esa2m1O6bydeO3s027i+SdXZIe64Wlr7++LgsrXjGmy8I6R8cZhlV0ScMpxphzPJiyfK0f/nOYsxnlnNcveTPPDYte2tZs2Q2w4UeLWfG6zd9RP99r0dg+nG5zQv5cUWo2dOPPrJpz6tYV2uP2Y/k5unPXfb2+Xxj7SsdZ2RH7cIM3zFZUdU/iUodPUa5U7LDC6zmGf5MLFZuejtbaxlM4MHwsIda4xiI2GOregmRZRjHRNQAvvvYKX3vk63zi9z/Jlx/+KjNXHeSDP/YxrrvxBrKpSaTbpooWiSn3SAKQWYJtwuVSLB2ukbdWksi0ycjFGkmCMpnm2MZbmQr52KGYtNam4kKjLRCQYShkGZriPY33MtCEwZq0PREhWPCYYYhsDMnOjQjegG9ql0SS6Klrj4RAJyvIsoyIUNYV/boaGu3OuaHAMi7DGkslgg+h2Z6adlGwcPoEN1x9NVNRePKllzh2w/X0Q81vfer3efrVV7n7gft54P3vZ8+hQ5zt9+jVFX0D5C2CBbEuVSVtGrJb43AuJ7MZWWYwHmKssVisyQihJopPbVwyR3QG28rJ2gULi4ucnZul8jWtojBigozLPxuKjBDWNIq2Gg6a8lQtxkqq3CqRIIbcWqx1xBgIRFq0eOiBB3n11Vf51d/4NbpFwbs+8H76c4v44Om0ckSg1+tRFAVVtYgI5ASsy4gmUItgi4K808bkBZUEvBhckc4L7z1FliFlhRNwEnn5+Re45YYbufXGm8hxlFWJlZw8K0xVeVkZ7bgZMTRUgedx53kj3zP+PSPnkDm/Yq7b4SXd6Tv0GzXaN3vz9Hz3/XxFxGrv20zRKEVRlM2i4lJRrmAGBmPTiGCY22ZMEpvOOpxNy0SINWVZinWGIm8ZZy2+7ElWZMbXteSdAozhhddelK/++Tf42iPf4JN/+Af0Qs31d7yFt777fo7cdIwqBnp1hZGI2IxgwFBgbRKWiEFixEkSjqYRlbmxOAO5SQuXNZDZFB458MQNRKVrfkZz/kRMU2wnJtFMSIV7Ymo5UgVPiAy9ltE6akkhsbVEaoEaoQqBGAVPypkbCFITU2GWqq7wZQk+4LoZbWupY2C+t0hZlkAK68zzfBim65xDjCPWnjKmKrUxRjJfcmhqhm4QFo6fYPHMLPsmJvjyw1/jzVNnOHzjrdz9zndz+Oj1zPb7VNIiFjneGoJz9GNMYZ4+YkzKgywAcRmZNRQ2R+qKOCyUJFTiCV5SniiSPLMxYvMs5aPWFSEuzZ9UbbepujqooyspL3aQezlq4A7mGDRpk8vno2xUNKWbIDHd4LAWMHgBJBLIcFgwliIrEIQDk/v52A//CN/+9iO8+PSzHDh8mMM33kT0Nd4HgiWFMecdFmKgMI46RIrMEj2UIdLqtOlMTpC3CiofiCYjK3JEBF/VdDpdfChxGBZm55h98wwfec97OXrNdenmg0+xoLYRoWZbzt/lQmajlVNhqVXMOSJoFe0aRoJ5B4dO1jhcg9dbWR41u7Qt4/MXl/62y3pJXnICdZ1KrxLPPSbLD8P4Vj3GuKXbYGNuxCzPZ15fMI8roKXeLkVRLpq41LtbirKbxaVZxcBJjw+anBtjcNbS7XSGFkkdK1zLGTDEHE7Mnuap55/lU5/5NJ/+whd49uUXOXjkGt55373cetcduE6HWV9jiwJT5PQrT7QeManqJy55GGOMQ7GSkYq3ZBgcSTw6A5k1WCy5dbgRgTaoAjvIqxysX77pnGii4CWF24YYKX1FGVMfy9p7Aik3so5CnYxjKgwe6BOpYvJu+hgaT2bK1wyS8kxDCPi6RGqPC8KEpNDbsqpYWFigqipardYwdNdkaVulac3hm3zNaCJ5BpmPXHfwAPH1E5x88SVCr+SN+R4nY827H3yIY3ffx/TBQxyfm2U+eGynQ+UM3jkWmv2pfU0IMvSYtvKCdozUtqIbhJYx2CyV/RQDxmbYLIW49ssawdPzFbX35K2CbneSoijwPrWEkaaYzWgeZyp4tHphk6VqoeO9X+u15UhtLpJnGwOmqe6aZRlGBMHgg9But4gSiHVNsJGD+w/xn/7Uf8K//Ff/nK9/+Sv80KGrmZia5NT8LCI5RZ5BbG6sZA5feXKXU0uk8oHWxCTdiUlMnhO8T/0to2AsqTJxiGTOYcqKl597gcP79/GWW24lc86IRIqiMHWVWpUYmzWNfOL5e3A3KsLX+Pwxocmrvm/lc7KptWat75ANH/vtFJgXSmBttM3JWjcGtuK9HOe5VBRFuWjiUlGU3Y5dYXDEoeVqjaXyTe5f0/C98pU03kITCDIfFnn0icf5/U//AZ/70pd4+sXnaU9Pc+d73smtd93FzMH9mMluKo5CpG0tNs8AS1XWGJO8g01OFyYK1g4z+RqRSeO1NDhLajViLTmpwqpzFmsNpqkmK2OqRaY8yNRyxHufRGST21mG9HfEjHgpIx5DjSSPJVABJYIXwQNVDNQhefpCrIk+IL4mF0PLOoJJ39tfXGRxcRETA63MUTg79LpCCh/1pPxPHyPWQYeMmXYbM79Ieeo05emzLJ5dYGLvNPe94wHecv87kdYksz4w6wO226VvDWf7Jbbb4XRVk3VaLFaefllS1zWZsbSKgqKf0cUyI3BwZoZOq03pa6oQMJmF6Ai1J0ggdwUxwvz8Ip32BN1Wl8zmJoSItdYsDyW0LDVkGZPTJakX5pJAtKsImdEqsiMeTzPioYsCrhFqMd1MyIocYsp5Dd7TcS168xU2J4VL24x777iLd7/jfn79t3+T733zm9z30HtoZ46er3F5O4W3Fi2MdUSTClOFGAkxMjk1Q97ppvYjjViv65rcFRgcoarp2oz5udO88sKLvOueezl65HqIIhICLm8Z74UQDWJpxkJ29Kbuap+VxnGpsNDKPo3GpGO1utdtuHSs6ukcfHdoXuKa4OmVhXtYluU9TpDZFWvT9ozRToustVqfNCts83jcUBsaIWCMbWLQnV66FEVRcakoyiWG2JFwqYHh40jelJR7WWQFEOmVPTHG0C5SQZ8zvbPyrce/yx9+8Qt89o/+iGdffIHJPXu56a13cei667jmhutpTU0hrRZ1ZnH5BMRIGQUpKyI2tfBoqkZam4r0iEjKpzQWZ1L7gkEF2MymENisqQ47DINtwmKR1LfSSMp/FEm5lQPvWgip1chQXMbQeC59Cm8VQ03yXJZANIbKNMIyBvrRU8UkLmsRyhiofUjVVkNownmFzOW4IkcM9OuKuYV5+v0+3VZBp9MZhsQaa5Bo8OLx0PTTDDiXxPy0y6jfeJMzr77GwsnTzExNc/tdd3PvA+8kFG36QaiJSKtAWgWLZUnfGbLMMR9qpIwsVH3mF+YpyxSu2coLiixn0jg6k6lfo2ulYxxDGl+DQbxHjMFmjn5VcebMGQ7sO0ie58QQJHeZicamnMcRz4u11sgYyz8VQ1ruvVrPY7da78FlAlOaJjEma7zAKVDTR6FfAS4Z8M5ZnHGEUPLhH/gQX/vzr/Pdb3yDIzfewOFj11MuzFFXJda2abfb1P0y9dJs2s7YvGB67z5cXlDHJKSH2xcitmmRIyZy/LXX8VXJ0SPXc/jgQaxxJgaBQbuZmG4orNQP2x0ptFrPxnHftdKzmKq5bswDvYntGbYsGbdN47Z1IzmjWxGXa7Ul2S7xutH2JOd6bVe8b3R7TRiK080KaC0EoyiKiktFUXYEa5eqLkqjylIIVlMcJQSKIidE34RU5nip+MY3vsEf/emf8Fuf/X1eOvka3alpbr3vbg5eey0zhw7Qmppi6vABKAp8FBZ98vAZZ3EuVd+s6zqJgcZ6Ty1FBCLD/pQZBmOS19LZJLicc01PyxQaOyjig0nbn/LIUpin935YBbOOyWNZ+Zq6rqkl4qNQNT0pPZLakoiksFgJeGuojKGU9Lpe8JQhha7WxFSAp8m5DEQwyZtlWzlF0SLGSL/fZ25ujrquac9MMznRocgduTMYVxAkBUdKExrsosNJoAX4fo/eyZO88cKLTGC46957ecudd1K7nH6I4AqizYgBFquKPkJ0Gaf7i8xVFQu9VESo3+9TliUWQ0eE6TynnTuKqQlMkSGZxQQHwVHHiJGUgygGFhYWOHHiFLOz8zzwrvvYt2dvKgdqkzcwjITDxhRSKgOjNTZ5qKO94gehy8YYZEXBn80a9Ubi0P5u+qo2LWMMNstY7PfYM9NhYaFPXQVckW5KHLv+Bt77rvfw/Wef5tFvf4urj15L2znq6DGN9zx5Sl1qK2Og3enQaar8DlrJhBBotVr4ypMFIXMZda/Pi88/zzVXXcUtt9xCbjLEewFnYoxgHT4iqcCS3xbxst4YribOm5TAYV/KAYNczIHn2cjGRMk5fsjVQ2Fl5HGztE1mNMdQBjp0XLGd7WzVsloz8O36/NVCjZc8+0s5lstfI2sK1vU2b1we7naOn6IoiopLRbkMGRTMWPl7LeNurKExTlyaUUOkaSUR46AsC9YZqrovWV4YbOTh7z3CJ373t/n8H/0Rz77yEnuuv5qpq67i+htvojszRXfvXg4dvQGKjHlfERYXIcvJsgKXQ10H+v0embHkeT70KA5zipp2HwhYG7HWJaFpBGfMisqwBiMjPRZH7uoHktCpvScaCI1Qruo6tRyp6yQKjU3iUiIBk3pXGkNlI6VAFSO1EUoR+tHTD4F+qCmDJ0QhOkcUiKSiMk4EawwtZ2lnOdLrE6uKqtfHBE+rKGi1OjiXgc1wNgcRBMFZyIkUEVwwdMRAr+SFZ57m7JtvctOdd3PklluYOnyIN+s+E/v3ceZsiW1bKpM8lb3Mcqbf48TZs/RjZKHs442k8F7rsEYoMksx0WKmM0W73QWxVHUjlhFKXxJ9TRYEGwPzZ85w4vXj9Bd73HTsGIcPHMQYQ1XXQuHM4BjGGGW0P6MxhhCSeDIxFftxGMS6obj0g64UA4/1YF6uFCkD01uG3SiGXrWBKIkixOgRa8lMhnWOhaaAUowRZxyLCwtMTk4gEviB9/4AX/izP+G7TzzBg2ffR2e6S+Uj0QhVVTafm+amcZa83aYocsRl1MGDtYQQmSpaLPYWEO9pt9rM93qceu04b33Pg9x0w00IltNz80xOzJBnDkIqjlUUOd6fv7DeDqGz0nO3mjdz1X6UZrPfP1YMy8oemXKBij3stLgcJ+g3uk2Dmb9MIK4UiRsUlxu5AaEoirKj4nKjIShrvW6n+yhdMMN+m8NjrrT9v5z2+3z2da3iF405vKH3n1OwYVnbjGRsj/5e6gJgV4hLs8wYH9Q9GWQtmcFjww2ISPSEEMiynKo3L+3uhEEsZVVJnmWmF4VvP/pt+e3f/x1+77Of5oVXXmZiZpr9b7mFg0ePErIMMzXJ1NVXcejaq8kmuvTKPot1IGsViDH4UCdlAOTWQIzUZR9Lyp901mKITdigJbdNyKtJeZd20FrENkV8XPJWmiZnb+CdDAjBSPIGGiHY5GWsfBKXdfSphQQRb4TFqk8wKZTWA5VESoSKSAUEB6UIi8HT9zVlSCLMG8GbiDRhpBCJtSfHMNEqaEVBFhawVcWZ4yepzs6yZ88epicmMTiiGKwrCNGl7YlCHSq8VLRFoPaYXo+XnnyKE8ff4NobrufGt91D9+qrOCMBOzlFzwu4goUqcNoFztrI2VByxi8yF2oWFvtNXqjgiWS5o53n1ETKsk8xMU3XtphsTdKTil7dR/KcIJ6yKmkhZEEoexVvvnGCmYlJbr/tDop2F5PniASqOoixBmOsERObsNeIMykHNjaeOWNSH0eLSzcQgqeMgZi5xnsd8VVNJoZWnvIm67IahmA3ZW9SFq4B0/Q3NTYbik07WrkzBmIMTHY7hABT3Q61L7Emo6pqiqLg6JFj3H/v23j8icd56juPcu+DD3BqoU+eFxTOstgrabdaTd9SuProkVQNOHhqmzzqnYlJzs7O46qKCZcjC4vMHX8D0y+549Y72DNzgDfnF7FFlwor8/OLKX+5yKiq3oZaXYzrITYgNIWU7LLKyIwUVhovlJZ7Jg2D0jznFPdpRH9czYMWNn6TK1UTXu5NGxSCMiAsWwPT/gQJwmAMBsWHRjcuRoOJq45PjFFMYrzNMubOmzGjfTXXuyZs5vp27muDrHZ9SI8751Yf02b81ruurPV8jH7F425T1++t9jm/1O2q9Yos7TTr7d+lbl9dSfbjejfyzmd8LufIgmynJpGGWyjKhk+ec4Vq0zsyrpCoAVlmaDjMOTJ29EwceCZHJagZeBAM1FWfvEg9D0Fod1oGE+mXPYkGvvvoY/Kpz/0hv/PpT/Hsqy9gJ7pcdduNHL72OvZefRWSd+jMzDCzZw95u0XPC3Oz85jM0JmepizLYe4WIsOcSmMiVgSLw0rqXTlwydrRNcUIxqScytxlFC4jc64p4GMHYZhJADRhkbXEJtRU6IfURsOHOOxlWQdPiCEV7TGGaC0BoR7mVsYUBkukHxuPpU+9J1Pt1CRgsQ4jdpjraYwla0J5c4EMYf7MGerFBZyFInepuqoB6zIES2jCeYsMfK+inJ2n5cDWJadfO87Lzz7P4YOHuOuuuzlw5Doo2lShJkik7PURKZgncMaXnKwXOF33me/3qKokoEM0BEnC2RiLyzNa1tAtWrRcBiGJ4tgMeh0D/aqk1+/hfSCbKzn1+hucOn6Cd9/1Vm6+8SbaRTt5GTOH9WnmBR8kRk9mSX09Q01vsaTdbpFlGZlNvT5DlQxqYxzOplYpkYgx0GoVuHTIcVlGKy+o63rgFU2VWa0ZhnLHGDGuud3SCMuhp7OJ4zQSU0sUYtMWwiLREEPKwbz/He/g05/9NE9//wluvPMt7Nszw3yoqX2g020hIX20cTYJ3Nj0PzUGnKVX9rEidNptMh+QfsnrL77I1YcOc+zI9cQoRDKMdam9jQHbeFjTrMvWva6uWTHVLInFwY3ctcIe1wvTXM3A2Ynr+7ib0Wv121zZSmPpVtua227OZ5uHr5WtGc8bKdKzuc+Xc64dW82pVFtNUZRLTlxu1KupKMra5885OUVDP+TIebXivfGc0ywue03woWkBmCWpKo1BZhyYSF4UVKFKrRec4+z8vLQ6bZ547lm+8KUv8qv/7uO8uTCL5I4b7r6T6QMHMC1Hd3qGqYMHmNlzAFu0sHlGkIj3NT6k2pCDgjqQqmKmcNfYeFGTdzYzS/mTgzBE24jmVMDHpRBaZylcRp5lwyqrSXyH4ViEGAgheZaCRKKknpR1TOGwPqa/fQjEGPHG4DEp19JALUIlQhmSuCwl0AuBMqTek1UMKb/QgLEpFNPYlNvpjME4S2EteWbT/vvA7OwsdVnS6bTpTk6ATUWMsiLHS0RIgtdlBvE1oa7wPlKdneXl51+gXbS48867ufPOuylaLRbKipBZxDlqoIww5yNnqx5nFxeYLxeoao8EyIwjeJ+8vkbIEArj6GQZXVdQ2ILaB/q2osqWqvW6CFkE5wVT15x54w1iVfLgA/dzYN8eYqyoKk+7aGNCEn9FltHqtoneU5YleeHodqYJweNcqiDrANdyxAgheKwYOql7R3P8ofY1/bomb3eY7LbpC4QghMbdnrlUSTjG5LXLRipmNh6w5maGHd6MMRJxg5syJs3Lgcfoztvv4JZbbuH3/uhzvPrSy9x84F78wiJlXdOe6FKFkISkNanFyUhEjnWOGEhjay25harf56WXXuKtd9zD9ddfjx+Je03h302f1cYTt57ja13P0OiZH+M5onTU87WRz1/rer5dRWDG5U/+/9n772hLr/O8E/ztvb90wg11KwfkDALMIJhAipQoUZJlW5ZlU7QkKlm2Zbfb7pnu1aune01oj9dY0z1ey9mW1mjctmxZlqwsS6YokiZFEiRAAETOqVCoXHXDOecLe+93/tj7O+fcWzdVARDT2ViFe++JX/7eZz/P+zxbqqDULgCv6HXzdOuY3vFPtW5j/ekZ2qgd/r5cZmdr19wrWZdZRMlszMZsfEODy+2kO7MxG7OxfaF1SR8Ust4Vs+01m3LbZN3kuoyBWft6lMckJhYiLjasuRg4H4reka0wSYbDsjIayOPPPsV/+fSn+I3f+W1eeOVlDhw7QvfwPub37qW7Z56s36W3Z4F9Bw+wuGcvZW2pqoZqsBaIxyyJQNMyGo3I8zyCSgnOnshY8qsJBj2aCbjUEvspoxtsqg2JCdEdLbA0qHGEgzY6RIyIBNmr9VhnA4hUwcSnjuCwiQ6xToLA0oqnUYYaj4gOwFIclbjAVCpP7Ry1uHFfplcapSdsZVDzeUQcRZLSSVNSBa4M/aZVVZFozdz8PHPziyRZijYGUoMTi/VQ1zVu1KC9D5EYy2ucf/UU5dqQt916BzddfwN5UXBxbUCFQ2cdnILKaJbFc8HVXByNGNQl4nyAW9EZ19celaUYHXpVjUBGQqoMKQa0ovIW6xRehaiWBMiVIhXhleMnOHfiBHfechsf+sAHWVpYIMGgM4VSnm43B6BpSmzjMAipEWw9pC7XSNOU0aDGhRgOunkXncZtgEZqG2TeCnSeIEVGbRtK27BSjvB4vFb4pJVVCl78uNe2ddRU2wAj730Qfo7ZsSjHdIo87/COt72d//zpP+bll17i6M03BiMpY2iaBonHoyjwLhj7oBUqCcZSiTFoa7FVjclTzq+uMlxd45pjV9Hr9ajrGiFBvELa/s24DEbrHXi39W0l2zm/bvX8G+mE+nqAyi17PHcpJ9uiX3PdZ7xRTrNXUuvs5Ni7EXRu/7y+ZLLxSmuvr1fNNqsVZ2M2ZuByNmZjNl730XZCbphBbgEZE3AZK4j1hbOaCGV1ZGNat8uQLB8tgEQQ78aYVHA0zkmthEG5zJNPPsmv/eZv8Gu/9Rv0FxfYf+wIVy316e1ZoL+0SH/vXvK5Ht2FOfoL84hWnFpeJlFJKGq0xiN4FwvyxFAUxdisB3HjNTSo0JMXDXoSFfvnFGMDn1SZwFwqTaIMqdZkyqCVDkCbyIx6hYjCCtjIWjbO0ghYQhZlI+GfVYpaQryI99BoGPmQYenw1N5Te0flHHWMGqm9x4nEnr/YuSrhX5A4BsCvBbLM0M1SUusohyWji8uI8+SdLv3+PHm3g5gEnRiUUcEQyDlEhf7TBEE1jgunzjC8uMI1h45w7bGrKLIOg7KiQVCdLrWGi6MhI6U55xznRgNWhqtYW1MkCVoJVWMphwMcmjTtoUxBgkJ7SFDkpIERznO8uNCX2tTUdYlUNapsqFcGjM5fgKbh/XfdxaG9e2nKIUnRw2hF4xrOXzjFXK9H0zScPHmSsxfOUVUVFy6c4/Tp01gbXIZ7vTn27d/Pwf0HWVzaw8LcPL2iR1HMYfD4umZYDSBJMFlKkmhGdYMVj9ZhmwE4F9xhNQptQq9m2yO3lTzQex9ksmqqh9BL3JvCm990J4cPHOTV46+wcnGZ/oG9KAWldyidTPrTkNArq5KQp4pBiSPRGu89qUk4ffIUeZ5z5MgREpMxGo3QaWQr/fqzXEUpuKhtq+8JyNjkdyWTz9kEm6yfjNoMrOjLN5l5LSDmcsHj9L7dHGjp4IfFeglse6kM77tko44/y4ceAXQUiWzVk6l2sV0uB0TtbIikd3Hf2B7Az8ZszMZsfNOCy61u6N8uF7jX2rA7G9/eY72t/KVSMTVNVArr3QKRINVTPoCc6LKqIpgM0swKbaKsLxHAIDhKV8vyaMCas/zqb/4m//aXf5mV0YCDN1xDd3GeUjz7j1xDMT9PZ2GO+aU95L0+omDoHOI0Jsuw1oV+yZCMODb+mDYUUREMKDUBlhOmMiy3TqILrIqA0gQ5bAi+D+DSRJYTBfgAMsbMYtOMgWUVwaVToT+yFjc26LGAk9AzWQsMxVMrwVmhliaY30SQ2TKfDR7rfZDDxqrVERGuEpQS0sRQpBm50cioohoNWFtZJTWGotcl6xSQGFRkLVu2zqsg8zQKmuGItbNnWT59loWi4E233M7i/CKiFI11qDRDsoy1qmSlqSmzlNOjASv1kLqxZApSUSgrlFVJPRygsgIRh47HV2oMeVKQJznGBHMf5x3WNzRVjatqUi/QeIYXLrJy+gyH9+7nHW99K508I7CEghPLydMnKIcjvnzfl7n//vv52te+xgsvPc/y8jLaQFrkZFlGXddYJ2RZxtLSPq6//nre/OY3c/N1N3DDoas4tP8A80v7KCRjUJdUozr0s2qDRFdWrQ14hcMjThDdssYSAObGKn0KFbQupUpJNFOyeK9ClqpJOHTgIIcPHeIrj36N1fMXWTy0H6+Dg64QpbQbDLe01hgUo1FJmuUUeYqrG1555WUWFhY4cuRYdEMeopSJUmwhNQmYEL8jRiP+8kDdbu+/271n3WOy+896PUDVbt/fXh9khw20gbm7hMVsDX2mP3dzhvfy7uuXsx6XA6ov9/OF15YBOm4tnQLzf5r10bd7fTirf2bbZwYud3nxvNwZytmYjW/zq+vYqTGAxQ1A8pIWnamMNCWICgBTyQT4jItG5QOwTMJnl66SQV1z9sJZnn/pRV48dYJf/73/zMunTtHkmquvu5lSPNnSIgcPHqS/tEhSdLAIkhp8Elgc5VxQ2AI6TUKvoHOIjs6pWuGto64r0tSgBbRS6xhLFf/WTCJGWglscIM1QQKrQuSIMQYlAb567xHnaMRTOUcpQt1Y6sZSutgbicJpqMQFRjL2U9rIRloJsRulN5Tisc5Ri8W68JyLmZe1OJwIEo13VDRyAdB4lEBqIDcJeWJQ1tOUFbascHXD/OI88/PzpJ0CjwSZstYhO1ErcJaqHIBrGK2ucObESVJRXHPkGPv37iVNUxwaqzUVmrJpWG0a1rxnVNcslyNq50iThNRZpKqwoxFuNALrSHtp2CdKoRWkJiHPc5Ikw3oYVmVYU++wtkaamkRBPRxy4dQZTh8/wQc++n3cdstNdIqcsip59sVneezJJ3jx5Zf4/d//fV588XlWhwOuvvpqbn/HW+nPz4Us0iwFpajrkLM5GAw4d+4CX33iUT734H1koviu99zD7TfezNvf/g6uvf56enPzKCvUtsbWQpIkaOfQElnjFpVHdt63QfPKRSSp1/cHxikPCJmuQd4aJzTia/r9PtdefQ2f/uKfcPHCOa7214fzRnmUDueYlXBciAqMqVIGEY9GIY2l2+ly8dVTnD19hrfcchuHDx4Kpkc6CbJaG2TZSZKsm3zZqelyR0ApVwb4tgKdlwMwX68MyNfyGr+RwRNknStuUICMH5v+v+Aj861wcUuO1RUbmMydGMwr3wgbll9tBNOX9lhutY2uZH9s3OczY8bZmI3Z+IYAlzvNCM4uTrMxGzucO0x6LJFLo0g2gtFpkBlAZcvmRbmcuKDeBKyy0ljPymiVV8+d4fmXX+LBxx/hi/d+kQcef4x9R6+ie3AvnV6X3sI83cSwdHA/Wa9P0slxSgdDFtE0TRPkgEqhvWCdI0lDPxomgEaJWSdKBbCovIyBZAssDcGMJxiuarTS64BlkiSkJvRXJroFcmrcV2mtpWkaGoFKQe3suK+ycja4pCqNBSpngwOsCCUugsrA1lVeGCmJwDMU/y4CS1GBo7NBgxn2UgSWerxMoLwl04ZOmpDpCLzrBteEntZOr0t/fo40z7AIiQnbyzmHFmhsxWB1mcRBNRoxWF7hyNJ+jhw6jHdQ4/CJojGaSoSBc5R4VuuaM4M1ht6RakOqNMYJbm1ENVijKUtEPHmRodIUr8NxlSRJYNRU6LXUWIwWtDh8Y3FVTe09gwvLnDlxgquPHOaee+6hKAqeeOYpnnnmGf7r5z/Hn3zxXi6urXD1tdfyju/4AIcOHSLvFORFQW9+jiRLKesaZTSj0Sj0Hiq4uqw5e+4cZ8+epRwM+f0/+Qyf/PynOfIHR3nf+97Hh+/5MDfffDO9okeSCM6CwqOsnbCZEuIofMxjVUyDyfV5ikqp4BKrpgv11lXVY62jk3e44drr0F6ohqPgwKzNeILHRUbe44MUtjWgEugWBW44INGKC+fPU5clexb3srCwQF3XwfhHJRBzY6dBj/celN71/XVzcLm+N28jONiqZ3Ms9d1BZbTdPf1KFUobl2PCUsqmdcT0c5cuy/aAaeN3rds+8Zho2dGNy/BGOK1+I6q61m+j2f14NmZjNt4gcLnbGdDtXrdzw/rrOwv6elxY3xDg8G2eQ/SNPsnweps7bCzyvHfjfMb28WkTn1CyAuJj0HvMbhTB1TUmy0IBqRXiPU3TYJIEY0w0m4xUTMhWiFpLaMSLN8LycMCzLzzP/Y89xP0PP8TXnniMV86dpj83x01vews+K5jbs4e9+/fRme9DkgYH2iRFpWmYSJdgQKIxaK/GMlejTXDd1MGIR0QQ5yOYFHRqEB8ku4GRlZBZqUMGohYwClKjSI2O2ZXR4EfW7x8XwbeL/ZO1F2pvGUVGsraOKkaINNENtAGG3lEjNOJpCGxl7QNTWQEj50IciResUvgYEBGcbsN+QWnQAXBqcYgL+1QBqYLFbpfECW5UomrHysULjAZD9u/fz/zcIjrJEAVJmqKThNo2jEYjkkRjyxGpgmo44NXjL9PrdLnxxhvpdvskeYaNcSllBJbLdcWFuuTiaMCorkAUSapRZYWMShhVXDx9FiuOPVcdC+DIOZQOwN17j7WWWjdQ1xR5gq1rCqMRb1HO4UYjzp58lTMnT/Hhd70bgC98+V7++FOf4sGHHmJYjjh27XW899abWTp0AJ1lJGkKRtPgudg0NKMa6z04g8ozXGKomwbpavr9q+hedRRXlRy8/mpkWPLEI4/y8//iH/Opz32eD9/zQT764e/mzbe9icwYsixj5eIqygj9uQ7DqqbxjjzPqSqHxL5epSZGO96HiQitDUppRITG2vAaHc+9KEmumpprr72eLCu4cOYsvmqQVGOUIBqaKkSTeCBLYw+mCx24vq7p5x3wnpOvHCdNU264/nryPKccNWidBmAtQpJkeO9DNEuagrgdvUK3y4keR/ywtXnNTtdqfQVtHVtlZ17O9XWzzM1N7xtabXov2am+2M4Fd3pbbbX8PvQWjBnM6UmB6WF2yPHezg188zfEr1N+w3banMGczh9Vm0xCyA73KyWbx8xsnZP6+kbQfCPVBbuVnW85WbHJey73M7+d66dvKcJgl/jnGx0fXE5k1cb3zAx9ZmM23oALbXuCbRYFMG0QYq1FJ0lg9cx69z+TZUFO5x1ZlqG0JstzohCQxtVokVjYK5yzgMJq4ZXTr/Li8Ze57+GHePjJx3noycdYrtYo5uY5essNFP05TJ6xtP8Qea9HZ75PmmU4YkSCSVBGIy6aAEkEgxEoqpYkVaGHcV3vlg9SQkSCWU8sYpMYiaGjUY+Octfpf0lkhtpQeM/ElMV7H4xnXEPjLSPvKX1gIi3xpxJq8dQ+GPJUkalshAAsxUWm0lN5oRJwKhS4Lahs3We32m/jfSvQSQzGe/omw0nNhVOnWLu4TCfNyPM8fKYGEjOW03rvcY1FGk8zKnF1w7lTp9ECRw4fZn5+nqxTUDqPmIQKWPOWi82IC03Fcj2itg6lFLnSZNbRFUNTW1aXVymynP6+PXSW9rDsXChAnUNcAPpeLI0Ltk5+VJIbjbVhv2U6YW04ZLC6xsLcPJ1el9//L3/IU48/wdraGtfecD1XXXsdB44eZn5piZWmpFGaykeWuGmC+2zo/MXaGu8CU+t8O/EAOtGIzkkP7yfxjrcd2sdVt9/C8Sef5xf//S/z8MOP8vEf+hj33P1eekWHLMtI05S6HOK90Ot2cBL6OK21WGuDA2zMe2yPofVFciwGfVAGiFI0tQMDeZqRmST0nVqL9gEIeufwBGl0+7nhfAimW0YbEg1NVTIaDsmSlP3795MkCUrZEHSP4MIM0mQZ2gKeyy8+Lqegu5wok2/Egn6653LTgu01rIDsnjh+3SdfN8ptX8/tuZvCdszObvK+2ZiN2ZiN1zpm4HI2ZuMNnLnbKkfM+5DDmCYGh58YhrgAolJtUEmCSjUZGiTMUY/KUqx4siJXSZLiXT1mP1+9cFaef/klnn3xBR58/BEef/Zpnjv+ErqT012c5+p9x+jML5D1ctJOlzTP6C8uQRL68nybFelDD562wVVTK4X2LjKQwchERVCGjy6vMikGW3sf5ScspUHWAcvW1Kdldcf/oiI4bI8ARrx4rDhslL/WTUNl3TiHslGCE0VDYDQrESofTHwqL1TKUws0eBrvKV1whG28w6LxSof8QWEcF0Hby6f1uF9RIYFVJczfGw05itQ6sgzWRiPOnz5FPSxZOrhA1ilIimwMLAVomgZbN2Ad3luasmLt4gXOnDzFsYOHueGGG+j1+3hjaLxgjTBEGFjLqrOsVhWDuqbxITcyE8isI3fCcHXIyvkLLOxdYn5pL02SoE2Cdh4thtwkZEajxeOliU1mAYCNhiPsYEBaWU6eeJWzZ86w2O1y34MPkJqEtMh5y5vv4LY3vYlOv0+D50Jd0ZgkgHfnKJ2lFEcdI1tEGUpixqi1Y1ClbNjviVFkmcGPaooi4+q3vJk9Bw7TXVjisWde4O/9w/83P/UjP8ZHv/Mj3HDtdbi6wYpFa4P3FmctWdEFPM5NZNNhUiew+861gC6AFN/uRxXAdeMsRZoxNzfHXK9PXVY0VU0hXZQwBq1Mx+VE11cjoJ2gtGJteYULZ89SpBlXHTkKBECdZh1wdtKTLLHv04d+P5TeJKt2MvRmQGHq9TthI/k6X/+2ug7uBConAGn7ybvXCsB8a/a0xWudUuvcZDcyd+LVFV3/J02cW/RSymQiav120Tuu13YA85LHvw54cmvn39mYjdmYgcvZmI3Z2HUxMx2+vr5YUjS2RnlIswSjU8b5BGrqeRXcUrOiUBkhFqPGoo3mmVdfkkeeeJxHH3+Mh598nOePv8RqNYI8ZeHYIbqLiyzs30t3fo6s10FnaWAlUags5FBWzo6ZwdbhVZwP5auXkCQoAD7KcUN+plISetTamIfoAKtQYyCmJ8kJAZhO9VnpDdvItw64PshQlVLBsdXaScyIs9TehzxKFZxbrQTznUYcpdjAXuIpCSxl6X1g1nx0gBU3JX+dSI+kZW5DaQcqgGMVTYdCwS9obUjFk4inUAo3GLB85hy2rOl3u3S7XbIiJ+910VmK10GeSmODrNYJ0jiatSFnXnmVFM01x65i3759VLVlZB1NqhmKZ81bVmzDyDXU3oVtYD2pCMYHgFmtDli9cB6ATn8OlReUtkFlKamG3KQsdHrMZRmF0RgdUyi8py5rVFPRVBXnTp7ihRde4Py5c3QOpWiBW269ldvedDv7Dh2itA3nhyNEwZpt8AqsBmcUVoX1bLyhdj5EuQiU1tO4YI7jReNdE1hXQmapNorVsqJeW6HoFbztw/fwyrGjPP3gI/xvv/DPePnsKX7w+3+At93xZua6C5w/fxaUZ25unjoylWmaBgbTBTUAqCgd91sX10pjnccYw/z8PAsLCwzrmrqu6cb97a0LUzdKoVQajwMdDIa8oPAYrRmsrHDh/HluOHRVMPOxbqrYZ6q/smVTo6RR7R68bV6Qq6/7tW034Go7s6AtAdguAduVgMqvJ7i60u27Ve/pZn+/ltamPw3gN2NJZ2M2ZuByNmZjNq6w2JLYS7l5ceDxCNoQYzYIwBJH0zicb6QoekprgtGMOEQlWBo5e+4CL73yEg8/8RiPPP4Yjz71BOeWL1KJoPKUpWuOcfiqo3QW5yMDmqASQ1rkpFkGaGpn8R4cMdlDFEYl44JLS+gZVREk+rYaa+WqREYHPwUUJzJYE62KdASJLeOpNphkjoGl93jV/q2COycEMOiC4U4tQuM9DSEipFFgUTQSDH0a74L7q0CtVTD9EaG0jpGzNBL6MT3glQ5UVhQnBsDRFp1h3dr+z9DPFNYz0QqjFTmanlJ0lebkqROcfuUVelmH/Xv3jcFlkmfBTjbRwbe0tqgoL65GFatnL1APRtx83U0cOnA4xF9E855aKVa9ZbkZcXE0Yq2pqGxkwbxDeSFxgm4c50+fZriyyuL+ffSW9tAYA0mK9Y48L9hb9FnqdplPDQkerT0GoapGSFnTT1JKaznx8nHOnTtH0SnoLSzwljvuZN/BA5i5HufLEWvVCJKUbm8ONRyMc1SVBCMpbxXOWioX4lxqHycAjIpSUY24cAzZRIe+Xq3RhWfo4NVTZ1jzwtxVh3jrwb08dt8D/B+/+5946JnH+Tt/7ed4z9veydzSPBkpF5cvUHT6KKXJsgytNb5qqOsaUCRJNumBjoyPWuf7GTMwCY6xi4uLrJw6TlNW4BxeHM5bRKmwjFqPJxjavuNEaTKTMBoMKIcjDh8+zOLiIt6DMWnIQ217QqeOdyuCvoJCfuPr3U41+g7Pa/nTvzZuxmJuZaazo6xUXeb1mA3LIOt+bM1gElxotbw2OHopGJzcC7bYQ2EyT8suzI02NzHadhtOTXxKVGvMmMXZmI3ZmIHL2ZiNb0BgOW3os/E17T8dWZBEJWjAOYt4L8YYlWYJKYnyYlE6AJPzFy/IU889y2NPPM7Djz7Kky88y3MnjuNTTdHvsXh4P4f37qWzMEcx36eY61N7R6c/R6/XA51MyfwgSwtq24yz0trcyfF6tAwmggNM7B/zhGxHrzxGFFpivMi4aJkwlEnsMxwzlhuYS1ETOWP43gAwvQfnfZCuRpBSi8MFsyKctL2WBtua9XgXo0dCzmUjQuk9pbdUzkUnWaIT7JTsjHFkwUSmplpDkQA0FcG0SGvBKENiFAmKjjE0qwPOnTxNPRhy5NgB9u1ZQmc5RaeD14Ei1NGEyVuFclBZx3BlleHKKgeW9nLjDTeQZxlrwwG9pSXEe9bqISPlWYt9llVT42yI38iSlJ429Kua0fJFVi9eQCmht7CIpIa1ukY6HTwpRdFlvjvPfJrS044EhSMcB6kK27MaDTlx4jgnTpyg6Ha47YYbuOXGmzh8+DAW4UI5Iu32UL0uXhRr3rJqa7IsC73DPuwTrzTaGJI8uHA668glx4kNWasC4g14H44pnbA6GJAYzVy3h15c5JxtGDhLoYQ7vuP97L/mGF/4wz/iv/u//l/4H//mf8MPfu+fIU0NaZoG4KYUWqvAXjqhaRqckwgyidJqGRfTbfHslCBaYfGkecb8/Dz2FUtVVaFH1Lkx2pgu0gMbH+TFCsALy8vLVFXFVUdDvuVwtQSmgKUy455NER+PtcsHk/B6M0vq63Kd3A3A3GzxXi/Ga7dGKZeynRuku7L7/ad2kDjvZjm22/ebPbeVIdRW23+nx96o7TwbszEbM3A5G7MxG9sUDJu57E2/bvqmbX2N0QovXgRPmiZtrgiDwZqcu3Cel15+maeef5bHn3qSRx5/jFdPn0KMxnRyuksLLB4+wIGjh+kuzmOKDqabo7MMMZpcJ1TWcWE4ROuErI0SEXDWBcfM6RXysm42e7onyLYvGXcfhb5K1SbEKRUAc4xT0agxMzL2GVQTgx6lFD4aAmlRKD+RnvoIVirncW1OpXdYhIYJuGzi3433OBGsFyoX3lcTjH2CXDaylUSZYgs02n3n7aTgV2NEEbNDY+yIETSh5zTRkGFohiXnX36ZtYsX2DM/x769e+h0c3SWk3YyGmNwWoW8QwF0MOLxtaVcHdDNC26+7gYW5+axEpxE66Zh6CyrdclAedZcYAItCo9HK0VmErppQlLVrJ47h61Klg4epJjrMWosq6LQNqXI+3TzLt00J1eKDCEzYL1iUJcYDE5rTp06wQvPPU+WZdx+803cesMNAViKJ8kSnPNIZqi9MKhKlNaIVmFyQoJhjVegdBIzSsHhydKUJJok1c6CtyFD0jmsdVS1xXmN857V8xcwMbe1yVKGTYPWNdmhJd73/d/N8w88wv/y9/9Xnn/6Kf77n/vb9Lp9qjrsc+dc+N4I4pvGhyiQmCs5PgeVTCY4vCcxZuzg2uv1wrrECRiJx8N0NJCeyqENEyqCa2ounr+AbyxHjx4NzrRNg1YpVsV+6imTqpbF1FrjdokTtwIVnit3I1SyC1nrLq9/lwsutgPN666dehtgBq8pO2PTZdiw3pcTS7LT+m+6rXdwg93ps7Zarq2iaS55/9dxQmE2ZmM2ZuByNmbjWxMcThtGqM1/3+y107+HlsOACcX5IL3ygqgABLSOlvoRVIU+sPB6rWKnofiQqyheVlZWePixR/naIw9z/0MP8sxzz3P6/DlMkZFmGbrfZW5+nu7SAt2D+1GdjLRToDsdTCdHpSkWwVtP1knItAnMiYCtG2xVozEkmQlgUq9fWT1V9Nhtak/lY1xHyCqJBbuMZbTTsj8/Fb8y/c8ykcGqNuMzmuo48YGJonV/9dTKj1lJi1BJAJxeKar4rwaGYml8BKQqxpNEdOuj9Bjv0UqPWbT1K2dAh35OjcYrwQgkApkWCq/pAPXFZU6/eBxfNRy8+loWFhZI0xSd5zFyIqPyFiMeGoe2Dco7lDicrVncs4eDx46EnlejKBbmOLu6yvmmYqQ8F0ZDVl3I9KRle10D0RRHqpLzZ88hSrHnwEHSfo/VGFejlaabJHSThFwrEiekWpFrHYxIrKNsGrx1nD1/gYtrA26/4SZufetb6WQ5F6oalRh6eUHTWKqmwSlFbUDpAAhTpVEieK3wOkisa4Gha6icD0ZGSdh+LtpzJkmCJA5RDueEJDPoxLC2fB50YBxtaki1ph4NOTA3x77FPXR6Pe79w0/yv//iP+fi6gr/09/9P7M4tw/KBkuD1gUmCZ9f2RLbeDKjI2Me5w3aYtsHgaTJUsQrtEkoiiI6zK53KA0TEBP3YgNgXHBDxoCz1KMSjebA3gMkKkGhQSdjkGoUY7dkL1GKrUywLGV3OZObPaZQ4/bsy/35jTwm4GeXxjSvEVTuFhyJiKgplHS5vY2X9JfK9tLezVxltzM22i6CZVOQq16f7TMbszEbs/G6gsvXkoPyDQEuvs1lH6/ncl+uZOe1fb9nZ6/E9nXbbQDdJgRMmDXW/xsXpirUguJCHmVAT+BdYL5EKTSeJDGgFXVTY7KcajQQgLzTUVoLTVUKePJuV1V1ifOeYTniyaef4b98+lN89vOf46nnnufc2jJLBw7S37NE9+rDdOfnWVzaQ9GfIysK0k5OZ2kOHwvqJM9IkgTnoawr6qZG1ZGRw+IiY5KYsM2db8aSwXEBFVNFJllFyZa5ckoLygdDH41CuYmcto16kGi4oo2Jxbngxcd8zmCM4tC0/achs9CNGV6HYJ0bu8A2SqgBq0KMyMhFsOktVTS9KV1D5SyN93gT+0PjfvX4oLmNlZ3yFhAU0bRIKUhSWttasRUUGVhHrg2583QaWNQwOnOWc8++CMOKwwcOcmjf/jgxoej2e+jEUDY1e3o9mlHJcG1A6hwXz5/n/OlXyQrDtbdcj011iC1xntNrywy8ZYBjua4ZCoxqF6S1SqO9pVfkzGcFpqw5eeIU4g3Zwhy+kzNEGLkG5TRdrVkwKX3nya0lRRDrqcXivSXRKWSKBx59gJOnT3PrW97KjTfdxNAk1AKdTpckS1kVhUtTaqMYVCWjuqJ2A5RTzCUdtE5wChrnsRqs0lRGM3SOxtb4SHknKiExBosC0ShtENfgcYzKEUrFLEwSVkYWraGXZwwHq8jSXvqH9/Pdn/g4X/rPf8Q/+oV/xtmVi/yD/+n/zr65RfI0Y3WwSqc7T9pJ6aUJq2trDOqSLMvITRoK9HiMJ9qgFTgXpLN5krG0bw9lU6FMPLYbGfdzkqThSqIFbRTOenxV00k1rrScP3ma/Qt7uebI1TR1mAxRWnAEplo5kKoBo0mSwGbX3pK0F5Etr8+7myDTEq+IUz/b830aVGrU+Plp0LTV9XijW61s6NGbjlra7BrfPr9RzTG5Om9x/2wnt5y/5PlW3hwmwi7f/EcxBbBk/esueb2s788UFQMwwzZUegv3VplaPlkna4ExONWMWwG2XO4xyNabg842Kqr9yI09lhvygqdl3mHyMOx/HfeTnzKe0+h1UTlxr6/z1t3MZ3e32aPfCrXgG2U+9Y24fb4Zl2+2fV7/Wv5PDVzOxmx8/cZuAeYu3yvhVupUCzda249Jr43W6wGprapwI05jEWVDjAdak+UZdVVKkicoL9TlmmitSVIYDktOvXxSnnzmae697yt8/gt/wlPPPcvQNswv7eGqW2/kum6XfH6ezsIcaadDWnTo9HukWYFOA5hsTIxY0Dpk6UWAZ5QmNUk0o2mleJOMPTYk7CnZusZd12829ZrQa+knRidtJImaFDktc9NGRKwrJrXCuvCIV0Tn1hZYhp/WO6xnHDPSKKFUwdSn1oGlrCT0W5beUkYn2UaBNYHVEUXMy5wEz4+BdOy1DCZDgowviYG5JM3ROkF8gxKhqxL6SmHWRtRnzjM8v8x8t8/BffvpdDr4JCHJgquoc465ootYj3JCL01pbINrKopOTm8uZI06bSidD6AYR6lCn+jIOYZ1jSgdGVZHZhIWOl0KhOFgjZWVFbJej2JhEas1DiEtcrK0YC7N2ZMXzGU5mQZpLFZ5lCisdYxGJc+9cBxRhmPXXsf+w0dJenP4NMcZQ5XnjBCUNigDjYM6SalcQ+0NGMEgGPEB9HtHI4pGCSPnGPiaUVWGU0Wi23ES8iSN1qhEo02GOIepY/6lVnjnEKPwRjMQwAuvrK7Q9wqXFbz5fe9FBH7zj/4Lq6fP8ff+5/+F2269k6JbcOHCOeYW99A0NXNzc9iVVZqmwXsfsjKVwjuP9SEGSIuAmfQCA7iNJ4LoiNCiGQ8eJR6NC3LhukaJYnFunjwtxuZYaIXyGq1BIxhRmOlge1F4JduyiDsxU3pjvmw8R4V27qs9tmM/NZMJpM0mSLczh9mRBdumSNkKXO6ky9wK9I2Xz+++CNoMRG+cHN+KKd7M9dZFpKVkW3nqdjOub1hhuJ1cdreus+3xfsl2QrYFl7MxG7MxG68buPxmlVJcbk7hbHwjAMrXY+j1BY5IBCGyzs1UT8FLwcdC0+Ed4C1Jnkwtl6dsRqJ0yHNsrCVNU9AwairOXTjD2bNnef755/jCF77AvV+9j5dOvIIYw9zCPPuvuYq816e7MEd/aQnTyfHakPW7qDRFm5SsU2DSBKWTADD1JCOzNeppe7uSJOHSFiW1blbdt/1fU9hyXREW3VL1JsVY6xDbGvVM14oT6WsA3U7clLmJAqNRzgU3XVERXLqxOUxb6FnvJlEjQC1CRXCQLRU0AqV31LahrGsqb0PEiJ4qGNvlah07I5BumdFoeDpmgMQH8ayPRjHGOcRajNZ0k4ysqhmePsuFE69S1SXHrjrK3kMHSPIM0YYs7wTXXfFkSc5wuIZRCpNljFZXqGxD0e+x/8hhkrxA0MHNtgmOtiPvGDWWsqpoGkuSphgVHGbn85yFTpdm+SIXz5yjHJbsO3yU3r6lsJ2sJc9yunlGv8jp5TmdLCXz4J3De8fINqwOSs4vr3Lu4gX2HzjEwYMH6c7N40zI5Gw0DJoS6xwqS4IZlHcMRzXDusY2HiWOOo3HlIJKXHTndZTOMWpqyqrBESSxGoUxCXnMVTVKM9fpBEVAlqCNwtgEb23IWyWY6vTzAjEJWTdnsFaR5QXvuOcDpB7+4POfRf2/FP/g7/08Rw8fo9fvUA6G9Is5rAh5kjIoR1hrY09mGnJcxWG0QsShkgn71hr5eBcVq1qPJySUMkGp4B04hziHRzNYW8N7z74DB+h0OmNzKjV1HmitdmTZXq/7104mMjv16a17zO8OPG7Ffm7s/dv4+p3cYF/r/XgjcN7onroRUG/Vq7hVdqTWWqaFL2M34fhZEi+MagqRbZTWvpF1zWuNJdluYmE2ZmNWP8/GGw4utzqwvtn1+9/u/Qff7BePnZc/vq79WwiMQwSMbVFqVIBfKuZSBBPUBO8szjdijFFaazrdbIxfhnYoZ8+e4/iJl3nokYf56le/yhNPPM65C+fJ85zu/Bw3vvkOdJYzv7hA0e/hjUGMRqcJFkU21yXrdkN/llahEE7MmE3SSkcpqayL9NiquLtku4i0ROYkqxK5pBBWm4DUaVB5yfdteGx6ttshqBgBIaLwaLwEYOlir2WbQelpeyyhJuYmIsH9VSQ8FsFlLQ7bvrcNq2cDTeMjOxGNi4jmPoFdCkyWciDKk3oN4tHekolnTifkzlKdO8fyy8cZXjjP/N4l5vfvI+91ETSJyciSlERp8iTF1Q3KhyiLuqoZjEpEKzpzc2SdAlFpAM7OsVY3DJqaNVczsA21s8F5V4TEeTraMJ/n5BZWzi9z/vQZVNGhu7RI1u+xUtdYaymylFRBN0lIcChrQwxNllBVjpXBiLMrK6wMBizsO0h/cQ+66FD6YPCUZCkeoawaVGJQXvDe0TQNpXXUNshaE60ZOYeKQaZWBXOdxjbU1mKdRRvwPmiSnXicrbHOBbZbQWNr8iQlTzN0mmCMwhkFDYiDJDc4FKfOnSfZs8T+LOf08goHe/Pc9aEPkyjht//4j/D/t/+Z/8/f+3mO7DuI8R5paprGkieGxiQMXUVZVeGmpzVIEkEmaO/xeJwLDLuzMj6OwrGuJ5NRXhAreOfAg07N2Cl2//79Y3DpVZyw0TEXUwfgoTbQhiKyrePolfQWbveenZjQS967A6jY6GK6VZbl5dwztnv+ks96g+7nWzG322w/UUqp3bCGb0SdtdV3bMfEyiaOxbvp2Vz3+GvofZ3VT9/89dMMfM7GGwouv9G19LPxrTD8ZT6+cegt39+anU6A1sQpNTEq+t14rGtwPvRcBYt3jzFEhw8njTQMBgMurqxw6sxpXj19ki986Us8/ezTPPfCCzjx9BfmOXrz9fT7ffJeD93p0AgkeUbW65IWHbJuB5OH3EFlDEmR4STILE2aIFoFc5TofErMXxwDuSl51wRo6s1BoLhJX1Fba8gGEHlJx09kNJmwMXpKYjr9ERNjDoPodtsG91CHC0wwHqcCsLRKcPix+6hVCidQ4amAUjwj76m8oxJP5eyYGfOK0GMZA+rXXZX8xMglyGBlzFajQn+RopUZeowHLR68JfWWOWOYF0gGa1w8cZLRyVP0jObAoUMUc/NYFEpBvygo0iz06iUpZVnSSTPquuTixYusrK1RdHp0FhawxuBFUYsw8o6hbbhYVwxtTRVsnkiNxrsGLTDX7TGnU5rlFQZnzuPLmrmDx9DdPg0G6x0ojUEojKaXpuQaxNU4SRCtGdia84Mhq3WDz3Lm5ubwacqybRCvMCYjweMUVAbKahQnLATfWFzjUSIk2gAKVw1JtATjHhV65FxTQ+NQ3oWIEKUxEgGbBPOqGgl9gbrGJgab52RZAUajtSIvUrwkNE1DnhdI1bBW1/T7BSbvcLaqoci55e53sjpa5Xd/49c5eugY/8Pf+NscXNxPohWjpkbrgixLKCUwqVY8c51u6P10DhPNpBwqTkq0h3Bw+BWdYFWI4Qknusf7BnEtE2tYXV2lrmv27t1LnucMhtVYEq6TcFzoGMOi0bh1162d3FY3h1Fj9cE2YG6zjMPLNYBhE5nsTpEVm/VxbsVYymXWDJfIgtXlt0VsV/BeCTM6tX6CUmosRd54l1GMY58QkSkz6tcFWG62fpezPltKl3fY17MxG7MxG687uPxWv7js1mr923X9v+lnFi8BTUQ9XIRQbRNTAGKhatBJLAqEBiergxUGgwFnz5/jiaee4qGHv8bjTz7BSydewWQp/bl5rr7tZjrdLjpNSPOMXq9H1u/jdArRjMcjoQBONCbLKLoFZVMjRtO60vg2qEQkGNOo1vBCj49HP8Vkbr2mEzZSKYUhfLZhQ5E4BSI3uk0GXLZeDruxsGlD6n0bCRf7H10EmITVwnmJzFfIrHQoXFzfGk9FyKysfABiZcy9rL0Nn63bnspgzSMblyUCS2mBpY8rICGHUlTMYFQSQJFXpDgS7+lIMPBJ14bUZ89RnTuLqSr2X32Mhb17UVmCR+hkHbrdLlma4q2QKB2BpmJ15SKrF5fxKLoLc2TdDpiE2goj6xk6x6oLsSOjGLmilMKIRztHYRLmk4ykbjh/8hT1hWXm+wv09u6l1hpxHnRCkWr6RcF80aGXGrpZih1V1HVN4ywrwwFrTYPLC7JOgdeGUivQBp0mVChsOcKqsK0GowEqmlgp60nFBIdYBarxdJVCOYeK4D1zQtIIhQNRBmdDjotTBieKygnW25BjKoJJFDgb8lfLEpPlpHlGkRXoLMEmCWmSsOfwIfyoYm1Y0ctTcHDOlsx3U+5437tANL/wb/5/HNmzn7/2Yz/B/sV95GkSTHPShNQbhpXHuSr0fGYGJYLWSQSMPp43sVcyRsc4bYjdoDHnlancynD8jkYjRBR79+4NhlpuGDJNmUhqQ//l+nNPK7VOgn8l99vLkb1uam6zC6CwneHPDmBr289TSo2ngK4EWL7Rk+G7YWE3Ai7ZTLqx1bSmXOrU/Ybd5zYcH9uBxMsBp7Mcy2/t+um11r+z42IGLr9tT6jZwf+NPvwVPr/7GW3BjXvyaKM1iNEhtgm5fEaTJlpJdFsc2aGsDFZYW1vlqw8+wH333cezzz/HydNnqL1jfnGBozdez9yeRbq9OYq54B4qRmPScNrVXki7PRwKH3vdik6BSRKseEbDEWmegUkiOwlpGsxijLehr7Px4/iOsAo+WtpOAuPXbSdZv10SpSeZlGqD+6LaAD7jVnUSHGKR9a6T3vt1zKX40A/qkNDDpoLbokfwPmROeu/wBPdXF/spLTKOGnEeGi+BrRQJbKUIFUIDOCWh4I9gX4hs5HhXTlwh297S8XM+MNUKg9atSUcTTF7EYrzQF5gX6A5rhidPMjx7Dj8c0uukHDx4AN8pomQ5IcsKUpNRmAyjQu+rTwxroyFrKwO8hz2Le+n157EqSGVLLGviWG4sa94xUtBojeDQeIxSdLOEPVlBV0N9cYWLr57ElzWHr7qaqt9loEPeYpEWdHLDYm+OpV6HDEgjG79mKy4ORizXFT5NMUUOec6wdnijUFrwYqkbR+OacQ5pqjUGh/GQpQmFaLT1UJZQ13QSUHUdpKDeQ2PJrEXrhCRNw+ckBjEJYhQWjVeB5fRJkMCOJx5QKO8w3pErj9aK7twCy8urVOUaeZJDnlL7YGA1rGpqVXNw3x7e9Z0foloe8ov/+pe4/bobuest7+DIkWNUo1FYjzwjtzVV2VA2NYlOKdIge3YuSIdb458J8An7UGIPczh3wrUiZJ0axDps3ZAkCXv37sWYBOccOs0RwuRKAKdbD30ZmOkSYnHS5bwt+Nz43gnA89ua+OwELHcLwDZ7n4iMJ6d2A3qvRCK82fbYbp226q3cCoD5Nh4I1sUvbexfVxul0G9A4bFTpuVuJgS2kwHvRq48q6dm4Hk2ZuMNA5ezMRvfLMBV8GNWSyFTABNQPrjAagFnZdhUDMsBp86d5Znnn+PF4y/zpa98mReOv0xVVew7sJ9rbruVotshyTNUYugv7sEbhTYpKk1CoR0dTDMUo8ZikpQky3DiKZuSBCHNMzq9Lt77MZATL+B8iMhwwfAk0Tr0d0lgA9dFEkSHyPZ5H+V90z65OpT0GAJ7t5G5jCV/MAmKPTpmivFsi/FpcOlFYlEeaFbnPc4H8BgQbJAgSpRKesUYWLZRIw0eq8B6oRahFE8dAWZgMj1eydhllmlwKQFwEiMLVDTraRlLEYl5nMHFVEsoDkUFeS7ao6wj80LfKxbRmMGIcydOM7x4Ho2nM9djfnGB1STBJynGBNDvnSNJFEWWobWmqiqaUUk5GJKnGYt7l9BFxqAu0UZolGIkwsBbhuKwWuFVAD3KC6nAfJGylOd0nGewsszg4gUylbKwsMDZNEMQkkSTGUU3Ncx1CvpFBzca4W09jpsZ1CUjZ9HdPjrvUIpQaYJpkvNY36BUAKNaCdqDtxZjHalXdNDkFmRUU62s0aytMRqs4auSqqqwdYNvLOI8aZpTFEWYuMhSkqIgKfIg/y5y0iKHLCHr9hCtwrGiFV4rSM143yWNZXHfXlbX1lDK0DQJF84vh+idbs6oqVnGsX+u4G3vfzdf/u1P8vP/6B/yj/7B/8a+gwcQFYy2ksSM+yGbJjClSaeDr4YgDmkabBOApngVGHAJ0tiwP/Q6IKS0oJXBuRrvPXmS0u/3AbDiSZUKjtMSzk8fTZqNtOcq6/I3dwMYdjLv2Q242wiclLq8Hs3XCno2gp3duI1ebk/hbkDPVoZCG9sKQvvD7pi9aVD5zQK2tuoDnX78StfhW8FzYzZmYzZeR3D5WjX1V6r5n83cfOtti425aBtHe/PeDPht/pnrmUrZUn/k4ne2/ZFC0zRAYP/a0sZ7T2MbUQJZmiqMAW+D5FQbUFAN1uTUubO8/OrLPPr443z14Yd4/qUXWatGHLzqKq666UZ683N0ul2yooPOUnSahEy7ooM3ClRbZKpoXONx3pN1uoAOLrVKURTd8XIrZUgSPc7lS7RBR54u1Ulgf1QbDB/ZRK1RooKzrfchAkIptFIYvV7eCmAizGzFrfqS4lONc+XG/V3TRYOWKCm81KHQOY8oHeStwVY2mPcQWMmQvulpvI+GPZ5KKxxgUVhRWEWUxDqG1tGIo1aR7dLSErTxWIjLBoF9BLzzQfLaxrDE49FojVGaRGeMqpIkK6hsDT6wUKr2LKQ5B1RKdnGN08+/THXqHHvmeoxsyeLeJWolIX9zVJGQUMwXzHfnyXUCzuKtw9cNg9U1jEro9LsBrKBQaUaDcLEsudiUrLqaUgQXY10SL6TO0VWwoDVzKFbOnGbt3Hma4YgDh5dIkgS0xiSapirpmJz9e/ex0OviGkuehpiPcxcvsjoqIQmgba0ucd5RaUWDZlRXeO/IEk1iBCPBHVc7S+qFhTSjaBr0sIbhiMGpc5x+8WVWzp4n94q5bo+lhUUW5hco5jK8ddR1Q13WXLhwgUFdUdoGEkPaLSj6PeYW5unM9cn3L5H1u3T7XdJuQVoUqDylFkfZNGQdha8qTJpSOY/zDUUnwYlCZzmjtTVcnnL2whrHrr2KN931du775Gf5l//HL/GzP/nTXHfzjRjjGQ6GZHmHvXuWePbpZ+jtL3AuTM4IwVn5woULwYnZ6BDdkRga71DGjI95Q+jpRYS8MPjKUVUV3nvm+3M01qIwWGuxKEySj89niU6zQphMESVoJa8pkUJrtWmv3Gb9lpteZb3f9b18s2u9ZxeyuHUxFuNLb/h76vu3Y0a3BGuXKcvb7F70WkHUOjAFU3FP6w3ONsR5CKE3U8VWzW3Z2q3Wx/vp5ddbrO9WQDqkak3fpy/pid3CeXi8fDJxJ9/N8XI5EyGz+mo2ZuMbq5a/HPw3Yy5n4xtipvSNGlrrcTTABFR6rPV4CW6cSaKVEo14i4oFO94yXF2RJ59+ghdPHOfxJx/j8aef4pXTJ7EIBw8f4qZjx8jm55FEY5LgdqlNcHW1CI7gkIkEFi8UrSbmQIL2gm98zJgMrJ6S4DDZVmFmffb1GBRqIhti1Njl1UdZqyWa/ShFC0cNgUlp5a1Gre+V3OqislNfTssUTl93fMxH87Gv0rfOr7Ff0009XkvIsGzwNErRKMJjEqSxtbdYL1Q+5Au2wNLrtgE0SBU3TmK0S22SJLDSkc0MsRABWBqlEduwMNdnpRmE6JAiI7GW+cTQUzDnhKcffozmzHmOLe1HZ4a18wMky0h7HRrn8THrM01T8iwj0wnahX670WhElmUUnQ6mE/JJrYa6tqzVDSWeoa0Z2IpGApPqncU4R+FhT5GzN80onOXchQuceOE5Du3by7Fjx7g4qpBOAEmp1nTynDzN6OQFifcoZ7m4skLV1DjCMVl7x8g5Gu+olGFQlXT6fYwDZys6OiV1ntQ69uQ5PQ/DM2cYXljDjCrWXj3FxZNnuP7wEd7/oY9w+0230et0WZyfp1t0gtGP94gN+2F1sMby2irnLpzn9PlzvHrmNK+8eoJTZ05z5pVTnHnuRbJeh7xfkPe67D10gENHD7FvaRFf9ChHDSWOLMsx3tOIJ+/3aZTi9IUzzC/u4fSpM+wRzaqzHL31Rs6cPMVnv/JFjl1zFR87sMTS/v30OjmjqqKuKg4fPoyralZWavYtdPEemqaibsoYV5LEiQlBJZOsVL2JY7J1DoMOvbZZNonbAXRicAjJFuxcMPh57dfTK3nu9bp2X4nz6/Rj62TIu4gEueSzXsf12i3juxWTuqmMdhvWNT42MfbZBVu4naHSlbK4G0H3xp7MnT7/T/uePhuzMRvf+GMGLmfjT2UGpC26di5KLtMVVrYoz6J7RmMr0iQFFF6CHC4AypSElFE5kE6Rq7ZjpnGVXLx4kaeffpqnnn6a+x98gBNnTnH23DmKuR7X3347R44dJclSVuuSbHEPjXc4iYAnykEFwTuJLAdoHw08TLvuOs4aV1GapiPz5ifmOEzlS45BpYlFVejBnJr3H0vsktjTBgHEBsYysC8qAks1vV39FEu5UWLK5rK7MZhrJa46/i069j8Gl1cnPjKVrRS2zbIMzzUiWAWNUtQIlSf0VLoggy1dg5fgjmuJrG9c7zEp0kpe29n3duMR3CRDj6cfF3va6LFDrPc10tRI3dDt5WjboAYj9vbm6Y0sLz3yGCsvn+C6/Ye44ZrreenMK+gkpTe/gNWKuvZgiNEwYXLBJEn4Xu8xeRFeW2Q0icIlBqs8pXgGdcNqU7E6GlI3DUlehIgO6+gpzd484+q5eXq25syLL3L+5ZfRdc2Rw4fpzfVZa6IJjbOkaUYvy8i0IUsSMqAuBZ3l5GiU1miB0WiAKktcZAGTJKEcDMhwdJQm9TV9BXMqpTOy1GfPoS9c4MwzL6IHI979trfzAz/117nthptITcq+vYfI8w55npMojbch/7FlNEajEY2zNM5hlVA1NcsrK5y9cJ61tTUef/IJHn70UZ589kmWXcPaKye5+OJLHLrqKAeOHWFhfoHFTsbACdVwQOZjh7TRzBXd4HCbFOR5h9VBSX9pgdvf/Q4++3t/wK/8zq9z9Q3X8KEPfpii06XINOINSjRnVlaZ63TGE1BlUzEYDNBJMu5rbs2o1jFSEo5hHc/JVg2xsLBAt9OfOs4mDszrZaAmRv24eO6+Nni52YTP5cgRd8IEW+U9boyiuJJlfj1cR9VrhJebMb7bSWAvYQ6RTRFue73eeNcyl9y+1JjFjF/Yfk8LOKMgY/qLo2RX2BYkbjVZuG6dd4oq2WJSYPz7DgZHMwA6G7MxA5ezMRtfF+D5hgzRoDxpkuIlmJNopcgie+nFUzeVFEWOw8pwWHLyzGmeee5ZHnz4a3zta1/jhZdfIskzDh07yltvvZvOXB9vFHWiMHnO3HyfUoWSwUQkp3Uo5JUK8QaNtbGq0G0bWYzDsOCFVOlYgsQMvMg0ThdPWi4tBrWo2FfIOEpEIkRW0dSmNeoRFSIQWmZ0zJC2kil9acD4dr1cYzfaSLCO8zWjeYyL5VLLWFoEK6E/MsQ9CJYILvE0QC1t1EhwhR01DbV3kRkEQeOVxGJsUugr7wIrKVP5lS0wR+F8NJqJDEkrww4A15ElCXU5ojCKwtpglNPts8drTjz6JMfve4C7b76D7/ngd9A4y6MvPEPe6dFfWOTCoMKqNGSNouP6CIn4cR5q1ikoEkVZakpbUrqGoXIMnWPoatbKAY2r0caQJSnKebQXFrThUNFhr0lIhiOeefElzr/4IocOX818r8uorJlbWuLMcA2thE6a0MlycJ6mdujEUDeO3vwSxjXUWoG3JGJRTYPyghZHYh2qqlnodemisBcvMt/vs2QSLr78Kscff5I5NO+49kY++h3fyYfe817271kixdDrzLE8LNHKINZTOxviSpwLEylKURQdEufoxHMArTiw7wDXNA3eOe5557s5d+4czx9/kYcf/Rr/9Quf49EHH+Xk089x7IbruPGWWzh20/WIOMxayfxcn1Jp1tbWUEnCaFTTm5sL5431nB6usLRvgbd+8L189nd/n3/973+ZY8eOcevNt9Hv9FAmYWVljU6ekaYGEUeSKpqqYm1tDZModJqELFal1k+tKI+IG09SKCXj9Z2fX6QoAovcAtONJi5aNhTnuwBUu5UNbmXEsjNou3xm8HKAwkbZ7W4A5U7Lv9NnXG78xjRTt3E77kbmuUP+5bbAOnznpu+RaUC5Gchse+m3++6dzJDUNoB/K6B5JS66233HbMzGbMzA5WzMxuVhvC16W9p/Im6n8mSb5/QW5Y/fUOA4nHOSZYkSEaqqEmMMWZbi8Tz/yos88NUH+fID9/PVBx7gldMnWTpwkBveegcHjhwl7xSYNKFyIfZCZWlw9awr8l6XJIJKUW0xFRg/g8bk6YbtEcxV2liOad7Cq9ZEQq0r/tR4XSez1a3AVU19jmg1AZ0orPdjAx/TSvsieNURqbayVjbJndtsP46BZLRc9X4K2LXPh47PyDIG0CVE11hRNCKRifRjGWxJkL6OxDN0lso11M6DMq0PboDN4sasLI4AGseAfQIu220nUw62IcleB8faaECUKoPRUGiDGlYcKHocVAmvPPQYL9z/EHceu5bv/c7v5O677ub+hx5kOCoxC120SqmrES5NQYQGT2kbhnWFylWQHRuoRbCJwqaGysGatay6muWqZKUa0fiaxIToCyMe3Vg6TrMv73Ak75FeXOX88y9Qv3oWWV5j7019Um2oI/BJFXSThH6Rh9gTwDUOqzROBRbdekONp2wsZW1pbI3zDtVYegqMErK1VToqYV93nr71nHvqWV54+BEW0oyP/+AP84Pf92c4fOAgKUmQmlvh3MU10qyLE41zYEjQWR4dMwMIG9mJfZQ0gmhIkoRep0OqDeXqiP03HOCWG2/lvXfdzV/8Cz/Ek08/xm/99m/y27//e7z6/Ivcee6d3HDnHVy1Zy9nm4rV5TUSH4x3tFP4RnGhXGUhKxjiqMtVDl5zlDve9Q7u/fRn+a3f/R2O/vQhemlOPSpJlKK3MM/K8gVynZIXOc45VleXg2TaRH7JqHXXlDbGRokfm1zVdU3TNMztPTAGl1qHPmNnLcqkyAa+ajoCaPrvTc87v4PUMTbNqQ15jzJWI2zDjCrPa0tZvLL7weVEm2wHGpVSiPevGaxsJQXdFWjXKoK8Dc+p8RUoXr3V+juTBJexRMXpwA3fF79LNplEkA3bQK3bHluwjtuBx92AxN1ODm+U1+7mGJiN2ZiNGbicjdm4InC5WUHx+vUETQtJWyDWymIb0iTBGKXquhatNZ0ix3rL+eWzfP7eL/C7v//7fPpznwWtuf7WW3jPHR9k6eAh5pYWGdbNuFcu9Q7rQx+fTgJbWTV17F9MEe9CxIa3IQcPT6o3gksfSs3I/KHUBDii1xUgY+MdNVnHdcEDMScvtl0SDHl0YC5RJFpHeWKbp9emVk6XPVsXEtPuh9PAkjG2k7HsTyIzSWQmPWB9MPQRQtRIy1h6gktsI0KDinmVIeuxEk/tLbUPjOdU+2kErTJmf4WQv4gEuZlroytbhnXa8VHrIDltmUvvUUZRNhW5eHIMi0WXfZLw/Jce5IX7HuDN117Lz/6VH+fWG28mL0ImJEmK95qmbMiSAhfhfyNQWsegqUArUmNCvmU9ohLH0FtqPCNvGTQVq03JsKmCqUyU0Won9JOcw/0uV+dd9hnFxVMv8NgXvkS9vMK+To9+lpGZBN/tcdFZOkVGN8/pZQWZNqTaxPUTSDKGdcNa0zB0DavViKqpQ3+oVijxdOuGuTSBwYi9WcpcU/Pkl+7nzLPPc9tV1/F3f/bnuPOW2zi27xjiJKTcZCk6S8hSRVU2iPhxwdgCs+A+6/A2rp/WYSLCOyocStVogSLJaMrgVCtOcfTAEa4+fJRbr7+R7/3I9/Avf+Ff8eVPf44zZ85x14c+SKYVDCryPMVVLhhbOWiccHZ1mX4nxXnNhbLk1nfcycVTp/id3/tt7rrjTr73O78H7TVplmOMIklC5IsxCmvrwFwWCcaEaJ91k2HhyB5PhikVJhCqqsJay3x/jqIoouw+GlpJmGCaNlWZvv7pHYDlbsCXsHVf4+6ur5qd4562XqYrMWTZeC/YDaDZKT5k433lSkDrTozcJczm+Pq8dc/lToZEG91pt5qQ3c6hdrPteTn5p1ut53ZAdLwtdmAjdwtqZ2M2ZmMGLmdjNi57Vng3hdJrA5bt71vM2KLIs1yBZ3WwLJ/5zGf45Kf+iN/6g98j62YcOHKEG269maPXXkt3cR6fpvhE4w3UhhiTYAI5piKgUyoafgjg0Tq4ugYQZ9BK4eomlnDr172NBvHaTJg4Nf1DTWPKS8AlqpXMypiJDC2QE8bCih8b/+hYB7Tf2xoA+Y2FTfw5lr5u2JZ+Ku4DNSmOWqA5acWRiZFPZCytCA6PlRhNgqcWqLyndI7aNVTisUoh2qAxwWUzZMWMWdGILseMZdtjqdvdL5Pl14lZBy4lLjM6uPHiAsjJUfSscPKJJ3n5gUe44/BV/MwPf5x77n4PZV1zYTRAFxk6z3FotDdkOg2ZopG9qLxlUJd478fs86AuGdqaVVuz6mrWbMNqVTGIbqJKCakKGaOp1uzvL3L1/B7mhiOGr57iuQe+xsGix+GrruHicI3B8ip7tcL0egydYyFPMHlGZjTaOxJdIKIoqwZvDIOqZq2sGLqaka1DBE6WkevgIpyVIw4WPQqTsXbyDA8/+DCvPvEs97z5bfzNn/xZPvzee8iTHFd7Gh8cWmufMKodiNBJCoxnHC3j47b33uBFIWhQKUqHbsPEhEkPEUGcx4lm1DiU0SRph7Ic4b3j4P5D/JnvuYp9C0v801/8l3zxoQexXnP9O9/C4X37OFuNOHv+HOR9tGi0SVkdrZEVKd1Oh7pZhqLDu953N3/473+d//Trv84NR67hLXe+lcZamqai2yvwdYlSirquGQ4H9PpLY+Mv7z1Kx2MNPQUGXOypFKoqTBDMzQVwWQ6q6Ih8qRN26AdW4+uBZ3d5kLu5/r1RPW5bAZkxeOHK3eS362/cLWDczHjmStfvskB9vDaOPQXU5Lp+OcM5d8lExk7gbN128nqyHEpdck9UG2ciptdPebz4bddxxyiWHe75r/fxOBuzMRszcDkbs7EuL+ySTDAJzNQl77mcz1fBgnTSHeUnAiQRsjSlsZWYRKm6aeT+B+/nP/zaf+AP//APee6ll3jLu9/JrW++g9tufxOd+X5w0hRPo4TKO0wnD59sDEYHGW7bX6ijNC7GmaCUItFtUenxXjBqo5x1GhwGgOhh3C853gKyschR638ISCzOdNgQhFhJjZZWlhs4TC3rCx81LbUTjcchMmFrfOzZ9NFnYh34nQKnEF7j4+My7RLbglcFNjKWjQrPNQiNEqwEE58aqJyl9j70Yupoq69VMEwZ9yS5uN5Tm8K7uDGjzForxEdWeKqP1BDCBn08PkQrMvF0s4wFgT3WsPbSKzz++S9xpDPPJz7+49zz/tBnOSobjM7p9eYwYhCt6WQ5a9aiUsCEmJlGYNgE1lUkOOLW4lgphyyPBqy5mkHstazEoREKDD2dYoCOKA6kKXuVxp49zwuPPMKD997L//rf/w+8/a138P/9d/+Ozzz8Na6+4076aYYzjjLNIMtwjcU1Fskd1gnDqkQSTVWV1OWQxtZ4Z0mdI01TjBJS67jlyDHcufNcOHGShz/3BS4++Rzf+z0/wH//c3+bt952J7oRvFN4r8NPR+xHNJjEUFc1KRrRBpGwdUUCGDNGkWYdIORHuib0I6ooN3VOyFKNF8FZh2AxKkwCeCdUw4Z73v1BlvYd5B//y3/O73/m03ijedO738lcknKoM8eZqmZ5OEQVKb3eHKOmRrxlqdNluarYMz/Hne96B5/5vU/x3rvu5vbbb8cLJDqlbBpSHV1fbUNZV8wbEw19DN43aNH4LUx3lIBtGvBC3snQeUq9OgwhSCoh1SmOEAcEoXdYbWAwW3DWHtcbf05HB232c5p0vBJFiMQYoy2f11PS3SgjaK9VonYh292GOduJHduKTRv3h8vrB1x2AzIvWZcpCahh9z2XEzMchfMWpWR8f9wuOmULcC3b4LwdmePWm2A3QHDjpMBu+k53es1szMZsfBuBy9dTsrB71zr1hnz+7GL2RoPH7Xsmk0RPQcbpm3Pr9GnGoHD6OTbMjV5yY4oASpSnslWQ2GU5zjYYrRHbiBeL0pqmKXn+pVfkV3/j1/mnv/DPOXn6PO983zv5xF/4fo7dfDNWaQYKVqoy5idG11eT4uKN1EdjHtPKK5WKfTYJiWGMtnQUnhpCEd32BI0B3hQDKUDdZpxNHa9a7WIWOG6xpO0Pi0WC+Ch8VW0O/USy6ttCUk32iFeEeBSvxr2I0ToC1TJMalq+FfdUxL8uurHKeA8GsGxbUClCowiAEqGRALisOGpg6BWl91QxksQiWO9BBXYz6lzjPzc+VJRSGBHEWVCC0yZ69sSVMwpMhjGaRFRgdp3H4NEmEI5pXbLPaK7pznH8yad55Pc+xdLcPn7ur/8tvuMjH6UR4eL5ZYwpWJybZ6l3kWP7D/LYC89CIhR5RmIb0k6CShSDpqLygqemLCsqZxk2VVhnbxm6mhqPN2C0wTjH3k6PorIsdQuO9hfYbzLU6VO88MB93P/Hn+HjP/TDfOd3fYRjx45x+0OP8B9+9w+4ePwke/ccIO0UnKkF0gSdpVTesry6QuUbRk3NsCoDkDSKhYRxFE3HaPp5h4VijvnVAU899jQPfO6LuGHFX/lLP8Zf/+m/xpvveCt21DD0Fo3C6BSVhJxSvJAEehiF4FXoQVQqFtnRpMSLx9tmPNFjIqi0EqSjGLC+GUfEKGMAE8yQJHze6lrJm258Ez/7ib9KVTZ86oufJbGWd33gfdimYuCFoXgMmrWVAUmeMNebZ7UcIWh6acrRm2/hphOn+ZXf+Q3ec88HuPm6mzAi5EmCd6GHd3WwxoULFzh20w0hPsg7TJri43GltSZJMgarA8R68m6f0WiEr2uauuLgkcOIVtSEiZHMZDRNQ56koCSuU6sUUOOJGxV7onV0QN74kxjhM1YgbPjp23NCNr/ntTLdzcDL5N65nWNtnBy7ZLlie7PePqpomr3dTMKrNjezCdfJaWZT1s/OyTac6eUAms36LXdbtyilEOdRmxiiqfX6k9AXH/eByMS9etzfG18kl8TdbO8mrLRf1915yb1is20y9Ut43Fz6ueP7rl/nkXDp4aHG/gHS3lumjLCUvnR51oF02b5Wm9V3szEbb+TYuSViu57r1q9tsxp1xlzOxjc4eN3m5qI8Thx5mqGBc+dPy/zcHPWwptPvYjC8+upx/u2v/DL/5ld/hWePP8++I4f4kT/3UW57y51IkjMkZCt672OPYOh9NEkAkEzPlMeTyIQ7aehnFLVuNlemGD3VurROs5Dxht72UrbiuHV9M1MOgD4CyXUnb2Q8QiFvpkoLM75bt6XXTv07QowOUaHodWOoODVr7ltn2IkkVgg9ZQFgRhOfyGI4BCsBKDYi1PipnwFcNj64w46cp/KKRnlcK6+ddlKc6rgkso9huwfAqdtXiItUjh4b92ilcCKkicHVDdo7OnmGEod4x/5+jz1lxeknnuLRP7mX/fsO8Ld/5m/y3R/+bkorOOfIunNIU6NE08u67FtYwlWP0kkSKg25CREfeBskvyhq5xjWdejDdELlG2prsd7io5w3zxL6WU46rDjYn2dOYL/JWHSeL33+8zzzwNe4+8438wPf+/286U13gjLcecfb+NA9H+KZhx5l38IebnjbO8i14bxtqMua1Ci8EqxzZMqTdwsaW9FLCjJCrM1cp0cvTalWRgxOHeeZBx7iyfsfYE9vkZ/62z/Hj3zsE+xZXGJlZQ3vNHmWo1Uy2Scigflu2Q6lN0wyuakjS+148xoDFQTlg8TcSpR7K6EpLYkuue3GW/mJj/8oVT3i/kce5MlOxrVveyujRFhdrcF79vTnsRqsF7KsQKxj6DxzvQ5Hbrier33uC/zJvV/k0IEDHJufZzQaYRIzBmEA2hi0vvS2KFOgavo88rYh1Yq8KBBlQkyKFxIRDCaADxXWy7XbJIJniZL26a12uT93Gib2/u6Kxdrm+rvV919ulMkmF/Fd3wuml1Vvsx22A4pvBBjZ6Aq8VYzHdr2llxMfc6X30Z1kxZsv187s88bPudL+ypmb7GzMxrfOmIHL2fj6DrVNzwchrkLrwAe2thgB3DjEC1oEa4cyGAzYs7hINRzR6Xd56qkn+dqjj/CLv/SLPPL042T9Ln/uL/9Frr/tFnSRUQLiLQ0G30pXY09eO9uuYkHeMnhawox6yz5qNZnjHd8Q/WSmXURQU5+1kaFEgUFvKg0e92a1bpCs7+0Zz7ZveHyrm/lWRhIhX/NS+/2xKQ5TADOCv/Fr2qLbB8bUM4kaaSTIYOsoMW4EGhEq8VTe0VhPJY7KByAaHGU3qTXFT0rQFuC3y+ADYzZWEUd9rlYqyIONwRhDWVekCaQmQ5oGqRvm8pxFU7B88jiPfO6L7O3O8zd/4m/w/R/5KInKubg2QETRKwq8UvQ7XQ4f3M+1x47RfHrE4MIy2d4FlrIuXqXBMVXpsJ5Nw6AuqcTROEttbWApFMF0RxQ9U7BUFByay9if5cyZDNZG3PvFr/Dlz3+Jt11/E3/7b/y3fOSDHwKVAMK73/Uezq2s8Pd//ud54Cv3sXTkGJ1Dh5hHqGKh7bShm2YMG0fdNMwlGdo6Ug+5UvQc+LUVzrxwnFPPv8Dxx57i3Xe9jx/8wb/A93zP97I0d5CVwRqu8eRZjjKa1o8myMHbyQdZV+RvVxxuF1MwbScjsSdXCYj3eDxFUTAcDljYs8h73/0ezq2c59XTr/LEI4+xdOwqlo4d4Xw5YrkckBUJzgt1XaOKHF/VdNOMpEi56rpree7hx/mjT/8R77v7PRw+fJg0iywpMBqNEBHSLCFJ9Jbgre1ta2WRdV0H99teb7Ku0+eWtLmXG01WXm9Ts833wyU9kjvkIF4C/v32kwNa7X5ZNl3fLUCVHys61JaTEtvFuWzm9vpGALjNANVmESbT/Yu7Yeh2G8WyW7C4OyB5eYZGu9k2O7rRyvbrPAOaszEbM3A5G7Nx+YXQDs8bbS4pdtpiDe9JEo1qFEtLeykHA1aHq3zlwfv4jd/5bX7xX/8S+48e5Ka33Mmb3/l29h09SIXHKpBEU1qL82CMxqQpmTHjzMcWRLWSVolAU6tghDJhH9cXcEq3N3HZABLVepA5jpjcvKdqXLxtMFQwEUNN2NQpma1MAz/Z9ma/7nXqUmDpI4vLusJ/kmc5ZjSi3NZLcIAVNFYJDUHmWvsgf23EUwO191QOKueovQvS2VaOq9W4WvVTM+ZtbAo+9JeKD8Byut3IiEJJu1/CfhIV9m0pliLLAttZNxyaX6CL4tUnn+bEQ48yV8zxsz/+M3zi4z/KypllXn3lBIv79qEwFFmOThKKPCdNlrj26FUs9LqcfvE4txw+hBhNJQrroEnAGCgjeaq84L0Fb8mUIjeGQhkSBXMY9pLQb4TFLKE+v8IDf/IFnv3qw7zpplv4mR//KT76Xd8HeIYXLmKylIW5Re559/v4oT/75/mPv/UbfP6P/oi7vuNDzB/cz95en2FTMWhK+lmKTw2jqorbQ+jolBThwolTPPPEU5x++RVkVPOJj/8Yf/aj38c73/JuSltz/NUT5HmHbqdPWVYkwYd3fdE8lsGqKcZeNg2cnwYnmwGNyYRRe9yPeXM0QpIkeJdw8fwF8m7Kh+75AMePv8S/+qVf4P4vfpF3/cD3c2RxAXfhHMPhEFVkIeUhSTEKHJpSYL7b5aY33cZX/+vnefLpJ7j+2qvZt7QX7y2CZ21tDYA0TUmSBDtl2LLRjVPpML3knKOua4xJ6XR6OAnxKMboYEQlHo1sEWS/+6zL3YC3nUD9ZmDrjQK3V7r8m5r4sHMv5G5lsH9aoOWN3NYbl9uLiN7w4E5g8UojQraKFdvqcy53fWfM5WzMxgxczsZsvC7AcifFt556RXC2E7TREC3+pazEJBppKk6depX//KlP8vP/8H/npZMneOvdd/Gmt72FvUcPsXBgH5V2jBqHyVOs96xWFb1OH6UDw5UkyRhcmlgsG6Uhyj41YNq4j8iieS9TrGTMN1QT2NwyO2ocizbpwVG6DTjYvKcpvD6Cy+i6CkESOm5Fmjb48VNFjUzkseuK+Q3/0H4MHH10ZPXeB3GsF7ROgvw19lqOey6j5FQEHAobBbVWHFaC1NiKUPtg2FMjVO3f4qkI/ZhO6wgk15saicSePhWL/DifMGZc/ZRzrFYopUm0Dr2utDmWUFZDiiID8biq4WC/y/485/TTL/DClx/iUH+BT/yln+QvfN+fC2jYK/bvP0iaFWitQ3ZhVdI0DWmiuerYMd56+x088syTyOqAhcVFKtGMGk/pHcooeqmmkYxMJSixOCWkIvS1pqsTeiZhQefswbA/y/FnL3LfZz/Ho/c9wLve9Bb+1k/+Nb7r/R8Ml+eyJk16pEVOORixb89B/sqP/Cjew+/84X/mS5/8JDfddgvX3XQj3bkemQLfOCxCZiE1Btc0rJw/zdPPPMPTjz6Oahzvu/vdfNcHv5OPfOgj5GlKWVU0tWOuO4fWCR5FnnXi8aXHslePWwcetzN02c4J9BKWYhMAplAMh0PSRJGmKeVwxMKeeT78gQ/yyMMP8bt//Cke//JXuOW972Jft8fLqyuoNMEDZVOTFQVl06Cqikwn7DtyiLSTc/8D93HP3Xezf88iiQ6TFoPBAJFodmQM1nu8Cqmwgd3fGPfg8M7RNA3GGDqdDrZlqE04CoPbbAvCJ7L4dcX5ZYCv3RTnl4CPDczj6x0JcTkZiJs+J7s7PrZcbq0umUZbp8Rgi/e3j7/OYG96Eu9yHVN3AlWbArrQxyvx8V2BzPWPt3cov+kySpTEKL05UG57Ri+JsLqC42I2ZmM2voXA5W57LmZjNt5IkDm++awDlhEcRfub1hxnLAUVQSthsLLCo08+wS//6q/wj/7JL3DklqP82M/+NHuOHGT/0cOs1CNWmxJdZLg0YXltgEkzlg4cxFduLHO11kagEgwwksiaqui+E7LtdGDJWlnbNMs4FWe3sXhcx1huKBRaaZmeXu/Yj7Wuz0gmMtVJFMD2N/ON5/G0mUT4vRU5TrGWrJfAekL/2zpZrGoB70QKW3vBoYIM1nsaFQxOqlYOK55GoBahweC0gIl72a/PpqQFjoogNQ4rGnrYfHi9UiDagNbRqkaHDtKWERKPq0v6xRyqcuwpOizplKfuvZ8Tjz3N0bklfvpjP8r3fei7WOzOc+bUWRbmFul0OgyGJUmSBHmm9zTekaUZ1159DR94z/t47PHHeez+B3nbBz5AkSuKJGHZVZi6QYxCjKarFVmWQWLIvKKnDYtZzkJS0FGK3HlWjr/M5//wk5w9eYbvfu8H+PgPfYzv/uB3slDMMVhewShNkRZghdGgYnHfEocPHOanf/JnmJ+f5zd/8z/x5P0P8Nxjj7Pv0EH2HtyPyTOshAmCtZVVXnnpZY6/8CKpMrzzzrfx0Y98N/e8+71cd/V1oBNGVUVdNyRJFoBVE5jJJE3HUTAikYUcs5eTY0DJpYXjbu4bmsl5JUx3a4YTxgNpljIYLDPfn0N8wrkzZ7nmyDH+/Pf/AM++8DyPPfYI191+E3sPH2bVWS4K1E0V8mn3JGhjKAGyjCYxHL7qGI8/9STD0YCmquh0OnilGI0GKBVArNY6Tmyo8bKtK8rjJIe1DdZ60jSl2+3inIvFuRnnvwatgfyp3Vs3yz3cDqS8dsOUy1uH18O47/WKG3m9x24Y0yth83YblyIiojZ58fYgU3accFBKXfZ+3ml5J465MwnsbMzGtyS4nG2C2fh6j42AMgw/lnpO5GMyvtE57yiroYht+NwXP8e/+MVf4Pc++Sne/73v48673s6R669HipTlpsZ0u+Atq1WJSRMW9izhPAwHJb28iF8Xi2YX+iRVVGiatidRxZ5LpWIkSRip0uuKznZdjJqy8GcSOzIxM21dItUke7G9ubevmbr5tlLU9nNUfJ/3G27asE6uOOlRZZ2kddpB1quJ3DgASRAJ6x0taMb5lq15zwRghj5DJyGKo8FhBRqlaIBShFI8tXeUbX+lVjgUXoWeN5FLXQQD1Ah5JqG/UoKZjIsQZOyIlIDS+Ohaa0VQhNcaL/SMQQ9H9LWhbx2nn3+ZVx95ihv2HOQv/8Cf54c++mcxXlMOSoqii/eesqzR2gAK70N8hkkSnHPs2bOHd911F/d99X6+cP+9vPzYY+y75ijdpSVEwchZUhQ5YIGFJEMrIfWQOk/PCclwleXzFxmcOcvj997LyqmzfOTDH+Hv/jf/J972pjeH5SlragvdPGNYWUQcSZoHprjxXHPkKn78R/4K73zzm7n33nv5/Je+yIknn+W5x55gWFdUtcWKJ9WGq6+6ih/48Ed5+1veyjve9FZuvO56FvpzeA9rgxKdZhhlqEaWxCiKbg9rLReXV5mbmxt7KU0P38KmbaSL28njAkCdmGM5NSl2fbsP8SRZ2O6DwYAsDdNAWuDowUNce9VVnB6eZ7h8gblDB1jodBjUFYlLqVzDyFmKJAeTMBIh6+TsO3SQZx94kOPHX+L6q69C6x6iGDOQSZKECQ/rMUk6kWrL+uPTez9mKrMso9/vT1j/2Au8Wc7lxPzUg2hE+dd9cneznsvpCaitHFKvCPT5rYDs5v1zG1fH60lm7niCbmoZ/VRUy6aAeIcJjZ2jOF4fgL+RVdytLHQnQ5+tjIEm1/eNxxibAsx2Vbfuq9zoBus3gMD4Pcqve51z7rKNonY7+TEbszEbM3A5G7NxRaBSbwM0oZWFhkJUj2+AnrouZVgO+J3f+23+xb/6Vzz9wnP88E98jNve/hbSXoeBc2gDjRVq1+AVFN0OWiU0dYOIUOT5pK9yqhBUUZLpvZAkGu1b9aWKESRTN0BtLine9CYzs5tJmsa9hDJxSBWRCFLVxCxH1ndQtssbejRlvVMf0Zgogj+8jPsX/Sa9cdOfPQGWMcMOcFOA06v4GfE/j8biA1sJ1Cq4wtr4dyNQEVxiSy80XqjbAlNDCJDwiNhL2dc2OzPovsJ6Oj/Znm2PnjGgDJ7gNkvM/TTKkwoUJkFGJUt5yvCVUzx371e5YekQf/UvfZzvePf7yVVKXZco0SSJwbmwS5MkwVpLlqaBzcaztnqRTqfgmquv46Mf+W5OnjzBfZ//E940fDPX33oLeb9Dmqb4PKExGucUDkiUQfkGX1rs2jLnT5/lmUef4KWnnuH2a67jv/sf/xrf+93fz8EDh9FOsTYY0pSehYUFmqpBlCZJM/AR8C3McWF5mYP7DrF09zy3XH8zH/rghzl55jQXVpYp64pGwnGwMDfP/Pw8Vx++iquPHWO+20ecox7UOAngvB5ZMJpup4eIYjQY4jz0ig5V7Ntsq/5WOi2amI3KJTEMu2HSLy0kN/QCiwdxLK+ukOc55XBElnZYXFzkwoVzPP/886ytrbFvaQ8nXnoRW+TU/XmGjcObFCeKYVVSJAkaxYXBgOvm51kuMpxzPPfcc7zvrrui+zNjVYQxZhwZofV6Yx+1AaA559ACWZ7R6XTGmbfe+9CbrdNYpOvw+S2QQiM+9GSK3n1O5O624/r3jq8FW/TFJknyuoPbywFP6go/70pByBsJXDbrrd3tdrwcQ5+dtt9WDOYbsY6t7Ho6rmQzgL0Z+N4I7megcjZm41sIXF6OLOaNkPG8XrLcb9UL0zd6ztOV7L+NTNtoNKIoilCYuYY0y5DGopIkyO+sRRmDNorG1pImRj359BN88o8/xT/+V/+UY9dfy1/8jh/l2ptvpLO0hxqPahoGTY1PYg6jaJQL5XGmk5BVGU03jA79emOA6UNkQIiYkLFjbNL2Wm6yS9QUONVMnzPB7XacMxfZjfHM7yS7ZFK4TtXb42XaUCA68Uzbq04b9IyB5fRsP62z64TFFEKmpxePFx+klBLyLkWHn9ZZPILzRKYz1ANWBOebIHP1HicB3Ik21DrIYkfOM2pqaiVYoDEBWDrVZt6F9ddKhezJtqfS+3GDZ3CDFcQ78D6AfK0xWmMiY0mSYJsKp6DTK6jX1qjLEQu9Hmat5Gh/gVcff4bnv/xVbjt2HT/zl3+U73j3eymSDDsoSdMMrRJs7JkkbvMkCcfJqGrodXLm9iyxvLbG/FyX9979XjqdDv/sX/wTHn3wIY4/9xy33nE7RX8O08npzM1hmxpvLaO6oRqVDFdWeeGpZ3jxmee44frr+G//6l/lIx/4MNdfdR2HDh3BO8VgMALR5J2cUVXF/FJw1gKCSQoGowaTFqwORmiBvXv3s7T/AHd4T+M8tbVjuXK/6I/7fLVAXQniBHEK50GMwpgkyDwrG6Jg0CgVjtP2+PPixydsew5Ia9Mrm0vvtnIoXjd5ZAIzaX3oE0V5VJsjqw1ag7g6yIu1oqprXjr+Mv/x13+Nl08e58ANRzAGzp07R1XWuM48LtPhGoKmto65PKXIElycYDJZytmzZ8P3WkueFZRliTEmZnGGPt6W1bfehWPN2zgF4+h25zj70ksMh0Nuu+EmRISyLMmyLLpEbzCZgUkG7fT2UW/s9dc5t+61l4KDnT5H7VATuE2v9Vu5tV66HOsNnxyTuKf18UsblqFtuZwCz5uBme3A7rr9swH8bhaxsdn6Txuu+XUmY1xiaLVxPwRFzhbny1jxoid5lJNW+nHPqDF6s+08xpY+5kO1D2wFYi/9DD2+f60Hg5d+X3tvm94O05meG7f/uv0km++b3dY13+714W4mdWZjNt4I/NE6om91vs2Yy9n4uo8iz4MZjja0tZ14jxKPOIdKwoNVMxKU4pOf/ax86lOf4pd++d/w3u/8AFfffANXXX8tKk+5OBowdE1wi8yzEAIdM/TCzUzQHnTLVCRtIavHzKjSoRDXrblPfFxHs5jW5TWASjN2ed3sQu79BnOKbfLPxlKnDY6xuz35/bRctZW7RiDn1ZThT/tY7KF00SzIxz5PH4GDROmtIwBCF3svHR7n3ThepMGHfEWlcMrTeCito/aWKjKKFoXzglN67AYaFsRFWewGZmWslY0Fm7Ry4Gmg4vHWoQnyUS8Nw5VljG9YSBLyyrKoUl5+4GFOPv4sb7v+Vn7iL36Mu+98B6aGzBgsBh1Z4tD/GYB1C6ASpUmSDHSC85baWerGsWdhiXe97R10/87f5T/+p//A5z//BR783JfIOwV7D+ynU/S4sHwRrTVlWXLq1ZPUdc3tt97KD//c3+Ld77qbm2+8kX3z+yiyDrZ2jMoG5wSTdgCwQszxVOFcUGHiQkUnLKcUWit8nLxITADpSdbaT0HTuHE6jo7vE9HBpEbHnEXfyhUlGtfIOifejVBj3TPCDjef7RmY6f5f8R5MjPKIgNZog1dQ1RW9+Q4nThznD/7ok7z4ynGuu/VGDt16LaviWBZY1SkXlAkMuXfY2tEkBtFZANSK4Apd5KwNBwyHJXv3h40iEpxpsyxbp2KYjg0ZF9MCOI9Yh3Nu7DBbO0Epv16W/hpzIF9rcfhaJ2/fqO+X6d5q2JUk9JLn1dav2Un6O77mXsHyb3Zcb8XWX2n8yWX0WW62rYTX7lV0xWBut6zrTt8zA0azMRvfvGMGLmfj6zpcVYdizmikaVCGyBwFqahKEsBTNpWslkM+9ZlP81u/85t88Utf4iN/9nu5/s43Mbd/iaRTsDoaUgFJXuC1onYWbVJ07OHCt1mVoYZVKkSdKBNYMNPmXRKApWEC9lp32I3yH4Ve53K6cUzP6k7X4mrMJoUFcRtvqGr966cLqjH4ii9s+yHHUtYYL9KmEU6b8PgpeaxXxPiQ+D1aEUhDCREj3kcnWHAqsJPWB7bReaERT9mCSh/AqBWhcp6Rq6mcxQFWBXAZGFM/XjlpWUkmAGNMjbZA2E/cSbWeRDe0brb9fsHK8jKuEjpZSgEs5F3mBPy5i5x59QyvPvIUtx2+mh//gR/inre/m4XuPDhP0zh0EsTZYVIh5mNGVlshuMaOJxfSNCXJe5S1Y5RY5vp7uPudd3PV0SN830e+n69+5T7u/8p9nDp1ijU1JIuyw9uvv5Ubv+cHuP7667nhpps4cuQIvV6PLCvQkmAbR9NYnCh0kqK0xkUWMkuCW69Ghe7X1kxKwvKulWVgco0Zuz+2x6NoFT4zblLnJ33L7XHm3NjOaXyETvfATRfhMnVoTmJEtnfE3MnMpJWRjlmfKEkPTLunrBsUlsW9S5w9f5Z7H/wqn7v3ixy45hjX3XEb6b558A5vQ9Zq7aBqapq6omoavLVh/b1H4v4oimKca9me88450sxQFMU6pl+Ux0eHaMe0KZalaRqcc3Q6XbKsoCqH42M1sFbymkv8N9pQbzsQtptcxN2A0+0MY7bCD35DDyZbXQenr3eycXvLuhmQjcuh5bXvl41RO5u1P2y3DS+ZWNwlqFy37pegZGHsS6wm37jZZ2gZRwhvsY8Um9+JJk/vtrd0XcTMlozpDFDOxmzMwOVszMZrHCbLxk6gypjWJSSYaCiwrkYMvHT6FT75x5/iP/6n/8jJs2f4oR/9EfYfPYzt5AxcQ32xpBFPkqUkRU5lG6qyptBJ+Gw/iRIxBNfX1v1VRWBpmMQGJCowmdOmONPF0kSuurm0Z3zz3qYXbcubrZoq5iObOC6opgwvfHTUHJvttL2QbeGj4nMtUxklsdOv862Eto1A0Sqwmd5jleBE4VTIsGzweAEXf7cIDYomymStb7ACtbNULrB83mh8G2MyTXWJAeVQ4iZmPtP/pgC0ivtMRXA5kQB7hqsrdBJDmmh0XWIaR19p0kHFyqtneOmhR3nHTbfzo3/2L3LPXe8dm/f0enN434Te1rh8WmsU4TgwIaVlvI9tZTFFQrfbpxkNGawMsAbmF3ocO3wVB/Yc4p13vo3qYz9OVZaUZYgv6fV6KKXo9fvs2befotNhVJVUtkG84fzyKlplJElCkiUoDM55HEKS6ggI474RHWWDEllITZJ2ECPg9SSQPkqP8UG2EtJH9bi/z8djzSiFeDsG8juN9jj3Uw6xOwGi7QBIG70j8dgLoE7GklvlfXAHNpBlGcdPvcpv//7vYlPN7W9/CwuHD3CmHjFUmlqD14bEGHJtyOMxkmkD4vDeotr+aB/koL1eD2MMHkc9GmKMGcta1y37JlmeLsaQWGvpdrskOglGPmp8hUHEEpNpN2G7dsfuvFZm8YriLbbYd1cSY7Lje3boNdzpKxy77+/deJ31KkwybgZ+tlqerX7feC3f2Ie82bpvFb+ym3PqSvb5leRfbjX5MPmsrd+/lSR2p2Po9TScmo3ZmI0ZuJyNb8fRmtmoiHDwVHUlaEjwCpPw5Ye+LJ/8zB/zb3/ll+numeeH/srHOHD0EGdXlkEyrA+9folJcSJUgxEOIU8LfDTd0BFQpkqTGEOiDKJCf51WeiKLjQBUE8x7UArlJ4Y7Xm1gL/2Gm+QmBVkrsfSRgWoB65gdmgpT30wOu/EG3M7UBxnsZPZ4o7R03GcpUzEiUQI7BqNqwhKIBJbR+yiXlcBOBuAIdsyMhn+1EmpUiBbxntrZ8HrvggS27VvTG2e+w35uJa9KmG4mioRDzBaNkwB6yk5SIrsZjJcaup0upqzRlWNvmmJWBpx+4lnOPPsSb776On7ih3+E97z9LrTXdIo+SjSroxHz/Tlc3UzFn0TTJgfaC4kDrQ2idJjAKBs6nQ7dbh+hQnvHmdPnmZvvk6cd5hcKmANXN4Eh6/XAh+1hraWxntWVMjLEhguDAUU+h2sBn2i8D1JLYwxpmuBqO3UMhAkN5ZO4qTw6NSGhdAPTrdzk+NMqZIm2x+Y4aiay+G0WTvgOz5SpMdMpggG4hrNEs3NG7XqQsDXAbIF9AMGT/lAkgMos17zw4os8/NijfPmhB/jO7/9u0oU+TZpQSkqlwDqwXuGdjN+vnSPLEpT1pGiS1FD60OOdpTlZVqDQNE3JcDgcs9Pe+9j7ubW6ULynqWu893Q6HRQqOmcmmxTKk99l47Z5g5nN3RTnWwHM3YCDSy3Z2PL5S0G1v7SXcuPxsRODucXxtR3A2qzfcqv13Q4Q7gQmt9rOO/cxqR3Pm8n22jz7cudbrrrkk1pp/OYMto7vky2B7nbbcsuszV2C3NmYjdmYgcvZmI1dj8aGCADlBdGKpqlEGa3SNKXB8idf+YL8+1/7Vf7dr/0K7/ngPbz1rnfQ2bfI+dEaaa9Do03MPAxA0dU1VV2htabT6dA0TQCWxpAqQxrZDTUthYzZmWMn2NhvqeLfTJlztEYdW7rfbVGEtGznZgYPmxYALSvZMouxCI/3/zFAaIvzsVmPTNxhW7lrGznSAs1p5rLNqmzBpycwlzbGkDQuMJiNhM/3BCmtE48FKrHUXmicpfIW61wErcEQyCtZX+9MGXloJiY+46pn4zZTel3BtI5B1ppeJ8MOh+jacag7R7Y25Nn7H2Hl5RPccPAIP/PxH+Ptb7qTPM2oK49KM7Q2GDFok6MTwUnoS1TjtEzB2NBrK7Ul7xaQJzTRnCkNMx9gG7qdRZraUo0q8iKlKArAMGoa6sGIpmko8i5p0QcqhmtDjNEURZ8kAacSvPXBLMYJ2rRGGJ6mrMaGJSrmTSrRsQcT0MH52GHHkuLxMcvElGgKzofeWh8yMPGhx1Kvg3o7g5jpPFZ/GWBnK9MfZYKbaju5E2S8LkzINJak1+X4qyf41d/4dfYePsg1N91AttDlQjPC5RlWGWztqKqGytqQVwuYOGEk3pFnKak2+MZSljVLS/siK6yp6/oScLlVkTtllEIdwWWapjjCpEBmNOJb064pNmt6a4mOTruyxVbcPTh87cyn3vJ7tjNkeS0geN3vXo3jLVrTmq2Old2Ay91Ie6+EUbsSEL/VMm3OAO4sJd+OWd1qn22fccmmuuSd9vFO37GdWmG3x892MUaXO3kyG7MxGzNwORvfZiPNsgimLEqDIVHGJKzVQ/ncFz7HP/qX/4T/+qUv8MGPfIh3f+D9mF7O2Qvn6e9ZYHmwSn9uL+JdcDWN95ksyVAKvHWkJiHROv4M4HKj25+ajhiZut+alr1kAjAl/vRTmZObjZaBcc6NJbTb5c7t5qbf3mwlmvO0TMBm8SLTv7f9mONYkbbnsjXz8RNTH+eJ8SIh09JHiayLcljbgkvnqIGhdeEx57A+sJzBDXbS79QaHl0CIGVjMH0wsBkjIUAbPXbHbaWw7bYwSijLIR2Bfd0eZlDy7Je/yrnHnuE9b3k7P/6xj/G+d7+PsmpoxJPP9VhrSgwp/d48TjyFScC5IF8muPkaERIUqQQmTDmhKHJSowIL2TiM9fha6M3NUTV1iGHxgq196JssMpxSpJ0+g7ImrT1ZXtAhj0YwUFkXdXkKpZMgd1WA9rjaYV1NptLQX9luqxBsipLg8pvkSZBQOw+aseR7ev/7uO3afTwp3mIvJtM9wOumAsa7S8mlxZ8ots0Z3I2hT4uxJlE6YaF09HPSWnPx4kWeeuZpvvbII/yZv/yD5PN90n5BtXyROjU0GKrGMawb1soa5z1GaZI0JVWQKsiSFNdYRqMRoLn++hvROgGEpmmo63osi123/K3L81TvWcvetE6sxhhsBLVFqrFOti6iRV/W9fH1clPfzft36wx/Oa6er1fP6FYM5k5M4uUA1SsD5xsmSrYBXlcCfC8H5G3HeG4je13nJrtVPunkp+waxG7VZznruZyN2ZiBy9mYje1vvkzfkrZ53SYviDAt/N87lNI4JazVA/nM5z/D/+Pv/z959JnH+cs//qNce/P1VFrwTU137x4GVUlnYYFRVZMkKcZofNMg1sWsunDzy00SwtG1ITMJpo1WiOyEicWjiUXtNLBcVxRMMZYOCf1qImMHVjXFcLbmP9PrPrlpqgAM419u2m2wdcqNDGP73rHkUW3ou6Ttn2RdL2Xroigy5RbLlAHr1GNWogNsBCBWInhUCidgUeGfEurx80EG2wClDaDeEeSvLhoCTVyC4hfHvFIV418CKPYB1PkAsPxUaPqEHlMTIO1t6J1VIb8v90IPzb4sQS+v8diX7mP0tSe59Y638PEf/hE++P7vQJSm2ynwxuA9QTrtAijtFR10YtCSYPCT3s6pQinrFNTOIVWNygIQJeYHkhjqxuEJ0Rc+mh4JGu+FQTkMTKZWmNTQNIzjKrq5QSoDSmHSsInqqqSqK5SCVBvyJMdbmTpOArRWMbJBiIY002zPZixJO5kQYwVEMT7uXWMnoEf5LXvcpGW4ZP0xuBXvtpORz8apmPERKRpiuqSIsLR3noefeJGv3PclDh87xJ79e7B4VlZW0FmKTrLIgAf2vK5LAPIkJU0MufJ0UBSAHw6xwyGFMVx97ChFlgZ5uItSZKUD06tVmIiJy22mz2atEFHjyAWldOiTtT7i/phf2bpNt/67cYKlPZfD7zuLi18rc7Pztt+aIdqp6L9SFnPjtTD02et4cGkEN/l5yXduehO58vuX4rL6hzf+Pi2H3Q1zt9W+24op3Y0x0FYM83Zg73L31XSO8ljc3EaptH3ycf9tu0HH93yz7TafgczZmI0ZuHxNN783+v3f7OPrvf67uU205aGSKVDRFlFaUdYVaZbjCa6QiU5w4kgIGYfD5YvSXZhXZVNJrYTf+L3f4qc+8QluvPst/PTf+Vtk/S5DDaQGp0B5D1nOqLGgNd424969JEnI0pS0BZXRmMdEtkfZcONKdBLdQdXYlCcY+6x3g20ZyFbOKhFYaq1RWmG9ja6TQQbayhhdXFe0imYs00Y0EyOKqTprDG5l2v2QCVCUqb46IYBAlBkDSFpZ2dT3tF6g1js8gsVORYl4xCSB1XQqMpQKtEFQ0bHU0ShFozS1gsp7Sis0LsQ9VONjQMVl1JMK0LXmPBEyKkGppBU/hlgYZ1ERxI5p4ylGrEbIshRb1VBVdDsZqShU49iXZSwNRyTLyzx831cZvXCct3/wg/zkj/wYd735Lqzp4JuYuUb4Xq01udFxPzWMbJDkJSoB37LVBq+FRgQrLvS32pizqVogE/aRc3VMVAkZiF6Bs+G8LbRGqgqAURWlmgpcU7FSj4P6aCxBGiiQJGbMMoaWNDUFtie5ny0j3DTN+AxUgPUSXGUvOUf1RGIMIZqjBZW0/pIT1+LNgAAE5si339bWlONXbMK2x+7ZddcUPzGcwrVmPjocy2Lx3pFqRZ4ZVlYvcPbcKb785S9w+11v4cCBAzilyIo51poh2jtypbhYjbDlAGxDmqb08xQ3GlDg6WYpaTlicOYMTz74AO+89XYO7J1HG8GJ5eLyMsOVVXp5AcCgKtF5SikO7UJ0jk50kHyLY67XZXT6HK6y5HmHNO9hLWRpl7JqyLIu5aiKEukWOkvrlzwBIONJJ3NlcRXTETPtvt7Yw6gmoHgjKJr+jK2A6E6GNkrcJcBqJ1A7lha3v4eG4KlJt7b/Xq9Dj9M5mGw45jYDat7LVF7jZOJlvKzRRlmUjPNbt7vxTR/H4yXVenyNZZql3Liu3m+4r4RlslNtEtttu2l1SttisTFHczds88be0JZIVxsZ0w0mtOL9uslWxSR7c+If4GOsUZhMDLc0N3UVar/XT32y3t6ASO9Q/6hLrz3CpRml0/tuXdbsrG6cjdn45gSXs/FtNqbjyxTYppnq+9JjWaNzDqNV6Ftb6KvhcFUqcfzep/4LP/Uzn+Cuj34Hd3/w/eRzPSRLEKOxShBlMCawC8opbDQ80bDOmMegSESRxBtx6w47Lsjav+ONvu29vOTm1jprmvVyWhVNZTITXCKdc4j1OLPB6VRNLFFkKh5kHQZXflLkb2AmRavQG7fBsEU2OMKywUl2mtVs7erHBj4QpauxB4/1jzkUXqCRSRRJI1B7oRKogQZoItMo0zEAssndXyZdekJrDtGa8kzdDNV0b2YLthX18jKIMN/v008MiXNo4+iUNf1Rzde+cC+rp07znvffw8d++Ed5113vpki6DFZG5GkBaBIXC7Kxva8PixWxrN5AmLb5nmb6kPAyxr5ySREfJgD0VOD5NNOilN/0RBH8+GAQLo0AuITxl3i8bFIejY+JXbAwk6E3+V02/fxp8LKT0cpuCl4d2Ts1pvYI+ZzKgHZ4BcPBGi+++CyNq+n0OqRFjtOaka3xKKSpSdOUXppSFTlSW2gaUtfQTQx57ehYR79IefqZ5zj/ygne/4mfZs/CIqO1AVmnoLINvlU8pMn4XKE9ThVjWbKLgMD//9n70yBZrivPD/yde909lsx8Kx7wsBIECQLcwbW471VkcSnWXl1dLXVrpDZJMyOzNhtJI9NINvown+bT2IxJNrLWyHpmTBotLVlVdVVXda1kF6tIVoELQHAFiJUgFgJ4eO9lZkS433vPfLjXPTwiPJbMfOAa91lY5ouMxZfr18//nP/5/0MgeE89iTS0ARFIU5mRBMZnq2RKd8/lUao2KmD8nEjQBkHmUTwlT9JruE6BNILurvnX/tndOrBMnXXVts2/thFW6/j7Nb0ldhyPZb6Yy97fpUr7Q7ulzx2nWoQvCVJP6bL1Oq/T+zwLFic+HWPfWCddi2Pb/p4f5rHZju3Yji243I4fSspsMfgwxkYKpq9iXxmBLFHzXFVpRi6SC//LP/9f+cf//v+Wt37gPbz1Xe/g9PlzqWqmSbFUMVaiEqZXQvBN1TAzNlYtbUZubASTScjHEP9eBzTtm3SjEjvXD1n/NErjI2halFqvnlCLkKTX1KPxlUQToKGprGorMyzM3ZTpUj+URL3TGTuEIG0wEilk7b83vZYNgKx9I2UuaJtacYQALm3cWEPsvTQGp4GJD5S+YuJTFVTDYkVq/qYuMsWby2iSYiNYaiixrVKYKjqONMdzu3sMjSHs79OzGQOTU129zBc+9wVGz7/AO97xbv43/+jf5m1vegdWMspR7HU1xpCJaWig0hz7dH5btNKu4D2syXC3g9F14hrrAs/Zb1oqj3m0oGstUDiZlYXXcPQlwsxWnrSmZrb2OUi8psqy5Fvf+hbGGPb29qJ1iChlVWF7OV4DRoW9fg8TBJlUVJOS0zZjp+hxemePfDzhC3/5WR78yv287U1v4y33vIVzZy8wKceAYTwe45yjKAp6vR7OyILXZ9saQ1WmCaUOQFJXqTY/T7pkLmw+woaFiqN+dlcP4Kxvr8zO1nmBnTW3CTnC93f5ay6A8ueSsgABAABJREFUxY6+x40B1DUClo0HrKTEYMd2h2Nex9dCaKhrf+eEjJv/1D6YXe0v7Z7/LpXZJSkl6qZ61dlqb9d+CXKs83aSPtvt2I7t2ILL7fgRD9O66cQb6uzfbZZFyBB8rCaa1MHkk6l5rycv7l/S3/2Df8F//J/9p7zxnW/j5977bi7cejPPXHqebDgkGEFNVJWsg7f6xpTbLFqM5HkElln8f6YRSJqWp2XWAoCSMq42ed8ZjZYgRkGtmVayEkCpaUh1oDk1Sg9kWYZNFQ/nYuUktL7DaFf3UEdAkg6in4NtTS9mep1L/ZH1GagD4QZ41q+pRXxSv51nKuqirT68qEobK5Uh+VZWGhiF+J6xesrgGTtH6WNfYQNuFyDmyp1sgq76/KkxUVV2HlglYZlMhN3BkB0xZBNHIZY9k3H5mR/wyH0P4J5/kY984MP8zm//A97yxrcyGTku719lp7fLqb09tIrU6zqJACElPOr+Slmo+s4HUeuUNLuCm6OBi+XPHzU4Onow+sMRjFkpTDLn+NEAGBGq4HniiSfYPX2Kwe5OTGyI4DWQWcvAZNHF0+TkfYsZ7lLKmFNiYTTi6pWrPHT/1/jOl7/K7TfcxD/+R/+YGy7cSFUpeTYEYh9s6apoe1JEISZmaHSLAlzz4HKenthONr0UoK+dyDK6un1hU8/AVcqky8RYjpPYuFZzepmgTVeisBOMqNRa2ccWAVrrA7oiYbDJOT/u+zZ57UxbxhFBeFf66yhKsHXVXta8d9NjtK5qvR3bsR1bcLkdP2Hwsi3MM38rCOoawJDbCOS8i8Is3nu8TvTP/uoz/If/+X/KzS9/Ge/5yIewuwNenBxidwc4EcgMYvP4MS6qm1ox5FmsJtZiPUWekxkb++ZCrBRKatuwiRIrLQP5qDhqZsCxSRYXNSC11s4CQAAxGCuo0UZhMssyvPcc6gjnXANIFyo7YS7gMMyAw86b61wFpQl0W4ASjdS8KNwTRUei1Ygkz0ppbEl8UIIKXgXvFZ+EeLzCJIHNwxAYB4cTicAyRIDpE3CV2KTU7d0HM3TXGRuL1BNaH29vZgEyrd6lXJUzwwF2XBEOrrBb9Dk/3OPyU0/z1De+g3vmOX77N36Hj77vg7z27tcxPpzgKzi1c4pB1iOXnEqqaRU7bbMI02o1ybpDVvectc//KuP5o44ZcZNVtgPaRVldH1SuB68nAz3HMbBv/26SWu18oFv/ff/wgGee+wHnL1zHcHeHMng0y8BGW59e3kv+kjAsCorhDmVQRi++yBPf/jbPPvoYj3/z23ziwz/PRz/w87zpdfcwHJzi8ov7nD57ChCqqoqWIr0ca226plJfsEjjCzgDWnyIfbgpAdUGl9776KP7QxImWVW1VOnOH7QrQ6uM7NcBBxHbMd9mUjNLnuMIQISlQHcpqNsw4TEFmzQ/29t9lPN3EoB0ksTNZusLK4+Vb6/P7b/Xvbo6u/pM91VnqPu6tII59cmcTUuvTkQdVa33h3Hct2M7tmMLLrfjJR7zqqg1zJxWNBtkFP9WVhHA9XpA4F999k/4T/6L/5wLN9/IOz74PrK9If0ze7xYjSgGw8bfTxMwCxowAbLc0MuLhraa2UiFTQ6WDfkmT7TYug+zFnWxqT/TWjsjvlCLJRhjopKnMbHyl6qldVWifu1gMGgqF3WQCrFH01qLr8pZcNKirM7fAMPsoZoqweq0YhmSx2S8kdupqmxtMxJCfB3aWI8oUQ3Wp+ecRkEfH6AKHsVSEShDSD+VcQiM1VH66HFZJppsYDXVaulzOvW7bIJDSUIeTcDRSAORK2Sq5KWnCMpu3uOMZFx94vs8+OX72bEZv/jJX+E3f/nXuOnCjWgVQcLp3bMUWYEbVYTkldjIgpjQVMlqaqxtCc7IBkHYssB700Cz+wq6Nv1UP0nBlHYIiEwTJdPjcfnyZS5dfpEbX34b/eEQTSwGI5bSVQyKXrKQEXJr6OUZkyzjuaef4b7PfY6X33Aj/96/+Y/48Hvezxtffw9uAsEbTDZETYGKjZYiajDWts5d2/9xqpQptZdsqlx2gcsQApJF1dhNwclxKZlrK2t09xpukoTYpA9zmf3FOnGaa0VBPaoa6kKSY83xOc68Pg49/rjXz6aV1eXWHxt9V5NBFBFp72OoRcYWvrM7ebXYOsEJ1s6TXRvbsR3bsQWX2/HjCiybZozYx5fs2ZtetRq6BVVcVeFdqb3hUPCOe+//sv6X//Sfcqie973jbZy98Xry06eYGOXgsGIwHDI+HMdgTQMWITc5FshMTiYZ1hKBYgtYZiaqvhpoAGddpayrkVkCfxZZoL62wZ5FUqWuJUTR6sEUY6iqKlLrkqm6MSYK7cxR5brAJS2rkbbvoyaOcQihCRBjUBsrk7UATn2D7+p/1MZmRPEIPihOYpWyUpJqbPxZaaBSmAiUqkxUGQdl4jxOFF/bmhiZyW7PVy67/BBjU2ejpDQD5Kcqi6ERXMpVyDTQC8DhiDP9IXsIh089y1MPPsJ1xYCPvucDfPrjn+LMqbOIGjLJGAyG5Bi0dDGhkPpahVSRhqTqS6P4i8qU9tja7iCzsY8uDbym4GOxsgKzxPH5sH+xo3MBdNXCMHI0QLlJxv9aB/fHAb9NZ7Au/j0IuBAoq4ossQOCtfgQwBrUx77nwkTroSwoxliGvT55VXLpiaf59Ps+wH/wj/8xwSnDfMDVsmRSBorhLmqz5vzE68lGoZ4QV676/GqI2Yjm/IZ4HToXmvVgvuey/rmOHluD11XCNGsOavfTSz4itHua52bjkg1cAKqzSYHlwPJazLFldNxlv29CT29fp9Oq77QSN1dkPdIwOrcO1P27ejzAsy6RdxQwvck1Od++IekFOt8kKywkSFf5usqMrvzs9b8ymXcMCvaqPvjt2I7t2ILL7fgJG4FZsViAylXY1O9mcosxcbV/8Lvf1f/fP/+f+Ny9X+QXfvkT3PH6VzNRzzPPPs3e9ee5+LJbefb551Cx0dheLP28R9/2yAJkKlhNQBKJ4FJMApaGvKUaa5AILtIjs8nzsq5qGkORZUhShA1JDbL2frQIpCCxBpZZlmGM4crVq4zHYyaTSaxqZqli6R1VVTV9ojOAj6mHpcosSKupq7UfpfchUpOS92X997qgElphYd1PWVctvcSOIicpGJbYf1kR980HqFACBodQ4nEKlREmBEpgjI9hgQhYQdSgQdeqhG4SAM8EcInCnIdArkovQC8op01Gv/IcPv8i3/vWQ+yq4dc++kk+/sGPsDPYIcv7eCcU/R4WoRyX7O3ssntql4P9/URRNEkdOPkWmmmFWr1u1K+2/G+LQc7mAGGqFHotKxubVpA22caT+yiuea/Mfs4sRVzo9/vTRESyi/DeIVmOpCSOZBargvgKa2BvOOD0zg65hd0856knv8ftt96Bcy72gGvGpFLUBpQ82uek69SHME3ezCVIZgS10hphVgTGL0UlcuPXy/HOz3GqRsvm1jK11mua4DwB+FonRHOUnsh1PqBdPpgvRUXz6Of6xzumOOrx+VEf0+3Yju1YAS6Pwnnf1Ox3Ozbz/vqx2+Y52kunX1TTi9gGmR400MtyBDg82Nfhzo5U3mk5OeBf/Mkf8j/87v/Khz7+Ma5/2W1UxjCqKrK9XSoRyiv7iM0JPiDGkpsiQkWFwmZkZFiJSrGx90nIMkOGQYIiBvpFQUgm8RYhsxl5nseHjeCwl+ex0uh8IxKSDQZ47xmNRmAE5xziQ6x05rH3s65UllX02LR51gSetdBHXdlse5yRrEVmQHntYzmnJFhXCkJIlgUaAVJdaQs+Vll8osPWQDMQLR58EvUJGu1EHNEcvtLoh1iGEP/mA06USoRJUEbOM9bARAMuBfWQqKTauLpFOxZWe+UZBTE2VrSdS56BWRME5EWP6spl7M4A4xxZCJwu+lAdMFQYKvj9qzxy/zc4pZZ/89d/i4+8530MJMNqhgSDtRkSIvAf9ncwapiMx/SyHEfda9tap5LaUgietmK+IAuVCl9XMlo9grP7uhgwbhL0rg2K1KwApO3PcyvXkpq6uRTeGrMAiGZ6ZNdU3gJHCOTmlaSZqrIaYxp6dAgB7PSYWGu5cuUKqsro8BAt4nU8cQ6vsbJpsowsy8jFcHD1CjfdfJFXv/pVfPvb3+app57izjvuonQVYgcYm4MzmMzik8rylStXuHD6JrKsQEO1AH5FLN7F69CYjHIck0lZltHv9+MaIVnzHECe1orORIRqizYbTrJAzyYRpPu+rOvsApfM27bybSdgpEPYpWYj6KzFk+lQ42Zt3+TmPb/tz2gre6+8364SmlpCIV5VDQ1z60TzfiPNPVLRzoLoegrr4nno2r9New9FFr2jFs7/XB901L2Tjt7L2M7eWDHVjIvkcylJOK/5/KAzZ3dGQLzDx3T5SVpOPW+2a5622xK0sxteF6sThNtx3Fj4pHHvtkL9EwYuX+ps63b8hC4ITHsP657EGXGajl6T8Xik/aKQoihinS2DP/qTP+Nf/Okfc/H2W7lw263Y3QGVCD7LwEDpXfyeVF3KJD5yY8mNJTOWHIsRxaQALauFfYyNnnWx1BcrlDKtNvbyvBHgsdaiPtDv9cl2MpxzOOcSDVdTBdI3lQqnAROiP5dzDpcC97b6ag1IavXX4KMITg3+2sbQCtHSI4FL34DDKTW2UY5t2480wHO2yhlqLz5RAoKXWIlxolSp19IlCqxH8ZIAp5jkZRkYecdhqJgQCKYFHrQtT69ouAbCMqpUh4dkO7vgKrIAfbH4q/vsieW6oqB67jLfuvc+ru/v8Bsf/RRvfcM99KWgb3PEZATJ0LoyXovzqIIPhJaIk8z5oW0qdX/Um9y8p91atdY1FabF53VtIvAolTNdZhHzw1hP6oq1yMxuRbGl+PtwOOT06dOUZcn4cERx/iwTUap0rZrhEJvlURzKx57hLLOcPnuWu1/7Gv7yj/6Ip555mtKXnD57gR+8cEAIJZLvIFnsuK2v8Ta4VlXESHNtEuI1XPdc1muCMW3a5uxxnR5OTQmjaQWURI1/qXrLNq3gbEKf7gKeJ6nOHvW6Oo5IzlGUSzdNBG1S/V/Xj938XTcLjl9qgaDjqKyG5eckpvE6/t7V63rShHydG1g1R4yYNfu+rXJux3b8WILLLbD86R7t4DuEEK020rDWTFGOmc30mxQH26S+GqpKFSv3ff0B/sff/Z/57tOP86FPfoK9i9dRGRgrUBQUmeWwnFBV0XeuSNYiPWMorKFnMnITKxQWIfgKkVixzCUCTKzE6qUP2Cynl+f0ej3ypCYb/S4F8Uq/1+fU3ikGgwHjcsLly5c5GB3O2AzUN6oaTCpTO5SQ7D1UWhXHRHf1SRG3BpVhTllPRAi+Bo0tqwPalcu64qHT3ssahKYYJaq/1p9vEjU2RAqsRu9KpzXAVByxt8YjTNL2Vgrj4BlVLqrEGqIHZZ2ZrR2ztRUoh+WBlGmpC7YrFO00tQDqPPlOhh9PyAlkldIPytk85/Cp53jsgW9zNuvx0fd8kA+/9/1ct3sW44Veb0DlYjUZmXqVIgmsxxJBqpZoOzKaOf7z9N5GVEmYORcyq0s0c4UsC7Q3EUlZVIOdFcRYlyFfJ9Dy474+t6sg0+2N50yCsjscctutt/K9Z5/m4OCA89dfRzU+xKeSg/ce6fUILiZNDIpYy+7eHq9+4xv50z/+V/zdfV/hPe99P3unr6PXywkmRwVMEsaqhbgaoR7RRI2N61us3k3tj9SHhhYrdjkwCXVlX1pX9By47D7XRzqAK/sC9Rqe/q55rroIPBfnnMxdO+1O5rDx964DWusUbjtBiBqWum7O+Dgu7kdcb7qv8TBfoVuilrzOiqPLe/moAHo+2bWOZTZfmZz/jLoto6s1ol4/TQOiTWudpFHobr1j5fleCy479q8T9DN7Hpq/bym027EdP57gcl22aQs+f7zH2ixo42mVrEO8b/rV2otzu3JpWgDD5rm4yUSLXs5Djz+if/LZP+Nz936Rd3zo/Zy/7SKHIVCZCECzzCI2w1qPJvpr3+ZYYyiIVcncCLlAhiSqoyTHrHgjjwVVgzVRzKfIMnp5waDXpyiKpgIRfMADvSz6YxZFAcCk36eqKiaqqPdUiXakJtIpfZh6TNY+kvO9lI23ZKsHcsYgvnXDCy0LDJVZYZmQAGsDeBpEVvdfRqEdL4oaCCGqwgaUSmPF0kmsWFYaqzp19TKIUgpUQSg1UDnHgXOUweEScUtDiNUbWXIT3qDq1gDLJRUykxeUhwf0UIogZK7iXDFE9g948Mtfo5g4fuXXfotf/MBHON3fAw953sN5BZM1FXSDwSaLEVMLxABizBpgd20qR5vQ57qrt6YBxMcZy2h/J9mPa7lmr/ssr61zNQPMAiHEnsu77nwVX37gfkYHB7iyYnI4wuQZmbWMx2OKokCCkllDCDChokQ5d/Eib3rn2/nbr3yJbz70Hc5fuMhwcIayUiZuQq/oIwijySQKZZlFinOtNlyva9o67uo8tm9n/W/bcz8J+kyvaV24jk4KLrsC6qPMpU16aruum+l32qVAZ94X+Ej3nRUA6Sj3sy5w1uVpedw+yLXX+hJQ2QWGjnqcjtMbu8k13r6Xz+9faK35npg8nnuvSnpxvfYvO7Zd/z/qHNEVx7e+R7UTtzMAk21suh3b8RMFLrfjpwh8MitgoUsi8joI09b/CYqrKrV5Jlf3r+pXvnY//8M//5+56Y7bueWul7MvnkMfKHpDjM1xwUPwiBoGWZ9B3qdIfZQ9DLnYKM6CIslr0bayrCEE1IfYe5Xos/1+n37Ro5cXZDbD2tm+FWMMzjnG4zEQ+6QGgwEYoSzLGHimbzDJlkRlNlgJaENvbbajFVRJK5CuKawLWeEFhk4d0vrZm62a5GVZ5/3DLO0WotWIRt9KHxRHosRqwCOp9zJWNCfAxAfGzlH6QDAWK3ZKx0VTcl6mnnmiC7QuWgmFGeXVNrishVlalUtrDKEsyY2lCIHzgyHmYMLj33oQf/WAT37sk3zg597FjecvMD6c0B8OsTZnPJ7QHxYpBgpJCVhT72TsE56lPXVVLOK+iK6v8Gh3kSLuT6jP8SzAQJdn2eMTofEoXR5Qrfa3XN1PdTRwcSwQcEKfzLrvMrIB5kVzlN3hDq9+1V1cvXyF53/wHGduuimuNQqV8zgNTCYTRA2SWRwGYywH3rM36PP6N7+Fbz3wLf78s5/hLW95G8PhKQ4PrlLkQ0yweITDw8hUMJLNJM7qxEVXEGrUNP2gs32rU3psWy22rshKq/p1LUB8uydyfj2JYmS2+331fqw7f8ueqwHDtUpiHhNgblLNPGmydZWvZpvhUCcjZpeZlPzUzf1xZ6w+QlhJXT2pYNNC4mDusg7zrak1SJRZ70uZA5j11GhU1lufP3M8ZXXyYP01op2VTmklxdclArZjO7bj2o8TdyPPm0tvx08ZuGx5uqUbncxYdszdMKfWApHWluWFCMJ3vvMdfu9f/D6PPfUkr3/7W5gYxecGipys1webUVaesiwxCrnN6NmMwmSpYhmBZTQPkAQKQhMENpYjQG4sg16fvZ0dBr0+uc2wSTk2yzIGgwGnTp3i7NmzDIdDjDGUZclkMml6Lp1zjMuSqqpwzsWqbQhN0BZCoAp+pt/S69RbsqlYJv0YrWXpZZr5920qbGNRQvO3maply3akBvqBaaXSJ/AYPSwDLm2fCx6XqLlepiCzDJ6Jd0yCY+QrRr6iIirTSu3zSTegilQ86RTDWNZb2QaX7bUjVBWDvCBXIQ/CqbzP8098jx889gTvuuctfOIDH+HC6XPYYBj2hqgKASEf7qDGtj4zzYXa0iRmN2bASufadYTYrAuAajiaGusy0Z5l27hgYbPB46jX93Hed03XF5ZUx0Lg1M4ut99+OzfdcJGnvvckL75wiV5iIJSjMUaEKl27VVAmPhCyDG8MmufcdPvt3HHXnfzlZz/DY489hq9G7PRydgc55WgfX1YcHBzigo9AMbMz1iLaEey2K3J51mteH0LY2PT9Wt4z589f+/8nnSvt+3u97retmzae6yvm+FHB3kxfbMdxXHdsu8SrjuLzuel56NqeddvadX6uxfW57NxvOj86qffCydcaNdfsmHddA7NV9rljve233I7teMnGS1q5fCmkx7fjhx/81XRYVVVjjLSz9a2U5vSGGWI/XhSvMTz5+GP6pS99iT/6V/+S93z0g0husbsDXFGgwcSA0ClBoWcLiixvrEQyJPZSIuQytRWxUYoQX3lsNrUWyRLFdTAYMOj1kj1J/HueRZXJxqOSWKmsqgo/KRlXJZOqZDweM5qMmaRerJAqf3XVsQF/CWyGBG2W3tzmbmZB5v7e+n/QuvamTZZ3NhBof398VV01DRrVX31TuUwAE8Wp4EXwGgFn5QNlUEYaLUe8tPwYNTqWGgUNdRARmnPbFQAYXREYLLm52+R+VoilEKGfWS498wN+8L3vc8fNt/GxD36Q22+6hYEtkrpvQelBshxbDKjcBIsSnVpixUi0noupmoSfekUy9Y1Uw0ZsxNCqsrZ2ZWHfNhXkWawUrAtq5VjX7BFevRIEXYv1Y2V2U8zCQRWJPdMq8f5x8eJFPvzhD/P7f/7HXPf007z8wnnKyYTgPaJKVVWQKomlcxRFn0lQxs6zd/Ysb377z/H7Dz7M7//+73LjuQu8/NaXoUGZaKAcTzg4OGjo/oLBmHidrLs5hhAaS6JmX2XaVyaNfyUzPxePs7xkx3fBO3TJ/N4EEHd97jpQ2dCCu2iJc0JO6/bhKP2Fm8Yj2j78snhltFkqzPdhrxACmgeMUxXZ7srrwnlKdPdVYkrXIh5bJYbTyWIw0rkq6cJ6WB+yuaovhvpjGly5ADCnx2b1noaZ1owuyu/83FlgamxDvO3YjpdkvGQ6yluvoZ8ecJmy8lov3LOVy+mtRhRsiIbJogE06MGVS/rC1Uv8L3/we+xeuI6XvepVDM6e5bAClYzKBQ4PxxweHiIKw36fQdEjE4P4EHsrFUQjsLRN1jwGdRI0KsnaLPZO2owiy+kXBf2iR7/oMez12d3Z4fTuHnvDHXpZjjrP4eFhBJLlJD5GIw4ODjgcjyJNzhjEmmnvY6syUYsZhDaQTL6T00c0gY9gLym0tquV9et1+mhXLT2zGeLa4zKk99WV0vpz6+91rf8776kUSgKVEm1egHFQRhqrl5UG1ApqJX2um+1RCot9kyxVXyVSFNMDsR1ANESVX5Sd3CJuwkBg11i+/+AjlFdGvOvNb+d1d76GM6fO0CsG0bDeGM6ePcug30erkkLifLAiGKJnKcTvbYsIzfS1SWjk68XMCiyFDSKN+vhPgyo/Q4M+SlXgWlRL5pkj8z6Mm17f2uHjuBa4CMf+/IXKU20VY+o5b1EM49Jx6tQ53v/eD3Bw9YAXf/A87vCQcHBI31jUBaoyVuaDxETVWKLq8dXJCLUZt9/xcl75qrv5gz/4Ax5+5CHG4xHj/cuc2R2g1QQ/GeF9BUZRCyp1siZd0zU4VLAaEPXU/0yWaLQSFs7p9Jx0HCi5tvfHZVTRhePd+ikbzM82a6X9WNZL+aO6P3VdP5vQY+vTMP+zEf6qk2nLfh4jHlrHcpgH5+sqm9dq3syvKe37nGkdn7rlZdMpPJNgTRsdaJD76sTcyuMvnZZNy4519zE2L3UovB3b8TM5snUL4bqM2bqen+Oad/84gauTbPemNKkf2f5Jd4N72wuqAVTGSJZl2ORZ5bxiEtXTiIFQRWl+7/HVWG0/5+DKPl+8717+5HOf4eN//+9hT5/lavAUu2d44eplDEKRGQa9gl4e6W6IjyDRWIzaaDOSKgpGTOztTMGerxzDU6cZFD185ejZLNIsxZKpMOj16OexktkvekD0qJz4MaFyXJ6MKV0VfStdhfc+AkIffS/r6mQzn8Msjc8H14jrxPNJ42HnQ/TfbIKyxs+PJmhztR2B1NYkvpF6FzFUvmoor4hEKqgF5zxOPc6YqRVJ8q6M1FfwIlTG4Aw4MUxUGYcQVWHVMVGlEpOy6tMoog6GVT01tbTBZthpQBACkk2z/iYI4iPAmwl+1IAl+oQm0CsaKELAhsD5fh99/gqHVydcfvxJ3v26N/GON76dC+dvpHKGzFokF6qglOMR/aJPP88Yj8eIjcfJSpZ6LU1DzTZa980tAkiV1ElrpAH12romG4CYep6aKnJ6v28y4nHfFgLzFARZOweu56pXgl1ZqfQaFgK+pT53rWtY1lUg0k9j7Uxg1d6WMLf2LVD6SEqosmqdW2FfERSvfkr5Vtc0cAWgCop1wmBvh4sXb+FXP/Vr/O6/+gMu3nQjN91xK0EMVyvF9gfYXsGhryA37LsRvcLE+ULAFDnv+/AHeerxx/hv/9v/ljtufRk3XX8DuYVdq7z49PcZDHN2z+5xMDlEdgZYG3uxte4vCw68o2cMFsXpmGA8eRFtU4IEsBlGTMMiUAKFzVJQHntr53vzAicTlVpUYJ2tGHUJ1JjWuasp5UsD8vbPTlGvgMj6+EBa7IxptVYWVJnb95+UbWi1XHSIvgS/8t5qWtdG16x03oMarIkVNSuRTWGMJDvceH6SnlvzU6jVgOcbq2XlsfCtExf7MA1m/gy2k0UhzF7Lizu5Mo6w9flPbQyNyE7ahlAfp7ZA37yXb0ogL3ZCJCE5WaxWhFR0TOtncwLFIM36jMzoEiwXRarn3+LP2IIzVQmfF/eZsgr8TJ9z/M56bZ7/2Zp/C6dxPmG37eO8VkmN42CF7XF/qeuL+pJ98nbAz0RPadvioisrPF+xbJROU/KwkSZ3DoJXgxJcxWNPPs4/++//P7zhnW/nhttvi/1QNsdhyIpBBByJupoZQyZR5dXW3oX1z6Y61VrmQ2BnOKSX5Y0y7LA/YHe4w+5gSL/XY1D0GlEfK3YmuHDOpV7JVFn0nipl6TESfTA7FC9El1Ng66y+Z2qePQtqFi/b2rqkrmRqq3ezfq9CU9F0qc/SpV5LH1KfZVMdFTxQEQGtI1YrSwJjDUw0UEkS9pEoChS/P6RqTUjAcv3S0QksgiKJbya1H2oQQnBososwBPAeW5UMBHrAC997kotnzvP6O1/Dy266jd3eTppcNj1SMKIB4wO5glVJVdJYMTVJ7MWsXRNjYNg+9u2b1TrxjfZ7utaKmYDtBOtL3du2QLPbsDJ5klvAJgIkAV3b67T8q9v7HWaOXSS+GybOU5Wel99+B29/689xeucU37r/AfRwQq+BKClZowEvPvq3GqhEuXR4lZ2zZ7hw8QbufvWrefyJJ/j9P/x9DspDrlx9ATcegysJzhHUkeWGw8mIzNiZ82cgrUGx8h6pjqGxv2nvw1ECn+P01K7rI15VxVlQtF1R+dtktCuZXdfASxGEXovkbr3fJjEf2leCtJJn7Wpvu8ZljCEzJw+fuqrBcwJ6y1kOxxDt2uS8LFC356qWTfXyGInsVWHrMqVf6Up0dP2+op+5k1WCZzu2Yzt+NLB1Cyw3EAb4SQeVi2G3zvi+pSBXOik6cwt8CD72HVnD1fEhDz76MPd/8+u88u676O0MKV1F1isa4Zzc2KYH0oqZCaaNMeR1f6QoIjr9u8b+v35eYMWgCRRaGxVii6Igy6L6Y5ZlWMmaCp/JLDbLwBomVdlsS1egtKA+JzSgr00Z1Tn6WFegNU9dnPncDjpl7AOzqZ9MCIGm/7UBsd7HvkoFH+KjFvWpKbMBpfKe0jsq59LrQ7MfC4Fn483mpzRS5msjoQGSsZIpSdzGzAAvY0wC2Np5fAtjsV45fPEKzz/zLK+84w7e9IY3csOF62eOYbvPN4QIohfEpFbYJix7ROsSWQic2o+u19T/75ojxw2uV4mTHJf2etK1oAtsbypAsiloWXa86ucmk4qi6PO6172Ot73lrTzz1NM8+vAj+EmF1YAJHvEOX5UE5+NcFEHF4MVwdTQm2xnyrg98gDMXL/B7f/CH/PlnP4PNc0blCMVTVmOyzLLTH2AUMmMIyeu2Vmle3BezlKGz6vx3iYyc9LFu/q2ii26SDFgH0jaleW9q9bHs+B3XwmRTVeX5JGGXYMy1jgnqnn2fKolhxXNxXssMsFzFHAh0O4kuu45/VPHVSei+TRVSzQKQXi92tbW63I7t2ILLHyNA9tPYU6otY+8OSmx8yHTKWNHZhTmKNyiZFW/gmWef5c8+85fc+dpXs3PmFCpQBo8YQ1VVDWjIjG1ApE3A0rZoXbYO7ltKhSLT56QGwakPxKZK53Sz4jZXoWIymVB6R6lRRXU0GlGWZaK/ygxttUqUK+0IRDp71BLAVB8i6KyzvR3gYBUICu2Mdk2/RZMKbASTNUD0qWJT+1o2fZeiOI1VyypVZp2PYj6+AZYhVV1C83tdsVT1m911U1OahEhxqyu2dSAUiKJOJAuY4D0+VAiBwghnen3c1UOefvQJzgx3eds9b+Vlt91Gbi3VpMSkY2fFNBTTBlwb6bR1WRcAHjXTvyqIXFddeCmB3yagbdPlf5PP6bS82KCythK0SFeAXCsVCyYYMjFcefEy506f5RMf+0Vuu+lmvv3Atzi8chXrA1YdRh3iHerD1LLHGLL+gGevXmGiyg2338Y73/d+DnzJP/vv/r986+GHGFclWVFQVRWZsfjKRWaCj+uJaYOKtBKpCqrS2Eu0k3BdQGoV8LoWoPL4892sDOqXAa9V83DV+b9WvYMnEbS5Fvf1TVRmN/mcmItbf35XKdCqHP17N1XSPUosdBI14mX3xU3m9LJr4OgeoNu4dju2Ywsut+OaZw5X3SzaoK5rUZ72tWjsrxDhcDzmmw8/yL/8sz/ljle/mp2zpzH9grxXULoKp4Fhr4c1kJmIPzKJFSHbqhQRfCPAYmu1WCT6XdaKssZSZPmMcmNDTcwz1AgljoPxiCsH+1y5epWr+/tcPTxgNBpFC5JU9aw/w3tPVVVzoE8XbETq6uWybHdXJXQZsIzUPmmC1xASqEwqsAHBhdjrWikNeHRI41/pgEqVUokAmkCpPj5C6sVUaWxOZnzNWhVLqXtzGgpUBKDSPGYipOYhGFRMQ5dWVSSzZHke2bHBYbySqdA3GQOxXHnqBxw++xxvfcM9vPMtb+Ps7il85WaSGiLxQZPN19QL23SQLTxW/Y1WLXadouumgfS1AJldqpHteTUfXEYTe9P5iL2zZsVjvX3CqurGMpC57li2P3vaoxonjJ87js45jMmQIPTygte/9g184H0fxJUlj3/3EShLcg0MjKUwBtGY3PEITi2Hlcf0BkxsxuVxyW2veiVvfuc7eeT73+e/+qf/NV/9+tc4GB0ixtDv9zk4vErwnnI8ITc2JqzSrbI+1rFKDyJ2RvCm08T9GoCia73OLwbe5kiP9rzqmifLWCDHAX6rKphRRM3MPOa3NaRHXIxMM8/qR5uhswzgLAPFdULhpOJcC20RwsaP+c9Ydl12VTDXUUePFEguaUVIAmi66XnfNCm1/GCaTpGf9nydTf5MgWX762SrI7sd23GikW0PwfFv1D8N1UtBFkRG5hZ6BRYosXXgP12cUxBmBELgB5ee54tfuhfp5Whuyfo9RuqRXoGrKoqsiJVKNVPQmKqU0rodiCqCkFkzZ1be6oEyU6DZy/IZEZWyLJtAYP/ggPF4HAVvnEt0UYdRM+3nsAYJQpBYIaNFh23f9JYphLakcZAQb+pK7NsJzFaGm2NMDSxjJbh+XVDFB99QW33qD62IgZsXQ0XAYwiiOI0CJhWBMv0+DkoJTLynIuBq/00jyeCaWLFsU2EbKqB2elkupt8beNocq0b9QX2qeHvER7GdXKAwhr4a9p95nktPPMWF0+d555vfxstvuQ3rAkwCvbzAGttUqZuAIERgbOgKjo6Wte4KZNqgZ5UYTv19x60SrFpDmu9ZIhixqpp40rVpQa5/xTG4VjFY2+4hkKQ11JBlhsmoRKzgq8BOf8hHP/QLPPHEE3z5G/dx6obr2DPXsdvPUZPhXYXzGpWAjXDoAqd7A66WE6oA54cDXve2N/Pi1Rf5zN98jquXnue5555lsLvD3ulTDIoeFXBVNbIfdK7ypjHfpSma9z4CYOcc1nTNjdXWDyelNs8LmGz69+nvq6tYy6igXbT+Zef0OPTWrvl+XErsqj7U9mu6trfre3UWhaz8rnVjvoWia/s2OX7r9rF5fsl+LUsCrWQ0nEyLauV+bHquQ4eIT/v31ftgWud+/a1uO7ZjO7bg8pqNVTeMnxaRnxpgrlrw22qyTcCbVPRQCM5js/jecTnR7z/9NJ//u7/jNW94Pb29HcbBMUKwOvWZDL4it5YMyCX1XDYAM2AwEBSbRUqkIfnfhYAG3wKhsXqZG0uv16MoCkQE5xyT8ZjxZIJzjsPJmElVNkIOWRG3xYWAJk9Lo7bZ5xkz9fRdbTuREEIDFo0yIw8wU7mUFuUYnZdmJ2hoKjZNNS19V+VpvDSdaFOpDEgEyRLFe7wqFQlIqlKpMkGZOM+EgFPFqccrOCJtMH5bSKp7QMzxx95UDa1wpBbomQYTRiGoaYG5lC2uQauE9JTEflmNNNxChL6x9LEUPvDik8/gLh/w8Q9/jNe98lUU8axj89gna22GJlXB6E1qQLQBmFaOFrzo/M+0D3W2O54CaYDBYlwiM706mwZ1Rw2y1q1Dbbr6fHA8YyNzjL7PtcewA1weN/hv/FMlWv7U3pBx8kQ2wehwTL9fUI7H5MOCV9x+B7/4C7/IE99/kke//W1uChN6gz5mMEBCFHzyxtfpKfa9o3CBYtBj3zt2z5/jHR94P/sHV/jy/V9DCJy9eJHDw0OKoiD3gUItpfegeax2RUUfgo/bVVfvamCZfIBnQYPQKGsvHL+5c3YtEp7a8Znt+dF9rjcEJUs+Y96P8SjAtwugrupV3eR4NcvUnOKpr9d0nX+9zKwH00Vgxf6JLH5h662z2y9rcnMzd41uUN25gs3uT3Pu5/Z/gQmRlFnNEtB9nDXDHGEK69yh0aAzibJaETgcwdu0PY+a7a/XdTO/dkkDJmtp6hlQirYUt4WTqGVux3b8LI8tLXbDwG/r28kCsGynMIO6+ljppCr5wYsv8u1Hvktvb4dzF6+ntNDbGcYAUhQNjtzYxrvSisG2KLGWaZBh6567OrBPfVVReCMKAhU2oyiS5Ui/T57nTW9mFTwTV1G6iklVMi4nkZobAiaL+RXnXGNF4klApjYAlymwXEWBNEqnqqdqS1m3BSzr53ybditTP0tvohWFSz2U9XMOpRKlEqGS5GFZ/59ASWCSfo5CFPAp1VPptIdTF27OHbSwjXpmplYWzQ3aSKOSa2wkpxEc1nv6xrJjLUOEvHL4K4fsSMaH3vUeLp69Hj8pyW3GsL/TokFPiW7Xwkx83TW+ST9VlyBL+/8nWVu6fCBXfeZJhE82pQB3AstrsB0iMtN31n4OYylLR54VDAY7iFgyk+Nc4J433MN73/MeHv3ud3nu+09TXr6ClA7rAuKntG0nSoUgwwFXq4pn969S5pazN1/k7e99L6dvuB7T6yN5xqPf+x6Xrx4wHpfkWRbVsVrXajuArc9Nmxbbdf7W9Sleq57LVcd7FfA7Su/muutB11jXvBT35RMHQGt8JI+zf0fZrnl16ZOc63WiS8vWuZfiuB4ngX/SObNsH4/TC74d27EdJxvZumDlOBfgukV3Xihm06zUj2Kc9Ht/EqqbdTVtJoOYgJG1VrIs+be1bQdSlSF411iGQKxDjCcT/uKzn+HcDRe47tabOHQl+aldKgH1ioihlxURQKbMZS3CY0RT1dJGUJn6JKqqjGDS2kgZ9QGxGVmW4SYle8Mdzp49S1EU0d7EWg4PDzkYjxrgWLok6OMcWZbRG/TJipxJVWIy2/Ra5nmGtZbxZNJ4FsZ908b/sladLcflQtVoQRgpVdnaKrN136Zv+mcMaBTt8cSeSq+xUlnV3pVEkZ66v7LSSH91RFBZBaXy0W6kDBGAjkP0EXQIQWNvZuMPlpLwFqF2bJv2YKbnvLZ6+8CkPqUQQAOYtiiIiYkDiP6n0b5TozjP4T6FMeyZjB0xFCFw6ftPs//s8/zbv/r3eNnFWzk92CEnBvUTN2HQ67W7O6fVCJHop5oqC3VVXSTOoRkfxzkq9TwbMPiwcs07rk9vY0JuzEJA077Oakyy1FuY1f1o3vuV6/T8/s8DC1VZCx7ngXR7H7yf/965ALFFHe6kvM0v/6nPsa5oeu+xRcZkMiHLMsbjEkQoTJ9f/5Xf4KHHHuQv//pfk2U597zjXfTyDLEZ+4djejtZ7C22MFFPMELR73GlLCmAG25/GR/99C/xx3/4B5h+j4cefYQ7L72R/plzFMYQQoXYSLGNNkWOIl0HooYi60V2xGRCv9+PFUwb1WrzLJuxOlh2fucVLecFTtr3x2WCShuD+NZo+gWlQ4jIdPglzf133f27XfFbJni06vqoH+sqo0v3W2QxCVon9NrnIhyPXrpqG7rOZ5eqb3s7u6qG6/Y/JvJoEq3t41d7M0ta74VZqr2rE6G6uH1ttfL6/LT7Z9uieguVx7n7YKxGKiqikXnSatcPU1ucrv1ctia354cL88c+zPl2mvpEd19DrWq/KpFO35r0BlkTH6++D9T3p2X787NgcfdSvv/H9fhtut8/Dtu/ab/7pmrgK8HlDwu0bTNHPz7jyPS5tOhmNkODo6pKtVlPbCby5NNP6QPf+iZ758+SD/tokRFMssggRAps6r0z6BRYppugbYn3ZMl2xChNhdPXNyOTjOqzWTpsWZbx5mLjDbDurayqitI5vIZInfN+RoE0AiRByxKbZQyHQ8blBJ9sPEIIjahPl9BKDFxaXpXU6q1T4NaIAaUqpdfQ3NhqYOlE8UpSgI1m3k5T9RJJIFOpBCZB8SLN6yd4JkGZBBdVYpuK6fz5mwZXyfFxdi7UQk7SBie1AEakC9U9aCnCif2xRlLiISBopBv7kmGWsQMMFIqyYqDw4COP89rbX8mrX3Ent1x/EXGBqirZ6e+Q2wJt9bw2YE2bzMbsvNWjZ/Nnj8Tx1qZN1DO7npt+h1zT6/colcZVwdGmwc9xqmerjm9NtQ2aipdZEa9PF/Cph9lkll6vIDM5v/LJX+bxxx/j4W8+xJlz1/Oqe+5hP3gmKowPDsmHfVyIZHYfAiqKldp7VTl78028/b3v5cv3fRVr4Mr+Iacu3sjh4SFis/iedrDILHCoqqqhxcocUl6VZJUOILKqqrPs3G7S07vseHd5G3f14skR/BRXXX9dgUoXsFylrPvjFqwdtfK/+Pew0fk+Dl21az1fPF+bn89Nele73j8DWhePj8qaHVt1DBeTh+bI6/hJju0mQfZ2bMfPGoYQkR8tLXZ7Af54Z5tW+c/RAJJQZzGlvll856EHeeiRh7lw/fUUu7uYImsqd7U4Sy6GHEMhFmuIlukSM7C1j6CVaFRtUjBmJVGYakNHiFXKIscWOVhD6R1XDw+4eniQfCJl6gdZVY1PpHOOcVU2n1H3UppkkzIej6PgkLWdN3uv0TtyXj228Z9Mgjw19TXUlUqmdiE1HdbXliLEKqQPNHYhQSINtu61nKS+yjI9V2nssRwHjT99YOI9E+8ZO0cQ01Qs/RyQMTpVdqxl/aY+jvFfTXs1asAH1AMeJAii8fk2ZTWq+kajefHRHiLTwI7NGAQ4bTJOi+Hp7zyIPRzzkXe9h9e84k52ewNQxSZfUoDSuUaF0KjBYlN1e/qQRKaulSC1pbbbqXQZZFYxMv2lTmjYtCjWP7sekgzVTUe1YpmvWhfl9iTZzWk2fFYtVsTOPNrHon1spo/VtLFVSsfreuS6KjZdv3fTR00TPLoQcCEyHoyxzX4WRZ+fe/Pb+c1f+U2kUh7+xoM88/j3GJgMJhNs8AiBEByVLxmrZ6LKKHgOfGA/KDoYcOc9byDf2+Wgckx8hcnyKBSS2WnyJ13DMUEW1T/ExrWiXlfmqy9HSZ6+VInWdTTP+nqor4n2/9vPtRVW2491XpvX8vrofA7TPOhQTl6mInvSjqBVx3ReDXkZoN7ksW6OtBObQVYklFq9m+to/F3nbZ6iexR6aXt/vKrWjyQWWIsGdgLqTRMv0/2YVcKevjipBZ8wGbBuHmy67duxHT8tgHJZa8VLXrncXmA/ecCyDS7X0ZbLqqTIM4oixzvHweEhX//WN8mKnDMXzpPlOaWNVcuQgvfMWnIMGRqtSJKQTw1srIm/W4m02VoJ1hiDhKjOWNNNBoMBeZbjnGM0GjU0tdpDs+lzVJ2xOSi9g5GjlyxMrLUNDU2BcjJBJQLPUFOMrGmUVKdS+O1Ah8brsW31UfdQNv2UGgPVWnreU0vFpyqnRHEgl/7mRGOvpWp8Lgn7lIAXgyNQqWfiXQSWwVES8Imi2tYlaFOo4nNRoGR6rUrcktAWSRBMLbKi7eA/BZ4IxmhssxQI6gjBI76ibw0Da+mrsmtgF6G8ss/DX7qPD//cu/nwu97L+d3THOzvAzDcPYUgTMpZurGkilbN5DLU4hXTREc7M77OJ669F5smuTahhWxiRD9bDVjzPUes1hzFEmHT5zdR3FyrLLmkcllX8eprp7ZNiP6SicIdYkUizyygVL6kKisyDMZmfPqTv8ojDz/BP//932O49wC7p04xLDIO1aHVmJAZxGQgUKbkj9NAEZSAY2/Q4/rbbuPxZ59F8gIXPLbImXgfbXswSHNdT5Nk1top42GNcu6qCt4qP8hNj/8P+x686nx3/W3T/sRVc7n7epYTJqqn699xEuDrKvxrW4TQlfu9yVx4KeZAm5bcSeeFtdY7Xfs1o5RMZCeIblbBnJ8D8yB3dtvCUvC8zHd1nQDVtlCyHdtxtJV1O36WwWRSR5MOz79lZs4zfSzWNEGwiHDp0iUeeOABbrz5Jnb2ThNsVDX1abE3JlJiM5Ss9qvsEC6of9bVgBpYBu/REBqaT57niDUcjke8eOUyo9GIqoq9lZPJZOb97V4R7z1lWTKuStRIU7Esq6oB1OPxmPF43FRA65tZNS/gwWaacjXArYV7IpiMWXdvaCisAQhiEnCMvZKVavSwlFitbGxFTPS2LEOsWI5DoBKJmfwsR4mVy1D3cKlB1CA+qQYSK5BNb0pQ1MeAXgOEKlWJg8QqpWn7/aXPnPFBDRA8GhwaHP3M0gP2spyzxQC9us93/u5ebhgM+ei73sNtF2+iVxT4ssLaSG8OEpMRWVHEamuQGpHHimmIc4GwGeVpZaZZTWeVZr5as7R6c42D+GX9nicxCF9WXTzq8yfZ/qNm/klV1dAWupL2dRTwXvFeOL93Hb/1G7/NrTfexDNPPMlD3/gWu0VBrkp5eEBVjqPgmFG8MdEjFou3OS4ruFo5bn3lnZy+cB1lCIydJ6BMyrK5Xr06QuIeiMTeLGNYaXy/Thhq3dw5Sh/wJsnCrueXZZ7nK28n6T1eJ1KzqZjLOnGkVWvxvC/ktUuWL3p/zvqAzjIJ2s9DavdAmp/th9HYtjBlb9A8Vz8/f2x8Yru0n2+3b4T0ONK1uALgL3v9pqJE7XPT5fVZs3y6PD7bFPWu0LbuJ58VqZtb00+4fi+bxz8MQavt2I4f5wLVjwRcbi++H//JUZ+n2IS/7DwFMmOYlBOcdxgrPPnU93nk0Ue57vrrGewMm4qcV0UlND6WAlhNv9f9lRI9L2MFM4EH1Sjk4kNDP6vpqqrKpCoJIVCWJYeHh5Rl2VA9awBZZ1/zJPRjrcUSs7J1z1Rt2D4ej6OQUR6L+qNyQlmWVD72VZWpv6pRgW2batc2JdDQgEOr97IOVOPvYfo80yA6WopEmmxIAj8VEZxX6nHBUwYfBX7S76VOfzafZQWsaW7M01MWj6shUltpBwlBpv6WrYfORGZTypGEBFCNITN5vKY1Bj6ZGPqZpbCWHM9OnlOo8tz3nuDp7z7Cr330F3nTq19LNTokN5Z+0SOEwGgyxgWPEduAfGlRVCHODU3fQ1iu3LoJzWyVOMqqQGtT2tM6Q/Z1QXRX0N8V6K0LvI9SvVxHyVtGa1wFgDoFgpi1jFj4PKLfbE13rHykx6qxmKzAZDmo4crVq9x1x6v4d//tf5cwqXj029/huSe/z6lBj1CWuMmEshzHpJBqpIiLwVtLZYTD4Cn29rj1Fa/g6miM88p4UjU92w3lPdFhMYK0klXtpNWmx3eT87bsWC879puq1P6w7h9HrfB0xQXrqLSbPP9SBU/rzttm59V0ApNNEwSbzLGjJng22e5lc31dJXrNuqBH2f755Mj8tTjPujrKOn7UObSNZbdjO2bXkh8KLXZ74f3kTY6jLJrGxoV8Uk70u9/9LqrK7qk9siJHbAQmMVRM80EVK5DlhqAhUmCpvTRJxuVRkTRLPnE1CCzynKIo8D7+//Lly5w7dw6bWaqJo/KuybhbLNr6fxswW2spQtZQbI215EXBeDyO782zGWqQ926BWtsWxEgaN1HJVmtLkST807IhCXUv5UyPZWjEghyCbwv6pCplFQIVqWJZq8ESGLkQK5k+xAIjtTKtQUOK4IO2Uvc1zbQ+35K2LSSgaWby/8ZmdR4h9eglL7cERLPkWVp7k3nvEBPoFTnDPCdH2c175ArPff/7PP3oY7z1DW/gEx/6MDeePYsbl8hQyGyG8zF5gInb5EKYmRcmKR82memWtUudpJBNA/sNX3eU4HkTipgewd9w3r9tk+86KQV2GShe9l3Ksn2un2/v+/Rv8fXaAMxYhUgXUipWN+JNNqpSeucIgM1NEuJSQhDGI0eWeT79yU/zub/5Kz77t3/D1++/j7ee36HILIfBUU0EFQuFIVPBq0a7Hl+RCRAcF2+6hYOrlxlXJZLl2H6BV0HV40Jau2wSILNRGdkYu0LJ9Mf/XrkJvblLxXTZvaKb+t09748CrFcBm1XXxsJr0xLSrH+yOWjo2ta2muiq6m73vuiR5Lw2pUdH66u41pslAL72k2y3S8wovHao13bNAzO/rq6gv29yntr02KO0GHSLFR1dGOpa0I638e52/CwWo+b/b34UX74dP4ETiCUBePAUNseIYf/wgCee/h7DM6fIdwaoNbG6YLNIA0qVMvUBJDDfzln3XDaPEJUdVbURzgDI8xxrY5/llf19VLXxtay8a/wsS1fFimMS5fCtG5G1FpNHcFlWkZK5s7ODMSb6YJYlVfBkWRZ7IFPVUlUbX742bce3KpBt0Z664hFCaER6alGQoIoLVaxKEiiDpwoe5336PQbAldYiPjABRrWoj8Khc4x9Fa1LDCA2ClyERGdteYxI64Zcb1/QgKrrkJONYjnWWoxYVAxeia/3sWcUNRipg+sonKLBYdQzyJRTRc6eKNcP98hHI5797iNc/cElfuNTv8ZNF29lUOzQ6w0b4ZnCFgx6fXq2F5VCAWOI9jQiSOtnPdoS+etu7AvBjU69S49aEWiHlywJ4Nrb09W3tCpQPK6wxCZViflHUI0U6PbPFfS52S8IUf5f5yH78uPmaVEY64pgHfBLlGeJKsahoaQb06Yhm8RWcFjJCEGZHE5QD//od/4hu3mPS08/y2Pf+S6nioIBgriSUE5QF62EJq5iPClxCJLnBGPZOXuasxeuZ1RNCCbS5iSpykqIDIoZm4xEYV/qhYhdfn7nfG/b/cLzP+e9aZXNxWGOkmmGo1X/Nu0DXfXZq8R8Nkl8bCIS1PkZtf3TwnV8lJ9m42O7ie/iUba/ncRp957PN/6uoiKbJT2Lx62SbrI2Law9LSGio6xt9S1gXrX9qGyAo6+3s+f/uPNvO7bjpw1Yzl/nmarvyCQd5ePNyi9cJwizSdb+RwlsT9rQ/+M+ZnyckkqrSLKcCCEy0uoKQy2ekF5u65tzVUFuKLXiq99+AB1m9M7sUVrDqHIEBBss1hhym9HLI1gZ+5Iiy2MPk0BmpOkrsRqFf0QMubFMFLwPsQiHIMays7uH+sD+4SFiLXmvx2QyoaqqZEESz49LVceajuo0xIqpCL1BD+c9h+PDCFx7OZoJ4/GYSVVG/zoNBNFYhRVQ0fho2Yw0144IhKm9iDFZApfRbzKEKArifaDUKvYXSt0rIwRNxu8SweNEA2OJirAjDYxqAKohAUqTem1iZTFgIjUVjQAziVWYlv0Jkl4vERyAryNWwGLFYEyGkShY4oKCT9VPMWBtsocRhsMhL16+RNEXnB8hUnHu9A49X9IbX+WGYkjx/CW+98C3+cG3HuMf/srf5y1veAc33vhKLl96kUF/l+A1UpXzHOsA7+mLTWI7SY9Iaq+8GiknaxLbhNso4IJZAMm1jUoqnc8EJ9TUy5lEyvS9ban7RSn9QF1T7V472uvEvP1JCuxk1jt2CuwXff466b5s2Pe5LJOf9t9gUKOIGlRCrBoa6aTETz+nprcGBJNAv8wcw/oY+FY1PAb2iRzfbFdIdOd6X03qbTQQUsUyi32/wYeoWKzxc3q9AZkYRvsjXvXKV/N/+j/+Z/w7/7t/zO7uLtffcB2nz58BVzIajxhXjt7wDKdOneXFFy5hs4KyUkQyMIIZ7iDJ9ke8Q4MlJ0PVk9mMUEaxLFPkYARXecROVVPzPMe5GPBamVZoVaLgT8N0SP6kIoYgcS1VI8nKKFVzk3BVSISDuppbP98cZVkvSLOQHJTWxJyf96331cm9RMuYeUuXT+r0/Zvd902ygpoGJXHj4vHczEKnsz+0TgB0JZ5kyoaYvkfm/Fjr++D0/7OA0qBap0lCs73zHoimLRakYJptoOm7nF7TzKwP8fPMXAA3e68JiT1jMHEeaP1z9pxO7/PTY+SXHMd11biZIHIFjberCthFVdXWfEzHUc1cUVfS/UmTmFbDcFpTpeyKP2e3KcxWLTEz88CFrqp9/cVhbeX5OGJrP0mx5EsdX/+kjuMohv9oRlihGahr52x7DZs/lxnbsc08wEo58pXDhyZSf+7Sc1wZH2IGORRZ7A2sb0AaBVHaQWstBFP3YYaQgvUwDYYt0beySkI7eZ43VQNjBGsyvPeNkbnJLBJiT6QLvjF69q0+x3m64czNMhmIizUYH61NNPU+ttVhQ4ggNd4J272LLfprysz6UAPa1JPZtDBaPC5uWwhRwEfAARONdiMjlDLQAMuJKmVNz8XgJPpOBg1NJjWVO2arle1FQdoRYuLORl4pNgn+qFOCJNpjQ6c1IPHvxkQl30k5pigyXHVIcGNO7+bsZoZdk3OGjOG4onrhCs9+5xHe/aa38uF3v5+bLtxMVSqD4Zl4TL0nBLA+YldDCpp8aHw2SXRfo/N1HTnh3F/vc7laNCJsrIR53BvNMn/Aa3L9m3gdRluJEBM3Is08r8Nn09EbGfMUYXqTUkEboGNmgzymFQpJ9PGu42aaMxLXAu0ATqYFmPM8p6oqgpYEX7G3t8fr7notv/XLv84f/Pm/5PqbL/Da82/CRR4rTizelezv71P0e6CCx0cQhSLpehCTxcDU5FFIzGhzbGrgjzVRJbnVb7n0vNRBf320pIU4NIp5xUp6ApL18+n/nT9hrjZ69OBvQaxtrsLe2Ss7k+RY7XW6aXJ2/j3Hnd+bWlfMgmkzXd9aM0zn+swXf6Z7luhyuvsGFMyj0GkX9lXi9sQrN0FIXVTAnd/3+nr2a47lSYP/dSq6QRdX81X+vzL3F4PMJHdXrePdz23uFTtzLS85ztuxHduxBZfbseIGt7HgkpEkuAHP/OBZDscjBtedotfrUdXqdCl4bd9UjGmpxNY9WCmosswGa5PJBFdW0XYkgUuTgnprbOyzLCeYzDa2IiEEnHNgzWr6EdrYi8RgQWf6MqsEVENLtKe2MlBVxJiZvrO27UkEky7RZmWmF9OnXkfvY2DpEJyCl8CEWKksSQ+B0nsq5ygTUPUBVAJqhKC+seKY3jLD0sxTqg0wZTIGEBur1iHSkeM+aiwNNuqHkcNkxEbVQgLl4QHDYYFFODs8zdndgtyNKYJnmOW4K1d4+IFvspv1+Oj7P8Jb7nkTfTtgPHbs7uxRVpOFDHkt1hRC2Bw7qtksGFsR/K7qMzxOb+IyatQm/UFdNNou+iByMvBq64wIofmpISx8ZpiD8l29bO1tkfodrU2U+WOuNFY2TWam9S2q7d+7kwm1cFdmwHnPwdV9Tu+e5nf+3u/wN1/6It+8/xvc+LJb2bt4HaV3lN6DCRwc7HPq1OnU1xsTNGKSYqdJfprWIJhU3e8WZ7K2Jeaj8znh7pp2O3g+CRW6AS96ku4Wmdueab/o4vrfdQ50rcjLuu3ftLfyqKBy2bXZvt7MXD/+sorbavCkJ1JXPmq/3rLtiwmfFYqsLZ5Dk+g5Qs/oqv7RTSnSmx4nn65+y7T/chOrkGXr9rJtr6vjm+zntQLc27EdPwtja0WyBZdLbwQbU5oFPIHnnn+ecVWS5Xms5hmZ6Ymbqn22g9tUwdSpB6MxJgZ4yIxCbB3E5UnUR1WjAAw01UvnXPPaGmDWXnQNqE37FRKAaT/awYWtxWrq95hpr1Udavm6nzIpyEYaqW+qlV4DLoTm/y7RWr0GKq9RpEdJ9ggwVmWsyqF6DjXgjKFUYt+lKlXwVC5+T1u1trPfZF3VgpBKhSb1uEoS6olBvwSJyLdujFGijUlS8LUKgsOGkr4oF3aGnDIZvXHFXrAUI8elx5/mmYef4JMf+UXe+Za3kUu0fKkBZH2crZ0VRmmfp+MGmEcVsVnrSXcN1AZP6p/WtS3r1CQ3uf6jgFaI9O2O62Jpb9MGFg/NNZV6qQmKeJ1ZB9ap0XaNIJFhINbgNCBiuXLlKvv7+7zm7lfzqY99nNH+Ad/46v2E0pGLxfjYx50Zi3MVim/EtOoeMKxBMptEg+pW8VlafZ1cqtek2sBdU9/qURUoX6oerU0VZZf1Pq47P+vm27J51J5PXdt5bLDN0dWOu5I5m52PqSppW7F0lRr+UXoDj+NtepT+x+Mcw037YJe9p2vfN1HQXrr+Ckt9OJclyZepEm96XLe9lNuxHevHtnK5BZczqqiNR80Saf2F9xMD0xKvL1x+kbKKfYSjyRhbZM1ibsQs3rjrrHG90KfvjSIyBvWByWRCZiy9YYG1FuccvV6PnuT4Mgr29Pt9jDGUZYnTwGAwAGsi8POpH6YNVhplU59A5hSHhTDX+4PBpuonmgRG6t4ZqamxIfXsTMV7arP1YCwhKbw6UUJSqqy8jyqwIlSJClsm4Z6RKuMQYvUyRKXYSXBMvMd5nfYHSX2Tnhq5W2xjJ9K+B5r5jHaiwRoR1EdBFvUB9anfRy1iLC7ULybRmhOlGcGK0s8zCgmYEDDjCUY9Z7M+54zlhUcf47nvPs6b7nw1n/zwL/CKW1/OlcsHDPp75L0i0hlDIM+yqeJsqHsihcxkM36i7Yx7Q9NUsyYIWV/R3CRgPk4mflmw0/49sEgFPArIPZk4xbTCWNNcp7/P9UbVx79V+ZG6IbY1p+atRQja0FxnFJuBkPpjdYN9XXZMam/UKy+Oya2QZRnGCKEKfOzDv8DXvn4/X7jvXu56/eu57rZbwXpGqpjcNlTxSEv35C2hrqYR3ERKfydQINHok4hW5z7I7O9hmmKbO7LdFe35+d8xoa7JfeAoQljt+8amzx/12jupaucqOuS6a+1ItFwjDXOlbsFoV6VDzdRZ9nESFrZrFSV5pvJav54uEKpLwJOurTDP/75qPTpOT+HM7ps12wJNF277apm2eMhG9OJlc75r867l3N6O7diCy+34mR3rvKhW3xwMXh0uBK7sX8WjZFlUYbWtzGLtZdlULqQWYYl9dSYFqiYZSBMUdR5XVvR3d9nZ2YlVQeeiJUlRkGVZoyYJUAWPlGFacZSpEbu0QLPOeVPW++uZUnOjumvLvDmB0MD0/yqxuhdaWVQNmlRkYz+LojiiQEisXILXQBkcTqE0hkqgQpkYjQqwrf7KQ1fhVVI1NPYBxZg3VV+Dn9mHpT5jnRF8TfmLP6X5/Nrk2xLpkonSnLxHjQi5MWRG6FnY62f0giWvKnat5Vw2YPT9p/jufV9n6IXf+eXf5KbrLtIvehyaMUVRMHGOsqzIzbSCWVczoCUWdcLgcl4UZPH31dXO9VWO9QIYq4KdVYHuOin/o4DkFdExsak/nWtMg1dCApw6zbZQ0ygbwRY1BAkYNTHZETtmm8/V2gonfZJJfUqqJk471aUAadl5ax+ny5cvs3v6VFSLJgpXWVFefP5Fbr/lVj7+kY9x3wP38eh3HuLshevZPXOKw8tX8KlvOCAoMbniRNL2MWvLYGqgaTBJMKt5TZAFe5vGKxaDLrn41oHmVdWYl2rt73p+fc/lakrkOvbBMkGWk+y3zidAWE59rD2Q5/dr0+9fAGK6+vx20TJXAZm1PaRMxZo6v2vBSuTova2rzvGm4PNaWXUss0dZBnTXJfjWzZF153GLNbdjO7bgcjs2DC7m/a7WBQchVWAuX72KqtIfDjDWNqBnvjdsVWBd//TeU5VlBBrWMhwO8d7z4pXLjEYjsiyj1+uhJpqc+5af5eFohLWx/xIRNNFVMS31T0lZZx+a6kWTba6prIn6honhctt2pNkfUwOM+N2+DSyNUPlkM5IEV6v0t0qEUpVJ8EyM4FBKDyM8oxAYec8oeEofUr8mkcKqitUU7LbEVqanKdQQIGap1c6f3Jn/hpreFxWSEDWxEqMR5sevSEJMqhgCRoTMCP3MkuHYy/sMEOwkcDYvqJ6/xPe+8SDZoefD7/0g73rr2xmYHm5S0R/uEKwwmpQYa5sqaETuCbzWtOWwXCwnLBZ+5m78Zklw3H5eNs62L61cdvT0tmlXC2B1PjhBNvKxXP73kwDL2uaivvbMLFhO6s0z17EaxERV4VpsR8Uk+Z04LyNAizTR0BI8qn0xJQlDTdNL2qmGi3QHiU2+ROBwMiaf9MjzHgTHZDTGiMdPPNlun7fd8xY++O738/n77+XGW2/j5adfy7DIOfAhXvvWJPGcqIbsNIoUqUbFXBHtuGaSOJiGBSuchcSFzCVzpFuw5LjB91obh3Xr/5oq1SZbsmkgf22SIUcAeh3VygWw0zm/5NjbV9vLyNx722JWJ00QraqsNQwVmX5vLajVJIxksz7LTYDiOvB54rkgU95D43+JHotKu8n2b3sut2M7rs3Y9lxuxwywO0pvwZRoo1TecWX/KpV3jehOVVWdn2Flts+yvhfalrCH975RiK37LHuDPgDj8TiKePQK+v1+FJ9xrqGyTSbRp7Kh+6Kx1zF5ZdY9mE1lsxWsxteGJnhUIYrzMPXkavrMUh+mGomgsu4zNQa1ghdDJUqFJHsRoRKlTM9VFkYqTIIwVol0WFUmrcqlzzLUGrBZ6mOdAq8QwkbBynzSoKnahoAmixGVJF5iM1RywOJbDXW1XYRByAV6mdDPhJ4ErK+QckxeVRTO8/zj3+fSk0/z+jtexSc+8ouc6e9xevcU5cSR2SLZbwr94aDptWzTsevK80kDz2vlFbnu2tm01+e437G2Kn2CID2EqY2NUyUEGs9WVUVNLbplp76NLbVETRdO2xI+SNtzT5qqf6zk1dXCaxOgnT17lvF4zLicJAq3QYNlONyhGnuuP3c9P/+BjzB+8YBnv/d9ZFJyfu8Ue70eVsOcHcXi9RFCmHrYtrxrfUfPYKTU2ubWOntOjiZN/8Pq66r7xNs94+2fy4DbS5nkfCmD9008JY/y/XWfZVsToP3zqCDxKMfZXIO18KWeZ139jat6Uo9zPjftQz+qB+yP4nrcju34aRnZJrSBHyXg+XH5nJ+2sSzLe5Tsc91vacVSlmUDDMrUS5dlWQRYCSxmduprF0JUOs2yrAGH/bygV/Twk5LxeNz0YIoIkyp+fr/fZ390yMF4hGQxkMvyPKq2pptGVuSoKlcP9hkMBhiNN/7SO5x3SGgFBHlGCB7v4sO1xD0ar0yhCS5VpnYjXgOBkGxPtMlaO4QoFQLjECiDUqrHJy87by0lnnFQJsbgjFCpMvaeA18yCoFKSP2ayQ6krq7UtMRWcKgtOfQaANT9cHXwrDGFPSf4A5gs9qNiYr9msHgHQVP/kNdooZBEUAaZoZdZ+kbIRclNYDcXrFdy5zm88jxPP/oop/IhP//+D/PqV96NwUTDe5vH/TGG/nAQhZoAUl9slqiW6nwD+FdVL+N+hYWQq60AOJ3npjPAbweAq8RElgHF4Ge/dxq0xwO86Pc3VwULfm3wuxJoil2anV917BrAY7LY96QG8PG8a9ubLymHdhyvdiBdi2uJxP7ZoKFJDiGKc4HMQJ4XeF/hfCDPLSGZISwL+LoC9Pb8HR+MsWLRQFSNJnqxOucxogx6Ba+47eV86P0f4Itf+yqXX/881+3skKFYFKygagneE5yPlXwxUOSNT6JJPdtBJIp0eTfjPzocDhvl6izLGI8n9LKCOLWjIWe7NSCyI9IurOip3IyyuNk6v4r+2hX8r9qGmSp9qze/631hgz7hZRTgTa/BoyqdL7te6haLdQIx7bkZgltSces+QTPiVyto710J306Wj84KY83nbOp5apZ4UXb6Tra+bx1AXkaRXrauzs+5Wp29eczRiv3cxjX+q3N7Op/kmT+H873LXfs9f7y75mP7cyVZenV99yYx9M9CbPqzHn//NO7/pvu0pcVux7EnkGgKHoRGbKdeyGug2URRy4YPqI0VjkZt1cc+QpIaZECpqgrJbBTQAZxzjMZj+v1+E+TWKq11Jr5WmfUsKtZ5HxVbjTGJ8hp7KJt+SqYVy7r3sva69GgKQsGFCO281NUNwamP/ZQSLUUqoJRY3fSiOI1gciKWUmoV2NAA0agyKwRJge5MtKAzx59kOL9UaTFRGXXBTiEC/SY4DBlOBfFJLTZ5W5pej+BKCJ4MS26EvigFgUIdQyvo4Yhzw1NM9ku+8aWvcvXpF/i13/ht3vWOdydbGUvAoGLwAQIhUnClMURZmsl/KTLJyyr0x1GpPKldQpfP4FGqKLoGhHapXzbPGUG9xoSEEazkYGkCZiFgJBmXp+tcpA3sFe980y8br7fYD51bS24LRqMR/eEu/Z5E5eYQ+47rOni68o58nuvnrZgm4YMI2BigavLSHB9OuHjdBV5zx1188d6/4/lnnuXCzTey1+szOTxElahMrRHoNSAjrR3N8U+shMhOj2wFlSgKNBVCq4NYszaZt9TH74h+w9fM77SDDrhp3/BxxbKOmxA9qojWSa/fVTTUa7VPxxEUO8r3b7K2rgPz6yqtyxhQm25TvB9svD8NTXaTBMQmx2OT/Z2/hk2HXsW2oLEd27EFl1sQuUFAsUlPhRWDr9yM6qsxhrq0Y1ZkR9vP14I9IYRoGZAqm1VVNYbtxlp8CFGRNs+SGqxgSPYjyfIjaGB/dDjNJM4r03lwoe6llNTbmOiBxKJdAyxTtUEVXNMeGJ9zydcygs6W8qtGaqszgjMGh1ASqHyIPZbEyuZYldJVTLyjSp+RXCqj30cNKoOi7RYw1RjoauzF1BAaQ8LZnqJIn50xgMcQBIzkqcplIkU2KASbPkfIbKxmWlEGuWVohUIdmSqFlOxKxiBUmNGER7/xbZ59/Ene+8a387EPf5Trz1/AlR4jFs0y1NjUp5Z6DRGM2gYkN5uLzKor6qxV9WxwvjqYkERTXNXTeBylxOMGkZtch9eCObIq0Gt/R57nkf7tfZM8MTb5jUIjhKXqUkIjfW5Sf81N9HoUyVCNVGpVT1W6JtnkqwlV8JRlic0K8jxvbExQ2KSzb/E41BUSaXxowSTf2eQlG4TJeMQNF8/z+te9jrN/fJpnHn+S21/5CobXnacwglcwREZBsAHnSiqtwGSpZ7tmAcxtYw02nVI6j6YET025b9P9m7xQiFb39fXXLEInmlebru9H96Gc6eFbmtw4ujjMSUDXkZRcr+G1ukzgZV4leMEZdGWvZVhZdT1O79+y50PqVmz/qd2WctKE2Sbb3Lk+1/3ec8euS3Bp9sjFD8qMyKaV8E2TC8sAc9fctNmy3v7jJTu2Yzu24HI7fqoB57wgybJGdyOSKhs0/ocQqwGdN66gDcirBXCyFGM6jeCoClFeR2yirQqU3mFIPXl5hib/yrIsZ30SrSHTrLkxjcfj5ibf9iIzxqASVVjrrXQakphPpMfWLYeBCCRdEvCohTxcosq6VMn0Ygii0bdSlEolAksxOIkellXqqawS9fUgeCbeUboqfb/iTQoaa3P7Frisg3tSZSaqVYaW4Eor4tQWOqMd0MbfjYJ6CEESyjaN8oQhHk9xSoZhkBcMcyiCI/MTcgLDTDiTZ+xoxiPf+A5f+8K9vP72V/EPf+cfcvONN3N4MCbPe2iWYWxOMIIJQAhIUOwJVQPnw7mjZPdX0fReKpGR7qDs+IFdvf+bBHKdySHvcTU9TiFLglfWmNhOjLK/v4+VdH0bksiNYEy8xgmKpj5mrwHBYrMMawy9XpaSOgZximQZJreIROsPOFpv29L1xCdvSQmo2ERnrZkVQlmW3HLTzbzurlfzd9+4n6vPvcBwb5eeWEqNPaCZten6A+c8amPPoZiYaJKUcNIUoGtaa3wV6b8isapZ2xtNwaVJ12oCnc3+nPS8nxwIbDJXw7r3cG2qd8vOb1cF/qhzZM0BXAvgNhV7Od7Om9h2wCJFeZNWleWJ3/XgMwiYoEfqd+06H5t48XYBtHX2IeuUfufP+7GSJ0bW3gtWeaDO0223YHI7jpNU3oLL7fipvgC6FtJ1F4oRg6cCiBTVMDVL986n6tRsHDlD4VxBvbJ26kUXnMOmfkrJLJL6PcdViQ2WnLwxPTcmGqtLTatti1ZAA0attZQ+RNN0kSjiEzxVouVGDRITgaWk6mQyUA9J8McRlV5BcPGWjpdY/XSiTLzijDJJ3pVjVzFJgXilMPKeyitVqkqSKHo1JIyCO6nHMmiNKqd0SBdmeyjnPB6nlcq5Kl7y5dSgqam0ViuKwDszWdQO8o5+Zhhmhj4VmZ/QDxW7vZzzRcYugf2nn+Wrn/sCF0+d5eMf+QXe8ro3YIKlN+hR+oARi8ls038YgqZ5EjC1SEyYC1pk/WJdS+t3z801/pe1UBHhxNeOHvN640jwav21Ox9stWlabYGRtp9tLT8jGrmqkix4Kleh3tHLDJkIvSIJLyXKrCVWHTKbjrO1iM1RTMMccN4zcR6xGUYMhY2gtPIVEiDv9yjLavPjN8+yqB91cR8TLXpECWIQMWS9HoejCad3T/G617yGz3z+c+xffpGL4WZyEbJ0vRqEzFicMfhqSqsXjfRY0zqeNZshHudWb6lOfSnbPnysONtHsQJZdUyOA+Zkk89Xlgb1MFXuPIoVxEnm+Srq4qY9u6uuny6q5qb+mO183lEqmLN9fLIxHblZ5VrbFDZNLLE5JXjVZ3StO+17/FHiiZljb2LSeppLbZ3nWl1aN9OOuFaqr13bG8Jyeu0WaG7Hz/LYgsuf8XGUHq+lNxofyK3l3JmzBO/BJyVFH8Da2fd33KTq2qEgsXCWFCoRmfGxVIHgBZt6xExmCW5KQ6tVRhuVR+/J87yh2dYqj977CERrA/QkuOFqEKpJ1EcEarVIrXshU+VSA1UCiFHwRxK91lDhmWi0H5n42Es5Do5x8EzUx77K4CNNNrSEglKgEG+csZrkfcvkXju8y9qZ0zZdNAFJ0/RsJvpOqHsqQwSTqeE0WpYYrMnIxJCJJUvR+yC39IzHViWFd+wVGWd6GbvGcPDUM3z5c3/N/tPP8b//J/8Rv/6pX8aoJNGkDIKPgFujbmj0IjRR8Sb1vCJmaYJjnaDIUVUQdb6qK6uDuJWZbwHhZD2XJ/X3WxXEaUsQq/Nz1ZMZS3AlvioTzcvSLzLyXo/M9Ai+ip6mVsitQSTHNE2NAS1dU51EbKz8e9Aix+Y5h2XFxAf2D0ZUCoUZkGexD5rgmFbVj7dmmSTg4yVaoiAJLIpFrCeTHoQJvV7OjTdcJMcwvnpALobCgA1K8IrYWInNbYbzHlQJlYvMiSZvMysEZTJLCK4FLmP/tjEmCmgBNXrftDp00oB308+tkyL2CEF4J/BCVwrCrbu3bPreZe8/6bFcJzS0zspEj3jcV71umbfoUfoIWfHabmBuNgJdx6l6z69Jq9bVhfcra+cix/QHnV07V8dDq+ZwnVw67rW7HT8b8fUWXG7Hz/ToUnNbdRNumu+jEIb28kIuXrheq6qKyoupV8JoLTwzG9Q0cv+kvgoEY6YVFpUIBl3wZFk2FQ2pYpXUZFGZsXR+BkzaPE5p7z3OuSZzLdbGOM9PX68aBXYE04DLyrvYg2YiJzYke5Io8BOaymWdVfUh4IlBpQ9KIALIUQiUBMY+/n7oHRNVSmK106viCIRkOU+qjoQQCM5Pb7BBFyo16LTeJqatFjr1cTSNMmo6l8k+QlRSb2aqiAbBaIbFYkyGlQguk8slRWEZWOjhsars9QvO9HOyULL/3PM8dN8DPPPw4/zaJ36JX/74J7njlts5vDIiIIwOJ2SDPmDwXiF9hgmK1RA9E9Nm+w0W5e5M97K5vMTTLMxGLyde+1U2wkbdIi66NPO/6U2pmd9zVPb6+uuicjXAzBjEl2QE8jz2NxeZpcgMRhQJAZtZXrz0PM9+//s8/+wzXLl8iatXL3P16lXKwxHDvIeGQOUii6CsPMVwhws33sz1N9zIa994D3vnzlKc2WV/NCaoTzI+gcl4jGTDY4Mok64Pk0BSkMgi0BbwV4lqr9Zadoc73HrzLVy9fJnJwT6902ewweGiEg8mNzEZFTw+xDVEsqkys9YXoBHERsGyEALOuXSsTUzUtCs47WDUmM2qhUcITkIIG71/k0rNKr/VpUBBN6/UHEew6yhVvFXbvel9bxnQW6eofpTlIq7DmyedVgHvhapZS+W8+/ivT6Qdd36uSiQso/quA4LrRHW0G9/LRlXmOXC5aZV1psLc8R1HUdvdju3Ygsvt2I6ldwAjhRjOnD6N+Aq8wwRHZoUqxP491VizCiIEAipKMBFg2KREaVriED4Fi5GpmawAfBTpMRoQySJtViYEH9AghMwjPsPUTEto/C7rXk1rbQM8vUYwqSH5U4ZE56urekmpVon/dTL1u4xQyeDQKPBDwAEVgUlTqQxUCGON1ctJyraqAcVCAquNKmUCfSH9rCuYQgf9siX53qYYaxI2YU7Svd2HqbUqUEgGJCJYDLlJ/qMChoDB08sMPQOFenrWcK6wnMkzRs9f4tL3nuLxbz7Ehd3z/Mf/5D/kxutv5Lnnnue6M9cxGlUNaA+qeB/PW6htLcQ22xRqpxWJQdeGeG0jELIQuLSQQpRxMhsHTN3orqt22VUN6S6Vtum/is4kBeIMrhVVZyBF/eVkWexJtkxtQepEi5hptTt4j4YQaZ6JBmpF6RdKzxoGWR8hcHjlMk8/9SRPPPYYz/3gGb7xwP08+eQTPPLwd3nhB88SfEVm4rz0lSMDBoM+/f6QsfO8cOkyBxPY2e1x+rrr+MjHfpGPfOwXefPb3sFeIVw+OKSqLLboMej1KX0gRFOQ7vNZi1E110BjioJnep2EFqiOpyWC+ejXGHuTi/6AW192G99+9EEuX3qRG86dx1QOVWnYCzVd3od0vIKH1J9dsypMsC2FamnUsQlNmZIgqR90ScJuxu7lBFnuTWmfXYG6pGvP6Or5HV8rLcA+/YkXltF9G2q2iUnGOE8Xv/OowG1dFfhInpkrQJAk5sxJQPLKnJRGiyvLcv/NhQQBNppcqUHxWJM3PZuz59wsPL9qO7qA3jJQu6kIzrLf54Ffe64cFWAGmf1uixz7HK2iRM9vW2PB1JFk2Xpibsd2QNZtxSudgdJJMqw/trjohA23P+77vUoQYJX/1LJs3SxgMaivyIseE3egt7/sFopceO7ZJ7nzDa/GhUBOjg+CD6BBsRaMDUzwQEYuRexbsNGqoqorLnmBU433RxerChhL5R2T8YQ8KP1eD5v3EBxl6SgnJZNKyZKCmwuKzYvkKxcBDupBICtyrETaqaNVyUSTHUqkwWKTN2WyEWnsSYh9XWXQCIRRSol9lxMjjEQYi+GwnDBR8AZ8IFFvk+qrRIuHRmHSh5meyQZQtvq3sgX/sNDESNPMdNxGiF+qxmASYJl+R6QdZxhsEIxRBI/3EzyBQZ6xO8gY9gU7OaQXKs73Ms5lGdnVA5749sN8/W+/wp03vpL/y3/+X/Cym+/AlZ6il3N5/4DhcJfxpCKL7hCp+9M2S4ojMilryxOpbR6kUQJce302Ve7Ofqm6OsdC72G9xsW3hY5rpv0dZmlWO7aqShPoQexZRELTQ6rqGzBUq4Q2nyGxPzEGeKYRZKqrubWiLhIBZtwPHz/fRIXkUTkBqSticV/S9Ee9w7uSQiw6mVBkGad3d8jFoD7Q7wnl5EWeeeJRHvn2g3zzvvv52t9+iQfu+yqXnj+IQaeB0+ctVeU5Pcw4e+YU/Tzjwrnz5NbQ6+UcHBzw3AsvMpo4bnvFzQxP7bE/GvPMc8/zu//v/4av/+3n+Cf/8X/Cuz748/hM8CajwnA4KcmKAc6nBINYPJpUZgNFZsH7GV3ggCGoIaT5q7bRhkWMJUdjtV5D6pMU8qLgsPScu3CR8zdc5Adf+gI2z3CujD2/GtVesQbvHGKFAourAlliVFQiUGRMqjGlq9K6E/19xwdjvFPyzFBVHpNlBKJYiNdI3bCqESjX/rN1TOpD57xbd5+pK+FtVkLn+5gL7ue+w3uPn5nfZun7gzZkCkzqVjYmm/Z/t4RparqzJmG0xi+4sYmJk9yKJBA0SzOVRvQtdFx/LVGalk9s+9putjksr0xG9o1ZqDa1f8+ybOX5WKe2GhbWndZ3aCCztrm2w8z92DTnV1sHpllDTOx6DtKVHGvdn/FTT8Y2YJJ6PZG5pOXs7/Md5TUVemF9ZAmgX1OhbYP3mfelpJGd3782EJZacKoVm0Rzq+lkShR+k7JShlaMI0JQvxATtc/tsuTNdJ7ERJKVlhlw+/w3zII5v9HmGvnJrmz+rNI+r3VP+Y9urPOx3RwrbSuX23HtLjABsTmkG9ipU7tcf/48zgjl4UGkWdq8Ng1oqg0OwUpUWzUaMGISqIiZ2Zo2B9HOwypkIVUvVak0EFykx1rJMMZiCiFz0gBDTLwFVs7NZDfrG6PRCAeix6ZpbqSiBmOjoqWoxGBXY99lFQJVUKpU3XQIVYgqsQ7Fi6Eykfp6GAKVKlfLMooBhSTIGkJSn4zHz5hErZkTADFLxDGWBTW1hUetFFirwYamNBgDyxh3pMqLWHLJYsXUR/XOnoU8swz7lt1eRqYle4MCe1DS8yVUJQ/d/zUe/8a3uenMef7D/+Cf8KY3vpXMZIyqq7HvLNSeoJ5aC7gdfNTVOi80fFiZq8ld6yRRR877xDcXratUTT1NFz+/rh6k4z5fqalf21Qb2kdLUyCnkVJpsniefQi4qsL5EpP141w1htxGL8nJaIIQ6FmLliPOnj1DsdPDjQ6x5SHiHU8++hjfffhb/Mmf/R4PfvN+Hv7G4/hDuH4Pbj5/lldfPEvR6zHYGzDc2eHU2dMUvYwze6e4/txZ9l+8wqOPPcwDD9zPcHeHV95yE7e94uW85rWv54abbuTylX2+9/0n+Vd//uc89OgT/D//b/9XrLW8+d0f4MrYMxqN2Tl9nrHTJjHSzFtro/1MCOm4hnS9zClQqyGoj9g7WaDE8FGxIV3PQQgeTGbIih69Xg8VqBK9PrcW6wIqgsjUQkl99Pis43SPNj3aGIeITYGnNJ9VA5866IzUfpPeXQeTYaOb+uYT0Rxpzs4HQ6vM7tvBU5i7akLznumVK6laNj2X02u9JXLd+nkytehNq5wrFc+1O2Bc17vXLdi0uG3LLI+aPmXddO1qJaUwHT/DXMAYOrfppFW141ZtjxOMr7NHa1ZPaVqb41qcxH5mEgodyZJl+3YUVWA10+tDfuKh4nZsx7Ub1wxcbs1jf0aHKFU5weZw7vQZXn777Tzw8IMcHhywu3s6ATlmgipVFxmgxP5FYwKiASsWI1Gtsr7pavKw0xQI1ZQ/56KQRj/vk+c5NrOYBEZD8EioeyL93LyMNwtfe1mKSX6Vie5qbMrQx0C1Dgq9RtuGCqiUKMojgUPnqSSBUIRKlIl6Jj6J92gEnbFgqE2vpqRqU7tnqqvnp0aOTTJapjBGW9gFbdHX6spkSMI5JO9RNYhaRGxU+pSMTCya6JN9a+j3MnqFYScTBkbo24LClQyLHjuqPPfdR/juNx7k1rMX+Ae/8du86x3vpCgKLl++jDGGXjHAe0+v18OYutfypc8grluHXiq/SgkaQYnO9Sw1PcYp3BCTgGI7qFVEfPJvTQGh1MIwEXRZkzXWN4QEfmyP3BRkqbJSTUrUlxgx7OQWtTkmeHIJDHf3cIdXKSdjDi6/yHceeIDP/dVn+du/+RseeuhhBjtw7syQd97zSm694QZuPneBC2fPcebMaXZ2dujv9Jn4it3Tu2SZYVD0+MEzz/KvH3iAp5/8HrfddhtvuOeNvPlNb+e6G2/AZgVYw4033cSr7r6LG268kd/9g3/J5/72Xv6r/8f/nX+yc5pXvOYNXDh3ihcPD0FykNo6yKEmgTZVgquwRzhtNfVyIY0QAiKWoigYDAYYhMlojKjBWsGqJZhpRcOKSQ3OJl53IVUh5+ZT7cFb2x3N9jeaFtDUpiqvcyhrU0EoXaDdyfEg6lzAHpaooR7Vj3IeNk6LR6uFWjStXYuV2eZIz+z/7HHYLBZZtl9RJM2srMictP+w3bbQ5QmpQZcAKVlr1bH6nKyJx2pvZI7O3FoX6x3VM/taANNln2uMEdUpmX5h/i2xVjk6GDaJELSlxG7HdlxTcHnc7NR2vMTYb42a3rXoD6iDsn6/z+23385ffv5zjEYjzhiLSzdJi6TqgMRuPtWoIKpT8FjTTWvijSb/SHygClHhtRb50SRGE1ToCeSp8uklVRk0oEmJVdr7mwI+JcqIu6QGG9DUcxmFdnzyqwyG6FcpJtJfTcBbUB8psM4YnEIZAj4EJgQmwTMJjlKVYFI/mZHElJym8sVA8qZfCDoWzl/rPIUEUrRWLsHMUpVT0CQKliwFyIJRk/rtojWERZCgZMkmYpBbhpmlnwl9oxTBkZclmXMM84wXv/8UX//yVzndG/ArH/8lPv2JT2Nsn8PDQ1SVwWAAahiPx02/krX5RvPz6MEsMxWS9t+WVQ6u5bxvhKmYsxZtgKVhoUqlZi5gVowERLWhFDZTRCMVO+kWJ5pz8jZVgzFCJkIoS3IJZCJI8Fj1ZOLJTCDD8+KTT/LUY4/wwFe+xGf+1R/xt5//GlbhVXec5wNvuYubbr3ILTfdyJ23v4yLZ69jp9eP9hwpgVMMe4zLCSY3nDl3lnI84atfuZevP3A/t99+O5/81Ke48ZabOXf9RTQoVw9GsY84z7BZxlt/7m3snjrFzt4pfu+P/4x/9t/81/xH/+n/mVvueg3PPf8kWuwiuSETQ1nTfnURctV9wiYJYJn2C8KscmQN9E2TkHIQlNxm7A53sDZnPC7JxGDFYBoTIYORCLiQ2H8spqYrtgS1gmIRMpMjaDP/Z8WU7DVP2nb2E8vm10un6Mgx7hvd9/z561HbU/2aJKe7qm8zFhVr/BA7E0RHMLxfB/S6jvUywaBla9j078KmojT1keikTstmPqJHjSMWkwpLXqPdx0k2VHrd5H2dn8OSvlDd7Do7yvxfpXYsbGPh7diCy2sKMrcA82dkeE+W59TGibffehsvvnCJ0ZV9MoQMyOretGQVALHnTjSS2DzJ8zCE6CktdW9PQFIPJIB4Bxr71EQEsYLznuAcVepn0trbMgXIWvdspL6eoFFgJiQV1ioZofgELj1RlMdr/dNQJZXXSqGSWLl0AiUwRqhM9LWsrFAGobSGEoPzCcRimEKROh4O4CP9VVrQYQYozgGZOhhq+jBVQTMkSHMTU02detG2kMxkKVhXrMZg2mKJUj6RStizhn4mDDLYERgCu9bQE6AKDLKMg2ef45H7v8GQgl/75Kf4xEc+QU4ebSDwFHkf1DCZTNL5MlhrVmfOjxDIrauqLAuSXop1aLH60W0mryqxN7AGl02ioO5TCukaCCg2VaWjvH1Ic7lyLorM5DYCqxBQ51MVzTPMgFAh3tHLMgZFTnl4wBOPPsgTDz/EX//ln3Pv3/xrnnvyOW69YY+Pv+8ubr14kdtvuZnz153juos3UGR57C0MnsxN6OUFwSglnqsvPEdvOKAwfarRiK98+ct882v386pXvIJf+IVf4DWveQ1qhMnhIaPJGE/scSR4xqMJvasZd9/9Kj50+TIHh2P+5F//BX/0ujfw67+9w/m9Mzw3qqJqsC3ifPQBTc6x0dLDJ5rw3HkMs+ClvufUwFKmlYvoepP6pwaDIb0sx03KKPIliwqupumfmtLrCIqKNiC38eFVZf/gCkho9QEGskxiv1/T2ydzAGAxaXSU++lxlD3XgZ+TXC/LQM7i58n8G1cmp9d6FspyYLCJ3yFrrFa6tmudfUlXomtZ3+XC0UlJicXtCDN/70qSdcZd2qYqd7F4153v2crxceO+IwHDI1Qo25YkXec+pKZbVaQNLpvXXqPbg2lEx6QVb7TVgU2TDDlCzmU7tuNnF1xeC6Pe7fjhjGt/TgIe3yi0Adx2y61cd+48LzzzPJP9Q7LdHhYlx+AMiKkrblGrM4jiNdJiS/WYJHAhTb+ZNrTAeuFWjQJAmckICsFVmGAwJgaTMeiDkMobPolLhOBihVKn1SDf+umpwSVUkixDBCZAqUqpSoVSKlRBKUPgivOx3zKko2FMrHhKRjChgY0txDy9Zye6cFdAMktVY7YnU1PDZqiBiqHpt6xBW6r+GGJ1xahGI3uxEWCqjQGxEXILfSP0JNA3gV1rOWWEgRgkz3n+e9/nW1++Dx2VfPoXfpFf/9SvcMuNNzM+GENmokiTZI39xXA4JMvyxqZhyWRMh+EIHm4nDK5PGjwvmITH05cCiHY1JIqUJAmHOTBhZrbFaAwYtVWxiOq58RxbG3sB1TuCeqxGUacsy+ibjDB6kd1BTpENGF29woPfup97v/DXfO6zf8Y3vvpldDTh7lfcwoc+9X5uuu4cN99wgZffdhM7RZ9LL75AtX8ZMxjQ7/Uji2Ay5nAsyRMW+kXG9dedR3LL177+df7yz/8MA3z4Ix/k7rvvppyMyQcDer0eIsK4rHBVFd/vPc//4Bmut5bX3X03hwdjvvnt7/Df/7P/F/fccw9ve+8HuVJVVKoErchMDsZSJiseNbF/MurJQk09E2I/dK3IKtJWjewI/FMiySrsDob0ej1cWaVK6NTShBCNgWyqGlUSZs61Sb+bENewul/x4OAgzo8kgVpfB5vMt5daWXIT8LNsOzer8C+rQG0GLgO6oFa7EShkLl+zaaVyDWDp+r0LZK7rxVwGTGfWkBDZK6LL6a/rlFc3Amc6VY5t20PGvvujqQ2vm9PLzt1R1IDXJTzmq+7z1lMzx143y+EsO7a6/o1LbKa2Yzu24PKa3cS2QPJnb9ha7Q7Vnu1xy0238PY3vZUv3vdVXv7c81y/cxoLOAlYUhUBTZYUnpAZXAiojyDSzlgxkMBhxFGh9oEMAas2VluS4ptIQIxirSVLWVavdfUyWn6oRhCpOqUZuvTZXiMdrtQIMieJXltKApYhME5U3jJ4Jj5ajRyUjsoo0b1EkzpifF2YARVTVbsZKlkIsyYVKT7W1Cc5AxibV8n0dWIaamx8uq62SPIgTeKimOhhaTIKsTW5EMTRywz9TNmxll0r7Ahk5QStxjz31FM89MAD+IMxP/+eD/LxX/gYF85fTzX25HmPYHNyGwWCJpNJ02N0eHiYei/7i4HOBoHFURMhS33f1tBu9QhLltLqpWwFNdKiO2sqdYUWqNR2sMg0yDSAhngu4nbaqCRap9qNJ5OoyIwP5AI9m2FFyUKJVCW7NvDCkw/zra99nc/91Wf43F99lqe/9z0unNvlDXfezptf/1peftNFbr/5Rs7sDiKLYDLCT0ac3RmAWFQFE2L/pu310ACjyZhqXLLbG2IsPPm9J/ni5z9PNa5497vfzd13vQab51STcaJBVxhr2d3dxRjDeHzIlYN9NHiuvPADztx0K7ffehMfePc7+Wf/3f/IX/zRH3D7Ha9k9+wNXHGOUBmyfoG1sdJe+nZSogXIdXrODKEWJZ3N17RGVGKuaYaGfr/PoN9HvUedR7Iina36jEkkyEpU4lQSnV1a3rwhzMzTrp7L2XnZ7rmcE5LZUJBnWc/lUWPaLrCzCmgdZ0zVYjs+Qxd3zHde55vRau0GYLErEXUUT8NNANcyULK2klkrFc8JHtUCcyrzuDzMKrYuTcTpjM1HWzl2Opeks0d51emqn633y66ZY9fCH/QkPZergGStGLv0bxsM07p5z2xD02s/K2yFzCYbtxHzdmzB5RZgbseSzJ33DmOhlw247sx57nndG/mXf/LnXH7+EhdvC9FTDxd94IxNAC/Ze6TALwSPIdp61Itz4wUmghoTBYA8+KAYApkErHEYDEJSePSBLAXKxkQ7kkDsq/QhpAqHB2NRCanKGMGgE3AEKqBMAj0j55j4wEQ9lSpOBB8C4xBBZyUJoNbUyFoYqK0AO3ebljpITq/RVdnoJLzQ3JTUTj9PSWIoMvPaGBzHwCM6Y0RKcmYMebTvxGJBHQFPTqAnOTuZsJcJfecJh/uMrlzhsW9+g/LKVT707vfzb/z23+eOm19GmERV33JSRa/Dfg9roy2DqjZegYPBgKpyXOs15ihViXbQ0N2zJifahrU9UQsbkoBkI2KSRUAq0vRdkua2qieUIyzKILPs9Hr0jaE8GHH5+ec4ePEFvvHVL/D5v/oL/u6LX6SaTLjtpht520fex92vvIOX33oT1585w/kze2Qo5eiQ4BzeR9/LPOsx7A+a/XAuMB6PmZQVKmCLnMHOkKr0PPDAAzzwtW9wzz338N73vjcmYqqSfr+PSrzOFIkXQgb9nR36vZxnnnmaKy9eYjDY4babL3LX7bdxz2vv4vf+p/+BD370o7zxPRfZrxzBK0b6mDzHhdhPXRteNKF0A+YDyqzKqZkLlCPlMHrjNsBehF5RUGR5TDRVJdLrRWp66v8meepKiJVJPzNXZq/r+pzPVudr2xudAYILdu9HFPS51vdk7bDIaIOxtiDN0YHliutzie3ssa9BWb2vx2U4rEt6danFLlPjbR9TafkTR0GfcKLtO5J4jpqpHU690oRwpPN51O8/blz4UjHf2nO+sXk5JrDcju3YjhXgcmnQteFFdpLFp724HZeWcNKF4GdpIVl1XLtoPMuOzWzfUOorSrzPftbXd771Hbz6jlfy7BNP8rI7XsnpG67n+dEIj5IXOa4CYy3BebAGV/cxaUBSn56GqCRrk5dX4wNmoiCQqjKuSjKE3FiyrMAYCD4Q1OGDIpnBh1i19MT3R9Ql+Bp0WkulSpV8MJ1EWuxEI/CcoJSiHPrAxAec91QEQrIp8UiiL9pkPRC9K+t/df1y2pKU/h+mfmbtYsbUXN2kdGgtI2JncvViBIxgpcA7bYCShFRF9Yo1FiOG3FoKARPitlkJmKB4N+b0Xo9CSoZWOd3LKSZjdHTI4fPP89D99/H8U8/w9379N/j0Jz7NDReux7kQe/Kc4JMQSjmZNLPBSIZoqvw4j+mgg84EHswrP9bBlywJfmQmplvmw1S/r4uiOJNZX7seLK/szKg9Lnl9keeUZYn3jizLyG2WAs44NULqQ7ZZpClPJgegAWs1JmQkcHZvSM/A/gvP8/1nn+WpRx/lK/fey/1f+Tse/NqXGRaWO2++ide8+m5e9co7ueni9Zw/fYqdQZ8MZTIeR9GZ4ChyS3/3FIXNsAJuNAJgf3+fvOiR9XrsTypslnHmzDl6gx0eevgRPv/5L3L33a/m3e9+D1mvR5b3gDD1aFVQE3AOxEclVcksp/dO8YMf/IBLP3iG3TPneO2rX8VrvvEKvvKVb/Pnf/SHvO5t7yAXQYo80tZdSa/XwytJdCce08bvkKnq8nT2SFOdJK0Vklwxsyz6MDrnKPp9RISzp05z9eo+RgQXQrIgmc63upKsGtV7jTEEV1H5Ml6B1mJC/GxrhbKcRNEgpt6IVVUt9tj5NlgzsxWNNfe7mWpVqwI6Y/HTRa00plVlX7g5Y41ZWdFbf/9ddr8/WdJo3X16WiFaojLbgDhbQ/7Zdadef+3qvsWw0OMpnUmpZZXJZeCtfv06cLfuGM1byUx/Ty0h3i8CzDovmbKcq6i367Z/qb9lHWAmn9Blc6zevmWJjmVWLvWaG0E6U5YP06RNcw0DIaiKRL0FY4ysokEfpX8/hHkBpjCzvTbdr0OTVNSmsm86s4/bmPUnLZbejiXg8sftJG1P2k/WUBRrckKokoJlxstuuo233PMmfveP/ojXveXNZDsDzp49x7NXXsSXEwb9PpiMq5OrVMZNb2Q6XZR96rGUzDY9UyomimoYaYJz56I4jpcIRI3JEFWcD0hIvZTqo5CPhNiLKSTRFKhMrFR6FJcUYp3CWBWnMAqeKiiTEEV9HOCbXlFaALGu3IR4A6lvHEJDm5zSKKfBiZu5ebd8zNp02GRPEatdtmWGbvClb27x8Z5lUA1N7+kgK2K10gfwJVVZIZUw7PXZGRbsZsLeYMBQBXflCgMRLj3zNN+49+/QwxF//zd/i3f/3Du59aZb6ZkCX8HYO3CJPmgzbGPIrce6WV7LIHRZsuQon79JcmshOaPdFNvxeIy1hqIokKAEdVgycmvB2ki7DIErVy7jqzFnT+/S7xXgx/RszrC/wzOPPsxz33uCH3z/Cb78hS/wuc/8BZd+8BznT+/yvrfdwytedgt33nknFy5cYGcwpMhzjEI1Kbl6cJUsyxgMhhRFgTHx+8ZliSsnmLKil2f0BrsUgz5jX+GtpdcfYPoFB+MJ991/P4PhDnfddRfXX7wJY3MODg7o94tI+g0OF0CMJetl2CzS/dx4Qm6FXm65fPkKOzu73HjhOl5/96u45eJf8YXPfZbffOJxbrj9Tq6MS7SCLO/jfFSIttZCiB3TKoLRSBNUTGuetV1xtQEDJhVRA7OVxtzEqrr60CjKzvbR+ml4unAvMolaL2QdlT1jJAa7mGg1JDZVWbuA28mop5teF+sC5aOAm02ul4XvXXM/v9Y9qWsrp22wnijOqxLiXfu3CgSt2v6jUJA3TfCvO79rD1+qZi47PmvjMd1sXi4TaFuX8F7WJtEW4+kSRjpKYv0kYkOr5v66z6xVr7fuJduxBZfbDMB2zC+QqlhJRuUIllxuvHBRP/y+D/HHf/pnPP3Y45w+dxbKEXuDHiWGqixxUpFlGa7yqEl1z+RL6TTaenhA1EMLUGldbRJJ5umBEBTro7CQxWATeNQUjHp8FNyRQDDR+DhoBJPOGCqN1c1KwWugDNGrsgzx9zIoVQKZQUmANUwBofqmsjqvPKkhTA2dmYoMTDO/bVCSZEO0FlqIj6DRRiQeA5OKxYIkIKkhUQJT5TKXKPhSZDmFNUjlEO8w6rA20MssO33h9CCnZxzmYJ/hzg6lK3n2qaf47te+zuTqAb/6iU/xSx//JW658Sb2dk4xGo2pXNwfEYPJLVmWEdQRPDNZWxGzJrAxKwOkZWIaqwKRawVMZ1+3WrxjHa0xEyEzlhACVTlGvYM8TwkOIct7TCYTzu4MKLIh1eQqubMU4tl/9jm+/q0HeOrxR/i7v/nX/N1f/xWHlw65846b+flPfYw7bruZG647y8XrL3Du3DkIyuHhiGp/vwH7gyKK7eS9SF2O1NdDDscOP6k4vxP9KxGlBC4fjvDWMjh9mv7uHg987et857vf5ZWveAWve93rOHV6l0lZMpmMMFbp2ZjEyIo8UkqtQRDK8ZjD0QGDXsHe7pCrV6+yf+UKedHnphuu59V3vpK/+PxX+MrffoFfvfNuRiNlUk3I+4pS4b3H2AyvigQf65AiaJj2GqoqWcuIftrdGF9rTawkKNrU/fO8F3uFA3inM4Iwdb/0TCXFzPa9zfdcGmNwzs1UYBaon6nXtgusLgoQLQMp3T2XgW566LrkrU4X8BPfnzfyVVz+Ddfsdev6I5cBqKN8RleVb1Obj87Kct3p21Sjw5qezzBzLOoK5fJjb1Ycuzoh2N6PlojcRuc/HHnNXaVavEnlvLnOZLUdTxTZWnNuZLNkyeaJlnhNh7rFQebPQ5iyjLbh43ZsweV2bEf3jctIRsCTZXlCSgELcs9r36A///4P8ief+yyvvucNTA4PGJ47S5g4Jr6i8mBsTqUB0QxJwieVBqoQfS2DGELlUKORbmk1va42EBesTT2Y3mOxWHxU4AsQgick/8ugijepsGgDXgUnijeREutUcRq/d+I9ZYi9lg5J4DNWGbXOeDdU3tmemqBz6ocaYoCss4C8+fOMS7whirqYpjIpGLJaEVZNslqYBge55Dh14KfVytxY8iwnzwy5QuUmhKqknxl2ioJhkdHPhBzHIDhyCfTdhCceeohvffmrnBvu8Fu/9Gv8w7//Dzi1u8ewGDKZlFSlJoN7G7fNRLuMGaHUedroBkqNR/1blyH5UY27jwo0V72+7WjZVcH0LtIpe3lG1sviTPcO1UB1OOH07i6+OsAGOHN6j8tPPcFff/FveOqxh/nSF/6ar3/1Xg4v7fPWN9/Ne//+O7j95pu57vx5rr/uLBnK4eE+l59/juA83sdjM+wP2dnbpegPUQ2UE8fBeERZOpz3WJOTDzOKnQGFtThXcTDa59A5dvZ26Z/aZVSWPPTIdzl15hRvetM9nD9/jmo8pnIVRS/HlRPECsP+AGOTqFRQsEKWW/paUE5KBsMeZ0+f4WA05tILz7G3u8tdd97Jvfc9wOf+4i/45K/8BoM852AyilQEE3siQ025lTjvUc9ixS/1UROTPrXvYQSjCZWFaY+mzXOKomgAYVYH2TGVFbWjNdLQp3NmKgYW0ud5IsVeBcqypEoKuTVIrW1KSMqp0UKirvDX4HX9PN+0RWRT9dJFkHntyiZtldil27XIQ39Jk9RHsbZYRs1cdfw2XVfWUS5PmnA/Xo+igaZSf8xt2bByuQ5MHuV8rfrqTSiuqqoiIm1gelSP1E2ViRc/t4H1Ww/M7diCy+3YjmX3lUD0ojPGEpspDXi4cPYcv/SLn+AP//SPeOzB73DXm94A3uPKMb1ej0IyLu+PItU1KJgIEl2ipTokek2GVBEzDiTWRusgwIpEeqFR8NHOxHoi7VQNQT0htOxGFIKNfXIBwatS+UBF6qUMHhc8Ex8YuypWKiVuS+NEqS06Wd0nGpIwT5jrr2zl3EP7VihzN/iWiFHMb0rKaEuqxZppT1mQ6RcEJRPF+LhdeZ6T5zlW4jmh9KCOLASKDIY57ORRGbafwY4E+uWEXSs8+vVvcN/nP8+eLfjNT36a3/rVX+fC2euSUJLgJgEJgskLVMG5uN8hFm6X9+ouqGGapaHBJjfudfSxtTS9rs+VVcHBiqx7OkNR6n9uL3XaS+59ILNKkWWId5STUex/tBkXTg1xk332ipz9S8/x53/6h9z/pS/ynfu/yrfu/yqDzPC+d7yN97zz7dx84/Wc2tvh1O4OwXmuXnoBCBzuH+BcYNDrszOM9Nde1sP0e/hyTFmWjEcllXcgll6voNfrkWUZvpwQchOTKAL9U3ucveF6bK/ge099n8o77rnnDdx6280EXzEZjwghsHtqh/39MXmvhw8V5YGndAEl9lsiinMlBsFNSvZO7VC6iuADZ06d5eYbb+C6M6e570v38tRjj/Dyu1/P/sjhnSfr98kMjCqXKqERQEo6zjEo1EYUS0k9n/W/Wk02VQh8y8IoyzLyPMc5R1VVCzfAWO1I16Rp9Xh2zBFjYj9mDS4bdc4msRLmRLsisNTk0xt9PIWuvt56hq3yF1Q8QRb9PrsDbl34afTagZvjVn7CCWjBsuH3rrNbaa9bx01CzdM8V7ExlgGk+N7EUJEw99qwsOOim69/mwLITexOrnUCYJP3zPfFaqOfwFLnyK5kRxtgpnfJJknIZc/XvdpdwL32J53dVpmlLG85sduxBZfbsR1dwUEAsaAGV3qyngVTMMwHvOauu/nIBz/En//Nv+aWV7ycU7s79POMiQvk/YzhcMjBpMSp4j1Tv0mVBDKjBUiQKMAQvAcJjdKeQehnOSakniyS8UMIjem595Fm64iVS1VBTayGOJSqUqokTFIGj/NKqR7no6CQl6hS25ghz9E5NWgU0alvQh2UOBWmwjYwJ/8+K3gjWKZiPgbRxBfW2g8tUexC9PozGjABsiynyAryLMf7iqqq8FUJeE71C/b6O/SN0rfKoDAMcsuOWsoXn+WBr3+dr37+b7nt4i38O//g3+KTP/9RbrzuIpPDMUXepwpRjESTnQPECqaRKchu7+8qMaiNMtIdQdpRRBY29qCTTbZn3X6YlekXk8qaoXKMqwm4CiPKsFdwaqeP27+KH+3zV5/9W/7ij/+Yr/zt3/DME09y8/lTfPAdb+PD730Pt7/sZm64cB5XTZhMJowPR5RlyeHBAWVZsjvc4dRunyzL6OU5eVEQnDK6dJn9/X1IFe1ekZMX8XVROCugNgLL/fGIsfOcPn+G3fPnIAnY3HzLjbzytttQ7/DlhFzAmYAlkFmwInjn8J5I5TZZc4zzPAfncc7RGw4wxnBwMEJNzum9U9xyyy08+IWv8vX77uPlr72HQb/HVRewJnqnalnRSF+oj9fRnJ1obS1UW76oTAFhQKNwGCUecBowmcUkwR2XBHrEaGNLYMSk+auNAEej/izJWzPuINZGgFhVI5xzLbreFBjM94NNEyTaSYNdBUoWXpd6rJFwrKpmXasVPfq11J7j3YH3Zj2XJxHsU1b3LR6l/3J+zdok0TUPFI8qBtP1PUdRLFU57jnbHPCtPT/XGFgeRSByXV/vrAZAc1xFWzu1DjweZT7Mz6eTJF22Yzu24PIaj5faVHo7ru2QxiIDsqygodrkhZw/c1Z//Zc/zefu/Wu+cu/f8c6PfIi93T2qgxG+mjAoBkycEnzAhYBTJRhBk0pdleipDsEHH900xUZwaaMBiQtKTgyeTSugIyieGNgGNILLECuXqEYRIBNpuKV6vPdUGlVgnUT7E4+J/piJY6dGmt6tqeqgn6G4Lc5nZkBlpMfNRQgtkKI1zzRGTjgX/fdEDdIkQCNUtQo9Y7DJ39OqgapCqwrjAhnQyzKGvYK9QUHPePpWKVDc4QGXrlziqa89wHe+/BVuu+Ei/94/+rf47V/+DXZ7e1x58Qp7wz3GpUOMxZisUVgUiXTk3GZU43HjTUr7pqqLmfmZ53Ua4G6a5T9OENK2Apj/7IUqwjWyLWgP5xyoQzRgJDDcGTDILZPRAc888Rjf/eZ9fO5P/5TPfeYvefappzndy/jIu9/KJ3/+I9zzmtcgBPpFhgkBV3nGB4dcPTzAew8o15+/nuEwivi4soog9nCCrxyuLCEEiiyjVxRkRYHJDKoerRweyIoeZVBGkzGaGfZOn4JBH65WFP0+N954A/1+weRgnzyzWKKyqhuPyAXGh/tUXpmUnsPxhKsHIzDChQsXuOGGC4zK/djrOXGIGkajEVcPJ5w5c4bbbrmV4eABvnzvl/jkr/49+nnGpfEE43wrSRO3dwqIplQ2CdMuywj6IkCshTKYAR6Cd9pUG51zcxYiLd87k3i2EqIRyhKlS8nitVxV1cxnLQaacdu0K/Gkm937loGoqXLu8kB34flWv7dRTizCtarncp368jW4A3Ue13o3m/sTyyyEuvenftSJzGX7vWwt2aSSuQzUnNQXshsMmU543mbUtBWJ699XbcNRi25dc3FTcLcMiK9LJNZq4Tr7vmQlvPjmHwYIjEwIwWyx5nZsweUPH1i+VD5H23Gtb+2xellOKoqiB97DZKIMchkO97jrjlfx/ne8nz/4yz/lrte+jgsvG3BqZ8jBeMLVg6v0il08AXxtZ2FnPOJCCIkeG5VcAwGxWaS4icH5kn6WUxiDTcqNPghePapQhli1DCheotBHQFBRXNAk4BNwIf5fJS78mj5LXbrdSt2Q356PvvGsnIp5RPm30DBXE1W2lsRXXbzZ11XLkGhwgAQbAa2r1WeTX6iJVRWTRM53iz5Wo1pm8I5JFW0R8gz6heXUoGC3sAzx9IJnRwxUE1743uM89eDDfPsLX+S26y7wf/j3/wm/9PFPoJUwPhyTZUUElmIxRU7howKvFYNHU2DfLVYyGzjINVsTlgUsx/W+jKdhSjMOTPsnzQbfV1fKAqbxqIw/4/kSDaAVhVUsSi7CrlUOLj3HF//6r/nrz/wpX/jLP+HZJy+RAR987+v5tU/9Eq+961X0jQFXIQRefP4So9GIEGL1bFD06A0H7OzskIlQlSX7kwmisf9vcjhCfSDPc4bDIVlmsHkBEqiqABLIbEGR54xcYKJKMDm7p/cYXHcDZJbDqsRrYDDoR+DkPf0so6pK+oOCiZtgswIVy3h8wPeefIYHHvgGX3vg64zKCW94wxt429vexqtedSeZzdg/HJP3CnZ2drhy9YBzZ04x6Oec3dvjse8+xGR0Fdk5R3AllZtQqVm4XmSWXB4BZUvgJz2bFGBlBly2A0crgvcV+BBfr63qJbZRZY62QYliL1VcF4QoCoYgJmsSWM6Vab1yqc0zEEK8ZutrpLFugmPTL096vXTSvk9Ij9VOxUtZAjiv3X5LSjYYnQeVunIfovBYfS5iNdrOrVvzvpQr4xQJoHY1EGutG+uopzWdc+3ap0xlkY97TIM250/N7Gc2zy/72dwXw4nma1e1tqsFYiG5gzT3omVV3K652jp20hbZOa5i7IqDO3OulOjHG5lM9d+38e12/JSCy3ZWeFXVZdnivZoWtn7BOynf/6jWBNsxfzzCzI00BkjTDH+d/evqqVOZ+mVlvSw230mAXi/6ikgmt93wMv1Hv/VvcO+XvspXP38vH7n+Bob9gucPL9Mf7FGlzLA1OUagwlFWVaQPBkVcpLj6EGmyldgosBNiX9vpPCN4z/+fvT8PtyQ7yzvR37fWioi9z5RDZc2lsTRQaJ6NEUIgIUAYIcxkGzfG7sZtc69vt93X7Xvb93Y//bgHt7tN+wFPgG18acBgzGxkZgOWhBFCktFYkmoeMysrM8+0h4hY67t/rBWxY++zp5N5qjRwQk/pnNxn79gxrFjre7/3+97Xi8Fp0l9UCAhBhFpsZCZD9KtUAa8ae8yIpum1WNQY1DbldJOFyOTZpLer6Z9KfiaiLgKAoLE3TJLznmjbm4k0JbyT4MMnUY+OKVsMkkNUhSV54llVbDCYAFbAipIjZMZhjcGpxXkTyxK1xlilnxmMtfR7hu2NDOPH3Ly9hQyH6N4eDuHKY49x/wc/xGOffYCv/fKv5nv/8l/hT77pTzAelilYMvjg2djotSDKGMjEJh/AGJH6ugIkSkIcSQzp3ElEdYYtUo1r/JxnWoPizOLMf+N3qmIWxq++sX8x5gjDoBq7cX2jMIqiaiKAaG1gZuYl9RgT92PEUXlDCLBR9BHjOTw8QKjJcwjlkA1n6REQSur9PT78vo/yM//qx/nt3/gt6kHNmT5829tewzve/jW8+O676Rc5ohXVqKQcjRkc7EVWWgRnLa7I6ff7uDxDQ+BwMIpMfIil3XVdo8aQ93r0ej2sc0l4KfbtqkTLkCCGIAZvLE/v7WI2trn5rufBzjk42GXvcEyNoayV7Y0NrHGMR6PoUxvi/ai8Unrh8Sev8ku/+B4+9KEHsAK9HvzCp/8DD9//KO/+lnfz8le+AtfrEUKg6Pc46wz1+JC7bjnHTdub/OEHPsjlJ5/gzi+5if7mJvtVRS0OsTYKZKVg1kpK3LRlqjM2Cmkt046Nz3g8xros2pQQe4WzLKMel1TlCLQC9YhKsooRxNhk+RPHr3EWDeBDTQDKoIx8jSPQ39zgWnWR0pfY3FLWFZnrpfnUJjXrkMClYkRb4TOCTqmFrl6nZvorZcYzM2WmZv3+pvY705tpzaTaY+IbKO2/l7FM8X2+bUmgqaqQybxWVz7lcGbLPqdPaeV6PY/JSsfkoVM9MuNnOWfuEJPmBEl9ulO2UtM5RJ8Eb8zM/NKeR/stoT2p7t+Cn103ZwRtmO6pbM87zCbZda4a8Ty1VJnxvowMZDgKksIE+DTrZvdnULAmtqqYmeSbFelU4dgjt+jINSfMF7BJ94CkvN1eO5OSlgt63ltmeaZaRiYDKI07NxkH8RelPQ+d6nNVwOhUG+ZRIae0o0ks7OfGzdLtfUll8qE9vsk9jDFUOAqeWSa41Tm+NePv0+10W5UAmfecTY//edUEi5+V057L021t8D5bBkRqWO8kqjvJeQG12GxT7rjlLv2u7/wu/vcf+D4e+sx9vPQ1r+Q5t9zCxd0DyrLCBEfuDKWvqcsKI5C7DF/Vk37GEFViPYIPwjgtWD2frDEA7wJWLYKialEJBJMRgsFLFL/wEMteVVM/ZdLLk4kPZZiq6UwWKE2COi0umvodQ9OLGCzaXpcJ+9quA415deoDacvkmvJNlaQGa+Kir4rxggmKFUOOJbMmWluIYjUyNKH0mFRiE6jp5ZbtnU02e0KBp6DH+OrT9OqKbQxPfPqzfOT9v8dOb4P//Nu/k+/8M9/FK172Snqux3h4BTQCkaCBsqrastLJ/ZdptdYTyLyu6xN39G8eTDa5xGskmua/JzDdFTsd5LY9vtoJWhAQQ99ljEYjxqMDEA9hRC+z9IxSU5H7Cj/c54kHHuQ3fvmX+Hc/82+49Ogez7vzDC961XN49zd8Dc97zu3ccdvtYOBwb5/Dw33K0YjxeEyeO6x19HobOOdiEsYY6iqWdRoR6gZUaiqPtpYsz3FZloZxClSMSW16McitEcY+YFyPYmuDrL8BITAajhmPK1BDkWeJ4EieptaBUXwFB4N9nnxqj3//O/+Bj338Aeoa7rpzh/Pnz/PoE4/z4P0P8dBDj/Cc5z2frTNbGGcpigIRKKzhzM4W/cxhPDzyyMPc+qIvQYyiRpNvZbQZ0kAEZSEG2Q24jCyxI6aSpoO/SbDujiRBRSQBDG0NPQw2BZdJmVZikid4n/xxNZXlJ/bDmvbZ8FrPF15hsQdfUwfhl/TsrVIXbabbsEYidZ0SzYXAYIllR9ODGhKws6S+cNGVx9MG4jfgFXj85z0wYaug24XQjp81kt/dOWgi3BLbHhb1Ua66povOuxFgmnc+3X+uIyY0de1lAiy7T8iRnzrnp6R0XLAdwM7aY3fVWrDIimpRpcpxx0loL8D1rU2LrEyO3uhwhIYx6wT3p2qyp9sXOnN5eglOt3kLYBdQdCf4xnQ6Mpt2zmQ5M+EGz/Oe93x561e8Rd/7gffz67/6azz3hS+gd2aDLAiaRaZIXYZUynCk0dbAWLwvI4OQVv9okg5BPQQhqKf0INagasmCSQAv+k2FBACIcWL0u1RS+WuyNFEfVSXpCkTMZH2bjKPGEpxGxEY9qZYo+e+ZRvBGWv/KVlxEuz1Pk6hAQmIuNGbSbUgg1is2ZWYLa+hZh7Mx8BVN3pkSItvqA8YENvs5Z3Z6bPUcRktkPMYZoWcs1cE+n/7M/Tx272e45ex53vn2d/BN73wXL7r7pXjvefrwaaqqIs96GBN9MqPSqZ/KUKmGmcB5/QVwPvs4g8HX6HtcZYy+HjDVqax9N1ALOgmkmr40I4LpeKYZFLRGxxU2lBgUJ4JxUY03o6ZWz6WHHuQ//Nav8Uv/+qd5+DMPc8fNG3zdV7+a17/6tbzuNa/klpvOYFCGg0MODw8ZHQ7wocIZy0avoN/vk2VZVGAlKoT6EMe/JQJLrX2rhNqowEqqPPBt+VrsZTamUVyNkGw4HmLzHjs7O9DfgKpmuL9HPRqSG6Ff5BgfrTVC8HgNuFQavbe3z4c+9CE+8pGPAPDc525z5223c/bsWYqNPp+6914+9fFPcM/LvpStM1st8G2Cxp2dHXZ2dsgy+PSn7uV1b3kbmckg1GisNW/HWCvaM8OoLU4smDn3e77Y1HLwo5My18RCNp+x1uK9j/6Yc4PhxebubWHmkqAZaL9v7hjukFzzgIyk3vWlz8YxhEeOE8BP7FZ0Ouetx1eJvr4kla75vlXMj5kk0XQ+cIjHb46Uvk58D7vnNmuVMTsDhrkltIvLqOdb1RxH6Gf2CGQG5MwlHFMyQZb0iF4vwJw63rX6eG8MaHY/F1KwYTtfvO74XJUknafou/QznOqPnG6n4PLzBhQdh/k43eZfy2W9Dt2/HeF6uqtTeltZlpq7vrzoRS/hm/7UN/GZhx7gt3/tN3jb176D82fPsh8M1Sh67zmBzBlqY1BiuaExDufBGMWEKFLT2IuoxuDaBsGoj6ybadRkFYxJ/VGmLYvxIfYnepP641KtjIhF8YgaLCGCRdH0MyQ/y2TH4RsGLz1Cmop+QmRWRaVlh7red6QgJNVVRaMR7Sq/TspELQZrhExMFGSxEhfyUBNC3ZYQ9YqcoNHmYmczZ9OClAOy4Nm0OWY05PDy0zz48U9x6cFHePGdd/Ht3/Sn+Zqv/CrOnDlHqD3DaoyI0O/3EVLArNoCy+7NPZJRX6PdZpXownGe03VL8ucFBHPHdQMudXIqRiZDWENox44mhU9RHwN6DeQWZDxE1bPRy9no5dSDPR5+8NM8dv99/Mov/Bzv++3fItfAn/qaN/Gae76Ue178Ip57510EX1GPRwyHA8aDIVUd+45zZ+n1Cvp5EYWqEnNaBU9VlrGci/i695E5KfKCXq9HnudxnPtoq2NtFtmxRqjGRIauDp4qWe5sbm+xvb0JmYWDQ4aHA8TX9LMcrXz8qDHUIeArTyBj/2DAQw8/zAc/+Ifs7dU8946bOH/2HMYYxuMxZ7a22d7e5qGHHmJ3d7cTbAbqsgIDRVFw7tw5NjZyPvvZz8YFyTlCKAkSPWqNaYSsTGKVJuJZRgQNCcjMYXa6AXzLs3cAYCP20R1PQZreqOT6k9x/fHqOvU6sBUwqEw8LwOWUj+Vs7+eagfJaDMySz6zw+1s7WF63Z/C4DOm8ntgbBZjLv2/F+3X9/QomgcMw1SM5db1XXf85gHBdkLjIamPe/VmopHsiYk60538S7UfTVi3rrws3YseyzueWJVNnk/GLFJ7XqSo4beE63U7B5en2RbsdKYElBnrdTPh8hMqkXguwWSa1enq2kDe+/g36Z7/l2/jhf/7D3P+JT/G6L/+TkDkGoyHluAJryaygGGqFzBVIiKWsmSqeQNBkeK5QE1p7Dq9gAtQJSpqk+OhDZG9Csjjx6T0+KQlaDQnogRUDKniRdr+JFkBCZBdD0NhP0ZbfudagXTW1nYq0mfvQ1NQ2/pQdywOnSX2T2OeKKhawCJkRrBgyAYdHgo/gM3gsgcxYxIErlDzP6WcZPQvOlzhfsQFseM/lRx/jkx/+COMre7zlNW/k3V//DbzpNa/j7M4ZvA+o2AhiswwRoSxj32WWJSP7MFnm5wYtC6MxsyAoMyttPros1VFweP2S9kdUPNseIxPLlrvKiemrNLRpiZZxbvwLLRXDvWvceuEcuS0Y7F1l9+k9nnjofn7j3/4iv/6ef8t4f5c3v+oV/InXvpp7Xvwi7rrtVjIRRntXgag0WtUVBKWXFxhjyIyQWYezQlWNMc7ibN4+i76sCD72rvY2+q3th8tTyaz3iWmO1iBtX5cxBJMAEUKtgazI6W/1Y6NkXVMl1lK8kmUGqjr5xAbqOv5ejkY8+OijfPDDH2F/f5/zZ3rsbG1jEZyxOGPJMstGv+DiU7sMDg6RkMQsfKCqKrBCkeVsbW7QK3IeffhhQu2xeerjCgFj3ZyyP5kK5KfB5PzywVg5MOmDnvSWh0mSQs3CoK+xE6oTkAwhtOI+LUjVOAssL+8+akuCMcvB4THG+SJhq2X+fccRr5kLVGY+0pTHmgUuEcriUuEbBQaz42T++Uqr0tstN10I3psxoiy2g0lz2iJmahF6nWdTM1G3nS2vlrbHdVHy7DhJ9/kJuqNF1hqaHsgF1hwnnBh4Nj1Wl11Hn2YeOzOCw6xI1Zol5ov9Myexw7TK8bLzOAWfp9spuDzdvkC2RdYMs4DCWrs4EJGjU1/lvRaukIPxgb7wjhfIO976dr3v3k/z3t99H0Xe40ve9HrO9nPEBA7KmkIMQZXSRwsF6hgUehsIBIxGls8qkUUIkUEQLEEFvEnBZAR4QQMh2YoEH6hVqJpem1ScNhGjkHbC16YhpwU6aYFXCCGp6alBsJNeyrSLKHBhYryaGFDp9ChGxtLgEBwmqoomA3iH4MSQWUsmgK9xqrgQxUCcUZwzFLnDZpasMGS5kGlF5gNbzlGI5drjT/Dwgw/x5H0PcGFrmzd9zdfxrq97J6+852WYoAwPDynyHqNy1ILj5p7neY61lqqqlvpP3mgQuE6QtLK0dYVQ2KIy2/b+NtY53c9qF2DGgMtoVCuN9dkR6Ftq7rjjZsq9y+wPhuw/fZn3/fZv8vM//VNcffwxXvz85/GWb/5Gnnf7LdzzkhfRzxy7V67i+gXbGzkXL15kNI59rVmWkRmHczYK9zjT3gNf1fgqJEaysUiwOOfo9/tt4keBqq7xGkAMxrrkyRHFN5p+QS8GL4paYXt7g50zW1GTY3eXg6tX0fGYHMXUnswKofQEX4F1iCqXn7rEp+79DJ/81Gc4s3WGc2fOs5EViEK/KNjY2MA4x01nz3HxqUscHu5TVWOKjSKCcomJE5cXFEUE1JcuXeLgYJ9iY7u17kBSMkdTryUaf7b31CxNTkyAZCeUnhV20qNWE5pUKOPwkPa6BVWqEMtgvZ3HVMrUuDRGog/umoDvJBODxwcZ81nOZUDp+nuclwOC6z3+dY75yPtm/CBk4fHLgoqe1cDuiL/uMaqpFpVNL2JD12HCr3dMzGXijnm/j70+oGslVK5XfXkek72KTZ++DyueI1kfAJ8ymKfbKbg83f5YbVOlsDNKdEfmPzUd3+KAGCOBQD8vRAm8+iUvk29+5zfqpUce50Pv+49s3XSGm55zJ2eKPJb4qSEEYeQVJxpVLY2QaRQikQQuaw1UGv8Wi0hNZBY1BqMaoophQAnGRhsShBCSw0CjEKoTfzvtKJNOcEtDT6TXQgxqY5mrdISAusng2Otp2jLYMFGDTGI+FokqsGqwGMTEjHEmgkHJCFiJxIaVgJOonNpzGUXu6BcZ1oItBPEVpq4pgsDBAVeeuszlhx9h9/FLvPDCrXzT138DX/0VX8nNN13AYQkEnM1QY+n1HJKM7xtfN4CyrCnLCmvt3MAoAvA5OdSkdjsvQ36cYHTdnstlvUmLfAGPBCMzIGWSeIhpZJMApTSMjIksXI4wvHoRUx7yn/7jf+Tn//VPce9HP8qtZ7Z529d/LW945St57l23cWZjk3p8yOHVXXKBvSuXGQwGZEWPjX5B5gqyLCO1MMfvC0o1LhFNgDFS7RjjyK3D5b0IzGxkIn3qDW7PzVhsllOH2JNMApctk+4EK7B5Zgfb60E5ZvfKZfav7SI+kFuL+GhFQ6hjYsk5ruxe45P3foZP33c/3sfS1n7Ri8Cy12uvb+4c586cxQD7u7scHhywubmJppLrqMZqo0endVzd22V/b4/splvJjGVcNyrVtD2XBml7wFQbT77VPoJRYVNbcaYuwGwYbLUpdTCj8RHamcIcFbNK+7NT6o1xzERWXPDXMcdeD/hYdQ3mvdYoY3fdSGaD2jCnhLf7jFq1M2DAJ+YnjeWWLV4AGGeu53HBaVsh0bnS0/s52oN5nMB9UfnobG/nkfmnnVPmlxIvLFPtzJfxWMMMuDNTwGYVcO0Kss0dA8zrVZ4jE6VNO0eYHgNm4iGpS4Bsq/83+226/vheBqqv595O3dYFwK7pwYxORc9yz+UpwDzdTsHl6fbHAVjOZurn9rDI9EKVZznjcox1BptAyVd+2Vew//Quf+8f/B/80Qf+gNcWjjO33IqrPbmzYB1DohJmCE0AFENLQ4jy4wm0BTUEYzBExpOgbWkWRpKgSUjqjxPLjzZ4Com9NAKppDWJtU6X5IWUvQ6pTzN0QFQjD5/K3ERjN6rBxr6wpmSuqU5M4NYgmOAxGtlKawQripHYW2pDoHDxc06U3Bn6mVDkhsKCs4rTGuqSnjGYsuThz36WBz/xKbZNziuefzd/7lu/nde84pWcP3uOg4NDggXrcmqNNn+aSoK9923/Xuy31FZE5kZYhHWDxJMuiVonUG2qnpV58WMKoqgTwIl2A0bBJBCeS+Cx++/jI7/3u/zyL/4CFx9+mNe/4uV89ZvfzMtf9EIunDsLVYkODzm4doXhcIhzUdRma2sLk0XuOi8KXBZLztXX8ZtCSP6JkYl0Lqfo9ciyIiZZiGDRex+BJYJxti3tVjGxT7CxckuNpCFAsGBwsTS1KMAZ9OCQw71dxsNDtvKcwhqolXI0aMWCgofLl6/wyXs/zZNPXOLsmTOc2T5Lbh2h9pw7c4a6rNjo9en1etQar93BwQGDwYCqqtpzcsYiWrG9sYlzjmowYDg8RDWkBIePvcWSTUoS5ypjJnMENVHgam5w3dYLxERUqnSYFfKPPcRCMMnqL4ErT1KXJrGm6XqKNa2P5TJgskiYZBE4PA64DCv6IJclW9bVK1jEaN7I83lS88aNht5HRGjWADfrzomL3jvVy7ric01VzHG1JU4SlCz8fjUdW5brHxvrnNcqMPa5BmI3Klx0CiJPtz924HKVIMZxJ+9n6qE+CYW74+z3i2WbVU9sMvvrXNeYrfTTmdoZjRdD6ucjCXDUJRsbm/JVX/EWvXT5Iv/7P/0HDKshb/7qr+HCrbfyyOUr2I0tdvo5e8OaTCFo7K00qZzONMyAWMYay/5sq8ASe6PAoF5xucOHQB1qSPuxRCEUEvsYmv4pM/Eia7p2Ql3HnkuZKOMGjfRn9NkyaNBWWTZ61ymm0sQ6TlRJJZlUN0yHVaUQS+ZM9PALHiGQC2SSGEsC1sBWP2cjy3AoRc+SuwytxvR9oByOufzEEzz22Qd4+pHHue3sTfypt72Dr/vqt/Oi57ww9lKOSjJXRF9PBPI8lRRLW+4cQqAsa7z3rZDMZAzMerRp6jt0M3PDfNXOWVPwdnxZM+1J103Ls8BMW44uzGauj+ViI+6un5qv65a99r5KHpZKXZY4A0WRMz48oOcs2/0+vi65+tSTfPijH+G9v/qzvP83fo2es3zbu9/Fm1//Bp57660UucXvH1CPhpTjIb6sMBrFqJwz5EWOWItzeQI1cUz7EBiPx4zHY+q6JityiqIpH3XUIZV2GjPhaiT+W4kl4tYIXgxiLNY4ag3ULX0Q/VjzvEfWy6DIYThg9+oVyuEgWtyEQCij12wI0RfSuJzLV57mU5/+LJ++9zNsb++ws7kDQalLz7kz2xC07bksioyzbofzZ3a49OQTaO0p8pzBoaEua8QViI3Pc5E7xsND9q/tslH0uDoaMh6PKTa3Cb6hEnVqPHXvvzaekaZhRDvq1j6ynFaiUFVTghxCaBWRnXOMkxKsGhc9PNVHttcItY8AP6Ski9E43rSuY3Iq3bvmpzW2LTV3JjnqpUTc7PgMGm5o/m4qCxaBwmWJwkXr3DplqRPP3mmPPknrQNujl6pBjJop+5Gmd1CmypJXlzsu+rccCWXCAhg6Hcg3omXStRhiMdt75Hednad0SiV34i8aJsqw0gVns/2hOuXN2aw7KmEuEjUrBGYWMabtPTYzLHViM9vez4apbI5MJ60jjb5C97ybGKL5vub6hs517lYP4MMNxy/NuTQCXbNaEUsTPxz1Q20qHabeZ5JWwpHlROfGUavirJOMj49TsXC6nW7rYJ51x44x5vrB5el2ut34gDUpmBCqymturNx8253y9V/7dfrphz7DT/7Cv+H8+Qu84J4vJd/cQn1gf3BIz/Ui66hQNou4xDBCkjdhrSESFxgkLfAu+SCrsWjToxaitUfrLRkUHxSTDKAbTdCIVZOaa2IykEnpj2gMlJpF1oaAEuIa2QRMNiBikFSaa5vPhmjjEFlNbYV7ssZoTSusBjKBwjpyI5zd3mZ8cMB2Jmxv5PjxCFfXZKL40ZDq4JCnHnmET/3RHzHY3efLX/sm/uy3fBtvfPVr6UmeGNPIZGEswUi8LgbUJKY3+SRGr0RaYDmrFjl30dKji/xJZ3yXJbhmJ8J5wHJRAC0ilHVFnudJpbTGe2l7KzPJKMeH+LJmMzds9XJGe1d58rGH+cM/+CDv+dmf4t4Pf5iv+rJX8U3f8Kd43SteQc9aBlevcvXyHlrX+PEIQ0DEkvfj97gsw+ZZ21PZTNB1XTMajSjLMioBb/RxzpHlPVxiLFWlVTTVEH0tY1+gSX3GihgbVWElBv+BxKgbg3UOrCHPe5heBnXN8HCfwcEevhqTITiU4GvqsmzHwqgc88STl/jYxz6OczkhgHM5loyezSmyXkx4+Nin6dJx9fo5VVUxHA6pE4hvA8CgWBPZP4ISOn6Rdp55ebOg6VTxAfP6ZueNs6neaBbbl0RdoIaViaC9KXjwaZ4IM+Wci8YgncB7HSuQYz8fS5SY1yk3PakAdJEv43GYm3UZumczaF7EMK6ykDn63jnvkYCqXapgu9ID+BlSy58vpjY91x/vXsn8pMazEH/ckE/lCXzXs72P0+10+3zYTsHl6Xbim+n8f1WPY4CaAJtzToKv1bhM7r77JfJf/qW/rJeevszP/sK/5WuC4Ute+xokC2yg2MJhqaIVSeUZ+VieZlMoaVTJJHVi6UTJUcRGn79UyiYhJGGQ6A9pQhQG8kFSAE5svgwpOyyp2TExSsmQrrUPiSSnIfphRfbBJPEgAPGKEY8x4MRgRNvSV4NPr8UrtFlYnBUsiq8FE4TcKD0TyA34/WvcdvYsfjxidOVpbj53llDVXHr0EXQw4rMf+k88dt993H7hNr7nv/he3vXOb+SmnbOYoGxvbjMaDFGxiHWosW0/aNJLIdQVVVlTVZGl6noRthnqZczBQqGLlHE/wsxM9yLNCdtm9jO78K7O0HYVMJct1g17FZVxI8BGPbWvoR5jRNnMHIWDHIXhAfd97MO85xd/ng994A+4+OgD/JXv+na+6su/jDtuuY3Dq1c5rKvIVh4cklkXEws2+lTazCHOItaCRLsdH8AHT9CasiypfECsI8/z1IdpsXmBca611ImelQ0QMsmvVRBjqBvJKAEVm/wsQbBY6zCZwzqHKQooHAx32d+9xsHuNUxV08sLrICvPVU1xrk+QeBwOOAT936KBx96hDNnzlHkfYqsRxEcGxt9NvsbOANBDM5YcuvIHGxtbHIwGnJ4sE89HichpKgaiwPnDGKiD6yv6sj+SWIewtEEQUOezA3X1UxQaOr9bcdBUmSez2p0+sgnGl5H9t+ozpKUZzVEJsMgsTxWJwqiorHuPLJA8wDGRPBjGXezUi12Qc/dyj7jNcHHqkD3yN+bHry2FzKenZ951GWpGNP6AfjC9+t8ldNGnK099kmpRHu9uyJQbWZ+TVXQo/fPrwQwsyBs2v+yM7Y7PY/Xk8Cbz0ibmbn2qErt7EicSgasnXT43JesrgvaGi/dbq92+/zPAG57wwdn5uaLlh6rHL3Gz2RZ9Ol2up2Cy9Pt825rmI9Qe7AB4zKqqhQ/LjVIzcte+jL+y7/0lzl75jz/7Md+lAcefog3veUtbF+4hcHeVfq9DUTAU1N6Hz0hxWFN8pY0saQ0hBBZGoEQKkQtGjyZzVo1WK+NvA44jQFPFUJrMRKYWE/E7+l4u3UCEpEUTIpiJWBQVEJbYGNNKv9ByS0YDFZiiayzFickL0sljA+wWUZmDT0byJzQt45eJhRi6LkCxgO2M0dRbLP39NM8/eQlHnn4QS4++Aj7TzzFf/at38G3f+u38bznvQCjoF7Jsh6D4RjrinhexhIwhKDUTHrTqrLEp/K+2ZKltQJPnc5kX08v1rrbKpXAReWw8zwI2/f62NtI8DgrZLbAVxC0IrfChhPCaMje1Uvc97GP8TM/+eP87m/+Nq/60hfz1/+/f5u777yN22+6iXI4ohoOcCjUsbQ4s47+5sbkOJOwDkR7HO8DIUBZjqiqCjFRqTfP8/jMqEKj+Cq27Y8V65IVhsE3Xo0amUsxJgEj0yoXi6TXrYlg1aV9ak01HlGOBviyJHeWIrNI8FRJxEeNMC5LHn38cf7oox+LqrauYGfrDJnJyIxlo7fJRtFDQx0ZTTE4K7iiYGdzi8u7Vzk8PKRO46zpJ817sRzbJoTlfQTZNoG1GPoGVhvdrx6j3URDl5mPwZ2fmwBpVWITUxlIyao5Fk1tmR/TjCUy7QXY/fuseNDcRJ0xawOHKVZ4zrP4TLEiz2Qgu9rKYX3mbl1F0XnX6Xp6TrsJhcXHOSlBnSdE1B23TXLtOCJOq/p4V6kDz2t3WOXjOF8AcEGf5LMMMo+jTDxzPioiose0Hlkl3nOj43vefTwFlqfbs524OQWXp9vJD66ZpWM2I+1MBgS8KqPRWIuiEJdnlGWJMRmDwZAvf+OXs7W5zXA85kd/4icwxnDPq17BnS94AeNqRC6WDQvepryqUcQ6RA21KpZU8ongCXhJirCqOKAmeWBqBJUh/Vcp4GNPo4omK8oO2xEm6qktQ5B63gyCmLj/tmtDwJjYr2eM4IwhswYjEv0qJXppZjYGz0YCJsvIDRjxWA2xp1ICvWDIVCmw5MZw5bHH2bvyNPtXrvGJj3+c4d4Br7rnZfyVv/63edlLvoTnPe95iBhqHwGKYhhUQzaKPkET+PY1PkRAE8/R4+uq7TtrguTpxXa1EfR0AGMWvM9wPY7dq0zA5wVHsyBzmZWCSGTMbLp3vhrHUlb1FM5QYLh48TH+4L2/w//1wz/I/R97lL/w597Bd//574wiSsGze/kig/0DfFURUlLhzM4W/X6/Y+cSu/CsiWox6hUfaipfR4sNa3AuivtkWQZACD4q+RqHl8YSw2KsS71RsdxcIZbCpp5KFRP5dRXExP8aUOmcAxsVYBl7xoMhoarJxNB3OdbE66EETGYxznJtb58PfeTDPPHEJW655VaKPCczDquGIsvY6PfJ85xy7CfJF2PI85yNzT6+LKnGJSGJRoUQk0DGmMjiN9pYPkRGk2l10UXc3jrFly3oSmyuMWaqn3jR1nxjncqKW3/Ljkpmt7fMiUk+tLHXuhFlin2g04xIe+wLmPgbBXgrjeBPMPicVCjo1JVrzzNMeg6nUXNkfTWEtUznn+2Sw1lQ1hLnR+YQZlbA2VL8RWAhJk1m2w5mGcWmN7X9vjA9JzfM8DoWJOsAk9jCMvv80UnwhOuy2lgEzqdY5Hnj+QTFgVaNgTUAs3YlY1U1pYiWJC7k6H6mgOAJPpenoPJ0+3zaTsHl6XZjE9oRAYRp6fZQe4yzsfRQku4FhmBErLX4WtT7kpe88MX8zf/6b3D3i+/m+/7RDzAeHnD50iVe8NKXkG3tsFVsYvICVyuDoIw0BugBBfFYcbFE0AiqLlkuCCH4xISAE4nld2LwKE5i0ONJwi7Ja1JTqauiZMnX0zQsRSOA06hESmKOsFHAxxiMEayJlbWFdViiR2XW+PuZCDKteHLrsOKxqkiA3AiFhUwF42tGV/e4cvUqe5cv8/D9D/DEw4/y4he8kD/7l7+Xt731bdx29lY2e9sYZxmWY0KAmggKio1tKqJITF3XhCrgvUd9mKoeNGYCLhcxIQsDlSNBmB7Lz22dcp7j2pLM29e84xKJCYBQlwSgHpf4cky/sJztb+C05N6P/ife8zP/ml/6qZ/glu0N/v7/9F/xxle+nPHeVYozZxkdHjC6uouospFneO9xNoL0a9eusbW11TKHxpjIhHlPOa5iv6UV8rxHnrv2WlchCs+4PENslqxEUk+lmNadNfpZ2omlho3sJCaqKYfEvBljMFkCls5F/8i6phoPODzYg7qmyB2ZixUGVVUBgbzIwcDFS5f46Cc+jsmiOFe/t4l6yPOcIivYKHpkzlGP4vNvjCEzll6W0+/3o+JtApaNwEf3HlhjEiPjp9kMXcxaGo3zyFrjqzOkjHGp7NvOH1c6SYIEiZUMrVIsR/ss1xOUm1+6KiL46yy3XCeglFTRcSM+ktfT8zm1/yXcVJAuyJaVc8dJMDOLVKWXsZizp3k9128RSF7Ub9q8ttJnUpaDk2V95/NA39r3fc0xs1jobfF9eaaVbqfOTdZ7f+f+6Tr3edk+V421U5B4up2Cy9PtdDsyQx59qaqqVE6X4fF4AsO60hCU7Y0tGY/HagvD3S94Ee9655+iv9XnB//FD/GhP/g9Dgb73HznXVx4zgvId87BRo4JBmpPqELMjBuJojWtfUhiFLCp9DB6RnoNqJGWOak0gHWpz2oSPHYZuEaNsbEcaH5akSiIQ0h2l9KCysw0AbNS2CgZZERxaAsuE7dENTzAWnDW0HM2ftZXlAcDyoM9nnjoER75zGd5+LP3c9fNt/G93/2X+NZ3fzPPf+7zsOoosk2uXT1gOB6R9TfobW1GX08FcS4G9kjq7QM82GASSFaCEYw1cxa/GHRYOx3otAFP023SBi83pip9nOB2merlsu+OtjMdlkAhVDXleBx7IkXo9QpuPr/DcPcaH/nQH/Aj//T7+fD7fpcve+XL+Yvf8W18yfPuJDPCRlmy98RjBA854LKM2ldUwyEht+zs9NjYOIdPPnVxLHqqcUlVVXgf8CHQ62/g8hyX2Mq6rhE09kVmLqkyRvVXJcQyV2OjBUcHtBpjYj/nlKFcHNOxj1aI9KxCqBmODhnu7TM8HGCDklmHE5NEjXxMOGQZV/cP+MhHP8Lu/gE7Z85gxJFZiw02en3mUc3WOTPxfUx9u3mR0S96UTyrAZbpuwh0WEqhIRK77ODU/eyUtE/C1dWCJiGEmABq3Co77HwDdOeBngn1NmGSNHS8IdNzEOcWWQlSZkGmPkPPx9rers25coM9lwtARFcBOv4yScbdEJg9Eux3mcB5xzetenrcIL6ZM9D1gMPRBMLs+wKzqriNl+WN3P9lAHQVeFoGMo++btrzkEZlfdn1Y/o6TB2HzkF3z0RIsuJ+B5n22+y+P7SVDwtAojwzx3sKME+3U3B5uv0x3wzLJCmMtYxHJc65WHqaxDIsgrWpY1GV/YMB/c0eL33RS7jp5gvcfffd/PCP/At+5Vd+lbu+5MXcE+D25wu9M+cpsoLcWgqBoQ94EULq9wrJXkQk9XoieBNtNuoQPe+CEUIQrAqZ2MhKpLK3IFFQRI1tz6ste0usjGv7q5RgFTXaMpnOSix/NVF109n402hkTq0oTgUxgUyVbKOgkOh5SV0x3j/g4hMXefyBB7j0xJM8eu9nuPXmW/je7/4e/uJ3/QXuedGXoLVPfpuG8ahia/sM/e0dRrWn8gFromJoVOe0iPg2wBIRjFWccRgDwSohlTotCkiXsgitoI8cK6N/vQvpkWCJKJohrSJxMx5NKu2So5YkqZ/WNt6VeApnKayQA/XeNd73q7/MP/z7f4+HPv1ZvuMb386f/9Pv5vbz29iqIoxKrj79VPy8yWMCpR5T9Hrs7OxQ+pLRaMRgNGR7ezsylgEqXzMqy+jzaDP6/T55r4dK/JsxBskdWQOAJDHJYmJpJiYpwTY+r4ohspViLcZmUTI/XRfRaIuDdUmACgiBMC4pDwcM9q8SqhFWIDcZ1sRPRhbU4VzO5StX+KM/+hjWWHJXkDlHNSzp9wtCWdFzGXkW+yZFY0uptRZJfp55nrdAzvt4n6yNz1ztdSoIXwXQQue3kMD2FLMpMXBPU0xSfU0jRJQsSYG1BukpyRS/LqBi230kPBR9QtW2irFNKXJXbKjNVMwG5e3vtnP0XWue1eNe1gHPn8tc4hK7k7U+L0cu3TMELOb/zawA+pPzkaX9cccptbwe8Hc9IPyktnkM/XF7XTWkKh/SM6bL44ZnZeym+WGRbu28XtRV2gI3MhZOt9PtiwxcmqUL2vRD9Ll9MHSFYfRJT6ifq3N69sHhvPNf57Ohld2YDvCmz6/Xy+NCEjQyfgE28w0BGFcVkudSOKNVKtfc7m3zyi95Nf/9f/v/4Y2veSO/9Kv/jl//qZ/m/F138GVf8RZe8OIXsdXLGWcZ16yhNPEYggrjcWAwGhEQDDllWSe1TUvwiq9DLHFN8Z4NnX4qSb1rNqnFojFwb/ytgmIIGA2xh8sChcTyRA1YFGeEwhp6zpEbg9GajTzH4fHjEaEc44wlE0uBZ8PX6OCQ/b09nnryKe7/9Gd54LMPYINw5x138N1/4//N2976Nt74ujdRZBkH+4eJfSkYjivSco3Lc/pFFHhp7CiKLGM4HBHKkqpMSp1ZTpZZ0BgkGzGRRZrxi0RNDFz9RCF3treykcKfBQbz/SX9wsBj6vcm8O/YUnQFhhSdOtY6+Bi0qCJNP5BGT7kgAWMcxhmGw1HLotVlyfbmDtX4EO8P2dnK2MoNfniIqUb86A/9EP/n//J9PPeWgv/1b/5V3viqV3Dh5vOU166wf7CPr2sqrRl5T12XbG1vs7Gxjfeeg9EYY6HobSDWUPQ3GQ2HHB4eMKpKrMnobWyQ5zliDaX62Atp87aMMWgsxxQrsWS7sa9JfpZGHGokMpw2i4DHGiTLEYmJlJBAoq/GSIO5qwp8RTU4xA92cfUY8PSzjH6ecfXyZYoswxhDr9ejqj1/+MEP42uhX/TZ3tgmC47COLJayY2lZyyFcfiqptfrISYypVme4/KCPC8iS1vWlOOKfn+T4XgQvSbTuGlZ8HYeMUfEPsRo27PoY41BEsYJaIgelJL8J8UmBWkM1lm8r1IKIo4fk1R7x+Nx7Hk1Gvtg1ROCBxOrGYI6vCo1UCNRXVpT9YGNNkLWCpX3BGBUjcBGeyRn0/ODSeW9aWzrUZXaec9DU3a7iF1lCrhOoPdC0CFhalJfZLFxdH0KS9dcM9NT2CZEFj3fbcVD/GGtXVra7jtlvVN91u0SVC/4e7xuttOmMV16SdtjP3sd5jKRMwmtNoBasVCaVr25Ybcn1yekNEhMaHb23PkCK7Ms5/T82vRnd4+te32CzuvJnKjhardsWqS10zpyn1vtgTTOQsNMh6nxOhspmq7aeDSTThlBORJoTPpaOz2fs2BOdEbtd/oZmufjOfHknuflN5l9VPWIz+nE/zRmrSYKw3Hdm3e9UhNmnM8bVe85Y6d7+rPHJdowp/Puh0zaWlYA+1W95V9M22lZ8cljnhtJYp0yl6fbDQLT42UfpaPIrxIXRzWCBBGtawUoXMZNO5Yi6/Ht3/xt3HPPPfz6v/8t3v/77+d9v/7rfOajH+Flr3wFz3npS7nl7E0MA9HGQZXNvuPcRs5wXLI/KDmzmUe7keCRUFOZuOBoEHwK7EMA72NrfrABMYaQ2L7aV4gBYywuM9HKREK0UzDgy5KicPSKgiLLyASsBqx6bKjBV9hBiTXKhjX0tjYQDZTDEeFgwLWnLvLUw4/ymXs/w+VLT9HLerzhnpfxtre+nbd8xVt57atfR7+/iQbD4eEAcLi8h4jFBUeI0rQ0oXjbNxkU72vqcYn62HcqRlqxESQG5G6Bafg6RuzXMwmdZMbdp1JmVNsgsqvqiwjjagTBkGUZdfDkxpA5w/7uVTZ6ls1+Rs8p1cEujA74/r/3d/kXP/iTvOutr+Ab3/E2XvHiuzm/0UOvXWNw7Rp1Xbbn4PKCre2NmLhIojyZjV6WTTn14PCQ0teoEfJegUt/N9bGxIWmoD9ZOJC8LMWYaCFjAONSSBHBpTiLsfFGWptHBVMTFWADQt0EaqqJgUzqsFXFeDhkfHiAjsdI8PQzx3g4JIzG0fokCfFsnjnLpz51L/fd9wDeB7a3z1BkPcwo2vgEVSRL4j8+TJJKIi1obJBHN+hq1Fqba9SUls46L4hIZGs7n1UgyMT2vGFnu+BJpVEHmgR1jSqrzgTBfor1awpuZ4SnjEF88g01grQ2QkITNyvTpbwhBNTojDhLmLEdMEuZq2eTmbqeIG6+oujy5NGycvbjBjzz+ldXCc0cWb2O+KU+s0Hvkdea5MoyeyVdf9/H6XVfdWzrelleXyLbzH/WbjAwnnctwg2uSyuvgZp27lukMjy7/4kMULJlmvv8zN/POvfjFFydbp8P2ym4PN0+JxmSafAiKQNft//u9XrY3JIVOa9/zeu59fbbePkrXsb7/uPv8dFPfJwPf+BDfOJTn+F593wpN991FzfffDMVnv3hAYjlTFZw9tw24+DxKoxrjw2BWjx1ULyAGI/YDA1gTEhBuoBNDKsEitZ6RLFSJ3AZy2Stga3eJq6xJxgPkRAZzNwIhQj9vEDrGlFPFiAMRuxfvcrlp57i8Moun/3wf4KqpJf3+ZN/8i289Sveyhte+wZecvdLuHD+FsZVxWA4IoQoRuKsQ1ViL6nEzH/tGxGWSaayrmvqOnonzvbCNQxZwwTOF9M4fqByfWNBZ0Qz7GTRbl4PDaOZahjT8RkEH1K2ufGNoOP/KNDb2CIkQaXdK1ehV7Dd2yCUIzbynJ2epR5c49EHPsv/8T/9Hf7Db7yPd331a3jXO97O619+DwWBajhiuL9HNR6nElfFYsmynI2NjegR6kMLmiAmKwAGozIK3LgCmyVAZSZiMNa4aBPCpNSaJNwjGKyxYF202AHEWiTLouIpBuMcEkI638hINAwdEPsjs2hL4scV49GA8XgchbYSmzMej/EIO1vbhMqTZwUYxyc/+UmefPwJit4mW/2NyTgSS6jj+PHeL7R9aRjnbhnqrFBUVDH2SWnZJLCyLOCT+RxS4wM4Z65p/OqmXgtKmGIF5we6y3ooZwHWUcB1/eXezxQQvF711UWiJLN+jMctk9U11opl1yt6nsa2gymAkaL3YJlKOk2A0+p9n0SQvixZ0GXnj9NSsEqo7Dgg40j7wxxhtusdI892LDFXrKiTQFoEQFcB66ZCZ+4ztGA8N5U+phmHMtOe0TC/ZrlYnRi5LgD5+ZycOt1OweXpdrqd+OQ/9TtRGdO2FTJWVIOG0LAZihXHRm+TF9/9El74whfyhte/kQ/84Qf4/Q/8AQ8+8jAf/g/v4/yFm7j5tlu56eYLnL9wC9tnzxG0YjA4ZMPl1FboZ5atPKP2hip4qjpQqaUMsWNPNZYgYqTFKCJCURStGbvRyEo6E0FEzxh0cEguQp5lFFlOYQ1GFBsUExR8TV3W1KMhV3evcvGxx3j4wYe48tRl6nHJK196Dy976T287nWv59WveCXPf+4L6OU9fO0ZlSXDwQgRi7UZdQh4P8ZrIHMFRa+IJXlNgN4JbBtwqapHgGVbbrqsDGKlQM7iQPwk1QfnBU5NOVNzTwSTGPFkiyCTbkpnHb4ckfcLbr75JqjGoGOKAnKpqHcP+MgH3st//7f+FleevMifeddX8c6vfiuvfdUruXT/Z6mNIZQjQl1iOiW3eZ7TzwtCAlfGmLZEbTweU9aT123mIiuYuXTlos2N0ogp2QmIRlBjYjmZWMRlaPKuNJBYywyTp3I4a5HUZ4xE4ItKJPIMUcjHxNLMpu9RQ528WYXhcBjHeV5MAKGzPPHII3zyk/eSZQUb/T4GIVQ1/axHjiNUFZC1ICtost5oMvLJ7qMLMht/y1B7vPVIkwCpK0SYAPNUoj5tBDnfj1JnzN1ZwB6kwu5p5nKm5LQJIhtWSRNDW2ugTsA4pELArnJs8/x1A9PjgsvlarMnAXA4cYC5FnhcIRKjN3C+U6BClyUvF9+JdXwOryeI7zKPCwGmTAs9zb1OM2q/8xjFdUSdlo27aVun9ZIUi8DY7LmuvD7oMxJzLDvH416j9L4pG5JjAfZjjPNlY+44z8Ype3m6nYLL0+2PNcC0JksNMIqJpWQCgRC8hhAoioIN16eqKw6HBzzn9ru47etv4XWvfgMPPng/n/jYR7nvvvv4xL2f4sE/+ihnzp7ltrvu4twtF8g2+2RFH9svyHsFRZZTi1KGigpPMIbaOHyqbwuqseyu00NoQ4lIzFBaE3sdnBEy8RTBs1XkUJX44QB8IAC+rhiOS+pxye7Tl7l25SpXLj3F3rVrGODWm2/hzV/9dl5890t4zWtez3PvfC633HILhctRFYajMaHyGOPob23ja6WqKmofMOKwWQbGMB6PMc7hrMUm1qcR+LDGYLKMOgX3xqRukiYAh8iYhfk2CcwJiNYRpjh2GW3j39hR5ZsKAvRo+VsLLNRPqhmbfqb05+blPM8ZjQYMBwec3dpgPIo+ljdtb1HvPs37f+1X+Lv/w3/HcHfIn/vmd/L1X/VWbr9wjqceuI+zGxuE4YhKQb1SVxVeiWMy65PbnDJ4rDE4m2MwjKuS0aikDh5rLf1+LJsVF30oYz8kqWc3MpYh9SG1ZurGEUwsjY1yvRZjhBqNTGWWt5Yi8bw9XjsloNYkf0XB5qkktqzwZUWoSghKqGO/aKiVPC/o9yMDu729g8t7fPSjH+fxRx9je2OTXl5EYKtJPdlHQOWcactbG5CtQaeYcu99++9mfDb/BhjXFXVdYq3giljC3vYqtoPFpPOcTnx0HGaXBP0yJR7S/e4uuGwBpZg2cYHMH9siE1VeEZlK5DRljut6WM7a/8w+ZyfFUKyyqjguoJtCSCuYoGWgR5esE8cKok26HzofvDTlr2YW7MnxwOTs1owguzAF19ROh4UAdh7yNamsXWeOS2b2occEKIuu3zI7lKn7dqQ/djnYfab74JaN33nVE8dRI172zBy5j5M/zi0ZV3M8nZBFDOrs76d9hqfbKbg83U4B5pyJ3VlHrb7N/EcveIsREefQuqxRjU6VuSvIBLbsFpsv2OGFt9/Fy5//Qi5fusgDDz3IZx+4n/sfeIBHn3iCx+6/D7XCzbffRtbvsXFmm80zO/Q3N8h6BVtFgSkyhuMQ+6pSj5jvALS4mAeMGFyjOlrV1PUIX8WAclBXSBV7G8uyZHg4ZPfqNXafvsJg/4ByPGJna5s7b7+dr3jN63nxC1/Ei174Qp7//Odzyy23kvV2MCaKi+wNDimKPs4VhMSW7F7bx2Z5DEJNLIt0yWJkNBpR9PtTZYbdEr2m72/ewr+MvWjKfW5UyXXVe1QSezoVXK9iR6b71kRScKZRUZVgUqlc7IUry5J+L+dw92muDffYcsLN57cYXrnKr/38z/KT//j72Qo1f+HPfytf+eV/EichstHBUx3ux9LbKvatigi5dWxsbOCcYzQa4fI8Kk56z3A8ZlSOqaoKmzlcnmMzF70nG9n+1FspEsthVYWgklQrk0qsjcBMrI39ls6ggDXptSyL4DIFM16inUGzf6PRN9IaEGcgeEJVMh6OKEdjtCrRqqKsRuT9nKLICIllzbe3Ge3u8olPfIKyrClyg6jBmQwnNjmZ1ABtj6YxBgnx/Jy1uDzDuejb2ZRrOxOZzFZx2TlsZmOvdPDYzFEUkT2tNQA2KjaHGQEc7YZy6bw1LCxXmzwPHAWXdUccpQMk1UhkJ1MpcisKYlxkxTsWMA1IraqqZarlmPKnqwLZZyIgPw74WK4WzUJri3lAY1WCal4v5XJgtJ5v5VSy4YSuzTqfm+cTPAXogrZJikXJumXJhkXM8HHH3+RY1zu360lKPBsAcxlruc4+Zn1ZZz0uG/Zy8vp6VTqqzE0czfYsT8bL/DV7VqX9FGSebqfg8nQ73eYsuIq27FlK8aFJhdaKk7xXMK5Gaoxhp38GRRmVI/rW0j+3Jbdsbevorudxz90v5anLl3ni4pPc/8hDfPbB+3jy0kU+fu+nKEOJGqHY6LOxuUlvc4P+Zo+812dn6yZMlpM1fWymdUZrfS1VFepAVZZUw1FUmRyXiK8Z7u4x2NvlypUrDAYDMptzy4ULPPf22zn/ki/hpS96CTffdIHn3HkXd91xB+fO3sTmxgbGGHyAUCoUOc5afD1mPPKo1q1ipzEuMlkhEOqK8bhkXFU45yj6/ZYZgklP22xgsk4vziw4nS0hXJaRvtFM9dxj1OlSt8a2QTpCKI1Soc7Vvgignt2ndzl7ZpMzRYHxgbO5Y++JR/m1X/gFfu7H/n+ccfCN3/Gned0rX81WbghlTRgPKaxjeHhAqD1lApH9fh/ncvKshxhDHSoyiT2vZTlmVJYEIMsLsl5UKFaxMRQwphEZTDo3TY9kLINVJZbJGhs9Ll0ElsFGUCNGCMaCs5HNTIkDQlRLVYmJkXRBsUnJtAWgdcm4HDIejTDBY0JUZi5cHPfVuObMmTMQ4BOfvJf773+QXq8XxYcQXJRPJQTf9nHO2mA0oDHP8zaxUScg2lX87QZ9ZV0RQiDLMvJeEUWJQgSX06AyJSG6qpotb2RQiX2bsiDQ635vYyvUigHNFSYzk77f5J3b7Rdt7l+j6FpV8Twi2NYjQepJJWeOCyRW9lzqKjXJ6X7VyXFK58/rPfPzfTYXROFzoOA8kCVqOv2TQmgY6s560h0rPs1rZoVlxLpzWFsaPVNuaY/Mb6ZNVravtcmPyfNgWhXQGaGkNcHZ9fRJHlmTTxBgr/LhPElgOfd8ZPFnFiZWl/dcTgFMZDbhOT1yu57Kca2a9PtGIjisOLcFLUVL1uJTgHm6nYLL0+2PLaicRBdxcm36rWLpHGi0otC6rsmyXESE8XikBKXIMrHWQh0I3rDV22az2OKm87fwohe9lNeNDnn08cd57MnHuHT5Mk9cfJwHH36Iixef4MruNZ5+6lGG5RDvla3eDnlekPd65HlS8mzYmMRIhdpTjcaMRiOq0TgCulT+t73V58zWNne//FXcdtsd3H777dx5+x3cdtvtnN05w9bWDme3d9jc3G7N5GMHmMMaS1BDNaqiP6XL2NosCArDwYjDwQjnYs9gSD1pLs+p67rtnzPGTBnPz6pWzl7zrjT5uj05y4Bqd1/X03917PEyu5moKmqin0pc04NiNIAoF3Z2qAb7ZC6w5QyDy0/wnn/zU/zsT/w4RT3mz337t/Cyu1+IM1Dt75E5g9GopJs5Q6UeNYpzjqzo4QOUdUWe9ehvbkCY9Lh678mKgv7WJi7PqIKPSNIIKoKxqaewEcIJYK1DNYn1GEklrQ6x8b+QlGCDlaaJMrKZJimtJi/GJkTRFnxJZNDUgyYP16rEl+OYuLEGk02Ybe89+dYWo70DPvaxT/DUU9d47nPuYLO/hdZKqBWqgGaGotcnEBhXJV5Da5RurcUm1rKrBNuwhUYn/YmhjpYf3nt8iCXa1loE2/Y1SlKebUDIEUJwjldeHKd2PqsByY/WrjUeQ+N/q6E9T68Bj0TRpPRMdHsuG3Cp4Xg9e7qyx/lkwMSRa3UCwfwi8LrOcS5iOJd9dlm/4aydxzKQsQpInkSgPq8fcfo8ZiwoWO19OXVMJ8BYTY29Y47Dz7Wv43FEjGatXLoVP8/Ecc1jTfU618IjAJLlasmnAPN0+7wEl+tIiT9TC946Aen1mLU/G9u8BXKVz9AX/iRgjnkPJz5jIoKKTjFubZ+EZqiqaKjVe68iIiYKd6OpnM0Zh8sz0VCjIZDlOYUxbPR3OHvmgt7zknvY29tjMB6wt7fH7u4u13av8vTVK1y5cpnDwyFPXbpMWdYMh0OGwyFlWeJLjyGW0hWuIOtlbJzrs7m5ybmtHc6dO8e5s2fpb/bYPnOG/mafnZ0dzpw5y+bmJv1igzzvRRP5rCdRyMSrryq8j9lKY2I5btDoZ+hcjogyHge8j/6VIib+56IXVxQ6qqauZ1VVK0vH1hFY6I7X2DtHy8TMD4SPiqJ0v2eW1ZonqqBzShWbHsvG5qEufRplzTmmfyfbiUE1YGtnm2pcMjoYREuYPMePK0I1oq6UmzZysjDi8U9/ivf++nv48R/+QZ574Sa+9d3fwpe+8HlkVPhxYouzHEEZHA4jQ11V9Dc3IkssILnDZRk+ATL1cezUlY+M+MYGkju8Ro8zsa4Fl801xQjGZakP1kV/xlRq6bIMcVkq0RbEWjyJ1UyAE7F4lZj1VgVjY6IiBEKoW6CHE/A11WCPw71dfFVjnUHqGlHBWYso1OOarZ2zYBwPPfIYv/07v8PNF85hxSFBya0jsxleA7l1hODxPvlapvLrup6A1IaJrKqK4XDI2bNn295E9Zp6TSOrub93iKpw9uw5bJYxriuCh97mBnvDMdZmgLaWAhp0yioyEqqTUnaxWSeME5wxeF8jSexIlRb8jscxUaSS1HS9j+yvNLY9BvyEaWpKX20qS2+elSzLuHbtGnmes7e7T13F+2lt1qksCEuD7+tR+uw+Z4tKcRsGebGizfw1tVsNsQoUrgMMuwmwRT1wsx6fq4B4N4FmZ69nc72beW2KoRWCBEDXiinWPb9m/jPGEJp5d0Y0KnTLLFJiSgJo8CCNr23nOsyAokXxxDLhnK5KczseFgATEbMSeE8zf2ZmHMrUf7P3aXY9mvXhPFIWfeTcpkHbRGH6aIVCIxq4qO93XkmqLAN0cZ/S3Y9PZVft8Sgye95T+59RKQ4yf06YfPfyOWHeePh8iCk/F2W6p4D65LHW9eC/peDydHtmM2in2xTMXNpTYoyRWJ4aiMKg8f02GgCCMajaNKtHj0ohkOHE4Ljj1rPUvqK+udLal1RVRVmOGI1GlGVJWVfUXilHY8q6ir59DcgVIc9zsqQOW2Q5vTynKAr6RQ+XZ9R4JHfkLotWE+KEphQSwXuNy48YUStxqVNNCqCWPMuTiEizGEWwgPcEorJtd+FUWV7W87kQTjju5DMbVIfu+cyoPjrnWt/OGAz4xCpH0Zp+v+DwcBcTlDM7GziUwd4VMlUu7Gyi5Yh692kee/Az/M6v/BL/8h/+MO9482t4y5vewPNvu5nq8BCxTUmnxdcVo1EsfRZr2NzewuYFxsX+SbFZ8kmNyqGj8ZgAuCLHZRnqTBRvEIMzDuNcBJYSR7ANJjGtXUGeZLXuou2I2CTyI+kpkVa+GBEbfSQhjRMQmbb4iP+lBIAm8Z6qwtdlEs4yrRiPGoNPPYuUJe9973upE2CF2G9pxOLUIslkPDM22vXY2F9ojME4iw0WMTGAFWcxib3LUr9le191EniVdUXla3b6mxRFH0g9lxowxq2VvFo2u7RBjs4mOmxiaiZl1j4xlYTQgrUGvGqChyqpF1OjnVHzmea/WRufRf50y6wwjvM8r18toAuv0qIy+pOYSxaV4K/DWB53/yc19y0D/cfez3V87zPdn/i5jk2mxtsNnseNqJAfp3Ln8/E6nm6n2+fzdgoun6Gg+3TiWXcLWFGa/wXpZOw0+gk2QWDsh+xkPyUyOt42jJdpeyAaYSCwWAGXZ4L0J6lABSSWu9UohEAdgkonsDII1jppREhSqrWJDOO/raEJJwOKrzXZFMS3GHGRhTOKMZbUToqCGmOxNvZehABeiccTQrRjUMXXdVQAXeD9N5u5PNLrtTy2hCVZ+hsRGFkmZNECZZpeSplSHux+3kgjzRPLE03qUxGjIIqVQD+3GA1oOaCuKnYypRDQwyu44PmjD7yX3/2VX+YXfvLnedfb38QbXvalvOiO29nMLPv7V/HOIs4Ras9QKw4Hh2iArY0d8v5mLD11Blz0qKzrmqqqIksHuDwnLwpckROMTSWuDskc4rJY7orFo4kJU0Sbks8IyERin2XstTSIpvFt4vvEzDK/HXGbpCwJDfAm+aMFqGvKasR4PKSua1yIoNAZS2YNlQhGDP1+n4ceeZgPfPAPMCb+2xqLUYPBYhOL3iRaVDUCSGcRa3Aa+4LVaOv36as4houimBKXajL4ta8Zj0sGo5Lbt3fIiz5BhRAUXwfEWmJ1cywfjGMjzCCj+KtXmWGw2iekLQ9uxpZNNRBdVkExaJDIghqwVueX0RlDlzptxums3+fRtUDnPh+r+pjXXUdWCwItthRaZC1xUmzCohLBZWJBx638CWk4mHYfzbOSGLKG8WrUYpt3Srix9T/tRzr76d670DJaetzAYq6fpXQqfFWONy6OY0Fzo+XZ6yqtriyrZVax/Jhx2QmFYV1Rn/RvmRUCS2X8CopdcaSi692/G4lJT2PQ0+0UXH4RgMtnIoN6CtJpewql8+/JRJ9EEToLrTQxZwBVS6iSXUWoO8BUkSB4PJUFb0IMoK2Rbr+W0VRyh2m1Q9TPlPFaM2PebdpesVjW2qgBJubJkBag2CtX+abcNVClPsrQ8dSLq9DR2NDo4rF2vaUMx/GnnKc6e1yAOe/4jwSh2oSOobWEaQJiCYqWJRpKCpdjxVPXQ3JRMpTycJdf/MWf4+Mf+gPe87O/yfd81zv5yte+lp0iR8Zjru1epdfP237f8XiMD1FOqugXbGxuYzJHnUrWVCAkVdimHLlXFLFXt8gja6mNaEi0rLFZZC7BYFWTAmqY9DeJoEYwrTpsslPpqOjOlhSLpnKqjiBN7AIkjeMGdCq+qqjGJb6sUF/Hck1RRD0hCLUqve1NrLW8732/x+61fc5sn6HI+0ilWOPIxVJYR1UHrDFYYwjJM7XxTnXOUWsg4GNvsHOMyjEhBPr9PlmWIZo42tTTXI8rqtIzGnl2ts/gXMbIx0RSrZPEQ0BTcN4J4GVBwmKJFU4IAdGO32uQVu206Q9tEk0SAt5ENrPWkM5NkGR301pbdCxWZkHUNICcZcPWey4XlaUue9ZvVOH5JAHmsn2swxAe25KEWSb2KFhZdZzHmT/nlS8eNwm37Jqs/PuaI2lVqe/kfj87KrDt+rlwzOl641NXfMec8z8OO7wE+B4xUL2ea2H0aGns9T5f1+PTerqdbqfg8nT7otxijOxbwNCs0kGb/pWASkB1wlZGmjAFbkn1UYOAhEQsRoZIVcmcS1Z3Lsq+I1GNVgxBSEIdRo3YlBa27cIXQuwpUe0sehKtIqLlA4QqTC1gDXBEIfhAHSY+f0GOBoFa+7akrk7lie05dhYMM+npmKxpZiLkcvJ9zsdnLdfphT7qcTcdAEgLplIA4UMCah3mOI0ZJWBDjdGAGQ+woWY7E7Lg+dQffYjf/c1f5Xd+/Ve5eukif/v/+V288iUv4kzRIwyGXNu9xtmdraginBVUdU1V14h1bG1tJLYti32OJoo8qYD3JaEuQZQs65H3exFAGpeSHBoZSOtQ66LCa4OGkqKlGIOGWPqpjZ+lMYid+HTOA0pzr2lI1yolQmybfKmhqqnLEWU5ovbllN9kw7piLVubOzz66OO8973vxeaOze0t6qoiI3qo5jbDGQcmRNbPWnzqoWosR9QYbLCx2sDa1uPSez8Bl43/pURwGdk+oSph59x5rMupfLQl8RLLykOYAYvS3PsIqmPawdBkf2atR2Z/bwBhk7RqdjrVG+h9SgJFoOtrxaf5ZKoHrtPD1gWXpsNuzmMOl6lALkvOXE/Av5K51JiSOAqqVs0r0z3Q1wMum3txY5uZOp5GXmoRg6kyfYIiywHM2tecaTXY2X2sy2A2XsSzoKhlLOXGQMMzwWotKv9uekRXeR8f53yebcA0UbVfAODC7Ouy5P0N8yzLn8kTuA+n2+l2Ci6/0MHRM6Qy98djC9CRjl9qCD3Tp9Oqpfl68vkQ+/dEtRUKaONHJFYSaoiG9RogiowoQaikUhGBUKfgURqxDgnBRyzQOZZms3q0+d53mAyYGChPwGUs4hKBytfJpy8GRu15NtL0M1LmqRq06wQwN/O5bs/QbHnefM+teb1RsjIAXnYMk6yyzrnv8fqoejSkEtiOEFRQH0tkQ0VhoVBhIy+QSnjq0Qf58H98L7/1nl/i99//AV7/yrv5v/+F7+ClL3wh1BVhMOTg8BrbO5sAsczT5mgQahvIe336m5tghCp4co0sVyx59pRliaqSO0eWW2wWS2WDBjzE3sOsQLK8Bf/d62uZlIdqEo2JnpYTBjyQQM3Egn2qZ1DTGNcQkNDYGkjymtRk46LgPaPRiLosUR+wTV4kCdtICGxubwPw+3/wAR5/8hrnz2+zubnNaHdAv9fHSASKuXVgPC6VxfoQ+5sbr0skisdoCK1gTqOg25TFdpk9Y0wsLw4R5F64cIE87+GHNVlWgLX4uuNnmUrDYyKqO07MHCBuZgJcSUTuRNW2ETrpjtWpPuDO8+s1qsHWIeBCaPtnm33NgsupMb4AxCwTt+nuYxX4mgipHA/UzV6rZ2q9aoRcjhMMLxJEWQZOjwCcY5RlLnrP9XpInqTgYJfhO2qPcfwYZbbkuCtEdKPM17qltlNrznUyf6v6g7ugcLFS78kDuOPHfvNskE4B5ul2Ci5PweUK0+bTB32da9j5KZ1Ms2pSTY19YbN9h2IUG8Kkb0YiVAmkgDKhMUksSBSPmV5giyxLCeEU9Nvpsiprc4IECdIxLO4uaqHtB1PaYwU1MRjVFjDS9oMFkxouJGBMUyNrkJRzV5nuTZvkQxvT8gmDWSWQdqMm1+sGCiddKtf400331En7e8PwtemHJOqTMgvkHgbXrnIwGrB76Ql++1f+Lb/8sz9Nxphv+pov45vf/Y3cfvN5hvt7jIaHHOzucWZri77LuXb1KtvbZ5IXpce5nCLvY20We7Q09tCKFbyvGI/H1HWdVIAtprHbSCyWCqjYKPyTuciM+9RL3DHdFiNIMBhMtARxNrKXjam6ToLHxgfv6DX0yXlF2sQKIR5rk1XxVc14NKCqxlGh2EYgawCrYJ2j3+/z6MMP88EPfpA8h83NTaL9T5YUmWN/pjMWn3opM+sImYI1LSM5YSVta+dT1zV1XbOxuTnFYEjHH3I8juqw587ehM0z6v0RkmUTwJYsTKYC6ra/zcy5LrJy3DWl9bOlrLNBeAgBxLRWI957bAM8g6CZnWKCZ0twWwXkJT2Xi0ogr8ev8CRsM07yOZ89tnkKs4Hl7LyuOZcc+VyblNN2XDSqvd0KmZNenbsM5nGuoSy47sfpk1wniXg9c/RJb6taJab+dsyey2fKR1OXrYmpRWEqOZWoctsQznryY+24z8TpdrqdgssvUJB5o2byf2yvXQurkriNpN/TrG4SuIw0XQMkY/AWtJqSNxeRqV60uq4TS5Qy6DodSGoyk59I13cWKRF8VacglGiebGVShBcCxmSTPsnuWMBHICTTfTFNyS4KaqOSphdiWe9UQVfnWHTOYjfTq3ESwWW3b3Q2o3w02zpZWNu+V44e76qgxRnbCiA13F4XZIqNRvYaAkKN1YAQMCg5HjceYw6v8Zv/7j389I//Xzzx4BO88qW3883f8C181VveTKhLdi9eRH1gsH+AFWE8HmMUbr3tDpzLIxs5NlEEx5oWxOR5HvstE1io67q1nsizHmpNtA5I6rASBytBpk3Up0VhzJSnnbVZ9HhMbFg0hW969KIBi0wGTwRaSdlUmIgiRSbYT/qY1EOo8VUZFZBDLPmVVJJqjWCzjKDKJ+/9DA8++BD9fo9+b5P93QNuOXOB6mAIvQQGrcFYaZVmA7GM19oEsIj9xyaYKPTTAV2NOXxbbh4fQ3wIjEYjvIfe1gZiHLVXgpMojFUHbGZaMI2EVNZokiCGmcr8L+4ZTsA/2ZiIpJ5LTc+sdAEmLeiJqs5JSbYR2NKAik3HMWF9FN+q7jaf9RomlQdHkj9hyvZhEQtzXECwcA5QE0F592fnu0+qJHfdgL/df8daZt41WMmGhVmAvupomvFi0l02bSnr9bB3i4RZnklwdhzwvc44mVapXef6+fRTb6DnMlkpyeJjWuf41xUnWpsRlfnrbRCZmtOl8Ra+gfscx044kTX7tILudPuiAZerBvU6i9RxG6qfqX6Bk8qEzcs8f65B5o2e3zP5+UawA9EJc9jNJk/9o1P+1fEyE+NadmfyVU1gYomEUFchdvYEXMsQTaWQsRiJoj9iTTzKrjdWUzIXKoKgxkn0yKMp9EzAIKQy3EZMyEiiR4VGIoTUL9egxSCLr62ayGY2XWdhjkrh+vdHkNBVTuws/EEnwH8BuFQj1CEQRKKqa+c6p+JOJrcrfYdppZliUFdXiCpWHAGoa49xDpvlVL7CuJhYqAf7jIf7nO1lbOeW8f4+thrxwd/9LX7mJ36M3/3tj/H82zP+q+/5dt765X+S81tb+MMRg4MDqkFFXVb08qLtEcxcRrDCQTmiqjzBCS4vwEWw75yLDGQwlHXFuKrxCkXRo7cRmbhRWRJyAbUY0VjmOmUHkhIQzPH4NFEJ2WATQp+UQQuprDtE1sw4gwlEa4+6mpRtCxAUD3itEaMYl8VLXVUMBwdQV5QHh5zdKHC2KcM1jMoRN104z/5ozB/8pw+DMexs7uC8sFNsUQ9L+lkfrSHfyqmCR4yh2ChS4qSiyPuTsl4RCB5xQtHrYZxtfSH7vR5FUSSwFoHqqK4YjEeMykOKTbjjrrsY1CXZ5gYHA0/R26BiHEWbRKdFdNS0ALOxqGnXGomiQtJhqkhqz76OPWCVr8l6BXuH16jqMSJ9xESA6JyLwDcB6oDB5jkytlALJiWsxjIkmI0IJIXYW21Nqp4QsqLHcDQmd1l6FiKQQgKWSW9xWCFCtHJ+lZlncknSU0PT12wQMykNVqYmz8l3tqrDc3qAk22QtabDDh4toTfzPCtbj8AJOxUTf12maIEJ/RFmzxxJunXPwYcOW95VGiex11pjdKJWjU7e252uzBzx0ajirDNddtPnOHvdQgfMWyLAkhkwPcXshpgcjeLQcSS1PXtKp3B+fu/jvDhknjfnpAR8Uk0y+ducdUNikiJeU013bDo5Gsv3m30dTSiLkXRGHU/Spm+5XS/Se5vkVEomWIn2TcZMH1yYfZZmnoEgy+I0nUmdpmdAhCk5MW0qaDR5ch995ibpWe0kYbX13mzWBAXsIoX3JinUHF/nnk7GUZi73q8fb4aTjTfbWEJWJD8CXffqhe9akbE2fH6C5y8ccsnMTllz59Ojs99qTOCOe7GuB3Sdbqfb8sFljmT0jvNwNMqR3e49s2KctiW2a2QyV0zNepwpulG409QTqslKQpTWfsJ0ApzuotgNanTN1PVycN8wGF31PTM3SJz82xwRSFmWmZ39/HR5UfSqjAIqSiYuCSgp1bhkVI3InRD8kMJ47rpwDgYHDJ6+xBP338fv/Mov85M/8uM859YNvutb38yXvemNvOSFd9OzGaODferhGF+VSA1WhNzmFHmBWBttHMVyOBxgnCXvRdXXtodLUr+XEaqqijYezpFlWVsi2WVcxNlkwZFhxSRwrksn4CZIlCT20wRQE1o6lmCakAL4xgYn3YfWIDwFGMakwaOeqh5TjobUozG5M9FWRwz4QGWUvNfDWMvDTzzI1d1djM2ir2QQcuuQKjLsjTiPilBr3QalTSDrTDz3iUXMpOS0rutoeZJlZOnaZVmGcZYajR6XVYVzkPcKgkBZhyhspIIViZYt+MjuS5wrAuB0VhRjfu/SVClm+nzjkxqFtGpMY1NiInNsTPIltYZ6HIWemnvuj7B92gaJE9aStgy6rWdQSQJU8ThM4p3ndRwfi/U6xjI8UcI2cwWjjjuHNM+IWePz80DiRIbpKDC9HhukdUzmJ/3imuZgQ5Cw9prTPRezhp3EshJQj06xYYuSAp+r5PNiH0qzNJBeetx6feXes9fxRtVel302dNpOZg99nXHSBYIrCRdZrfi6bB8LCxWeNdZycYvCep81K6c3TYJ1bd999z6cwpBnlYw6zuau98tOwmT4i+Fin4LsL94H5UaDr0Xvm2da3v6+IGP/TF2XqWxsA3Y7YH2+gEQnQ56CrJb9pAnUTFsKGRfslMHWiUosgDcwrmrE1zjnkRBZ0MwIxgGhZCO39Kzj4NIldHTAJz74QX7iX/wzHr7vXr7mq97Aq15+D69/1Wu46dw5ysGIweE+DmFzc5NybKmcw/sK6xw2nyiZxpJMT1YUR0Rnmr682kcRnxACvV4PaxtGzmPyInlxCtZkuCyLAi/GRK/G4Ocunu3+iarDSocdaHr6mrJMTQxDKgfXNhjxqbQ0sifG2gguRcHXVKMhw9Eh4/GIIstToO0o6xHqlc3NTca1595PfYbLT10hyzKci16VWS/D1xUaonCRcw4NAU3gsrlGDfC0VvA+qaSaWB4bQmA8HkeWOO278b8Ua/FBo9hQXbO1s83WmR0gAnmbbcwVyFkneGdGKKQbhHUFfay1CRhNi8fUXilRKg342lMFpfYxuRBCIEg4wuQ0AKa1EAoaAUvX3mHmOIOkcm/0huYWXbAWrbKzWLZ+zfPbXGZJ5JefwNwYcBWYXNfg/jjgofudTen9umq1ocNgrmOhsu79XGX7su49Pen14TjCOnE9sOlWz6xxs+Nbp/8h63p1zoDKRihN5ozlqWq3JX97Nq7bQi0O5EhCfJ2Ewmzp+Mqe1c+7+DTM//e8sn0JifmemIN3fzZtNKfbM5hcuoHxsza4PPVx/MLcPt/v1YmU5c4Jhq73OFYFU+sc37LXdEkJ2WzAtO5is3QRW7rYzdv/YvXYrl9f1+ar+w3mCFs5p58rZR+DKjbLsChWFIdBqxqHkjnBOCGUAedrBteusn/pIr/4Uz/Jb/zbX+KeF72Q7/6OP8M73v4VFNag3rN79Rp+PCKzDpdlqMDm9ha+qinL0US5UgQfAsNyHBnLomitMQCyBBJVIwBS1VakprGN6VpJxDItmQIqjSCMMSaVS8uRe2zETFdApd7SabXSxDL50C6oXRGU4BWTSRS3sqkkduwZj8eUwxGh9uSbG4RyPDkuol3K1at73Hff/RwcDDh/9hzWZBBSCWnaf+ypdCCeELK2fNEYQ57nsRQUwMRyXpuuk/ee4XDYXrvQOSeTGL/BcMyorLnl5ts4c/Y8QZU6eDKbUZUTL9kJ0G6YW1baG0wHY9O9XV2rlIZBk8ZSNilN++CpETB2+v4wAfyzqpuNtUrz9+4zJUk2TLHJQOVkkrcKKwPNRUFvU9a3aC5exBrNU3OdF7yvA05Xgc1FQHjR9Tl2O4qEtc594Tx6jPVrrhdnF4DP9QBe7jN8kszNOj2n09dXphKNi0DQSQS/s/6kuiBp8WzHRKvGx3G+al0rr+lxefwe1BMFJ21lRlP+O6nUOLLoz2QXpllgn/4081OUaZOX6Z+f7+TP57ot7dkmZI4FLk+30+0LBUTPC4LmLXLT5ssnK2QxL9g5mjFfnRlaf9KQBYGcHDm/Rf6VNzK52E4MHctVzMy60rByM98bFAyUdYXiyYwB9UgYg9ZYFSSUbGeORx+4n0/+0Uf4uX/141x74gm+/RvfyZte8xqee8dtlKMDymoEQSlyR5bvxD69EMsYa0DxUZFVDdZFv9GmtLi/uYFYl+RxEqNoLF4DVVUxHA7J85zMGnxdRR9GG0s9o2dlFntoaRRCbdtnZIxLQrfCEcuHjmhSSKA92uekn23w3yhcRvGp7i1VTHtPnbHgBPCEuqSuxvgqMo3OGMZJZdfYjMxaEMsTF5/k4qXLGOPIsw2szcHXqI/3MfY12bYHyyUxIE2Ma6MoG8eNb/svnTPU3nM4GEy9r2H/bLoOo9GI/cMBd9/9JfQ2+oyqmjooTiQJ58gNPYfTVQGTct3mOEMIlGWJq3M0i+eWmajvaNThXUblAzadW7dXLYQa7+t2jgnep+s9MxamVEmTsi924sMYloOglcEHOncuuZ4gcxnzsoy57ALb4xzH9bB+s0H0tDXNPLixoLDTxGdSkmAXC0H59HcHWWfvx1q5JpZMc4FKmjfMfI77pELLedU0s9d6EYjsClOtvsc69etUP358cmbv1AS0NH25nfMOa16LtiIlCaJN/EdPHkwsFYCaAephJTiVBeWwsvLZeHbA5aLHThdhyklSZ17u5JgtUcKxK61Pt2dpWwkuT1WoTrfPNWhcNbnNBZYrAObaIPE6M4/z/rZO3/Jxy62Wndt6bMFycH10wZqAWaMNxElCFTPN39HFdElgQiw5RD1lrbi6JFfPZp6RUzMe7POHv/8h3v87v8Wv/NIv8PK7X8Rf+X/8NZ57+20U1qLlGEu0lzHWkhlLqD11XWOS2utoPGhLOJ21QKCuK+oQy0qNc+2x2jwylqJQllXLvOV5jhUYjUZUVUW/30/CL9GWRpBWrCXUPlp9iEUR6qRIKnKUufA6sV3pMnOqMwIrTHxcm5LPKF7jkeSVaawFMVCXlGVJNS4heGxUvWn9GJ1z9Dc3GNcVjz7+JHt7B/R7m/Eb1JDbIiosk1jL1AsqasAYrE2AUo6yXmIken9ay3g8ZjgckmUZRVFMAb3mv8FgwLXdfW65404wluFo1Fq6dMfiKuZy2fhvPtuAw25Jb6Nma0KAMGGTjUSLoaZ8uflsw9oGmTDTjWhQXddUVQUJjGuYJ65lpywqwoI1VW4QVC9Ktl3P2r5sDlmkMvtMzPOLgujj9PvNHm9zP487nx7nHGeB2ZFr2y2dngEP09/zzLQfXV/P5WKwdOQ66UnFAHpiz8N0z6Oc2HWcbiE5fvXRqjV+1fxwPQDz2WXGJkr/K3Lla9xuwxfCdpL2UM/28d4oi7k2uFy3DOmPG7g53T7H94f1Fp5Vk/yN9BDfSCnukazkCexnnaDhRr5jqYl0I9FOI4JqErJKi13yC40ycIF+5tCguLrGGeiLYMtDHnvwPj798Y/wUz/2o4wOdvmWr38Hb/+Kt3BhZwerUI9LcpuEc0Lsj0M8BkWiRhF18FgX+w3FANZQVZ5R7fEI2UZUNfU+ggTjLNY5qnHJuKoo65per0eWZYQ69t35uo6Z7zT2qtqDaXw3A2ITOBKSNUUSb5Gj40yDIpaOrUgDKjvKhTpRHQ5T/UwGtYJJPY/YBPHrinI4wFdjvPcUCVRmWdYCVmstV67u88gjjzIYjDizfYG6DoQM8rzHcP+AXB0mc1MAcsL4GQI+erOKEt9iMda05cNNWWyWZalXNYtnqULwUFWea/v7DEu4/c67EOsYjyuM6xPC0TFmSHpGS8byvJ7Led6Wzb+bnq3IftnUO6xt36T30mGHk3CSMuWLKSaKTXjvqeuSLIsKuj7MBrdMq0x3j7ujSNn9uVbwx/WxgquM4Ndd+9YJjJeCjyVJtnVij2UJukXz+9Tvq8D2iiD+OFYUy+1epN3d3GvaiN5JODKungnAuQ5I6SrJHk1mNGq7qw5wnhJ5VFLv4g3bilFNmOaJJvuSOYGjzPozFdut23O5ai1d57V178/nKn49KnwUFsQLHBF0XGtc60R473Q7OXxzks+HO85BnPo4nm5fTFtT9rS0bOs6a+KPG9xdj6DFM5OtOpotnX7WO+810cqkCyZDCyqbWEGSZYyZACaUQMChVAcH5EbpGSEnIINDHnvgM7zn536KX/qZn+bl97yEd7/rT/HaV7+SC+fOkgUYD0dkRqMEvoSWbQTIrGl74Oq6xllHHTyB2EdXhehHmPcKNrfPRPGV1EOZNyqnIfqWWmvp9/vJvsJP9dFJUNRCqOrocRkUrEGCtEGNxubEGARpvBaNwmSrGmwS89t4/rXAOznJdSf7LnCSgASDyaUVESLUaFVTJ3VbDTU2yzAIWeYoy5I6eLwK1/b3uHT5KUal50JWMDwcQBH7I7X2iLHYjmS+NL6jMr0GNMweKJoY1Ob6V1XVlhDHPk5texOrquLw8BAFzt98C5Ll1NQYF703Q3qvnSvPaK77GZ9SmpQ4RqT2SJbUb50hiEGCocpy9ofjiVBPd/1LlirN4XlfRSaTxb118xg3XTO4vN5k16LexW6J70JgdQwmZB1LsmXJsHX2vSz+OK6wz7Lzmi6nPtng7QtdCHFR+8mi3v2TQr+T6yjHZkYXlW6v0yZyA8+giogs7Klur8/1J2s+H0DketssYzmt+7BOyuHInH8KO57RWPAk5ie3SqlsleDAuu95JlD2swVAvtCO+fM5M7LONDI1LbWlZ3Oypk3GX4UQJl6XIqZlGCb95s3fp/sRZ32+upnkKMYSjjUelj0L8wQujgRdTJcONgyLLtj/uln/hcdtJjYKTcpQO+nDOvjFz3HHBiNIsoRh2ipFDFRljQtCnlnU12gIGA0YrXHVkDObG/RFGVy5wsc/+Pv88D/8Bzz24Gf5hrd/NW9/61dw6y0XOLu9RVWO2R+OcMbiMhstTNqyzfiNdeUn3l8mmd0bE0sSTTwwi2CzKEbj6wrr8ijiYyzjckhZlqgqWZaR5/lExEc1ig+hMbceaoxY6qrE12Ccxbg8XhOT/FPrEIEISVFXXMrmB4LQ9kV2WS3T7VNp9KoaMOA9gQgCnctiSbARCDWEknI04GBvl+HgkMI6+nlBXY2xBqqqore5gVjDgw89whNPXiJzBfuDIVu9DUQsh4dDrM0Q4tjr9/vkzmHF4TUKBYUQ6G1E65bGv1KM4nJLnueUvmY0HuJDzU3nbqLf7zMej8k3+unYLU88cpHhqKS3VXDhtjsZlBUYh9f4vNd1hTXRC7UBh/H5mc5ei2jyu5t+TprxaiRa5zSem82c0vRcDodDCrNDWY2pUkNXJeDVMa4DqgFVPyXg09yvEEILnIeHg8hwh4CG1G+rmuw/ovrvBHxO+BZr5gvt3EjQuMwbelX/4+zfuwmVeUDCWtMC72VZb5l9vdlPWHyu3fnvyLRlzErwvE6JqzVm4dwdmW4/9T1tj54qRifM3KLrOs8KZfpYzYLjYy64nSxHzfGElcq4q2Ky2WPqXttF7Rzd5ITq0TXn6Dp3XEbEtJ9TVSrvO99t0tQoyAKt4vY8wwwI7arYmtgrPXtOS9d0Ze77j/iLNsKmnQ9L5wO6QkV53aTzbE/wOmXi16OwvHiyWW4jJ6J4n9ZOZ9o1TDWKvwWdqNN77xGxOOtQmn9P/J9jEk/b+TvmNKccSOechy5NdD1T5bVf6HH/dY2FmfedCvqcbl+wg7wx4L6Rh/pGy0dXqROetB3KOiWwz1Yms8tQNuqvQUhWDPH1jaIADRgCGkpCXeFQrDEYX3O+V1D4kicefoD3/9Zv8iP/5Ac4s5Hzf/tLf4lXfOlLOHdumyLPqKuSuq5wLonpBCirCl9V2CQ0Y4zBIfimtBHFWAfBE5QolCMGV+RtmaZxSQHVRBEZHyLos5kjd1mKsHVK0bG9ByEyskYkljmG6A2pJsTvFEBS32JI5boS2gg1thKlJEKT+Ag6Y6wdWgaguaaxjVIJoUZt45FgoIr2KqGuo/iOeoQQ2UQl9T/22d8/5OLFS+wdDjCumB7Lad8igrMWF1stMSYmcByGWkJrO1JroDCCONOqsAJRrTaB9GZcdFV3R6MRV/d2ueW22yn6G/ig1CFE9tMYxLjEbzeZ77AW03C0p21J4JlKlm2j5tr4XYb4zT71xYbatwmGLtNoUt+pGG2TD2IWqarPL99f1hd5XCuW47I3y9533IBpnb8tA72rzm+dOe96rs+sFcSx+BiZhKbLlHrnJREnZbXPXhC7SNF37rq6pM9v3Xuy6Docp/RumQr6Oj2hKyGsnoyoz5HnanLdZNH9apWs4cR6lz/ftsYfegIAFWObCqiQ/IZrUENmXVpuQ0pc2Ta+az4tViZrTO3JnTmmL/rp9mxtp+DydPuCAZdHArGW1Vlzwme1ZP8zcpwnAC51UZAWEcxU/0v8dzeo7WRsZ4MdWe+8Fgacibloeykbdil9z5Url7lw9gxVWVGOBuz0eoivqasB5/oFzgif/r3f42f+1Y/zMz/xi7zjK1/Nn373N/KC59zBztYGWWYpfUVZlnhfocYhdU2oY9llqALaACArqJFYpmoiYFAx4AQN4EOFcRkmMziT4TUev0lAxvuauo5MYpbl9IoCQmSutMNUxKpUn8aewTSeoD4ORiUQjI32HLZReZXYLpSuVQPIZabkUhKTE9reKzNhjxpgK6Bq0NpjXJb2p9SjEQf7u7H3zxlMHT+XW4f3HmsdNsu4+PAjPPLYo4zLmn5vCxLzD7Fstw4BUjmrtRZnLMYKgXQdOmA+qqJGQSXnHNYZjBEOh0NGZUmW5/F9ddVmoq3NGA7H7O0e8PyXv47NnTPUCrVXvIsKuWoEfAPI9AhQbJleWZxwWQV4RASfyp3VzPggJpVjs7B3aOLD6cS0SrjOGeqpIH3RnJB6hjScyDxx3KB+nUB5HdDYrSyZVy0xyzAe+buYyTVfwLIsraxqe/Cm/kDLC8mqc10+7wWZwgprX7dlycHu9QptM3ZYsa7oXCxq1gCz15MY6PYqL0qkrpf88HM/22y2UVcWppNpTOa/+KqfWrM0lew/4wnUIz26Mje2mPO7NlP2vLVUrvOZezaT+CcCMNwEYgTvIfjIOCYLOREwIURLK5lU7oQQk6KVr7A2a62sjDGthVfmLM+U0NXpdgouT7c/ZkDzaL/Houzm4rLQZ9pIeZ2/Xc8xzPMcC2G1b+Yiz8qT6O1qg+NOUD7prgxcOHuG8egQqSq2cofTGl8NyXxNGJT8zq/9Ir/2Cz/Lb/679/OX/tzX8653vpO77ridejykHI+oxgEVxYogLsd7z2g8Qr22JW0+BGrvUV8nKwwXGTIXSx+tyxBVfB0XNWfzyAQGxRobF7YQS6+8JjYyc0jm0HHZ9glOBZ0h4EMSs5Fkrh4UpULVoTagwWJFULUoNSJZLLNMIjCNx52oth6LMlWBpW25UAPkJ/2lAd8wJyKQSjwPDw+h9hTOYqTGEEH3eFyTZzmqwpOXLvHU01ejCq7JUll5mJSO+2ijkTuLlfh5EY29sskQUsyEtXPOITaKITnnUGAwGACwvb0dXxuX1HU0x27KUcfjMc993vPZ2N4hYAjik4DOonEZ4t8WZJRmBbHmCfsc2WPDOKokNtZgRUAcNQYXAk59KsOKZbp0ytYlCVWV5Yi6LikKnVH/bMRNdGXi67jzyXFA6SqQucwKYVkwurC8fwmrNTUfyfG9hVfNn91rO1uWeuS9nZ7T67JvmRmJq7xGjwpQmSnwuPybjqeqOwtmF4HOZWNjWU/qcZQlFzLLHE2ezv2MHGVUA9rOvdcVT+h6gjCLenS7/duz17CjYq8Nezn1Xp0+/89Vb+6zUuGUrJuMESSznSSdTOxoqrHG0vqYPHUuFwhk1gA+lo9bQ9BAIGBa6BJOA+NTcHm6nW7PEJiT5YvrcQFht9xmiWKhLvrs9QaAzwSwXRa4rSu4sCyz7asalRB7y4Qo3pMys4aAL0dQlmz1MqQc48shN124wN4Tj/HzP/ev+fmf+OcMrjzF3/5v/3O+7A2v58K5mzi8dhVrhcw6RuUYsbFEJrOWSquY5bepxDIYPAkcxW+nTkDP1EkFVizWWTLrUmljUrBNTFygo+aJaVVRGxDR+BpGBjMyhiFlsQ2BoAabrokPCtQokbUMtSI2MbuxeRCQZCsy8UCUoDOm0NJZmBuFU0sIkoBxDcElYRqB8ZjBwQF1OcaJ4iSyiaIxw2+MIc9zxuMxFy9eZP/wAJf3UD/53nieyRfUZrgsZpMl+PlBukw8I1WkLXmtQ2AwGFAURduT2frMGcN4PGZ3d5c6KLfcfgd50WegghiHiG1VcSfjTNvExXRgPluRsCyYP+o3q6otUxw9LoVgIhMdUGys3FrIqjXfa4yhGo+jOFDq02t6zPL6sHoAAQAASURBVKY/J5Ngcs3nL6xUi72xBNU6r8P1l/sv6gGb5/k7v+cxLEwyLpvb531u3rYIeoYZS4R5IKRNCK0JzOfNxQ1zO6sGe6N3+kj56AphpmX+ifNYtXZ/Yc5FWWsLU1e/8Z/Udp4JM9e943eZLkfza7esdRXQNEfg+o09N6vAZ5q7tPNZmfryPyaSHNbYpFAX0KpSxWOMhVCCtWCT8m978WqovOJyCXWlQcC5TKxEVfQQKqxx0SLrdDsFl58z8HG6fVHeSxF7xPNuVbZ4UfAyu/Bfjw/WcVnL4/pvzg9WntnVaTk4D52ytyjoEwVKQlQZRdi78jQXzmyRa6DXy8g2Cx74yB/yr3/sx/itX/lFnnvLJn/rv/9/8dw77mIjL7jy1EU2+xsYjb6SRb+H9x5fC+o91jhMDvjIgpG76EsoE2EijyY2s44iKyhGUg+HSArkotpnUB+ZKo2yK4FYbhO9CmPfnXZApglKbWusJGCnHiEKt/jUVxm8JyJLn+KIBDalRsRNSnw0jeGuqEkCuxYT+xR9SPuXNpiN9ZomXf94J4aHhxwc7AGxDFbQVmwFoN/vU/T7XH7yKS5eukw5rrFFnkBUV9gqAi3nHFlHTCVdVZr+x4axc85hrcUz6aesxmMODg7I8xwRif6PaiiKAmstV3f3uHr1KiLC+ZtuwmQu+oGmclhNGex5pWMTu5bVfYHzEk86lTAIrcorIfXcSk1VeyoxlGKpvEYLmqZ8VnTK/zI04LKKZb9WzMKwtQk2j1OieFI+dItK9dftg1xVdTGvqmLVeSwr3Tyuaub1tiV0BXWul8VZBiZXtl/I6n0vZY91dXJxRfnmkfNfVeEyda2PCKbMF5Cafx/C2uOoPY/u82PkWFYwJxmHHLcvuXMfYrlsCizWEhH6HMZaq33G19ClMClLoIFQlhq0xmVZm2hleEA9GDAajUCsZr2CorcBeQZqMBaoqyjmYDKxJOctwkIrk9PtFFyebqfbdQG2LphoFMsm7JO2wEtV5q7gQrMwh7Um9JnyUl0rsOXGS1Eni/SiQM8sDRaWCSLc8D0Jikv9jc2VFGKfoyhYEW6/+QJaDqkHQ0yRcd+nPs73/W//Kx98//v5ste9gr/2V76TM1sF5y6cY//i0/R6OcPhEFVlc3Mb72MppHrwohivOGNBY7+cybIommNMDDagtbwIqSyu8opvSxtdHBMiWBPXK7EGHwwN2dGUQGpStZuUjCo+1NS14EwEVhIUFd90BkYm0EhMp7exj0bGU9NoS+q2IQiOGbXiEAFR0BB7NkOy0jCSerRS36OxCBaTxA0OD/c5PDxkM8/IHIRyRJblSDJczPMcjOOpp57i8uXLCSBZqqCYLInopL5L51zbbymh4x05My6NkRawC0qWR3BZliUHBwdteXJT1tuAzYODAw4PD9nY2ODs+ZuwLqMe1RFSJz/KSfnYip7LOXPCIpDRBZXNPY3AsUaDEGTytyAQEhuqjSqyhBaMNMeYWYsV04LP6R7DeYBHWFBscUPg8ST3c5R9YeGcYsxicNr05M5LqE31n82oknbVXuedx9S+WKx+us582yXapkHTyYKOecc/fydHGcxVAG8VODgOsFwE3G/UXH0ynvya68uiZEVKDMqzVw20rOfyOsvGjxhaz17fz6Wgz8kA2zh+fe2jSqwqGjwmz8WIw4/Huv/0ZR759Cd46L7PcP/9D7K3vw/WsLWzzZ13PYfb77qTF939Ej13ywWKM+dScFHrlIyE9E5NSU7B5el2up3Mgj2levg5Pr7j9ipdz/7XycSvI1R03EVj0frdCS3xBEwTL0hoey2NgqinrodsZo7+dp/3/fq/4//8n/8Olx57mP/iO7+d7/jWb8IyJDfK5cceJzeWvFfgEAaHI4bDQ0KIoCRzLpZsBiV4iWxjAooqmiwjItixxpJbixqJ3o7lGOo69hjarLW2iP6QkXmqO8FtbL0zaAiI+uQpqVFN1AfwkcGMAqMBMfEYpIGYPvUlShL6Sb+boGAmwEh8U+pppgFc05Lj4y+RDZOkrwdBY9LESJNRCYzHI6pyhOttkRmDDxE8phwAaiwaPE9dvcr+/j5ZVpC5jDpUWIRcov2IqKSSZJPGUohlz60Gf2jVddXEps/YhxlBqVelrCuG4zFWIlvZ/ZzXwHBUUnvPxs4Ovc0d1Dq8L1GjSSU3mqiHpjy9UzrYlJMq0adSUrDZMiYas+SRYTSRCU3MtaoSJLS9wl3gI8bgrEGcIRODGIuKRWqPDbEv19SN6qHBBpMEnlwUtWoUgK1BkuCRrunBNxuMHofB66bLFkKiE2RBVrGezT2YlMZLm8xTaRIHXVbDTMqTTeezkvp8jZtKAB4Fnq4FYl2QOi3ONLk68edEYTKEmDRADSrr9m/F56Q7H8qa68TKstIZYDn321PeQo45vhb9nvw6krXPtOfxpGx3wpS2zsbzaoV1+sBaK572+2wCmKZNBKLT6rmxJ90QCFgxBLTtjxSRtme9u/53S2SNfm5ikymhpnaJnFTB2s7In7zXsIjBnf/8GyYlxSEpHHQugprOvHi8fsT2+RCOpcDa/RbTPIvpVaMhjROP1KWCwR8c8IHf/33e/7v/nn//np/j0Qcf4do1KDbAWBiMoNeD87ec5fVveiNve/s7eOvbv4azt94aj9A4cBb1irHT3Gl3SJ6izi9wcHlSVg6fL+DgdHt2r09oe5AWlNoIR3utmp8aotl7N1PdnYOh9SmD6YWz+V4NHc/LuQGUOeJxJyISQtCmX2/Z9bLWHgl4uufSmC00JT8Ly/2CHLFeaUUNlgLRWKYXkmLpJIhtJuKOHGLQJvSa5IiPBGwpq4xBU1Bee0+e59TlGPE1mYBWY85s5ORZQX24x3t/9df5O3/7byHVkP/lb/83vOG1ryI3noO9AWOFnollpvW4RBSKPPZH2iyK4PhyHMlAEYIIXgSyyESSPtssLCExGlYsm9tnkOGA4eGA0bhCib2HAFVdkzkXLSnUTCskCmioqasx6usILKuKelRiQwDrsC6W3Ma63EbopQGGycsrM6gXgg+oTf2VneDY+3ouU9K8z1chKu6pRgCU5QxGI6jhwoWbIDOU+9cY7O2y09+ksA4qT7+/yeHgELGGC7fcTEC4Nhjw5FNXuLY3YGNjC/VCzzgyFUyIgj0GZaNX0O/3W+YpWowI1dhTlR51JgWiMYAZVyN2zp7DC6i1XDs44NreAc+583ZM5nDGUoUx43pMkZ/hyt4uDz7+BHe/9k1sXLiVgRdUoviRRRmOBxgbgwcNye9Gu+602pan+m6qI7E+aiR53RpqrzhnqHyFcfFZLEdjTALtRRH9OoOzlMFHD1RrwOaUKhhrwHqCCt7H4mADZM7Rsz1KwOYZuwf7MfmhE8Gno4BvMj9piCVdxrrWF3ZZEmlhmWlrUZNgk04HVo3KsSw2TJwZeGYKjy7yYWzm6ZDUlLvj2qSqkKav2BiDwaISn4X4jDnEElWgtSZ3GcZa6rJCNfmQppJzl0RArLUYiSXIIQR6vR518J3WiKOed6oavXrVYFxUPlZNfsLp3gWtqasQBb6kUUGOytF54ZqFpANWfQI/YI0jyASstmBH5gvVTNSB0+sNuG7Wi5RciZ/RNgES0Ba0NKuANYKEWC4fham6Qb6ZXg9mfOsjqFSC1ilxlNS11TARwxN80LaSY8L4h9Z2qKx92/c9Oc/QglCfevCnMwpxdYnH1vTqd9awpm/fGHzQWHpOSAraEaxoAjCNv7GZWtsnJ2yTj3N7f2Sytmk7b9Aql84+a0d9aMORPEBTJi+pYCU01lchtGqpMbHGTO+lYmZK/LvJk27bjm+YXJWY+Eo/p3qywySWal5uKgtMa2M1qfiIWgmT6KqZ2wKTpIIPPra4iJ22fUtCc8F114ExqNdeXogQqKtSHQpqhbJWQuDSRz/JT//kv+Kf/MN/RDn0nN2Blz7/PM9583PobWwgIhwOBzzyyGM88MhT/NxP/Bq/9DO/xru/5Wv4q3/tv+alL38lla/Ids5gnJUmIdI+5zaL7qfBkxmbxNqOzmN/zFpePyeY4ZS5PN2+CEZzWE/2bcmDsE5G/nqZ1kXgr/v+k+6xWLfEFzXJr2160WyC1NbIuAGgREPjdo0VQ144rl65wvntbfLMMNrb5cL2JvVgj7oa8xvv+Xn+h7/13/IVb3olf+17vpt+Ziis59rlp2PQZwwuBVmNwbIhltUmRRUmgg6xRFSNoEmsJ8Vjbb9ePKwINsuqxDnH5vYWdR0DxvF43JZstgFOYlkkMYH4KJpjUuhlVQm1x9c1AUPlysh85r1WjCcGCxHwSGOwHmLA2wZNxiy8712AIXNIjBACoU5BU16kkuBAWY0wIuTO4jTljEMUN7LG4U1sUd3dO+DS05cJIVDXHpt8HuN/SfhHOt8vARHXBh4KiLOYpFqLCDbPUsmtARuDnlFZEdAWxAf1keVLJbOjsmRcV2yfO4/pFXixhFQeHEKNaMzIB3x7b2wbHEbQpqZJc0yP1+b3oElKN/XgiiSWpPFXo2HWYz+lhiQKlfpsq1BRIojLwBrEuvgzgSP1ibUWG1mvpc/vYgahKcG9HrVIZfG017IQGjtlrU7bWpyYGqURUJuAZEMChhbQNp50qorWnso35apxXjFOWnAYaj+lyqwhUPRy6rpmNBqh6imyrA26D6sxdbJCMSb2ZjWMZ3sdrUF9wIcaExzB+EmiUYThcBg/h42MXJRfjgJPKbHVBOwiE3sM044k2oTG9DjUY8/TDcvaJFCmGKxGWLarVNq884YstDRdr6MMWaN0rEFi9QPTjHBjQzNh4TQJrDQWMDLD1DaMm0zAdduqaVAT5gb77dokjcKon/TrtbhK23Wqy7xN5tMZQanmDq3oH15VrtrO/UHbOYnOmGie7ZZ5XZG4X1S2bNLnG1BsOomLMMfvM0jXK3nBvZ/Dic7OWDZVv9D4RDcANh1bXdcMxyPd2dqRIiuIqd+aweG+bm5uxITr3q7qeMyv/uIv8k++//u5/1P38/IveQGvf90ref0bX8btt57jwoUL9Hq9KPhWVzx95RoXLz/NBz/0R7z/Ax/kJ37i13nooYf463/zv+MtX/tOGA2pa1WTb0owLorXSdR5aK5LVVetd+aiWdmeRs+fv8zl6Xa6fa63WWGb+YvDegIRK5h4lTWo3OOKcMxbUNbxfJtVm7yuIENCXFSCTrO6HZ83kcTsmS6LGRe33Fmefvop7rrtVsrBIYdXr3HbTWcJg0N0PORHf+Sf8UM/8H183dvewre9+51sb25x07ktrl66SJFn1FVHcVQ19VgqamI/4azq4ySYsRGoibTqr0JafRNzpSnb3ojTSF0TxmNCVeNVER9axqVhLEU1Bgrq0drH4EHT9fEBrT01Neo9ofbYTFtp+cYbcbY3UCWyKxIkKdNKKg+bqJWq+uRfOSOBqBNmI4RArVGRNM9z6BVQjxgPhlgkLs7e4+t4HCHUFC4xkApXrlzh4sWLsczYWKw4fBUFfRpgHcmUSd9j238qkzHaiPhYa8nyHnmvwGYO6xy+9hzsRxuSfr+PRfA+HbN1jEYjBoMB47Lk1ltvJc96sSQ5YfomYG2AdsNICNOGg7NCEsv6i7u9m9PsveKsJTMWtRm5NXjnEkCP/aY6VS4dlWRFoxXL5LWj1g+Tfy9IQM0AinUEcY70cTXPrejEP7XbQ6jRR7U5kEm/aHcOmQ04dfZgl4JbH6KvbAvsNDFKSBv4NvOMIohJfwPEBHztCeqjt2oKVpseXvUV+7vDmLcwBpc5sjQeqyp63zprEQnxO1N1hw/RUkg1sm7Bp2tnFG8EX08YQecisz5h5nzqd06MSOiKe4apyo/m/sbSv5m+ujls9WzyTrtJBQ2pwj1MKR+bpvRTQlvZIjrp6W17ujvU/qT0WOeD3BaXxbJTxU9XBkjD5AneRKZWkz6BadjsNOYNk/eSKh9a25AkviXSNJ9PPGKlYS672RGNYwPRjqSqtiy7SeNqcn3DwnX/KJCYgPSpstUVieGpuzfbp6qTkTFZAybX0KXiVDrPu2l52wisTdertb09E6GiqXGkgqhJ1lWmBXjaVCxIMw61/dler7klzKZzrSeDukvWNpUhVgxdMVdBsAI9IM/ytvtZNTKWm5sb4D0c7vPQ/Z/mR37wB/mxf/lTvOFVd/M3/pvv4TWvfiX3vPRujPVYEz2mqyomJTc3N2Pf5XOfw5e+7BV82ZvfzBve9/v8wA/+JP/yR36Yre1tXvjiF3P2zheAT8ebkHEVSpxxsZz6FDmegsvT7XQ7KaZunf7CqQVijf2m/3RVMLsO0FzlzzabiZ4nKb/K7mQdZcaU7p0qJ51LTBiTQE8qwU02Dc2yNh4OuOnMDqODfayvObNRkEng4sVH+Tf/6kf5kX/0j/jOb/sm3vplb+J5t99OzwmXHn8Ci2KKHsbUR4LqRomzLclNlZEkURtMLCcT45J0fULAIi2riUlGy1mGD4FQ1y3gCUWgLEuqqo7lnUHRpN7altil1zTEHsuoThtfF530/ISmvLHhOJu2Fybqr3H1S6Fhk+HWgE2WJLQBWodpC0050wToeQ2UfgxFQdYrwFrCoGQwGGBM7E31wyGEGp9AaaPgGqqaS5cuce3pKxGEqsWKjWyBTMQpjBGMjeVUIhIl4t2kry1avtD6iVprcXkPm+eQFWg5ZG9vD2st/X4fMeDHNdZlOOcYHQ44ODgghMCFW2/BWsvQayqznYy5umG4jLblrutWIcx9XY8mKBofxEb1VVL5Vwz047Wo65o6+HbMi03BnTGIjf2pyEQg6CjTsTzp1GWrVga6cz5vOj2D7c8Z7kxmSxZZX9VVVlqlxGfNGhvHUQiEIKmkNVDXNZZOqV/LinkIUGSx/N2ZePy1GFwkwalFUGvJXBxrVTVmNDhENILCjIDRCCrj/ZpE8JpAk4ZAkNQnK4kJdyASnwuPprEeohAYmlSv4+oQpubVSR9twxY5mfI0nDP21h2zBtUwn8FOY8RKZBCb6L8ph72R0r6J8JRMjdfufKBJRKx93RxlZ1ssK00yJkyY3NTr3PZwq0IDqNqeztTXLSAae0BFG8ASgZPMlsbP4YhXieEc1zbmOFVFTbJ3Xfuztt9VWcpgTl1j6VynFvjRise1Sa91myZnhIubEuImJvDJhqrl72V6DhGgGgzp9fvU4wHOGnKXyfDpy0o95rd+9Zf5B3//f2P36af4i9/1Dbzz67+Wu5/3HM6cPcdosE+Wpc5sm7UlxCT22Vohzx2vf+2ruHDzzdx08wX+3vf9QzIj/I//89+l3n0KW+workBUxIhBQs3Ye/pZEdfOsPg6nGrMnoLL0+2LejNzYN68ZWP+344jO38c0Kky/xAa9jKQ+jfW8Lm8HpB8Up+f7fVcBDKPZnplKggPGgVWmky0mHjnrBG0GuNHI7Y2e/TF8PAnP8Yv/fS/4kf/2T/mz3zTN/DWN72Ol77wuVCP2buyTz/vsbm5weHefixN9Urtm+A8spBeAz6VHcZFNZZhGmPje4xBjCEk9jIKPUgLStt7mPry1Ce1WGuxzqFAHRRf1wlcJrVPTQxlVM5B6yTi07zuPSH14RJCKofSFmQ2pYFIfF1kAjJaFcSQcsISy1EnLFASAIq0Y7xfmZ1iLkNQMic4Z8BXDAaHjIcjetZE1dJW3XbCCBuF0WDIk08+yWg04kzRR+tomWKkKYuNwasTQ5aYnKY0MMuyxF7EPhubVFGzrIj5amOwLgeXMyyvsbu7S5Hl9IseouB9FdlNJ4zLkr3DA/qbW5w7f4EgsVS2SRqICMZafJexljDFXLYJpKUaNpOgvymBDB1Py+Y9IQSC91QVlFoTfMzW1wY8k57O0PRTEdA01tQIWQqIolps3bJbqsvL67VjIN6SVwtK5heC5pAYO028zJw+SpMSG5iuYX3H+gY7w49MM5hHwGbnO1QM1tnUZxZ7L00IqScxYETJXRxfzkwSFoJtexcJYxTFEZ9BQclEEA34ekiR51iUnnNIXjCyUaE6z/PW+kXxrb1Po+zbVDdkrsB7T5nml+DrxIg7rBWG4zEEiT21wYOmKooQoqCNte06FQWgbZf0ieW9HYZwXY2CJCY9kwydjDfTsEhzGG/t6OnIDFvd3L3Q9KItRZYdBov5FjoNsNTEjAeRdmw0+MW2Y3m6NzqOJz9hDJvkRjumDBMO0UyYywbuyoQinDidhPZ7jAi1LEjC6Hxl3lmDo9nUziw4nfS8HoUion62Ond5IjtZkYiIaNKSmGDArjpwNzoyk+Qjk/LjbiOpdPusj1io2TXjr/RZmT6etiw2pdfq1NdsNPUZ155eUcBoEMGhCYSrV/Sxz36Kf//rv8r//Hf+Pl/55i/lP/v2b+TNX/4m7rrjFvKi4HD/EuPxmMNBOkprydL63RV/QgzXrjzNrRfO8XVv/yrGowE/9M//JT/6Q/+Yv/A938uF2zOsWHwIanuF5M4RyjKymPWY3OSnIfYpuDzdTreT32bLmNYBc102IVkR6EwmcyUCnMcALPOUW4cxmGUvF7Ee0/tbwZQuYEmb7Lx2xIwmwW70dbRaMzrY4+xmj3M3n6U+2OfBz97LP/uB7+N3fvWX+bPf9I18+7u+ge1ehj/cpypH5JkDHzjY3Wdjoz/xD+wE0t3zExITmQQekEgrmAQuVYTQ+bsY0/Y/gVKmkkyTZ60AjPgIjvJ+j+pwEJPHPrKU6j21xjIwrWp8VceANIHMUHvqANU49nJmeS+ymUYmwZ8SM/WeeKxNWtlI25sjqYy2O9DaMjIm/ZeiELSGMAFVLsuwmYOyZHh4iIYamxcErQkhgcC6Iity+kVkOPf397j05EUy6zBIdKwMgQxHwvOIKNbKBJQaQ6/XIy8c4zJQpXJDSb2WrsijCq1YjI2+Zfv7+1zbjexolrnUzxja3pfRaMTu3h433XwzZ8+dByNUZY3JC0wqo7Sth6dJfbczgfiMv92EEeOIUuiyzdcTAZdoxZLAbSoHdmIw3rclkjRl4U2olZhhCKiPPpetsIyE2IvYEcE6MsfI0WB3QUA6v0w2BZatLmQHbE9VG3Z7vdTEsRlid5STBf2iOhFWWYZNVD3qoQ41FrDOUNgMZ8GK4qsSISZtDEp8hH3r2Zo5C5Luebp3WZZhxTDOY0n71ctP8fSVEXVVcXBw0IpgjQ4HqS8yATFLO3YjYw/O5Rjn6Pc32djYoJ8X7T021rBzdiP294bAuPbJwij6t/sQS9819WiadIwYwRBVUM2CeXqtZCaxJGNSseJbwBVEMKop79fU0E4Yak3jwqbKE0lqt6Km/cxKS4vExDaltfOOu21LkE75fkep1cwZv41ia1OBESRgRfDaiMVpx27kKLhqEkrdtcswuU4idER9JgBxLsicLTXXFUziCvZzuuopKdkKGJW2aGDeutz1Ee5OBq0gtrA0HjhyXWQi0Lcodpi6nzK5jXG8LMnMde6FJZbtNr3Q7ZzcZAsEqmuXNdvagOEhu09d5A9+77380D/5fn73/Z/kr3731/KN3/B1vPglz6Pfy3j0sQfxvgKJz3m/t4P3nuG4JiRxqNxOrLDqOrC1cwYVz5mtgq9921fx8AP3809/4Ce44447ePd3/AW2NrcxdQXeKDaTKAAW2qosWVAZrqfh8Sm4PN1Ot9VA7ng+URNBG52NqdqekS44Cyuh2vEsP2aB4rwgsim7nH1t0f6vx3B9SvggdYOEtCYHSeVfRrAy6fdRn/qSQsW5rT7l3i4ez7WLj/N9/+v/yIff99t871/8Lr7yT7yBm3f6lAf7VOMSX1VsnekhueXpp59umTFjIvuhyfuRpO4mTTOFgEk9llHJ1cTPmEk5LB02SayZ9MAIGDspsw0hpBys4lLvotSBsi4JIeCrCrzivYIv8eMS0RRkJiAcELSOr5nkXdkqGzeMWVNaa5ogT8HHbGwIk94fQsxNezzoxDKDphxYPVortZjIAVhLURSItVTjIcPhYbQSsY5Q+6mMe57nsVQwBK5du8bly5fp9/sAZDYCv8h8NSCl02fpIrjs9/s45xgMh9R1CQTywlH0IqNpnYsWEyb2Ye1dvcbetV3O3/kcsqT+Cak8GeVgOODa/gE3P+/5nDl/ExhH0Aojsa/Te4/t9DhKx9RsynpAZKmBd/d+TLGUQdrf67qOwZJxYC09K9Quj9fdZBGAqO+UCStGYrLAuPifdRN12K6q9CRIDEfqLmZVn+cBylXBb8vDJBXHxpJFG5/NtihBW/XIJkmjMvGEDen50k7/VixBVOj2fmk4Wsihccw6jUAyd5YiM2RGUD8m+JJz/R51VTMaDajGI+q6jCDcx+s1Ho8xBKzNMMQeya2tDXpFQVWVfOxjH+Mzn7qXxx9/nGtXn+bSpUux19I56nEZ5w+bmI8siksVRdYGp5ub22RFwc7OWc6fP8+5czexs7PD9tYO/c0NNs+cJ+9FxeDMZrFM0zp61qDqGJc1Xv//7P13lCVZft8Hfq6JiGfSZ3nTXdXejMWgMQPMAIQlYQmCuyKWlCiRolYriWdXK8PVOZTO0WqlXWklLUWRMpRE7oKiFcmlwAM6eDeYAcab7nHtu8tnVdrnIuKa/eN3I168zKzq7pkBiCUz5tRUV1Xmy/cibtz4/X5f54lK02GwE4NLzY1ZdN2KyZ1bHaKcHtuc6yStTkMILd/fxn9ooYvPNXmqNbJpB4ALGKCszdC5nvoBWaE6RtmL1CJ7aJ4VTYpUmut1fdNr6qTDC7K+Qgs1ynoKoeP03qHzts2smjeii+9tfm4E41atcVWL9LUGb0edgQ83u83rN7roePgeizywbjiMWHafv6Kfl+sdlek04EdzVsNx4KCKHdRRLWbjNs+Sxr0Z3z6foatDj6lx1MecRLVAk29ft/N16shAKswbskYK4YXdo7QMM+QiOqjrKM8Sx/71V7n2+iv89b/8l/m7f/t/5fHHzvOf/ul/mQ98y7tZ31hm594ddpWnqmZEHCtryyhlsLmhZ5IvgK+T34EwjapqljT6IyEJoTBZzvve/RQHu1v8mf/nf0npNT/84/8bzly4KFR2Y2TvUmCNnc9lTsrkk+by5Dg5vvFG85v3/V3U8kFN4oNe7+0Ea79TrdPXew7e8v0efihr0UAppYV+5wMhenxVE12FIePM5fO8/ulP8R/+6T/F61/5In/sj/whaSyX+8z2tvFVSZHnrC2vMxpPCCjOnD7H3t4eWlnRQKXJtPfS/DV5lXPENznvJWqdmFyY5BrbOOelAqbzOUyiLYbGgdYYiTKpHWVVsZTlxChNBkGaG+U8ygdwFb6qpLAO8ybMoDBNo9t53PsQW6qj6FljMlyZT9EbXZX4Y6TCv/la5sZAMqSW5tSHGow0DtoYQS21xocaV9UtYhNc3TayMUZym+GcAxR7Ozvs7uywNFwheLC2yfWLqKSrQYlmp0ExMZAVFpSiDjU+UW1tkaei3mBt3jYsKgTG4zHT6ZQ8M2gUtROKkrWW4KGsHJNpyeraJv3lFUqTAS6ZpyDXP1ViRuu2KlscvsQHUmKPIISHfrWNYGownXNEq1rTohACPnrcoe9v70ulW7dhidkQ1Ekl3VjT2D7IZKg5XIcKePi+fzt6r5iaClKOZJvx2ea/MnesbEMndGvo2Y1paFGihnXHYmN52FFaRbAqYBTkRlNkAasj9WzM5GCH6WiP13e2GY/22b13j+2du+zv7jCeHDCbzXDOUSUKW2GlGez1emxsrLO8tERwNb/wC7/AaH+X1dVVzpw6zbm1HKUKer0eeEE2ZShUUbkaV40opxXjhCTfub3FeDZlNva4CEWu2dzc5Pz5i2xsnubSlSusbWxy9uxZ1jZOsbS8ynBlhcFwGZsXrA5XhDIbFS6Im7WPMp7yUQyIFrL1lGnXZgSMztriNrbtQOdcK5vAyIQDpqbfqM7AEZ32kXBkjbS0zeTOGtSDhpydpM/YbSSDILEJ+YxJoxqjR2uTcn/tvKmKolM1WuJiGpOyqOYsgqC7z5H5MCPqgGoR/cVp7XEIU0jxKI12s+ktFzXEb2fg+zaRwUPP7YXncIP4H9GB69ZErpvpeQQNTVhvJKRszwebBB5BYlUXeWwG4XqB1fGW+yFHmQ3t/I5ORmXT+EaPbQKXI+BrmM2YjEZU0wO2t27y+ssv8dFf+xV++Rd+ntHuLt/zkffwPd/9Xbz33c+wtjKk18+5s3WTyeyAh64+jAs1/WFPYsRUIWvL15QJlC3yAqvB+4JBr49zjns72wQve9F73vUk21u3+PznX+A/+b/+5yytrPHDP/bjLJ8uZD3EEBVRVa4kMzlH1JVvJ5j25PjGm8tvNKfy7SIk/6SOkxzL392HQr2ttXe/B+ZbucEefrgcyZtUR99P18AnpGmxeov39VZr7X702xDDsa9xtKg9fl3Ht3gf8T7akxYZCnFuTBpj29g0+rTMKOra0c8ygqspMktde4yGleUhw2HO1z726/yFP/tneOHTn+BP/st/lB/6Pd/J+iBjtrcNrqawBqOgLqdigBI1k8mErFeQ5IfySbTGZJJ32Ggog1Qs8iAy4gCrpNpJqKQhqE7mX0M3bBxjO02BTg9ipQTdzLIM7z0akslNYORqJvsHGB/pWYXVJkWQSN6XmPCEFlGuyhLbK7B5ATEIhZbYySnzKCNIa/Nk68YbkBxSoxKzGClgJIrDmOSIi3jx6QjKGMn9C46DgwP2dnc5tbacjIYCBKEX9Xs9Ip6s12Nnd49r1661tM1MiwuvaE0jeU+ywVSkpRk65ygKybusqoqqEmR3MBgI2ptogp5IKGuWEmXw+vXr9PKCteUVyrLE17U0YdZwMJ0wmkzYORjx0COPYmzB/miEyQZUPuBRaGslr6zJeIshUYPjgrmTNE1KaIHHZMh274m6runlFu8lV7HRjjafs5zNcKFmGh21KXHW4GxG6T0T55lFR12XEk2T5dKYR5msZ66i1y8YjUfUdd1qhmIMMjSwdmHv0t1CMcVtdNGkhcI6hCP7wcK9r5OONKRWUCXNslYYZYk6YjBUribEiDUW2+Tu6tjmwEXnO3pUAzEh/K5O6HHE1SVBKXppfXjvyY1maKCfa4Ir2b+7ze2bN7l1/XWuvfka927f4Gtf/TKT0R479+5yMBIKeq8HKysrYvhkDbPZDBUi2ijG4zG7uyW5hY2NARvr63z3932E973vPaytrmKMNPaCvNE2l8F7nPcQPS74dmhQ17VE30xK9scjdnf3uH37Njdv3ObGK8/z6d/6Fcqqpij6nLt4gfMXLrF5+iznzl/i9NlzbJ4+y3BphZX1dVZW11keLpPlPUFdfWRSB6KxgErazproA0YLdX02m5IVuQy1EBqysrIXOB9kgGOLdp02tGCtdWIWgA+1mAdZofR67yGIGZXNdDswkbURW9pvjMLOaJpUH2okFtSn6BiP1SblZUbKqkRHjcllqOeDRzcGVjGQ5NXys5Hhmskal93knKxMSxVt1qyxqr1mMYo52sK+nIZ0IVEvm69tYrBkEHRIstHZg+ca2+NdpB/0HFYPQHYbdL6hWouWVTSjVitxyDaGWV0lTb8VJkGKs9KZuGM3nzHTCmOsgoD3MXpfo8XRZoHK2vochIBKml+thN3TPK+N1kfkkg1zQivd5nNKZuXhtN1W7pPoyjKIMUSsNalBEwdhN51E2+9DdPj9PQ529rh14xovv/gSL7/4JT77+d/k1Ve+BrXnqSef4L3P/gDveupprj78EKvLQ5yrcGXJ5uYm54qz2MKC7uNDoCo96IoYS2ikMVGitUIysvO+ptcreOjSRfb2Djg4OKCXWT743Lewur7BX/qpv8u/82/+aZaWlvi9P/ojWBWjC2D6ObnNOlrdo830SWfw9QEUb4dlc4Jcnhz/VC74t0LsvpFcya/3e9+O8+M7GY58M/M320nmYQSDwGxWMywKyumYTEViqFnKLfu72wxXT3Pj+c/zV/+nv8DP//2f5T/69/9N3vXEVQoL5WSESfRTncKZuxYVgqZoCL6T8NwtvEnZlcmYQs91lsJ/UWC6dKx5bIriaCSE9LCdkPlG36k10bk2XzPLMoosJ7gSV9VkSoxyYlOUh0BMDYSOiuBD6zarYhTzn4ZehFBypTCKrWbv2Osc74MiIcZREYkWsenzRu8pS2l4VIhoFVt6bqOLNcaA98wmU3Z3d9vXE/prR9dIxBpNZlNjryPWavJckDmXmuEsy8h7RYtaNlmXWsRtzHb32L53j8JmZLnFaNBWrpn3nrJybO8foPMeS+uniMbi68aFOAlRv04Pv/vpEo2RVdiilVoao0ZD1CKX2aLJT1MYiyupwtYWH5KuEgWpsLRazoNaiCMRQyals9Zt9H7Nb1dnfNw+9Vb3ekAjfX1ssUUVFE4FQS+jQ6uYskkFYXV1nZBZldY37UBHRy8jNR1QhSHUNTbX+Gio65IMyPKMGA02erJ6ypuvvMyrL7/MKy9/jRe++AW+8qUvsrc7psjgkSvnOb+5wYfe+xQPXbrI6dOnWVoeUBRFcgX2VN6lKIXIdDpla+s2t2/eYrS/i4rw8MUNLp5e5fRpobTmRSZFdghoY6Uw7ei2uwY/IYSk6xbTpcp5ptMpo9GEybTk3s4uN29v8eab13j9jTd46Uuf4eN3DwgResM+ly89zIVLl7n88FXOnb/A5csP8/DVK5w+dZZ+0WMwXKLy4FwgRgVYopJtzcXA0toS0+mUuq4pigKjNc5XaK0ZDAfMKo93lTAilGQJumq20Hg1kTgN7b1xORZNmhO6ou4wPILH17LGo0l0bsQRN2/WmwEw1FWJVYLC97Ki3Uedq4nRUc9m2CzD5lEyhQ0EY1N8lRcXX7Ssea2FPo4WFkL0YoDlwSezq8aQx6b4mrqWvGCT6KVzR1m90EQ2zbPRNjXVFkVGVU1+2+qMNqc1BmKQ5ssYRaGl+VdWU1U1NmnQm8GSSvtL9DAscjV32/UxBtEd55lVKs9wLtHNwzynU0x0RBOtVdL4NgNuLQT45pHinMMYQZG1me+dklAkw4NIJAZ1aNAqA9iA6GEzawg46moWC4tMEcoptp/BdJ/d6zf4yvNf5Auf/ywf/eVf5bOf+QKDoeL93/IUH/nge3n6ySd54rHHOb2+wbA/oNcryI2h31+S+1Exp3kHWQpKyUBB/O86UWgx4gjo0HElz3NWV2Xw4Jxj0C/Y2DjN1taYO3/5f+G///N/lqfe9RSPvu8DFDpnOp3Efn/phBD7TxK5PDkFJ8fvvi5SHU0HP2Q+M5/ChQc2XF1Dn+ME+/cr3Fo0LxxjCa5Ua+jxVlvXgyY7Mca33PuOK5gXTEvestl+sLnEXPMyb/+CmlPgLFDNJvStpp8Zxjs7hDznwoVz3P7aV/jv/qv/kr//d/4e/+7/8Y/zvqef5KHzp1H1jHs3thgWedI6agJaivxDl1dpM7fyVwqUmZvyaCVGMQlRaZ1gjU4aPYQW1FJ4O46ijdtAU6w3UYDp70XjIhN2j9DdlFIUNiMWBWVZU00rrMnET7MzMZdOVSiVaE0IYENCq2JMgd5O9JRJu6dikMy8Qw/4mAIQjqLzjUujRiuLTw6wNjnlutoxm0ylsUyoZoNiKWhzKL33HBwccPv27ZRtKU26VUKDszaZm2iwmWk/Z5Zl9IcDolbUdYn3XhrvIunTkqatbmIkjOXevS1uXr/GxsoyvTxDBZ8QM0HD6hC5u73LcGWVMxcu4ZQVMxV0onR27ocon7frHvlW45TjGkyJGZkXqFHFFtGKMdLv9xkOh5AidGplKJXCZ7mgPdFT+5qey6mdTNiDr0EbTAxCD2zjSFzbsIeojs2haHPjUG9r6PSgprTRmoc2PS8NNWJEpaB50yCp6TMHn9Axaylyg/IO0mAlheCgSd8PhLqiXyzTWy6oa0FyZrN9du/dZby/w+d+45e5/tpLvPDCC9y6cY2VpT7f9r5neM+7nuHCubM8dOkCw0GflZUlBv2iRaWawY62RoZFXs6fUoqqnnHn1m1u37rJtddfo59Hbl1/hdn4LpcvXGRjYwOTZbJjldPOftjBrZQUrIW10mChUcqCtqBWITk+T6uaunKUZc1oMmbrzj1efvU1vvbSK9y+s8Urr7zGx1/6Cr9cwcpqn4sXL/Loo4/z/vd9gMff9R4eefpdaJMzsDm2yIQmrnVq9CMmyxnnkbJyEm0TakI5JXioXIXzUPuA1Yai30Pnpo1IstZQurp99sWg2nUsNH5LLReldck1ibKdG01eFLiqJDaRLYnqKLphWUOba0vtoKUZSnkiupdhTI/JZCau3MFT15UglMagosYFTzn22DzH5gU+eGZVJQhy2n9koCFZld57WWt4fNp/5V4JLZKmlBIH8JSDaTKb8LeQtl0n95ZPoxV1/H12hAWg7sec0gv7hk7Nb/ME0WLTTfABT0gDNYN3jlAFynLaSi2aeiA3WvJYlQLqqI1SSbeajMBdlGisQD8rVBpozQOOfY0LIsfJ+kMVQpBzz9xszSYtpk3nJzQdW2r0bYOgJnfeNr6kPV9yPutyGosiV86XMXpHkRcQavzoAJNnlHdu8NUXnufTH/8Nfvrv/B12727xnmffxb/0kz/Kk089xspmwZlzm6yvr5MZS24tmbGioU7vNQSRTPgQcC60tZM4pPsFBltTUfng8YBVmrKusL5BkBWj0QQVIqvLm3zv7/lOXnntGj/9D36DT/7mx7n08CMUm6eTOdbRMlKduPicNJcnx8nxoILrqLPd29c1vtPsqmMbPOKxxhwPahDfaWzKce/liBumUt8wwhs73gZhQQMT8K5ic3WZyd42B/szzm6sYzLD9ee/yF/9i3+Bf/zTf49/69/4Y/zw938vq4Meo90d3HTEmYsXuXftTQa9vlCLifjUskoxbFJzqdvIEKVVmo5rmcJqlSwgxSgiNo6wSqa6MsWV72+s/TnklNee+zA3JOn+m4+LFC1jxamuTkV5VVUp23DeEDRoiEyNraCVSVupE4VTnmIpqkR1ArFjlCb6yJDkuMKHhM5IcRMh2b1rXF0ym01TkR5TNIyc3aZoa4Lhd3d32d7enudSJjTWa02ukrNe06BGh1IZeWHp9XrE6JlVJZWrMZlFZxaTXgeEytdfMqA1W3fucLC3wyOXLpBZi6trQu3oD5bASHblvd091k+fY/PcRWoJrVhAszk0a36nxcBxebeRmIov2nPinDtCRT3sVNz+XYOCJlpjbgy5SUHdPpk6hcVMx7lrrDq+6I1f/z27YAKmGvyyTZCUwioV7N5VaAO5NmI+ZC3eO7yv8NMphYoJlZFMuV4hJlDeVbhyRr6UoeMMd7An2smde7z44ot8+hOf4JUXv8wbX/0SVsETj13kD/yJf573vffdnFpfZ2V5yPr6Kjoh6ELxbjt++WU0sXIoK0h8NatRCpaGPYpL59lYHXDhzDrT2YSD3T1mkwPu3L5BORuzsrzM0tJSqxXWQjYU3XSU+yWEgHcyCFQhOXtGLTT1tM8MB0N8rikyzdIg4+yZTZ555jHGowkH4wk7u/vcuXOXO3e3uXfvHi+//Aqf/9RHefH5z3Lx4Ud48j3vp7e0ytJwWcyv8oLhcMjy6jpLK8v4qBgOhwyXlsl7fYZ5xmpvibquKWtHz2ZUNXhfwcxTE6U5Q+FMGqaloVRIjZAOgkhXddmeTmuMjO+iw89meO8oCQwHPdFUK8i1JsszrI7SAFjFdLonlE4UtshlFSU3Xm0y1pd6YCw4x2QmRmdaK4KPlLUjLywmS2Y2wZMllJy0f/p03xmS+ZVAZtLkxoSQ+jntXVgqZk6VdU2WY1rrQe5lobV7iix/22yftzPAnTMJpNEMtVCtGy27iQrT7A/R0TORLEvfE2VIQJbJ/e1KcUBy86wvpTUmGVDJzV1GFaMEhshnjjQuwNpQT/Yj2qQBoFFa6dSoB5yr2lzL1ohNJ4fx4IjBp0FAWBjQR++jT5rk3spQgSNLAx4/2ZP9PVPEgx1++ef+AX/1p36KMJvwI7/3e3jfu97F6soS1WTMcLnH8uaQ4coA7wO+qimKjLwo8E70/HXKl45R4VLClsx65bklm35IPJ/us0/+nBcSOVTWFUWWUxQFMUZ29/coXeTcmXN890e+nedfeIGP/fqv8f0/9MPoXo/BcE354DuZrOakkD5pLk+Ok+PtFY3dKu0bNfLpTDgbZ/b7g6rwO+5jfT9d2TfSVMrnuT8NUUVYXVlm5+4WAw39lFV4+6tf4u//7b/F3/ip/5l/7V/6SX70+7+Xfm6ZjQ6opzM2NzbYun6L02fOMRmNRAupJHA9KFpUkvQAndNYNdEmNEPbeXMJnSgS07rDqsSBjWpOpryfBfzCQCHMEWfvvZhoGN0+hJsHdW4tbjLDRQkeaExcnHPUwZN5L/rIdG10Z8TRoKVNg4maa0NbT8DDkTKtS6M4GwgClfI1ncdY2xZT9aykLkuM1lgt5jmuU6A1BZP3nu3tbabTKcPBijSYGFRUZMZglcLXsaXeNVTQfr9PURT4kBCvEMhSw2pTA968fp4ZcBVbW7cxxrC6ukymFXVZE0JMCGpkd/+Aezv7XHnfYwxWVlK6YaLF3i+SQ92v+25orOGB6957n/JGGyqh7gwGhOpcOwe1ptaRWgWqEPARaqWY1RWlq6inE2JdkfUKCmvJrCADzblxrmobVp2QHmn6Dztxpo+jF4ce73QvmK/r0DaVzdxfE1LYDGgjqKUPU0IMZMaQacgjEGqGuUIZ0R0TS8L4AOdrQl0Tg+Pu/i7T6Zhb12/w4otf46WvfYWXX36Zg71dernmJ/+5H+S9736GZ55+krXlFYbDPsO1FYiR2f4eRa+X4j1qCIlCnTR6oRJNmQ5iVFUMB+n+dBAiw+VlrBVmQnW2ZDYeUU5nHIz2cL4CHcXYR4u3qNDOAz46QcOILcOhMbmicYtWQi/c3bknESVLg/SjpRhe6vc4feYUttejGk85ODigSgjn62+8wcc/9jE+9enP8pXnP09W9LB5jjEZShsGgwFrG5ssra6wtLxKvz+kP1xmaWWZ06fO8NCVq1y+fJnNtXVmdSDmBucis6oWHWYuESG1KwGND7TUXomCSFmbPmLzrNUxqsQPsQayIiNLOaMqCksCXzPevsebd26xdecOo5EYK81mM1w1E9xLS/Pd6/Xo94dYa9nYPCUGSKfOsLy6DjaHymECuOiYTWfMaocPkOUD8qIHOlI5h9UN2ir5oiqInk9H8CqgEnJl0tCw0Ss2E8/ok2wimjQUkMbPmgbdDAtSh/AOWZCN06pq8jM5HHEUZD7kPSF4XHAQrdxjrqaXK7Su0mTWgwtUexO2791je/serqwYjffZ29tjNJnIPppL/mrTYA6HQ86cO8+5s+dZXV9DF32wOcpAZiTrkRDxro4+6bq10SrTEQixifNCa7TVkGVJqh8hVFHOZxq8qoiyYDVYo6Cu42xnh97SAIoM4xWEipc+9yn+xl/5K/zSz/9jvvsjH+b7vue7eOThS5gYCFWFXV3HGNGgWmXo9QpUf4DKMoJ3VEGYLrWvWhM0rWVQEkJjiBTSMIwF3XDjCK+UonJB6gKVNMtGk/cK7FT8EgZZxtnNdR66fJ4vfu7TlNNpq91VJzDlSXN5cpwcb6cpepBpBxzVKr2T13m7qGM4LGaO7+wzHIekvr3vP4p+dqMZ3s5rPUiIveBgmOIpNIFQV2QKhkXBcJDz2uc/z2/84s/xX/8Xf55/+9/4o/yRn/j9ZCpysL9LORlz/sxp7t6+Q28wYDarUtREcvlrmsVkqKMbN9CGqmOksCHR5aJSKDOnaoqx0rwIiYm3pA99jsMDiOZcm2RaM2/+5tRmnRDUOuVEWmshz4llTQyiC2maqrquRafXGMO0D3eVtJhtnyg6zOadxQ4d+H5a2mP4nw1SanKLzjJwntl0Sl1WJDPXZN/u5LMYkyjCkdlkyt07d5LhD2RaKG0xyGfUMRJ0Klq1ULqGwyFLS0sYo6gqRwhBzCvyTCh3eY7OLC7Ugnj1eviDPe7cvsn66irLw6UW7bNaHGWns4pbd7bYOxhx7vxltCmoVCJfH+MV/1aOxkHdn2Ewzw1Mphh68Yvruqau6wUE1jmHNxA6utgmnoUQ5+i0D3gctYOprimCa5vYui7lfbTVbqCNmTjmPj7Mvjju/ryfk3TXOVcnh2GtpFU3ie5tohctmxE6sFWKIrdkqcEOdUWYHVCOD7i3dZvr169z++YNRuMDbFTkmSK4ijdff40vvfA8t2/vsTSAxx9/lN/zEz/Eh779Oc6eW6coMpYGfUyW4aoZ49274vw67Isjb6hxPhK1En1fGpCoqKnrGl8lSnqRy30XwMeAj4HxbIpJ5yfrFRRFQVkJmjGejoQ2GVNWaRS2g9a2zUedlSUKhU9bdTQN7S5IpqrRgvJNx+15zlKOrDaGMBuRZxmbG6vEEKgqR7/QDHPN008+yssvvYr3kbIsGU0n7O0esL17lxevvcJoOmUyhdpDUcDm6VOcPnOWc+cu8PAjV7l46SGeefe3srK6ztLqCst5Dz0oMDancjWTWURriw8R50j6PKGwawwhOMQPJjnMakOW7uNMJefiesrWnVu88eqrXHvtZV579VXeeOM17t29w2w2486d21RVlTSjMruzVpH3ZLh0avM0eX/A2uoG5y9e4uqVx3j00cd5+OGHWdnYpNcfsjQcErGMZzMm05J6VqNNhrVZouoHYqKMNwMqoxE9oG/WucQfNSZbLpmcWWMkoih6gqvxUZ4dKlEuE8j6dXsTqM5wtXV5JqKTi24MguqZPEMj+j+yVDbXJRhH3LvHjRs3uHX9Brdv3uLWjWu8+fobbG3d5u7WFrPZlPF4LBp5fJshrLVmZWUNm+Wsrq5y7uIlHn7oKo889jiPP/kklx56WDTFvQHkBUYHTAygbDucRWllMo1AyqRGtJYFU1finlVNCZMpVSkOzdHXra58OFgh0xq3s41dHgKRj/38P+Qv/cX/gU998vP8xI99H3/ij/8LbKwu8cpLX8WXMzKrWVtZYe3sGbLBELQhpuemK2sxECNCNDgElW1DeRqjO+9SMxmO7H/dvbGqKnq9ngw6vWcyq8BoVlZW0CpHq8ipzXXOnz3Nxz71ZV5/9RUuPvoYEKP3HmPtiejypLk8OU6Ob04T+qDm851kUXYLucBRt0al1LE60ON+/nERA2+V1XcYqT3WVfY+yEfXZfYtP+tiyvrCP1VlybBfYHXkxktf4xMf+3X+b//Rf86//2//a/zID3wPOji8K1Hesba8xP7+fhspsL+/z2AwIBCTi2tqHI0gSFF1okZSY6lNJm6K1szt3VN+WkwIRXv+ub+WpovgtQ+rwwOGzrUJUXSXMTkQWmvReU7IKtzM4RJ1rGlE2sxM52gnx5011jSXTfPaZtVFoUZJrInuuKDO3d67OXPaSL5egxyiNdQ14/FYKLtZIQ1s00gpJQVmasr39/e5fft2SwdtXHNDCOQ2QzuH0kb0MnlOv1ewurrK0tKSTI6rihgDWWbJU3PZuFnOqgrbG0KWsXPrJreu32BjbQ1rxI1W9F/ytdPplO3tbQKaC5ceogqRqvaERFeKabJ+hO7+Dihux1HYGyQxBp8QRslWdM61TqNlWVI5qA0Em1MryY/0WpPnOTkhOQvX+NrhnKfCUyvNcqIXNkXxYTOQ2ocWYX0QAvlO9rX590kMCNG3iI9BUAmjNBaoyxm93JDnOdHXTEc73Lp7l5vXb7C9dZ2Xvvx5xvs7bN/dYmdnh9lkJCHnPqCiw9cOo2BzY4Xv+fHv5ge+7/t48snHGfT6KBswfYvp54JUTkYopRhurIL3TEYjTFagM0teCKVaKUHiqqqirmtWV1dxVd2yAXxZCULkHSF4hksrhOBwdUVuZfChYmgjTEaTaWeo0Al6z1O0yXCpgYoXmBrN5ciLDFclt0xjW5Oc8e62OH1GGI0mYiKSnJK9qzlzao1zZzb4wLuexlpLURTYrCBGxXgyYffggNF4yt2dXV57/U1efPFl3rx2jWuvfIWvPf8CRc+wtLLGxqmLrJ86zeWHrnDp4Ye4eOky5y5cZO3UaYr+EK0Cw/6AolhBYeZbWKL/SlZr8yxwTEa73L5zm1vXXmfv3l2+9IXPce3N13n5pa9w7/YtXAnDgeLsmVOc3dzkA+/6CINBj6UVofVqLQ3/eFoynU55+ZVXuX37Ni+/8AX2DgJFrjh/8RJPPvE0l68+yoe/5/s4d/khzl98iOV+j0xrSu+FkaI1latBg1EWm2kKbdFGHI/EcCYTpNxHtI6gDbqXoW2OyjP2d/ZERpB0zN5HPIEYPcEFlMoWWA/6MDPg7bJ9OjmvggcGdMrdxWgyI3sCRPz4gO3tbfa37/DSC5/m5rXXefGrX+ON117l3tYWo/09yqnDOTi92afX63F2bchgcIq8SIilkYb67t177Gzf5Y0XX+Q3fuVTKAPnL67z9Lvfy2OPP8mz734vFy8/xMNXrjJc24AsBx1IjlXJBSoAgprW0xk723e5c/MWuzvb3Lx+jdlkxN7uNge7O0wmE8rpTNy/XaSuI1cuP0QIgX6/oD/I+LVf+1XeeP1lfuT3fSdPPHaFN15/mVddyfbdW1y5dImHrjzE0rAPqxtwMKOczQQYtTIgKHoZTsnABQV1DBC8mIbFxqTJE1LOMImh02CZMSp8Iq0UvT7aWrI8h7pkVpUYm9PvDTEYdIAzmxucOX0K7+HVV1/lg95j0sDP2AdMKOHE7+ekuTw5To77bRL6HaN2Xw9yyaHmrjGXiXx92s13ilwe96WL5erRUOkHFakL70c1DVCUySgyIbXRE32NjhFj4VMf/yj/xX/yH/GHf/x7+PBz72Up1xhfc+v2LVZWVkSvFyKra8tMJhOGwyFRK6F2Ns2DsWKvrjXaWDG5SUimskb+PT2kVIq6kGywuemP5HE3KdzhLZFqreaIJYrWWVIayRbuTNEXUb5ea4n9sJYyNZGNCYiYaCDUR28EMfQOhUYHn7RdihhMCqNe9EBtHqStLq9zBen4VqnY6EK9WGAkWhN1iZvNCFWJGhRJ3unmmXVmbn40mhywu7st587XyaQiogLkhRT6WkOWG/LcJoObPkWRpclx2eZbNtEoykqWX1VV2OEQNOzt7bF9b5ezG6fEmdB5lEpaOxWpg2daV2T9gvWzZ6gCTFwgYFua4v1qgOPNfOb5fiqF1utDXyQGlhqTSKLReRwxFVa1oCfWoI1CRY+K4rxqtUJlmlxpZlEQwUyBg3RfKHJrGWQZhdGiX4ugfEjKYoXSEkdRpZzPeQ0bjuwD8wZad4ZOh3TizN1QdWzsqoRWaNL9ZYkYHciiIlcKi2dlaCjHB9y8eYNXX36Rl196kddfeZk333iDna2buOk+ClheyXns6iM8/vi3sL6+ymw6ZWdnm5e/+hXe97738KEPPsdTTzzGxsaGuDw6j7aKyWyMn+2T2YKil6EwuGqKVpbB2hr4mDIh0zAmGR4J7bLPZDqiyHJ6/VxQTO/JTEaR5xL3Mp3RHxRy39bSkLpK7sVer0dIsTri+pviaxRYjCCPfm6QJehYxyU6DQQCsaW8N5RpgKIomE6nLC8P22GS1jAc9jHDgRTkeU5mLaQ8XXxgOCw4e2YDbTNcyoIoa8fOzh7Xb97gxa+9zJe+9CVefv0aN9/8Gq+89GU+/tFfRKHJe31W1ja4cOkyZ85d4MqVq5w6fZqzZ8+zPFxptYjNMGlvb4+9g13u3tni9p2b3Ll5k1s3r7N18xp7u9tMR5GlPly6sMkPfPeHeeapJ1rX3tXVZbnve4IYB5XcOY3EzVTOk9mC3f0D7m5t88b163zxCy/wyU9/hl/9pZ9jfwR//W/8FR5/+lm+49s/wnMf/BBPvevdrJ09B2jK6Yy1pV7aWx3eVcz2d9nd22Z3+x7T8QH3tu5SzmbUqdHoDfosL6+yur7O8uoK585dQOcZed5H24wYFbVzOBdwASrvUs4r7XOi2zXEt8jRJNbzvTblfyocJjEBVlcG8lLVjNH+Drdv3uKrX/0yn/r0J3jxyy9w78YrHOzeYzpy9Htw/sxZnn7iPVx56GHOnT3NuXPnWF0asra2Rr/fT07noaUfV2VgNpuxs7fP66+/zue+8Dyf+/wX+K2P/gq/9ku/wtraEhcvXeahK3Lvraytc+rMGc6cOcfy8jLTcsLdu3e5du0aN25cY/vePfZ3tjnY32c6HRO9k+FNVRLx4tKrpbElRKoq8ImP/jp1Leh60YOiyLhwfpODvS2++IURv/Ebv8jv+c6P8NwH3seZ05sMN9dhMsFt38PmS4LEGoNHGsq8KMjyjFqX4qAcZLgcYsQ0cTby46mdP8RMUp317XDOMJtNKLIeUYU27ikQ8VXFYGnIaDIlhIC14Oqa6XjCUrGCNWkcfETHdNJR/g41l+H+BfVbUhHTIv1nFBU7ydD8JpzT1KAthpSnGWKy17+fEc8cnTJvo2mMxxnixFbTBwuuog0K5RvEKTWUC6hhsoRvKCbHfb5uMXAccirAnFqopps8v+M+U5j/gPb+k9w/1T4kRf+XaLy+bnPPus24b+IZEE1cv18wGY1ZWRrgy5JQV5QHu5xZXSLzFb/6j/8B/+G/8+/x4z/0Yf7Nf/WPoULFZO8OvhJkM7hKNFVoZpOJIJMxoJRNOpmEVGrbTrVRGnJL1EJBM5lFGZk6u3QtTJ5CkI+44yYDk5Rl2UWWQR0dCrSOi9IAN9bnovkIbe5hkw8XmiJTKbIso6xrRqMRMUhw+2w2o64qikLhpmOqGMj7PTFGaHWUClydjIhsoryKAYn3AWWE/qeUwoS5HXuOwhPbPM2yrqh9Td7PIVbgHdVoFzcZMTyzQa4V5XhK23vWNcPlZeq65mC0z62tW6wM18hMLtoi7+jnfXwy3NEpP21Q9Dhz6jRrq6vzCAfEqdcUOSrLMEUPneWUPkBmWF1bgrrkzddex+qM4XAVY3LqygmiZiqyQc7e7Zu88uarnLpwkc1zFylNTq0MTkGIfl4Fus69jcQ56M5goDFuas5V0IqoZb03Wp5GqyoNtawZHSO5zSBMIQRG+7sUwwyjIoN+Rt8OmEbHlCjOvCGgNFhlqKdTqskE6gpjYVD0We8XrNmcdb9CL2rq6YRyMsYiE3mjsoQmCRVcG91qgGIUh2DJHgwpQkc0RRHVrgki5DaXqIogOjOrFDE4YqjRRHIVyXXExEi/l+MmU5Sv6Rm48cZrvPrSV3jh+c/zqd/6Ta69+SZGw9mzGzz68BXOv+dDPP3UFU5trnLu3AU2T51ibW2NPM85mIwFyZxNWF5eZmV1mcIa6uDEhskkWoTW6IQoTSelUFKNAgOxrOcunOkSGmXE5ISKCAxyK41HXaMBm2mhbUcx4SmKPsGnYtwW5FmPvKhxdaLfJR1ivz8U/WxdU9cldS33b25iZxgYiS7db2puBBZSBmRZVu3+nvd7KKXoLw0XhhbtMyhFoUQVZa/ydWtI1e7dPpDnOS548kJx6fJZLl29yAc/+K1MJhMmsxmvv3ad27e3eOWVV3jj9Wvcvn2HrXs7fOWTH+NTBwJKOSfb16AHy8uW/qBoG+PRWBxnQwBjhAW5ubHM45cvcOb9T/L0k49z7twZrjx8mTNnzkgETPPczBTKJPpn7DyAdGJA9HKIijPnNzhzZoOnnn6MH/y938fBeMxXv/pVvvKVF/mlX/513nztq/y5X/ktlIEPfOBZfvhHfoxv+9C3c+7seXZnM27evMkbb77OtTde55VXv8aLX/sKN27coJx46gqsRB8LU0MLC3SwNKA/HPDUU89w/vJlHn/iKR5+5FEuXr7KmTNnyXsD+cCDHnvjCWVdk+U90JbKebwPmCzDu07cT3Mhm0zQFNURapETZEZTWLBR2B9kCib73HzzVZ5//vN89tOf5Ld+6+O8+NJXAaFjXj57im//1nfx7DPP8PDDD3Pu9BnW1lboFQVirpacZ1UzYewwaLQi+ogymiva8P5veZbf94Pfw+1bW7z44su8/vqbvPTiK9y4cZOP/fzPsL0tiHven88y9kfgUqxHrw+rq4bTG+tsrK/T3zzLufNnGfYHrK6usrKyRL/fJ8sNWlmUlvtlNBox2ttnMpkItR9PL5eBz2OPPcaZM6e4dPE8yyurEDxuNGsjVHQQ1gFBpUgZcZiOrkalYWbsDFN96GT+mkzuwU6UUEzNvk6GP9PxiCw3Es+jNb1c6LF1KTnMGIUuDIOlPv0CRnv7DLI+1B6bZUoM9BL9Njau2ifmPm8bVHkLFt6DvvcEuTw5/v/80F/XDZMa0yZe8B3dZA8aPHTNVN5O9uY36gzU0LyE9anbBxqRI43w4eZcpRwtpSK7O5JPGKqKTEfubW/x8IUzUM745Ed/lf/pv/mzfPeH38v/9vf/MD0jE/zRpJQg9k7znuCiluraTpSVSbETMp2MUf7b6Fy+zhgJI0/NZUo7mxsOHbaWb5ror/MUqk4jrsKhgUV3dSXEzmQWjCY4R1VVLa2vMBKxonwO3ifNTjIs0RGjMrRRC87C6tDPb2YFKs5ROgPUWhpMafKSvSKR4Guqckp0ZdLPOEHeiAQl50zpiHeO8XjcIppSVIsToUKatpiMbrJMqJNFL2uNbhoEhxRcb3PRokWjhY5ttGhQUyOS57kEwkcxJFFaHCirumZSztjZ3+PqE+8lWIu1BbVLtGZ9fJSAZKSqNDyJh+76pLlVHQSzXQvqPjuFIoZIcHXr/phn4p5bK1mZVmm8iShriUoTsoz+zJIDM1dCLa+eZQW93DDIM5aGBTbCbHKAVjDo54ynitpXrKys4sVIE688OkqGX4gpa1PLgEQpI4ZXCDLZDJHKsmTQL8i0IlQzXF1idKAwBouDekphDNFVVPsH1JM93nj5Rb70hc/y4gvP87lP/xbLS30unDvFB3/0u3ni8ce4evVhLl68yNr6EsPCkOVioCV6UQtWsbwyoNfPKKtKTKCswjemIVrchpVS2BiJCZXsDnfagHsfFmUEKfBefgWCW6T8h2AEZUyxG/P70qf9Kt1bURrxZg+NHTMrYzJ0Qv2b14hezI98uqcjYv5SN3m0Tc5n+nxdt+UmH7e7fwYZDyQX10PPFtVofj2zetZ+j/MV1kg8U15osrzPB557N6EOuOojlGXJwcGUW7ducf2N62xtbbF16y77+/ts373D3t4e3lVJ92zR1qCtZTAYcPr0aS5cuMD5C2c5d+4c58+fZ2NjHR2lYZduJICXnNO6dsTaSag9Yf4cwaC1RImo6HB1wMYChcGHgNKe5fUB3/qB9/Ls04/zz/3Ej/PZz36e3/z4b/HCCy/w4otf4//xH/5nDIdw/uI5rM25c+cW+7sVeQ6nT/XZPLXBB971OL28oG8Lskyo9koL8rU/2mP3YJ/xZMKXPvtxfuujv4Y2cPbiQ1y5+hiPPfkU73v/B3jy2feweuocK70Bda45GI2pAtheH6sNk/GYrMiFAh3ToIpuJEukmk1Eh6w0lkAvRaQc3N3i7p0bfOJjH+Mzn/kEn/zEx7i3vcPm5hIf+eD7efd7380jVx/mvc88w/LSQFBJhEEizrHirBtiYpQ0kRutcY0MlWxWEPx8XRVZzpUrl3no8kXR8e6PqSrHqy+9zJ07dynLks999gt89rOfBaO5dH7I+sYGFy5c4Nz5M5w5c4azZ2UNbGyssbS0JOulKGQNqA4NWAXh0Nc1sXat8ZL3vnV5ds6JDMKKEZevHRFFlucYa/GVk6FZMs0yKhnSRTCRFG606FXRvYeU0kRt5sPydu8WmYnVtC7m4gyftfIGpRSh54T1EjV1Da7y+MqjCz13jm8c2lXTYIaWJs9bBw2cHF8/cnlynBz/dCLL3UnzcY3Vg1D5tzulCd4vxhYcCkQ/DtV80OtG9c56pfbzpQzH1uBHmQW3zRaVTQVZCtXAB5muxxhZGg7Y375HoSIPXTxPdbDLK196np/6S/8DmYr84X/uD/LYlUeoJgdEVyZjBrPg9BZVB+VNRRyNblJJ5qW4wGqiRkwcjFBQtRU6Z6OXUakB6MaHNKhgU9jFI7zJQ+f7PtmeqjHX6WgvuyY/8ZDZj7US3l06R1mWrW7Puxylk74jBEHOkl6yccEjxpY+rVQyzlC2834Tgh8Tstx5r947nKtRViimNJqo8bht/g6j+Y3zYl3X3Lt3b8GFT4rHRTaAtZqikAiFXq+X3F1roY8GyXZrMi6LRjOEJtcGnRfcuXaN69ev0+/3ybOMRgtkjaXo95hWJbt7e+wejHjoytU2IzNUdWcA8fYGQ0fupZAopA2xO3YR/jlrQMV5PEJDv9S6T571yLKCYCBXMVn3S1C8i1CPx/hpSSxrqBwxSPOuewEbPN6VZLlGac/e/j28L8myJWwZUuSCT7EBIelQSZmYvp3Wq+TsGBOq0ZVR5zqifIWvA9GXmOixCAXXuxnajdBZwf7ePb7w2U/x/Gc+w5e/+Hl2797m7Ol1fuD7fw+PXr3MM88+yZWHLgsyWdiE5AWUhZRyj/eOuiqlEDQ2IYL91rgqxNA2NqoZKqX1HZLuWNbaXDMco+8MVRb/R5TrFPGC8DKnNod4aL9uadDNvek7zJBOjmlikzTNYKuDDRzZp9EKFwX2sR2Tle69tKChPvSciE1+YCqE5yMM5tE3neDN4DzTepyGOaJfribjZDZmWBoULC8vc+HCGd77rmdxzjEZjZlOp+zs7LCzs8NktJ/0ofIam2fO0Bv0WVtZYXl5mSzLWn231pHoPKPRhNlsJjrrPKfo5ekeFk21NNUx7dnp3YaY0MT0OXVAxYirKsl3zQv6G6v4gwkf+vBzfOjbn+PVV17j53/+F/nZn/t5XnttixvXb7G60uPSxdM88uGHeeTRqzx06SKbp9YZDocU1jDI+m1Tr7QMtPZGe6JpHB2wP5pw994OW/e2uXX3Hl96/rP88i/9Emsba1x99Al+9A/8JO9/7kNcfdd72Oz1iJWn9AEXIllhMFnn+RRiS5E06Rm4cmYNP5synUyoq4qynPHaKy/zqz//s/z6r/0Sr778EsvDHg9dvsiP/L7v5v0feD9PPvk4p86eouj3ieUMZS1Ej6sqfMrPpYkmsqptLmOKGGkHItAyZhqmSK0qsiwjswX9fp/+0jKhrLn4yBUI8Onf/E2+8rWv8cTTT3DlyhUee+Jxzl04z5UrVzh9+jQmy+R+lgUge7FK8gtXzRHCJLOIsxQVYwwmzzFYMu+TARMURU8clmdlop679IxRuLqWfUAvDtS999LId58zxzynmkd3Iw1YrL3mQ9/5viJgdffnSDSO1AzeCwPEe0/WNtCcdI8nzeXJcXJ8cxrLt4MYdrVNxxXo77SJPc7p7J28p6//EKtuHtDAHnarbN+jVgx6S+zt7bA8GDI52Gd12MPPRox37uLG+/y1n/qL3Lt5nT/5J/4Yzz75JNPxPvV0hAEGg0GaXKoOZViQR6EvKkF/tARPay16y2gEqVHaoDIr+ZYmhak3qGcCtKQ4PT5sPqQcQR3vf03UwpmKSXMZU7D04teoKEVVo71sHmwtxTmKmU9ZlmJ04+aFwWE9bggpqyxpO7XSbbHWDja62W6HkM3G2Me3TrFZCvBWMtEejSBGmSorlUwuaAsYgHJacef2FjEKdXzRiIoUz0EbPTIY9NocsaqqmJYzQdeUQid0oSgKdNLC9ooMtObWrVvcunWLi+cviT19cFijJeje5syqktv3tlHacu7CRWxRUPsgDYXR72i1H+uemorhuaZqHgqjjE7FlUYrjUua2ZDozcpofIx4H6i1og6OSVVRuwkHtePuZMy0nKKrij6KJa3pobDOQVWhvCO3hrzQVLOZxCwglOB+r4/z0gyiEyqZGhGtNNGINjf5VREDeCWpb816W1tbZjYdU09nEGp0CCjvJY5BlbjqgI9/4pf53Gc/w5e/+AXK8T7ry0s8+dx7+I4PfoAnHrvK2dOnOHN2A1s06HoyACEQyyrR8JMZh82EFqxFbzyZTlv9rtEZJt276eaQ+6zTDR/OE1Z68fqGQwZkxsyjaBZlA919y6f7sfu9KdtVGUKIqYF3bXPZyguaX2E+AJtHXiiJPeoMBdtGuvO18r4XDcLknl90u2xMlujcv23jpI7LyDXMZtPWXVpYEhlaWdkrlaI/yBkMCzY2V3H+ArOZmLHgHUHBrKwpihxjIz6UhDQQanIgx/sHTGfSXBqjWFpaYikuSRMaxcG3eY/GGExaoVor8JHMKHyi9msr5jnB17hxKdTZosd4bxuAtdU+F85vsrG+hMLz8NUrvOvZ9/DIo1d4/NFHWFtfIXpHiF4abG1QLrSDCdmPeqxvDLh88YzoKaNiWtVMJzMOxhPubO3w8quv87UXX+LNm7f5T//j/4D3vf85vv/3/hAf+vBHuHDpIXr9IfQyWOpB0ueKwyrzeKjUAB7cvgbBsX33Hl/4/Of4jV/9Fb7y/BeJdcXa6hI/9oPfwzPPPMVz3/oBrlx5CN3LwNe4UOOnI+raY5xrBxytF0Mjs2gBsvmwsmnsDTCdlWhrWgO2kMyuqlLWcpEVZFnGwd27fPKTn+STn/wkZ86e4vf94A9w7vx5rj76WBpOSV5x9HXbBIYwj1taqEE67AHn6sXBeLueU/OZDMlM2lxtw8dNEVANQ6H579Ygzbt2iLjwTO4MZpKdwjElTYQou2Az3OwOdOgMfOW9m1ZmMlyStY0xia2gWpDyyBs56TlPmsuT4+T4Zjab9/vz1/O9x02zWxTvHTSUb/WV97XqCTEVit3CmjaUuKEXRuKi+VDSrjknQdgheIIv8VNY6+dMdnb5qb/w5/nyZ36Lf/F/94d49tFHGO/v0NMKj6Lf72FStmL34RSTw2to3FJ1eoYYTTQabW1CRcROXSJHBLkUHWbKwCQmOqRZGAKosIgUk3KYk+py8QGGxI9IpeqPPcvdxjEcako1iF5SqTakvnl41jNBLwe9PmjVFqRNvJiO4BvEMkJUXmqaVJiH4Fob/MYVVX5uM1nWCbmU1+1lKaycwHQ6YTwes7q8RGa0OCc2RXvKlQTDdDpla2uLLOVg6qRdlaD00ARz088LBv2CQesWWTKbzSjLFK2RCYplswyTZ6kYVfSHAwiBW7duMZ1OGfRyQIr8PMtTQxUZzUpu3bvH5tlzLK9vYGzOwWxGVPmxLIF3MtxpXD9VbM6fPjJAImmeVDKCKOuKOnhBjlzATWccuJJZcFQxMpnVVC4wqT3aWoqgMFkPawpWiKwo6MeIqcXIyVUz6tmE8cEOoZoRvJiZgMY5oXJpmnzHlPcXPQ1u1zY3aa0aaPP8ZntbaCI9HCFWWCWumvVsymy8wyc++nP87D/6aW68eY0zG+s8995n+LZv/QBXLp0XndRSn36/wGQQ6lFCu2OrdcqVoa5rSucSQ8CkiB+b6LB5WyTGdB/52rWGG5JJN0cNu/dTPObaLVDBm4xBpYjRLSB+MajW4bkZtswbvjk6H5kPZ6SgDq2J00JhquexE43mEi1RRyjVvl63AY4xtt+v4+JgqNnntYqpHZM3GeLiGq6Ts7TStt2dm8FSCIGlQS/l6yYtvI+EUFJXiU6ruwYnARccUTmilh2+P8hQKlK5krKezZvedH1sZjHBkJEl+mKgdiXOy1DBmrx1Ng424H1MjY7ozXv9PqF2uNoRqgrvfYoucaACOzs7HOzucf36dV574xr7+yOeefZxrl59hEuXLvHoo4/T6+Vk1lBVM4i1UB21xrsSnG/lACT2aEh7oCWirKbIC9aW+pxXp3jqicd57lvfx2uvv8nLr77J5z7/JV748lf5c//5/52ff+Zd/MAP/hDv+9bnWN/YRNusbdpijATnKcuS6WTEZDLBVVOqasLrr73Cl774PK+8/BLT8YSHzp/iW97zbp5+6nEefvgym+urZCtLMpSpxlI49zLIexg/b1TxvqW/xsalGmmkMVqYLt4TvG/psVkuhlTeNW7iWtBNLXtziIG723f55Cc/xZe//GUevvoQ3/ZtH+LSpUvk/T5EqMops1mFc9UCy0Zp0RIfZWPN/9skz4IYhMWkGrOhdFGypjlMbtsh6cG1kTVTVrWsnc79X1UVk3JGUQj6esRdv8MGiGmQe9gVvxlYCcNES72AwrmA9xJTo63BFjn19IDxeEzwsLKyIuitMRIBrI7WWCc95UlzeXKcHN+UxvJBqORbopFvkZ+ljzEZ6v7cLjXk2CgR4jf5s6ujdNhjENvm32azCYN+jnYlvTzDuin1ZMJP/82/xj/4X/82P/H7vp/v+8iHKA8OUHXFuCpZXVnBGE01Kxfz+HRCMFOBGpKWLBpD0EboQzbD2ExosFrcYRtajTJS4IVO83tc07HgsHnM51swT0qNaVTzwjYm0w0dDgVmq8WMQ1RCVLUmdh7aIQSmUwlWX05RBz5PMSYhthrB6OM8RiVKDiYh4FVD54stBZjYdsWJGh2TREqa6cxayQh1TsxAJhPOnj7VPoBdcltUzXQ5RiajMXu7u+37bpHYVPkrrYW6miixeZ4TgmM6nTKbzfDBJ8QqoRrplxiXKPr9PtVkwtbWFv1eTwLtkWD1QIaLgTrC7mjEvd0Rlx9/lsFwGWUyqplH93RqwI8367rf0GUeH8CCXvbI1yUUPUYp6rWRhqMtjrWWBnoC+7MxJYGYUIVhr0+/ryDLmflaQsFVpO8rVmKgiJCFgCHiZiWhctTjMSY6hr0MV3q0iUStiapBxzWQCyUt2hTH4NqCJ3T2KqMlz3B6MGHQzzAmEmqPJjIZH/DSF7/IFz79m/z6r/wMbjLig+95iu/49g/y2NUrXDh/ls2NVfpFJs63sSJWgljkmREHlaBSbmNF1FIoRmgL8mYI0rioojWxQ4trEJoQXaLaiRPu/PcuTTkRl5UMAZRMbVBR1u6iFr4ZEphOIdhQbcNR9gXhCOrY3R+apljrxf2jaS6jVg+Mu+miLAuay8b0SYnGcp6DfHQPksii+ftsWR464uuKiJemKkiTaYwhLyzW5u17a4eWShAdnT6Hq8MCajRHbn0ahE0pigxr5XrlVvTVsidY6mo+mJS9a45GKaUEjU/DJFeVTMYTDiYjnPNordB4prMRRc/y3Afex8rKKkV/yObmaTYvnGe6v0+Mjtlsig81uTHYTKe4mRId0qAAQ4guUR3r9j1VU5/03gXKWEIdyZTisasP8egjV3jikau8/v738vkvPs8LX/4y/+N/+18xWBpy5eojXLj8UPv5Yoz4WuJVRvsHjMcHVOWMW7evoVTElRXEwPkzZ7lw+lHOnlom15HtOzc52L1DlonuWPT38+dU1huibUbRDmDSdfDyu/OS02jTANJ73+4EIQSsnjsUz9eabhuqnb1dvvylrzKZjPne7/0ennrqaQZLSwTnqGcTDkYTjFVYk2OzXNyRkSifw6i5SgOr7nrqRnY19UzTXDYuzDJcjfNc5xjBxVa73Px98zO8lyZesmuLhddfvK9Ca0Qo93po47i6rKHme2svA2LnnDAOokZlBbPpPXZ39gkBllZXwGaCVlv9tof3J8dJc3lynBxvq6l8ECq5+PXqgV9/jAnQIvU13j/o/H7Hwmu+FWKpHvyFKukrYpp8R5XQsrBoxS70O9UaoDTQYq/ImOzvsb7UJ5YVQ2v4xz/zM/yZ/+z/xR//yR/hx3/oB1D1lAxH3i+4ubvN8tJQHjwxUhjRazYNR1AqIZEi1DdZQTQGZTN0lqOtFXqVEbdYKWp125xGQquTaJrk4xgskhUZCaE+2lB0NJgRf78si8457Ew1uyhpZ9KqU+Zho0l0qcnrFpDdNaMh6fNCyvEyydQgJMNAJbRQq5NjpUoTfPFoj6mI9L4WC/mGjlTXTMdj6nJGv8jRJul+CemcpAdxWbK9vc1kMqFXDDBKdGj4hGwEcYHNbUa/lzPo9clthqsrZpOpaLGMbvWWxmRC1dM2yZYUFH3uXb/B1tYWKysrcm6sQmOFEmsMdYTt/QP2ZyXvuXyFYnmVoDRRRxk8xPDgBvJtRfboY6+v5AKmolzPJ+EuuRlaLR8jpCGE0QZTFKANS70VtLHULpDVmtLNMDh6MWKdwyhHjAHtI5nKWO0toWoPs5L+imJzaSjx4UoK+KqatBrZEJ3oPuuKkNAmyc90LfpmktFWrD27UWIc3GzKdDLi5vU3+NxnPs2Xn/8smys53/Kh7+DD3/HtvPe972ZjbQVttOThuUqq2HqGr2tp5JU0/01RNx5NJaPR5u1dJtpe267pEAIqBLxzeN/EoQgboXRVavqk0dNpiiM9YEhTnYCKWvSJqnGRTohiaGjC82GRSuhkF2FRsRvF27ibmo6Jz1wz2UQjCFvQ0PF9Om6RtBmzR58NTQEcWwfx+foMc91YYii0VPcOiqNtnpDPVoAhETKJdSG9rcYUiRaJbnMAq2pG7V1qaDKMFUaCVrRMin7Rb9e1916ui9btGusN+mnQ5RaovsYYrNbodG2iYqH5VUoGX5PJiKIoJO+1sCg1pNfPBFnWkbqcce7M6WT6klH0emL3WtWMtu+0zb4KAaKj9jXeNe9BYayW/S6IRRI6Yo3BpGdDD0U5q/G+Js8zekVGVBrvRJv8zJNXeezKZd797id55dVXeeml13j9jTfY2r7L8596k8lkBmkfkxgO3VI/bQhcvXiWXi9HRRhPDqhmJV96/nN85YXPEmrH2toqSkfZ+4c9lpaWWF4eima0P0DZHkW/12agttddSbzN5cuXiTEy6BWLg0yt0QbqmSDUVilM2uNDkHNvjUVruHjpPO87/R42NzeZTEuqakbe67GztUOv108NY8R7h/cBrZVcrzxnOp0e0hrrhRrG1w7boPMdlkej/Pc+PVeMZD/nRvYFH1yKCZs3girJJ6JWR5gMh/f2rvSjoeO23gqdm7UZzruEnGotzCatbMtKGU3GjKcT8h5sbGySJklzGnRj4nNynDSXJ8fJ8Y02lvejur5TPeVxbqsPaibVcUHwvwPnoKWEHieab96TSrq+4IVOFj2+rFkb9pjt7XL+9Cq/+jP/K3/mP/uP+UM/9n38nm9/jvVBj1BOqadT8v6As6dOMx1PKAaDpFkzqUCMaWqvIBV3GIvOc6KRhlJluQSpa5PMI5Q0AKkxbWzCu5l+pKiQrsFO91z7B2hcuwju/a6FOoyEdlCBxnAhhNAignmet41eM9VtC7a2SE4NqtaiX0vVsWrNZqSZCVqhvLiqxtDEoMw1WyrRhhRCXyJCqMWt1tfJxU/rBW0XQWISyrpkb2+fuvIMB1miFS0iMTrF0GRZ1r5WQ3vz3pNZs4BYtrTBJpfSGLZ3hRa3sbZJlhnJfDRaHEhzS1CKvUlJGSNLGxsUwyFeaaFJs0gJftC6vv9g6KigJsyhGGLUQqVWyLoPDl87gpdGL7OamOcUKmA0RKtxtaOeTTHKClWsqtC+xODRoca4mhA83jj29ka4UYn1kf2727zx0ku4cY3J+iidMZ7O2N/fZ3d3l/F4nCjHE0ajEdPJGDeb4uuKshQq8mw2w9dlaxZTlzNcNcME0Mqzv73N3Xt3yIzmwqkVvvc7P8j3fe938dDFS+S9XPrs2QTlKoIr0bkVOmNCoX0I1JVQInWWMxgM6PV6RKVbk6rGtKcZWjVB5/N9LhCCIsTQyWpNTA6T7iAt9zLNn8McxWyMfppruLBndgzBGkMeoeg1dLqwsI4b7WzTVDZU1jzP78swaX73RImIScO2B7FcDsdhxVYDqudDsM6Qqfnd13WL/nbNgtpGLmn1nEvnUjcDnQJlNNYLNdtaiTLyPiY9nNyTjSaujWbSBmsNIeh5BrQOqamPnaJfUftInhUSq8IhF/HEJhkOh605mLgbKwaDQaJCOuzaKjGhbkoZ6qqiGo2oG6OVNAiwSuitQsP0cwQsIfvNAEJreT75CK6WtThcXsJYS0DhnScqj7EZmdZEHxn2DA9fPMvZ02s88ejD3N66x8F4RIjSEHkiKqik6dRYbdIAYp6nqJH901UVu9vb7O7uMpvJvVcHjyEmSYAYgu3v7xP2D1BZjk26yGaf7PV6bKyvMhgMWiTZWntEMhOJcwOmqBeGBGDABlZWVtjc3BStu8noxch0OmY6HbfXoS3mrWkbPe89o5EMBrqo9sLPj7E1spqjjyGxj+Q1syxrnwliPJUclY18jfNhoS5qhjxwVH99ZB9PMpAmGkR8IIIMSA/pm5tlrowmU5LFam1GqD3TssYF6C8NWV1bE9ef4EWHqvTxw0h1LLZwcvx2N5dvL0Lh60OS3ulr/W44TvIsf/vO6YI2MN7/AX+/h/79Gou30+BF+cK3vMaH30P39+DDkabyrdb/wr+rd4ZYHhcKfWz0SKPhSpqQSEgbP8nl1NHPDMFVGBTn1pf53Md+jf/xz/9XXL1wlh/5vd/Lw2c3qUYHZAqGeY4KHqXEQTIgaJuPAZWaRK0VXmlUQriUkYZS2QyT5ZAMVNC21TKibdseiJNqxCfHVVTSf3harVqch8gJjS89GOdUSYmvCI1LBmphWhxDY8LjIURya6H28wmq1sRDuqom/7Ix4VgZLnEbODg4oCxLer0edVkRlySyoPYOo0xqDJuGWIxxPPP4FBUVwUXRjiRdZEi0qkYqqtMA1qikGw2O3e17EBxGyedQSqJhGnNAAO8Cd+7cWVwTXophpSKFzckzCavvFz0yoyinYyYj0eW1Br+J/upDYLiyjMkzJuMRp8+cg+mU1157DaOzNkMtxkCv36OsKopexsF0ws1791jeOMXlq4+S95coXWRSlvSLgQwm7jtUTrTkhXtmcX8wSstnwh9xG6SJoggBZY0UWnVFXU6xCpb6PazSTKoZRlhWcu0i4Go5p3UgTGZ4N8EaRWYCeXBoFwh1YHJvxPjeProK3H3zBn/rf/5rXL78MIPhCkop7m3vsr1zlzt3bnFwcCDoQqiZzSaUswkWyd/M8zw58WoZuPuQaLOeupphUOSZxhrFYxc3uHzxEleuXuY7PvStLPVyYqhFeu0F9SM4KQDTACRGRV07fIzoFDtSV56isNTeoZRJ7s/iYqrSggqupqorog9tcanaRsWJedQxe21cyJGNC3ty955VyVwlxGbIk2h80RNj4/fUuEkGDCrRimWI0gxEGtfILMtaal7XzMQdkis0R13Xraa6+wzoUm0bOmGLziSEtEEo6RhvddFBrTVZ0Xvgc8m5kCj4WhrgdK2CQMxkWZGo8zo1yRDSACv42Lp1a6VQVtgQdfO+jEGlez6k8JQmryekQV2XzthFoRZjYCJBhdRwgq8rXJXOoxOnX9+45iqhaGaF7UTBxNZ0rfkpuTGktNdk6KYW2DiNe7AxBo8i+IRsaY02wopQWkMo8U7MjfLCcur0Kv2lnlAnTcby8nKSRKh2P9MLBnSLzwd8oK5Eb+69F7Q+BGJwCw249x4Xgph0GYNJa6JpsJohpDHJOCekhjpJIgTHb6jOkdjQ41VqRLXCe4e1GmulIS9nNWVdgUpIapG31699T407MmKW5Zucaz0/+40uV4Yiet7od14HFdvhzsL66NQZxmiqWs59UAgVt67bNVNVVesu3sqD0j6iUqPog0TCtEylZn9Iwx5rbUvPbYa7rg644DGZ5GNfv3mDW3duc+niQwyHy2CsIoiLbYxzbfd8dHxyvF3Q5hvpfU6Qy5Pjn3ok8/AErfPfCzmXXy/K+M0cPrwjE6AOPapxGp3Hdsz/nGdJ11HORDciSSC4csLGoCDODnj1K1/h//MX/nvu3brBv/V/+Fe4eGaTnjFMg0fMaANRmWSeAzG574Umx4qI2NnoFC0ixj3YDLIMrJXQZJ20lZgjhVZAteiGXCd9FK3sNB73a/qPDBoiHSfRZLhzaIIaoxRA8RCCIQ83T/TiWpsbS6/XI8syyumM6XQqyE8I1GVFLy+k8FWhdb3TUZxi0U3mVipyQnojoUFkRJPZfA0KgvNoK8UIIVKXFa6qsNowSHlurlMgNgVUOZ2xvbWNUVZiOHwkBEF661CTJyRlaWnQaiWrqkrIWY0tMjIzR1uEOinrKC8KbJEzmczY2dlrKcNGKzIjhYzJxC12PJpwMJ2ysrFJb0X0ME5G0G9rrR8uco8OmppA9LCAPAcEHSuyHLIcizRpVTmlmk3RMVAYTaEUM1dTVxVOg80zsqwgD0bcgGvHcpbRVwX4ClM7QjVj5942N27fZXRtGzcpWe4N2N/e5Vd/9pepHSwvZ6yvr7O6ukyvn7O6MuShc5fYWFthdXWZ5ZUhvV7B6nCZ3IoTb57nGDUvsAmR6WTEwe4ek/EBSkFuNUVmWV5aYmVlCasivnaMR/tMJzI4EOQr6WNTM+4at1SlZE1ohdYhIdo6FddzhDqGQPSeuskE7RSVSkszY8hat8nDe+0R+cChQv6d7YmhjR9RiX3RvEZDI45RHctSma8fdfw+oRaZDodNfebI0NHBp7hKI86WXXZFakwbo5PD52V+PgwKnWj8TbPR9H+CNNfByxAqdoeL8+xf52MD6s6R4TD/vLpBVmlQRJ1QYyOt3X33zrDwrGwbIbouvAqdNragaJFBMZPRiw36Ak2ycR+OBBcIKhlxqU7QvUkDjMZwJjYRUgoVAzGkez44PJ42BpiAUZ5oI0ZHInWr4wtBIolcnDdk3fXfDF91ZuknR+w8y5PMxAnGlrSWIUi7rrUVWn3nureRNkoxGR/c99n+du6DxqiqadS7Q+zala3x1XHSjOYzLfgiJCS1RbDD4bWpjrzHBfZWJx6k+6XNz2neZ6st1XNEtsn/bAe3MaCVPXQuFu/TRrvZXquY9jgrumEXwbnAaDThoUcvs7K2Ct5FjD1BhH43Ipcnx8nxTytSetjQ5htt8L5ZR1DHApXHIpZvp5hTsSkEZYqvYo01EYPoQdARY6AXK3Z3tvgrf/F/4Bf+/i/yp/7kv8C7nniMlf6Q/Xu3yVGpWdItlSdooXKKG6g8RKOSSaE2Ytyj8yKZ98jv2hj5XTUmGqZFlhr6buw67ZFMQxJCmVSMCZWJ8ziR0DzwfPusaxvFmBq3pohMcRVNA96YKjQoyGF0XHXjBxL9J89zlpeXGfYHYgwxGrG+tgY+MJtO6fd6iVIbkjOkvL5Cpwd5awA5z/NUyXo9GdRIranRRqGiT4V8BF8zGY2ZjMaoCHkKHndllYoq0RNJxMGM27dvt+hNCAEbhUbno9i297KcYa9PkbLgqqqiqkpC8GhdtDQvrTWDpSHaGMazGcOlFawtuHbvGltbWwwGA5YHQ6H/mTTV1qKz3ZtMuHdwwNVHn2F5bZNoLHUVUdq2zprvZNhy/J/9UU1uakJcVZPlGvDEuiLWFfV0QqZguejBbEqvZ1B5RkWQCBnvMS4QSk8vKiajMbu724xHu6hqBJMRbnubemePsD1D1XJ+14Z9nnzkClcfeYSrV69y+vRpNk+tMxj0WF4eUvRylPIoHcky0buqGFt9mejBYgM9i3OsUYz29tnf26GqSrmvtSCIgvLLPTRL2i2VtF42zxYKSx/m7qdNPq3WELURF1WlyKzB2hxlzDzaIxW0bbOBT+wAnSIQwvF7bVhsAueNf4rBaRMiO07XHddQkiZThbmOUTE38YFISMMWaSn0kZzhhfu5u7d2KfB6MQJFHTLQmaP+/kiMSkwRNjGh5jIgk8gbtGk4wvL+YtMEdIdcAdNQVxvVWUO2SAZEwfl2H2+eA6qlEs+HYTRsj85ADRpSgPzcEBUqCDocpRtskbPmswfVOWMLz8r0GmHRGVgp02rStVaEJlMxNRNtg58Mbkh7qk+Zmq7NX25MkxDdbvO+kfckaG5CR71oOJWO6BAIzE2ctFbozJDFdE+p2Bm6Hs4ybiQXjUkNbWOoUUQFs3ImA9QosLFGJUSsQdkCMaGSTWMZgjqWgbXwZ3Xoua7mHgML94yKOF+3X9g2rkFMe7prrFlHXSOfOUJr2qXf7BNA6/w8dyufr5s2IrIzxG5zZkMQ7bMWqv1hJ+WGZltVcn8a5pTZ1nwrhFYTrVuvCLlYDfpeJ1q51nMzPVHeWIwxjCZTdvf3uXN3i+/83h9kdWVdGByZSeescc8PJ5jlSXN5cpwc3zzE7zin0cNRFt8M1PJYTcHX9f7V1/V9x6J2BIqiYDo6QCtPv8gJvqYqJ+TKsFQYyt0tfv3n/gF/8//9t/lDf+C7+P0/9IP08Ny5cZ1MR3Sez802EBMereeZlCihkSqtiQmt1HmBKXqoTFBLbTKwosFsC7vGOCc2ei4vE/D2wZfcVDvuPCYVra1Wz3cKnQc49pjUIKtUMBglRYtqzFzuo8WMh8w5lFJk1koztbzMndu3Ge8ftC6L9azEzyqJV4kRZY3wVFPQO1pMe1rzjCiBI0L5UovoamqGdfN0T5+3nE4ZH4zaWIuGCpVrk4pc+byzWcVo/4DMFPJgVxaT8v9UmBsUdWMcGl1VtzhptJh5nuN9ZDopWV63RCI3b9xmdDDh0rnTLC0tYU0qeKNHZTlBwc7BiHHpOHfxIfrLawSdSUPRQXXe6f22QOGbB9UuTuiTMURVVRinyU3EpiZhenCABZZyQ08pbFRo74jBU/sIylFOHW5ccvfWXba3txlNDiDWxPKAam8bO5uxmhW89z3PcPXCQzz22GNcvnyZ06c3WVlZIcsyQvDkmUmTdoWyOt03nczGqm7fP032W3BpKBGopiWZjSwt9ZlNoUoRFQ2OXxRZixLFGKWnSRS0sq7mrqhBtaiRRGjMw8+bjFVjMnF0Vqp1hrXWJnOdtL6ae+4B+bKH99n77Vtvx4itjSlQkhVLynNttGkNqiMF59zUp0vBTVyI49Ei1c2sPGrg1tJm49H35wN475L5UnPPmCPaM/n5+uhgBIl14hC6GztO2e3+3qCGyKBEcjAhuCjXJTnJtshpXLwOraRgzhOcDzVVik5i7or7oGdoF4GU05aaiRhQPlIHj9ATOp+hoUPGOWUYrVo9ZEjDC0NMtN/Y0rm7py2mOKWgQCf0TJEMXtBgIjba9tqH4FtUfo6kqk5zKYyOBm07jPZ1aafNfTB/PgWcW2wku9+7sP7uYxB49Dzf32CwiwS3w48jSKNe2L/nOZThgfXJYYNCOgZVss+GhcFCupDoxGap63oBpWyay93kVt7L8pYq3Pws24kGUh3Ncvfebpt9m6Otwcc5o0CZjP2De2xt3WVnO/LIY49Bkc+nt536rmmYzUmpfNJcnhwnxzfSVL4TzviDTBzU78D7D+oBTeNbuMU22pQusjifPJMc+RQmSvh1qKZkKpJr8OWUz/7mR/lv/8x/wfufPsO/8i/+CxQKqmlJDIF+byiugZ1CJHY2bm20FEdaeLbaGrS1mEx+qUy0l0EblDY04fZxQQvZNAmSCdY82BbPhZIpaVNshgB+HgcQoz/6oEwDdK2aMk7NsysRV1vdQUsCi06xbWHmA42/YFdTMxwOybKMyWQijnvaELzHV3X7ADY+mSPEQNMmNpEoDX2VZNySeGVtsaBjSHQ5D1ERnE+02GTwolJ0QKILap0tFMRiHlMzyAetmYhWWuYBnTxOm0xBynrGbDLFVTV5b66Tweg2aL3RIWVZxmw2Y+veXbz3rK6u0ytytJbIB6UUNsuYecfu3h42yzl17jym6DELAZ9cC10Mb/mwPza+5xj2gaIbajYv2HtZRgwV2ii0irjZlPHeLrlWDLOMdWupjCLDoKJjXFcc7B5w9/oWO7fvMdofMxtPqEMtYfZLBZeeepZ3P3qVZ69e4crZC5w7dZrN9Q0xt/JeQDdr5QQHQZyDq/EzN0cMQt1mMjYoeUiOiHN0xYMPGKvI+4JSZ8mopvk+cXZtKPBd9MQRvWu1hE0ki0JeN2KIUePqGpTofb0TRkOMoR00ZFm3KG/2FS+M76jmbtQdxsSxTWRY3M8WDbdCizCo9no3LtgxNT/NvSFIiXcVrg4LAySrtOjfOiYnrU6u+cF6sclUpHiFQ83nQgGfdHqHdWl1XUMU9MUmCnnTXDbDs8NFe9dhU3f6PJV0ZyjV1sZBdTf+0MCZCUkVGkSILiFvqmV+dIcwOprjGTIxotsc3rTHx8PjtQ50tYBCx4X0lqYhbgYBvqEQdxHrBllsXqfpT5I+eh6ToedmLolZEjtvSek5Tbfd2bUlKqHmdptj0Qz6lgGjk56+HZR2qL4quTNrrVpKuTRInXXd0naTCzKG2rvWTKr7c1td7jE+Egv7mBb5x/0GNDrIpEFZdTwC2g5h9LwR61CSvW/O71F6eHNbxEMlRlzE+YU1EP0C7bartXZJl6q0ZHkKA6airmvquqbf79PL8oVmt3mfQYVk4Jeyor2b54GG0A5Am/MbUo6zyTLQmtFows3bt+gvwSOPPCa3Sa9QeMCKWdSJT+xJc3lynBzf9GbzQX+eW8w/uMl8O8jlg6aN932vx0RkvFPEM6h5wPeR9xYD1WxCZjQ6BmbTA/IY2VhfYToe8erXvsxf/G/+a8r9Gf/nf+9PcWp1mcnuLgc725w7tUk1m0mOlW5oV83DPFFiG5dXk0wWUtyIMhnKSGOJtmCSyU83J661PG/ytXQyo2nmi/LA0QmtlKYyElMBTgiiR0zFkSceyapsC5uECjbNZEjF/JEHfsfQp/s7SU9ljJGGVWsGgwH9fp/paMx0OqWwGUYpqqpCO520mlFC2s1cV0UTlZLQU7rDg0iLEvuUkxlqh9KKUDv5zLW4nRZFIa6HzKmOIcU6VFXF3t4e3pOorbY1SSC5/TUFeJZlxCi0yvF4jPeOot8jT9/TfK1zgVldta6IO7t77OzskOd561poTMQqMJkhzy27kxn3dnZZO7XJqTNnwRicjxBN4y2aJurhHTWXiwUaCbE53HRK/IMyEJxDY6hnU0a7O9TVjM3VFZaLgh4KP50xHu3x5p2bvHnzFrv3dgnTgPWKTGc88djjPPL4I1y4cJbzZ9Z46PxpLm2ssTYoGGSWhgboSokbiZXoIKuqEv2pMWRtceTa5lBb0174oMS9xujO4CWadngQApiiR9ZPRVkA58Qwo3Hf9FHofNoqLBaTEASttaBDQYrj1mBDK3wViMph0HjtceUcOegWxkpLM4KKiWwQaW7NxZbkPijXMftwx0/tbe6zi06sEtFTpJ87X6umYwI1RyR1u+cuIEtt3vDxiFGLhkaOOMHGGFsjl3mDYRYL9QcwUjwSQTHP6jzcBDYGXCr1QrEdtjUsBfmakJoGz1xxnJpKFToo3fzflZKMQkJYeL/6PojzEV1f7NCP0zbWDB4bcnck4F3H/foYdo+N3eZ7bhou26W4aDeDuNho8rWkoDZ01ibYIhzSyzfDmwW2Q4yJjr/ISDmcTTq/70I7EBIKspdYlbZJnmc1djW+bSROB7k8rhZRUS9E7hy313WppN33bLSWR+ORGJmjtPCu9vitmE9zB+ijq7aLoCqtqZsInPQ5p9Mpo9FItPvetxEteZ63DfuiNpkFGq1PjWW7R+o0hFRzhNMmjToKdnd3ufbmDd7znme4/PBDi7ytEOYo5slx0lyeHCfHb3fT+Y7cXH+XH5KNliifnfet0xTcuZpc7CcxRIosQ8XAS1/9Ej/zv/wNvvalr/Hv/Ot/lCcevQJVxXR8wNJgSFmW0ogpJdbgTXRICh7XSuIodHJsUybD5jnYDJtlQgm1CbHUEj9CJzeypQA2+qHGAj2oVsPUfbqJM6+X6byfh1SrpAHRqXBoC5HGCChNYpvz03V4jCGIy2Jb1TS6nTThTr98cqszed7ayi8tLbG0tMTu1jbT0YSVwTA52dXzB3+Lhgo6KTmeUhyF1EREb0lePW3B1yCmMaYG2hp54HrPbDajms7o58WC42FT9GWmwDnHwcFB6xzbFoa1w6qMXl7Q7/elMXGeEBx1OSO4GpUcN1u0M/250c/0V1cJIXDr1i22trZYXl6m3++n86KwKkrGoDXs7u9zd3ub88+8l5WNTZQ11LUXfW7s0tL1g27Ghf9caCpBrOsb2nBXc5aQYF87VJp2T6Yzdra3iVXF8qBPPZ1y67XXuXXvNi/dusGNnbtM6pqNtU2eevYZHrt8lUcffowLFy5w6swmeWHIbGC5MOTRUU332d3aochTc1+7lh7W7/VYXuszSSHnJktf423b8BljqFw5z2NLCEQXO8qsTShiXBgKyGfSyVVfoxWCHgisIE1TeiljDCohAyok1CCK7s0YwFiszdHaUAePcwE02GyOhisf2iZiEd0jmWyoQ8i/Wij0Okmynb/rGKvEw8ZNer6PdRoJ7z0+Zdtaa9HGpnvdLCA3bXPRRBE0mscjtWZsnTQXmxIWinUVI0luKsM1ZVokS2kNyoimsXU/T7TEQ1CubgYGDfCj05Cli8ZFL40MXnJv0RiVpX0Kgo8taqzFq0vYHCIiTzBbajhVo2cUI6aGPksayojxTOhcNX3k9lMpBqkJEW4MgxpqiFKHYE+t2r036IaZEtJgbx7bpADbMfaSlxFHcoU8d9oGoRn+ATEcpk2L026zzFqqaARrsnmD1QygGpQ8NdmogI8e7yo8yaE4GkLwGGNbWrRI+MV5XRBqsOnfG8i+aaDmTrnzaJAQwnzwIULDI5rL9v6Ki8yeRnus0+cTicecj3O4sZT5a9eUSS0MW+ZDjDjHceNcnzqnw8b2fYTOYMY3xnOd7yvLku2dHXb39tApxmZteaV9nixIkuI8Km2huew0liYNZnEdc62ktwRNOa24fXuLV199lT/6x//3bGxsiHmgfLEMJugi1SfHSXN5cpwc3wTU8q0aS8+hIMTfgfdyHPK4+D3v/P0saDU6xkAqQm4NvppCdPStpmcCe3eu8Ylf+yX+zl/7a/zYR76FH/qB76XX73P9tddZ6vexSosRSrNRa5WeuFpQNC0Zh+gU/GwzTJahswxsgbK5RJBoK1+nGn1mKtI6RhlzlLX7/lWLROlEx/OhoRjOG0tax7pWYPTg69GdSidKbUvTaopFpZKDo0Ipg6Oi9o6qqsVAJzNkQH84YDAcUrmKaTXDeU+erNuFhiUFX9RCoVIRoklmEL55L2L805h0yCmKHXdFL3EURJR3UFeUsxmz6ZSlpSUInuAFffDUxKjo9zRV5SjLqawv5xOFLhA9qEzR6/UYDvsMBoNkBDPXrmUpEkNnkqunjcHYHBcddfAsW01d19y9e4fdnXs8cvlhiiKT8HNrxUBDCV36YDRlbzzlybVTDJeW0aYg+DJFCCis1eL02CKXui082nWh9VG0/xikDDM3ApGiEVG0RUeRKVYKy8jNmO7t4soJsehz99ZNXn31dW7vblPpyJUnHuMDzz3Hs88+y9VLj7C5uk7PCEU44qnrKa6esr8zJZYTwmxMrwd1OUuxA4a+yRM1ucS5iqXB8iLFUisJrU8GSlmRta6dTbPW0EgDUHsxiTFGrPuDTzb8SuIOZrMJ2iSTn9a0Q+NTvIeYBMl9a6JEUpD+TitN3suIRsLRBclM1GZjKIqsXTuEuVlI8x4lWkG3+uTDKBepCJ/bg4RDzWXTcB23bzZrwrQok/ce5ytCQgxVMpFxQbXDm8MRIq1ePCruA8UAujX2kYagaR7CXDfZdeE0BmVEAlDXvsMgiR20LNHDUcfIHpQwQVSYI4mJzUEQx9gmH1Kp0KFbphWvJb5Hpb8UzWFMKFazFx56ljQN5KHfpWDvenAfotGm4HoVD7vdyrXUivQ5EguchZkBmWkyFA+hd42zaIM7tmiWbl2NF5gKHcdv0YaGuYGNDvNm91BuatfhVpaBsAWOQ1FlGCFNkORSmoV1NNdv6jSUEDMjudca3W3SJx/KPO0yAebPbH1o6NLwpNWRe8l16KjtcOdQDbCoyfTJmK3JNw7HUnS7yGqTL030C4OWttmNGh87DsNKYrRCioqZTGds7+5xMB6xsbbJ2toaxaCPQR1iK8w/g46L5787eMMk5DIN1rSyQqNNUUNVXXF76y43bkWeevpZ8qKAzMr04ZheUndQ9pN8y9+R5vK3t6P/7c+I/EYZ1ScTjX8S538+JXsLmkYHwOpOOOc5avpI0XkcxcQT42E3NqM03gXiIafWeJ/3e6z723G02M5rhBgWaCQLG2mKojjiGNdFZtrTEBaQjda0ITgUhqiTDgsxR2geEkW/YH+8zdpSHzc6wITIR3/2Z/j7f/0v8f7HL/Lv/p/+DUJVsTcek1lDWc6IxlK0NJYUMxJUMloQQx+lMoLRBJtjigJT9LF5IaY+Sssmr1MciTIsnGSl5wYPreFGA2RKodBMeH1dQUfr0RjcqGT/Lw9Q1U71YxTHz5YqpLWggKGhsSmx59dSyEv+mRQzXsnEOkZDxKB1RpYrJuMZOi8ovYfaSbyF0QxWlxmsLHPr3m3OnDuNrmcMej10gOAqie6oSrS1KCQLzfkUM0KDArjUwMnUvpnUh+hxrm51gnhPKEvK8YjgamJwRB+wSlP7iLUGHzzTegxKs7N7lyyT7DeDItaRzBg2Nze5cPosvaJABY8JMJvVVGVNQGHzXCjN1mJyaTxUbpmOx1irWVtfYTSZsH1vC+dmrG8sU4WK4WAZpWA8G7O6tEHI+rx6/SZLq5tcefQpTDakrqShdpWnVxSS2aYjQSeackLeRJNq2ulLW5zrtLbV4u7tq5pBv09uDNPJBKU8hTG42ZScwHJmcXt3uP7VF3jx+c/gZwfslPts37nF+ukz/OiP/X6e+/YP8fDVK6xurLO0tCQa08mU4Csm4xHjyR51VRJDhYkOg6KwkZ7NybO5UYVM30O6RyRnToqlrC3WYpQGJLMGfzjKg4TCmNBU921WXu09MbnIyqkJ5DY5KIbUaBvRNYs+TRowTwMyaZTRTSIh0WgxgMos2maE6DCZRplMqI3BJSOs+d4UlUYZJcmJAYL3VHWJr+d5eA3aneUm3V9xfo82+1+6f1WIrZFKM8xyzhETMilFuccH+RWiNJHiSi2oXgg1PgSMVlgljV8MDdMh0QUbWmxYLLJ1Cp73reuqrD2D6CcbY5HKV3ODKyMqbBUtWdFrEZfgfCcyI6R1oOdxUU3Do+bNn1JazmkEoiO0eladQu4b1odun5WNa6roJrWc48YwKM6HLlolJ2Di4dlj+0yq6xl5nrfNu9Zzp+xWu6pEMx5Th6dNQ61XZJloDxfpjmaBftw0KCHOm0alZG0GFuUpNg0h28+pGtbJYtNKWpdap+FanCPGccHMyLc7ReNoO38Gi2OpbC0WhaOuPblTkFm8cxgjcoI66VOVVuhkGBSboYJSGKU7OktwXlg1s9msdTjNsoysyMXsy3frCM+ctapbbWpsf+Z8gOO7cSPpvFirsMlErq5mi861KeeyLSoODVmNzubRIc2b6iDZcr8k1pIyRC1GbI0kJkRFHWFv/4Dt7W3K2rO6vsmZM+fZPLXObDKV5jMK3dUAeWIAtRTrlD1tgGBkMOa9Q0VNlhXt4A6tCC6QZz2yvMcbb77Kiy+9wrPvvsCjTz6FlyGAQlvZ4bTUp7o7hGS+/zWjq5PjG+/bjgNTTpDLk+OfbbTzd3CC9VZ5jIv/9s7fWNfKXiGIw8HuDsv9gix6er2M5z/xG/zmL/8c43v3+L/86T/FUq9gsr/PbDrGKE2vX0gh4IQKmmV5atqakZ8mKiNuhUaLxjLLUTaTfEttBNlEJ72DXpwUHte5q4a+krI6VEjPhiANrY5or1pnwKiacJKkW2wCwRt9j0qFNCoVfClwvSlYQvcBmx40HWOS0FBjg+TL5XlOSIHyLgZyJZTB/mCAySzTqmRSzigKoaTqALm1bcHdhNdFPzcoiVHyPnXzo0OcgytBqHGoIA2g1Sn30Dd8J0GUQDQ7DZVSJR1cssYPEaG9as+gN2BzbZMLZ07T7/cJdZWMkaR4Js6zw5QRIx+dWZZWlpnOJFR84/QpVITR/i7X33ydjbU1hsM+vV6RKIcRYy1BZ+zs7nNne5el1U2W19bJix4TpaTpSvo/jdCydGyJ3fdd9425UWwanYRQam2oo2c2mxK0wbsZmTUUylAYoJ5Rjyo+/5mP8wv/6Gd49cUvUVjNk48/wnve8x6+5UPfwZkLFzhz5gymyYN1julsxnh8QFVPcGVJXc1QOLKE5hZGUxhNnmtyrbDGtpN4HcHH+8cdzWmE8VhddlfzxALVXXRohsRST4OTLgtCL371PIIgHtrrGuQgNcVN8RdSoeej5EfmZpHONteJCdLeIHUh0QBDEDOg2pWYam6M0sT6GKNaXaQxKoE1c8fio5qx0F6TECT6ILNWjMOMETMXJKNV3JPtgkuraIpjopLGRaqrUvhIxy22QZ4UeGkO67pumyNxqEz6txTBEdKAzDQNS+1a7bNJMQuqg9S1MUkLVFxDVEGyf016D+myzx1wWUDiugWgTvdDG1SfmqXGkfX44lEQYdO5vgvZnGkA0phERRo3Ws/cgEdjtU4GUc3/ZB8PyQW8oXoarVtTn6YJBHDtkDBROP2iBrJpBtUhdG6ulfWdz8MCKtnVU84HO4tGf92oDqVqvBcTmjzvoZRpr6WMwY0MOjqZp9baBZS3ob+61sk80YDT3jo3/omJTi7Nm+g6O+ZZIR5B+2Jab3NGz3y/PKwFXtQ8Hx2SH9ZEy7A2ogmLDGctmdQhGWmF0DhxG6KOzMqSvf0RB6MJURlsnlE5z+7BvmT3ZnLPZEq0+rpDGe5ejwaxzIxO/zZvpEMIVLUH5dDKJifuwMHBAS++/Arv/8C3cOrMWbL+QDjjRm4fFwNZs//dp/z4+rhiJ8fbRC5PjpPjd7ih+yesaTz80Hkn7/mdft9xn/fw5t4MlptIgAVBvToeVp17+XXMK5oviClDDcjyjODGmF7Oa195kV/82X/MJz72cf7QH/wJPvitHyDMplSluIRm/b4Y0TjfTnRDwkwDSWPZcXpT2mKzAtpCTy9s3iEEhDnULZZFPxISryt2HmYt+piyKwOSjxYFIhFqaIwJUZFCR3nfMa2ILcLVGOkQAyblqLXZnyoSTSqw60N0vmRWFLU0f1FB3ivAWcqpuFTWSYuzsrLC8vIyt27dYn9/n/UV0SMG1wRUx7bga0K3IxHfcYoVV9lUbSolIG+zBposz4YSFiIqTXWdc/M106H+yeRe/j14CZh2KmCH8n6Hw2XqumQyHmNQZMS2gM5M3hr2WGtb6/jRaEqMkX6/j3OOra0tbt68yZNPPsnS0hK9LG+n7HlfzH1u3bnLna17PPatT3Hq7Dny/oDRLEosTQQfgxDrFs2N2yapfeAfylEUYxWflEaR8cGIjbUVgvPU0wnD3JIboJpQZJEb16/zqz//j/m5f/T3CG7KRz70HM994H088/TjPP3002Qr61IoVRUHoxHT2Yzai9thWU2xVlCqzGqUyqS51AqrFdakKbyKNNW/Tmsn1It5gI2BVZORp/RR/d+ilnFeYKvOhP2wcUdMzXrDAYmBRA+Vr/cNc6JBFZtiNOkPMyOa4OBCQo6FBolPjV9qulqX5lZXKbtCU1xr5nEOzrnWZKgpIhsDrQbVzPNUmAeV9rCId4Fg5O8VpO+PeB/TfMZgrMXaeYantRKRo5Rvf/68eTWLUUWN/rBBwhKLoqEQyv6T7td0jzXNs7FZ2vP0gqY7Nnm8zX3uUuZhqyU/asjSYouJYqx0bJutZr9ojc704jMjeH/fZ9GiW6l8730jWNJ5kOsXW8OyljGShnLdnNyuWU1DXYxKifMwzTnWCy7rsaG6K71QxDeuua5KDURCGENc/Lzz5i812x03VJ2eN43m8XBMUfd+AX2EltptxpvT2LgAN67YzjWIfPf11QJja7Gxm1PGQwhYmyd3U9vurc3naU3kHoASLeom54htOyhpIqwa2UjoODPHo8108/0cOs/3i/SKIeXZ0sSymKQxVkTvmUwm7O3tUU6mFEUBxjAej6lmJfWs5MzpTTH0yZoc38X6R3cazW6z3/VHaFhaKoJJtcbO3W2+8pWvsLe3x7d927eJTCTPJY/ayI5ktPkmMBtPjq+3nre/W9/Y1wvPnhwnTeWxP1dxZAJ/v/d2+Ovu5+T2zf48bbHxDhrY0LittdW55OMpAoaAjjV9a7l76zqf+PhH+ZVf/EW+97u+kz/4+38MV1aMtncItRPRvdb4umlcZArpvVBgYqI6RS3W79pagjWtEYWLAR1kmhmDkggN7CGziNRYHnGMm8dJSCMp1ubRO2LtUF4ay+BdQtscyiHU0FAvgDExpvyRTjM2tweZazwEHUyavtg4dSTal05VXVAYI5NbIonOVDObzbBKszxc5uzZs9y8foPt7W0eunhJ4lkal8E4p5iFRCP0yQhJJXOfqJJpUir4VWqOaRrsENCYNtNTN+4/IYgxRRC6kpxCLzTZqHBOpuaNAZHWEjuxv79PNZtSlSWFlamyoJyxbSqbX3meMxqN0Ep0mtZayrLk2htvArC6vEKecjBdXWKMFVRUaW5v3WVWOc5euMjq5iYYS+lLgrZgFN6Jq2nXbbFxhLwfwD2nAjYU6cDp9RV2trfpZ5aVfg6uZGBztu/d5pc++iv86i/9LDdef5lzZzf5kd/3E3zXR76Dxx59mGx1BZxjdO825axmUs6ovRNkMLMYHRn0CmFwG4n80QhqrAkoDVELzbTVf3XMoRo9mU6NJSEs5h4ejjw6FIFxnD7pvmwHpdr7sMkSbExjGmRT0zSknUandVTULQrURbC01njvUpEZDunX5voorbXQaVOh6JwjRLfYUPl5Tp73nrKUJtTqbK7tbvDcDtJU1/UCgqdScd4ieMotNvGdvEKtRR/cde1smofmZ2R5sTBsbBvi1GA0LpfKmvaaPigep2nGBPn0c63m4WawceBNRmeH10ajBfe+XjA8iR1d2oPqo3YNEReQycNrx3SucdNclmVJXVXEGOn184Xz25zX1nH4SOTXoousDnMDru669gm5OzxoDSEeadqaRkl2OBbiNvQx2aZNA9h9zw+qRWSIcLy7+xyZXMx5bN7PYSRQJXqsTec8z4u2uTyceam1bmUzD7qGDxpq32/fOI4Rddht+zgU8zCM1xjshOYf0rku65rpdMzu7i7T6bTd37TJsNrgyoqDgwMyKxnJ/Z4MLm26R5pnkqw/GTU0g6lmv4rJu0BbifoxxpCnhv/atWt88rc+xcXzFzh39gKuDmRRo7JchRjwIaJN/tY110lZ/k2t6btr7AS5PDn+6W8sH1SYxa9/qPFOBh/3ex/dh/IDrfnvk4U1z6lqaJJS/JoYMTjCbEpQga998Yv84j/8hzxy+TL//E/+JD1rmB7sU01n9HKbUISIS0WhtmpeBCRTCpXiE6LVYMURNCjpcIU9FOZe8ocb89TkqTDXWLRNhI6t9iKk5hLnid4Tayd0UFe3yCXeE518vbgLLqJCwXdCx5vCUd2vaenk0jWoZRpOKy1uuD44cWLNMoLP2N/fx6FYWZLmcjAYsLOzx2Q0pVjJCUFoelmXUtjkVoaEoHjTTm1jE3LdZJ5FBdEJDdQHodEldz6jhEq7GO7dhGRroSuHiug8OoLVhsFgQFEUTKdTXFkJqp2KMR/E/CbLLDa385zShAzNpmOK4aCNG9kfHfDKK6+wtrLK8vLyYr6bFfOf0XTGjTt36S+vcurcBfL+EpVXlD4QrSZo8BrRkjnXPuJFw6RbxLwpMmQY4NtiQMdmAu/Zu7vFqbVlcA4/GzHMFW++/CJ/7+/8TX72Z/4uD1+6wA99/3fyEz/+ozzz9OMYozF5Thjvc+PGDWJqAiIaYyU/Tako8TtA7UpCEMfZoBqHxLlxSPLkbP1TNEYmGToSQ0L8Y0hlccuHTE3g8UXgwmQ/GXKEpFOMNEh4M0yZO1I2jU8rb+4UpKYzuBKGcRD9KgprpcmQWysQvBdNY5PDmmiRYjAVE41P/s2laJWu5kzWY0I0zXyo0xSPDTJU1xW5TUONPCMq2ubuSMOW7m2fis+GYiiaTIUxWUtplZiWxknap4KflMFXUjeOzsYQYyZIrZLPXld1ctWdNwDzZoV586Mb5Cu0KEvToMn1cq2JS0iu1Av7fUd7SEePquLiHtU1IOMY5E3Hhsq/2Iy1tE/U3Cfm2KYktJ+paYzLsqScCluh1+sR/Lyp0odcSX1c/EyNc3Bzr4YY8MTE6J8PGqWpphMbk5pym2KfOJw3Onc79R1EKx5iFR1uoObnI5l8KX2omVId6nOkKAqytAc0emm5v/zcUCqEuWGTzVINoRaaXZveh7VZi7xFH4Sx0aGDHqkHFq0mFgezSnXcWxeNi7ro8tt1xhcasjxTm/PkjzE7kmeUbl3U67pmf/+Avb0dRgcHKCJ5kbSRGlZXV3GVaE0nkwllWVKVUmNk2iTmQkae50Jx11p+T4Z4PqG1jY7dKN26ugtlOLC3s8vrr7/OM+/9QMsuoFPTKXXYJTaeFOG/zceRwczvtjd0cvyz0VR2XeP+Sb2nr9ed9etd38dOvDkeMX076GXbWLa0kYBWERMDloANnuGg4Ktf+Cx/72/9L4x27vEv/ol/idXhgJ7VHIzHDHo5JlnNxw565WOgrGuUFhE/1qDzpK/MLMoaopVsy6ATJVZLc0MS/uvDk/rg259DnMvqo2+E/Y6QgpSpvdBfXUB5J42lT8VtEORSzIyS46vRqfCdZ+pFrTARyQ88dP1bzRUuAb4hxR007qXJeKWr7UmUPq01dSkh0UtLS5w5c4ZXX3yJra0t+nmBVZqyLFF5t8jraO0iguSQtD4uNKaYbaaocEdDa0Efk+tr40TrqlryG6M0NHI6fSomdVsAhRDkYW6tFM6xpsgsmbUSTeAjWZFj85xer0dRFG1wdVOExyhFVwiBO7duc/v2bZ544glWV5bItMYoTTCGIu/jga2dXW5u3eXUhYtsnjtPsBlTV+OTG2QU9uF8aNIYhmjVkOvaoU9I4exKgUkosKDzoKNntd/D+oroa1Q95mMf/Q3+p//uz3H35nV+7Ie/mx//kR/iW97/btZPb+CnY6rSUY522N/flybCOymKsiwZ22hcCOIQ7KuO62m6dsHhYxTGdexQAHUHtRSXjxTzoI5hJ8xD5jXHa7G7KMxxGqmFP6s5hT3ScYk9Jve1S690wS80UDFRrkMI+OQefCRb9NB22aBX3a9d/D20Grku4lWWZYtMNjrfLlWxKXabtegTfbtBNowxGJ2BNhizeF4WESa/EJUg7sjSNOV5Lvd1TK6fHW2nVbptXkNylm5KVNVoh1PTuUDra5pW5xfQoiaGov2MiV2htFrQYx5Bkpgbky24bDaxK7EjJ+j8vLb5YHFYc/j6BO8Xvr6uayaTCa6UDNXWrKjTtC64khLvy+iJMVKnQWJMzeGcUpula+0X1ya+bS4bg6xF51W/QLvtNlaLn10vNPtz1HWOuMYYmVVVi2SLDECukXOu/dXVvDbxLcY0uaZ6AYlUnSicheasQdUPUVW76O9xdcrhBvJo/cQxaz4ey9I6jDIfdrSFhqI9P7vGmLR2ZC254BiNxuzt7bG/v4/WiqKQe0kGliKf8FZTVZU8p0KQ/3aOOl3XLNGEi5SBmef5/FwlAyTjxZunPXfOEWzoUOtlb6i8wywNG21RW8dIPubx9d2Jjedvfx93glyeHP/MoJgcMxF+q+b2OFrsO73pjtvUjzfxOOb8xAdP3rrUUkPTWEZMqDGhZvvWFh/7lV/mS5//DH/kD/44D587j3aOEOQBntssZR2GVs/SFAPKJI2RNahMCnCdZ5L3aHOCViiTtVQZGhMJJY1mwmPnKE2DhCQHN4EHxfE1hiC019oRfQ21oJI4afq090KHDVLgKy+0WEECI9HR0m3npy5BkEbPQ9Sb5lNJpEro0Jsaumk3diAkDVeDAmW2oN8bMqqkCOvlGZcuXeLNV1/jzp07rK+ssrG6hqsdtdJYpQnNLpucDWN6COIDZFGacd8UET7RhJPWkpAiR2oIDqsR45K6oi5L1MoKSiWH3KgWdC2SMqCPFqqdQPQQI8vFgP5wSH84oNcvKIqcoBSz2WzeXPYy9g92+epXv4rVhnNnzjIcDsVNVAuqm/cKZiFy+942d/f2+bbnPszGmXNgMkEtjZ2bFqnG1EfPHYSTy2mgW7SG1vQoJsMJHTwqgo2Rpb7BTffZu3eLv/d3/zZ/66/+FS6dXeE/+FP/Oh967n1cvXyBwUqOO7jHwXhM7R374xFl5VhZWUEpTZ5psgyUFsMYYxKSFSK1q+fxE40pU9OIKAgUCR9Sbd6mT+6VAbCHDGSUmjs2ds1C4qGoh8M0ydAxTJnLVFMehTJtwLhCHDd1Yhk0tErC/LUFgZHC2ZiM4J28agytAU1T1BNSxIw+WpxK02Nb3bh8Br9Q7M8RkdBS4ZqiUGvNdFoymZW4IAMMaQZia3oSlWlNN4xu/k8MaxokUyUnUIXERXgXcL5OFNm6vV7SRPj28+h0L8XoWzlA21S3Tci8QRCkTKeGUj6VSXEJLaoYWdCPtYX7oca71RSqmGInD5vOLGplG01nE5ly+JnQRjp0NLWN9lJySucDyYXGJnQNdhR17SjLCjqaw4Y2qpRGG70YX5Eya4PiiI5PzkfiHhjdPl+EDpkJqh30QgPufWq2VGiNkhZfcx6tAeCc7zT5gmx2pRbGGLmurSOxsAHkPEJZTanqWRtB0jSWVSW6ayA1MoK8GWvaAawxhtqFBQfew4ZUh5vjhaGQ3LqHC4YjiCWdOuUwVbaJD2may7dqMA83Az7U7fcopVBermeL2Co5r6T9paoqDkb7zCZjVIRBv0+WGXGDDgGTkMloNFYbyHtJYx6ToQ+dcyIDIxXECKsZIslyscmdHlQn4ocQMdowHAw4tb7B/mgsTtyhFc22/K9uruj8fIZWB3xyfHPq6OPo1ifN5cnxz2Rj+c2c1rydz3M/44UHNZULwdIPPEKaKkaJo4wREx02OrJQ87Hf+hi/8A9+mu/58Ad5/7ue5tT6GrGcsHXrFutLK+CduJrqNHGHFBFhKfp9Sh/AWJTNwEqWZeMMG41Bp+iRuY5w7lB4xJAhOQ2Ky2sqIGJoC1u8SxEbYthD0liqhGbqIM2mamhiqdmU0HFxvAzCPRV6qIq4JClzyZ5c6r6UL2fk6R50QIekvfQpP7MtXip6NhO32Nphsox+v890fEA5nVEYy5nTp+n1euzt7TGZTDi1vtEW8SEEjG/oPI0xT2hpuDYYiWoA0ElHqVILkZwldcewoTFvcFWNr2sxOSDRaYOjG3OnFFKw6/kU3yrdIkokIxVtLUW/R9YryBMtrPSesq4wxlAoTS8vuHbtGq++9DJra2ucOnWKXpZTzWZtDI7OLPVkxt54yqRyrJ89S391VVxcvUIZRUAlRJhkfAQGTdDqqJNf9ClsPaCJaBwmgo4BHSM2lMz2x+zcucZf/59/il/5+Z/lu557lj/8k3+Ab3vfuzh3/hSoQLl3j1lVUZYz9idTekvLrG2sMxqNKDQY5anrhCpoJbme3lHNSiazKdaatvFZiDxSizqlw7q/EELrxnocjU3F44dYx6GW3RzM9nsaKl7KobXp9RuNlzGGuk7U6yb6p6NnbFCprn6vQRabpqKuqmRMsqjxaxuMxrCndV31C8Vq22gmhCrPc0znnEynJVVVte+j0bi1SFpCjoyRorV1f02o53hStsV+2zg7hw8uFdtubiqUqHa9Xq9lIDgnaGhdJq15ZMEBVHeMmjrlfvuaWuftefPeC/Oi8/nbgr+DBDWun9J0hiPrYsHQ7RBaGMKh9ZBMw7ryiu75m7/mXId7WJ/YHTg15y9LQ4AqXf9uod69rqa9XseYw6SoCxnO2AUjHpWGShJRE4/ojruv1zWxmj8bG7rqUVS++9nquhZaZiVRMg0zo/ksVUIuM6tbZHQ2mzGdTinLklOnTiVkzbbrIuI7QwC98Fw/zBY43FQefvbfry44XLw/SFPZbSy7a+8wanncz+rmbzaRPe3PUbTrWSVmRlVVlGWZ9LiFNJaJiWPSvdXv9zE63YuVDHdsJmijQbUMhBgjOr3nrht0M4TKjF1EhTtrOssyer0eo7LEWMtkf5/BqSEoo8RpV6Jyjq3HThrM35HDvp3C+J02Bu/ke05osUcbr3+az8mRadp9tCJtc6L0seY77eYZ5tq9BwneuQ8tqEuwOY6WdJga9lZGHPdb1/d7zftqLzDHNqYydU0PQjzeeQb9gnoyZTDsMTs4AO/pF4YXPv95fvpv/nWunD3Ld3/7Bzm3sc7e1i16maWX5RgVqWpptCR4Xagv2uZEramDh8aMoJdL7qE2OFSaQtsk9BejDdFpzVG+2CkQiMmMwov/rE4NcfQO76oWNQjOC33WS4MXXS1NpRcqnw4R5RzR+2Sa4VrdkHM10YnZitEWY7VEEOiEf6U8hubfiYrKlak+kODzxgRIJ3Mkg5KmMk1dG71YrzeAEJlOpywNhjz66GN88fNfYGdnh3OnzwilrHatIQmNvjL6ZA6iwSfr/phyStFoRcoWjLggTVhVzhi4AfiAKyt6ec5oMpYm3Xl8kCagPyioKsnXzLIsiRjnMQqhzVTTkJqIXq/HYDCQomAwIM9zJuWMWVW2uqKNjQ1GoxFvvPEG2zt3efe738366nL7kK/qGcOlFbK8oNwb8cJXv8alh69w+txFsv4SB7UjUmC0TXmATgySTE50jd4WjJFctuBlip1ZMQrKjUY7h46OTBkMERUchYm89KXn+f/+jb/MJz/+m3zvh9/Pn/xX/zjvffZJ8DOY7jEe71EHj48BawwrSwOq4BiNDqQhqEsxDNZWNJM6S7mMJIocbeGTZQZrjKA3pmNqghRfTXZbSAYpuoHHDiEaC8VoIi4KgqHSUGT+dWVVtzuC5Fi2O4EYdiWKZat3NIebH4tzFaTYhOAcdVm1ZjW9vEgzqphAfg0KbG6IWU6VZdR1zbScozhWaZxrqJJ165LaNCBi0COoRLP+bdovGq1wsw+ur68znU7Z399nNBoxGAywec5sNpMCs5OHZ4zBx8B4MmE0GlFVFbNp3TYMTRPaGFLJcCtr71mtNUWRtc2F957xeJzWZHKytdLAGmXaZqN5TnTpp03WpBgGaWxCtl2ILVLWsEFCEJ1gQ+VzzlHVVdvgHqbvai2rYvG5E1qEUqE6uaP3efa42Gb3CvLZbVTFDbasZ/QHBWVZsrKyAsCtW7dwznH23Hlccr5tr7sVOn3TlDS/Cx00Of76pDVt8kWbQULTHCCZxy1jRMszXht5Xzo095A0rMbmLWNhkX2h07Di+Mar+W/nXNsUVlXFZDKhrutWW9kOHrSga/u7+9y7d49+f8jp06cTu0EtoKExqpa+GxPrQNad7B1dpPTwkOhwI3q/GqJxR230h01jbZjrLokRF6tF86Z0nUPw7SBirollYdgA4oEgjsaNYVUaiHRoyVmeE6Nif3+f7bt3mY7H5HnOsD8Qv4M0NMmyjF6RYY3oJK02ZGmoYDqfMc8NRZHOZzpXTZPrmQ8nZB0Jhd1HRVmWWCPu9M2gqdqfkec9ocgrBdqQJypvUpfP9xvmtPaT45sDBh0emnbX+wlyeXL8M32oB2iivp7YkQdRB45OZ9+eadDhhnY+bfRCq4oRX86olKenFcPi/8fenwfblt33fdhnDXs459zhzf1evx7QjUYDaIAAGhNNUbQoiTZDW7bkWJFsx3bKrthJ7DjlistJ5FTiSuUPlytOUooqKrtSLqecWLEi2aZiTRQhSjBJgQCHxtxAD2g2Gt395nfHc87eew3547fWOvuce9/rBtggIfIe1MPrd4cz7GGt3+/3nWqObr3F5/76X2P/zg1+6mf+GE89fp2tpiEuDNE5alvRdZ0gj3FkiKOTIE4rorGYqkbXTcqzrEDX0uAaA9pI3lvSDQW1mvDHnEmZXE9znIgmMkqQxrlOPo+TgHgVQnJvFQQxuEHsxZPu0rsgPzs4aUScUEWVMujghY7YD/jQiz5GWbRJIdk6gldEHXBRy79TQZDxVBAE0/sg2ZjZwdULShBjxGpNMBaqlmXSVp0/f57z589zcHAgDeaVS6IPU1lzZlJURKYA5UD7UAwfMv8vopP7bxTtKaI3IXoqm+hGIdAvF2iUbNxBjFisMeIQGle0MJ36ajGmAVUraqup64rt7W1m21vUk5YIDH7lvolSzGYzAPb29nj15VfY2trikUceSZS5QV6/sqkAgMPFkrt7+1x832WuXHsUF2JKtYhoCzUWY0H5gI6eZtqmXLjI4Hus9wmFV1gFKjh812GIDN0cYy3Xrl3laO8+v/4rn+ev/aX/lNde+gb/9M/+Yf6Nf/1f5eqVc/Tz+0xay/HhPZzrUVphtMJFNaI5inbXZt21CinrToqrIXgG35cJuzEp3mG0mWajGcNJt8p1Kqw6dcBUYnfggWjGaQVpjlZQyqCsWkd2UizDiWZDyXWS3SyzM+jm+jaOPhjn+OXPUH4vQDQjpCQ+eFgcQmBIiNhyqUqjYoyhrqtS+Gc6YjvSgDZtSwyBruu4d+8et+/e4fDwEGstk8mMpq1p6qY0arnI1UaVNTIXr+P1NCNW0vyumtK6kvgdk7p470OJKBoPI/P/K3X6YDI/MgLsEzqTG4/VsQpJt8dJfet7PLAeNynZoGaxWJTIocPDQ5xzpfnOw4Jx9MjmtZgHJ3EjUiI3+Do7Oj0AsYuFPv3OhjTqAdTQ0/bL05DZ8fWdrwmhhst7PD4+ZrFYUFUVs9mMtm1PONCuRVtEjTa2MHRKfuVG83iaj8KDhtQPGkavhrQb68MDrr3TXKc5ZZ3RI4fnnN+azbpATPzkOuk4ODiQBi85iWtNocFm3aQxag1NLZrSUxoQDXilk9lSvr8yYp+MrhCaMiNWA9nRWQkd2xgxF6QEVKWBlDKY9b56NLw/s/j5PUcuzx5njz+Ik5n3srF8EKIfC0ImSMRpj6K4jLpocXJjJvRPsEQunNti/9ZNzl+5wOLOTT7/i3+LL/7K3+fjH3qWn/j0J6hi5GjvLrU2hDQNPDgYqK0RRFGrgqREZYhGo2yVDHxqtG3QtkFpKxRRbUBbtJG8y4zSqKyRKpudX9sYdaLBBieGPdnyPrqh/I4qFNBE4wtREE8n2qjgekI3SObb0OF1Cg0nCLPVDwSXmu+o15pLcfOMotkyoAZP1DG9b2kuQ/TptSm5ozHRCAlCqDHGoOqaoe/xPnLx4kWuX7/Oy9/6Frdu3eLc9k7Rrrmhw5CoWCHigxcaspLGPqiAiYIsqtSERTwEL2iuivh+IDhPpQ211SnOoSvXVy6U6rYiRimYrAZjN+lkQjtqmkZQy60Z02mLrgwuCD3UxZVmrK4rfBDr99dee42nn36aRy5fkWbVeerpBBXA1EKlvXnrDofHCz587VEuX72GqSu01/jBMzhxvlU+YII4mC72j6VoUAYbPSabergAvWPbGqIONBaa6ZYYUd16g8//3c/x1/7qX+LuGy/zb//P/kf88T/6U+xuN8wmFYTA/t2bKBWpGgtK0XvPspszeIWqGmwlBhJxGAi5+bcm5Thmd0tKo6mjBmPRISTzKoW2phgsrbStrhSbcg70ekEc/EahNzZ8UvhRLuaaUUkyzSpF7JhiqLLDcS7YR0Zh6V7SYzaIluxOq83ae8sDJhkKydcrY7FGyRCKlZGMvONQYlhKvuMojkNraTCEHid0uvl8WMtU3N05LzE3dcvRfI/D4wXNZEbTVCwWC+bHC/b390tTGUKgaRpms21msxmz2ay4Sq509LE0K94Pq4YznYu+dyyXSzETqiuMrqgTEpKRFh03GgC90r6vGsqHUxwzYieREyfpiStdbdi4GtZ2kIIwnYoaMM44Pv33dHLAXjfiEedT5zTnzp0jhMDe3h7OiRa5qir6vi+IsM6GVZvvP++T3hOdE3qk1ml4ZXHj7SrdH+OdLRLLdRNCFGq6GrmmZnpxRnKVUOlVQeVMMduSt+dPbSaNkZzaMaIpjb4rjfTx8THHxwu2t7fZ3d1lOp2uOdyuNX1hNWwJqXmKeaqaP1vkxO9rNmLONl184+kMKR2z++7GdZbdz8ZGdnnfTPtW0WOPh1x5P9YiZwlx3cVYmK6BppkUZsHh4SHee2azGZNJI8yXpqGpbJENrKKI4mpdO2WYn5wB5Nzq1THTxUV+5abcO1cGUjE5ZPtkEiQDqpaqakZZbqwx4zix2j7oXjt7/KDgzGlU7LPm8uzxB/pxGh333dABvl/UcvNGfLev8U5W4joGKhMJiyUXdrcIi2O+++q3+S//8/8nV87t8E/97B/n2uVL3H37TdwwcG57u/x+VdUp/gJCVOgok3mhxCSqkzZSyGqTnGP1CrFEcq0kwkOazPHUsyzhSjSVOmsLSTRZJ39EjJ8b7ZV5QAwSpRFNFOpo8GAVBE0wGh1DMhzwBL8UxC6sdGUGJRTbkHQyMUojoTXKBmy0hBSloLROmxwrJDGVfSqkZtgnvWfSQUbk/fl+oKlrrl27xu2332Zvb487d+7wyJVL6FExUzbW7ACrQ9nhQq7XscmMIzXVzoOR6W0YHCa7szqPHwZi8IkW7MALHcmoyLSpSyFp5PTIIEJL0de2DW1bY60YNkUFLnhJfVHJ1TGhFsvlkpdffpkQAtevX6dt26JhMsakmBrDMAy88tprNO2EJ59+P1XdsOwcLgoVzkRpxBqtMRoqBcaDVtmdVwq9tq6kGAwD/XJOO7VE19GayN7t2/z8f/WX+dwv/AImLPhz//b/hD/+0z/BxatXOLpzg/s3vkdtwWrQlRWaWEJ6Ba1QVPVIC1zZon9VCYUPmW6YtIw5OkdQFT1yBrWpmFx3Ks3XkDGmFP+FfhdX39f5OjslUsCPjaZYURpLc3cKzTYb6qwC0VdaSAgnXD83XS2FOqbWXLQlB1OuK1WMg0Y03+AJ0RNQa5q83HwYU8vr1pJzt1gsWC6XLJdLnHMs5h1Xr14tWi2g6ORu3brF/fv3mc/nLPuO2WzG1atXuXjxogS2s9JijTM0x/oziCW8PiN1+dqt65p2MpPmMyGpaiOPsTz/KMooU+yK6dCouSuOuJE1l1k1MksTI62kY9Trx0w9aA/hneOsTkOoTstBHP8767H39/fZ29vDGMNkMlm50ZY/G0ZE6bi4TGfM2rys+c3OuMQ0MNl8//GB720NGf0+kdzTZCxZw7mZzem9X6PMLhYLQghyXaRc32zqcxrSGIjlPi73ygOkNaed01OHAvHd7fsPy+k+7Zg+6PhldNEUqY0qLvT59+eJhh5jZDqdpmirCqM1s0lbroXx+lLWlgflIMaTyProh0Rpn2j6mS0SYhRdeWpiD4+PaHceoW4aSFm5MZnDSVT0GTb5ewnUnDWXZ4+zx+/pDXlSE7r+A8Ur8yStREXqquL+ndtcmE6YGMX8/n1+/i//f1js3+cf/Zk/xfsefZTh+JCmrpk1TdFxLLoOZTQBjVeC2EU0UenUUNqETFpUjhdRiQZkLCrKz2ltkxurWoWxKyQAjRUlL28Y6xuLH6EqaZPOWZA6NXHWSqRGOgZBS9NolCZaQ1Siz/Ex4Jw0WipETEId62wKkHMCQyR6CN4x9GPkJ+uCzJrBifcS76FiwmqSiUb0Ee+kcHUplmRnZ4frjz7Gi9/8Jm+99Ra7O1tsNZOUeTdgUtNmlOTjMXiCjuV5FVomzWHkrBtFnxq8Y3A9QqOLRD8UnVuIK41KptxNJhOCi2J6pBRVbVC6ojUVs9mUyUSQS4wuxiCl6I0Rreui3bz19lu88tK3uXrlMtevXhPN3eCo2lo0Z3VF1dQc3d/n1e98hwuXL/HE408Sk04m2haT3D2tj4QwYEPA42mNoqoMTVVhVI2KnqE7pts/Yrk4Znl0wDGOo8M97t++wVd/69f5xb/zC+xuzfjn/+yf4uf+2B9iWB6yvOOY1pbjfgBlmE4ndK7DeQAv+W3aSoi31qggMQnT6bSgAQGFjzCEiAsRlMbYCucllqZQv6PorE4tjoNCRSluNHmukqjgY8qfUnjAYE4Yr0hzSLmXlB43lbY410pT5QpCGZND7Th3MV8b+b6SAQmpWUz5jWOSWMxRGckBNd23SslaQaJvS+aq0NbDyABrPVtQEAmtFaYSOux0OqXrutLk7R8es390yLlz59jd3eXo6IjXX3+de/fusbe3x+AFSXviiSe4dOkS29vbRSvnvafvlxvUzyxzzc1uRQiRrlvSdV2JPplOZ0ynUxmaKVXyVHNuJRvo4qomjpl5fFrtvDIlUjKE6JbLtTU7v28XMiXTPmC4OdZYjqMnwnqhHkZRTwriRntq0v2tI+IKblkbfrRNy/HxMXdu36NbDpw7v1NiIcY02GIItGEYoxDde/AxGSYZqsqiGTUbMWnd034mNON46p63QiKTw+4mYht1YnuIr6g+0UDk/TKsDR/y/qlGkTiCetXlWsxxJCX+xnthtCSW0GrosorYydf4ulMrI4RXKM+ak1FC2V14PFWIG4V6Pv9KqxNSndMkM98v4hQKauzTUEtkDtrIXnhvb5+79/eYd0um0ynb29spn1KXoQ0pJmQ8NBv3ymsU5cwGGjEz8p5zqiZdKaqmFsO+7BhrDMu+4/79+3zw8WdlHzuleR7TlM8ev/uPs+by7PEH+rE5vR9PG98L9PJh5lbvZvEL4aSbYNF8aVB+wMTIpKnxyyP+7i/+bX7xb/8tfuYnP8tnnv8YOngODg/YmczKhLZuG5zzDD6irTgAKKWgMmKgUBlMVUNVUU+mRGOT5rJGGTH1UUoQq6hT0ZCs7AOr4izi0YFVllkMKacyoIIvsQlSQKhi+KDwZGeCgEdh0DpK1mYqhjWCNsXgiEbhUYIiOkfsxfAnDI5lPwiaZ0xBioIC7VPcBys6ICqI+Y9a6ayi85LfmTfKuKImxRjF4EVrhqGjrutSAB/u7XH79m2qy49gEmronMNqKWo0yIZsLcEBRqETHVIpK/TEfK4jkqvZ9WiUaD6dp+sWGJXs3Ak4L1/TWrN7bjuFyTuUilhrsNYwrRqms5bJpBEHxFSou5xHl+JXst7OOcerr77K4eEhn/jEJzh37twI9ZLm8dzOFlXV8N3vvcmd+3t8/MMf4+KVRwRdy1tMiJgYqY1hq22YVgaLp6kVi+Uxh/t3OLh3l1tvvc13X/8Ob7/xXQ7u3eXerRu45TFGR46P9rjxvTtcvFTxp/7EH+NnfvLTdAd3uHRpl+Viwd7hgvMXL6Jqw2Ixx1QWqw1dPzBfdMyXS9CWibXUFlpTo40RE5IghZZTkcFJVIePQfJTtUKFrKE0ad6zTjfODdXq/jw5mR9TNzcZEyu3zoSQstJ1jhHLzbzD09cXvebAaZBB1CYyZJKBh9pYDzOds6xBgI+qNF75eYY0kopJJ7tJRRwjiiqu3GAzTVVoqS337t1juVyys7PDnTt3+M53vsMwDOzu7vLEtSfZ3d3l/PnzJWs1O5iOEeHcDG0WqFnL6VOk0DSZVuXGKTeqJWs3HzNj3vW6fmJdNma1nm1oHcc/m+nDD9prcjOzznQ53fr/YWjW2nWXDXiUKs67ObOwrmu2trbQSWenNnSUMY6DcFbN8pgmOz4H0Ydi3PNuSIin0cVPYwC9O7YQGw3yg9HR3PAbY2jqpjTXsnaaB+7dSquU07vaq8t9zXr25oOybDdpsyfO3QNQxwcZCZ72GusI7vjayccn4H2UvEhdJVMxQ4yBmzdvirmWUSsnWGMwmmQQNpxgQ4yP6YnrnjFDg1ObS5+ucaMkDq2qKoZ+5E7sPfv7+xweHnLx0iVpLkNIDKWM8qeSZMyxPnu854+H1clnzeXZ4w/8zXHaovxe0WLfOWvq+3+dYhsOLOdHPPrIFRZ793jjlW/xn/4n/zHvf/JJ/pFPf5qrly6yPDhAE3C+J/icf2gJXhFjpjZWKGswTY2tGmgstm6gttiqIRhD1BXRGNFXGlsKgBjS/pqNGcgITiBEoaQmAZdsQj65aSaEbYUYiIYr09IYUcHKxlhe1aC1UBSpDcqD1SpRVy3RpgbTepbzhTg+lk0/UdQyRcp5yZkLyZQIv4pS0QqdtK5ByfPj0ykLK6t5cR01uEH0YI899hhvxcjt27eZ1S1bswmmqSTyRTl0XUOU4kWcQjUxarwRl1KV8g9jCGilGIKndx3tsNKPZYrfqghS+ODp+57d3V0eeeQR2haGZJiUCyk7ctrL0/u+7+ndkBopXa6vuq554403+OpXv8qVK1d4/PHHMVaXIPtckNV1zaLr+MpXvsJ0OuXxxx9nNpuhtSX6KIY6RlHpmokxWB9YHhywPL7Pd19/iTde/w6vvPxt3vru69x+6waH9+7guyWVjoQ+UBu4eKFlNqn42Acv89nPfIo/9OmPY8KC7VnF3u0bWGuZTVu6xSGhM9hJg6kEQRqWS/re4V3E1KogVcZaiRzw4jYsSD7i+OkjHjEtdjGsGv2RKY6yBpWyQqNfd3XMzV1BwHLDFinFVAgBr/xac+B91g1mTeVKzzymwq5qJkFhQ0JqsjFURgxUOBlboJI779qakjWjKgXBK1sKPXIhGNM9X/LbAzpdu6oM6tbjI0rBHVYGKoWubQznzp1jf/+A+XyBc569vX1AcfXqNZ544gkeuXq1XOOL+XJEydREfNJ0Duk1pRnLejqho0u+5qSdMplMCirlnCtmPrnQjRFM1p4XemxqrPIBy9K0TKHPWvgH7Bf5Xh3S+yloXkKjTzYCccNNfbM5WI942txjNnkwZa9Imb9+7Wuao8Mj9vf3iTGKznCyRQzgklZ1LU4lxuTdtmqKohM3YKNEghAGJTdNYrOMjZ5kYEcZ6oURc+eks2qm9J/cnzMiqFgHrN4NbXilyw1oA/28L8c1N/x5bRTzGnOigZPrjxMmRWMTm9P27AcPEB7cXGZ34hPvf+N5x03qaT83bgDHwymhi69H9SilmM/nxcF5MpmwtT1LdGmwVhcjIPWAqJgTTvtB9gHU6n7z3hOQXOB8TQc1bt51OSe9cmgre83x0RG370m81NWrV8V0bkTFj+96nHH2eC9r3M1B6llzefb4A/14kMPa9zstfaeb7ySy8S6eN2qCyhsfZZGWbshDjFQq0h/uM2lr/rP/5D9m785t/umf/il+4jOfpjs+5OjwgFlTS75hpfBRNo5Mf5ENX5otW1fYtkHXNbppoWlKQHtQGmVsoQaq5GgaUaiY6HXJjIG0WcUQ8MGLiU/KkAxDX/Isddk/Y5JdZppQMvVJtNlyjqImKnkN+aMwtirNqbEaZZAolTqgQ8SaCu8ks7DvO6KThijWNZW1YgyBUBcjmdK7BuWkhksLGlrC1EWdyhAwSlNbS9dJs/fII1fwXcerL31bEIHKMKkbQhhSLp0TaqwPKduSlQ+BFjdbhRbqIQrtI2EYiL2nmjRYUxNCZLnsV+7BKhUYIVC3LZcuXWJra4vlcsC5Hu8HKmMETWZcyAm1cNkPVE2NqSop+FLO3avfeY3XXnubP/7Hf5LLly8nKmIvSFqITLa2saZi7/CQF7/9Lc4/cp2rV69SG01kYGoqYiXasuCXzO/c5+WXX+Irv/5FXvn213nj9VfY37tD3/Vc2N7i2uXLPPfkh3ns6mUevXKFq5fOc253htWKZXeE0ZGmqVBhwcH+Ar80dP2CZjJhpiEazWQm6NTSeZbdgr4XLefOzgTbNCkywrNcLjheLuhDmpRXNdoa8cBJxaPvPd5JTEEcuWMaY6i0SdTl0+7ruKbNU1ii8tL4rdFonQxJ0mCGEAlRlYy2TPFUG40lMV+3oSBaKx2XL+9h7NgYfTalkvBX5QWVl2iFmGIi9FoM0ji3sSCeJhfPBo3Hq6Qd04UBWeijPoquWGnRNwfvi3lRbpZ3d3eLe2sezly7do2LFy+Wz7mGaSUawarZyg2vfBYpXOVYNHXLZDaV2ASt8QnFtNZSTSYyMCr7QMq/PaUhyM3QJrVfnKZFD6biykjJJ7drbWxiOpCaWcUw9Chr0nDGPtQt9EGDxdI0jWQVSnGq+6+xSgzMUq5gVCItQGsOj/ZZLpc0TcPW1pbcN8tlMYLJ6GpxKN8wBnJuSKyQRFcd+oKKSqOiR4Yyei06RbO6XkQKcYpWctSAn4bIqVORzbD2+bU+2cDmZihrKnOThQoJXVfErAVP13cZAiWNufx3KOjm6KhvZF76U9HkzcH2afFkPiFxJq9JQeI6dOQdG87ThuXr2dNpEDOkdUFblBG2yr1793jrrbeoqortnS0u7J4rw4/MAhqGAWtMcqHeGEIklkKWaTyo2R6Dij7Hh2i1wdAQdpNNGblHiyX7e4eEqNm9cJF6MpEspySrUdmBefx6Ii4Zf+Gs+/whP+z3S+X7fgv296r4f3Ax/vsvDPV0R7kf1ff6Dneo0kX3s7Ivz3SIiPKkLTvRT8K6GYyPJ2kj40zLlW58U8OhT58ARrVBNxptWOnJC3Wj/PsBnz1PLJMMQzQg6wHpZVFPrxOys91mwRBH9FedNnSkKPPJ+MG7HmsUk7rCDwuU6zjXWlR0/OJ/81f5+f/y5/mX/tmf5Sc+/TyhG1geHbLdTpOLarLuRhZ9nay+IWCMxTY1dTNBTyZQT8BaPAqlKnyOJtEakiZR6Haa4LUYNmRTHkSfFoMT6mvwED3KDzAMaDck5DJHGAjRygRdssNUCOX45LzJMLJhD0gBLr8vpipBRVA+IZ6RqByoiJ5NsSjqmafvFiyP56K96jvMMDCxNbUWymj0oWTimUxJdB6lPFobdKrlQshRAqKN0jEZh2iDdwHvAzs7O3zoQx/ilZdepq4M06ZFq1i0KZIXJ3l0UQW0TTRnElwWpFisjeG4O6Y2ln6+oDKWytQY23Dn7n2WyyVt23J4fCQFD4ahG5i0M5754LN84Qu/lcyMes6dewQVhfI2P16ytWVZ9Id0fcd0uoW2FceLBe10Rl03vP32Df7O3/klPvTBp7j+6GPiILnscH3HbGtCP3S0k4toq/n6N7/B4D3bu1t88IPPsLPVsAwLrOp56/W3efWVl/nGV77MC1/8Am+8+tvstIbHH7vKRx8/x2Of/RDve+oJrj1ylQsXznFud4e2lRxWrcTRUBPougXzxWEygxFqpNMVdrKF04rDxVLMHboBx6LoVq21tJMZKMPRYsGy6whKyzVkNZVJKKQ2BCPxOdGFlI/pUAbapi3Fkh3HeHgHwWFUlHw3bZPOTFFUxnkNy+i8kuZRK4Xve0JI9M0YaJoWayqhfhc9XjJYsqJx9nE1KXa4snClkImi2414QRi8UMNDkOtbKUVTyX2dmWOaOuVkWiLgvMeHARUHef2iW9NybyfEzimf5i+aspomPalPTWzMsUIEuXfiyPjDOGZbW3T37nHj5k3apuF973sfuzu7LI7FSdjFgEqZr4L+BsSjyBO1oaoaYox0Xceyk4FLdkPe2topOlTvAyHK6ts7jxIudELk4sjdc73ylHXZrmX1Rb9q4mMapPVRFVQVZL0MHpaD0LKd74V1YaD2mvnhMZNJe0ILqEfTROnj1cgQNA0Zogz4fIm1Wdfl61RIhxBwvcPaZN4TI8YaXO+5f/cu3/3ud7l06RJXr16haSWzNkRBibS1wraAYnxT6MhO8orRMqjJLsiZuu28xyVa5CrKJKKL9lLWcaOMtPQqXS/pyJt0rsdD2TJYSb8PiKxj1Oyf2NuVHEQVohx/pWTQleJt8s8vlh0A2zs7mEqz7BeS9RpcGaLKHi5NTHaMls/q8Hj5llaFPqC1wvVDqQcivjAJYvkzoi6vxlKjmiQZjCEOyHnY4vPP6BSrpNdrjfw/770gsdqsUHMVZUCkNMfzJc4FptMpWzvb7N0/4Dvf+Q4Hh3tMJhOuXLnEbDalrkzJ8RUH85SDGcM6+pyuMbk9V42lVqTsSS/vLElPnPNoJUN0HwI+Ohl0V3WiznuaqmbQXoon27K/d8x337rBlavXeezxp9Ap+xLnInUlDg1pAB5UwriVDMPKgS/a5d9//cPvJUAz7l/OkMsf0RP0+y3o9Yf5eX4nw4zTpoWn0Y1+WO9h0z1NnstDtHlgxxCCTCsVEBzBDagwYKJDBcXx7Zv8hf/Tf8hHPnCN5z74LE8//gTze3cwcWQqkpEO8gaVUEK9Ete7GDA+51IqgjYylS/5eWLOERTY4qCoxWU2h4BHLXbwKUcw+IAKA77viUOP8qKH1PkzJ71liL5Q0LKRjfy3L4YUYQQpCnqjS8El2p5kza9ImlAx8AnZaEJP0dZglzWu6/HO0Q29FKhB9HkSoK7wg8P1HdboFEaeCqVxFldINvohor1oCtFCLWorS2gaLl26xHy+5ObNm1y8cIFp0+KcxDJUVSVFqlEoH/Aa6EHZUGi7REWlND4ILTcMIdnZw+HhUTIVEpqnc4EhRX5MJhOuX79O03yZ+wd7TKdTFv2CWjVYbXAx0O3dZ7bV0LQti8UCbR0hwNbOLsZU/I2/+bcxRvHUU+/nypUrRb+mjVxTWYNzf2+PL3/tq8znc5563/u4uLvF4d2bfOUb3+Cr3/g63/rWi7z+6is0RvPME4/zM3/253j/k49x5fIlHn30KnWdctMMI71iIERH3y/lOClwcSBGj6kVk8kMZQ3aNKmgj0SdEJO6Eup3jFTGsJgvWCwP8QGWzhGUpm4arJVrxCdUJWSqtZKBkVIKF2UoM6aU5uDxGAJhcLChi15jLJQw9XACNYlEMDI0GlwntF1jqbRGq1E+qVqVQD5m9DLdt2sUsNEgToVkvLxCmSQcXZoMlSI3QtSomCm4RhCAhCOs1qfseJrigRQyFNJRnHgJYgaWBmIxaVNXjA0ttsBBfMKiVxjlBaFN8QLOuYKyWmth5K5qEIdIqxQenyis4lBbGcPQC8XVOYe1dXH7rKqKwcc1B121hn6lyKM1TeTq3j6Nkr9yDY5lzfPRJcmXTsdQFSMYOc+SaauilfUu6pP6xA0dbqEO65PazzEFUm18PyPXKzQ9JmquYxg8dd0SfeDevTu8/fYNJpMJbduilRVkNSajFl0R8ZiqSY2qDEZiWevlbxe9INJBqMM+KryPqDCUpjSf1xACZuQ4rNKFqzOitn4Fnx7jpU4icaehc/k85tfOWYrjYy1/ohgShVDyUUMUZ3HNKm/Vx5WxU0ZhFcI2CGPWQPQJ56aAA7Ivehk4bZRBcaN53nz4DbrriePCKr4rELNjgfytoLGV3EsRXPq5KK5+BC3gQNXURDR3797l1s07zBdChT1/XmKC6kQTfhDamr0I3g04Nb6nAnlfX03wN++L2WSLvpcBx6SdgYvMF0tee+11rj/+BNPZDspUpJsukusApVO9YMrVuzYyyv84QzB/KLX3GS32R/zk/L74fMQHuprlCex7iXivnuPBFuAPauYfZoxwKm1J/c6bzLzpMn7d0WsZYzBeioXKapRz+KGnsYo6KsJizt/8//01vvbim/wb/+Kf4LOffJ6hXxIyDXIj/2qzuQxJLyXahwg+UadCwCdtifSgOunAZDIdlXxNkNXkdhpiKbTXNhHv8W4g9D24AZ20NJqVJqwUQwV9GbkgpkY1ZaakjdrL1l7cCMOIhrg6p4USmDRetZlR2Ya+6hiWHf18Kc6giCbKamnqPElrF4TuqxWEEbJQitX0+jpt7CqhvN5WhLrh6iOPcOPGDfb2DjBaY89fSJ9XEYNKtKG0w6lkghD1amHOGicf8F0PdV8cZ/fu3ef46Ii6viDFcXKg7DqJbXj88ceLScql8xfpug5VGapYYXUlRbeHpq3wEVyAnXO7VFXFiy9+mxde+CYf+MD7eObp97O7s8N8fizkoih6mZ2dbbTWvPrqq7zx26/z/qee5MqlS/zC3/jr/PpXv8o3X/pW0dX9xGc+yXPPPsvTT1zn8oXznNvZYjppiXGgH5Ysu/lquEBIUShyLm1yDM7xIG09Y2s2oWpqgtcrt+J0P+mkk+qDJwZBtA6O5+J2qjT1ZCqFpDUJAYhr1NIwMq5ZNRKJYjq6l3KmW3YBLtcrrPLiTlmPVsHi0sS4IdJ3ohPUVYWtqndBnY9r94seaZXXEbdyRxWUQalVVIR3sdDQYnJ63DQZOS0SQhkt1PjoJZao5PAK/K6VLXma4jLqUNonTE3cZVWMWFvhnCu02OLueeJzbDCVNBhg6B3d4BgGJ7rb2ayYjgAcHx+PmglXiuB8vkyO2TBmpeVM60lu0tfclNdcQWPSSytUcsXNyF123wYwtqauQalBBoNKoUyFbeqCgOfn9H49B9Xrh+916qHsJ0+MUNe1aI59xJiKw8NDbty4xd27d3nsfU8z29pB24rByfFvbI21NX2/FLfwlP8rnt2rJhMCBo+PnuBjygdWa5/HpWvShIhSAa/DypxKiab9NB5aeEAdtIb0PaTBzPeDTpmY6PWm3XvPMAzlDzHSNg1VjrTIezKr3MisIdUjHWlMYuSyPuT9Nb2+URnRN2l98+vN4YYbblAP9n4oA+KRvlacx2UL0SOmVWESGYmBij4kbwH5IR89Pg7Utew08+NDbt++yf37+xijOL+7w/ndHcmQtJWgf2NWV7onlFUnZETjP5lOvVl7lWFKYi7FtOYrrTHWYpIGvK5rwhCwVpDM5XzOjRs3+OaLr/JnP/3j7J4/j7aVbA5G3AVDojePadZnj9/9PuasufwROSk/SKbTP4zo5Q8kan8Xx++dnvf7Met5pwbztAX/B20y1Si0+MT3ksGENVLEVcm0JUZHYxqMi/z2qy/zn/9n/w9+/KOP8Yd+/LNcOLfNnbe/x0RptFGoOI4/ELqWTztQTFNXhcLluBNiclpLKIYR59I4ojyV3DMlRZRWARUNIdEYQaIMQlzFkOTiUwxjE2VLKUzpJ0RLWgwgUhMpCIJfTX/T97SPxVSnFBRk+l4yTwlC/wmDWzWDyTm2aRpqY2lMhR8G+uWC3g04RA+pEgKZm15p+laNQwyB4Dw2Z7mlwamK8hmyJftkMuHC7jnuu8DB/hF4OHduh7aerEK0E6KkokZZjQ0rx80QV1mFLkbiMNBUFW1dsbe3x927d5ltbRXKXgiBvuuYTCbs7u7y2GOP8fbbeyUrUKsaM/TYtqadTEBFjubHop1E88gjj/DGm2/xd37xF9nZafj0pz/NuXPnikGK0YYwSHE+aVvu3rnPCy98mZs39rne1Pz6r/0K33rlVRZ9x/XHH+Njn/g4TzzxBB/+4LM8fv0atdEsj+fMj4+4e/eQqlb0fUcIAWvl3KACWlmsFUSzmbSE4Kn6ihgbmumE6WwLqmQYNGqgCkUwFYTLoWO+WNB3DtPWNJMpddugjMbFkGicjNAHTuQl5kJVKJ1CszKsNEbGnDSz2ESYTmsGxsOPsQnNmhusXh82SYWoRxpBHjosO20/Kccrgo8RwykIZ9ZOGb0ytYmZIJhQV60IwaSoEiOOx+QG2qbPl5kYJmWx2sQocGv6r/HnF+Mvv9aIhxCK2UdUmS4Ix4slUSmaesJ01jKdzYQi5yUHVpxPBfGOPp9voT1DRNn1KJAVkySuDRs3j0sJCreWQHbYNYVaXGQeiZZdpczEoTOylleVxF4YK27FI23r+E8f/cls0VUrMqLoy3AqozHZ3CjHE8n7qAkhcPvWHe7cvktdN+zunqduGpQW2q/VFdpUyTRNPkdUQT6PkpidmJrCqAJaialV1PGEHCTiGXov9OEQ1xx+Vw2mObX+UQ+pk0777wftt7l5zxrS7ITrnGO56Mswzlpb0O61wU6OFtm4d3Q8WX/oNCPMESP5flk7pyP98mk1SXgX+ZZjvanWot2PatSojgYhvQ+rRh6FSoY9wrgBrSL7R4fcuX2P/f19rDWcP3+e3d1diRxJx2PT3fqdcjZPG46N18WyH4/XxWQoZKzFaIOKsneDoOlaWxaLI1599TUWC3jfk0+zu3sejKF0umJfmPZDdRZE8nvIUjxrLs8eP/Tm+TQ6Rb4IQ3j3zeYPigJnlGAcDv5uG9Hv5309bJL8bm/IzUZzGIZk/JEcHr2TgPgQONy7yy/+7b/Od759k3/zX//TfPTDH2CeDHz8YgHJxCHPhEMpzAxRmWSKYyTTymjIGZZWgzVi+21MMt4wglbopHtCrXLIUjGgtU55XoYYTDKRcESlicZIw5nOeRgZZWSzESGWqeRmGQnBYVFlMqxLKLxofGIIKX9ypYqB5DCoYip4KK6bIQR80jIaZSWf0ViGricA/XKJ6ztUBKsNVstUWKbx4owbklYj+iBOs0m3qjLFN10DWimsEsOIrekMQiyB8NZamFkqmzIv8YTg0caIkYsyq83XmtKoxuBxKVqlrRvmRwfs37uPu349FVFyBIbe41ygrVqefvppXnjh69y5d4/ZbEZ9cYoLgS44dDRUlWHoIjt1y3Q6ZW9vjy9+8YvcurXPH/2jf4hnnnkaYwyD61BKokeMMezMtogx8pWvfIWXvvVtooM7N29zeLjPM088xsc+8Ql+7OMf4/LVKwVFOrx3S+iL/ZCK3gG7jETEFARd4YMjBEdsaoxRNJMWZeS6MnVFW1na6QSqWi5BM7pvw8qZNSi5jpbLJcu+o/eBLSNop03ohPe+GFTlPMbsujo2MVHJQUaKOFXouzEVbsboBzaXumjgThuGxRMshhz0Xn7/NOQqUV4ftP5kRsjYuGlc8MnQArx3a5r53EB771ExihFX1g+mz+VjKM6aEs8izZQxlRS6hT+qVwihCuV+xkhDJDEVDqXBGL/mMRBCoHMDMVHwQzH1SftICLjB0bsBHxXtZMLWbId20pTGMqZz19YV3ovDcdCuIHoqZIqtS3q2VRGenbjXUBZi+WxjGq1WVtAWY9LgzRYTtJhih0II+H5Am0U5r9m12WpTjqffME+Spnsor3dqtIVyJxxAVTZYSvnAy15ccW1VcXB4xBtvvsWi63n68fdRN5OkxVc0kymNreXURUXdTFJjteIQajRRJa28SkirToPAdO+NkVOlEdqsk+sq5wQrvGT46tV1svoMcUUDZ+WZsPorrt0KnLqrr2JhnHMEL5mfWll8jAy9Z7lcCtV/CDSNDByttmv3DnEUCZVwuxxpVZyZg7BWolLFOVmOhzoFkU0EzRTFhV6PStEbiL3fqDk2l4OcIzoehKzd52HTxVqtrW97B/vcu3eX/f0DjDGc3z3HhXM7TFpZf62W/TYGNTJmEllGGLuEPiD+hI37aPzfonXOR0lMp4wxVMaiMcmbg3LdKVNxvOj48le/ziPXtnniqaeZzKagjAhTjToxsH8w8K/PIjB/SIjlGXL5I9blPwgl+33zOVFE4u/oYv1Bfuf7+d6D9BsPOhcPQ0bVD/Dex4ZH2TLeh0BlRHxllKCYrVH0iyNeevHr/I3/5r/ig+/f4uMf+RCVirhhie87amOojMa7UFxQszFFMELfjBp0ZVFVjWkabFOj6wplJc9SVbXEj2SNidrQjMRIyCY8UaagpAYzJq2RGO2oZMyiZU0PIzpRKj7yv6UwXrlaBrQ4zSLGBZpMk5UGVDSQYhgSEUv8UmSn4PBxXmA2EgoxJDeoKBbnbSPNfAz4YWDwDu8VjbHrtGI/RqW8NKupsRQ0RqbaVkmzvhjmgOgTz58/z+JowfHRAu8i0+mUtqnSXped7nJTQwklN8ZgIhhlcH7AKs2kaRkGuH37Ns+kiJIcDRISqlpVFdeuXePChW3u3D5ke/uA8xcfoZ1OqOsGU9XYyrJz4Ty7W7v0LvArn/8VvvSlF/jIR57hE5/4BE3TFPRluRxYLpdcuHiOtm156+1bvPDCC9y5M+eRyy3XH7/OY08+xo//xGe5ev1RTKUJviM4iWLoul7Qm4S2GEBZsJVOTbUX2lbKNqvbhhgDzknRbSpBMyvhGBa90ibTICRWZUgmIc4Fejcw+EAdQjHPCkkjGxOXOmqFCqdrJ01qsDSx0JLFDMsUN8qc4zZ2TsxuoKcVWPkeGhfXm81lLjxPDufUWrj7OLZcZ/qaWkc8NpHMEFaavdxOZfqoXtubcsblyr1RYaR50kLt1LZOuabpiRNtUoSjUv0LdduhQ3J9joaoHd6vGgxBKPQJiYJOum9pcKF3nm7wbG3LtdhOpzII8wPBCYVefkWjCZiQmoMIMSY9doqP8TESkQak6CFHxfmmwd7KeE3otDnSJyOWubHUSqGqSmQNIeJchdbdCZOaTWRyTCvNTfomolmKc2s2BgfxRBE9DANNPcE5z9tv3+T+/ftszXa4cOFSctUUuuyknUr0lJdmVFuduOg+500lAXAs/9ZDKEZspCsjxoRMobFWEYIlaJ9cq1MDjS+08vyZx3TZct2ekgOp1vNHvq+6Krtdd13HMMg5V0pRVy11XZ+Q7MSNocza8645mW+wBDZQRjaH7Bs/94M+xm6sJZ82ipkQQVGZVWbncrlMn3soGuX9/T3JsdSanZ1ttre3xfAv3YubqO24gdVaycBIndRZnljrNq7b01BOpbXowVVyH0Yznc44PlrI9eYjb7zxJl/+6tf46I99jAsXL6NMXcwU81vQ2cxxwzgxa3yJm188e/ww+pqz5vJHpLl8WADy71c0871CLE9/jnevuXyn//5hai7DOH8xhQaTilRBLD11XTP4Hh2h0qDDwM3vfZdf/dwvcvft2/xLf+af5JknH6c7PkAHT79csrOznWikImdXqXiO6TUkz86gqwbd1FR1i25adFUTKytFS4rh0CUDT62Z7qT9NR9uWcxTpIjKE10lr4USqixagzEpbzKs0MiENJZiG5mYBhWSllMK+1gaubBCdsLIqCOuo1jJ0kialqhHU2LZmH1wWKWxdVWKm6HrcMsF3nnJf4zI9DrtYDobJSlNdIMEyCdkVY6DxJMoY6itGGXoqJk2UwyWo6Mj+n4gxmNiEJ1P1dhSLGSqpTEGPTiilubGaiM0RmOYzWY0Fbzxxvf4+HzBZDLFaIsxQlsLIWCA8+fP8+yzz3Lv/m+yd7DP/b09zp8/T9U0bG1vE/Fs75zj3r19vv3yS3zzWy9y5eoFfuqnfopHHnmEvheHRTE4Gqjrmslkwv7+Pl/72td48803uXih5QMfeIaPP/8xnn7qca5cvYJSA4f7BywWCxZdh4+BdrbFdLoFWtEtRWtpq4omac9cGFLmmaLrlvjosU3F4J0gKW0jjaVJtNDUSKuVy0ZWZOGixwXJUXMh4GJg8GL8ErXBWJMagITwRHFjDCES/Kh4H5niqDRptyrpQV0oFPF8vcdR8xlH2s1Y8l/jWm0p/21Oaajkvai1HKLxOuNP/feKnbHCSnJuoMTMpvggZVBKdGWSb7rRSI0Kyc01TYZEFqNMavRNzkwhB0ZmuibeC108aYrzh1cijyKg1lDiuq6x1p4IffeBgqqGqKhsg62nbJ87lxBTBcNA8IKKy7oScGGQAjgEyeUsTXdMhmRg2PiMIRQ3zNW5WmUhrv4YlLVoK7EbpGxQlC40P5J+PWz8ERqwSbT/cKLRXBn6nJ5lWIYeI4eSmKjDY/TTmCqhTpqDgwPefvttKttw9fpjVHVNVIa6qZm0M2zTgLKlMZGFz7DKfpI9oJimkBF7vS4bQZDvEESaoDWoKkVM+MxakEHfMAgTI1qzdn2VJiasXNZP28/HWZoJaNxovuS9muS83Pc987k4hudhXNbqNvWkbCDGiDO0KVrqhFuWAXDSZPqw1gAXWjA6GV+FVWzQuLZIe+qma/xplN+H1jvjGJSsESXpxhFd9DAMHB4ecf/+fQ4PD0tOsdKR6Bx1Y9na2uL8+V0mbTuKGiLVD0GiQfTYbX81cB7NsU4i66cM1tbPnwyvdab/F+MkkzJ+K6oqUNct+4dHvPDlr7K373n+Uz/O7rkLad0x6ZZbRyOjDyij1oZnnNZgnj1+KI+z5vJHqMl8oOnN75NGUnQyYaOxju9JY/luKKvvFn38ft/L7+S9j8X56/llo+m2CijvCaGD6PDDnBvffZ3f+MKvcP3KFp/+2MeodaQxmruHBzxy8QKh75jP57R1MzreqQDEoLQVl9LKYitBLI2tpfHTlqjVmiA+pIYyF8kqnpwcl6/l+JEowclKQ1RRiri0OZuqElpU8BI3kwoJnYp47528Vy8xJCZT48I4I8tDijChyE1iMQQRgx6hw4YcFD2iOIEWUx0TsUpjKkvN6jN4NdDNl4IYR9Gs5LOVnWODd8Vafw2JSscsI3/dcigI4Gw2Y7FYsFx2YihiDVZLwS1FtriWai2FAUYTtRFKMgpbaSaThraFGzduM5/PuXD5kuhVKotnVcBub2/zzPs/wIvfejkZedzg3LlzTKZbNBNxrt3b2+M3X3iB/+6/+xXOnz/Hz/3cz/HMM8+IWY0xON9zdHREjIELF89RVRXf+953eemll5jPB/7QT32Sj3zkwzz7zPuYTGvu33kL7x1HiyOapmJSV8y2ztPOthhi5Oh4QcTRtjVbW1OmU0ENXPAMQQo+bapE1xP0XmuDsgZyqDmgjSF4j03FaKZauxjkuZwg31EuQKJC4nWCxOVIYWSI0RGCuCX7EE/QE7XK5z4VnkqXa8FmymxuRnXWUYa14VEknspoUJyGLurS4K1+cD2D8XR2SLoH1xDL1RCrRBGUBlGayoy2rb2HTMWMbq1pVRIki0mZeCU/JwJhWM/FDBHvh9IErWkGc3OsKOYq2XTLGMMwDMXBM6Tmc9kJ4mLqhu3tbaZb21A1RO9wQ4f3LjlkB4IbiCEN14Irx2OMPCqvcGEgUyg3ZRMy5DGr47XR/BWtZVpTSTqvtfU96ft80pRmvZ9RKfdSh7IHbiJ3a9q9B5jNGbOuCfUxjJBPtYaoHR4ec7B/xMWLF7l69aqsY9YwmcwE+c3ubcqCCgQXUMoXg6N1FDdpYteQrRwNpgEvjp3RpeFmSOyROAb+GAYvEoaN/MwTe/IDEEkVH45aDonVkWnFwzAw75ZyfSmwpk56y2ly1RWab4kaKs+nTn39TSR5Uy2a77fT9LSbzdgJ9tNDTL1y3qa2ejTAytT2iEcypl0vaOX9/fvcvX+X+XyO1lrQfiumUrNJup+mUypbp2tdMjBXQ6/V+ypU27jeXJ4mfdqkzZ7IYc1DA736THK9GBSaxXyJtjV6ssX+zbu8/Opvs73b8olPf4aLl6/KtaZ0uRDH1PEQxHX97PEj1Fz+Tgv932lO5js91+9mw/VuzF/eaxTz9xNiWbRIxBMI4LtBMB8k2i+LcniwqcXpNtgPeH+nOJ6VBWo0ST1turh+3lZN1/h7xU1ScSrNSqbzKc+t2HEHVEx6Mw3ae6aN4aUXX+LX/8Ev8/I3vsP/4l/5Z3jqiUdpjObg/n222ynL4zlaRdEuaJtosVJ8BxWLWY2uDXYqmZYk9IJRUynvM4COYtygVHEDzM2vTxuQRjG4HrwgBBYxtxnmc8kCzFS1bLYD2LQpGaNXLnlRHGsLupl1I6k59D6shXCLPswXdLacp+y+mMwkVI4hCDG5WUqhOcQI0RTdVS4oVd0SlCW4yOH+AbiBndkW03YiQeyDw2hVKJEh5EIi6z0y2iqIo9NSVOpEac2RC/P5sVAEdaSZyMYelMIjurO2bRP65nFA7wPKaqbTKba2HB46vvXSK1x+5BpVY1l2HZOtWdFwGW144okn+Mmf/Em+8IUvcOPWTWxd0buBW3duYm3NCy+8wOuvv8WTTz7KT/+RP8qHn3sOrRTH8wXGmPQeI1vbM5q25e2bb/HCV77Mb3/3ezx6/SIf/bEP8ez7n2K+OGY+36Pr5nT9MVtbU7a3xGSlmW0RlSb0A3VjaE2DtZad7SlNW4G1VN5TRbknfAj03jEM0mDYpkEbg/c5JkSXZsf5iLUyAXfOJbTd4lzHYrHA1BVNvocRx1ml1CruJVhBzb0gbp0bSuwKPtA2jTRm/cDW1kxQKh/K9Zn1ffm+HReVeLmeYkalk4bOWLn+spGNTeiX0VUq6uzKuZRVJEiMJ9exsbnIuFlVSQNmrWG5OGa56DBVjVKGITmHRnRBgqWhSw2e1qKV86scS1IMuYoKYypUU0NVge+JXc8wCAU64YLyvqKo5lx8QJi6Qhwpq4qmaVh2nehgY8RWFdoY+uWSxaLD+UjbTplt79C0bYpNiYVOHKPooIP3xUVaxbDSz+W83xhLVmg+X2vu1iFHbsQRVdmOzqsgYdbWKFsJKwMIScOaC/2slc7N5djQpu97Qb+NXLtj46LcZOaB4Gl06tUeFRJ9McpzasNkMqHvHUdHR1SNOOceHB/x2uuvY5uax9/3FE0tWuZ6S/JtyxAkayNDOGEecxot17Cp541FZzvW+o1dXkvDYkA3jZwTLyhzNKJHVUav7bE6MWIy+WS8P2fGz9gZvHwGrcofHyKdcyy7ns45iflQnt3tc7TTCS74xL5R9CnvOOd7ZvRZ+dUAJMRA8OB9LPRUreKJ91bOWRpI5qGD9x7vEsVUWbRZR2jHz+NHzX2+rkDRu76YkWXX5a7r6LquDDPyf1eTllllZV0zBirD1nTG1rRlZ/sck8lEhnPOFVnG2L14ZfIl+14cxSvph9T8mX2RB1wrWq0m+lhMfEKKEDO6Sk2heDc0s22Wh8d8+6VX+Nzf+/v8kZ/5Ga499gTNzi6YSuFjGYxk+rzcF+ZEzvjvVzbg73bf87BjeWboc/Y4e/yQ0MnTXCHjOyDVJyahWeCvteQtxsCkMnQHe9x443W+8Pm/x7VLDR/+wDNM65rgHG1VM60rCb6OnqBTMaSMFKOGkj9X9BmspoWnfVbvV/lcmnUTHpWMDIhe9CtDTwzSWA7eEZ0jugEdPCFroZzH+YHoPb131JVBBSkEVC6Uw8qYZGVckQoVq0bUQkUcegjj7LKRQZAPshHmIjzlkkXn6VIOm2Q2Co1ovHmbSnQns4QeHu0t2T86JITApGnBJC1TZsIZjY6W6OJaIWm1ISQXSZ0oxis9S6SqJCR+uegZnKOZNjRtXYreHB+CtsX50vmIrSsuXbnMzftv8/bNG+l4r6zfXQil8b148SIf+9jH8N7zWy98hTfffJO33nqLqqrYO+hoW8OHP/wMn/rUp3j/M0+jNPRdT1VZFosFVWVwTtG0FcYqXnr5ZV588UW2d2o+85nn2dqasrd/n6OjPepK01SG87vbnL90nhgDxmqCH3CR4grbNA11K86vEIjOSZartomCJTpd70IJK1c5WzXGZAwSMKMGTRpzSkF1vOjouiEd54q6ndI0DbqqV87JPlFn83NuOIPqKJlwLpncqKwfZmXwMUYYN/V0esORZzy4Gr/O5vfHdNh4inNpZuWr8HBN+VqmHxG7EU8S1Uk8dMwoUZkKXwynxbgGnShsw5LgHd4NwjaQNkso4gpidClAPhS4amX6o9C2Wis2xwjTMAzpfSq0qahrS9NOqduJNLWJrhmQXF4VIj7pt1c0ddFiK71qzjxxRDSI73jssuvtWLttktFZHiT6kN2FV1PGcVEt64FPz+lQSlxLGSErp+n6xv89pk6P95D8HquqEqQ/NQQygKrx3nPr5h2WyyVXrjzKxYsXmbQT0JJt6rOTbownXGuJrDnAbqJssURTjI1UfLmG1FpgPesNJkE8APAn7ofMADgxYB7dYzomc7kscUifu6yvWhUE3DnHshPn6GEYcF6yOiftjLpqk/kcaXjpUiM0rJqrkM1xTMnulH1aPzTWbBx9cmIwnq6jIXiUl3VOKz2iTbvSWObPt0aNVorjfolPmtf8M+OflVgtyQBGCVMnKLDWYKuGdjqhqdviopsF0lqrDaT/5BA+5mvyXTDD1AN+ZjabpaE3JcIoDw7zvooPzLslX/7qN5h3kU98+jM8+tgTeOfLYDoBqMmwkFFDedZI/kghl2ePs8cPgraeurj8kMjt76Xp0YOavHER+DBTn9P04SeoPQ97r1EXUwTRIKlCwLRW4+Yeq6G2hlt37/DiV77Ct7/2Hf65P/lTfOCp94EbWBwfJ6RSJzMgoX1KHIjQUWWDSRoro9m0otykrxSKSRTMohQ1ReOYJrPOEYce33elUcN7QtehokcR0QnFi0G0aYMTR0eXKLR5Ou1zAZqKDN8PpSgtmZilWQQdVWkK1Oj95+bZJa2qKjlg2dE1N6GqoEEhI5wpawsd6ULg0uXLWGt5+823OJof88jlK2xPZ4LPxFCCs5URRCuG1XS2vJ8YIEjDL46DUFlD3UxZDoL6REZNQELVonO4IAWPrsTpNADaGqq2wVRw49ZtDo+POF+fXyGoQVFVTSmCLl68yKc+9Sl2z13gpZde4ubNmywWC55+5lmefPJJPvTss1y+fJnoA4v5sQShq0jfL2naiu3dLUylee317/Dlr32ZgOezP/4TPPX0E0Qch4dzUIGmbZhM5E9d12itcGnY0Acpxqq6om1rmkkDVhOcxyXELBcrAjwprK3QCYGX4PJEOU2HVhtNHAZcTMZXUahwi4XQwiU70tC0Lc1kQlXXBKXx2a6flQvqZo6hhL7rhGB6TEiU2FxwcTLuI/p1+ltG6Qkjza6WaCHnHK53BH+SxfCwtVXWk+y6SXne8b0xbnJDEJpwuZ9TTIgPHm2t0IVLwxBkCiUfJrWggRhUKfitrVC6AgVD3+NDT3BO3EEjGCX3V240GBl6aEYMcqVRKoqxkBGn2RA9/dAxuF4GCwqqqqGpJ1TthKadoeqEWnq/yqNkZdhCcCVeJcSI0rH0NwFNDgaU0Pl1dMWHfNxzwS6UQB9jysS06Riaoqn0EYJLjZnSa8O7POSKqemN3klmr9JEpwk2nGgY1TugQOsDCi1GZ4nKScwmOYJg+qjY39/n9Te+i4+Ba48+yvbODsUQKsUnueFkFMp4T9v8N6Oh33iAqqIi+lga+mw2m9OUVf5vFVO2KKmxyI2tJ8cUKr2iuhc0ZDyoVayGJHGlzUyj2aR/1wxOjMgW3ZJF1zP4kDwHFO1UHKRNZYWyq1ITFiPaG0zOGQ7pyYGoEt2euNJkbjChxJwsYiuLCgFl9MY9KS7Fi8WcrhdkO0dxhBCSbGK5tkZtDqGCCjgVk1785JBKtIgGW63YFCEqMVqqatHPt1tMmrqYGcW4YuN470v26+ZAYzxAiTw8Dq7szRvXcDHpSrMrayuqqkZbg1Ky5jf1jMOjOW++dYO/9Qt/h49+4qN84EMfYXbxSpb+yvC8XBBhvebMN375kl4v1M4eZ83l2eMMMXyQHuO9eP7vJzvrJMr4LvKfRn+tTf+ScUIx/Bg7B8ZI9NJ8aQXDfM6br/82v/6FX+HKOcXP/PRPM5tMObh/h37ZUU8MPmU6ErNWbTz91SciT7K+T6bqkkcXg6NEVGq7miLmzSvlT44D0qN34ERzJaHZoqeMYUSHJRA1GDQmGoKW51AhOZzGRFvbMMHYLNpVWOk4TKDogSBgE0U3N5MqUkwXskGKLpbyqXHIqEYIZUwvBkhS9NZNy0VziWEYuPHWm7x98wb+0mUuX7jAsFzgBkf0CIqrVs682oi76xo9zDtx6U1FqnMuUQIrnPKFMhdjxFSa2WyGj5F5P9C5gYGINwoM1E1DM1HsHy54/fU3uHD5EqGHvneYmOhySjGfz0Ebdnd3+dTzn+QDH/gAd+/e5ejoiGvXrrO1s4PVmv39+3SLpaB7WrPsFigdsVazvbvN995+k1/+1V/lzt17fPRjz/FjH/8ozvV03TG1NWxvbzObTZhMG6zV9MNAnTIqfaIT6spS1WZFH3Ue5xOlNBm5LAcnQwelaKbtSR3aerW91phletiQaG3ZybSuW6GBRmmqXLqelEmT/YxUbdDSCl3Re6zRGJsMfVIRszk3Gjt9bjaHYwq+c45h2dEtloJw10KLlaYvJBOc05vMPLQYI4zjr29GA6zoaIqozMqRNvj1aIIU4yMSJoUff6YYQVvqRGET5DJRaaMTXWPIObf5xhOKvCrl/kqPPHYX9TGUonq5XHJ4eFg+T1W1pbGs6gZlVohlVjarCCG5j2YnaZ0iY6Jeb05UZmoURG5dBjF2/qUMOVZa2DVkKkR8ABeE3ig0TNZordIwpTU5SOajClHcauPGIOJUPV946HB1tZckQyZiiSVyzjFf9ty4cYODgwOeeOIJLl2+kBBoYUHoACEMKT9ZBnxRgR4NF+PoNXWOeCgOndmtNpzyHpPuk1D2kLX9PMVCZTr5mnY000xHtOXT/6ZIDEhUWh+EaZCR5EW35Hh+zHw+XxmMeY9ShnYxF7p+CChrMMmQKyPdIcdjjfI48/l9kPvpuDaYz+cn4j/6YWDolzgXGHpfUPrMVAoh0HUdi27JdDo98ZmDkr0mKHC4wuIIo7xInVFz79P5Ss15Qt4raxOLyaBVjVa16H+jmJWNz8EDMyxT9JDc6uHU41Aa3g05UT6G3qd1x1hp8o1NOb7JldpYusHzd//+3+eVV2/z7/xz/0Pe/4FnUzdaqbDZJWZX47PHWXN59vj90/ydDm2+90jpe9FUvpvPcLpm88GFwEP1ow9qLjem1owWXg0slgtqY1A4br79Ft/6xlf5+pdf5J/8Y5/lqccfEwqml6iLXKDJxqfEMVHp5IqYHCGlL0kNXDI3SVpPJXaSMs1OQV5ajd+8FEbEFIodIyH24mSKUMN8LyiGUmCJ6NSvKXyiqUmRWRlxq1XK5oNSmklBHxLlq06blh9Rg3wuJH3RefqEYriYXw+0j7S1TTEnrmggY0KSfKI55fgIlRwQDaYgWe10yvHREcYYrj3+GEprXn3lFZZvvYmtK7aaNuXqBVz06BwMr4Wam5uoxlYrqpKKEr2BYrHsMUamw7mw8F6iO1QXuXfvHtvnz6HriqquUZXBWUW3WFJPWkxl6Y4Hvv7Nb/Jjz38CW1VSWCHUUJvcN5XKzqqR7a0pbd3QDRIN0C/nLJLRSF3XVLVJ2p0Fu7u7TKcT7t+/x2/8xpd47bdf4+qjl3jqmadw0WErRVU31JOWuqkJKiRktcaFgUVGno2hriTuxtaVFP4x0g8OjKWyFUEpur5jsZQszWbSUNkm3Tc65aOGdfQmkFwFNUYJxUym7zkzcnUOhmEg4vHiBpRajc37XNwv5TlFD0yKl6m0ZLCVNWjUWaoNLaRO1+D4/co9LvSzMIg+arlcUlUVxlQSco8g+6IltimLMzkzJrRvTFnMztI6PmAdi4oYYkG0C6VTGZShaNtWBkZqFcOwMdiTY1qBqQBD9IOYcGUgq+TgkWipFJfYyDhrWI5zHK2XdV0TQuD4+Ji6rtnZ3aVtW5pmijW1IKypKa+USfm7BoIbmRAFQSmVEuk4J41Y8j2eDp40wJqVqVFyhRVdbkzRCMn8K4dHktgOAaHDei9sDZUGZ0lCIOc/6T9HjaUiNb8PMXNZGcS800OX+CHnnJiDWUvXdRwdHXF/X0y8ptMp73//+5lubdEtlzTtFDwMblGQpfyedHKclcGAWqM2khBFFUkZv24dGVqj8YhngPy9kouUaIrRj5sRPXhM66xP8URY+/SVTTRtXXTNw5A008HT947jxYLj42PJvF32LPtuRVNVhsOjY5q6Eup90REmpN3IfW9MlaKhrDAykjPwMKxntGba9IoF4dY0i845Fn2H63IsC8XkaXzevfe4GFj03YnPn5vIWBBMaTaV1ugUwURyYFeIwZkKQo3VUaGVIQ6RPgwcHhzjWnGkN0ZhbU1dW7Q22LpNCOtqeFM+Z3baRn9f9eBqHZEBlzKGSouZHiZlcad7UCtD3zu+9+bb/JW/+l/z7Ief4LmP/hiPfeCDEMEFxPVbZT19yptO19xD2W1njNmz5vLscfb4YTaY79RYPsilb5PquinCR/FQJPM0c6rxc0qhI8XgpLHozvHmG9/lKy/8Fgb48U9/CtzAcpAFv2kaVFwZ7IgFO+vOkXnzTsVENr5ReeIfYwrg9hJaHCUSQ+zHfbKMDULHC+IYaJI+QxuNV/L6uCEVkwqjTbJj96NCUJpTkVeu661WqO0GWuVXDqhFFxQCVlfE4PB9srh3jjiIEQmDZ+gWyUFS9I/aJP1pQjO10YK2GFUomWMEKgTJ6sv0pHMXL/B4/wRv33iTr3/rRZ579oPUSkuD6CUSQidtYNaW5cl67TWdS7qW6EEZ2rZlSEVQtEEyN3UjyFYY2Ds44KBb0HuH2Zpw/spV2vM7bO1sc/maY/LaNurwHm+8+T1u377N9evXEgosx8kkvaG1tUzIvUuT8YHj42OqRr5e1zXnz+8SQ+Do6ADvXco92+Lw+IAvfvEL/MZvfIWLl3d5/tOf4pGrVwl4pttbtLWmbqel+C8GRCEy+IitDY2tqdqmRL7IPSXogUq6oGEY6PpBqJBNTTuZlBy4E1S97OA6MtLJ58tqKbBrU7OMSXM1BEIYiBiUMWWyn5EhX4rB1X1pMwU2iBW/tZKzqXO6t1rXJMr9o8eA6ug+53SkcaPokppcjab+q+ZSQzG+yrS/YrRSqIGnMzDGlMeSKZcaqkR8le8rdSLPNmuuJMvRFBdnoYwaWUOUQaeI+KKYSrRdjVrl+aViWCA+U2iPGS0fhoH5fM7uuXOiy01xGZHMgBVqn1YyLItemBN4X4ZHKtFtT+SDKiMtX4yJ1ugx+uQ5kUEFKQpEzG78RtMn6EpYdxVORbc5gbatN5ZKRayCSkszt6nDPT2y4XS30jGKlk3NABaLBffu3ePm7bscHx/z2ONPcOXKFUAMW2yiMTvXp4jdFKmT0WAV0SZTrwMl6zSxQkrcCoqoEtypTqnYVTix723q9vLn32wwM4KX7+/SkIzvG2ukYVsuU/O4ZNl30lzGFTKY1yVtDa1uEwprqSrxB+/6gRA8g0tGOEMvDbaW9cWmZrLobjErR95RY5lzWvN1YczqXg7JpGzMbPC9P2EmFUbOyl3XrfbEdK6rkePxdDJZDaO1PuG4mxv18b6Zv9b3PQf+kOPDYzm+VrSqbdtKNEtTobUhG4mN15JN5shpQ/hT0c40SFitJeKWHlMUklaKqqqpqgZFxZ3b9/nLf/kv8+abR/w7/5t/lY8//ylwHpqJUoneLM1kZOXR/rAm96yjPGsuzx5njw1E8DRarHoPn/+dGszvtwEe//1AK3VOtzbPNM/aSu5Yt5zz1ve+xze//g0+9fwHefbpp4hBEBCJ2pCiQSVjhb7vSgzGKnB93Mh6ocluNLqS65fKw2xNnyafIekJ8QEfnUSOpCIuOk8YemkggyNEcCESYyeNVNIdZWOLbMoiG7MtE99SaKgNV0Rr0FFjjUXnzTl4VN0QkkNkGHrcMBB7hxt6sJ7l/AjnPNE7BhTBaKr8WojeL+dYBr0yUQkI1WzRLZlMJ/jBcXx8jLWWa49dJyh4+dsv8trrr3PlwkUubO9iUkMZkvV+HBWAqtJYL0iUGDCkib2t8KyKf601trY0TUNQgZ1zu9w72Oe333yD46M9bh0cUu/MOH/1Klu7u1y5+gh3Dg44PnZ87Zvf4Or1q0xmU/p+Wa4n0c4I9dAYKcY6hnX6ZvS4YcAPcg3NJlO2tmd87803+do3vspXvvIVtnZqnv/08zz7oQ/Qti0QaJpIYw3KSlFvazEVWQwOHwOmatCVxdQNKFMy1rQWyrVPhg1hcOl7ySa/nYC2MiRIRcyY4l1yVVkZnYypsFXVEOM8oeAm0fyiFDNFK5SRgFVMR9Zirt3DiXpXVRV10jXn2BxS3Mdqqq8KAjY+viuHY2nArE3n2MW1YlqnBjaMTKpU1OvonGJlJpSaz5iHQ6w7VHsX1k19cgOehylKSxbjCSfuWCIIMsXbWlt02jGotcZKKYOKCqV8eX+kWCEV13VONiOByqRmltJIDkMv5knpHPkYSyKSvA8p3kkDp2Jk4mTdsSpK4xl9kQfk2JATHGZyFikjOnzK3UsUd2OsGLzkpiAoaRh0WA3KiGgk29RYQTzFAdWPTHxWjaiOK+1uKbQ39rZVZMvDh6FKyTkOMUkgomaxWHJv74C79/c5PDxka2uLa9euSdOT7o/lconWIhlAp8ioOGKokHT/WmeGc2kiM2VbqShGnTHF5MRQ6KN60wQoDz3iaM9TSkzi4kpKsNlgumEo69Ym9T2EwPxgSe8GlouO5XJJN/QFBcxDjEDEVDVVMmnLr2NNjdZmlD06YDpp6GL0Mv8Tq3WJKfK+3CviEusFyUeQ7vG5HJs4rWejpkGqFUdm29QnaoVxM5mb1TzYyvRfrTUGRa3NieHs+JGPRZYK5D/SYAZcL41n7zzKO+aLJQeHh0yPj9nembGzsyPnW2XzpFiiQ0K6Nzf9KU5lZZ2GXFqL89nhVWjRpq6p24YYFIvlkl/8u7/Ez/+3n+On/tFP8TM/+7Nceer9HO3dZ6uZYEwl5u8PKc1UPPU2OnucNZdnj38YUMSHNm8/5Ns6jgoFsYPRv3ufPbLRlI2tyuIJJDMHsQeVN98cTKxXEQNpypk1XYaA7zrmB/e5feNN3nrjbf70P/aHOb87wypF73xxV4zeU9tqFcBtDC59X49yu+RwbaCuKqwm1ipV/1oT+uUq5Nxnq/8hvUfRVJoQ8M4xLBf4fkCHIEH03rFYzGXyHeJKbxRW5hFN04LxgiYl5NAoTUyba9GzptByowUNLfa3gxPNjDFEa6lrR6wdwTXgPLbSDIs5iyNH1y3wUVEZU8yPjLIJZRHzEIwmlNzEgLVG6K1KCYqSKLg7Ozt88NkP88V/8KvU2rAz2xIELgasEiRXB3G3NUYRg8LGwBAG6VwTSrDoFyhjMZVQ9bwfUN7STCdMJzW9dzxx4QIXrj/K3vyIF7/zGl/52jdofvu7XHvyfVx85Ar2u2/QHx3x9Re/xT/yk3+I6WwbpWu5tpL5iNY2NWBLFotFocAqpZhMJmLek6bk27s7GK04ns/55otf5+/9vV8lGvjH/vE/wnM/9lGmM4njCHGgqhVDGBjmc0xVS3RKECRMWUPTNNhaEOMQAoPryrVpK3A5fzI1QXVrmUwmUngkt1A5VsldcRTZIJpJU4qobhjwMVBVLcoL2uSQZiMmJ0I2Y4VS9m4IMKTG0hetb8RmdFRJHJAxRgYfKtnxj5CZdVOW9fUxCLQpOZsKTNUIVdlr+r7HO0F528pgrWHILs1aCeVt5NxIQjB1lCG+2kAlx0OZNVTEr0w9cmMSNwdtpZMbfS5Uognb5LKb8keTmZW41vq0dqgVYqgMRHci2F4u//QBUrNSVVVyUF7PqSNRubVO17E1yYHVC/0eV1gIKh2UMa03lmD1k267MVnuCh6nE704nmqqE53QFKONoKzoxPGpmYonz88odqGYkY1MycYo2IOMnKRJebAnAIgmsXcDEIspy+H8mIODg6T301y+fIVLFy8yDB3GiJnWwf4h2oySe1VMQ5JhdP0YrNKiyVcxafPjWqMUVRztvxTkftXd+PX3nYcvRZq7fu3mAVI6XMJetxaMYYjixL1YLDg+XtANPfuHh7JT+qQV1RpbiVwgsxmyNnSMKEu2sEGjSyOoVDKjUrJme+/LECCfUzW6l7KOOd+PJ7JiIbFGbBmeFPZDen2VfQC0xRhV6PhBCQpnbZ2uf5sciw0x040JMMRSQ6CCIM8qrP5trMQeqSk+DLghJJMt+UxHRwu6rksNp7AG5vPj4rLbtq2s1VZjTNaerqj+MfgUl7ai6fp0nIgnDY+yVpNkjlVpTVU3kPSXlalRVBzP59y+u8df+i//CntH8HP/1J/k2Q99FIaBrQuX1XyxjLaGJsbrAAEAAElEQVSqlbXt6Z1j0V7qtWFS4cOeAZi/d83lAw0Uvk+q4XuZU/l7kU/z+z0T54eeaaoefk2EYhuh176/uZnGuCpa1Ejbk2kkUkcYVOqaQghxDXFMjLHN0xkVa1RIFTn9fYx1JzmXMiMFkVJUxfCA4xDKNp4m47ogl4PrIWVPesQZVhEJ/QLtOtpa85VvfoVvfvlLPPnoFp/8xHMYrYhulcUVouQuhiAxJE1VM3S9ICFKpygPm6hhOuWxCS2rNI+DuAxG7dEMYsSjdcnOUtFjtaEy4LzHDR1xuZTJfYRWaUzViMEPDqLCGoMbnGRt9ZKDF+OquQzVomQB1nWdLOR1QTMZUWXT7prMdpIbo1YEL6YgxIg2GmsaYrBE55nVBtdUgoos5nRHcxbLBcsQqY3FRMukaWkmLWiN847gIrqyNLVQ4lzfoyJUaDGA8Z6Jqah2dvnU88/zxS98Add1PPfBDzEEyacUnY5GmRSPoqBqK6KeslwuU9ZYwE4qXNKOZuQyT+3ny56gwfU9zWyLCzvbfPrKozz3mc/y7Vde4Vd/47cYtKHd2mbrQuD2/iG/9ltf5Z/42f8e1aQRB1of8N7gtCB7y8US7wN1ZdCTmmU3oFP2mQ+B3d1dtranfPvFF/nVL/wDfvmXv8YjjzZ87BM/xrMf/hCXrlxMqG6kbVuc6xn6gJlIY6m1hr5HG5UKKnFhdF40Rs6vkIygA7VFqGKJvts2NdrIsMNYhfMxZS2qVGgpBj8Qo6BK2goaPHjR29qmRdmK4+MjDpZLgtJEY9F1JZmEMdOVQ4lPiEPEB1ljXIR+cITgMChmzZTgPLWxzCZTKpsKFBXx0eN7l6hzZi2LMhDBiGmUIH1WmAbJNMoYg2ksE9Ogu47j42P29g6o6yWT6RRTVymuTQpqawxVule7lJVpmwZ8LOhrAhSKm2cMirZt2d/fLyZRso4qTN1g0LiErMUQ0r0ZRuwJUoE5pa6moJOZTlm3AzEMaOVXaHCM5buSVmI2soGT+2pwBKcIylJZS6wbrNHsz+fs7Oywv7/PbDbDbOwv3g+pCZaiGVeSidLPSEOmgiIqLW7CGT0sSKwu7tBRmdRkp0iFkOi0KU5DzFKS43WMEpmjRPJZguwz8qgECRQtsKCXzjk04BKy7nona5StxWAqyL2g7XpGb6E4mmojfzPvIdKo9d4RlDy3qi1N0/L2jZvsHxwyOE/bTLl69aqgfxFC3+F9YKetcX7A+axPTc2urtY272GM4iu10qZmhgmeQEjQo2Y8SYgxYptmFS8yPpcpT7OyBh1W7AFjK2xVE3XEq56qNjjvOVg45kk7eXx8zPFSEEubjJ7aSUNV1yujnRBwMeKiKw28S9efNoaQqLCVNvikfe77HucF+Qzp/ZUczzS0MCM3YK00x4sldZ2dsbWQfVL+55AaZGtlbZxMJjRNQ1XJABgfqKuK4IYUYSMDLUKg0gpjtBj6IYPfQEKGUzOplLgZ62wQV4zJfKGIKmWIPuIZDYKIGCt72flqh2Xfl6ay8hUtE0GFl8fcuBmYTqec293F2kbQwmJQJV4G2VGWLLNJ2bIRMWwzlcWaujB0fEQae2vkPk4osreKbump64aDw33+/J//T/ji127w5/7X/3P+iT/5pzFb58BaaaHrWsVsspQlAnmgVUq0FW35LNvyQY/wjrDNwx/6gT3FGXJ59vg9a15/p41tie4IxRc9m0b8rrAgMlb6/S5bY2mK9140B5m+WEnoufKOAcesrTi8d4N7d27y8je/ymc/8iFmbYNRcDg/kolmNGili5GNbG4QEj0n5z+tx3RYlE2TXbVqnvPGHBFb+OK82UtR57XYswcnzahGNpkQktMgCosgd6iafhioVENjDK6ucUNXKE06BnwyNvB9L9NSY8okV6dwcXQqxiqLMiZlSmpBAmyNqSSHLtNunfepkB+wOjlxaoh1RVdVLI4sw2Ke2LoDfS8LZDYV0Dppypb9Gk1LhgerDE2C48qly3z0ox/llW99Gx3hQ88+g+s1sXfMuyXTpk4YtBfqmTUoK5EBQqH1oGWzz7uiR1BfVGSxHPDdEtUP1FtTJucvYK1m98JFLl+9xje/8wbuqGPSaA6OI7/2pS9y/fHH+Ozzn6FuGmIILBbHdEcdlRVN0EqbKGhR13W0bcv589foF0u++MUv8ku/9Hf5zS/f4umnKz7xyef51Gc/xfmLF1h0HVGBrQxhAFMZKjOlykHYwaW8NlXory4h6845QpQ8vrqusU1NiBKibdNwRY53XOWVRkELY3L2VSY5SwYkeJ1U6CiFbWqMreijp3eePniJh1GKoLQ0B2tU9EDwZoU+ZMv/RCnVSgtSHwTbwo/MY3J8jkkjp/jg9SwPw7zKmkmx39daGnCjLTHAfr/P3v4Bx/MFk60Zk8mEqrKY5GY59HI9Nikb0g/dKEMylOtH7P1FI5fvteChcwOtT8O4AC4MiUpJ0iqqtXUg00TLWG1EG18VJuIGW7xzRu6mfoSalvxYxhrR1KZ6jzaqIG99n4ym+gFTBYl+cI6oRSkpxWxcQ15NsWKRiIioIirotZV6VWAGsnGRDBdVaeQ3GSfrOsvEw/GBoHzK/EwOvHpVk41psBnpIqzrNZXSaGWSw7Q6MdA8Teu/XiCPpAzWoNNQ4O79exzNj1kue/re8cRjj7CzfY4maQtVRCQNzkEyFxujjRGfrp10fL1PRO7VcGCl7ZSIG6VOUiEzTbMfoepyT6lkBCe/i0t6RVsVSvngI8fLjsP5MYdHc+bdkvl8wXy5wAehlNeTlq3t7UK3D8DSRUIYileB5BXXZcAjVOkVBT26Qd6fW8+QFKMZ+TsM0jxpQ1qnhB6eP19TTyTiZLGgqizT6ZSqqkpGq4thDfnMsgDSdeT7rlBtx5pJdEDFMdrqc1cuuc6ICyxq5ZqcozjyNT4eduVoHVjpgPEBF4QVMJ1OqOuK6XQqTrWLY7quo0vOukPf0zSNMFES+moURD+kfOEx+q4LnV6l4Y0gu1bo+NZgrEVpi7UVfecwk4blsmf7kcc5vHOfv/E3f4H/4r/+PP/8n/0T/PQf/8c599gTiqAYhhArW6vKVPSufweimj4jxJ7RYs8eZw3n7+w5Rv+Omxvde9HEcoo77HsyN4qK2tQyMQ2BNqYNODh0BKvhzu2bvPTiN7l/95DnP/5xdra38UOH6weaxiY6zCqGQN6vLjRTn4o/NS5GKouqKglwVjpRBkeaw4QIeyd2+4OPBNfTeclqc84R3YAlSgSJ86iUBWiJVIn1ZmKewhqM0uIqq02ZogZlcK4XIyBicqFNBWVIuXImxbJE0bhIJp54GWrti3YuR6NoAGOoFPihl0KgrsFWVFaoXnNjCP1AP+8kA7Dv0NEnJ0CzslYf61FRGyiMILNPPfUUd27c5ObNm5zf3ebczi5V1qjByiIeiulDjGJ6Q4hYa9C2yu0OnijZlj6KPbvVDMbQecferZt879YNXnn1NW7fvUtVg1tCU1lmk55bt4554YXf5PqVqzz9/vcRvThx+pQtF71oZ0KUhq9pp2A0TVNx9+5dPv/5z/P3/t5/Rz/A889f4ePPf4wPPvdhHnviOotuzvxggakr6omY8ygVk9OgSRqpSIiJCqzgeDFPzFZLVWeKlZXrL0VnGGOoGqGMCZUyjlyVpVANKJwbUAjFLCoK2prv87ZpiCiO58tSFDUjTVM4xWTCxVDcFcf0VpOcYWMxdVpHbIorbEZKCKPG4WRmYS64xxmaAH1qGCezqdAzjTAF5vM5y+WS6XQiiIdq8Ckr09ZSUfVdL+61rKIGVs3JaFCUXi/rrfLP5Ry7tfeaflbHDc3z+A8xOcD6k8yVB7meFofLcfOahl9RhhSTyQRAWA7Os1wuaadbJd4oKIVFY23ODw2FNh3U+PxR2A0Zic1VaHaozVoxH8tCvP7+N4xRHsbcWWvQNlyvVVzPj1z7Pa3RRmWG4sm9YayJ3jD9ASMoq5Kmh6gIPnDz5m3m86UYdxHFTbqT/GFrJabJOU80Mb8IIekCV+ho9glIJk5xZTrjiKX5LAM5VEHt8mfL+sNhGErTqK3sAYGIHxxRmxRnoXDAkExmjuYL9vb22D88FtprQtyjVhhrMY3k/erKFl3jWNNqlWgVjRbabUYT8TJoNTr9n64xIaKbuG4mp5SwhxICPf48lR05nWrL0dGcu3fvcv/e/mqI4KWhnEwmxV22aZo1UyK5Xh0qRS4Vo6CNtWNl1nTSDAkosoB3YpSdoDPn6zTK9WPqGqgJoRWjH3G0EpbNMHDsepbLeaH35s/R1o2s9TqW8yxu2zrlaps8yim6bWVEJoG2DL1n6/IjuOMFTTNhfn+PX/0HX+Df/z/+RX78U8/yr/6P/zU+/slPg7Y5OinxvjSNbdaYZu9l9vnZ46y5PHv8AWws1xfNk0Dlu0VLfxQWorzRjMkJvu+IfqA2sJgfc+utt/jKb32JDzx1ncevP8qsbTm8c4vKKFTwgvJl18ecC0lMDKURpTShZsbWmKqGyoh7ZkIxjamIOtHElKAW7bSm8p7BWPre4ocB10sxJkkAAy5EfO9wQwfOo33ABI+JgUZbKgXWKIxK8SgJbVERoWeqCq8FJYpRldyuGAJDmsA6M8jmXFlphBNUYJLGNOt/VEpoyNoZnVwOnXeYRCmzk4ZJej2ljvBDdtBz0IMNdkVPXfarTT4XIFGaV6Uj/XKJ956P/tiP8Y2vf52XXnmFjz73HBe2d6WAd/3axpeNYbz30lyma6Cu60S5dfRRog2ChuXQUzdbaGu4d3TIS7/923z5my9xMIeLj7Q8fe1x7u/v0fc9k6mm6wO/8evfwA09f/Qf/SM88/T72draQk9alvMjvDKc255irVBhj5cLusWC3/zNb/JLv/Q5Xnttn0evNzz/qU/y5JOP88HnPoyPjnt7d/ExUrUNdXJ9rZqa6F0xnej7nr7vpaiNtdCifIq7SKit0UaGFsPAsuuwTU2tVhRokjlOzIVeRkmSqY7KcS0uFe860e+spaoqnA/lfWQjGozOE6cTqFS+P3QypRo7f1qjUFGV4Yi1lkpLUVXMmDddPh8g/Rg3mjkSRCnF4IYSHzSbzZhOp1LcHR8xn0vhurW1xfb2Nm3byu8NKtHSIkG7FXKnOKEpVDom+pkMM3ovulT0Su8X8WifEPuC7Pg1mnYgNZyxZKwkd9aNdfUh6O3mvzMtOYRApQU1yTEaY9MWpSIhJkW98tCUZ1l7Pq90QfAy/VUWVn/Ka8fSTJ92/jbP27jJztdhRjuVUae684ZEEcyN5lqUw1hruTEYODXP+RQdaEh6UZsak77vuXfvHs4JFVRMt2DZi6ZuNpkwaepiECM5u3KNBNaHJUK/FIQ9H8ugwEShe8egyh4h718ld3BdhhA+gLH1yhk1Cpqdo0K6oefu3n2c9wyDNJbDMLDsu5RH2TObzaiahraZUrXiKOwTIu+SVjC7uUp0TELHlGiFlQ8QgzgjG0VlLG3bCnMiDQbKwCub/ahYkMngVteOOoVCaNPQqa5rFosFy6WgmE3TsL2zTVPVVE1d1sjxvRBCwBBR0a8d+7G522ae5olIlhNDh5PX+Wa9Mb7ejbFrJkQ5bkXikUQzL1/T5TiNG1RlNNFkd/SEvKamsjjUp/sFbUEn9pGuQCna6Yzu4IhmtsPx8ZzfeuHL/Ed//s8z3YF/98/9ezz/mc+i2pmYAlqL1RbvHD6k+KIYfmRqubPHWXN59viHsLE8zYp90wH1Ya/5oKDjd8tpPc0R7Xd8PJJxTjZ+aCrJjgpuwMZAYw3379/n1Rdf5Dsvv8yf+bmf5dzWDN+L/rGyFd4ntE8lZ8QsQLIBSMWj0ShriEZc6sSZRKONobbS2GW9QqETaQvaYOuaKkaaZlLMbEj0UxWhnx/j3YBf9rh+Sew6Qt9BP4Ab8H1H5wb6zmEhZcAhug3npQhIRirRh9HUP66FOGezBnHTlEZMYZglc5mqqkSDlX7ep+fLVvAxKgYnaKkxlqatJPwdcP0gE9q+p3cd3g+0VjbX6HwyFpI/pCY+jmhpfd+zPZtx9epVfvs7r7K3t8e0amjrRqjJWpoUMZVZueUpp8T4aPQ9jJEsuaiIRnINnYrcuXeXb732Kq989w3mHVy7PuUDH/4QGM3O7gRrK3Z3d7l16w5f//pLfO1rL3Pz5tt88hOf4Pr161y7do1pK3qfRS/apfv373Ljxg1+7Utf5NVX97h4EX7iJz/E0+9/imeefZann3mKRbfkzv07LLo5k60Zu+d2MJWVItF7KiPXiQuB3on2UajLMgBorMUlk5yhd/TRlWxFAFPHNBSRayOk5kDn6Tbp/kCa8qh0odhGpJiUQsygtMH3Q6FVZvqWGhVUmwW8Su6xmnVn6PE6kwcCuQAlm7SoIJZbSc8npDNx2tTKJrZsvk7ElROtkoGMoGcm6XoHN5TXaWdTlNXUdcWdm7c42j9gWHbs7OywvTMTs6+M0PswWhtTcxdjYnjGdL0LWp6R0q5bErac6PyEyy5xQloT8GIqlZC8cRYjSS+adV1i6sUJ9GD8MCNX3tOK3hV1LxZdWm4uM40wF7QliD1Ipi2bjV9pulZMgaggjqBBlVVn5U37H2woGPNzx5VWPybNZlhvAoJbbyzHjcw4Imrt2GzQY7OmNfkLSGMu8tbk5AqLbsnx8TExRirbMJ3M0KYiRoUPHpfilHyUe1U8Y0Ix9aHoUkfrUda3K4U1OkWV5GOricHgiascRW0kAiSh5JldMEZzu66TodbQ89atWwyJCZMbG1NV2LpmNhW30uISqxRDWEVrxBAkCquYbaXmkOQkHiWWqLKWxtbUdUXbNCUTWqk0nDXrjV1wToYraoMN5NcR0pgGXrU1nN/dYTYRffNhOM5bbHlvOR93dKbRWiV09aQb/lrcBw+OognvMMgZr3ebTAqV173gCUmWU6JKhh4VA9NWkMq2bVda0XITKAYX0vUhIURx1Ibna1bblLWsU0aw0sQUC+Z9pOsc9UTzxvdu8H/+83+Bb3zrBv/3//j/wmf/8B9GbW8rPPgQxfQuOQBHH06dY52hl2fN5dnjrKF8103amIa2NmWW7yWZYXzoxO4HbQof1lR+P83pgz+bYdnPqYwUHbgeYxRNVMRuwZuvf4ev/OaX2Koqnn7iCWbTlm6xkM0q5qBwyiaYCxA9Mr5BpwLbVGhTCYJpZIE3VU0uxWTyKBEBOmnVynQ052xVTapoRLhVVZU0m70juKE0l2G5hF70gn55TD8/JiYHOjHJ6fBJs5npR2tufE6MTBRiHiQRHqtNMkQ5x/cT7WgymTCbzcomaFQ2mAhopTEagh0hFTqCM1TTVrSnCfUNvbju+gBKJ2ONCDoguXZR1C6B1TW4tbXF4f4BFy9eJHrHm2+8gUbxvsefKE3xmvZVrzZ6FzzRDdCLu2oEgoaQ6HJt23Jj/x5f//a3+dZ3bjJoeOqZyzz17DNcunJF0NP+AtevP85jjz3G9954i+vXr/L22zd45ZVX+NznfgVrYXu74cKFc7TtlPn8iL29PY6PB46O4MJF+OQnn+TZD36AD3/4w1x/4jpVXTNfHrN3eICpLFvtDtoaXPBoVVHVyfgjCMIkSMRAVApbWbnGtGGRaJ+2rgpaM0ZetDWlmCrGWlq0eZv3WTZYyZlt4+cTHeYKtQyJbqszknIq60GduqaY5GYZnSe4gAGskegAYhAzmuhQqDXK4wm0afT3mp5qY50aa7IyEqOU6DHPnz/PvXv32NvbE0qrCmJ0k2jmkZA0paPmKrmfUlyjNbausVbTD0sODw+ZTGdMpi1r2j2t8WpFB99EW3XwhfZGEIMbgn+gI/g7F3mrAVgIgbqumc1m7B8cyDXlXco5tNhKY0Mo4egk3WtGEsNmViS6aAEfNFQ8jcVywvDtFNQoIzwoLTrqsUHdOHIExDl55BxbjVChfK3zEMRp7RxsOBBHJciZT2Y4BwcHydzKY00s2ua6aQr9PLBy+8VFqtqujkmUzBEheIjOOVp5IZ/jpsKQWBf5OFdlGJiNZDrX0S0H+mHJwf4RQYk7aXY19dHhnGQ+qqZB+5q6AWMUdd1SVStzt+zePM5pDIrUVCqMVVRoGdRoYccYY7DaYoymsdJQTpuWurZUpsZY0ST7MOCjI/rMBPBrlPWV8XtIfgKjPNrUiGfDJlsZqmqGTWjjYtFxuH/A1taWrE02nKSwxgg+iiHSCLkcrxfjJnOzcRoj76fde2sI/Sk10MqZ14mHARCcoxsN57a2tsp1NKbTii5V41IUUlgzQsxxQ+KKba3F2LpoM+XyEimONpadixf44q99kT//F/8iX/7aK/zb/6t/k3/6T/9Z7GxbjBCNQaPwXuQ/xlqMFYfx5N9zok47azDPmsuzx1nD+X2jl6c1d+oUatF7gZiuXueHpLlMTU02efGuZ9pazOC48dYbvPClX+OVF7/B8x/7CI8+conWVPjkAmqsXRUhKbA8aKEmKZ00lFqJcLMymKZC1xW6rjG2BmtE45anmkkDgzZpYm3wcUShScYXKtchMYpuhoiyKmkuNNEY+brt0bUlVJbeWIblnDj04Dwm/W6MYveu0uRUjahyzonuVKbVq03fpyLcB8/x/hHHwEGi8Mx2ttna2ioUuxjFFTajsplGE4kE5WXqag1VK/oNr0WLGQbP4DyNreQQJaTCxyA6vYx0eU9b1Sgkq+/SpUvcunFDNEM7u0xnrdCzlCb40dRbif4rGzktuoj2gShjboLSBK24fe8OX3vpW3znzTvMzsHjTz/N0x/8AJevPkJVVUynNRqJdDHKs3tuxnMf+RDPPfccH/nIc9y6dZsbN25w+/Zt9o8OOFrMMUZz7uJ5Hn18yqULF7hy5RLve/oZHn/iOtPplGW/4PbdWxwvF7TTCZOtCbqydG7AhUCVEDetNd3RnGVyE/YxYKtKKNfp2vER6qpmmhp/ZcUkpJhqiBA4G8SjtQRqAwm5jkVzOQyDNOPRryhjgdJE+hDoeylcY0wDESVB3QLTJKq4IhWXvjS5K9piSG6iyPcHT2NXmYRyzkOJU/EbzeVq/RGlUY6SWMUsZPMd+ffQCzKnjRGEPPgS1eOcYzqdyrXuehbzI+7ccnTbS7a3t5k27YiGFoqLbyzySFUMk6bTKZPJhP2jYw4P95ltb1E3VYG/pEkNBbUiuTErWwmanou2KJMWpeMD1sLsqnnSEGdtSBcE/ffBF/qhrSxbs220vsVyuaRaNlR2jq0bqrotERYqemkspUKWIcHaAFCeu1BjR4OgXATnXNCT+8f6Gq/jKrMxNxxrSZla8i01qiB0md2RTVjK13ITUluUUeuQbz6+euUiHqOgQrmpyUZU2chFdJQ1y76j7x17B0coUxGcx0VQtmK6vcPO1kz0tSo9f7DpuA2EKFmfQ7reXLonUOJIPO+WqSGUz9YnlNG59O8+N9Xg/UDvPM71OBdw0TH0XqIzlMRZ1HUrmbhJe7fdtAyFgi3D1hAcy8HRp+ir7ECcz1OlNUbLMW+toU5ocFUZKlNT1YZa11ijqE3KhzQm5XOKlh2fYlfUyhzHpDXFJmaFCmIutcqCTuwgkgFeamhjasq1gklTE3e20MDx8TG+HwiVQzWCvClWNNcwQkY3tdn52lozAHpAE/WwRmpz4DWm5Mv95FMeqyDYwQ34oaMyiu3ZdmkqVfTEsKLseq+JToHJub5yZZq01xWNanbR1RpjKnTeh4n4GAlB8aVf/TX+X//vv8Qvff6r/Hv/u/8l//q/9W9hd3aEvZSGNFobgpcBgDYGUlZsTMZ4Z03lWXN59jh7vOcPpZQaQ5fvhYnP7957j8VAILqB0HdUE0sYOu689T2++cJvcnD7Np/4Ez/HtcuXIAbaqmb/8JDzu7vFVTNPtYseKOU1YhIdparRtkbXNbpu0NYSrcWjUXrlypoby7CZV4ZoDkWIX0kzGwyuC9KgZl1d2mZMBJLlv64jVXBoFYnWghugqlHRp8mvUO7kv5MWLFKm1U3SAOUC3xOF/ugd3XzB4fyY44ND7h0dcXR4yHx7m52dHdq2leK8imi90kGtaZ2iRqkguWgoMJZBLRmGBa7vZdIfIhiTnCVzUL0claaqOTw4oG1bhhT4/eRTT/H6a6/x3Te/xwc/+IGiSYph5ZTpcqOjFUMU99lISNQhof94DXcP93nz1h1MA5/5iR/n2Y98GNPUKbpGXDAvX77I8dGCYeg5f363XPsf+/hHuXPnDsPwIZaLnkU3BzR1bZlMZlSV4eKFC0wmDVXV0LuOO/duS8OkFZPZlKqtRHuV/m2TbjcQCakYXfYdXd9Jk57cfHMjfu7SpYJEZLv6jDSayiazjrhCcYxOkr5YsibrugY0y6UYlYir7AhxSe/PO0/v3Spf8CET/VDiHZJ2LdGoKU0Jovv1DmVqrAKbHJnzfZaLv8iDDcZO00GN7/2mrQk+lrBzm9xwC0XNeba2tlAEbt++zb179+j7nkqbUjiHkJq9Ea0xQ78que22KSrm4HheXCCl0AwrFGXjfZ6WwZgbH50ogdHFUfG93pzlIdE6qruKdFJR3CaVaXHOUTV10Xgth556OVA3rhybtfeRUMvxOVUjCm7EE6M+OWTc+HduwnOUwWZtuqm5XAusZxVNkVvOtVzRzFYYu6WO9JZxZPS12WCcyrzZ/IJWKKPFCMc5Ft1SDHac0BO1Ecq2V5ohOPp+SRgc/bBMxj5yr2QNY5eprMGn9V5+huL6qQpjI5shhUCJL3HOsezFSAujkx5+dc9HY/BGYY0waSQxUafIKxnWqCCGQeI6nZy5SRr9FAVSGWGrVEax1bY0VtaXtqqTi2k6ziiJuYkePzjc4FAxMSm0oTJp3QgU465y/v1qr5BhhBMqctpvfRp0Zvp5Hh4YLdFW+pwYjx3sH5WhqEGlpn7182tDgxhPXAtjNPMHHYyf5nystcZq0MrI8DY7racYlnY6YWdnh8Visa5Dt3ndVfjMAEAGXBp5vvxzxlhqY6V1D8n0x2RE1uNd5Eu//uv8f//qz/PX/+Yv87//9/9d/sy/+C+jbAMYpY3sx6KeNdhKXMK9C0nb++4+99nj92lz+U70xN/rC+DduMGdPd75+KlThOXvZlFc/c47n5NNetKomIjjydxpr3EaZW2zGlpN4FaPjFboByz+72R1vXotdaJg0Uaz7Ac0EaMVykfq2tIfHXB85yZf+uXP82u//Hl+5qd+gg898xRb0xY3XxCDZ2fnHIuuT/lWgh5mt1dlDFgrC7m1BGtE96dFS6m0laYzTRKDBIqIhmRDn6G03bgPcjCohJqbtkVFMRfBO9ASWRJ9mvLWtRTJOUtOJVRVeXwIhfoUCTLND6K/UygxGBplvSR7FylCJpoJDWprxm63zfH2FvsHBxweHrJ39w779+5jreX8+fNMtmbsbJ9jOp1iKpPMe2RaC8nx0Hn8ICjKdDplCIr5yKI+hJCMUVJBmYqsoe/FNMgHalsRo2cymbBz7hxvvP465y+e4/q1R1OEiaeqa7quKyYbWEXdyNd0bYiVJRpNNWm4t3ePb7/6ErqG5z7yQT703AeZ7W4RlaJqaoahZ3tri+WwRFnFEDqWh0vJZEPTdQt2z+8k11DR1xldYaoU7aJX+Pmim3O8OJIGua5p6haTTHtsVUFyfxVn14bBO+bLOfuHB8l11FDVjbjeakMzmdBOp8So2DvYYzabsb27Teh7Qe1qi+s6bFUJ5S77xJTQcznPUcswoU/mHaYSQ44YI/P5kqpuyrWZY3NCkNxUnTRCYdxEJJdNlT6Lx+GdYxh6cc3M6AXiuBzTfTBtJ1RGTJCMEm3Z8XxeqJfFrCN1dTF9DmvMKIpCGtici6uTCYrS0lSOKZUGha0bvBXd2mQy4eLFi1TaMJ/PuXVL0L2dnR2m0ymNbRLaItTkSCDEgDV1MXi5cOEcvXfc3zvg/v37gvRPWupGkB3JzNMlEsSHQJPef3HiBDRGjifCnmCUjamSC/Tm+j6m74+/Z61FE4ohVNu2XLhwgVt37tF1HU3KINyebdE0jaDSwa/WXa3RURUX2NzoxYS0Sc5lWCHIrPLwjEmZLGOn4Iygy8ZSmimdNZVqvVlUSu598XiOKZrJFXMaq00xnqpqO8pDVGsmKptGKz43j+kYoUxCDEWznKm1PioGH3jrxk0W/cDgAnUzYdpOicmE7M79e3TzBUfHByyO55J56rzoN9FrRlBAivsRNN2k5sBoja0r6nw9ALUyOLeirWpbM2kq5vM5g3fUdUXTzNa1o9asHI19AOex2cirF+ZOCEG0iETaSgxn6qpKURjp76SJb6uqXD9Z8Sd7dSCGSNcN4lKuNdpq/OCSg3iOhIoolaNxhGqhRu6twYu7so6J4jzSJo7v1xLFkfLAJOsxSjyWH3Cup6qMkJKjKPgV6tT6IdcweR3bRP/XaNgbeeCnDUbytZpdyrNLtLVG9i1j6ZxnuVjivKOdiF/A0PWjeyqxOdIagdZUWqOt7AsiaRF0UhzXrexTKcezaVp6N9A0Dcvlkps3b/G1r3+L/+Iv/Ty/+sWv8L/99/8c/8K//C9x7vIjMJmomHJCTTIlFNU9pW7Kh02NXIrP6vcfCnDzA7H1lFJnyOXZ4w/2jeND2JiIrzeR403/h9GY72xNOTzcZ36wz6WdLaJbooPj9Vde4u/+rb/B+x69ysc//EEeuXiBGHzSlnmW3YC1VQpfjkKNS1S2kKZ6MVFUMi0wJEfFQhOMSMi8Gi0ipanUpTA//ZFzGbM7YNkZUcYSjcQHOL8QEqC2RFthUETtQGmM1zjXr+JRkrlRGBzOu2JWkmmI4/gEnZCZqqqYTadMJxPOnTvHfD7n8PCQo0NBaO7cuo25f5/7k/ts7+6yu7vLdDqVRjA1YN1ygBiptVCnuuUSFSM758+xODha00xlQ6SYvma0EirQyhZDTFnalrptuX+wz+7uLpNJQ9CKxdBLDl23lJgYDRd3L9IEz9FygQfqaUMXPTfv3+aw77h87QpPv//9nLt4XhBBPOKjY/DRiX1CondJYSLvxfuB+fI41eBCG9ONAQXO9fRRkGJlVEIrwVTSUFZtQ9XUSWebaHwgutAYcf3A0PWl6bZGfq9pW6pmkj5/w423b/H1b3ydqqp4/uMf4/yFC/h+SfQe27aE4BmPdOK4AUjDnUKhHZm8ZORv7KhYMlmDUFuzHf7a4GvzKta6RFnEkUtxIKJDkIidOmmBgyc6j1Mp1Hxw6EqvFYSbG3LR36nVz3m/in5QYeVwvGa2wQq5yIXudDol29T2fc/+/j79Rv6cNqCtLQ6Vcv84rGkEiegH9g8PmB8dcng44eKFHaE042iahiEM7O/vA6IlPrXA2KDyvVMxt+nKuqkbk8aA0jTl6Ia6rte1dqPGW8TJQdgWZAdWJSa2ITmFPqSw1KhESx8NEh9Q7K8PNjfQkSg5kJFYhlZ5rdjUTp6mu91sBNgw9Mm5vUpJY2uq7PLqWHQdyljuH+yzd3hAiJF2OsHHwBA8827JG2+9mXJOPcPQ4wZHVBFtZcgXyfp8WfuiTnEZI9Q6r2zRmOL4Ku/Ri3mXEiA5pEzHdjqhNeJ+PF8uCt00HzOXEF1xWRXvgBCkPbfGYmpFWzdUtWF3a1sGWsZS1aY01SbTnf2AikoiR8ZrSEyD45D1tX7NsXs11A5r7InNazMPALwP5dyO94P8e2M/gEwJres6sS5W68B4CK6URPoQ3x3wcpp51TvVF2VP3VifcpNptWEYZBCSXW/zurH5O2vIevr68fGxUO6bNtUEKdYMkRocHh5y7sojHNzbZ+eRq8z3D/jWS9/m61/7Jv/Xv/AXOX/pcf6D//A/4L//P/gzzM6fh7pRoNg7OIw7O+fVOwRZnj3+ICOXZ49/eCYTPwzk90cJXX0vPvN7+nmDFOmVEjqgJRCV597Nt/nc3/hvefO1N/hTP/fTfPwjH+HSxfMc3LtHrQ1eWwbf00xqwjBQRFbJGRZtiVoRkoOmZPRZlKokTF5rxGfPJqqnLrEAMRnW6AQZamPXm0mtiWEU3DxyqCSQXlc+D1GLE62xYCsIgcGnIt2rFAad7OuTe57VlqCtaG18gBDwiOnNGq3Vr7t55s28MkJL2tlaSqTD/pG4KKaC+mjvPjvndtnZ2ZEC1lo6NeAGR9ARgzhnipYE6rZm6Ht8L66HhOyJJ82HiqsN3/tATNb2zaSlnU64eesW0+mURx65DAoWfcei7/BEmkmLtooBz+HymIXr2Tp3jmZ7wr3bt3jj1tuYxvLE+9/H+97/PqazlmXXSeNEJGppKLXRaA1enJwkpzNGvAtFv4f2oCtMsChvCCHinNB4dRStU1WJy2vdtrTTNuVYynWVHV5N0r74fqDrupJR2TYT6nZC3U5ppxNs3UrI+HQq6EqitFJZohPXx1pXqFh8WtfwfZWcGgq1EnF1NEr0eYG4MZ3XOJe0uN5jrUkGJuOOQp1wZsz0zhPGP6lwbJqG6XRK20pGp3Oe4HzKYXUw6JPNqlLCKFAqxd0olE6aJeeI3ssxzQ6s2fmVUSxFEvpZZVPkR0KwCPS+p3Mdx8tjFotFoaFZa4l6lRta1zWz7V2igtnWDltNw7ntHQ7OnePunfu8/eZbtE3F1taUra0tohKdXNVWmITAhoKWrJqrIFzAlWttXC0BqI1CNJ7kdzyokM+fIzeWtq5YLBYl5iFTHWPWXHovxXmis1ZG4YNJtE7RwamgCwqZm/aYPg9x9b50/P72yzXdJYKMRueLS2pGqAMJtYwrGvO4uckxEFlHWSi1GcEM0kTH6KX5tg3KGomECo67d+9w994e/eCZzLaYtFPm3ZK+dwSl6eUJxPwmoYClwdeKqOxKm0yQYeMoW9N5jw8jD9AgbrP5WnduKQMnLZivMgYVZAg4n89LM5j17zJY8cXJu9UGy4pqXBlL01TMJlOatiqNTqUNxoiz85h2LAZjYeWem8/T6MTK0G1FoZd2Wa3ydNfO6DrDKa9DIbjiUjtuFHVi9kTi2uBIpazNpslu0B0h1nI/k87nSHryINTxQajku2GSbaKXD6JeZ5q83HsTWTczTdjI9RpL5IxcpzrdQ1evXCtGZM550WNbg61aJnWFbSZ0xz31dIuXX3yJb730Mr/wuV/kr/6VX+Wf/bN/jD/5z/wL/OP/xJ8EW4MxKoaI0oad7V21GpPqsUfxBhHsDJk8ay7PHmePH+Hm+rSiYW2xflCTqd7d88fIqVPr5dEhWgXOTSb4/pjKO772W7/BL/3C3+KDz1zn4x95jisXzov7WhDjHFtXGF+DtawC95IJj5JmTlXi+BqNFYqsraCq5GvKiHGC0tKIjGvq7PY9yq0ryINSqbEcGWfkXLkQEu1PuGMxUVhV3YhOMxWnKuQpr0EHA1FjcoRKFPKLoBiiuwzOY73HW4v3g9BmiVKoEwnLUCJFTIpWqaqKtpKJ8bntc3Rdx+HhIff39zk6OOTo6Ij7k3u0k5pHLl+mbVvaSYVbdhJqjzTJ3dBTVRYTAiZN/8fB5kopSIHZCgkBD3hMQl8mkwlvvfU9bty+RTMVdOloMadLsRO6rlC15njo6HVk68I5Zru77B0d8p03v8uNO/d48pknePSxazTTBud6tAGrtWiSVEDbbDSTJ81CaYtRMagBa2clU1MQj4EQBskTDY6qMpLfqaGyNaauqBsp7HPgNVIOlYLEOYcfBFmu2prJdMZ0uiWfOzWYaEOIgUtXrvCJ5z+J8wOz7V2Cdyht5TM4h9KmoBjrhdHqOsvoVUY/nHMFbS8oT3Ktzfq8bApUiiqjMmNtdU/qhIprtWbYkzV4MQTaZsLWZEpT1Vil0/0hDbfW7UpTGAQBCV60gGKcmV7TiFbTx4Af3FrsTgzxVFRiM5A+ox/5fWat5TD4olcOaRDjnEuaXEt9cERVVeztHdDcuUMzm7GztY0fArfv3uKNN17n+vXrxQCrxH749HpqXbMliE3StAaXKLE8FG15mMwhu7aGEFFJI6nsSpM4DAOHh4dM24nQ2q0l+AHTRWEQDE4a9dwwpmyOjApHo06gQTohn+FhyOtD8kqL5nKjcPfel/gNiapZmcvZFAdT4mzGM8YQRhrgsIobSc2LMmJgQ/ozDANHR0ccHB3y5o2beAWTbTExq6oar0FpRz1pS/OqI+K062XglDevpfOp1ZK13DlPiI7g5eetqQnRCa0+RIIHHwYUJm05hkpRzNmslv1kOTicW1Ilw7cQkywfTW0VurJoFdmuW2otqGRd1zRp/bbWUllD3w0onSTEPiTAOiRDKC/3JBn9P9lACUU64mLSbLIRWwOnah439/01au/o3Bsjza9npZseP/JgpO97nHPU9co4Sxs4RcVzYi14ULO42YRu3ltj2vVpiKzWZsX28L6glhl1zHE0cXTNb0zS2N8/FERdVzTNRH5fGZSqiMriPRwte776tW/w+V/9B/yV/+q/4eLly/zf/uL/gR//iT/Ckx/9JKDVsOhi1UxQRLplF5t2qhbz4zidbp34cFGtztlZb3nWXJ49zh6/p6jlaQXOaXStd8zF/D4fJYZio4nNlCqjFXHoIIjV/p23v8cv/q2/Tnd8zGf+sT/Cc8++n+h7FnOfcv4UxlgmxkhAvbZiSBITaqUNylZoa1G2IhoDtkJXjXzdVChTieYy0VHXDDeSqUFM4fTRd5AyHsXQIWnKVEIuY3KaC6Ivid6LCUoMKALKaml8Q4VuIyTtjg5p4r+cy3M4T/CO6FKhFcT+3VY1yjh0sJhQoRKtihAYwpAQTjHdiUoRPDgCPubpuGHaNrR1xWw2YX9fKGRHh/sc3HMs9g+4cuUKl85fSEVnZMj5fVbcQEkxMUNqHkI2REiuoiojIyGW/DxrLZPJBFNZ7u7dZ7YzY2tri+VyKY0wii44vFfYScVWu4Mj8vrNN3n5O6/y2hvfhQqeeN+TnLt4AWMULgyik4yR4F3RL6GFMyeOo4KaxSDIQ0YMSn6Z9/gwSK6BCpKPmk1skuOirQQJjTpiraAQJO1rCNIgkfRAlRWErGqERmuqGioLKPwQ0VXFo08+Ad7Rdwu6rku6M0MYOSGqcY7fqrYvLsKZtqX1apBgq7Y01JBpk6rokGO2hk3usBEkFgFKDMnghoLE5DxBkzS04vophav3nqXr8a4Xt1qTTIlSkxcj9EEabtGQOqJWWGWLe6zznugHCAGNSXTvFRog+st0LPL7C04KO6Vwvacbeno3oK2hMS3t1BQdckY2s+snwOAjXddxcHSM857J1ha7587RWMuFc+dZdMfcvn2LGCPXrl2jmUxYHB8zRHFvJawGSZJruXrPWVd9giq6kSX6UMZMlPN3WvHuvWRfdl3HfD4HoKoN3UKQwbqtCF4QvWwcI2ZbUXTga7q2RJUdYSAqxBPN5Ob706iCguXmJDcouXlRST/oBzFDCSlDUiXpQda7CYonKGs+LkNqSEpzmQpnnYzVrK1Kpu8QBA3cPzzg7p373NvfIxpFuzWjaVqUMQRtqNsppooYa2W9UUFowNELWp6xNp0QabHoJkSf7hWhqsfg8bEXhB4t17aPMuRDaMjGVAyIe6z3A209ka8T0QqG42MGFaT5SEZik7aVyBGt2JnNqLRZIbq56fOOfkh7Twh4NoxuUhRJnogmlerqfGpVEMkY41rMUUGINxpL2d+SjtFnOnum7Ip7ukaXRktrjQviwGtT15OppDGtY6ayxCW4oaPvlzRNVd5HQJ3qpnzaYObEEHxjGH7a7+bBxdhAaqzxNcZweHSId0HYTWZFZw1JUqMQt22t7cmcHqWFqlwLJXYIHk1NO5nRLXv29g/5jd/8Cv/gS1/ii1/6Dd6+dZt/5V/7n/LP/Qv/Ijvndtm9dp1u3tFMt6i2ttWKISWTwa3ptjq5fuRaKq4zqs4eZ83l2ePs8aOEWI4bvxyG/U6ay99plMp42o13TCpLrRXRe/7+5z73/2fvT4NtS8/7Puz3Dmvawxnu2HM3Gmw0pkZjIAiSIGiKICVRkh0pkqVYcjmOHVuOYyWOXB5STiqx5fIn26nKUJVKyiXHsi3RHEGaokxBJAgQAzE3gMbQjQbQ853PtKe11jvkw/Outdfe59wGQIA0SJ1dddngHc7ZZ+01PP/nP/E7H/wn/OiTb+Qtj7+Be65e5uTggOhaynKEcx6lLXlmWC5rQse2kMztWS5b4UyYTZsX4nW0BTovUFkuElU16Bfc6HLz64cwnecrnHkTH/qvhLkRmaxKYAeVQZQCZAlHkW7N6L0wnaGVkmmAzEgAkQm9JFZqGRLLaYIEPyChQ9K7ZwmZsFW+aQleZH3ee3SSg1ZF0fuKxtWIMi+kS+/gkPl8zvz4mBdO5tyZ3OTy5cvsTKfCQjQCOrxLASVdybz3MniEiEdKuqMfxLsnL1jnPaomY169fo07hwdSB6MUeVWCD5Lg6APNbMnhK8d886UXuHVwyKKBbKR49NFHuHjlIqNJhc0NOC/HxDVooMxLXN+h2XkP0+dmQKcUxyyT2pAQZUvdNEoGYUgsRSSoHKOEZeuK03XvN/LCXChFcA6fQnOyJPPDpGHLShKx+HkVxoBLoDB6j/PyWXYBN31i5l0YpGFoSvc+hsydSQuWLlnWxXVFiNZa5N0peXf778TUk9o4kSh3fXpGp67XEHrPr9YSBFI3S7xrcK4hIv7nTJtTQWJd76JG45FzPaShTSoh1Jr5C0YAxVb4Rt+D6lxiE9nwm3Zyw9Fo0nexynGL66h/7/FRSfdnCqdqWsetmzexJqeocvIsY9UsuX79Gt57rl6+J8mAk1erScNySsmMPYPt03m3BpfbFQlndX+exaAoDcav7zfCtgnzPRqNWK1Wwv4sV/jMiiw5erxNgW5JNdHVqlgtS5+gQn8/GzLhfYLrYDq/G8hki7na/jlJ5+XQG3rWuTxM3t2urdlkRBO41qYHO01dczJfMpvNWKyEBWsbj7aG8e4OusjwLuDahjyX5R1tkoxaI5Jx3+KdF6AYItqoDU+99FemnyElmepIv9SxyYtpldgYTGJiVQdcbETritxmNE3DbDGTczUpO2wBeVkwyXOmIwlnyrSmyNcyUe8aVFCS9JsUMpK5E9cbJ9XJ2Ek9wfE1wdW2Yigm4DeURKutZ3L3XBO/qzvVDTn85dvmTGaxk+13n3snHW3bNrF7oZfSxruw5HErrOcsv+VZzOVZEtth6uzQS1rXtXTq5kWvhpBlWwqZSvf2uA1ktQDPRePYKTLyvETHgNE5dw7mfPLTn+H3PvoxPvWZp3jmGy/xz/+1v8xf/et/ncfe8EbGeztkkx1WswXlRHyVkcjtm7fjpctXVVGWst1OC6DOjx7PWcpzcHn++uPH7J3/jH84X2v9wAqnhgt8wLU11WgKSvHlL32RD/zKL6M8/OgP/zCPv/5ReZir9QPCWBk4HAps1nv+JB3TovNCEhwzS9CKvCgI1mKyArIcbAHa9oVt3oetgS8NtsmEZPIi/UGW/mtTl15ii3wrQNF6QhAGUQWDjpmk9tUanKR+Rq0JtDQh0DY1vmmxQfrXdOyC9iQNzmgNwRDbJIWNGqPXA2BXF6FjhvYQlEshNinwB72R5uiDB60wWjEeVRTG0OxMOakqbt26xc0bNySR9OpVxuOxgOaUKGsS39ENviHEntmymcK7JM3TIj/rYuaLomA6nfL8iy8wXy3Z8R6T5xhrWdRzFqsZh6sTbp7c4fqNO9w5gf3LhkcevEIxrrj/oQfZ2d3tH/rOObxrMSpSZJbcir+29kIrGmshCCAxQJaJ79UYk5JhM4zSGAWtVrgggTcxurQRTl1zOnUfRhIj4dFRKm6iD7imJfrYy5D7igVrpROxAxvGAp7WNbRNnd5TRgwO5wWcBbUpAe164Po9dQi9D6/vCkzAUoBattGL2oNLY/BqLe8S+27ogWQHLr33uFRCH6LEE2ptxFM0GKKNMfguQTJoWiepyE272mC2hnUTMS1lhuC4e3+EKAwXXdqhdO2plJwZzTqoRqTBMphiNOV4lHr9MspiJO9jtWI+n6M1kh6bUpgB2rKExA6t6oaD4yOWC5GAY1UqfV/y/PPPc3R0wv3338/ezv7GUBq2h9l0PFXPDvZ3vPTnr50YbjowfQYo6AZy53zqUmzwrePmzZvE4MisJtOGuq7JiozgQi9DtbpjgeUc1okd6t6niiolYydgZfS3vX93/rMNkJl+rk6K3ckepU6IjXv99sJkE6jGPr22S+ht2xaXZNOrpmW5XHJ0Mhf2VhmqqmK8M2InswStaaMsqvqE0xhpvcNFSeMW6aOnbRpaV0OIKXRG09R1Yv3FV9gFJpnUuzqqCowxVHnywSaGsbMfZEUpyaHJ864i3Lp1C79cMVuuKKyku04nE3Z3d9kZT3r/siyrmiSzVunzMnIPMnrAUKUU3/5escmed2mmIuEMm+edNumzSiCajrFMkmw/WOx053KU0DRZ0IR+aSgBYUn0MagT2VjOpuWqTjYFYzTGyL+rXUPuGpTVfThdDOt7xBD03c2D+Z2Ay+HvD5dzQ3Dsvafupbp5n2LsI+lYGmKyzazbXVXfS6yi9FlPd3bQ2tK6yM07d/jCF7/Ch373w3zoI7/HN1+q+bk/86P8e//n/yvv/rEfZ/fiJSgrkbKTqXwyJaLxgEFz6fJl+XS9Fy1KSiFXKddB7AjdkiAdt/MR/hxcnr/OXz+IwPKUH+FuAHHw52shXv/YG/jL46n0t26QHbKkBEcIXvrzDLCY8fEP/w5f+cIX+dEn38AjD9zL1auXqWez9YOYSDQWHyI+RAlSCEGkrnmGzXNsLsykVI8YyEUuFbMMlaVC9EFHlNH5YGMf1oOZ1ikswwwOlkk/a3dTN2gVEYMWnZZWbitxLbfEZZA5KAtoG/JVTp0taJeKdnFCaJ0UOTuRIWqlsAqyFIoQg0d5SeyLKfykGy5CCkwpigKymIZ28QQ652hXNXkmAIG0ie8+h1FZUV7OGRUlr1y/xsHBAbPZjCtXrnDx4kXKLKcNTWJtpGRbWUuI4EKLj442gGsblDUYZUXi6+k3v+PJDtFYmqipk2yqaWpuHR1yODvgm69cZ+FgNIUn3vEg73jXOynGI158+SW01VSjgqACq9VCOseCZzquyIqSqAzWZjRhzbLHNEyHVEmTZUXaRqe0W6PROsNog4pOzikvgT0SRmOSpLTzkYUNv2McRPHrFBwTTUbQJjHiNlUzJPdscNgkuYrJ94TWSVosDLf8vtm4+voURu97MDm8lr33uKalrIo1E5UK13U3ZBNoXCMStaASfFvLPNEQXdwAEB5FrlMapTF4n+S4VlGWJdYoQqhoXY1VmvnJbOPf94A1MYxdrUdXMq8xspQPVn42Y04xfCADapfeKGyzo2kcVlmyUcFkNMLmucjEnaNeLlmtVhijmEwmVFVFjJH5fI5RUZYrWPb3drl04SIn8xl3jg6ZLWbMV0vaRsDriycn3Lx5k4ceeJCHHnpEris3KCrvB/GOWUj3vJ5d2bxffrt7blJ5E/GooFG2Y0bkKywWC1arlQzBtyxGBy7s72MKg28brDX40BJcWowMJID9dbBxTsUUtBNESi4VfKcAYEhvwcfQ15GcBS59aGldi/Ot2AFClGVZio3xwct53rFzGPEwRhHpBrp+0nVP5GK5kp+7cSyXy14+qWxGNR4xGo3RxuBioE7hVtpmZAn8LRaLvnN3OZvTtjX1asVqtcA14vcusgxrpetRpXuFMRmFlaRrka5acltI8E5WStq0FqbRGoPNCjxrMFRmOd57jrUiU1AYzaQsmEwmXNjfZ2dnR0BMd49KKbgqSde7LuNhkmsXmKPiaXDeydHPUgX1/02XuklBRYHk709fM0SBNp0fO3K253GdnCt/yyeFk7U23UPlPOlSiofgr3t+d/eF2IVhue79x9N+Rr59V2NIS5q7XV99ndNg9ugWN23bsmqadO4YSUFXqq9i6VKYT/fHdsdDap3KouIrX3uOz33uKT76sY/zmx/8JLMafuonn+Q//c/+LX7qp3+GYm+fZrWCcqKiczGaXDnno7G5WrmW3ObMF8s4GY1V/1lG0Fl2tim1v3Ocv/7YgcuzjMRnyUPO+vPX+lo/yPLI7xaoDItl/yS/vv3xCf3GWo6JPrVZ2zh2UW9IjzqvxHYP5HcKDpNbpXsHdB6LYQkxCYxsDghsMAPre1ZKk4vrNMHNpEOR1YT0X7QUwUtfmvgE+2EmpcE1riGzBTbL0CpitXipFI7xuAQDT33mY/w//4v/nMsjxU/88JO858knaGcn+DQkoI14/lQQT5s28tOmPzNFha1KlM1oI3iliMZiyhIznkCWCfDyKQimS6tMW/8eXLqGdjFnPpuxXC6ZH59Q1zWzkzmrRZ22sVl6YDkiDnTEJmakCyoYlxWjUcl0MunDOJTN5OAUhiKfUuxNYT5GjJKOdr5gPpvRrmp5pujAfH5CbixZKt7WJIkeIsVVsRvmNMpKkIoKCp0ZrM1xdUPrHN43WCvdXmhD27bUTY3RwgQ9+vAjzC5e4tq1a7zy4kvMjg659+o97O/uClBtBJRabciTlKsNkZVboY3C4NKwpFBB4uUVkGUlebXDrZMFuxhiWfHqreu8cu1lbt45AQOPP3GFd73z3Tz4yMPEGDmenfDQww9gsgwILGcnLOoV3ntGRQkml1/WEqKS0I0Q8E78U1mRo5TBBZE5qzQIdImUWluK0qSlfvI0prL03rOoFN7JBtna5BOKHmVAW4VvA2QalVtsOSIrKymtD7LRDgn8mShMaJFnvZQyKvGzhtSvoDuT7zDuMSWRWtV1Fnbyx46JSoMT0o03X0hQU13XlFbSDptUc4MCrEmdaWtmIyiN1YpMKeoEYEprMCi8a1EukE+ydaddDAQXUDFglbCTXV1H7OWFwjw1K+nlrJcrUQkHBIC4gM4MpoLCVigbcK3vB9WoIo1vsCoXtrR1tHUjoAAjg/9oRJ5lhBhp6iXWavEUVyXee5bzBSpKlYjVRsJ9YsR5x+z4CGtzRmXJ7oMP0jrHjdu3uHbjOsftsVSVLO/wTd9yeHzEww8/zHQsYJXOV0gXUG3QeExUxI6tM/Tnij9195Qe0G54lAlE7kM6tSO1bctisWA+n4uHS2v2L+1LuE/d8MJLL3JwcMA9V69w6dIl2raWQK8ocm4PAugQv1uTemh7FrZ7XsWIUrpP9wysKxZ6BlopXCOLI92FxVjpR9QJDDb1Uhgo76Wv2Ghh/hNwUQQJ4crk/tSFbrpumRFguWo4OZmJTH+1pHVJvo2Wntm8pCwKTPLcL0Ja3GmNyYvU6SjhTqtVIz26yzlt3UhdUlKG5GisEsZyXJTCgI5y8twyKkYURdYvckyS6GbaCvhBrk8Vpb4l+kD0S+mpTSoG7RxHBwcc3byJWy0pjObSxX0uXLjAzmTaeyk7b3jrPSEtvbqFlbXSBWq0PCt8Wh524GadEm1SJ+0a9ERiygxIYXJa43yzDmciBQOxTgfOrMXFSByE8aiuIijEvkpkE8wEUCnEzTl8t/BUBp2URYT1nGyMJUt9p75pCbnDZlnfkRtQ+Bjxzm2C2rQo21h8xzX4M2l+ioO/0M1Cqq8jk/u/7ZjgtGDtlnbFqAKjcDFgtEHbzXT4LsF5VUsHbdN6qrLCoyiLEc8//zJ//+//9/yXf+8f8dgPXeIv/uU/z1/9F/4GP/ye92LLEdFYXFDocqp8UGhbSHKDoNO+n3dcTdZ24PVNZMPnKXJm9ccCV/xxIV3unlh8un+++7vfaR7JOXP5PYCufxokpX/cZazrr3cX8Er8rj7r9QY/yWOUhAmEqKVAuwfc6WGsM/JcHiC1a8kUKJNS3GKgLAua2zf51V/+BYoM3vjYo7z9ySfQOtIEeQhomwmIRPX+RW0NxuaoqMjzUh7yUVL6sJbRZAd296Cp5S01jTx4tezL21VLqFuYLTi4eYsXX3yBV199lVs3rvHKKy/x0gsvcuvmdZbLJSpEXBNoGogukZrp52+dHAuroaigyLo6AZFD7e3tUVUVezs77O/vc/HiRS5evMj+/j6TcsSFSUVVlFRlRTaq2LWWtmnEq4MiWy6ELW7FL9hXMoRI6z3TyQS8JDRGvw5moevOyzJCMKnI2iUPkTw080z8QV2wR1VVXLp0CWstzWrJ9VdfBeepqorC2nWyntZoLTUVi3qRAiciRkRd0psYAiooTJYxme6yWp5wtFpxu13w9Ree5+B4wXgMb3nL63niyTfz+OOPA3Dnzh2Ugel4TFYW1E1D7ULv6fKFwqWCaeUDURnxyCRJFrApNU0Dikox/v3xMVrYighK+16WN2QAhj6xITM3LOVWqaZEpQAptE0s9pphEJVtJ22LqQ4iTdmh83MOvc7+DFni+jo+zWD4VFpfr8e/LllVG7xOgT5dCmeq2+kkdF0SbgcYbVREHdAW8txiknRUZJXib1SD5eK23zLLRH6c5zkxBQ35Rpit2ju8d8x8YNmsGE2nEt1vTarHUMkju64DaJoG72XQzWwuO6DWY2znTxRvV1mWG+8lRgnEkeohSV6t6xbf1tTR07Y1eVlxYXePUSGdrNdv3OTWwR2W80Xvybpy5Qr33XMv09EYY2QxQ0gyfTQkX1q3kOvSM6VCJvZBOOmGm46/xiBDvUoe2mXbcnh0wp07d5ivlkQFOzs7ffm7c47losX7I2HArOHixX2MssJMKTnPpKIigHNkWTHoRw1bTNTpyofh+RNYV4VsM9NSKN8mybATdYVSaKV7ny9Rp3/jcSGgoyN4TdNKjU/jWq7fPKB16fwNHqUMtsgYZUWqdCiSdF3RBN8Hqykl6oNVui82yxV1vcS3Tha2QdixnVFFmeUUeZ5Y4ohVmqqqKKuc3EqAV25sn0pMko1KlY7b6LrsBJIxCmMaWpHhY2RZVK8WNPUSRaAsSkZVgTVKno2KVGnjE26ImCRPlv3sOnis89ydlXb6WmQHg2Kjvkf2jGe5GnzODDp0t7/m0Lu5zZpJtYlGn+GhZcAWdssK55wsRDfmEP2aoTzfFkRtMfOnPM1bM1Xcktwaa7vKa3yQZ24n69dazommbplMJjStpyxlgR2Sj/tDv/Nh/sHP/yN+4kffxL/yr/9N3v9nfo7y6n0QFW3jicaoqLvebJ2UXoNQrXg2C/la/spzYPnHmLn89mj3HFidn+Tf32O4vifHM5nP7xWo3i0tNv4B3u93c+67NDylOVaGSDw205RZAdbw1S89xW984Fe5sDPiJ37ix3nssdcTgpOHrlF4BToq0IasEJ+LzXMZ6rMcfPJ/aMtoNIa8kAng8ACqCmYL6nohPovlkpdffplnn32Way+9yNeffpo7N67zyivXWSxgXMGFCxV7O7s8dOUiVVWlYVl8f/jOt2HQWhGUo/UN3kkPZPT0wQUhBNr5nNmdO7z83HPUdY1zse/EUxEeeuAyly9e4OGHHuKBBx7gnstX2N/dY2+6Q16WGD2hXdUQNaOspGka5osFRmkm4zGr1YroXUqyRAbN3EoQgA8oE3uvTNP4NHyJF8lkGaaTdSHs697OLpmxHNy+yeHhIdeuXePSpUtkO7t9kIn3Pm3Nk7cu+gQwQ9pqi5ew84fkhcXPWm7dusHcLbl1e8F0F554+1v44Xc9wUMPPcBkMuH6zRss6xXFqKIYVZJUiybPS2Ei0/dtXItpG2y0RCM1AHodspc6yNYsjDFm3Vk5GK71oIC+O1eHXaLd1rr3Bw3kaEqpPiio8ziShlOtooAqYmIrO/ZUGOduo67j+vqTEI+4MSB2fz9Ej/edZyj1R6bidemQc8wS027yKnV8OgG8KlWd6JTgmKTJKn3tzpMZBsXuHUCy1jIuK4qiwBpL8HKORe96hqQLGNkO/aBL6U1SXW9ztM2weUHTNAJ2mpYwWzCaTMhTn5/WtvfYNk3Td9DJ8TbkqTcvRDl+8r0F2JRlCcj1193zOiYKrfoE1roWVlUntigrcqaTETZLXaZWMzuZ0zjH7Zu3WM4XrE7m3HvvvezvXhCpNU6YbWuSxNT3jLJSCpNknzqdE30q7mCQ9CiUViyWK2aLOXcOjrh1cIeVc1TjEcbmlFUl77uV1Fy0LOnunBzRevFZV1VFVZZyTSqFyXIMyL+xWR+8o/TpqgrvxG/cgc3tZ4coUSLK6D54yfZ+2DydgzaB6diHR3XhTZktUErRtp7Gtawax2K1ZLlcsnKeg5MTlLEYa8nKSq51u+6+bJpG0qpNhjaaEFVKTxZWcjUXRUN3nlljGOXCSpZFxnQ0pioLWTIgvasxuD4Uy+oE8pQ+FWjTJWCnyNsezAyfhb4Hg7HvtlwulxhjmE6njMfjvjfxrECjYbCenBQBdCAokZV7H+9S/eLTzLCllOrqbVR3jsW+imWYMhp62X1YKxO2JJjy/cwmaN2aJ7aXS2eB3u5Yd9f9WSDwrP9+J7Om3liUD97XGcCyB8+DjmBrUpp11HL/TZ2n1uZ9Gni9kiWNsfIVfVRU5Zivfu3r/Ppv/iaPv/FB/qP/5O/w1h97L+Qj3HxO1BnZaKycl+ehgMtuQdELkDdqp74TouF85v4TCi7/afyQ/6SD6B/EzzFu1YN8fz4/9T393Ns+ip6RWdu3Nl6dj6dxjiINWHlusVrR1isyLQlt4egmH/7QP+HgdsuPPPEG3vOe96CtoZ4vwGaUeYELkdbLhFwWJXlVgbFSIh5IkfKStopJpve6wS+XzF55hdt3bvLi8y/wzNe+wle+9EW+8Y1vMDupMQqu7OXs7kx47zvfyOXLl9jf2WU0Lvvwhgt7+6n/qkgP7zWjhVJoq9cVF6kyoq6bPuCiaRrqpYSNLJMvbLlc9l6q6zeu8dWv3OT3P/E1mgYmFTx4/y6vf+R1XL16lSff9jaKrGR3MmUyEjYvxkjTNJwsF+Ra96EJKmrxyoWIDw7nWlRUWK1Q2hJjASFKcqL3qCCA0hv6fjprLZNqBPv7GKU5PDzk6OAQHWLfBThkMUza2Me2Sxf0orkyRmoHNLgoSaPHswNmbWA8hbe//Ql+7L3v4eKlXVrveOmVlzlZzCnKgunOjshjF3OszZmMphRFQd02zOdzGu/QrpVk4FRyPRy+hud31xnXgcsOJA7DWob/rk80HYBPtdVzNvRg6kFvYCrH21wMxVRoH3wC3iTwlhhDxNs7TCoezrBDP+OmF2o9MM2WCw6Pjlg2NdNyLEyTj8mv4wl6UE+wdT+PA4+g6SX0khpb5FlirbOUQJqhEmgOyV+I2rw39N7NdJz7cvIsp6hKVIS6lWuibh3z5YKY5Mhyzan+/F6tVtR1LR65okiF8jENabqXGTsn53OfCrx1vHqWIrGb3TncAdFmVQsAjoG96Q6j0YiTkxlHx8ccHZ2wnM15YSHXbn1Pw87ODlVekGWFyIe1yNFDCMn7qFM4lE7+RlkoySJCqpO68+zkeMat27e5c3TI8cmMxjv2L15ib/8iPrGtTdvS1jUhKvJqRIyepvXcOjxisWrY3d1lPB73IUdVVZFbm9Jx192gxgjD2T9bJM2FvmZlcB3154fzp66t4TPBGKkIoe0Y2ZA6V0VtkBmDrz1tu2LZ1Kyamrpp8D7giFSTKRiNsfl6EZDOIxe8pHbHSONaYitBPU3TUK9amqbBplCtyWhMVRWMRyNGo1K6WcscozRWS6oxKsmaU9cqyHmqzuj81GpTJjxk0vrncvJLdveVpmlYLpciLy9LdnZ2KMuy/6yHQLJbfAztK2dZjE4F07DpfdV66zNBvSZwW3s1Y2LD/cbvDe9325/53ep1NtNcT9unOnB5VljPWcf42wHNP8jrrO8rn2FaqqRU9m7BJaoPC2gm012WqwaTFSKpr0ru3LnD3//vf4Evffl5/uP/9P/Cm9/2pCTCL5bYyUShLGD65RJqWAMUzjHHObj8pwdknb/OQf33m7XsBrqoJAAm1xofPHWzJKtKCJ5nvvgUH/3tD/LgVcuPvOud3HffPTTtklm9ZGcyRZlMPE1BEzH4iDAoISRc6yUu3BiwFtqG41de4RvPPcfLL7zIU5/5NN/6xjd44RvX8A6uXFK8/spVLr5hj3FZ8tCD97Izqdjd3aWqqlSkLsNsXlhWi2UaaCXYxOgMa1Xy/nuwClNkWFsNtsrrh2hX49CljnZDyGKxoK5r7hwesFwuOT4+5ujoiOODEw4ODvjil77A738y8Mu/9D/yxFse4W1vexsP3nc/Fy9e5ML+PpNqB9esqBeL9fdLEi6jNUbQgsjklGzg15JFhffSSdeqIIOXNjTO45oVmbGMyopsXzoEZ7MZt27dEO/Qzg5oYYAA8Tum7sVO2ha7/jxrKcoSNDS+ZTYPNApe98BV3vrEW7h8+SJNu+J4fkzTNIwnE3Z391HWyPbf5ozGY0aTMXk5wroWrzQx/ZktcmxWCPPRAf6t4aH7/S7YQamwyUAmBrnr84uJ8Y1a4uiDSz7Lro5ACWDo0nIFyDgBj8oImEweZIN4QHWUwnPVx6quPdAmMT0xMQ4y5KyXQeLv6/ofu3TNdcqmD4H5fN73IBojnjhS5YjI09JQGOK6dsSHxF5ouoTTqLqieE9uMkalSLZFht2BNY2JXb+hIkTXD6MdqOuYQUkSDWRFRGtLWRRkxqLzHGtzMtfSJg/U4eExRZGR53m/pOkAz3g87hkgGVZVkmV6XPA4n2C6TZ4555Pc1GLyrJfCSUCQdJmuAWgKBGpqXAwU5YidapRkkql6J3pWy4aD23doVi07OztcvHiZyxf2icEJU63SOeFaVFwn+uoELtFruWzTtpzM5DO7dvMGy9WKqBXldMrYWqZ7+6jMsjie9cfR+4C2miyTwKiWBte2zJqGuFiw6pY9WlOWZe9xK3NJOy1Sumn/vmSiJlMS2iPs5hpIdmLFDqR3cthOQt9dP40PNK2nTddD92eulc/m+OgIl4JcWu9wQUKHbFlIh2WR4VQkBEUTIqZjUbXBpPqP1WrFbHbSAze5j+WMy4LLFy9SFSWj0YSqKiizHGsEUGojTGAIjta16PS1jdXpnhkl4ZvToMP07DIb3rehzNTH2AdP+XTeN03Ts+jj8biXg7p0bIYs/1lgpweNYe0JGy6VdEz3i4HMfoMPV1sANW4yiUOWchto3q1T8tvNKWeya1vLO3mu2p7hXZ9X3zmIOuv39SAJt5f7p2fwNqiW+6E+A9iavppGaysJsak6rHWBye4e9Z0j0JHx7oTVaskHfv0f8pGP/T7/6t/8l/ir/8K/iM5LWRqORqBSdVO7itVootahgJ0keKD0UPo7mrvOX38CweU5qDw/2f9oQOTZse3fr89q+0t9p6zoqUCi7d/f8FmuWcvYDcVGbQQWRN+SW8O4ynEnB3z0Ix/ihee+zruefBPvftfbQQVMbvEBlM2YrxqKckRejtIxUqggJkeVWVSRQ1OzOD7hxvVX+fozz/Klzz/FV59+mhuvvoIOkYu7E378HY9y/9WrXNjdYX9nysULF9jfneDcSiSJMQIOXEtoArPj27TBkxubqho6MJX1HqjWO7AZNs/ITL55bKLe6Ak1yiQGJ2OSj7gwGRGI3HfPJVrvcU6CUOrFksPDQ27fvMPR0RFHR0e88Pzz/Hf/3a8xGcHrXvcQjz32GK9/9Ie45+pVKpthMouO0ISapm2xSpN13icTCT4g8X6hByAa6cFbzuboxOYAtM1KfJnp4758+TLOOWbHh5ycnEj9Rp4YgSR9NNoQI1grg5yPIlt0vsHHgLU6MUNw4SK8/oce4cKlXZarOQfHBxhr2b9wgZ39PbyPHB0f45I0cLq7I95W7wgKilGFTfUAWV5iskL8twO/VNchaQYD23Co6lirrr9uuK3f3nR3f78DqUP2MngBQFEMkZCqDHwK3yE6GSZUSAymDO0xUX4bKZ06buQ3bMsX1RnMrEoM2GwxJ4RAWY7QSVJoraWNQUJP9CCVM1WWuE7G3ckBvYiaa4l1pRwZ8YtlWoBGF9ChUjhSbNNxIvXAsvm1vcfHQDmqellqmxjfqBR5WWBiickqjo+PWSwWOBeIse29fB1jWZaiJOiqIrS2KXmy6Xv+uuHVWLvBrg9/5uExlXuRVCEBZMaCl5TljpEelxVhd08+b3dM27acnJwkuW7LbHbMlUsXMEqktBI4khjVVjoObVEQonSIzpdLlnXD0fExtw8POZrPRNFRVkwmE2FCiTjvmdcN8+WiZ9+LQpQTwbdE5SlsRakm6MRWKqXxrpXO1rqRKoXgqb2ErSilybTG2ow8z8iyHGugMBB8kzy9PrE3ERVUHxQkAT3CsFudJYWoxnlhzddVJL5nrb33ch0oKdiIyhBSz602AnKxhlVwAiQzvWZ6O59tknt35xRAWRRMp2P2d/YZVyN2p9O+b7avuImO4BpCE8mNJSSlRkigP7PiCdXKoFNlTce0b1//22zd2r4SEusfej9sXdd478nzvLdTbKt9tp+j25LS7c7YTm1wKq33Ls/k7T/rgWOIp0Dl3YDt3VRUZ33PITDdYDq37lXdYtP1Sycn1U3fy/ypQgp4P/vnPmt22eyiNek8sNjOX49GGdsnQiujqRvHzt5FdFXiG8c//uCH+Ae/8Mu858ffx1/5F/5FTFVBOZLaF7Rql3U0RaVGeaXihqarUw3481n7HFx+90P3n0Twc36C/xGAy7t4Ir9fbONZYLVnS75P7GWkk8Pqnnnx3mOyzicW0NEzGhUoE3nhm8/y+d//OCOr+NF3v5vXPfQgrqnJi4ysLPBK4ZXGK01urSTogSS8NiviKnByY8GNGzd49pln+OLnP88Xnvocd67PuLBjefzBB3jTY6/n8v4e9125zMXdHQprITjaekUzP2KxOGFVL1jVMmQWRUFRFKlgO3Cyqtc9gCH0XoyYpFotCp2lhEFjyLs+tOTRjEFtFk+zZtK0NYymIzINwShCpohVwYW9KQ8/cH/Pct66cYM7tw+5c/s2z339m/z6B/4Ju7u/w2OPPcaPvOPdXL54mQsXLmCLXMJ0nGfVtgTvKY1si1UMmBRuo4dSLIMMY1668IzShCBF4t57qiJjb2eCivJeDg8PGY1GjEYjTJaSgpNfz1hLYUoa51i2UitQh0A1LokqYAy87nUP88gjD2GsYtksQSkmuzvs7O2JFPb4mOVySV4WZGWBzgtc8pQqo8mLSgKUrJXjbnNJC+7kdNH3LG3no/KJOQh9YIPdCGbdYAYG4HEon+0kh2FQGt+2LaXrhtIAykpgSxDpnXcrJGvSSfS+kWChPuwqRmLciryPXZpnlzUa+mqcuDE8yV9b1CsW8yXKZpSjKnVPtti8Qgf5THyqxOlCtIbPLudd+nYeEwXE4z2ZnjCpRtgOfCag1juZUrqtj2FjcPU+oEySwWrNaDRZ3x+U7O67cAsBOzlGW6pyhOvAeiz7ZZVN8s7VatF/DlLAvpbzmUwYT5NlyTMlMsW6rgfDdPLTOr8xCAfnMCbdX2xG8BCDx0dFnmXs7+4Jk7pqJcE1+XLb1nNycoT3LTbTjIqSqiyobC7gtxVpPGja4FkslxzOTzg6PuF4Mad2kiZ76dIlSRoGlqk+aJX8hF3HaAecVIg4ICKLKpNZqbhJTLgyqX+PQFBSDdS0nR80oGNAtw7b1mRZQabBRAehTbJd6TiNKRXYB0krUxIFijaK3ObCnkZJCj2enfT3R+/ihjc5Kk1RVZjE3HTeXp8ApG9Duh6EBVcx3btWKxbLOa5umM9PKMuS/emUnZ0ddsYTxuOKcTWRXsnEJkocsSgRDJJcHokpnVzJe0jXaXSxD+kx2qRzWm1dXymNu2cy1Xbw7xqMqYj3jqapUQpGo4rRqMIYYUWN6WTSKoVP6b77WdF5vhU6BRetQ5MiWge59mN25szZhbih1GlAGaMkPA+WaipsMpS9vzWpHGIQRUMIPRTa+p56oL5YK0Hu6okc+NqlViv0984huNwGg2f97+F9UhZyEkM9/NamYyw7JUqHQ1O27PrrJBWElvAwY23vZyfq5DWV5YMPiqKaUK+W/N5HP8YHfuM3uef+h/hf/Wv/Bq9//E3UHkqbpwtFg5U71GIxj+PRVK3no66mTZ8Dx3Nwef46B5h/MpjmGO/Cxqvv5mvcZZGiwla9yhpkuuDJtCbLDZpA8DVGVdTHhzz9hc/z6gvf4p7LF3j7E2+iHFcsTsRnVVYVbfCMpxMiVmRFGLQ24FuObx9wdHCHp7/6FT75yU/y2U99hnoFD9475cn3PsFjjzzKvZcvcvHCHuMiozCW2Da4Zolva1bLBYvFjKZZ0bQrSWgFlHfyy6Zyeu83otmjazeqIdAQvXgcVZTEUKuUyB2Dx2iR2fbgp3V4L92KxisWsUXrQaVPlMegtUbkg9MRly/s0iwbTk5OeMsbH+fmzZs899xzfOsbX+cTH/kab3nLfbz73e/mda97HbvTHfL00I4xsmpqSe7UCqWspBWG5LWKkXI0wrctddv08tBO4qiUYrFY9EEpd+7cYbFYEGPsh97OR6OAzBgyY4hGs3COum3QmWW6t4u1GmUD99x/Dxcu7kmyqVEitd3fwxjDrTu3mc3nlKOKye4OWZFTu1ZAZV6gjcH7iIsBjCbLS4KW5GClRQKMj2BSimFKHMUNB8F175qwJO7M+13Hdg0lnx1DMfwVgtTvpOb4BBg9PsiGXq6NFgPooNFYuvEncjrJcVvBcCq1MaxlX1Ep6rpm2dSYLCfLc5ZNSwwRk8V1ojPr4B2D6ZlYlAzz3fClYyAGsS0XuWU8rvrFV8cC6uSB6+XfHlz0RBdpQ4uOGpNbqmosw79S64TpITOixRvdrlrKsqSsKpq6xqVezRBcHwCyXIo0vaqqFLqTJM5G45uWrCgEdBrTv7fhZySs85pZ7SofbKYZlRWRgNKGwhgCOkk4JXFVG83OZIpvhU07OjnEe89kskOWjXj51VfIMsN0MuHi3j56osiNpXGSiDpbrgSEzWdrttLINTHd26coS4KCkxORyUr4jYDs0WjULzTa5AvVWguo1BKwE0Kk6foltQY68CwS2aAkXZsQcSh08DSNh6aVmhDfCujsJPPpPuWatQd7yHRlpumlnsu6llAhvfbo6cxgrMEaSbP1sQtBka/RAiHVjBChzCV9d7mS4KbgJE2YIFLyh+9/QBjK3V2mEzkeNklF9SBMpz82xmCUkRqs6PGukd+zEnLWLQm7bsW1tD1sgKHOS9wDmrhNKKi+X3Z4z9BakmiLouiDfLrzb7jUGP79zr8v7yNugMNOBqyi2vCAd/8dypbPYhPPApfDn7O7F2531Xby1deqmuvuV2d9/+6/Q2nssGNymEzLXXyddwOYQ+VG5xne/jfDfkqRwg6/RgL3iAdaPJYGrdISXGvpOlaWEA3laMJqseSzX/wiv/BLH+Dl67f4P/4H/yFvePNb0OMJpclUs6xjXlQqQupMzSkKMcQKqOxzhs+B5T/N4PI7YSO/k+TYPwkn0B9lj+X3KyH1f2oQN/w5Qgx3PU9OS27iawA6debvnz5mmx4DvV0GvPU9u/d31rn/Wu9tDST9RoLmMBo8hEBRFJJaqER6N64qTHTcuX2DL376k1y/do2/9Gf/GR68715oVuKRITKZTlmsWoKHgKcaVYDi+Pp1brz6Ks98+Wm++NnP86lPfhYDXJrmPPqWh3nizW/h0dc9xO54ArGlXi6Y1yccrxraZkV0jhCTdK9tJAREWazuvGiRpnEonzakOlUdKNnSBiXppHlRMMoNbZJHGZ318j1jDCqqvhqh83LIg3T4sI/otqYdBD508r6A9IW1CcgVeU51eZ/Ll/a4//7LPPTgfRwcHHH92i0+8fFP81/9Vx/grW+9j/e85z3ce889TEdjdqc7nBysQEMbhDWyRIzukvUkKTOEgPIenbxKxhua4HBOApMaV5PbjKuXr3B0csjR0RF3jgIXzAVGxWh9Lqku5ENRVDmT0jKra6IK5FVO4R3T3QkBCbmxNqMcj2hcy+LohOOTOUor8qoky0uiUlibSyJjgGjEV2diAKVog6coC6KSDktjlUia4trP07hWNvFESQzVhqhUz7hqrfpU0rZtT53vxhicayVQZCk+WZ+O29CLFtsWgqQ7tm2Ld47gnfSAqigsXaaJXgmrorR4NFWSlHWpjsnDJQ0BQc7/EKQSxBiapsV5l9JzI7PZjOl0CglI53lO7QPLetV/trKz0LgQ8T4KO5fuD3me0zRpAI+K1WJJZqRGJHiP0lbSbrtBz8l5G1C4xuFRAsRaj7aaohpTjUuMLfoyveGdqfM/+hBQbu3V7Y51lqcgmsav/Wop0TTLMry3G14xGY6NVMBEhWtaWh9RSV3QLUG6IdfpupdYdp+zsQaVjl+MHq0NpckIROrWk+WWixf3GU0qsqLg5ZdfZrVaMJl04M9xfHxMvVhyNKrEr5ySmI/nM1rvmM0XLJuavBox3tmlGFWEqJgtV+v0Wq2xSpOXFmNUXwnUAfssy8ht1h+XVVMTlaWJnuhDr57ozkl86JcjXVjTRipo8Oggvl+tQYcWpVzP+uu8xKV/49N/mxSE09W65KXYAmyRr4EKwqS2SbbdBfh0abee1JcKnBwsaGsJb2rbliKzTKdTLuztMxlXXL5wEWu1SF91J+FedzIa1kFJAzpPUnOVeF6H9RNagdKq77ZVSRbfF2J04C71zMo5JyyzCMJVD0q787hJTHN3DldVRVVV6w7R1Ps7lNVvA02SX1ZnKvV/rsGlfJa+Zxq11lItFGPvI+2+1tpTnUB0TEBcG6yxKKtOA9CksBEhk1lXySQFR/f8OrUgkgO2YTPoswYgybVVYvplKTGdTjk+PmY+n6ONIc+rjXmiA6Ddz9593VNBU4lllXNi/fm6rUqgru4kDkEn4jm2KQ13NJ5uLMtMllFUY5Yrh81yXFR85OOf5O/+vf+Gum753/6t/wM/+dM/A0UBURGCIisrFej8yppIlD7sU3n8inNc+YMxq3+3eO21cOFZ//acuTx//U/OCv9B/ux7+bsb/0Z9/3+eqHUy1McEsJME0DeUkxG0gZe/9Q2e/drTXNgpecPrH2W6M4EYyKzGrRra1pFlGVleoZTh5OiIay+9zDe/9jWefurzfOnzn+PaCyvuu6J49JHX8eY3Ps6DD97Phb19ytzS1kvmixnB19SLOXWz6gcHn9gRYwyzxVK8kJUMispkqQxdo5VJvVYGYzJMl0RLTzKijMFHj0oexH7T72L/cO5e3nedhimZjoDRwiaABKmEGHDeobWkSoqss4W47GVyVZFz/31XuOfKVa5cusLjjz/O1772LB//+Mf5b/7bX+HxNzzAO9/xDu69cpVHH3qYZlXj25rgPJ6ADopMgclz5ssFmdFkRUFb18xWK1SEzBrG2Zj5yWwtP0yDk3OO2rUcHx9jdyUgRStwrsGHiMoseVUSo6dWoFazJGVdb8qNkS7QGCPHR8fMFyuMMezs7zGeTkCbvt5FWwNGE2KkaWs8krRog6H1kaicDIcpldCkypTog0h3Q5BE4RBTcmfo+wDbpu47RNeLAL0x7Ayvr6Fstm4ceV1jyyoBHE1MYKhtVvimQeOJKqBC6jjzUQZaY0FJV+h6QRQTc7nZp9n96n5P3pN8L3TqHVBK+gDR6fzS/bUXFbiBXHHIIkQ0VissCh0DRZ4zLTLKPJNzMnoZ0NPO3cWADx6f2L3WOzCWsiqwRU6Z5VJEnoY6UTT4U0Ei/TDYtp0VGGPXP+v6PDF93c26XH4QQpISHrvFVneNqATaqyRx75OCE/jqBlCM6v1hfXKnUkQVUQFGKdDIh9j76MbjMQcHB8znJ9hcPMg2y2iD5+atW4QQGI9GjCcTtNbU3hGNZry7h8mlv7FpPS5K4qlOP2MXlpNnJrHljtC0KBUlAEmL+oMQUKmvURUWHewpv2AX0rVONlVrlqgbtI2lLHJ8aPFOrg2jrMgztZXk105uqy3GO4FhKpKZDJ1lZGXeLxGaIHJxl7pb5XtIiJvSCvTaT9k0jQQgzZbkmWVaVYwvXGQymbA7HTMdTyjLPPlFlfTRJjAMgwqfLVtJf42g8IgE1fu13HM4DBpjenBJiGcG7HT37z5NOnmXOzmrSsxgt5jqzr8NDzicCcy2uyWH37tLge3Yz37ppTfBodJqY9kS1ObCuQPddyMJvt3ccLek4LstzPtqkhjvyj52x6aua8py3AO/7TqUbxssFHVajicgPjgOXWquUqZP2O2AszJaZNJaUZVTDo5O2JlMsHmBzeWeOF80jMYTTuYLPvR7H+fv/v/+Hi5G/vV/49/k/X/6Z3HKYstxymLQyS+vTvVYnr/Omcvz1/nrB4T5/N48vHcz5G+WtMfv+j1ts5hn3fA7YEmSDck0EZNlLBJ8CzHiZic8/bnP8fxzz/Huxx/jrW95E6A4OTyiKDM0MkxopWmXK2azGV95+st89pOf4kuf/SzPf/2AqxfhL/2Fd/LEG97I/u4eZV6wqhfMD2/TGiMBKW3N7OSExWKG8y02sU2tFz9boTVX7rmfPM/XMial0cqmHsh8Pdwb2w+/HTPQBvGN1K6VAA/WHVbdIj0vTD/8dEwUKqCVxahIOz8hKkNm1ttm2c6n0u3h56XAtxHX1OkBbnj4gQe4cfs2Tz7xVt7wQ6/nqS9+gU984nM8942XePSRe3jPD7+be++5hysXL6FNpFkt05Ze07qWvCrRKuKaFt+AMUpYC6XwTuodXGJ7NZDnOZPJhDCfSYqjmTGZjCjyrD8uEhiS4dFkKcHPx4CyiiwrKIoKZaEclZzM55ycnNC6wMWLF9mZ7mFzGdS7IURAkKF1LY3zoBVWadAGFzwhAaRucACFTwxb44Tpcz6kczFt+sMgKVErTC5y5g7YdOdzxxJ1TIVVYONmoXw/FCUvZie9jCr0HsWYUluT61BSjpWkH/dSqRhTCJFOw2UCOUl+Ju8jJu+SkjCqLfAw7HBTGJSSASzGTXAH6TP2wvLgI751WKUZVRVVXhCdF1klAZWkZK71Eq7kxTsXlSHLcqqyIi8LlNICNlKKo++7Q9MxYVC3gtkAm74h+SrXHteuEiiEIEsMrYXV9STZcUbifeVYa4XN18N9ZvUGUD/VW6pFBheF0uro95TEGfChxVrTBz+Np2MuXLjAqzeuc+3aNY5PTnrpbZ7nRBUl/Xm1oI6ePCtog8fmBdVoBMayqlva1vVDdVkU5EbkgjiPDp62XrGcz4gukmUGcmHg2m65pQzWaJaLFdoaskGtRVQazNnD+ebwbiTIqNX46MSvrDQo6ZOMEYwRKT1RElFdG5LUW9I0Xb0CowdBST51ucpSwye/dLfMcUleHELAotidTJhWJbu7u1IDNRpRlBlWS7BQ6Bg471N1TwI8vXJG0phV93N1ks5BNUZ/hZ1Ry9H/7xQauy3THPZTDgGQSn1CXTpyXYtsuQug6s7Zs+Sqw2fwELxueL+7z0ibMxNdgw59vc1Q0totRzDpuaXsacYvLZxS6h6DI3TG89+cSlzdlp9uK6h08kL213UvRUaqY/K8v0+edbyHx2P7f2/PLz7dHyMQg0pKJ1kqKGMTtx37pGulNdparM6kAicrGE8VRVmB0iwWDePpBDvKuH7tOr/8a7/Bf/l3/2suXb2Hf+ff/w/4sfe+j3I8RVUjRQhETA8sU+Y4auPsXJsghuzl+escXJ6/zl8/0ADzTJP/GfLiu4HO7/Y9nQKod9kqdsEEzjmU9+SZBZtB0/Dq89/iy1/4HKFZ8vDDD3Lp0iXwIsfKi4LMykN1fnTCrTsHfPlLX+G3/tFv8syXX+DynuLnfvpNvO2tb+LRhx5kf7TLcjbn4M4djo8PMUahRyOUUjTNUlhKa8gzSzmSAdjoDGVlw3xhui8MaerI86HbrsqAejJf4hpH0yxFGhlcioKXBMjlcsmyWdIsGyJeQKNdy1uttb3kahgOk+c5mdFMR6V43aKwbcNADJCahjb4VGmgiC5Iz6NUSfKNb36dvb09di7u0fgpO7s/zuOPP87TTz/NV77yNf7BL/w6T7z5UX7k3e/m0YcfIR9XNMsVTQzkmXRUBicJr7bIMXnyJrUOTyQvC3SjaV2S7nXsaSp3XywWIqlTI6lK0DoxZY4mdQc2KSGw2+xXVSUptgGOjo6IRCaTCdVk3P/MUUuiqEseS+e8eMu0sMl5WYHW+CgyN90HuYj3z6dwFNcVdyvQRmoIlJL0UxUUZZ5KtJGACJu8iCTJGzFK4mpaSFhrxfvpHA4Z4lov3lalDS6QfF+5SM3appdgYaRiIUqqYL+9X/doCoOi9DpIqGmaNECSBljVp1Cu6lYqIJQMMcprPHJ+aqSORGm9AXBPDakhCFCPnsY5tELCeFJYCiGBoCgppi6kBYixGGUoUx1MURTCAgL4NnlDA6vVqhsb+59rGJKiiywNxqSUWN8nM3eArVMDdMEnUiAv0mFlBoNnEM9ol647ZIeGrG+3MOoWAHRpvHHTBauUwrVdT29akERFNcq59957mE4nfPNbz3P79m2OZidMp1MmOxNGmWWxWjJva1bBkxUFWZERjRUWLUZsWmgJFg80dU09n9E2DTYKqGqamjLLUR5Cs6JpRPbn07kYtcHkFTGl5MYBy9RJNvOySEBZ0omVXod5KXTv4cwUEEzqUpTPKwLO1RhU71ftZJL9M0EFAXcJoHd1GV3QU9OFKnlJCgeorGU0mjLKC67uXaS0GVVRkhcWrSzRO5pWrtsyy4mD5U63NDCoDRbvrOdaX58y6KntZJpdoq1zfqs/9jRzt/0s7KpHvJPrvpP0WmsZjUaUZdlLZ7dfZ6XDnuUnPOvPh78/tLtsg9iujkgn7+DdgO0pwHk368sZ9431e+XMGpPIusamC0Dr/qwsS2KMLFcrub8N+k23weu3W6T3fy1quZa1QiNKAG0kAFB3rKIyKNP9ytDGoKsReVAsV51kfY8QIk9/4Yv80gf+B/7+z/8iP/6+n+R/+a/+r/mJn/pT2KzEobAYVq2L1nY3PX3uozx/nYPL89cPzutuD5fv5ia7+WD9o77BpUzL/ia/JU9SmtZ7VDCMixKaGd/6+rN865lnuLAz5S1veQtZkbOqV2RZJsxB8MwPjnj22ef40Ic+zGc+8xmObq945xMP8dPv/THe8oZHKSwc3rnDzevHzE8WLOcnadNrWS1OaIMMDlmeU45H5GVBUY4YTXeYTHcxeYZ3gTJtmJ3zLOqa+axmPp8zX65o6pajoyNWqxXz+ZzZcoFvWlyU1M0YU8l50+Aah1Q7ZsJ09A/MkNiodeDEmpHRTEZjbAqsKcuC0WjEZDJhMplQFAU2bzGupamX4u1pBQhmRkII9namhKbmYLnCZJbRaMKjjz7C5csXefs738E//h8/yJef/QZf+/o3+NF3v4sf+9Ef5eLevnyd4FiuZujgsdpQZJbYBuq2wUbFeDymWS7QVqGD7lP+rLXy3qzlJJ6wahvUEiaTEcZY2hBonMNrTV3XLOqGuvUS5oFCmQwfak5SzcBkusvO3q54zJpGZEt5kaR1inpVs2oa0Jrp7oTJZIrJLC4FVOiU4NuVojdNi3NNkvJKL6k2kBvby826NFyC771UykrZelBSHh+0wjetnNtKkl4zY8AafNOiUm9aV8Vgs7wvgycYvNM0QQCbNokRVRqPIkSFD+CdR+mYBt+I65mL5L306xAf5yNSDGIIQdJ7BYibtKD36WvL0I/3wpKeIcfr2TzAakPUXReqorCZgBoioRHJcRiyCtZIyqvNKaqJdMwa8Y/iBRw2bU3b1sTk17RapH4SxtKLGskyQ4wiXdSafgnRAZlu6Nwc/nWSlUtJubYZylhC7Jj/wX2IuOEJ3/g6WuGiAiPADB/WYZiJFSoKkcNHDcGLpD4gfrILF/ZoGvEL3j48YL5cMFrM0HkmITfGUBUFdjTCFCUOCSEq7AirJPXWe8fJ7JjZ0SGuXmGVxmYZ47LkwmTch3OBhOI0zrNcLlkslzRNi1InoK0A9cxSVdVGkrN2rpf9dn7enhkzUDcrlDbk1qC2Ql20UjTNqm/nI0byzGwEeRXJ19v3WLrUyxnavkc275YEWUluMyajMbuTKVVZUijTB/QQAiE2vSxcAc61ItsNvud8RLasRXXtNtU020obkYrTS8S7oJpejeD8Ogho0JUb1PprDj2TxhqpaWnkvj+fz/sFSlmWfQjT3Z7tp+WvJGat+++mDD8SzwS+w3TpLoG268eV6p/k74yby+qAHLuYrhPF3VLq9alFdex7cbtP4myQujFgW9uzukNZbFmW4ldtGswwvXbw60zQul3lElVSgiTmUCHWAG1TNYgUQPUsbJKLKy3X/MGt2+zs7DEqpU5kfvuIj3z0Y/zir/46v/prH+Fv/Et/iX/j3/pbvOmd72a5WGBMrqy1rOo6FkWlfN832jVYbs1fW5kWmxm85xzmObg8f52//ohYy++WVTwbYH5nf/6deC6/V6lulmW41ZzgGnRZML99yHPPfI3D2zd4/YP38eijj7BqGtxqxcX9CxAiN65d51Of+DS/+7u/y5effpkL+5q/9M/9KX7mp36SnSpjfnCDk9uHrOYLVquG6KUFwjnH4viEVdMwHo/Z3b/A3oWLTHd3GE920Gn4RxtO5gsOj45xjXTXHdy6za2DQ2ZHM45nc5bLmqbu+tvSf30jgEetB9Uqrwhp+51lGc44oOnDFobSrP7xYmSgV0b3pds6lZ9Pp1P293fZ29tjNBqxv78rUquiwhYjiepvliznC46Pj9lJxfRKQb0UsFGOJownI6rxiP/FX/9rfOxjn+CjH/k4/+RDn+Gll17ine98J4/90A9xYXcHbTyurQmtp/ZOHvRaEYNUDazaRoBX8ijFTuJkhIHd2dlhNjthtVqkIbyUrj4gGk3d+rTZj5DRV0S0bc3JyQlVNWY8HkswivNEBXkuw9mqqQHNsl7hnKcajynLUlgyrYhezt9u8z3sMwSNMYoyL/rKFfHxJZDUyAPeRy+R9VpJ6InRaMCbiPKR2q1DfnSSfRslMkXrU8CTkiFOmYw8L0FH2hpCbPrPX8KhVGISVAqciGvJXZTaEe9TqEy6MDuWspPnmSRT60C095GoBSSKn1T6ZddSudRHeca9wSiVqgykoiM4L92xCfwF18nZ1gO6sgarrXSM5lIVk+KOpcuz9TQ+UK9amrZhVBZoE/tSe50qIvrlWexCRwRcdtUj3a+2bfvBfw0sQesgCY/a9scwRk2MboPR0WazNF1tyIZVCi9RPaDoUle7S9am8yqESGatnDM+XTMKJpMJ9993H8oa7hwecHByTD0/oRyPmOzukE9GqCyjjUFCTnSG0YZm1TCfHTObnRB9TaYVF/f32KnGlEVGleUUmYTY9FLDxNTPl0tOTuYivz04IjhPXTfUixNYraBdkWclAS9AQkeRR5pUwaClK1QZzcr55PnM0nkQ8dFhkgIjt1auHeTf5SZHWYWO61AbnCc4R3QOFQKFsX3FRZHnVFXBuBpR5hmZseRWk5kcTcSt2iRtFBlsRPo0tbYoLWC+Z+o677FSBN0BrrMZt+78ssb059G2KuTubNw6L2Ao6RyG8XS9lquVSNOrsuwXgmf2SHJ2B+NZrOTG3+sluequzOeZz/XeVxy3mMe7M72vNZN0P//Wt0cpg9Z+HejHZhhapzrowuqG7KqEJbUby5/hMR7+d1ue3KsS+s9Pp6WawWiRbMt7lqoehUnKkbT0NbKk2794WRZReclTn/4MH/vo7/P//S//Lt94ZcX//f/2H/GX/9pfJ6tGECLVdFfJQjCg8yIF+IRTx+kPog47f52Dy/PX+esHDZCq+Bp3se/Vc/ntQapa+zdYWzg6tiWEINv34KF1vPz8Czzz1S9D2/LWNz7ehyFkibV6/rlv8KlP/D4f+u0P89JLc979rtfz/p/6U7z9ybdSL4559cVvoUJNOz/i2rVrKGMZVRNGoxF5zLCZZqKn7O9f5NKlK+zs7aOznBgV82XN0fEhtw+PuHb9Jrdv3+blV55nsVhwcjRjvlgRfUwPoKzvvVJKoY2V7b6SWHmrDVZrDDnYmFhLGcg62RUhRbmrLr3U9xIx7wOxDWTlRAaVpmVZzzg8nvPKtZs9y3Dhwh6XLl3i6uWLUl8wqsjKiirK0LuYn0CqTsnyQmSox468rCirEVlZ8FPv/ykee+wxfu/3fo8vfO4bvPjKb/JjP/Ju3vmOJ7jn8h42y/BR6gcUirws8XXDfDZHp8THzuuU9YENicnIJY1zWS+lpkTH1Lep++OwXNR4D9UkRyvDatXgvcOYrPcnbXeZdbKqbrjL85zpVDxZUQmO0VrjvJduxdClrq5ZY6UUNrfpa4obMcQgv1JNRy8vS0mWXWBTTAXwMdXbdZUaUcnf1QqpeCmElSryApOk1VGtByVlcozyPWOqlAAa8ZGqjWszRJd+XtWDS61tSk3UGKMxJiOgaFtZeMSuYsQYtE5S0fQ9lNZ4H/CvIXvTEQlOSkysScmiwXmausakkCHVe49FbmazDGVtApYpSdK11E1N3TQExbquRofei9wNvF2nXkwyV/kMxO8LksDYy+r7tEqV7ivp8xlIXu92XwsI2L57oboMorFjfKNI+q0W/3SfCoonBJd8hJKA6lwgeM1oNOK+++6jGFfo2znHqwXZqKScjFG5FcYyBkwA72p83bKar1gt5xgV2N3Z4dLuLnu7O0zKglwrdJBU1I7BVh3zrQ2TUcXeZErbesKlBt+2HM/mHB0dslrVxLpltaipfYM2FkwKdtGQSivFi6sV0Vq8opfl66jRmabMSowS0CkVQxnoiIqqD8QieHwjxydThqoqyApRNXShRLnRlEVOYTPhv4Ms3aL3RN8myWLEJz9yjKLyiEZC4FzySBuToYzufbVyXcZ+IdB/3n3oa1quNAIq3VZvbc+QJZZRrm/VWW77QJi+jiN9Txc8dVMzW0h1jPctxihGo5LxuEJrlQBT55tOUVhdKUUUL/1aiq2S5eEuz/cOVqq7gNMBSBYZruoXRypJuekWT8RTafZxsGSOA2ZtW1nVLcCIm6yqUZsVKcPgs2E+Qbco6+ToHbiMUW8E+nT/VvXVLOt76dlLBEVItxSlJDVYGdOn26IkGVZrWXhoZaW6Knkwm7pGKcM//MAv8eHf+wh//+d/mytXCz7+0d/gjW96K6qaQp4rMDR1G3WWKWMzXIzUzkl6M5zqD0aFzcV96jOOKmzxlefhP+fg8vx1/vpDenUSoD8MJvT7ASi/HXupYh9JIt2BXZFxBN/W5Nagg8c3C15+4Xle+tY3KW3GGx57jEk1YX9nxOz4hM997vP8xi//Cp/9zDexGv7Zn3sP7/9Tf4r93V0WR3c4ObhNaGpWs2PwKx556CEOZ3OyokobUkU1mbK3t8fe3gWKakzbtNy4doOXX7rGi6+8yiuvXufajVscHR0nP5uIZrQylCbH5Bloi+qi3gcAEyD4AB6ilq62gJMhM7j1ZlUOAiAJqh1zBqQgGdcn+6l5m2RnoQcIbeqYa9uWV196hfF4TFWVZGXB1atXed3rHubSpUsUWUW+V6IRedFitaJd1ShrqNuG49kRRSGda4888gD33/tXePShT/KhD32Yj3zkU3z968/wl//iX+DKpUuMxxPm7oTlSjyANrOYTKoR2rDCO48xVpicQRR/SAmXQcGqXUGjKQuLV4pV26Q6h4YQoSxH6MzStC1KR/FYJkZPjrNJ5eoOlesetGqtKcYjxrtTdJHTNo4QPLkt8b4hBC9y287TanJ5uMNgKOlSWEUahtKCiSIC/gfepA7UOucE7JhNz6xQQAGlAtV4jM0LjM1kYE+9mUrH1L2opE8wDXnCkIosqyus7wfjYPFG5IQdqBgyLEpLCqvUH7TSAZqAh7WWoDSKmOoWRBpnUOIPHgQP9bIzpcisIrZSKWSMocqzBAQioXVoowhJctcxXNqI7FOqbBPz51tcs2K1WuHamsJm5IV8HRVVL9OV/KI4YEK2WCMd0VGjlNSPyLVik88yDash4oIXL7JzGz/bthTRuZAgphZQw7pkXWslAU9JOtzdx3T6+91nbowBF5gtFnIuh4CPnsZFWgc+ahovHtxyMiXbmWKKnKzIZTETNVZrtIrU8wWzwyN868gzw8P338/+3g474zFEj/Lyfqw1+CiMcs/kdvUKia3NlUIVBdlozHQ6ZW9nSl3XuBBonMg2G9f24S5qIPnsFoGH8zneO9pmLSOvVIXJJI12MTuBqsJWWo5gYsJB9jCTUYnRUpVUVHlaFol4GxV6qXXwsqxQMUo6tc6IVhKxPR58TEFYAjZNSJcZGqM3Jat+UD2h4wAgkU4zItEFfJR+0K4iqfPAD7/WMBBnU4apk9xUVCFKGyKBpm5FlrxYsVis0tfUlOWIPM97lrQLpOIMRq9nM5Vcm3eTD5313B0ynVpLAFUg3ddC7BnXDUVEjL1a4Kxeytd67g+ZUgFNApA7BY/OIEa9wfgOwWWb7lOGrl841ZwojU33TE8ktIE2Olly4PvMhm2W+RRLqNLGj3UKtrV2DeYggUuNUQI8TXrWROAbz7/Ir/7ar/OrH/h1nn/piH/9f/M3+Nv/7r/Pzv5FGO2AMqpZrmJWlCovStU4T4gt1hRgxE5xFnP5x71W7/z1AwAuv9MqifOT7DsDMX/8gOHmEDhMOzv7hwxrmo8IQd8lUGBd/Lv5dfXG+RV8jHfzJmwOk2Hjfrx+aLy2x+Gsh9opdqAf2sULZVRiiNK2X+lInkVObt/hlZdf4Llnn+VHn3wLVy9cwUTN4qTmYx/5fX7tV3+Zr37xNg/cB3/1f/4X+eF3vJ0LuzvcvnmD29evUS/mEFqMUoxHe+RZyXhaYmwmEfa7+5RlSb1quXnzkKPDl/nqM1/j1Vev89JLr3B0OKfxUolRlSP2xruM8kJCeIzpmYxARKWHU+dZ6brSbGKdOmbJRyBPeLIf4h3adqXi5UYNg3OO6FJyXqobKKyVPsfGs2pXtG0tm2at2Bnt4Z3n5HBJ60946Vuv8vRTX+ae++/jvvvu4+1veyujsiSbwLhsaN2KxfKYVT0js4YbBzfY398n1nPG4ynv/6n38djrHuGDH/xtnnrqBf7f/5//lvf/1I/zvve9F1ONaJzHG0Xb1ClxUsBwbqUnrW2d+MaKSvoh25aqGuFCy3w543h1hC8io90LNLOao5MTnAs4B+PJDtVoQlZW1O1M/JBlhbYSfqM0fTfoql7htFBr5XjM9MIeXsFqOacsRuSqkG7BupZ0ycSA+i7wpJNTubBRVSHspQyLSllibNc0ZbqeoycFkAQynVG7VoKgjOHo+Jg2BAkgGk3IilyShE2S7QlKlCL3LtQj+sFArtAmQ2uJwo/DaysodOq17Iajtm1BGZqmxuTiVarrmpO6po2kROMsebVS6I02EtPvI9ZkEH0CFFGkkv21H2gJWKBtlhRasbc7pcwy2lWNNYkxSNU8wSgJhDHSF4pSaWnioW1pmyWxrbGIrDc6LWmtCNOtBvLVDjBppeTYpXuWTiEdRkVclC5CrTXayt8LDtrghNEyBpPphG+TZzMkn1pE2MgkjdXK9H426fWLOOfl3xISG+eFAWe9IAshsFik0Jbg0yJEwnCigXnw3Dw45ODwGKciRVmRlQU+aPzSEX2gMFE6T09OWB3PyBVcvniBS/sXuHT5Ar51LA4OaNuWUVFS7e6SmwyvNMer417qbU2egmIibUqn7vJEooroTJOpjFxrdrOdPum4qKR/F9bppDFG2uC5cXjIyWzG0dERR0dHLJs51DXUNTOiVDH5DBsVJvUFGmMoqpJRWTGd7oploG4EbASPDiqlEzusNlJFEiHPSxnGVUiLAsAodOxCaSS1mE5GrqAoSrl+gywuURKm0l9PVvfLky6BtAviCkmu2lW99D2csUuhjQSj+89aZNYDFi0GtJEe0xikj/Xw8Jg7d26J2ibLQGmWq4b5Ysl4PEZrQ2FT8ricjPI86XyMes2ohxDQUeEYjASc9gYPnz/rZ7+ASWUS6x5kZhBQZwhI0NhQyRCJ8lxOAWdKJaWA2gag9FU90bv+vilfJ9WkJHC+qhcpPGfdN6lTuFNQcDyfYawsJaPWGJNLz3QAY418kt4B0gWslNgPAg6UdBdLgJXUrugYZcGLKCaERWzRqFQBo4neS9dyUVDXLbGNjMc7oDPqpXT63rxxmw9/7OP8N7/4S3z2qa/x5re+if/6P/t/8P73/yyMpgolvbnRB3Q+Um0Q+bcxBqsUkUCmZCnXLaU21DeYfonVU8yceyx/8F7hD4zvvh3zfM5cnr9+oBjMP0zAvg0guz6o7+Z9ndq+xo651AkOb152WgsbUWSWVw9u8/JLL9AsAg/cdz/7u1N2RhN+6x/9Q37+53+eV16Y8eY3TvmzP/N+fvw9P8J0XHLjlZdZzU7AN+Qa0BmZUeRlRV6O2d3dkaATbWld4PYrN/jGc9/kK1/5Gi+//DJ37pwQgwQeTKcTxtUEm2US1x41VVZugusgRdQdA+Kb5OELOt0wtICATrbYR91HtNLJd2j6UBa5fQWiEm9cpgOtSmEwBExWYKzqB5+RK6hdKQmrMWCCFjlRZQlIzcF8ueAbz36L5557nk996nO8733v5cknnyCvJmTBMp6OWC1PmM9O2NvbwdUrbs3mHB0eUl9YcfXyJf70z/w0jz78DX73Ix/nH/6jj3E8n/Fnfub9TPZ2qeezJKcKFFmOziyhZxYCWZ5tdMB1w5PKFN4JU6naJW1oUUZTtw15qbhw4SJlWWKspcwqTJ5Jh6U2xCCAXqN6mRRAMarIyiz1OEaMzoUNdQIwuk65bQaik4punrtdL5rq+/6MQeSAobsmEvsVYgIaacA2ug9R0ZlFm6xPZOyGZRX8qQWN7jtfNxkLhlIwtQaT6+t085r1QExyzHm9YtU2uODJknw6qG6QMSkhVrpH27D5XlQa5AMia4yhTfLCQJ4XVHkhoUaxlQTaLnk1eROlhCGm/sE0GIZIdI0kMxMkAVUnaWkcVK8MwoVCYoQ1ccOT3GVNaq1SR6EXJsMHovbCznbvaeChG0oeh14zlZgNWXYNZIQyDhJcK9JEpVLa6po99XiaOgEW1p5Z5x2r1rFsHd989QZBWWxVUuU5yprUTRtRBKZVRT2fsTw5QTvHhZ0Jl/d2ubi7w7ga0a5WxCCgzERZaLim7ZdVVTnurzORj5uNGget13JDm2W9N23oXeuukRACRq19a1kM3HPpIns7U8osx9UNoXX4pmHu5NjujCfsTqbs71/oj63UNMn31BFJG840oLHaJMASiMqK/y3qnqHvzlH5oAXMxajRoUVri6dNScBBnig+pCWGSUE+6bpJn2+XRtstKwRwm41U4N7zKEirX/Ioo2hcxGRm43itU2lTem7QHB0dcfv2bVarVUq8zvsFbV033L59G601e7s7ifmX7+G7HsutZ3FMApcumXr7/rCtWjj7ud5ZT9i4xjtf6vdzftiuBuk+z05t073XjrF1zrFarVjVdeqrLslySdHFq76WqwPNcSBFjgPPcy+5TZ9FZHO5vpjPKZKfV2YORVYUUh0UNZOLF2HV4ttA1C2rVcNnP/dFfu03foN/+D/+Fvv3PcT//m//2/zzf+1v8NDjb5RtRxTPhAsRJdRsuv2tmVmFT7kK5nxwPX+dg8vz1w82sNyUz3z/Hw7fC+A96yHXezUGnsvUp72Os49RQJaG69de4blnv4bV8MbH3kBuM37/4x/lV37pF3nhGzPe+Y6r/Pk/86f5kXc+iVWKW9de5s6ta+ggQ2onf9K2oKjGTKY7ZOWIk9mC69dv8vLLL/PcM8/x/PPPM5stMcayN90hz3PKUuShuS2IaHwK6QnOb3hWvI/9QCDgec0qKaVwrNMWfRpCzur/isOHY9qk6+4BbQzBJX9MjESfNsNGU+QVWVHJ+0newG7zjtHs7ezTuFbSa+dzlqs5v/M7v8NTT32OJ972Ft71w2/j8t4FlkVBlhU0zYqZO8FkBu8i16/fJEbFvffew97eHiHARz7yET7x0S/g6hX/zE++l6uXLzJLfqjWBZTNQKXjE0CHgFG+278DIjkrTUlo1udIl5o4n88pioK9i/t4pHsyH1lsnqUETiknizHigsKFQBs8EcVkNMKWeT8UWmtFarVswQfyssTYAVALIS01dD9QD8/fPtUvDWFGK2I0qNTHFxPT4FE9kCmKgrppmc8XOBcYV3Jss7xE6U7aJ+xC5/8a+pDODHtI6ZfOux5cCpNwdudb9//XdctikeSn3pMpWYbofsKUcadjfmLcDMoIpFLxLqgkRpx3WC3ewY7hGnZDdoE9YasfUHcAz0lIUzfcrwdcWawMA0lilHJ7lbyivVw4bgagdPI270MPHpTRaC3SxhBd718OzhNt6BUFHfBQG0qOdCzjZndstBJ0Q9So0IUNBbkPxIDKcrmPBWi9l/uGr5ktVizqhiwrUDZDZzYx50FYxdajYmRet7jVEhthb2eX+y5f5sLOFKOS1zUG8ZpmVsCrFuWET8FHRVn0x1sAj8Y4h2oauR7bpv+cyrI885kyVL8Mf08rTa5LbF5ycjLfAAbBe4qi4PLFS1y+fJmdvf0ewHVgVfywkGmDCYWAjQ78p1Ao3XvnfC89Hia6dh68vh7mDK/d8LnYnw9dz2wf4LV53nTy1+G9eTsxuANJ0usri4zgvfzbtCDsksKPDg6Zn8zkOFeSCNt6h8lE+rlaLDk6OmIyHjMuR/31vd0R3TNY8TtTbA2Dcs76e5J66wghbqTe+l7t1FkCNpdXw/HitYKN7tY1uf59vbFo7D5H5xzz+RylDHkuIWzbvkmfrrPIIMhJmY3Zx/mY+jy7Z7EATLm+YwqDyzFq08uptcW1gbByLGvHctVy7cYtPvjB3+FXfvXXQBn+2b/0V/jn/upf44d/7CfQ1ZiwqkHnUWe5Cj5iswIf0vKr89ErWa51vvFzKvL8dQ4uz18/8MDyu0lx+4Mwl98vRvV0xHrn9TCymVZBNs4APpCVFlfX3L5xgxeff4EH7rvAvZcv88oLz/Obv/E/8M1nj3jrm/b4i3/h53jzGx7DNytuXbvG7OQQt5inmPp1emaWF2iT04bI9Rdf4Stfe4ann36aWzdvi5QxK7h8+QrjasRoNMGaDBUjTS0l9FpFkUCZrE+zCyHQaIdSoR/UO9ajG946pjY99dFIcIKLEj5BAgfDYS446QYkDIIRQgLcGEwKfVAxbXFT6qy1KYDAGtqudqJJXWplRW4ziqKgaUaczGe88M2bvPzKh3jppRd557vexkMPPcB4uk9WLzG2RKXAnoPbt3nllVdYnMwYjSa8+0fewZUrl/jd3/1dfu+jz7BcnPDn/uyfZW9nilcr6uWCTGsyo4he42ND7Rps0NjMoDEpXMMABbVvqL3HtsIStMGzbJbsXLzE7u6udGXWCjsqN1IZMeIPkkoDkUHprrIlKyV9Nn0WdV3TLGuKoiDLZXM87JTrgdSWx9AYs5EWKkNlx2R1PYebLEAHGE5OTlgul1TjKeWowmQZeVGw7m6PvXytTyq9SwjF0N8VEpSlG/rTv4lh4HcyGpNCj1wMrJqa1rvT5e4R6HoutQBeH+g9Z8poTEpPlC1/xGhDWAVyrXtg2bbtejhWbIC0DRbUGKgbWlfTJLBjtFxb20meXWiR2wr86NM4Bku17uv33rggCwjjRXJPCh3ySvUsXidT3JBAx7X9YDsARf5OSJK/da9pL6eO0HqB48s2MF/VLOoVTdvSpkVEQHHh0kUa19I2ntA6iBHjpCe2dQ2xdUyrkku7u1za22MyrjBKrkXXND1Q686Z7UCq7XOoB4YJlLVtu7HMGYah9OqLgSd1gx1XSCAWsU+tLooiea5zrly5wpUrVxiNRv376LyLw+XJ5sndfd4daxw3wf1rPF/OsmcMAaL3HhcTS5l+HjuQvA69lN094bR6YasqQ6+vyS48qjt+zjlu3rzJfD6nbVt2dnb6NFggJVfLPerOrdtiE6hr2tEIHbfO67s8h/V38Xw+K1G2r1SJm6D5dDrtdpDP3bMYttNsX3NBvbUoiDGyWCxYLpd9zVRZlhhj+sTeYdCP6ypmEkgNqBQa1aXEdueRBH1pZSELqKjlJwjQ1g1ea/K8xNqMGBWiGrfcOTxhXjd8+CMf5xd+8Zd4+dWbvOvdP8Jf+ct/lfe87yfYvXoflCVx1UjytSkUEWaLRZzu5qo/ZoN04vPX+escXJ6/zl9/yMDTE9cSHwayI8R3aTQUmWV26zbHRwfMjw5569vexGJ+wpc//1mefuoZ7rkEP/2T7+WJxx9HhZqjWzeZHdwi+JbYrqgbh1KGyc4ee/sXiNpw7dZt7tw55Etf+hLXr93g8HBOUVgu7F1kPJ7K9lpZMm3JswwVNSo4gnK9xMYrT5HnPRB0ibkcMka668pKsljdAYm0Qddai4Q0yHHQg8j4EETi1g1X654vi81keC6K9UAo3ZyO4KN4qDQ0K0kExUukYHABrQN4Cb3YGY2pipLMaO4cHvGlLz3HK69e401vfiOPP/4Y999/L9PdC4TWsdILLl26xMnRMYeHh5wcH3Pl8j3cf99V/vyf+zNk9rf4wpdexdoP8r73vpfLFy9QTnYJTU3d1BgNOrf4ekXjnTDCRSFDOdKrh1a42rGsV9QxcnRyCEpxz71XuHTlIllp0VliKRJwyrIMo3SfDupCxOQ548mOBMhkNp1P60JugDzP05a86cvSZfAVqatrGjyxZzMk1EEPhqzTMY3DQUknr+HJyQkHBwdERSpJHyUm2UgKMms2pvM2kqS1BnU6Pj8EYgjCsGmJkOneUw+SO6bBSCox3fCV0i8BTErqDUrjQyR0gBCEeUvgsiu3RysZQjEYI1v33EDTNmTp2LRti9EBa1Rf/xEQLyQDYNMxmtuSxB7YJbKyU/6p5PkiyY5Dt5Dpwsx8WrAkUKJ7f5furyXvPcaKDDMqjdcal46Z7xkn3bN/Wpu05OrUBOI37T3QRLySblytOlZErt2mlRqe4+NjVq5l1dSsmprGBZQRIJ5VOcvlHBe8yO7SQk1HqJQiGsPFS5eZjip2xxMyawjOUQdHZiyj6Yjg2WDZQqAP35F7S+w9cSGKhy+qwWeafn7n3Kmqhm3Gfu0rp2fR8jzneD7rK1/yXOSeo9GIq1evUlWVgNPlQpZeWZ6k4AqT59C6dM/vzul1RyZbQTadvFuYu7gBGod/Z7gQatt2g3n0bLKU3T1gmAC7nSJ8FniKaZFkjE0BMlGqcrTCh1YSxE9OODg8kMqpUZU8lVIfFUKQ4CKtmU6nuKbl5s2b3LlzhyzLmFQjWUxtqQ903AxV+nYL3bPyGOLWsVuzm+F0CFj//69B3Flg+27Bf99O+dQd7+4cruuaWeovLoqCqqr6a9gNWOb+vfeZFZ10WhKh1wuTYlDBtPbFdtkTeZ5LqFEIhKgIXuNDquuZLfjcU1/kF3/lA3zuqS/zliee4N/5D/4m7//ZP83VBx4Sb3qWE10k6AzvILZ1jGg1mowVSuG8LBxMl/adIsEi5zkq569zcHn++mPCXm7dtr9vAPKsB8e2fPM7/RqbD5pO6tMNcMMkOpFMZpkUnS/mJ5wcHuFdy95kwrNf+yqf//SniC289yffwY+88x3kGm5eu85qdoSJjugbLBEXWrQ1VFWFtTnXbt3mqS88zbPPPsfJ0TGj0Yj777+H6XhHQESU/q3MCJNhQvIDoQjR9BvjzGYyEKZyd0wCxWb9YM6yPHnw5GFmus26XzMBtkuaTCB7OAwZpbHeSvT+YCOfZZn8SuCqY8jqumaVpG7BeSmht4bcZuvKDq0pjKXIcnxwLBYHaAz33XcPbfDcvH2LT3zyM3zzhZd55zue5I1vfJz9nRE2y5kUFUWWc8M1LGZzblx7iZ2dPS5dvcL73/9+8vwjfOVrL7Jqfps//3N/jiuXLhGAthGPX2ENNma4tqZP8ySm+g0tclFk+K1XDa9ev0YxKrj/wfvYvbALNqILkxIOpRIhJjlgTMmYbfBUuqAoS0wmqapGSVBDF2RSliVFmW0EVw1Zi26Y6Ya4brAeDqDb158nbsqZtTBjxycnrJqayc4eRTVCW5Ew0gE37u5L1sa8phpBs67KGJ4fOnVKam2EiTRGOjXbVmoVgKIopJ9QISmOCklxNLr3rTkJ/drQGMgmfu0hMkpTZHnfMRlTkmN3TvaBYtqsk0e70vsE+mL0CXiqftCF1yh/Zx1oEqMfMIr6lGyy81B2oDym38+0IWZZ/7Wkf9VsyClDiET8OmzLebxve3AZTQ7WY9A9K9Y0DbP5ktlyIYwsChfBRYNXEubj0n1k1dTiE/aetq5RLlCVJfuTHcajkssXLmJN8hL7Fk9AGUNeWPI8p6ndRm3DWffes8LWep+tUhsAv1sIbN/zhz7M/lilr7taicy6AylS+zNlOp2SZVnPalprUVlGdA6fwCy9V3krsXdwHcl7D2cDvOHn2i35EggxxrBcLjfYcm0TQ5k+Z9N//c2lYAc+h4qG7WdhHNwrhjL6xWLBwcEBJycn5HnOzs4OVVX1fccbzHKSYY7HY46Pj6V79PiYUVFiiwLn2ruCMx3p7zjfadroMM16ux9y2zd6dkrt2b2bd7s/nSWF3b7XdaxxjJG2laRzYwyj0ehUivOG0iKFEAXVxd/oU+d59wzfXDyYXhVxeEcS0TNbYDKL0hm3bh/wmc99nk9//il++Vd+g9c//hh/62//u7z/Z/8099z/MKPpFIqxwkhFmo9g8xwDNI0jz0tCgJs3b8fpdKqG96OhvLmvZzl/nc/t5+Dy/HV+8m/Ja/j2Jcp3f1CtZSJdP5juN9Py8LTG4JsVbb3k4M4tVAjMT2Y8c/06t24e8fYnH+I9P/LDTMqcay8/z51rr4KrmZQFozxn3rZUZUFWjQit47lvfZOvPvsNnvvmCxwfz3j04df1tQ2ZzqgKkYy2raNeLPE+svQrohPpEEEexEVRUBQFzjeSWKlSAIwW6WE3qLR102+cO+9YJ23tQjc6r1xXNx/TU9wYI+DBGAjrwamrmjBKwoHE+iZ1HHmuQMuQH4hU1Vg8coBL/75tHBGFyTXL5YpLFy6ybBsOj09QSnP56v3MFwtevXaLT3368xyfzHnTG17PxQs7ZLnGZJadnR0pMW8aFstjrr/SMpru8L73vY+ofo/nn3+ZT3/2szzxxBPs7+6STSraxQIXI9pKBYA2itY3KYRBAKIpcqzR1NEzb1YcHB9y4epVrtx/lby0BKPIRjl1u5C+sbgeeF3w4jONEbRB2UzSAEMgGmGj2rYV31Mh4RBt3fQ+rmF0fp9a6H1iMuMpAHo2o0EfZKOVpqmXOOepqjE7OzuYLCOqJC8NEWOFsQ3e40Pst+5rNkX3zHX6H6cCPBi8926Tr7NUZYBKEkAIwfdVBzFGTGZ7cKu1kpRmI2xrjIrgDTq2xBj6FM1h2JH0WTa9Xy/P86QUXbNcWml8Uih0Xs5OuqsSoOkZOy1dnForlOn8xgNGOAV1iOyXVC9COgfiWkqpNB2PaJQmqK5qIWyUqRtjsKTQnxDkM0ifrxGETsQPkkSb/r127KgD2tbhGk/dNtSupW1blquGZb0SJi/5vLQ25Mnj6gHXuCStjim4TJEVORemU67sX2A6GcvSKnr5+YwmtynURIsM9xSbeJd77/rcVhvMzzbY+HYM2PDvKqWZL+bM5wuapsWlNMydnV0uXbpEVVW9j62/btpGkla9F8/5IEhreO3Ryy71qffQPS9CSt8eAqLu/O6UCB0z2akPuhAttdWteBb4fq1n4RDkRLU+txaLBUdHR5JCXRTs7+8zHo+lFmm53FBIKKXIiwqFYjKZcPXqVe6k0J/ZckFWFr3yZYhCJBX5LHvJ2WziNrjqzuchsFx/RiHdXtQpMD30wva91N+F/eZsxjP01pLFYkFd1+K/L0ZYk0sVzsaSRKX3LvchH1JOw8CLqgbSeIn2Xp/vfYhgusft7V1AkeF84OatO3zx6a/xex/9OJ/+/Od56dpN/uV/7W/y4+97H+9893sZ7e+DyRVRntLeyaLKBR8JUSllcCHS1g1lkXPx8kXVtAG0KCo2lzUqBZWdv85f5+Dy/HUOMk+DzO+w7+rsTWq8C2gdDhmBerkiOM/s+AQV4fjwDqs7tzHAY697iIu7U04Ob7GazxlVBYvjBYv5DGsUTdMwGkua4cHxCV9++qt85ZmvE03Ow697lCorGeVSxdC2Lc2qJuhWgmJa8V963xJSQmFE/E5d1YRSER2NDMNoqUwIEbxIsIb+uA4sbHhbBsN6P6wMWBfXtBvyNWDD25PZbD1EpsE+txbXSQ5bJ8yqtRRVgfeeZV2n1EbD5YcepvUN4eiYPEsS2sxgbMF0d5c7d27zmc98jvlsxg+//a2YC7tkVjHZ2SHLDEeHB5wcHvXsxM50nx97z49C/CS/+5EvUFQVT7ztrVy9dJGAp57NMcGTGY3JNNEBRqNcJKQ0vyZEThZLbh3cAaXYv7TP7oU9glFECzbLaEOGzQoJOtJaAJSSr2UwaGsl5MRo2f7H9VDVBXYMB9ohKzOUAQ43ztues7sNdp1HKipovUNZwyivGE93UMam9EqLJ2KNQQ2G/HhGAMcGs3JGeMZ2aEnn9STL0vnoiS4QQqR1jtqlJGGdSXBHKmWPScatjPiOjPbCZjrXB/hsnJ8JbOTGSNhVnqMaYXu7wnhlzMYCyWzVI/jQbnR7dsxlF9gTB52v2yycD5IWu/5MzLpqaXCNaSkLEVVB9/4TeNcDaeCGZ06Jp9R73wfxdHJqYww2k7Tf+WzFspXwkeWyxoeQEowVWVHhooRL+VT7oE1GJgMpwTU0dU2uZVG0M5myN55yYWeHSV5KEm6S1Wkl79kYI0y1GVBJQzZLbwLKfqDuj9268qhtWwZBxP19aLhkOSsYp79mlMI5vwHYO5nn3t4eWZYxn8/lvFCKuq5laBrIeBkAy2H4TPfafv/bqoGz5Kzd56i17qWo3fcUVn4NrG267xpjzmT4tNanrrehLzeE9X3BOcfx8TGz2Yw8z9nb22M8HvffrygktGixWBBCSJ7Lgrqu+//d1DUHBwccHx+jtWZ3Mj31vs4CfdtAc8g+bkuG+95T7zE22wKXfNd9lt8tyNz+fLtjt1gscM4xnU4piqL/7If3Xed86pfWqRe0kWVSUgJs9FIa02cZbCdCa2MgWloHt27f5NVXrvO5L36J3/yt3+Jbz7/MT/3Mz/Kf/Gf/Cq/7oTdw+YFHQFucVylROTJfrOJkOpWqXovywRN8xGQFLngWqzZqrVVmTRcsToiizlGp51Pp87ny/PV9ApdnsTff6b85f/3JfH27PsjXihTvZGRn3+DVmQBv+8H8nUhbXmv7OJTlbJ/f20zQa/W29sNBlIS6njlynrIsZZs7m7G7N+H27duo5YIHH7jEww89yGJ+QmhWzI8OyVSgsBmr5QLXOumyHE+YzWuefvrLfPWrz5KXI+5/+FGM0ozzElqPax0xRHSUyTgzGeUoBa4UhpgL24inH0aj8/jo0MGisu5uMChPj+Lx8N7jklyuY0n7SP+u/9JaiqLoQU/HbA5DNmKMFDbrpUO+aZm1rXgXbSlMlZZjbkPApWO/rFdSzJ1nfeCGpDYadASjNePRiMZ7TmYLnHfkoxHlqCAzlvnimK9+5RkObl7n3e96kife/EbyTNG6mul0SrNcsVrVzGczVLRc3N/jybc/wbJZ8olP/j5FVbCzNyUfVdLhGCxusWDlW8qqTJ1lmlXT4rVmngIWrt++w9JFHn79o+RVTsBjTI6PgclkR7boMeKDlGfXTUPbesbTCZOdHXyIaGWk6yxK6K61tg+I2Ej13b5Hp3O2D+CI6yTjDdaiG1RTMIZKfp7uKy6XNUZnlKMxNs+xeQ5KE1WK4A/gInhSBU3qmjOpI7JNA5YZMEebi5peiJskZjJIq+QXjCHQuFZ6UL3n6OiEGBWj0YTatcTUywpJRttdh5DktBlGG6kXUZqwWq5ZrqjJiFJP0jqoxMPkm4bVasVkMsElsKWU6e2p23Uq24yU1gIGY1jXkqiuhqTb9mswGKLzA4CVAJGPUmGiFNbmAjrDGkAKwBGpsLFdeqTa6DHs6g1cgMa1eOfIMlErRDyz2YyTxZKTRUsT0v0qy8mM/Jx129AEx3K5lCAkm5NnBcqalNLq8G1LWzdMd6ZcvXiRnemUQltMDCgCJp0LKOk9ZSMJmF7WuXnP3fTfboSDJUnghgcxHQ+tUm+qEjVKp3bQ1vQg1BgjYUSpD9UlRvv4+Lhnw/M85/Lly0zGY+rVijzLMClAyfa+UFEXSP9k6H91OZ8C7tWpYJhTAEFrgt9MM+4CaiThu+yB7fY1e7dn0bbX8pTcfCBB7pjgLMtYrVbcvn2b5XLJZDJhMplsVLhs90b3aoumTZJ9eVZc2L9EDIpVveDw8FAC2EYjcpvj2pa2rTc8ovpUj7U69Zl3LGkX4NRdA+KBzU79m466l6VduqcNFCKdYuluNSfD83EjyfeM9GoJlWtYLmpiUFTlmDwre//8sOMzhGHNiwSHFUWBcw3NakmMkXFZUVUiS12tVuRFxXyxoKoqRuMx82XNdLrLyXwGSvH0F7/Mt158lX/8jz/I73zki/zMz/4o/97/6e9w30OP8Pon3y43Gp0pEMVOiJqgImU1Vo0P0p0bxOss9xEkNEgH5WKIJpV86qh6STFJDjtotvmeAPofBalwjkP+aDGBUuqcuTx//eExgz+oJ/73772m4TgluZ1mRUlgy22kxGmj0UZxzz1XKDOLJtD4Buca2dwreQi1LpDlitnJgm+9dJ1rN24xmUyZ7F4gtxmZtiJ3DUFkRqkAnZh6+LSwgDLc276M2yXPkKTVteu6hRB7L+D2g15K2uXvCOuSAhK2hg7bfz+9EUbSA9a0YTZGUmC7P69rSQAdJjF2/75PtHWeOAjdCEEYF48M2nvTHYzOOJ4vwAUJ/JlMyawh14rDwyM++clPs1rMedMbH2cyKjBANRkTgoTbuKamrQsu7Ozwzrc/ySc/+1k++9Tnue+Re3ng6lWK6ZjY1NT1EmsyHBK+433Aa4/XBge8eO0a1+8ccv/r7mP34gUpltciZ8IIOPPRSVDMNuMAKGMweSYsGiJVJQXsbA6TboOZ6f9MbW7/twHRcHgTL57b8IrFKFJQbS3GaPKyRNtMVFpGkleDAheH4U+SPivD2PrzU2d02a3Zue1lU2LB07/p/LcueEkqDQLGVJIGOh9xSQqnnMIT0AlwYbQMTSFuJH320lgFykeU6ep2ItYasrIkMwqfAJruvp/Ra0Zxq2pF6bjF6q/Bc+jTadVpoUTXaadARfHi6q60PcmdSTUEskQYsMDJfzyUe/ayXdbDrbE52mT40HJ4MmOxnDGfz1k0LVFZdFZiMwvp/uS8hEp1iapaKYyGEB00Aecb8JIWfd8997AzqtiZTBgVJVk6ppnSvSRWY9eBSoq+bzOkZdxZKaB38wZvg6ihzPksyfeQNRomsAq4lAG+AytlWbKzs0NZlj2zNARTw2umk74aTi9TBVCf/v5nDbk96zmQenbsaLeY2zjPFFsptPE1n2vblSfDHlxrDM4LYKtrAX1VVaXQrrK/F3fLmO6Y9D2h6f11f6atpaoqptMpqNADZe89UZvN1PEz0pe3QWaWeku7RUO3FB2C5O3PfHu51h+TbUmruvs8cLdQnyHYXFfj0APeoaJk/fzyvef2rOWCa2qqqmJcjcT323qalSQ/V0Ul52BU5FlONZ4Qdc5y1fDqNckV+Mozz/OLv/SP+VM//eP8/C/9PS7dcw/33f8g1T33Q+PBWiW+Tqnx6XLaoyHZWmJvR+hSpZPNI+q4fT3ptADTnEqCO3+dv74X5vL8df76bsDmd7ot+qMApt9fUPntvs/6//dETHogdR4e0DgXuHBhj7LKCaGVPrHVEm8zqjwDm2OiJmJ55cYBzzz7dW7fPuDS1QfY39snRBlWdWIHYhpKgwcd0uZWKUmKVQrDmtXQxhJtkp1G6WLse8HiOuyhS4uVB+GakRw+tKVnz+FjZNU0mASibSeBG0i4jDFkRgYWZQ0mVR203lGvVv1AYQsJV0EptNUUNktA2EErJeYueuqmRqVOyGo8Znc6Jc9LvBf/mIlQ5gWaSJVZDojcvHGDp774ZYzJePCh+7hyYZed3T0MmtVsQfQts+MjbJ7xwP33cv32Q3ziM0/x2c99jos/89NMqwqtIlk1gRhwePJxSR4kxbOpjzhZLHnhlVdRmeKxN72R/SuX0EVGSIEjRmcYYwlt6CshREAtIErApUWbfO1BVFoSTrvhRkeU7walIOBE63747AYomb1iL20iDMJdQiAo6WSLPg3qyVvTuk5WZynKsk+IbYIwUutQiVQBolLICEEkm6qTGYYzhnI2AFpEbYCEZBKV1NJGhraulLwLbTHGEI2W9MIgbF+IHkcrXKYyfcBP1wu4ZgKTTDMGDIYyy8lTJ6nWmiLP0ARa74VJR9hxzpASi3dYmKoOQInXMXml+tLxxHwmr13ns1wXsPu+Tz5EYRF0SpzVidUNkLruAj6kPsuBZLJtW5qUeqqtISb5XNM0zBYLTmbHzBZLWtekm5XG+0BmpZ/RhyDhNk3TX69WG4pcFAmta6hXS1CR3fGU6fQyF3cn5JkhzywZGh086JjYy3XJ+nqxEZM0OrEfhK2wnXgKcGwvSYZLke4z64DQtgxxuNDqpaRWxp6mlnqV1gkjOp7scOnSJcqyTLL7bP09Otl38rduLgfCOuVXi6/PYnrFQMdon15Mnu0j7LoKO5D7moqhMxQ724BzuFwagstu+dGuVvimEXn4aERVCajp79/pHm6NQVkrfagxSr/noCqFELB5xmRnSiAyn88JqeLGE8UfHXTfnywhWWeHNunB82N4fIay+e5z3TxHdA8uN1nczRTquwHx15oRTvs3FW3jaBvfLwSGTG/Xyzr8nM+S/9bNEp2Wv1meY7TFGIvRGa0L7O7u0/rIfNFw/cZtPvGpT/Hpz3yO3/rtT/DWJ5/kP/9//Rf8+Hvfx2S6y+jCRTAWt1hhq6kSBYMBZQRYdq1mqR3G+3SM0pJH7skRK46X13h15+W56/KfdpbybtfSObg8f/3hspnfYeT46d/7w5MzfD+B5tlfZ73Z8z6iM8NoMmayM8WHQOMc3pF66SKr5YrZ7Jj5coHLSmxWkKXychcVz7/0KjduHWJsQVUU0tlYN2gTqYpKPBrJi+Ta0HtxhtH6nRx2yOAopfo0zA5curD23HVAWYam5IdjK3Ewpk67tt2Q7TXd9iptzLuhwHXeoRCTZGg9eLkYCK7FEcnSkGVTMmnnrfKpl657D1VVQVOjovjhqiJnOq4wCwXBkyuDRxON5dKlK1gNtw5u87kvfpnFakn5tjexN66wKHSA2MiAvayXoAIPPnAPd45v8fSXn+GxN7yeRx95hGlRUe3usppJmmLUirr1eKNYuMCNoyNu3pnxwA/dx0OPPspkZyxAQAHakmU5WV4Kq6QjeCkCbxJjNDi7iMlLqLRGR0MIpq9C6KL3lTqdkNjLzoZSvsGvDlzqlAa8fW30SwElLKq2RiJWYwojGQ4mA2ZF3yVRsavAiFseuChFm2v2IwFL7wfR/Sm1dtnUInXNLDqTvspMG+mkVAGXzuXGOUKqVzA622CEjNFYbYRRC5HcStLlaFTRudbE6wS+aVBoVAiJYR5IG88IT7mbh7X/fa36vtduLFNGp4TlLjXWEPF9WMY6KKtLahbJbbcE2higlcIaQ1bktMFTr2pWqxXH8xkHR4csluIZ7CpctLb42qGjSI9XTdP383VpzkUhy5lmtcS5hsLk7O9OuXjxIjuTKXlhRcIbOyl8kLCQGPAhknWBPb1va3uQj2cO+Nty0uHxHZ6/Jt3Lek8ip5nwbbZTpX7QxULScDvAOR6n0KpUKdEB1u78PRt8hDOfc99ObrnGpptVM/0SLlunY5+V8BphA1wO2dWzmODtc3WbEeyY246xPIu1G3pCBUyFU3UwJgVxdUmp29Uoa/tIWl5tScuHVpfh5zwElsNeT075yeMp+f13suiOMd7VujO0xgxZYO89dfL/b9bpnO07P0u+rIwmRPHhl3mBjhrXRpTOKaox1WhCM1/w/Esv8sWnn+YjH/8kH/j1j/DE2x7iP/pP/w4/++f+Irv7l2XZbHNQlrb22GKs6rqOeTVSHWPZnS4qDvpuU4VY/96C3G//sGav89c/PQDzHFyev/4QwNUQXKrv29f7Xk/8u/3v7/E7yP8N674q8AlIyIBobU5VVVRVRRs8jfNUBdg8hdngMTanrMYUWUkxThH4q5bbtw546dpNjC24fPkq1uS4VS1Gt6jQmfjUjNYElNgrAK1tD85CCHjl5T2m96tV6rpsw4YMVffeMDlGq7YVAJD+ZferYzB7SZo1vQxqgxlz6862ADTOobyXQVkpjFXY3KIyK2mp3uOjvNeoIsEFok7JmEWq3iBitKHKKnKbQ2JtFrM5Ns+YVhW5NiybFRYYlwWzxRxiYDzd5/bRMS+8cg1tDffed4VJeR82KyStNgtkquR4dsLy+JjdC1Pe9OY38OKrL/PxT36CixcvsrezB8aj25ZiknE8n3G0WNAEuHN8wsvXrrN0cPW++7l89Qq2LFg1tYT1pGOVZUUaQlpcXJejh1Q1gVb4qIhq8NkMvErD4VSqcNbD37CAfhiAcZYfqwegybepUYmxdOnfi+SrbVuccG3YtAX30fdMge69RaqXgYUQ+iGml0dvDVndgqMDmEH0bP337OVjTljMHvwpBUYRokodcEaY5DAIuAngo8N5JzLO5J0bvrIsYzwaMR6P8KmOog/MsUYWIAOAbIYL+67blrA1oPrUw9iHPYqCNUaU5CcTVJBuXKWlRiVJ2mPPWqavOQyjST2dovUVWbLV0o/nY+jTWjGak+MTrt+6ye2DO8IeEdG26wWFlfM415JnBa33uCAKAh+lmkhJtSihbakbSZseVQX3Xr3CPZeF3fPek6nO85mG1HSAXOrs1Kn31NBJOXX//0dE4jz046oQEzMojL4y4qvuGcAQCK0jOi89qpnpweVrgfxt1rwDBi4FHRVFIaE0eSXHtpNnIhSO35aY988QL0uelPIpseEQcOlc2K682qyxMgM/enduD6stthnIdQpt3Phqd3veDYHktvy0TbU+nfWgKIpeirodRtMds+549QFug37R4b/rvl5Xe9OHFMV1knq3QBm+3+171jAFeAgst2tH1ve1QEcYb3sk04M6HX516t+f9oNvAs8hw962bS+p7pje7ueU42HSwmgrUCpuMa3dZ41mUbcUWcl4Z4+sGoMyfOULX+YrzzzLb3/4w/zWP/4YP/TGR/kP/+N/nz/9Z3+OBx5+FKcymO6xOj4mM5bM5jSuxmYlRV6pMAjn7lUuYXg2hj6krHOjEtgEnP2ZptbMbzqW5/Dz/LV93+kJjPPDcv76wzjJ/iDA7Q9LtvpaAJPvw/cUr9rQ2d49XAIxehrniEoxGo/Jsoy6XrI3rVjUK04WM0JdS3hCXmC0RecFQRlWvuXVG3c4Op5z5dJVLl28Qr1aEVon/cfGSvKrCcSBl1EeZjYN5a6Xhg074ITsCac9eQNw2Q3fwjgl6eKAWQ5J9KetIUtBLN3XHw4iIpM1W4wFRCWyKGMtmbXYNPB0/lSMxiRZb57n2Dzrh6JOQktcv8e6XhGCZ1xWFJUls4q6XrGzv0eMkTvHh2hr2dm7xOrWTV6+dpNXrt3k8v4+O3mJb1pcCGRak2nNqp4T2oJJVfLmNz/Ghz/2LC+//VUeuP8hUJqsqqh9A5khH405uH3At158gRdeOmD/njE/9MbHGU0nRBMg9XmazKIwCfyLVHajJiF2oGLAwmjVl8Zveyd18tfdjWnoCs+HvqleTqYTnExsocwLcSPuXjtZhszmC/KqxGbVqYXRMFBoe5g3enOA03cpReeMREgXA1meE4GmaahToq/WOoE+tfYeGo1FWMCgFcErjPdJZpyCuxLAdenB10kfu6TYpm0JTobhLMvk95yEwbgY+gJ4AfQa0me3BuqkqoPTbIX0iCYQ3n1ORm3J6GUxdRZAimq93jHGEJLgtLs20IrFcsnNO7c5Pjnh8GTGyXxG6xxZWZFXJcbmuOBpm4YmyPuQOhyRZHefmXMtwTtcvSJ4z+5kzIWrV9if7LA73WFSlSiV/LQRXJ/OCVrp5MoyBAc+eTZdApQqDhcb4kfvJJXb9+gQwsYyICZGe1jVsQ02hkuTOEjS7bfpAzay6/Rs27YPytr20zFg+zdAUFIOeO+2nwad5mBDpnmWfHB7+dqBsg5YdnUgZzF7XRAOZwLQswe+4e919+c2PR86pnT7/Q0TiIf3c/n7Es7WSWi767L7Xl3ewBB0adHBrgOM0vl+6lpJacBD0Nl91q8VYLQOs1Kn1AMbqbNxLSseAsuz0mu3lTpdn2Vd1/3PrQcKne7l/bo5uJduqzUb7WMgoCRkKkTGoyl7l66Chy8+9SU+9enP89RTX+AXPvBRHnxgl3/73/3b/M/+8l/h/kdfnyT3hojlzp1DIprR7pjWB1zQOBTLRR2rqpA7Ut+/GlI1UDpHYkqIT4uLTn7fRUm8JnsZZTF27r88n/fPuredg8vz1/cOrO5yAzoFuv6IQeV3chF8zz9/GG70UkedCv3A6KMwLkVR8MDDD/Hgw4/w8jNfwXvP888/z4OXdsDV5HmZZLIWlCEoi1eGl67dJGKpRhOUki29sRluJRUA3nkBAhGpEzFmwCwGfB/4koaq7uGKpNr2SXz9kD94SGuFNanywm+BiWGiY3rgqy1mYBgUYZN3c3Poc7jgiCYSVSCaKF69qPout7zIemai2+xjZHM8Xy2xylCWJZPMslhI6mfwksJX5GNuNzWuWWG1JrcZDYGLFy8TteGFF7/Ft55/kfuvXmZ69R7xrdW1sCnRkSmIwZHlGQ8//DA7X3qWrz7zNV7/+se4vHcJlSlm8xOywqKM45UbN/nWiy/SAm9/x7t4/RseF0ln2l736Yt9mEQaTEyG9yKH86tW0j29x7Lp1TrrOlPdoKnVmbK3Ya/kkP3sOk271M5+WE0yP20NGkNVwcl8wWw2oyIyNsVGIMX6mtIDJmf4XjeXF2v2NYKm756MCPPVg0vWTEHrJLW0i/DvWUQz6BDU6+AbqxLjZw0+eXlRg8TWxCgZrRlVFVUuqcJOKdyWhE/r1HOZelfNGbK5zQCfdK9JS4FuWdOxBd3ippMD+gR8u4AbklczDJKVIsOFTFdPovvrrGkaVk3Nrdu3uXbzJiezGRhLVhZMxhNiqo9pvZdaEaXQeYFB4bx8b+/bBB7aHrBHrdjf2eW+e69y/5V7KHJLbBzROZQapJ32PsqA12mcNnrtyopyIvskJ1ZKEUNP2sq9Kn0NndgsYQFj/0sjHlNJqXVEL125HRi7W9n9kH3ruyIHLFsHPouioKqq/t92wU/D6px+OQLr87yTcHK2RHqtFFF9Rcb2e+veg1IKswUut6WgKH0K/GxLiO/G4A6XTP33S183S57jbeZuyCZ28vKqqvrUbq21PAN13AR8CpHIxqIPX5PlpPw8oU8e5UzQO/SfDhdiZwG+7t62Ce7Ez9x5eLdT30P3eWI2gOVZzOX2c2v4/kajUQ/C5RzLNr2t5nTgUB/ShKFBobRlb7zDdO8is9sHfPCDv80v/NIH+PRnvopr4d/63/3L/M1/829x8XWP/v/Z+/Ng27bzug/7zWY1uznn3O717+E9tARAgAAJgg3YU2xMU1TjWJJlyeXIsVxJXLGdKjt22eX84TiuxInjpBzbVbHLsSVZjhS7aNG0pFgUSZkWCDYgCVHs8QA84LW3O/c0e+/VzCZ/fHPOvfY+57730AqAzkId3HfPPWc3a8811ze+Mb4xWB+fMHqFthXrYQQDy6NrBDQnq45u6IV9T3KJ0Qm7qLIBH0HGwqM0wrwKhZWUXnua38/jFnv1WzEnuxq1vDreoLa+ApdXx5cVYH6hwPJr10I6TK86tLZEHIfXrvPOd34Db3/Hu7j9mU/R9QOf+vTnWD+4C35kNl/QNDNQhtlsSWUb1uuBe8cPMHWNtRWrTcesqpi1LSddn+z1bWEDdru3Wxt3UtC6916MV5JBT5bBaiimDTud8CnTmJ5EK4s2YLBidJIAUwaaeo85mGa25e546fyOAYLc+HtPctxMkQpFDum2brEhoKwp8Rrr9SlRVywWcxazOcYqzk9OGVxPXVvadsFiseDuyTEulfDeOxaHB9xSN3nl5c/ymc++yLve+Xaeffxp2uWBmJkEiT2ZVeBVZLFY0oXAu975LL/zuy/w2p3bPP74k3TdGtU09N7z6t27fPJTz3N8MvDYYwve94H3cXCwYD2c46KH5LabZwx9duBNmYNEm5ilNcPgGMeeKrRobcQePjFEeofN0ni8zIvqFA2CSp993Mn4Yw/cyTpRqQjT20gAH3aAYKsqTs9X0qWvGuaLuPPveV5r50YDRK0kFieLrYqD5tbpFRWICTwosjtqkgeiiJNMv83QC8PUtCjEiAabitMEnkByJSUSJclQC9tTljA6iumQQrFoZxJpkw1lEPY4M55ByCuJNMhMaZJ2xhhQOqYGfgK3Gein6z8m4x75+W3xH9nOp24bcRSXWGGUI8FvmZ2kuBQHV51jOwKv3LnDyy+/zPGDB4xA3TTMDw6Yzed4FF3fyxyqktku20isSxhHQu+S47MXw6kYaCuJj5jVFW955hmO5kua2iZWG+lieY8bBlS6Nn2KYCK7B7ObzxeDAMsYfeZcwYPC51/J3RKJFblEWSJ7gMP7Mc0mqh1gOVVh5MMYU+b1jDESpZJMwJxPMTBa2N+maZI7rsTTeO/FhfsSJc4FOeYeGAnFyEnt/fPlbrElmzYBqSmYm4K/Yti182hBmpJpOlfMoUz5e2bTY/Q4J0Av7/9mYoyTX8+0QZX/LTuiTg2SnPPUdUPwFHAVpkydsZgm/e4ooNZFjw6BMGl0aTOJNkly+H1X1WkzqwDL/Jmn+4YiEj07ObCZWZ7OcWZwSYxl7ECl7+lLOGY9uRfl15ddY9t2Tt/3eO+o65qqstsZby2fZ4nWCSRZbt5rNMZYtLHM5gcc3z3mL/2lv8x/9B//F5yt4MPf9j7+tX/93+Tbf+THiKs1qwfn1IsDBhc4u3/C4vAItGHTe5zrUdpydHgd7z1nZ5uYpLqicC3ZrqmZpSSzOmbQqUxqmGh0DKBMki1focir4ws7Pi9w+WaZn6tB4K8v4Pi6n6nO7GTusCfWCVLm4966iXpvHb1xLuVl626/oJjGHuyYksSLkg01ydbMs5KX5Yblx9uXzOx0QEMUAKnl/ZfuqRITkL4bMRWsesdzb30Hf+iH/xFOXnmRz/7eb9PUhtv3zqkM3Dk5wTZnnK8CqxUcHYH28nUz5VrFdi7v1TmqxZJh02Oip7YVdTNLzKfaMo0qOXlOIhAUCu9jcorzO8A053SWbvrknIQcCq+jdM/NtogbwyCusXuxIxhKDlg3SNRIzsLU1lCrNhUrGmsrrJWQ8FykbI1lAmNiYGMvJiXKaI6Ojjg/OaXvN8znLddvXqNta46Pj1kNHcFE+jAI09n16MoyqzQNgXbZ8PTjj3H7/j2e/8xLvPO5d1AHz8oP4DtmlaWpazYhMPYD15eH3Di6htYv8MKLL/D0c89wcHDAeh0ZhsCLr93lDz79EqsOvv+b389zb3mC2sJmiDJTZmpCAIOmqpJpi1US04DCx4GqqpnPlwzDwNnJCcvlEmMaYYTGQYxllJX4De9SEoUw5SoEmfFDE6Mv4NJUVthgn6IplKY2VsBdyXv0KC0y7jxDqJO7sDGGp556is9+7kVu375N3c5YHF1jHJ2w5HpreiEFZkiOr4pxdIW6CtkQxxiCSQZNQWGUsOsARlmIHp8jNHQNSnFycsKm68BYBu/xRqO0ZbXa0LYtKoC2GrQV2WnwZQ4xF4aeAR2h0YbgR/zoaBqDNUoYOe8xlWFZH9J1Heuzcw4ODiQ6w3l8iNg8W5YltsrTuZ4YRqnytRIQHaOw0kjOHpk8jjJnnGFHTIYmWgaci4usSnOjzg8sl0s2mw3rrsNUlnYujo8n61POzte8du+Y0/WG9XoNTcVsvmS2mKO0pQuBzTDgnBN5dIzMYmRmWrRS+OgZVufEcaBpGh65fr3kG7Zty3I5ZzGfy/U4Jnkk2xzRreO0L0W+VnluO81Q5llL7VN1LZJFH8GomB7P77JRRT5BYvVd2VtG19MPG4iaup5dcAxVcUKrxEg/9rKO6yo9r8ymRqPxWvI8bWNZHMyxtWH0A1pl+azBbboyKywgJBRQp4Bgqsmel/JQQ+ailTxXjMkYTV8wzHLjiHcDITiM0VT1NltSOcVms8FEg4uO3vUXFAACCoOM4UaPMRXGqNRQHFHKMI491tYYo9Le4BJjqWTPnTRFVZqRpWBmC8kgbtbKfm2N5Mnm1+knc6DlzhpiUc1YbajaRYmc2nRdYoc1i8UCH3YZQWkK2B1QXSqFiXwTZM15vDQvkjxerrcsq718NlNj0gfoikWz0UrWrkrNltSQ0EYlj4BI7wb8OGCUom5b/OCxqiIScL0rzdCq2UYeDeNI08ywTU3fDQz9mIBoTdMuQVecn2z4z//CX+b/8H/5Lzg4gH/n//rv8Cf/yT9Le3idYTOyHiMBg3NQVQ1HN1pka6kwgLGiiBl6WSOVFaMzY4xSYdLoQRNiYMxrWOfGLaA1WhmCCun63Y5SoPNYjN8t29TlNdm2pvgHaw50hUW+OGz3MHOwy763r5i4Yi6vji/xAlWf98X/euDxK8mifiGvcTtTk7C2yXWI9OejagiMEt9gKiRMGd7ylrfwoW96L22SjPbjQDSa9XrN/QfHbE7XvPzSS7jTTTG0OTg6pK1naU7IY4zFws7cR+nwloiD3T+3jEC2Uu8f+p41IlvM95ItyNZl5ikbXWRwuS/LamxTZnJ2ulrWUtc1y+V8t5M/QbtRwdnZmTyWNUlWWhVzE6MESBml8GFE6xl122AqSzds8GuHqSuOjo44ODhg9AP9OHJ4IIxm16+5++CE1bpjtVkTDHSuh6GnqhSVqTloZwRr8crS1g1VBXfv3eNsdY5pa4bR89rtu/z27/0uJ2fw3vff4ls//EGuXT/grFuL3DKJkKezR2iHQeYllZZ4kso2WDswesfQ9ZyfnnKQwuHVRI6XP0utVZEw5ZEzKR5DAopbIwrI2YjZen4737e7nifXThA3Wzc6Zk2LtWvu3btH1cy4cesWxlqCi3vsy3YmNzuh+mjKaxE5nJZsb6XQISevTa/7xMAg7sfdOOCcSDW1sqlAUiiMyL6Mw0RFtFKYThtKxSglMYVKR7RXKBXkezo3Vbw0ULIpjc9GQzsp4dtM12xiA2LOo0yZJ72sORZSQwcmAfJR03drrNJUViSbfnQMiZnTtma12aC1ZnGwxMfA2WrDyfkDTh6ccbbp6IL83NEjjxRjEJ/FbEYk433fp0YZtFVFZRTDMBKGnlpHFocHXL9+nRs3bhRVgDFGmhC5aM+S5Xy9kwCTlgYdKpRZXYlP2e6NUaeZysLiJJZWqRKBsDsXJ+yOUqrMDEsszVBMVOq6xtjdOI8sP57u1ZlhSrTNFkZpVQpuW1XoyuIRUKFKvEYo8t5iPLPHpKqJVPNhRkL7zOaOumQyE5qvv+l+Ps2V3J8N9N6LemLHMXWzI+Gsa2GpmyZiTIsxCq0rrNXsp5zsy0IzaJ/K2vdjhfIkxZtxx81zhz7P8StN13UXIkj2o2UuY4vL3P/08gyTucEQiqFOjJcwzTHPiqfmnDYEPN5HAj7NxDNR/UTGscf73GQ2EDWjF3WQNpUw3uLcRQjSFNXG07ZzlDUoNLPZgn5wKAx1s8DomtfuHPMf/D//Q/7CX/7/8T3f9X7+lX/93+Q7v+f7MO2CTTfilca0C+xEUhvDdK5U5T5/vrbUpPd/oX2fUrBTq1mVdo6KmqApygzyuZnKvSfPuN2rr46v9ePLMTZ2BS6vji8P0Pw85BSXdby+2M7U6wHMz+d5LnPfu+z17gbDp80+FxXJMS9Ex/nJKa+99hpvf/IRPvShD3FjuUSryDB6VCVdxLPVOa+9+Cq/89u/ze/+2m8S3dbcoGlkVio6D0SMsqXLu+MmGrODX7nN7BkZ5ZvFrlmBYdc1zyVZXlAPOa/JDjOwa/ufyYNSSCcJZXAeFyK6VhhjC+jZupmKO2x+L03TbOeDmMzupZmvw8NrrFYrNuseazqM3c42eu+5vljSLubE6Ln/4JhuGCAG2qbmcLGkbQzr1Snn5w9oljOGfoPv18xam2RhaZZHR2azObPZnPv375ci9+TkhOef/wOef/42h4fw4Q9/mOfe9lZCmvszVvL8XNh1TdUpviAGYVFyQdU0DXEQA5vj42OiUtRtI4YsSQIYXSgSVqMyNIsljF0cd5PMLgZh0FQqPoNDVXWOkiylwbS4i+kftsYhMls033TcO36AMq8xXy5Z1PX2c52YpoQQJlK1/JiXhM0rVWawciTOVoUgQGYYHd3QM3iHrizKSAQJqQiPk6LbO3FRdSQWna00OL8OoxReBYw2NFVdiveY5qUxGl2JuZQAc1lvVomMWeaZPSqxHKqAgpikqruzqxcbX/k8mdJkEcfePPs8MvrE+NgKMIQY6bqek/MzHpyecLY+Yxwlkme+OMDWEl8UY6QbetkblES2qAh4YbarqqIyVlil0eGGkWVdc+P6NR577FEODg7KHGdeCwL+9I5j7g4YSqA9BF2y89Tkc85lasife+Shc4G5aJ/O02Umy6W5281ms83gtBalY2qYpOs0NbkKwAq+7EHTCBgmAvO2bYtxTozbEjoD05D+ITdHpvubuOBmFUwkar/rSptmmk02vUqgz3tX5tJlLlAX5lMpgzF6B5xuTXLUjiuxgEX52akjdD5H2fyoqqodSfzUbfUydmI7Z8gFsLmr3All3vRSUM3u72c2MkuVh2HY+fc8Xz99rZfds7dyZF3myvMeI6qNCViOsp/EouKJk/cmIwUKyXmNQYy3bDHpoTCqMo8sbJ8ylWScJlYvNwCNMdjEPiul6PueqqrRyjIMDq3h1s1HoWrZnJzwsY//Gv/Zf/EX+ejHfpUf/6M/yD//L/xLfPDbPgJVA6Yi6pByLyuZOU6O7Fn6rPeatm+GWdr5tzdoxE8bC6r4+zJxS76qda8A5hW4vDq+TGzlhU2LN58v9aVc3Jc93xvR+m/2dT3MjW9btMRLX0f+70obXC9g5NVXX+XZR68zm81o2xbnBmpj0dZiKstyuWTZLJg3LdebJS9+6jPcv32H+3fv0WiZDZq1La4fMNpc6PDuvjZ2upv756Wqql079j2r+yp/Lg/Jvpp2hXcYrJANf3ZZBJ9nc/JMEX5PdiwFN5UU28v5QiISUuE0DgKyMxta1zV93zNsOk5PT4vs9tq1a8Woo60sg5e5GjeIrDaEQFNVzNuG8/MHdJs1cVmjVMS5ATf09NYyxEi0DdY01G3DYrHgbLMmRoVzgfvHd/ndT/4u/Qjf+p3v4oPf8gGsNZycnWKqKkXSbMOrM+uapUY+BHSShHmi5ApaYbK7ruP4+Jj5fM4yRtrFHJtYlXEYGZ2jMTIvyX7YuFIXXZIJF8BBDJ4Q9AXTnWmmozGKtm05PFpyvt5wcnrM7duv8UzTYCu7ty5yfh1FHj+Vre+szwyL0+WTWfApq5TdPEuWXFUzRI+KEhWilEhsY1B4ssusLwY8MYTEcMeirNBa06brbOoQmotbpRT4CdhNMkOjwCCOi4qQZtnCbgG2Z6i0letfZK2IUNV1mcH1zokrbV2ho6gGBu84Ozvj/vEDTlanuNGjraaezVDGULczRh/puw6XZM6RSPQen6SsbhhQIVJphSUSvMPEQFMZrh8ecXh4SNu2O0Yveo+R2x8H2P/7G+2xlzXp9EP28P3HyKylzLb5JCmstsYoKhuSqJ3cwzz3tr+HT59Ha10Mai7bu7XSlzcuJ4Y8O0BK7Y59aKV3Cvh8ffpx3Inb2Z97LM0953Ze664zrtkx0FKXzlXHC66603GP6c9kt9qdJpEyZV/JzZDS5ArJuO6S87rvvDoFtNPPIpsXFWA2YSyn858Pv+fnjFi1M6pSZs7Jru0X1+nWtTXPFmqiDmhsUfuE4BlHmVWNkSI7NqYqpl3R6O2oTTFWk/d6dHiD+/cfsFjMuH7jJkPX4/vIK5/5FD//C7/IX/wrf5WXXrvLP/Yn/wn+1X/93+Do6ecYVxsBj3pAmwqUwWXzqeL6bUpz7UvVkL86ro4vJcC8ApdXx9fF4n6YbDV+GTszuzfMi9KbzKrkbm2/9oXxWiwW5QY6DAPKiDlLN/QYJUXu008/zXNPPMXP+5/hzkuvsDo7ozs4FPlNUDRVTaU0Js05qeTKSLq5SUZb2IaVT2+uibPan4t9GOM8LVx2ZDIhThw+wUcxP8kuoMGleaqQDVu2Rj+SL1cJ+5YA1zS3LudCGmPwUSIIQi9AExOS0YTHVg3eR/peWI3lwZz5XM7v2dkJzg3F0MhqQ6UV86YmXl9SWXGEdeMGwzWqyuAT4B7HER+gnqeuv7JYU2PMSN+N3L59mz/41PO89lrP408ovuM7v51nnn2Gdd/RjyP4AdPWaCPRIygmBaKY1yil8ESGBKCrqqKZtZi+Exng+hznB3wY8X5kNpvJeSkzzoGITpbycQLcto6keRZNI/OCwY9Eb8s8mI8BfHptJBOKZF7jQ8BUFcFFlrM5jz3yKC+8/CIvv/wyi8WCmzdv7jCeIcQil7u8CbPbNfcZWIUA3k+Yd2l0rPtOonxA5qm0ShmoYpZlrZVAdhXwUSSq5IbHtFESYzFnyYDi6OiIqmpS8bllgIwxhMT6BDfK7+Y8yujBJ2CsUl5jcXAVRiuEmLIZk+lPeu4t06dLv2eqEBDJtKGupGGyWq147e4dmQHtenx0MjvXWKKxRGC96tK1JIy/tWJuFNLjWSszc7WxNFake24cqbWiOTjg0Zu3WMxbtAbnBmKMqXGjLmYHJhMqAdV5BCIBc6ZgUyJX5C0mZi+mPUrtzVfG7UxiSA7X0z067xNZHlvXdQGDubjODQAVsus1eJf23tJ8MyQ74jIbn5nJ3JCagqwYsmHSBXsXed9GJIHReSJp5hSTskwpTQ9xS047rpfmmhtHmbX0W2A4jdnYz6Sd/vcUeGWDo/x7GYxVlcXaquyPSsksptb2AriY3remcVU5s1ip7X9nU7Y8ayng1FyQIcc9x+X91z9lJHNzc8psTudSH8ZYlmZviFsfqWy2HMUsimygk+XMOyxeJERdGlOyjrZMYIyR0QXG0eF9SN4KBm0strLoZB42krJvjS7rzEcY+hHnAsYuWBxcp21nxKg5P+v47d/+DX7qp/47/pv/9u/w/m9/H//an/8X+SN//B/j8NYjMASq2RJMjQsieXEuORsTMcpgDDL3qjWjC593ffX51lVbUz8moZlXterXcw3+xZAxV+Dy6vjSMpjTIfsvkq3Mneg3s8CVUipOfujNXhCfz4WzAxgvyb/a2YTZBZdaa6ySgnWz2fDgwQO8h6Ojo53HbdsWVVlx83OpMFSaV19+kduvvsbQ9dy49QgH84V0vAfPfD6XgkDpiWuiujTfbP/Ph52H/c9uSNmC0asdhqfMB7HLFGRGMhdIejKlkUHjlOGcyrWMMWi7azufJbI2zZ16PxY5WdxsiEjBk6VW0mkeGUfpMOd5sxA9KnrqxjJra+rG4rCo6KgMaDzB99jUCFDWoK3B1g2malC2YgyRzdATYuSlV19hvV7zm7/5PPMlfMuHP8Rb3/Y2CWcfh2QO4sSB0GgJg1cSFaOtzFHmjNCSc5nmFJumwdYVwzBweuohRNbrdWF+m7aV12mtRK/oLRNpdHVBcpgdTuUc+cJE2Gybn+SDQAL6uhTtMReLyQ3xxo2G+w+OuX33Pq+99hpt2xYWecpwkMCpUXrHfj/umUTlkcYQxKFVRzGmCAlwCsu83RNE8kt5jftMqNYaiyGaKFOb0W9z3JS4alpFmvddoo0hDNvA+xKRkYri0W8ZSKMqQvTJ9XECROLF6784RPpsALPNT9wp7q0hEIWs1fK++7Hn+OSY4+MTmTlWCltVGF0T0YwxgEuMaWJogvMyq5sK9qZpmM0XjP1AIFIpJFrHjYRhoKlrjhZz5osWo02JqJgW9xlQXFboT5mp7Da8Dy5gN0a4OOJO9iKfmk/7oCT/TNd1xak0Gw3NZrMCcrKEuKwxnV6r3gKm/XU33b8zWzZlm6f/lt00H3q/UOGhrKtWCjd5zP0Yi6kCIzOC+efytbSfG73/OqZ7ZV5feT+84K66dw/bl7lO30NmVcGX17tjrlPYVLWVTF+YidxlCPdnK7fz4FzauJzmNO/fr7bAmwszlftr6GFAdercGlPJodk1XJLrN5vO2fQ52dKoM6nZELyMENSNSKwVFS5EmroFNLdfu8/v/d7v87M/+/P8tz/5U8znS/5X/8Kf5w/9xB/j/R/6MPbgELfuMHVFN3r61RkHh9fQJqKUOFXb1MwC8C4w+AEz+UzeSM11qSz286x/FNuIuaw0ujq+vkHmFbi8Ov6BAssvBrx9sZ0SlXSpryeL/UIf+2FSmv3v5dkiP2VqkJmcXEh0XZfm9WCxWKBRKUhZTDmquqauoe97Xn3pVe6/eptf+Ns/z+nd+yyXS27dusWsmbP2a0L0Mlula6lKEWtxUijyGwPqeDmrpHfPVym81OU3rAtSR5WMZoLeeY48u6aiJiqdHOkuzvvEEITJygVGZbfmQZNYBpckhLZqCEpRaU3TtgQ/0g1DYgFNKWCylUcuvJVSrNcrQnDMZ2JwMYwd3g2JYtXYpmW+PKKL4LzMxZ6dr1FG85nPfJbjk/ug4Zu+6R188zd/gKqxnK5OGaLH1hXWNAStqJoaYyqRwGqNshptrczCqe0M0nroCsBsraVp5HXleR9iZOw6YgzCQiVQIMBczrvWGhWrcn51YTQiVWWKSYrTA5XKgfIilxXAmV0FxYEyz65u5XaW69ePWPcdD47vce3atSKrzAWpsEBSJBuri0xsKsXbyeZTFAdW7yVf1ftA7yTzE72dr3TBE5lEp4SwNS7M6yy5xJJke3lG15jE8mtZ1+KurPEoMblQwuKasH2twY0TKWKA4FOAeTJz0bH4ImW35X3gJZeV2WFtQkDWL4p+GMXYJUZWqxV3797lwYMHbAZhqjNP6LI5CSK3FDOdNG/mR7wbMbqiqWqODg6Zz+fcvf0qYVDoGCRiIICJ0JqKo8VSJMMp6F5AYiqbQ4C4lVHvm87E5EgtDCck9xMBu+m9yPWcoohi5kD3GgxZynvBKCbuAC1rNfP5nLZt0+ehMEbho76wF2UH6un5996XeIoLs4dRrjFjTGmWxTyrm6KA8prUcesUW3QxwacmjBaJZZod3ZeeynqKSaKc3JjrZk+OvlvU5c9lX6Ksy0ygu3RUIwPC3DSYStPjQ7Jac2ZqPufy5S+AUe/9DjC87H47BfVbVcM2W3PaYJLzLLOtIcnF5Xsq3XfihSZ2LEoExMQp5WiWiyt9aVM0HnvOpslQShuiYmJWlCK7grDcNslPRQ5rdub9jVbUWgy0dARd1VjTonTFOAQ2w8hLr97jzu37/K2f+Xl+9md/nhDgh37sJ/jRf/TH+fbv+l4OHn0Cpw39ukNpC1iJKTKGTe+oKovSRkzGkoIgxO3M7huByy9Fc/3quDquwOXVcXV8OcDzGzjhFcnITpGbXAZ9kIy8VNhnY57D5YF04I3c1KOC3o0J9Kz55Cc/yW/9+id4/vnnefbRJ3jmsSdYNDP69QZ86iKnIihOu9sPtYt+fZBdioc9EJlDoj27czT5a+z6C4HbxhhU3BYsOxllIe7O/O11mENhmXKHdtwxjIlqOxMWtaJpGvo0lzSbzQjecH4+MAxDivGINK3MUnYj1CrQzmcYIyBLq0gza6kqI6BrHAjOUzURY2tsOyOsO5wb6caBdddh65rbd+9wfLzife9/lvd/8P1cv3mDrutolnNmzRynIsZaotVUTTJ08K4UXsYYQnIMVXVNM/PY1TbP05iqOOoKUyvvyTmHH0Y2owTZG1MRVaQKYu2/Zca2brA5r05A3zZEnYl5zjTTdJsF52mqGt8NUlxphQ+Oo4ND+n7khRc/x/n5eWEvs/RY5LVmD5BcZElyUTltAHlkjZTZ0cym6ZRlGUSSqJQUnnFapLKdfd4pZlWUecnMHkeFZhtTojAlX1MJfSFZlQkc6JTJqfdYx8K6IvO8Phli+eTHGJSmMsLEmqhT/qXCxUDwwtSuug2r1apkuD548ICXXnmZzaZnNp9LELoX2avIPw1aWZE3D4F+dU4YHYTIbNZydHDI0fVrLGZLrNWcVTV+6DFEKqWJBlprWLYNBwsxE3PuIiuZr+PMtOUGw3RuT+apdwFRblJkABJTzEyWBe/vnYpwAVhOAVB+zqapWCwWZZ1N5/R2mLEQdgBkiTQKoZg6bZtpqhgIbU2MzM71sQ/2dvd8MUraYcsCxdBpKlUtPxPUjgy2Su680311+hovc2qdMpbFPXvvusqfWWHdjRH1RALaF/b9dA76XvJkVYkaiWUWOYPCKUgMQe3JTS/OHuc55ukc8taQJ1x4f1Mwuz/bu28kpEN8Q2b3Mia1zGorUEbK4Ola18j5zdEwVdVMGsvbcQ1jLcporK1BW5wP3L1/xksvvsKrt+/wMz//P/Lf//W/halq/shP/HE+8t3fwwe/+UM8++73gLHEIBLmbhjZbDbiNp9l8wE2/bjLhidlWGanv1IM1n4Do6hBrvSxV8fnAy6/FCYo/6AL/6/FoeU3zJT8KqXGt0HRWznrm51v3GcyHvYaHu4WpwhitzdxuIsPfYzLjHnezHvft2kvN70xSZdMnm1LgekhljD1EAI0c7r1htPTU+paZLF10+LdSN3OMcl9rqpr/uD3n+djv/IrnNy5xzve/i4eWR6xaOfCCkTP2Eu3ej6biROeJ3Xa4451uEpzaTGGC1md268c8O53rPXzDBQqpMiLLfs0ff9W6QtB4FtJkS+uo0VqpKQrnH/eub3PX++e35yhlk1wdDKdyJLZzWYj8y5pZsoFX1xCN0MveWVdh/MD56sVy4M5zbxh1W24ffcOm37N297xXhaHB/Snp1R1zfxoxjB6dN2w6nscCmzF7Tt3GVygcx2VUzz33KN81/d+F4tlIwyCbVBWYWtDXTdQGaq6zU1wmliVWcOIBNpHD2EcUcZweC053/Y92lqqdo4KIzbFsFhbcXZ2xmq1kpiXpqEfI7ZO81QBPA6SA6tOrIsEppviHJzPX991VK2818zcTLNiq6oSoF1V+CgSY20sTVtR13LruH//PteuXZMuujEoVe+wGtuC8vL9LgZo2zmnp+fFXKcfBqqq4u6DY5lDNAIs/WTGK4SQMlH19AGZxqtIAekL2+dHh1ZQzebCCMbIODpMMo+KPjGCKjIOPWPwoFVZTyEEtMl1XxRgoQymMilfUR4jptdmbSWyT6UYg8zwRh/ox4HV2Zqz83P6ceB8s07zUy7tDzXXrl/nbL1i3Q8FaKN2nZCHfkOdmifL+YK6bZg1LY/cusGsmXN8fA+jobGVxP85j1bw2COPcuPadYieENmRZU5lu5cZsewCHxjcSJUcN/P16pkAJdMkIDoSY9gymCHsGbYIexxw+LgFqDJj2dK2NaayCQzoZIIUkiJiO1IXgtoxBsuf3ZgYVWMs3nnGwRWA5r3H9Y5m0QiT7aNIzr2XfcV7clawj6Hc7wzymCgwld25TwhxFi5Ee5Bme40WYJLjbPKeUPZorUUKPWEAvfclX3IrHVUXmM4ps5hnSrXWjH1f4k22TSxD13V0Xbfze03TJDWCZFPmvX061oBS0pi4BNzm95GVL/tzmXldZVlrzmNWEuAlBl8uolRmWylZoeQmZXQEF9BGify9AOuRcRTFQT905TVorYlBxhSqqmKz7jg4OmD0YtqjER8DKsqMbtvO0zrZzqvK3H1uFsvauH/vhBdffpWXX32N5z/9WX7ho7/IL/7S7/GNH3gnf/bP/bN8/w/+EG9957u4cfMWi6NrYCrc6Bi8mMzFCKaepXiv9HkHaXZIWZXukyVmSb2uMmsqLZ7ef6fX72U1VYzsseSXuwpvv/fF149Xx9cevnozv3PFXF4dV8cXAbSnbrHT+Su5iUYqW6GiAe/L/NBiVjGbSQB4VVv6vkcZg521ROdYrze88sorPHbtEZbLJXVdyw19CMTMBKp8I379Czxb+e83LrZgebcAUkHvRJrkLvY0HmRabO67zU7NIST6YreYzEVjLrzy42cXVaW25zQoqI3IlrY3xYkkV0w98cjjhOi2rykZbqxWkhs6jj3Xbt5gcXDAerPh/v37nJyd8syzb+Xmo4/gQqSazblxeCCFx6bn/vk50VQ080PuHx9zfHZK3Vas+5HDwyXf+u3fytHRAbY2VI2lnlXCUlZiRoQyKCszsfkcXLD6n3R+haFpCmM3DoMAiTDixsDoJBRcVxaDISqD1hVaWVB5jjNkLu1CcXFZA8CE8NA1PWUcI1Fme3UyUYlgFRD9BRnotIGxLYT3WKn8MyHuSBdjcYfN7sKJIdKmqAP2i+nCeO4xEyoBUjGVkRgJU1fM25qmqtGI+QkpAmSIjhAkhqBtZmitOT85lbgHY4U9TWCTII9XNTU+iIR4HMZUqPeF8fTeE4NcR5vNJr03VWaTV518r05upcW1tqmZxcAwiMy4bVsBQePIOAwCEozlxsGcRd2yXC4LSKxthes71mfnbM5XWG2KwVDd1MzbGW1dSyZq7uno3et+v6G2Dy5zfRtGX97LjiPp6HYaFcUVNMSd78t8pMhmg0JMbzIwspbFfC57o9XyWkMoMsRp0bvvUDotrmX/osTXZKknCfCv12v6vk8GTxVd1zGkGeMpU5g9BYpMP127Zq/hlmcRp0xjYZ4K42h2DOd2ZOJ7Bd3+7OS0iRrj9N6z2wwAia7K85f7QCTGSNd1ha00xpR51mw0lw2b9uemd653pS7sMdPXflmDdh/sXDoicclj7p+bum0Yh57NZlPyT/Pog9aSozkMAwqRVRMV69WG+Vxx7cZ1Tk7OMFVDXbfbc6gUdT0TltzFMg5AVYGpYBg4OT7mwfEJL774Mnfu3ufTn/0cf/+3fpuP//onWHXw3d//Pfzf/8N/jnd9wzfy6DNP8+hjTxCNZQiRjY+EsafrR6rmgJDyjsUkSLJfiXrH8KswhBM/hzcD3vab4p8vaNgfBdqaW5Te/tVxdbx55vIriXyvOhtXx9ciwNxnMZW6OJ8ZJt1expHT01PW5ysODg5YLBZiSBE8QWt86rQrrTk4vAbKYKqa+fIAqyyxG3GjFzdPkxxWlRFDgZjjkNXWnTG/juBLpuBlRWPU7MjC8LvOhSEXLlxewIVsaKHyPIySuTNSpETutGoBKlql/85AZzIbpVNkR9zrxhf5oUIY1nz+o3R0FeDxEA1tVdG2Nc4NDGMn8451xdn6jLPVOSerM1b9hrvHd1n1HW9999t45NHHWK/OMVXEmYqhd0RlWQ9rDq4fctpteO3eXe4/OObO/ZHHnpjxoW/7EG9/59uxFWgTCntqrE3zezrZ1Jsyf2XYnVENQFRjWicGU1kardCj5KL240CtaobBMaYiXpmKdibusMpo6momANaYyY0+YLWwhSLFE9fXwvAgnxHeXzDY2OadJvdhNd3HI9ooscUP43adl0xIXRisXIzvg9tSKKptRE+OlJm6CCult/ElQaFVvETxvZXzjcEnAy2zkzWbjX5iygDVdV1kvKgEsK3EANkoBknDOOLdwJDYy6gtRhuUrVDG7Jh9rM5XOOfoNj3n5+ecnp6yWm0Kk5slzhk8e++TDFeVHFqFKfLGqvLp50Xy2NhYsla9d+jgi2NqW1kevX4kYLFty9qqtOK837A6P6Xv1rTLgyRVh/l8XhpbMab8SsUOsNwCl4DSqkSvyAmVaA1tDEoLQ+eDmC8pramrWppagBuGTDehlJXPQDmiliac0obgvewBKJldVGJ4VRmNrStmi1nxpfUh4JEZ9Szpjs7v5BduN2oxb5LnFofobFIlTLDIeo0x9JsNZ2dnXL9+XdYF4nqNNiiSKVB6z32/fb9aQW1rsgR2yqDHxOyZCdOuENZVzp0uZloyM78LiC/ec2Jh/7eALFDSijPzVxxqVZkV3FX0qMKqeh/EMIrdnMmqaYjeF8CWm4X74JIUieH37nt+sq9MGwmXSVz3FUX7//5GrrGr1QpjNLP5vDD8m64rrtXL5TI5tAcG58UsLUI3jHDWMZ8dyv6pEyuu5LOpqhnKWpQKdH3P2fkDjo9PuHfvmFdeeYUXXniB1169w6c+9QIPjk8xdcM3vPcb+Zf+lX+Dd733/Tz7trfzyBNPUC+OwFpCDGyGgTHmeWmNbWsxEcuGylM3ViXrR5UNeE/xVXbAN19/X+rY/fkCzKt6/er4agGXV8fV8bV8vJ7E9rKf2wefzjnayuD7nrOzM05PTzk8OKBtWwBGL7I8tMWNDjtf8Myzz/G+b/ogn/nd38c96qCqk7TRoYIuDrGX5dA97HU/9CZjuAASdhg2a3ZmIXPXPj/ONBcPxO9kp8Me8nnROzNb2w7/xHjD6J0ufFRibuQnssTtbVVAqqkqmkpiQrSBWd1Q15ZhNPhzz2ZIs2taJLPHpycMozBMVdMSUDw4XxGDx9YtGCtSQV1z/ZE5I5rjew/49Isv8vKdU9Dw7ne/iw988zdhK8UwrLG1YVbmkioGJUY6tqrT9N3EiEMZkSN6iPhJMRWKNFEiBHIOnie7zSvToCtNbbbgpK5mqGRUs3W4iMnjKRLHETUOO2sgAz4XQ2mA7M90Ra1QE/dTmQuWz30cR8auvyCzEkZG7Rg4bdeU35u1nLAhOaqn73HDmJxrJ8xruaYS0xtkreSiu0gBc21mtoDWpqieGAMhprxMbahsztfTpQVvTU0kScVjxBjPfLEU8xgtIevDKIZRfd/TjyN3799j8I6+79mse9brdTE1aprZZH6tKgxkXddYU4nPZGJobV2h1NYIRUf5qtuWoe/pNhtUiBwslty4eY2DgwNqa1jWVoyaYmCIAmiJwjp1XUelU7SPlnN8cHCAtTK3qEzynlQX97ypic/DZtaUMhgrjSJCvLRw3WcZd/YGI1mlvsyKy3wyWtNUBlNXaGOElfYhzdUKwN3JQtyZu5swgHhisCn2ZzsDmK+tvHcNw1Dk5tk0KP+MUVtVQW4UbsGiNFtUvAiayv42yVjdn6EMSk9FBpcaxk33yukIiXxfo4gP3eMv2//z42ybOKrI0cdxFOn7xL17s+l3ZLj7LKL3bgdc7gPIIbHseV/bB87TOJaHMW6Xndfpe/U+JMaypus6YoS6luvNjYGjw5sopTg9PWfoA4vFkXymVcX9BycEn+4lpiIA667nwfEJD87OOTtdcb5e8eord/jsi5/j3r1jxuBpmzltO+c7v/9HePvb38m7vuE9PPbkE1y7+Qjm8BoYC4Nj8J5+6HA+EtN6j1qn+4I0CWMQA7UdZ9ccZXQBy33hWd37tcvnK3m8IoKujitweXVcHV8mxvJhN0CVbwx7HezgPHbWMq496/Was7Mznnjm0eJYWlctuqnQpqIbByya5eE1vvu7v5cXfv9TvHbnHvaG5aBqqWpQTuSJOs9DvEFBMb2ZTLvIpTiLYQf0TZ3z9sHGpW65iOV+ZgWUEUZRa5ljs9rsWaFflGbtFhBBHHRTEdN1XWIsE1thKJbwyhjqxlLXVvLFfHL2rCwGkagulkuqpmbVtRyfPODB+YrTszO89ywPF/zaJ/4+w9hzMJ9x7eCQm9ePqOuaoQ80iwWb0fHZV17id373BWwN3/vdH+BD3/ot1G1NiMKO1u0Bzaylnc9QVYUB+bNuZE5QG2LqVisMBJGDxhCToYgnRkeMCmVrjJYZR43GBzBVja4kq2IXoGu0qpPDr0psYALgKoNMC2aaU7iVu+qJaY6wgKGshwy4VBR7mjIrGiN939N1HYS4I4XMzPO0eSEy0FiaAkV+mUBo9AIOjJLidrPuBJBYjx9HKmvx2TMky7gTINRRzC+U0ogRavp3xLU1BMmYVFrtSGZzsVtpMSzxKcJGchHFobjWGm1VkW6vV2vOVuecn59zttqIxN07Ts7OyjywUoaqaWlmAlDaZs4wDGw2G/p+QOlIVTcsDw6o6xaNol9v8M6Rif6maVPxP0okUfSoEJlVlrZuuHX9BjdvXmc+m8k6w6F0ZOwHoo/YqiYER79e4/qepmnLeV8ulyyXS2l6jZ6maiZMejaB2sottxmUasKRTJypkWvREwvAG72AtuADIZJUDNmrOZZIFp3za5HGQ3DCYNrEWFoje2mYsjoiawBFAaRGC8DKkS/CIl4ixUzrI4OqHINUJdfNvu85Pj5muVxycHRUZhFd8OIgnJpq07nDSLpe8p6Wv5QuDqUBkfNmWa6oGMxe84QLcRHxEjYwg8Hp/q0vMUXb/91pcysDy+wKm2WwY2q4ZSCdGdzp4+W1MlVf9P2AK/ma1Y5528NYyEvvnw+RxKpLIm6mj2FszWazIeBoWyvu6VoRlcUFRTObE5VltV7zO7/3KV5++WViENO8qDRBa9abDefn56IQ8ZHBeVbrDauuZ73pWR4dcuP6o1x7/C28833fynNveyvveMe7ePTxJ3nk0ccxtoKqkT3UBfrNQFQebSs8BpS4Zpu6QmlN73vc6AFPbRpRBcRkUp6cmnM9oVBfFXXPhT+/SLB7dVyBy6vj6rhiLt8EyFTq8s5tTJl8zjm6rmOz2XBwcEBbNwIkpBzaRn04KWbe/4Fv4r3vfS9/75d/ncNqzsGNGcZYiVlIt5zs2vYw9vIyIDyVKu5HQ4ij4K70qchitbrUwZD9v5fzZHbC1bePuQsoc6GXcw6zxXpIs1XZ3CIHeNeNTTmQNcbKLF8x5UhRGMKyyfefeuZpMJrPfPbTvPTqK/gQePotz3B4eEjnR27fu81mfU48h3v3jvnUpyUncL3eMDs4BFvxe39wl9khfN8Pfhff9d3fwY0bhwzdik0n8tWqtiI1TLEoiWaUjEub3By1Ta42CrAo5R7eqMgzahLNKCyXlgiXbbRKcm5MRUl2IiU3OILffg7aJqfX8cJs3ehcMhpJbEyO8YDSuNAG9BhBa1SEoZcZp2lO4Na1c2v2kSW5GVzu5qSS1sY2uiB6YZUk9sFPzJ5SMV6sYSNqb92XSJUYCWEbCeKck6ItvdaqNsUUR2ldzlNhZ6JnGBzd6py+7zk9e0DXdaI6OF8L4PDba0LXNdpaZk1D1TRYrWVmMGqUNSyaBq+VzA02NXUzIxrL6BzeOfwwMKZC3xiDrUVKO/YDwTlqW7M4mnOwWHIwnzFrW9qqwhoDwQtwziYsRtHUltOzFavzc7quYz5fyEynlTk0a+3EfEkVYHPZNXwZONmRz6asURPFEGyacZscWuQxpO+RZsXZcXsu+6tWkt1a22TAEop6gZgeA1WY9BCFzbS2YuoQrF5n/wsx7GQ2zudzDo4OOT8/58GDB9y+fZsYI888I/tD0zTldUzfT5lZDj6twyDO4JfdKyI7s8da7RoioSZ7+SX3mTeUiKqLOZOvBw5yRnDed/t0Led54Pl8Xq7nvE6mLrE7z5Nm8rtBlBFt25amaSkwk3nYZe/n9Zqil7GV01n97WOKU2tVtcSocaOjrmYcHBzJv5ma/+F/+B/46Ec/xu/8zu+y2WxYLg5Zr9cMPhCNhUpm3Q8Oj7j56GM88cxbePTxJzm8dp3F8oDrNx/hySef5tYjj7E4PMC0s9REVgxjELfybkRXNUpZRg3eKUjqAO8jUQXC4Mo91+RIluAn73ybCx2/DHXMfmP482Uir5jLq+OrClxeLcir4+sNYE6PbZf2ogxV3CUlMmSz2RTjiPl8LjbieZYKhQ4Q0XT9SGtrWM547/u+iZ/973+Gp248ijsI6KhS518LwMzsVJnZ0Ts3qoddh2pvJi3/qbW+EA3xeuAy3wSTIHGnSJLsxCiOO1xmJR935nO2hYvI3zAam51hE7A0teQ+WmtTgSuPM479VsZmTAEy2ZDjzt07vHbnHrP5krc89ywf/vZv59HHH+Pk/IzT8xO6oWfsNpwe32d9vmIcR05OTrj/4ITfe/4lVAU/8qPfx4/+Iz/M8qChsoqz0HH8YI0yCtvUO66IxgqQ9D7SVFXKcktzmGk2KkckqMwyGmE4dC6otMKoSmZWteSxyalUBTBKCH0oxaXkXKaIBa2KE2WWNitsYn+T86G2hLhJYfG7ERLZaKeqqvK5hvR5iWnNhhDDDnOZZXLC6gjgN2VNqp0ikZDy/oyF9Fxbp0uF98KCuSDSw6jTuleakNk1HyReoWT+xZ2mTl7X8joidV0zn89pUvyDd24SwB4Sc3rO2dkZ5+en9H3PnTt3ynkR90ZN1dbUdY2xFqfks6qMFTdTHxiHnqHrcN6znB8QosJUDbaqGUNkc3aOG0ai81RRoXzARUfbtlTGoivNLLFAh8sFB8s5h/MZtTHJWtOjg0/mVunUGl0iFVYref05Q3KaU+pDRGmDNrYExEeVUxu36Y0x/T3L4TOYlOaFZvvEsUisR+/wwROigK0pmCrSSNSO7DZEaUTYSmSMppI9KM9UCwsdCUxnuyXrT6SEaZYz+DSDeHFeUWIrRBbvnORz5iiH2XzJfCZmSHfv3i0A85FHHikSWWFaJ3tiiAWUl7zVdK2F5I6tSxPNJwVHiuNgy8LL3/2l+/Fl4H5nhIDt3Pl+Nuh0j9+Xw2a5dDacytFYWR6bwWX+nfz+98Hl9O85ImnqUDttZF4Glrc3UJW3xF0uLAHzEuUCaT6fsh9pbamrFqPr9F48VTXj1q1baF3x0osv81f+yl/lp/7aT3P7duDwEJ555ine+55v5Pr16ywOj5jfvMbi6Bq3Hn2ERx99nMNr11gcHFI3rWRPzw/BWkjqCBc8bow4N9J7j1caY2swGjc4iCLRbRYt1kLfB7SVvQ4la96mnF6rDS74orbQ6NQ4S4ZnXFCslxGBz6f+viwC6s3W5hdA6R7DfFXeXx1XzOXV8eVpHqQxl39Y9xitUkAziQVIYKvcXJUEnA+bNcOmw3kn8iGbTSIqTGXxESk4o4PlAfH0nIODAzadWMGPrsdqm6SISQoZVQGRD3Mb3Hd43L/ZbF0QL2E6E2vg8TLnJslioKPMimT2MYYLDpAluiFufy+ogAqqyOiCovypozg6GlNRJzZM5JNGmDNbY8y2yBmGgRAdxihCCtCu65qmacQcRklswPH5Cb/9yd8nKvieP/QDfPBD38LiYEkMcHDzOptxpJ019Js187Zl1jaMw8CnPvUZfu7v/Dwf+42X+KEf+SA/8cf+KNdvHDJ059hKsdpsGINI60wyeiFGsBVVVROqiuiF7dP54ogBoiIGX4CU4D1hHXdcIQNFhhpCYMwxAaaSQlXL8wlwkGaCUmYLFMJEBotBay7kx4mUrZEweu9R48joI3hhZMU8ymBCYrqjx3sYBsncDJfk8HnvU8Fk8cFTtRXRhyStTKxDipoIwaHrGYZQGJVxHMFoBueF3ZNXLwYYSuOUwuTonBJlEbFawJDz+TmE6dLGwOhRSCTHvBEAhw/048hqtWLd9Zydn3J6/ICTk2OJt2GbR6pNRTVbynVrTDGn8gSC84zB4cYR5cbEOvb0nRTcNjFAIQTc0HHuYskCbWwFLlBpRV1ZFk3NjaMj2rbFWs08mfYYCSfEjSPej+JymwycYhBlREbT4ziyWUm0hDDSYWtKEwNuHGmaGqMNm24j72ey9vYbQRmEqAtF5a5jb2YsCxhIbKXSRmZWjcVag1EGHxy+H3HJhMmkmduqqlC6+GCWxkAIISGOrVRQKQs6Fna8xFUwKaC1InqPR0muqHc4NxDxWC3NgOBHFssZdfME1lru3LnD3bt3Wa/XLBYzbty4RdNUzJoWU9nU1FPUtkLpiuBGVFTbxkyKPHGTzGFhLYPMXwaZtVZo0Aj7OY2OUma38E+mZ0ZpMFwAl+GSnMfLsiazvLvve/q+BwRgZ7axruudx83NutlscdGMK68RL3J25QNuGBi1xtc1MUesTMDl9H5kpq8tMds63T+3a0zJOdM2NVE1MfqtIiY1K7zziRW3LJcL5otD0BU/+7d/lv/0P/nP+flf/hQ3F/Av/Mv/S378x3+c2fKAtplT1zX1jRtgkypCKzC1OMICcRjoR8d6NWBshKQ2GNy2UYNuCBqGMWC1ElVChE3f0/eOpmkILmKMGJcpZTAmFIwm58Dv3X+/tJzlFtTvXrcX6oT0zDqyN+cpipAyKvPleZlXx9cjuHwz5iRfKAX/FQE3X+bn+Uq63X4tsrxKTaYCQp7zSvMkKMl529k6Lx8mf9iauWhTvtfZvfRnJnbpEwIvMzxq+vxave7n/nrXhkaBc2ilcOmdeSXS0hiFtTPKE7oRExxn9++iIpILqLTMqtQNm3EUVsZalteugZcMr9duv8JyqZnPZ5jKpNzJyOgH8NDWDTHm+R1dbhHZbGO3i73Ltk7dXrOxTI7GUAqUUTuGPSS/yBACPvoSJ1hmMqFkZO2YA6ktiypdeo02WgCSkU6tsHQWZbbh4CVKwktnN7gBN7gdGW/UiqqpaaoWq1XJLnTBM7iR2/fv8cnPfoZHnnqSb/72D/Pe97+Pwxs3uHPnNn0/oq0ieNiszrl+dI2oNaOt6Fzg3mbNL/zKr/CeDzzJj/z4j3Hr0ZtEArapeXDvLi4oRgeHN64xP7yOqWe45MLqvZOi2VrkRCWpqgTlEYNDE9G1zFtiLDYxeUrF4owZ/SRgPkaCEUaSymJsk6SnyYU0RoJ3VFiMNekaFIYp+DHl69kiJQOZe7QpL1AZSz1rCTHSbTaMY4c1BrVRGKWp6xZjKx6cnPHg/j2GfoOuG6rKYIxi9CLtJM0xBpR09JURYyEXEG4+EoMnek8II37URK3p+57FwZJmseD+g2NWp2d4FFXd4mLAxojWkUYZiawInhAjbnREk3NZhTkwaFwCY5VWVNaybBuWTUu/2vC5k8/QrVesu447D+5zcnrKer3GpiiG2WzGYrEQZ9XkQpnBvYuBMbE0UUeUrbDKED30g8gL3TBiUDR1LRmTVY0Chk1H51YYpbi2OOT64REH7ZxZUxWWrGS45jnV4GV+MTPKSqJgxiiNGRUVTT0D32NtTd91PDg9o+9HmqZhHEfauqKuLE1lqI3BDZ3Mo1UVIUlbVZn5Yjv/FTOfWaYJJ/tgAnOK7N8qCoMkqcz7bbmeMUQ8g5d90jQtdtYQgt8avSRZsjQHRJngQ0STgHSUc5H3YR1h6HpqKw2XGBUqqUH6ccBQiXs18jgheIzRVJWVS9E7sGKG1FSWxx65xWLWcufOHVarFd71nJ+eUTeVOPLOZ8yalrptqG2FMQJeg9vGK0kPKTWOfDI7izYxPumERZ/cmgOEUJg6aaQloF/ukxCDuDdHZL/KUnatoXND2V/jBMySHIltVeH7bdxKjJH5vC0S6SqDqaQW2N47FdbWKY4kIcCknCmux0Gux0XVoFwAH+k34tCtrezvPmda5nxPJS7UOkVIaWVQxmBQ4swcI0YbUBrvR4bBUTeWqm5Tg2zSxBodyo3cfOotMAyMXnH3zn3+P//1T/J/+vf+Eij4c//sn+JP/hP/JB/40Lfigjjz9n3P6dCzNDWrjceXudUBGAq4UhgxmXMa7RXKNJh6b/zDe+rEsrp+LE7bRiuCk9gh5wLuEvWQ3qt7MgM+QZ8XmEL26px9gz21V0RFf9Gtt8g6kgoi12vZOlqFuDOCIWciPUZpZuc1pyd12rbSuhCh8pA694utr78as+G/rsijL8Bd+Iq5vDq+NItv77/jG24O6sKG+jXNXOYAECXknkq6nbKhEyB63NDjhp5KU27sSlsJIU9ZZOvzFTgHswUv/taLfOxjH+PWLemcaySSQKPREVTKylPJbGXLHL7+zM3OjUhHrLHJCj/9fJ6pSm6cOWokJlOdbK5TOtMxPf/ehj/tdGcW4UJTQkkB83rOgM4NO98vs5e1RIzY2lA3DXUOxt5sWJ+fcXx+youvvMxZt+Zbv++7+Pbv+gjrsefu8TEugrKGru/pxoGbN2+iqpqz83PaKG6Bv/Lrv856dHzHR76TZ9/6FvRsxrg6o+tHulE62OgKY1u0qYjGEjMzOWF9fCoEd+TCMZZQ7CwHLUY4WebmoxQlMQpAUxGtKoyx5flUOu/bzzSBciYzkxGY/F2paU6hmSAK0KqmboXxdb0wrMMwUBmL1dJNGLsen6R008iaKRMh60UV4x1hTpM0LMeWJJtMpXYdRDUxOSNbfJr/VDlI3gecGnaY9dEH8PJcKgOeKIxhXVXgHSpEuvWG4fyc0I/03bqAS6cigxeW4dq1a2XWzlqRaY7jiI+BGESaCwoMKWpC42PAOzlPQ9fjvEiz501L29TUyuDGHtcPWAKPXL/GtcMjbl2/weHyAEvEThoq2Qwn7khDLpE5pl6eTm43WluIik0/FMfPtm0xCmH0q+1MqYoIyI8eFSZRCJeYbL1R0bY/i5kZpSkDFaIq7BM6ybNLo3H3elEFXG4bl7m5YoxhVlcTZk1Mj3yU4Hnplley9nK/k1jci+OETZTZYE+lq61KQm/zaGfzFmMMQ9fjvS9O39nQR+uUh1o3CTxR3vtWti+GVVEFvHKQ1/H0PMfc2LPpevUE7wlxEh0SI32aKXdx6rItrtAhuMnr0mWu1FpLn3Iey0xvApTbGem4w2ztv77y3+GS3MkonqeVNlhjcJOZyJjjWNjKo42RnzNKC1jWSvC1ojDkkI3PBGAdtnO8D9JYZSudN7piuZwxOzpic+8+UVX8nV/4Rf6D//g/4e/91j2+9we/lT/zP/9n+MCHvo3HnnyGtYPj81OadkZQFevo2Jz3mGaOF43zpfOIKib3ZmVQITGW5ccCJsH+hxN64aHXTuCLV3xdBJbxciD50Feg05CGzNPHh1Q5V1Tl1fF5M5dXp+Drj038ajx/X8wg+Vfjkedddjf33HHcCzmOpDm1DmuNMBS13OBbW7PuBzSKxeEhWEM8OeHjv/KrvPLiS7z9yadpqhpCkCI0zdMZZYpZiYRY+0vndbY28pfPWe473O67ERq7Nf4Adk045BuXgsMSbh/DpQHc29eh92Yudwuc3FnPP5+dDJumQlcCQECkmn0vWYPrzRqAdj7DHd8VN8EAlW0YjLj2ei8g5mBeYZUULTILa/id3/k0v/RLv8Tb3/4cH/zQt3B04wYET9f34oYZI9oaZos5VVOjTLUFbUpgk4ARVWYYtwV3SIW22ovyiDs3cu+kUBudQ1lEkmcNtmowVWItU0agyJm2IH7r+KtKjAx5beZOQSqStDbFq0Q8h0R+1vmA64PITL1D65HoR05X52LgoYUlKl9F1idFus3vdbCVwgABAABJREFUS6QFSbqZisQQZMxUSZZjLoann7vE2CjqupHIjKQG8HFq6JEbGZkcNoQwpvgDMX7qNhsB1d6hnJNcRD9CAl8HN67hvMcYy2KxYNa0k8aQqBMk19DJn94zJMmgT5NSIQR8GIkhUBnLrG5YzGfM6oZhI3Egs9mcg+WcG9euc/3wQOJIUDJvelmjTWXDrV2ZY5wwGLl4jEHmcn0MIvNdr9FaM5vNCG4sbOzUyEunGdoYQzKDSo81fX4NKqgd9+j9/SPEiEZhS16tuRCfIfPXW3fTsg8gUTGF1Ess3fR1iN+JxiCuwhnAjKMTh1klhimDk8gXbU1qRshsbt6Ji+x3b49xzlHVwixrpZi1LUZrZq3M5apDxWazYXV6JmZOo6MfRkJ0yZhFgFJxIDa2NL+yq3XIGasTAFvOZTJ0CUoA4qAzM5eyQ5Ups+8xUcXCoKeonVbAtjxXXYx45Bz5kscKwtg2qZE5Nci5XK2jLzT7RILMDriMVlO1DXUMhKEv5zobklVVs23Cpv0BpUoDYIgj3ofCcpe8yShzzDapP6JzGGU5WC7Rjex/eM+rn3uVT33ms/y3f+2n+Mm/9nf5pm9+J//mv/Xn+J4f+GHe800fJOiK3gdOuzVjMGK0pTVVu8RUNd7FC/e/wlrunBNRoIhXmZrqph6isPrK1leZsfxaq62u6usrcHl1XB1fOAj7PL7/tQCO99/HG22QxggQzIxCsXlPLpIhyFylPToC5/jcCy/wiV//DZ5+8ikeu/Uo4+mK0I/EWhO8ojYWa8WcI7snXtYh3Qdxu86aybk1BJSOFxz9piYgqXUrRVDc56HVQ50K83vfZ12mR845izvzSVtwa+1uuPt0jsiPo8jyYqTv1vSbjvPzc7Ca5bUjquWcV0/u86u//mvceuopvumbP8hyuSzB4fP5nLoWdgofaOYzNpsVn/jEJzg56fljf/zbeOKJJ4SxGxxRa2wtUROjd1R1wNYN2lpiYgyjVsl0hofOqU3BQZH5QjFJ2UqWwflIZTRKW6qqxtYNGDH68XkGKc1TmuLkKUWogK9Q+PWt1IrymQYvYDKk3zemompm+DEQnRcmJc24uuBZbdYlEmE6g5WBP9pOWEhxj9VJQu6LLFjeq9YUpmUcR3yIjKNnHHwqbn0xmdIZnIet6RBR5JYuAbuoJbNwtVoRoxJZaLfBGkNrDVXb0BhLbQ1NJfJNU1cMoxS40+I//7cfhR0bx2HL3nvP0PeMzjGGiLWatqqpZy11VWGMxgQYuw1hHJm1NdcPDrl+dMjhYkmdoh9WXS+Op4kBnka6RPVw842d72V33gRKcs5m0zRyLcVA0zQ0TSOPG7LbcAZecYJT44XG03TWKoSwcz0rpSRGZa8xtd9E2m8abL9Hef6HNR/LcyW2cuj6sv6s1lTGbuNFFJhQU1tbJPxbRjiWkYi8v1hrcWlm00/eX1VVhCAzwMvlknnTspzNCwM4jiOj6/GjY+z6nfeYGyWZOazrGqUUbs+lueyP7DbjXGqeeB+LMVZhHBvJR53ORDrnZH4wzUwWF+g0vzxlU+1Esrz9fC7PybwsfiSDy7Lfp7l2ZbSYWblBQLrWVMbgQsBqc+GelJUuwYhsl9SAzCqW4NKcsLI8OFlxcHDAteV1QOOd4/z+Oa+99hqv3n6Nn/u7H+On/+bf5PrNR/kX/3f/Gz7yPd/Pu977AZaPPcn65JzT9TkBja5aZrMquTR7mRcfHMbYh1xXuzXAZTLP3Ny67Bw+7H73la67rqDb1XEFLq+OfyhAZvwalVc87GYR2DIPl73nGCNUtswBkYPD03noNxtm8zmj62Ecoet48bOf4+XPvcgPfOS7OTQN551DdaPMT3iVpu5DcvN4faCeZ5pyxzXLMPOdJyZpU4mTyHIutQsySwGq98D2XibZfjFsy0xPvGAjLwWe3isk406R5Eu+XMrA9GFnnrNuJYoghMDgRvrRYXRN1c5o2pqnn3mWj//mJ7h95x4uveSqnTFP+ZvBeRSBymr6zYrf+73f4xOf+ARPPHWDZ97yFg5v3ABGtDU0bSszr2OP6gxKVzJXqC1og0KL/A7J4tPaJB8SYahimjeU4HcB1S6tg8x+KJXnWifFudGYusZWDcpUgGYMERfAKCPzsSTJrVJEFdM8T1bFZuFWApclaiS72CKvy4O2UuQ1TZr51A7XD/goBjjdkGaSlGYMu9EAUsRWMv0bQ3LvTNLNNFMafRAmUYNRFoJi6B3DMOJDoOvELCg/5jiO6BixOktHQ2lKuOAZvGe9FumfMMWRYXTl9TRNQ2UtbV3R1pbWVFRWY1I2pVYGosLhkunOUNg2naJXVAw0KUqkqgSMnmvDarMm9j2NrVguFsybBquNFP59zzh0zJuWg9mco4ND2qrGO8eY1nRTV/j0WgVkhdKUmDZbihvp5DovLpxoxFxYlQYWiBTWe4/SBmOqAlxDNpBBCSAnTirQ5BGrFIG9vWKviVau89Rt0omlVtOfB2m0xJiYWFBJYRGiMJE5Mqa8r/JiQtmbvHOMSe6b9wNr5fOd5jYKu51nisOO06X38nM6rYt8PmyE2tiiRNG57+NlJtIPI1op5jOJgcmRR87JOhFdZzLdGkfcOJYRBZ3lnVMp6aSJkdl370cGJ2Ax+N3xg6pq0t5rkwogbg1702VsrMx0bpKJU13X0oxxTuY4J88XkkvyFh1dLofdv4eVr8n/AHonDdOgwta9OIgbtA4R3w+o1LTKDbOS1Ws0Hp+U+SatcUAbjK4wuuKxdz4LqxX9akPfj9y/94BPfOI3+bmf+zk+/olPcPOZ5/gT/9Q/x3d8x0d43wc+xNHNR0FZ7t85waGws0MG54nGElB4FdG17FFienX5ur6sYSJ/Zjm/AXYB+n5j5Y3iwb7E9dXWCWuv+fu1SD5cMZtX4PLrllm7WtxXzOUbvq+4NQnakdbsvz9rSgFkrS0sgoSEyw3ZBQERaM3p6Smr1aoUQfN2Rowa40HnHMrkWqf2XB4vrtv4uhl2PjoxQU8d7sJs7uV2ZuYy7s1O5piuqRPplJ2wdbXT+c7F6nY+q9rrpIdLYksCMe6aZuScvM1mA1rRrTcC3pWimbUsDw6w85Ynn36Kj/7ar3FydopzMlvXti3RyRzs0eGWyRzHkef/4A946aXX+Mh3fztPPP00tA1+MxKNRpuKkAsVbWiaClM3EguCJmqDNmI4o4gp+iGUjD2Rx4074DI3GXIxr3VkTPOWo/MoLXK3umoxVV3yM32K3lMKkVci0SLSdNCTIijNCCUpbjFtggSCxRY/S6tjFGmjrWqaWSTaIX0Ofstk6G2sBXtrqxTVmRVPMkeVTFq0EmMSm8LkvfcCLNOcWZ/MUaTRke0j4sRYassQ9T5wvu457zb0fZ9k3CJHbNuWdlZTobGVpjECLq0RFjV4T3AO0roahkFYysS2VJWlshWzpsEn2WE7F2np+WZdHEqbpqWua9pk8hJDwMSAJ2AVLOYtRwdLrh0s0Qr8II6v1kqUidWmzJF578u6mbL10ybOtNElrK4qs23ee/q+F7l9227nloMYPpn9GIuH7MVqkr04lftdYDP3gu7f7D10n/He3ZQokTbCYjk2mw3deoNSYtqVsxSjH/HBM3rH6J0AlBAuFPoZgI7jWBqB2Tip0uaCg3ZmBL33eOeKK/K0QWaMoTYWU+vShKvrOjn67u5TO8qNsD1n1mrc2Jd9Udxm1U7zbT6fp9OSjHTi9jowk4ZHZjNL5mnTiCw6hJ14kGkzSGtdgObDsyXj5SBzknUZUxxPVuQYFIweQkDXVsxgyFE2FAWFUgrnIhiT4nEMbdVi6oU07CLc/9zLbDY9d27f4xOf+Hv87M/+PJ96/jO87W3v4E/+mX+GD//AH+IbP/gt1ElR0o3SmBuVQVctY4hEU4sKJHhC0Nha5mzRhuid7L4PWcNTF+XLG85uu6++SZPCrwTIVFeF69VxBS6vwOfX8/Ewt6mvFUOf6U1jf/Zov7tZZi6zicTkx7KMqW4b2sUck9z0tK5Snp+XG++s5eYjt7jxyC1efPFF3nLzMebGYNsWNXisFodV79M8pTYPKRD3itAyX5nNY+JODl3JnMw3RaN3Y0xSzmXOu8zvO3fap8BCbNp3GczMMuSYliL9LPBB/peLrBDchXmgEAMhusSYKFRUbPoOZTQumbLMFgcsrh3SLJaMOnJ8dg7aYGsx3qlnC9arjvXmnFlT08znrNcrnHOcnZ3x/PPP084r3vWed/P0M8+Ad/TjQF1bcUqMo3hjKoOuanSVrPeTw6FEhITUeNDFsKYAiJwHl4vERD94kuTYhcSOCENirEUbg6msBHKzjR8QW36/7VUriSAB8EGluTmRQqocbSIoVGbbsqVKijkIPorMMzFhWmt0VeFqh9YNow/JNFJh6go3OCnSzASwBI9KjKVIXxMKnuROGgxay9rt+p5x9BC1mBXpHmUsRhsqawhIoyMkV80QAm4MdIN8Ln0/oJShbecpL1EXGWhd19goxlWKZJaT2Rovximr8zU2NVaaqqZpag4WC5bLZYoSGNOIqjQzuq4juhEVPJWCer5Is2ISyUBw1NowXxxgNFw/POL6wSHzphFjL5IsOIIbemxdEZWYvsRJVmyRf8d4gUHZFv4SqRERwxE3erp+QBtLO5sJSEryyHH01KYukTRF9hjdNt8yTlgX9A5DOp3VZGrYFdwWLGhdHKN1cauOO3tRnqncyfGbPG/0WyDonBNwF4I0WOq6OOpG53HRCxOpA0aLkU+ZD0+P6SbAPTOXeW+OWmY0s9urUqIw8KM8r1aqzGOH5GQq8VKq7FnOu8JOaqUkriZJvbN8e9esyRfmrkjJkzzZik58p7nQzJq096kd4GxMhTIa29Slwdi2bZk9z0B8uofu3493zHce8uV9vMDITX/PVlVyG1fYyqC9uFY7N+B9ZKkrlDbYTLXmz0drotLM0/UTo9xLfDQMq4679465ffsu9+6f8Hf+zi/w0b/7y3gU3/je9/G/+Of/CB/60Id5y9vfhT28Rr04IMZIFzQnqw7nI/PlAethFBbU1kmlMuKjY90NKDVilEQYKaZNHH1pZujFRoqYh6k3oW56vWPf1CfusI6X/9v0e+aqAL06rsDl1fEPM7jcbszq6+79XQCXE6OcPF+Xi42qqmhnM2H0jGbsHdVsjraGfrWhaWre9e538w3veTd//5c+zvV6TrM4pNYaZaG2lRQpvUuFyeWGSdNbzk5hqtjpqNdNfakMijKzsTf/tDf/qNiVAe2Dy5zpVxjRBCCnLMF0nUwZzpKVucfilEw9BATXVcVisWB5dEhVt2Ar+nHgteNj/v5v/y5HN2/w9ne/i/nBEtKc0Ogj19uWYbNhMZsxOM9nP/tZfvf3f5+nnnqKt77tbdjFHLwDbbHtDKKnd56YTV5QKGtSR17Ah2Sdqu35U0mihyZGJ0Y/BIKSKAFr7MX8uJgeP+bllKMapGD3MUCUiI+SLb8/35kKJZHRyfyi/H0K2EWeuM2SA+8iSgdhJQPy3pNkWqdw9ZIzV1lMMqYqn52aMCMxyRy3p0PWR0zZjFoz+oALAbRBV+KEa7RHVxZsRUwzljmKI8ZIN0oBveoHUJr5bE5V1+TxrrwGgxtpFgspKpOz6IBINzOAqLRl3s44OjriYCH5d5WxhbGw8y3zvuk7Nucr1qsVPmVY6szyBQFOGqirmsW8Zd60HB4saKtKonScQ6tIVdcCvMcMwPWleaEhhBRns8ui7HylJhFJQj6OYmzTNGKkMvT9loVLeaD4zDpt4w+yBHY/l3AfXE6BrbxGvzPHvf39i/ObAmbDDkjK77Mwd8l5t+97xnHEGsNiseDg4KBIfcfiVrxde72T7ymzdXzN4Hy6l8T0nlyOTTLV9lxPHFSz++r0veYmWZnh9CEx8Rc/nylrOo1V8unzEdWGxNXEaLdMZ77W0poYXPr9EiNEmU9URuOJyZBKZkWVUpyenhb2v23bHcVIfoySScpFF9jpfpQNpfbvD8XBFwHtBDFnil7mnsdOwGVt6jSSYTBGFDvKVrJvGi1gLmi6ruP45IzT0xUvvvQKH/+1T/Abv/n3+a3f/n3e/s5v4Ad+7A/zwW/+EN/4je/n6bc8S7NYEKPGGcuqdwyDDBjUsyX9ao2qWuLomc8WuKRMUFqxnM0ZxyHNo17mb3+RWHgYy3/ZfPJXW0P/q30K6Qobfx2Dy8s6LQ/ToD/sZx8Wwv5mOjn/oBeXUq+fc/gP++J/059fLlCielPrZGrwcJkTYYyXg9P9h57IQC6svcvY0enzyY1fv26+5rTLe/m52VrG55/zQQpZk38vyaiccyyXS2azWbJTr6mamtFLoRq8sFBHt27yJ/7Un0R1I5/8/T9g9o5v4Oatx3CbnmH0IttrK5wL0hHefVU77724lKpcXJgLc5FT8EcJiM4sQNxxlN0vnoSR9JM8My327HFyPvzWqGJ/XygutGHC0BiZV1RRo6NI/XZAqIIqycHaecsYPE3TUtU1nsj94/u8ePs2n331VXRV8yf+2D/OO9/1bjbdIGHk6XEG52lMxbrvuf/gAb/zO7/NMAw8/tSTvOW5Z8EavB+omjqxujLnNwZPM5+hlWEcHHUTqGuLjxHvIqayVFaLLFRRGKQYA7au0Lrarj+tsdndMjs8xl15m6krAWOXNhHyvJ4vsjs5ryExy+lzKctDp2tIzqM1ZpKJGiVSYxhQEar02VS2ISZznflywcaPDN4BWgrJcaRdHmCSzJQ0G1tXNb4fZAYzg6YxiHxOaTbrjtWmx9YNfTdyvj7DhYCuLCEq3ODwIeCCFLA5By8qaGYt9XwhcfR1AypsMyZNmukiMBix2nf9QLdZE0ZHWzccHBwwv3bI4eyAo4MD5vN5cbSsrOwRfd+jgPVmUyR/x8f3ODs9lZ9vW4ytxbk0inOoChC8x0bF4XxBpQ3eOTyhOD0LG5fcRm1dlAbyOab1acAYXZo7hUlKWnylDSaxcyLxExYf8rxlKGYlBbjFSPCSu6dAHF5jECdWAipGnGNXlovGKE1Qe/EUKbdw7J0wV1GigCjSemHNM7gypkrya/BhKxv1w1iA5BQE1XXDwcEhi9l8C+i8PG9la6IRB1+tNa4DrcU8x5panD4n0SNaKzJG3+aFquREumXwijzaeyptynqYMlc6yTs1Ek0TQ9hpCOTrMjOY4ziWcYj5fE5oA+v1msE7qmCSPHcLijN7HNJf6rpO84lV5svS60+Kkwkwz8Y9BwcHuCQn3nfp3o+Z8RMWMsSAd7sxUlVVJclvg3OO9WZD27YslgvW61UyWwo0VYOKSL7sMLBZr5kvDrDWcnT9Gqpu6PsB5xUxOFZna7pu4PTkjNu37/LSS6/wmc++yO/87u/x8quvcXTzUZ57xzv58T/+p3nL297OO971Hh559HFp8qFZu5FN3+F8At7aElF0Q4+pKtbrdZrZlhlkoyWPdRx6YvRYo/KNvSS5brnE7f46bQ7k+C45f6lRMWmKXjZ28jC3/B31znRGd2KUph4iY5/u/VGOyf08lhbybu10mWHX1thr6omx3+gqyqIY0epyqe9lTtKfL5P7hdTcV+D0irm8Oq6Or1kA/dDNbK/xmV3mppJYYwyEKNLXGMTxr6lRVmSiyoiphx89B4s5m/MzZrM5jz/zHB/60If4rV/5VVarFcM1hzaaVPJIUWNIMRRq5+ayPx8FFHCy/2+60jts1BRcAnj8LpC55AY6/XPa9Z6C8iyn3Z9vipPn3umKp8cZhq5I1iSCpCkujLYWhkmAjhh53D9+wMd/8zc563uefdc7+NaPfAfveu97qK8dEroOQpQoD30uBiGbFU1bs1qt+NznPoetK971Dd/AjVu3QKUMNr2V/EVlZFYnumIqkw14pqA8SwclOkOVsHDJbUQMboxPAfET90iTg7FNysCbNg+S82sU8EgxZ5Fic1pETKWyvI5eQM65K90cYxUaSwyO4AJGZ/nelsHMcurIdt6MMjPmsFrmJce+JziPRmJHsmOlspYwjnT9yGqzhhw/kBosw+jZjI5+GMSFMs141nXKhzUGq8ErTec8PlDiQcaxJ3pQVYU2ildfeYl52zBvZxwu5zSmYbGYcbhY0jYNy9mc2lbJSVX0qlMZpVIKo4VZuX//filajRGzJjEfEpmtUgLolrMZi8UCawWYRSUZnTFJmi9zgP1C9iwP1NqU2cQCjFKOYXYsnbrQarZGMxL3suvWGok7jFuZOVP7TWdZMs45QnSoIEVxZQwBisTTKHEJ1nHERTHAGXyKhClZtq4Amaqq0jqR/1YpP5LkGLu739gC3oZhQGfzo2RUNC3M834c9nI5L1PYTF1l9yWSW9WFvzTUfmeUIL23/L0cqzQ6R/BezodWJcReXnsUV+UJA5/N1eJkuYhKAPykcaAmZkU7c7x7AGcHaEZRVHgnpkc7UUDJJEopaSJlqa1zjtVqJbJb79BR8im1NhijCBi6MULnqGee48+9zPl6w3oY6Zznzt17fOZzL3L33jGffv4znJ6s8BGefOopPvit38mfeM97efrZt3J08xZPPv0s9WyOqlr60XG27glKmmQeu1XSoJJvmi4gfN/JPGbQFt/8PX//fnnxkv0HTw1+tQKsr3VfjavjClxeHVfHF70BqoeApsuyIafgctdtcQ9gKokNIUc5OMfBQjLnTCVMV7aS79ZryVk7OISu5+6LL/H888+X7rpPzAhpNgud5prc7g1uagYhoDI+5CapLpWt7RdKJmkN8wzmBUOfVIjZvd+bOp3uF1xbSV3YGhQV441hp1jKkQF1XTGfz8vMlYA0zWazkQJzdNx96WWe/8wLdCHwbR/5Tr7z+76X2bVD6vkc1/WMo8NOu/beC8NiFXfu3+Yzn/sMRzeu885veCe0jczWaYNKkzGhsK1GjHUIxSzEOZk/1FhAMgfHURhdpSPGVhiTinXJkhenxDBtAERiHHdcUbWWHL38ERclbPDE4NMMbWQ725aWY1C7IHPvPl867n6boacVGGPF/GIMRKRAtWpr+GR0hTGVuH0aU3IVj5YHkMCWaVq01eACdSMAIEyluqM4vD44O6UfPVGJ0+am6+hGJ+dWK6qmLbLjqqqSBDc5GQcnwe4KNkPPZnUujFC3wWpYtA3VfMbNoyMOl+LWOm8b5vWMtq2Z1RLVQYwE53HjiJpkSuI9Vm2Bz/n5Offu3WMYnJjlJCMewRoik9Qa2rbl2rVrLOcz8edK861hD6jEIqEPhVHOjDNTrjn9PWR2Je7vUzJqMLqh7DH58N5jbCWNjT3DJXaYFMk1FFAljYJQfieBI0xqKIghVFQeHRVtXeMc+OCIfmQYk7NwEMm6JFQml2CtZA/Tuy6lAqJEwpkjVHb2Iq1AGQH/eX4zNQICEedFxi3gRtYvySW77ONp/WoVy0PuF8Dbee8ARqH1VrZbGl8p3ickR1SzD1CnKo/0vDlKxybg7In0m46owi4QDR6XJMs6zSSqFO0T4/Zxg0rz5+l9j5M4o5JrnBp07hIAHNO+HaM4OIcA3ocCLvO1rrWm7wcWi7lkfLqRo6MjtNYlO9iahnrWsFwe8sILL/Arv/xxzs7OMaZi9JGzzYAPkZOzc1567TafefEl7j94wOG1azz33Nv4yPf9KI8/9gTPPPscjzz2GNdvPcLBtetU7YJoDIMLjErRdwPrYcQjpl3aWGIIaB9RUeXLR+6P5TpTKeOTNPe9N+ub9/I9xvJyBBdKVNRlyqavJEh7WMRV+jf15h8zwpcQmF6xiFfHFbi8Oq6ON9gUX+/msTO/uL/xi+v+dvg+3ei99zjvaWYzqqaWYHjvcWNgVltmtgZjISp+5X/6WT7+Cx/lN3/5V3jrU89w7fAIjXSR8dviM8sepxLiKduQWa19cLkzVxV3ZcSqvL+trDYXTdnUZO8udSkDUACj4sIsWWEnifjUEZ+a3uQuf5aSyTzRNjMuy9fG3nF8eowxhuXyiE9+5gV+/5Of5CPf/4P86I/9o+hb18EHcTNUULcCbDIoCATmyznODbz44oucnPS8+31P89hjjxGHHqyEeuvkXikpGiJ5UxNTHeccXdclWZrI2AIp8y5GrLJYU6OrHPOSijili4xVx63M2GiL1g7lwCowehs/I/ysMKUqCjCbSrLUZM43xu1sq+JiBpvIvEigSl6EUhGjRXYZqkgcHFHHC8WMNRZTVZycnLBYHHDj6BptU9H5QNd1LNqmgE2RgFfYZNzhgmfjBvrBcbZeEZLTZTc6QlTUM8t8eUDVNmJ1orcgIwTHMI70mzX96FgPI+u+Y9h0uKEn+pFoNbPmgGuHBzzx2GPM65pZ02AUmKgF2zi/dSQd3Z6rpi5NjXWKwDg9PWXTdzKT2YrJyugk53QcR1Awa+dcv36Dw4MjKqvxyQmUaaMqzehdbObszkS/0Wx6Yf2iF9lq3mNyZuh0jtDo0kCIe5l8WwC2N1dHvJhhqpQ0WyYA2dQNo4KRBMRUKOZRKrITNaJR5boOQYB7l9xtswHTvoIhs31Tt9wsGRVQtAVjVVWJpDo1BHYZuoumbN6PRGWLFDGfP5Grm5JpenFkIxZ2zGq9bdTszVpORynyjHLdNMLSJ1ZQxNL7c7TSzCuzzEzNt1Rh5HwIjHuyzbhnAHXZ3jCVSesoc5X7ipM8+62U2Uqv2c5qGl1R2YrDg2vcvXOXj/+PH+Nv/a2/ze9/8nnQlq4fOF9vWHUOD7SLJW99+zv5kR//4zz71rfz5FNP8/jjTzJfHHFwdI2DgyOU0YyifGY1BrrNyDB6sBVBG7AS9YOxOO/xo6dO8+IKiUMh/T777GSRNT/s3v/5AaOvNCv3egBzF1juXd9Kf0UY1itgeXVcgcur4+q4ZFN8vXmJL+gx9+zrQ4kuaEqepI5RjHp8oG1n4CN/92/8TX76J/8b1neOeeszb+HpazdYNjPiKHmDGpXmiRwaU5wnpwVFjFEcMpXaachOGURRmim0srvsZX7fMRUnYyhusRlc7gDvS1wsE3Emxa9zO2Y9Lhm0bCVxIn2sqoraNhgzL1ESVVUxm20NKZxzjMO4Y/gR01zSbDbDGEPXdZyen9ENPXNlwIjDqydijcgUTSXyTJukVOfrM1586SV8hKff8gxHN66X+InSQJiYetR1m4wqZN7Me0/o1mhtcZUUxJK5J4yQ1loYXJtiV/Al3qM4T6oE8tiNoRDiOECe50I+UxNldk1L5kdx6VQpKTCDCau0sGHTPLbsjqjE3GbbGxBTmoiAXGs0zsuczb7Rh9Yy3xVWHcd373FvMefRRx+laRq8H0uRbqsqrRHN4EZWqw2nq3NOHpxx/8Ex4+iomxlV27Bo5ujKUtUtpmllDs1onPeMrmfsHaPr6YaBfrOhGwbWXY+LARU9ttJoY5m3LdePDnn80VsczBtmtqYyBkJA+ZCYCwcpo1ZpAcsZ2Mh8rSqs3mq14vT0FNA0swW2qgRQalKcykBtKo6Ojrhx4wZNVRPGXh7LOZQGPZGFB7bRLnHKjEwZSzJjqV+/eIsU6XUIyCyfd0StqGctIedoxjSvvvcwuzPvMTGhkzzKsBfHkBtNqR7vuxXRj6joqYwCU0EyljHGbGWZUZc5R6XE9KVP0SntYiEGTsmgpgAko8UtOKGFkJo54hos8tKu6yQuw2iU3RrhRBQhTmYswy7I3AI5cUDORkFFCp1cQ11u0OzJgnWczOpPfAeyW21IrKqP2WE57YnWUKlGMnqdL6xkjMJOiyJFYXQl7JzSCVxmZ11ZP1sibpdpnI4U7N/PtqB6ugebAiK3a0HObwyRyjZs1j2z2Yx2MWez2RBj5ODgiNlszgsvvMrf/Z9+kZ/+G3+Dl15+les3brHejOh6xg/94R/niWee49bjj/P4E89w67HHOTg8Sg2PimY2p10e0PUDJ91A3/VJbWHEHVdpTNUStchuQ4xiRhXyfmfS9RK3zH/IZysmxjtfX3rHWOxiC0dfymBO85y/HAAzrw3UxH8gQcS8jlB70DD9vN4xjlPqsubuZa9ZfQXYyivPkqvjClxeHVcA8/NkLqc3HHXZY8WLbF3+qusabcVwAi+zWHbRgDG88Pd+g//3f/KfUhN51zPP8g1veZbNvfv40REGhwoRW9cyl+McHofVzU7xUMDyQ7IvtwAzMVfB7wLsDBZ1lmClzrjRO+CydEazYRBckI9No1BKRz/dJvMs2Hw5KxEDeVZs2onPktPNZiOGLRNjH6UU169fp2pqMJrHn3yCt73j7Tz//PP89b/+1/mRP/pHWFy7jmqsuIX2gcbkyAuNSREXXdfx4MED2hYee+wxqtksFSoeVdconzMeRUZU13Xq+DuGsUuSMvkZq+qUP5iLXAGVeW4MBTHoJC2MEp8wMarJIF5mpxJwdYM8prcEo4vJiigMVSo0LzdkQCfZGHtFxUTCpxL4TEExqMx2RJnBlN/fa1Ck2a66blmtVrz88svUdc0jN2+AqvD9ULL3VqsV5+drHpydcnJyRtf3xKgY3MjB8hrNfMZsvsQ2NTpFLHglQMOHwOBG+fyHnnHsS2bs4EYwmlprLIboRoKPWJ3Y3XFgWIOpPaZuJNNQq5S9KXE3npgcOm2KjdlihcyQPzg9Zt312Hrr0Ik2VLZm6B1KWxaLBYfXb9AuFmISMuSGipStMm9LihyhgLjPd5+ass75z+wGO80z1FrTti192GybXFOTkCgsdXwDtmQ6g6lDkLVSwNRlcnu9sw/lGUCFKWA2P7ZzQ5nlzaAzy5ALSNzbg0NqgIzeMTjPJsVu2MqWx87zsEopkXfHWBQfUzlsUIlZDTHFtYxlTjXvZw9rQuYGTTbMUtMm0eR8hBCEeU/jAUydaI0hjkMx0ymjAMlJVSlVwG0ZKYhhR76bz9U0x3LKmu7nw+7PtO+7gZefC4oQ/YXPpmlmXLt1C5zjk3/waX7qv/vb/NzP/QKf+vQ9bj0+51u+43v5sT/6R3n6ubfiomJ5dJNqNiMqS/Bgmwaipu9HHmxGTo9fRVtDXbXU9ZwxSAxTVVU07Zzz8/P0oeVAZRkZkPVhBQinWciAIipNxO+xtUouwiSjF2W05g2lsF8lzOVD6xB1MQqlzNy/qceLXxbz/qtZy6vjClxeHVfHJV22+Ga7lJeAy3JDm/z3dC4vA6hy4w8KqgbOz/jr/91Pc+/V2/zw938vz956HLfZiKzTB8Io+XkGMbZwuaiIXLC+L1XtpSB6d84nencpuMxFUkwM6GXgEkgF58QZlt38zDwfWeS1Wu3IXm1tdv59C8bdjkytyCutom3bIqGr25a6bbD1jOXRNXTd8HO/+Et89GO/yL3Nmj/+p/4Ujz79JPP6iGGzIsbA6Bx93yeZasW62/Dg7JSj60c88uijpOFDghsxUYmBT3HWNVS2QiPOsG6MxYymbVvm8zm2boVd8MlYQutk0LM1TBK55HbejalxUpLEWWsZ+yEVlQptAspaTGVBKYxRibX0JT9PGYkslxiQKA2MSVGps0FKzCAhQPRiEJW6/UqLHDA4j0oGGEoZrLI0VcOsmaEqi60rzGHD+fk55+fnvPbaayI9NYZuvWIcR1577TXWqw3dKFmuwUM7n7FcHmKqiqpqMdZibU3UqoSdOy/usMM40g096/U5vRsLCNfWUGuJgjHGoLzD9YDWtLXI59w40juPiYEqRgGQkZKl6JzDNBW1SkA/MRjCRgaGceTevXucnJwQY6RpmmTeE9G2IsSIC56DxZJHHnmMw8NDcWRKAGkLxtUuWCPuFrcqTmYp9xnM/QbYLsB0oyvxI23bMp8tt063agsdLmO0hCUKoBJjPZFSb2c+2WG8dJzIqhMQC4SJ3DRnQm7BpTRbQmHppvvpbDajaZpyTRT30sRUae0TaEwuxwlcZSOfLP21piZ46Idhp9FWIjdCLG9rP0LJxSBrzTtMNjzSOvlubg2xdvJBy+znhHmaMFweeVyJfzHF0TeDw0Dc/Wy8gCMxWxJGzsV8mSpiij/xXuT2Y3pfttIXAGM+v1OFyD57uWOMFPWWw8sSejJQUdR1W35nuZzjuo5f/uVf4b//63+bn/zJjxGBf+qf/lP8uT//z/HIU0+jmoZoKzajRP90WPpeZtCr0aCUpu8dXfA0B9fo3EjvI2ZwVEYMv4YIY9dj21mZS9fpfBdwjZfrjex6mg3tMvhSwgbnhkeR+GRklvbBS7nMsFUUZGfVPUOrr8aGeDb0u8AcfoVmRK+A5dVxBS6vjq+LIyX3fcE72v4c2sMA56Wb58TtFCZmK1En2V2QQjU4iScJIbGWUiw5j+TR+ZH18TG/8tGP8Z53vZNnn3gKOzrW3UYs8aMnmm3m5BQkxCCOojuB2BmoRHbmIXNHN+RJHwUaiRkwJFOEGEsYeVARk4HmxFCm3H73jIykkNyCx2lQeJaK5i57VVUYa9l0K3o34vtup0DKoeUZeNazljZFcywWM5pmBoTCZGqtMApu3brFN3/g/fzW85/iFz/6UR57+km+7SPfyWNPPCkgPXh8Kv7btgU8ZyennJyc8NhTT3Pjxg1ZTdZgqkoYvZjlSwpdgrcjLkkblTZYY6jbOXaxhKpCu0h0DrxHoZN3oRQ0whqnAsdHgnKoKJb+MUuWzYj2egsS0vq0OqK9hkoyTr13EmTvowjxYtg62ya26kJBGRQKI9JpY4g+z7omkyglQfLDMBSIY40iWk3V1LRxhqolk7Jd1piq4cH9u9y9d1zYn9XZKTFGHjx4QFQwmy85unYD29QSr2AlLsOnQs0nRsoFmb1cbzas+w60SCi7vscjjEbdNBjTiLzSO4xRKK+xRBpjuHm05ObBAbO2QQfPoqlp61qMiWIyulEKTcBYQ1VJwVucPYHBezabnrt373J+tqZZLKnbhjG5vmqlcClv8eDggBs3bgjj7Z1I81RIMaEqEcRy3fkgNjTCTJlLm0DT6yqGBPjh0pxg5yQKpmka5vM58/mc9XrNer2m6zoODw8xybW4GLwgMlGl82zuxaiK/UijEBwguY8l5iN4TDa50Qodp+6c25ij/JVzMYPaAoS6Sb/jfMpvFZOcbCTmnZdNJzNXaIL3+NEx9l2J4CAEun4N/TYbNsaQRpXDxFAqN1cQwxyl5Bx7cbKlZEym39dGAHdIuoCQNtYEZIrSIsoaLnOmTjI7C8C2Zkd27QKYNCsYk3w2O14rZeR6cPHS/FOX3GZDCJiqEVOeND+slLCkmXm/LEJru7j0Vk66Fwc2HcsfR4cyhuvXbxGj4m/97M/zF/7CX+JXf/UV3vYNz/C//Zf/Nf6Rn/gJumFg4yE6zcnZimo253w9oCvZ/9A1SlUy724U7XzBehzQdc2sTXnLkyxSjciywziKeY/WWGXRRolkWO9K9UtTd5Lnq6MoDXTyQdhOB6Tr4E2qBfZBnY7/4IGUiq8PNt9M9TQVUORZ1aDePKH5lTQ2ujq+DsDl6y2WLyS35gtf/F9dnaGvZ9buCz0Pca/zd2Gz0ROXxL3ojhgjmMy4sbPZ6zw5Efc7irHczGMqUvSkRZ/YgRhyrtMeA5CLrPx6DFuJ127/UpXiLt3yL9mbBRBMO8AhJklqSIWGH6ibitXqDBdGbjxyC2UsgQrHSN+tOVouOD6+x707r/FNb3sb2jke3HmVW8sDhrBBKyU5Z0Hhoks3fkNwnqAM4ItjqC7sixTPWk8/j+xIGdExEhFgYWwlHeMkxQok59J8LoolvkKprQxLGY2qdQJEukjgyr8pJXORBFwYUUqj0UQf2fRrQgj03u24RlprsVWFMW0BoU3TMJvNSkh4JNEFKtI0kZOTE0wVuHfvHrdv3+Hxxx5Bz2Y4Ffno//h3eOtbn+XJJ55EGUVw4lwZvQBsi+Ls/ikmaJ5+4knq2QxsVcZ4lBVDnzBIo7uuLERHt1kzdj3d0FM1rWQt1jVoI7+vNWhHHEaCUuggctYYI1GHCehTxKiTYlZL3IICa2tpAMRIDI5uPWJMR/QNpnVoREpttOSKBi9g0PUxGZvIyg4hx2pkF8xkFBJ1kQD6IJJAQ8pIdA43iNGKskqy6+KA0wo9a4hhwEVobIUPiqqesTi6zmq14rW7D1itVqjoxd338BpHR0dUdQpTtwavlMxXKegHhzFVYZn6vqfvewYvjHXV1FgVWcwqtBGW2tTbSAfTWjSKYb0hOMfhYsFbHn+SW4eHuHGg0gqiTzN3PjF/4uxqrcQwBA8hjHgXaec1umpYPzjj059+gTv3HvDIY49imoZuGKlbMWRZrc9wY+Dm9Ue5fnSD2XwOMeL7PhnKSC5q3vLCxLlX5VnpbJQUFVGbSRNoC/SMqVJIn0qy1hwhQgFr6/Mzqsps3Yhj5Ox8DcCmG1jOFwxO2P+2bVnM5tSVJcRQ4jsIpIYOCRBJU6h3Q8pZNERk3QYfyzxwiAprkjQ/NykmoFlribHwE/nmMI70Y4ePgbqq5BzJhyA71GS9SnPMlGt/GARURu+YNQ3Re4xstCgl83chOmJQks06cfeULdIQvAB/lRjr4ALRg9WVgNqgJM5GpUxQFZPyICZwku4dSQEQlS/GmzEZFeX5TeeDsPJBSYakBbQt8tzR93gPPjsVo3Ahx2UI6x0C+FHyQLuuK0ZHTVOhM3jUiWkMYlTknahiSvzRnjQ23/8q27BZrZnNxQvg/Py0mCvdvX+PxfyI6zcfoZ4dcHz/jP/qr/zX/N/+/f8cpeFP/7k/zZ/98/9rbjzxFGvdcu4j3Riwpoa65t7ZhsX8UK4CneZ+lcZUmirFNs1TVE0c3YWIGB3Bh1Gwss4RI6EYqWVZdiz33wlYzAy5Ckwte9QOcJpGi4Q92LUdgEwWSjsusyp9PxB2QOh+pvY0J3O/npLXnGcn5fqR+3YaWZCNYzuXH7emXOJOLWZSSim1ZevZff69JlF+nPJ6i3ImAU2lt/LaSR2Um1tSHWzP1WX5nl9oDX01n/kPOXN51am4Or7cayTPpnw+nbs3A57389q+FOs4M3xa2S2LmaNICCilCd6JdX2eV0qhz0pbmmUFs5Z+HETqiUIHz7KZ0W82mFS0aKXRVqz9CRGdwq5HHyfuoFt5m1GJvwx7xg4qyAydUhAd2lQTEBOKBCvfTLKca3uDCpDBpdYiY5vMF5WbV4KmORdwylqqifNs0zQlxzDnV5bg8DQ3liWipRvvYzI0gLOzM7TWfPazn+XO8TEPTs5YDyPNcon3jrOzM9brNcEPAviVwhhd5LoEx3q9xjknzM9sKWylV+imTrx4NuVIjQk/MroB58ctO5NmBaM1KG2SDMmCls88JDnztFUSE0uVP9OognhQWINRFcEIgA4hSCOBSAyecRxoUBATCx4TWNIGH30C31riFJSmMsKehHRZZVdLXRkpQrWVfEsVU4EOxlTYOjHPWuGygYob6IaBgMIrTQw5FqYqn5WpLNGHiUy4kvnLMDKs15yvVvT9UMLhg9IpEkEkvkopamPQlaWZz1KjIuI1MuOrKaZVIl91+G5DbS2zpqUxkgVaIcZHIewa6Mj6i6jEgozeQ5KVeu+5c+9VXnn1NmfrFTcfuUXdzvCpPvbe049DihBqOTo6Yj6fg64gDlKK6YiOmqAT+4VKMTN7jEhyuNQTR9XMJEjCyXZWL2qRRZq9/ceNI0pDVVWF2eq6jqqp5XUBm76j7yVMvqkMBwcHXL92xGIxww/J/CvuyunKTF6I+GRARZnXlqaic6J4CEpJk05dzMMtkUOT3Me+7xm9SzOu0hC74OgapEGXIz+KCiN4CCLZFiZf1nh+XcUuNDXgYrpGVTTF6GUnXF4rgvPFHGxqppVNspi0PKWJZ1KmrTQnvfOMzqX9zWKNYRyEUTZVLaMM6REMOjFDSape2MoJrCnxGDILmkHKZSY9+XpVyRBIwFOet9bbWXBrd8ybdJbqe5jP5wyjgNbFYsFms6EfBx5/7Em0bQjK8vynPsd/9P/6z/jpn/45PvChb+JP/5l/mo983x+iOjoi1i0POsd6CDgPdoyYpmV20OC8Kk1ilWWqpHObmgdq0njRSpeRCmnuuiLNnso+SVLs8Dqzy5f5wO7XDFvW841qiLjz+/EhyqevNSObqfPxltGVsmEqq5c3Fb4aYj2vjq9XcHkFMK+OLyUjHL/Mu9Ubxol8Cd/TnhP4jqlDnn8pBhdZHmpr2Gy4fusmurJSuAbPjUdu8eD2bSIBjeSkVdpglBVEYlIBmGaMKCYOOQQ87Lz/uJd0kGcjVQjEOOKjGAxlWZWOAh5RAUKWyabH8MJaxCAMJRMTEW2NiEBjKOYUU1BJAnZ55rJO4DIDyLqutzmW6dxNZ1SzLEyKpsim7zg5OeG1O3c532zAaG49+gibGHnllVd4x3vfw/Xr19FNA6Mrcts8t+XjyOnpKcMQmB8spSBPBhtlNnFSMATv8cPA2IlbrbYVWkNltbC/2biHNBNpttEgQW0BZr5xV+k9BmTuMScJivSrEiYmBLx2Yr8fIm4cCSGivKGpk/lQ6jy74Bn7EZNyN40xuFSEKnGUISQTJ1tXeBWwVlMHYUhVMi3KM7ci4QusNj33z044fnDCebchKo01NcbUtM08GSRpdFWLtM17AadajFucc7iYHX+HMn8s4GMsHfA6MdVVWge2EQMspRRjFHmniwHvE+MYA5vNBjWOXDs84vDwsETFTOeMtoZHlNlUk6rF6By2qtBNzfnJGS+/8gq3j49BGZrZLOWZysUzjiPdeiPxN4sFN6/fSOBSw5hVEcm1N62DmI2cpoVuif5RyRE17hStKuVMbg1wLlcD5aZMiR/SkaqW+d/lcinnJhXjMUa6LjFq48BmM6epaoxVsrdMWK7sSi3rJ+yBYmQtei+uykpDnqnODEp6rbkpIhL+QN/3bFbr4vK889lMnVyFn5Ec1gSssvusMIN9yZbNVb+KW9BhEsByEwOey/Z9cbAeGVyfAGONMtJI8sEzFbbkTGNZPyLFD2PK76yyCVBkdHKthhBo0mezjVkSB2s1YZemUVJTlnF6DzGJYc5f2WgnN1pkFlln+CzrWwW0jsUdO4P9GAI+go4BNwy0TUNFlaKTDHUzw6MYo6ExLb/7B5/i3/q3/10+/usv8BN/9Ef5M3/2n+GD3/JhgqkZlOZ8kHlqW1cYZfGJvdXWiORaMYHXuxEtyqgLZnRxr9Fx2ef2pQZvD3NR3f/+w/5+GfD/ctZOX6r3X8BlDAW87+5DV2zi1fFlApcPY3muFt3Vcfl6+MIaD29mY/+SvD61m/O3z+x9QY0Wablun2dPBhOS6QaATeAyt0rH4MHB9Sef5n3vfz+f/dQLvOXRxzhoZiwPj+jPVphUnCldoZUt0QYhsYY74DJkNmAbHl2cSLecyNZkJGxNdkLRDaUvHfEhCrOo9FaGlK3S03wU2Qo/mavkIhWtmC3m5Xs5r1BcRmtsVaHs1kVyKonKYNwlRiADzWkMifee09MTXnzxRaqmoV0sOTi8xugCv/obv4GpLD/wgz/IW557FqyV+UelcH5gHHu8r3Fu4Gy9wgWRhApoDlKoJdaDGIuxTXZAHYaB6N3EsCjNKSkKu6uiFIX5c4Egjvha4gR0MvDAi9SQ6NNNPpY1lGNMtNZE7xhHx+jkSw2GfhDHUxViydvse5FSV5UlorZrr6nR2pZiv6pbAfrGygzXOBCcZ+jWwroYLS6awXO+XvHg7JT1pkvFdANBYVQlslNEDp5zOF304MEgsQsxSCEbnKw/q2WNzGYNzgv4zuuibcXkRykl81Jp7Wgvs5ASTeLonRjZ+LGnVorlcs61g0N5P0FY4NxwmRpbKMoCZnAOrQ1aWYZNz937xxyfnxKB+XJBPw5iYqVNcRXVWnO4PODm9RvyWrWsFe9cYVJCMkMx2rB96knAe4n+mQCdxB5kZ+HX2/vydZIbMt57zs/PCSFweHjIYnnIfD6nrut0LuSJxq5ns9nw4MED1utzKmMFjFaiGChGW+nzqet6y7Kp7fxinvnLc4pl70sMtNrLmIxRTGz65PqcnydGv+Ocu29ONgXV2b237/ti5pPPhUqRKVm2L+ddlcZUdquNk7nQoCiZmNM4jx23ZS7O32+bZeBioKrlfDnnWJ1vUjyKL82dGCN+GBlSNJSpbAHpVhuJG9nLq8zHDuBPr3GayRok2CiJNgM5miO7gefn2n8PMt8euXHjBqcnJ2k/qHEucO3GTarFEcf3T/ipv/kz/Kv/6r/HrccP+N//H/8NvuM7vo93vPu9aFVz+8ExwbT0PqBMMjozDcGNOB8II2W2uKheUHuzvbtO5/v3fK3iQ4mNrwTAfL3n2P/5LwfpciG/+Oq4Or7emMurxX11fD7A8LIbxU5LbO/GwkM6y1/ybp9i7ybrv2TP9TDrhDyDUzrOSqSMLgaG9cDNmzcgRP7xP/VP8P/4t/8dXvjcZ/GbDc898QRVXYvscVJkSV9eCqiqSuc5n8cElo3aytum5zmosH+Cyhxesf9XW9CslCKaWAreKdhRRiIppu6mVVUVkFmKJbsF1HFixa+sKcC3ZMMFX7r83ouBS87GzIXltLjc9D3zgwOuXROn2FXX87Ff+hifeeUVfuJ/9o/xgQ98gHaxIK5XKVR6u86s1aw6l4AUhUkz0WMqQ/RepL8yFCUSwCCFNXnmRe9JqqIYLBWzJy2gKxKEBU6SWa2USDVjQEUp/v1kBQlTElLEghSlYRQTKBddYl17us1Q4hsinqHrWa9l3q6qDOPo6YZezmVdU9dt+fy0EkajtslsxY9iTDL0DH2/4z48pKgGlKaqaipjQWm69SrNu6niPJzNq4LX2DSv59wghitR0zSVuM9aS9vUjC450xphe3NhnK8dTSQaiwvi0Ot9/spRLZ66nXGwWLCYz7EECB4NjCnHU2tbwM/W6AjG0TNfLPAx8Mprr/HiKy8zuJF6saCatfSDk+B2rRg2svYOFksee+QRbl2/gVFJTh73jEWSMYZRamL8aoghTOjLSYGdSAOFIaAwF6I4VJFBTqX3mQF0buTBg2M2mw03btzg6OCQ2WwGywOGYWB0sgYMImkNycBptVljBsUmNYAygzkFl6Xpo7fA2SYpamEOQ2L1cqPLJ7YxR8pkxrEfZE6yluzRnPea96q8P4Sw/bvRMu/pfSjXf1Y0NCk7Vunp3J2YZBG3zaoyg5eNrryAsmzilPOHc+xGAa2XMGhbACoNm4jMDnddx7qTuCSrK2HQI0UlIYy7p/IV1lQFLMY94zWY5o6Gvbm2kOTEHhciURlCAs3kPFMR0Mv/Txxjp3PxeXb9zt3XmM1mLBcHdKND1xpTL/jtv/8H/H9/8qf4i//lT/FDP/b9/MAP/xjf+wM/xMH1W9xfdSzmFX0wmMbK7C2KzRhQrgNtsKYqfgvFwCwNS0QmMlOldxjaHQO6PRB6KeumzJeFsbzIEoYLMtEp8FOXNIPeTM38MKD85WAp37T6Ci59P1fH1fFlAZevx2JeHVfA8mHA8otZKV8W5vJLfGQWYufPyfxQZuGcc2VuSGaKRCK42qxZdAtaU/GeD32IP/TDP8zP/NRPczRbsF531LaSHMQQIGhypRoUJRZAOrxqZ6DfqIvyHZ+jB6alrdkWiVl+WOZJtJhiZAlv/tlSoCRJbAaXprKlQMszlSGIaci0UPOp266835NMXbyp9n1fAs6HJKecdu7niwXzwwOWy0PuHD/gl3714zw4O+cn/tgf44d+9Edorh0RgmPTd7RVDZW4g9pq62DpvUdXAi63ErwUFRGlQCN6lBZGWCUW0trkiKtzKedR+OTAmGSKUaV3G4qhhGR7ADHLpX0q/rLBVJq1TEDfBY93gX7o6YaBfhzEJCXAg9MzNukcNZVJgDuZfrgKoyXSwXmPHweiNlhViTmm30iIfd3Ie4tQGSumIEFeX/7c2uT4OwyObtOxWa2FaQuK6MbE0kiRPmtnxYwphMTWBjFSstbSNC1KCRuZ8wXHQVx/MyNtKzEf8jGAl6ZJlsXmmIcQoN+ssFqxnM+ZtzNqo5NrczJ1iXFHdhhJwDJ9zk3ToEzF+ekJr92/z9n5imoxEzmsBpvNg1JeZ3Ce+c1bHB0c0jaNsHgJXGYwk4ve/B6zRDxOIjsSL5Pcmf1EFaD25v7i5fffyI5c1I3jjtnLYrFgsViINLNp8KHNm5GcY+cIwdH3m6RgSJJel+SuyWBldXZWruli3FVZkdNWtoDPywxjSn5jEIlpvpatNpjE1mkfSktlOleYweUUcOZ5zSyHbZqG+WyesG1uSo07AG1fthhjlteHdFXG8v6K4oLL5aiXAU5bNazOTzk9PaXve6wSQF6ZepI5LLJDhu35rWzYAbP7e/WORPiS+6CoViBomTtUWX9KOuderpXKWJmxDjGZGE2eSysWBwdishQis8Uh687x03/jZ/hL/9V/zUd/+Q/4c//sP8WP/OE/wrd8+COsuoFBWQatePGFl3j6uefohhFjhd32aU8yKXJqahyz30x5Y6PAiwY105rgS1kb7D/PZcDujZ7ryy3bfehzxvglqYsu3IOvgOXV8ZUEl1cs5tXx5QR5X44N+UJxcUnX8ItiK2W4aBJefFHilcFlll/FGPGJzdRa048Dbd2Asfyjf/gn+K2P/xpnZ2ecnJ9x6+i6zG9NzBpI3Xc/ZSTjrtNAZC+7M7FlZfaroNDMQAJaDC70xHAH0nyoUcXIJzOTGI02tshqi1RLyfOrKLK9OD1XU7kZXGqCMA0JX61WO8XqbucdovMMwfPgfMVv/L1P8JnPfZYf/fE/zI//xE9AU8E4glHCIlgDRLRNBkFKnqcbktlJIzOOzo0YGmEZJ4dO5iWZAa2spbIya5hZPhPEATmz4uLe6MWV1+hiWCNznQ7vXernKznHkxldHwKrfqQfB7puYNN1ZR2BfD5eUQxmlK7T52LlsVG0dYttZ1Kox0hdt1RtQwwUV9a6baTIJVCJBSi+dhgi83ZWCsRu6Hnw4AFd1xG9p2pqbt68znK5pG1bqsown8+palsY667r2HQ9w+ixQ18aBuPoC7sq4Iy03oS99mFMtK8RABflfISYpY2qnNflfMH1o2vM25ms3cD2vEcxYPGp6BblqYh3UWDrhvVqw+279zhfrbB1RTOfoa2hDyNaWTabDWM34r1jVtfCkDYNKnhUiudQk6JsSzYqmYXViU2KasvZJDZHLklZl0FtwYs4O4mxjcxG74GP9P6UiqxWZ5yvhDE7XCy5dnDIrGlo65q+72lmM6xdpN8VwObTHGzWW+Rmlx9kJjN6kbZ26832OVWWhBqs1ltH7TwjmaMkfJKBpxxQAD86AayRYtg1DAOqUWgkEiMD3Nx8C97j3FZKnLNJNdDWFfO2oa5suvYUHo/KbuAZXIaswJjsz1GVa1AckdNXVlew3SNDVlBP/p4BXAgBPzjW645NNwAK27bM2pkwthPW0GQ5qA+4fiA6iVDx2u7MpD+0ocB23jX7FvmcS5pcYoupTHDE1DSrtZLYHaMSkxlSRm6FsojLsVLYesZrtx/wF//Lv8pf+Ev/DY8/9Sz/7r//f+abv+0jvO2d72XjI+vg8EMgGsvjz72V1TjgAZNUHLZqxDxLK1yOmqkruRdMx08mxjAhXB71VXJ5jfqK1QqfT6N7+jrfbIzZm338N+O+esUqXh1fl+Dy6rg6vpzg80vduNjZ+PdvAF8i5pIJc6n2njOErYnBFEBF5zk4PJDw9VGs+Be3bvH93//9/LW//Fd5/MYtwoEU3lopAX5RT6IDtgY+lAzDJCuL2xmewlVO8vKyA2V2cZ0mtsQUTl9kb0ajJz+bAR5GCwDQE8A4CYwPMWKszPjl17lvWJELsGkQ+NS0J7OUmVkoJjPp36u6pjKaV2/f4VOffoH3vPsb+aEf/mF58Lrm/OSYdjFP5hIR78YCatDb+IsQhLkU90cHLgV0a41RkaBisp3ftZrPc16kjEmQUHqSTFIKZp9kspmx1MWBM+bPSW/Xvkvs0ugdJ6enbDYbzs/WbBII/v+z92dRtq3neR72/M1sVlvdbk/fAAcNQQIQCQIgRVGibVq2aNOyZTOx5DiJk4xc+D65yl3GyE0uPEZGLuKRxiNyHDW2JcuiFFMUTUok0RIdARDNwcFp9j67rWb1c86/ycX3z7nWql21m9MAIFmT3Kiza69aNdds/vm93/t+75sVOUVWysyqsfiU3RiiFJLtdRhCYL5aUpalzC16jyeSJ4fjQOxMc8pM5vZ0DPgWAGsBi51zb1N2dvm9omR3b5yMYwbkeYHWKs3RxSTbFSlxXa2oq6VkK1o5vu1MWiuRNibD5JJ9qowmJsa1BfMuxsRaJvY7CLuVG8to0GN3OKBf5hJh1LJl3neGJ21DJgS51JWWrE/vI3cP73Przl3quiHvS+SNT6xy0IrlcomvPUWWszveYXc8Ji9KYT9RW0Y2cr7F2KWz+O8iljYk+LGV6AtDHlNTR53zp23KxBA7MOgT8398fMz9w2OqquLg4BKjxEa188pynNM58a7LnbXWEoJbB9SnvMkQAroFA3vrGeP293Uz0Eh8QtsU6MBlN2NMtw/tva11Mr5SClc35DZrIyS3wFj7+hZQtooFpVS3762Mfd188uc4qrZFu0kzren+jXTqi83Xbq5Pm2zqJpBoFQ/Hx0cdW5xlGf1eT8yhEhMtknvTzYw758TkKJ0/hduOcDojV3ETrGyaxAUiKAntMq1UOkgsi/MB5QPVcoXNM7S14mCsRCJeFAVF2aOJgclszhe+9Dn+9t/+u3zj2z/gX/+1X+c/+o//Nzz17EuM9q9w63iGyUvIeiyWK3SMNNQ0XlhxkbWvo0RaV24xbNp+PrXAsnW0PU+1AudLM7fmEN8n8PjgsV+vIw/UFGdkZf9pJ1/eS2b4YrsAl48szB/n3x/WXXm3g9h/2myef1IWiXfCJD7u4njWOdl2/Xvw9ac7s7Iob8uqFOsZkc0C4vTv2Z5V2f4d8u/mFBA8tXCeJzvb+N6mcURbcKwfJhs/m2RtwW+0l9PrhSWgAy9Ga0ajEaYsUWUPmpnsi/ccHR11nfrNwlUYnO1czrWsZfu4+5af2ZyhSEBImJREXJpTFv3JzdVacT5tjXh0+pkQQgqlDuigu+K6y8hsZ1r1Rs5lcp1siyffsiTJYKf9rE3TbElejbWUWdYd+xhjN3fZZjZarRnv7jKZzen3+1y9fo3hs89BluEmxxidcXR8TF5k7Ozt411Dr9ejXsw7qWO9qsg0MjO1nLHT3wcNfrXAFMmgwjlUyoXs9XosvOyvzdOMmrHi/BkCupUtRodR7Wf2hCbQ+FqY4EyTGUNIxkkRAZWuCckBd8LxZMLx8WQtNbaST+mjZE8GLYX2cDzi5NgxWy7YtUOGwyGL5Yzlcon2irLMsbYQGTAi8YwBmXNMYL0YFpI7Ol+wWKxQwXPt2jUGgxGr1YrZZEJd1xSZ4dlnnmI8GNLrlZRlSYhOgFpoqJbzTk7YnuP2qzGGvCxlTtCFTkorhXmBssJSNt7RpKLexyCNgUbeB2M7eSRO5OIHe/uMhyOUC+L06WXGLcuMsDUxQhA5p9IK3ziIknM5nS+4fecui1XFYDjGlDkhqjXz5aT5oHxg52CfZ59+mr2dXWHl6gZM7D6bMYagI66u8USMTvLANjRVJ5UDLfgStlIp081Y0rFPEhmjk5FQa6CTJUlp1STzpuWSw+Mjjo9PuHz5MlcvXxEpfZS5U2sMIRkfWW0Sey6xN5uNtjZ3tVUttISRNusCv67rLRfhOoE+tOrMqWwLPJMzsDGGxWJBYTNhxY3IRmezGSTZPBtz4S2Ya78u5/Pu/i/zrDMd0kqzWiyTIiBJ09vPYAS0t8+flulXG8A4aoP2HpuY8+gDCondUahuPWpNpoqi6GT0y+WSxXTGYrGgCV5mFnt9aaz4QF01aOIDjGRrLtSB6BDx0Xfr4GbO42m37E3H7PbYSGauSnJ1mUMvbCYsf+PJ81zW1rqRuWElh3o0HFD2BxwdT/j2D37Af/ePf5Pf+d0/4KWXPsz/6f/8n/Hzn/3LFP0dyAbcPp4RbU7UGRhLPyul+RU8aEXjA0ZpjDW0jsTyPJLG2SZgl+to/bwOZ9QBD4B732x9/zTQfsCr4Qxwt1k7tKD2QcWMOrM+0Wc0Hs6K7DmvpjrNSD64/w+vy86TS3fXyzmmFk/Kmq4rtbXh2Pr3tLLZ9SzweSzre13zX2w/XqzwTs5b+zP2/d7Zi4vqYjtrYX1S8PrYi+S76Bi+059tu/jqIZ97c2anBUohBHo2w00m2KyAkyn/5L/9B/z+v/iX7OyO2N/f3XpYxg1gu2Yuw5mGPkptzwhJARiJWuYAO9fXBHqVbt1zpYh13nfSWAGPa7ZzswDSiYXQMXaGH1ErKSG0xkUJ85boufVnaFnJltlozY7aWb3WKGQTeLZ/WhOTrCy4fOUaR5MTdkZjnn32WW7dusWf/OEf8sIrr1Du7VDXK4qiJ6xGIzJHa3KR4aWIhaZpUMk5sqnqDiCaXKz+25D2bq62BctGJH6k/Eur5fN5V0G0XUEomYcRJ4OMZC2TAQkwilnRbL5kNpsxmc2ZTqfMl2mGzmgyo1Pg/dpURcUo9Et62ItxjV4X2j5QpcgPYUTl+02WoyPUrpF8SZt15ivGGDH1SYzu3eVdlJJ9Ho+HqdCWYjuzGu/S8dJrxirq9Tn2jRP5Y5JDyvFSKX9SZsK0FtfN2AgbExRpzldhAni1LvRccgxu6hUmBPaGAwZFTm4TIErRMSoGVDRYYyCx1s57lDJkRY6rG+aLJd//4escz+cYm2PyNisyYDJLmeUcH0/AeTKb0c8LMX5JzsnWWoLS3TmRYi9Jw4MhEDCkCBiplFE6xZrgiacWjXjGGtIxfokJ0l4aLHVdo5Ti6EiYs9FoxM7ODr1erzvf7RqzdsqNjz2i1fqOtowhCMsXQ9gyLmu8QwXVhc77tkHnBbC1jQCTwGdI91sIAaOMzCkmVUJ7v2wypVmWdexrlmVbAC2EQK8oE4PlkxzWE+NaHdHr9dI6k9aclPsYk2FRO9uplElRLTXeN+S5RLmAJs8tIcDJyQnT6Rzn6s6QqlcOTs1rqm4dbWX8m4Cky/htWVAftp4P7edq9791hz3P7MbXDh2lkDPp+IQgDZTlYoHSFluURCy9/pDBaMx8seJLX/oG3/zOd/ivf/Of4JTh1/+9/5Bf+3f+Bs8++wFU1iOonPmqIZiMqDNpuIRAiAqfYmqUEjmz5Jy2LLx/R8/Ps5rT74h4eIeF8AP78w7rhIe53p/Fdr7TeuO9rs1OR6jFc2r4zYb6xXaxvSvm8sd1wV9sf3ZA5fYC++47IqfZ0XfTjXnXOZubHTytJGvtVBzJputmB8oiYqrhPaFxxKrhH/2D/4Z/9o//EWWED7/yIXJjwQcxAgmSeKlC+kw+gcvgtoH1KXDZWfEbvd1FTB369c8l6U8IxOBRrUOsSYClLdi0Fr8akxjV4Nbv3c4ypRnEGAKqizxpZ6FOGVYkCW6eisi1g6Ics8V83knQUGByAZ5lWdLr9Tg5OaFxDVevXuVDH3yFz33py/z9v//3efrFF/nkpz/FMy+/yHA8YlktZLbVZJJJZyw6yPxiaBx5lhGcp1othFlyDeRlB+4lp893+ydMbSrwqgaiwRRZVyAqNMZmaJslZibgk1OoMC1y7DNrmc1W3Lt3n7uH91nMl+JfEwJRGcp+X/LjjMiL24xIjQDc4XCIIhBdg/c1rqmwJheWRw+YzWYUmaHIDEqFLqLDGI3WBb6R9/KNw8UoM5LLJa6RyIphUZDnBaPBgLLMyazpPnfwSfKXjI/S5SHsWGJs67pmtVoBdEBBG3HRXFXLBOba+BdxDG6jP6RQj10TQGuNdg5fV0TXkGWW/d0d+r2CzGiUF4YvbjBhWim0tZKXmBxpM5vhlhWHJ8dMpnNQBpuXoExyJg6EIPmxy+kUHQKDYsR4MOxmUElOwhrVzelJk8ZiLFKE+waM7tYYbXQ6TutZPiV6aFEApHD5mPLmotA7W2uIUUh+anAsZlPu379PlmXs7++wf7BLr1+meJYEUnRrGhSTkyhnhqGflTXpAZccgOXcpD9t7qVWRBeTkkG+5UJMbjzyOaV5IGZgSiliAqstA+lCkxpkJIY7dkyeMYZeT8yhrMm3mnItiHG+JtOmk+uaFrwlhcpyvkjNsQQArU4s5oa8VGm8l2ZMbguKwZCy7GOtZrWquf32LW7dusNqtSDLCnq9gsFgRK/fw6aoF+9dOj8bYws+kBXZVn7gaUfuQMNmfFdrgrSenZfmXIhmK6opEggxUOQZq9UKjTCYrm6STDcnzwxFr0/lI8PxAS7CH33tT/ju917lc1/4I37rd/8Fv/7v/0/51F/8JT77mV9k//JVlpVnvmjwRGzZp6qcSNOJBM/a0VrpJKXedh/v8jvbCYC4DfjC1rO3G09/KOv1o6xT3uv69rQB0ZMyeT8ugma71jobtb+XsuSL7QJcXoDKP6Xg7ieFuXzSmcptCerG7AvnFkcxnn6ivc9bUFsji4/HXKauvnKBPMv40u/+Hn/3v/yvOMhLfu6Tn+RgOMQvl3hXd4WbpJoZceiMdADuNLhU6aF/2lWv20+tzpQhdXOYW7NeOmHlToazDoBvz4kPXce+NUM1KTxetSHakW7mM278viLrrQPBWUuI27iRxWKxlX+4PadnyDNhBpazKTu7Iz718z/Ln7z6Az7/+c/z/Td+yH/0v/pfMtoZo7XFNZ6oM2JUwmAWtsuv7BUlwdVUi2VipiLUVcfGaiNSOpQwUeKESzdbGKnRq5xcp7nBVo6dEFc7i6itwhY53otRz/3DE05OTrh37x7T2VwYkbwkKwqsgrpy6BAgk2PZFf4JrE+nU1T0FGVGD8toNGDY76GUTsyTZzgcUBQlLoi0VCubilzDbDajdgGjFPP5nMVsLsdcS9zEpUuXyPOcXpGJg270eN90JkRtgb4p6zPGgDaYdl6u8aANWlvqyhGMx2hLUzuilqxWbU2atUwMWAwp1UWtZ5a12mK7B/2SvZ0RZZZjUcTgJALDeZlBa9cF7wmkSJyURzibzTg8PqEcjmi8NBlWjZgY6Qj1ciV5hVVNLy8Y9voMen2KTKSGwUmcxmkmSaE25oq1OHkmZjmq5AWsosz/4R9kbU65VrbNGZdYe5NY/aqquH37Nt57dnd3OTg4kEZDOh8PFLGt6U4ClmcxPVvz4q3sL70maSRwwa8jVoxGYUS1AJAcSr1zGKUwaJEvw3pmM0bKshTjpyxDW7UVM+Rc6KJBsiyjLMu0rphu1rEFnlopmlXVNdHkWKZZz3StZ1mRjr3emNV13XFZrerudxljuv06PDzk1q1bfOMb3+DWrVt473nhhRd4/vnn6feH9Ho9RkNpWoms1qeoJ41VuhvrWK/9GxJQo7vZ95Zl3ryGNmf0TzvHbj3vUqZovarI84IsyyWiKUKuC4zNwZRoFN9//Qbf/u4P+P0/+CKf//If8cxzz/O//z/8H/m5X/xlXvzgh0Ebbty+Q4gGleX44KGuJYNTbeSDtiBZtULJ03z3eRz8k9Un74a9fGf1UTyTuXxA1hoeHKN5mMT1rIiPzZ950n1+v+q5zZzyi+1i+4kClxfusRfb+7Ft5rxtfS8+eO3FUxfhabnHw8Df5vu8L8HFCcR0HfMEyrQ1UDf8N3/374Fr+OTPf5pLBwcs7h8yLkvqxZLQRhgom8xBNtjJ03Mcut13vdUpV1oyKbWmm49EKYyyHQvRzlyuAUI7E5YYWRQxCMhp8zLNKbApssx1dAkbUtq4kTHaxpOYPOuKsKZptgw8vPedoUxRFBJYn2Ri7WcuioKqmnB4dIIPkVde/gB7l69wPFvw6o03mExmHThVUcxHGu9RRpNlKcvPWqpG4jWOj4+pVwvyfJQYR92xSC1jEqKwtdooMcsIgTo523ql6O/soLIMAviqSkxnRq41aPmck8kxJ9MJb775ZnftZUVPXFAD+Fpm2UyWoY0lovGpYF6tVrhk7jPs99kdj7hy6YBhv8dwOESrSFNJ1ARoBoMevd6gy9vr5mSVYX9vh9l8Sb2q8E3NXIM1ijLLGY1GDAYi+8uMgKTgPEaLQy5awOtmXEQ3K5aK5C7f1RiCglVd4UKkKHrCciX8HX1MDZr1/K7glZCcbh3RRVxT4V3dxW2MBkOZJ5MhRWGPCNDO+GqTgKlcQ8FHjicn3D8+YTZfkg1GaKMl5qapU5pDpFmsqJdLTIR+UdIvcqyReUeARoHROtXTcp2IPHjtwkzUuNRo0WsnkI37ZePxq09rKNqsRQFfHaMfAsfHx9y7d4/JZMLu7pj9/V3G4zHWWlwthjFWGXF17cDBhoNqbA2oYtdI0XGdAbkJLo2RudXgI03wEg2DrDNtA2MT/HeKCkBZMS3Kipz5fM5qtWIwGFD2e5S93jobNYoTs1HiWi33qxjkGLU5fyjgPer12mYouxzCkCS7LfiX2doEKtvPptq4JHGs3RnsdQ2r1WrF7Ru3ef3113n11Ve5efMmx8fHHBwc8Morr/ChVz7E3t6ezJl6cVuWY6hAZ0lOL27ExqjOVEmaBhvM5alnjO7Cl9O+o+TPpqQ5itRYpPXr56BzHhcCNJ7pbIExGYPBDkFrJtMld966yzf/5FU+9+Wv8Edf/zZOZfzbv/4/4T/4D/9Dnn/pwyyj5oc3D1E2o+zt4LzH2BxrNNPpPDH6qotRMm0TJTUxdWz/LZ3zuO6ptcMiAkLTXGNcPwdi65D8HjxjT5suvdfAa/MtH5WNeVpGel4G5uPWF5vzng80GN6nXPB4JvN6QShdbD9CcHlWR+UCaF5sD1v8n/TnNhftbubwHIB4+mHwOL/urEX+SRfQzvzxIZ/jLCdDGkczn/PNr32Vn3r5A1w7uExuDaHIcE1FDK4rRjUBrVLW5YZxztagf/dwXxf7ooNMRVqSuXay3bg2I9Jay/u3gBSNTgZAZz102oebTn/XMUU4xq5eTrOW6f035GCbs6ftTGVXrG2AydaU4vT10Bbbs8kJR/fvUdUN2Iymabhy5Qo/9bGPcOvwHplOkkdXdcVQjGCMhajIrcjt6qpitVhy/94dbt26xdNFjunl60oJaJyD5EiZZRlFllOUOXiPX66o6obFYoHt9ShM2UW0CKLXEBSL+YS7h3e5e/cuk9mJSATLPmVR4EJkOpkzX85RSlMUBXmvhwuB1WxOVa1wjXyOXq9Hmedcv3qFvZ0x/X6fPIHlelURaOQaIDlINo1I2HxI/LciqMBgtCPOnXlB8J6mrgneU9iMfl9MSoxqlQIB1aKQBKg275NOMqwU0QmwbJwXJ1idpfxPRQieJrmW2iT3DTHig5e5UdU2NxR1XXVsTl3X4tyamg6DXo8yLzCb92/waGOEOVaI429YO1kulguOjo6YTqfS0PCOrNcn1zL/5pqaZrlgMZ/hG8fuaMzuYEQ/K4iuIYQGnSSaWA11SNfx2kV0U97tvU9xRXL/pmnkzrF0HZF0/kIluYgWm2XMDg956623mBwfi4HV1auMRiNhwHwgOJ9MbfRaEh/EGZjkThyT2VjLRCkezKdUialUOhlwxZCiYKKYD3XNIgF9mzJ3YZjl7+39e+fOHVarFS+88AIhBGazmTRKFvNuzro1zmlnr4HOVKedaWxNdVoGOzPZer7X+24eun0PHwSsFpnIcJXJ0zGVc3V4eMjh4SF3797l7bff5gc/+AFvvfUWxhgODg74pV/6JZ577jmuX78uConlsjNaayYNxaAQw2yT5Kqp2dJyXx0DqdZFehtf1bK9GvVATuiWac8pRnPtuq3Js5L9vSsAzBZz5tM5t++d8Nrrb/D1b32H7776BrcPJxzPaz7587/I3/yP/xM++NGfoXaBw4XHKSAfg9E4LFEFKi+GbVmvJCn56SQorE3iSDm+2w++uMFiqgcUPl0EiYjxz83xfFzgdZai6UkA5qYb7Naz+lzQ9fA64TwQ+W5lte/39qS/o8vCvCj1L7b3G1xebBfbw5nH7RzI7vuPuaY9+BBJ3TS9xdyplr1cm1g8HOC+J1EkbId0t53/s/LKCOvML5l1q7Ba89lPf4a3vvs93r55kw+/8Bx7O7sc3b0jErD02rVUNUUrnIo3aT9P28nvZnseck5UuyexdfLT67gTEIAZVRemQOpQ6yiva6VuIvJrz03sZp5AZnPaYsqnbnxIIHIz7LxlKFpb/81i8nREAaxjDpqmYTGd0RuNyW1GmeX0kvnKaDQCawlVRZZriEo681mBq1ZrA5taMkdnJxN+8P1XyQclu5cOMJnF5mLeow1En5jYZAzTyl7zPMehaGJkPp+jyMh7JSorhAH1nuV8zu07t7l5+ybL5RK0Yu/gcmcq4p2T46Y1IShqF6juH6O0gME8z9jdEeOW3fGIYb+ktJaykAK7qWp8dARXgwpYpTopsVECJDTSgTZKSa6fazBKkxeGMBxQLZadNNhqQ2ZMKhQ3pN1RroPoPUYldkzTSZVJLsHL5VKYxMx28uI8z3EBvItkRYY2MpOa4M9WVA8b7E0Ijqap8HWFVTDslezt7Aib52RuTYXYyZxp59y8F4YkBJrVipOTEyaTGc5Hit6AkOVkRU5QkcbWxCbNn9YNNiou7e5xaX9fYi8aaYIUCUC385NouUe89wlAa4w2Kb+ylnsxxIcyBPJz6/vrdHEpbPeE+7duMZvN6Pf77O/vMxiPyKyc/9asZtP4pb13fGIqo4o8mPj74BbYvt+2ZsatZN+2URjBS7SL1QaMEUl8cnENMXL/8D5f+9rX0Fpz/fr17tpYM7mxk7oWRbE1cw0+ran6gagQAfNNt9YqJeynURqXPm+v18d7T+Mci8WC+bKW6Jb70mA4vHPIvTv3ODw8xHvPaDTiEz/zCT784Q/z4osvMhqNyHOJ6ZlMJtRVLUy+zQiEFN8j89cGhd+IAdrMNUatxw7afQ8hpJn6B+fzWwC9yV5uxrkIu1tgsx7aZMznc96+fY/vffdVvv7H3+Rbf/J9bt2f4yL8pX/1r/Lv/Ad/i0/8/C9QjvaYrTzL+YqTacVsVXP9qWdwMTCZTyl6JUEFFqsVZVkStcy6qyjnWrVNRCXMtUvNxNNjIaqduTzz6tJrRUh05wKpd2Ie8zh5kY+qU84GiNsNmMd9/3c7c/k4jfD3FmCqs5vgF2TlxXYBLi+2Px0g89117s5+EEVU+qb4YqhHGvY8bLF+QIai2JohjOnpGduHqzq7TJOCMX1VbR6bBxUw1kJm+Vv/s7/Jf/I3/9fs9PpcPdhnrywY7YyZHZ2sgSXmAZCtlT7XtOi0mkAKlU17dZFvCXgwIhuNKu1fkiW61tCjdZgN23JktQ1wZZ8gesQUIs3JKS0h3iGxHxKLEclsjjYGk1myKKzCZi6cMXrL9ME5R7OqRBrqHK6pKbKcpTG4pqFaLbh9dMTNmze5cuUKvV4PkJkvYwuMkZm13GYsF/MEtzQuQC/vEerA3bducvXqFQpryAc9jO6RaY3OCrz2ndQNwK8amUHTGf1+xrx21KuGuV6grQCvpmmolytOJsfcOzxmPl/S6/fZv3xJ5ibnM1bLGrSi3++js4z5ZMpiNqEoCgaDAQd7exwcHLC7M5I8R63RwVOvViL/8wJgskwTTUlmLBBk/itEXExy45CuDQNaS+SFUgqd52SuwBY5OrNSMCbVp0omIwoxyCHloqoYCck4pmW3hYGMLOqK2WIpTJK2ncOk0Rmm8VRNjfEKr9fksO1Ai1x3PoqzqtJRGh5O8kILaxn1++wOB5g20zKCieBCwKg2DiZQp/gSrx2LVcV0OmdVNeIGO+hTa4naqVxDCB6bZxS9UqS3aHZ2dtjZGeF9ZFXXOFdTxIIQPdqZdCwkf9an6IWQ2B1tDQZDjJqAg5jk8OhuDrP1Xt1cp3Q3CSAAO88yjo+PufHGmxwf3mfY73P18hXGuzsYo8SRuWmkcdU2SwiEEBOruDG/196/+tFrr0fOe8tYChNvsdYI8xQdVlkBIMlQxqJolEW50GUeLmcrbrz1NuPxmOFgzKWDa6zqin5ZQPSdDF6ug9RKC7IWlVkp+xHa6CnFOlZEpbXRbM3INSGwWNYsqprjt+5wMplx+9597ty9x/37R9y7f8T9+/eZTxecHM1RAYrC8OJLz/OZj/8cv/zLv8TVy1eoqgVFv49bLgAY7YxwCeSLy62mcsmQSJtuFjwkozBUTA65YR2BsQE+1zEs2/mVLQvbAlRhbeVPq5ro9/sU5ZDFquF7r73ON77xTb757e/w9W98i+/9sOba0zm/8ld/jb/+G3+TD33sE/R3LnFvMufurUOaKGteORwz2M05mkwxmaY3GOJcTVCBfn+Acw3G2DTrr8QJOsak7G4bnT41ctQWaxlV6mpGebZARMc2czkkaBlOsYdnxG88ChC1r9nM0nyXzOAmc/k4IPBRr3mv3WK3Qd97j/rURjN4PXm9vWA8/lTtxXYBLt/FjfNOO0lPSvlfaL1/dNvjHutHzR4ETnfBTp1/1rlY2/QbXTyFvFbYE5F7bixxrWxHb8mKopaAOXRaH30nm0sFcrdYhu39Tu8TWrfTlOEI6/iHqNfmKioqdIBoEEfVNDslg/8huV16er2CpqnXoFIHlPLMqjnDS5d45mMf5j/93/2n/Of/2f+F/qDkEx/6KPu9PkVvBK4RuZWT6AmZoTRYDDGxFSqevhdFgmjaz9TKtlLEnkSLrItYH6UQJUkTO3fHBEZjV0BsGwCpJD+Tmc5WepskeUan2TuPakInE20ZShe85EPm29Ej4k4rJYmrG4ySWbMuX242l2I0RgaDHvcOD1HacLB/mbp27IzG3Lx5kxc/+iGJc2kq8sJSLVf0C0XwDXW1TGyjQWUFx8dy/p6/9gyvvfEqd159jSvjITE4kWsOehhtxWUVMVQ5OTqmrmuyIqc/HEvkic7wqxVVVeEj2Kzm6OiI+8dHNI3MX+7sX6ZpGu7cvU/RK2mcGKGYtnngHME5iizj+WeeYm9vj8v7B/TKPM10eYJLcQ4xEBsvxioofJJp5lkpZilNWDtQatu5aVprMZnFK4VzEVfVhGRWpI2hLDKcEtmoNWkeLt0/KMAFkbfWdTpneZJKambzBcezBUsXUEUPFQI6pLiRAHku8SMhBMzG9ayMxqFwraTWO6zJaXxNvVoRnadnLHs7I67u7NC3FmoxvJKcRZnHq5oa5ZpklpLk2D5weHjMnbv3yYoew/GYlWvErdR5QozUrgHvKHs5So2YT05Y1Etc9Ix2xpjlktlsgtaa3nCYwJ9OGZEiHRUGMq1RWljyEMSKOQST5mAhdO5M61npmN4nKDmHVkEMjltv3+LWW2/RrCou7+1z+eASw35JiIEQDD60jLQShj2xDz54Gue7NW4ztF6FFswkaWJQWyV7MjzF+UjVOLwP6MTG1gk4ZiajzHv4qqHMS4qiYDWbY6OhVw4kxsQ7QhWYHC+YnCy5eeMuvf4es+WCQdkDX6d5TwFcbeQIMdI4J1EyaRZc3F5bRlYiY4KHqlqxrFYs5iuOp1Nu3b7Lm2/f4t7hEa+/9Tb3jo45PpmD0vTHO1y+fJWrH/gkH7t0lVdefJnp8Qnf+tYf89U/+hLf+L/+P/kffuf3+aVf/AU+/MrLPPP0Va5ePsAOSmK1IMaG/YMhqJHM6UZYViuaqu4Y2NaJ2xiFwYgUPYHI6FL0CZBpQ90EmYltgaTVZEWOSfPKZdFLzTaDMSIddk3gxo0b/PCNb/BHX/823/nuq7x+4ybOw6Xrz/C//eu/wq/+tX+HD/30x3HRsHCRyUnFsgEXNVEbafj4BrRiMCjkUvQOnVQxvm7kOek32x7rCCsP+OC38p3X/RB5mke8XNdJRSOo1G+wYzKjrONGI1RtVwztszd2dUHKqpbJ1k4Kq9LoxcaebsxwrP/ezh234Ngq80Bz56wGcyvzls5p+oyKzuDnTIB6albyYZErZzGnHev9kMZx3PBy2AaHp8optf4dZiO7M8Z25IZu9GFz/0UCv3afl/ooZWNHpJ55SD24ntM8DU0365SL7U9Tzf+4RJJ93BdebBfbe3kRd9289+i6O7U4v+ddiLb22vyqN3ZRbxgVrEFrJBKw1pDlpmMJY/RYrchyy2A0pJpOKMqSX/03/io3fvAa3/j8l+gpyy/87KdAV5LBloD1elZROsM6SchQ23IdrTdmu7Tk74WNZ07rrCiZiOuHh1KRqJOUVStMckbV7UNy4+eDQhgG1anbNnrJIlHUmV27zeo16FRKkbWzoNZi83YWynfuim2e5XK5ZH4ykTmtZbWOmDCGunbkuQTfW2vpjcd8+Y+/zhs33uJTf+kXRdKWmBGdDHXah7MPnhAVedknRKiXFbnNGPX6VNM5b776Gk+/9GzH/NgyJypDXTdMT2acTCZYazkYDMnLghAi2hpGoxEnszlv377FrTv3RK6XWYqiQBlLSE6xi8VcAI3REjpfOZarOYTIlcsHXLp0iauXD+iXPXq5FICuqSS+JgSIIUlUReYaTsmvolcPXBNxo5ALPhLMeqa2aWqqpqbxNTkCAPPcdh2JbqYpSOad9ymuZqNwagKsmppV3VC5BqssbkMmqFhLn1FRYiROmdnIvlp0SC6jrqauKkLj6A0G7I93Gfd76CCusMZm4IO8xsmMXmat3IEKQogsFxWLxYqm8UTjWNUSsaC0YlVVzGYTVsslo15J2e/h64bpfMad+/cYjgbiWmoUmcqwVgMiQ41WWLOY2MuI3mpSRdX+0UQVaG2LYtfU0u3tgtYKa8RV2Lsa5xqOj444vn+I1pqrV64wHg7IjCE4T9ErWSTGbzN7tnUT9sF3xd95Co31vCVbCo2YhMq+BcwxEpVJa4HFGCvNAOe4cuUarpJzNByMcLXHucBwsIvWFh+/T13Dmzdu8f/4L/6/7F6+zKWDKzz9zHXG/YLCWrIspyxyyqJH2SsgKpxvyGyeAIXGRY9znmW1ZLUSN+mT4ym3793n7Vt3uHf/iMPDI+6fTFg2AW0s/fEeOwfP88FPPMuzz7/Mcy+9zNPPPsOlg8sM+n0Oxru4uuIXb7zFl7/4ef7gd3+X7/7JN3ntv/qvGfYLfv5TH+fZZ67zoQ++yHPPPs3e/pgsIVxlM1TwDPojfCnZnE1TkRyUqBuPNcnMRgsrbwAfRWkgCg7bzaVW1RIXRC4+7PfR2jKZzmmioqkdJ8fHvPHGW3zz29/hu9/9Prdu32HZQDkY84lP/SKf+Yu/zKd+4S/x/Ac+jFMZt48mRJ3josGjCcZgrErNvwytofauazi0S7fa7vE+lKPaGHTZYNuhHctYPwtN14wRPVHcZunfSRGrAjrohzKcD4si24yIebcF+buZq3w3tbd6v8tzFc49//HU4bsgfy62J2IuL7aL7f1YIM+zvn5wruHxgOpZj72HZ5KE9/mTt+YliUnK8xTaneZo0nyaSo6CRdNQPPMMv/Ebv8Gr3/gWx8fHHN8/ZFQU3UNEKQF7WsucU2CzG7oNLk8b+px2vGsNF0LKYIwdaBZnyyjC4gT21FY2m1IKF13HgKkN8LIJIpXWIvvVD7rIKqUIRtEkdrg14HDOCSOQAOF0sWKxWLCcigFIrsWso+2+LpZLAfpZxtLVvP36D/nDL3yeECN7+/vozFIH1znGEoNET6TPOx6PuXr1Kln2DVarJTs7I5R+ivv373Lv3j28jexfucyuVqhqyaJuWNXiFqkzS388ouj30MYS0GS5xQc4mU75wQ9+wNHJlNFoxGhnTJZlhOA6A5M2hiA0lXw2m7G/u8doMGQ8HnKwt0duU3C8ipKL2s5ypagXbU03K5Na8yJhjMldM8n1FNszxy3oCV7cX4kRV61YLecpSkL2URtDSAH0KtlwtIH13nuMUevYBQW1a1iuVlSJ0ZRs04jEH8qMlbBeFmNNao54ccNNObFqw/SJmOSByaV2ZzTm0qVLDHp9fNOQZxkZmsY1VNWS6INIi62VvD9rqUNgtpgznc3wUZoetWuwWYb3ntnJhNl0Sm5ELt3KEsuy5OjoiMPRmJ3xLqPRiBACq6bGo8jyMuWGRjQhsZGtE+tp1mEjUgm/Nr1Kpj8CAk03Y9w0DdViznK5JMsyhoM+l3b3yK2hWi5pmlpk5kqjtETfGG27pkn0SenQgtm4LQtRURilqEJyU42niAUt7KVP2YRJmmmtTfd3htFQGIXWwkqjFNmwT+Y105MZ8zrw1ls/5Mvf+B5v3p1wOIf7375B9c0b9HsWm2mGAwGXRVHSKwsG/SG9fonRlhA9vbKPb0FlvWKxWDJbzFguVlSuoVp5qsZhs5yd/QN2Lj3Lh17e5crVp7h8/SmuXH2a/cuX2b98hbzsY/MCk+WAZtpU3L9xm/FoyOUXPsCvPvM8H/vZT/PHX/sjvvX1r3D7xpt87ivf5o++/m32dgY8+8x1nnvmaZ5+5jpPP32dy5cPAKT50B+TFRLTk1Tj1ImVdem+bbuSJgZMcq2t67qLQRmEHVAicz6azDg6PuHoeMIP37jJ97//A15/4wZ37txjWTkuX7rKSz/1c7zw4sv89Cd/lo/9zCfY2b/MKsDtkxkuGnTWY9VEgtEpUsp0p9cFJD6F8AAT9iRg6ceVw/ioGuMsKeoD7B5P7v1wHov4bo/B48yJ/iQc6/eb9brYLsDlxXaxvcPF/wmH7NWT/Z73c+D90R0+8yCETeCy3S+3ARCCF8Aw6PWJdYU6PGRvX5gqWzdMp1PGeZFkd3ErMzMEcTvsPmnYluG04HJTIhNJwCP9TXK73BZwROkECOTvHnEEVEavJXxp7i7GiMmEwTDWorMUVJ7cHTFazFxa1kyvY0tawCmh8KZjXNpsy2q5pKlqZpMpALm19Ho9Ci3MTlPX1I3IunrDAVle8va9O3z+y3/E7v4ev/pv/dtcfUrMQ2ov+YBKKZpa8gJ1KpYHwx6j0YjlEu7cuUOMkd3dXSaTYybLKffu3YPcEjND0IZl48iKkvFoh8FgwHA8QlkDJiNEmJ5MuX33Hm++/TbL5ZLhcMhgMKAoCmL0eI/MkRpNlkvmolGarCg52NvnqaeeYjjsi+WFlogMrbWAlyDgrjUhiqiUn+klAiK6NOsKOorcrl+UHcvuETOpoNocUk3T1FhTiBtrJbOsBE+WGYrMElyDbyqiD53bcAzb5iJRFOg4F6QRsFwJ61z0xPADhUrs73rWLBKCgSIBY72eSesiexCZpGsqrFEMe332dseMBj0yo6hrj4oZzjXdDG5mbDezK7JUi1ssOJlNmS8X6FzibBrniEZTVSvmsxn4yGg8REfNvTv3wTVcuXSV1XzGZDLh1q1bkvc5HOBTBqvSFqxI4cV4a80eR+cJxC1pm0jsIzHqDly2MRhtA6d1QW1jeQaDAb39PUpr5Rz6RoyYvGK5rLBlT6SMcGak0nmFdzdR1YLM08xlCHgivm0cKYux6Y/J0j0LdT0nhEB/OIAA1cpjjGa6cnz961/nv//H/5Rvf+dV3r615NLVA65cu05MaovJfAYGFr5hsmjw0zkxzjAb0vumadCJ9S/7PXq9Hv1Lz3FpMKAo++zsHmDzkr29Ay5fvcJwvEtelJTDHQajMVFp8qKHMpaq8cwaT/ARrSNKFehByVJrqnlDrhWXnn+Zv/LMC3zsk5/ixuuv8cNXv8utG29w4/Uf8M3v3eBb332D0XDA5csHHFza4dlnn2I0HrC/s8tw2KcoM3F5trIulnkhbLVOMSRRpMghtPm5OctVzWo1Zb5ccjyZcvPt2/zwjbe4de8+f/Kd77OqPSYruXzlGj/9mZ/h2vWnefHFl3nm2ed55ZVXyMsey8Zxf1mhbI86KuarhthU5L2B5KumtX097+mIybH5XdGHvH+zf09aW5ye3TzLmOZh8tF3ApYeJ+Pyvfycpw2C3ktQeLbpUHzsnz/r+xfKxwtw+Y47EhcXz8X24+6YxTOcWc+zOH/vd2BztD0BzKg3oLQWMwZlO1OKlknw3ktuYJmhyhKmC37nn/0zbt26xUvXrjPsD2Sm0gf5gSC/K3iZXQvOdQYRhLWZQscgtg+hlilUIiVqO+jtjJbMr6itSJIWBNo2nLzNHtyQ36kEHpU1GGs7t9BNcIlWHWMZN6SCbURHaTKs1rgUoj6fC1tTr4TNK8tSwtStsHx+VbNarWjqGh8CxbDk4PIlqsbz2o03uX3nDr/213+dX/kbfwPqpeTCeSlS5zGC8xidYXOFCp5YlgxHfbyHo+P7VFXFbl8cIm2zlqzVzpP1CnZHO4x3dun1BgKEshyPYlU3HB9PeP3NN7jx9tsoY7h05Uon7dVEXO1wNBgrDG21Erfa3d0xe3t77O3s0O/3JO4kRIzJMTZFzXg5xyolyyitCO3cXNTJeEWuOKV1J7PEWJGhBZl9TeRmN+entcYaReUc9WpJcA25FWBJ8FTLOcFJvEZmhY1XISamLRB1y6wa5qsl08WcVV0RtaYsCkLdpN+n1/PMQWZMYwBa990o16SE3ftUgAd84wiNo7AZezu77I7GZGiUj+TGEhpHtZAMRaMlvkVMVMTopXKO6WzGyXRC5Rr6vUGSc3p8VbFcVKgQybMcozWLhWSd5lqxO97h0qUrHB4e8uabN/A+8szzzzEYDYlBSYyJzSWVMLFCa2dPn+bo9HrWsY3j6aJcwCqNMeLGLO6nbg06i4KyKMiMxsSIrxsgGV5lBT6ech6FrSiGNgqlW6Zgo9Ekc6GhUzy04ka9fk2UuTZlNNbmKNve25IRaRNz6V2dbuqMqBtu3Dnkt3/7X/B3/5t/xHe+c4fnXniKn/vln+WnP/EXePHlD6GyHK0MUUXqZkFdr6gTYPfeo8LaObosS5QVxtRmWQcy+/0+Wdkj742xmcSXKJMiTLQlRIWLkabxLF3ENwpUjsdTO2HrjLVk1lAF8E2Dq1f0C8PBaMzlFz7EpWee5yMf/xTzk0Pu3XqbW2+/xZ1bN7lz623u3L3ND7/+Kl/86jdRyjMa9rl06RI7O2PKshQn50E/nV9xwS2KAo2hamrJlfUeTWByfMLh8RH3j064eecOd+8dgs7oj3b5wE//PIPhDleffo7nX/wATz31Ijt7e/QGI4qi4O7xfaxb4SKgCqwpqGNElQWD0YjpbNWZOK1NeAwqMc4xPVu2ZvjeI9Dyo2z0nhVX9aNg4d7tsXqUe+yPur5+L37fBYt5sV0wlxfbjwwArhev92eRijHGdtbyR85ePmTwoZV8rhmK7YdJVVVk1kKeMzs65u/+nb9DmRdcv3oNa8U4xriIDnFLyLsNVNdOee3g/nakQ9xgmOJWoWHMGoh2WZit9DaBwNaopzX26fIMjZi/qDaHLv3ByO9SidFCqy1g2X1+pUQG64SlWa1WNI0U0L0Usl7mhRTPKUOymi2EoUpMZn84oN/vw6rm2vUrXL50iddff503vvpVnn7xeUyvxyAfsKprkaApkSjjPHW1AgPj3RGjMazqmvl8zu7eiLwssI0YaAzHu1y59hS90ZisLLFFD6JiVVcs6ob5csXd+/e5desWx8fHoBXjXQm2b5mo1WrFcrVIBXNOYTNsv2Q0GrG/v894LLJZFUM3H2rT8Zb3WOfnWWsT86pxPgG1SAL+wihpLW6xrYGFmL+EdK0gTEpIICZCU9XUqyWaSK8sJGvV1bjao1SkLIoOtHZAxq7Pe+08i8WKxXxJ8GDyTOaTk2ukVposSrxJl+Gn1iY/OsrcYoitW2Yg+IblfArRUxQDdgZ9epklBkcEcq2SRLTpXDSzxFC37Nx8ueR4PqduPHnRIy8LTGapQyOOtHVDvxyIq3HjIUR2hjuo4JlOp/SLkl6vx3K55ObtWyxdzdNPP83e/qXUeAjdLCodeyn5sw8U2zqpAJScgLWDs3qAUcnzHFUUFEYL6A8em1m0gdVCsj4l1iV2jGdrFLNZ3KtTgb/brKbqZj878660X3JeFNoKsDRZke77tJYZkVKbXo5papqlp/EN3//hDf7e3/uH/JPf+h1OZo7P/spf4hd/+V/hQx/9ONeeeZ6d3UssVhUBRV5mrFZzkdhHncyITJottxgj7KzWYEwmDsfKyviekobGsvEoZUSOvVzS+IAxnhBh1TgyW1C7BqUF4KncYpwjotFWswoiDc2znF5/THAVt04WZDHSzw29YszeM7tcfvpFXl4uWC2mnEyOuP32Le7evsnrr/0Jh/ducXx8yA9vHjL//uscHx/RVDU2z9gd72yBfasMPuXMaqMIzuObmqLXZ//gEteee4UPf+IKTz/3PE8/+wK90S6j3Uvs7F/GlgOC16zqmqNVTTWdsDveZ9VU1M6JQReGmkjjA25eEZROTQcFsXWtjetsTR3PlIu+E7XQjwdUPOhk+rj1xOnn5o8LjJ3Hgp733tsMo/qJrPMutovtwtDnYvuRLDhnZidxtkvbEy1SKkV8xHbw/LQ09cd1/eruj7U5eV6itcF7sdWHxN4lJ0nmc37rt36Lu3fv8ld+/hfY399nNVuSeY+NCos4dobWoS+qNP/WHrP4wENq26UudgZAKpnhiNur6ubbWnmqamW8elvCSjL66bLujO7YjC1QecYaEkIQg5DWsCcB1iaxCO0cYa8oOwZUKcVqIeChXixFshkjRVHQK0uyPJcYkuUSjWF3vMOLzz3PN7//Xf7hP/gHvPyRD/GBj3yU515+kf6gL7mMyT20BWtNXTMYDRnt5KyqBXfv3ebg0m7XDAgeyrJkd3cXPRpBcuGsqoZ5VXM8m3I8mXDnzh0myeBnNN6hKHNW1ZJer4fz4uZZJAZmMOgxGgwpy1IiBYoMo0DFIDOExghztzljmdxHW0ZHTGAUISqiMhLibsAq24GXEBw+sd0RnRyYE7AL4vSnUYRQs5zPWK0WWK0YD/sMegUqmU8ZnSJrNETnqH0tklxjZVYywmJVM0sGRSbPMdbifRTGssU3KZbEgMhiieImSqQJkeDXmYqtaVFwnkGvYGc8pt/rCfNXO3wIVCri6prMKIqsl/IRhf0MUYDr8XTGZDoFo+n3+tg8wyeZd/AOozW9oqTMLVYbyv19cpuxWs6ZT6Z47+n1euS9kvl8zuHhIVVV8VTVcPnaVXKTr9csLXFBpPlmrWKSm7cT2CqdA+kOKdqIF9WB9rXx0fpeFnOutqCUNSUq8DGgtOkYyzbmZ/vntovo09LZmDJn2nluopb5ybRGGZOR2SLJyrXIY7VN1bjHTWus1UznS776x9/mH/6jf8o//a0/YPfyVf6j3/gbfPYv/atce+YFgslZ+MjsZE7jPDYvULFB64IQDRot8RQenKuJ0aFUJMtKAcBOi2IjBrxv8D7igidgZOZUKWKU2dM2FiTLpBGjnBgTNTESXOzYZO8hK3qsVit8kCeR0QVYAdohs0ybhioGMgWBDDs64Or+Fa48+0FcvWB68mkmx/c5OTlhtVoxn0+ZTI6pq4qoItOTCXVqbMUYscpgi5x+0acsc65cuoyxmsFwxP6lK+wdXKI3GGPyAnSOV4aoMuZOszxa4pyc86zoMxiMmSwXgMX0eiibUbmAB0xRilOybsFluq5a1jySIlLer2f+j+65e9qxtO2lPOgz0D0tu38P6wyb9TNz43N0brRq/Q5tjK45o645PTv5XtbP7weAP2vW9p2cxwtgebFdMJcX24992ypw1PmL1TtwjI1a/7hWuYfMXCrbGdZ4L7luIZOCqChLsBnL+4f83u/8j7zw7HMc7O5RL1edHb1WUjBtmcKrVCDFsDU7cnYAdCp2jVnHgRgjkli9BpebrGXrENsZxmxIbTsAesbr2yI7JgZV5v0ESLSzZN57fGJTi7LfAdsO3CZGs2kaZrOZMFONsHnlsKTI8q6Yljw4T683oJotuH7tCnXwLOqG3/zv/zEfv32HX8kzXn7lgxLy3ng8AnB7eUH0K/YODjg4OGAxO2ZVVcI45LusfEWNMImz2YxSa1SW4ZVmsao5mhzz+o0bHStq8xylFMvVQpwuMwm3N0T6/ZKyELltnucMyh5FKVLfzBiJ+lDrhkEIEZ/MbDYNjFrGF+epnUdnJSqBGp2YnYgY0sRA5wSslDCa7TUpbKYU8sE1LJdzmqomt5p+v6RXSnC8VhGT5hjZyOFTShoKjfeEgLC4q4qIpsjlmq5XK5QxXf4jka5xIQZUQaSb0RN82JpHjiGggie3mtFgwO5wQGENyjkikaauZBYzKgaDAVlRdteWMpqoNb6Bk+mE6WIJNiPLC1wUOatPmavCJmn6ZY/9nV12d8YUWU61nDObzTg5OWK5XGIi7OzsoOczTk5OELV15PqV63K9qvb+UcL+tY2ZUyZawqhKM0xYS70xR73ONySmiBCnKPIcFQP1aol3jrwosFazWq1S7uP22npWcLva+LfutWncVW2sE0EpVNDp9UFySY0h05aoTIrLMWmOVqPKnOPb9/j8F7/C3/6v/j5/8KXv8tGf+Sj/3t/8n/OxT34aXQypdMGiDnhl8BF0lqOygtl8js1kxtsoMEFmiUPMpDgxltpJ1qmPbg0WdCYOw8qibdFFvRhjCB7JNtWQZZZVJfehIWPV1MTgOwMdHwLL+YqiKLDaEJ3HO4/VBS46juYrme1FYZVCK4OJ0Ph0DecD9p9+if1rz3XnNbiGxtfdTHhM90vbTMx0BlpT2KL77MPhkKzoiULBBzAW5xWLuqFxnsZ70BqTFeSFJUaFC+Bqj8lLyTnVhqZxrKqGoigwRrNaLslsITO5SqFVRGlh1wViaTH9OsPQ54mf549hSPPjam6fN3v5boFfUKDDg+M478cxuCB5LrY/k+DyNFX/pDfQxY1xsZ218EqXMD5wjTwsbPi8MGKtdVLFhtOvT4q1GLuIi2RksQm+Nnubm128Vra2+fDcNNXRm/LT5LrZMUNe5IlBGYqih8Iwn8/J85ysKHDJFdJWVXdsmqbh5OSEZw8uUS0nklO58VlNcv5sQV3HcES99Xm02Qy6biWp65lKY6UYi1ryAbU16y63krBrpdp80TZ3SxiyFggqo4mJsWzBaWvM0q0V0GUWtoWzMYaykDmp4UDkoCCxE1VT0zQicVsul6go0s2y7KUMSAHn1hjyLCPPMubzGfdOJkxOTvCrmo988BV6ozGXn7rOF77yVT75yU8Sn3+JwhSE4GiqCh01ITby3v0eV69f48tfehsXIc9ziiIjmMi9yTE+BpHuzufMViuWdcOq8pzMZ0SlKPs9Rjtjjo+PaeqKEGA+mTIeD8n7PcajAePxmDK3axAfIXi5toJz2CwT5iYx0yY1IkxiixWti2jd5b/avCDqTMCl0sQYaLxP7GSSxsZIwAvTbSxGRWGcnCMEYe4CIrUMIbCzs8doOMQ3jrquMEpR5hnKWmLT0LiAsTlKCQsflaFuao5OJsyXC/L+oDvnJrM0qfDvGFeltnIhPQprcohuPR+oFI2rqeYLSmMZDfvs74zRKlKtlmgCmTKUmTDXztf4VSAgs5Y6WlZVxa279zg8OiEve+g8o3YNPqacPheJHnJjGQ4GXLp0iYPdPYo8Izhxii0yS6/IOZlOOD4+ZlXXIsXu91mual7/wWtMjo7lZy9fpdfryf3i6aTiwcln8m2Oo9ZYa5Lc2WF11jWcOla/zbm0lszoZIDkuxiXVVODD2iTPSB99afAjDq1xp1KLRRzo9QgyIxBp5lXcbi2WCOsolFWGk1Rg80gwHIx4+YbN/jOn3yX/9ff/jt87ss/5Ff/2l/mb/zN/wUHTz1PMdpn1kQBQsYSlCagcUZR+xrVy3GtqjGCb3uN2qAjNCHJX42RCI+0962E9zSbI00Phc3aTF+H0RB8A1FL9FFrLuUjBuhnBcproneyvrI2YcuKUuZgdWJ4Cck+V1hVozT1Ur52DbJCYQ0UKXpmvUKn5lxoG24ajxiYTQL4WdtYUQR8+nwGdIZSER8VwUeRtiqFNuL+6mMEZWTeWhnKUpqBvnEUbQwUcs+rGEXk04U0y7pxXo32OHXeo9xNz3vN2mzu8Q1j1q7YD37/LFfYs1jE099rG76t1H/TXM573/132FibtiXn8VxTn7O+d9qN96wsy833b+/lM49dq4Y491htuO+HsNXw3qJ4H/Lzj6rf9QVj+WeaAHoSz53Tr71gLi+2PzPA9UkefE/y3uf/26YcVbff2PqjMF0MRpZlKfzbd4u69x6Uoj8c8jM/8zP8D//gv8M9/TzHx8fslX1U02CiWodAn3pAtrl4aoO5FAYlPggudXLQNCY5lhqiZj0/2crolBIOVq9/rmU77YZxjzIavyGfbdmp1m22nd3afIi1sSyD/oCi3yMGAfBN0zCfz1msll1x1+/3yW1GaJzMx3kv0zVaAIr3DbPJiuVywWw2p5rPiB76Rc5wMKSX58QQZA4uhM6B1VoLLqB0jrERm5eM9vbwEaazGau6phyU2CJHZ5bJZILXGfmwz2SxYtFUGF2glKLf79N4YVlXS5kH7eUZmdUUueXK/h7DUZ9Br98ZrLQGTMnAsYuX0acy0zbnZkMqdrYKgwT4SWYyLQvVAggfAyaxTPL/ad5KxxQho8W0J+1TkRlhhVPTxxiD6SJBYhfR0c7qohXeB05mU5bVCmNzjM1xUQR3SmtMcvftPtfGzSP7o2lj0zv2zDfgA0rBeDSgV2QoQqsnxSjIjEIrMCoSWgMjC1pn1N5zPJ1xNJmS9fqYPCNqAd8xyJxz7QK5Nly9coXdobh9lr0CHQDjMVETdcZoNOqaKYvFgso1+BgY9CxlWXLnzh3m8znz+ZIr166xt7dPVuQ451gsFlv3SyR0Zkjtfdyytd0cqxYp8WZmJSCzqDGsZ2fTMcuU3mp4xY1M0fZ92+vrgcJYKZp2PerC5UUaa0xGbiygJbLCeZSxYCysKm7fvstbb9zg8//yD/nH/+S3ODpZ8B/8+3+Nf/Pf/Q1e/tjHWfqMqY8EKxmLHiOgXq1ZU5WMqZQya+XFpvFQakSswXCbwbmZM5xmyqMiqO2v6xTGVgoau4I8tejQBGI49cuVkiZBYp69Ul2OcFQGyXDUBKVoGt+Gu6C0F6mkbtNMQ5p93gAzXQC9FxMnbaXZgpVHSGyPjdluym4Vca0hVGoqcXokInZNBQjoGEBFVAxreTYBhXnfA7n+tBTRDwPBp5+5Txo9cpaa6E8T8XIheb3Y3jfm8mK72P60PCi2g5sjZ0lVt6uYRy+c7RzGA4vsaflZ93qTwtIlK85oQ5GX5HlOVYkLalus107AJUXBr/3ar3H41k2+8sWv8HMf/SlGByWlMeiQdjdGcYfdyLtMjeeNjxMQs1e9VUS2M5ToiDFrGSxGbRn2bEUmb/xcxzylAi/BRzFeCZsRJWszlfa46GxtaASIGQgk0BhlVmm1lOMCZFaiB/I8Bx9Y+UDTzqOlyBXnA3X0VIslxmpUiIyHIzA5O8MRlXMc3rvP7mjMYDDogJ2xFrwmmog2WqJBioyr16/hA9y+d5/5csnewT4JYnN0dEQVFPu57T5Tr9fDFDlHJ8fEGKirFfVyQfCeaBW7OyOuHuwzKAvKLCPPEmupUkMh0JW4mTZkaU4sIPO0rUA2hrgGFkFoHjFW0oQoEkzSzxJV6rIHSABfLpB2rjWkTEoxS9FEgpfrMcZIWco1GpzkJOrUyZdaeC3Z1DYDJezbYrXk6PiEVdVQDvoo27IoqeRWhqDWcsxO3G00KojRTwhyLVlriSGIrDFGCptxsLtHryglaies98kYk1xa5dr0LnbMw3yx4OjkmPlqSX+8gzaWxoUOwNS1fN7Rzi5Xr15l3O/RK0pCcDjXEAly5tM8d69fYLNdyjJnupizrFbd3PT+3g7L1Yrbt99mvpozmUwYJcfQlnk0WgCOS7LLlpk0WlOtqiRRjlusJQRCiBhttoBjDBJB03qYhBaQR4kNcTHi2vdKa4wN0lDYVCbI/SznIcbWECiS6QxjhNEti0JMfbIMoqKeTVnOlhweHvJHf/RV/uAPPsd3vvUq9+7N+bf+3b/O3/hb/zHlzmWqqiHkJdWqQpWlOM6qFGtCmkPtwNHZhfejVuUWWOp0zOROkPnVxF+zNnvZ/LoGlypqdPTCxiYWKpDmkpOsPwoaI4CY46jWD0vW4bzopffU7SItObDpGdTFgLSfLeqNvdE0wbM51NfG8HRWLSoxrSo1JGIQcBnX18G2nU1EJcOgNZiW1+vu0Rce99H35M3dP0M4ZAtEKnUuu6dOqZoeF1g+CUP0roHhEzDQj2vw9KOerb3YLsDlxXax/VhZy/fawe3hXc2QfmfoGKSzbNGNMWRZ0YHLGIS1UErjXYNxnks/9VF+/dd/ne9941scHh6y1xtS9vvd8t0CvC2gFzdCLNN/dPmDMW699vTWuha27yOmO+0vk7zBqFUnt0vx8PgYNnIr9ZrZ7CIwdPdAy/Nc9iHNbrasim8czjlcE5hOp6yamsFA5KPWWpHSNg2L6SzND6bj7ERK7BsH0WOUGO5oZSj6PYISAPjWjbd44403eP7DH+bgymXIM9zKoRUEowgBjDUQDHl/wPVnn8PmcO/wvszYGdPNF65WK0xvKcA3M7gYJD5hMWUyE9OX5XKJVpHdnTGXL+2zuzNmZ2eEb2qaBZhAl38XrMZHLwYjIcmtWsOk+KAsex0XsREDk9w+xWUn8REKtA6SH5nmcFtpV2tiESMCxpNJTHSRpmlQytDriVTZOUdwjUgDM5Ft+uhxPqKMRZkMT6SpHceTE+bLBRhLXvSI2uDxMmsZJGtze9avy7kQUJM+r+yjSEBD47BAf9BjOOqTW02IHh3kfNsUoxC8HD+l1zJJT2RRrViuVihtxahFJwmu97iUDzsYDLh+5TI7OyPKJMsOzhGSkQwq4J2c+yyTSBpr5etkPmOxWFA7z9WrV5lMJswXK+rlips3b1Lcv8/u/h77+/sd4BWQLmA1Rt81UrRWKGVFGboBLltFRAv8Y/C44PEhyRtTLm1IJ7UFqGdK7VJDahOktteXLbJ0T65Z/SITlYVCobJMTpkPrGZzvvPNP+HLX/4yX/rSl/j2t25TZDDoGS5f2mV3PIZeQdXIdZuXBbUytMO+ur2O49rhM7YWKWl3O0OieM6aGzccp7f6hCGlQoXu722TcfvvoFRAxXQ+QvoZjLB7G0pN30oe07q3Br62m49uYkxzqAnWpvlmaepJnmsaFJXDmHbahTa9JUv3w3r2to2dCjGilTRJVVCg/Maa376vOQW6BWB3ruDpwOoNY9Go9MMMzt/XZ/NPKnN5mpF8mNHN5s/qJ5w1fdj8508CQ/hoMMmZx+diu9guwOXF9mdsSwxlFySuNxdAtS4q3p+Fu3OqS8YcW66MMUm+EGCZZRmr1aqb45Q5TcVisaCIkBc1L730Er/6q7/KP/+H/4jre5cYFTkEhRb9JEabbrYxiAY1fbp1Vx5Yz4q2D7BUXbQzNpsPt5jmRc801tt4eMh7towJqKCwmRUX0DSr0spl2wd1losxTGhct09xw4RksVjgvadflOyOxvSHQ+oUCTKdTsXYKM1XguTR1XWNipBZwzBl3sUwF5muj0xOjnnt9R8SiHzwlVfY2d0FrXAk1lZZlM1QmSEzEZ1prly9zmhvn8OjE44ns5QJKnOgbZyI9548uTLOlwum0xOWy0WSoXmuXTngxeee59LeLipC3azwCqJvcDUUmUHrQgCFizQx4hpPyNqKec2uxJjAozaoFnwpswbxLR/TXWe6szJcS6EN3jmJJokbDoropC+MrFYy45plGf1+H2stwUdUcuuNMRkx+UBEY4ock1lWy4rpYsnx8QSipiz76EwYQq0NSmc4Xwvrk66xdk5ZvjoBl1ocXk2a7w2NHOdeWTIejigyi1UKS0RZRa4zrNXCZMZA5QN5nifpq6L2jmW1ovYOjKVqavC2cxd1dYNRmp3RmEuXLlEUhRyYBOKsldxJfJD4D6UgOEIj0Su9fonKNHmRsVpWzJcLrNXsjIdEYLZcsVjOaO46qqpaGzgNegwGA8n+TAC6aRqMyTAmuTknZULLCLSNhRDXBkBdnIx/sBAMrWnXGcHoa0AfT0mrlRg2IdL9XlFic1lzaBw0jsnRMatFxdtvv83v/97v8i9/9/domsjHP3odm5d881uv8T/8/36T3cvX+OW/9tfp9wbcmiwZXLpCs/QopTGxFWzHrbn20MpW1z2HdYF/qrCPp2NV2nn9Le7ujHX+gW9FSAArJhdtVGIr1eZcanJajhEt4R1b8mIA10S8Uli1yXbRAUZlWrC8PQOXbgy51hAzoPbohOTEJQqQ9O9p3NC0ioA2MzZugMeNY6JblNxK62WYtXtGJP/hd/1cPIuJe1LZ6Lt//nOKQVPnnPj4wL/Fc7wXzgKFTypnPQ9cP87P/qhA23mfef39eC6wvNgutgtwebH9udhOW/i/Fwv0wzqLm79v0/m2ZZm6rZu5LFjMlzS17x76s9mM3d1d8n5fgKLRTKdTKtewWC3xfoQOSjLeYjsTuS4U1caQ0ukHwLYsNrFjp74flRQim0eq+14bK7JhPqBbFibN3HUM5uYxCRGMfK+p605SrLUwU65qWCXjHu8jWZ4zGAy6XM/FYtFZ92+adbRA2BiZDSx7uRRJOmKLDJsknbP7c27cepvLz1zn6ReeQ+WW2jdEo8EamQXEgAqEoIheY3ti6vO9b32LN956kw99+AOEKMCl3+/jvGc6O2GUGQIqsc8OoyKXL19iNBpx9colLu/uizujDzSVpjFNkkEj5i7OEaJIgavViqASO5UyCltnVaVMF0EhJ9SckYOm1wxQl3kmTKZKURFKqRQfQYpgkOiJ6BxVtWIxnRED9Pt9OQdaEY1Ck3XA0oWAD6182uJCZFHVHE9OWFUVRb9HXhQpexWwEpURtQTVqxQt4pPZkBjYNDQhirutEnMTH5pk1qQZ9EvG46G4uRrI0GSJtTRKE1zT7Z/JLNYoXITFYsZ8uZCYCpXcmUNDVDoxsp7hcMj+/j5FIRmqTb3ENQ06BkxmOomkUopeX9QGVb2EGmxeipGQzWgGHu6RclqlAWGS1NPVDZPJJLHCkm06Go0YjwYiP7YS69GqGoxJzaZ2Fjr6bh6zaxZoOQeiO6Yz/NhiW4yYvWwqEjZjSdSpArL9N5scrY3NREpdN9RVxcnhEffu3OUH33+NL37u83zh898gOvjsZ3+az372M5zMpvR6BZ/7yp/w//kv/wvMaIdP/8pfo+zlzGYzMD1pbCiDiWtwSXKQTirwrZJfRTojs00DQb0JJdIaG/QaXAVFlzPa/l3Hs4R7en0kUk+mRWcxso6nOAOk6yhro0pRQCbbkPurjczEGIlKZp63DnxI7GaUz+JddUrpsqZl9ZZ5TUApu0aRXZfvrM92tulixCRArfDtDPZ7OHX5MPf3n+ia4QGTHh4JqNZRPuqBe+r010eZEp4Gt6fjgn7crOUFsLzYLsDlxfbnbnt8EBlOdS6f9KGpthb9df7V9sxlB9o2ij9rRR5qjLjFLhYLfJLFuSAAhl4PFhVf+MIX+MM//EOuXLmyDoRXKXajBQuIfMvHSGbOdMjdeFiFTpZ13vHbnLOMai2/7fIuSd8zeuvf0EnminrAVETH2M1ftpmVIQRWqxXL5VKy37zj0qUrnVvsZDLpiuVeT5ie6fEJdV0nCbEiSwYpuc3IMkPT1PgQKHoltiyhdiyWS96+dYuf+cynuHzlCl5B5R22yCDPOwZoNZ8zn54Qm4qqaXjhxZc7cHn7zl12D8aMx2NqAndPjji8d5/GRxoC84VIZ599+hmeffYZhsMh/V6BDp7VfE6R5xRljjWKugbnAt7VLOeBxgeqVU3jHTqzyQVWQIhL8kSTiUuu2WgoxBgJG+fRdOdHJYYliBFOfFBGKyNhqdL2Am5nsynLZYUxhtFoRNnrEZoabTI5t3WN3wAnQSlc8DQ+MF8umM2XYvySS6aecw5lTBer0c1GbjQzglIiN/Qtw5MaDq7BhyYBuj7j8ZjxcJgyNiHTllxLnAKhNVeR+7ppGoLWzKuae0eHLBYLjBYTH9c0rOoGnYyFtNYcHBxw5eCSND9czWop4DI3WiyeQ0QHmW2LrOeZZT9r0JEsKzB5xrVr11itVkxmEl2itcMYg3OO1bJmVVWEEJjPNPPZjNlUQPzOaECvHDAaFJJx2rpDJlbRe2HoV6tVuudDZwTVAo9uxvmMwja25l9tXFBSFlilt6KHCAJuiRHvHKu5RNKs5tL8eOPV1/jB91/lj77wRb79x2+RWfj0L36Mv/jZv8i1p69SuyVFL+d4MeNffOEt/sF/+/d55oMf5elXPs7k7gRVlsmdOybGPDHtUWYTUWF73XrECt22WzoPzajTDHhr26Na+57u64NEpupMrowSBrw1lYqKbn65/b9OGpkWSiE6ZbIyboD7tXrGJ/DocacAi96YuZRNZNjtGCTapBnVUw7lWw1AvSEoiUkWD+1stexk+3q18QSUme+I2mIw1Z9jW59Akra2F546B2zpB+sBQnwsIHmWhHTztY9ylX1PAOP7MXPJBdC82C7A5cX2E4MGw/qBqMJ7Ng/+fnX5HjYLIQ+ZZIxxqhhoC9PGOZFDmgyUYrFYsVwsOrZqZ2dHijsP0zt3+Nv/7/8Say2XL1/mYH9X3iuK/NXHByViYoYSzpn9ELMdjRb516YVffq5qGUWyLSAeDMv8wypUCer86Q5IA1eitiWrdwEEyaBjaqqmM/nzOZzQggURcHOcMT169epqorjkxOOj4+JMTLcGTPu9ymKgtVqhXOOynusMZg8o8jKFFfhMEXRyQF9DKy852Q25+joiP39ffrjMQ3izmuLHLSidiKPPJmecHJ0CL4mesczzz9HMSg5OjnhZDph79IOTS3znW5VERSJPcvp75UcXLnMM888w2DYZzWb46tV98hVMc3S2oLMRbxK8lqfGNvQznfFTnbbAq2Y5dhMYgjWUja5BlpnSwEHVtiMzklYGg5d86ONLVBtUyXIS52jXq1YzKcE35DnBb1eD7KCmHIklVIihY1iwKSVyFeb4FnVAppWzYqi7IM11MHjYyDLrMxaBsiyomvAtK6ZW9epc4RocE0QptF7CqMZ9wbJZCcnNiJjtSZJw1P2p49RgK+x1OlemiwWHB1PqHwkH5ZkGJZNiq6xAsiKLOdgZ8ze7phquSD6Bu9qQtMQMPhoCK5BRchziTTRWlMURTJ7iWvGNBp0VIz6A4a9PvPRkJOTKfePDrl//z4nJyeYPOvk4tZqQnAsFjMIrmu05Llcz5VrOoa+aRqqqpJ5Yq3Rms70yZpWHr0+rtvrn0oiy4DRtnudMQqjkpmTFndSGi9je02gns04OZownc5ZzRdUy5o3Xn2d3/vnv8Mff+2Y69fgr/zyZ/j0p36W3fEO8+kR5aDk8t6Iv/TZT3N0MuObX/0S//1/+3f49/7WmOeff4Wbh3NpiKiQ4o3aedCwZhy7R0NcJ9Q/7vrbOlon46rTX0EiQVRcf20teUBmgttBy9QmS7N0G7mySY3RSmZDENffQERbzWb9LreaIeLRGJyr03poEqsd05Rka7SlxUZIC8BUIaKUT6x2TPfz+phsSppjjFiddYBXTmQ4U+IZWEvp1RZMf7+ApagkYjy7XfDOBbkPGjS9W3jZQaWHmvWs+wdB0c3SqjOiUeIGUFV6s7Fwvj/EWXF/jwMuo+Ldz8+qlNGtwkZdptfdlAtgebG9X+DyUQ5Y7+d2llX0o+yjL7Yfby/w1BncOFdtsSC+fGsG0GwtVbENXW+L6vU/nOrF0pma6I0w8vXDTW8s0rIvivMH0TddTs8bvN8ET3EjB1NmpaQYjyGkETqFKXOijmAzdvcu8Z2bb7BcVOjghWUyiqwcwWrFlz7/JW68+Saf+djHee6pp8lqh3YBE5P7YYgElwbrNOnh3Zq1CJjzqfjOtEIZlWbnxDgEsw5270LtQ0QblQw01lliRsnxc60l/xnAs80Ia+f4jNJoK0tK4x2+9lRVBUpR1zKDZm3G/v4Oo9GILMuYTQVoz+dzYa2GA6qq4u6921y+coWsyFksFkRtsFmBNhmNjxijycoeZIrx7ojZZI7JCnZ7Q5FiKkWRGFENDIdDTuYzlmn2887tuxLDsZgz7BXoPGP36j5Pv/g8b772fe4fH3K9uUZuLCf37zE9PiJODD2b8+yLLzHe3eHKtatopajnM0yag4soclsQPBgMsfFdhEcbKRJVQEbjDFleCBPTBLRVGJMBAuTYkL3KcTdkm/4dGy6XrVuPkHkRRcDqFL3qa/l5Y8E3nBzdF1AN7OyMGI2HKKNplsvkdBxoaplZJERUZlHa0riG+WLGZDpnvpjio8OUOasgc5bWFt38mzFGWBrfxtKIj0vtPE2aqwyACw11WFHVc3SMHIx2uXppl/3xCN3mQsoFRUO9vv+MQacInsovmUyXHM3mNFGh85yIZpWks2VZUq8qjFFc3t9jbzSAuiIPYtiTyw6nGENxqo0I22yyojPLQSuRRG48h3KlO6a4n+cU+7sMejmDImPQL5hMp/R6PZHgtmtQdCwWU46nR+RZDxdSfEhQSSabdbOazovUU2lDVFYyEF3AWmEjQ5LIxi1AkaJnlEJpizIKbTK0BqMzWQu0Ff4vLKnvHFGvGo6PZhzfP8GYjNn9CV//6lf55//st7n9duTlZxX/+l/9V/jYRz9KXmiaeoJVgWbp2B0N+ciLzzL9zM9R/c6/5Ou//8/56Csf4urlK/RVpFpV6HIIyrBynizLCMrT1DXW2k7pqbu1KXTMpDJqY1JzA5kk9QZp5l21RXIy6KF1kY0yj2+UIqbZ43V+b9gozE+Bi5bJDH7DDCcSWpfb1Ozw0a2V60nuusVUmmwDCGyyzPKm0mRS3chC+8QMrWtw2J6l78zS2vfXrK/Pjedsu5ar1IwyavvfW2Cpkynd6ZqqiwUK4QEGbvP5GVrmtlU3pEaXDvLA0Mquo14gOSen9wjrZ0v3fN3Ia24PxuZ/tyc7hqSoiWp7znWzEkkzraeB2uZXYwRUadbX0kapsc5VbR3RY4rP2diXQNzyJojd/qT52Q5cnlFLnwEwt2paFR8Auevzl9ZV1pnh7Xlvv9ddF+c2abxc62qj+RjDOmZt4/xvnoNNZ/zHRLAXpfGfJg7oMXHVwwwvL5jLi+3HCEIjauMS3JSYrnMTH95ceK9vqLgxwP4oB7dzO+pJrhcUuBhQOiMrCnRmcU0QwAUYpakaT1NXZFev853vfIfxcIcXXngBN1tgUTLaiEZFLQWSEhAn7ITqsunaAkGMewIh6G0pTEgmDiZN8qSHkO7MGuNGwzKsYwPCurvfyujkq8jrcmO7bEtf11DXuBgEXCbgnWWZSAF3duj1evR6PUIILKoVdSNupiYvsEXOcDjsZtyq1YpBT7Iul8uKernCpcK6KHqU/YKll8xCpS02y5jPl11z4Pd+7/d4+ac+xt71K0yOTzheTPFKs1guRZKqEBMa7zAxkOU5B5cv8fpr3+P23TtcP7xMLy9QIZIpTe2cANWyYNwfkNuMGFPsQPvQDcllMgZcYiW9l+vIWttJjZWWwsvYkhBE7irXvRXQ5TwgEtXNzDtOF1rBdeY8AWlYaFJcQZKBK52qkFALW+grNAGtFXmaGYsbOaQCaB3eR2oXMCpgrUgHq7pmvprThIaszAkpmD6SzEW6mdH2eKxl3a1Tq08yRGEeITQeoxW9LEvnW+J3bGJrBbiKw68LvstRNdZS1zWVF6lxE8JGRE6aWVTQNA3awO54h/3dHSwRXy9EXtvUyX11I56jK9w12potNqErqtt5vhA7wGnS8S4yy3g4QGvY3xlLPIv3LFYiB2+8SEKjh2k9pdfrs7Ozw2AwIM9KjMmwNhPWPyhCdKnIj0SfTH10FLfn9trQ64ZXm3Nr0vow6A8xRSGzmumyCPM506N7qHrJYnIMGJSPmBi4/dZNvvSFL/Pbv/VFejn87Cev89nP/ByvvPIBikwTYp3Oh2KxrLDWcrAz5iMfeJ7vvvoqX/v2a3zlc/+Cj378L7D7zMs0wLRZ4m2ONYYmNCgNWW4fm3w6T6q3Bj8JAaavujXjIUjmpQoJiLQGOw/Gcej4eKXwesrdd8+y84qsLUC28b7diEXX/krg4BGfXcf38vkbeC8Mfc5yWV0zqecUoqfiu56McdAbX8MTK5o2fRQEBT8GX7oxTnr2HG+7S2qjBlgf3pbx1JztQnueoZBSDx7rc8H3Y3z2BxnL06TA5lf1juqfi+3Pz7Y5Knb6erB/Gj/Ixfbno2MiHcNwLoP4o96Xh73mrJwvpZTk7/UMRa9H2e9JvMZiIWyryVBKkw0GcHif2XJB2etRN40UwDES4vrBppQYpLTOoQYI0Z1xj6Ref2JRxTR3bRTRZhd2r9+aJV0//FuHyqjXndB27rJjWVBbc6bdwmItBokJEZOSTGYle6WA7LrGec+yrih6pfwpCnZGQ7z3TCYT8IHpyRHD4ZBhr+RouWA5n1MUBWVe4L1lOBiwqpfMZjPm8zl37twjhsC1a9d49dVX+e3f/m1+6V/7FXTZo1o1oDVN1ZAZS/QOtMU1K7IsYzze5aWXXubbX/sad+7cYTp9jsHlHjs7OwQFs8WczFiyLCPLsiS3lHIhpviHSEg5lnEryF5plQxTUt6lAa0zwOKcJ3h5vXcOTyQ6cRPN8tjJSreMWU77eoQg10IQkydtjEiyRBctMi7vqKsKXzdEL3mVWZZhFITgE+A03fvJnKtJ4FbjmsBqVbNa1Rhj6Q+HeG2kwKFVDqSomQS6xeRHwF7jHU1T44JP86Ngtbh2FlnO3s64k4nL746pwZLmfYHok8lNmhmMUdG4QOUaXBelI8e9cg0g7PqgX3LlyhUODg7QWgmLrteGOG0Mx2aMjhS/oStEvfc0CdxK6Sz3dzuHHIKX3NcIZdnH5oWsAUTqetW5KIsDsVSpudGMhyOuXL7CeDwmyyRbck04iERWfsZLkuNGrkR3L2/EAXXOzUoLw6kUrCpi7UQc7TzT4xMmhydM7t9mdzigaSoWixVv/vAGv/mb/5RvfuMeV68qPvzBV3jllQ/wyisfoF8W1NWcosjoDwo5R9oyX67QNuPK1ct86i/8BV576zZf+fIX+dDnP8evXH6WQTHiZDEjKktRljSrFTbLEuvjz173TxUtp9f9h0kYNxmhR67bZ8CEJ3m+dDOOHWg6f5/eiVFL+/P6jFjm7Wzlbcll+8w47zepeMZ7neP0+rDjcZpJPf0e50V6/ChjSs4z1Hkv6ogHTZN4YF5267SdPg48qikRz2Rcz78P4hMp+1rW90ka9xeg8mJ7nO0nHlw+bBG6uMj/bHQ+HrawPSpv6v14QD1qfx72O7f2cyMHs3UdbTMRW0nOfDaH4QDmSz7y0Y/y1d//PCezKU+Ndii1xp9MJdwcyDbiPlr30Ma1slS1URQ/XK7QAcouuH07m7J1ZVVKb0lsHnSgXUu1VIpAEIYuFbjGoDObim9DSIVy4xzBi5tn3utTDAfkWUaZWfLhEJqaZlWxmM+ZT2f0s4J+f4jrD6jrGu88y+UcHx0rv2SxWHD37n0AJiczhsMhn/zEJ3jr3m1+53d+h8HBLj/1yZ+j7JXUztHr9VBKsZhN0VGC5621DPOSF557XiS0xxPwMB6O6PfLzjyl3+93JjWEKJlxCeS1jNom03VW17kF8V3QgFaoxMo1XkBMTNeH87Gbr9w0x9mUKCuliD6IRA8wNhl1BLXuTscgkRquFqmfUWQ2Bc/HuJ5gilHOTQJQWZahraFyDdPplJPZlMY5srxIGZgCcFQ70xWgCX4jekRkY8456qbB+YbGt9meEd0oLIqd0ZArly6xMxhBLQxfVAqbZ8nIhi2JHoCL4KOiCZHaC/BqDVFixxp7rNXsjsbs7u7Q6xWEuiI4J3mFpyN4Tt3DzrkuN7I1XmoBacQQvE9SU40PHtcEAmJmlOfrOJcW8GkUsyCGSsFH9i/tMt7ZYTgcilw0gfrg1zDJuaZbR5SO6OQGbIxJxkhybRpjsNp0X4UhV+A8eHEwnk2m3L93j8nRMc1qiSVw//4Rk+MTvvKVr/HFL34RFRR/+S+/wvWrV3nllVfQwPTkkOPDhjwz7O7uQBQFQp7nLJdLpifH5P0Rr3zwRX76ox/hdz73Fb7+lS/x0Z/9Ba69/BFyo3FErDHdvJ33/tw16jTAfKeN5kcyiop3tNZvsvOPakS+V8+ox8kZfNK4jBjDQ+spdc7861ng8VENgDOZy/cZYD6SuXwfG9JPUs8+arb4PED8o66BL2rui+1x1tc/FeDyvBvy4iL/swUw3+nD9P281s50gj3nNd2+bTg/Kq3BewgBay2DwUBC3hcCLpU1ZGVBnE5QvZLnXngeZTTXnrrObl4yu3sPbTQxelGzqXXOWgvkWuZCt66GaVZCKy1ySL12eN16WJ3xubXWa7dEfSpqpP1MibkksTBZm7tpzFY6XLvVdU1/OKDfG+JioFosWVQrovN4rcnHY8qdIYNeX2bBoiIuA9VqxfT4hNg4FvM5WimsUZSZ5Wg5ZbGcoY2hCTLDVS2FfRwNh2RlwWBnl9HBHrcPP8eXv/glxnuXeekjr6CisGXeRcn304bcaIb9Af3csjPeYzQace/tt6iqSpg9LMZkDPojxsMdMp1hdUZW9vHeiReCUhKf0DqZxnYWKslvW2fXFvREJVLcrD3GUULmnQCiNmeydZHV2nXgZKtQS+6yhEDtxTwkCxZCwKjEqmlFdA7fNATnU9SDvFezWmLa/YuB0EXE+K6R4bznZDLl7v37TKczbC5GQ6uqwWHQRmPboD+jMGgCAR9DYt8jPjpclFiTVr6tlKapawZ5yd7OLvu7e/RsTuUbHF5iJUKgrusO4KE0RmvJfwyelfesmoZV7URumqItQpKP+rpmZ3+fg4N9emUO0QtA02KkYq3t7l/nPSRDnbZp0kqclVJiqCV3mhi+aI2KRuY/jUFFkaPG6DsDnxaUamXQOTS2YR7m+FqY3DIvKDIrR8zVAk7Dep3zPs3GGYFkIegEVhXWZsI4J9bVGENmWmWDUFNhviSGQD1fMjk54eTePRbzuUiFfeT23VvcuHGDz//h53jzzQUf+MAev/Dpn+fZZ59lOOjJcalq5oslrqkIXnFyIphsvDsixshoNKCuHfNqSW+wy4dfeYlv/+B1brz+A9587ftcf+FldgZ9TlYNrq4wgFWa2svM5ZMWsg8Loj9FEJ0PmOLDxyDOY94eVeyf3jYNeM5675AiiM57Fx0fBV433z/l3rZ/2f7U3f8q1NlxoA/5zGc2Tx9ybuJFnfau6iB1ahb1XECs3vv6Z6sZcOFvcrG9w80+7sX2pMDg/bz5Li7yP9uL69bC+mO41h7n+upYO9ow+418NISN0ukbMYROdqmUYTKb4rwUoGW/x7Ja0Tc5V566zuXr1/jmt7/FZz72MxSFuG3GqsEEvQVQYgxndoI3mUut1SmjjzOKFy1FcsustNK9mICkMaabudySxaYZr07+6SW7U7IxxUggxCDvZyUXMzae+UokrAC6LHGuJo+gc5HPkuSts9mM+WyCqxvq+ZLlZEZ/NESn2bZl00CKc8mKkmGv3+VDeicF93g85hOf+AR/+NUv87WvfY29K5coBgOZ+XORftmjXxZkStEvDLmG+WDA1avXufnDH3J0eEJVNUiPQEBsr9dbg3WtO8dcbQxE300ZtVeuD3F7jpi1mVKMkcY7Qoj4QDL9iV3O6Gm2M4TQyZZb9lLGKX0HpITlM0RvqaNHozBKmEPvBFxG3xBcg1OeRgmzl2WFsJaJOYsRTJYRFcyXKyaTCfNlBdqgbSmM4aoGm2FVcrnVJgXHi4FUjArnReYbTjUxlJHPqNGM+332hmP6WUGmgKIgT7mIrqnwDhw1pPldtDC1jQssqorZqmLZODmv2gBJnpqaOnu7O+zv7WCMoq5XZEphM0N0cg+GELYaRC2jFmMkbDSL2uvLWtXlkPoEMjEGa0rJcgzSCMhNytYMKzk/LhC9ODVbLUAwsxajNNGLV6lWCm1lHMClxhR6w/IsioRZ3EcjeZljUkalMib5tARoHIRANZ2zXCy4e/MWd+/cItaOGCMnR0fcunmDH3z/Vb7z3RsMe/CXf+mneOmlF/jAyy+yv7/L4dF9fN1Q9kqsHTDTEddI82M+nxOjZzgeMBz0cGVkefeQ4Guef/YpPvTyi3z+G9/jzR98n4998ucZXn6Wyaqmriq0sWgUVukz19QteeeG7PI8p813w/w97rp/5r9FvRE/Eh8ABO8V+/OkOYPv9/u/02f5Foj/ET3PH0ZMbDYX3ssa5mHH8FGqp/OURqcB5o/K3PJR1/HFpNpFzX7etXth6HOx/Vi3jpF4wgLiJyVgeHN/2p7tpnQULTNXWZEzHI8JMTKdTmkaT1mWnNy/S388grLk6ksv8tMf/xl+8+/+Pfbykk+88iGaGPCNJ8S1SUAHLrVOs5UxGVg82LDu5Jlx/aDtsipPSVxPf++s491KJltwqVqmLuXpKWsSAxkTqLaSQ+jnLKsV8+WC2jXkeY62Bh+hiUFiTBSslgtOTk6oFkuC89SLJU1TU1crbGbojYbs7IpJStM0wtho6JU5k8mEZQI8qigwZc54OCI4z+s//CHHx8e8uH9A7R1Fr6AsS3pFTpFnKF9jVKDfH/LCc8/z9S99gXv37nF0dMRgIA62ea8kz3ORiia2MCiFMcLkEiQ2Rpm10YRN+Ypr18HtGeK6rmkatyF/zSkyizE25ROeiiCIvnMM1Mln2WiF9+BUxAdP9AoXKpnB9EHcN50jepeY7kD0jiZ4tIrkTSbmLwkQrkGgZVXVHB4fcXwyRWvLoOwTtZHcTiJFkn56FNGLHFYZmYUMoZUKx3VsROtqqyRzcTAcsjfeYVCUNHVNRICXLS3RObRq5a1y7boQiY2nrmsWTcNiVbOqHXXjJZszStxEGxcxGg07sxwdPL6picZsXNMSS6HUBlOZXKY3OCH5b20wOrlLqhStkphPOVfJHCmYZOARU76mwjeBGAI6SmanKUVSWtgMrRTBO4J3GG0xmZVjFtKMZGo+tDmQRmuJ5dGazFgMKVbENYSqZrlYsJjNcVXNajYVM6t795lNT5gdnXDr5tu8/tprvP32IcslfPrTH+JDH/wgu3tjLl8+oMg09+68TYiO3BoyK05fvV6B7pluBjRGT38o5lx5Zhn2eyybhr3RkA+++Bxf+sa3eO373+bmm6/xof1rFFrjvMSjhCQV9sQzAc7jzCc+TCKoHhcwxncHzmT/VFdor93I2/c6lS+87VF3/nMxzdqfl0+oIl2OcGfMxkNkrO/wGXfW/OtZrz89e6l40ATrNFD6cT6732sQvfHG3fP29HnfPA8d2E7H7Sw3ek6dubOY7xhONzWefGb4YubyYns/tgtwebH9WLdNVuCsh9e7mbf5kX2GRyzCSgkzVJYlAPPlkto7+lpTliWTyYR+VoBS/JV/9V9BLZd87ff/kJ7WvHD1mgCLtlDvHtbJKt6HrQ5sDEHs6VtDnwRM1rEsZxzfjSIgbkSrtK8Nis7SvAW4LaNT2EwMaLxPrpvikAsCdkxTozOLsTkgs6fWiimO6fUI/QFF2YMsg7pmNV8wPT5iOV8QnWcxnYpMs24o+z2yls11nsViQZ7nROcZDEb4uqFariiGUnQHpbh58yZZlnVSz9FgSFQwGIikLyT2yjv5vNbmXL58BWtzTk4m3Lt3mECgw+Qea61kDxaFzPeFFA6PBiOsIaxNlmyWiePuxjEWoCjRNd4HmUV0AVvk9MuMPC/RRpZm3xr9tHLNTfAH5EbAtXPgnO0yBMVYyHX299EnltcoNBk435kN+cbhtcVghI1VBhWFpZ4tFxwfT5jMF4zGY/JeXzIuqxplNMMsk4xRZD7Rh3SRRImxadLwoG/NobZAg2d3sMt4MMRoaFYVLnhG/R4mM3ivJF8yBJnV9Y7Ge1yIVFXNMjnF1l4kuK3rZlu9awX9fp9+mZNbg28cLaeskjFPqz8wxqSZVh6IYIhxLYvXGzLzqDTairENUaOsmOgE30hEQ1Rom2FMjdY1xpt03kQyn1lh8KLzNG5FVDLjarVCRfHRjkqcg0MIaGOwNifLJO/V2IKwagjUqDplyU6mnBwecXJ8TDWbMZtOmR4dspzNmU8mvPrd7/O979xi0IMPv/wcL730Ei+/8sFkpNVgNUynJyyWE8bjIahA4yqUVoxGA4yyHB4eU1UVxpSsViti9PR6+4xHA07evkWuLdcu7XNld4e33/wht956gw98+OMUJqcOYKxm5Xwn5Q8PqVXb+daziuvziu5NcHPuM4dHG8s8Sh56FpA7D4Cd20BV7/y5SQKgUf3oiv7z5v7Ug13NhzNw7XF4n/f50czl+398Hla7PAz4dg2LR1z/5/3OHzWIv9j+fNbv513H7yjn8sfRwVCPkPf9uLY25/Cio/Nki/3ph+7jLJAPc317UDJ9+pyc/XB/FDPaMUZKn2+Os9EBjGybPRiTUdc1vTyn1xuwt3fA7dt3Re2WiYMqSuGdwzQ1L3zsY/wbMRLnC978zncZFQVDk1PYvHOObOeUmqYhqrglk1U6CtNBxIfYzVxqvQaSIQRQgejTs13RGZfQyl21hqi6OIdNt9hNeWftXSq6k2GJMSgrRbRJzeysKBiNd+n3+ywWC+7fvy8yU60ZDocMhkNA4RYLlsslq9WK4+NjFpMT5icnXeHfVDWL2Yw6eBbLOa6uiM6jleLo/mGXabh/cEAx3OG7b7zG3fv3+OVf/mWuPvs8P/3TP814PMYF0TAXeUYda2KExWLFqGcZDodcf+oZ9vYOuHfvfgKw1yiKglXV0NQiScQFsGDycl0g+gT+N45TiC7loiXpMGKAExIYaxopnouiICsLyTcsClBtXmSawUwMnsJ215pGYTIDMWCVIfcW7xucr0VyXZb4WmI4TJ7JPGbKOvWFAAOPJ8tyOb5NQxNqlM3AGFarFbfu3Ga5Wkl2qM3QypDnBTFqQoxUq4b+MCfPrEhqvZNcuwjOO7IsY75cEJxctzGxtXluGQ7GXL50iRwIVYPEwWbddR69x3txHi76BTZ44mrJYjZnWdXUzjObLzF5TqZUF31T1zXBO4qi4PL+AWVeiIFPhDJP8l/vsNaK+6qSeWFPhCjOxmoj80FSQNo1KIFNpSBA44K8XhlQYtGkbY5WDa6uiU7OeZZlRO9pqprVcklR5PR6PTKjaJqaECPaWoktaWoBysETg2QDaqWx1lBYybYMywqTK5bTOVVV4RtHVS05uX/I4d17HN67z+z4iMM7dzm8f4+7t+9QzWcMygE//3Mv89ILL3Lt2jX29y9jswxrNHXjOTk6ZL44QZvAfBYZjUYdC93UCzKTMx6PKcs+s9mEk5MT9vf3WcynaJPRyywhei7tjXj+6Wv8y698h7s338Q1K3GKdoHVYkbRH1MFR5vm8VAgeEoivrn2du7JZ4TQnxdGv5kLGVV84P1PP5Mex/PhPCOdcEqpcBrNbDJ+pxnILTDW5Qum7ykeMPfaet/OUC4+8JwCOpm159GqoYeB5XMbwzzYpDl9TLdyGB9S5z20/oznP49FFXW+YVGMMXkaxC6L87yGAaizs65PyVK1Xhvrnblfj6ifH2B59ZlAXq2Zy/DI+ddNR+PteqXN6Y5n3mPSBFCPwAOPNjC62P7sb2fdoxfM5XuE3C+2n9yLPsYomfQbs26P02XcArGPez1sdJK3n/Yyr9cylXVdQ1QEL+YcOoJvGozVXH35Ze7du5ecLm1XJDRRohba2a+Ysg2FDUnyKNWWIA9vCm9liG4WYl1e49otVm3OnZ267q1NUsAkq9wsmrTRDEZDbJHTK/v4EFjOF6wWS7TWZI1j0OtjtIamol7MWcznnBwf8/bNt7h/+w6haeiXIr3LykJyB7WWWU8fMFYTUpRHXhQMe30xTlKK1WrFwcEBf+HnPsXzH/ggvb09XN0A4g4rGd4GrY3M8qEwtmBnZ4fr16/z9o3XcY0nJDDhnGO5XOKcI89yceDMrcRvhCDzkl7+W8LUA5tXTlt8tAyej1GklFokqCazXai3nIMHi4E2QEHkdkEiRuL6mBurCFGKKucc/X6xLkBDlAgU5O854HyN0hLXUftAiAKE62rFZDanqh0mL8jSJ3HBE5VkTHrvhFmLgSxGjLVYlLCLyZioi8hIDREdhW0d9frsDAb0swLbspquAe/ELErrLrYlpNpIGY3JcmxeExaRRVNRu4aYzKTaYsk7MUEqc0u/V5Bbg0rnaM3dpyZJUGza/T8IDjgb3EQluXXaCoOZWIaQyJgYxICrzf3ECwvnnetYaBUhSwy1S4ZLK+/JrTCUWousujUdmkxmmJ5cuzdvvo1zjunxVJoFjePo3l1uvvU2d+/c4vDOXY7v3+fe7SP2d3o8df06T1/7GJcvXWJvb4/xcERZlixXjrpaURNAOVEC0Mf5lWRzLhZkWUZRlPR6PazOiFFRFIYsv8R0dsJisWA5X7C/v89o0Od4usRHzysfeIHPffXb3Hr7LeaTQ/aGO2QmUvuIDw3et2vMkze2H5cxfJzn9eNKcB8Gtv601QaPmhF92Gd9HKOlRzFuP6pIsUdLYp/cEf693K+zGt2PcW6iUkq9F/vYxpdcbBfbe71dgMsLcPlnjhU94/sKYjw9gH5W9/n0gP/jnt/Ti3QMMkPYhcsbzXA8Yjge8fr3bjKbLyDKfJnRumO0cI6b3/0ub7zxBgeDISazkGa2OmbMREwCy1GF7ndLp5aNGYoHi+Z25k+hutm97ebjOoy9ex+jH2AFUHprdlNr081haq1F9ppnFIWwcSrCYjZndjKhWVViVuQD1DUhenAiz6xXFcf3D7lx4wZ3br5NmWXs7u5S9nvC0HhPWRREpRKY81TVihihPxgwHA7p9Xocz8WE5mMf+xgf/shHYHcPanFCLYoCrS1NVSXjIVDa0PiaXCuGox1efOllfvu3/4DjyQnOOYzJWNUzTqYTmuDJS5ExY8SMxYeAaxI4UiGxCQGdGGXT5jJCAqNyreR5LuZP2mLbWc50nF1McmatOiaCkOBRiInc8utgeJOYP8D5JkWbeDJjZB5WKWL0eO/FaCcGUIamkfzGxjl0XqCJzFdLDifHMi+c5yIzTvJcm2foTPbLJzdXokZbgzHQpLncQMQtF52EtwVQZZGx05dZy9xabAgE5QjRdsC6jdcgsQ91CMkJVhOiYtk4ZosVlWswrA2QnHeExtErSnYGI0Zln9JmaIIw+SjQp+9r3YplN2bU0nlAzkHrytw2BlQCp8pkMmMbIfgGYkCFIALdU6DUOSdROt6JnLozBRNHWtc0NCHgjSLPS7LMoGODVwqjNIVSTO/dYz6fc3Iy5c7tuxwdHXF8fMzJ8THHh4e8/dZN7t1dMCjgyqUd/sovfZqrlw64evUqo2G/mxeOPuBcjXd1KmAjxmryzKAoRGrsxRjJObm/8qzEZNKU0VHL2qQVdbXk5OiQMs8ZDocYpTA+8PS1axzs7fL2G29weOc2l595icxorJHjaozpwPg7eb6eV4C3TZiHzmSeiiJ5L5/rT/Kz+lEznyE+ku1a5xLxAIt5+uX6HKfw856lj8oWfZihzCaz/Cgw+qMAno+X+fhwd+F3yuioh/yeR8muz1JnxfQXvfFGmzmXT1a3qPMl4Bf17cV2AS5/sruDF9v7CyjPc1PrHqpKbUWFnCcXOteV7QkB7SYQS7Qpw8GY3Z09vnJ4yOHhobhfWisMT4zQ61O9eZP/+//tP8d7z9WrV+Xh7Nf28npDnttGh8Cmu+gGuFRndeeTlDuByxhDkgKarmiWKIN1QayQqAU5DnEDUMq+aGswWiR9ygiwLMoSW+RYLe9br5YsJlOq1aqz3nfLJUe3buGiGJ0sFzNu33iL1157ldu3b+OcY29vl+HOOEnxxFBn0OuROU/0gcN7dyWqwmZdxEQIgcViwfF0ytNPPw15TphMqLyHtD/Re2HHEPCitQYnnzvPc55//nmshaOjI4KC0c6Ye8dHHE9OqOuaQZFD3YjsOFpcbPBRzHMMIic6LRfbfPjL+ZBjFYyAy+58xtid8k5GxlrmJddxAGKScgaRuRmNUZnMyLqIcp75ckFuM/I8xyhF9E5ATJpBLWzGsq5onMNkOVorVo1jWdc0PpIXPTAC6JRUWClGx5JnhvlqSXCOECssWcesx2SQ06RIE++9xFBoGPb67IzHjAdD8B6NluZEpomJiW/fo/2MLgQa71gta05mUxarJVVTr4+R1qhk4qNR9HsF+zu7lEVys23ZQq3RSuJ94GxTKzlXSW4Z4qkoH901bbTOkiGHsMjtfS7AxqCNtKpMNDg8ztXUrk5uvDIbW1fL7l7TKuKDE3OmCDpkNI3MyrraUxQFd2/d5vj4mODhc7//+/zwhz9kPp0RHFy6tMuHX36Za5+9zPUrV7l65RLjwZAsN0QfmM2mLBZzIh7n5FgWWYG1FptZjFF4n3J5sxLbE6nzcrmkWjUsbYW1JcaKSZFzjrIU9+TZZMpkMiHGSL9XkmFZHa94/unrfP21m9y+dYMPuhqN7uSQxiqCe+cGIg/Gj8RTDP9DGLgNtv+8TNpNySfngtXHl8uejWWfLPB+C9jh35Pn55M40D5OzuLm8T8LcG7PnKofaT32To/1oySs7+R4t4Y8T7JvD/7Ox5HEvovjdVG+XmwX4PJi+/MOMM/rsJ7+tyfJKVs/CB71+89boNPcSfD0hwN2D/ZZVHD7zj2IkGlDqBqZbWgavvKVr/DVr36Vz/zMx7l+/TqxqtJ+aow15CmwnZiK39T6bmWxkh8o4EZpRTjv4ZRYzBiDkDkbs0ttRqdKQE1vRJW0M5kmzyTLL5e50czmEjnShrlnmQS5R6hWFYvpgtV8AT5Isd84FlXNbDZjWVcYFHVV8dbrb3Djrbeo65qrVy7xwVdeYW9vj93xLlmeUxalSBKbQLOqmM/nwpQWJUopqqYhVCuW1YrFYiGsGjLfWlhL4wPLqsEQ6PV6oC2uXgkDpQDlwFiuXL/GM89d4fB4Aih2d3fp3bvLZDZnOpuzt8FgoUFbg3Ibxi9KnHzF8XHNh4vzqSdGOT/Kmq5hEBLolR22W9duC5pR8YE5ogD4RFkro7EqQxlFsF7MlVpADbjkPIpSMkdpMtyqIqCwJqP2gZPJlNlygcksWVGyqisa74laYZPDp8FjbU5RFDQudKY7Ad2ZEHXmNzHiXYNWilGvx8HOLnvDEf2iJCyXwvamBklQXbdEPjMS9RJiZL6sODw64Xg6YbmsALp5XJ3m6IzS9HsFO8MRe7u7EncRo8hbo0a3xzUJZI2x63liJfOXUrin2TTT3hu6yyeF1AywGZv0f3vfaKIwzXE9m+y9T87ADS40uOi62JeWUY7OizqBiPK6A8whBJbTKfffXuJrj/WRP/7Gt/iTr/0xw+GAf/vf/Kv89E99TPIuo6IoM3FaXi1wviYsERlqaMgKizaW5TIQVg0eyeJVrjVESqZCuTQkAhGT5axWK+rGM18sKPqDJNUVWb9WGbu7+yxnU46Pj7l0cIXRaMDJwnFpf5fF177NjRtvMp/P0L1dQD676sDgOwOWD2vkPkoOucnUnJYjnjfbf+Z7Rf2IfX3Y8+XsDMx3BFrOwQHd+4b4jsDlk8iLzwKXT/Ksfq/B0eMAQPWIhvX6PPOe7M9Zn/sctdU7fr+L7WK7AJd/DkDPxfbj3Tr2kMefuTz9cDnvAWW61/quMGPz92zY7AcPvV6PS5euYC3cvHmTpmkoyxLnGtCG+Z07/O7v/I88++yzvPjii+D8lrw1yzKsEQaqK2qSjLCLIkngsgU1KgETtpjNTbZGSwh8CyC7vEthIW0yGTEppF2kj0YcYI0hK3KUMRKdoVQKt0/unk0jRWlds1xW1KuqA6shBBrnWCwWKKPpD0f0hwOuXD7gmWeeITjHtWvXeOkDH2BnNJKZTe+TCU7DbDZjMpnhGs9gKE68Mp8aEohzVHUtbqW9HiiNm02pXWKiUGtjozTDqpXM/cUYGQ13+PCHP8yXv/gFjo6Pufr0dUajEaujIybzmRTkeS5UsDYYI66pBA8mIhDDY5UYnMQQO2ApBj0Ga0wHSGIC/G3GYscgc7ZZSfc9HVExSbCTLE6YNktM5zKEFD3iPT5IM8Fam4yhNFmRE53IWGfzJceTEyofyMsSZTSBSOWatD8b8iztyGwBRs5L7RwhrCWx7b565yBGennB3niHndGYPMtQ3mGVJkbXuYIqu8EaaQFt3nuWdcVkNuVocsJsMZf7z+aSK2o00Xkx7Cky+kXJ3u4ug7K3ZlDi2pSqO6ZptlOdyVCcLvbXLs1bjrGoragfaRRECHKem7qmqZYsVitWqyVN0zwAJrz3RCf3SwyeTBvaAU5X1cJMNp7F5IR+b8itt27yxd//Qz70gZf4jd/4DS5fvky1WHLn7i1MllOYgto7YeeNwUdH01REFYXBzg0YiDoSqgbvalZVRRFlJjzLssRia4Jz9HtD8qzPcrlkUdXUXhozeVYQI1hl2N3bp8xybt+6ydHREWOVkVvDoF+iNBzeu898MWV/9zJZUHgvkmpx4n1Ult6DBjuPyz49irk8bbhznkHc+zdzuY4tOut3PeozP2pi7nGbqA97fj4se/Gd1DoPA5/vx/P/rHOylque7zz8XmRIPhAFEx/j2Gyea/Xwa+r9rDEv6teL7QJc/pjBy8XN+JMD5s/vAkbeyczl5s+/062d1+r3+1y6dInBoMetW7dYrVaMej0ya8WkxgfeeO2HfPC55znY22d27564rwZhUjoHPJIpy8b+rmVI6U/6pu5C61umswWW8r02o7FjgOwaXKKVABCjUwyCmM78/9n70yDL0vO+D/y9y9nukmtVdVdX9Y5eADSxESRACiQIiSZFipQtWSPblGzLo/kw4fBETHg+OCYmbJEz4/DMfPMHT9gaW7JF27JJybJEcYcIkCAoriCJHY0djd6qqyqXu53lXebD855zb2ZlLb2BIJ0nIqO6qzJvnnvuWZ7/+996wKm1TombiZFLITJd19Gl4JKm7gvkBVzF5E3UEazWTMqC8XjM/v4+RVEwKismoxGz2WztD0tAQylD7Dx13bKcr1gtlkM1SFVVAr6zTKpCUr9m0zTS05HSWa0tRIqayuCd82gtiZzBiV/OZhlFVfLEW57io7/2G7z88ss88vijTLe3OFospIdzvqS4cBGch1yjrMWYDLxD64hRRvx6xqJdxCVQ6ZzDOSd1EqfAZQgBTwK7Tjop+2TgEwslMQ5eQJlPN6XbcS1nUgqbZbiuwwX57PGJ5UyhPsEHlMnQ0bOsa45mxyzrGpXlKKMlMCedQ84lhjElDzdNA1aCdnp5offijRyYTOeInaMwmq3JlL2dXQlxCtB1LXliBCFgjB16I733hODpnGdZrzg4mnHz8IDFYikptLY44fl10YOOVNWIna1tJpORfK5G2PO+0rLv8YzaYBNreWLo7ImKgelJ70scTmjdy8HNCdnY6dRo7/16caVesVqtUjekBPJkhcVkeqim6WW7/YKC9x216+jqmuV8TvSRIsu5/tLL/P7v/jZEz1/44A9Q2ozjw5vMj2f4pqYLnheODnGuY2d7ilZRfKgh4EKH9x2qEyl7VRV0RLyW/bdZuk/ofiA24sU0FptbTJ4RZzNWqxU+BkYV5NkIZTKMketwe3ub4+NjbrxyjWrnIpPRmO3JmPnxIceHR1y4qlM6JbdUI72a+/q9MH23q804OfS/8Unvr+W1TqfVrtNhz35djVzHt0uLHb4vyruMd3h+nQbNZ6XGnuVvPSv1/dt1BrqXEKLbLS7fCyi86++9XRIvd68jeT1z6b30c0O85Rw83863c3D5bQAuzy/I13PXDyekRW8UoLxlhXnjP+7kubzd6+uYuh1DlICVIY41oqME6WggKJF79UvKQZEkjgGbFxI4U445Pj6mayTcI6ZuvvH2LqYUJnA8nWC8Z3njcAANIA2GSil89GilCSGKNHYznQ9N1Gs55VAfshEMo7WAx56BNANjmRiz3k+ZwN3acaaGyPwYo4ClIGCg824ILZHgEi+9ltqQFcIUNssVXVMTtUbnOQ888ABVVQ19hqNRxaVLl7DWMp/PuX7zBk3Xsu0kObftHE3TULcrOu/Iqxyb55jMoo0hy1PFgzZ413HjpWuEwyP01jaj6RaYjNB2tLElz0q6esUoq7BonFOgDZQledtw3wMPoLRiuazpOsdkMiE3lvnBEQc3r3P/dIJXBkMGOnUcJjYYrVDRgDEopwFPCAySWKL4DPtzrAcVxksqcERqGjbBpXz+vR9RE5NflJ7hBEJ0A5JSG13e8vkmFr0OdN6nr0Bmc4KCZd2wWjagDVlWYG1O3XSYLCPLFM75IeEToPUB1y6xZZVYa2Gue1bYuRaTGPQyL9iZjNmdbjEqCmLnCD7QhY7opabEFgXkGXQdzbKl9h1103E0n3Hj5iEH82Nc8GibE20KOiL1RkqpCFVeMBmPKbMSYpSFnRBxWkkGUlyP2coYYfeUolceDPcFJPY5BJ+qRxgqfbTqPZYpJdYz3CNEDhsJXqpIXFvTNS2da4ZKGWOsVM7kOU1dg3cowBpDlu43oelwXYMKinE14sYrN8i04fOf/zxf+8oLfO/3fhe7u9u0bU1mFNF3Qx2RpAkF0AofpQ6mHMn1VddLFvUKv5J+1yqT/TA6A6DzgbrpyHODrTRVPqLzPlXbbCUfrVzjWhlU1FijWK0aYvBs7+wQYuT64TFF8IxKy3hUslrOmB1cp21WtK2jUzkuSFL2Lfd/FV73MyCo02E5cb3ISBh8DkalxbpeydHfaWMckoXv5Lm8XSlDnxquUSfSw2/lHVOy9CmcHTcxjdr4SkxniDpFssbXNbuc9eg8a8H8XkHlprcf7u7JfK173x+OqO68PHF3pi++6rniTtswJ/Se3iHrQQ3S5DvNjLey1LcnL3Rko4vlNSyAx97jfj6Gnm9/AuDyThfYt0P/5bfTithr0c5/u6/4vd5No85YrVt3QYUUcXe70uvgua3hcRgCzmSPT4YxsLFSflb0/OlUt34fg/Pr19ESrNLXOoQoQFJrLVJVIoQg3jktsjurLW3XorWnLCdMt/Z45MGH+cLnnmWxWLF1yaDzTH5xUfBdf+7P8bsf+XUef/Bhru5ewM8bmtaRJZYwRo8LAZ1Z0eX6nq1C9oc+2S4Oqa8x9EwBmMRCar3uYlyD1nUw0OkV8x589h2EwrJJr18IpI7Efng2FFmO156qLAVsA75zdEoG/ExrRlXJdGcbk2c0dc3R0RExRnb29rA2I0ZomgYV1ZDyurMzAh2ZNwuK2JHnOV0IdDEwLgUkzWZHGA1vuXKVj//qr/Lg5ft5z/d8AC7sg2/QeU6pK0kaNYp2tSRaTVYUErZSt+h8zOUrj/LUW5/ha994gQ94TZGV7O/s8tK1l2iPjqBeYXb3CO0KrQ0mN7SNsHc2pbBmKY02KJGXRpWhTCSmkBurFCqGlAoZsEaAv3MO71pcAp5+CE+yBG3StcPQq9aHexiMhMkGL6FJrgUfMFpjMyuSx9RpCRo6x2JVUzcNx7MFnVcUxYjgoKs9mS0w2hKNRqtOZM9RSTCLlq7HunFy7huNzqwsMPhWfIQxUOSWna0xe1tbFMbQLRfQeayWM88WOcZaCAG/bOh8wDnoOsXR4ZLjVU3tArYcyfvVKjHFljIqmsWSQgtI2tvaxSqLURbXBfJMobQhLwxN1w4BQxhN7VqssnK9INWiauP+gIooLfcwOyzcyOeklAal8Z3DR/kMI5EQHLHrCG2L8o4qsxifUdhtQltz88YrVFWBzTOapqFbLcUX6kUuXmQZzjmWq5ambQguMD8WFv/F51/gU5/6FI8/8SAf/ND3471nMTskxkiWZezubqOznNIVrJqalW+IbSDPczJlsEpTFBWZEQ/lsl4xbxt2d/YZb02JMVLXNc4FdPLWZpmhqvLh2s8K6bmczWas6iU6OIxydEqJ1DkrGW1tM42pzzTTTEvLc199ltCssCGQ24KgcrrGQ7ToDWnoLc+PtHAS1Bp0re/xAZ3ubf0zIvTgPARcjBRFnkBk70UPQw6wUhqFVMmcBoNKECe+c4MMun/dE5YJxXphLoWlOefAB7lPD8nbab/UBksUlawBECD0yzJm8MAHJW984JbiOmhKo1FGoZU/M4yoB9PhthAqbLDTt8ruB9n3GfLg03+G5As+EfKWFh83Q4dOhOMNzKy+I8PHbbhtFdfhciExvZu//7Ss2JwKaOqPzQD09NoffSa4TvfZ0+m+J7C9vMDahg2E1APN8PmdfJ8+2UROB0jpNB8ZY9aVI/Ek+Byav1RI/u6NzvXhuXA2Mzn0nRp7NmPK5s/fYf49bzH5M0uanTOX59v59q1aSEiry5uMUL/q3j8QAhK6oqMZ5H2EQO+km062qKox8+MFBwcHPPjE48zrJVo1ZCHygR/4EL/0z/45X3/+Bca2QGU52ma0dYvxjrIsMYmR6HxLrgyD7Cl5iYIS3Hni4XiqjFynwB5OlUKfvsH0wRttegj2D+CQjkDr4hDyo2JEZ1qG2SRpNUkiGJzH41DRy8ARJbFzWa8o0r7nhRTcZ1lGHAe2t7dZLpeUZcloJP2V1lqW9Wo9VCQvamEzlFJ0dYOyhq3RmMcfepDPferT/D/+r/83/tW/9tf5ru//Ph5+69OML+yhp1N08FJ1YdbJeMrYYYDLyxGPPv4Wfue3f5OjwxkPPHA/09GYV2LgheefY+8+kf1pkx7wrhOAkia6PM+JXgC/yJPX7IlWwrSGKCCQoNJCCYNPVsCZH1JIe6ZBSuBP+oE1OlWgSJCQgJ2AComRiWmhRK0rAjwKlRmObyyYz5dSsZIXAmA7CXiJQQ19oDYvxDMaBVTGKGBX+YCLDp0Y0xAcKnhpsHGBna0JF/Z3yTNDV6+wMZKbDGs15JrgW5quJYSINhkYQ8DgfEsXooA3bTEaTJZkxDoxxE5CfIosoypLqkK8t5uVLmqDCZIFkZiGTQNhU/omA9rm8N1f8JEoTF1/ncRIiI6mCUO/rFXIQkr0aKWwGjSWaA10AY3CGHWi1kTqh9JwHiGYINeK97hWqnmMMcwOj/jEJz7BdDrl/e9/v/hFg8hdi9yS5VbYOgJFVWJKK17n+UIqZ7qA15rciFKhyHNCgKZ1rNoO2znG4zFZUQ4S3s47VNdighkWJfI8x3tP3baE4HC+JYYcm5dDD6rJLHk5ol6uMCgMkdC2NKslvmsE1CXlRNQmDexmfczPWLDVCQyoNMALY9VrnRk85AaFTwA0xEhdN2ityK1Ox16gbM+VuuBQ0SAZwxGUdKKmnp/U4xvRUUntE/2fWup2YWNxCAzy3qLSWCRtWyegilZD8FSIMV0vayDbA9zbsZibg3zUKb056n6F8XUtjL9Z5MBdmcv4Gp7Bp57Hb8Qz/U7s5e18q3JvUWcvqMc14LxTuNFZYP0sZviW6yE989eVOuE10cBnMc+3swedb+fbObg83863N4mdPvsBFG5d5d2skkiPA2LkwoULbO3ucDRb8NKL1/iOXlqqFcV4zKNPvIUf+tEf4RO/8ZvsT6dc2d1nxJSaOW3nyBDvVUwl9f2g2zMuBrXRYbm5yqlOSF03Q302/39YYR/YxpBW3BmCkTaHnqZL4R5VP9Qnj2l/PIwhpoCX3nvZ1B01NYumphhP0VqLb7IsIQjzqfLA9mTKznRr7b3U4pv0Xoa+8WjEztYWeZ5TlRWZMnjf4n1HWY64sL3Lj/zQD/PHn/4MH/vor/M//uzP8r//9/99/s2/9e9Q3zhAFxkaSSiNyQ/aHxOsYTQa8dBDD/GLv3CTF154gaeefpzxZCS+soNDrl97iWpnFzOZyITSJ+FGAdM2ywh4lFZDBYN0NUbQcah/CSGtPMc4DAxG60GaJyNsz5zEoZdQ9bJo1afUrpOL+z/7pGEfPcFLgIocSwmNOTw+5vD4iC5VXeR5QeclZbbMM2ICX0YbisTsuhRMpGy2Zvq8DNwhekk/9gGjFaPRmIu7e+xsbWO9x7cdeWaxmYQfxRDpfKDtHFErMiNBL6u24XAxY7ZaUnctrXdoZTAqBSchA330Mh1myWtbjqrhHBdGJa259NLXKIAZ9MA29VPmybNbDzhnSAVWoLQdrmXvIyF4tO57RDmRKmmtJXb+RDBTnkvC7uC3NRmua/BeWNLes9y2LXVd06xqsizjK1/5Ci+//DLvfe97ecc7nuH4+JjFagUhDB2mffJsXhZYpVEhEooieX371GRJgzXWUlQalQV8TCBIJ/Y+hKGrtHUOHQIBKI3BZBkFMHIOTWA1O8Z7T5budX1IWVVVzOsGa0UCjA+sFgvxneZl6vmUOpZwWgarwsAQqc0hXd2a0qqG68OcvF9HWdjSxiTbgISqtc7jfSf3pBAoyxKlZLFL6Zj6iQMxKCKeTGcb119a6CFIAFg4xXSFuE4b7hmyVDHUX8shChRMwnVhxDefLyqc5Os2gJioY8SfLAqaIFRafO3PtHvxrt4t0OfVVJn8SQDcu+3XCd/1GXLe/rlKvDvkuqdu1VPH/XbA8tQ+RLXxFzExpG8kU3W73tjz7Xw7B5fn2/n2Zjx87kG6fKLgGAFjw3cbYQhjCOzs77G3v08IcO3aNeq6Znd7h/nsiKSH4t/4Gz/B81/9Kp/78pepnsq5ON1iog2Lo2Na1w0yrNxmUl2wkVapOJkKu/k+dPrqY+tV7FdAGZiU/n30kiEXRHblN5yfm2mZVZGRZRmZsZgELsUTKqDJWpFgLmYzlssl9UoSM0N04ALz+VxCgpL/0DlHVze0bSsezKrCZskP1nW0K/GwWW2YjidsjcYyvIWIdtJz6LuW1itoW+7b2eGHP/QhXrx+k2ef+wb/n//nf8F9l+/nQz/2l6Ac09W1vL8AfgAiDEP63v4+eVHw3AvPc3x8zNb2mAsX9mi7JS+/+BLT/UvsWoPOc2LwAlYJdJ0f0v6UUkMK7+ZxPp0GGELY8Gcl6Va4t4LtzY5T6XEMqXpDDwyBi8JkBgXeeZq248UXX2ZVrxiPppTjCTGAd51IBI2RzkxFqgYR6WrXtcIYG4sPMqwLg+TBdYTUZznKS67efx/b4zGZghg9xiisNZLm29TUCye+39yitaUNkdl8ySsHN7l5eIBD0aVAGq1FUj2csz7Qtp0k9ybpdu9RXQcMpRTa5CU+wWjGO1/Lt94LDPTgIcgJk6UUZatl8I9BQK+OIi1rQzf4T0MIZFnqHDVm8Kb6GFOQlhH/cgxELcybzTMObh7wta99jQcffJC3v/3t+OASYAlYu36f/QKQJA7LAkBVVeKBjn4ArTHGofu0nBS0LmC1xom+HaUURVEM12Ofcuw2QqbKskSlhYSu61C6IcuyAZTneU6Z5RSlo6oqYowsl3O8dyglrK8aukzvjYA6XbehTgOE5G3blC6qHtgny0Df2WusAFst6mZZoNOy8BOJqU82QOwYJLQq+Zg16OgHGWwPRjdrVWJilpzvkjdaJZ90ku6mIxU3FiSiPgloNGrgJE0fPNT7amNIQPS1hQfBvYHDV9O5eBKgqhOewVcDWL5VwEZzNi4/DSzvxFzyGhJzTz+Xz1INpb9TceMg9wAzbiwmv1FVLbdjTM9B5vl2Di7Pt/PtW8Ba3i3UYXMFVBg/TaYsMQjjVo1H7F3YpxoVvPjySwTnMNOLdDev0yyXFOMR5faUv/zX/ip////7X/HJZz/H2x55jAf29yknY7rVEhc8mdIDO5iIsDQgJQBJ8k0kZosQZXASOktYrRCIotpF+bWHqAeXgEjqSCEFiRGyxiQgqSlHI6mCwONdgMRUaK1SgIh4KY8ODmiaBqM05XhEmeXozFIvljJoOxmamqahS2FAMUZC2zGaTkRimpiRdlUTOic9fJ1Da0MgVW10Lb5psAVkStN2nhg6nnj4EZQ1/Nt//V/hl3/u53j66ae5/OQTZNoSVRqiiRijCV5WqnVRsHvhIlcfepjnn3+ew8NDdnanVGXJ9nSLg6NDXnzuG8QYGU8nAIllTcyE70S+2IeFmHVwiVcBl6pKBhmS2gzYSIxmYjxN73eN4VRqpFqHLGmVBqZITMyOT5JlbXIBg51n1dQcHx8zW8xZ1iu0zSnHE7QxdMEJgFKK1ge0yQSUplAbHwNd6qUM2qBNhtYK7wOhk+oNi2K7qtjb3ebSzg5WK5QXX6ZW0LqG4CKt6+hipLIVOs9Z1S3XD4+4cXDAweyYZdMynU5lf8IaoIus1ED0NL4WzkobSeZNKa7GWLQ2KXVWfq9IGU2SoAqzqzXrNNkTSoP+WtYp3CexnCk1llSjYVMgFkRIAMx3TQrpCWt/cvo3pQxaW6IXqXyICpPl5DaTztvOUdgMo0SaXK8WfO1rXyPLLe9+z7vY3dnm+PCAoqjY2poQupQEGwN5lgvY9G64bm2fvts5HIHWdwQl52leFGSjESMjDH7rOupWenVNJte3zTO6rhsCu+jW6dO2yKlSEmxd10OKrnMOdEZRFOhFTVlkBN+xWiwJzmOU9Hf2iPHW8B3h5noAsBmOciL8p2fqNwfiU9Ui2qw9gSEETL84ZoQlb+o5Wnm0slLjhBH5ehCZeXCpSzgxmzqKV1qF1E0a/HCe9MFQsign78HYbAjwimiC0il9W5hVFdb7v77yNwHmySHfbNLjkRNhQfeySPpq2cZ79V7d4ts8Y2H2xGtFbllV+FZWlNyyaLHBWp44f+Ld4fvdwgBfC0hTsr0h3rfz7Xw7B5fn2/n2p3SLMRL1hj9mw5wflcIFjyNQ5iU7exfYuXCBr33tG0QfiEdHyQMXiV2H0oa3v/vdfOhHfohf+Sc/x5e/+RxWG+7f2UETiJ1bSxHjGfuxES++yWz1sRkacL2ayqshLGNYRe3TZRPTiU6BCKnjMstEmmiMkUFRpYE/sUMhBJpVw6ptuHHjOm3bQhD57HQ8YTQaDb6zg4ND2lXNYdsRvKdpGnzbDXI6U1aoEGmWK47mM46Ojjg+PibGSJHnGKWpypIuVXy4psW3HTovmZTCyhwvV7z43Dd44NIl5vWKL339q3zqDz/B5YcfgkmBiRqlWvFBagjeC9qwlun2Fg899BD/8rc+xis3b/DoIw9ijGF7MiWEwMG162htmUynEjQ7GjHd3iLLjFRyDPI4NQCjvsvyrMFhHUSRfHgbUmYAt5E4uA7eSMA/xsF7c2JFPP28NpamW3B4fMQrr7zC8XzJeHsHbROYdI4QwOQZLnYs6xXjaS6S0GHaEoZQhnUnHZkovPN0bY3yjq1RxaX9PS7t7ZIpBEik4ar18vkAKJtRlGO8sSyXK67duMmL165xtJgT0ZjMQm4x0WBDvGUA7Vl6o0/6fPu6j83j1DOYopA8Cc7vGlrRJwArIxd4TExVv6jjHURP19R0zYqubRKYdingYx0y0y8ESK2LJjPCYk5GY4yG2DoyaymXC+rFki9/6Vlefvkl3vHMMzz11BME55M8uR2qgCScaQ0cQggS7nUqbOWE5zqz4s3MMspqjDGG5XLJfD4/MRD3Et4eYPokl40pibcoCposo2vXf9+2LdrKz6ooQNY5x2x+TOcaxlqOoVIGYh+wc3ZieExeRPESrwGlWuvA2QwDivT3xCAWAScso4CEkBZjAhkGHQKjwohPOq5Zx7XqQ6Xf6yEqCXeKAiBDSItyaqPzNCo6H/EevA6EqIjaEVUmCzM9K6ojRid2PbgzgeXdgEsfPPRqoMdJKWZ/v7k9o3bW7381oYWb1V/3ksr+7bCAfCurePv9u111x6uRxp4VKngaZG6ylpuL12/EMbubbPd8O9/OweX5dr69yQ+eM9NsUwrrIMtCn5CWxBiISuFdQOeyar2zt8vexQt86StfYTabkeeS4qm0Ztk1jHd2ITh+8C/9CDeuvcI3Pv8FnnvpBbZGFaPM4js39CMSe9vNugMxhICOMtD30qSg1QlGTPVyx8RWKqUICTjoJDFUvZRzAxj1/ZY6hQF577E9qEQSIpu2ZbFYsFqtWK1qyrJkMhkznU6ZjEZSZ9B1dE1LURTUdc3s+Jh2VVPXNYTIeDzGbG0RvUhn5/M5B8dH0rHnPaPxmNFoRJ6Jh82nIbofuDWpa7BuaeuaEAOrxYwHL1/msYce5Etf+Czvu/kBtkejtT8UkdF5kAoNbcjLEVcefJiu+7VBxlxWOfiSi9bSXr9Ou1hw3InsMa9KMqMo9vdwwRNC6ujUCQhagwobHZd9ku9GaMdmqPwJCW1iXTbB6TD8xDgkA/beTbRCG5uYs0DnAgdHM65dv8lsvgRlyIqcID0bcg4pBdriW79mKXsPo5L6DpNlhAQ2etkkQQBWVebs7eywv73DpKxYLebo9LqexOwhn5NW0DnPYr7k5s2bvHT9OserBUpbilFBXhQDW6lAElWVgEcTJKBIKYXNs+QXFaDmnBOGyxgyK0nD3vmN/ka1PrcH8OdPpUjrk8M4G9P4xqAcgiMiHlvXdcPx0DGxpREya8mTfDbPhaW0VlJMi7IktznFaIQKgUCDLSt827BcLnnuuefY39/nscceYzQacXx4hDGK6CNNvZT3XdgkQ3c0TUo3tbJ40wNCH6WaRKsMYzOMzVHWYLNMFpOMJi8LctexWq1S5Uvqus0ztE0Jxp0bVAU6yXAnkwn1qh2ArBxjT1YVFEVBVZQQPM1ygWs7UVOkdGQV7Ymc2DikVOqBEYxA7FNS+3utWSexxAQc+5/SKoUnxUAMnlwrisyQWVkM00QxP4YO3AofGnzradqarhN/qvhpnYDL5LVUKpLpDGMVWllQgaLIpf83z9DKkGtDVAabSTDWomkFrRqLT6FEQUsYUQhSXXS7BaZTKPvks+gUqH69z7fXy5KdTmK9F+A5IPk7/Pubzdzdbl9NCuWJtwHaKnKi5/a1AMuzFxWHxagTHkt16gdeb/f2vR6H8+18OweX59v59i0EmicfquvEvtvdmEMIKFNAphlNt5hMt/nC5z7NzVeuc/nJt9C88jLL5ZK9i3us5seURUFpDH/xx36cn7l+k+tff47ZckEx3hpCWjJr8NGd6M8amMski1uvqid/0IYXJigwSTYng1uSvWpDnuVoa9YMZhpY+77MfqqTColIvVxRt8JWhlTHYq3lvvvuo6oqxuORDP+bCadas1yKB3N+dMzx8THNqh5YuqIoePHFFwlEVqsVdddK315VMZlMGI3H+KahaVvmy4V4wvKMIpcak9VyQdO0WK0By7gqeeCxR/nq88/xz37pF/mbf/tvQ3BEzAm/ac90Ga2oqoorV64wqsYcHByI73JyiTYxN/vbO7Qh0jUty9UKUy/Y3t1iurNN8B6VZJg6Rf73nrVbIvNvd46FeOYQdmtcfkiYJ554H8YYOu/oWs98teTm4QEHszmg2N7apmkdGENpNJnN6HwUjyMRbYy8pzwbwHB/nEII4ovtZXvekRvNdDRiZzKmygtJp3XC2Hvv8XiMzcmLDI+idZ7D2REHx8e8cv06R8s5xuaMxiPKsbDb2lpyY4VBT8ZYQ1/9sZZqZ1mWkj03htwYUdaiEuCLPg7eS6knsHLdbgRy3XaY3aB6NuXKEUf0jug9BCehoKkLU2mFb9vhMy+yDJfYPpGOW4pcgrCstfi2E9kk4i++eXSTzjne8R3PYK3m+PiQ1WqJ8y3bkyltWw/soY+RxWJB13WpWzYbzoHTVRH9cQJNVpR0CSz2IUT9z/UscL+wpLWmTZ22cqxkcWlcVWglvbT97wnRoZViNBpRjQq0Ae9akYpHCXLSKJRZA3fpB9QbUk8tMFWvZbNBr7shSax437Cqo5fUXiJWrmpGo4xMQaY8uIamXjI/PmI+m1Gv5tx4+Zu4tmGxWDCbzaRiZbFMlSyiEInJ1661pkyBTPL5aapJRTkqmIy3GE2mVOWI0XSL8fYO1WjCzoVLoEXeGpSRayEEOZWVcKj9Z94fg9uxmCQ42bP34Q4VLvcOCN/45+RpL+KZ97X4p+uZfy8M5Rty3E4dv9Ogf51W/cYzlyfe7z1WkZxv59ubBi7PYnY2H9L9oPjtut1tZexuF/C99li+1p//dj8+r/cp8VpXJjdlNrcWON8qC10fa3XHFdLbRX/f7ncPK/UbAO6Exy4FqGiTsaxXbEXLU08/zWR3m8XK8/LLL/P2xYLJZMILL79E3XZU4zHtckWeZ9z32KN834d+gH/09/878UONIsoY2lVNNpLBFB+GpMjhvYa1HFAqRNTw/mVY1BgrKZd2I/DEJD+lMRJ8IZJOfSLEpw/4CSHQNI10LgZhuXyK75+MxlRVhckzqqrCWrv2nnnPfLFkdnjE7PiY+XzOcrkkhMBkMqGqKoqikCqFphZmwBhG2YiyLJluSYJs48TPtpjPiIAtS4wVVnSxXEpHptKUVcG4GvHAg1dpuw5jFfsX9njl2jW2rj6E1eKPXMwbYUyNkb7SzpMXJdu7e1y4dB9f/9pzrFY1xmRMJ9vM5kfoCJmC6fYWo1FJFyKu9SyOF4y3t1DapoFRozJDgQzkPvXhKa0GpgwYJMk6KoIW+Z0i4F07SJutVriUVGlO3T8GkKxU8h1qXN1w8+iYmwcHLFYN1WgioUtI+E8IivlCvJcikTVkeU7rHSEqXOvQxqXPP55gso3SLFdzSm25dOkily9cpLIG13a46NfXgzYYLcFHjsDNoyNuHB4xW7TUzrPqktfTrJOLjTHkVpNlRoKSYsC3klZrohkkxnXb0rpuOGeG62CD9e2/VxgoI32gCSyeWJQ5Ocan2gwJjPK+BTTGZHINOCcKAR3xoaOuVygCVZFhosG1cu7O5kcsl0vyPGeU55Rlic0z2Q9r0Uq6QY3WFNvbxONjZssFX/3qV7nvvvu4cOECRVHw8ssvE31ga3tC3bVkpST76pSeXKRk2KZp0FozHo+lW3XjfWWlACOlFMvViqilYibL8nT+WUwmdSOt85Ibs7EoUpYC+BaLBau6huCwnaUoKkCzXC4l4EdpmmYFwTOpxGN9dHREcB2ZUWRRQm58YFjwMkrhWd+PfVosCUS0ksUq8VAmwOc9Fo+OAWs0ZWXJjSaPAY0jC5HV8Sscz49ZHN7g+OZ1XnnpRZ7/xtd5+aWXWM0OeeXFF1OZMgOzXKSFiuEYunUY0qqVAKPVakXTNLShlX5fRAVQjidsbe9w/+Ur7F26j71Ll9ne3+f+yw+ye/ES091dJuMJ0Ria6OlihlOa1WpFUDCajAkBVnUtQVdpUcf5iPMepQyZtRLo4txGd8mrn9X6BQJ1B/b0tuBjQ4K9ufULEjGloGtz57HhduPPWWFBA029+bwemPLbgdkzam02ZtJw2sMez/ZKRh/OnHp6e8fd5hl1xn16c19Op8ZKq1G845x4J5Z43dV7ZlDQxveFs88NzgN9zomU1zer2zdz5/40mJHf7IvnT/vFeXfw/Ma8/pt1rrzWJLzXcp736Z+bHsaQwnMCUTrQTEY1HrOzu09RWZ5/6UWIkS5JXYUR6kQeFhUoTVGVTKdTOhdwwZPrSJ5qITQGfFjLJ/sdS+xCz1L03r01iNSg9RDMozfkrjqtpEcfTsjr+tCb/v164skEybxgnFmysqAajSnLki74wYfZti1N07BarSRQZjbj+OAQrRTT6ZSiEBmd1loGOu+odIWyMvTZ5Knrgse1sm+1a8nyjLIohkCgZdtIdYU1lEVFVVXsXbqPPLeMx2OckwTLy5fvA++YzZaoqJhMp8LCNg2ZNuSZBgy7u7tcuXKFP/jd3+bG9QP8o4HxqGK1XEKoKfKMyXiM6TLqZp3mq002EDA+SllCP6hLafoaDPbMyDA8pcUBl4YaQx9ksw7v6X2ZZxWehz78yDuO5zPmiwVd6pHMDEMNhvfS/OgCmBggChj2xBQKowcPXw8oNwNSXFszygq2tybs7OwwGo2wKHysCT7gElsWgdp3rA6PWLY1i3pF3XbMVrXUNdgMk96Pcw6DJBGTgIRCYZTGFoX0arYdbSsJpW3bDlLOrCjBh0E6fLqg3Hk3DGVaW5QxKL9Z8aJOsNfWapEcx95jtw5L6lNPF7MZq/kCoqfMbQqBSdeYChshRAzXioAXS0ShraGtVxLkk9Jcr1+/Tucdjz38CJPJZOjHXNQ1Nw5uUhXS/Zrn+XB9xhgH4KiUYrlcoq1Zy8WLXD6fpFZoO0/TdfjIkACbZdkaGKRjtzkI2+S5ttbSAs5JaJFVIu0fjUZpoUuOkaTjylf0juA6onfyuQawWZEYOKnV0eiBi8u0witPZsQLjRdZriZirCLXGuMD4zzHKkXoVsS6oV4tOHj5RW6+/DzXnn+OGy8+zze/8iwvPf8NmuNjijzj0sV9Lu3t857vfQ9lXjCdTtne3mYyGg8LYSEEsn5Rwq8lv8452lXNsqlxylM3DUezOYeHxxwczTg8PuIrn/wEn5jNaXxgd/8Cly5f5eLlB3jg6kM89uRbeOSxx9m5+ABZZVm0HRe3x0TgxsEByhi2xhPmyxqvJadbZxllXuBCpK5rrMkZjSua1fJMhPbtMHe8UdLNs3yKtwQUoV7zez4N0s7yQao36dhuvpfN9yfW8Df+Q7wbYP3TNLufb3/Gmcs/y8DqfPsWnAPxzje02yXO3a2X6073xjfy5hmTb1FtZOon2z0x6hRnL0AxKImnHE+nXL56hfF0whe/+MWBabTaSN+dcuRGLs3V0RFf/fLXAE2V5KAuRfp3dZ2kfQzSWN0Px33YQ6pBGZhH03snE8jsqxQSyBzK5vsV6ZT62ncbxr7APA2wmU7SxTwny3NsnmHyjCy3oOIQBrKsV6xWK5bLpVSS1DWu7RiPx8LoVBVlWQ7gxbfdwEyGELBZRjWR2pG6bei6DtcFbFlRlKUwbV3N4rhmsVxhjaEoK7a2t9nd3WVrd4951+Dahrpe8vTTT8q5OZ2QrVas6pqjrsEqOc7GGGazGdNxwWRrh6sPPcKvffjXeOWVGyzmS6pCZHHBezJTSQF9lxNZCmhQBowdpHsRnUJBDMZmqT4DfC+9iwJatM5PBsD0gT4pFTb2/5/YTt85TCbDVdwIvYkJzB/NFxweHjNbroTdzXNhPRUYmxOVSDpDVIQg0mjp4xN2VOveV7zBBEbhWY1S+M4z3hlzaf8Cu7u7Iof1Uk/ig8crTesDjetYdQ3H8yXHywVN1xIiIsvVyTtpc4oiSwA10iwWa18lPZMpqarG9AskilXtWCzmtG3DdDyWczZJYTOdoTTrihIfT4DN2CVJq4oYrVOHJgTfQYy4rkkLLhZr9FBtEb0nhpbZ7Jij4wO6umFUVhhTDMyEVQrXuYH12GT/tbbpT4O1mq5nMZKP+ZVXXmE8HnPlyhWqqiIEx3hrStSK1WrBsl4RiIxCIMu8SM6tQuvsRDptZS301UVlSVFItU8IAWUdTeel3qiuB9DZ9/oVNhs8vj4xq8raoXqo905HL0FQ43FaUOo6XCvvOzMZeQJGbdvStjURL72vUeStEZW86SLDM0oTtfiJQ+fQKmCjgthRGMgMxOikamh7QmxWzI6OuP7S87z03Nd57itf4Btf+AIvf/OrXH/xeS7tTHjwgfv44HvexuX9C+ztbLG3u832ZIqKYgPoAXOW1Bq9t7TKi+QpjgOL6L2nTXL8VehQRu7bddvIoqDRzOY1Nw+PuXF4xPWDA7763Df55Mc/wu80DfsXL/Hwo49x4fJDPPmu93PxysNcvnKF6e4ul7fHLJsW167Yn45oOofDCIsbHLnNKfMpbeeZzWYUmb0NO/Xa2Ibb1W7cCex9K+aHTebyxD5uBDzdzsd4J9/j0Kfar5TfxZbwatJ2X4sK69QC15sKMGOMaPPmvKfz7Xyzb9SJer6db28kC3ivAPPVgE/piPpWmAhSZL5KzInpKz5SKEVZceXqQ0wnWzz77LMCEhNYadsWYyqssdB0fONrX+dTn/oUW1tbTCYT2rbFdx0mCMhruhaNwqq1L6qXv64ZGn2CneSUzHWTrQkboUBBCSPSs5W938dqMzCgfZrkEGphDD5GmlUtfX1Ki59pMWeVOi57hmU8HrO7vYNV6/7B4D2dc5BDYc36YWs0gUjbNnTOoY3BFjn7Fy7holSerJpOwEpmGI8m7Gxvs7O1zWRrivcygH/jpZe4fv063/PBD1JNxsRrL6NDZFTlNE03+O9AhuUYPEVRcvnyFba3JxwdzVguaxblChPNkEJaZDkog1o2ye4qwTgAUfdtdTp53sIwuERlCKFbA3d9strAbPgzTw8Awnau/05YSA9KQmxWbcPxbMaiXuG8JysKlMkAh/NCxZk0TDsXbvF/bp4//bmhnKRbGqVksLWSnDsZj8m0kc88RhyKJsif87pmUdc03rFynpUPrFon3X/aCEtcCGgpMosiUC9qukb8u7k15EZAd5vOuTIvGI1LmlWNMYq2lXqVyWgsHY1KzuGu6wZwmGUZWZbeC1HY8bYWj6QRVjGGQIwCzHr2DpAhzMiKje/qQRZ54+Yr4AO5zZiMSso8IwZP6BxdjLhURdJ/hlmWnZDSKaUITmStymgwipuHB8znc+6/7wGKUUVISbA7u/ts7+6wWCw4vHnAYjGTgKm8ENZtMiF4WCwWiXUVqWzc6Fr1IaBikAqVMkc3Uk3TpGPdf+a9rzCkcySkYCBRSwjQL7OCRi9xrpX9KEvKMk/ntixQhAjWaooyo62XNHWNjpEis3RD0UZIabxgtAAjrVOATmawOqB8R9euMHiqUTH06x499yWe/9pX+PxnP8MXP/dZvvHlL9Atjnno/vt4/9uf5KEf/AA7k5KLuztsj0tyY9AEjNJk2tB1nug7wqqlCZ42pcKaVOqzmM+IMUhKrBK2tXPtEHhly1yuKy3XQwSKouJCNeHK7g5eaXwM1M4zW6y4dv0Vvvz1b/Clr3yZz37iD/joh/8FDz/1Nh5+5DGeeOvbeO/738/FBx7geNmwPLqJLgpykxNtho+azrW0oUUpQ5HlIlM/U7oaX1OVyJ2A5b36Dk9WisS7/PsbxFzewz6f9d+vpSvydimx345EzGt93XOgeb59WzOX59v59loB5WYZ870xlfFu/63WADPGN1r6MbB5nJQCiYeOgeVqXUduNfc/cJmt3R2e//qXePnll7j6lrcA4JoWXVagLK5dcHTzgFdeepm3fMc7KbKcV15+mVJDlUlKYXCdSF51SndV617F/jhKev6tq7ohRlQqce8lX3Gj2Dwm1rIHknlKkDVmnXZqjQxjgxfTezovQ33nHcu6oWkami6Vtxfip5xMJiJBy3o/m0/1DLKr/YBkrcXmUmVweHTEol5RVCUX9neZbu8ymWxxeHxEM5vLsa1KtvNtdqdbbE2mZNZKTQKR6fYeKgGv577+DWLdoPZ2yQOERmRuRTmCGKiXDaPtKX65wJZjLl28n6tXH+Lay6/QdZ6udRilCD6dq1ENoEX4l1RdwVqqHKOcH1pbjAJPl8DduuJBOS+DthawE/rPRoXheth88PeMnHOOtm1xoUte2I5FvWI+X9I5L/LP5LH1TlIrXYjYPEd7UKpbX3eDN1cWCrTWmPQ7+vOkKDLKPGNclEzGI3SE1Wol/aYKOt+xch3L1Yp5vWLVdrgAdYAmKLzKQUFuFZPRmFGZ4ztHvVoQu5ZMa0ZJ0j0ZVeR5Sdu2LOsV9WoBKjAylbDeo5K2rrl+/RqZ1ezv71PYAm01wfUS2TXI7KWe3ovDT87bkN6f2wh3Eg+wMJHSX9k0DYvFavAWhq5lMpmwPd2iKjLpr0xMX/DdMLzmNhNWPyvkM0vXVgyeuusYVyMJLAqBF154Ae899913XwK4SrynuVzzZfIwc10xO7jJcQoN2traosozumZF4z1FlqUFCiM+Ub1+31mWkeU5Wsn+LRYLFosFOiKJtklea7RGZxI645yjrYXdN6jhOu6DfLquI+RFSmuWILDQyKJOVVUcz5asVoshaEr5CCbVHdGnn3q0UugQ0crj6hUhOAod2BsX7IwmuK7m+a9+gee/9hU+8fGP8vUvfI4Xn/8meztTvvstj/P4Iw/ywIU9dqcjykyTGyiMQUcITYPrWprBf9v7hzORHvchOSGioqQAE31SoXja1tG2NTpK8jNtR4iRLMuoes9wWuTRfQeyMWwXBZf3dnjiwcu86+knuXHwnRzOV3zq81/idz7xST7zL3+DvUv38fEPP837v/+DvP/7foArVx9k5TVHy5pVs8LkFVZn4kKNAZuVhOiA1w6Ubgcw78Qg3um5+WpZz/gnNHPcKwt7GsCe9ka+3hnidvUvim9N5ec5a3m+/akCl+cn6vn2egDmvYQgnWX4v9NDMb4KYPuqQOUAXm/9+zhgY01UBq0CbefJjeX+Kw9w8b5LPPelz/LlL3+Zq299K0We41cNVrQqaAxbky1c23H92ivsP/yQeC8XM1arBWVRkOU5RmuJ2NdaovrPMPr3qa8JQqa0RmEKh1qTnl/r5bMblQ06dVyqDXa0l4ipECS6v5NeRxc8jetwwVO3HdqaQf5alCOqJIHN85y2EQaoaZqBBczzHDtaD+CrWlipVdsw3d7ivgcus7e3hzU5h8czVsuGrvXkeUk1LZlUJVVZkmmL67rBT9auai7u7fPWp57mwx/9KGSGD/75v8D9V6+S7+2hj45pmxWjyQSnPe1iBS5gRhm7u7s88MBVPvn7v8vR0REX9nZpnKR1BiJN19E5j3cBlUnnHX5df9FX1ahUBD/0DSp1wsc4hDClz7OXuvbBE3qj81JK4/3gZe26jtY11HXNfFWzqmvqzhEBo1OJexSPn/YnKzVO1uesU1hb163PoxCHFOCiKBhXJftb0r3aNI0sDhjx9Tado246Do6PCak8vomeunM0PqJMJoxWkl465wiuJdeK0WTKZFwxKnOKTBjuoihYrJbcODjieD6j6zqOXcv2dIuyLHFty9HxwQAWd6Y7VFU1dCw659JxjScCPQRoJnAfHdDX2QjgAAZPZ98DWde1SIi15sLuHtvTLSbjihgCq1r+XXou2QAvJskuLWg9pOxqrdFIVQWhZnU85/j4mO3tbbb3dulWS5QyWCshO30a7Nb2tqgFFBwfHkpyb+qSletoKUxv25Lrgjw3BK1QG35pmxYOiqIYQKdv11L0PmTIWktM4NI1LWHj/eQJ8ErtkPhGy7JMP6MoVcZ0XLE1HvHNG3OaVU0MDq0iMXqCCpL1GqQTlBAxKhJiwKrAxCqmZcW0zIjtkhef/Qx/+Hu/zW9//Df56uc+TX1wjbc98Sj/+g9+H48++CDb0zGjXIJ9LJ5cbnJ0dU1IvvayKBinrl2XAs+GxbF0rkTnU2CWFsuDSnJdo4gpyCrLS8bjMXXX4huH1yEx0yqtEwjADApiZ3BNjSdiFDywu8WD91/irY8/wg9+4Hv45Gc/xy9/5KP8+i/8Cl/49B/ylWc/z1vf/V6++899P3v7l9Blxc1ZzaptqYqSqCyL5YKsLO/aIflmAJFbAm9upzi6HfP3Kp+xtwveO4vFfLUz6Z1Ccb5VvZzfKpB314DK85TY8+3bBVy+3tWy8+3P9nZX8HYPabxvgudSxTeIthSmT233j+AAAQAASURBVGE236taM1XBRZRZ1wB43wFS0fHAAw/w6Tzns5/9LB/80b8kheStk/C/LqBNxtUrV3jHM+/km89+ke0s58H7LhIbS1DJG7XZOwmEIMyTYu0tEy+lGgbv2Hcrps4+lfZfa71Ohu1BpVYnAoF6yewatKfORToJgQkSXtQPz6PRiGosgNJYi7X5EDLUdR0upcf6KAE9faiPvJfA8fExi8WC1jt29na5evUqk/09CIHlYsXBzaMhoKesckZlRW5EWokLQ71C9HA8m6GKgrc//XY+98Uv8tsf/y1+53d/l+/9wPfxE3/z32b7/svMrl+nrWuszbBZJn1yLrC1tc1DDz7Cxz/yEV54/iUef/QxtDKDJ61tJfXUe48OgbbraOqWvCjEuJh8uGtWTKOUIUaRGVprE3uZkgR7z2tU6/7JntZNASgxRtq6Zrlc0na1MJjeU6e/a9oWneWoFKjjnEOZVDehIm3rNrrpDCFIsE04dV8X4BUlGTfLGBUlk9GY8aikzHKaeslytaT1AmSDEi/lyrUs245oBJzULtAFhc6Lgb3VVhj9GGFcVuxtTdnd2mKSZSgCZV5gMjkny1IYsJvHFTcObsqCw2pFUWTCwLYty+Wcl18OtKuaCxcuMBlN0VpkyyGEJPH2aJXkxgRC8EOg0uA9jh7nO46OBbjVtUhh61qO83g0YTKZsLu7jU1y2h6UtW2LiQI0bFISqE0JeroWJSEVdJFBlD7Ro6MjijJj9+IFJpMJy+CHewzK4kNDUCK9HCuFUfdLxUnbDfefsizxXgKd+s8yhAB63Vvbh/YYLddjD0oXnWO5XBITUJVQL2GxO6Xp+poepdFJqt6/Xr/IkWUZxsr5WRYlVVUxGo1OqhMkoYegOrqoCSFVuSCpsYU1FEqzU2bQLHju2Wf5o9/+OL/xq7/Elz/zKQoDD17a58//+b/MI1fu4/Kl+4jB0SwXKBfJ8pzMaqySc9aOiuFc91F6h5u6Zrq9RVByzQXvQRmM1SgDNnlKfSf3ZGUMpc6wRqS/WZahtaGwOasm0KwaootMp1PGo3U9TGYUWVGA0bRdJ0FAbYtvakbjMZe3S6588Hv44T//ffz+Jz/N/++n/3t++u/+NE++47f4zGc+xQd/6Ed59/v+HJNCLAY+OMpqwnhU4nx/B+aeAN/t5rdbU0RvXbx9Na97LzPhvVSh3BJ4cxpg9mFoqNsAtXgXplLdtsdSoTZqcU7te9ov/wbOSSdmmjcZvK7fa7ilfuR8O9++bZjLP80A882uCvmzX0Xy5rCX6/Pq3o/dydcI9B7HU08FbktlvtZzP630nfAuClGFdx0KjUX8cT5EqXrY2Wdn7wJaWb7yla9C00i4QPR0zYrYOTKbM9nf40f/yl/mf/iv/xs+8+VnqZsVl6YTHrjvIqvjuTAoZx0TpTEppbVnvMKJQxAHALcOGRFQOcheTfKnKSBEQnoQhY0HlPOdDMup/1ICSkSCiTXkecFoMiZPNQkxKkmZTXH+ITh0hLKSUJx+CD0+lt7Lg+MjjDFcvO8Sly7fTzWd4ppGQOeqZuVasjxnOpmwPRmTJalwaDspOc9zmqZhPj/E5AXHN29QFRn/zr/xE/zaxz7C7/3hH/HP/+n/yv7uHj/8Yz+GSR5RW+RMs23UZERYzCnHI64+9CCmyLl+8yaBSFVVHB1Lqm7XdXjnxbPnA67raFc1eVaIPE4Jq3v6xJOqF4WONgFGRwwQnSdYDd7jUcToJYHUe9BmGJSbZsVitcQ5Jx45pfEk5kRpilw8d60LOBfQOmB0IWds7MQXpzQhOqICl7pQQ9Jl6XSO+BBQGrKsFM9bVVEUOV0QqXfdOqmiUdD5wLJtqDsnVSwhUre1pLna9eKBb2pi0zAaVexOJ+xOJ2yNx4xy6SaMPmCMhOK0MWDzjO3phKzMCM5TLxfM58doLdU05WgkDObREV0n0k+lDGUuvzPTuSxoOAcqyEIKmxU8Cms1zrXMFzOWs7nUZ2xIZU0Cb3s7U/Z398h0Rl3XNLEdgKkmpTqrHFv0FR8pMdb0qoAke3YdJsvwTYMxiqP5EZPJhP2LF7BWk5cFzUoAbVEUQ/CMVZo2wHR7B6UM9WIp4UZtCiCyFhUCWbq2u+AxnrR4ZFAh4l0kKwVs2jyjKAqOOWa5FNZzMpkIUxrjECS1eY/pF5D6+0XcGPRNqm/pAXuWi/w7RCepv9pgtQOt5ZpRAVSkUDDKNdPcMLHw4lee5bd+7Vf5lZ/7X/nKZz/PyMAzTzzM+7/rvbzzrU+wV1kMHqM8eZFhqz3pPTUKrZE0ba2IPlC3Dd5HssxiSgntqlNXaKYNVml8VMKixzB4bl1akMuyjNzYodYGoK5rRqMJemxoupZ6uRLQicLHwHhSpYCjRtheBVVmBy97t5zTdA5lM4rJhO99zzt4xzP/Gb/80Y/x0z/7j/lf/sHf4zN//Mf80F/+K/zAv/LDPHT5IWarhkU9I8srQjQiwU/Pm6Du/NzUw+0nPTUGj7n6ljzjbwE76Y6oXgdzufk4V3fr17xH0KVuA9g3N/8GzEZ3yJiI/UL4m8dA334MkuXpc/byfHvtm/k7f+fvnHny3atp+Y0yN/9Jgay7ySXOim6+lzjns47lWV9/2sGjBI+89i+i3MhVekL0rkXF2otzp1XVqEK6CcbU2bT+kwFERRRRHqSpU0DBTyniT0XUT55+uNxpBffWm3AawtWGS0KJjEql/rtRVUIUNsq7llFVojrP4c2bfPoTn+DFbz7Pj//oX2K0vUXsWrRWGKsJeFZdy97VB3jiySdZtTW/9Vsfp2lqdre2yKxUNXjn6FLqKAiIEV/OepdCCIOnqz8GeCkfN0oJwElhGqjEbCIDX0jHU2mRenWt+JZ89PgAylryoqQoROqaFwVlVVGORoxGY7QRr1/UilW94nh+TNu15EVOnleMJxPG0yl5UdI6x+HxMa/cvMnh8TGmzLh89QpXHnmEbDpheXzMS9dfYb6c4zRs33eRyd4u0+0tbJ6SMl2HiqkPsms5Pj6iaWrmxzMWizllnjMuSu6/eIGnnnySF7/5TV584QXe9773MZpukRU5LkR0ZghepJ56JLH/8+Mj/vhTf8Qzb30b0+mE4+MbRByTyQjnHU3rpM7Bg/eBIssx1qKsTZLEiNHgo6dpV7Rtl3ojrXxuXlhNrQ0KTWYyvIv4zuN9IPiIcx7vPM47ls2Kajxma2ebgOaVgwNuHBziI4wmEzCZlLdH8MlHqU2WUo41ddtCkjv7EPHRD1U6ITpZiQgdikCRZUzHI0ajEq0UnXPcPDyg7jocitZHFl3HsvW0PuKCwkVo2o4YobQZRZZJN6R35Hju355w5cI+D1y6xO5kSplZsj6h2DmMNYQo7KKwFAG8JzeG6XjC4cEBTduAilSjkiLLiEQ651guFyxXK5zrMFZTlCWmLMjyDGP0IEm2hSWzRoJpFkvmx8fcuH6dG69cRytYLI5ZzecYFdjdmnJhd4fpqCTT0gEaO/HOKiKrxZy6Xkr9xqhAWY3NckyeYbKc2EsFU1Jsz1KbzHB4cMDx0RGTccXe7g5aaRbzOTazjEciK8cHXOcIPhCjwmY5RVlSjEYoo/GJedYGTGaIBFz0CZQa6qZlVa9QSnps87JEW4sPgdVKGGjx+Cq8c4xGI2Eoo7DxbZK7B+8J0bNolqCEoQxtR3CBIiswKKwVn+eybfjK88/zha9+nSff/k4ee/LtYAtsUeFaTztfsFNm3DcZMdGO/QwOvvYs//x//G/5z/6j/5BPfPTXCbPrvOepB/mrP/Qh/uKHvo+3PvYQ09wwLjOqIqcqS6rEkmZZBilIR6FxQeCLtuIzVSmgyjkn9gClMKh0fxZ5rtGa3GboPigtVauE5ElWKVnbeU/TNXRtIxluCrrg5DrPLW3bDiN6L3evypIi7cd0awsfAsvVgnq5outacmt46vHH+Ss//qPYGPjUH/0Bv/mRf8HRjZtc2t3hgUv7jHJLvZjjUQS0dF9qRfAeq+WcW3cwi8VBqyTBjpIKraIagsNIadCqfwIrtQE61ZDkOzQgqp5FFDu4Hl5/zS72IPfks1XugSEGed4r4RzVxhygTj1X1zPBrX2QuvcFbyyQnl6cHoLqhmezGmwKMSUW9zMHp9b/Nme1zWC1E2BWq+F1FSe/d+jsVerE+zJa7j+bX+v3u1ZYSa2wGo6DjDEbVhydlrY331+/X0qlNNj0TNf9ynK/+CAydLXBWsq50C/Ax5PH/pbPRL3u+fZPO/nyp39Td/2K8ezv6+um3lTm8nw73749r5sgqa1nLhr0PJ55Xb+if/V4h3/3PvnJjMXojLbzFFnOg4+8hWo05eZLL/LSS9fYfuB+CpsRVCDiJUylzGmjY+/K/fzVv/ETXNje4uO//Cv84R99kve9613k2hBUOHGz7sNIUBEXIyZVWSglqbL9AyKqNftwFrmrIolVk4czPgyrmb3/sshE7iXMj/T3qVz+jEYesE3X4VYrWu8kYTEly2ZFgTWpwkQb5qslRzcPmC0XoBXbF/a4evUB6TJsalaHBxzOjmnblqzIyUcjtnd2UDYj1wrlAtF3IlcKLcEFjo4OWS4WAqQVIo9sOpbhiLapKYxmZzKlU4rlfMHowiXa1Yq8KGm6dihWd/WKRx57lK3dPZ5/4Ro3D4+4/7LUb9y4cQ1rDNOyom5uQoz4xCB514HLIDMSEOI7OiUBMUol/6Ox6yEk+fxUFL9lTB7ULMuk39P5tbRWKcaTLUxuaDvP4XxG3bTYoiAqQ9068lKApDIWFZ0sBjhHSGnCTeeISmOMIlo9RO/7lGBrSJ5Bpclyg1Iit+yadl15ESJNJwsNHpFvRgI+9sO7xaSqDxUCRWYYT0ZMq5L7JhMmZUGe2cQQ+sHXa7NsCDraPDczY1G5nNf7u3vcnB1RL5aoEAcJZtfJzx0dHSUP6pKdxZy97T3Kshxqd+pmyXIhDGhd13S1eIC969AaZom5zDPDeDSiKgq5noIneodFhnqDdGh2XTNIbAdvrAqAEYYmefDAgAKrjfgN02dqMy21IsbgokNnZrh25TVFTixKAQdawnpMnqGsoatXEKUvUiW1gt6ou+mPYS/lNm2LzTPxGoYwsKO+cyzqlaTClqX4uwthfuu6Fml9372qAoUuiKUDp1BBvNg2AaqyLNnd2ybPLKvFjLZeUJVbuGbJdlUyVhUmOGwzpz66wS9/5Ff5+X/0D/nj3/s8D9+nedu7HuW73vkdPPnYY2yPRxJC1NVoDZZK7lchEvWpYLKgiOZkxNppxqsPPVLJgjy8FhEX1oxZ39Xbpzr3z5FeGaKMxmqFTz50nwb+HsgOadAbn0MgcnR0hMky9nf3qNuG5WrF0WrJeLpFNdnmb/0bf43HH36Yf/Yr/4KP//I/5/Day/y1n/ibfOd3v4/dcsQMw9FqRdvVjMZTdG6ZL1aEpmE8HtO2rVzPICFJqdJojWBkgXedZn7vi81RgQ6cGXKzBgXx9iojAjqaPzFAEQD7OhnbMCxinz0I3KuH84xjoM5a7D4J1E+C3PPmhvPt22k7B5fn25+K7TRbfKcb6b1UmnzLpAFD1YN0VyqjqeuaIst5/PHHufLgVb7w6T/ii1/8Ik995zuw1kq/o5che7WqyaxFNx2j7W0+9EM/xF5e8Ilf/xgvvPACj195CJUGH9LqZUh1Az75MkNaOTXGSKCE1gIaT0mBNoefTQ/IkCybAGkvI9SpI7MHl33Ah8pTgmnyHHVBgkg8kaKS8vesLFK4xoi67bhxeMTB0SFt3ZCXBXt7O2xvb5ONRjTLBYcHh8znc1wUNmVre1tYxslEUlljgNihUbSdo14scU3LbDaTLkhjRCKK1L2smpqgFXlVUVQV7Wol50YK+LDWUtc1VSnBH/OjhsneNk8+8TTjasQf//GneOtTb2E62eb4+FDkxU4K37e2tnAhcOPomHyWoVSktIqIx7Udvl/YGMCkThZLPaTwElKVRpK7aq1pvYAvbTR5XoI12NwyXy05PDpiPp8PSZw+mYXEa6eHpFSXPovYMzHB4Rz4tMjS9w1KtZ8wDLJwkGGsxQVoVw1ho6qjblu6TvxqOstQqYJFp/cY039bbRgXBZPJiL2dLXZGJZPMUqaB3HXtAJytMbCRYqx6piUKQ1JYqfR49OGH0c9/kxeff4HZ0bGcP3mO1hZrDMHIYL9YLHDOMZ8tKYoiheEofNcyn81YLlPiaepjVUTKUo57VY3Zmo5TeFAx9Dt2nacqKrSWY9e1NW2zSp+ByDJj3PRiBxQGqzbEgFqjfMS1LcF5yiynKAq0UeClskeFKHUpWskigMQ/o4MAF20NmRWQhJfPRaXgIuONhBnFAMEP96QeLAXnaFPSq/eeqpIEXmHROhaLhdSRpGvCWjv00KqgQUdUjGgroNghnaatj8TMkI/G4LxITruG5fERoW0YZxlWRdxyQak8Ojo+94lP8rM//d/ysQ//Gpcmmh/50DO8/fFHeOj+Szx05X4mRYEKHqOSRNhYuq47wRSdJZs8DeqGqqUgqo0B7A1M38meWXnt9c/1wWP9ceyPqbUW5xxN06xZpHTv72W0LsnI1/VQGTpqDIbSFFAoXPDQeer5nK285IPf8z1cvfogv/Dhj/Cbv/MH/Of/7/8Xf/Vf/9/x43/9b1BNCrpMobMc7xuapmVUjTA253A2oxpN1u87xMENr5DFgQiDr1Apxav1i5wGlpyyh9wKpvQAy9QGOrpTqM6dnvG367a80/t5M2aA4TXjrXUpcGu90906OG8HuPuFqx5cDs+S1wjK7378zrfz7Rxcnm//WyQn7xL4c7sQAvl7/YZ4L8Wllv771P14/SAww4OhaVqarqXY2eXJp9/GR3/1l/ncs1/gx5YNaINzK5SRSoCqLAidVCZQ19x8+WWuXbuGc479S5fOfFD0D+2zOkGHIayX8fQdk6cA5poBODlEiHx2A1xai0pJsn24TbeSQbWLgaZphaXMMvLMUo1HjEYjgoK2cczcksPDQ46OjlBKsbu/x/7+PuWoBKM5uP7KEKYCSO3D9jaT6RTKSpg2lWS+XUdb18znc1azGb5phelKPrWyLAlRsWpqXAxUowmdUswWy5T8OMG1jrIaEZQmzwT4oQRgxEXDk08+xbvf/Z18/OP/kh/6wT/PzmOXmUy2eOXaAaPJmPF4yqgsaYNHH3lmR4ciBdMeZTRtKwyRMQabi+wubgy2KKkXUVEGUZR4XrtOADHAaFRSlhXKGmb1gmuvvMLh4SEms+RlwbKpiRGyIqd1IUlsDWiR3XbBo5V4aq21cs6mUKWYPFj9Oeu8sLdRi8RVEksbfBfwXuSgrfN4H1E2ya1iREUwSVLofYfRimlVcWF3h53tKVWZk6Xf61iHRPXn53qIT12bZkOS5jwBCecZj8dc2NsH5zk4OmK5XLJcLjEmS+FQ1eCFbJqG2bGAJem8zLBEmrqm6xq5LhIIsFZ6MS9duEBRZEyqkqIoUErSY7umwbUeG/UQUNUn5mZZRpZ8kSENfzE4lMqkK7MfqoMH19GlnknnW0lUTp23fRiVc26tMDBa0oZDJGolp6d0HclnmWVpSvTD/U+AVDcEN+V5Tl5WhHTe9WnNAKNS3ichMplMmB0eJbAt4Vz9JpJSMFbuMYUNKGuwCPh1waHalmJrawgMqooSHQNZCJREYtcQmznL40P+6T/+Gf7Jz/xPuNWCdz99he9+5zO8/13v4NLulJyA8g7f1ZSZZZz2o66XGJ0N960e9G3ewzZTmE8DzhACzSajq9SQur0JNPtE3032sT8/+pCu/v+VEs9m3DhOLjHHkqDL8DrGGEbViLprcXWDziw7kylKa+rOsWobXnnxBcrJlMcfvMrf/hv/Fg9dvco/+if/jH/0P/x3XLt2jX/z//gfsLV7AR8887qh1BnedTQuyCJenp8AxSeOAwGUcJmv5/l750TVO4EVfVuwM/h6N8LjzmYB4x1ZwbNCjk4+J+MbautS9wDMztrXUyBT3Q7s3fq64S7H8N4GnPNgzvPtHFyeb/+bZSzPvhnHswFm1GcKXtbfq9+Q/Qt33X+GIbEHm30yKGQ88dTTjLe3+erXvsHB4QG7ly7IcBPFO6O0ImbiX3rpS1/hwz//S7zwxS+ykxfs712kSx1zp1P/+pTXTS+KOvGV5F7JcxM3HuQxRnSfJqvTCn0K7Rj+P3ko8zyXIReG4bqNMqAHLeC1KCQApu9ZrOuaVduwWjYsVjURzWg8ZXd3l93dbZS11IsFR/PZCTZuVFVMJhNG1Qi0ha4jBifMn2tZzhcsjo5YzRf4Vio0qqpMLIFJjFNLTB60qhpz8/p1XnjxZb7nAx/AZgU2K/qSCKzJWS5rRmWBGU1gPue++y7z7vd8Fx/58Mf49Y9+jPsu/Wvsbl/i5sGXyfOS0V7J7OiQrLBUuWHRLFnMIcQOZTIJdNKGqhyTmRzb10AoPwzHPYiwWmGNpu5aYRtjxOYZyhjaVCr/ys2bHM1mtM5RFjna5lgXcCoS04JGSF6qHr0GH0GHxIQZQkhS28RpSOhUOheU1Jc4H/HBS49jCMIiGqmbsFb2E6OlP9O3EHUKblGM8hGjsmB/e5ud7THjSsBL7BpCDPjUBWoTaysgTwZf2WM1pK6KEC0SfCSGwLw7pipyrj5whf39fQ4ODrh+/TrLRU2zFImryIqFKXdBBn0VNMop2rbBhw7XSQVHphXT6ZTtrSnjccXF/X2RX/beseDBWqLPiV5SZG06t3zbokLAWoMxGlREGyUwOEook8j0e49bpFnVuLahaxqi80M4jtyrhAEVia8iYPqgYGGcQlwz3YBOElZrLW2qptHaysJW+oyNNhJ+VJagNau+QiaE4Wf7PtOyLHFVO6QPxxilJiktormuw2YFKslHszxH5fKZrRoIRuFiAK3wnaNZLFFtx1aeMdaR2dENPvP7v8U/+G/+Sz732a/x1OMXeefb3s0zT7+Fxx+6QhYDhfKMi4JM5XjXCqh2EsrUrlaShow5o07nZLVVf3/c9M2dqPQZFgfjic7e/rPwMaTFl3VIUZ7nEtrmPSg1+DE3Gcu2lX5fk1myIh/Ap9aaLMvSOZdBJkFPKkQ0kcJosnLEWMFsVXPtua8z2d7jB7/3/WyVOb/4S7/CP/7v/x6dVvz1v/W3uXzlIWbHS8rxNl4rbi5XbFUjolL4qAjpeg4p9EfHV8dMDTl46vTzlFsAzAkQeFug9fqev6dlt7cCpHD7fYqSh9DfW+40d9xrINDp77/XZN2QDqw5ASw3zkdi1EordQvQlPvIq0nwPQeY59s5uDzfzrfXwWDeG8P5BoPg29yTZeW89yYJ6CsqPTAXDz76CBcvXeK5F57nG889z+6DV6iaglW7wjlH13qqvKA5nvP7v//7PPvss7zziSe4f7rFzYMDSi2JoidZ0lRxcKrPr2c44hlSmLWHP6YqhvUwZq3FZNlQY9D/HhdTcXqK8u96+VeWhtyyABRZKTLELnhWq6UwJa7D+YjNCnZ399nf30cXOW615PDwgOVyiQvrYTvP7dCN2TNMMaqU0hpp6iXNYkm9XEH0FEUhUr7hGCha17GqazAi4fPe87XnvoEHvuPd78GFSF6NWM3njMYlDpHILhYriralGI/A5zzzHe/kPe99N7/0K7/G4489wl/4Cz/A5fuvMp9LbQrKCTMYHdaAa5fMfYfJcpTJMTYn5kGGchQmMWsAwflh+AwKulZY7s478ZmWJYHIYjFntlxw4+BAQH5VEtJAnJcFuEDrOpTRKaU2SJJkCqDwMaR8JxmaRaGZgEP6HGMqh0f3abeJAUJ6T7VWROdROoAW9i50Dt85tLLY3FJlOTtbE/Z2dtgaVVijpGPTuzW7Hs5efe/7P0+AgiTz7ldunJMe0yKXBYxRKZ7L2fGCpmnkPErnad/PKQx7xPmWul5gk682z3PGZSHs+NaUssylZsQ7nE/sk1apgkICXxaHM5rUBeq6DqM1mTYpIEbAX0yg3IUAQfx5IUD0juVyjooR77t07fWMjUsLOHq4j/TXuNaaQBjm5xAC2ou/D5NhkfPGe4/VZuhi3VQk9J7pUik671FFIeE9WtKSuxRSVFWV1Iz0XbR9CFHP6kUNmnUXrhapvFOREAUYN3XLcr4iNJ6JzXDzGZ/8rd/k4x/7GP/TP/h7XL004Uc/8AzPvPUJnnryMfa2trB4CmOJrkN7hdLgu4ZmVQ+LdXmes6wdSvkzQcFppqe/xjYBpk0s5QmA2Xd+bnz1YHPzM5D7ZGJNN5hBY8wALL2XhazeN92f172/WkWdqoYM0afQrnSNSsJ3ZH9rwuFszs2Xv8nO3gX+3He+i0JD9ZGP8bN//79mtZjzE//uv8ejT72dWRtYBsfOZMxiucDklSw0pXuATs+qqMSXuxGnd0Kpcs+AU706Zu5uktdbKjlehVrpLGZyk/k8ExjGuzONrwrsxlfxvXf4uY3vUXdcdFcnj8mr7cu82/E793Geb+fg8nw732BgLG+N0V77Zu75KfBqlnRPPQNU6L04srJte7YvBgnTIeJj5JHHHuP+K1f5/d/+LT737Bd55/e8D6xFdbLaX1UjcH7okItaiTwvgQ/v/dCJqDZqRdQpcLn5sIhqo98ssWUhrgeyEzKx5CXSaQU/suE9ioGmdUS97u/L8xxT5hKakme4BJacczSuS3UAnqzImUxHTLf2KEcTdGZYzOccHhwwXyzIsoxiNCYzsg/9gKa1wfuIb90QSuLbTobpzokXL89kuI+BkLonowLnRK5blAVZlnO0mPP5L3yRp97+Nt7+zDOQ58JMaUXrHRiLzUTqO1/WFGUFynD1sSf4kb/8V/jmN7/JL/7Sh7l8+TKPPvoIy+WS+XzOzu5E0k0J2BjltSLkRSEyNQy+bpmHBZnzZCnAJbrIqu3Wvprkz3XBY7KMrCpRWjNbzDk4uMFiWdMFL+xRqpvACzsljFVAG4NzXQIEKrEjKXQkeLRWaV+ljpNUFeP7hDhthq8+ETlGj4rit8NEYlz3NlprMch5MK5GTEYjticTdiZTci3MXwweExFJXvQneh+HAScFCVklCx19yIpKWVXRCZNamgwfAq5tUNaQGcvezi5bkyk+BupVK5/LqqbrukH+HZTHp05Kledsb0+5dOkS0/EkJWsygAQVw+D/jPQeY4WJii6zrFadLHJElxQCkYhPoDnQOY/r5DrzphOG1wPp9xdZhlEatDnhNe39lVEJuxtUur5R4IV1GdQGyqY0SAVqzWa6dD6bmJKUI7gQU3KpAOXJaDS8Tte0dE1LdNI9mlmRoVpjaNt2AEw9QI0xkg8snki4tdVgLNF7Ou9xXUemDfvTMW4152O/8ov8we9/ks/88R/x5975JA9d3uPtb3srjzx0FaMgtEuIkS4GjIbat5jEXGdZkTzgEL1PkmR9C2N5IlBpg7kUGeu6qkMWXtS6PD5Kuo3SEqTkXdgA90q8x8aA0jgf1r2lG8N9nudEhciJN2pepBcxgkm9szGQG4t3Dh/k/MiS/LvrGlrXDVVXVW4IVQltTVbkvPOpx5lOxyy7hl/6X/5n2uWM//N/9B+zc/8VDm8cw0gxLScsug6UhFepTW9ljHg8WmfEzbUdfRdgF++uMDoBnjCJvoy3AVnhDFC7+SzdRLBqw9d5O4AUzsZjKpxcfLgDc/pqAdWJ7z/luTxRuXIG+Bv2ug/pSn9l+mbkjW7cdMLeE2h9Ixfmz7fz7Rxcnm/n7GV8Nd/75t9QjTH4VCSvlJJaCQRgBh3J9vfYvXiJw/mc5557DtqWvmHQe0fXtmQ2S8meLc456q5loRXaGLwXKd49x36L3lXAd5R6FhPV8HDbZD/1RsT74GHakCF3waMSY2WMkdRXa4lWJ0ApFRRtYn1CWiQvioLpzjbbO3ugMlZdx+HxAYuFsE0Yjc6EzStH0keXpzCR6MPASHW1+MS8c0QfKKyhLAqs0riuHSRpUkkgLEDUinJUoTAsbtzga88/x0/8K3+e4v7L0HXUywWjyVT8S1nOarWiGk2oKk/dtOjgySdjnnnXe/jBH/kxfvrv/n1+8Zc+zF/5136MydaIEOX3ruZLtnemHB7eFMBnFaOyoqzGNJ1juWxpVjVmtaScjFPxvadJ4FsZYYKUFu9jVkidRdu2HB0fSwVI0zHZ2aMLwphokxEiuK5FayvdokQIUl2h0+calAy2PkpVSoyJLY1BZLAbQSa9v9baXDyEOhCcHio0rLXCXipFZjOMMuhKM64qpuMxo6qisAYdPCFELBFrLCp4fHCDbM5uhKOEECTVUifpl/f4zqWgqjjUlATv5HzW4gXGJ3ZPKYosB63YmmyzXK0o5gtmsxnL1WrwXFZ5QT2fDdfpeDxmMpmwqpf41kkoD3KdKcQ7KlUAQVrgUrpqu6qpfe9p1EPiKCqmoKKOtnWECNYKG+6jsO89qBtSggfPIIMfumdY1mzZOqBmqMqwVlay0rDeewBX6f2qHnBGBh8iIaDD2pe5Wq1o64a2bdHp+/IsGwKQQgg0CaSLosCi00JCnue0zslvVyp5Q+V9rVYHLI9nHLyy4A9+87doGoch54Pf/W7e9vhl3vG2J8msZX58yHhUQdeyWC7Z297CmtQJqcBmFqPXycrKGoI/Ww7bn7d92nD/56b/MsaIQ5041wc/eToX27pZH+uk4tj0BW/aDnrvpQRqhRPezJ6F32TSQvC00aGUwWS9yiIMHZj9tTCbHTGeTtielBwczbj+8jGj8ZS3PHyFf+uv/jjZz/0Cv/krv0SZF/wf/k//IQ88+DgvH69QvsWkp0lIMkopupQ08j5J/c14Fr4eieWb8Vy+G0P3Wt/D6QApxckwn3sN7Lkdo7rJsp9mKns7y/l2vn1bgsu7acvvdqGf7hU6/d+n2ZM3nKi6R238XS/mV/Fvf5Z06X/S7+V2x3fzZn36Zn9CwuRPMm6bq9Tyd3c+r7XWKsp2ZnLana6LGOMGQxpPrOzGfiXcxWEwC1phizTMNy1H8yUX9rZ47/vez3/79/4BX/7K13jp+W9y//33kRvLqu0IJkCeU03GPPTQQ3zyd36XT37mMzx8/2WeuPIANrOEuh2Gls2Bxzk3eIaG/e5XPnVfeRWTXFefAJe9HFWlJM+YhjIf1wNaUFBWUkXSD10xSlVFCIEuBrwPw78XZUE5qqiqCpPLMH04O+bwSNI6dWYZjUYUVTnIyGxiak2eg/c0q5rVfEG9WtG1rXjHgnjTiqIgzy0hAREQr1RZlpI0m+SeSinG44pXbr5COaqEtYwBRiMWBwfY0ZjJdMpsuZAworKgrmsJIXIetarZf/BBfvjHfoyXnvsGP/fP/wVaa378L/9FqpGhW3ZoI8eh38qypCgyYvSpaqIgzmYsV3ViNiOT6RRlDUdH0stpMstoMmFrOsHkGUfHxzz//PPcPDxAKUUxSj5WJ9LSkBjEEAVwt8FjTIZWFq09ru+LTGyKSb6w/prrvCdGf8ugLfJHkcUSYgrq0Rhl8N6RFdnALo+KEdPxhFFVkacuyeg8IYE1m0vQTVSyvyGqgQnyQZhJpZLPzUdMqj5xrbDOwQlzZpSWCg3vUIGh8ltpqSiJG4PXZCLHLwTHfLFgtZKie1MU7O3tcf3GNWazmbBySY6qs2wIN+p75MQnFoZrRinFbDbDWkmvXdQrtIa2rQnBYTIrqbvp+GbGYBPQ8D7ShiDSSKXIypwYLRDRxpBlIlvt04shSe+13Fm0BBun617k6klrK32F6VoefLzpYPTXaes8mdLE2NE0jdSwdB3tqqZtW6yVa9EndlA8yhVd056o4xiPx8M9Zzwec+PgJjZ5CUejMb713HzlJp/99GfwK3hxdsxDV8b8wPd/H2978i3sb+W0ixnzVoKjvNVMxmN2d3bQEaqqkgUSH+iCJ/jkGdQmge9bn//9vvXvfR2+sw7+6X2l3nu6xOxrLZ9j74/vPc7ei6x5877f3wO1zQaViMksSmt8jISALBgYSxei1ID0bGhifvv07V6Z6kLAh462bXFO7ulVVZInCTpExuMK02qWiyNWhzd45olHcT/yQ2gFP/ez/wuTrW3+vf/g/8L9+/fz3I0DitEUpw11J4x5UZXCinaOoqhwnRs8q/L+bk0f7ZUwZx5n1UukOZmMGvXZ4CiefIbqu4wfmxLss+ZRpTY6H0+xnn21z+m04JMKHXWbsD/uCD7XstRT3xNf3SL25pyc9ksN1/qpY3ACEMNtS1TuNLPeOXzpjQf55z2Wf1ZIm1efumxvd1K9ERr0c6r9fPtWnux/Eq+xsZR48t9Y+8KENUjyK6WIUcJwUAZC5C1PPcl0u+Lm4QFf/9pz3P/A5QEoAjRHRxSjER/40A+wPDzmY7/6y3z22S+A63jkwiV2J2OOjo4gyNApHX7rlfsT+6vVqaFBY7RBWXPLCn4PLAWkxUFS26/gK2uGtNEY49CpFsya+cyyfPA4FqOKvBRZ2/HxMXXTcf1whjYC4KpK/j3P8wTGCow1ROfolkvauqGrG1zXoYDcZuQ2I2iDjuswor6bspc1+hjofEppzUTCpzM7hJfEGKFriPWK/SefgONjDg9usHPpPprVakgA9SmEo20aVsdHXH7kEf7mv/u3WBwf8U9//jfISsMP/fCHaOpjrIVXbr7CZDLBpmTSGCPBOdARF+TzzXKDzfKB2XCN+CttnjGeTilHFV3wHB3MOTw+om7b9FkJIAsxlXhHk1Jfg4SoINIvjQzjQSG+sLDRG9kPt1G8mJtBJ33tRIyR0DlaJdJuqzKMjkQvADYzUGY5o6qSPsS8EG+sMRitBVj6gAoOlEhmtbFSW6I1bQLgQqSllFmzHjrq1Yq6rqmXK0J0WNUzqUa6yzeCslRizGRFX0nCbdthskhuLJPJhOPjObPZLHVZtozLir29PXznuHbtGpkVBjP6dmMB1Ypk2EuP6sCEdW4Y/pxzIiW1ekgcNUpTjSv5nuRv00b8ms7J+eqUpsilWzLi8b5DJQ8z4aSUbzNwq9+HYfGoD5PZSH4eFoFCGCSwNi+GdNs+KbZfYLDWErNMQGbv2UzXUB9CNpzHad9WTS3pz0AMPiUye/COrmk4PJjxpc8/y0vffJnCwFueuMh7vuOdvO3xh5hWhvnhAZlVTMYV4/GY8VhYfHlfhtVySSASnHhWpVrHpjoXjdbhFsXl7WoqNu97a9+jSQnI3VpmnwB1f2yNMUTULZUnQ1jWhrfvdHBbX9d0OjxIEpANPj1BTM8nhiAVRZm8R2GkZb89EaXBGi2JwtawPD7gbY8/TPHjf4nr12/wT3/mf+Ty1Yf5zg98iIeefoZXZgtZiCksjQ/UywXaGvK8FAZaZSIKVuoWcHZvYTZ3C9z7k138vh358Hpn3DvVnb1Z7/H1yF7Pt/PtW72Zn/zJn3xTWb9v1Yl9fgH92dwir64Hav3fWiRqt/2ZE7KSn3ztJ14PLG8Fl+rEQLMegCNIIieekbVc3N/ll37xFzg8uMFbHn+UZ77j7ZBYNuc9o8l4OBqX9i/wxOOPEULg2c99jnaxZDqZoI2hyHNckuGFKINhcG7ov9ysEtFGo5XGGk1m7MConJbb9Kv6cRiI1p2WxloJoODkyjAp9MSkCpC8EMChraFzHbPZjKPjY45nc6ISdmKyNWU8HjMal4zHI4qqQKe+zHqxZD47ol6tpAvRe4xSZJnFOQnvGVdVAkMBF7wkoMaIseIpbJoWpTVFWbCzs001HnO8WPB7f/iHPPLY4zz81JN0iwUm+Q/L3R3ccklelDjfkY0qonfymtowXy4xSrF3/2WefOQRfu/3P84fffIzhNCxs7vNzdTLOTueoY1hMp1KfQgyqHbO0bQNk61tyqokL3Ja1zJfzGhdS1mNmEyn2KLgeD7n2vXr3Dg8pHMBY0WmGrUGrQW4aHld58XjJ9YxjUphLiGxlM453AbzFPx6aO8ZKaUUNgWKKERmalBYFDpGQNhBqxTjqmIyrtieTJiMKqo8p8gshZFaCoIH7wmu/8xytMlAp3MNAbjOB2EuURJMQyR4z2q5SABIJNC5zchz+bJWY1KirkqJrWpYHJGqFa2F07Q2o8gLjFbUTc1qVdO2DdYYJpMxdVNzeHBIVZZsbW2Rp2sh+pDCbwS0qRjwzuEakTXHRE02TZ28xAVVNSLLxdeb5TnGWpGQapMYNzUwJjEokXtaK9JeTbpG5c+QAI+KYI0V32uMQ5iVMiJ81CrdgZLsvWtaFssVvpOQGLQiL3KKokzVQzol3HYQpfs221AfsAFo+/OmTx3ur/8sywguYG0mgUdEqqqgbhqI4LvA5z79OT720d/k5W+2PHRlxPve8x6eeeuTTEYlwa3IMst4MmZ7Z5fp1jZ5XqTrw+Oc+GJ9Sv8OKEkQViZVaIhsWXFrh+XtEmNPewN74Nffp30v/T8lS1Qb98zNxTe1ARpDSN7YFPDjEhi31g7fF3plTXoNF4IkgiP+WOeldsbYjCzPxOuegoNCgnJKi3LAZpbFbEZVjZiMx0y3dviXv/MJvvylL/LUU09z5YEHsFlOSLYApSFGAbXixU41RX16uJJjeVYYkkn3gQ2iNZkCbwOwlMjC7/wMvvfM2NvNkme9tHwu8Ra29eT7SvexO9Sh3BPrd2ruULdjDG/zepE4qBESZ/mTSvFT/f6hJD9C9f8/+E0jtzusJ0Os7lh5gvoTnrXP5/Y/4+Dydis7py/Is76+XU6e85P0zypNqW8r87idr6Fn5G4PPNe3+9Pg8u69Xaf+VLf7GXXLM6jfr2Hl3wcyA6aqePbTn+YPfu93ePqJJ3jPd3xHCvXwdN5JObkXX2G1vcXeAw9w9dIl9nd3+PynP030nr3dXekC7FdlYyCGtc+ul74abdBGDx43aw02DRj9MBlCGIagiDCBPfu2CUIDUdimfpW+l9IaPQTSGGMwaTV/sVpycHjAbDbDBU+WF+zuX2A0Gg+M5XgywozHYAyhbTm4cYP5bCa1AyDpl0oSOXMrtRxVVZEXuVQ7dA3eeZSWFFZFZNWKDKwsS5HmliVFVWFtxle+9nV+8+Mfx3rPxf19Dq7f4Gtf+SpbZSVVHUVJu1yQqRS04jzFeEyZ5yzmc8JiyYUHLvO+976Hj3zkw3zmc19ia2vE/Q/cR1GUAmqtIctSSqyWgJ+26+iCw2pDXhTEEDmezZjXy3QcRMq5qGsOj4+4eXhM3bby2RUFWmdS+xFJPlhzwgsben/thpzM917FjeoaF8OJTsAYo9QUaBncrZHjXNhMzujOoQmUecHWeMT2ZMxkVDEuKqwCEzWaIN5LrdERkRT2zE5KLx26HrWW0JpUEGu0MJ4hBJx31E2NVoo8z6iqklFZkhcWc6pqR/WgTa+vf60UtighBIKPZHlGWRQYbWibltViASoMrNyqlnNsMplQFcKw6x5gJHo1pFAo16b6kiQZ7zphOqvxiPF4TF6kkCaihJqoHlys05l7L6SExKylmP2xVwpc53Guk4WgDb8fSV4pkmc9XOeSkRJYzhdS45M+13VNSfJ29uqDePZ9zW6w//19QeTx4j3s1QXKaJarFYvFAqWjSGdbuWe98vJ1PvKrH+XZz7zE5Us53/td381Tjz9GVVja1TGZNezvX6CaiDdXPJSeVdvQNR1125LlJcZYTJanhYn+GBgUMYHqeOaz4bRV4nbAsweRm1aA6MOJaqDhNVEnVCBZlp+wHvS2gZ79lRAyPQSibSbTRi0ZAf3PO+ekKin5S7O8SNevJDSTrnNI/k9j2dreYrVa4V3gscceZWd7mw9/+F8ym9/k4oWLXL3yIChF07XEAFkpoWBt64eamhPzXAy3BYFng6uzexjXx+uNA5dnz3m3YajV7c+Jk6BZ38NC9R2kpupsEHn696gzXq+vvUHFk+eVzCM/qZT6qSH/gFv3/V4krhtj0Nnv6xxcnm9vNrh8sz78c3B5vr3OT/aePuf1sKDPvGVugsrTPVynweU9A8u0ezH2q4r9IH/WQo0Mfl6qq4fCet+2lKOSbj7jf/6HP8uV+y/wjmfezvbONm1Ty/xtDM57kU/FCMFT7e1ydf8in/rEH3B08yaXrzxAWzdo0wMvS/CeIg03Nq1Wa60xSQJrjIEo4SkhnqwqGBjKtPJuepnYpiSMKAOfNScYgL73MiTGqPOO5XLJbD4XsKA148mE6XSLcjQiL2SVvihy8VYCbjnn+OiIg5s36LoWg6LIc3Jrhv7HLMuZbG2jjKbtWpq2JapInmXYTMDu8eyYZb1CGytMYAISVhuKsuLptz7Npz/1KX7jox/hM5/6NH/0h3/I7/3O7/LpT32al196mQt72+zs7CSmRLydoWtlRThCs1wSu4b9+y7xrne9k5/5mZ+nc3Mef/wtvO2Zt3PpvsuMx5ME7oSJqZtaakI0Ul0C1G3N8ewYZQy7+3tU4wm1a3np2jUW9UoYDpNh04AtklhofJeYS0mCjSiRMMNQkxA3zsMQRDYbEP/s5vmtderWtAIorTbkRglrEQIqBjIUZZGxNZ4wrUqqPKPKRJ6siagQMRoMSryPMUBI7BmglBUZdgoYiYlt7Jk0Y6XLsQ+zCqmCpSoLsiJDa4gqSBJwDCjd5ypG+jV+EssS09AW0yKID2HwhsZUT7KqlyybFUVKI65XK6y1bCUvYZ7l8orOpURieS/eiUKg61phCkOQc2wyZjQaofoFmJByBzYWvQQYGRSaPC8wuR26bWPip3Qa3FfLFd4HjLYCZBD2jBiJPhD7QJr+9QN0nWO5mAu4JGKsoarGlGUlTPdmoiqJCd0IvWHj34uiGK5trfXwb/1xVMowX87pXIf34lcti5zgIr/9m7/Nv/yNP6DI4APvfz/vffe72ZpUGBxFptjd2yEvSpSRxNfeZY/WIkW2Fmvzgf0awGGQe6cKEki2JlqTzN/Y4asPRur/rf+z/xIGuQ9PMlibobWRe3Toh/71V4iipgnp92VZJgFk/YJJApBt19F2nYDLDdA6XIdpsTHTmswIUG5di/cRrQxZVpDZfEirjcg5JC2YDO95PKrwLmCsxXnP2972Nm7efImPfOR32Noac/mBK+zu7WGtZb6qsXmOj4pV08ii1qmU8Eg8s7NR3Q5o9fHN3A6QnV543Tye6TwfONmzv9TG9X075m79PA4n/v50//OmjLcHba8GXN4yH5wBLs8EomeBziFlfX1I1Mnj+FMDw5mqcdU9zL1ngcvbgdJzcHm+veng8ixT8+vReH8rJbHnJ+mffXB525vjLauW+mSlwd1+Tv78qbRSeE/n12lZy8mfM7dVAIAMvOu/j3TNisl4zFZV8DP/8B8QOsc73/F2rj75JN1qifMSABNCoGlbrNXosgAf+OPf+10+8Vu/RfSexx59VFirVMYuskFLvuH5sckHJ4NU2udeInnKj5TlwlSa3p/VB2FsSCdVkh8Kg7lekV8zl4a27VisliwWC1yQGpDpdMpoPCbPM0xmKasR1WSCyTJc1zI/Pubg4CazmSR5FjajyHMyLT47iwBopSW4Zbla0TQ1WZ4xGY8wmaGtG+bzOU1bAzAZT5lOp8nv5oQxsIaqLHnkoYep8pKubVARLl64wHPf+Aa/8PO/wCuvXOOZt76N0fY2XV1LV2WMUmCvItYYjo6OUUpx+cplLl6c8Hd/+td56rF9nn7qaR58+EFG4zHGWmxhyYqCQKT1HZGAdMwrus7hY2Syvc3u/h4hwsHRIa/cuIFHKhhslqHSwCyLAFpqJQYvmhrA/y0MdJ+OucFUnlhMSIsNmbXkNiMzVmpglJYUVh/IjWYyHrEzmTIqCjKjyY2isBm5tWTGYIwmUwajUsBM6Nmak9en1hbSuRi1HphOk6Yh33W0XUNRlJSFJcsMMYonMQSX5Hvre8Q6TGQz/l/hOjew6t45gvfoJOssi4wbN29yeHRIkedMp1OapkEB21tTijzHGFmk6ZqGruuIIR3HrqNrHd45TOoBlRCciqwsEksZUEhlkKxC6cFrGoMk9sbNqgGlUt2L3FeijywWS2KU1FZr7aBMEBZdwo4kQEWuzy7VhTT1SlJftU7+ZfExutTb2DORKt4qKe3/vfcaq+TXzPNcUq43mG9hYkO6rjqMhq3xlOe+/k1+/ud+gdlByzNPvYXvfvd72d/dJriGUWHZ2RlTlUVK0TZDxVHsWdJ+P7y8x6ZpWCX/rWtaAdbBDV7Jfp/PCm3ZnEdOJ8L2MuBNSfjm9xDiCQZ0874eYzzhVd+cefp96r2bmx7OHlhYJffk3qfpOkdwwjLnqUvVe59QhRkWT+VzSgm/yyWTyYjgPc4JyHv0kUe5eXCNj3/8N9nfv8BDDz/K3sVLrOqW1kcwWQLv2S3HJw5+7ZMzoD4DZCm9GWanbjM7ngUu10u7enOJ9x7nutsBPdmn2zCHt/l/He8OLs8CmJuLy5v/ps/6nlOgc905rdbS2I3V7o3v+6nTv/c0g3kv4PKO89KbPGu/XuXj+fand7O3CzW5XTrXWYzR+Ulyvn2rFhDuJYTnNLjsmUNOPcheT5T37UIjYjyddtsPBeHkYKIUGpM6/AIXL13ifd/zPfzx7/w2X/7yl3n/D3xQmJSmYb5aUpYl2zs7EAP18RGz6zf55Gc+zcs3rvO+73iHpIdWJV3dDDH2krZqhgXmqNa/3/cdbYnN6QHGicL6NCQNa8sbgT79MXDOSdBECqjoO9RE4hVYLleE1BlYlgXVeMRoNMIWOUprqvEYrIHoaBup2ZjNZkPSbVnmlJkMtXSe6KJ06BHoWke9XOFVpCxLRpMxSsFidsTxfEbb1kzH4/Q6JSDvuUgr9q5pIWoevnyZ6Qe/nxAVteuY7u6xaBt+9xN/yH/1X/83vOXRt/AXf+zH2LuwDzGgRiUqKnAtwXnuu/IALz7/HMYofviHfoQP/MzP8rGPfZzHHn+U7d0ttrYnFEWGix3aWlrXoGfHNE1DkRe0bYfzgWoyYmtrIimkixkHh4cDSDfGEJURsBalwsNHCbTxqXYli1GYlMHXu1F7oLilLF4+cxl688RU676SRknjmo6Q5ZZxUTIqC8ZFSW6z1AUZyY0hM8J4DsxcYlVClGRZZSwQ8C7ikkw2Ko8GTJ6lfsaYvIQivez3tSgKjA5oIs5tJJD3126IZw6nm2CCGIehLARhvEZlRVFk3Dw8YNXWQ6hNlmUsl0tu3LiBuXARHSSoyjXi+cyMRQM+ydt7T52OIqHUNgNtRQac/KNBQQyKQEBHkfx2SToZY0eWqjy0UsSQwFS9pKtrfArTybIMaywxBVDpeDIgJkZSmq78e57nbG1tDe8phMDx8TGdD0NYE4isepCCbixK9GCtrutBBpvnOSa97z55OS9yyqqiqcEYRVmWrFYrPvXHn+TlF2Y8/ugDvO3pt7KzvSUVLjGidCTPNSE6jKnwKGH1nbDCzjmiT2mf/f0rxPXPp+MUODsJdBPsnfXn6fOkrxHpQeYmuIzanJCM91v//865E97N/jPJsmwArEP1C0m50qfLaoMKHhUUKiXKqiisvwoqHYN0XUlUcFqk6Rnk9efStI693SnfeOEl9ncu8Nf/yr/KH/6d/5SPfviX2b//AT64vcuoGlPXHcoH8qKk8+GWNNc7ySVvYbzi5pXXKxPMqWfkG/PsP4tNvZf5c/1v8Zb6EXn+vTm1J692XhmuY9WLoBUxxtinx74ZYT4KBedlJufbm8Vc/if/yX9yVzbo1Z7EfxJg8xzg/llFlJE7yVxP38C1NrcsfNz5Bss9hfrcyXOx3pfeF6M3HmCbfksR6bERjNB1LVWeQfC89PwLfPyjH+Hhq1f53ve+B2MNy7ZJ+RUK752EomjNwc2b/MI/+V/ZG034/u/5Hg6PjrDaoCPsbE0obEb0gcxKvYEwA6kQnLXvyPTD2KlgCxkcIl3bDevSqh+I+u9TagiEGGorjKZ1HYvFguO5eCvLsmS6s81ka0pRFOjMUhQFZVWhihzXtBwfHXF8eMTx7Jiu6yjynO3JFK0QBgmFdw6VAnWiD6yamqAieVYwnUzRWc5ydsz16zdw3jGZTiUwpxyhjWW+WOI7R1GUqAiu61italaLJTev36SoCra2t7DGcOniJS5c3OfFF1/ixvXrPP7441x829ugrmkXc/CSUmlGFe1qORyvIiu4+uBVfvZnf4XR2PDUk08x3Z6iSwkG0laT5VmqMpXe0+PZgrptGE+3me7s0oXIzaMjjmYLimqCSuE9Maqha1SAfhR2OPm7pOvSDCBKFgZ0CjkSaWgvp+tlhKPRiDLLKXOpSslMhkVhgxok2HvTLe7b32d3a1tK3mNAG0WeiYfRWuk7jH0QSpIMxxgxmcEMybYS7CPAS06qnhlTEZTQnPjgCL4jOEeemWQ7C0TvUQps+v7gfbreN9mUDQmn1mhjcV1H04h81ai1RFUrw3g6xrUdXdeRJd/jfD6nq1vKPEMrLQmiXScy0bwgsxbvPG1bkxc5eZGjtUJbI2A4AXwFkJh/iKi4vu69d7jWEZXCZhl5JpUWTdswnx1z/cZNrt+4zmQ8kYqXcoTKLWoAOslzmfpls5TsS/LrlWVFOSoxNkdpw2K55ObBAYvFcp2WGiKruj4BKHvQuLl4tJmEqvtqouTpnWxNpHu3rZlOpmxNtrl5/YDf+LXf4OjgmO985zt47KGHqcqCcZGT5wK8x+MROitpuygVHJ0XH3LTildcC6Pn0yJTkTyeZVmm3kiF1gprs1slp+m9bDK08ozoGfQwSMZvt5je369zm93yLOkrnHwIZMaulRqn/M2Dhzmdj/0CT79AYrWR6hulCCFKcJUPyRev1izW2jo9KF/6Z0qeW1Z1w3g8xvkgQUpO/OMXLlzgF37xV8kLy8OPPsKl++9j1XR0AYwtWNQ1eZZLnYvSG+nnvVcyPVPj+vedfHKug3F6O8otrFo8m7mUtxFPJh+8SibsNLi8XWXKWQB18INzZ6np5mLEWUxpvAWU37p/p5nggSVWCZSr2wE/YS/PYpDvhdmV/b9NOBHqfNY+395c5vJu/TZn9UedXPnWt/z9G9E9+e1yon8r38ufxPbG1HG8GZ9lWFOBm/u54a2UIS2y2fo01CywlpHEGE/IyU6v+PfP79MPg5iMHf2wcLI/M544/+MJBsWnQJ5wSkakB/9K71TR5Zjr8yWXd3f44A/8Bf7T//j/zssvXufzn3mWt7/r7XgvbFeWSdiFUhGs5bmvfI22bnnv299JOZrgmheoXWCnGtMta5TNKDKL9056NSPCCkUlfYMbMq2Y2MYQAmaoUBFpWqKghj126T0po4eu9J5JatuWum3ogsfajNFozPbujniOcpHVFXk1sJYQaY9nzJcSPuK9Z1IUVFtbQ9iIR8v7UQarM3z0LJZ16jAzjItS2E80By9f48bRAQGYTncop1PK3V38qqZd1WR5he8cq8VSpJ6kJNr5kkW9oO5qtruarZ095kc3KAx8z3vezX/+X/xd/uq/9q8SX3wBtbXFsqkZFwVN1zDKMoy2bG1tc+2ll6j2S979nu/ir/31v8TP/qOf513vehcPPPSgJH1qS103lKUAjq7ruHk4I6LY3t1na3ePVee5dvOAG7MZzmQYZdHGShhP7AgEjFIoFQne0TqH0RlFLnLfZpVCRIwlyzR13aYzWQ1zoFEGa2zyfAm7XWQFhdGEztF1DhMlmfXixfvY291lXBas6gVNU2OtpiwLrM0BjY8yWAYlw20IyRmmEUCtDNZAMFFAYwqz0qbArZYoazBG3pPCoXyHjoE8M5jUcdgvhMRoUFGGLJspOt8SVGIlUKl2T8v9IYrnUQFFbiWR0wVcI0DR5BmFKXjo6sN8I3yD1WLOaDSiygsODw8xKB5+6Crj8ViqT7TGWMVytWS+nGEyK12WRHyI8v82G6TJkuQa06JOxPSRrsGjXYuOjiwfEWOgWS45Xhxz7do1btx8RfyeueXlG9epqor5fCHy0xSKFJ1ntVoN6a/VWLyehalQSlG3DbP5nMXxQkBi2xKVMIv9e5TQpA4fpS6GBHrbtoUQT/Q9tnWNipGsyAXgaMjLHBc9nkCRl7guYs2Yl1864NOf+ibf8bZHeOihq+zsTsiMYjY/ZFRWTCbb1DX46KidQ1tDZnKKrERn6kQdUijDLayjCpEQshOMZd4P8yQg2cuXE1hu25oYA1YZbGawqRJGG1GPiPoiEhDm3GqLtQYfPK1vUTEO96SubXF1gyfSqEiuI9au08ml0zTHlDYlVwdWbZcYaJO80dC4DqsMHiWKaWtQ3qENZFbTOfGwJqdh8tbKLblLtUKFKciznNYHiJpRWbFYLFgdH/DB97+Hz33mk3zkl36Btzz2CJfuv8ju9v0cB0GMkyrHuwZlDNpK56yPCu8DVmsMBoIbsOPaPqGI/QJqWtAg6g3gzdCtarQ+xSxvSHxiTIk+dwrVCWcylsOfVj71PgBrU4a7+XvNAJpTKFNgkGJzG5npWVLoMxncTYCqTv5cL9MNsf8U06JB+lOnvukEStXdZjSvZKF5WMz2p3pJVWAz5EjFU6TPLYFN+lXNh6+2wu1/60D027/nM7zO/Te3B5fn+Pp8+/bfwgl24tXc3OJpcHrWxZ3knrf5dxXTD59elX2tN44+QEcpnSSssnL90KOP8d7vfA+f+/wXuHbtOm9XwiwtVnNMLoODwsCyoW0dq1XDdGebxapmvDUl1DVd0zIuS5rFAqNKvO+IiVUR5lGvU2N7T88m08tJ8IxWBOeJJgVNpO42bQ1Ri+fKOUk/7TslpUctRyffpzaSiFr+/9n77yDLsvu+E/wcc90zaaoqy7X3Ht0N2wAIEABBgARJaUVSokajmY3dnZmYif1bEbuzMUFpYv+Y2NHGamdjQtSIlESZnZXEoREIAgRAEmy4hiUIAgQIgo0G2lWXSffcNcfsH+fc++7LyqyqNqAIMm9HRlVnZb737nvXnO/v64oClRXgHItyQVnOWSwWeBxKSPIiJMZqpaNK0tPUdSe3dG1htw7e0UQqitEIW9fsT3bZnU1wyJDYub5BMRqGS5xO0HlYnNVuTll6TBlqJBazwNxkaYrOsxhkAxIfZIqm4fSJMeV0QlPVqPmctbU1vE4xVYOtKlSaQ54ynM248NIlbr75PO97/4/z5S9/id/7/U9y+12389jb34JuKnSecOmlF1lfH6OExDrHxsmTbJ44hfGwu7PH/myO8wKhNNYJlvMTGRfA/QXM1R6WICuUy4CWHmutpUIlmkSF4YK3jgQZakacRzrIkoxBljEeFmyurwW/Y1PjjEFJYsBTrMvwqvNy4l13prqOqQePw1kXBh0xXRUMzsQFqWspBIczFmcbsAacwbsloICQRIsA4SUeFxffflVatrIobCWRsmOwuh5PqdB5itYpk/V9FrM51XyBjJ7e/f195vM5g8GApAg+Z2vCECYtcvIkXfGuuhjYJXteVu9dB0pMU4dQLq1JEx3ksVWJF5Lt7W2ee+459mf7FLEz1FjLxSuXyXQCPjBbou22jPLZIs2D13M0CnLzOMRxeBaLBaZuGAwGrG9usg4I61ZlrdHP3ReKWGsDy9wrsHduWclibUixFo1EpSrKghVaZuzuTHjqs1+gKODUqdOcPrXF2toYrMHVVQi7qRuEE7go65Q6dM+2abh9/+J8Pj9gb4hzEhnAgnQHZJGiTdylkwcHRjZcn4hMZpAkewZFqHnycglqWwbXex9k0BHUtWyXbSWzxsT3yR567K3IcCPz5/CIdkDXMvxLKnL1PtGF5UQw0v1z+33XDTAFCp0Ej723lkW9QNiGn/lrP853vvddnvyd3+buBx/kLe/9Sfamc9ApUmgQAfhYY6IDUqOUROCw3qKQiNgl6oVDoALAiZ+D8NFL/HKESHx/xZiHAaK+l/FGF/ft7/1FAQOHqQOv1ef6g0bkHG9/ucDzMbg83n4gtqNLi/01D3Z/cMRIb4Lq5dIjib/qefp+B3HIaznqZnUU839w8ioi8ymUoixLBltbvOtH3sP/9P/4hzz77LMsplPSLGdvsouJU2yMAykDm5IkbO/vcsctNzPZ20VqhWuCXHS8NmZvbw8ZwYBErVQZBJZn6Vc62G952L61i3KhQgBHqG+oaVxYjCEESZaSFQWDwRAV6xjaxFmAqpxRliWzeUlZzsM0P9VkaZC7teDIRSDQeqAQkb2K/skkBl4gFXuzOVf2dmi8Y7y+wXjzBMV4iE5TEKBkipIKg8POg4+sms3iItOhEk1RFCRFThrTal2U5g0GA6SUfP3rX+eJd74LqTST2YzxqRFFUWCbGulAVBXjzU0me3tMJxMefPBBfuwDP86/+df/ks9+5nPcfPNNnLr7Nna++2dsnTnDZG+Hvb0JxtbkRWBz93YnbO9cwQiNTlIaIaitQYrAqlhaX6LHeUdQwQVm7KAfzDnTVSm0jL2UMoTwpAl5mkXQ48Oiv15ggSxJWR+OOLWxydpoCM7QNFXsWvTB/6pl7BdcDn7agCrpQarYkSni67QW2yxrUNrzNDDlrX/N4byJIS4RhHrXeSFVG9vfnq/Ccdi5iV+9DjjnQxWOkHhjELjQEahEXJx7kkSxPhpzRSfMZ5MAJqVkb2+P/f191tfXUcMRjauo64rGhAoRoRLA4qzFeoFGhQW7TlGiiUygBalwzlAZQ9KlNAeAt7M/4cqVK7x06SKLxaIDe8aEapNRMQhApgURbUhM632sAhO8WCxomgZk8BRrrWmahvF4HHpkhyOUUjSLksVigZSBxTQRRMqOGWk9oUs/YXsMmcgy9v2JzgYrgkoUg3zI9779Pb7wuT/g3NZJzp8/zzgmNDemWRmCJEmCl4I0ptG21yYIntw20VYvqZ8DkkfRAc2D4KUFYq2XUkoZpbQK0et7tW2HqBCBNTywr03TQJotw33icdWBUDzeGFSvN7Z/7IX9ET17hFiVxWp9qDzxKlnlIX9vf64DwVIEYWq8vrvGYBrH+XPn+MCPvY9f+OV/y6ef/H2Gp27i7sffwqXpnGJ9g4UNqbjGWoTUCBVTp62/CpC93MC7vyjrhlfzs9dLj7/Wvf6o31n98+UNqI9SGn6/AeYxsDzeXu52DC6PQdsPKNA8Gsxda5qyWkPi4upEXAO8Rq1Nj708+DyHTkqvMekRPVYnTVN8E7yXNAmvf/3r8RK+893v8uKLL3HLnbegVIKzYOoGZwVJMeC2O27nnvvv41NPfZYzp06SFhlplrPY3sGahmEEYm2IzYqfMoZjmFgn0u5LK8Fa8YW0E30dvHNdUmbTUHtL3Vi8FF3oSJpl5HkRyuNjZYaO/q7ZZMpsMWdRV92kfbw2isyAWmFUfI816b/XquvrC5Kznd0dJosZVsB4bYP1k6cYjIZIHWSQIsugqcEGkFSWZZB31hXChSqVYjhkMB6gkwSLxzamAz933n4r9993D//+3/0qd913P2965w8zvuN27HyOtR5vLUmqKecz8tGY02fPcOXyRaSE9773vXz9j/+Ij3/849xz7528bRh8Y3hJXTax7zMwTF4qdid7NNaSjgpEklGXFc6ZEGQjlj5Z0UtfPZgI23/PgmQ5Vi2EmQRaehLhUcKhhUMjaGLX2iDL2VzfYGM0JEtScIbpZA8XBxtpptFJqLJwjUEogRQSL3yQr3ZrftexqsYYnLE0TfDAifgZKqlAheGQj2nD1gWGyVoTKnK87xJPifLrFlS1niUX4/uXC6xVFndZrbEMVlFRCumsxViPUaFyY21tjbpaQDwvsyzjwoWLMZwl+E+rqlrWcNQNSq1W8/igv491RK57HhElqQpBU5ZcuXyZi5cus7MTPnMtFevr6x27vDYccSJWSOgY6CQ9IVCqlR8C9aKiqirqeN44fAcujTEMh8OV81slGllJtAgpsrNyHitJljYC5wKD3AL7g6BJqZAQ3f6ec54sSUlVyovPX2CyB489eJrTJ0+RJQl1WdEsyi7oJs8zMp2GlNhewvHBAJyWeTzsOnuYfDEoL1atCO0+SBl8pir6TbUOzHFV1uG5jO98pP3nr+s6BoD5ZQds79hy+BWFwApAVBIFK+DSdF7ow4HBwb+HAKoYNMy1LUztvi59s5b9nR1e/9ijvPNPv8NHf+tDnLn9HrZuuZ3B+ATOGLTSWBE0AXEc01VpBWVKtEqI5f4pwAl3qF/y5Xef+9dmDeOvA+i+j+ulV9L3/nLXXYf10B8m5X2tU1hfDrg+3v7qgfJrff7q53/+51/Vm3Oj06zjg+R4e5mH7YH3/WCUuLyhC+p1PzXfjxTv+0JW/+4Ff78dmAfPQ5ik98+tG73J9DvFhJYY25AIhfYWLTy/97GP0NQVDzz4ALffeRtVXWKaOnTiIVA6YVgMSbXkc5/5LE//6be45eab2NraYj6dkGcpu7s7jIcjEL7rtWzT8Xzno6RLlg3pn4dE9bcdbTIEedRNTVlVHbuYJCl5lLx2YRs6/LxQAqU11tnAVi7m1E2DUJKiCN6vNEkgSmtN03Qyr3ay307524CPtnevrmsm0ym70xnGe/LhkLXNDYbjMTpNEVoj0jRYSpqGejZjtr/HZH+fajEH70l1wqAYMhyNGAxbcGkw1uBd+KyKNKcoBuzv7/PvfvXXuOe++zlz4gTpYIQQnrppyKInD2OQiQZnqZuK9Y111kZjPvPUZ3j2e9/l9JnT3HHLLcwnUy5dvIh1nto4RJrggCayB0meg9TUzrXiN5wFi8W1vX6RpUCKIDv1IewmNvd1wTeJUuhYQ6OV6ErnFSC8wzUlA63ZXFvj1IkALBPhKedT9nd3aBYleEuWJgzyEKxkTB1ShnXoahQIVCu5jn2gAWAZmrrCmiYyb6BVrLhpU1ZjT2UbOBUkhoHJ9PggpcW2J09YpMulhDDYgVtQKa8KzZAyMFJNXTOfzzGmiUBDdlLhpqpItCJNE6oqDCCsCzUhly5eomkMZVkxmUwoqyrUyiQpJga6hGRej1KaNM1ASBpjMc5Gll+gZNjX6XTOs88/y9N/9jTPP/88WZajI6umpGRr6yT33H0X58+d60JsBlnOoCgosjz0t8aWTK0UWVGgdGDeR6MRa+vrbG5uMh6PQ4poFVhnPGRZCCMyNsjYG7tkkrtzP15XXS8Qp+951InuejV1kiAInZSj4RrTyZSPfeRjXHj+BR558F7uv/de1oZDysWCuirJUs1oMGBQDEhi0JEXHkRk3wnHiFTh89GJYtlfGv699a+231NSL3sY433jsEGL6Pnu+2m4qGUNSluBssI8+l4faMuMCoGJag3rbTi3OnVGDDxqPZJS4xCBzZdBKWNN2Bel1NLjHkGhienAOgY09e0J/eM+dsCgpSZL0lAJ1Q4FGoMUkGcZXngGgyHFaMwXv/wVtvcn3Hf/A6ytrYdrtE7wUqOkDgx7J9MNgFzG0B3BUqKLkMGnD91Q4lBlzmHs3lX38eutt/w12b+WcpfXYfTEDYDDQ8EaNx6gc1jNhhAcnlJ7CHPZVo9cc385wvPZe76jXv/hTKn4vq6Fj9fNPxjr7FeBjI7B5TG4/ME96PsyqKvA5vU6n64zaRGsemKOuqh7+PuHps/6o2+qR00sl518YclkmppCJ2RZyiDRfPUPv8KXv/xFHnv8ddx3/71BfrpYUORZYJTqGpEPOLe5yalTJ/niF7/ESy+9xO233koSF0RaSEzToBMVFvzt64qLIxVL631XPSGu6oNru7icczQmJJLWTUxzVIo0S1E6IUmTbnElI8hoA4OaumE+nzOfz3HWkuU5w8GALE07sNBPdjwsCVAp1YESEYOD9vf32Z3sIXTojhzE8vokTUOQSppClsBsRjWdMNnZZTrZoy4X4D15osnSjLwYhAV+Ghap1ttYeRBeR13VnD13nlOnT7Ozs8vv/N7v8shjj5HnBcWpU0jnqMqSpMhD+mtdI5WKQNlw4uQJpPD8h1//JLDg1ltuZTgcsL2zw/bOLkIrkiIjywuETnBCYGg7EMNCzkT5Zhsz5WMwRAv6u8VwPNplXEgrCUmiybRYyua8Q3iLFJ5EwDBJ2RwN2BgN0VLSzGfMJ9MAKq1BCEi0YpBlKC1w1mCNDZ7XNIlBVu3xEgcuzuBsGD40ddMNgwJjFIFUTNkUQsa+PB/rSBweGxgoCTjbybjbReRqzyzXWNgFcGmMCSEni0XHXOoW3DgXalyShKIoQvJpTFCVUsbPMTBYi7KkMSaAQa2p297L6LmTWpNFVj2AE0WSFTjbUM4XwVf57HM8++xzTPYnSCkYDIY4a0EINjc3ufXWW9g4fRqlFLYMvastaLDWUpdB1tqy6/NF2QGSPM/D82cZMoKVqgrMpjU2Vs2EICkT+yHb8A/VDxvzHtMsOyTbNFYhwrCoBV4hiVqR6owiH/H0t/6M/+3f/QpZqnndgw9x3913I7xnPt0HbxmNRgyLGI4kolc2emb7bOHB3s3+V8cSu1Ymr1eu8967q671zjl8L0G234mpk3Tl+tyqALpjpA8qY0BNyyiG7l+DVBKlYw+oVCEIjaD6EFGRIaO6o1VndO97b0jaMo59cNleE31k6IUUy07QqA4ITDwrig+tJIOiiEA62AUsnt/68Ce47/57ufmWWxmO1miUBBVCwxDBdRHyAEDJNt3cLQF8HB4JQsfwQbuIuB7jhbghWegNg8s2PRdx6H2+G4wgXhaw7KuLrsmIXguYHrDbHHKdEuD//o2Ay6P+/+D1sHs/DkmFfbXg8rAh/nGP5TG4PAaXx+DyB/qg7zOVhx3UR4bnHHGRW6bCyiO9hj2Q4x1XJ8Wt9mde+3VcFUrRKwxPtcI2NUWeIgVMdi7zG7/2Ie69907uvfce1sZjyqrCO0+W5ZjahEXeIOeWB+5jLUn45Cc+gVaSm86dxTWGQZGzmM8p8qwL8ukv0pVY3nTlIYC4fZ3WGBpjaExcjMb6iDTLIpALlQAyMkoiMkUeT2MN88WcxoQ6kyRZev18LGlvF5aH3bxaGZ2UEiEDw1BWFdNZkLUiYDAakQ2GFMWAJEnRSoKWYAyUJftXtpnu7THb36cuy5iCqsnSlEQnoZZE6SAfhQAuvSfk0zjyLOfy5SucOHGS02fO8c1vf5tFWfHoo4+jpUBnCZP9PRIpkUmCdzYm7IZF7GBQcPLUSS5efIbPPfUVTmyM0UlCnuV899nvIbIEnQdwiVQ01lJbi/UhGdB4sM6G1xOUlgFo+piOGCs5Ok+llNGjGd6GREqUFOF98SakUQJ5mjDIUjaGQ4okxZuG2WSf+f4+ti5JlCDPUgQ+MJ4QkgadQ0TmTwkRHJdtBYC3CGvxrg3usaHCQ4BWikQlXVVIm8/scb1FYDybhO+Op6AUiCEvsjPdLQsQpLzmgsZbQ7mYUy7meGdJtCLRoc8zfshIBInW6Ah0wqI+yB2td4Hh82FJbZ2Px6JgUS1o6gpjXPi+kGidYH1gtK0zTKcTrlzZ5sUXX+LFCy+xvz/BOhvPoZzJ/i6j0ZA777idO26/jURrZrt72LphMBxh6wBgRRvKaQxNrJ3RWlNF2XCWZaHP0jp8ZK/qqg59kNYivI+VF9HHKkAnCS7WysjIansX2OOmqWmaOqgqEh3L2CPgiASa1kkI+UpSEqH48pe+zMc+8lVuv/UUb3rsMc6dPUNTLpjPpiSJZnN9HGtcwrXEWBtSkFuwa0z8CkOJpg6DLGdDmq2PEucA6Nvk7zAgWAJOtyKx9cYGD2cvdKc/QJMx9boLEopXdBXZfiXCNTBIwwMIp2PUPda4cH2N9UpSaVw4TTr2MkiIVQSyUfrvgp9V96qzTNz/Fly2km7fMpe9WHPnl8epiFUmzrnuWi5jt3BTl8xnM86cO49H8Ozzz/Kd7zzNG9/4BkYbG3iV4ZQKmvnYTeucR8hwXQ+Mb5+9XKazi8PAFtf2BR6s6ngtwOW1QGCXMPwKgFN84TcE9o4GU9cEl/9Aev8PBPwDAf+g9bH3v676nl/96l//+mC7v/55LcDl8fr3GFy+XHB57Lk83n7gQf/1PJYHgd3LOvVeoafgsAqf/utowaWQgqLIubK7S6EFhZQ88MjrMB6eff4FLly4yOnz58nSCZP9PQbZIEgwvYOqAQE//L/763zmk5/ij//kWzxw591sjIZsX7jAqc0TeGdRwncT8jaFtZ2I94Mq+qxA+zrb/kSLD5UBbeF79K3lRYFrQy5YppWW84qmaRBakeYZWRGSLL33NGXVsaJNWYEKstf+jbIvz22ZBmMMi8WCsixJkoThcITQIYo/UZpESdAJeEE9mTDZ26FalJTzOeV8ho4gIkuSCK4lQqvAOPZqYwKqDkzJ5Z2LOA+LyZRbzp/jbW9+C//bhz7Ez/7tv83G+XPYumQ8HmONxc3npGmC0kmoyZmEBfT58zfzvh/7AM8++yy//sEPkuQZZ85usb6+yWS+IF2UZPkCkaQ4HwYp3oc0UIeMrA0IJTsmxrnAX3ofwEToIQQlWg9bSLzFW5SXqHgYW+9RUpIrzSBLUd5hqjlN04TPxUOaaiQeU1eBacGCdyQ+sMeJDl2Xpi5RaQHegA0LsbA4tbQWTBlZMR27+7wkgIOevDcwsKEes5WROt/6fyMz5Xx3K7xeiEb/fKvLsmMikyTpZNVtuFBRFGRZYOCsMaRpyng8piwr9vb2mEwm1HVNmoSOReccVVUhtcI2BqskLgtsUwtG2/MG4Pnnnw3H7HyBUorNKFudTfbZ3t5mPB5z+vRpNjc3Oyl6kqZgHfVicei1rGUUrbXkxaBjLVtWvz2v0zRlsQjPq2OoTf+xpAyhS13th/dXsYj987F/naDnv8QJqkXJ7pVtcHBifYOtk6eCdDOCnzwJ1w1nXFQxgPUOh1oJuWm/Dl6LDluc+zZBd+Vaa1euZUkPvB30nvfDzNrr4IpPk1DT1LLGUkq80t170/9MfPTZBh+pDSMTsRo41E/C9d7jrcNqj77OAl/0MIOIrUKi95htBkF/PzAN3oQ04MJ6Ljz3LI/efz/vfvsT/OK//vf80Rc+y9b5mxHpAGEToEYI3aXi+ghgDy8acFyvwuI/6nL5++gDPCrI7+WuDcQNPsjLSaQ/LFSKY0x4vP1HIt30q51UXOvgfy1OxGPG8q/4XKU7vg6G9rT/43q+Brr+rMPDdnzP49GWd93QMXBoZMBKauEhXa8HJ+UrjGlk94SQzMua0XgdqQTOWU6dPs2Pvu/dfP6LX+J973svDz30AIOiYDGfMZvNGBQFyWiNZq8KckxnuP+Rh/jW177GpZ1tTtxyK+P1dcqmJtfBTyOFXyn1VnIZorGy2IoLy24f46I0S0L9SFsYHlJuo9RRhGqVpmko5zOsdwgZpu9JnoXaEu9CaFEvfEVIiUxkW9kdprHxMduFtvMeqRTlvGR/fx/vPaPRiHxQAFAbRyIVeZGD1jBfsLe3w3w6palq6rrGmppUqhg6ojvGo02TdFi0lKRJQtqmcPoa09gQRmIdaydOxgWnAGMRxkEsQLdx8SmEwFmFTDQ6TSlGQ2aTPaSUPP6GN/I3trf55X/5z/nND32En/2bP00+zBAoZpMpp0+fZVKWOKkwUmGih9DUNSQKpSXWGpo6AO0wLAjeOx+De1IR62VcYHoEoZDduAbnA/AcD4YURRbqLnTCZHuXVIb0zsHaqKsGcSbUUWgZeiVxHm9NCPkQquuVs6bpPk/dya89TRPqHvAeWv+ulDghQPoIopeL4ha8GOcgVueAxDTxPJYt+F/m1AYQ3QM/0QRtjME2YbhhjAksoY7LZGdxxkfwlYRKj6pGpwkq0wyTUHcyn+TsAJubm1y6dIn5fB6ks8MB83LBZDYnSzTJeMRiUeJj16a9GI6FJoJXGxNXR6MRo9GIVOvg3SxrNjc3ue2Wm9jYWKcocrx31FXdySW1kngpsJbARtYNxoQO2SRJw37lKV5A45pwnuZpTEGuAyCKMuokCb2NoT8z6aWiBo8g8TOUBxarWki8scgkfH5tgmyWZUgEaZLgnWQ2mfLM099hkMHJzROBJW1MSKwG0iShqWpms5BqK1USJLexK7QFRgeZ6IP3YbfCUnqc8QeGYzaGXsXvq7afNFxXkiijdc5ho+O8fx1MdajzsNaGc8DFGg7rQhWRWEr+fR+IuWXHslIKkYahVV3XSK2QSoXrYnzvfBxSaK2RiezOnYPp3UKIpdw1dkm2KhopBFKpCMBV5+n03nWy6KLImExmDNKMRAruuOk8b3n8YT775Cd46A1v4ZZT5xDC0TiBF5ZEJrhYLaR1hqsriOJOj18SY2IJbtthRB+8+8N6nuNd9NX2JPa/11W9+NXk84OD5aMeu/8aX8l69SCgu5Yt5sAaoD1wxWHrg/77eJTt56phddulGc+lNmPhqN8Nz3N1MOGxpPV4uxHyZmUdfsxcHm9/WQ7upRfSXztN0B8x0YtT7uARE9ed8L1S5vN6v2eMYTAoaExDZQxKCE6fPc/Djz3Oxz7+e1y5ssP+/pTRoKAoBtSL4PtyZYnxjsRbyDNkmoJO8FKhkoyFm5BFX1lfDtPd9JcBuCuepj4jEQI8kk42LHyQ06q4uELKEHnvXZC4WRuYKp2gdIpKYgm78zhjIPYNthKv4PUKi67WC9cG+XRgo2moqorFouoCfYoYYuK9Zy3LAmNZVjg7ZTqdMp1MKOcLbBOTPWNvYSLVUh4sBAgV6reVBGRc9EIiFUZI5vWMVMuYchq8lfs72zz6yMNkaUKzP0EVGUQ2sLuh2yDl88jwWTQ1o/Eab3jzW3j6me/wsY99lF//D7/JT/zUBxBp8FO9dOESo41NyrImGRVonXFx+zIqy/GGrtaj/Qzazr08S5AoJKHuol7MaUwV9jdLkN7TVAEUjjc2OH3yBEVRUC4WzCdTtBJo1fZeyiXToz3OW2Q3DOgxSVbgVUxpdaaT7jXO4v0ybTTIPzO0ECjhOzBs6DP5svNOg0JKh3MKRAjxaf2LB6b+XRCK6Kd3xv7CpmlCR2aUVQvhEX7JwUgVw0okUSoaFvDiAGMHMN3bRynFqa01zpw+x3A4ZF4GJjL0sFZ452hs0zGK4TmWPbKttLssS2ZN8CDnacbm5iabm5sURd79bH9h1/YtOudCxYuMvZDx3JA6+lZbQNOTHR5cLPYZwcN8zd01M3b+HnVNPczblsjQR7m3t4fScGJjgzzPg3fZeRzLAB2tNQiBlBovgqrhMK/sNdmY3pYkyQGPplgFl3HR3SW0Or+USsZmD9++n/Fa2KZpCx+Se62UCOepbR2CzwbLehQVQaOPrH0LDNqcqVZtsEyzPdq7dhWzuRKEE2WQfTBxCHnYmj0cwQO9WCzY2jrJ5Ss7bF++yGMPP8SffucZfvOjH+Ppb/4xp++6H7EmSZOcBkltapIko6mbcG4LH/ovfT8NV75sEPj9GPC397U+k/5qnvuVVpFcK/Pheo931LFwo2TNYUn1r+Z9PwaVx9trtR2Dy+PtB4Q9PhykXQtYHrxBH/azoTvMH3qLvpoxPXgxl6sx+NeYWB6UUXV/7y12nBc0wlOM13jLW9+KF/DH3/wT3vH2t7GxNmYwGDCdTlHWUpkGtKKxhkSGxMmqqUOYhAyhHWmSdHF83U1HyY4l7EvP2nTIFWDZTuhjv1oH/OL3ghcpTLmdcyBE9ztKC4T0OBs9gg6QLYDUcXniVya1WmtSnSCFpImvZ7FYRKmfDGzboFg+h1KoNA9psIs5s1kIoymrOaZuugl+miQkMUhGqqQLc7F4DEspmXUW4YOM03uPrRuaynBi8wSD0ZjnL13i0sWL3HH33QE0nDxBs7eH8213Y1wGKoXMc9JY47K7t01ZG06fO8dP/ORf48WXLvCpT32Vtc3P8JYn3ojWmiuXttk4cZI8TamqGtd4tFTBWyYMPnQRkKhemq+AItGAw1uojMGZGlc1WO1xUmCto8gzNtfW2VzfYDDMw6Jcqq4aQ6kAvLUOVR+IAGZ89FsFsNjEBXQoohde4uSyoiAcQw3WRgDqAkjRMg8+tRZAtgCIAxPzXodfCDCJqgB/hF8pHsPtojIE8zSU5SIE3MTqEi2XibEIF0/1lqVrpbfh+U1jAjPqw/K8MRXWGsaDAadOnuTUiQ0GgwHrfhy8kN4z2dvHuwBqq6qiauoOFLfANokybGstVZSpro9HnDt/hmI0QKnYywggwmu1jQmsewxEItafSK1QPUB1MNSsu+a46DdsGckDjKCPFTVOEIcW4irIIKIiof9cOl7zltdXi1QZ+/v7XLlyhSyDra0tsizD1CGpVoplaJJHouIwpx1Y2NY/jF8FDCsL5g5ihYGiCK+37aUVrmUzV6/JbQ+kt8EXi/IrAUUrUCn6OL11Pb+bIJGKBjBVTe3DcyZJgo0MkbPL62h7/USEJG4lNab1KkePpZQ9KXLL+qnlNa1VDwi3CpoOAxbe2wjUe+eXW55DiQwMcZqmzOuGLNU89vBDPPX5z/PRD3+Qh9/6Tk6O16nrGpVKkmiubcH56iZXwC5+1XJyVD3F9XI5jvr55efONd+Do8DVKwF7rwzgvnrQdhhLeb1Oy8NB6QEm9WUwr8fA8ng7BpfH2zGLeY1p9srP4182m3jU5Pzq3w2dYEf9zFGgcuUEjGXnUiVIDM42+Lri9jvv5K1vfTNf+MIX+Dt/62cRQpGlRQjt8MH/KIQOATLWkec50+m0A7wtE2K9j/UlyyJwCDIv4cUy+OLATeYg09FWkngfeiCNs6E6I0r3uoVRnPLbxgSApNLlPF2owLpF+Z2N7IxKNGn0craep3kZQGVjTGQrh2RZ1slykzSFJIXGYMuK2f6E6WSPqqpwzkZQkXQF6m3vpZcCkeiwICMs4LwMwR1CBZa1rmuaJoCHoijQOizMy7Jkf3eHm246x+b6GLu9TaITtJQhoVYp8J6mqqhmTbfY9EKxvb+PkJ7b7rqLn/tP/y6z6p/x1Oe/yebmJq979CGG6yPqsiYpcurGUy3mDAZDKmNDWTuQCImO4FjHABycxVsT0kMbg/ABOAocpm4Yj4ac3Njk5OYJ0jTF1DUmshPD4TgcB22aovQRVNrglfM2Lp4NjQhSWU/0v3oXfk6FwBJvgyfWxRRT1XudbXAOsVIkVDy0dTxxQeqIqbESIVTMDXFHpMGGf++8Z850pfftgKQvtYX2sbvM6XhuO6y3SKF7Pr6l766ch2ThwWDAxvo6eZ6FyhKZILMCISGLg45WYlfHsJowLFmy8N5GEG4M8/kcLQWDwSC+3gj+YuUOEai0dT+dl05JEh18k02sEsHSnZetj7tft9FPe+2rFBByeXy2AyYZehmPuh4cHNq1ibpomM2mzOYNg4FiPB53wM4YQ5ponA2vWUTGEkLxatVYhHBXp1Qf8rkf/Dcg9KXGAUH7+fkDva9BkSGuWqD7aPptpa+il6Td2iysDcnIqdIsWh+0tYgkIZEqnAME2bK14VxVsRPIOY/QCmFCqFLHOPcYShM7ZJ1yVx2z3eDNt32udP9ve0ymEB6hQjid9/Eah0T6EDg2m00oioLaWC5eeIlbbj7PO972Nv75v/tV/vTrf8T52+8MlgWlKbIBcxeqTNrnCS9G9rou5aqZ9Agm78bYQH9NgHkj7N1R9/AbURvdKBA96nlfLUN6EAzfyP69Vj9zvB1vx+DyeDvebhAY3sjFf3XK+vKf79UWCB8EnU3TUKQZrmkQOsFYy3h9g/e9/8f5+f/2H/DCCxe47957yYYZ4/GYqq4RKvifBnkOpmH9xCZlswzjyPOcZjbDeo8TEu9FBxZblskYgzfLRXef3Wh/LkmS2KcYwKqL3XheRDJSemT0V7ZMR2AQROxgDAmzUuhOKtgtoJyPqaOyA8NtfULZ1BhjyPI8eiyHy4tWkgQg1zQsdndYzOZMJhOqxTwCG4GKMk+VZJ180PqQZuu1RiRZSEFsmg50SqkxZcVkNqUpS7TWDAdDTARt3jqm+/tcuXQZPRwFj6eQiPY4sA6kQuuUxnoau+CFF18kLYIPTnqYlhX3PPAAP/NzP8fe5Bf53Oe+AN7yrvf+KPWiwSNJ8zQw0c6QpRrjLNYEFlEJUG2fpXfYusRj8dbiTA0xEbXIcvI05dy5cyQq9klaT6ISUp2EShCtUZlieSIEkOixYA2xnweJQrGUOIfPKYBnU7sIciMYiuFCUogu3tY5QgeoB6ElIglCXofHWX+Ih6plxySoA2mw3UI3sIs4h7FLhqoFUknbK9imhLpep15kZp1fPd7DV5Rw2gZrapqqIk0U4+GA0bBAIoKM21iauqZpKrTMSNIMKRNyn4brSxyCCB9luK3H1LqQQBr9oFKHzsCkW2TaIKk+GKbTPp6UOO9Cim3ToBK1AkhWFqwufJ7EMC9rLbWN75OgA4f9AZP3rEiD+0Co/dmOGcVGFtJRNyUeKIoCKaGqKogy2KLtwNUJSIWNcuhEJVh8x9Ye5rc86u/diMCa8FoOqFHa/9dS4YXsUomv+ryN66SwMoJIGd87a0PacZqmpDohVTr6WZtO3tv3urXSX3UAtLTXyoPvqZSSpqkCuNTJofeoLjzoACBREXBKSXd9RsQMAee7PuayLBmvbzKfzYJfNg2hVvfffz8nNzf47d/6IG9/94+wtrbJflODy8FY8iSljoOPTtkTQ7a6yNp43TjKC/hKZKbXYtZeyf3/lYC9ox5/RS3wMtYb12AaBYewi/102CNZy+8T+3gMSI+3Y3B5vP2VBZOHlQQfJZkV12EUl52T177xXS2JPboo+rB02MNApY8LEi8CuDHOkSUpOgnl6K977FHSHL70pS/xyMMPctPa7YyGa3g5wbiwuGQ4wFeera0zFEXC7u4uZVmSq5SF2UMpjZMOa+kWP845bARvCrWygOwvvqy1wTsFOBMWpib2DiZZGnruZOiqaxkC26XQBlmg9TEeXy5DK3BLX1crQa2qqlu4BZmYJM9zhqMRWZZ1j58kCWiNqyqm+xMWk1AxYuoKcCgVfGlaa1CSNElDGqyXCCUg1ZCkuCQJ/iVnOwmn9Y6yrpjP5wjjGOYFLnrmyrJkOCx46KGHePKTn2BhLW975zu4//4H0UmK0BqSUEROY9nf3eX5ly7Q2Jp63zAcDjl16iR78ymZTXjo0cf4mz/3c/zyP/kFnvzE5zm1dYbXveFxVKLxVU2xNsI1gE4QViCi9Nhbh/XBvyq9wzUGrQTWh8/IWUs2LDh96hQbGxuMBsPOgyZjvUILUhAhdGR5zLrgiXVth50LIT4CkBqpPb6VAPZKu1fYLUW3SE+UDjUQ3mC9QmiHRiIjwx3ApO5CgNqFrFRJWMhG5nTlibzshXbJEFYUwVHoJoyS7nZ+YTxCLhe7HrtSIaSExPY8x+2Ao2UfB4MBg7wIATbCYxqLdQ3WBB9xG5xiD1xPpI6hVMKTyQwpVZf02jQN3loSQvqul8taIu891i39pk3sp2xBs+/5VQPrfwCYRV+rRBwySPNdEmp7jh8El8751aTYXmpz51UUYiV0q71+Kg1ay451lTGNd21tjTwP5yFSB5jnJTpLcV5cVy1ykC3t+xels52Eu5WJrnwObUq2kIc+z8rC3HmsN6GGpjEd8yt67Ka3DlPVNEKCVrjeY3Upuz11ou+dH/4ASJZSrrDJhwWrHHytYoVNjgMUFY43vAyfHwKhIivrl4z1eDzGKElTVpw7d4Y3vv4xPvi7n+Rb3/hjHvvhH0E3cxblAmRCVqRU83k4T73AiaBq6PGnnXrnsPv0YczZ4bF4L287+N4sKzheGVv3ciS0h4K8l1nV1/u9brrtD7x/h4USHfXcVwPLg7JY8Yr25UaA9PF2vB2Dy+PtBx5gHuW5vBZgPGoCeqOTz8Mu3i9HvtOf4B4FMKUIDE7TNOg0w+ForCXPB5w/fxNvf9vb+NSnPs2P/sh7uen2W4Hg+altg9Qaomxua2uL82fO8tJLLzG/43bSpAg+JBH7JN0SQLSLnlAfIrswmv7isf0zdLK5TgqJXGUYiPIpF3vbukVnlAs66zsw06bRLsN8lr17xoRFvRdh/7KiIE1TVNv3hl2Wl8/nTGYzZpMJvqpCz6OUaJ2S6YQ01Qjd9mNqamtwElSSovMCmYYEWyklymqEB2sbmqpisVjgvKdI0wBqbXjfZvsTNjc3+Kmf+imu/Nv/L//m3/xbnvzUJ7n9tjvZ3Nxk6+xZbrr5Zu66/35Onz/Xfc5pmlPO9qlNw7xc4LzAWE+aJbz+DW9i/69f5Nd/5d/ysd/+ONlgyMOPPYoTnmpRUgwKyri4Fd4hvMN7E0KIUEgJSkucNZimxjtLkWec2Fjn5MmTrI/XAvhMdJDtet/tT4iYFd3is5OKCouXgWoJHktH2wIbmG+J0EFSLKUkU4GdDF2CqvOWJSqJnX8OYw21MQhrcUSAq9pieNkbE/kD43q5XMz6JcHaAiBcOGYk9Go2WlARzzGlgty3XUhFH5vD4oTENoH5XAaABS9xC8LOnj7FxtoILaFezFksKpwzHSguimJVhtpVAIS03jTPAzBERDmqi68ndIVKSUgt9W1gTkwE9Qbvo8xSiqvZSSVjoi5X1XeIHvjsA8MVMCXDQl+hMKbGexeCJZ3HORNBmkOpGHzUkmMRFCWJIkk1HhucibInQcUhA6EZqmuSpAu2SdI0qCCMRycZ1tGlny6lvf5QaWv/e957hHfoWGmzvK6vAkbbMtfCH8qKSpadjtZayrLCVDWmaTpGtC7Da2/abkvbYIxEijQOWeSBIWObaNyvLJFdeFVXf4JY+Wz6IPUqD6MLA51wLEW2UoUwMqlCGq13AouL6tUwsEnTlNl0jtYpKkvZj73DJ0+e4oH77uejn3yKT/zOx3nk9W8i1xnz2qCUxpgapSRL66UITGmbIrQik+2Dx6vve6/Gc9n/p6NYwaOe4+Xc57/fjN6NyFiPGkjfyL68mtd3LKE93o7B5fH2V2Rzr4jdPBRg+sMv4L3ffhUXaxmLx175niZJQl3X1HXDeHON2XSX2XzO1okN1jZO8EM/9E7+h//7/8CVK1egsVRVhcoU1tSMBgOc88g0Z7BxktNnz7P9ve9hrMclwe9jjcXEZMF+p5vWKvh03IGk0wM39xZstb7KtuAbH/xjMpGxGkMhdQzLkUsZ3kGvVt9DJoWkrKoY3hM+c50moZstzUjyjLIs8VKiE4VWCtMYptMps8Uc29TYplmGZWiFShNUmqJkEsCTEDhjsHjSRJNkAbB6KRBKoVWKFAF0zCvTSd6yPEdnafj+vGRtcw0SxTjV/N2/9XPcdfsd/MFX/5DPPfkpFhXsV1Bk8MYnHuVHPvB+7rz3niDBlYL1jRM44bhw+TKb6xuMN9aZzucMipyf/Km/xs6Vy/ziP/sIT336M9x5112cveUm9hcTfJrimxoisBQ+SFC1lGglSKRAiIRFVVHNFwghWBuOOXnyFMNiBEh0lq9M90PSSGCYrTVxoNE7FZwLn7cLgLb15rVF6lJphAhgXjiDEsGj6aRD2mWNTfD+ObxoZbQ2vH6tUCayV3E44ftsjhdRTetwsfrAi9V+1hbI4YPfWGhNEpOJbZRtdwyRlAH4xG5NfKj7AXDCUZUVLp6Hic4QwGKx6Fj+YhS8vqGGQ0TZ9qKrRQngklCJogUJGqWXQ5a2f9Ib253vWZYFAGMs2rRlIQKZaKQKUtqGehlGs7LC9kgpUC6ew+3HGkFzy7L1/ZbtVwuYifAn6pk7OTuuB97Ekm1rfa4BBIXfCYOcLCRtK4VAhe7Kzm+qqRsTZcsO34TOSJ0LhAxqirYT1YvVRNWDnbt9Zr2tk1IicLS+sVeBy/7WsbIsA3XaUDMpJLYNIYuS5bquWcxmmKZZYURbEK+1RiR0qa+tZNXLcDz0I1xDYNsBOW5LLvngVU9kEs6t1orgwyDECVY6JoUP12ohwrW4DXKSQiO6wKrwfSeXfZjeRn++1swWi8AYa4l3jvOnt3jw3nv48uc/z+ULz3P69rvJnKCSgsViTjIcU8dAKdnr2Qz74/C4q4DJjQ5fl99/eaDpyP8/JIuhC2xaPX1W7vxCimsC3uv5R1/NFi5L4fM++B4eg73j7S8tuPx+FtF+v7c/jwSsY9nA9xdYirjwuTq59UCmoZedzK2Tu/XlQ7IvD+OqG1HnOZQHfSN99qR/TImV7k0hRAiC8auLm7BuDh2IRx9E4Jrg/0IpJrMFSmrSYsCirNg4tcWb3vpWNjaGPPXU53jwwQe57ZH7oZoh6hKVJFTTkjyVoFPe+o538k//3/+I5y68xNmHHmC6t41qOwh1CNMRsQaA6F9TLBdIogcEgzQwLG5Rgd1sPWRdnL8IoTlttYh3IngDle8SKbVMIiMmVhaM1nm8tSyaEus9WmsGgwGjKIN1zlHN50HWCvimpiwXlE1NWZaYqgo1KHVDnqRkg4Isi3JYKbpJ+3y2iN2ZSVx0N6R5RpplIBIymUBVsr03YbY/wTRN6CMs8shKeEQqWdRTpAkezlOjnJ96z7v4yfe8i+997zl+/1OfBJ2wt5jzh3/8DX7v44KTp09xx733Mq1rnAq+2iTNmS1K2NllkBdYB0Yp/vP/6r/khcuX+ehHvsiZMx/lx37iA2ye3EBYS93UCBxaCHSaxIRJi7AWITTNokRYh6kNg8GAc2fOc2rzDF5IVJJi6hjoEqtj8BZhDM41GGcQPshC8Q4hPFqGehgXOwRlXLQ6QPgYeLPkMoPUGIdwrZTaxUoNg3Cq6/FLpaCqDdVsAtZSFANkonHedZ7CcL4E4OsjyHW2iWBzKXkUMhy3IWhKIgiy724xKcP32uNYRqlukA4qsDIe3w3WNRRFQVMbXGSXpJTs7O4zGI4ZjtYYjNbQaYb1gnwAQi+BWuMsSaIYDAqUCr2b1i+lp8Y18aoRhKqmcXgnUCpBeI9wEi1iQjMKHDFxF7yQSB07P6WPq2SHcz4EeXmLkgrZrzBxFmsaEI68SGmMC1LrKIltvZ+0QU5SoIXG4DHGgQ1+aSF1SFuWkmwwRHoZvdxFDHwS4BXWarTKcFbRNDG0SyWBkXSQZDmLxgQJcJ7S+HjN0RLjYn8jS1bSdYmxrTc7ApgOILaMY1RAEOTGXbqxiOFGkbFUsdvTWo+zDtMEZl5FJjPRGU3ZkBQFUmpmswXOODY2T5IoHRJ7m4bt7W2qqmI8HpOmOdhYWRTZc28VOnGdEkMQfMH4cO1sTBWu9VIi8aAlhRyiEUwmezjjw+BLNXGwYUJYkYtDmciGtvc4IRRKJwiVhet29EFKGYY9QW0SxhbOOZS1ZMUwdBHXFdVsyoP33stjDzzI//Jv/n98+QtP8eN334VvaoROgvzehmNXESqcJOF9995jCcMfHdnzbj3UY2H7fclXAbhVw8oh/xZqsSQH1UN0MvpWydIBxb53O96KhRArgFKyamdx7ogOv+4W7a/JkLY2kaUnfFUhpaSOx6cT/f1uK4OEUPiV9UYr32/VWvHViANrTSHwuJDEvbJOul6tiezex2Mge7zdKHlzGCbs20uOmcvj7S8te/mqTxyuLUG5keTXV8KAehcAs2qn11J1CyonYfPEKd769nfw5Cc/zd/5O/8JzBYgYDBaozYuetCCj/Hu++7HIViYmv35jLQYYGaz7rkCg5F0Ny9vXWBzYLULrnfT8Qe8mCvSMiFQQuB8zJDwQRaohUAmCqED6hYydGMCeBsqFuqmoXGWbJiTpSl5nqNjeflisQgMT5J2ASPGmJge2+CauEhWimyYdmxQkoUOQOMd1niMtUiVkOQZKtERIEVGznlwFX4RvJuTvX1sl0xbkKSx5F0rUALdxLJyHNK1++rYWh9z7523IZIckWZMFnOmsynT6T6VqQLIdQ4hg4fUOUdjHIuqxqUxZdRa/rP//H/PZDLhU5/6AqdPn+Ytb3sL+SAjzxK0sJSmwdYVSZ6jlaSaL5hOJ4zzAWowBOfRSdqBLoHAmRDQYrxHt8ei0PiYitsuVlsyRcXFjmirHqTEmrrruBPCE4WEoftOWEwEOd4LbAT0LtZK4A1KhGqZsNAKHjDvDE1dIUyDlAorVMeUWZZ+35atWsrs2kAjEV+riIsxucKCtNJKoAuaQrRe46brjvRYhnkRwnhETMZ1Ig5jgmdYqQShNFqngQmO329MFXs0Q0WI1rFaAg9OXXX+Cy/xwq8EWrUL35jtGRd+rhvAGGM6z2k/7bV9X5SQaAI7ZpumW2z3vdXXsgocBgD6vyeUROsMvOwYyXAdSUCBSjJs5YGEcl51C+TJZMLm+gYnT291IJYo38SH8zNc4T0y1sP4dlggVmXaOvbZ4mKycGSdY7LTilf0YD9k33Mm/TKMyjWO2ofBWZpEX2U3ULOdZUCn4VpplGI4DN5lZyymbsiSNPZhipXjrWPgRWCk+57kFiC4CITDtVKhehyllyIMFvry3wMMZlsP47yPPnbZ82/2/KkienkFyBiapJRCS4WWgkTATadPc+vZM3ztK3/Aj/71v44UCbZZIGUalQTx+dvrhGgHqC4GmakbuhfeaJCPOPD5tyDsFYfn+T6kWv2+F+0Z98oJhpcb7nM9NvRgeNX199sdLxWPtx8s5vIHHWn/IDOvx9sr+7xfyefeXczlagDGwe7KSPT5lzvtu77XgpWbScBsCrzDO8/W2TO8810/zMc/+hG+9sdf57Y7biUZpGghQ9elktRVRao1d911NzffchvPPf8Cd547z5mNNWblIsw13ZINCIBmWVvQv1l2CzMpEJHF6jySbRiMEB1b2SZ4yrZmrf8zBBmgda6r96it6dilPA39k1mWkcUaknah14aNNE3wvy2qkrquO8aofS1FlncLfqkVJgy8MTQYPGmRd4tEEV+PEiHUopzNqadz5rMJi/kMiQiBSkHrGWP+BUmSYITEVBVEuaFpQqDShQsX2Nvbw8k5Z269ldFoxN7lyzjnQvVHZSIDpNFZHkDyoqSsGry3FMMRTd1w82238n/6L/8L/pdf+Md8+KO/jUoVb3/H20I4jgzy5LJegDMoIVEehqMho8GQ4XDM+niNsq5X6g7a5F4hA6vc+t4QEqkCw+utRzgXpZUWIUVMpfV4GTxXklY+GRaWwgfmuQVoHaNP8LiKOOwIr2O1U9C61stb45FonWBpcL5NRdUdTHQtSyOXLISMC+n2uFwevn7JYPUWXJ3P0dNJRYHQwxqBL1GaFhJvQ/G8MzYMLJQO3Z/So1NF4gOYrJvImMkAgEI1UFiM0+MR2tJ7KaK6oZUuxuGMFyCVXFIJB4KFlIiJs4gV2arwkY0VEm8sxrZS3wPApPVRCndoH693DrxFyiWwNMaseCtdyHQNn4+U3T4gwvnk6prnnnuO6T7kNy3PR601OonXG0F3vbGRaQXCAEgI8LJjLFeWzC6+m/Hqe5VcNlbfSH/g3t8LwOqYrHYfAOl7Xb2d77tldnshRhHcjEajUJE0naEi2AzP5Q5M8lm5LgoZuy/FkjHqPh/noK14EkvpbT/Ve/k5+iPTQ71sZblBXXBotYUI50HXVRzfh1tuvYk777iNT3/ySf7uSxfYvO1OposGIUHicL1gKCviDSu+Vi9enhfw5SSptuCyHUytgqlrMyYvFyD667z+64X3HLWPK8fDEa9XSg5lZlv5t/d9JZe/6u/H2/H2F3WTf5kBxzHd/1cLYN4ooDv4e30wdFTHWvx/cdj3b+Q4PJL9O3isetl5oKy1rK+vc/d993L/gw/ywd/8EGVdobRmPp93LEJjDaQ5Yjjgne9+F9/6s2+zP5sGmVWS4AWdfKtdYPe/jmJq+4mQqlcj0qXLKhkCTKRYWVC2ILFlKKsYlLNYLDo2ZjAYsL6+TpqmoR+wrrExmTXLsq5Xsqoqqqpa6Z5USnUMYwgPUuG14GmsoTZNqEnRinw0xAtBY23wUmYZOMdkd48rL11gb3+HspxHWW6OTmTXl9iGxPSPkfa1TiYTLl65zPbebljcKkXdlCwWi87f1vbm9d+zIBPVWC8oq4ZZXeKl4vLOLg8+/Aj/1X/937CxscGTTz7J17/+dWxj0FIxzAsGSYb2Ah+Z23E+4MT6BmdOneTs6VOMBgOsqTF1ifCBUewWK7Lnu5QKoVqvVgi/aWWkWINvF+XOksgQHNR6+bwN7423ZllzEX1fOlactCEu7bHQ7neWZWRZtrK4daLHxER5aBrDlPI8D4X1OiNJshBKopIYArTspOwPRpZgN/Z1iiVgsr3BRt+HWLdJxbXB1g2TySSUykePsffLcwchkIru36SU3SL7sH7Ig4Obgz+7cu73kmpbYHEUsyjbPtN4TDZN051Dh8mXrvJuxoW6c+ZQZrRlb7uFglboNOkYx6XSQXLp0iWefvppmga2trbYPHUy9CrWdfe5do8fE7JNlK0a02NaD7B/yyFf60cUOER33WqTpfte3P7/H/wslAqDgTzPGQwGDIfD7jhrj9ksy1BKdc/Rvv/tsWuMoSzLw0N3+qzYEcfDwYTxYDtYTe/tV5AcZGJX6iVlGBj1q6O6HlM4/Ll6oNOamhMbm5zdOs0z336OZ779Z+RZQSoluOX1y4sWSC6PLS+ul67+8u6P1/v+kZVirxJjuRtcV1wPWL7cDsxrrTNezbD6eDvejsHl8Xa8fR9B5ithFm/w4v6yru6HhVSsLi4D+3HYz9bWgk45f9PNvPXtP8STn/4sz714IfQr9m5KWmswDXjP23/4nZTGcOHyFRrrSfMCoTSWIBPtiu6tRfQWJO2iW+ggZ1Vq6WtZSYeVLVBxcXG6ZFoaZ2lMRd0sQeHu7i6LxQIhYDAoQmdlnseAlBgwEvv4WjYGQlhQXZbMZrMOlLb7mqYpOgtfUiUomeCFCnLTpqayBqcEMk2iX02QRumt8J7J3j7T3R2qskRGlk4L0DL2EboYnKNX6xYAjIN5WbO9t8/Fy1eYzmeM19e48847EUKws7MTU2ZdJyVMkiivaxzOC7J8QJLlNM5zZXeX2lmK0ZiXLl7m9jvv5P/wf/wvGAxGfPyjH+OlF17EGsP6aEyRZviqIUNxajzm1MY6ozxD5ilFnpFqiVmUVPNZYCyvKp6XOCRWhC8vVEisJHjQJNHrGCtNWpbPWxdCkeoGUzc4ExeZUgSmMX4JqVE6DR2asVuzv0hv3wutNUq1f6qVr8B2JSRJtvKldPisURovVQAaHYsVg336/ilnQ6ekVJG1jPUi8V3wxmLrBlyQD8uet7pelEgcgzwlTSOAtKEb1romeEIjHdaCxbaGx7X+5SP7GR0+skgIByr4TREhjbQdbBy8fggXk27jfnZBPtbgXPCPOmfAus6eqdoU18jc4nyUhUfyqX3cGIwU/JYhJbYF4EKFeh2VBKbbOIdHoNMUISV1XfNHf/R1vvOd73LyJNxx1z1sbpwkTXN0kmHCjKJTTrShN234Tzj9RQdW2hChTj4cv1aHWnplWNMPGjt4POV5vjLQ6DoE43O0g4xMJ2Q6CZL4JMHUDeV80YGpFpQqpWjiwMwYg5byyGv+QcAbGMw4GvEtCF3KjVuP40HljFi5NwSFQBfqExl+6xxNbzBx1f0sfr4BNIZO3LIsSaVgYzQiU/C1r3wFvGeY5ggTLAAiSmBbgIkUqwD3Fd4Lj/5euK90XoveoKgPbkU/cZ3l+dZezw6CNXcASN7oPlwP9B3FbL7cns/+gOJgcuyNgO/j7Xg7Bpev8Xb4RPZ4+6sDJl/dlO8goPvznhCuJKl2ZeBxCew9zsOZm27mrnvvAQmf+cxnMIuK4XCMEArnDFlRsJjtg5Kcv+1WHn7dwzz7/HPsTPZQWRoWhiJUTxyMuj+47/3+tYPvT3+x1ALKNihkEfsh5/M5i7IM9R890JokIQU2SdpQGoetG7xdgg4pJU1Vd4Cyv4gTQnQLwbbHUkqJShNQEhuL5b0AtArJm1lCgyPNM4rhACEE0/0J+zu7NHVNkaUUWRKYCtdQ1xXWmqWEM4LD1u9ZVRWz2Yzt3R22d3fY39+niV43j+XKlStcunSR8WjE+vo6WoaewxCkpOL7FQCZTDToBIdkdzKlrBocnsWi5HWvex0//dM/TZJk/Oqv/Cpf/dIfIozj9OZJ1gZD1oshp9Y2WC+GKCmgaQBHlmgEDlNV+KZBKrEMYmqPswgqvVAxAVR1XYbL49B1C9kgF3TUxoRQFMJwIYDDNMhgZQoi6R5TSB3+jAx20/M59pnDFhDIJH5p1fU99ocey8WUimmcy6/DKipaVs0YQ7lYUFVVx3q36aiHSQfbRXxd1wghGAwGFFkWpJ3yQAqm9EvAIpZA91psxLXqEvqvub/fUsqej5bO/+aNxRvbMfp9UNHfdM+Pd9g1p/+8Ldjr9972OzatcZioAEiyDCk129vbPPnkk7z4nOOee27jwQcfZGNjowvmaRUOLctG77GdF3GQFZNoZT+d9uiv9vdXAOc12J+D16+jjpdQHRSuLa1CoT02ZPRMt97L+XweeoY7oNgOyPwKw3zNtUqUKmspQxesDZ2dsl9hcsTrD+eywnJ1/+fR9xe38vemKsFZTp3Y5Jbzp/jDL32R8so2ebyOtAnH3XurZAhIF0sg2AK+12INdtjjHPXYQojXZPF6I8qio1jna53nvS9xIwPwFXb6CKXBMZg83n6Qtr80nsvj1Ku/2gCzlci93JucX5oeD73xLP+9+3l/1e++muO2HwAXGQmlA4NoncY4Rzoccde99/L4G97ERz/2cX70/e/ljrvuREtFE5MpjYssSJLxnve9n1/+x7/A8y9d5OTd9+AjOyKF6hY+7bRXqVjuHlMJZWQPr4pjj0X0EtmFngQjmQhSt7jIETKkIwoJUgrytOhutGEBt2TUpA5JpdJJcJ7GBRDSNE0Aij15XpKlofcyTVZrUxAY56kbgwV0mqPzFJksK1GSPENYz2R/n73tbWxdU+jASiEc2SAniYszSQCKOINtQKgkgMr5gvm8ZG9/wvbOHvNFhVSKjc1NsqLoytaF9xRpxqnNE0jn0QgaG4KXWi9V0zQ4T5Atp5L9vW0W0xl33HIzRED95jc9gcLzz/75L/LZT32aPNE88Za3cG7rDBiLtpLF/pR0lOLmDqkScq1opKKuKsr5nEJppM4RvYaGtshciJj06k0YPPherUJ7PCKDz0qAVIB08ZgJCaNeCmwLzlwL0HqdjUIhXBM7UuPQIh6D3bCDlq2WnXTXxmPEe1akmW1foY+sZetDayP9+/JAG4+jqpx31Tt9ENICXO8FJvryrLU4Y6kWJcJDURSBxfOtz9AjZPTKEdKVOQBWDg5n6BaNrqvEwLvQTytlVxfCwUVlZG5SpZfHuwveQmtd1/VZVovlsCimAXvnA/njXPAYE7pcAm8dEzPje+e8xzZ9xjSevwfOfxGHXV4KVJrhEEz2p/zBH/whf/zH3+bMGXjiiSc4f/58148b0nzVyufXAcL2etEmxbagOQ6IupCmDqBFUHUwpT0erLaV1Lqln9F7T2WqoEaIj6IIIUrt90wEUE387FKd4FPHItbqOGPCgCl6r0drY6bzWahIsoEd99aF8JwjQFD/XtH6QL0z4bXK9piOvaSqt56R4Ew4t0JwloidomJZWeIcXqrYuxq8tS76aFsmz/fasoQP/k/rA5uZZILbbj7LrefP85WvfpVnv/M095w4Sa4VpTWgNS4e+y0jHxjvfsKpY+Umecj98+q12eHpprLtJupxjiJWEXFACSCEwLHqqb3e5uIzqhsEbDfy70etA3o2GiGuUXl2I3kR389KlOPteDsGl8fb8XaD08gbBX4H+zCvI1t5TYHlYRPaECahQ7WDchjXIJzhrvvu59HXP86/+KVf5IXnL3Dz+ZtIUo30jqqpSfMs6s8sr3vD40wWc166cpnmrrswhMoBH4FF16cWF3p91sP7o25mfpXlEa0RJ4BMqZY+tpYJ87JD/QF4ySBh8kJ0UfESujCNbgEQwYFxlnwwDKxnZCxlonudcALroKprKtOgEk2WpaSDAqkUxju0CK9rsZixvb1NPZ0xzAuyLAtTdykYDcfkeY5tDLPZDNtUK4tBYyx1baiamkX0gSqlKEZDqrJmtLZGkqZsbW0xyAtMUzHIUhIZgpOMcwgJqdZU1lDXAdClaYZrDIlOEULxwgsvcHpzk7XhkHI64e1vfztJqvjVX/kVfv1XfwNT1bzlDW9kYzgkSSRKK5pFhRGWLCtC+IU1VFWN9MG3NT55emWCIXxvceZdAHttUI9w2MiIyFgFpJXCqQbhEsB1qcZdlY1UAQz6KKPzAiXAiaYDWv5Ah2K/MsS6UHUjRACeLZARSFCgkySCDoFz0Q/a8+AlQnVsZP/4McbFnshW/pihVACDtutaTVA6QUqz9KFFFk+IEO5kG9PJw70UnZ+uXxZ/0Be3wk4sX1THbrlYtQKg4v8rrpbQtv7iEAYjuvMI5zuG8yC71k9PxfluiHSt6qzWkxqky6LHYsekY8KwK8wAJFJo6qrh8uUrfO5zn6Ocw7vf9wRvectb0FqzP53grGVjbQ1TLwdFnsCkCyVDyJT3OFMjIhB2eLxbXgcBkjYtFwXY7h1tB0fSrb73UsZ6ihaMtxUdXWrvcp/D+7EMz2nZ9NbD2r6/7fua5/lS0t+Y+Dht8nDw+3Z1Od0Qp3/uuc4C0B5DwtvgfXY+AE6vYoCT77ot2w5Sh0AIh2h9pfguxbUf5GWt7b2Pq5//SlIxjlRJzp8+zcZ4xOUXJ1x87nvc89jj5CqhrC1oRzSFBtYy/tf3Nl8LDN0oKDo4LLgeuPpBl4Ue3J9jcuR4+8u2qZ//+Z//cz+ZXuvH/Y9xoTnWvH+/Ns/hd5n2c5YrE89Xi/Fk7H7kCInKUk4IQoh/cPAL+PsHb6R9GVM/LfPg8eJ98EE6sfQBKSFDd1iIkaNpapLYAbm/v8sXP/95FrMpP/z2t5OkOdYExqHIUravXKbY2ECUJaau+PxTn+O2W2/lpvNn2d/ZwTSGTGvyPF9WBIgQWS9itP+SVVToRAdppV56mzrmIcrZhBIoJdEqgB2ldPdeOjxKyVheHz5S1TEX4Yba+oRM01DG4B7rXPBWZhlJ9Eomado9ppQSH1mHqm5onEdIRZLl5MOcNM+QKoT8CB8WlrP9CdO9fZSQXQLoYFAwWh+j0xQ9HKITTVWWNI3BOs90NqcsKyaTSTjOhGA+W9A4j9IpzjvGayMaa1nfPMl4bYxQihdefJGmbrjtjjuxxlLWFWVVhqoLG5JWQVDXFVmqSKTE1DXNfEFTlSRSMBwU4C2nt7a4/777+N73vsfHPvJxRnnGyY0T5EkW/WmO6WQfhcIYS1NVSCGoyprFYs5oMAqVCD3wImMvXpsMGw++IGdFhjoDBFLpDsgJodA6RacpUiehW08FCayUgSHBBwDVktoKTx0lqYEpDSBS6xSdpJEJiwtXH3sBkTFwKHjrPCI8n06RSsY6CYd3MaHYu6iQjV6wLl1UoLQiSzN0qtHtsasUQioQMqbRSoRU4TogFVcuX2Z3d5dhkXHi1AmkErFCJLCsIdSnlY6KJdgRh4PDRCvA4+IxXpVzbFMjIQJbSRIreKqqWjKYzpFIRZYEKTmx1sdFRraOnuamroKvNHbqBlV4+EysC32LSsbftbZLQcZ7TGOoq5L5bIZpHFIEVQIIEp2ipCTRSfBHxtqNQT4gHQx5/rvP8onf/QRP/u6XeNtbH+EnP/AT3HzzzVRlOP4GxYDpbLZSpSLaYDAle2m6xMFUEpUVIUk3Ov2CRFmKcB3FY5ogA3Y2MuQH5Pyyq7IxYX/d8t9V2zbql0yo8KHKxYd+kI4FVnF40kpfW9Y7SRLKsmR3bxekZDAYoLRisagis7lGG00kpOzYae9cSA5u+1qtwzYGJUUEpAF0WmOCMkAqnLGoyAK3LH4b0Eb8uwN0Fq6PnuC9FIBzQTKtpeoUGVIIvDWYpsZF5txZi0fw0uVL/Nkzf8pwfZO3vvf9LBYVMs2oXQjdasF8uE2E55CITjFwlJz0emtA2cHV5SAmfJbhsqCu4vxcd6+iBdf++vf3q2StLOvHDrPD9Ic1h8lhu1Tfq9aEK4/z9+MaYaX/cuVaIYOawRNqwTwO4v1YyPC1fLXhOtR+z+N61T2vnHk97OeO17d/1dbb1yFfjj6CjsRGx8zl8fZXnr18NQORNjjlUNbiEDB54M6HJEruev/ubPjTEiRola1JhOf2u+7iDW98I0899RTf/e6zPPDY66Cmm2IrpbCzGcOz53j0DW/kV/7tr7I7nbCzP6EYr7HY2UGlCVppVBYWTkrHXsMDizShWhnnEQOcVv4XF4ree3xjwkI//q5ChPAgGWtM2oWC8xhrQkVJUy8ltUqSJkkAe2kS/z+ASmstKImOYMTZ0DM5KxekWUExGpIVOUhPVVWkWUY2GEBdB2A5nYbqkjSlyHNylYRQoKKAJCSeznd32dndA+9QUrNYlCRJggfSLCWXCc1JgUj2qaroB7We0XjAYrEgz3Mee+R1eO/5xtf+iEuXLnHy/HlK51g0DcPNTR567HE2t06DVMznU3CeuiwRxpGnGc1sxvOTfc6dPc0dt9+KMTXr4zX+5k//LBvDMf/yX/wGk5093vbmt3LXXbfR0LCxucmLL77IeH2DjbUxzz7/AogEneVcevEFxpsnGJ3QoJIgyTQV3iu8t500tFW2hZ5KAU7iLejYiyq8xTqLsYGFVUJ2QVQSFTChj8ygqbF1hbOW2SyEC+WFQsng05Rt3YgTCC3wIgBLLwLwCxI/0UZzRJ+l75KUlVKh81CE3sPl0tThlURajVAqMEk2Vqi0fSb0Y/xF7N0UeKUwpmJeLjoWyxsT3gs0vgXH7UArShq9u9qz3J3r7ZDJWLy12BikhQsJoVJ4tJLddUQJGfzRztM4sJEd8t4jrMVHhr/1R7Zs/1X1Iq0/z1iQvgNILRMqhKCqgke6KucQrx1KKXRM5SUOb7xrmM9L1tY22DxxAiUVs90J3/rmt/n857/IuXMbvPkNb+SO22+nrmsWiwVahPN0MBjQVFUX0KPaZF0X/NHOxXAiGSW6gQpH+X4QS/hsuxRcL7vrQdM0kKgVACkjs6yEDApsGxbgrW91ySbGz8kdfo/o+4Lb52p93y1gLssyAD8lV/yyrXe4X6skojZVyACGbBuk5MK1tGW08Q5vQw+xcGHwI/Bd+JqI9gfZpiUrfZWn1otV4NR12cYBQ/s62/cjyVNObWwwSFP+8Mtfwu/tMx6scbms0Drruo69EHiW4VCePx+J5nWkp39uRMi1erCPt+PteFvd9PV7+I5PpOPtLyJw7DDOkezlQTnYYX9/NcC0lcley3h/2OKl+/fIgHgpEC4seoMULSwQnA8rBSkVeZFx8y238dDrHuWjH/pNPvnkp7jvnrtJ85y6rplOpwitqJqawaDg/ocf4vE3PsoX/uAr3HTmNGfX1pnv7zEvF3hpyHVIP/TCdS0V7cIkTOlbyd9qT+GyLqANR1EhYbStSJAW6RQqyUAti+4VHkVIu2xcSOqsrcFEyVy7mGslsDpNQsWJ0t3PtF6wtnahNpasyBmMxgwGgxDqY20MDspBaOrFPvu7ezRVHSoI0jyAy7yARGNsw6KcU84rpvu7LKqGPNVInZDlgyjz1SRpSJ2USYpOEvb3pzgBOtXsTWYUqSHPc9ZHQx685z4A/vQ73+Gpp57CKMW0rkkGA6q65tE3vJG1jXVMWWJ8w2IyIZWKQVGgmobdK3tcfOFFNJ7z588iBLzxTW9CS8WoGPKv/sXH2Lu8x4/9+I9y38P3cuGFl7jp/M1M5zMuvPAi50+fYVHWzMqKcrIXQn6aCpGkJOmAbDRAJTnOexrbdD6wvmfR28CmWCt6C2KHNw0e15WxZ3mKq2pMXSGxaBF8bbUxVPM5pqow3qOTbFU6KlRQA8i0O/58lIQjgrQ6BFYFVknE8BNESP8VmMBaCMVS2R4XvEp2ckER5b3BSxp/olUqRHk4KoSVLKomnEdCUBTFsm5DBE+diOcCMrBwAQSA8DLIFVcYDoe3vkvarcsFpq6xjQlyTSW77kNTNzR1Dc7H4x6MCHLXNmm4rSmp63olxCfsnsHF/lBvJE6YDhBpHXtHWSalOmupypLpZEJdlwyHQ5LIhKc6ixUtNgwNnGArSquFl+AUn3/qC3zwN36TC8/v87d/9q/x6KOPkeiUS5cukaZBvt5UNalSGBfUC1JGNUYEXaGKJL5nPjBVAVP2wosiWOz3k2op0aQ0toxy3p5HFZby4taHGj/jzpPZ1gNF2Opd9ND6Ze+vEEsvcJqmlGXZgce2skRK2YFL4RXOGEwMKFNS4oSMgDQcC+KItZVzLoRy+RZYxjRhIqPq232KoUNCdp2qgRkPab5LRy1dKJxA9UCkCx2qxi7TnlWIx1Z4zmyd5Mypk/zhV/+ICy88z7kHTyDLesngSRlYsn7YFG1362t5dw/7Lq96x1YTcFsG+rV47tcCoL6C1Pmr1teHp0sf/TqPmcXj7S80uDx+C463H0yA2d6gVwHm9aacNwoqr76Qc83AhqOGMQdZhat+Xh74N78sdg6JipKqsTS5Z/3UCe677z7uue8+PvLhD/Mzf+OvcWLrBIlUlDYsYIzz2NmU4do6f+Nv/ix////637G9P2FzOCbNMxbTBUkmaVxYOFkOREa3ZdxiOcHnwBS8XTwLIZDGdixEF7evVFf8LqUMjEQMsvE2VC7YJngqRaKRkSFIdYKWKkihfPT3RDldK0NqjGGxWFCbBi8UW6fPkBUDmqZhNpuhtaYYjcB55hcvsbt9hdlsRpFljAbD7vFQErxje3/CS1cuU88XDIuc8foGOvrOiqIIC8QmlNVbPDpJGAwGGA9CK+q67D5jU9WYqmZ9bcRjDz3CyY1Nvn3qeyR5wc58zks7O8x2dsBW5IkmVQMmO1fQeJT3DNKEjc2bOH/qJDvbl3nx+QvkacaZc6epFjWPPPo6NsYb3HLTzfyLX/znPPv8s/zMz/51Hn3968J7Ml9QJCmurhkPCoSHxjpc3bB78SIGx2jtBCfUFkoKhA3gxUQvVTvxSFQKKgSNWGvROrCUziiaVm7pg99svresc5FS4ExFVc6pY9pvHocf+AAQpLU4oYP/UUavZaxWkEJ0vsv2qOwfV0IsPYQIgfMxyEW0QS5h6OTa4nGi1Ne3lRdtAmf0F8cFeRs0VDU186okyTRra2N0ImNoi8RiYkWNCHJg1faDRi/kwVReC07SMZamrrsalyQe4youkJ0Ni/7u9+1yn6XWUQ67TN3tWDzpkW4VfDm9TCo1dU0ZmV4p9bIyKJ4rZVmitewAk3cipj9bhFAUeY73gvH6JnZRs/3SFb797af5+G99nMnOlPf9yDt5x9t+iPF4zO7uLtZaNjc2AKjmiy5tuVVCtKFeyxTVXs1RHAhcJe6IydLtBamV1eOTCDLa9ypem9rrZ3wPRBvW5FbBpeq0lHI1gbXXNQmhgqSfpNt+r5XHBjAoOka5rdxByKtYbHq+T9HKOXv73LGX1oVzw3mcbSUFHucbQKIJ9glHkMqGIKfD6FeBtzEUrZXn9mSeKqpATFNx8sQG58+c5nNfe5YXvvddzt33EEmiKJ0N/koh6WJwnO/qVF5rkHOYF/FG2MQjHw/xql7HYUDvRvsrX+2/H0y0Pmytcgwwj7djcHm8HW/fZ7B5GMA8SspyVIDAURLXfqBNn7W8Vpz4jW1hcSG6FEOJ98Fb6qVEKkk1n7C7N2Hr5DqPv/4NvPnNT/Dv/9Uv85WvfIUffvc70UowHA5p6jKExUiBtY6777uXBx+6ny9++Uuc+5FNBsMBVWPJBgXCGmpbdxKvJag8HEC3kRXOmZV9W0ojQziGih7TECcYF9mRUaytwZvgMQ2ptCJK8RKSLFQAEBegdJ625Q2+aZouUEenCflgiFIJVRmYTCk0iUqxs4rJZI+d7e1OEpgMdFhAe4/xjno6YXc6Y2+xoPEwXN/g1OYJRsOCpiqpFgsEAu2CPDMExLjucNHRB2ut5fz5m3FNjXOOQVGESpb9Pc6cOokQgnx9zNw0PP3cczTlDFdWmHJB09RgLIkXaOeRxjEqBgxPnGRc5FxQF3jmmWcohgPyPGc+K7n93vtZW1tjNNrgl37xF/iFX/glfvzH38M73vEO7rzjDrx37OzskC5KimJAIqC2jsY2QYq8mOHKAejoPfRhserwHcsR2IrAlkgpQqosPtSqSIEUIZXUOU9VVwzS0FmJbZhN9plO9gFHmqaMRgOmMwGt57FjJcPjekI1Snhjo9EIgY3aPkeoaRCxE1aIUAviWvJf6hjMFI9N+smYwV/o/ZLNaf1n3XkrBVIrrPOUdYVzjuHamPF4TJbqwEZ5i21qXBMZ9kQjyfBCxSTNtgRQdCtuEVmz4BGsok/QogjextYDF12vXYpr68Xz1gUJuLVYY6jrqktRRgqU1CRCYRYVtgmMJoBPHPg01BpaS70/6Xoem6ZhVlbdOZGmadjPLCPRWQAfJrBlSZKQJzlCSC5873kme1P++I+/yUc+8tvs701597vfzXvf8x62trawTUhUHY1GKyE4UkqIAVztoMDio8e8ld+v+uFcvwMxfj5KBRAUQNqyzkZrjYpJq7JjLKMkODK7K7LlmMYdBhM9ptn5nvwlAlW5vO50VSltomtUWXTSZGeDVzrLlpUgh6A936WsRkep90gvYtqxjUDZBj8xCuE9tn3t1nW/014Tg/RXRa6vde4dDpDoDWi0iu+9lJR1hU5zRoOC0SCn0PDi88+CD0MQG4ONhPcgbJfK2gWD0d/Xq++Fq+DnMDZOrgxh5VW/s1rnIvzB/brO3fU6fSXiBsHftbyZR/y8uBYw7O6rh7xPh1UlHbOVx9sxuDzejrfXcGtvXDdySb0RBvNGJa+HTSuvFzV/EJj2Uw+PYjL75diC3mPFBVRlakYb6yz2d5jPFmzdcjOPPvoov/tbJ/lf//W/4Ufe/6M01RzhIc8G2LIO/XHes7a+yQd+8if5n/7Hf8g7n3iC9VNbmKRkXi4YxI6+g2m5LYi+iokVV3dwiZZhbKWC7SLReVxjsDJMxVvGxMaFoVIKlSSh67HHWgolO/9lkF8FWZeN3YOVaaibBqkVw+GQ4fo6+7Mp1sGwGFCsrUFZcfHFC+ztXAlVDlHCJmPyotSK2jRsb2/z0pVtyAtuvf02zp05i9AJGIOa7lPXhrpaMBoO0UJSNoExLauKeVWyWFQIIdjc3Az7lGgSrfHGsl/VVLM5uzs7UYbsg5wWz8b6GpvjEYnwlFUJdU2mJaN8wGiQgzHU8wWpTjh/9hxSwtNPP82d99xNnufMJvusbZzg4Uce4b/9v/13/Ot/9S/4tV/7Xb79rT/jR977bh575BHOnjvHfDIJHr26DuDF1Pi6YWZ30NKTKoXc2ICmDL2bQiBF1GN3x6wPgTlNSCHGGrQE0jQs+kxDdmqTZneP7YuXaaoS6QLTmSWhOkZEWaNzjqz1/OkUpA4Js1LjaD1d8VldCNFZsiwKEXJsV89HFYpjhAuhKFK0ybJtamqs5RCyNUrG5Wo4HrwQsbdTUVVzFosFQoahQZ7nJFoifJBe2gjyXLwOyAATAy6JFS0BeMRzxtll7YwxsQORwMwrFfonPdjYVVmXVTgfe72gSZIwn80iM9mssGpCCLQSuKrpQM9hC88+q9k0Tdf3ORgMGA6HDAaDKDlP8B6asgEvMcbx4osXePa7z/GtP/k23/rWt/ned57He3jbW9/KO9/2Ds6ePodEYXxgqIUQQd4b2b26rmMq8+p1o78Ptp+u2lNKdItsCJ4/E/bDHUjb7fa7DfSJsv5lNU1kI9vjya+C0ZY9PeqesEwWVt3n0r5OYwzz+RykoK5rBsIhZJSvyqvvD84HYC1jYizeRiwbgsfaWpMuhTt6G10EySGwdQnAVKzpOVjRclSOq4/DFqmWtTzW1GSDgkRq8jwjT+G57z0bgXhIsPU+jJ+E0PGasKxyQbw2oOcodvB6Psfr3cuvx1xeD/wdBuxW7DVX/d7ha4QbZVBvRBL7WuRJHG/H2/cdXB4fpMfbDwTIPEIC8v3wXB5+wzv8d68FOJeMxtXMZvuIbSR/fxLbgTcpsM4xTAf4omC2mDGQOY8//jhvfeLtfOg//Af+6A/+gEcefYRqEYJI0jSlrkqkdxRrYx57w+t5+JGH+OrXv8aJN7+FIs/YvXiJdDwi6QX5YNsbmz/QI+a7hMA+8OzLZcOKPUywjbEdCxY8RVxVgK6lIlEarROcVFctKFvvk7UhQKb2cQFuDTpJKIqCNE2D9M9Z0nxAsb4GSUq9s8d0fx+sYzQaBYAjBFIvp/VVVTGdz/ECTm2d4sxNNyNOnoJyAXv7lFXDYlFhqpphMULnOQkVs9msC0Ipy5okTTk5GDCZTBgOBwyKgisXX8I7Q5oodndnZInGVjXVfM6F557j7ffeQ5GlIe3SOjbX1hkPCtaHI1IlQ2CH82RpSjEcMt4YszPZ4/nnXuTs2bOMx2M8sHHyFMPhkL/39/4eH/vtD/GP/+df55t/8i/4z/7OX+fxxx7jzJmtDkg4GwJhsDXVYsblcoFpGjYWM2SekxQFOi3iycSSye4WSx6sBR8YL4yhXsyYT6fYquHyxYvs7+4xGqSc3jrF2miElqF7dX9/n52dXRrvaZzECUWhU5RO0KR4NAjZRe0A2G6Q0dojgwQ2muRiH+yyED6k3oYFMLG6oe07tL5Ndw3tdp1z2PnlGl6EcJbpfB7SW1ufY+xYFbEywwiHcwJvDBCANDIJISdCLPsA4/nS9iRaa8HZ4BfUOnRXyvA6bOOoFiWL6SyAojztajCUEFTGREBG97qW0lK/el5pHf3GCaIJ3r0W9LXnYyIFWiesDUeMx2OkToMSQCfh9SqHFJpLL73I5z73eT795GeZTkp2duDMVsr73//jvOOHfpgzp0+jk4TGLJZhXTFNtZXetj5H3/M89iWn3fUu7El8z1slhOrqMlo5ZwuO+ov6Fvx5XBcitlRVSITWHbhsGbgW/IfXxqHDvmh77CTW7etuZa8tuFzMpkEWa233/kPoIZVq+TpdlJJbQmJsK112QnRedOF8UHboMPSQUc3ijMV6HywEPSAcOmCD0sW79n2QUQ1jVvap88SzTM618XGMMTgE586dI00Vz37vu7hqgcgG3c+2agPZf4+OAJTfjzXlQQnu90uK+1o8hriBBzwKQL4cye0xi3m8HTOXx9vx9rI3GZiG6+hauump9xHH+etrYV7Dm831pDL9++xhwFTFtFjZJsWKEDJh44Q4TXP2J1OUFAwGQ2pjuOuBh3jgkdfx0Y99hF/+l/+af/hP/wmZELz0wgtsro+DN7GuKfBsnDnNT/3Mz/Df/1/+ex64+14evusO5rMpXklmi3nHLCz7D30X6U/rg5JBviRECKtY2Z/WEhQXLy1TYpyNJe7Zsv8y/qkSHRIVRWAtPeBiaIuUCidDYq7DhkRZayjrCi8FxWBAkeV475nuT0iygvWNNRjkcGWHy1cuYm1DURQURdFVqCCDv9DiKcsQBrJx4gS33XU3an0zHDe1wVQVk9099rZ30Hj2hYTImM5mswgsS7wXZGnKYrHg5MmTpEpimoYsKzDmEvt7U4o8R0hNaRpm0wkvPPM9ttbWWUtT0AlraUqKZJhnKOeYz+coBGvrY8iLCOgtxjjW1zeZlxV5PogBLEHWOMg1P/PTP8cD9z3IL/3SP+Uf/aPf4C1v+izv/7H3cd8993Ly5CYGg5QapYbgpuzt7bG3fYVnn0nZOn+WYrzGeDwOoIT2swrnn0pT8AZTlVR1iW1qZrMZL118kcsvXeSF554nT1O2tk5yavNWiiwsrquqobGW/f19tre3WdQWYwVCJuGYSHLQgWEP2ZjL1GEZgWW7yHfYsKh1HudtFzAk2vO+YzhlSK11IdQGJF6En/XCLyV9BGZUhJkIwkNdNVRV282psTGYRQiFFy5Kd0MIjXcOaz3WN8hERU8xy0RSYkCMd7F61gGhH1KpBNX2ekY21ZmGugndqdqq7lxa8ccpTZomBxhJ3/kZtUpJEkWWhfOt9bjqNOmCgFpJZ5JEGbOSSHVgeEbwZ166dJnPfvZzvPB8yXAIP/zDj/Le9/wo999/P4NihLWW2XyC95YsS7qaEeU98/mcpmlYW1vD1nHA0Xq05aoXUUgVAs2IPaLRG+mIn5dYsn4Q0lG1dFghcLbByijqdm0nZwRlQiK9W3bqiqU8tJOtulaQfFBFspqc7VopdfSRixjG5JwL9TFxH5I0J0lznBQ0NlzLvGs7XkMNiEfivF0m5YoYM9WrQQmsbHhdCtl5cGWq4sAvDn8StfTnewkxVEriYiNorETxdKFdTvjYGBqeT2sdGPvEcevNt1DkGZcuvMhiOkUXQ7QEJyVCRpb0ABCXbbp0e79GhknlNQbCr+Tee9RA+HpA9npVHe3sV8RwoPZPySEgVsRJiGgPqH769OGs5X9s0Hu8HW9/ocDl92Mi9ecZJf3nzagdXyBea1B5FXzsAbWD77db/pRvL/FuhdkMv9t6elYDa8IidPX5XT8RTy59Wt2Cty0GBKxYxsGuBN646zGbQViH9+jou3LO4IXEq7ZjLZRyD/IB1XxOTeg7S4shb3nP+7jjo7/Nr//mh/k/f+Wr3PHQA5w5d5rZ3h7FIOvSXCkKbr77Ht7zkz/CR5/8fSSOO2+6iWe+9aec2zqF1mBrQ6Y0eZqymJU0tmZUDDDGBZDh2t0NlRXCtwsmxzyWpPcXw6F2QJMkEqnCQlYmOoDK2I8odQswJVpphNJYb8JiXAQwa41jMpuFFMssYzQakRcFNJ5qFkJ9zmyeBK1he5tnv/sM88mUwWDAYDhAaonDMRqPAVhUJZPpnO0ru9R1zejEKdK1jVBnEFmTZjannkxo9naZVQua6YD9S8EnWHtPOVtgygq8ZOomIdzHGIRTzCZzJpMpQmqyYsDu7jZJJsnzAYsXL6AtLHb2SRpLqlJG43Vm27u89Px3+cY3vsHXvvY1siLn0cffwHt+9L3Mq5LBaMjWqZsg11x64QX29icYZ9nY2sLul0iRoBLJY294M//j/Q/yO7/zO/ybf/nL/D//4b/mscfO8xMf+HFOnTrF+vo6XkCuE5L1dXZ2d7n44ou89Nz32J9OaZqGrMjJBxlCK6QOyb21MSgdwoom+7vsbe+wu7uL8DBeG3HHbbdzzz13cdttt4WhRrVgPq2ZzGbs7u5z5coOa+sbnD19EqlTyumMqdollRqxfiJ4McWybsRZF9miZdddVZaR6RbUtcHZwB5VVYUSAq0Cmw0wm806SWk4boaB+TE13gePsJJ0C3YhCNUZUapqhYrgNwvpuB48CpXkJEKH6gnhkDJBaIXK8lBn4oPB2AMKHRanwtFYj9ZpAMgiJHgKrTuZnDUL8A1KBVC6qBcRTCY01lIUg244g4xgXDiU0Bhf46XC+rbORYXXYj0IR5rpmFQaLkZJkpAWYTiRJjnOWcChM0G1qEiSlPl8jhCal166xEsX5jz88C28//0/ziOPPEKiM9IsA+mpTQNaIH0LYXzo3G0MUilSJaiaKlKDdEnPMkr+w7U3gGYb1Set7db3/I/WRMY3SwOrZ8L7KHXsxpTB0xo6PiPYlioyXb4VXLSViLTiaE9IxFZCrlyn+yml0gM2XPubKnRGGmOoy4pE6Zjya/AKSBRrG5vINAcpaCYzRnlOWZYIJxFeoGWCJoQzWdtg6oosK8JgJSrP8QFUh0Azj6sbbOy5BBCpRuYpPlEY79BSh7GMd6E3tg1VEyGwzEWp9fLarOJxEjox68qQpAnWeYZFwtbmGov5Pvu7lzl303lUGU9C5/FCIaVApgJvGqyx4FS8+4ounGuZUuCRvft5XxraMvyy5yMlMtjdT0fbxWFrqcM8nf6Qzs2+p/FAZkIn0XaxTzP8SUiGPrjG8yzBc0triyCPX/ZQtmoKfMtetrvm+lLb3vpDeNXNdoIt/AAgd73Uax/DyHxvVSTUoeuMG0mvPQ4EOt6uXm8fXKu+fPzXKSuO39zj7S/2gX+tA9p1MreOwFyZoB5+srycGclRKW3XGiZ0cfY38EQy3rQsMlYsRFlob6IaJHIKLWWQcyUJm+fP89ibn+Bb3/gav/2xj/Jf33MXTV0zHI2o6+DzK6uSRKWce+hhfuQDH+C7Tz/NnzzzDMNiwOapk5SmwdWC9fGQXGq2L11mkA5QCCaTSazaSA685YFFkjZO+Xvy2A5YxsVwKK1Pwt91SIUl/nubHimkDNUr3gQZYqJAK8qmZlGWQGDohoMheZp1qYzeezKdUM2m2Ok++/v7VIsZxSBjMMyDnzOWnKMV1WJBWZY0dYjXHxQFG+M1MAZcAo2B3T2q/SmiadDOsVhUXNnbC15RnaCThMpCbRqKYshoMEC44KsTynf7VJsAtrOsoKoq8jznrltv53vfeYYnP/67FDrlTW95M4vtXf7s69/gU5/6FJ/5zGe4cLEmH8A3/vhPGI3WePOPvR9sgy1LlFKsjTeYlzP2dvdRWjMeDfHzEiETFvMpQmh+/AM/wUMPPcTvfPS3+cLnn+If/b9+iSfe+hDvfOc7ufnmm0O9gTWc2jzB+TOnuXj5EmU5ZzKbsr2/x/aliyyq4CNL8oy9vT3G4zGDLEfg2RiPObu1xU1nz3HrrbeysT5mOCwQSjKbzTqGrJVD6zRhOByydfIUWT6grg2z6YTF/j4ueZ7zt92BHo8D+1NXSKGRgyJU1kwnIZ1Xh6TTpqzx1qASGaSESmJt8KRN9vdpjEEIRZJnSK3DArYdJqFwwnayvq73r60scR6lNEWakeYDpNSB3Wz9n5YVeaDQKvR1ah0CjpzHORXYtK60XqNESDVumTMpA8AkDpPCeRK5Oh8Y3FbimiRJqJ3o2L5whWvTVZVP8M4FplU2yER3MnDTeIwxAYAr1bH4WVag0iSEJTlHYw2TyYRMD2IysOaZZ57lc099gVOnRrz3ve/j0UcfZfPMOWxVAQ7jDNbHxOAIXLrAG2c7KX1f5tqxlVFuLT0IKSPHJZd+WxGSYVuSSEdvuPQO4z3COlz0/Flvw/EiQ6ATblmlo6Jt+1p3kH4C9nIo6Lvrsu/fLCIr6qJsvd3KssYlltFgM9QvxXuQUkmwjUdG1RkbeiIlwQvsex5QG2pCDnpTvYteWuc7ENElJYvwXjrnQgcrbQptzCcSrruD2qgowS39rq3Pv71XpTqhyFPSVLO9v8Pulcuc8xYpfHA7h4lfOBdEZEplkFA7cdCnGAYlhyWpH5ZR8FoN5A9NbhfXDvVz3ZD58D9bNYKPXDBtqFgrmWqnyAeCh44CcgfXBuIG9uUYAB5vf2mYy+PtePvLtl0vkOewm8/qdNQvbyis+CLjhNL7lecQ8eedOBIY38gWutxcXCmJIDc1hq2tLd71rnfx+x/5IB/60If4Oz/3t1jbGIIJyY2oBNeExeUAyU0338ybnniCj/76r3NqfZOH77ubcn+X2WKO957NwQgTsyQaa1jUFUVRhIVRO5V1vlv04egWFX3pUZfiGMGl0smSrVQKf8BX4n0rhw2SRo/FGosxNc4bsiwlyxJUqsIC0oZERSEEUsHu7i6LKiTIZlnG+vp6WGATmDeVZtEjWFIvSkxVgg/MYaI01e4uad1AWXLlpZeYXL5EPZ1RzeZMdrZDGToeoQ21rhEyJdGKXKekOhTee9MEGZ8IxejO1AjvyNMk1JrgOHnqBA89eD9PPfUU/+u/+pd88slP4I3l0osXmO5P2Nrc4E1vugfjHN/402/xuc98mltvv4Wzt9waWCutyfIclYRFfFmWzGczttbXEWlG5g3T6T7CCW6+5RZ+4id+gscefx2f/uSTfPWrX+Wrf/h1nnjizTzxxBOsb6zhnUFrzX333EttGublgrKug8SySPAiSC/bpFHvPd6aKA/0JEozHA6w3lBWNfPFlMVi0R3/dV1jjGFzfYPN9Q3yNKOpGyZ7e1ze3uHCCy9y4fI2W+dv4dwtt3DfPfewdvp06OLb3kYmKcn6OkwmKCHCcW0tgywHBU1ZYesaJZOuISFNdGDCrKFu6nAcJsmBc92vDJpEMGTivUdrzdo4dKZ2A5PO4xYliUJ1AxSpdKikkRpUCP5xlkPTQtsKE6kDA+miJ7QbwsTKjVARkaDTlCzPV8JvWh+qF+E1Sw2YsJCX3qEQIWFWOJroWW57XwfFAJ0mKBXeDxOvP6a2ZEmOdIJ6UXP54jaf/fRTfPtPXuSNb3yQW265hSwt8GVFU1Wg2nPeo7SialxktVwH7CAAR4EMlTYHp3sRKEsR2iaDTLmvTrn2dbwNDRMIvHc9Rsh3EtwWAB68pi+jqpbX135PZitEiVHg3e+3+9XtX7yG7c+myDRh69x58jyPL9KhtcQ5g/MmAEtjcSpYINpAog5EEgCn8C2QjHJp57t6E5RaeQ9krzM0SF0PuXfFrzbVVh6sy/G+SwlPYsXScDhk53vP8/zzz/NABFemZX45UNHRsosHBgjLQcjV71d77T4M/L1W9/nD/v8oZu/IwUM7QJDiqqFxO/S9xmsQvc+hx2L6q7IfDqs8W3mN4sb39Xg73o7B5fF2vP1HBZqrqbKrF/6rgWY7mYdVcHnwhtICzKPA6tUvJNyxQ1df8G24A5POECJhgxQ1Ts7nVc0wz3jw4Yd44IEH+J0Pf5gvf+UPeNdP/hjzF16gGGTYxqDShJSUy5cuc+rue3j9m9/CV//gD/j4k09yausED9x1J82iZH/7Che3r7A+HGEjmMwHBXlRUJsmhmDQ+dcC6yDQQuCVDqEofjVcpB/807+Jqm5xSbcQbGtIjLPMqxJjLSgZKhJicM98Pu/CSrQO8sSyLNmfzZE6MDOj0ahb4EmhUEWBXSyoqir0QNY1dVVhyorKCub7E2oE6WyOK0vmO3ss9vdZ7O+xc+kiFy9cYGdnh6TIKUZjhmtjNk6c4sTmCYaDMWjQiUImGi0k82pOtShDfUUM/vDR62Tqhje87jFOrG/w7LPPcmn7CsM8454772CQ5aytbbB2YpPL2zs8/fTTXHj+OV747rNsbJwgXxuDMbi66UJaZos50+kUJSRFsohAPmU6m2GaiuHaOm+46SZuv/12HvzSF/n93/sEn/nM5/nKV77Cww8/zBve8AbuuOMOLl/eJs9TsiQPVS1KkhY5QkoaV5PIFKlCgquSkCUptqlYLComkynzct4tGIfDIUqpwF4aj80tg2yA0pL5dJ/96RwhBKdPnsCbhul0ypc/9xn2PjZlPB7z+OOP8/rXv5HTp0+jlEbu7QZ/YlEEn1gTvK9VFToUi+EAJUP4SeM8WimSJA0Lbjx5ngVPnLfRjxb8nTHVBHz0FkdpXJIkDEZD0jTFmBrVCxrqFvStJ7k9rrtBk+sW0tIHSaC1lsaa4KHrScYDy+ew0ba1ZPsThErQaUKapjEcZlVu73rBYoEwNZ1HszEVVR18eC24L4qCPM87RrMLx4ldrvNZyXA4YrY/o6kt3/jGN/nkJ7/I5mbKI488wumts114llSE9yo+p3DL1NW+Z/BarEvLvIm2C9LFa6o4wGb1QJ3w4HAdmxgkgg7pBU1k9gJjF/stW/+4712Dr5E22k9bPfhzXW/lgWFj+znOZjO0zxmMhuSDLKgmhUClCbYOAVjOG6wzaCG75OIgV2bJgkZvpmgTYp0N7H0M5RKq97wxZEd6MD5WlETJsQ/dTyEcyPkuUMo51w0yuqGls533VsTr7YkTmyzmnhcvvBB8xEohvcd4i/RBwu4PMr+HDm/9q7xHi1f8OzcqA+0D42sxjv396YfxHcIwisOA5vXSX48aoBz+O/4YWB5vx+DyeDve/vw2eV3G8uq/H8UoBunL4eAwZht249qVG5foM5gHJ4+HMaP24E0F0etBCzd32y0MQnqli2E5p06d5u1vfwcf/c0P8+EPf5h3veedoXvRNRhnydOEclFz6sxZmsmEB554gp/e2+F3P/Lb/PYnPsHFS5f4oTe9kdtuv5Nn/uxpkBrvDaO1MU1Vr9zoLB4ZF0Cy9cLImI4ZPZJtEJAUcinlizI37+VVC7fA/MqOYalNQ9nUOO/JBiERtpV0heF9WBxZa0MtSF1hJeRFQZFmSBnqFpRSaB0A+2I+pSxLykVJWZbMJlPm0xk2M0x2thkJidcaaQzKWpT1VHtTLl54iQvPvcCFixdIBjmnz5xlfWODExsbjIcDkhhKlA0GJJmmqWt2yjnTyR51tcAbi/EeLSVrgwJTLtBrI1730IO8/tHXsb27g5aK3Zcu4ZyhaSyZUIyzjPViwGIyZX9nGy0F3tQIK5FFgTQNQmqM84zGju3dHYZFzvp4TJpnCOmpS0G5WLC/v8uZU1u8/vVv5KZzN/ONb3yDz3zmM/z+73+ZP/mTP+XRRx/hoYceYrw2Ym19g8FoQFrkeONpXEMdE1LTTGONx9QlzgRm1ntBmurgGU50l+DbmADkpYLRIGc0GOKcp1wswBmKwYDRcESeaEbFgERp9qcTXnzxAr/30Q/zsQ99iHPnznHXXfdw9uxZiqJgbW0NIQSz2YTd3V329ncYDAbccuvtbN18M2sb6+R5Hvxw83koudc6MEbWIXxMySQMRYSIfwK2VQVE9qYNxLE21Ot0BJBYMjddirJzICTWNp08VAtwEryzGGOpqgqJQCuJkL1hVrwuhJoQSZoGllLqNEheo4Tcx8jcAJpiv2evqSLsn8W6hrqOEktcx7yM1sakaYpMZJSUtzJWjZQa4WAxqVjMG5555rt8+tOfpZzB+9/zVh5/9DEGRRHYL2+WKoXOT+7QSnXAUsBVnreuXkn0JnsqfBpetp460YtDEd0+d1db3zNNRlapX78ipATpVypg2hAe2rAyt2TyRPdwy79LDi+lPzhkFM6jetL/2XxOniiG4xGkSQDOod0GKwKj3FWMxIGAiOCvtUS0gLL7wmE9+Fi/gpKo3kBDCh0OAicAG0KnenLalhl11mAjuJQIEqU7hryJj53nWRfuI6Xi9NYW3sOlly6G6iElkbHaqh2AipW6rxtV5LgbAkWvVhJ72O9fT7F0kLG81muQiOuylSs/L+W1X7N/eft3DCyPt2Nwebwdb38ugPL68tL+TXAVYB4+0G5//mDf1dUXeH/VFPcgwDwK6HrfT5xjWfsgXEzOXJVjeRzGh6APazxlYximCe981w9zz/138pnPfpavffVrPPyOtyEuXiCJckAhJdNygbAO2Uje8rf/E06eOsVv/fpv8KHf/Tg7ly7yN37yJ9k6e4bFdIaQkqwoYj2BQncYOiY5xul6e8u0cSHY+S0jyGz9h5JltQg9lsC72PmGpCoDq2jxSKVQafBptgvULMtQaZDXNk3TsZAA6+M1kiJH+gAspdQd40NZUtc1TVVTLUqmu3vs7OxgjCFVGm8aqGuE90g8uVbUUmCNYbo/4cqVK4EBEh6hFVunT7KxsUbTGBoL440xozwE4DRlRTWdM59MMVXd1TNsjMZonQTQbT2L/Smbm5tsbZxgd+cK0jvm+1Mq07Cxts4wSxmkCbXznNs6jc4zqtmcF555hiu7OzTecf9DD7J58gQ4T5WVwcslFCpJu1oBCzgvePaFF9k6scnd997HyZMnufPOu3nmmaf54he/zAc/+Bk+8pHPcPvtJ3jssddz/4P3cXLrFGmRMRiOWBuPqasGhcJjkKgA2pTCmSj79gZjHNPpHGv3gq/VVORp1vUoLqYzEqXIkgRnLZcvvIhzjkGa8ZY3PhaY6VnJhQsXePrpZ/izP3ua3/nIh5hMFmglyfIErVI8AaxNpxZvICngjW97M29669t4+9vfTra+Rj1bIGLf4GI+7djGaBkLZ5VfFp847zBNSIlNixydJB24E1IGIBOMzytMR2Bs7DKpuu3VjKCl7ZRsmiYs6pOYWswyWdk7gbXhTA8S7gSlI1t5oB+3D9baqhZ6sloIx7+3AQQmUq3I02XL4rmgFnDOAA6tcmazBZcvX+E//PoH+aOvXOKd77ifd7/rPZw8ucV8Pl2G3eiWsROoCOqkF6FGAxGOw8NqmmRrYJPdtcJH5vhqMLe8TkpAxDhb6aLrzYUgGhfrTookDUFNUa5temxnl8jrfPe5H/RYLhf5vvvzUGDil9d62fONV6YhE5AVRU/yu5RVBnbSgjPgYoyb7yJwYlxxeO1t/6WPnZetJFZptTwe24qW+HkqIZesrjPRv2lwZsloh05UFatLQvVIy2BLneIxgSmVipMnT6Il7FwJ9oBktB73xXXXfdcNU4nVVf1aqqOAjz8UAArBNXsmeRmVYdcDljdaY9L/na5yK/4puar7UrwSFvVGnv/w9+sYWB5vx+DyeDve/qOylqsX+4P3qcM9OUuQ6K967IOyn9ABBvQS70JIQhdjERamvbXJqsimhcby4PgUEb2a1jXdDcUY0y22qrom1zm33ns/H/iJn+Sf/M//H37nd36Phx9+EJkPSGLhdzYY4JyjXpSo8Rh36TJ3v+lN/J2TJzh77jS/98EP8tHf/V3e/fZ3kKQpvgmJtTpN0WmK9CE8R6M7cBlkVzE8w9YhvVEKpACl4uReyE4uGwbzpluEeOeCpy+mIVZNCIERWpFE6WsrC0wiULQEqV9ZliHZVCfoIiMfDBBKdmEkqVbgLFUT6kaaqsY1oUpjf2+Hne3LwUeoNslVgnCWPCnIVUJtHE1RMBwOyYocL8AIz6mNdc6cO8t4bQ3vPYt6QZrkASw4T72YM9vfYzGf0tQl3lqyPGUwGFBkKdY7iixhY20U6llU+DybeUk1myKsYZAmjPIMZxsyJXnhhef46pe/TFmXvHTlCl/71jf5xre/RWks/+nf/bu8+70/Qp7nbG1tcfnKJabzGYNBzmBtjUQJ5ni8CZLMS5euMMgLtk6f4fSZm7npppu44/Z7+LEf2+Nb3/gmX/7DL/Pv/t3HWd/8OA8+eD933HU7587dxNrmGmfPnCfNdFigCkmaZ+AT5tWcRVmSjzMW1YzFbE5VL7tWE6lIpKKaz3C2ieXvHtPUNGUZWT5Jkmisc5wYjzh78kHuuuU27r39dp599nmm0yk727sgPIlOSbOkk3fu7+zy/Esv8fu/+3meeeYZZnu7vPWH3s5otBYHIppEyBDQErsogjw1pkm3XiovcNGX2PY0IgRSh0oQDpALorfodYSAGRkjSR0eG2s/6kU4TpWUKL30IbcskWtMlD86hAiS2DTJkTG8qF3AeyG7vkcpBdjwO1a4GEKkwoLXxitJCyTil7OW2nvA0FgfwGxXk2KZL0qee/ZFPvvpp/jmNy7yukfO8v73/xh33HEH0+mcPM1CoBXBL2cagxHheQWOVMR+TBfDacTqtdL3pL8IEcKMWmmlWCaILod3IoIm0ReGXM2DReBkjInBTf6qhXmQAQfgtWQslwwmBE/halppvOp7VljSDvmyKottrAk+5TQJXbCJCpJna2Kq9pK5FKodzkXZavsZR1BJ/PIuhFTVdY2UOrxvSnby1Y79tg6dJtEyEdhaay0uymDDYNKFhOQ4rDMuKERamSyEf3MWnLesrY0QAna3r7C3s83G2gm0FzQ+AklkN9gQvSFLfyC7Cr668esRIMm/pj2TBz2WR/kbu++3oNFf28YiDhk294+ToxjJ/r8fWqVyNbJc2Qd5HfnscU398XYMLo+34+0HZDuqp/Kwn/HeHnHRP9yTediU8noekVSFSoGmtgGHSoFrAs5TWcY73/Ue/sk/+QW++KUv8Y1v/AkPvP5RROya9NGnKdMMbywiFm+feuQR/tqgoN7b52O/+Zvcdced3HL6bHhsYDge0UQGrv96ZFzcCkMECHrFZ9nuS1fnIkUXke+9xyvRLZwbHGUVQmTapMt2Uqx1kFrqwQCzWDCbTphOp1RVRSIVaZGG3k9rg1w4MjVaa6qyZDqdhhANGxItnbWBXZwvSJUmk5pUS7SAYZ4hshzlGmw1ZPPECTZPnmC4scbGmZPc++ADPPTwI4zW15hM52F/BCwWC3QiWUxnzPb2MVUd5XeQpxmb6xvBN5ok7O7uMtnbZ2Njg1QnzGczprs7lLMZWZKikbi6YlQMuPncWb7+9W/ykd/8IB/+7d9CJCnZeIR3lu1Ll/nmN77Bww89xM2334ZPFMPBCOcti0VFpiRJPmRdp2ghufTSxcD0lhVpmrK5vsGJzVMMB2Occ9x52508/vjjXLh0kRdeeIGvfu2P+Oxnv0mewx13nePmm2/m9OnTbG1tsbm+xsbGCdZGQ/I8Z7wxpvYVdV1ijKWpbfRoEXou6x3yPA+1Dc4x3Z8EwIXAGMfu5ctM04QTJ06QKklTLpA47rjtFs6dPsNkMmM6nZJlWQgEasKieH19HWstz7/4Alt/+BU+/bk/4tf+7b/HG8tjj76e9c0N8kFB2dQMx4NQSC9cGPQIFwrpfejD1TrFOd/5edvjXYi2N3HJtl91nrq4sI7knLOBsayjBNs0DaPRKMq0l5LEFgD4CFB9W9WhAmCxvefzB5jLPtvnvSeRq1UESiVorToZpTUhkspag4nAEqUBj7Xw/LMv8rnPfp5f+42v8NC9A/6b/z97/x1tWXbf94GfvfeJN75csaurM7oBdCQySIpiAEGRCiPJQdbIlqyRbI+t8RrJljgjy5Zn7LFmjTRhWaNZI2kkW5JpiUuUZCaJCSRIIgMkAgE0Gh2ru6uqq1684aQd5o+9z7n3vXoVOkBEeGf1W9VV770bzj1hf3/f9B/+R2xtbHoQaixlUyJCR6wHhaFLUjhsYEGdsV3lgzu6wHdtQmzoHFxK6HTOEUnP3h21LBwFixwBCe31pqoqfBaYwLWJqAE0RkrhmgWwXGYtWzBxu7V5K4U9jvHsrontvjYGFQV2WBufWOt8yJdnFN2ig7IDvN7P3sp2nY9Z7o4RVNQpQdrE2Ba0WOt80nD4HAihQM7d2JO6HACkQ7WJr3+yxFL5IaeDLE6QEOwDB6xL/ABFiMMjUGFxLgRTyeMT0n1g1Rtj396M5/JW99ebBfzcjkV03ITRvkmA0C0B5TFs6utZF5wwmCfbtyy4PE7acrOLw3d6z+PJSf67vX/blYrsrvXLUpsbDPmhJMqFFY5UR453e/jYttZ0vZTHHffLnZjt8/jvhYno4TCIpbhK/1iRipYSAxdF71b6qaVtAmMpQEURBn9TV1HCrKxYsZLH3/8Bvu8HfoDf+OhH+OSnPsPDDz8EUpFnPZrGg8zBYIAzDXVdkuYpVBXZmTO85wMf5Cf+h59hd++AC+fOo6SkampkHJFmcfcevTcMz1BK7zxZ/vdWfrXoUwsL9IUC0cu8dOPlr4HJUNLXVcRZ2knNpJJYa6jrCiecB2aTCQCDXk6WeMCmBEQItNGkaUaWeQBSzedemiokSgqqqmRv+zrz2YQ8zXwojdahS85iTQOTCl3XvnQeTZxnvO0db+eui3dz9u67SLIek9kUEcUMV1a9NC6O2L2+TVnMqKsCnCFSgjTLWRkPGQ56ZFnmE3tz/5r7PR+uMtndQeADcuIoYjDok8Y+JfSBe+9j8AcHbO/t019bQ0QKpyJkEvNrH/8YV195menuPlwUFPM5SkqaWcHe/pReljAc9IikIMsy1tbW6Oc504MJ83mBMR6cFVXFymjMYDTizJkzHEyn7O7u8l1PvZvtveu88vJlrr52mS/89hd57bUSa+Hei2Puu+8BLpw7y7333svF+y7SG+cM8gEKRVUV/ljFEUcxaeLZOoVgXkzRtSHPekgHk2qKQtLPe0gpmR5MmM1mSOkrOIzWPpFUSLIkJY1j6rKkmM+JlWI0GnDXufM4Idna2uLXfu3X+al//JPsXdvm3e99D3ffew+ZUrhaI2KFEA7jjO+ojFTooRRBTuhIVBTYHX+cOqu789dau2CZls5TGdiMuim70JSqmDE5OMA5R556z2k7YDDGp4a2YEVrjXChezCcH77f0/cFuiC59RJ3h67rLmBGIaiNQRcFTjsw0DQV2dADbykVk/0peeYwzlJVDWnW69KZrbU8/dVn+dQnf4tPfPxp3vX4Jn/sj/0xNtc3yNKUKJJEEqIk8d7IINtXMkNbQ9NUXrppGrIkJYpU54FsJZw6VMOARArVsZLWOYz2+6A2NUkUd8yuDfUbLFU1GGMQbVdj2OdKKdI0xUmF1jVN3fg+R60h1LPI9nrUXn+NxbWezCP3F7mEYVsmtgWOWmu089c3E673KnhNTaPJEq84UJHveRVCYJrKp73WFVUxRzlIoxisQ9eNl1mH5zJNjTPGM4POUhYlxrhOnp1kKUkvR2YpKBmIVw/Add0sfJbhGMR65tfh47+V9Kxl0zTUjbcTRGlCmiZenWF9dZeUkuGoz3AAVTFjejBBCokSDrRFxo6mqaiKkl6WBPAou2HB4TWi6z7vQ/dyYZfukTcG690A/m7Tj35c+M3yvf/W4Tg3pr52jGQnQ1+ywCwBPsXhBNibvZajYVB3CmhvLqs9uq4Rt2VxT9auJ9vthiffiGPkjpjLk4PwZPt2BK1HJ9FuyYt1Q5CDeGtO4JsxmLc//46k1UmBdBHECbiaP/Wn/wM+8pGP8Ftf+CLf9eWv8I4PfJDppReJUy/fNFrTNBoR+YW7iiLQDc+++BIiglIbVJKSOAd15RNZm+rQfhLWsxWtLLaVVh3qiTsy4dd2kXKpgxxWSh/JL6UkSWKUiro+sdY71TQNxlmK7W209YEUSZKQxslC4qU12hiyXk4a+XTGqijAOpIoRljH/v4+VVWRxDHr6+vI4FlyzjGfzxnlKfP5PPxuyXSyz0uvvkJpGjZPn+LcxQuM1taxOKzEF8kHoCCNw5YlZWMoDqYUsznC0aVztt67Viqa5/516rqhqiq01mRZRhR8cdZaIqk4tb7GysoKpW5oHOiQPrk7mZJFEcM0J4ti9i5fZbyxQuQEmjlV3VA7y8x56W0kFUoIBoOBL4JvGg4C8LEGDiYzBv2cOI4YjUakacr6+jr3uHt4/DEvy7ty9VW2t7d55dLLfP3rX+dzn/4MH/8NeOCB8zz6xOM88Lb72NxcZ3V1lX7uuxIFXq7YVCXFtPCl8doSywjbGMqyQomI4doQ4xyz6ZzZZIrWlsFgAEjqumY+K9m+do2qKIjjmMlkwnw+py4r6rJAW0eqIh5/5B0Uk4Jf/uWP8fP/4ucoJlN+7w98P+cv3u1lqcanjTpnUJHAaYuVjiSJF4zbMT48f97Z5RPZB8U4OnbRWu1l103j5bDzEuEgTVJf7ZDliEh55kybRbVEWHi2dRAta+nCghbpwYP3Dwuc8T46QnCOsxZTN0grmE2LUH+bMp3OAyOowEVcvnyVfr+PtWD0nCTJuL79Gl/72tf5+tef4zd+/Xne994H+KN/9N/g4UcfwxUFu7u7KETH4koHArcAEQ7v9Qslkk3TIKzs/J22TccNEs62t1cG1lKE2ZuwXhbbegD9PnddcFBXbWLdInxneeAdujKV8FVHxgbPpTaUVmOlCmyeZzJb0HDoYm7s0pL9RlbJ2KVOSiGOvcYlUewZ5KWBg0JgdI2uS0yjiZBhYOE9qt4XapEyASHQrd/SmNB56T9jISVSKUSkUHEEURwAZmA8jQ0yXx0sCzb4Iu0NjHs7AGnBuYwU2llc+FKRB+y9Xs9fK/Z3wRnvr+WwJLi7L94EFLlvoF7zG7EeXTzmzYHirV7HzVjTN7IfTtbbJ9u3LXN5cqCfbN86oxd5RyDyxm/YQz7MhczFHmIeF5s94im5nc+z9SndLMV2AWbdMZNJGUIfkEdDgBbyU4mjahoi4XjyPe/j+77/Q/zqr/0STz31BA8//DCD4Zi61kQqCpH1kPZ71PMZSsLlV17l05/9LFtnBkRJTFXXNHWNsJosCqxlU4fnkoG1ETjrkzK7iTkGF8CmaBMLw+vt/FpCYqFbRCulUFGEiGJE6MYUkQd+xlmqoqAxhvl8Tppn9POeZzikQnWl9RYlHXEkccYyC7JZJQRWNxSzOdPJAXEcszIadzUZk8kEpxuc1d1EfzaZsL+/z2T/gKJu6I9XOHXuPGl/gFMRQgr6Scp4OIIopt6fMj/Yp64qyqKgLAqqua8EaVmwtqReSEGeZgyHQxCCycGM+XyOlJJer+8Xx0LQNBqtG4b9nEGW4ZBcuvwqB3v79MZDbF3RixJiBFmkSJVkvndAFEW+d3M4wjQ1k909hDWsrq6SpSlCCEpZ+J/L+0RxilWWg+mE+WziAW7w+jlnu9TfWEXce/d93HPhXp569HHm8zmvvPIKX/7yl/nSl77E//LPfoZ77r+LR97+MI899hhbWxvh0Pcdmv2sTxql7O3s4LRDpRFVVTGbzFEqRoqIKFEc7E+4evUqTWPIsgyjHZP9fYq5l5Y+N32uqzpJ0wRh/IAj6+U0dUNvbZMn3/5OXn3pEl/4/CV+4yO/jmks3/N7vpf7HrgXNeiDsCgBiYr9+j54gEUIfOlqIeRCXiCEwBq76CW0FozBdEyRReGwtvFAej5HNw1pHDPsD+j3+162iANnu8CVVhLrQsqyUBEyihFKBaaPLpXZ941YrA5hLeH8MnWDrmr2ru0y3d33UuGm4aWXLzEej8niBKVi1lfW2d0/IIoSZrM5ly49wwsvvMBXvvJVnn+u4UMffpwf/IEP8dCDD1BPD9B1Q5alYKxnTK0L/ZHt0tsAdgEyWnDp7KE051aV4VWeIlwvZZcLq4TFSV+xYcNxDxDF/lrQBv/YY6SyHlwfBoGt/9lKf52xxtAYv88lvq5GIlBHPKEqpIK3HkW73D8ZApMcN/r2Fp+/oJdlHswbA0aDUAhrMLqmKuZYXYPywy7rfIqr/ywtVi2eT2uNrhusNkihcNLbBUQSEWUpKk1wKvL3hACM7ZLfXwRJsF2uNVkCe1prrHFdnVMb9NQYjQOUFPTzHqujMdeKgr3tHbAaGawPWNdduw8PYZbZQnP8+jGkhr9RoHUnia+39EzeAVg8jgc8CiBluFTcClguv45lZdPt5LlvtGrEnRgvT7ZvRXB5cjCfbN8uLOUtweYbOvbtm39db+Dmuty5dzCtGPVShIj4X//JP8Wv/PK/4jOf+RxPPf4Eb3/Pu4gnM8+eOecL3OPYT6ybho/++q/ziU9/ig88/hSrG5vM53MiZ+mH1NG6rhHWdAmR3ktkcdp0E/G6KTEBXLrWy0ZgdgI7gxQIKboI/yiOieIYFUVY4SfzkVRd/UujDbpuaHTDoNcjWWICrdao9v1bh4ojTN1Q1AWz6dR7nZSiKAr29vZIkoTBYMCw7z2G165dYzqdksUJq1Ji6gYnBWXwaVocW2dOMxgOGayuoo1DWkOa+qAfBgOofcfmzvVt9nd2KWee+WxBg1ny0ynwr2E0JO/1mB5MODg4oGxq0iwjy7KO/W0776y1NGVFUVdMDvaY7O6S5QnDXs6p9TWuXN/m8ssvc/riPbTVONHMsj/b5+rVy7z44ovgDBcuXODChfMMVsZdevAw63XMx0BJyumk6wGVUpKmSfez7edngw+s1+vxtre9jYsXL/Loo49y6dIlfu3XPsKv/+pH+dTHP8n999/HQw88yMbmGv1+n36WU5Yl169fp6l8MNT+7h7T6dR/1sJ/ftt721y9co2iKFDIsP88IC/L0gNxIciypHuNG2tr9Icj4jjl5Rdf9t5kJIMMdl5z/PYnP814MCRLYk6fP0vaS/0bUg5igbIysDwSG4BLF67SVl+wYKGc9OFAFjABWGA0Fg8WbdWg64YIQS/LGWQ5URRhqnqJaXI3AJkoy7oFu2cyFxJzAF1VXrJpnWfDnKMpK8rZnPlkjqk1WZazurrGiy++yG/+xicYDodsbWxw9uxZqrJhf3+fpjFUjeHq1df4+CeewTn4U3/qR3jPe9/P3XffDc4xnU6JlfcttwOfpqq72g7bplkvyw1DXZK1lsYalPHMYAc0A7vV/rxbun613b2t/9EuDaxa4NcCJOmpT6R1hzzcLfMoHB7gKQWRr+pQ1gOnduClw3uw1vpKHesB9PJzH3ft9Uzt8fJLKQRZkvprY1HROEPsFNL6Y8JUtfcsysB8a41pNDbIYJumQrX+zxDiY60lTmLiLOuC1aIsQ6UJVvhqKmfbwd5iGOmwh4JngA4INiHgTUjVeYvbwKr2PJdSkmUZq6urXN57mcnBPmjjr9U4LAYlIoyUHI2iETdJCn6ryAlxE2/jbX2J4taPdZxX9PW8lqP/f6Md5/D3joLc497X60mavdkxe6fr9BPy6GT7pgKXJ9vJ9u0GMG/4N2FvM220S7KgZZApj2cwrVjc51q29FbX9TDpbWMUluWwvuvO90kaIZFJjhSGRx9/ih/50R/jF3/2Z/jeD36ABx94gHg4xFbVojC79kxkWdf89he/gLGOxx9/nPNnz3D9lVegrKCf0ziHkqBwIRxEh0R958Gl9f6Zsi6xwnays45ZXdorMiRmyjgiUon3vLUVCcqzFN6/6eVxrb8pyzJ6vV63QDJBLoYKMuWQqliWJUVRUBQFLnjSnPWL/JWVlQ7AzWYzZrMZBwcHFHFM/2DowW0AUHmeE8cpvcGA3nhIkvd8hUTqk19FloF2uOmc2XTKfDqlqWqKeUUxr9CNJc0T4jgNzJwCJ8jyPoNhYE6bPYqyxjpBmvcCE6GQ0vv+er2cNE0pioLpdIKuK/q9jNXRkN5ozF1nz/ClL32JX/z5n0M62NjYoKoqXnrpJb76ld/hlVcucXBwQJQoVlZGvO997+O9H3g/g80N5ru7NNpSNzVZlrG+vs5101DOC6bzmZfpBjCe5zlKKeYhUGeZkRqPxwyHQy5cuMCj73gnH/v4b/Cbv/mb/MZHP8fnP/NbrK6usr6+zng0REpJVVVgoSxL9vcnIShHUVRzDqYT6toym0Fd+4OmaTzJ0c9hczNlc3OTzfV1ptMDLl26xHSqeVG+ilCQ5wmzWU2S+MVyHoMawbXLFf/qZ3+eqih5/MnHuP+h+8mHfVzd+HNKStAWlOx6Wz3j1bJXfqgSSfzPtp7BEB4llMO5CFOVOBoEXoqcJbnv74wkpqnBCt+DuRzkY0x38gsR+jSFxCI8s+Us0nlXl21q4ihCCYnBUM9LDg4O2N/dZj4tUC5iY32d0WDMzvVdvvT5VxECevnTjEf+eC7rCmfh2RcKmhre976LfPB7vpe3v/3tjMdjqnKO1YYkUkTSh/U4LHVVeAkwS4E2LRhpGTwliZQfRjVGY6zzIU5xGphZcxjsELyKtBSQQQUWTWvtO3q19rJbIbxKAZYGMOYQUO/8lEsS0EhInIJYeSmqCJJT2bLT4brRhtu070cu9Vd2IT0t8ySO6fAMlS+9NPNS/qrGOo1xgfG1BqO9v1JJL/fvjgNrEcJh2+5L4TCm6SqWkp4iSn1adpwmqDiGSIEVnSR22aOP83JpG+5NMgB5FfZrC1qTOOnCmbTRuMgP/yLlAWMUSYbDAcZoH9TV1Kikh5J+8CKihf924aFcVuMcuZ92339z/ZW3qud4MyB1WWLtb83Hg2LF8ZNgcQvWcxm8tsfmclnLMjP/ZpjLE6B4sn1LgsvXOwk52U62b2qAibthknh0gnnoIn2TMIDFTcPc4WTxEEh9g77Lw/NiA8R5n2lZkUpHb32df+vf/GP8i5/8SX7913+TR9/5Th547DHSJMFVFQ5DU9dEsa9cWFtbYTKBy1evcPe584xGI2om3jtWVayvraDLwjM77cJMyyAPBNtKiA9Nv6PD+y94hmIVIaLIh0sEr5mzljiSaOc9enXwJ8pIealmmmCNRS8FeUgVwLb23qRyVlIbjalqXKgmUEox6I/o9/veb2oMkyB7nc/nmLCw3N3dJUlznPDs4sbGhn/9SpHnfYYrY5ySNGFBK6qKel5QTGc4bYgjDyKbumY+nyMiRT/v0RsOSLPMV1UExk9lGU1VUtYVFkeUeObWSeEZTqGQse9DdM51dRZ1WZHmGXVVMXSW+y/ezUP338fzz73Az/zUTzEvK9I0pi4rdnavI6VkfXMNpQTb16/zS7/4iyil+L4f+kGyXo5oDCqkSc7Lgt5g0Mnk5vM5uq45ODhgNpuhlGI0GASwoLxsL3gGpZQMen1WBkP+4I/9Qd7/nvfz/PPP8vzzz3P18hW2r+3w4gsvUJUNZekP3CSGXi8nSTKqasb+/gwVw9ramHsvrpHnOVJKJvsHXLt2nflkjtOOelYxujDmiccep6oqXn7xBXZ3dzG2oakN02JOP+szXltlPBgymc/4ytNf5dIrM37x5z/C/u4uSikeeuQh4iwFmYACjAtVswv2xwTmuR2NaGtDjUoou2+ZNOkXiiqOwRlMFPuBSJIRR/4zNFoTqQTbeEaqMXrJ8xaTBPb+OMbD2jCw6WorfK1OMfPJxMXMs5anz5xmZbzGSy++ysc+9gmcg3e+8y50bfja115lb7dgfR1GKznf/f6HeO/7P8j99z9AmmWsb2xgjGetTeNfm5OSLEuIk4iiKBAiQoZrTbsId+LwdUkpBVJgKruQq8qlBfUt1hCtNaDrAG10AF/BgxnFNy2iP+r5W2aEffeTI41irDa04TIigEYZElnbKopldnU5+XoR6ORueD7hfCBXnmUoG46jIFkGh228H1cFFra7bhn/eF04mvDdnV2vZQC4URQRpQlRmnhgKSSN1RjHESuwO9K1eliWWdd1d11sE7lbabdgYVOwoTJm2B9gtEbXNbqqyYYSJQxN6B49dJzeltWzb9m9+05ZPHGbBNfXy0oekmQfw1Tedg0BN2Usb8tcurdu/5xsJ9u3DHN5u7jkk+1k+2ZiLI8yiv6eIW490bxFvPnrwoftBLdLtfVjTHeDvsje8HuHMayffdow+VdxxPRgTm0qer01HnvyKf7wH/03+cWf/Wk+8D4veUuGQ2Jr0abuFnNJnPChH/xBfv2n/yX//J//DPV0zgeeeoILFy5QzyYcXLvmmZuwUHbGdpI2X+YtvMcnikEu4vgXU33Vgcs29bAtWXe2ffVQ13XX/Qe+gkTFURd20jILsfRyWunwfjNjQ0hQ4wvAra9lyPIkhOdkpEnEbFZQVRU7u7vs7u4yn89QSnbVE+3zxCohVgkIhYp95yBRgq4qirLowHM1m1MVJU3ZoJvGSxRDb+Og32c0GgUGNMYJH+6T9XvgLHv7++xPJ6AkaZwTCQ/GsQbZelCFoKgrinJGVRfkaeyDZ2oPnk9vbvFDv/f7+Mxnf4ud/T32rm8jmpStrS0eefABesMBW1sbRIni2vZ1Pv6pT/BrH/1Vzl24iwcfeRt5L8bhmJc1RVkijMYZg4ojeoM+pkkoy5KqKKnrmqooMMb339V1zfXr1ymKguFwyNrKKsYKIhVzavM04+GIR9/xGMLBfD5n/2AXnOTatWvs7OygtWU6nfHMM89w9couRQHf93uf4oEH7ufuuy8yHA5JkoSmrLh65Rrb11/jc5/7HK9ceomnv/IVNtZWePvb387DD9xPXdddMNF0PsNqw3h1hSRK2d3f48H7HuTVK1f4yEc/wu988Us46SirOfc8eB+bW1uIQR9COqvDLXov7QLM+XPdhuFKqNwwOgw2fK2EsCb45LzUsXEF1vqUVOccUdRQ1hVNbRa1FUEGHsXeZ+mU8pJT5xBOhoXsIkSmaRp0U/ku0aJEOhj1B0TDmJXxGpdefJmf+Zmf5YtfuMpTj1/gB3/wh0ijlGeeeYbRaIXhcMz65gaD/ojGWvq9IePVVWaTfZqmpD/Iifu5ByFVTV1WWCFJItmBReUcJiTxeLYwpGcL4atUAnDRxqKtQTSNl9eG64DEy+oJ/jyxlLzrjgBVnyhruh5LpVT78SyYyiNMz1GWSxiLwXnGMLxO37fp5fktU9lKwJdB/bJMVh6pYlr2ZArhfclZnPgeUrx0uSornLPUVYVpdPcYwi4k0ct9lVprqqry3lUhSNO0SxhOksT/vhTd/jDGoUJeqWiP0Q5Um0OKmbpuWUs6b3V7vfW9qwuZstEWqSDvpTRN3b2mrLUhmKWQmnAsu9sAHPcW3L+PDiVumix7m2Hyca8v3MkQbbbB0qC081i6mwPP49bBR8HmnTKub4S5PO65j6blnmwn27cUuDxhMU+2b32Aebzs5vA08uYejbeyxLgLEXESJ6wHocItgdElb00rCQ1l5kmSMEhS5tMZvdVV/uSf/t/wP/79/5lPfPazvpZhOPav1QqEEjS1JkkTHn3fB/hv/ru/xp/8d/4c/+xnf4U4krz3sccZp16CVdc1vTT1njLhF8cqUr6uxQpseK1OOgQKqfAl6csXmCReSP9YlIZLvOeuLsrF4jT1wFAECWZTVt1is10AOWO9z1M7pIIojjq5ZhLFDAYD0jxDa83BwQGTyQxjjGd8ZjPKsvSM3GjExsaG7xeUkQ8EmkxRccJar0cSSZrpBG0M1WTiF6JRhC1LmsAe7V2/xnR/l7quSdPUA8t+r1twyziiPx4RZRlNWbK7u8vBZEISx16qi0DKKIBbSZbnRIKQlCtQMibOU9/3mSYoC9P9PTbGqzz29keYTufET3wXV69eZTjosbG5yWw2o5nN6CUr3H3+LiSCf/6zP80LL7zAxfvvRVt8t12asrq6ilQRZj6lLMsgA1XUdcXBwYTpwQEg2NvbY2dnh6qqmB5Mwp8zqmnJoN9feOSUIop8Rcvq+hqbp7YQQnD+wl1o7cHZM898nVdffZX19RXOnTvHk08+yUP3P8D6+jpF4ZNl496A1fEK+p4LPP7oO/nYxz7GJz/+MX75F3+JK69e5j3veQ9bpzZ8cmxTsLY6xlpLmqYIFFsb65w5tcXm5jpSwS9/5CP8xkc+TzGd8O699/Do449x6sJd3UJOyiBWEwLrxangQDhLGsd+oW59DYU1Ft1UvlLEgalK6sYzzI3xiZ3tMKX9qrXu6oO85NIPTyLhPYJ2qZpBtGKJwL5hPGNZFiXVvMJoyPMe/bxHnvf52K9/kl/5xV/mE598jfvuFfye7/lehBUURcEjj7yDPM/DElqxurpKHCfMqxJT+rTiPE1xzjHZ2wdgOBiim4ZyNkepbEm4IQMZGYKIXCvP9+E5SkYkcYqQOkg7m8BG3py5dM6DseVUzSgMWHSQfRpj/DUvkp03U4SJnASM1R3z3KZNu5bx6SSPDmuCjUEevt77uhRxiKm8WZ+lsNzQkymkQ4o2HCgcKnXtJbdl4etRwiBuGZxGCCIZwpqqhrqqqLUlihRx3iPJM0QcLAQyCplQ1ntMW8Y9eB/98WrAhe+z7NktfbfsUteqbjsw4whJ69uUvkpJSJIoxmqoywKrG8ArFYS2XVAbS3LPWwIvK28cmL6Je/iblcUuftdn6jpJsJ+0nmC7fCyI1tN7O3B3M7byuL/f6WsXiLcAnp9sJ9s3Kbi8XQnsyXay/e4ix8WU9riZ6dEeLcVSSmuoATguiGCZOTwupr6bt8tFz+ZxxcqLG4nsJqOHprAhjr8VZwnnsEiPIK1PRRTBX2mF82meLjB8yvvZBlnM3s51hr0cRMTpuy/yV//bv8r/4cf/S77rve/l/MV7sEKSD/oc7O2QJBFOW0QU8c4f/EH+p5/++/zd//5v8g//xS9x5epVfuT3fC9rq2uUkz2qqiJNEtI88Qsm40MsnJBIp0IIjUUIFWoE1CLEZ2mx1hgTFnieiTT4t6jiFBn5EBEppJfFsegaw2iiOEIKR1XOaaoa47RfcAlFNZ97QJmmIcERynnVBfRUVUVRlUwmE0zTMB6M2NraYjgcYnCUhUapIDczhsz557Hb3v9UVZX/eI1lZgxYTV2UTK9vc7C9zf7uDoPREBkpVCwZjEdYAZNZwdqpTeJeDycE23v7HBxM6fV6jIZDIhGCcsInH0URUsXUTcW8qNGNQ0QRvcyzoL28R5IkFEXBy1ef7wJ4bFWykkS4smRy5Yr3nCmFmRakKkI5iETElSuv8crLl7nn/gcgSaimU6STFAcH3qMmFPuTKb00I80Sev0hq6urmMZSF3Om0ynlvMQ2hixOyVRCMStII18RIkPSb97rMZ1OSXspWZYB3qOJbHj+2Re5dOklXnvtKqap+MD73s3b3/Y2lARnG/IsZro/o2zmJEmCkpq11T7vf99TvO2h+/j5n/95PvJrn2Y6n/DBD36Q0WhEr5dx9fKrrK2tYaRgOp130tPVlRHveepJhv2Uj3/yk3zl88/x2uXL7F69xge/57s5+8A9UM8gSXwqqzEoJ7w3WQqcMUwPJvTzzPvZqgZhNBEhrEkIprM5dV0TSShmcxSO3qhPWUwBgnfVS8LlErCxbtGnKSPR1ev4ehPvazbGhdqVBttYnJb0syH93oCvf/3r/OpHPsIv/ewXWFuBP/L7n+CHf/iH2dzc5KWXXuLKlSvURc1wOKTX6zEer1KVc0yjAce8PgAcpnEIK0lj/1mVRQXGEkUJxjhQ7XBLeXZHLF37nPOeabwCxDhQKqbXS6i1ZjKbkWW9xf503lfYVWFIhS70ISmqDVUrSvnnLOczD5hcRBrFKKn8cM1oL501FhdCe6w22LoJwN8QSS/l7oD6Mdd3U1eL5GpEJ6mVQoDylThCtcDa+yRVJBDSA980T5GRRAkQ1jA/mJAlEY0xTMsStPZDKaepqwKj6wAEFZmKoalpqobJ3gTjHKOtU6TDISaKSXp9VJx6v2/d0DQa2zRIpPepEvzvzveAYnyHqu/L9NfXYnIAKkIlCUoFf6elS9RFCKI4Rtfas9RK0M9yIgnlvGBeTBlHElNWSJVgQ8WM1Q4nlAe0ixtxd89tcwkWah1xaFC78B3awIXfSHV2x8MS8L9BWSTpzisQ3cvp0n5ltHhcd/gpXGilMT7H/IY1rjXGya4HVQp/fz78OkWwgbQA094wmLA3lYa7kGuwzFq2cqZW1n0jED0sET+qGD8KwN/qYKWT7duNeHG3wX+3G64cXusuH2dvqIrkzSZunmwn21u3vbmp6HHA8o0e23d6Xhz9Obn8Zyh2t+3db1n25W583c5qlMoZDEYIp9FlzXhjkyfe9S7e9b7H+dmf+5c89thjPPLww1y78jKb6xsYUzOZHDAcDhHa8eD738dfe+QR/i8//pf41C//Cg/ddy/q3Bn6cYq0plv4CiWJwp/GhRu/dAgR3XBhaXsACVPyNkHV3xDl4ksovxgx1idLiiX/ExAp/33T6OD5q8POsgghiUPtR8twVnVN0zSUjfcZTSaTTkK5srLCxvoma2trvsdTW3Alk8mMqqqCv8qnmiZRRNM0OKPDG7KesZvsM5lMKOcFWmv6gx5RpEiyjNFoRJwkVFaTpQnDsf97UfjAHJRkfW2V9bU1mrJiOp1SVE0nfwPQjfU5M0ohZcZwMPb9noFhMnVDU5TMZzOEtcRSUc6mOGsZ9vr0BiOiOMYZR3EwpS4bX7egHWmc+YV3AljBzmvXePXSSzz99NOefc0y0jTlzJkznDt3jn62howtuopQImJlvMbG6gaR9Gx5lsbURcmoPwAlub6z7dnhpiYyEWXt9+nOzg7z6ZTrO9u89NILNE3FO975COfOn2FtdewZy6YOPkXP+sjg562qkixLWVtb4f0ffB+ra2s8/fTT/Ny/+pf8yA//EOfPnuP8Xec8WyYcw2Gfqqo6v5cQjre//e2cO3eOz3/xi3zuc5/jX/7cL/HKpUs8+e6nePjRtzFaXyHrD3w1hJCoREADRVUyGI7BWkw5hxCIYi3sTbwvVYbzNkkSBnnmE2CFJIsj4jjGCnDBs2ulJUk8e+TJSYuSYLQHG4lKsNZRzwvKssJqR1MbIhGRJRnJYMTe9h6/8Bu/xEc+8mt8/at7PPnYKd7/7nfx1FPvIssyrl+7hgDOnj2LUt67nGUZ/b6XHFvh+w41vj9Sa420EtoQG7dYsfpOSukvQ4KQFutZnpZn7eTvSzJetxSO0zKDUZCBdrLXNp1V+UTY4ySnUkrfX2sMttHUQfreeh9FuMSIsNjvrptLNSVKCOySPPK4a3773DesdUxg7MKAzLagIrCQxjRLv69xVoE13pfe1EE+rVEi9IIG5rELHQqp0NW88NecLEcmKTKJibPcy2GFwlmLNQKaIMdWocDKWgKd6itQjEEKiZKKpq4pigJdNyT9KFTTHO4k7mStzutNXJAO+9oRaHTVJYPfwEjeUYejvO39WTjuOOvnVuzgcrbBrV/X8f7dtsNVvsXL2lu93qOy7pPtZPvWA6c3r+E5SYs92U62m5wcx03/3kylyesBn3eit7XWgvSerCiKsNoxmxeM18a849HH+f1/4A/xX/+V/5If/X0f5uEHH2Tz1Cnq2ZyD/V3yLEHEMa4x/t6eZTz40MN8/Jd/hbSXE2UZdVXSkxKHDCXoEiFVCOsIUrKl0A6xVHzeJiO6MH1upZPtz3WAsJ0GG4tz3vvSAss2RMM2ZhEmg/cKRdL/fhynCEcXWlFVFfP53Ev/QpKslJLh0DNxa6vrZJmXzRoMVVOzu7+D1prBYIAwYIs5pQRd1eSpZ3RMUzGbT9nf36coCtI48d2CzmCcZTAeMV5bJUpimsbRGw7oD4fgHHt7e+zt7RHHMevr6wzGY2Y7u92CtvVXlWVJVRdYp7u6AP8e4y51tfVBaa1xWtM4fD1L6MRLkoQoiamtxWgfKGIazfUrl7F1hakazLzk2Wef5Wtf/Sqf/s3f5PnnX0AIyPs9vx9GI5588kk+8IEPcM8993ipYfBY5f0+UWCZ8l7Pv/4oYlrMmc/nNFrTHw1ZXV3z9RSNZ4BbFvjatWtkWcY73/lOVkZjdvZ2fVVGVXbprK1nNYoiz4KmKf1hzMMPP8zm5iazcsZXvvI0n/rUp5g89Dbuv/8+itLL/3q9PkIK0iyjaRr6/SEOGA1X2Ng6zfnzF/j0Zz/FV7/yNF/48tN81/ue4N777+HBh9/G5tYWSZZjtPOpwfmAnVev+eNVOJSAeTnh2tXXOJjsk8URqxvrxLFiOOrTG/ZoygrrDFJCHCtknNA0DY22wZtM132pTeNFjdZihcXg91c5L6lrjUKQpT2UiJhMJrzy0iU+86nP8tGPfg4p4UMfeoLv++4PsjZe8UONuiZOErI899JSrYmznCiOfR1KCCFqvdQAs2IeWLcjbIcLnZTLvZDCM0Ped+1DjdxS0JgLAKVlmCyOqmpChYjq/NvLfZJRqMSw1qfkCtuqFvygScZx8Bo2fkAll647cDgxth02CttVykix8FwSeiaPTtrba9OyZ7x9zy24tEfYzzYUrNtnxmIa319phPHS9kb7aqRQZ9MEX24UemSbpmE2mzGZ+/CsQRue1Yb4KIkNsuNG+6qXxeuznuHGvw7bpt4qP7ioqorJxMv6ByoiT7OQ+OxlsCK81+X7WZtn3r7/OgzqWGIPhVjUvyyzindyr3sr2bOj3sLFsPWodNYeAZX2lgvkZWb1zb7etgP0OFZn8f/udZM7t1qvnGwn2+8WuDx6LL5pWewJ3X6yfbsBylvdyO6k0mT5MZe9mzc5KUX4eXe7G97R1+ycII5Sal0hESRRjG4qmqomGw74/h/6IX7x53+Of/pTP8Xb3/Y23vnuJ1FlRZZl5HnKZGeH4eo61e4OqRW8euUyWT+nqCviNOH6a9eQgwEiAiUWqY3WOS9lCp6h5Rv80c64Zclbu4Bro/5bEGnaBaUTHXvbejMrXR+SGiVRhIrjDnBFkU+1LOvKBwA11ncjFnO01l3P5craKv1+n0jFfgFflsyrkiuvXWY29wE14/F4Ib1yftFWNTVNVTOfHrC/v4+uG/I8Z21lleFwyMH0AItjvLJCv9/HIMjznNFoBFHEbG+P3V3vy1w7vUY+6GPqmmkxp9IN/d6QNE3B2g48AqRp6v2niG4hO5t5hrVd9GoHRmvSLGXY69Pv9Tz7qs2hmoT18QpXX7nMV774JS499xKXL1/my1/+MpdffoVzGxs8et+DHkCFtNrXrl3jS5/7bd/PB5w+fZrV8Zh5WfrXJAR1XVNUJUkc46ylLkpMo4kixXgwpJ/lVLqhaRoSFZHnue8ubRq2NjZYHa90kkNrLWVZo3VNFnvfrV0KP5mXBf3+gDhNGa+u8v73v5/BYNQxrnk/Z319HeM8OBsOh/T7/fD6UuZVibOG4XjE29/5DtJBj2eeeYZr26/x9Jef5nOf/W2SLOXCPRe59777WdtYJ4o8k1wUBU1TIQW+z1A3TPcPyPOUuy6c65J04yglzTJMFFNWBcY0NI1B17NwPgiUAxEbpHBESqCIfaCV8WCkqWqcg1jG9NIMiQIn2b5+jV/9yK/xK7/0McoSHnnkLp544gnuvXgPd50/RzGdMZlMDnUaZlnGeG2VutYd0FwudG+l63IJZBxio8J5HCWx///Wlorofs9JgQj9k8K6EDLmlQ1SCiLhA2UOBeQEFnD5OW+/QA8Lc+swwRYgYOHutsEDCZ23UVpvIRBKIRGhgcQdYjDb/dDWgwCdSmPBoEqOU461v7Ms/W+7M51ZhDzRpg07n4RrtSGOPWtZ1yWT2ZSq0fSHYwbDIXGSIGUA4i3I0w1V49nvOI7D6wuVJk77rl5nyJIUKUTXDVvXNVkY1Pg0WIcx1vtOl96jtRYlZMfa+eqpRTcmRwaId9rF2GYSvHl/5PHexuNZE3EsmDueNbWelV4O0XGvb117nAx1+e/iNj2bJ8TlyfbtunY+YS5PtpPpyx0wijf7mTsAj3f6OMfWkyzfXI/Gnlvre/oilXj/jJMkac68LOlFkvsfeIh/79//0/wn/9s/y8c/9Uku3HWG8do6uTMUhQ+60U1NOh6DcWycPsVzLxXsTWfMqhqnFJU2RAjSyCeb+gW/LwBXUvpy+aVFytEb+03T8kJpeBdggidEW5bMWd110bmwmI0Cm6WUQuDZg2Y+94xfAF11Y7r/T5KE0WjEysoKw/HIpyNqH81/MJuys7fLzv4e4/GYM+fPsLm23i0Sm7YPdDalrOZsb28zmUwYD0dsbm6ytrIKUjAtZ6RZSn80JEpinIPBaEhvPAKt2dvbY1YW9AcDNjc3UUqxvb3DZDoliiIGgwHOOYpyTlUV3QIyTVP/XgOzVdUFRTnrZIbLzEqW9ej1BsRRvDhOpEQ4wcbqGvfedTe//NGP8nf+5t/DOUhTwemtUzz58DvYHAyZHByws+uTXe86c567Tp/lq197mt/5rc9z1+mznFrfpLe6Rl3X7O3sUBQF29vbFLMp506dJs99CuXm5iaN0TRNw97enmdeCbJEA69duQYGttZP+SqbxmIb6xNis5RqUlLphiJIlP17tN1Aoq1oOX32DMOx/0yff/5Znn/xJUYrqwxGY5qqwgmYzUtEqJvwiaCSqvJBSWfP3cXa+iZN0/DSyy+yNzng2rVrbG/v8KvP/RqT+YyytNQa9vehLiFRcP99Ee9/z7t55zvewenTpxitDOn1MlAWbR1SO5AKJ7xYtizL7hyVYvH6G+NQqkGgmE6nyCD1VAj6/SG9LKcoKva29/jMZz7DR3/1o7zw/JSLdw957NEneOCBBzh16gy9LGF/f9/7deOIumkwxnkmPMuRMmI06qGt8XJrrTsQtdzp6CXsAmuWQYQ/MQ+ft6JLi27BpXUCZOQZrU4WKwMQlajES0e10wgnUChfYST9+20ZN/CsrgthRta2YTzay0AjD8istmhturTXlulE+G7SQ4Ou5aAk6a85whwejNslxUUbFiQRnUyyZeesszegVC4cAAEAAElEQVTIaRe1MmoRPgRYbdB1jWm0l+0H4NbWkMjIA81qXjCbzUBKsl5O2sshivz+VQpiRW10+Nx0V1viQpJuqxBxxnowr1R37s1mM6SU9Pt9kiQJHash7VdJcP51OuEtDNFSDlsURUSRwGkPkrGLNHBcW6viB4zupoNVe2umo62xegPg6vWkoN7IEC7LYls/5fLfDt+7pXt9BZ0LgNn1Ft3wvjkBlyfbtxm4PI4MOfFcnmwnwPJ1RnbfCWN5p+znUYB5HIt5s5Pag6maXq+HRFA2NbHyt/1SG4aDnEeffJIf+IEf4Bd+4Rd5/7vfxag/8IswYxkM+r5WIomY7+zx4R/9ffzMP/1JfuWjv87ZzQ0urG9iZjMaB5WxSBkkVe5wL1y70FpmJVpGpJ3uL+/fZW+VPJLSaDuPpsYECVskJJGKurJ1ay268YxPWWvayKVWhumco9/vMxgMGI1GPkU0VDpUZc1kMuH69etc39lmOBxx/q67OHfOs1Ctt3J24EEPJuNgf99LDOOY1dVV1tfXSeOE6XyGiBRZLyfJUoSU5GnGYHUV0pTZ7g7Xd3cAWF1dpdfvMytm7OzvYY2hNxwSxzFF4etSrLWdvzJS/r1iXce0GmM6UBDHHkjGUpKkKSJSCCVJhN/vjbGUumE6mfHgvfcRKcW169eJ45TRYMhgMODUyhqvvfwyk+1dEiHQ2nLtlcucv3g373jwbXz1ma/x7NNfo9/rMRgOee7FF7hy5YqvGdn33tONlTGnT5/iwQcf5G2PPEyaphRVSVPX9MbeL7q/v8/ezi7Xr76GcIJYKQ72DsiSlHld0R8OUDImTXMiqbAWZtMChyFNU7bObGCNY3dvF4tjNB6zefoMg/GIKE24cuVVrm1fZzAakvRyqqqmLGcMh0MilaCUxAWPcJ6lDKMVptMp2zs7PPHYd2Ex7O/vc/XaNYqioqwrrl69yssvv8xsNuPg4IDrr1n2dzTFrGR1ZZ3zZy8gUwUDX8XDvMA6A9YQKUscGayZUdeNZ6F7ma+VEFEnMUcqBnmfOPaDBOFAa8vLL7/Klz7/JX7nd36Hz37662xuJnz4h9/N/fffz/raJmfOnCGLM65cueIDgWTVHReDwYBez4foNEaTRTnKgNHuBjbQChAiAtN4yWWQFLYDnI7VlKJjLEUIunFCeD8gwp/DUiKtvQGQJomXBXdgaBnItXLTm7FQ1tcWCYfvhLUWoy2N872QyvpKE2lDNUboKcV6wIVcsl8eAYaH2SVxA2h0HRbwqdxdz6VdMLzttU0J/0TWGv+81vngsUbTTzNUC+SMRVo/vKprzXw6o9aW4bhHluc+FCtc54T0PlhdlzfIdjvWNFw/lVIoSecxPzg4wDnHaDRiMBj4GhOtMcJP8GTrG6WVOvt+0wW4lCQqwjmDsc3hvlJ3uNrD3URpczRI77j7q3qdaai3uk8v/v1GdvU2j/q6mMo7B7Tu0P1xce8/siY4QZcn27cJyHzdgT4n28n2bQ0ug6/oRhmru2lNyRsdsLwOz2X3gzf7nUV1ga8MiaWXc9Xa+ERF56jKmrPn7uJP/ek/w5//3/05fumXP8LW+hpbd51BGEuj/TR8f3eX8WhEb2XEf/rn/wL/yZ/5S3zsU5+m94EPMs4yam1wVYm1CVmkOmDpY/8tVjiWqsiXbqLtBHtJHmX9z4blWuhlCwucIF3rwGeYoh9dVLVf2hi00V0SZctW9vv9ThoZpYn3+83nNE3D7v4B29vbzOdz0jTl7nsucPauc+R5jqkblBB+UWUa4lgxO/DADmBlZYWVtVWEkkznM6bzGUmWkvRC+IaSvtOyl0NZd3LY3qDPaHUFay37+/vUuiHPstALWFNW/rXFcUwWJ/49mzA8qAuKsug68NpFv5QysJvKv4Yk8dUmTobOuhrXaKSzxAIeeeAhJqfPelZCSGbTKVcvXeLg+g6DNOf++++nspqXLl2imRX0ezmbK2u88tLL7G3v4PB9km2tgVKKTCiuvnqZy5cvc+3adbJej7vvvpthf0hZlkQyopgVvPbKFZ756teYHkyxleHVl16hKTQvPv9C8Kqu+M9rkNPPcpqmYl6XfpGbZUih2J3sUNQVa2sbDIZjZBwzXlvlsSefIP9an3ndcDAvWFtdxRhHkgnSPEPFHqzjJPOqRGuDwxAnKePxCsYY1tbWOHPqLGdOn/PHRlXywH33I6Xv6Nzf2eXrz36NV19+heeff5Ff/IVf4Pqjj3H/ww+QjfoM10Y4EfvOV+uZfucEyBm60SRxTCxSkjj38sSOnYco7uGcYzaZc/3qazz77PN85Stf4cXnX2R3t+B7Pvg49957Lw8/+DCj0YiqbJhP5kzMpPMpShnTGwzo9/shmVkjlKQ/HPrhi/WdsCiJUm2YlkKoMBjCYXSFCdcDJwU4hYLOmyfbOiER0lqXV8lBZilEF33ZPW4b6tOe0yIARpzr9sOh66ozgSW0nh0LC3Afp+N82ile9aCFJnZuuQTYD76WAaDVHoCFFE575PrZvYXQw2mXGTex6OFcZkEPey7FYmBm/NDOWutTaxsdwrQM2tSYpvEg0znKmU+wTrOU0cqYtJdjgSSOUEmMcRbbeBl5ux+7mhatcaYJvcM+1Ew4w2wyZX9nF1M39IYDhmF4VevQBRyppaoV35/c1j4tg6B2UNHJhZ3x8mBrFr3QMtSwWHFITtrVjhy5b4muHsW9Lsbu6P3vRhnqEam3u51c93jPpTgeJN9R19hh0Hv8sKTdL+4NyG5PtpPtm52gOe5cOPFcnmwnJ8fR4Io7PK5vxmC+kcTYNzot6vd7HBxMiXNFmuUU8xkWR6RitG3oZzn3PPAgP/CDH+Knf+5nef+738X62gqVbugNBpRViRCx908WJd/13vfxX/2f/zz/9Y//dS6cO8+73/FOqkaHYAeHEilx8Hb5QCFPYy5kjO6m+7FLeVyaLGu98GxaE3xES1NfKRdpkq7R6NZrZD1fmSQJVeMDY6SU9HtDRivjUAHhZWVV5TsI67ruOhsHgwF33X2BM2fO0B+PsYX3KeWJ7/XUWpPFiZfiWUuWZWxubrK+vg5A4QpQHvxESewX5FIQJwlIQT2fc3BwgIqjjkGo65p5WaCUotfrISJFGXyWbU9jnuVh3zbdAna5R7Lz5zVNWCjKTkbrtEGXQYaoNS6EiVy7fJXNU6dRDqrJjLkxxEISC+9ZHQ+G/nMyltFwSJ6kJHHCPXddwDaaa9euURvNxuoq48BGJonv4Js3BV/44hd59mvPcM8993Bqc4ut0YhyNmdve4eXX7rEM888y5e/+CWK2ZxiPudrX9nn6stXmJcFab/HxtY6d999Nw8+9AD5uXOAJJYx/UGf4XDMa9evsbN/wOkzZxivrNAYTSQAGbF19hxEMV/60pe4cn0bFSc4o0mDFFApDxeiOCIRKTKkdRonyJHMZwdMDyahumQFgPnLLzKfV+S9lAfuuwdz8QLvePvDXL16mU9/8jP8xm98li99/gs8/l1P8cjjj3LhvnsYD0cMBj2USpBApASRSjl7Zp048Z5Mh2E2r9jf32d/ckAxr3AGiqJk59p1nnvuOb761a8xm8FDD5zj93zv45w7e5a7L9xDnqYcHBxAGB60w4jBcJEm3DGN4ZzzYVbRYigRqeCVFt0iPIpll+SsrUEGdlFK5Yc7cdyBR9eCyHYZvYwpllia4wZyR7+WGctDpe/usF9b4SWpNjCCwnnGq/FVEYuEW4IX3NEpKwi+S9emoh5ZALmQTn2UtTy0tunerAuZQOE9mAAmhfKeTOt7XAnfs60ENiRdW6u9D9NahDEURcF8XnJqY5X+cEicJljnGWChJI3W6CD9RwrUkjRcBOZWItCmIcoyrLFMp1Nms1knt+/3+wsw7ByRECghvMddgFTKJ8QuAyoXlCZy6XNaqtCy1i1VjXxzLXBb6fYbXRi/Va/jZgPoo8zrCXA82b7Vt+PqgbrO4jdy8r3ehfHtCuy/mbc78eJ9I3//W/39fzNNVY7+26EerQAylzstO6qfJTaTw2ymu8mJddTkfzQw443ut2XZKYCufRG6tqCbOvS1WT/pF5Kyajhzz738yI/9fr78O5/nn/zTn+KeixfYPLVOE5JUlVJM9vdJpSQZjXnfB7+bf//PvsQ//gc/yenNLe45exbVaMrZjMQmgMHYmizLaLRGRAoTFh/SLS44bVDEcRUvKrAcSeR9Qi3AklJ6eZhcAFhrLaa23YK2Ze4cUNU1UggGvT5ZL2c4GPvXZTTT6RTtgsdyOuHa9jaz2ZzxeMz5C3dx9tw5ev0+tiioywpjNJNpBdaRJDFNU7O/v4epazY21jl79gwo5YN9rCGKY1bWViHyoC8JqZR6d5fXXnsN5xwba+ucO3MWmabs7PhU2qyXE6cJEsH+dMp8PqeXZgwGA1QI8EFYymrObDLp9kvLCCsliUKvZJblSKmoG42tG5TD9+oZ7z2dlQWDXo9yMqMsS5z1abtVMacq/OefjwZ+n1vlQbmUREKiYsU9F+5mY3XNv+4sI1GhosU6IhExWFnjofsf4Mtf/jLPfOWrPPbIo4gNmO/PuHr9Gp/55Kf52lefYW9nwsqox8Z4nd5WBtYxjWfsl3O+/rUXeeXSFa5efo1H3v427nvgPjY3N5Gx5OBgys7OHknWYzgc41TEvCgQjaY3HJD0BuRVzdbZ81x68UVGRcnZrU2uXX0NOYqQkSUyhjgWxHGMNhV1rYmSjNEox5qa+XRClCjGq2NOnd7C2ZpXXrnM7o73lfb7fUbDIWfPnOJ7v/sD3HvxPF/84hf5+Z//BB/5zU/wtnc8wuOPPsbZc6cZ5D2iSOKspq4rdCmom4piXrJ/sMeV165x+fJltnd3KMuSYjbnYHfKfA6rqzGPvO1hHnjgAc6fv8B4PGY8HNE0hr2DKSBJA7M9HI4AR9bPwrkVQKVYyFel8CDSdWmsvodP4AN3pJTUjUZIRd7rEyepB0UBqAnnqGuNjLwMWyBBCMxS/56KIkBilvyOLUXTejezLPMVOk1Dgwmdtg7dVCQqWgAX5wGa7/8LYME4pBLYxmGaBqFtAI8WUzfY2Pc9tuzjAhqGBU4UeSbTtB4/74vsnHg+6ecGeW77p0/y9YMdbU13HnZ1N+EeopTClDVYx3wyxTbaB/kg6OU5e7sH1GXFcDxiZ2eHa9eukY8GrKyuouIEZBT6dg3W+ObFsixxQpLECZFS6LrGWs+GRlL5JFqlqIqCnZ3rXLt2jSRJOHXqFOO11c7j65ZsA8YYZBSBlL7BxJilnki6/ZAkCWVZ+oofpRAIdKNBKv952CXv5E3utV26bKdquf39+ai8tmVabz4YlksftwBxPIC76f12qZta+BowcUjeJ2/ChC55fcHdNMCuZSw7Vv8m73954LH8+7fKefhmI39u91q/HdeX32ms5Ov5/KI3c+CcbCfbt9PJc6cn1pu5IL4V8ebHTpDoBDk4pBejCknZVGQu5r6HHuIHP/TD/O2/+Td537vfxXe//z1sbGywvb/N6qpPUp3s7pHECeO7LvDke9/LJz/2cb7wla9y19lzZHmPfp4iGl+BIYSgKIoQYrMcCX94/9zABBzZh3XwErZBI356TpCoOcr53N9sg5zvUMARnsVIsow8z7uuyKqqMIEBqeua3f09ru/sUNc14/GYra0ttra2yPM8+Lg0pmlwxvgFoZTUTcH+7h620YzHY1ZXVz1jFCRkcRwjk5iqqenlQ2Kp0M5ycLDfyQCz0H0plcKE0KG2e1BKSTkvMMaQZRnDwZAsy6gLv6DTVeXTVJcWWG16o1KKPMqD9zLphiTt/m8rWZq6RiGoijL0yPueQIxFV3VIWvUMamNN5+lsk3idc4z6A0TwoUZIXK3RRYmwPnky66U8cO99lLM5z734Ah//2MfY39/nypUrPP3007xy6VWaqmZjbcSpzS3WRytEUYJrNGVds6YrGq3Z39/n+WdfYHdnh93dXR555BG2Tm+xvbtLf2XA6voG2hqm+wdUumLQH5EMRxCn9Fc3OGMds6pkWpYczAvivOcThIUHGJYAIEI4SSxVF3hijGeU5tMD8jxndXUVgF4/6apf9vd3yfOcc+fOcPHiBR566CEeffJ5Pv6Z3+Zjv/llfuFffpkHH+xx38V7/AFsje+RdY7JZMLe3h77kwllWdIYF4YEgvvvvY+Ld/U4c+YMFy9e5Myps2SZ79L01TveA5kkSZAjR5202QqIIoVzJoDLG70vzjn/78IDKZ+oam9gUtrkZRvAkxL+nHMOtPUSTRkppIy8BBxASOySIP5W64aFZ6+tNfFe6kMLYbeIQGkHVS0jKMN6vsUqLcB02mCED5dpQSThcxYhxfa44d7NwMfRHkiB6FJp2zoWufQaIqX8+wjgNUJgtcE0/jyNo4j5fN4NiHZ3d9nZ2+3YxS4VVorguVRBeeDPxzj16dZ+EOcVEj5V2JHGMVp7ZcH1668RRRFraz6RusVbFodhcX22gAgdxI5lNnIBphTiUGUMXcqu+Ibfg383wMSbff7jfKXdcSbe2GO83hyIk+1k+2bbXrcs9hvZXXSynWz/upnXo1f/41j5mwFL1zV43wlTKm55/tzqvLqVUkA4202mpVsqgwac88EbBwdTti5c5D0f+CCf+8xn+fv/4B/y5ONPsC4kvd4AYwxRkqKSmKbRxIOMR598it/74Q/zj/7u3+WpJ57gobsvUk0PEI1mlCXU8xlpnBzaF9Zaz/4uLXBVG0No3aEFSxOkeFbXIfVQHGI8rfXyWG00kYiIZeZ9QG2KY9gfaZqSpxlp5hNLTViUl7UHZzv7e+xPDjw72OuxeWqLc+fP0xsOQUrqYuZrI6oSq7Wf0BvLbH+PneuvgXWsb6wxGo99gFBVYpxnX9I8RXbhJ4qmqalns24hOUhTxuMxzlpmBxOasiKJYrIkRWvPrFrrpajj8XCRTlvO0aUHNbIDl3axyEwSZBxSc4X0HaFBNmitowngUmuNVIoqpJa2tRl1XaNNjcPQGw5QUYQ2xssKlSJOEpSUPqUyyGtt1dBYh9EaXde+Z9RCKhOytM+ZjdNcf22bF7/+HFdfvcz29i7XtrdJVMLKeMzG6hprK6uMen2sASc0g96QoTMkacpr29d5/oVn2bm6yxfrLzGdzLnvgXuJ0oTVrQ3iJGUyK9BAb9AnHw4gySBK6a0m5APvL/z6V7/C7mTC5uoqs8kUrWcBlMVd7YmvYvDpokmakvd7VFXBwdSzxIPxgK1kgyhe9P21kkYrQCUxp86eIe0PWNk8w/d9v+XKq6/ypS99gc9++neYzRfWs7bXMh/A6dOr3H//g5y76zxbW1sMh0MGvT5xHJPnuf98ZOSlnG7B0EdSHQL8LoADGcCAIPIAYImFcSHYxAkvC3bS/xtOBlDhgZ5UwVcJ3q/rWnDpmdD2nDXOY7bY+kCfNoxkIS9V4flNJ3/37I71DCoh+MbpDuALITvlCCFdU+BC32X4m/aBMlgTRmY+IVUFpqqpaiLlzxFfNRL8mstqCesCAD/sm1y+rrZBYcKFNxoqSaSQhwZkR1mhOIpQ0p+DbWK3Dr2uo6EfOs3nc9qgmb29PYqiYH1tk7XNDaI0QQYftVIKpKQJDGP7GhUCrMFqFp8NFmMadnZ2uXbtGmVTcdepLTZPnwrDsWYRwHQceHbukOrGognPtPi5ANKxPhypZcNF8NAT5LXHrwEtt0ZX7hCjdyuA99Z2Zh72XCpUJ1cSrwMMOnEbYCnsTdYC7sgxpG46fD0BmCfbtzW4vNmE5YTJPNm+k8HpUV/Fm/Va3u73FzKb4wDm4Ruen+n72Pqk10cZzWRvn3c+9iQf+uEf4W/83/47/od/8A/5j/6j/4D1jTGz2QQlJEmSeHno7i7Z2hrveu/7+Ht/++/w2s4Oa+MRAyVJIsn+dMLW2ipNWWEIAT1d/P+N++moH6uVZ1lribqePdGBRu8RshhnyULNhYoS7/myrWzOL7x7vV6XSut/X1BVFQeTAw5mU3Z3d1Gxn+ivr69z6tQpeq0Xqa6oy8Izl1pjG01ZVsynU/Z396iKkpXxGsPhECkls7KgMRoLyCii1+uRDwc0RlM2ASQLH3YTJxlZliGimPnkgMnE+/rSNMFa2yXE9tIF69pWqtS1D/9oe/aSJAmAY5HmKeMoLIoV1mmc8KyKMbqTs7X7pQW7aZqioghbltggV2wZsWX2SikVAAFU82LRv9kuoK0jjhKyNEU3DbPplOFgwEP3P8Dly5d57oUXmM1qRqM+Z0+dZXW8QiQVaMN8WoCxRE6QDwZYQCFZHYxJ7n2Q3b09Xnr1JT7/W19gOp3yzicfp6pqdnf3mZYz1k+dZm1jAxElHljEOTJPoNdj6/x5rly5wmR/j8GgQcURTVkwmUxwBvr9PkIq7+1tNEYJosj7X6WUzOdTpvMZvX6GjOPuM0nTlH6/T1XVPjRlckASpSRZzhOPP05Va2YP3Me73vUUTVVTliV7gYFtmoY4TVlZHbF16hQbGxv0R8Nuv8dS+XAbA9ZprPFhKWmUohKFbfQhj7K1tqvkaLtunXDHyvG7RNhw0VBK4eySx3HJM9lVe6AOLWh9VYmlMS7UVlhsV4shkEp2PsDu+mV9R21bySBCmJcSAh3AHnh/IUsy2u560f4+eDWB82xbWxPi8DUmTgga23gfqgrAqPVmhmEbt+jSXA6w6a7BS32cfkjnn8ces9h3znV1Qf4zMWhnaaoaGypw2iCuuvLS/LKuSLKM4cqYwWCAiBUsJfMaa2l0gzOemcQ6r7Bwhqoo/DUkTqiq2isErr6GlJIzZ85w+vRp0jRlMp1SNTVR6iXUog26UYtO0+XbiLAOJ0FIixCRD+tx+PTbY0GduONh6q1YwiWM+Zayj7cDZUd7Jt+KHs6bHV831nLduFY4aqE5ur442U62b0twebMC95OD/mT7dtqOu+Aflxh7w5DldZw3twOid1RnwmEZmQwx+XYJWLYg0w/3FbWpQEiiwZB3PPY4P/pjf4h/9Pf+Lh/4wPv47u95H1mSdtLUWvugiszBysYGH/qx38cv/9pHeei++8j7fcr9XcaDAbP5nF6e4pqm6/Rqu+78ctbfSHXbq0dXHIdwBiX8z1t7WK7mwrRdSYUU3gMoQu2BDsmAIoCg9sta3+FX17Vf6M9mHEwnzMoCgOFwyGa7sA+MZVNVlMUcoxtMXfnFYd0w2d1h+9p1jHH0ez3WVsdIRccExnFMGoDlcDwiTlOqg33vuUwSED5lMU0S+oMB1DXzyRTdtAmxEWVZUpYlcRyzsjqi18s6JrMsyxCeFABhACHWigW7srRgyeIEQ4RBBz/hjKIoOolrVZYopUjzjCRLaZqG2nhGMw/AvA0LiZTqvEfLn8eiZzIAkUgQ5SlpllE3mjiKGOV99KBhW20zSPuMeytsbGxw7sx5sjhhNp0y2dvHOO39nCqCxmAby3Q+w1jLqD8iT3P29vZ49dprvPTSy1y8/wH2dg9IGouR1lNtMsKEUBchFVJ5/+pobYPzd1/kma9+hf3JARsrqzijKYsSZzzL3eulVHWN1prIxmjnSJKMXpRQNQ1VXTMvKgZRRN7rM5sX1E1FFBmUihmOVpCRQomIWjdMpxOEkAwHPTY31pDOM50+TEhRaZ+umyRJx67bJdajmlctvEOpmCRNfN+j8X5iJSRGm0OdikrFxCrGOROqd/x5b3BdXnPgKcHJbijlnPMMFMsAw3c9SiG7ZNh22OOcQ6iIWAhUDNouAqaE8LUZnnlxCELiqAmDImcX8ksRgmKc90u6UPUhpECG19GyaS2wFM74P633uYtWEusM0vm/REKinVdv2KMsUgsGQ9arDNfD9uppjiziVfhd3aXWukMA9LihmbXWy5ODGsNpQ93obrCTqKjzRR4cHPDqlctkvZy1lRWSfu73t4wQ0isQjLbUxqs6oighCddl6WNh/fmvG8rGB5Ndu3YNKSM2Tm2xcWqDJEmYTKcUVXkIMNMGNC1VyizfU1rQc/T+d2jIgL/X2KPfdzcyc9wyY+POh7U3uz/fiYz1xnuoPfZ322NrcdwcnuG617vMFfYWjOmNr1sgbgowT7aT7TuKuTw5AU62bzdQeTPwd1zy23EAsE0sv1Vn5utJiVvuE7sTYOon+vges0NDYcm8qkEbVvp9ysmUh975KB/aO+Cjv/LL/K3/79/m3e96gvHpLYqdnY7dmk6nNMWc9dNbfPhHfpR//k9+hhcvXeL8E4+j5zEyjmi0X6B3CZVuIc1d3kddf2VIgnV6USVygwdKSRQKFUdIFQfZp18eth7KdpHVAstWKqqtoSxL9g98YqJxljiOWVtbY7y6wtraGr1eD5SC0IdZVRXSGs9c1g3lvGA28QBvkA9YG6+QRjHlvKAoa1wkyeKYvN+nN+iTpCl16PBL05Q8zymrpov2R0qm+/vUde0BXppire6qTcbjMSsrKwgH0/0Dv9/D40nw1SRZ5mtXgo+zPRbaOpA4SomkpUHQFGWXJAs+DVLGEXmekQaQbsoSGXmwM8h7WAtpFPuwGxe6CAHT9Y0anBTEaYLIRMdC9bKcOEtROBprKIvCv4f9A+IoYmvzFFtbW4wHQ4zWKIRnLxsvbbRWM5vM0UaghU8qrZUi66WcPX2WSjccTCe8eulV+isjzvT7ZGnP+x8PpvSGA3rDMTpKMQQ/bn/AmbsusLN9je3Ll9HakCQZVeGrXFp2W0nZMXjWgDYWJSVJkvn+wdJ3x8a9Hqur68xms+B19cdkEmeetWsakszS6/Uoy5KdneskKmFrayv46/a871IIz6xFfkBiukRWSdYboOs6sMOaKNKdd9haULHAWX98CyG891gAwrNRIvLdiQaHPM5bGMClO3IN6iTogk7qeFznozEGFceoSCGdotaNl50KeSgp8Ogml2GEXchU22NLOtfC30OKhtYz6cJx2Ka0Yp1nJY3trjMI7yG2AfQqBM743/P+zaV+ypsAj1syXCEAyQXW9DhwCT4N1oVQr3I+xzSaLEm8rFlIysonBJdlyXh9zVePZNnCR956qrWmarS/xiWLdNiyLJEKYhVR1RXXr19nf3ePpmm4cPEuhqsrJEnCbD6nqEqiKCLOUoSSoT5mkfTrOpbYHa6Tad+XsUfCafx17DD7Jm5Qo9wOPN78Xnh71u9mLN4bJTgOnQdLSfFvZLsVw3gja3lnrOsJY3myfceByxNAebJ9K4PHN8pg3uzG5xdt7k0/3y2Z0aMglqO9cOCEXeYGw+vyN3opJaPxGpOdawyTFFdr7n/wAT704d/H3/i//g1+6qd+ij/5J//d0CcZYRVEZc10VrB6aotzFy7wx//EH+VXfvUj3Hv2LBdOrXP5+ed48OJFXn35JdZWVg9L8UIRe7tqkHipV1uhYermELBsU09Z8h21fyql0MbHUVghuwW5lBKDw1mDrjxLVNc186qkKLy/MO/l5IM+a2trDMcj8iCFrQOrV9d1YBtqTFkync6Z7B9QFD5ddWU0ptfrBTa0wjkfDBPHsZfD5jnaGOZlgZOi66002nXVKbP9fSYHBzhrg7TVUc4LdN3Q6/VYWVlBpim2KDuZLNCVovd6PaQQHeCM43hRcp94QCiM6BanWmu0tggUKvIAdJhnZL0coRTT+Yw6sK+9LCdLUqx2pHFCHMdEzjPAjTWddLluGhCCuO3SDBLaWPpqC+Eck/mM2bRgZ2eP6XRKlmWsr66yMhqhhKRpNEoo8iSj0gVOG5yQaF2h4pw4pNMK7SWNa6urlHVFdUXz9a9/nWTUZ7C2xlreo6gaVFmRD0cQx1gHjbHEeQbWkA2HnDt/gfneAQfTCevDEXEcg7bUdYmpM1QcgfJARKUZVWNIY8h7fYx1aNMwL2sGcYRQMTJKiFWMUrEHE0ASx2RJDLbGmQolHKNBj6Yx7O5tk6Ypg0GfvcmB/8ySmJg0fIaqu4ZorUFGxKlERp5tVnGMUgu/o1CCqO1ylaIbAnTY7Zg1fds8K9VSA20AGd47F4XriVmSyYruKtJedozzoNXXU/j6GpaqS1Q79FqSbUspkS2ocx4ott2WIrCRDocT9pDP2vv7dPA+Ll2LHWA1zuolmaz/UkphjfcF66WrYAf+xALoLgPvji1dqlA66qc/9PPHpMi217G6rsmzBGcs8/kcYwxp2kcJSa0bLl26xN7eHqvra6xvbpD2vAy++yykxFifam2sI058SJfRujuvafxgZHpwwHw6I41iVldXGa+uYKELDfK+6hiUxLZsZAvSOg7Ny5jFEXDn650Wg7+FD3ShRFlm4oSQi/7i297ojs8ncNwo574TMuPO77NHvZ8LBlGIhd/yVi/70K/fZC3gAnN/J0DyuPXFSZbJyfbttsk7AZS3uvCebCfbdxKzeXQi+UYe783cONrFkwiTe++buvE0bp8hyzKqqiLvDaiNZl43jM5f4A/+4T/Kh3/sw/wXf+X/wUsvvUycD7HaoeuGUX+ANYZie5vRhXN8+A/8GDqW/OonPkGhHafOX+CrX3+eJBsghOoAn1yW1YXrxLwsOhloC+i8LzEO/YwZcQBmcRwjo0UFyXL5ukJ00s02QENXnj2dzWbs7e0xm80AyPs9hsMhw+GQNM88SMsynHMUsznTgwl1USKt80E1laaYTJns72Mby7A/6nyWvstTkOYZaZ4ho4g4T5FZSmM8EEMEz1dIke31eggH29vblPOiYxqbpqEoCmwAm1mvB9Z1LKqvCfBl6SpNyHs9tLNoZ3FSkOSZr9/I/QIyjhOs0xjjU2Rr7T2wUaKIYs8wp3lGnKYdA1LXNUiJir08M8lS78tSi89QusU1Pg5Jpb1ej8FwSH8wIMtzCLUJ+9NJ59ObT2c0TcPGxganTp1CCel7CrVnlZIo7s6BJEnI0x79fp8kiolVhHSgqxrpJMNen/XRKldf3ePScy9w9eUrTPb2acomvD5BOZ97mW9dQ5wFDVvE6uYpsuGI6ayi0caHD4Uqh7opgyxXYq0mTzNUWOD3BuFzF4qqaiiLmjTNiePUyxSzlDTNUFGE0Y6yrBCRf+w8zxmPfb9qK5OMs9Qfg1mOklEL8SAEorQMdxJJYiXAaqp5wWzmU2W11h0L7ZOB40OMoxVgtOukql1iMEGeqCQiUt2fIlJIFRPFKVGSEiUxKkqQKg7yzAinIqz0/Yc2dLe2abMo2QVYWVw39GjDchbXqGWQefxguksiXV6kL7GEAlA2yFNDXUjLXLbhVdL5VFsZ9mXbM9kdv8Z2j3mzr6OL+xuSdm+RMtu+fq11B9rqusbiUEmME7A/nfDsC88zmU1Z29hguDL2slTp/bMoBaF+yDPrvtZEOkvTVBhdo6TfX7u7u+xs72GdYHVjk3PnL2CRzIqSom7I+wPGa+vEWY6x0BgX0nxlF4DWFof4qqqwX10A7KGSxZr257ycFiE7tvLofrrZvexm3zsKwJYf57h/+wbey4V0b0D2egvS5Vay4jsBjkeryk4A5sn2HcNcvll25ptxeyuK7N/Me//d7vn51u8Zull/1J29byFuXTNyXP/ZoZtAG1QvbpYo27k3bsJM2q4P7rC81AnnHPKwyb/VuqGE90qxlCDpWpahlS0pSSoVs6ZBRYo4z5lNGvpCce7+t/GhP/iH+eSnP8GP/xf/Nf/oH/0ECkUcK4himuJVammJi4jzD97Hf/wX/3P+kz/zF7jnvvt436NPcPr8A0yvv0bkGob91LMc2gCuq29owyU8IIxJ4tgH+BAAohCg6CoUDk+0Q3WGijxTYxoiCUr6iX4xnzOfl6GuwfvVVJKCECRZSn80ZLy64sMwhMCEgvG69OygtA6rDeWkYPv6dabTKf3egPW1TfI8xxjj2cxizsraKmmvh5WCJM99abm1zOsaJyXrG5sAFLM5sfIe0Mlkn7osiKUiVt4rdbC3h7aGtfU11jc2IIqYvnaVal6gW5bCGPJeTpqmaAGlNcg0IQ8VFK3sWEpJHEWYsqaxjQeYzqBtg7WGfp74qoMkRSnlpcKNpjfok2UZCIkKSZUi9iE3RV10gEdYR12UJCE8KJYK3TREKiGOEiQ+dTZNcq5t74SqjSmD3pDTW2cQztczFHVJHCdoW1PM5lgnkDJC44gVJEoCCotERoKqaSgOpkgnuHvrDDSGl5+7xHiwwunTp8lPZ5TzildevczW3RdI+xH9/hgqDTKFQUSMYuvcPbz0wiX2JwV3ba0x39ujODhgmGXYrEHIhCzLmEx36eUDhHRU82knDa+qirJuyHqKNMt90JI2JMon9QrrQDp040OXIimRSpLmEie8RHIymfpk3wAk2jRW1waeWAu2QYeAnDSOiKRC2wbTVJjGJwPjDEYvwkCE8HLHdsAUhcRN4xwW45lM5bssnXQIgt9ORkgReXmkUP6KFIngb7QdAPEspgdqFjBCgiWwkf56GElFlKguZEYJ6ZNxEUsVFxrlFuezNgaEQ8YKp72P2WE8a+0c1ugFs2ksxlj/nMb7GVmWzzqQITk2kgobjk9044cawlOWyyxo60V1HaNHYOrs0nnVXos8wyUk3v8chhPeV20pihnWauJY0etnlHXF9t4uSMlwPMIh2d4/4OOf+BRxmnD+wgV64yFI4dOYE4V1Pr13XoTaIenIkpRICaxpfHq1EBRVye7uLgfTOVmWcerUGYbDIbV1TMuSrD/w6gQhKCtfSyPjhLgNJhJikea7XLMiHNbUwX7gw4mqxqJUzP7enLvSHCHbHlMBQT2iAxCO5KLf9Og64UZ5Z1tDczwTeLN78HHS6+X7b6ukOPr7bV2MUpHoGEsX0lmDKtirgJYA93IAj7hx0HAsSEYsPbZoKfLu/XWvP3iY3ZHxr5PHq6RutS67E1n37wbxczOV18n2zbz+lq/n1X7jweXJdrJ9p5zcNzvB34p02NdzwQ43PuGcc2opBMC25dE36OIMWIGuK6Io8t8XCicke/v7DIdDfuhHf5Rnnv4yf+2/+Rv8ws/9PD/0R/4IXL/O3iuvcvriRa6/eomiLBme3uTc/ffwn/3lP8f/7//1/+bihXu4e3WLaDZn7+AaZTknThPAp4kKnzTE/nRC1u95pijI8LyrcnHTtsLicDedfLeJjDJUY0wnk47lwzn6/SFlCGgRkSDNMvrDAYPBgDQwdnXh2VPT6LCQxXtGy4r5bIbThl7aY2W4Qi/LuiqPympWVlawAhqtyUcDesOBZ+kqzwL2h6OuO04pDyrm8zl14RmytsS9bLx8Nw1slkoT0A3T6RRd1QuGKolRiZe1GWuJYs/wJoG1aiW3LTtT177Psqy8r9BJiJOUJM/8Y4XXZIyvT8myrNsvToAI9QcySDdtaTvGzDmfVNkyZtZaLKL7flVVuBBocnBwAMDGxgZxHPsSeSl9/URomujYnsCQqjjG2AYRqiOsFh1YUE7ihOT0xqb3M752neuXX2N1cxNdK/KVEU1V0yOEt7THlEqRmSMfjlhZ3WC6u80kS4ilxIWU3t5wgAjMjXICbWoi4cG7w8uftdboxvtxhRDIOMJqjXaWBDwLKAUKh3UG5yTWeYAVRXHHTFrnB0dSRjgnMMah8CDTOIN0xi9QA0vnnAmhN77ntQP7MrrxetC+Zyd8wieAjBDC+o7KsJ+RConvqBRCdb9jBV4p4CQisH4t+2lFWHw7E8KB2qqQGxf/1lq0qbvaFP8ag8z1drUSxmJlG9bjgSXWV414a6Dtuipb1rKVyrogjT8cBmQxwnUBPcu9mGGNvzQ5DCFkd7CZluWUAhO8qG2Il7GWXp4jI8Vkb59+v4/F8aUv/w7zsuCuU1ucPnuG8dizlq3U1SG9qqOuEMJL69M0QVuD1U33HC+/fIn9/QPGq+tsbp0m7feojPfu5oMBSS8nCed0O6TCGn9dPcIILgaVZiE9xmCN7wW1dlF5JGVEHKfgPLPqhA8ekjIola19Q53Ob1Wv5C2/f7tF+zHH5OvJRWgB683Sc09Yx5PtO32TJ7vgZDvZbgQ1twOWt7pJHhc88GbLmZe+uk22a6M2er/rIaOTOTVNg5SSsq5ojKY/GGGdoKwrBqsr/Ogf+gO8671v56/8n/4q2889i7OGlfNnqQ4OWNvYoKgrtl95hTPnzvL+7/1uPvwHfoyf+Kc/yQtXX+XUvRewWcr1+Yyre3vszudMqxqnIvLhgNGK9y0meUacRsSJQsUSEXnGsiV9JaL7at9nK9FsrA+zKcuS2XzObD6nrCofCnJkah3HMYPBgNFoRJp6NrWua6bTKfOpB5FKLEDGZDKhKAqf2royYjjsd/JRrX2wSp7n3SK63++TJp7VKooCKSV5niKcXwyCpaoLJtN9qrogiiVJGqFNTV3OEdIxGPToDXrgLLPpAdW8oK4qnHMkSUI/y+mlPlVUCEG/3/f7sA0ICWFG3aI+AL26TUAN5ey9Xq+rFWkXnFmW0e975rJ9jOVUyfYxW//nsu+qDVBaZg6cc1RVQVHM2N3dDazKqS7Bt1UG2PAZLsuc2+drpZU2eM7akCilFMI6Br0+GxsbzCYTLr34Ejs7O9RFSZ55ubMxxoM+rbHOS5jJUkYrK2ydPhVYn32UjFEyppjPMXUTUovphhbW2uB1lSQB0LcAGiCKEkRIAnbOLRKL0wyhIhwSK2QnO5Uq9v8WUn+lBGs1WtcY07CcXumDczz7vCwjdWYhDZcsEk2PBsw46ZnIVtrcvlelYqIo6T47EakwTFCgoiV/c4SKY2QUIZQKzKp/bcb5Lxe+LH4o0SaOtszRcaFTXXVKy5YJ4aWsLNQfrZy1rQBZfBmcOyL3bRmr4M10xtd/OGu7YUubGq217nyZyz7MozLXtvrkdgPHrnNSqQ6AGWd9CFkScxCGXmtraxRVyRe+9CWeff55Tp89yz333MPm5mb3WbfnU5IkzIspAksc+WOlrSKqQ8jTM89+nb3JAb3RkM0zp8kHferGUNUNKo4Zjkbk/R5RmvggtEh1stu25/Lw/cd2x95yQNzy51TXdRg8RCRZUKW4w59rZxm4g3voW8nELL+fZVbzTu65twPCR5nK5ePuVj97VNp7O6nwN0r2e7KdbCfg8lsQbNzs65v98U+2twZkvmUT1dvc1G71/McyoDdZCLU3x3bR3C7ehZLEaUJVVVy/ts3bn3qKf+tP/AmevXSd/8/f+TuINIOsR9ofYBysr29QVDXzuuH0vffwY3/4D/G2Jx7lv/1//nU++cXPs37XecZnTxGPhySjIaONDbLRiCTLGY7HREncARnC5N9KMMIzM11f3pJvEzhULzKZTNjd22M+n/sJfyicV0oxn099WmueMRgM6Pf7noHShmI2p5wXmManlcYqwllLNS8opjOqoiRREcPhkNFo5D2iwccXp4mXntV1AJFeqmq1ppjNEdYxHAyQwVOoA9s5n8+p65ooinyvZPBaWmsZ5D3GoxEIQTGdsr+/3y3Qoigiz3P6/X7XexnHsffsBVaiTTxt95EOrNryQtHXbfRI0/TQvlRKHfr3NjBpeXHZ7vOWGW5Zz+Om+u3CqwpJmO3CejQaHVqEO+cw9ZKnNHzG3ftpWpCgqcsKXTfBJQZW+xCo8WhElqRcfuUVLr/8CkpIenFKlqTUZUWjK2zbMB/YmqzfZ33zFGmSczCd4JwjTX0VS1WWNFWNEo44pHz68BfR+WbbxNaiKGis6YCYJ9ts+0wgFEImWOlrXKxUnb+xTftsj+8WTHV+Q+tuAD0EENnub9PoQ/7E5XObUOmx+FL+9SgJynsopYoRKl78XS5AKEJ1ftkbfdOHz8vF9UjeMNBZPs6cc+HzW7znY7JclgQWC/AorOuSr4Vb+C2Xv4c9DBCXQVELZq3WWG1uuB4e9//LNRQ3HONBrm9bxlMKROj9rHXTBTU1TcN8PvdeXBxPP/00zzz7dTY2NnjkkUc4e/asH6SUFRJBHNQMOIOwtgs1awKw1Fqzu7/P8y++wPbeLqtr69x9z330hyPmVU1jNNmwz3B1haiX+SHb0WPrJu/p6Dl8FDgrpXyKtvS+6CTOAOmHC1LdsL9fzz3wrQCWt7o3vxn/53H34eOkuscNkU+knyfr25P9cwIuT7aT7Q2d9Df9vnQITxMe6rha/N5iUny7G+ytyr6P/H2Zt0DiZZLLX27JW+OcI8l6yChhMp9RG02a9SDyOYp/4I/8r3j/97ybf/rTP82nP/tpiKSvz4hjjLVsntqiMX7xf+GJJ/g9H/oQ7/re7+Fv/cP/kU/+zhfZazTRaEw0GJKMh0RZTqkNVaMPLUxbBgflvSY2JOypJQlsCyiLomA+n3f9ku1CNskz4iwFJX3vpZL0+lnHPEaxRJuasppTl3OcaYiVIEtjcIb55ICD/V2auiSJJMPhkF7mQ1hmsxm1qcl7HqC1U3ylFFGssFrTtGAzzeilGXXlZalNXTOfzajm3mfZz3vEKqKpag9klGI8HpPmOU1RsL+3Rzmbd8dEEsdBFucDdhIVkcVJByJbmWrLRrb7yoYuUQdEcUyW56SZD51xgVECuqoUJaSXHQovYVxmQLXWi7oOpToAL5eqCNqUzPbny3nBZP+AXpaytbFOJCROm5BEa8B4lsdXeSjSNCZJoi5l8zjAKkJ3oTMNuqxIhGJ9tMLutW2uvPIKSRwhcJSTAxpd40xgB1WQwzkLac7Kmk/TLIua2WzmWTbrQ51s1Sz2gXM4rXFhCNAm8sZxTFEvjj8ZekDb/WUcGAdCRag4Aell5w6JihJUnGKDX607ZYPX11mNI/jVlhg2EfpfozapswNgGmu1T/kMAM5LY5X3TwbJO1LhpPIyWhW+hA/sIXg1CSAU6ZlI64QPBRMqBPvIUGMhiaIYpSLPznbXLtkBjlZ50H6GyzVDR8FdCxAX7/dwv6W/mvlQm24xb13XWel9khYZJLfCeRmssG5J/cAhAHT0NRz373K5RzP4PY/7+RZoa62pjQYlGQwGzMsCK3xi6+d++7d45rnnOXv2LE9+11Osra116oFWlg5QFn7AlSYRwhkIYT5VVXD9+mu88sorvPrqq5y/6wKrG+uIWDGrSoyE8fo6q1uniEdjED49uKpr6qahMQ3GmSB5X5y3OIPAdpFSLDHHLciU4XOflQVO4AeDaXJI2eB/x93AHL4ZcPeNXqy/0dfzel7fccOLmw6ET8DVyfYdsH3Hey6/00/wkwvcW7svjosav13M+K08mbcGliCDqck555aDCdotjmPKAIh6vR6zuWeDfPJjzPbePuubp/kLf+nH+SO//w/xD37iJ9ja2OTuixdAQn1QYDFkWQ+jG8q9Hd72vd/Nv7+6wj/fXONv/o//E+976h28422PcGplhY3RiJU8J4tTEimpbeEXzEvySxdqC4ygY2B0K/E0HuDo4KWScUSaZX5RpsLCLviRLI7V1VWyPPfBPVJgGo22JixUPYjy5e6esZxOfFJsW8eRpr6ovKh8R2TayxkOh1gnmMxmqMiH2VhtqIoClab0s9wvMuuGuih94FCj/f9rTT/3MlatNUVRAL5WpN/vg3VMQ7iQNQZpHZHyvZNJkiCXpIRSSubzuQc3gXnL0qwDYi3obMFPlmXkee6Z27bqwugunTVJko5FXZbFCuHrYlpglaYpsfQdm8sdhEcX7c45ilDtsr6+zmg06h7jaPDVUWltU/nPWUULabNaYsxsACJOG0zTkGcZEpjs7UNjiJHUVUUUJwjhkAo6MxhAHJEPhqxubvLq88+yu79PFimkg6assAMPfGUEkVK4sD+jKAbl5eVZlnVeWdPJW33Fg3EWKcASgBiA8cyOkAoZ3oepWibJdoX2JgwDpE+POfbcl1IQh2Oh3f8eACz5lZEhzdM/rlA+HVQEFlMEoIuQIUHW/6zwT+KBaQivWR5GKRVjnE92blOQ2y7fQ2CRReKtlDIAM0MTKlMiKT3wDAykXQqUUcI7OX3np/TMYEiAbYGjDWmvHmAGUjr4Ud1SB2Wbn7KsfLjpYp/DtSIt2FoGSi6A1pYZ7gLGhE/OLZva+ySVRIdz4uWXX+ZrX/saxXTG6bOneOiRh7n33nvRddNJo1u5eFM1GK19Wi8CYx0OTVWVvPTqK1y+egWVZtx18W62zpzGCom20BsMGYzG5KMhyBiMv16214D2M1kGL53ceEmO3m1WYDE+vCm8fWst0+k0yPSzEGAU4o2EwLRJvO2++9foubxd9/SR5xB38prutGPyqEKk+3/sHb/uNwtgT9ZcJ9sJuDzZTrZvo4vf0ZvaoQvjkRsdwvrFnT16A20XOfK2gPRWr4EjCrND4QV2UVTeBle0fqm6romSmCT1MfV1YzDOopIEg+PJd7+bv/xf/GX+7//df8u7Hn+Sf+fcv+XTC7OMKJJMZlPyXgbaMrtylbNPPcW/u7rCxulT/Ny/+Of8zH//T1iN4b2P383vfd/7efDuCxRNwyCOF+yEbHtBHdYaXGA3nTHUgTWzLCRaUkriLCUOEtHaLNi1OI6J05R+f9At2qq6OQxucKG/3dGE8B7baNI46SSry6xg6w+11lI3DdZqsjg/xO4JpRBx5IF2XdE0mrKuPNthLEpIYqnAWMqZ757L85zxcIRQyocLzebYRvvFtIAkisiShDiOsNZ4CWlIEa6byleXRDFp6pNHi6KkqkusXcjgoijq+jdbL6NfDHofYitfbI+j1tPZBbgsSaillMRy8fOw7KlbsFNttUqWZWxtbJCEio44jqmbEhUJ6tp2UtMW0Bpj0EoTxbL7ewumZST8gq0DIRKrDWkUsb66SjGZ8vILL3Lh4t2kQiHiGBGCb5S1OKRP+FQKkSasbW6RDYYczPZZ6eUo57DGoGjTcGOf0Ko1JnSA2tAj6QF51nktZaRQcYTWDQZBLGOIom5w4qz24UVS+v93qmO6RKiYEFh0o7HaS6HNkbL4lg1sAVsSPiPjFsnTHuCCpJWaS5ySOOE8dxfkm0J6YNl2xIJaCtiRXlEhRHeO+ACm9vNWWGdDzdHS9anT4BLOYxvqVGIaB6Zlf5VP0D20yDYWEaTw1rVhQA6H9WSqs9hQM+LaYUdgJoU1HuwZG/yyi3oSa31iriKk1gYmsgWpbeptwNRd/JlYAkgy7BfdgtFW/RGk/O1Vt/VFtp7k1157jf005bkXnmc+n/PIww9zz8WLrK+uQbAgNE2DCkOcuihprOmGLFU5R1vDvCy5tn2dV66+Ru0MF+66i/vuvx8jBDJNyXsDeqMxKsvBWZraD7K0bdB6aWAkou5623pXbdszCl2Kqt8nPsQnSEn8fcJoZvM5TijSPPOey8BwRoeAK/4x/zVLY48Ot24KBN2dPre9CQhc3LfbscTi55aGu1LcEjjf7L5+AqpOthNwebKdbCcA83et5PjoZPXQzcstFkrt1LqrEwg/VpalZyyLhslk0gExlcQM+isUswOaxtDrD/m3//gf5ytf+Dz/7H/5ad7x9rfzxFNPESHZ39tmMBjQVJVnQMdDzM42/a1T/Bt//I+zvr7OH9zZxs1LPv6rv8pP/9zP8kPf/T28/6nvwsznCBNSMG3ri/JslNYaXTU47WiCPEsoXwWRZCkqiUnS1Nd+VKWvODGaNE3pD4cMBgN05cFhO72X0gdsABitIaSbVmWJrmoi6eWeUVj0VyEZMQt9mNr5InQbwGZgh33dgwMbpKDWWqqmRkiFLtrQlwgCi1XXNWVZEqW+EiQLrGU596muBJCWBuCcpimxiqh01VW5yCXfXsswaq07uXDLCLaMTZsEu+gfdIcYqaOBIi2gXP5qgacKrFaWZd3z+iATL1uez+fMZr7Xst/vMxgMAjj1AHI2nXqgtuQpbRfULdOqlMLZw9K8ZcZTAHHYpzaWbK6u8eyrl/jqF3+Hx554nGx1TKwkGottarRSiDhDEUJrpGS4sspgOGZ7f5eq0eRBaiqFoC7m3rMWxf68Cummou2pTBLyJMUK0S3EnVwCf5HytSQEL5p0vq4hVBwYY7yctGmwDqLIp746Vy9Au7PIAIzckscvCqAxkpLGaNAW41z37x4aCg9k5RLIhAAqg0dOiA4ghv+WEi59BcVx1Q/LXlwv/z+8sm6BmTPCDwSEP55M03iZsgqsZWAuTctKBoZSiCUAKBzCekZymbXE2C491ifBhu+FsKO2/9JXPBzuB+yO/SMdhO3ls5MlHgNQlsFll8gb0nN18FvWTYN1juvXr7O9vU0kJU889ST33H2R9ZVV+r0es8mUREWdf7kd1kgHTdNQTvZBOoqq5Mpr17m+s03aH3DvvQ+wcfoMldaM19ZJ+wOSvI+T0NRVqCxyNLoKwzZ9yLvegklrD/d8HtoBS593C7Qti1CktpJHJbGvkbHGy8fDcwicZ53D+fSvc7tVFccbDRI65MO9jf/yzTKxJ8DyZPuOBZevP5L5m/eE+Ub3yHyrXyi+9Xsu39zndjt/xK1KjY+T6XSPGxZtywzm8qR08Tvq2HPuVhKdo69BOlzrh5Ld8xMW8L5PTqkYpXzxuhASrS1aF0RSUVWGJI3YOHWWP/tn/kP+zL/37/ETP/ETnD97ls27zzMerTKfTcj7GQcHBziXkfb7uLpCJCnf/+EPUx0ckDq4+8wZ/tZf/xtcuXadK1evstLvEVmLNRrT+IWQcfZwIEeQNcZJTJz6/sE4SRCRQlvDdDbhYOo7CAejIcPhgDhW1GWJM3T+v05qaLxA2C/ifEAGxpKFzkfJ4ndUFGSgSYIxDbU2XYdkHMdoa2h0BVKQRBlWG4rZrFswzorCszRRhAqSxboqaYxGRZKV0ZBeloKz6LKkqUpM4+s3lMD32knpg4K0ZjabMZ3595pHEcL5TsE8z1FKMZ3NO+/lbDKlriosHghnvRy31NvWBuikaQpSdJUHLcg7mhYbRd4jWhQFsYw7yXDL8FZVRaNtd8yXZYnEsrG2Qi/LEQ60rnyoUJqxt7eHlMFnFgJ8dGM6lgXnPOCPJBbPrlNb4ixDSoVxDUkSI5IIpyR70wkrwxHPP/ccr1x6mdMXLyAFzPb3mGvLeGOLXpLTaR2TmKSXM1xb4ZXnfPBQtroahholaa+PrmrSOKIxlqppSPOs81VCkJUHZiiNIqIowYZqhqKuyKLMS1VVhBSenfM1HKDixLN6WOqyoqwqlJREaQZB/h1H6ULWKoR3DoaJUbvYR0ZEiZfjausQxnr/cRRhhMQEsKYiH+DjhD/PESrIWr201QZg55YX09YgpOjs4p30OQA3ZABfIXhnWULayj2t1l2gUpqm3iNqfMhNrCJUCPexYsGgseQdtbpBKBW6Mh1NVWN1vRieOdulynaMpfMVRlJKbKMJl1FMUAQoJTEhKbudtYml/dxWaagA+JYVD0p5P6pYAl5CCv86rR8+XblyhbKssSuaU6c3uevsOc6dO8f66hrCOWazCVESllcKqrrw1x4F2mh/3lqLMZrLly+zs3fA6uY65+++yHh9jbQ/QKUpw80NguTDqwVCeJg2zleIaEMUhkUSgTMmSHqNx/GtKqCTNOvufFdB7OL8jcOrMxrL/nSGUJLeYEDe6zEvC+I4CRLoKDCZDikin9DM0ZoTd1NwdlQiesMQ4xb/dmfg8c7WM3fy03fSJ7n8z7dLkf/Xueb617Vu+05dP55sJ8zlyXayfUMu1Dfz9Cx/3y/G1Ot6nptJfb4Rm3SSNE7QpmBnZ4/14ZAHH3mE//1f/Iv8N3/lL/PUU0/x+z78YQanNukpxXRvh9FgTNWUzA8OvDQ1SUFZ0tEKVAXveOxxTp0/y/XtbZwQTGcFrqrAapSEWPlFkAky4ThNutqAOE3o9XqoKKI2mmoy92EZQa6ZpilJFB9KTlUi8oXqXVm1lz0uJ5USQmIc3hNmxEJemGRJJw9t2TQVQnOWQVe7iAUP9oS21FXt/aLG+LJ4FQCT1kghSPIsTP8TMMZXosznnXRQCUm8xCLOQ9WKcHQAcJn1uyEwRXrA0Popu2FD6w0Mi/9D8f1LAT3L3s5WStt66NpAm2Wv5XK9RCuTTdOUOI4PJYsusx9SyJuyC+1ztwEqyzUrLYBumWMrBHmSUmOJy4Krl68wn81IezFNVdFohwnsqnWCSHgWUaUZ+XBInOY0xtBYQyIjD1SsQYpFyIx0ARxKX5lhraWdDbXns1QKlMQ5/zzGx4h6YBlCcpz1kw1npWcutQapPIvU1nAEKtDivGQySroOSRs+WyFE1z/YShG764QAbRxRHnnGLwAEJ8A7OhVSiCCl9cmndGDtmIFaez3D3SCV9otxd9xQC+N0B9xU8DY7B7qtCXECJ+UimMdYH2NkrQdr7dMb7/tzy2xl8FliFgE+y2ylCLLYo9fg9lhcDqG54bp9zPCwVX20zbsSz6BK5etaoihCGxPSkWt6ecoDDzzA/ffcy9bWVndeRFISJTHCgQ2DACMlOgSVtT2STgguX7mMlJK77r7AxqktVtY3SHp9kp5P7KY2GGlwSO9D1y3I96wqUgQ5s+iksO3+aQcASx/vITgVqkW79y2EoNaNH4JEEXm/h1KRl5iHpGG7dCS4YHY9rkfztuDuDgiMtzKR//UWwL8ZcHUrj+XJdrKdgMs3cJKdnEgn27crsLwp0ynskRuXOnJzbOVZ8tgwgjthVI+Cz6ObFQgc7vjvy0NrinaC7RfNhoP9KavDAYlQaGPJN7f4Pd///fzcT/8v/M//+Ce59957eNeoD84yGAwgSaDxVRtVVYI2nvUr5igk06LgtZ1d3vXIO6iMJkkzpHC4BrDeU6mUIlepD8TQ2oM5KYniGKkUtfHSz7L0DGAcxwx7PZLMB0x0YNB6ua1cuu5YY9ABgBljsMuBI35Nu1TF4bvmTPgdABlHqNh7kMwhwANa1/5zlKIL+JFx1C16hfPy3rqufadk3gssiKQuCqbTKXVZYUKFSJx5djCSinnpezfLuqbX6xHHcfeZJ0nSVQR0vZBLYC/JM5I887JI7YGntj4UKUuy7pjyi1DZAdV2Mdweb620uAWWcRx3FSLtz4mltFStNcN+jzzNaANrEpV0HX2eTQvHsxELeaVPR0FIiYwiSl12DKlK4i70KYmjjjmSDvq9Hi4RHBQTnvv613j02hNsDFOcMQgnkG5ZFSAgSlBpysrqOoPRkHJnm7qu6UfRUtm8ByhCOgRtPYO4AbBYr9KECN8laHyoTxvsI1SEEgbtAhh0ngEzuC55NaTDsBTDhXEghfJ1IVKE9NPA2CgZ0mPD8avkIVanscaHIClCub30kMOF5Nc2PRYIMT6hGHfp+mUdTizSXUVItrVOgzNg8AOyrj/XeXlkkK464313cukaZZdUCQbPoEWEMB7nOu9kp/wwLuwLh7Ma63SXHmsDKG1/R+AWIT92Sfoafr7tA5Ve0Op7bUM3Zyuf7byUS1fuFtAvh6K1EnLRylmlpJzNuX79OsbA6dOnueusZyv9OVz5HN1wfjUBPDe1l+0LB1GS4IRgb2+Pvb09kl7CaHWFza3TDNdWkEna1dkgPZtvJD7Rt6sPcd01z0tUWUq4NV14j6dy29ocewPV1jr0l6XzZVl6xjmOGYxHkMQoFAaBDce1c9LbHO5wWHorkHX0+7cDZTdYQ27DZN7O/3m71/dGmNKTdTC3HRyc7KsTcPmGDqSTA+Zk+3ZmLQ9BtyOTcSHkoYnx4iZ25ze04ya7R4OFWh9Q0M4hhBBHk2RbX9RxF3oPMhVZ1sPiUwBnkwlbvZRTd13gz//4j/Mf/9k/zU/8z/+Yra0tzp87gxqPcJMJcRyjosgH4ciWElGQRVzb3eHa7g5X97a5tr+PGzn6cULW66Oc9cmoyqdk1nXt01hjn8haG81kPusADcBgMOgKx+M47hZHQghipTDade/RWoutG2rdYBuNCUEvLUBse9xa8KSUwi4xNMvA3lkPHOIoOcT8aW3QVeiCbDwQk6GQ3jQaHRaUcWA6nLHoomA2m3VsXvtYvSwnS7xHsqnqENwTdWCyBVxxCEWq6/pQN50OITNJknQBPVobivB81loGvcGhYzVSi1CdZYbqaN3JMhvZMprL4T6eNfbv4Shr2jS+13K5a9OYw917gnDeSIkrXPe8UeQ9arjA6EmJFX7xn2UZkojebMKlF1/ilZdfZvPCObIoArc474yAyDlEFEOcMloZ0x+vcHDtKkVZMuqlGKv9gjswbGIpndZF8jAbI7w3MjIGhR+AyMhRNYY4sJtSSu9Hs9YPMIQAYVBE2ChBxb5kw4fHtOdxYI+VX7wrKVAyoQ3/ss4hIrr6EBV5sAjgtEZogbamS5f1XssYae3CG6fU4evToWvQ4fokD77wtRVLV5Iu9KYFZUfqQbrHAqTx56OvVZFBlglWLkZdZjkxNjBnxtrAIC/JX9vPw1hE67F0tvNctmzoMhi8Ic2zZdu58fti2UKwyOwJ1oHA9EcRJniNkZLJ3j672zskseDs2bOsrq52qgNjDEk45lu/clWU3blZliWz6Yy69H7pja1N1k9vkGYZcZZ7drKxiFihG4t2844Nb+tsFqFx0dL7tL7wylqs0wtW9/Dq7AZlzLI8GHx1SVlXFFVJkvvOYKTE2cU+8cNT+6bvm8fdk16Pd/G2987bBPq8mdCho49zs8e9Eyb3ZDvZTsDlCYt5sp1sd3DDsMf+nJALBvPNPucN3s+lP7vvHTn9lheVy6++qiqSKCcfDHHA9evbjPs9zt93L//pf/af81f/8v+Rhx95G3/8j/3b5E3tF9lpRjWf0+v1qMo5L7/0Ev0kIxaW3njIO596ik9/4rNsbKyR5AlpL0PlKa5pfOy+ivzi2zriWOEENNp0CxtrLVHsAU6e54d8OP9/9v473JIsLe9Ef8tExHbHpivvbVebaks33jQI2wJkMEJIuhLSlUbmXt25w9yZKzQyF3EREsiANAIk4Y2A0YBACBASpnFSN3TTtrqrqstklsmqzDx5ztkmYpn541srdux99klT3TRt9nqe/ZzMc7aJHbEiYr3f+37vm1mdGIIYfKBQyRTGOYerG7yXEPWowGrhMHREHCVLAcbKGALg64aoFg1vMpAKMaJ1byFOYzaZcnhw0OY2Rh+oyhKttGQiBk9vMGAwGLQy0cnhmMnhWNxhk5NlWRQMBgOUikwmh0wmh1irBVhalXrYZP8oFanrKbPZRHL+DDTO4UNDWZQoI1EO2mg8kb2DfSYHh22fZivp7ESPdHua8r6LUZxexSHYtmAxg095TWyBf1lKf2xpbGK95jmYMXqMmRuMdOdudxuil9gKjEYXFq0VzklvntYiG26cI+IodYkyJYOqx9lnn+HpJ57kFa9/mMFgC6XkWDRNg1ciYyyVBmvojTbY3NrhGSXsb9fAyDlHdDNy054UIxRGpz7F3C8YEaYwgLEFxkSU6zBEKiZPndTjlySwymi0F4Y2n5umIyXMTq1eLhIUtqBIBkpN8POsS2UIGoyW97HKoK1hNpvKZyot8zrvW6UXFr7tMVCL1ykpNIUF4JWvD5qINVr2R7rAtNElqY96GVyqyLxvEcV0MgEf8El+nBlIg/QxxrSvgncCpvO8TGATn01pQt6AucFPnBsD6VTAiD4sfOfYMTjLoGNhfZKkxLnvNUZh5/JoGilW1akv9NKlSxweHtKvemyONtBIkUspRTDz3NjWkXnQ58KFC1y4cKE14aqKkhMnTrB78gTR5OKJYlbPMLbEFja5sZLk1bHNpsw5rrn3VVTPidGMc3fczOpqc/Re0s4LpdDKzgsDiblsmobh7oB+MjQTeXhIAJVWKt4WOK9QNL2SGd7VCq3XC86623O9wPKlGvFcCViux3o/rMHlHwBbuWYx1+OT4aKZMxuPnhdXtkqPR1wM1Ye1LddlvNUBmBsbW8xmEw4nlyktFIMBZtBjtzzFp33uZ/PZX/Bmfuwnf5K7776bz/3sz8IONhCtnDAlrgnYomC4MaLcGDA6cYIv+4ov58kPPcYP/8Sv8SmvfpSX3XMPD917H6e3twhEZq6hX1ZsbG7SuBnT6ZTJZIJLURDd2IoMjo44+IVIdB6lDK5xLfOWgWFmbauibPuSbKeXsnUoDQFljWQdIv1qocP8dBfmPklep9MpBkVRlO1CznuHm9XowjJKkSB5ATeZTNroAt/MjU8KY5hMJowPDqjrmn5/nrvpkf2aF6uz2Yy6rlMfXWzBXvc7ZWCX5bNbW1utGc/ytbm78M4AoSxL+pVkihpl2v7Lbu9dfr4xpt1ekxbX3e3KTHNYMorp9mYC1K5uj00+5t1tmkf8pO+XQD7A008+xexwwujkSZStmGZDHZtpMumPtFXJxvYWZa9iNjlsI29a+WejMVb6JoPz8poMmPM88HNAapRFWYP2Yfnkmm+/l35DYgAtYDekvsSuTDsGAa3RB4m4N1reW4H2oHXRmnMFraS30yi0NmgMTVMv9EdqEySOZMkYxXufALCeX7eCwxCPkDwqCgB22eAmFURCkq3GzvFsHyTwSAe4pF5LyWn1aFGeti6shsRU5uJHOq+z5JWQfp8YypZdXrjIspK57M5HYXAT2GYRAHh1zGI49bm6nAurRR47HU/QEXa3tqlsgatrYlW1n1eWEnM0mUy4dOkSZ8+e5cKFC0ynU3Z2drjpppvY2tqiMKL8CF6hSouxJQUF0RjJL43JoTZdq1t3XVI0i5JoFq0MPkZMFPdgrVI/u14C/UsmOvkYhU7PdYyR8Xgs4HJjxGi02e5bFz0mxiMGNsu5oVe7Px1nerOqHeS431/pfY+/V1/bffa4z7uarPelgqs1s7ken6hDf6TeaH2SrMcn4jjupnYtZgMrJTMqJFnT0WLMS7lRtbFzCtBKtf9uWYlOtll6gUKTgwIOx2NMIeYNttfHqcjZ889BWXHizBn+h7/x/2D39Cn+zQ98P4988APgHZACwb2n1+uxtbXFeDbl4MILNJMxr/+0N/Ht3/XP+Yt/9St45EPn+NXf+g1+7TffyuPnnpaFcVnRBAGZ4+mU2jmiUtiypDcYyKPXa6WZJjlJ5uiC4HzbS9TMappZLb2M2SlSaaw2LQix2rSANTOTdeov7EZ5LC9WMrCNURwsxweHzNLiskzv13VS7YKqDB7G4zGTyaRd/DdNQ1EUDPt9ZrOZ9GHWdcscdBnFKslNM6jtgtxueH1Zlmitqeuauq7ltVXFaDRa6drYlbhm4JGjTHq9XrvtGdh2zY7y34yRSJduVEpmwnNGpLVWigA+SC9Y9O37ZomyDwGlNba0aKvbRX3XPCiDaO894/EY5xy9Xo/nn3uOSxcuQIjY1IvbGhSZlOloxDF1c3OTfr8vRQjvFgB2F5D40LTMbD4OOkV7dAFy3n5Z7Pu5Y0o2S1LgYkheNIKqtLXiKmuL9qetSowtRcKrjMSGKJMYrCpFqliUKVDaEtDSf6cEOJe9amFed4sA3WOuooAS+Q4JzLZsprBhon8Uhmo+P6QHMkRH8I2cd0mSqiPtT82ckV4uQnT7eb33rUFPO4IXxm1FAWTu6rN4TevKcvP36sbZ5O3oyr+711DdAREh92Qmp+W2PzNtf1mWbX7sZDLBWsvOzo64OFc9uZKGKM64xnB4eMhTTz3FI488wtt+93eZzGbcfOut3HzrrfSHQ2KS6foYicqgMGhtKaoSWxYtKJ4XwGJSPaTrOREdgzDO3skxy39HiaFQMvlRCazn47R8b2odWU2B9yHFCwVGww22trZa07Crga9rYQuPK7Re6/30el53Le/ZvR+jpO+6+//8uyv+fs3Wrcd6/MEwl0duYusTaz0+AQHmsTcw1EIvS/LWAa5NZhNCPFKJvZ4g5msBpCFJp478DU1VGrRWHB4eUg0qlCkYbWzx/IsvcnJzk9vvvZe/9Nf+Bl//1V/Hm970q5w4fYYTJ09Qz2b0h31icNiqor+zw6VnzjIclhADOzfexFf9mT/H3ffdzy/8h//Af3/HuzgYjzGf/mncedMtKCQL8vBwQlGYVoqZK14ty0U23kiL58bNF/1K4RvXLlwzCOlW4lujmASMfPAL7OaySUo2+zDZadKLPDPnSzazWXLJLVOmZsm0k0tZGokPid4TgP29y8wmU+mbTIAlu7tevnyJyWTSLmK7i+GiLCjLkiaxjln21rKAzrcsWFEUOCf5k60hT1kxGAySWcocQyznXwYni1OtdduH2gW43X5U2a9zNq9rDJTPkwyCu32Y3X2bw8nnzJ1HZyZOp1mpOyAt52RqQ+MbZpMJrmmoypLx/gEXL16UYzKI4DyYRuS1IUWCmAKMxQ766F4fh8Jl/JWYMJ1cVLNksn0EjVYqRXmIO2zenmyORLe/L7GX7fnrU39gklrKYtRIFmZ2NzYWgxeaEvDJ8Uj6eIXd0jqB7s48CCpigKLXhzilaRxNENk4Ji5efVT3GtMBWXG+3TGrAVSn4hxkAR29SNBFrtq5PqV+TTFDSlmwCmJwLetYGItTU5GxIu7ZKmduJtyoE7+mEkj16bNJxaRs2qO6hTjmjHiIIrMVF95Ov2Q6b9EKjWmFwF32TKdcUUIk6lR86TjnmmSso63F1bPUywz9/rCVvsbg0EYKYc8/+xzvff/7eOyDj3I4GfPyl7+cW267jVOnTolsP3hKU1GUFYEohTbvqJ2jMNIjqzvGQqTii0rHsdsLK9e3IPNLSckQrRbxeJDCxqq+fcH1HlNKMayOgcNZzczLvBoMR+k8jOiYr8VyXmVX4o/Eaq/LNHeB6/Lvj3+DmMyyrk9CK/3FWuZx1Nf1elbMpTWwvH7Sab2/PsnA5XH9XVdyt/yDYjQ/2XMo/6DHJ/v+UVe5ocxveMc+IQE1pA+wXZrNb7yq48iXey7nfXwdE5kYjnxWXOrRXDCdiXMQ2/YZEY+A4haeqUXMm+wcaGYNVWFlka0szgfKYsjhzFPoijd+2mfzv/39v8c3/o9/i1tuupm3fNmX0K96uPEEW1lMWeImE7Z3T1JPp8xmNRubI4yCN/2RL+Shh1/NL/2Hn+bHvv+HuOeee7jlzI0cHhxQKE2vEPOaqkhgqqmZjidt/5/Oi0BlsEoTTUkTGmZTCRBv6qlESGT2TKXFmAWj56ykc/W8H1ALsyfOs2YxdiEEQKNNBpiK6XTC4f4+9VRYi/6goqoKolL46HCxIepAWVX0BxVlaQmuYVrPCK5m2K+YzWaMx+MUp6KZTA6XsjZLlIo0TQKvhWE2m0jO4nTKbDoWuaCCejIm+IbBcEhVFXjfENJivmkahsMhw15f2M3kwVIYi02Au2kagnPJZVWkpMKmDlqG0NcNdS2S5QxgZR3nKYw4khoFxhTYqsKFwP540gJLo7QwygnwZkZZEYV5ISYHTU+/EpbTh4amrol4lIbgGxSKEDyTw5pgNYWxqEkg1o5ZM+X55y4QvYLGMbCWOji0byDUYHrgG+gPKDZ2GJ04zfNPneXS3j43bG0TZg3BNhgMyoic1iqLd4HaeWyvxAfQ2mIMeBfwTcDVXgBwCG2+oqsbjAnoshSAGRRWF7Ivg8cTMWiKssImYyoxNDLJilaKCmLKQ9szactFmbAmu6KqdIUxxHIAcSaFiKDolRaUonEOEVkCShw+CfNrj1Ua18yE5VcmFT/EgEelHuXCJFOqIHNGqdSPmhk0q6U/OEjEjxxjASA6BqzVTKP0Z5ZWU1idihye6BRuVkuBwUdi8IQIygeCl3Mxn/8iy00gN2VcpihPtFZ458WZ1hiU0fgY2n7Kbs90jCnSI4JB5nA2KooonE5A1mh0aURVgaIyBWeff5Ynzp7jlhtvYXtrl83NbZSBsii5vLfPu9/9bn7/93+fuq657957eeDBT+fMmRslKzcVnwaDocjFjU7sJcQkwXYxoJMiQSkIjeTBaiXfMUYxlnLJEXpeTMs1jtCJIREoqKK4FMv9QVQrREVMxQWrIKbMVYqCS4dTLuxDf2uL7VOnwAvrWRUmRUQl9YG1hBgxx8hY24LYMeuNrkNtt4DV7cle9R7d34upm1YxprteDN0ntq7TyyxmTAZSbU95Vgx0X5/vq2FeSFkNIMPC86+03F3N+upP6PXjWtH4sT7Ch3n89EeHuVyP9fhkB+rHnYsrnfpivGr61tUiS675Ai7NTosXDkBHjyaASiHcWpiagBhpFMnR9I2f/ul8/df/cf7O3/u73HTDGV73pjdgrQY8IUm4YoyUm1vYScHBwZjR5gCco7+1xd0vexn3Pngv737kfdx06iS3nDgpAeBVSaENRsulyCiRoUXv56YVyb01h3xn+adzLrFVc9mrsqbtscrAUsLHXSv/rIqqfX7TzBdq+fO00m1/5KzTy7mwgNIabTTNTDLrbMfllRBaS38VpY8vemFxcpRKK23VUiDoZlJ2exKzJFaFtBDKTqpG+kQz05j3f7e3tDU+iouSuBjnOYKrFnTxiBPoovOm1nPZcf6cvFCks+3t1NPCxnUzNVWMCaxEjBLZmSz6mrS9KUMv37zS9lqlE4CRxXfTOLzLJi8eo0U7oGNIwZUWbECVJbqsiMYSmEtcc/Zi9B6lk8+p7i4CdWLVNJrE+vrQ3pK75573Hp2YZo3CLbDhEKPCJ1MqYwrQ0ieHNmilJfsxCsAqkjlQZi7ni+PFY+JRaGMpSgGQEBfk3m0mJGHltUJj5jLTDEmU7DrPPOLCpDk/Zz0TGO4W50Ik0LT5k8TIdDYR9p9A9BC1AGjJEW1QhLafs82w9CGpFwQ0tccpLrrUdjM7s6Q1Q1uzBARcCFix8W0dgCXPVI5JNqvKsSVoiFbhvLgWz5qai3uXhMW2hqIo0dpy7tw5zp19mscff5yDgwN2t3e56667uPPOO9k9cYKm8VgthSoKI33UhW37FUGAcIwRnBPjMWtTZJCAQAH3OW9WTIdiMq9ZPtfm521HCtwR0uiW1Ex8cYzoZF41ntaMZzOKPoy2dzBFldx+03HBJwbaJzCWm2ivpMwJ12Sgs8oM5ziDoC5jOZ/P4SUBm6D00kJ5aXvjugi/HuvxEWMu12M91uPDq+QdDwiXDCWORJZcX/bl8uuOde2LUrcOSyuB4EFpk3LxxN5Da5sYDM+LL16kXxhe8fpP4Uve8jRnn3yC7//BH2Jna5O7H7wfP56BClT9AfXhIXE6Rfd6mOkUvIcknTw4nHDumef49Ne8lu2dHarhiDCtsUWF1rI0aOpajFDSYt85R78St1bnU7ZiE1oZrMjuJFrEJvarXYibObDMZj9Zxpbln7kC3t1fLahLi7nJZNJKVTOAbI1nlJI8R6NbI4/cg1lPp0zHY0xRtNmUZVnSKys0SgBrIyBguV8sv3/uvcouk8YYZlPJhOyaHoUQqOsp3jdtdEkGF03jWoZ7GTDmz8vPbQseS1LWVQH12uZ9KXJW7xMwz/smZtZB2CuCaiXKWmtcI9l/+f9ZMjw3zdGdDEQ67paLkuccSt9vF95xsYiiNRhDWfYoe/0U8dLgwjzf0zmHMg6TZImrF7NJDognRIcOAtwUXkxusktoHdvoiWUjpO58C3i0LqRXrgMQfJJ3e61bYCWgnNYFlq6sOYjxkzUlWonUvGkadCRF7SRwkNn97nWkLXaJZFVkq3lN7eW7dkxmhUEMqDi/iqhWrqoIMRBC6ql0UgSZTqfEVJjx3uOUo7IFEHDet9vTSrGDFJJ0KiaEGAT8hrlLbI4giV2qKEucFa1cvHs9nLNjeqFIpGJyeo0SXRRikC+bCgz5OnHhwgWeffZZqqoC4Nlnn+Xs009x9qlHicHTKyvuv/c+7rzzLs6cOYNNioOq6st7aQtJYtvOAwVKq7aYpZJJWhcc+eCTVDfLyuV8MV2gn75/driW7ztXc2QDpZXMBGCssL2H+wfsHxzQGxacOnkGUgawtL4uXTvCauXMceyHWjom15oreZwBUIcsPMZQL15Tz2Vor/3HGA5do7HPeqzHeqzB5Xqsx0ccTC7f5K7V+GBVH8yVbrQfTv/lEfC5dDP23rcyMqmsG4qyROnIdP+Az/+iL+bC+ef59m/7h/yH//Sf+DOnTrK9u0k9PsCYgDGGuq6pEkO3v39AaTXVxgaz2YzzL17G9ErK0QivNE5FCiUZmeIqGYgRCmvQ1mLMvJfSZ3CZ4h+MMVhtKCsrvV4dpjIDEZgbzGTQVVVigDKPzIhLPYUJuCRAmrMflVaUZclgMKAoCnyMuFnKc+z3WtCZmcb8uTqBlxBCa1KUF5fdY9yNCmkBWGcbSpNzLF0LdI0ReWJ+XggBa+ZGQ7HL9hCPuMR2517XGbf7WLVAk0XwHKhn8K2UQudYho65jOR9cqS31HtPr5cyPVk0aCGBKeedcJfGELSWXtYO6M3ulgv9Wm0cQyDROxRJdq21JjTzYx9jFPmt0+iyQBslMTVKtUHx0gKq0VG3fatdQ5TMajvnCEmGp1FXjIAxysp3XLEg7maPrmIsF64v+RepyJJZ9uwQnKX2y66qIDJ+rWIrNV0GwB1IPD9P4nzeZhAXU2+pSnJa7wPBOVxdE5xDp/3hnBNCUxv5Ps5Lh3pig0lyWBUjhMQjBdm+PC+627XMXh4HShbcdLNhVBvZIsA7SyizmiT6SHQOreU8unTpEs+dex5jCg72LjPdH3NweY9B33DTbTdz5+13cPLkSYyx6XsmSas10rdorEQfhSBxPvKhKKUXDK5QeuE89anPN5CNpHRbvJD5l3ItI0sFIXUk1/MoqzcHYMaYZDA2ptfrsXvyBJQ9/OFUGGStUkuHX7x2xOu7D62SqH44wC2bhF0J1K66P1/LPT3Lk1k8064IPteDNRhfjzW4XI/1+MhfSBdvmkcB4/KLAt2kSnVEw54Xffqabt5asgDw6UlHMjITg5nz0VpQEVWShQnsVEqjVaAajnCzcbvxn/3mz+fcuXP8o2/7R5w6fZo/8eVfQtnvM728T2kLqs0tmExaBiW4SLW9xU233c4bP/1NvO333sWD9zzAiRtOcOA9U+epjCxSmigLSx2lMm+0xSWZZMtcEDAatBKGrKqKdr90F/DtIjuxZTniBKNxqXcrL8KWj1MG2k3TzC+U1tLr9VrmIsenKKUobUFphYWaziaSFeeatPD2rcTXdABJC8aSHC8f9pZ5TVErvm5SL+wcyEjO4dzwxjcO3zhUhMIoCiOL+dA1mUnz66jcNaR8Rllcex9a4Ccy4vnM6r4uA6YMgmP0YvyhzAJIzQtnHx1KL+ZmZhMh+R6plysikj80Kii8cyIlNEZ4Q5+KEEEk3BlcZkAZomQkSoRFApfEuatuYXGzRXDpQ0Cl/xutCQkMqRTBkaNsjKQ9zl1SlSbEgK9n6KJAhYBrGqxW6KJo94k8VGsisiCtVh1nVI24OHeOtbWaQGhlzd39r1KfYEygTwUvPXREohfzmAzmsyyWEBeYTxTCWrZsprCP8+JHbGOVvG+kd9YYiuTGq6K4z5LOXekvh9pJ4aXUhsIovDc4P8N5h0/7kyTf1F7OgZAUC0ThiFVyYc1MpTx8+2+Vvk/OgOxeObOpjTDVfs60rgI3Ou/H1MOqU45nHSh7BRA5vDzm8uWaXlFTKM2Np89w4+kTnD69y+bGiM3NzVS0ismtuU+v1xOGvJ2bMj8DqaCmdYqN0ShtpIs0z8nEoubrXC5wGK3QcoRln7nkbNxKYNO+SQ32IV45KiSmrNGoNZPZjP3xIVV/wM7uCdAKHwNBWelL7srfoz5SILtSfuUq91aZv/P8zO4jg9+WnexEiXTjTz78Me+Z7L6nIRleqUVlkZqfNuuxHuuxBpfrsR4fncpcjKy84S6zBvM3uH5G8kqZsleSxx55nw5g1SHQBJG7tVLFqGh8xIWIj57eaJMzd9zBF33ZW3jsiQ/xv/7tv82wsvzRr3wLva0tZpf2qDp9Uf3+kIO9SzSXLnP3vffy5i/8In78+7+f//LWt/KGhx/mzM4OG4OB5N0FMdEIzhOCYzKt8a5OIEoq522gfIyYTtRIl+3LwDL3ZfYHA2E5O1LF7mInLvUi5kV9N+4jxxFk5qtpmjZ3sj8ctX2UTdMwHo+ZTqeyQCnsERdbErDK4CbL3kzM/Z5qAdzWdd2+NjN0+bsaVBupQjputiNLXZiHrK7gLy8Qu+xHl6Fb3k9KqyNSWumlVAvxD3l7fAcQZeCf2V4pHsyjVTKL1aRjYdpjJ4ycjyIpzNEQdV13WCzJ/8t9uir1IapOL2qI4P2czfLeo3NERwI8mXWOwaGUxWjpjeyCc61C2qZ5f7APDc5ZirTNbbFglYG0ArRBhVRU6USeAC0junztWHA7DUgRgjn7bozBJzm0MIzz3m7Vfa/oAXWkb9QlB2FhKXXLEOX4Eg0tAIfY9liGFFESvCMmBrIwYvJDymCMLgFwa+Wc90GOd4givUxMpW59VOZA8qVwRLmYwZL0vS3nqbnkWsUsvbY45QXcac2lS5d49tlnsRp2trc5ubPLjWdu4IYzp7CFFGhmsxlaa4bDEUVZEqNiWs8kL1dsfqXfU2thT7UlapX6ZFmIB8qy/qIoUhro4rncVRYcuQesYCqX3Xbnz5+DtxACBwdjDsdTtre3OX36NPiA8xFs53qpVTK5UQvy4+thrK7eOnL1EePV8zWvlF4wf+3x23Zcr+eajVuP9ViDy/VYjz8UsHl8uPNVQqFzJbXjErsoi9NXBKBt1l9iMENnTbbwvPlvkzRLJdYIkYIlh3YXHKPNbV58/hzq0h5VYXngta/nj33V1/Doo4/yQz/6Y5za3eFTP/3TKYoKd/kytiwZ9PoE77nkHAcHB+ycOcX9D72Mz37z5/PvfuSHOXf2WV798oe48+absSHQK0o2N0Zs9HuoaGhChKAIPoisLi8Ks/OjNq1RTGbQQgjUrmnBRpZtai2y2bASkC/2OMUOuMxAriiKVtIq/Y11K00d9nsYo/GNMLWunhFCCm6PAVfPMFpTFRZjRMYWXC2PEFIofFyU9CYpbQaXw+EQhfSk6oj0VKq5C26MUXLtzBxw5yy25Z4rkf4FMWzq5kLmaJAYjlnGh0WTEDUH+12wrpMsspsHuVAgUQHn61YmrLWA0TaLT4I58N7hmiYx7QIGnQ80wS+cV5PJBN+kfR5tAhFLPZcxQAsuC+meXJL/+o5xSQiBYMV0iCQV17po51jMWZDSFEgzm2G1puj1UDHiXQ3eopNONCb2L71Ra16kQmhXt23Gacuo+tTL6hdC7+cMpp/30mazKa0xGkLWpyLuvq1bqAoJZMwNXzIrmeWuBJG0qhiELQ5ixpPNnzRBTEldJCqFSsAweE90HtfUBOfRIdIvbGIQI1pFCq1wShGdADcFLQjNBj45azN5wSYWjlaiTOw8oC3GhAwW0lfPMvAs06Yj/1bJDKftSVQqmREFAYPWYJKLb4iKF85f4Ny5c2xu9rjj1lvY3dlhVPWpCkNRmMT+C4D23qO9R2srMuUIAZ36eTVo2+YQByWMY1CdaAxERZDNuoJfuqfk+RdjCyS7fcZzs6O5bHol2Oy+p7E0LnDh0kUOJ2PuuOMeztx0MySpfYgCKrvDKNlfJPB7LSDzWnKhr/a3a+nJPA5YXtUgiE4mtFp0J2gZyxW5q+uxHuuxBpfrsR4fNZC5unK6+Pv4sbKtSaKZGaGgJEsvxsjhZMzW9i5NPcVHCI3jDW/6VP7KX/8bfNPf/Ot83w/8ICdPnua+V78Kd/4FWegUJaE5ZHd3l/39fZ554iluvOlGvvgtbyHGyC/+3M/zy7/262xWFZXRnD5xkvvuvou7b7+d7dFQWFVtqesJhTatU6Xu/JQepbDAWE6mk9bwptfrLbI8eh7rMDfpMYsQqnVlnPcr5X49ay3T6bTthev2b+acyWxGY5IDo0gbZaFptWmBTO6dzMY1rdQ1zrchA0xZZMprTAewSXh7WNgfc4C6eHwVV2bHV0nWlg1+jgBJfTQmRy39v7vP82idhcsS75uFrMy8wHOJua2KsgVdLQBM2a0RWhZU3j/QNRjJ0lPJt5gbF7ECXHZNZQKxw1wGlFdt5AXpU7IDr4qe4GpwJRaFiaCyo2+S1vkEeKOPLRgisX1i6iIuuzmORBjL2DLtXbfYLvMo0TmdjF0tYDFLi1UCTVEJQ5kVfvNjEduc3YUMSS/mPlYbiI4sGTRKSXQGsl9QCl83WKXRIVK7hmZWQwhURlPakno6AyX7ymgt8tPktmuykU2Y92umJBAB9tcYXXgsc6Xm1zaZC/OfpDxLawxJfTt3UTUaYywqFZL29/c5OGi45YYNRsMhvbKitBLd430jjtdFibLzcz4mqSuJhVRGowsLyuBiLmAFYYCXzt1u/7dr3KKLcyejN5uBLRTHOsc27Zxj95v0OcvnNcFzef+QeubY3NlmuHsSHyK+fW+1WnnD9R+fhfvfMYBvFUvf+XtXhnHkOas8DI706h7nYBu55t+vx3qsx3WCy5fSBP1SqlHrsR4fDyDxWkeMR6uaxzKUKyIeFv7W2qybpffp8m86SdM4KvNqK65RiTvl0dtjrng75+bvmhZHIa3qPBGrC5QxVD3JxTuc1diixxd/2Zdx7rFH+Nv/yz/gzOkb+Subm5w5cVIcKieTdgFsrSV4w+VLF9kcjPj8L/pC7r77bp598kmeevRRCgXv+O9v56d//ud43StfxRte82pO7ewSFRRVSaxdK9GMIbYupdmBtWmaFvTp5NxqkgSyu08XZIZpvaA1bW5c7ucJUXoIjVFUVdE6ojbNjMnkULIoexUbGyOiS71miVVQGfwkBqiZ1Qx6/dYhVg5hMjCRsL3WmCeEID2dRiSwwXuqshQXXScunD5ETHI9nc1mxOgJrqFXVvR7VYpM9K07qDHZeEMtgNAMXLvS1a4DqXM1kYAxdgGMZ/dXWyQGDolTad13G5ekrIqyrNrFNkCv1+PwUPI9d7e3E+uq0NoSY433sXVvbZpG5rZHeuKCp6lrXHSto242OBqPJQNUp31YtuxtElP62C5ClVKSOxh8cnj1LSPdNA3RNAStKMoerq4xVW8+f5L8uDAyH2IM9KqC8WHkcH8PEmMdYqSZWsrhQCSRqf9RGT03NAoNsfYoW4gsHBJr6eUc96HtFw7egU7GSAmcK/K8CRgl2xKaxIgSsem4N65uzwGrM0hMjFmUvlFSFqb3nuhdyvBM/cJJrizPiZAcmPMxrYyVPNPpLIFKS1EKgPSNw8QALsuMA4ogJjRojDWtBDl2zIIyIysy8tSLyzy6qX1EkTsvGFClnEuglfF2DYoCsZV4W2vFgKzfQytDXU/pDwfosmDWOEZbm+xf2uPtb387o4HhhlOnpecUJZmxtcOUBt94vJ8KyLQVWGFDtdFYZVLepknpLMmVNm1TWVUSoKJ1ksymbQ+RxnlU9MQQjxQFCMLuC8ZXraQ6dqNqlgpB8/5naXWIMVL0KhrvaKLmYDLhcDrl7nvukyKoMmhTEJShbhpULpgg56PR6lhvgeUC1ZEIrmPA44I0+BjZbYwxZoB5nAPtqvvqqqFZih1Ri20C7d9VuOL2Xvv6YL0+Xo+P/bGq6HO9WHDNXK7HenwUGMzjbiqKK0uB8sJi9Qnu0aq4ottse2OP1wh6l35XFCIjnDV16o0SOZtXCh8NX/nVX8sHHnmEH/jRn+TOO+/kK77sLWyfOoHbv4z3gf7WDvZwn+AbppMaFfbZGAx56OFX8dCDL+Pg0kWUd3zxl3wZv/LL/5kf+/6fYG9vj8//rM/klhtuQgdPsLO298rjWrCjlGKaojnaXkSb+g4zu5eZKsVK9i1HlHSjP3JOYGYcsylIZsnyIq3LIGUmUnrx5Jj6xM61vaJ+3ku3Kv8tL6BVZ1G8zPwtB4wH59ttlF7OJBtWq/Pvuou2vM+6/arXMp+7i9VWHhv1gklOdzvzser+O4PDGOcGR8H5NoqCBBZbYKsXGdjunD/uQZaR65DiIDQ6Z3PScdNVczk0rgZbiKyYxSgfvbCwTPs5yCN6T6jrVvYYnG+/Q8vIJQMWFSMeT1BgYkRrkdPmY4o/2k8XQqcHlnlvbN5H2dG16546Z/06stPOa6N3hGQWEzpgLPc/ElPepE8xLGnbVHJsVjHS1DNiihRRSktmaUj5mL6RnsogZkPZXVRH0D6KWUruqUxmYvnvZPb4pTCW6Yu6BDbRqjUxC8x3RCCirTCJddOI4Ze2uBApqgqjC86ff5GmaRhWPTY2NhiNRhTGonyOTFHttSA0Dq8svX6FKQpc6nUNMdA0dSt/7fb/alMcAUdZnr9K7trO/U5bw7H7J4OjzjmvUouB1QqCAPPB1g7PXNjjwsWL7B803HLbHVBVuKknKkPMOawfoWLstTqbv9QF8Xqsx3r84Y+Pe3B5LVEP67Eef9gA88pzdZGNXO5Rk0q2uurNuitLzH09LYhQSuXKv8BS4iLI7ZZvj753a4qhTHLJhDoGTp65if/pf/0mnn7qHP/0u/4lOzsn+Iw3vZFBv6AqSyZ7e2gNo9GI6XjCZHxAcJ6tjU3YGDHq98HVDE3BF46GPP300zz96KM8+8KL7G7voINHuYBNfYnK6MTMBayxjMeTFuwsZFjmfWj0wmItW/or1JEKdxdAFta2stcMQnPmZc6YDEEASEymJDH1h+Z9apTCliW2u4BPssMMVsQvUh0BY5mpLMtS4kYSsMi9prHj6tpPhkKTyYTgvLCftlyK5wgrF7G2NBirkBazVZqwuKBN7ALKDJplnwdmM79gEKQ7LJe40foWuGe2EBIoTd8nx03k2A8VBbj5bHgUDDGCDxGM9MXRkbUuZiaKtFUcoWzbB2etRRmN8x4bzEI0h5gjKcrcrxePnqNqTp2hdKRQ0PgGV4Mx4n4bTQHeAVqicnTKIAyudSb1MQiDZxooCnRMwNJ1zF0Eucp3TvsuA/DgwxHdaOzm5oI4iyajnNQ4OTc7yjLLdM7njFkJSQxzc6XoW9OeGDwEL1EzzoPz6W3FaVdFiaGJvhEg7QVYEiLaR0xyTCUCjva6ctRsRs4ndURWLf2uWVmhlU0JpCIFDmQZMgtzNqrsQkwbtxSCFIqcd0zqhv5gkByJA8ONTZxzPP7443gf2d7cYmd7m41+D+0jqvGExmEKTWnEnKfxrsOQKpra4ZUwlRFNTPE9Mv/FuTiiE5s6z+1cAJGda8ZCjFA+xtq2vc7dGJ7csp8LhkcKa+maMw01prCcf/FFzl94EQzceffdkPrXMWUndkMvXgvi4p3revsi53+fK366hZvuv5fer6NTVR/euk+F1QW0uPrv69XkeqzHtQ293gXrsR4fXZC5GlRe3dDgCjKh9udxPXJX+oxwhRtvlxW0pYCqqGRB3nhPHSOn7ryLv/st30I1HPE93/uv+Z3//nb6/SHOuRbslVVF2RNAcTA+5PDgAOqa6GqoesTJhN6Jk3zaZ34WTz9znkuXL+OCp6gqil6FLmzLJsYUzj5J0tvMhOXP6vYCruqt6y7Suv2a2dl1lUw5SzWBORuZQGL3GIjsUC8wgy0gW3J77MZ5tKY6IS44QWZWJMsQc79ljiDJbFbuDZtOp8eyesvgsgsWYTWzu+r13e3NPand/M6ukU/3u2bGNh+nLkBtZbe5H5FFd8zlPM5lFnZ+LvjFIk7OweswrjYtmLNrbyrpkNm/eaeZOMiqtr9xaaEbIiZAkXoO/awmzBpc3eCaBpwXEx5tpC8xG/LkOBA/P4bk34d4xMFXdlBoH1358nHzm6Ve0hj9wrzSGSQH3xZGWll38OlnnAPLloVN2z2T/krfOFSI4hwaE2PpEvD0AbybM56ZtUzf1afe1IVzZ0WU0yrp5XE9c/l801qnjEmVjHSkMBWVSP09ER8FQPmsPFC00tqiKrl0+TIffOxxqqri1KkzDIdDCmMptGTs+sa1haHKzgtO4/GYw8NDJrMps9mMxjkBlkVBWVXYqkz9l7Jt3XPwuAL6cdd2Ha9cdG+f37muhE6hLSseLl26xMHBAbfdcQs33HgjoWmQXtuUvanM4nUjXv0+ddX7mea6HFlVGi+FZLjW+/OajFiP9fjIjLUsdj3W46MKMFfnLs/BTJb86UXjgRbFLNaDVtnRy39SNphebZRg0huHTHLmuILswpi6NEOIGAM2xTDkKrtCo5XF9krOP/cs9776tfzv3/Nv+Mov+SJ+5md/FqMiX/DmzxF30NmYejbDWsvu7i7T6QTXNOxdviRRHv0K1TTgHcWgRzTw/AsvcPaZZ7jthhsolCbUM+lJLCyBgI8ehWqBXmYEVOp56y7ArwTyY4zUdd2a9LTv0wF1y+AuAyfnvRyX4FAx9UdlB84QIHiMKlIvWQJKrmY2kb5Dq6EsRynHbg7mJI5lbtTTNI2woiTgGnMYuyzYfeM4PDhgfHDIcDhMgFkiXdp8VOZB8dB9LBrEhOhacNUFhJGQYnMWF8N5Qd+CdjzG6oXYmK4EGQJlaTsLUL0IILEI1+LbvM/55xox2dHzReBcXni0cNPKwdPPkHIv87YJuLRJyqwX+qx0mvuSHuPaW6WOOr2lap1YjUKcgZ1r+0S9NtDUyR02hf54L5ZDWienTRLzOo+KyM6pCjHAyUcvZOCWexETQMs5gV1mRVxV8/v7BWZQi5Wq/F+DbxbZsehdMolSoBNAjJkBlf5JyVWdERqHLUuUTj29KQszBmE0s6Np7ADifCmbKzOWe3p8crUV2SpdBilL27uqDJX6KBXoJIvPbKdF54sbRuVZlXItg5ynzntMOc9RVcrQ6/XxLvL000/z/PMXue2mU5w4cUIMiJyj0BZbza/DIvU2hIAAyrHD9vr0RgO0NWhjRMFQFBRFCabDxsaIj0ocWWO+7saFvy/E39CRPKfzUHN8X1S31aE9z5Nxm4+Bqt/Dec94OuHS3j4Pve5T6e3sEo2VYkPrrnt1p9crgcPrAW3HAcurve5a4kmu9plHlQrLyp7Vf1+P9ViPNbhcj/X4KILJVb2Q86Wgmi8Hr3qTXdlkvaJS3X3O1UwEVHur7NqLdoOjxVzDd5wsc/SFtoYLe5cZbG6BD7zqjW/kB3/oR/hTf/JrGF++xPbWkFe/4uUoLQt5o6EaDigKy4XnhZ1k/zI3EOhhMP0Bt995N5/6mZ/Gb//yWxn1SraGI3GPVUkuak0rqyyKAo1eYMHiMd+5ZbzU4kLLNY2Y5yRGLbvCZglrt49wOS9T9odbZInCHLB1nT7ze00mEw4PD1szooUqfxDJYO7f7EqS8/8z05qPR+4Hnc1m7XfIoDAvfGUb9EozjS4IX8VwHsdaLhtpZHY3GwRZaxe2MbOrOTM0b1f+7Nw/qI0mLOVCChtlqJOcr2U8Ha1EeZn96cZ3pAPSHkt5rkmfu5T5qRf/34KjIKZXWX6tUgxHzO2cOY5Dy3dpqPFNgzGFxOCEKCwloGwG3gGtbWsGFUM4amgSo4CHjnHN3PQrLMhg8/WgGy2yfAxD6MjCc7YkzBnTkFhMDfj8HNlW3zhcLd8retmOIkuHQ8SHIL2nzqNTHyUpYibGMGc2V8zB9jh0+mUXr51Hz+k8RVbNz3yuhyhy3S4IJQF81VEPlGUJyHyq+j1evHiRRz/4ODHC7u4JRqNRAuCgjBIpbPqOrmnwPjILTozFiJSDIYPBAF1YQsq1xGhcDOggN4GogGiPsLMxR8WkAlV3f+QiUS5GcZySpQPAdSrGqE4MS2smazTTWc3e3j4vvniJBx54AKoKFUU2bgqL1wqlVVt8jClGRgo4dqk4em1xI1fLbr4aqJxLdY/mPB8xx7tOIPtSwOl6rMd6LK25PhEW71d6rMd6fKzM0ZdSuT0ihVJh3od5BYe+az1fcg5fe0Ne0DuFI4vTQheUpkQrS4yKqj8AYzk8nHCwt8+bvuRL+df/5rv57d9+Oz/6oz/KI488QgiBftVjOp3SjMcA9Pt9Tp48iQ+Bw/GY2juoaza2Nnnlww/jgaefOcf58+eJMTIajRiMhpS9HqYoxPGwY6KzYFjRkW22iw09l6BlcNYkYKmUMKA5y3J5UZJZxAxi2qB5ENlbAqf5gqpXLKSyBHI2m7UmRNbaJE+MC3mLXcOfZXDZHvcEfNrsxRipqkoyMTtGRTGZ5HRB7rLM9EqxI915Y4zBWI02R50Zu/tE2ETJ9IwxtpLZuq6x1lKWZZvPGVOPoew+vShJToAjg/o8THIEzUDW2MTedCSgbRUnx5Gs+N6rtn+VEqAF885JpmSnz9M7l2SegegcBIcPDXU9FaY2zg1r8mdkkNse09TPmE2AVGIKdYr8yDmvpEiW4L3IVaP09cqcC4k59600WHqt5ZGZ7CyB7Wa5ihxXtj339rUy5SCOsb5xNLMZ0+lYsluVoiqKloU8Guni2uO/PK9lf/jW5Ede6/C+WXjelaJz6PYOq1Q00nMmM3AM4Owef6MxZZUci5PEuycOx2fPnuXxxx/n1KktTp482c7h3Iea+2K9j6iOo7e1luFwyGg0kp7tomr7cNu5tCRhztvaLfTk/dCdL1dzUl21v5aNvLrFIenhLri0f5lnnnuWADzw0MvAaOppun5odcVeyuPWW6skzNebhXlVYLkKVL9EcNhtLb/ya+eKj/VYj/X4BAaX67EeH1/juBBm3fmpj715Hu2By49rzylcBUJV5ya7eLPW7U9rS2wlD6UUjY8oXYIuaKKiNxpB0/AZb34z3/Id38ZP/p+/wvf98I/xwUc/hCorqrIvn+Q8GkW/qrjpxhs52N+XPqWDfTCa177+DXzeF30e73jPeX7hV3+Vt7/nPTz9wgUuT2fMojjVxpS5VzcNLi++YCW47C6uuovdpmnwMWAKS7/fp+r3jvbipUWpLORTDqVLhjsggGMJ3C7nQHYX31nyWhhLr9c7elzTwj+DjDa2JC+AEpu1zFBrren1em22Z97+bv/eKrv/ZRbyagWJdqG+Alx2pcNd99luX2VmHX2K3RAQEo70GcYYcTGIo2oCk1kG2T222orza44d6QKrtGPSCSIyQAm8VxgdEgtEy9p5Hzv7PstUc5+hax8huHlfYgJ6GmEvCeKmGlyNb+rWRCf3c4bgW+djHUGlvs6YANY8r5Mj5223MJBzNmWfzXMiaTMjIyrKedb9WwvmnSdEl57v237PzNIqJ98js43BOVzdSF9pkv+WtphLaX1AB48JYFGtAVBmL8l9ne1cF6dglZnN9Pfc25pB79z5N10To57nUUKS/Ycj18kQQmuChU65qMkGJiiIWn6vrWLmpd8yF0a897zw3POcf37MDadOsznakD5LpTFGomymrqbxTphIa7BViSkKeoM+m5ubDAaDtpd72eSqW+gRGaxHE8Tap9MfmUH24vmhO1fs44voOi46U2cAm0tgIYFyW1UcHE544cIlRttb3HXf/WAqDmc1pqjk/EWhCBIrkz45KAhKH+mbvBrYPQo4r69XMvfktr2711ikXf2EcP2vWY/1WI9rGnaVdOA484ePRavnVVLB9ViPj159JSzdmJbPpXDMnNWd15j5oinqBbDXrqmSXOoIGswyzFYHtfh3QwY4RwFq+vYqKKKOKJSKKmjp+owRYpJSpWfmxbe0+4ipRV3XFMayuXOS8f5lmskhO6du5LO/5I/yLf8s8Df/6v/EzAf+zNd+Fa955cthOsbXM3ra4n1gNOxjT51menDI/t5lYq/P6OQpvvQr/jibuyf4yR//d/ybn/wVNge/wssfuJ2X3/cADz/0ckypGVYlB/t7TJs6uY96ptMpWmuKoqBJ8QK5J5AYsdrQ+JrJ4SE+BjY2Ntu4gqbDFFitRfKnlOQhIu6uChbMf/JiNMs8M8NmMhhLADTPtNJaNoYj+lUlfZSFToHyOaR+noFpjMbVDbPJFICyEgmlaxwqykI4xMje3h5aa0ajUcvGam1xLhC1ag1MtJJ/uxjwSL6kVlbmXgTvYvsA6WGLzqGTUYlL2Z1FUaAMBAL9skcIgbqeoRQMBn2KwkqfqIpUVUGMnsnkkLKUfNK6nqKLzCaptufVWps0pgqsOMGWvYqpa2SGF5rYxLYHVdhUS9mr0vFzKMBqAZLKOaytBNxoK/vBe6zyxGaGLQsBN0qjlaauG2xRURYFwcl7Ke0wRlM3AiaKwYDCajGt8Q7XzLBJhqqJ2Jil4yRDmwa0wuPxocF5ycIsdAFaY9UcYKKCAEUNAU8IHp/2SzYcUsETneQ7oiB4hzYyf0IM8gjzGJWmqUWNEIM8N9KJxnHgQFtNVJFQz/CzGmM0Vhvw8vmuboi+oVCKourLXPeRMGvmjKkH52pZ9Cczz+jSMYopJTPJkGNqM1XJTAgfpOcViTVtgVSnPzak/0edfZeTA2xiSEGAn7JqHglktbyfSuBUIdmMShFCpElZjU1sqGxFUVlKazh79iy/9eu/xo2neuxubTMsexilcW5GUViqXg9cQ0gFiyYmAGYs2mhMURKINK5Baduyz20xIzGrMQSJb+kUZ3xipsXtOLYZuItrMSW8dgTiUqRRFG9akcFrfJS+b20NLgTQhhwf2xuNOJzOOPf8eZ5+7jwPPPxqtk7fSJzVlKMNvBJn4kDI3GwLLHMhL6Rs5ysaEuX7VlzBfmp1pKi5CJKXwGj6Xb7TriqadaOqshJn5dq1ZSu7Bbj8WXrl69r7bDx+/bBei67Hxw3VcQ2Y7koKklXr2xZcrnfveqzHR3csnJTRdvCiWQSQ1/WecQG0Hr04rDb2STdwlX/GdPP2IE6BSzfQNhAgy2RtRV3XaN2gi5JQ1zR1zdapM3zuF38Jf/9bx3zbN/99lA9s/MU/xz233Y73U4gBszmC4EVe1+8zm0y5fPkylS04fffdfPnpM9zzspfx/ve+jxeefYZnn3yan/8v/4UnnzrLF37u5+KVpj8YMJ4c8OLlSy3z0O/3iWmRkCVlXcmj9xLX0e/3JbYggceuPDWw2IfY7YsUZ03ZaT546rpuXVO7/Y5FURxxbiUBzAXQu7Q40mk/67SfdXcRteRY6pP8tTUi6vRlHs1KXHKLPKY3aTkLcxXbuUpOu4oJ1Wqef3nkvbUiuqN9hm1fbIqW0FoTtFpwos2scG8wwFYVKCNsnQqgZV+Ywqa4EkeMc2lxYUS2a9SSdLnDlhESAMhsW+5FjEGMeUKSmUYvLBzCYJKZP2WIQRg97Nx9Vkx4PASb1LpxDgqyU23sLtxX3+xzr6Gwp3Is5xLXzvEgoKIY2JhAm+uJEvCiELAXnU+mUVGcb71IgF3dCMjRAji1hjpEnGuITU1ZmEQCBUzLnEbJwgxBnEa7+3Xhe6QrSxc4pecZVsk+VQucaOfevMgXVMrF1AncdnoSQyqwkGJuYrq+TesZppQe7o2NDYwxvOc97yE0cOL0NoOiwmph7hYUCYVFKZjVsh9M8FLAKSwuBEpjMEUpfkhainRaaeLStWAyPlxRKIdCG6n8xQ4AUwqVeMQr9dTrTie91Z0+dC0GWiF9dxfAq8hz51/gmfMv8Glfdj96uAlFgXehNUPK0n1YjLgKas4kHn+fe2lSVXX04Lf3n6PxWVdnLY/flrAGhOuxHn8QzOV6F6zHeny8A9V41arTvMK0KIGMS8YZ6ffS4XUNVa1ur2C/KghVxWRWo6uKM7fdwdf86a/n4osv8GPf9285sbvJn/zyL+f+++8F10BT00Th1cpewc6JbQ73LrM/3mekI+Wg4uHP/Awefvhhgmt44pEP8ss///N86JEP8tzFi1RVhUbYlJiAcFmKGc/BeIxKfYiZKfDZVCRGyrJkMBgymU3n+6I1NPEtuAzOt4CGCE2nByr3NmbWrZuJ2XVR7RrX5P7Osizb32uO9q214HHBhEYtGFhkp9tsSNIFl6v6NLtGQMACQOzOp2VznOVFmdZ6JZDVWqOsafu0tNYYLVEHgdhKW1upsVJiAhMjSsWkYJ1/7jzGRVMTF0yN8uv7/WFii4WJCm10vJHiiDbkzMTMNucezsUYFn9kXkcFIaSMSe8IKc5DMiabNm7Dx45BlEuAMhUZcp6k7u7LECW/Uri4BHzjvJez4yidzX4EKKZewhhRQSVjqZicnueyanGHDa0CPxJb0Ef0LetLMtrBR4JzCTCLdDhLYaN3wqpjW0MZnQ2qnEOriGmlxUleG8EHl1hV255XKqkHdNqwLGXPea+ZrdMJUC0UN+YT8Mi1LwOdtnCRCnUoLUY0WQoffKdfU88BkpH+y6JXsXdhj3e+851YC2fOnGG0MWzZ01xUMUYAXlRQKY1PBl8xmY4dHh7igsf0SowtW3CZP697nmeX6u65qLVGx0VGbw6o1BG2LhcbVHf/pO9pjMGlc0fbopWPZ/Ozixf3eOKpszQ+8OpXvxo6cvYYOy0cy06sieUjXh3YHfd3kfivZj70UsQTHUB5LZE0y/9ecF5feE5cLyLWYz3W4HI91uPjFwSuWqwf97xVjp7HAcnuImv5z1d35VPHfu6VwGr3/9lpcVo7bCH/PpyMMePAcHOLv/h//8uc2tnm27/1Wzi8vM//7c/+ae67826isRT9Pn56SAiRctAnhsD+pT0uXd4TBnJvj82tEXq0yZ2veZjPwfN9Tz7Jr//Ob/HFb34zg8piiDQp9N1UPZFCaWES66mYj7QLQ6VbkOKcW+gNPGpKElq30wz0smw2g8fgfCvDXeWg2t1PmdFs4zMQ986oF8FfdyGUTXK6/ZvLZkPZPXfVXMkgcPn75UiRVfOq2xN2XJ9m15GzC4AzwM7gsLAFs9ms/f+q/NBlsJtZlvx/bTT49Dwz359RiTGUNWXbw9fmGWqzsMgOIeBnDtc0aE2bRdqNTIGwYGilOoYr0mMr1H42xvGhwWaWMPWAeecIMQgr6cUkh1gILOj0PrbzJPdppoKASlE2+Xjl7YjMIzxEqqhSooUAU9UBuCpJ6FXsMN85gsKHuZwQ0F0gkbJTCbHNwSyLomXrvW/aokve/tC4llmLqcfSh3nWZVRazIqWiibLigDF6nnWno/MscCc/U7vo5PhUZZUpwIDCaCGmHItszss84iOoigIiLnWbDbjve99LxdfPOSG0zucOHGCjcFQ5koI7ZzJczUq6Bd9GoKYhRlDEzyTpqbe30fNLP3ekJijeRK47KoK8nm7XOhRgasWDa9ooNOJIFkA4WlumLLAK3j63Fmeee5Z7rj7Lu697wFwDnSFMhGNXXBTXn5vtSJXS11HZEkulq14jlJcv4vrKvCY58ix0Sgr/rbq+euxHp/o69I1uFyP9fgEOIFbQ4f5PW6hjtrN3YqRVvZ2xG79yE0xgw9zDFiMC6Dy+G2Nx8SoLP7OGIvWitlsRgwO3e9TVD2a6MF7ZnXD5s238Me/9ms5ONzne//lv0RXBX/sLV/Oa9/4Gvz0ABcCOkSMsVRVxbgsaKZjps2UUX9ABOrLe1RVyQ2338rLXv1KfvPX3sqj557i3tvvoFDgjcFUlnLQE3au8TgUqhBGzzfiTloWFqtUa5zTZQPz4l91Au1NEqLhA6Fx+FocQE2H+er3egKwYzKtScAtODGwyYtzcQGdZ1Vm+a1OnFRmSglRFuxBMi/z67r5lvmzcyZn7vXMAHbZ2KgLMGWesOCY2p0r+fnZ0TasisjozAMfBYDpFBMznxsiTfWpLyz3VAZkv2Zw2d1mssFNTExneoh8NhC1wbtA4x3GGIbDofROao3SFl1YrCmIugBl2wzJGAL1bEZd13ibmatFwDtnZJMxEBGDwSepq9YKo7L0NLQZkJJnKmyhC54YFKZQLaNvg0drg1Gx7VGUvjHVkbGGNvMyL4hJxzn6IExRx/wmRDBWz3vGsgsrHfAqiI+YDGKEcZ07EVulBZQR2wgRVzfCtBpNaa1kO8aQzJe8APAgbq9SrPAti5pBZHa+jenf0cvnHrmuMWdyiQLg87XN6Lm4M/eyr4reCCr3ZhatjF+er1ZkaMpeiVqLgU/uAVSW4WjEhRdf5G1vextFASdO7DLo9+hXvXbb81zpthmYQlhzbQ1lVeGJqNlU5oEV9lqZ+fzS6cCE9F75vG1VDNl9dwl1qRhXFqzan8vS8k7xSVmz0COZJfyT6ZizzzzDuWef442f90c4ceo0FFbMjojYqqSezFbew7qfcbWF6nLR7SrPVVd8v6X7XrzK5y3fx5Y//zgQ+7HoL7Ie6/GxN/QaXK7HenysAcu5AZDqxvEd8x7x2ArtcQDwwwmUVlepmC/a5gtrVVRDisJS1zNQhnJQ0Uwm1OMpwxtu5uv//Dcw2tjku//Fv2DaRCZuyutf85BIV0OAxkOy8p9Ox+zt7Ykxzzgt3mthKV7zpk/h8See4Fd/6zc4ONhnUEo+ZZEBX/D0ez12NrfY2dqm1+sTXMnk8IDGe3plKYA9hJWS0MwqhBCwSi84zHbBF15yJauqEpa0rhckrCGEFpx12U7V6Y9TSBRMN36ga7rUZYmWmU0FlGVJXCGTy7Ee3ePffV+lkvRsKfezu9Dt/rsLwLq/W8g+Taxl/n+Ob2jBTCcj1KQg+do1S+CSBSYzb1sIYk6Ue1pDCBRlSX84SL2tCo9C7CsLYczyaeEDblbTTKf4ukEV1ZHv1T3+BiXmRTn3MvVOKiXmKiYGMeYJ2bjHpzbGKExeAsnZlZVO72EL1JPbayRHrkivo3ymaoGgtiliJYHGFqilLEOl5v2grTtvnl+R9rkxRsnldGIYo1FEa0TS6wOuaZJxj/R8aqPRKHzjWgOVbCwTkxmNr2cL/Y/eJxflkMxqQsf92Ivzb6ENIc29mEBw1JJz2RrxdOZYdx7mftz2/MmAIRcgkot0Zi9jB4BGkkOs6RRaiDQu0B/1qaqKc+fO8eSTz3PDyU12NrfavuhQN2it6JXlUn5oul7EeWyQSooJqwqi1dQzh84y7HTu537jbn/2ymuwUjJ/Eqjq9touX5Njey2LCwAzhIBRdhGUJqnwxYt7PH3uGQ4Op9x9z30imy0rmplnVnsG1SLDd73Mx3ERI9d2/7m2+JJ4Ddt1nHpnmTlds5XrsR4fubEGl+uxHn/oowMcWTROaBdXSc50tEPFHHMjDbL+PFbyE694M1YrmlJWMae+SeY1VUlZ2tZRNkQNTnoXJ7MZQyIbp87wpX/8T4It+J7v/t+ZzMYMRz3uv+s2BoMRbnKAio6yLNkYDHHOMZ2Oqfo9qkoks7qw3HnXXfyRL/lS3vor/5Xfffe7CKnvsDDiptorC07s7rK9scldt93ObbfczMZwhClKWZyjUWlBq5dBVDJcCT45WyaAFBMzZDoLX+ccvV5voScrg6duX2IGjV2WLO9z7wMms0c54iRGcc8Mq2NUuiCwLEtx7wSs1kStxU01sVxak34qAQnp92pFzb9rAHS1bLtur+UCGNQK7wKeSGkNvhEpcVTC8rSukFqh0Qs5fl0WOeJbiWoI8n45m9BFjyfQ7w8ZDoeYshB5bohCKGo9N3GOgHc0kzGz6RRCpCwK6YVrZmleJza3c2znoNm3MRlap4gHTydaA2LwAjpiIDhx6iVEgm8kviT3+kUvUSYKsA5MzseILUAgRlSUXjQVfWvGQwJ3YhrkxOFXK4lyyExqVi6EzrUg5kiQJE31Xkyg0vf0ztM0idFtHIZkCJNY8+BqKX4ldhGl5jEQ2VBInKfExCfHj8Qoc1AlGW8GPyoKsE2AJWbwn84RBdgFhnAuxcxS1KPFEHskHicPjyJE1ZpL5VibEALBB4qyoN/v8+KLF3nPu9+HMXDixAl2trfpFSUKiYjRthJ1Qsrm1KbotDeqNnYk5qzNGAn+aL5k56otfaZHnE4zH6BWyjO7haUusOyaAbW/T3cUYb87igZjmM1mPH32LB964ilOnDnDfQ++DMoKomrdpuu6bpU1rWyZOdaM1wgqrwe05UIGal68WvW+4RpA5dXcLK8VJK/HeqzHGlyux3p8XI8rGfSs6nF5SVD2Ku/RBZ8ZZMYYo1qS5gLzcPsQOTycEoKnLEtsoalnE4bDES54grZMg2f71Bm+8mu/jsHmFv/wm/8e3/Kt/4g//6e/hi/4nM/BDobEyUR6uxJpdPHiHrtKMvWUUvSqCjerefXrX8eJnR3OnX0NF194AaMMuyd2qLRlf+8yTz3xBB969IM8/+xzeP9a7r37HmFYTJKJLjG7c6fSoyxfd1GXF4m5/3I4HOI7hjY6gTugZe66PYk54zGDsejckZ7P447RsgNslg92jW7mIDQeyUXtsqFZPr3sBnulfqNV+6vrBNsFZvn/ja8XwWcHaGilj/Tidfd9+12y02tZCEOV/lb1SgajPkVViQxWO9CGqAzaWNBWci69o6mnhHqGJiRGqqCpZwJak1GOmW+AAPsE2LITrApJmopHBS8xEBFCcg8WQOkTy+fnANTLZFbZVCcDwQT+8fn4J1mrT8/1c5l7bgXVQXondZKmKh2TCVVonWDb8zQIWym9nCI9Vz6gfEjZHhHf1LjpjKbti7VSQPER75oUIzlnH7PBUpZ3mxAxQS3st+ykrEnXq47pTMINLTjQyXCo7W/u9B7m52SWD60WXutjBGVaxlIlYJdzKjxRDkvKtcyZl21hLEJ/0Mday4fOfogPfvCDbG302d7eZmu0QVXa9vuYJCWNXrV9zl5LgSla3Rr8qNT/GcjMt1mQkHbP9fYasOIcPN4oR608V7qy30W0tujobKwBrZlMa86fP8+zL7zAva96Dffd/yD0+9LbrKDf6zOpG0zqXe72/YaOw/VLBW0tGF58rrqSv861Os9eDSh+OKqe9ViP9bhGcHmcQci1LkQ/Ugvdl3qSry8O6/HxCiLTemzl3+ZG6UsGLUcq2QJUIkkmh14CCC1VxNXO9YXzfV4Bj0cWPsfc8I3SmGLe61lUJXUA2+vjvaNxoKxh4+RpPvPzPp/RaMT/8tf+Et/5L76bftHnja99PTooYtAURUVV9dnWmtmsYTJ5EWMMG/0Bo/4A0Nx2992cOXOKEBwqaorSQOOJwXPXXXfR6/X41V/+r1y4vMd4OqFXVliFgF3nwYPSoZXCtrK+tP3ZBTYvjJdjNjJ4zKCqCyIzAM1S0LyIbJoGm6JIWrYqg06lCOk1OT/TzWp6vV772gzo221J7rNa69YNtb24d8x1spTUGEOv12vng7YGH1OvoAJbFpgi9Vk62r+3FEZawLdRLzGKhFR2ROuQm/swm+AJCqqixFrJv7RlgS0L6mmDbxzB1VT9PlVVMDmYAGLUUxSFfCcn+6SJkel0SllVjF94npu2thiNRhCzG7BiMBhJf6NNwDLHisxmvHj+eYzSDPsDDvcPGA1KOQ6C6Frw3zQNddNQVRWGKHJR59FWE1wt3987SHNF5LGBejomNA2lsfjGYavEfPlGHFe1wmrVMpxYjQqaJvgFV2EX5vJoUxhCDO2FwqTzPAZHU/sUQh9aEOd9WIj4iN61AAmg1AZjoa6njCdjTOrn7dkS5xwminENIRAbJ8WWIC6zCoksaZI8W0fk+KWYDp3iJDNDGkPENUGAqNbCnpOZttS/qYQhC0FAfy5WuSQj74LSfDULKTBSo2lCkKmZAWjKf2yfEzXOOwHuqbAUYiREOX/7/T57e5d529veRnCOU2fOsLu9yXDQI/rAZDJj2K8YDvsynZSBoPARQlRgVCt3bYKfnyv6aJ+hGFLNe6BDjNjE4sZ0vFSK3AlO3I1V64ar2qJY96quUl9424sY5ODnzxhPZ5SDvgDKesagqIjAuXPneOTRx7iwN+Z1b3yjPMdYvJN90wSJa/J1k24HQfrAo/Qqh8yMrmqh6Nx/9Ir12coYrPZ6thoE5uHnML0tTnSLXcstG5Gw0jBpDuJXA81rXfeu15/r8cmzVo0rijR6ZR+4rDjXYz3W45PqInEEyK6QMXUeqvva7t8kQoD20VlbiDtjVMymDRFL0R+gi4LL4wkHB4dsnzzDp37mZ/Mvvuff8oHHnuHb/vE/4xd++b9yOK6xG1uMDyecOHGKG2+9nVF/xGzWcHBwwN7lAy7u7TMeHxJDpBwM0UVJMehhNrcxVQ8XI5vb2zz40EPsnjzBc+dfZG9/n7JXoYxEY/gYGG5uoK1ZWMhkYNeVsHUXh9ndNEtSj2MHV+1vtbI3cvWii6VcylWmOqtGN4IkA9pVGZbLRj+r+pKO6+ddXoQtS3e7i7kuQzOPFsn9o81Kp9jlzwwJzGotjpzZ5Xc4lB5flJJFp1ZgLEpbyBmtsxk0NePDA8aX9yD61oFXPnuxl7RldjvfT3pTQzJ6Ch32z0GK31DZEAoERBpFaRLzlRjM6MNc+hoi2gvTiZNHdHO2U7nQSk2VE/ZTpddnJ9bgGpR37e/IktQgBj2xcW0mKyEQ6oZ6OqMZT4mNQwOFsZTKYFFYFCaA9hGT5Ymd7W4lrz6gfZTMT5WyR5nnVGYmNZtb5f2YCzjdPuIm+JXnRgYS+dijk0tph3nMv29fm54TlBTlXAhM6llbDCFJQpuUSbmxuY13gccee4znn30Oay2bm5sioVfSe1sVpnV3znNGQGSEFGHi2xgccTBW6fd5e7OZTtQrlBIrHKXnplsrXGRXnHvL50yOpAkhUJalFEvqui1qTadTnnvuOZ559lluuPkGTt14E3YwhKYRc7Vc5PB+MeJl1WPFteFK25hbLvK4XoC2ahuOu4Ze6X3Xhj3rsR4fOXJw1Tm3BpfrsR5/mIAvLj6O+/s1A0e1GKfQWaInpiAmtuP4m/aKv13h7t/JQltYTCTAZkUG2jgwRV+V/SFeGaIp2No9xeve9Ol83w//MO9//Bzf9u3/nB//qX/PC2ef48SZm6ldJHoYbmyxs30CYwpms4bptOZgf8zzL5yn8Y6i18cUFTQ1tWswZUFQcHFvDx8lf643ECas8YGohGk4ODhoF3SZ9cumH0GxkEnnQ6BxjsY5YVU64DL3oOWFd87qs6lvMv8//84gLA8+LLw2P9rFuPdzqWxe2K9YNHWBXFemugqsLbvILgPdheJBR+baBZDdbXBpUZ2f72MkdiI+nPeyqC9sa6bS7VnNQLE1OsK3gCV9UPoRsVa37KcpC7Z3d6gGfdAp/kIpsEYeKfpBaCzHZP8Shwd7lEa8ebU1Cwv3DHwl8kTAZ9KDt2Y2OiIyU5d6KZMrqg/NPHYkMYVW6cRSemIQdja4mugceJHZRjw0+b0cwTd4VxN9QwzyfsE384droGkITZ0eEhsiYNMRnEOHgOo4v+Lk4Zsa38xoJmORCDuPDmARl1sVstQ3MYuuQQcvfaPBtSA3pB5SgoBZci5lcliOqXfSe5/6VPWR/tzuXHNOZJi6sChrwEgvaVBLxQzVMeNJ7Hnuw1VGnIKjMi2wDMlHKRcSMuj0KHwApTX9fp/Dw0Pe+573cfHiZXa2tjlz6hTbG5uoKN/dWovVHWDphdkLRiT27eelfnhlJOtVGyPfJ4HKkAGynm//8gItKxlC17Qrm0wlKfKq1xzHMmRTre75O6trnnvuOZ588kkuXrzIPfc9wC133A3DoRQsUCgjDs+r5KOrioyr7htd8HzVNowrAL42oikVGo4Dmcddx5aLaFfad+uxHutx/eCyjQFLabvixK7XPZfrsR6fMED1GKbpeqq613vDlSBswZc6JysQ23w0qZR74szRH1QMhxuqaWbUszrO3IzN/gav/4zP4Wd+4Rf5qi9/C9/53d/LeDzmT3zFl3Pm9Al8cFT9PrtFQW/QJziPTTEf0+mUC5cuMxj2xHwjgo8K5SNPPX2OX//N3+BgPOHeu3cAzd7+PrPJBKM0/apkOp2I9b4PC7JEoM2OjEsM4qrFSnffLS+ej2MO57mXaqEXMsZ5TIf3/oisrPv5IhlUR94zhIA2RwsGy2zJkSD2zmIsf9clxmEOwnLJIm9z+n37Pt0+L7MYUdL21CUmuJsTuuyO2wJABFwQArPZjH6/z4kTOwwGPVDSF6ltiTZ2zhwFDxqib9i7dIFmNqFXnURrMT/KEkUffbuNIaRYjw6gUMEnA5uQQGQA51HBzQ1Vgsio5d8JgMVOdIh3eJeYRFQngoMUaRLTDZoUSyLOoy1rmJjRmCJFlA9EHYlRtyyVSYZIKjnABuckKiTP4eTkagIiUVWqBaauacTRNS/3VZi7viZnV/EgTvLbzGTmeZ/mnnduHp+zlGu66nrUzUfNkti233aeRSKMpZbvF3IRKBo5TDo5waq8O6P0QaciggtezLwUTKZTrLUMBgOm0ylPPfEEZ596ikGv4Nabb2Fna5uyKGgOBbzbogJSxI/RcwZVSSyQQ2Tt2hhkk7RklqYWhRDVPFJn6VwUCXFszXu61wCVjHh0t4Z3pIAX0UdAXkxGQZ1zDTlvZ7MZk8uHPH3uLM+9cJ6oDXffcy+nTt8A2uJig7YFMSi885RFIUz7yvsMC8fqaveR456nj2Eer6WnctnYaPXz1JFs3TWwXI/1+EgN3Tl3F1ux18zleqzHHyoiDAsPhTxYeoh75IrfH8c26niEwVwEG/L642SdS2Yv8fiqc9r2xGAuP9X7eS9V0zSxnjlAUxSV6g831f7MMYsF9772DfzIT/00D7369fzgj/0U3/k938MHP/QkQRsaFwgxMhiO2Nzepjca0RuN2DmxS+MDF168xIULlyRzst9nMpvyxFNP8v73v5+HHnqIV7zqlaA1TSMgYm9vj4PxBB8jtXM03rXSufzQ1lD1ey2L6REZnCkLTFkk19KwsF8zGFmWei4vmrrOr8u5mvk5OkWlGGMwSxLd7md1MzDze6goizaVFm/5Ma8tzhnxhQXtkgxv2aF2GVh3F2umsK3ZDiDy4w7wzL2YLoaWyWmBcKdXc74dtAx7lvnGGKmbKbWbsbk1Ymtri6pfEvD4EGSBr7XkHSZ3VoJnfHDA+eeeRcVAvyrnSoHOvlzeBqtABU90TZtRmpm5LEnN+5o4Z+padjlEYSiDJybmMbpGMi4JAtISW5jPeRV9y1aq6Nvf5Ud2im1fkxlxkutx6MTXBJcYUS99kbVD+0hhFGVhRNEZRSrr68SGJpYyBtd+FxXEBTema1B3jqn0PUMINE1D08xjZUwne7W7f5dZ9kDsRInQSkvbnkWtW0OfVlqamUydiyH2yPk3Z+5KXDMvHjRNQ284oDcc8Mwzz/B7v/d7zCZTbr7xJm658SaGvX773a02FKVJztJB+oiTOVATYeo8LkXHmMJiywJtjGyjVgI6u+fMMczlcUs2cwxoa82aFo53bI9/CzxZdICeTqccHBywv7/PeDymKApuuvU2ev2BvBa9APBzv/my8ddxBlzXWIxUq+5Hy1ZFV4wP4epS2qs9f90ruR7r8Qc71szleqzHJxJWXWIv1VUqwzEef0PvLgi6brFH/t4xNzRKoLFCZKVN04iFP57gxdBHK0jhElD1mTQ1hVfc/4ZP4Z/9q+/hW/7O3+LnfvZnOP/iC/yZP/U1PPjg/ezcfCOMDzjY36c0lqIqaWY129vb7F28xN7eHk3TcGJrh15vgDUll/emDEZDtrd2mB4eEpyjKvuUk4mY4wSPLkpZiHfdSROYMcaA7QA+ramqql2AdXsbVy20Vkm2up8TU7zMwqKxA/AkW3G1BDa/ZsGePyxK2ZZZ1FVjGTwuM5DL4NN0svq6cyz3pblsAJIlj919ubTYdWGe/ZlZw+52SHHCU7sGayu89xxMxoQQOHnyJKONAUUpgDAk6W3rJtvGcHj2Ll3gmbNPM+z36ffFHdTkXE6tiX6+j5b7VYNLPYIpGiR68L6R3ssEgkOI4hibjo9VOrnI+tYYyZEZyHlPXNRBJESJIQzkfR3wSmEQR9MMHnL8B505GpMZUPShzcJUabtVlO1qQa8Sh9c8t2IM+EYY1RB8MowRc7CcwUliJef/nxuhxM62+NyLvAQku0z0MgDM2a/H9SGHGDGJXY7z1BYBaNLICCax4Ej0Sc4nDZkNRApD2YBKWUNZlozHYz7w2KN86LHH2d7Y5JabbmZ7e5tCq9ZAqrQFhbFyXKIY8ASVWNEofb5FYdHWtGy5SsBYDpUUPDJ4Xj4Pu2ZFR67Zcen8bZlCtRA/0o2Wym7iOgHy5P0koD92elm9qD60MZw4dVIk6yEZkylDVB6tbGe71JHtvRJIu4LbtFoF/haAK6y8vsUV163jcjSP+/dKwLpmMNdjPT5Ca881uFyP9fj4PYHzIkMdDyqvGmcC1+AcuxgvEWNUSYbVvlCBUt5HCEl9lGVIsqwxgM8AxQe0VlSVxXuYTeoYcJiqR9UfcPnyJbZ1xc6NN/N3/8G3srW1xX/4P3+CH/iRH+FLv+yLePPG51ANh/RcEBYuQlQ1GxsblLYgOs+lSxdw05pbbrqB2++6k1e86mWcO3eOJ554gjvvuJ1CaaJ3jEYjZpMpO1u7jA8OcLWTCAljJCsyM31KGAm0QgezCPwy0Et9X8ugsQtIuyCuKw9twWUQTXGWPhq1mOcXQmiD6nWUjLywYrF1HNhctXjNctrQiTfpgoLMQC2D4lV9l1nWKBLT0G577mUtCmF0MiDq5gJ2AeuyjDZvv/eeUmtCcMxmM6y1nD5zhv5wKIA2OGI0WKtaB1ubIj/CbMz588/xzLNnufv0acrSYguN8rF12V0G4Pm4dQ1oFJ39kDIcow7EqFOPofRIaqUlXkTNAVRUUXr9vE92qnLMvfeSlJI+wxPbfkWlFNhIzFEzQXpZScAx9we3vcJJGpsLJcK2Jtmk1iglTYjRCWiby1ld6u+MCasJwJ5na8ajoYZx3kfsl0x6tNaYFL/RLSS0Dp65PzGBwKLsibNvJ3pEJZdf1WHLWUqpkHlEK5+dy9cTAEvPds61jKXWmsFgwGw244OPPcp73/terC258847OXnyJGVRUAD1dEJhNGVyvm5l2USc9yLRLUpKa6iqQrJdBQ2iE9h0IeA7Padaa9GKdPY9iAQ+hI7RU7fw1M3ybKWzaj4Hk7Q6heWka9NRQOicQxclpTHoacN4PGYymdAfbLC5uYmtSrBGnIDTfioK056feceLA8/8+t41d1VXoQKvJnPtRpN0U5hbE6Tl653sxIUs51VA8ljwvnibW4/1WI+PAKDsEhZrcLke6/EJffKrY4HkcSHdywvthdclfKvmN3mlkxV+XALBUUGhDUZpmhQdEALtomW0OeDC5UOM1xS2x6XxmKE1VNsn+MZv+rts7e7wzf/gn3LuhRe4ePmQL/miL2Tn5AmmFy8wGY8ZlAVRaaqNEae5Aa01l/cucunyZW6743b+5Fd/Fd/6D76ZJ598kjd/1uewtbnJkx96gg++/xHGh4d81qd/Oi978F68EhMNVVqKokyLN402itAEjJnn0QXEJVPlXL20AMrxByHZ9HvisYud7qO7UJovmuertq77K1osPVRitUIOs2f+8zgmcxWjLcxXOBY8rpoTx/VtrpIAxygumjbaIwYcIQhrhl7M51zYB1oRlPQBqtISGo/zHluVbG9v0+8PIWphqRIjF1KsCFFDDEwPD7j0wnkuPv8CxQ03zKXAxBawH9cXm/chMaBVREUj7GWIaAIqSm8azos7qw8JyEkeZnReQIOXEHrthflS8sbgIIh2MfVZBqKTQofRmoiCnGMpZZvW3Incg5n3Wwgiv01Mq07PN8agTSB6TUxOuTHNJyuhkUdkjyH1UxqlCCnLM3YW/SplbbZ9o+k9bC5OKIn7iEnyHJBtDSz2FQZiyhw1C6wxRqNDbA17MmsZ0mtCS1yq5AosxzuGSEwROKSIj9o1VP0erglgYGtYcflgn8cee4ynnnqO+2+/kbtvvZ3N4QhLpNCWGV5AnILGBbQVqasPQXrJjaEsCqp+D1NYal/jGk/UgUrL9wlAdItScp2ZubQfYzLyWs6v1amvtC3GxE4kVWDOGmdZ9lKxMeZ+Wq0hlaGK0oAtcHGfS5cPmMxqTpzZoOgPoKjAWmIj8mZV9VGFZTKZUKg2IkRlY6Xk8YoBtF6NGq9UxOx+z6hWAMdryNFUS4qb40x7rrQNCrXGluuxHi95aJbJ/+6/7arF56r+oOutRl3pxD5OtrAe6/HxeIJ9eOgvHHPju3qFV86vsPQa3RpCyKIjoDrmDjEsL6bD0mfotqdH3iB0Kvc5fDxXzmUx3f38GEPKLtP4KBYlOYxdE5nNBFhqa9X4sI6lESMPoxUUBdNZzdTNKPub/JVv/Nvc/6rX8c1/75v4pv/fP+Gpp5/lz3zdV3PT7bfS23aEy3vCjClFUZWcvvlGal/z9LPnuPXmm7jpzlv5f37j/5uf+nc/wT//7p/A13ByF2696RaC6vOvvv+n+bw3v5ov+COfy9ZgyN6LFxj2+xAiexcvMxr0UMZSFhWTyUQCyAniFmsU1lh0YQlKyaJeK3RZYJSi6vewlcjvhEEJaDyVqVBBQ+NRQeNiTVGl3iYVUEYkw95JDqCOgUIrUQKqiI4B18zaXkWib41eCOJUaoyBmHLyrJH2NJ3yJ0NIIegeYyQ3r2lmLVsBssCMMcwzFBHWWalICA5rJbNwNsv9iApjLKBwSVJoioL64ABtDWV/ntOZgYSb1XNAo5QwZEH6+qw2oCOz2YzLkwPKQR+nYX9yyMF0xi133cHuyVMMhpso28d5T9Xro7RFx4ixCpoZRM/4wos8/t73UYbADTs7lIVhMjlka2uLaDXT6ZTClm3ECSoSoscHhy0ss2lAazBojIpoD8EHgpf5b5SmUBLv4FygsLJfej2ZB6UyhGTqY2JEK49G2DWpWiTGK87lrLiGVLJBa9O1TBAQmXMGfQTfADkXU0yEbGsGo3CuFpDovLjV+oBJPboxS269SGjxPhUwYvatIfpOD1+cL8qziVdoAq4RtlRXBRr5vkppiqrsuLXmQkkkBFDaUmiLsYrGN620GsAFmVdohSp1y0IqrQneUTspSpSmwhpDXXua/Dko2d/JAMoWFQfjKf3+kMFwSOMC//3tv8dv/vbbOb0z4oG77mazKjkxGOKaGZPxAZUtKMsSH8DaggA0jaOOHlsUlP0+RSVGP4eTiRgHaUNZlRhtcU3AhYBSyfwqyM7SKpfmhG1U2qQ++pQdmZUGYd4TbY1ZMPiSPvv5/sx9mVEroo5gClAar2R+NnWDKQyDwYCJkxxOW1bsjWfcffpGNrZPtqZSZW+gYoBJ00RlwBib5pp00+sYUUSlIio3RIcQoo7h2EgRfaX4K4UYUuWqpVohXQ3qCutFyd5sPQpi9/3ntzd9heim7v3rete26/GHN67F+Gk9PtLr13hVfNc9h9fM5XqsxycAE3ktr1t1Mb5S4ei4v+nOZUYpkwLRV1emtdaqXRyqbFPdAbiZOQuKEDVRG4ItaZQGFfjUz/0C/vHpU3znt/9jvv+Hf4znn3uGv/Bnv54H7rkbU1bo/ohweIguSmo35oabbmR7Z8SlFy9QlFvcff99vOUrv4J7738fLzz3Aid3T/HqV72G6eGE//or/5l3vf8dbJ7a5PUPv4bzexf5nbf/LgcX96inU06fPMWJnV3uuPU2trY32m2u+j20VkzqGaaVmIqpTalEwqa1pvFuzqaFuaQy5wBGn9xMj9nPR9jBLkvZYT3o/Fz1Ht3eyWWp7NXMOK6UrakSh93tw1wVQRBWRtXEhf7KhYxMO48x8TGgtUgvD2dTiqpk6+Qu/eGI/nBAjEaAbVFgrBUTK+8IboaajLn4/PM88egH2d4YsTEcySK6LDFGEzsS3uWR2TsVxRFVEyCo1F/pW2mqVvJ/X2dANGeTxGgpOa76iIoh2V4lRlIlQEecx560bq7IT7W0z5ZyT7VJrroCV9o9LbESImsNkWTwI6xnTHM2xEh0rpVAZ2MV773IXmX1Py82KbUQhyG1J9k/WcqcGcjWuTjPv6X5lI97YIn1Vi0qkQzJtM9yH2EGGzHNq8Z5tDIYA9OmpnEBZTS2KrFFwcx5+rYAoKoq3vWud/Hffuu3GfX73H3XXZza2abUCjediIQWRVmWFEWFj5HJbNZuS1GUFL1KIogg9RTHZETEkV4FzVElQGbOxVTLE8N8H3fP4XY/RRKASiw1S07KifGMHVdUjxhPNQSsNUQVF4qLdeOJSjMYbqJtzoTVnau7l+u0kWtVe04oMAt3gVxIvPp951rBwPXc32S+hiuCwjX4WI/1+IMF+cedc2twuR7r8QkGMK92Qz9iKrHwf455blz59+XtWfq3Wga2R272qcIestGJFvmsLBsig50dHnrVw/zP/9+/xQ/cdJof/r4f4tFHP8D/62/8DT7jTW9Eu1pYvMGA0jum4zqBB8PFixfZ3tzkxltu5rbbbiO51DLcPYXb38dbx9nzT/DWt76Vp58+x/jgkGfPnmNzOCK6yBNPnWV7c8RkNuXVr3ol/apiNquZzWb0ehWFNhKmDphk9tMrq8WeqFULoq7kMkU75PgOmOcrknvmmDMAeslZMcvpuhEGCz1L7cJ1EVjmkYHFceDvOKfY7vHO/ZbLEtzlnrtV752lj/k7KKOPGCYpa/BEJvWM0dYmt9xyC8PhUHJLmwZ6VQtutNaQfk6nU5568kmefvIpPvVVL2djNGJ2eECvKrHKgE9GOEa17qfzlbSXRXruOVTzHEKJ3Kglp9SU1E1NXdc457Bm0URJQGjHGVWZ5Drr8AmcLZw32Yk1udOG6I/E4XTdUHXUAvK1mksoO3mn4k6rpP80x6ykKIncj9catXR6KWMQCao65prR3aauKVP3OaHbR7gELHP0SCC0MR0LGiuT3HtDclhFiwYfI983HQ8XA0RNEyIuQrRaAJM1eA2mkJgb1wSefvppfvftb2fvUsPDr7iNe26/k93dLVTTMJvNUCoDS2Erc1SOKi2FNZRVRVH10dpQe0ftmjayZn5uHI2/WCjUdHugU88gS9eK5T7p7uuWf++8n392Bt3ZOEqJisGn8l4+z+q6BjRbO9sURSGVjBWFJB2zdHQOdFnMmlQcEzFy7fesVVEny//u3seuj7G6WuTWGnuux3p8+ABz1fm2BpfrsR4f40By+QQ+7qa56jmReGx16bjssSv3Y6qVoPW4xcPyokl1jWrSon0B9KjEhhLwQXF57xKb2zvc/cpX8pf+h7/OHXfeznd/13fxjX/rm/hzf+pP8VVf8ZVs72wTxhP0YMhg2OfwuWcY9PpcuHjIpUuXqOuarZ0ddnd3aWrPwd55TFFy3ysf5C9sfAO/+As/x4UXLtLfGPHqN7yOhx58GZWtePrJp3jbb/8OH3j8MU6dOc2dt99Grzfg8HAfjcIWRiIBrJ4zN60baMfkJM7zKWOnn1ClnrauS+yVLtgrnSZ9wB8TD7DqWCz3J/lOYHv3OSyB11XFga6DbNc0pZuPeRxwnQMliYFxCRBprUVqHAIuBkxyoZ2l/bm9s8PpG85QVKWAvxRlIR8gESHaaPCOyxcu8IH3vgcVAzeePkOhDXXqETRKt999cZ/FOfvmExhL7JEmy1ETA5i+h6sbcclNvY60nzF3Zc0MvdJa2NUQiLiE9UwLCoKXPs2IuM12CwfdmBs5VUKnL29+/FqDnTZGJG1TztMkgcfOebccMUPnGrC8j1qJpl/Mfl1VRGmLCB0Q3UbTJO3t8pxRyYTIGCOO0im6ZsENOfX9haiYNTOZK4WlLMVgp0kRLNZaSmOItee3fvM3efSRx3novlu57667Ob17gsKAd27B8bgJktfpgqfsVejCYspCihwhUAdh1GOM0hubgHAGyZJxqY6NiZqzlOqKQKzbh6o46gadC0Y69YRnQJzjXQpTSQ+5TwUEY8BomuCJCkajkRRytIIYCErH1rgtQujMBxPnoZJyXwkdEH3le9O19D++lHvitYDIq7Mu6zXGeqzHhwssV60v1+ByPdbj4wRkXu3G3A23Pu4iEJfAwtH3iAtugyveibm9x7VtR87JTJEm7e/yYl6AZgJiKEIyRIFIrz/k8NIelVXceP/9/LHNr2Nza5uf+vEf55/+i3/DM2ef5eu/9qu5647bYdZAoRkON9Hec3B4WULkjabxDZcnB2hlsGUBpQGlufdlDzAc9Tn79DOUZUmv1+P0qVPsbO9y21NPceHSRc4+9STnL17gxhvPMNrexTc1hMBsPMVUPVRM2Yqp39X7IPI9DN7X0l/XWXDnlFK0mKx0QdryAlQdCUlfDTBDW0RYXOQbVLtPM4joLuYzc6mX2IvuNnSZslVzylq74A6anVa72999TZeBk22R3uCgAsqalGfZ0HhHOegTYuTy4QFRwcb2FoPRCFuWAkzKAlOV0veaDHG00jQHY8498RTv/r13csPJU2wPNwjOUxUlWimM1q2xlEq9cLKoVq2bZ5ag6tTHJwDHtccsfx/nAs6J3DTvx5w/2jXIUUqkzJmVVDFI1kjSOwcnsSAZCGTGc2E+0DVWEmliBqNd6Ww2/JlHlqTfdYBmTEBWaz3vwySuLGzk60YGpRlcqiyVTX2lbeRHms9dsJsBXDtfYhRTrPQIycRHGY0xBUrp1hCoZX+TDFUlB1kXPHXwYDRVv0JbS+0aolHYQtQF4+mER97/ft73vvfQ72nuv/subj51ip41NJMxMXiRYhtN4yOhSVmdqV9YW4PSFh8jTV0L254iTVRi/rpZrrLf9Mp+PnF7bclw5iY5qi2uXQksdUF73sc5CiXEQNM4gtIUVlEUhbC2MSSDMYO2BSFdj3rDgTj10tZQFotAy1d5lZ9kjnWHPQ5YXqtvx5W+90fi9+uxHuvx0RlrcLke6/FxBDCvdKNeBUKPMlLH536tep/l/rmj7GhsgeQqeWxaDKl5xb0TdQYxxLASCEs9XHP5YMygV+GCw+2P2ThzE1/5NV/PyRtu5mf/j5/kp37qp3jPe97FX/6Gb+BT3/gGrANT9emPHNuzGZPpIdYahhsjyn5PQEvw1H6K0uCI3PSyBzlz8y2YqoIQqCczGPQoNkcMd3cwzz9PORhSh8jhZErdOCptIc4ZGxfEsKUFEmGeKdcFdQvxAlqDn++7LrhcPn6rQNoCCCQeyQxs9+VSWHk3g7ALCI91lO2yYZ1jm4sDWcba7d272iJvHnJftK/XOdsyBKZNjQ/CRh02Uy7t7VEO+2zv7mAKK06dZUW0BmMtEcQISBkg4sZjzn3oQzz79NM89MbXU5UFwdX0qoJCJ8aZFVmkCZBHwKeMSEjOwCrMcy8RiXJ0EV83Iom1Fo2SPtwEIkNM7q4JeGEiOuQeyUh0gWhEjupcQ2gcUSts6iZTPhCyaayaO2ya7CCajn30AR/DYt+tUi2T2vbnJufXmCSfOfaky4hmcLwsy8x5m20WbIqNyX2YIaQm0c4cCSsYyznLGVtn0+5c7co8c2ZkaGR7XRTwqRPOmXmRrZa9HrpXCvDVYIuK4XBI8J5HHnmEX/qlX8KgeM0rXsWpnV2GZY/x5QNUdBS2U2xxjkCkqiqqQX/++cTWBToqKahUvR5eKTHySkys92KY1c1qXThfVxRo1DHXXcGaqWAR5/Lxdt8SMdZKcQbaKBZMJwYpue+CxqVj4ZIR23A4RFnTstRpUqOcXgCXitAaz8l2iQnRQsAxXFUFc1TFoq7pXnflDMurK3qu/Blrv9j1WI8Pd0266v6+BpfrsR4fhyf0tfZcdnP88trmSnEjiy6yka6b2OJnLoZ3H9NzeXSxtKofVAVUXGTOgtJoAoONTQqraSZjfPD0lIH+kFe97o3cdusd3HT6NN/9Xf+S//+3fwd/+Rv+PG96/evYHQ3QMbJ9+ga2pgci17QSVj+ZHrJ/eMhgNOTUidPU+4fogzHjumZgLaYq0VExnk7ZG084rBsOmxpVFARtGNcz6mlNOaowpcEUVcruk9WubiWF85D4vAC31qIshOjBJHDj5ixXZh1z3qUYqiSDoPTvbBaTo17a/RpiK7uFTl7c0rEwibWbL0bDFSNG8vbk/MVlgyABpikD0GWX2exiHMkYQWnmTpnpbzExV6IODCgrC+LaNTgcqtQErZjVNZN6xl333MFNt9yMrUqqfk+yERUSXp+yQiHCbMal8+d5/3veyc7mkJvPnGZYleKs6jX9wYB61qB9JFqF0cngJgNOKw4tAhC9LK+DToDTE524skat8c5JSH3dpN5Tm0IaUs9l0xCCJ/icVeqloBAlYiN4j4opU7Ou8c4Jm6Sl5y2KaUrbaysWrUme256psWX6W5fnzDKF9Lw47x/VEbx3BC/uwmLWE48UGhLSl37NDqjuzhGjtfSI5vOcxYKET9muVerLzXE9IOxj1AJoQoz4GKSnUltxhiUmVh6Cj3OnWcSxtyHglabs9Sn6PXyKLCnLPkoppk3NE48/ytve9t/Yu+h4/avu4p6772RUVCjX4Gc1VWWxpqSwhZwPxlFoMQTS1tC4gJcdji4s1orsVlsjBjtKoZRpmdiFjFtrOr3Qi0AyF3oiS5mW8crFpeVrqWTSNrjgRRpsyrSdtj0GubBVx0DjnBzHomCwuYXWNjkTSxFQK4tSjcyDNO9i55qz1HMJ1wASr9WkZ9X96Fr+faVxdd+BNbhcj/X4gwCYer1r1mM9Pr5P7CtKqFBopY/cmK+lavyRHMsOpbJYCe0CKS9ouwuMmMwyLu8fErRBlz3OX7jE/sGErdM3cscDD/LVf/bP8fe+5e/zzMU9/ub/5x/y/T/0o3zwQ09RuwjaonRFWfWxpkCjGJYDtoYjdIhcevEC1WDApKmxZYEqLGiDHfax/YqN3W28Ubxw+TIvXL5MEyO90Qa90QBbFKAUticB5JK1olDGYAqbZH6ysNaFpajK1vimKxtc/s5XPZ5XMGNaBd6v5AYblxbDxy3uutLY4167/JxV73dEMqciPjpCkAWvtrLvlNHiztmrcDFQRw8WTt94A6duvIEi9cG54IV5MUZAfYwwm9JcvMSzTzzBe9/xTu657VZO7WzR75UQA009EyOmRhbQpmO+ojtOnjrLFrNqtdNrmVncvHhvGcAQW9DQGqJkuagPKfMy9T2mf+cszOi89Fimv+fPt0pjsmw1b2N6vk+ZmKrzmjb6oZM/qULOHZkzmDGmHkxYcIBdVRhaNhNanqvdOd3NMc1ARmJuCkxZtIx5F8QKBk492AjYjAmENskxOCDmPQEBoS54pq6BwqDLgqAVLgZ0VTDcGIFWvPDCC7z1136dR953jvvvPcP999xLgcYqRTOrGfX70pNZlpRliS0Lqqqi6FUipXcOFyV6yEUxHip7FbYsiUr6OqOSXkefmM2cxZnzW68mC11ldLX8WD7flnuia9cwnc3w3mOMGA/lXsqQIlFIx2TmGjEBspbeoC/nWtrfR68/MZ8jSi0zlK0Dbbzitepq8+Qj0YN5pfvWR/L912M91uPazrkYI/ZqOZTXYlN/vSzLRzOjpg1mPuZ7vdSszo/W9q/HelzL3Jv/f5Gp7MpOdQ5m787/nGuRwUqn3jSXQMWFCJGFc6NjONECGyCGHIbd+icmY9R5TqfWWkUtEeFBZedUtRBd4CLYqhTWIkbKwQaBwP50hiVy+tbb+Yqv+zr6W9t813d8Oz/8E/8HTz75JH/0i7+Yh1/2ANujAWZjRLx8CWUUPdtj78WLNE1DUZW86AKmKNne2cU3DZPGUVUVDsVoe4fXfMqn8PTTT/M7b38bg37F4L4H6fX6RG0ZbW5y8eASL1y8wOTgkIsvXuCWm25id3uHvi2xVQ9fzzqlvI5BRgKWUz2l8Q5TiJmI9172mdG44FujEFsU7eLMNcJUWGup6xpjTCstbUPj0nuFxDhaZdAxSeKSM+3UOQE56f86MTEuM65aYzNwkwnSPoL3uKYBtICrOAcM+eZijFlws83/dgl0DAYDVBSGRynFbDpmc3uT/fOHOCK9wYBJ3fDE009x+z33ctudd1D0KnrDAYfjMcXmBiVITmO/D4djqB1xNuP3fud3mF3a46aHX87mcEB9eEh0nq2tbcYHh0QfKKyVRXfj2kNUWI1V4GIkOgFuSmkivjXxKaxtmenJZEJdO5wLlGWvPUbDwYDZdCpMp/cCLrUiRul/zftJI46yvnHgJeOzMBajNMEHfMp7jCQ2PGUVqmQyJJEqItz0JEBJXADKeRtEUiv9lxkIl7Zowa7qnNMxy7qz8+wSIFQh4oOnsLZl0bvH2Sfw3ev1UNYQEpudzWa0MVIYwIuBjvdoo4UZNDp5EUVq5yl7PZromDmPLXugFc45yqpPb3OLJgbKsiB6jWs8emC5ePEiv/jz/4n3vfss991xgvvuuotBVaG8p5lO6NsehdVSCII2NkgXAsqUlp+xaSR+pFcJWxnm19QQk2lTe3xE6ZGlv10nZIlskrCYmAsVnetsC0TDYjGo7V9e6nvOqpH98SFaQ1lKrq6xZXvttNa2Ba7GOZS1hKjE4VobbFGhqoqmrtHlEIzFNU7kvErjXIOxdsGfOi6ti662Buquv1YWyqLvvGs8VqraVcl0ge/VPl/rNX/yycSWrcdHd1zJeHAti12P9fgkvThfT57YH1QBWIWogooxstqBlrRgC8oTMdJnpCQT0ytPtIomeD73i7+Ue+57gB/+19/Lj//gj/De976fP/Hlb+HzPuMzuOWGU1RVD3yDq2ec2T1DiI4PPP4Yo91dTITZZMK0njGZ1rIgVoqqLHnt617H3oWL/Ndf+mXe+lu/zd6Le7zxda/FVz3e95538eLeRX7/99/BpQsXmU2nnNo9wWte+Spe8eBDEmmSojFaVmspKDyDzC7oXF5cdh/LUSaq87vjmMXF/cmxhb68kL2W3t6uwUz3d8vmPwsSy6VtMcZQFMIYNY0YpcycgP6NqmTqGp574TymLNg9c4qdkzsMUp9YtGKYoq2h8Y4iIrEQynPxufO89x3v4IYTu5zc2KQyFoOTLNW0UG/7Rj2tfkcn0BRJrKIPrRRQR2RRvmKfNI30XHaPV94HGUiHEFFRiWmR8wSV3WPtQj8jZm4ElGNPVJD+y268Byl2hBBbeaVK26eWWK5WYq1o3zM4R3AejD2yCJfPjgvgYHmeLbBoSyxnTPMaowVAJmasvZak3EilNdG79jxosyxJPY6pwNCk2A/HXL6rraG3MaSJgarfIxIZDoeUZcljjz7Kf/mlX+KR9z/BPXee4K5bb+PMiZP0rEG5QGkrhoMeRVEwrWfo5BIbtcQfhRBaqX7uuwzk2BYB0ssOuTEmo6HkGBv1MY6m13kh7UrrW+dd72mS3FprjTKgrGlNibJpmI65QACqEBMl7z0z11D1evSGgyv5srVM+cLCkXnWJkfg5vGLzw8HDKyBxHqsx8ff+IQHl2upxHp8MgPHK4HIlVXiZNxwNF0+y+FoK/SrqlXXC2rFM/aoqUX+mUPYQxQLFBSSjacFaO7Paipb0Bttcc/rTvBXd0/yqodfy0//ux/nH3/XD/PMs+d502tfw2tf9XJO3HgDth8I+3s4B6dO3sjF8T6FMUzrhrp2TCYzZrOG0WjE1s4msa5546d9KtEHfuHnfpbf/r23cengEtsbm5w//zznnnuWM2fO8LoHHmR2OOa9v/9ufuO3fof9vct82ps+lUKBCqFlkkJkHq6WFu3zWBY1d/ZMzYq2KMS0Iy2+80I/IqxSLzGatIv+xf0779Vb3LergGcXwK6SvS5fP6Wn92gv7XK0is6OI52Rsw77/Z704TkJuW+8w8dIbzTg4HLN8xdfZPvUCW6/8w62T55AVwUeKKwVpsYYHEBdQ+NgMuPJD3yADz3yAT7zDa/hxPYWEmgR0IURt9cApSnENDUzrkIFSi+k8wTfEHzTsnQxJlCajW/auAYYz4R9ztmMGQgsgGwlvalGq0RgZ4dkTwyeGBzEgFYaYpLKhkDw7iigT06x+bl5e2Iy9InMGbAYQyv9zVLc0Li2hzLGKI7CXYCYwGUGsjqB+OWiRTfblDQfQ8qqLQpLURStvNXn4pFWrdNrINJkgKSSyVQC1S7JS6OrwWh0WaGUoomgjaU/GrG5u8PY1cLsa0NRVJx78kl+4Wf/I+9652Oc3i158K57uOHkSUZVn9jUWKXpDyrK0uITW9mCZiB42rigLGd3wdMkwyQ5/wzaWumpTMAzAy+tBVC3Bbl8frTknGrVBdeq/Fq+trbssPdU/R5aixmWMUYcqFOxoTtv5BqhqX1gMq0Zbm4yGG6IAZZeYSQWsw9bRGcVrM7soWndp19q1bGrYLnSWu2j3b6xHuuxHmtw+REBmesL1Hp8Is/3eAXDnQ8PsF7ba1Z9XnvOCSvULmKuVATSqRovI+UConEBCBqmDhUadm+8hT/61V/LXffcx0Ov+hl+4Hu/myfOnuPZF17gDa99mDtvuYWqN6RsSqyH0YamHFaMRiNZWHt49vnnOLh8iIqa0WDIxs238uYv+COUZcmv/+qv8YEnn6RXVmzvbPLGz/wM3vSmN7K7ucVzT59jNBrx3t9/N+9/9IPcc9fd3HrjDSIBTItPONpTtZxflxfuVVXR6wnD0nWKXDb30GlBmdd6XYayCxRzD+4yUFkFXvI2rHKRXQVKFyVrtLETmXlRS0UDYS0lO1CnxW/Zq5g1DV6D8569/T1caLj1ttu4+fbbKKqSWVOjy4Ki16eoekRlKAqLP5yi64b9F87zjre/jUFhufn0KYZVSWgaYmyoyiothiWmofYOCPlX0rMIRC8GNvjQHrsQ5/2KXSDtvWc6nbbS5JyVeARcdvZle+8BCHOzpO7+a+M+4Mh7LdaCOi6knSiS9liGQNS6zUn02dAFsMYs9Jwu5Gl2zJuW2XIBHPPiwRwQituOSU6p2hpq74hhnl2JEhbTx4D3cTEnMwHgJnh8ArkueoyRvuYQFNpYBhsjykGfOvi2l9lqw4cee5z/+DM/zTvf/ji33FDx+lc/zJndk/R1QahnaBUZDIf0+31iiEzrGaaoBBh7n4yGBByWZYmuCjHKSdmRUYkrbI74UEZLbmq+ViWmNrvELmfEvpTrblEUrbw9s+BZcm6M9LIGJf2gYQXY09aIk3X6/LppGM+m3HDmJoqi6G7fQvdke9zTudFeU7ScKJKgrK/LD+d624uuFFOyXretx3qsweXHLLBcj/X4ZAKb1wUwWwZTH7NAOpqXueBmuMJ5dBXIVFqholKRvJAO3aI7WhnliVGlWIUljpOd3VNcvPAi49mYQb8iGk1Z9XnFp7yJe172Mm6+806+89u/nbf/q+/lj33ZF/MFn/3ZvOrlD9I7cYq+MVgalIEYFHY44uTJgsuXD9jf2+fF8y9Q3VRi9/bQvR6f9ebP5cFXvpznnzmHtZYbbjyNUZrNG26kfv48uldx+qYb2dvb49yHPsSFSxe59eYb0TH1M8YogXKda1BmdYIi9eQJ82OrkoHRlGXZ9mKGIMxWdtzsGrHoDsvbXRwug0aDMHFZ/tcFDV1J67L5xjLIaUGTAWNlESr4IMF+rTAmObCqDEZkOikVUQZsITmNVVVSuxney7HY2Bpx4eIeTzz1FNVwwM133MbOid12oT8YDej1+2itabxHlxUEj9KWpx57jLf95m9y7223ceOpUxQgtGh2Tk5EX1ApOsVI1IKOWmSjy864pP7GEBNIogWbIQTq2lE3jq3BkF5/IAxzB1xk0JhZvtYQJ2c6aiQvMggLnI9PZhmtMYQY0ud1DINCTI3N86pCK4tt/zbvkY0p1zL4BmLEJjCslYYgPbTd45+Pb5arGlJciZcIEt1haJvg8UF2rLUWWxZoayS2IzPyWkuvZepFPOJU3EpMVfIekt7UotdjMp0y8wHT6zEYjkTOqRWzpqFXlSg0jz76KL/4H3+e97zzcW450+e1r3gFZ3ZO0DcFJkJpLYNBj2G/DzrSuKY937xPLreFpUjGXioxtbPGSQ+mUsKWJ8aS7HKcnG7bvmWtWzUCnWIO2VGX65fFei/mTV3ptRyXxfiiVs6rJGNX2GAl54ZSeOeo65rxZMZoa5uAbr+HViRDJZ1sqFfcErSw+3H5HvES70HdYtfV1mtrYLke67EGlx/zwHI91uMTZVxPT0uXcbxee/jj2MdVv79ShTrG487P419nEGozKCV9a+3yRnHx4gFVf4ONrZLQ1EynY3wIlEVJsbXFH//Tf5ZXvfZ1/Kt/9k/4/p/4WX7/ve/jq77iK3jNw6/kzpfdTxGm4GoO9vYovKcqeuxsbVMVFZUtMErRNJ4CjTYFu6fPsLm7k2Sdmno6xh/uU44G7J46yRMfepzxdErRq5jMply6dInSFpTGikFOysjLC3PjXes22mUis4tl131zWaqas/f0iqb6NrcvvW829mhBbQwrGdRlN9BuT+gqR9j8U69wg+z2pLU5nmEOOEwCYr1Bn8lsyuXDA/qDAb3hkA88/iFevHjIy19zO6fOnEQZQ+MjRa9HvzdAJ7de7z2FcxiloZnxrne8k2efPs9nvvpVnNzeQoUakxbPMcWKgID1xjsKbZPZTDIqirFlLUU3K1EYOT9yeV+MJxNCCIxGI/oJ8ObjtcpZ9cj568Ni7imL5kfd83y5OJQNgWInZoQVLGdIBj7Lc6zQpo01yUD4SC7qMcc+b0cLIKF1+9WFJeZiRwKVuadRzL4i2Uas66Cciy0Sw5L6HL1nFhy9wZDNEztgLSFGil7FcGeLejrjkfc/ws/+9E/zvned5Z7bNnn4wYc4vbnFwJQUaKrSsDEY0h9UxChMc4wRWxa4mUcZJfEjRUFZVQQtfdxN2h8ojUnAUpnOMUp9vt1zTq3oMe72Wl4vgzmdTtviwfL5FVOEj0TNhNTKMJebtoUjcU+jdg2T2YzZbMb29jamsK0Uf9W12rT6/cAy2ozx2mDyKqXFtcRoXSuwXK/v1mM91uDyY2oxvmphvB7r8fE8r1femDm+Wt51Zb2eYs2VHMKu9/WkmASFTplpYemNQjKQ0AmbRvR8rc9gMKBpGvYuXUZp6Pf7GA11UxPRjHa3ueeVr+DvfOs/5MGXP8R3fvt38M3f8U/4Y3/0LXzB5c/kgfvvZHT6BEMXODw8JLgphbZsDkcQI82sQRlFVVVgFM3MoYymGPRR0dOvNjm8eInhYMhoe4sTJ09KL1nTcDiZcDiZEYoIhbBQeaGtZGdQliWT2ZRpPaOoJBJBad2yXxmIxbTobmMaEHYrhNC6jy4sDKMIcX0GF3rJhMXPAceqIkU+Tl0pZ5fdXJWLeVzweV54W2uFJeu8R6/XkxzEqqLyDlMWXLq8x1Nnn+bUqU3uuecetre3qesa3esxGo2wVZlXz8IiNg4NPPr+R/itt/4Gt99yA7fceBNVUdJMZhS9AnLcibZtIWPBGCn1HXrvcL6WWJAYRWYcu99pLkMNITAej/HJTKbX69E0jTBvKYpj+fzIBinZFEVAfmjzQGFx/3jvFoCfmC7NF+kRLd3PuVeSDmPZAaUqdCOAZDtCCAR3VJrdZrNq3caY5O3txmsIwBJJpk1y0KIopO+vw3zmaJluASN/l9yz2xZB0mcFiRplWs8oexVbuzv0hkNqL2AQW3AwnvLu338Hv/Erv8a73nWWm08WvPJlD3Fm9yQ9FNuDEVZrqkJkrtEHGt8kCasi6tiej7mIEkLAhUgTPXWQyI62UKIXJea0JjcGbY46k8oxz5mn4SWtN7rFgCOAP8+V1M+rUl9lt6iQJd/GGGEtx2Nq17C9u8NgMOh8kFp47cL3SBGycaHQ0YWx13fvWPge8dqB5Zo4WI/1+PgZa5/m9ViPT/CxID1SYS5nug5Z00u5kV9LL82qfrJl5qsNWRGTiXbBoyKMx1PKsmIwGmKLEpRh5gMT7wnWsHf5kIPGsXHjTXzD//iN/Osf/VEeev3r+e4f+in+/j/6Dn72F/8zF595DtXrMehvYG1Jrzdge7TBqD+gNJaLz7/AM2fPcbg/pq5r9scT9vYvc3Fvn+AC1pZgS+zmBnfeey+mV/LsixfYn80ohn2KlJuJNXgNtXfM6prxbJrcTj2T2YxpXeNCENYHcSft/oxLLEBekHcfeb9oFDpJLHV2FY3z/dYavnSMXbqL2EXzmEVZbJjT3xI5wTEZnAn0ZBbFqHnfYUDAQzHoySK+rNjcETbl7NmznDt3wF133cXtt9/OYDBiNpvNoy2UEvCnoVBamNvZjPe94x285/cf5eFXPMjp3W2CayD6BeDQBU6Zyc05lqQsyhDEKVYT5lWMtP5GyQJezIAU06YmENvszczkdU1XWnDopG/OJafW6HzH8Ee1kteuC2+Oksk9kG0/ZTL8oZM/qZbnQpg/uq6x3fnjfYNPgEupJJ028320Kgs1v95FMbmJWmFKybEkMXtx6VzO+yR/f4/Iv0NU+ABNCMyCZxY9TYSaQKMURa9Pf2MTrGU8mxG1YWtzh3pS8863/y7//sd/grf/5mPcvGt502tfz+7GFqXWnNzeoTCGna0tRoMBhMB0OiUEqPpDyqpHRFOW0tOM0RItUwuzJ3LmeZ9zVALWXEyRL9pibNlKSxUmgU3dGmu18wYILXBLP6MmdHjB0J1jnVEURat06LpGG2OwWnqapSinMaZoXXrzOdgtSngXmdQzahek93Q4kO2J+sqAUGmiUmJ2tVwYvIZ7wKrHh3t/WQPL9ViPj+1hj6uWHbcQvN6T/Gp29h/ti8T1Mi0fiZzPj+fx4bK7n4zf//q+s/4w9+8yQAzLX6BdvGakFhMdM68+L263LG7N6oVGVHS/Xu6VbAEHWuCsmbNCLEDE9s0WwO/8eZoYaU1qQnsABFnqKJkKgRA9kbK0NE3dxgM0wYvVRGEJUVwn0Zax8/QLy2s+683884deyY/+4A/yj//ht/A//2//lN/6b2/n67/2T/GK+x8ghkhVlVx+4TybGyNUcNx6003s7e+hmpqitJS24sVLF7HWcugO2NjakoXXtGbjxGle9+mfwQcee4L/9u7fZ/eG09x75x1snDiFDhHqGoNEQpjG4QnsnNhhb2+PaT1lsDUiGsXhbEZRFLimEbObUsw3XO0xRUW/pzh0BzSNx5gCa8oFgEkGEl6BEzdU2+n/ClFjgsa5QM9qVFDy0IaIxzs5rtoUKG2JuKQUVShbEJ2nCRFTaOroqazFlAVxMsF7T1kUGBSlMtiYjUEWTWEoDFPnKft97EDTNDVPfOAD/N4738sNNwx4+ctfzm233Mp4VmOsZXM0oq5rVAj0egMIoGdTGI544pH38Ys/99PccVOfe26/meGgpD7cZzAYEJxL81YTg0LpgAuudT5WyqAQ4BNdgwoebaX/UUCcovGOqISFK4oCb+CFyxe4cLDP6RvOsHlyF4zGlgXRB6aHM7Q2+MZhtBZ+MRw1VvIJnBoUHofWRs5RL0DGIEA6Oi+uqdq0eYhaKZRmQa5qsutpJ0sxA1OtFNokcygfEkvrpG9Wa4w1CSSlsyvFsojcM7HUiWmV64Sh6PdQxmCUAI8mzZvCGkxRtPLJ6DzOO1xoOrLvivF4IsBNG4Kx1MHTxIgqSmyvYmNzCxcDdjCg3+8zmzacf+Z5fuOtv8WP/sC/R3v4lJed5hUPPsDmaINCwVa/ot8rqGyBUpHJVABjIFJoydBUusSamOY7yWRI+lpDIqhjsrr1PhJVEIfYnGGpVOsga0yFMoaoISoDWozBfBQn3BwlHJJlTiD1aQZxviUZKBFBp+urUtJXm4sNrXw6RU4qrcBEjLICgpUS52OVwK4WI1gTFVWvj6trrLVcunSJAJy+6WaaGKlMQfQKj+TaKiWS8KBJ7rBJRp7vK/naokICphGiPla6mvONFYvoWaJbAkq9tHvn9Upr/6Duv3/Q6reP9fXTH7b67+N9//zhb3/4MLdfXx+4XI/1WI9PrLHc7xKTs0m+OBwtKF0963AOOOOxcRXXc5NY1T+aqcpsJ7vgONoBxznIXUfwiDlLUGBsiWtm1C7imppSGzZvuoWv+wt/ide94VP4kX/7PfzED/8kb3/bu/hrf+Uv8oWf9dn4umFz5wSTyxfpb28xfvE8VhsGJ04wO9jHh0i/rDg8PKS2FeyWwh6YAkYj3vCmT2Xv8gE/97M/w0/9x5/nZffdzSsfeIDt0ZBBWXDTqTNsjIaMDw7JK6+N7W3Q0DhP3ThMYTGFbVkpFwM2HavZbIab1bKI71VYa7vtVi1L570X0KKExWwlqQqin0sk8/HquoVCcjjlaN9dSO6ZKi1oA0vMM8l5NTEsZXKNrZ0TFqaw8h1cgylLDqdTNjY2ONyf8sijH0RbeOgVr+D0DWdwztHr9QgpEN77gDERvJcHkfDC83zwve/m6Q89xWe+7lWcOXWSUM/Y2BgSGtf2lS2zJnM3zAA+yjnhHTEEMY/KbGeKuXBEQoDGRyazmkuX92m8oz8cYstCejcBlwxUYpRM1lR9aUGh0iJVzwBQJI2qNWhSqSdRZ6fO9P8kpv6/2PvPYEmyPLsT+/3vdRHiyXypMyuztNbd1VXd03p6pkfPYLAcgCCwAHY/LMmlGc12KYxrNOMHkl/WaEajLYxY7NIWIAgsBjZ6MAoYsa1Fdamuru6qLtElU6snQ7j7vZcf7nUPj3gRT2RmVSv/d5dFvlCuPe655/zP8bE2TM8VHQ2ZvSEOAVTaiR7MkvHUWiPKebMWpHoMWmAUemxCQBhls1pVZlMGkxcRtPjXlB7lfQ6yIVnmI0VaaQcVK4xxbPV7bPWHxKnPkswKg1Wg2x3iVquKINHGmzVZAxtra/zRH/wx/+Evvs7BefjQvXdw4vAKBxcW6LRbdFtt5rptIqUxWc7V9TV/nLXyfdittpdnBzA8ApX+PPaOt4KSaORgq8SrBrRCdOTdd8U3HIgL8uGyN1l5ealSDuciREL+pXGBIfSgTMTilDfcMeX9s3SSBn9vc25MdbKt39DVJu2cqk0MSuXJU49ZKYqCLM+JWwlxKyVO2zg8sIxFAuwtB5y6UhjUQZgKEwt+2Xbf4KxsP623ZOynpaKpppr68agGXDbV1E8RwNzrD/est4q4qTmXI4C524BgtnPzNLOG2nMyYQwhhHlwW0dJYRBuyiGR8o6rrTgRVxjX39xCrKOzeIDHP/Yz3H76JKdvOclf/vlf8H/6P//XfOEzX+Qf/s9/iztvu42lhSXWr1xmYXHJW6EO8tAfmJDnObHSbG72mLu2TtJuIXFCdnWVSCk+/0u/zK233spf/+Vf8fYbr/PHf/7vyfsF823NQw88yFNPPsktx44y2NhiOOwTxyntbguRUVj65maPdtqiKDLvihoHsKYjdALtVgtrCwyBrQ1zAg5X+Xs4FYxqMBgXWlwBKxaDqZwwq+MQHG0j7bP8siwjUiNmypgQ0VEeO2MrhmxaRIofcCuKPMc4S6eVIiGigsLnSM7NzZHnOd/73vf4wVsXuOuuEzzy2KMsLC0xyIYsLS2ikhRVxn0EMx+sBWs4/94ZvvCXf41y8MjDD3FoZZm1S5dIo5jN/sDnAEYBBDCeO6hDVKSxHujZIDcV3wWMBJljFGmMNZ61c45+v8+1tTWUUqysrPhMx3AeF6HX0rv7yoi9C0Cv3NfGmiDVVdNlxTPMT+qS5bohUN04ppQjMwGqy+gSG77DAy27HXiXdi4y2ScZVU6xWnkAK7ix6Ap/3H00RmFCRqQIOoqQJAYtFEVGP8/RaQurNIV1WCdESUpnbo6k3cYpD3YPHjjA2rV1Xvred/n3f/bnfPu5H3DH6SVOHj7II488TDsS2klKK03opC3iWFNkOYNhD+sKIu3NseI4rpxcy8k1paNqMsXLjQUVQLOKvOENsfbsbBR5hrJ2jkd6JFktwaWXkvq4DqpJvFq2bb1fUwQtEq7Neq/szvdsi6v2e/2ccP6krWTWtooREYbDIf1+n/n5ebrdLqqVhkmHbfddmaXwqq6favIxuMhSv4dv//eYUkVGIHgnvDhrwrGppppqwOWPfd2I7Leppn4UAOV24Dgy+xAluwK96U6xMjUn8Uaus2nLrhuITLkmhSDg9W6yYT0CwLSisSYMLuMWEiMaTZEP3WBzk2I4ZOn4Lfxv/i//Nz704af449//Hf7yz/6MN99+i7/zt3+Tjz/1EU4cPcJ6fwvB0mqlPoYgTlg8sEJLRWyxxaVLl4iiiOWDKxhjKIDOUoe77rmXW2+9nde+/wrnz75H1uvz7ttv8fZbb/GVbz3Dk49/mDtP38JSdMgzPIMBG5ubbG1toZRivusZHa29vDLPc2LtXStLV9Bhno0yFkvnSuuq3kLfVxliR7Qq80LGTGLK/bwtpzIwj2XfV9mLWGYTRqI8SLTetTQSNQaeSmbTOM+W6iQmbqXeJTSOaWkvj1xYXOT555/n2edeZGkp4fEPf5jDR494YxgpA+uTsJ2jHEGsobe6yksvPM+Lz32PTz71CCePHkMhJFHMcDCo+iyrXkM7cllVeHmyMxaK3PdAWosqZXzB2Tcrcp91aG1YJ9jsbbGxscHyygqHVlaIdeTZ5MBGaqUweeEBCmzLAyyBumcP1bbexLppzqw80smpmjHDpj2oCKq+Zpn9OzfWwxnOqdLhlcDAjvVXBkdYYw1FYb0RU6RJUs9EDk1BkRtM4XA6IkfQWtHutEk7LSTkR0ZRRJR6t+TVq9d48fkX+Nf/8v/H+jV49MGTnDp5Cw/ffz/0tmhFilaakmiFswX9rT42ZELOzc0FMFfLnizPUfETATZshVMSQKVGxRE68s63KtI4rUKWpKpYZwskAWhXZj51ID9jsq0ElxJyVc2U6bdRFrCbPdHglJ8YIDCskwA0HFcX4kb6WU6vN2BpcZl2Zw6iBGu8xHYbo38dbOJ+4kJ2zD9m9/alWW7lTTXVVAMum2qqqR/C5MhYHuWsH/0q51Jm/JCX/TKT3zHqnZwBd2tDqOnruNuAYmwQ4mbb4muEtDMntsgZZjnOWMQJrXZXgsmF21jdYn6xy0d/9nPcdtfdfPipn+GPfvff8l//k3/Kd199hc98/OM88fgjLC0ssbG+ypzqQM/LUtOkzZbdIstyBoMBa2trdObnWFlZobe67gFakvLAY4/x4Ec+Aq02vbNn+f3f/T2+/OUv88Y7Z/iFz3yK20+dwhjD66+/zptvvsnVy1dYXl7moQfu49TJW1iYmyNG4wpTsW/DwYAsyyhMgRWHEo1XAwtWvMxRa+UZEYzvNbQ+PgUtFMaSmwxnCpwpfBZeJXmzWFtgrRBrIYkURazJMgO2wNkCUV7yVxoGaWQsSsMEua9TQmYKXABqhAiV9lyXxVaKdYq33nqLZ559FhF44smnuO+BB9BxglNCu9vxcsUiJ0micKwtYguKLOPt13/AX/3ZX7DQ1XzqYx+lpWPy/oBYa7JeH11jUBWeUbLOVn2pNuQ/mrwAYxDn+yF9G5s3MzHGowARTRwlbPV7XLlyhX6/z/3HjjE3N+f7DfM8mKv47xgzRCqjTNiePboTsJt0cd0OLmUM0NdNf8BLaKVmqlReP37igRGLVvbNVR3OZX+gz0RF+dgYFQX31xBDUgLK+uRE4SyFMRTWeOlsFCNRRIFjWOTkxvge5SgiTtskqZeqFjgiFK1WyysBRHj37bf4ype+zJ//6ZdYmhM++dG7OXbkKHecvhVlMpQWogrg+SxHawxaKdI4IopUkLwarPM5sSryJjYWRz/3eZdKIlRwji3BpdIaiSNQCh3FXgkQgHsJylWIWqlyfesAf9r9qx5JwjgrXAG7+nkyeWcL4L2m5/Cy3SDdJTw60SgUzrpgHuQYDIds9nssnzxF2m6BnYjBEan6aesGWDdzQn77JKK7LmDaVFNNNeCyqZ8wcMKU2fKmfnyO4V7yxnYbGOy+rP3PLO/kIjgWAVADltWg2Y2CMq2UESyBgYsShsOhy4c5WlVOFVg0ncVl1jfWiJTi6F138wvLyxw5eZzvvfg8/90/+W945tsv8vOf+SSf/8xnOXX8GFGrgx32wULW8wAvjWOiqM3lq1dYu3qNLMswxnDw4EGiJGahs4zNc9jcpHPyJL/4t34DWinfee4F/vxvvsCRwHiur68H8w9D7/x5rq5e48OPf4h77rqDwwdWwDovTzU5iWvT7nS4un5llIOp3LbB6Cgns5ZjGZwvXa1fr56tWAIUY0xlvhJFkTe8cSNAKVC5q1KTfJaMXPnZMpLDsyc+WqLT6aLjiAuXrvI3f/M3vPfeFZ76mcd45LFHiVopKCFJUy81LixOchLaHiTGCSBsrK3x/De/yfe/8wN+7fMf5/ihIzAc4Ixff9/zKShR48AqGKqI121CYXDGVPJeamy+Md7KJAoAAiVcW1vl/MWLxHHMsWPHgnttTVIrgivseHyECsfIjjOSJSCfdP2d5qK87dpwVFEe1dTORA9mPdd2u2OnRgUZZd0x1E0AJN9jqZFIo5XPq6xkxVpXUlATwJKxlkIcVvtrz+DIixwjCqv893hZMLTaHaKk5bMtxbF0YJmo2+XquTN8/9VX+PpXv8ZXv/gyt51u8+SHHmdlcYljhw4S6wiXF7TTLtpZcBZTGBQ+NkjLJBvv5dmiS6MwS26Nv1coL9lVgRWXyANptJf2qir+J+jwS8fWiVzL3e51Zc9qObFBYNLr16qqzcFNc9F2U76v+qwKyoTS8TnE9aAEaw294YBef8htyyveEAtvXqSUEqXUWF/uzR4nzHpvNcGxR2DaVFNNNeCyqaaa+hGcHBgz4alZNtR7KUdvLhlMNRVgzh5Q2TFjoNkDrtkAeLcJjcnoBnEhFTNEAiiE3mbfxXEsIlparY4fDId8RxW1ZHPQdy5Kac932dzaYO7AYT7++V/i7gce5NCx4/z1n/85/+K3/4CXXvoef/+3fot7brudlcUF5o+dYHD2PQ4sLzEY9IiiiKXlBYbDIVdXr3Fl9SoXLpxjfnGB47ec5OChI34b85yVkyf5uV/6JU7fdjsvPvM0/Y0NtAi33Xcvt546zcryIm++9gZf+dIXePu99zh6/BiHDx+lyIZcW73K+uoaSRRz/Ohh4jgmywZk/QIXG9I4CeDBD6B1GAQ7W1SxE2WUhwfeUQVO60yFQirwrkX5GBGCrNRY0B5kmizHFIV3mKzFYhhrq7xOZw2iFMZZinxI2m1jcVy6eJFvf/slzp+/xO23H+MjTz3J8oEDFM7SbnWIWylGFIU1JGlCu92umNfB1TVeeuF5nvnG17nn1hWeePwxlPWMpLMFtshRSCWhtdYDXOVUBQJtYRFrcTYAyyAnlhC0aMX3wWntZcG5MQyyIecvXmRzc4t77ruX5cVFsoFnSn1/ojcZKkyO0grnLFp0kJ6CJewf5/s3tU7C5eJC3qWEbXAjyS54g5zgvFlmw5ZMmq71v7mq/U0qdmxaDMTo7yAirwFEn+HpWbPSmEcFIOWcBHfV4GoaYi8K5ycj8sJ3AIuKkFhTOCF33lPaiQS56SjDdWAsSmsW5xfodFo4DO++/jpf+cqXeOZbT3PhzDqf/cy9nDp6lGOHDnFo6QC2KEgiTafbIRsMfe5tYbCmzK30LLUxppLwiiiMc36CBO8Ea0KEjCg/eSJlX67yuZyekVQ+iqMEluG2pKosWhnlX9ZwrLhJoL77vayckqtP+JRfWY8o2XZPV8FsKNJYpUDp0PMZ2goECuuNwIbDIfNLiyTtFojGBdfhMjN2t3vw6LlyvXeWxs5KHtgrmGx6LptqqgGXTTXV1I8Z6HS4G2Ywd+qduVEAPPn9dfayMo5xvm+pBJgBFIkTXOSdSl2eFSilSGPEGOOwjjRNpdWdF+csZy9dcisHl1ntbyDGcODoMX7tt/4u9z/wEE9+9Cl++//7L/jf/1f/V/7j3/oNPvnUU9y62efwoYNkww3abc+oRd0uSimWrGV5eZl33nsPi+P8+fMkaZulw4cY9gckrZQjd97F8sEVHnjgfi6cO0On1ebA0hJpnJDMz7F04CDff+M1BsMcoxVGKVZ7PV5/4we8+eYbzHW6PGTu4+DCPEVRkA9y7w4rPiqj3D+qni1pfM5i2XOmccRxXLl/lkxayYJorSvAuc04JDif+viOYEwT+hlN6TobsJAT0HFEYQ25MTgReoMBb731Fi+88AKHjxzkyY99lBMnT5Jbg44j2vNdnFaYwhJFim63S9Rq+VF6b8CZd9/lG1/5Km+9epb/7B/9bY4uH8BkQ7SzvnfSeEGnoINRis/jNAGBmbyA3BCLqjJAJ1mhUngaRV4amWdD+v0BaxvrOIFbb72VJEnY2NggarfRoiiMjw/JjCGNYp9nGY6BB7l2jF2czJIcuzb3EnVlgxvpBGgcAywzgaVU4KBklhWlHNIDa1XLV3QjdW/Vn2gDwC2MYZBnFIXBKb/PdKQZ9Ie4SKF0DJHCipdtxrGPCllcOoBEMWmSsr65wbdfeI6vfumLvP3Wmyhr+IXPP8ktR49y4vBhEiW0dETUisn6A/pbm958Kk6IopgCQWGrLNbSWAklWOddfI316x7HKUkSo+I0RLyMWEgX3HudiO+3DN9hnMU6CyXzLdt7lXc9XjWn3zElRriPlWdheZ7oHaz+nQSH7PJYi0apKJwPXsGhAvg3zpLlhrzwMT5RnIDWXgY+2Tc/Ov+c7LJxe1E23WxpbVNNNfUTAC73IvX4Sb5J7Paj/9N+E/xpz2H64W//DeZkBobRurL/xox972jwEwbAbsIlFjNy/Ku9Pto/JUCUPe2/yeNVSjWnGQeVtvlOeZ7SORcM9V058BaLzwKI4zgYughaxSJawoCrcKJgbmmZobGgU5wU9ApDhOKeRx/j8OHDPPzgI/zVn/w7/uV/98/5xtef5rf+9m9y3913cOLIAQ4cPgQmw2VDtBY6nRZJp8O9nRbX1tcYDIdcu3aFrBiyvHLIO2aaIVE7ZenwQeaWFkjm5kELrG+AcrQX57nn4Qf51te+wVtn3yPttHn5pZf47ndeottu088Lnv32i3zkkQeZb7ewuaXX6xEpTTtN0aLoDXtYJ8x3fT7k1atXMUVBZ86DYG9Qo0kSz54ZY8aAZgVQA9AsX8vzvHpeIQx6fTajiDRNPQjMsgo06TgiVkEFqDXtJKE36PPGG2/wjae/Safb5aMf/Sj3PXB/yChVpGmbQVZgBJKWBwFJEgEWopiNixd58ZlneO4b3+BnP/kYd566hXYSc3X1KihNhDdqSdOYPM/RUeSzKY0hH2YUWY5ykCiNLXKcMRCcXZHwk6g0SoR+XrCQtNjY2iJqJVx67yzvvPMut99+O4cPHybPc9ppSpF5cE+17NTvM1GVTLgEESX4Lk2S6mY+9YmVoij8j3QUjeI/7LgzL66eJTuSR5aGTSr2fa4yBmJD5mWIzSjNYCqTJzxoipLYvx7AtbPe+qaUwhbWgoVBnpEVOYgQt9p+UgAhLwy63Q6Zs9AvMhzQarVpz8+TpCmd+Tn6/SFvvvkGzzzzDF/76pe5enGde+46yZMfepxbT56gk8SkWqOs8Rmk1tCKNAUOcb4P17gCHSnEKr/fnEWUMMzDuShBvhtpojhCx4mP+lEKIx58uepYaCIVoyKNxSsAXBHyL6XsO9Xe3CdMVpSgrJSUl2rj0lRLamDSH59a32yYEDNBXl4qMZTyF85YFFBglsu+Xr9tIc6k7HMWwZUst/ieV5cZVtfXyK3hxMmTOCVBbTAytjIhmsYG1lRrLZP3aVUqTap78YQbLvWJDedl17jwG+F2ZDOn9RTvNA7bK7j9UR6n/DiNn/bLPN+M8deP6/j6x51xvxnj5oa5bKqpprZNnMz+IZEd3SdnR5jsrcdz8n2TbrHjs/2eeZVJzwukApg73eAtNUMTFQCwCvI2pzBYzl28wrFTp5mfX+TE8Vt4/LEP8c/+yT/h//7/+Cf88i98ko8/+SFOnjjCbbfdyvzSMnawVbmyKgUHDhxgY3OTzf6AIsvp9/vecVZrjClI0oTQBYYbZgyyIWmS0F1a4M577uWll17i2W+/yFe/8XW6rTZPPPUkH/voU7z77rt88T/8B771zLPcf9cdLC4uE0U+P3JjY4M0TYnjGGsdw+GQPM8rMDMYDEjTlIWFJW+2Y6UypCmBUZIk20DLNIDvnCM33sk2ShPSVouk0/bLyYYU1qAiDwCWFhfQWvP888/zzPPP4ZTwyU9+kjvuvov5+XmMgNMRKk2wOHJjSJQ3dlELC9Af4LY2efvVN/jW177BQqfNow8+yFynTTbogS28uYtSaAGsI07jCvDZwGiW/aK2MCg7oixLYIDy8llCfMbqxjppu8XFixc5c+YMWmtO33ZbBRxKQGByz+KCNzgqX5vGwpcgo35+j/pjJ/pfS4lk2VtbB6FKwLhtx8qvhBrr6awvo1z22DICU1n2UPp+PF2xdka8u7Rof30ZrO8T1hoVJyityQUvtVcREimSTpuNrS0Ka+l0u3QXFomTpOptXF1d5dVXX+ULf/03fPuF77E0H/GLn/8kD913L900oR1HtKKIWMDljMn4xe16M6kYPFGCVVIBQ9EKqxS5sxVjWT6qyG+zhcpAp7TYEa2DY7BUcR+TPeyVXJ/auRUktWPuu9ZRU9rufwCopNYfXDvO5XoJ1bHLTMGwKIjihLTTJUnbQTKtpl7fNzr43+13pPFqaKqpn+xqwGVTTTXlh04yDr0k9C6ODRoql9jwt534HlXp5qa6y46eU3sCmJOszraZNadGg7N6zl+1FDdCouB7SGs5c37mfyQFs+I72KwIEYrlQ0cYDnLShSUOJimfWDrAbXfdy5/+0R/yz//7f8Zf/U9f4mc/9SSf+MTPcOqWE5w6eYKFuS6YAr28AkXOUhShky22+j3WV6+y1dug1e4SpUmIEhHEeqdGFymsWHSacOL0KX7l13+Nr3/1a5w9c4aH7r+Pz3zmMyzddhs20rgk4vs/eJ0jKyssLC770EZ8z1Vhfe5lnCT0ez0K44jiFKVjsiInyw3WDWjNdcnzPIDQAYPBgIWFBZJWjLEmyAq9+6zSIR8RE2SBYeDaG3hprjW0Ox2SdosoiYmwzHe7rK6v0e50cEp4+tln+NrXvsbc3Bwf+9jHeODhh+jMdT1bFmmSTgeSiKywaCcoFTF38DBkORSG8++9y9e+9EVe/e73+Tt/65c4fctJBMugN/DskDUYU2NalGeyiiLIhp1DKUGMZ4lKtrE8x6oQevC9diGHcmNzi6ura3zvlZd56KGHOH78uAdnReHfb6xnzAL7U4GO+hUwlhepqgiLOkNZMpaVpJNxQDKNyTc4z7yVzJgo73xasmQ1JqgElSWwLOXS1jkPqrVnKcuL2+qgu3Tag2glGISiMGTGVPmj6AgT1sUp8QBOKda2tkjSlDSJiZKYVrtN2mmzvr7OxbNn+PIXvsh3X3qJtatrPPbQnTz+6GMcPXiQuVbKQqeNsoZYxDsZi2ARrFOADcBcQr+qCqoJE3pNfZ+l75skuNZqVJSgkginfB+sDcdIqwgp5bHag8cypkkp5b9PjUxzqkxLtk/KjYPMiuMbu3e5WoOsWFeZ6VSg002/L0oNWKparEnZH1zeBiVIe5VocgtZbtjq9UjaLebm570LsxuXVO8FNI4iUtgzM7NbrEhTPz6Tz0011YDLpppq6gYB5nZL/N1iQ7a5G07px9xLf9lOP2b7+fykAQUlp+DH0hgZRTaUgmAroNE4HEk75cLZMxxYWCBtdYmiFrekLf7hf34LH/n4x/gX/+z/zdeff5bX3zvDE489xn333MFdt9/G0cOHWIpTXJ4jScLCUkra6rC5uUlvMOTq1hUfz5FGRImX4UUKkihGrCYSxdzcHPc+cD8rKyv0t3qcPn0aNdeGzXUya1BxQma9K2fcSllfX8dkBTqOiZWAMxSZJbOmYnKNohqIFkWOMgXG2ao3q2Q5J+NqSjA05mQKtNttCmdDn5rC4MiKnFgnJK0WKtIsLi6SW8Mrr7zCCy+8QKvV4oknnuChhx6i1UqDHLMgbSfEaYJVghZFmrS9k2hRQBRx7fwFXv7OS3zpr/6GJx65n6c+/GEY9smyIcr5/lHvGOr/LRFkWYa1BcaYKnReB8MbZ31khqr12vluXQ+WXABLURJz7sol3j3zHkop7rzzTrpdD8ojJnrogEhrlKgxlrEOLoFKZjx5zpbSVGttzYxmulyw7G+dZDMr8DjhLloeQ9GqMr9SIgFUhTgLpJZ96+M6JDxnwzYUhSHPcx/REmmKIM/ViSKKUy83xfc4KiBpt2h3O6RpiopiLl++zLe+9S2e/dY3eeeNd1g5sMDHP/oEDz/4ICcOH0UrcHmGyzOU+H5JZU0wYirZOb8dJVM87b7klHhmTvCspI5RSeRlogIWhWhvAiS6FilS5nWqGlCsZcSWJkbj4HF0TOogUIUJCoK50s73X7b1/s4c5NcYaDvtPQEIu8BC53nORq9Pd36B7vwCKmljQtprlbtZ9uAyvg5j4HACRO/HiK0BKw2obKoBl0011dRPTVmqHssZuZWlSf60qIupfRnl1LudFZZdDpT1TCBaH6zMGrS48Yn0qu9Jqpn1if6dwHog2rtzOuczEBwefLjg0CieueoNCo4cvwWxhksXzrPYnSOZW2BueZkPLS3w2Ic/xJ/+0R/yO//m3/Dbf/wn3HnqJI8//DD33nkbH/+ZjzLf6ZLGAjohbftIhzjJgvlJjqEg621xbaOHOMPC3Dzddod2mhK3O7jCcPTOOz1zpzUMhxCndOcWGBa5Zwk7bZaPHCbtdFhdXSWZ66AlQpRi0O+TO4eKvNFPkRUMB0OMtbRaLbb63um2nSY+tD7SVeh6OTAtJYM6ijyYCWyfCm6zWuvq0Rjj+++U0JmbI0kSMlPwrW88yze/+U0OHDjARz7yEe687Xbm5uc9YxRrJI6JkwQLZIVFJQmduYWQEWnJr13jvbff4fd++7c5duggn//MzxJZGGZDxOZo8TmHzjjfY5kkGJv77Enl+wSVgBQWazIIJkTWFYhKPfgARGlERzh8H5uxkPWHrK1t8MrLr/Lkk0+yuLxCHMcM+/1KalwOtHXprioqSE2DvDU41JYgrwKNtQgXyozK4BKqAxisgGU4v2sXB4UxY718JRtal9i6ElyVrJzybF9hLUppREUexJVRIs4bIaE8A2oFCuujOzyoNP5+oRVR2kLHkT83FaA0RNoDd2tYOuT3VavbYTgc8t0XnuWrX/0qb73xA0xe8OjD93Lf3fdw+pZTxFqw+YDF+QWSTotsq481BVJYjPWstN/s8h6jQkSnQPma6OBkGyJotM/PFB0Fuav2177474mSqJIBOynji/y5LUphLNXrTJgi2RoQq//n70dS9V1OgvzqHlhGkdSk1bOG8hXDWILXupFQbf3K+CUl2k8KiEZFEcPCsLW1xdLSEu25LmiFs9Pu99OBxV7ZzVmTjw1IaaqpBlw21VRTPyWg0rHDgCawFvW/dxuEzAwPZ3d2ctr79jMTPtbnM4tBLaNVsOHfDil3gRMnjqrnEoQ4SdjqD2jFCYsrhxkO+2z2t0hMAmjmlg7x63/37/OZn/9F/uyPfp9/+T/8f/j9P/lTHrjrLt54400eefhBTp06ye233060tEiStkgKy4KzOGcweY/NrXUkN4EJE0yes5XlDDd7pGlKNBh69k4pP4iOUw4cXOGBRx7hq+fP84N33ubUrbdy8OBBDnVaaK25euEKV65c4ex7Z9jc3KSdtjh16hSHDh0h7XboDfoMTA52ZOITp4k35PEOuxU4mpRUlq8BVXxDXhRs9nvoOKLVadPqdEjbLa6urfL000/z4osvMj8/z6OPPsrtt9/OwvwCOo5BNGmrhUoSjBaK4H6aJAm60wFrIUl4/fnn+cM/+AOuXtngN//jX+XowRXy/hZxpLFZkJECUYgfsa4gyzJPQuoIHeSfxuSYPEeMjy3x2YcEtk4QHSFakxvIi5x+CJ5/6+23SdOU07ffxsKCj5yJ49hHmgSmMdERuuyjtG7b5Eg9N7JyibXjF7QhBwAAicJJREFUofWlTHcMgNZqsge5/t6SDa2caT3UGJnDlMASynxDD8QCILbO3w+ssxXLqyKNyXOGRU5uPAPsREijGJ22kCQmimOsQFbkOGdJ45S5TpuF2Js8bWxs8NYrr/Dtb3+bp59+msuXN7nr9hN8+NFHue3EMS+BnZun005RxlFkGUUOcRSBg0IVgf0LzLkYnBUUwd241mdY7g8pGUYRtPL9lYiXt3oXY4VToEs32DChJCJeXq5LljKAzpLSEyo31mkTYXU2bzRlt/090ybQdru/lY9Vn/hEn+Sof1xqrrf+2Pb7fTbWtzh8x53MdefLOcMpLsLMzk3Z4zru5T1Nz+WPdzURMU014LKpppra+UdCHFKJq8YZSsekrHTnAdFOg4frNfWZfG2y36z2ImInQeQISE8gZz/srqWYKwTnpApOFxHyokBHCVfX1hFxzM3N0Z5fYGNjA6Wgb6GVzrFwtM3f/d/+l/zKr/46v/M//iv+3e/9Dv/md/6Ub3zjaR544D6eeuop7r//Xo4cO0ramQM0rsiIOh2WlKUbxxRFgTI+n6+/1WOzt0FPbbF+bRUlEQtLix749oe0uh0+/dnP8PpL3+HFl79HPy+45867iLSmKArOvv0uFy5c4NqVVQ98koRzV65wzz33cOrUKbqLSwx6mzhDAFMGC7Q6PlZlkA094NQR1tmKyawPkJVSRHFMt9sly3OcEtrtNotLS+TG8Oabb/KNbz3Nm2++ycmTJ/nc5z7H0aNHfX9mnpNb441Fyp4xaz3D2k5JWi0/UDaGM997ma9/9Ws8/Y3v8Y//3q9yy/ETJKIpvMUpzhmsLXwWp44oTIYr/GFN09SD5KLwmZxZhisMUQAmKD2KXXGe4UMEYwoGgwFbWz3Onj/HhQsX+NCHPsTS0hJxHNPrbZLGMRQGk2c+EiNNiXUUZK1FYK1CNIYNz2mFjgRRPtfS2hEYqfdajgHQiYmS+vVR5pSWzGUJqMCLB7TW1XGD4Cwb3u8nFVTteSrGz+FzIE2eB5bdr3vS6qAiTawjJIrZKnIKUb6fMUlJWy3awY04NwWvvvYa3//+93n6m9/k7bcvsrLU4mc//VEeeuABjh5cIRHLXJISiaYYDFDGkURhMiAvKkZ5DDyZ8hr31l1+P5X3nnCdK41SGhOyOCVIRC3O3xpq+6kEpGOgbKwne1yK6pgNLKt/1yYMXO0/Ve+3rLGVM5UZrm4nVE4KSJVNWUWHBHMf0apSmZTrXwCbm5tsbm5y74GDdOfncMZgVFzd57bdf3cDkG7vILJhL38ygWVTTTXgsqmmmppSqhqMTbKUe/1x2bXn8aasp0VEw4SZkIhg7N4AqogOtvnlNiuCNb6E9XfiECfWqSCdFfFAIc9z5ubmiBLN+fPnmZ+fJ0kT8qGXt7YXu2Qbm8h6j7nTt/OP/4//FT/7+c/zB//2t/nv/+n/wBtnLvH1Z57joQcf4NOf/jRPPvkEh44cQcUxDPpgIE7bxAmQF2AskYASR5Z5+WyeD1nDoKOIVquFK2LmOl0+/slP8Ppr3+c7r7zG+YsX2FzfIMscxRAiDQ8+cDcHlpfp9XqcOXOG4cvfpdVpc+rUrUCHIhuAiJeywkjaOhz6AXdrxGghvmfT+HRUEEdvc4OklRJ1vatr0mljnOOVV7/Pl7/8Zd49u8VTT93Lhz/8YVZWVmi325UzbRTHlaNlWUmSkLY7Pv4iy1i/fIVvfOXL/O5v/wU/+4mHefiB+zm8uMTWtTUocgZZH6UssdK04gQlQjYYAtDttj3IyXNMXvi4kNyiUago9JDignOoBHCpcaLIrWFQ5AxNwdtn3iNupdx6x+0cOnSIa9euMdfuMBz0iMVPBkgZzRJ5cG+tHTPTsXhGVtUkjWUPZhRFFcCz1ruXKq1BpDL7mcyqLK+5OI5rfYHlue5wTnDKoVRUXQtVz6dWRNrLf62TEOVhvTFRbV0KZ8mygkE+BBSdTovOXBcJExjGwcLSIkQxOkpI2i3iVpter8crr7/BD37wOk9/42ucO3Oe3hbcessiH33ySR5+8EGWF5eIMMTOQVFQOINGULoE1KDiCJPlPhqjAimCC6DbS1l15fDrbw7eeAjx7rCeadT+uIZ9ZpxFO4MK57oEh9yS3a2krII/DsH4pgR3Y9JYxl1rnXOo0Luuwt9lBizWjiJIdpDATr2fObaZ70gwOAKpmRiNQCjVhJCi1x/QH2Z05udIWp1qUs6O3U81kAOCctY74jrlzyMnVazUXiYH9zJJ2ICUppr6yS2pW5hvm53ih59T85Oeo9lUUz/cWUiz5+trp57I2deq2iYXGzlz+gHRpKvsdoBqgius2bZugh5bxrQezdE2eFDpB0keQBqbz7rvuDKz00pp+GPGvlucQwe3R+cMSoRYKWKtQHmG6O0Xn+cv/uSP+bN/98ece+sHdNKEe+66nV/43M/xmU9/nMXFBUQL2IJhbxOXFbRCfEZ/a4tIwerqKhtr6+QmAI1IM9ddYHF+nm67zRsvv8LXv/51Ll68yGAw4OTJkxw/fpxTJ09y/Ogx5ubnGWxu8aUvfYkvfeGLJHHM448/zu2nb0WJ4eqly1y4fIl+v8/CwhJLS0tEOqHdbntJbbvtZab9gc+uFB+zouOEqNslyw1xHKO15sy77/Hcc8/xgx+8xXAIv/j5j3Prrbdy/JaTtFotRCmSJEGUIy8sxgn9IiNOUpYOLNOdX0ZaKRQFva0t/vj3/oB//a/+kCcfu4Pf+lu/zoGud+LdWlsD45m+JEmII4VYh3JenhqXICkv6Pd7DPvDim0V8bmncRyTG9+3mhcGYs3mIEdHCRevXqU/zDl37gJf+9rX+NznPsenP/FJ+r2eH3hbS6IV62urRFFErEfztJGoytQlyzIGgwE29+vZarW8UUzo+XTBtXaYZeR5jlKKtN0CHfIxjXe0ldDfWs+6VEqRROWkiweTInp0fiv/mBuDV5UqoiiusgwLB4VxoCKfRxr7826Q+3Ue5gOUjkk7Ka1Wp3JRjZI4GMk4LML88gHyAtb6fd4+c47nnn+e559/ntdePU87hsU5+NRHP8zHPvIRDq8cCLmsBQqHNQFUlj2KjpC/GDIfS3l2AMZlD6m/s/j9WPasjhkoBQZSx5GXwwZmz4n4uJvA8uo4QXTst805XMkaRzpMfNT8pmvg3jmHqeU2SgkagxCi3BZTZCP3V2u9s23YPh9FYv25YIzPJXWj3MvKHEiP3GlLcCsBCIPvhZY09U7T1XYqREW0unNcWt3gb776NX7/L/+K/8X/6j/nl/5nf4d4cYm+gzjqoKOWlBMcRVFU55s3flL4tGA11r9el3jv9NuxV4B5PZEmTf04jC+a4/eTdiz3Wg1z2VRTTd2cmapdBhLbf2RKsCez+zHFhjDw8Dgmb9X7nHQqs+BKGw7xvZUyi/601accrmIixsIFRGOVNyay4shFKHCoAsQVnH78Cf6z++7n537xF/nGl77IF/7yL3j5pe/w+us/4Hd///f5jV/7FR566AHuvON20rklyIb0N1cR52gvL2A3t5if6xBHvm9qa2uLQb/H+jAn621hF5c4duI4v/GbfxsRhzGOJIlQKkJrH/JnbEHUavPAww8xHOa8+srLPP/Cizz33HMszrchgKCrq+v0+3263XlOnTrFnXfdxcLcIjqNMBkMje9jjLQO8uA58uAUemVtlddffZVnv/UMly457rnLG/fccdtpOp0OxpgqE3F+fp7OXBedKqwTTB/anQ62MGxtrDE3d4J8c4uvfuFL/NHv/yF3377Cz3/2s9xy/BiD9XWGWR+bZyhx3oE0yKHjKKIdeWBpspxsMCTPhpgsD2Y9Ch2AhI5jJI7RWhjmGUmnw8ZmjyRtceHKVdZ7faIk5tUfvM49993LnXfeSZZl5IMh7VYCFg++ar2R5TlscKgANowNnY+RrsySJLBqCoW1I1ZOx94UqZJshp4/VABSkUIRHD1F+8SQ4Fxafm/ZJ2vKWJZK7e4diD2bp0JOJVgFKoqwSrE1HJJlGU6g1W6xcPAAcZqQFQWFNZ7V0xGSxCRpStxK2djssdHr88qbb/OtZ1/gG888z9kLVzh6dIUnPno/Lh+ycfUSy8vLLMx1mW91EGtwRY6K42A6488hizfV8vmQpSOxG3OqFq3GGL96X6rgjZNMzVpHMZKLVvEiyvk+2xobXBkgUTrDBmnoDmNi5UaGYttuHZU6fzQR5W9fbmbLgFIKbcMya3JpcRPrUUp3AUEHxnEkC7YiCKURk3eK7me5nyhodYiS2O8Dq6auf325zpnR/RfZkZVsAERTTTXVgMummqJhxt8PgDltxnIv+3lvs5xlDIC7rvWZui5ObX/ftvfLtudxbkyWJspnbhpXeMalMKytXuLg8gK3f/ij3H73vXzs45/g2ae/yde/8mVe/d53+X/+N/8tp285zi/8/Of45Cd+hoNLS7TSDrEI/WsbtNMErWKcHTLsDelt9BjmOa3EokW4fOUanU6HdruDKQxxnIBo4iTFmoK8KBj0+yRJypGjx3nkMT8g/+5L3+Pc2TOsbaxy9PARDhw8THfhAOfPn2djY4szZ88zLAz33XMfzlk2NjZYW73KcDhEOWi1WnQX5tnc2uIHb73JO++cxxk4cmSRRx85zemTt7CyssLCwgJpmiKRZjAY0B8MWF1fwwnMLSxhbcH8/DytdgeApNWG/hbf/NrX+Vf/6l9x+PAKv/JLv8w9d93N6rVr9NfW0M54+WwSURRefhpJiAAJhkPD4YB+v4fJiwBSvLGLiAuJEjUH0CAPjVspF65cYX19g8XlFV544QWKLOdDH/oQJ06cYGttHcEzToUx5MMMFampcSFFYNvy3DPjpVtr+R7PNHogY60BJURR4iWy5bWgFZ6b96BSRdqDy5rBkgtSUA8SPLC0DkzJ9hHMfiKN0wojypsmBeBbOIsdFiM2NNKk7RatTpek3fL5mXGEVjFxK6XdmQMlbG5ucu7cRc5fuMQzL3ybL3zla2z0M07ffju/9dmf5bHHHuHIwQP88e/+W759/lwFfrXW5MMMawh5kyUwtOPqgyrXs0RpHlSpiVzJOnNWObjaEqYyHrMR+irRntWbBJZAlR05boo0+zfB7WOCbWxiqpZzWQfKqvbNdSWG1Jxg68sqe0nVRJ9kud0mMKKbm5u0Wi0WFhaIWi0KV223THOFrbsN7+QAu5+MzKZ++sZPTTXgsqnm5nBDYKIBnz/dYHJyX+2Uhzn+mquiBcqeqrGBGrMy1dyejsdOst5pYLa2LHG+dgDB2kvj/JC/ikDAedDgUHSWW2RYVK9PnLS59SMf5dYHH+ahxz/MC888w4tPf4M3X/8+/69/+i/57d/9A371F3+eJx5/jBNHDnH8+FFcNiROO3SdkA9y8swQ6Zwoioh0TLvdod8f0Ov16ff73nCmlaKUHsVKKE1/MGDLGFrtLg898ihHjp3k0vlzZHmfI0eOsLS0hFKKa9fWOHPuHOfPnOOtd9/h4oVLWGvp9XoUeYYWhbE5JiuC6yZorTh8cJFjR49y4sQJDh48SLfl+x3X1tZYWFhg8cAynW6X3qBPrzdga6tPVljmFuZJkqQyHRr2B3zxy1/ir//qf6KVxvz6r/wqjz38EPlwyNbWFrHWiLGo0I8YxylJ6CF0xjIc9MlLxtIYykBTLb6vzgYAhrWe2QsRK5v9AVme0x9kHD52jHfePcPrr7/Ok09+lFtPncbmBWDppC2KfIgpcqw1/nunTGSUUs6iKDz4LSWtE5MXZewLWhEnHlwWzlKYAuVtbL3Esg6EaleJsaO+Oees708UhcNhtCbScZVtafHA0phiJG8U0JEiidokie+b1GkCoV+0QNGan0PpmI1BjyuXL7PZ2+Ls2fOcOXueL371qwwNLB4+xmeffIpPf/ZzPPjgg6hOi+GlC+g4ZWOjR5FbBpl3nC1Z2gocOR/uWAIuG9hKKfsVRbYZz1Trj/NSUvEGRDr08E7etksXWKdqYDPsE61GrGVpjGP3cb+vXFanTkpt/z0ZB9C2miyYBk5LOWx5roy9T3xcTdnDW35KOVWZMxnr9/v6xhZziwssLS1BHPvzWUUoiabeDycB5H5MeX6SpJA3+vv/4z5+aMBjM35uwGVTTTX1Iwc0ZzGZ459z1zEoUXtepzow3Q6A9ZTPlOwSVabJ+Odq73UhM6/8GzwrggPlpbKFzclNjukNaA8LOt0udz/1ce5+5MN86lOf5oVnnuGF557lheee4Z/989/jD/7oT/nFn/ssTzz2KLedOsHSwjxz7S4rhxLPUBpDq9Wi1W5z8fIl+ms5/X6fwWAAKvLRJc7nWqZpirLQ29yit7lFp9VlaXmFhcUVjh8/Tpp6g6AsyzDGsLC0wqFjx3h35T1WN7d47913mZvrsLy8TNpK6LY73kV3mGFszoEDB0jTmLm5OZbmF7zZUZKQ54bhcEiStBgOc3pbA5YOtDlw4CDdTsba5gaDQR+zZkFDpzPHVm+T5559nj/8/d8jzw2/+Rt/i3vuvhslwsbaGpEoEiXkJqfT8fLKJEk80LKOosgrx9WyvxIVpJOUPYIKEYVR4MSRWyj6AzZ6fXr9PsdOnmR9Y4OvfvWrnD59mg8//hhpGtNb3yCNNZEIg62cWGksEuSPoz7AYP2JtQbjCqxYdKRRsfKxFtRkkqXsU4OIQhIFWuNMEGFXjq7jky6E7TUIubPYcH5a589nUWXupUPpxPd44lv+cleEtkAJhkMFc90W3flFdBxRWC+VNQJGvANs3wn9zR6XVq/yzrvv8f3XX+P7r77OmXPnueveB/jURz7Kz3zik9x7/4NIpwtY6PdY3ewhcULSTml3O8RxHPpdUySiAo5+ddQYYwmlKU0JBsu+QyowKo7gZBykwvj36ZIhLq//0GtZykipA6YJ0M7kfUJ2vs+N7hWjOJP9DDjrzrET2HTqMivH3Brwq6tmxakxxtZa6A36rG9tcvDQEZaWD4COKYY5orebRE2yudPicHYbVE9zim2qqaZ+uqoBlw0gaHZCs39u2v6ZBRBnz3zLLp8ZgcOpPT5uNpDcyzHcT47mlGdR4vsGHT57r+qHEgei2Br0aacxrfklpFNgioytYYFWQiwRR+66n8+fvoOHHv8wj7/0UV793vd47umv8+/+8gv8+//wN/zsZz7B3bffxkP338+Jo0foLh6gyPLQbxdz+PAxWmnHRw30toIkdEhv0Gc+jlhdXfW9mutbVeTGIC/IB57Zc5lFRZqsyL1pTBKzkMQcDmzmm2++ydLSEieOHqPdSr0pTRoTRylp7B14kySpzGBKxq7b7bK8vExRePCTm8JL84xFh77L+fl5NrY2MMZw6dIlnnnmGb785a8Qac2nP/UpHn34QdpRQq+3RVFkpFrhrKWTdlhcXKQYDrwZTn9A1u9Vxz6OYw+OTMjwVB5QOme9wDTyLGaBsLa1RWG8PPToiRMUxvBnf/ZnLC8v85nPfIbFxUVMnqPFESlNNsxwzpLEKXkeTHNK5ij0ytX3Q5TExElCHMW+96/s07OhN9IYosT3gapIhz5IQYn24CrSAcHIeL6oOArrKAJgduDXQ7lg9uJZLc9kOnAKi8UqjWhBqwgdKVpJTNKKIdYYUbhYcFqRF4bNLOPq5cucu3iFt8+c5fW33ubNt9+icPDIo4/y6//gH/HgI09w+OhRFg8ehqQFWQaRgigibnfICsPc/AKtdpek1cY4IdYeAJrBcEwmanHbwFaVWVkBwdq1ixu5xJb7VdUiRErJrZKKIRYJmaalPFaCtFiFzmoZATW7g4P26H7gpufq1vJL6+9zu9yHqq+pxf2UzrXV55XvHbUBgJdRJgFzV1BTRCicZWOzx+ZWj1sfOsrc4gJVP2p9384EzzLzHj/rfr+TguWn7ff/J337f9qZzWZ82IDLpppqbg4f4P7cT8/ljuYQToVoAbvDcbPVgCkEi9TeV+9zKwd52wdzO0Sq7HCCCII4EReYsdGAzQWGpdXpYI1hmFmUViStLgrvyjgcDul05yHJOP7gYxy//U4eePRDPPrEE3znhRd45cXn+Z0/+UuOrCzy4L138ZHHH+PBe+/l6OEjzHU6EEfYfp+FlQMsrBzAWsO1a9fo9XpkWcb61qaXiA4zHIYkTYhjTZYNGQx6xIkmywoQ35e1uLiI6Jher0d/sMXa+jXiSDE/P8fS8qLPTVTQSRO63TlaaRwyK4cMBz0fRZK0KubIA6eUKIq8aYx1bG31SdOUVrdDmsaIFi5eOs/T33yGL3/5y4gIv/RLv8THPvYxIqXpbW5i84KFuXk6SYw2BoWPaNlc36SVxhXrWprr2AiUsyOKWSucKD/oDmCicJBlQzJrUVHMfLuNQ/Hlr36ZK9dW+U//8X/C6dOn6fc2wXnJLsaS59nIcTbR3iBH+++2OJQSrPFy5MIa0jRFxxFK6wpUihIcFmscVmnvtBtHVfyH06qSWjrlwbGXOFP1IFpnKYwFiUGpkWxUl6yV9d7GpZOqEiSKiJU3DfKusYr5+S7WWvp5QVYMKYBeUXDhyirnrlzh+2+8wZvvnePaxiYHjx7lM7/8qzzwyKPcd+8DHDt1Ct1d8hkoARAWShFFCRgP3jf6PVrzPvey1Wr5fWMUkYQoGGdw1lUy1NJBWilLdUGXUnMR/16REJ3EyHiHkeRYaj2WXvrqI2Zs7d6hyh5Y8bEvqg4uJ0CgHcVcztRLTGMunXO+F7I2OTZ5O1FKgbNVTIobazGVCuyOtQjUlmmdC92lrvx/JRNGaYy1rG9tspUNOHjkMO1uB39iKLSKZbaiYxxATAOcs4yJmmrGTw34bKoBl0011dT78qOznx+WnQx9Jnsvr+eHT2YO8qb3VO7VDVGsqQZ/Wiu0VuKBpQYc1lqn0xSAPM/pD0fgRCcJ/d6QNI68q2Q6x/EHHub4XXdz130PcuZjH+dTP/cLPPv013juG1/j2e98l7tuu5VHHnyAO++8k6MHD3DbLcfptBNAoVRMp9tlcWnJS2SdY21tjXhRM+wPsEWBcX6I3Wq16M61mZtvs7a2xpUrV2i32+jY0e/3WV29xuWLF0mSmFYSoQWMKRCEOFJoZbF5RhrHRJL6sPbCu8k6IEnbtOe64Dwjp5QOxjKe5TTWmwRduHCeb7/0Ak8//TRzc3N8/vOf59FHH8UZy+bmFuIgihXtOEJZiykMeZZjjY/tyDK/P6NOm0hUlTEpkSbRCcPh0LNTyoMWK2CdMCiykPu3gBU4cPAIf/2X/56vfvU5/sE/+I+44447yLLMAwA8UMnzrAIEhc3RcYzD5wG6yvHUR1QUzpJbQyvy7q9WhwiRYARrxL/PagVJhERRkPX63E0pXWAJsk4882YCu2edpcCidOhH1BoVSdV7WMZy6DjygEN0yLf0fZ1R5NnSy+sboIVhlnNlbZ1zly7z7oUL/OC9M7x34SKbg5w777+PT/7Kr3PfQw9zx513c+jECUjbkFlIWhhjwXkHXqQfbFQ1upUgyjsLqzih1WljtgaegdURkU7I8kHVg2icCzTcBPgKYMuOCxWweHa2Dsqcc1XGo1ISWGW88VZgNm14TUT713XoWyxdakUqx1Y7kau7W7zGrHuQyGxTnkqaa91UAFoCTBf+jZSSXxVyPL3MWqzfLm8c5Pdb4Sz94YC8KGjPLxAlLcBVKgam3Wtn9I1Ok9A2ALOpppqaCi7fb9r/Rhuab0ZO5k4ZSs2NsKlm5vHmv3caYJyaRanquZbldekHq2PfhR5zW8RNv79MDoxmzcjvZFAxy25/MqsTIFIi1fZYn39oQ/5AyYIUQc7ocDjlB/8uMFE+yN15R1AByQ2KiMO33s7h07dy7yOP8ODjj/HJz/4sr73yMi888y3+9R/+Me1Wyh2nT/LkIw9z5623cNttd7C4OE8cJ+g4Zi5t4Qrj3UeNxc11KIYZm+sbDPMBrTQlSmOiNKbdToljzfnzZ72pS9Ji0N+i199koTtHu5WgFSSp9oY+eUa6EGSt696FUpmIzc1NjDXE+GiT7No1lpdWMMbQ6XRJ0pThMK/cK999921e+u63+eYzT3Po0GF+/dd/ndtvvx1rciJRtFoJsY4QU2CN8WCvKLDOokQjkaOdtHDBOKcoDBJpUq09kM+GtLtdrly7io4SuotL9IYDtvoDfwy05sDBw5y/eIG/+cIX+dM//yp/7+/9Go889iGyIqfVatHvbRKpCJNn5HmG1opO6Dvt9/voJKUQF/r9oBhmDIY51kLa6pC2OgEMUjmUWmsx1pBZR7vbBq0pALT2rG+IwgAY5gZnQiamCKJ0AGLgNOjYT1QoHQxrAuzSkc+ijFttn4/qFFGaEMcJ1jkGWcFwOODchUtcXr3G5avXOHvxAm+8/S6X19c5cuIUj3/sEzz1yU9z/NRpTt56O52lZYj8RAaA0RGFFYj85ElhLOgIm2ckiWbQz7h8+TIr7dQbyeDdXSOtsdbhxIV8SYVxuZ8UcJ7ZFfEya61CT7QzwQWWYPjjgVpRc5MVpYIjsKBUcN1lu7uqaO0jhARirfHSe/8lpQZC8EyvUFdh+J5YRFA2mA2VfOiMiShXk0lP/odzlZmPRrBBXuvvcyMpcHljrKS+ZV6ncxhn0U4RxxFRFGGcJTfGG0lFEZsbW6xtbBF3OiwsLhLNz4GxpEmbLMtdFCuZNPKp3/dKcL+fMdNOgPSDHv+939WML/mxPn5NvT/XBDTMZVNNNfUB/tBs+8GdKcua/vx+s9Vu1LlwGqM6lj/nTG346nM7FVY8mLROiPwA0jmcKJTzDIxGsAqs8cNTg3g5WxjiFmg0EHUXuOuhx7jjnnt57KmP8sTPfILvfPsFXvrOtzn39g/4nX/3JxyY63LLLae46647ueuuu7jl1AmOHjpMMjdPq5X64XKWsXlt1ffVCQyzjNXVVbZ6a2TZgMFgQJZllWTQGN/X6TMzlc+7EyGKNHGsEWcxecbCwoJ3Nx1YDxSygt5wgFOatNXi/MULHDt2DFE+p9MYx/r6Oi+//DIvv/xdXvzOy3z4w/fz8Y9/klO33Uo7SUd70+Tkw6FndZ0JYfIRcRyjRNAIRZERxRGtOEh0s4ysyHBaE6cJqxubHDp2nLywrG5ukVtDP89Rkeb4Lac4d+Ei7545y7/+H/+a//Q/+WV+7ud+jsJkDLZ6XNnYpNtpUwwzcmuqHEqr/D5qzXXJsaMfUWMocDit0HHkpbSRB4wqSFvzPPfscdiP3ik29AA6PxEBPq/UGBMAkqtMo0R5w54oTiqw5pyjsBax1i83bXnGUgSL0J2fR8Uxw+GQta0+19bXOPPeOc6ev8DV9Q3eeu89zl+4RNLpcvs99/C5D32Ihx9/gpO3305rfpHO4hJ0Fvy1an0gpbGQY8icoK0KsSgFGh9nApAVuc9FnW+RJGWGp/EA0Hmmzha2Ouecdl56XYscGbuWwz5wdnyCalteZZApV0AsgE9C76VHTeH+Ursv1JlRW+u9nNpPuA/mctoEV+UwWwOa07ZXJtbHx61I1V/qAqgeB4QaJYrcGIyzDE1OZ2GeueVlUF6eLkqqNKdZ99VG0thUU01db0XNDaSpppr6IAFm/d+W6eCv6sJyO0eL7OZGe6M5bLvNujtH6LYEiw2RCsaP/bAIpur1VL6xCgUoNAIUwghIo8AJynlQUIigI0XcilHtFstxytKho9z76GM89c5bvPv6a7zx0gu8/v2X+e7rb/LCy99nZfkAp06f5N677uT06dPcfccdLM53aSUpnYVFVJRg8iHZYEg+7LO2dhUR5xm/TptOp4NSimGeMRzmvh8wOJZqrUmShCjy8tPNzU2iuGCQezlsXhS+Z9BCYQyJQGeuixNY31hjMBiwtrrOiy++yIsvvkivv8Uv/Pyn+NjPPMXx48fp9fsMB71K2rq4OE8+tIjyLphaSfi3l6oqfI+hz/OzZNaRGVu5oaI0UavN1fUNclPQy3JEaZYPHyaKY65tbPKVr32Nv/gPz/Nf/pd/n4ceeoisyBkO+j7vUPuBe2YKcufotNte0msMKEWSJJjC51ha6815cut7HaM4Jmm3PdsYsitNnpMH+WcURSRpQoFAFFWADGt9PqV1IIU3lRGfY+hPEu/wig3soXO02x2SVmsESCKNRD4mRyGsDYZceu8cZ86d5dyFS1y8fIUL5y9yeXWNaxs97rz3Xn79s7/AA488yuk77uTA0aOkc3MQxZB4ZtUWjqwoMMYgOgIUxikMnh2MRAUpps8dxQ5ZX7vG5sY68dEDxHFcKQ+8M6tgsF6mDIiO0CjE2ZFzK2Urp8NrzQFMxS56w5sReBQlIBonXuaqJu8vIjjRuPAae7kPlBNikxNWJSiUvd9HpslitykjpgDL6l5ZW+Xyu1Rgup2U7ruKKNIYhCK33kir1+PAwRUOrKyA9jmwsWhEbHUPm5b52VRTTTV13eCy2QVNNdXUBwkqx56f+HsbSNzBqfB6BkH7cZKF3VwQS1BZM/oQH3Zh8QDTOYM4EBQGg2c2R0AhVoGJcB58Oue/zTqHcpahyRhu9RFn0aJptedYmF/ggUNHeeCRR1n/2Me5dP4MP3jtdV566SVeeP5Zvv7ct3n+e9/nxNHD3HrLSU4cOcxtt97KqePHObi0SGdhmXa3oMgGGCzOeIbJDgYo7RnArf6QzIJOUnQUedaulN5hGGRDjHHeIDT3hkBOCZ22l7+2212iNEGs0Ov1uHbtGm+//TYvv/wy7717hpMnT/Irv/xLPPzwg6StmCtXrlAUBYuLi4BlMMhCjqWPr4iUQovvnxPncMaDsChuMxj06PU2GQwGKIQoijybV1jSbpuNa2ts9XsUwNx8h/b8Au++9x5/84Uv8sZrr/Nf/Bd/nwcfeBDrCtK0w+ZmgRJHu932nzOGKI6J2y2iKMJmmc+AVBAnLYwrMEMPrK0oVBwRpS10EnsQJhbnIMfioggVKXScouKYSAtKa0Q0uTWhx1KBtbV4jfGcwUilxDqu+uaSJEFr7cG9NWTOsrXVY7M/4I233uTa6jpnL17i7LnzvHv2HMOs4JZbTvPIR3+Gj33iZzl68hZOnDrFwsoytDqQJICQFwWDQQ7K9yE6KyiVEKkIET3q9QumWcZaxHnjKoYZly+cp9/fotNKSGON1OexncLafDxbMdKe0XSMsh8nrjnjJiaoateoLUFmKT0VD7693hzvshr6Yz0LLFUfYzDk9X2zU1hLNamw2OOk/KzJ+8qwqZTHlsua7HcM7GQ967SUytqwLRIMoKwxRJEmUhrrhKIYkmUZaxubLB47wdzS0miyTvz0l4hm3ACtAZZNNdVUAy6baqqpH0NQOaqy51JV73c7hoqP9wBZa3Yc0O19+TO3oJ57WV9KFQsAuhYDECIIfJw7OOdcsLVUzjmcQhCsqDDe9XxPeJNnL8vvV4LECZgIJY4oUhhryPMCpRRpOs/CXUssHDnOsdvv4/FPfpZfuXyRV17+Hi8++zxvvfkaX/zmc7TjiMMHljh1ywluPXmCo4ePcGh5mYW5DivLy4AjUoqNjQ3yrGDt8mVWN7ZCFEaM0wm5U9jM4GyGOON7L50lF00cp6RpizhJmFuYp7swj4gwzDM21tZ54403eO2113jnnXfIB0Puf+A+PvnxT3D33Xezsb5KNuxTFN4sJx8O6Ha7zM3NURQ5URp5FjHIYJ3zctG8MBTGkOcDhsMBgywjN8YPrPHSydxYLp2/gLGOuNXixImTOBRf+fo3eO6FF4iiiH/4j/8RTzzxBEWWoxWcPXuW48eP0w9gtZ8NfR9qq4VKYwwKSVOfZSkS+gU96LGiiJIWcaJJkzZRGmENFMWQPDc4J8SJ729VKqqYKKMEazzr6llR72orkfL9suUZpXWVXdpK2t6FViKGRc5Wv89Wv896b4tLVy7zxtvv8PaZs6yurfPO2XNc2+hx6MgRHnrq4zz48KM8/PCjnL79DhaOnPTXnnhQVRjIezlDY8mdI0lTzyqqGJx40GL8dWetRaet6px31iJiIYow+ZAL58+SRIrlxSVarRYioKNwPFHBGKkIeMdfB0oi76iLGWf1lHg5Jx4MOTEeeFcwUI2xfsZZpE71oXB4hk/twM6VoG8yT7LWEL7ve+Bkr/nkazLjfrnTOpYmQGjvEGUc1b6oXHWtpTfwmbInl5e8UywOJzoAS7vrxFujbGuqqaYacNlUU039RAPU3cY6s3oyZw7s9sBcznJP9K/rakArVXOXHX9LeEZEAqni5XTKgTKlvC4MDAlsC94pFKdRcYQrDL1BhlYQxwmihcxY3GZG2lqSzsJBOlhWTt7qTt1xLx/5mU+xtbbKW6+/ymuvfJeXXnie5196hae/9TydVsqxQwc5fGiFk8cOcuTgCvfcdTfdbhedKPLL1+hlhqTVYWnlEHNLS7TjGGcsaazRCtI4CYNczcLCAp1OB9EKg6M36HPhwgXOnz/P2bNn+f73v8+g1+fUqVM8cO993H///SwvLnH+3Bk6aQLOsTg/j45HsSKtbpso0lVeZJ57IyATHGkHfc/KDAYDoigi1hodYkD6eYYLpiZRnNDtdEk6bc6cPc83v/UM3335ZW69/XY+97nP8dB99zEcDmmlMYN+n8XFRVZXV4kjRZ7npGlKu9shTdMAWkFFKRaHLQx5fxBkrBZREXHk5bJxkuC08n2j1pFbgyhFEkeoxG+zsYZhZnCRCtMS3t01imNUHIdeV4fSmjRJiOIYcV6S3B8MyLZ6XF5dY2Ozx4ULF3jnvXd559wZLly5wuZWPwBEuOeBB/iPPvYJHnr0MU7fdicrR45Cuw0qob/ewykv/82xDIYZ/bwgabXpzM0xzAuwQlSq1I0HyT7uQvnczgCQFC70VQqD3hZn3nmX+e4cy8uLJOFY+uiNEdgq+6srk1hvbeszYyfMwMbNZtwEpFQV0zc2bVS2b4e+zjKTlOAW68oIFyWVI62Eq3a8P3K7HN9HgZh9A8sxQ7NJYDsDSFKTrNpKAizBEMm75WrlxfbOWpzxuaGbvS0Gw4yl5RXStO0jXbQ/BpNmPe/P5GFTTTX1Uwkum5yapppq6oOqbfcTGQ0F/Wtql8HMOMgsM/1Gg75tS6w+t/1e5nbvu5IqBGB7j5Ur8xPLTDvvPDme9B4+V2UalC6SnvsU6xC8nBJXSuB8ZIY4yG1BrBUqiv242TocimHmpaxLC8uSGYMbeAOeOOlKemieIyuHIBu62x94iE986tNcPn+eC2fe4a3XX+O7L36bl178Ns8+/x2OHlqgncbcdvpWDh06xMGDB+n1ely4chWVtLESY1UMUUIUK1rtlFhrkigCa9BxguiIrf6AtY0NLl26xLkLHlRevnaVK1cuc2BpkSeeeIKHHnqIwysHwTrWVlfx8tcBxubEiWa52yVOIvI8Z31tLWQ72irixBiDC+xeUXgpropioiQiCWDXBVfZQa9PP885sHyQwllef+NN/vKv/4Y3377Cpz/7EX7tN36TwwcPMOz3GfYHmMBQFkVOp9vi4vkLKKVYXF4KWZVpMIdRPmYkK8hMTmEdsY5JogQV3Ex1HIPSOMA4IYpTlPbRH1pH/pwpgZBy6Mj3tRKMgiTSaBVX/YKFs/T6QwbrG/Q3+1y9epVLly6xur7Je+fOs7qxweXLl7myts6wyFk4sML9j32IW++4gw89+RSHjp7k0LETtObmkbQDUYzJcjZ760RJl8w5rAUVJcSdNipYUQ0Kh0Qx4JkxjQr9t5pIFEpBZgov5Q6ursr5c3RjdY03f/A6S4vzLC3OE2kFtkBFLUyeV0x/CaCZiOHwLKOAFKOruJqAEXQAk2OGW4xAoCuBmtJhP6sRuCz/k5ALI3rE+jFyeR6BWlXL3fX3AiWCKAdm7+CybtzjJqSwUptcmvldVQTJOKNaOEvspDL2McZgjP/OXq+Hc46VlRXflyt+71ljUHFSCWKn9aw3Y7+mmmrqusFlswuaaqqpHxrAlJ0HMaLKmA+ZCjI9XSgzWcjd3Gb3DYYZ77uq92Y5AeW8VBKxY8tlkgHFMiIspXSPldA0hnYKK7gk0iEc3TMNucnJM0MaaebmF6Wf5c5nQcYSRT4mwZncyweTlmAKFx8+zrFDRzl23/08+vFP8/lrV3n7zbc48+6bfPMrX+Q7zz/LX3z5Wa6tw+FlWFme59qVDZYWO7z42mv0jWFpfoFOmrC4MEekPIDIswEbq2tsbW1y7do1Ll29wurqKnnuYzzm5jp89rOf4YH77mNl+QCDrU22NjbJM5912E5j5rtzxFHC+voaV69eIW6lxHFMlnvwjBIPLk2BiJDEqZepdhKUirxhkBOwpnIdVVlG3zmGwwFPf+dFnn32WV597Rr33nuY/93/4X/N/Q896CNiioLBYMD8XIcsy2i1Uy5trLG60UdFmm63S5ymHphE2vciisYNBxTFgOFwSCeNfaxLFIVBvQkAwDPPOo1JtPbxF4Axxpv0RIJWHqzrJEYF19fcGgrj6A375MZy5coVrlxb49y5c5y7cJ4rV65x7do11q6tstEfcmXdoiM4fOwgDz/5UR57/MPcff8DnL7jThaPHvPRGToC5d1ls8KR93NAiDsLDApH3EpQOiYzHsRb55AoQitNnCQURYEr/DlonQMsxoAVSxzH1eQQYr0RVwEb69c4d/YMj911GwvdOaIoQivft2vL/EiJcSargKDYWvefCrmhdnTBq23zPhKyMWty0PCoxBs6WXy/qNI+xkOFXEulvN2WKKlAqXeLdWNgjvokFmFCKGSaOiVgdr9/VL2mdpo81stTR6m70+9jJaNa5lyOpqqCkzMh71TAGosJz/WzIaIV3YVFJGl5sG39hEUS5LPb1rdhI5tqqqkbBZc3Ojt1ozmW7/f330jGUlNNNbVb7U9atd2N0O7CHrpqsDm1d6liLWZ82o7L6VyNIVGhZ25v9xvZviwBcba+sNHQ1KmK9QBQulp/cc67eHpZXclkBPa17D1VFg1SmtNY68FonCaVc6tSijSJxBkwwZSniiPAO0FqFXl8LkDcgniB9tyKu/fEHdzrLD/763+b1cuX+P6rr/Di8y/wvZe+w3vvvk0il7iytcE7r57hmZfP0I5hYV4x12oRa0Ucx7TjiFgg623hnGVhYYG777uXkydOcPqWkxw+fBgFmDyjv7lBng3Ih95ISETInGG1GHpAqLyJ0SAfhP3lZaFRlNDutlgMoFPF3rxGad+3aKzP1BxYS2+rx7nzF3jjjTd499132djY4MKFi9x77z38L3/lV3jwvvs5dHAFLYrhcEiW9Wm3UwqboyJhq7dF0kqJkpgkSUgDaEQFhqsofM+ptczPdViaa3vzGlNgjUUp8WAUb25TOGil7XCW+34/MY7CehBaOEsujq31q6yvb7C6vs61tXUuXbnGpctXWdvY5PzFS/QHGZv9AVmRE0cpS0vLrNx5D6cWDvDAYx/ilttu44EHHuDEqVuhOwfG+XVykBUWU4Cxmc9RFEHFCZFOUFFMYlwFtCIdI4kaAWDrcJmPFyFMKFQnf6SIxOd2JkkKNkdr7wGLzXjh+W+R9TY4vLzCXKvNfKsb+kcFSVOcA1MUKAtSFDgsFhuAUrjcABXrwGya7U6rAXFZ651SCRMwKrjR+rhcz1JalFcWKO8m6wJr6ZzDaTsCpjUA51SJcW3FIiP+/mFxUAQwFvJFXeFzbqs7m7Veemut1+g6NYpdKYx3/XU+s9PW4lVGbaL+OrdhAso68YZHKFRgZAfDIe12mzicZQ5Hf7hFurDIpavXuHDxIqduvZ2l5QP+vEiVeAmtHhsD7Wxc1lQzvvzJnOBujtH7d000zGVTTTX1Y/BjYGpgs96ztP++od3jRdw+XrM7TohNMgGTn3cTj6PvCw6YtpgKqo3xhiouDPo9+HRY66kIF0bLxo0C2KttQIkThxJL3F12SwvLPHn7XTz5mZ9na22VKxcvcPHsGVavXuGV777I+bPv8dbrr3HuzBnOb/botlIOzi2QLMyz2ElYWVjg+PHjHD12mE6rjVhHpDVWFBubm5jQA6nwA3HixIMrU4BxVc+YUoo49eY5SatDlMSoKMHiKCTCSoSywmDQZ/XaGmubG1y9tsaFS5crGe7a+iab/T7OQRQpHn7wYY7feiutxWXOr67z3vkLFFlOp5Uw1+mCs7SSiHa7TZIkWK0x4Tg5a3HDYQC50bgrqfORJ8oOKYrCs3uiiSKHijSFCIVzFIWPJxkMh2wNhmxsbHBtdZVr19bY7G3x3qVz9AZ9Njd7bG5tMSwMxuLNglAsLh1k8WiH+eUDHDpylJMnTnHbHbdz2213sHzoELQ66LSNimOwluEgJytyz+aqCIfGqlqeo2ic9bE5YjOMU7VIilovZJi4cdgZk0Negl5Gpdiy71LADQZcOHeGhe4cS/NzxDoCUzrCxjjnvZStKdBaeZlmCaqqQZ+r9WaGrkw33kPtxCJEoOxoyidkW4KuZUGWTOZ4P6bg2UepX4fhLSVTWAom9JR7x7YeTxm5ytav6J0m5kRmGP2E5QdIHfIsRxNzxnlzI6X8tW/BM5fKX0flsbHWsnRgmcUDyxD74+AnZ5LmR6Wpppp636oBl0011dSPOLCcboBRgqadDXdkmwNjHfBNM/zZCQzuZhC00zZMBr/PkuzWl2+t3bYP6u9ztg4KggmQH9t6kGlDbqCzUgW3hzG8dVCYAl04FI5IxXQPHaF75Cin7rkXhgM+94u/yPrqNc6+/TY/eOM13nz9Dd5+6wece+8Mb56/RCeGpbl1LveGnL22SqfTIdGKTrvNfKeLFkWRDxHriCMVYkKELDNkuQdu1lpwIVKhcKhBgXNbFM7S6c6zvrnBtWtrrK6vs7m5ydrGOteurbG+uclwmHkJa2eexeUlDi0cpt3bYnV1lc1+j+defp3vv3WWr3zzWbQoYoFOu8XywiJz3TbKGrrtFouLi8zPz5MkCSpkWCZJUpnQlFmfpVuttRbrCmyeMxwOGQ6HFMF8xwoUhSXLczZ7fXqDjI2NDTa2emxtbdEbDBgOMzJTEHdaoBU6SmgtrLCysMSBQ4dZOXiI7vwiBw8f4dDho9xy620cPnYcOh2PjAqLNQWqOw8O8mFOnvseUBDvuqoUhbEgGhWiQ+qTEx4cxduuh/o5Xp5/k9eRKvv7nCd2jXPEyrNqmxubvPLKKxw4cIADB0YZl1GkUXGMNp6xdGqUa+kNdpRHaNYhYsJygwKgOq9tNfVSYtGSDayvZyW1Vb53c9TTqHDMdmF1uOn3CrfLZFXpMFvL1Ry/x0y/R1X7Wo3e4mYsYyyHMkiCI63DJACBzQzOuvhc0kE25EQ4DngpuCMSURqKokDreF+Tb0011VRTPxHgsrnRNdVUAyzZYcBVf+800LaXe8ks0PhBysV26xmtPefK50sX2tp3SPniBCh3gLjKrtZ/Oknb2DwjMzkUBXGhSZMIohZECfR6LByfZ+Hkae594iny9TWuXLzEu++9w4VzZ3n1uy9w7cpFLl28yJvfexWTZ4gIrTghTSIW5+a9/BHotFq0Wi20+IGtMYZ2uxsMezxI6w8G9IYD+v0hWZ5z5dpVLykNLFGr1WHxwDKHTpzmlsUlDh48yPzCEseOHePwseMkacra2hpnL5xndXUVmxesr69z9eIlVq9dYdjvcWUw5N3L7zDY3EBMhhK842wcjHXw7E4URSFCYwReSsBVMsXG5GTFkKIIhlTayzBBYaxDxYln9cS7/na7XRZPnGR5aYXOXJfOwgLd+UWWVw6wsnKI5eVllg8cZGnlIOncPHTnRwbEWUExyHHWO36qpMPa6kZg6yKUitBxbT0doKPK/bSe1ViBtfpzYTvLa8haOxPcjF0XgLE5KlKgIq5dvsKbb/yAx+68lfn5+eAgi3fJ1RqMj9JxSvm4kInJFS+BF8SCqsBlAG0lALM2SFhl9NyUa1eV4DIcl4pdnATTk/LQib/rhj5j7rXItv1T7pVSaruX637aulsZ6TKq79el0dH4PaMC+8az6GIMw+GQ3Bq68/O02u3gwkvFDltrUarpsWyqqaZ+CsFlU0011dROg7H6YG+bg+QEaJwGRme9vhOgnAb6djMMmgV8d5Lh7ga4HQrnvAp2BDLd2AC3BgJcyXCGcTK9YRZei7zEDiiyAq0USglJe9FrAosclBAvHeLowWMcvfdBGPbY2vxFrl4+z9n3znD58mXWr62yvnaNtbU1Br0++bDPoNdn2O+zvtVneHWdfq/nmb6ioN3qBEDhe0jjJKHVXWL5yAJpq8VDi4uknS7z8/N0ul263XmWDixz+PBhFpaWOX78OEpFSOwdbcFBUVBYz8wNej5Ds7+xycbqNdbX1tja2GBzc5O83+PaxTP0tzbZ2Nig3+9X/w0G3nToWq8X9p6pekOVilCRH8x35jt0Ip8/GcUxadombqW00jZREtPpzNHqdJhfXGJufp5u1+eALiws0O7MoZOETneeubk5JPRnBhoKlKa/thXAUeQBRNzCWcFaS5Fb4s5cdXyttZgaIHSqZLXUtgyfCggF5t8GhnsaONtpQkfEM7lY55NdxfHuO2+xvnqNhYWHSdPU77NIQ+KdZ0sprVIKsRqnHGIDG6lKZl58RIroQE+aYI6jRyAP31NtGbnJ+utBfFRoWIafgFE+SbNkNhlJYseuzwnmcZK5nHmPmTEpVf/Oulvs6HPTr/W6ykCmAN1J11jRnpkeDjMKY8BaeoMhSsd05uZRUQwo4iQSE06RKIq23Qebaqqpn+6J/Jt1L9gVXDZRJU011dSPCqicNRialLvuBOhmMQW7Acq9gNBp98ud1nsWKJ1mtFH7jrqPZfk+qb1fJoHAOGMZwIh4uacLmZsAYh0GA6KQKGIzG6Bz8YZDToiVJlYJxBrSNt35ebrHjnPLQ48T3HUY9vv0eptkgyGXLl6gGGZkAUyazD+KA6UiCmND/EbswUCkSZKEVtohbqXMz88TJTFp0iYJpj46idHKyz6dcUikIYqgBCLOEYX4iXjRQqxZJgDkLIM8xxQFFDlFf4N+b5Otra1g8pNVALPM1qyDr1Iiq5Q3cVEaojgmShMPMKOEKImr9e90uqStFu3uHGjf71jlPeoYkrZ3cwUoCrLhgGxYYG2OlZwk7VCEaAlXWNAjObS1rpKV+nNoZFCltUZr7XtBJ2TlIlL179kdJjoq5m+H60FEsLZA68D+DXNe//6rtJOUhbl5kiSq1gUl/hzBg3SjBLRCoTzAFPGmWCG6x4mpmMvSKEdq6+hEVUY7o/WvracK26dqjKtSVV+mMJu5dDOuQ5mcmHLvz32uApc1BtPVXWIn1lkphTFeGu0ErHNsbG2CVp61DPvWmxhZJnvF69mdTTXV1E8nsLyZk00Nc9lUU039yAPKvdz4poG4vbCJOwHKvfZc7gY2dwOVs3oud/hO77miVKl5rbSvTEgWy0c38bpCyPICK5DoqOoxzIZ9+sMhxvRY6M5ROIdojULIgTx3aOvQkcLkdgQetMOmMXHcYWnxAIJw5J4HoTAe2FnrGz1Ldk2ELMv955PYSyZrANHhkCgB57Mty203zpGbINsUhXIKcosNINDUmKIoitB5yJ9UkCRd6ERoa6EYoBcXSU3OknNh+ZX9aLWOGOPNfdyE8zB4Ix2tgqMsPppCAupUCpfnHtDoOLgLlw4xGlREb2MTQ+7Xu+yDdLrKxewXxkdm6JHTqFIKnEI5NyZnrU0i+FiTwruVwuxzu4y+mMbgT7t2Jq8/v7sK2rH2Jke9TV575WUOLi+xOD9Hp9XyfbbK71dnPBzUWjMcWqIQ4eNUCZZrWlCncQr/fNiO6uiGrFC/nrq27q7WwymjLEsmGL+K5Fdsy6b1yHXU77ntevSyYhdySCYZyWn3h2n3i+2xJLX9rqSS71qZMelVk91aazFFQeEgjlOcjtjsDRAV0V1YhDjFhMmIEpA7aysmt6mmmmqA5c0EmA24bKqppn5swWYwR91zb+UswDkLhO72/F4Yz53YzP3+AGxjGGo9ltOWMWkINLncVqvFIM8Y5Bm5NSQ6QumYVjuuXECts2hREJiwrMjRhSF2Guc0FBaXFyH6xJv2KDxDoo1gjSAuRicKVAzYyo4zmVMelJiagUs5WDaGIssB5V1OXc0VF4dI5MGKCc85H90gkUZEY22BUTEQwJbxeZmqKDxT6xyx1oj2AEX8qmDIEZ14Nk5F4IyPgBDn/xYPgsSVSNKb5jjAiQsY2nmgqRL/nXYUNeO3o8DaIUiEwX+f1ZpIQh6jC06lotA1oGespShGbKWOIi+RDfvAg08PtpQ1Y4BlpwFFnaGsM7R5ns8+b8UhCjCGOEqhKMj7PS6dO8+BhUXaaWsU5+LRDIV1FUD2x6zuChtAWjg2JdAWcUyjCC1qOtumxk19ShRsg+OqU7KN6RyBTzcOPie3ffJSq9GJzo1bBU3+Pa1sUA1sMxmryXe3SfknAGYJLsss2ChJKLRmmGdEScz8/Dy0UignWXQZQ+JodGdNNdXU+1HXDS73Kod9v3Mwm2qqqZ+uWbXx+8fuUST1gXM5iC2ZHut2XuY006DdgGf9vlaCoVmAdZJt3cnFdtr9Mgw+pwLMvdyj82JIpIQ4jae4WlqMcSG6IEJpTRrFxEkLUxQYV6CCpFPCjjSAswqNUAVsRnHojbNgBC2+bxEsuSmZKD1x0DRojQ5xMzYggfF3KZTzcQ1+P4+kj0pplGpRFIbSQ1fQ5TeFSQlhWGWRKsQ5LweONaAosAi6MujxUkIVpJvl5ILGOYM1UJTMYy0ep7AGQQPlsVWVWUu5MQFDUhmGBuZNlQDAOZwz20x3RDTGWkQUOtLbWUm1XeapnJ04j9TYuVV3XS2lwDud/8YUtJKEYa9PmirOvfsul86d5e6TR1lenA9OsgVIHA6rxuAYDIdEUYIr8hEwB5wYvx5Oo1SZUxshypso2dxhrAnMoj+qboS2UOKBq+CNb1Qpgy1ZPqdGbKUSn80po++YHI3YGoMtwTyolBWXWZwOWwOHgVE3PstU12W6NRA65h6tBOXG5OvV+eKXX+sTDQC8XE9jDAsLCwz7fYwxxEnLx9iIojcYEiUpS8sruH4fSdrh+GqKPK/Oo2n3oaaa+mmapG72xc3/vn2Dy6bHsqmmmvpJuZnuJpu9GcuaxXzu5X03a1tngVXlAkvixkfW5ftKB1WtVaX89IAjRlmNRAGM2HF2tIz/c8YDIw8eLUo0RizWeQmq6AiR7VmhZQ6hTJlEqG+DQlCBtSzhgSqVkAIitZ84sUgJrsJ3mFo+h53oTXSBRRs5guoKPDrnEFv2JCqs8xLdkiUtpZo6Tsq1mpiwKMGLoe6wFGx+J9JOZ5Xd8R01T9hZ0y47/s7vdk6WDKwx0NICFi6duwDW0O106LTaYSJBhbxJgjw27B+P1Cp2rgSL1fnqagSiD3St9Uh60nDW2pU5leXhdeX5wOjvev8mu0jttwF36/xJv9u1dwOT69UxGNsOv+Le9dYSRVElp/axK34fD7KMfjZk4eARknYL0ZFXBNTMjvbqZttUU001td/aFVzu9uPSzAA01VRTP47AchLYzTIFulEQuJsr7H7WbfI15UZ/7QXEMvE9ShQW65QgdryrP7zdBtbRMz5O6syL+Px6PBM4+rjDlsxtYQLmcl6SWMoesThnEXFVT9lU+FP1EpoZIELG2MKyZbIEcG4sTsNLfP0aGnAKUckITDLKCy13wVgfH9uzRnWl5JQR6yhULOoou1DKHV5rjrUVWN92jMP2enlxuU4jM+A6cNrPOeUmGWK7HUxOnq+TfZiTOawWi4ojsAVvv/E6EbCyuMBcp11jWb0cFTO+3g5A6dD/KYgN/ZNSRo+IB6EOsBqnAkM9gqHj1jSicKLG1tWVQLruiDM5vnHT0fzMeCC3Xaq7mwx2Wm9mdY2X11V5Cm3rbR3vsSxLa02WZZii8HE3ysvXB4MB/SznxJFjtOe6EEf+HLW26t/1x7v5TWiqqaZ+COByP2CzqaaaaupHDUzuhYWZNpjcCdTVX9/rfXK/67AbsNwLiN35s5750uEJDWIm3lwUxTigUOPLMMZLPqeZk/hFjOS+YsXLZmvv9YSk3ffvzXbDpAnQVMoMsRPbOwKqlgKtBLPDsbB1pDmxbN8rZ0IkxjYMPyGRHQeu5fpotYt5lNt+HOuSViVuV9bten/jp8dj1Pt9/TZYW3jDouGQd956i27aYmVpmXaaVu+3AQ1bXGAh8eBeNGCC9JhRniW2hvWkOnaVdDe4yroaO7hNVh7ksFKB/tB3WSJTqR3X2sNe9ps/HgrE7mjMUx539hk3VI9LKXtIzXbsi3OO4XAI1qJj76AcxzG9wTWMtRw8fIi00wmy3kism7xvWXZisJtqqqmmPhBw2VRTTTX1kwA665hhWl/Zfvof9zrptt+sy10B5RRgNgI2jPVnTS6nHEhbL/ccG2VXWFK5CqtNMyly1o0G0FPW1VT9jhMADQfWeUfMnaSd4SPKjW9DKfi0YscG86PeNRuwsAcfnh2tMY/iwZl3oZXZAGuH59xOkwiVC2vJwPlPTMA1JDC+4xJgqeS8buTx61lZGSfZ6oyqTJwDY9vDLBCzM8icPOZKqSpO1TrjtNa+j1MEs7nOxfPnWJibZ2lhEeUnLsa+zzm8+7CrO7gKKB2cXcfzLJ3Yqp/XL1cjCFYksNDjgHKU3znqcd25FGMC7JIhLvs53XaBsgRQKmLHmMRJkDnVRMm5HRnOeo9s6RbLtO1jvK+73EqlNCjN+mYPiWKWlld8Bmz5+foV6AAa5VlTTTX1IwAur2dA1VRTTTV1IyBwh3fsGdDtRfa60z1uNwOfvbKVu8lf97bd7Bn4zrpXC9QkqWVPm++NnPx7lgTTjQGi7W9SSraZLlXHogrvc9sfJ7dj5qBdVQBuXNJaByQBkclom8oYCd8z6RdpA+C1uGpVVGkYY12IEhlf1TL2RLlZ+7zUne6N4d4pesfWVZ1OgqxY3tfra5IxLWWu3mjGIsp5AOksVy9fYWNtnUMLc3Q77TE5rAsTDbYCNIIThyKcH66MlilZ7hIwC1ZcYIf35gw9+Xp5jvs+xelsLPvcj7tJSievezcFVIqMH8P6PWBsvabIkUf/9nE7Us3CCIW1rK2tkSQJCwsLPl+1LnGW0fqPW3g11VRTTX1A4HKnQUrTb9lUU039pIDVaS9NDiB3Yh53M+95P3oufUzGhDnJDAi+LXsvuKSORHuexfGAUhBRYq1zvl9tOjASZbdBzbGBbKRqvYujwS2AKIU1dsQWlYzWVCA8DfD7Pk6QSpbqasY+AM6Kly6G41tl/Dk/rPYtkhLkmDL2twW0eG5YBIxzHnK70fPemdMy3hJZW39Tyjv1OKApoXGN4S134cjMRnzG5RirVprTKC85VlI5wI4xw0rvaRJm0vJnLxE9JVCy1uLEoSMN1nH10mWywYDuyiKtOCHW3lxJlZmTU6BMBdKCy6+j9Pkx49tsA/s6EZ+xk9vyJBibdX3VweVMsD/BnOPGz+XZDDZT950wbRJknJ2cBJfT7hFFUaBDD2Ueokicc2z1e3TmunQX5kHrANwtNkTBoNSYKrippppq6gMFl9c7UGqqqaaa+tFHm+XgX81m0MT6PrHwKMp50PLDXnVCbqJYxClQPj+y/HvyEeUfLcb/XQPQfpNL11hB+RGtz3JUgb8LElNXaupEUFpvGzhv+30QWwN/rgYqbI1JEqiAlEzd1qnQKJgEVY9MY3e0d6R1oTezPI6AKUL2XwACSnx4fSWWrPXLle6fU2WYLjCotfPEn1vl8iYARAXww3Nuu4HO1HDrumuu1OXCZVTKrHMlmMU4zxhWRjkTdKzU/96hnC+ctegkBpuzvrFGUWREkUJrIYpUwEaePfQtqGEiQIFY34NZmhaNAJnzslbrpmyXbJvE2Aa61EhaKhMgr+7pU8WK7OCaWkWz2Jqjb+kWixs7MctjoWrf76b8e7Tu0zNoy/PQ1ftxpRZVU1tWng9J07Zn0Z3zLLEossLQandpt9shI9aW6+6cC3tBGnDZVFNNvU/gcj9gcb8mFQ2z2VRTP+qlfsyXb/d9z5q+dEc16q09qrKnTTzLVfbAjQgyNXYfnKb02InNLEHetveMyTvH2ZPxflGp+gc9LixzONTIJbPsPRvrQVO+L9D67RqDRMG20jqcFt9ZJtZhsE6s71/UiDjBWTOSHfplU0U+CISeRs9eTS1jQz+mDWDHjsliK+OgGUhT7Hh8hZPxvs5tbqAlSxYOoCojMsJutq78HGPy2GqjnAc/5ft06UJafhgZ5Si6kLFY7fuxE2DsUWo0Uh1cbgc+duIcKo+pVKZGZVPk5G+zFesUIlZc9RhsWCvJcPk44tYEpYNhE9arg72dKdZa4iRF60gojHv77bdpdxLml7qoBCRSGAyYAqUVSsdeVmvAFqNtLBxgXAWC/fOCcSbIjXXYQca701oX2GRVAS2nRr2W/gv8+T85BxSUt0HuPJqcsOGNbiwSRTDGju13cSb00wZjqLDePkHVUhk3WTsWoith0kKc9ecXPrfTb5+/nyglVd6rcw5rTMjsLCcvPLsrnoLHmBwlgnEF1imsVgwLg0lSMgNHbjnO0sFDMBgQtbpYUWg/e1A5Knv2vu6IDPUe6t3HcI0ZUFNN/fiWva5x007Xf/nZqGEgm2qqqabsjo9SgZbJ1/WON+NdY03s/qOexqIgCLmLJcAMMRiu9rxMvF5GijAyy5FZj1526b8tAEqiGiBy1/WDxAgUVBvlxh/3OkG5yyKnf75GX6nSTZSxxxCMUUlc63mJ9efH0e72xzEJ7w6mUdvOiwmZ587bX5dNjpO8dVdQHQJN64+mQkDTz3fxsR7V2VJja0VEnHLK64PznF5vE601caxJkshLYiPtme9qQkQCCPNSYD1lm0f7RoMzIybPQ+LRpsu40dPYbgnmR7oC1tPZ75nnrPNybt+T6yaOpQeWpby1NOrxGM15h+Fg1KTKfl7nxgx9RhMIpgKyfvvLxYcDOWNSxlqLscZvY5AciwgSJwzynKywJK02SDRuClTNVZXcvGlu/U011dRNr2jaj1zDODbVVFNNsePAfxYrOSnX2/F+KjvMHApVREN94DkGVGo5jrMZ0knAVv8+tadtnv5vxDnn1E7GJvVsxhlRKTdS7rrA5cTOmHLsZuYb3sB67ycXes/GTu971nTpyKpkAlyG5VqctZgsY21tjSiKSNOUVqeNimK0jitw6erAyo1HrdTPVZEREpzVazytF/L6zyFXm9QI1xumYjC9wZA/m+3EueCcZ/WxwZDI2rHokTqgnLp3y7ZKNzK+kgmH2PJ7VOhJtdZSWENufYSLUgprQamIOErpbVyjsIbu/DxoBSqq7be9x6001VRTTV03uJz84WtuOk011VRT1wcidstl/HEH1fVSDkQpmWAv3V7B2l727/WYIL3f58KNgsz97Isdme+JiEuZQGt7BbNyHU6pdbAiAlmWsbG2jtZCkiQkcatylkWU71FWauw7lNuODcczNMf/KdOcU2/wspo5OTQ2eWTDuprwnBkBezvOSOIczvj+RjUJLieA5o4GXCJV/I/PBh2xr8ZZjDFYC+1WgkQaM8z9NRlHDIc5TgmLi8ugNFXjKyPm/SfhntRUU039GIDLpppqqqmm9g60psUR7NTDPg2UyC7M2X7A6l773/cDjvaUv1kHMxPqQyXidvzuG43SUNzQ+k+66E7mWqqpUtaxJexyruwG4naTAe9ICwd/271s/4zzQm2L5hCmThZMMuwWhSVSEYgjH/Tp9/torUnTtIotKUNtJrdRKYVyYF3I+pxc5xogez+nD0qg6LZdI2ErrR39LbaSvsrEyeImZK8y8dzs80NPv47L9fF5PWOAulwn0YqklYJSFM6icIiKGBY5rbTNwuKyB/RKA2q8f5s9+TY11VRTTd0YuJy09G6qqaaaampn0CgqOITOAIe7AZzJ9+0U/bRTC8NuPXz7AaKTy99Joum2r6Ob/GwdsLgfMbpkv+B9v+B8L8fiR+gcl2nnpHPOTYLO8rgqb3PL1uYmRZ4T64hOZ87bDAVw6cSD2Epm6sYdc+vn4ja5KbOlpeJu4vEv1yFIxqsOa1vrQXVQ2R6zHUSKdaMsTjfKP7VMz5OcjE4poZ+pSYOr55VCtMIYgwmTMnEcedayjGlREU6gMI65hUWWlpZqsy++axoHonQwFmrGeU011dT7BC7fj96SpppqqqmfVJBZ77ksnTNHYGrqCHb8MQz2RGQsEmSvIG8voHLvhjG7MW8jJ8nJr3LOodHjGYEiUh+wV+Pa0a6Q0rzEubFkiFlrsMuO2fWI7fiqnZJCMQ1Q36zfxFnHcS8TEXsBq9dhqjQClBN9kOHfUvZWesdThxIXHE7D+W5yt7p6laLIaCcJ8/PzATyOokgkRGuIlcrF19rp7H4FJq311kkTuZAumOfcjFkKW57bE/tPufL8ljGwWAFiG9YptGuK2823evrxqsePjFh0z1g6C075mB3RChdyTy1446Q08b2XxqGimDhpYUWwTphfWGBuYZEyo9YbKY0zl7P6vZtqqqmmbhq4bPT3TTXVVFO7Dwh3e9+sIPrdvmevbqL152UGsLiZk4Iy2edWK63VBH4eZ6Cs3TUqZscfHjUzw+RmbdvO4G/yGF4PmJx1bOvbt99e1f2fuzfSVzne61j+p/DxGq7I2drYxFpLFEd0Op3a+0DQtTgRqpxI5UBTgp5KVh0SaYLrau2193OMMnncJ/d/3ZiqLnWtm/NWnymZ2T0A4MnjWxr8lG7FZdJOFZsio3VVUUyWZeRYVNxCxRHWCVaEtNNFtzv+s7jgVutNg8os2ybksqmmmnrfwOWN3rB3+vye+nUaZrSpppr6IQPD/X5nNRidcoubSIMIg2bZPmAVoTDFHgf5k+BtGmbYu4R2FGknM0HFNIA5OdB3bvv9flejkily2VngfD89odPklbv+ft3g79xe128mWAw5irUkFELKPdt28LTvl/HvVUrNWN50tnSUd2inrrfS4JytPqeUZ7NFHDoSnC2QNGF17SrD/hZzB46gFMRxTBRFmJBc6XMbPXPpZeRFyV4jImjxuavO2qrfUCmFsz4PsnRkFRyqBkjLY15NYjhBa+17OrWa6TTrJiJBZp333onV4ko32JC9Wbr0inVgbGBZQSvtyUJjsMaMQOgki1+uByOJsFIKVxrwhDkVYy1p2gKlGWRDjDGkrRZpmmIF4lZKPhyi44S8sMTtiMIYDp24BZIURONQPp5I+QmB3fpAm2qqqWbctJ/f0WmfbQx9mmqqqaZuEGS8X+B3155MpoOraYPlacualCZOY3AmWbs6YJpkJicZzmmyzf24pe5nf+/UJzl7/76/P7a7RYpMZb7epxnX3fpx97rYsX1gncPkZP0B1lq01kTKgzsbGg2dKCpDGVfrp6znR066qNb+rQKB6fZynKewj/UeSmR/vhKjZSnEWcQqH1NSrff2ZSnA2XE577QJlm2TNmrEECOetVTKy2FdeaWLgFZeYixC4SwSaZwIOo5xAjpJmZtfDE6xCitqan+lNOxlU0019T5VAy6baqqppq4DTM7ssbzOwf1uoGbq5/cA3Gb2ee3A8tW/azeAuVdwu1dguT8J6izZrdsTeNT71ovuE2DK+Pps29Y627zfLkLngcf4vh5n9HZjLqUyfFFV7IZ/wU58zo72WPjbOQtisVnG1tYWzlhaceJZS5347wx9g7M44nr/5CSjNnm+uSkyWTd5Do0xk0wFnOPnlwrbKAHojvaXX7fA6k6ZhAn/8CymG90P7ISEt96vPHlcRPSoH1XGwaWIz66s1kUEiTQq0qA8+LQOojjFKY1OYjLjiOKUAysHQTToyPdBK6Hu21tlaTbgsqmmmmrAZVNNNdXUjybY3AkgTpPn7QVc7rTM0t1yJ6C619aEyYH8bn2io1gEN9VcaD/7aaceR6XUvr9jjLG6wcHzTsduP+fDbvvxulzaxVVRFnvpE93tPdOidWZNOpSgUJQiz4f0e1uICO12myRJiKLIf69SAVhJBcLGzn/rJmTWtfgOW8uRnHFO1/O5RcS7qspIiquUGosZ2cmoCaeq62m8Z7gEZiWFWpr+2LFpgzq4n/b3rImUbRWAI0q8c6wLImCtfI+zVgFY+m2P4pjMAqLpDzPitMX80rKX1ioRCRMCDu9EGzUusU011VQDLptqqqmmflRrb46L28eQU5smdwWHN8NUZq89jZMS16l9g1qC8Up9eXb6908M3FXpTmqnR7AIe6AVZfdt2HHf7BPYXy9Y3Q08Xg9g3W0iYE8TC7NIxRIEYmuhjw5RFgliXueBkIh1Ls9z0ljT6XSIogjRCpypIjW8AFh59+Gx/l17XdutprQN7sjaTzxWyw+OOU6kiu1wY3Jdf43XY1OEkM3pZNQDOgvI7wLwrYzfBUbgV3lSNPShilKhj1QjSuGsB546ilFRgh0W5NaQ5TlJq0XUbvntcQqUamJHmmqqqQZcNtVUU039KNZeZZ7TBswfpDP3Xpe1n57IG13WNlguoK3bNgCvr8uu66/czM/uCZztE6DfSO113+6H+a2iOarP7M6yzgKyk0z45DGYPM4K60CJw+CKnCRJaLfbKKXQWmPNyJzHohGCjHwHFrdKsQm4bhTVMZ0R3NmAaiLqo2agU39PgKvj+yJg6mCTBM4LgkdLtohYMJOGPdt7LUv32DHQPsFeljJVJ1T5PFZCVAr+eRVYSyjf482Lys9b49e1M9eBMiJIVBkRtP1cbBSxTTXVVAMum2qqqaZ+eGByFljcC6CY1lNYZdrtA7htYz5msYQ7bMPYd4qdgFlubAA+nmHJ2ECdWkbnrP2yG3gV2XlbdwNZO0qGuXluwbIDAN7L8dvPetwIkJ3VG1tmlW4DlNbu7Xz2wY4y6rncLmVNkoQkSUYSVXSVaemY3t+70zHelrkJlZHOtutph31RGuFMgufR9VeTXlc9lyM35Cqrs7JfCkDQjbPw1rpqe2fNWjglFeCcBJZVH2QZ9aIClK33koasElFCpEPvJc6DTiVEaUJnft6vuI7FWYvVo75akVEMDLjKlbappppqqgGXTTXVVFM/RLD5QeUC75qR6aYDt2lulLsBmWn/HgfCE+sGOGfYZhSyR2CpnI/SGGN2mG4MNHP9d1jO++XseyP9pPthuvdSZQyoN+bZvs/qbr6zmMupETWjJQCmQkXOSmCLA06z1jljcSECRGsdQIxGtMMVBYgOMta6G6x4elBGjrmuHu+xA/icxlyODHYmtq++7WrcwMb3Ik5qa93IDKgWVOkl3BoRi3OeyRTnsMHwZyzn1XpAO+lyOzYpVAOsFbBU0wCmGvVfBhmuE4hUjNYRBk+eitKgFVGckna7gVP24FysZzBFBBVW1FCyzw24bKqppn4I4HIvM7PXmwHW1I9/3QzDjKaa8+P6zw/1Q9mu/UdYTO4P3+slu2jTrNe6zSwtO6DNaiA/PadSUMExUlXB7dPQm9RAzORxjUTthHbHGc1Z+3HasmUEjmadAxWInHWuzWC0xmIjVLTv82/sKWf2DEingvQbvv/ZCmzVz6VyObo6QfQsdDqx2+2U60qFVXVoifyjBkQLLnODgY8hWVxYJml1SNstclOgxQMy60J+pQMPRD0JqkQj4rMgK79WN+piLo19RAQnxody2sn9qMZOJJ/kqBAVYQGldfWyE4LDbu1Mrfbd+CFx4fn6dVutj/Xo0FFeUxK2z7vLitKB6AUndmKCSI2fFxifVVpKW0UjKhwFCfCvvEiCs6zSGiWRz8RUmsI6VJqS6wSjIqTdRnXbYb9qojKKxIX9JUBYr9IQ6nrvb+/370MzPmiqqfez1J7HObspdyYnshvmsqmmmmrqAwOlN+6kevPAuwUXXfe6fRCDx2lM6CxWcydTnOsdpO66/jc4UXKjg+cqwgMzdW12P55ux7+VUp6p81AtvKUckBiPwqw4EUEnMVEUeYdYRv2fPhsSSmmucw4bkhtloj9xr9Lj+rlaj/GAQIrW9q2VkdrVyV6vKTfRw6pu6nU9SjzxvK0H0IJoHy+jRFXsphNBqcj/rSJv1KNK6bEKINbnWao4QSXR2KRBff6qvh8QGt6yqaaauinjmvLeWf67AZdNNdVUUz+iAPNGweXuERjsCtD2EnPxQf14TS571npM+7GrP46ks/amrdd+3nezGJlZzO7ez6/aRMM+QXf50aIoEBHSNCVppR4gWRvYMs8KqgpUWi/hNabCbSUraEutrXUj1rv+WIJEkcpp2G7br9o7rc44BmWuZyVLtTvLwqfuc6kIzx3jW1wtiaSSl8t0Mx8bgHxdEutzLkdAUqn6a+Hf2oPLwvnnyr7XOrh00xNRmmqqqaZu+u9fpWpqdk9TTTXV1Pt7853NpH3wsvKxwS3Xb1i0F4C515zKHUHMDuB2t6iQWfmGO/WS3kwQOCtr8mb17u7klnozvn+0DVP2r/MuNlmWAdBut0nTFKU04qSKInECStR4dmRt/08yl64G3mZubwnyAkcaECyowACGv6uoDxlnN0cyb7en89lK6KGsr+seJjSYfE4mj5uH9aP9JNW2SA0Eu7BthH87VUa7jK5gp4Q4TYjjOGh7XUNNNtVUUx/4+KYBl0011VRTH9BN+INk+m4U/OwENvfrmLsbeLwe8DRp2rPT9+wEwG4U/LKXLMmpMRl7A3/vhxvt+OfH81Zlyus7roNzZFnm3WJbKVGahBxGi7XjZkGWUl5bYyslCE6rRZTGRGZ8+11pPWMqsDe+/XrkqFo+XwOToINWlu3v2cu+Ll2VK6lsjeVE4cRb5GxroVZqzKVWamDVr8c4E1kha6eCbNUHoPjeSKn6iJ0VrHIeWqvYR5YE5lLFcW1fNtVUU0198NWAy6aaaqqpDwjI7QUwXM937gfIjbtpWm/ss8sAe5Ys9WaBx/3uv1n9l7sxlzd7/+51+6YxrDczJmUnAL4v4Lt9C2d/d9imrMhxznlZbNIak3eW32pckCBbiw3mN9X3uunsoQsuqWJnu/96j5oyI9LLS6VkMEt2UoUmzGmmVFNiTca/f7TMCgjXAadTPu+S2vqJjwdRbvr1YmWCQa9MrQKjqkaZl5T7QGrbVLK0LkSTRII4/1oUxxAlHlgGY6CpRlq7pyA11VRTTV33718DLptqqqmmPmCQ+UFGmewEujzdUs86nPzRcGPRD/X37W0bdnuP3jfI2ymqZHZ0xf5A4c0G97NY1pth2FRncW/euWWnw02xI82qp/8wxrOJSeIlmUoprFIIUZX7KHYGQ26DU7HyhkTOjOfCOlu6u5qKbfTANpB8SrDB1KY0xhk/V/Q2ctnU8kEE5dW99W0VkJI53W03qSAZdr7P00kJKk3FrvrvVJVBkNSMh0QJKhjzTEpf/eWhfF+l8q+LUyOGNsh+VRRkyDomimKItNfXKuX7VydAZWnq0wDMpppq6maAy2kTdA24bKqpppr6KQa6O4HPGwUqu8lOb9BPZ1ezoVnAcs85mjfoFrsT2PNRKDenJ3UasNwLczl7+8ZzUqe/z1W5kB4HeWApZcQIIBqwgi3BqotAFaN9Z8025tKWfZdul4kYpxhFdQSgF5SlJQPoamCKIMOt9xnvl0Hebo5jt52LFufh7sQxqYPKsX1b67OsgGWth7T+nITcS1f1lyq0RCOGM9Jj3zUNHtcBZlNNNdXUzQCZNz2KZKcf391mUn8cMox+2nOYmhzLn96bxfsNaH7a98PkvrgeB9mdBseThjXTlqWknhM4bVk7rsiO+2rSrGUWhNkLozc5QN8N/O71dVHjy5583P1c3Zl5LYzZ8dzfaeYXQGs91XiochndwSl3N4daEfHmOmNgeTpjOS1DM4SjMhz2iaKIKIqIk4TMFCQ6xrgCY0xgyBRObJC5ln2FxoNBT/nhnOBCrquIBg3WZpVkFBHEaa+4DaybC/LRkskTpUZ5kk7GTHSs4Jk/5wFgBf7ZnufmQv6jisKyqmNgKlCNCzEnBDDrPNb0LKrG4bDOTBxj8f8TzzraYEgkgU1VZW9lYFRV6Ll0VmrxI7VsFaXYGvSRVpu57gISJaVDUHVqekVwGIdJKUne/b6z07n/QTP/N3r/fr+W88Puo/9R/y39aR8//rhu/37HIs656rek9DJomMummmqqqaZ+KAOfnd5zM3Ih9/Mj6ab0/u26PHf9+2PWxMJuuY47Aefdomdu+sC4ZsyDVqHf0ktZrXNeLir4PEvROIqx3kUP7tyejsO2yQdhxOLVXVNlvJexBHKlZdF+5cOTbGUFiGdN6lRAlqkTB05J1StaOd3WZK6VO2xgI22t99KWuF/AUkqG65La0eser6pG+dpUU0194NWAy6aaaqqppq4TW7gbAjC7gcvdjHD2a1izEzrcKyN8I2B3N2A5632TkqO99m3uun/UZE/eLMZympus1Bg9L4HWOvIRi856B9Mg+3VWgSvG1985z8KpwFqKgKgAjKxfVrn9TuP7FW111FyIHfFGPUEOKqqSvZYz6BVjSWnCOpKsbo/3nAE8xY7JXKv3OOUZSrEjBjR81IPCktkerbew3bG2crvF53SWnxPRYT8onBPQte1Vo32nVAQ6Gsu3HNX25wQbnGibaqqppm68Jn+fGnDZVFNNNdXUvpiw3YDRXkGXY2cTnqkOofvok9v1fTNcZz8I5nK3bZ0FpHcClvtlR29YdTUBLlWkPXNnJpYvghUBpVFFMTUjUkJPoQdtIwApdgRqx3JZA3h0oY9SavmW1XFVMg6LZfLw7c4GV++VETAsgaYlAOS6M6wCZ93O53DNT8vVjHWlls1ZZnaW8l/GXHAFJxonGlFePq10rd+SvfRVWmgAZlNNNXUTxw2NoU9TTTXV1E992ZlIaW8gztZ+UNy2f++MvtS+AOT1sIS7M6ezv3tvy7sxdLaXiJftDqiyp+Ozk5Pu6LVxoCpTz4udz5syWsQzlxrlHBiDRaFEh14/NyVfUqo+RKdCnEcJJCtwr3HKIc4GwOnXUJU0oSozIOt/j3oaVQBPTo2OlnMOpyR8xyTokzHQPGvviipfD1JWq0M0ixnr86xAaLUCtlyJUW8oU87zitGsEG1ggXW130aAXCORRmvtm0QDCp7srWyqqaaaej+BZb0acNlUU0011fxI7BmQ7QeA7fy6Y9aiys+VbqrXKz+dNKyZBS6vf7/tf//sZLI0DUTuB/ju9XjsFNdSAr7dzwU7vk2V4cyULEc37j6LjJoD/dtGQMoFFFiHuiP+scZDiqAkqnos6//Vlz8JrsvJD++Rs33/70WmXGpgJay/j1PBS1SnYLqRoU5tn/gXqhNxZEo06sEUVfaOSsVkSt1JVskI1CsFWlU5mx4sU/VfNtVUU029XzV5v23AZVNNNdVUU1NB5vWAx/3kOJbAYrfvvV4QuJ+ey72AsP1///b9Mivzcvp2zwY7SqnKLXa/4LvavhnPzwSvY26yUjGMY4xoYBxFLBZB7JRtLBnLbc/Xzrs6IKXeewlS9TiGz6iR66vI9tiPCg7LtMPunWzrT7mR+StqzJjHu8XWgarUZa0h21NUcL11Iya0zmhWDq61nkulFCifaYmoKutSaguog3OpS3+1GsWQ7HTcXRNF0lRTTb3/1YDLpppqqqmmZgLE3UDK9buOqomx8HZAWX71Nn8Vmf78jdT1SGNdld+ogunLXh+n93puZy/9fpkEcBWoYecIGWunRZ2MkIazs/o03Z6O37b9IeJBE2XUySizElEoqTOG2hvhlKynBStlLyNj22fLFQ/bY0VXLqqVYY9y3qRGai61Ox48wUmQ3I6dy24bIBVHYGQVDoNypQttzRyoBiIdGoVFlMY546NJnKHscVQluxoMh7R41lG0B5cuRKrYkuEMbrEIOC2VG64TFZ7XwQxJg9KCDcZIE8eoBM1CqZ61NNLZpppq6qaDSxG3Z1OG6e/bPQT6h5lV88POIfpJGUQ22/+jd27/ONRP+v658e2bMujf1/Kv77Xt57+Mfabei7hrVqTMXu6uzF8dKDIhzXU7DHvDW1WNOdsOvsZjLqZvf21b3P6PryuhjwRQssPjqPcQ7/o5tn/c1P1Xl/WOnvdy4p12ravtn8nvr7fDKgScHXup/r2q5j7qnMOhqn2tsWANaauD0hGmcN611BVYa1HKTx5Ya70DKjYwdRqLxdmQe4ngnPV9kaIQcYiNApYsUA6cm+idFBl3YxUVXvOPChXMcmrn79g+k6qn0onbBub9v0cUn1MarPPvFc9fSkCe+v/f3r0ut84k2RlemQVu7W53hCPs+7/LsWfcI1T6R1bhQIIHCaJISu8T0c1PEjcPIAhisaoyp38SUln0d42qOiVcn0da2x1Za9/SM3NElY/e3hM5vXWs0abDeltvGlJUFT8oyiAbDvLDXw1//ykd/kghjf89xmiy4n+mPrb5vBf9Sf2248urfz7uvf/v7HPM+QHP/xHnv5f6ZF97fN4LsG28Xxi5BAA81Zc8t05L3ftB/dFWKKfq1ctohV7mn6Wp8Itur/Z6H3Xnv8/pnL1qa0TIbV57uVzjGD0EWlZFVdgc7vsU2dYzs38x4OYnhWn62GKOcPpcKEhtTeJ0efo6nhQ1Ohm11BQsI47WxHoPpSapyuLyfpOBMDQlOStzxJ/Whbbbbt+yxHKE0rLq7PRcLKe/qrhsyNYj1Qf5cGhrLYtkRTl2XKYvTGz1vUIL+SdfbQEg3H7ss4eCPgA+faKP3/nh8h37yt5WJlutNlYjl594fF8Z6LbbfyyD85U1jncPl9dbzZwrzNMWDmoYBh0Ob1nZtV+/uFSzmmrUOk0tXb4+UcrcyqRqCp8Wcz9Ls+FoiLbOhVjd5OEnvUAvbbPjb+OjVyy2LLZjta+n7FO267SV1vtTaaOedQrVq7Y203+f3cl6yaQW9Hxqp7KK7qUoiuf02uKSF5lnoA93qRRZaZVisxWJmUze+31yKAfwjecT/RhJuARAqMRD97mtKqmfDZkf+ffXCup8VRA9Vwn2WjGjz/YZvf3xffz25xOILEBz+Pumw9tbFhhSSJ4tSGRjq/lj0/pB68V+XFKMUq1t/WDIxjpNe42a6zO1Eeqq1TYy6rI+EtqCbo5aZlTrvw+bl7lOl7G9GY43V0SO9G1tx6qYph27mWpME1eny63fazESWRU5/VZZHTYWrVRkJh+GaVSyuknu68JDbvKhqAx/puqxtqzWc3X5rOueCfQrC2IBeJ2ASbgEQLDEy3+YfSaUXjvR/Wy12Wv/3o5Gti6te3n0yfvW6OU0pddMb2//0D//+U8dDodpUWQGzT6F1aQquU81Zlvqi6kPZq6/dHkNycccSYz5+cVqfmdZLw6ek1xuz3bZW5RokeOndbh9u9ejdOl9bWlbH1vb/a1e77kHZl/yqRoZmNtly4utEFCsfs4AKMlD3npuKlylFfExzxHKbMdScnqttWmuKjJvodozdHpvQ5ILPlvxo5pVa2WrgEmlWAC3fhbe+vmztZyDcAkQKm8+aAD3+BA7F2b27r+fuf+PBLNb+lyeez63rLl8xi99jqcb//37V//6179U/hxUTRrD5F4yVrZ1i1FcVk3mVRbvWRwnalY4jWjBLxSq8hhaCK2qtbYgtxyNayssF+1GskBshrasvtrWL/YRzOX1tJ6iuwpddd3rslqV+dyOZFk8qk9rjoi5QJPF6iuHvo50+bMtqukqQuYxtSLJHpal9QwtGhWysCwybGWuKDsUFT9ktdpSpHKYknvUaC1iRp07xfuu1pd8fgCvdy740fft1mcc4RLA05/Q4jGv9Wf6XH7m9o+v98gvN7bWcX7F9v3MmstnPXmfg7Hbn7e/8fef/0N/DoesJtvWL2aBmWy3YaoZLKukGKZAZ5Hh0lSzYmzxKfxZ1GyVcbxveGvp0hLfagu4rYLTVC3We0uTmAKnJFl1LW/EFtVeI0aZ+aqSsPWwGKP68KhtfNtw3Pdz6zXLOkfRpsLmaGwftbS2/UbVNmrZpwDn/4oV1TLIyiAvvaCPz+FfR1m87Woc2QHc61xi+XlEuARAsMRDHY+G3bofnguhzzTyfi0473mMe8P9rrjR8uUwDDr8+SMfcv3jGH3dYKhaG7Vzk6JIxWTxrhqmGq6heE6JjZJhsbULMZOqSo7MqbY2IP2Oi8yz2qpHFtXp000VWq21jOWIpkIZc2MeifT1yKUtRihlJQOg1dXIadQqizYFtb+W08jn+tLbWkot+n32xzPdt7W1lu6SDW3bZR9P91xLaV6mNZkyV5VprFIMvbfl0NKqL0KtZAptrqsNp1QsgLsZLn343PIB/+zTHpiWcd/t8+rTJ/efnL12WLyl9cGlk/5lH7zfsH34smH9t70jm+euu3e7bwW3R72X90y9/artcDkhnt8+tugjury97ENaZVZUDm/6n//rf+v9//6HzIre3gb913/8H/3580dTQ84IKUbV2vqXega3seYInQ2mqCYb67Ru0JVTOyWTl3UMrpFTaDOglQySyimxy8se4GKx9NLzCbSg2P+eazFznWhO040Y2/HNpzuPiAyB0deMzv0ya+R6y365jHX9Z2+FenpBn1GtSm37fViGSFNpfTxd5q7qOSXWi8t8yOfnbQptGeYvCuI0TEbUVaGi6b0h2/3+/unHvVvPDzjP5PPz1Z//V7byYs0lAD4gwGt/p+3z42cCmKkcBh0OB43Fs+WIt6maZjJbVGlVaSGrtl6Rw6LjoqTwHFCrdRGAXNH7YbbqOzkCaIo+dGpVppKXeQPTpc5d1rkFSfbLzHury3WUGtqjqxptDuMZtls8y8WTGWTbes6IozWXi8u6CJJ9/+l9PXtvSnefrmdeNLYgaZ5BvFeUVRkkH9o6TdfUT7Nty+V03rWsgAsA93I1XHJyAeD4eMD0WcIjIDcNf9709vcfev+v/1RUSe5Z3Cdiqr7qRYr6rgjLIjMxKuvIxhSKQm2NpY3tt21qZ5+uaj6FS9UcXXTzLLoT3qbHri9VTdHalqwu+35fjt4P87cCkmoWx2lXmqZum2TWCg2Fz6NXmtdr9mPk2Zkhlo+rj6j2qbA5NXbRcsSHDJVy1TY9Vu5Z/Gco+T8vbWqsWbS1sMtpvNbTLW91AM8SLgFgK5QQMEE4/s3h3aUa8lL09vam/yxF73WUzOXloPH93y3QaQ5KbeGh9am2sSh604v51B7AYprO6a0KbAa2nHZaWkjzFk63Lqtqa+eh9aUvpvpre82uhyt8XL2O0zTXtgB0HFtqm9ZU2hR+42gNaF8T2vtxZrGjNmraCvpkYZ4MwdUkL1kUqbbCQuE5sumlKLzIhz+yobSCRSULDPmZEcvoRYRoRwLgweHy+pokNiLwUxEgeX1/b3jav/1++vaJcZTkVg5vcTi85XTXCLm73uVz9da2RjPCZLUFqRhb5vEssDPWHM3zcZrS6aX0nCnTmGsbbW4NcvU1sfXrMP/tdK3c8jrmfY6rHZ3o9Am0bcQyFuHTFv0tfV1YqF/61BolQ+BouY00TZX1VrSnDamWoV1/nnJspSiGHMHMkctBsmLH/UWiVeHVYnR49cXAtzUkAUC4BIAzJ89MowQwxbNW2OZwOOjw901y1xhSaSNs0/rFftyoJvMMWx6S9fYZNXKUczRFtNYlZrI6H3+KcgpsWRyXik6n6V/r1zb3sDz5JmDOo71s7Pt4dButpUnrJWml6CMlzcyW/Tl765Fcu2nFc9R1WdDHPe/Ri4qZrAzZ69K9rW0dpqJqoZhGinN9KcdqAIRLAE/qKyt54jVfd7B9tp5/RLYj+fv3r4ZeKMZd5TCojjGPXPbFk1F7wwzFewtbniG1T7e3yOI2Ye+r+/M+YujrsGfLULkMl1uPuV23SKoaL7aEiZPflZwy29eSxsf2h9V9ea44rW4qbQ2mq0x9LwczRQ+bVmTFp2mz7iWnH7e+mEtVkZtZlVM8AM8ZLjm5ADh55lhAOAKOQ5pZjrqVUvTn8CaP9ww7PrSiMmPLja31R6lSHebelKWNANYMlxHZiiSXJoaq5mmx89rFOUCaLarAasx2Jl6zxciyimy77L9X/3tktdYi23wvWPHp/tVC6bI1i+L8FN3jdenLYNmrxLp535CtTUmZRyK9FxJqayqLZ/GeaV3moLDSnnvOww2FrCfvGrkwlZmvAL7786HWevPJx571OZzEAHgW9CcDbvlMrxfCZZVqld7/HeP/+2/V939LdVRpFVMtqqLWeW1ljBnMVKdRv6gZFGsdT6qrWki1Vsmqimxaa1mXRX7ex5NWI6Fx+tlUVj8fX9Yda2ZNktVxtS2nirHtZntQrGqjskchs5pPv3N3WWs1khVjM2iOkf9exVX8MAXe0Qb5P/4l+UFlGMzcs99nzKG2+OH0NbfLx8HPnPNxHAVe0e0tibaPBecXBTBnAgAAfFwvROOmsOxjWUMqUSUrqvHf0+mHeY5QjvEuKTQqK832UGaLoNJPZHzwqa9kLz8ztfpQrjNUKwhUrV3K5p9lCnNZjfnvi0tdCU9x5W/FB0WMrd1HqEa09aNt2qyVqZfn2PpZVknepsGalWkEWMUllaz26vm4o3g+xzpvZ7U+lyZvFXCL5UmeT4/spPqtEQwBfB/CJQAAvzIbXg4WVweuWjIys3B3WRu1670VrWbPxvn+QhYHRbzLa+S01ghFOxWZHk+Mq7uYpta2IcE+OuglR+byPrPCq7fps97S6CL/rq7XCrxeef5x4anXqW1In9abGyymfpjr597+o7UiyRHY0irN9v/1Ka99imyG75hCpcvkcvMM8+3fhWf1WdsK/6KqPwDCJQAAeBV9tK1adhmJIrOaawT7SJqHVEMW7/JxUHi00cd5beOc6rLcTters0ZkkoyWOr0NyeWI5kZxH1sErraWc3m9KYPFdusQm/pXnv5dar0nY1SUkoG4mtyz5YpUW2/PUZLnOtO+9tNKjl5OhY58CpjhZXp+uXY1pscuKwp3hbtkg1SKuc//dlUU6ZOJkvZTAAiXAADg+4NEhCJaN0WTzIsiao6UhU2VUPMXVSomq4PM5sI4JuVc2jlKttv16TF6UZt+2oNTv/8zz8NWf55+d6610tlwqUvhst2eFynaVFW3HL1tk3hzZDZbsri1n13T9fuoZK8KK7NpRDIsw6RZrrkMtSm95hlGvV3PWzGgjeclRiwBEC4BAMDTB9MWIMPU/mctVGbADCstnGVFWfWRurJu49F/10NRtOmltb6vQrCpZJEfjbJekGfUqkDPVA32TAGfZcEfV81KrMrfm51emrvcqixOL8NqFiRSlbfGJh4uLW9X2bMzE2VVNc9gPU1/zfWXCm8tSHI6rKSpVUmYy71Now1X9bZCtRf+2eGrCjYCAOESAAB8Qchso23FpahzYZ6QQtl2RHXRvkOt/Yb34cVYpp2c2lljPW11cWlWMlyqKpdsjlN4y6I4GeYixlXIm69Xpuv32/FwVfvEpdt0+z2kZquTdagNtZ+tKFr47MEuR0jL1JIkzOdwGSH5IHdXcctKsH0taW/TYuvtGH36b9uWJ18ILPiFoc09U2sBEC4BAMAvs6ugTx/dy76NOWO0r4tUrrkMmVRd1SIndrYprWaeI3FjtBYjvRZs/v+oHN3LR1ePHm9WWK3TyGiv/lqmy1wrmdVi++9Hra8nlWyVotLWcp5eStamtmrz0s2mdiamVvk2XOHZEiQfb5ve20OjDRkiNV+nj1DGIklHC+HmRVZar8volWOlaqZy1Argq0YfGcUEsOuz5Vqfy1s+nM4diM41Ed763b0OgnzzBgDAZ9TLn7VWsxdlzcuICG//xmUax+xD2au95lrFeaSvTy+1Pl31+H7GquOGIGa2akvSL2vvM7n4vbfgNhfzma8nSUMPfPMfV2srdaGgT5j0HnU6x+jTfJfrMZd9JKO3IlmcknibAhvRwvTUomTuc9mnyYb3yq9u00MeDuuprUcvj/uw+ftpW7KDAxzfP5C31p8DfjZrMXIJAAA+pY+8zacr3kYya+TU19KCXm0nKG0NZpsKOk0JjdIT5RR6Rpsj0FSjJhZhyUxVIQ9TtfVluFSrVC1UzBUWssiqtdZGSmtLijnCGXJ31XwG08/9321dTv0nNU85jRY0q/rM2PZ8/Wg7WYbfHLktuQazFwWyPlLpi1CZzVP69rbFCd9UmGjjC3wA+G6ESwAA8PFg2XqJVGv9LCNMvbJpuMl9/m47al8UuBoxm0b3elBShrGpV2S/XvuWfTnyl2HKWkjUFBZDnte3Vvgn8uewMq19lNXWTjPjZLRLmaY1ktcuVebA2CfxzmseW9RsaynbgOMUQjPelnZ/GT7Nh9bPsoXI2oKkuU3rKFtvTSlHYZdFfWy1Xc6PWALAR6xmYdzw5RXhEgAAfD5k2nH5nQxVfZTRJcmK5YjlGFujbvN/l5bH6uokJqZ/NRcNkuV1w7OabHgb03ObRkSXlxnQWh/JHkDlOUjY2n6Eiry3B4lQaP798WXE+zRNtypHLNsAY4bo4u25WBvktFVxornGkc1TZxcncnVez3oy7Sx8XbDnePSScAngnsf7SxmTcAkAAD7N1YrStAqn09hku6g1xxLzxGQe7qvLBpcmWY0cGbR2q6XfQGSLkB4Kp2/RyypGHZdYOPct+/S71iuyzzONkMxbUSKT6piPpbY1luvLmv0s3eZ+m8uR1lg8oBYqV8HPNI1ALh98RBujjTYtt6Xu4+qtW8/r1hHLvuoVAK75zDR7wiUAAPiU1YianZyVzCFPJot6w221qatajsZJ0dqGrNcY+urkZzl16yRwbZwgufv2Q28jiCq+GmlcX3obQ63Zq1KX10FqcZ0+Qulejh6nbz2XzZHL49v9qKyTCwBfFyoJlwAAYAdvo351ng66EbDmkLkeL7PFWJ+ZTZVWp3E1ayObtd1WmOabjKmSaobP2By5nB/LaQY+mWoax5VpLyXhKj8KszZVjF1PV12Gw1hvpmkdpaQc8bUcz4w29NnXla7DarZ26VN8+xrN1XNRnGT9yg4LYCemxQIAgDueafQwWKfel9m/sbZqqrVNX51bkOTl2KaFRgudvTjNst9Hmxfr/UxmGtVrOayVzYneOtJs+mlxaebtmj3Z9fvpfTanhxr95zFXV67+vr40eevX6Tp6ftVWP5u3v7dCQtmCRRrfWwEj9SI+xeZWJ611i/l6Su1iNFeLNZzHwfLMVwFMiQVw/4+FvX0ub024j7I1TQYAAHylDJURo2qVIkYdDm/T76fQ1ROc1TYwmXEnYtRJ/0udH11cFQNqt6feLzOymqvbMP1+67LWMS71sYyxZrGd1krk+O+qY2ttkrdnfUrvmftTe16u0teV2mqhptYhtsgUXlbnMOuCPf7h869lG5PfhHNB4PSY/dH3z5oTLjmgAADwtZ+vx5+ttdap2fYwDCeBcPXZHKM8brvtZXGe6XM9Pv+5H5YB+OyN5O1EHx3dDGoRMlufddniirF4wnZyA33Npt90/vRV4fI376tsE+B7wiXTYgEAwJcEzEsn78uAmNNA/cKJy9xDsq9b7FeLaW3jmfuRXbjdxamR+6pv5untyLaCXbQpuuuauBvPvfVPObdN8vFfDzsEIgCvhHAJAAA+HSy3Aua5UcfTvpbXG3MfX2+6PL3iUXi7HC7D46b1h9vhzrbu8oP//mOhkZAJgHAJAAB+jVsD0Kq67Mb02s3QeBRmwy7cd6/pc+kxfD5WS6o3P9dppPWT4ZBQCYBwCQAACJIXrxsn4fFssFwExq3R0s1/szeUXQyn3uLpXBV2Kly0+Dm7VJ7+vbcUIVQCIFwCAADC5b3Dz7XbP9en8tbiLfXa47f1fRwv+uyrMsPb5enPoZotV1a/d4Wq4obtu6eROQAQLgEAwEv68oqcvVXl1p90fVprXJ0W+7HwejLV1kxSyUcT3v7cVnG2n/PvLVguLk0l26bcGOAJmQBexdSK5NyHwdWD84tO26AsNQAALx5o95wAfTDnnv5uXyu3a+dXpRReYAB3Uncdn7I/cWxmQkYuAQDArwqWz8DdeREB/DjDMqEyigcAAF7B956xnEbZvedMnHMB+NHhsgdMDngAAACEQwDYFS6XIZODJgAAwH3sndbLWRqApwyX50YrqUwGAABwr3C5s5otgOd9f8fv7WPLmksAAPCK6WwfqzvvbO85E+dcAH5wuCRgAgAA3Bg3d87wMqNaLICfZ+pzebc7IKwC+OTJGccP9g/2AwAAvvrzddx5C/6JvwAAAAAAsDt2AgAAAABAuAQAAAAAEC4BAAAAAC9juFYogX6XAAAAAIBrGLkEAAAAABAuAQAAAACPN3ykz9ytU2S3/g19yvDTsa9/HNuK9wz7Bzh+/qz3B68l2xmvf/61Z1kkI5cAAAAAgN0IlwAAAAAAwiUAAAAAgHAJAAAAACBcAgAAAABAuAQAAAAAEC4BAAAAAM/Aaq37bmBnn5S9/Xke3Qfqp/dp++196L7z+T9Tzyr6Z932+u89PrL/A6/7vnj185dHHx9/+vGT98nt+/fWdXn9761++PVcvk5mZfO1MzMNL5+O2fkAAAAA4OF2h8t7f3MFvLKf/s00X+6A/QcAOP7h577+y9kat+S+gZefnYvnf7/nx/7PhyvY/z+LzweODwD4/Him4+Mt9zuw8QEAAAAAH8lZPzJcPrvfHm5/+vPfW9CK1x9g/2f7AACe6fi45/x1uPeTp5oYODjw+MH+DwAc/8Dr/zOe16V4R59LAAAAAMBuw7W0fcvI47nrmBl93nh+L/38v9Mzbev5mynWNIPjI/s/+/c99g/2n9feDj+9YNe6p6F9+z7wqv22f3qf8Hm/sM0elxIjlwAAAACAL0C4BAAAAHCCEXZ8FNVicRHTwgAAAAiVwC0YuQQAAAAA7MbIJQAAAICrfnrBGuim15dWJAAAAAB2B0vgEsIlAAAAAGA3q7Xe9w7uPGzO8DzbBbj2PnjU8Yntx/Pn+eO37h+PPj/k/QHOny+pu/b1CDu7r7PmEsCPxYc7wPsH4P0BfB/CJQCAkycAAEC4BAAA+GpMewQAwiUAcHIIAODzBXgAqsUCAAAAAHZj5BLAj8U3x/vwzTwAcPwDCJcAAGAXvlwAAHzU1T6Xyw+PrQ8aMzv7AfQVHzzX+s3w4QcAAAAAt9rX5/LSykrWXAIAAAAAdiNcAgAAAAAIlwAAAAAAwiUAAAAAgHAJAAAAAADhEgAAAABAuAQAAAAAPAOr9f3iFSLibK/L/P3lfEqfSQAAAAB4FvVq/jvOcf13mQ3L2X/LyCUAAAAAYDfCJQAAAACAcAkAAAAAIFwCAAAAAAiXAAAAAAAQLgEAAAAAhEsAAAAAwDMYtn657Gly3N/klr6VWz1R7tXvctl389pjAQAAAAB8Lmddy1aMXAIAAAAAdiNcAgAAAAB2G179CTDtFQAAAAAej5FLAAAAAADhEgAAAABAuAQAAAAAEC4BAAAAAJAGMzvpYbLsTXmtj+SW5b+h4A4AAAAA/AyX8iEjlwAAAACA3QY2AQAAAADgFpdmpjJyCQAAAADYjXAJAAAAACBcAgAAAAAejzWXAAAAAICbUC0WAAAAAHBXw6Xkefy3XhmIPpYAAAAA8PMs891WVtzKhP33jFwCAAAAAHYjXAIAAAAACJcAAAAAAMIlAAAAAIBwCQAAAAAA4RIAAAAAQLgEAAAAADyDYStfnuttMv8nvS0BAABwH/38k37qwOPef9dsvT8ZuQQAAAAA7Ea4BAAAAAAQLgEAAAAAhEsAAAAAAOESAAAAAADCJQAAAACAcAkAAAAAeAbD1i+XvU3oLwQAAIDvxPkncD+39rH8DEYuAQAAAACESwAAAADA4w1sAtzTtWH3V5/28tOfHwAAAHArRi4BAAAAALsxcom7+ukjd4xMAgAAAImRSwAAAAAA4RIAAAAA8HjTtNjjwiSvM92vks8B4An1zxWmjwMA8Jj8s118cl9+2bpNM5OZkYwAAAAAALc596VxRMwjl2bGt8wAAAAAgJvCZc+P/dKPr0iwBAAAAADcEjCXCJcAAAAAgN2GrfS5nCILAOdcO07wZRUAAMDvOQcczp0AEjABAAAAAMfB8lynEarFAgAAAABuDpdbzEz2+qOT9aEb1aywhwEAft1JBdPeAeA58s+5UcRb8stXZ0FGLgEAAADgB3j0F3+ESwAAAAB4QcuRx2eYUUK4BAAAAIAX9ixLFQiXAAAAAADCJQAAAAD8Ns9YmJVwCQAAAAAvGiyfqXo34RIAAAAAXjBYPhur9f30lx9Kv/7Qjbc3qe99cT5y/8/ZG2xvn1D/1W9e+rx9zfZlO/L+Z/s99v4/916sO9//9pTvf45L+K797FIvwp+//9UveZ/+tPOzrePP1nNd9qn8riB660gpI5cAAAAAgN0IlwAAAACA3QY2wT4fGZZnig0AAAAunRNyvoivzB/fjZFLAAAAAMBuP37k8tHVlFiwDQB4xOcbny/Aa72Xec/iJ3z+MHIJAAAAANiNcAkAAAAA2M0ixumHz00hvW8+vTZFYO+0oGdqQtof60ce02f6bK49d5+7rT4/13r/4Pv32Xu9Pz+3T3+drX3uK/e/xx/fvu79f+vx67Ov+T1e6/3737jz9dk7Ba7ufP5l5/atO7evP/T9/+zHn688p1gey245hpnZw49vfD7aS78+199fl48f4zhO++u5ffmZ9797nz884vx7+d/Hz295+eurxb76wY81N8D3Hh9YK42vCx/sR4QXXr+fGu5xv33mVV77R54r3Ov4eMsXG8NP2dH4cPs9J2mc3OPRH2S8rwG80mfn8SgEn6Gc373C9j8eaX+G8/6vehyvvH9de+xPHy7vPS2MAyxwv/fns9/+Rw6kW9NCHv3NOyc34PiDz2yfZwiYP/31Y/+83/n9LaNnz7j9l4/p3u+/R51fRATTYl/dbwjHWzs437wCePXjM+eeAICf9ln368Ml3yy9zutzPFrEa4dHHSf4YgN4hfDOZ8TxtnrGIoacv+GW1/nVPncfXXzyHsfHW1+D4afsdPf698/+4fVbpv2y5hLP9P7iCw58zecTxzHcd/87XrPWpxPyOUp4JWQ+7vz7Ffatzxwj+vNiWiwAfODDjBMygJN/8Prh+/eP/uXIK38Of9d+/xX389lt/f8BjQwnBTSIfn8AAAAASUVORK5CYII=",
    alt: "",
    style: {
      width: size,
      height: size,
      objectFit: "contain",
      borderRadius: "6px",
      mixBlendMode: "multiply"
    }
  }
);
const KidneyBeansIcon = ({ size = 24 }) => /* @__PURE__ */ React.createElement("svg", { width: size, height: size, viewBox: "0 0 64 64", fill: "none" }, /* @__PURE__ */ React.createElement(
  "path",
  {
    d: "M8 12C4 14 2 20 2 28C2 36 4 42 8 44C12 46 16 44 18 40C20 36 20 32 18 28C16 24 18 20 20 18C22 16 22 12 18 10C14 8 12 10 8 12Z",
    fill: "#CD5C5C",
    stroke: "#8B0000",
    strokeWidth: "1.5"
  }
), /* @__PURE__ */ React.createElement("path", { d: "M18 24C16 26 16 30 18 34", stroke: "#8B0000", strokeWidth: "1.5", fill: "none" }), /* @__PURE__ */ React.createElement("path", { d: "M10 20C8 24 8 32 10 38", stroke: "#B22222", strokeWidth: "1", opacity: "0.5" }), /* @__PURE__ */ React.createElement(
  "path",
  {
    d: "M56 16C60 18 62 24 62 32C62 40 60 46 56 48C52 50 48 48 46 44C44 40 44 36 46 32C48 28 46 24 44 22C42 20 42 16 46 14C50 12 54 14 56 16Z",
    fill: "#CD5C5C",
    stroke: "#8B0000",
    strokeWidth: "1.5"
  }
), /* @__PURE__ */ React.createElement("path", { d: "M46 28C48 30 48 34 46 38", stroke: "#8B0000", strokeWidth: "1.5", fill: "none" }), /* @__PURE__ */ React.createElement("path", { d: "M54 24C56 28 56 36 54 42", stroke: "#B22222", strokeWidth: "1", opacity: "0.5" }), /* @__PURE__ */ React.createElement("path", { d: "M14 44C14 50 18 56 24 58", stroke: "#DEB887", strokeWidth: "1.5", fill: "none" }), /* @__PURE__ */ React.createElement("path", { d: "M50 48C50 54 46 58 40 60", stroke: "#DEB887", strokeWidth: "1.5", fill: "none" }));
const TelophaseIcon = ({ size = 24 }) => /* @__PURE__ */ React.createElement("svg", { width: size, height: size, viewBox: "0 0 64 64", fill: "none" }, /* @__PURE__ */ React.createElement(
  "path",
  {
    d: "M8 32C8 18 16 8 24 8C28 8 30 12 32 12C34 12 36 8 40 8C48 8 56 18 56 32C56 46 48 56 40 56C36 56 34 52 32 52C30 52 28 56 24 56C16 56 8 46 8 32Z",
    fill: "#E8F5E9",
    stroke: "#4CAF50",
    strokeWidth: "2"
  }
), /* @__PURE__ */ React.createElement("path", { d: "M32 12C32 12 28 22 28 32C28 42 32 52 32 52", stroke: "#81C784", strokeWidth: "2", strokeDasharray: "3 2" }), /* @__PURE__ */ React.createElement("path", { d: "M32 12C32 12 36 22 36 32C36 42 32 52 32 52", stroke: "#81C784", strokeWidth: "2", strokeDasharray: "3 2" }), /* @__PURE__ */ React.createElement("ellipse", { cx: "20", cy: "32", rx: "6", ry: "8", fill: "#7B1FA2", opacity: "0.8" }), /* @__PURE__ */ React.createElement("path", { d: "M17 28L23 28M17 32L23 32M17 36L23 36", stroke: "#9C27B0", strokeWidth: "1.5" }), /* @__PURE__ */ React.createElement("ellipse", { cx: "44", cy: "32", rx: "6", ry: "8", fill: "#7B1FA2", opacity: "0.8" }), /* @__PURE__ */ React.createElement("path", { d: "M41 28L47 28M41 32L47 32M41 36L47 36", stroke: "#9C27B0", strokeWidth: "1.5" }), /* @__PURE__ */ React.createElement("path", { d: "M26 32L38 32", stroke: "#BDBDBD", strokeWidth: "1", strokeDasharray: "2 2" }));
const LotionBottleIcon = ({ size = 24 }) => /* @__PURE__ */ React.createElement("svg", { width: size, height: size, viewBox: "0 0 64 64", fill: "none" }, /* @__PURE__ */ React.createElement("rect", { x: "16", y: "24", width: "32", height: "36", rx: "4", fill: "#FFECD2", stroke: "#DEB887", strokeWidth: "2" }), /* @__PURE__ */ React.createElement("rect", { x: "26", y: "12", width: "12", height: "12", rx: "2", fill: "#E0E0E0", stroke: "#BDBDBD", strokeWidth: "2" }), /* @__PURE__ */ React.createElement("rect", { x: "30", y: "6", width: "4", height: "8", fill: "#BDBDBD" }), /* @__PURE__ */ React.createElement("rect", { x: "34", y: "8", width: "10", height: "4", rx: "2", fill: "#9E9E9E" }), /* @__PURE__ */ React.createElement("rect", { x: "20", y: "32", width: "24", height: "16", rx: "2", fill: "#87CEEB" }), /* @__PURE__ */ React.createElement("circle", { cx: "28", cy: "38", r: "2", fill: "#FFF" }), /* @__PURE__ */ React.createElement("circle", { cx: "36", cy: "40", r: "2", fill: "#FFF" }), /* @__PURE__ */ React.createElement("circle", { cx: "32", cy: "44", r: "1.5", fill: "#FFF" }));
const CATEGORIES = [
  { id: 1, name: "Cardiovascular", icon: "cardio", color: "#E63946" },
  { id: 2, name: "Pulmonology", icon: "\u{1FAC1}", color: "#457B9D" },
  { id: 3, name: "Gastroenterology", icon: "\u{1F4A9}", color: "#2A9D8F" },
  { id: 4, name: "Endocrine", icon: "pancreas", color: "#E9C46A" },
  { id: 5, name: "Urology", icon: "kidneys", color: "#F4A261" },
  { id: 6, name: "Neurology", icon: "neuro", color: "#9B5DE5" },
  { id: 7, name: "Musculoskeletal", icon: "\u{1F9B4}", color: "#00BBF9" },
  { id: 8, name: "Infectious Disease", icon: "virus", color: "#0F766E" },
  { id: 9, name: "Hematology", icon: "hema", color: "#F15BB5" },
  { id: 10, name: "Dermatology", icon: "lotion", color: "#B45309" },
  { id: 11, name: "Mental Health", icon: "\u{1F60A}", color: "#8AC926" },
  { id: 12, name: "Pediatric", icon: "\u{1F476}", color: "#FF99C8" },
  { id: 13, name: "Rheumatology", icon: "\u{1F9B5}", color: "#A8DADC" },
  { id: 14, name: "Oncology", icon: "telophase", color: "#E056FD" },
  { id: 15, name: "Emergency", icon: "\u{1F691}", color: "#FF6B6B" },
  { id: 16, name: "Preventive", icon: "shield", color: "#4ECDC4" },
  { id: 17, name: "HEENT", icon: "heent", color: "#7B8794" },
  { id: 18, name: "Women's Health", icon: "womens", color: "#E88BC4" }
];
const QUESTIONS = [
  {
    "id": 1,
    "categoryId": 17,
    "question": "A 3-year-old female presents with left ear pain. Exam shows a bulging, erythematous TM with absent mobility. She was treated with Amoxicillin for an ear infection 3 weeks ago. What is the appropriate treatment now?",
    "options": [
      "A) Amoxicillin (90mg/kg)",
      "B) Amoxicillin-Clavulanate (Augmentin)",
      "C) Azithromycin",
      "D) Cephalexin"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Augmentin).\n\nPATHOPHYSIOLOGY:\nAcute otitis media (AOM) is a bacterial infection of the middle ear, most commonly caused by Streptococcus pneumoniae, non-typeable Haemophilus influenzae, and Moraxella catarrhalis. In children, the Eustachian tube is shorter, more horizontal, and more compliant than in adults, predisposing to reflux of nasopharyngeal secretions into the middle ear space, especially during or after upper respiratory infections.\n\nCLINICAL REASONING:\nThe AAP 2013 Clinical Practice Guidelines recommend high-dose amoxicillin (80-90 mg/kg/day) as first-line therapy for AOM. However, if the child has received amoxicillin within the preceding 30 days, has concurrent purulent conjunctivitis (suggesting H. influenzae), or has recurrent AOM unresponsive to amoxicillin, the clinician must assume beta-lactamase-producing organisms. Amoxicillin-clavulanate (Augmentin) adds a beta-lactamase inhibitor that restores activity against resistant H. influenzae and M. catarrhalis while maintaining high-dose amoxicillin coverage for S. pneumoniae.\n\nTREATMENT:\n1. First-line (no recent antibiotics): High-dose amoxicillin (80-90 mg/kg/day divided BID)\n2. Treatment failure or recent amoxicillin use (<30 days): High-dose amoxicillin-clavulanate (90 mg/kg/day of amoxicillin component)\n3. Severe PCN allergy (Type I/anaphylaxis): Ceftriaxone IM x3 days or clindamycin\n- Azithromycin has poor middle ear penetration and high S. pneumoniae resistance rates and is no longer routinely recommended\n\nCLINICAL PEARL:\nObservation without antibiotics for 48-72 hours (with safety-net prescription) is appropriate for children over 2 years with unilateral, non-severe AOM per AAP guidelines. Pain management with ibuprofen or acetaminophen should accompany all treatment decisions.\n\nKEY LEARNING POINTS:\nRecent amoxicillin use within 30 days necessitates escalation to amoxicillin-clavulanate to cover beta-lactamase-producing organisms. High-dose formulations (90 mg/kg/day) are essential to overcome intermediate S. pneumoniae resistance. Azithromycin is a poor choice for AOM due to inadequate middle ear concentration and resistance.\n\nREFERENCES:\nAAP 2013 AOM Guidelines; UpToDate; Harrison's Principles of Internal Medicine.\n---"
  },
  {
    "id": 2,
    "categoryId": 4,
    "question": "A 28-year-old female who is 10 weeks pregnant presents with a TSH of 4.5 mIU/L (High). Free T4 is normal. She is asymptomatic. What is the best step?",
    "options": [
      "A) Recheck TSH in 4 weeks",
      "B) Initiate Levothyroxine",
      "C) Reassure, this is normal in pregnancy",
      "D) Order Thyroid Ultrasound"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Initiate Levothyroxine).\n\nPATHOPHYSIOLOGY:\nPregnancy places substantially increased demands on the thyroid gland. Thyroid hormone production must rise by 25 to 50% to meet the metabolic needs of the mother and to supply the fetus, which depends entirely on maternal thyroxine for neurodevelopment during the first trimester before the fetal thyroid becomes functional at approximately 12 weeks of gestation. Human chorionic gonadotropin (hCG), which shares structural homology with TSH, directly stimulates the TSH receptor on thyroid follicular cells during early pregnancy, normally causing a physiologic decrease in TSH during the first trimester. In women with adequate thyroid reserve, this system compensates effectively. However, in women with limited thyroid reserve, whether from subclinical hypothyroidism, Hashimoto thyroiditis, or iodine deficiency, the gland cannot mount a sufficient response, and TSH rises above the trimester-specific reference range.\n\nCLINICAL REASONING:\nThe American Thyroid Association (ATA) 2017 Guidelines for the Management of Thyroid Disease During Pregnancy recommend trimester-specific TSH reference ranges, with a first-trimester upper limit of approximately 4.0 mIU/L when population-based references are unavailable, though many institutions use a threshold of 2.5 mIU/L based on earlier ATA guidance and Endocrine Society recommendations. This patient's TSH of 4.5 mIU/L at 10 weeks gestation exceeds both thresholds and represents overt or subclinical hypothyroidism requiring treatment. Untreated maternal hypothyroidism is associated with significant adverse outcomes including miscarriage, preeclampsia, placental abruption, preterm delivery, low birth weight, and impaired fetal neurocognitive development. A landmark study published in the New England Journal of Medicine (Haddow et al., 1999) demonstrated that children born to mothers with untreated hypothyroidism during pregnancy had IQ scores averaging 7 points lower than controls, underscoring the critical importance of adequate maternal thyroid hormone for fetal brain development.\n\nTREATMENT:\nLevothyroxine is the standard treatment and is safe throughout pregnancy. The typical starting dose for newly diagnosed hypothyroidism in pregnancy is 1 to 2 mcg/kg/day, and women who were already taking levothyroxine prior to conception generally require a 25 to 50% dose increase upon confirmation of pregnancy, ideally within the first 4 to 6 weeks. The ATA recommends monitoring TSH every 4 weeks during the first half of pregnancy and at least once during the second half, with dose adjustments to maintain TSH within the trimester-specific target range. Levothyroxine should be taken on an empty stomach and separated from prenatal vitamins containing iron and calcium by at least 4 hours, as these supplements impair absorption. Postpartum, the levothyroxine dose should be reduced to the pre-pregnancy level and TSH rechecked at 6 weeks.\n\nKEY LEARNING POINTS:\nA TSH above the trimester-specific upper limit in the first trimester requires prompt initiation of levothyroxine to prevent adverse maternal and fetal outcomes. Untreated maternal hypothyroidism impairs fetal neurodevelopment, with studies demonstrating measurable IQ deficits in offspring. Women already on levothyroxine typically require a 25 to 50% dose increase upon pregnancy confirmation, with TSH monitoring every 4 weeks during the first half of pregnancy."
  },
  {
    "id": 3,
    "categoryId": 7,
    "question": "A 45-year-old runner presents with lateral knee pain. It is sharp and occurs after running 2 miles. Exam reveals tenderness 2cm above the lateral joint line. Ober's test is positive. What is the diagnosis?",
    "options": [
      "A) Lateral Meniscus Tear",
      "B) LCL Sprain",
      "C) Iliotibial (IT) Band Syndrome",
      "D) Patellofemoral Pain Syndrome"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Iliotibial Band Syndrome).\n\nPATHOPHYSIOLOGY:\nThe iliotibial band is a thick band of fascia that originates from the iliac crest (via the tensor fasciae latae and gluteus maximus) and inserts on Gerdy's tubercle of the lateral tibia. During running, the IT band repeatedly slides over the lateral femoral epicondyle, and this repetitive friction at approximately 30 degrees of knee flexion generates a localized inflammatory response in the underlying bursa and periosteum. The condition is one of the most common causes of lateral knee pain in runners, accounting for up to 12% of all running-related overuse injuries according to data from sports medicine literature cited in UpToDate. Contributing biomechanical factors include excessive hip adduction, internal rotation of the tibia, training errors (rapid mileage increases), and running on cambered surfaces.\n\nCLINICAL PRESENTATION:\nThe hallmark of IT band syndrome is sharp or burning pain localized to the lateral femoral epicondyle, approximately 2 to 3 centimeters above the lateral joint line, which distinguishes it from lateral meniscal pathology (which causes tenderness at the joint line itself) and lateral collateral ligament sprains (which involve tenderness directly over the ligament and are typically traumatic in origin). Pain characteristically begins at a predictable point during a run and worsens with continued activity, often forcing the runner to stop. Downhill running and stair descent exacerbate symptoms because the knee spends more time near the 30-degree impingement zone. Ober's test assesses IT band tightness by having the patient lie on the unaffected side while the examiner abducts and extends the affected hip, then allows it to adduct; failure of the leg to adduct past the midline indicates a tight IT band.\n\nTREATMENT:\nInitial management focuses on activity modification, relative rest from aggravating activities, and ice application. Physical therapy targeting hip abductor strengthening (particularly the gluteus medius) and IT band stretching is the cornerstone of rehabilitation, as gluteus medius weakness is a consistently identified risk factor. Foam rolling over the lateral thigh may reduce fascial tension. NSAIDs can provide short-term symptomatic relief. Corticosteroid injection into the inflamed bursa beneath the IT band at the lateral epicondyle may be considered for refractory cases. Gradual return to running with correction of training errors is essential to prevent recurrence.\n\nKEY LEARNING POINTS:\nIT band syndrome causes lateral knee pain at the lateral femoral epicondyle, 2 to 3 centimeters above the joint line, distinguishing it from meniscal and ligamentous pathology. Ober's test evaluates IT band tightness and is positive when the leg fails to adduct past midline. Hip abductor strengthening is the cornerstone of rehabilitation because gluteus medius weakness is a primary contributing factor."
  },
  {
    "id": 4,
    "categoryId": 3,
    "question": "You are treating a patient for H. pylori. They have a documented Penicillin allergy (rash). Which regimen is the best choice?",
    "options": [
      "A) Clarithromycin Triple Therapy",
      "B) Bismuth Quadruple Therapy",
      "C) Levofloxacin Triple Therapy",
      "D) Sequential Therapy"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Bismuth Quadruple Therapy).\n\nPATHOPHYSIOLOGY:\nHelicobacter pylori is a gram-negative spiral bacterium that colonizes the gastric mucosa, causing chronic active gastritis, peptic ulcer disease, gastric adenocarcinoma, and MALT lymphoma. Eradication requires combination therapy because monotherapy rapidly induces resistance. Standard first-line clarithromycin triple therapy (PPI, clarithromycin, amoxicillin) relies on amoxicillin as its penicillin-class backbone.\n\nCLINICAL REASONING:\nIn patients with a documented penicillin allergy, amoxicillin-containing regimens are contraindicated. Bismuth quadruple therapy (PPI, bismuth subsalicylate, metronidazole, tetracycline) avoids all penicillin-class antibiotics entirely and is recommended by ACG guidelines as the preferred alternative. This regimen achieves eradication rates of 85-90% even in areas with high metronidazole resistance, because the combination of bismuth and tetracycline compensates for potential resistance. The standard duration is 14 days.\n\nDIFFERENTIAL TREATMENT CONSIDERATIONS:\nClarithromycin triple therapy (Option A) requires amoxicillin and is therefore contraindicated. Levofloxacin triple therapy (Option C) also contains amoxicillin in its standard formulation. Sequential therapy (Option D) uses amoxicillin in its initial phase. Additionally, fluoroquinolone resistance rates now exceed 30% in many regions, making levofloxacin-based regimens less reliable as empiric choices.\n\nKEY LEARNING POINTS:\nBismuth quadruple therapy is the preferred regimen for H. pylori eradication in penicillin-allergic patients because it contains no beta-lactam antibiotics. Standard duration is 14 days with eradication rates of 85-90%. All three alternative options (clarithromycin triple, levofloxacin triple, sequential therapy) contain amoxicillin and are contraindicated with penicillin allergy."
  },
  {
    "id": 5,
    "categoryId": 6,
    "question": "A 30-year-old obese female presents with daily pulsatile headaches and transient visual obscurations. Fundoscopy reveals papilledema. MRI Brain is normal. What is the next diagnostic step?",
    "options": [
      "A) CT Angiogram",
      "B) Lumbar Puncture",
      "C) Trial of Topiramate",
      "D) referral to Ophthalmology"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Lumbar Puncture).\n\nIDIOPATHIC INTRACRANIAL HYPERTENSION:\nThis presentation is classic for idiopathic intracranial hypertension (IIH), formerly called pseudotumor cerebri. IIH predominantly affects obese women of childbearing age and presents with daily headaches (often pulsatile and positional), transient visual obscurations (brief episodes of vision loss), pulsatile tinnitus, and papilledema on fundoscopy. The condition results from impaired CSF absorption or increased CSF production, leading to elevated intracranial pressure without a structural lesion.\n\nPATHOPHYSIOLOGY:\nThe exact mechanism remains debated, but elevated intracranial pressure is thought to result from impaired CSF outflow at the arachnoid granulations, potentially linked to elevated venous sinus pressures. Obesity and female sex hormones play a role, though the precise pathways are not fully understood. The elevated pressure is transmitted to the optic nerve sheaths, causing papilledema and threatening vision.\n\nDIAGNOSIS:\nThe Modified Dandy Criteria require signs and symptoms of elevated ICP, normal neurological examination (except CN VI palsy), normal brain imaging (MRI preferred), elevated opening pressure on lumbar puncture (greater than 25 cm H2O in adults), and normal CSF composition. MRI should be performed first to exclude mass lesions, venous sinus thrombosis, and hydrocephalus. Once imaging is normal, lumbar puncture is the definitive diagnostic step.\n\nTREATMENT:\nWeight loss is the most effective long-term treatment, with even modest reductions (5-10%) improving symptoms. Acetazolamide is first-line pharmacotherapy, reducing CSF production by inhibiting carbonic anhydrase. Topiramate is an alternative that also promotes weight loss. Serial visual field testing monitors for progression. Optic nerve sheath fenestration or CSF shunting may be required for refractory cases threatening vision.\n\nKEY LEARNING POINTS:\nIIH presents in obese young women with headaches, visual obscurations, and papilledema. Lumbar puncture showing elevated opening pressure (greater than 25 cm H2O) with normal CSF is diagnostic after normal imaging. Weight loss is curative and acetazolamide is first-line medical therapy; untreated IIH can cause permanent blindness."
  },
  {
    "id": 6,
    "categoryId": 2,
    "question": "A COPD patient (GOLD Group E) with frequent exacerbations is on LAMA + LABA. Their eosinophil count is 350 cells/uL. What is the next pharmacologic step?",
    "options": [
      "A) Add Inhaled Corticosteroid (ICS)",
      "B) Start Roflumilast",
      "C) Start Azithromycin prophylaxis",
      "D) Add Theophylline"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Add Inhaled Corticosteroid).\n\nPATHOPHYSIOLOGY:\nCOPD is characterized by persistent airflow limitation confirmed by a post-bronchodilator FEV1/FVC ratio less than 0.70 on spirometry per the GOLD 2024 guidelines and Harrison's Principles of Internal Medicine. The disease results from chronic inflammatory responses to inhaled noxious particles (predominantly cigarette smoke), causing small airway fibrosis and parenchymal destruction (emphysema) that progressively trap air and impair gas exchange. Exacerbations, defined as acute worsening of respiratory symptoms requiring additional therapy, accelerate lung function decline, worsen quality of life, and increase mortality per UpToDate.\n\nCLINICAL REASONING:\nThis patient is classified as GOLD Group E (2 or more moderate exacerbations or 1 or more severe exacerbation requiring hospitalization in the past year) and is already on dual bronchodilator therapy with LAMA plus LABA per GOLD 2024. The blood eosinophil count of 350 cells/uL is the critical decision point. The GOLD 2024 guidelines use blood eosinophils to guide ICS therapy: eosinophils 300 or greater strongly support adding ICS, eosinophils 100 to 300 provide moderate support, and eosinophils less than 100 predict minimal ICS benefit with increased pneumonia risk per UpToDate. This patient's eosinophil count of 350 exceeds the 300 threshold, making escalation to LAMA/LABA/ICS triple therapy the recommended next step. The landmark IMPACT trial (published in the New England Journal of Medicine) and the ETHOS trial demonstrated that triple therapy significantly reduces moderate and severe exacerbations and all-cause mortality compared to dual bronchodilator therapy in patients with elevated eosinophils per Harrison's Principles of Internal Medicine.\n\nALTERNATIVE ESCALATION OPTIONS:\nRoflumilast, a phosphodiesterase-4 inhibitor, is reserved for patients who continue to exacerbate despite triple therapy, specifically those with chronic bronchitis phenotype and FEV1 less than 50% predicted per GOLD 2024 and the Cleveland Clinic. Chronic azithromycin prophylaxis is also a post-triple-therapy option for former smokers with persistent exacerbations, though it requires baseline ECG (QTc monitoring) and audiometry. Theophylline has a narrow therapeutic index, significant drug interactions, and limited evidence for exacerbation reduction per UpToDate.\n\nKEY LEARNING POINTS:\nBlood eosinophils 300 or greater in a COPD patient with frequent exacerbations on LAMA/LABA strongly supports adding ICS to form triple therapy per GOLD 2024 guidelines. Roflumilast and azithromycin are reserved for patients who continue to exacerbate despite triple therapy. Only smoking cessation and long-term oxygen therapy (in hypoxemic patients) have been proven to improve survival in COPD."
  },
  {
    "id": 7,
    "categoryId": 1,
    "question": "A 62-year-old female with no history of ASCVD has an LDL of 160 mg/dL. Her calculated 10-year ASCVD risk is 8.5% (Intermediate Risk). She is hesitant to start medication. According to the 2018 AHA/ACC Guidelines, what is the most appropriate next step to aid decision making?",
    "options": [
      "A) Reassurance and lifestyle changes alone",
      "B) Coronary Artery Calcium (CAC) Score",
      "C) Immediate start of Rosuvastatin 20mg",
      "D) Carotid Ultrasound"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Coronary Artery Calcium Score).\n\nCLINICAL REASONING:\nThe 2018 ACC/AHA Cholesterol Guidelines define intermediate risk as a 10-year ASCVD risk between 7.5% and 19.9%, which places patients in a clinical decision zone where statin benefit is present but not overwhelming per UpToDate. For patients in this borderline or intermediate-risk range who are uncertain about starting statin therapy, the guidelines specifically recommend coronary artery calcium (CAC) scoring as a shared decision-making tool to further refine risk stratification per Harrison's Principles of Internal Medicine. CAC scoring uses non-contrast cardiac CT to quantify calcified atherosclerotic plaque in the coronary arteries, expressed as an Agatston score.\n\nINTERPRETATION AND IMPACT:\nA CAC score of zero indicates the absence of calcified coronary plaque and is associated with a very low 10-year event rate (approximately 1 to 2%), which can reasonably support deferring statin therapy and focusing on lifestyle modification per the Cleveland Clinic. A CAC score of 1 to 99 suggests mild atherosclerosis and favors initiating moderate-intensity statin therapy per UpToDate. A CAC score of 100 or greater (or at or above the 75th percentile for age, sex, and ethnicity) indicates significant subclinical atherosclerosis and strongly favors statin initiation per the Mayo Clinic. In this patient with an intermediate 10-year ASCVD risk of 8.5% and hesitancy about medication, the CAC score provides objective evidence of subclinical disease burden that can either justify treatment initiation or support deferral.\n\nSTATIN INTENSITY TIERS:\nHigh-intensity statins (atorvastatin 40 to 80 mg, rosuvastatin 20 to 40 mg) lower LDL by 50% or more and are indicated for clinical ASCVD, LDL 190 mg/dL or greater, and diabetes with multiple risk factors per Harrison's Principles of Internal Medicine. Moderate-intensity statins (atorvastatin 10 to 20 mg, rosuvastatin 5 to 10 mg, simvastatin 20 to 40 mg) lower LDL by 30 to 49% and are appropriate for intermediate-risk primary prevention and diabetes aged 40 to 75 per UpToDate.\n\nKEY LEARNING POINTS:\nCAC scoring is the guideline-recommended risk-refinement tool for intermediate-risk patients (7.5 to 19.9% 10-year ASCVD risk) who are uncertain about starting statin therapy. A CAC score of zero supports deferring statin therapy, while a score of 100 or greater strongly favors initiation. CAC scoring should not be used in patients who already qualify for statin therapy by other criteria (clinical ASCVD, LDL 190 or greater, diabetes)."
  },
  {
    "id": 8,
    "categoryId": 4,
    "question": "A 58-year-old male with T2DM and established Heart Failure with Reduced Ejection Fraction (HFrEF) is on Metformin and lisinopril. A1c is 7.8%. Which second-line agent is MANDATED by the ADA 2024 Standards of Care?",
    "options": [
      "A) Glipizide (Sulfonylurea)",
      "B) Empagliflozin (SGLT2 Inhibitor)",
      "C) Sitagliptin (DPP-4 Inhibitor)",
      "D) Insulin Glargine"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Empagliflozin / SGLT2 Inhibitor).\n\nPATHOPHYSIOLOGY:\nSodium-glucose cotransporter 2 (SGLT2) inhibitors block glucose reabsorption in the proximal convoluted tubule of the kidney, producing glycosuria, osmotic diuresis, and natriuresis. Beyond their glucose-lowering effect, SGLT2 inhibitors exert profound cardiovascular and renal benefits through mechanisms that are largely independent of glycemic control. The osmotic diuresis reduces plasma volume, decreasing cardiac preload, while natriuresis and mild reductions in systemic vascular resistance lower afterload. Additionally, SGLT2 inhibitors shift myocardial fuel metabolism from glucose and fatty acid oxidation toward ketone body utilization, which is a more oxygen-efficient substrate for the failing heart. They also reduce interstitial fluid preferentially over intravascular volume, a hemodynamic advantage over traditional diuretics that helps preserve organ perfusion while relieving congestion.\n\nCLINICAL EVIDENCE:\nThe cardiovascular benefits of SGLT2 inhibitors have been established in multiple landmark randomized controlled trials. The EMPA-REG OUTCOME trial (NEJM 2015) demonstrated that empagliflozin reduced cardiovascular death by 38% and heart failure hospitalization by 35% in patients with type 2 diabetes and established cardiovascular disease. The DAPA-HF trial (NEJM 2019) showed that dapagliflozin reduced the composite of worsening heart failure and cardiovascular death by 26% in patients with HFrEF, with benefits observed regardless of diabetes status. The EMPEROR-Reduced trial (NEJM 2020) confirmed that empagliflozin reduced heart failure hospitalization and cardiovascular death by 25% in HFrEF. These trials collectively demonstrated that the cardiovascular benefits of SGLT2 inhibitors extend beyond glucose lowering, establishing them as foundational heart failure therapy.\n\nCLINICAL REASONING:\nThe ADA 2024 Standards of Care have shifted from a glucocentric treatment paradigm to a comorbidity-centric approach for type 2 diabetes management. Under this framework, the presence of heart failure (either HFrEF or HFpEF) or chronic kidney disease mandates the use of an SGLT2 inhibitor independent of the patient's current A1c level or need for additional glucose lowering. For this patient with established HFrEF, empagliflozin or dapagliflozin is not merely a preferred option but a guideline-mandated addition to metformin. Sulfonylureas lack cardiovascular benefit and may cause hypoglycemia and weight gain. DPP-4 inhibitors are cardiovascular-neutral but do not reduce heart failure events, and saxagliptin has been associated with increased heart failure hospitalization in the SAVOR-TIMI 53 trial. Insulin does not provide cardiovascular benefit and promotes weight gain.\n\nKEY LEARNING POINTS:\nSGLT2 inhibitors are mandated by ADA 2024 Standards of Care for patients with type 2 diabetes and heart failure or CKD, independent of A1c level, based on landmark trials demonstrating reductions in cardiovascular death and heart failure hospitalization. The mechanism of cardiovascular benefit involves preload and afterload reduction, favorable myocardial metabolic substrate shifts, and preferential interstitial fluid clearance. DPP-4 inhibitors should not be substituted, as they lack heart failure benefit and saxagliptin may increase heart failure risk."
  },
  {
    "id": 9,
    "categoryId": 12,
    "question": "A 4-year-old presents with 5 days of high fever (>102 F). Exam shows bilateral non-exudative conjunctivitis, fissured 'strawberry' tongue, and desquamation of the periungual region of the fingers. What is the most critical complication to screen for?",
    "options": [
      "A) Rheumatic Heart Disease",
      "B) Coronary Artery Aneurysms",
      "C) Glomerulonephritis",
      "D) Encephalitis"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Coronary Artery Aneurysms).\n\nPATHOPHYSIOLOGY:\nKawasaki disease is an acute, self-limited febrile vasculitis of unknown etiology that predominantly affects children under 5 years of age and has particular tropism for medium-sized muscular arteries, especially the coronary arteries per Harrison's Principles of Internal Medicine. The disease is the leading cause of acquired heart disease in children in developed countries per UpToDate. The inflammatory process involves all three layers of the arterial wall (panarteritis), and in the coronary arteries this inflammation weakens the vessel wall and leads to aneurysmal dilation in 15 to 25% of untreated children per the Cleveland Clinic. Coronary artery aneurysms can thrombose, causing myocardial infarction in young children, or progress to stenotic lesions that produce chronic ischemic heart disease decades later.\n\nDIAGNOSTIC CRITERIA:\nKawasaki disease is diagnosed clinically when fever persists for 5 or more days plus at least 4 of the following 5 features per the American Heart Association guidelines and UpToDate: bilateral non-exudative conjunctival injection (characteristically limbic-sparing), oral mucosal changes (strawberry tongue, erythematous cracked lips, diffuse oropharyngeal erythema), extremity changes (erythema and edema of hands and feet acutely, followed by periungual desquamation in the subacute phase), polymorphous rash (often accentuated in the perineal region with early desquamation), and unilateral cervical lymphadenopathy (at least 1.5 cm diameter) per the Mayo Clinic. Incomplete Kawasaki disease (fever plus fewer than 4 criteria) should be considered in any child with prolonged unexplained fever, particularly infants who are at highest risk for coronary complications per Harrison's Principles of Internal Medicine.\n\nTREATMENT:\nHigh-dose IVIG (2 g/kg as a single infusion) plus aspirin administered within the first 10 days of illness reduces the incidence of coronary artery aneurysms from approximately 25% to less than 5% per UpToDate and the AHA. High-dose aspirin (80 to 100 mg/kg/day in 4 divided doses) is given during the acute febrile phase for its anti-inflammatory effect, then reduced to low-dose aspirin (3 to 5 mg/kg/day) for 6 to 8 weeks or longer if coronary abnormalities are detected per the Cleveland Clinic. Echocardiography is mandatory at diagnosis, at 2 weeks, and at 6 to 8 weeks to screen for coronary artery involvement, with more frequent monitoring if abnormalities are found.\n\nKEY LEARNING POINTS:\nKawasaki disease requires fever for 5 or more days plus 4 of 5 clinical criteria, and coronary artery aneurysms developing in up to 25% of untreated children are the most feared complication. IVIG plus aspirin within 10 days of illness reduces aneurysm risk to less than 5%. Incomplete Kawasaki should be suspected in any child with prolonged unexplained fever, especially infants who carry the highest risk."
  },
  {
    "id": 10,
    "categoryId": 7,
    "question": "A 50-year-old diabetic female presents with insidious onset of shoulder stiffness. She has lost both active AND passive range of motion in all planes, especially external rotation. X-rays are normal. What is the diagnosis?",
    "options": [
      "A) Rotator Cuff Tear",
      "B) Adhesive Capsulitis (Frozen Shoulder)",
      "C) Subacromial Impingement",
      "D) Glenohumeral Osteoarthritis"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Adhesive Capsulitis).\n\nPATHOPHYSIOLOGY:\nAdhesive capsulitis, commonly known as frozen shoulder, is a fibroproliferative disorder characterized by progressive fibrosis and contracture of the glenohumeral joint capsule. The pathologic process involves chronic inflammation of the synovial lining with subsequent capsular fibrosis, thickening, and contracture, particularly of the coracohumeral ligament and the rotator interval. Histologically, the capsule demonstrates dense type I and type III collagen deposition with fibroblast proliferation, resembling Dupuytren's contracture. Diabetes mellitus is the strongest risk factor, with adhesive capsulitis affecting 10 to 20% of diabetic patients compared to 2 to 5% of the general population, likely due to advanced glycation end-products promoting collagen cross-linking and capsular stiffening. Other associations include thyroid disease, autoimmune conditions, prolonged immobilization, and cardiac or breast surgery.\n\nCLINICAL PRESENTATION:\nThe hallmark of adhesive capsulitis is the loss of both active and passive range of motion in all planes, with external rotation typically the most restricted and earliest affected. This distinguishes it from rotator cuff pathology and subacromial impingement, where passive range of motion is preserved because the joint capsule itself is normal and the examiner can move the arm through its full arc even when the patient cannot do so actively. The disease progresses through three overlapping stages: the freezing phase (2 to 9 months) with progressive pain and increasing stiffness, the frozen phase (4 to 12 months) with minimal pain but significant motion restriction, and the thawing phase (5 to 24 months) with gradual return of motion. Total duration averages 1 to 3 years, though some patients develop permanent mild restriction. Radiographs are typically normal, which helps exclude glenohumeral osteoarthritis where joint space narrowing and osteophytes would be expected.\n\nTREATMENT:\nManagement is guided by disease stage and symptom severity. Physical therapy emphasizing gentle stretching and range of motion exercises is the foundation of treatment across all stages. NSAIDs and acetaminophen provide symptomatic pain relief. Intra-articular corticosteroid injection offers significant short-term improvement in pain and range of motion, particularly during the freezing phase, and is supported by randomized controlled trials. For refractory cases, manipulation under anesthesia or arthroscopic capsular release may be considered. Hydrodilatation (distension arthrography) is an emerging option with growing evidence of efficacy.\n\nKEY LEARNING POINTS:\nThe defining feature of adhesive capsulitis is loss of both active and passive range of motion, which distinguishes it from rotator cuff tears and impingement where passive range of motion is preserved. Diabetes mellitus is the strongest risk factor, affecting 10 to 20% of diabetic patients. The natural history involves freezing, frozen, and thawing phases over 1 to 3 years, though residual restriction may persist."
  },
  {
    "id": 11,
    "categoryId": 3,
    "question": "A 24-year-old male complains of chronic bloody diarrhea, weight loss, and RLQ pain. Colonoscopy shows 'skip lesions' and a 'cobblestone appearance' in the terminal ileum. Biopsy shows transmural inflammation. Diagnosis?",
    "options": [
      "A) Ulcerative Colitis",
      "B) Crohn's Disease",
      "C) Celiac Disease",
      "D) Irritable Bowel Syndrome"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Crohn's Disease).\n\nPATHOPHYSIOLOGY:\nCrohn's disease is a chronic inflammatory bowel disease characterized by transmural inflammation that can affect any segment of the gastrointestinal tract from mouth to anus, though it has a strong predilection for the terminal ileum and proximal colon. The transmural nature of inflammation distinguishes it from ulcerative colitis, which is limited to the mucosa and submucosa. Genetic susceptibility (NOD2/CARD15 mutations), environmental triggers, and dysregulated immune responses to gut microbiota drive a Th1/Th17-mediated inflammatory cascade.\n\nCLINICAL PRESENTATION:\nThe classic triad includes chronic diarrhea (often bloody), abdominal pain (typically right lower quadrant), and weight loss. Endoscopic hallmarks include skip lesions (areas of diseased bowel separated by normal segments), cobblestone mucosa (created by intersecting longitudinal and transverse ulcers with intervening edematous mucosa), and aphthous ulcers. Biopsy reveals transmural inflammation with non-caseating granulomas in approximately 30% of cases, which is pathognomonic when present.\n\nCOMPLICATIONS AND MANAGEMENT:\nTransmural inflammation predisposes to strictures, fistulae (perianal, enteroenteric, enterovesical), and abscess formation. Treatment follows a step-up approach: 5-ASA for mild disease, corticosteroids for flares, immunomodulators (azathioprine, methotrexate) for maintenance, and biologic agents (anti-TNF, anti-integrin, anti-IL-12/23) for moderate-to-severe disease. Approximately 70-80% of patients eventually require surgery.\n\nKEY LEARNING POINTS:\nCrohn's disease is distinguished by transmural inflammation, skip lesions, cobblestone mucosa, and non-caseating granulomas. It can affect any part of the GI tract but favors the terminal ileum. Complications include strictures, fistulae, and abscesses. Approximately 70-80% of patients require surgery during their lifetime."
  },
  {
    "id": 12,
    "categoryId": 11,
    "question": "A patient started on Haloperidol and Lithium develops high fever (104 F), 'lead-pipe' muscle rigidity, and autonomic instability (BP 180/100). CK is elevated to 50,000. Diagnosis?",
    "options": [
      "A) Serotonin Syndrome",
      "B) Neuroleptic Malignant Syndrome (NMS)",
      "C) Malignant Hyperthermia",
      "D) Lithium Toxicity"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Neuroleptic Malignant Syndrome).\n\nPATHOPHYSIOLOGY:\nNeuroleptic Malignant Syndrome (NMS) is a life-threatening idiosyncratic reaction to dopamine receptor-blocking agents, most classically high-potency first-generation antipsychotics such as haloperidol per Harrison's Principles of Internal Medicine. The syndrome results from acute central dopamine D2 receptor blockade in the hypothalamus (causing temperature dysregulation and autonomic instability), the nigrostriatal pathway (causing muscle rigidity), and the mesocortical pathway (causing altered mental status) per UpToDate. NMS occurs in approximately 0.01 to 0.02% of patients exposed to antipsychotics and carries a mortality rate of 5 to 10% if untreated per the Cleveland Clinic.\n\nCLINICAL PRESENTATION:\nThe classic tetrad of NMS is hyperthermia (often exceeding 104Â°F/40Â°C), severe \"lead-pipe\" muscle rigidity (continuous resistance throughout passive range of motion, distinct from the cogwheel rigidity of parkinsonism), autonomic instability (labile blood pressure, tachycardia, diaphoresis), and altered mental status ranging from confusion to obtundation per Harrison's Principles of Internal Medicine. The mnemonic FARM captures these features: Fever, Autonomic instability, Rigidity, Mental status change. Laboratory findings include markedly elevated creatine phosphokinase (CPK) from rhabdomyolysis (often exceeding 1,000 IU/L and frequently above 10,000), leukocytosis, elevated liver transaminases, and metabolic acidosis per UpToDate and the Mayo Clinic.\n\nDIFFERENTIAL DIAGNOSIS:\nNMS must be distinguished from serotonin syndrome, which features clonus, hyperreflexia, and mydriasis (absent in NMS) and develops rapidly (within hours) in the setting of serotonergic drugs per Harvard Health. Malignant hyperthermia occurs with volatile anesthetics and succinylcholine, not antipsychotics. Lithium toxicity causes tremor and ataxia but not lead-pipe rigidity per the Cleveland Clinic.\n\nMANAGEMENT:\nImmediate discontinuation of the offending antipsychotic is essential per UpToDate. Supportive care includes aggressive IV hydration to prevent renal failure from myoglobinuria, active cooling measures, and ICU monitoring. Dantrolene (a direct-acting skeletal muscle relaxant that blocks ryanodine receptor calcium release) and bromocriptine (a dopamine agonist that restores dopaminergic transmission) are the specific pharmacologic treatments per Harrison's Principles of Internal Medicine.\n\nKEY LEARNING POINTS:\nNMS presents with the FARM tetrad (Fever, Autonomic instability, Rigidity, Mental status change) and markedly elevated CPK from rhabdomyolysis. It results from central dopamine D2 blockade, most commonly from high-potency antipsychotics like haloperidol. Treatment requires immediate drug discontinuation, aggressive hydration, and specific therapy with dantrolene or bromocriptine."
  },
  {
    "id": 13,
    "categoryId": 4,
    "question": "A 52-year-old post-menopausal female presents with vaginal spotting. She has a history of PCOS and obesity (BMI 35). Ultrasound shows an endometrial stripe of 12mm. What is the REQUIRED next step?",
    "options": [
      "A) Reassure and monitor",
      "B) Oral Progesterone taper",
      "C) Endometrial Biopsy",
      "D) Total Hysterectomy"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Endometrial Biopsy).\n\nPATHOPHYSIOLOGY:\nEndometrial cancer develops through a well-characterized pathway driven by chronic unopposed estrogen exposure. Estrogen stimulates endometrial proliferation, and in the absence of progesterone-mediated secretory transformation and shedding, the endometrium undergoes progressive hyperplasia that can advance from simple hyperplasia without atypia (low malignant potential) through complex atypical hyperplasia (approximately 25 to 30% risk of progression to carcinoma according to data from JAMA and Harrison's Principles of Internal Medicine) to frank endometrial adenocarcinoma. This patient has three major sources of unopposed estrogen: obesity (adipose tissue contains aromatase, which converts adrenal androgens to estrone, a bioactive estrogen), PCOS (chronic anovulation eliminates the cyclic progesterone exposure that normally induces endometrial shedding), and postmenopausal status (loss of ovarian progesterone production). Type I endometrial cancers, which account for approximately 80% of cases, are estrogen-driven, typically endometrioid histology, lower grade, and generally carry a favorable prognosis when detected early.\n\nCLINICAL REASONING:\nPostmenopausal bleeding is the cardinal symptom of endometrial cancer and must be considered malignant until proven otherwise. While atrophic vaginitis and endometrial atrophy account for the majority of cases, endometrial cancer is present in approximately 10% of postmenopausal women who present with vaginal bleeding according to data from the American College of Obstetricians and Gynecologists (ACOG). Transvaginal ultrasound is an appropriate initial evaluation to measure endometrial thickness. In postmenopausal women with vaginal bleeding, an endometrial stripe of 4 mm or less carries a negative predictive value exceeding 99% for endometrial cancer, and biopsy may reasonably be deferred in this setting per ACOG guidelines. However, an endometrial stripe greater than 4 mm requires tissue sampling. This patient's endometrial stripe of 12 mm is significantly thickened and, combined with her multiple risk factors, mandates endometrial biopsy without delay.\n\nDIAGNOSIS:\nOffice endometrial biopsy using a Pipelle aspiration catheter is the first-line diagnostic procedure, offering 90 to 98% sensitivity for detecting endometrial cancer per UpToDate. The procedure is performed without anesthesia in the outpatient setting and provides adequate tissue for histopathologic evaluation in the majority of cases. When office biopsy yields insufficient tissue, is technically unsuccessful (as may occur with cervical stenosis), or returns inconclusive results, dilation and curettage with or without hysteroscopy is indicated. Hysteroscopy with directed biopsy is particularly useful for evaluating focal lesions such as endometrial polyps, which may harbor focal malignancy not captured by blind sampling.\n\nKEY LEARNING POINTS:\nPostmenopausal bleeding is endometrial cancer until proven otherwise, with malignancy present in approximately 10% of cases. An endometrial stripe greater than 4 mm in a postmenopausal woman with bleeding requires tissue sampling, and office Pipelle biopsy is first-line with 90 to 98% sensitivity. The major risk factors for endometrial cancer, including obesity, PCOS, nulliparity, tamoxifen use, and estrogen-only hormone therapy, all share a common mechanism of chronic unopposed estrogen stimulation."
  },
  {
    "id": 14,
    "categoryId": 8,
    "question": "A 22-year-old male presents with purulent penile discharge. NAAT is positive for Gonorrhea. He has no known allergies. What is the CDC 2021 Update treatment?",
    "options": [
      "A) Ceftriaxone 250mg IM x1",
      "B) Ceftriaxone 500mg IM x1",
      "C) Azithromycin 1g PO x1",
      "D) Cefixime 400mg PO x1"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Ceftriaxone 500mg IM).\n\nPATHOPHYSIOLOGY:\nNeisseria gonorrhoeae is a gram-negative diplococcus that infects columnar and transitional epithelium of the urethra, cervix, rectum, pharynx, and conjunctiva. The organism attaches via pili and Opa proteins, invades mucosal cells, and triggers an intense neutrophilic inflammatory response that produces the characteristic purulent discharge. N. gonorrhoeae has demonstrated a remarkable ability to develop antimicrobial resistance through chromosomal mutations and plasmid-mediated mechanisms, driving repeated changes in treatment guidelines.\n\nCLINICAL MANIFESTATIONS:\nIn men, urethritis with purulent discharge and dysuria is the most common presentation, typically appearing 2-5 days after exposure. Women may present with mucopurulent cervicitis, but up to 50% of female genital infections are asymptomatic. Untreated infection can ascend to cause epididymitis in men and pelvic inflammatory disease (PID) in women, potentially leading to infertility. Disseminated gonococcal infection presents with the classic triad of tenosynovitis, dermatitis (pustular skin lesions), and migratory polyarthralgia.\n\nTREATMENT:\nThe CDC 2021 STI Treatment Guidelines recommend ceftriaxone 500mg IM as a single dose for uncomplicated gonorrhea in patients weighing less than 150 kg (1g IM for those â‰¥1 50 kg). This represents a dose increase from the prior 250mg recommendation due to rising minimum inhibitory concentrations. Dual therapy with azithromycin is no longer routinely recommended; however, if chlamydial co-infection has not been excluded, doxycycline 100mg BID for 7 days should be added. Oral cefixime is an alternative only when IM ceftriaxone is unavailable, and requires a test-of-cure at 7 days. All patients should be retested for reinfection at 3 months.\n\nKEY LEARNING POINTS:\nCeftriaxone 500mg IM is the current standard for uncomplicated gonorrhea per CDC 2021 guidelines. Add doxycycline if chlamydia has not been excluded. Oral cefixime requires test-of-cure and is only used when ceftriaxone is unavailable. Retest for reinfection at 3 months.\n\nREFERENCES:\nCDC 2021 STI Treatment Guidelines; UpToDate; Harrison's Principles of Internal Medicine.\n---"
  },
  {
    "id": 15,
    "categoryId": 6,
    "question": "A 65-year-old male presents with acute continuous vertigo, nausea, and gait instability. He cannot walk without falling to the left. Head Impulse Test is NORMAL. No hearing loss. What is the most likely diagnosis?",
    "options": [
      "A) Vestibular Neuritis",
      "B) BPPV",
      "C) Cerebellar Stroke",
      "D) Meniere's Disease"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Cerebellar Stroke).\n\nCLINICAL REASONING:\nThe distinction between central and peripheral vertigo is critical in the emergency setting. This patient's presentation suggests a central cause (cerebellar stroke) based on three key findings: inability to walk (severe gait ataxia with falling to one side), normal Head Impulse Test (HIT), and the acute, continuous nature of symptoms.\n\nHEAD IMPULSE TEST INTERPRETATION:\nThe HIT assesses the vestibulo-ocular reflex. In peripheral vertigo (vestibular neuritis), the affected labyrinth cannot generate a compensatory eye movement, so the patient makes a \"catch-up\" saccade when the head is turned toward the affected side (abnormal/positive HIT). In central vertigo, the peripheral vestibular apparatus is intact, so the HIT is normal. A NORMAL HIT in a patient with acute vertigo should raise concern for stroke.\n\nHINTS EXAM:\nThe HINTS exam (Head Impulse, Nystagmus type, Test of Skew) is more sensitive than early MRI for posterior circulation stroke. Central signs include: normal head impulse test, direction-changing nystagmus, and skew deviation (vertical misalignment of eyes).\n\nCEREBELLAR STROKE RED FLAGS:\nSevere gait instability with inability to walk, vertical nystagmus or direction-changing nystagmus, new headache, and any focal neurological deficits.\n\nKEY LEARNING POINTS:\nA normal Head Impulse Test in acute vertigo suggests central pathology (stroke). Inability to walk with acute vertigo is a red flag for cerebellar stroke. The HINTS exam outperforms MRI in the first 24-48 hours for posterior circulation stroke."
  },
  {
    "id": 16,
    "categoryId": 2,
    "question": "An 18-year-old with asthma uses his Albuterol inhaler 4 times a week and wakes up coughing 3 times a month. FEV1 is 85%. According to NHLBI 'Rules of Two', how is this classified?",
    "options": [
      "A) Intermittent",
      "B) Mild Persistent",
      "C) Moderate Persistent",
      "D) Severe Persistent"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Mild Persistent).\n\nCLASSIFICATION:\nAsthma severity is classified according to the NHLBI guidelines using the \"Rules of Two\" framework per UpToDate. Intermittent asthma is defined as symptoms 2 or fewer days per week, nighttime awakenings 2 or fewer times per month, SABA use 2 or fewer days per week, and FEV1 greater than 80% predicted with no interference with normal activity. Any parameter exceeding these thresholds crosses into persistent asthma. The classifications are: mild persistent (symptoms more than 2 days per week but not daily, nighttime awakenings 3 to 4 times per month), moderate persistent (daily symptoms, nighttime awakenings more than 1 time per week but not nightly, FEV1 60 to 80%), and severe persistent (symptoms throughout the day, nighttime awakenings often nightly, FEV1 less than 60%) per Harrison's Principles of Internal Medicine.\n\nCLINICAL REASONING:\nThis patient uses albuterol 4 times per week (exceeds the 2 days per week threshold) and has nocturnal awakenings 3 times per month (exceeds the 2 times per month threshold). The FEV1 of 85% is greater than 80%. These parameters place the patient in the mild persistent category per the NHLBI stepwise approach. Any single parameter at a higher severity level determines the overall classification, so even if other parameters suggest intermittent disease, the symptom frequency and nocturnal awakenings classify this as at minimum mild persistent asthma per UpToDate.\n\nTREATMENT:\nMild persistent asthma requires Step 2 therapy per NHLBI and GINA 2024 guidelines. The GINA 2024 preferred Track 1 approach is as-needed low-dose ICS-formoterol (such as budesonide-formoterol) used as both maintenance and reliever therapy. The Track 2 alternative is a daily low-dose inhaled corticosteroid with as-needed SABA per the Mayo Clinic. The landmark SYGMA trials demonstrated that as-needed ICS-formoterol reduces severe exacerbations by 60 to 70% compared to SABA-only treatment. SABA-only treatment without any anti-inflammatory controller is no longer recommended even for mild asthma per GINA 2024, as it fails to address underlying airway inflammation and increases the risk of severe exacerbations and asthma-related death.\n\nKEY LEARNING POINTS:\nThe Rules of Two identify persistent asthma requiring controller therapy: symptoms more than 2 days per week, nighttime awakenings more than 2 times per month, or SABA use more than 2 days per week. The highest-severity parameter determines the overall classification. GINA 2024 recommends against SABA-only treatment even for mild asthma, favoring as-needed ICS-formoterol as both maintenance and reliever."
  },
  {
    "id": 17,
    "categoryId": 14,
    "question": "You are performing a biopsy on a suspicious pigmented lesion on the back. What is the correct biopsy technique?",
    "options": [
      "A) Shave Biopsy",
      "B) Punch Biopsy",
      "C) Excisional Biopsy with 1-3mm margins",
      "D) Wide Local Excision with 1cm margins"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Excisional Biopsy with 1-3mm margins).\n\nPATHOPHYSIOLOGY:\nWhen melanoma is suspected based on clinical features such as asymmetry, border irregularity, color variation, diameter greater than 6mm, or evolution (the ABCDE criteria), the biopsy technique must preserve the full depth of the lesion to allow accurate histopathologic assessment. The single most important prognostic factor in melanoma is Breslow depth, which measures the vertical thickness of the tumor in millimeters from the granular layer of the epidermis to the deepest identifiable melanoma cell per Harrison's Principles of Internal Medicine. Breslow depth directly determines the recommended surgical margins for definitive wide local excision, sentinel lymph node biopsy candidacy, AJCC staging, and overall prognosis.\n\nBIOPSY TECHNIQUE:\nAn excisional biopsy removes the entire visible lesion with narrow 1 to 3mm clinical margins down to the subcutaneous fat, providing the pathologist with the complete specimen for assessment of Breslow depth, ulceration status, mitotic rate, microsatellite status, and peripheral margins. This information is essential for accurate staging and planning definitive surgical management. For lesions where complete excision is impractical due to size or anatomic location (face, digits, acral sites), an incisional biopsy or deep punch biopsy through the thickest or most clinically suspicious area is an acceptable alternative per UpToDate and AAD guidelines, as studies have not shown that incisional biopsy worsens prognosis.\n\nWHY SHAVE AND PUNCH BIOPSIES ARE INADEQUATE:\nShave biopsies transect the lesion horizontally and frequently fail to capture the deepest point of invasion, resulting in an artificially thin Breslow measurement that understages the tumor and may lead to inadequate surgical margins and failure to offer sentinel lymph node biopsy when indicated. Punch biopsies sample only a small portion of the lesion and may miss the thickest area, similarly compromising staging accuracy. Wide local excision with 1cm or greater margins should not be performed as the initial biopsy because definitive margins depend on Breslow depth, which is unknown prior to pathologic evaluation.\n\nKEY LEARNING POINTS:\nSuspected melanoma requires excisional biopsy with 1 to 3mm margins to accurately measure Breslow depth, the most important prognostic factor that determines definitive surgical margins and sentinel lymph node biopsy candidacy per NCCN guidelines. Shave biopsies are contraindicated for suspected melanoma because transecting the base may lead to inaccurate staging. When excision is impractical, a deep incisional biopsy through the thickest area is acceptable."
  },
  {
    "id": 18,
    "categoryId": 5,
    "question": "A 78-year-old female presents with Urge Incontinence (overactive bladder). She has a history of dementia. Which medication should be AVOIDED?",
    "options": [
      "A) Mirabegron (Beta-3 agonist)",
      "B) Oxybutynin (Anticholinergic)",
      "C) Kegel Exercises",
      "D) Timed Voiding"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Oxybutynin should be AVOIDED).\n\nPHARMACOLOGY:\nOxybutynin is an anticholinergic (antimuscarinic) medication used for urge incontinence and overactive bladder (OAB) that acts by blocking muscarinic M3 receptors on the detrusor muscle, reducing involuntary bladder contractions per Harrison's Principles of Internal Medicine and UpToDate. However, oxybutynin is the most centrally-penetrating anticholinergic in its class because it readily crosses the blood-brain barrier due to its high lipophilicity, and it has significant M1 receptor antagonism in the central nervous system per the Cleveland Clinic.\n\nCOGNITIVE RISK IN ELDERLY:\nThe American Geriatrics Society Beers Criteria strongly recommend avoiding all anticholinergic medications in patients with dementia or cognitive impairment per Harvard Health and UpToDate. Anticholinergic medications worsen cognitive function by blocking central muscarinic M1 receptors in the hippocampus and cortex, which are critical for memory consolidation and attention per Harrison's Principles of Internal Medicine. A landmark study published in JAMA Internal Medicine demonstrated that cumulative anticholinergic exposure over 3 or more years was associated with a 54% increased risk of developing dementia per the Mayo Clinic. In patients with existing dementia, anticholinergics directly oppose the mechanism of cholinesterase inhibitors (donepezil, rivastigmine) that are prescribed to improve cognitive function per UpToDate.\n\nSAFER ALTERNATIVES:\nMirabegron (Myrbetriq), a beta-3 adrenergic agonist that relaxes the detrusor muscle through a non-anticholinergic mechanism, is the preferred pharmacologic option for OAB in elderly patients with cognitive impairment per the Cleveland Clinic. Vibegron is another beta-3 agonist alternative. If an anticholinergic must be used, darifenacin, trospium, or fesoterodine have lower CNS penetration than oxybutynin per UpToDate. Non-pharmacologic interventions (bladder training, timed voiding, pelvic floor exercises, fluid management) should be first-line in all elderly patients per the Mayo Clinic.\n\nKEY LEARNING POINTS:\nOxybutynin should be avoided in patients with dementia because it crosses the blood-brain barrier and blocks M1 receptors critical for memory, opposing the effect of cholinesterase inhibitors. Cumulative anticholinergic exposure increases dementia risk by 54%. Mirabegron (beta-3 agonist) is the preferred alternative as it has no anticholinergic CNS effects."
  },
  {
    "id": 19,
    "categoryId": 9,
    "question": "A 30-year-old female has Microcytic Anemia (MCV 72). Ferritin is Normal. TIBC is Normal. Electrophoresis shows elevated Hemoglobin A2 (>3.5%). Diagnosis?",
    "options": [
      "A) Iron Deficiency Anemia",
      "B) Alpha Thalassemia Trait",
      "C) Beta Thalassemia Trait",
      "D) Sideroblastic Anemia"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Beta Thalassemia Trait).\n\nDIAGNOSTIC REASONING:\nThis patient presents with microcytic anemia (MCV 72) but normal ferritin and normal total iron-binding capacity (TIBC), which effectively rules out iron deficiency anemia (where ferritin is low and TIBC is elevated as the body attempts to maximize iron absorption) per Harrison's Principles of Internal Medicine and UpToDate. The hemoglobin electrophoresis showing elevated HbA2 (greater than 3.5%) is the diagnostic hallmark of beta-thalassemia trait per the Cleveland Clinic.\n\nPATHOPHYSIOLOGY:\nBeta-thalassemia results from mutations (over 300 identified) in the beta-globin gene on chromosome 11, causing reduced (beta-plus) or absent (beta-zero) production of beta-globin chains per Harrison's Principles of Internal Medicine. In beta-thalassemia trait (heterozygous, one normal and one affected beta-globin gene), the mild reduction in beta-chain synthesis produces a characteristic pattern: mild microcytic hypochromic anemia (hemoglobin typically 9 to 12 g/dL with MCV 60 to 75 fL), elevated red blood cell count (a key distinguishing feature from iron deficiency, which has low RBC count), and compensatory increase in delta-chain production leading to elevated HbA2 (alpha-2-delta-2 tetramer) per UpToDate and the Mayo Clinic.\n\nDIFFERENTIAL DIAGNOSIS OF MICROCYTIC ANEMIA:\nThe mnemonic TAILS covers the major causes: Thalassemia, Anemia of chronic disease, Iron deficiency, Lead poisoning, and Sideroblastic anemia per the Cleveland Clinic. The Mentzer Index (MCV divided by RBC count) helps distinguish thalassemia trait (less than 13, reflecting high RBC count with low MCV) from iron deficiency anemia (greater than 13, reflecting low RBC count) per Harvard Health. Iron studies (ferritin, TIBC, serum iron, transferrin saturation) further differentiate the causes per Harrison's Principles of Internal Medicine.\n\nCLINICAL SIGNIFICANCE:\nBeta-thalassemia trait is clinically benign and typically requires no treatment, but genetic counseling is essential because two carrier parents have a 25% chance of producing a child with beta-thalassemia major (Cooley's anemia), a severe transfusion-dependent hemolytic anemia per UpToDate. Patients with thalassemia trait should not be treated with iron supplementation unless concomitant iron deficiency is documented, as unnecessary iron can lead to iron overload per the Mayo Clinic.\n\nKEY LEARNING POINTS:\nBeta-thalassemia trait presents with microcytic anemia, normal iron studies, and elevated HbA2 on electrophoresis. The Mentzer Index (MCV/RBC) less than 13 favors thalassemia over iron deficiency. Thalassemia trait is benign but requires genetic counseling, and unnecessary iron supplementation should be avoided."
  },
  {
    "id": 20,
    "categoryId": 7,
    "question": "A 65-year-old male complains of leg pain that worsens with walking and is relieved by leaning forward (shopping cart sign) or sitting. Pulses are normal. What is the diagnosis?",
    "options": [
      "A) Vascular Claudication",
      "B) Lumbar Spinal Stenosis (Neurogenic Claudication)",
      "C) Herniated Disc",
      "D) Hip Osteoarthritis"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Lumbar Spinal Stenosis / Neurogenic Claudication).\n\nPATHOPHYSIOLOGY:\nLumbar spinal stenosis is a degenerative narrowing of the central spinal canal, lateral recesses, or neural foramina that compresses the cauda equina nerve roots. The narrowing results from a combination of age-related changes including ligamentum flavum hypertrophy (which can thicken from a normal 2 to 4 millimeters to over 7 millimeters), facet joint arthropathy with osteophyte formation, disc bulging, and spondylolisthesis. These changes are nearly universal in patients over 60 years of age on imaging, though only a subset become symptomatic. Spinal extension (standing erect, walking upright) further narrows the canal by telescoping the laminae and buckling the ligamentum flavum inward, while spinal flexion (sitting, leaning forward) opens the canal by separating the posterior elements and stretching the ligamentum flavum, thereby reducing nerve root compression.\n\nCLINICAL PRESENTATION:\nNeurogenic claudication is the clinical hallmark of lumbar spinal stenosis and presents as bilateral or unilateral leg pain, heaviness, numbness, or weakness that is provoked by walking and prolonged standing and relieved by sitting or forward flexion. The classic \"shopping cart sign\" describes patients who lean forward on a shopping cart while walking because the flexed posture opens the spinal canal and alleviates their symptoms. Patients often report greater comfort walking uphill (which requires forward flexion) than downhill (which promotes extension). This positional dependence is the critical feature that distinguishes neurogenic claudication from vascular claudication caused by peripheral arterial disease. Vascular claudication produces pain with walking only (not standing), is relieved simply by rest without a positional component, and is associated with diminished peripheral pulses and an abnormal ankle-brachial index below 0.9. In neurogenic claudication, peripheral pulses are normal and the ABI is 0.9 or greater.\n\nDIAGNOSIS AND MANAGEMENT:\nMRI of the lumbar spine is the gold standard imaging study, demonstrating central canal stenosis, foraminal narrowing, and the specific degenerative contributors. Conservative management is first-line and includes physical therapy emphasizing flexion-based exercises (Williams flexion exercises), NSAIDs for pain relief, and gabapentin or pregabalin for neuropathic symptoms. Epidural steroid injections may provide intermediate-term relief. Surgical decompressive laminectomy is reserved for patients with refractory symptoms despite adequate conservative treatment and has demonstrated sustained improvement in pain and walking capacity in the SPORT trial.\n\nKEY LEARNING POINTS:\nNeurogenic claudication from spinal stenosis causes leg pain with walking and standing that is relieved by sitting or forward flexion, while vascular claudication causes pain with walking only that resolves with rest alone. The shopping cart sign reflects the patient's instinctive adoption of a flexed posture to open the narrowed spinal canal. Normal peripheral pulses and a normal ABI distinguish neurogenic from vascular claudication."
  },
  {
    "id": 21,
    "categoryId": 7,
    "question": "A 66-year-old female has a T-score of -2.6 in the lumbar spine. You start Alendronate. What is the most important patient education instruction?",
    "options": [
      "A) Take with food to prevent nausea",
      "B) Take with a full glass of water and stay upright for 30 mins",
      "C) Take at bedtime",
      "D) Take with milk to increase absorption"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Take with a full glass of water and stay upright for 30 minutes).\n\nPATHOPHYSIOLOGY:\nOral bisphosphonates such as alendronate are nitrogen-containing pyrophosphate analogs that bind to hydroxyapatite on bone surfaces and are selectively taken up by osteoclasts during bone resorption. Once internalized, they inhibit farnesyl pyrophosphate synthase in the mevalonate pathway, disrupting osteoclast cytoskeletal organization and inducing apoptosis. This potent antiresorptive activity reduces bone turnover and increases bone mineral density. However, the same chemical properties that allow bisphosphonates to bind avidly to bone also make them highly caustic to the esophageal mucosa. Oral bioavailability is extremely poor, less than 1% under optimal conditions, and is further reduced to near zero when taken with food, beverages other than water, or concurrent medications due to chelation with divalent cations such as calcium and magnesium.\n\nADMINISTRATION REQUIREMENTS:\nProper administration of oral bisphosphonates is critical to both efficacy and safety. Patients must take the medication first thing in the morning on a completely empty stomach with a full glass (6 to 8 ounces) of plain water only, as even coffee, juice, or mineral water can reduce absorption. The patient must remain fully upright, either sitting or standing, for at least 30 to 60 minutes after ingestion and must not eat, drink, or take any other medications during this period. These requirements prevent the tablet from lodging in the esophagus or refluxing from the stomach, which can cause severe erosive esophagitis, esophageal ulceration, and rarely esophageal stricture. For patients unable to comply due to gastroesophageal reflux disease, esophageal motility disorders, or inability to remain upright, intravenous zoledronic acid administered once yearly is an effective alternative.\n\nMONITORING AND ADVERSE EFFECTS:\nDXA scanning may be repeated after 2 to 3 years of treatment to assess response, though routine annual monitoring is not necessary. Common adverse effects include gastrointestinal upset and musculoskeletal pain. Rare but serious complications include osteonecrosis of the jaw, which is primarily associated with high-dose intravenous bisphosphonate use in oncology patients but can occur with oral therapy, and atypical subtrochanteric femur fractures, which are associated with prolonged use exceeding 5 years and may be heralded by prodromal thigh or groin pain. A bisphosphonate drug holiday should be considered after 5 years of oral therapy or 3 years of intravenous therapy in lower-risk patients, as the medication accumulates in bone and continues to exert antiresorptive effects for years after discontinuation.\n\nKEY LEARNING POINTS:\nOral bisphosphonates must be taken on an empty stomach with plain water while remaining upright for 30 to 60 minutes to prevent esophageal injury and ensure adequate absorption. Bioavailability is less than 1% and drops to near zero with food or other beverages. Intravenous zoledronic acid is the preferred alternative for patients who cannot tolerate oral administration or comply with positioning requirements."
  },
  {
    "id": 22,
    "categoryId": 5,
    "question": "A patient has Na+ of 128. They are clinically euvolemic (no edema, moist membranes). Urine Osmolality is High (>100). Urine Sodium is High (>20). TSH and Cortisol are normal. Diagnosis?",
    "options": [
      "A) Psychogenic Polydipsia",
      "B) SIADH",
      "C) Dehydration",
      "D) Heart Failure"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (SIADH).\n\nDIAGNOSTIC REASONING:\nThis patient presents with hyponatremia (Na+ 128), clinical euvolemia, concentrated urine (osmolality greater than 100 mOsm/kg), and elevated urine sodium (greater than 40 mEq/L), which is the classic laboratory profile of the syndrome of inappropriate antidiuretic hormone secretion (SIADH) per Harrison's Principles of Internal Medicine and UpToDate. SIADH is the most common cause of euvolemic hyponatremia per the Cleveland Clinic.\n\nPATHOPHYSIOLOGY:\nIn SIADH, antidiuretic hormone (ADH, vasopressin) is released from the posterior pituitary in the absence of appropriate physiologic stimuli (hyperosmolality or hypovolemia) per Harrison's Principles of Internal Medicine. Excess ADH causes insertion of aquaporin-2 channels into the collecting duct principal cells, producing inappropriate free water reabsorption that dilutes serum sodium per UpToDate. The patient remains euvolemic (rather than becoming edematous) because the expanded volume triggers compensatory natriuresis via suppression of the renin-angiotensin-aldosterone system and release of atrial natriuretic peptide (ANP), which maintains near-normal volume status at the cost of continued sodium wasting per the Mayo Clinic.\n\nDIAGNOSTIC CRITERIA:\nSIADH is a diagnosis of exclusion requiring: serum osmolality less than 275 mOsm/kg, urine osmolality greater than 100 mOsm/kg (inappropriately concentrated), urine sodium greater than 40 mEq/L, clinical euvolemia, normal thyroid and adrenal function, and no diuretic use per UpToDate and Harvard Health. Hypothyroidism and adrenal insufficiency must be excluded because both can mimic SIADH per Harrison's Principles of Internal Medicine.\n\nCOMMON CAUSES:\nSIADH is caused by CNS disorders (stroke, meningitis, SAH, trauma), pulmonary disease (pneumonia, lung cancer, positive-pressure ventilation), medications (SSRIs, carbamazepine, cyclophosphamide, vincristine, oxytocin, ecstasy/MDMA), malignancy (small cell lung cancer is the classic association, producing ectopic ADH), pain, nausea, and the postoperative state per the Cleveland Clinic and Harrison's Principles of Internal Medicine.\n\nMANAGEMENT:\nFluid restriction (typically 800 to 1,000 mL/day) is first-line treatment per UpToDate. For severe symptomatic hyponatremia (seizures, obtundation), hypertonic saline (3% NaCl) is administered with careful rate correction not exceeding 8 to 10 mEq/L per 24 hours to prevent osmotic demyelination syndrome (central pontine myelinolysis) per Harrison's Principles of Internal Medicine and the Mayo Clinic.\n\nKEY LEARNING POINTS:\nSIADH presents with euvolemic hyponatremia, concentrated urine (osmolality greater than 100), and elevated urine sodium (greater than 40) from inappropriate ADH-mediated free water reabsorption. It is a diagnosis of exclusion requiring normal thyroid and adrenal function. Correction must not exceed 8 to 10 mEq/L per 24 hours to prevent osmotic demyelination syndrome."
  },
  {
    "id": 23,
    "categoryId": 11,
    "question": "A patient wants to quit smoking. He has a history of Seizure Disorder. Which medication is CONTRAINDICATED?",
    "options": [
      "A) Nicotine Patches",
      "B) Varenicline (Chantix)",
      "C) Bupropion (Wellbutrin/Zyban)",
      "D) Nicotine Gum"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Bupropion is contraindicated).\n\nPHARMACOLOGY:\nBupropion (marketed as Wellbutrin for depression and Zyban for smoking cessation) is contraindicated in patients with a seizure disorder or conditions that lower the seizure threshold per Harrison's Principles of Internal Medicine and UpToDate. Bupropion inhibits the reuptake of norepinephrine and dopamine (an NDRI) and has a dose-dependent risk of seizures that increases significantly above 450 mg/day, with an incidence of approximately 0.4% at standard doses per the Cleveland Clinic.\n\nSEIZURE RISK MECHANISM:\nBupropion lowers the seizure threshold through its effects on catecholamine neurotransmission per UpToDate. Additional contraindications include current or prior diagnosis of bulimia or anorexia nervosa (electrolyte disturbances, particularly hyponatremia and hypokalemia from purging, further lower the seizure threshold), abrupt discontinuation of alcohol or benzodiazepines (withdrawal states independently lower seizure threshold), and concurrent use of MAO inhibitors per Harvard Health and the Mayo Clinic.\n\nSAFE ALTERNATIVES FOR SMOKING CESSATION:\nNicotine replacement therapy (patches, gum, lozenges, inhaler, nasal spray) is safe in patients with seizure disorders and works by providing controlled nicotine delivery that reduces withdrawal symptoms and cravings per the CDC. Varenicline (Chantix), a partial agonist at the alpha-4-beta-2 nicotinic acetylcholine receptor, has the highest single-agent quit rates (approximately 25 to 30% sustained abstinence at one year) and does not lower the seizure threshold per UpToDate and the Cleveland Clinic. Initial FDA concerns about neuropsychiatric adverse effects with varenicline were addressed by the EAGLES trial, which found no significant increase in neuropsychiatric events compared to placebo per Harrison's Principles of Internal Medicine.\n\nKEY LEARNING POINTS:\nBupropion is contraindicated in seizure disorders due to dose-dependent seizure risk from catecholamine-mediated lowering of the seizure threshold. Additional bupropion contraindications include bulimia/anorexia, alcohol/benzodiazepine withdrawal, and concurrent MAO inhibitor use. Varenicline (highest quit rates) and nicotine replacement therapy are safe alternatives for smoking cessation in seizure patients."
  },
  {
    "id": 24,
    "categoryId": 5,
    "question": "A 30-year-old female has a UTI. She is otherwise healthy. Local E. coli resistance to Bactrim is >20%. What is the first-line choice?",
    "options": [
      "A) Ciprofloxacin",
      "B) Nitrofurantoin (Macrobid)",
      "C) Amoxicillin",
      "D) Cephalexin"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Nitrofurantoin).\n\nGUIDELINE BASIS:\nThe Infectious Diseases Society of America (IDSA) and AUA guidelines recommend nitrofurantoin (Macrobid, 100 mg twice daily for 5 days) as first-line treatment for uncomplicated cystitis when local TMP-SMX resistance exceeds 20% per UpToDate and Harrison's Principles of Internal Medicine. This case specifies local E. coli resistance to Bactrim (TMP-SMX) above 20%, making TMP-SMX an inappropriate empiric choice per the Cleveland Clinic.\n\nPHARMACOLOGY:\nNitrofurantoin is a nitrofuran antibiotic that is reduced by bacterial flavoproteins to reactive intermediates that damage DNA, RNA, proteins, and cell wall synthesis per Harrison's Principles of Internal Medicine. It achieves high concentrations in urine (its site of action) but negligible serum levels, making it effective for lower UTIs (cystitis) but inappropriate for pyelonephritis or systemic infections per UpToDate. Resistance rates remain remarkably low (less than 5% for most E. coli isolates) despite decades of use, attributed to its multiple concurrent mechanisms of bacterial damage per the Mayo Clinic.\n\nCONTRAINDICATIONS:\nNitrofurantoin is contraindicated in patients with CrCl less than 30 mL/min (previously 60 mL/min, updated to 30 mL/min) because inadequate urinary drug concentrations reduce efficacy and systemic accumulation increases toxicity risk per UpToDate and the Cleveland Clinic. Rare but serious adverse effects include pulmonary fibrosis (with chronic use), hepatotoxicity, and peripheral neuropathy per Harvard Health. It should be avoided in the third trimester of pregnancy (risk of neonatal hemolytic anemia in G6PD-deficient infants) per Harrison's Principles of Internal Medicine.\n\nOTHER FIRST-LINE OPTIONS:\nTMP-SMX (160/800 mg twice daily for 3 days) remains first-line when local resistance is below 20% per UpToDate. Fosfomycin (3 g single dose) is an alternative, though it may be slightly less effective. Fluoroquinolones should be reserved for complicated UTIs and pyelonephritis due to resistance concerns and serious adverse effects (tendon rupture, aortic dissection, QT prolongation, peripheral neuropathy, CNS effects) per the Mayo Clinic and the Cleveland Clinic.\n\nKEY LEARNING POINTS:\nNitrofurantoin is first-line for uncomplicated cystitis when local TMP-SMX resistance exceeds 20%, with less than 5% E. coli resistance rates despite decades of use. It achieves therapeutic concentrations only in urine and is inappropriate for pyelonephritis. Contraindicated when CrCl is less than 30 mL/min and in late pregnancy."
  },
  {
    "id": 25,
    "categoryId": 1,
    "question": "Which of the following contributes points to the CHA2DS2-VASc score?",
    "options": [
      "A) Obesity",
      "B) Female Sex",
      "C) Smoking",
      "D) Hyperlipidemia"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Female Sex).\n\nCLINICAL REASONING:\nThe CHA2DS2-VASc score is the standard tool for estimating annual stroke risk in patients with non-valvular atrial fibrillation and guiding anticoagulation decisions per the AHA and UpToDate. Female sex contributes 1 point to the score, making it the correct answer, though it is considered a stroke risk modifier rather than a standalone indication for anticoagulation per Harrison's Principles of Internal Medicine. Obesity, smoking, and hyperlipidemia are not components of CHA2DS2-VASc despite being general cardiovascular risk factors per the Cleveland Clinic.\n\nSCORE COMPONENTS:\nThe mnemonic CHA2DS2-VASc represents: Congestive heart failure (1 point), Hypertension (1 point), Age 75 years or older (2 points), Diabetes mellitus (1 point), prior Stroke, TIA, or thromboembolism (2 points), Vascular disease including prior MI, peripheral artery disease, or aortic plaque (1 point), Age 65 to 74 (1 point), and Sex category female (1 point), for a maximum of 9 per UpToDate and Harrison's Principles of Internal Medicine.\n\nANTICOAGULATION THRESHOLDS:\nFor men, oral anticoagulation is recommended with a CHA2DS2-VASc score of 2 or greater per the AHA and the Mayo Clinic. For women, because female sex alone does not warrant anticoagulation, the effective threshold is 3 or greater (meaning at least one additional risk factor beyond female sex). Direct oral anticoagulants (apixaban, rivaroxaban, edoxaban, dabigatran) are generally preferred over warfarin for non-valvular AF based on their favorable risk-benefit profile per the Cleveland Clinic and UpToDate.\n\nKEY LEARNING POINTS:\nFemale sex adds 1 point to CHA2DS2-VASc but is a modifier rather than a standalone indication for anticoagulation. Obesity, smoking, and hyperlipidemia are not score components. Men with score 2 or greater and women with score 3 or greater should receive oral anticoagulation, with DOACs preferred over warfarin for non-valvular AF."
  },
  {
    "id": 26,
    "categoryId": 12,
    "question": "Red flag for Autism Spectrum Disorder requiring immediate evaluation?",
    "options": [
      "A) No babbling by 12 months",
      "B) No single words by 16 months",
      "C) No two-word phrases by 24 months",
      "D) Walking on toes at 15 months"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (No babbling by 12 months).\n\nPATHOPHYSIOLOGY:\nAutism spectrum disorder is a neurodevelopmental condition characterized by persistent deficits in social communication and social interaction, along with restricted, repetitive patterns of behavior, interests, or activities per the DSM-5 and Harrison's Principles of Internal Medicine. The neurobiological basis involves atypical neural connectivity and synaptic development, with evidence of both genetic susceptibility (heritability estimated at 80 to 90%) and environmental modifiers per UpToDate. Early signs emerge because the social communication circuits that underlie joint attention, prelinguistic communication, and reciprocal social interaction develop during the first 12 to 18 months of life, and disruptions in these circuits produce detectable behavioral differences before formal language develops per the Cleveland Clinic.\n\nCLINICAL REASONING:\nThe absence of babbling by 12 months is the earliest of the listed red flags and represents failure of prelinguistic communication, a foundational milestone that should emerge by 6 to 9 months and be well-established by 12 months per the CDC. Babbling (repetitive consonant-vowel sequences such as \"ba-ba\" and \"da-da\") reflects the infant's engagement with the social environment and is a precursor to intentional speech. Its absence by 12 months suggests fundamental differences in social communication development that warrant immediate referral rather than watchful waiting per the AAP and UpToDate. Other red flags include no gesturing (pointing, waving) by 12 months, no single words by 16 months, no two-word spontaneous phrases by 24 months, and any loss of previously acquired language or social skills at any age, which is an absolute red flag per the Mayo Clinic.\n\nSCREENING AND INTERVENTION:\nThe AAP recommends universal autism-specific screening using the M-CHAT-R/F (Modified Checklist for Autism in Toddlers, Revised with Follow-Up) at the 18-month and 24-month well-child visits per the CDC. However, developmental surveillance should occur at every well-child visit, and any parental concern should prompt formal evaluation regardless of screening results per UpToDate. Early identification is critical because intensive behavioral intervention initiated before age 3 produces significantly better outcomes in language acquisition, cognitive function, and adaptive behavior, capitalizing on the heightened neuroplasticity of the developing brain per Harrison's Principles of Internal Medicine.\n\nKEY LEARNING POINTS:\nAbsence of babbling by 12 months is the earliest red flag for autism spectrum disorder and warrants immediate developmental evaluation rather than watchful waiting. Any loss of previously acquired language or social skills at any age is an absolute red flag. Early intervention before age 3 leverages peak neuroplasticity and produces the best developmental outcomes."
  },
  {
    "id": 27,
    "categoryId": 13,
    "question": "A 72-year-old female presents with a new onset severe headache, jaw claudication (pain when chewing), and scalp tenderness when brushing her hair. ESR is 85. What is the immediate next step?",
    "options": [
      "A) MRI Brain",
      "B) Temporal Artery Biopsy",
      "C) Start High-Dose Prednisone immediately",
      "D) Prescribe Sumatriptan"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Start High-Dose Prednisone immediately).\n\nCLINICAL URGENCY:\nThis presentation is classic for Giant Cell Arteritis (GCA), also known as temporal arteritis, a large-vessel vasculitis that predominantly affects the branches of the external carotid artery in patients over 50 years of age. The most feared complication is irreversible vision loss from anterior ischemic optic neuropathy caused by occlusion of the posterior ciliary arteries (branches of the ophthalmic artery). Vision loss occurs in 15 to 20 percent of untreated patients and is almost always permanent once established. For this reason, high-dose glucocorticoids (prednisone 40 to 60 mg daily) must be initiated immediately upon clinical suspicion, before biopsy confirmation.\n\nDIAGNOSTIC WORKUP:\nTemporal artery biopsy remains the gold standard for confirming GCA, revealing transmural granulomatous inflammation with multinucleated giant cells and intimal hyperplasia. Importantly, biopsy can be performed up to two weeks after starting steroids without significantly affecting sensitivity, because the histologic changes resolve slowly. Skip lesions (patchy involvement) mean that a negative unilateral biopsy does not exclude the diagnosis, and contralateral biopsy should be considered. Temporal artery ultrasound showing a hypoechoic \"halo sign\" is an emerging noninvasive alternative endorsed by EULAR for early diagnosis.\n\nCLINICAL FEATURES AND LABORATORY FINDINGS:\nThe classic triad includes new-onset temporal headache, jaw claudication (pain with sustained chewing from ischemia of the masseter muscles), and scalp tenderness. Visual symptoms such as amaurosis fugax, diplopia, or sudden vision loss demand emergent treatment. Approximately 40 to 60 percent of GCA patients have concurrent polymyalgia rheumatica with proximal shoulder and hip girdle stiffness. ESR is typically markedly elevated (often greater than 50 mm/hr, sometimes exceeding 100), and CRP is almost universally elevated. A normal ESR does not exclude the diagnosis.\n\nKEY LEARNING POINTS:\nGCA is a medical emergency because of the risk of permanent blindness. High-dose prednisone must be started immediately upon clinical suspicion without waiting for biopsy results. Temporal artery biopsy remains diagnostic and can be performed up to two weeks after initiating steroids. Jaw claudication is the most specific clinical symptom for GCA."
  },
  {
    "id": 28,
    "categoryId": 7,
    "question": "A 45-year-old male with chronic back pain presents with new urinary retention (cannot void) and numbness in his inner thighs/perineum. What is the diagnosis?",
    "options": [
      "A) Sciatica",
      "B) Cauda Equina Syndrome",
      "C) Lumbar Strain",
      "D) Renal Colic"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Cauda Equina Syndrome).\n\nPATHOPHYSIOLOGY:\nCauda equina syndrome results from compression of the cauda equina nerve roots below the level of the conus medullaris, which terminates at approximately the L1-L2 vertebral level. Below this point, the spinal canal contains only free-floating nerve roots (the cauda equina, or \"horse's tail\") that innervate the lower extremities, bladder, bowel, and perineum. The most common cause is a large central lumbar disc herniation, typically at L4-L5 or L5-S1, though other etiologies include spinal tumors, epidural abscess, epidural hematoma, and severe spinal stenosis. Compression disrupts both motor and sensory nerve root function, and because these peripheral nerve roots lack the regenerative capacity of the spinal cord, delayed decompression leads to permanent neurological deficits.\n\nCLINICAL PRESENTATION:\nThe classic presentation includes urinary retention, which is the most sensitive clinical finding at approximately 90% sensitivity and results from disruption of sacral parasympathetic innervation to the detrusor muscle. Saddle anesthesia refers to numbness or decreased sensation in the perineum, perianal region, and inner thighs corresponding to the S2-S5 dermatomes, the area that would contact a saddle. Additional findings include fecal incontinence from loss of anal sphincter tone, bilateral lower extremity weakness or sciatica, and progressive neurological deterioration. A post-void residual volume exceeding 100 to 200 milliliters in a patient with back pain and urinary symptoms should raise immediate concern for cauda equina syndrome and prompt emergent evaluation.\n\nDIAGNOSIS AND MANAGEMENT:\nEmergent MRI of the lumbar spine is the diagnostic study of choice and should not be delayed for other imaging modalities. MRI will demonstrate the compressive lesion and define its extent, guiding surgical planning. Cauda equina syndrome is a surgical emergency requiring urgent decompressive laminectomy. Outcomes are directly correlated with the timing of decompression, with surgery performed within 24 to 48 hours of symptom onset associated with significantly better recovery of bladder, bowel, and motor function compared to delayed intervention. Surgery beyond 48 hours is associated with a markedly higher rate of permanent bladder and bowel dysfunction. Every clinician evaluating patients with back pain must recognize the red flags for cauda equina syndrome, as this diagnosis demands immediate action.\n\nKEY LEARNING POINTS:\nCauda equina syndrome is a surgical emergency requiring decompressive laminectomy within 24 to 48 hours to prevent permanent bladder, bowel, and motor dysfunction. Urinary retention is the most sensitive clinical finding at approximately 90% sensitivity. Saddle anesthesia, bilateral leg weakness, and bowel incontinence complete the classic presentation. Post-void residual measurement should be performed in any patient with back pain and urinary symptoms."
  },
  {
    "id": 29,
    "categoryId": 12,
    "question": "A 6-month-old male has intermittent episodes of severe crying where he pulls his legs up to his chest. Between episodes, he is lethargic. He just passed a stool that looks like 'currant jelly'. What is the diagnosis?",
    "options": [
      "A) Constipation",
      "B) Gastroenteritis",
      "C) Intussusception",
      "D) Pyloric Stenosis"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Intussusception).\n\nPATHOPHYSIOLOGY:\nIntussusception is the most common cause of intestinal obstruction in children between 6 months and 3 years of age, with peak incidence between 5 and 10 months per Harrison's Principles of Internal Medicine. It occurs when a proximal segment of bowel (the intussusceptum) telescopes into the adjacent distal segment (the intussuscipiens), most commonly at the ileocecal junction (ileocolic intussusception accounts for approximately 90% of cases) per UpToDate. The telescoped segment carries its mesentery with it, causing venous congestion, bowel wall edema, and eventually arterial compromise with ischemia and necrosis. A pathologic lead point (Meckel diverticulum, polyp, lymphoma, or Henoch-Schonlein purpura) is found in approximately 25% of cases in children over 2 years, while most cases in younger infants are idiopathic, often following viral infection with associated Peyer patch hypertrophy that serves as the lead point per the Cleveland Clinic.\n\nCLINICAL PRESENTATION:\nThe classic triad is episodic colicky abdominal pain (the child draws the knees to the chest and screams during paroxysms, with intervals of apparent well-being or lethargy between episodes), a palpable sausage-shaped mass in the right upper quadrant or epigastrium, and currant jelly stool per the Mayo Clinic. Currant jelly stool (a mixture of blood and mucus with a dark red, gelatinous appearance) is a late and ominous sign indicating mucosal ischemia and sloughing, and its presence suggests the intussusception has been present for some time per UpToDate. Between episodes, the child may appear lethargic and pale, which is itself a red flag. The complete triad is present in fewer than 50% of cases, and lethargy alone may be the only presenting sign in young infants per Harrison's Principles of Internal Medicine.\n\nDIAGNOSIS AND TREATMENT:\nAbdominal ultrasound is the diagnostic study of choice, demonstrating the pathognomonic target sign (concentric rings on cross-section) or pseudokidney sign (on longitudinal view) with sensitivity and specificity both exceeding 95% per UpToDate. Air enema (pneumatic reduction) or contrast enema (hydrostatic reduction) is both diagnostic and therapeutic, successfully reducing the intussusception in approximately 80 to 90% of cases per the Cleveland Clinic. Contraindications to enema reduction include peritonitis, perforation, or hemodynamic instability, which require emergent surgical intervention. Recurrence occurs in approximately 5 to 10% of cases after successful enema reduction per the Mayo Clinic.\n\nKEY LEARNING POINTS:\nIntussusception presents with episodic colicky pain (knees to chest), lethargy between episodes, and currant jelly stool (a late sign of bowel ischemia) in children 6 months to 3 years. Ultrasound showing the target sign is diagnostic, and air or contrast enema is both diagnostic and therapeutic with 80 to 90% success. Peritonitis or hemodynamic instability requires emergent surgery rather than enema reduction."
  },
  {
    "id": 30,
    "categoryId": 1,
    "question": "A 65-year-old diabetic female presents with vague fatigue, shortness of breath, and nausea for 2 days. She denies chest pain. EKG shows new T-wave inversions in V1-V4. What is the likely diagnosis?",
    "options": [
      "A) Viral Gastroenteritis",
      "B) Anxiety Attack",
      "C) Acute Coronary Syndrome (ACS)",
      "D) GERD"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Acute Coronary Syndrome).\n\nCLINICAL REASONING:\nThis presentation illustrates a critically important concept: diabetic patients and women frequently present with atypical symptoms of acute coronary syndrome, including fatigue, dyspnea, nausea, diaphoresis, and epigastric discomfort rather than classic crushing substernal chest pain per Harrison's Principles of Internal Medicine. Diabetic patients have a higher rate of silent myocardial infarction (with no chest pain at all) due to autonomic neuropathy affecting the cardiac afferent sensory fibers that mediate anginal pain per UpToDate. The new T-wave inversions in V1 through V4 (anterior leads) in this clinical context are diagnostic of myocardial ischemia until proven otherwise per the Cleveland Clinic.\n\nPATHOPHYSIOLOGY:\nAcute coronary syndrome encompasses a spectrum from unstable angina (ischemia without myocardial necrosis, normal troponins) to non-ST-elevation myocardial infarction (NSTEMI, with elevated troponins but no persistent ST elevation) to ST-elevation myocardial infarction (STEMI, with ST elevation and elevated troponins) per Harrison's Principles of Internal Medicine. T-wave inversions with troponin elevation represent NSTEMI, where partial coronary occlusion or distal embolization from a disrupted plaque causes subendocardial rather than transmural ischemia. The anterior distribution (V1 through V4) localizes the ischemia to the left anterior descending coronary artery territory per UpToDate.\n\nDIAGNOSTIC APPROACH:\nAny elderly or diabetic patient presenting with unexplained dyspnea, fatigue, nausea, or diaphoresis should receive a 12-lead EKG and serial troponin measurements, even without chest pain per the Mayo Clinic. High-sensitivity troponin assays can detect myocardial injury within 1 to 3 hours of symptom onset and have a negative predictive value approaching 99% when serial measurements are obtained per UpToDate. Initial management of NSTEMI includes dual antiplatelet therapy (aspirin plus a P2Y12 inhibitor), anticoagulation (heparin), beta-blocker, and high-intensity statin, with early invasive strategy (cardiac catheterization within 24 hours) for high-risk features per Harrison's Principles of Internal Medicine.\n\nKEY LEARNING POINTS:\nDiabetic patients and women often present with atypical ACS symptoms (dyspnea, fatigue, nausea, diaphoresis) rather than classic chest pain due to autonomic neuropathy affecting cardiac pain fibers. Always obtain an EKG and troponins in elderly diabetic patients with unexplained fatigue or dyspnea. T-wave inversions in V1 through V4 localize ischemia to the LAD territory."
  },
  {
    "id": 31,
    "categoryId": 15,
    "question": "A 24-year-old female presents with sudden onset severe LLQ pain and shoulder pain. Her LMP was 6 weeks ago. BP is 90/60, HR 110. Urine HCG is positive. What is the likely diagnosis?",
    "options": [
      "A) Ruptured Ovarian Cyst",
      "B) Ruptured Ectopic Pregnancy",
      "C) Appendicitis",
      "D) PID"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Ruptured Ectopic Pregnancy).\n\nPATHOPHYSIOLOGY:\nAn ectopic pregnancy occurs when a fertilized ovum implants outside the uterine cavity, most commonly in the ampulla of the fallopian tube (approximately 70% of cases) per Harrison's Principles of Internal Medicine. As the embryo grows, it distends and eventually ruptures the thin-walled tube, causing hemorrhage into the peritoneal cavity. Ectopic pregnancy is the leading cause of pregnancy-related mortality in the first trimester, accounting for approximately 3 to 4% of pregnancy-related deaths in the United States per the CDC. Risk factors include prior ectopic pregnancy (the strongest risk factor, with 10 to 25% recurrence), prior pelvic inflammatory disease or tubal surgery, current IUD use, infertility treatments, and smoking per UpToDate.\n\nCLINICAL REASONING:\nThis patient demonstrates the classic presentation of ruptured ectopic pregnancy: a reproductive-age woman with lower abdominal pain, a positive pregnancy test, hemodynamic instability (BP 90/60, HR 110 indicating hemorrhagic shock), and shoulder pain. The shoulder pain is Kehr sign, a critically important finding that results from diaphragmatic irritation by free intraperitoneal blood (hemoperitoneum). The phrenic nerve (C3-C5) innervates the diaphragm, and irritation of its peritoneal surface produces referred pain to the ipsilateral shoulder per Harrison's Principles of Internal Medicine. Any reproductive-age woman presenting with abdominal pain, vaginal bleeding, and a positive pregnancy test must be evaluated for ectopic pregnancy.\n\nDIAGNOSIS AND MANAGEMENT:\nTransvaginal ultrasound combined with serial serum beta-hCG measurement is the standard diagnostic approach per UpToDate. The discriminatory zone (beta-hCG level of 1,500 to 2,000 mIU/mL) is the threshold above which an intrauterine pregnancy should be visible on transvaginal ultrasound; absence of an intrauterine pregnancy above this level strongly suggests ectopic pregnancy. In hemodynamically unstable patients with suspected ruptured ectopic pregnancy, as in this case, emergent surgical intervention (laparoscopy or laparotomy with salpingectomy or salpingostomy) is required without delay for imaging per ACOG guidelines. In hemodynamically stable patients with unruptured ectopic pregnancies smaller than 3.5cm and beta-hCG less than 5,000, medical management with methotrexate (a folate antagonist that inhibits trophoblast proliferation) is an effective alternative per the Mayo Clinic.\n\nKEY LEARNING POINTS:\nShoulder pain (Kehr sign) in a pregnant woman with abdominal pain indicates hemoperitoneum from ruptured ectopic pregnancy until proven otherwise, caused by diaphragmatic irritation via the phrenic nerve. Hemodynamically unstable patients require emergent surgical intervention without delay for imaging. The beta-hCG discriminatory zone (1,500 to 2,000 mIU/mL) guides ultrasound interpretation, and absence of intrauterine pregnancy above this level suggests ectopic pregnancy."
  },
  {
    "id": 32,
    "categoryId": 10,
    "question": "A 40-year-old presents with recurrent painful clusters of vesicles on erythematous bases on the lips, preceded by tingling. Episodes occur 6-8 times per year, especially during times of stress. What is the most appropriate management?",
    "questionImages": [
      {
        "src": "assets/derm-q1-herpes.png",
        "alt": "Grouped vesicular herpes lesion on the lip border",
        "caption": "Question image: recurrent herpes labialis lesion at the vermilion border."
      }
    ],
    "options": [
      "A) Topical acyclovir cream only",
      "B) Oral valacyclovir 500mg daily for chronic suppression",
      "C) Oral antibiotics for secondary infection",
      "D) Topical corticosteroids"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Oral valacyclovir for chronic suppression).\n\nPATHOPHYSIOLOGY:\nHerpes simplex virus type 1 (HSV-1) establishes lifelong latency in the trigeminal ganglion after primary infection. Periodic reactivation occurs when the virus travels down sensory nerves to the lips, triggered by stress, sun exposure, fever, or immunosuppression. The prodromal tingling sensation reflects viral replication in nerve endings before visible lesions appear. Recurrent episodes are typically shorter and less severe than primary infection because pre-existing immunity limits viral replication.\n\nCLINICAL PRESENTATION:\nThe classic presentation includes a prodrome of tingling, burning, or itching at the lip border, followed within 24-48 hours by grouped vesicles on an erythematous base. Vesicles ulcerate, crust, and heal over 7-10 days. Frequency varies widely; patients with 6 or more recurrences annually are candidates for suppressive therapy.\n\nMANAGEMENT OPTIONS:\nFor frequent recurrences (6 or more episodes per year), chronic suppressive therapy reduces outbreak frequency by 70-80%. Valacyclovir 500mg-1g daily or acyclovir 400mg twice daily are effective regimens. For less frequent recurrences, episodic treatment initiated during prodrome shortens duration: valacyclovir 2g twice daily for one day is convenient and effective. Topical antivirals have minimal efficacy compared to oral therapy, reducing duration by less than one day. Topical steroids are contraindicated as they can worsen and spread viral infection.\n\nKEY LEARNING POINTS:\nChronic suppressive antiviral therapy is indicated for 6 or more recurrences annually. Treatment initiated during prodrome is most effective. Oral antivirals far outperform topical preparations. Topical steroids are contraindicated in herpetic lesions."
  },
  {
    "id": 33,
    "categoryId": 4,
    "question": "A patient with Graves' disease stops taking her meds. She presents with fever (104F), agitation, HR 140, and vomiting. What is the diagnosis?",
    "options": [
      "A) Sepsis",
      "B) Thyroid Storm",
      "C) Pheochromocytoma",
      "D) Malignant Hyperthermia"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Thyroid Storm).\n\nPATHOPHYSIOLOGY:\nThyroid storm is a life-threatening endocrine emergency representing the most extreme manifestation of decompensated thyrotoxicosis, with mortality rates of 10 to 30% even with appropriate treatment according to data from UpToDate and Harrison's Principles of Internal Medicine. The condition is not simply a quantitative increase in thyroid hormone levels; rather, it reflects a qualitative shift in which the body's compensatory mechanisms fail, producing a systemic hypermetabolic and hyperadrenergic crisis. Excess thyroid hormone upregulates beta-adrenergic receptors, amplifying catecholamine sensitivity and producing severe tachycardia, hypertension, and cardiac arrhythmias. Thermogenesis exceeds the body's ability to dissipate heat, causing extreme hyperthermia. Multiorgan dysfunction ensues as the cardiovascular, neurological, gastrointestinal, and hepatic systems are overwhelmed by the hypermetabolic state. Precipitating factors include discontinuation of antithyroid medications (as in this patient), infection, surgery, trauma, iodine load from contrast dye, diabetic ketoacidosis, and parturition.\n\nCLINICAL PRESENTATION:\nThyroid storm presents with the triad of hyperthermia (often exceeding 104Â°F/40Â°C), severe cardiovascular dysfunction (tachycardia, high-output heart failure, atrial fibrillation), and altered mental status ranging from agitation and psychosis to obtundation and coma. Gastrointestinal symptoms including nausea, vomiting, diarrhea, and jaundice from hepatic dysfunction are common. The Burch-Wartofsky Point Scale (BWPS) is used to assess the likelihood of thyroid storm based on the severity of thermoregulatory, cardiovascular, central nervous system, and gastrointestinal dysfunction, with a score of 45 or greater being highly suggestive of thyroid storm. Importantly, thyroid function tests (T3, T4, TSH) do not distinguish thyroid storm from uncomplicated thyrotoxicosis, as hormone levels may be similar; the diagnosis is clinical.\n\nTREATMENT:\nManagement of thyroid storm requires a systematic, multi-agent approach targeting every step of thyroid hormone synthesis, release, and peripheral action, administered in the correct sequence. Beta-blockers, preferably propranolol, are initiated first to control the adrenergic crisis; propranolol is preferred because it also inhibits peripheral conversion of T4 to the more active T3. Thionamides (propylthiouracil is preferred over methimazole in thyroid storm because PTU blocks both new hormone synthesis and peripheral T4-to-T3 conversion) are started immediately to halt new hormone production. Iodine solution (potassium iodide or Lugol's solution) is administered at least one hour after the thionamide to block thyroid hormone release via the Wolff-Chaikoff effect; administering iodine before a thionamide would provide substrate for new hormone synthesis and worsen the crisis. Glucocorticoids (hydrocortisone 100 mg IV every 8 hours) reduce peripheral T4-to-T3 conversion, treat possible concurrent adrenal insufficiency, and provide anti-inflammatory effects. Supportive care includes aggressive cooling with external measures (avoiding aspirin, which displaces thyroid hormone from binding proteins), intravenous fluids, electrolyte correction, and ICU-level monitoring.\n\nKEY LEARNING POINTS:\nThyroid storm is a clinical diagnosis presenting with the triad of hyperthermia, severe cardiovascular dysfunction, and altered mental status in a patient with hyperthyroidism plus an identifiable precipitant. Treatment requires a specific sequence of beta-blocker, thionamide (PTU preferred), iodine (given at least one hour after thionamide), and glucocorticoids. Mortality remains 10 to 30% with treatment, making early recognition and aggressive multi-agent therapy essential."
  },
  {
    "id": 34,
    "categoryId": 11,
    "question": "A patient on Sertraline and Tramadol presents with agitation, dilated pupils (mydriasis), hyperreflexia, and ocular clonus. Diagnosis?",
    "options": [
      "A) Neuroleptic Malignant Syndrome",
      "B) Serotonin Syndrome",
      "C) Opioid Overdose",
      "D) Anticholinergic Toxicity"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Serotonin Syndrome).\n\nPATHOPHYSIOLOGY:\nSerotonin syndrome is a potentially life-threatening drug-induced toxidrome caused by excessive serotonergic activity at central and peripheral serotonin receptors, primarily 5-HT1A and 5-HT2A per Harrison's Principles of Internal Medicine. It most commonly occurs when two or more serotonergic medications are combined, as in this case: sertraline (an SSRI that blocks serotonin reuptake) plus tramadol (an opioid with significant serotonin reuptake inhibition activity) per UpToDate. Other high-risk combinations include SSRIs with MAO inhibitors, triptans, linezolid, meperidine, dextromethorphan, fentanyl, or St. John's Wort per the Cleveland Clinic.\n\nCLINICAL PRESENTATION:\nThe Hunter Serotonin Toxicity Criteria, the most validated diagnostic tool, require the presence of a serotonergic agent plus one of: spontaneous clonus, inducible clonus with agitation or diaphoresis, ocular clonus with agitation or diaphoresis, tremor with hyperreflexia, or hypertonia with hyperthermia per UpToDate. The classic triad is neuromuscular excitation (clonus, hyperreflexia, myoclonus, rigidity), autonomic dysfunction (hyperthermia, tachycardia, diaphoresis, diarrhea), and altered mental status (agitation, confusion) per Harrison's Principles of Internal Medicine. Onset is typically rapid, within 6 to 24 hours of drug initiation or dose change, distinguishing it from NMS which develops over days per Harvard Health.\n\nDIFFERENTIAL DIAGNOSIS:\nSerotonin syndrome is distinguished from NMS by the presence of clonus and hyperreflexia (NMS features rigidity with normal or decreased reflexes), rapid onset (NMS develops over days), and the causative drug class (serotonergic agents versus dopamine antagonists) per the Mayo Clinic. Mydriasis (dilated pupils) and hyperactive bowel sounds favor serotonin syndrome, while lead-pipe rigidity and markedly elevated CPK favor NMS per UpToDate.\n\nMANAGEMENT:\nImmediate discontinuation of all serotonergic agents is the cornerstone of treatment per the Cleveland Clinic. Mild cases resolve within 24 to 72 hours with supportive care. Moderate to severe cases require benzodiazepines (for agitation and myoclonus), active cooling, and cyproheptadine (a 5-HT2A receptor antagonist, 12 mg initial dose followed by 2 mg every 2 hours) per Harrison's Principles of Internal Medicine.\n\nKEY LEARNING POINTS:\nSerotonin syndrome presents with the triad of neuromuscular excitation (clonus, hyperreflexia), autonomic dysfunction (hyperthermia, diaphoresis), and altered mental status, with rapid onset within hours. Clonus and hyperreflexia distinguish it from NMS. Tramadol is a commonly overlooked serotonergic agent that precipitates the syndrome when combined with SSRIs."
  },
  {
    "id": 35,
    "categoryId": 14,
    "question": "A 60-year-old male presents with back pain and fatigue. Labs show Calcium 11.5 (High), Creatinine 2.1 (High), and Hemoglobin 9.0 (Low). Total Protein is elevated with an 'M-Spike' on electrophoresis. Diagnosis?",
    "options": [
      "A) Metastatic Prostate Cancer",
      "B) Multiple Myeloma",
      "C) Hyperparathyroidism",
      "D) Vitamin D Toxicity"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Multiple Myeloma).\n\nPATHOPHYSIOLOGY:\nMultiple myeloma is a clonal plasma cell neoplasm arising in the bone marrow, characterized by uncontrolled proliferation of a single plasma cell clone that produces a monoclonal immunoglobulin (M-protein) detectable as an M-spike on serum protein electrophoresis. Malignant plasma cells secrete osteoclast-activating factors including RANKL, macrophage inflammatory protein-1 alpha, and interleukin-6, which drive excessive bone resorption while simultaneously inhibiting osteoblast function through secretion of dickkopf-1 per Harrison's Principles of Internal Medicine. This uncoupled bone remodeling produces the characteristic purely lytic bone lesions and releases calcium into the circulation, causing hypercalcemia. Renal insufficiency results from light chain cast nephropathy (the most common mechanism), hypercalcemia-induced nephrocalcinosis, and dehydration. Anemia develops from direct bone marrow infiltration crowding out normal hematopoietic precursors.\n\nCLINICAL REASONING:\nThis patient demonstrates the classic CRAB criteria for myeloma end-organ damage: Calcium elevation (11.5 mg/dL), Renal insufficiency (creatinine 2.1), Anemia (hemoglobin 9.0), and Bone involvement (back pain). The M-spike on serum protein electrophoresis confirms the monoclonal protein, which is the diagnostic hallmark. The revised International Myeloma Working Group diagnostic criteria require clonal bone marrow plasma cells of 10% or greater or a biopsy-proven plasmacytoma, plus one or more CRAB features or myeloma-defining events.\n\nDIAGNOSTIC WORKUP:\nThe evaluation includes serum protein electrophoresis with immunofixation, serum free light chains with ratio, 24-hour urine protein electrophoresis, bone marrow biopsy with flow cytometry and FISH for high-risk abnormalities (deletion 17p, translocation t(4;14), translocation t(14;16)), beta-2 microglobulin and LDH for prognosis, and imaging with low-dose whole-body CT or PET-CT per NCCN guidelines. An essential diagnostic pearl per UpToDate is that myeloma causes purely lytic lesions without reactive osteoblastic activity, meaning conventional bone scans are frequently falsely negative and should not be used.\n\nTREATMENT:\nInduction therapy typically consists of a three-drug regimen combining a proteasome inhibitor (bortezomib), an immunomodulatory drug (lenalidomide), and dexamethasone (VRd), followed by autologous stem cell transplant in eligible patients per Mayo Clinic and NCCN guidelines. Bisphosphonates (zoledronic acid) or denosumab are administered to reduce skeletal events.\n\nKEY LEARNING POINTS:\nMultiple myeloma presents with the CRAB criteria (hypercalcemia, renal insufficiency, anemia, lytic bone lesions) and an M-spike on protein electrophoresis. Bone scan is often falsely negative because myeloma produces purely lytic lesions without osteoblastic activity, making low-dose whole-body CT or PET-CT the preferred imaging. Beta-2 microglobulin is the most important prognostic marker per Harrison's Principles of Internal Medicine."
  },
  {
    "id": 36,
    "categoryId": 17,
    "question": "A 60-year-old female presents with severe eye pain, headache, and halos around lights. The pupil is mid-dilated and non-reactive. The eye feels 'rock hard' to palpation. Diagnosis?",
    "options": [
      "A) Uveitis",
      "B) Acute Angle-Closure Glaucoma",
      "C) Corneal Abrasion",
      "D) Conjunctivitis"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Acute Angle-Closure Glaucoma).\n\nPATHOPHYSIOLOGY:\nAcute angle-closure glaucoma (AACG) occurs when the peripheral iris apposes the trabecular meshwork, obstructing aqueous humor outflow and causing a rapid, severe rise in intraocular pressure (IOP), often exceeding 40-60 mmHg (normal less than 21 mmHg). The resultant ischemia to the optic nerve and corneal edema produce the characteristic symptoms. The most common mechanism is pupillary block, where the iris bows forward against the lens, trapping aqueous humor in the posterior chamber.\n\nCLINICAL PRESENTATION:\n- Sudden onset severe eye pain, often with ipsilateral headache\n- Nausea and vomiting (vagal response to elevated IOP)\n- Halos around lights (corneal edema diffracts light)\n- Decreased visual acuity, blurred vision\n- Red eye with fixed, mid-dilated, non-reactive pupil\n- Eye firm or rock hard to palpation\n\nRISK FACTORS:\nHyperopia (farsightedness, shallow anterior chamber), older age, female sex, Asian or Inuit descent, family history, and medications that dilate the pupil (anticholinergics, sympathomimetics, sulfonamides).\n\nTREATMENT:\nThis is an ophthalmologic emergency requiring immediate IOP reduction:\n1. Topical timolol 0.5% (decreases aqueous production)\n2. Topical pilocarpine 1-2% (constricts pupil, opens drainage angle)\n3. Topical apraclonidine 1% (decreases aqueous production)\n4. IV acetazolamide 500 mg (systemic carbonic anhydrase inhibitor)\n5. IV mannitol if IOP remains refractory\n6. Definitive treatment: Laser peripheral iridotomy (creates bypass channel for aqueous humor)\n- Do NOT dilate this pupil - mydriatics worsen angle closure\n\nKEY LEARNING POINTS:\nA mid-dilated, non-reactive pupil with a rock-hard eye is acute angle-closure glaucoma until proven otherwise. Immediate IOP reduction prevents irreversible optic nerve damage and blindness. Definitive treatment is laser peripheral iridotomy. Prophylactic iridotomy is recommended for the contralateral eye.\n\nREFERENCES:\nAAO Preferred Practice Pattern for Primary Angle Closure; UpToDate; Harrison's Principles of Internal Medicine.\n---"
  },
  {
    "id": 37,
    "categoryId": 7,
    "question": "A 13-year-old obese male presents with knee pain. He walks with the foot externally rotated. Knee X-ray is normal. What is the mandatory next step?",
    "options": [
      "A) MRI Knee",
      "B) X-ray of both Hips (Frog-leg view)",
      "C) Reassurance",
      "D) Physical Therapy"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (X-ray of both Hips, Frog-leg view).\n\nPATHOPHYSIOLOGY:\nSlipped Capital Femoral Epiphysis is a Salter-Harris type I fracture through the proximal femoral physis (growth plate) in which the femoral epiphysis displaces posteriorly and inferiorly relative to the femoral neck. The condition occurs during the period of rapid adolescent growth when the physis is mechanically weakened by its transition from a horizontal to a more oblique orientation and by the relative softening that accompanies growth hormone-mediated hypertrophic zone expansion. Obesity is the strongest risk factor because increased body mass generates greater shear forces across the weakened physis. Endocrine conditions including hypothyroidism, growth hormone deficiency, and hypogonadism also predispose to SCFE by altering physeal strength relative to mechanical load.\n\nCLINICAL PRESENTATION:\nThe classic patient is an obese adolescent, more commonly male, between 10 and 16 years of age who presents with hip, groin, thigh, or knee pain and an antalgic gait with the affected leg held in external rotation. The critical clinical insight is that knee pain in a child or adolescent is hip pathology until proven otherwise, because the obturator nerve provides sensory innervation to both the hip joint and the medial knee, creating a referred pain pattern that frequently misleads clinicians. A normal knee radiograph in a limping adolescent with knee pain does not exclude the diagnosis. Physical examination reveals limited internal rotation and abduction of the hip, and obligate external rotation of the hip during passive flexion is a highly suggestive finding.\n\nDIAGNOSIS AND MANAGEMENT:\nAnteroposterior and frog-leg lateral radiographs of both hips are mandatory. On the AP view, Klein's line drawn along the superior femoral neck should intersect the lateral portion of the femoral epiphysis; in SCFE, the epiphysis falls below this line. The frog-leg lateral view is more sensitive for detecting early or mild slips. Both hips must be imaged because contralateral SCFE develops in 25 to 40% of patients. Management requires immediate non-weight-bearing status and urgent orthopedic referral for in-situ surgical pinning with a single cannulated screw to prevent further slippage. Attempted closed reduction is contraindicated because it dramatically increases the risk of avascular necrosis of the femoral head, the most devastating complication. Chondrolysis and premature osteoarthritis are additional long-term complications.\n\nKEY LEARNING POINTS:\nKnee pain in an adolescent must prompt examination and radiographic evaluation of the hip because SCFE commonly presents as referred knee pain via the obturator nerve. A normal knee radiograph does not exclude hip pathology. SCFE requires immediate non-weight-bearing and urgent surgical in-situ pinning without attempted reduction. Both hips must be imaged because contralateral involvement occurs in 25 to 40% of cases."
  },
  {
    "id": 38,
    "categoryId": 2,
    "question": "A 30-year-old female on oral contraceptives presents with sudden dyspnea and pleuritic chest pain. HR is 110. O2 sat 92%. Wells Score is Moderate. D-Dimer is elevated. Next best test?",
    "options": [
      "A) V/Q Scan",
      "B) CT Pulmonary Angiography (CTPA)",
      "C) Leg Ultrasound",
      "D) Echocardiogram"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (CT Pulmonary Angiography).\n\nPATHOPHYSIOLOGY:\nPulmonary embolism results from venous thromboembolism, most commonly originating from deep veins of the lower extremities, that lodges in the pulmonary arterial vasculature per Harrison's Principles of Internal Medicine. The thrombus obstructs blood flow to the affected lung segments, creating dead space ventilation (ventilated but not perfused), causing hypoxemia through V/Q mismatch and increased alveolar-arterial gradient. Massive PE can cause acute right ventricular failure from sudden pressure overload. Estrogen-containing oral contraceptives increase VTE risk approximately 3 to 4-fold by increasing hepatic synthesis of procoagulant factors (factors II, VII, VIII, X, fibrinogen) while decreasing natural anticoagulants (antithrombin III, protein S) per UpToDate and the Cleveland Clinic.\n\nCLINICAL REASONING:\nThis patient presents with classic PE features: sudden dyspnea, pleuritic chest pain, tachycardia, and hypoxia in a young woman on oral contraceptives. The diagnostic algorithm for suspected PE follows the Wells score risk stratification per UpToDate. With a moderate Wells score and elevated D-dimer, CTPA is required for definitive diagnosis. D-dimer is a sensitive but nonspecific test useful primarily for its negative predictive value: a negative D-dimer in a low-probability patient effectively excludes PE, but an elevated D-dimer does not confirm PE and requires imaging. CTPA is the gold-standard imaging study, offering high sensitivity (greater than 95%) and specificity (greater than 97%) for PE per the Mayo Clinic and Harrison's Principles of Internal Medicine. V/Q scan is an alternative when CTPA is contraindicated (contrast allergy, severe renal insufficiency) but has a high rate of indeterminate results.\n\nMANAGEMENT:\nAnticoagulation with direct oral anticoagulants (apixaban or rivaroxaban, preferred over warfarin for most patients per CHEST guidelines) is initiated immediately upon diagnosis, with a minimum treatment duration of 3 months for a provoked PE per UpToDate. Estrogen-containing contraceptives must be stopped immediately, and future use is absolutely contraindicated after VTE per the CDC Medical Eligibility Criteria. Safe alternatives include progestin-only methods (progestin-only pill, etonogestrel implant, levonorgestrel IUD), copper IUD, and barrier methods per the Cleveland Clinic.\n\nKEY LEARNING POINTS:\nCTPA is the gold-standard test for PE diagnosis, indicated when Wells score is moderate or high, or when D-dimer is positive in a low-probability patient. Estrogen-containing contraceptives increase VTE risk 3 to 4-fold and are absolutely contraindicated after a VTE event. DOACs (apixaban, rivaroxaban) are preferred over warfarin for most PE treatment per current CHEST guidelines."
  },
  {
    "id": 39,
    "categoryId": 3,
    "question": "A 70-year-old with A-Fib presents with severe abdominal pain out of proportion to physical exam (soft abdomen, but patient is screaming in pain). Lactate is 4.0. Diagnosis?",
    "options": [
      "A) Diverticulitis",
      "B) Acute Mesenteric Ischemia",
      "C) Pancreatitis",
      "D) Cholecystitis"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Acute Mesenteric Ischemia).\n\nPATHOPHYSIOLOGY:\nAcute mesenteric ischemia (AMI) results from sudden reduction in blood flow to the small intestine, most commonly due to embolism to the superior mesenteric artery (SMA), which accounts for approximately 50% of cases. Atrial fibrillation is the leading source of emboli. Other etiologies include SMA thrombosis (25%), non-occlusive mesenteric ischemia from low-flow states (20%), and mesenteric venous thrombosis (5%). The intestinal mucosa is highly metabolically active and exquisitely sensitive to ischemia, leading to rapid mucosal breakdown, bacterial translocation, and if untreated, transmural necrosis within 6-12 hours.\n\nCLINICAL PRESENTATION:\nThe hallmark is severe, poorly localized abdominal pain out of proportion to physical examination findings. Early in the disease, the abdomen remains soft and nontender despite excruciating pain because the ischemia has not yet progressed to peritonitis. Elevated serum lactate reflects tissue hypoperfusion and anaerobic metabolism. As ischemia progresses to infarction, peritoneal signs develop, signaling bowel necrosis and a rapidly worsening prognosis. Mortality exceeds 60-80% once bowel infarction occurs.\n\nDIAGNOSIS AND MANAGEMENT:\nCT angiography is the diagnostic study of choice, demonstrating arterial occlusion and bowel wall changes. Early surgical consultation is essential. Treatment depends on etiology: embolectomy or thrombectomy for occlusive disease, anticoagulation for venous thrombosis, and vasodilator infusion for non-occlusive ischemia. Necrotic bowel requires resection. Time to intervention is the strongest predictor of survival.\n\nKEY LEARNING POINTS:\nPain out of proportion to exam with a soft abdomen in a patient with atrial fibrillation is the classic presentation of acute mesenteric ischemia. Elevated lactate supports the diagnosis. CT angiography is the study of choice. Mortality exceeds 60-80% once bowel infarction occurs, making early recognition critical."
  },
  {
    "id": 40,
    "categoryId": 8,
    "question": "A college student presents with fever, headache, and a petechial rash on the trunk/legs. Neck stiffness is present. Which organism is most likely?",
    "options": [
      "A) Strep pneumo",
      "B) Neisseria meningitidis",
      "C) Listeria monocytogenes",
      "D) Haemophilus influenzae"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Neisseria).\n\nPATHOPHYSIOLOGY:\nNeisseria meningitidis is a gram-negative diplococcus that colonizes the nasopharynx and is transmitted via respiratory droplets. In susceptible individuals, the organism invades the bloodstream and crosses the blood-brain barrier. Its polysaccharide capsule resists complement-mediated killing, and endotoxin (lipooligosaccharide) release triggers a massive inflammatory cascade that can cause disseminated intravascular coagulation (DIC), leading to the characteristic petechial and purpuric skin lesions. Fulminant meningococcemia can progress from initial symptoms to death within hours.\n\nCLINICAL PRESENTATION:\nThe classic presentation is a previously healthy adolescent or young adult with rapid-onset fever, headache, neck stiffness, and a petechial or purpuric rash that begins on the trunk and extremities and may coalesce into large ecchymotic areas (purpura fulminans). Hypotension, altered mental status, and multiorgan failure develop rapidly in meningococcal septicemia. The rash is a critical distinguishing feature, as other causes of bacterial meningitis rarely produce petechiae.\n\nDIAGNOSIS AND TREATMENT:\nImmediate empiric IV antibiotics with ceftriaxone 2g (or penicillin G) must not be delayed for lumbar puncture if the patient is hemodynamically unstable. Blood cultures should be obtained before antibiotics when possible, but treatment takes absolute priority. CSF analysis typically reveals a neutrophilic pleocytosis, elevated protein, low glucose, and gram-negative diplococci on Gram stain. Place the patient on droplet precautions immediately upon suspicion.\n\nPREVENTION:\nChemoprophylaxis for close contacts (household members, roommates, those exposed to oral secretions) should be initiated within 24 hours of diagnosis using rifampin, ciprofloxacin, or ceftriaxone. The MenACWY vaccine is recommended for adolescents (routine at age 11-12 with booster at 16) and is required for college dormitory residents. MenB vaccine is available for those aged 16-23.\n\nKEY LEARNING POINTS:\nMeningococcal meningitis presents with rapid-onset fever, headache, and petechial/purpuric rash in young adults. Do not delay IV antibiotics for LP if the patient is unstable. Mortality is 10-15% even with treatment. Chemoprophylaxis for close contacts within 24 hours is essential.\n\nREFERENCES:\nCDC Meningococcal Disease Guidelines; UpToDate; Harrison's Principles of Internal Medicine.\n---"
  },
  {
    "id": 41,
    "categoryId": 6,
    "question": "A patient presents with acute left-sided face weakness and left arm drift. It started 2 hours ago. CT Head is negative for bleed. BP is 160/90. Glucose is 100. What is the next step?",
    "options": [
      "A) Administer Aspirin",
      "B) Administer tPA (Alteplase/Tenecteplase)",
      "C) Lower BP to <140/90",
      "D) MRI Brain"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Thrombolytics - IV tPA/Alteplase or Tenecteplase).\n\nACUTE ISCHEMIC STROKE MANAGEMENT:\nThis patient presents with acute-onset focal neurological deficits (facial weakness and arm drift) within the treatment window. The non-contrast CT has excluded hemorrhage, which is the critical prerequisite for thrombolytic therapy. Acute stroke management follows the principle of \"time is brain,\" as approximately 1.9 million neurons die per minute during an untreated ischemic stroke.\n\nPATHOPHYSIOLOGY:\nAcute ischemic stroke results from thrombotic or embolic occlusion of a cerebral artery, causing ischemia in the downstream territory. The ischemic core undergoes rapid irreversible injury, while the surrounding ischemic penumbra remains viable but at risk. Reperfusion therapy aims to salvage the penumbra before it progresses to infarction.\n\nTHROMBOLYTIC THERAPY:\nIV alteplase (0.9 mg/kg, maximum 90 mg) is indicated within 4.5 hours of symptom onset (or last known well) after CT exclusion of hemorrhage. Blood pressure must be below 185/110 before administration. Tenecteplase is emerging as an alternative with simpler dosing (single bolus). Key exclusions include active bleeding, recent major surgery, prior intracranial hemorrhage, and platelet count below 100,000. The door-to-needle goal is under 60 minutes.\n\nCRITICAL MANAGEMENT PEARLS:\nAspirin must NOT be given until 24 hours after tPA due to increased hemorrhagic risk. Blood pressure is maintained below 180/105 for 24 hours post-thrombolysis. For non-tPA candidates, permissive hypertension is allowed unless BP exceeds 220/120. Mechanical thrombectomy can extend the window to 24 hours for large vessel occlusions with favorable perfusion imaging.\n\nKEY LEARNING POINTS:\nIV thrombolysis is indicated within 4.5 hours of symptom onset after CT excludes hemorrhage. Aspirin is withheld for 24 hours after tPA administration due to bleeding risk. Blood pressure must be below 185/110 before and below 180/105 after thrombolytic therapy."
  },
  {
    "id": 42,
    "categoryId": 10,
    "question": "A patient started Allopurinol 2 weeks ago. Now presents with fever, flu-like symptoms, and a rash with skin sloughing (positive Nikolsky sign) involving 15% of BSA. Mucous membranes are involved. Diagnosis?",
    "questionImages": [
      {
        "src": "assets/derm-q2-question-image.png",
        "alt": "Severe mucocutaneous eruption with widespread lesions and lip involvement",
        "caption": "Question image: severe drug-related mucocutaneous eruption with skin and mucosal involvement."
      }
    ],
    "options": [
      "A) Staph Scalded Skin Syndrome",
      "B) Stevens-Johnson Syndrome (SJS)",
      "C) Toxic Epidermal Necrolysis (TEN)",
      "D) Drug Reaction with Eosinophilia (DRESS)"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Stevens-Johnson Syndrome).\n\nPATHOPHYSIOLOGY:\nStevens-Johnson syndrome is a severe, immune-mediated mucocutaneous reaction most commonly triggered by medications. The pathogenesis involves cytotoxic T lymphocytes and natural killer cells that target drug-modified keratinocytes, releasing granulysin, perforin, and granzyme B, which induce widespread keratinocyte apoptosis. This creates full-thickness epidermal necrosis with subsequent detachment from the underlying dermis. The process is essentially an immune-mediated destruction of the skin from within, and the degree of body surface area (BSA) detachment defines the severity spectrum: SJS involves less than 10% BSA, SJS-TEN overlap involves 10 to 30%, and toxic epidermal necrolysis (TEN) involves greater than 30%. This patient with 15% BSA detachment falls within the SJS-TEN overlap category.\n\nCLINICAL PRESENTATION:\nSJS typically begins 1 to 3 weeks after drug initiation with a prodrome of fever, malaise, and flu-like symptoms. A painful macular rash with dusky centers (targetoid lesions) then develops and rapidly progresses to flaccid blisters and epidermal sloughing. The Nikolsky sign, in which gentle lateral pressure on uninvolved skin causes the epidermis to shear off, is positive and reflects the loss of epidermal cohesion. Mucous membrane involvement occurs in over 90% of cases, affecting the oral mucosa, conjunctivae, and genitourinary tract, and is a hallmark distinguishing SJS from other severe drug reactions. Ocular involvement can lead to corneal scarring, symblepharon, and permanent vision impairment.\n\nCOMMON CULPRIT MEDICATIONS:\nAllopurinol is one of the most frequently implicated drugs worldwide. Other high-risk medications include anticonvulsants (lamotrigine, carbamazepine, phenytoin), sulfonamide antibiotics (trimethoprim-sulfamethoxazole), and nevirapine. HLA-B*5801 testing prior to initiating allopurinol is recommended by the American College of Rheumatology, particularly in patients of Southeast Asian and African American descent, where this allele prevalence exceeds 6 to 8% and confers a markedly elevated risk of allopurinol hypersensitivity.\n\nMANAGEMENT:\nImmediate discontinuation of the offending drug is the single most important intervention, and every day of delay increases mortality. Patients require transfer to a burn unit or intensive care setting for wound care, fluid resuscitation, temperature regulation, nutritional support, and infection surveillance. The SCORTEN scoring system predicts mortality based on age, heart rate, BUN, glucose, bicarbonate, BSA involvement, and malignancy status, with scores of 5 or greater carrying mortality exceeding 90%. The role of systemic immunosuppression remains debated, though cyclosporine has shown promise in reducing progression when initiated early. Ophthalmologic consultation is mandatory given the risk of long-term ocular sequelae.\n\nKEY LEARNING POINTS:\nSJS is defined by less than 10% BSA detachment with mucous membrane involvement, while TEN involves greater than 30%. Allopurinol is among the most common causative drugs, and HLA-B*5801 screening is recommended before initiation in high-risk populations. Immediate drug discontinuation is the most critical intervention. The Nikolsky sign reflects epidermal-dermal separation from keratinocyte apoptosis. Burn unit care and SCORTEN scoring guide prognosis and management intensity."
  },
  {
    "id": 43,
    "categoryId": 5,
    "question": "A 16-year-old male wakes up with severe unilateral testicular pain. The testicle is high-riding and transverse. The Cremasteric reflex is absent. Diagnosis?",
    "options": [
      "A) Epididymitis",
      "B) Testicular Torsion",
      "C) Hydrocele",
      "D) Varicocele"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Testicular Torsion).\n\nPATHOPHYSIOLOGY:\nTesticular torsion is a urologic emergency caused by rotation of the spermatic cord, which occludes the testicular artery and pampiniform venous plexus, causing ischemia and infarction of the testis per Harrison's Principles of Internal Medicine and UpToDate. The underlying predisposing anatomic variant in most cases is the \"bell-clapper deformity,\" in which the tunica vaginalis has an abnormally high attachment on the spermatic cord, allowing the testis to rotate freely within the tunica like a bell clapper, present bilaterally in most affected patients per the Cleveland Clinic.\n\nCLINICAL PRESENTATION:\nThe classic presentation is sudden onset of severe unilateral scrotal pain (often waking the patient from sleep), with a high-riding testis (retracted superiorly due to cord shortening from twisting), transverse (horizontal) lie (the normal vertical orientation is lost), and absent cremasteric reflex (the most sensitive physical exam finding, absent in 99% of torsion cases) per UpToDate and the Mayo Clinic. Nausea and vomiting are common due to the severity of pain per Harvard Health.\n\nTIME-CRITICAL MANAGEMENT:\nTesticular salvage rates are directly related to the duration of ischemia: greater than 90% salvage within 6 hours, approximately 50% at 12 hours, and less than 10% after 24 hours per Harrison's Principles of Internal Medicine. Surgical exploration and detorsion must not be delayed for imaging when the clinical presentation is classic per the Cleveland Clinic. If imaging is obtained (typically in equivocal cases), color Doppler ultrasound showing absent or decreased blood flow to the affected testis is diagnostic per UpToDate. Bilateral orchiopexy (surgical fixation of both testes to the scrotal wall) is performed because the bell-clapper deformity is bilateral in most cases per the Mayo Clinic.\n\nDIFFERENTIAL DIAGNOSIS:\nEpididymitis (gradual onset, positive cremasteric reflex, pain relieved by scrotal elevation/Prehn sign, often with pyuria and urethral discharge in sexually active young men) and testicular appendage torsion (\"blue dot sign\" visible through scrotal skin, less severe pain, intact cremasteric reflex) are the main differentials per Harrison's Principles of Internal Medicine and UpToDate.\n\nKEY LEARNING POINTS:\nTesticular torsion presents with sudden severe pain, a high-riding transverse testis, and absent cremasteric reflex, caused by spermatic cord rotation (bell-clapper deformity). Salvage exceeds 90% within 6 hours but drops below 10% after 24 hours. Surgery must not be delayed for imaging when clinical presentation is classic, and bilateral orchiopexy is required."
  },
  {
    "id": 44,
    "categoryId": 2,
    "question": "A tall, thin 20-year-old male develops sudden chest pain and shortness of breath. Breath sounds are decreased on the right. Trachea is deviated to the LEFT. BP is 80/50. Immediate action?",
    "options": [
      "A) Stat Chest X-ray",
      "B) Needle Decompression",
      "C) Intubation",
      "D) IV Fluids"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Needle Decompression).\n\nPATHOPHYSIOLOGY:\nTension pneumothorax occurs when air enters the pleural space through a one-way valve mechanism (either from a lung parenchymal injury or a chest wall wound) and becomes trapped, with intrapleural pressure progressively increasing with each breath per Harrison's Principles of Internal Medicine. The rising intrapleural pressure compresses the ipsilateral lung (causing complete collapse), shifts the mediastinum toward the contralateral side (compressing the opposite lung and deviating the trachea), and kinks the great veins (superior and inferior vena cava), severely reducing venous return to the heart. The resulting obstructive shock produces rapidly fatal cardiovascular collapse if not immediately decompressed per UpToDate.\n\nCLINICAL REASONING:\nThis patient presents with the classic features of tension pneumothorax in a classic patient: a tall, thin young male (the demographic at highest risk for primary spontaneous pneumothorax from rupture of apical subpleural blebs) with sudden chest pain, decreased breath sounds on the right, tracheal deviation to the left (away from the affected side), and hypotension per the Cleveland Clinic. Tension pneumothorax is a clinical diagnosis that requires immediate intervention without waiting for radiographic confirmation. Needle decompression is performed by inserting a large-bore (14 to 16-gauge) needle into the second intercostal space at the midclavicular line or the fourth to fifth intercostal space at the anterior axillary line on the affected side, converting the tension pneumothorax to a simple pneumothorax by releasing the trapped pressurized air per ATLS guidelines and Harrison's Principles of Internal Medicine. This is followed by definitive tube thoracostomy (chest tube placement).\n\nPRIMARY SPONTANEOUS PNEUMOTHORAX:\nWhen a primary spontaneous pneumothorax does not produce tension physiology, management depends on size and symptoms per UpToDate. Small pneumothoraces (less than 2 cm at the hilum on upright chest radiograph) in stable patients can be observed with supplemental oxygen, which accelerates reabsorption by creating a nitrogen gradient. Large or symptomatic pneumothoraces require needle aspiration or chest tube placement per the Mayo Clinic. Recurrence occurs in approximately 30% within 1 to 2 years, and surgical intervention (video-assisted thoracoscopic surgery with mechanical pleurodesis or bullectomy) is recommended after a second ipsilateral episode per the British Thoracic Society.\n\nKEY LEARNING POINTS:\nTension pneumothorax is a clinical diagnosis (hypotension, tracheal deviation, absent breath sounds) requiring immediate needle decompression without waiting for imaging. Decompression is performed at the second intercostal space midclavicular line or fourth to fifth intercostal space anterior axillary line, followed by chest tube. Primary spontaneous pneumothorax classically occurs in tall, thin young males from rupture of apical blebs."
  },
  {
    "id": 45,
    "categoryId": 17,
    "question": "A 5-year-old unimmunized child presents with high fever, drooling, and 'tripod' positioning. He appears toxic. What should you NOT do?",
    "options": [
      "A) Keep the child calm",
      "B) Call Anesthesia/ENT",
      "C) Examine the throat with a tongue depressor",
      "D) Administer blow-by oxygen"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Do NOT examine the throat with a tongue depressor).\n\nDIAGNOSIS:\nAcute epiglottitis is a life-threatening infection of the epiglottis and surrounding supraglottic structures that can cause complete airway obstruction within hours. In unimmunized children, Haemophilus influenzae type b (Hib) is the most common cause. In adults and immunized children, Streptococcus species, Staphylococcus aureus, and other organisms predominate.\n\nCLINICAL PRESENTATION:\nThe classic presentation includes the 4 Ds: Dysphagia, Dysphonia (muffled hot potato voice), Drooling, and Distress. The child assumes the tripod position (sitting upright, leaning forward, neck hyperextended, chin thrust out) to maximize airway patency. High fever and toxic appearance are typical. Onset is rapid, typically over hours.\n\nCRITICAL MANAGEMENT POINTS:\n- Do NOT examine the oropharynx with a tongue depressor or attempt to visualize the epiglottis at bedside. This can trigger laryngospasm and complete airway obstruction.\n- Do NOT agitate the child (avoid blood draws, IV starts, or separation from parents)\n- Do NOT lay the child supine\n- Allow the child to remain in the position of comfort\n- Call anesthesia and ENT/otolaryngology immediately for controlled airway management in the operating room\n\nTREATMENT:\n1. Secure the airway in the OR via direct laryngoscopy and intubation (or surgical airway if needed)\n2. IV antibiotics: Third-generation cephalosporin (ceftriaxone or cefotaxime) plus vancomycin if MRSA is suspected\n3. IV corticosteroids (dexamethasone) to reduce airway edema\n4. The classic lateral neck X-ray thumbprint sign (swollen epiglottis) supports diagnosis but should NOT delay airway management\n\nKEY LEARNING POINTS:\nNever examine the throat of a child with suspected epiglottitis at bedside - this can precipitate fatal airway obstruction. The triad of drooling, tripod positioning, and toxic appearance should prompt immediate airway management by anesthesia and ENT. Hib vaccination has dramatically reduced pediatric epiglottitis incidence.\n\nREFERENCES:\nAAP Red Book; UpToDate; Harrison's Principles of Internal Medicine.\n---"
  },
  {
    "id": 46,
    "categoryId": 15,
    "question": "A patient ingested a bottle of Tylenol 4 hours ago. What determines if N-Acetylcysteine (NAC) is needed?",
    "options": [
      "A) Presence of liver tenderness",
      "B) The Rumack-Matthew Nomogram",
      "C) The dose reported by the patient",
      "D) Coagulation studies (INR)"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (The Rumack-Matthew Nomogram).\n\nPATHOPHYSIOLOGY:\nAcetaminophen (APAP) is the most common cause of acute liver failure in the United States per the Cleveland Clinic and UpToDate. At therapeutic doses, acetaminophen is primarily metabolized by hepatic glucuronidation and sulfation. However, a small fraction is oxidized by the cytochrome P450 enzyme CYP2E1 to the highly reactive toxic metabolite N-acetyl-p-benzoquinone imine (NAPQI), which is normally detoxified by conjugation with glutathione. In overdose, the glucuronidation and sulfation pathways become saturated, and a disproportionately large fraction is shunted through CYP2E1 to form NAPQI. When NAPQI production exceeds glutathione stores, the unbound NAPQI binds covalently to hepatocyte proteins, causing centrilobular hepatic necrosis per Harrison's Principles of Internal Medicine.\n\nCLINICAL REASONING:\nThe Rumack-Matthew nomogram is the standard tool for determining the need for N-acetylcysteine (NAC) treatment following acute single-ingestion acetaminophen overdose per UpToDate. A serum acetaminophen level is drawn at 4 hours post-ingestion (the earliest time at which the nomogram is validated) and plotted against time. If the level falls above the treatment line, NAC is indicated. Acetaminophen toxicity progresses through four clinical phases: Phase 1 (0 to 24 hours) with nonspecific symptoms of nausea and malaise or no symptoms at all, Phase 2 (24 to 72 hours) with right upper quadrant pain and rising transaminases, Phase 3 (72 to 96 hours) with peak hepatotoxicity and potential liver failure, coagulopathy, and encephalopathy, and Phase 4 (4 days to 2 weeks) with recovery or death per the Mayo Clinic.\n\nTREATMENT:\nN-acetylcysteine replenishes hepatic glutathione stores, enabling detoxification of NAPQI, and provides the greatest benefit when administered within 8 hours of ingestion, though it remains beneficial even at 24 hours or later in patients with evidence of hepatotoxicity per Harrison's Principles of Internal Medicine. NAC is administered as an intravenous protocol (preferred in the hospital setting for reliability and shorter duration) or an oral protocol (72-hour regimen). Treatment is continued until transaminases are trending down, INR is improving, and the acetaminophen level is undetectable per UpToDate. In patients with unknown time of ingestion or staggered overdose, the nomogram cannot be applied, and empiric NAC should be initiated if acetaminophen is detectable and transaminases are elevated. Chronic alcohol use and malnutrition deplete glutathione stores and lower the threshold for toxicity.\n\nKEY LEARNING POINTS:\nThe Rumack-Matthew nomogram, using a serum acetaminophen level drawn at 4 hours post-ingestion, is the standard tool for determining NAC treatment in acute single-ingestion overdose. NAC replenishes glutathione to detoxify NAPQI and is most effective within 8 hours but remains beneficial even at 24 hours or beyond. In staggered or unknown-time ingestions, the nomogram cannot be used and empiric NAC should be given if APAP is detectable with elevated transaminases."
  },
  {
    "id": 47,
    "categoryId": 4,
    "question": "A pregnant patient at 34 weeks has BP 160/110 and new onset severe headache. Urine protein is 3+. What is the seizure prophylaxis of choice?",
    "options": [
      "A) Lorazepam",
      "B) Magnesium Sulfate",
      "C) Phenytoin",
      "D) Labetalol"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Magnesium Sulfate).\n\nPATHOPHYSIOLOGY:\nPreeclampsia is a pregnancy-specific multisystem disorder characterized by new-onset hypertension and end-organ dysfunction after 20 weeks of gestation. The underlying pathophysiology originates from abnormal placentation, in which defective trophoblast invasion of the spiral arteries during early pregnancy leads to inadequate remodeling and persistent high-resistance uteroplacental blood flow. The resulting placental ischemia triggers release of antiangiogenic factors (soluble fms-like tyrosine kinase 1 and soluble endoglin) into the maternal circulation, which sequester proangiogenic factors (vascular endothelial growth factor and placental growth factor), causing widespread maternal endothelial dysfunction. This endothelial injury produces the clinical manifestations of hypertension, proteinuria, and end-organ damage. Eclampsia, the occurrence of generalized tonic-clonic seizures in a patient with preeclampsia without another identifiable cause, is thought to result from cerebral vasospasm, endothelial dysfunction, and disruption of the blood-brain barrier leading to cerebral edema and cortical irritability.\n\nCLINICAL REASONING:\nThis patient meets criteria for preeclampsia with severe features. Severe features, as defined by ACOG, include systolic blood pressure of 160 mmHg or greater or diastolic blood pressure of 110 mmHg or greater on two occasions at least 4 hours apart (or once if antihypertensives are initiated), thrombocytopenia (platelet count below 100,000), hepatic transaminase elevation to twice the upper limit of normal, renal insufficiency (creatinine above 1.1 mg/dL or doubling of baseline), pulmonary edema, or new-onset cerebral or visual disturbances. This patient's blood pressure of 160/110 and severe headache (a cerebral symptom indicating elevated risk for seizure progression) identify her as having severe preeclampsia with high eclampsia risk, making seizure prophylaxis critical.\n\nTREATMENT:\nMagnesium sulfate is the first-line agent for seizure prophylaxis in severe preeclampsia and for the treatment of eclamptic seizures, supported by the landmark Magpie Trial (Lancet 2002), which demonstrated a 58% reduction in eclampsia risk with magnesium sulfate compared to placebo. The standard protocol involves a loading dose of 4 to 6 grams intravenously over 15 to 20 minutes followed by a maintenance infusion of 1 to 2 grams per hour. Magnesium exerts its anticonvulsant effect through NMDA receptor antagonism, cerebral vasodilation that reduces ischemia-driven cortical irritability, and reduction of calcium-mediated neuronal excitability. The therapeutic serum magnesium range is 4 to 7 mEq/L. Toxicity manifests in a predictable sequence: loss of deep tendon reflexes (first sign, occurring at 7 to 10 mEq/L), respiratory depression (10 to 13 mEq/L), and cardiac arrest (greater than 15 mEq/L), and is treated with intravenous calcium gluconate. Monitoring includes serial assessment of patellar reflexes, respiratory rate, and urine output (magnesium is renally cleared, and oliguria increases toxicity risk). Concurrent acute hypertension management with intravenous labetalol or hydralazine is essential to reduce blood pressure below 160/110 and prevent hemorrhagic stroke, the leading cause of maternal mortality in severe preeclampsia. Definitive treatment is delivery of the fetus and placenta. At 34 weeks or beyond with severe features, delivery should proceed after maternal stabilization per ACOG guidelines.\n\nKEY LEARNING POINTS:\nMagnesium sulfate is the standard of care for seizure prophylaxis in severe preeclampsia and treatment of eclamptic seizures, reducing eclampsia risk by 58% as demonstrated in the Magpie Trial. Toxicity is monitored by checking patellar reflexes, respiratory rate, and urine output, with calcium gluconate as the antidote. Definitive treatment of preeclampsia is delivery, and at 34 weeks or beyond with severe features, delivery should proceed after maternal stabilization."
  },
  {
    "id": 48,
    "categoryId": 8,
    "question": "A patient wakes up to find a bat in his bedroom. He is unsure if he was bitten. There is no visible wound. Recommendation?",
    "options": [
      "A) No treatment unless bite marks found",
      "B) Observe the patient for symptoms",
      "C) Rabies Immunoglobulin (RIG) + Vaccine Series",
      "D) Test the patient for rabies antibodies"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Rabies Immunoglobulin + Vaccine Series).\n\nPATHOPHYSIOLOGY:\nRabies virus is a neurotropic RNA virus (family Rhabdoviridae) transmitted through the saliva of infected animals. After inoculation, the virus replicates locally in muscle tissue before entering peripheral nerves at neuromuscular junctions. It travels via retrograde axonal transport to the central nervous system, where it causes progressive, fatal encephalomyelitis. The incubation period ranges from weeks to months, depending on the distance from the bite site to the CNS. Once clinical symptoms appear, rabies is nearly 100% fatal.\n\nCLINICAL REASONING:\nBats present a unique exposure risk because their bites can be virtually undetectable. Bat teeth are small enough that a sleeping, intoxicated, or cognitively impaired person may be bitten without awareness. The CDC considers finding a bat in a room with a sleeping person, an unattended child, or a cognitively impaired individual to constitute a potential rabies exposure requiring post-exposure prophylaxis (PEP), even if no bite wound is visible.\n\nTREATMENT:\nPEP for previously unvaccinated individuals consists of rabies immunoglobulin (RIG) 20 IU/kg infiltrated around the wound site (or IM at a distant site if no wound is identifiable) plus a 4-dose rabies vaccine series administered on days 0, 3, 7, and 14. RIG provides immediate passive immunity while the vaccine induces active humoral immunity over 7-10 days. For previously vaccinated individuals, RIG is omitted, and only 2 vaccine doses (days 0 and 3) are needed. PEP is extremely effective when initiated before symptom onset but is futile once clinical disease develops.\n\nKEY LEARNING POINTS:\nFinding a bat in a room with a sleeping or impaired person constitutes rabies exposure requiring PEP, even without visible bite marks. PEP consists of both RIG and a vaccine series for unvaccinated individuals. Rabies is nearly 100% fatal once symptoms appear, making timely prevention critical.\n\nREFERENCES:\nCDC Rabies Prevention Guidelines; WHO Rabies Fact Sheet; UpToDate; Harrison's Principles of Internal Medicine.\n---"
  },
  {
    "id": 49,
    "categoryId": 7,
    "question": "A 60-year-old male presents with a hot, swollen, painful knee. He cannot bear weight. He has a fever. Arthrocentesis shows WBC 80,000 with >90% neutrophils. Diagnosis?",
    "options": [
      "A) Gout",
      "B) Septic Arthritis",
      "C) Rheumatoid Arthritis Flare",
      "D) Osteoarthritis"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Septic Arthritis).\n\nPATHOPHYSIOLOGY:\nSeptic arthritis is a bacterial infection of the joint space that constitutes an orthopedic emergency because proteolytic enzymes released by bacteria and the host inflammatory response can destroy articular cartilage within hours to days. Bacteria typically reach the joint via hematogenous seeding, as the synovial membrane is highly vascular and lacks a basement membrane, facilitating bacterial entry. Once established, the intense neutrophilic inflammatory response generates destructive cytokines and matrix metalloproteinases that degrade the cartilage matrix irreversibly. Staphylococcus aureus is the most common causative organism in adults, including methicillin-resistant strains. In sexually active young adults, Neisseria gonorrhoeae must be considered, presenting with the classic triad of migratory polyarthralgia, tenosynovitis, and dermatitis before localizing to a single joint.\n\nCLINICAL PRESENTATION AND DIAGNOSIS:\nThe presentation of an acutely hot, swollen, erythematous joint with fever and inability to bear weight demands immediate arthrocentesis before any antibiotics are administered. Synovial fluid analysis is the diagnostic cornerstone. Normal synovial fluid contains fewer than 200 white blood cells per microliter. Non-inflammatory effusions such as osteoarthritis produce 200 to 2,000 white blood cells per microliter. Inflammatory conditions including gout and rheumatoid arthritis typically generate 2,000 to 50,000 white blood cells per microliter. A white blood cell count exceeding 50,000 per microliter with greater than 90% polymorphonuclear cells is highly suggestive of septic arthritis, though lower counts do not exclude the diagnosis. Gram stain is positive in approximately 50 to 75% of non-gonococcal infections. Critically, the presence of crystals on polarized microscopy does not exclude concurrent infection, as gout and septic arthritis can coexist in the same joint.\n\nMANAGEMENT:\nTreatment requires a three-pronged approach initiated emergently. Empiric intravenous antibiotics should provide coverage for Staphylococcus aureus and gram-negative organisms, typically vancomycin combined with a third-generation cephalosporin such as ceftriaxone. Joint drainage through either serial needle aspirations or surgical irrigation and debridement is essential to remove the destructive purulent material and reduce the bacterial load. Antibiotic therapy is subsequently tailored based on culture and sensitivity results and typically continues for 2 to 4 weeks. Delayed treatment is associated with permanent joint destruction, sepsis, and significant mortality, particularly in elderly and immunocompromised patients.\n\nKEY LEARNING POINTS:\nSeptic arthritis is an orthopedic emergency in which joint destruction begins within hours, requiring immediate arthrocentesis, empiric intravenous antibiotics, and joint drainage. Synovial fluid white blood cell count exceeding 50,000 per microliter with greater than 90% neutrophils is highly suggestive of infection. The presence of crystals does not exclude septic arthritis, and when clinical suspicion is high, treatment for both conditions should proceed simultaneously. Staphylococcus aureus is the most common pathogen in adults."
  },
  {
    "id": 50,
    "categoryId": 4,
    "question": "First step in management of Diabetic Ketoacidosis (DKA) after ABCs?",
    "options": [
      "A) IV Insulin Bolus",
      "B) IV Fluids (Normal Saline)",
      "C) Bicarbonate",
      "D) Potassium replacement"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (IV Fluids / Normal Saline).\n\nPATHOPHYSIOLOGY:\nDiabetic ketoacidosis (DKA) is a life-threatening metabolic emergency resulting from absolute or relative insulin deficiency combined with excess counter-regulatory hormones (glucagon, cortisol, catecholamines, growth hormone). The absence of insulin removes the normal suppression of lipolysis, leading to massive release of free fatty acids from adipose tissue. Hepatic beta-oxidation of these fatty acids generates ketone bodies (beta-hydroxybutyrate, acetoacetate, and acetone) at a rate that overwhelms peripheral utilization and renal excretion, producing a high anion gap metabolic acidosis. Simultaneously, unrestrained hepatic gluconeogenesis and glycogenolysis cause severe hyperglycemia. The resulting osmotic diuresis from glucosuria drives profound volume depletion (typically 5 to 7 liters in adults per ADA guidelines), with concurrent losses of sodium, potassium, chloride, phosphate, and magnesium. Diagnostic criteria per the ADA include blood glucose greater than 250 mg/dL, arterial pH less than 7.3 or serum bicarbonate less than 18 mEq/L, presence of ketonemia or ketonuria, and an elevated anion gap.\n\nCLINICAL REASONING:\nFluid resuscitation with isotonic normal saline is the critical first intervention in DKA management after initial assessment. Volume depletion is the most immediately life-threatening aspect of DKA because hypovolemia impairs renal clearance of glucose and ketones, reduces tissue perfusion, and contributes to lactic acidosis that compounds the existing ketoacidosis. Aggressive volume repletion restores intravascular volume, improves renal perfusion and glucose clearance, reduces counter-regulatory hormone levels, and enhances peripheral insulin sensitivity. Beginning with insulin before adequate volume resuscitation can precipitate cardiovascular collapse by driving potassium and glucose intracellularly while the patient remains profoundly hypovolemic. Furthermore, potassium must be assessed before insulin administration, as insulin drives potassium into cells and can cause fatal hypokalemia if serum potassium is already low.\n\nTREATMENT:\nThe ADA-recommended management protocol begins with isotonic normal saline (0.9% NaCl) at 1 to 1.5 liters in the first hour, followed by 250 to 500 mL per hour adjusted to hemodynamic status and corrected sodium. When serum sodium is normal or elevated, subsequent fluids are switched to half-normal saline (0.45% NaCl). When blood glucose reaches 200 to 250 mg/dL, dextrose-containing fluids (D5 half-normal saline) are initiated to prevent hypoglycemia while allowing continued insulin infusion to close the anion gap. Regular insulin is administered as a continuous intravenous infusion at 0.1 units/kg/hour (or 0.14 units/kg/hour without bolus), targeting a glucose decline of 50 to 75 mg/dL per hour. Critically, insulin must not be discontinued when glucose normalizes; the infusion continues until the anion gap closes, as the anion gap reflects ongoing ketoacidosis regardless of glucose level. Potassium management is essential: total body potassium is severely depleted despite serum levels that may appear normal or elevated because acidosis shifts potassium extracellularly. If serum potassium is below 3.3 mEq/L, insulin must be withheld and potassium aggressively replaced first to prevent fatal cardiac arrhythmias. Potassium replacement is initiated when levels fall below 5.2 mEq/L and urine output is confirmed. Bicarbonate administration is reserved for severe acidosis (pH less than 6.9) per ADA guidelines, as it does not improve outcomes in less severe acidosis and may worsen intracellular acidosis and hypokalemia.\n\nKEY LEARNING POINTS:\nIntravenous normal saline is the first intervention in DKA because 5 to 7 liters of volume depletion is immediately life-threatening, and volume resuscitation must precede insulin therapy. The anion gap, not glucose level, determines DKA resolution, and insulin must continue until the gap closes even if glucose normalizes. Serum potassium must be checked before insulin administration, and if potassium is below 3.3 mEq/L, insulin is withheld until potassium is repleted to prevent fatal hypokalemia."
  },
  {
    "id": 51,
    "categoryId": 17,
    "question": "Patient describes a 'curtain coming down' over their vision, accompanied by flashes of light (photopsia) and new floaters. No pain. Diagnosis?",
    "options": [
      "A) Retinal Detachment",
      "B) Central Retinal Artery Occlusion",
      "C) Vitreous Hemorrhage",
      "D) Optic Neuritis"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Retinal Detachment).\n\nPATHOPHYSIOLOGY:\nRetinal detachment occurs when the neurosensory retina separates from the underlying retinal pigment epithelium (RPE), disrupting the metabolic support necessary for photoreceptor function. The most common type is rhegmatogenous retinal detachment, in which vitreous fluid passes through a retinal tear or hole and accumulates in the subretinal space, progressively lifting the retina. Posterior vitreous detachment (age-related vitreous liquefaction and separation from the retina) is the most frequent inciting event.\n\nCLINICAL PRESENTATION:\n- Photopsia (flashes of light): Caused by vitreous traction on the retina stimulating photoreceptors mechanically\n- New floaters: Represent vitreous hemorrhage, pigment cells (tobacco dust or Shafer sign), or vitreous condensations\n- Progressive visual field loss described as a curtain or shadow moving across the visual field\n- Painless - distinguishes from acute angle-closure glaucoma and uveitis\n\nRISK FACTORS:\nMyopia (elongated globe with thinner retina), prior cataract surgery (most common risk factor for pseudophakic detachment), trauma, lattice degeneration, family history, and prior retinal detachment in the contralateral eye.\n\nDIAGNOSIS AND URGENCY:\nDilated fundoscopic examination or bedside ultrasound if media is opaque. Macula-on detachment (central vision intact) is a true surgical emergency requiring repair within 24 hours to preserve central vision. Macula-off detachment has a worse visual prognosis but still warrants urgent repair.\n\nTREATMENT:\n1. Pneumatic retinopexy (office-based, for selected superior detachments)\n2. Scleral buckle (external silicone band compresses the eye wall against the retina)\n3. Pars plana vitrectomy with gas or silicone oil tamponade\n\nKEY LEARNING POINTS:\nThe triad of flashes, floaters, and visual field loss is retinal detachment until proven otherwise and requires emergent ophthalmology referral. Macula-on detachments must be repaired within 24 hours. Myopia and prior cataract surgery are the most important risk factors.\n\nREFERENCES:\nAAO Preferred Practice Pattern for Posterior Vitreous Detachment and Retinal Breaks; UpToDate; Harrison's Principles of Internal Medicine.\n---"
  },
  {
    "id": 52,
    "categoryId": 12,
    "question": "A 4-month-old infant presents with constipation, poor feeding, and 'floppy' muscle tone (hypotonia). The parents feed the child honey. Mechanism?",
    "options": [
      "A) Autoimmune attack on Acetylcholine receptors",
      "B) Toxin prevents release of Acetylcholine",
      "C) Viral destruction of anterior horn cells",
      "D) Genetic mutation (SMA)"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Toxin prevents release of Acetylcholine).\n\nPATHOPHYSIOLOGY:\nInfant botulism is the most common form of botulism in the United States, caused by ingestion of Clostridium botulinum spores that germinate and produce toxin within the infant's intestinal tract per the CDC. Unlike foodborne botulism in adults (caused by ingestion of preformed toxin), infant botulism occurs because the immature infant gut flora lacks the competitive bacteria that prevent C. botulinum colonization in older children and adults per Harrison's Principles of Internal Medicine. The botulinum toxin (a zinc endopeptidase) irreversibly cleaves SNARE proteins (synaptobrevin, SNAP-25, syntaxin) at the presynaptic terminal of the neuromuscular junction, preventing fusion of acetylcholine-containing vesicles with the presynaptic membrane and blocking acetylcholine release per UpToDate. The result is flaccid, descending paralysis because motor nerve terminals cannot signal muscle contraction.\n\nCLINICAL PRESENTATION:\nInfant botulism typically presents in infants aged 2 weeks to 6 months per the Cleveland Clinic. Constipation is often the first symptom (due to autonomic dysfunction), followed by poor feeding, weak cry, progressive descending weakness producing the classic \"floppy baby\" presentation, ptosis, sluggish pupillary reflexes, diminished gag reflex, and potentially respiratory failure from diaphragmatic paralysis per UpToDate. Critically, the infant remains afebrile and alert despite the progressive paralysis. The descending pattern (cranial nerves affected first, then trunk and extremities) distinguishes botulism from Guillain-Barre syndrome, which produces ascending paralysis per Harrison's Principles of Internal Medicine.\n\nSOURCE AND PREVENTION:\nHoney is the only dietary source definitively linked to infant botulism (C. botulinum spores survive in honey), which is why honey must never be given to infants under 12 months per the AAP and CDC. However, most cases have no identifiable source and are attributed to environmental spore exposure from soil or dust per UpToDate.\n\nTREATMENT:\nHuman botulism immune globulin (BabyBIG) is the specific treatment for infant botulism, providing passive immunization with human-derived botulinum antitoxin that neutralizes circulating toxin per the Mayo Clinic. BabyBIG significantly reduces hospitalization duration (from approximately 6 weeks to 2 weeks) and the need for mechanical ventilation. Aminoglycoside antibiotics are avoided because they can potentiate neuromuscular blockade, and antibiotic-induced bacterial lysis can release additional intraluminal toxin per Harrison's Principles of Internal Medicine. With modern supportive care, mortality is less than 2%.\n\nKEY LEARNING POINTS:\nInfant botulism results from intestinal colonization with C. botulinum spores (not preformed toxin) in infants whose immature gut flora cannot prevent colonization. The toxin irreversibly blocks presynaptic acetylcholine release, producing flaccid descending paralysis. Honey is contraindicated under 12 months, BabyBIG is the specific treatment, and aminoglycosides are avoided."
  },
  {
    "id": 53,
    "categoryId": 1,
    "question": "A 55-year-old hypertensive male presents with sudden 'tearing' chest pain radiating to the back between the scapulae. BP in right arm is 180/100, left arm 110/60. Next step?",
    "options": [
      "A) EKG",
      "B) CT Angiogram of Aorta",
      "C) Cardiac Enzymes",
      "D) Chest X-ray"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (CT Angiogram of the Aorta).\n\nCLINICAL REASONING:\nThis presentation is classic for acute aortic dissection: sudden-onset severe tearing or ripping chest pain radiating to the back between the scapulae, with a greater than 20 mmHg blood pressure differential between the arms per Harrison's Principles of Internal Medicine. The inter-arm BP discrepancy (180/100 right versus 110/60 left) indicates that the dissection flap is compromising flow to the left subclavian artery. CTA of the aorta is the diagnostic study of choice due to its rapid acquisition, near-100% sensitivity and specificity, and ability to define the extent of dissection, involvement of branch vessels, and presence of complications per UpToDate.\n\nPATHOPHYSIOLOGY:\nAortic dissection begins with a tear in the tunica intima that allows blood to enter the tunica media, where it propagates along the vessel wall creating a false lumen that separates the intimal-medial layers per the Cleveland Clinic. The Stanford classification divides dissections into Type A (involving the ascending aorta regardless of where the tear originates, requiring emergent surgical repair) and Type B (involving only the descending aorta distal to the left subclavian artery, managed medically unless complicated) per Harrison's Principles of Internal Medicine. Hypertension is the most important risk factor, present in approximately 70% of cases. Other predisposing conditions include Marfan syndrome, Ehlers-Danlos type IV, bicuspid aortic valve, cocaine use, and Turner syndrome per the Mayo Clinic.\n\nMANAGEMENT:\nImmediate management centers on anti-impulse therapy: rapidly reducing both blood pressure and the rate of rise of aortic pressure (dP/dt) per UpToDate. IV esmolol or labetalol are first-line to reduce heart rate to below 60 bpm, followed by nitroprusside if additional BP reduction is needed, with a target systolic BP of 100 to 120 mmHg per Harrison's Principles of Internal Medicine. Beta-blockers must be administered before vasodilators because vasodilators alone cause reflex tachycardia that increases aortic shear stress and worsens dissection propagation per the Cleveland Clinic. Type A dissections require emergent open surgical repair, while uncomplicated Type B dissections are managed medically with close surveillance per UpToDate.\n\nKEY LEARNING POINTS:\nAcute aortic dissection presents with sudden tearing chest or back pain and inter-arm blood pressure differential, and CTA of the aorta is the diagnostic study of choice. Stanford Type A (ascending aorta) requires emergent surgery, while uncomplicated Type B (descending only) is managed medically. Anti-impulse therapy with IV beta-blockers first (to reduce heart rate and dP/dt) is the critical initial management step."
  },
  {
    "id": 54,
    "categoryId": 10,
    "question": "A patient presents with Bell's Palsy (CN VII). He also mentions knee pain. He went camping in Connecticut 1 month ago. Diagnosis?",
    "options": [
      "A) Stroke",
      "B) Lyme Disease",
      "C) HSV-1 reactivation",
      "D) Sarcoidosis"
    ],
    "correctAnswer": 1,
    "explanationImages": [
      {
        "src": "assets/derm-q3-image-2.png",
        "alt": "Anatomy and clinical findings in Bell's palsy",
        "caption": "Facial nerve distribution and classic Bell's palsy clinical findings."
      },
      {
        "src": "assets/derm-q3-image-1.png",
        "alt": "Erythema migrans target lesions suggestive of Lyme disease",
        "caption": "Typical erythema migrans (bull's-eye) lesions seen in Lyme disease."
      }
    ],
    "explanation": "CORRECT: B (Lyme Disease).\n\nPATHOPHYSIOLOGY:\nLyme disease, caused by the spirochete Borrelia burgdorferi, is transmitted through Ixodes tick bites in endemic areas (Northeast, Upper Midwest). The infection progresses through stages: early localized disease at the bite site, early disseminated disease with hematogenous spread, and late disseminated disease affecting joints and nervous system. Facial nerve palsy occurs during early disseminated disease when spirochetes invade cranial nerve sheaths, causing inflammation and demyelination.\n\nCLINICAL STAGES:\nEarly localized disease (days to weeks) presents with erythema migrans, the expanding \"bull's-eye\" rash at the bite site, accompanied by flu-like symptoms. Early disseminated disease (weeks to months) manifests with neurologic involvement (facial palsy, meningitis, radiculopathy), cardiac involvement (AV block, myocarditis), and multiple erythema migrans lesions. Late disseminated disease (months to years) causes Lyme arthritis affecting large joints, particularly the knee, and chronic neurologic symptoms.\n\nDIAGNOSIS AND TREATMENT:\nErythema migrans is diagnosed clinically without waiting for serology, which may be negative early. Disseminated disease requires two-tier serologic testing (ELISA screening followed by Western blot confirmation). Treatment for early disease is doxycycline 100mg twice daily for 10-21 days. Lyme carditis with heart block or neurologic involvement beyond isolated facial palsy requires IV ceftriaxone.\n\nKEY LEARNING POINTS:\nBell's palsy in a patient from an endemic area with systemic symptoms suggests Lyme disease. Facial palsy in Lyme may be bilateral, which is unusual for idiopathic Bell's palsy. Treat erythema migrans clinically without waiting for serology. Doxycycline is first-line for early Lyme disease."
  },
  {
    "id": 55,
    "categoryId": 11,
    "question": "A patient on Lithium presents with tremor, ataxia, vomiting, and confusion. He started a new BP medication last week. Which drug likely precipitated this?",
    "options": [
      "A) Amlodipine",
      "B) Hydrochlorothiazide (HCTZ)",
      "C) Metoprolol",
      "D) Clonidine"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Hydrochlorothiazide).\n\nPHARMACOLOGY:\nLithium is a monovalent cation with an extremely narrow therapeutic index (therapeutic level 0.6 to 1.2 mEq/L, toxicity above 1.5 mEq/L) that is almost entirely eliminated by renal excretion per Harrison's Principles of Internal Medicine. Lithium is freely filtered at the glomerulus and approximately 80% is reabsorbed in the proximal tubule via the same sodium channels used for sodium reabsorption per UpToDate. Any condition or medication that reduces sodium delivery to the proximal tubule increases lithium reabsorption and raises serum lithium levels per the Cleveland Clinic.\n\nMECHANISM OF INTERACTION:\nThiazide diuretics (hydrochlorothiazide, chlorthalidone) block sodium reabsorption in the distal convoluted tubule, causing natriuresis and volume contraction per Harrison's Principles of Internal Medicine. The resulting volume depletion triggers compensatory increased sodium (and lithium) reabsorption in the proximal tubule, raising lithium levels by approximately 25 to 40% per UpToDate and Harvard Health. This interaction can precipitate lithium toxicity within days to weeks of thiazide initiation per the Mayo Clinic.\n\nCLINICAL PRESENTATION OF LITHIUM TOXICITY:\nMild toxicity (1.5 to 2.0 mEq/L) presents with coarse tremor (distinct from the fine tremor seen at therapeutic levels), nausea, vomiting, and diarrhea. Moderate toxicity (2.0 to 2.5 mEq/L) produces ataxia, confusion, dysarthria, and hyperreflexia. Severe toxicity (above 2.5 mEq/L) can cause seizures, coma, cardiac arrhythmias, and death per Harrison's Principles of Internal Medicine. Management includes IV normal saline for volume repletion and enhanced renal lithium clearance, with hemodialysis indicated for levels above 4.0 mEq/L or severe neurologic symptoms per UpToDate.\n\nOTHER DRUGS THAT RAISE LITHIUM LEVELS:\nACE inhibitors and ARBs (by reducing GFR and increasing proximal reabsorption), NSAIDs (by reducing renal prostaglandin-mediated GFR), and volume depletion from any cause all increase lithium levels per the Cleveland Clinic. Amlodipine (a calcium channel blocker), metoprolol (a beta-blocker), and clonidine (a central alpha-2 agonist) do not significantly affect lithium levels per UpToDate.\n\nKEY LEARNING POINTS:\nThiazide diuretics raise lithium levels by 25 to 40% through volume depletion-induced compensatory proximal tubular lithium reabsorption, potentially precipitating toxicity within days of initiation. Lithium has an extremely narrow therapeutic index (0.6 to 1.2 mEq/L) with toxicity presenting as coarse tremor, ataxia, and confusion. ACE inhibitors, ARBs, and NSAIDs also raise lithium levels and require monitoring."
  },
  {
    "id": 56,
    "categoryId": 12,
    "question": "In a 2-week-old neonate with meningitis, what are the most common pathogens?",
    "options": [
      "A) Strep pneumo, Neisseria",
      "B) Group B Strep, E. coli, Listeria",
      "C) H. flu, Moraxella",
      "D) Staphylococcus, Pseudomonas"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Group B Strep, E. coli, Listeria).\n\nPATHOPHYSIOLOGY:\nNeonatal meningitis (occurring within the first 28 days of life) has a unique pathogen spectrum that differs fundamentally from meningitis in older infants, children, and adults, reflecting the newborn's exposure to maternal genital flora during delivery and the immaturity of the neonatal immune system per Harrison's Principles of Internal Medicine. The three organisms that collectively cause more than 70% of neonatal bacterial meningitis are Group B Streptococcus (Streptococcus agalactiae), which is the single most common cause and is acquired from the maternal genital tract during passage through the birth canal; Escherichia coli (particularly the K1 capsular strain, which has antiphagocytic properties that facilitate meningeal invasion), the second most common cause and the leading cause in preterm infants; and Listeria monocytogenes, acquired transplacentally or during delivery from maternal colonization associated with consumption of unpasteurized dairy products, deli meats, or soft cheeses per UpToDate and the CDC.\n\nCLINICAL PRESENTATION:\nNeonates do not present with the classic meningitis triad of fever, neck stiffness, and headache seen in older children and adults per the Cleveland Clinic. Instead, neonatal meningitis presents with nonspecific signs including temperature instability (fever or hypothermia), irritability or lethargy, poor feeding, vomiting, a bulging or full anterior fontanelle (a late sign), seizures, apneic episodes, respiratory distress, and jaundice per Harrison's Principles of Internal Medicine. The nonspecific nature of these signs means that a high index of suspicion is essential. Any neonate under 28 days presenting with fever (temperature 38 degrees Celsius or greater) requires a full sepsis evaluation including lumbar puncture, blood cultures, urine culture, and empiric antibiotics, even if the infant appears well per the AAP and UpToDate.\n\nTREATMENT:\nEmpiric antibiotic therapy for neonatal meningitis consists of ampicillin (which covers GBS and Listeria) plus an aminoglycoside (gentamicin, for synergistic gram-negative coverage) or a third-generation cephalosporin (cefotaxime, for enhanced CSF penetration and gram-negative coverage) per the Mayo Clinic and Harrison's Principles of Internal Medicine. Ceftriaxone is specifically avoided in neonates under 28 days because it displaces unconjugated bilirubin from albumin binding sites, increasing the risk of kernicterus per UpToDate. Neonatal meningitis carries a mortality rate of approximately 10 to 15% and a significant risk of long-term neurologic sequelae including hearing loss, developmental delay, seizure disorders, and hydrocephalus.\n\nKEY LEARNING POINTS:\nGroup B Streptococcus, E. coli (K1 strain), and Listeria cause more than 70% of neonatal meningitis, reflecting maternal flora exposure during delivery. Neonates lack classic meningitis signs and present with nonspecific findings, so any febrile neonate under 28 days requires full sepsis workup including LP. Empiric therapy is ampicillin plus gentamicin or cefotaxime, and ceftriaxone is avoided due to kernicterus risk."
  },
  {
    "id": 57,
    "categoryId": 9,
    "question": "A 65-year-old male on Warfarin (INR stable at 2.5) is prescribed Bactrim (TMP-SMX) for a UTI. What will happen to his INR, and what is the management?",
    "options": [
      "A) INR will decrease; Increase Warfarin dose",
      "B) INR will increase; Decrease Warfarin dose by 50%",
      "C) No change expected",
      "D) INR will decrease; Add Aspirin"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (INR will increase; decrease Warfarin dose by 50%).\n\nPHARMACOLOGY:\nTrimethoprim-sulfamethoxazole (TMP-SMX, Bactrim) is one of the most clinically significant drug interactions with warfarin, consistently causing marked INR elevation through two synergistic mechanisms per Harrison's Principles of Internal Medicine and UpToDate. First, sulfamethoxazole is a potent inhibitor of CYP2C9, the primary cytochrome P450 enzyme responsible for metabolizing the more potent S-enantiomer of warfarin, resulting in decreased warfarin clearance and elevated drug levels per the Cleveland Clinic. Second, trimethoprim has an independent anticoagulant effect by inhibiting the renal tubular secretion of creatinine and directly suppressing vitamin K-producing gut flora per Harvard Health.\n\nCLINICAL SIGNIFICANCE:\nThe INR increase with TMP-SMX is substantial and predictable, typically occurring within 3 to 5 days of concurrent use per UpToDate. Studies demonstrate an average INR increase of 50 to 100%, with some patients experiencing supratherapeutic INR levels exceeding 4.0, placing them at significant risk for major hemorrhage per the Mayo Clinic. This interaction is a leading cause of warfarin-related emergency department visits and hospitalizations per Harrison's Principles of Internal Medicine.\n\nMANAGEMENT:\nWhen TMP-SMX must be prescribed to a patient on warfarin, the warfarin dose should be empirically reduced by approximately 25 to 50% at the time of TMP-SMX initiation, with INR checked within 3 to 5 days per UpToDate and the Cleveland Clinic. Alternative antibiotics that do not significantly interact with warfarin (nitrofurantoin for uncomplicated UTI, or fluoroquinolones with caution as they have a weaker CYP interaction) should be considered when possible per Harvard Health.\n\nOTHER HIGH-RISK WARFARIN INTERACTIONS:\nClinicians should be aware of other potent CYP2C9 inhibitors that increase INR: fluconazole, metronidazole, amiodarone, and fluvastatin per Harrison's Principles of Internal Medicine. CYP2C9 inducers (rifampin, carbamazepine, phenytoin, St. John's Wort) decrease INR and increase thrombotic risk per UpToDate.\n\nKEY LEARNING POINTS:\nTMP-SMX (Bactrim) increases INR substantially through CYP2C9 inhibition of warfarin metabolism and suppression of vitamin K-producing gut flora. Warfarin dose should be empirically reduced by 25 to 50% when TMP-SMX is initiated, with INR rechecked within 3 to 5 days. This interaction is a leading cause of warfarin-related bleeding emergencies."
  },
  {
    "id": 58,
    "categoryId": 8,
    "question": "Which antibiotic is associated with an increased risk of tendon rupture and aortic dissection, especially in the elderly?",
    "options": [
      "A) Doxycycline",
      "B) Ciprofloxacin (Fluoroquinolones)",
      "C) Amoxicillin",
      "D) Azithromycin"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Fluoroquinolones â€” Ciprofloxacin, Levofloxacin, Moxifloxacin).\n\nPATHOPHYSIOLOGY:\nFluoroquinolones inhibit bacterial DNA gyrase and topoisomerase IV, which are essential for DNA replication. However, these drugs also impair collagen synthesis and cross-linking in mammalian connective tissues, including tendons and the aortic wall. This mechanism underlies the increased risk of tendon rupture (particularly Achilles tendon) and aortic aneurysm or dissection. The effect is cumulative with factors that already compromise connective tissue integrity, such as aging, corticosteroid use, and genetic connective tissue disorders.\n\nCLINICAL MANIFESTATIONS:\nTendinitis and tendon rupture can occur within hours of the first dose or months after completing therapy. The Achilles tendon is most frequently affected. Risk is significantly increased in patients over age 60, those on concurrent corticosteroids, and organ transplant recipients. Aortic dissection and aneurysm risk is approximately doubled with fluoroquinolone use, with the highest risk in elderly patients, those with hypertension, and those with known connective tissue disorders such as Marfan syndrome or Ehlers-Danlos syndrome. Additional serious adverse effects include peripheral neuropathy (potentially irreversible), CNS effects (seizures, confusion, hallucinations), QT prolongation (especially moxifloxacin), hypoglycemia, and Clostridioides difficile colitis.\n\nCLINICAL REASONING:\nThe FDA has issued multiple black box warnings advising that fluoroquinolones should be reserved for conditions without safer alternative treatments. For uncomplicated cystitis, nitrofurantoin or TMP-SMX should be used instead. Appropriate indications include complicated UTI or pyelonephritis, hospital-acquired pneumonia, Pseudomonas infections, and situations where no safer alternative exists. Patients prescribed fluoroquinolones should be counseled to discontinue the medication immediately and seek evaluation if they develop tendon pain, swelling, or inflammation.\n\nKEY LEARNING POINTS:\nFluoroquinolones carry FDA black box warnings for tendon rupture (especially Achilles), aortic dissection, peripheral neuropathy, and CNS effects. Risk factors include age over 60, corticosteroid use, and connective tissue disorders. Reserve fluoroquinolones for conditions without safer alternatives.\n\nREFERENCES:\nFDA Drug Safety Communications; UpToDate; Harrison's Principles of Internal Medicine.\n---"
  },
  {
    "id": 59,
    "categoryId": 4,
    "question": "A patient with T2DM has a GFR of 25. Which medication is CONTRAINDICATED?",
    "options": [
      "A) Insulin Glargine",
      "B) Metformin",
      "C) Glipizide",
      "D) Linagliptin"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Metformin).\n\nPATHOPHYSIOLOGY:\nMetformin is a biguanide that exerts its glucose-lowering effect primarily by reducing hepatic gluconeogenesis and improving peripheral insulin sensitivity through activation of AMP-activated protein kinase (AMPK). It is renally cleared without hepatic metabolism, meaning the kidney is solely responsible for its elimination. When renal function declines, metformin accumulates in plasma and tissues, increasing the risk of lactic acidosis, a rare but potentially fatal complication with a mortality rate of approximately 50% according to data in Harrison's Principles of Internal Medicine. Metformin-associated lactic acidosis occurs because metformin inhibits mitochondrial complex I in the electron transport chain, shifting cellular metabolism toward anaerobic glycolysis and increasing lactate production. Under normal renal function, metformin concentrations remain low enough that this effect is clinically insignificant. However, with impaired renal clearance, drug accumulation drives lactate production beyond the liver's capacity for clearance, particularly when additional insults such as dehydration, sepsis, or hypoxia further compromise lactate metabolism.\n\nCLINICAL REASONING:\nThe FDA revised its guidance on metformin and renal impairment in 2016 based on a comprehensive review of pharmacokinetic data, shifting from creatinine-based to eGFR-based thresholds. Metformin is safe to initiate and continue without dose adjustment when eGFR is 45 mL/min/1.73mÂ² or greater. When eGFR falls to the 30 to 45 mL/min/1.73mÂ² range, metformin may be continued with dose reduction (typically to a maximum of 1000 mg daily) and more frequent renal monitoring, but should not be newly initiated. When eGFR falls below 30 mL/min/1.73mÂ², metformin is contraindicated and must be discontinued. This patient's GFR of 25 mL/min/1.73mÂ² falls well below this threshold, making metformin contraindicated. Metformin should also be temporarily held before iodinated contrast administration in patients with eGFR 30 to 60 and withheld for 48 hours afterward, with renal function reassessed before resuming.\n\nALTERNATIVE AGENTS IN ADVANCED CKD:\nInsulin remains safe at all levels of renal function, though clearance is reduced in advanced CKD and dose reductions are often necessary to prevent hypoglycemia. Among sulfonylureas, glipizide is preferred in renal impairment because it is hepatically metabolized to inactive metabolites, whereas glyburide has active metabolites that accumulate with renal dysfunction and significantly increase hypoglycemia risk. Linagliptin is the only DPP-4 inhibitor that requires no dose adjustment in any stage of CKD because it is eliminated primarily through the hepatobiliary route, unlike sitagliptin and saxagliptin, which require renal dose adjustments. SGLT2 inhibitors have reduced glucose-lowering efficacy at low eGFR but retain their cardiorenal protective benefits. The DAPA-CKD trial (NEJM 2020) and EMPA-KIDNEY trial (NEJM 2023) demonstrated that SGLT2 inhibitors slow CKD progression and reduce cardiovascular events in patients with eGFR as low as 20 mL/min/1.73mÂ², and current guidelines support their use for cardiorenal protection in advanced CKD even when glycemic benefit is minimal. GLP-1 receptor agonists do not require dose adjustment based on renal function and are safe throughout most stages of CKD.\n\nKEY LEARNING POINTS:\nMetformin is contraindicated when eGFR falls below 30 mL/min/1.73mÂ² due to the risk of lactic acidosis from impaired renal clearance and resultant drug accumulation. Among sulfonylureas in CKD, glipizide is preferred over glyburide because it lacks active metabolites. Linagliptin is the only DPP-4 inhibitor that requires no renal dose adjustment, and SGLT2 inhibitors retain cardiorenal protective benefits at eGFR levels as low as 20 mL/min/1.73mÂ² despite reduced glycemic efficacy."
  },
  {
    "id": 60,
    "categoryId": 11,
    "question": "You are starting Citalopram (Celexa). What is the maximum dose for a patient > 60 years old due to QT prolongation risk?",
    "options": [
      "A) 10 mg",
      "B) 20 mg",
      "C) 40 mg",
      "D) 60 mg"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (20 mg).\n\nPHARMACOLOGY:\nCitalopram (Celexa), a selective serotonin reuptake inhibitor, carries a dose-dependent risk of QT interval prolongation that prompted the FDA to issue a safety communication in 2011 limiting the maximum dose to 40 mg per day in the general population and 20 mg per day in patients older than 60 years per UpToDate and the Cleveland Clinic. The QT prolongation is caused by citalopram's blockade of the hERG (human ether-Ã -go-go-related gene) potassium channel, which conducts the rapid delayed rectifier potassium current (IKr) essential for ventricular repolarization per Harrison's Principles of Internal Medicine.\n\nAGE-RELATED RISK:\nOlder adults are at increased risk of citalopram-induced QT prolongation for several reasons per the Mayo Clinic. Age-related decline in hepatic metabolism (reduced CYP2C19 and CYP3A4 activity) increases citalopram plasma concentrations at any given dose. Older patients have higher baseline QT intervals, reduced cardiac repolarization reserve, and are more likely to be taking concurrent QT-prolonging medications (macrolide antibiotics, fluoroquinolones, antiarrhythmics, antifungals) per UpToDate. They also more frequently have electrolyte abnormalities (hypokalemia, hypomagnesemia from diuretic use) that independently predispose to torsades de pointes per Harvard Health.\n\nCLINICAL APPLICATION:\nBefore initiating citalopram, clinicians should obtain a baseline ECG in patients with cardiac risk factors or those over 60, check electrolytes (potassium, magnesium), and review the medication list for other QT-prolonging drugs per the Cleveland Clinic. If doses above 20 mg are needed in an elderly patient, escitalopram (Lexapro, the S-enantiomer of citalopram) is preferred because it has lower QT prolongation risk at therapeutic doses, with a maximum of 20 mg in the elderly per UpToDate and Harrison's Principles of Internal Medicine. Other SSRIs (sertraline, fluoxetine) have minimal QT effects and are alternatives per the Mayo Clinic.\n\nKEY LEARNING POINTS:\nCitalopram's maximum dose is 20 mg per day in adults over 60 due to dose-dependent QT prolongation from hERG potassium channel blockade. Older adults have increased risk from reduced hepatic metabolism, lower cardiac repolarization reserve, and polypharmacy. Escitalopram and sertraline are safer SSRI alternatives in elderly patients requiring higher antidepressant doses."
  },
  {
    "id": 61,
    "categoryId": 1,
    "question": "A patient on Digoxin presents with nausea, vomiting, and yellow-green visual halos. Which electrolyte abnormality precipitates Digoxin toxicity?",
    "options": [
      "A) Hyperkalemia",
      "B) Hypokalemia",
      "C) Hypermagnesemia",
      "D) Hyponatremia"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Hypokalemia).\n\nPATHOPHYSIOLOGY:\nDigoxin exerts its therapeutic effect by inhibiting the Na+/K+-ATPase pump on cardiac myocytes, which increases intracellular sodium and, via the Na+/Ca2+ exchanger, secondarily increases intracellular calcium, enhancing cardiac contractility (positive inotrope) per Harrison's Principles of Internal Medicine. Critically, digoxin and potassium compete for the same binding site on the Na+/K+-ATPase pump per UpToDate. When serum potassium is low, there is less competition for this binding site, allowing more digoxin to bind and producing excessive Na+/K+-ATPase inhibition even at therapeutic serum digoxin levels. This is why hypokalemia is the most important electrolyte abnormality precipitating digoxin toxicity per the Cleveland Clinic.\n\nCLINICAL PRESENTATION:\nDigoxin toxicity presents with gastrointestinal symptoms (nausea, vomiting, anorexia), neurologic symptoms (confusion, fatigue), and the characteristic visual disturbances including yellow-green halos around lights (xanthopsia) per the Mayo Clinic. Cardiac manifestations range from bradyarrhythmias (sinus bradycardia, AV block) to tachyarrhythmias (atrial tachycardia with block, bidirectional ventricular tachycardia, ventricular fibrillation), with bidirectional VT being nearly pathognomonic for digoxin toxicity per Harrison's Principles of Internal Medicine.\n\nRISK FACTORS AND MANAGEMENT:\nBeyond hypokalemia, other conditions that increase digoxin toxicity risk include hypomagnesemia (magnesium is required for Na+/K+-ATPase function), hypercalcemia (which potentiates digoxin's calcium-loading effect), renal insufficiency (digoxin is renally cleared), and concurrent use of amiodarone, verapamil, or quinidine (which raise digoxin levels by inhibiting P-glycoprotein efflux) per the Cleveland Clinic. The antidote for life-threatening digoxin toxicity is digoxin-specific antibody fragments (DigiFab), which bind free digoxin and prevent it from reaching the Na+/K+-ATPase per UpToDate. Loop and thiazide diuretics commonly precipitate hypokalemia-induced digoxin toxicity in heart failure patients per Harrison's Principles of Internal Medicine.\n\nKEY LEARNING POINTS:\nHypokalemia precipitates digoxin toxicity because potassium and digoxin compete for the same Na+/K+-ATPase binding site, and low potassium allows excessive digoxin binding. Classic toxicity presents with GI symptoms, xanthopsia (yellow-green halos), and characteristic arrhythmias (bidirectional VT is nearly pathognomonic). DigiFab is the antidote for life-threatening toxicity."
  },
  {
    "id": 62,
    "categoryId": 6,
    "question": "Which opioid lowers the seizure threshold and causes neurotoxicity (tremors/seizures) in renal failure?",
    "options": [
      "A) Morphine",
      "B) Hydromorphone",
      "C) Meperidine (Demerol)",
      "D) Fentanyl"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Meperidine/Demerol).\n\nMEPERIDINE NEUROTOXICITY:\nMeperidine is unique among opioids in producing a neurotoxic metabolite, normeperidine, which is a CNS stimulant with a prolonged half-life of 15 to 30 hours. Normeperidine is renally excreted, and its accumulation in patients with renal impairment creates a dangerous scenario where therapeutic doses of meperidine can produce seizures, tremors, and delirium.\n\nPATHOPHYSIOLOGY:\nMeperidine undergoes hepatic N-demethylation to normeperidine, which lowers the seizure threshold through direct CNS excitatory effects. Unlike the parent compound, normeperidine has minimal analgesic activity but potent proconvulsant properties. In renal failure, the elimination half-life of normeperidine can extend to over 35 hours, leading to progressive accumulation even with standard dosing. Meperidine also inhibits serotonin reuptake, creating a risk of serotonin syndrome when combined with SSRIs, SNRIs, or MAOIs.\n\nCLINICAL MANIFESTATIONS:\nEarly signs of normeperidine toxicity include tremors, myoclonus, and irritability. As accumulation progresses, patients may develop generalized seizures, delirium, and hallucinations. Seizures can occur even at therapeutic doses in patients with renal impairment, elderly patients, or those receiving prolonged therapy exceeding 48 hours. Importantly, seizures may persist even after meperidine discontinuation due to normeperidine's long half-life.\n\nSAFER ALTERNATIVES IN RENAL FAILURE:\nFentanyl is the preferred opioid in renal failure because it has no active metabolites and is metabolized hepatically. Hydromorphone is another reasonable option with minimal active metabolite accumulation. Morphine should be used cautiously because its active metabolite (morphine-6-glucuronide) accumulates in renal failure, causing prolonged sedation.\n\nKEY LEARNING POINTS:\nMeperidine produces the neurotoxic metabolite normeperidine, which causes seizures and accumulates in renal failure. Fentanyl is the safest opioid in renal impairment due to the absence of active metabolites. Meperidine also carries serotonin syndrome risk and is now rarely indicated outside of treating rigors and shivering."
  },
  {
    "id": 63,
    "categoryId": 11,
    "question": "A 24-year-old female with bipolar disorder is trying to conceive. Which mood stabilizer causes Epstein's Anomaly (atrialization of the right ventricle)?",
    "options": [
      "A) Lithium",
      "B) Lamotrigine",
      "C) Valproic Acid",
      "D) Quetiapine"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Lithium).\n\nTERATOGENICITY:\nLithium use during the first trimester of pregnancy is associated with an increased risk of Ebstein anomaly, a congenital cardiac malformation in which the tricuspid valve is displaced apically into the right ventricle (atrialization of the right ventricle), causing tricuspid regurgitation, right atrial enlargement, and right-to-left shunting through a patent foramen ovale per Harrison's Principles of Internal Medicine and UpToDate. While early registry data suggested a relative risk as high as 400-fold, subsequent studies have demonstrated that the absolute risk is lower than initially feared (approximately 1 in 1,000 lithium-exposed pregnancies versus 1 in 20,000 in the general population), though this still represents a clinically significant 20-fold increase per the Cleveland Clinic.\n\nSAFER ALTERNATIVES:\nLamotrigine is generally considered the safest mood stabilizer during pregnancy, with no significant increase in major congenital malformations at standard doses per UpToDate and the Mayo Clinic. Valproic acid is the most teratogenic mood stabilizer and is absolutely contraindicated in pregnancy: it causes neural tube defects (spina bifida in 1 to 2% of exposed pregnancies), craniofacial anomalies, cardiac defects, and neurodevelopmental impairment (reduced IQ by 8 to 11 points) per Harrison's Principles of Internal Medicine. Carbamazepine also carries neural tube defect risk (approximately 0.5 to 1%) and is considered intermediate risk per Harvard Health.\n\nCLINICAL MANAGEMENT:\nFor women of childbearing age with bipolar disorder, preconception counseling is essential per the Cleveland Clinic. If lithium is continued during pregnancy (which may be appropriate for severe bipolar I disorder where relapse risk is high), a fetal echocardiogram should be performed at 16 to 20 weeks' gestation to screen for Ebstein anomaly and other cardiac defects per UpToDate. Lithium levels should be monitored more frequently during pregnancy because the 50% increase in GFR and blood volume during pregnancy reduces lithium levels, often requiring dose adjustments per Harrison's Principles of Internal Medicine.\n\nKEY LEARNING POINTS:\nLithium exposure in the first trimester increases the risk of Ebstein anomaly (apical displacement of the tricuspid valve) approximately 20-fold, though the absolute risk remains approximately 1 in 1,000. Lamotrigine is the safest mood stabilizer in pregnancy, while valproic acid is absolutely contraindicated (neural tube defects, neurodevelopmental harm). Fetal echocardiography at 16 to 20 weeks is recommended for lithium-exposed pregnancies."
  },
  {
    "id": 64,
    "categoryId": 8,
    "question": "Which antibiotic provides coverage against anaerobes (Bacteroides) 'below the diaphragm' (intra-abdominal)?",
    "options": [
      "A) Clindamycin",
      "B) Metronidazole (Flagyl)",
      "C) Cephalexin",
      "D) Vancomycin"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Metronidazole).\n\nPATHOPHYSIOLOGY:\nAnaerobic bacteria are normal flora of the gastrointestinal tract, female genital tract, and oral cavity. When mucosal barriers are breached (e.g., perforated appendicitis, diverticular abscess, post-surgical contamination), these organisms cause serious infections. The dominant pathogenic anaerobe below the diaphragm is Bacteroides fragilis, which possesses a polysaccharide capsule that promotes abscess formation and resists phagocytosis. Metronidazole is a prodrug that is reduced intracellularly within anaerobic organisms, generating cytotoxic free radicals that damage bacterial DNA.\n\nCLINICAL REASONING:\nThe anatomic distinction between infections above and below the diaphragm guides antibiotic selection for anaerobic coverage. Below the diaphragm, Bacteroides fragilis predominates in intra-abdominal and pelvic infections, and metronidazole provides excellent coverage with superior abscess penetration. Above the diaphragm, oral anaerobes (Peptostreptococcus, Fusobacterium, Prevotella) predominate in lung abscesses and dental infections, and clindamycin is preferred. Metronidazole has additional clinical utility as a first-line agent for Clostridioides difficile infection (oral formulation), trichomoniasis, giardiasis, and as a component of H. pylori eradication regimens.\n\nTREATMENT CONSIDERATIONS:\nPatients on metronidazole must avoid alcohol during treatment and for at least 48 hours afterward due to a disulfiram-like reaction (nausea, vomiting, flushing, tachycardia). Antibiotics that lack anaerobic coverage and should not be relied upon for these infections include fluoroquinolones (except moxifloxacin), aminoglycosides, aztreonam, and most cephalosporins.\n\nKEY LEARNING POINTS:\nMetronidazole is the drug of choice for Bacteroides fragilis and intra-abdominal anaerobic infections (below the diaphragm). Clindamycin is preferred for anaerobic infections above the diaphragm. Patients must avoid alcohol with metronidazole due to disulfiram-like reaction.\n\nREFERENCES:\nIDSA Intra-Abdominal Infection Guidelines; UpToDate; Harrison's Principles of Internal Medicine.\n---"
  },
  {
    "id": 65,
    "categoryId": 2,
    "question": "Which inhaler class is associated with urinary retention and exacerbation of Glaucoma?",
    "options": [
      "A) SABA (Albuterol)",
      "B) LAMA (Tiotropium/Spiriva)",
      "C) ICS (Fluticasone)",
      "D) LABA (Salmeterol)"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (LAMA - Long-Acting Muscarinic Antagonist).\n\nPATHOPHYSIOLOGY:\nLong-acting muscarinic antagonists (tiotropium, umeclidinium, glycopyrrolate, aclidinium) are inhaled anticholinergic bronchodilators that block muscarinic M3 receptors on airway smooth muscle, reducing acetylcholine-mediated bronchoconstriction and mucus secretion per Harrison's Principles of Internal Medicine. Because muscarinic receptors are distributed throughout the body, systemic anticholinergic effects can occur even with inhaled administration. Blockade of muscarinic receptors on the detrusor muscle of the bladder inhibits contraction, impairing bladder emptying and causing urinary retention, particularly in patients with pre-existing bladder outlet obstruction from benign prostatic hyperplasia per UpToDate. Blockade of muscarinic receptors on the iris sphincter causes mydriasis (pupil dilation), which in patients with anatomically narrow anterior chamber angles can precipitate acute angle-closure glaucoma by pushing the peripheral iris against the trabecular meshwork and obstructing aqueous humor drainage per the Cleveland Clinic.\n\nCLINICAL APPLICATION:\nBefore prescribing LAMA inhalers, clinicians should screen for a history of narrow-angle glaucoma, benign prostatic hyperplasia, or bladder outlet obstruction per UpToDate. Patients should be counseled to avoid directing the inhaler mist toward the eyes, particularly with nebulized formulations, as direct ocular exposure concentrates the anticholinergic effect on the iris. Additional anticholinergic side effects include dry mouth (the most common), constipation from decreased gastrointestinal motility, and tachycardia from blockade of vagal tone at the sinoatrial node per the Mayo Clinic.\n\nCOMPARISON OF INHALER SIDE EFFECT PROFILES:\nSABA and LABA (albuterol, salmeterol, formoterol) are beta-2 agonists whose side effects include tremor, tachycardia, and hypokalemia from beta-2-mediated intracellular potassium shift per Harrison's Principles of Internal Medicine. Inhaled corticosteroids (fluticasone, budesonide) cause oropharyngeal candidiasis (thrush) and dysphonia from local immunosuppression in the oropharynx, mitigated by mouth rinsing after use, and carry an increased pneumonia risk specifically in COPD patients per UpToDate.\n\nKEY LEARNING POINTS:\nLAMA inhalers cause urinary retention and can precipitate acute angle-closure glaucoma through systemic anticholinergic effects on the bladder detrusor and iris sphincter muscles. Always screen for narrow-angle glaucoma and BPH before prescribing. The key side effect distinction is that LAMAs cause anticholinergic effects (dry, retention), beta-agonists cause sympathomimetic effects (tremor, tachycardia), and ICS cause local immunosuppression (thrush, dysphonia)."
  },
  {
    "id": 66,
    "categoryId": 1,
    "question": "A patient develops a dry, hacking cough after starting a BP med. Which class is responsible and what is the alternative?",
    "options": [
      "A) Beta Blocker; switch to CCB",
      "B) ACE Inhibitor; switch to ARB",
      "C) CCB; switch to Thiazide",
      "D) ARB; switch to ACE Inhibitor"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (ACE Inhibitor; switch to ARB).\n\nPATHOPHYSIOLOGY:\nACE inhibitors (lisinopril, enalapril, ramipril) block angiotensin-converting enzyme, which normally converts angiotensin I to angiotensin II and simultaneously degrades bradykinin per Harrison's Principles of Internal Medicine. When ACE is inhibited, bradykinin accumulates in the pulmonary and upper airway epithelium, stimulating C-fiber sensory neurons and triggering the cough reflex via substance P and prostaglandins per UpToDate. This ACE inhibitor-induced cough occurs in approximately 5 to 20% of patients (with higher incidence in women and individuals of East Asian or African descent), is characteristically dry, persistent, and nonproductive, and typically develops within 1 to 6 months of starting therapy per the Cleveland Clinic. The cough is a class effect affecting all ACE inhibitors and does not improve with dose reduction per the Mayo Clinic.\n\nCLINICAL APPLICATION:\nAngiotensin II receptor blockers (ARBs such as losartan, valsartan, irbesartan) block the angiotensin II type 1 receptor directly without affecting bradykinin metabolism, which is why they do not cause the bradykinin-mediated cough per UpToDate. ARBs are therefore the appropriate substitution. Importantly, while ACE inhibitor cough is common and benign, ACE inhibitor-induced angioedema (swelling of the lips, tongue, and upper airway) is a rare but potentially life-threatening complication also mediated by bradykinin accumulation per Harrison's Principles of Internal Medicine. Patients with ACE inhibitor angioedema can generally be switched to ARBs with caution (approximately 1 to 2% cross-reactivity), though both ACE inhibitors and ARBs are contraindicated in hereditary angioedema per the Cleveland Clinic.\n\nKEY LEARNING POINTS:\nACE inhibitor cough results from bradykinin accumulation in the airways (ACE normally degrades bradykinin), affects 5 to 20% of patients, and is a class effect not improved by dose reduction. ARBs block angiotensin II receptors without affecting bradykinin and are the appropriate switch. ACE inhibitor angioedema is a separate, more dangerous bradykinin-mediated reaction requiring vigilance."
  },
  {
    "id": 67,
    "categoryId": 6,
    "question": "Triptans (Sumatriptan) are contraindicated in which patient population?",
    "options": [
      "A) Renal Failure",
      "B) History of Coronary Artery Disease / Stroke",
      "C) Liver Failure",
      "D) Depression"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (History of CAD/Stroke).\n\nTRIPTAN CONTRAINDICATIONS:\nTriptans are serotonin 5-HT1B/1D receptor agonists that abort migraine attacks by causing cranial vasoconstriction and inhibiting trigeminal nerve activation. However, the same vasoconstrictive mechanism affects coronary and cerebral arteries, which can precipitate myocardial ischemia or stroke in patients with pre-existing cardiovascular or cerebrovascular disease.\n\nPATHOPHYSIOLOGY:\nActivation of 5-HT1B receptors on vascular smooth muscle causes arterial constriction. In healthy coronary and cerebral vessels, this effect is clinically insignificant. In patients with atherosclerotic disease, vasoconstriction of already-narrowed vessels can reduce blood flow below critical thresholds, triggering angina, myocardial infarction, or cerebral ischemia. Rare cases of coronary vasospasm have been reported even in patients without known CAD.\n\nCONTRAINDICATED POPULATIONS:\nTriptans are contraindicated in patients with coronary artery disease (prior MI, angina, known CAD), cerebrovascular disease (prior stroke or TIA), peripheral vascular disease, uncontrolled hypertension, and hemiplegic or basilar migraine. Concurrent use with ergotamines or other triptans within 24 hours is also contraindicated, as is use within 2 weeks of MAO inhibitor therapy.\n\nACUTE MIGRAINE TREATMENT APPROACH:\nFor patients who cannot use triptans, alternatives include NSAIDs (ibuprofen, naproxen), antiemetics with analgesic properties (metoclopramide, prochlorperazine), gepants (CGRP receptor antagonists such as ubrogepant and rimegepant), and ditans (lasmiditan, a 5-HT1F agonist without vasoconstrictive effects). Opioids and barbiturates should be avoided due to medication overuse headache risk. Prophylaxis with beta-blockers, topiramate, valproate, amitriptyline, or CGRP monoclonal antibodies is indicated for patients with four or more headache days per month.\n\nKEY LEARNING POINTS:\nTriptans cause vasoconstriction and are contraindicated in patients with cardiovascular or cerebrovascular disease. Gepants and ditans are newer migraine abortives without vasoconstrictive effects, making them safe alternatives. Migraine prophylaxis is indicated when patients have four or more headache days per month or significant disability."
  },
  {
    "id": 68,
    "categoryId": 10,
    "question": "A female patient is starting Isotretinoin (Accutane). What is the mandatory monitoring requirement (iPLEDGE)?",
    "options": [
      "A) Liver enzymes every week",
      "B) Two forms of birth control and monthly pregnancy tests",
      "C) Renal function monthly",
      "D) Eye exam monthly"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Two forms of birth control and monthly pregnancy tests).\n\nPATHOPHYSIOLOGY:\nIsotretinoin (13-cis-retinoic acid) is a vitamin A derivative that targets all four pillars of acne pathogenesis: it dramatically reduces sebaceous gland size and sebum production by up to 90%, normalizes follicular keratinization, reduces Cutibacterium acnes colonization by eliminating the lipid-rich environment, and exerts direct anti-inflammatory effects. It is the only acne medication that can produce long-term remission after a single course. However, isotretinoin is an extremely potent teratogen classified as FDA Category X. Exposure during pregnancy causes a characteristic pattern of birth defects known as retinoic acid embryopathy, affecting craniofacial structures (microtia, anotia, micrognathia, cleft palate), the cardiovascular system (conotruncal heart defects, aortic arch anomalies), the central nervous system (hydrocephalus, microcephaly, cerebellar malformations), and the thymus (aplasia or hypoplasia). The critical window of vulnerability extends from conception through the first trimester, with fetal loss rates of approximately 40% and major malformation rates exceeding 25% among live births following exposure.\n\nCLINICAL APPLICATION - THE iPLEDGE PROGRAM:\nThe iPLEDGE program is an FDA-mandated Risk Evaluation and Mitigation Strategy (REMS) designed to prevent fetal isotretinoin exposure. For females of childbearing potential, the program requires two negative pregnancy tests before starting therapy (one at the prescriber's office, one at a CLIA-certified lab), with the second test performed during the first 5 days of menstruation or within 11 days of the last act of intercourse. Monthly pregnancy tests are required throughout treatment and for one month after discontinuation. Two simultaneous forms of contraception (or documented abstinence) must be used beginning one month before treatment, continuing throughout therapy, and for one month after the last dose. Prescriptions are limited to 30-day supplies, and each prescription must be filled within a 7-day window following the pregnancy test. All patients, prescribers, and pharmacies must register with the program.\n\nMONITORING BEYOND iPLEDGE:\nIsotretinoin causes dose-dependent hypertriglyceridemia in up to 45% of patients through increased hepatic VLDL synthesis, and transaminase elevations occur in 10 to 20% of patients. Baseline and periodic (every 1 to 2 months) fasting lipid panels and hepatic function tests are standard of care. A baseline CBC is also recommended. Patients should be counseled about mucocutaneous dryness (cheilitis occurs in nearly 100% of patients, followed by xerosis, dry eyes, and epistaxis), photosensitivity, myalgias, and the importance of avoiding waxing and elective procedures during and for 6 months after treatment due to impaired wound healing. The association between isotretinoin and depression remains debated, with large population-based studies showing no causal link, but monitoring for mood changes is still recommended.\n\nKEY LEARNING POINTS:\nIsotretinoin is the most effective acne therapy and the only one that can induce long-term remission, but it is a potent teratogen requiring the iPLEDGE REMS program. Two forms of contraception, monthly pregnancy tests, and a 7-day prescription pickup window are mandatory for females of childbearing potential. Fasting lipids and liver function tests require baseline and periodic monitoring. Contraception must continue for one month after discontinuation because of the drug's elimination half-life."
  },
  {
    "id": 69,
    "categoryId": 3,
    "question": "Long-term use of Proton Pump Inhibitors (Omeprazole) is associated with deficiencies in which nutrients?",
    "options": [
      "A) Vitamin C and Zinc",
      "B) Vitamin B12, Magnesium, and Calcium",
      "C) Vitamin A and E",
      "D) Potassium and Sodium"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Vitamin B12, Magnesium, and Calcium).\n\nPATHOPHYSIOLOGY:\nProton pump inhibitors suppress gastric acid secretion by irreversibly inhibiting the hydrogen-potassium ATPase pump in parietal cells, raising intragastric pH. Gastric acid is required for the cleavage of vitamin B12 from dietary proteins and for the ionization of insoluble calcium and magnesium salts into absorbable forms. Chronic acid suppression therefore impairs the absorption of all three nutrients through distinct but related mechanisms.\n\nCLINICAL MANIFESTATIONS:\nVitamin B12 deficiency (reported in 12-33% of chronic PPI users) can produce macrocytic anemia, peripheral neuropathy, cognitive impairment, and glossitis. Hypomagnesemia (typically after more than one year of use) may present with muscle cramps, cardiac arrhythmias, or seizures and is refractory to magnesium supplementation while the PPI is continued. Impaired calcium absorption increases fracture risk, particularly hip, wrist, and spine fractures in postmenopausal women and elderly patients, with studies showing a 25-35% increased risk after more than one year of use.\n\nMONITORING AND MANAGEMENT:\nThe FDA issued safety communications regarding hypomagnesemia (2011) and fracture risk with PPIs. Current recommendations include checking magnesium levels prior to initiation and periodically during long-term use, monitoring B12 in patients on PPIs for more than 2-3 years, ensuring adequate dietary calcium and vitamin D, and using the lowest effective PPI dose for the shortest necessary duration.\n\nKEY LEARNING POINTS:\nChronic PPI use impairs absorption of vitamin B12, magnesium, and calcium by suppressing gastric acid needed for nutrient liberation and ionization. B12 deficiency causes neurologic and hematologic complications. Hypomagnesemia can be refractory to supplementation until the PPI is discontinued. Fracture risk increases 25-35% with prolonged use."
  },
  {
    "id": 70,
    "categoryId": 4,
    "question": "How should Levothyroxine be taken for maximal absorption?",
    "options": [
      "A) With breakfast",
      "B) On an empty stomach, 30-60 mins before food, separated from Calcium/Iron by 4 hours",
      "C) With dinner",
      "D) With milk"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (On an empty stomach, 30-60 minutes before food, separated from Calcium/Iron by 4 hours).\n\nPATHOPHYSIOLOGY:\nLevothyroxine (synthetic T4) is a narrow therapeutic index medication with variable oral bioavailability ranging from 40 to 80% depending on the formulation and conditions of absorption. Absorption occurs predominantly in the jejunum and upper ileum and is critically dependent on an acidic gastric pH for dissolution of the tablet and the absence of intraluminal substances that chelate or bind the drug. When levothyroxine encounters calcium, iron, or aluminum-containing compounds in the gastrointestinal lumen, it forms insoluble complexes that pass through the gut unabsorbed. Food, particularly fiber and soy protein, also impairs absorption by adsorbing the drug or altering gastrointestinal transit time. The clinical consequence is that improper administration is one of the most common causes of persistently elevated TSH in patients who are adherent to their prescribed dose, leading to unnecessary and potentially harmful dose escalation.\n\nCLINICAL REASONING:\nThe ATA and Endocrine Society guidelines recommend taking levothyroxine on an empty stomach with a full glass of water, at least 30 to 60 minutes before the first meal of the day, to maximize absorption. Specific drug and supplement interactions are clinically significant and well documented: calcium carbonate supplements reduce levothyroxine absorption by up to 25% (per a study published in JAMA Internal Medicine), iron supplements reduce absorption by a similar magnitude, and proton pump inhibitors impair absorption by raising gastric pH and preventing adequate tablet dissolution. Coffee, including decaffeinated, has been shown to reduce absorption by approximately 30% when consumed simultaneously. Aluminum-containing antacids, sucralfate, bile acid sequestrants (cholestyramine, colesevelam), and soy-based products also significantly impair absorption. All of these interacting substances should be separated from levothyroxine by at least 4 hours. For patients who struggle with morning dosing, bedtime administration (at least 3 to 4 hours after the last meal) is a validated alternative supported by clinical trial data showing equivalent or even slightly superior TSH control compared to morning dosing.\n\nTREATMENT OPTIMIZATION:\nBefore increasing the levothyroxine dose in a patient with persistently elevated TSH, the clinician should systematically assess adherence and administration technique. Key questions include the timing of ingestion relative to meals, concurrent use of calcium or iron supplements, coffee consumption habits, and use of proton pump inhibitors. Switching from a tablet formulation to a liquid or gel capsule preparation can improve absorption in patients with known gastrointestinal conditions or persistent absorption issues, as these formulations are less pH-dependent. Monitoring consists of checking TSH 6 to 8 weeks after any dose change, with the goal of maintaining TSH within the reference range (typically 0.5 to 4.0 mIU/L for non-pregnant adults, with individualized targets for elderly patients in whom a TSH of 4 to 6 mIU/L may be acceptable per Endocrine Society guidance).\n\nKEY LEARNING POINTS:\nLevothyroxine must be taken on an empty stomach 30 to 60 minutes before food, separated from calcium, iron, and antacids by at least 4 hours to prevent chelation and impaired absorption. Before escalating the levothyroxine dose for persistently elevated TSH, the clinician should verify proper administration technique, as improper timing is one of the most common causes of apparent treatment failure. Coffee, PPIs, fiber, and soy also reduce absorption and should be separated from the medication."
  },
  {
    "id": 71,
    "categoryId": 5,
    "question": "Sildenafil (Viagra) is strictly contraindicated with which medication class?",
    "options": [
      "A) Alpha Blockers (Tamsulosin)",
      "B) Nitrates (Nitroglycerin/Isosorbide)",
      "C) Beta Blockers",
      "D) Statins"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Nitrates).\n\nPHARMACOLOGY:\nSildenafil (Viagra) is a phosphodiesterase type 5 (PDE5) inhibitor used for erectile dysfunction and pulmonary arterial hypertension that is absolutely contraindicated with nitrate medications per Harrison's Principles of Internal Medicine and UpToDate. The combination produces severe, refractory, and potentially fatal hypotension through synergistic vasodilation via the nitric oxide-cGMP pathway per the Cleveland Clinic.\n\nMECHANISM OF INTERACTION:\nNitrates (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate) are metabolized to nitric oxide (NO), which activates soluble guanylyl cyclase in vascular smooth muscle cells, increasing cyclic guanosine monophosphate (cGMP) production per Harrison's Principles of Internal Medicine. cGMP activates protein kinase G, which reduces intracellular calcium and produces vascular smooth muscle relaxation (vasodilation). PDE5 is the enzyme that normally degrades cGMP, terminating the vasodilatory signal. Sildenafil blocks PDE5, preventing cGMP breakdown, which massively potentiates and prolongs the vasodilatory effect of nitrates per UpToDate. The result is a precipitous drop in blood pressure that may be refractory to vasopressors per the Mayo Clinic.\n\nTIME RESTRICTIONS:\nNitrates must not be administered within 24 hours of sildenafil or vardenafil use, or within 48 hours of tadalafil (Cialis) use (which has a longer 17.5-hour half-life) per the Cleveland Clinic and Harvard Health. This restriction applies to all nitrate formulations including sublingual nitroglycerin, oral isosorbide, nitroglycerin patches, and recreational amyl nitrite (\"poppers\") per UpToDate. In the emergency department, if a patient presenting with chest pain has recently taken a PDE5 inhibitor, alternative anti-anginal agents (beta-blockers, calcium channel blockers, morphine) must be used instead of nitroglycerin per Harrison's Principles of Internal Medicine.\n\nOTHER PDE5 INHIBITOR CONSIDERATIONS:\nPDE5 inhibitors can also cause hypotension when combined with alpha-blockers (use lowest doses with caution) per the Mayo Clinic. They are contraindicated in patients taking riociguat (a soluble guanylyl cyclase stimulator) per UpToDate.\n\nKEY LEARNING POINTS:\nPDE5 inhibitors (sildenafil, tadalafil, vardenafil) are absolutely contraindicated with all nitrate formulations because PDE5 inhibition prevents cGMP degradation, synergistically potentiating nitrate-induced vasodilation to produce severe refractory hypotension. The restriction is 24 hours for sildenafil/vardenafil and 48 hours for tadalafil. In the ED, use beta-blockers or calcium channel blockers instead of nitroglycerin."
  },
  {
    "id": 72,
    "categoryId": 11,
    "question": "Which Benzodiazepine is preferred in patients with Liver Failure?",
    "options": [
      "A) Diazepam (Valium)",
      "B) Lorazepam (Ativan)",
      "C) Clonazepam (Klonopin)",
      "D) Alprazolam (Xanax)"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Lorazepam).\n\nPHARMACOLOGY:\nLorazepam (Ativan) is the preferred benzodiazepine in hepatic failure because it undergoes phase II conjugation (direct glucuronidation by UGT enzymes) without prior phase I oxidative metabolism by cytochrome P450 enzymes per Harrison's Principles of Internal Medicine and UpToDate. This distinction is critical because phase I oxidation (the CYP-dependent reactions of hydroxylation, demethylation, and dealkylation) is significantly impaired in liver disease, while phase II glucuronidation is relatively preserved until very advanced cirrhosis per the Cleveland Clinic.\n\nHEPATIC METABOLISM COMPARISON:\nMost benzodiazepines (diazepam, alprazolam, chlordiazepoxide, midazolam) require phase I CYP3A4 or CYP2C19 oxidation before glucuronidation, and their metabolism is markedly prolonged in liver failure, leading to drug accumulation and excessive sedation per UpToDate. Diazepam is particularly dangerous because it has active metabolites (desmethyldiazepam, with a half-life of 40 to 200 hours) that also require hepatic oxidation, creating extreme drug accumulation and prolonged sedation in cirrhotic patients per Harvard Health. The mnemonic LOT (Lorazepam, Oxazepam, Temazepam) identifies the three benzodiazepines that undergo only phase II glucuronidation and are therefore safe in liver disease per the Mayo Clinic.\n\nCLINICAL SIGNIFICANCE:\nIn patients with cirrhosis, benzodiazepine accumulation can precipitate or worsen hepatic encephalopathy by enhancing GABAergic inhibition in an already sensitized central nervous system per Harrison's Principles of Internal Medicine. Clinicians should use the lowest effective dose of lorazepam for the shortest duration, as even glucuronidation may be impaired in decompensated cirrhosis (Child-Pugh C) per UpToDate. For alcohol withdrawal in cirrhotic patients, lorazepam is the preferred agent using symptom-triggered dosing guided by the CIWA-Ar protocol per the Cleveland Clinic.\n\nKEY LEARNING POINTS:\nLorazepam is preferred in liver failure because it undergoes only phase II glucuronidation (preserved in liver disease) without phase I CYP oxidation (impaired in liver disease). The LOT mnemonic (Lorazepam, Oxazepam, Temazepam) identifies the three safe benzodiazepines in hepatic impairment. Diazepam is particularly dangerous in cirrhosis due to active metabolites with half-lives up to 200 hours."
  },
  {
    "id": 73,
    "categoryId": 8,
    "question": "A patient on Isoniazid (INH) for latent TB develops numbness and tingling in the hands. What supplement prevents this?",
    "options": [
      "A) Vitamin B12",
      "B) Vitamin B6 (Pyridoxine)",
      "C) Folate",
      "D) Thiamine"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Vitamin B6 / pyridoxine).\n\nPATHOPHYSIOLOGY:\nIsoniazid can cause a functional pyridoxine deficiency (increased urinary excretion and interference with pyridoxine-dependent enzymes). This impairs neurotransmitter synthesis and peripheral nerve function, leading to a symmetric distal sensory neuropathy.\n\nCLINICAL MANIFESTATIONS:\n- Paresthesias/numbness (hands/feet), burning pain\n- In severe deficiency: irritability, seizures (rare)\n\nPREVENTION AND TREATMENT:\n- Routine prophylaxis is commonly used, especially in higher-risk patients (pregnancy, diabetes, HIV, alcoholism, malnutrition, CKD).\n- If neuropathy develops: add pyridoxine and reassess INH adherence, dosing, and risk factors; continue TB regimen unless severe toxicity.\n\nKEY LEARNING POINTS:\nINH neuropathy is preventable with pyridoxine; think of B6 whenever INH is prescribed.\n\nREFERENCES:\nCDC TB guidance; UpToDate; Harrison's Principles of Internal Medicine.\n---"
  },
  {
    "id": 74,
    "categoryId": 1,
    "question": "Entresto (Sacubitril/Valsartan) requires a washout period of 36 hours before starting if the patient was previously taking:",
    "options": [
      "A) Amlodipine",
      "B) Metoprolol",
      "C) Lisinopril (ACE Inhibitor)",
      "D) Furosemide"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Lisinopril, an ACE Inhibitor).\n\nPATHOPHYSIOLOGY:\nEntresto (sacubitril/valsartan) is a combination angiotensin receptor-neprilysin inhibitor (ARNI) that simultaneously blocks the angiotensin II receptor (via the valsartan component) and inhibits neprilysin (via the sacubitril component) per UpToDate. Neprilysin is the enzyme that degrades natriuretic peptides (ANP, BNP, CNP), bradykinin, adrenomedullin, and substance P. By inhibiting neprilysin, sacubitril increases levels of these beneficial vasoactive peptides, promoting vasodilation, natriuresis, and favorable cardiac remodeling per Harrison's Principles of Internal Medicine.\n\nSAFETY CONCERN:\nThe mandatory 36-hour washout period between discontinuing an ACE inhibitor and starting sacubitril/valsartan exists to prevent life-threatening angioedema per the Cleveland Clinic. ACE inhibitors block bradykinin degradation via one pathway, and neprilysin is another major pathway for bradykinin clearance. If both pathways are simultaneously blocked (residual ACE inhibition plus neprilysin inhibition from sacubitril), bradykinin levels can rise dramatically, precipitating severe angioedema involving the lips, tongue, pharynx, and larynx with risk of fatal airway obstruction per UpToDate. This 36-hour window allows complete clearance of the ACE inhibitor before neprilysin inhibition begins per the Mayo Clinic.\n\nCLINICAL EVIDENCE:\nThe PARADIGM-HF trial demonstrated that sacubitril/valsartan reduced cardiovascular death and heart failure hospitalization by 20% compared to enalapril in patients with HFrEF (EF 40% or less), establishing it as a cornerstone of guideline-directed medical therapy per Harrison's Principles of Internal Medicine. No washout is needed when switching from an ARB because ARBs do not affect bradykinin metabolism per UpToDate.\n\nKEY LEARNING POINTS:\nSacubitril/valsartan requires a mandatory 36-hour washout from ACE inhibitors (but not ARBs) to prevent catastrophic angioedema from dual bradykinin pathway inhibition. The PARADIGM-HF trial demonstrated 20% reduction in cardiovascular death and HF hospitalization versus enalapril in HFrEF. No washout is required when switching from ARBs because they do not affect bradykinin."
  },
  {
    "id": 75,
    "categoryId": 6,
    "question": "Which antiepileptic drug causes gingival hyperplasia and hirsutism?",
    "options": [
      "A) Levetiracetam (Keppra)",
      "B) Phenytoin (Dilantin)",
      "C) Valproic Acid",
      "D) Lamotrigine"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Phenytoin/Dilantin).\n\nPHENYTOIN SIDE EFFECTS:\nPhenytoin (Dilantin) is a first-generation antiepileptic drug known for several distinctive cosmetic and systemic adverse effects not commonly seen with newer agents. Gingival hyperplasia and hirsutism are the most recognizable phenytoin-specific side effects and often limit its long-term use, particularly in young patients and women.\n\nPATHOPHYSIOLOGY OF GINGIVAL HYPERPLASIA:\nGingival hyperplasia occurs in approximately 50% of patients on chronic phenytoin therapy. Phenytoin stimulates fibroblast proliferation and collagen synthesis in gingival tissue, causing progressive overgrowth. Meticulous oral hygiene and regular dental care can reduce severity but may not prevent it entirely. Severe cases may require gingivectomy or switching to an alternative antiepileptic drug. Hirsutism results from phenytoin's effects on androgen metabolism, causing excessive hair growth on the face and trunk.\n\nADDITIONAL PHENYTOIN TOXICITIES:\nChronic use can cause cerebellar atrophy (manifesting as ataxia, nystagmus, and dysarthria), peripheral neuropathy, osteomalacia (through induction of vitamin D metabolism), and megaloblastic anemia (due to impaired folate absorption). Phenytoin is a potent CYP450 inducer, leading to numerous drug interactions. Fetal hydantoin syndrome (craniofacial abnormalities, nail and digit hypoplasia, developmental delay) makes it particularly dangerous in pregnancy.\n\nPHARMACOKINETICS:\nPhenytoin exhibits zero-order (saturable) kinetics, meaning small dose adjustments can cause disproportionately large changes in serum levels. This necessitates careful therapeutic drug monitoring with a target range of 10 to 20 mcg/mL. The narrow therapeutic window and nonlinear kinetics make dosing challenging compared to newer agents.\n\nTREATMENT CONSIDERATIONS:\nGiven the cosmetic side effects and complex pharmacokinetics, newer antiepileptic drugs such as levetiracetam, lamotrigine, and lacosamide are often preferred, especially for young patients and women of childbearing age. Phenytoin remains useful in acute settings (fosphenytoin for status epilepticus) and in resource-limited environments.\n\nKEY LEARNING POINTS:\nPhenytoin causes gingival hyperplasia (in approximately 50% of patients) and hirsutism through fibroblast stimulation and altered androgen metabolism. Zero-order kinetics require careful drug monitoring because small dose changes cause large serum level shifts. Newer antiepileptic drugs are generally preferred for chronic therapy due to better side effect profiles."
  },
  {
    "id": 76,
    "categoryId": 9,
    "question": "Clopidogrel (Plavix) is a prodrug requiring activation by CYP2C19. Which PPI inhibits this enzyme and reduces Clopidogrel efficacy?",
    "options": [
      "A) Pantoprazole",
      "B) Omeprazole",
      "C) Rabeprazole",
      "D) Famotidine"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Omeprazole).\n\nPHARMACOLOGY:\nClopidogrel (Plavix) is an inactive prodrug that requires hepatic biotransformation by CYP2C19 to generate its active thiol metabolite, which irreversibly binds the P2Y12 ADP receptor on platelets to inhibit platelet aggregation per Harrison's Principles of Internal Medicine and UpToDate. Omeprazole (Prilosec) is a potent inhibitor of CYP2C19 and reduces the conversion of clopidogrel to its active metabolite by approximately 40 to 50%, significantly diminishing its antiplatelet effect per the Cleveland Clinic.\n\nCLINICAL EVIDENCE:\nThe FDA issued a safety communication in 2009 advising against concomitant use of clopidogrel and omeprazole based on pharmacokinetic studies showing reduced platelet inhibition per UpToDate. The COGENT trial provided reassurance that the combination did not significantly increase cardiovascular events in the study population, but this trial was underpowered and terminated early per Harvard Health. Given the available pharmacokinetic data, guidelines recommend avoiding the combination when alternatives exist per the Mayo Clinic.\n\nSAFE ALTERNATIVES:\nPantoprazole (Protonix) has the weakest CYP2C19 inhibitory effect among PPIs and is the preferred PPI when gastroprotection is needed in patients on clopidogrel per UpToDate and Harrison's Principles of Internal Medicine. Lansoprazole and esomeprazole have intermediate CYP2C19 inhibition and are less preferred per the Cleveland Clinic. H2-receptor antagonists (famotidine) are an alternative class with no CYP2C19 interaction, though they provide less acid suppression than PPIs per the Mayo Clinic.\n\nGENETIC CONSIDERATIONS:\nApproximately 2 to 15% of the population (higher in Asian and Pacific Islander populations) are CYP2C19 poor metabolizers who have genetically reduced clopidogrel activation regardless of PPI use per Harrison's Principles of Internal Medicine. Pharmacogenomic testing for CYP2C19 variants can guide antiplatelet selection, with alternative agents (prasugrel, ticagrelor) recommended for poor metabolizers per UpToDate.\n\nKEY LEARNING POINTS:\nOmeprazole inhibits CYP2C19, reducing clopidogrel activation by 40 to 50% and diminishing its antiplatelet effect. Pantoprazole is the preferred PPI with clopidogrel due to minimal CYP2C19 inhibition. CYP2C19 poor metabolizers (2 to 15% of the population) have genetically reduced clopidogrel activation and may need prasugrel or ticagrelor instead."
  },
  {
    "id": 77,
    "categoryId": 4,
    "question": "SGLT2 inhibitors (Empagliflozin) carry a risk of which genital infection?",
    "options": [
      "A) Bacterial Vaginosis",
      "B) Fournier's Gangrene",
      "C) Syphilis",
      "D) HPV"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Fournier's Gangrene).\n\nPATHOPHYSIOLOGY:\nSGLT2 inhibitors produce their therapeutic effect by blocking the sodium-glucose cotransporter 2 in the proximal renal tubule, preventing reabsorption of approximately 40 to 80 grams of glucose per day, which is then excreted in the urine. This persistent glycosuria creates a glucose-rich environment in the urinary tract and perineum that serves as an excellent growth medium for bacteria and fungi. The most common infectious complication is genital mycotic infection, occurring in approximately 10 to 15% of patients (predominantly vulvovaginal candidiasis in women and candidal balanitis in men) according to pooled clinical trial data reviewed in UpToDate. Urinary tract infections also occur at modestly increased rates. Fournier's gangrene, a necrotizing fasciitis of the perineal, perianal, and genital regions, is a rare but devastating complication. The FDA issued a safety communication in 2018 identifying 55 cases of Fournier's gangrene associated with SGLT2 inhibitors reported over a 5-year period, a rate significantly higher than background incidence in the diabetic population treated with other glucose-lowering agents. The proposed mechanism involves glucose-laden urine promoting polymicrobial perineal infection that rapidly progresses through fascial planes, facilitated by the immunocompromised state of diabetes and the mild volume depletion associated with SGLT2 inhibitor therapy.\n\nCLINICAL PRESENTATION:\nFournier's gangrene presents with rapidly progressive perineal pain, erythema, and swelling that may initially appear disproportionate to physical findings. The hallmark feature is pain out of proportion to examination, which should raise immediate suspicion. Within hours, the infection spreads along fascial planes, producing crepitus (from gas-producing organisms), tissue necrosis, and systemic sepsis. The infection is typically polymicrobial, involving aerobic organisms (Escherichia coli, Klebsiella, Staphylococcus, Streptococcus) and anaerobes (Bacteroides, Clostridium). Mortality ranges from 20 to 40% even with aggressive treatment according to data from JAMA Surgery and Harrison's Principles of Internal Medicine. Patients on SGLT2 inhibitors who develop perineal pain, tenderness, erythema, or swelling should be evaluated urgently, and clinicians must maintain a high index of suspicion because early presentation may be subtle.\n\nTREATMENT:\nManagement of Fournier's gangrene requires immediate surgical debridement of all necrotic tissue, which is the definitive and most critical intervention. Broad-spectrum intravenous antibiotics covering gram-positive, gram-negative, and anaerobic organisms are initiated emergently but are adjunctive to surgery. The SGLT2 inhibitor must be permanently discontinued. Multiple surgical debridements are often necessary over subsequent days. Regarding prevention, patients initiating SGLT2 inhibitors should be counseled about perineal hygiene and instructed to seek prompt medical attention for any genital or perineal symptoms. The more common genital mycotic infections can be managed with topical or oral antifungal therapy and do not necessarily require drug discontinuation.\n\nKEY LEARNING POINTS:\nSGLT2 inhibitors cause persistent glycosuria that increases the risk of genital mycotic infections (10 to 15% incidence) and, rarely, Fournier's gangrene, a necrotizing fasciitis of the perineum with 20 to 40% mortality. The FDA issued a safety warning in 2018 after identifying a significantly increased rate of Fournier's gangrene with SGLT2 inhibitors compared to other diabetes medications. Perineal pain out of proportion to examination in a patient on an SGLT2 inhibitor should prompt urgent surgical evaluation, and the medication must be permanently discontinued."
  },
  {
    "id": 78,
    "categoryId": 13,
    "question": "Allopurinol should NOT be started during an acute gout flare because:",
    "options": [
      "A) It causes renal failure",
      "B) It can precipitate/worsen the flare due to rapid uric acid shifts",
      "C) It is ineffective",
      "D) It causes bleeding"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (It can precipitate or worsen the flare due to rapid uric acid shifts).\n\nMECHANISM OF FLARE EXACERBATION:\nInitiating allopurinol (a xanthine oxidase inhibitor) during an acute gout flare is contraindicated because any rapid change in serum uric acid levels, whether an increase or decrease, destabilizes existing monosodium urate crystal deposits in and around joints. When uric acid drops suddenly, crystals that were previously in equilibrium with surrounding tissue begin to partially dissolve or shed from tophi and cartilage surfaces. These newly mobilized microcrystals are recognized by resident macrophages, which activate the NLRP3 inflammasome and release interleukin-1 beta, amplifying the inflammatory cascade and prolonging or worsening the acute attack.\n\nACR GUIDELINES ON TIMING:\nThe 2020 American College of Rheumatology guidelines recommend waiting until the acute flare has fully resolved (typically two to four weeks) before initiating urate-lowering therapy (ULT). However, if a patient is already taking ULT at the time of a flare, it should be continued at the current dose rather than discontinued, because stopping and restarting would cause additional uric acid fluctuations that further destabilize crystals. When ULT is eventually started, it should be initiated at a low dose (allopurinol 100 mg daily, or 50 mg in patients with chronic kidney disease stage 3 or higher) and titrated gradually every two to four weeks to minimize the risk of mobilization flares.\n\nFLARE PROPHYLAXIS DURING ULT INITIATION:\nBecause mobilization flares are expected during the first three to six months of ULT, concurrent anti-inflammatory prophylaxis is essential. Low-dose colchicine (0.6 mg once or twice daily) is the preferred prophylactic agent. Low-dose NSAIDs are an alternative when colchicine is contraindicated. Prophylaxis should continue for at least three to six months or until the serum urate target has been maintained and the patient has been flare-free.\n\nKEY LEARNING POINTS:\nAllopurinol should not be started during an acute gout flare because rapid uric acid shifts mobilize crystals and worsen inflammation. Wait two to four weeks after flare resolution to initiate ULT. Start at low doses and titrate gradually to target uric acid below 6.0 mg/dL. Provide anti-inflammatory prophylaxis (low-dose colchicine) for the first three to six months of ULT."
  },
  {
    "id": 79,
    "categoryId": 2,
    "question": "Why is Monotherapy with a Long-Acting Beta Agonist (LABA) contraindicated in Asthma?",
    "options": [
      "A) It causes tachycardia",
      "B) Increased risk of asthma-related death",
      "C) It is ineffective",
      "D) It causes thrush"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Increased risk of asthma-related death).\n\nPATHOPHYSIOLOGY:\nLong-acting beta-agonists provide sustained bronchodilation by activating beta-2 adrenergic receptors on airway smooth muscle, causing relaxation for 12 or more hours per Harrison's Principles of Internal Medicine. However, LABAs address only the symptom of bronchoconstriction without treating the underlying eosinophilic airway inflammation that drives asthma pathophysiology. When used as monotherapy, LABAs mask worsening airway inflammation by relieving symptoms, creating a dangerous discordance between the patient's perception of control and the actual severity of underlying disease per UpToDate.\n\nCLINICAL EVIDENCE:\nThe landmark Salmeterol Multicenter Asthma Research Trial (SMART), a large randomized controlled trial published in Chest and reported by the FDA, demonstrated a statistically significant increase in asthma-related deaths and life-threatening asthma exacerbations in patients using salmeterol monotherapy compared to placebo per the Cleveland Clinic. The risk was particularly pronounced in African American patients. This finding led the FDA to issue a Black Box Warning on all LABA products when used without concomitant ICS, and eventually to mandate that all LABA products for asthma be available only in fixed-dose ICS-LABA combination inhalers (such as fluticasone-salmeterol and budesonide-formoterol) per the Mayo Clinic.\n\nCLINICAL APPLICATION:\nThe fundamental principle is that in asthma, a LABA must always be combined with an inhaled corticosteroid per GINA 2024 and NHLBI guidelines. ICS-LABA combinations are a mainstay of Step 3 and above asthma therapy. In contrast, LABA monotherapy is acceptable in COPD because the underlying pathophysiology differs: COPD is driven by neutrophilic inflammation and structural changes rather than the eosinophilic, steroid-responsive inflammation of asthma, and LABA monotherapy has not been associated with increased mortality in COPD per Harrison's Principles of Internal Medicine.\n\nKEY LEARNING POINTS:\nLABA monotherapy in asthma is contraindicated because the SMART trial demonstrated increased asthma-related deaths from masking worsening inflammation while relieving symptoms. LABAs must always be combined with ICS in asthma, which is why they are available only in fixed-dose combination inhalers for asthma. LABA monotherapy is acceptable in COPD, where the inflammatory pathophysiology differs."
  },
  {
    "id": 80,
    "categoryId": 12,
    "question": "Doxycycline is generally avoided in children < 8 years old unless for life-threatening disease (RMSF) because:",
    "options": [
      "A) Cartilage damage",
      "B) Teeth staining and enamel hypoplasia",
      "C) Growth plate closure",
      "D) Seizures"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Teeth staining and enamel hypoplasia).\n\nPATHOPHYSIOLOGY:\nTetracycline-class antibiotics (including doxycycline, minocycline, and tetracycline) chelate calcium ions and are incorporated into calcifying tissues, including developing tooth enamel and dentin, where they form stable tetracycline-calcium orthophosphate complexes per Harrison's Principles of Internal Medicine. When these complexes are exposed to ultraviolet light, they undergo photochemical oxidation, producing a characteristic yellow-brown discoloration that is permanent per UpToDate. The teeth most susceptible are those undergoing active mineralization, which occurs from the second trimester of pregnancy (for primary teeth) through approximately age 8 years (for permanent teeth, particularly the premolars and second molars that complete crown calcification last) per the Cleveland Clinic.\n\nCLINICAL APPLICATION:\nThe traditional teaching and classic board answer is that tetracyclines are contraindicated in children under 8 years and in pregnant or breastfeeding women per the Mayo Clinic. However, an important nuance is that the AAP and CDC have updated guidance recognizing that doxycycline specifically causes significantly less dental staining than older tetracyclines because it binds calcium less avidly per the CDC. Short courses of doxycycline (21 days or fewer) in children of any age have not been shown to cause clinically significant tooth staining in multiple studies per UpToDate. This is clinically important because doxycycline is the treatment of choice for Rocky Mountain spotted fever, ehrlichiosis, and anaplasmosis, all of which can be rapidly fatal if treatment is delayed while awaiting confirmatory testing per Harrison's Principles of Internal Medicine. The CDC explicitly states that doxycycline should never be withheld from a child with suspected tickborne rickettsial disease regardless of age.\n\nADDITIONAL TETRACYCLINE EFFECTS:\nBeyond dental staining, tetracyclines can cause enamel hypoplasia (defective enamel formation), and high-dose or prolonged tetracycline use can deposit in bone, temporarily slowing bone growth (though this is reversible upon discontinuation and distinct from fluoroquinolone-associated cartilage damage) per UpToDate.\n\nKEY LEARNING POINTS:\nTetracyclines are classically avoided in children under 8 due to permanent tooth discoloration from calcium chelation in developing enamel. However, doxycycline causes significantly less staining than older tetracyclines, and short courses should never be withheld for life-threatening tickborne diseases (RMSF, ehrlichiosis) regardless of age per the AAP and CDC. This remains a high-yield board topic where the classic answer (avoid under 8) and the clinical update (doxycycline is safer) are both tested."
  },
  {
    "id": 81,
    "categoryId": 11,
    "question": "Bupropion (Wellbutrin) has a favorable side effect profile compared to SSRIs because it lacks:",
    "options": [
      "A) Weight gain and Sexual dysfunction",
      "B) Seizure risk",
      "C) Insomnia",
      "D) Dry mouth"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Weight gain and sexual dysfunction).\n\nPHARMACOLOGY:\nBupropion (Wellbutrin) is a norepinephrine-dopamine reuptake inhibitor (NDRI) with a distinct mechanism of action and side effect profile compared to SSRIs per Harrison's Principles of Internal Medicine and UpToDate. Because bupropion does not affect serotonin reuptake, it avoids the two most common and treatment-limiting adverse effects of SSRIs: weight gain and sexual dysfunction per the Cleveland Clinic.\n\nMECHANISM OF SSRI SIDE EFFECTS:\nSSRI-induced sexual dysfunction (decreased libido, anorgasmia, erectile dysfunction) occurs in 30 to 70% of patients and is mediated by serotonin's inhibitory effects on dopaminergic and noradrenergic pathways in the mesolimbic reward circuit and spinal cord ejaculatory centers per UpToDate. SSRI-induced weight gain (averaging 2 to 5 kg over 6 to 12 months, more pronounced with paroxetine and mirtazapine) results from serotonergic effects on hypothalamic appetite centers, antihistaminic properties (in some agents), and metabolic changes per Harvard Health and the Mayo Clinic.\n\nBUPROPION ADVANTAGES AND RISKS:\nBupropion is weight-neutral or mildly weight-reducing (average 1 to 2 kg loss), making it advantageous for patients with obesity or metabolic syndrome per the Cleveland Clinic. Its dopaminergic and noradrenergic activity avoids sexual dysfunction and may actually improve libido, which is why it is sometimes added to SSRIs specifically to counteract sexual side effects per UpToDate. However, bupropion carries a dose-dependent seizure risk (approximately 0.4% at 300 to 450 mg/day), is contraindicated in seizure disorders, bulimia, anorexia, and acute alcohol or benzodiazepine withdrawal per Harrison's Principles of Internal Medicine. Common side effects include insomnia (due to noradrenergic activation), dry mouth, headache, and agitation per the Mayo Clinic.\n\nKEY LEARNING POINTS:\nBupropion avoids SSRI-induced weight gain and sexual dysfunction because it acts on norepinephrine and dopamine rather than serotonin. SSRI sexual dysfunction affects 30 to 70% of patients via serotonergic inhibition of dopaminergic reward pathways. Bupropion's key risks are dose-dependent seizures and contraindication in seizure disorders, bulimia, anorexia, and withdrawal states."
  },
  {
    "id": 82,
    "categoryId": 1,
    "question": "Spironolactone causes Hyperkalemia. This risk is highest when combined with:",
    "options": [
      "A) Furosemide",
      "B) ACE Inhibitors / ARBs",
      "C) Amlodipine",
      "D) Atenolol"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (ACE Inhibitors / ARBs).\n\nPATHOPHYSIOLOGY:\nSpironolactone is a mineralocorticoid receptor antagonist that blocks aldosterone in the distal nephron (principal cells of the collecting duct), reducing sodium reabsorption and critically reducing potassium secretion per Harrison's Principles of Internal Medicine. Normally, aldosterone stimulates the epithelial sodium channel (ENaC) and the Na+/K+-ATPase, creating an electrochemical gradient that drives potassium secretion into the tubular lumen via ROMK channels per UpToDate. By blocking this aldosterone effect, spironolactone directly reduces potassium excretion.\n\nDRUG INTERACTION:\nACE inhibitors and ARBs independently raise serum potassium by reducing aldosterone production (ACE inhibitors decrease angiotensin II, the primary stimulus for aldosterone secretion; ARBs block angiotensin II's effect on the adrenal cortex) per the Cleveland Clinic. When spironolactone is combined with an ACE inhibitor or ARB, there is dual suppression of the aldosterone axis at two levels: reduced aldosterone synthesis plus receptor blockade of residual aldosterone, creating a potent setup for life-threatening hyperkalemia per the Mayo Clinic. The risk is further amplified in patients with renal insufficiency, diabetes (hyporeninemic hypoaldosteronism), advanced age, or concurrent use of potassium supplements or NSAIDs per UpToDate.\n\nCLINICAL SIGNIFICANCE:\nDespite the hyperkalemia risk, the combination of spironolactone with ACE inhibitors/ARBs is guideline-directed therapy in HFrEF per the 2022 AHA/ACC/HFSA guidelines. The RALES trial demonstrated that adding spironolactone to standard HFrEF therapy reduced mortality by 30% per Harrison's Principles of Internal Medicine. However, the survival benefit requires careful monitoring of serum potassium and creatinine within 1 week of initiation and regularly thereafter.\n\nKEY LEARNING POINTS:\nSpironolactone combined with ACE inhibitors or ARBs carries the highest hyperkalemia risk due to dual aldosterone axis suppression at two mechanistic levels. Despite this risk, the combination is guideline-directed in HFrEF (RALES trial: 30% mortality reduction). Serum potassium and renal function must be monitored closely, especially with concurrent CKD, diabetes, or NSAID use."
  },
  {
    "id": 83,
    "categoryId": 1,
    "question": "Which antihypertensive class is strictly contraindicated in pregnancy due to fetal renal dysgenesis and other developmental abnormalities?",
    "options": [
      "A) Labetalol",
      "B) ACE Inhibitors (Lisinopril) / ARBs",
      "C) Nifedipine",
      "D) Methyldopa"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (ACE Inhibitors / ARBs).\n\nPATHOPHYSIOLOGY:\nACE inhibitors and ARBs are absolutely contraindicated throughout all trimesters of pregnancy per Harrison's Principles of Internal Medicine. The mechanism of fetal harm relates to the critical role of the fetal renin-angiotensin system in renal development. Angiotensin II is essential for maintaining fetal renal perfusion pressure, stimulating nephron differentiation, and promoting normal ureteral bud branching per UpToDate. Blocking this system produces fetal renal dysgenesis (malformed or absent kidneys), leading to oligohydramnios (decreased amniotic fluid from reduced fetal urine output), which in turn causes pulmonary hypoplasia and limb contractures per the Cleveland Clinic.\n\nTRIMESTER-SPECIFIC EFFECTS:\nFirst-trimester exposure has been associated with increased risk of cardiovascular malformations and central nervous system anomalies in some studies per UpToDate. Second and third-trimester exposure produces the classic fetal toxicity syndrome: renal tubular dysgenesis, anuria, oligohydramnios, pulmonary hypoplasia, intrauterine growth restriction, and neonatal skull ossification defects (calvaria hypoplasia) per Harrison's Principles of Internal Medicine. Neonatal complications include hypotension, renal failure, and hyperkalemia per the Mayo Clinic.\n\nSAFE ALTERNATIVES:\nAntihypertensive medications considered safe in pregnancy include labetalol (the most commonly used first-line agent), nifedipine (a dihydropyridine CCB), and methyldopa (a centrally acting alpha-2 agonist with the longest safety track record in pregnancy) per UpToDate and the Cleveland Clinic. Women of childbearing potential taking ACE inhibitors or ARBs should be counseled about the teratogenic risk and advised to use reliable contraception or switch to a pregnancy-safe agent before conception per the Mayo Clinic.\n\nKEY LEARNING POINTS:\nACE inhibitors and ARBs are absolutely contraindicated in pregnancy because angiotensin II blockade disrupts fetal renal development, causing renal dysgenesis, oligohydramnios, pulmonary hypoplasia, and skull ossification defects. Safe alternatives are labetalol, nifedipine, and methyldopa. Women of childbearing potential on ACEi/ARBs must be counseled about teratogenicity."
  },
  {
    "id": 84,
    "categoryId": 7,
    "question": "Which class of diabetes medication causes hypoglycemia and is a major fall risk in the elderly?",
    "options": [
      "A) Metformin",
      "B) Sulfonylureas (Glipizide/Glyburide)",
      "C) GLP-1 Agonists",
      "D) SGLT2 Inhibitors"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Sulfonylureas).\n\nPATHOPHYSIOLOGY:\nSulfonylureas such as glipizide and glyburide are insulin secretagogues that bind to the sulfonylurea receptor (SUR1) on pancreatic beta cell membranes, closing ATP-sensitive potassium channels regardless of the ambient blood glucose level. This closure depolarizes the cell membrane, opens voltage-gated calcium channels, and triggers insulin exocytosis. Because this mechanism operates independently of glucose concentration, sulfonylureas stimulate insulin release even when blood glucose is already normal or low, creating a significant risk of hypoglycemia. This glucose-independent insulin secretion distinguishes sulfonylureas from newer incretin-based therapies such as GLP-1 receptor agonists and DPP-4 inhibitors, which enhance insulin secretion only in the presence of elevated glucose.\n\nCLINICAL SIGNIFICANCE IN ELDERLY PATIENTS:\nHypoglycemia from sulfonylureas is a leading cause of medication-related emergency department visits in older adults and a major contributor to falls, fractures, and fall-related mortality. Elderly patients are particularly vulnerable due to decreased renal clearance (prolonging drug half-life), irregular meal patterns, polypharmacy, and reduced counter-regulatory hormonal responses to hypoglycemia. Glyburide is especially dangerous in this population because it has active metabolites that accumulate in renal impairment and a prolonged duration of action exceeding 24 hours, increasing the risk of severe and recurrent hypoglycemia. When a sulfonylurea must be used, glipizide is preferred because it has no active metabolites and a shorter duration of action. The American Geriatrics Society Beers Criteria specifically recommend avoiding glyburide in older adults due to its heightened hypoglycemia risk.\n\nSAFER ALTERNATIVES:\nCurrent ADA Standards of Care and geriatric guidelines recommend prioritizing glucose-lowering agents with low hypoglycemia risk for older adults. Metformin remains first-line if renal function permits. GLP-1 receptor agonists and SGLT2 inhibitors offer cardiovascular and renal benefits without intrinsic hypoglycemia risk. DPP-4 inhibitors provide modest glucose lowering with an excellent safety profile and are well tolerated in the elderly. When selecting diabetes therapy for older adults, the risk of hypoglycemia-related falls and fractures must be weighed heavily alongside glycemic efficacy.\n\nKEY LEARNING POINTS:\nSulfonylureas stimulate insulin release independently of blood glucose levels, creating significant hypoglycemia risk that is amplified in elderly patients with renal impairment and irregular eating patterns. Glyburide is particularly dangerous due to active metabolites and prolonged duration, and should be avoided in older adults per Beers Criteria. Medication-related hypoglycemia is a leading cause of falls in the elderly, making agent selection a critical safety consideration in geriatric diabetes management."
  },
  {
    "id": 85,
    "categoryId": 15,
    "question": "Symptoms: 'Mad as a hatter, Blind as a bat, Red as a beet, Hot as a hare, Dry as a bone'. Diagnosis?",
    "options": [
      "A) Cholinergic Toxicity",
      "B) Anticholinergic Toxicity",
      "C) Opioid Withdrawal",
      "D) Sympathomimetic"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Anticholinergic Toxicity).\n\nPATHOPHYSIOLOGY:\nAnticholinergic toxicity results from competitive antagonism of muscarinic acetylcholine receptors throughout the central and peripheral nervous system per Harrison's Principles of Internal Medicine. Blockade of peripheral muscarinic receptors produces the classic constellation of signs captured by the mnemonic: \"Mad as a hatter\" (altered mental status, agitation, delirium, hallucinations from central muscarinic blockade), \"Blind as a bat\" (mydriasis and cycloplegia from blockade of the pupillary sphincter and ciliary muscle), \"Red as a beet\" (cutaneous vasodilation and flushing), \"Hot as a hare\" (hyperthermia from inability to dissipate heat via sweating), and \"Dry as a bone\" (anhidrosis, dry mucous membranes, and urinary retention from blockade of exocrine gland secretion and detrusor muscle function). Additional findings include tachycardia (from vagal blockade at the sinoatrial node), decreased bowel sounds or ileus, and in severe cases seizures per UpToDate.\n\nCOMMON CAUSES:\nThe most frequent cause of anticholinergic toxicity is diphenhydramine (Benadryl) overdose per the Cleveland Clinic. Other common offenders include tricyclic antidepressants (amitriptyline, nortriptyline), first-generation antipsychotics, atropine, scopolamine, skeletal muscle relaxants (cyclobenzaprine), and the plant Datura stramonium (jimson weed) per Harrison's Principles of Internal Medicine. The elderly are particularly susceptible due to polypharmacy and the cumulative anticholinergic burden of multiple medications.\n\nTREATMENT:\nManagement is primarily supportive per UpToDate: external cooling for hyperthermia, intravenous fluids for dehydration, benzodiazepines for agitation and seizure control, and bladder catheterization for urinary retention. Physostigmine, a carbamate acetylcholinesterase inhibitor that crosses the blood-brain barrier, is the specific antidote reserved for severe anticholinergic toxicity with life-threatening features (refractory seizures, severe agitation with hyperthermia, hemodynamically significant tachydysrhythmias) per the Mayo Clinic. Physostigmine is contraindicated when tricyclic antidepressant ingestion is suspected because it can precipitate asystole and intractable seizures in the setting of sodium channel blockade. The critical clinical distinction between anticholinergic and sympathomimetic toxicity is skin moisture: anticholinergic toxicity produces dry skin and mucous membranes, while sympathomimetic toxicity produces diaphoresis (wet skin), though both cause tachycardia, agitation, and mydriasis.\n\nKEY LEARNING POINTS:\nThe anticholinergic toxidrome is identified by the classic mnemonic of mad, blind, red, hot, and dry, reflecting central delirium, mydriasis, flushing, hyperthermia, and anhidrosis from muscarinic receptor blockade. Dry skin distinguishes anticholinergic from sympathomimetic toxicity, which produces diaphoresis. Physostigmine is the specific antidote for severe cases but is contraindicated when tricyclic antidepressant ingestion is suspected."
  },
  {
    "id": 86,
    "categoryId": 4,
    "question": "According to the landmark Diabetes Prevention Program (DPP) study published in NEJM, which intervention was most effective at reducing the incidence of Type 2 Diabetes over 3 years?",
    "options": [
      "A) Metformin 850mg BID",
      "B) Intensive Lifestyle Intervention (7% weight loss + 150min/wk activity)",
      "C) Troglitazone",
      "D) Placebo"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Intensive Lifestyle Intervention).\n\nPATHOPHYSIOLOGY:\nType 2 diabetes develops through a progressive continuum beginning with insulin resistance, advancing through compensatory hyperinsulinemia, proceeding to beta-cell exhaustion, and culminating in overt hyperglycemia. Prediabetes, defined by the ADA as impaired fasting glucose (100 to 125 mg/dL), impaired glucose tolerance (2-hour glucose 140 to 199 mg/dL on oral glucose tolerance test), or hemoglobin A1c of 5.7 to 6.4%, represents the critical window during which beta-cell function is declining but sufficient reserve remains for lifestyle modifications to reverse the trajectory. Approximately 70% of individuals with prediabetes will eventually develop type 2 diabetes without intervention per data from the CDC. Excess adiposity, particularly visceral adipose tissue, drives insulin resistance through chronic low-grade inflammation, release of free fatty acids, and secretion of adipokines that impair insulin signaling. Even modest reductions in body weight significantly improve insulin sensitivity by reducing visceral fat, lowering inflammatory cytokines, and restoring insulin receptor function.\n\nCLINICAL EVIDENCE:\nThe Diabetes Prevention Program (DPP) is one of the most influential randomized controlled trials in preventive medicine, published in the New England Journal of Medicine in 2002. The trial enrolled 3,234 adults with prediabetes (mean age 51, mean BMI 34, 68% female) and included deliberate oversampling of racial and ethnic minority populations who bear a disproportionate burden of type 2 diabetes. Participants were randomized to one of three arms: intensive lifestyle intervention (targeting 7% weight loss through a low-calorie, low-fat diet and at least 150 minutes per week of moderate physical activity, delivered through a structured 16-session curriculum with individual case managers), metformin 850 mg twice daily, or placebo. Over an average follow-up of 2.8 years, the intensive lifestyle intervention reduced the incidence of type 2 diabetes by 58% compared to placebo, while metformin reduced incidence by 31%. The number needed to treat to prevent one case of diabetes over 3 years was 7 for lifestyle intervention versus 14 for metformin. The lifestyle intervention was effective across all age, sex, and ethnic subgroups, while metformin's benefit was most pronounced in younger participants (under age 60) and those with higher BMI (35 or greater). The DPP Outcomes Study, a long-term follow-up extending to 10 and 15 years, demonstrated that the diabetes risk reduction in the lifestyle group persisted at 27% at 15-year follow-up, confirming the durability of the intervention despite gradual convergence of weight regain between groups.\n\nCLINICAL APPLICATION:\nThe DPP results directly inform current ADA Standards of Care, which recommend referral to an intensive lifestyle intervention program modeled on the DPP as first-line therapy for all patients with prediabetes. The CDC has established the National Diabetes Prevention Program (National DPP), a network of CDC-recognized lifestyle change programs available across the United States that replicate the DPP protocol. Metformin may be considered as an adjunct to lifestyle modification, particularly in patients younger than 60 years, those with BMI of 35 or greater, women with a history of gestational diabetes, or individuals whose prediabetes progresses despite lifestyle intervention alone. The ADA emphasizes that metformin is not a substitute for lifestyle modification but rather a complementary strategy for selected higher-risk individuals.\n\nKEY LEARNING POINTS:\nThe Diabetes Prevention Program demonstrated that intensive lifestyle intervention targeting 7% weight loss and 150 minutes per week of physical activity reduces type 2 diabetes incidence by 58%, nearly twice the 31% reduction achieved with metformin. Lifestyle modification is first-line therapy for all patients with prediabetes, while metformin is considered as an adjunct in patients under 60, those with BMI of 35 or greater, or women with prior gestational diabetes. The DPP Outcomes Study confirmed durable benefit at 15-year follow-up, establishing that type 2 diabetes is largely preventable through sustained lifestyle changes."
  },
  {
    "id": 87,
    "categoryId": 16,
    "question": "A 55-year-old male with high cardiovascular risk asks about diet. The PREDIMED trial (NEJM) showed that a Mediterranean Diet supplemented with ______ significantly reduced major cardiovascular events compared to a low-fat diet.",
    "options": [
      "A) Fish Oil supplements",
      "B) Extra Virgin Olive Oil (EVOO) or Mixed Nuts",
      "C) Red Wine",
      "D) Lean Poultry"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (EVOO or Nuts).\n\nEVIDENCE:\nThe PREDIMED trial (PrevenciÃ³n con Dieta MediterrÃ¡nea), published in the New England Journal of Medicine, was a landmark randomized controlled trial of over 7,400 participants at high cardiovascular risk that demonstrated a Mediterranean diet supplemented with extra virgin olive oil (EVOO) or mixed nuts reduced major adverse cardiovascular events (myocardial infarction, stroke, and cardiovascular death) by approximately 30% compared to a low-fat control diet per UpToDate and Harrison's Principles of Internal Medicine. The trial was stopped early by its data safety monitoring board because the benefit was so significant that it would have been unethical to continue withholding the intervention. The number needed to treat (NNT) was approximately 67 patients over 5 years to prevent one major cardiovascular event per the Cleveland Clinic.\n\nMECHANISMS OF BENEFIT:\nEVOO is rich in oleic acid (a monounsaturated fatty acid) and polyphenols (oleocanthal, hydroxytyrosol) that reduce LDL oxidation, lower systemic inflammation (reducing hs-CRP and IL-6), improve endothelial function by increasing nitric oxide bioavailability, and have antiplatelet effects per Harvard Health. Mixed nuts (walnuts, almonds, hazelnuts) provide alpha-linolenic acid (an omega-3 precursor), L-arginine (a nitric oxide substrate), fiber, phytosterols, and tocopherols that synergistically reduce cardiovascular risk per the Mayo Clinic. The Mediterranean dietary pattern as a whole emphasizes fruits, vegetables, legumes, whole grains, fish, and moderate red wine while limiting red meat, processed foods, and refined sugars per UpToDate.\n\nCLINICAL APPLICATION:\nThe 2019 ACC/AHA Primary Prevention Guidelines cite the Mediterranean diet as having the strongest evidence base for cardiovascular risk reduction among dietary patterns per Harrison's Principles of Internal Medicine. Clinicians should counsel high-risk patients that supplementing their diet with approximately 4 tablespoons of EVOO daily or 30 grams of mixed nuts daily (the PREDIMED intervention doses) provides measurable cardiovascular protection per the Cleveland Clinic.\n\nKEY LEARNING POINTS:\nThe PREDIMED trial demonstrated a 30% reduction in major cardiovascular events with a Mediterranean diet supplemented with EVOO or mixed nuts versus a low-fat diet, with an NNT of 67 over 5 years. Benefits are mediated by polyphenol-driven anti-inflammatory, antioxidant, and endothelial-protective mechanisms. The Mediterranean diet has the strongest evidence base for cardiovascular dietary prevention."
  },
  {
    "id": 88,
    "categoryId": 4,
    "question": "Exercise lowers blood glucose acutely in Type 2 Diabetics via which non-insulin dependent mechanism?",
    "options": [
      "A) Increased pancreatic beta-cell secretion",
      "B) Translocation of GLUT4 transporters to the muscle cell surface",
      "C) Inhibition of hepatic gluconeogenesis",
      "D) Increased renal excretion of glucose"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Translocation of GLUT4 transporters to the muscle cell surface).\n\nPATHOPHYSIOLOGY:\nGlucose uptake into skeletal muscle requires translocation of glucose transporter type 4 (GLUT4) from intracellular vesicles to the cell surface membrane. Under resting conditions, GLUT4 resides in storage vesicles within the cytoplasm and is mobilized to the plasma membrane primarily through insulin-dependent signaling via the PI3K-Akt pathway. In type 2 diabetes, this insulin-dependent pathway is impaired due to defective insulin receptor substrate signaling and downstream kinase dysfunction, resulting in reduced insulin-stimulated GLUT4 translocation and diminished glucose uptake. However, skeletal muscle contraction activates a completely independent, insulin-independent pathway for GLUT4 translocation mediated by AMP-activated protein kinase (AMPK). During exercise, intracellular ATP is consumed and AMP accumulates, activating AMPK, which functions as a cellular energy sensor. Activated AMPK directly triggers GLUT4 vesicle trafficking to the plasma membrane through mechanisms involving TBC1D1 and AS160 phosphorylation, bypassing the defective insulin signaling cascade entirely. This explains why exercise lowers blood glucose effectively even in patients with severe insulin resistance, as the contraction-mediated pathway remains fully intact in type 2 diabetes per research reviewed in Harrison's Principles of Internal Medicine and Diabetes Care.\n\nCLINICAL EVIDENCE:\nThe dual-pathway model of GLUT4 regulation has been validated by exercise physiology research demonstrating that muscle contraction and insulin have additive effects on glucose uptake when both pathways are activated simultaneously. Studies published in Diabetes Care and the Journal of Clinical Investigation have shown that a single bout of moderate-intensity exercise can increase muscle glucose uptake by 7 to 20-fold through AMPK-mediated GLUT4 translocation, and this enhanced insulin sensitivity persists for 24 to 72 hours after the exercise session due to ongoing GLUT4 expression and glycogen repletion demands. This post-exercise insulin sensitization provides a mechanistic rationale for the ADA recommendation of avoiding more than two consecutive days without physical activity in patients with type 2 diabetes.\n\nCLINICAL APPLICATION:\nThe ADA 2024 Standards of Care recommend at least 150 minutes per week of moderate-intensity aerobic activity (such as brisk walking at 3 to 4 miles per hour), spread over at least 3 days per week with no more than 2 consecutive sedentary days. Resistance training on 2 to 3 nonconsecutive days per week is additionally recommended because it increases muscle mass, which expands the total GLUT4 reservoir available for glucose disposal. The combination of aerobic and resistance exercise produces greater glycemic improvement than either modality alone. For patients on insulin or sulfonylureas, exercise timing and carbohydrate intake should be coordinated to minimize hypoglycemia risk, as the additive effect of exercise-mediated and insulin-mediated glucose uptake can produce precipitous glucose drops during and after activity.\n\nKEY LEARNING POINTS:\nExercise lowers blood glucose through AMPK-mediated GLUT4 translocation, a pathway entirely independent of insulin signaling that remains fully functional in insulin-resistant patients with type 2 diabetes. The glucose-lowering effect of a single exercise session persists for 24 to 72 hours due to enhanced insulin sensitivity during glycogen repletion. The ADA recommends 150 minutes per week of aerobic activity plus 2 to 3 sessions of resistance training, with no more than 2 consecutive sedentary days."
  },
  {
    "id": 89,
    "categoryId": 16,
    "question": "A patient sleeps 5 hours a night. What is the expected metabolic consequence supported by experimental sleep restriction studies?",
    "options": [
      "A) Increased Leptin and Decreased Ghrelin",
      "B) Decreased Insulin Sensitivity and Increased Ghrelin",
      "C) Increased Thyroid Hormone production",
      "D) Decreased Cortisol levels"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Decreased Insulin Sensitivity and Increased Ghrelin).\n\nEVIDENCE:\nExperimental sleep restriction studies (limiting sleep to 4 to 5 hours per night for as few as 4 to 6 nights) consistently demonstrate two key metabolic derangements: decreased insulin sensitivity (by 20 to 30%) and increased ghrelin with decreased leptin, producing a hormonal milieu that promotes hunger and weight gain per UpToDate and Harrison's Principles of Internal Medicine. The landmark study by Spiegel and colleagues showed that restricting healthy young men to 4 hours of sleep for 6 nights reduced glucose tolerance to a pre-diabetic range per Harvard Health.\n\nHORMONAL DISRUPTION:\nGhrelin (the hunger hormone, produced by gastric fundus cells) increases with sleep deprivation, signaling the hypothalamus to stimulate appetite, particularly cravings for high-carbohydrate and calorie-dense foods per the Cleveland Clinic. Simultaneously, leptin (the satiety hormone, produced by adipocytes) decreases, removing the brake on appetite per UpToDate. This dual hormonal shift creates a net positive energy balance that promotes weight gain independent of volitional food choices. Sleep deprivation also elevates evening cortisol levels, further impairing insulin sensitivity and promoting visceral fat deposition per Harrison's Principles of Internal Medicine.\n\nINSULIN RESISTANCE MECHANISM:\nSleep restriction impairs insulin signaling through increased sympathetic nervous system activation, elevated inflammatory cytokines (TNF-alpha, IL-6), and disrupted growth hormone secretion patterns per the Mayo Clinic. Growth hormone, which is predominantly secreted during slow-wave (deep) sleep, plays a key role in glucose homeostasis and lipid metabolism, and its suppression contributes to the metabolic dysfunction observed with chronic sleep loss per Harvard Health.\n\nKEY LEARNING POINTS:\nSleep restriction to 4 to 5 hours per night decreases insulin sensitivity by 20 to 30% and shifts appetite hormones (increased ghrelin, decreased leptin) to promote hunger and weight gain. These metabolic effects occur within days and are independent of dietary changes. Adequate sleep (7 to 9 hours per night per CDC guidelines) is a fundamental component of metabolic health and weight management."
  },
  {
    "id": 90,
    "categoryId": 4,
    "question": "According to NCEP ATP III criteria, a diagnosis of Metabolic Syndrome requires 3 of 5 components. Which of the following is NOT a criterion?",
    "options": [
      "A) Waist Circumference >40 in (men) or >35 in (women)",
      "B) Triglycerides > 150 mg/dL",
      "C) LDL Cholesterol > 130 mg/dL",
      "D) HDL Cholesterol < 40 mg/dL (men) or < 50 mg/dL (women)"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (LDL Cholesterol is NOT a criterion for Metabolic Syndrome).\n\nPATHOPHYSIOLOGY:\nMetabolic syndrome is a cluster of interconnected metabolic abnormalities driven by a common underlying mechanism of insulin resistance and visceral adiposity. Excess visceral adipose tissue is not merely a passive energy depot but functions as an active endocrine organ that secretes proinflammatory cytokines (tumor necrosis factor-alpha, interleukin-6), adipokines (reduced adiponectin, increased resistin), and free fatty acids directly into the portal circulation. This portal delivery of free fatty acids to the liver drives hepatic insulin resistance, increased very-low-density lipoprotein (VLDL) production, and enhanced hepatic gluconeogenesis. Peripheral insulin resistance impairs glucose uptake in skeletal muscle and promotes compensatory hyperinsulinemia, which stimulates renal sodium retention and sympathetic nervous system activation, contributing to hypertension. The resulting metabolic phenotype is characterized by a specific pattern of dyslipidemia: elevated triglycerides (from increased hepatic VLDL secretion) and reduced HDL cholesterol (from accelerated HDL catabolism driven by cholesteryl ester transfer protein activity in the setting of hypertriglyceridemia), along with the formation of small, dense LDL particles that are more atherogenic despite potentially normal total LDL levels.\n\nDIAGNOSTIC CRITERIA:\nThe National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) criteria, which remain the most widely used definition in clinical practice and are endorsed by the AHA and NHLBI, require the presence of three or more of the following five components: waist circumference greater than 40 inches (102 cm) in men or greater than 35 inches (88 cm) in women, triglycerides 150 mg/dL or greater (or on drug treatment for elevated triglycerides), HDL cholesterol less than 40 mg/dL in men or less than 50 mg/dL in women (or on drug treatment for reduced HDL), blood pressure 130/85 mmHg or greater (or on antihypertensive drug treatment), and fasting glucose 100 mg/dL or greater (or on drug treatment for elevated glucose). Importantly, LDL cholesterol is not included in these criteria. While elevated LDL is an independent and powerful cardiovascular risk factor, it does not correlate with the insulin resistance phenotype that defines metabolic syndrome. A patient can have severely elevated LDL from familial hypercholesterolemia without any features of metabolic syndrome, and conversely, a patient with full metabolic syndrome may have a normal calculated LDL level while harboring highly atherogenic small dense LDL particles. Ethnicity-specific waist circumference thresholds are recommended by the International Diabetes Federation (IDF), with lower cut-points for Asian populations (90 cm for men, 80 cm for women) reflecting their greater visceral adiposity at lower overall BMI.\n\nCLINICAL SIGNIFICANCE:\nMetabolic syndrome confers a 5-fold increased risk of developing type 2 diabetes and a 2-fold increased risk of cardiovascular disease over the subsequent 5 to 10 years according to data from JAMA and the Framingham Heart Study. It is strongly associated with non-alcoholic fatty liver disease (now termed metabolic dysfunction-associated steatotic liver disease, or MASLD), polycystic ovary syndrome, obstructive sleep apnea, and hyperuricemia with gout. Management centers on lifestyle modification targeting 7 to 10% weight loss through caloric restriction and at least 150 minutes per week of moderate physical activity, with pharmacotherapy directed at individual components (statins for dyslipidemia, antihypertensives, metformin or other agents for dysglycemia) when lifestyle measures are insufficient.\n\nKEY LEARNING POINTS:\nMetabolic syndrome requires three of five criteria: elevated waist circumference, elevated triglycerides, reduced HDL, elevated blood pressure, and elevated fasting glucose. LDL cholesterol is not included because the characteristic dyslipidemia of insulin resistance is defined by high triglycerides and low HDL rather than elevated LDL. Metabolic syndrome confers a 5-fold increased risk of type 2 diabetes and 2-fold increased risk of cardiovascular disease."
  },
  {
    "id": 91,
    "categoryId": 11,
    "question": "For mild-to-moderate Generalized Anxiety Disorder (GAD), which non-pharmacologic intervention has efficacy comparable to pharmacotherapy in meta-analyses?",
    "options": [
      "A) Lavender aromatherapy",
      "B) Cognitive Behavioral Therapy (CBT)",
      "C) Psychoanalysis",
      "D) Vitamin D supplementation"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Cognitive Behavioral Therapy).\n\nEVIDENCE:\nCognitive Behavioral Therapy (CBT) has the strongest evidence base among psychotherapies for generalized anxiety disorder (GAD) and is recommended as a first-line treatment (equivalent to pharmacotherapy) by the APA, NICE, and multiple international guidelines per UpToDate and Harrison's Principles of Internal Medicine. Multiple meta-analyses demonstrate that CBT produces clinically significant reductions in anxiety symptoms with effect sizes comparable to SSRIs and SNRIs, with the added advantage of more durable effects after treatment discontinuation per the Cleveland Clinic.\n\nMECHANISM:\nCBT for GAD targets the cognitive distortions and maladaptive behavioral patterns that perpetuate chronic worry per Harvard Health. The cognitive component teaches patients to identify, challenge, and restructure automatic negative thoughts and catastrophic predictions (such as probability overestimation and catastrophizing) through techniques including cognitive restructuring, Socratic questioning, and thought records per UpToDate. The behavioral component employs graded exposure to feared situations, behavioral activation, relaxation training (progressive muscle relaxation, diaphragmatic breathing), and worry scheduling (confining worry to a designated time period) to reduce avoidance behaviors that maintain anxiety per the Mayo Clinic.\n\nCLINICAL APPLICATION:\nA typical CBT course for GAD consists of 8 to 16 weekly sessions per Harrison's Principles of Internal Medicine. For mild to moderate GAD, CBT monotherapy is appropriate and avoids medication side effects. For moderate to severe GAD, combination therapy (CBT plus an SSRI or SNRI) produces superior outcomes to either alone per UpToDate. SSRIs (sertraline, escitalopram) and SNRIs (venlafaxine, duloxetine) are first-line pharmacologic options, while benzodiazepines should be reserved for short-term use due to dependence risk per the Cleveland Clinic and the Mayo Clinic.\n\nKEY LEARNING POINTS:\nCBT is first-line treatment for mild to moderate GAD with efficacy comparable to pharmacotherapy and more durable effects after treatment ends. It targets cognitive distortions (catastrophizing, probability overestimation) and maladaptive avoidance through cognitive restructuring and graded exposure. For moderate to severe GAD, combining CBT with an SSRI or SNRI produces the best outcomes."
  },
  {
    "id": 92,
    "categoryId": 4,
    "question": "The first-line treatment for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD/NAFLD) is?",
    "options": [
      "A) Vitamin E",
      "B) Pioglitazone",
      "C) Weight loss of 7-10%",
      "D) Metformin"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Weight loss of 7-10%).\n\nPATHOPHYSIOLOGY:\nMetabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD) encompasses a spectrum ranging from simple hepatic steatosis (fat accumulation in more than 5% of hepatocytes) through steatohepatitis (MASH, formerly NASH) with lobular inflammation and hepatocyte ballooning, to progressive fibrosis and ultimately cirrhosis. The disease is driven fundamentally by insulin resistance and metabolic dysfunction. In the insulin-resistant state, impaired suppression of adipose tissue lipolysis delivers excess free fatty acids to the liver, while hyperinsulinemia simultaneously upregulates hepatic de novo lipogenesis through sterol regulatory element-binding protein 1c (SREBP-1c) activation. The resulting lipid overload exceeds hepatocyte oxidative capacity, generating reactive oxygen species, lipid peroxidation products, and endoplasmic reticulum stress that activate inflammatory pathways (NF-kB, JNK) and stellate cell fibrogenesis. MASLD is now the most common chronic liver disease worldwide, affecting approximately 30% of the global adult population per data from the Journal of Hepatology, and is the fastest-growing indication for liver transplantation in the United States.\n\nCLINICAL REASONING:\nWeight loss directly addresses the root pathophysiology of MASLD by reducing visceral adiposity, improving hepatic insulin sensitivity, decreasing portal free fatty acid delivery, and downregulating de novo lipogenesis. Evidence from multiple randomized controlled trials, including a pivotal study published in Gastroenterology (Vilar-Gomez et al., 2015), has demonstrated a dose-response relationship between weight loss and histologic improvement: weight loss of 5% or greater improves hepatic steatosis, weight loss of 7 to 10% resolves steatohepatitis in the majority of patients, and weight loss exceeding 10% can induce fibrosis regression. This evidence base supports the AASLD 2023 Practice Guidance recommendation that weight loss of 7 to 10% through lifestyle modification (hypocaloric diet and regular physical activity) is the first-line treatment for all patients with MASLD and MASH.\n\nTREATMENT:\nLifestyle modification targeting 7 to 10% weight loss is achieved through a combination of caloric restriction (deficit of 500 to 1000 kcal/day) and structured physical activity (150 to 200 minutes per week of moderate-intensity aerobic exercise). The Mediterranean diet has the strongest evidence base among dietary patterns for MASLD, with randomized trial data demonstrating reduction in hepatic steatosis independent of weight loss, likely through anti-inflammatory effects of monounsaturated fatty acids and polyphenols. Reduction of refined carbohydrates and sugar-sweetened beverages is particularly important given the role of fructose in driving hepatic de novo lipogenesis. For patients with biopsy-confirmed MASH and fibrosis who do not achieve adequate improvement with lifestyle modification alone, pharmacotherapy options include resmetirom (Rezdiffra), a thyroid hormone receptor-beta selective agonist that became the first FDA-approved medication specifically for MASH with moderate to advanced fibrosis in March 2024. GLP-1 receptor agonists, particularly semaglutide, have demonstrated significant improvement in MASH resolution in randomized trials (NEJM 2021) and offer the additional benefit of substantial weight loss. Pioglitazone improves liver histology in patients with MASH regardless of diabetes status but is limited by weight gain, fluid retention, and fracture risk. Vitamin E at 800 IU daily has demonstrated benefit in non-diabetic patients with MASH based on the PIVENS trial (NEJM 2010) but is not recommended for diabetic patients or those with simple steatosis without steatohepatitis. Alcohol avoidance and avoidance of hepatotoxic medications are essential adjuncts.\n\nKEY LEARNING POINTS:\nWeight loss of 7 to 10% is the cornerstone first-line treatment for MASLD and MASH, with a dose-response relationship between weight loss magnitude and histologic improvement including fibrosis regression above 10%. Resmetirom is the first FDA-approved medication specifically for MASH with fibrosis, and GLP-1 agonists such as semaglutide show significant promise. Vitamin E is effective only in non-diabetic patients with biopsy-confirmed MASH, and pioglitazone is limited by weight gain and fluid retention."
  },
        {
      "id": 93,
      "categoryId": 16,
      "question": "In most adults, the most evidence-supported way time-restricted eating (TRE) improves cardiometabolic markers is by:",
      "options": [
        "A) Activating liver \u201cdetox\u201d pathways that lower LDL independent of diet quality",
        "B) Helping reduce total calorie intake, promoting weight loss and downstream improvements in insulin sensitivity and metabolic risk factors",
        "C) Permanently increasing basal metabolic rate even when calories are unchanged",
        "D) Producing large improvements in HbA1c and lipids even when weight and calories are unchanged, in most people"
      ],
      "correctAnswer": 1,
      "explanation": "CORRECT: B (Reduced energy intake leading to weight loss).\n\nPATHOPHYSIOLOGY:\nMost cardiometabolic improvement from dietary interventions is mediated by changes in total energy intake and body weight. Weight loss reduces visceral adiposity, improves hepatic and peripheral insulin sensitivity, lowers blood pressure, and often improves triglycerides.\n\nCLINICAL REASONING:\nTime-restricted eating (TRE), a form of intermittent fasting, often works in practice because a shorter eating window can reduce late-evening eating and snacking, making it easier to consume fewer calories. Major clinical summaries (e.g., Mayo Clinic and Cleveland Clinic) emphasize that intermittent fasting can aid weight loss and related metabolic improvements, but that benefits vary and are not unique if calories and weight change are the same.\n\nEVIDENCE:\nRandomized trials comparing TRE with conventional daily calorie restriction commonly show similar outcomes when weight loss is similar, suggesting the primary driver for most patients is reduced caloric intake/weight loss rather than a large fasting-specific effect independent of energy balance.\n\nCLINICAL APPLICATION:\nTRE can be reasonable if it is sustainable and fits the patient\u2019s preferences. Use caution in patients at risk of hypoglycemia (e.g., insulin or sulfonylureas) and avoid in pregnancy, underweight patients, or those with an eating disorder history. Individualize to the patient\u2019s comorbidities, medications, and goals.\n\nKEY LEARNING POINTS:\nFor most adults, TRE improves metabolic health primarily by helping reduce total calorie intake and facilitating weight loss, with downstream improvements in insulin sensitivity and cardiometabolic risk factors.\n\nREFERENCES:\nMayo Clinic (Intermittent fasting FAQ); Cleveland Clinic (Intermittent fasting overview); major randomized trials in NEJM/JAMA-network journals.\n---"
    },
  {
    "id": 94,
    "categoryId": 11,
    "question": "The 'SMILE' trial (and others) demonstrated that aerobic exercise in Major Depressive Disorder (MDD) is:",
    "options": [
      "A) Ineffective compared to Zoloft",
      "B) Effective only as an adjunct",
      "C) As effective as Sertraline after 4 months",
      "D) Dangerous due to fatigue"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (As effective as Sertraline after 4 months).\n\nEVIDENCE:\nThe SMILE trial (Standard Medical Intervention and Long-term Exercise) randomized adults with major depressive disorder (MDD) to supervised aerobic exercise, sertraline (an SSRI), or combined exercise plus sertraline per Harvard Health. At 4 months, all three groups achieved equivalent reductions in depression severity, demonstrating that structured aerobic exercise was as effective as pharmacotherapy for MDD per UpToDate. At 10-month follow-up, the exercise group had significantly lower relapse rates than the sertraline-only group, suggesting more durable antidepressant effects per the Mayo Clinic.\n\nNEUROBIOLOGICAL MECHANISMS:\nExercise produces antidepressant effects through multiple converging mechanisms per Harrison's Principles of Internal Medicine. Aerobic exercise potently increases brain-derived neurotrophic factor (BDNF), which promotes hippocampal neurogenesis and synaptic plasticity, directly countering the hippocampal volume loss observed in depression. Exercise increases serotonin, norepinephrine, and dopamine neurotransmission (the same monoamine targets of antidepressant medications). It reduces hypothalamic-pituitary-adrenal (HPA) axis hyperactivity and cortisol levels, addressing the stress-hormone dysregulation central to depression per UpToDate. Exercise also reduces systemic inflammation (IL-6, TNF-alpha, CRP), which is increasingly recognized as a pathogenic factor in depression per the Cleveland Clinic.\n\nCLINICAL APPLICATION:\nThe 2024 ACP guidelines and multiple international guidelines recommend exercise as both a standalone and adjunctive treatment for MDD per UpToDate. The effective dose in trials is typically 150 minutes per week of moderate-intensity aerobic activity (brisk walking, cycling, swimming), consistent with general physical activity guidelines per the CDC. Exercise prescriptions should be specific (type, intensity, frequency, duration) to maximize adherence and should be incorporated into collaborative treatment planning per the Mayo Clinic.\n\nKEY LEARNING POINTS:\nThe SMILE trial demonstrated that structured aerobic exercise is as effective as sertraline for MDD at 4 months, with lower relapse rates at 10-month follow-up. Mechanisms include increased BDNF and hippocampal neurogenesis, enhanced monoamine neurotransmission, reduced HPA axis hyperactivity, and decreased systemic inflammation. Exercise at 150 minutes per week of moderate intensity is an evidence-based treatment for depression."
  },
  {
    "id": 95,
    "categoryId": 16,
    "question": "Which dietary fat is most strongly associated with improved insulin sensitivity and reduced inflammation?",
    "options": [
      "A) Saturated Fat (Palmitic acid)",
      "B) Trans Fat",
      "C) Omega-3 Polyunsaturated Fats (EPA/DHA)",
      "D) Omega-6 Polyunsaturated Fats"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Omega-3 Polyunsaturated Fats, EPA/DHA).\n\nPATHOPHYSIOLOGY:\nOmega-3 polyunsaturated fatty acids, specifically eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are the dietary fats most strongly associated with improved insulin sensitivity and reduced systemic inflammation per Harrison's Principles of Internal Medicine and UpToDate. EPA and DHA are found predominantly in fatty fish (salmon, mackerel, sardines, herring) and in smaller amounts in walnuts and flaxseed (as alpha-linolenic acid, which is inefficiently converted to EPA/DHA) per the Mayo Clinic.\n\nANTI-INFLAMMATORY MECHANISMS:\nEPA and DHA serve as precursors to specialized pro-resolving mediators (SPMs) including resolvins, protectins, and maresins, which are bioactive lipids that actively resolve inflammation rather than merely suppressing it per Harrison's Principles of Internal Medicine. Unlike NSAIDs that block prostaglandin synthesis, SPMs promote macrophage clearance of cellular debris, reduce neutrophil infiltration, and restore tissue homeostasis per UpToDate. EPA and DHA also competitively inhibit arachidonic acid metabolism, reducing production of pro-inflammatory eicosanoids (prostaglandin E2, thromboxane A2, leukotriene B4) and shifting the eicosanoid profile toward anti-inflammatory mediators per the Cleveland Clinic.\n\nINSULIN SENSITIVITY:\nOmega-3 fatty acids improve insulin sensitivity by incorporating into cell membrane phospholipids, increasing membrane fluidity, and enhancing insulin receptor signaling per Harvard Health. They also reduce hepatic lipogenesis, lower triglycerides (by 20 to 30% at pharmacologic doses), and decrease visceral adipose tissue inflammation per UpToDate. In contrast, saturated fats promote insulin resistance through ceramide accumulation and toll-like receptor 4 (TLR4) activation, while trans fats impair membrane fluidity and worsen inflammatory signaling per Harrison's Principles of Internal Medicine.\n\nKEY LEARNING POINTS:\nOmega-3 fatty acids (EPA/DHA) improve insulin sensitivity and reduce inflammation by generating specialized pro-resolving mediators (resolvins, protectins) that actively resolve inflammation. They competitively displace arachidonic acid, shifting eicosanoid production away from pro-inflammatory prostaglandins. Fatty fish is the best dietary source, as conversion from plant-based alpha-linolenic acid is inefficient."
  },
  {
    "id": 96,
    "categoryId": 4,
    "question": "Why is Waist Circumference a better predictor of metabolic risk than BMI?",
    "options": [
      "A) It is easier to measure",
      "B) It serves as a proxy for Visceral Adipose Tissue (VAT)",
      "C) It corrects for height",
      "D) It is not better than BMI"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (It serves as a proxy for Visceral Adipose Tissue).\n\nPATHOPHYSIOLOGY:\nAdipose tissue distribution, rather than total body fat mass alone, is a critical determinant of cardiometabolic risk. Visceral adipose tissue (VAT), which accumulates within the abdominal cavity surrounding the mesentery and omentum, is fundamentally different from subcutaneous adipose tissue in its metabolic behavior. Visceral adipocytes are more metabolically active, more sensitive to lipolytic stimuli, and more resistant to the antilipolytic effects of insulin compared to subcutaneous adipocytes. They release free fatty acids directly into the portal circulation, where first-pass hepatic exposure drives insulin resistance, increased VLDL triglyceride production, hepatic steatosis, and enhanced gluconeogenesis. Visceral fat also functions as a proinflammatory endocrine organ, secreting elevated levels of interleukin-6, tumor necrosis factor-alpha, plasminogen activator inhibitor-1, and angiotensinogen while producing reduced levels of the insulin-sensitizing adipokine adiponectin. This proinflammatory and insulin-resistant milieu generated by excess visceral fat is the mechanistic link between central obesity and the development of type 2 diabetes, cardiovascular disease, metabolic syndrome, and MASLD per data from Harrison's Principles of Internal Medicine and the Framingham Heart Study.\n\nCLINICAL REASONING:\nBMI, calculated as weight in kilograms divided by height in meters squared, is a useful population-level screening tool but has significant limitations as an individual-level predictor of metabolic risk. BMI cannot distinguish between lean mass and fat mass (a muscular athlete and a sedentary individual with excess visceral fat can share the same BMI), and it cannot differentiate visceral from subcutaneous fat distribution. This limitation is clinically significant because individuals with normal BMI but elevated visceral adiposity, a phenotype termed metabolically obese normal weight (MONW) or normal-weight obesity, carry substantially increased cardiometabolic risk that would be missed by BMI-based screening alone. Studies published in JAMA and the Annals of Internal Medicine have demonstrated that waist circumference predicts cardiovascular events, type 2 diabetes, and all-cause mortality independently of and more accurately than BMI, particularly in the intermediate BMI range of 25 to 35 where metabolic heterogeneity is greatest. Waist circumference is measured at the level of the iliac crest at the end of normal expiration and serves as a validated clinical proxy for visceral adipose tissue volume as quantified by CT or MRI.\n\nRISK THRESHOLDS:\nThe NCEP ATP III and AHA/NHLBI define elevated waist circumference as greater than 40 inches (102 cm) in men and greater than 35 inches (88 cm) in women for populations of European descent. The International Diabetes Federation recognizes ethnicity-specific thresholds, with lower cut-points for South Asian, Chinese, and Japanese populations (90 cm for men, 80 cm for women) reflecting the higher visceral fat deposition and metabolic risk observed at lower waist circumferences in these groups. The waist-to-height ratio, with a target of less than 0.5, has emerged as an additional anthropometric tool that adjusts for body frame and has shown strong predictive accuracy for cardiometabolic risk across diverse populations.\n\nKEY LEARNING POINTS:\nWaist circumference is a superior predictor of cardiometabolic risk compared to BMI because it serves as a clinical proxy for visceral adipose tissue, which drives insulin resistance, inflammation, and metabolic dysfunction through portal delivery of free fatty acids and proinflammatory cytokines. Elevated thresholds are greater than 40 inches in men and greater than 35 inches in women, with lower cut-points for Asian populations. Normal-BMI individuals with elevated waist circumference (metabolically obese normal weight phenotype) carry significant cardiometabolic risk that BMI-based screening alone would miss."
  },
  {
    "id": 97,
    "categoryId": 16,
    "question": "Resistance training is essential in aging populations primarily to prevent:",
    "options": [
      "A) Cellulite",
      "B) Sarcopenia",
      "C) Hypotension",
      "D) Varicose veins"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Sarcopenia).\n\nPATHOPHYSIOLOGY:\nSarcopenia is the progressive, age-related loss of skeletal muscle mass, strength, and function that begins around age 30 and accelerates significantly after age 60, with muscle mass declining approximately 3 to 8% per decade per Harrison's Principles of Internal Medicine and UpToDate. The pathophysiology involves multiple converging mechanisms: declining anabolic hormones (testosterone, growth hormone, IGF-1), increased inflammatory cytokines (TNF-alpha, IL-6) that promote muscle catabolism, mitochondrial dysfunction in myocytes, motor neuron loss with denervation of muscle fibers, and reduced satellite cell (muscle stem cell) regenerative capacity per the Cleveland Clinic.\n\nCLINICAL SIGNIFICANCE:\nSarcopenia is a major driver of frailty, falls, fractures, functional dependence, and mortality in older adults per the Mayo Clinic. Loss of muscle mass reduces basal metabolic rate (muscle is the body's largest metabolic organ), contributing to age-related weight gain and insulin resistance. Sarcopenia also impairs glucose disposal since skeletal muscle is responsible for approximately 80% of insulin-stimulated glucose uptake, creating a vicious cycle of metabolic deterioration per Harvard Health and Harrison's Principles of Internal Medicine.\n\nRESISTANCE TRAINING EVIDENCE:\nResistance (strength) training is the most effective intervention for preventing and reversing sarcopenia per UpToDate. Progressive resistance exercise stimulates muscle protein synthesis through the mTOR (mechanistic target of rapamycin) pathway, increases satellite cell activation, improves neuromuscular recruitment, and enhances mitochondrial biogenesis per the Cleveland Clinic. The CDC and ACSM recommend adults perform resistance training targeting all major muscle groups at least 2 days per week, with evidence showing benefits even in adults over age 90 per the Mayo Clinic. Adequate protein intake (1.0 to 1.2 g/kg/day for older adults, higher than the standard RDA of 0.8 g/kg/day) supports the anabolic response to resistance exercise per UpToDate.\n\nKEY LEARNING POINTS:\nSarcopenia (age-related muscle loss of 3 to 8% per decade) is a major driver of frailty, falls, metabolic dysfunction, and mortality in older adults. Resistance training is the most effective intervention, stimulating muscle protein synthesis via the mTOR pathway and providing benefits even in the very elderly. Older adults should perform resistance training at least twice weekly with adequate protein intake of 1.0 to 1.2 g/kg/day."
  },
  {
    "id": 98,
    "categoryId": 11,
    "question": "Which of the following is a core component of the 'Maslach Burnout Inventory'?",
    "options": [
      "A) Depression",
      "B) Depersonalization / Cynicism",
      "C) Insomnia",
      "D) Anxiety"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Depersonalization/Cynicism).\n\nDEFINITION:\nThe Maslach Burnout Inventory (MBI), developed by Christina Maslach and Susan Jackson, is the most widely used and validated research instrument for measuring occupational burnout per Harvard Health and the Mayo Clinic. The MBI defines burnout as a three-dimensional syndrome consisting of emotional exhaustion (feeling emotionally drained and depleted by work), depersonalization/cynicism (a detached, negative, or cynical attitude toward patients or clients), and reduced personal accomplishment (feeling ineffective and questioning the value of one's work) per UpToDate.\n\nCLINICAL SIGNIFICANCE:\nDepersonalization, characterized by treating patients as objects rather than individuals and developing a callous or dismissive attitude, is considered the interpersonal dimension of burnout and is particularly concerning in healthcare because it directly impairs the therapeutic relationship and patient care quality per the Cleveland Clinic. Studies demonstrate that physician burnout (affecting approximately 40 to 50% of US physicians) is associated with increased medical errors, reduced patient satisfaction, higher malpractice claims, and increased physician substance abuse and suicidality per Harvard Health and Harrison's Principles of Internal Medicine.\n\nDISTINCTION FROM DEPRESSION:\nBurnout is occupationally specific (symptoms are tied to the work context and improve with vacation or job change), whereas major depressive disorder is pervasive across all life domains per the Mayo Clinic. However, the two conditions frequently co-occur, and prolonged burnout is a risk factor for developing clinical depression per UpToDate. The WHO International Classification of Diseases (ICD-11) classifies burnout as an occupational phenomenon rather than a medical condition per Harvard Health.\n\nKEY LEARNING POINTS:\nThe Maslach Burnout Inventory measures three dimensions: emotional exhaustion, depersonalization/cynicism, and reduced personal accomplishment. Depersonalization (treating patients as objects) is the interpersonal component that directly impairs patient care. Burnout affects approximately 40 to 50% of US physicians and is associated with medical errors, malpractice, and physician suicidality."
  },
  {
    "id": 99,
    "categoryId": 16,
    "question": "What is the recommended daily intake of fiber, and what is the average American intake?",
    "options": [
      "A) Rec: 10g; Avg: 10g",
      "B) Rec: 25-30g; Avg: 15g",
      "C) Rec: 50g; Avg: 30g",
      "D) Rec: 15g; Avg: 25g"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Recommended 25 to 30g; Average American intake approximately 15g).\n\nEVIDENCE:\nThe Academy of Nutrition and Dietetics and the USDA Dietary Guidelines recommend 25 to 30 grams of dietary fiber per day (25g for women, 38g for men per the Institute of Medicine), yet the average American consumes only approximately 15 grams daily, a deficit termed the fiber gap per UpToDate and the Mayo Clinic. Only about 5% of Americans meet the recommended fiber intake, making fiber one of the most significant nutrient shortfalls in the Western diet per Harvard Health.\n\nPATHOPHYSIOLOGY OF FIBER BENEFITS:\nDietary fiber provides health benefits through multiple mechanisms per Harrison's Principles of Internal Medicine. Soluble fiber (found in oats, beans, barley, psyllium) forms a viscous gel in the intestinal lumen that slows glucose absorption (improving glycemic control), binds bile acids (lowering LDL cholesterol by forcing hepatic bile acid resynthesis from cholesterol), and increases satiety. Insoluble fiber (found in whole wheat, vegetables, nuts) adds bulk to stool, accelerates colonic transit, and reduces constipation per the Cleveland Clinic. Critically, gut bacteria ferment fiber into short-chain fatty acids (SCFAs), predominantly butyrate, propionate, and acetate, which serve as the primary energy source for colonocytes, strengthen the intestinal epithelial barrier, reduce systemic inflammation, and may protect against colorectal cancer per UpToDate.\n\nCLINICAL IMPACT:\nMeta-analyses demonstrate that each 10-gram increase in daily fiber intake is associated with approximately 10% reduction in colorectal cancer risk and 14% reduction in coronary events per Harvard Health and the Mayo Clinic. High-fiber diets also reduce the risk of type 2 diabetes, obesity, and diverticular disease per Harrison's Principles of Internal Medicine.\n\nKEY LEARNING POINTS:\nThe recommended daily fiber intake is 25 to 30 grams, but the average American consumes only about 15 grams (only 5% meet guidelines). Fiber benefits include LDL reduction via bile acid binding, improved glycemic control, and production of short-chain fatty acids (especially butyrate) that nourish colonocytes and reduce systemic inflammation. Each 10g/day increase in fiber reduces colorectal cancer risk by approximately 10%."
  },
  {
    "id": 100,
    "categoryId": 1,
    "question": "A 55-year-old Black male with no history of DM or CKD presents for BP management. BP is 152/92. Which initial monotherapy provides the best stroke reduction benefit for this specific demographic?",
    "options": [
      "A) Lisinopril (ACEi)",
      "B) Losartan (ARB)",
      "C) Amlodipine (CCB)",
      "D) Metoprolol Succinate"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Amlodipine, a CCB).\n\nCLINICAL REASONING:\nThe 2017 ACC/AHA Hypertension Guidelines and multiple landmark trials (ALLHAT being the most influential) demonstrate that in Black patients without diabetes or chronic kidney disease, thiazide-type diuretics and calcium channel blockers provide superior blood pressure reduction and greater stroke risk reduction compared to ACE inhibitors per Harrison's Principles of Internal Medicine. The ALLHAT trial (over 33,000 patients) found that Black patients randomized to the ACE inhibitor lisinopril had a 40% higher rate of stroke compared to those randomized to the CCB amlodipine or the thiazide chlorthalidone per UpToDate. This difference is attributed to lower circulating renin levels in Black patients, which reduces the efficacy of RAAS-targeting agents (ACE inhibitors and ARBs) as monotherapy per the Cleveland Clinic.\n\nPATHOPHYSIOLOGY:\nBlack patients as a population tend to have lower plasma renin activity and a more volume-dependent (salt-sensitive) form of hypertension, with greater reliance on sodium retention and increased peripheral vascular resistance as the drivers of elevated blood pressure per Harrison's Principles of Internal Medicine. CCBs (amlodipine, nifedipine) directly relax vascular smooth muscle regardless of renin status by blocking L-type calcium channels, making them effective first-line agents in this population per the Mayo Clinic. Thiazide diuretics (chlorthalidone, hydrochlorothiazide) address the volume-sensitive component. Importantly, when combination therapy is used (which is common given that most hypertensive patients require 2 or more agents), ACE inhibitors and ARBs are effective and appropriate as add-on therapy per UpToDate.\n\nKEY LEARNING POINTS:\nIn Black patients without diabetes or CKD, CCBs or thiazide diuretics are preferred first-line monotherapy due to the typically low-renin, volume-sensitive hypertension physiology. The ALLHAT trial demonstrated 40% higher stroke rates with ACE inhibitor monotherapy versus CCB or thiazide in Black patients. ACE inhibitors and ARBs are effective as add-on agents in combination regimens."
  },
  {
    "id": 101,
    "categoryId": 4,
    "question": "The root cause driver of Polycystic Ovarian Syndrome (PCOS) in the majority of patients is:",
    "options": [
      "A) Estrogen deficiency",
      "B) Insulin Resistance / Hyperinsulinemia",
      "C) Prolactin excess",
      "D) Thyroid dysfunction"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Insulin Resistance / Hyperinsulinemia).\n\nPATHOPHYSIOLOGY:\nInsulin resistance affects 50-70% of PCOS patients regardless of BMI. When insulin levels are chronically elevated, three key disruptions occur in reproductive physiology. First, hyperinsulinemia directly stimulates ovarian theca cells to overproduce androgens, particularly testosterone. Second, high insulin suppresses hepatic production of sex hormone-binding globulin (SHBG), which increases the fraction of free, biologically active testosterone. Third, the hyperandrogenic environment impairs normal follicular development, leading to anovulation and the characteristic \"string of pearls\" appearance of arrested follicles on ultrasound.\n\nCLINICAL MANIFESTATIONS:\nThe downstream effects of this hormonal disruption include oligomenorrhea or amenorrhea from anovulation, hirsutism and acne from androgen excess, infertility from failed ovulation, acanthosis nigricans as a visible marker of insulin resistance, and central/abdominal obesity.\n\nMETABOLIC CONSEQUENCES:\nPCOS carries significant long-term metabolic risks including a 4-fold increased risk of developing type 2 diabetes, elevated cardiovascular disease risk, and high prevalence of non-alcoholic fatty liver disease (NAFLD).\n\nTREATMENT APPROACH:\nLifestyle modification is first-line therapy, as even 5-10% weight loss can restore ovulatory cycles. Combined oral contraceptives address menstrual irregularity and suppress androgen production. Metformin improves insulin sensitivity and may restore ovulation in some patients. Inositol supplements have emerging evidence for improving insulin sensitivity. For patients seeking pregnancy, letrozole is now the preferred first-line ovulation induction agent over clomiphene citrate."
  },
  {
    "id": 102,
    "categoryId": 16,
    "question": "Studies of 'Blue Zones' (areas with highest longevity) share which common dietary characteristic?",
    "options": [
      "A) Strict Veganism",
      "B) High protein / Keto",
      "C) Plant-slant (95% plant-based) with legumes as a staple",
      "D) Heavy reliance on dairy"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Plant-slant diet with legumes as a staple).\n\nEVIDENCE:\nThe Blue Zones research, led by Dan Buettner in collaboration with National Geographic and the National Institute on Aging, identified five regions with the highest concentrations of centenarians: Okinawa (Japan), Sardinia (Italy), Nicoya Peninsula (Costa Rica), Ikaria (Greece), and Loma Linda (California, specifically Seventh-day Adventists) per Harvard Health. Despite geographic and cultural diversity, these populations share common dietary and lifestyle patterns that correlate with exceptional longevity per the Mayo Clinic.\n\nDIETARY COMMONALITIES:\nAll five Blue Zones follow a predominantly plant-based dietary pattern (approximately 95% of calories from plant sources) with legumes (beans, lentils, chickpeas) as a daily staple, consuming roughly half a cup to one cup per day per Harvard Health. Legumes provide a unique combination of plant protein, soluble and insoluble fiber, resistant starch, folate, iron, and polyphenols with very low caloric density per UpToDate. Meat is consumed sparingly (approximately 5 times per month in small portions), diets are rich in whole grains and vegetables, and caloric intake is moderate, often following the Okinawan practice of hara hachi bu (eating until 80% full) per the Cleveland Clinic.\n\nLIFESTYLE FACTORS:\nBeyond diet, Blue Zones populations share natural daily movement (gardening, walking) rather than structured exercise, strong social connections and sense of community, a sense of purpose (ikigai in Okinawa, plan de vida in Nicoya), moderate alcohol consumption (particularly red wine in Sardinia and Ikaria), stress-reduction rituals, and faith-based community participation per Harvard Health and the Mayo Clinic.\n\nKEY LEARNING POINTS:\nBlue Zones populations share a plant-predominant dietary pattern (approximately 95% plant-based) with legumes as the cornerstone protein source, consumed daily. Despite cultural diversity, all five zones emphasize whole foods, moderate caloric intake, daily natural movement, strong social bonds, and sense of purpose. Legumes provide a unique combination of protein, fiber, and resistant starch at very low caloric density."
  },
  {
    "id": 103,
    "categoryId": 11,
    "question": "Mindfulness-Based Stress Reduction (MBSR) has been shown to reduce cortical thinning in which brain area associated with aging?",
    "options": [
      "A) Amygdala",
      "B) Prefrontal Cortex",
      "C) Brainstem",
      "D) Cerebellum"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Prefrontal Cortex).\n\nNEUROSCIENCE:\nMindfulness-Based Stress Reduction (MBSR), an 8-week structured program developed by Jon Kabat-Zinn at the University of Massachusetts Medical Center, has been shown through neuroimaging studies to preserve cortical thickness in the prefrontal cortex, a brain region that normally thins with aging per Harvard Health and UpToDate. The prefrontal cortex is responsible for executive functions including decision-making, attention regulation, working memory, impulse control, and top-down emotional regulation of the amygdala per Harrison's Principles of Internal Medicine.\n\nNEUROPLASTICITY EVIDENCE:\nA landmark study from Harvard Medical School (Lazar et al.) using MRI demonstrated that experienced meditators had significantly greater cortical thickness in the prefrontal cortex and right anterior insula compared to age-matched controls, and that this difference was most pronounced in older participants, suggesting that meditation may offset age-related cortical thinning per Harvard Health. A subsequent randomized controlled trial showed that 8 weeks of MBSR produced measurable increases in gray matter density in the hippocampus (memory consolidation), temporoparietal junction (empathy and perspective-taking), and posterior cingulate cortex (self-referential processing), while decreasing gray matter density in the amygdala (threat detection and fear response) per the Cleveland Clinic and UpToDate.\n\nCLINICAL APPLICATIONS:\nMBSR has demonstrated efficacy in randomized trials for chronic pain, anxiety disorders, depression relapse prevention (Mindfulness-Based Cognitive Therapy, MBCT), insomnia, and stress-related conditions per the Mayo Clinic. The APA recognizes MBCT as an evidence-based treatment for preventing depressive relapse in patients with three or more prior episodes, with efficacy comparable to maintenance antidepressant therapy per Harrison's Principles of Internal Medicine.\n\nKEY LEARNING POINTS:\nMBSR preserves prefrontal cortical thickness (executive function, emotional regulation) against age-related thinning. Harvard neuroimaging studies demonstrate that 8 weeks of MBSR increases gray matter density in the hippocampus and reduces amygdala gray matter density. MBCT is evidence-based for preventing depressive relapse with efficacy comparable to maintenance antidepressants."
  },
  {
    "id": 104,
    "categoryId": 4,
    "question": "Why is Liquid Fructose (soda/juice) more metabolically damaging than Glucose?",
    "options": [
      "A) It spikes insulin higher",
      "B) It bypasses PFK-1 regulation in the liver",
      "C) It is not absorbed",
      "D) It is excreted by the kidneys"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (It bypasses PFK-1 regulation in the liver).\n\nPATHOPHYSIOLOGY:\nThe metabolic toxicity of liquid fructose is explained by a fundamental difference in hepatic substrate handling between glucose and fructose. Glucose metabolism in the liver is tightly regulated by phosphofructokinase-1 (PFK-1), the rate-limiting enzyme of glycolysis, which is allosterically inhibited by ATP and citrate when cellular energy stores are replete. This feedback mechanism ensures that glucose is metabolized in proportion to the cell's energy needs, with excess glucose directed toward glycogen synthesis rather than lipogenesis. Fructose, in contrast, enters the glycolytic pathway below the PFK-1 checkpoint through a two-step process: fructokinase (ketohexokinase) rapidly phosphorylates fructose to fructose-1-phosphate, which is then cleaved by aldolase B into glyceraldehyde and dihydroxyacetone phosphate, both of which enter glycolysis at the triose phosphate level. Because fructokinase has no negative feedback regulation and operates at near-maximal velocity regardless of cellular energy status, fructose is metabolized in an uncontrolled, essentially unlimited manner. This floods the hepatocyte with triose phosphate intermediates that overwhelm oxidative pathways and are shunted into de novo lipogenesis, generating triglycerides, VLDL particles, and intrahepatic fat accumulation.\n\nMETABOLIC CONSEQUENCES:\nThe unregulated hepatic metabolism of fructose produces a cascade of interconnected metabolic harms that have been characterized through research published in the Journal of Hepatology, JAMA, and Nature Reviews Endocrinology. First, the rapid phosphorylation of fructose by fructokinase transiently depletes intracellular ATP and inorganic phosphate, generating AMP that is degraded through the purine degradation pathway to uric acid. Hyperuricemia from chronic fructose consumption contributes to gout, endothelial dysfunction, and hypertension through inhibition of endothelial nitric oxide synthase. Second, the excess triose phosphate substrate drives de novo lipogenesis at rates far exceeding those produced by equivalent glucose loads, directly promoting hepatic steatosis and the development of MASLD. Third, chronic fructose-driven lipogenesis induces hepatic insulin resistance through diacylglycerol-mediated activation of protein kinase C-epsilon, impairing hepatic insulin signaling and promoting systemic hyperinsulinemia. Fourth, unlike glucose, fructose does not stimulate pancreatic insulin secretion or suppress ghrelin (the hunger hormone), and it fails to stimulate leptin release, meaning the brain receives no satiety signals despite substantial caloric intake, promoting overconsumption.\n\nCLINICAL CONTEXT:\nThe distinction between liquid fructose from sugar-sweetened beverages and fructose consumed within intact whole fruit is clinically essential. Whole fruit contains fiber that dramatically slows intestinal fructose absorption, allowing the liver to process the sugar gradually within its regulatory capacity. The fiber also promotes satiety and limits total consumption, and the accompanying vitamins, polyphenols, and antioxidants provide independent metabolic benefits. Epidemiologic data from large prospective cohort studies published in the BMJ and JAMA have consistently demonstrated that sugar-sweetened beverage consumption is associated with increased risk of type 2 diabetes, cardiovascular disease, MASLD, and obesity, while whole fruit consumption is associated with reduced risk of these same conditions. The AHA recommends limiting added sugar intake to no more than 25 grams per day for women and 36 grams per day for men, with particular emphasis on eliminating sugar-sweetened beverages.\n\nKEY LEARNING POINTS:\nLiquid fructose bypasses PFK-1 regulation in the liver, allowing uncontrolled metabolism that floods hepatocytes with lipogenic substrate, drives de novo lipogenesis and hepatic steatosis, depletes ATP generating uric acid, and fails to trigger satiety signaling. Whole fruit is metabolically distinct from liquid fructose because fiber slows absorption and limits consumption. The AHA recommends limiting added sugar to 25 grams per day for women and 36 grams per day for men."
  },
  {
    "id": 105,
    "categoryId": 1,
    "question": "The DASH Diet emphasizes high intake of which electrolyte to lower blood pressure?",
    "options": [
      "A) Sodium",
      "B) Potassium",
      "C) Chloride",
      "D) Iron"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Potassium).\n\nCLINICAL REASONING:\nThe DASH (Dietary Approaches to Stop Hypertension) diet emphasizes high intake of potassium through fruits, vegetables, whole grains, and low-fat dairy products as a core mechanism for blood pressure reduction per the Mayo Clinic. The original DASH trial and the subsequent DASH-Sodium trial demonstrated that the DASH dietary pattern reduces systolic blood pressure by approximately 5 to 6 mmHg in hypertensive individuals and 3 mmHg in normotensive individuals, with additional reductions when combined with sodium restriction per Harrison's Principles of Internal Medicine.\n\nPATHOPHYSIOLOGY:\nPotassium lowers blood pressure through several physiologic mechanisms per UpToDate. It promotes natriuresis (sodium excretion) by inhibiting sodium reabsorption in the proximal tubule and suppressing renin secretion. Potassium causes direct vasodilation by hyperpolarizing vascular smooth muscle cells through activation of the Na+/K+-ATPase and inward-rectifier potassium channels, and it reduces sympathetic nervous system activity per Harrison's Principles of Internal Medicine. The recommended potassium intake for blood pressure reduction is approximately 3,500 to 5,000 mg per day per the Cleveland Clinic. Rich dietary sources include bananas, potatoes, spinach, avocados, beans, and citrus fruits.\n\nTHE DASH DIET COMPONENTS:\nBeyond potassium, the DASH diet is rich in calcium, magnesium, and fiber while being low in sodium (ideally less than 1,500 mg/day for the maximum BP-lowering effect), saturated fat, and added sugars per UpToDate. The combination of these nutrients produces greater blood pressure reduction than any single nutrient supplement alone per the Mayo Clinic. The 2017 ACC/AHA Hypertension Guidelines recommend the DASH diet as a first-line lifestyle intervention for all patients with elevated blood pressure or stage 1 hypertension per Harrison's Principles of Internal Medicine.\n\nKEY LEARNING POINTS:\nThe DASH diet emphasizes high potassium intake (3,500 to 5,000 mg/day) through fruits, vegetables, and low-fat dairy, which lowers blood pressure via natriuresis, direct vasodilation, and reduced sympathetic activity. The DASH trial showed approximately 5 to 6 mmHg systolic BP reduction in hypertensive patients, with greater benefit when combined with sodium restriction to less than 1,500 mg/day."
  },
  {
    "id": 106,
    "categoryId": 4,
    "question": "Which lab marker is the most sensitive early indicator of insulin resistance, often elevating years before A1c?",
    "options": [
      "A) Fasting Glucose",
      "B) Fasting Insulin (or HOMA-IR)",
      "C) LDL Cholesterol",
      "D) TSH"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Fasting Insulin or HOMA-IR).\n\nPATHOPHYSIOLOGY:\nThe natural history of type 2 diabetes follows a prolonged preclinical trajectory spanning years to decades during which insulin resistance is present but glucose homeostasis is maintained through compensatory beta-cell hyperfunction. In the earliest stage, peripheral insulin resistance in skeletal muscle, adipose tissue, and the liver requires progressively increasing insulin secretion to maintain normal glucose disposal and suppress hepatic glucose output. During this compensatory phase, fasting glucose and hemoglobin A1c remain within normal reference ranges because the beta cells are successfully increasing insulin production to overcome tissue resistance. Fasting glucose begins to rise only after beta-cell secretory capacity has declined by approximately 50 to 80% from its peak compensatory output, a point at which the disease process is already substantially advanced per data from the United Kingdom Prospective Diabetes Study (UKPDS) and research reviewed in Harrison's Principles of Internal Medicine. This means that glucose-based diagnostic tests (fasting glucose, oral glucose tolerance test, and HbA1c) are inherently late markers that detect the disease only after significant and potentially irreversible beta-cell loss has occurred, missing the optimal window for preventive intervention.\n\nCLINICAL REASONING:\nFasting insulin measurement captures the compensatory hyperinsulinemia phase years before glucose derangement becomes detectable. In a fasting state, insulin levels reflect the amount of insulin required to maintain basal glucose homeostasis, and elevated fasting insulin (generally above 10 to 12 microIU/mL, though reference ranges vary by assay and laboratory) indicates that the pancreas is working above baseline capacity to suppress hepatic glucose output, signaling underlying insulin resistance. The Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) refines this measurement by incorporating both fasting insulin and fasting glucose into a validated formula: (fasting insulin in microIU/mL multiplied by fasting glucose in mg/dL) divided by 405. HOMA-IR values below 1.0 indicate optimal insulin sensitivity, values between 1.0 and 2.0 are generally considered normal, values above 2.0 suggest insulin resistance, and values exceeding 2.5 to 3.0 indicate significant insulin resistance warranting clinical attention. HOMA-IR has been validated against the hyperinsulinemic-euglycemic clamp (the gold standard for measuring insulin sensitivity) and demonstrates strong correlation in research and clinical settings per studies published in Diabetes Care and the Journal of Clinical Endocrinology and Metabolism.\n\nCLINICAL APPLICATION:\nEarly identification of insulin resistance through fasting insulin or HOMA-IR enables timely implementation of lifestyle interventions during the period when they are most effective at preventing progression to prediabetes and diabetes, as demonstrated by the Diabetes Prevention Program. Beyond diabetes prediction, elevated fasting insulin serves as a unifying biomarker for the metabolic syndrome phenotype, correlating with visceral adiposity, atherogenic dyslipidemia, hypertension, MASLD, and polycystic ovary syndrome, in which hyperinsulinemia directly stimulates ovarian theca cell androgen production. A practical clinical alternative when fasting insulin is not readily available is the triglyceride-to-HDL ratio, where values exceeding 3.0 have been shown to correlate with insulin resistance and small dense LDL particles. It is important to note that HOMA-IR is not validated for patients already receiving exogenous insulin or insulin secretagogues, as these medications alter the relationship between fasting insulin and glucose on which the model depends.\n\nKEY LEARNING POINTS:\nFasting insulin and HOMA-IR detect compensatory hyperinsulinemia years before fasting glucose or HbA1c become abnormal, as glucose-based tests only rise after 50 to 80% of beta-cell secretory capacity has been lost. HOMA-IR is calculated as (fasting insulin multiplied by fasting glucose) divided by 405, with values above 2.5 indicating significant insulin resistance. Early detection of insulin resistance enables timely lifestyle intervention during the window of greatest effectiveness for diabetes prevention."
  },
  {
    "id": 107,
    "categoryId": 11,
    "question": "Which factor is the most potent stimulator of BDNF (Brain-Derived Neurotrophic Factor)?",
    "options": [
      "A) Sudoku puzzles",
      "B) Aerobic Exercise",
      "C) Vitamin C",
      "D) Classical music"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Aerobic Exercise).\n\nNEUROBIOLOGY:\nBrain-derived neurotrophic factor (BDNF) is the most abundant neurotrophin in the central nervous system and plays a critical role in neuronal survival, synaptic plasticity, long-term potentiation (the cellular basis of learning and memory), and hippocampal neurogenesis per Harrison's Principles of Internal Medicine and UpToDate. Aerobic exercise is the most potent known stimulator of BDNF expression, producing increases of 2 to 3-fold in peripheral BDNF levels acutely and sustained elevations with chronic training per Harvard Health.\n\nMECHANISM:\nDuring aerobic exercise, skeletal muscle contraction produces signaling molecules (myokines, including irisin and cathepsin B) that cross the blood-brain barrier and stimulate BDNF transcription in hippocampal neurons via activation of the PGC-1-alpha/FNDC5/irisin pathway per UpToDate. Lactate produced during exercise also crosses the blood-brain barrier and activates the SIRT1/PGC-1-alpha signaling cascade, further upregulating BDNF expression per the Cleveland Clinic. The hippocampus is particularly responsive to exercise-induced BDNF because of its high density of TrkB receptors (the cognate receptor for BDNF) and its unique capacity for adult neurogenesis in the dentate gyrus per Harrison's Principles of Internal Medicine.\n\nCLINICAL SIGNIFICANCE:\nReduced BDNF levels are a consistent finding in major depressive disorder, Alzheimer's disease, and age-related cognitive decline per the Mayo Clinic. Exercise-induced BDNF elevation is a key mechanism underlying the antidepressant, anxiolytic, and neuroprotective effects of physical activity per UpToDate. Randomized trials demonstrate that aerobic exercise increases hippocampal volume by approximately 2% (equivalent to reversing 1 to 2 years of age-related volume loss) in older adults, an effect mediated by BDNF-driven neurogenesis per Harvard Health. Cognitive activities (puzzles, reading) have modest effects on synaptic strengthening but do not significantly increase BDNF production or drive neurogenesis per the Cleveland Clinic.\n\nKEY LEARNING POINTS:\nAerobic exercise is the most potent stimulator of BDNF, producing 2 to 3-fold increases via the irisin/PGC-1-alpha pathway from exercising muscle. BDNF drives hippocampal neurogenesis, and exercise increases hippocampal volume by approximately 2% in older adults. Low BDNF levels are implicated in depression, Alzheimer's disease, and cognitive decline, making exercise a neuroprotective intervention."
  },
  {
    "id": 108,
    "categoryId": 16,
    "question": "What is the timeline for cardiovascular risk reduction after smoking cessation?",
    "options": [
      "A) 10 years to see any benefit",
      "B) HR and BP drop in 20 mins; MI risk drops 50% in 1 year",
      "C) Damage is permanent",
      "D) 5 years for BP to normalize"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (HR and BP drop in 20 minutes; MI risk drops 50% in 1 year).\n\nPATHOPHYSIOLOGY OF SMOKING-INDUCED DAMAGE:\nCigarette smoke causes cardiovascular harm through multiple simultaneous mechanisms per Harrison's Principles of Internal Medicine. Nicotine activates the sympathetic nervous system, increasing heart rate, blood pressure, and myocardial oxygen demand. Carbon monoxide binds hemoglobin (forming carboxyhemoglobin) with 200 times the affinity of oxygen, reducing oxygen-carrying capacity and promoting tissue hypoxia. Smoke constituents damage vascular endothelium, reduce nitric oxide bioavailability, promote LDL oxidation, increase platelet aggregation, and elevate fibrinogen levels, creating a prothrombotic, pro-atherogenic milieu per UpToDate and the Cleveland Clinic.\n\nCESSATION TIMELINE:\nWithin 20 minutes of the last cigarette, heart rate and blood pressure begin to normalize as the acute sympathomimetic effects of nicotine dissipate per the CDC. Within 12 hours, carbon monoxide levels drop to normal, restoring oxygen-carrying capacity. Within 2 to 12 weeks, circulation improves and lung function begins to recover. At 1 year, the excess risk of coronary heart disease is reduced by approximately 50% compared to a continuing smoker per the Mayo Clinic and Harvard Health. At 5 years, stroke risk approaches that of a never-smoker. At 10 years, lung cancer mortality is approximately half that of a continuing smoker. At 15 years, coronary heart disease risk approaches that of a never-smoker per Harrison's Principles of Internal Medicine and the CDC.\n\nCLINICAL APPLICATION:\nSmoking cessation is the single most impactful preventive intervention a clinician can facilitate, with a number needed to treat (NNT) for mortality benefit that exceeds virtually any pharmacologic intervention per UpToDate. FDA-approved cessation aids include nicotine replacement therapy (patch, gum, lozenge, inhaler, nasal spray), varenicline (Chantix, a partial nicotinic receptor agonist with the highest quit rates), and bupropion (Wellbutrin/Zyban) per the Cleveland Clinic. Combining behavioral counseling with pharmacotherapy produces the highest sustained quit rates per the Mayo Clinic.\n\nKEY LEARNING POINTS:\nHemodynamic benefits of smoking cessation begin within 20 minutes (HR and BP normalization), MI risk drops 50% at 1 year, and coronary risk approaches never-smoker levels at 15 years. Smoking cessation is the single most impactful preventive intervention in medicine. Varenicline has the highest quit rates among FDA-approved cessation pharmacotherapies, and combining medication with behavioral counseling optimizes outcomes."
  },
  {
    "id": 109,
    "categoryId": 13,
    "question": "Hyperuricemia (High Uric Acid) is not just a cause of gout, but an independent risk factor for:",
    "options": [
      "A) Hypertension and Metabolic Syndrome",
      "B) Hypothyroidism",
      "C) Osteoporosis",
      "D) Asthma"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Hypertension and Metabolic Syndrome).\n\nPATHOPHYSIOLOGY OF URIC ACID-MEDIATED VASCULAR DAMAGE:\nElevated serum uric acid exerts harmful effects on the cardiovascular system through several mechanisms that are independent of crystal deposition and gout. Uric acid activates the renin-angiotensin system, stimulates vascular smooth muscle proliferation, and induces endothelial dysfunction by reducing nitric oxide bioavailability. In the kidney, hyperuricemia causes afferent arteriolar vasoconstriction and tubulointerstitial inflammation, leading to sodium retention and impaired pressure natriuresis. These effects explain why hyperuricemia precedes and predicts the development of hypertension, particularly in adolescents and young adults. Additionally, uric acid promotes oxidative stress and inflammation in adipose tissue, contributing to insulin resistance.\n\nEPIDEMIOLOGICAL ASSOCIATIONS:\nLarge prospective studies consistently demonstrate that hyperuricemia independently predicts hypertension, metabolic syndrome, type 2 diabetes, chronic kidney disease progression, and cardiovascular events. The Framingham Heart Study showed that each 1 mg/dL increase in serum uric acid is associated with a 13% increased risk of cardiovascular mortality in men. In the metabolic syndrome cluster, hyperuricemia correlates strongly with central obesity, insulin resistance, dyslipidemia, and elevated blood pressure, likely because fructose metabolism simultaneously generates uric acid and drives hepatic de novo lipogenesis.\n\nCLINICAL IMPLICATIONS FOR PRIMARY CARE:\nWhen evaluating a patient with elevated uric acid, consider it a marker of broader cardiometabolic risk rather than simply a gout predictor. Screen for hypertension, metabolic syndrome, and chronic kidney disease. Lifestyle interventions that lower uric acid, such as reducing fructose and alcohol intake, weight loss, and limiting purine-rich foods, simultaneously address multiple metabolic risk factors.\n\nKEY LEARNING POINTS:\nHyperuricemia is an independent risk factor for hypertension, metabolic syndrome, CKD progression, and cardiovascular mortality. The mechanisms include RAAS activation, endothelial dysfunction, and promotion of insulin resistance. An elevated uric acid should prompt evaluation for cardiometabolic comorbidities beyond gout risk assessment."
  },
  {
    "id": 110,
    "categoryId": 11,
    "question": "According to the Harvard Study of Adult Development (longest longitudinal study on humans), the #1 predictor of happiness and longevity is:",
    "options": [
      "A) Cholesterol levels",
      "B) Quality of Relationships",
      "C) Financial success",
      "D) Genetic profile"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Quality of Relationships).\n\nEVIDENCE:\nThe Harvard Study of Adult Development, initiated in 1938 and now spanning over 85 years across multiple generations, is the longest longitudinal study of human health and well-being ever conducted per Harvard Health. The study has followed two original cohorts (268 Harvard College sophomores and 456 inner-city Boston men) and subsequently their spouses and offspring, with comprehensive assessments including questionnaires, medical examinations, brain imaging, and blood biomarkers per the Mayo Clinic.\n\nCORE FINDING:\nThe single strongest predictor of both life satisfaction and physical health at age 80 was not cholesterol levels, socioeconomic status, fame, or IQ, but the quality of close personal relationships at age 50 per Harvard Health and UpToDate. Individuals with warm, secure, and supportive relationships experienced less cognitive decline, maintained better physical function, lived longer, and reported greater happiness than those who were socially isolated or in conflicted relationships per the Cleveland Clinic. Robert Waldinger, the study's current director, summarized: close relationships are the factor that most consistently predicted healthy aging across all measures studied.\n\nBIOLOGICAL MECHANISMS:\nSecure social bonds buffer the physiologic stress response by reducing HPA axis activation and cortisol production, lowering sympathetic nervous system tone, and dampening systemic inflammation (reduced CRP, IL-6, fibrinogen) per Harrison's Principles of Internal Medicine. Social connection activates oxytocin and endogenous opioid pathways that promote parasympathetic tone, emotional regulation, and immune function per UpToDate. Conversely, loneliness and social isolation activate the conserved transcriptional response to adversity (CTRA), upregulating inflammatory gene expression and downregulating antiviral immune responses per Harvard Health.\n\nKEY LEARNING POINTS:\nThe Harvard Study of Adult Development (85+ years, the longest human longitudinal study) found that quality of relationships at age 50 is the strongest predictor of health and happiness at age 80. Close relationships buffer physiologic stress responses by reducing cortisol, sympathetic tone, and systemic inflammation. Social isolation activates inflammatory gene expression and is an independent mortality risk factor."
  },
  {
    "id": 111,
    "categoryId": 16,
    "question": "Why are Ultra-Processed Foods harmful to human health?",
    "options": [
      "A) They contain too much protein",
      "B) They are high in fiber",
      "C) They bypass satiety mechanisms, promote overconsumption, disrupt the gut microbiome, and drive metabolic dysfunction",
      "D) They are difficult to digest"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (They bypass satiety mechanisms, promote overconsumption, disrupt the gut microbiome, and drive metabolic dysfunction).\n\nDEFINITION AND PREVALENCE:\nUltra-processed foods (UPFs), as defined by the NOVA classification system, are industrial formulations made mostly or entirely from substances derived from foods and additives, with little or no intact whole food per Harvard Health. UPFs include soft drinks, packaged snacks, reconstituted meat products, instant noodles, and most fast food. They constitute approximately 58% of total caloric intake in the American diet and nearly 90% of added sugar consumption per UpToDate and the Cleveland Clinic.\n\nMECHANISMS OF HARM:\nUPFs promote overconsumption through several pathways per Harrison's Principles of Internal Medicine. They are engineered for hyper-palatability by optimizing combinations of sugar, salt, fat, and flavor enhancers that activate dopaminergic reward circuits in a manner analogous to addictive substances. They have high caloric density with low fiber and water content, which bypasses normal satiety signaling from gastric stretch receptors and gut hormones (GLP-1, PYY, CCK) per UpToDate. A landmark NIH randomized controlled trial by Hall and colleagues (2019) demonstrated that participants consuming an ultra-processed diet for 2 weeks ate approximately 500 more calories per day and gained 2 pounds compared to an unprocessed diet matched for macronutrients, sodium, sugar, and fiber, establishing that food processing itself drives overconsumption per Harvard Health.\n\nMETABOLIC AND MICROBIOME EFFECTS:\nUPFs disrupt the gut microbiome by providing rapidly absorbed simple sugars and lacking the dietary fiber that sustains beneficial commensal bacteria per the Cleveland Clinic. Additives such as emulsifiers (polysorbate 80, carboxymethylcellulose) have been shown in animal models to erode the protective mucus layer of the intestinal epithelium, promoting intestinal permeability and systemic inflammation per UpToDate. Large prospective cohort studies (NutriNet-SantÃ©, UK Biobank) have associated high UPF consumption with increased risk of obesity, type 2 diabetes, cardiovascular disease, depression, and all-cause mortality per the Mayo Clinic.\n\nKEY LEARNING POINTS:\nUltra-processed foods constitute approximately 58% of American caloric intake and drive overconsumption through hyper-palatability engineering that activates dopaminergic reward circuits and bypasses satiety mechanisms. The NIH Hall study showed UPFs cause approximately 500 extra calories per day of intake independent of macronutrient composition. UPFs also disrupt the gut microbiome and are associated with increased cardiovascular, metabolic, and all-cause mortality risk."
  },
  {
    "id": 112,
    "categoryId": 14,
    "question": "Insulin resistance and Hyperinsulinemia are strongly linked to an increased risk of which cancers?",
    "options": [
      "A) Lung and Brain",
      "B) Breast, Colon, and Endometrial",
      "C) Leukemia",
      "D) Skin cancer"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Breast, Colon, and Endometrial).\n\nPATHOPHYSIOLOGY:\nInsulin is an anabolic hormone that promotes cell proliferation through activation of the insulin receptor and cross-activation of the insulin-like growth factor-1 (IGF-1) receptor, both of which signal through the PI3K-Akt-mTOR pathway to stimulate cell growth and inhibit apoptosis per Harrison's Principles of Internal Medicine. In states of chronic insulin resistance and compensatory hyperinsulinemia, such as obesity, metabolic syndrome, and type 2 diabetes, these mitogenic pathways are persistently activated in susceptible tissues. Adipose tissue also produces excess estrogen through peripheral aromatization of androgens, directly stimulating proliferation of estrogen receptor-positive tissues in the breast and endometrium. Chronic low-grade inflammation associated with visceral adiposity produces elevated levels of tumor necrosis factor-alpha and interleukin-6 that promote a microenvironment conducive to tumor development.\n\nCLINICAL EVIDENCE:\nThe International Agency for Research on Cancer has identified sufficient evidence linking excess body fat to at least 13 cancer types per the CDC, with the strongest associations for endometrial cancer (relative risk approximately 7-fold for BMI greater than 40), esophageal adenocarcinoma, and colorectal cancer. Breast cancer risk in postmenopausal women increases approximately 12% for every 5 kg/m2 increase in BMI, mediated primarily through elevated circulating estrogen. Colorectal cancer risk increases approximately 30% with obesity, driven by hyperinsulinemia-mediated proliferation of colonic epithelial cells.\n\nCLINICAL APPLICATION:\nWeight management and physical activity are among the most impactful modifiable cancer risk reduction strategies. The American Cancer Society recommends 150 to 300 minutes of moderate-intensity physical activity per week. Metformin, which reduces circulating insulin levels, is under active investigation in cancer prevention trials, with observational data suggesting reduced cancer incidence among diabetic patients taking metformin per review in the Journal of Clinical Oncology.\n\nKEY LEARNING POINTS:\nHyperinsulinemia promotes cancer through activation of the IGF-1 and PI3K-Akt-mTOR mitogenic pathways, with breast, colorectal, and endometrial cancers showing the strongest associations per the CDC and IARC. Obesity drives cancer risk through hyperinsulinemia, excess peripheral estrogen production, and chronic inflammation. Weight management and physical activity are among the most effective modifiable strategies for cancer risk reduction."
  },
  {
    "id": 113,
    "categoryId": 16,
    "question": "In Motivational Interviewing (MI), the 'OARS' acronym stands for:",
    "options": [
      "A) Open-ended questions, Affirmations, Reflections, Summaries",
      "B) Order, Advise, Repeat, Schedule",
      "C) Observe, Assess, React, Support",
      "D) Object, Argue, Reframe, Stop"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Open-ended questions, Affirmations, Reflections, Summaries).\n\nCLINICAL FRAMEWORK:\nMotivational Interviewing (MI) is an evidence-based, patient-centered counseling method developed by William Miller and Stephen Rollnick that enhances intrinsic motivation for behavior change by exploring and resolving ambivalence per UpToDate and Harrison's Principles of Internal Medicine. MI moves away from the traditional expert-driven (prescriptive) model of patient education toward a collaborative, guiding approach that elicits the patient's own reasons and motivation for change per the Mayo Clinic. Multiple systematic reviews and meta-analyses have demonstrated MI's effectiveness for smoking cessation, alcohol reduction, weight management, medication adherence, and chronic disease self-management per Harvard Health.\n\nOARS COMPONENTS:\nOpen-ended questions (such as 'What concerns you most about your drinking?') invite the patient to elaborate and explore their own thinking, rather than providing yes/no answers that close down conversation per UpToDate. Affirmations acknowledge the patient's strengths, efforts, and past successes (such as 'It took courage to bring this up today'), building self-efficacy and therapeutic alliance. Reflective listening is the cornerstone skill, where the clinician mirrors back the patient's statements to deepen understanding and demonstrate empathy (such as 'It sounds like you want to quit but are worried about the stress'). Summaries collect and synthesize what the patient has said, reinforcing change talk while organizing the conversation per the Cleveland Clinic.\n\nSPIRIT OF MI:\nThe underlying spirit of MI rests on four principles: partnership (collaborative rather than authoritarian), acceptance (respecting autonomy and affirming worth), compassion (prioritizing the patient's welfare), and evocation (drawing out the patient's own ideas rather than imposing the clinician's) per UpToDate. MI specifically avoids the righting reflex, the clinician's natural tendency to correct, advise, or fix, which paradoxically increases patient resistance per Harrison's Principles of Internal Medicine.\n\nKEY LEARNING POINTS:\nOARS stands for Open-ended questions, Affirmations, Reflective listening, and Summaries, forming the core communication skills of Motivational Interviewing. MI is an evidence-based approach that enhances intrinsic motivation by resolving ambivalence through collaboration rather than prescription. The clinician avoids the righting reflex and instead draws out the patient's own reasons for change."
  },
  {
    "id": 114,
    "categoryId": 4,
    "question": "A patient on Semaglutide (Wegovy) for weight loss presents with severe, persistent mid-epigastric pain radiating to the back and vomiting. What is the diagnosis and next step?",
    "options": [
      "A) Gastroparesis; Stop med and hydration",
      "B) Acute Pancreatitis; Stop med and send to ER",
      "C) GERD; Start Omeprazole",
      "D) Cholecystitis; Order Ultrasound"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Acute Pancreatitis; Stop med and send to ER).\n\nPATHOPHYSIOLOGY:\nGLP-1 receptor agonists carry a recognized risk of acute pancreatitis. Proposed mechanisms include direct pancreatic acinar cell stimulation and gallbladder dysmotility promoting biliary sludge and gallstones, which can trigger biliary pancreatitis.\n\nCLINICAL PRESENTATION:\nSevere, persistent epigastric pain radiating to the back with nausea and vomiting is the classic pattern. This differs markedly from the transient nausea common during GLP-1 initiation. Serum lipase greater than three times the upper limit of normal confirms the diagnosis.\n\nMANAGEMENT:\nImmediately discontinue the GLP-1 agonist and refer for emergency evaluation. The medication must be permanently discontinued; rechallenge is contraindicated.\n\nKEY LEARNING POINTS:\nAcute pancreatitis is a rare but serious GLP-1 agonist adverse effect. Epigastric pain radiating to the back warrants immediate drug discontinuation and ER referral. Never restart GLP-1 therapy after drug-induced pancreatitis."
  },
  {
    "id": 115,
    "categoryId": 4,
    "question": "Potential benefits of assessing 'Time in Range' with a Continuous Glucose Monitor (CGM) over solely relying on A1c levels to determine control of Type 2 DM include:",
    "options": [
      "A) Time in Range is less accurate than A1c",
      "B) Detection of glycemic variability and hypoglycemia that A1c alone cannot reveal",
      "C) Time in Range eliminates the need for any fingerstick glucose testing",
      "D) A1c provides more actionable data for medication adjustment"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Detection of glycemic variability and hypoglycemia that A1c alone cannot reveal).\n\nPATHOPHYSIOLOGY:\nHemoglobin A1c reflects the proportion of hemoglobin that has undergone non-enzymatic glycation and provides an estimate of average blood glucose over the preceding 2 to 3 months (corresponding to the lifespan of circulating erythrocytes). While A1c has been the cornerstone of diabetes monitoring for decades, it is fundamentally a measure of central tendency that cannot capture the distribution, variability, or temporal pattern of glucose values. Two patients with an identical A1c of 7.0% (estimated average glucose of 154 mg/dL) may have vastly different glycemic profiles: one with stable glucose between 130 and 180 mg/dL throughout the day, and another with frequent oscillations between 50 and 300 mg/dL averaging to the same value. Glycemic variability, defined as the amplitude and frequency of glucose fluctuations, has been increasingly recognized as an independent contributor to diabetic complications through mechanisms involving oxidative stress, endothelial dysfunction, and inflammatory pathway activation. Research published in Diabetes Care and The Lancet Diabetes and Endocrinology has demonstrated that glucose variability, as measured by standard deviation or coefficient of variation of CGM data, predicts microvascular and macrovascular complications beyond what A1c alone captures. Additionally, A1c has well-documented analytical limitations: it is unreliable in conditions that alter red blood cell turnover (hemolytic anemias, iron deficiency anemia, recent transfusion, erythropoietin therapy), in hemoglobinopathies (sickle cell trait, thalassemia), in chronic kidney disease (particularly stages 4 and 5 where carbamylated hemoglobin interferes), and during pregnancy.\n\nCLINICAL REASONING:\nContinuous glucose monitoring (CGM) addresses the fundamental limitations of A1c by providing a complete glucose profile with measurements taken every 1 to 5 minutes, generating approximately 288 to 1440 data points per day. The primary CGM-derived metric is Time in Range (TIR), defined as the percentage of time glucose remains within the target range of 70 to 180 mg/dL for most adults with diabetes. The 2019 International Consensus on Time in Range, published in Diabetes Care and endorsed by the ADA, established standardized targets: TIR greater than 70% (approximately 17 hours per day) for most adults with type 1 or type 2 diabetes, with less than 4% of time below 70 mg/dL (Time Below Range) and less than 1% below 54 mg/dL to minimize hypoglycemia risk. For older or high-risk patients, a TIR target of greater than 50% with less than 1% below 70 mg/dL is recommended. Each 10% increase in TIR has been shown to correlate with clinically meaningful reductions in retinopathy progression and microalbuminuria in analyses from the DCCT dataset. Beyond TIR, CGM reveals clinically actionable patterns invisible to A1c: nocturnal hypoglycemia (often asymptomatic and dangerous), postprandial glucose excursions that guide dietary and medication adjustments, the dawn phenomenon (early morning glucose rises driven by cortisol and growth hormone surges), and the glycemic impact of specific foods, activities, and stressors.\n\nCLINICAL APPLICATION:\nThe ADA 2024 Standards of Care recommend CGM for all patients with type 1 diabetes and for patients with type 2 diabetes on intensive insulin regimens. CGM use is also increasingly supported for patients with type 2 diabetes on basal insulin or non-insulin therapies when glycemic targets are not being met or when hypoglycemia is a concern. The Ambulatory Glucose Profile (AGP) report, a standardized CGM summary endorsed by the International Diabetes Center, presents 14 days of glucose data as a visual display showing the median glucose, interquartile range, and 10th to 90th percentile glucose values across a 24-hour period, enabling rapid pattern recognition. The glucose management indicator (GMI), a CGM-derived estimate of A1c based on mean sensor glucose, can substitute for laboratory A1c when the latter is unreliable. A1c and TIR should be viewed as complementary rather than competing metrics, with A1c providing a long-term average and CGM-derived metrics providing the granular detail necessary for precision therapy adjustments.\n\nKEY LEARNING POINTS:\nA1c is a measure of average glucose that cannot reveal glycemic variability or hypoglycemia, both of which independently contribute to diabetic complications. Time in Range targets greater than 70% with less than 4% below 70 mg/dL for most adults, and each 10% increase in TIR correlates with meaningful reductions in microvascular complications. CGM reveals actionable patterns including nocturnal hypoglycemia, postprandial excursions, and dawn phenomenon that enable precision therapy adjustments beyond what A1c-guided management can achieve."
  },
  {
    "id": 116,
    "categoryId": 1,
    "question": "A 50-year-old patient is on Amlodipine, Lisinopril, and HCTZ at max doses. BP remains 150/95. Potassium is 3.3 (Low). What is the most likely secondary cause?",
    "options": [
      "A) Pheochromocytoma",
      "B) Primary Hyperaldosteronism (Conn's)",
      "C) Renal Artery Stenosis",
      "D) Cushing's Syndrome"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Primary Hyperaldosteronism / Conn Syndrome).\n\nCLINICAL REASONING:\nThis patient has resistant hypertension (uncontrolled BP despite adherence to 3 antihypertensive agents at maximum doses including a diuretic) combined with unexplained hypokalemia (potassium 3.3 mEq/L) per Harrison's Principles of Internal Medicine. The combination of treatment-resistant hypertension and spontaneous or diuretic-exacerbated hypokalemia is the classic presentation of primary hyperaldosteronism, which is now recognized as the most common cause of secondary hypertension, affecting 5 to 15% of all hypertensive patients and up to 20% of those with resistant hypertension per UpToDate.\n\nPATHOPHYSIOLOGY:\nPrimary hyperaldosteronism involves autonomous aldosterone secretion from the adrenal glands (either from a unilateral aldosterone-producing adenoma, known as Conn syndrome, or bilateral adrenal hyperplasia) that is independent of the renin-angiotensin system per the Cleveland Clinic. Excess aldosterone stimulates sodium reabsorption via ENaC channels in the collecting duct (causing volume expansion and hypertension) and simultaneously drives potassium secretion into the tubular lumen (causing hypokalemia). However, it is important to note that up to 50% of patients with primary hyperaldosteronism are normokalemic, so the absence of hypokalemia does not exclude the diagnosis per UpToDate.\n\nDIAGNOSTIC APPROACH:\nThe screening test is the plasma aldosterone-to-renin ratio (ARR), which shows elevated aldosterone with suppressed renin (high ratio, typically greater than 30 with aldosterone greater than 15 ng/dL) per the Mayo Clinic. Confirmatory testing (oral sodium loading test, saline infusion test, or fludrocortisone suppression test) follows a positive screen per Harrison's Principles of Internal Medicine. Adrenal CT and adrenal vein sampling distinguish unilateral adenoma (treated surgically with adrenalectomy) from bilateral hyperplasia (treated medically with mineralocorticoid receptor antagonists such as spironolactone or eplerenone) per UpToDate.\n\nKEY LEARNING POINTS:\nResistant hypertension with hypokalemia is the classic clue for primary hyperaldosteronism (Conn syndrome), the most common cause of secondary hypertension. The aldosterone-to-renin ratio is the screening test (high aldosterone, suppressed renin). Up to 50% of patients are normokalemic, so screening should be considered in all patients with resistant hypertension regardless of potassium level."
  },
  {
    "id": 117,
    "categoryId": 7,
    "question": "A patient complains of shoulder pain. You perform a 'Spurling's Test' (Neck extension + rotation to affected side + axial load), which reproduces pain radiating down the arm. The problem is:",
    "options": [
      "A) Rotator Cuff Tear",
      "B) Cervical Radiculopathy (Disc herniation)",
      "C) AC Joint Separation",
      "D) Thoracic Outlet Syndrome"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Cervical Radiculopathy).\n\nCERVICAL RADICULOPATHY AND REFERRED SHOULDER PAIN:\nA positive Spurling's test is highly specific (approximately 93%) for cervical radiculopathy and effectively redirects the clinical picture from the shoulder to the cervical spine. Many patients with cervical nerve root compression present with shoulder pain as their chief complaint because the C5 and C6 dermatomes overlap the shoulder region, creating a referred pain pattern that mimics primary shoulder pathology. The key clinical insight is that if shoulder range of motion is full and painless but Spurling's test reproduces radiating arm pain, the cervical spine is the culprit.\n\nPATHOPHYSIOLOGY:\nCervical radiculopathy occurs when a nerve root is compressed as it exits the neural foramen, most commonly at C5-C6 or C6-C7. In younger patients, the typical cause is posterolateral disc herniation; in older patients, foraminal stenosis from degenerative spondylosis and uncovertebral joint hypertrophy predominates. Compression of the nerve root produces both local inflammation and mechanical irritation, generating pain that radiates along the affected dermatome. C6 radiculopathy produces pain traveling from the neck through the shoulder and lateral arm to the thumb and index finger, which is why patients frequently localize their complaint to the shoulder.\n\nSPURLING'S TEST MECHANISM:\nThe maneuver combines three components that collectively narrow the neural foramen by approximately 20 to 30%. Cervical extension closes the posterior disc space and buckles the ligamentum flavum into the canal. Ipsilateral rotation narrows the foramen on the side of rotation. Axial compression further reduces foraminal volume. If a herniated disc or osteophyte is already encroaching on the nerve root, this additional narrowing reproduces or exacerbates radicular symptoms (pain, paresthesias, or numbness radiating into the arm). A positive test reproduces the patient's radicular symptoms, not merely neck pain.\n\nCLINICAL EVALUATION:\nWhen evaluating shoulder pain, the clinician must differentiate intrinsic shoulder pathology (rotator cuff injury, impingement, AC joint disease) from extrinsic causes (cervical radiculopathy, thoracic outlet syndrome). Full painless shoulder range of motion with a positive Spurling's test strongly suggests cervical origin. Additional cervical radiculopathy findings include dermatomal sensory changes, myotomal weakness (biceps weakness and diminished biceps reflex for C6; triceps weakness and diminished triceps reflex for C7), and symptom exacerbation with neck movement. MRI of the cervical spine is the preferred imaging modality when radiculopathy is suspected and red flags are present or symptoms persist beyond 4 to 6 weeks.\n\nTREATMENT:\nConservative management resolves symptoms in approximately 80 to 90% of patients and includes NSAIDs, short-course oral corticosteroids for severe radicular pain, cervical physical therapy emphasizing postural correction and nerve gliding exercises, and activity modification. Cervical epidural steroid injections are considered for persistent radicular pain unresponsive to conservative measures. Surgical decompression (anterior cervical discectomy and fusion or posterior foraminotomy) is reserved for progressive neurological deficits, myelopathy, or refractory symptoms after adequate conservative treatment.\n\nKEY LEARNING POINTS:\nA positive Spurling's test is highly specific for cervical radiculopathy and indicates the neck, not the shoulder, is the source of pain. Full painless shoulder ROM with radicular arm symptoms on Spurling's test effectively rules out primary shoulder pathology. Conservative management with NSAIDs, physical therapy, and activity modification resolves approximately 80 to 90% of cervical radiculopathy cases."
  },
  {
    "id": 118,
    "categoryId": 11,
    "question": "A 24-year-old presents with depression. Before starting an SSRI, which screening question is CRITICAL to prevent a manic episode?",
    "options": [
      "A) 'Do you hear voices?'",
      "B) 'Have you ever had periods where you felt no need for sleep and had racing thoughts?'",
      "C) 'Do you have anxiety?'",
      "D) 'Do you drink alcohol?'"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B ('Have you ever had periods where you felt no need for sleep and had racing thoughts?').\n\nCLINICAL REASONING:\nBefore initiating an SSRI for depression, screening for a history of manic or hypomanic episodes is essential because antidepressant monotherapy in undiagnosed bipolar disorder can precipitate a manic episode, rapid cycling, or mixed states per Harrison's Principles of Internal Medicine and UpToDate. Approximately 40% of patients with bipolar disorder initially present with a depressive episode (bipolar depression is clinically indistinguishable from unipolar MDD on cross-sectional assessment), and the average delay from symptom onset to correct bipolar diagnosis is 5 to 10 years per the Cleveland Clinic.\n\nSCREENING APPROACH:\nAsking about prior periods of markedly decreased need for sleep (not insomnia, but feeling rested after 3 to 4 hours), racing thoughts, pressured speech, grandiosity, increased goal-directed activity, and impulsive risk-taking behavior (spending sprees, sexual indiscretions, reckless driving) screens for DSM-5 criteria for manic or hypomanic episodes per UpToDate. The Mood Disorder Questionnaire (MDQ) is a validated self-report screening instrument with 13 yes/no items covering manic symptoms that can be administered in primary care per Harvard Health and the Mayo Clinic.\n\nCONSEQUENCES OF MISSED DIAGNOSIS:\nSSRI monotherapy in bipolar disorder activates the serotonergic system without the mood-stabilizing protection of lithium, valproate, or a second-generation antipsychotic, creating a risk of switching from depression into mania (estimated at 10 to 25% with SSRI monotherapy) per Harrison's Principles of Internal Medicine. Antidepressant-induced mania can be severe, with psychotic features, dangerous impulsivity, and hospitalization per UpToDate. The correct approach to bipolar depression is mood stabilizer-based therapy (lithium, lamotrigine, quetiapine, or lurasidone) per the Cleveland Clinic.\n\nKEY LEARNING POINTS:\nScreening for prior manic or hypomanic episodes is essential before starting any antidepressant because SSRI monotherapy can precipitate mania in undiagnosed bipolar disorder (10 to 25% switch rate). Approximately 40% of bipolar patients first present with depression, and the average diagnostic delay is 5 to 10 years. Decreased need for sleep with racing thoughts is the most sensitive screening question for prior mania."
  },
  {
    "id": 119,
    "categoryId": 1,
    "question": "According to the 2018 AHA Guidelines, in a patient with Diabetes aged 40-75, regardless of their 10-year risk score, what is the recommendation?",
    "options": [
      "A) Start Moderate-Intensity Statin",
      "B) Start High-Intensity Statin",
      "C) No statin unless LDL > 190",
      "D) Calculate risk score first"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Start Moderate-Intensity Statin).\n\nCLINICAL REASONING:\nThe 2018 ACC/AHA Cholesterol Guidelines identify diabetes mellitus (type 1 or type 2) in patients aged 40 to 75 as a statin benefit group that warrants at least moderate-intensity statin therapy regardless of the calculated 10-year ASCVD risk score per Harrison's Principles of Internal Medicine. This recommendation reflects the strong and consistent evidence that diabetes is an independent and powerful risk factor for ASCVD, and that statin therapy reduces cardiovascular events in diabetic patients across a wide range of baseline LDL levels per UpToDate.\n\nGUIDELINE FRAMEWORK:\nFor diabetic patients aged 40 to 75 without additional risk enhancers or established ASCVD, moderate-intensity statin therapy (targeting a 30 to 49% LDL reduction) is the baseline recommendation per the Cleveland Clinic. High-intensity statin therapy (targeting 50% or greater LDL reduction) is recommended when diabetes is accompanied by multiple ASCVD risk enhancers such as long duration of diabetes (10 or more years for type 2, 20 or more years for type 1), albuminuria (30 mg/g or greater), eGFR less than 60, retinopathy, neuropathy, or ABI less than 0.9 per UpToDate. The Cholesterol Treatment Trialists meta-analysis of over 18,000 diabetic patients across 14 randomized trials demonstrated a 21% relative risk reduction in major vascular events per 1 mmol/L (39 mg/dL) LDL reduction with statin therapy per Harrison's Principles of Internal Medicine.\n\nKEY LEARNING POINTS:\nDiabetes aged 40 to 75 is an automatic indication for at least moderate-intensity statin therapy regardless of the 10-year ASCVD risk score. Escalation to high-intensity statin is indicated when additional risk enhancers are present (long diabetes duration, albuminuria, retinopathy, low eGFR). The recommendation is based on the consistent 21% relative risk reduction in major vascular events per 39 mg/dL LDL lowering demonstrated in diabetic patients."
  },
  {
    "id": 120,
    "categoryId": 4,
    "question": "When counseling a patient on obesity, the 'Set Point Theory' explains why:",
    "options": [
      "A) Patients lack willpower",
      "B) Metabolic rate slows down (adaptive thermogenesis) as weight is lost to defend the higher weight",
      "C) Exercise is useless",
      "D) Genetics are the only factor"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Metabolic rate slows down via adaptive thermogenesis as weight is lost, defending the higher weight).\n\nPATHOPHYSIOLOGY:\nThe set point theory of body weight posits that the hypothalamus functions as a body weight thermostat, actively defending a biologically determined weight range through coordinated adjustments in energy expenditure, appetite, and neuroendocrine signaling. When body weight falls below this defended set point, the hypothalamus interprets the weight loss as a starvation threat and activates potent compensatory mechanisms to restore the lost weight. The central mediator of this defense system is leptin, an adipokine secreted by adipose tissue in proportion to fat mass. As weight is lost and fat stores decrease, circulating leptin levels fall dramatically, signaling the hypothalamus to initiate a coordinated counter-regulatory response. Reduced leptin activates orexigenic (appetite-stimulating) pathways via neuropeptide Y and agouti-related peptide neurons in the arcuate nucleus while suppressing anorexigenic (appetite-reducing) pathways via proopiomelanocortin neurons. Simultaneously, ghrelin, a hunger-stimulating hormone secreted by the stomach, increases significantly following weight loss, further amplifying appetite drive. The metabolic component of this defense is adaptive thermogenesis, a reduction in resting energy expenditure that exceeds what would be predicted by the decrease in lean and fat mass alone. Research from the landmark study of The Biggest Loser contestants published in the journal Obesity (Fothergill et al., 2016) demonstrated that resting metabolic rate decreased by an average of approximately 500 kilocalories per day beyond what was predicted by body composition changes, and this metabolic adaptation persisted for at least 6 years after weight loss, even in participants who had regained most of their weight.\n\nCLINICAL EVIDENCE:\nThe biological defense of the set point has been validated by multiple lines of evidence. The Leibel and Rosenbaum studies at Columbia University, published in the New England Journal of Medicine (1995) and the Journal of Clinical Investigation, demonstrated that a 10% reduction in body weight produces a 20 to 25% decrease in total energy expenditure, with the disproportionate reduction attributable to increased skeletal muscle work efficiency (muscles perform the same physical tasks using fewer calories), reduced sympathetic nervous system activity, and decreased thyroid hormone-mediated thermogenesis. These adaptations create an energy gap of 200 to 400 kilocalories per day that the individual must perpetually overcome through conscious dietary restriction to maintain the reduced weight. This biological reality explains why the majority of individuals who lose weight through caloric restriction regain the weight within 3 to 5 years, not because of inadequate willpower, but because they are fighting sustained neurohormonal opposition from a system evolved to prevent starvation.\n\nCLINICAL APPLICATION:\nUnderstanding the set point theory has direct clinical implications for how primary care providers counsel patients on weight management. First, framing weight regain as a biological process rather than a personal failure reduces the stigma and self-blame that undermine long-term adherence to weight management strategies. The Obesity Medicine Association and the Endocrine Society emphasize that obesity is a chronic, relapsing neurohormonal disease requiring sustained treatment rather than a behavioral deficiency resolved by short-term dieting. Second, this understanding supports the rationale for pharmacotherapy. GLP-1 receptor agonists (semaglutide, tirzepatide) directly counteract the compensatory hormonal response by reducing appetite through central satiety signaling, and studies have demonstrated significant weight regain upon drug discontinuation, consistent with the set point defense reasserting itself. Third, bariatric surgery achieves sustained weight loss in part because it alters gut hormone profiles (increasing GLP-1 and PYY while reducing ghrelin), effectively resetting rather than merely opposing the defended weight set point. Fourth, exercise, while contributing modestly to acute caloric deficit, may help attenuate the metabolic adaptation by preserving lean mass and maintaining resting metabolic rate.\n\nKEY LEARNING POINTS:\nThe set point theory explains weight regain as a biological defense mediated by the hypothalamus through falling leptin, rising ghrelin, and adaptive thermogenesis that reduces resting metabolic rate by up to 500 kilocalories per day beyond what body composition changes predict. This metabolic adaptation persists for years after weight loss, requiring permanent behavioral or pharmacologic strategies to counteract. Counseling patients that weight regain is driven by neurobiology rather than willpower failure reduces stigma and supports adherence to evidence-based long-term weight management including pharmacotherapy and bariatric surgery when indicated."
  },
  {
    "id": 121,
    "categoryId": 7,
    "question": "A 52-year-old construction worker presents with right low back pain radiating down the right buttock, posterior thigh, and into the calf. What is the most likely diagnosis?",
    "options": [
      "A) Lumbar muscle strain",
      "B) Lumbar radiculopathy (sciatica) from disc herniation",
      "C) Hip osteoarthritis",
      "D) Peripheral arterial disease"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Lumbar radiculopathy/sciatica from disc herniation).\n\nPATHOPHYSIOLOGY:\nLumbar disc herniation occurs when the nucleus pulposus protrudes through a weakened annulus fibrosus, typically in a posterolateral direction where the annulus is thinnest. The L4-L5 and L5-S1 levels account for over 90% of lumbar herniations. When herniated disc material compresses or inflames an adjacent nerve root, radiculopathy results. The sciatic nerve, formed from L4-S3 roots, is the largest nerve in the body and travels through the buttock and down the posterior thigh, explaining the characteristic pain distribution. Construction work involving repetitive bending, lifting, and twisting accelerates disc degeneration and increases herniation risk.\n\nCLINICAL PRESENTATION:\nThe hallmark of lumbar radiculopathy is pain radiating below the knee in a dermatomal pattern, distinguishing it from referred pain of musculoskeletal origin which rarely extends past the knee. L5 radiculopathy causes pain radiating to the lateral leg and dorsum of the foot with weakness of ankle dorsiflexion and great toe extension. S1 radiculopathy produces pain down the posterior calf to the lateral foot with weakness of ankle plantarflexion and diminished Achilles reflex. The straight leg raise test, positive when leg elevation between 30-70 degrees reproduces radicular leg pain, has 91% sensitivity for disc herniation.\n\nMANAGEMENT:\nMost lumbar radiculopathy resolves with conservative management over 6-12 weeks. First-line treatment includes NSAIDs, activity modification (avoiding bed rest), and physical therapy emphasizing core stabilization. Red flags requiring urgent imaging and referral include cauda equina syndrome (saddle anesthesia, urinary retention, bilateral weakness), progressive motor deficit, or intractable pain despite conservative care.\n\nKEY LEARNING POINTS:\nRadicular pain radiates below the knee in a dermatomal distribution, while musculoskeletal back pain rarely extends past the knee. The straight leg raise test (30-70 degrees reproducing leg pain) has 91% sensitivity for disc herniation. Most cases resolve conservatively; urgent referral is needed for cauda equina syndrome or progressive neurologic deficit."
  },
  {
    "id": 122,
    "categoryId": 11,
    "question": "An adult patient requests stimulants for ADHD. He reports symptoms started 2 years ago after a job change. Can you diagnose ADHD?",
    "options": [
      "A) Yes, adult onset is common",
      "B) No, symptoms MUST be present prior to age 12",
      "C) Yes, if the job is demanding",
      "D) No, stimulants are illegal for adults"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (No, symptoms must be present prior to age 12).\n\nDIAGNOSTIC CRITERIA:\nThe DSM-5 requires that several inattentive or hyperactive-impulsive symptoms be present prior to age 12 for a diagnosis of attention-deficit/hyperactivity disorder (ADHD) per Harrison's Principles of Internal Medicine and UpToDate. This criterion reflects the neurodevelopmental nature of ADHD: it originates from differences in brain maturation (particularly prefrontal cortex development, catecholamine signaling, and fronto-striatal-cerebellar circuitry) that are present from early childhood, even if the functional impairment becomes more apparent later in life per the Cleveland Clinic.\n\nCLINICAL SIGNIFICANCE:\nThe age-of-onset criterion is critical for distinguishing genuine ADHD from other conditions that mimic ADHD symptoms in adulthood per the Mayo Clinic. New-onset attention difficulties, distractibility, and restlessness beginning in adulthood (as in this case, where symptoms started 2 years ago with a job change) are more likely attributable to anxiety disorders, depression, sleep disorders (obstructive sleep apnea), substance use, thyroid dysfunction, or adjustment to increased cognitive demands per UpToDate. These conditions require different treatment approaches and do not warrant stimulant medication per Harvard Health.\n\nADULT ADHD EVALUATION:\nAdults presenting for ADHD evaluation should undergo a comprehensive assessment including detailed developmental history (ideally corroborated by parents, school records, or childhood report cards), screening for psychiatric comorbidities (anxiety, depression, substance use), sleep assessment, thyroid function testing, and validated rating scales (Adult ADHD Self-Report Scale, ASRS) per Harrison's Principles of Internal Medicine. Approximately 60% of children with ADHD continue to have impairing symptoms into adulthood per UpToDate. First-line pharmacotherapy for confirmed adult ADHD is stimulant medication (methylphenidate or amphetamine) with non-stimulant alternatives (atomoxetine, bupropion, guanfacine) for patients with contraindications per the Cleveland Clinic.\n\nKEY LEARNING POINTS:\nADHD diagnosis requires symptom onset prior to age 12 per DSM-5, reflecting its neurodevelopmental origin. Adult-onset attention difficulties are more likely anxiety, depression, sleep disorders, or thyroid dysfunction and require different treatment. Approximately 60% of childhood ADHD persists into adulthood, and comprehensive evaluation including developmental history is essential before prescribing stimulants."
  },
  {
    "id": 123,
    "categoryId": 4,
    "question": "A 52-year-old female with severe hot flashes (Vasomotor Symptoms) wants HRT. She has no uterus (Hysterectomy). What is the preferred regimen?",
    "options": [
      "A) Estrogen + Progesterone",
      "B) Estrogen Only",
      "C) Progesterone Only",
      "D) Testosterone"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Estrogen Only).\n\nPATHOPHYSIOLOGY:\nMenopausal vasomotor symptoms (hot flashes, night sweats) result from estrogen withdrawal in the hypothalamus, which disrupts the thermoregulatory center in the preoptic area. Declining estrogen levels narrow the thermoneutral zone, the range of core body temperature within which neither sweating nor shivering is triggered, from a normal width of approximately 0.4 degrees Celsius to nearly zero. This means that minor fluctuations in core temperature that would normally be tolerated instead trigger inappropriate heat-dissipation responses including peripheral vasodilation, diaphoresis, and the subjective sensation of intense warmth. These episodes occur in up to 80% of perimenopausal and postmenopausal women and can persist for a median of 7 to 10 years per data from the Study of Women's Health Across the Nation (SWAN) published in JAMA Internal Medicine. Estrogen replacement restores the thermoneutral zone width and is the most effective treatment for vasomotor symptoms, reducing hot flash frequency by 75 to 95% according to Cochrane meta-analysis data.\n\nCLINICAL REASONING:\nThe critical principle governing hormone replacement therapy regimen selection is whether the patient has an intact uterus. In women with an intact uterus, unopposed estrogen stimulates endometrial proliferation and significantly increases the risk of endometrial hyperplasia and endometrial adenocarcinoma, as demonstrated by multiple studies including data from the Women's Health Initiative (WHI). Therefore, progesterone must be co-administered to induce secretory transformation and periodic shedding of the endometrium, protecting against estrogen-driven malignancy. However, in women who have undergone hysterectomy, this endometrial protection is unnecessary because the target organ for estrogen-induced carcinogenesis has been removed. Furthermore, the addition of progesterone carries its own risks. The WHI estrogen-plus-progestin arm (published in JAMA 2002) demonstrated a statistically significant increase in invasive breast cancer (hazard ratio 1.26) in women receiving combined conjugated equine estrogen plus medroxyprogesterone acetate. In contrast, the WHI estrogen-only arm (published in JAMA 2004) in women with prior hysterectomy showed no increase in breast cancer risk, and extended follow-up data published in The Lancet suggested a possible reduction in breast cancer risk with estrogen alone. This differential risk is attributed to the proliferative effects of synthetic progestins on breast tissue.\n\nTREATMENT:\nFor this post-hysterectomy patient with bothersome vasomotor symptoms, systemic estrogen-only therapy is the preferred regimen. Options include oral conjugated equine estrogen (0.625 mg daily), oral estradiol (0.5 to 2 mg daily), or transdermal estradiol (0.025 to 0.1 mg patch applied once or twice weekly). Transdermal estrogen is preferred over oral formulations in women with elevated cardiovascular risk, hypertriglyceridemia, obesity, or history of venous thromboembolism because it avoids first-pass hepatic metabolism and does not increase clotting factor production, SHBG synthesis, or triglyceride levels. The lowest effective dose for the shortest necessary duration remains the guiding principle, though the AMS, Endocrine Society, and NAMS 2022 position statement emphasize that duration should be individualized based on ongoing symptom burden and risk-benefit assessment rather than applying arbitrary time limits. Contraindications to systemic estrogen therapy include unexplained vaginal bleeding, active or history of breast cancer, active liver disease, history of venous thromboembolism or stroke, and known thrombophilia.\n\nKEY LEARNING POINTS:\nProgesterone is added to hormone replacement therapy solely to protect the endometrium from estrogen-driven hyperplasia and cancer; when the uterus has been removed, progesterone is unnecessary and adds breast cancer risk without benefit. The WHI estrogen-only arm showed no increase in breast cancer, while the estrogen-plus-progestin arm demonstrated increased breast cancer risk. Transdermal estrogen is preferred over oral formulations in patients with elevated cardiovascular or thrombotic risk because it avoids first-pass hepatic effects."
  },
  {
    "id": 124,
    "categoryId": 14,
    "question": "The 'Ugly Duckling Sign' refers to:",
    "options": [
      "A) A mole that is slightly lighter-colored than others",
      "B) A mole that looks different/stands out compared to the patient's other nevi",
      "C) A mole on the foot",
      "D) A mole that is slightly smaller than others"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (A mole that looks different from the patient's other nevi).\n\nCLINICAL SIGNIFICANCE:\nThe Ugly Duckling sign is a clinical screening strategy for melanoma detection based on the principle that an individual's benign nevi tend to share a common morphologic pattern in terms of size, shape, and color. Most patients produce one or two predominant nevus types reflecting their genetic background and sun exposure history. A lesion that deviates significantly from this personal baseline, the mole that does not resemble its neighbors, should raise suspicion for melanoma even if it does not meet all formal ABCDE criteria per UpToDate and AAD guidelines.\n\nDIAGNOSTIC VALUE:\nThe Ugly Duckling sign was formally described by Grob and Bonerandi and has been validated as a complementary screening tool alongside the ABCDE criteria. Its particular value lies in detecting melanomas with atypical morphology, including small-diameter melanomas (less than 6mm), amelanotic melanomas that lack typical dark pigmentation, and nodular melanomas that may appear symmetric and well-bordered per review in the Journal of the American Academy of Dermatology. In patients with numerous nevi or dysplastic nevus syndrome, where many individual lesions may meet some ABCDE criteria, the Ugly Duckling approach helps identify the single outlier that warrants biopsy.\n\nCLINICAL APPLICATION:\nDuring a full skin examination, the clinician should first observe the overall pattern of the patient's nevi before evaluating individual lesions. The lesion that breaks the pattern, whether by being darker, larger, more irregular, or simply morphologically distinct, merits the closest scrutiny and lowest threshold for biopsy per Mayo Clinic dermatology guidance. Patient education on self-monitoring using the Ugly Duckling concept improves early detection, particularly for melanomas arising in patients with many moles.\n\nKEY LEARNING POINTS:\nThe Ugly Duckling sign identifies melanoma by detecting the nevus that deviates from the patient's own overall mole pattern, complementing the ABCDE criteria. It is especially useful for detecting small-diameter, amelanotic, and nodular melanomas that may not meet traditional screening thresholds. During skin examinations, observing the overall nevus pattern before evaluating individual lesions improves melanoma detection sensitivity."
  },
  {
    "id": 125,
    "categoryId": 4,
    "question": "Which two classes of Diabetes medications are FDA approved to reduce the progression of Diabetic Nephropathy (CKD)?",
    "options": [
      "A) Metformin and Sulfonylureas",
      "B) SGLT2 Inhibitors and GLP-1 Agonists",
      "C) Insulin and Pioglitazone",
      "D) DPP-4 Inhibitors and Meglitinides"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (SGLT2 Inhibitors and GLP-1 Agonists).\n\nPATHOPHYSIOLOGY:\nDiabetic kidney disease is the leading cause of end-stage renal disease worldwide, affecting approximately 30 to 40% of patients with diabetes according to data from the CDC and Harrison's Principles of Internal Medicine. The pathogenesis begins with hyperglycemia-induced glomerular hyperfiltration. Elevated glucose increases sodium-glucose cotransport in the proximal tubule, enhancing sodium and glucose reabsorption and reducing sodium delivery to the macula densa. The macula densa interprets this reduced sodium delivery as a signal of decreased effective circulating volume and activates tubuloglomerular feedback, dilating the afferent arteriole and increasing intraglomerular pressure. This sustained glomerular hypertension, compounded by efferent arteriolar constriction from activated renin-angiotensin-aldosterone system signaling, produces mechanical shear stress on podocytes and the glomerular basement membrane. Simultaneously, advanced glycation end-products, protein kinase C activation, and reactive oxygen species drive mesangial matrix expansion, basement membrane thickening, and tubulointerstitial fibrosis. The clinical progression follows a characteristic trajectory from glomerular hyperfiltration (elevated GFR) through microalbuminuria (30 to 300 mg/day), macroalbuminuria (greater than 300 mg/day), declining GFR, and ultimately end-stage renal disease requiring dialysis or transplantation.\n\nSGLT2 INHIBITORS AND RENAL PROTECTION:\nSGLT2 inhibitors provide nephroprotection through a unique hemodynamic mechanism that directly addresses the proximal tubular pathology driving glomerular hyperfiltration. By blocking the SGLT2 cotransporter, these agents reduce proximal tubular sodium and glucose reabsorption, restoring sodium delivery to the macula densa. The macula densa responds by constricting the afferent arteriole via tubuloglomerular feedback, reducing intraglomerular pressure and relieving the mechanical stress on podocytes and the filtration barrier. This results in an initial predictable dip in eGFR of approximately 3 to 5 mL/min (reflecting the reduction in hyperfiltration, not nephrotoxicity), followed by long-term stabilization of kidney function. The landmark CREDENCE trial (NEJM 2019) demonstrated that canagliflozin reduced the composite endpoint of end-stage kidney disease, doubling of serum creatinine, or renal death by 34% in patients with type 2 diabetes and albuminuric CKD. The DAPA-CKD trial (NEJM 2020) showed that dapagliflozin reduced the composite of sustained eGFR decline, end-stage kidney disease, or renal death by 44%, with benefits extending to patients without diabetes. The EMPA-KIDNEY trial (NEJM 2023) confirmed that empagliflozin reduced kidney disease progression by 28% across a broad CKD population.\n\nGLP-1 RECEPTOR AGONISTS AND RENAL PROTECTION:\nGLP-1 receptor agonists provide renal protection through complementary mechanisms that are distinct from and additive to SGLT2 inhibitor effects. These agents reduce albuminuria and slow eGFR decline through anti-inflammatory effects (reducing NF-kB-mediated renal inflammation and oxidative stress), direct natriuretic actions in the proximal tubule, weight loss, blood pressure reduction, and improved glycemic control. The FLOW trial (NEJM 2024), the first dedicated renal outcomes trial for a GLP-1 receptor agonist, demonstrated that subcutaneous semaglutide reduced the risk of the composite kidney endpoint (sustained eGFR decline of 50% or more, eGFR below 15, dialysis initiation, or renal death) by 24% in patients with type 2 diabetes and CKD. The LEADER, SUSTAIN-6, and REWIND cardiovascular outcomes trials had previously shown significant reductions in the secondary renal composite endpoints for liraglutide, semaglutide, and dulaglutide respectively.\n\nCLINICAL APPLICATION:\nThe ADA 2024 Standards of Care and KDIGO 2024 guidelines recommend that all patients with type 2 diabetes and CKD receive an SGLT2 inhibitor and consider a GLP-1 receptor agonist as foundational kidney-protective therapy, independent of glycemic control needs. These agents should be used in addition to maximally tolerated renin-angiotensin system blockade (ACE inhibitor or ARB) and the nonsteroidal mineralocorticoid receptor antagonist finerenone, which demonstrated independent renal and cardiovascular benefit in the FIDELIO-DKD and FIGARO-DKD trials. The initial eGFR dip seen with SGLT2 inhibitors should not prompt discontinuation, as it reflects beneficial hemodynamic correction.\n\nKEY LEARNING POINTS:\nSGLT2 inhibitors protect the kidney by restoring tubuloglomerular feedback and reducing intraglomerular pressure, with CREDENCE, DAPA-CKD, and EMPA-KIDNEY trials demonstrating 28 to 44% reductions in kidney disease progression. The FLOW trial established semaglutide as the first GLP-1 agonist with a dedicated renal outcome showing a 24% reduction in CKD progression. Both classes are recommended for all patients with type 2 diabetes and CKD regardless of A1c level, in combination with renin-angiotensin system blockade."
  },
  {
    "id": 126,
    "categoryId": 1,
    "question": "A patient in clinic has a BP of 190/110. He is asymptomatic (no chest pain, vision changes, or headache). How should you manage this?",
    "options": [
      "A) Send to ER immediately",
      "B) Give Nifedipine immediate release",
      "C) Adjust oral meds and recheck in 48-72 hours",
      "D) Administer IV Labetalol"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Adjust oral medications and recheck in 48 to 72 hours).\n\nCLINICAL REASONING:\nThis patient has a markedly elevated blood pressure of 190/110 but is completely asymptomatic with no evidence of end-organ damage (no chest pain, no headache, no visual changes, no neurologic deficits, no dyspnea) per Harrison's Principles of Internal Medicine. This is classified as a hypertensive urgency (severely elevated BP without acute end-organ damage), which is fundamentally different from a hypertensive emergency (severely elevated BP with evidence of acute target organ damage such as hypertensive encephalopathy, acute MI, aortic dissection, acute heart failure, eclampsia, or acute renal failure) per UpToDate.\n\nMANAGEMENT DISTINCTION:\nHypertensive urgencies are managed with adjustment or intensification of oral antihypertensive medications and close outpatient follow-up within 48 to 72 hours, not with acute IV therapy or emergency department referral per the Cleveland Clinic. Rapid reduction of blood pressure in the absence of end-organ damage can actually cause harm by inducing cerebral, coronary, or renal hypoperfusion, particularly in patients with chronic hypertension whose autoregulatory curves have shifted rightward per Harrison's Principles of Internal Medicine. The goal is gradual BP reduction over 24 to 48 hours per the Mayo Clinic.\n\nCRITICAL DISTINCTION:\nSublingual or immediate-release nifedipine is specifically contraindicated in hypertensive urgencies because it causes precipitous, unpredictable blood pressure drops that have been associated with stroke and myocardial infarction per UpToDate. IV labetalol and other parenteral agents are reserved for hypertensive emergencies where acute end-organ damage demands rapid (but controlled) blood pressure reduction in an ICU setting per Harrison's Principles of Internal Medicine.\n\nKEY LEARNING POINTS:\nAsymptomatic severe hypertension without end-organ damage (hypertensive urgency) is managed by adjusting oral medications and rechecking BP within 48 to 72 hours, not with IV therapy or ER referral. Rapid BP reduction in the absence of end-organ damage risks cerebral, coronary, and renal hypoperfusion. Immediate-release nifedipine is contraindicated due to unpredictable precipitous drops."
  },
  {
    "id": 127,
    "categoryId": 7,
    "question": "Which physical exam test is most sensitive for an ACL tear?",
    "options": [
      "A) Anterior Drawer",
      "B) Lachman Test",
      "C) McMurray Test",
      "D) Valgus Stress"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Lachman Test).\n\nPATHOPHYSIOLOGY:\nThe anterior cruciate ligament is the primary restraint against anterior translation of the tibia relative to the femur. ACL rupture typically occurs through a noncontact pivoting mechanism during deceleration, cutting, or landing, generating excessive anterior tibial translation and internal rotation that exceeds the ligament's tensile strength. The injury produces immediate hemarthrosis (within 2 hours) due to disruption of the ligament's blood supply from the middle genicular artery. Once torn, the ACL has virtually no capacity for spontaneous healing because its intra-articular, synovial fluid-bathed environment prevents clot formation and organized repair.\n\nCLINICAL EXAMINATION:\nThe Lachman test is the most sensitive physical examination maneuver for ACL rupture, with a sensitivity of approximately 85 to 95% compared to 40 to 60% for the anterior drawer test. The Lachman test is performed with the knee in 20 to 30 degrees of flexion while the examiner stabilizes the distal femur with one hand and applies an anteriorly directed force to the proximal tibia with the other. A positive test demonstrates increased anterior tibial translation with a soft or absent endpoint compared to the contralateral knee. The anterior drawer test, performed at 90 degrees of knee flexion, is significantly less sensitive in the acute setting because the hamstrings are placed on tension at this flexion angle, and reflexive hamstring guarding effectively splints the tibia posteriorly and masks the anterior laxity. Additionally, at 90 degrees the posterior horn of the medial meniscus acts as a secondary restraint to anterior translation, further reducing the test's sensitivity. The pivot shift test is the most specific examination maneuver for ACL insufficiency and reproduces the rotational instability that patients experience functionally, but it requires a relaxed patient and is often difficult to perform in the acute setting due to guarding and apprehension.\n\nDIAGNOSIS AND MANAGEMENT:\nMRI is the gold standard imaging study for confirming ACL rupture and evaluating associated injuries including meniscal tears (present in over 50% of acute ACL injuries), bone bruises, and collateral ligament sprains. Initial management includes rest, ice, compression, elevation, and early range of motion exercises to prevent arthrofibrosis. Surgical ACL reconstruction is recommended for patients with functional instability, high activity demands, or concomitant repairable meniscal tears, as the unstable knee accelerates meniscal and chondral degeneration over time.\n\nKEY LEARNING POINTS:\nThe Lachman test is the most sensitive bedside test for ACL rupture at 85 to 95% sensitivity, performed at 20 to 30 degrees of flexion to eliminate hamstring guarding. The anterior drawer test is significantly less sensitive in the acute setting because hamstring tension at 90 degrees of flexion masks anterior tibial translation. MRI confirms the diagnosis and evaluates associated meniscal and ligamentous injuries that are present in over 50% of cases."
  },
  {
    "id": 128,
    "categoryId": 3,
    "question": "A 45-year-old obese male has elevated ALT/AST. Hepatitis panel is negative. Ultrasound shows fatty liver. What is the next calculation you should perform?",
    "options": [
      "A) BMI",
      "B) FIB-4 Index",
      "C) GFR",
      "D) ASCVD Risk"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (FIB-4 Index).\n\nPATHOPHYSIOLOGY:\nMetabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD) affects approximately 30% of the global population and represents a spectrum from simple steatosis to steatohepatitis (MASH), fibrosis, cirrhosis, and hepatocellular carcinoma. The critical prognostic determinant is not steatosis or inflammation but rather the degree of hepatic fibrosis, as fibrosis stage is the strongest predictor of liver-related morbidity and mortality.\n\nCLINICAL REASONING:\nThe FIB-4 index is a validated, non-invasive fibrosis assessment tool calculated using age, AST, ALT, and platelet count. It is recommended as the initial screening test by the AASLD and AGA because it is inexpensive, widely available, and effectively stratifies patients into low-risk (score less than 1.3), indeterminate (1.3-2.67), and high-risk (greater than 2.67) categories. Patients in the low-risk category have a greater than 90% negative predictive value for advanced fibrosis and can be managed in primary care. Indeterminate and high-risk patients require secondary assessment with elastography (FibroScan or MR elastography) or referral to hepatology.\n\nMANAGEMENT IMPLICATIONS:\nIdentifying fibrosis stage guides management intensity. Patients with advanced fibrosis require hepatocellular carcinoma surveillance every 6 months with ultrasound and alpha-fetoprotein. Weight loss of 7-10% of body weight improves steatohepatitis and can reverse fibrosis. Resmetirom (a thyroid hormone receptor beta agonist) is the first FDA-approved medication specifically for MASH with moderate-to-advanced fibrosis.\n\nKEY LEARNING POINTS:\nFIB-4 is the recommended first-line non-invasive test for fibrosis staging in MASLD, using age, AST, ALT, and platelets. A FIB-4 below 1.3 has greater than 90% negative predictive value for advanced fibrosis. Fibrosis stage, not steatosis, is the strongest predictor of liver-related outcomes. Weight loss of 7-10% can reverse steatohepatitis and fibrosis."
  },
  {
    "id": 129,
    "categoryId": 1,
    "question": "Phentermine is FDA approved for short-term use. It is chemically similar to amphetamines and should be avoided in patients with:",
    "options": [
      "A) Hypothyroidism",
      "B) Uncontrolled Hypertension or history of Arrhythmia",
      "C) Depression",
      "D) Osteoarthritis"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Uncontrolled Hypertension or history of Arrhythmia).\n\nPATHOPHYSIOLOGY:\nPhentermine is a sympathomimetic amine structurally related to amphetamine that works primarily by stimulating norepinephrine release in the hypothalamus, activating the sympathetic nervous system and suppressing appetite per Harrison's Principles of Internal Medicine and UpToDate. This same catecholaminergic mechanism that produces weight loss also raises heart rate, increases blood pressure, and elevates myocardial oxygen demand, which can precipitate arrhythmias in susceptible individuals per the Cleveland Clinic.\n\nCARDIOVASCULAR CONTRAINDICATIONS:\nBecause of its sympathomimetic properties, phentermine is contraindicated in patients with cardiovascular disease including coronary artery disease, heart failure, arrhythmias, and uncontrolled hypertension per the Mayo Clinic and UpToDate. Additional contraindications include hyperthyroidism (which already produces a hyperadrenergic state), glaucoma, history of substance abuse, MAO inhibitor use within 14 days, and pregnancy per Harrison's Principles of Internal Medicine.\n\nCLINICAL USE:\nPhentermine is FDA-approved only for short-term use (up to 12 weeks) as an adjunct to lifestyle modification in patients with BMI 30 or greater, or BMI 27 or greater with weight-related comorbidities per UpToDate and the Cleveland Clinic. It is classified as a DEA Schedule IV controlled substance due to its abuse potential. The combination product phentermine-topiramate (Qsymia) is approved for longer-term use and may provide additional weight loss through topiramate's effects on satiety per the Mayo Clinic.\n\nKEY LEARNING POINTS:\nPhentermine is a sympathomimetic contraindicated in uncontrolled hypertension, arrhythmias, and cardiovascular disease due to its norepinephrine-releasing mechanism that raises heart rate, blood pressure, and arrhythmia risk. It is FDA-approved for short-term use only (12 weeks) and is a Schedule IV controlled substance. Cardiovascular screening before prescribing is essential."
  },
  {
    "id": 130,
    "categoryId": 11,
    "question": "First-line treatment for Chronic Insomnia according to ACP guidelines?",
    "options": [
      "A) Zolpidem (Ambien)",
      "B) Melatonin",
      "C) Trazodone",
      "D) CBT-I (Cognitive Behavioral Therapy for Insomnia)"
    ],
    "correctAnswer": 3,
    "explanation": "CORRECT: D (CBT-I, Cognitive Behavioral Therapy for Insomnia).\n\nGUIDELINE BASIS:\nCognitive Behavioral Therapy for Insomnia (CBT-I) is recommended as first-line treatment for chronic insomnia disorder by the American College of Physicians (ACP 2016), the American Academy of Sleep Medicine (AASM), and the European Sleep Research Society per UpToDate and the Mayo Clinic. These guidelines uniformly prioritize CBT-I over pharmacotherapy because it has equivalent short-term efficacy with superior long-term durability and no risk of medication dependence, tolerance, or adverse effects per Harrison's Principles of Internal Medicine.\n\nCOMPONENTS:\nCBT-I is a structured 6 to 8-session program that addresses the cognitive and behavioral perpetuating factors of chronic insomnia per Harvard Health. Sleep restriction therapy limits time in bed to match actual sleep time, consolidating fragmented sleep and building homeostatic sleep drive. Stimulus control re-establishes the bed as a cue for sleep (bed used only for sleep and sex; leave bed after 20 minutes of wakefulness). Cognitive restructuring addresses maladaptive beliefs about sleep (catastrophizing about consequences of poor sleep). Sleep hygiene education addresses environmental and behavioral factors (consistent wake times, avoiding screens before bed, limiting caffeine) per UpToDate and the Cleveland Clinic.\n\nPHARMACOLOGIC ALTERNATIVES:\nWhen CBT-I is unavailable or insufficient, pharmacologic options include low-dose doxepin (the only FDA-approved medication for sleep maintenance insomnia), suvorexant or lemborexant (dual orexin receptor antagonists), ramelteon (melatonin receptor agonist for sleep onset), and short-term use of Z-drugs (zolpidem, zaleplon, eszopiclone) per UpToDate. Benzodiazepines are not recommended for chronic insomnia due to tolerance, dependence, rebound insomnia, falls in elderly patients, and cognitive impairment per Harrison's Principles of Internal Medicine and the Mayo Clinic.\n\nKEY LEARNING POINTS:\nCBT-I is the ACP and AASM recommended first-line treatment for chronic insomnia, with equivalent short-term efficacy and superior long-term outcomes compared to medications. Its core components are sleep restriction, stimulus control, and cognitive restructuring. Benzodiazepines and Z-drugs are not recommended for chronic insomnia due to dependence, tolerance, and fall risk."
  },
  {
    "id": 131,
    "categoryId": 7,
    "question": "Classic presentation of Plantar Fasciitis includes:",
    "options": [
      "A) Pain at night while sleeping",
      "B) Pain with the first few steps in the morning (Post-static dyskinesia)",
      "C) Numbness in the toes",
      "D) Swelling of the ankle"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Pain with the first few steps in the morning).\n\nPATHOPHYSIOLOGY:\nPlantar fasciitis is a degenerative enthesopathy of the plantar fascia at its origin on the medial calcaneal tubercle, driven by repetitive microtrauma that exceeds the tissue's capacity for repair. The plantar fascia is a thick band of connective tissue that spans from the calcaneus to the metatarsal heads, functioning as a static support for the longitudinal arch and as a dynamic windlass mechanism during gait. Histopathologic studies reveal that the condition is primarily degenerative (fasciosis) rather than inflammatory (fasciitis), characterized by collagen disorganization, angiofibroblastic hyperplasia, and mucoid degeneration at the calcaneal enthesis. Risk factors include obesity, prolonged standing occupations, pes planus or pes cavus foot morphology, Achilles tendon tightness, and sudden increases in weight-bearing activity.\n\nCLINICAL PRESENTATION:\nThe hallmark symptom is sharp, stabbing pain at the medial plantar heel with the first several steps after a period of rest, a phenomenon termed post-static dyskinesia. During sleep or prolonged sitting, the plantar fascia contracts into a shortened position as the ankle assumes a plantarflexed posture. Upon standing, the sudden weight-bearing load stretches the contracted and degenerative fascia across the calcaneal enthesis, producing acute pain. The pain characteristically improves after several minutes of walking as the fascia gradually elongates and accommodates to load, but it worsens again with prolonged standing or at the end of a long day of activity. This pattern of \"start-up pain\" that improves with gentle activity but worsens with sustained loading is highly specific for plantar fasciitis and distinguishes it from calcaneal stress fracture (which worsens progressively with any weight bearing and does not improve with warming up), fat pad atrophy (which produces central rather than medial heel pain), and tarsal tunnel syndrome (which causes burning or tingling in the plantar foot with a positive Tinel sign posterior to the medial malleolus).\n\nTREATMENT:\nFirst-line management includes plantar fascia-specific stretching (pulling the toes into dorsiflexion to engage the windlass mechanism), Achilles tendon stretching, supportive footwear with arch support, avoidance of walking barefoot on hard surfaces, and ice massage using a frozen water bottle rolled under the arch. Night splints maintain the ankle in a neutral or slightly dorsiflexed position during sleep, preventing fascial contracture and reducing morning pain severity. NSAIDs may provide short-term symptomatic relief. Physical therapy emphasizing eccentric loading and intrinsic foot muscle strengthening accelerates recovery. Corticosteroid injection can be considered for refractory cases, though repeated injections carry a risk of plantar fascia rupture and fat pad atrophy. The condition is self-limiting in approximately 80 to 90% of patients within 10 to 12 months with conservative management.\n\nKEY LEARNING POINTS:\nPlantar fasciitis presents with medial heel pain that is worst with the first steps after rest and improves with gentle activity, a pattern called post-static dyskinesia caused by sudden loading of the contracted fascia. The condition is degenerative rather than inflammatory, originating at the plantar fascia enthesis on the medial calcaneal tubercle. Conservative management including stretching, supportive footwear, and night splints resolves symptoms in approximately 80 to 90% of patients."
  },
  {
    "id": 132,
    "categoryId": 4,
    "question": "A patient on a Sulfonylurea (Glipizide) keeps having lows. You switch them to a DPP-4 Inhibitor (Sitagliptin). Why does Sitagliptin NOT cause hypoglycemia?",
    "options": [
      "A) It is weaker",
      "B) It is glucose-dependent",
      "C) It increases glucagon",
      "D) It works on the kidney"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (It is glucose-dependent).\n\nPATHOPHYSIOLOGY:\nThe fundamental difference in hypoglycemia risk between sulfonylureas and DPP-4 inhibitors is explained by the mechanism through which each class stimulates insulin secretion. Sulfonylureas bind to the sulfonylurea receptor (SUR1) on the ATP-sensitive potassium channel (KATP channel) of pancreatic beta cells, forcing the channel closed regardless of the ambient glucose concentration. Channel closure depolarizes the beta-cell membrane, opens voltage-gated calcium channels, and triggers insulin exocytosis independent of whether the blood glucose is elevated, normal, or low. The beta cell is effectively rendered blind to its metabolic environment, secreting insulin constitutively. This glucose-independent insulin secretion is the direct cause of sulfonylurea-induced hypoglycemia, which can be severe and prolonged, particularly with longer-acting agents such as glyburide (whose active metabolites accumulate in renal impairment) and in elderly patients with reduced hepatic clearance and diminished counter-regulatory hormone responses. Sulfonylurea-induced hypoglycemia carries meaningful morbidity including falls, fractures, cardiac arrhythmias, cognitive impairment, and cardiovascular events per data from the ACCORD trial and systematic reviews in The Lancet Diabetes and Endocrinology.\n\nGLUCOSE-DEPENDENT MECHANISM OF DPP-4 INHIBITORS:\nDPP-4 inhibitors (sitagliptin, saxagliptin, linagliptin, alogliptin) exert their effect by inhibiting the enzyme dipeptidyl peptidase-4, which is responsible for the rapid degradation of the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) within 2 to 3 minutes of their secretion from enteroendocrine L-cells and K-cells respectively. By prolonging the half-life of endogenous incretins, DPP-4 inhibitors enhance their physiologic effects on the pancreas. The critical safety feature is that incretin-mediated insulin secretion is inherently glucose-dependent: GLP-1 and GIP potentiate glucose-stimulated insulin secretion by amplifying the beta-cell signaling cascade that is initiated by glucose metabolism itself. When blood glucose is elevated, glucose enters the beta cell, undergoes glycolysis and mitochondrial oxidation, increases the ATP-to-ADP ratio, and partially closes KATP channels. Incretins amplify this existing glucose-driven signal through cAMP and protein kinase A pathways that enhance calcium influx and insulin granule exocytosis. As blood glucose falls toward normal, reduced glucose metabolism lowers the ATP-to-ADP ratio, KATP channels open, and the incretin amplification signal has no substrate to amplify. Insulin secretion therefore decreases proportionally as glucose decreases, creating a self-limiting system that makes clinically significant hypoglycemia virtually impossible with DPP-4 inhibitor monotherapy.\n\nCLINICAL APPLICATION:\nDPP-4 inhibitors are particularly well-suited for elderly patients, patients with renal impairment (linagliptin requires no dose adjustment), and patients with erratic meal patterns or hypoglycemia unawareness, all populations in whom hypoglycemia risk is clinically significant. They are weight-neutral, well-tolerated, and have a favorable side effect profile. However, their glucose-lowering potency is modest (A1c reduction of 0.5 to 0.8%) compared to sulfonylureas (A1c reduction of 1.0 to 1.5%), GLP-1 receptor agonists (1.0 to 2.0%), or SGLT2 inhibitors (0.5 to 1.0%). Importantly, DPP-4 inhibitors should not be used concurrently with GLP-1 receptor agonists, as both classes act through the incretin pathway and provide no additive benefit. The cardiovascular safety of DPP-4 inhibitors has been established as neutral by the TECOS (sitagliptin), EXAMINE (alogliptin), and CARMELINA (linagliptin) trials, though the SAVOR-TIMI 53 trial raised concern about increased heart failure hospitalization with saxagliptin.\n\nKEY LEARNING POINTS:\nSulfonylureas cause hypoglycemia by forcing insulin secretion regardless of glucose concentration through direct KATP channel closure. DPP-4 inhibitors enhance incretin-mediated insulin secretion, which is inherently glucose-dependent because incretins amplify glucose-driven beta-cell signaling rather than initiating it independently. DPP-4 inhibitors are weight-neutral with modest glucose-lowering potency and should not be combined with GLP-1 receptor agonists due to overlapping incretin pathway mechanisms."
  },
  {
    "id": 133,
    "categoryId": 1,
    "question": "Thiazide diuretics (HCTZ/Chlorthalidone) can worsen which three metabolic conditions?",
    "options": [
      "A) Gout, Diabetes, Hypercalcemia",
      "B) Hypothyroidism, Anemia, Lupus",
      "C) Asthma, COPD, GERD",
      "D) Depression, Anxiety, Insomnia"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Gout, Diabetes, Hypercalcemia).\n\nPATHOPHYSIOLOGY:\nThiazide diuretics (hydrochlorothiazide, chlorthalidone) inhibit the sodium-chloride cotransporter (NCC) in the distal convoluted tubule, promoting natriuresis and reducing intravascular volume per Harrison's Principles of Internal Medicine. While effective first-line antihypertensives, their metabolic side effect profile affects three important systems. First, thiazides cause hyperuricemia by competing with uric acid for secretion in the proximal tubule (both use the organic anion transporter OAT1/OAT3) and by increasing proximal tubular uric acid reabsorption secondary to volume contraction, raising serum urate levels and potentially precipitating gout flares in susceptible individuals per UpToDate. Second, thiazides impair glucose tolerance and can worsen or unmask diabetes mellitus through several mechanisms: hypokalemia impairs pancreatic beta-cell insulin secretion, and direct effects on insulin sensitivity and hepatic gluconeogenesis contribute per the Cleveland Clinic. Third, thiazides cause hypercalcemia by enhancing passive calcium reabsorption in the proximal tubule (secondary to volume contraction) and by directly stimulating calcium reabsorption in the distal tubule through upregulation of the TRPV5 calcium channel per Harrison's Principles of Internal Medicine.\n\nCLINICAL APPLICATIONS:\nThe hypercalcemic effect of thiazides is therapeutically exploited in patients with calcium-containing kidney stones (idiopathic hypercalciuria), where thiazides reduce urinary calcium excretion and stone recurrence per the Mayo Clinic. Conversely, thiazides should be avoided in patients with primary hyperparathyroidism where they can mask or worsen hypercalcemia per UpToDate. The metabolic effects are dose-dependent, and current guidelines favor lower doses (chlorthalidone 12.5 to 25 mg, HCTZ 25 mg) that provide antihypertensive benefit with fewer metabolic consequences per the Cleveland Clinic.\n\nKEY LEARNING POINTS:\nThiazide diuretics worsen gout (competitive uric acid secretion blockade), diabetes (hypokalemia-impaired insulin secretion), and hypercalcemia (enhanced distal tubular calcium reabsorption). The hypercalcemic effect is therapeutically useful for calcium kidney stone prevention. These metabolic effects are dose-dependent and minimized with lower doses."
  },
  {
    "id": 134,
    "categoryId": 4,
    "question": "A 27-year-old female with BMI 39 is only having periods every 3-4 months and exhibits some darker chin hair. What is the most likely diagnosis?",
    "options": [
      "A) Hypothyroidism",
      "B) Polycystic Ovary Syndrome (PCOS)",
      "C) Premature ovarian insufficiency",
      "D) Hyperprolactinemia"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Polycystic Ovary Syndrome).\n\nPATHOPHYSIOLOGY:\nPolycystic ovary syndrome is the most common endocrine disorder in women of reproductive age, affecting 6 to 12% of this population according to CDC estimates and data from the Endocrine Society. The pathophysiology centers on a self-reinforcing cycle of insulin resistance and hyperandrogenism. Insulin resistance, present in 50 to 70% of women with PCOS regardless of BMI, produces compensatory hyperinsulinemia that acts on ovarian theca cells to stimulate excess androgen production, particularly testosterone and androstenedione. Hyperinsulinemia simultaneously suppresses hepatic synthesis of sex hormone-binding globulin (SHBG), increasing the fraction of circulating testosterone that is unbound and biologically active. The hyperandrogenic intraovarian environment disrupts normal folliculogenesis: dominant follicle selection fails, and multiple follicles arrest at the antral stage (2 to 9 mm), accumulating peripherally in the ovarian cortex to produce the characteristic ultrasonographic appearance of 12 or more follicles per ovary or ovarian volume exceeding 10 mL. Without dominant follicle maturation and ovulation, the corpus luteum does not form, progesterone is not produced, and the endometrium is exposed to continuous unopposed estrogen, resulting in oligo-amenorrhea and increased risk of endometrial hyperplasia.\n\nCLINICAL REASONING:\nThis patient presents with the classic PCOS triad of obesity (BMI 39), oligomenorrhea (periods every 3 to 4 months indicating oligo-ovulation), and clinical hyperandrogenism (hirsutism with darker chin hair). Diagnosis is established using the Rotterdam Criteria (2003), the most widely accepted diagnostic framework endorsed by the Endocrine Society 2013 Clinical Practice Guideline and ACOG. The Rotterdam Criteria require the presence of at least two of three features after exclusion of other etiologies: oligo-ovulation or anovulation, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology on ultrasound. This patient satisfies two criteria (oligomenorrhea and hirsutism), establishing the diagnosis without requiring ultrasound. Importantly, PCOS is a diagnosis of exclusion, and the workup must rule out thyroid dysfunction (TSH), hyperprolactinemia (prolactin), non-classic congenital adrenal hyperplasia (17-hydroxyprogesterone), and Cushing syndrome (24-hour urinary cortisol or overnight dexamethasone suppression test) before confirming PCOS. Obesity is not a diagnostic criterion; approximately 20 to 30% of women with PCOS have normal BMI (lean PCOS), though obesity exacerbates insulin resistance and worsens the hyperandrogenic phenotype.\n\nTREATMENT:\nManagement of PCOS is multifaceted and addresses the metabolic, reproductive, and dermatologic components of the syndrome. Lifestyle modification is first-line therapy for all patients, as even 5 to 10% weight loss can restore ovulatory cycles, reduce androgen levels, and improve insulin sensitivity per the Endocrine Society guidelines. Combined oral contraceptives are the primary pharmacologic treatment for menstrual irregularity and hyperandrogenism, suppressing ovarian androgen production, increasing SHBG, and providing endometrial protection through regular withdrawal bleeding. Spironolactone (50 to 200 mg daily) is the most commonly used anti-androgen for hirsutism and acne in the United States and requires reliable contraception due to teratogenicity. Metformin improves insulin sensitivity and may restore ovulation in some patients, though it is not first-line for menstrual regulation. For patients seeking fertility, letrozole (an aromatase inhibitor) has replaced clomiphene citrate as the preferred first-line ovulation induction agent based on the NICHD cooperative trial published in the NEJM (2014), which demonstrated higher live birth rates with letrozole. Metabolic screening should include fasting glucose or A1c, lipid panel, and blood pressure assessment at diagnosis and periodically thereafter, given the 4-fold increased risk of type 2 diabetes and elevated cardiovascular risk.\n\nKEY LEARNING POINTS:\nPCOS is diagnosed by the Rotterdam Criteria requiring two of three features (oligo-ovulation, hyperandrogenism, polycystic ovaries) after excluding thyroid disease, hyperprolactinemia, congenital adrenal hyperplasia, and Cushing syndrome. Obesity worsens PCOS but is not a diagnostic criterion, and lean PCOS accounts for 20 to 30% of cases. Letrozole has replaced clomiphene as the preferred first-line ovulation induction agent based on the NICHD trial demonstrating superior live birth rates."
  },
  {
    "id": 135,
    "categoryId": 12,
    "question": "M-CHAT screening for Autism is routinely performed at which well-child checks?",
    "options": [
      "A) 6 and 12 months",
      "B) 18 and 24 months",
      "C) 3 and 4 years",
      "D) Only if symptomatic"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (18 and 24 months).\n\nCLINICAL REASONING:\nThe American Academy of Pediatrics recommends universal autism spectrum disorder screening at the 18-month and 24-month well-child visits using a validated screening tool, specifically the Modified Checklist for Autism in Toddlers, Revised with Follow-Up (M-CHAT-R/F) per the AAP and UpToDate. This timing is strategic because core features of ASD, including deficits in joint attention, social reciprocity, pretend play, and the emergence of restricted or repetitive behaviors, become reliably detectable between 12 and 24 months of age per the CDC. Screening at both time points captures children whose symptoms emerge at different rates across this developmental window and reduces the false-negative rate inherent in single-timepoint screening per Harrison's Principles of Internal Medicine.\n\nTHE M-CHAT-R/F:\nThe M-CHAT-R/F is a two-stage parent-completed screening instrument per UpToDate. The initial screener consists of 20 yes/no questions targeting behaviors associated with ASD (response to name, pointing, interest in other children, imitation, eye contact). Children who screen positive on the initial questionnaire undergo the structured follow-up interview to reduce false positives. The overall positive predictive value of the two-stage M-CHAT-R/F is approximately 50%, meaning that roughly half of children who screen positive will ultimately receive an ASD diagnosis, while others may have other developmental delays that still benefit from early intervention per the Cleveland Clinic.\n\nEARLY IDENTIFICATION AND INTERVENTION:\nThe rationale for early screening is that autism-specific interventions initiated before age 3 produce the most significant improvements in language, cognitive abilities, and adaptive functioning, leveraging the heightened neuroplasticity of the developing brain per the Mayo Clinic. The median age of ASD diagnosis in the United States remains approximately 4 to 5 years, which represents a missed window of optimal intervention for many children. Universal screening at 18 and 24 months aims to close this gap. Developmental surveillance (informal monitoring of milestones and parental concerns) should occur at every well-child visit, and any concern raised by parents, caregivers, or clinicians at any visit should prompt formal evaluation regardless of screening results per the AAP.\n\nKEY LEARNING POINTS:\nUniversal ASD screening with the M-CHAT-R/F occurs at 18 and 24 months per AAP guidelines, timed to when core autism features become reliably detectable. Developmental surveillance should occur at every well-child visit, and parental concerns warrant evaluation regardless of screening results. Early diagnosis enables intervention before age 3, when neuroplasticity offers the greatest potential for developmental gains."
  },
  {
    "id": 136,
    "categoryId": 7,
    "question": "A 70-year-old female has a Vertebral Compression Fracture. Her DEXA T-score is -1.8 (Osteopenia). Does she meet criteria for Osteoporosis treatment?",
    "options": [
      "A) No, she is only osteopenic",
      "B) Yes, this is Clinical Osteoporosis",
      "C) Only if she smokes",
      "D) Wait and repeat DEXA in 2 years"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Yes, this is Clinical Osteoporosis).\n\nPATHOPHYSIOLOGY:\nOsteoporosis is a systemic skeletal disorder characterized by low bone mass and microarchitectural deterioration of bone tissue, resulting in increased bone fragility and susceptibility to fracture. While the diagnosis is typically established by a dual-energy X-ray absorptiometry T-score of negative 2.5 or lower, the presence of a fragility fracture, defined as a fracture resulting from low-energy trauma equivalent to a fall from standing height or less, establishes a clinical diagnosis of osteoporosis regardless of bone mineral density. Vertebral compression fractures are the most common osteoporotic fractures, and their presence indicates that the bone's structural integrity has already been compromised to the point of mechanical failure. A prior vertebral fracture is the single strongest predictor of future fracture, increasing the risk of subsequent vertebral fracture by 4 to 5-fold and the risk of hip fracture by 2 to 3-fold within the following year.\n\nCLINICAL REASONING:\nThis patient's T-score of negative 1.8 falls in the osteopenia range (between negative 1.0 and negative 2.5) by densitometric criteria alone. However, the vertebral compression fracture overrides the T-score and establishes osteoporosis as the clinical diagnosis, mandating pharmacologic treatment. This distinction is critical because relying solely on T-score thresholds would inappropriately delay treatment in a patient who has already demonstrated skeletal fragility through fracture. The AACE, NOGG, and Endocrine Society guidelines all recognize fragility fracture as an independent diagnostic criterion for osteoporosis that requires treatment initiation.\n\nTREATMENT:\nFollowing a vertebral compression fracture, a secondary osteoporosis workup should be performed including vitamin D level, basic metabolic panel, CBC, TSH, and consideration of parathyroid hormone, celiac serologies, and serum and urine protein electrophoresis to exclude secondary causes. For patients at high fracture risk (prior vertebral or hip fracture), current guidelines from AACE and the Endocrine Society recommend initial treatment with an anabolic agent such as teriparatide or romosozumab for the first 1 to 2 years, followed by transition to an antiresorptive agent such as a bisphosphonate or denosumab, because this anabolic-first sequencing builds bone more effectively than starting with antiresorptive therapy alone. For patients at moderate risk, bisphosphonate therapy with oral alendronate or intravenous zoledronic acid is appropriate first-line treatment. Calcium and vitamin D supplementation, fall prevention strategies, and weight-bearing exercise are essential adjuncts.\n\nKEY LEARNING POINTS:\nA fragility fracture of the hip or spine establishes a clinical diagnosis of osteoporosis and mandates pharmacologic treatment regardless of T-score. Prior vertebral fracture is the strongest predictor of future fracture, increasing subsequent vertebral fracture risk by 4 to 5-fold. For high-risk patients with vertebral fractures, anabolic-first therapy followed by antiresorptive consolidation is the preferred treatment sequence."
  },
  {
    "id": 137,
    "categoryId": 11,
    "question": "A patient stops Paroxetine (Paxil) abruptly. 2 days later they feel dizzy, have 'brain zaps', and nausea. Diagnosis?",
    "options": [
      "A) Relapse of Depression",
      "B) Serotonin Discontinuation Syndrome",
      "C) Viral labyrinthitis",
      "D) Stroke"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Serotonin Discontinuation Syndrome).\n\nPATHOPHYSIOLOGY:\nSerotonin discontinuation syndrome (also called SSRI/SNRI discontinuation syndrome) occurs when serotonergic antidepressants are abruptly stopped or rapidly tapered, triggering a constellation of neurologic, gastrointestinal, and psychological symptoms within 1 to 4 days of cessation per Harrison's Principles of Internal Medicine and UpToDate. The syndrome results from sudden loss of serotonergic tone at postsynaptic receptors that have been downregulated during chronic SSRI exposure; these receptors require time to upregulate back to baseline sensitivity per the Cleveland Clinic.\n\nHIGH-RISK MEDICATIONS:\nParoxetine (Paxil) has the highest incidence of discontinuation syndrome among SSRIs due to its short half-life (approximately 21 hours), potent serotonin reuptake inhibition, and anticholinergic rebound properties per UpToDate and Harvard Health. Venlafaxine (Effexor), an SNRI with a half-life of only 5 hours, also has very high discontinuation risk per the Mayo Clinic. Fluoxetine (Prozac) has the lowest risk because its active metabolite norfluoxetine has a half-life of 4 to 16 days, providing a built-in self-taper per Harrison's Principles of Internal Medicine.\n\nCLINICAL PRESENTATION:\nThe mnemonic FINISH captures the key symptoms: Flu-like symptoms (fatigue, myalgias, chills), Insomnia, Nausea, Imbalance (dizziness, vertigo), Sensory disturbances (\"brain zaps\" described as electric shock-like sensations in the head, the most characteristic symptom), and Hyperarousal (anxiety, agitation, irritability) per UpToDate. Symptoms are self-limited, typically resolving within 1 to 2 weeks, but can be highly distressing per the Cleveland Clinic.\n\nPREVENTION AND MANAGEMENT:\nAll SSRIs and SNRIs (except fluoxetine) should be tapered gradually over a minimum of 2 to 4 weeks, with longer tapers for higher doses and longer duration of use per Harrison's Principles of Internal Medicine. If discontinuation syndrome is severe, restarting the medication at the previous dose and then tapering more slowly is the most effective treatment. Switching to fluoxetine (taking advantage of its long half-life) before discontinuation is a useful bridge strategy for difficult tapers per UpToDate and the Mayo Clinic.\n\nKEY LEARNING POINTS:\nSerotonin discontinuation syndrome (FINISH: Flu-like, Insomnia, Nausea, Imbalance, Sensory disturbances, Hyperarousal) occurs 1 to 4 days after abrupt SSRI cessation, with \"brain zaps\" as the hallmark. Paroxetine and venlafaxine have the highest risk due to short half-lives. SSRIs should be tapered over 2 to 4 weeks minimum, and fluoxetine can serve as a bridge for difficult tapers."
  },
  {
    "id": 138,
    "categoryId": 6,
    "question": "A family brings in an 80-year-old male for 'memory loss'. It started SUDDENLY 1 week ago and fluctuates during the day. He sees animals in the room. This is:",
    "options": [
      "A) Alzheimer's Disease",
      "B) Delirium",
      "C) Lewy Body Dementia",
      "D) Normal Aging"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Delirium).\n\nDISTINGUISHING DELIRIUM FROM DEMENTIA:\nThe key clinical features in this case point to delirium rather than dementia: sudden onset (over 1 week vs. months/years), fluctuating course throughout the day, and visual hallucinations (seeing animals). These features distinguish delirium from the insidious, progressive course of dementia.\n\nDELIRIUM CHARACTERISTICS:\nDelirium is an acute confusional state characterized by disturbance in attention and awareness that develops over hours to days, fluctuates in severity, and represents a change from baseline. Visual hallucinations are common. It always has an underlying medical cause that must be identified and treated.\n\nDEMENTIA CHARACTERISTICS:\nDementia develops insidiously over months to years with progressive decline and stable day-to-day symptoms (not fluctuating). Memory loss is prominent early, but attention is relatively preserved until advanced stages. Hallucinations are uncommon except in Lewy body dementia.\n\nDELIRIUM WORKUP:\nSearch for underlying causes: infection (UTI, pneumonia), metabolic derangements (electrolytes, glucose, renal/hepatic function), medications (anticholinergics, opioids, benzodiazepines), substance withdrawal, urinary retention, fecal impaction, pain, and hypoxia.\n\nKEY LEARNING POINTS:\nSudden onset, fluctuating course, and visual hallucinations indicate delirium, not dementia. Delirium always has an underlying cause that must be identified. Dementia is insidious and progressive without significant day-to-day fluctuation."
  },
  {
    "id": 139,
    "categoryId": 16,
    "question": "USPSTF Lung Cancer screening now begins at age:",
    "options": [
      "A) 55",
      "B) 50",
      "C) 60",
      "D) 45"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Age 50).\n\nGUIDELINE UPDATE:\nThe USPSTF 2021 recommendation for lung cancer screening with low-dose computed tomography (LDCT) expanded eligibility by lowering the starting age from 55 to 50 and reducing the smoking history requirement from 30 to 20 pack-years per UpToDate and the Mayo Clinic. Current criteria are: age 50 to 80 years, 20 pack-year or greater smoking history, and currently smoking or quit within the past 15 years per the CDC. Screening should be discontinued once a person has not smoked for 15 years or develops a health problem that substantially limits life expectancy or the ability to have curative lung surgery per Harrison's Principles of Internal Medicine.\n\nEVIDENCE BASIS:\nThe National Lung Screening Trial (NLST) demonstrated that annual LDCT screening reduced lung cancer mortality by 20% compared to chest radiography in high-risk adults per UpToDate. The NELSON trial (Nederlands-Leuvens Longkanker Screenings Onderzoek) confirmed these findings in a European population, showing 24% lung cancer mortality reduction in men and up to 33% in women per the Cleveland Clinic. The expanded criteria were designed to improve equity and capture a broader at-risk population, particularly women and African Americans who develop lung cancer at lower pack-year exposures per Harvard Health.\n\nCLINICAL CONSIDERATIONS:\nLDCT screening has a high false-positive rate (approximately 25% of screened patients have positive findings, most of which are benign), requiring careful shared decision-making about the risks of follow-up procedures (biopsy, surgery) and the anxiety associated with indeterminate nodules per the Mayo Clinic. The USPSTF recommends shared decision-making conversations that include the benefits, limitations, and potential harms of screening per UpToDate.\n\nKEY LEARNING POINTS:\nUSPSTF lung cancer screening criteria are age 50 to 80, 20 or more pack-year smoking history, and current smoker or quit within 15 years, using annual LDCT. The NLST and NELSON trials demonstrated 20 to 33% lung cancer mortality reduction with screening. The high false-positive rate (approximately 25%) necessitates shared decision-making about benefits and harms."
  },
  {
    "id": 140,
    "categoryId": 4,
    "question": "A patient wants Wegovy but has a personal history of Medullary Thyroid Cancer. Is this safe?",
    "options": [
      "A) Yes, risk is only in rodents",
      "B) No, it is Contraindicated",
      "C) Yes, if TSH is monitored",
      "D) Only at low doses"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (No, it is Contraindicated).\n\nPATHOPHYSIOLOGY:\nAll GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide, tirzepatide, exenatide) carry an FDA Black Box Warning regarding the risk of thyroid C-cell tumors based on preclinical data. In rodent studies, GLP-1 receptor agonists caused dose-dependent and treatment duration-dependent increases in C-cell hyperplasia, C-cell adenomas, and medullary thyroid carcinoma (MTC) in rats and mice. The proposed mechanism involves direct GLP-1 receptor-mediated stimulation of C-cell proliferation: thyroid C-cells (parafollicular cells) express GLP-1 receptors, and sustained agonism in rodent models activates calcitonin gene transcription and promotes C-cell proliferation through cAMP-dependent signaling pathways. Importantly, the relevance of these findings to humans remains uncertain. Human thyroid C-cells express GLP-1 receptors at substantially lower density than rodent C-cells, and clinical data including analysis of the FDA Adverse Event Reporting System and large cardiovascular outcomes trials (LEADER, SUSTAIN-6, REWIND, SELECT) have not demonstrated an increased incidence of MTC in humans treated with GLP-1 receptor agonists compared to background population rates. A meta-analysis published in The Lancet Diabetes and Endocrinology found no signal for increased thyroid cancer risk. Nevertheless, the preclinical signal is sufficiently concerning that the FDA mandates the contraindication as a precautionary measure.\n\nCLINICAL REASONING:\nGLP-1 receptor agonists are contraindicated in patients with a personal or family history of medullary thyroid carcinoma and in patients with Multiple Endocrine Neoplasia type 2 (MEN2) syndrome. MEN2 is an autosomal dominant syndrome caused by activating mutations in the RET proto-oncogene that predisposes to medullary thyroid carcinoma (which develops in virtually 100% of MEN2A and MEN2B patients), pheochromocytoma, and hyperparathyroidism (in MEN2A). In patients with existing MTC or genetic predisposition to MTC through MEN2, the theoretical risk of GLP-1 receptor-mediated C-cell stimulation is considered unacceptable, even though human evidence is lacking. The distinction between medullary thyroid carcinoma and the far more common differentiated thyroid cancers (papillary and follicular) is essential: papillary thyroid carcinoma, which accounts for approximately 80% of all thyroid cancers, and follicular thyroid carcinoma arise from thyroid follicular cells, not C-cells, and do not express relevant GLP-1 receptors. Therefore, a personal history of papillary or follicular thyroid cancer is not a contraindication to GLP-1 receptor agonist therapy per the prescribing information and Endocrine Society guidance.\n\nMONITORING:\nRoutine calcitonin monitoring or thyroid ultrasound screening is not recommended by the FDA, ATA, or Endocrine Society for patients on GLP-1 receptor agonists without risk factors for MTC, as the clinical utility has not been established and false-positive results could lead to unnecessary procedures. However, patients should be counseled to report any new thyroid mass, dysphagia, dysphonia, or persistent neck swelling, which may warrant further evaluation. Before initiating GLP-1 receptor agonist therapy, clinicians should screen for personal and family history of MTC and MEN2 through targeted history-taking.\n\nKEY LEARNING POINTS:\nAll GLP-1 receptor agonists carry a Black Box Warning and are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome, based on rodent studies showing C-cell tumor development. This contraindication does not apply to the more common papillary or follicular thyroid cancers, which arise from follicular cells rather than GLP-1 receptor-expressing C-cells. Human clinical data have not confirmed increased MTC risk, but the precautionary contraindication remains in effect."
  },
  {
    "id": 141,
    "categoryId": 1,
    "question": "Best way to confirm White Coat Hypertension?",
    "options": [
      "A) Have the nurse check it",
      "B) Ambulatory Blood Pressure Monitoring (ABPM) or Home logs",
      "C) Treat empirically",
      "D) Check it lying down"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Ambulatory Blood Pressure Monitoring or Home BP Logs).\n\nCLINICAL REASONING:\nWhite coat hypertension is defined as persistently elevated office blood pressure readings (140/90 mmHg or greater) with normal out-of-office blood pressure readings (daytime ambulatory average less than 135/85 mmHg or home average less than 135/85 mmHg) per the 2017 ACC/AHA Guidelines and UpToDate. It occurs in approximately 15 to 30% of patients diagnosed with hypertension based on office readings alone per Harrison's Principles of Internal Medicine. White coat hypertension results from a sympathetic nervous system-mediated stress response to the clinical environment, producing transient blood pressure elevation that does not reflect the patient's usual hemodynamic state per the Cleveland Clinic.\n\nDIAGNOSTIC GOLD STANDARD:\n24-hour ambulatory blood pressure monitoring (ABPM) is the gold standard for confirming white coat hypertension per UpToDate. The device measures blood pressure at regular intervals (typically every 15 to 30 minutes during the day and every 30 to 60 minutes at night) over a full 24-hour cycle, providing daytime, nighttime, and overall mean blood pressure values. ABPM also assesses nocturnal dipping (the normal 10 to 20% decrease in blood pressure during sleep), the absence of which (non-dipping pattern) is an independent cardiovascular risk factor per Harrison's Principles of Internal Medicine. Home blood pressure monitoring (HBPM) with a validated device is an acceptable alternative when ABPM is unavailable, with duplicate readings taken morning and evening for at least 3 to 7 days per the Mayo Clinic.\n\nCLINICAL SIGNIFICANCE:\nWhite coat hypertension carries a lower cardiovascular risk than sustained hypertension but may not be entirely benign, as some studies suggest a modestly increased risk of progression to sustained hypertension and cardiovascular events compared to true normotension per UpToDate. Patients with confirmed white coat hypertension should receive lifestyle counseling and annual monitoring with out-of-office BP assessment rather than pharmacotherapy per the Cleveland Clinic.\n\nKEY LEARNING POINTS:\nABPM is the gold standard for diagnosing white coat hypertension (elevated office BP with normal out-of-office BP), occurring in 15 to 30% of patients diagnosed by office readings alone. Home BP monitoring is an acceptable alternative (duplicate readings, morning and evening, for 3 to 7 days). White coat hypertension warrants lifestyle modification and monitoring rather than pharmacotherapy."
  },
  {
    "id": 142,
    "categoryId": 7,
    "question": "Classic X-ray finding in chronic, untreated Gout?",
    "options": [
      "A) Joint space narrowing",
      "B) Rat-bite erosions (punched out lesions)",
      "C) Osteophytes",
      "D) Bamboo spine"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Rat-bite erosions / punched-out lesions).\n\nPATHOPHYSIOLOGY:\nGout results from deposition of monosodium urate crystals in joints and periarticular soft tissues when serum uric acid chronically exceeds its saturation threshold of approximately 6.8 mg/dL at physiologic temperature and pH. In chronic untreated gout, persistent hyperuricemia leads to the formation of tophi, which are organized deposits of monosodium urate crystals surrounded by a granulomatous inflammatory reaction of macrophages, giant cells, and fibrous tissue. These tophi can form within the joint space, in periarticular soft tissues, and critically, adjacent to bone, where the chronic inflammatory response activates osteoclasts and erodes into the underlying cortex through a combination of pressure necrosis and cytokine-mediated bone resorption.\n\nRADIOGRAPHIC FINDINGS:\nThe hallmark radiographic finding of chronic tophaceous gout is well-defined, \"punched-out\" or \"rat-bite\" periarticular erosions with sclerotic borders and characteristic overhanging edges of cortical bone, known as the Martel sign. The overhanging edges result from the tophus eroding into the bone while the overlying cortex remains partially intact and extends over the defect like an awning. These erosions are typically asymmetric, located in a juxta-articular distribution, and may be accompanied by adjacent soft tissue nodular densities representing the tophi themselves. A distinguishing feature of gouty erosions is that joint space width is preserved until late in the disease course, because articular cartilage is not the primary target of the destructive process. This preservation of joint space helps differentiate chronic gout from rheumatoid arthritis, in which periarticular osteopenia and uniform joint space narrowing occur early due to pannus-mediated cartilage destruction. Osteoarthritis is distinguished by asymmetric joint space narrowing and marginal osteophytes without erosions. Ankylosing spondylitis produces the characteristic bamboo spine appearance from vertebral body fusion, which is entirely distinct from peripheral gouty erosions.\n\nDIAGNOSIS AND MANAGEMENT:\nRadiographic changes typically require years of inadequately treated hyperuricemia to develop and represent advanced disease. Plain radiographs are often normal in early or acute gout, showing only soft tissue swelling. Dual-energy CT is an emerging imaging modality that can detect urate crystal deposits with high specificity before radiographic erosions appear, and is increasingly used to confirm the diagnosis in atypical presentations. The cornerstone of chronic gout management is urate-lowering therapy titrated to a serum urate target below 6.0 mg/dL, which gradually dissolves existing crystal deposits, shrinks tophi, and prevents further erosive damage over months to years.\n\nKEY LEARNING POINTS:\nChronic tophaceous gout produces punched-out periarticular erosions with overhanging edges (Martel sign) and characteristically preserved joint space, distinguishing it from rheumatoid arthritis and osteoarthritis. Radiographic erosions represent advanced disease that develops over years of inadequately treated hyperuricemia. Urate-lowering therapy targeting serum uric acid below 6.0 mg/dL gradually dissolves crystal deposits and prevents further joint destruction."
  },
  {
    "id": 143,
    "categoryId": 17,
    "question": "A patient has a vesicular rash on the tip of the nose (Hutchinson's Sign). This warrants urgent referral to:",
    "options": [
      "A) Dermatology",
      "B) Ophthalmology",
      "C) Neurology",
      "D) ENT"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Ophthalmology).\n\nPATHOPHYSIOLOGY:\nHerpes zoster ophthalmicus (HZO) results from reactivation of varicella-zoster virus (VZV) latent in the trigeminal (gasserian) ganglion, specifically within the ophthalmic division (V1). The nasociliary branch of V1 innervates both the tip of the nose (via the external nasal nerve) and the cornea. A vesicular rash on the nasal tip (Hutchinson sign) indicates nasociliary nerve involvement and confers a significantly increased risk (approximately 76%) of ocular complications, including keratitis, anterior uveitis, and secondary glaucoma.\n\nCLINICAL PRESENTATION:\n- Prodromal pain, tingling, or hyperesthesia in the V1 distribution (forehead, upper eyelid, nose)\n- Unilateral dermatomal vesicular rash that does not cross midline\n- Hutchinson sign: Vesicles on the tip, side, or root of the nose\n- Ocular involvement may include conjunctivitis, episcleritis, keratitis (dendritic or stromal), anterior uveitis, and elevated IOP\n\nDIAGNOSIS:\nClinical diagnosis based on characteristic dermatomal distribution. Hutchinson sign warrants urgent ophthalmology referral even in the absence of current eye symptoms, as ocular complications can develop days to weeks after rash onset.\n\nTREATMENT:\n1. Antiviral therapy: Valacyclovir 1g TID or acyclovir 800mg 5x/day for 7 days, ideally started within 72 hours of rash onset\n2. Ophthalmology referral: Slit-lamp examination to evaluate for keratitis, uveitis, and IOP elevation\n3. Topical steroids and cycloplegics (prescribed by ophthalmology) for anterior uveitis\n4. Pain management: Often requires combination therapy; postherpetic neuralgia is common in V1 distribution\n\nKEY LEARNING POINTS:\nHutchinson sign (vesicles on the nasal tip) indicates nasociliary nerve involvement and a high probability of ocular complications requiring urgent ophthalmology referral. HZO can cause vision-threatening keratitis and uveitis even after the rash resolves. Shingrix vaccination (recombinant, adjuvanted) is recommended for adults 50 and older to prevent herpes zoster and its complications.\n\nREFERENCES:\nAAO; CDC ACIP Shingrix recommendations; UpToDate; Harrison's Principles of Internal Medicine.\n---"
  },
  {
    "id": 144,
    "categoryId": 3,
    "question": "A 35-year-old female complains of severe bloating and distension that worsens throughout the day. She has constipation-predominant IBS. A 'Low FODMAP' diet has provided minimal relief. What is a common, often missed differential diagnosis?",
    "options": [
      "A) Gastroparesis",
      "B) Small Intestinal Bacterial Overgrowth (SIBO)",
      "C) Zollinger-Ellison Syndrome",
      "D) Wilson's Disease"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Small Intestinal Bacterial Overgrowth - SIBO).\n\nCLINICAL PRESENTATION:\nSIBO classically presents with bloating that worsens throughout the day (as bacteria ferment ingested carbohydrates), distension, flatulence, and often diarrhea. The pattern of worsening as the day progresses and improving overnight is characteristic.\n\nPATHOPHYSIOLOGY:\nNormally, the small intestine has relatively few bacteria compared to the colon. In SIBO, colonic-type bacteria overgrow in the small intestine, fermenting carbohydrates before they can be absorbed. This produces hydrogen and methane gas (bloating), damages the intestinal mucosa (malabsorption), and deconjugates bile acids (fat malabsorption, steatorrhea).\n\nRISK FACTORS:\nImpaired motility (diabetes, scleroderma, opioids), anatomic abnormalities (strictures, blind loops, post-surgical), reduced gastric acid (PPIs), immune deficiency, and IBS with constipation predispose to SIBO.\n\nDIAGNOSIS AND TREATMENT:\nGlucose or lactulose breath testing detects hydrogen/methane production. Treatment is antibiotics, most commonly rifaximin (non-absorbed, gut-selective). Addressing underlying cause is essential to prevent recurrence. A low-FODMAP diet may help symptoms.\n\nKEY LEARNING POINTS:\nSIBO causes bloating that worsens throughout the day due to bacterial fermentation of carbohydrates. Risk factors include PPI use, diabetes, and prior abdominal surgery. Breath testing diagnoses; rifaximin is first-line treatment."
  },
  {
    "id": 145,
    "categoryId": 3,
    "question": "A 50-year-old male with chronic GERD has been on Omeprazole 40mg daily for 10 years. He is asymptomatic. According to ACG guidelines, he should be screened for Barrett's Esophagus if he has:",
    "options": [
      "A) No risk factors needed; all GERD patients get screened",
      "B) Chronic symptoms (>5 yrs) AND 2+ risk factors (Male, White, Age >50, Obesity, Family Hx)",
      "C) Only if he develops dysphagia",
      "D) Only if he smokes"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Chronic symptoms greater than 5 years AND 2 or more risk factors).\n\nPATHOPHYSIOLOGY:\nBarrett's esophagus develops when chronic gastroesophageal reflux causes the normal stratified squamous epithelium of the distal esophagus to undergo intestinal metaplasia, replacing it with specialized columnar epithelium containing goblet cells. This metaplastic change represents an adaptive response to chronic acid and bile exposure but carries a significantly increased risk of progression to esophageal adenocarcinoma, estimated at 0.5% per year.\n\nSCREENING CRITERIA:\nThe ACG guidelines recommend screening with upper endoscopy in patients with chronic GERD symptoms lasting more than 5 years who also have two or more additional risk factors: male sex, Caucasian race, age over 50, central obesity (waist circumference greater than 102 cm in men or greater than 88 cm in women), current or past smoking history, and first-degree family history of Barrett's esophagus or esophageal adenocarcinoma. Routine endoscopy for all GERD patients is not recommended because the vast majority will never develop Barrett's esophagus.\n\nDIAGNOSIS AND SURVEILLANCE:\nDiagnosis requires both endoscopic visualization of salmon-colored mucosa extending above the gastroesophageal junction and histologic confirmation of intestinal metaplasia with goblet cells. Once diagnosed, surveillance intervals depend on the presence and degree of dysplasia: no dysplasia warrants repeat endoscopy every 3-5 years, low-grade dysplasia every 6-12 months, and high-grade dysplasia prompts endoscopic eradication therapy with radiofrequency ablation.\n\nKEY LEARNING POINTS:\nBarrett's esophagus screening requires chronic GERD greater than 5 years plus two or more risk factors (male, white, age over 50, central obesity, smoking, family history). Routine EGD is not indicated for all GERD patients. Barrett's carries a 0.5% annual risk of esophageal adenocarcinoma. High-grade dysplasia is treated with endoscopic radiofrequency ablation."
  },
  {
    "id": 146,
    "categoryId": 3,
    "question": "A 60-year-old female presents with mild LLQ pain and low-grade fever. CT confirms acute uncomplicated diverticulitis (no abscess/perforation). She is immunocompetent and tolerating liquids. What is the AGA guideline-recommended treatment?",
    "options": [
      "A) Ciprofloxacin + Metronidazole",
      "B) Amoxicillin-Clavulanate",
      "C) Clear liquid diet and observation (No Antibiotics)",
      "D) Surgical resection"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Selective Antibiotics â€” observation without antibiotics is appropriate).\n\nPATHOPHYSIOLOGY:\nDiverticulitis occurs when a diverticulum becomes inflamed or micro-perforated, traditionally attributed to fecalith obstruction. However, current understanding recognizes that mucosal inflammation, altered microbiome composition, and visceral hypersensitivity play important roles. Uncomplicated diverticulitis, defined as inflammation without abscess, perforation, obstruction, or fistula, accounts for approximately 75% of cases and has an excellent prognosis.\n\nPARADIGM SHIFT IN MANAGEMENT:\nThe AGA guideline and multiple randomized controlled trials (including the DIABOLO and AVOD trials) have demonstrated that immunocompetent patients with CT-confirmed uncomplicated diverticulitis have equivalent outcomes whether treated with or without antibiotics. Recovery time, complication rates, recurrence rates, and need for surgery showed no significant differences between antibiotic and no-antibiotic groups. This reflects the evolving understanding that uncomplicated diverticulitis is primarily an inflammatory rather than infectious process.\n\nCLINICAL APPLICATION:\nAppropriate candidates for observation without antibiotics include immunocompetent patients with CT-confirmed uncomplicated disease who are tolerating oral intake, have no significant comorbidities, and have reliable follow-up. Antibiotics remain indicated for complicated diverticulitis (abscess, perforation, fistula), immunosuppressed patients, patients with significant comorbidities, and those with systemic signs of sepsis. When antibiotics are prescribed, the standard regimen is ciprofloxacin plus metronidazole or amoxicillin-clavulanate for 7-10 days.\n\nKEY LEARNING POINTS:\nAGA guidelines now recommend selective rather than routine antibiotic use for uncomplicated diverticulitis in immunocompetent patients. Randomized trials show equivalent outcomes with and without antibiotics. This reflects the understanding that uncomplicated diverticulitis is primarily inflammatory, not infectious. Antibiotics remain essential for complicated disease and immunosuppressed patients."
  },
  {
    "id": 147,
    "categoryId": 3,
    "question": "A 65-year-old female presents with chronic, watery, non-bloody diarrhea. Colonoscopy reveals visually normal mucosa. What MUST be done to rule out Microscopic Colitis?",
    "options": [
      "A) Stool O&P",
      "B) Random biopsies of the colon",
      "C) CT Abdomen",
      "D) Prometheus IBS blood panel"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Random biopsies of the colon).\n\nPATHOPHYSIOLOGY:\nMicroscopic colitis encompasses two subtypes, lymphocytic colitis and collagenous colitis, both characterized by chronic inflammation visible only on histology. In lymphocytic colitis, there is an increase in intraepithelial lymphocytes (greater than 20 per 100 epithelial cells). In collagenous colitis, a thickened subepithelial collagen band (greater than 10 micrometers) is the hallmark finding. The condition predominantly affects women over age 60 and is strongly associated with autoimmune disorders, celiac disease, and certain medications including PPIs, NSAIDs, SSRIs, and statins.\n\nCLINICAL PRESENTATION:\nPatients present with chronic, watery, non-bloody diarrhea that may produce 4-9 stools per day and can persist for months to years. Fecal urgency and nocturnal diarrhea are common, leading to significant impact on quality of life. Abdominal pain is typically mild or absent. Importantly, inflammatory markers and stool studies are usually normal.\n\nDIAGNOSIS:\nThe defining feature of microscopic colitis is that the colonic mucosa appears completely normal on endoscopic inspection, making it a diagnosis that is invisible to the naked eye. Random biopsies from both the right and left colon during colonoscopy are absolutely required because the histologic changes may be patchy. Without biopsies, the diagnosis will be missed entirely.\n\nMANAGEMENT:\nOral budesonide is the first-line treatment, with clinical remission rates of 80% or higher within 2-4 weeks. Offending medications should be discontinued. Cholestyramine and bismuth subsalicylate are alternative options. Relapse is common upon budesonide discontinuation, and some patients require low-dose maintenance therapy.\n\nKEY LEARNING POINTS:\nMicroscopic colitis causes chronic watery diarrhea with a visually normal colonoscopy, making random biopsies from both sides of the colon essential for diagnosis. It predominantly affects women over 60 and is associated with PPIs, NSAIDs, and SSRIs. Oral budesonide achieves remission in over 80% of cases."
  },
  {
    "id": 148,
    "categoryId": 3,
    "question": "Which medication is an antispasmodic specifically useful for post-prandial abdominal pain/cramping in IBS?",
    "options": [
      "A) Loperamide",
      "B) Dicyclomine (Bentyl)",
      "C) Ondansetron",
      "D) Famotidine"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Dicyclomine/Bentyl).\n\nPATHOPHYSIOLOGY:\nIrritable bowel syndrome involves visceral hypersensitivity and disordered gastrointestinal motility, with the gastrocolic reflex (increased colonic contractility triggered by gastric distension after eating) often amplified. This exaggerated reflex produces post-prandial abdominal cramping and urgency that significantly impairs quality of life. Smooth muscle spasm in the colon is a major driver of pain in IBS.\n\nMECHANISM OF ACTION:\nDicyclomine is an anticholinergic antispasmodic that blocks muscarinic receptors on gastrointestinal smooth muscle, reducing the amplitude and frequency of colonic contractions. It also has a direct smooth muscle relaxant effect independent of its anticholinergic activity. A Cochrane meta-analysis demonstrated that antispasmodics are significantly more effective than placebo for global IBS symptom improvement, with a number needed to treat of approximately 5.\n\nCLINICAL APPLICATION:\nDicyclomine is most effective when taken 30-60 minutes before meals to preemptively blunt the gastrocolic reflex, rather than after symptoms have already developed. The typical starting dose is 20 mg four times daily before meals. Hyoscyamine is an alternative anticholinergic antispasmodic with similar efficacy. Common side effects include dry mouth, blurred vision, urinary retention, and constipation, and these agents should be used with caution in elderly patients due to anticholinergic burden.\n\nKEY LEARNING POINTS:\nDicyclomine is an anticholinergic antispasmodic that reduces post-prandial IBS cramping by blocking the amplified gastrocolic reflex. It should be taken 30-60 minutes before meals for maximal benefit. Antispasmodics have a number needed to treat of approximately 5 for IBS symptom improvement. Anticholinergic side effects require caution in elderly patients."
  },
  {
    "id": 149,
    "categoryId": 3,
    "question": "A patient goes 'Gluten Free' on their own for 6 months and now wants to be tested for Celiac Disease. What is the correct approach?",
    "options": [
      "A) Order tTG-IgA immediately",
      "B) Order HLA-DQ2/DQ8 genetic testing",
      "C) Gluten Challenge (eat gluten daily for 2-6 weeks) then test",
      "D) Colonoscopy"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Gluten challenge â€” the patient must be eating gluten for accurate testing).\n\nPATHOPHYSIOLOGY:\nCeliac disease is an autoimmune enteropathy triggered by gluten exposure in genetically susceptible individuals (HLA-DQ2 or HLA-DQ8 positive). Gluten-derived gliadin peptides activate an adaptive immune response that produces tissue transglutaminase IgA (tTG-IgA) antibodies and causes villous atrophy in the small intestine. Critically, both the serologic markers and the histologic changes are dependent on ongoing gluten exposure and will normalize on a gluten-free diet.\n\nCLINICAL REASONING:\nA patient who has been gluten-free for 6 months will likely have negative tTG-IgA and normal duodenal biopsies even if they truly have celiac disease, producing a false-negative result. The ACG guideline recommends a gluten challenge, in which the patient consumes the equivalent of at least 3 grams of gluten daily (approximately 1-2 slices of wheat bread) for a minimum of 2 weeks, ideally 6-8 weeks, before serologic testing. Some patients may not tolerate a full challenge duration, and testing can be performed earlier if symptoms recur, as antibodies may rise within 2 weeks of gluten reintroduction.\n\nALTERNATIVE APPROACH:\nHLA-DQ2/DQ8 genetic testing (Option B) can be performed regardless of diet because it tests for inherited genes, not immune response. However, HLA testing can only exclude celiac disease (negative predictive value greater than 99%) but cannot confirm it, as approximately 30-40% of the general population carries these alleles without having celiac disease.\n\nKEY LEARNING POINTS:\nCeliac serologies and biopsies require active gluten ingestion to be accurate and will be falsely negative on a gluten-free diet. A gluten challenge of 3 grams daily for 2-6 weeks is required before testing. HLA-DQ2/DQ8 testing is diet-independent but can only exclude, not confirm, celiac disease. Approximately 30-40% of the population carries HLA-DQ2 or DQ8 without having celiac disease."
  },
  {
    "id": 150,
    "categoryId": 3,
    "question": "In a patient with dyspepsia (heartburn/indigestion), which symptom is an absolute indication for immediate Upper Endoscopy (EGD)?",
    "options": [
      "A) Bloating",
      "B) Dysphagia (Difficulty swallowing)",
      "C) Nausea",
      "D) Belching"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Dysphagia â€” difficulty swallowing).\n\nPATHOPHYSIOLOGY:\nDysphagia indicates mechanical obstruction or motility disorder of the esophagus and raises concern for serious underlying pathology including esophageal stricture (peptic or radiation-induced), esophageal adenocarcinoma, squamous cell carcinoma, eosinophilic esophagitis, esophageal rings or webs, and achalasia. In the context of chronic dyspepsia or GERD, new-onset dysphagia may signal the development of a peptic stricture from chronic inflammation or, more ominously, malignant transformation of Barrett's esophagus.\n\nCLINICAL SIGNIFICANCE:\nDysphagia is classified as an alarm feature (also called a red flag) in dyspepsia guidelines from the ACG and AGA. Other alarm features include unintentional weight loss greater than 5% of body weight, evidence of gastrointestinal bleeding (melena, hematemesis, iron deficiency anemia), persistent vomiting, palpable abdominal mass, and progressive dysphagia. The presence of any alarm feature mandates prompt upper endoscopy regardless of age or duration of symptoms, because empiric acid suppression without endoscopic evaluation risks delaying the diagnosis of malignancy.\n\nDIAGNOSTIC APPROACH:\nUpper endoscopy (EGD) allows direct visualization, tissue sampling, and potential therapeutic intervention (dilation of strictures). For patients under 60 without alarm features, the ACG recommends a non-invasive test-and-treat strategy for H. pylori before proceeding to endoscopy. Patients over 60 with new-onset dyspepsia should undergo endoscopy to rule out gastric malignancy, as gastric cancer incidence increases significantly with age.\n\nKEY LEARNING POINTS:\nDysphagia is an alarm feature requiring immediate upper endoscopy regardless of age or symptom duration. Other alarm features include weight loss, GI bleeding, and persistent vomiting. Alarm features bypass the test-and-treat H. pylori strategy. In patients over 60 with new-onset dyspepsia, EGD is indicated to rule out gastric malignancy."
  },
  {
    "id": 151,
    "categoryId": 3,
    "question": "You treated a patient for H. pylori. You need to confirm eradication (Test of Cure). Which test is INAPPROPRIATE?",
    "options": [
      "A) Urea Breath Test",
      "B) Stool Antigen Test",
      "C) Serum Antibody (IgG)",
      "D) Repeat Biopsy (if EGD indicated)"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Serum Antibody IgG).\n\nPATHOPHYSIOLOGY:\nHelicobacter pylori infection triggers a systemic immune response with production of IgG antibodies against bacterial antigens. These antibodies persist in the circulation for months to years after successful eradication, reflecting immunologic memory rather than active infection. Consequently, IgG serology cannot distinguish between active infection and prior exposure, making it fundamentally unsuitable for confirming eradication.\n\nAPPROPRIATE TESTS OF CURE:\nThe urea breath test (Option A) detects active H. pylori urease activity by measuring labeled carbon dioxide in exhaled breath after ingestion of carbon-13 or carbon-14 labeled urea. The stool antigen test (Option B) uses monoclonal antibodies to detect H. pylori antigens in feces and reflects current infection status. Both tests have sensitivity and specificity exceeding 95% for confirming eradication. Repeat biopsy during endoscopy (Option D) is appropriate when EGD is indicated for other reasons such as complicated ulcer disease or gastric ulcer follow-up.\n\nTESTING REQUIREMENTS:\nTest of cure should be performed at least 4 weeks after completing antibiotic therapy and at least 1-2 weeks after discontinuing PPI therapy. PPIs suppress H. pylori metabolic activity without eradicating it, which can produce false-negative results on breath testing and stool antigen testing. Bismuth compounds and antibiotics must also be withheld for a minimum of 4 weeks prior to testing.\n\nKEY LEARNING POINTS:\nSerum IgG antibodies persist for months to years after eradication and cannot confirm cure. Urea breath test and stool antigen test are the preferred non-invasive tests of cure with greater than 95% accuracy. PPIs must be discontinued 1-2 weeks before testing to avoid false negatives. Test of cure is performed at least 4 weeks after completing antibiotic therapy."
  },
  {
    "id": 152,
    "categoryId": 3,
    "question": "A patient has chronic epigastric pain and early satiety. EGD is normal. H. pylori is negative. This is Functional Dyspepsia. Which class of antidepressants can be helpful for the visceral pain component?",
    "options": [
      "A) Tricyclic Antidepressants (Amitriptyline)",
      "B) MAOIs",
      "C) Benzodiazepines",
      "D) Stimulants"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Tricyclic Antidepressants â€” Amitriptyline).\n\nPATHOPHYSIOLOGY:\nFunctional dyspepsia is a disorder of gut-brain interaction characterized by epigastric pain, postprandial fullness, early satiation, and epigastric burning in the absence of structural pathology on endoscopy. The pathophysiology involves visceral hypersensitivity (augmented perception of normal gastric stimuli), impaired gastric accommodation (failure of the fundus to relax after eating), delayed gastric emptying, and central nervous system dysregulation of pain processing. The gut-brain axis, mediated through vagal afferents and central pain modulation pathways, plays a central role.\n\nMECHANISM OF ACTION:\nTricyclic antidepressants modulate visceral pain through multiple mechanisms: they inhibit norepinephrine and serotonin reuptake in descending pain inhibitory pathways, block sodium channels in peripheral visceral afferent neurons, and have anticholinergic effects that slow gastric motility. The analgesic effect occurs at doses far below those required for antidepressant activity, typically 10-50 mg nightly. The landmark FD-TCA trial published in Gastroenterology demonstrated that amitriptyline provided significant symptomatic relief compared to placebo, particularly for the epigastric pain syndrome subtype.\n\nCLINICAL APPLICATION:\nAmitriptyline is typically started at 10 mg at bedtime and titrated upward by 10 mg every 2-4 weeks to a maximum of 50 mg, allowing time for therapeutic effect. Common side effects include dry mouth, constipation, drowsiness, and weight gain. SSRIs have not shown consistent benefit for functional dyspepsia. Mirtazapine may be considered when early satiation and weight loss are prominent due to its appetite-stimulating effects.\n\nKEY LEARNING POINTS:\nFunctional dyspepsia is a disorder of gut-brain interaction involving visceral hypersensitivity and central pain dysregulation. Low-dose tricyclic antidepressants (amitriptyline 10-50 mg nightly) modulate visceral pain through descending inhibitory pathways. TCAs are particularly effective for the epigastric pain syndrome subtype. SSRIs have not shown consistent benefit for functional dyspepsia."
  },
  {
    "id": 153,
    "categoryId": 3,
    "question": "Current ACG first-line treatment for an initial episode of non-severe Clostridioides difficile (C. diff) infection?",
    "options": [
      "A) Oral Metronidazole",
      "B) Oral Fidaxomicin or Oral Vancomycin",
      "C) IV Vancomycin",
      "D) Fecal Transplant"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Fidaxomicin or Oral Vancomycin).\n\nPATHOPHYSIOLOGY:\nClostridioides difficile is a spore-forming, toxin-producing anaerobic bacterium that causes infection when the normal gut microbiome is disrupted, most commonly by antibiotic exposure. C. difficile produces toxin A (enterotoxin) and toxin B (cytotoxin), which cause intestinal epithelial cell death, neutrophilic inflammation, and pseudomembrane formation. The disease spectrum ranges from mild diarrhea to fulminant colitis with toxic megacolon, perforation, and death.\n\nCURRENT GUIDELINE RECOMMENDATIONS:\nThe ACG and IDSA guidelines recommend oral fidaxomicin (200 mg twice daily for 10 days) as the preferred first-line agent for initial non-severe C. difficile infection, with oral vancomycin (125 mg four times daily for 10 days) as an acceptable alternative. Fidaxomicin is preferred because it produces significantly lower recurrence rates compared to vancomycin (approximately 13% versus 27%) due to its narrow-spectrum activity that preserves the anaerobic gut microbiome. Oral metronidazole is no longer recommended as first-line therapy due to inferior cure rates compared to vancomycin.\n\nSEVERITY STRATIFICATION:\nNon-severe disease is defined by white blood cell count below 15,000 and serum creatinine below 1.5 mg/dL. Severe disease (WBC greater than 15,000 or creatinine greater than 1.5) warrants oral vancomycin or fidaxomicin. Fulminant disease (hypotension, shock, ileus, toxic megacolon) requires oral vancomycin 500 mg four times daily plus intravenous metronidazole 500 mg every 8 hours, with rectal vancomycin instillation if ileus is present. Fecal microbiota transplantation is recommended after two or more recurrences.\n\nKEY LEARNING POINTS:\nFidaxomicin or oral vancomycin are first-line for initial non-severe C. difficile infection, replacing metronidazole. Fidaxomicin is preferred due to lower recurrence rates (13% versus 27%). Severity is stratified by WBC and creatinine. Fecal microbiota transplantation is recommended after two or more recurrences."
  },
  {
    "id": 154,
    "categoryId": 3,
    "question": "A patient on a PPI for GERD asks about stopping. You advise tapering slowly to avoid:",
    "options": [
      "A) Withdrawal seizures",
      "B) Rebound Acid Hypersecretion",
      "C) Hypotension",
      "D) Constipation"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Rebound Acid Hypersecretion).\n\nPATHOPHYSIOLOGY:\nDuring chronic PPI use, the body compensates for reduced acid by increasing gastrin secretion and parietal cell mass (hyperplasia). When the PPI is stopped abruptly, these upregulated mechanisms produce acid output that exceeds pre-treatment levels, causing rebound symptoms worse than the original complaint.\n\nCLINICAL PRESENTATION:\nPatients who abruptly discontinue PPIs often experience severe heartburn, dyspepsia, and acid regurgitation within days, even if they had minimal symptoms before starting the medication. This can create a cycle of dependence where patients believe they \"need\" the PPI.\n\nDURATION AND MANAGEMENT:\nRebound hypersecretion can last 2-4 weeks or longer. Gradual tapering over 2-4 weeks reduces rebound severity. Strategies include dose reduction (from twice daily to once daily, then every other day), switching to H2 blockers as a bridge, and using antacids for breakthrough symptoms during the taper.\n\nCLINICAL IMPLICATIONS:\nThis phenomenon contributes to long-term PPI overuse. Patients should be counseled before starting PPIs that discontinuation may temporarily worsen symptoms, and a tapering plan should be established.\n\nKEY LEARNING POINTS:\nAbrupt PPI discontinuation causes rebound acid hypersecretion due to compensatory gastrin elevation and parietal cell hyperplasia. Symptoms can exceed baseline and last 2-4 weeks. Gradual tapering over 2-4 weeks minimizes rebound effects."
  },
  {
    "id": 155,
    "categoryId": 3,
    "question": "A patient with chronic constipation has failed fiber, water, and laxatives. They report 'straining' even with soft stool and a feeling of incomplete evacuation. The next best diagnostic test is:",
    "options": [
      "A) Colonoscopy",
      "B) Anorectal Manometry",
      "C) CT Abdomen",
      "D) Sitz Marker Study"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Anorectal Manometry).\n\nPATHOPHYSIOLOGY:\nDyssynergic defecation (also called pelvic floor dyssynergia) is a functional defecation disorder in which the pelvic floor muscles and external anal sphincter paradoxically contract rather than relax during attempted evacuation. Under normal conditions, the act of defecation involves coordinated relaxation of the puborectalis muscle and external anal sphincter combined with increased intra-abdominal pressure. In dyssynergia, this coordination fails, producing a functional outlet obstruction that prevents effective evacuation even when stool is soft.\n\nCLINICAL PRESENTATION:\nPatients typically describe excessive straining with defecation, a sensation of incomplete evacuation, the need for digital facilitation, and symptoms that persist despite adequate fiber intake, hydration, and osmotic laxatives. The diagnosis should be suspected in any patient with chronic constipation refractory to standard medical therapy, particularly when straining occurs even with soft stool formation. Dyssynergic defecation accounts for approximately 40% of patients referred for refractory constipation.\n\nDIAGNOSIS AND TREATMENT:\nAnorectal manometry is the key diagnostic test, measuring sphincter pressures and coordination during simulated defecation. It identifies the paradoxical contraction pattern by demonstrating increased rather than decreased anal sphincter pressure during bearing down. Balloon expulsion testing is a complementary test in which the patient attempts to expel a water-filled balloon, with failure to expel within 60 seconds supporting the diagnosis. The gold-standard treatment is pelvic floor biofeedback therapy, which retrains patients to properly coordinate relaxation during defecation and achieves success rates of 70-80% in randomized trials.\n\nKEY LEARNING POINTS:\nDyssynergic defecation causes refractory constipation due to paradoxical pelvic floor contraction during evacuation. Anorectal manometry is the diagnostic test of choice, demonstrating paradoxical sphincter contraction. Biofeedback therapy is the gold-standard treatment with 70-80% success rates. Suspect this diagnosis when constipation persists despite adequate softening of stool."
  },
  {
    "id": 156,
    "categoryId": 3,
    "question": "The Low FODMAP diet reduces bloating by restricting:",
    "options": [
      "A) Fat and Protein",
      "B) Fermentable Oligo-, Di-, Mono-saccharides And Polyols",
      "C) Gluten and Casein",
      "D) Histamine rich foods"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Fermentable Oligo-, Di-, Mono-saccharides And Polyols).\n\nPATHOPHYSIOLOGY:\nFODMAPs are short-chain carbohydrates that share two key properties: they are poorly absorbed in the small intestine and are rapidly fermented by colonic bacteria. This combination produces both an osmotic effect (drawing water into the intestinal lumen, causing diarrhea) and a gas-producing effect (bacterial fermentation generates hydrogen, methane, and carbon dioxide, causing bloating and distension). Common high-FODMAP foods include garlic, onions, wheat, apples, pears, milk (lactose), honey (excess fructose), beans (galacto-oligosaccharides), and sugar-free sweeteners containing sorbitol or mannitol.\n\nCLINICAL APPLICATION:\nThe low FODMAP diet is an evidence-based dietary intervention for IBS, with randomized trials demonstrating symptom improvement in 50-80% of patients. The diet is implemented in three phases: elimination (strict FODMAP restriction for 2-6 weeks), reintroduction (systematic testing of individual FODMAP groups to identify personal triggers), and personalization (long-term modified diet avoiding only identified triggers). The reintroduction phase is critical because the goal is not lifelong restriction but rather identification of individual sensitivities.\n\nCLINICAL CONSIDERATIONS:\nThe diet should be supervised by a dietitian experienced in FODMAPs to ensure nutritional adequacy and proper reintroduction methodology. Long-term strict FODMAP restriction is not recommended because it reduces beneficial bifidobacteria and overall microbial diversity. The diet may also reduce caloric intake, particularly in patients who are already underweight. It is not appropriate for diagnosing or managing celiac disease, food allergies, or inflammatory bowel disease.\n\nKEY LEARNING POINTS:\nFODMAPs are poorly absorbed, rapidly fermented carbohydrates that cause osmotic diarrhea and gas production in the colon. The low FODMAP diet improves IBS symptoms in 50-80% of patients through a three-phase approach: elimination, reintroduction, and personalization. Long-term strict restriction is discouraged due to adverse effects on the gut microbiome. Dietitian supervision ensures proper implementation."
  },
  {
    "id": 157,
    "categoryId": 3,
    "question": "Gilbert's Syndrome typically presents as:",
    "options": [
      "A) Elevated Direct Bilirubin and itching",
      "B) Isolated Mild Indirect (Unconjugated) Hyperbilirubinemia, often triggered by stress/fasting",
      "C) Elevated ALT/AST > 1000",
      "D) Elevated Alkaline Phosphatase"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Isolated mild indirect/unconjugated hyperbilirubinemia, often triggered by stress or fasting).\n\nPATHOPHYSIOLOGY:\nGilbert's syndrome is the most common inherited disorder of bilirubin metabolism, affecting approximately 5-10% of the population. It results from a genetic polymorphism in the UGT1A1 gene promoter region (typically a TA repeat insertion) that reduces the activity of uridine diphosphate-glucuronosyltransferase to approximately 30% of normal. This enzyme is responsible for conjugating indirect (unconjugated) bilirubin in hepatocytes, making it water-soluble for biliary excretion. The reduced enzyme activity causes mild accumulation of unconjugated bilirubin, typically between 1-3 mg/dL.\n\nCLINICAL PRESENTATION:\nGilbert's syndrome is characteristically asymptomatic and discovered incidentally on routine laboratory testing. Episodes of visible jaundice or scleral icterus may be precipitated by fasting (reduced hepatic UDP-glucuronic acid availability), physical stress, illness, sleep deprivation, dehydration, or menstruation. Importantly, all liver enzymes (AST, ALT, alkaline phosphatase, GGT) are completely normal, direct bilirubin is normal, and there is no evidence of hemolysis (normal reticulocyte count, haptoglobin, and LDH). The condition is entirely benign and requires no treatment.\n\nDIFFERENTIAL DIAGNOSIS:\nOther causes of unconjugated hyperbilirubinemia include hemolytic anemias (elevated LDH, low haptoglobin, reticulocytosis), ineffective erythropoiesis (megaloblastic anemia, thalassemia), and Crigler-Najjar syndrome (types I and II, which present with more severe hyperbilirubinemia, often in neonates). Elevated direct bilirubin suggests hepatocellular disease or biliary obstruction and is not consistent with Gilbert's syndrome.\n\nKEY LEARNING POINTS:\nGilbert's syndrome affects 5-10% of the population and results from reduced UGT1A1 enzyme activity causing mild unconjugated hyperbilirubinemia. Jaundice is triggered by fasting, stress, or illness. All liver enzymes and direct bilirubin are normal. It is entirely benign and requires no treatment, but awareness prevents unnecessary workup."
  },
  {
    "id": 158,
    "categoryId": 3,
    "question": "Most common cause of Lower GI Bleed (hematochezia) in adults > 60?",
    "options": [
      "A) Colon Cancer",
      "B) Diverticulosis",
      "C) Hemorrhoids",
      "D) IBD"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Diverticulosis).\n\nPATHOPHYSIOLOGY:\nDiverticulosis affects over 50% of adults over age 60 in Western countries. Diverticula form when mucosa herniates through weak points in the colonic wall where vasa recta penetrate the muscular layer. These arterial vessels become draped over the dome of the diverticulum, separated from the lumen only by thin mucosa. Erosion of these exposed vessels causes painless, often massive hemorrhage. Despite the dramatic presentation, approximately 80% of diverticular bleeds stop spontaneously.\n\nCLINICAL PRESENTATION:\nDiverticular bleeding typically presents with sudden, painless, large-volume hematochezia (bright red or maroon blood per rectum). Unlike diverticulitis, there is no abdominal pain, fever, or leukocytosis. Hemodynamic instability may occur with significant blood loss. The bleeding source is usually in the right colon (ascending or cecum), even though diverticula are more common in the left colon, because right-sided diverticula have wider necks and thinner walls.\n\nDIFFERENTIAL DIAGNOSIS:\nOther common causes of lower GI bleeding include hemorrhoids (most common overall cause of rectal bleeding, typically small volume with defecation), angiodysplasia (arteriovenous malformations, more common in elderly and those with renal disease or aortic stenosis), colorectal cancer and polyps, ischemic colitis (typically causes bloody diarrhea with abdominal pain), and inflammatory bowel disease.\n\nMANAGEMENT:\nInitial management includes hemodynamic resuscitation and correction of coagulopathy. Colonoscopy after bowel preparation is both diagnostic and potentially therapeutic (epinephrine injection, clipping, or cautery). CT angiography or tagged red blood cell scan can localize active bleeding when colonoscopy is not feasible.\n\nKEY LEARNING POINTS:\nDiverticulosis is the most common cause of major lower GI bleeding in adults. Bleeding is typically painless and massive but stops spontaneously in 80% of cases. Right-sided diverticula bleed more often despite left-sided predominance. Colonoscopy is diagnostic and therapeutic after stabilization."
  },
  {
    "id": 159,
    "categoryId": 3,
    "question": "Which vitamin deficiency is commonly seen in SIBO because bacteria consume it?",
    "options": [
      "A) Vitamin K",
      "B) Vitamin B12",
      "C) Folate",
      "D) Vitamin C"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Vitamin B12).\n\nPATHOPHYSIOLOGY:\nIn small intestinal bacterial overgrowth (SIBO), colonic-type bacteria proliferate abnormally in the small bowel, where they compete with the host for nutrients. These bacteria avidly consume vitamin B12 (cobalamin) and utilize it for their own metabolic processes, significantly reducing the amount available for absorption in the terminal ileum. In a clinically important contrast, bacterial metabolism actually produces folate as a byproduct, which explains why patients with SIBO characteristically have low B12 but normal or elevated folate levels. This dissociation between B12 and folate is an important diagnostic clue that helps distinguish SIBO from other causes of macrocytic anemia.\n\nCLINICAL MANIFESTATIONS:\nB12 deficiency in SIBO can produce macrocytic anemia (MCV greater than 100 fL), glossitis, and angular cheilitis. Neurologic complications develop with prolonged deficiency and include peripheral neuropathy (paresthesias in a stocking-glove distribution), subacute combined degeneration of the spinal cord (posterior column and lateral corticospinal tract demyelination), gait ataxia, and cognitive impairment. Neurologic damage may be irreversible if not corrected promptly.\n\nDIAGNOSIS AND TREATMENT:\nSerum B12 levels should be checked in all symptomatic SIBO patients, particularly those with anemia or neurologic symptoms. Methylmalonic acid and homocysteine levels are more sensitive markers of functional B12 deficiency when serum B12 is borderline (200-400 pg/mL). Treatment requires both eradication of SIBO (typically with rifaximin) and B12 repletion. Parenteral B12 (intramuscular injections) may be preferred initially in patients with significant malabsorption or neurologic involvement, as oral supplementation depends on intact absorption.\n\nKEY LEARNING POINTS:\nSIBO causes B12 deficiency because overgrown bacteria consume B12, while simultaneously producing folate, creating a characteristic low B12 with normal or elevated folate pattern. Neurologic complications of B12 deficiency can be irreversible. Methylmalonic acid is a sensitive marker when B12 is borderline. Treatment addresses both SIBO eradication and B12 repletion."
  },
  {
    "id": 160,
    "categoryId": 3,
    "question": "Chronic Pancreatitis (often alcohol-induced) leads to Exocrine Insufficiency. The classic symptom is:",
    "options": [
      "A) Constipation",
      "B) Steatorrhea (Greasy, floating, foul-smelling stool)",
      "C) Melena",
      "D) Hematemesis"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Steatorrhea).\n\nPATHOPHYSIOLOGY:\nChronic pancreatitis is a progressive inflammatory condition that destroys pancreatic parenchyma over years, replacing functional acinar and islet tissue with fibrosis and calcification. Alcohol accounts for approximately 50-70% of cases, with the remainder caused by genetic mutations (PRSS1, SPINK1, CFTR), autoimmune disease, recurrent acute pancreatitis, and idiopathic causes. The exocrine pancreas has enormous functional reserve, and steatorrhea does not develop until approximately 90% of lipase-secreting capacity has been lost, meaning that fat malabsorption represents advanced, irreversible disease.\n\nCLINICAL PRESENTATION:\nSteatorrhea is the hallmark of exocrine pancreatic insufficiency. Stools are characteristically pale, greasy, bulky, foul-smelling, and float due to their high fat content. Patients may notice an oily residue in the toilet bowl or stools that are difficult to flush. Fat malabsorption leads to deficiency of fat-soluble vitamins (A, D, E, K), causing night blindness, osteoporosis, coagulopathy, and neuropathy. Weight loss occurs despite adequate caloric intake. Chronic epigastric pain radiating to the back is common and often requires escalating analgesia.\n\nDIAGNOSIS AND MANAGEMENT:\nFecal elastase-1 is the preferred non-invasive test for exocrine insufficiency, with levels below 200 mcg/g indicating insufficiency and below 100 mcg/g indicating severe insufficiency. CT imaging may reveal pancreatic calcifications, ductal dilation, and parenchymal atrophy, which are pathognomonic for chronic pancreatitis. Pancreatic enzyme replacement therapy (PERT) with meals is the cornerstone of treatment. Lipase doses of 40,000-50,000 units per meal and 25,000 units per snack are typical starting points, titrated to symptom response. A PPI may be added to prevent acid degradation of enzyme supplements. Alcohol cessation is essential to slow disease progression.\n\nKEY LEARNING POINTS:\nSteatorrhea indicates that over 90% of exocrine function has been lost and represents advanced chronic pancreatitis. Fecal elastase-1 is the preferred non-invasive diagnostic test. Pancreatic enzyme replacement therapy with meals is the mainstay of treatment. Fat-soluble vitamin deficiencies (A, D, E, K) should be monitored in all patients with exocrine insufficiency."
  },
  {
    "id": 161,
    "categoryId": 16,
    "question": "A patient has a first-degree relative with Colon Cancer diagnosed at age 50. When should the patient begin screening?",
    "options": [
      "A) Age 45",
      "B) Age 40 (or 10 years before diagnosis)",
      "C) Age 50",
      "D) Age 35"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Age 40 or 10 years before the relative's diagnosis, whichever comes first).\n\nGUIDELINE BASIS:\nFor individuals with a first-degree relative (parent, sibling, or child) diagnosed with colorectal cancer before age 60, both the ACS and ACG recommend initiating screening at age 40 or 10 years before the age of the relative's diagnosis, whichever is earlier per UpToDate and the Cleveland Clinic. In this case, the relative was diagnosed at age 50, so screening should begin at age 40 (10 years prior). Colonoscopy is the preferred screening modality for high-risk individuals and should be repeated every 5 years (rather than the standard 10-year interval for average-risk patients) per Harrison's Principles of Internal Medicine.\n\nRISK STRATIFICATION:\nHaving a first-degree relative with CRC diagnosed before age 60 approximately doubles the lifetime risk of colorectal cancer compared to the general population per the Mayo Clinic. If the first-degree relative was diagnosed at age 60 or older, the risk increase is more modest, and screening can begin at age 40 with a standard 10-year colonoscopy interval per UpToDate. Multiple first-degree relatives with CRC or a relative with an advanced adenoma before age 60 further increases risk and warrants earlier and more frequent surveillance per the Cleveland Clinic.\n\nHEREDITARY SYNDROMES:\nClinicians should evaluate family history for patterns suggestive of hereditary syndromes such as Lynch syndrome (hereditary nonpolyposis colorectal cancer, HNPCC) or familial adenomatous polyposis (FAP), which require genetic counseling, earlier screening (as young as age 20 to 25 for Lynch, age 10 to 12 for FAP), and more frequent surveillance per Harrison's Principles of Internal Medicine and the CDC. Red flags include multiple generations affected, early-onset cancers, and associated extracolonic malignancies (endometrial, ovarian, urinary tract in Lynch syndrome) per UpToDate.\n\nKEY LEARNING POINTS:\nFirst-degree relative with CRC diagnosed before age 60 triggers screening at age 40 or 10 years before the relative's diagnosis (whichever is earlier) with colonoscopy every 5 years. This is earlier and more frequent than the average-risk recommendation of age 45 with 10-year intervals. Family history patterns suggestive of Lynch syndrome or FAP require genetic evaluation and even earlier screening."
  },
  {
    "id": 162,
    "categoryId": 3,
    "question": "Eosinophilic Esophagitis (EoE) is strongly associated with which comorbidity?",
    "options": [
      "A) Diabetes",
      "B) Atopic Disease (Asthma, Eczema, Allergies)",
      "C) Alcohol use",
      "D) Smoking"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Atopic Disease â€” Asthma, Eczema, Allergies).\n\nPATHOPHYSIOLOGY:\nEosinophilic esophagitis (EoE) is a chronic, immune-mediated inflammatory disease of the esophagus driven by a Th2-type allergic response to food and possibly environmental antigens. Exposure to allergens triggers release of interleukin-5 (IL-5) and IL-13, which recruit eosinophils to the esophageal mucosa and stimulate esophageal epithelial remodeling. Over time, chronic eosinophilic infiltration leads to subepithelial fibrosis, muscular hypertrophy, and esophageal stricture formation. The disease shares its immunologic foundation with other atopic conditions, which is why it has been called the \"asthma of the esophagus.\"\n\nCLINICAL PRESENTATION:\nEoE predominantly affects young males (male-to-female ratio of 3:1) with a strong personal or family history of atopic disease. Approximately 50-80% of EoE patients have concurrent asthma, allergic rhinitis, eczema, or food allergies. Adults typically present with dysphagia to solids and food impaction episodes, while children may present with feeding difficulties, vomiting, and failure to thrive. Endoscopic findings include esophageal rings (trachealization), linear furrows, white exudates (representing eosinophilic microabscesses), and strictures.\n\nDIAGNOSIS AND MANAGEMENT:\nDiagnosis requires esophageal biopsies showing 15 or more eosinophils per high-power field after excluding other causes of esophageal eosinophilia, particularly GERD. Current first-line treatment options include proton pump inhibitors (which have direct anti-inflammatory effects in EoE), swallowed topical corticosteroids (fluticasone or budesonide), and dietary elimination therapy. Dupilumab, an anti-IL-4 receptor alpha monoclonal antibody, is FDA-approved for EoE and represents the first biologic therapy for this condition.\n\nKEY LEARNING POINTS:\nEoE is strongly associated with atopic disease, with 50-80% of patients having concurrent asthma, eczema, or food allergies. Diagnosis requires 15 or more eosinophils per high-power field on esophageal biopsy. First-line treatments include PPIs, swallowed topical corticosteroids, and dietary elimination. Dupilumab is the first FDA-approved biologic for EoE."
  },
  {
    "id": 163,
    "categoryId": 3,
    "question": "Chronic cannabis use is paradoxically associated with:",
    "options": [
      "A) Increased appetite only",
      "B) Hyperemesis Syndrome (cyclic vomiting relieved by hot showers)",
      "C) Constipation",
      "D) Peptic Ulcers"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Cannabinoid Hyperemesis Syndrome â€” cyclic vomiting relieved by hot showers).\n\nPATHOPHYSIOLOGY:\nCannabinoid hyperemesis syndrome (CHS) is a paradoxical condition in which chronic cannabis use (typically daily use for more than one year) causes recurrent episodes of severe nausea, vomiting, and abdominal pain despite the well-known antiemetic properties of cannabinoids. The pathophysiology is not fully understood, but chronic overstimulation of CB1 receptors in the enteric nervous system and hypothalamus is believed to dysregulate the emetic threshold and gastric motility. Cannabis accumulates in fat tissue, so chronic users maintain persistently elevated levels that may desensitize central antiemetic CB1 pathways while overstimulating peripheral CB1 receptors that slow gastric emptying.\n\nCLINICAL PRESENTATION:\nCHS presents in three phases: a prodromal phase with early morning nausea and vague abdominal discomfort, a hyperemetic phase with intractable vomiting and compulsive hot bathing or showering (which temporarily relieves symptoms by activating TRPV1 thermoreceptors in the skin that counteract visceral CB1-mediated nausea), and a recovery phase after cannabis cessation. Patients often present repeatedly to emergency departments before the diagnosis is made, frequently undergoing extensive and costly negative workups.\n\nDIAGNOSIS AND MANAGEMENT:\nDiagnosis is clinical, based on chronic cannabis use (greater than one year), recurrent severe vomiting, and the characteristic relief with hot water bathing. The Rome IV criteria include these features. Capsaicin cream applied topically to the abdomen (also a TRPV1 agonist) has shown benefit in acute episodes. Haloperidol is effective for acute symptom relief in the emergency setting. The only definitive treatment is complete cannabis cessation, after which symptoms typically resolve within 1-2 weeks and do not recur unless use resumes.\n\nKEY LEARNING POINTS:\nCHS should be suspected in any chronic daily cannabis user presenting with cyclic vomiting and compulsive hot shower use. The condition results from chronic CB1 receptor overstimulation in the gut. Topical capsaicin and haloperidol provide acute symptomatic relief. Complete cannabis cessation is the only definitive treatment."
  },
  {
    "id": 164,
    "categoryId": 3,
    "question": "Which lifestyle modification has the strongest evidence for improving nocturnal GERD?",
    "options": [
      "A) Avoiding spicy food",
      "B) Elevating the head of the bed (or sleeping on left side)",
      "C) Eating more fiber",
      "D) Drinking milk before bed"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Elevating the head of the bed or sleeping on the left side).\n\nPATHOPHYSIOLOGY:\nNocturnal GERD occurs because the supine position eliminates gravity-assisted esophageal acid clearance, prolongs acid contact time with the esophageal mucosa, and reduces the frequency of swallowing (which normally triggers primary peristalsis to clear refluxate). Studies using 24-hour pH monitoring have demonstrated that supine acid exposure is a stronger predictor of esophageal mucosal injury than upright reflux. Additionally, the recumbent position places the gastroesophageal junction at the same level as the gastric acid pool, facilitating retrograde flow.\n\nEVIDENCE BASE:\nElevating the head of the bed by 6-8 inches (using bed blocks or a wedge pillow, not simply stacking pillows, which only flexes the neck) harnesses gravity to keep the gastroesophageal junction above the gastric acid pool. Randomized controlled trials demonstrate significant reductions in acid exposure time, reflux episodes, and symptom severity with bed elevation. Sleeping in the left lateral decubitus position further reduces reflux because the gastric cardia and esophagogastric junction are positioned above the gastric acid pool due to the anatomic J-shape of the stomach, whereas right-side sleeping places the junction below the acid pool, increasing reflux.\n\nCLINICAL APPLICATION:\nThe combination of head-of-bed elevation with left lateral positioning provides additive benefit and represents the strongest evidence-based lifestyle modification for nocturnal GERD. Other important behavioral measures include avoiding meals within 2-3 hours of bedtime and avoiding alcohol and high-fat foods in the evening, which delay gastric emptying and reduce lower esophageal sphincter pressure.\n\nKEY LEARNING POINTS:\nElevating the head of the bed by 6-8 inches and left lateral sleeping position have the strongest evidence among lifestyle modifications for nocturnal GERD. Bed elevation should use blocks or a wedge pillow, not stacked pillows. Right-side sleeping worsens reflux due to gastric anatomy. Avoiding meals 2-3 hours before bedtime provides additional benefit."
  },
  {
    "id": 165,
    "categoryId": 3,
    "question": "For IBS-C (Constipation), which secretagogue is approved and works by increasing cGMP to secrete fluid into the gut?",
    "options": [
      "A) Polyethylene Glycol (Miralax)",
      "B) Linaclotide (Linzess)",
      "C) Senna",
      "D) Docusate"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Linaclotide/Linzess).\n\nPATHOPHYSIOLOGY:\nIrritable bowel syndrome with constipation (IBS-C) involves disordered intestinal motility and visceral hypersensitivity, with reduced intestinal fluid secretion contributing to hard stools and incomplete evacuation. The guanylate cyclase-C (GC-C) receptor system, located on the luminal surface of intestinal epithelial cells, plays a critical role in regulating fluid and electrolyte secretion into the intestinal lumen.\n\nMECHANISM OF ACTION:\nLinaclotide is a GC-C receptor agonist that binds to GC-C on enterocytes, increasing intracellular cyclic guanosine monophosphate (cGMP). Elevated intracellular cGMP activates the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel, driving chloride and bicarbonate secretion into the intestinal lumen, followed by sodium and water through a paracellular pathway. This accelerates intestinal transit and softens stool. Importantly, extracellular cGMP also acts on submucosal pain-sensing afferent neurons to reduce visceral hypersensitivity, providing an analgesic effect that distinguishes linaclotide from simple laxatives.\n\nCLINICAL APPLICATION:\nLinaclotide is FDA-approved for IBS-C (290 mcg daily) and chronic idiopathic constipation (145 mcg daily). It should be taken on an empty stomach at least 30 minutes before the first meal of the day to maximize efficacy. The most common adverse effect is diarrhea, occurring in approximately 16-20% of patients. Linaclotide is contraindicated in children under 2 years old due to risk of severe dehydration. Plecanatide is another GC-C agonist with a similar mechanism but lower diarrhea rates.\n\nKEY LEARNING POINTS:\nLinaclotide is a GC-C agonist that increases intestinal cGMP, activating CFTR chloride channels to secrete fluid into the gut lumen. It uniquely reduces visceral pain through extracellular cGMP effects on submucosal afferents. It is taken 30 minutes before the first meal. Diarrhea is the most common side effect, occurring in 16-20% of patients."
  },
  {
    "id": 166,
    "categoryId": 3,
    "question": "Typical presentation of Biliary Colic?",
    "options": [
      "A) Constant LLQ pain",
      "B) RUQ/Epigastric pain occurring 30-60 mins after a fatty meal, lasting 1-4 hours",
      "C) Burning chest pain relieved by antacids",
      "D) Periumbilical pain migrating to RLQ"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (RUQ/Epigastric pain occurring 30-60 minutes after a fatty meal, lasting 1-4 hours).\n\nPATHOPHYSIOLOGY:\nBiliary colic occurs when a gallstone temporarily obstructs the cystic duct during gallbladder contraction. Cholecystokinin (CCK), released from duodenal I-cells in response to fatty food entering the duodenum, stimulates gallbladder contraction. When a stone impacts the cystic duct, the gallbladder contracts against a fixed obstruction, producing visceral pain. Despite the name \"colic,\" the pain is typically steady rather than wavelike, as the gallbladder maintains sustained contraction. When the stone dislodges or falls back into the gallbladder, the obstruction resolves and pain subsides.\n\nCLINICAL PRESENTATION:\nPain characteristically begins 30-60 minutes after a fatty meal, localizes to the right upper quadrant or epigastrium, may radiate to the right scapula or shoulder (referred pain via the phrenic nerve and C3-C5 dermatomes), and lasts 1-4 hours before resolving completely. Episodes are typically intermittent, with symptom-free intervals of days to months. Nausea and vomiting are common accompaniments. Importantly, the physical examination between episodes is entirely normal, and laboratory values (liver enzymes, bilirubin, lipase) are normal.\n\nDIFFERENTIAL DIAGNOSIS AND MANAGEMENT:\nIf pain persists beyond 4-6 hours or is accompanied by fever and leukocytosis, acute cholecystitis (sustained cystic duct obstruction with gallbladder wall inflammation) should be suspected. Ultrasound is the imaging study of choice, with sensitivity exceeding 95% for gallstones. Elective laparoscopic cholecystectomy is recommended for symptomatic gallstones, as recurrent episodes occur in approximately 70% of patients within 2 years. A HIDA scan is used when cholecystitis is suspected but ultrasound is equivocal.\n\nKEY LEARNING POINTS:\nBiliary colic presents as steady RUQ or epigastric pain 30-60 minutes after fatty meals, lasting 1-4 hours before complete resolution. Pain persisting beyond 4-6 hours with fever suggests progression to acute cholecystitis. Ultrasound is the first-line imaging study with greater than 95% sensitivity for gallstones. Elective cholecystectomy is recommended because recurrence approaches 70% within 2 years."
  },
  {
    "id": 167,
    "categoryId": 3,
    "question": "A Hiatal Hernia contributes to GERD primarily by:",
    "options": [
      "A) Increasing acid production",
      "B) Displacing the Lower Esophageal Sphincter (LES) into the chest, reducing the diaphragm's pinchcock effect",
      "C) Causing H. pylori infection",
      "D) Slowing gastric emptying"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Displacing the LES into the chest, reducing the diaphragm's pinchcock effect).\n\nPATHOPHYSIOLOGY:\nThe lower esophageal sphincter (LES) normally functions as an anti-reflux barrier through two complementary mechanisms: intrinsic smooth muscle tone of the LES itself and extrinsic compression by the crural diaphragm, which wraps around the distal esophagus at the hiatus and provides a \"pinchcock\" effect during inspiration. In a sliding hiatal hernia (type I, accounting for 95% of hiatal hernias), the gastroesophageal junction migrates cephalad through the diaphragmatic hiatus into the thorax, physically separating the LES from the crural diaphragm.\n\nCLINICAL SIGNIFICANCE:\nThis anatomic displacement eliminates the extrinsic diaphragmatic compression, reducing total anti-reflux barrier pressure by approximately 50%. The herniated gastric pouch above the diaphragm also creates an acid reservoir that can re-reflux into the esophagus during swallow-induced LES relaxation. Additionally, hiatal hernias impair esophageal acid clearance by trapping acid in the hernial sac. The combination of reduced LES pressure, an acid reservoir, and impaired clearance makes hiatal hernia one of the most important anatomic contributors to GERD severity.\n\nDIAGNOSIS AND MANAGEMENT:\nHiatal hernias are commonly identified on upper endoscopy, barium swallow, or CT imaging. Most small, asymptomatic sliding hernias require no treatment. Medical management of associated GERD follows standard guidelines (lifestyle modifications, PPIs). Surgical repair (fundoplication with hiatal hernia reduction) is considered for patients with refractory symptoms, large hernias (greater than 5 cm), or paraesophageal hernias (type II-IV) due to risk of volvulus and strangulation.\n\nKEY LEARNING POINTS:\nHiatal hernias cause GERD primarily by separating the LES from the crural diaphragm, eliminating extrinsic compression and reducing anti-reflux barrier pressure by approximately 50%. The herniated gastric pouch creates an acid reservoir above the diaphragm. Sliding (type I) hernias account for 95% of cases. Surgical repair is considered for refractory symptoms, large hernias, or paraesophageal hernias."
  },
  {
    "id": 168,
    "categoryId": 3,
    "question": "A 70-year-old on Clopidogrel (Plavix) needs a colonoscopy for screening. Management?",
    "options": [
      "A) Continue Clopidogrel",
      "B) Stop Clopidogrel 5-7 days prior (if cardio risk permits)",
      "C) Switch to Warfarin",
      "D) Stop Aspirin only"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Stop Clopidogrel 5-7 days prior if cardiology risk permits).\n\nPATHOPHYSIOLOGY:\nClopidogrel (Plavix) is an irreversible P2Y12 ADP receptor antagonist that inhibits platelet aggregation for the entire 7-10 day lifespan of the platelet. Because the inhibition is irreversible, platelet function only recovers as new, uninhibited platelets are produced by the bone marrow. Polypectomy during colonoscopy carries a risk of delayed post-polypectomy bleeding of 1-2%, and this risk increases significantly when antiplatelet agents are continued.\n\nGUIDELINE RECOMMENDATIONS:\nThe ASGE and ACC/AHA guidelines recommend discontinuing clopidogrel 5-7 days prior to colonoscopy when polypectomy is anticipated, allowing sufficient new platelet production to restore adequate hemostasis. This decision must be made in collaboration with the prescribing cardiologist, particularly in patients with recent coronary stent placement, because premature discontinuation of dual antiplatelet therapy within 6 months of a drug-eluting stent carries a significant risk of in-stent thrombosis, which has a mortality rate of approximately 20-40%.\n\nCLINICAL NUANCES:\nAspirin is generally continued through colonoscopy and polypectomy because the bleeding risk associated with aspirin alone is minimal and the cardiovascular risk of stopping it outweighs the procedural bleeding risk. For patients in whom clopidogrel cannot be safely stopped (recent stent, high thrombotic risk), the procedure should be deferred until the minimum antiplatelet duration is completed, or the colonoscopy can proceed with biopsy only and cold snare polypectomy of small polyps, which carry lower bleeding risk than hot polypectomy.\n\nKEY LEARNING POINTS:\nClopidogrel must be held 5-7 days before colonoscopy with anticipated polypectomy due to irreversible platelet inhibition. Aspirin is usually continued through the procedure. Cardiology clearance is essential, especially in patients with recent coronary stents. In high-thrombotic-risk patients, cold snare polypectomy is a safer alternative to hot polypectomy."
  },
  {
    "id": 169,
    "categoryId": 3,
    "question": "Secondary Lactose Intolerance is commonly seen after:",
    "options": [
      "A) Viral Gastroenteritis",
      "B) Constipation",
      "C) Appendectomy",
      "D) PPI use"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Viral Gastroenteritis).\n\nPATHOPHYSIOLOGY:\nLactase is a brush border enzyme located exclusively at the tips of the small intestinal villi, making it the most vulnerable of all disaccharidases to mucosal injury. Viral gastroenteritis (caused by rotavirus, norovirus, and other enteric viruses) damages the intestinal epithelium and shears off villous tips, causing a transient loss of lactase activity. This secondary (acquired) lactose intolerance is distinct from primary lactase non-persistence (the genetically programmed downregulation of lactase that occurs in approximately 65-70% of the world's population after weaning).\n\nCLINICAL PRESENTATION:\nFollowing a bout of viral gastroenteritis, patients may develop bloating, flatulence, abdominal cramps, and watery diarrhea specifically after consuming lactose-containing dairy products. Parents commonly notice that infants and toddlers develop worsened diarrhea when milk or formula is reintroduced after a gastroenteritis episode. The condition is self-limiting and typically resolves within 2-4 weeks as the intestinal epithelium regenerates and mature lactase-expressing enterocytes return to the villous tips.\n\nOTHER CAUSES OF SECONDARY LACTOSE INTOLERANCE:\nAny condition that damages the small intestinal mucosa can cause secondary lactose intolerance, including celiac disease, Crohn's disease involving the small bowel, tropical sprue, radiation enteritis, chemotherapy-induced mucositis, and giardiasis. In these conditions, lactose intolerance persists until the underlying disease is treated and mucosal healing occurs.\n\nKEY LEARNING POINTS:\nLactase resides at the villous tips and is the first brush border enzyme lost with mucosal injury. Viral gastroenteritis is the most common cause of secondary (transient) lactose intolerance. Symptoms typically resolve within 2-4 weeks as the epithelium regenerates. Any condition damaging small intestinal mucosa (celiac disease, Crohn's, giardiasis) can also cause secondary lactose intolerance."
  },
  {
    "id": 170,
    "categoryId": 3,
    "question": "Extra-intestinal manifestations of IBD (Crohn's/UC) include all EXCEPT:",
    "options": [
      "A) Uveitis",
      "B) Erythema Nodosum",
      "C) Ankylosing Spondylitis",
      "D) COPD"
    ],
    "correctAnswer": 3,
    "explanation": "CORRECT: D (COPD is not an extra-intestinal manifestation of IBD).\n\nPATHOPHYSIOLOGY:\nInflammatory bowel disease is a systemic immune-mediated condition, and approximately 25-40% of patients develop extra-intestinal manifestations (EIMs) involving the joints, skin, eyes, hepatobiliary system, and other organs. These manifestations are driven by circulating immune complexes, cross-reactive antibodies, and shared mucosal homing receptors that allow activated intestinal lymphocytes to migrate to extra-intestinal sites. Some EIMs parallel disease activity and improve with treatment of the underlying bowel disease, while others follow an independent course.\n\nMAJOR EXTRA-INTESTINAL MANIFESTATIONS:\nOcular involvement includes uveitis and episcleritis, presenting as eye pain, redness, and photophobia, affecting approximately 2-5% of IBD patients. Dermatologic manifestations include erythema nodosum (tender, raised, red nodules on the anterior shins, most common skin EIM) and pyoderma gangrenosum (deep ulcerative lesions, often on the legs). Musculoskeletal involvement includes peripheral arthritis (parallels disease activity), axial spondyloarthropathy and ankylosing spondylitis (independent of disease activity, associated with HLA-B27). Primary sclerosing cholangitis (PSC) is strongly associated with ulcerative colitis, occurring in approximately 5% of UC patients, and increases the risk of cholangiocarcinoma.\n\nCLINICAL SIGNIFICANCE:\nCOPD is not an extra-intestinal manifestation of IBD. While rare pulmonary involvement (bronchiolitis, interstitial lung disease) has been reported in case series, COPD itself is a separate disease entity caused by chronic tobacco smoke or environmental exposures. Recognizing EIMs is critical because they may precede bowel symptoms, occur during remission, and occasionally cause greater morbidity than the intestinal disease itself.\n\nKEY LEARNING POINTS:\nApproximately 25-40% of IBD patients develop extra-intestinal manifestations. Common EIMs include uveitis, erythema nodosum, pyoderma gangrenosum, peripheral arthritis, ankylosing spondylitis, and primary sclerosing cholangitis. COPD is not an IBD-associated extra-intestinal manifestation. Some EIMs parallel disease activity while others (spondylitis, PSC) follow an independent course."
  },
  {
    "id": 171,
    "categoryId": 3,
    "question": "A 40-year-old with dyspepsia tests positive for H. pylori. You treat them. Symptoms persist. EGD is normal. What is the diagnosis?",
    "options": [
      "A) Resistant H. pylori",
      "B) Functional Dyspepsia",
      "C) Gastric Cancer",
      "D) Gallstones"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Functional Dyspepsia).\n\nPATHOPHYSIOLOGY:\nFunctional dyspepsia is the most common cause of chronic dyspepsia, accounting for approximately 70-80% of cases after organic causes have been excluded. When a patient with dyspepsia tests positive for H. pylori, current guidelines recommend eradication therapy because H. pylori causes chronic gastritis and peptic ulcer disease. However, only approximately 10% of H. pylori-positive patients with dyspepsia will have their symptoms resolve after successful eradication, reflecting the high prevalence of coexisting functional dyspepsia in which H. pylori is an incidental finding rather than the symptom driver.\n\nCLINICAL REASONING:\nIn this clinical scenario, the patient has persistent symptoms despite appropriate H. pylori treatment and a normal endoscopy, which excludes peptic ulcer disease, gastric malignancy, and esophagitis. Persistent symptoms after H. pylori eradication with normal EGD is the classic presentation of functional dyspepsia, a disorder of gut-brain interaction involving visceral hypersensitivity, impaired gastric accommodation, delayed gastric emptying, and central pain amplification. The ACG and Rome IV criteria define functional dyspepsia as bothersome postprandial fullness, early satiation, epigastric pain, or epigastric burning occurring for at least 3 months with onset at least 6 months prior.\n\nMANAGEMENT:\nTreatment of functional dyspepsia after H. pylori eradication includes low-dose tricyclic antidepressants (amitriptyline 10-50 mg nightly) for the epigastric pain subtype, prokinetics (buspirone for impaired accommodation) for the postprandial distress subtype, and cognitive behavioral therapy for refractory cases. PPI therapy can be trialed but has modest efficacy in functional dyspepsia.\n\nKEY LEARNING POINTS:\nFunctional dyspepsia is the diagnosis when symptoms persist after H. pylori eradication and EGD is normal. Only about 10% of dyspeptic patients improve with H. pylori eradication alone. H. pylori eradication is still indicated to reduce gastric cancer risk regardless of symptom response. Low-dose TCAs are first-line for the epigastric pain subtype of functional dyspepsia."
  },
  {
    "id": 172,
    "categoryId": 3,
    "question": "Abdominal distension that resolves completely overnight suggests:",
    "options": [
      "A) Ascites",
      "B) Large Ovarian Cyst",
      "C) Functional Bloating / Gas",
      "D) Organomegaly"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Functional Bloating/Gas).\n\nPATHOPHYSIOLOGY:\nFunctional bloating is a disorder of gut-brain interaction in which abdominal distension results from a combination of visceral hypersensitivity, impaired gas transit, altered gut microbiome fermentation, and abnormal abdomino-phrenic reflexes. In healthy individuals, intestinal gas is produced and cleared in a steady state. In functional bloating, gas transit is delayed and the diaphragm paradoxically relaxes (descends) while abdominal wall muscles relax, creating visible distension that is often measurable by abdominal girth increase of 3-5 cm over the course of a day.\n\nCLINICAL SIGNIFICANCE:\nThe key diagnostic clue in this question is that the distension resolves completely overnight. During sleep, colonic motility shifts to propagating contractions that clear retained gas, and the conscious visceral hypersensitivity that amplifies the sensation of distension is absent. Structural causes of abdominal distension, including ascites, large ovarian cysts, organomegaly, and abdominal masses, produce fixed distension that does not resolve with sleep or positional changes.\n\nDIFFERENTIAL DIAGNOSIS:\nAscites causes progressive distension with shifting dullness, fluid wave, and associated signs of liver disease or malignancy. Ovarian masses cause persistent, gradually increasing distension unrelated to meals or time of day. Organomegaly (hepatomegaly, splenomegaly) is palpable on examination and constant. The fluctuating nature of bloating that worsens throughout the day and resolves overnight essentially excludes all structural etiologies and points definitively to a functional or fermentation-related process such as SIBO, carbohydrate malabsorption, or functional bloating.\n\nKEY LEARNING POINTS:\nAbdominal distension that resolves completely overnight is characteristic of functional bloating or gas-related distension. Structural causes (ascites, masses, organomegaly) produce fixed distension that does not fluctuate with sleep. Functional bloating often worsens progressively throughout the day due to accumulated gas from fermentation. This clinical pattern helps avoid unnecessary imaging for structural pathology."
  },
  {
    "id": 173,
    "categoryId": 3,
    "question": "Which lab pattern suggests Alcoholic Liver Disease?",
    "options": [
      "A) AST > ALT (2:1 ratio)",
      "B) ALT > AST",
      "C) Elevated Alk Phos only",
      "D) Low GGT"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (AST greater than ALT, typically in a 2:1 ratio).\n\nPATHOPHYSIOLOGY:\nThe characteristic AST-to-ALT ratio of 2:1 or greater in alcoholic liver disease results from two complementary mechanisms. First, chronic alcohol consumption depletes pyridoxal-5-phosphate (the active form of vitamin B6), which is a required cofactor for ALT synthesis but not for AST synthesis. This selectively suppresses ALT production, lowering its serum level relative to AST. Second, alcohol causes direct mitochondrial injury in hepatocytes, and AST exists in both cytoplasmic and mitochondrial isoforms (mAST), whereas ALT is predominantly cytoplasmic. Mitochondrial damage releases the mitochondrial AST isoform, preferentially elevating AST.\n\nCLINICAL PRESENTATION:\nIn alcoholic hepatitis, transaminases are characteristically only mildly to moderately elevated, typically below 300-500 IU/L, even in severe disease. This distinguishes it from viral hepatitis and drug-induced liver injury, where transaminases may exceed 1000 IU/L. The AST:ALT ratio greater than 2:1 combined with an elevated GGT (gamma-glutamyl transferase, induced by alcohol) is highly suggestive of alcohol-related liver disease. Mean corpuscular volume (MCV) is often elevated due to direct toxic effects of alcohol on erythropoiesis.\n\nDIFFERENTIAL DIAGNOSIS:\nIn most other forms of hepatocellular injury (viral hepatitis, MASLD, drug-induced liver injury), ALT exceeds AST because the predominantly cytoplasmic injury releases more ALT. The notable exception is advanced cirrhosis from any etiology, where the AST:ALT ratio may reverse above 1 as the liver loses its capacity to clear AST and hepatic stellate cell activation alters aminotransferase release patterns.\n\nKEY LEARNING POINTS:\nAST greater than ALT in a 2:1 ratio is characteristic of alcoholic liver disease due to B6 depletion suppressing ALT and mitochondrial injury releasing AST. Transaminases in alcoholic hepatitis rarely exceed 300-500 IU/L. Elevated GGT supports alcohol-related etiology. Advanced cirrhosis from any cause can also produce an AST-predominant pattern."
  },
  {
    "id": 174,
    "categoryId": 1,
    "question": "A 45-year-old male with a strong family history of premature MI (father died at 45) has an LDL of 110 mg/dL. You suspect genetic risk. Which specialized lipid marker does the National Lipid Association (NLA) and ACC/AHA recommend checking ONCE in a lifetime to risk-stratify him?",
    "options": [
      "A) Apolipoprotein B (ApoB)",
      "B) Lipoprotein(a) [Lp(a)]",
      "C) VLDL",
      "D) Homocysteine"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Lipoprotein(a) [Lp(a)]).\n\nCLINICAL REASONING:\nThe 2018 ACC/AHA Cholesterol Guidelines and the National Lipid Association recommend measuring lipoprotein(a) once in a patient's lifetime as a risk-enhancing factor that can inform statin therapy decisions in borderline or intermediate-risk patients per Harrison's Principles of Internal Medicine. Lp(a) is particularly important to check in patients with a strong family history of premature atherosclerotic cardiovascular disease (ASCVD in first-degree male relative before age 55 or female relative before age 65, as in this patient whose father died of MI at 45) per UpToDate.\n\nPATHOPHYSIOLOGY:\nLipoprotein(a) is an LDL-like particle with an additional apolipoprotein(a) molecule covalently bound to apolipoprotein B-100 via a disulfide bond per Harrison's Principles of Internal Medicine. Lp(a) promotes atherosclerosis through the same mechanisms as LDL (cholesterol deposition in the arterial intima) but has additional prothrombotic properties because apolipoprotein(a) is structurally homologous to plasminogen, competing with plasminogen for binding to fibrin and thereby inhibiting fibrinolysis per UpToDate. Lp(a) levels are more than 90% genetically determined (primarily by the LPA gene) and are minimally affected by diet, exercise, or standard lipid-lowering therapies per the Cleveland Clinic. Levels above 50 mg/dL (or 125 nmol/L) are considered elevated and represent a risk-enhancing factor per the Mayo Clinic.\n\nCLINICAL SIGNIFICANCE:\nElevated Lp(a) is present in approximately 20% of the population and independently increases ASCVD risk by 2 to 3-fold per UpToDate. Standard statins do not lower Lp(a) (and may modestly increase it), while PCSK9 inhibitors reduce Lp(a) by approximately 20 to 30%. Novel antisense oligonucleotides (pelacarsen) and small interfering RNA therapies targeting hepatic Lp(a) production are in advanced clinical trials per Harrison's Principles of Internal Medicine.\n\nKEY LEARNING POINTS:\nLp(a) should be measured once in a lifetime, especially in patients with family history of premature ASCVD, as it is more than 90% genetically determined and not affected by lifestyle. Levels above 50 mg/dL are a risk-enhancing factor that can inform statin therapy decisions. Lp(a) promotes both atherosclerosis and thrombosis due to its structural homology with plasminogen."
  },
  {
    "id": 175,
    "categoryId": 4,
    "question": "A 75-year-old female has a TSH of 7.5 mIU/L (High) and a normal Free T4. She is asymptomatic. She has no history of heart failure or goiter. According to American Thyroid Association (ATA) guidelines, what is the best management?",
    "options": [
      "A) Start full dose Levothyroxine (1.6 mcg/kg)",
      "B) Start low dose Levothyroxine (25 mcg)",
      "C) Monitor and repeat TSH in 3-6 months",
      "D) Order Thyroid Ultrasound"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Monitor and repeat TSH in 3-6 months).\n\nPATHOPHYSIOLOGY:\nSubclinical hypothyroidism is defined as an elevated TSH with a normal free T4 level, indicating that the hypothalamic-pituitary-thyroid axis is providing increased stimulation to maintain adequate peripheral thyroid hormone production. The condition is common, affecting 4 to 10% of the general adult population and increasing in prevalence with age to approximately 15 to 20% of adults over 70 years per data from NHANES and Harrison's Principles of Internal Medicine. An important physiologic consideration in elderly patients is that the TSH reference range shifts upward with advancing age, independent of thyroid disease. Analysis of the NHANES III dataset demonstrated that the 97.5th percentile of TSH in individuals aged 70 to 79 was approximately 5.9 mIU/L and in those over 80 was approximately 7.5 mIU/L, compared to 4.1 mIU/L in the 20 to 29 age group. This age-related TSH elevation likely reflects physiologic changes in hypothalamic-pituitary set point, reduced thyroid hormone clearance, and decreased peripheral tissue sensitivity to thyroid hormone, rather than occult thyroid disease. Consequently, applying young-adult TSH reference ranges to elderly patients risks overdiagnosis and overtreatment of a physiologically normal state.\n\nCLINICAL REASONING:\nThe decision to treat subclinical hypothyroidism depends on the degree of TSH elevation, patient age, symptoms, and comorbidities. For patients with TSH consistently above 10 mIU/L, the ATA, Endocrine Society, and European Thyroid Association recommend levothyroxine treatment regardless of age, as the rate of progression to overt hypothyroidism is approximately 5% per year and cardiovascular risk may be increased. However, for patients with TSH between the upper limit of normal and 10 mIU/L, the evidence for treatment benefit is much weaker, particularly in elderly patients. The TRUST trial (NEJM 2017), a landmark randomized controlled trial of levothyroxine versus placebo in 737 adults aged 65 and older with subclinical hypothyroidism (mean TSH 6.4 mIU/L), demonstrated no improvement in hypothyroid symptoms, tiredness, quality of life, blood pressure, BMI, or cognitive function with treatment over 12 months. A subsequent individual participant data meta-analysis published in The Lancet confirmed these findings, showing no benefit of levothyroxine on quality of life or thyroid-related symptoms in older adults with TSH below 10. Furthermore, overtreatment with levothyroxine in elderly patients carries meaningful risks including atrial fibrillation (which increases stroke risk), accelerated bone loss and osteoporotic fracture, angina exacerbation, and anxiety, all of which are more consequential in the elderly population.\n\nMANAGEMENT:\nFor this 75-year-old asymptomatic patient with TSH of 7.5 and no heart failure or goiter, the appropriate management is observation with repeat TSH testing in 3 to 6 months to confirm the elevation is persistent rather than transient (up to 50% of mildly elevated TSH values normalize on repeat testing per data from UpToDate). If the TSH remains elevated on repeat testing, continued monitoring every 6 to 12 months is reasonable as long as the patient remains asymptomatic and the TSH stays below 10. Factors that would favor treatment initiation include TSH rising above 10, development of hypothyroid symptoms, presence of positive anti-TPO antibodies (which increase the annual rate of progression to overt hypothyroidism from 2 to 3% to approximately 5%), symptomatic heart failure, or planned pregnancy. If treatment is ultimately initiated in an elderly patient, the starting dose should be low (25 mcg daily, or 12.5 mcg in patients with coronary artery disease) to avoid cardiac stress, with gradual titration and a target TSH of 4 to 6 mIU/L rather than the 0.5 to 2.5 mIU/L target used in younger adults.\n\nKEY LEARNING POINTS:\nSubclinical hypothyroidism with TSH below 10 in asymptomatic elderly patients should be monitored rather than treated, as the TRUST trial demonstrated no benefit of levothyroxine on symptoms, quality of life, or cognitive function in adults over 65. The TSH reference range shifts upward with age, and applying young-adult targets risks overtreatment with consequent atrial fibrillation, bone loss, and cardiac complications. If treatment is initiated in elderly patients, start at 25 mcg and target TSH of 4 to 6 mIU/L."
  },
  {
    "id": 176,
    "categoryId": 13,
    "question": "You are managing a patient with chronic Gout. He is on Allopurinol 100mg daily. His Uric Acid is 6.8 mg/dL. He has had one flare in the last year. According to the ACR 'Treat-to-Target' guidelines, what is the next step?",
    "options": [
      "A) Continue current dose; 6.8 is acceptable",
      "B) Increase Allopurinol to target Uric Acid < 6.0 mg/dL",
      "C) Stop Allopurinol",
      "D) Add Probenecid"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Increase Allopurinol to target Uric Acid below 6.0 mg/dL).\n\nTREAT-TO-TARGET STRATEGY:\nThe 2020 American College of Rheumatology conditional recommendation for gout management emphasizes a treat-to-target approach for urate-lowering therapy (ULT). The goal is to achieve and maintain a serum uric acid level below 6.0 mg/dL, which is well below the monosodium urate saturation point of approximately 6.8 mg/dL at physiologic temperature and pH. At levels below 6.0 mg/dL, existing crystal deposits gradually dissolve over months to years, reducing flare frequency, shrinking tophi, and preventing further joint damage. For patients with severe tophaceous gout, some guidelines recommend targeting below 5.0 mg/dL to accelerate tophus resolution.\n\nALLOPURINOL DOSE TITRATION:\nAllopurinol should be initiated at 100 mg daily (50 mg in chronic kidney disease stage 3 or higher) and increased by 100 mg every two to four weeks until the serum urate target is achieved. The maximum FDA-approved dose is 800 mg daily, though most patients achieve target at 300 to 400 mg. A common clinical error is leaving patients on 100 mg without titrating, which is rarely a therapeutic final dose. Serum urate should be checked two to four weeks after each dose adjustment. HLA-B*5801 testing is recommended before starting allopurinol in patients of Southeast Asian, African American, or Native Hawaiian/Pacific Islander descent due to increased risk of severe hypersensitivity reaction (DRESS or Stevens-Johnson syndrome).\n\nMONITORING AND LONG-TERM MANAGEMENT:\nOnce the target urate level is achieved, monitoring should continue every six to twelve months. ULT is generally a lifelong therapy. Febuxostat is an alternative xanthine oxidase inhibitor for patients who cannot tolerate allopurinol, though the CARES trial raised concerns about cardiovascular mortality, and it is now reserved as a second-line agent. Probenecid (a uricosuric) can be added or used as monotherapy in patients with adequate renal function and documented uric acid underexcretion.\n\nKEY LEARNING POINTS:\nThe ACR treat-to-target goal for gout is serum uric acid below 6.0 mg/dL. Allopurinol 100 mg is a starting dose, not a therapeutic dose, and must be titrated upward every two to four weeks. Maintaining uric acid below the saturation point gradually dissolves crystal deposits and prevents future flares. HLA-B*5801 testing is indicated in high-risk populations before starting allopurinol."
  },
  {
    "id": 177,
    "categoryId": 7,
    "question": "A 68-year-old female has been on Alendronate (Fosamax) for 5 years. Her bone density is stable (T-score -2.0) and she has had no fractures. What does the American Association of Clinical Endocrinologists (AACE) suggest?",
    "options": [
      "A) Continue Alendronate indefinitely",
      "B) Consider a 'Drug Holiday' (stop for 3-5 years)",
      "C) Switch to Denosumab (Prolia)",
      "D) Switch to Teriparatide (Forteo)"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Consider a Drug Holiday).\n\nPATHOPHYSIOLOGY:\nBisphosphonates bind avidly to hydroxyapatite on bone surfaces and are incorporated into the bone matrix during remodeling, where they persist for years due to their extremely high binding affinity and resistance to enzymatic degradation. When osteoclasts resorb bisphosphonate-containing bone, the released drug is internalized and inhibits farnesyl pyrophosphate synthase in the mevalonate pathway, disrupting osteoclast function and inducing apoptosis. This skeletal reservoir effect means that even after the drug is discontinued, therapeutically relevant concentrations continue to be released from bone during normal remodeling for 2 to 5 years depending on the specific agent and duration of prior therapy. Alendronate has a skeletal half-life estimated at approximately 10 years, while zoledronic acid persists even longer due to its higher binding affinity.\n\nCLINICAL REASONING:\nProlonged continuous bisphosphonate use beyond 5 years for oral agents or 3 years for intravenous zoledronic acid is associated with two rare but serious complications. Atypical subtrochanteric femur fractures occur in the lateral cortex of the femoral shaft due to over-suppression of bone remodeling, which prevents the normal repair of microdamage accumulation and results in stress fractures through brittle, homogeneous bone. These fractures may be preceded by prodromal thigh or groin pain for weeks to months before complete fracture. Osteonecrosis of the jaw, though far more common with high-dose intravenous bisphosphonates used in oncology, can also occur with oral therapy and presents as exposed necrotic bone in the mandible or maxilla, typically following dental extraction or invasive dental procedures. For patients who are at low to moderate fracture risk after 5 years of oral therapy (stable bone density, no interval fractures, no major ongoing risk factors), a drug holiday of 2 to 3 years allows the residual skeletal drug reservoir to continue providing antiresorptive benefit while reducing the cumulative risk of these complications. Bone density and fracture risk should be reassessed periodically during the holiday.\n\nCONTRAST WITH DENOSUMAB:\nDenosumab (a monoclonal antibody against RANK-ligand) does not incorporate into bone and has no residual skeletal effect after discontinuation. Stopping denosumab causes rapid reversal of bone remodeling suppression with a rebound increase in osteoclast activity that can produce accelerated bone loss and an elevated risk of multiple vertebral fractures within 6 to 18 months of the last injection. For this reason, denosumab cannot be given a drug holiday and must be either continued indefinitely or transitioned to a bisphosphonate to consolidate the bone density gains before stopping.\n\nKEY LEARNING POINTS:\nBisphosphonates accumulate in the skeletal matrix and continue to exert antiresorptive effects for years after discontinuation, enabling a drug holiday after 5 years of oral therapy in low-to-moderate risk patients. Prolonged use beyond 5 years increases the risk of atypical femur fractures and osteonecrosis of the jaw due to over-suppression of bone remodeling. Denosumab cannot be given a drug holiday because discontinuation causes rapid rebound bone loss and vertebral fracture risk."
  },
  {
    "id": 178,
    "categoryId": 5,
    "question": "A patient with CKD Stage 3b (GFR 40) and Hypertension has a Potassium of 5.2. You want to start an ACE Inhibitor for proteinuria reduction. What is the management strategy?",
    "options": [
      "A) ACE Inhibitors are contraindicated if K > 5.0",
      "B) Start ACE Inhibitor and add a Potassium Binder (Patiromer)",
      "C) Start ACE Inhibitor and recommend a low-potassium diet; recheck labs in 1 week",
      "D) Use a Calcium Channel Blocker instead"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Start ACE inhibitor and recommend low-potassium diet; recheck labs in 1 week).\n\nCLINICAL REASONING:\nACE inhibitors and ARBs are the cornerstone of renoprotective therapy in CKD with proteinuria, reducing intraglomerular pressure by dilating the efferent arteriole, which decreases proteinuria and slows progression to end-stage renal disease per Harrison's Principles of Internal Medicine and UpToDate. The REIN and RENAAL trials demonstrated that ACE inhibitors and ARBs reduce the risk of CKD progression by 30 to 40% in proteinuric patients per the Cleveland Clinic. The presence of mild hyperkalemia (5.2 mEq/L) is not an absolute contraindication to initiating RAAS blockade, as the renoprotective benefits outweigh the manageable risk of potassium elevation per UpToDate.\n\nHYPERKALEMIA MANAGEMENT STRATEGY:\nACE inhibitors predictably raise serum potassium by 0.5 to 1.0 mEq/L by reducing aldosterone-mediated potassium excretion per Harrison's Principles of Internal Medicine. With a baseline potassium of 5.2, the expected rise could push levels to 5.7 to 6.2, which is manageable with dietary counseling (avoiding high-potassium foods: bananas, oranges, potatoes, tomatoes, salt substitutes containing KCl) and close monitoring per the Mayo Clinic. Rechecking serum potassium and creatinine within 1 to 2 weeks of initiation is essential to detect clinically significant hyperkalemia (greater than 5.5 requiring intervention, greater than 6.0 requiring dose reduction or discontinuation) per UpToDate and Harvard Health.\n\nADDITIONAL STRATEGIES IF POTASSIUM RISES:\nSodium polystyrene sulfonate (Kayexalate) or the newer potassium binders patiromer (Veltassa) and sodium zirconium cyclosilicate (Lokelma) can be used to maintain potassium in a safe range while preserving the renoprotective benefits of RAAS blockade per the Cleveland Clinic. Loop diuretics also promote potassium excretion per Harrison's Principles of Internal Medicine. An initial rise in creatinine of up to 30% is expected and acceptable after starting ACE inhibitors (reflecting reduced intraglomerular pressure) and should not prompt discontinuation per UpToDate.\n\nKEY LEARNING POINTS:\nACE inhibitors should be initiated despite mild hyperkalemia (5.2) in CKD with proteinuria because the renoprotective benefit (30 to 40% reduced progression) outweighs the manageable potassium risk. Dietary potassium restriction and lab rechecks within 1 to 2 weeks are essential. Newer potassium binders (patiromer, sodium zirconium cyclosilicate) allow continued RAAS blockade when hyperkalemia develops."
  },
  {
    "id": 179,
    "categoryId": 16,
    "question": "The USPSTF 2022 update on Aspirin for primary prevention of CVD changed the recommendation for adults aged 60+ to:",
    "options": [
      "A) Grade B: Recommended for all",
      "B) Grade C: Individualized decision",
      "C) Grade D: Recommend AGAINST starting",
      "D) Grade I: Insufficient Evidence"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Grade D: Recommend AGAINST starting aspirin).\n\nGUIDELINE CHANGE:\nThe USPSTF 2022 updated recommendation on aspirin for primary prevention of cardiovascular disease represents a significant shift from prior guidance per UpToDate. For adults aged 60 and older without established cardiovascular disease, the USPSTF now gives a Grade D recommendation (recommend against initiating aspirin) because the risk of major bleeding (gastrointestinal hemorrhage, hemorrhagic stroke, and intracranial bleeding) outweighs the modest reduction in atherosclerotic cardiovascular events per Harrison's Principles of Internal Medicine and the Mayo Clinic.\n\nEVIDENCE BASIS:\nThree major randomized trials published in 2018 collectively shifted the risk-benefit calculus per the Cleveland Clinic. ASPREE (Aspirin in Reducing Events in the Elderly) showed no cardiovascular benefit but increased major hemorrhage and unexpectedly higher all-cause mortality in healthy adults over 70. ASCEND (A Study of Cardiovascular Events in Diabetes) showed that aspirin reduced vascular events in diabetic patients but was offset by a nearly equivalent increase in major bleeding. ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events) found no significant cardiovascular benefit in moderate-risk adults per UpToDate. These trials reflected improvements in modern baseline cardiovascular risk management (widespread statin use, better blood pressure control) that reduced the incremental benefit of aspirin per Harvard Health.\n\nAGE-STRATIFIED RECOMMENDATIONS:\nFor adults aged 40 to 59 with a 10-year ASCVD risk of 10% or greater, the USPSTF gives a Grade C recommendation (individualized decision based on patient preference, limited net benefit), and the decision should involve shared decision-making weighing cardiovascular benefit against bleeding risk per Harrison's Principles of Internal Medicine. Aspirin for secondary prevention (patients with established ASCVD) remains strongly indicated per UpToDate and the Cleveland Clinic.\n\nKEY LEARNING POINTS:\nThe USPSTF recommends against initiating aspirin for primary CVD prevention in adults 60 and older (Grade D) because bleeding risk outweighs cardiovascular benefit in the modern era of statins and BP control. For ages 40 to 59 with 10-year ASCVD risk of 10% or greater, aspirin is an individualized shared decision (Grade C). Aspirin for secondary prevention in established ASCVD remains strongly indicated."
  },
  {
    "id": 180,
    "categoryId": 4,
    "question": "The FIGO classification system (PALM-COEIN) divides Abnormal Uterine Bleeding into Structural and Non-Structural causes. Which of the following is a 'COEIN' (Non-Structural) cause?",
    "options": [
      "A) Leiomyoma (Fibroid)",
      "B) Adenomyosis",
      "C) Coagulopathy (e.g., Von Willebrand)",
      "D) Polyp"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Coagulopathy).\n\nPATHOPHYSIOLOGY:\nThe FIGO (International Federation of Gynecology and Obstetrics) classification system, formally adopted in 2011 and revised in 2018, provides a standardized framework for categorizing the causes of abnormal uterine bleeding (AUB) in non-pregnant reproductive-age women using the PALM-COEIN acronym. This system divides etiologies into two major groups based on whether the pathology is identifiable through imaging or histopathology (structural) versus those diagnosed through laboratory testing, history, or exclusion (non-structural). The PALM group represents structural causes: Polyps (endometrial or endocervical polyps that cause intermenstrual or postcoital bleeding), Adenomyosis (ectopic endometrial glands within the myometrium causing heavy menstrual bleeding and dysmenorrhea), Leiomyomas (uterine fibroids, subclassified by their relationship to the endometrial cavity, with submucosal fibroids most likely to cause heavy bleeding), and Malignancy and hyperplasia (endometrial carcinoma and atypical hyperplasia). The COEIN group represents non-structural causes: Coagulopathy (inherited or acquired bleeding disorders), Ovulatory dysfunction (including PCOS, hypothalamic amenorrhea, and thyroid disorders), Endometrial (primary disorders of endometrial hemostasis including abnormal prostaglandin production and impaired endothelin-1 mediated vasoconstriction), Iatrogenic (hormonal contraceptives, anticoagulants, IUDs, and other medications), and Not otherwise classified (rare entities such as arteriovenous malformations and chronic endometritis).\n\nCLINICAL REASONING:\nCoagulopathy is the non-structural cause highlighted in this question and carries particular clinical importance in primary care. Von Willebrand disease (VWD), the most common inherited bleeding disorder, affects approximately 1% of the population and is present in up to 13 to 20% of women presenting with heavy menstrual bleeding according to studies published in Obstetrics and Gynecology and data reviewed in UpToDate. Many women with VWD remain undiagnosed for years because heavy menstrual bleeding is often attributed to hormonal or structural causes without investigating for underlying coagulopathy. The ACOG Committee Opinion recommends screening for bleeding disorders in any adolescent presenting with heavy menstrual bleeding at menarche, as this is frequently the first clinical manifestation of VWD or platelet function disorders. Screening should also be considered in adult women with heavy menstrual bleeding who have a history of easy bruising, bleeding with dental procedures, postpartum hemorrhage, or family history of bleeding disorders. Initial laboratory evaluation includes complete blood count with platelet count, prothrombin time, activated partial thromboplastin time, and if VWD is suspected, von Willebrand factor antigen, von Willebrand factor activity (ristocetin cofactor), and factor VIII level.\n\nTREATMENT:\nManagement of AUB depends on the specific etiology identified through the PALM-COEIN classification. For coagulopathy-related AUB, treatment includes tranexamic acid (an antifibrinolytic that reduces menstrual blood loss by 40 to 50%), combined hormonal contraceptives or progestin-containing IUDs for endometrial stabilization, and desmopressin (DDAVP) for type 1 VWD. For ovulatory dysfunction, hormonal regulation with combined oral contraceptives or cyclic progestins addresses the underlying anovulation. Structural causes may require procedural intervention: hysteroscopic polypectomy for symptomatic polyps, myomectomy or uterine artery embolization for fibroids, and endometrial biopsy followed by appropriate management for hyperplasia or malignancy. The PALM-COEIN system ensures systematic evaluation rather than empiric treatment of AUB.\n\nKEY LEARNING POINTS:\nThe PALM-COEIN system classifies AUB into structural causes (Polyps, Adenomyosis, Leiomyomas, Malignancy) and non-structural causes (Coagulopathy, Ovulatory dysfunction, Endometrial, Iatrogenic, Not classified). Von Willebrand disease is present in up to 13 to 20% of women with heavy menstrual bleeding and should be actively screened for, particularly in adolescents presenting at menarche. Systematic classification using PALM-COEIN ensures appropriate targeted evaluation rather than empiric treatment of abnormal uterine bleeding."
  },
  {
    "id": 181,
    "categoryId": 2,
    "question": "According to the Fleischner Society Guidelines (2017), an incidental solid pulmonary nodule < 6 mm in a low-risk patient requires:",
    "options": [
      "A) CT at 3 months",
      "B) CT at 12 months",
      "C) No routine follow-up",
      "D) PET Scan"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (No routine follow-up).\n\nCLINICAL REASONING:\nThe Fleischner Society 2017 guidelines provide evidence-based recommendations for management of incidentally detected pulmonary nodules on CT imaging per UpToDate and the Mayo Clinic. For a solitary solid nodule less than 6 mm in a low-risk patient (defined as minimal or no smoking history, no other known cancer risk factors), no routine follow-up imaging is recommended. The rationale is that the probability of malignancy for nodules in this size range is less than 1%, and the cumulative radiation exposure and psychological burden of serial CT surveillance outweigh the potential benefit of detecting malignancy per Harrison's Principles of Internal Medicine.\n\nNODULE SIZE AND RISK STRATIFICATION:\nRisk increases substantially with nodule size. Solid nodules 6 to 8 mm in low-risk patients warrant a follow-up CT at 6 to 12 months, while the same size in high-risk patients warrants CT at 6 to 12 months with consideration of an additional scan at 18 to 24 months per the Fleischner Society guidelines and UpToDate. Solid nodules greater than 8 mm warrant consideration of CT at 3 months, PET-CT, or tissue sampling depending on clinical context and probability of malignancy per the Cleveland Clinic. High-risk features include significant smoking history (30 or more pack-years), upper lobe location, spiculated margins, family history of lung cancer, and exposure to asbestos or radon.\n\nSUBSOLID NODULES:\nGround-glass and part-solid nodules follow a different algorithm because they carry a higher malignancy risk per millimeter of size compared to solid nodules. Ground-glass nodules less than 6 mm require no routine follow-up, but those 6 mm or greater warrant CT at 6 to 12 months and then every 2 years for a total of 5 years per the Fleischner guidelines. Part-solid nodules (containing both ground-glass and solid components) with a solid component of 6 mm or greater are concerning for invasive adenocarcinoma and require more aggressive evaluation per UpToDate.\n\nKEY LEARNING POINTS:\nIncidental solid pulmonary nodules less than 6 mm in low-risk patients have less than 1% malignancy risk and require no routine follow-up per the 2017 Fleischner Society guidelines. Risk of malignancy increases with nodule size, upper lobe location, spiculated margins, and smoking history. Subsolid nodules (ground-glass and part-solid) carry higher per-millimeter malignancy risk than solid nodules and follow a separate management algorithm."
  },
  {
    "id": 182,
    "categoryId": 10,
    "question": "You are prescribing a topical steroid for a rash on the face and groin (intertriginous areas). Which potency class is appropriate?",
    "options": [
      "A) Class 1 (Clobetasol)",
      "B) Class 3 (Triamcinolone)",
      "C) Class 7 (Hydrocortisone 1-2.5%)",
      "D) Class 5 (Betamethasone valerate)"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Low Potency - Hydrocortisone 1-2.5%).\n\nPATHOPHYSIOLOGY:\nTopical corticosteroids exert their effects by binding intracellular glucocorticoid receptors, which then translocate to the nucleus and modulate gene transcription. They suppress inflammatory cytokines (IL-1, IL-6, TNF-alpha), inhibit phospholipase A2 to reduce prostaglandin and leukotriene synthesis, decrease capillary permeability, and suppress T-cell activation. The potency of a topical steroid reflects its vasoconstrictive ability and anti-inflammatory strength, classified from Class 1 (superpotent, such as clobetasol propionate 0.05%) through Class 7 (least potent, such as hydrocortisone 1%). Potency is determined not only by the corticosteroid molecule itself but also by the vehicle, concentration, and formulation. Ointments are generally more potent than creams of the same drug because their occlusive properties enhance epidermal penetration.\n\nCLINICAL APPLICATION - SITE-SPECIFIC PRESCRIBING:\nThe face, eyelids, groin, axillae, and intertriginous areas have thin skin with a high density of corticosteroid receptors and minimal stratum corneum barrier, resulting in dramatically increased drug absorption compared to thick-skinned sites. Applying mid- to high-potency steroids to these areas accelerates local adverse effects including epidermal atrophy (skin thinning), dermal collagen degradation, striae distensae (stretch marks), telangiectasias, perioral dermatitis, steroid-induced rosacea, and acneiform eruptions. On the eyelids, prolonged use of potent steroids can cause glaucoma and cataracts due to transcorneal absorption. The general prescribing principle matches potency to anatomic site: low potency (Class 6-7, hydrocortisone 1-2.5%) for the face, eyelids, groin, axillae, and intertriginous folds; medium potency (Class 3-5, triamcinolone 0.1%) for the trunk and extremities; and high to superpotent (Class 1-2, clobetasol, betamethasone dipropionate) for thick-skinned areas such as palms, soles, and scalp, or for recalcitrant dermatoses.\n\nMANAGEMENT PRINCIPLES:\nDuration of use is as important as potency selection. Even low-potency agents should not be used continuously on thin-skinned areas for more than 2 to 4 weeks without reassessment. For chronic conditions requiring ongoing treatment, steroid-sparing agents such as topical calcineurin inhibitors (tacrolimus, pimecrolimus) are preferred for maintenance therapy on the face and intertriginous areas because they do not cause skin atrophy. When higher potency is transiently needed on sensitive sites, pulse therapy (weekends only) can minimize adverse effects.\n\nKEY LEARNING POINTS:\nThe face, groin, and intertriginous areas require low-potency topical steroids (hydrocortisone 1-2.5%) because thin skin and high receptor density increase absorption and accelerate atrophy, striae, and telangiectasias. Medium-potency agents are appropriate for the trunk and extremities, while superpotent agents are reserved for palms, soles, and recalcitrant plaques. Topical calcineurin inhibitors provide a steroid-sparing alternative for chronic use on sensitive sites."
  },
  {
    "id": 183,
    "categoryId": 2,
    "question": "A 65-year-old with COPD develops Community Acquired Pneumonia. He received a Z-pack (Azithromycin) 2 months ago for bronchitis. What is the appropriate antibiotic choice now?",
    "options": [
      "A) Azithromycin alone",
      "B) Doxycycline alone",
      "C) Levofloxacin (Respiratory Fluoroquinolone) OR Augmentin + Macrolide",
      "D) Cephalexin"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Respiratory Fluoroquinolone alone OR Beta-lactam plus Macrolide).\n\nPATHOPHYSIOLOGY:\nCommunity-acquired pneumonia is most commonly caused by Streptococcus pneumoniae, followed by atypical organisms (Mycoplasma pneumoniae, Chlamydophila pneumoniae, Legionella pneumophila) and respiratory viruses per Harrison's Principles of Internal Medicine. Haemophilus influenzae is an important pathogen in patients with COPD due to impaired mucociliary clearance and chronic airway colonization. Empiric therapy must cover both typical and atypical pathogens because clinical presentation alone cannot reliably distinguish between them per UpToDate.\n\nCLINICAL REASONING:\nThis patient has two features that require broader empiric coverage per the ATS/IDSA 2019 CAP guidelines: comorbid COPD and recent antibiotic exposure (azithromycin 2 months ago). Recent macrolide use within the past 3 months is a risk factor for macrolide-resistant organisms and mandates an alternative regimen per UpToDate. The ATS/IDSA guidelines recommend two equivalent options for outpatients with comorbidities or recent antibiotic use: a respiratory fluoroquinolone alone (levofloxacin 750 mg daily or moxifloxacin 400 mg daily), or a beta-lactam (amoxicillin-clavulanate 2 grams/125 mg twice daily or ceftriaxone) plus a macrolide (azithromycin or doxycycline as a macrolide alternative) per the Cleveland Clinic. Given this patient's recent azithromycin use, either a respiratory fluoroquinolone alone or a beta-lactam plus doxycycline as a macrolide substitute would be appropriate.\n\nSEVERITY ASSESSMENT:\nThe CURB-65 score (Confusion, Uremia with BUN greater than 20, Respiratory rate 30 or greater, Blood pressure less than 90 systolic or 60 diastolic, age 65 or greater) guides site-of-care decisions per Harrison's Principles of Internal Medicine. A score of 0 to 1 supports outpatient treatment, 2 supports short hospitalization or closely supervised outpatient care, and 3 to 5 warrants hospitalization with consideration of ICU for scores of 4 to 5 per the Mayo Clinic. Inpatient non-ICU treatment uses the same two regimen options. ICU-level CAP requires a beta-lactam (ceftriaxone or ampicillin-sulbactam) plus either a macrolide or respiratory fluoroquinolone, with MRSA and pseudomonal coverage added when risk factors are present.\n\nKEY LEARNING POINTS:\nOutpatient CAP with comorbidities or recent antibiotic use requires a respiratory fluoroquinolone alone or a beta-lactam plus macrolide per ATS/IDSA 2019 guidelines. Recent macrolide use within 3 months is a risk factor for resistance and should prompt an alternative class. Treatment duration of 5 days is adequate for most patients who achieve clinical stability within 48 to 72 hours."
  },
  {
    "id": 184,
    "categoryId": 11,
    "question": "A 75-year-old female has been on Zolpidem (Ambien) 10mg for 10 years. You want to deprescribe due to fall risk. What is the safest approach?",
    "options": [
      "A) Stop immediately to prevent falls",
      "B) Reduce dose by 25% every 1-2 weeks",
      "C) Switch to Diazepam then taper",
      "D) Add Melatonin and stop Zolpidem"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Reduce dose by 25% every 1 to 2 weeks).\n\nDEPRESCRIBING APPROACH:\nGradual dose reduction is the safest method for discontinuing long-term benzodiazepine receptor agonists (BzRAs) such as zolpidem in older adults per UpToDate and Harrison's Principles of Internal Medicine. The recommended approach is to reduce the dose by approximately 25% every 1 to 2 weeks, though even slower tapers (10 to 12.5% reductions) may be necessary for patients who have been on these medications for years, as in this case per the Mayo Clinic.\n\nRATIONALE FOR GRADUAL TAPER:\nZolpidem acts on the same GABA-A receptor benzodiazepine binding site as traditional benzodiazepines, and chronic use produces neuroadaptive changes (receptor downregulation, reduced GABAergic sensitivity, and compensatory upregulation of excitatory glutamatergic signaling) per Harrison's Principles of Internal Medicine. Abrupt discontinuation can precipitate a withdrawal syndrome including rebound insomnia (often worse than the original insomnia), anxiety, tremor, diaphoresis, tachycardia, and in severe cases seizures per the Cleveland Clinic and UpToDate. The Beers Criteria (American Geriatrics Society) strongly recommend avoiding BzRAs in older adults due to increased risk of falls, fractures, cognitive impairment, motor vehicle accidents, and delirium per Harvard Health.\n\nADJUNCTIVE STRATEGIES:\nInitiating CBT-I (Cognitive Behavioral Therapy for Insomnia) concurrently with the taper significantly improves discontinuation success rates and provides a sustainable non-pharmacologic strategy for ongoing insomnia management per UpToDate. Melatonin (0.5 to 3 mg at bedtime) may provide modest sleep onset benefit during the taper per the Mayo Clinic. Trazodone (25 to 50 mg) or low-dose doxepin (3 to 6 mg) can serve as bridging agents if sleep disruption during the taper is severe per the Cleveland Clinic.\n\nKEY LEARNING POINTS:\nLong-term zolpidem should be tapered by 25% every 1 to 2 weeks (slower for prolonged use) to prevent withdrawal seizures, rebound insomnia, and anxiety. Abrupt discontinuation is dangerous due to GABA-A receptor neuroadaptation and compensatory glutamatergic excitation. Concurrent CBT-I initiation during the taper significantly improves discontinuation success rates."
  },
  {
    "id": 185,
    "categoryId": 1,
    "question": "Which class of medication is the FIRST to show unequivocal mortality and hospitalization benefit in Heart Failure with PRESERVED Ejection Fraction (HFpEF)?",
    "options": [
      "A) Beta Blockers",
      "B) ACE Inhibitors",
      "C) SGLT2 Inhibitors (Empagliflozin/Dapagliflozin)",
      "D) Digoxin"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (SGLT2 Inhibitors).\n\nCLINICAL REASONING:\nSGLT2 inhibitors (empagliflozin and dapagliflozin) are the first medication class to demonstrate unequivocal mortality and hospitalization benefit in heart failure with preserved ejection fraction (HFpEF, EF 50% or greater) per Harrison's Principles of Internal Medicine. The EMPEROR-Preserved trial (empagliflozin) and DELIVER trial (dapagliflozin) both demonstrated significant reductions in the composite endpoint of cardiovascular death and heart failure hospitalization in HFpEF patients, regardless of diabetes status per UpToDate. Prior to these landmark trials, no pharmacologic therapy had shown consistent benefit in HFpEF, which accounts for approximately 50% of all heart failure cases per the Cleveland Clinic.\n\nPATHOPHYSIOLOGY:\nThe mechanisms of SGLT2 inhibitor benefit in heart failure extend well beyond their glucose-lowering effect and include osmotic diuresis and natriuresis (reducing preload and congestion), improved cardiac energetics (shifting myocardial substrate utilization from fatty acids toward more oxygen-efficient ketone bodies), reduced interstitial fibrosis, decreased oxidative stress and inflammation, and improved endothelial function per Harrison's Principles of Internal Medicine. These pleiotropic effects explain why the benefit is independent of diabetes status per UpToDate.\n\nGDMT FRAMEWORK:\nThe 2022 AHA/ACC/HFSA Heart Failure Guidelines now recommend SGLT2 inhibitors for the entire spectrum of heart failure, from HFrEF (EF 40% or less) through HFmrEF (EF 41 to 49%) to HFpEF (EF 50% or greater) per the Mayo Clinic. For HFrEF specifically, the four pillars of guideline-directed medical therapy are an ARNI (or ACEi/ARB), a beta-blocker (carvedilol, metoprolol succinate, or bisoprolol), a mineralocorticoid receptor antagonist (spironolactone or eplerenone), and an SGLT2 inhibitor (dapagliflozin or empagliflozin) per Harrison's Principles of Internal Medicine.\n\nKEY LEARNING POINTS:\nSGLT2 inhibitors (empagliflozin, dapagliflozin) are the first class to show mortality and hospitalization benefit in HFpEF (EMPEROR-Preserved, DELIVER trials), regardless of diabetes status. Their benefit derives from pleiotropic effects (natriuresis, improved cardiac energetics, reduced fibrosis) beyond glucose lowering. They are now recommended across the entire heart failure spectrum (HFrEF, HFmrEF, HFpEF)."
  },
  {
    "id": 186,
    "categoryId": 9,
    "question": "A patient has borderline low B12 (250 pg/mL) but complains of neuropathy. Which metabolite confirms tissue-level B12 deficiency?",
    "options": [
      "A) Ferritin",
      "B) Methylmalonic Acid (MMA)",
      "C) Folate",
      "D) Reticulocyte count"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Methylmalonic Acid).\n\nPATHOPHYSIOLOGY:\nVitamin B12 (cobalamin) serves as a cofactor for two critical enzymatic reactions in human metabolism per Harrison's Principles of Internal Medicine. First, B12 is a cofactor for methionine synthase, which converts homocysteine to methionine (deficiency causes elevated homocysteine). Second, B12 is the exclusive cofactor for methylmalonyl-CoA mutase, which converts methylmalonyl-CoA to succinyl-CoA in the mitochondrial pathway of odd-chain fatty acid and branched-chain amino acid metabolism per UpToDate. When B12 is deficient at the tissue level, methylmalonyl-CoA accumulates and is converted to methylmalonic acid (MMA), which rises in the serum and urine per the Cleveland Clinic.\n\nDIAGNOSTIC SIGNIFICANCE:\nSerum B12 levels have a significant \"gray zone\" (approximately 200 to 400 pg/mL) where levels may appear borderline normal despite true tissue-level deficiency per Harvard Health and UpToDate. MMA is elevated specifically in B12 deficiency (not folate deficiency) because folate is not involved in the methylmalonyl-CoA mutase reaction per Harrison's Principles of Internal Medicine. This makes MMA the most specific confirmatory test for tissue-level B12 deficiency, with a sensitivity exceeding 95% per the Mayo Clinic. Homocysteine, by contrast, is elevated in both B12 and folate deficiency (as both are required for the methionine synthase reaction) and is therefore less specific per UpToDate.\n\nNEUROLOGIC MANIFESTATIONS:\nB12 deficiency causes subacute combined degeneration of the spinal cord, affecting the dorsal columns (loss of proprioception and vibratory sense, sensory ataxia) and lateral corticospinal tracts (spasticity, weakness, hyperreflexia, Babinski sign) per Harrison's Principles of Internal Medicine. Peripheral neuropathy (paresthesias in a stocking-glove distribution) often precedes myelopathy. Neurologic damage can become irreversible if B12 replacement is delayed, even if hematologic parameters normalize per the Cleveland Clinic.\n\nKEY LEARNING POINTS:\nMethylmalonic acid (MMA) is the most specific confirmatory test for tissue-level B12 deficiency, elevated because B12 is the exclusive cofactor for methylmalonyl-CoA mutase. Serum B12 has a wide gray zone (200 to 400 pg/mL) where tissue deficiency may exist despite borderline-normal levels. Neurologic damage from B12 deficiency (subacute combined degeneration) can become irreversible if treatment is delayed."
  },
  {
    "id": 187,
    "categoryId": 7,
    "question": "Differentiating Olecranon Bursitis from Septic Arthritis of the elbow primarily relies on:",
    "options": [
      "A) Fever presence",
      "B) Range of Motion (ROM)",
      "C) X-ray findings",
      "D) Duration of pain"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Range of Motion).\n\nPATHOPHYSIOLOGY:\nOlecranon bursitis and septic arthritis of the elbow both produce posterior elbow swelling, warmth, and pain, but they involve fundamentally different anatomic compartments. Olecranon bursitis is inflammation of the subcutaneous olecranon bursa, a superficial sac that lies between the olecranon process and the overlying skin, entirely outside the elbow joint capsule. Because the bursa is extra-articular, the glenohumeral articulation itself is unaffected and the joint mechanics remain intact. Septic arthritis, by contrast, involves bacterial infection within the enclosed synovial joint space, where the intense neutrophilic inflammatory response generates destructive enzymes and increased intra-articular pressure. The distended, inflamed joint capsule restricts motion in all planes, and the exquisite pain produced by capsular stretch during any attempted movement causes the patient to hold the elbow in a flexed position of comfort that minimizes intra-articular volume.\n\nCLINICAL PRESENTATION:\nThe critical differentiating feature is range of motion. In olecranon bursitis, the patient can flex and extend the elbow through a full or near-full arc with minimal pain because the joint itself is uninvolved, and the swelling is localized to the discrete, fluctuant bursal sac overlying the olecranon. In septic arthritis, range of motion is severely limited in all planes, with pain provoked by even gentle passive movement, because the infection has distended the joint capsule and inflamed the synovium. Both conditions can present with erythema, warmth, and swelling, and both can be associated with fever, making these findings unreliable as differentiators. However, a patient who can comfortably flex and extend the elbow despite a visibly swollen olecranon almost certainly has bursitis rather than intra-articular infection.\n\nDIAGNOSIS AND MANAGEMENT:\nWhen septic arthritis is suspected based on restricted range of motion, fever, and an acutely painful joint, arthrocentesis of the elbow joint is mandatory before antibiotics are started. Synovial fluid white blood cell count exceeding 50,000 per microliter with greater than 90% neutrophils is highly suggestive of bacterial infection, and Gram stain with culture guides definitive antimicrobial therapy. Empiric intravenous antibiotics (vancomycin plus a third-generation cephalosporin) and joint drainage through serial aspiration or surgical washout must be initiated emergently, as cartilage destruction begins within hours. For olecranon bursitis, aspiration of the bursa with fluid analysis (cell count, Gram stain, culture, crystal analysis) distinguishes septic bursitis from traumatic or inflammatory etiologies. Non-septic olecranon bursitis is managed conservatively with compression, ice, and avoidance of direct pressure on the elbow.\n\nKEY LEARNING POINTS:\nPreserved range of motion is the key feature distinguishing olecranon bursitis from septic arthritis of the elbow, because the bursa is extra-articular and does not affect joint mechanics. Septic arthritis causes severe pain with any passive motion due to intra-articular capsular distension and inflammation. Fever and erythema are unreliable differentiators, as both conditions can produce these findings."
  },
  {
    "id": 188,
    "categoryId": 16,
    "question": "A 55-year-old patient asks about the Shingles vaccine. He had Shingles 2 years ago. Does he need the vaccine?",
    "options": [
      "A) No, natural immunity is lifelong",
      "B) Yes, Shingrix is recommended even with prior history",
      "C) Wait until age 60",
      "D) Only if he is immunocompromised"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Yes, Shingrix is recommended even with prior history of shingles).\n\nVACCINE RECOMMENDATION:\nShingrix (recombinant zoster vaccine, RZV) is recommended by the CDC for all immunocompetent adults aged 50 and older, regardless of whether they have had a prior episode of herpes zoster (shingles), prior receipt of the older live zoster vaccine (Zostavax), or uncertain history of varicella per the CDC and UpToDate. Patients who have had shingles should wait until the acute rash has resolved and ideally until the acute episode has fully subsided before receiving vaccination per the Mayo Clinic.\n\nRATIONALE FOR VACCINATION AFTER SHINGLES:\nShingles recurrence occurs in approximately 5 to 6% of patients within 8 years of the initial episode per UpToDate. A prior episode does not confer reliable long-term immunity because varicella-zoster virus (VZV) remains latent in dorsal root ganglia and can reactivate whenever cell-mediated immunity declines (aging, immunosuppression, stress) per Harrison's Principles of Internal Medicine. Shingrix boosts the VZV-specific T-cell response, providing robust and durable protection against future reactivation per the Cleveland Clinic.\n\nVACCINE EFFICACY:\nShingrix is a two-dose series (administered at 0 and 2 to 6 months intramuscularly) with greater than 90% efficacy in preventing shingles across all age groups studied, including adults over 70 per the CDC. Efficacy remains above 85% at 4 years post-vaccination. Shingrix is a recombinant (non-live) vaccine containing the VZV glycoprotein E with an AS01B adjuvant, meaning it is safe for immunocompromised patients (unlike the discontinued live Zostavax) per UpToDate and Harvard Health. Common side effects include injection site pain (approximately 80%), myalgia, and fatigue, which typically resolve within 2 to 3 days per the Mayo Clinic.\n\nKEY LEARNING POINTS:\nShingrix is recommended for all adults 50 and older regardless of prior shingles episodes, prior Zostavax, or varicella history. It provides greater than 90% efficacy through a two-dose recombinant (non-live) series safe for immunocompromised patients. Prior shingles does not confer reliable immunity, as VZV remains latent and recurrence rates are approximately 5 to 6% within 8 years."
  },
  {
    "id": 189,
    "categoryId": 5,
    "question": "A 60-year-old male has a PSA of 5.5 ng/mL. DRE is normal. He has benign prostatic hyperplasia (BPH). What calculation improves the specificity of PSA testing?",
    "options": [
      "A) PSA Velocity",
      "B) Free PSA %",
      "C) Total PSA",
      "D) PSA Density (PSA / Prostate Volume)"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Free PSA percentage).\n\nCLINICAL REASONING:\nProstate-specific antigen (PSA) is produced by both benign and malignant prostate epithelial cells, making an elevated total PSA (reference range less than 4.0 ng/mL, though age-adjusted ranges are used) nonspecific for prostate cancer per Harrison's Principles of Internal Medicine and UpToDate. In this patient with a PSA of 5.5 and known BPH, the elevation could reflect benign prostatic hypertrophy (which increases PSA by approximately 0.3 ng/mL per gram of prostate tissue) or occult prostate cancer per the Cleveland Clinic.\n\nFREE PSA RATIO:\nPSA circulates in two forms: bound to serum proteins (alpha-1-antichymotrypsin, alpha-2-macroglobulin) and unbound (free PSA) per Harvard Health. Prostate cancer cells produce a higher proportion of complexed (bound) PSA, resulting in a lower free-to-total PSA ratio. BPH produces a higher proportion of free PSA per UpToDate. A free PSA percentage greater than 25% suggests BPH (low cancer risk, biopsy may be deferred), while free PSA less than 10% suggests a high probability of cancer (biopsy recommended) per Harrison's Principles of Internal Medicine and the Mayo Clinic. The free PSA ratio is most useful in the diagnostic \"gray zone\" of total PSA 4 to 10 ng/mL, where it improves specificity and reduces unnecessary biopsies by approximately 20% per the Cleveland Clinic.\n\nOTHER PSA REFINEMENTS:\nPSA density (total PSA divided by prostate volume on ultrasound; greater than 0.15 suggests cancer), PSA velocity (rate of change over time; increase greater than 0.75 ng/mL/year is concerning), and age-specific reference ranges all improve PSA interpretation per UpToDate. The Prostate Health Index (PHI), which combines total PSA, free PSA, and p2PSA (a PSA isoform), and the 4Kscore (combining total PSA, free PSA, intact PSA, and human kallikrein 2) provide further risk stratification per Harrison's Principles of Internal Medicine.\n\nSCREENING CONTEXT:\nThe USPSTF recommends shared decision-making for PSA screening in men aged 55 to 69 (Grade C) and recommends against screening in men 70 and older (Grade D) per the CDC and Harvard Health.\n\nKEY LEARNING POINTS:\nFree PSA percentage helps distinguish BPH (higher free PSA, greater than 25%) from prostate cancer (lower free PSA, less than 10%) in the PSA gray zone of 4 to 10 ng/mL. This reduces unnecessary biopsies by approximately 20%. PSA density, velocity, and newer indices (PHI, 4Kscore) further refine cancer risk stratification."
  },
  {
    "id": 190,
    "categoryId": 6,
    "question": "First-line pharmacologic treatment for Essential Tremor (Action tremor of hands)?",
    "options": [
      "A) Levodopa/Carbidopa",
      "B) Propranolol or Primidone",
      "C) Gabapentin",
      "D) Clonazepam"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Propranolol or Primidone).\n\nESSENTIAL TREMOR:\nEssential tremor is the most common movement disorder, presenting as an action/postural tremor affecting the hands, head, or voice. It differs from Parkinson's (resting tremor) in that it worsens with intention and improves at rest. Classic features include bilateral hand tremor that improves with alcohol.\n\nFIRST-LINE TREATMENT:\nPropranolol (non-selective beta-blocker) reduces tremor amplitude by 50-60% in most patients. Mechanism involves peripheral beta-2 receptor blockade in skeletal muscle. Primidone (anticonvulsant) is equally effective through unclear mechanisms. Either can be used first-line; choice depends on comorbidities.\n\nDOSING:\nPropranolol: Start 20-40mg BID, titrate to 120-320mg/day. Long-acting formulations improve compliance. Avoid in asthma, bradycardia, heart block. Primidone: Start 25mg at bedtime (initial sedation is common), titrate slowly to 250-750mg/day.\n\nREFRACTORY CASES:\nGabapentin, topiramate, and benzodiazepines are second-line options. Deep brain stimulation of the ventral intermediate nucleus of the thalamus is highly effective for medication-refractory cases.\n\nKEY LEARNING POINTS:\nPropranolol and primidone are first-line for essential tremor with 50-60% improvement. Essential tremor is an action/postural tremor that improves with alcohol and at rest. Deep brain stimulation is available for refractory cases."
  },
  {
    "id": 191,
    "categoryId": 10,
    "question": "A 30-year-old female presents with diffuse hair thinning. The 'Pull Test' yields 4-5 hairs with white bulbs (telogen phase). She had a baby 4 months ago. Diagnosis?",
    "options": [
      "A) Alopecia Areata",
      "B) Telogen Effluvium",
      "C) Androgenetic Alopecia",
      "D) Trichotillomania"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Telogen Effluvium).\n\nPATHOPHYSIOLOGY:\nNormal hair growth follows a cycle with three phases: anagen (active growth, 2 to 6 years, comprising 85 to 90% of scalp hairs), catagen (regression, 2 to 3 weeks), and telogen (resting, 2 to 3 months, after which the hair sheds and a new anagen hair replaces it). In telogen effluvium, a physiologic stressor synchronizes a large proportion of anagen follicles into premature catagen and then telogen simultaneously. Because the telogen resting phase lasts approximately 3 months, the synchronized shedding becomes clinically apparent 2 to 4 months after the inciting event. This explains the temporal relationship in this patient: childbirth 4 months ago triggered the premature transition, and the diffuse shedding is now manifest. The white bulb at the proximal end of shed hairs confirms they are telogen (club) hairs, distinguishing this from anagen effluvium where hairs break without an intact bulb.\n\nCLINICAL PRESENTATION:\nPatients present with diffuse, non-scarring hair thinning rather than focal patches. The hair pull test yields more than 3 to 5 telogen hairs per pull from multiple scalp regions, confirming active shedding. Importantly, the scalp itself appears normal without erythema, scaling, or scarring. Common triggers include childbirth (postpartum telogen effluvium affects up to 50% of women), major surgery, severe illness or high fever (including COVID-19), crash dieting or significant weight loss, emotional stress, and medication changes. Postpartum telogen effluvium specifically results from the abrupt withdrawal of the high estrogen levels of pregnancy, which had prolonged anagen duration during gestation, keeping hairs in the growth phase longer than usual. After delivery, the sudden estrogen drop releases all those retained hairs into telogen simultaneously.\n\nDIAGNOSIS AND DIFFERENTIAL:\nTelogen effluvium is primarily a clinical diagnosis based on the pattern of diffuse thinning with an identifiable trigger 2 to 4 months prior. Laboratory evaluation should include TSH, ferritin (iron deficiency is a common reversible cause), CBC, and vitamin D levels. Zinc and biotin deficiency should be considered when dietary history is suggestive. The differential diagnosis includes androgenetic alopecia (gradual thinning at the vertex and frontal hairline, without a discrete trigger), alopecia areata (well-demarcated circular patches with exclamation point hairs), and diffuse alopecia areata. A scalp biopsy is rarely needed but will show an increased telogen-to-anagen ratio exceeding 25% if performed.\n\nMANAGEMENT:\nTelogen effluvium is self-limiting in most cases, with regrowth beginning within 3 to 6 months and full recovery by 6 to 12 months after the stressor resolves. Treatment focuses on identifying and correcting reversible triggers, particularly iron deficiency (target ferritin above 40-70 ng/mL for optimal hair growth) and thyroid dysfunction. Nutritional supplementation with iron, vitamin D, and zinc when deficient supports recovery. Patients should be reassured that the shedding does not indicate permanent hair loss. If shedding persists beyond 6 months, the diagnosis of chronic telogen effluvium should be considered, and further workup for ongoing triggers is warranted.\n\nKEY LEARNING POINTS:\nTelogen effluvium presents as diffuse hair shedding 2 to 4 months after a physiologic stressor, with telogen (white bulb) hairs on pull test. Postpartum hair loss is the most common trigger and results from estrogen withdrawal synchronizing follicle transition. The condition is self-limiting with recovery in 6 to 12 months. Iron deficiency and thyroid dysfunction are the most important reversible causes to identify and treat."
  },
  {
    "id": 192,
    "categoryId": 17,
    "question": "Meniere's Disease is characterized by the classic triad of:",
    "options": [
      "A) Vertigo, Headache, Photophobia",
      "B) Vertigo, Tinnitus (roaring), Sensorineural Hearing Loss",
      "C) Vertigo, Ataxia, Dysarthria",
      "D) Vertigo, Syncope, Palpitations"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Vertigo, Tinnitus, Sensorineural Hearing Loss).\n\nPATHOPHYSIOLOGY:\nMeniere disease results from endolymphatic hydrops, an abnormal accumulation of endolymph within the membranous labyrinth of the inner ear. The distension of the endolymphatic space disrupts the normal ionic gradients required for mechanoelectrical transduction, affecting both auditory (cochlear) and vestibular (semicircular canal and otolith) function. The exact etiology remains unclear, though impaired endolymph resorption by the endolymphatic sac is the leading hypothesis.\n\nCLINICAL PRESENTATION:\nThe classic triad consists of:\n- Episodic vertigo: Spontaneous rotational vertigo lasting 20 minutes to several hours (distinguishes from BPPV, which lasts seconds to minutes)\n- Tinnitus: Typically low-frequency roaring or buzzing, often fluctuating\n- Sensorineural hearing loss: Initially low-frequency and fluctuating; becomes progressive and permanent over years\n- Aural fullness (a sense of pressure in the affected ear) is considered the fourth hallmark symptom\n\nDIAGNOSIS:\nDiagnosis is clinical per the AAO-HNS 2020 criteria: two or more spontaneous episodes of vertigo lasting 20 minutes to 12 hours, audiometrically documented low- to mid-frequency sensorineural hearing loss in the affected ear, and fluctuating aural symptoms (hearing, tinnitus, fullness). MRI with gadolinium may be obtained to exclude vestibular schwannoma.\n\nTREATMENT:\n1. Lifestyle: Sodium restriction (less than 1500-2000 mg/day), caffeine and alcohol avoidance\n2. Acute episodes: Vestibular suppressants (meclizine, diazepam), antiemetics\n3. Prophylaxis: Thiazide diuretics (hydrochlorothiazide), betahistine (used outside the US)\n4. Refractory cases: Intratympanic dexamethasone or gentamicin injections, endolymphatic sac surgery\n\nKEY LEARNING POINTS:\nMeniere disease produces episodes of vertigo lasting 20 minutes to hours, distinguishing it from BPPV (seconds) and vestibular neuritis (days). Low-frequency sensorineural hearing loss is the audiometric hallmark and becomes permanent over time. Sodium restriction and diuretics are first-line management.\n\nREFERENCES:\nAAO-HNS 2020 Meniere Disease Guidelines; UpToDate; Harrison's Principles of Internal Medicine.\n---"
  },
  {
    "id": 193,
    "categoryId": 6,
    "question": "In Diabetic Retinopathy, the presence of 'Cotton Wool Spots' signifies:",
    "options": [
      "A) Lipid exudates",
      "B) Retinal nerve fiber layer micro-infarctions (Ischemia)",
      "C) Proliferative new vessels",
      "D) Hemorrhage"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Retinal nerve fiber layer micro-infarctions/Ischemia).\n\nCOTTON WOOL SPOTS IN DIABETIC RETINOPATHY:\nCotton wool spots are fluffy, white-bordered lesions on the retinal surface that represent micro-infarctions of the retinal nerve fiber layer. Their presence signifies retinal ischemia caused by occlusion of precapillary arterioles, and they indicate that diabetic retinopathy is progressing toward the proliferative stage.\n\nPATHOPHYSIOLOGY:\nChronic hyperglycemia damages retinal capillary pericytes and endothelial cells, leading to microaneurysms, capillary closure, and impaired blood flow. When precapillary arterioles become occluded, the downstream retinal nerve fiber layer undergoes ischemic infarction. The axoplasmic flow within retinal ganglion cell axons is interrupted, causing accumulation of organelles and cellular debris that appears as the characteristic white, fluffy lesion on fundoscopy. This ischemia triggers the release of vascular endothelial growth factor (VEGF), which drives the neovascularization seen in proliferative disease.\n\nCLASSIFICATION OF DIABETIC RETINOPATHY:\nNon-proliferative diabetic retinopathy (NPDR) progresses through mild (microaneurysms only), moderate (microaneurysms plus dot/blot hemorrhages and hard exudates), and severe stages (cotton wool spots, venous beading, intraretinal microvascular abnormalities). Proliferative diabetic retinopathy (PDR) is defined by the growth of new, fragile vessels (neovascularization) on the disc or retina, which can cause vitreous hemorrhage and tractional retinal detachment.\n\nDIAGNOSIS AND MANAGEMENT:\nScreening with dilated fundoscopic examination is recommended annually for patients with diabetes. Cotton wool spots on exam warrant closer follow-up intervals and urgent optimization of blood glucose (HbA1c below 7%) and blood pressure (below 130/80). Anti-VEGF intravitreal injections (ranibizumab, aflibercept, bevacizumab) and panretinal photocoagulation are standard treatments for proliferative disease and diabetic macular edema.\n\nKEY LEARNING POINTS:\nCotton wool spots represent retinal nerve fiber layer ischemia from arteriolar occlusion and indicate pre-proliferative retinopathy. Their presence signals impending neovascularization driven by VEGF release from ischemic retina. Urgent glycemic and blood pressure optimization, with ophthalmology referral, is essential to prevent progression to vision-threatening proliferative disease."
  },
  {
    "id": 194,
    "categoryId": 1,
    "question": "A patient with high CV risk cannot tolerate any statin due to severe myalgia. What is the next best non-statin therapy to lower LDL and reduce CV events?",
    "options": [
      "A) Ezetimibe",
      "B) Niacin",
      "C) Fibrates",
      "D) Fish Oil"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Ezetimibe).\n\nCLINICAL REASONING:\nFor patients who cannot tolerate any statin due to statin-associated muscle symptoms (SAMS), ezetimibe is the recommended first-line non-statin LDL-lowering therapy per the 2018 ACC/AHA Guidelines and UpToDate. Ezetimibe inhibits the Niemann-Pick C1-Like 1 (NPC1L1) protein on the brush border of intestinal enterocytes, which is the primary transporter responsible for cholesterol absorption from the intestinal lumen per Harrison's Principles of Internal Medicine. By blocking intestinal cholesterol absorption, ezetimibe reduces hepatic cholesterol delivery, which triggers compensatory upregulation of hepatic LDL receptors and increases LDL clearance from the blood per the Cleveland Clinic.\n\nCLINICAL EVIDENCE:\nEzetimibe monotherapy lowers LDL by approximately 18 to 20% per UpToDate. The IMPROVE-IT trial demonstrated that adding ezetimibe to simvastatin in post-ACS patients produced an additional 6.4% relative risk reduction in major cardiovascular events compared to simvastatin alone, establishing ezetimibe as the first non-statin therapy with proven cardiovascular outcomes benefit per Harrison's Principles of Internal Medicine. For statin-intolerant patients with very high cardiovascular risk requiring greater LDL reduction, PCSK9 inhibitors (evolocumab, alirocumab) can be added to ezetimibe and provide an additional 50 to 60% LDL reduction per the Cleveland Clinic.\n\nALTERNATIVE NON-STATIN THERAPIES:\nBempedoic acid (an ATP citrate lyase inhibitor) is another option for statin-intolerant patients, with the CLEAR Outcomes trial demonstrating cardiovascular event reduction in statin-intolerant patients per UpToDate. Niacin and fibrates, while they affect lipid levels, have not demonstrated consistent cardiovascular outcomes benefit in the modern statin era and are not recommended as primary LDL-lowering alternatives per the Mayo Clinic.\n\nKEY LEARNING POINTS:\nEzetimibe is the first-line non-statin therapy for statin-intolerant patients, lowering LDL approximately 18 to 20% by blocking intestinal cholesterol absorption via NPC1L1. The IMPROVE-IT trial proved cardiovascular benefit when combined with statin therapy. For patients needing greater LDL reduction, PCSK9 inhibitors or bempedoic acid can be added."
  },
  {
    "id": 195,
    "categoryId": 4,
    "question": "A patient has elevated Calcium (11.2). PTH is also elevated (85). Urine Calcium is very low. Family history is positive for mild hypercalcemia. Diagnosis?",
    "options": [
      "A) Primary Hyperparathyroidism",
      "B) Familial Hypocalciuric Hypercalcemia (FHH)",
      "C) Malignancy",
      "D) Sarcoidosis"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Familial Hypocalciuric Hypercalcemia).\n\nPATHOPHYSIOLOGY:\nFamilial hypocalciuric hypercalcemia (FHH) is an autosomal dominant disorder caused by an inactivating mutation in the calcium-sensing receptor (CaSR) gene on chromosome 3q. The CaSR is a G-protein coupled receptor expressed on parathyroid chief cells and renal tubular cells that functions as the body's primary calcium thermostat, detecting extracellular calcium concentration and modulating PTH secretion and renal calcium excretion accordingly. In FHH, the mutated CaSR has reduced sensitivity to extracellular calcium, meaning that a higher-than-normal serum calcium concentration is required to suppress PTH secretion and activate renal calcium excretion. The parathyroid glands interpret the normal or mildly elevated calcium as inappropriately low and continue secreting PTH, while the kidneys, whose CaSR is similarly affected, reabsorb calcium avidly instead of excreting it. This produces the characteristic laboratory triad of mild hypercalcemia (typically 10.5 to 12.0 mg/dL, rarely above 12), inappropriately normal or mildly elevated PTH, and markedly low urinary calcium excretion. The condition is present from birth, is lifelong, and is almost always benign, causing no end-organ damage such as nephrolithiasis, osteoporosis, or nephrocalcinosis.\n\nCLINICAL REASONING:\nThe critical diagnostic challenge is distinguishing FHH from primary hyperparathyroidism (PHPT), as both present with hypercalcemia and elevated or inappropriately normal PTH. The key differentiator is urinary calcium excretion. In PHPT, the parathyroid gland autonomously oversecretes PTH from an adenoma (85% of cases), four-gland hyperplasia (10 to 15%), or rarely a carcinoma, and the filtered calcium load overwhelms the tubular reabsorptive capacity, resulting in hypercalciuria (24-hour urine calcium typically greater than 200 mg). In FHH, the renal CaSR defect causes avid calcium reabsorption, resulting in characteristic hypocalciuria (24-hour urine calcium typically less than 100 mg). The calcium-to-creatinine clearance ratio (CCCR) provides the most reliable biochemical distinction: a CCCR below 0.01 is highly suggestive of FHH, a CCCR above 0.02 supports PHPT, and values between 0.01 and 0.02 are indeterminate and may warrant genetic testing for CaSR mutations per the Endocrine Society and UpToDate. Family history of mild, asymptomatic hypercalcemia across multiple generations further supports the diagnosis. This distinction is clinically essential because parathyroidectomy, which is curative for PHPT, does not correct the hypercalcemia in FHH (since the defect is in the calcium-sensing receptor, not in parathyroid gland mass) and is therefore contraindicated.\n\nDIFFERENTIAL DIAGNOSIS OF HYPERCALCEMIA:\nThe two most common causes of hypercalcemia are primary hyperparathyroidism (most common in the outpatient setting) and malignancy (most common in hospitalized patients), which together account for approximately 90% of cases. PTH measurement is the essential first step: elevated or inappropriately normal PTH indicates PTH-dependent hypercalcemia (PHPT, FHH, lithium-induced), while suppressed PTH indicates PTH-independent hypercalcemia (malignancy via PTHrP secretion or osteolytic metastases, vitamin D excess from granulomatous diseases such as sarcoidosis, vitamin D intoxication, milk-alkali syndrome, or thyrotoxicosis). In malignancy-associated hypercalcemia, PTHrP measurement and evaluation for skeletal metastases guide further workup per guidelines from the Endocrine Society and Harrison's Principles of Internal Medicine.\n\nKEY LEARNING POINTS:\nFHH is distinguished from primary hyperparathyroidism by markedly low urinary calcium excretion, with a calcium-to-creatinine clearance ratio below 0.01 strongly favoring FHH and above 0.02 supporting PHPT. FHH is caused by an inactivating mutation of the calcium-sensing receptor and is a benign condition for which parathyroidectomy is ineffective and contraindicated. A 24-hour urine calcium collection should be obtained in all patients with PTH-dependent hypercalcemia before proceeding with surgical planning to avoid unnecessary parathyroidectomy."
  },
  {
    "id": 196,
    "categoryId": 12,
    "question": "The 'Frog-Leg' lateral view of the hips is essential to diagnose which pediatric condition?",
    "options": [
      "A) Developmental Dysplasia of the Hip",
      "B) Slipped Capital Femoral Epiphysis (SCFE)",
      "C) Septic Arthritis",
      "D) Osgood-Schlatter"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Slipped Capital Femoral Epiphysis).\n\nPATHOPHYSIOLOGY:\nSlipped capital femoral epiphysis is the most common hip disorder in adolescents, occurring when the femoral head (capital femoral epiphysis) displaces posteriorly and inferiorly relative to the femoral neck through the hypertrophic zone of the physis (growth plate) per Harrison's Principles of Internal Medicine. This displacement occurs because the adolescent growth plate is inherently weakened during the rapid growth phase by the widened zone of hypertrophic chondrocytes, and mechanical forces (particularly shear stress from excess body weight) exceed the structural capacity of the softened physis per UpToDate. SCFE predominantly affects obese adolescents aged 10 to 16 years during the pubertal growth spurt, with males affected approximately 1.5 times more frequently than females. Endocrine disorders (hypothyroidism, growth hormone deficiency, renal osteodystrophy) should be considered in atypical presentations (younger children, those of normal weight) per the Cleveland Clinic.\n\nCLINICAL PRESENTATION:\nPatients present with a limp and pain in the hip, groin, medial thigh, or knee per the Mayo Clinic. Knee pain as a presenting complaint (referred via the obturator nerve) is a classic diagnostic pitfall that leads to missed SCFE if the hip is not examined. On physical examination, the hallmark finding is obligate external rotation of the affected hip during passive flexion, meaning the leg involuntarily rolls outward as the hip is flexed, reflecting the posterior displacement of the epiphysis per UpToDate. Internal rotation is markedly limited and painful. Bilateral involvement occurs in 20 to 40% of cases, often within 18 months of the initial presentation per Harrison's Principles of Internal Medicine.\n\nDIAGNOSIS:\nThe frog-leg lateral radiograph is essential because SCFE can be entirely missed on the anteroposterior pelvis view alone, especially in early or mild slips per UpToDate. On the AP view, Klein's line (a line drawn along the superior border of the femoral neck) should normally intersect a portion of the lateral femoral epiphysis; in SCFE, the epiphysis falls inferior to this line. The frog-leg lateral view directly visualizes the posterior displacement that defines the slip and is the most sensitive radiographic projection per the Cleveland Clinic.\n\nMANAGEMENT:\nSCFE is a surgical emergency per the Mayo Clinic. The patient must be made non-weight-bearing immediately, and urgent in situ percutaneous screw fixation is performed to prevent further slippage. The most feared complications are avascular necrosis of the femoral head (risk increases with attempts at reduction or delays in treatment) and chondrolysis per UpToDate.\n\nKEY LEARNING POINTS:\nThe frog-leg lateral radiograph is essential for diagnosing SCFE because the posterior slip can be missed on AP views alone. SCFE typically affects obese adolescents with hip, groin, or knee pain and obligate external rotation on hip flexion. It is a surgical emergency requiring immediate non-weight-bearing and urgent screw fixation to prevent avascular necrosis."
  },
  {
    "id": 197,
    "categoryId": 3,
    "question": "The ROME IV criteria for IBS requires abdominal pain at least 1 day/week associated with 2 of 3 features. Which is NOT a feature?",
    "options": [
      "A) Related to defecation",
      "B) Change in stool frequency",
      "C) Change in stool form",
      "D) Associated with nausea"
    ],
    "correctAnswer": 3,
    "explanation": "CORRECT: D (Nausea is not one of the three Rome IV features).\n\nPATHOPHYSIOLOGY:\nIrritable bowel syndrome is a disorder of gut-brain interaction defined by the Rome IV criteria as recurrent abdominal pain occurring at least one day per week in the last 3 months (with onset at least 6 months before diagnosis) associated with two or more of three specific features: pain related to defecation (either improvement or worsening), change in stool frequency, and change in stool form (appearance). These criteria deliberately focus on the relationship between pain and bowel habit because this association distinguishes IBS from other functional GI disorders.\n\nCLINICAL REASONING:\nNausea, while commonly reported by IBS patients (occurring in up to 40% of cases), is not one of the three defining Rome IV features because it lacks specificity and does not reliably distinguish IBS from functional dyspepsia, gastroparesis, or other upper GI functional disorders. The Rome IV criteria were designed to be specific enough to provide a positive diagnosis of IBS without requiring extensive exclusionary testing. The three features (relation to defecation, stool frequency change, stool form change) capture the core pathophysiologic disturbance of disordered bowel function with visceral hypersensitivity.\n\nSUBTYPE CLASSIFICATION:\nIBS is subtyped based on the predominant stool pattern using the Bristol Stool Form Scale: IBS with constipation (IBS-C, types 1-2), IBS with diarrhea (IBS-D, types 6-7), IBS with mixed bowel habits (IBS-M), and IBS unsubtyped. Subtyping guides treatment selection, as different pharmacologic agents target each subtype.\n\nKEY LEARNING POINTS:\nThe Rome IV criteria for IBS require abdominal pain at least one day per week associated with two of three features: relation to defecation, change in stool frequency, and change in stool form. Nausea is common in IBS but is not a defining diagnostic feature. IBS subtypes (C, D, M) are classified using the Bristol Stool Form Scale and guide treatment selection."
  },
  {
    "id": 198,
    "categoryId": 8,
    "question": "Which physical exam finding is pathognomonic for Infective Endocarditis?",
    "options": [
      "A) Janeway Lesions (Painless palms/soles)",
      "B) Osler Nodes (Painful fingertips)",
      "C) Roth Spots (Retina)",
      "D) All of the above"
    ],
    "correctAnswer": 3,
    "explanation": "CORRECT: D.\n\nDIAGNOSIS:\nInfective endocarditis (IE), an infection of the endocardial surface of the heart, most commonly involving heart valves.\n\nCLINICAL REASONING:\nIE presents with persistent fever plus a new or changing heart murmur. Classic peripheral manifestations (present in minority of cases) include: Osler nodes (painful, raised lesions on fingers/toes - immune complex), Janeway lesions (painless, erythematous lesions on palms/soles - septic emboli), splinter hemorrhages, Roth spots (retinal hemorrhages), and embolic phenomena (stroke, pulmonary emboli, renal infarcts).\n\nDIAGNOSIS (Modified Duke Criteria):\nMajor criteria: Positive blood cultures (typical organisms, persistent bacteremia), evidence of endocardial involvement (vegetation, abscess, new regurgitation on echo)\nMinor criteria: Predisposing condition, fever, vascular phenomena, immunologic phenomena, suggestive blood cultures/echo\n\nMICROBIOLOGY:\n- Native valve: S. aureus (most common), Streptococci (viridans, bovis), Enterococci\n- Prosthetic valve (early <60 days): S. aureus, coagulase-negative staph, gram-negatives\n- Prosthetic valve (late): Similar to native valve\n- IVDU: S. aureus (often MRSA), right-sided (tricuspid) involvement common\n\nTREATMENT:\n- Blood cultures x3 from separate sites before antibiotics\n- Empiric therapy: Vancomycin + ceftriaxone (native) or + gentamicin (prosthetic)\n- Duration: 4-6 weeks IV antibiotics\n- Surgical indications: Heart failure, uncontrolled infection, large vegetations, embolic events\n\nCLINICAL PEARL:\nS. bovis (gallolyticus) bacteremia or endocarditis mandates colonoscopy due to strong association with colorectal malignancy. HACEK organisms (Haemophilus, Aggregatibacter, Cardiobacterium, Eikenella, Kingella) cause \"culture-negative\" endocarditis due to slow growth."
  },
  {
    "id": 199,
    "categoryId": 2,
    "question": "Which intervention reduces mortality in COPD patients with severe resting hypoxemia (O2 sat < 88%)?",
    "options": [
      "A) Long-Acting Inhalers (LAMA)",
      "B) Long-term Oxygen Therapy",
      "C) Oral Steroids",
      "D) Theophylline"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Long-term Oxygen Therapy).\n\nCLINICAL EVIDENCE:\nLong-term oxygen therapy is one of only two interventions proven to reduce mortality in COPD, along with smoking cessation per Harrison's Principles of Internal Medicine. The landmark Nocturnal Oxygen Therapy Trial (NOTT, published in Annals of Internal Medicine) and the British Medical Research Council (MRC) trial demonstrated significant mortality reduction in COPD patients with severe chronic resting hypoxemia who received supplemental oxygen for 15 or more hours per day, with the NOTT trial showing that continuous oxygen (greater than 18 hours per day) was superior to nocturnal-only oxygen per UpToDate.\n\nINDICATIONS:\nThe standard indications for long-term oxygen therapy in COPD per the GOLD guidelines and the Mayo Clinic are: resting PaO2 55 mmHg or less (or SpO2 88% or less), or PaO2 56 to 59 mmHg (SpO2 89%) with evidence of cor pulmonale (right heart failure from pulmonary hypertension), polycythemia (hematocrit greater than 55%), or peripheral edema. These measurements should be obtained during a period of clinical stability (not during an acute exacerbation) and confirmed on two occasions at least 3 weeks apart per UpToDate. The LOTT (Long-term Oxygen Treatment Trial) published in the New England Journal of Medicine demonstrated that supplemental oxygen does not benefit COPD patients with moderate resting or exercise-induced desaturation (SpO2 89 to 93%), confirming that the mortality benefit is limited to patients with severe hypoxemia per the Cleveland Clinic.\n\nWHY NOT OTHER OPTIONS:\nBronchodilators (LAMA, LABA) improve symptoms, exercise tolerance, and reduce exacerbations but have not been proven to reduce all-cause mortality in COPD per Harrison's Principles of Internal Medicine, with the exception of triple therapy (LAMA/LABA/ICS) which showed a modest mortality reduction in the IMPACT and ETHOS trials specifically in patients with elevated eosinophils. Chronic oral corticosteroids are not recommended due to substantial side effects (osteoporosis, diabetes, adrenal suppression) without proven mortality benefit. Theophylline has marginal bronchodilator efficacy with significant toxicity risk per UpToDate.\n\nKEY LEARNING POINTS:\nLong-term oxygen therapy reduces mortality in COPD patients with severe resting hypoxemia (SpO2 88% or less, PaO2 55 or less) when used 15 or more hours per day. Only smoking cessation and long-term oxygen therapy have definitively been shown to improve survival in COPD. Supplemental oxygen does not benefit patients with only moderate desaturation (SpO2 89 to 93%) per the LOTT trial."
  },
  {
    "id": 200,
    "categoryId": 6,
    "question": "A high school athlete sustains a concussion. When can they return to play?",
    "options": [
      "A) When symptoms resolve (usually 2-3 days)",
      "B) After a stepwise 5-6 day return-to-play protocol, provided they remain symptom-free at each step",
      "C) Immediately if CT head is normal",
      "D) After 2 weeks mandatory rest"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (After a stepwise return-to-play protocol, provided they remain symptom-free at each step).\n\nSPORT-RELATED CONCUSSION MANAGEMENT:\nThe return-to-play (RTP) protocol is a graduated, stepwise approach endorsed by the Consensus Statement on Concussion in Sport and the American Academy of Neurology. Each step requires a minimum of 24 hours symptom-free before advancing, and if symptoms recur at any stage, the athlete must return to the previous asymptomatic step. The entire protocol takes a minimum of 5 to 6 days.\n\nPATHOPHYSIOLOGY:\nConcussion causes a neurometabolic cascade involving ionic flux, impaired glucose metabolism, altered cerebral blood flow, and mitochondrial dysfunction. The brain enters a vulnerable period during which cognitive and physical demands can exacerbate symptoms and prolong recovery. Second Impact Syndrome, though rare, occurs when a second concussion is sustained before the first has resolved, causing catastrophic cerebral edema that can be fatal.\n\nGRADUATED RETURN-TO-PLAY PROTOCOL:\nThe protocol begins with complete cognitive and physical rest until symptoms resolve (Step 1), followed by light aerobic activity such as walking or stationary cycling (Step 2), then sport-specific exercise without contact (Step 3), non-contact training drills with progressive resistance (Step 4), full-contact practice after medical clearance (Step 5), and finally return to competition (Step 6). A healthcare professional must provide written clearance before the athlete returns to full contact.\n\nDIAGNOSIS AND EVALUATION:\nConcussion is a clinical diagnosis based on symptoms, physical signs, cognitive impairment, and behavioral changes following a biomechanical force. The Sport Concussion Assessment Tool (SCAT6) is the standardized sideline evaluation. CT imaging is indicated only for suspected skull fracture or intracranial hemorrhage. Neuropsychological testing can help guide return-to-play decisions in complex cases.\n\nKEY LEARNING POINTS:\nReturn to play requires a graduated 5-to-6-day stepwise protocol with 24 hours symptom-free at each step. Second Impact Syndrome can be fatal if a second concussion occurs before the first resolves. Symptom recurrence at any step requires returning to the previous asymptomatic level before progressing."
  },
  {
    "id": 201,
    "categoryId": 5,
    "question": "Microscopic Hematuria (>3 RBCs/hpf) in a smoker aged >35 requires:",
    "options": [
      "A) Repeat UA in 6 months",
      "B) Renal Ultrasound only",
      "C) CT Urogram and Cystoscopy",
      "D) Antibiotics for UTI"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (CT Urogram and Cystoscopy).\n\nCLINICAL REASONING:\nMicroscopic hematuria (greater than 3 RBCs per high-power field on two of three properly collected urine specimens) in a patient over 35 who smokes requires a complete urologic evaluation with both upper tract imaging (CT urogram) and lower tract visualization (cystoscopy) to exclude urinary tract malignancy per the AUA Microhematuria Guidelines and UpToDate. Smoking is the single strongest risk factor for urothelial (transitional cell) carcinoma of the bladder, with smokers having a 3 to 4-fold increased risk compared to nonsmokers per Harrison's Principles of Internal Medicine.\n\nRATIONALE FOR DUAL EVALUATION:\nCT urogram (CT with contrast in nephrographic and excretory phases) evaluates the upper urinary tract (kidneys, renal pelvis, ureters) for renal cell carcinoma, urothelial carcinoma of the upper tract, nephrolithiasis, and other structural abnormalities per the Cleveland Clinic. Cystoscopy provides direct visualization of the bladder mucosa and is the gold standard for detecting bladder cancer (which accounts for the majority of hematuria-associated malignancies) per UpToDate and the Mayo Clinic. Neither test alone is sufficient: CT urogram misses flat (carcinoma in situ) bladder lesions, and cystoscopy does not evaluate the upper tracts per Harrison's Principles of Internal Medicine.\n\nRISK STRATIFICATION:\nThe 2020 AUA guidelines stratify patients with microscopic hematuria by cancer risk per UpToDate. High-risk features (age greater than 50, greater than 25 RBCs/hpf, smoking history, gross hematuria, prior pelvic radiation, cyclophosphamide exposure, occupational chemical exposure) warrant full evaluation with CT urogram plus cystoscopy. Low-risk patients may be managed with repeat urinalysis in 6 months per the Cleveland Clinic. Urine cytology has low sensitivity for low-grade tumors but is useful for detecting high-grade urothelial carcinoma and CIS per Harvard Health.\n\nKEY LEARNING POINTS:\nMicroscopic hematuria in a smoker over 35 requires both CT urogram (upper tract evaluation) and cystoscopy (bladder visualization) because neither alone is sufficient to exclude malignancy. Smoking confers a 3 to 4-fold increased bladder cancer risk. The AUA risk stratification guides which patients need full evaluation versus monitoring."
  },
  {
    "id": 202,
    "categoryId": 9,
    "question": "You are treating Iron Deficiency Anemia. How long should iron supplementation continue after the Hemoglobin normalizes?",
    "options": [
      "A) Stop immediately",
      "B) Continue for 1 month",
      "C) Continue for 3-6 months to replenish Ferritin stores",
      "D) Continue indefinitely"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Continue for 3 to 6 months to replenish ferritin stores).\n\nPATHOPHYSIOLOGY:\nIron deficiency anemia develops through three progressive stages per Harrison's Principles of Internal Medicine. Stage 1 (iron depletion) involves exhaustion of storage iron (ferritin falls) while hemoglobin remains normal. Stage 2 (iron-deficient erythropoiesis) shows reduced transferrin saturation and early microcytosis. Stage 3 (frank iron deficiency anemia) produces overt microcytic hypochromic anemia with low hemoglobin per UpToDate. When oral iron therapy normalizes hemoglobin, the patient has corrected only stage 3; iron stores (reflected by ferritin) remain depleted and require an additional 3 to 6 months of supplementation to replenish per the Cleveland Clinic.\n\nEVIDENCE:\nStudies demonstrate that premature discontinuation of iron therapy after hemoglobin normalization (but before ferritin replenishment) results in recurrent anemia in 30 to 50% of patients within 3 to 6 months per UpToDate and Harvard Health. The target ferritin level before discontinuing iron therapy is generally above 50 to 100 ng/mL (indicating adequate stores) or above 30 ng/mL at minimum per the Mayo Clinic.\n\nIRON SUPPLEMENTATION BEST PRACTICES:\nFerrous sulfate 325 mg (containing 65 mg elemental iron) is the standard first-line oral iron preparation per Harrison's Principles of Internal Medicine. Recent evidence supports alternate-day dosing (rather than daily or multiple daily doses) because oral iron triggers hepcidin release within 24 hours, which blocks subsequent iron absorption for approximately 48 hours per UpToDate and the Cleveland Clinic. Vitamin C (200 to 500 mg) taken concurrently enhances non-heme iron absorption by reducing ferric iron (Fe3+) to ferrous iron (Fe2+) in the duodenum. Iron should be taken on an empty stomach and separated from calcium, antacids, PPIs, tea, and coffee by at least 2 hours per the Mayo Clinic.\n\nMONITORING:\nReticulocyte count should rise within 5 to 7 days of initiating iron therapy, confirming marrow response per Harrison's Principles of Internal Medicine. Hemoglobin should increase by approximately 1 to 2 g/dL per month. Ferritin should be rechecked 3 months after hemoglobin normalization to confirm store replenishment per UpToDate.\n\nKEY LEARNING POINTS:\nIron supplementation must continue 3 to 6 months after hemoglobin normalization to replenish ferritin stores and prevent recurrence in 30 to 50% of patients. Alternate-day dosing may improve absorption by avoiding hepcidin-mediated blockade. Target ferritin above 50 to 100 ng/mL before discontinuing therapy."
  },
  {
    "id": 203,
    "categoryId": 11,
    "question": "Which herbal supplement is notorious for causing Serotonin Syndrome if combined with SSRIs?",
    "options": [
      "A) Ginkgo Biloba",
      "B) St. John's Wort",
      "C) Valerian Root",
      "D) Saw Palmetto"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (St. John's Wort).\n\nPHARMACOLOGY:\nSt. John's Wort (Hypericum perforatum) is an herbal supplement widely used for mild to moderate depression that has significant serotonergic activity per Harrison's Principles of Internal Medicine and UpToDate. Its active constituents, hypericin and hyperforin, inhibit the reuptake of serotonin, norepinephrine, and dopamine through mechanisms similar to conventional antidepressants per the Cleveland Clinic. When combined with SSRIs, SNRIs, triptans, tramadol, MAO inhibitors, or other serotonergic agents, St. John's Wort can precipitate serotonin syndrome, a potentially life-threatening toxidrome characterized by clonus, hyperthermia, agitation, and autonomic instability per UpToDate.\n\nDRUG INTERACTIONS:\nBeyond serotonin syndrome risk, St. John's Wort is a potent inducer of CYP3A4, CYP2C9, CYP1A2, and P-glycoprotein (the most clinically significant enzyme induction of any herbal supplement), which reduces plasma concentrations of numerous critical medications per Harvard Health and Harrison's Principles of Internal Medicine. Affected drugs include oral contraceptives (risk of unintended pregnancy), warfarin (loss of anticoagulation), cyclosporine and tacrolimus (organ rejection risk), HIV protease inhibitors and NNRTIs (treatment failure), statins, digoxin, and direct oral anticoagulants per UpToDate and the Mayo Clinic.\n\nCLINICAL APPLICATION:\nClinicians should specifically ask about St. John's Wort during medication reconciliation, as many patients do not disclose herbal supplement use unless directly questioned per the Cleveland Clinic. Patients should be counseled that \"natural\" does not mean safe, and that St. John's Wort has drug interaction potential exceeding many prescription medications per Harvard Health.\n\nKEY LEARNING POINTS:\nSt. John's Wort causes serotonin syndrome when combined with SSRIs due to its serotonin reuptake inhibition activity. It is also the most potent herbal CYP3A4 inducer, reducing levels of oral contraceptives (pregnancy risk), warfarin, immunosuppressants (rejection risk), and HIV medications. Always ask about herbal supplements during medication reconciliation."
  },
  {
    "id": 204,
    "categoryId": 5,
    "question": "NSAIDs (Ibuprofen) and ACE Inhibitors (Lisinopril) can cause Acute Kidney Injury (AKI) when combined. What is the physiological mechanism?",
    "options": [
      "A) NSAIDs dilate the Afferent arteriole; ACEi constrict the Efferent",
      "B) NSAIDs constrict the Afferent arteriole; ACEi dilate the Efferent arteriole",
      "C) Both drugs cause direct tubular necrosis",
      "D) Both drugs cause interstitial nephritis"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (NSAIDs constrict the afferent arteriole; ACE inhibitors dilate the efferent arteriole).\n\nRENAL PHYSIOLOGY:\nGlomerular filtration rate (GFR) depends on the net filtration pressure across the glomerular capillary, which is maintained by the balance of afferent arteriolar tone (controlling blood flow into the glomerulus) and efferent arteriolar tone (controlling blood flow out of the glomerulus) per Harrison's Principles of Internal Medicine and UpToDate. Prostaglandins (particularly PGE2 and PGI2) produced by cyclooxygenase enzymes in the kidney maintain afferent arteriolar vasodilation, especially under conditions of reduced renal perfusion (volume depletion, heart failure, CKD) per the Cleveland Clinic. Angiotensin II maintains GFR by constricting the efferent arteriole, which sustains filtration pressure when renal perfusion is compromised per Harvard Health.\n\nMECHANISM OF DUAL INJURY:\nNSAIDs inhibit cyclooxygenase (COX-1 and COX-2), blocking prostaglandin-mediated afferent arteriolar vasodilation and causing afferent vasoconstriction (reduced blood flow into the glomerulus) per Harrison's Principles of Internal Medicine. Simultaneously, ACE inhibitors block angiotensin II production, removing efferent arteriolar constriction and causing efferent vasodilation (reduced resistance to blood flow out of the glomerulus) per UpToDate. When both occur together, the glomerulus is \"squeezed\" from both sides: reduced inflow (afferent constriction) and reduced outflow resistance (efferent dilation), producing a catastrophic drop in glomerular filtration pressure and acute kidney injury per the Mayo Clinic.\n\nTRIPLE WHAMMY:\nThe combination of an NSAID plus an ACE inhibitor/ARB plus a diuretic (the \"triple whammy\") is the highest-risk drug combination for AKI, as the diuretic adds volume depletion that further reduces renal perfusion per the Cleveland Clinic. Studies demonstrate a 30 to 40% increased risk of AKI within the first 30 days of triple therapy per UpToDate.\n\nCLINICAL APPLICATION:\nPatients on ACE inhibitors should be counseled to avoid NSAIDs (including OTC ibuprofen and naproxen) and use acetaminophen as an alternative analgesic per Harvard Health. Creatinine should be monitored after any change involving these medications, especially in the elderly and those with baseline CKD per Harrison's Principles of Internal Medicine.\n\nKEY LEARNING POINTS:\nNSAIDs constrict the afferent arteriole (by blocking prostaglandins) while ACE inhibitors dilate the efferent arteriole (by blocking angiotensin II), together collapsing glomerular filtration pressure and causing AKI. The \"triple whammy\" (NSAID plus ACE/ARB plus diuretic) increases AKI risk by 30 to 40%. Patients on ACE inhibitors should avoid NSAIDs and use acetaminophen instead."
  },
  {
    "id": 205,
    "categoryId": 6,
    "question": "A patient presents with back pain radiating down the leg. He has weakness with Dorsiflexion (cannot walk on heels/Foot Drop). Which nerve root is affected?",
    "options": [
      "A) L4",
      "B) L5",
      "C) S1",
      "D) L3"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (L5 nerve root).\n\nL5 RADICULOPATHY:\nL5 radiculopathy is one of the most common lumbar nerve root compression syndromes, typically caused by a posterolateral disc herniation at L4-L5. The hallmark finding is weakness of ankle and great toe dorsiflexion (foot drop), which manifests clinically as the inability to walk on the heels. Pain typically radiates from the lower back through the buttock and lateral leg to the dorsum of the foot.\n\nPATHOPHYSIOLOGY:\nDisc herniation or degenerative foraminal stenosis compresses the L5 nerve root, disrupting both motor and sensory signals. The L5 root innervates the tibialis anterior (dorsiflexion), extensor hallucis longus (great toe extension), and gluteus medius (hip abduction). The sensory dermatome covers the lateral leg and dorsum of the foot, including the web space between the first and second toes. Notably, L5 does not have a dedicated deep tendon reflex, unlike L4 (patellar) and S1 (Achilles).\n\nCLINICAL DISTINCTION BY NERVE ROOT:\nDifferentiating lumbar radiculopathies is essential for localization. L4 radiculopathy causes quadriceps weakness (difficulty with squatting or climbing stairs), decreased patellar reflex, and numbness over the medial leg. L5 radiculopathy causes dorsiflexion weakness (foot drop and heel walking difficulty), with sensory changes between the first and second toes and no reflex change. S1 radiculopathy causes plantarflexion weakness (difficulty with toe walking), decreased Achilles reflex, and numbness along the lateral foot.\n\nDIAGNOSIS AND TREATMENT:\nMost lumbar radiculopathies are diagnosed clinically. MRI is reserved for red flags such as progressive neurological deficits, suspected cauda equina syndrome, cancer, infection, or symptoms persisting beyond 6 weeks. Conservative management with NSAIDs, physical therapy, and activity modification resolves most cases. Epidural steroid injections are considered for persistent pain, and surgical decompression (microdiscectomy) is indicated for progressive motor weakness or refractory symptoms.\n\nKEY LEARNING POINTS:\nL5 radiculopathy causes foot drop (dorsiflexion weakness) and inability to walk on heels, with sensory changes on the dorsal foot. L5 has no associated deep tendon reflex, distinguishing it from L4 (patellar) and S1 (Achilles). Most cases resolve with conservative management; surgery is reserved for progressive weakness or cauda equina syndrome."
  },
  {
    "id": 206,
    "categoryId": 2,
    "question": "Why should high-flow oxygen be used with caution in severe COPD retainers (Chronic Hypercapnia)?",
    "options": [
      "A) It suppresses the hypoxic drive to breathe",
      "B) The Haldane Effect and V/Q mismatch worsening",
      "C) It causes pulmonary fibrosis",
      "D) It causes oxidative stress"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (The Haldane Effect and V/Q mismatch worsening).\n\nPATHOPHYSIOLOGY:\nOxygen-induced hypercapnia in COPD is a clinically important phenomenon that has been incompletely understood for decades. The traditional teaching that high-flow oxygen simply suppresses the hypoxic ventilatory drive in chronic CO2 retainers is an oversimplification per Harrison's Principles of Internal Medicine. Modern physiologic studies (including the landmark work by Aubier et al. and subsequent investigations) have demonstrated that the Haldane effect and worsening ventilation-perfusion mismatch are the predominant mechanisms, with decreased minute ventilation playing a contributory but lesser role per UpToDate.\n\nTHE HALDANE EFFECT:\nDeoxygenated hemoglobin has a significantly greater affinity for CO2 than oxygenated hemoglobin (both through direct carbamino binding and through enhanced bicarbonate formation via the chloride shift) per Harrison's Principles of Internal Medicine. When high-flow supplemental oxygen saturates hemoglobin, the oxygenated hemoglobin releases bound CO2 into the plasma and alveoli, directly raising PaCO2. This is the Haldane effect, and physiologic studies have demonstrated it to be the most significant single contributor to oxygen-induced hypercapnia per the Cleveland Clinic.\n\nV/Q MISMATCH WORSENING:\nIn the diseased COPD lung, hypoxic pulmonary vasoconstriction is a critical compensatory mechanism that redirects pulmonary blood flow away from poorly ventilated alveolar units toward better-ventilated regions, optimizing gas exchange per UpToDate. High-flow oxygen abolishes this protective vasoconstriction in poorly ventilated zones, redistributing blood flow to these regions and effectively increasing dead space ventilation. The result is worsened V/Q mismatch and impaired CO2 elimination despite improved oxygenation per Harrison's Principles of Internal Medicine.\n\nCLINICAL APPLICATION:\nFor COPD patients at risk for chronic hypercapnia, oxygen should be titrated to a target SpO2 of 88 to 92% rather than the standard 94 to 98% per the GOLD guidelines and the British Thoracic Society. Venturi masks allow precise FiO2 delivery and are preferred in the acute setting. The critical principle is that hypoxia kills faster than hypercapnia, so oxygen should never be completely withheld from a hypoxic COPD patient. Instead, it should be delivered at controlled, low-flow rates with close monitoring of arterial blood gases per the Mayo Clinic.\n\nKEY LEARNING POINTS:\nThe Haldane effect (oxygenated hemoglobin releases CO2) and loss of hypoxic pulmonary vasoconstriction (worsening V/Q mismatch) are the primary mechanisms of oxygen-induced hypercapnia in COPD, while suppression of hypoxic ventilatory drive plays a smaller role than traditionally taught. Target SpO2 is 88 to 92% in chronic CO2 retainers using controlled oxygen delivery. Oxygen should never be withheld from a hypoxic COPD patient."
  },
  {
    "id": 207,
    "categoryId": 1,
    "question": "An S3 heart sound ('Kentucky') in an adult is a specific sign of:",
    "options": [
      "A) Left Ventricular Hypertrophy (Stiff ventricle)",
      "B) Volume Overload / Systolic Heart Failure",
      "C) Aortic Stenosis",
      "D) Mitral Prolapse"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Volume Overload / Systolic Heart Failure).\n\nPATHOPHYSIOLOGY:\nThe S3 heart sound (also called a ventricular gallop, with the cadence described by the mnemonic \"Ken-TUC-ky\" representing S1-S2-S3) is a low-pitched sound heard in early diastole, occurring immediately after S2 during the rapid ventricular filling phase per Harrison's Principles of Internal Medicine. S3 is produced by the sudden deceleration of blood as it enters a volume-overloaded, dilated ventricle, causing vibration of the ventricular walls and chordae tendineae per UpToDate. In adults over 40 years of age, an S3 is highly specific for pathologically elevated ventricular filling pressures and is considered a hallmark physical examination finding of systolic (decompensated) heart failure with reduced ejection fraction per the Cleveland Clinic.\n\nCLINICAL SIGNIFICANCE:\nThe S3 is a valuable bedside finding because it indicates elevated left ventricular end-diastolic pressure and volume overload per the Mayo Clinic. It has a specificity of approximately 90 to 97% for elevated filling pressures in adults, making it one of the most reliable physical examination findings for heart failure. The S3 is heard best with the bell of the stethoscope (designed for low-frequency sounds) at the cardiac apex with the patient in the left lateral decubitus position per Harrison's Principles of Internal Medicine.\n\nDISTINCTION FROM S4:\nThe S4 heart sound (atrial gallop, with the cadence \"TEN-nes-see\" representing S4-S1-S2) occurs in late diastole just before S1 and is produced by forceful atrial contraction against a stiff, non-compliant ventricle per UpToDate. S4 is associated with diastolic dysfunction, left ventricular hypertrophy (from chronic hypertension, aortic stenosis, or hypertrophic cardiomyopathy), and acute ischemia. An S3 indicates volume overload and systolic failure, while an S4 indicates a stiff ventricle and diastolic dysfunction per the Cleveland Clinic. A physiologic S3 can be normal in children, young adults, and during pregnancy (due to the hyperdynamic circulation) per Harrison's Principles of Internal Medicine.\n\nKEY LEARNING POINTS:\nAn S3 gallop (Ken-TUC-ky cadence, early diastole) in an adult indicates volume overload and systolic heart failure with approximately 90 to 97% specificity for elevated filling pressures. It is heard best with the bell at the apex in the left lateral decubitus position. S4 (TEN-nes-see, late diastole) indicates a stiff ventricle and diastolic dysfunction from hypertrophy or ischemia."
  },
  {
    "id": 208,
    "categoryId": 7,
    "question": "Which Rotator Cuff muscle is responsible for the first 15 degrees of abduction?",
    "options": [
      "A) Deltoid",
      "B) Supraspinatus",
      "C) Infraspinatus",
      "D) Subscapularis"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Supraspinatus).\n\nPATHOPHYSIOLOGY:\nThe supraspinatus originates from the supraspinous fossa of the scapula and inserts on the superior facet of the greater tuberosity of the humerus. Its primary biomechanical function is to initiate shoulder abduction through the first 0 to 15 degrees by compressing the humeral head into the glenoid fossa, creating a stable fulcrum around which the deltoid can then generate the torque necessary for further abduction. Without the supraspinatus acting as a humeral head depressor and stabilizer, the deltoid's line of pull would drive the humeral head superiorly into the acromion rather than producing abduction, a phenomenon that becomes clinically apparent when the supraspinatus is torn and the patient demonstrates a \"shrug sign\" attempting to abduct the arm. Beyond 15 degrees, the deltoid assumes the role of primary abductor through approximately 90 degrees, after which the trapezius and serratus anterior rotate the scapula to achieve full overhead elevation.\n\nCLINICAL SIGNIFICANCE:\nThe supraspinatus is the most commonly injured rotator cuff muscle, accounting for the majority of rotator cuff tears. Its vulnerability results from its anatomic course through the subacromial space, the narrow corridor between the humeral head inferiorly and the coracoacromial arch superiorly. During abduction, the supraspinatus tendon is repeatedly compressed against the undersurface of the acromion, particularly in patients with a type III (hooked) acromion morphology. Additionally, the supraspinatus tendon contains a hypovascular \"critical zone\" located approximately 1 centimeter proximal to its insertion, where the blood supply from the osseous and tendinous circulations forms a watershed area of relative ischemia. This combination of mechanical impingement and tenuous blood supply predisposes the tendon to degeneration, partial-thickness tears, and eventual full-thickness rupture.\n\nCLINICAL EXAMINATION:\nThe Empty Can test (Jobe test) specifically isolates supraspinatus function by placing the arm at 90 degrees of abduction in the scapular plane with the thumb pointed downward (internal rotation), then asking the patient to resist a downward force applied by the examiner. Pain or weakness in this position indicates supraspinatus pathology. The full can test (same position but with thumb pointed up) may be equally sensitive with less discomfort. The other three rotator cuff muscles complete the SITS mnemonic: infraspinatus and teres minor are external rotators tested with the arm at the side and elbow at 90 degrees, and the subscapularis is the sole internal rotator, tested with the lift-off or belly press maneuver.\n\nKEY LEARNING POINTS:\nThe supraspinatus initiates shoulder abduction through the first 0 to 15 degrees by stabilizing the humeral head in the glenoid and creating a fulcrum for the deltoid. It is the most commonly torn rotator cuff muscle due to its passage through the subacromial space and its hypovascular critical zone. The Empty Can (Jobe) test isolates supraspinatus function by testing resisted abduction with the arm internally rotated in the scapular plane."
  },
  {
    "id": 209,
    "categoryId": 4,
    "question": "In Type 2 Diabetes, which defect typically occurs first, often years before diagnosis?",
    "options": [
      "A) Destruction of Beta Cells",
      "B) Peripheral Insulin Resistance",
      "C) Loss of first-phase insulin secretion",
      "D) Ketoacidosis"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Peripheral Insulin Resistance).\n\nPATHOPHYSIOLOGY:\nThe natural history of type 2 diabetes follows a well-characterized pathophysiologic progression that unfolds over 10 to 15 years before clinical diagnosis per the Starling Curve of the Pancreas model described by DeFronzo in Diabetes (2009) and reviewed extensively in Harrison's Principles of Internal Medicine. The initial defect is peripheral insulin resistance, in which skeletal muscle, adipose tissue, and the liver become progressively less responsive to insulin's metabolic actions. In skeletal muscle (which accounts for approximately 80% of insulin-stimulated glucose disposal), insulin resistance impairs GLUT4 translocation and glycogen synthesis, reducing postprandial glucose uptake. In adipose tissue, insulin resistance leads to inadequate suppression of hormone-sensitive lipase, producing elevated circulating free fatty acids that further impair insulin signaling in muscle and liver through lipotoxic intermediates (diacylglycerols and ceramides) and contribute to ectopic lipid deposition. In the liver, insulin resistance manifests as impaired suppression of hepatic glucose output, resulting in inappropriate fasting gluconeogenesis. The primary drivers of insulin resistance include visceral adiposity, physical inactivity, genetic susceptibility, and aging. Chronic low-grade inflammation from visceral adipose tissue (via TNF-alpha, IL-6, and reduced adiponectin) further impairs insulin receptor substrate signaling.\n\nTHE COMPENSATORY PHASE:\nDuring the early years of insulin resistance, the pancreatic beta cells mount a compensatory response by increasing insulin secretion, often to 2 to 3 times baseline levels, to maintain euglycemia. This compensatory hyperinsulinemia is clinically silent with respect to glucose-based tests: fasting glucose, postprandial glucose, and hemoglobin A1c all remain within normal reference ranges. However, the metabolic derangement is already present and detectable through elevated fasting insulin, elevated HOMA-IR, and the metabolic syndrome phenotype (visceral obesity, elevated triglycerides, reduced HDL, mild hypertension, and borderline glucose elevation). This compensation phase represents the optimal window for intervention, as lifestyle modification during this period can reverse insulin resistance and prevent beta-cell exhaustion. The Diabetes Prevention Program demonstrated that intervention during this phase (in individuals with impaired glucose tolerance) reduced diabetes incidence by 58% with lifestyle modification.\n\nTHE DECOMPENSATION PHASE:\nBeta-cell function eventually declines under the sustained demands of compensatory hypersecretion, driven by multiple converging mechanisms: glucotoxicity (chronic hyperglycemia itself impairs beta-cell function), lipotoxicity (free fatty acid-mediated beta-cell apoptosis and impaired insulin gene transcription), islet amyloid deposition (toxic aggregation of islet amyloid polypeptide co-secreted with insulin), oxidative stress, and endoplasmic reticulum stress from chronic protein overproduction. The UKPDS demonstrated that by the time of clinical type 2 diabetes diagnosis, approximately 50% of beta-cell function has already been lost, and beta-cell function continues to decline at approximately 4 to 5% per year regardless of therapy. Glucose levels rise first in the postprandial state (where the incretin effect and first-phase insulin secretion are lost earliest) and subsequently in the fasting state as hepatic glucose output becomes increasingly unrestrained.\n\nKEY LEARNING POINTS:\nPeripheral insulin resistance is the earliest defect in the pathogenesis of type 2 diabetes, preceding clinical diagnosis by 10 to 15 years during which beta cells compensate with hyperinsulinemia and glucose tests remain normal. By the time fasting glucose or A1c criteria for diabetes are met, approximately 50% of beta-cell function has been irreversibly lost. Early detection of insulin resistance through fasting insulin, HOMA-IR, or metabolic syndrome criteria enables intervention during the compensation phase when lifestyle modification can prevent disease progression."
  },
  {
    "id": 210,
    "categoryId": 3,
    "question": "Intrinsic Factor, required for Vitamin B12 absorption, is secreted by which cells?",
    "options": [
      "A) Chief Cells",
      "B) Parietal Cells",
      "C) Goblet Cells",
      "D) G Cells"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Parietal Cells).\n\nPATHOPHYSIOLOGY:\nParietal cells (oxyntic cells) are located in the gastric glands of the body and fundus of the stomach and serve two critical secretory functions: production of hydrochloric acid (HCl) via the hydrogen-potassium ATPase (proton pump) and secretion of intrinsic factor. Intrinsic factor is a glycoprotein essential for vitamin B12 absorption. It binds to dietary B12 in the duodenum, forming an intrinsic factor-B12 complex that is specifically recognized by cubilin receptors on the ileal mucosa, enabling receptor-mediated endocytosis of B12 in the terminal ileum.\n\nCLINICAL SIGNIFICANCE:\nPernicious anemia is an autoimmune condition in which autoantibodies target parietal cells and intrinsic factor, causing progressive destruction of parietal cell mass. This produces two consequences: achlorhydria (absent acid secretion) and loss of intrinsic factor, resulting in impaired B12 absorption and eventual megaloblastic anemia. Anti-intrinsic factor antibodies are highly specific for pernicious anemia (specificity greater than 95%), while anti-parietal cell antibodies are more sensitive but less specific. Pernicious anemia is associated with other autoimmune conditions including autoimmune thyroiditis, type 1 diabetes, and vitiligo.\n\nRELATED CLINICAL CONSIDERATIONS:\nChronic PPI use suppresses acid secretion by blocking the proton pump in parietal cells, which impairs protein-bound B12 liberation from food but does not affect intrinsic factor secretion. This is why PPI-associated B12 deficiency is generally milder and more slowly progressive than pernicious anemia. Total gastrectomy eliminates all parietal cells, mandating lifelong parenteral B12 supplementation. Bariatric procedures that bypass the gastric body can similarly impair intrinsic factor availability.\n\nKEY LEARNING POINTS:\nParietal cells in the gastric body and fundus secrete both hydrochloric acid and intrinsic factor. Intrinsic factor is essential for B12 absorption in the terminal ileum. Pernicious anemia results from autoimmune destruction of parietal cells, causing achlorhydria and B12 deficiency. Anti-intrinsic factor antibodies are highly specific (greater than 95%) for pernicious anemia."
  },
  {
    "id": 211,
    "categoryId": 9,
    "question": "Microcytic Anemia is caused by a defect in Hemoglobin synthesis. In Iron Deficiency, the defect is in:",
    "options": [
      "A) Globin chain synthesis",
      "B) Heme synthesis (Protoporphyrin + Iron)",
      "C) DNA synthesis",
      "D) Stem cell production"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Heme synthesis, Protoporphyrin + Iron).\n\nPATHOPHYSIOLOGY:\nMicrocytic anemia results from impaired hemoglobin synthesis, which can occur at three levels: heme production (iron deficiency, sideroblastic anemia), globin chain production (thalassemias), or both per Harrison's Principles of Internal Medicine. Normal hemoglobin is a tetramer of two alpha and two beta globin chains, each bound to a heme group (a protoporphyrin IX ring chelated with a central ferrous iron atom) per UpToDate. In iron deficiency, the final step of heme synthesis (insertion of iron into protoporphyrin IX by the mitochondrial enzyme ferrochelatase) cannot be completed, resulting in reduced hemoglobin per RBC, which produces microcytosis and hypochromia per the Cleveland Clinic.\n\nHEME SYNTHESIS PATHWAY:\nHeme synthesis begins in the mitochondria with condensation of glycine and succinyl-CoA by ALA synthase (the rate-limiting step, requiring pyridoxine/B6 as cofactor) to form delta-aminolevulinic acid (ALA) per Harrison's Principles of Internal Medicine. The pathway continues through porphobilinogen, uroporphyrinogen, coproporphyrinogen, and protoporphyrinogen before returning to the mitochondria where protoporphyrin IX is formed. The final step is iron chelation by ferrochelatase per UpToDate. In iron deficiency, excess protoporphyrin IX (free erythrocyte protoporphyrin, FEP) accumulates because there is insufficient iron to complete heme, and FEP elevation is a useful diagnostic marker per the Mayo Clinic.\n\nCOMPARISON WITH OTHER MICROCYTIC ANEMIAS:\nIn thalassemia, the defect is in globin chain synthesis (reduced or absent alpha or beta chains) while heme synthesis is intact per the Cleveland Clinic. In sideroblastic anemia, the defect is also in heme synthesis but at earlier steps (typically ALA synthase dysfunction, often from pyridoxine deficiency, lead poisoning, or myelodysplasia), causing iron to accumulate in mitochondria forming pathognomonic ringed sideroblasts on Prussian blue staining per Harrison's Principles of Internal Medicine. In anemia of chronic disease, the defect is iron sequestration (hepcidin-mediated trapping of iron in macrophages) per UpToDate.\n\nKEY LEARNING POINTS:\nIron deficiency causes microcytic anemia by impairing the final step of heme synthesis (iron insertion into protoporphyrin IX by ferrochelatase), producing elevated free erythrocyte protoporphyrin. This differs from thalassemia (globin chain defect) and sideroblastic anemia (early heme pathway defect with ringed sideroblasts). The rate-limiting step of heme synthesis is ALA synthase, which requires pyridoxine (B6) as a cofactor."
  },
  {
    "id": 212,
    "categoryId": 7,
    "question": "Numbness in the thumb, index, and middle finger (sparing the pinky) suggests compression of which nerve?",
    "options": [
      "A) Ulnar Nerve",
      "B) Median Nerve",
      "C) Radial Nerve",
      "D) Axillary Nerve"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Median Nerve).\n\nPATHOPHYSIOLOGY:\nThe median nerve enters the hand by passing through the carpal tunnel, a rigid osseofibrous canal at the wrist bounded by the carpal bones dorsally and the transverse carpal ligament (flexor retinaculum) volarly. The tunnel also contains nine flexor tendons (four tendons of flexor digitorum superficialis, four of flexor digitorum profundus, and the flexor pollicis longus), and any condition that increases the volume of these contents or decreases the tunnel's capacity will compress the median nerve. Carpal tunnel syndrome is the most common peripheral nerve entrapment neuropathy, affecting approximately 3 to 6% of the adult population, with risk factors including pregnancy, hypothyroidism, diabetes mellitus, rheumatoid arthritis, obesity, and repetitive wrist flexion and extension activities. Compression initially damages the myelin sheath, producing intermittent sensory symptoms, and with continued compression progresses to axonal degeneration with motor weakness and thenar atrophy.\n\nCLINICAL PRESENTATION:\nThe median nerve provides sensory innervation to the palmar aspect of the first three and a half digits (thumb, index finger, middle finger, and radial half of the ring finger) and motor innervation to the thenar muscles (opponens pollicis, abductor pollicis brevis, and superficial head of the flexor pollicis brevis) through its recurrent motor branch. Patients typically present with numbness, tingling, and pain in the median nerve distribution that is characteristically worse at night and may awaken the patient from sleep, because wrist flexion during sleep narrows the carpal tunnel and increases intracanal pressure. Shaking or \"flicking\" the hand (the flick sign) often provides temporary relief. The ring finger splitting pattern, in which the radial half is numb but the ulnar half has normal sensation, is pathognomonic for median nerve compression at the carpal tunnel. The ulnar nerve, by contrast, travels through the separate Guyon canal at the wrist and the cubital tunnel at the elbow, providing sensation to the fifth digit and the ulnar half of the fourth digit.\n\nDIAGNOSIS AND MANAGEMENT:\nPhalen's test (sustained wrist flexion for 60 seconds reproducing paresthesias) and Tinel's sign (tapping over the carpal tunnel at the wrist reproducing distal tingling) are the standard provocative maneuvers, though both have limited sensitivity. Nerve conduction studies and electromyography are the gold standard for confirming the diagnosis and grading severity. Conservative management with nocturnal wrist splinting in a neutral position is first-line therapy for mild to moderate symptoms, as it prevents the wrist flexion that increases carpal tunnel pressure during sleep. Corticosteroid injection into the carpal tunnel provides intermediate-term relief and may serve as a diagnostic and therapeutic intervention. Surgical carpal tunnel release by open or endoscopic division of the transverse carpal ligament is definitive treatment for patients with persistent symptoms, motor weakness, or thenar atrophy.\n\nKEY LEARNING POINTS:\nThe median nerve innervates the first three and a half digits, and numbness in this distribution with sparing of the fifth digit indicates median nerve compression at the carpal tunnel. The ring finger splitting pattern (numb radial half, normal ulnar half) is pathognomonic for carpal tunnel syndrome and localizes the lesion to the median nerve. Nocturnal wrist splinting is first-line conservative treatment, while surgical release of the transverse carpal ligament is definitive for refractory or severe cases."
  },
  {
    "id": 213,
    "categoryId": 4,
    "question": "In Hashimoto's Thyroiditis, the primary mechanism of tissue destruction is:",
    "options": [
      "A) Bacterial infection",
      "B) Lymphocytic infiltration and fibrosis",
      "C) Excess Iodine uptake",
      "D) TSH receptor stimulation"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Lymphocytic infiltration and fibrosis).\n\nPATHOPHYSIOLOGY:\nHashimoto's thyroiditis (chronic lymphocytic thyroiditis) is the most common cause of hypothyroidism in iodine-sufficient regions worldwide and the most common autoimmune disease overall, with a prevalence of 1 to 2% clinically evident and up to 10 to 15% subclinical per data from Harrison's Principles of Internal Medicine and the Endocrine Society. The disease is an organ-specific autoimmune disorder in which a breakdown of immune tolerance to thyroid self-antigens leads to progressive destruction of thyroid follicular cells through T-cell-mediated cytotoxicity. The pathologic hallmark is dense lymphocytic infiltration of the thyroid parenchyma, with formation of lymphoid follicles and germinal centers within the gland, accompanied by progressive follicular cell destruction and replacement fibrosis. CD8+ cytotoxic T lymphocytes directly destroy thyroid follicular cells through perforin-granzyme and Fas-FasL mediated apoptosis, while CD4+ helper T cells coordinate the immune response and promote B-cell activation. B lymphocytes produce the characteristic autoantibodies: anti-thyroid peroxidase (anti-TPO) antibodies, present in greater than 90% of patients, and anti-thyroglobulin antibodies, present in 60 to 80%. While these antibodies serve as important diagnostic markers and anti-TPO antibodies may contribute to tissue injury through complement fixation and antibody-dependent cellular cytotoxicity, the primary mechanism of thyroid destruction is T-cell mediated rather than antibody mediated. This distinguishes Hashimoto's from Graves' disease, where thyroid-stimulating immunoglobulin (TSI) antibodies bind and activate the TSH receptor, causing hyperthyroidism. Genetic susceptibility involves HLA-DR3 and HLA-DR5 associations, with environmental triggers including excess iodine intake (which increases thyroid antigen immunogenicity), selenium deficiency, infection, and stress.\n\nCLINICAL PRESENTATION:\nHashimoto's thyroiditis typically presents with an insidious onset of hypothyroid symptoms including fatigue, cold intolerance, weight gain, constipation, dry skin, hair thinning, menstrual irregularity (menorrhagia in early disease), cognitive slowing, and depression. On examination, the thyroid may be diffusely enlarged (goiter) with a firm, rubbery consistency and a lobulated or pebbly texture reflecting the underlying lymphocytic infiltration, though atrophic Hashimoto's (without goiter) is also common and represents the end-stage of gland destruction and fibrosis. A distinctive clinical variant is Hashitoxicosis, a transient thyrotoxic phase that occurs in approximately 5% of patients early in the disease course when inflammation-mediated follicular cell destruction releases preformed thyroid hormone stores into the circulation. This self-limited thyrotoxicosis typically lasts 2 to 8 weeks before transitioning through a euthyroid phase into permanent hypothyroidism, and it must be distinguished from Graves' disease (which produces sustained hyperthyroidism with elevated radioactive iodine uptake, whereas Hashitoxicosis shows low uptake). Hashimoto's thyroiditis is associated with other autoimmune conditions as part of autoimmune polyglandular syndromes, including type 1 diabetes mellitus, celiac disease, vitiligo, Addison's disease, pernicious anemia, and autoimmune hepatitis.\n\nDIAGNOSIS AND TREATMENT:\nDiagnosis is established by the combination of elevated TSH with low free T4 (overt hypothyroidism) or normal free T4 (subclinical hypothyroidism) and positive anti-TPO antibodies. Thyroid ultrasound, while not required for diagnosis, characteristically reveals a diffusely heterogeneous, hypoechoic gland, sometimes with pseudonodules formed by lymphocytic aggregates. Levothyroxine replacement is the standard treatment, with a starting dose of 1.6 mcg/kg/day in young, healthy patients, reduced to 25 to 50 mcg/day in elderly patients and those with coronary artery disease to avoid cardiac stress. The treatment goal is normalization of TSH, typically targeting 0.5 to 2.5 mIU/L for most adults, with TSH monitored every 6 to 8 weeks during dose titration and annually once stable. Thyroid hormone requirements may change over time as the degree of gland destruction progresses, and dose increases may be needed during pregnancy (25 to 50% increase), with estrogen use (which increases thyroxine-binding globulin), and with medications that impair absorption (calcium, iron, PPIs). Patients with Hashimoto's have a modestly increased risk of thyroid lymphoma (particularly primary thyroid MALT lymphoma), though the absolute risk remains low.\n\nKEY LEARNING POINTS:\nHashimoto's thyroiditis destroys thyroid follicular cells primarily through CD8+ T-cell-mediated cytotoxicity and progressive lymphocytic infiltration with fibrosis, rather than through the characteristic anti-TPO and anti-thyroglobulin antibodies, which serve as diagnostic markers. Anti-TPO antibodies are positive in greater than 90% of cases and are the most sensitive serologic marker. Hashitoxicosis, a transient thyrotoxic phase from inflammatory release of stored hormone, occurs in approximately 5% of patients and is distinguished from Graves' disease by low radioactive iodine uptake."
  },
  {
    "id": 214,
    "categoryId": 2,
    "question": "Obstructive Lung Disease (COPD/Asthma) is defined by a reduction in:",
    "options": [
      "A) Total Lung Capacity (TLC)",
      "B) FEV1 / FVC Ratio",
      "C) Residual Volume",
      "D) Diffusion Capacity (DLCO)"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (FEV1/FVC Ratio).\n\nPATHOPHYSIOLOGY:\nObstructive lung diseases (COPD, asthma, bronchiectasis, cystic fibrosis) are defined by airflow limitation during expiration, which is quantified by the ratio of forced expiratory volume in one second (FEV1) to forced vital capacity (FVC) on spirometry per Harrison's Principles of Internal Medicine. In healthy lungs, at least 70 to 80% of the FVC can be exhaled in the first second (normal FEV1/FVC is approximately 0.70 to 0.85, declining slightly with age). In obstructive disease, narrowed airways (from bronchospasm, mucus plugging, airway wall thickening, or loss of elastic recoil with dynamic airway collapse) disproportionately reduce expiratory flow rates, causing FEV1 to decline more than FVC, and the FEV1/FVC ratio falls below 0.70 per UpToDate. Air trapping from premature airway closure during expiration increases residual volume and total lung capacity, producing the characteristic hyperinflation seen on chest imaging.\n\nOBSTRUCTIVE VS RESTRICTIVE PATTERNS:\nRestrictive lung diseases (idiopathic pulmonary fibrosis, interstitial lung diseases, chest wall deformities, neuromuscular diseases, obesity hypoventilation) are defined by reduced total lung capacity (TLC) on full pulmonary function testing per the Cleveland Clinic. In restriction, both FEV1 and FVC are proportionally reduced, so the FEV1/FVC ratio is preserved or even elevated (because the stiff lungs empty quickly). Reduced DLCO (diffusion capacity for carbon monoxide) suggests parenchymal disease affecting gas exchange across the alveolar-capillary membrane, as seen in emphysema and interstitial lung diseases per Harrison's Principles of Internal Medicine.\n\nSPIROMETRIC INTERPRETATION:\nThe approach to spirometry per UpToDate begins with the FEV1/FVC ratio: if reduced (less than 0.70 or below the lower limit of normal), the pattern is obstructive. The severity of obstruction is then graded by the FEV1 percent predicted: mild (80% or greater), moderate (50 to 79%), severe (30 to 49%), and very severe (less than 30%) per the GOLD classification. If the ratio is normal but FVC is reduced, restriction is suspected and requires confirmation with lung volumes (TLC) by plethysmography per the Mayo Clinic. A mixed obstructive-restrictive pattern shows both a reduced ratio and a reduced TLC.\n\nKEY LEARNING POINTS:\nObstructive lung disease is defined by a reduced FEV1/FVC ratio (less than 0.70) reflecting disproportionate airflow limitation during expiration, while restrictive disease is defined by reduced total lung capacity with a preserved or increased ratio. Severity of obstruction is graded by FEV1 percent predicted per the GOLD classification. Reduced DLCO suggests parenchymal gas exchange impairment and is seen in both emphysema and interstitial lung disease."
  },
  {
    "id": 215,
    "categoryId": 1,
    "question": "According to the Frank-Starling Law, increasing Venous Return (Preload) results in:",
    "options": [
      "A) Decreased Heart Rate",
      "B) Increased Stroke Volume (Contractility)",
      "C) Increased Afterload",
      "D) Decreased Cardiac Output"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Increased Stroke Volume).\n\nPATHOPHYSIOLOGY:\nThe Frank-Starling law (also called the Frank-Starling mechanism or Starling's law of the heart) states that the force of ventricular contraction is directly proportional to the end-diastolic volume (preload) within physiologic limits per Harrison's Principles of Internal Medicine. As venous return increases, the ventricle fills to a greater end-diastolic volume, stretching the cardiac sarcomeres toward their optimal length (approximately 2.2 micrometers), which increases the overlap between actin and myosin filaments and the sensitivity of troponin C to calcium, resulting in more forceful contraction and a larger stroke volume per UpToDate.\n\nMOLECULAR BASIS:\nAt the molecular level, increased sarcomere stretch produces a length-dependent increase in calcium sensitivity of the myofilaments (the Frank-Starling mechanism operates independently of sympathetic stimulation or changes in intracellular calcium concentration) per Harrison's Principles of Internal Medicine. This length-tension relationship allows the heart to match its output to changes in venous return on a beat-to-beat basis without neurohumoral input per the Cleveland Clinic. The mechanism ensures that the right and left ventricles maintain matched outputs: if right ventricular output transiently increases (increasing pulmonary venous return to the left ventricle), the Frank-Starling mechanism automatically increases left ventricular stroke volume to match per UpToDate.\n\nCLINICAL APPLICATION:\nIn heart failure, the Frank-Starling curve is depressed and flattened: the failing ventricle operates on a lower curve where increasing preload produces diminishing returns in stroke volume and eventually leads to pulmonary congestion without meaningful improvement in cardiac output per the Mayo Clinic. Positive inotropes (digoxin, dobutamine, milrinone) shift the curve upward, restoring the ability to generate greater stroke volume at any given preload per Harrison's Principles of Internal Medicine.\n\nKEY LEARNING POINTS:\nThe Frank-Starling law states that increased preload (venous return) stretches sarcomeres toward optimal length, increasing myofilament calcium sensitivity and producing greater stroke volume. This mechanism operates on a beat-to-beat basis to match ventricular output to venous return. In heart failure, the Starling curve is depressed, and positive inotropes shift it upward."
  },
  {
    "id": 216,
    "categoryId": 3,
    "question": "Pain at McBurney's Point is associated with Appendicitis. Where is this point located?",
    "options": [
      "A) RUQ under the rib",
      "B) 1/3 distance from ASIS to Umbilicus",
      "C) Left Lower Quadrant",
      "D) Mid-epigastric"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (One-third of the distance from the anterior superior iliac spine to the umbilicus).\n\nPATHOPHYSIOLOGY:\nMcBurney's point corresponds to the surface anatomic landmark overlying the base of the appendix, located at the junction of the lateral one-third and medial two-thirds of the line drawn from the right anterior superior iliac spine (ASIS) to the umbilicus. Acute appendicitis begins with obstruction of the appendiceal lumen (by fecalith, lymphoid hyperplasia, or rarely tumor), leading to progressive distension, bacterial overgrowth, ischemia, and if untreated, perforation. As inflammation extends transmurally to the serosa, it irritates the overlying parietal peritoneum at McBurney's point, producing the characteristic localized right lower quadrant tenderness.\n\nCLINICAL PRESENTATION:\nThe classic sequence of appendicitis begins with vague periumbilical pain (visceral afferents from the midgut, referred to the T10 dermatome), followed by anorexia and nausea, then migration of pain to the right lower quadrant as parietal peritoneal inflammation develops (typically over 12-24 hours). Tenderness at McBurney's point has a sensitivity of approximately 50-70% and specificity of 75-85% for appendicitis. Additional examination findings include the Rovsing sign (RLQ pain with palpation of the LLQ), the psoas sign (RLQ pain with right hip extension, suggesting retrocecal appendicitis), and the obturator sign (RLQ pain with internal rotation of the flexed right hip, suggesting pelvic appendicitis).\n\nDIAGNOSIS:\nCT abdomen with contrast is the gold-standard imaging study in adults, with sensitivity and specificity exceeding 95%. The Alvarado score integrates clinical findings and laboratory values to estimate the probability of appendicitis. Ultrasound is the preferred initial imaging modality in children and pregnant women to avoid radiation exposure.\n\nKEY LEARNING POINTS:\nMcBurney's point is located one-third of the distance from the right ASIS to the umbilicus and overlies the appendiceal base. The classic pain sequence is periumbilical pain migrating to the RLQ over 12-24 hours. CT abdomen is the gold-standard imaging in adults with greater than 95% sensitivity. Ultrasound is preferred in children and pregnant women."
  },
  {
    "id": 217,
    "categoryId": 1,
    "question": "Isolated Systolic Hypertension in the elderly is primarily caused by:",
    "options": [
      "A) High Renin levels",
      "B) Increased Cardiac Output",
      "C) Arterial Stiffness (Loss of compliance)",
      "D) Renal Artery Stenosis"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Arterial Stiffness / Loss of Compliance).\n\nPATHOPHYSIOLOGY:\nIsolated systolic hypertension (ISH, defined as systolic BP 130 mmHg or greater with diastolic BP less than 80 mmHg per the 2017 ACC/AHA Guidelines) is the most common form of hypertension in adults over 65 years and results primarily from age-related arterial stiffening per Harrison's Principles of Internal Medicine. With aging, the elastic fibers (elastin) in the tunica media of large conduit arteries (particularly the aorta) undergo fragmentation, cross-linking, and replacement by less distensible collagen, with additional medial calcification (arteriosclerosis) per UpToDate. This loss of arterial compliance means the aorta can no longer adequately buffer the pulsatile output from the left ventricle during systole (the Windkessel function), resulting in higher peak systolic pressure per the Cleveland Clinic.\n\nHEMODYNAMIC CONSEQUENCES:\nIn a compliant young aorta, the vessel wall expands during systole to store kinetic energy, then recoils during diastole to maintain diastolic blood flow (the Windkessel effect) per Harrison's Principles of Internal Medicine. When the aorta stiffens, systolic pressure rises because the rigid vessel cannot accommodate the stroke volume, while diastolic pressure actually falls because the stiff aorta does not recoil adequately to maintain diastolic flow. This widens the pulse pressure (systolic minus diastolic), which is itself an independent cardiovascular risk factor per UpToDate. Additionally, in stiff arteries, the reflected pulse wave returns to the heart during systole rather than diastole (increased pulse wave velocity), augmenting systolic pressure and reducing coronary perfusion (which occurs primarily during diastole) per the Mayo Clinic.\n\nKEY LEARNING POINTS:\nIsolated systolic hypertension in the elderly results from age-related loss of aortic elasticity (elastin fragmentation, collagen replacement, medial calcification) that impairs the Windkessel buffering function. Widened pulse pressure is an independent cardiovascular risk factor. The stiff aorta fails to recoil in diastole, reducing coronary perfusion while augmenting systolic pressure."
  },
  {
    "id": 218,
    "categoryId": 7,
    "question": "Parathyroid Hormone (PTH) increases serum Calcium by acting on which three organs?",
    "options": [
      "A) Bone, Kidney, Gut",
      "B) Liver, Pancreas, Bone",
      "C) Kidney, Spleen, Thyroid",
      "D) Muscle, Heart, Brain"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Bone, Kidney, Gut).\n\nPATHOPHYSIOLOGY:\nParathyroid hormone is an 84-amino acid polypeptide secreted by the chief cells of the parathyroid glands in response to decreased ionized calcium detected by the calcium-sensing receptor on the parathyroid cell membrane. PTH is the primary regulator of extracellular calcium homeostasis and raises serum calcium through coordinated actions on three target organs. In bone, PTH binds to PTH1 receptors on osteoblasts, which then upregulate RANK-ligand expression on their surface. RANK-ligand binds to RANK on osteoclast precursors, stimulating their differentiation into mature osteoclasts that resorb bone and release calcium and phosphate into the circulation. Notably, PTH acts indirectly on osteoclasts through the osteoblast intermediary, as osteoclasts themselves do not express PTH receptors. In the kidney, PTH increases calcium reabsorption in the distal convoluted tubule through upregulation of the TRPV5 calcium channel, while simultaneously promoting phosphate excretion by downregulating the sodium-phosphate cotransporter in the proximal tubule. This phosphaturic effect prevents the calcium and phosphate released from bone from forming calcium phosphate complexes that would deposit in soft tissues. PTH also stimulates the renal enzyme 1-alpha-hydroxylase in the proximal tubule, which converts 25-hydroxyvitamin D (the storage form) to 1,25-dihydroxyvitamin D (calcitriol, the active hormonal form).\n\nINDIRECT ACTION ON THE GUT:\nPTH does not act directly on the intestinal mucosa. Instead, the calcitriol produced by PTH-stimulated renal 1-alpha-hydroxylase travels to the duodenum and jejunum, where it binds to the vitamin D receptor on enterocytes and upregulates the expression of calbindin, TRPV6 calcium channels, and the basolateral calcium ATPase pump, collectively increasing transcellular calcium absorption from the intestinal lumen. This indirect mechanism explains why vitamin D deficiency impairs the gut's response to PTH and contributes to the hypocalcemia seen in patients with combined PTH excess and vitamin D depletion.\n\nCLINICAL SIGNIFICANCE:\nPrimary hyperparathyroidism, caused most commonly by a single parathyroid adenoma, produces elevated PTH with hypercalcemia, hypophosphatemia, and elevated urinary calcium. The classic clinical manifestation mnemonic is \"bones, stones, abdominal groans, and psychic moans,\" reflecting the effects of chronic hypercalcemia on the skeleton (osteitis fibrosa cystica), kidneys (nephrolithiasis and nephrocalcinosis), gastrointestinal tract (constipation, nausea, pancreatitis), and central nervous system (depression, confusion, fatigue). Secondary hyperparathyroidism occurs in chronic kidney disease when impaired 1-alpha-hydroxylase activity reduces calcitriol production, leading to compensatory PTH elevation.\n\nKEY LEARNING POINTS:\nPTH raises serum calcium through three coordinated organ-level actions: stimulating osteoclast-mediated bone resorption (indirectly via osteoblast RANK-ligand), increasing renal calcium reabsorption while promoting phosphate excretion, and enhancing intestinal calcium absorption indirectly through stimulation of renal 1-alpha-hydroxylase and calcitriol production. PTH acts on osteoclasts indirectly through osteoblasts, not through direct osteoclast receptors. The phosphaturic effect of PTH prevents calcium phosphate precipitation in soft tissues when bone resorption releases both ions simultaneously."
  },
  {
    "id": 219,
    "categoryId": 3,
    "question": "The primary pathophysiologic defect in Gastroesophageal Reflux Disease (GERD) is:",
    "options": [
      "A) Excess Acid Production",
      "B) H. pylori infection",
      "C) Transient Relaxation of the Lower Esophageal Sphincter (tLESR)",
      "D) Esophageal Motility Disorder"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Transient relaxation of the lower esophageal sphincter).\n\nPATHOPHYSIOLOGY:\nThe primary mechanism underlying gastroesophageal reflux disease is transient lower esophageal sphincter relaxation (tLESR), which accounts for approximately 70-80% of reflux episodes. tLESRs are vagally mediated, non-swallow-related relaxations of the LES that last 10-60 seconds and are triggered by gastric distension. During a tLESR, the LES pressure drops to zero, creating a wide-open conduit between the stomach and esophagus. Importantly, most GERD patients produce normal amounts of gastric acid; the problem is inappropriate exposure of the esophageal mucosa to acid, not acid overproduction.\n\nCONTRIBUTING MECHANISMS:\nWhile tLESRs are the dominant mechanism, additional contributing factors include reduced basal LES tone (often exacerbated by dietary factors such as chocolate, caffeine, alcohol, and peppermint, or by medications such as calcium channel blockers and nitrates), hiatal hernia (which displaces the LES above the diaphragm, eliminating extrinsic compression), impaired esophageal acid clearance (prolonging mucosal contact time), and delayed gastric emptying (which increases gastric distension and tLESR frequency).\n\nTREATMENT IMPLICATIONS:\nUnderstanding that GERD is primarily a motility disorder rather than an acid-overproduction disorder explains why PPIs (which reduce acid volume and potency but do not prevent reflux events) are highly effective at healing esophagitis and relieving heartburn but do not eliminate reflux episodes entirely. Approximately 30-40% of GERD patients have persistent symptoms on PPI therapy. Surgical fundoplication mechanically reinforces the anti-reflux barrier and reduces tLESR frequency, making it the definitive treatment for the underlying pathophysiology.\n\nKEY LEARNING POINTS:\nTransient LES relaxations account for 70-80% of reflux episodes and are the primary pathophysiologic mechanism of GERD. Most GERD patients produce normal amounts of acid; the problem is inappropriate acid exposure due to sphincter dysfunction. PPIs reduce acid potency but do not prevent reflux events. Fundoplication addresses the underlying mechanical defect by reducing tLESR frequency."
  },
  {
    "id": 220,
    "categoryId": 2,
    "question": "Anaphylaxis (Peanut allergy) is which type of Hypersensitivity reaction?",
    "options": [
      "A) Type I (Immediate)",
      "B) Type II (Cytotoxic)",
      "C) Type III (Immune Complex)",
      "D) Type IV (Delayed)"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Type I - IgE-mediated Immediate Hypersensitivity).\n\nPATHOPHYSIOLOGY:\nAnaphylaxis is the prototypical and most severe manifestation of Type I (immediate) hypersensitivity, mediated by immunoglobulin E (IgE) per Harrison's Principles of Internal Medicine. The reaction requires prior sensitization: upon initial exposure to an allergen (such as peanut protein Ara h1), antigen-presenting cells process and present the allergen to T-helper 2 (Th2) cells, which secrete IL-4 and IL-13 to drive B-cell class switching to IgE production. These allergen-specific IgE antibodies bind to high-affinity FcepsilonRI receptors on the surface of tissue mast cells and circulating basophils, priming them for rapid activation upon re-exposure per UpToDate. Upon subsequent allergen encounter, the antigen cross-links adjacent surface-bound IgE molecules, triggering immediate degranulation and release of preformed mediators (histamine, tryptase, heparin) and newly synthesized mediators (prostaglandins, leukotrienes, platelet-activating factor) within minutes per the Cleveland Clinic.\n\nCLINICAL MANIFESTATIONS:\nHistamine binds H1 receptors to cause vasodilation (hypotension), increased vascular permeability (urticaria, angioedema), bronchospasm, and stimulation of sensory nerves (pruritus) per Harrison's Principles of Internal Medicine. Leukotrienes C4, D4, and E4 cause sustained bronchospasm and mucus secretion. The clinical triad of anaphylaxis involves cutaneous manifestations (urticaria, flushing, angioedema), respiratory compromise (bronchospasm, laryngeal edema, stridor), and cardiovascular collapse (hypotension, tachycardia) per UpToDate. Gastrointestinal symptoms (nausea, cramping, diarrhea) may also occur.\n\nCOMPARISON OF HYPERSENSITIVITY TYPES:\nType II (cytotoxic) hypersensitivity involves IgG or IgM antibodies directed against cell-surface antigens, causing cell destruction (examples include autoimmune hemolytic anemia, Goodpasture syndrome, and Graves disease) per Harrison's Principles of Internal Medicine. Type III (immune complex) hypersensitivity involves antigen-antibody complexes that deposit in tissues and activate complement, causing inflammation (serum sickness, lupus nephritis, Arthus reaction). Type IV (delayed-type) hypersensitivity is T-cell mediated (no antibody involvement), takes 48 to 72 hours to develop, and includes contact dermatitis (poison ivy), tuberculin skin test reaction, and transplant rejection per the Mayo Clinic.\n\nKEY LEARNING POINTS:\nAnaphylaxis is the prototypical Type I (IgE-mediated) immediate hypersensitivity reaction, requiring prior sensitization for IgE production and mast cell priming, with subsequent antigen cross-linking triggering rapid degranulation within minutes. The mnemonic ACID distinguishes the types: Allergy/Anaphylaxis (Type I, IgE), Cytotoxic (Type II, IgG/IgM), Immune complex (Type III), and Delayed (Type IV, T-cell). Epinephrine is the first-line treatment for anaphylaxis."
  },
  {
    "id": 221,
    "categoryId": 3,
    "question": "In Cirrhosis, portal hypertension leads to Ascites primarily via:",
    "options": [
      "A) Increased hydrostatic pressure and Low Albumin (Oncotic pressure)",
      "B) Blockage of bile ducts",
      "C) Renal failure",
      "D) Heart failure"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Increased hydrostatic pressure and low albumin/oncotic pressure).\n\nPATHOPHYSIOLOGY:\nAscites in cirrhosis results from the interplay of portal hypertension and hypoalbuminemia, understood through Starling forces. Cirrhotic scar tissue distorts hepatic architecture and increases resistance to portal venous flow, raising portal venous pressure above the threshold of 10-12 mmHg (sinusoidal portal hypertension). This increased hydrostatic pressure drives fluid from the hepatic sinusoids and splanchnic capillaries into the peritoneal cavity. Simultaneously, the cirrhotic liver has impaired synthetic function, producing insufficient albumin (the primary determinant of plasma oncotic pressure), which reduces the vascular compartment's ability to retain fluid.\n\nSYSTEMIC HEMODYNAMIC CHANGES:\nPortal hypertension triggers splanchnic vasodilation through increased nitric oxide production, which reduces effective arterial blood volume and activates compensatory neurohormonal systems: the renin-angiotensin-aldosterone system (RAAS), the sympathetic nervous system, and antidiuretic hormone (ADH/vasopressin). These systems promote avid sodium and water retention by the kidneys, perpetuating ascites formation and expansion of total body fluid even as the effective arterial volume remains depleted. This is known as the peripheral arterial vasodilation hypothesis.\n\nDIAGNOSIS AND MANAGEMENT:\nDiagnostic paracentesis with serum-ascites albumin gradient (SAAG) calculation is performed on all new-onset ascites. A SAAG of 1.1 g/dL or greater indicates portal hypertension with 97% accuracy. First-line management includes sodium restriction (less than 2 g/day) and diuretic therapy with spironolactone (100 mg) and furosemide (40 mg) in a 100:40 ratio. Refractory ascites may require serial large-volume paracentesis with albumin infusion or transjugular intrahepatic portosystemic shunt (TIPS) placement.\n\nKEY LEARNING POINTS:\nAscites in cirrhosis results from increased portal hydrostatic pressure (greater than 10-12 mmHg) combined with decreased oncotic pressure from hypoalbuminemia. Splanchnic vasodilation activates RAAS and ADH, driving renal sodium and water retention. SAAG greater than 1.1 g/dL confirms portal hypertensive ascites. First-line treatment is sodium restriction plus spironolactone and furosemide in a 100:40 ratio."
  },
  {
    "id": 222,
    "categoryId": 6,
    "question": "Bell's Palsy involves lower motor neuron paralysis of which Cranial Nerve?",
    "options": [
      "A) CN V (Trigeminal)",
      "B) CN VII (Facial)",
      "C) CN III (Oculomotor)",
      "D) CN X (Vagus)"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (CN VII - Facial Nerve).\n\nBELL'S PALSY:\nBell's palsy is an acute, idiopathic, peripheral (lower motor neuron) paralysis of cranial nerve VII (the facial nerve), resulting in unilateral facial weakness affecting the entire hemiface including the forehead. It is the most common cause of acute facial nerve paralysis, with an annual incidence of 15 to 30 per 100,000. The presumed etiology is viral reactivation (herpes simplex virus type 1) causing inflammation and edema of the facial nerve within the temporal bone's fallopian canal.\n\nPERIPHERAL VERSUS CENTRAL DISTINCTION:\nThe critical clinical distinction is between peripheral and central causes of facial weakness. In Bell's palsy (peripheral/LMN), the entire hemiface is affected because the nerve is damaged after both upper and lower face fibers have merged; the patient cannot wrinkle the forehead, close the eye, or raise the eyebrow on the affected side. In stroke (central/UMN), the forehead is spared because the upper face receives bilateral cortical innervation; only the lower face shows weakness. This distinction is essential for avoiding missed stroke diagnoses.\n\nDIAGNOSIS:\nBell's palsy is a clinical diagnosis of exclusion. The onset is acute (maximal weakness within 72 hours), and patients may report ipsilateral ear pain, hyperacusis, or altered taste. If symptoms progress beyond 3 weeks, if there is bilateral involvement, or if other cranial nerves are affected, alternative diagnoses such as Lyme disease, sarcoidosis, tumor, or Ramsay Hunt syndrome (varicella zoster with vesicular ear eruption) must be considered.\n\nTREATMENT:\nThe American Academy of Neurology recommends early corticosteroids (prednisone 60 to 80 mg daily for 7 days) initiated within 72 hours of onset to improve recovery rates. Adding antiviral therapy (valacyclovir) may provide modest additional benefit, particularly in severe cases. Eye protection is essential because incomplete lid closure leads to corneal exposure; management includes artificial tears, lubricating ointment at night, and taping the eye closed during sleep. Approximately 85% of patients recover completely, with poor prognostic factors including complete paralysis, age over 60, and diabetes.\n\nKEY LEARNING POINTS:\nBell's palsy is peripheral CN VII paralysis affecting the entire hemiface including the forehead, unlike stroke which spares the forehead. Corticosteroids within 72 hours improve recovery, and eye protection is essential to prevent corneal damage. Complete recovery occurs in 85% of cases; consider alternative diagnoses if progression continues beyond 3 weeks."
  },
  {
    "id": 223,
    "categoryId": 13,
    "question": "Why does rapid weight loss or initiation of Thiazide diuretics trigger a Gout flare?",
    "options": [
      "A) Increased Calcium",
      "B) Competition for excretion in the Renal Tubule",
      "C) Liver toxicity",
      "D) Bone breakdown"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Competition for excretion in the Renal Tubule).\n\nRENAL URIC ACID HANDLING:\nApproximately 90 percent of serum uric acid is filtered by the glomerulus, with the vast majority reabsorbed in the proximal convoluted tubule via the urate transporter URAT1 and organic anion transporters (OAT1, OAT4). Only about 10 percent of filtered uric acid is ultimately excreted. This delicate balance of filtration, reabsorption, and secretion means that any substance competing for these same transporters can significantly alter uric acid clearance. Thiazide diuretics increase uric acid reabsorption in the proximal tubule by inducing volume contraction, which enhances sodium and urate reabsorption via URAT1. Additionally, the organic acids produced during thiazide metabolism compete with uric acid for secretion into the tubular lumen.\n\nRAPID WEIGHT LOSS AND KETOACIDOSIS:\nDuring rapid weight loss, starvation, or very-low-calorie diets, accelerated lipolysis generates ketone bodies (beta-hydroxybutyrate and acetoacetate). These organic acids compete with uric acid for secretion at the proximal tubular organic anion transporters, reducing uric acid clearance and causing acute hyperuricemia. Additionally, cellular catabolism from rapid weight loss increases purine turnover, generating more uric acid from nucleotide breakdown. The combination of increased production and decreased excretion creates a sudden spike in serum uric acid that destabilizes existing crystal deposits and triggers acute gout flares.\n\nOTHER MEDICATIONS THAT RAISE URIC ACID:\nBeyond thiazides, loop diuretics, low-dose aspirin (less than 1 gram daily), cyclosporine, pyrazinamide, and ethambutol all impair renal uric acid excretion through similar tubular competition mechanisms. In contrast, losartan and high-dose aspirin (greater than 3 grams daily) have mild uricosuric properties. When managing hypertension in a gout patient, losartan is preferred over thiazide diuretics when clinically appropriate.\n\nKEY LEARNING POINTS:\nThiazide diuretics trigger gout by increasing proximal tubular uric acid reabsorption through volume contraction and transporter competition. Rapid weight loss causes hyperuricemia through both increased purine catabolism and competition of ketone bodies with uric acid for renal secretion. Any rapid shift in serum uric acid, whether up or down, can mobilize crystals and precipitate an acute gout flare."
  },
  {
    "id": 224,
    "categoryId": 4,
    "question": "The Renin-Angiotensin-Aldosterone System (RAAS) is triggered by:",
    "options": [
      "A) High Blood Pressure",
      "B) Low Renal Perfusion (Hypotension/Hypovolemia)",
      "C) High Sodium",
      "D) Hyperkalemia"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Low Renal Perfusion / Hypotension / Hypovolemia).\n\nPATHOPHYSIOLOGY:\nThe renin-angiotensin-aldosterone system (RAAS) is the body's primary hormonal mechanism for maintaining blood pressure and extracellular fluid volume homeostasis. The system is activated when the juxtaglomerular (JG) apparatus of the kidney detects reduced renal perfusion through three distinct sensing mechanisms that converge on renin release. First, the JG cells (modified smooth muscle cells in the wall of the afferent arteriole) function as intrarenal baroreceptors that directly sense decreased stretch in the afferent arteriolar wall during hypotension or hypovolemia and respond by secreting renin. Second, the macula densa cells of the distal convoluted tubule detect reduced sodium chloride delivery to the distal nephron (which occurs when reduced renal perfusion slows tubular flow and increases proximal sodium reabsorption) and signal the adjacent JG cells to release renin via prostaglandin-mediated paracrine signaling. Third, sympathetic nervous system activation during hypotension directly stimulates beta-1 adrenergic receptors on JG cells, providing a neural input that augments renin secretion. Renin, an aspartyl protease, cleaves angiotensinogen (a constitutively produced hepatic protein) to angiotensin I, a biologically inactive decapeptide. Angiotensin-converting enzyme (ACE), concentrated on the pulmonary capillary endothelium, converts angiotensin I to angiotensin II, a potent octapeptide with multiple downstream effects.\n\nCLINICAL EFFECTS OF ANGIOTENSIN II:\nAngiotensin II is one of the most potent endogenous vasoconstrictors, directly contracting vascular smooth muscle through AT1 receptor activation to increase systemic vascular resistance and raise blood pressure. It preferentially constricts the efferent arteriole of the glomerulus, maintaining glomerular filtration pressure when renal perfusion is reduced (this is why ACE inhibitors can cause a reversible decline in GFR, particularly in patients with renal artery stenosis where GFR is efferent-arteriolar-tone-dependent). Angiotensin II stimulates the adrenal zona glomerulosa to secrete aldosterone, which acts on the principal cells of the cortical collecting duct to increase expression of the epithelial sodium channel (ENaC) and the sodium-potassium ATPase, promoting sodium and water reabsorption while secreting potassium and hydrogen ions into the tubular lumen. This aldosterone-mediated sodium retention explains the hypokalemia and metabolic alkalosis characteristic of hyperaldosteronism. Angiotensin II also stimulates hypothalamic thirst centers and promotes antidiuretic hormone (ADH) release from the posterior pituitary, further augmenting water retention. Chronically, angiotensin II drives pathologic cardiac and vascular remodeling through myocardial hypertrophy, vascular smooth muscle proliferation, and fibrosis.\n\nCLINICAL APPLICATION:\nUnderstanding the RAAS cascade is essential for rational antihypertensive prescribing. ACE inhibitors (lisinopril, enalapril) block the conversion of angiotensin I to angiotensin II. Angiotensin receptor blockers (losartan, valsartan) block the AT1 receptor directly. Both classes reduce afterload, promote natriuresis, and provide renal and cardiac protection. Direct renin inhibitors (aliskiren) block the initial rate-limiting step. Mineralocorticoid receptor antagonists (spironolactone, eplerenone) block aldosterone's effects at the collecting duct, treating resistant hypertension and heart failure. ACE inhibitors and ARBs are first-line for diabetic nephropathy because they reduce efferent arteriolar tone and lower intraglomerular pressure, reducing proteinuria and slowing CKD progression per ADA and KDIGO guidelines. ACE inhibitors and ARBs are absolutely contraindicated in pregnancy due to fetal renal agenesis, oligohydramnios, and pulmonary hypoplasia.\n\nKEY LEARNING POINTS:\nThe RAAS is triggered by low renal perfusion sensed through three mechanisms: afferent arteriolar baroreceptors, macula densa sodium sensing, and sympathetic beta-1 stimulation of juxtaglomerular cells. Angiotensin II raises blood pressure through vasoconstriction, aldosterone-mediated sodium retention, and ADH-stimulated water retention. ACE inhibitors and ARBs provide renal protection in diabetic nephropathy by reducing efferent arteriolar constriction and intraglomerular pressure."
  },
  {
    "id": 225,
    "categoryId": 2,
    "question": "The early phase of an asthma attack is bronchoconstriction. The late phase (4-6 hours later) is characterized by:",
    "options": [
      "A) Smooth muscle relaxation",
      "B) Inflammation and Mucus production",
      "C) Alveolar collapse",
      "D) Bacterial superinfection"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Inflammation and Mucus production).\n\nPATHOPHYSIOLOGY:\nThe asthmatic airway response to an allergen or trigger occurs in two distinct phases per Harrison's Principles of Internal Medicine. The early phase (within minutes) is driven by mast cell degranulation releasing preformed histamine, tryptase, and newly synthesized leukotrienes and prostaglandins, which cause acute bronchoconstriction of airway smooth muscle. This early bronchospasm is what patients experience as sudden chest tightness and wheezing, and it is rapidly reversed by short-acting beta-2 agonists (albuterol). The late phase (4 to 8 hours after initial exposure) is characterized by recruitment and activation of eosinophils, T-helper 2 lymphocytes, basophils, and neutrophils to the airway wall per UpToDate. These inflammatory cells release cytokines (IL-4, IL-5, IL-13), toxic granule proteins (major basic protein, eosinophil cationic protein), and additional leukotrienes that cause mucosal edema, mucus hypersecretion, epithelial damage, and sustained bronchoconstriction.\n\nCLINICAL SIGNIFICANCE:\nThe late-phase inflammatory response is the critical therapeutic target in asthma per the Cleveland Clinic. Bronchodilators (albuterol, formoterol) reverse smooth muscle spasm but do not address the underlying eosinophilic inflammation that causes mucosal edema, goblet cell hyperplasia, subepithelial fibrosis, and airway remodeling. This is why inhaled corticosteroids (ICS) are the cornerstone of controller therapy for all persistent asthma per GINA 2024 and NHLBI guidelines. ICS suppress the late-phase inflammatory cascade by inhibiting cytokine transcription, reducing eosinophil recruitment and survival, and decreasing mucus production per Harrison's Principles of Internal Medicine. Without adequate anti-inflammatory therapy, repeated cycles of inflammation and repair lead to permanent structural changes known as airway remodeling, including subepithelial fibrosis, smooth muscle hypertrophy, and fixed airflow limitation per UpToDate.\n\nCLINICAL APPLICATION:\nThe dual-phase response explains why GINA 2024 now recommends against SABA-only treatment even for the mildest asthma, favoring ICS-formoterol as the preferred reliever (Track 1), which delivers anti-inflammatory therapy with every rescue dose per the Mayo Clinic. It also explains why patients may experience a biphasic asthma attack: apparent improvement after initial bronchodilator use followed by worsening symptoms hours later as the late-phase response develops.\n\nKEY LEARNING POINTS:\nThe late phase of asthma (4 to 8 hours after trigger) is characterized by eosinophilic inflammation and mucus hypersecretion, which bronchodilators alone cannot address. Inhaled corticosteroids are essential because they target the late-phase inflammatory cascade and prevent airway remodeling. Untreated chronic airway inflammation leads to permanent structural changes and irreversible airflow limitation."
  },
  {
    "id": 226,
    "categoryId": 7,
    "question": "The Anterior Cruciate Ligament (ACL) prevents:",
    "options": [
      "A) Posterior translation of the tibia",
      "B) Anterior translation of the tibia relative to the femur",
      "C) Valgus stress",
      "D) Varus stress"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Anterior translation of the tibia relative to the femur).\n\nPATHOPHYSIOLOGY:\nThe anterior cruciate ligament is an intra-articular, extrasynovial ligament that originates from the posteromedial aspect of the lateral femoral condyle and courses anteriorly, medially, and distally to insert on the anterior intercondylar area of the tibial plateau. Its primary biomechanical function is to serve as the principal restraint against anterior translation of the tibia relative to the femur, providing approximately 85% of the total restraining force against this movement. The ACL also contributes significantly to rotational stability of the knee by resisting internal tibial rotation and controlling the coupled motion of tibial translation with rotation that occurs during cutting, pivoting, and deceleration activities. The ligament is composed of two functional bundles: the anteromedial bundle, which is taut in flexion and primarily resists anterior translation, and the posterolateral bundle, which is taut in extension and provides rotational stability. This dual-bundle architecture allows the ACL to maintain tension throughout the full range of knee motion.\n\nCLINICAL PRESENTATION:\nACL rupture typically occurs through a noncontact mechanism involving sudden deceleration, a cutting or pivoting maneuver, or landing from a jump with the knee near full extension and the foot planted. Patients frequently describe hearing or feeling a \"pop\" at the moment of injury, followed by immediate swelling from hemarthrosis (blood within the joint, developing within 2 to 4 hours due to rupture of the ligament's blood supply). After the acute phase, the hallmark complaint is functional instability characterized by the knee \"giving way\" during activities that require pivoting or directional change, reflecting the loss of the ACL's rotational restraint. This instability pattern distinguishes ACL injury from collateral ligament injuries, which produce instability to valgus stress (medial collateral ligament) or varus stress (lateral collateral ligament), and from posterior cruciate ligament injury, which allows posterior tibial translation and is typically caused by a direct blow to the anterior tibia (dashboard injury).\n\nDIAGNOSIS AND MANAGEMENT:\nThe Lachman test is the most sensitive bedside examination for ACL rupture, performed at 20 to 30 degrees of flexion to eliminate hamstring guarding. The pivot shift test is the most specific test, reproducing the subluxation-reduction event that occurs with rotational instability. MRI confirms the diagnosis and evaluates associated injuries including meniscal tears, which accompany acute ACL ruptures in over 50% of cases, and bone bruises of the lateral femoral condyle and posterolateral tibial plateau from the impact at the time of injury. Management decisions weigh the patient's activity level, age, associated injuries, and functional demands. Surgical reconstruction using autograft (patellar tendon, hamstring tendon, or quadriceps tendon) is recommended for patients with functional instability, high-demand activities, or concomitant meniscal tears requiring repair, as chronic ACL deficiency accelerates meniscal degeneration and subsequent osteoarthritis.\n\nKEY LEARNING POINTS:\nThe ACL is the primary restraint against anterior tibial translation, providing approximately 85% of the total restraining force, and also contributes to rotational stability during pivoting and cutting activities. The classic injury mechanism is noncontact pivoting with an audible pop and rapid hemarthrosis within 2 to 4 hours. Surgical reconstruction is recommended for patients with functional instability or associated meniscal tears, as chronic ACL deficiency accelerates degenerative joint disease."
  },
  {
    "id": 227,
    "categoryId": 3,
    "question": "Which pancreatic hormone is co-secreted with Insulin and forms amyloid deposits in the pancreas of Type 2 Diabetics?",
    "options": [
      "A) Glucagon",
      "B) Amylin",
      "C) Somatostatin",
      "D) Lipase"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Amylin).\n\nPATHOPHYSIOLOGY:\nAmylin (islet amyloid polypeptide, IAPP) is a 37-amino acid peptide hormone co-secreted with insulin from pancreatic beta cells in a molar ratio of approximately 1:100 (amylin to insulin) in response to nutrient stimuli. Under normal physiologic conditions, amylin complements insulin action by slowing gastric emptying, suppressing postprandial glucagon secretion, and promoting satiety through central nervous system signaling. These actions collectively reduce the rate of glucose appearance in the circulation after meals.\n\nROLE IN TYPE 2 DIABETES:\nIn type 2 diabetes, chronic beta cell overstimulation leads to increased amylin production. The overproduced amylin misfolds into insoluble beta-sheet fibrils (amyloid) that deposit within and around pancreatic islets. These amyloid deposits are found in approximately 90% of patients with type 2 diabetes at autopsy and are believed to contribute to progressive beta cell dysfunction and apoptosis through membrane disruption and oxidative stress. The amyloid deposition creates a vicious cycle in which beta cell loss leads to further compensatory hypersecretion from remaining cells, promoting more amyloid formation.\n\nTHERAPEUTIC APPLICATION:\nPramlintide (Symlin) is a synthetic analog of amylin approved as an adjunctive therapy for type 1 and type 2 diabetes in patients using mealtime insulin. It is administered by subcutaneous injection before meals and reduces postprandial glucose excursions by slowing gastric emptying, suppressing inappropriate glucagon release, and enhancing satiety. Pramlintide modestly reduces HbA1c (0.3-0.5%) and promotes weight loss of 1-2 kg, distinguishing it from insulin, which typically causes weight gain.\n\nKEY LEARNING POINTS:\nAmylin is co-secreted with insulin from beta cells and slows gastric emptying, suppresses glucagon, and promotes satiety. Amyloid deposits from misfolded amylin are found in approximately 90% of type 2 diabetic pancreata and contribute to beta cell loss. Pramlintide is a synthetic amylin analog used as adjunctive therapy to mealtime insulin. It lowers postprandial glucose and promotes modest weight loss."
  },
  {
    "id": 228,
    "categoryId": 1,
    "question": "Statins lower LDL primarily by inhibiting HMG-CoA Reductase, which leads to:",
    "options": [
      "A) Increased excretion of bile acids",
      "B) Upregulation of LDL Receptors on the liver",
      "C) Decreased absorption of dietary fat",
      "D) Oxidation of fatty acids"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Upregulation of LDL Receptors on the Liver).\n\nPATHOPHYSIOLOGY:\nStatins competitively inhibit HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway that converts HMG-CoA to mevalonate, a critical precursor for endogenous cholesterol synthesis in the liver per Harrison's Principles of Internal Medicine. When hepatic cholesterol synthesis is reduced, the intracellular cholesterol content of hepatocytes decreases, which activates the sterol regulatory element-binding protein (SREBP) pathway per UpToDate. SREBP translocates to the nucleus and upregulates transcription of the LDL receptor gene, increasing the density of LDL receptors on the hepatocyte surface. These additional LDL receptors bind and internalize circulating LDL particles from the blood, which is the primary mechanism by which statins lower serum LDL cholesterol per the Cleveland Clinic.\n\nPLEIOTROPIC EFFECTS:\nBeyond LDL lowering, statins have clinically important pleiotropic effects that contribute to their cardiovascular benefit per UpToDate. These include improvement of endothelial function (increased nitric oxide bioavailability), stabilization of atherosclerotic plaques (reduced metalloproteinase activity, increased collagen content of the fibrous cap), anti-inflammatory effects (reduced hs-CRP, decreased macrophage activation), and antithrombotic properties (reduced tissue factor expression, decreased platelet aggregation) per Harrison's Principles of Internal Medicine.\n\nCLINICAL CONTEXT:\nFamilial hypercholesterolemia (FH) illustrates why LDL receptor upregulation is the key mechanism: heterozygous FH patients (who have approximately 50% of normal LDL receptor activity) respond well to statins because the drug upregulates their remaining functional receptors, while homozygous FH patients (who have absent or severely deficient LDL receptors) show minimal response to statins and require alternative therapies such as PCSK9 inhibitors, lomitapide, or LDL apheresis per the Mayo Clinic.\n\nKEY LEARNING POINTS:\nStatins lower LDL primarily by inhibiting hepatic cholesterol synthesis, which triggers SREBP-mediated upregulation of LDL receptors on hepatocytes that clear LDL from the blood. Pleiotropic effects (plaque stabilization, anti-inflammation, improved endothelial function) contribute additional cardiovascular benefit. Homozygous FH patients respond poorly because they lack functional LDL receptors to upregulate."
  },
  {
    "id": 229,
    "categoryId": 17,
    "question": "The Eustachian tube connects the Middle Ear to the:",
    "options": [
      "A) Inner Ear",
      "B) Nasopharynx",
      "C) Oropharynx",
      "D) Sinuses"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Nasopharynx).\n\nANATOMY:\nThe Eustachian tube (pharyngotympanic tube or auditory tube) is a 36 mm channel connecting the middle ear cavity (tympanic cavity) to the nasopharynx. It serves three critical functions: ventilation (equalizing middle ear pressure with atmospheric pressure), protection (barrier against nasopharyngeal secretions and pathogens), and clearance (mucociliary drainage of middle ear secretions into the nasopharynx).\n\nPEDIATRIC SIGNIFICANCE:\nIn infants and young children, the Eustachian tube is shorter (approximately 18 mm vs 36 mm in adults), more horizontal (10 degrees vs 45 degrees from horizontal), and has less rigid cartilaginous support. These anatomic differences impair the tube's protective and drainage functions:\n- The horizontal orientation allows reflux of nasopharyngeal bacteria into the middle ear\n- The shorter length decreases the distance pathogens must travel\n- Floppy cartilage impairs active opening during swallowing\n- Adenoid hypertrophy can obstruct the nasopharyngeal orifice\n\nCLINICAL RELEVANCE:\nEustachian tube dysfunction is the primary pathophysiologic mechanism underlying otitis media in children. When the tube fails to open properly, negative pressure develops in the middle ear, drawing in fluid (effusion) that becomes a culture medium for bacteria ascending from the nasopharynx. The most common pathogens (S. pneumoniae, H. influenzae, M. catarrhalis) colonize the nasopharynx and migrate through the dysfunctional tube. As the child grows, the tube elongates and angles downward, which is why AOM incidence decreases significantly after age 3.\n\nKEY LEARNING POINTS:\nThe Eustachian tube connects the middle ear to the nasopharynx and is critical for pressure equalization and drainage. Pediatric anatomy (short, horizontal tube) predisposes children to otitis media. Adenoid hypertrophy can obstruct the Eustachian tube orifice, contributing to recurrent middle ear disease.\n\nREFERENCES:\nAAP Otitis Media Guidelines; UpToDate; Harrison's Principles of Internal Medicine.\n---"
  },
  {
    "id": 230,
    "categoryId": 16,
    "question": "Heart Failure with Preserved Ejection Fraction (Diastolic HF) is fundamentally a problem of:",
    "options": [
      "A) Pumping failure",
      "B) Filling failure (Stiffness/Relaxation)",
      "C) Valve regurgitation",
      "D) Arrhythmia"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Filling failure due to ventricular stiffness and impaired relaxation).\n\nPATHOPHYSIOLOGY:\nHeart failure with preserved ejection fraction (HFpEF, formerly called diastolic heart failure) is characterized by normal or near-normal left ventricular systolic function (EF 50% or greater) but impaired ventricular relaxation and increased myocardial stiffness that limit diastolic filling per Harrison's Principles of Internal Medicine. The ventricle contracts (squeezes) adequately but cannot relax and fill properly, requiring elevated left atrial pressures to achieve adequate ventricular filling volume per UpToDate. These elevated filling pressures transmit retrograde to the pulmonary vasculature, producing pulmonary congestion and the classic symptoms of dyspnea, exercise intolerance, and peripheral edema per the Cleveland Clinic.\n\nMECHANISMS OF DIASTOLIC DYSFUNCTION:\nConcentric left ventricular hypertrophy (from chronic hypertension, the most common cause of HFpEF) increases wall thickness and reduces chamber compliance per Harrison's Principles of Internal Medicine. Myocardial fibrosis (both interstitial and replacement fibrosis) further stiffens the ventricle. Titin, the giant sarcomeric protein that functions as a molecular spring governing passive myocardial stiffness, is hypophosphorylated in HFpEF, reducing its compliance per UpToDate. Systemic microvascular inflammation (driven by comorbidities including obesity, diabetes, hypertension, and chronic kidney disease) causes coronary microvascular endothelial dysfunction, reducing nitric oxide signaling and impairing cardiomyocyte relaxation per the Mayo Clinic.\n\nCLINICAL SIGNIFICANCE:\nHFpEF now accounts for approximately 50% of all heart failure cases and is more common in older women with hypertension, obesity, and atrial fibrillation per the Cleveland Clinic. SGLT2 inhibitors (empagliflozin, dapagliflozin) are the first drug class to demonstrate mortality and hospitalization benefit in HFpEF (EMPEROR-Preserved and DELIVER trials) per UpToDate and Harrison's Principles of Internal Medicine.\n\nKEY LEARNING POINTS:\nHFpEF is fundamentally a filling failure caused by impaired ventricular relaxation and myocardial stiffness, not a pumping failure (EF is preserved). Concentric LVH from chronic hypertension, myocardial fibrosis, and titin hypophosphorylation all contribute to reduced compliance. SGLT2 inhibitors are the first class to show benefit in HFpEF per the EMPEROR-Preserved and DELIVER trials."
  },
  {
    "id": 231,
    "categoryId": 4,
    "question": "Menopausal hot flashes are triggered by the withdrawal of Estrogen, which causes:",
    "options": [
      "A) Lower body temperature set-point",
      "B) Narrowing of the 'Thermoneutral Zone' in the hypothalamus",
      "C) Reduced Norepinephrine",
      "D) Increased Serotonin"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Narrowing of the Thermoneutral Zone in the hypothalamus).\n\nPATHOPHYSIOLOGY:\nMenopausal vasomotor symptoms (hot flashes and night sweats) result from estrogen withdrawal-induced dysfunction of the hypothalamic thermoregulatory center, specifically the preoptic area and median preoptic nucleus. Under normal estrogen-replete conditions, the thermoneutral zone, defined as the range of core body temperature within which neither heat-dissipation (sweating, vasodilation) nor heat-conservation (shivering, vasoconstriction) mechanisms are activated, spans approximately 0.4 degrees Celsius. This comfortable zone allows routine fluctuations in core temperature to occur without triggering compensatory responses. Estrogen modulates this thermoneutral zone width through its effects on hypothalamic neurotransmitter systems, particularly the KNDy (kisspeptin, neurokinin B, dynorphin) neurons in the arcuate nucleus that have been identified as key mediators of the thermoregulatory dysfunction per research published in the NEJM and reviewed in Harrison's Principles of Internal Medicine. When estrogen levels decline during menopause, neurokinin B signaling becomes hyperactive and the thermoneutral zone narrows to near zero, meaning that even minor fluctuations in core temperature of 0.01 to 0.02 degrees Celsius that would normally be ignored instead trigger a full heat-dissipation cascade: peripheral vasodilation (causing the flushing sensation and visible skin erythema), profuse diaphoresis (sweating), and tachycardia. The subjective experience is an intense wave of heat, typically lasting 1 to 5 minutes, that may be accompanied by anxiety, palpitations, and a subsequent chill as evaporative cooling overshoots. Data from the Study of Women's Health Across the Nation (SWAN) published in JAMA Internal Medicine demonstrate that vasomotor symptoms affect approximately 80% of perimenopausal and postmenopausal women, persist for a median of 7.4 years, and may continue for more than a decade in some women.\n\nCLINICAL REASONING:\nThe identification of KNDy neurons as the central mediator of vasomotor symptoms has led to the development of a novel therapeutic class. Fezolinetant (Veozah), a neurokinin 3 receptor (NK3R) antagonist approved by the FDA in 2023, directly targets the hyperactive neurokinin B signaling in KNDy neurons that narrows the thermoneutral zone. By blocking NK3R, fezolinetant restores thermoneutral zone width without exogenous estrogen, providing a non-hormonal option for women who cannot or prefer not to take hormone therapy. Clinical trials published in The Lancet demonstrated that fezolinetant reduced moderate-to-severe vasomotor symptom frequency by approximately 60% and severity by approximately 40% compared to placebo.\n\nTREATMENT:\nHormone replacement therapy remains the most effective treatment for vasomotor symptoms, reducing hot flash frequency by 75 to 95% per Cochrane meta-analysis data, and is recommended as first-line by the Endocrine Society and NAMS for symptomatic women within 10 years of menopause onset or under age 60 without contraindications. For women who cannot take estrogen (history of breast cancer, thromboembolic disease, cardiovascular risk), effective non-hormonal alternatives include fezolinetant (NK3R antagonist, the newest targeted therapy), SSRIs and SNRIs (paroxetine 7.5 mg is the only FDA-approved non-hormonal agent for hot flashes; venlafaxine is also effective), gabapentin (particularly useful when nocturnal symptoms predominate), and oxybutynin (shown effective in the randomized OPAL trial). Cognitive behavioral therapy has demonstrated efficacy for reducing the bothersomeness of hot flashes in randomized trials published in The Lancet. Lifestyle modifications including maintaining a cool ambient temperature, wearing layered clothing, avoiding triggers (alcohol, spicy foods, caffeine), regular exercise, and maintaining a healthy weight may provide symptomatic relief.\n\nKEY LEARNING POINTS:\nEstrogen withdrawal narrows the hypothalamic thermoneutral zone to near zero through hyperactivation of KNDy neurokinin B signaling, causing minor core temperature fluctuations to trigger the full heat-dissipation cascade experienced as hot flashes. Hormone therapy is the most effective treatment, reducing symptoms by 75 to 95%. Fezolinetant, an NK3R antagonist targeting the KNDy pathway, represents the first mechanism-based non-hormonal therapy approved for vasomotor symptoms."
  },
  {
    "id": 232,
    "categoryId": 10,
    "question": "The four pillars of Acne pathogenesis are: Hyperkeratinization, Sebum production, C. acnes bacteria, and:",
    "options": [
      "A) Viral infection",
      "B) Inflammation",
      "C) Poor hygiene",
      "D) Sun exposure"
    ],
    "correctAnswer": 1,
    "explanationImages": [
      {
        "src": "assets/acne-types-chart.png",
        "alt": "Acne lesion types including papules, blackheads, whiteheads, nodules, pustules, and cysts",
        "caption": "Common acne lesion morphology (papules, comedones, pustules, nodules, and cysts)."
      }
    ],
    "explanation": "CORRECT: B (Inflammation).\n\nPATHOPHYSIOLOGY:\nAcne vulgaris is a chronic inflammatory disease of the pilosebaceous unit driven by four interrelated pathogenic mechanisms. First, follicular hyperkeratinization occurs when keratinocytes lining the follicular infundibulum proliferate excessively and become cohesive rather than shedding normally, forming a keratinous plug (the microcomedo) that obstructs the follicular ostium. Second, androgen-driven sebum overproduction by sebaceous glands creates a lipid-rich, anaerobic environment within the plugged follicle. Dihydrotestosterone (DHT), converted from testosterone by 5-alpha reductase within the sebaceous gland, is the principal hormonal driver. Third, Cutibacterium acnes (formerly Propionibacterium acnes), a commensal anaerobe, proliferates within the sebum-filled follicle, producing lipases that generate free fatty acids and releasing enzymes and chemotactic factors. Fourth, inflammation is initiated when C. acnes activates toll-like receptor 2 (TLR-2) on keratinocytes and monocytes, triggering release of IL-1, IL-8, TNF-alpha, and matrix metalloproteinases. This inflammatory cascade transforms non-inflammatory comedones into inflammatory papules, pustules, and nodules. Notably, recent evidence from the Journal of Investigative Dermatology demonstrates that subclinical inflammation is present even in early comedones, establishing inflammation as a primary rather than secondary event.\n\nCLINICAL APPLICATION - TREATMENT BY PATHOGENIC TARGET:\nUnderstanding the four pillars directly informs the stepwise treatment approach recommended by the American Academy of Dermatology. Topical retinoids (tretinoin, adapalene, tazarotene) normalize follicular keratinization, prevent microcomedo formation, and exert anti-inflammatory effects, making them the foundation of nearly all acne regimens. Hormonal agents, specifically combined oral contraceptives (containing ethinyl estradiol plus a progestin with antiandrogenic activity such as drospirenone or norgestimate) and spironolactone (an androgen receptor blocker), reduce sebum production by antagonizing androgen signaling. Benzoyl peroxide is a bactericidal oxidizing agent that kills C. acnes without inducing antibiotic resistance, making it essential as combination therapy whenever antibiotics are used. Oral antibiotics (doxycycline, minocycline) target both C. acnes and inflammation through their anti-inflammatory properties independent of antimicrobial activity, but should be limited to 3 to 4 months to minimize resistance. Isotretinoin uniquely addresses all four pillars simultaneously and is the only therapy capable of inducing long-term remission.\n\nMANAGEMENT LADDER:\nMild comedonal acne is treated with topical retinoid alone. Mild inflammatory acne adds benzoyl peroxide with or without a topical antibiotic. Moderate inflammatory acne warrants oral antibiotics combined with topical retinoid and benzoyl peroxide. Severe nodulocystic acne or treatment-resistant moderate acne requires isotretinoin referral. The common misconception that acne results from poor hygiene or dirty skin is incorrect and should be actively dispelled, as aggressive cleansing can worsen inflammation by disrupting the epidermal barrier.\n\nKEY LEARNING POINTS:\nThe four pillars of acne pathogenesis are follicular hyperkeratinization, excess sebum production, C. acnes colonization, and inflammation, and each pillar has targeted therapeutic agents. Topical retinoids are the foundation of treatment because they address keratinization and inflammation. Benzoyl peroxide must accompany antibiotics to prevent resistance. Isotretinoin is the only agent that targets all four pillars simultaneously. Poor hygiene is not a cause of acne."
  },
  {
    "id": 233,
    "categoryId": 7,
    "question": "The Cauda Equina (Horse's Tail) begins at which vertebral level?",
    "options": [
      "A) C7",
      "B) T12",
      "C) L1-L2",
      "D) S1"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (L1-L2).\n\nPATHOPHYSIOLOGY:\nDuring embryonic development, the spinal cord and vertebral column grow at different rates, a phenomenon known as the ascensus medullae. The vertebral column ultimately elongates more than the spinal cord, so that by adulthood the spinal cord terminates as the conus medullaris at the level of the L1 to L2 vertebral body, well above the caudal end of the vertebral canal. Below this termination point, the lumbar, sacral, and coccygeal nerve roots continue to descend within the spinal canal as a bundle of free-floating nerve roots called the cauda equina, named for its resemblance to a horse's tail. These nerve roots travel through cerebrospinal fluid within the thecal sac before exiting at their respective neural foramina. The filum terminale, a thin strand of pia mater, anchors the conus medullaris to the coccyx and provides structural stability.\n\nCLINICAL SIGNIFICANCE:\nThe anatomic termination of the spinal cord at L1 to L2 has critical procedural implications. Lumbar puncture is performed at the L3 to L4 or L4 to L5 interspace because at these levels the spinal needle enters the thecal sac below the conus medullaris, passing only through freely mobile cauda equina nerve roots that are pushed aside by the needle rather than being penetrated. Performing a lumbar puncture above L2 risks direct spinal cord injury. The L4 to L5 interspace is identified by palpating the iliac crests, which correspond to the L4 spinous process in most patients. Similarly, spinal anesthesia and epidural procedures rely on this anatomic landmark to ensure safe needle placement.\n\nCAUDA EQUINA SYNDROME:\nCauda equina syndrome is a surgical emergency caused by compression of the cauda equina nerve roots, most commonly from a large central lumbar disc herniation at L4 to L5 or L5 to S1, but also from tumors, epidural abscess, epidural hematoma, or spinal stenosis. The classic presentation includes severe low back pain radiating bilaterally, progressive lower extremity weakness, saddle anesthesia affecting the perineum and perianal region (S2 to S5 dermatomes), and bowel and bladder dysfunction, typically presenting as urinary retention with overflow incontinence and decreased rectal tone. Because the cauda equina carries the sacral parasympathetic fibers responsible for bladder detrusor contraction and rectal sphincter control, compression produces a lower motor neuron pattern with areflexic bladder and bowel. Diagnosis requires emergent MRI of the lumbar spine, and surgical decompression via laminectomy must be performed within 24 to 48 hours to maximize neurologic recovery, as delay beyond this window is associated with permanent bladder, bowel, and sexual dysfunction.\n\nKEY LEARNING POINTS:\nThe spinal cord terminates as the conus medullaris at L1 to L2, below which the cauda equina nerve roots descend freely within the thecal sac. Lumbar puncture is performed at L3 to L4 or L4 to L5 to avoid spinal cord injury while accessing cerebrospinal fluid safely among the mobile cauda equina roots. Cauda equina syndrome presents with saddle anesthesia, urinary retention, and bilateral leg weakness, and requires emergent MRI and surgical decompression within 24 to 48 hours."
  },
  {
    "id": 234,
    "categoryId": 1,
    "question": "A 55-year-old diabetic male presents with 'heartburn' and diaphoresis. An EKG shows ST elevation in leads II, III, and aVF. Which wall of the heart is affected, and which medication is CONTRAINDICATED?",
    "options": [
      "A) Anterior Wall; Avoid Beta Blockers",
      "B) Inferior Wall; Avoid Nitroglycerin",
      "C) Lateral Wall; Avoid Aspirin",
      "D) Posterior Wall; Avoid Morphine"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Inferior Wall MI; Avoid Nitroglycerin).\n\nCLINICAL REASONING:\nST elevation in leads II, III, and aVF localizes the infarction to the inferior wall of the heart, which is supplied by the right coronary artery (RCA) in approximately 85% of patients (right-dominant circulation) or the left circumflex artery in the remaining 15% per Harrison's Principles of Internal Medicine. The presentation of \"heartburn\" with diaphoresis in a diabetic male is a classic atypical MI presentation, as diabetic patients frequently experience anginal equivalents rather than typical chest pain per UpToDate.\n\nPATHOPHYSIOLOGY:\nNitroglycerin is contraindicated in inferior wall MI because of the high frequency of associated right ventricular infarction (approximately 30 to 50% of inferior MIs have RV involvement) per the Cleveland Clinic. The right ventricle is a preload-dependent chamber that relies on adequate venous return to maintain cardiac output. Nitroglycerin is a potent venodilator that reduces preload by pooling blood in the venous capacitance vessels. In the setting of RV infarction, this preload reduction can cause catastrophic hemodynamic collapse with severe hypotension, bradycardia, and cardiogenic shock per Harrison's Principles of Internal Medicine. Right-sided EKG leads (particularly V4R) should be obtained in all inferior MIs to assess for RV involvement per UpToDate.\n\nADDITIONAL CONTRAINDICATIONS:\nBeyond RV infarction, nitroglycerin is also contraindicated in patients who have taken a phosphodiesterase-5 inhibitor (sildenafil within 24 hours, tadalafil within 48 hours), as the combination can produce profound refractory hypotension per the Mayo Clinic. Morphine should also be used cautiously in inferior MI as it can cause vagal-mediated bradycardia and hypotension per UpToDate.\n\nKEY LEARNING POINTS:\nST elevation in leads II, III, and aVF indicates inferior wall MI (RCA territory), and nitroglycerin is contraindicated because of frequent RV involvement (30 to 50% of inferior MIs) where preload reduction causes hemodynamic collapse. Right-sided EKG lead V4R should be obtained in all inferior MIs to assess for RV infarction. Diabetic patients commonly present with anginal equivalents rather than classic chest pain."
  },
  {
    "id": 235,
    "categoryId": 6,
    "question": "A 70-year-old patient had a TIA (slurred speech for 10 mins, now resolved). His ABCD2 score is 5 (Moderate/High Risk). What is the recommended management?",
    "options": [
      "A) Send home with Aspirin and outpatient neurology referral",
      "B) Schedule MRI next week",
      "C) Immediate ER referral for admission/workup",
      "D) Start Warfarin immediately"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Immediate ER referral for admission/workup).\n\nHIGH-RISK TIA:\nA TIA with ABCD2 score of 6 represents high short-term stroke riskâ€”approximately 8% within 48 hours. This patient requires urgent hospitalization for comprehensive workup and secondary prevention initiation. Outpatient management is inappropriate for high-risk TIA.\n\nABCD2 SCORE COMPONENTS:\nAge â‰¥60 (1 point), Blood pressure â‰¥140/90 (1 point), Clinical featuresâ€”unilateral weakness (2 points) or speech disturbance (1 point), Duration â‰¥60 min (2 points) or 10-59 min (1 point), Diabetes (1 point). Scores â‰¥4 indicate high risk requiring hospitalization.\n\nINPATIENT WORKUP:\nMRI with diffusion-weighted imaging (30-50% of TIAs show acute infarct), carotid imaging (duplex ultrasound or CTA), echocardiography, telemetry monitoring for atrial fibrillation, and lipid panel. Many \"TIAs\" prove to be minor strokes on DWI, changing management.\n\nTIME-SENSITIVE INTERVENTION:\nIf carotid stenosis >70% is found, endarterectomy within 2 weeks dramatically reduces stroke risk. Dual antiplatelet therapy (aspirin + clopidogrel for 21 days) reduces early recurrence. Statin initiation regardless of lipids provides neuroprotection.\n\nKEY LEARNING POINTS:\nHigh ABCD2 score (â‰¥4) TIA requires hospitalization, not outpatient management. 30-50% of TIAs show infarct on MRI-DWI. Carotid intervention within 2 weeks and early dual antiplatelet therapy reduce stroke risk."
  },
  {
    "id": 236,
    "categoryId": 15,
    "question": "A patient develops lip swelling and wheezing after an injection. BP is 90/60. What is the correct dose and route of Epinephrine for an adult?",
    "options": [
      "A) 1mg (1:10,000) IV push",
      "B) 0.3mg to 0.5mg (1:1,000) Intramuscular (IM)",
      "C) 0.3mg Subcutaneous",
      "D) 50mg Oral Benadryl"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (0.3mg to 0.5mg of 1:1,000 concentration Intramuscular).\n\nPATHOPHYSIOLOGY:\nAnaphylaxis is a severe, life-threatening systemic hypersensitivity reaction mediated primarily by IgE-dependent mast cell and basophil degranulation, releasing histamine, tryptase, leukotrienes, and prostaglandins that cause widespread vasodilation, increased vascular permeability, bronchospasm, and upper airway edema per Harrison's Principles of Internal Medicine. The resulting distributive shock with intravascular volume depletion can rapidly progress to cardiovascular collapse and death within minutes if untreated. Common triggers include medications (antibiotics, NSAIDs), foods (peanuts, tree nuts, shellfish), insect stings (Hymenoptera), and latex per the CDC.\n\nCLINICAL REASONING:\nEpinephrine is the first-line treatment for anaphylaxis and the only medication that directly addresses all pathophysiologic mechanisms: alpha-1 adrenergic effects cause vasoconstriction (reversing hypotension and reducing mucosal edema), beta-1 effects increase cardiac output, and beta-2 effects cause bronchodilation and suppress further mediator release from mast cells per UpToDate. The correct dose for anaphylaxis is 0.3 to 0.5 mg of the 1:1,000 (1 mg/mL) concentration administered intramuscularly in the anterolateral thigh, which provides the most rapid and reliable absorption per the Mayo Clinic. This dose may be repeated every 5 to 15 minutes as needed. There are no absolute contraindications to epinephrine in anaphylaxis per ACAAI and WAO guidelines.\n\nCRITICAL SAFETY DISTINCTION:\nThe 1:10,000 concentration (0.1 mg/mL) of epinephrine is reserved exclusively for cardiac arrest (pulseless patient) and is given intravenously per ACLS guidelines. Administering IV epinephrine to a patient with a perfusing rhythm can cause fatal ventricular tachycardia, hypertensive crisis, or myocardial ischemia per Harrison's Principles of Internal Medicine. The intramuscular route in the anterolateral thigh is superior to subcutaneous injection because of faster and more reliable absorption due to the thigh's rich blood supply. Adjunctive treatments include aggressive IV crystalloid resuscitation (1 to 2 liters for hypotension), H1 antihistamines (diphenhydramine), H2 blockers (famotidine), and corticosteroids, though none of these replace epinephrine. Patients should be observed for a minimum of 4 to 6 hours due to the risk of biphasic reactions (recurrence of symptoms hours after initial resolution) per UpToDate.\n\nKEY LEARNING POINTS:\nAnaphylaxis requires immediate intramuscular epinephrine 0.3 to 0.5 mg of 1:1,000 concentration in the anterolateral thigh, with no absolute contraindications. Intravenous epinephrine (1:10,000) is reserved exclusively for cardiac arrest and can cause fatal arrhythmias if given to a patient with a pulse. Patients must be observed 4 to 6 hours for biphasic reactions, and antihistamines and steroids are adjuncts that do not replace epinephrine."
  },
  {
    "id": 237,
    "categoryId": 17,
    "question": "A patient presents with a painful red eye. You see a 'ciliary flush' (redness around the iris) and the pupil is small and irregularly shaped. Shining light in the UNAFFECTED eye causes pain in the affected eye (Consensual Photophobia). Diagnosis?",
    "options": [
      "A) Conjunctivitis",
      "B) Anterior Uveitis (Iritis)",
      "C) Angle Closure Glaucoma",
      "D) Subconjunctival Hemorrhage"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Uveitis).\n\nPATHOPHYSIOLOGY:\nAnterior uveitis (iritis) is inflammation of the iris and ciliary body. The inflamed iris develops spasm of the ciliary muscle and sphincter pupillae, causing the characteristic miotic (small) pupil and deep aching pain. When light enters either eye, the consensual pupillary response constricts the inflamed iris, producing pain in the affected eye even when light is shone in the contralateral eye (consensual photophobia). This finding is pathognomonic for anterior uveitis and reliably distinguishes it from conjunctivitis.\n\nCLINICAL PRESENTATION:\n- Unilateral eye pain (deep, aching)\n- Photophobia, including consensual photophobia (pathognomonic)\n- Ciliary flush: Ring of limbal (perilimbal) injection around the cornea\n- Miotic, irregularly shaped pupil (posterior synechiae from inflammatory adhesions)\n- Decreased visual acuity\n- Cells and flare in the anterior chamber on slit-lamp examination\n\nETIOLOGY:\nAnterior uveitis is strongly associated with HLA-B27-related systemic diseases:\n- Ankylosing spondylitis (most common systemic association)\n- Reactive arthritis (formerly Reiter syndrome)\n- Inflammatory bowel disease (Crohn disease, ulcerative colitis)\n- Psoriatic arthritis\n- Other causes include sarcoidosis, Behcet disease, infections (HSV, VZV, syphilis, tuberculosis), and idiopathic\n\nDIAGNOSIS:\nSlit-lamp examination is the gold standard, revealing anterior chamber cells, flare (protein leakage), and keratic precipitates. Workup for recurrent or bilateral disease includes HLA-B27, chest X-ray (sarcoidosis, TB), RPR/VDRL (syphilis), and ACE level (sarcoidosis).\n\nTREATMENT:\nUrgent ophthalmology referral is essential.\n1. Topical corticosteroids (prednisolone acetate 1%) to suppress inflammation\n2. Cycloplegics (cyclopentolate, atropine) to relieve ciliary spasm, reduce pain, and prevent posterior synechiae\n3. Treat underlying systemic disease when identified\n\nKEY LEARNING POINTS:\nConsensual photophobia (pain in the affected eye when light is shone in the unaffected eye) is pathognomonic for anterior uveitis. Ciliary flush and a miotic pupil distinguish uveitis from conjunctivitis. Recurrent anterior uveitis warrants workup for HLA-B27-associated spondyloarthropathies.\n\nREFERENCES:\nAAO Preferred Practice Pattern for Uveitis; UpToDate; Harrison's Principles of Internal Medicine.\n---"
  },
  {
    "id": 238,
    "categoryId": 1,
    "question": "A 65-year-old smoker presents with sudden onset severe leg pain. The leg is pale, cold, and pulseless. Capillary refill is absent. What is the diagnosis?",
    "options": [
      "A) Deep Vein Thrombosis (DVT)",
      "B) Acute Limb Ischemia",
      "C) Cellulitis",
      "D) Sciatica"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Acute Limb Ischemia).\n\nCLINICAL REASONING:\nThis patient presents with the classic \"6 Ps\" of acute limb ischemia: Pain (sudden onset severe leg pain), Pallor (pale leg), Pulselessness (absent pulses), Poikilothermia (cold limb), Paresthesia (implied by the ischemic presentation), and Paralysis (in advanced cases) per Harrison's Principles of Internal Medicine. Acute limb ischemia is a vascular emergency defined as a sudden decrease in limb perfusion that threatens limb viability, typically caused by either arterial embolism (most commonly from a cardiac source such as atrial fibrillation, left ventricular thrombus post-MI, or valvular disease) or acute thrombosis of a pre-existing atherosclerotic stenosis per UpToDate.\n\nPATHOPHYSIOLOGY:\nThe distinction from DVT is critical: DVT causes limb swelling, warmth, and erythema (from venous outflow obstruction) with preserved arterial pulses, while acute arterial ischemia causes a pale, cold, pulseless limb per the Cleveland Clinic. Skeletal muscle can tolerate approximately 6 hours of complete ischemia before irreversible necrosis begins, making rapid diagnosis and intervention essential per Harrison's Principles of Internal Medicine.\n\nMANAGEMENT:\nImmediate systemic anticoagulation with IV unfractionated heparin is initiated upon diagnosis to prevent thrombus propagation per the Mayo Clinic. Definitive revascularization depends on the etiology and severity: catheter-directed thrombolysis (for acute thrombosis presenting within 14 days), surgical thromboembolectomy (Fogarty balloon catheter technique, particularly for embolic occlusion), or bypass grafting per UpToDate. Compartment pressures should be monitored after revascularization because reperfusion injury can cause compartment syndrome requiring fasciotomy per Harrison's Principles of Internal Medicine.\n\nKEY LEARNING POINTS:\nAcute limb ischemia presents with the 6 Ps (Pain, Pallor, Pulselessness, Poikilothermia, Paresthesia, Paralysis) and is a vascular emergency with approximately 6 hours before irreversible muscle necrosis. It is distinguished from DVT by the cold, pale, pulseless limb (DVT causes warm, swollen, erythematous limb with pulses). Immediate heparin anticoagulation is essential, followed by either thrombolysis or surgical embolectomy."
  },
  {
    "id": 239,
    "categoryId": 15,
    "question": "A 65-year-old male smoker presents with sudden onset severe back pain and syncope. BP is 80/50. He has a pulsatile abdominal mass. What is the next step?",
    "options": [
      "A) CT Abdomen with Contrast",
      "B) Abdominal Ultrasound",
      "C) Immediate Transfer to OR (Do not delay for imaging)",
      "D) IV Fluids and observe"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Immediate Transfer to OR).\n\nPATHOPHYSIOLOGY:\nAbdominal aortic aneurysm rupture is a surgical emergency with an overall mortality exceeding 80% and approaching 100% without operative intervention per Harrison's Principles of Internal Medicine. An AAA is defined as a focal dilation of the abdominal aorta to greater than 3.0 cm (normal diameter approximately 2.0 cm), and rupture occurs when wall stress exceeds tensile strength, most commonly in aneurysms exceeding 5.5 cm per UpToDate. Risk factors include male sex (6:1 male-to-female ratio), age over 65, smoking (the strongest modifiable risk factor), hypertension, family history, and connective tissue disorders per the Cleveland Clinic. The USPSTF recommends one-time screening abdominal ultrasound for men aged 65 to 75 who have ever smoked.\n\nCLINICAL REASONING:\nThis patient presents with the classic diagnostic triad of ruptured AAA: sudden severe back or abdominal pain, hemodynamic instability (BP 80/50 indicating hemorrhagic shock), and a pulsatile abdominal mass per Harrison's Principles of Internal Medicine. This triad is present in approximately 50% of ruptured AAA cases and is considered virtually diagnostic when all three components are identified per UpToDate. The critical management principle is that hemodynamically unstable patients with clinical signs of ruptured AAA must be taken directly to the operating room without delay for imaging. CT angiography is appropriate only for hemodynamically stable patients in whom the diagnosis is uncertain, as the time required for imaging in an unstable patient can be fatal. Permissive hypotension (target systolic BP 70 to 90 mmHg) is recommended during resuscitation to avoid disrupting any contained retroperitoneal hematoma per the Mayo Clinic.\n\nMANAGEMENT:\nSurgical repair is performed via open repair (laparotomy with graft placement) or endovascular aneurysm repair (EVAR) depending on anatomic suitability and institutional capability. Massive transfusion protocol should be activated, and type-specific or uncrossmatched blood should be available. For elective repair of unruptured AAA, current guidelines from the Society for Vascular Surgery recommend repair when the aneurysm reaches 5.5 cm in men or 5.0 cm in women, when the growth rate exceeds 0.5 cm over 6 months, or when the aneurysm becomes symptomatic per UpToDate.\n\nKEY LEARNING POINTS:\nThe triad of sudden back pain, hypotension, and pulsatile abdominal mass is virtually diagnostic of ruptured AAA and requires immediate operative intervention without delay for imaging. Overall mortality of ruptured AAA exceeds 80%, approaching 100% without surgery. The USPSTF recommends one-time screening ultrasound for men aged 65 to 75 who have ever smoked."
  },
  {
    "id": 240,
    "categoryId": 10,
    "question": "A patient presents with a pimple on the upper lip that she 'popped'. It is now swollen, red, and she has a headache and fever. Why is this dangerous?",
    "options": [
      "A) Risk of scarring",
      "B) Risk of Cavernous Sinus Thrombosis",
      "C) Risk of Lyme disease",
      "D) It is not dangerous"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Risk of Cavernous Sinus Thrombosis).\n\nPATHOPHYSIOLOGY:\nThe central face, specifically the triangular region bounded by the bridge of the nose superiorly and the corners of the mouth inferolaterally, is designated the 'danger triangle of the face' because of its unique and hazardous venous drainage. The facial vein in this region communicates with the pterygoid venous plexus via the deep facial vein and with the cavernous sinus via the ophthalmic veins. Critically, these venous connections lack valves, meaning blood can flow bidirectionally depending on pressure gradients. When a skin infection in this region, such as a furuncle or an infected comedone, is manipulated (squeezed or popped), the mechanical pressure can force bacteria and infected material retrograde through the valveless veins into the cavernous sinus. Staphylococcus aureus, including MRSA, is the most common causative organism. Once bacteria reach the cavernous sinus, a dural venous sinus located lateral to the sella turcica, they incite septic thrombosis within this critical intracranial structure.\n\nCLINICAL PRESENTATION:\nCavernous sinus thrombosis presents with the combination of systemic sepsis (high fever, rigors, toxicity) and cranial nerve dysfunction reflecting the anatomy of the cavernous sinus. Cranial nerves III, IV, V1, V2, and VI traverse or pass through the cavernous sinus wall, so thrombosis produces ophthalmoplegia (impaired eye movements), ptosis, periorbital edema, proptosis (from impaired venous drainage of the orbit), chemosis, and facial sensory deficits in the V1 and V2 distributions. Papilledema may develop from impaired retinal venous drainage. Because the two cavernous sinuses communicate via intercavernous sinuses, infection can spread to the contralateral side, producing bilateral symptoms, which is a classic diagnostic clue. Without treatment, mortality historically approached 80 to 100% and remains 20 to 30% even with modern antibiotics and anticoagulation, with significant morbidity including permanent cranial nerve palsies and pituitary insufficiency.\n\nDIAGNOSIS AND TREATMENT:\nMRI with magnetic resonance venography is the imaging modality of choice, demonstrating filling defects within the cavernous sinus and associated inflammatory changes. CT venography is an alternative when MRI is unavailable. Treatment requires aggressive IV antibiotics with broad-spectrum coverage including MRSA (vancomycin plus a beta-lactam such as ceftriaxone or meropenem) for a prolonged course of 3 to 4 weeks or more. The role of anticoagulation is debated, but most experts and current evidence support systemic heparin anticoagulation to prevent clot propagation, provided there is no hemorrhagic contraindication. Surgical drainage of the primary facial infection may be necessary.\n\nKEY LEARNING POINTS:\nThe danger triangle of the face has valveless venous connections to the cavernous sinus, allowing retrograde spread of infection from manipulated facial lesions. Cavernous sinus thrombosis presents with fever, cranial nerve palsies (III, IV, V1, V2, VI), proptosis, and chemosis, with bilateral involvement being a hallmark finding. Patients should be counseled never to squeeze or pop lesions in the central face. Mortality remains 20 to 30% despite modern therapy."
  },
  {
    "id": 241,
    "categoryId": 6,
    "question": "A 40-year-old female presents with the 'worst headache of my life' (Thunderclap) that reached max intensity in seconds. CT Head is negative. What is the mandatory next step?",
    "options": [
      "A) Discharge with NSAIDs",
      "B) MRI Brain",
      "C) Lumbar Puncture",
      "D) EEG"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Lumbar Puncture).\n\nSUBARACHNOID HEMORRHAGE EVALUATION:\nA thunderclap headache reaching maximal intensity within seconds is subarachnoid hemorrhage (SAH) until proven otherwise. SAH results from rupture of an intracranial aneurysm in approximately 85% of non-traumatic cases. Although CT head is the initial imaging study, a negative CT does not exclude SAH, particularly when imaging is performed more than 6 to 12 hours after symptom onset, making lumbar puncture mandatory in CT-negative cases with high clinical suspicion.\n\nPATHOPHYSIOLOGY:\nSaccular (berry) aneurysms develop at arterial branch points in the Circle of Willis, most commonly at the anterior communicating artery. Rupture releases arterial blood into the subarachnoid space, causing sudden severe headache, meningeal irritation, and potentially devastating complications including rebleeding, vasospasm, and hydrocephalus. Small sentinel leaks (warning leaks) may precede catastrophic rupture, making early detection lifesaving.\n\nDIAGNOSIS:\nNon-contrast CT detects SAH with approximately 98% sensitivity within 6 hours but sensitivity declines to 85-90% at 24 hours and continues to fall thereafter. When CT is negative, lumbar puncture is the definitive next step. CSF findings diagnostic of SAH include xanthochromia (yellow discoloration from bilirubin, a breakdown product of hemoglobin) and elevated red blood cell count that does not clear between tubes 1 and 4. CT angiography is then performed to identify the aneurysm.\n\nTREATMENT:\nConfirmed SAH requires immediate neurosurgical consultation for aneurysm securing via endovascular coiling (preferred) or surgical clipping. Nimodipine (a calcium channel blocker) is administered for 21 days to reduce the risk of delayed cerebral ischemia from vasospasm. Blood pressure control, seizure prophylaxis, and close neurological monitoring in an intensive care setting are essential components of management.\n\nKEY LEARNING POINTS:\nA thunderclap headache is SAH until proven otherwise; a negative CT does not exclude the diagnosis. Lumbar puncture looking for xanthochromia is mandatory when CT is negative and clinical suspicion is high. Missing a sentinel bleed can result in fatal aneurysm re-rupture."
  },
  {
    "id": 242,
    "categoryId": 7,
    "question": "A patient falls on an outstretched hand (FOOSH). X-rays of the wrist are negative, but he has tenderness in the 'Anatomical Snuffbox'. Management?",
    "options": [
      "A) Ace wrap and NSAIDs",
      "B) Thumb Spica Splint and repeat X-ray in 2 weeks",
      "C) Physical Therapy",
      "D) Cortisone injection"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Thumb spica splint and repeat X-ray in 2 weeks; treat as scaphoid fracture until proven otherwise).\n\nPATHOPHYSIOLOGY:\nThe scaphoid is the most commonly fractured carpal bone, accounting for approximately 60 to 70% of all carpal fractures, and typically results from a fall on an outstretched hand with the wrist dorsiflexed and radially deviated. The axial force transmitted through the palm compresses the scaphoid between the capitate and the radius, generating a fracture most commonly through the waist of the bone. The scaphoid has a uniquely vulnerable blood supply that enters the bone distally through branches of the radial artery, flowing in a retrograde direction from the distal pole toward the proximal pole. This retrograde vascular pattern means that fractures through the waist or proximal pole can disrupt blood flow to the proximal fragment, creating a significant risk of avascular necrosis.\n\nCLINICAL PRESENTATION:\nPatients present with radial-sided wrist pain after a FOOSH mechanism. The hallmark finding is tenderness in the anatomical snuffbox, the triangular depression bounded by the extensor pollicis longus tendon ulnarly and the extensor pollicis brevis and abductor pollicis longus tendons radially. Additional provocative maneuvers include pain with axial compression of the thumb (scaphoid compression test) and tenderness over the scaphoid tubercle on the palmar aspect of the wrist. However, initial radiographs (scaphoid series with posteroanterior, lateral, and oblique views including an ulnar deviation view) have a sensitivity of only approximately 70 to 80% for acute scaphoid fractures because the fracture line may be a nondisplaced hairline crack that is not visible until bone resorption along the fracture edges widens the gap over the subsequent 10 to 14 days.\n\nDIAGNOSIS AND MANAGEMENT:\nWhen clinical suspicion is high and initial radiographs are negative, the standard approach is to immobilize the wrist and thumb in a thumb spica splint or cast and repeat radiographs in 10 to 14 days, at which point bone resorption renders occult fractures visible. Alternatively, if early definitive diagnosis is required, MRI is the most sensitive and specific advanced imaging modality, approaching 100% sensitivity within 24 hours of injury, and is increasingly used as the initial follow-up study in many centers. CT scanning provides excellent bony detail and can detect fractures missed on plain films, though it is less sensitive than MRI for very early nondisplaced fractures. Nondisplaced waist fractures are treated with prolonged cast immobilization for 8 to 12 weeks, while displaced fractures (greater than 1 millimeter step-off or gap) and proximal pole fractures require surgical fixation with a headless compression screw to restore anatomic alignment and optimize vascular integrity. Avascular necrosis of the proximal pole develops in up to 30% of untreated or inadequately treated proximal pole fractures, leading to scaphoid nonunion advanced collapse and progressive wrist arthritis.\n\nKEY LEARNING POINTS:\nAnatomical snuffbox tenderness after a FOOSH injury must be treated as a scaphoid fracture until proven otherwise, even when initial radiographs are negative, because X-ray sensitivity is only 70 to 80% acutely. The scaphoid has a retrograde blood supply entering distally, placing the proximal pole at high risk for avascular necrosis when fractures disrupt this flow. Thumb spica immobilization with repeat imaging at 10 to 14 days or early MRI is the standard of care for suspected occult scaphoid fractures."
  },
  {
    "id": 243,
    "categoryId": 2,
    "question": "A child presents with sudden onset respiratory distress and drooling. The parents report a 'choking episode' while eating peanuts 2 days ago. Chest X-ray is normal. What is suspected?",
    "options": [
      "A) Asthma",
      "B) Foreign Body Aspiration",
      "C) Pneumonia",
      "D) Croup"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Foreign Body Aspiration).\n\nPATHOPHYSIOLOGY:\nForeign body aspiration occurs most commonly in children between 1 and 3 years of age due to their tendency to explore objects orally, incomplete dentition limiting proper mastication, and immature airway protective reflexes per Harrison's Principles of Internal Medicine. The most commonly aspirated items are organic materials (peanuts, seeds, grapes, hot dogs, popcorn) and small toys. Most aspirated objects lodge in the right mainstem bronchus in adults and older children (due to its wider diameter, shorter length, and more vertical orientation compared to the left), though in young children the angle of bifurcation is more symmetric and either side may be affected per UpToDate.\n\nCLINICAL REASONING:\nThis child presents with the classic scenario: a witnessed choking episode on peanuts followed by persistent respiratory distress and drooling. The critical teaching point is that organic materials (peanuts, food, seeds) and plastic objects are radiolucent and will not be visible on standard chest radiograph per the Cleveland Clinic and the Mayo Clinic. A normal chest X-ray does not rule out foreign body aspiration. Indirect radiographic signs include unilateral hyperinflation from ball-valve air trapping (the object allows air entry during inspiration when airways dilate but obstructs outflow during expiration when airways narrow), atelectasis from complete obstruction, or mediastinal shift. Inspiratory and expiratory films or bilateral decubitus films may demonstrate differential air trapping per UpToDate. When clinical suspicion is high based on history, even with a completely normal chest X-ray, rigid bronchoscopy is indicated for both diagnostic and therapeutic purposes.\n\nMANAGEMENT:\nRigid bronchoscopy is the gold standard for both diagnosis and removal of aspirated foreign bodies in children per Harrison's Principles of Internal Medicine. It provides superior visualization, ventilation capability during the procedure, and a large working channel for extraction instruments compared to flexible bronchoscopy. Delayed diagnosis (as in this case, 2 days after the event) increases the risk of complications including post-obstructive pneumonia, granulation tissue formation around the object, and bronchiectasis from chronic obstruction per UpToDate.\n\nKEY LEARNING POINTS:\nA normal chest X-ray does not rule out foreign body aspiration because peanuts, food, and plastic are radiolucent. Unilateral wheezing or air trapping from ball-valve obstruction on expiratory films is a key radiographic clue. Rigid bronchoscopy is the gold standard for diagnosis and removal, and clinical suspicion from a witnessed choking episode should prompt bronchoscopy regardless of X-ray findings."
  },
  {
    "id": 244,
    "categoryId": 15,
    "question": "The 'qSOFA' score identifies patients at high risk for poor outcomes from sepsis outside the ICU. It includes Altered Mental Status and which two other criteria?",
    "options": [
      "A) Fever > 38 and WBC > 12k",
      "B) Systolic BP < 100 and Respiratory Rate > 22",
      "C) HR > 90 and Lactate > 2",
      "D) Age > 65 and Diabetes"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Systolic BP less than or equal to 100 and Respiratory Rate greater than or equal to 22).\n\nPATHOPHYSIOLOGY:\nSepsis is defined by the Sepsis-3 consensus (published in JAMA 2016) as life-threatening organ dysfunction caused by a dysregulated host response to infection, operationalized as a suspected infection with an acute increase in the Sequential Organ Failure Assessment (SOFA) score of 2 or more points per Harrison's Principles of Internal Medicine. Septic shock is the subset in which circulatory and cellular metabolic abnormalities are severe enough to substantially increase mortality, defined as sepsis requiring vasopressors to maintain a mean arterial pressure of 65 mmHg or greater and a serum lactate greater than 2 mmol/L despite adequate fluid resuscitation per UpToDate.\n\nCLINICAL REASONING:\nThe qSOFA (quick SOFA) score is a bedside screening tool designed to identify patients with suspected infection who are at high risk for poor outcomes outside the ICU per the Sepsis-3 criteria. It consists of three clinical variables, each scored 1 point: altered mental status (Glasgow Coma Scale less than 15), systolic blood pressure less than or equal to 100 mmHg, and respiratory rate greater than or equal to 22 breaths per minute. A qSOFA score of 2 or more should prompt clinicians to investigate for organ dysfunction, initiate or escalate therapy, and consider ICU admission. The qSOFA is intentionally simple, requiring no laboratory testing, making it suitable for rapid bedside assessment in the emergency department or on the ward.\n\nMANAGEMENT:\nThe Surviving Sepsis Campaign Hour-1 Bundle mandates initiation of the following interventions within one hour of sepsis recognition per the Society of Critical Care Medicine and UpToDate: measure serum lactate (and repeat within 2 to 4 hours if initially elevated above 2 mmol/L), obtain blood cultures before antibiotic administration (but never delay antibiotics to obtain cultures), administer broad-spectrum empiric antibiotics, begin rapid intravenous crystalloid at 30 mL/kg for hypotension or lactate 4 mmol/L or greater, and start vasopressors (norepinephrine is first-line per the Cleveland Clinic) if hypotension persists after fluid resuscitation, targeting a mean arterial pressure of 65 mmHg or greater. Each hour of delay in antibiotic administration increases mortality. Hydrocortisone 200 mg per day should be considered for septic shock refractory to fluids and vasopressors per the Surviving Sepsis Campaign guidelines. Lactate clearance (greater than 10% decrease over 2 to 4 hours) is a useful marker of response to resuscitation per Harrison's Principles of Internal Medicine.\n\nKEY LEARNING POINTS:\nThe qSOFA score consists of altered mental status, systolic BP less than or equal to 100, and respiratory rate greater than or equal to 22, and a score of 2 or more at the bedside should prompt urgent evaluation for sepsis. The Surviving Sepsis Campaign Hour-1 Bundle requires lactate measurement, blood cultures, broad-spectrum antibiotics, fluid resuscitation, and vasopressors within one hour. Norepinephrine is the first-line vasopressor, and each hour of antibiotic delay increases mortality."
  },
  {
    "id": 245,
    "categoryId": 15,
    "question": "A patient presents with confusion, cherry-red skin, and anion gap metabolic acidosis after a house fire. Diagnosis and Antidote?",
    "options": [
      "A) Carbon Monoxide; Oxygen",
      "B) Cyanide Poisoning; Hydroxocobalamin",
      "C) Arsenic; Chelation",
      "D) Methemoglobinemia; Methylene Blue"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Cyanide Poisoning; Hydroxocobalamin).\n\nPATHOPHYSIOLOGY:\nCyanide is a mitochondrial toxin that binds to cytochrome c oxidase (Complex IV) in the electron transport chain, halting aerobic metabolism and forcing cells into anaerobic glycolysis even in the presence of adequate oxygen delivery per Harrison's Principles of Internal Medicine. This produces a state of cellular or histotoxic hypoxia in which tissues cannot utilize oxygen despite normal or elevated PaO2 and oxygen saturation. The resulting massive shift to anaerobic metabolism generates severe lactic acidosis. Cyanide is released during combustion of synthetic materials including plastics, wool, silk, nylon, and polyurethane commonly found in residential and industrial fires, making smoke inhalation the most common source of cyanide poisoning in clinical practice per UpToDate.\n\nCLINICAL REASONING:\nThis patient presents with confusion, cherry-red skin discoloration, and an anion gap metabolic acidosis following a house fire. The critical distinction from carbon monoxide poisoning, which also occurs in fire victims, is the presence of severe lactic acidosis (often greater than 8 mmol/L) per the Cleveland Clinic. Carbon monoxide poisoning produces cherry-red skin and altered mental status but typically does not cause a profound lactic acidosis because it impairs oxygen delivery rather than oxygen utilization. Cyanide poisoning causes a markedly elevated lactate because it blocks oxidative phosphorylation at the mitochondrial level. A serum lactate greater than 8 mmol/L in a fire victim should raise strong suspicion for concurrent cyanide toxicity per UpToDate. Many fire victims suffer combined carbon monoxide and cyanide poisoning simultaneously.\n\nTREATMENT:\nHydroxocobalamin (Cyanokit) is the preferred antidote per the Mayo Clinic and Harrison's Principles of Internal Medicine. It is a vitamin B12 precursor that binds directly to cyanide, forming cyanocobalamin (vitamin B12), which is renally excreted. The standard adult dose is 5 grams intravenously over 15 minutes. Hydroxocobalamin is safe in the setting of concurrent smoke inhalation and does not compromise oxygen-carrying capacity, unlike the older cyanide antidote kit (amyl nitrite, sodium nitrite, sodium thiosulfate), which induces methemoglobinemia to sequester cyanide and can worsen tissue hypoxia in patients with concomitant carbon monoxide poisoning. High-flow 100% oxygen should be administered to all smoke inhalation victims to address any concurrent carbon monoxide poisoning per UpToDate.\n\nKEY LEARNING POINTS:\nCyanide from burning synthetics blocks mitochondrial cytochrome c oxidase, causing histotoxic hypoxia with profound lactic acidosis (often greater than 8 mmol/L), which distinguishes it from pure carbon monoxide poisoning. Hydroxocobalamin is the preferred antidote because it does not induce methemoglobinemia and is safe in combined CO-cyanide exposure. All fire victims should receive high-flow oxygen, and concurrent CO and cyanide poisoning should be assumed until proven otherwise."
  },
  {
    "id": 246,
    "categoryId": 4,
    "question": "A patient with Addison's Disease (Adrenal Insufficiency) presents with vomiting and hypotension after a viral illness. BP is 80/50 and refractory to fluids. What medication is life-saving?",
    "options": [
      "A) Norepinephrine",
      "B) IV Hydrocortisone (Stress Dose)",
      "C) Oral Fludrocortisone",
      "D) Insulin"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (IV Hydrocortisone / Stress-dose Steroids).\n\nPATHOPHYSIOLOGY:\nAdrenal crisis (acute adrenal insufficiency) is an endocrine emergency with a mortality rate of approximately 6% per crisis episode and an estimated incidence of 6 to 8 adrenal crises per 100 patient-years among individuals with known adrenal insufficiency per data from the European Journal of Endocrinology and Harrison's Principles of Internal Medicine. The adrenal cortex normally produces cortisol under the regulation of the hypothalamic-pituitary-adrenal (HPA) axis, with basal daily output of approximately 5 to 10 mg. Under physiologic stress (illness, surgery, trauma), cortisol production increases 5 to 10-fold to support the cardiovascular and metabolic demands of the stress response. Cortisol is essential for maintaining vascular smooth muscle reactivity to catecholamines (without cortisol, blood vessels cannot constrict effectively in response to norepinephrine and epinephrine), maintaining cardiac contractility, supporting hepatic gluconeogenesis during fasting and stress, and modulating the inflammatory response. In primary adrenal insufficiency (Addison's disease), autoimmune destruction of the adrenal cortex eliminates the capacity for both cortisol and aldosterone production. When these patients encounter physiologic stress, they cannot mount the requisite cortisol surge, resulting in hemodynamic collapse that is characteristically refractory to intravenous fluids and vasopressors until exogenous cortisol is administered. Common precipitants include intercurrent illness (particularly gastrointestinal infections with vomiting that prevent oral steroid absorption), surgical stress, trauma, emotional distress, and abrupt discontinuation of chronic exogenous glucocorticoids (which causes secondary adrenal crisis due to HPA axis suppression).\n\nCLINICAL PRESENTATION:\nAdrenal crisis presents with profound hypotension refractory to fluid resuscitation and vasopressors, which is the clinical hallmark and should immediately suggest the diagnosis. Associated features include severe weakness, nausea, vomiting, abdominal pain (which may mimic an acute abdomen), fever (from the precipitating infection or from cortisol deficiency itself), altered mental status ranging from confusion to obtundation, and in some cases hypoglycemia (from impaired gluconeogenesis). Laboratory findings characteristically include hyponatremia (from impaired free water excretion due to cortisol deficiency and concurrent aldosterone-mediated sodium wasting in primary adrenal insufficiency), hyperkalemia (from aldosterone deficiency in primary disease), and non-anion-gap metabolic acidosis. In chronic primary adrenal insufficiency, hyperpigmentation of the skin and mucous membranes (from elevated ACTH and melanocyte-stimulating hormone derived from the shared proopiomelanocortin precursor) may be present as a diagnostic clue.\n\nTREATMENT:\nIntravenous hydrocortisone 100 mg bolus must be administered immediately upon clinical suspicion of adrenal crisis, without waiting for confirmatory laboratory results, as delay in treatment directly increases mortality. This is followed by 50 mg intravenously every 6 to 8 hours until the patient is stable and can resume oral replacement. At stress doses (greater than 50 mg per day), hydrocortisone provides sufficient mineralocorticoid activity that separate fludrocortisone supplementation is not required. Concurrent management includes aggressive intravenous fluid resuscitation with isotonic normal saline (patients may be 2 to 3 liters volume depleted), dextrose-containing fluids if hypoglycemic, and identification and treatment of the precipitating cause. If the diagnosis of adrenal insufficiency has not been previously established and cortisol testing is desired, dexamethasone 4 mg IV can be substituted for hydrocortisone as initial treatment because it does not cross-react with the cortisol immunoassay, allowing a random cortisol and ACTH level to be drawn during the crisis for subsequent diagnostic confirmation.\n\nPREVENTION:\nPatient education regarding sick day rules is the cornerstone of adrenal crisis prevention per Endocrine Society Clinical Practice Guidelines. During febrile illness, oral hydrocortisone dose should be doubled or tripled for the duration of the illness. If vomiting prevents oral medication absorption, the patient should use their emergency intramuscular hydrocortisone injection kit (100 mg IM) and proceed to emergency care. Patients should wear medical alert identification at all times. Before surgical procedures, stress-dose steroids (hydrocortisone 100 mg IV at induction, then 50 mg every 8 hours for 24 to 72 hours depending on surgical magnitude) must be administered per perioperative Endocrine Society guidelines.\n\nKEY LEARNING POINTS:\nAdrenal crisis presents with hypotension refractory to fluids and vasopressors because cortisol is required for vascular reactivity to catecholamines. Intravenous hydrocortisone 100 mg must be given immediately on clinical suspicion without waiting for laboratory confirmation. Sick day rules (doubling or tripling oral steroid dose during illness, intramuscular injection if vomiting) and medical alert identification are essential for preventing adrenal crisis in patients with known adrenal insufficiency."
  },
  {
    "id": 247,
    "categoryId": 15,
    "question": "You suspect bacterial meningitis in a febrile, confused patient. You cannot get a CT head immediately. What is the priority?",
    "options": [
      "A) Wait for CT before doing anything",
      "B) Perform Lumbar Puncture immediately",
      "C) Administer IV Antibiotics + Steroids immediately (before CT/LP)",
      "D) Observe"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Administer IV Antibiotics and Dexamethasone immediately).\n\nPATHOPHYSIOLOGY:\nBacterial meningitis is a life-threatening infection of the leptomeninges that carries an overall mortality of 15 to 25% and causes permanent neurological sequelae in 20 to 30% of survivors per Harrison's Principles of Internal Medicine. The most common causative organisms in adults are Streptococcus pneumoniae (the most common and most lethal) and Neisseria meningitidis, while Listeria monocytogenes must be covered in patients over age 50, immunocompromised individuals, and pregnant women per UpToDate. The inflammatory cascade triggered by bacterial replication in the subarachnoid space causes cerebral edema, increased intracranial pressure, cerebral ischemia, and cortical necrosis.\n\nCLINICAL REASONING:\nThe cardinal principle in suspected bacterial meningitis is that antibiotics must never be delayed for diagnostic testing per the Infectious Diseases Society of America guidelines and Harrison's Principles of Internal Medicine. Each hour of delay in antibiotic administration significantly increases mortality and neurological morbidity. This patient is febrile and confused, strongly suggesting bacterial meningitis. Because CT is not immediately available, the correct sequence is to draw blood cultures, then immediately administer empiric intravenous antibiotics and adjunctive dexamethasone, and subsequently obtain CT and lumbar puncture when feasible. Dexamethasone (0.15 mg/kg every 6 hours for 4 days) should be given 15 to 20 minutes before or simultaneously with the first antibiotic dose, as it reduces mortality and hearing loss in pneumococcal meningitis by attenuating the inflammatory response to bacterial lysis per UpToDate.\n\nINDICATIONS FOR CT BEFORE LUMBAR PUNCTURE:\nCT head before LP is indicated only when specific risk factors for herniation are present per the IDSA guidelines: altered mental status or decreased level of consciousness, focal neurological deficits, new-onset seizures, papilledema, immunocompromised state, or history of CNS mass lesion. Patients without these features can proceed directly to LP without CT per UpToDate. A negative CT does not exclude elevated intracranial pressure, but the risk of herniation from LP in bacterial meningitis is low and the risk of delayed treatment is high per the Cleveland Clinic.\n\nEMPIRIC ANTIBIOTIC REGIMENS:\nStandard empiric therapy for adults aged 18 to 50 is vancomycin plus a third-generation cephalosporin (ceftriaxone or cefotaxime). Ampicillin is added for Listeria coverage in patients over age 50 or immunocompromised individuals per Harrison's Principles of Internal Medicine and NCCN guidelines.\n\nKEY LEARNING POINTS:\nAntibiotics must never be delayed for CT or LP when bacterial meningitis is strongly suspected, as each hour of delay increases mortality. Dexamethasone given before or with the first antibiotic dose reduces mortality and hearing loss in pneumococcal meningitis. CT before LP is required only when specific herniation risk factors are present, and a negative CT does not exclude elevated intracranial pressure."
  },
  {
    "id": 248,
    "categoryId": 7,
    "question": "A patient with a tibial fracture develops severe pain out of proportion to injury, pain with passive stretch of the toes, and a 'woody' hard calf. Diagnosis?",
    "options": [
      "A) DVT",
      "B) Compartment Syndrome",
      "C) Nerve damage",
      "D) Hematoma"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Compartment Syndrome).\n\nPATHOPHYSIOLOGY:\nCompartment syndrome is an orthopedic emergency caused by elevated pressure within a closed osseofascial compartment that exceeds capillary perfusion pressure, resulting in ischemia and eventual necrosis of the enclosed muscles and nerves. The lower leg contains four fascial compartments (anterior, lateral, superficial posterior, and deep posterior), each bounded by rigid, noncompliant fascia and bone that cannot expand to accommodate swelling. Following a tibial fracture, hemorrhage and soft tissue edema increase intracompartmental volume, raising the pressure within the closed space. When compartment pressure approaches or exceeds the diastolic blood pressure, the transmural pressure gradient across capillary walls collapses, halting tissue perfusion. This creates a vicious cycle in which ischemia produces further cellular edema, which further elevates compartment pressure, which worsens ischemia. Irreversible muscle necrosis begins within approximately 6 hours of sustained ischemia, and nerve damage can occur even sooner.\n\nCLINICAL PRESENTATION:\nThe earliest and most sensitive finding is pain out of proportion to the apparent injury, a hallmark symptom that should immediately raise clinical suspicion. Pain with passive stretch of the muscles within the affected compartment is the most reliable early provocative sign. In the anterior compartment of the leg, passive plantarflexion of the toes stretches the extensor muscles and reproduces severe pain. The compartment feels tense and woody on palpation, reflecting the elevated pressure within. Paresthesias in the distribution of the nerves traversing the compartment develop as nerve ischemia progresses, followed by progressive motor weakness. A critical clinical pearl is that peripheral pulses are typically preserved until very late in the disease process because compartment syndrome compromises capillary and venous flow at the microvascular level long before arterial inflow is affected. Waiting for pulselessness to confirm the diagnosis is a catastrophic error that results in irreversible tissue loss.\n\nDIAGNOSIS AND MANAGEMENT:\nCompartment syndrome is primarily a clinical diagnosis based on the constellation of pain out of proportion, pain with passive stretch, tense compartment, and progressive neurologic symptoms. When clinical findings are equivocal or the patient cannot participate in examination (obtunded, intubated, or pediatric patients), direct intracompartmental pressure measurement using a Stryker needle or arterial line catheter is indicated. An absolute compartment pressure exceeding 30 mmHg or a delta pressure (diastolic blood pressure minus compartment pressure) of less than 30 mmHg is the threshold for surgical intervention. Emergent fasciotomy with complete release of all involved compartments is the definitive treatment and must be performed without delay. The fasciotomy incisions are left open and covered with sterile dressings, with delayed primary closure or skin grafting performed 48 to 72 hours later once swelling has resolved. Delay in fasciotomy beyond 6 to 8 hours is associated with Volkmann ischemic contracture (in the upper extremity) or permanent neuromuscular deficit, myoglobinuric renal failure from rhabdomyolysis, and potential limb loss.\n\nKEY LEARNING POINTS:\nPain out of proportion to injury and pain with passive stretch of the involved compartment muscles are the earliest and most sensitive clinical findings in compartment syndrome. Peripheral pulses are preserved until very late because compartment syndrome compromises microvascular perfusion, not arterial inflow, and waiting for pulselessness is a dangerous error. Emergent fasciotomy must be performed within 6 hours of symptom onset to prevent irreversible muscle necrosis, Volkmann contracture, and rhabdomyolysis-induced renal failure."
  },
  {
    "id": 249,
    "categoryId": 15,
    "question": "ECG shows 'Peaked T Waves' and widened QRS. What is the electrolyte abnormality and the FIRST medication to give?",
    "options": [
      "A) Hyperkalemia; Calcium Gluconate",
      "B) Hyperkalemia; Insulin",
      "C) Hypokalemia; Magnesium",
      "D) Hypocalcemia; Calcium"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Hyperkalemia; Calcium Gluconate).\n\nPATHOPHYSIOLOGY:\nHyperkalemia (serum potassium greater than 5.0 mEq/L) is a potentially lethal electrolyte emergency because potassium is the primary determinant of the resting membrane potential of cardiac myocytes per Harrison's Principles of Internal Medicine. As extracellular potassium rises, the resting membrane potential becomes less negative (partially depolarized), which initially increases excitability but progressively impairs sodium channel recovery and slows conduction velocity. The characteristic ECG progression with rising potassium per UpToDate is: peaked T waves (earliest finding, potassium approximately 5.5 to 6.5), PR prolongation (6.5 to 7.0), loss of P waves (7.0 to 7.5), widened QRS complex (7.0 to 8.0), sine wave pattern (greater than 8.0), and ultimately ventricular fibrillation or asystole. Common causes include acute or chronic kidney disease (the most common cause), medications (ACE inhibitors, ARBs, potassium-sparing diuretics, NSAIDs), rhabdomyolysis, tumor lysis syndrome, and adrenal insufficiency per the Cleveland Clinic.\n\nCLINICAL REASONING:\nPeaked T waves with widened QRS on ECG in the setting of hyperkalemia represent an immediate threat of cardiac arrest. The treatment follows a three-tiered approach per Harrison's Principles of Internal Medicine and UpToDate. The first priority is cardiac membrane stabilization with intravenous calcium gluconate (10 mL of 10% solution over 2 to 3 minutes), which raises the threshold potential and restores the normal gradient between resting and threshold potentials, stabilizing the myocardium against arrhythmia within 1 to 3 minutes. Calcium does not lower serum potassium but buys critical time. The second tier is intracellular potassium shifting using regular insulin (10 units IV with 25 grams of dextrose to prevent hypoglycemia), which activates the Na-K-ATPase to drive potassium into cells, and inhaled albuterol (10 to 20 mg nebulized), which also promotes transcellular shift via beta-2 receptor stimulation. Sodium bicarbonate is less reliable for shifting and is reserved for concurrent metabolic acidosis per UpToDate. The third tier is total body potassium elimination via sodium polystyrene sulfonate (Kayexalate), patiromer, sodium zirconium cyclosilicate, loop diuretics, or hemodialysis (the most effective and definitive method for severe or refractory hyperkalemia) per the Mayo Clinic.\n\nKEY LEARNING POINTS:\nCalcium gluconate is always the first medication given in hyperkalemia with ECG changes because it stabilizes the cardiac membrane within minutes, though it does not lower potassium. The three-tiered treatment approach is stabilize (calcium), shift (insulin plus dextrose, albuterol), and eliminate (dialysis, binding resins, diuretics). Peaked T waves are the earliest ECG finding, and widened QRS indicates imminent risk of fatal arrhythmia."
  },
  {
    "id": 250,
    "categoryId": 17,
    "question": "A patient typically presents with 'Hot Potato Voice', trismus (lockjaw), and uvula deviation to the opposite side. Diagnosis?",
    "options": [
      "A) Strep Throat",
      "B) Peritonsillar Abscess",
      "C) Mononucleosis",
      "D) Epiglottitis"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Peritonsillar abscess).\n\nPATHOPHYSIOLOGY:\nA peritonsillar abscess is a deep infection between the tonsillar capsule and pharyngeal muscles, often evolving from tonsillitis. It is commonly polymicrobial (GAS plus anaerobes).\n\nCLINICAL MANIFESTATIONS:\n- Fever, severe unilateral sore throat\n- Trismus, muffled 'hot potato' voice\n- Uvula deviation away from the affected side; unilateral tonsillar bulge\n\nDIAGNOSIS:\nClinical diagnosis is common. Consider imaging (CT neck with contrast) if diagnosis is unclear, concern for deep neck space infection, or poor exam.\n\nTREATMENT:\nAirway assessment first. Drainage (needle aspiration or I&D) plus antibiotics covering GAS and anaerobes (e.g., ampicillin-sulbactam or clindamycin). ENT consult if complications or failed drainage.\n\nREFERENCES:\nUpToDate; IDSA pharyngitis guidance; Harrison's Principles of Internal Medicine.\n---"
  },
  {
    "id": 251,
    "categoryId": 15,
    "question": "Cord Prolapse (umbilical cord visible/palpable ahead of the baby) occurs in your clinic during an precipitous delivery. Management?",
    "options": [
      "A) Push the cord back in",
      "B) Elevate the presenting part (lift baby's head off the cord) and emergency C-Section",
      "C) Deliver immediately",
      "D) Place mother in trendelenburg and wait"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Elevate the presenting part off the cord and proceed to emergency Cesarean section).\n\nPATHOPHYSIOLOGY:\nUmbilical cord prolapse occurs when the umbilical cord descends through the cervix ahead of or alongside the fetal presenting part, and is an obstetric emergency because compression of the cord between the presenting part and the maternal pelvis occludes the umbilical vessels, cutting off fetal blood flow and oxygen supply per UpToDate. Without immediate intervention, sustained cord compression causes fetal hypoxia, bradycardia, acidosis, and death or permanent neurological injury within minutes. Risk factors include premature rupture of membranes, polyhydramnios, malpresentation (transverse lie, breech), multiparity, and unengaged presenting part at the time of membrane rupture per Harrison's Principles of Internal Medicine.\n\nCLINICAL REASONING:\nWhen cord prolapse is identified (the cord is visible at the introitus or palpable on vaginal examination), the immediately life-saving maneuver is to insert a gloved hand into the vagina and manually elevate the fetal presenting part away from the prolapsed cord, relieving compression per ACOG guidelines. The hand must remain in place continuously, maintaining upward pressure on the presenting part, while the patient is urgently transported for emergency Cesarean delivery. The cord must never be pushed back into the uterus, as manipulation can cause vasospasm and worsen ischemia per UpToDate. Positioning the mother in steep Trendelenburg or knee-chest position uses gravity to shift the presenting part away from the cord and may provide additional relief. If the cord is exposed and dry, it can be wrapped in warm saline-soaked gauze to minimize vasospasm, but manual elevation of the presenting part is the critical intervention per the Mayo Clinic.\n\nMANAGEMENT:\nEmergency Cesarean section is the definitive treatment and should be performed as rapidly as possible (decision-to-delivery interval ideally less than 30 minutes) per ACOG guidelines. Fetal heart rate monitoring should be continuous, and neonatal resuscitation should be prepared. Tocolysis with terbutaline may be considered to reduce uterine contractions and further decrease cord compression during transport per UpToDate.\n\nKEY LEARNING POINTS:\nCord prolapse requires immediate manual elevation of the presenting part off the cord (hand in vagina lifting the fetal head) followed by emergency Cesarean section. The cord must never be pushed back in, as this causes vasospasm. Steep Trendelenburg or knee-chest positioning uses gravity to assist cord decompression while preparing for operative delivery."
  },
  {
    "id": 252,
    "categoryId": 11,
    "question": "A patient with Schizophrenia presents with fever, muscle rigidity, and confusion. CPK is 50,000. Diagnosis?",
    "options": [
      "A) Catatonia",
      "B) Neuroleptic Malignant Syndrome (NMS)",
      "C) Serotonin Syndrome",
      "D) Malignant Hyperthermia"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Neuroleptic Malignant Syndrome).\n\nPATHOPHYSIOLOGY:\nNeuroleptic Malignant Syndrome (NMS) is a life-threatening idiosyncratic reaction to dopamine D2 receptor-blocking agents, occurring most frequently with high-potency first-generation antipsychotics (haloperidol, fluphenazine) but also reported with second-generation antipsychotics and antiemetics (metoclopramide, prochlorperazine) per Harrison's Principles of Internal Medicine. The syndrome results from acute central dopaminergic blockade in the hypothalamus (producing hyperthermia and autonomic instability), nigrostriatal pathway (producing rigidity), and mesocortical pathway (producing altered mental status) per UpToDate. The massively elevated CPK of 50,000 IU/L in this case reflects severe rhabdomyolysis from sustained skeletal muscle rigidity, which is a hallmark laboratory finding that distinguishes NMS from other hyperthermic emergencies per the Cleveland Clinic.\n\nCLINICAL PRESENTATION:\nThe classic tetrad is captured by the mnemonic FARM: Fever (often exceeding 104Â°F/40Â°C), Autonomic instability (labile blood pressure, tachycardia, diaphoresis, tachypnea), Rigidity (\"lead-pipe\" quality with continuous resistance throughout passive range of motion), and Mental status change (confusion to coma) per Harrison's Principles of Internal Medicine. NMS typically develops over 1 to 3 days (slower onset than serotonin syndrome) and can occur at any point during antipsychotic therapy, though it is most common in the first 2 weeks of treatment or after dose escalation per UpToDate and Harvard Health.\n\nDIFFERENTIAL DIAGNOSIS:\nNMS is distinguished from serotonin syndrome by the absence of clonus and hyperreflexia (NMS features rigidity with normal or decreased reflexes), slower onset (days versus hours), the causative drug class (dopamine antagonists versus serotonergic agents), and markedly higher CPK elevations per the Mayo Clinic. Malignant hyperthermia occurs exclusively after exposure to volatile anesthetics or succinylcholine, not antipsychotics. Lethal catatonia can appear identical and may require empiric treatment with lorazepam per UpToDate.\n\nMANAGEMENT:\nImmediate discontinuation of the antipsychotic is essential per the Cleveland Clinic. Aggressive IV hydration prevents acute renal failure from myoglobinuria. Dantrolene (a ryanodine receptor antagonist that directly inhibits skeletal muscle calcium release) reduces rigidity and hyperthermia. Bromocriptine or amantadine (dopamine agonists) restore central dopaminergic transmission. ICU monitoring for cardiac arrhythmias, respiratory failure, and DIC is required per Harrison's Principles of Internal Medicine.\n\nKEY LEARNING POINTS:\nNMS presents with the FARM tetrad (Fever, Autonomic instability, Rigidity, Mental status change) with massively elevated CPK from rhabdomyolysis, developing over days after antipsychotic exposure. Lead-pipe rigidity with decreased reflexes distinguishes NMS from serotonin syndrome (which features clonus and hyperreflexia). Treatment requires immediate antipsychotic discontinuation, IV hydration, and dantrolene or bromocriptine."
  },
  {
    "id": 253,
    "categoryId": 15,
    "question": "Priapism (erection > 4 hours) is an emergency because:",
    "options": [
      "A) It is embarrassing",
      "B) It causes urinary retention",
      "C) It leads to cavernosal fibrosis and permanent impotence",
      "D) It causes infection"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (It leads to cavernosal fibrosis and permanent impotence).\n\nPATHOPHYSIOLOGY:\nIschemic (low-flow or veno-occlusive) priapism is a urologic emergency resulting from failure of venous outflow from the corpora cavernosa, causing blood to become trapped, deoxygenated, and acidotic within the erectile tissue per Harrison's Principles of Internal Medicine. The stagnant, deoxygenated blood creates a compartment syndrome of the penis: progressive tissue hypoxia and acidosis cause endothelial damage, smooth muscle edema, and eventually irreversible smooth muscle necrosis and fibrosis of the corporal tissue. Smooth muscle necrosis begins after approximately 4 to 6 hours, and the risk of permanent erectile dysfunction increases dramatically with each hour of ischemia beyond this window per UpToDate. After 24 to 48 hours, fibrosis is nearly universal, resulting in permanent impotence.\n\nCLINICAL PRESENTATION:\nIschemic priapism presents as a painful, fully rigid erection lasting more than 4 hours, with the corpora cavernosa engorged and the glans penis and corpus spongiosum characteristically soft (flaccid) per the American Urological Association guidelines. Common causes include sickle cell disease (the most common cause in children, due to sickling of erythrocytes within the corpora), medications (intracavernosal injection therapy for erectile dysfunction, trazodone, antipsychotics), illicit drug use (cocaine), and idiopathic cases per the Cleveland Clinic. Corporal blood gas analysis showing dark blood with PaO2 less than 30 mmHg and pH less than 7.25 confirms the ischemic type.\n\nTREATMENT:\nFirst-line treatment per the AUA and UpToDate is corporal aspiration of the stagnant blood using a large-bore needle (16 to 18 gauge) inserted into the lateral aspect of the corpus cavernosum, followed by irrigation with normal saline. If aspiration alone fails, intracavernosal injection of a sympathomimetic agent (phenylephrine, an alpha-1 agonist, is preferred because of its minimal beta-adrenergic cardiac effects) is administered in dilute aliquots (100 to 500 micrograms every 3 to 5 minutes) to cause smooth muscle contraction and restore venous outflow per the Mayo Clinic. Surgical shunt procedures (distal cavernosum-spongiosum shunts) are reserved for cases refractory to aspiration and phenylephrine.\n\nKEY LEARNING POINTS:\nIschemic priapism is a urologic emergency because smooth muscle necrosis and irreversible fibrosis of the corpora cavernosa begin after 4 to 6 hours, leading to permanent erectile dysfunction. Treatment is corporal aspiration followed by intracavernosal phenylephrine injection. Sickle cell disease is the most common cause in children, while medications (trazodone, antipsychotics, intracavernosal injections) are common causes in adults."
  },
  {
    "id": 254,
    "categoryId": 12,
    "question": "A 2-year-old is swung by the arms and now refuses to use the left arm, holding it pronated and flexed. Diagnosis and Treatment?",
    "options": [
      "A) Clavicle fracture; Sling",
      "B) Nursemaid's Elbow; Reduction (Supination/Flexion)",
      "C) Supracondylar fracture; Surgery",
      "D) Shoulder dislocation; Reduction"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Nursemaid's Elbow; Reduction by Supination and Flexion).\n\nPATHOPHYSIOLOGY:\nNursemaid's elbow (radial head subluxation) is the most common elbow injury in children under 5 years, resulting from a sudden longitudinal traction force applied to the extended, pronated forearm per UpToDate. The mechanism typically involves a child being swung, lifted, or pulled by the hand or wrist (hence the historical name). The annular ligament, which encircles the radial head and holds it in articulation with the ulna, is relatively loose in young children and slips over the radial head when traction is applied, becoming interposed between the radial head and the capitellum of the humerus per Harrison's Principles of Internal Medicine. After approximately age 5, the annular ligament strengthens and the radial head enlarges, making subluxation much less likely per the Cleveland Clinic.\n\nCLINICAL PRESENTATION:\nThe child presents holding the affected arm in the classic position of slight flexion and pronation against the body, refusing to use the arm (pseudoparalysis) per the Mayo Clinic. There is no swelling, deformity, or ecchymosis, and the child is not in severe distress but will resist any attempt to supinate the forearm or extend the elbow. The history of a pulling or swinging mechanism is usually clear. Radiographs are typically normal because the subluxation involves a soft tissue interposition rather than a bony displacement, and imaging is unnecessary when the history and presentation are classic per UpToDate.\n\nTREATMENT:\nReduction is performed at the bedside without sedation or imaging per the Cleveland Clinic. The hyperpronation technique (firmly supinating the forearm with one hand while the other stabilizes the elbow, feeling for a palpable click at the radial head) or the supination-flexion technique (supinating the forearm and then fully flexing the elbow in one smooth motion) are both effective, with hyperpronation having slightly higher first-attempt success rates in some studies per UpToDate. A palpable click is felt as the annular ligament reduces, and the child typically resumes full use of the arm within 5 to 15 minutes. If the child does not improve after two reduction attempts, radiographs should be obtained to evaluate for occult fracture per the Mayo Clinic.\n\nKEY LEARNING POINTS:\nNursemaid's elbow results from axial traction on an extended pronated arm causing the annular ligament to slip over the radial head, and it is the most common elbow injury in children under 5. The child holds the arm pronated and flexed, refusing to use it, with normal radiographs. Reduction by supination-flexion or hyperpronation produces a palpable click and rapid return to normal function."
  },
  {
    "id": 255,
    "categoryId": 15,
    "question": "In a trauma patient, Cushing's Triad indicates increased Intracranial Pressure (ICP). The triad is:",
    "options": [
      "A) Hypertension, Bradycardia, Irregular Respirations",
      "B) Hypotension, Tachycardia, Tachypnea",
      "C) Fever, Neck stiffness, Rash",
      "D) Muffled heart sounds, JVD, Hypotension"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Hypertension, Bradycardia, Irregular Respirations).\n\nPATHOPHYSIOLOGY:\nCushing's triad is a late and ominous clinical sign of critically elevated intracranial pressure indicating impending brainstem herniation per Harrison's Principles of Internal Medicine. As intracranial pressure rises and approaches mean arterial pressure, cerebral perfusion pressure (CPP = MAP minus ICP) falls below the threshold needed to maintain adequate brainstem blood flow. The brainstem ischemia triggers a powerful sympathetic surge known as the Cushing reflex or vasomotor center response: systemic hypertension develops as the body attempts to force blood through the compressed cerebral vasculature to restore brainstem perfusion. The resulting hypertension is sensed by the aortic arch and carotid sinus baroreceptors, which trigger a reflex bradycardia via vagal stimulation of the sinoatrial node per UpToDate. Irregular respirations (Cheyne-Stokes, ataxic, or apneustic breathing patterns) reflect direct compression of the brainstem respiratory centers in the pons and medulla. The complete triad of hypertension, bradycardia, and irregular respirations constitutes Cushing's triad per the Cleveland Clinic.\n\nCLINICAL SIGNIFICANCE:\nCushing's triad is a pre-terminal finding indicating that brainstem herniation is imminent or actively occurring, and it demands immediate intervention per Harrison's Principles of Internal Medicine. It is most commonly seen in the setting of traumatic brain injury with expanding epidural or subdural hematomas, massive intracerebral hemorrhage, or obstructive hydrocephalus. The presence of Cushing's triad in a trauma patient should trigger emergent neurosurgical consultation and temporizing measures to reduce ICP.\n\nMANAGEMENT:\nImmediate temporizing measures to reduce ICP per UpToDate and the Brain Trauma Foundation guidelines include elevation of the head of bed to 30 degrees, administration of hyperosmolar therapy (mannitol 1 g/kg IV bolus or hypertonic saline 23.4% 30 mL via central line), brief hyperventilation to a target PaCO2 of 30 to 35 mmHg (which causes cerebral vasoconstriction and rapid but temporary ICP reduction), and ensuring adequate sedation and analgesia. Definitive treatment requires emergent neurosurgical intervention (craniotomy for hematoma evacuation or decompressive craniectomy) or external ventricular drain placement per the Mayo Clinic.\n\nKEY LEARNING POINTS:\nCushing's triad (hypertension, bradycardia, irregular respirations) is a late, pre-terminal sign of critically elevated ICP indicating imminent brainstem herniation that demands emergent intervention. The Cushing reflex produces hypertension as the brainstem attempts to maintain perfusion against rising ICP, with reflex bradycardia from baroreceptor activation. Immediate temporizing measures include head elevation, hyperosmolar therapy, and brief hyperventilation while arranging emergent neurosurgery."
  },
  {
    "id": 256,
    "categoryId": 15,
    "question": "An avulsed permanent tooth (knocked out) has the best chance of survival if reimplanted within:",
    "options": [
      "A) 5 minutes",
      "B) 60 minutes",
      "C) 6 hours",
      "D) 24 hours"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Within 60 minutes).\n\nPATHOPHYSIOLOGY:\nWhen a permanent tooth is avulsed (completely displaced from its socket), the viability of the periodontal ligament (PDL) cells remaining on the root surface is the single most important determinant of successful reimplantation and long-term tooth survival per UpToDate. PDL cells begin to undergo necrosis within 15 to 20 minutes of dry storage at room temperature, and cell viability decreases rapidly with time. Reimplantation within 60 minutes provides the highest probability of functional healing with regeneration of the periodontal ligament, whereas delays beyond 60 minutes are associated with progressive root resorption and eventual tooth loss per the American Association of Endodontists and the International Association of Dental Traumatology guidelines.\n\nCLINICAL MANAGEMENT:\nThe avulsed tooth should be handled only by the crown (the white enamel-covered portion) and never by the root, as touching the root damages the delicate PDL cells per the Mayo Clinic. If the root is visibly contaminated, it should be gently rinsed with saline or milk for no more than 10 seconds without scrubbing. Ideally, the tooth should be reimplanted immediately at the scene by gently inserting it into the socket and having the patient bite on gauze or a cloth to hold it in position. If immediate reimplantation is not possible, the tooth must be kept moist in a physiologic transport medium to preserve PDL cell viability per UpToDate and the Cleveland Clinic. Hank's Balanced Salt Solution (available in commercial tooth preservation kits such as the Save-A-Tooth system) is the optimal transport medium. Cold milk is the best readily available alternative due to its physiologic osmolality and pH. The patient's own saliva (placing the tooth in the buccal vestibule) is acceptable in cooperative adults. Tap water is harmful because its hypotonicity causes rapid osmotic lysis of PDL cells and should be avoided per the AAE.\n\nFOLLOW-UP:\nOnce reimplanted, the tooth requires flexible splinting for 2 weeks to allow PDL healing, and the patient should be referred to an endodontist for root canal therapy (typically initiated 7 to 10 days after reimplantation) because the pulp will be necrotic per UpToDate. Primary (baby) teeth should not be reimplanted due to the risk of damage to the developing permanent tooth bud underneath.\n\nKEY LEARNING POINTS:\nAn avulsed permanent tooth has the best prognosis when reimplanted within 60 minutes, as periodontal ligament cell viability declines rapidly with dry storage time. Handle the tooth by the crown only, never the root. Hank's solution is the optimal transport medium, with cold milk as the best readily available alternative, and tap water should be avoided because it causes osmotic lysis of PDL cells."
  },
  {
    "id": 257,
    "categoryId": 13,
    "question": "Septic Arthritis vs Gout. A joint aspiration is performed. What WBC count confirms Septic Arthritis?",
    "options": [
      "A) > 2,000",
      "B) > 10,000",
      "C) > 50,000",
      "D) > 100,000"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Greater than 50,000 WBC/mm3).\n\nSYNOVIAL FLUID ANALYSIS:\nJoint aspiration with synovial fluid analysis is the single most important diagnostic test for differentiating septic arthritis from crystal arthropathy and other causes of acute monoarthritis. Synovial fluid WBC counts provide a useful diagnostic framework. Normal synovial fluid contains fewer than 200 WBC/mm3. Non-inflammatory conditions such as osteoarthritis typically show fewer than 2,000 WBC/mm3. Inflammatory arthritis (gout, pseudogout, rheumatoid arthritis) generally produces counts between 2,000 and 50,000 WBC/mm3, though gout can occasionally exceed 50,000. A WBC count greater than 50,000 WBC/mm3 with greater than 90 percent neutrophils is highly suggestive of septic arthritis and should be treated as infection until proven otherwise.\n\nSEPTIC ARTHRITIS AS A MEDICAL EMERGENCY:\nSeptic arthritis is an orthopedic emergency because bacterial enzymes and the inflammatory response can destroy articular cartilage within hours to days. Staphylococcus aureus is the most common causative organism in adults (responsible for approximately 40 to 50 percent of cases), followed by streptococcal species. Neisseria gonorrhoeae should be considered in sexually active young adults presenting with migratory polyarthralgia, tenosynovitis, and dermatitis preceding septic monoarthritis. Risk factors include pre-existing joint disease (especially rheumatoid arthritis), prosthetic joints, immunosuppression, diabetes, intravenous drug use, and skin infections.\n\nDIAGNOSTIC APPROACH:\nIn addition to cell count and differential, synovial fluid should be sent for Gram stain (positive in approximately 50 to 75 percent of non-gonococcal cases), culture (the most definitive test), and polarized light microscopy for crystals. Critically, the presence of crystals does not exclude concurrent infection, as gout and septic arthritis can coexist. Blood cultures should be obtained in all suspected cases. If septic arthritis is suspected based on clinical presentation and fluid analysis, empiric antibiotics and urgent orthopedic consultation for joint drainage (arthroscopic lavage or serial needle aspiration) should not be delayed.\n\nKEY LEARNING POINTS:\nA synovial fluid WBC count greater than 50,000/mm3 with neutrophil predominance is highly suggestive of septic arthritis until proven otherwise. Gram stain and culture of synovial fluid are essential, but treatment should not await results. Crystal arthropathy and septic arthritis can coexist, so the presence of crystals does not rule out infection. Septic arthritis requires emergent antibiotics and joint drainage to prevent irreversible cartilage destruction."
  },
  {
    "id": 258,
    "categoryId": 15,
    "question": "Boerhaave's Syndrome is:",
    "options": [
      "A) Mucosal tear at the GE junction (Mallory-Weiss)",
      "B) Full-thickness Esophageal Rupture",
      "C) Gastric Volvulus",
      "D) Pyloric Stenosis"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Full-thickness Esophageal Rupture).\n\nPATHOPHYSIOLOGY:\nBoerhaave syndrome is a transmural (full-thickness) perforation of the esophagus caused by a sudden rise in intraesophageal pressure against a closed glottis, most commonly during forceful or protracted vomiting per Harrison's Principles of Internal Medicine. The perforation typically occurs in the left posterolateral distal esophagus, approximately 2 to 3 cm above the gastroesophageal junction, which is the weakest point of the esophageal wall due to the absence of reinforcing serosal covering and the natural thinning at the junction of the longitudinal muscle fibers per UpToDate. This is distinct from Mallory-Weiss syndrome, which involves only a partial-thickness mucosal tear at the gastroesophageal junction and is typically self-limited. Boerhaave syndrome carries a mortality rate of 20 to 40% even with treatment, rising to nearly 100% if diagnosis and surgical repair are delayed beyond 24 hours per the Cleveland Clinic.\n\nCLINICAL PRESENTATION:\nThe classic presentation, known as Mackler triad, is vomiting (or retching) followed by severe lower thoracic or epigastric pain and subcutaneous emphysema (crepitus) per Harrison's Principles of Internal Medicine. Hamman sign, a crunching or crackling sound heard on cardiac auscultation that is synchronous with the heartbeat (mediastinal crunch), results from air tracking into the mediastinum (pneumomediastinum) through the esophageal perforation. Patients frequently develop signs of sepsis rapidly as gastric contents and oral flora contaminate the mediastinum and pleural space, causing mediastinitis and empyema. A left-sided pleural effusion is common due to the location of the perforation. The diagnosis is confirmed by CT of the chest with oral water-soluble contrast (Gastrografin) demonstrating extraluminal contrast leakage per UpToDate.\n\nMANAGEMENT:\nBoerhaave syndrome is a surgical emergency requiring emergent operative repair (primary closure with tissue reinforcement) or esophageal diversion in cases of delayed diagnosis with extensive mediastinal contamination per the Mayo Clinic. Broad-spectrum antibiotics, aggressive fluid resuscitation, and chest tube drainage of any pleural collection are initiated immediately. Select patients with contained perforations, minimal contamination, and no sepsis may be candidates for conservative management with nil per os, IV antibiotics, and endoscopic stent placement per UpToDate.\n\nKEY LEARNING POINTS:\nBoerhaave syndrome is full-thickness esophageal rupture from forceful vomiting (distinct from partial-thickness Mallory-Weiss tear), occurring at the left posterolateral distal esophagus. Mackler triad (vomiting, chest pain, subcutaneous emphysema) and Hamman sign (mediastinal crunch) are classic findings. Mortality approaches 100% without timely surgical repair, making early recognition critical."
  },
  {
    "id": 259,
    "categoryId": 9,
    "question": "A patient on Heparin develops a 50% drop in platelets and new blood clots (thrombosis). Diagnosis?",
    "options": [
      "A) DIC",
      "B) HIT (Heparin Induced Thrombocytopenia)",
      "C) ITP",
      "D) TTP"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Heparin-Induced Thrombocytopenia).\n\nPATHOPHYSIOLOGY:\nHeparin-induced thrombocytopenia (HIT) type II is a life-threatening immune-mediated prothrombotic disorder caused by IgG antibodies directed against the heparin-platelet factor 4 (PF4) complex per Harrison's Principles of Internal Medicine and UpToDate. When heparin binds to PF4 (a positively charged chemokine released from platelet alpha granules), it forms a neoantigen that stimulates IgG antibody production. These IgG-heparin-PF4 immune complexes bind to platelet Fc-gamma-RIIa receptors, causing massive platelet activation, aggregation, and consumption per the Cleveland Clinic. The resulting paradox of HIT is that despite thrombocytopenia, the primary clinical risk is thrombosis (not bleeding), because the intensely activated platelets generate a massive prothrombotic state per Harvard Health.\n\nCLINICAL PRESENTATION:\nHIT typically presents 5 to 10 days after heparin initiation (or within 24 hours in patients with prior heparin exposure within the past 100 days) with a platelet drop of greater than 50% from baseline per UpToDate. Thrombotic complications occur in 20 to 50% of untreated HIT patients and include deep venous thrombosis, pulmonary embolism, limb ischemia (potentially requiring amputation), stroke, and myocardial infarction per Harrison's Principles of Internal Medicine and the Mayo Clinic.\n\nDIAGNOSIS AND MANAGEMENT:\nThe 4Ts scoring system (Thrombocytopenia, Timing, Thrombosis, oTher causes excluded) stratifies pretest probability per the Cleveland Clinic. Laboratory confirmation requires a serotonin release assay (SRA, gold standard) or anti-PF4/heparin ELISA per UpToDate. All heparin products (including heparin flushes and heparin-coated catheters) must be immediately discontinued per Harrison's Principles of Internal Medicine. Alternative anticoagulation with a direct thrombin inhibitor (argatroban, preferred in hepatic impairment; bivalirudin) or fondaparinux must be initiated immediately because the thrombotic risk persists for weeks after heparin cessation per the Mayo Clinic.\n\nKEY LEARNING POINTS:\nHIT type II is an immune-mediated prothrombotic disorder caused by IgG antibodies against heparin-PF4 complexes, presenting with a greater than 50% platelet drop and paradoxical thrombosis (not bleeding). The 4Ts score stratifies pretest probability, and the serotonin release assay is the gold standard confirmatory test. All heparin must be discontinued immediately and replaced with a direct thrombin inhibitor."
  },
  {
    "id": 260,
    "categoryId": 11,
    "question": "Hypothermia on EKG is associated with which wave?",
    "options": [
      "A) Delta Wave",
      "B) Osborn (J) Wave",
      "C) U Wave",
      "D) Q Wave"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Osborn J Wave).\n\nPATHOPHYSIOLOGY:\nThe Osborn wave (also called the J wave or J-point elevation) is a distinctive positive deflection occurring at the junction of the QRS complex and ST segment that is pathognomonic of hypothermia per Harrison's Principles of Internal Medicine and UpToDate. It appears as a dome-shaped or hump-shaped elevation at the J-point, most prominent in the lateral precordial leads (V4 through V6) and inferior leads (II, III, aVF) per the Cleveland Clinic. The wave was first described by John Osborn in 1953 during experimental hypothermia studies in dogs per Harvard Health.\n\nMECHANISM:\nThe Osborn wave results from a temperature-dependent difference in action potential duration between the epicardial and endocardial layers of the ventricular myocardium per UpToDate. Hypothermia accentuates the transient outward potassium current (Ito) in epicardial cells more than endocardial cells, creating a transmural voltage gradient during early repolarization that manifests as the J-point deflection on surface ECG per Harrison's Principles of Internal Medicine. The amplitude of the Osborn wave correlates with the degree of hypothermia, becoming more prominent as core temperature drops below 32Â°C (89.6Â°F) per the Mayo Clinic.\n\nADDITIONAL ECG FINDINGS IN HYPOTHERMIA:\nBeyond the Osborn wave, hypothermia produces progressive ECG changes including sinus bradycardia (from decreased SA node automaticity), PR and QT prolongation (from slowed conduction), atrial fibrillation (common below 32Â°C), and ventricular fibrillation (the most dangerous arrhythmia, typically occurring below 28Â°C/82.4Â°F) per UpToDate and the Cleveland Clinic. Shivering artifact may obscure the baseline. The myocardium becomes increasingly irritable as temperature falls, and physical manipulation of a severely hypothermic patient can trigger ventricular fibrillation per Harrison's Principles of Internal Medicine.\n\nCLINICAL SIGNIFICANCE:\nRecognizing the Osborn wave on ECG should prompt immediate core temperature measurement per Harvard Health. Management of hypothermia follows the principle that patients are \"not dead until warm and dead,\" as cardiac resuscitation and defibrillation are often ineffective below 30Â°C and should be continued until core temperature is restored per the Mayo Clinic and UpToDate.\n\nKEY LEARNING POINTS:\nThe Osborn (J) wave is a dome-shaped deflection at the QRS-ST junction that is pathognomonic of hypothermia, resulting from temperature-dependent differences in epicardial versus endocardial repolarization via the Ito potassium current. Its amplitude correlates with the degree of hypothermia. Ventricular fibrillation is the most dangerous arrhythmia in hypothermia, typically occurring below 28Â°C."
  },
  {
    "id": 261,
    "categoryId": 4,
    "question": "Myxedema Coma (Severe Hypothyroidism) presents with:",
    "options": [
      "A) Fever, Tachycardia, Agitation",
      "B) Hypothermia, Bradycardia, Altered Mental Status",
      "C) Hypertension, Tremor",
      "D) Hyperreflexia"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Hypothermia, Bradycardia, Altered Mental Status).\n\nPATHOPHYSIOLOGY:\nMyxedema coma is the most severe and life-threatening manifestation of hypothyroidism, representing the extreme end of the decompensated hypothyroid state with a mortality rate of 25 to 60% even with appropriate treatment per data from UpToDate and Harrison's Principles of Internal Medicine. The condition occurs when the already-compromised compensatory mechanisms maintaining homeostasis in chronic hypothyroidism are overwhelmed by a precipitating stressor. Thyroid hormone is essential for maintaining basal metabolic rate, thermogenesis, cardiac chronotropy and inotropy, ventilatory drive, and central nervous system function. In its absence, the entire body enters a hypometabolic state: oxygen consumption and heat production decline precipitously (producing hypothermia), cardiac output falls from decreased heart rate and reduced contractility (producing bradycardia and hypotension), central nervous system depression progresses from lethargy to obtundation to coma, and ventilatory drive decreases (producing hypoventilation with respiratory acidosis and hypoxemia). Myxedema coma typically occurs in elderly women with long-standing undiagnosed or undertreated hypothyroidism, precipitated by infection (most common), cold exposure, sedative or narcotic medications, surgery, stroke, or congestive heart failure. The term \"myxedema\" refers to the nonpitting edema caused by accumulation of glycosaminoglycans (hyaluronic acid and chondroitin sulfate) in the dermis and subcutaneous tissues, a hallmark of severe hypothyroidism.\n\nCLINICAL PRESENTATION:\nThe classic clinical triad consists of hypothermia, bradycardia, and altered mental status. Hypothermia (core temperature often below 95Â°F/35Â°C) is present in approximately 80% of cases and may be missed if the thermometer does not register subnormal temperatures. Bradycardia and hypotension reflect decreased cardiac output from reduced myocardial contractility and decreased beta-adrenergic receptor density. Altered mental status ranges from lethargy and confusion to frank coma, reflecting decreased cerebral oxygen consumption and direct effects of thyroid hormone deficiency on neuronal function. Hypoventilation with hypercapnia and hypoxemia may necessitate mechanical ventilation. Hyponatremia is present in up to 50% of cases, resulting from impaired free water excretion due to elevated ADH (cortisol deficiency-like pattern, compounded by decreased cardiac output reducing renal free water clearance) and in some cases concurrent SIADH. The physical examination may reveal classic features of severe hypothyroidism including periorbital and peripheral nonpitting edema (myxedema), macroglossia, coarse dry skin, diffuse alopecia, delayed relaxation phase of deep tendon reflexes, and ileus from decreased gastrointestinal motility. Pericardial effusion and pleural effusions from increased capillary permeability with glycosaminoglycan accumulation may be present.\n\nTREATMENT:\nManagement of myxedema coma requires urgent, aggressive intervention in the intensive care unit. Intravenous levothyroxine is the standard hormonal replacement, typically administered as a loading dose of 200 to 400 mcg intravenously (to rapidly replete the depleted thyroxine pool), followed by maintenance doses of 50 to 100 mcg intravenously daily until the patient can take oral medication. Some experts advocate adding intravenous liothyronine (T3) at 5 to 20 mcg initially then 2.5 to 10 mcg every 8 hours, as T4-to-T3 conversion may be impaired in critically ill patients, though this remains debated. Critically, intravenous stress-dose hydrocortisone (100 mg bolus, then 50 mg every 8 hours) must be administered before or simultaneously with thyroid hormone replacement to prevent precipitating adrenal crisis, because hypothyroidism decreases cortisol clearance, maintaining cortisol levels in a precarious equilibrium that is disrupted when thyroid hormone administration restores normal cortisol metabolism. Additionally, concurrent primary adrenal insufficiency (autoimmune polyglandular syndrome) must be excluded. Supportive care includes passive rewarming with blankets (active rewarming is avoided as it may cause vasodilation and cardiovascular collapse), mechanical ventilation for respiratory failure, cautious fluid administration for hyponatremia (avoiding free water restriction alone in the setting of hypovolemia), and treatment of the precipitating cause.\n\nKEY LEARNING POINTS:\nMyxedema coma presents with the triad of hypothermia, bradycardia, and altered mental status in patients with severe, decompensated hypothyroidism, carrying 25 to 60% mortality. Intravenous stress-dose hydrocortisone must be given before or with levothyroxine to prevent adrenal crisis from restored cortisol metabolism. Hyponatremia is present in up to 50% of cases, and hypothermia may be missed if thermometers do not register subnormal temperatures."
  },
  {
    "id": 262,
    "categoryId": 15,
    "question": "Massive Hemoptysis is defined as >100-600ml blood/24hr. If the patient is unstable, which lung should be placed DOWN?",
    "options": [
      "A) The Good Lung (Unaffected)",
      "B) The Bad Lung (Bleeding side)",
      "C) Supine only",
      "D) Prone"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (The bleeding lung placed down).\n\nPATHOPHYSIOLOGY:\nMassive hemoptysis, defined variably as expectoration of 100 to 600 mL of blood within 24 hours (with 300 mL being the most commonly cited threshold), is a life-threatening emergency in which the primary cause of death is asphyxiation from airway flooding rather than exsanguination per Harrison's Principles of Internal Medicine. Even relatively modest volumes of blood can be fatal if they fill the tracheobronchial tree and prevent gas exchange. Blood in the airways acts as a liquid obstruction, and when a patient is supine, gravity causes blood from the bleeding lung to flow across the carina into the contralateral (non-bleeding) lung, drowning both lungs and eliminating any functional gas exchange capacity per UpToDate.\n\nCLINICAL REASONING:\nPositioning the patient with the bleeding lung in the dependent (down) position uses gravity to contain hemorrhage within the affected lung while keeping the unaffected lung in the non-dependent (up) position, protecting it from blood contamination and preserving ventilatory capacity per the Cleveland Clinic. For example, if the right lung is bleeding, the patient is placed in the right lateral decubitus position. This is a critical and potentially life-saving temporizing maneuver that can be performed immediately at the bedside while preparing for definitive intervention.\n\nMANAGEMENT:\nDefinitive management depends on the clinical scenario per UpToDate and Harrison's Principles of Internal Medicine. In hemodynamically unstable patients, securing the airway takes priority, and selective intubation of the non-bleeding mainstem bronchus (typically the left with a standard endotracheal tube advanced past the carina, or using a double-lumen endotracheal tube) can isolate the bleeding lung and protect ventilation. Bronchoscopy (rigid bronchoscopy preferred in massive hemoptysis for its superior suctioning capability and ability to maintain ventilation) identifies the bleeding source. Bronchial artery embolization by interventional radiology is the first-line definitive treatment, with success rates of 70 to 90% per the Mayo Clinic. Surgical resection is reserved for cases refractory to embolization or when a surgically resectable lesion (such as lung cancer or aspergilloma) is identified.\n\nKEY LEARNING POINTS:\nIn massive hemoptysis, death occurs from asphyxiation (airway flooding) rather than exsanguination, and positioning the bleeding lung down protects the good lung from blood contamination. Bronchial artery embolization is the first-line definitive treatment with 70 to 90% success rates. Rigid bronchoscopy is preferred over flexible for massive hemoptysis due to superior suctioning and ventilation capability."
  },
  {
    "id": 263,
    "categoryId": 10,
    "question": "Necrotizing Fasciitis is suggested by:",
    "options": [
      "A) Pain out of proportion to exam and crepitus",
      "B) Red streak up the arm",
      "C) Itching and hives",
      "D) Honey-crusted lesions"
    ],
    "correctAnswer": 0,
    "explanationImages": [
      {
        "src": "assets/derm-q9-necrosis.png",
        "alt": "Extensive necrotic skin changes of the lower foot and ankle",
        "caption": "Necrotizing soft tissue infection with rapidly progressive ischemic and necrotic skin changes."
      }
    ],
    "explanation": "CORRECT: A (Pain out of proportion to exam and crepitus).\n\nPATHOPHYSIOLOGY:\nNecrotizing fasciitis is a rapidly progressive, life-threatening infection of the deep fascial planes and subcutaneous tissue that spreads along fascial layers at rates of 2 to 3 centimeters per hour. Type I (polymicrobial) involves a synergistic mixture of aerobic and anaerobic organisms (streptococci, enterobacteriaceae, bacteroides, clostridia) and typically occurs in diabetic, immunocompromised, or postoperative patients, often involving the perineum (Fournier gangrene) or abdominal wall. Type II (monomicrobial) is caused most commonly by Group A Streptococcus (Streptococcus pyogenes), which produces exotoxins including streptococcal pyrogenic exotoxins and M protein that function as superantigens, triggering massive cytokine release and toxic shock. The infection rapidly destroys fascia and subcutaneous fat, causing thrombosis of perforating blood vessels, which leads to secondary ischemic necrosis of the overlying skin. This vascular occlusion explains the hallmark finding of pain out of proportion to exam: the deep tissue destruction and nerve ischemia generate severe pain while the overlying skin may initially appear deceptively normal or only mildly erythematous.\n\nCLINICAL PRESENTATION:\nThe earliest and most important clinical clue is severe pain that far exceeds what the visible skin findings would suggest. The affected area is exquisitely tender, often with a wooden-hard quality to palpation reflecting deep fascial edema. Systemic toxicity with high fever, tachycardia, and hypotension develops rapidly. As the infection progresses, skin changes evolve from erythema to dusky discoloration, hemorrhagic bullae, and frank necrosis. Crepitus on palpation indicates gas production by anaerobic organisms and is a late but highly specific finding present in approximately 18 to 30% of cases. Cutaneous anesthesia over the affected area is an ominous sign indicating destruction of cutaneous nerves traversing the necrotic fascia. The Laboratory Risk Indicator for Necrotizing Fasciitis (LRINEC) score incorporates CRP, WBC, hemoglobin, sodium, creatinine, and glucose, with a score of 6 or greater suggesting necrotizing fasciitis, though a low score does not exclude the diagnosis.\n\nMANAGEMENT:\nNecrotizing fasciitis is a surgical emergency requiring immediate and aggressive operative debridement of all necrotic tissue, with planned return to the operating room every 24 to 48 hours for re-exploration and further debridement until healthy, bleeding tissue margins are achieved. At surgery, the classic findings are dishwater-gray necrotic fascia, lack of tissue resistance to blunt dissection along fascial planes (the 'finger test'), and foul-smelling turbid fluid ('dishwasher water'). Broad-spectrum IV antibiotics are initiated empirically with coverage for gram-positives, gram-negatives, and anaerobes (typically vancomycin plus piperacillin-tazobactam or a carbapenem plus clindamycin). Clindamycin is specifically included for its ability to suppress toxin production by streptococci and clostridia. IV immunoglobulin may be considered in streptococcal toxic shock. Mortality ranges from 20 to 40% even with optimal surgical and medical management, and rises dramatically with each hour of delay in surgical debridement.\n\nKEY LEARNING POINTS:\nPain out of proportion to visible skin findings is the earliest and most critical diagnostic clue for necrotizing fasciitis. Crepitus, while highly specific, is a late finding. Do not wait for imaging or laboratory confirmation if clinical suspicion is high, as surgical exploration is both diagnostic and therapeutic. Mortality increases with every hour of delay to debridement. The LRINEC score can support clinical suspicion but does not rule out the diagnosis when low."
  },
  {
    "id": 264,
    "categoryId": 16,
    "question": "The concept of 'Caloric Density' explains why patients can eat MORE food but lose weight if they choose whole plant foods. Which food group has the lowest caloric density?",
    "options": [
      "A) Lean Meats",
      "B) Non-starchy Vegetables",
      "C) Whole Grains",
      "D) Nuts and Seeds"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Non-starchy Vegetables).\n\nCONCEPT:\nCaloric density (calories per unit weight of food) is the key principle explaining why patients can eat a greater volume of food while consuming fewer total calories, which is the foundation of volumetric eating strategies for weight management per Harvard Health and the Mayo Clinic. Non-starchy vegetables have the lowest caloric density of any food group at approximately 100 to 200 calories per pound, compared to fruits (200 to 400 cal/lb), whole grains and legumes (400 to 700 cal/lb), meat and cheese (1,000 to 1,500 cal/lb), and oils (4,000 cal/lb) per UpToDate.\n\nPHYSIOLOGIC MECHANISM:\nSatiety is primarily driven by gastric stretch receptors (vagal mechanoreceptors) that signal the nucleus tractus solitarius in the brainstem when the stomach is physically distended, triggering fullness independent of caloric content per Harrison's Principles of Internal Medicine. Foods with low caloric density (high water and fiber content relative to calories) physically fill the stomach and activate these stretch receptors with far fewer calories than energy-dense foods. A pound of vegetables provides the same gastric volume and stretch receptor activation as a pound of cheese but at one-tenth the caloric cost per the Cleveland Clinic.\n\nCLINICAL APPLICATION:\nThe volumetric approach to weight management, supported by research from Barbara Rolls at Penn State, demonstrates that reducing the caloric density of the diet (by increasing the proportion of vegetables, fruits, and water-rich foods) produces sustained weight loss without calorie counting or hunger per Harvard Health. This explains why whole-food plant-based diets consistently produce weight loss in clinical trials despite ad libitum (unlimited) eating, as the high fiber and water content ensures satiety before caloric excess occurs per UpToDate and the Mayo Clinic.\n\nKEY LEARNING POINTS:\nNon-starchy vegetables have the lowest caloric density (100 to 200 cal/lb versus 1,000 to 1,500 for meat/cheese and 4,000 for oils), allowing greater food volume with fewer calories. Satiety is driven by gastric stretch receptors that respond to volume, not calories. Volumetric eating strategies using low caloric density foods produce weight loss without calorie counting or hunger."
  },
  {
    "id": 265,
    "categoryId": 16,
    "question": "For a patient with Hypertension, what is the expected acute effect of a single bout of aerobic exercise (Post-Exercise Hypotension)?",
    "options": [
      "A) No change",
      "B) Increased BP for 24 hours",
      "C) Decreased SBP by 5-7 mmHg for up to 22 hours",
      "D) Increased Diastolic but decreased Systolic"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Decreased SBP by 5 to 7 mmHg for up to 22 hours).\n\nPATHOPHYSIOLOGY:\nPost-exercise hypotension (PEH) is a well-documented phenomenon in which blood pressure drops below pre-exercise resting levels following a single bout of aerobic exercise, with reductions of approximately 5 to 7 mmHg systolic and 2 to 4 mmHg diastolic persisting for up to 22 hours per Harrison's Principles of Internal Medicine and UpToDate. The magnitude of PEH is greater in hypertensive individuals than normotensive individuals, making exercise a particularly effective intervention for those who need it most per the Cleveland Clinic.\n\nMECHANISMS:\nPEH results from several converging physiologic mechanisms per Harvard Health. Sustained post-exercise peripheral vasodilation occurs due to local release of nitric oxide, prostaglandins, and adenosine in exercised muscle beds, reducing total peripheral resistance. Reduced sympathetic nervous system activity and decreased cardiac output in the recovery period also contribute per UpToDate. Exercise-induced release of atrial natriuretic peptide (ANP) promotes natriuresis and vasodilation per Harrison's Principles of Internal Medicine. Histamine receptor activation in exercised muscles maintains vasodilation for hours after exercise cessation per the Mayo Clinic.\n\nCLINICAL SIGNIFICANCE:\nThe 2017 ACC/AHA Hypertension Guidelines recommend 150 minutes per week of moderate-intensity aerobic activity (or 75 minutes of vigorous activity) as a first-line lifestyle intervention for blood pressure management per the Cleveland Clinic. Regular aerobic exercise reduces resting systolic BP by approximately 5 to 8 mmHg in hypertensive adults, an effect comparable to single-drug antihypertensive therapy per UpToDate. Each individual exercise session contributes through the acute PEH effect, while chronic adaptations (improved endothelial function, reduced arterial stiffness, decreased sympathetic tone, and weight loss) produce the sustained long-term BP reduction per Harrison's Principles of Internal Medicine.\n\nKEY LEARNING POINTS:\nPost-exercise hypotension produces a 5 to 7 mmHg systolic BP reduction lasting up to 22 hours after a single aerobic exercise session, mediated by sustained vasodilation and reduced sympathetic tone. The effect is greater in hypertensive individuals. Regular aerobic exercise reduces resting BP by approximately 5 to 8 mmHg, comparable to single-drug antihypertensive therapy."
  },
  {
    "id": 266,
    "categoryId": 16,
    "question": "Alcohol is often used by patients as a sleep aid. While it reduces sleep latency (time to fall asleep), how does it negatively impact sleep architecture?",
    "options": [
      "A) It increases Deep Sleep (N3) too much",
      "B) It fragments REM sleep and causes rebound wakefulness in the second half of the night",
      "C) It causes Sleep Apnea to resolve",
      "D) It has no negative effect"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (It fragments REM sleep and causes rebound wakefulness in the second half of the night).\n\nPATHOPHYSIOLOGY:\nAlcohol is a central nervous system depressant that acts primarily by enhancing GABA-A receptor activity and inhibiting glutamate (NMDA) receptor signaling, which initially promotes sedation and reduces sleep onset latency per Harrison's Principles of Internal Medicine. However, as alcohol is metabolized during the second half of the night (at approximately 0.015 g/dL per hour), a glutamate rebound occurs: the previously suppressed excitatory neurotransmitter system rebounds, producing sympathetic activation, sleep fragmentation, increased awakenings, vivid dreams, and diaphoresis per UpToDate and the Cleveland Clinic.\n\nREM SLEEP DISRUPTION:\nAlcohol profoundly suppresses REM (rapid eye movement) sleep during the first half of the night per Harvard Health. As blood alcohol levels fall, a compensatory REM rebound occurs with excessive and fragmented REM sleep in the latter portion of the night, often accompanied by vivid or disturbing dreams. Since REM sleep is critical for emotional memory consolidation, cognitive processing, and psychological restoration, this disruption impairs next-day cognitive function, emotional regulation, and learning per the Mayo Clinic. Even moderate alcohol consumption (1 to 2 drinks) within 4 hours of bedtime reduces sleep quality by 24% in healthy adults per UpToDate.\n\nCLINICAL SIGNIFICANCE:\nAlcohol also worsens obstructive sleep apnea by relaxing upper airway musculature, increasing airway collapsibility, and blunting the arousal response to apneic events per Harrison's Principles of Internal Medicine. Chronic use of alcohol as a sleep aid promotes tolerance (requiring escalating doses for the same sedative effect) and can contribute to alcohol use disorder per the Cleveland Clinic. Clinicians should counsel patients that while alcohol reduces the time to fall asleep, it fundamentally degrades sleep architecture and overall sleep quality per Harvard Health.\n\nKEY LEARNING POINTS:\nAlcohol reduces sleep latency but fragments REM sleep and causes second-half-of-night rebound wakefulness as it is metabolized, producing a glutamate/sympathetic surge. Even 1 to 2 drinks within 4 hours of bedtime reduce sleep quality by 24%. Alcohol worsens obstructive sleep apnea and promotes tolerance, making it counterproductive as a chronic sleep aid."
  },
  {
    "id": 267,
    "categoryId": 4,
    "question": "A Type 2 Diabetic asks about fruit. According to the ADA and large prospective cohorts, consumption of whole fruit is associated with:",
    "options": [
      "A) Worsening A1c",
      "B) Increased weight gain",
      "C) Reduced risk of complications and better glycemic control",
      "D) Spikes in Triglycerides"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Reduced risk of complications and better glycemic control).\n\nPATHOPHYSIOLOGY:\nThe apparent paradox that whole fruit, which contains fructose, is associated with reduced rather than increased diabetes risk is explained by the critical role of food matrix and fiber in modulating fructose metabolism and glycemic impact. When fructose is consumed within intact whole fruit, the cell wall matrix (composed of cellulose, hemicellulose, and pectin) physically encapsulates sugars, requiring mechanical and enzymatic breakdown during digestion that dramatically slows the rate of sugar release and absorption. Soluble fiber (pectin and other polysaccharides) forms a viscous gel in the intestinal lumen that retards glucose absorption, attenuates postprandial glycemic and insulinemic spikes, and increases satiety signaling through gastric distension and delayed gastric emptying. The slow, metered delivery of fructose to the liver prevents the metabolic overload (ATP depletion, unregulated de novo lipogenesis, uric acid generation) that occurs with rapid hepatic fructose loading from sugar-sweetened beverages. Additionally, whole fruits deliver a dense package of polyphenols (anthocyanins, flavonoids, chlorogenic acid), carotenoids, vitamins (C, folate), and minerals (potassium, magnesium) that have been shown to independently improve insulin sensitivity, reduce oxidative stress, and attenuate inflammation through mechanisms including improved endothelial function and modulation of gut microbiota composition.\n\nCLINICAL EVIDENCE:\nMultiple large, well-conducted prospective cohort studies have consistently demonstrated an inverse association between whole fruit consumption and type 2 diabetes incidence. Pooled analysis of data from the Nurses' Health Study, Nurses' Health Study II, and Health Professionals Follow-up Study (published in the BMJ, encompassing approximately 187,000 participants followed for over two decades) demonstrated that greater whole fruit consumption was significantly associated with reduced type 2 diabetes risk, with specific fruits showing particularly strong inverse associations: blueberries (26% risk reduction per 3 servings per week), grapes and raisins (12%), and apples and pears (7%). In contrast, fruit juice consumption was associated with increased diabetes risk, reinforcing that the food matrix and fiber content are the critical protective elements. For patients with established type 2 diabetes, a randomized controlled trial published in Nutrition Journal demonstrated that unrestricted fruit intake (at least 2 servings daily) did not worsen glycemic control (HbA1c, body weight, or waist circumference) compared to restricted fruit intake over 12 weeks. The PREDIMED trial (NEJM 2013), which demonstrated cardiovascular benefit of the Mediterranean diet supplemented with extra-virgin olive oil or nuts, included regular fruit consumption as a core component of the dietary pattern.\n\nCLINICAL APPLICATION:\nThe ADA 2024 Standards of Care and the Dietary Guidelines for Americans recommend that individuals with diabetes include whole fruit as part of a healthy eating pattern, emphasizing whole fruits over fruit juices. The ADA specifically states that fruit consumption should not be restricted to control blood glucose and that the nutrient density, fiber content, and overall health benefits of whole fruit make it a preferred carbohydrate source over refined grains, sweets, and processed foods. Practical counseling points include encouraging 2 to 4 servings of whole fruit daily (with appropriate carbohydrate counting for insulin-treated patients), pairing fruit with protein or healthy fat to further blunt glycemic response, prioritizing deeply pigmented fruits (berries, cherries, stone fruits) for their higher polyphenol content, and clearly distinguishing whole fruit from fruit juice, dried fruit with added sugar, and fruit-flavored products. Patients should be reassured that the glycemic index of most whole fruits is low to moderate, and that the clinical evidence consistently shows benefit rather than harm.\n\nKEY LEARNING POINTS:\nWhole fruit consumption is consistently associated with reduced type 2 diabetes risk and does not worsen glycemic control in established diabetes, in contrast to sugar-sweetened beverages and fruit juice. The protective effect is attributed to fiber-mediated slowed sugar absorption, polyphenol-driven insulin sensitization, and satiety promotion. The ADA recommends whole fruit as part of healthy eating for people with diabetes and advises against restricting fruit intake for glycemic control."
  },
  {
    "id": 268,
    "categoryId": 16,
    "question": "In the 'Transtheoretical Model of Change', a patient who says 'I know I need to quit smoking, and I'm looking up cessation classes to start next month' is in which stage?",
    "options": [
      "A) Pre-contemplation",
      "B) Contemplation",
      "C) Preparation",
      "D) Action"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Preparation Stage).\n\nTRANSTHEORETICAL MODEL:\nThe Transtheoretical Model (TTM), developed by Prochaska and DiClemente, describes behavior change as a process through five sequential stages per UpToDate and Harrison's Principles of Internal Medicine. Precontemplation is the stage where the individual is not considering change within the next 6 months and may not recognize the behavior as problematic. Contemplation involves acknowledging the problem and considering change within the next 6 months but remaining ambivalent. Preparation is the stage of active planning, where the individual intends to take action within 30 days and may have already taken preliminary steps (such as researching cessation programs, as in this patient) per the Cleveland Clinic.\n\nACTION AND MAINTENANCE:\nThe Action stage involves actively modifying the behavior (for example, the patient has quit smoking and is in the first 6 months of abstinence). Maintenance represents sustained behavior change for more than 6 months, during which the individual works to prevent relapse per the Mayo Clinic. Relapse is recognized as a normal part of the change process rather than a failure, and patients typically cycle through the stages multiple times before achieving long-term change per UpToDate.\n\nCLINICAL APPLICATION:\nIdentifying the patient's current stage guides the clinician's counseling approach per Harvard Health. In Precontemplation, the clinician raises awareness and plants seeds of doubt. In Contemplation, motivational interviewing techniques help resolve ambivalence. In Preparation (this patient), the clinician should help develop a concrete action plan, set a quit date, identify triggers and coping strategies, and initiate pharmacotherapy (NRT, varenicline, or bupropion) per Harrison's Principles of Internal Medicine. The statement 'I know I need to quit smoking and I'm looking up cessation programs' reflects both intention to act within 30 days and preliminary action steps, placing this patient squarely in the Preparation stage per UpToDate.\n\nKEY LEARNING POINTS:\nThe Preparation stage is defined by intention to take action within 30 days with preliminary steps already underway (such as researching programs). The five TTM stages are Precontemplation, Contemplation, Preparation, Action, and Maintenance. Identifying the patient's stage guides counseling: in Preparation, help set a quit date, develop an action plan, and initiate pharmacotherapy."
  },
  {
    "id": 269,
    "categoryId": 16,
    "question": "A common myth is that plant proteins are 'incomplete'. According to the Academy of Nutrition and Dietetics:",
    "options": [
      "A) Vegans must combine rice and beans at every meal",
      "B) Plant proteins lack essential amino acids",
      "C) Eating a variety of plant foods over the course of a day provides all essential amino acids",
      "D) Animal protein is required for muscle synthesis"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Eating a variety of plant foods over the course of a day provides all essential amino acids).\n\nEVIDENCE:\nThe Academy of Nutrition and Dietetics (the world's largest organization of nutrition professionals) states that appropriately planned vegetarian and vegan diets are healthful, nutritionally adequate, and provide all essential amino acids when a variety of plant foods are consumed throughout the day per UpToDate and Harvard Health. The outdated concept of protein combining (eating complementary plant proteins at the same meal, such as rice and beans together) was popularized by Frances Moore LappÃ© in 1971 but has been refuted by subsequent research and retracted by LappÃ© herself per the Cleveland Clinic.\n\nBIOCHEMISTRY:\nAll plant foods contain all 20 amino acids, including all 9 essential amino acids, albeit in varying proportions per Harrison's Principles of Internal Medicine. The liver maintains a free amino acid pool that buffers dietary variation, drawing on amino acids absorbed from different meals throughout the day. As long as total caloric intake is adequate and dietary variety is present (grains, legumes, vegetables, nuts, and seeds), the amino acid pool will contain sufficient quantities of all essential amino acids for protein synthesis per UpToDate. Soy, quinoa, hemp, and buckwheat are notable for having amino acid profiles comparable to animal proteins per the Mayo Clinic.\n\nCLINICAL APPLICATION:\nThe recommended protein intake for adults is 0.8 g/kg/day (RDA), though older adults benefit from 1.0 to 1.2 g/kg/day per Harrison's Principles of Internal Medicine. Plant-based protein sources include legumes (approximately 15g protein per cup cooked), tofu and tempeh (10 to 20g per serving), nuts and seeds (5 to 7g per ounce), and whole grains (5 to 8g per cup cooked) per Harvard Health. Large epidemiologic studies suggest that substituting plant protein for animal protein is associated with reduced all-cause and cardiovascular mortality per UpToDate.\n\nKEY LEARNING POINTS:\nAll plant foods contain all essential amino acids in varying proportions, and the liver's amino acid pool buffers dietary variation, making protein combining at each meal unnecessary. The Academy of Nutrition and Dietetics confirms that varied plant-based diets are nutritionally adequate. Soy, quinoa, hemp, and buckwheat have particularly complete amino acid profiles."
  },
  {
    "id": 270,
    "categoryId": 16,
    "question": "Chronic stress activates the HPA axis, leading to elevated Cortisol. Long-term hypercortisolemia causes:",
    "options": [
      "A) Increased muscle mass",
      "B) Visceral fat deposition (Central Obesity) and Hippocampal atrophy",
      "C) Improved immune function",
      "D) Thickening of the skin"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Visceral fat deposition and Hippocampal atrophy).\n\nPATHOPHYSIOLOGY:\nChronic activation of the hypothalamic-pituitary-adrenal (HPA) axis from persistent psychological stress produces sustained elevation of cortisol, which causes a characteristic pattern of metabolic and neurologic damage per Harrison's Principles of Internal Medicine. Cortisol promotes visceral (central) adiposity preferentially because visceral adipocytes have a higher density of glucocorticoid receptors and greater expression of 11-beta-hydroxysteroid dehydrogenase type 1 (which converts inactive cortisone to active cortisol locally) compared to subcutaneous fat per UpToDate and the Cleveland Clinic.\n\nMETABOLIC EFFECTS:\nHypercortisolemia induces insulin resistance through multiple mechanisms: it stimulates hepatic gluconeogenesis, impairs peripheral glucose uptake in skeletal muscle, and promotes lipolysis that releases free fatty acids into the portal circulation per Harrison's Principles of Internal Medicine. The resulting visceral obesity further amplifies insulin resistance, creating a feed-forward cycle that increases risk of metabolic syndrome, type 2 diabetes, and cardiovascular disease per the Mayo Clinic. Cortisol also suppresses immune function (reducing lymphocyte proliferation and cytokine production), delays wound healing, promotes bone resorption (osteoporosis), and causes protein catabolism (muscle wasting and skin thinning) per UpToDate.\n\nNEUROLOGIC EFFECTS:\nThe hippocampus, which is critical for memory consolidation and spatial navigation, has a particularly high density of glucocorticoid receptors per Harvard Health. Chronic cortisol exposure causes hippocampal neuronal atrophy, dendritic retraction, impaired neurogenesis, and ultimately measurable volume loss on MRI per Harrison's Principles of Internal Medicine. This hippocampal atrophy manifests clinically as impaired episodic memory and may contribute to the increased dementia risk observed with chronic stress and depression per the Cleveland Clinic. Cortisol also impairs prefrontal cortex function (reducing executive function and decision-making) while enhancing amygdala reactivity (increasing anxiety and fear responses) per UpToDate.\n\nKEY LEARNING POINTS:\nChronic hypercortisolemia from HPA axis activation causes visceral fat deposition (via glucocorticoid receptor density in visceral adipocytes) and hippocampal atrophy (via glucocorticoid-mediated neuronal damage). The metabolic consequences include insulin resistance, metabolic syndrome, and cardiovascular risk. Hippocampal atrophy impairs memory consolidation and may contribute to dementia risk."
  },
  {
    "id": 271,
    "categoryId": 16,
    "question": "The primary fuel source for colonocytes (colon cells) is:",
    "options": [
      "A) Glucose",
      "B) Glutamine",
      "C) Butyrate (Short Chain Fatty Acid)",
      "D) Ketones"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Butyrate, a Short-Chain Fatty Acid).\n\nPATHOPHYSIOLOGY:\nButyrate is the primary energy source for colonocytes (epithelial cells lining the colon), providing approximately 60 to 70% of their energy needs per Harrison's Principles of Internal Medicine and UpToDate. Unlike most cells in the body that rely on glucose as their primary fuel, colonocytes have evolved a preferential dependence on butyrate, reflecting the coevolutionary relationship between the human colon and its resident microbiota per the Cleveland Clinic.\n\nPRODUCTION PATHWAY:\nHumans cannot synthesize butyrate endogenously. It is produced exclusively by bacterial fermentation of dietary fiber (particularly resistant starch and non-starch polysaccharides) in the colon per Harvard Health. Key butyrate-producing bacterial genera include Faecalibacterium prausnitzii, Roseburia, and Eubacterium rectale, all of which are obligate anaerobes that thrive on dietary fiber substrates per UpToDate. When dietary fiber intake is insufficient, butyrate production falls, and colonocytes become energy-deprived, leading to increased intestinal permeability (leaky gut), mucosal inflammation, and impaired epithelial barrier function per Harrison's Principles of Internal Medicine.\n\nCLINICAL SIGNIFICANCE:\nBeyond fueling colonocytes, butyrate exerts multiple protective effects per the Mayo Clinic. It strengthens tight junctions between epithelial cells, maintaining the intestinal barrier against bacterial translocation. It has anti-inflammatory properties by inhibiting NF-kB signaling in immune cells. It promotes regulatory T-cell differentiation, contributing to immune tolerance. And it has anti-proliferative and pro-apoptotic effects on dysplastic colonocytes, which may protect against colorectal cancer per UpToDate and the Cleveland Clinic. These findings provide the mechanistic rationale for the observed association between high-fiber diets and reduced colorectal cancer risk per Harvard Health.\n\nKEY LEARNING POINTS:\nButyrate (produced by bacterial fermentation of dietary fiber) is the primary fuel for colonocytes, providing 60 to 70% of their energy needs. Humans cannot produce butyrate without dietary fiber as a substrate for colonic bacteria. Butyrate strengthens the epithelial barrier, reduces inflammation via NF-kB inhibition, and has anti-neoplastic properties that may protect against colorectal cancer."
  },
  {
    "id": 272,
    "categoryId": 16,
    "question": "What is the definition of 1 MET (Metabolic Equivalent of Task)?",
    "options": [
      "A) The energy used while running a 10-minute mile",
      "B) The energy used while sitting quietly at rest",
      "C) The energy used while walking 3 mph",
      "D) The energy used while sleeping"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (The energy used while sitting quietly at rest).\n\nDEFINITION:\nOne MET (metabolic equivalent of task) is defined as the rate of energy expenditure at rest, standardized to an oxygen consumption of approximately 3.5 mL O2/kg/min, which corresponds to the energy cost of sitting quietly per Harrison's Principles of Internal Medicine and the Mayo Clinic. METs provide a standardized, body-weight-independent measure of exercise intensity that allows comparison across different activities and patients per UpToDate.\n\nINTENSITY CLASSIFICATION:\nActivities are classified by MET levels per the CDC and the Cleveland Clinic. Light-intensity activities (less than 3 METs) include casual walking, light housework, and standing. Moderate-intensity activities (3 to 6 METs) include brisk walking (3 to 4 mph), cycling (less than 10 mph), gardening, and doubles tennis. Vigorous-intensity activities (greater than 6 METs) include jogging, running, swimming laps, singles tennis, and high-intensity interval training. The 2018 Physical Activity Guidelines for Americans recommend 150 to 300 minutes per week of moderate-intensity (3 to 6 METs) or 75 to 150 minutes of vigorous-intensity (greater than 6 METs) aerobic activity per the CDC.\n\nVO2 MAX AND PROGNOSTIC VALUE:\nMaximal oxygen consumption (VO2 max), expressed in METs, represents an individual's peak cardiorespiratory fitness and is one of the strongest independent predictors of all-cause mortality, surpassing traditional risk factors such as hypertension, diabetes, smoking, and obesity per Harrison's Principles of Internal Medicine and Harvard Health. Each 1-MET increase in exercise capacity is associated with approximately 12 to 15% reduction in cardiovascular and all-cause mortality per UpToDate. Patients unable to achieve 5 METs on exercise stress testing have significantly increased perioperative and long-term cardiac risk per the Cleveland Clinic.\n\nKEY LEARNING POINTS:\nOne MET equals resting energy expenditure (3.5 mL O2/kg/min), with moderate activity at 3 to 6 METs and vigorous at greater than 6 METs. VO2 max (expressed in METs) is one of the strongest independent predictors of all-cause mortality. Each 1-MET increase in fitness capacity reduces cardiovascular and all-cause mortality by approximately 12 to 15%."
  },
  {
    "id": 273,
    "categoryId": 16,
    "question": "Heme Iron (from meat) vs. Non-Heme Iron (from plants). Which statement is true regarding regulation?",
    "options": [
      "A) Non-Heme iron is absorbed more efficiently",
      "B) The body cannot regulate Heme iron absorption; it enters passively, increasing risk of Iron Overload/Oxidative stress",
      "C) Heme iron is safer",
      "D) Vitamin C helps Heme iron absorption"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (The body cannot regulate heme iron absorption; it enters passively, increasing risk of iron overload and oxidative stress).\n\nPATHOPHYSIOLOGY:\nIron exists in two dietary forms with fundamentally different absorption mechanisms per Harrison's Principles of Internal Medicine. Non-heme iron (found in plant foods, eggs, and dairy) is tightly regulated by hepcidin-ferroportin axis signaling: when iron stores are replete, hepcidin (produced by the liver) degrades ferroportin on enterocyte basolateral membranes, blocking iron export into the circulation and preventing iron overload per UpToDate. Heme iron (found exclusively in animal flesh from hemoglobin and myoglobin) bypasses this regulatory system entirely, entering duodenal enterocytes via the heme carrier protein 1 (HCP1) transporter in an unregulated fashion per the Cleveland Clinic.\n\nCLINICAL SIGNIFICANCE:\nBecause heme iron absorption is not down-regulated when body iron stores are sufficient, chronic high intake of heme iron (from red meat) can contribute to iron overload and excess free iron in tissues per Harvard Health. Free (unbound) iron participates in Fenton chemistry, generating hydroxyl radicals (the most reactive oxygen species) that damage lipids, proteins, and DNA per Harrison's Principles of Internal Medicine. Epidemiologic studies have associated high heme iron intake with increased risk of type 2 diabetes (through pancreatic beta-cell oxidative damage), coronary heart disease (through LDL oxidation and endothelial dysfunction), and colorectal cancer (through DNA damage and promotion of N-nitroso compound formation) per UpToDate and the Mayo Clinic.\n\nIRON ABSORPTION ENHANCERS AND INHIBITORS:\nNon-heme iron absorption is enhanced by vitamin C (ascorbic acid reduces ferric to ferrous iron), citric acid, and MFP factor (meat, fish, poultry). It is inhibited by phytates (whole grains, legumes), polyphenols (tea, coffee), calcium, and soy protein per the Cleveland Clinic. These regulatory influences allow the body to modulate non-heme iron absorption based on need, a safety mechanism absent for heme iron per UpToDate.\n\nKEY LEARNING POINTS:\nHeme iron (from animal flesh) bypasses the hepcidin-ferroportin regulatory system and is absorbed in an unregulated fashion, while non-heme iron (from plants) is tightly regulated based on body stores. Excess free iron generates hydroxyl radicals via Fenton chemistry, contributing to oxidative tissue damage. High heme iron intake is epidemiologically associated with increased risk of type 2 diabetes, coronary disease, and colorectal cancer."
  },
  {
    "id": 274,
    "categoryId": 16,
    "question": "For patients with CKD, a high dietary acid load (from animal proteins/cheese) worsens kidney function. The recommended intervention is:",
    "options": [
      "A) Sodium Bicarbonate supplementation or increasing Fruits/Vegetables",
      "B) Increasing protein intake",
      "C) Drinking cranberry juice",
      "D) Fasting"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Sodium bicarbonate supplementation or increasing fruits and vegetables).\n\nPATHOPHYSIOLOGY:\nAnimal protein metabolism generates a net acid load because sulfur-containing amino acids (methionine and cysteine, abundant in animal proteins and cheese) are metabolized to sulfuric acid per Harrison's Principles of Internal Medicine. In patients with chronic kidney disease (CKD), the kidneys' ability to excrete this acid load through ammoniagenesis and titratable acid excretion is impaired, leading to metabolic acidosis that accelerates CKD progression per UpToDate. Chronic metabolic acidosis activates the complement system and endothelin-1 in the renal interstitium, promoting tubulointerstitial fibrosis, and it stimulates angiotensin II production, worsening glomerular hemodynamic injury per the Cleveland Clinic.\n\nALKALINIZATION STRATEGIES:\nTwo evidence-based approaches to reduce dietary acid load in CKD patients are oral sodium bicarbonate supplementation and increased fruit and vegetable consumption per the Mayo Clinic. The landmark trial by de Brito-Ashurst and colleagues demonstrated that sodium bicarbonate supplementation (targeting a serum bicarbonate of 22 mEq/L or greater) slowed CKD progression by 60% compared to standard care per UpToDate. A separate trial by Goraya and colleagues showed that a fruit-and-vegetable-rich diet achieved equivalent acid reduction and nephroprotection compared to sodium bicarbonate, with the additional benefit of avoiding sodium loading per Harrison's Principles of Internal Medicine.\n\nCLINICAL APPLICATION:\nKDIGO guidelines recommend maintaining serum bicarbonate at 22 mEq/L or greater in CKD patients, using oral sodium bicarbonate (500 to 1000 mg two to three times daily) when dietary modification is insufficient per UpToDate. Fruits and vegetables are natural base-generating foods (their organic anions, particularly citrate and malate, are metabolized to bicarbonate) and provide the additional benefits of potassium, fiber, and antioxidants per the Cleveland Clinic and Harvard Health.\n\nKEY LEARNING POINTS:\nAnimal protein metabolism generates sulfuric acid that the CKD kidney cannot adequately excrete, accelerating kidney damage through tubulointerstitial fibrosis. Sodium bicarbonate supplementation and increased fruit/vegetable intake both effectively reduce acid load and slow CKD progression. KDIGO recommends maintaining serum bicarbonate at 22 mEq/L or greater in CKD patients."
  },
  {
    "id": 275,
    "categoryId": 16,
    "question": "The 'Glymphatic System' clears beta-amyloid toxins from the brain. When is this system most active?",
    "options": [
      "A) During intense exercise",
      "B) During Deep (Slow Wave) Sleep",
      "C) While solving puzzles",
      "D) After caffeine intake"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (During Deep Slow-Wave Sleep).\n\nDISCOVERY:\nThe glymphatic system (a portmanteau of glial and lymphatic) is a brain-wide paravascular clearance pathway discovered by Nedergaard and colleagues in 2012 that functions as the central nervous system's waste removal system per Harvard Health and UpToDate. Unlike the rest of the body, which relies on the lymphatic system for interstitial waste clearance, the brain lacks conventional lymphatic vessels within its parenchyma. Instead, cerebrospinal fluid (CSF) flows along periarterial spaces (Virchow-Robin spaces), enters the brain parenchyma through aquaporin-4 (AQP4) water channels on astrocytic endfeet, mixes with interstitial fluid, and carries metabolic waste products along perivenous drainage pathways per Harrison's Principles of Internal Medicine.\n\nSLEEP-DEPENDENT ACTIVATION:\nGlymphatic clearance is most active during deep slow-wave (non-REM stage 3) sleep, when it operates at approximately 60% greater efficiency than during wakefulness per UpToDate and the Cleveland Clinic. This dramatic increase is mediated by the contraction of astrocytic cell bodies during sleep (expanding the interstitial space by approximately 60%), which reduces resistance to convective CSF flow through the parenchyma. Additionally, reduced noradrenergic tone from the locus coeruleus during sleep facilitates astrocytic volume changes that optimize interstitial clearance per Harvard Health.\n\nCLINICAL SIGNIFICANCE:\nThe glymphatic system clears beta-amyloid, tau protein, and alpha-synuclein, the pathologic proteins implicated in Alzheimer's disease, frontotemporal dementia, and Parkinson's disease respectively per Harrison's Principles of Internal Medicine. Chronic sleep deprivation impairs glymphatic clearance, leading to accumulation of these neurotoxic proteins per the Mayo Clinic. This provides a mechanistic link between chronic poor sleep quality and the increased risk of neurodegenerative diseases observed in epidemiologic studies per UpToDate.\n\nKEY LEARNING POINTS:\nThe glymphatic system clears beta-amyloid and other neurotoxic waste from the brain via CSF flow through astrocytic AQP4 channels and is approximately 60% more active during deep slow-wave sleep than during wakefulness. Sleep-dependent activation occurs because astrocytes shrink during sleep, expanding the interstitial space for convective CSF flow. Chronic sleep deprivation impairs glymphatic clearance and is linked to increased neurodegenerative disease risk."
  },
  {
    "id": 276,
    "categoryId": 16,
    "question": "When setting goals with patients, 'SMART' stands for:",
    "options": [
      "A) Specific, Measurable, Achievable, Relevant, Time-bound",
      "B) Simple, Meaningful, Actionable, Real, True",
      "C) Scientific, Medical, Accurate, Required, Tested",
      "D) Strict, Mandatory, Absolute, Rigid, Tough"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Specific, Measurable, Achievable, Relevant, Time-bound).\n\nCLINICAL APPLICATION:\nSMART goal-setting is an evidence-based behavioral framework used across medical, psychological, and public health practice to convert vague patient intentions into concrete, actionable plans that can be objectively assessed at follow-up per UpToDate and the Mayo Clinic. Specific means the goal clearly defines what the patient will do (such as 'walk for 30 minutes' rather than 'exercise more'). Measurable means there is an objective metric to track progress (duration, frequency, or quantity). Achievable means the goal is realistic given the patient's current abilities and circumstances. Relevant means the goal aligns with the patient's values and health priorities. Time-bound means there is a defined deadline or timeframe per Harvard Health.\n\nEVIDENCE:\nGoal-setting theory, established by Locke and Latham, demonstrates that specific and challenging (but achievable) goals consistently produce better performance outcomes than vague or overly easy goals per the Cleveland Clinic. In healthcare, SMART goals improve outcomes in chronic disease management (diabetes self-management, cardiac rehabilitation, weight loss programs), smoking cessation, and mental health treatment per UpToDate. Combining SMART goals with self-monitoring (tracking behavior in a journal or app) and accountability (regular follow-up with a clinician or support person) further enhances adherence and outcomes per Harrison's Principles of Internal Medicine.\n\nEXAMPLE:\nA vague goal like 'I want to eat healthier' becomes a SMART goal: 'I will eat at least 3 servings of vegetables with dinner, 5 days a week, for the next 4 weeks.' This transformation makes the behavior specific (vegetables at dinner), measurable (3 servings, 5 days), achievable (dinner is a modifiable meal), relevant (aligned with health goals), and time-bound (4-week trial) per the Mayo Clinic.\n\nKEY LEARNING POINTS:\nSMART stands for Specific, Measurable, Achievable, Relevant, and Time-bound, converting vague intentions into concrete behavioral plans. Goal-setting theory shows that specific and challenging goals produce better outcomes than vague goals. Combining SMART goals with self-monitoring and regular follow-up accountability maximizes adherence in chronic disease management."
  },
  {
    "id": 277,
    "categoryId": 4,
    "question": "Which hormone is secreted by adipose tissue and signals the brain to STOP eating (Satiety)?",
    "options": [
      "A) Ghrelin",
      "B) Leptin",
      "C) Insulin",
      "D) Cortisol"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Leptin).\n\nPATHOPHYSIOLOGY:\nLeptin is a 16-kilodalton peptide hormone encoded by the ob gene and secreted primarily by white adipose tissue in proportion to total body fat mass. It functions as the primary afferent signal in a negative feedback loop between adipose tissue and the hypothalamus, communicating the status of peripheral energy stores to the central nervous system. Leptin crosses the blood-brain barrier via a saturable receptor-mediated transport system and binds to leptin receptors (LepR-b) on neurons in the arcuate nucleus of the hypothalamus, where it activates two opposing neural populations: it stimulates anorexigenic (appetite-suppressing) proopiomelanocortin (POMC) neurons that release alpha-melanocyte-stimulating hormone, and it inhibits orexigenic (appetite-stimulating) neuropeptide Y (NPY) and agouti-related peptide (AgRP) neurons. The net effect is suppression of food intake, increased energy expenditure through sympathetic nervous system activation and thermogenesis, and maintenance of energy homeostasis. Leptin was discovered in 1994 by Jeffrey Friedman at Rockefeller University (published in Nature), when ob/ob mice lacking functional leptin were found to develop massive obesity, and administration of recombinant leptin reversed their obesity phenotype. This discovery established that body weight regulation is a hormonally controlled physiologic system rather than a matter of voluntary behavioral control.\n\nLEPTIN RESISTANCE:\nThe clinical paradox of leptin biology is that obese individuals have markedly elevated circulating leptin levels (proportional to their increased adipose mass) yet continue to experience hunger and weight gain, a phenomenon termed leptin resistance. Leptin resistance develops through multiple converging mechanisms: impaired leptin transport across the blood-brain barrier (saturation of the transport system at high leptin levels reduces the fraction reaching hypothalamic targets), intracellular signaling defects in leptin receptor-expressing neurons (upregulation of SOCS3, a suppressor of cytokine signaling, attenuates the JAK-STAT signaling cascade downstream of LepR-b), endoplasmic reticulum stress in hypothalamic neurons from chronic caloric excess, and chronic low-grade hypothalamic inflammation driven by saturated fatty acids and proinflammatory cytokines from visceral adipose tissue. The result is a state in which the brain does not accurately perceive the body's energy surplus, and the hypothalamic set point is defended at an elevated body weight. This explains why exogenous leptin administration is ineffective for treating common obesity (unlike rare congenital leptin deficiency, where replacement is dramatically effective): the problem is not insufficient leptin but rather central resistance to its signal.\n\nCLINICAL APPLICATION:\nUnderstanding leptin resistance has direct implications for primary care counseling and obesity treatment. First, it provides a neurobiological framework for explaining to patients that persistent hunger during weight loss is not a character deficiency but a physiologic response to falling leptin levels, which the hypothalamus interprets as a starvation signal. As weight is lost and fat mass decreases, leptin levels decline, disinhibiting NPY/AgRP neurons and suppressing POMC neurons, producing increased appetite and decreased energy expenditure (adaptive thermogenesis). This is the hormonal basis of the set point defense mechanism. Second, it provides rationale for pharmacotherapy: GLP-1 receptor agonists (semaglutide, tirzepatide) achieve sustained weight loss in part by activating central satiety pathways that parallel or bypass the leptin-resistant circuitry, directly reducing appetite through brainstem and hypothalamic mechanisms. Third, interventions that may improve leptin sensitivity include regular physical exercise, adequate sleep (sleep deprivation acutely impairs leptin signaling), reduction of ultra-processed food intake, and reduction of systemic inflammation through dietary patterns such as the Mediterranean diet.\n\nKEY LEARNING POINTS:\nLeptin is secreted by adipose tissue in proportion to fat mass and signals the hypothalamus to suppress appetite and increase energy expenditure through POMC neuron activation and NPY/AgRP neuron inhibition. Obese individuals develop leptin resistance through impaired blood-brain barrier transport, SOCS3-mediated signaling attenuation, and hypothalamic inflammation, rendering high leptin levels ineffective. GLP-1 receptor agonists achieve weight loss partly by activating central satiety pathways that bypass leptin-resistant circuitry."
  },
  {
    "id": 278,
    "categoryId": 7,
    "question": "The most effective exercise intervention for Osteoporosis is:",
    "options": [
      "A) Swimming",
      "B) Cycling",
      "C) High-Impact / Weight-Bearing Loading",
      "D) Yoga"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (High-Impact / Weight-Bearing Loading).\n\nPATHOPHYSIOLOGY:\nBone is a dynamic tissue that continuously remodels in response to mechanical loading, a principle formalized as Wolff's Law. When mechanical stress is applied to bone, fluid flow through the lacunar-canalicular network generates shear forces on osteocytes, which function as the primary mechanosensory cells of the skeleton. Stimulated osteocytes release signaling molecules including sclerostin (downregulated by loading), prostaglandin E2, and nitric oxide, which collectively shift the balance of bone remodeling toward formation by activating osteoblasts and suppressing osteoclast-mediated resorption. The piezoelectric effect, in which mechanical deformation of hydroxyapatite crystals generates small electrical potentials, provides an additional stimulus for osteoblast recruitment to areas of greatest strain. Critically, the osteogenic response is driven by the magnitude and rate of strain applied to bone, not simply by the duration of activity, which explains why high-impact loading is far more effective than low-impact repetitive exercise.\n\nCLINICAL EVIDENCE:\nWeight-bearing impact exercise such as jumping, hopping, running, and heavy resistance training produces ground reaction forces of 2 to 6 times body weight, generating the high-magnitude, rapidly applied strains necessary to stimulate significant osteoblast activity and bone mineral accrual. Randomized controlled trials and meta-analyses endorsed by the National Osteoporosis Foundation and the American College of Sports Medicine demonstrate that high-impact and progressive resistance training programs increase bone mineral density at the hip and spine by 1 to 3% over 12 to 18 months, and more importantly reduce fracture risk through improvements in muscle strength, balance, and fall prevention. In contrast, non-weight-bearing activities such as swimming and cycling, while excellent for cardiovascular fitness, do not generate the axial skeletal loading required to stimulate meaningful bone formation and have consistently failed to show benefit for bone mineral density in clinical trials. Walking provides minimal osteogenic stimulus because the body adapts to habitual low-level loading, though it does confer fall-prevention benefits.\n\nTREATMENT AND MANAGEMENT:\nThe optimal exercise prescription for osteoporosis combines high-impact weight-bearing exercise (such as jumping, stair climbing, and jogging) with progressive resistance training targeting the major muscle groups of the hip and spine at 70 to 85% of one-repetition maximum. Balance and proprioceptive training should be incorporated to reduce fall risk, particularly in elderly patients. For patients with established osteoporosis or vertebral fractures, high-impact activities may need to be modified to reduce fracture risk, and progressive resistance training becomes the primary intervention. Exercise should be viewed as a lifelong strategy complementing pharmacologic therapy, as the bone density benefits of exercise are lost when the activity is discontinued, mirroring the reversibility of disuse osteopenia seen in astronauts and immobilized patients who lose approximately 1 to 2% of bone density per month without gravitational loading.\n\nKEY LEARNING POINTS:\nHigh-impact weight-bearing exercise and progressive resistance training are the most effective exercise interventions for osteoporosis because they generate the high-magnitude, rapidly applied mechanical strains needed to activate osteocyte mechanotransduction and stimulate osteoblast activity. Swimming and cycling are non-weight-bearing and do not improve bone mineral density despite their cardiovascular benefits. Exercise must be maintained lifelong, as bone density gains are lost upon cessation, and balance training should be incorporated to reduce fall-related fracture risk."
  },
  {
    "id": 279,
    "categoryId": 16,
    "question": "Sulforaphane, a potent inducer of the Nrf2 pathway (cellular antioxidant defense), is found most abundantly in:",
    "options": [
      "A) Blueberries",
      "B) Broccoli Sprouts / Cruciferous Vegetables",
      "C) Red Wine",
      "D) Turmeric"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Broccoli Sprouts and Cruciferous Vegetables).\n\nBIOCHEMISTRY:\nSulforaphane is an isothiocyanate compound formed when cruciferous vegetables (broccoli, Brussels sprouts, kale, cauliflower, cabbage) are chopped, chewed, or otherwise mechanically disrupted, releasing the enzyme myrosinase that converts the precursor glucoraphanin into active sulforaphane per UpToDate and Harvard Health. Broccoli sprouts contain 20 to 100 times higher concentrations of glucoraphanin than mature broccoli, making them the most concentrated dietary source of sulforaphane per the Cleveland Clinic.\n\nNRF2 PATHWAY:\nSulforaphane is the most potent naturally occurring inducer of the Nrf2 (nuclear factor erythroid 2-related factor 2) pathway, the master regulator of cellular antioxidant defense per Harrison's Principles of Internal Medicine. Under normal conditions, Nrf2 is sequestered in the cytoplasm by Keap1 (Kelch-like ECH-associated protein 1) and targeted for proteasomal degradation. Sulforaphane modifies cysteine residues on Keap1, releasing Nrf2, which translocates to the nucleus and binds to antioxidant response elements (AREs) in the promoter regions of over 200 cytoprotective genes per UpToDate. These genes encode phase II detoxification enzymes (glutathione S-transferases, NAD(P)H quinone oxidoreductase 1), antioxidant proteins (heme oxygenase-1, thioredoxin reductase), and glutathione synthesis enzymes, collectively enhancing cellular resilience against oxidative and electrophilic stress per the Cleveland Clinic.\n\nCLINICAL EVIDENCE:\nClinical trials have demonstrated that broccoli sprout extracts reduce markers of oxidative stress, improve insulin sensitivity in type 2 diabetes, and enhance detoxification of airborne pollutants (benzene, acrolein) in populations with high environmental exposure per Harvard Health. Cooking methods affect sulforaphane availability: steaming preserves myrosinase activity, while boiling and microwaving at high temperatures can destroy it. Adding mustard seed powder (an exogenous myrosinase source) to cooked cruciferous vegetables can restore sulforaphane production per the Mayo Clinic.\n\nKEY LEARNING POINTS:\nSulforaphane from cruciferous vegetables (most concentrated in broccoli sprouts) is the most potent natural Nrf2 pathway inducer, activating over 200 cytoprotective genes involved in antioxidant defense and detoxification. The compound is formed by myrosinase converting glucoraphanin when vegetables are chopped or chewed. Steaming preserves myrosinase activity, while boiling destroys it; adding mustard seed powder can restore sulforaphane production in cooked vegetables."
  },
  {
    "id": 280,
    "categoryId": 16,
    "question": "The 'STOP-BANG' questionnaire screens for:",
    "options": [
      "A) Alcohol Use Disorder",
      "B) Obstructive Sleep Apnea (OSA)",
      "C) Depression",
      "D) Fall Risk"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Obstructive Sleep Apnea).\n\nSCREENING TOOL:\nThe STOP-BANG questionnaire is a validated, widely used screening instrument for obstructive sleep apnea (OSA) that consists of eight yes/no questions corresponding to the mnemonic: Snoring (loud enough to be heard through closed doors), Tiredness (excessive daytime sleepiness), Observed apnea (witnessed breathing cessation during sleep), high blood Pressure (treated or untreated hypertension), BMI greater than 35, Age greater than 50, Neck circumference greater than 40 cm (approximately 16 inches), and Gender male per UpToDate and the Cleveland Clinic. A score of 3 or greater indicates high risk for OSA and warrants referral for polysomnography (sleep study) per the Mayo Clinic.\n\nCLINICAL SIGNIFICANCE OF OSA:\nOSA is characterized by repetitive upper airway collapse during sleep, causing intermittent hypoxia, sleep fragmentation, and sympathetic nervous system activation per Harrison's Principles of Internal Medicine. These pathophysiologic consequences drive a cascade of cardiovascular complications including resistant hypertension (OSA is the most common identifiable cause of resistant hypertension), atrial fibrillation, pulmonary hypertension, coronary artery disease, heart failure, and stroke per UpToDate. OSA also causes insulin resistance, impaired glucose tolerance, and nonalcoholic fatty liver disease through intermittent hypoxia-induced oxidative stress and systemic inflammation per the Cleveland Clinic.\n\nDIAGNOSIS AND TREATMENT:\nPolysomnography remains the gold standard for diagnosis, with OSA severity classified by the apnea-hypopnea index (AHI): mild (5 to 14 events/hour), moderate (15 to 29), and severe (30 or greater) per Harrison's Principles of Internal Medicine. Continuous positive airway pressure (CPAP) is first-line therapy, reducing the AHI, improving daytime sleepiness, lowering blood pressure (by 2 to 3 mmHg), and reducing cardiovascular event risk per the Mayo Clinic and Harvard Health.\n\nKEY LEARNING POINTS:\nSTOP-BANG screens for obstructive sleep apnea with eight yes/no items (Snoring, Tiredness, Observed apnea, Pressure, BMI greater than 35, Age greater than 50, Neck greater than 40 cm, Gender male), with a score of 3 or greater indicating high risk. OSA is the most common identifiable cause of resistant hypertension. CPAP is first-line therapy, reducing AHI, daytime somnolence, and cardiovascular risk."
  },
  {
    "id": 281,
    "categoryId": 16,
    "question": "Autophagy ('Self-Eating') is a cellular cleanup process where cells recycle damaged organelles. It is upregulated by:",
    "options": [
      "A) High Insulin levels",
      "B) Continuous grazing",
      "C) Fasting / Caloric Restriction and Exercise",
      "D) High protein diet"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Fasting, Caloric Restriction, and Exercise).\n\nPATHOPHYSIOLOGY:\nAutophagy (from Greek auto meaning self and phagein meaning to eat) is a highly conserved cellular process in which damaged organelles, misfolded proteins, and dysfunctional mitochondria are sequestered within double-membrane vesicles called autophagosomes and delivered to lysosomes for degradation and recycling per Harrison's Principles of Internal Medicine and UpToDate. Yoshinori Ohsumi received the 2016 Nobel Prize in Physiology or Medicine for elucidating the molecular mechanisms of autophagy per Harvard Health.\n\nREGULATION:\nAutophagy is primarily regulated by the opposing actions of two nutrient-sensing pathways per the Cleveland Clinic. mTOR (mechanistic target of rapamycin), activated by amino acids, insulin, and growth factors, is the master suppressor of autophagy when nutrients are abundant (growth mode). AMPK (AMP-activated protein kinase), activated by energy depletion, fasting, caloric restriction, and exercise, is the master activator of autophagy when nutrients are scarce (repair mode) per UpToDate. During fasting or caloric restriction, declining insulin levels reduce mTOR activity, while rising AMP:ATP ratios activate AMPK, together shifting the cell from anabolic (growth) to catabolic (recycling) programs per Harrison's Principles of Internal Medicine. Exercise independently activates autophagy through AMPK activation and increased oxidative stress signaling per the Mayo Clinic.\n\nCLINICAL SIGNIFICANCE:\nImpaired autophagy is implicated in aging, neurodegeneration (accumulation of misfolded proteins in Alzheimer's and Parkinson's disease), cancer (failure to clear damaged DNA and organelles), and cardiomyopathy per UpToDate and Harvard Health. Enhancing autophagy through periodic fasting, caloric restriction, and regular exercise is hypothesized to promote cellular health and longevity, though optimal protocols for humans remain under investigation per the Cleveland Clinic.\n\nKEY LEARNING POINTS:\nAutophagy is a cellular recycling process that clears damaged organelles and misfolded proteins, regulated by the opposing mTOR (nutrient-sensing suppressor) and AMPK (energy-depletion activator) pathways. Fasting, caloric restriction, and exercise activate autophagy by reducing mTOR signaling and activating AMPK. Impaired autophagy is implicated in aging, neurodegeneration, and cancer."
  },
  {
    "id": 282,
    "categoryId": 16,
    "question": "A patient asks about Vaping (E-cigarettes) to quit smoking. The USPSTF and CDC stance is:",
    "options": [
      "A) It is FDA approved for cessation",
      "B) It is completely safe water vapor",
      "C) There is insufficient evidence to recommend it; FDA-approved aids (NRT/Chantix) are preferred",
      "D) It is more harmful than cigarettes"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Insufficient evidence to recommend e-cigarettes; FDA-approved aids are preferred).\n\nCURRENT GUIDANCE:\nThe USPSTF, CDC, and American Lung Association state that there is insufficient evidence to recommend electronic cigarettes (e-cigarettes, vaping devices) as a smoking cessation tool per the CDC and UpToDate. While e-cigarettes likely expose users to fewer toxicants than combustible cigarettes, their long-term safety profile is unknown, and they are not FDA-approved for smoking cessation per the Mayo Clinic. FDA-approved cessation pharmacotherapies with established efficacy and safety include nicotine replacement therapy (patch, gum, lozenge, inhaler, nasal spray), varenicline (Chantix), and bupropion (Zyban) per Harrison's Principles of Internal Medicine.\n\nCONCERNS:\nE-cigarettes deliver nicotine via heated aerosol containing propylene glycol, vegetable glycerin, flavorings, and ultrafine particles that penetrate deep into the lungs per the Cleveland Clinic. EVALI (e-cigarette or vaping product use-associated lung injury), identified in 2019, was linked primarily to vitamin E acetate in THC-containing cartridges but raised broader concerns about inhalation toxicity per the CDC. E-cigarettes frequently perpetuate nicotine dependence rather than resolving it, with many dual users continuing both vaping and smoking per UpToDate. Youth uptake of e-cigarettes has created a new epidemic of nicotine addiction, with the Surgeon General declaring youth vaping an epidemic in 2018 per Harvard Health.\n\nCLINICAL APPLICATION:\nFor patients interested in smoking cessation, clinicians should offer FDA-approved pharmacotherapy combined with behavioral counseling as first-line treatment per UpToDate and the Mayo Clinic. Varenicline has the highest single-agent quit rates (approximately 25 to 30% sustained abstinence at 1 year). Combination NRT (patch plus short-acting form such as gum or lozenge) approaches varenicline efficacy. If a patient is already using e-cigarettes and has successfully quit combustible cigarettes, the clinician should encourage eventual cessation of e-cigarettes as well per the Cleveland Clinic.\n\nKEY LEARNING POINTS:\nThe USPSTF and CDC do not recommend e-cigarettes for smoking cessation due to insufficient evidence and unknown long-term safety. FDA-approved cessation aids (varenicline, NRT, bupropion) have established efficacy and are preferred. E-cigarettes often perpetuate nicotine dependence and have contributed to a youth nicotine addiction epidemic."
  },
  {
    "id": 283,
    "categoryId": 16,
    "question": "Social Isolation is an independent risk factor for mortality comparable to:",
    "options": [
      "A) Eating junk food",
      "B) Smoking 15 cigarettes a day",
      "C) Drinking 1 beer a day",
      "D) Living in a city"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Comparable to smoking approximately 15 cigarettes per day).\n\nEVIDENCE:\nThe U.S. Surgeon General's 2023 advisory on social isolation and loneliness identified social disconnection as a major public health crisis, with mortality risk comparable to smoking up to 15 cigarettes per day per the CDC and Harvard Health. A landmark meta-analysis by Holt-Lunstad and colleagues (encompassing 148 studies and over 300,000 participants) found that individuals with strong social relationships had a 50% increased likelihood of survival compared to those with weak social connections, an effect size exceeding that of many established risk factors including obesity and physical inactivity per UpToDate.\n\nBIOLOGIC MECHANISMS:\nSocial isolation activates the same neurobiological stress pathways as physical threats per Harrison's Principles of Internal Medicine. Chronic loneliness increases sympathetic nervous system activity, elevates cortisol and inflammatory markers (CRP, IL-6, fibrinogen), disrupts sleep architecture, and impairs immune function (reduced natural killer cell activity and impaired vaccine responses) per the Cleveland Clinic. The conserved transcriptional response to adversity (CTRA), identified by Cole and colleagues, shows that social isolation upregulates pro-inflammatory gene expression and downregulates antiviral and antibody-related gene expression at the molecular level per Harvard Health.\n\nCLINICAL SIGNIFICANCE:\nSocial isolation increases the risk of coronary heart disease by approximately 29%, stroke by 32%, and all-cause dementia by 50% per the Mayo Clinic and UpToDate. Depression and anxiety rates are significantly higher in socially isolated individuals. Clinicians should screen for social isolation (particularly in elderly patients, those with chronic illness, and post-bereavement) and consider social prescribing, referring patients to community groups, volunteer organizations, and structured social activities as a health intervention per Harrison's Principles of Internal Medicine.\n\nKEY LEARNING POINTS:\nSocial isolation carries mortality risk comparable to smoking 15 cigarettes per day and exceeds the risk conferred by obesity and physical inactivity. Biological mechanisms include chronic sympathetic activation, elevated cortisol and inflammatory markers, and impaired immune function. Clinicians should screen for social isolation and consider social prescribing as a health intervention."
  },
  {
    "id": 284,
    "categoryId": 16,
    "question": "Which dietary sugar is the primary driver of De Novo Lipogenesis (fat production) in the liver?",
    "options": [
      "A) Glucose",
      "B) Fructose",
      "C) Galactose",
      "D) Maltose"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Fructose).\n\nPATHOPHYSIOLOGY:\nFructose is the primary dietary sugar driving de novo lipogenesis (DNL, the hepatic synthesis of new fat from non-fat substrates) because of its unique metabolic pathway per Harrison's Principles of Internal Medicine. Unlike glucose, which can be metabolized by virtually every cell in the body via glycolysis and is regulated by insulin-mediated feedback mechanisms, fructose is metabolized almost exclusively by the liver through fructokinase (ketohexokinase), which has no negative feedback regulation per UpToDate. This means a large fructose load (such as from sugar-sweetened beverages) is rapidly and completely phosphorylated by the liver, depleting hepatic ATP and generating massive substrate flux into lipogenic pathways per the Cleveland Clinic.\n\nMECHANISM:\nFructose metabolism bypasses the key regulatory enzyme of glycolysis (phosphofructokinase), flooding the liver with glyceraldehyde-3-phosphate and acetyl-CoA that are channeled directly into de novo lipogenesis per Harrison's Principles of Internal Medicine. The resulting newly synthesized triglycerides are either exported as VLDL (raising serum triglycerides) or accumulate as intrahepatic fat (contributing to nonalcoholic fatty liver disease, NAFLD) per UpToDate. Fructose also stimulates SREBP-1c (sterol regulatory element-binding protein), the master transcription factor for lipogenic genes, further amplifying fat synthesis per Harvard Health.\n\nCLINICAL IMPACT:\nEpidemiologic and interventional studies associate high fructose intake (primarily from sugar-sweetened beverages and added sugars, not whole fruit) with NAFLD, hypertriglyceridemia, insulin resistance, visceral adiposity, and increased uric acid production (fructose metabolism generates uric acid as a byproduct of ATP depletion) per the Mayo Clinic. Whole fruit, despite containing fructose, delivers it in a fiber matrix that slows absorption and limits hepatic fructose flux, and is associated with metabolic benefit rather than harm per UpToDate.\n\nKEY LEARNING POINTS:\nFructose is the primary driver of hepatic de novo lipogenesis because it is metabolized exclusively by the liver through an unregulated pathway (fructokinase) that bypasses glycolytic feedback control. This produces hypertriglyceridemia, NAFLD, and hyperuricemia. Whole fruit is protective because fiber slows fructose absorption, but sugar-sweetened beverages deliver concentrated fructose loads that overwhelm hepatic capacity."
  },
  {
    "id": 285,
    "categoryId": 16,
    "question": "The DASH Diet (Dietary Approaches to Stop Hypertension) is rich in Calcium, Magnesium, and:",
    "options": [
      "A) Sodium",
      "B) Potassium",
      "C) Iron",
      "D) Zinc"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Potassium).\n\nMECHANISM:\nThe DASH diet (Dietary Approaches to Stop Hypertension) achieves blood pressure reduction through a high intake of three key minerals: potassium (approximately 4,700 mg/day), calcium (approximately 1,250 mg/day), and magnesium (approximately 500 mg/day), with potassium being the most emphasized electrolyte per Harrison's Principles of Internal Medicine and UpToDate. Potassium lowers blood pressure by promoting renal sodium excretion (natriuresis) through inhibition of sodium reabsorption in the proximal tubule and suppression of the renin-angiotensin-aldosterone system per the Cleveland Clinic. It also causes direct vasodilation by hyperpolarizing vascular smooth muscle cells through activation of the Na+/K+-ATPase and inward-rectifier potassium channels, and it reduces sympathetic nervous system activity per the Mayo Clinic.\n\nDASH DIET EVIDENCE:\nThe original DASH trial demonstrated that the DASH dietary pattern reduced systolic blood pressure by approximately 5.5 mmHg in hypertensive individuals and 3 mmHg in normotensive individuals compared to a typical American diet per UpToDate. The DASH-Sodium trial showed that combining the DASH diet with sodium restriction to 1,500 mg/day produced additional reductions of 6 to 11 mmHg systolic, approaching the efficacy of single-drug antihypertensive therapy per Harvard Health and Harrison's Principles of Internal Medicine.\n\nDIETARY SOURCES:\nRich potassium sources in the DASH diet include bananas, potatoes, sweet potatoes, spinach, avocados, beans, lentils, citrus fruits, and low-fat dairy products per the Mayo Clinic. The 2017 ACC/AHA Hypertension Guidelines recommend the DASH diet as a first-line lifestyle modification for all patients with elevated blood pressure per the Cleveland Clinic.\n\nKEY LEARNING POINTS:\nThe DASH diet emphasizes potassium (4,700 mg/day), calcium, and magnesium from fruits, vegetables, whole grains, and low-fat dairy. Potassium lowers blood pressure via natriuresis, direct vasodilation, and reduced sympathetic tone. DASH plus sodium restriction to 1,500 mg/day achieves 6 to 11 mmHg systolic BP reduction, comparable to single-drug antihypertensive therapy."
  },
  {
    "id": 286,
    "categoryId": 16,
    "question": "Telomeres are protective caps on DNA. Which lifestyle factor is associated with SHORTER telomeres (accelerated aging)?",
    "options": [
      "A) Meditation",
      "B) Whole Food Plant Based Diet",
      "C) Sedentary behavior and Processed Meats",
      "D) Moderate Exercise"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Sedentary behavior and processed meat consumption).\n\nTELOMERE BIOLOGY:\nTelomeres are repetitive nucleotide sequences (TTAGGG in humans) capping the ends of chromosomes that protect genomic integrity during cell division per Harrison's Principles of Internal Medicine. With each mitotic division, telomeres shorten by approximately 50 to 200 base pairs because DNA polymerase cannot fully replicate the 3-prime end of linear chromosomes (the end replication problem) per UpToDate. When telomeres reach a critically short length, cells enter replicative senescence (permanent growth arrest) or apoptosis, contributing to tissue aging and organ dysfunction per the Cleveland Clinic.\n\nLIFESTYLE AND TELOMERE LENGTH:\nTelomere length is influenced by both genetic inheritance and modifiable lifestyle factors per Harvard Health. Oxidative stress and chronic inflammation accelerate telomere shortening by damaging the guanine-rich telomeric DNA (guanine is particularly susceptible to oxidative modification) and by increasing cell turnover rates per Harrison's Principles of Internal Medicine. Sedentary behavior, processed meat consumption, smoking, obesity, chronic psychological stress, and sleep deprivation are all associated with shorter telomeres per UpToDate and the Mayo Clinic. Conversely, regular physical activity, plant-rich diets, stress management, and adequate sleep are associated with preserved telomere length and increased telomerase activity per Harvard Health.\n\nCLINICAL EVIDENCE:\nThe landmark Ornish trial demonstrated that comprehensive lifestyle changes (plant-based diet, moderate exercise, stress management, social support) increased telomerase activity by approximately 30% at 3 months and were associated with telomere lengthening at 5-year follow-up per the Cleveland Clinic. Processed meats are associated with shorter telomeres likely through their content of heme iron (pro-oxidant), advanced glycation end products (AGEs), nitrosamines, and sodium, all of which promote oxidative stress and inflammation per UpToDate.\n\nKEY LEARNING POINTS:\nTelomeres shorten with each cell division and are accelerated by oxidative stress and inflammation from sedentary behavior, processed meat consumption, smoking, and chronic stress. The Ornish trial demonstrated that comprehensive lifestyle changes increase telomerase activity by 30% and can lengthen telomeres. Regular physical activity and plant-rich diets are associated with preserved telomere length."
  },
  {
    "id": 287,
    "categoryId": 11,
    "question": "In the treatment of Depression, which nutrient is often depleted and has shown benefit as an adjunct therapy?",
    "options": [
      "A) Vitamin C",
      "B) Omega-3 Fatty Acids (EPA)",
      "C) Calcium",
      "D) Vitamin K"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Omega-3 Fatty Acids, EPA).\n\nEVIDENCE:\nOmega-3 polyunsaturated fatty acids, specifically eicosapentaenoic acid (EPA), have demonstrated benefit as adjunctive therapy for major depressive disorder (MDD) in multiple randomized controlled trials and meta-analyses per UpToDate and Harrison's Principles of Internal Medicine. A meta-analysis published in Translational Psychiatry pooling over 26 RCTs found that EPA-predominant formulations (EPA alone or with EPA:DHA ratio greater than 2:1) produced statistically significant improvements in depressive symptoms compared to placebo, while DHA-predominant formulations did not per Harvard Health. The International Society for Nutritional Psychiatry Research recommends EPA at 1 to 2 grams per day as an adjunct to standard antidepressant therapy per the Cleveland Clinic.\n\nPATHOPHYSIOLOGY:\nDepression is increasingly understood as a neuroimmune disorder with elevated pro-inflammatory cytokines (IL-6, TNF-alpha, CRP) that disrupt serotonin synthesis, promote tryptophan degradation via the kynurenine pathway, impair BDNF signaling, and contribute to hippocampal neuroinflammation per Harrison's Principles of Internal Medicine. EPA exerts antidepressant effects by reducing neuroinflammation through multiple mechanisms: it competes with arachidonic acid for cyclooxygenase and lipoxygenase enzymes, shifting eicosanoid production away from pro-inflammatory prostaglandins and leukotrienes toward anti-inflammatory resolvins and protectins per UpToDate. EPA also modulates microglial activation, enhances serotonin release by improving cell membrane fluidity in presynaptic neurons, and supports BDNF expression per the Mayo Clinic.\n\nCLINICAL APPLICATION:\nOmega-3 supplementation is most effective as an augmentation strategy when added to standard antidepressant therapy rather than as monotherapy per UpToDate. Patients with elevated inflammatory markers (CRP greater than 3 mg/L) may show the greatest benefit, supporting the neuroinflammatory mechanism per Harvard Health. The 2024 ACP guidelines for MDD do not include omega-3 as a primary recommendation but acknowledge accumulating evidence for its adjunctive role per the Cleveland Clinic. Dietary sources include fatty fish (salmon, mackerel, sardines, anchovies), with supplemental EPA typically delivered as fish oil or purified EPA ethyl ester per the Mayo Clinic.\n\nKEY LEARNING POINTS:\nEPA-predominant omega-3 supplementation (1 to 2 g/day) has evidence as adjunctive therapy for depression, particularly in patients with elevated inflammatory markers. EPA reduces neuroinflammation by competing with arachidonic acid and generating pro-resolving mediators (resolvins, protectins). DHA-predominant formulations have not shown antidepressant efficacy, making the EPA:DHA ratio critical in formulation selection."
  },
  {
    "id": 288,
    "categoryId": 17,
    "question": "Which two carotenoids accumulate in the macula of the eye and protect against Age-Related Macular Degeneration (AMD)?",
    "options": [
      "A) Beta-carotene and Alpha-carotene",
      "B) Lutein and Zeaxanthin",
      "C) Lycopene and Astaxanthin",
      "D) Retinol and Retinal"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Lutein and zeaxanthin).\n\nPATHOPHYSIOLOGY:\nLutein and zeaxanthin are xanthophyll carotenoids that accumulate selectively in the macula lutea of the retina, forming the macular pigment. They serve two critical protective functions: filtering high-energy blue light (400-480 nm wavelength) before it reaches the photoreceptors, and scavenging reactive oxygen species generated by the constant photo-oxidative stress in retinal tissue. The macula is especially vulnerable to oxidative damage due to its high metabolic rate, dense concentration of polyunsaturated fatty acids, and intense light exposure.\n\nCLINICAL CONTEXT:\nAge-related macular degeneration (AMD) is the leading cause of irreversible blindness in adults over 50 in developed countries. The AREDS2 trial (Age-Related Eye Disease Study 2, NEI/NIH) established the current evidence-based supplementation formula for patients with intermediate or advanced AMD:\n- Vitamin C 500 mg\n- Vitamin E 400 IU\n- Lutein 10 mg + Zeaxanthin 2 mg (replaced beta-carotene from the original AREDS formula)\n- Zinc 80 mg + Copper 2 mg\n\nCRITICAL UPDATE:\nAREDS2 replaced beta-carotene with lutein/zeaxanthin because beta-carotene significantly increases lung cancer risk in current and former smokers (per the CARET and ATBC trials). Lutein and zeaxanthin demonstrated equivalent or superior efficacy without this risk.\n\nDIETARY SOURCES:\n- Lutein/zeaxanthin: Dark leafy greens (kale, spinach, collards), egg yolks, corn, orange peppers\n- Higher dietary intake is independently associated with reduced AMD risk in epidemiologic studies\n\nPRIMARY CARE PEARL:\nAREDS2 supplements are recommended only for intermediate or advanced AMD, not for primary prevention. Smoking cessation remains the single most impactful modifiable risk factor for AMD prevention.\n\nKEY LEARNING POINTS:\nLutein and zeaxanthin are the macular carotenoids that filter blue light and provide antioxidant protection. The AREDS2 formula uses lutein/zeaxanthin instead of beta-carotene to avoid increased lung cancer risk in smokers. AREDS2 supplementation is indicated for intermediate and advanced AMD, not for primary prevention.\n\nREFERENCES:\nNEI AREDS2 Trial; AAO AMD Preferred Practice Pattern; UpToDate; Harrison's Principles of Internal Medicine.\n---"
  },
  {
    "id": 289,
    "categoryId": 16,
    "question": "Erectile Dysfunction (ED) is often considered:",
    "options": [
      "A) A normal part of aging",
      "B) The 'Canary in the Coal Mine' for Cardiovascular Disease",
      "C) Only a hormonal issue (Low T)",
      "D) A psychological issue"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (The 'Canary in the Coal Mine' for Cardiovascular Disease).\n\nPATHOPHYSIOLOGY:\nErectile dysfunction (ED) is now recognized as an early clinical manifestation of systemic endothelial dysfunction and atherosclerosis that often precedes symptomatic coronary artery disease by 3 to 5 years per Harrison's Principles of Internal Medicine and UpToDate. The mechanistic basis for this temporal relationship is vascular diameter: the penile arteries (1 to 2 mm diameter) are smaller than the coronary arteries (3 to 4 mm), carotid arteries (5 to 7 mm), and iliac/femoral arteries (6 to 8 mm) per the Cleveland Clinic. Because atherosclerotic plaque develops systemically, the smallest-diameter arteries become flow-limiting first, making ED the earliest clinical symptom of generalized vascular disease per the Mayo Clinic.\n\nENDOTHELIAL DYSFUNCTION:\nErection depends on nitric oxide (NO) release from endothelial cells and nitrergic nerves in the corpus cavernosum, which activates guanylate cyclase, increases cGMP, and produces smooth muscle relaxation and blood engorgement per Harrison's Principles of Internal Medicine. The same endothelial dysfunction (reduced NO bioavailability from oxidative stress, inflammation, and dyslipidemia) that impairs erectile function also underlies coronary endothelial dysfunction and accelerates atherogenesis per UpToDate.\n\nCLINICAL SIGNIFICANCE:\nMultiple large prospective studies have demonstrated that ED is an independent risk factor for future myocardial infarction, stroke, and cardiovascular death, with a relative risk increase of approximately 1.5 to 2.0-fold per Harvard Health. A man presenting with new-onset ED (particularly if under age 60 with no obvious psychological or medication-related cause) should be evaluated for cardiovascular risk factors including lipid panel, fasting glucose, blood pressure, smoking status, and family history per the Cleveland Clinic. The Princeton III Consensus guidelines recommend cardiovascular risk stratification for all men with ED per UpToDate.\n\nKEY LEARNING POINTS:\nED is an early marker of systemic atherosclerosis that precedes symptomatic coronary disease by 3 to 5 years because penile arteries (1 to 2 mm) occlude before larger coronary arteries (3 to 4 mm). ED results from endothelial dysfunction with reduced nitric oxide bioavailability, the same mechanism underlying coronary disease. Men with new-onset ED should undergo cardiovascular risk factor assessment per Princeton III guidelines."
  },
  {
    "id": 290,
    "categoryId": 16,
    "question": "Which vitamin prevents Neural Tube Defects and should be supplemented BEFORE conception?",
    "options": [
      "A) Vitamin D",
      "B) Folate (Vitamin B9)",
      "C) Vitamin B12",
      "D) Iron"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Folate, Vitamin B9).\n\nPATHOPHYSIOLOGY:\nNeural tube closure occurs between days 21 and 28 after conception (approximately 6 weeks gestational age), before most women are aware of their pregnancy per Harrison's Principles of Internal Medicine. Folate (vitamin B9) is essential for DNA synthesis, specifically providing one-carbon units for thymidylate synthase (converting deoxyuridylate to thymidylate) and for purine synthesis, both of which are required for the rapid cell division occurring during neural tube closure per UpToDate. Folate deficiency during this critical window impairs neural tube fusion, resulting in anencephaly (failure of cranial neural tube closure, uniformly fatal) or spina bifida (failure of caudal neural tube closure, causing paralysis and neurogenic bladder) per the Cleveland Clinic.\n\nPREVENTION:\nThe USPSTF recommends that all women of reproductive age who are planning or capable of pregnancy take a daily folic acid supplement of 400 to 800 micrograms beginning at least one month before conception and continuing through the first trimester per the CDC and the Mayo Clinic. Women with a prior pregnancy affected by a neural tube defect require a higher dose of 4 mg daily per UpToDate. The United States mandated folic acid fortification of enriched grain products (flour, bread, cereals, pasta) in 1998, which has reduced the incidence of neural tube defects by approximately 25 to 30% per Harvard Health and the CDC.\n\nDIETARY SOURCES:\nFolate-rich foods include dark leafy greens (spinach, kale), legumes (lentils, chickpeas), asparagus, citrus fruits, and fortified grains per the Mayo Clinic. The synthetic form (folic acid) used in supplements and fortification has approximately 70% higher bioavailability than natural food folate because it does not require enzymatic conversion by dihydrofolate reductase before entering the folate cycle per Harrison's Principles of Internal Medicine.\n\nKEY LEARNING POINTS:\nFolic acid supplementation (400 to 800 mcg daily) must begin before conception because neural tube closure occurs by day 28 (before most women know they are pregnant). USPSTF recommends supplementation for all women of reproductive age capable of pregnancy. US grain fortification since 1998 has reduced neural tube defects by approximately 25 to 30%."
  },
  {
    "id": 291,
    "categoryId": 14,
    "question": "The World Health Organization (WHO) classifies Processed Meat (Bacon, Sausage, Deli meat) as:",
    "options": [
      "A) Group 2A: Probably Carcinogenic",
      "B) Group 1: Carcinogenic to Humans (Same category as Tobacco/Asbestos)",
      "C) Group 2B: Possibly Carcinogenic",
      "D) Safe in moderation"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Group 1: Carcinogenic to Humans).\n\nCLASSIFICATION:\nThe International Agency for Research on Cancer, a specialized agency of the World Health Organization, classified processed meat as a Group 1 carcinogen in 2015, placing it in the same evidence category as tobacco smoking and asbestos. This classification means there is sufficient epidemiologic and mechanistic evidence to conclude that processed meat causes cancer in humans, specifically colorectal cancer per the WHO and CDC. Processed meat includes any meat transformed through salting, curing, fermentation, smoking, or other preservation processes, such as bacon, sausage, hot dogs, deli meats, and ham. Red meat (beef, pork, lamb) was classified as Group 2A (probably carcinogenic), one tier below.\n\nPATHOPHYSIOLOGY:\nSeveral mechanisms explain the carcinogenicity of processed meat per Harrison's Principles of Internal Medicine. N-nitroso compounds are formed endogenously when nitrites and nitrates used as preservatives react with amino acids in the gastrointestinal tract, producing potent alkylating agents that directly damage colonocyte DNA. Heme iron catalyzes lipid peroxidation in the colonic lumen, generating cytotoxic and genotoxic aldehydes. Heterocyclic amines and polycyclic aromatic hydrocarbons produced during high-temperature cooking are established mutagens. The IARC meta-analysis estimated that each 50-gram daily serving of processed meat increases colorectal cancer risk by approximately 18%.\n\nCLINICAL APPLICATION:\nThe American Institute for Cancer Research and World Cancer Research Fund recommend limiting red meat to no more than three servings per week (approximately 350 to 500 grams cooked weight) and avoiding processed meat entirely for cancer prevention. In primary care, replacing processed meats with poultry, fish, legumes, or plant-based protein is a meaningful and achievable risk reduction strategy, particularly for patients with additional colorectal cancer risk factors.\n\nKEY LEARNING POINTS:\nProcessed meat is a WHO/IARC Group 1 carcinogen with sufficient evidence for causing colorectal cancer, while red meat is Group 2A (probable carcinogen). Each 50-gram daily serving of processed meat increases colorectal cancer risk by approximately 18% through N-nitroso compound formation, heme iron-catalyzed lipid peroxidation, and heterocyclic amine generation. The AICR recommends avoiding processed meat and limiting red meat to three or fewer servings per week."
  },
  {
    "id": 292,
    "categoryId": 16,
    "question": "Soluble Fiber (Oats, Beans) lowers cholesterol by:",
    "options": [
      "A) Binding bile acids in the gut and excreting them",
      "B) Speeding up metabolism",
      "C) Blocking fat digestion",
      "D) Dilating blood vessels"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Binding bile acids in the gut and excreting them).\n\nMECHANISM:\nSoluble fiber (found in oats, beans, barley, psyllium, flaxseed, and apples) forms a viscous gel in the intestinal lumen that physically entraps bile acids and prevents their reabsorption in the terminal ileum per Harrison's Principles of Internal Medicine. Normally, approximately 95% of bile acids are efficiently recycled through enterohepatic circulation, returning to the liver via the portal vein. When soluble fiber binds bile acids and carries them out in the feces, the liver must synthesize replacement bile acids from its primary substrate: cholesterol per UpToDate and the Cleveland Clinic.\n\nHEPATIC RESPONSE:\nThe resulting hepatic cholesterol depletion triggers a compensatory upregulation of LDL receptor expression on hepatocyte surfaces (mediated by SREBP-2, the same transcription factor pathway activated by statins), increasing clearance of LDL-cholesterol from the bloodstream per Harrison's Principles of Internal Medicine. This mechanism is additive with statin therapy, which is why adding soluble fiber to statin treatment produces additional LDL lowering beyond statin monotherapy per UpToDate.\n\nCLINICAL EVIDENCE:\nMeta-analyses demonstrate that 5 to 10 grams per day of soluble fiber reduces LDL cholesterol by approximately 5 to 10% per the Mayo Clinic and Harvard Health. Psyllium husk (Metamucil) at 10 to 12 grams per day and beta-glucan from oats at 3 grams per day are the best-studied soluble fibers for cholesterol reduction. The 2018 ACC/AHA Cholesterol Guidelines include increased soluble fiber intake as a recommended lifestyle intervention to enhance LDL lowering per the Cleveland Clinic. Beyond bile acid binding, soluble fiber also reduces cholesterol absorption, slows gastric emptying (improving postprandial glycemia), and produces short-chain fatty acids through colonic fermentation that may independently modulate hepatic cholesterol synthesis per UpToDate.\n\nKEY LEARNING POINTS:\nSoluble fiber lowers LDL cholesterol by binding bile acids in the gut and forcing hepatic bile acid resynthesis from cholesterol, which upregulates LDL receptor expression via SREBP-2. This mechanism is additive with statins. Five to 10 grams per day of soluble fiber (oats, psyllium, beans) reduces LDL by approximately 5 to 10%."
  },
  {
    "id": 293,
    "categoryId": 16,
    "question": "Blue Light exposure at night suppresses which hormone?",
    "options": [
      "A) Cortisol",
      "B) Melatonin",
      "C) Insulin",
      "D) Testosterone"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Melatonin).\n\nPATHOPHYSIOLOGY:\nBlue light (wavelength approximately 460 to 480 nm), emitted at high intensity by LED screens on smartphones, tablets, computers, and televisions, suppresses melatonin secretion by activating intrinsically photosensitive retinal ganglion cells (ipRGCs) that contain the photopigment melanopsin per Harrison's Principles of Internal Medicine and UpToDate. These ipRGCs project via the retinohypothalamic tract to the suprachiasmatic nucleus (SCN), the master circadian clock in the anterior hypothalamus, which in turn inhibits the pineal gland from producing melatonin per the Cleveland Clinic.\n\nMELATONIN PHYSIOLOGY:\nMelatonin is a chronobiotic hormone secreted by the pineal gland in response to darkness, with levels rising approximately 2 hours before habitual bedtime (dim light melatonin onset, DLMO) and peaking between 2 and 4 AM per Harvard Health. Melatonin does not directly induce sleep but rather signals to the brain that it is nighttime, promoting sleep onset and circadian entrainment per UpToDate. Even relatively low levels of evening blue light exposure (100 to 200 lux from a tablet at reading distance) can suppress melatonin production by up to 50% and delay DLMO by 1 to 2 hours per the Mayo Clinic.\n\nCLINICAL APPLICATION:\nSleep hygiene recommendations include avoiding screen use for 1 to 2 hours before bedtime, using blue-light-filtering glasses or device settings (night mode) in the evening, and maximizing bright light exposure during the daytime to reinforce robust circadian rhythms per Harvard Health and the CDC. Exogenous melatonin (0.5 to 3 mg taken 1 to 2 hours before desired bedtime) is most effective for circadian rhythm disorders (jet lag, delayed sleep-wake phase disorder, shift work disorder) rather than primary insomnia per UpToDate and Harrison's Principles of Internal Medicine.\n\nKEY LEARNING POINTS:\nBlue light (460 to 480 nm) from screens suppresses melatonin by activating melanopsin-containing retinal ganglion cells that signal the SCN to inhibit pineal gland secretion. Even low-intensity evening screen exposure can suppress melatonin by 50% and delay sleep onset by 1 to 2 hours. Screen avoidance before bedtime and bright daytime light exposure support healthy circadian melatonin rhythms."
  },
  {
    "id": 294,
    "categoryId": 7,
    "question": "According to the American College of Physicians (ACP) guidelines for chronic low back pain, which non-pharmacologic treatment is recommended as a first-line intervention before NSAIDs?",
    "options": [
      "A) Bed rest",
      "B) Mindfulness-Based Stress Reduction (MBSR), Yoga, or Tai Chi",
      "C) Lumbar support brace",
      "D) TENS unit"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Mindfulness-Based Stress Reduction, Yoga, or Tai Chi).\n\nPATHOPHYSIOLOGY:\nChronic low back pain, defined as pain persisting beyond 12 weeks, is the leading cause of disability worldwide and affects approximately 20% of adults with acute low back pain who develop chronic symptoms. While acute low back pain is often attributable to identifiable musculoligamentous strain or disc pathology, chronic low back pain involves complex neurobiological changes including central sensitization, in which persistent nociceptive input reorganizes spinal cord and cortical pain processing circuits, amplifying pain perception even after the initial tissue injury has healed. Psychosocial factors including catastrophizing, fear-avoidance behavior, depression, and poor self-efficacy are stronger predictors of chronicity than structural imaging findings, which is why the biopsychosocial model of pain management has become the standard framework endorsed by the ACP, APS, and international guidelines.\n\nCLINICAL EVIDENCE:\nThe 2017 American College of Physicians clinical practice guideline for chronic low back pain, published in the Annals of Internal Medicine, provides a strong recommendation that clinicians and patients should initially select non-pharmacologic treatment before considering medications. The evidence review found moderate-quality evidence supporting several mind-body and movement-based therapies. Mindfulness-based stress reduction, typically delivered as an 8-week program of guided meditation, body scanning, and yoga, demonstrated clinically meaningful improvements in pain intensity and functional limitation by modulating the affective and cognitive dimensions of pain processing through prefrontal cortical regulation of the amygdala and anterior cingulate cortex. Yoga (particularly viniyoga and Iyengar styles studied in randomized controlled trials) improved pain, function, and disability scores at 12 weeks compared to usual care, with benefits sustained at 6 to 12 months. Tai chi, a low-impact mind-body exercise emphasizing slow controlled movements and postural awareness, showed similar benefits through improvements in core stability, proprioception, and pain self-efficacy. Additional non-pharmacologic options with supporting evidence include exercise therapy, multidisciplinary rehabilitation, acupuncture, spinal manipulation, and cognitive behavioral therapy.\n\nTREATMENT AND MANAGEMENT:\nWhen non-pharmacologic therapies provide insufficient relief, the ACP guideline recommends NSAIDs as first-line pharmacologic therapy for chronic low back pain, with tramadol or duloxetine as second-line options. Opioids should be considered only as a last resort when all other therapies have failed, and only after a thorough discussion of the risks including addiction, overdose, and hyperalgesia. Importantly, the guideline recommends against the use of acetaminophen for low back pain based on evidence showing no benefit over placebo. Systemic corticosteroids, benzodiazepines, and gabapentinoids have insufficient evidence to support routine use. Imaging should be reserved for patients with red flag symptoms (progressive neurologic deficit, suspected cancer, infection, or cauda equina syndrome) rather than performed routinely, as incidental findings on MRI correlate poorly with symptoms and can lead to unnecessary interventions.\n\nKEY LEARNING POINTS:\nThe ACP strongly recommends non-pharmacologic therapies including mindfulness-based stress reduction, yoga, and tai chi as first-line treatment for chronic low back pain before initiating medications. These mind-body interventions address the biopsychosocial dimensions of chronic pain, particularly central sensitization and fear-avoidance behavior, which are stronger predictors of disability than structural findings on imaging. When pharmacotherapy is needed, NSAIDs are first-line, acetaminophen is not recommended, and opioids should be reserved as a last resort."
  },
  {
    "id": 295,
    "categoryId": 3,
    "question": "Which herbal supplement has strong evidence (and ACG guideline support) for reducing abdominal pain and bloating in IBS via calcium channel blockade in smooth muscle?",
    "options": [
      "A) Ginger",
      "B) Peppermint Oil",
      "C) Aloe Vera",
      "D) Slippery Elm"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Peppermint Oil).\n\nPATHOPHYSIOLOGY:\nAbdominal pain and cramping in IBS result from exaggerated smooth muscle contractions in the colon combined with visceral hypersensitivity. The smooth muscle tone of the gastrointestinal tract is regulated in part by voltage-gated calcium channels; when calcium influx is reduced, smooth muscle relaxes and spasm-associated pain diminishes.\n\nMECHANISM OF ACTION:\nL-menthol, the primary active constituent of peppermint oil, acts as a natural calcium channel antagonist on intestinal smooth muscle cells. By blocking calcium influx through L-type voltage-gated calcium channels, it produces direct smooth muscle relaxation, reduces colonic motility, and decreases spasm-related pain. Additionally, peppermint oil activates TRPM8 (cold-sensing) receptors and kappa-opioid receptors in the gut, which contribute to its analgesic and anti-nociceptive effects. A meta-analysis of randomized controlled trials demonstrated that peppermint oil significantly improves global IBS symptoms and abdominal pain compared to placebo, with a number needed to treat of approximately 3-4.\n\nCLINICAL APPLICATION:\nThe ACG guidelines conditionally recommend enteric-coated peppermint oil capsules for IBS-related abdominal pain. Enteric coating is essential to prevent premature release in the stomach, which can cause heartburn by relaxing the lower esophageal sphincter. The typical dose is 180-200 mg taken 30-60 minutes before meals, two to three times daily. Peppermint oil should be used with caution in patients with severe GERD. Other antispasmodic options include dicyclomine and hyoscyamine (anticholinergic agents), though peppermint oil has a more favorable side-effect profile.\n\nKEY LEARNING POINTS:\nPeppermint oil acts as a natural calcium channel blocker on intestinal smooth muscle and has ACG guideline support for IBS-related pain. Enteric-coated capsules are essential to prevent heartburn from LES relaxation. The number needed to treat is approximately 3-4 for global IBS symptom improvement. It should be taken 30-60 minutes before meals."
  },
  {
    "id": 296,
    "categoryId": 6,
    "question": "Which two supplements have Level A/B evidence from the American Academy of Neurology for migraine prophylaxis?",
    "options": [
      "A) Vitamin C and Zinc",
      "B) Magnesium and Riboflavin (Vitamin B2)",
      "C) Calcium and Vitamin D",
      "D) Fish Oil and Vitamin E"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Magnesium and Riboflavin/Vitamin B2).\n\nEVIDENCE-BASED SUPPLEMENTS FOR MIGRAINE PROPHYLAXIS:\nThe American Academy of Neurology (AAN) and the American Headache Society have reviewed evidence for complementary migraine prophylaxis. Magnesium (400 to 600 mg daily) and riboflavin (vitamin B2, 400 mg daily) carry Level B evidence (probably effective) for reducing migraine frequency. These supplements are particularly appealing for patients who prefer non-pharmacologic approaches or who have contraindications to standard prophylactic medications.\n\nPATHOPHYSIOLOGY AND MECHANISM:\nMagnesium plays a critical role in neuronal stability and neurotransmitter release. Magnesium deficiency has been demonstrated in the serum and brain tissue of migraine patients, and supplementation stabilizes neuronal membranes, blocks NMDA glutamate receptors, and reduces cortical spreading depression (the electrophysiological basis of migraine aura). Riboflavin is a precursor to flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD), essential cofactors in mitochondrial oxidative phosphorylation. Impaired mitochondrial energy metabolism has been implicated in migraine pathogenesis, and riboflavin supplementation enhances cerebral energy production.\n\nADDITIONAL SUPPLEMENTS WITH EVIDENCE:\nCoenzyme Q10 (100 mg three times daily) and feverfew also have supporting evidence, though less robust than magnesium and riboflavin. Butterbur (Petasites) previously had Level A evidence but was withdrawn from the market in some countries due to hepatotoxicity concerns from pyrrolizidine alkaloids.\n\nCOMPREHENSIVE MIGRAINE MANAGEMENT:\nFor acute treatment, NSAIDs and triptans are first-line (triptans for moderate to severe attacks). Prophylaxis is indicated when migraines occur four or more days per month or cause significant disability. First-line pharmacologic prophylaxis includes beta-blockers (propranolol), topiramate, valproate, and amitriptyline. CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab) represent a newer targeted approach. Medication overuse headache should be avoided by limiting acute analgesic use to fewer than 10 days per month.\n\nKEY LEARNING POINTS:\nMagnesium and riboflavin carry AAN Level B evidence for migraine prophylaxis through neuronal membrane stabilization and mitochondrial energy enhancement respectively. Prophylaxis is indicated for four or more migraine days per month. Supplements can be combined with standard pharmacologic prophylaxis for additive benefit."
  },
  {
    "id": 297,
    "categoryId": 3,
    "question": "Ginger is clinically proven and safe for nausea in which condition, supported by ACOG (OBGYN) guidelines?",
    "options": [
      "A) Opioid-induced nausea",
      "B) Pregnancy-induced nausea (Morning Sickness)",
      "C) Vertigo",
      "D) Diabetic Gastroparesis"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Pregnancy-induced nausea/Morning Sickness).\n\nPATHOPHYSIOLOGY:\nNausea and vomiting of pregnancy (NVP) affects approximately 70-80% of pregnant women, typically beginning between weeks 4-7 of gestation and resolving by weeks 12-16. The exact pathophysiology involves rising levels of human chorionic gonadotropin (hCG), estrogen, and progesterone, as well as alterations in gastric motility and enhanced olfactory sensitivity. The term \"morning sickness\" is a misnomer, as symptoms can occur at any time of day.\n\nMECHANISM OF ACTION:\nGinger (Zingiber officinale) contains bioactive compounds, primarily gingerols and shogaols, that exert antiemetic effects through multiple mechanisms: antagonism of serotonin 5-HT3 receptors in the gastrointestinal tract and chemoreceptor trigger zone (the same target as ondansetron), direct prokinetic effects that accelerate gastric emptying, and cholinergic antagonism in the vestibular system. Multiple randomized controlled trials have demonstrated that ginger at doses of 1 gram per day in divided doses (typically 250 mg four times daily) significantly reduces nausea and vomiting in pregnancy compared to placebo.\n\nGUIDELINE SUPPORT:\nThe American College of Obstetricians and Gynecologists (ACOG) recommends ginger as a first-line non-pharmacologic intervention for NVP. It is classified as safe in pregnancy with no evidence of teratogenicity, increased risk of preterm birth, or adverse neonatal outcomes at recommended doses. Ginger can be used alone for mild symptoms or in combination with pyridoxine (vitamin B6) and doxylamine, which is the ACOG-recommended first-line pharmacologic regimen.\n\nKEY LEARNING POINTS:\nGinger at 1 gram per day in divided doses is an ACOG-recommended first-line non-pharmacologic treatment for pregnancy-induced nausea. It acts primarily through serotonin 5-HT3 receptor antagonism and prokinetic effects. No evidence of teratogenicity exists at recommended doses. It can be used alone for mild symptoms or in combination with vitamin B6 and doxylamine."
  },
  {
    "id": 298,
    "categoryId": 11,
    "question": "S-Adenosylmethionine (SAMe) is an over-the-counter supplement used for Depression. What is a critical risk to screen for before a patient takes it?",
    "options": [
      "A) Iron deficiency",
      "B) Bipolar Disorder",
      "C) Gout",
      "D) Hypertension"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Bipolar Disorder).\n\nCLINICAL REASONING:\nS-Adenosylmethionine (SAMe) is a naturally occurring methyl donor involved in over 100 methylation reactions in the body, including the synthesis of monoamine neurotransmitters (serotonin, norepinephrine, dopamine) per UpToDate and Harvard Health. SAMe supplementation enhances monoaminergic neurotransmission, which accounts for its antidepressant properties but also creates the same risk as any monoamine-enhancing agent: the potential to precipitate a manic or hypomanic episode in patients with undiagnosed or known bipolar disorder per Harrison's Principles of Internal Medicine.\n\nEVIDENCE FOR ANTIDEPRESSANT EFFICACY:\nSeveral randomized controlled trials have demonstrated that SAMe (800 to 1,600 mg/day) is superior to placebo and comparable to tricyclic antidepressants for mild to moderate unipolar depression per the Cleveland Clinic. An AHRQ systematic review concluded that SAMe has evidence supporting its use for depression, though the overall quality of available trials is moderate per UpToDate. SAMe is available as an over-the-counter dietary supplement in the United States (it is a prescription medication in several European countries) and has a generally favorable side effect profile including mild GI upset, insomnia, and anxiety per the Mayo Clinic.\n\nMANIC SWITCH RISK:\nJust as SSRI monotherapy can trigger mania in bipolar patients, SAMe augmentation of monoamine neurotransmission can precipitate manic episodes in patients with bipolar disorder per Harrison's Principles of Internal Medicine. Case reports document SAMe-induced mania, hypomania, and mixed states per UpToDate. Before recommending or approving SAMe for any patient with depressive symptoms, clinicians must screen for a history of manic or hypomanic episodes (decreased need for sleep, racing thoughts, grandiosity, impulsive behavior, pressured speech) using tools such as the Mood Disorder Questionnaire (MDQ) per Harvard Health and the Cleveland Clinic.\n\nKEY LEARNING POINTS:\nSAMe is an endogenous methyl donor that enhances monoamine neurotransmitter synthesis and has evidence for mild to moderate unipolar depression. The critical risk before use is undiagnosed bipolar disorder, as SAMe can precipitate manic episodes through the same monoaminergic mechanism that produces its antidepressant effect. Clinicians must screen for prior manic or hypomanic episodes before any patient takes SAMe."
  },
  {
    "id": 299,
    "categoryId": 1,
    "question": "Coenzyme Q10 (CoQ10) is often recommended for patients on Statins to address which side effect?",
    "options": [
      "A) Liver toxicity",
      "B) Statin-Associated Muscle Symptoms (SAMS)",
      "C) Cognitive decline",
      "D) Insomnia"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Statin-Associated Muscle Symptoms).\n\nCLINICAL REASONING:\nCoenzyme Q10 (ubiquinone) is an essential cofactor in the mitochondrial electron transport chain (complexes I through III) and a potent lipid-soluble antioxidant per Harrison's Principles of Internal Medicine. Statins inhibit HMG-CoA reductase in the mevalonate pathway, which is also the biosynthetic pathway for CoQ10 (the mevalonate pathway produces both cholesterol and CoQ10 via a shared farnesyl pyrophosphate intermediate) per UpToDate. By reducing mevalonate production, statins decrease endogenous CoQ10 synthesis by approximately 20 to 40%, leading to reduced serum and potentially reduced skeletal muscle CoQ10 levels per the Cleveland Clinic.\n\nPATHOPHYSIOLOGY:\nStatin-associated muscle symptoms (SAMS) encompass a spectrum from myalgia (muscle pain without CK elevation, the most common form affecting 5 to 10% of statin users) to myopathy (muscle pain with elevated CK) to the rare but serious rhabdomyolysis (massive CK elevation with myoglobinuria and risk of acute kidney injury) per Harrison's Principles of Internal Medicine. The CoQ10 depletion hypothesis proposes that reduced mitochondrial CoQ10 impairs oxidative phosphorylation in skeletal muscle, leading to energy deficit, increased oxidative stress, and muscle fiber damage per UpToDate.\n\nEVIDENCE AND RECOMMENDATIONS:\nThe evidence for CoQ10 supplementation alleviating SAMS remains mixed, with some randomized controlled trials showing modest benefit and others showing no significant difference from placebo per the Mayo Clinic. Despite this inconsistency, CoQ10 supplementation (100 to 200 mg daily) is commonly recommended as a low-risk intervention given its favorable safety profile and the plausible mechanistic rationale per the Cleveland Clinic. The ACC/AHA guidelines note that CoQ10 may be considered for patients with SAMS but do not make a strong recommendation due to insufficient evidence per UpToDate.\n\nKEY LEARNING POINTS:\nCoQ10 supplementation targets statin-associated muscle symptoms because statins reduce endogenous CoQ10 production through the shared mevalonate biosynthetic pathway. SAMS ranges from myalgia (5 to 10% of users) to rare rhabdomyolysis. Evidence for CoQ10 benefit is mixed, but supplementation (100 to 200 mg daily) is a reasonable low-risk intervention."
  },
  {
    "id": 300,
    "categoryId": 16,
    "question": "Melatonin is most effective for which type of sleep disturbance?",
    "options": [
      "A) Sleep Maintenance Insomnia (waking up at 2 AM)",
      "B) Circadian Rhythm Disorders (Jet Lag / Shift Work) and Sleep Onset",
      "C) Sleep Apnea",
      "D) Restless Leg Syndrome"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Circadian Rhythm Disorders such as Jet Lag and Shift Work, and Sleep Onset).\n\nPHARMACOLOGY:\nMelatonin is a chronobiotic (circadian rhythm-shifting) agent, not a conventional sedative-hypnotic per Harrison's Principles of Internal Medicine. Unlike benzodiazepines or Z-drugs (zolpidem, zaleplon) that induce sleep through GABAergic sedation, melatonin works by binding to MT1 and MT2 receptors in the suprachiasmatic nucleus (SCN), signaling darkness to the master circadian clock and shifting the timing of sleep propensity per UpToDate. This mechanism makes melatonin most effective for conditions involving circadian misalignment rather than primary insomnia per the Cleveland Clinic.\n\nEVIDENCE BY INDICATION:\nFor jet lag, a Cochrane systematic review concluded that melatonin (0.5 to 5 mg taken at destination bedtime) is effective, particularly for eastward travel across 5 or more time zones per Harvard Health. For delayed sleep-wake phase disorder (common in adolescents and young adults), low-dose melatonin (0.5 to 1 mg) administered 3 to 5 hours before habitual sleep onset can advance the circadian clock and improve sleep onset timing per UpToDate. For shift work disorder, melatonin taken before the desired daytime sleep period modestly improves sleep duration per the Mayo Clinic. For primary insomnia without circadian misalignment, melatonin's evidence is weaker and effect sizes are small (reducing sleep onset latency by approximately 7 minutes in meta-analyses) per Harrison's Principles of Internal Medicine.\n\nCLINICAL PEARLS:\nMelatonin has a favorable safety profile with no significant dependence, tolerance, or withdrawal per the Cleveland Clinic. Timing of administration is more important than dose: for sleep onset, take 1 to 2 hours before desired bedtime; for circadian advance (jet lag, DSWPD), take 3 to 5 hours before habitual sleep onset. Ramelteon (Rozerem) is a prescription MT1/MT2 agonist FDA-approved for insomnia with sleep onset difficulty, with no abuse potential or DEA scheduling per UpToDate.\n\nKEY LEARNING POINTS:\nMelatonin is a chronobiotic agent most effective for circadian rhythm disorders (jet lag, delayed sleep phase, shift work) rather than primary insomnia. It works by signaling darkness to the SCN via MT1/MT2 receptors, not through sedation. Timing of administration is more important than dose, and it has no significant dependence or tolerance potential."
  },
  {
    "id": 301,
    "categoryId": 13,
    "question": "Turmeric (Curcumin) has poor bioavailability on its own. It should be consumed with ______ to increase absorption by 2000%.",
    "options": [
      "A) Vitamin C",
      "B) Black Pepper (Piperine) and Fat",
      "C) Sugar",
      "D) Protein"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Black Pepper containing Piperine, and Fat).\n\nPHARMACOKINETICS OF CURCUMIN:\nCurcumin, the principal bioactive polyphenol in turmeric (Curcuma longa), has potent anti-inflammatory and antioxidant properties in vitro but is limited by extremely poor oral bioavailability, estimated at less than 1 percent. The primary pharmacokinetic barriers are rapid Phase II hepatic metabolism (glucuronidation and sulfation), rapid intestinal metabolism, poor aqueous solubility, and limited gastrointestinal absorption. Without enhancement strategies, orally administered curcumin is largely metabolized before reaching systemic circulation, resulting in negligible plasma concentrations.\n\nPIPERINE ENHANCEMENT MECHANISM:\nPiperine, an alkaloid found in black pepper (Piper nigrum), dramatically enhances curcumin bioavailability by approximately 2,000 percent according to the landmark study by Shoba et al. published in Planta Medica. Piperine achieves this by inhibiting hepatic and intestinal glucuronidation, the primary pathway of curcumin elimination. Specifically, piperine inhibits UDP-glucuronosyltransferase enzymes, slowing the conjugation and clearance of curcumin and allowing it to remain in its unconjugated, bioactive form in plasma for longer. Additionally, piperine may enhance absorption by increasing intestinal permeability and inhibiting intestinal P-glycoprotein efflux pumps.\n\nROLE OF DIETARY FAT:\nCurcumin is highly lipophilic and poorly soluble in water. Co-administration with dietary fat enhances absorption by promoting incorporation into mixed micelles during digestion, facilitating transport across the intestinal epithelium via lymphatic uptake rather than portal circulation. This bypasses first-pass hepatic metabolism, further improving bioavailability. Novel formulations including liposomal curcumin, nanoparticle preparations, and curcumin-phospholipid complexes exploit this lipophilicity to achieve even greater absorption.\n\nKEY LEARNING POINTS:\nCurcumin has less than 1 percent oral bioavailability due to rapid hepatic glucuronidation and poor water solubility. Piperine from black pepper inhibits glucuronidation, increasing curcumin bioavailability by approximately 2,000 percent. Co-administration with fat enhances absorption through micelle formation and lymphatic uptake. Patients interested in curcumin supplementation should be advised to take it with black pepper and a fat-containing meal."
  },
  {
    "id": 302,
    "categoryId": 11,
    "question": "Which herbal supplement has demonstrated efficacy comparable to Benzodiazepines for Generalized Anxiety Disorder (GAD) in some trials, but carries a risk of hepatotoxicity?",
    "options": [
      "A) Valerian Root",
      "B) Kava Kava",
      "C) Chamomile",
      "D) Lavender"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Kava Kava).\n\nEVIDENCE:\nKava (Piper methysticum), a plant native to the South Pacific, has demonstrated anxiolytic efficacy comparable to low-dose benzodiazepines in several randomized controlled trials for generalized anxiety disorder per UpToDate and Harvard Health. A Cochrane systematic review of 11 RCTs found that kava extract significantly reduced anxiety symptoms compared to placebo, with effect sizes approaching those of standard anxiolytic medications per the Cleveland Clinic. The active compounds, kavalactones (particularly kavain, dihydrokavain, and methysticin), modulate GABA-A receptor binding, inhibit voltage-gated sodium and calcium channels, reduce norepinephrine reuptake, and modulate MAO-B activity per Harrison's Principles of Internal Medicine.\n\nHEPATOTOXICITY RISK:\nDespite its anxiolytic efficacy, kava carries a significant risk of hepatotoxicity ranging from transient liver enzyme elevation to fulminant hepatic failure requiring liver transplantation per UpToDate and the Mayo Clinic. This led to kava being banned or restricted in several European countries (Germany, France, United Kingdom, Switzerland) in the early 2000s, though some restrictions have since been relaxed. The mechanism of hepatotoxicity is not fully understood but may involve CYP2D6 poor metabolizer phenotype (concentrating hepatotoxic metabolites), glutathione depletion in the liver, inhibition of cyclooxygenase enzymes, or contamination with hepatotoxic stem peelings in low-quality preparations per Harrison's Principles of Internal Medicine and the Cleveland Clinic.\n\nCLINICAL APPLICATION:\nGiven the hepatotoxicity risk, kava is not recommended as a first-line treatment for anxiety by any major medical guideline per UpToDate. Patients who choose to use kava should be counseled about liver toxicity risk, should have baseline and periodic liver function monitoring, and should avoid concurrent use of alcohol, acetaminophen, or other hepatotoxic substances per Harvard Health. Safer evidence-based alternatives for GAD include CBT, SSRIs (sertraline, escitalopram), SNRIs (venlafaxine, duloxetine), and buspirone per the Mayo Clinic.\n\nKEY LEARNING POINTS:\nKava has demonstrated anxiolytic efficacy comparable to benzodiazepines through GABA-A modulation and sodium/calcium channel effects. However, it carries significant hepatotoxicity risk including fulminant liver failure, leading to bans in several European countries. Kava is not recommended as first-line therapy; CBT, SSRIs, and SNRIs are preferred for GAD."
  },
  {
    "id": 303,
    "categoryId": 3,
    "question": "The probiotic yeast *Saccharomyces boulardii* has the strongest evidence for preventing:",
    "options": [
      "A) Constipation",
      "B) Antibiotic-Associated Diarrhea and C. diff recurrence",
      "C) Acid Reflux",
      "D) Gastroparesis"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Antibiotic-associated diarrhea and C. difficile recurrence).\n\nPATHOPHYSIOLOGY:\nAntibiotic-associated diarrhea (AAD) occurs in approximately 5-35% of patients receiving antibiotics, resulting from disruption of the normal colonic microbiome that allows overgrowth of pathogenic organisms (particularly C. difficile) and loss of the metabolic functions provided by commensal bacteria (including short-chain fatty acid production and bile acid metabolism). C. difficile recurrence affects approximately 20-25% of patients after initial treatment, driven by persistent spore colonization in a microbiome that lacks the competitive exclusion provided by normal flora.\n\nMECHANISM OF ACTION:\nSaccharomyces boulardii is a non-pathogenic yeast (taxonomically a strain of S. cerevisiae) with unique properties that make it an ideal probiotic for antibiotic-associated conditions. As a yeast, it is inherently resistant to all antibacterial antibiotics and can therefore maintain its population during antibiotic therapy. Its protective mechanisms include secretion of a 54-kDa serine protease that cleaves C. difficile toxin A and its receptor, stimulation of secretory IgA production, enhancement of enterocyte brush border enzyme activity, and trophic effects on intestinal mucosa through release of polyamines.\n\nCLINICAL EVIDENCE:\nMeta-analyses of randomized controlled trials demonstrate that S. boulardii reduces the risk of antibiotic-associated diarrhea by approximately 50% (number needed to treat of approximately 10) and reduces C. difficile recurrence by approximately 50-60% when used as adjunctive therapy with standard antibiotic treatment. The typical dose is 250-500 mg twice daily, started with the first antibiotic dose and continued for 2-4 weeks after antibiotic completion. S. boulardii should not be used in immunocompromised patients or those with central venous catheters due to rare reports of fungemia.\n\nKEY LEARNING POINTS:\nS. boulardii has the strongest probiotic evidence base for preventing antibiotic-associated diarrhea and reducing C. difficile recurrence. As a yeast, it is resistant to antibacterial antibiotics and maintains its activity during antibiotic therapy. It reduces AAD risk by approximately 50% with a number needed to treat of 10. It is contraindicated in immunocompromised patients due to rare fungemia risk."
  },
  {
    "id": 304,
    "categoryId": 6,
    "question": "Biofeedback is an evidence-based therapy effective for:",
    "options": [
      "A) Tension Headaches and Migraines",
      "B) Alzheimer's prevention",
      "C) Parkinson's tremor",
      "D) Stroke recovery"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Tension Headaches and Migraines).\n\nBIOFEEDBACK FOR HEADACHE MANAGEMENT:\nBiofeedback is an evidence-based behavioral therapy recognized by the American Academy of Neurology and the Association for Applied Psychophysiology and Biofeedback as an effective non-pharmacologic treatment for both tension-type headaches and migraines. It carries Grade A evidence for migraine prevention and is recommended as a first-line option in patients who prefer non-pharmacologic therapy, are pregnant, have medication contraindications, or experience medication overuse headache.\n\nPATHOPHYSIOLOGY AND MECHANISM:\nBiofeedback trains patients to gain voluntary control over physiological processes that are normally automatic, including muscle tension, skin temperature, and heart rate variability. Using electronic sensors, patients receive real-time visual or auditory feedback about their physiological state. For tension headaches, electromyographic (EMG) biofeedback monitors trapezius and frontalis muscle tension, teaching patients to recognize and reduce the sustained muscle contraction that perpetuates pain. For migraines, thermal biofeedback trains patients to increase peripheral skin temperature (reflecting vasodilation and sympathetic deactivation), which helps modulate the autonomic nervous system dysregulation implicated in migraine pathogenesis.\n\nCLINICAL EVIDENCE:\nStudies endorsed by the AAN demonstrate that biofeedback reduces headache frequency by 35 to 55% for migraines and 40 to 60% for tension-type headaches, comparable to some pharmacologic prophylactic agents. The effects are durable, with maintained improvement at long-term follow-up. Biofeedback can be combined with cognitive behavioral therapy and relaxation training for enhanced outcomes.\n\nTREATMENT CONTEXT:\nBiofeedback typically requires 8 to 12 sessions with a trained therapist. It is particularly valuable in populations where medication is less desirable, such as pregnant women, children, and patients with polypharmacy. While biofeedback has been investigated in other neurological conditions, the strongest evidence for clinical efficacy remains in headache management.\n\nKEY LEARNING POINTS:\nBiofeedback carries Grade A evidence for migraine prophylaxis and is effective for both tension-type headaches and migraines. EMG biofeedback targets muscle tension in tension headaches, while thermal biofeedback modulates autonomic function in migraines. It is particularly valuable when pharmacologic therapy is contraindicated or when patients prefer non-drug approaches."
  },
  {
    "id": 305,
    "categoryId": 7,
    "question": "When supplementing Vitamin D for bone health, which other vitamin is often added to ensure Calcium is deposited in bone rather than soft tissue (arteries)?",
    "options": [
      "A) Vitamin A",
      "B) Vitamin K2",
      "C) Vitamin E",
      "D) Vitamin B6"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Vitamin K2).\n\nPATHOPHYSIOLOGY:\nVitamin D3 (cholecalciferol) enhances intestinal calcium absorption by stimulating enterocyte expression of calbindin, TRPV6 calcium channels, and basolateral calcium ATPase through the vitamin D receptor and calcitriol signaling pathway. However, increasing serum calcium alone does not ensure appropriate skeletal deposition. Vitamin K2 (menaquinone) serves as the essential cofactor for gamma-glutamyl carboxylase, the enzyme responsible for post-translational gamma-carboxylation of specific glutamic acid residues on vitamin K-dependent proteins. Two of these proteins are critical to calcium homeostasis in bone and vasculature. Osteocalcin, produced by osteoblasts, requires vitamin K2-dependent carboxylation to bind calcium ions with high affinity and incorporate them into the hydroxyapatite crystal lattice of the bone matrix. In its undercarboxylated form (produced when vitamin K2 is insufficient), osteocalcin has markedly reduced calcium-binding capacity, impairing bone mineralization. Matrix Gla protein, expressed by vascular smooth muscle cells and chondrocytes, similarly requires vitamin K2-dependent carboxylation to function as a potent inhibitor of vascular and soft tissue calcification by actively chelating calcium away from arterial walls.\n\nCLINICAL SIGNIFICANCE:\nThe concept of the calcium paradox describes the clinical observation that patients can simultaneously develop osteoporosis (insufficient calcium in bone) and vascular calcification (excessive calcium in arteries). This paradox is partly explained by vitamin K2 insufficiency, which impairs both osteocalcin-mediated skeletal calcium deposition and matrix Gla protein-mediated vascular calcium inhibition. Epidemiologic data from the Rotterdam Study demonstrated that higher dietary vitamin K2 intake (primarily from fermented foods) was associated with reduced aortic calcification, reduced cardiovascular mortality, and reduced all-cause mortality, independent of other dietary factors. The prospective Prospect-EPIC cohort similarly found that menaquinone intake was inversely associated with coronary heart disease risk. While these observational findings are suggestive, large-scale randomized controlled trials are still needed to establish definitive causation.\n\nTREATMENT AND MANAGEMENT:\nVitamin K2 exists in several subtypes, of which menaquinone-4 (MK-4) and menaquinone-7 (MK-7) are the most clinically studied. MK-7, derived from the Japanese fermented soybean product natto, has a significantly longer half-life (approximately 72 hours versus 1 to 2 hours for MK-4), providing sustained carboxylation activity with once-daily dosing. Dietary sources of K2 include natto (the richest source by a wide margin), hard and soft cheeses, egg yolks, and organ meats, though dietary intake in Western populations is often low. Vitamin K2 supplementation is generally considered safe, but patients on warfarin or other vitamin K antagonist anticoagulants must be counseled that vitamin K2 can antagonize the anticoagulant effect, as warfarin works precisely by inhibiting the vitamin K-dependent carboxylation cycle. Vitamin K1 (phylloquinone), found in green leafy vegetables, primarily supports hepatic synthesis of coagulation factors and has minimal activity in the extrahepatic carboxylation of osteocalcin and matrix Gla protein.\n\nKEY LEARNING POINTS:\nVitamin K2 activates osteocalcin to deposit calcium into bone and matrix Gla protein to prevent calcium deposition in arterial walls, complementing vitamin D3 which increases calcium absorption from the gut. The calcium paradox of simultaneous osteoporosis and vascular calcification can be partly explained by inadequate vitamin K2-dependent carboxylation of these regulatory proteins. Patients on warfarin must be cautioned about vitamin K2 supplementation because it antagonizes vitamin K-dependent anticoagulant activity."
  },
  {
    "id": 306,
    "categoryId": 4,
    "question": "Which mineral is often depleted in diabetics and aids in insulin sensitivity?",
    "options": [
      "A) Calcium",
      "B) Magnesium",
      "C) Sodium",
      "D) Iron"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Magnesium).\n\nPATHOPHYSIOLOGY:\nMagnesium is an essential divalent cation that serves as a cofactor for more than 300 enzymatic reactions in the body, with particularly critical roles in glucose metabolism and insulin signaling. In the insulin signaling pathway, magnesium is required for autophosphorylation of the insulin receptor tyrosine kinase, the essential first step in transducing the insulin signal from receptor binding to intracellular glucose uptake via GLUT4 translocation. When intracellular magnesium is depleted, insulin receptor tyrosine kinase activity is impaired, and post-receptor signaling through the PI3K-Akt pathway is attenuated, producing a state of cellular insulin resistance independent of other factors. Simultaneously, magnesium depletion increases intracellular calcium concentrations (magnesium normally antagonizes calcium entry through voltage-gated channels), and elevated intracellular calcium impairs insulin-stimulated glucose transport and contributes to beta-cell dysfunction by promoting premature insulin secretion and eventual beta-cell exhaustion. Patients with type 2 diabetes are particularly vulnerable to a self-reinforcing cycle of magnesium depletion: insulin resistance and hyperinsulinemia reduce renal tubular magnesium reabsorption (insulin normally stimulates magnesium reabsorption in the thick ascending limb and distal convoluted tubule via the TRPM6 channel), and osmotic diuresis from glycosuria further increases urinary magnesium wasting. The prevalence of hypomagnesemia in patients with type 2 diabetes ranges from 14 to 48% compared to 2.5 to 15% in the general population per data from Diabetes Care and a systematic review in the World Journal of Diabetes.\n\nCLINICAL EVIDENCE:\nEpidemiologic evidence strongly supports the association between magnesium status and diabetes risk. A meta-analysis published in the Journal of Internal Medicine encompassing over 500,000 participants across 25 prospective cohort studies demonstrated a significant inverse dose-response relationship between dietary magnesium intake and type 2 diabetes incidence, with each 100 mg per day increase in magnesium intake associated with an approximately 8 to 13% reduction in diabetes risk. The Framingham Offspring Study similarly demonstrated that individuals in the highest quartile of magnesium intake had significantly lower HOMA-IR values and fasting insulin levels compared to those in the lowest quartile. Randomized controlled trials of magnesium supplementation in patients with type 2 diabetes and hypomagnesemia have demonstrated improvements in fasting glucose, HOMA-IR, and HbA1c, though effect sizes are modest (HbA1c reduction of approximately 0.3% in meta-analyses published in Nutrients and Diabetes, Obesity and Metabolism). Magnesium supplementation has also demonstrated benefit for insulin sensitivity in individuals with prediabetes and metabolic syndrome.\n\nCLINICAL APPLICATION:\nSerum magnesium should be checked in patients with type 2 diabetes, particularly those with poor glycemic control, recurrent muscle cramps, arrhythmias, or concurrent use of magnesium-depleting medications including loop and thiazide diuretics, proton pump inhibitors (which impair intestinal magnesium absorption through inhibition of TRPM6/7 channels), and calcineurin inhibitors. Normal serum magnesium (1.7 to 2.2 mg/dL) does not exclude intracellular depletion, as only 1% of total body magnesium resides in the extracellular compartment, and serum levels are maintained at the expense of intracellular and bone stores. When supplementation is indicated, magnesium glycinate or magnesium taurate are preferred oral formulations due to superior bioavailability and lower incidence of gastrointestinal side effects compared to magnesium oxide (which has bioavailability of only 4%). The recommended supplemental dose for insulin resistance is 250 to 400 mg of elemental magnesium daily. Dietary sources rich in magnesium include dark leafy greens, nuts (almonds, cashews), seeds (pumpkin, chia), legumes, and whole grains. Renal function should be assessed before supplementation, as magnesium accumulates in patients with eGFR below 30 mL/min and may cause dangerous hypermagnesemia.\n\nKEY LEARNING POINTS:\nMagnesium is required for insulin receptor tyrosine kinase autophosphorylation, the critical first step in insulin signal transduction, and its deficiency directly impairs insulin sensitivity independent of other factors. Hypomagnesemia affects 14 to 48% of patients with type 2 diabetes due to insulin resistance-mediated renal wasting and osmotic diuresis. Magnesium glycinate at 250 to 400 mg daily is the preferred supplemental form, and serum magnesium levels may not reflect intracellular depletion."
  },
  {
    "id": 307,
    "categoryId": 4,
    "question": "A pregnant patient asks about Acupuncture. The NIH Consensus Statement and clinical trials support its use for:",
    "options": [
      "A) Inducing labor (in late term) and Hyperemesis Gravidarum",
      "B) Preventing Preeclampsia",
      "C) Correcting fetal chromosomal abnormalities",
      "D) Treating Gestational Diabetes"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Inducing labor in late term and Hyperemesis Gravidarum).\n\nPATHOPHYSIOLOGY:\nAcupuncture is a component of traditional Chinese medicine that involves the insertion of thin needles at specific anatomical points to modulate physiologic processes. The proposed mechanisms of action relevant to pregnancy include stimulation of endorphin release, modulation of autonomic nervous system activity, alteration of prostaglandin and oxytocin signaling, and activation of descending inhibitory pain pathways through A-delta and C fiber stimulation. In the context of pregnancy-related nausea and vomiting, acupuncture and acupressure at the Pericardium 6 (P6 or Neiguan) point, located on the volar aspect of the forearm approximately 2 inches proximal to the wrist crease between the tendons of the palmaris longus and flexor carpi radialis, is proposed to modulate vagal afferent signaling to the chemoreceptor trigger zone and the nucleus tractus solitarius in the brainstem, reducing the emetic reflex. For labor induction, acupuncture at points including Spleen 6 (SP6), Large Intestine 4 (LI4), and Bladder 67 (BL67) is proposed to stimulate uterine contractility through enhanced oxytocin receptor sensitivity and prostaglandin release.\n\nCLINICAL EVIDENCE:\nThe 1997 NIH Consensus Statement on Acupuncture identified nausea (including pregnancy-related nausea) as one of the conditions for which acupuncture demonstrated sufficient evidence of efficacy to warrant recommendation. Subsequent systematic reviews and meta-analyses have provided varying levels of support. For nausea and vomiting of pregnancy (including hyperemesis gravidarum), a Cochrane systematic review found evidence supporting P6 acupressure for reducing nausea severity, and ACOG recognizes acupressure and acupuncture as non-pharmacologic options for managing nausea in pregnancy per Practice Bulletin 189. Acupressure wristbands (Sea-Bands) targeting P6 are widely available and provide a patient-directed option. For labor induction, the evidence is more mixed but growing. A systematic review published in BJOG found that acupuncture was associated with increased cervical ripening (Bishop score improvement) and reduced need for medical induction methods in post-term pregnancies, though the quality of evidence was rated as moderate. Moxibustion at BL67 for breech presentation has been studied in several randomized trials, with a Cochrane review finding some evidence of increased cephalic version rates, though heterogeneity across studies limits firm conclusions.\n\nCLINICAL APPLICATION:\nAcupuncture performed by trained, licensed practitioners using sterile disposable needles is generally considered safe during pregnancy when contraindicated points (those traditionally associated with promoting uterine contractions, such as SP6 and LI4, during early pregnancy) are avoided per the safety guidelines of the American Academy of Medical Acupuncture and the National Certification Commission for Acupuncture and Oriental Medicine. Common side effects are minor and include localized bruising, transient soreness, and occasional lightheadedness. There are no documented teratogenic effects. For primary care providers, acupuncture represents a reasonable adjunctive option for patients with pregnancy-related nausea who have not responded to first-line interventions (dietary modifications, vitamin B6, doxylamine) or who prefer non-pharmacologic approaches. It can also be discussed as an option for patients approaching or past their estimated due date who wish to attempt natural labor induction before medical induction. It is important to note that acupuncture has no role in preventing preeclampsia, treating gestational diabetes, or addressing fetal chromosomal abnormalities, all of which require evidence-based medical management.\n\nKEY LEARNING POINTS:\nAcupuncture and acupressure at the P6 point have the strongest evidence base for pregnancy-related nausea and vomiting, with recognition from the NIH Consensus Statement and ACOG. Evidence for acupuncture-assisted labor induction is moderate but growing, showing improved cervical ripening and reduced need for medical induction in some studies. Acupuncture is safe during pregnancy when performed by trained practitioners using appropriate point selection and sterile technique."
  },
  {
    "id": 308,
    "categoryId": 1,
    "question": "Red Yeast Rice contains Monacolin K, which is chemically identical to:",
    "options": [
      "A) Metformin",
      "B) Lovastatin",
      "C) Aspirin",
      "D) Lisinopril"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Lovastatin).\n\nCLINICAL REASONING:\nRed yeast rice is produced by fermenting rice with the mold Monascus purpureus, which generates monacolin K, a compound that is chemically identical to lovastatin (originally marketed as Mevacor, the first FDA-approved statin) per Harrison's Principles of Internal Medicine and UpToDate. Monacolin K inhibits HMG-CoA reductase through the exact same mechanism as prescription lovastatin, reducing hepatic cholesterol synthesis and triggering compensatory upregulation of LDL receptor expression on hepatocyte surfaces, thereby increasing clearance of circulating LDL particles per the Cleveland Clinic.\n\nEFFICACY AND RISKS:\nStandardized red yeast rice products containing clinically meaningful amounts of monacolin K can lower LDL cholesterol by approximately 15 to 25%, comparable to low-dose prescription statin therapy per UpToDate. However, because monacolin K is functionally lovastatin, red yeast rice carries the same spectrum of adverse effects: myalgia and myopathy, hepatotoxicity (transaminase elevation), drug interactions (particularly with CYP3A4 inhibitors such as clarithromycin, itraconazole, and grapefruit juice that also affect lovastatin metabolism), and potential teratogenicity per Harrison's Principles of Internal Medicine. Patients who experienced true statin intolerance (as opposed to nocebo effect) may also be intolerant to red yeast rice for the same pharmacologic reason per the Mayo Clinic.\n\nREGULATORY AND SAFETY CONCERNS:\nThe FDA considers supplements containing significant monacolin K to be unapproved drug products, which has led many manufacturers to reduce or remove monacolin K from their formulations to avoid regulatory action per UpToDate. This means commercial red yeast rice products vary enormously in potency, and many contain little to no active ingredient. Additionally, some products are contaminated with citrinin, a nephrotoxic and potentially hepatotoxic mycotoxin produced during the fermentation process, posing a safety concern not present with prescription statins per the Cleveland Clinic.\n\nKEY LEARNING POINTS:\nRed yeast rice contains monacolin K, which is chemically identical to the prescription statin lovastatin and lowers LDL through HMG-CoA reductase inhibition. It carries the same benefits and risks as prescription lovastatin, including myopathy, hepatotoxicity, and drug interactions. Product quality is highly variable, citrinin contamination is a concern, and patients with true statin intolerance may also react to red yeast rice."
  },
  {
    "id": 309,
    "categoryId": 4,
    "question": "Black Cohosh is a popular supplement for hot flashes. What is the current consensus on its safety regarding the liver?",
    "options": [
      "A) It is perfectly safe",
      "B) Rare cases of liver toxicity have been reported; monitor LFTs",
      "C) It causes kidney failure",
      "D) It causes heart arrhythmias"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Rare cases of liver toxicity have been reported; monitor LFTs).\n\nPATHOPHYSIOLOGY:\nBlack cohosh (Actaea racemosa, formerly Cimicifuga racemosa) is a perennial herb native to North America that has been widely used as a botanical supplement for the management of menopausal vasomotor symptoms (hot flashes) and other climacteric complaints. The precise mechanism of action remains incompletely understood. Early hypotheses that black cohosh functioned as a phytoestrogen binding to estrogen receptors have largely been refuted by subsequent research. Current evidence suggests that its effects may be mediated through serotonergic activity (binding to serotonin receptors 5-HT1A and 5-HT7, modulating central thermoregulatory pathways), dopaminergic activity (binding to D2 receptors, which may explain its effects on mood and hot flashes), opioid receptor modulation, and anti-inflammatory properties of its triterpene glycoside constituents (actein, 23-epi-26-deoxyactein, cimicifugoside). The hepatotoxic potential of black cohosh has been a subject of regulatory concern since case reports of liver injury emerged in the early 2000s. The Australian Therapeutic Goods Administration, the European Medicines Agency, and Health Canada have all issued safety advisories regarding hepatotoxicity.\n\nCLINICAL EVIDENCE:\nThe evidence regarding black cohosh hepatotoxicity consists primarily of case reports and pharmacovigilance data rather than prospective clinical trial data. Approximately 80 to 90 cases of liver injury temporally associated with black cohosh use have been reported worldwide per a comprehensive review published in Menopause and the United States Pharmacopeia safety review. The hepatic injury pattern includes hepatocellular damage, cholestatic injury, and a pattern resembling autoimmune hepatitis with positive autoantibodies and interface hepatitis on biopsy. Several cases progressed to acute liver failure requiring liver transplantation, and at least a few fatalities have been reported. However, the absolute risk appears to be very low given the estimated millions of users worldwide, and a definitive causal relationship has been difficult to establish because of confounding factors including concurrent medication use, pre-existing liver disease, and potential product contamination or adulteration with hepatotoxic plant species. Regarding efficacy for hot flashes, the evidence is mixed and inconclusive. Several randomized controlled trials have shown modest benefit over placebo for vasomotor symptom reduction, while others (including a large NIH-funded trial published in the Annals of Internal Medicine) have found no significant difference from placebo. A Cochrane systematic review concluded that there is insufficient evidence to support the efficacy of black cohosh for menopausal symptoms.\n\nCLINICAL APPLICATION:\nPrimary care providers should be prepared to discuss black cohosh with menopausal patients, as it is one of the most commonly used botanical supplements for hot flashes. Key counseling points include the fact that efficacy data are mixed and overall do not clearly demonstrate benefit beyond placebo, and that rare but potentially serious hepatotoxicity has been reported. Patients who choose to use black cohosh despite uncertain efficacy should be advised to use standardized preparations from reputable manufacturers (to minimize contamination risk), limit duration of use to 6 months or less per the German Commission E recommendation, and report any symptoms suggestive of liver injury including jaundice, dark urine, right upper quadrant pain, nausea, and unusual fatigue. Baseline liver function tests before initiation and periodic monitoring during use are reasonable precautions, though no formal monitoring protocol has been established by major medical societies. Black cohosh should be avoided in patients with pre-existing liver disease, active hepatitis, or concurrent use of other potentially hepatotoxic medications. Evidence-based alternatives for vasomotor symptoms include hormone therapy (most effective), SSRIs and SNRIs (paroxetine, venlafaxine), fezolinetant, gabapentin, and cognitive behavioral therapy.\n\nKEY LEARNING POINTS:\nBlack cohosh has been associated with rare cases of hepatotoxicity including autoimmune hepatitis-like injury and acute liver failure requiring transplantation, prompting safety advisories from regulatory agencies worldwide. Efficacy for menopausal hot flashes is not clearly demonstrated beyond placebo in systematic reviews. Patients using black cohosh should have baseline and periodic liver function monitoring, limit duration of use, and be counseled on symptoms of hepatotoxicity."
  },
  {
    "id": 310,
    "categoryId": 1,
    "question": "The 'Resperate' device is FDA-cleared for lowering blood pressure. How does it work?",
    "options": [
      "A) Electrical stimulation of the vagus nerve",
      "B) Guided Slow Paced Breathing (< 10 breaths/min)",
      "C) Acupuncture",
      "D) Transcranial magnetic stimulation"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Guided Slow Paced Breathing).\n\nCLINICAL REASONING:\nThe Resperate device is an FDA-cleared, non-pharmacologic device for adjunctive blood pressure reduction that works by guiding the user through device-paced slow breathing at a rate of fewer than 10 breaths per minute (typically 4 to 6 breaths per minute) for 15-minute sessions per UpToDate. The device uses a sensor to detect the user's respiratory pattern and provides musical tones that guide inhalation and exhalation, gradually slowing the breathing rate and prolonging exhalation over the session.\n\nPATHOPHYSIOLOGY:\nSlow paced breathing reduces blood pressure through several autonomic mechanisms per Harrison's Principles of Internal Medicine. It increases vagal (parasympathetic) tone and reduces sympathetic nervous system activation, shifting the autonomic balance toward parasympathetic predominance. Prolonged exhalation enhances the respiratory sinus arrhythmia (the normal heart rate variability with breathing), which augments baroreflex sensitivity and reduces peripheral vascular resistance per the Cleveland Clinic. Multiple meta-analyses suggest that device-guided breathing can produce modest systolic BP reductions of approximately 3 to 9 mmHg, though the evidence is heterogeneous in quality per the Mayo Clinic.\n\nCLINICAL CONTEXT:\nThe AHA has reviewed device-guided breathing and concluded that it may be considered as an adjunct to standard pharmacologic and lifestyle interventions for hypertension, though it is not a substitute for first-line therapies per UpToDate. It is particularly appealing for patients seeking non-pharmacologic approaches or as a complement to medication in patients with mildly elevated blood pressure per the Cleveland Clinic.\n\nKEY LEARNING POINTS:\nThe Resperate device is FDA-cleared for blood pressure reduction through guided slow paced breathing at fewer than 10 breaths per minute, which shifts autonomic balance toward parasympathetic dominance and reduces peripheral vascular resistance. Evidence suggests modest systolic BP reductions of 3 to 9 mmHg. It is an adjunct to, not a replacement for, standard antihypertensive therapy."
  },
  {
    "id": 311,
    "categoryId": 16,
    "question": "Tai Chi has been shown in randomized trials (NEJM) to produce results similar to or better than aerobic exercise for:",
    "options": [
      "A) Weight loss",
      "B) Fibromyalgia symptom management",
      "C) Building muscle mass",
      "D) Acute infection"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Fibromyalgia symptom management).\n\nPATHOPHYSIOLOGY:\nFibromyalgia is a chronic pain condition characterized by central sensitization, in which the central nervous system amplifies pain signaling and reduces descending pain inhibition, producing widespread musculoskeletal pain, fatigue, sleep disturbance, and cognitive dysfunction. The pathophysiology involves dysregulation of neurotransmitters including substance P (elevated in cerebrospinal fluid), serotonin and norepinephrine (reduced), and alterations in hypothalamic-pituitary-adrenal axis function. Exercise is a cornerstone of fibromyalgia management, but many patients struggle with conventional aerobic exercise due to post-exertional pain flares.\n\nCLINICAL EVIDENCE:\nA landmark randomized controlled trial published in the New England Journal of Medicine (Wang et al., 2018) demonstrated that tai chi produced equal or superior outcomes compared to aerobic exercise for fibromyalgia across multiple domains including pain, fatigue, sleep quality, depression, and overall quality of life. Patients randomized to tai chi (twice weekly for 24 weeks) showed significantly greater improvement in the Fibromyalgia Impact Questionnaire than those performing supervised aerobic exercise. The benefits persisted at 52-week follow-up.\n\nMECHANISM OF BENEFIT:\nTai chi is a mind-body practice that integrates slow, flowing movements with deep breathing, meditation, and body awareness. This combination addresses multiple pathophysiologic mechanisms simultaneously: the gentle movement improves physical conditioning without triggering post-exertional pain flares, the meditative component reduces sympathetic nervous system hyperactivity and cortisol dysregulation, and the body awareness training helps modulate central sensitization. Unlike conventional exercise, tai chi engages descending pain inhibition pathways through mindfulness and relaxation.\n\nKEY LEARNING POINTS:\nTai chi is equal or superior to aerobic exercise for fibromyalgia management according to an NEJM randomized controlled trial. It addresses central sensitization through combined gentle movement, meditation, and body awareness. Benefits span pain, fatigue, sleep, depression, and quality of life. It is particularly valuable for patients who cannot tolerate conventional aerobic exercise."
  },
  {
    "id": 312,
    "categoryId": 5,
    "question": "Saw Palmetto is widely used for BPH. The most recent large-scale Cochrane review concluded:",
    "options": [
      "A) It is superior to Tamsulosin",
      "B) It is no better than placebo for urinary flow or nighttime waking",
      "C) It shrinks the prostate by 50%",
      "D) It causes sexual dysfunction"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (No better than placebo for urinary flow or nighttime waking).\n\nEVIDENCE:\nSaw palmetto (Serenoa repens) is one of the most widely used herbal supplements for benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS), with an estimated 2 million men using it in the United States alone per UpToDate and Harvard Health. However, the most rigorous evidence, including a large Cochrane systematic review of 32 randomized controlled trials, concluded that saw palmetto extract is no more effective than placebo for improving urinary flow rates (peak urinary flow, Qmax), reducing nocturia, decreasing International Prostate Symptom Score (IPSS), or reducing prostate size per Harrison's Principles of Internal Medicine.\n\nLANDMARK TRIALS:\nThe STEP trial (Saw Palmetto for Treatment of Enlarged Prostates), a double-blind RCT funded by the NIH, found no significant difference between saw palmetto 320 mg daily and placebo for the American Urological Association Symptom Index (AUA-SI), peak urinary flow rate, or quality of life measures per the Cleveland Clinic. A follow-up study using escalating doses up to 960 mg three times the standard dose also showed no benefit over placebo per UpToDate and the Mayo Clinic.\n\nPHARMACOLOGY:\nSaw palmetto extract contains fatty acids and phytosterols proposed to inhibit 5-alpha reductase (reducing dihydrotestosterone), provide anti-inflammatory effects, and have anti-androgenic properties per Harvard Health. Despite plausible mechanisms, these have not translated into clinically meaningful outcomes in rigorous trials per Harrison's Principles of Internal Medicine.\n\nEVIDENCE-BASED BPH TREATMENT:\nFor patients with moderate to severe LUTS from BPH, evidence-based options include alpha-1 adrenergic blockers (tamsulosin, alfuzosin) for rapid symptom relief, 5-alpha reductase inhibitors (finasteride, dutasteride) for prostate volume reduction in large prostates, and combination therapy for moderate to large prostates per UpToDate. Tadalafil (PDE5 inhibitor) is FDA-approved for BPH/LUTS with or without concurrent ED per the Cleveland Clinic.\n\nKEY LEARNING POINTS:\nThe Cochrane review and NIH-funded STEP trial demonstrate that saw palmetto is no more effective than placebo for BPH symptoms, urinary flow, or nocturia, even at triple the standard dose. Evidence-based BPH treatments include alpha-blockers (tamsulosin), 5-alpha reductase inhibitors (finasteride), and combination therapy. Patients should be counseled that \"natural\" does not mean effective."
  },
  {
    "id": 313,
    "categoryId": 13,
    "question": "Zinc lozenges can shorten the duration of the common cold if taken within 24 hours. What is the mechanism?",
    "options": [
      "A) Killing bacteria",
      "B) Inhibiting Rhinovirus replication in the nasal mucosa",
      "C) Increasing white blood cells",
      "D) Lowering fever"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Inhibiting Rhinovirus replication in the nasal mucosa).\n\nMECHANISM OF ACTION:\nThe proposed mechanism by which zinc exerts antiviral activity centers on direct interference with rhinovirus, the causative agent of the majority of common colds. In vitro studies demonstrate that ionic zinc (Zn2+) inhibits rhinovirus replication by blocking viral RNA-dependent RNA polymerase activity and by interfering with viral capsid protein cleavage necessary for uncoating. Additionally, zinc ions may physically block the ICAM-1 receptor on nasal epithelial cells, preventing rhinovirus attachment and cell entry. Zinc also modulates local immune responses by enhancing interferon-gamma production and supporting natural killer cell cytotoxicity, contributing to more rapid viral clearance.\n\nCLINICAL EVIDENCE:\nA Cochrane systematic review and meta-analysis found that zinc lozenges or syrup administered within 24 hours of symptom onset reduced the duration of the common cold by approximately one to two days in adults. The benefit appears to depend on formulation (zinc acetate and zinc gluconate lozenges delivering greater than 75 mg of elemental zinc per day show the most consistent benefit), dose, and crucially, early initiation. Zinc lozenges taken after 24 hours of symptom onset show minimal benefit. The lozenge form is preferred because it allows prolonged contact of zinc ions with the nasopharyngeal mucosa, where rhinovirus replication occurs.\n\nADVERSE EFFECTS AND SAFETY:\nCommon side effects of zinc lozenges include dysgeusia (bad or metallic taste) and nausea. Prolonged supplementation at high doses (greater than 40 mg elemental zinc daily for extended periods) can cause copper deficiency, leading to sideroblastic anemia and neutropenia. Intranasal zinc gel formulations should be strictly avoided because they have been associated with irreversible anosmia (permanent loss of smell), prompting FDA safety warnings and voluntary market withdrawal.\n\nKEY LEARNING POINTS:\nZinc inhibits rhinovirus replication and attachment in the nasal mucosa. Clinical benefit requires initiation within 24 hours of symptom onset, with lozenge formulations providing the most consistent evidence for shortening cold duration by one to two days. Intranasal zinc must be avoided due to risk of permanent anosmia. Prolonged high-dose zinc supplementation can cause copper deficiency."
  },
  {
    "id": 314,
    "categoryId": 9,
    "question": "A patient on Warfarin starts taking a 'Green Superfood' powder. What will likely happen to their INR?",
    "options": [
      "A) INR will increase (Bleeding risk)",
      "B) INR will decrease (Clotting risk)",
      "C) No change",
      "D) Powder causes Warfarin malabsorption"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (INR will decrease, creating clotting risk).\n\nPHARMACOLOGY:\nWarfarin exerts its anticoagulant effect by inhibiting vitamin K epoxide reductase (VKORC1), the enzyme that regenerates reduced vitamin K (the active form required as a cofactor for gamma-carboxylation of clotting factors II, VII, IX, and X, as well as the anticoagulant proteins C and S) per Harrison's Principles of Internal Medicine and UpToDate. \"Green superfood\" powders typically contain high concentrations of vitamin K1 (phylloquinone) from ingredients such as spinach, kale, spirulina, chlorella, wheatgrass, and broccoli per the Cleveland Clinic.\n\nMECHANISM OF INTERACTION:\nExogenous vitamin K1 from dietary supplements directly replenishes the substrate that warfarin is designed to deplete, effectively overriding warfarin's anticoagulant mechanism and causing the INR to fall toward normal (subtherapeutic) levels per UpToDate and Harvard Health. This creates a dangerous gap in anticoagulation for patients with indications such as atrial fibrillation (stroke prevention), mechanical heart valves (valve thrombosis risk), or venous thromboembolism per the Mayo Clinic.\n\nCLINICAL GUIDANCE:\nPatients on warfarin should maintain consistent daily vitamin K intake rather than avoiding vitamin K entirely per Harrison's Principles of Internal Medicine. The key principle is consistency: fluctuations in vitamin K intake (either sudden increases from supplements/dietary changes or sudden decreases from illness or appetite loss) cause INR instability per UpToDate. Patients should be specifically counseled to notify their provider before starting any new supplement, particularly green superfood powders, multivitamins containing vitamin K, or significant dietary changes involving leafy green vegetables per the Cleveland Clinic. INR should be rechecked within 3 to 7 days of any dietary change per the Mayo Clinic.\n\nKEY LEARNING POINTS:\nGreen superfood powders contain high vitamin K1 concentrations that override warfarin's inhibition of VKORC1, causing INR to decrease and creating dangerous thrombotic risk. The key counseling point for warfarin patients is consistency in vitamin K intake rather than avoidance. Patients must notify providers before starting any new supplement."
  },
  {
    "id": 315,
    "categoryId": 4,
    "question": "Excessive supplementation with Biotin (Vitamin B7) for hair/nails causes what error in thyroid labs?",
    "options": [
      "A) True Hyperthyroidism",
      "B) Falsely Low TSH and Falsely High T4 (Mimics Graves')",
      "C) Falsely High TSH",
      "D) Liver damage"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Falsely Low TSH and Falsely High T4, mimicking Graves' disease).\n\nPATHOPHYSIOLOGY:\nBiotin (vitamin B7, also known as vitamin H) is a water-soluble B vitamin that serves as an essential cofactor for five carboxylase enzymes involved in fatty acid synthesis, amino acid catabolism, and gluconeogenesis. It is widely available as a dietary supplement marketed for strengthening hair, skin, and nails, typically at doses of 5,000 to 10,000 mcg (5 to 10 mg) daily, which is 167 to 333 times the adequate intake of 30 mcg per day established by the National Academies. At these supraphysiologic doses, biotin accumulates in the serum at concentrations sufficient to cause clinically significant analytical interference with a large number of common immunoassays. The mechanism of interference relates to the widespread use of biotin-streptavidin chemistry as the capture or signal-generation platform in modern immunoassay systems. Streptavidin is a bacterial protein with extraordinarily high binding affinity for biotin (dissociation constant approximately 10 to the negative 15 molar), and this interaction is exploited in immunoassay design to immobilize or detect analyte-antibody complexes. When a patient has excess biotin in their serum, the exogenous biotin competes with biotinylated assay reagents for streptavidin binding sites, disrupting the assay chemistry and producing erroneous results. The direction of the error depends on the assay format: in competitive (sandwich-free) immunoassays (used for small analytes like free T4, free T3, cortisol, and vitamin D), biotin interference produces falsely elevated results, while in sandwich (two-site) immunoassays (used for large analytes like TSH, troponin, PTH, and BNP), biotin interference produces falsely decreased results.\n\nCLINICAL REASONING:\nThe clinical consequence of biotin interference on thyroid function testing is the production of a laboratory pattern that closely mimics hyperthyroidism: falsely low TSH (from interference with the sandwich TSH assay) combined with falsely elevated free T4 and free T3 (from interference with the competitive free thyroid hormone assays). This pattern is biochemically indistinguishable from Graves' disease or other causes of endogenous thyrotoxicosis, and has led to documented cases of patients being misdiagnosed with hyperthyroidism, undergoing unnecessary radioactive iodine uptake scans, being inappropriately started on antithyroid medications (methimazole), and in at least one published case, undergoing thyroidectomy based on spurious laboratory results per reports in the NEJM and Thyroid. The FDA issued a safety communication in 2017 warning about biotin interference after receiving reports of a patient death from missed myocardial infarction when high-sensitivity troponin was falsely lowered by biotin, and cases of false Graves' disease diagnoses. Conversely, biotin can cause falsely normal or low TSH in a truly hypothyroid patient, masking a diagnosis that requires treatment.\n\nAFFECTED ASSAYS:\nBeyond thyroid function tests, biotin interferes with a broad range of clinically important immunoassays using biotin-streptavidin platforms, including high-sensitivity troponin (falsely low, potentially missing acute MI), BNP and NT-proBNP (falsely low, potentially missing heart failure), PTH (falsely low), cortisol (falsely high), ferritin (falsely high or low depending on platform), 25-hydroxyvitamin D (falsely high), PSA (falsely low, potentially missing prostate cancer), beta-hCG (falsely high or low depending on platform), DHEA-S, testosterone, estradiol, and FSH/LH. The magnitude of interference is dose-dependent: supplements providing 5 to 10 mg cause significant interference, while the 30 mcg present in standard multivitamins generally does not. Notably, patients with multiple sclerosis treated with high-dose biotin (300 mg daily, used investigationally) are at extremely high risk for laboratory interference across virtually all streptavidin-based assays.\n\nCLINICAL APPLICATION:\nThe critical preventive measure is to ask all patients about biotin supplementation before ordering immunoassay-based laboratory tests. The FDA recommends discontinuing biotin for at least 2 days (48 to 72 hours) before blood draw for standard supplement doses (5 to 10 mg daily), and up to 7 days for high-dose biotin therapy. Clinicians should maintain a high index of suspicion for biotin interference when laboratory results are discordant with the clinical presentation, particularly when thyroid function tests suggest hyperthyroidism in an asymptomatic patient or when troponin is unexpectedly normal in a patient with clinical features of acute coronary syndrome. If interference is suspected, the test should be repeated after an appropriate biotin washout period, or the laboratory can be asked to run the assay on a non-streptavidin-based platform if available.\n\nKEY LEARNING POINTS:\nHigh-dose biotin supplements (5 to 10 mg daily, commonly taken for hair and nail growth) interfere with biotin-streptavidin immunoassay platforms, producing falsely low TSH and falsely high free T4 that mimic Graves' disease, and also affecting troponin, BNP, PTH, and numerous other assays. The FDA issued a safety communication in 2017 after reports of misdiagnosis and adverse outcomes. Biotin should be discontinued for at least 48 to 72 hours before immunoassay-based blood testing, and clinicians should ask about biotin use whenever lab results are discordant with the clinical picture."
  },
  {
    "id": 316,
    "categoryId": 3,
    "question": "The 'Elimination Diet' is the gold standard for diagnosing:",
    "options": [
      "A) IgE Food Allergies (Anaphylaxis)",
      "B) IgG Food Sensitivities / Intolerances",
      "C) Celiac Disease",
      "D) Gastric Cancer"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (IgG Food Sensitivities/Intolerances).\n\nPATHOPHYSIOLOGY:\nFood sensitivities (also called food intolerances) are non-IgE-mediated adverse reactions to foods that produce delayed symptoms including bloating, abdominal pain, fatigue, headaches, and brain fog, typically occurring hours to days after ingestion. Unlike IgE-mediated food allergies (which produce immediate, potentially life-threatening reactions such as anaphylaxis, urticaria, and angioedema and are reliably diagnosed with skin prick testing or serum-specific IgE), food sensitivities involve poorly characterized immune or non-immune mechanisms that current serologic testing cannot reliably identify.\n\nCLINICAL REASONING:\nCommercial IgG food sensitivity panels (measuring IgG or IgG4 antibodies to various food antigens) are widely marketed but have been consistently shown to lack clinical validity. IgG antibodies to foods are part of the normal immune response to dietary exposure and reflect physiologic tolerance, not pathologic sensitivity. The AAAAI, EAACI, and CSACI have all issued position statements advising against IgG food sensitivity testing due to the absence of supporting evidence and the potential for unnecessary dietary restriction. The elimination diet remains the gold standard for identifying true food triggers.\n\nMETHODOLOGY:\nThe elimination diet involves removing suspected trigger foods (commonly gluten, dairy, soy, eggs, corn, and artificial additives) for 2-6 weeks, then systematically reintroducing them one at a time at 3-day intervals while monitoring for symptom recurrence. Each reintroduction should be consumed at normal portions for 2-3 days, followed by a washout period. Symptom recurrence upon reintroduction and resolution upon re-elimination confirms a causal relationship. Dietitian supervision is recommended to ensure nutritional adequacy.\n\nKEY LEARNING POINTS:\nThe elimination diet is the gold standard for diagnosing food sensitivities because IgG food sensitivity panels lack clinical validity and are not recommended by allergy societies. Food sensitivities are distinct from IgE-mediated food allergies. The diet involves 2-6 weeks of elimination followed by systematic reintroduction at 3-day intervals. Dietitian supervision ensures proper implementation and nutritional adequacy."
  },
  {
    "id": 317,
    "categoryId": 6,
    "question": "A ketogenic diet (High Fat, Low Carb) is an FDA-approved medical therapy for:",
    "options": [
      "A) Weight loss",
      "B) Drug-resistant Epilepsy in children",
      "C) Alzheimer's",
      "D) ADHD"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Drug-resistant Epilepsy in children).\n\nKETOGENIC DIET FOR EPILEPSY:\nThe ketogenic diet is a high-fat, low-carbohydrate, adequate-protein dietary therapy that has been used since the 1920s for drug-resistant epilepsy. It carries strong evidence from randomized controlled trials and is endorsed by the International League Against Epilepsy as an effective treatment option when two or more appropriately chosen antiepileptic drugs fail to achieve seizure freedom. The classic ketogenic diet uses a 4:1 ratio of fat to combined protein and carbohydrate.\n\nPATHOPHYSIOLOGY AND MECHANISM:\nWhen carbohydrate intake is severely restricted, the liver converts fatty acids into ketone bodies (beta-hydroxybutyrate, acetoacetate, and acetone), which cross the blood-brain barrier and serve as an alternative fuel source for neurons. The anticonvulsant mechanism is multifactorial and includes enhanced GABAergic inhibition, reduced neuronal excitability through ketone body effects on ATP-sensitive potassium channels, decreased glutamate-mediated excitation, and anti-inflammatory and neuroprotective effects. The shift in cerebral energy metabolism fundamentally alters the neuronal environment in ways that dampen seizure activity.\n\nCLINICAL EFFECTIVENESS:\nApproximately 50% of children with drug-resistant epilepsy achieve a greater than 50% reduction in seizure frequency on the ketogenic diet, and about 10 to 15% become seizure-free. It is particularly effective in certain conditions including glucose transporter type 1 (GLUT1) deficiency syndrome and pyruvate dehydrogenase deficiency, where it is considered the treatment of choice.\n\nPRACTICAL CONSIDERATIONS:\nThe diet requires close supervision by a specialized nutritional team. Potential adverse effects include kidney stones, hyperlipidemia, growth retardation, constipation, and nutritional deficiencies. Modified versions including the modified Atkins diet and low glycemic index treatment offer less restrictive alternatives with similar efficacy for some patients.\n\nKEY LEARNING POINTS:\nThe ketogenic diet is an established treatment for drug-resistant epilepsy, particularly in children, with approximately 50% of patients achieving significant seizure reduction. Ketone bodies provide an alternative cerebral fuel that dampens neuronal excitability through multiple mechanisms. It is the treatment of choice in GLUT1 deficiency syndrome and pyruvate dehydrogenase deficiency."
  },
  {
    "id": 318,
    "categoryId": 7,
    "question": "Glucosamine and Chondroitin Sulfate are popular for Knee Osteoarthritis. The GAIT trial showed efficacy primarily in:",
    "options": [
      "A) Mild pain",
      "B) Moderate-to-Severe pain (subset of patients)",
      "C) Preventing cartilage loss",
      "D) Rheumatoid Arthritis"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Moderate-to-Severe pain subset).\n\nPATHOPHYSIOLOGY:\nOsteoarthritis of the knee involves progressive degradation of articular cartilage, a tissue composed of type II collagen fibers embedded in a proteoglycan-rich extracellular matrix produced and maintained by chondrocytes. Glucosamine is an amino monosaccharide that serves as a precursor for the glycosaminoglycan chains of proteoglycans, the molecules responsible for the compressive resilience and water-retaining capacity of cartilage. Chondroitin sulfate is itself a major glycosaminoglycan component of the cartilage matrix. The therapeutic hypothesis is that oral supplementation with these structural building blocks could support cartilage repair, reduce matrix metalloproteinase-mediated degradation, and exert modest anti-inflammatory effects by inhibiting nuclear factor kappa-B signaling and interleukin-1 beta-mediated catabolic pathways in chondrocytes.\n\nCLINICAL EVIDENCE:\nThe Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT), published in the New England Journal of Medicine in 2006, was a landmark NIH-funded, multicenter, randomized, double-blind, placebo-controlled trial involving 1,583 patients with symptomatic knee osteoarthritis. The trial evaluated glucosamine hydrochloride 1,500 mg daily, chondroitin sulfate 1,200 mg daily, their combination, celecoxib 200 mg daily, and placebo over 24 weeks. In the overall study population, neither glucosamine alone, chondroitin alone, nor the combination achieved a statistically significant reduction in knee pain compared to placebo. However, a prespecified subgroup analysis of patients with moderate-to-severe knee pain (Western Ontario and McMaster Universities Osteoarthritis Index pain subscale of 301 to 400) demonstrated that the combination of glucosamine plus chondroitin sulfate produced a statistically significant 25% improvement in pain scores compared to placebo, a response rate of 79.2% versus 54.3% for placebo. Celecoxib was effective across all pain severity subgroups. The GAIT ancillary structural study, which evaluated radiographic joint space narrowing over 2 years, found no significant disease-modifying effect for any supplement group.\n\nTREATMENT AND MANAGEMENT:\nBased on the GAIT results and subsequent meta-analyses, the American College of Rheumatology conditionally recommends against the use of glucosamine and chondroitin for knee osteoarthritis in their 2019 guidelines, citing inconsistent evidence of efficacy. However, many clinicians adopt a pragmatic approach, offering a time-limited trial of 3 months for patients with moderate-to-severe pain who prefer complementary approaches or who have contraindications to NSAIDs, with discontinuation if no symptomatic improvement is observed. When a trial is undertaken, glucosamine sulfate (the formulation used in positive European trials, distinct from the hydrochloride salt used in GAIT) at 1,500 mg daily combined with chondroitin sulfate at 1,200 mg daily is the preferred regimen. These supplements have an excellent safety profile, with adverse effects comparable to placebo and no significant drug interactions, though glucosamine may theoretically affect glycemic control in diabetic patients and chondroitin may potentiate warfarin anticoagulation.\n\nKEY LEARNING POINTS:\nThe GAIT trial showed no benefit of glucosamine or chondroitin over placebo in the overall population with knee osteoarthritis, but a prespecified subgroup with moderate-to-severe pain showed significant benefit with the combination therapy. Glucosamine sulfate is the preferred formulation based on European trial data, and a 3-month empiric trial is a reasonable pragmatic approach for patients with moderate-to-severe symptoms. No disease-modifying structural benefit has been demonstrated, and the ACR conditionally recommends against routine use."
  },
  {
    "id": 319,
    "categoryId": 11,
    "question": "St. John's Wort is effective for mild depression, but it is dangerous because it is a potent:",
    "options": [
      "A) CYP 3A4 Inducer",
      "B) CYP 3A4 Inhibitor",
      "C) Renal toxin",
      "D) Sedative"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (CYP 3A4 Inducer).\n\nPHARMACOLOGY:\nSt. John's Wort (Hypericum perforatum) is the most potent known herbal inducer of the cytochrome P450 enzyme system, particularly CYP3A4 (the most clinically important drug-metabolizing enzyme, responsible for metabolizing approximately 50% of all prescription medications) per Harrison's Principles of Internal Medicine and UpToDate. The active constituent hyperforin activates the pregnane X receptor (PXR), a nuclear transcription factor that upregulates CYP3A4, CYP2C9, CYP1A2, and P-glycoprotein (MDR1) gene expression in the liver and intestinal epithelium per the Cleveland Clinic.\n\nCLINICAL CONSEQUENCES:\nEnzyme induction accelerates the metabolism of substrate drugs, reducing their plasma concentrations to subtherapeutic levels and causing treatment failures with potentially life-threatening consequences per UpToDate. Critical interactions include oral contraceptives (breakthrough bleeding and unintended pregnancy from reduced ethinyl estradiol levels), warfarin (loss of anticoagulation with thromboembolic risk), cyclosporine and tacrolimus (organ transplant rejection from subtherapeutic immunosuppression), HIV protease inhibitors and NNRTIs (viral resistance from subtherapeutic antiviral levels), direct oral anticoagulants, digoxin, statins, calcium channel blockers, and methadone per Harvard Health and Harrison's Principles of Internal Medicine.\n\nDISTINCTION FROM INHIBITION:\nEnzyme induction (which St. John's Wort causes) increases enzyme production over days to weeks, lowering drug levels. This is the opposite of enzyme inhibition (which drugs like ketoconazole, grapefruit juice, and erythromycin cause), which blocks enzyme activity and raises drug levels per the Mayo Clinic. The full induction effect of St. John's Wort develops over approximately 1 to 2 weeks of consistent use and may persist for a similar period after discontinuation per UpToDate.\n\nKEY LEARNING POINTS:\nSt. John's Wort is the most potent herbal CYP3A4 inducer, activating PXR to upregulate CYP3A4, CYP2C9, CYP1A2, and P-glycoprotein. This reduces plasma levels of oral contraceptives (pregnancy risk), warfarin (thrombosis risk), immunosuppressants (rejection risk), and HIV medications (resistance risk). Clinicians must specifically screen for St. John's Wort during medication reconciliation."
  },
  {
    "id": 320,
    "categoryId": 16,
    "question": "Adaptogens (e.g., Ashwagandha, Rhodiola) are theorized to work by:",
    "options": [
      "A) Increasing Testosterone",
      "B) Modulating the HPA Axis and cortisol response to stress",
      "C) Sedating the brainstem",
      "D) Acting as a placebo"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Modulating the HPA Axis and cortisol response to stress).\n\nDEFINITION:\nAdaptogens are a category of herbal products theorized to improve the body's resistance to physical, chemical, and biological stressors by modulating the hypothalamic-pituitary-adrenal (HPA) axis and cortisol response per UpToDate and the Cleveland Clinic. The term was coined by Soviet scientist Nikolai Lazarev in 1947, with the concept formalized by Israel Brekhman, who defined adaptogens as substances that increase nonspecific resistance to stress, have a normalizing (bidirectional) effect on physiology, and are relatively nontoxic per Harvard Health.\n\nPROPOSED MECHANISMS:\nThe most studied adaptogens include ashwagandha (Withania somnifera), rhodiola (Rhodiola rosea), and eleuthero (Eleutherococcus senticosus) per the Mayo Clinic. Proposed mechanisms include modulation of cortisol secretion (reducing peak cortisol in acute stress while supporting baseline cortisol function), regulation of heat shock protein 70 (Hsp70) expression (which stabilizes cellular proteins under stress), modulation of nitric oxide production, and effects on neuropeptide Y (NPY) signaling per UpToDate. A systematic review of ashwagandha showed modest reductions in serum cortisol (approximately 11 to 32%) and perceived stress scores in randomized trials, though study quality was variable and sample sizes were small per Harrison's Principles of Internal Medicine.\n\nCLINICAL LIMITATIONS:\nThe evidence base for adaptogens remains limited by small, heterogeneous trials with variable preparations, doses, and endpoints per the Cleveland Clinic. Standardization is a major concern because the active constituent concentrations vary widely between products and brands. Important drug interactions exist: ashwagandha may potentiate thyroid hormone, sedatives, and immunosuppressants. Clinicians should advise patients that while preliminary evidence is promising for stress and cortisol modulation, adaptogens should complement (not replace) evidence-based stress management strategies including exercise, sleep hygiene, cognitive behavioral therapy, and social connection per Harvard Health and UpToDate.\n\nKEY LEARNING POINTS:\nAdaptogens (ashwagandha, rhodiola) are theorized to improve stress resilience by modulating HPA axis cortisol responses, Hsp70 expression, and neuropeptide Y signaling. Evidence shows modest cortisol reductions (11 to 32%) with ashwagandha, but overall evidence quality is limited. Adaptogens should complement, not replace, evidence-based stress management strategies."
  },
  {
    "id": 321,
    "categoryId": 4,
    "question": "Omega-3 Fatty Acids (EPA/DHA) are often used in ADHD. A meta-analysis suggests the effect size is:",
    "options": [
      "A) Equal to Ritalin",
      "B) Small but statistically significant",
      "C) Zero",
      "D) Harmful"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Small but statistically significant).\n\nPATHOPHYSIOLOGY:\nThe rationale for omega-3 fatty acid supplementation in attention-deficit/hyperactivity disorder (ADHD) is grounded in the essential role of long-chain polyunsaturated fatty acids in brain structure and neurotransmitter function. The human brain is approximately 60% lipid by dry weight, and omega-3 fatty acids, particularly docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), are critical structural components of neuronal cell membrane phospholipids. DHA is concentrated in synaptic membranes where it modulates membrane fluidity, receptor conformation, and signal transduction efficiency. EPA serves primarily as an anti-inflammatory mediator, reducing neuroinflammation through competitive inhibition of arachidonic acid-derived proinflammatory eicosanoids (prostaglandins and leukotrienes) and through production of specialized pro-resolving mediators (resolvins and protectins). Both fatty acids influence dopaminergic and serotonergic neurotransmission: omega-3 deficiency has been shown to reduce dopamine receptor density in the frontal cortex and impair dopamine release in animal models, while supplementation enhances dopaminergic signaling in prefrontal circuits critical for attention and executive function. Multiple studies have documented that children with ADHD have significantly lower blood levels of omega-3 fatty acids compared to age-matched controls, and the degree of deficiency correlates with symptom severity per data reviewed in the Journal of the American Academy of Child and Adolescent Psychiatry.\n\nCLINICAL EVIDENCE:\nThe evidence for omega-3 supplementation in ADHD has been evaluated in several meta-analyses of randomized controlled trials. A comprehensive meta-analysis published in the Journal of Clinical Psychiatry (Bloch and Qawasmi, 2011) encompassing 10 trials and 699 children found a statistically significant but small effect of omega-3 supplementation on ADHD symptoms, with a pooled effect size of 0.31 for inattention and 0.22 for hyperactivity. A subsequent and larger meta-analysis published in Neuropsychopharmacology (Chang et al., 2018) analyzing 16 randomized controlled trials confirmed a modest but significant benefit, with EPA-predominant formulations showing greater efficacy than DHA-predominant preparations. For context, the effect size of stimulant medications (methylphenidate, amphetamine) for ADHD symptoms is approximately 0.8 to 1.0, making omega-3 supplementation approximately one-quarter to one-third as effective as first-line pharmacotherapy. A Lancet Psychiatry review of nutritional interventions in mental health disorders similarly concluded that omega-3 supplementation shows the most consistent evidence among nutritional approaches for ADHD, though the effect size remains modest.\n\nCLINICAL APPLICATION:\nOmega-3 fatty acid supplementation should be positioned as an adjunctive intervention in ADHD management rather than a replacement for first-line treatments including behavioral therapy and stimulant or non-stimulant medications. The evidence best supports EPA-predominant formulations (with EPA content of at least 500 mg daily), as EPA appears to drive the clinical benefit more than DHA based on subgroup analyses in the meta-analytic literature. Supplementation may be most beneficial in patients with documented low omega-3 blood levels, mild symptom severity, or as an adjunct in patients with partial response to standard pharmacotherapy. Omega-3 supplementation is generally well tolerated with minimal side effects (mild gastrointestinal complaints, fishy aftertaste) and has an excellent safety profile, making it a reasonable consideration for families who wish to explore complementary approaches or for patients who are hesitant about or unable to tolerate stimulant medications. Dietary sources of EPA and DHA include fatty fish (salmon, mackerel, sardines, herring), and the AHA recommends at least two servings of fatty fish per week for general cardiovascular health.\n\nKEY LEARNING POINTS:\nOmega-3 fatty acid supplementation produces a small but statistically significant improvement in ADHD symptoms (effect size approximately 0.2 to 0.3), roughly one-quarter to one-third the effect of stimulant medications. EPA-predominant formulations at doses of at least 500 mg daily appear most effective. Omega-3s should be considered as an adjunct to standard ADHD treatment rather than a replacement, and may be most beneficial in patients with documented omega-3 deficiency."
  },
  {
    "id": 322,
    "categoryId": 14,
    "question": "A cancer patient wants to take high-dose antioxidants (Vitamin C, E) during radiation therapy. You advise:",
    "options": [
      "A) Go ahead, it protects healthy cells",
      "B) Avoid, as it may protect the cancer cells from the oxidative damage of radiation",
      "C) It has no effect",
      "D) Only take Vitamin E"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Caution; antioxidants may reduce efficacy of radiation by protecting cancer cells).\n\nPATHOPHYSIOLOGY:\nRadiation therapy kills cancer cells primarily by generating reactive oxygen species (ROS) that cause lethal double-strand DNA breaks. Approximately 60 to 70% of radiation-induced cellular damage is mediated through ROS produced by radiolysis of intracellular water per Harrison's Principles of Internal Medicine, with the remaining damage occurring through direct DNA ionization. Similarly, several chemotherapy agents including alkylating agents, platinum compounds, and anthracyclines exert their cytotoxic effects at least partially through oxidative mechanisms. High-dose exogenous antioxidant supplements could theoretically reduce treatment efficacy by neutralizing the very ROS intended to destroy tumor cells.\n\nCLINICAL EVIDENCE:\nThe Alpha-Tocopherol Beta-Carotene Cancer Prevention (ATBC) trial demonstrated that beta-carotene supplementation paradoxically increased lung cancer incidence and mortality in smokers by 18%, and the CARET trial confirmed this with a 28% increase in lung cancer incidence among high-risk participants taking beta-carotene plus retinol per the National Cancer Institute. Retrospective studies have shown trends toward worse disease-free survival in cancer patients taking high-dose antioxidants during treatment. A systematic review in the Journal of the National Cancer Institute concluded that potential harm from antioxidant supplementation during cancer treatment cannot be excluded.\n\nCLINICAL APPLICATION:\nASCO and the American Cancer Society recommend against high-dose antioxidant supplements (vitamin C, vitamin E, beta-carotene, selenium) during active radiation or oxidative chemotherapy per their respective clinical guidelines. This recommendation applies specifically to supplemental doses that far exceed physiologic levels, not to antioxidants consumed through whole foods at normal dietary levels, which are generally considered safe and potentially beneficial during treatment. After treatment completion, supplementation is a separate consideration with less concern for treatment interference. The treating oncologist should always be consulted.\n\nKEY LEARNING POINTS:\nHigh-dose antioxidant supplements during radiation may protect cancer cells by neutralizing the reactive oxygen species that mediate the majority of radiation-induced damage. The ATBC and CARET trials demonstrated paradoxically increased cancer incidence with beta-carotene supplementation in at-risk populations. ASCO and the American Cancer Society recommend against high-dose antioxidant supplements during active cancer treatment, while dietary antioxidants from whole foods are generally acceptable."
  },
  {
    "id": 323,
    "categoryId": 16,
    "question": "In Integrative Medicine, the 'Placebo Effect' is viewed as:",
    "options": [
      "A) A nuisance to be eliminated",
      "B) A physiological response mediated by endorphins and expectation, to be harnessed ethically",
      "C) Evidence that the patient is faking",
      "D) Only relevant in psychology"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (A physiological response mediated by endorphins and expectation, to be harnessed ethically).\n\nNEUROBIOLOGY:\nThe placebo effect is a genuine physiological phenomenon involving measurable changes in brain activity, neurotransmitter release, and peripheral physiology in response to inert treatments administered within a therapeutic context per Harrison's Principles of Internal Medicine and UpToDate. Functional neuroimaging studies demonstrate that placebo analgesia activates endogenous opioid pathways (confirmed by naloxone reversal), the endocannabinoid system, and dopaminergic reward circuits in the nucleus accumbens, ventral tegmental area, and prefrontal cortex per the Cleveland Clinic. Placebo treatments for Parkinson's disease produce measurable dopamine release in the striatum, and placebo bronchodilators produce subjective (though not spirometric) improvement in asthma per Harvard Health.\n\nTHERAPEUTIC CONTEXT:\nThe magnitude of the placebo response is influenced by the therapeutic ritual: provider warmth and empathy, confident positive framing, sensory characteristics of the treatment (larger pills, injections versus pills, branded versus generic), and the patient's prior treatment experiences and expectations per UpToDate. The provider-patient relationship itself is a powerful active ingredient in healing, independent of specific pharmacologic or procedural interventions per the Mayo Clinic. Open-label placebos (where patients are told they are receiving a placebo) have shown benefit in irritable bowel syndrome, chronic low back pain, and cancer-related fatigue, suggesting that the therapeutic ritual and expectation framework contribute to benefit even without deception per Harrison's Principles of Internal Medicine.\n\nINTEGRATIVE MEDICINE PERSPECTIVE:\nRather than viewing the placebo effect as a confound to be eliminated, integrative medicine conceptualizes it as an endogenous healing response to be ethically maximized through optimized therapeutic encounters, empathic communication, positive expectation framing, and treatment rituals per Harvard Health and UpToDate. This approach does not endorse deception but rather leverages the neurobiology of healing through the clinician-patient interaction per the Cleveland Clinic.\n\nKEY LEARNING POINTS:\nThe placebo effect involves genuine neurobiological responses including endogenous opioid release, dopaminergic activation, and endocannabinoid signaling, measurable on functional neuroimaging. The therapeutic relationship, provider empathy, and treatment ritual are active ingredients that modulate these responses. Open-label placebos demonstrate that benefit occurs even without deception, supporting ethical harnessing of placebo mechanisms."
  },
  {
    "id": 324,
    "categoryId": 9,
    "question": "Which hormone is the master regulator of systemic iron homeostasis, blocking iron absorption in the gut when stores are high?",
    "options": [
      "A) Erythropoietin",
      "B) Hepcidin",
      "C) Ferritin",
      "D) Transferrin"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Hepcidin).\n\nPHYSIOLOGY:\nHepcidin is a 25-amino acid peptide hormone produced primarily by hepatocytes that serves as the master regulator of systemic iron homeostasis per Harrison's Principles of Internal Medicine and UpToDate. Hepcidin controls iron availability by binding to and inducing internalization and degradation of ferroportin, the only known cellular iron export channel found on enterocytes (controlling dietary iron absorption), macrophages (controlling iron recycling from senescent red blood cells), and hepatocytes (controlling iron storage release) per the Cleveland Clinic.\n\nREGULATION:\nHepcidin expression is upregulated by high iron stores (sensed via transferrin saturation and the HFE/TfR2/HJV signaling complex on hepatocytes), inflammation (IL-6 directly induces hepcidin transcription via the JAK-STAT3 pathway, explaining iron sequestration in anemia of chronic disease), and infection (iron restriction as an innate immune defense against siderophilic pathogens) per Harrison's Principles of Internal Medicine. Hepcidin is downregulated by iron deficiency, erythropoietic drive (via erythroferrone produced by erythroblasts), hypoxia (via HIF pathway), and pregnancy per UpToDate and Harvard Health.\n\nCLINICAL SIGNIFICANCE:\nHepcidin excess is the central mechanism of anemia of chronic disease (also called anemia of inflammation), where IL-6-driven hepcidin elevation blocks iron absorption and traps iron in macrophages despite adequate or increased total body iron stores per the Mayo Clinic. This produces the characteristic iron profile of low serum iron, low TIBC, normal to elevated ferritin, and low transferrin saturation per Harrison's Principles of Internal Medicine. Conversely, inappropriately low hepcidin (as in hereditary hemochromatosis from HFE gene mutations) permits unregulated iron absorption leading to iron overload per UpToDate and the Cleveland Clinic.\n\nKEY LEARNING POINTS:\nHepcidin is the master regulator of iron homeostasis, controlling iron absorption and recycling by degrading ferroportin (the sole cellular iron export channel). Hepcidin excess (driven by IL-6 in inflammation) causes anemia of chronic disease by sequestering iron in macrophages. Hepcidin deficiency (as in hereditary hemochromatosis) causes unregulated iron absorption and iron overload."
  },
  {
    "id": 325,
    "categoryId": 9,
    "question": "You are evaluating a 2-year-old with Microcytic Anemia (MCV 65). The Mentzer Index (MCV / RBC count) is < 13. What is the most likely diagnosis?",
    "options": [
      "A) Iron Deficiency Anemia",
      "B) Thalassemia Trait",
      "C) Lead Poisoning",
      "D) B12 Deficiency"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Thalassemia Trait).\n\nDIAGNOSTIC REASONING:\nThe Mentzer Index (MCV divided by RBC count) is a simple, rapid screening tool to distinguish thalassemia trait from iron deficiency anemia in the setting of microcytic anemia per Harrison's Principles of Internal Medicine and UpToDate. A Mentzer Index less than 13 favors thalassemia trait, while greater than 13 favors iron deficiency per the Cleveland Clinic. In this 2-year-old with MCV 65 and a Mentzer Index less than 13, thalassemia trait is the most likely diagnosis per the Mayo Clinic.\n\nPATHOPHYSIOLOGY:\nIn thalassemia trait, the mild reduction in globin chain production produces smaller red blood cells (low MCV) but the bone marrow compensates by increasing erythropoiesis, resulting in a characteristically elevated RBC count per Harrison's Principles of Internal Medicine. This combination of low MCV with high RBC count produces a low Mentzer Index. In iron deficiency anemia, both hemoglobin content per cell (low MCV) and total red cell production (low RBC count) are reduced because iron is required for heme synthesis in all new erythrocytes, producing a high Mentzer Index per UpToDate.\n\nPEDIATRIC CONSIDERATIONS:\nThalassemia trait is particularly important to identify in the pediatric population to avoid unnecessary iron supplementation (which can cause iron overload in thalassemia) and to provide genetic counseling to families per the Cleveland Clinic. In a 2-year-old, iron deficiency is extremely common (from dietary transition and rapid growth), so the Mentzer Index provides a valuable first step in differentiating the two most common causes of microcytic anemia per Harvard Health. Confirmatory testing includes hemoglobin electrophoresis (elevated HbA2 in beta-thalassemia trait) and iron studies (ferritin, TIBC) per the Mayo Clinic.\n\nADDITIONAL DIAGNOSTIC CLUES:\nThe peripheral smear in thalassemia trait shows target cells, microcytes, and a normal to mildly elevated red cell distribution width (RDW), while iron deficiency produces more marked anisocytosis with elevated RDW per Harrison's Principles of Internal Medicine and UpToDate.\n\nKEY LEARNING POINTS:\nThe Mentzer Index (MCV/RBC count) less than 13 favors thalassemia trait (low MCV with compensatory high RBC count), while greater than 13 favors iron deficiency (low MCV with low RBC count). Thalassemia trait in children should not be treated with iron, and confirmatory testing includes hemoglobin electrophoresis. RDW is typically normal in thalassemia trait but elevated in iron deficiency."
  },
  {
    "id": 326,
    "categoryId": 9,
    "question": "A patient with anemia has a Reticulocyte Count of 0.1% (Low). This indicates the anemia is due to:",
    "options": [
      "A) Hemolysis (Destruction)",
      "B) Acute Blood Loss",
      "C) Bone Marrow Production Failure",
      "D) Splenic Sequestration"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Bone Marrow Production Failure).\n\nPATHOPHYSIOLOGY:\nThe reticulocyte count measures the proportion of immature red blood cells (reticulocytes, which still contain residual ribosomal RNA) released from the bone marrow into the circulation, providing a direct assessment of erythropoietic activity per Harrison's Principles of Internal Medicine and UpToDate. A low reticulocyte count (less than 0.5 to 1% or less than 25,000/microL absolute reticulocyte count) in the setting of anemia indicates that the bone marrow is failing to mount an appropriate compensatory erythropoietic response, pointing to a production failure (hypoproliferative) mechanism per the Cleveland Clinic.\n\nCLASSIFICATION OF ANEMIA BY RETICULOCYTE COUNT:\nThis single test divides anemias into two fundamental categories per Harrison's Principles of Internal Medicine. Hypoproliferative anemias (low reticulocyte count) include iron deficiency, B12/folate deficiency, anemia of chronic disease, aplastic anemia, myelodysplastic syndrome, pure red cell aplasia, renal failure (erythropoietin deficiency), and marrow infiltration (myelophthisis from metastatic disease, fibrosis, or granulomas) per UpToDate. Hyperproliferative anemias (elevated reticulocyte count, typically greater than 2 to 3%) indicate that the marrow is responding appropriately to red cell destruction or loss, pointing to hemolysis (autoimmune, mechanical, sickle cell, G6PD deficiency, hereditary spherocytosis) or acute blood loss per the Mayo Clinic.\n\nRETICULOCYTE PRODUCTION INDEX:\nThe raw reticulocyte percentage can be misleadingly elevated in severe anemia because it is calculated relative to a reduced total RBC count per Harvard Health. The reticulocyte production index (RPI) corrects for both the degree of anemia and the premature release of reticulocytes (shift reticulocytes with longer maturation time), providing a more accurate assessment of marrow response: RPI greater than 2 indicates appropriate marrow response, while less than 2 indicates inadequate production per Harrison's Principles of Internal Medicine.\n\nKEY LEARNING POINTS:\nA low reticulocyte count in anemia indicates bone marrow production failure (hypoproliferative anemia), encompassing iron deficiency, B12/folate deficiency, aplastic anemia, and marrow infiltration. A high reticulocyte count indicates appropriate marrow response to peripheral red cell destruction (hemolysis) or blood loss. The reticulocyte production index corrects the raw percentage for anemia severity."
  },
  {
    "id": 327,
    "categoryId": 9,
    "question": "Von Willebrand Disease (vWD) is the most common inherited bleeding disorder. What is the dual function of von Willebrand Factor (vWF)?",
    "options": [
      "A) Activates Factor X and lyses clots",
      "B) Binds platelets to injured endothelium AND carries Factor VIII",
      "C) Converts Fibrinogen to Fibrin",
      "D) Inhibits Vitamin K"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Binds platelets to injured endothelium AND carries Factor VIII).\n\nPHYSIOLOGY:\nVon Willebrand factor (vWF) is a large multimeric glycoprotein synthesized by endothelial cells and megakaryocytes that plays two essential and complementary roles in hemostasis per Harrison's Principles of Internal Medicine and UpToDate. First, vWF mediates platelet adhesion to exposed subendothelial collagen at sites of vascular injury by serving as a bridge between platelet glycoprotein Ib (GPIb) receptors and collagen fibrils, a function critical in high-shear environments (arterioles and capillaries) where platelets cannot adhere to collagen directly per the Cleveland Clinic. Second, vWF serves as the carrier protein for coagulation Factor VIII, protecting it from premature proteolytic degradation by activated protein C and extending its plasma half-life from approximately 2 hours (unbound) to 12 hours (vWF-bound) per Harvard Health.\n\nCLINICAL SIGNIFICANCE:\nVon Willebrand disease (vWD) is the most common inherited bleeding disorder, affecting approximately 1% of the population per Harrison's Principles of Internal Medicine. The dual function of vWF explains the characteristic bleeding pattern: mucocutaneous bleeding (epistaxis, menorrhagia, gingival bleeding, easy bruising, GI bleeding) from defective platelet adhesion, and prolonged aPTT from secondary Factor VIII deficiency per UpToDate and the Mayo Clinic. Type 1 (partial quantitative deficiency, 75 to 80% of cases) is usually mild, Type 2 (qualitative dysfunction of vWF multimers) has multiple subtypes, and Type 3 (complete absence of vWF) is rare and severe per the Cleveland Clinic.\n\nTREATMENT:\nDesmopressin (DDAVP) is first-line treatment for Type 1 vWD, stimulating release of stored vWF from endothelial Weibel-Palade bodies per Harrison's Principles of Internal Medicine. For Type 2 (where released vWF is dysfunctional) and Type 3 (no vWF to release), vWF-containing Factor VIII concentrates (Humate-P) are required per UpToDate.\n\nKEY LEARNING POINTS:\nVon Willebrand factor has dual hemostatic functions: bridging platelets to injured endothelium (GPIb-collagen adhesion) and carrying/stabilizing Factor VIII. Deficiency causes mucocutaneous bleeding (platelet adhesion defect) plus prolonged aPTT (secondary Factor VIII deficiency). Desmopressin is first-line for Type 1 vWD by releasing stored vWF from endothelial cells."
  },
  {
    "id": 328,
    "categoryId": 9,
    "question": "Immune Thrombocytopenia (ITP) in children is typically triggered by:",
    "options": [
      "A) A viral illness 1-3 weeks prior",
      "B) Bacterial Sepsis",
      "C) Trauma",
      "D) Iron deficiency"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (A viral illness 1 to 3 weeks prior).\n\nPATHOPHYSIOLOGY:\nImmune thrombocytopenia (ITP) in children is an autoimmune disorder in which IgG antibodies (most commonly directed against platelet GPIIb/IIIa or GPIb/IX surface glycoproteins) bind to platelets, causing their accelerated destruction by splenic macrophages via Fc receptor-mediated phagocytosis per Harrison's Principles of Internal Medicine and UpToDate. In approximately 60 to 75% of pediatric ITP cases, the onset follows a viral illness (upper respiratory infection, varicella, measles, EBV, CMV, parvovirus B19) by 1 to 3 weeks, suggesting molecular mimicry or nonspecific immune activation as the triggering mechanism per the Cleveland Clinic.\n\nCLINICAL PRESENTATION:\nPediatric ITP classically presents in a previously healthy child aged 2 to 6 years with sudden onset of petechiae, purpura, and mucocutaneous bleeding (epistaxis, gingival bleeding) following a viral prodrome per the Mayo Clinic. The hallmark is isolated thrombocytopenia (often below 20,000/microL) with an otherwise normal CBC (normal hemoglobin, normal WBC, normal peripheral smear morphology except for large platelets reflecting marrow compensation) per Harrison's Principles of Internal Medicine. The child typically appears well despite dramatic-appearing skin findings per Harvard Health.\n\nPEDIATRIC VERSUS ADULT ITP:\nPediatric ITP is typically self-limited, with 80% of cases resolving spontaneously within 6 to 12 months without treatment per UpToDate. Adult ITP tends to be chronic (lasting more than 12 months in over 50% of cases), has no viral trigger, is more common in women, and usually requires treatment per the Cleveland Clinic.\n\nMANAGEMENT:\nFor children with platelet counts above 20,000/microL and no active bleeding, observation alone is appropriate per Harrison's Principles of Internal Medicine. For significant bleeding or very low counts, first-line treatments include corticosteroids (prednisone or dexamethasone), IVIG (which blocks splenic Fc receptors, temporarily reducing platelet destruction), and anti-D immunoglobulin (in Rh-positive, non-splenectomized patients) per UpToDate and the Mayo Clinic.\n\nKEY LEARNING POINTS:\nPediatric ITP is triggered by a viral illness in 60 to 75% of cases, presenting 1 to 3 weeks after infection with sudden isolated thrombocytopenia, petechiae, and mucocutaneous bleeding in an otherwise well child. Unlike adult ITP, 80% of pediatric cases resolve spontaneously within 6 to 12 months. Observation is appropriate for counts above 20,000 without active bleeding."
  },
  {
    "id": 329,
    "categoryId": 14,
    "question": "A 65-year-old male has an incidental finding of WBC 40,000 with 85% Lymphocytes. The blood smear shows 'Smudge Cells'. Diagnosis?",
    "options": [
      "A) Acute Myeloid Leukemia (AML)",
      "B) Chronic Lymphocytic Leukemia (CLL)",
      "C) CML",
      "D) Mononucleosis"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Chronic Lymphocytic Leukemia).\n\nPATHOPHYSIOLOGY:\nChronic lymphocytic leukemia is the most common adult leukemia in Western countries, with a median age at diagnosis of approximately 70 years per Harrison's Principles of Internal Medicine. CLL is a clonal malignancy of mature B lymphocytes that accumulate in the peripheral blood, bone marrow, lymph nodes, and spleen. The malignant B cells co-express CD5 (normally a T-cell marker) with B-cell markers CD19, CD20 (dim), and CD23, a combination that is virtually diagnostic on flow cytometry per UpToDate. These cells are inherently fragile due to cytoskeletal abnormalities, and when a blood smear is prepared, mechanical forces rupture the cells, producing the characteristic smudge cells (also called basket cells) that are a hallmark morphologic finding.\n\nCLINICAL PRESENTATION:\nCLL is frequently discovered incidentally on routine blood work with an unexpected lymphocytosis, as in this patient. Diagnosis requires an absolute lymphocyte count greater than 5,000 per microliter sustained for at least 3 months per the International Workshop on CLL criteria. Most patients are asymptomatic at diagnosis. When symptoms develop, they include painless lymphadenopathy, splenomegaly, fatigue, and recurrent infections from hypogammaglobulinemia. Autoimmune hemolytic anemia and immune thrombocytopenia are recognized complications. Richter transformation to aggressive diffuse large B-cell lymphoma occurs in approximately 2 to 10% of patients per the Cleveland Clinic.\n\nMANAGEMENT:\nMany patients with early-stage, asymptomatic CLL are managed with active surveillance (watch and wait), as randomized trials have demonstrated no survival benefit from early treatment per UpToDate. Treatment is indicated for progressive cytopenias, massive or symptomatic lymphadenopathy or splenomegaly, constitutional symptoms, or rapidly rising lymphocyte counts. Modern therapy has been transformed by targeted agents including BTK inhibitors (ibrutinib, acalabrutinib) and BCL-2 inhibitors (venetoclax), which have largely replaced chemoimmunotherapy per NCCN guidelines.\n\nKEY LEARNING POINTS:\nCLL is the most common adult leukemia in Western countries and is characterized by mature B-cell lymphocytosis with smudge cells on peripheral smear reflecting the fragility of the malignant lymphocytes. Flow cytometry showing CD5-positive, CD19-positive, CD20-dim, CD23-positive B cells is virtually diagnostic. Many patients are managed with active surveillance, with treatment initiated only for progressive symptoms or cytopenias."
  },
  {
    "id": 330,
    "categoryId": 9,
    "question": "Thrombotic Thrombocytopenic Purpura (TTP) is a medical emergency characterized by the 'Pentad' of symptoms. Which is NOT part of the pentad?",
    "options": [
      "A) Thrombocytopenia",
      "B) Microangiopathic Hemolytic Anemia (Schistocytes)",
      "C) Fever",
      "D) Joint Swelling"
    ],
    "correctAnswer": 3,
    "explanation": "CORRECT: D (Joint Swelling is NOT part of the TTP pentad).\n\nPATHOPHYSIOLOGY:\nThrombotic thrombocytopenic purpura (TTP) is a life-threatening thrombotic microangiopathy caused by severe deficiency of ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13), the enzyme responsible for cleaving ultra-large von Willebrand factor (UL-vWF) multimers released from endothelial cells per Harrison's Principles of Internal Medicine and UpToDate. When ADAMTS13 activity falls below 10% (either from autoantibody inhibition in acquired TTP or from inherited mutations in congenital TTP), UL-vWF multimers accumulate and cause spontaneous platelet aggregation in the microvasculature, forming platelet-rich thrombi that occlude arterioles and capillaries throughout the body per the Cleveland Clinic.\n\nTHE CLASSIC PENTAD:\nThe historical TTP pentad consists of thrombocytopenia (from platelet consumption in microthrombi), microangiopathic hemolytic anemia (MAHA, with schistocytes on peripheral smear from mechanical shearing of RBCs through occluded microvasculature), neurologic symptoms (confusion, headache, seizures, focal deficits from cerebral microthrombi), renal impairment (from renal microvascular occlusion), and fever per Harrison's Principles of Internal Medicine. However, the complete pentad is present in fewer than 5% of patients at diagnosis, and waiting for all five features delays life-saving treatment per UpToDate and Harvard Health. Joint swelling is not part of this pentad and is more characteristic of autoimmune conditions such as rheumatoid arthritis or systemic lupus erythematosus per the Mayo Clinic.\n\nDIAGNOSIS AND MANAGEMENT:\nTTP should be suspected in any patient with thrombocytopenia plus MAHA (schistocytes on smear), and treatment with plasma exchange (plasmapheresis) must begin emergently, as untreated TTP has a mortality exceeding 90% per Harrison's Principles of Internal Medicine. Plasma exchange removes the autoantibody and UL-vWF multimers while replacing ADAMTS13 per UpToDate. Adjunctive caplacizumab (an anti-vWF nanobody) and rituximab (anti-CD20) are increasingly used per the Cleveland Clinic.\n\nKEY LEARNING POINTS:\nThe TTP pentad is thrombocytopenia, microangiopathic hemolytic anemia (schistocytes), neurologic symptoms, renal impairment, and fever; joint swelling is not included. TTP results from severe ADAMTS13 deficiency causing ultra-large vWF multimer accumulation and microvascular platelet aggregation. Untreated mortality exceeds 90%, and emergent plasma exchange is life-saving."
  },
  {
    "id": 331,
    "categoryId": 9,
    "question": "Hydroxyurea is the standard of care for severe Sickle Cell Disease because it:",
    "options": [
      "A) Thins the blood",
      "B) Increases production of Fetal Hemoglobin (HbF)",
      "C) Suppresses the immune system",
      "D) Dilates blood vessels"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Increases production of Fetal Hemoglobin).\n\nPHARMACOLOGY:\nHydroxyurea is the cornerstone disease-modifying therapy for sickle cell disease (SCD), with its primary therapeutic mechanism being induction of fetal hemoglobin (HbF, alpha-2-gamma-2) production in erythroid precursors per Harrison's Principles of Internal Medicine and UpToDate. HbF does not contain the mutant beta-S globin chain (which contains the valine-for-glutamic acid substitution at position 6 that causes hemoglobin S polymerization under deoxygenated conditions), and therefore HbF does not participate in the sickling process per the Cleveland Clinic.\n\nMECHANISM:\nHydroxyurea is a ribonucleotide reductase inhibitor that induces HbF through several proposed mechanisms: selective cytotoxicity to late erythroid progenitors (allowing earlier progenitors with higher gamma-globin expression to preferentially survive and differentiate), nitric oxide-mediated activation of soluble guanylyl cyclase, and epigenetic modifications of the gamma-globin gene promoter per UpToDate and Harvard Health. Additional benefits include reduced neutrophil and monocyte counts (decreasing vaso-occlusive adhesion events), decreased WBC-endothelial adhesion, improved red cell hydration, and increased nitric oxide bioavailability per Harrison's Principles of Internal Medicine.\n\nCLINICAL EVIDENCE:\nThe landmark MSH (Multicenter Study of Hydroxyurea) trial demonstrated that hydroxyurea reduced the frequency of painful vaso-occlusive crises by approximately 50%, reduced acute chest syndrome episodes, decreased transfusion requirements, and reduced hospitalizations per the Cleveland Clinic and the Mayo Clinic. Long-term follow-up data show a significant mortality benefit with sustained use per UpToDate. The BABY HUG trial demonstrated safety and efficacy in children as young as 9 months per Harrison's Principles of Internal Medicine.\n\nKEY LEARNING POINTS:\nHydroxyurea reduces sickle cell crises by approximately 50% primarily by inducing fetal hemoglobin (HbF), which cannot participate in HbS polymerization and sickling. Additional benefits include reduced WBC adhesion and improved nitric oxide bioavailability. It is recommended for all patients with severe SCD, with evidence supporting use from infancy (BABY HUG trial)."
  },
  {
    "id": 332,
    "categoryId": 9,
    "question": "In Hereditary Hemochromatosis, the HFE gene mutation leads to:",
    "options": [
      "A) Excessive Iron excretion",
      "B) Unregulated Iron absorption from the gut",
      "C) Inability to bind Iron to Transferrin",
      "D) Destruction of Red Blood Cells"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Unregulated iron absorption from the gut).\n\nPATHOPHYSIOLOGY:\nHereditary hemochromatosis (HH) is the most common autosomal recessive genetic disorder in individuals of Northern European descent, with a prevalence of approximately 1 in 200 to 300 for the homozygous C282Y mutation in the HFE gene on chromosome 6 per Harrison's Principles of Internal Medicine and UpToDate. The HFE protein normally forms a complex with transferrin receptor 2 (TfR2) and hemojuvelin (HJV) on hepatocyte surfaces that senses iron-loaded transferrin and signals upregulation of hepcidin synthesis per the Cleveland Clinic. When HFE is dysfunctional, this iron-sensing mechanism fails, hepcidin levels remain inappropriately low, and ferroportin (the sole cellular iron exporter on enterocytes and macrophages) remains active and uninhibited, resulting in unregulated intestinal iron absorption of 3 to 4 mg/day (versus the normal 1 to 2 mg/day) per UpToDate and Harvard Health.\n\nCLINICAL MANIFESTATIONS:\nProgressive iron accumulation over decades deposits iron in parenchymal cells of multiple organs per Harrison's Principles of Internal Medicine. The classic presentation includes hepatic fibrosis and cirrhosis (with 200-fold increased hepatocellular carcinoma risk), diabetes mellitus (\"bronze diabetes\" from pancreatic beta-cell iron deposition), cardiomyopathy (both dilated and restrictive), hypogonadotropic hypogonadism (pituitary iron deposition), arthropathy (particularly second and third metacarpophalangeal joints), and skin hyperpigmentation per the Mayo Clinic and the Cleveland Clinic.\n\nDIAGNOSIS AND MANAGEMENT:\nElevated transferrin saturation (greater than 45%) is the earliest and most sensitive screening marker, followed by elevated ferritin per UpToDate. HFE gene testing confirms the diagnosis. Treatment is therapeutic phlebotomy (removal of 500 mL blood weekly until ferritin falls below 50 ng/mL, then maintenance phlebotomy every 2 to 4 months) per Harrison's Principles of Internal Medicine. First-degree relatives should be screened with HFE genotyping and iron studies per the Cleveland Clinic.\n\nKEY LEARNING POINTS:\nHereditary hemochromatosis results from HFE gene mutations causing inappropriately low hepcidin, leading to unregulated iron absorption via uninhibited ferroportin. Iron deposits cause cirrhosis (200-fold HCC risk), diabetes, cardiomyopathy, and hypogonadism. Transferrin saturation greater than 45% is the earliest screening marker, and therapeutic phlebotomy is the treatment."
  },
  {
    "id": 333,
    "categoryId": 9,
    "question": "Factor V Leiden is the most common inherited thrombophilia. It increases clotting risk by:",
    "options": [
      "A) Causing Factor V to be resistant to degradation by Protein C",
      "B) Increasing Factor V production 10-fold",
      "C) Removing Factor V from the blood",
      "D) Activating platelets directly"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Causing Factor V to be resistant to degradation by Protein C).\n\nPATHOPHYSIOLOGY:\nFactor V Leiden is the most common inherited thrombophilia, present in approximately 5% of Caucasian populations (less common in African and Asian populations) per Harrison's Principles of Internal Medicine and UpToDate. The mutation is a single nucleotide substitution (G1691A) in the Factor V gene that replaces arginine with glutamine at position 506 (R506Q), which is the primary cleavage site where activated protein C (APC) normally inactivates Factor Va per the Cleveland Clinic. The mutant Factor V Leiden is activated normally to Factor Va (functioning as a procoagulant cofactor in the prothrombinase complex) but resists proteolytic inactivation by APC, resulting in prolonged Factor Va activity and excessive thrombin generation per UpToDate.\n\nTHROMBOTIC RISK:\nHeterozygous Factor V Leiden carriers have a 3 to 8-fold increased risk of venous thromboembolism (VTE) over their lifetime, while homozygous carriers have a 50 to 80-fold increased risk per Harrison's Principles of Internal Medicine and Harvard Health. The thrombotic risk is primarily venous (deep vein thrombosis, pulmonary embolism) rather than arterial, and is significantly amplified by concurrent risk factors including oral contraceptive use (35-fold risk when combined with heterozygous FVL), pregnancy, surgery, immobilization, and obesity per the Mayo Clinic and UpToDate.\n\nCLINICAL APPLICATION:\nTesting for Factor V Leiden is performed using the APC resistance assay (functional screening) followed by confirmatory genetic testing per the Cleveland Clinic. Routine population screening is not recommended; testing is indicated for patients with unprovoked VTE (especially before age 50), recurrent VTE, VTE at unusual sites (cerebral venous sinus, mesenteric, portal), and strong family history of VTE per Harrison's Principles of Internal Medicine. Heterozygous carriers with a single provoked VTE do not require lifelong anticoagulation, while those with recurrent or unprovoked events may benefit from extended anticoagulation per UpToDate.\n\nKEY LEARNING POINTS:\nFactor V Leiden (R506Q mutation) causes activated protein C resistance, the most common inherited thrombophilia (5% of Caucasians). Heterozygotes have 3 to 8-fold VTE risk, amplified to 35-fold by oral contraceptive use. The thrombotic risk is venous, not arterial, and testing is indicated for unprovoked VTE, recurrent VTE, or strong family history."
  },
  {
    "id": 334,
    "categoryId": 9,
    "question": "G6PD Deficiency causes hemolysis when patients are exposed to oxidative stressors. Which is a classic trigger?",
    "options": [
      "A) Fava Beans",
      "B) Penicillin",
      "C) Sunlight",
      "D) Gluten"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Fava Beans).\n\nPATHOPHYSIOLOGY:\nGlucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common human enzymopathy, affecting over 400 million people worldwide with highest prevalence in malaria-endemic regions (Africa, Mediterranean, Middle East, Southeast Asia) due to heterozygote advantage against Plasmodium falciparum malaria per Harrison's Principles of Internal Medicine and UpToDate. G6PD is the rate-limiting enzyme of the hexose monophosphate shunt (pentose phosphate pathway), which generates NADPH, the essential reducing agent that maintains glutathione in its reduced form (GSH) per the Cleveland Clinic. Reduced glutathione protects hemoglobin and red cell membranes from oxidative damage. Without adequate G6PD, red blood cells cannot regenerate NADPH and are exquisitely vulnerable to oxidative stress per Harvard Health.\n\nOXIDATIVE TRIGGERS:\nFava beans (Vicia faba) contain the oxidant compounds vicine and convicine (and their aglycones divicine and isouramil), which generate reactive oxygen species that overwhelm the G6PD-deficient red cell's diminished antioxidant defense per Harrison's Principles of Internal Medicine. The resulting oxidative damage denatures hemoglobin (forming Heinz bodies, precipitates of denatured hemoglobin visible with crystal violet staining) and damages the red cell membrane, leading to both intravascular and extravascular hemolysis per UpToDate. Other classic triggers include medications (primaquine, dapsone, sulfonamides, nitrofurantoin, rasburicase, methylene blue) and infections (which generate oxidative stress via the neutrophil respiratory burst) per the Mayo Clinic.\n\nCLINICAL PRESENTATION:\nAcute hemolytic episodes present 1 to 3 days after oxidant exposure with dark urine (hemoglobinuria), jaundice, fatigue, tachycardia, and back/abdominal pain per the Cleveland Clinic. Laboratory findings include anemia, elevated LDH, indirect hyperbilirubinemia, low haptoglobin, reticulocytosis, and Heinz bodies on special staining. The peripheral smear characteristically shows \"bite cells\" (where splenic macrophages have removed Heinz body inclusions) per Harrison's Principles of Internal Medicine.\n\nKEY LEARNING POINTS:\nFava beans are a classic G6PD deficiency trigger, containing vicine and convicine that generate oxidative stress in NADPH-depleted red cells. G6PD deficiency is the most common enzymopathy worldwide, with selective advantage against malaria. The hemolytic episode produces Heinz bodies (denatured hemoglobin) and bite cells (post-splenic removal of inclusions)."
  },
  {
    "id": 335,
    "categoryId": 9,
    "question": "Folate Deficiency and B12 Deficiency both cause Megaloblastic Anemia. B12 deficiency is distinguished by:",
    "options": [
      "A) Jaundice",
      "B) Neurologic symptoms (Paresthesia, Ataxia)",
      "C) Glossitis",
      "D) Diarrhea"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Neurologic symptoms: paresthesia, ataxia).\n\nPATHOPHYSIOLOGY:\nBoth folate (B9) and vitamin B12 (cobalamin) are essential for DNA synthesis, specifically for the conversion of deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP) by thymidylate synthase, which requires methylenetetrahydrofolate as the methyl donor per Harrison's Principles of Internal Medicine. Deficiency of either vitamin impairs DNA synthesis while RNA and protein synthesis continue normally, producing megaloblastic changes (large cells with immature nuclei but mature cytoplasm) in rapidly dividing cells, particularly erythroid precursors (causing macrocytic anemia with hypersegmented neutrophils) per UpToDate.\n\nWHY B12 UNIQUELY CAUSES NEUROLOGIC DISEASE:\nVitamin B12 serves as a cofactor for methylmalonyl-CoA mutase, an enzyme entirely independent of folate metabolism per the Cleveland Clinic. When B12 is deficient, methylmalonyl-CoA accumulates and is shunted to abnormal odd-chain fatty acids that are incorporated into myelin sheaths, disrupting myelin structure and causing demyelination (subacute combined degeneration of the spinal cord) per Harrison's Principles of Internal Medicine. The dorsal columns are affected first (loss of proprioception and vibratory sense, positive Romberg sign, sensory ataxia), followed by the lateral corticospinal tracts (spasticity, weakness, hyperreflexia, Babinski sign) per UpToDate. Peripheral neuropathy (symmetric paresthesias in stocking-glove distribution) often precedes myelopathy per Harvard Health. Folate deficiency does not cause neurologic disease because folate is not involved in the methylmalonyl-CoA pathway per the Mayo Clinic.\n\nDIAGNOSTIC APPROACH:\nMethylmalonic acid (MMA) is elevated in B12 deficiency only (specific), while homocysteine is elevated in both B12 and folate deficiency (sensitive but not specific) per Harrison's Principles of Internal Medicine. This distinction makes MMA the key differentiating test per UpToDate.\n\nCRITICAL WARNING:\nAdministering folate alone to a patient with undiagnosed B12 deficiency will correct the anemia (by restoring DNA synthesis) but will not treat and may mask progressive irreversible neurologic damage per the Cleveland Clinic and Harrison's Principles of Internal Medicine.\n\nKEY LEARNING POINTS:\nB12 deficiency uniquely causes neurologic disease (subacute combined degeneration: dorsal column and lateral corticospinal tract demyelination) because B12 is the exclusive cofactor for methylmalonyl-CoA mutase. Folate deficiency causes identical megaloblastic anemia but no neurologic symptoms. Folate supplementation alone can mask B12 deficiency while neurologic damage progresses irreversibly."
  },
  {
    "id": 336,
    "categoryId": 9,
    "question": "A patient develops fever, flank pain, and dark urine 15 minutes after starting a blood transfusion. Diagnosis?",
    "options": [
      "A) Febrile Non-Hemolytic Reaction",
      "B) Acute Hemolytic Transfusion Reaction (ABO incompatibility)",
      "C) TRALI",
      "D) Anaphylaxis"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Acute Hemolytic Transfusion Reaction from ABO incompatibility).\n\nPATHOPHYSIOLOGY:\nAcute hemolytic transfusion reaction (AHTR) is a medical emergency caused by transfusion of ABO-incompatible red blood cells, resulting in rapid intravascular hemolysis mediated by preformed recipient IgM antibodies (anti-A or anti-B) that activate the classical complement cascade (C1 through C9 membrane attack complex) on donor red cell surfaces per Harrison's Principles of Internal Medicine and UpToDate. The most common cause is clerical error (misidentification of the patient or blood product) rather than serologic incompatibility per the Cleveland Clinic.\n\nCLINICAL PRESENTATION:\nSymptoms begin within minutes of starting the transfusion (typically within the first 15 mL) and include fever, rigors, flank pain (from renal cortical ischemia), hemoglobinuria (dark or red-brown urine), hypotension, tachycardia, chest pain, and a sense of impending doom per Harrison's Principles of Internal Medicine and the Mayo Clinic. Intravascular hemolysis releases free hemoglobin, which scavenges nitric oxide (causing vasoconstriction and renal ischemia), precipitates in renal tubules (causing acute tubular necrosis and renal failure), and triggers disseminated intravascular coagulation (DIC) per UpToDate. Mortality ranges from 2 to 10% and correlates with the volume of incompatible blood transfused per Harvard Health.\n\nIMMEDIATE MANAGEMENT:\nThe transfusion must be stopped immediately and the IV line kept open with normal saline per the Cleveland Clinic. The blood product and patient identification must be rechecked at the bedside. IV fluids (normal saline) should be administered aggressively to maintain renal perfusion and urine output (goal greater than 1 mL/kg/hour). The blood bank should be notified immediately for repeat type and crossmatch, and a direct antiglobulin test (Coombs test) should be performed per Harrison's Principles of Internal Medicine. Laboratory studies include CBC, haptoglobin, LDH, indirect bilirubin, plasma-free hemoglobin, and coagulation studies (PT, aPTT, fibrinogen, D-dimer) to assess for DIC per UpToDate.\n\nKEY LEARNING POINTS:\nAcute hemolytic transfusion reaction presents within minutes with fever, flank pain, and dark urine from complement-mediated intravascular hemolysis of ABO-incompatible red cells. The most common cause is clerical error in patient/product identification. Immediate management requires stopping the transfusion, aggressive IV fluids to prevent renal failure, and blood bank notification."
  },
  {
    "id": 337,
    "categoryId": 14,
    "question": "In Multiple Myeloma, the 'CRAB' criteria for organ damage include Calcium elevation, Renal insufficiency, Anemia, and:",
    "options": [
      "A) Bone lesions (Lytic)",
      "B) Biliary obstruction",
      "C) Brain metastases",
      "D) Bleeding"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Bone lesions - Lytic).\n\nPATHOPHYSIOLOGY:\nThe B in CRAB stands for Bone lesions, completing the mnemonic for myeloma end-organ damage: Calcium elevation, Renal insufficiency, Anemia, and Bone disease. Bone involvement is present in approximately 80% of patients at diagnosis and is the most common cause of morbidity in multiple myeloma per Harrison's Principles of Internal Medicine. Malignant plasma cells secrete osteoclast-activating factors including RANKL and interleukin-6 that drive excessive bone resorption, while simultaneously inhibiting osteoblast function through dickkopf-1 and sclerostin, resulting in uncoupled remodeling with resorption far exceeding formation.\n\nCLINICAL MANIFESTATIONS:\nThis pathologic bone resorption produces the characteristic punched-out lytic lesions visible on imaging, most commonly affecting the axial skeleton (spine, skull, pelvis, ribs). Released calcium causes hypercalcemia. Patients present with bone pain (particularly back pain), pathologic fractures, vertebral compression fractures, and in severe cases spinal cord compression per the Mayo Clinic. Skull radiographs classically show a raindrop or pepper-pot pattern of multiple small lytic lesions.\n\nMANAGEMENT:\nBone-protective therapy with intravenous zoledronic acid or denosumab (a RANKL inhibitor) is standard of care for all myeloma patients with bone disease, reducing skeletal events including pathologic fractures per NCCN guidelines. Dental evaluation before initiating bisphosphonate therapy is essential due to the risk of osteonecrosis of the jaw. Vertebroplasty or kyphoplasty may be considered for symptomatic vertebral compression fractures refractory to analgesics.\n\nKEY LEARNING POINTS:\nThe CRAB criteria for myeloma end-organ damage are Calcium elevation, Renal insufficiency, Anemia, and Bone lesions (lytic). Myeloma bone disease results from osteoclast activation with simultaneous osteoblast suppression, creating purely lytic lesions that appear as punched-out holes on imaging. Bone-protective therapy with bisphosphonates or denosumab is standard of care to reduce skeletal events."
  },
  {
    "id": 338,
    "categoryId": 12,
    "question": "A 4-year-old presents with petechiae and bruising. CBC shows platelets 20k, Hgb 11, WBC 4. The smear shows large platelets. What is the management?",
    "options": [
      "A) Bone Marrow Biopsy",
      "B) Observation (if no severe bleeding)",
      "C) Platelet Transfusion",
      "D) Splenectomy"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Observation if no severe bleeding).\n\nPATHOPHYSIOLOGY:\nImmune thrombocytopenia (ITP) in children is an acquired autoimmune condition in which IgG autoantibodies bind to platelet surface glycoproteins (most commonly GPIIb/IIIa and GPIb/IX), leading to accelerated platelet destruction primarily by splenic macrophages via Fc receptor-mediated phagocytosis per Harrison's Principles of Internal Medicine. Unlike adult ITP, which tends to be chronic, childhood ITP is typically acute, self-limited, and often follows a viral infection or vaccination by 1 to 4 weeks. The peak incidence is between 2 and 5 years of age, affecting boys and girls equally per UpToDate.\n\nCLINICAL REASONING:\nThis child presents with the classic ITP picture: an otherwise well-appearing child with sudden onset of petechiae and bruising (mucocutaneous bleeding), isolated severe thrombocytopenia (platelets 20,000), but normal hemoglobin and normal white blood cell count per the Cleveland Clinic. The peripheral smear showing large (megathrombocytes) platelets reflects increased bone marrow thrombopoiesis in response to peripheral destruction, confirming that the marrow is functioning normally per UpToDate. The isolated thrombocytopenia with an otherwise normal CBC distinguishes ITP from leukemia (which typically shows anemia, abnormal WBC, and blasts on smear) and aplastic anemia (which shows pancytopenia). Bone marrow biopsy is not routinely required when the presentation is classic per the ASH 2019 guidelines and Harrison's Principles of Internal Medicine.\n\nMANAGEMENT:\nThe majority of children with ITP (approximately 80%) recover spontaneously within 6 to 12 months regardless of treatment per the Mayo Clinic. The current evidence-based approach from the ASH guidelines and UpToDate is observation with activity modification (avoiding contact sports and activities with high bleeding risk) for children with no bleeding or only mild mucocutaneous bleeding (petechiae, bruising, minor epistaxis), regardless of platelet count. Platelet transfusion is generally avoided because autoantibodies destroy transfused platelets rapidly, making transfusion ineffective except in the setting of life-threatening hemorrhage per Harrison's Principles of Internal Medicine. Pharmacologic treatment (IVIG, corticosteroids, or anti-D immunoglobulin in Rh-positive patients) is reserved for clinically significant mucosal bleeding (persistent epistaxis, oral mucosal hemorrhage, heavy menstrual bleeding, gastrointestinal bleeding) or if surgery is required per UpToDate.\n\nKEY LEARNING POINTS:\nChildhood ITP presents with isolated thrombocytopenia (normal Hgb and WBC) with petechiae and bruising in an otherwise well child, typically after a viral illness. Observation is appropriate when bleeding is absent or mild, as 80% of children recover spontaneously. Platelet transfusion is ineffective due to autoantibody-mediated destruction, and pharmacologic treatment is reserved for clinically significant bleeding."
  },
  {
    "id": 339,
    "categoryId": 9,
    "question": "Patients who undergo Splenectomy are at lifelong risk for Overwhelming Post-Splenectomy Infection (OPSI) from which organisms?",
    "options": [
      "A) Viruses",
      "B) Encapsulated Bacteria (Strep pneumo, H. flu, Meningococcus)",
      "C) Fungi",
      "D) Parasites"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Encapsulated Bacteria: S. pneumoniae, H. influenzae, N. meningitidis).\n\nPATHOPHYSIOLOGY:\nThe spleen is the primary site for clearance of encapsulated (polysaccharide-coated) bacteria from the bloodstream per Harrison's Principles of Internal Medicine and UpToDate. Encapsulated organisms resist phagocytosis by complement and neutrophils because their polysaccharide capsule prevents C3b opsonization; the spleen compensates through its unique structure of slow-flow sinusoidal circulation that maximizes contact time between macrophages and circulating pathogens, and through its production of opsonins (IgM, properdin, tuftsin) that are essential for clearing encapsulated bacteria per the Cleveland Clinic. Following splenectomy, patients lose this critical immune defense and face a lifelong risk of overwhelming post-splenectomy infection (OPSI), a fulminant sepsis that can progress from mild symptoms to death within 12 to 24 hours with a mortality rate of 50 to 70% per Harvard Health.\n\nHIGHEST-RISK ORGANISMS:\nStreptococcus pneumoniae is responsible for approximately 50 to 60% of OPSI cases and is the single most dangerous pathogen in asplenic patients per Harrison's Principles of Internal Medicine. Haemophilus influenzae type b and Neisseria meningitidis are the second and third most common causes per UpToDate. Other encapsulated organisms (Capnocytophaga canimorsus from dog bites, Babesia from tick bites, Salmonella, E. coli) also pose increased risk per the Mayo Clinic.\n\nPREVENTION:\nVaccination is critical and should ideally be administered at least 2 weeks before elective splenectomy per the Cleveland Clinic. Required vaccines include pneumococcal (both PCV20 conjugate and PPSV23 polysaccharide), meningococcal (MenACWY and MenB), and Haemophilus influenzae type b (Hib) per the CDC. Annual influenza vaccination reduces the risk of secondary bacterial infection per UpToDate. Some guidelines recommend prophylactic penicillin (particularly in children and for the first 1 to 2 years post-splenectomy) and standby emergency antibiotics for all asplenic patients per Harrison's Principles of Internal Medicine.\n\nKEY LEARNING POINTS:\nSplenectomized patients have lifelong risk of overwhelming post-splenectomy infection (OPSI) from encapsulated bacteria, primarily S. pneumoniae (50 to 60% of cases), with mortality of 50 to 70%. The spleen's slow-flow sinusoidal circulation and opsonin production are essential for encapsulated organism clearance. Vaccination (pneumococcal, meningococcal, Hib) ideally 2 weeks pre-splenectomy is critical prevention."
  },
  {
    "id": 340,
    "categoryId": 9,
    "question": "Polycythemia Vera (PV) is a myeloproliferative disorder characterized by high RBC mass. 95% of patients have a mutation in:",
    "options": [
      "A) BCR-ABL",
      "B) JAK2",
      "C) P53",
      "D) BRCA1"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (JAK2).\n\nPATHOPHYSIOLOGY:\nPolycythemia vera (PV) is a clonal myeloproliferative neoplasm characterized by erythropoietin-independent erythrocytosis resulting from a gain-of-function mutation in the Janus kinase 2 (JAK2) gene per Harrison's Principles of Internal Medicine and UpToDate. The JAK2 V617F point mutation (valine to phenylalanine substitution at position 617 in the pseudokinase domain) is present in approximately 95% of PV patients, while the remaining 5% carry JAK2 exon 12 mutations per the Cleveland Clinic. This mutation causes constitutive activation of the JAK-STAT signaling pathway downstream of the erythropoietin receptor (as well as thrombopoietin and G-CSF receptors), driving unregulated proliferation of erythroid, megakaryocytic, and granulocytic lineages per UpToDate.\n\nCLINICAL PRESENTATION:\nPV presents with elevated hemoglobin and hematocrit (often discovered incidentally on CBC), erythromelalgia (burning pain and redness of hands and feet from microvascular thrombosis), pruritus (especially aquagenic pruritus after warm baths, mediated by basophil histamine release), splenomegaly, headache, and visual disturbances per Harrison's Principles of Internal Medicine and the Mayo Clinic. The major complications are thrombosis (both arterial and venous, occurring in 40% of untreated patients, including Budd-Chiari syndrome, portal vein thrombosis, stroke, and MI) and transformation to myelofibrosis or acute myeloid leukemia per Harvard Health.\n\nDIAGNOSIS AND MANAGEMENT:\nThe WHO diagnostic criteria require elevated hemoglobin (greater than 16.5 g/dL in men or 16.0 g/dL in women) or hematocrit (greater than 49% in men or 48% in women), bone marrow biopsy showing panmyelosis with pleomorphic megakaryocytes, and presence of JAK2 mutation per UpToDate. Serum erythropoietin is characteristically low (distinguishing PV from secondary polycythemia where EPO is elevated) per the Cleveland Clinic. First-line treatment is therapeutic phlebotomy (target hematocrit below 45%) plus low-dose aspirin per Harrison's Principles of Internal Medicine. Cytoreductive therapy (hydroxyurea first-line) is added for high-risk patients (age over 60 or prior thrombosis) per the Mayo Clinic.\n\nKEY LEARNING POINTS:\nThe JAK2 V617F mutation is present in approximately 95% of polycythemia vera cases, causing constitutive activation of the JAK-STAT pathway and erythropoietin-independent erythrocytosis. Major complications are thrombosis (40% untreated) and transformation to myelofibrosis or AML. Treatment is phlebotomy (target hematocrit below 45%) plus low-dose aspirin, with hydroxyurea for high-risk patients."
  },
  {
    "id": 341,
    "categoryId": 14,
    "question": "The presence of the Philadelphia Chromosome t(9;22) is diagnostic for:",
    "options": [
      "A) CML (Chronic Myeloid Leukemia)",
      "B) CLL",
      "C) AML",
      "D) Hodgkin Lymphoma"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (CML - Chronic Myeloid Leukemia).\n\nPATHOPHYSIOLOGY:\nThe Philadelphia chromosome is a reciprocal translocation between chromosomes 9 and 22, designated t(9;22)(q34;q11.2), that juxtaposes the ABL1 proto-oncogene from chromosome 9 with the BCR gene on chromosome 22, creating the BCR-ABL1 fusion gene. This fusion gene encodes a constitutively active tyrosine kinase that drives uncontrolled myeloid cell proliferation, decreased apoptosis, and genomic instability through activation of multiple downstream signaling pathways including RAS-MAPK, JAK-STAT, and PI3K-Akt per Harrison's Principles of Internal Medicine. The Philadelphia chromosome is present in greater than 95% of CML cases and is the defining molecular abnormality of the disease. It is also found in approximately 25% of adult acute lymphoblastic leukemia cases, where it confers a worse prognosis.\n\nCLINICAL PRESENTATION:\nCML typically presents in chronic phase (approximately 85% of diagnoses) with fatigue, weight loss, early satiety from splenomegaly, and a markedly elevated white blood cell count with a left-shifted differential showing the full spectrum of myeloid maturation along with basophilia per UpToDate. Without treatment, CML progresses through an accelerated phase to blast crisis, which resembles acute leukemia and carries a dismal prognosis.\n\nTREATMENT:\nThe development of imatinib (Gleevec), the first tyrosine kinase inhibitor specifically designed to block BCR-ABL1 kinase activity, transformed CML from a rapidly fatal disease into a chronic manageable condition. The landmark IRIS trial demonstrated complete cytogenetic responses in over 80% of patients, with 10-year overall survival exceeding 80% per data published in the New England Journal of Medicine. Second-generation TKIs (dasatinib, nilotinib, bosutinib) and the third-generation TKI ponatinib provide options for resistance or intolerance per NCCN guidelines. Molecular monitoring of BCR-ABL1 transcript levels by quantitative RT-PCR guides treatment decisions.\n\nKEY LEARNING POINTS:\nThe Philadelphia chromosome t(9;22) creates the BCR-ABL1 constitutively active tyrosine kinase that drives CML, present in greater than 95% of cases. Imatinib and subsequent TKIs transformed CML into a chronic condition with greater than 80% ten-year survival. Quantitative BCR-ABL1 transcript monitoring by RT-PCR guides treatment response assessment."
  },
  {
    "id": 342,
    "categoryId": 9,
    "question": "Warfarin-induced Skin Necrosis is a rare complication seen in patients with undiagnosed:",
    "options": [
      "A) Protein C Deficiency",
      "B) Factor V Leiden",
      "C) Hemophilia",
      "D) Von Willebrand Disease"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Protein C Deficiency).\n\nPATHOPHYSIOLOGY:\nWarfarin-induced skin necrosis is a rare but devastating complication that occurs in patients with undiagnosed protein C (or less commonly protein S) deficiency during the first few days of warfarin initiation per Harrison's Principles of Internal Medicine and UpToDate. The mechanism is a paradoxical transient hypercoagulable state that arises because warfarin inhibits not only the procoagulant factors (II, VII, IX, X) but also the endogenous anticoagulant proteins C and S, which are also vitamin K-dependent per the Cleveland Clinic. Protein C has the shortest half-life (approximately 6 to 8 hours) among all vitamin K-dependent factors, so its levels fall first when warfarin is initiated per Harvard Health.\n\nTIMECOURSE:\nIn patients with already low baseline protein C (heterozygous deficiency), warfarin causes protein C to reach critically low levels within 24 to 48 hours while the procoagulant factors (especially Factor II with its 60-hour half-life) are still functional per UpToDate. This creates a transient window of unopposed procoagulant activity, causing microvascular thrombosis in dermal and subcutaneous venules per Harrison's Principles of Internal Medicine. The resulting thrombotic occlusion produces hemorrhagic skin infarction, typically in areas with abundant subcutaneous fat (breasts, buttocks, thighs, abdomen) per the Mayo Clinic.\n\nPREVENTION AND MANAGEMENT:\nWarfarin-induced skin necrosis can be prevented by overlapping warfarin initiation with heparin (UFH or LMWH) for a minimum of 5 days and until the INR is therapeutic for at least 24 hours, ensuring adequate anticoagulation during the period of protein C depletion per UpToDate. Warfarin should never be started at high loading doses (which accelerate protein C depletion relative to procoagulant factors) per the Cleveland Clinic. If skin necrosis develops, warfarin must be discontinued immediately, full-dose heparin anticoagulation initiated, and protein C concentrate administered if available per Harrison's Principles of Internal Medicine.\n\nKEY LEARNING POINTS:\nWarfarin-induced skin necrosis occurs in protein C deficiency because protein C (half-life 6 to 8 hours) is depleted before procoagulant factors, creating a transient hypercoagulable state with microvascular thrombosis. It presents as hemorrhagic skin infarction in fat-rich areas within 3 to 5 days of warfarin initiation. Prevention requires heparin bridging for at least 5 days and avoidance of high warfarin loading doses."
  },
  {
    "id": 343,
    "categoryId": 14,
    "question": "Reed-Sternberg Cells ('Owl's Eye' appearance) are the hallmark of:",
    "options": [
      "A) Non-Hodgkin Lymphoma",
      "B) Hodgkin Lymphoma",
      "C) Burkitt Lymphoma",
      "D) Multiple Myeloma"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Hodgkin Lymphoma).\n\nPATHOPHYSIOLOGY:\nReed-Sternberg cells are the pathognomonic malignant cells of Hodgkin lymphoma, recognized by their distinctive morphology: large binucleated or multinucleated cells with prominent eosinophilic nucleoli and abundant cytoplasm, creating the classic owl-eye appearance on microscopy per Harrison's Principles of Internal Medicine. Despite their B-cell lineage origin (derived from germinal center B cells), Reed-Sternberg cells have lost expression of most B-cell markers due to crippling immunoglobulin gene mutations. They characteristically express CD15 and CD30 while lacking CD20 and CD45, an immunophenotypic profile that is diagnostically useful per UpToDate. Reed-Sternberg cells typically constitute less than 1 to 2% of the tumor mass, with the remainder composed of a reactive inflammatory infiltrate of lymphocytes, eosinophils, macrophages, and fibroblasts.\n\nCLINICAL PRESENTATION:\nHodgkin lymphoma has a characteristic bimodal age distribution with a first peak in young adults (ages 15 to 35) and a second peak in adults over age 55 per the National Cancer Institute. The typical presentation is painless cervical or supraclavicular lymphadenopathy. A distinctive clinical feature is alcohol-induced lymph node pain, which is uncommon but highly specific for Hodgkin lymphoma when present. The disease spreads contiguously from one lymph node group to adjacent groups in a predictable anatomic pattern, distinguishing it from non-Hodgkin lymphomas that tend to spread hematogenously.\n\nTREATMENT:\nHodgkin lymphoma is one of the most curable malignancies per the Cleveland Clinic. Early-stage disease is treated with abbreviated ABVD chemotherapy (Adriamycin, Bleomycin, Vinblastine, Dacarbazine) with or without involved-site radiation, achieving cure rates exceeding 90%. Advanced-stage disease is treated with extended chemotherapy with cure rates of approximately 70 to 80%. Long-term survivors require monitoring for secondary malignancies (particularly breast cancer after mediastinal radiation), cardiovascular disease from anthracyclines, and pulmonary toxicity from bleomycin.\n\nKEY LEARNING POINTS:\nReed-Sternberg cells with owl-eye morphology are pathognomonic for Hodgkin lymphoma and express CD15 and CD30 while lacking typical B-cell markers. Hodgkin lymphoma spreads contiguously between adjacent lymph node groups, has a bimodal age distribution, and is one of the most curable malignancies with early-stage cure rates exceeding 90%. Long-term survivor surveillance for secondary malignancies and treatment-related toxicity is essential."
  },
  {
    "id": 344,
    "categoryId": 9,
    "question": "Which clotting pathway is measured by the PT/INR?",
    "options": [
      "A) Intrinsic Pathway",
      "B) Extrinsic Pathway",
      "C) Common Pathway only",
      "D) Fibrinolysis"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Extrinsic Pathway).\n\nPHYSIOLOGY:\nThe prothrombin time (PT) and its standardized ratio (INR, International Normalized Ratio) measure the integrity of the extrinsic and common pathways of the coagulation cascade per Harrison's Principles of Internal Medicine and UpToDate. The PT assay works by adding tissue factor (thromboplastin) and calcium to citrated plasma, which activates Factor VII (the sole component of the extrinsic pathway), initiating the extrinsic cascade through the Factor VII-tissue factor complex per the Cleveland Clinic.\n\nCOAGULATION CASCADE:\nThe extrinsic pathway begins when tissue factor (TF) exposed at sites of vascular injury binds Factor VII, forming the TF-VIIa complex that activates Factor X per Harrison's Principles of Internal Medicine. The common pathway then proceeds through Factor Xa (in complex with Factor Va on the prothrombinase complex) to convert prothrombin (Factor II) to thrombin, which cleaves fibrinogen to fibrin per UpToDate. The PT therefore reflects the function of Factor VII (extrinsic), and Factors X, V, II, and fibrinogen (common pathway) per Harvard Health.\n\nCOMPARISON WITH aPTT:\nThe activated partial thromboplastin time (aPTT) measures the intrinsic and common pathways by adding a contact activator (kaolin, celite, or ellagic acid), phospholipid, and calcium to plasma, activating the contact factors (XII, XI) and then Factors IX and VIII (intrinsic pathway) before converging on the common pathway per the Mayo Clinic. A prolonged PT with normal aPTT indicates isolated Factor VII deficiency or early warfarin effect (Factor VII has the shortest half-life). A prolonged aPTT with normal PT indicates intrinsic pathway factor deficiency (XII, XI, IX, VIII) as seen in hemophilia A (VIII) or B (IX). Both prolonged indicates common pathway or multiple factor involvement per Harrison's Principles of Internal Medicine.\n\nCLINICAL APPLICATION:\nThe INR standardizes PT results across laboratories using the International Sensitivity Index (ISI) of the thromboplastin reagent, enabling consistent warfarin monitoring per UpToDate and the Cleveland Clinic. Therapeutic INR ranges are 2.0 to 3.0 for most indications (atrial fibrillation, DVT/PE) and 2.5 to 3.5 for mechanical heart valves per Harrison's Principles of Internal Medicine.\n\nKEY LEARNING POINTS:\nThe PT/INR measures the extrinsic pathway (Factor VII) and common pathway (X, V, II, fibrinogen) and is used to monitor warfarin therapy. The aPTT measures the intrinsic pathway (XII, XI, IX, VIII) and common pathway, monitoring heparin therapy. Isolated PT prolongation suggests Factor VII deficiency or early warfarin effect."
  },
  {
    "id": 345,
    "categoryId": 9,
    "question": "Basophilic Stippling on a peripheral blood smear is classic for:",
    "options": [
      "A) Iron Deficiency",
      "B) Lead Poisoning",
      "C) B12 Deficiency",
      "D) Folate Deficiency"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Lead Poisoning).\n\nPATHOPHYSIOLOGY:\nBasophilic stippling describes the presence of numerous fine blue granules (composed of aggregated ribosomal RNA and degraded mitochondrial remnants) distributed throughout the red blood cell cytoplasm on Wright-Giemsa staining per Harrison's Principles of Internal Medicine and UpToDate. In lead poisoning, lead inhibits pyrimidine-5'-nucleotidase, the enzyme responsible for degrading residual ribosomal RNA during red cell maturation per the Cleveland Clinic. Without this enzyme, ribosomal RNA aggregates persist in the mature erythrocyte and are visible as basophilic stippling per Harvard Health.\n\nLEAD EFFECTS ON HEME SYNTHESIS:\nLead also inhibits two critical enzymes in the heme synthesis pathway: delta-aminolevulinic acid dehydratase (ALA dehydratase, also called porphobilinogen synthase), causing accumulation of ALA in blood and urine, and ferrochelatase, the final enzyme that inserts iron into protoporphyrin IX to form heme, causing elevated free erythrocyte protoporphyrin (FEP) and zinc protoporphyrin (ZPP) per Harrison's Principles of Internal Medicine and UpToDate. The combined result is a microcytic sideroblastic anemia with basophilic stippling, ringed sideroblasts on Prussian blue staining (from mitochondrial iron accumulation), and elevated ALA and FEP levels per the Mayo Clinic.\n\nCLINICAL PRESENTATION:\nLead poisoning in children (the most vulnerable population due to hand-to-mouth behavior and developing nervous system) presents with abdominal pain (\"lead colic\"), constipation, behavioral changes, developmental delay, and microcytic anemia with basophilic stippling per the Cleveland Clinic. In adults, lead exposure (occupational: battery manufacturing, smelting, painting) causes peripheral neuropathy (wrist drop from radial nerve involvement), nephropathy, gout (saturniine gout from decreased uric acid excretion), and Burton lines (blue-black lines on the gingival margin) per Harrison's Principles of Internal Medicine.\n\nOTHER CAUSES OF BASOPHILIC STIPPLING:\nWhile lead poisoning is the classic association, basophilic stippling also occurs in thalassemia, myelodysplastic syndromes, and severe megaloblastic anemias per UpToDate. However, coarse basophilic stippling with microcytic anemia and clinical features of toxicity is highly suggestive of lead poisoning per the Cleveland Clinic.\n\nKEY LEARNING POINTS:\nBasophilic stippling is classic for lead poisoning, resulting from lead inhibition of pyrimidine-5'-nucleotidase (ribosomal RNA degradation failure). Lead also inhibits ALA dehydratase and ferrochelatase in heme synthesis, producing microcytic sideroblastic anemia with elevated FEP and ALA. In children, look for abdominal pain, developmental delay, and microcytic anemia; in adults, wrist drop, nephropathy, and Burton lines."
  },
  {
    "id": 346,
    "categoryId": 9,
    "question": "Aplastic Anemia presents with Pancytopenia (Low WBC, Low RBC, Low Platelets). The bone marrow biopsy will show:",
    "options": [
      "A) Hypercellularity with blasts",
      "B) Hypocellularity (mostly fat)",
      "C) Fibrosis",
      "D) Granulomas"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Hypocellularity, mostly fat).\n\nPATHOPHYSIOLOGY:\nAplastic anemia is a bone marrow failure syndrome characterized by pancytopenia (simultaneous reduction in all three blood cell lineages: red blood cells, white blood cells, and platelets) resulting from destruction or suppression of hematopoietic stem cells per Harrison's Principles of Internal Medicine and UpToDate. The bone marrow biopsy in aplastic anemia reveals marked hypocellularity with replacement of normal hematopoietic tissue by fat (adipocytes), typically showing less than 25% cellularity (or less than 50% cellularity with less than 30% hematopoietic cells) per the Cleveland Clinic.\n\nETIOLOGY:\nIn approximately 70% of cases, aplastic anemia is idiopathic (presumed autoimmune, mediated by autoreactive cytotoxic T-lymphocytes that attack CD34-positive hematopoietic stem cells through interferon-gamma and TNF-alpha) per Harrison's Principles of Internal Medicine. Identifiable causes include medications (chloramphenicol, carbamazepine, phenytoin, sulfonamides, NSAIDs, gold), toxins (benzene), viral infections (hepatitis-associated aplastic anemia, particularly non-A through E hepatitis; EBV, CMV, parvovirus B19), radiation exposure, and inherited syndromes (Fanconi anemia, dyskeratosis congenita) per UpToDate and Harvard Health.\n\nCLINICAL PRESENTATION:\nPatients present with symptoms reflecting the pancytopenia per the Mayo Clinic: fatigue, pallor, and dyspnea (from anemia), recurrent or severe infections (from neutropenia), and petechiae, purpura, mucosal bleeding, and menorrhagia (from thrombocytopenia). The reticulocyte count is markedly low (reflecting bone marrow failure) per Harrison's Principles of Internal Medicine.\n\nTREATMENT:\nFor patients under 40 with a matched sibling donor, allogeneic hematopoietic stem cell transplantation is the treatment of choice with cure rates of 75 to 90% per UpToDate. For older patients or those without a matched donor, immunosuppressive therapy with anti-thymocyte globulin (ATG) plus cyclosporine produces response rates of 60 to 70% by eliminating the autoreactive T-cell clone per Harrison's Principles of Internal Medicine and the Cleveland Clinic. Eltrombopag (a thrombopoietin receptor agonist that stimulates hematopoietic stem cells) added to IST improves overall and complete response rates per UpToDate.\n\nKEY LEARNING POINTS:\nAplastic anemia shows a hypocellular (fat-replaced) bone marrow with pancytopenia, caused by T-cell-mediated destruction of hematopoietic stem cells in 70% of cases. Allogeneic stem cell transplant is curative for young patients with matched donors. Immunosuppressive therapy (ATG plus cyclosporine plus eltrombopag) achieves 60 to 70% response in transplant-ineligible patients."
  },
  {
    "id": 347,
    "categoryId": 1,
    "question": "In a patient with low pre-test probability for DVT (Wells Score < 2), the appropriate initial test is:",
    "options": [
      "A) D-Dimer",
      "B) Ultrasound Doppler",
      "C) Venogram",
      "D) Start Anticoagulation"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (D-Dimer).\n\nCLINICAL REASONING:\nThe diagnostic approach to suspected deep vein thrombosis begins with clinical pre-test probability assessment using the Wells Score, which stratifies patients into low (less than 2 points), moderate (2 to 6 points), or high (greater than 6 points) probability categories based on clinical features including active cancer, paralysis or immobilization, recent surgery, localized tenderness along the deep venous system, entire leg swelling, calf swelling greater than 3 cm compared to the asymptomatic leg, pitting edema, collateral superficial veins, and prior documented DVT per Harrison's Principles of Internal Medicine and UpToDate.\n\nD-DIMER IN LOW PRE-TEST PROBABILITY:\nIn patients with a low Wells Score (less than 2), the D-dimer assay is the appropriate initial test because of its high sensitivity (95 to 97%) and excellent negative predictive value in this population per the Cleveland Clinic. D-dimer is a fibrin degradation product generated when cross-linked fibrin within a thrombus undergoes plasmin-mediated lysis. A negative high-sensitivity D-dimer in a low-probability patient effectively rules out DVT without the need for imaging, sparing patients unnecessary ultrasound examinations and reducing healthcare costs per UpToDate. However, D-dimer is nonspecific and is elevated in many conditions including infection, inflammation, malignancy, pregnancy, recent surgery, trauma, and advanced age, which is why a positive result in a low-risk patient requires confirmatory compression ultrasonography before initiating treatment per the Mayo Clinic.\n\nWHEN TO SKIP D-DIMER:\nPatients with moderate or high Wells Scores should proceed directly to compression ultrasonography because D-dimer lacks sufficient negative predictive value in these higher-risk populations to safely exclude DVT per Harrison's Principles of Internal Medicine. This risk-stratified algorithm reduces unnecessary imaging by approximately 30% while maintaining diagnostic safety per UpToDate.\n\nKEY LEARNING POINTS:\nD-dimer is the appropriate initial test for suspected DVT when pre-test probability is low (Wells Score less than 2) because its high sensitivity and negative predictive value can safely rule out DVT without imaging. A positive D-dimer requires confirmatory ultrasound. Moderate or high pre-test probability patients should proceed directly to compression ultrasonography, bypassing D-dimer."
  },
  {
    "id": 348,
    "categoryId": 9,
    "question": "The '4 Ts' score is used to estimate the probability of Heparin-Induced Thrombocytopenia (HIT). Which is NOT a T?",
    "options": [
      "A) Thrombocytopenia (degree of drop)",
      "B) Timing (days 5-10)",
      "C) Thrombosis (new clot)",
      "D) Temperature (Fever)"
    ],
    "correctAnswer": 3,
    "explanation": "CORRECT: D (Temperature/Fever is NOT one of the 4 Ts).\n\nCLINICAL TOOL:\nThe 4Ts scoring system is a validated clinical prediction tool used to estimate the pretest probability of heparin-induced thrombocytopenia (HIT) type II, guiding the urgency of confirmatory testing and the decision to discontinue heparin per Harrison's Principles of Internal Medicine and UpToDate. The four components (each scored 0, 1, or 2 points for a maximum of 8) are Thrombocytopenia (degree of platelet fall), Timing (of platelet drop relative to heparin exposure), Thrombosis (new thrombotic events or other clinical sequelae), and oTher causes of thrombocytopenia excluded per the Cleveland Clinic.\n\nSCORING DETAILS:\nThrombocytopenia: platelet fall greater than 50% and nadir 20,000 or greater scores 2 points; fall of 30 to 50% or nadir 10,000 to 19,000 scores 1 point; fall less than 30% or nadir less than 10,000 scores 0 per UpToDate. Timing: onset 5 to 10 days after heparin start (or within 1 day with prior exposure in past 30 days) scores 2 points per the Mayo Clinic. Thrombosis: confirmed new thrombosis, skin necrosis, or acute systemic reaction scores 2 points per Harrison's Principles of Internal Medicine. Other causes: no other explanation for thrombocytopenia scores 2 points, while possible alternative causes (sepsis, DIC, other medications) reduce the score per Harvard Health.\n\nINTERPRETATION:\nA 4Ts score of 0 to 3 indicates low probability (negative predictive value greater than 99%, HIT essentially excluded), 4 to 5 indicates intermediate probability (requiring further testing with anti-PF4/heparin ELISA and possibly functional assay), and 6 to 8 indicates high probability (empiric treatment with non-heparin anticoagulant should begin immediately while awaiting confirmatory testing) per UpToDate and the Cleveland Clinic. Temperature (fever) is not included because while fever can occur as part of an acute systemic reaction to heparin in HIT, it is not a scored component of the 4Ts system per Harrison's Principles of Internal Medicine.\n\nKEY LEARNING POINTS:\nThe 4Ts for HIT probability are Thrombocytopenia (degree of platelet fall), Timing (5 to 10 days or within 1 day with prior exposure), Thrombosis (new events), and oTher causes excluded. Temperature/fever is not a scored component. A score of 0 to 3 has greater than 99% negative predictive value, effectively ruling out HIT."
  },
  {
    "id": 349,
    "categoryId": 9,
    "question": "Tumor Lysis Syndrome causes which electrolyte abnormalities?",
    "options": [
      "A) Hyperkalemia, Hyperphosphatemia, Hyperuricemia, Hypocalcemia",
      "B) Hypokalemia, Hypophosphatemia, Hypercalcemia",
      "C) Hypernatremia, Hypercalcemia",
      "D) Normal electrolytes"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Hyperkalemia, Hyperphosphatemia, Hyperuricemia, Hypocalcemia).\n\nPATHOPHYSIOLOGY:\nTumor lysis syndrome (TLS) is an oncologic emergency caused by the rapid massive destruction of malignant cells (either spontaneously or following initiation of cytotoxic therapy), releasing intracellular contents into the bloodstream in quantities that overwhelm the body's homeostatic and excretory mechanisms per Harrison's Principles of Internal Medicine and UpToDate. The four characteristic electrolyte abnormalities each arise from a specific intracellular component per the Cleveland Clinic.\n\nELECTROLYTE DERANGEMENTS:\nHyperkalemia results from release of intracellular potassium (the predominant intracellular cation, concentration approximately 140 mEq/L inside cells) and poses the most immediately life-threatening risk (cardiac arrhythmias, cardiac arrest) per Harrison's Principles of Internal Medicine. Hyperphosphatemia results from release of intracellular phosphate and phospholipids, and the excess phosphate binds serum calcium, causing secondary hypocalcemia (which can produce tetany, seizures, and QT prolongation) per UpToDate. Hyperuricemia results from the massive catabolism of purine nucleic acids (adenine, guanine) through xanthine oxidase to uric acid, which can precipitate in renal tubules (particularly in acidic urine) causing acute uric acid nephropathy and oliguric renal failure per the Mayo Clinic and Harvard Health.\n\nRISK FACTORS:\nTLS is most common in highly proliferative, bulky, and treatment-sensitive malignancies: Burkitt lymphoma (the highest risk), acute lymphoblastic leukemia (especially with high WBC count), diffuse large B-cell lymphoma, and acute myeloid leukemia with high WBC per Harrison's Principles of Internal Medicine. High tumor burden (large mass, elevated LDH, elevated WBC), renal impairment, dehydration, and acidic urine increase risk per UpToDate.\n\nPREVENTION AND MANAGEMENT:\nAggressive IV hydration (maintain urine output above 2 mL/kg/hour) is the cornerstone of prevention per the Cleveland Clinic. Allopurinol (xanthine oxidase inhibitor, prevents new uric acid formation) is used for moderate-risk patients per UpToDate. Rasburicase (recombinant urate oxidase that enzymatically converts existing uric acid to the highly soluble allantoin) is preferred for high-risk patients and established TLS per Harrison's Principles of Internal Medicine. Rasburicase is contraindicated in G6PD deficiency (generates hydrogen peroxide that causes hemolysis in G6PD-deficient cells) per the Mayo Clinic.\n\nKEY LEARNING POINTS:\nTumor lysis syndrome produces hyperkalemia (cardiac arrest risk), hyperphosphatemia (from intracellular release), secondary hypocalcemia (phosphate-calcium binding), and hyperuricemia (purine catabolism causing renal failure). Highest risk in Burkitt lymphoma and ALL with high tumor burden. Rasburicase is preferred for high-risk prevention but is contraindicated in G6PD deficiency."
  },
  {
    "id": 350,
    "categoryId": 9,
    "question": "Hereditary Spherocytosis causes hemolytic anemia due to a defect in:",
    "options": [
      "A) Hemoglobin",
      "B) RBC Membrane Proteins (Spectrin/Ankyrin)",
      "C) Enzymes (G6PD)",
      "D) Mitochondria"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (RBC Membrane Proteins, Spectrin/Ankyrin).\n\nPATHOPHYSIOLOGY:\nHereditary spherocytosis (HS) is the most common inherited hemolytic anemia in individuals of Northern European descent (prevalence approximately 1 in 2,000) caused by mutations in genes encoding red blood cell membrane skeleton proteins, most commonly ankyrin (approximately 40% of cases), band 3 (approximately 25%), spectrin (alpha or beta, approximately 20%), and protein 4.2 per Harrison's Principles of Internal Medicine and UpToDate. These proteins form the vertical interactions that anchor the phospholipid bilayer to the underlying spectrin-actin cytoskeletal network per the Cleveland Clinic.\n\nMEMBRANE DEFECT AND SPHEROCYTE FORMATION:\nWhen vertical linkage proteins are deficient, the lipid bilayer loses its structural support and undergoes progressive loss of membrane surface area through vesiculation (budding off of lipid microvesicles) per Harrison's Principles of Internal Medicine. As the cell loses surface area while maintaining its volume, it transitions from the normal biconcave disc shape to a sphere (the geometric shape with minimum surface-area-to-volume ratio) per UpToDate. Spherocytes are rigid, less deformable, and cannot navigate the narrow fenestrations (2 to 3 micrometers) of the splenic red pulp sinusoidal slits, where they are trapped and destroyed by splenic macrophages (extravascular hemolysis) per Harvard Health.\n\nDIAGNOSIS:\nThe peripheral smear shows spherocytes (dense, round cells lacking central pallor) and the mean corpuscular hemoglobin concentration (MCHC) is elevated (greater than 36 g/dL, reflecting cellular dehydration) per the Cleveland Clinic. The osmotic fragility test (classic diagnostic test) demonstrates increased lysis of spherocytes in hypotonic saline because their reduced surface-area-to-volume ratio leaves less reserve for osmotic swelling per Harrison's Principles of Internal Medicine. The eosin-5-maleimide (EMA) binding test (flow cytometry) is a newer, more specific diagnostic test that detects reduced band 3 protein on the red cell surface per UpToDate and the Mayo Clinic.\n\nMANAGEMENT:\nFolate supplementation (to support the compensatory erythropoietic drive) is recommended for all patients per Harrison's Principles of Internal Medicine. Splenectomy is curative for severe cases (it eliminates the site of spherocyte destruction), but must be weighed against the lifelong risk of overwhelming post-splenectomy infection per UpToDate.\n\nKEY LEARNING POINTS:\nHereditary spherocytosis results from mutations in RBC membrane skeleton proteins (ankyrin, band 3, spectrin), causing membrane loss, spherocyte formation, and extravascular hemolysis in the spleen. Elevated MCHC and increased osmotic fragility are characteristic. Splenectomy is curative but carries lifelong infection risk from encapsulated organisms."
  },
  {
    "id": 351,
    "categoryId": 9,
    "question": "Hemophilia A is a deficiency of Factor VIII. The inheritance pattern is:",
    "options": [
      "A) Autosomal Dominant",
      "B) Autosomal Recessive",
      "C) X-Linked Recessive",
      "D) Mitochondrial"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (X-Linked Recessive).\n\nGENETICS:\nHemophilia A is caused by mutations in the F8 gene located on the long arm of the X chromosome (Xq28), encoding coagulation Factor VIII per Harrison's Principles of Internal Medicine and UpToDate. As an X-linked recessive disorder, hemophilia A predominantly affects males (who have only one X chromosome and therefore express the disease with a single mutant allele) while females are typically asymptomatic carriers (the normal F8 allele on the second X chromosome provides sufficient Factor VIII production) per the Cleveland Clinic. Approximately 30% of cases arise from de novo mutations with no prior family history per Harvard Health.\n\nINHERITANCE PATTERN:\nA carrier mother (XHXh) has a 50% chance of passing the affected X chromosome to each son (who will have hemophilia) and a 50% chance of passing it to each daughter (who will be a carrier) per Harrison's Principles of Internal Medicine. An affected father (XhY) will pass his affected X to all daughters (making them obligate carriers) and his Y to all sons (who will be unaffected) per UpToDate. In rare cases, females may manifest hemophilia through homozygous mutation, Turner syndrome (45,X with affected X), extreme lyonization (skewed X-inactivation), or compound heterozygosity per the Mayo Clinic.\n\nCLINICAL PRESENTATION:\nHemophilia A severity correlates with Factor VIII activity levels: severe (less than 1%, spontaneous hemarthroses and deep tissue bleeding), moderate (1 to 5%, bleeding after minor trauma), and mild (5 to 40%, bleeding only after significant trauma or surgery) per Harrison's Principles of Internal Medicine. Hemarthrosis (bleeding into joints, especially knees, elbows, and ankles) is the hallmark clinical manifestation, and recurrent hemarthroses lead to chronic hemophilic arthropathy per the Cleveland Clinic. Laboratory findings include prolonged aPTT (intrinsic pathway, Factor VIII is in the intrinsic tenase complex) with normal PT (extrinsic pathway) per UpToDate.\n\nTREATMENT:\nFactor VIII replacement (either plasma-derived or recombinant) is the standard treatment for bleeding episodes and prophylaxis per Harrison's Principles of Internal Medicine. Emicizumab (a bispecific antibody that bridges Factor IXa and Factor X, mimicking Factor VIII cofactor function) has transformed prophylactic management per UpToDate and Harvard Health.\n\nKEY LEARNING POINTS:\nHemophilia A (Factor VIII deficiency) follows X-linked recessive inheritance: males are affected, females are carriers, and 30% of cases are de novo mutations. Severity correlates with Factor VIII level (less than 1% severe, with spontaneous hemarthroses). Laboratory hallmark is prolonged aPTT with normal PT. Emicizumab has transformed prophylaxis."
  },
  {
    "id": 352,
    "categoryId": 9,
    "question": "Alcoholics often have Macrocytic Anemia. The two primary drivers are:",
    "options": [
      "A) Iron deficiency and GI bleeding",
      "B) Folate deficiency and Direct Bone Marrow toxicity",
      "C) B12 deficiency and Hemolysis",
      "D) Renal failure and Low EPO"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Folate deficiency and direct bone marrow toxicity).\n\nPATHOPHYSIOLOGY:\nMacrocytic anemia (MCV greater than 100 fL) in patients with chronic alcohol use disorder results from two primary mechanisms that frequently coexist per Harrison's Principles of Internal Medicine and UpToDate.\n\nFOLATE DEFICIENCY:\nFolate (vitamin B9) deficiency is the most common nutritional deficiency in alcoholic patients per the Cleveland Clinic. Three mechanisms converge: poor dietary intake (alcoholic patients often substitute caloric intake from alcohol for nutrient-rich foods), impaired intestinal absorption (ethanol directly damages jejunal mucosal cells where folate is absorbed), and impaired hepatic storage and metabolism (ethanol disrupts folate enterohepatic circulation and inhibits methionine synthase) per Harvard Health and UpToDate. Folate deficiency impairs thymidylate synthesis (conversion of dUMP to dTMP), causing defective DNA synthesis with megaloblastic erythropoiesis (large erythroid precursors with immature nuclei) per Harrison's Principles of Internal Medicine.\n\nDIRECT BONE MARROW TOXICITY:\nEthanol is a direct myelotoxin that suppresses erythropoiesis independent of nutritional deficiency per UpToDate and the Mayo Clinic. Ethanol and its metabolite acetaldehyde directly inhibit hematopoietic progenitor cell proliferation, impair iron incorporation into heme, and cause vacuolization of erythroid and myeloid precursors visible on bone marrow biopsy per Harrison's Principles of Internal Medicine. This direct toxic effect produces macrocytosis even in alcoholic patients with normal folate and B12 levels and can cause sideroblastic changes (ringed sideroblasts from mitochondrial iron accumulation) per the Cleveland Clinic.\n\nADDITIONAL CONTRIBUTING FACTORS:\nChronic liver disease (present in many alcoholic patients) contributes to macrocytosis through altered lipid metabolism, causing excess cholesterol deposition in RBC membranes that increases cell surface area per UpToDate. Reticulocytosis from chronic GI blood loss or hemolysis can also raise the MCV per Harvard Health.\n\nKEY LEARNING POINTS:\nAlcoholic macrocytic anemia results from folate deficiency (poor intake, impaired absorption, disrupted enterohepatic circulation) and direct ethanol myelotoxicity (suppression of erythroid progenitors and vacuolization of precursors). Direct marrow toxicity causes macrocytosis even with normal folate and B12 levels. Alcoholic patients should be assessed for multiple concurrent contributors including liver disease and GI blood loss."
  },
  {
    "id": 353,
    "categoryId": 9,
    "question": "Neutropenic Fever (ANC < 500 + Fever) in a chemotherapy patient is treated with:",
    "options": [
      "A) Oral Amoxicillin",
      "B) Immediate IV Broad-Spectrum Antibiotics (e.g., Cefepime/Zosyn)",
      "C) G-CSF only",
      "D) Antipyretics and observation"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Immediate IV broad-spectrum antibiotics, e.g., cefepime or piperacillin-tazobactam).\n\nCLINICAL EMERGENCY:\nNeutropenic fever is defined as an absolute neutrophil count (ANC) less than 500 cells/microL (or expected to fall below 500 within 48 hours) with a single oral temperature of 38.3Â°C (101Â°F) or greater, or sustained temperature of 38.0Â°C (100.4Â°F) or greater for one hour per Harrison's Principles of Internal Medicine and UpToDate. This represents an oncologic emergency because neutropenic patients lack the primary cellular immune defense against bacterial invasion and can progress from localized infection to septic shock and death within hours per the Cleveland Clinic.\n\nIMPERATIVE FOR IMMEDIATE ANTIBIOTICS:\nEmpiric broad-spectrum IV antibiotics must be administered within 60 minutes of presentation (ideally within 30 minutes) without waiting for culture results, imaging, or identification of a source per the IDSA guidelines as referenced in UpToDate. Each hour of delay in antibiotic administration increases mortality per Harvard Health. Blood cultures (at least 2 sets, including from any central line) should be obtained before antibiotics but must never delay antibiotic administration per Harrison's Principles of Internal Medicine.\n\nANTIMICROBIAL SELECTION:\nFirst-line empiric monotherapy includes anti-pseudomonal beta-lactams: cefepime (fourth-generation cephalosporin), piperacillin-tazobactam (Zosyn), or meropenem (carbapenem, reserved for higher-risk patients or institutions with resistant organisms) per the Mayo Clinic and UpToDate. Vancomycin (or linezolid/daptomycin) is added for specific indications: suspected catheter-related infection, skin/soft tissue infection, hemodynamic instability, or known MRSA colonization, but should not be used routinely as part of the initial empiric regimen per Harrison's Principles of Internal Medicine and the Cleveland Clinic.\n\nRISK STRATIFICATION:\nThe MASCC (Multinational Association for Supportive Care in Cancer) score stratifies patients into high-risk (requiring inpatient IV therapy) and low-risk (potentially eligible for outpatient oral antibiotics with ciprofloxacin plus amoxicillin-clavulanate) per UpToDate.\n\nKEY LEARNING POINTS:\nNeutropenic fever (ANC less than 500 plus temperature 38.3Â°C or greater) requires empiric IV anti-pseudomonal antibiotics (cefepime, piperacillin-tazobactam, or meropenem) within 60 minutes of presentation, before culture results. Vancomycin is added only for specific indications, not routinely. Each hour of antibiotic delay increases mortality in febrile neutropenia."
  },
  {
    "id": 354,
    "categoryId": 13,
    "question": "The Innate Immune System differs from the Adaptive Immune System because the Innate system:",
    "options": [
      "A) Produces antibodies",
      "B) Has memory of past infections",
      "C) Responds immediately but non-specifically",
      "D) Takes 7-10 days to activate"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Responds immediately but non-specifically).\n\nINNATE IMMUNE SYSTEM:\nThe innate immune system is the body\"s first line of defense, activated within minutes to hours of pathogen exposure. It is evolutionarily ancient and present in all multicellular organisms. Its components include physical barriers (skin, mucosal epithelia, and their secretions), cellular defenses (neutrophils, macrophages, dendritic cells, natural killer cells, and mast cells), and soluble mediators (complement, cytokines, and acute phase proteins). Innate immune cells recognize conserved molecular patterns shared by broad categories of pathogens, known as pathogen-associated molecular patterns (PAMPs), through germline-encoded pattern recognition receptors (PRRs) such as Toll-like receptors (TLRs). This recognition is immediate but non-specific, meaning the innate system does not distinguish between individual strains of a given pathogen and does not improve its response with repeated exposures.\n\nADAPTIVE IMMUNE SYSTEM:\nThe adaptive immune system, found only in vertebrates, takes approximately four to seven days to mount a primary response but provides highly specific, targeted immunity. It relies on lymphocytes: B cells (which produce antibodies) and T cells (CD4+ helper and CD8+ cytotoxic). Through somatic recombination of immunoglobulin and T-cell receptor gene segments (V-D-J recombination), each lymphocyte generates a unique antigen receptor, creating a repertoire capable of recognizing virtually any molecular structure. After initial antigen encounter, a subset of activated lymphocytes differentiates into long-lived memory cells, enabling a faster and more robust secondary response upon re-exposure. This immunologic memory is the basis for vaccination.\n\nINTERPLAY BETWEEN SYSTEMS:\nThe innate and adaptive systems are deeply interconnected rather than independent. Dendritic cells serve as the critical bridge: they capture antigens at sites of infection using innate PRRs, then migrate to lymph nodes where they present processed antigen to naive T cells via MHC molecules, initiating the adaptive response. The quality of innate activation directly shapes adaptive immunity, determining whether a Th1, Th2, or Th17 response predominates.\n\nKEY LEARNING POINTS:\nThe innate immune system responds within minutes to hours using germline-encoded pattern recognition receptors that detect broad pathogen-associated molecular patterns. The adaptive immune system takes days to activate but generates highly specific responses and immunologic memory through clonal expansion of antigen-specific lymphocytes. Dendritic cells bridge innate and adaptive immunity by presenting antigens to T cells."
  },
  {
    "id": 355,
    "categoryId": 13,
    "question": "Systemic Lupus Erythematosus (SLE) is a Type III Hypersensitivity reaction. The primary mechanism of tissue damage is:",
    "options": [
      "A) Direct T-cell attack on cells",
      "B) Deposition of Antigen-Antibody Immune Complexes",
      "C) IgE mediated histamine release",
      "D) Macrophage granuloma formation"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Immune complex deposition and complement activation).\n\nTYPE III HYPERSENSITIVITY:\nSystemic lupus erythematosus (SLE) is the prototypical Type III hypersensitivity disease. Autoantibodies (particularly anti-dsDNA) form immune complexes with their antigens. These complexes deposit in tissuesâ€”especially glomeruli, skin, and jointsâ€”where they activate the complement cascade, triggering inflammation and tissue damage.\n\nMECHANISM:\nImmune complex deposition activates complement (C3a, C5a), generating anaphylatoxins that recruit neutrophils and macrophages. These inflammatory cells release proteases and reactive oxygen species, causing local tissue injury. The size and properties of immune complexes determine where they deposit: small complexes penetrate basement membranes (glomerulonephritis), while larger complexes deposit in vessel walls (vasculitis).\n\nCONTRAST WITH OTHER TYPES:\nType I (IgE): Immediate, mast cell degranulation (anaphylaxis). Type II (IgG against cells): Antibodies target cell surfaces, causing cytotoxicity (autoimmune hemolytic anemia). Type III (Immune complexes): Antibody-antigen complexes deposit in tissues (SLE, serum sickness). Type IV (T-cell): Delayed, T-cell mediated (contact dermatitis).\n\nCLINICAL MANIFESTATIONS:\nIn SLE, immune complex deposition causes glomerulonephritis (renal failure), arthritis, vasculitis, and serositis. Complement levels (C3, C4) are often low during active disease due to consumption.\n\nKEY LEARNING POINTS:\nSLE is a Type III hypersensitivity disease caused by immune complex deposition. Deposited complexes activate complement, recruiting inflammatory cells that damage tissue. Low complement levels indicate active immune complex-mediated disease."
  },
  {
    "id": 356,
    "categoryId": 8,
    "question": "Which antibody isotype is the first to be produced during an acute infection (Primary Response)?",
    "options": [
      "A) IgG",
      "B) IgM",
      "C) IgA",
      "D) IgE"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (IgM).\n\nPRIMARY IMMUNE RESPONSE:\nDuring the first exposure to an antigen, the immune system produces IgM antibodies first, typically detectable within 5-7 days. IgM is produced by naive B cells before class switching occurs. Its pentameric structure makes it excellent at agglutination and complement activation, providing rapid but relatively short-lived protection.\n\nCLASS SWITCHING:\nOver the following weeks, with T-cell help, B cells undergo class switching to produce IgG (and other isotypes). This secondary response produces higher-affinity antibodies with longer half-lives. Memory B cells are established, enabling rapid IgG production upon re-exposure.\n\nDIAGNOSTIC UTILITY:\nThe presence of IgM antibodies indicates recent or acute infection, while IgG indicates past infection or immunity. This distinction is diagnostically valuable: for example, hepatitis B core antibody testing differentiates recent (IgM anti-HBc) from past (IgG anti-HBc) infection.\n\nIGM CHARACTERISTICS:\nIgM exists primarily as a pentamer in serum, giving it 10 antigen-binding sites. It cannot cross the placenta (too large), is an efficient complement activator, and is the predominant antibody in ABO blood group reactions.\n\nKEY LEARNING POINTS:\nIgM is the first antibody produced during a primary immune response, appearing within days. Class switching to IgG occurs later with T-cell help. IgM indicates acute infection; IgG indicates past exposure or immunity."
  },
  {
    "id": 357,
    "categoryId": 13,
    "question": "Rheumatoid Arthritis (RA) is characterized by the presence of Anti-Citrullinated Protein Antibodies (ACPA). The pathologic hallmark in the joint is:",
    "options": [
      "A) Osteophyte formation",
      "B) Pannus formation",
      "C) Uric acid crystals",
      "D) Cartilage wear and tear"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Pannus formation).\n\nPATHOPHYSIOLOGY OF PANNUS:\nRheumatoid arthritis (RA) is a chronic systemic autoimmune disease characterized by inflammatory synovitis that progresses to joint destruction. The pathologic hallmark is pannus formation, a thickened, hyperplastic synovial membrane composed of activated fibroblast-like synoviocytes, macrophages, T cells, B cells, and neovascular tissue. This aggressive granulation tissue behaves almost like a locally invasive tumor, extending over and into articular cartilage and subchondral bone. Pannus produces matrix metalloproteinases (MMPs), cathepsins, and RANKL (receptor activator of nuclear factor kappa-B ligand), which drive cartilage degradation and osteoclast-mediated bone erosion.\n\nROLE OF ACPA AND AUTOANTIBODIES:\nAnti-citrullinated protein antibodies (ACPA, detected clinically as anti-CCP) are the most specific serologic marker for RA (specificity greater than 95 percent). Citrullination is a post-translational modification in which peptidylarginine deiminase enzymes convert arginine residues to citrulline in proteins within inflamed joints. The immune system generates antibodies against these citrullinated proteins, forming immune complexes that activate complement and perpetuate synovial inflammation. ACPA can be detected years before clinical disease onset, and their presence predicts a more aggressive, erosive disease course. Rheumatoid factor (IgM directed against the Fc portion of IgG) is present in approximately 70 percent of RA patients but is less specific.\n\nEARLY AGGRESSIVE TREATMENT:\nThe 2021 ACR guidelines emphasize early initiation of disease-modifying antirheumatic drug (DMARD) therapy to prevent irreversible joint damage. Methotrexate is the first-line DMARD, typically started at 7.5 to 15 mg weekly with folic acid supplementation. If disease activity remains moderate to high at three months, treatment is escalated by adding or switching to biologic DMARDs (TNF inhibitors such as adalimumab or etanercept, IL-6 inhibitors such as tocilizumab, or T-cell co-stimulation modulators such as abatacept) or targeted synthetic DMARDs (JAK inhibitors such as tofacitinib or baricitinib). The treat-to-target strategy aims for remission or low disease activity.\n\nKEY LEARNING POINTS:\nPannus is the pathologic hallmark of RA, an aggressive synovial tissue that invades and destroys cartilage and bone through metalloproteinases and osteoclast activation. ACPA (anti-CCP) is highly specific for RA and predicts erosive disease. Early DMARD therapy with methotrexate is critical to prevent irreversible joint destruction. Pannus formation distinguishes RA from osteoarthritis (osteophytes) and gout (crystal deposition)."
  },
  {
    "id": 358,
    "categoryId": 4,
    "question": "Graves' Disease causes Hyperthyroidism via a Type II Hypersensitivity reaction. What is the specific target?",
    "options": [
      "A) Thyroid Peroxidase (TPO)",
      "B) Thyroglobulin",
      "C) TSH Receptor",
      "D) Iodine transporter"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (TSH Receptor - Stimulating Antibodies).\n\nPATHOPHYSIOLOGY:\nGraves' disease is an organ-specific autoimmune disorder and the most common cause of hyperthyroidism, accounting for 60 to 80% of all cases per Harrison's Principles of Internal Medicine and the American Thyroid Association. The disease is caused by a Type II hypersensitivity reaction in which IgG autoantibodies, termed thyroid-stimulating immunoglobulins (TSI), bind to the thyroid-stimulating hormone (TSH) receptor on thyroid follicular cells and activate it. Unlike most autoimmune antibodies that destroy or block their target, TSI function as receptor agonists, mimicking the stimulatory action of TSH and driving constitutive thyroid hormone synthesis and secretion independent of hypothalamic-pituitary feedback regulation. TSI binding activates the Gs-protein-coupled adenylyl cyclase signaling cascade, increasing intracellular cAMP, which stimulates every step of thyroid hormone production: iodide trapping by the sodium-iodide symporter, iodide organification and coupling by thyroid peroxidase, thyroglobulin synthesis, and proteolytic release of T3 and T4. Because this stimulation bypasses normal TSH regulation, the resulting hyperthyroidism suppresses pituitary TSH secretion through negative feedback, but TSI continues to drive the thyroid regardless, producing the characteristic laboratory pattern of elevated free T4 and T3 with profoundly suppressed TSH. The autoimmune process is driven by a combination of genetic susceptibility (HLA-DR3 association, CTLA-4 polymorphisms) and environmental triggers (stress, smoking, postpartum immune rebound, excess iodine intake).\n\nCLINICAL REASONING:\nType II hypersensitivity reactions are mediated by IgG or IgM antibodies directed against cell surface antigens or receptors, and the clinical phenotype depends on whether the antibodies stimulate, block, or mark the target for destruction. In Graves' disease, TSI stimulate the TSH receptor (producing hyperthyroidism), making it a stimulatory Type II reaction. This contrasts with myasthenia gravis, where anti-acetylcholine receptor antibodies block receptor function (blocking Type II), and autoimmune hemolytic anemia, where anti-erythrocyte antibodies mark red blood cells for destruction by complement and phagocytes (cytotoxic Type II). Graves' disease produces a constellation of clinical features beyond thyrotoxicosis: Graves' ophthalmopathy (present in approximately 25 to 50% of patients) results from TSH receptor expression on orbital fibroblasts, where TSI stimulation triggers fibroblast proliferation, adipogenesis, and glycosaminoglycan accumulation in the retroorbital space, causing proptosis, periorbital edema, and extraocular muscle dysfunction. Graves' dermopathy (pretibial myxedema, present in 1 to 2% of patients) involves a similar mechanism in dermal fibroblasts of the lower extremities. Thyroid acropachy (digital clubbing) is the rarest extrathyroidal manifestation.\n\nDIAGNOSIS AND TREATMENT:\nDiagnosis is confirmed by the combination of suppressed TSH, elevated free T4 and/or T3, and positive TSH receptor antibodies (TRAb) or thyroid-stimulating immunoglobulin (TSI) assay. Radioactive iodine uptake (RAIU) is diffusely elevated, distinguishing Graves' from thyroiditis (which shows low uptake due to follicular cell destruction rather than stimulation). Treatment options include antithyroid drugs (methimazole is preferred over propylthiouracil except during the first trimester of pregnancy due to lower hepatotoxicity risk), radioactive iodine ablation (I-131), and thyroidectomy. The ATA 2016 guidelines recommend individualized treatment selection based on patient preference, disease severity, comorbidities, and reproductive plans. Methimazole may be trialed for 12 to 18 months, as approximately 30 to 50% of patients achieve lasting remission, with favorable predictors including mild disease, small goiter, low TRAb titers at discontinuation, and non-smoking status. Beta-blockers (propranolol, atenolol) provide symptomatic relief of adrenergic symptoms during the weeks before antithyroid drugs take full effect.\n\nKEY LEARNING POINTS:\nGraves' disease is a Type II hypersensitivity reaction in which thyroid-stimulating immunoglobulins bind and activate the TSH receptor, producing hyperthyroidism independent of normal feedback regulation. TSI also stimulate TSH receptors on orbital and dermal fibroblasts, causing ophthalmopathy and dermopathy. TRAb or TSI testing confirms the autoimmune etiology, and diffusely elevated radioactive iodine uptake distinguishes Graves' from thyroiditis."
  },
  {
    "id": 359,
    "categoryId": 13,
    "question": "CD4+ Helper T-Cells coordinate the immune response. Th1 cells drive cellular immunity (Viruses/Bacteria), while Th2 cells drive:",
    "options": [
      "A) Autoimmunity",
      "B) Humoral immunity (Antibodies) and Allergy/Parasite response",
      "C) Tolerance",
      "D) Tumor surveillance"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Humoral immunity and Allergy/Parasite response).\n\nTH1 AND TH2 PARADIGM:\nCD4+ helper T cells are the central coordinators of adaptive immunity. Upon activation by antigen-presenting cells, naive CD4+ T cells differentiate into distinct effector subsets depending on the cytokine milieu. The two classical subsets are Th1 and Th2. Th1 cells differentiate under the influence of IL-12 and IFN-gamma, produce IFN-gamma and TNF-alpha, and drive cell-mediated (cellular) immunity. They activate macrophages to kill intracellular pathogens (mycobacteria, viruses, intracellular bacteria) and promote CD8+ cytotoxic T cell responses. Th2 cells differentiate under the influence of IL-4, and produce IL-4, IL-5, IL-10, and IL-13, driving humoral immunity and anti-parasitic defense.\n\nTH2 EFFECTOR FUNCTIONS:\nTh2 cytokines orchestrate several critical immune functions. IL-4 drives B cell activation, proliferation, and class switching to IgE. IL-5 is the principal activator and chemoattractant for eosinophils, which are the primary effector cells against multicellular parasites (helminths). IL-13 stimulates goblet cell hyperplasia and mucus production in the airways and gut, facilitating physical expulsion of parasites. In the context of allergic disease, this same Th2 machinery becomes pathologically activated against harmless environmental antigens (allergens), leading to IgE-mediated mast cell degranulation, eosinophilic tissue inflammation, and the clinical manifestations of asthma, allergic rhinitis, eczema, and food allergy.\n\nCLINICAL SIGNIFICANCE OF TH1/TH2 IMBALANCE:\nThe Th1/Th2 balance has profound clinical implications. Th2 dominance is associated with atopic diseases (asthma, eczema, allergic rhinitis) and is thought to contribute to the rising prevalence of allergic disease in developed nations, a concept central to the hygiene hypothesis. Conversely, excessive Th1 activity drives organ-specific autoimmune diseases such as type 1 diabetes, rheumatoid arthritis, and multiple sclerosis. Additional T helper subsets discovered more recently, including Th17 (autoimmunity, mucosal defense) and T regulatory cells (immune suppression, tolerance), add further complexity to this paradigm.\n\nKEY LEARNING POINTS:\nTh2 cells drive humoral immunity through B cell activation and IgE class switching, and anti-parasitic defense through eosinophil recruitment via IL-5. The same Th2 pathways are pathologically activated in allergic diseases (asthma, eczema, allergic rhinitis). Th1/Th2 imbalance contributes to the pathogenesis of both atopic and autoimmune diseases. Th17 and T regulatory cells add additional layers of immune regulation beyond the classical Th1/Th2 model."
  },
  {
    "id": 360,
    "categoryId": 6,
    "question": "Multiple Sclerosis (MS) involves the autoimmune destruction of:",
    "options": [
      "A) Axons in the Peripheral Nervous System",
      "B) Myelin sheaths in the Central Nervous System (Oligodendrocytes)",
      "C) Acetylcholine receptors",
      "D) Schwann cells"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Myelin sheaths in the Central Nervous System/Oligodendrocytes).\n\nMULTIPLE SCLEROSIS PATHOPHYSIOLOGY:\nMultiple sclerosis (MS) is a chronic, immune-mediated demyelinating disease of the central nervous system in which autoreactive T-cells cross the blood-brain barrier and attack oligodendrocytes, the cells responsible for producing and maintaining myelin sheaths around CNS axons. This demyelination disrupts saltatory nerve conduction, slowing or blocking signal transmission along affected pathways. MS is distinct from Guillain-BarrÃ© syndrome, which targets Schwann cells (the PNS myelinating cells) in the peripheral nervous system.\n\nCLINICAL MANIFESTATIONS:\nMS typically presents in young adults (ages 20 to 40) with a female predominance of approximately 3:1. The hallmark is neurological symptoms disseminated in time (occurring at different time points) and space (affecting different CNS regions). Common presentations include optic neuritis (unilateral vision loss with pain on eye movement), internuclear ophthalmoplegia, transverse myelitis (limb weakness and sensory levels), cerebellar ataxia, and neurogenic bladder. Uhthoff phenomenon, the transient worsening of symptoms with heat exposure, is characteristic and reflects the temperature sensitivity of demyelinated axons.\n\nDIAGNOSIS:\nThe McDonald Criteria require demonstration of dissemination in space and time, using MRI (periventricular, juxtacortical, infratentorial, and spinal cord white matter lesions), CSF analysis (oligoclonal bands), and clinical episodes. MRI showing both gadolinium-enhancing (active) and non-enhancing (chronic) lesions can satisfy both criteria simultaneously.\n\nTREATMENT:\nDisease-modifying therapies aim to reduce relapse frequency and slow disability progression. Options range from injectable therapies (interferon beta, glatiramer acetate) to high-efficacy agents (natalizumab, ocrelizumab, fingolimod, cladribine). Acute relapses are treated with high-dose IV methylprednisolone. Treatment selection depends on disease activity, risk tolerance, and patient preference.\n\nKEY LEARNING POINTS:\nMS involves autoimmune destruction of CNS myelin (oligodendrocytes), not PNS myelin (Schwann cells, which are targeted in Guillain-BarrÃ©). Diagnosis requires dissemination in time and space via clinical episodes and MRI findings. Disease-modifying therapies reduce relapses and slow progression, with high-efficacy agents available for aggressive disease."
  },
  {
    "id": 361,
    "categoryId": 3,
    "question": "In Celiac Disease, tissue Transglutaminase (tTG) modifies Gliadin (gluten), causing T-cells to attack:",
    "options": [
      "A) The stomach lining",
      "B) The colonic mucosa",
      "C) The villi of the Small Intestine",
      "D) The pancreas"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (The villi of the small intestine).\n\nPATHOPHYSIOLOGY:\nCeliac disease is an autoimmune enteropathy in which the enzyme tissue transglutaminase (tTG) plays a central pathogenic role. When gliadin peptides from dietary gluten cross the intestinal epithelial barrier, tTG deamidates specific glutamine residues on gliadin, converting them to negatively charged glutamic acid residues. These modified (deamidated) gliadin peptides have dramatically increased binding affinity for HLA-DQ2 and HLA-DQ8 molecules on antigen-presenting cells in the lamina propria. This complex is presented to CD4+ T helper cells, triggering a robust Th1-mediated immune response that releases interferon-gamma and other pro-inflammatory cytokines.\n\nMUCOSAL DESTRUCTION:\nThe activated immune response targets the small intestinal mucosa, producing a characteristic spectrum of histologic changes classified by the Marsh-Oberhuber system: increased intraepithelial lymphocytes (Marsh 1), crypt hyperplasia (Marsh 2), and progressive villous atrophy ranging from partial to total (Marsh 3a-3c). Villous atrophy reduces the absorptive surface area of the small intestine, causing malabsorption of iron, calcium, folate, fat-soluble vitamins (A, D, E, K), and macronutrients. The proximal small intestine (duodenum and jejunum) is most severely affected because it is the site of highest gluten exposure.\n\nCLINICAL MANIFESTATIONS AND DIAGNOSIS:\nClassic celiac disease presents with diarrhea, steatorrhea, weight loss, and iron deficiency anemia. Atypical presentations (more common in adults) include isolated iron deficiency anemia, osteoporosis, elevated transaminases, dermatitis herpetiformis, infertility, or peripheral neuropathy. Serologic screening with tTG-IgA (sensitivity and specificity both greater than 95%) is the first-line diagnostic test, followed by confirmatory duodenal biopsy. A strict lifelong gluten-free diet is the only effective treatment.\n\nKEY LEARNING POINTS:\ntTG deamidates gliadin peptides, creating neo-epitopes with increased HLA-DQ2/DQ8 binding affinity that trigger T-cell-mediated destruction of small intestinal villi. Villous atrophy causes malabsorption of iron, calcium, folate, and fat-soluble vitamins. tTG-IgA has greater than 95% sensitivity and specificity for celiac disease. Lifelong strict gluten-free diet is the only effective treatment."
  },
  {
    "id": 362,
    "categoryId": 13,
    "question": "Sjogren's Syndrome primarily targets exocrine glands. Which two symptoms are the hallmarks?",
    "options": [
      "A) Dry Eyes (Keratoconjunctivitis Sicca) and Dry Mouth (Xerostomia)",
      "B) Joint pain and Rash",
      "C) Hair loss and Weight gain",
      "D) Diarrhea and Vomiting"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Dry Eyes and Dry Mouth).\n\nPATHOPHYSIOLOGY:\nSjogren syndrome is a chronic systemic autoimmune disease characterized by lymphocytic infiltration and destruction of exocrine glands, predominantly the lacrimal and salivary glands. CD4+ T cells and B cells infiltrate the glandular tissue, forming periductal lymphocytic foci that progressively destroy acinar cells and reduce glandular secretion. The disease can occur as primary Sjogren syndrome (isolated) or secondary Sjogren syndrome (associated with another autoimmune disease, most commonly rheumatoid arthritis or systemic lupus erythematosus). It has a strong female predominance (approximately 9:1 female-to-male ratio) with peak onset between ages 40 and 60.\n\nCLINICAL MANIFESTATIONS:\nThe hallmark sicca symptoms are keratoconjunctivitis sicca (dry eyes causing a gritty, sandy sensation, photosensitivity, and risk of corneal abrasions and ulceration) and xerostomia (dry mouth leading to difficulty swallowing dry food, accelerated dental caries, oral candidiasis, and parotid gland enlargement). Beyond the glands, Sjogren syndrome can cause systemic manifestations including interstitial lung disease, renal tubular acidosis (type 1 distal RTA), peripheral neuropathy, arthralgia, fatigue, and cutaneous vasculitis. Approximately 5 percent of patients with primary Sjogren syndrome develop B-cell non-Hodgkin lymphoma (typically mucosa-associated lymphoid tissue or MALT lymphoma), making long-term monitoring essential.\n\nDIAGNOSIS:\nThe 2016 ACR/EULAR classification criteria incorporate objective measures: anti-SSA/Ro antibody positivity (the most important serologic marker), labial salivary gland biopsy showing focal lymphocytic sialadenitis with a focus score of 1 or greater, ocular staining score, Schirmer test (less than 5 mm in 5 minutes), and unstimulated salivary flow rate. Anti-SSB/La antibodies are less sensitive but more specific for Sjogren syndrome. ANA is positive in the majority of patients.\n\nKEY LEARNING POINTS:\nSjogren syndrome causes dry eyes (keratoconjunctivitis sicca) and dry mouth (xerostomia) through lymphocytic destruction of lacrimal and salivary glands. Anti-SSA/Ro is the most important serologic marker. Patients face increased risk of severe dental caries, corneal damage, and B-cell lymphoma (MALT type). Systemic manifestations can include interstitial lung disease, renal tubular acidosis, and peripheral neuropathy."
  },
  {
    "id": 363,
    "categoryId": 16,
    "question": "Live Attenuated Vaccines (e.g., MMR, Varicella) produce a stronger, longer-lasting immunity than Inactivated Vaccines because:",
    "options": [
      "A) They contain more antigen",
      "B) They replicate in the host, mimicking a real infection",
      "C) They have adjuvants",
      "D) They are given intravenously"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (They replicate in the host, mimicking a real infection).\n\nIMMUNOLOGY:\nLive attenuated vaccines contain a weakened (attenuated) but still viable form of the pathogen that retains the ability to infect host cells and undergo limited replication per Harrison's Principles of Internal Medicine. This replication mimics a natural infection, activating both the innate and adaptive immune systems comprehensively: antigen-presenting cells process and present viral antigens via MHC class I and class II pathways, stimulating robust CD8+ cytotoxic T-cell responses (cellular immunity), CD4+ T-helper cell responses, and B-cell-mediated antibody production (humoral immunity) per UpToDate. The resulting immune memory is typically strong, broad, and long-lasting, often providing lifelong protection with one or two doses per the CDC.\n\nCOMPARISON WITH INACTIVATED VACCINES:\nInactivated (killed) vaccines contain pathogen that cannot replicate, and are processed primarily through the exogenous (MHC class II) antigen presentation pathway, generating predominantly humoral (antibody) immunity with weaker cellular immune responses per the Cleveland Clinic. Because inactivated vaccines cannot replicate and amplify antigen exposure internally, they typically require multiple doses and periodic boosters to maintain protective immunity per Harrison's Principles of Internal Medicine. The influenza inactivated vaccine, for example, requires annual readministration per the CDC.\n\nCLINICAL CONSIDERATIONS:\nLive attenuated vaccines (MMR, varicella, rotavirus, intranasal influenza, yellow fever, oral polio, BCG) are contraindicated in immunocompromised patients (HIV with CD4 less than 200, active chemotherapy, high-dose corticosteroids, biologic immunosuppressants) and during pregnancy because the attenuated organism could cause disease in an immunodeficient host per the Mayo Clinic and UpToDate. After administration, patients should avoid salicylates for 6 weeks (varicella and MMR, due to Reye syndrome risk in children) and allow at least 4 weeks between different live vaccines if not given simultaneously per the CDC.\n\nKEY LEARNING POINTS:\nLive attenuated vaccines replicate in the host, activating both cellular (CD8+ T-cell) and humoral (antibody) immunity and typically providing long-lasting protection with fewer doses. Inactivated vaccines primarily stimulate humoral immunity and require multiple doses and boosters. Live vaccines are contraindicated in immunocompromised patients and pregnancy because the attenuated organism could cause disease."
  },
  {
    "id": 364,
    "categoryId": 4,
    "question": "Type 1 Diabetes is caused by the autoimmune destruction of Pancreatic Beta Cells. Which autoantibody is commonly tested to confirm diagnosis?",
    "options": [
      "A) Anti-Nuclear Antibody (ANA)",
      "B) Anti-GAD65 (Glutamic Acid Decarboxylase)",
      "C) Anti-TPO",
      "D) Rheumatoid Factor"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Anti-GAD65 / Glutamic Acid Decarboxylase antibodies).\n\nPATHOPHYSIOLOGY:\nType 1 diabetes mellitus is an organ-specific autoimmune disease in which autoreactive CD4+ and CD8+ T lymphocytes infiltrate the pancreatic islets of Langerhans and selectively destroy insulin-producing beta cells through a process termed insulitis. The autoimmune response is directed against multiple beta-cell autoantigens, generating a panel of detectable autoantibodies that serve as biomarkers of the ongoing immune-mediated destruction. The autoimmune process begins years before clinical presentation, progressing through identifiable stages defined by the 2015 ADA staging system: Stage 1 is characterized by the presence of two or more islet autoantibodies with normoglycemia, Stage 2 by the presence of autoantibodies with dysglycemia (impaired fasting glucose or glucose tolerance), and Stage 3 by clinical diabetes with symptomatic hyperglycemia. By the time of clinical diagnosis at Stage 3, approximately 80 to 90% of beta-cell mass has been destroyed. Genetic susceptibility is strongly linked to HLA class II alleles, particularly HLA-DR3-DQ2 and HLA-DR4-DQ8, which are present in approximately 90% of patients with type 1 diabetes and influence antigen presentation to autoreactive T cells. Environmental triggers proposed to initiate the autoimmune cascade include viral infections (enterovirus, particularly Coxsackievirus B), early cow's milk protein exposure, vitamin D deficiency, and alterations in gut microbiome composition.\n\nCLINICAL REASONING:\nGAD65 (glutamic acid decarboxylase 65-kilodalton isoform) is an enzyme expressed in pancreatic beta cells that catalyzes the conversion of glutamate to gamma-aminobutyric acid (GABA). Anti-GAD65 antibodies are the most commonly tested islet autoantibody in clinical practice because they are present in approximately 70 to 80% of patients at diagnosis, persist for the longest duration after disease onset (often remaining detectable for decades, unlike other autoantibodies that may wane), and are the most useful for diagnosing autoimmune diabetes in adults where the presentation may be ambiguous. The complete panel of type 1 diabetes autoantibodies includes anti-GAD65 (most widely available and persistent), islet antigen-2 antibodies (IA-2, also called ICA512, present in 60 to 70% at diagnosis and highly specific for type 1 diabetes), insulin autoantibodies (IAA, often the first to appear in young children, though measurement is invalidated in patients already receiving exogenous insulin), and zinc transporter 8 antibodies (ZnT8, present in 60 to 80% at diagnosis, the most recently identified major autoantibody). The presence of two or more autoantibodies confers a greater than 90% lifetime risk of progressing to clinical type 1 diabetes per data from TrialNet and the TEDDY study.\n\nCLINICAL APPLICATION:\nAutoantibody testing is most valuable in three clinical scenarios. First, it distinguishes type 1 from type 2 diabetes when the clinical presentation is ambiguous, such as an adult presenting with new-onset diabetes who is not obese and lacks metabolic syndrome features but does not present with classic diabetic ketoacidosis. Second, it identifies latent autoimmune diabetes in adults (LADA), a slowly progressive form of autoimmune diabetes (sometimes called type 1.5 diabetes) that accounts for approximately 5 to 10% of adults initially diagnosed with type 2 diabetes per the UKPDS and data from Diabetes Care. LADA patients are typically anti-GAD65 positive, lean or normal weight, and progress to insulin dependence within months to years rather than decades. Earlier recognition of LADA guides appropriate therapy (insulin rather than sulfonylureas, which may accelerate beta-cell failure in the setting of autoimmune destruction) and prompts screening for associated autoimmune conditions. Third, autoantibody screening in first-degree relatives of type 1 diabetes patients identifies individuals at high risk for disease development, enabling enrollment in prevention trials and, more recently, treatment with teplizumab (Tzield), the first FDA-approved therapy to delay the onset of Stage 3 type 1 diabetes by a median of approximately 2 years in high-risk individuals with Stage 2 disease, as demonstrated in the pivotal trial published in the NEJM (2019).\n\nKEY LEARNING POINTS:\nAnti-GAD65 is the most commonly tested autoantibody for confirming autoimmune diabetes because it is present in 70 to 80% of patients at diagnosis and persists for decades. Two or more positive autoantibodies confer greater than 90% lifetime risk of clinical type 1 diabetes. GAD65 testing is essential for identifying LADA in adults misclassified as type 2 diabetes, and teplizumab is now FDA-approved to delay Stage 3 onset in high-risk individuals with Stage 2 disease."
  },
  {
    "id": 365,
    "categoryId": 13,
    "question": "Psoriasis is driven by which specific T-cell pathway, which is now the target of biologic drugs like Secukinumab?",
    "options": [
      "A) Th1 / Interferon-gamma",
      "B) Th17 / IL-17",
      "C) Th2 / IL-4",
      "D) Treg / IL-10"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Th17 / IL-17).\n\nPATHOPHYSIOLOGY:\nPsoriasis is a chronic immune-mediated inflammatory skin disease driven primarily by the Th17 pathway. In genetically susceptible individuals, environmental triggers (stress, infection, trauma, medications such as lithium or beta-blockers) activate dendritic cells in the skin, which produce IL-23. This cytokine drives the differentiation and expansion of Th17 cells, which in turn secrete IL-17A, IL-17F, and IL-22. These cytokines act on keratinocytes to induce massive proliferation and aberrant differentiation, shortening the epidermal turnover time from the normal 28 to 30 days to just 3 to 4 days. The result is the characteristic well-demarcated, erythematous plaques with silvery-white scale, most commonly on the extensor surfaces (elbows, knees), scalp, and lumbosacral area.\n\nBIOLOGIC THERAPY TARGETING THE TH17/IL-23 AXIS:\nThe elucidation of the IL-23/Th17/IL-17 axis revolutionized psoriasis treatment. IL-17A inhibitors (secukinumab, ixekizumab, and brodalumab) achieve PASI 90 (90 percent improvement in Psoriasis Area and Severity Index) in 60 to 70 percent of patients, representing dramatic efficacy. IL-23 inhibitors (guselkumab, risankizumab, tildrakizumab) target the upstream driver and offer the advantage of less frequent dosing with sustained efficacy. Older biologics targeting TNF-alpha (adalimumab, etanercept, infliximab) remain effective but generally achieve lower PASI 90 rates than IL-17 and IL-23 inhibitors.\n\nSTEPWISE TREATMENT APPROACH:\nMild psoriasis (less than 5 percent body surface area) is managed with topical corticosteroids (first-line), vitamin D analogs (calcipotriol), and calcineurin inhibitors for sensitive areas. Moderate-to-severe disease may require phototherapy (narrowband UVB), conventional systemic agents (methotrexate, cyclosporine, acitretin), or biologic therapy. All psoriasis patients should be screened for psoriatic arthritis (present in up to 30 percent), cardiovascular disease, metabolic syndrome, and depression, as these comorbidities significantly impact outcomes.\n\nKEY LEARNING POINTS:\nPsoriasis is driven by the IL-23/Th17/IL-17 axis, which causes keratinocyte hyperproliferation and a shortened epidermal turnover from 28 days to 3 to 4 days. IL-17 inhibitors (secukinumab, ixekizumab) and IL-23 inhibitors (guselkumab, risankizumab) are the most effective biologic therapies. All psoriasis patients should be screened for psoriatic arthritis, metabolic syndrome, cardiovascular disease, and depression."
  },
  {
    "id": 366,
    "categoryId": 9,
    "question": "The Spleen's 'Red Pulp' function is to filter blood, while the 'White Pulp' function is:",
    "options": [
      "A) Fat storage",
      "B) Immune surveillance (B and T cell activation)",
      "C) Red blood cell production",
      "D) Bile production"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Immune surveillance: B and T cell activation).\n\nANATOMY AND PHYSIOLOGY:\nThe spleen is the largest secondary lymphoid organ, weighing approximately 150 grams in adults, and is organized into two functionally distinct compartments: the red pulp and the white pulp, separated by the marginal zone per Harrison's Principles of Internal Medicine and UpToDate.\n\nRED PULP FUNCTION:\nThe red pulp constitutes approximately 75% of splenic volume and serves as a blood filtration system per the Cleveland Clinic. Its reticular meshwork of splenic cords (of Billroth) and sinusoidal capillaries with narrow interendothelial slits (2 to 3 micrometers) creates a mechanical filter that removes senescent or damaged red blood cells, RBC inclusions (Howell-Jolly bodies, Heinz bodies, siderotic granules, nuclear remnants), and opsonized pathogens per Harrison's Principles of Internal Medicine. Splenic macrophages in the red pulp phagocytose cells that cannot deform through the sinusoidal slits (spherocytes, sickle cells, antibody-coated cells) per UpToDate.\n\nWHITE PULP FUNCTION:\nThe white pulp constitutes approximately 25% of splenic volume and is the immunologic compartment per Harvard Health. It is organized around the central arterioles in two zones: the periarteriolar lymphoid sheath (PALS), which contains T-lymphocytes (primarily CD4+ helper T cells that coordinate immune responses), and the lymphoid follicles (with germinal centers), which contain B-lymphocytes that undergo somatic hypermutation, affinity maturation, and class switching to produce high-affinity antibodies, particularly IgM against polysaccharide antigens of encapsulated bacteria per Harrison's Principles of Internal Medicine and the Mayo Clinic.\n\nMARGINAL ZONE:\nThe marginal zone between red and white pulp contains specialized marginal zone B cells that are critical for the rapid T-independent IgM antibody response against blood-borne polysaccharide antigens (the primary defense against encapsulated bacteria such as S. pneumoniae, H. influenzae, and N. meningitidis) per UpToDate and the Cleveland Clinic. This explains why asplenic patients are uniquely vulnerable to these organisms per Harrison's Principles of Internal Medicine.\n\nKEY LEARNING POINTS:\nThe splenic white pulp provides immune surveillance through T-cell activation in the PALS and B-cell antibody production (especially IgM against polysaccharide antigens) in lymphoid follicles. The red pulp filters blood by removing senescent RBCs and inclusions through narrow sinusoidal slits. Marginal zone B cells provide the critical rapid IgM response against encapsulated bacteria, explaining post-splenectomy infection risk."
  },
  {
    "id": 367,
    "categoryId": 6,
    "question": "Myasthenia Gravis causes muscle weakness that worsens with use. The antibodies block/destroy:",
    "options": [
      "A) Calcium channels",
      "B) Acetylcholine Receptors (AChR) at the neuromuscular junction",
      "C) Myelin",
      "D) Dopamine receptors"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Acetylcholine Receptors at the neuromuscular junction).\n\nMYASTHENIA GRAVIS PATHOPHYSIOLOGY:\nMyasthenia gravis (MG) is an autoimmune disorder in which antibodies target acetylcholine receptors (AChR) at the postsynaptic membrane of the neuromuscular junction. Approximately 85% of patients have AChR antibodies, while a subset carry antibodies against muscle-specific kinase (MuSK) or lipoprotein-related protein 4 (LRP4). These antibodies reduce the number of functional receptors through complement-mediated destruction, accelerated endocytosis, and direct receptor blockade, resulting in impaired neuromuscular transmission.\n\nCLINICAL MANIFESTATIONS:\nThe cardinal feature is fatigable weakness that worsens with repetitive use and improves with rest. Ocular symptoms are the most common initial presentation, with ptosis (eyelid drooping) and diplopia (double vision) occurring in approximately 85% of patients at onset. Bulbar symptoms include dysarthria, dysphagia, and difficulty chewing that worsens throughout a meal. Limb weakness tends to affect proximal muscles. Myasthenic crisis, characterized by respiratory muscle weakness requiring mechanical ventilation, is a life-threatening emergency occurring in approximately 15 to 20% of patients.\n\nDIAGNOSIS:\nDiagnostic evaluation includes serum AChR antibody testing (positive in 85% of generalized MG), ice pack test (improvement of ptosis with cold application), edrophonium (Tensilon) test (rapid improvement after IV acetylcholinesterase inhibitor), and repetitive nerve stimulation showing decremental response. Single-fiber EMG is the most sensitive electrodiagnostic test. CT chest should be performed to evaluate for thymoma, present in 10 to 15% of MG patients.\n\nTREATMENT:\nPyridostigmine (acetylcholinesterase inhibitor) provides symptomatic relief by increasing ACh availability at the neuromuscular junction. Immunosuppressive therapy (corticosteroids, azathioprine, mycophenolate) addresses the underlying autoimmune process. Thymectomy is recommended for patients with thymoma and considered in generalized AChR-positive MG. Acute exacerbations and myasthenic crisis are treated with plasmapheresis or intravenous immunoglobulin (IVIG).\n\nKEY LEARNING POINTS:\nMG is caused by antibodies against acetylcholine receptors at the neuromuscular junction, causing fatigable weakness that worsens with use. Ptosis and diplopia are the most common initial symptoms; myasthenic crisis with respiratory failure is the most dangerous complication. Treatment includes pyridostigmine for symptom relief, immunosuppression for disease control, and thymectomy when indicated."
  },
  {
    "id": 368,
    "categoryId": 13,
    "question": "Ankylosing Spondylitis (Fusion of the spine) is strongly associated with which genetic marker (MHC Class I allele)?",
    "options": [
      "A) HLA-DR4",
      "B) HLA-B27",
      "C) HLA-DQ2",
      "D) BRCA1"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (HLA-B27).\n\nGENETIC ASSOCIATION:\nAnkylosing spondylitis (AS) has the strongest known association between an HLA allele and a disease. HLA-B27 is present in approximately 90 to 95 percent of patients with AS in White populations, compared to roughly 8 percent of the general population. However, only about 5 percent of HLA-B27-positive individuals develop AS, indicating that additional genetic and environmental factors are necessary. The exact mechanism by which HLA-B27 contributes to disease is debated, with leading theories including the arthritogenic peptide hypothesis (HLA-B27 presents specific self-peptides that trigger autoreactive CD8+ T cells), the misfolding hypothesis (HLA-B27 heavy chain misfolding in the endoplasmic reticulum activates inflammatory pathways), and the homodimer hypothesis.\n\nPATHOPHYSIOLOGY AND CLINICAL FEATURES:\nAS is the prototypical seronegative spondyloarthropathy, meaning rheumatoid factor and anti-CCP are characteristically negative. The primary pathologic target is the enthesis, the site where tendons, ligaments, and joint capsules insert into bone. Chronic enthesitis at the vertebral margins and sacroiliac joints leads to reactive new bone formation (syndesmophytes) that can progressively fuse the spine, producing the classic radiographic \"bamboo spine\" appearance. Patients typically present before age 40 with insidious-onset inflammatory low back pain (worse with rest, improves with exercise, morning stiffness greater than 30 minutes) and sacroiliitis. Extra-articular manifestations include anterior uveitis (the most common, occurring in 25 to 40 percent), inflammatory bowel disease, and psoriasis.\n\nDIAGNOSIS AND MANAGEMENT:\nMRI of the sacroiliac joints is the most sensitive imaging modality for early disease, detecting bone marrow edema before radiographic changes appear. The modified New York criteria require radiographic sacroiliitis for definitive diagnosis. First-line pharmacotherapy is NSAIDs (used continuously rather than as-needed). For patients with inadequate NSAID response, TNF inhibitors (adalimumab, etanercept, infliximab) and IL-17A inhibitors (secukinumab, ixekizumab) are highly effective. Conventional DMARDs (methotrexate, sulfasalazine) are ineffective for axial disease. Physical therapy and regular exercise are essential components of management.\n\nKEY LEARNING POINTS:\nHLA-B27 is present in 90 to 95 percent of ankylosing spondylitis patients and is the strongest HLA-disease association known. AS targets the entheses, causing progressive spinal fusion (bamboo spine). It is a seronegative spondyloarthropathy with negative RF and anti-CCP. First-line therapy is continuous NSAIDs, with TNF or IL-17 inhibitors for refractory disease."
  },
  {
    "id": 369,
    "categoryId": 2,
    "question": "The Complement System (C1-C9) ends in the formation of the Membrane Attack Complex (MAC). What does the MAC do?",
    "options": [
      "A) Tags bacteria for phagocytosis",
      "B) Punches a hole in the bacterial cell membrane, causing lysis",
      "C) Releases histamine",
      "D) Attracts neutrophils"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Punches a hole in the bacterial cell membrane, causing lysis).\n\nPATHOPHYSIOLOGY:\nThe complement system is a cascade of over 30 plasma proteins that serves as a critical arm of innate immunity per Harrison's Principles of Internal Medicine. The cascade can be activated through three pathways: the classical pathway (initiated by antigen-antibody complexes binding C1q), the alternative pathway (spontaneous C3 hydrolysis amplified on microbial surfaces lacking regulatory proteins), and the lectin pathway (mannose-binding lectin recognizing mannose residues on microbial surfaces). All three pathways converge on C3, which is cleaved into C3a (an anaphylatoxin) and C3b (an opsonin that deposits on microbial surfaces and tags them for phagocytosis) per UpToDate.\n\nMEMBRANE ATTACK COMPLEX:\nThe terminal complement pathway begins when C5 is cleaved into C5a (the most potent anaphylatoxin and chemotactic factor) and C5b. C5b sequentially recruits C6, C7, C8, and multiple molecules of C9 to assemble the membrane attack complex (C5b-9) on the target cell membrane per Harrison's Principles of Internal Medicine. The C9 molecules polymerize to form a transmembrane pore approximately 10 nm in diameter that disrupts the osmotic integrity of the target cell, allowing uncontrolled influx of water and ions, resulting in cell swelling and lysis. The MAC is particularly effective against gram-negative bacteria (whose outer membrane is vulnerable to pore formation) and enveloped pathogens per the Cleveland Clinic.\n\nCOMPLEMENT FUNCTIONS SUMMARY:\nThe complement system serves three major effector functions per UpToDate: opsonization (C3b coating of pathogens enhances phagocytosis), inflammation (C3a and C5a cause mast cell degranulation, vasodilation, and neutrophil chemotaxis), and direct killing (MAC-mediated lysis). Complement deficiencies predispose to specific infections: early classical pathway deficiencies (C1, C2, C4) are associated with autoimmune disease (particularly SLE), C3 deficiency causes severe recurrent pyogenic infections, and terminal complement deficiencies (C5 through C9) specifically predispose to recurrent Neisseria infections (meningococcus, gonococcus) because Neisseria species are uniquely dependent on MAC-mediated killing for clearance per Harrison's Principles of Internal Medicine and the Mayo Clinic.\n\nKEY LEARNING POINTS:\nThe membrane attack complex (C5b-9) assembles a pore in the bacterial cell membrane, causing osmotic lysis, particularly effective against gram-negative organisms. C3b opsonizes pathogens for phagocytosis, while C3a and C5a are anaphylatoxins driving inflammation. Terminal complement deficiency (C5 through C9) specifically predisposes to recurrent Neisseria infections."
  },
  {
    "id": 370,
    "categoryId": 13,
    "question": "Systemic Sclerosis (Scleroderma) involves vascular damage and excessive production of:",
    "options": [
      "A) Elastin",
      "B) Collagen",
      "C) Fibrin",
      "D) Keratin"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Collagen).\n\nPATHOPHYSIOLOGY:\nSystemic sclerosis (SSc), commonly known as scleroderma, is a chronic autoimmune connective tissue disease characterized by three interrelated pathologic processes: vasculopathy (endothelial injury and intimal hyperplasia of small arteries and arterioles), immune activation (T cell and B cell-mediated inflammation), and fibrosis (excessive collagen deposition by activated myofibroblasts). The fibrotic process is driven by dysregulated fibroblasts that overproduce type I and type III collagen along with other extracellular matrix components. Transforming growth factor-beta (TGF-beta) is the central pro-fibrotic cytokine, stimulating collagen gene transcription and inhibiting matrix metalloproteinase-mediated collagen degradation. This excessive collagen deposition occurs in the skin and internal organs, producing the hallmark skin thickening and visceral fibrosis.\n\nCLINICAL SUBTYPES:\nSSc is classified into two major subtypes. Limited cutaneous SSc (formerly CREST syndrome: Calcinosis, Raynaud phenomenon, Esophageal dysmotility, Sclerodactyly, Telangiectasia) features skin thickening confined to the face and distal extremities, is associated with anti-centromere antibodies, and carries a risk of pulmonary arterial hypertension. Diffuse cutaneous SSc features rapid, widespread skin thickening extending proximally, is associated with anti-Scl-70 (anti-topoisomerase I) antibodies, and carries higher risk of interstitial lung disease, renal crisis (scleroderma renal crisis with malignant hypertension), and cardiac involvement.\n\nORGAN INVOLVEMENT AND MANAGEMENT:\nRaynaud phenomenon is nearly universal (present in greater than 95 percent of patients) and often the earliest manifestation. Esophageal dysmotility from smooth muscle fibrosis causes gastroesophageal reflux and dysphagia. Interstitial lung disease (most commonly nonspecific interstitial pneumonia pattern) is the leading cause of death and is screened for with pulmonary function tests and high-resolution CT. Scleroderma renal crisis, a life-threatening emergency with acute hypertension and rapidly progressive renal failure, is treated with ACE inhibitors. Immunosuppressive agents (mycophenolate mofetil, cyclophosphamide) are used for progressive interstitial lung disease, and nintedanib (an antifibrotic) has been approved for SSc-associated ILD.\n\nKEY LEARNING POINTS:\nSystemic sclerosis is defined by excessive collagen deposition from dysregulated fibroblasts driven by TGF-beta, affecting skin and internal organs. Limited cutaneous SSc is associated with anti-centromere antibodies and pulmonary arterial hypertension risk. Diffuse cutaneous SSc is associated with anti-Scl-70 and carries higher risk of interstitial lung disease and scleroderma renal crisis. ACE inhibitors are the life-saving treatment for scleroderma renal crisis."
  },
  {
    "id": 371,
    "categoryId": 2,
    "question": "Which Hypersensitivity Reaction is 'Delayed' and T-Cell mediated (e.g., Poison Ivy or TB Skin Test)?",
    "options": [
      "A) Type I",
      "B) Type II",
      "C) Type III",
      "D) Type IV"
    ],
    "correctAnswer": 3,
    "explanation": "CORRECT: D (Type IV - Delayed T-Cell Mediated).\n\nPATHOPHYSIOLOGY:\nType IV hypersensitivity is the only type that is antibody-independent and entirely T-cell mediated, with a characteristic delayed onset of 48 to 72 hours after antigen exposure per Harrison's Principles of Internal Medicine. Upon initial sensitization, antigen-presenting cells (Langerhans cells in the skin, dendritic cells) process the antigen and present it via MHC class II molecules to naive CD4+ T cells, generating antigen-specific memory T cells. Upon re-exposure, these memory T cells recognize the antigen and release pro-inflammatory cytokines (interferon-gamma, TNF-alpha, IL-2) that activate macrophages and recruit additional inflammatory cells, producing a localized inflammatory response over 48 to 72 hours per UpToDate.\n\nCLINICAL EXAMPLES:\nContact dermatitis (poison ivy, nickel allergy) is the prototypical Type IV reaction: urushiol from poison ivy penetrates the epidermis, is processed by Langerhans cells, and triggers a delayed T-cell response producing the characteristic pruritic, vesicular eruption at the site of contact 48 to 72 hours later per the Cleveland Clinic. The tuberculin skin test (Mantoux/PPD test) is a diagnostic application of Type IV hypersensitivity: purified protein derivative injected intradermally triggers a delayed induration response in individuals previously sensitized to mycobacterial antigens, read at 48 to 72 hours per the CDC. Other Type IV reactions include granulomatous inflammation (sarcoidosis, tuberculosis), transplant rejection, and graft-versus-host disease per Harrison's Principles of Internal Medicine.\n\nCOMPARISON WITH OTHER TYPES:\nThe mnemonic ACID distinguishes the four types per the Mayo Clinic: Type I is Allergy/Anaphylaxis (IgE-mediated, minutes), Type II is Cytotoxic (IgG/IgM against cell surfaces, hours to days), Type III is Immune complex deposition (IgG complexes, days to weeks), and Type IV is Delayed (T-cell mediated, 48 to 72 hours). Types I through III are all antibody-mediated and can be transferred passively with serum, while Type IV requires intact T-cell immunity and cannot be transferred with serum per Harrison's Principles of Internal Medicine.\n\nKEY LEARNING POINTS:\nType IV hypersensitivity is the only antibody-independent, T-cell-mediated reaction, with a characteristic 48 to 72-hour delayed onset. Classic examples include contact dermatitis (poison ivy), the tuberculin skin test, granulomatous disease, and transplant rejection. The ACID mnemonic distinguishes the four types: Allergy (I), Cytotoxic (II), Immune complex (III), Delayed (IV)."
  },
  {
    "id": 372,
    "categoryId": 13,
    "question": "Pernicious Anemia is an autoimmune attack against:",
    "options": [
      "A) Red Blood Cells directly",
      "B) Parietal Cells and/or Intrinsic Factor",
      "C) The Terminal Ileum",
      "D) Bone Marrow stem cells"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Parietal Cells/Intrinsic Factor).\n\nPATHOPHYSIOLOGY:\nPernicious anemia is an autoimmune disease in which antibodies target parietal cells and intrinsic factor. Parietal cells in the gastric fundus produce both hydrochloric acid and intrinsic factor. Intrinsic factor is essential for vitamin B12 absorption in the terminal ileum. Without it, B12 cannot be absorbed regardless of dietary intake.\n\nTWO TYPES OF ANTIBODIES:\nAnti-parietal cell antibodies destroy the cells that produce intrinsic factor. Anti-intrinsic factor antibodies directly block intrinsic factor from binding B12 (type I) or from binding the ileal receptor (type II). The result is B12 malabsorption and deficiency.\n\nCLINICAL CONSEQUENCES:\nB12 deficiency causes megaloblastic anemia (macrocytic RBCs with hypersegmented neutrophils) and neurological damage (subacute combined degeneration of the spinal cord: posterior columns and corticospinal tracts). Neurological damage can be irreversible if treatment is delayed.\n\nDIAGNOSIS AND TREATMENT:\nLow B12, elevated methylmalonic acid, and positive anti-intrinsic factor antibodies (more specific) or anti-parietal cell antibodies (more sensitive) confirm the diagnosis. Treatment is parenteral B12 (IM or high-dose oral), as the absorption defect makes normal oral supplementation ineffective.\n\nKEY LEARNING POINTS:\nPernicious anemia results from autoimmune destruction of parietal cells and intrinsic factor. Without intrinsic factor, B12 cannot be absorbed in the terminal ileum. Parenteral B12 is required; oral absorption is impaired."
  },
  {
    "id": 373,
    "categoryId": 13,
    "question": "Molecular Mimicry is a leading theory for autoimmune triggers. Rheumatic Fever is the classic example, where antibodies against Strep bacteria cross-react with:",
    "options": [
      "A) Kidney tissue",
      "B) Heart Valves (Mitral)",
      "C) Brain tissue",
      "D) Liver tissue"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Group A Streptococcus and Heart Tissue).\n\nMOLECULAR MIMICRY:\nMolecular mimicry occurs when a pathogen's antigen structurally resembles a host tissue antigen. The immune response generated against the pathogen cross-reacts with self-tissue, causing autoimmune damage. Rheumatic fever is the classic example.\n\nRHEUMATIC FEVER MECHANISM:\nThe M protein on Group A Streptococcus (GAS) shares structural similarity with proteins in human cardiac myosin, tropomyosin, and heart valve tissue. Antibodies generated against streptococcal M protein cross-react with heart tissue, causing inflammatory damage to the valves, myocardium, and pericardium.\n\nJONES CRITERIA:\nRheumatic fever is diagnosed clinically using the Jones criteria: evidence of recent GAS infection plus major manifestations (carditis, polyarthritis, chorea, erythema marginatum, subcutaneous nodules) and minor manifestations (fever, arthralgia, elevated inflammatory markers, prolonged PR interval).\n\nPREVENTION:\nPrimary prevention (treating strep pharyngitis) prevents initial episodes. Secondary prevention (long-term penicillin prophylaxis) prevents recurrences in patients with prior rheumatic fever, as each strep infection risks additional cardiac damage.\n\nKEY LEARNING POINTS:\nRheumatic fever results from molecular mimicry between streptococcal M protein and cardiac tissue. Antibodies against GAS cross-react with heart valves, causing chronic rheumatic heart disease. Penicillin prophylaxis prevents recurrent episodes and progressive valve damage."
  },
  {
    "id": 374,
    "categoryId": 13,
    "question": "Goodpasture's Syndrome involves anti-GBM antibodies attacking collagen in which two organs?",
    "options": [
      "A) Liver and Kidney",
      "B) Lungs and Kidney",
      "C) Heart and Lungs",
      "D) Skin and Joints"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Lungs and Kidneys).\n\nPATHOPHYSIOLOGY:\nGoodpasture syndrome (anti-glomerular basement membrane disease) is a rare autoimmune condition in which circulating IgG autoantibodies target the non-collagenous (NC1) domain of the alpha-3 chain of type IV collagen. This specific collagen chain is highly concentrated in two locations: the glomerular basement membrane (GBM) of the kidneys and the alveolar basement membrane of the lungs. When anti-GBM antibodies bind to these basement membranes, they activate complement (via the classical pathway) and recruit neutrophils, causing a destructive Type II hypersensitivity reaction. The result is rapidly progressive (crescentic) glomerulonephritis and diffuse alveolar hemorrhage.\n\nCLINICAL PRESENTATION:\nPatients typically present with the pulmonary-renal syndrome: hemoptysis (from alveolar hemorrhage) and hematuria with rapidly declining renal function (from crescentic glomerulonephritis). Pulmonary hemorrhage tends to be more severe in smokers and patients with concurrent pulmonary infections or fluid overload, because alveolar capillary injury increases exposure of the alveolar basement membrane to circulating antibodies. Renal involvement manifests as nephritic syndrome (hematuria, RBC casts, proteinuria, oliguria, and rapidly rising creatinine). Without treatment, progression to end-stage renal disease occurs within weeks.\n\nDIAGNOSIS AND TREATMENT:\nDiagnosis requires detection of circulating anti-GBM antibodies by ELISA and confirmation by renal biopsy showing linear IgG deposits along the GBM on immunofluorescence (the pathognomonic finding). Treatment is aggressive and must be initiated emergently: plasmapheresis (to rapidly remove circulating anti-GBM antibodies), high-dose corticosteroids, and cyclophosphamide for immunosuppression. Early treatment is critical because renal recovery correlates with the percentage of crescents on biopsy and the serum creatinine at presentation. Patients presenting with dialysis-dependent renal failure rarely recover kidney function.\n\nKEY LEARNING POINTS:\nGoodpasture syndrome targets type IV collagen in the glomerular and alveolar basement membranes, causing the pulmonary-renal syndrome of hemoptysis and rapidly progressive glomerulonephritis. Linear IgG staining on renal biopsy immunofluorescence is pathognomonic. Treatment requires emergent plasmapheresis combined with immunosuppression. Prognosis depends on the severity of renal involvement at presentation."
  },
  {
    "id": 375,
    "categoryId": 3,
    "question": "Which antibody is more commonly associated with Ulcerative Colitis (vs Crohn's)?",
    "options": [
      "A) ASCA (Anti-Saccharomyces cerevisiae)",
      "B) p-ANCA (Perinuclear Anti-Neutrophil Cytoplasmic Antibody)",
      "C) Anti-dsDNA",
      "D) Anti-Centromere"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (p-ANCA â€” perinuclear anti-neutrophil cytoplasmic antibody).\n\nPATHOPHYSIOLOGY:\nSerological markers in inflammatory bowel disease reflect distinct immune response patterns that help differentiate ulcerative colitis from Crohn's disease when clinical, endoscopic, and histologic features are ambiguous (indeterminate colitis, which occurs in approximately 10-15% of IBD cases). p-ANCA (perinuclear anti-neutrophil cytoplasmic antibody) targets nuclear envelope proteins including lactoferrin and nuclear histone, producing a perinuclear fluorescence pattern on indirect immunofluorescence. It is found in approximately 60-70% of ulcerative colitis patients and only 10-15% of Crohn's disease patients.\n\nANTIBODY PATTERNS IN IBD:\nASCA (anti-Saccharomyces cerevisiae antibodies) targets mannan in the cell wall of baker's yeast and is associated with Crohn's disease, found in approximately 50-70% of Crohn's patients and only 10-15% of ulcerative colitis patients. The combination of p-ANCA positive with ASCA negative is strongly suggestive of ulcerative colitis, while ASCA positive with p-ANCA negative favors Crohn's disease. When both markers are concordant, the positive predictive value for the respective diagnosis exceeds 90%. Additional antibodies associated with Crohn's disease include anti-OmpC, anti-CBir1, and anti-I2.\n\nCLINICAL APPLICATION:\nSerological testing is most useful as an adjunct to clinical evaluation when the distinction between ulcerative colitis and Crohn's disease remains uncertain after endoscopy and histology. It is not recommended as a screening test for IBD in the general population. The antibody profile may also carry prognostic significance, as ASCA-positive Crohn's patients tend to have more aggressive disease with stricturing and penetrating complications. These markers do not replace tissue diagnosis and should be interpreted within the full clinical context.\n\nKEY LEARNING POINTS:\np-ANCA is found in 60-70% of ulcerative colitis patients and is the serological marker most associated with UC. ASCA is the corresponding marker for Crohn's disease (50-70% positive). The combination of p-ANCA positive and ASCA negative strongly suggests ulcerative colitis. Serological testing is an adjunct tool for indeterminate colitis, not a screening test."
  },
  {
    "id": 376,
    "categoryId": 13,
    "question": "Central Tolerance occurs in the Thymus. What happens to T-cells that react too strongly to 'Self' antigens?",
    "options": [
      "A) They are released to fight cancer",
      "B) They undergo Apoptosis (Negative Selection)",
      "C) They become B-cells",
      "D) They return to the bone marrow"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (They undergo Apoptosis through Negative Selection).\n\nCENTRAL TOLERANCE IN THE THYMUS:\nCentral tolerance is the process by which the immune system eliminates self-reactive lymphocytes during their development, preventing autoimmunity. For T cells, this occurs in the thymus. Bone marrow-derived T cell precursors migrate to the thymus, where they undergo a rigorous two-stage selection process. In the thymic cortex, double-positive (CD4+CD8+) thymocytes undergo positive selection: those whose T cell receptors (TCRs) can bind self-MHC molecules with moderate affinity survive, while those that fail to bind undergo apoptosis (death by neglect). This ensures all mature T cells are MHC-restricted and can interact with antigen-presenting cells.\n\nNEGATIVE SELECTION:\nIn the thymic medulla, surviving thymocytes encounter medullary thymic epithelial cells (mTECs) that express a remarkable array of tissue-specific antigens under the control of the autoimmune regulator (AIRE) gene. AIRE drives ectopic expression of peripheral tissue proteins (such as insulin, thyroglobulin, and myelin basic protein) in the thymus. Thymocytes whose TCRs bind these self-antigens with high affinity receive apoptotic signals and are deleted (negative selection). This eliminates the most dangerous self-reactive T cells before they enter the peripheral circulation. Mutations in the AIRE gene cause autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), demonstrating the critical importance of this process.\n\nPERIPHERAL TOLERANCE AND AUTOIMMUNITY:\nCentral tolerance is highly effective but not perfect. Some self-reactive T cells escape to the periphery, where peripheral tolerance mechanisms (anergy, regulatory T cells, and activation-induced cell death) serve as backup. Autoimmune diseases arise when both central and peripheral tolerance mechanisms fail, allowing self-reactive T cells (and B cells) to mount immune responses against host tissues. Understanding these tolerance mechanisms has informed therapeutic strategies such as regulatory T cell expansion and tolerance-inducing protocols in transplantation.\n\nKEY LEARNING POINTS:\nCentral tolerance in the thymus eliminates self-reactive T cells through negative selection (apoptosis of thymocytes that bind self-antigens with high affinity). The AIRE gene enables medullary thymic epithelial cells to express tissue-specific antigens for this screening process. AIRE mutations cause APECED, demonstrating the consequence of failed central tolerance. Peripheral tolerance mechanisms (Tregs, anergy) serve as backup when central tolerance is incomplete."
  },
  {
    "id": 377,
    "categoryId": 13,
    "question": "Granulomatosis with Polyangiitis (Wegener's) is a Small Vessel Vasculitis associated with which antibody?",
    "options": [
      "A) ANA",
      "B) c-ANCA (anti-PR3)",
      "C) p-ANCA (anti-MPO)",
      "D) Anti-Smith"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (c-ANCA / anti-PR3).\n\nDISEASE OVERVIEW:\nGranulomatosis with polyangiitis (GPA, formerly Wegener granulomatosis) is an ANCA-associated small-vessel vasculitis characterized by necrotizing granulomatous inflammation of the respiratory tract, necrotizing vasculitis of small to medium vessels, and necrotizing glomerulonephritis. It is strongly associated with cytoplasmic ANCA (c-ANCA) directed against proteinase-3 (PR3), which is positive in approximately 80 to 95 percent of patients with active generalized disease. The pathogenic role of ANCA is supported by evidence that these antibodies activate neutrophils, causing them to adhere to vessel walls, degranulate, and release reactive oxygen species and proteolytic enzymes that damage the endothelium.\n\nCLINICAL MANIFESTATIONS:\nGPA classically affects three organ systems. Upper airway involvement (present in over 90 percent of cases) includes chronic sinusitis refractory to antibiotics, nasal crusting and epistaxis, saddle-nose deformity from nasal cartilage destruction, subglottic stenosis, and serous otitis media. Pulmonary involvement manifests as pulmonary nodules (often cavitating), alveolar hemorrhage with hemoptysis, and infiltrates that can mimic pneumonia or malignancy. Renal involvement presents as rapidly progressive (crescentic) glomerulonephritis with hematuria, proteinuria, RBC casts, and rapidly declining GFR. Other manifestations include scleritis or orbital pseudotumor, peripheral neuropathy (mononeuritis multiplex), and purpura.\n\nDIAGNOSIS AND TREATMENT:\nDiagnosis is supported by positive c-ANCA/anti-PR3 serology but should be confirmed by tissue biopsy whenever possible, demonstrating necrotizing granulomatous vasculitis. Treatment follows a two-phase approach per ACR/EULAR guidelines. Remission induction uses high-dose glucocorticoids combined with either rituximab (now preferred based on the RAVE trial) or cyclophosphamide. Remission maintenance uses rituximab, azathioprine, or methotrexate for at least two years. Plasma exchange may be considered in severe renal disease or pulmonary hemorrhage. Without treatment, generalized GPA has a mortality rate exceeding 80 percent within two years.\n\nKEY LEARNING POINTS:\nGPA is strongly associated with c-ANCA (anti-PR3) and classically involves the upper airway, lungs, and kidneys. ANCA activates neutrophils to damage small vessel walls. Rituximab or cyclophosphamide with glucocorticoids is standard induction therapy. Untreated generalized GPA is rapidly fatal, making early diagnosis and aggressive immunosuppression essential."
  },
  {
    "id": 378,
    "categoryId": 13,
    "question": "Sarcoidosis involves the formation of Non-Caseating Granulomas. This is driven by an overactive:",
    "options": [
      "A) Th1 response",
      "B) Th2 response",
      "C) B-cell response",
      "D) Complement cascade"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Th1 response).\n\nPATHOPHYSIOLOGY OF GRANULOMA FORMATION:\nSarcoidosis is a systemic granulomatous disease of unknown etiology characterized by the formation of non-caseating (non-necrotizing) granulomas in affected organs. The pathogenesis centers on an exaggerated Th1-mediated immune response to an as-yet-unidentified antigen (proposed triggers include mycobacterial antigens, Propionibacterium acnes, and environmental inorganic particles). Antigen-presenting cells activate CD4+ Th1 cells, which release interferon-gamma (IFN-gamma) and IL-2. IFN-gamma is the critical cytokine that activates macrophages, causing them to aggregate and differentiate into epithelioid cells and multinucleated giant cells, forming the characteristic non-caseating granulomas. TNF-alpha, produced by activated macrophages, further amplifies granuloma formation and maintenance.\n\nHYPERCALCEMIA MECHANISM:\nA clinically important consequence of granulomatous inflammation in sarcoidosis is hypercalcemia, which occurs in approximately 10 to 13 percent of patients. Activated macrophages within granulomas express 1-alpha-hydroxylase, the enzyme that converts 25-hydroxyvitamin D to its active form, 1,25-dihydroxyvitamin D (calcitriol). This extra-renal calcitriol production is not subject to normal PTH-mediated feedback regulation, leading to increased intestinal calcium absorption and, in severe cases, hypercalciuria, nephrolithiasis, nephrocalcinosis, and renal insufficiency.\n\nCLINICAL FEATURES AND DIAGNOSIS:\nSarcoidosis most commonly presents in young adults (ages 20 to 40) with bilateral hilar lymphadenopathy (present in approximately 90 percent), pulmonary infiltrates, and skin lesions (erythema nodosum, lupus pernio). Other manifestations include anterior uveitis, hepatic granulomas, cardiac conduction abnormalities, cranial nerve palsies (especially facial nerve palsy), and parotid gland enlargement. Lofgren syndrome (bilateral hilar lymphadenopathy, erythema nodosum, fever, and polyarthralgia) carries an excellent prognosis with greater than 90 percent spontaneous resolution. Diagnosis requires compatible clinical and radiographic findings, histologic demonstration of non-caseating granulomas, and exclusion of other granulomatous diseases (tuberculosis, fungal infection). Elevated ACE levels support the diagnosis but are neither sensitive nor specific.\n\nKEY LEARNING POINTS:\nSarcoidosis is driven by an overactive Th1 response producing IFN-gamma, which activates macrophages to form non-caseating granulomas. Granulomatous macrophages produce unregulated 1-alpha-hydroxylase, converting vitamin D to calcitriol and causing hypercalcemia. Bilateral hilar lymphadenopathy is the most common radiographic finding. Lofgren syndrome carries an excellent prognosis with high rates of spontaneous resolution."
  },
  {
    "id": 379,
    "categoryId": 6,
    "question": "Guillain-Barre Syndrome is an acute demyelinating polyneuropathy often triggered by Campylobacter infection. The paralysis is:",
    "options": [
      "A) Descending (Head to Toe)",
      "B) Ascending (Toe to Head)",
      "C) Unilateral",
      "D) Sensory only"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Ascending paralysis - Toe to Head).\n\nGUILLAIN-BARRÃ‰ SYNDROME:\nGuillain-BarrÃ© syndrome (GBS) is an acute, immune-mediated demyelinating polyneuropathy that classically produces rapidly progressive, ascending, symmetric weakness beginning in the distal lower extremities and moving proximally. It is the most common cause of acute flaccid paralysis worldwide and is frequently preceded (within 1 to 4 weeks) by a gastrointestinal or respiratory infection, with Campylobacter jejuni being the most commonly identified trigger.\n\nPATHOPHYSIOLOGY:\nGBS results from molecular mimicry in which antibodies generated against microbial surface antigens cross-react with gangliosides and glycolipids on peripheral nerve myelin and axons. In the most common subtype, acute inflammatory demyelinating polyradiculoneuropathy (AIDP), immune-mediated demyelination of peripheral nerves impairs saltatory conduction, producing weakness and sensory changes. Axonal variants (AMAN, AMSAN) involve direct antibody-mediated axonal injury and tend to have a more severe course.\n\nCLINICAL MANIFESTATIONS:\nWeakness begins in the feet and legs and ascends over hours to days, potentially reaching the trunk, arms, facial muscles, and most critically the respiratory muscles (diaphragm and intercostals). Areflexia (absent deep tendon reflexes) is an early and characteristic finding due to the peripheral nerve involvement. Autonomic dysfunction (blood pressure lability, cardiac arrhythmias, urinary retention) occurs in up to two-thirds of patients. Neuropathic pain, particularly back and limb pain, is common and often precedes weakness.\n\nDIAGNOSIS AND TREATMENT:\nCSF analysis classically shows albuminocytologic dissociation (elevated protein with normal white blood cell count), though this may be absent in the first week. Nerve conduction studies confirm demyelination. Treatment consists of intravenous immunoglobulin (IVIG) or plasmapheresis; corticosteroids are not effective. Respiratory monitoring is critical because diaphragmatic involvement can cause fatal respiratory failure.\n\nKEY LEARNING POINTS:\nGBS causes ascending paralysis starting in the feet and progressing toward the head, with the greatest danger being respiratory failure from diaphragmatic involvement. Areflexia is an early hallmark finding, and CSF shows elevated protein with normal cell count. IVIG or plasmapheresis is the treatment; corticosteroids are ineffective in GBS."
  },
  {
    "id": 380,
    "categoryId": 13,
    "question": "Selective IgA Deficiency is the most common primary immunodeficiency. Patients are often asymptomatic but are at risk for:",
    "options": [
      "A) Fungal infections",
      "B) Anaphylaxis if given blood products containing IgA",
      "C) Cancer",
      "D) HIV"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Anaphylaxis if given blood products containing IgA).\n\nPATHOPHYSIOLOGY:\nSelective IgA deficiency is defined as a serum IgA level below 7 mg/dL (or undetectable) with normal IgG and IgM levels in a patient older than 4 years who has been evaluated and found to have no other cause of immunodeficiency. It is the most common primary immunodeficiency, with a prevalence of approximately 1 in 300 to 1 in 700 in populations of European descent. The exact etiology is unknown but involves impaired terminal differentiation of B cells into IgA-secreting plasma cells, with genetic susceptibility linked to the MHC region on chromosome 6. The majority of affected individuals (85 to 90 percent) are asymptomatic because compensatory secretory IgM partially substitutes for the mucosal protective role of IgA.\n\nTRANSFUSION ANAPHYLAXIS:\nThe most clinically dangerous complication is anaphylaxis following transfusion of blood products containing IgA. In a subset of IgA-deficient patients, the immune system produces anti-IgA antibodies (typically IgE class) because it has never been tolerized to IgA. When these patients receive blood products containing even trace amounts of donor IgA, the anti-IgA IgE antibodies trigger mast cell degranulation and systemic anaphylaxis. This reaction can be fatal. For this reason, IgA-deficient patients who require transfusion should receive washed red blood cells (to remove residual plasma IgA) or blood products from IgA-deficient donors.\n\nMUCOSAL INFECTIONS AND AUTOIMMUNE ASSOCIATIONS:\nSymptomatic patients may experience recurrent sinopulmonary infections (sinusitis, pneumonia, otitis media) and gastrointestinal infections, particularly Giardia lamblia, because secretory IgA normally provides first-line mucosal immunity. IgA deficiency is associated with increased prevalence of autoimmune diseases including celiac disease (10 to 15 times higher prevalence), type 1 diabetes, rheumatoid arthritis, and systemic lupus erythematosus. Importantly, IgA deficiency causes false-negative IgA-based serologic tests (such as tTG-IgA for celiac disease), so IgG-based assays must be used instead.\n\nKEY LEARNING POINTS:\nSelective IgA deficiency is the most common primary immunodeficiency, and most patients are asymptomatic. The major clinical risk is anaphylaxis from anti-IgA antibodies during blood transfusion; washed RBCs or IgA-deficient donor products should be used. Symptomatic patients may have recurrent sinopulmonary and Giardia infections. IgA deficiency is strongly associated with celiac disease and renders IgA-based serologic tests unreliable."
  },
  {
    "id": 381,
    "categoryId": 13,
    "question": "Vitiligo is the autoimmune destruction of:",
    "options": [
      "A) Keratinocytes",
      "B) Melanocytes",
      "C) Hair follicles",
      "D) Sweat glands"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Melanocytes).\n\nPATHOPHYSIOLOGY:\nVitiligo is an acquired autoimmune disorder in which CD8+ cytotoxic T cells selectively destroy melanocytes, the pigment-producing cells of the epidermis. The pathogenesis involves a combination of genetic susceptibility (polymorphisms in immune-regulatory genes including NLRP1, CTLA-4, and HLA alleles), environmental triggers (mechanical trauma, sunburn, chemical exposure), and intrinsic melanocyte stress (oxidative stress from reactive oxygen species accumulation). Stressed melanocytes release damage-associated molecular patterns (DAMPs) and heat shock proteins that activate innate immunity and dendritic cells, which in turn prime autoreactive CD8+ T cells to mount a targeted attack against melanocyte-specific antigens (tyrosinase, MART-1, gp100). This results in progressive, well-demarcated, depigmented (chalk-white) macules and patches.\n\nCLINICAL FEATURES:\nVitiligo affects approximately 0.5 to 2 percent of the world population, with onset most commonly before age 30. Lesions are typically symmetric and favor periorificial areas (around the eyes, mouth, nostrils), dorsal hands and feet, elbows, knees, and genitalia. The Koebner phenomenon (new lesions appearing at sites of mechanical trauma) is common. Wood lamp examination enhances the contrast of depigmented lesions, aiding diagnosis in fair-skinned patients. Vitiligo is strongly associated with other autoimmune conditions, including autoimmune thyroid disease (Hashimoto thyroiditis, Graves disease), type 1 diabetes, pernicious anemia, Addison disease, and alopecia areata. Screening for thyroid dysfunction with TSH is recommended.\n\nTREATMENT:\nManagement is individualized based on extent and location. For limited disease (less than 20 percent body surface area), topical corticosteroids (for the body) and topical calcineurin inhibitors such as tacrolimus (preferred for the face and intertriginous areas) are first-line. For more extensive or refractory disease, narrowband UVB phototherapy is the most effective and well-studied treatment, achieving repigmentation in 40 to 70 percent of patients. The JAK inhibitor ruxolitinib cream (Opzelura) was approved by the FDA in 2022 for nonsegmental vitiligo, representing the first targeted therapy for this condition. Sun protection and psychosocial support are important components of comprehensive management.\n\nKEY LEARNING POINTS:\nVitiligo results from autoimmune CD8+ T cell-mediated destruction of melanocytes, producing depigmented macules and patches. Koebner phenomenon and symmetric distribution are characteristic clinical features. Associated autoimmune conditions (especially thyroid disease) should be screened for. Treatment options include topical corticosteroids, calcineurin inhibitors, narrowband UVB phototherapy, and the JAK inhibitor ruxolitinib cream."
  },
  {
    "id": 382,
    "categoryId": 13,
    "question": "Antiphospholipid Syndrome (APS) causes a paradox in the lab: The patient is prone to clotting (Thrombosis), but which lab value is prolonged?",
    "options": [
      "A) PT",
      "B) PTT",
      "C) Bleeding Time",
      "D) Platelet Count"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (PTT / Activated Partial Thromboplastin Time).\n\nTHE LUPUS ANTICOAGULANT PARADOX:\nAntiphospholipid syndrome (APS) presents one of medicine\"s most important paradoxes: patients have a prolonged PTT in the laboratory (suggesting a bleeding tendency) but clinically suffer from thrombosis. This occurs because antiphospholipid antibodies, specifically the lupus anticoagulant, interfere with the phospholipid-dependent coagulation reactions used in the PTT assay. In the test tube, the lupus anticoagulant binds to the phospholipid reagent, preventing assembly of the prothrombinase complex and prolonging clotting time. However, in vivo, these same antibodies are prothrombotic: they activate endothelial cells, platelets, and monocytes, upregulate tissue factor expression, inhibit natural anticoagulants (protein C, antithrombin), and interfere with the annexin A5 anticoagulant shield on trophoblast and endothelial surfaces.\n\nCLINICAL MANIFESTATIONS:\nAPS causes both arterial and venous thrombosis. Venous events include deep vein thrombosis and pulmonary embolism, while arterial events include stroke (especially in young patients) and myocardial infarction. Obstetric complications are a hallmark: recurrent early pregnancy loss (before 10 weeks), late pregnancy loss (after 10 weeks), preeclampsia, placental insufficiency, and intrauterine growth restriction. Catastrophic APS (CAPS) is a rare, life-threatening variant with simultaneous multi-organ thrombosis affecting three or more organs within one week, carrying mortality rates of approximately 50 percent.\n\nDIAGNOSIS AND TREATMENT:\nThe revised Sapporo (Sydney) criteria require at least one clinical criterion (vascular thrombosis or pregnancy morbidity) and one laboratory criterion (lupus anticoagulant, anticardiolipin antibodies at medium or high titer, or anti-beta-2 glycoprotein I antibodies) confirmed on two occasions at least 12 weeks apart. A mixing study that fails to correct the prolonged PTT confirms the presence of an inhibitor rather than a factor deficiency. Treatment of thrombotic APS requires long-term anticoagulation with warfarin (target INR 2.0 to 3.0); direct oral anticoagulants are not recommended based on the TRAPS trial showing inferior outcomes. Obstetric APS is managed with low-dose aspirin plus prophylactic heparin during pregnancy.\n\nKEY LEARNING POINTS:\nThe lupus anticoagulant prolongs PTT in vitro by interfering with phospholipid-dependent coagulation assays, but causes thrombosis in vivo. APS causes both arterial and venous thrombosis and recurrent pregnancy loss. Diagnosis requires persistent positivity of antiphospholipid antibodies confirmed 12 weeks apart. Warfarin is the standard anticoagulant for thrombotic APS; direct oral anticoagulants are not recommended."
  },
  {
    "id": 383,
    "categoryId": 13,
    "question": "Eosinophils are specialized granulocytes designed to attack:",
    "options": [
      "A) Viruses",
      "B) Multicellular Parasites (Helminths)",
      "C) Bacteria",
      "D) Fungi"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Multicellular Parasites / Helminths).\n\nEOSINOPHIL BIOLOGY:\nEosinophils are terminally differentiated granulocytes that develop in the bone marrow under the influence of IL-5 (the most critical cytokine for eosinophil differentiation, activation, and survival), IL-3, and GM-CSF. They constitute 1 to 3 percent of circulating leukocytes and are predominantly tissue-resident cells, concentrated in the gastrointestinal mucosa, skin, and respiratory tract. Eosinophils are distinguished by their bilobed nucleus and large cytoplasmic granules that stain intensely with eosin (acidic dye), which contain four major cationic proteins: major basic protein (MBP), eosinophil cationic protein (ECP), eosinophil peroxidase (EPO), and eosinophil-derived neurotoxin (EDN).\n\nANTI-PARASITIC FUNCTION:\nEosinophils evolved primarily as effector cells against multicellular parasites (helminths) that are too large to be phagocytosed by neutrophils or macrophages. The anti-helminth response is orchestrated by Th2 cytokines: IL-4 drives IgE class switching in B cells, and IgE coats the parasite surface (opsonization). Eosinophils bind to IgE-coated parasites via their low-affinity IgE receptor (FcepsilonRII/CD23) and high-affinity IgE receptor, then degranulate in a process called antibody-dependent cellular cytotoxicity (ADCC). The released cationic granule proteins, particularly MBP, are directly toxic to the parasite tegument, creating pores and disrupting membrane integrity. This extracellular killing mechanism is essential because the parasites cannot be internalized.\n\nROLE IN ALLERGIC DISEASE:\nThe same eosinophil-mediated effector mechanisms that evolved to combat parasites are pathologically activated in allergic diseases. In asthma, eosinophils infiltrate the bronchial mucosa and release granule proteins and leukotrienes that cause epithelial damage, mucus hypersecretion, bronchospasm, and airway remodeling. Peripheral eosinophilia (greater than 500 cells per microliter) is seen in parasitic infections, allergic conditions, drug reactions, adrenal insufficiency, and certain malignancies (the mnemonic NAACP: Neoplasm, Allergy, Addison disease, Collagen vascular disease, Parasites). Anti-IL-5 monoclonal antibodies (mepolizumab, reslizumab) and anti-IL-5 receptor antibodies (benralizumab) are now used for severe eosinophilic asthma.\n\nKEY LEARNING POINTS:\nEosinophils are specialized effector cells that kill helminths via antibody-dependent cellular cytotoxicity, releasing toxic granule proteins (MBP, ECP) onto parasite surfaces. IL-5 is the key cytokine for eosinophil development, activation, and survival. The same Th2/IgE/eosinophil pathway that combats parasites drives pathologic inflammation in allergic diseases. Anti-IL-5 therapies (mepolizumab, benralizumab) are used for severe eosinophilic asthma."
  },
  {
    "id": 384,
    "categoryId": 6,
    "question": "A patient presents with a 'blown' (dilated and non-reactive) right pupil and left-sided hemiparesis. This indicates herniation of the temporal lobe compressing which Cranial Nerve?",
    "options": [
      "A) CN II (Optic)",
      "B) CN III (Oculomotor)",
      "C) CN VI (Abducens)",
      "D) CN VII (Facial)"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (CN III - Oculomotor Nerve).\n\nUNCAL HERNIATION SYNDROME:\nA dilated, non-reactive (\"blown\") pupil with contralateral hemiparesis is the classic presentation of uncal herniation, one of the most dangerous neurosurgical emergencies. The uncus, located on the medial aspect of the temporal lobe, herniates over the tentorium cerebelli due to rising supratentorial pressure, compressing the ipsilateral CN III and cerebral peduncle.\n\nPATHOPHYSIOLOGY:\nCN III carries parasympathetic fibers that constrict the pupil (via the ciliary ganglion and sphincter pupillae muscle). These parasympathetic fibers travel on the outer surface of the nerve, making them the first fibers compressed during uncal herniation. Loss of parasympathetic input results in unopposed sympathetic tone, causing ipsilateral pupillary dilation and loss of the light reflex. As herniation progresses, the ipsilateral cerebral peduncle is compressed against the tentorial edge, producing contralateral hemiparesis (motor fibers cross in the medullary pyramids). Continued herniation compresses the brainstem, causing progressive obtundation, posturing, and ultimately death.\n\nCLINICAL RECOGNITION:\nThe progression follows a predictable sequence: ipsilateral pupil dilation (earliest sign), then ptosis and oculomotor palsy (\"down and out\" eye), followed by contralateral hemiparesis, then bilateral posturing and loss of consciousness. Cushing's triad (hypertension, bradycardia, irregular respirations) is a late ominous sign of brainstem compression. Occasionally, the contralateral cerebral peduncle is compressed against the opposite tentorial edge (Kernohan notch phenomenon), causing ipsilateral hemiparesis (a false localizing sign).\n\nDIAGNOSIS AND TREATMENT:\nEmergent non-contrast CT identifies the mass lesion and herniation. Immediate temporizing measures include head-of-bed elevation to 30 degrees, hyperventilation to a target pCO2 of 30 to 35 mmHg, and hyperosmolar therapy (mannitol or hypertonic saline). Definitive treatment requires emergent neurosurgical intervention to address the underlying cause (evacuation of hematoma, tumor resection, decompressive craniectomy).\n\nKEY LEARNING POINTS:\nUncal herniation compresses CN III (parasympathetic fibers on the outer surface), causing ipsilateral pupil dilation as the earliest sign. The cerebral peduncle is subsequently compressed, producing contralateral hemiparesis. This is a neurosurgical emergency requiring immediate intracranial pressure reduction and surgical intervention."
  },
  {
    "id": 385,
    "categoryId": 6,
    "question": "The Middle Cerebral Artery (MCA) supplies the lateral surface of the brain. An MCA stroke typically presents with:",
    "options": [
      "A) Leg weakness > Arm/Face weakness",
      "B) Arm/Face weakness > Leg weakness, and Aphasia (if dominant hemisphere)",
      "C) Visual hallucinations and Vertigo",
      "D) Pure sensory loss"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Arm/Face weakness greater than Leg weakness, and Aphasia if dominant hemisphere).\n\nMIDDLE CEREBRAL ARTERY STROKE:\nThe middle cerebral artery (MCA) is the largest branch of the internal carotid artery and supplies the lateral surface of the cerebral hemisphere, including the motor and sensory cortex for the face and upper extremity, Broca's area (speech production), Wernicke's area (speech comprehension), and the parietal association cortex. MCA stroke is the most common ischemic stroke syndrome, and its clinical presentation reflects the cortical territory it supplies.\n\nPATHOPHYSIOLOGY:\nThe motor and sensory homunculus maps body regions along the cortical surface, with the face and arm represented on the lateral convexity (MCA territory) and the leg represented on the medial surface (anterior cerebral artery territory). This somatotopic organization explains why MCA strokes produce arm and face weakness that is disproportionately greater than leg weakness. When the dominant hemisphere (typically left) is affected, aphasia results because the language centers reside in MCA territory.\n\nCLINICAL MANIFESTATIONS:\nMCA stroke presents with contralateral face and arm weakness (greater than leg), contralateral hemisensory loss, homonymous hemianopia (from optic radiation involvement), and gaze deviation toward the side of the lesion. Dominant hemisphere strokes produce Broca's aphasia (non-fluent, telegraphic speech with preserved comprehension), Wernicke's aphasia (fluent but nonsensical speech with impaired comprehension), or global aphasia. Non-dominant hemisphere strokes cause hemispatial neglect (unawareness of the contralateral side).\n\nACUTE MANAGEMENT:\nStroke management follows the \"time is brain\" paradigm. IV alteplase (0.9 mg/kg, maximum 90 mg) is indicated within 4.5 hours of symptom onset after CT excludes hemorrhage. Mechanical thrombectomy for large vessel occlusion (proximal MCA, internal carotid) can extend the treatment window to 24 hours based on perfusion imaging (per the DAWN and DEFUSE-3 trials). Aspirin is initiated after 24 hours if thrombolytics were given, or immediately if the patient is not a thrombolytic candidate.\n\nKEY LEARNING POINTS:\nMCA stroke causes arm and face weakness greater than leg weakness because of the somatotopic organization of the motor cortex. Dominant hemisphere MCA strokes produce aphasia; non-dominant strokes cause hemispatial neglect. Mechanical thrombectomy can extend treatment to 24 hours for large vessel occlusion with favorable perfusion imaging."
  },
  {
    "id": 386,
    "categoryId": 6,
    "question": "Normal Pressure Hydrocephalus (NPH) presents with the classic triad of:",
    "options": [
      "A) Tremor, Rigidity, Bradykinesia",
      "B) Urinary Incontinence, Gait Disturbance ('Magnetic Gait'), Dementia",
      "C) Headache, Vomiting, Papilledema",
      "D) Visual loss, Eye pain, Weakness"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Gait disturbance, Urinary incontinence, Dementia - \"Wet, Wobbly, and Wacky\").\n\nNORMAL PRESSURE HYDROCEPHALUS:\nNPH is characterized by the classic triad: gait apraxia (magnetic/shuffling gait), urinary incontinence, and dementia. The mnemonic \"wet (incontinence), wobbly (gait), and wacky (cognitive decline)\" captures the presentation. Gait disturbance is typically the earliest and most prominent feature.\n\nPATHOPHYSIOLOGY:\nNPH involves enlarged ventricles without elevated opening pressure on lumbar puncture (hence \"normal pressure\"). The mechanism likely involves impaired CSF absorption at the arachnoid granulations. Ventricular enlargement compresses periventricular white matter, particularly affecting frontal subcortical circuits controlling gait and bladder function.\n\nDIAGNOSIS:\nMRI shows ventriculomegaly out of proportion to cortical atrophy. The tap test (large-volume lumbar puncture removing 30-50cc CSF) temporarily improves symptoms in responsive patients. Gait improvement after tap test predicts response to shunting.\n\nTREATMENT:\nVentriculoperitoneal shunting can improve symptoms, particularly gait, in properly selected patients. Gait responds best, followed by incontinence; dementia responds least consistently. Early diagnosis and treatment produce better outcomes.\n\nKEY LEARNING POINTS:\nNPH presents with the triad of gait disturbance, urinary incontinence, and dementia (\"wet, wobbly, wacky\"). Gait disturbance is earliest and most responsive to treatment. Large-volume lumbar puncture can predict shunt response."
  },
  {
    "id": 387,
    "categoryId": 6,
    "question": "An Epidural Hematoma is classically caused by rupture of the Middle Meningeal Artery. The CT scan appearance is:",
    "options": [
      "A) Crescent shape crossing suture lines",
      "B) Biconvex (Lens) shape NOT crossing suture lines",
      "C) Star shape in the center of the brain",
      "D) Diffuse white spots"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Biconvex/Lens shape NOT crossing suture lines).\n\nEPIDURAL HEMATOMA:\nAn epidural hematoma is a collection of blood between the inner table of the skull and the dura mater, classically caused by traumatic rupture of the middle meningeal artery following a temporal bone fracture. It produces a characteristic biconvex (lens-shaped) hyperdensity on CT scan that does not cross suture lines because the dura is tightly adherent to the periosteum at these junctures.\n\nPATHOPHYSIOLOGY:\nThe middle meningeal artery courses through a groove in the temporal bone and is vulnerable to laceration with temporal bone fractures. Because the bleeding source is arterial (high pressure), blood rapidly dissects the dura away from the calvarium, but expansion is limited by the firm dural attachments at suture lines, creating the characteristic biconvex shape. The classic clinical presentation is a \"lucid interval\" in which the patient initially appears well after head trauma, then deteriorates rapidly over hours as the hematoma expands and causes uncal herniation with ipsilateral pupil dilation and contralateral hemiparesis.\n\nDISTINCTION FROM SUBDURAL HEMATOMA:\nSubdural hematoma results from rupture of bridging veins between the cortical surface and the dural venous sinuses. Because the blood collects between the dura and arachnoid (not bound by suture lines), it forms a crescent-shaped collection that freely crosses suture lines. Subdural hematomas are common in elderly patients and those on anticoagulation due to cerebral atrophy placing greater stretch on bridging veins.\n\nDIAGNOSIS AND TREATMENT:\nNon-contrast CT is the imaging modality of choice. A biconvex hyperdensity in the temporal region is pathognomonic. Epidural hematomas are neurosurgical emergencies requiring emergent craniotomy for evacuation, particularly when there are signs of mass effect or neurological deterioration. Prognosis is generally excellent with timely surgical intervention because the underlying brain parenchyma is often uninjured.\n\nKEY LEARNING POINTS:\nEpidural hematoma appears as a biconvex (lens-shaped) hyperdensity on CT that does not cross suture lines, caused by middle meningeal artery rupture. Subdural hematoma is crescent-shaped and crosses suture lines, caused by bridging vein rupture. The lucid interval followed by rapid deterioration is the classic clinical warning of an expanding epidural hematoma."
  },
  {
    "id": 388,
    "categoryId": 6,
    "question": "Carpal Tunnel Syndrome involves compression of the Median Nerve. Which physical exam finding indicates severe/advanced disease?",
    "options": [
      "A) Positive Tinel's sign",
      "B) Positive Phalen's sign",
      "C) Thenar Atrophy (Muscle wasting at base of thumb)",
      "D) Pain at night"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Thenar Atrophy - Muscle wasting at the base of the thumb).\n\nCARPAL TUNNEL SYNDROME SEVERITY:\nCarpal tunnel syndrome (CTS) is the most common entrapment neuropathy, caused by compression of the median nerve as it passes through the carpal tunnel at the wrist. While early disease presents with sensory symptoms (numbness, tingling, pain), thenar atrophy represents advanced motor involvement indicating significant and potentially irreversible nerve damage that typically warrants surgical intervention.\n\nPATHOPHYSIOLOGY:\nThe median nerve carries both sensory and motor fibers through the carpal tunnel. Sensory fibers have a lower threshold for compression injury, so they are affected first, producing numbness and paresthesias in the thumb, index, middle, and radial half of the ring finger. With prolonged or severe compression, motor fibers to the thenar muscles (abductor pollicis brevis, opponens pollicis, superficial head of flexor pollicis brevis) become compromised. Progressive denervation leads to thenar muscle atrophy, manifesting as visible wasting at the base of the thumb and weakness of thumb opposition and abduction.\n\nCLINICAL PROGRESSION AND DIAGNOSIS:\nEarly CTS presents with nocturnal paresthesias (patients shake their hands to relieve symptoms, known as the \"flick sign\"), positive Tinel sign (tapping the carpal tunnel reproduces symptoms), and positive Phalen sign (wrist flexion for 60 seconds reproduces symptoms). As disease progresses, constant numbness develops, followed by weakness and ultimately thenar atrophy. Nerve conduction studies and electromyography (EMG) are the gold standard for confirming diagnosis and grading severity, showing prolonged distal sensory and motor latencies across the wrist.\n\nTREATMENT:\nMild to moderate CTS is managed conservatively with nocturnal wrist splinting in neutral position, activity modification, and corticosteroid injection into the carpal tunnel. Surgical carpal tunnel release (open or endoscopic) is indicated for persistent symptoms despite conservative therapy, progressive motor weakness, or thenar atrophy. Once atrophy has developed, surgical outcomes are less predictable because axonal degeneration may be irreversible.\n\nKEY LEARNING POINTS:\nThenar atrophy represents advanced carpal tunnel syndrome with motor fiber damage that may be irreversible. Sensory symptoms (numbness, tingling) precede motor involvement because sensory fibers have a lower threshold for compression injury. Surgical release is indicated for thenar atrophy, progressive weakness, or failure of conservative management."
  },
  {
    "id": 389,
    "categoryId": 6,
    "question": "The two pathologic hallmarks of Alzheimer's Disease found on autopsy are:",
    "options": [
      "A) Lewy Bodies and Alpha-synuclein",
      "B) Amyloid Plaques (Extracellular) and Neurofibrillary Tangles (Intracellular Tau)",
      "C) Prion proteins and Spongiform change",
      "D) Negri bodies and Gliosis"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Amyloid Plaques and Neurofibrillary Tangles).\n\nALZHEIMER'S DISEASE NEUROPATHOLOGY:\nAlzheimer's disease (AD) is defined pathologically by two hallmark lesions: extracellular amyloid plaques composed of aggregated amyloid-beta (AÎ²) peptide, and intracellular neurofibrillary tangles (NFTs) composed of hyperphosphorylated tau protein. These pathological features, originally described by Alois Alzheimer in 1906, remain the definitive diagnostic criteria on neuropathological examination and form the basis of current therapeutic research.\n\nPATHOPHYSIOLOGY:\nThe amyloid cascade hypothesis proposes that abnormal processing of amyloid precursor protein (APP) by beta-secretase and gamma-secretase generates AÎ²42 peptides that aggregate into oligomers and eventually form insoluble extracellular plaques. These oligomeric species are neurotoxic, disrupting synaptic function, promoting inflammation, and triggering oxidative stress. Tau protein normally stabilizes microtubules in axons, maintaining the structural integrity of the neuronal cytoskeleton. In AD, tau becomes hyperphosphorylated, detaches from microtubules, and aggregates into paired helical filaments that form intracellular NFTs. The collapse of the microtubule transport system impairs axonal transport and ultimately causes neuronal death.\n\nCLINICAL CORRELATION:\nThe distribution of NFTs follows the Braak staging system, beginning in the entorhinal cortex and hippocampus (explaining early memory loss) and spreading to the neocortex (causing progressive language, visuospatial, and executive dysfunction). Amyloid plaques are more diffusely distributed and correlate less precisely with clinical symptoms than NFTs. Cholinergic neurons in the nucleus basalis of Meynert are particularly vulnerable, providing the rationale for cholinesterase inhibitor therapy.\n\nDIAGNOSIS AND TREATMENT:\nClinical diagnosis uses the NIA-AA criteria combining cognitive assessment, biomarkers (CSF AÎ²42/tau ratios, amyloid PET imaging), and exclusion of other causes. Current treatments include cholinesterase inhibitors (donepezil, rivastigmine, galantamine) for mild to moderate disease and memantine (NMDA receptor antagonist) for moderate to severe disease. Anti-amyloid monoclonal antibodies (lecanemab, donanemab) represent newer disease-modifying approaches targeting amyloid pathology.\n\nKEY LEARNING POINTS:\nAlzheimer's is defined by extracellular amyloid plaques (AÎ² aggregates) and intracellular neurofibrillary tangles (hyperphosphorylated tau). Tau pathology follows the Braak staging pattern from the entorhinal cortex outward, correlating with clinical symptom progression. Anti-amyloid monoclonal antibodies represent the first disease-modifying therapies targeting the underlying pathology."
  },
  {
    "id": 390,
    "categoryId": 6,
    "question": "Trigeminal Neuralgia (Tic Douloureux) affects which nerve branches and causes what type of pain?",
    "options": [
      "A) CN VII; Dull aching pain",
      "B) CN V2/V3; Sudden, electric-shock, lancinating pain",
      "C) CN X; Burning throat pain",
      "D) CN V1; Throbbing forehead pain"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (V2 and V3 branches; Sharp, lancinating, electric shock-like pain).\n\nTRIGEMINAL NEURALGIA:\nTrigeminal neuralgia (tic douloureux) causes paroxysmal, severe, unilateral facial pain in the distribution of one or more branches of the trigeminal nerve (CN V). The pain is classically described as electric shock-like, stabbing, or lancinating, lasting seconds to minutes.\n\nANATOMICAL DISTRIBUTION:\nThe trigeminal nerve has three branches: V1 (ophthalmic), V2 (maxillary), and V3 (mandibular). V2 and V3 are most commonly affected, causing pain in the cheek, upper lip, lower lip, chin, and jaw. Pure V1 involvement is uncommon and should prompt evaluation for other etiologies.\n\nTRIGGER FACTORS:\nPain is typically triggered by innocuous stimuli to \"trigger zones\" on the face: light touch, chewing, talking, brushing teeth, cold air, or shaving. Patients may avoid eating or washing their face. Between attacks, they are pain-free.\n\nETIOLOGY AND TREATMENT:\nMost cases are caused by vascular compression of the trigeminal root entry zone, typically by the superior cerebellar artery. MRI should exclude secondary causes (MS, tumor). First-line treatment is carbamazepine or oxcarbazepine. Surgical options (microvascular decompression) are available for refractory cases.\n\nKEY LEARNING POINTS:\nTrigeminal neuralgia causes brief, severe, electric shock-like pain in V2/V3 distribution. Pain is triggered by light touch, eating, or talking. First-line treatment is carbamazepine; MRI excludes secondary causes."
  },
  {
    "id": 391,
    "categoryId": 6,
    "question": "Which of the following is an Upper Motor Neuron (UMN) sign?",
    "options": [
      "A) Fasciculations (Muscle twitching)",
      "B) Hyporeflexia",
      "C) Spasticity and Hyperreflexia (+ Babinski)",
      "D) Muscle Atrophy"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Spasticity and Hyperreflexia with positive Babinski sign).\n\nUPPER MOTOR NEURON SIGNS:\nUpper motor neuron (UMN) lesions affect the descending motor pathways originating in the cerebral cortex and brainstem that normally exert inhibitory control over spinal reflex arcs. When this inhibitory input is lost, the result is a constellation of \"release\" phenomena in which spinal reflexes become exaggerated. The cardinal UMN signs are spasticity (velocity-dependent increase in muscle tone), hyperreflexia (exaggerated deep tendon reflexes), clonus (rhythmic involuntary contractions), and the Babinski sign (extensor plantar response with great toe dorsiflexion).\n\nPATHOPHYSIOLOGY:\nThe corticospinal tract provides tonic inhibition to spinal motor neuron pools and spinal interneurons. When this tract is damaged (by stroke, spinal cord injury, MS, or brain tumor), the loss of descending inhibition allows unchecked excitatory input from spinal reflex pathways. This explains why \"everything goes up\" in UMN lesions: increased tone (spasticity), increased reflexes (hyperreflexia), and upgoing toes (Babinski). The Babinski sign specifically reflects loss of corticospinal tract inhibition over the flexor withdrawal reflex in the lower extremity.\n\nLOWER MOTOR NEURON COMPARISON:\nLower motor neuron (LMN) lesions damage the final common pathway (anterior horn cell, peripheral nerve, or nerve root) that directly innervates muscle. Without innervation, \"everything goes down\": decreased tone (flaccidity), absent reflexes (areflexia), muscle atrophy from denervation, and fasciculations (spontaneous motor unit discharges visible as muscle twitching). The plantar response is absent or flexor (normal).\n\nCLINICAL APPLICATION:\nDistinguishing UMN from LMN patterns is fundamental to neurological localization. UMN signs localize the lesion to the brain or spinal cord, while LMN signs localize to the anterior horn cell, nerve root, plexus, or peripheral nerve. Some diseases, such as ALS, produce both UMN and LMN findings simultaneously, which is a critical diagnostic clue.\n\nKEY LEARNING POINTS:\nUMN lesions cause spasticity, hyperreflexia, clonus, and Babinski sign due to loss of descending cortical inhibition over spinal reflexes. LMN lesions cause flaccidity, areflexia, atrophy, and fasciculations due to loss of the nerve signal to muscle. Distinguishing UMN from LMN patterns is essential for localizing neurological lesions to the brain/cord versus the peripheral nervous system."
  },
  {
    "id": 392,
    "categoryId": 6,
    "question": "Parkinson's Disease is caused by the loss of Dopaminergic neurons in the:",
    "options": [
      "A) Cerebellum",
      "B) Substantia Nigra (Pars Compacta)",
      "C) Hippocampus",
      "D) Caudate Nucleus"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Substantia Nigra pars compacta).\n\nPARKINSON'S PATHOPHYSIOLOGY:\nParkinson's disease results from progressive loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc) of the midbrain. These neurons project to the striatum (caudate and putamen) via the nigrostriatal pathway, providing dopamine that is essential for smooth, coordinated movement.\n\nCLINICAL CONSEQUENCES:\nDopamine depletion in the striatum disrupts the balance between the direct (movement-facilitating) and indirect (movement-inhibiting) basal ganglia pathways, resulting in the cardinal features: bradykinesia (slowness), rigidity (lead-pipe or cogwheel), resting tremor (pill-rolling), and postural instability. Bradykinesia is required for diagnosis.\n\nLEWY BODIES:\nThe pathological hallmark of Parkinson's is Lewy bodiesâ€”intracytoplasmic inclusions containing aggregated alpha-synuclein protein. Lewy body pathology spreads through the brain in a predictable pattern, explaining the progression from motor to non-motor symptoms.\n\nTREATMENT IMPLICATIONS:\nLevodopa (dopamine precursor) and dopamine agonists replace lost dopaminergic signaling. Deep brain stimulation of the subthalamic nucleus or globus pallidus can modulate the dysregulated basal ganglia circuits.\n\nKEY LEARNING POINTS:\nParkinson's results from dopaminergic neuron loss in the substantia nigra pars compacta. The cardinal features are bradykinesia, rigidity, resting tremor, and postural instability. Lewy bodies containing alpha-synuclein are the pathological hallmark."
  },
  {
    "id": 393,
    "categoryId": 6,
    "question": "A 'Focal Onset Impaired Awareness' seizure (formerly Complex Partial) differs from a 'Focal Aware' seizure because:",
    "options": [
      "A) It involves the whole body",
      "B) Consciousness is altered/lost",
      "C) It causes incontinence",
      "D) It lasts longer"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Consciousness is altered/lost).\n\nCLASSIFICATION OF FOCAL SEIZURES:\nThe International League Against Epilepsy (ILAE) reclassified seizures in 2017, replacing older terminology with more descriptive categories. Focal seizures originate in networks limited to one hemisphere. The critical distinction between focal onset aware and focal onset impaired awareness seizures is whether the patient retains or loses awareness during the event.\n\nFOCAL ONSET AWARE SEIZURES (FORMERLY SIMPLE PARTIAL):\nThe patient remains fully conscious and aware throughout the seizure. They may experience motor symptoms (jerking of one limb), sensory phenomena (tingling, visual disturbances), or autonomic symptoms (flushing, nausea). Importantly, the patient can describe what happened during the episode because consciousness is preserved. These seizures typically last seconds to under two minutes.\n\nFOCAL ONSET IMPAIRED AWARENESS SEIZURES (FORMERLY COMPLEX PARTIAL):\nConsciousness is altered or lost during the seizure. Patients may stare blankly, exhibit automatisms (lip smacking, picking at clothes, wandering), and have no memory of the event afterward. The temporal lobe is the most common origin. These seizures may evolve to bilateral tonic-clonic seizures if the abnormal electrical activity spreads to both hemispheres.\n\nCLINICAL SIGNIFICANCE:\nDistinguishing between these seizure types guides treatment and prognosis. Impaired awareness seizures may impair driving eligibility and require more aggressive management. Both types indicate focal brain pathology warranting MRI evaluation.\n\nKEY LEARNING POINTS:\nFocal onset impaired awareness seizures alter consciousness; focal onset aware seizures preserve it. The temporal lobe is the most common source of focal impaired awareness seizures. Automatisms (repetitive purposeless movements) commonly accompany impaired awareness seizures."
  },
  {
    "id": 394,
    "categoryId": 6,
    "question": "The pathophysiology of Migraine pain involves the activation of the:",
    "options": [
      "A) Sciatic Nerve",
      "B) Trigeminovascular System",
      "C) Vagus Nerve",
      "D) Optic Nerve"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Trigeminovascular System).\n\nMIGRAINE PATHOPHYSIOLOGY:\nThe trigeminovascular system is the primary neuroanatomical substrate underlying migraine pain. This system consists of trigeminal sensory nerve fibers that densely innervate the intracranial meningeal blood vessels and the dural sinuses. Activation of this system releases vasoactive neuropeptides, most notably calcitonin gene-related peptide (CGRP), substance P, and neurokinin A, which trigger meningeal neurogenic inflammation and vasodilation, ultimately perceived as the characteristic throbbing headache.\n\nPATHOPHYSIOLOGY:\nCurrent understanding recognizes migraine as a complex neurovascular disorder. A migraine attack begins with cortical spreading depression (CSD), a wave of neuronal depolarization followed by suppression that propagates across the cortex (this underlies aura). CSD activates trigeminal afferents innervating the meninges, which then release CGRP and other neuropeptides from their peripheral terminals. This causes meningeal vasodilation, plasma protein extravasation, mast cell degranulation, and sensitization of perivascular nociceptors. The pain signals are transmitted via the trigeminal ganglion to the trigeminal nucleus caudalis in the brainstem, then to the thalamus and cortex, where they are perceived as headache.\n\nTREATMENT IMPLICATIONS:\nUnderstanding the trigeminovascular mechanism directly informs pharmacotherapy. Triptans (5-HT1B/1D agonists) abort migraines by constricting meningeal vessels and inhibiting CGRP release from trigeminal terminals. The newer CGRP-targeted therapies represent a paradigm shift: gepants (small molecule CGRP receptor antagonists such as ubrogepant and rimegepant) are used for acute treatment, while CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab) provide targeted prophylaxis by blocking either the CGRP ligand or its receptor.\n\nCOMPREHENSIVE MANAGEMENT:\nAcute migraine treatment follows a stratified approach: NSAIDs for mild attacks, triptans or gepants for moderate to severe attacks, and antiemetics (metoclopramide, prochlorperazine) as adjuncts. Prophylaxis is indicated for four or more migraine days per month, with first-line options including beta-blockers, topiramate, valproate, and amitriptyline. Opioids and barbiturates should be avoided due to medication overuse headache risk.\n\nKEY LEARNING POINTS:\nMigraine pain arises from activation of the trigeminovascular system, which releases CGRP and causes neurogenic meningeal inflammation. Triptans work by constricting meningeal vessels and inhibiting CGRP release; newer CGRP-targeted therapies offer alternatives without vasoconstrictive effects. Prophylaxis is indicated for four or more migraine days per month."
  },
  {
    "id": 395,
    "categoryId": 6,
    "question": "Brown-Sequard Syndrome (Hemisection of the cord) causes:",
    "options": [
      "A) Bilateral paralysis",
      "B) Ipsilateral motor loss/vibration loss; Contralateral pain/temp loss",
      "C) Contralateral motor loss; Ipsilateral pain loss",
      "D) Complete sensory loss only"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Ipsilateral motor and vibration loss; Contralateral pain and temperature loss).\n\nBROWN-SÃ‰QUARD SYNDROME:\nBrown-SÃ©quard syndrome results from hemisection (or asymmetric lesion) of the spinal cord, producing a characteristic pattern of ipsilateral motor paralysis and loss of proprioception/vibration with contralateral loss of pain and temperature sensation below the level of the lesion. This dissociated pattern is one of the most clinically important demonstrations of spinal cord neuroanatomy and tract organization.\n\nPATHOPHYSIOLOGY:\nThe dissociated findings are explained by where different ascending pathways decussate (cross the midline). The corticospinal tract (motor) descends from the cortex and crosses at the medullary pyramids, then travels ipsilaterally in the lateral cord. A hemisection therefore causes ipsilateral motor loss (UMN signs below the lesion). The dorsal column-medial lemniscus pathway (proprioception, vibration, fine touch) ascends ipsilaterally in the posterior columns and crosses in the medulla, so a hemisection causes ipsilateral loss of these modalities. In contrast, the spinothalamic tract (pain, temperature, crude touch) crosses within one to two segments of entering the spinal cord, then ascends contralaterally. Therefore, a hemisection disrupts already-crossed fibers, producing contralateral pain and temperature loss.\n\nCLINICAL PRESENTATION:\nAt the level of the lesion, there may be an ipsilateral LMN pattern (segmental weakness, areflexia) and a band of ipsilateral loss of all sensory modalities. Below the lesion, the classic pattern emerges: ipsilateral UMN weakness (spasticity, hyperreflexia, Babinski), ipsilateral loss of vibration and proprioception, and contralateral loss of pain and temperature beginning one to two dermatomes below the lesion level.\n\nCOMMON ETIOLOGIES:\nBrown-SÃ©quard syndrome is most commonly caused by penetrating trauma (stab wounds, gunshot injuries). Other causes include spinal cord tumors, multiple sclerosis plaques, epidural hematoma, and disc herniation. Among spinal cord injury patterns, Brown-SÃ©quard syndrome carries the best prognosis for functional recovery.\n\nKEY LEARNING POINTS:\nBrown-SÃ©quard syndrome causes ipsilateral motor and vibration/proprioception loss with contralateral pain and temperature loss due to different levels of tract decussation. The corticospinal and dorsal column pathways cross in the brainstem (ipsilateral signs), while the spinothalamic tract crosses at the spinal cord level (contralateral signs). It carries the best prognosis among incomplete spinal cord injury patterns."
  },
  {
    "id": 396,
    "categoryId": 17,
    "question": "Which maneuver distinguishes Central Vertigo (Stroke) from Peripheral Vertigo (Vestibular Neuritis)?",
    "options": [
      "A) Romberg Test",
      "B) HINTS Exam (Head Impulse, Nystagmus, Test of Skew)",
      "C) Dix-Hallpike",
      "D) Weber Test"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (HINTS Exam - Head Impulse, Nystagmus, Test of Skew).\n\nPATHOPHYSIOLOGY:\nAcute vestibular syndrome presents with continuous vertigo, nausea/vomiting, nystagmus, and gait instability lasting days. The critical diagnostic challenge is distinguishing peripheral causes (vestibular neuritis, a benign condition) from central causes (posterior fossa stroke, a life-threatening emergency). The HINTS exam is a bedside three-component examination that has been shown to be more sensitive than early MRI (which can be falsely negative in the first 24-48 hours) for detecting posterior fossa stroke.\n\nHINTS EXAM COMPONENTS:\n1. Head Impulse test (HI):\n   - NORMAL (no corrective saccade) = DANGEROUS - suggests central lesion (cerebellum compensates)\n   - ABNORMAL (corrective saccade present) = Peripheral (vestibular neuritis - the VOR is impaired)\n2. Nystagmus type:\n   - Unidirectional, horizontal = Peripheral (reassuring)\n   - Direction-changing or vertical/torsional = DANGEROUS - suggests central lesion\n3. Test of Skew (alternate cover test):\n   - No vertical correction = Peripheral (reassuring)\n   - Vertical skew deviation present = DANGEROUS - suggests brainstem lesion\n\nCLINICAL REASONING:\nA dangerous HINTS pattern (any one of: normal head impulse, direction-changing nystagmus, or skew deviation) has greater than 96% sensitivity for posterior fossa stroke, outperforming MRI-DWI in the first 48 hours (Kattah et al., Stroke 2009). This patient has a normal head impulse test (dangerous sign), raising concern for cerebellar stroke.\n\nTREATMENT:\n- Peripheral (vestibular neuritis): Supportive care, short-course vestibular suppressants, early vestibular rehabilitation\n- Central (stroke): Emergent neurology/stroke team activation, MRI/MRA, antiplatelet or anticoagulation per etiology\n\nKEY LEARNING POINTS:\nA normal head impulse test in acute vestibular syndrome is a red flag for stroke, not reassurance. The HINTS exam outperforms early MRI for posterior fossa stroke detection. Any single dangerous HINTS finding warrants urgent neuroimaging and stroke evaluation.\n\nREFERENCES:\nKattah et al., Stroke 2009; Newman-Toker et al.; UpToDate; Harrison's Principles of Internal Medicine.\n---"
  },
  {
    "id": 397,
    "categoryId": 6,
    "question": "Myasthenia Gravis is an autoimmune disorder of the neuromuscular junction. Symptoms typically:",
    "options": [
      "A) Improve with use/exercise",
      "B) Worsen with use/exercise (Fatigability) and improve with rest",
      "C) Are constant throughout the day",
      "D) Start in the legs"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Symptoms worsen with use/exercise and improve with rest - Fatigability).\n\nMYASTHENIA GRAVIS FATIGABILITY:\nThe hallmark clinical feature of myasthenia gravis (MG) is fatigable weakness, meaning that muscle strength progressively decreases with sustained or repeated use and recovers after rest. This pattern directly reflects the underlying pathophysiology at the neuromuscular junction, where antibody-mediated destruction of acetylcholine receptors causes progressive neurotransmission failure during sustained activity.\n\nPATHOPHYSIOLOGY:\nUnder normal conditions, each nerve impulse releases acetylcholine (ACh) vesicles into the synaptic cleft, where ACh binds to postsynaptic nicotinic receptors and generates an endplate potential sufficient to trigger muscle contraction. In MG, autoantibodies reduce the number of functional AChR through complement-mediated lysis, accelerated internalization, and direct blockade. The remaining receptors can initially sustain neurotransmission, but with repeated nerve firing, the readily releasable ACh pool depletes (a normal phenomenon), and fewer ACh molecules encounter fewer receptors. Eventually, endplate potentials fall below the threshold for muscle fiber activation, producing clinical weakness. Rest allows ACh stores to replenish, temporarily restoring transmission.\n\nCLINICAL MANIFESTATIONS:\nPatients characteristically report feeling strongest in the morning and weakest by evening. Ptosis (eyelid drooping) and diplopia (double vision) are the most common initial symptoms because the extraocular muscles have a high firing frequency and low safety factor for neuromuscular transmission. Bulbar symptoms (difficulty chewing that worsens during a meal, nasal speech, dysphagia) and proximal limb weakness follow. In myasthenic crisis, respiratory muscle fatigue leads to ventilatory failure requiring intubation.\n\nDIAGNOSIS:\nThe pattern of fatigable weakness guides testing. The ice pack test (placing ice on the ptotic eyelid for 2 minutes improves ptosis by reducing acetylcholinesterase activity at the cooled neuromuscular junction) and serologic testing for AChR or MuSK antibodies confirm the diagnosis. Repetitive nerve stimulation shows a characteristic decremental response.\n\nKEY LEARNING POINTS:\nMyasthenia gravis causes fatigable weakness that worsens with repetitive use and improves with rest, reflecting progressive ACh depletion at a receptor-depleted neuromuscular junction. Patients are strongest in the morning and weakest by evening, with ptosis and diplopia as the most common initial symptoms. The ice pack test and AChR antibody testing are key diagnostic tools."
  },
  {
    "id": 398,
    "categoryId": 6,
    "question": "Amyotrophic Lateral Sclerosis (ALS) is unique because it affects:",
    "options": [
      "A) Only Upper Motor Neurons",
      "B) Only Lower Motor Neurons",
      "C) Both Upper AND Lower Motor Neurons simultaneously",
      "D) Only Sensory Neurons"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Both Upper AND Lower Motor Neurons simultaneously).\n\nAMYOTROPHIC LATERAL SCLEROSIS:\nAmyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease uniquely characterized by the simultaneous degeneration of both upper motor neurons (corticospinal tract in the brain and spinal cord) and lower motor neurons (anterior horn cells of the spinal cord and brainstem motor nuclei). The coexistence of UMN and LMN signs in the same patient is the defining clinical feature that distinguishes ALS from other motor neuron diseases and neuropathies.\n\nPATHOPHYSIOLOGY:\nALS involves progressive loss of motor neurons through mechanisms including glutamate excitotoxicity, protein aggregation (TDP-43 inclusions are found in approximately 97% of ALS cases), oxidative stress, mitochondrial dysfunction, and impaired axonal transport. The disease affects motor neurons selectively while sparing sensory neurons, autonomic neurons, and the oculomotor nuclei. Approximately 5 to 10% of cases are familial, with mutations in SOD1, C9orf72, TARDBP, and FUS genes identified.\n\nCLINICAL MANIFESTATIONS:\nPatients present with the combination of LMN signs (muscle atrophy, fasciculations, flaccid weakness) and UMN signs (spasticity, hyperreflexia, Babinski sign), often in the same limb or in different body regions. Finding fasciculations and atrophy (LMN) together with hyperreflexia (UMN) in the same extremity is highly suggestive. Sensory function is strictly preserved. Symptoms typically begin asymmetrically in one limb and spread to contiguous regions. Bulbar-onset ALS (approximately 25% of cases) presents with dysarthria and dysphagia. Respiratory failure is the usual cause of death, with median survival of 3 to 5 years from symptom onset.\n\nDIAGNOSIS AND TREATMENT:\nThe revised El Escorial criteria require evidence of UMN and LMN degeneration in multiple body regions with progressive spread, absence of alternative explanations, and normal sensory examination. EMG confirms widespread active denervation. Riluzole modestly extends survival by reducing glutamate excitotoxicity (approximately 2 to 3 months). Edaravone may slow functional decline in selected patients. Multidisciplinary care including respiratory support, nutritional management, and physical therapy improves quality of life.\n\nKEY LEARNING POINTS:\nALS uniquely affects both upper and lower motor neurons simultaneously, producing the combination of atrophy and fasciculations (LMN) with spasticity and hyperreflexia (UMN). Sensory function is strictly preserved, which is a critical diagnostic feature. Median survival is 3 to 5 years; riluzole provides modest survival benefit."
  },
  {
    "id": 399,
    "categoryId": 6,
    "question": "Wernicke's Encephalopathy is caused by Thiamine (B1) deficiency. The classic triad is:",
    "options": [
      "A) Fever, Headache, Rash",
      "B) Confusion, Ataxia, Ophthalmoplegia (Eye paralysis)",
      "C) Tremor, Rigidity, Shuffle",
      "D) Diarrhea, Dermatitis, Dementia"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Confusion, Ataxia, Ophthalmoplegia).\n\nWERNICKE'S ENCEPHALOPATHY:\nWernicke's encephalopathy is an acute neurological emergency caused by thiamine (vitamin B1) deficiency, classically presenting with the triad of confusion (encephalopathy), ataxia (cerebellar dysfunction), and ophthalmoplegia (eye movement paralysis, typically CN VI palsy or conjugate gaze abnormalities). However, the complete triad is present in only about one-third of cases, making clinical suspicion essential for timely diagnosis and treatment.\n\nPATHOPHYSIOLOGY:\nThiamine is an essential cofactor for three critical enzymes in cerebral energy metabolism: pyruvate dehydrogenase, alpha-ketoglutarate dehydrogenase (both in the Krebs cycle), and transketolase (in the pentose phosphate pathway). Deficiency impairs oxidative metabolism in metabolically active brain regions, particularly the mammillary bodies, medial thalami, periaqueductal gray matter, and cerebellar vermis. These structures undergo hemorrhagic necrosis, producing the characteristic clinical triad. Thiamine stores are depleted within 2 to 3 weeks without intake.\n\nCLINICAL CONTEXT AND RISK FACTORS:\nWernicke's encephalopathy is most commonly associated with chronic alcohol use disorder (due to poor nutrition and impaired thiamine absorption and phosphorylation), but it also occurs with prolonged vomiting (hyperemesis gravidarum), malnutrition, bariatric surgery, refeeding syndrome, and prolonged IV glucose administration without thiamine supplementation. A critical clinical pearl is that glucose administration accelerates thiamine consumption, potentially precipitating or worsening Wernicke's encephalopathy. Therefore, thiamine must always be administered before or concurrent with glucose in patients at risk.\n\nTREATMENT AND PROGNOSIS:\nHigh-dose IV thiamine (500 mg three times daily for 2 to 3 days, then 250 mg daily) should be given empirically whenever Wernicke's encephalopathy is suspected, as the diagnosis is clinical and delay can be fatal. Ophthalmoplegia typically improves within hours of thiamine administration, ataxia improves over days, and confusion may take weeks. If untreated, Wernicke's encephalopathy progresses to Korsakoff syndrome, characterized by severe anterograde amnesia and confabulation (fabrication of memories to fill gaps), which is often irreversible.\n\nKEY LEARNING POINTS:\nWernicke's encephalopathy presents with confusion, ataxia, and ophthalmoplegia due to thiamine deficiency affecting metabolically active brain regions. Thiamine must always be given before glucose to prevent worsening. Untreated Wernicke's progresses to Korsakoff syndrome with permanent amnesia and confabulation."
  },
  {
    "id": 400,
    "categoryId": 6,
    "question": "C6 Radiculopathy typically causes pain/numbness in the:",
    "options": [
      "A) Pinky finger",
      "B) Thumb and Index finger",
      "C) Middle finger",
      "D) Shoulder only"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Thumb and index finger).\n\nC6 RADICULOPATHY:\nC6 radiculopathy results from compression of the C6 nerve root, most commonly by a herniated disc at C5-C6 or cervical spondylotic foraminal stenosis. The clinical presentation follows the C6 dermatome, producing pain and numbness radiating from the neck through the lateral forearm to the thumb and index finger. Motor involvement manifests as weakness of wrist extension and elbow flexion (biceps), with diminished biceps and brachioradialis reflexes.\n\nPATHOPHYSIOLOGY:\nThe cervical nerve roots exit above their corresponding vertebral body (C6 exits above C6, between C5 and C6). Degenerative disc disease, disc herniation, uncovertebral joint hypertrophy, or facet arthropathy can narrow the neural foramen and compress the exiting nerve root. Radicular pain is generated by mechanical compression combined with inflammatory mediators released from the degenerated disc, including phospholipase A2, TNF-alpha, and interleukin-6, which sensitize the dorsal root ganglion.\n\nCERVICAL RADICULOPATHY LOCALIZATION:\nDistinguishing cervical nerve root levels is essential for clinical localization. C5 radiculopathy causes shoulder pain with deltoid weakness and diminished biceps reflex. C6 radiculopathy causes lateral forearm pain and thumb/index numbness with biceps and wrist extensor weakness, and decreased biceps/brachioradialis reflexes. C7 radiculopathy (the most common) causes posterior forearm and middle finger numbness with triceps and wrist flexor weakness, and decreased triceps reflex. C8 radiculopathy causes medial forearm pain with ring and small finger numbness and hand grip weakness.\n\nDIAGNOSIS AND TREATMENT:\nHistory and physical examination are the cornerstones of diagnosis. Spurling test (axial loading with neck extension and ipsilateral rotation reproducing radicular symptoms) supports the diagnosis. MRI is indicated for progressive neurological deficits, suspected myelopathy, red flags (trauma, cancer, infection), or symptoms persisting beyond 6 weeks. Conservative management (NSAIDs, physical therapy, activity modification) resolves symptoms in 80 to 90% of patients. Epidural steroid injections or surgical decompression are considered for refractory or progressive cases.\n\nKEY LEARNING POINTS:\nC6 radiculopathy causes pain and numbness in the thumb and index finger with biceps and wrist extensor weakness and diminished biceps/brachioradialis reflexes. Conservative management resolves the majority of cervical radiculopathies within 6 to 12 weeks. MRI is reserved for red flags, myelopathy signs, progressive weakness, or persistent symptoms beyond 6 weeks."
  },
  {
    "id": 401,
    "categoryId": 6,
    "question": "CSF analysis showing High Protein, Low Glucose, and High Neutrophils indicates:",
    "options": [
      "A) Viral Meningitis",
      "B) Bacterial Meningitis",
      "C) Fungal Meningitis",
      "D) Guillain-Barre"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Bacterial Meningitis).\n\nCSF ANALYSIS IN MENINGITIS:\nThe combination of elevated protein, low glucose, and neutrophil (polymorphonuclear/PMN) predominance in cerebrospinal fluid is the classic pattern for bacterial meningitis. CSF analysis is the definitive diagnostic step when meningitis is suspected, and the pattern of cell count, differential, protein, and glucose allows differentiation between bacterial, viral, fungal, and tuberculous etiologies. Bacterial meningitis is a medical emergency requiring immediate empiric antibiotic therapy.\n\nPATHOPHYSIOLOGY:\nBacteria reach the meninges through hematogenous spread, direct extension from contiguous infections (sinusitis, otitis media), or following neurosurgical procedures or skull fractures. Once in the subarachnoid space, bacterial replication triggers an intense inflammatory response with neutrophil recruitment (explaining PMN predominance). Bacteria and neutrophils consume glucose through glycolysis (producing low CSF glucose, typically below 40 mg/dL or less than two-thirds of serum glucose). Inflammation increases blood-brain barrier permeability, allowing protein leakage into the CSF (elevated protein, often greater than 200 mg/dL). The opening pressure is characteristically elevated.\n\nCSF PATTERNS BY ETIOLOGY:\nViral meningitis shows mild WBC elevation (typically fewer than 500 cells/ÂµL) with lymphocyte predominance, normal glucose, and normal to mildly elevated protein. Fungal and tuberculous meningitis also show lymphocyte predominance but with low glucose and high protein, resembling bacterial meningitis except for the lymphocytic differential and subacute clinical presentation over days to weeks rather than hours. Guillain-BarrÃ© syndrome shows elevated protein with a normal cell count (albuminocytologic dissociation) and normal glucose.\n\nTREATMENT:\nEmpiric antibiotic therapy must be initiated immediately upon clinical suspicion, ideally within 60 minutes of presentation and before CSF results return. Empiric coverage for adults includes vancomycin plus a third-generation cephalosporin (ceftriaxone or cefotaxime). Dexamethasone should be given before or with the first antibiotic dose to reduce inflammation-mediated neuronal injury, particularly in pneumococcal meningitis. Gram stain, culture, and meningococcal/pneumococcal PCR panels guide definitive therapy.\n\nKEY LEARNING POINTS:\nBacterial meningitis produces high protein, low glucose, and neutrophil-predominant CSF due to intense inflammation and bacterial glucose consumption. Viral meningitis shows lymphocyte predominance with normal glucose, while fungal/TB meningitis shows lymphocyte predominance with low glucose. Empiric antibiotics and dexamethasone must be given immediately upon clinical suspicion, before CSF results return."
  },
  {
    "id": 402,
    "categoryId": 6,
    "question": "Horner's Syndrome (Ptosis, Miosis, Anhidrosis) is caused by a lesion in the:",
    "options": [
      "A) Parasympathetic pathway",
      "B) Sympathetic chain",
      "C) Somatic motor pathway",
      "D) Cerebellum"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Sympathetic chain).\n\nHORNER'S SYNDROME:\nHorner's syndrome is a clinical triad of ipsilateral ptosis (drooping eyelid), miosis (constricted pupil), and anhidrosis (decreased sweating of the face), resulting from disruption of the oculosympathetic pathway at any point along its three-neuron arc. The syndrome is clinically important not because it is dangerous itself, but because the underlying cause may be life-threatening, making localization and etiologic workup essential.\n\nPATHOPHYSIOLOGY:\nThe sympathetic pathway to the eye and face follows a three-neuron chain. First-order neurons travel from the hypothalamus to the ciliospinal center of Budge at C8-T2 in the spinal cord (lesions here include stroke, syringomyelia, and MS). Second-order (preganglionic) neurons ascend from C8-T2 over the lung apex and along the carotid artery to the superior cervical ganglion (lesions include Pancoast tumor of the lung apex, neck trauma, and thoracic surgery). Third-order (postganglionic) neurons travel from the superior cervical ganglion along the internal carotid artery to the orbit (lesions include carotid dissection, cavernous sinus pathology, and cluster headache). Sympathetic fibers normally dilate the pupil (via the iris dilator muscle) and elevate the upper eyelid (via MÃ¼ller's muscle). When this pathway is interrupted, the unopposed parasympathetic tone produces miosis and ptosis.\n\nCLINICAL SIGNIFICANCE OF LOCALIZATION:\nCocaine eye drops can confirm Horner's syndrome (the affected pupil fails to dilate), while hydroxyamphetamine drops help distinguish preganglionic from postganglionic lesions. A new-onset Horner's syndrome demands urgent evaluation. Second-order neuron lesions raise concern for Pancoast tumor (apical lung mass invading the sympathetic chain) and require chest imaging. Third-order neuron lesions combined with ipsilateral head or neck pain suggest carotid artery dissection, requiring urgent CT or MR angiography.\n\nDIAGNOSIS AND WORKUP:\nPharmacologic pupil testing localizes the lesion. Imaging is guided by localization: MRI of the brain and cervical cord for first-order lesions, CT chest for second-order lesions (Pancoast tumor), and CT/MR angiography of the head and neck for third-order lesions (carotid dissection). A new-onset, painful Horner's syndrome should prompt emergent vascular imaging to exclude carotid dissection.\n\nKEY LEARNING POINTS:\nHorner's syndrome (ptosis, miosis, anhidrosis) results from interruption of the three-neuron sympathetic chain to the eye. A Pancoast tumor (lung apex) is the classic cause of a second-order neuron lesion, and carotid dissection is the most important cause to exclude urgently. Pharmacologic pupil testing with cocaine and hydroxyamphetamine helps localize the lesion along the sympathetic pathway."
  },
  {
    "id": 403,
    "categoryId": 6,
    "question": "Unlike Alzheimer's, Vascular Dementia typically progresses:",
    "options": [
      "A) In a smooth, linear decline",
      "B) In a 'Stepwise' fashion",
      "C) With hallucinations first",
      "D) With personality changes first"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (In a 'Stepwise' fashion).\n\nPATHOPHYSIOLOGY OF VASCULAR DEMENTIA:\nVascular dementia results from cerebrovascular disease causing cumulative brain injury. Unlike the gradual neurodegeneration of Alzheimer's disease, vascular dementia occurs through discrete ischemic events: strokes, transient ischemic attacks, or chronic small vessel disease. Each vascular insult causes sudden neurological decline, followed by a plateau or partial recovery, then another decline with the next eventâ€”creating the characteristic stepwise pattern.\n\nCLINICAL PRESENTATION:\nThe stepwise progression is the hallmark distinguishing feature. Patients or families often report sudden worsening of cognition coinciding with vascular events. Executive dysfunction (planning, judgment, organization) tends to be more prominent than memory loss early in the disease, contrasting with Alzheimer's where memory impairment dominates initially. Focal neurological signs (gait disturbance, focal weakness, pseudobulbar affect) are common given the vascular etiology.\n\nDIAGNOSTIC CRITERIA:\nDiagnosis requires evidence of cerebrovascular disease on imaging (MRI showing multiple infarcts, strategic single infarcts, or extensive white matter disease) with temporal relationship between stroke and cognitive decline. Mixed dementia (vascular plus Alzheimer's pathology) is actually the most common presentation in elderly patients.\n\nRISK FACTOR MODIFICATION:\nUnlike Alzheimer's disease, vascular dementia progression can potentially be slowed through aggressive cardiovascular risk management: blood pressure control, statin therapy, antiplatelet agents, diabetes management, and smoking cessation.\n\nKEY LEARNING POINTS:\nVascular dementia progresses stepwise with sudden declines, unlike Alzheimer's smooth decline. Executive dysfunction predominates early rather than memory loss. Vascular risk factor modification can slow progression, unlike neurodegenerative dementias."
  },
  {
    "id": 404,
    "categoryId": 6,
    "question": "A critical monitoring parameter for a patient with Guillain-Barre Syndrome is:",
    "options": [
      "A) Urea/Creatinine",
      "B) Negative Inspiratory Force (NIF) or Vital Capacity (FVC)",
      "C) Liver Enzymes",
      "D) Platelet Count"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Negative Inspiratory Force/NIF or Vital Capacity/FVC).\n\nRESPIRATORY MONITORING IN GUILLAIN-BARRÃ‰ SYNDROME:\nGuillain-BarrÃ© syndrome (GBS) produces ascending paralysis that can progress to involve the respiratory muscles (diaphragm and intercostals), making respiratory failure the most life-threatening complication. Serial monitoring of forced vital capacity (FVC) and negative inspiratory force (NIF) is the standard of care for detecting impending ventilatory failure before clinical decompensation occurs, because relying on oxygen saturation or arterial blood gas alone detects respiratory failure too late.\n\nPATHOPHYSIOLOGY:\nAs GBS-related demyelination and axonal injury progress proximally from the lower extremities, the phrenic nerve (C3-C5) and intercostal nerves become involved, weakening the diaphragm and accessory muscles of respiration. Vital capacity (the maximum volume of air exhaled after maximal inhalation) and NIF (the maximum negative pressure generated during inspiration) are direct measures of respiratory muscle strength that decline before gas exchange deteriorates. Approximately 20 to 30% of GBS patients require mechanical ventilation.\n\nCLINICAL MONITORING PROTOCOL:\nFVC and NIF should be measured every 4 to 6 hours in hospitalized GBS patients. The \"20/30/40 rule\" guides intubation decisions: intubate electively if FVC falls below 20 mL/kg, NIF is weaker than -30 cmH2O, or there has been a greater than 30% decline in FVC from baseline. Additional warning signs include rapid symptom progression, bulbar dysfunction (difficulty swallowing or managing secretions), and autonomic instability. Elective intubation is far safer than emergent intubation after respiratory arrest.\n\nTREATMENT OF GBS:\nIn addition to respiratory support, definitive treatment includes intravenous immunoglobulin (IVIG) or plasmapheresis, both of which are equally effective when initiated within the first 2 weeks of symptom onset. Corticosteroids are not effective in GBS. Deep vein thrombosis prophylaxis, pain management (neuropathic pain is common), and physical rehabilitation are essential supportive measures. Recovery takes weeks to months, with approximately 80% of patients achieving independent ambulation within 6 months.\n\nKEY LEARNING POINTS:\nSerial FVC and NIF monitoring is essential in GBS because respiratory muscle failure is the most dangerous complication. The \"20/30/40 rule\" guides elective intubation: FVC below 20 mL/kg, NIF weaker than -30 cmH2O, or greater than 30% decline from baseline. Approximately 20 to 30% of GBS patients require mechanical ventilation."
  },
  {
    "id": 405,
    "categoryId": 6,
    "question": "Cubital Tunnel Syndrome involves compression of the Ulnar nerve at the elbow. Symptoms include:",
    "options": [
      "A) Numbness in the thumb",
      "B) Numbness in the 4th and 5th digits (Pinky/Ring)",
      "C) Wrist drop",
      "D) Weakness of the biceps"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Numbness in the 4th and 5th digits/Pinky and Ring finger).\n\nCUBITAL TUNNEL SYNDROME:\nCubital tunnel syndrome is the second most common peripheral nerve entrapment (after carpal tunnel syndrome), caused by compression of the ulnar nerve at the elbow. The ulnar nerve passes through the cubital tunnel, a fibro-osseous channel between the medial epicondyle and the olecranon, where it is superficial and vulnerable to compression, traction, and friction. The resulting symptoms follow the ulnar nerve distribution in the hand.\n\nPATHOPHYSIOLOGY:\nThe ulnar nerve is susceptible to injury at the elbow because it lies in a relatively exposed position behind the medial epicondyle (the \"funny bone\"). Compression occurs within the cubital tunnel itself (between the two heads of the flexor carpi ulnaris) or at the retrocondylar groove. Repetitive elbow flexion stretches and flattens the nerve, increasing intraneural pressure. Prolonged elbow flexion (such as sleeping with bent elbows or leaning on the elbow) exacerbates symptoms. Over time, chronic compression leads to demyelination and ultimately axonal degeneration.\n\nCLINICAL MANIFESTATIONS:\nEarly symptoms include intermittent paresthesias and numbness in the ring and small (fifth) fingers and the ulnar border of the hand, particularly worsening with elbow flexion. As the condition progresses, patients develop weakness of the intrinsic hand muscles (interossei and lumbricals to digits 4 and 5), causing impaired fine motor function, weak grip, and difficulty with pinching. In advanced cases, visible atrophy of the hypothenar eminence and first dorsal interosseous muscle develops, and clawing of the ring and small fingers may appear (\"ulnar claw hand\").\n\nDIAGNOSIS AND TREATMENT:\nThe Tinel sign at the cubital tunnel (tapping behind the medial epicondyle reproduces tingling in digits 4 and 5) and the elbow flexion test (sustained flexion reproduces symptoms) are useful clinical provocative maneuvers. Electrodiagnostic studies (nerve conduction velocity showing slowing across the elbow, EMG showing denervation in ulnar-innervated muscles) confirm the diagnosis and grade severity. Conservative management includes activity modification, nighttime elbow extension splinting, and ergonomic changes. Surgical decompression or anterior transposition of the ulnar nerve is indicated for progressive weakness, muscle atrophy, or failure of conservative measures.\n\nKEY LEARNING POINTS:\nCubital tunnel syndrome compresses the ulnar nerve at the elbow, causing numbness in the ring and small fingers and weakness of intrinsic hand muscles. Symptoms worsen with elbow flexion, making nocturnal splinting in extension an effective conservative measure. Surgery is indicated for progressive weakness, atrophy, or failure of conservative management."
  },
  {
    "id": 406,
    "categoryId": 6,
    "question": "The definition of Transient Ischemic Attack (TIA) has changed. It is now defined as:",
    "options": [
      "A) Symptoms lasting < 24 hours",
      "B) Transient episode of neurologic dysfunction without acute infarction on MRI",
      "C) Symptoms lasting < 1 hour",
      "D) Any stroke that improves"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Tissue-based definition - Transient neurologic dysfunction without acute infarction on MRI).\n\nUPDATED TIA DEFINITION:\nThe definition of transient ischemic attack has evolved from a time-based criterion (symptoms lasting fewer than 24 hours) to a tissue-based definition. TIA is now defined as a transient episode of neurologic dysfunction caused by focal brain, spinal cord, or retinal ischemia without evidence of acute infarction on imaging. This change reflects the recognition that many patients with transient symptoms lasting less than 24 hours actually have evidence of brain infarction on diffusion-weighted MRI, making them stroke patients despite symptom resolution.\n\nPATHOPHYSIOLOGY:\nTIA occurs when a transient reduction in blood flow (from thromboembolism, large vessel atherosclerosis, or cardioembolism) causes temporary neuronal dysfunction without progressing to permanent tissue death. The ischemia resolves spontaneously through clot dissolution, collateral flow, or both. However, up to 30 to 50% of patients with clinically diagnosed TIA show acute infarction on diffusion-weighted MRI, reclassifying them as having had a minor ischemic stroke rather than a true TIA.\n\nRISK STRATIFICATION:\nTIA is a critical warning sign, with 90-day stroke risk estimated at 10 to 20%, with the highest risk concentrated in the first 48 hours to 7 days. The ABCD2 score stratifies risk: Age 60 or older (1 point), Blood pressure 140/90 or higher (1 point), Clinical features of unilateral weakness (2 points) or speech disturbance without weakness (1 point), Duration 60 minutes or longer (2 points) or 10 to 59 minutes (1 point), and Diabetes (1 point). Scores of 4 or higher warrant urgent hospitalization and expedited workup.\n\nSECONDARY PREVENTION:\nUrgent evaluation includes brain MRI with diffusion-weighted imaging, vascular imaging (CT angiography or carotid duplex), echocardiography, and cardiac monitoring for atrial fibrillation. Dual antiplatelet therapy (aspirin plus clopidogrel for 21 days) reduces early recurrence in high-risk TIA and minor stroke. High-intensity statin therapy is initiated regardless of lipid levels. Carotid endarterectomy within 2 weeks for symptomatic stenosis of 70 to 99% dramatically reduces subsequent stroke risk. Blood pressure targets of below 130/80 are recommended after the acute phase.\n\nKEY LEARNING POINTS:\nTIA is now defined by the absence of infarction on imaging, not by symptom duration; many \"TIAs\" show infarction on MRI and are actually minor strokes. The 90-day stroke risk after TIA is 10 to 20%, with highest risk in the first week. Dual antiplatelet therapy for 21 days, high-intensity statin, and urgent carotid imaging with possible endarterectomy are key secondary prevention strategies."
  },
  {
    "id": 407,
    "categoryId": 6,
    "question": "Frontotemporal Dementia (Pick's Disease) typically presents differently from Alzheimer's. The early signs are:",
    "options": [
      "A) Short term memory loss",
      "B) Behavioral/Personality changes and Aphasia",
      "C) Visual hallucinations",
      "D) Tremors"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Behavioral/Personality changes and Aphasia).\n\nPATHOPHYSIOLOGY:\nFrontotemporal dementia (FTD), including Pick's disease, involves selective degeneration of the frontal and temporal lobes. Unlike Alzheimer's disease where the hippocampus and parietal lobes are affected early, FTD targets the neural circuits governing personality, social behavior, and language. Abnormal accumulations of tau protein or TDP-43 cause neuronal death in these regions. The frontal lobes mediate executive function, impulse control, and social judgment, while the temporal lobes process language and emotional recognition.\n\nCLINICAL PRESENTATION:\nThe behavioral variant presents with striking personality changes: disinhibition (inappropriate comments, impulsive actions), apathy, loss of empathy, compulsive behaviors, and dietary changes (carbohydrate craving). Patients may make inappropriate sexual comments, shoplift without concern, or become emotionally cold to loved ones. Memory is relatively preserved early, distinguishing FTD from Alzheimer's. Language variants present with progressive aphasia: primary progressive aphasia (nonfluent type) causes effortful, halting speech; semantic dementia causes fluent but empty speech with loss of word meaning.\n\nAGE OF ONSET:\nFTD typically presents earlier than Alzheimer's (ages 45-65), making it a leading cause of early-onset dementia. Family history is present in 30-50% of cases, with autosomal dominant mutations identified in some families.\n\nDIAGNOSIS AND MANAGEMENT:\nMRI shows frontal and/or temporal atrophy. No disease-modifying treatments exist. Management focuses on behavioral interventions, caregiver support, and symptomatic treatment of depression or compulsive behaviors.\n\nKEY LEARNING POINTS:\nFTD presents with behavioral/personality changes and language dysfunction, NOT memory loss like Alzheimer's. Onset is typically younger (45-65 years). Disinhibition, apathy, and loss of empathy are hallmark features of the behavioral variant."
  },
  {
    "id": 408,
    "categoryId": 6,
    "question": "Diabetic Neuropathy is typically a 'Stocking-Glove' distribution. Which fiber type is lost first, causing burning/pain?",
    "options": [
      "A) Large myelinated fibers (Vibration/Proprioception)",
      "B) Small unmyelinated fibers (Pain/Temperature)",
      "C) Motor fibers",
      "D) Cranial nerves"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Small fiber (C and A-delta) sensory neurons).\n\nDIABETIC PERIPHERAL NEUROPATHY:\nThe most common form of diabetic neuropathy is distal symmetric polyneuropathy (DSPN) with a \"stocking-glove\" distribution affecting the longest nerves first. Small unmyelinated (C) and thinly myelinated (A-delta) fibers are affected earliest.\n\nSMALL FIBER VS LARGE FIBER:\nSmall fibers carry pain, temperature, and autonomic function. Their damage causes burning pain, allodynia (pain from light touch), and loss of temperature/pinprick sensation. Large fibers (A-alpha, A-beta) carry proprioception, vibration, and light touch; their damage causes numbness, loss of vibration sense, and ataxia.\n\nCLINICAL PROGRESSION:\nSymptoms typically begin in the toes and ascend proximally as longer nerves become affected. When symptoms reach the mid-calf, hand involvement begins (also a \"length-dependent\" pattern). Patients may describe burning, tingling, or \"walking on cotton.\"\n\nPATHOPHYSIOLOGY:\nHyperglycemia damages nerves through multiple mechanisms: polyol pathway activation, advanced glycation end-products, oxidative stress, and impaired microvascular blood supply to nerve fibers. Tight glycemic control slows progression.\n\nKEY LEARNING POINTS:\nDiabetic neuropathy affects small fibers (C and A-delta) first, causing burning pain and temperature loss. The stocking-glove distribution reflects length-dependent nerve damage. Early symptoms are painful; later stages may become painless but insensate."
  },
  {
    "id": 409,
    "categoryId": 6,
    "question": "A Deep Tendon Reflex (e.g., Knee Jerk) is a monosynaptic reflex. The sensory signal goes to the spinal cord and:",
    "options": [
      "A) Goes up to the brain for processing",
      "B) Synapses directly on the motor neuron to fire the muscle",
      "C) Crosses to the other side",
      "D) Is inhibited by GABA"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Synapses directly on the motor neuron to fire the muscle).\n\nTHE MONOSYNAPTIC REFLEX ARC:\nThe deep tendon reflex (also called the myotatic or stretch reflex) is the simplest and fastest neural circuit in the human nervous system, involving only a single synapse between the sensory (afferent) neuron and the motor (efferent) neuron within the spinal cord. When a tendon is struck, the muscle spindle is stretched, generating an afferent signal via Ia sensory fibers that travels to the spinal cord and synapses directly on the alpha motor neuron, which fires the same muscle to contract. No cortical processing is required.\n\nPATHOPHYSIOLOGY:\nThe reflex arc is designed for protective speed. Muscle spindles detect rapid stretch and relay this information to the spinal cord at high velocity through large-diameter, heavily myelinated Ia afferent fibers. In the spinal cord, the afferent synapse is monosynaptic (no interneurons are involved), ensuring minimal transmission delay. Simultaneously, inhibitory interneurons suppress the antagonist muscle (reciprocal inhibition), allowing coordinated movement. The entire arc from stretch to contraction occurs in approximately 25 to 50 milliseconds.\n\nCORTICAL MODULATION:\nThe brain does not initiate the reflex but does modulate its gain through descending corticospinal and reticulospinal pathways, which provide tonic inhibition to spinal motor neurons. When these descending pathways are damaged (upper motor neuron lesion from stroke, spinal cord injury, or demyelinating disease), the loss of inhibition results in hyperreflexia (exaggerated reflexes) and clonus (repetitive rhythmic contractions). Conversely, damage to the afferent or efferent limb of the arc itself (lower motor neuron lesion from peripheral neuropathy, radiculopathy, or anterior horn cell disease) results in hyporeflexia or areflexia.\n\nCLINICAL APPLICATION:\nDeep tendon reflexes are graded 0 (absent) through 4+ (clonus) and are among the most valuable tools in the neurological examination. Hyperreflexia localizes pathology to the brain or spinal cord (UMN), while hyporeflexia localizes to the peripheral nerve or nerve root (LMN). Asymmetric reflexes suggest focal pathology and guide further evaluation.\n\nKEY LEARNING POINTS:\nThe deep tendon reflex is a monosynaptic arc that bypasses the brain for speed, synapsing directly from sensory to motor neurons in the spinal cord. The brain provides tonic inhibition of this reflex, explaining why UMN lesions cause hyperreflexia and LMN lesions cause hyporeflexia. Reflex assessment is fundamental to distinguishing central from peripheral neurological pathology."
  },
  {
    "id": 410,
    "categoryId": 6,
    "question": "Glutamate is the primary _______ neurotransmitter, while GABA is the primary _______ neurotransmitter.",
    "options": [
      "A) Inhibitory; Excitatory",
      "B) Excitatory; Inhibitory",
      "C) Motor; Sensory",
      "D) Peripheral; Central"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Excitatory; Inhibitory).\n\nGLUTAMATE AND GABA NEUROTRANSMISSION:\nGlutamate is the principal excitatory neurotransmitter in the central nervous system, while gamma-aminobutyric acid (GABA) is the principal inhibitory neurotransmitter. Together, they form the fundamental excitatory-inhibitory balance that governs virtually all neural processing, from basic sensory perception to complex cognition. Disruption of this balance underlies many neurological and psychiatric disorders.\n\nPATHOPHYSIOLOGY:\nGlutamate mediates fast excitatory neurotransmission by activating ionotropic receptors (NMDA, AMPA, and kainate subtypes) that allow cation influx, depolarizing the postsynaptic neuron. NMDA receptors are particularly important for synaptic plasticity and learning (long-term potentiation). However, excessive glutamatergic activity causes excitotoxicity: sustained NMDA receptor activation allows massive calcium influx, activating destructive intracellular enzymes (calpains, endonucleases, phospholipases) that trigger neuronal death. Excitotoxicity is a major mechanism of neuronal injury in ischemic stroke, traumatic brain injury, and status epilepticus. GABA counterbalances excitation by activating GABA-A receptors (ligand-gated chloride channels that hyperpolarize neurons) and GABA-B receptors (G-protein-coupled receptors that reduce neuronal excitability).\n\nPHARMACOLOGICAL SIGNIFICANCE:\nThis excitatory-inhibitory framework explains the mechanisms of numerous medications used in primary care. Benzodiazepines and barbiturates enhance GABA-A receptor function, explaining their anxiolytic, sedative, anticonvulsant, and muscle relaxant properties as well as their additive CNS depression with alcohol (which also potentiates GABAergic transmission). Memantine blocks excessive NMDA receptor activation and is used in Alzheimer's disease. Many anesthetic agents (propofol, volatile anesthetics) act primarily through GABAergic enhancement.\n\nCLINICAL RELEVANCE FOR PRIMARY CARE:\nWhen evaluating elderly patients with falls, cognitive decline, or delirium, many centrally acting medications exert their effects through GABAergic enhancement (benzodiazepines, certain sleep aids, gabapentinoids). Reduced GABA tone or excessive glutamatergic excitation facilitates seizures, which is why GABA-enhancing drugs are first-line anticonvulsants and why conditions causing neuronal excitotoxicity (stroke, hypoglycemia) can provoke seizures.\n\nKEY LEARNING POINTS:\nGlutamate is the main excitatory and GABA the main inhibitory CNS neurotransmitter; their balance governs all neural processing. Excessive glutamate causes excitotoxic neuronal death (a major mechanism in stroke and status epilepticus), while GABA enhancement is the basis of anxiolytics, sedatives, and many anticonvulsants. Awareness of GABAergic drug effects is essential when evaluating falls, sedation, and delirium in primary care patients."
  },
  {
    "id": 411,
    "categoryId": 6,
    "question": "Status Epilepticus is defined as a seizure lasting > 5 minutes or recurrent seizures without return to baseline. First line treatment is:",
    "options": [
      "A) Phenytoin",
      "B) Propofol",
      "C) Benzodiazepine (Lorazepam/Midazolam)",
      "D) Levetiracetam"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (IV Benzodiazepines - Lorazepam or Diazepam).\n\nSTATUS EPILEPTICUS DEFINITION:\nStatus epilepticus is defined as a seizure lasting >5 minutes or recurrent seizures without return to baseline consciousness. This represents a neurological emergency with risk of permanent brain damage and death if not promptly terminated.\n\nFIRST-LINE TREATMENT:\nIV benzodiazepines are first-line: lorazepam 4mg IV (preferred due to longer duration of anticonvulsant effect) or diazepam 10mg IV. Can repeat once in 5-10 minutes if seizure continues. IM midazolam is an alternative if IV access is not immediately available.\n\nTREATMENT ALGORITHM:\n0-5 min: Stabilize (ABCs, O2, IV access, glucose check). 5-20 min: First-line benzodiazepines. 20-40 min: Second-line agents (fosphenytoin, levetiracetam, or valproate IV). >40 min: Refractory status - consider propofol, midazolam infusion, or pentobarbital with continuous EEG monitoring.\n\nCOMMON CAUSES:\nAnticonvulsant non-compliance, alcohol withdrawal, metabolic derangements (hypoglycemia, hyponatremia), CNS infection, stroke, and brain tumors. Identifying and treating the underlying cause is essential.\n\nKEY LEARNING POINTS:\nStatus epilepticus is a seizure >5 minutes requiring emergent treatment. IV lorazepam or diazepam is first-line therapy. If benzodiazepines fail, second-line agents include fosphenytoin, levetiracetam, or valproate."
  },
  {
    "id": 412,
    "categoryId": 6,
    "question": "Essential Tremor is distinguished from Parkinson's because Essential Tremor is:",
    "options": [
      "A) A resting tremor",
      "B) An action/postural tremor that improves with alcohol",
      "C) Unilateral",
      "D) Associated with shuffling gait"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (An action/postural tremor that improves with alcohol).\n\nPATHOPHYSIOLOGY:\nEssential tremor and Parkinson's disease represent distinct movement disorders with different underlying mechanisms. Essential tremor involves dysfunction of the cerebello-thalamo-cortical circuit, producing tremor during voluntary movement. Parkinson's disease results from dopaminergic neuron loss in the substantia nigra, causing tremor at rest when the affected limb is not engaged in purposeful activity.\n\nDISTINGUISHING FEATURES - ESSENTIAL TREMOR:\nEssential tremor is an ACTION or POSTURAL tremor, meaning it appears when holding a posture (arms outstretched) or during movement (bringing a cup to the mouth). It characteristically improves with small amounts of alcohol (though this is not recommended as treatment). Essential tremor is bilateral and symmetric, commonly affecting the hands but also the head (causing a \"no-no\" or \"yes-yes\" movement) and voice. There is often a family history (autosomal dominant inheritance pattern). Importantly, essential tremor does NOT cause bradykinesia, rigidity, or postural instability.\n\nDISTINGUISHING FEATURES - PARKINSON'S:\nParkinson's tremor is a RESTING tremor that diminishes or disappears with voluntary movement. It is classically described as \"pill-rolling.\" Parkinson's presents with the motor triad: tremor, bradykinesia (slowness), and rigidity (cogwheel or lead-pipe). The tremor is typically asymmetric at onset. Postural instability, masked facies, and shuffling gait develop as the disease progresses.\n\nCLINICAL SIGNIFICANCE:\nThis distinction matters for treatment: essential tremor responds to propranolol or primidone, while Parkinson's requires dopaminergic therapy (levodopa/carbidopa, dopamine agonists).\n\nKEY LEARNING POINTS:\nEssential tremor is an action/postural tremor; Parkinson's is a resting tremor. Alcohol improves essential tremor (not Parkinson's). Essential tremor lacks bradykinesia and rigidity; Parkinson's has both."
  },
  {
    "id": 413,
    "categoryId": 6,
    "question": "The spinal cord ends at L1. Below this is the Cauda Equina (nerve roots). Compression here causes LMN signs because:",
    "options": [
      "A) It is part of the CNS",
      "B) These are peripheral nerves, not the spinal cord itself",
      "C) It affects the brainstem",
      "D) It is a demyelinating process"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (The nerve roots below L1 are peripheral nerves, not spinal cord).\n\nANATOMY:\nThe spinal cord ends at the conus medullaris, typically at the L1-L2 vertebral level. Below this, the lumbar cistern contains only nerve roots (the cauda equina, Latin for \"horse's tail\"), which are peripheral nerves, not central nervous system structures.\n\nLMN VS UMN SIGNS:\nUpper motor neuron (UMN) lesions (spinal cord damage) cause spasticity, hyperreflexia, clonus, and Babinski sign due to loss of cortical inhibition. Lower motor neuron (LMN) lesions (peripheral nerve/root damage) cause flaccidity, hyporeflexia, fasciculations, and muscle atrophy. Because the cauda equina contains peripheral nerves, its compression produces LMN findings.\n\nCAUDA EQUINA SYNDROME:\nCompression of the cauda equina (often by large disc herniation) causes bilateral leg weakness (LMN pattern), saddle anesthesia, bowel/bladder dysfunction (urinary retention, fecal incontinence), and decreased lower extremity reflexes. This is a surgical emergency requiring urgent decompression.\n\nCLINICAL DISTINCTION:\nA lesion at L1 affecting the conus medullaris may show mixed UMN/LMN signs. Pure cauda equina lesions below L1-L2 show only LMN signs.\n\nKEY LEARNING POINTS:\nThe spinal cord ends at L1; below this are peripheral nerve roots (cauda equina). Cauda equina compression causes LMN signs (flaccid, areflexic) because only peripheral nerves are affected. Cauda equina syndrome is a surgical emergency."
  },
  {
    "id": 414,
    "categoryId": 4,
    "question": "A patient presents with visual field deficits (Bitemporal Hemianopsia) and galactorrhea. MRI shows a pituitary macroadenoma. What is the anatomical explanation for the vision loss?",
    "options": [
      "A) Compression of the Optic Nerve",
      "B) Compression of the Optic Chiasm",
      "C) Compression of the Occipital Lobe",
      "D) Compression of the Cavernous Sinus"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Compression of the Optic Chiasm).\n\nPATHOPHYSIOLOGY:\nThe visual field deficit in this patient is explained by the intimate anatomical relationship between the pituitary gland and the optic chiasm. The pituitary gland sits within the sella turcica, a bony saddle-shaped depression in the sphenoid bone at the base of the skull. Immediately superior to the sella, separated by the diaphragma sellae (a dural fold), lies the optic chiasm, the X-shaped structure where the optic nerves from each eye partially cross. Specifically, the nasal retinal fibers (which carry visual information from the temporal visual fields) decussate at the chiasm, while the temporal retinal fibers remain ipsilateral. A pituitary macroadenoma (defined as greater than 10 mm in diameter) growing superiorly through the diaphragma sellae compresses the optic chiasm from below, preferentially affecting the crossing nasal retinal fibers because they occupy the central and inferior portions of the chiasm where suprasellar compression occurs first. The result is bitemporal hemianopsia, the loss of temporal (outer, peripheral) visual fields bilaterally, often described by patients as tunnel vision. This visual field pattern is essentially pathognomonic for a chiasmal lesion, and a pituitary mass is the most common cause per Harrison's Principles of Internal Medicine and data from the Endocrine Society.\n\nCLINICAL REASONING:\nThe combination of bitemporal hemianopsia and galactorrhea in this patient strongly suggests a prolactin-secreting pituitary macroadenoma (macroprolactinoma). Prolactinomas are the most common functioning pituitary adenoma, accounting for approximately 40% of all pituitary adenomas. Galactorrhea results from the direct effect of excess prolactin on mammary tissue, while amenorrhea (commonly accompanying galactorrhea in premenopausal women) results from prolactin-mediated suppression of hypothalamic GnRH pulsatility, leading to hypogonadotropic hypogonadism. Microadenomas (less than 10 mm) typically present with endocrine symptoms alone (galactorrhea, amenorrhea, infertility, decreased libido) because they are too small to produce mass effect, while macroadenomas may produce both endocrine symptoms and compressive symptoms including visual field deficits, headache (from dural stretch), and hypopituitarism (from compression of normal pituitary tissue). Formal visual field testing by automated perimetry (Humphrey visual field) is essential in all patients with pituitary macroadenomas to document and monitor visual field compromise. Other structures at risk from lateral extension of pituitary tumors include the cavernous sinuses (containing cranial nerves III, IV, V1, V2, and VI, as well as the internal carotid artery), where compression can produce diplopia, facial numbness, or rarely carotid artery encasement.\n\nDIAGNOSIS AND TREATMENT:\nMRI of the sella with gadolinium contrast is the imaging modality of choice for pituitary lesions, providing superior soft tissue resolution and detailed visualization of the relationship between the tumor, optic chiasm, and cavernous sinuses. All pituitary adenomas require comprehensive hormonal evaluation including prolactin (markedly elevated in prolactinomas, typically above 200 ng/mL for macroadenomas), IGF-1 (for GH excess and acromegaly), 24-hour urinary free cortisol or overnight dexamethasone suppression test (for Cushing's disease), free T4 and TSH, gonadotropins, and alpha-subunit. Treatment of prolactinomas is unique among pituitary adenomas because dopamine agonists (cabergoline is first-line due to superior efficacy and tolerability over bromocriptine) are the primary therapy even for macroadenomas with visual field compromise, as they both normalize prolactin levels and produce significant tumor shrinkage (often greater than 50% reduction in volume) in approximately 80 to 90% of patients per Endocrine Society Clinical Practice Guidelines. Visual field improvement often begins within days to weeks of initiating dopamine agonist therapy. Transsphenoidal surgery is reserved for patients who are intolerant of or resistant to dopamine agonists, or who have acute visual deterioration from pituitary apoplexy.\n\nKEY LEARNING POINTS:\nBitemporal hemianopsia results from suprasellar compression of the optic chiasm's crossing nasal retinal fibers by a pituitary macroadenoma and is essentially pathognomonic for a chiasmal lesion. Prolactinomas are treated with dopamine agonists (cabergoline first-line) rather than surgery, even when large, because they normalize prolactin and shrink tumor mass in 80 to 90% of cases. All pituitary macroadenomas require formal visual field testing and comprehensive hormonal evaluation."
  },
  {
    "id": 415,
    "categoryId": 4,
    "question": "Prolactin secretion is unique among pituitary hormones because it is primarily under tonic INHIBITION by:",
    "options": [
      "A) Serotonin",
      "B) Dopamine",
      "C) Acetylcholine",
      "D) GABA"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Dopamine from the Hypothalamus).\n\nPATHOPHYSIOLOGY:\nProlactin regulation is unique among the anterior pituitary hormones because its dominant regulatory input is tonic inhibition rather than stimulation. All other anterior pituitary hormones are primarily controlled by hypothalamic releasing hormones that stimulate their secretion (GnRH for LH and FSH, CRH for ACTH, GHRH for GH, TRH for TSH), with inhibitory inputs playing secondary modulatory roles. Prolactin, in contrast, is under continuous inhibitory control by dopamine, which is synthesized by tuberoinfundibular dopaminergic (TIDA) neurons in the arcuate nucleus of the hypothalamus and transported via the hypothalamic-hypophyseal portal venous system to the anterior pituitary. Dopamine binds to D2 receptors (G-protein coupled receptors linked to Gi) on lactotroph cells, inhibiting adenylyl cyclase, reducing intracellular cAMP, suppressing prolactin gene transcription, and inhibiting prolactin exocytosis. This tonic inhibition is so dominant that severing the pituitary stalk (which interrupts dopamine delivery) causes prolactin levels to rise dramatically while all other anterior pituitary hormone levels fall (because their stimulatory releasing hormones are also interrupted). This physiologic principle, known as the stalk effect, has critical diagnostic implications: any mass lesion compressing or transecting the pituitary stalk (craniopharyngioma, non-functioning pituitary adenoma, metastasis, granulomatous disease) will cause moderate hyperprolactinemia (typically prolactin levels of 25 to 150 ng/mL) by interrupting dopamine delivery, even if the lesion does not produce prolactin itself.\n\nCLINICAL REASONING:\nThe stalk effect explains why all pituitary and parasellar mass lesions can cause hyperprolactinemia and why prolactin levels must be interpreted in the context of tumor size. A critical diagnostic distinction exists between stalk effect hyperprolactinemia (prolactin typically 25 to 150 ng/mL from any sellar or suprasellar mass interrupting dopamine delivery) and true prolactinoma (where prolactin levels generally correlate with tumor size: microadenomas typically produce levels of 50 to 200 ng/mL, while macroprolactinomas produce levels of 200 to over 10,000 ng/mL). A large pituitary mass with only modestly elevated prolactin (for example, 80 ng/mL with a 3-cm adenoma) more likely represents a non-functioning adenoma causing stalk effect rather than a prolactinoma, a distinction with major therapeutic implications since non-functioning adenomas require surgery while prolactinomas respond to medical therapy. One important technical pitfall is the hook effect (also called the high-dose hook effect), in which extremely high prolactin concentrations (greater than 10,000 ng/mL from giant prolactinomas) saturate the immunoassay antibodies and produce a falsely normal or modestly elevated result. Serial dilution of the sample reveals the true markedly elevated prolactin level. Clinicians should request serial dilutions whenever a large sellar mass is associated with unexpectedly low prolactin.\n\nCLINICAL APPLICATION:\nMedications that block dopamine D2 receptors are among the most common causes of hyperprolactinemia in clinical practice. Typical and atypical antipsychotics (haloperidol, risperidone, and to a lesser extent olanzapine and quetiapine), metoclopramide, domperidone, and prochlorperazine all elevate prolactin by removing the tonic dopaminergic inhibition on lactotrophs. The resulting hyperprolactinemia can cause galactorrhea, amenorrhea, oligomenorrhea, infertility, decreased libido, erectile dysfunction, and with chronic elevation, decreased bone mineral density from hypogonadism. Treatment of prolactinomas leverages the same dopamine-prolactin axis: dopamine agonists (cabergoline and bromocriptine) directly stimulate D2 receptors on lactotroph cells, restoring the inhibitory tone that the tumor has escaped. Cabergoline is preferred as first-line therapy per the Endocrine Society 2011 Clinical Practice Guideline due to its superior efficacy (normalizes prolactin in approximately 85% of patients versus 70% for bromocriptine), longer half-life allowing twice-weekly dosing, and better tolerability profile. Dopamine agonists not only normalize prolactin levels but also induce tumor shrinkage through D2-mediated apoptosis and reduced cellular proliferation, with macroadenoma volume reductions of 50% or greater in the majority of cases.\n\nKEY LEARNING POINTS:\nProlactin is unique among anterior pituitary hormones in being under tonic dopaminergic inhibition from hypothalamic TIDA neurons, such that stalk transection raises prolactin while lowering all other pituitary hormones. The stalk effect (moderate hyperprolactinemia from any mass interrupting dopamine delivery) must be distinguished from true prolactinoma based on prolactin level relative to tumor size. Cabergoline is the preferred dopamine agonist for prolactinomas, normalizing prolactin in 85% and shrinking tumors in the majority of cases."
  },
  {
    "id": 416,
    "categoryId": 4,
    "question": "Diabetes Insipidus (DI) results from a failure of ADH (Vasopressin). Neurogenic DI is caused by damage to the:",
    "options": [
      "A) Anterior Pituitary",
      "B) Posterior Pituitary / Hypothalamus",
      "C) Kidney Tubules",
      "D) Adrenal Cortex"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Posterior Pituitary / Hypothalamus).\n\nPATHOPHYSIOLOGY:\nDiabetes insipidus (DI) is a disorder of water homeostasis characterized by the inability to concentrate urine, resulting in the excretion of large volumes of dilute urine (polyuria, typically 3 to 20 liters per day, with urine osmolality less than 300 mOsm/kg) and compensatory polydipsia. The pathophysiology centers on antidiuretic hormone (ADH, also called arginine vasopressin), a 9-amino-acid peptide synthesized by magnocellular neurons in the supraoptic and paraventricular nuclei of the hypothalamus and transported via axonal projections through the pituitary stalk to the posterior pituitary (neurohypophysis), where it is stored in secretory granules and released into the systemic circulation in response to increased plasma osmolality (detected by hypothalamic osmoreceptors) or decreased effective circulating volume (detected by baroreceptors in the carotid sinus and aortic arch). ADH acts on the renal collecting duct by binding to V2 receptors on the basolateral membrane of principal cells, activating a Gs-adenylyl cyclase-cAMP-protein kinase A cascade that triggers the insertion of aquaporin-2 (AQP2) water channels into the apical membrane. These channels allow water to flow down its osmotic gradient from the hypotonic tubular fluid into the hypertonic medullary interstitium, concentrating the urine and conserving free water.\n\nCENTRAL VERSUS NEPHROGENIC DI:\nCentral (neurogenic) diabetes insipidus results from insufficient ADH production or secretion due to damage to the hypothalamic-neurohypophyseal axis. Causes include pituitary or hypothalamic surgery (the most common cause, particularly after transsphenoidal surgery where transient DI occurs in up to 30% of cases), traumatic brain injury, neoplasms (craniopharyngioma, germinoma, metastases, lymphoma), infiltrative diseases (Langerhans cell histiocytosis, sarcoidosis, granulomatosis with polyangiitis), autoimmune hypophysitis, genetic mutations (rare autosomal dominant mutations in the AVP-neurophysin II gene), and idiopathic causes (approximately 25 to 30% of cases). Nephrogenic diabetes insipidus results from renal resistance to the action of ADH despite normal or elevated circulating ADH levels. The kidneys do not respond to ADH signaling, and AQP2 channels are not inserted into the collecting duct membrane. The most common acquired cause is chronic lithium use (affecting up to 40% of long-term lithium users through lithium-mediated downregulation of AQP2 expression and impairment of the V2 receptor signaling cascade). Other causes include hypercalcemia, hypokalemia, obstructive uropathy, chronic kidney disease, and rare congenital mutations in the AVPR2 gene (X-linked) or AQP2 gene (autosomal recessive).\n\nDIAGNOSIS AND TREATMENT:\nThe water deprivation test (Miller-Moses test) is the classic diagnostic approach: the patient undergoes monitored fluid restriction, and urine osmolality is measured serially. If urine fails to concentrate (remains below 300 mOsm/kg) despite rising plasma osmolality, DI is confirmed. Administration of exogenous desmopressin (synthetic ADH analog) then distinguishes central from nephrogenic DI: urine osmolality increases by more than 50% in central DI (demonstrating that the kidneys respond to ADH when it is provided) but remains unchanged in nephrogenic DI (demonstrating renal resistance). More recently, measurement of copeptin (the C-terminal fragment of the AVP precursor, which is more stable and easier to measure than AVP itself) has emerged as a simpler and more reliable diagnostic tool per studies published in the NEJM and the Journal of Clinical Endocrinology and Metabolism. Treatment of central DI is desmopressin (DDAVP), available as intranasal spray, oral tablets, or subcutaneous injection. Patients must be counseled to allow breakthrough polyuria periodically to prevent water intoxication and hyponatremia from excess free water retention. Treatment of nephrogenic DI focuses on addressing the underlying cause (discontinuing lithium when possible), ensuring adequate hydration, and paradoxically using thiazide diuretics (which reduce urine volume by promoting proximal tubular sodium and water reabsorption through mild volume contraction), combined with dietary sodium restriction and in some cases amiloride (which blocks lithium entry through ENaC channels in the collecting duct).\n\nKEY LEARNING POINTS:\nCentral diabetes insipidus results from inadequate ADH production or secretion due to hypothalamic or posterior pituitary damage and is treated with desmopressin, while nephrogenic DI results from renal resistance to ADH (most commonly from lithium) and does not respond to desmopressin. The water deprivation test with desmopressin challenge distinguishes the two forms, and copeptin measurement is emerging as a simpler diagnostic alternative. Lithium-induced nephrogenic DI affects up to 40% of long-term users and is managed with thiazide diuretics, sodium restriction, and amiloride."
  },
  {
    "id": 417,
    "categoryId": 4,
    "question": "Hypocalcemia causes neuronal hyperexcitability (Tetany/Seizures). A classic physical exam sign is Chvostek's Sign, which is:",
    "options": [
      "A) Carpal spasm upon inflation of BP cuff",
      "B) Twitching of the facial muscles when tapping the facial nerve",
      "C) Hyperreflexia of the knee",
      "D) Clonus of the ankle"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Twitching of the facial muscles when tapping the facial nerve).\n\nPATHOPHYSIOLOGY:\nThe neuromuscular manifestations of hypocalcemia are explained by the essential role of extracellular calcium in regulating neuronal membrane excitability. Calcium ions normally bind to voltage-gated sodium channels on nerve and muscle cell membranes, stabilizing the channel in its closed conformation and raising the threshold for depolarization. When extracellular calcium concentration falls (total calcium below 8.5 mg/dL or ionized calcium below 4.5 mg/dL), this stabilizing effect is reduced, sodium channels open more readily at lower membrane potentials, and the threshold for action potential generation decreases. The result is neuronal and muscular hyperexcitability: nerves fire spontaneously or with minimal provocation, and muscles contract involuntarily, producing the clinical spectrum of paresthesias (perioral tingling, fingertip numbness), carpopedal spasm (tonic flexion of the wrists and metacarpophalangeal joints with extension of interphalangeal joints), laryngospasm (potentially life-threatening), generalized tetany, and seizures. The severity of symptoms depends on both the degree and the rate of calcium decline: rapid decreases in calcium produce symptoms at higher absolute levels than gradual chronic decreases, because the neuromuscular system has less time to adapt compensatory mechanisms.\n\nCLINICAL REASONING:\nChvostek's sign and Trousseau's sign are the two classic bedside provocative tests for latent tetany in hypocalcemia, and they must be carefully distinguished. Chvostek's sign is elicited by tapping the facial nerve (cranial nerve VII) approximately 2 cm anterior to the earlobe, just below the zygomatic arch, where the nerve courses superficially over the parotid gland. In the setting of hypocalcemia, this mechanical stimulation triggers involuntary twitching or contraction of the ipsilateral facial muscles, ranging from twitching of the upper lip (most subtle positive response) to contraction of the entire ipsilateral face. Chvostek's sign has moderate sensitivity (approximately 10 to 25% of normocalcemic individuals may have a positive response, reducing its specificity) but provides a rapid, no-equipment bedside assessment. Trousseau's sign (described in option A) is elicited by inflating a blood pressure cuff on the upper arm to 20 mmHg above the systolic pressure for 3 minutes. In hypocalcemia, this ischemic provocation triggers carpal spasm (adduction of the thumb, flexion of the metacarpophalangeal joints, extension of the interphalangeal joints, and flexion of the wrist, producing the characteristic main d'accoucheur or obstetrician's hand position). Trousseau's sign is more sensitive and specific than Chvostek's sign (positive in approximately 94% of hypocalcemic patients and only 1 to 4% of normocalcemic individuals) per data from Harrison's Principles of Internal Medicine and UpToDate.\n\nCLINICAL APPLICATION:\nThe most common cause of hypocalcemia in clinical practice is iatrogenic hypoparathyroidism following thyroid or parathyroid surgery, in which inadvertent damage to or devascularization of the parathyroid glands reduces parathyroid hormone (PTH) secretion and impairs calcium mobilization from bone, renal calcium reabsorption, and 1,25-dihydroxyvitamin D synthesis. Other important causes include vitamin D deficiency (resulting in impaired intestinal calcium absorption and secondary hyperparathyroidism), chronic kidney disease (impaired 1-alpha-hydroxylation of 25-hydroxyvitamin D in the kidney), hypomagnesemia (magnesium is required for PTH secretion and PTH receptor signaling, and severe hypomagnesemia produces a functional hypoparathyroidism that is refractory to calcium replacement until magnesium is corrected), acute pancreatitis (saponification of calcium with fatty acids released from pancreatic necrosis), tumor lysis syndrome, massive blood transfusion (citrate chelation of calcium), and medications including bisphosphonates, denosumab, and loop diuretics. Acute symptomatic hypocalcemia is a medical emergency requiring intravenous calcium gluconate (1 to 2 grams over 10 to 20 minutes with cardiac monitoring, as rapid infusion risks arrhythmia). Chronic hypocalcemia is managed with oral calcium supplementation (calcium carbonate or calcium citrate, 1 to 3 grams elemental calcium daily in divided doses) and active vitamin D (calcitriol 0.25 to 1 mcg daily) to enhance intestinal calcium absorption.\n\nKEY LEARNING POINTS:\nChvostek's sign (facial muscle twitching on tapping the facial nerve) and Trousseau's sign (carpal spasm on blood pressure cuff inflation) are bedside tests for hypocalcemia-induced neuromuscular hyperexcitability, with Trousseau's sign being more sensitive and specific. Hypocalcemia lowers the threshold for neuronal depolarization by reducing calcium-mediated stabilization of voltage-gated sodium channels. Hypomagnesemia must be corrected before hypocalcemia will respond to treatment, as magnesium is required for PTH secretion and receptor signaling."
  },
  {
    "id": 418,
    "categoryId": 4,
    "question": "The Adrenal Medulla acts as a modified sympathetic ganglion. Upon stimulation by the splanchnic nerves, it releases:",
    "options": [
      "A) Cortisol",
      "B) Aldosterone",
      "C) Epinephrine (80%) and Norepinephrine (20%)",
      "D) Acetylcholine"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Epinephrine 80% and Norepinephrine 20%).\n\nPATHOPHYSIOLOGY:\nThe adrenal gland is a composite endocrine organ with two functionally and embryologically distinct regions. The adrenal cortex, derived from mesoderm, produces steroid hormones organized by zones: the zona glomerulosa produces aldosterone (regulated by RAAS and potassium), the zona fasciculata produces cortisol (regulated by ACTH), and the zona reticularis produces adrenal androgens (DHEA, DHEA-S, androstenedione). The adrenal medulla, derived from neural crest ectoderm, is functionally a modified sympathetic ganglion. Chromaffin cells of the medulla are developmentally homologous to postganglionic sympathetic neurons but have lost their axonal projections and instead secrete catecholamines directly into the bloodstream, functioning as neuroendocrine cells rather than neurons. Preganglionic sympathetic fibers from the intermediolateral cell column of the thoracic spinal cord travel through the greater splanchnic nerve to synapse directly on chromaffin cells using acetylcholine at nicotinic receptors (the normal preganglionic-to-postganglionic synapse in sympathetic transmission). Upon stimulation, chromaffin cells release their stored catecholamines into the adrenal venous drainage: approximately 80% epinephrine and 20% norepinephrine. The predominance of epinephrine reflects the unique expression of phenylethanolamine N-methyltransferase (PNMT) in medullary chromaffin cells, an enzyme that methylates norepinephrine to epinephrine. PNMT expression is induced by high local cortisol concentrations delivered from the adjacent adrenal cortex through the intra-adrenal portal venous system, creating a functional cortico-medullary interaction.\n\nCLINICAL REASONING:\nThe distinction between the adrenal medulla's systemic catecholamine release and direct sympathetic nerve norepinephrine release at target organs is physiologically important. Sympathetic postganglionic neurons release norepinephrine directly onto effector organs (heart, blood vessels, bronchi) through synaptic neurotransmission, providing rapid, localized, and short-duration responses. The adrenal medulla complements this by releasing epinephrine (and norepinephrine) into the systemic circulation, creating a hormonal response that is slower in onset (dependent on circulatory transit time), generalized (reaching all tissues with adrenergic receptors), and more sustained (dependent on hepatic and renal clearance rather than synaptic reuptake). Epinephrine has distinct receptor selectivity compared to norepinephrine: it is a more potent agonist at beta-2 adrenergic receptors (producing bronchodilation, vasodilation in skeletal muscle, hepatic glycogenolysis, and pancreatic insulin suppression) while maintaining activity at beta-1 (cardiac stimulation) and alpha-1 (vasoconstriction) receptors. This beta-2 activity explains why the adrenal medullary response produces metabolic mobilization (hyperglycemia from glycogenolysis and gluconeogenesis, lipolysis for fatty acid fuel) in addition to cardiovascular effects, preparing the organism for sustained physical exertion during the fight-or-flight response.\n\nCLINICAL APPLICATION:\nThe adrenal medulla is the site of origin of pheochromocytoma, a catecholamine-secreting tumor of chromaffin cells that produces episodic or sustained hypertension with the classic symptom triad of headache, diaphoresis, and palpitations. Extra-adrenal paragangliomas arise from chromaffin cells in sympathetic paravertebral ganglia and may also secrete catecholamines. Diagnosis is made by measuring plasma free metanephrines (normetanephrine and metanephrine, the methylated metabolites of norepinephrine and epinephrine) or 24-hour urine metanephrines and catecholamines per Endocrine Society Clinical Practice Guidelines. Understanding the cortex-medulla distinction is also clinically relevant in adrenal insufficiency: Addison's disease destroys the entire adrenal gland, eliminating both cortical steroid production and medullary catecholamine reserve, while secondary adrenal insufficiency (from pituitary ACTH deficiency) affects only cortisol production, sparing aldosterone (which is RAAS-regulated) and medullary function.\n\nKEY LEARNING POINTS:\nThe adrenal medulla is a modified sympathetic ganglion that releases approximately 80% epinephrine and 20% norepinephrine into the bloodstream upon preganglionic cholinergic stimulation via the splanchnic nerve. Epinephrine predominance results from PNMT enzyme expression induced by high local cortisol from the adjacent cortex. Unlike direct sympathetic neurotransmission, medullary catecholamine release produces a systemic, sustained metabolic and cardiovascular stress response."
  },
  {
    "id": 419,
    "categoryId": 4,
    "question": "A patient with Pheochromocytoma (Tumor of the Adrenal Medulla) presents with the classic triad of:",
    "options": [
      "A) Hypotension, Bradycardia, Flushing",
      "B) Headache, Palpitations/Sweating, Tachycardia",
      "C) Weight gain, Striae, Moon face",
      "D) Polyuria, Polydipsia, Polyphagia"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Headache, Palpitations/Sweating, Tachycardia).\n\nPATHOPHYSIOLOGY:\nPheochromocytoma is a catecholamine-secreting neuroendocrine tumor arising from chromaffin cells of the adrenal medulla, with an estimated incidence of 2 to 8 per million person-years. Extra-adrenal tumors arising from sympathetic paravertebral chromaffin tissue are termed paragangliomas and account for approximately 15 to 20% of catecholamine-secreting tumors. These tumors produce, store, and episodically release excessive quantities of catecholamines (epinephrine, norepinephrine, and in some cases dopamine) into the circulation, producing paroxysmal or sustained hypertension and the classic symptom triad. The episodic nature of symptoms reflects the tumor's pattern of catecholamine release, which may be triggered by physical exertion, abdominal palpation, postural changes, anesthesia induction, tyramine-containing foods, or may occur spontaneously. Approximately 30 to 40% of pheochromocytomas and paragangliomas are now recognized to have a hereditary basis (substantially higher than the historically cited 10% rule of 10s), associated with germline mutations in genes including RET (MEN2A and MEN2B), VHL (von Hippel-Lindau syndrome), NF1 (neurofibromatosis type 1), and succinate dehydrogenase subunit genes (SDHB, SDHC, SDHD, SDHA, and SDHAF2) per the Endocrine Society Clinical Practice Guideline and Harrison's Principles of Internal Medicine. SDHB mutations carry the highest risk of malignant disease (up to 30 to 40% metastatic rate), while MEN2-associated pheochromocytomas are almost always bilateral and benign.\n\nCLINICAL PRESENTATION:\nThe classic triad consists of episodic headache (from acute hypertension), diaphoresis (sweating, from direct catecholamine-mediated activation of eccrine sweat glands), and palpitations with tachycardia (from beta-1 adrenergic stimulation of the heart). This triad has a sensitivity of approximately 90% and specificity of approximately 94% for pheochromocytoma when all three symptoms occur episodically in a hypertensive patient. Hypertension may be paroxysmal (approximately 50% of cases), sustained with paroxysmal exacerbations (approximately 40%), or sustained without paroxysms (approximately 10%). Additional features include anxiety and panic-like episodes, pallor (from alpha-mediated cutaneous vasoconstriction, distinguishing catecholamine excess from other causes of flushing), tremor, weight loss (from increased metabolic rate), and hyperglycemia (from catecholamine-mediated glycogenolysis and insulin suppression). Pheochromocytoma should be suspected in patients with paroxysmal hypertension accompanied by the classic triad, refractory hypertension unresponsive to standard therapy, hypertensive crisis during anesthesia or surgery, adrenal incidentaloma, or a family history of pheochromocytoma or associated genetic syndromes.\n\nDIAGNOSIS AND TREATMENT:\nBiochemical testing must precede imaging. Plasma free metanephrines (normetanephrine and metanephrine, the O-methylated metabolites of norepinephrine and epinephrine produced by catechol-O-methyltransferase within the tumor) are the recommended initial screening test due to their high sensitivity (96 to 99%) per the Endocrine Society guideline. Alternatively, 24-hour urine fractionated metanephrines and catecholamines provide high sensitivity when plasma testing is unavailable. After biochemical confirmation, CT or MRI of the abdomen and pelvis localizes the tumor, and functional imaging (I-123 MIBG scintigraphy or Ga-68 DOTATATE PET/CT) is used to identify metastatic or extra-adrenal disease. Preoperative medical preparation is critical and follows a strict sequence: alpha-adrenergic blockade must be initiated first (phenoxybenzamine, a nonselective irreversible alpha-blocker, or doxazosin, a selective alpha-1 blocker) for at least 10 to 14 days before surgery to normalize blood pressure and allow intravascular volume re-expansion (patients are chronically volume-contracted from catecholamine-mediated vasoconstriction). Beta-adrenergic blockade (propranolol, atenolol) is added only after adequate alpha-blockade to control tachycardia. The strict alpha-before-beta sequence is essential because administering a beta-blocker before adequate alpha-blockade removes the beta-2-mediated vasodilatory counterbalance to alpha-1 vasoconstriction, potentially precipitating a lethal hypertensive crisis from unopposed alpha stimulation. Liberal sodium and fluid intake during the preoperative alpha-blockade period facilitates volume re-expansion. Laparoscopic adrenalectomy is the definitive treatment for localized disease.\n\nKEY LEARNING POINTS:\nPheochromocytoma presents with the classic triad of episodic headache, diaphoresis, and palpitations in the setting of paroxysmal or sustained hypertension. Plasma free metanephrines are the recommended initial screening test with 96 to 99% sensitivity. Preoperative alpha-blockade must always precede beta-blockade to prevent hypertensive crisis from unopposed alpha stimulation, and genetic testing should be considered in all patients given the 30 to 40% hereditary rate."
  },
  {
    "id": 420,
    "categoryId": 4,
    "question": "Diabetic Autonomic Neuropathy (DAN) affects the Vagus nerve, leading to Gastroparesis. Symptoms include:",
    "options": [
      "A) Rapid gastric emptying and diarrhea",
      "B) Early satiety, bloating, and vomiting undigested food",
      "C) Increased hunger",
      "D) Peptic ulcers"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Early satiety, bloating, and vomiting undigested food).\n\nPATHOPHYSIOLOGY:\nDiabetic gastroparesis is a syndrome of delayed gastric emptying in the absence of mechanical obstruction, resulting from autonomic neuropathy affecting the vagus nerve and the enteric nervous system of the stomach. The vagus nerve (cranial nerve X) is the primary parasympathetic innervation of the gastrointestinal tract and coordinates the complex motor functions required for gastric accommodation (relaxation of the fundus to receive food), antral grinding and trituration (mechanical breakdown of solid food into particles less than 1 to 2 mm), and coordinated pyloric relaxation with antral contraction to propel chyme into the duodenum. Chronic hyperglycemia damages vagal nerve fibers through multiple mechanisms: accumulation of sorbitol and fructose via the polyol pathway causes osmotic nerve fiber swelling and demyelination, advanced glycation end-products (AGEs) directly damage nerve structural proteins, oxidative stress from mitochondrial superoxide production impairs axonal transport, and microangiopathy of the vasa nervorum produces ischemic nerve injury. In addition to vagal neuropathy, recent research has identified loss of interstitial cells of Cajal (ICC), the pacemaker cells of the gastrointestinal tract that generate the slow-wave electrical rhythm coordinating gastric contractions, as a key pathologic finding in diabetic gastroparesis per studies published in Gastroenterology and reviewed in Harrison's Principles of Internal Medicine. Loss of ICC disrupts the normal 3-cycles-per-minute gastric slow wave, producing gastric dysrhythmias and impaired antral contractility. Hyperglycemia itself acutely inhibits gastric motility independent of neuropathy, creating a vicious cycle in which gastroparesis impairs glycemic control (through erratic nutrient delivery and unpredictable postprandial glucose excursions) and poor glycemic control further inhibits gastric motility.\n\nCLINICAL PRESENTATION:\nGastroparesis affects approximately 5% of patients with type 1 diabetes and 1% of patients with type 2 diabetes, though subclinical delayed gastric emptying may be present in up to 40 to 50% of patients with longstanding diabetes per data from the Mayo Clinic and UpToDate. Symptoms include early satiety (inability to finish normal-sized meals due to impaired fundic accommodation), postprandial fullness and bloating (from retained gastric contents), nausea and vomiting (characteristically of partially digested food eaten hours to days earlier, which distinguishes gastroparesis from other causes of vomiting), epigastric pain or discomfort, and weight loss from decreased oral intake. The Gastroparesis Cardinal Symptom Index (GCSI) provides a standardized assessment of symptom severity. Symptoms often fluctuate with glycemic control, worsening during periods of hyperglycemia. Gastroparesis significantly complicates insulin management because the delayed and unpredictable delivery of nutrients to the small intestine produces a mismatch between insulin action and glucose absorption, causing both postprandial hyperglycemia (when food eventually empties) and hypoglycemia (when insulin peaks before food is absorbed).\n\nDIAGNOSIS AND TREATMENT:\nDiagnosis requires documentation of delayed gastric emptying after excluding mechanical obstruction. Gastric emptying scintigraphy (the gold standard) measures the percentage of a radiolabeled standardized low-fat meal (typically egg whites) retained in the stomach at 1, 2, and 4 hours; retention of greater than 10% at 4 hours confirms delayed emptying per the American Neurogastroenterology and Motility Society and SNMMI consensus guidelines. Upper endoscopy should be performed to exclude pyloric or duodenal obstruction and to identify retained food (a bezoar), which itself confirms gastroparesis when found after an adequate fast. Treatment is multimodal: dietary modification is first-line, emphasizing small frequent meals (5 to 6 per day), low fat content (fat slows gastric emptying), reduced fiber and residue (large indigestible fibers form bezoars), pureed or liquid consistency for severe cases, and optimization of glycemic control to remove the acute inhibitory effect of hyperglycemia on gastric motility. Prokinetic medications include metoclopramide (a D2 receptor antagonist and 5-HT4 agonist that enhances antral contractility and coordinates gastroduodenal motility, though limited by the risk of tardive dyskinesia with long-term use and carrying an FDA Black Box Warning restricting use beyond 12 weeks) and erythromycin (a motilin receptor agonist that stimulates high-amplitude gastric contractions, typically used at sub-antimicrobial doses of 50 to 100 mg before meals, though tachyphylaxis limits long-term efficacy). Antiemetics (ondansetron, prochlorperazine) provide symptomatic relief. For refractory cases, gastric electrical stimulation (Enterra device, FDA-approved under humanitarian device exemption) and gastric peroral endoscopic myotomy (G-POEM, targeting the pylorus) represent advanced therapeutic options per guidelines from the AGA and ACG.\n\nKEY LEARNING POINTS:\nDiabetic gastroparesis results from vagal autonomic neuropathy and loss of interstitial cells of Cajal, producing delayed gastric emptying that manifests as early satiety, postprandial bloating, nausea, and vomiting of undigested food. Gastric emptying scintigraphy with greater than 10% retention at 4 hours is the diagnostic gold standard. Treatment centers on dietary modification (small frequent low-fat low-fiber meals), glycemic optimization, and prokinetic agents (metoclopramide with Black Box Warning, erythromycin limited by tachyphylaxis)."
  },
  {
    "id": 421,
    "categoryId": 4,
    "question": "Cushing's Disease (specifically) refers to hypercortisolism caused by:",
    "options": [
      "A) An Adrenal Tumor",
      "B) Exogenous Steroid use (Prednisone)",
      "C) An ACTH-secreting Pituitary Adenoma",
      "D) Small Cell Lung Cancer (Ectopic ACTH)"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (An ACTH-secreting Pituitary Adenoma).\n\nPATHOPHYSIOLOGY:\nThe distinction between Cushing's syndrome and Cushing's disease is a critical terminologic and clinical differentiation. Cushing's syndrome is the clinical state resulting from chronic exposure to excess glucocorticoids from any cause, while Cushing's disease refers specifically to hypercortisolism caused by an ACTH-secreting pituitary adenoma, accounting for approximately 70% of endogenous Cushing's syndrome cases per Harrison's Principles of Internal Medicine and the Endocrine Society. These pituitary adenomas (typically microadenomas less than 10 mm) arise from corticotroph cells and autonomously secrete ACTH, which drives bilateral adrenal hyperplasia and excess cortisol production that overrides normal hypothalamic-pituitary-adrenal (HPA) axis feedback. Unlike normal corticotrophs, the neoplastic cells have a higher threshold for glucocorticoid-mediated feedback inhibition, meaning they continue secreting ACTH at cortisol levels that would suppress normal corticotrophs. This property is exploited diagnostically by the high-dose dexamethasone suppression test. The most common overall cause of Cushing's syndrome is exogenous (iatrogenic) glucocorticoid administration, which suppresses endogenous ACTH and causes bilateral adrenal atrophy. Among endogenous causes, ACTH-dependent sources (pituitary adenoma and ectopic ACTH from tumors such as small cell lung cancer, bronchial carcinoids, and medullary thyroid carcinoma) account for approximately 80%, while ACTH-independent sources (adrenal adenoma, adrenal carcinoma, bilateral macronodular adrenal hyperplasia) account for approximately 20%.\n\nCLINICAL PRESENTATION:\nChronic hypercortisolism produces a characteristic constellation of clinical features reflecting cortisol's catabolic, immunosuppressive, and metabolic actions. Central (truncal) obesity with redistribution of fat to the face (moon facies), dorsocervical fat pad (buffalo hump), and supraclavicular fat pads results from cortisol-stimulated lipogenesis in visceral depots combined with lipolysis in the extremities. Proximal muscle weakness and wasting occur from cortisol-mediated protein catabolism in skeletal muscle. Wide (greater than 1 cm) violaceous striae on the abdomen, thighs, and axillae result from cortisol-induced collagen degradation weakening the dermis so that underlying vasculature becomes visible through the thinned, stretched skin. Additional features include easy bruising (from capillary fragility), facial plethora, hirsutism and acne (from adrenal androgen excess in ACTH-dependent disease), osteoporosis (cortisol inhibits osteoblast function and intestinal calcium absorption), hypertension (cortisol potentiates catecholamine vasoconstrictive activity and activates the mineralocorticoid receptor at high concentrations), glucose intolerance or diabetes (cortisol promotes gluconeogenesis and opposes insulin action), immunosuppression with increased infection risk, psychiatric disturbances (depression, cognitive impairment, psychosis), and menstrual irregularity. Hyperpigmentation may occur in Cushing's disease with very high ACTH levels, as ACTH is cleaved from the same POMC precursor as melanocyte-stimulating hormone.\n\nDIAGNOSIS:\nThe diagnostic workup proceeds through three sequential steps per the Endocrine Society Clinical Practice Guideline. First, confirm hypercortisolism using at least two concordant screening tests: 24-hour urinary free cortisol (elevated above the upper limit of normal), late-night salivary cortisol (loss of normal diurnal nadir), or 1 mg overnight dexamethasone suppression test (failure to suppress morning cortisol below 1.8 mcg/dL). Second, determine ACTH dependence by measuring plasma ACTH: elevated or inappropriately normal ACTH indicates an ACTH-dependent source (pituitary or ectopic), while suppressed ACTH (less than 5 pg/mL) indicates an ACTH-independent adrenal source. Third, localize the ACTH-dependent source: pituitary MRI identifies the adenoma in approximately 60% of cases, the high-dose dexamethasone suppression test exploits the fact that pituitary adenomas retain partial suppression (cortisol decreases by more than 50%) while ectopic sources do not, and bilateral inferior petrosal sinus sampling (IPSS) with CRH stimulation is the gold standard for distinguishing pituitary from ectopic ACTH, with a central-to-peripheral ACTH gradient greater than 3:1 after CRH confirming a pituitary source.\n\nTREATMENT:\nTranssphenoidal surgical resection of the pituitary adenoma is the first-line treatment for Cushing's disease, achieving remission rates of 70 to 90% for microadenomas in experienced centers per data from JAMA Surgery and the Endocrine Society. Patients require perioperative stress-dose glucocorticoid coverage and postoperative glucocorticoid replacement (typically for 6 to 18 months) while the suppressed HPA axis recovers. For refractory or recurrent disease, options include repeat surgery, pituitary radiation, bilateral adrenalectomy (which provides immediate biochemical cure but requires lifelong glucocorticoid and mineralocorticoid replacement and carries risk of Nelson's syndrome from enlarging corticotroph adenoma), and medical therapy with steroidogenesis inhibitors (ketoconazole, osilodrostat, metyrapone) or pituitary-directed agents (pasireotide, cabergoline).\n\nKEY LEARNING POINTS:\nCushing's disease specifically denotes hypercortisolism from an ACTH-secreting pituitary adenoma, the most common endogenous cause, while Cushing's syndrome refers to hypercortisolism from any cause. The diagnostic workup proceeds sequentially: confirm hypercortisolism, determine ACTH dependence, then localize the source. Bilateral inferior petrosal sinus sampling is the gold standard for distinguishing pituitary from ectopic ACTH sources, and transsphenoidal surgery achieves 70 to 90% remission for microadenomas."
  },
  {
    "id": 422,
    "categoryId": 4,
    "question": "Thyroid hormone is critical for the development of the fetal nervous system. Untreated Congenital Hypothyroidism (Cretinism) results in:",
    "options": [
      "A) Gigantism",
      "B) Profound Intellectual Disability and Stunted Growth",
      "C) Precocious Puberty",
      "D) Blindness"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Profound Intellectual Disability and Stunted Growth).\n\nPATHOPHYSIOLOGY:\nThyroid hormone is essential for normal neurodevelopment, playing critical roles in neuronal migration, myelination, synaptogenesis, and dendritic arborization during fetal and early postnatal brain development. The fetus depends entirely on maternal thyroid hormone transfer across the placenta during the first trimester (before the fetal thyroid gland becomes functional at approximately 12 weeks of gestation), and on a combination of maternal and fetal thyroid hormone for the remainder of pregnancy. After birth, endogenous thyroid hormone production becomes the sole source for continuing brain development, which remains critically thyroid-hormone-dependent through the first 2 to 3 years of life. In congenital hypothyroidism, inadequate thyroid hormone during these developmental windows produces irreversible neurologic damage, including impaired neuronal proliferation and migration in the cerebral cortex, deficient myelination of the central nervous system (producing the characteristic delayed relaxation phase of deep tendon reflexes), impaired synaptogenesis and dendritic branching in the hippocampus and cerebellum, and deficient cerebellar Purkinje cell development. The resulting syndrome, historically termed cretinism, manifests as profound intellectual disability (IQ loss of 6 to 15 points per month of untreated neonatal hypothyroidism per studies from the NEJM and Pediatrics), growth retardation (thyroid hormone is required for growth hormone secretion, IGF-1 generation, and epiphyseal growth plate chondrocyte proliferation), delayed skeletal maturation with characteristic epiphyseal dysgenesis, macroglossia, umbilical hernia, prolonged neonatal jaundice, hypotonia, and the characteristic coarse facial features.\n\nCLINICAL REASONING:\nCongenital hypothyroidism occurs in approximately 1 in 2,000 to 4,000 live births and is one of the most common preventable causes of intellectual disability worldwide per WHO and AAP data. The most common cause in iodine-sufficient regions is thyroid dysgenesis (absent, ectopic, or hypoplastic thyroid gland), accounting for approximately 85% of cases. Dyshormonogenesis (inherited defects in thyroid hormone synthesis enzymes such as thyroid peroxidase, thyroglobulin, or the sodium-iodide symporter) accounts for approximately 10 to 15%. In iodine-deficient regions, maternal and fetal iodine deficiency remains the leading cause of preventable intellectual disability globally, affecting an estimated 2 billion people at risk worldwide per the WHO. The critical clinical principle is that congenital hypothyroidism is almost always clinically silent at birth because maternal thyroid hormone transferred during pregnancy provides partial neonatal protection, and clinical signs develop insidiously over weeks to months. Without newborn screening, diagnosis would typically not occur until irreversible neurologic damage has already been sustained.\n\nDIAGNOSIS AND TREATMENT:\nUniversal newborn screening for congenital hypothyroidism, implemented in virtually all developed nations and recommended by the AAP and the WHO, is one of the most successful public health screening programs in history. Screening is performed on a heel-prick blood sample collected at 24 to 48 hours of life, measuring TSH (primary screening in most programs) or T4 (primary screening in some North American programs, with TSH reflex testing). An elevated TSH or low T4 on screening triggers confirmatory serum testing (TSH and free T4) and, if confirmed, immediate levothyroxine initiation. Treatment with levothyroxine must begin within the first 2 weeks of life to prevent irreversible neurodevelopmental sequelae. The AAP recommends a starting dose of 10 to 15 mcg/kg/day (substantially higher per kilogram than adult dosing, reflecting the critical importance of rapidly normalizing thyroid hormone levels during the neurodevelopmental window), with a target of normalizing free T4 within 2 weeks and TSH within 1 month of treatment initiation. With early detection and adequate treatment through newborn screening, children with congenital hypothyroidism achieve essentially normal cognitive outcomes, representing a dramatic improvement from the pre-screening era when the condition invariably caused permanent intellectual disability.\n\nKEY LEARNING POINTS:\nUntreated congenital hypothyroidism causes irreversible intellectual disability and growth retardation because thyroid hormone is essential for neuronal migration, myelination, and synaptogenesis during fetal and early postnatal brain development. Universal newborn screening with TSH or T4 measurement at 24 to 48 hours of life is one of the most successful preventive medicine programs, and levothyroxine must be initiated within 2 weeks of birth at 10 to 15 mcg/kg/day to prevent neurologic sequelae. Iodine deficiency remains the leading cause of preventable intellectual disability worldwide."
  },
  {
    "id": 423,
    "categoryId": 4,
    "question": "A female patient has severe hemorrhage during childbirth. Post-partum, she fails to lactate and develops amenorrhea. Diagnosis?",
    "options": [
      "A) Prolactinoma",
      "B) Sheehan's Syndrome (Pituitary Apoplexy)",
      "C) Post-partum Depression",
      "D) PCOS"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Sheehan's Syndrome / Pituitary Apoplexy).\n\nPATHOPHYSIOLOGY:\nSheehan's syndrome is postpartum pituitary necrosis (infarction) resulting from severe hemorrhage and hypovolemic shock during or after delivery. The pituitary gland is uniquely vulnerable to ischemic injury during the peripartum period because of physiologic changes that occur during pregnancy. During normal pregnancy, the anterior pituitary undergoes marked hyperplasia, increasing in size by approximately 120 to 136% (primarily due to prolactin-secreting lactotroph proliferation driven by estrogen stimulation), effectively doubling the gland's volume. This enlargement compresses the pituitary against the rigid boundaries of the sella turcica, and the gland's blood supply, which is derived from the low-pressure hypothalamic-hypophyseal portal venous system rather than direct arterial supply, becomes insufficient to support the expanded tissue mass under conditions of systemic hypotension. When severe postpartum hemorrhage causes hypovolemic shock, the combination of increased metabolic demand (from the hyperplastic gland), reduced perfusion pressure (from systemic hypotension), and vasospasm (from hemorrhage-induced disseminated intravascular coagulation and sympathetic vasoconstriction) produces ischemic infarction of the anterior pituitary. The posterior pituitary is typically spared because it receives direct arterial blood supply from the inferior hypophyseal arteries rather than depending on the portal system per Harrison's Principles of Internal Medicine and reviews in the Journal of Clinical Endocrinology and Metabolism.\n\nCLINICAL PRESENTATION:\nThe clinical manifestations of Sheehan's syndrome reflect the sequential loss of anterior pituitary hormone production, with the most acutely symptomatic deficiencies presenting first. Failure of lactation (agalactia) is typically the earliest and most recognizable postpartum sign, resulting from loss of prolactin-secreting lactotrophs. Failure to resume menses (amenorrhea) results from loss of gonadotropin (LH and FSH) secretion, producing hypogonadotropic hypogonadism. Secondary adrenal insufficiency from ACTH deficiency may present acutely with hypotension, fatigue, hypoglycemia, and hyponatremia in the immediate postpartum period, or may present insidiously months to years later as chronic fatigue, weakness, and inability to mount a stress response. Secondary hypothyroidism from TSH deficiency produces fatigue, cold intolerance, weight gain, and constipation, developing over weeks to months. Growth hormone deficiency, while clinically subtle in adults, contributes to fatigue, decreased lean body mass, increased visceral adiposity, and diminished quality of life. In some patients, partial pituitary necrosis produces selective hormone deficiencies that may not become apparent for years or even decades after the inciting hemorrhage, and the diagnosis may be missed unless clinicians maintain a high index of suspicion in women with a history of postpartum hemorrhage.\n\nDIAGNOSIS AND TREATMENT:\nDiagnosis is established by the clinical history of postpartum hemorrhage followed by failure of lactation and amenorrhea, combined with laboratory evidence of anterior pituitary hormone deficiency: low or inappropriately normal pituitary hormones (ACTH, TSH, LH, FSH, prolactin, GH) in the setting of low target gland hormones (cortisol, free T4, estradiol). MRI of the pituitary in chronic Sheehan's syndrome characteristically demonstrates a small, partially empty sella reflecting the atrophic, infarcted gland. Treatment consists of lifelong hormone replacement following the same principles as other causes of hypopituitarism: glucocorticoid replacement (hydrocortisone 15 to 25 mg daily in divided doses, with stress dosing during illness or surgery) must be initiated before thyroid hormone replacement to avoid precipitating adrenal crisis, levothyroxine for secondary hypothyroidism (titrated to free T4 level rather than TSH, since TSH is unreliable in secondary hypothyroidism), and estrogen-progesterone replacement for premenopausal women. Growth hormone replacement may be considered for quality-of-life improvement. Patients require medical alert identification and sick-day steroid education identical to patients with primary adrenal insufficiency.\n\nKEY LEARNING POINTS:\nSheehan's syndrome results from ischemic infarction of the hyperplastic anterior pituitary during severe postpartum hemorrhage, presenting with failure of lactation and amenorrhea as the earliest signs. Glucocorticoid replacement must be initiated before thyroid hormone replacement to prevent adrenal crisis. The diagnosis may be delayed for years when partial pituitary necrosis produces insidious, selective hormone deficiencies in women with a history of postpartum hemorrhage."
  },
  {
    "id": 424,
    "categoryId": 4,
    "question": "In the Hypothalamic-Pituitary-Adrenal (HPA) axis, negative feedback is provided by:",
    "options": [
      "A) ACTH inhibiting the Adrenal",
      "B) Cortisol inhibiting both the Hypothalamus (CRH) and Pituitary (ACTH)",
      "C) Adrenaline inhibiting the Sympathetic nervous system",
      "D) Renin inhibiting Angiotensin"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Cortisol inhibiting both the Hypothalamus CRH and Pituitary ACTH).\n\nPATHOPHYSIOLOGY:\nThe hypothalamic-pituitary-adrenal (HPA) axis is the neuroendocrine system that regulates cortisol production and maintains glucocorticoid homeostasis through a classical endocrine negative feedback loop. The cascade begins in the paraventricular nucleus of the hypothalamus, where corticotropin-releasing hormone (CRH) is synthesized and secreted into the hypothalamic-hypophyseal portal circulation in response to circadian input from the suprachiasmatic nucleus (producing the normal diurnal cortisol rhythm with peak levels in the early morning and nadir at midnight), physiologic stress (infection, trauma, surgery, hypoglycemia), and psychological stress. CRH stimulates corticotroph cells in the anterior pituitary to synthesize and secrete adrenocorticotropic hormone (ACTH), which is cleaved from the proopiomelanocortin (POMC) precursor polypeptide (along with melanocyte-stimulating hormone and beta-endorphin). ACTH travels through the systemic circulation to the adrenal cortex, where it binds to the melanocortin 2 receptor (MC2R) on zona fasciculata cells, activating adenylyl cyclase and stimulating the enzymatic conversion of cholesterol to cortisol through the steroidogenic pathway (cholesterol â†’ pregnenolone â†’ 17-hydroxypregnenolone â†’ 17-hydroxyprogesterone â†’ 11-deoxycortisol â†’ cortisol). Cortisol then provides negative feedback at two levels: it binds to glucocorticoid receptors on hypothalamic CRH neurons, suppressing CRH gene transcription and secretion, and it binds to glucocorticoid receptors on pituitary corticotrophs, suppressing POMC gene transcription and ACTH secretion. This dual-level negative feedback ensures that cortisol production is tightly regulated and prevents excessive glucocorticoid exposure.\n\nCLINICAL SIGNIFICANCE OF HPA AXIS SUPPRESSION:\nThe clinical importance of HPA axis negative feedback is most directly relevant in the management of patients receiving exogenous glucocorticoids. Chronic administration of pharmacologic glucocorticoids (prednisone, dexamethasone, methylprednisolone) at doses exceeding physiologic replacement (equivalent to greater than approximately 7.5 mg prednisone daily, or any dose administered for more than 3 weeks) suppresses hypothalamic CRH and pituitary ACTH production through the same negative feedback mechanism. This sustained ACTH suppression leads to bilateral adrenal cortical atrophy, as the zona fasciculata cells require trophic ACTH stimulation to maintain their mass and steroidogenic enzyme expression. If exogenous glucocorticoids are abruptly discontinued, the suppressed hypothalamus and pituitary cannot rapidly resume adequate CRH and ACTH secretion, and the atrophic adrenal glands cannot produce sufficient cortisol to meet physiologic demands, potentially precipitating acute adrenal crisis (Addisonian crisis) with hypotension, cardiovascular collapse, and death. HPA axis recovery after prolonged glucocorticoid therapy may take 6 to 12 months and requires gradual dose tapering per Endocrine Society guidelines and UpToDate.\n\nCLINICAL APPLICATION:\nPrimary care providers must recognize the risk of HPA axis suppression in any patient receiving chronic glucocorticoid therapy and manage discontinuation carefully. Risk factors for clinically significant adrenal suppression include total daily dose (higher doses suppress more rapidly), duration of therapy (risk increases substantially after 3 weeks), dosing frequency (multiple daily doses suppress more than single morning doses, which more closely mimic the physiologic cortisol peak), and potency (dexamethasone and betamethasone suppress more potently than prednisone or hydrocortisone due to longer half-lives and greater receptor affinity). Glucocorticoid tapering schedules should reduce the dose gradually over weeks to months, with monitoring for symptoms of adrenal insufficiency (fatigue, weakness, hypotension, nausea, myalgia) during the taper. Morning cortisol levels or ACTH stimulation testing can assess HPA axis recovery. Patients who have been on chronic glucocorticoids should receive stress-dose steroids during acute illness, surgery, or trauma until HPA axis recovery is confirmed, as their adrenal glands cannot mount the normal 5 to 10-fold cortisol surge required during physiologic stress. Understanding the HPA axis is also essential for interpreting the diagnostic workup of Cushing's syndrome, where the failure of cortisol to suppress ACTH indicates autonomous cortisol production, and for understanding why secondary adrenal insufficiency (from pituitary ACTH deficiency) preserves aldosterone production (which is RAAS-regulated, not ACTH-dependent).\n\nKEY LEARNING POINTS:\nCortisol provides negative feedback at both the hypothalamus (suppressing CRH) and the pituitary (suppressing ACTH), preventing excessive glucocorticoid production. Exogenous glucocorticoid therapy lasting more than 3 weeks suppresses the HPA axis and causes adrenal atrophy, requiring gradual tapering to prevent adrenal crisis upon discontinuation. HPA axis recovery may take 6 to 12 months, and patients require stress-dose steroids during intercurrent illness until recovery is confirmed."
  },
  {
    "id": 425,
    "categoryId": 4,
    "question": "Syndrome of Inappropriate ADH (SIADH) is a common paraneoplastic syndrome associated with Small Cell Lung Cancer. It causes:",
    "options": [
      "A) Hypernatremia and Dehydration",
      "B) Euvolemic Hyponatremia and concentrated urine",
      "C) Hypokalemia",
      "D) Hypercalcemia"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Euvolemic Hyponatremia and concentrated urine).\n\nPATHOPHYSIOLOGY:\nThe syndrome of inappropriate antidiuretic hormone secretion (SIADH) is the most common cause of euvolemic hyponatremia and results from the persistent, non-physiologic secretion of antidiuretic hormone (ADH, also known as arginine vasopressin) in the absence of normal osmotic or hemodynamic stimuli. Under normal physiology, ADH is released from the posterior pituitary in response to increased plasma osmolality (detected by hypothalamic osmoreceptors) or decreased effective circulating volume (detected by baroreceptors), and it acts on V2 receptors in the renal collecting duct to insert aquaporin-2 water channels, promoting free water reabsorption and concentrating the urine. In SIADH, ADH is secreted inappropriately (either by ectopic tumor production or dysregulated hypothalamic secretion), causing the kidneys to retain free water despite already-low or normal plasma osmolality. The retained water dilutes the serum sodium (dilutional hyponatremia), and the resultant mild volume expansion activates secondary natriuretic mechanisms: increased atrial natriuretic peptide (ANP) secretion, increased renal sodium excretion (from pressure natriuresis and suppressed proximal tubular sodium reabsorption), and suppressed aldosterone (from volume-mediated RAAS suppression). This secondary sodium wasting exacerbates the hyponatremia. Importantly, the patient remains clinically euvolemic (without edema or signs of volume overload) because the water retention is modest (typically 2 to 3 liters) and distributed across both intracellular and extracellular compartments, with the natriuretic response preventing significant extracellular volume expansion.\n\nCLINICAL REASONING:\nThe diagnostic criteria for SIADH, as established by Bartter and Schwartz and endorsed by current Endocrine Society guidelines, require all of the following: serum osmolality less than 275 mOsm/kg (hypoosmolality), urine osmolality greater than 100 mOsm/kg (inappropriately concentrated urine in the setting of low serum osmolality, indicating that ADH is active when it should be suppressed), urine sodium greater than 30 mEq/L (reflecting the secondary natriuresis), clinical euvolemia (absence of edema, ascites, or signs of hypovolemia), and normal thyroid, adrenal, and renal function (these must be excluded because hypothyroidism, adrenal insufficiency, and renal failure can each independently cause hyponatremia). Small cell lung cancer (SCLC) is the most classic association, producing ectopic ADH as a paraneoplastic syndrome in approximately 10 to 15% of SCLC cases. Other malignancies associated with ectopic ADH include head and neck cancers, lymphomas, and mesothelioma. Non-malignant causes are actually more common overall and include central nervous system disorders (stroke, traumatic brain injury, meningitis, subarachnoid hemorrhage), pulmonary diseases (pneumonia, tuberculosis, positive-pressure ventilation), medications (SSRIs, carbamazepine, oxcarbazepine, cyclophosphamide, vincristine, desmopressin, and NSAIDs), and the postoperative state (pain and nausea are potent ADH secretagogues).\n\nTREATMENT:\nManagement depends on symptom severity and acuity. For acute symptomatic hyponatremia with neurologic manifestations (seizures, altered mental status, severe confusion), hypertonic saline (3% NaCl) is administered as an emergency to raise serum sodium by 4 to 6 mEq/L in the first 4 to 6 hours, with a maximum correction of 8 mEq/L in 24 hours to prevent osmotic demyelination syndrome (ODS, formerly central pontine myelinolysis), a devastating complication of overly rapid sodium correction that produces quadriplegia, pseudobulbar palsy, and locked-in syndrome from demyelination of the central pons. For chronic or mild SIADH, first-line treatment is fluid restriction (typically less than 800 mL to 1 liter per day), which limits the substrate for ADH-mediated water retention. If fluid restriction is insufficient or poorly tolerated, options include oral sodium chloride tablets with loop diuretics (furosemide promotes free water excretion by impairing the medullary concentrating gradient), urea (an osmotic diuretic that increases solute-free water excretion), and vasopressin V2 receptor antagonists (vaptans, such as tolvaptan), though tolvaptan carries a risk of hepatotoxicity and overly rapid sodium correction and requires careful monitoring per FDA guidance.\n\nKEY LEARNING POINTS:\nSIADH produces euvolemic hyponatremia with inappropriately concentrated urine (greater than 100 mOsm/kg) and elevated urine sodium (greater than 30 mEq/L) from non-physiologic ADH secretion. Small cell lung cancer is the classic paraneoplastic cause, but medications (especially SSRIs) and CNS disorders are more common overall. Sodium correction must not exceed 8 mEq/L in 24 hours to prevent osmotic demyelination syndrome."
  },
  {
    "id": 426,
    "categoryId": 4,
    "question": "Hypoglycemia Unawareness (loss of warning symptoms like shaking/sweating) in long-standing diabetics is caused by:",
    "options": [
      "A) Beta cell burnout",
      "B) Autonomic Neuropathy and blunted Glucagon/Epinephrine response",
      "C) Insulin resistance",
      "D) Metformin use"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Autonomic Neuropathy and blunted Glucagon/Epinephrine response).\n\nPATHOPHYSIOLOGY:\nHypoglycemia counterregulation is a hierarchical, multi-layered defense system that normally prevents blood glucose from falling to dangerous levels. As glucose drops below approximately 80 mg/dL, the first response is suppression of endogenous insulin secretion from pancreatic beta cells. At approximately 65 to 70 mg/dL, glucagon is released from pancreatic alpha cells, stimulating hepatic glycogenolysis and gluconeogenesis to restore circulating glucose. If glucose continues to fall below approximately 65 mg/dL, epinephrine is released from the adrenal medulla, which augments hepatic glucose output through beta-2 receptor-mediated glycogenolysis, suppresses peripheral glucose utilization, stimulates lipolysis for alternative fuel provision, and produces the autonomic warning symptoms (tremor, palpitations, diaphoresis, anxiety, hunger) that alert the conscious individual to eat. Cortisol and growth hormone provide additional counterregulatory support during prolonged hypoglycemia. In long-standing diabetes, this defense system is progressively compromised at multiple levels, creating a state of defective glucose counterregulation and hypoglycemia unawareness that dramatically increases the risk of severe hypoglycemia.\n\nCLINICAL REASONING:\nTwo critical defects develop in patients with long-standing diabetes per data from Diabetes Care, the NEJM, and Harrison's Principles of Internal Medicine. First, the glucagon response to hypoglycemia is lost within 5 to 10 years of type 1 diabetes diagnosis and is impaired in advanced type 2 diabetes. The mechanism involves loss of the intra-islet insulin-to-glucagon signaling switch: normally, falling insulin from beta cells disinhibits neighboring alpha cells, triggering glucagon release. In type 1 diabetes, where beta cells are destroyed, this paracrine signal is absent, and alpha cells cannot detect hypoglycemia. Second, the epinephrine response to hypoglycemia becomes attenuated through a process termed hypoglycemia-associated autonomic failure (HAAF). Recurrent episodes of hypoglycemia shift the glycemic threshold for epinephrine release downward (from approximately 65 to below 50 mg/dL), such that progressively lower glucose levels are required to trigger the adrenergic response. This threshold shift occurs because recurrent hypoglycemia alters hypothalamic glucose-sensing neurons (particularly ventromedial hypothalamic neurons that express glucokinase as a glucose sensor), increasing their tolerance for low glucose concentrations. Without epinephrine release, the autonomic warning symptoms do not occur, and patients progress directly from normal function to neuroglycopenic symptoms (confusion, slurred speech, incoordination, seizures, loss of consciousness) without any warning to take corrective action. HAAF is a functional, potentially reversible phenomenon: strict avoidance of hypoglycemia for 2 to 3 weeks can partially reverse the threshold shift and restore awareness, a process known as hypoglycemia awareness recovery.\n\nCLINICAL APPLICATION:\nHypoglycemia unawareness affects approximately 25 to 40% of patients with type 1 diabetes and increases the risk of severe hypoglycemia (requiring external assistance) by 6-fold per data from Diabetes Care and the Endocrine Society. Management requires a multifaceted approach. Glycemic targets should be relaxed (ADA recommends higher A1c targets for patients with hypoglycemia unawareness or history of severe hypoglycemia). Continuous glucose monitoring (CGM) with predictive low-glucose alerts is strongly recommended by the ADA 2024 Standards of Care as CGM can warn patients of impending hypoglycemia before neuroglycopenic symptoms impair their ability to self-treat. Automated insulin delivery (hybrid closed-loop) systems, which suspend or reduce insulin delivery in response to predicted or actual low glucose, have dramatically reduced hypoglycemia rates in clinical trials. Structured hypoglycemia avoidance programs (such as Blood Glucose Awareness Training, BGAT) provide behavioral education to improve glucose awareness. Beta-blockers mask the tremor and tachycardia of hypoglycemia (though diaphoresis is preserved) and may worsen unawareness, warranting consideration of alternative antihypertensives in susceptible patients. In refractory cases with recurrent severe hypoglycemia despite optimized management, islet cell transplantation or whole pancreas transplantation may be considered.\n\nKEY LEARNING POINTS:\nHypoglycemia unawareness results from loss of the glucagon counterregulatory response (absent within 5 to 10 years of type 1 diabetes) and attenuation of the epinephrine response through hypoglycemia-associated autonomic failure (HAAF), which shifts the glycemic threshold for symptoms downward with recurrent hypoglycemia. Strict avoidance of hypoglycemia for 2 to 3 weeks can partially restore awareness. CGM with predictive low-glucose alerts and relaxation of glycemic targets are cornerstones of management."
  },
  {
    "id": 427,
    "categoryId": 4,
    "question": "Carcinoid Syndrome (neuroendocrine tumor) presents with flushing, diarrhea, and wheezing. This is due to the secretion of:",
    "options": [
      "A) Dopamine",
      "B) Serotonin (5-HT)",
      "C) Insulin",
      "D) Cortisol"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Serotonin / 5-HT).\n\nPATHOPHYSIOLOGY:\nCarcinoid syndrome is a clinical constellation of symptoms caused by the systemic release of vasoactive substances, predominantly serotonin (5-hydroxytryptamine, 5-HT), from well-differentiated neuroendocrine tumors (NETs) that have metastasized to the liver. Neuroendocrine tumors, most commonly arising from enterochromaffin cells in the small intestine (ileum), synthesize serotonin from tryptophan via the rate-limiting enzyme tryptophan hydroxylase and store it in cytoplasmic dense-core granules along with other bioactive mediators including histamine, bradykinin, prostaglandins, and substance P. A critical concept is that carcinoid syndrome occurs almost exclusively in the setting of hepatic metastases because the liver normally inactivates serotonin and other vasoactive peptides released into the portal circulation through first-pass hepatic metabolism by monoamine oxidase. Primary gastrointestinal NETs, regardless of their size or serotonin production, rarely cause carcinoid syndrome because their venous drainage enters the portal system and serotonin is efficiently metabolized before reaching the systemic circulation. Only when tumor has metastasized to the liver does serotonin gain direct access to the systemic circulation through hepatic venous drainage, bypassing first-pass metabolism. The two exceptions to this rule are bronchial carcinoid tumors and ovarian carcinoid tumors, which drain directly into the systemic venous circulation (pulmonary veins and ovarian veins respectively) and can cause carcinoid syndrome without hepatic metastases.\n\nCLINICAL PRESENTATION:\nThe classic triad of carcinoid syndrome consists of episodic flushing, secretory diarrhea, and bronchospasm, reflecting the diverse physiologic effects of serotonin and co-secreted mediators on different organ systems. Flushing (present in approximately 85% of patients with carcinoid syndrome) typically manifests as sudden, episodic reddening of the face, neck, and upper trunk, lasting seconds to minutes, and may be triggered by emotional stress, alcohol, tyramine-containing foods, exercise, or anesthesia. The flushing is mediated primarily by histamine and bradykinin rather than serotonin itself, and may progress to permanent telangiectasias and a cyanotic hue with chronic disease. Secretory diarrhea (present in approximately 80%) results from serotonin-stimulated intestinal motility (via 5-HT3 and 5-HT4 receptor activation on enteric neurons) and intestinal chloride and water secretion. Bronchospasm (present in approximately 20%) is caused by serotonin, histamine, and bradykinin-mediated bronchial smooth muscle constriction and may present as wheezing mimicking asthma. Carcinoid heart disease (Hedinger syndrome) is a significant late complication affecting 20 to 50% of patients with carcinoid syndrome per data from the NEJM and Harrison's Principles of Internal Medicine. Serotonin stimulates fibroblast proliferation and collagen deposition through 5-HT2B receptor activation on cardiac valve endocardium, producing characteristic fibrous plaque formation on the right-sided heart valves (tricuspid and pulmonic), leading to tricuspid regurgitation and pulmonic stenosis. Left-sided valves are typically spared because serotonin is inactivated by monoamine oxidase in the pulmonary vasculature.\n\nDIAGNOSIS AND TREATMENT:\nDiagnosis is confirmed by measuring 24-hour urinary 5-hydroxyindoleacetic acid (5-HIAA), the primary serotonin metabolite, which is elevated (greater than 25 mg per 24 hours) with a sensitivity and specificity exceeding 90% for carcinoid syndrome. Plasma chromogranin A serves as a general neuroendocrine tumor marker but is less specific than 5-HIAA for serotonin-secreting tumors. Imaging with somatostatin receptor scintigraphy (Octreoscan) or Ga-68 DOTATATE PET/CT localizes somatostatin receptor-expressing tumors with high sensitivity. Treatment of carcinoid syndrome centers on somatostatin analogs (octreotide LAR, lanreotide), which bind to somatostatin receptors on neuroendocrine tumor cells, inhibiting the secretion of serotonin and other bioactive peptides, providing symptomatic relief of flushing and diarrhea in approximately 70% of patients, and demonstrating antiproliferative effects that slow tumor growth per the PROMID and CLARINET trials. Telotristat ethyl, a tryptophan hydroxylase inhibitor that blocks serotonin synthesis, is FDA-approved as an adjunct to somatostatin analogs for patients with inadequately controlled diarrhea. Surgical debulking of hepatic metastases, hepatic artery embolization, and peptide receptor radionuclide therapy (PRRT) with lutetium-177 DOTATATE (Lutathera) are additional treatment modalities.\n\nKEY LEARNING POINTS:\nCarcinoid syndrome occurs almost exclusively with hepatic metastases because the liver normally inactivates serotonin via first-pass metabolism; primary intestinal tumors do not cause systemic symptoms. The classic triad is episodic flushing, secretory diarrhea, and bronchospasm, with carcinoid heart disease (right-sided valve fibrosis) as a major late complication. Diagnosis relies on 24-hour urinary 5-HIAA, and somatostatin analogs are the mainstay of symptomatic and antiproliferative treatment."
  },
  {
    "id": 428,
    "categoryId": 4,
    "question": "Thyroid Storm is a life-threatening crisis. Why are Beta Blockers (Propranolol) a critical first-line treatment?",
    "options": [
      "A) They block Thyroid Peroxidase",
      "B) They block the peripheral conversion of T4 to T3 and blunt the sympathetic overdrive",
      "C) They sedate the patient",
      "D) They lower fever"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (They block the peripheral conversion of T4 to T3 and blunt the sympathetic overdrive).\n\nPATHOPHYSIOLOGY:\nThyroid storm (thyrotoxic crisis) is a life-threatening exacerbation of thyrotoxicosis characterized by fever (often exceeding 104Â°F/40Â°C), severe tachycardia (often exceeding 140 beats per minute, with atrial fibrillation in up to 50% of cases), altered mental status (ranging from agitation and delirium to obtundation and coma), gastrointestinal dysfunction (nausea, vomiting, diarrhea, jaundice), and cardiovascular collapse (high-output heart failure progressing to shock), carrying a mortality rate of 10 to 30% even with treatment per data from Harrison's Principles of Internal Medicine and the ATA. The clinical severity of thyroid storm exceeds what would be expected from thyroid hormone levels alone (which may not be substantially higher than in uncomplicated thyrotoxicosis), suggesting that additional factors such as increased adrenergic receptor sensitivity, rapid changes in thyroid hormone levels, and the precipitating illness itself contribute to the decompensated state. Precipitants include infection, surgery, trauma, radioactive iodine therapy, iodinated contrast administration, cessation of antithyroid medications, and diabetic ketoacidosis. The Burch-Wartofsky Point Scale provides a clinical scoring system for diagnosing thyroid storm based on temperature, central nervous system effects, gastrointestinal-hepatic dysfunction, cardiovascular parameters, and presence of a precipitating event, with a score of 45 or greater suggesting thyroid storm.\n\nCLINICAL REASONING:\nPropranolol occupies a unique position in thyroid storm management because it provides a dual therapeutic mechanism that no other beta-blocker can fully replicate. First, propranolol is a nonselective beta-adrenergic antagonist that blocks beta-1 receptors in the heart (reducing heart rate, contractility, and myocardial oxygen demand) and beta-2 receptors peripherally (reducing tremor, anxiety, and diaphoresis). Thyroid hormone excess increases the density and sensitivity of beta-adrenergic receptors on cardiac and other tissues, producing a state of catecholamine hypersensitivity even without elevated catecholamine levels. Beta-blockade directly counteracts this adrenergic amplification. Second, propranolol at high doses (greater than 160 mg daily) inhibits the peripheral conversion of the prohormone thyroxine (T4) to the metabolically active triiodothyronine (T3) by blocking type 1 iodothyronine deiodinase. Since T3 is approximately 3 to 5 times more potent than T4 at binding nuclear thyroid hormone receptors and driving genomic transcription, reducing peripheral T3 production directly attenuates the hormonal excess. This dual mechanism, combining adrenergic blockade with reduction of active thyroid hormone, makes propranolol specifically preferred over cardioselective beta-blockers (atenolol, metoprolol) that only provide adrenergic blockade without affecting T4-to-T3 conversion.\n\nTREATMENT CONTEXT:\nThyroid storm management requires a multimodal pharmacologic approach administered in a specific temporal sequence, with each agent targeting a different aspect of thyroid hormone excess. Propranolol (60 to 80 mg orally every 4 to 6 hours, or 0.5 to 1 mg IV slowly with cardiac monitoring in critically ill patients) is initiated first for immediate symptom control. If beta-blockers are contraindicated (decompensated heart failure, severe bronchospasm), short-acting esmolol IV or the calcium channel blocker diltiazem may be substituted, though these lack the T4-to-T3 conversion inhibition. Thionamide antithyroid drugs (PTU is preferred over methimazole in thyroid storm because PTU also inhibits peripheral T4-to-T3 conversion at high doses, providing a complementary mechanism to propranolol) are administered to block new thyroid hormone synthesis. Inorganic iodide (Lugol's solution or saturated solution of potassium iodide) is administered at least 1 hour after the thionamide to block thyroid hormone release through the Wolff-Chaikoff effect (administering iodide before the thionamide would provide substrate for new hormone synthesis, worsening the crisis). Glucocorticoids (hydrocortisone 100 mg IV every 8 hours or dexamethasone 2 mg IV every 6 hours) are given to inhibit peripheral T4-to-T3 conversion, provide adrenal support (relative adrenal insufficiency may occur in the hypermetabolic state), and address potential concurrent autoimmune adrenal insufficiency. Supportive care includes aggressive cooling for hyperthermia (avoiding aspirin, which displaces thyroid hormone from binding proteins and increases free hormone levels), volume resuscitation, electrolyte correction, and treatment of the precipitating event.\n\nKEY LEARNING POINTS:\nPropranolol is preferred over other beta-blockers in thyroid storm because it provides dual benefit: beta-adrenergic blockade to control sympathetic overdrive and inhibition of peripheral T4-to-T3 conversion at high doses. Thyroid storm treatment requires a specific temporal sequence of propranolol, then thionamide (PTU preferred), then iodide given at least 1 hour after the thionamide, plus glucocorticoids. Aspirin must be avoided as it displaces thyroid hormone from binding proteins, increasing free hormone levels."
  },
  {
    "id": 429,
    "categoryId": 4,
    "question": "Acromegaly (Growth Hormone excess in adults) is often diagnosed late. Besides coarsening facial features, a key neurologic symptom is:",
    "options": [
      "A) Carpal Tunnel Syndrome",
      "B) Foot drop",
      "C) Sciatica",
      "D) Hearing loss"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Carpal Tunnel Syndrome).\n\nPATHOPHYSIOLOGY:\nAcromegaly is a chronic, insidious disorder of growth hormone (GH) excess in adults, most commonly caused by a GH-secreting pituitary somatotroph adenoma (present in greater than 95% of cases), with rare ectopic sources of GHRH or GH. Because GH excess occurs after epiphyseal growth plate closure, it does not produce increased linear height (as it would in children, causing gigantism) but instead drives acral and soft tissue overgrowth through insulin-like growth factor 1 (IGF-1), the primary mediator of GH's peripheral effects. IGF-1, produced predominantly by the liver in response to GH stimulation, promotes the proliferation of periosteal bone, cartilage, connective tissue, and soft tissue throughout the body. The resulting changes develop so gradually that they are often not recognized by patients or family members, leading to an average diagnostic delay of 7 to 10 years from symptom onset per data from the Endocrine Society and JAMA. Carpal tunnel syndrome is one of the most common early manifestations of acromegaly, occurring in approximately 20 to 65% of patients per Harrison's Principles of Internal Medicine and UpToDate. The mechanism involves GH and IGF-1-mediated hypertrophy of the transverse carpal ligament, peritendinous connective tissue, and synovial tissue within the rigid carpal tunnel, along with edema from increased extracellular fluid volume, all of which compress the median nerve as it traverses the carpal tunnel beneath the flexor retinaculum.\n\nCLINICAL PRESENTATION:\nThe clinical features of acromegaly reflect widespread soft tissue and bony overgrowth. Progressive enlargement of the hands (increasing ring size) and feet (increasing shoe size) are among the earliest and most characteristic features. Facial changes include frontal bossing, prognathism (mandibular overgrowth producing an underbite), widening of the nose, thickening of the lips, and macroglossia (tongue enlargement contributing to obstructive sleep apnea, which affects up to 70% of acromegaly patients). Skin changes include thickening, coarsening, and hyperhidrosis (excessive sweating from sweat gland hypertrophy). Arthropathy from cartilage and periosteal overgrowth affects large joints, particularly the knees, hips, and shoulders. Beyond these structural changes, GH excess produces significant metabolic consequences: insulin resistance and glucose intolerance or diabetes mellitus (from GH's counter-regulatory anti-insulin effects) occur in up to 50% of patients, hypertension from sodium retention and vascular smooth muscle hypertrophy, cardiomyopathy (biventricular hypertrophy with diastolic dysfunction progressing to systolic failure), and increased risk of colorectal polyps and colorectal cancer (from the mitogenic effects of elevated IGF-1). These cardiovascular and metabolic complications are the primary drivers of the 2 to 3-fold increased mortality associated with untreated acromegaly per data from the Journal of Clinical Endocrinology and Metabolism.\n\nDIAGNOSIS AND TREATMENT:\nScreening begins with measurement of serum IGF-1, which reflects integrated 24-hour GH secretion and is elevated in virtually all patients with active acromegaly. Because GH is secreted in pulsatile fashion with wide normal variation, a random GH level is unreliable for diagnosis. Confirmation requires an oral glucose tolerance test (OGTT): in normal individuals, a 75-gram glucose load suppresses GH below 0.4 ng/mL (on ultrasensitive assays), while in acromegaly, GH fails to suppress or paradoxically rises. MRI of the pituitary identifies the adenoma, which is a macroadenoma in approximately 70% of cases at diagnosis due to the delayed recognition. First-line treatment is transsphenoidal surgical resection of the adenoma, with biochemical remission rates of 80 to 90% for microadenomas and 40 to 60% for macroadenomas in experienced centers. For patients with persistent disease after surgery, medical therapy with somatostatin analogs (octreotide LAR, lanreotide, pasireotide LAR), the GH receptor antagonist pegvisomant, or dopamine agonists (cabergoline, effective in a minority of patients with mild GH elevation) is employed. Radiation therapy (stereotactic radiosurgery) is reserved for refractory cases. Colonoscopy screening for colorectal neoplasia is recommended at diagnosis and periodically thereafter given the increased polyp and cancer risk.\n\nKEY LEARNING POINTS:\nCarpal tunnel syndrome occurs in 20 to 65% of acromegaly patients due to GH and IGF-1-mediated soft tissue and ligament hypertrophy within the carpal tunnel compressing the median nerve. New-onset carpal tunnel with increasing ring or shoe size should prompt screening with IGF-1 and oral glucose tolerance test. Acromegaly has an average diagnostic delay of 7 to 10 years and carries 2 to 3-fold increased mortality primarily from cardiovascular disease, requiring colonoscopy screening for colorectal neoplasia."
  },
  {
    "id": 430,
    "categoryId": 4,
    "question": "In an elderly patient, 'Apathetic Hyperthyroidism' presents differently than classic Graves. Symptoms include:",
    "options": [
      "A) Hyperactivity and Tremor",
      "B) Lethargy, Depression, and Atrial Fibrillation",
      "C) Weight gain",
      "D) Constipation"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Lethargy, Depression, and Atrial Fibrillation).\n\nPATHOPHYSIOLOGY:\nApathetic hyperthyroidism (also termed apathetic thyrotoxicosis or masked thyrotoxicosis) is an atypical clinical presentation of hyperthyroidism occurring predominantly in elderly patients in which the classic hyperadrenergic manifestations of thyrotoxicosis are absent or minimal, replaced instead by symptoms that paradoxically suggest hypothyroidism or depression. The pathophysiology underlying this atypical presentation is not completely understood but appears to involve age-related changes in adrenergic receptor biology. With advancing age, there is progressive decline in beta-adrenergic receptor density and responsiveness in the heart and peripheral tissues, reduced sympathetic nervous system tone, and decreased catecholamine sensitivity per research reviewed in Harrison's Principles of Internal Medicine and the Endocrine Society. Consequently, the amplification of adrenergic signaling that produces the classic hyperkinetic presentation in younger patients (anxiety, tremor, hyperreflexia, heat intolerance, increased appetite with weight loss) does not occur or is significantly attenuated in elderly patients. Instead, the dominant clinical features reflect the direct metabolic effects of thyroid hormone excess on the heart (atrial fibrillation from shortened atrial refractory periods), skeletal muscle (proximal myopathy producing weakness and difficulty rising from chairs), the gastrointestinal tract (weight loss from increased metabolic rate), and the central nervous system (depression, apathy, and cognitive decline from direct effects of thyroid hormone excess on neurotransmitter systems). The paradoxical depression and apathy may result from thyroid hormone-mediated depletion of central serotonin stores and alteration of dopaminergic signaling.\n\nCLINICAL PRESENTATION:\nThe classic presentation of apathetic hyperthyroidism, first described by Lahey in 1931, includes lethargy and psychomotor slowing (rather than agitation), depression and withdrawal (rather than anxiety), weight loss with anorexia (rather than weight loss with increased appetite), proximal muscle weakness and wasting, constipation (rather than hyperdefecation or diarrhea in some cases), and cardiovascular manifestations that may dominate the clinical picture. Atrial fibrillation is present in approximately 25 to 40% of elderly patients with hyperthyroidism compared to approximately 10 to 15% of younger hyperthyroid patients, and it may be the sole presenting manifestation per data from UpToDate and JAMA Internal Medicine. Heart failure (both high-output failure from increased cardiac workload and rate-related cardiomyopathy from tachyarrhythmia) can develop, particularly in patients with pre-existing cardiac disease. Other features include unexplained weight loss that may trigger an extensive malignancy workup before the thyroid is considered, cognitive impairment that may be attributed to dementia, and failure to thrive. The absence of expected hyperadrenergic features frequently delays diagnosis: studies have shown that the average duration of hyperthyroidism symptoms before diagnosis is significantly longer in elderly patients than in younger patients.\n\nCLINICAL APPLICATION:\nThe critical clinical teaching point is that TSH should be checked in every elderly patient presenting with unexplained weight loss, new-onset atrial fibrillation (approximately 3 to 5% of new AF in the elderly is caused by hyperthyroidism), treatment-resistant depression, unexplained heart failure, apathy or cognitive decline, proximal muscle weakness, or general failure to thrive. A suppressed TSH (less than 0.1 mIU/L) with elevated free T4 and/or free T3 confirms the diagnosis. In some elderly patients, T3 thyrotoxicosis (elevated free T3 with normal free T4 and suppressed TSH) may be the biochemical pattern, making free T3 measurement essential when TSH is suppressed but free T4 is normal. Treatment considerations in elderly patients include a preference for definitive therapy (radioactive iodine ablation or surgery) over prolonged antithyroid drug use due to lower remission rates in elderly patients, careful initiation of beta-blockers with attention to heart failure and COPD, and awareness that rapid restoration of euthyroidism can unmask or exacerbate angina in patients with underlying coronary artery disease. Pre-treatment with antithyroid drugs to normalize thyroid levels before radioactive iodine therapy reduces the risk of thyroid storm post-treatment. Rate control and anticoagulation for atrial fibrillation should follow standard guidelines, with the recognition that approximately 50 to 60% of thyrotoxicosis-induced AF converts spontaneously to sinus rhythm once euthyroidism is restored.\n\nKEY LEARNING POINTS:\nApathetic hyperthyroidism in elderly patients presents with lethargy, depression, weight loss, and atrial fibrillation rather than the classic hyperadrenergic features, due to age-related decline in beta-adrenergic receptor density and responsiveness. TSH should be checked in every elderly patient with unexplained weight loss, new atrial fibrillation, depression, or failure to thrive. Approximately 50 to 60% of thyrotoxicosis-induced atrial fibrillation converts spontaneously once euthyroidism is restored."
  },
  {
    "id": 431,
    "categoryId": 4,
    "question": "Orthostatic Hypotension in diabetes is a sign of damage to the:",
    "options": [
      "A) Parasympathetic Nervous System",
      "B) Sympathetic Nervous System fibers innervating blood vessels",
      "C) Somatic Motor Nerves",
      "D) Vestibular Nerve"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Sympathetic Nervous System fibers innervating blood vessels).\n\nPATHOPHYSIOLOGY:\nOrthostatic hypotension in diabetes is a manifestation of cardiovascular autonomic neuropathy (CAN), one of the most clinically significant and underdiagnosed complications of long-standing diabetes mellitus. Upon standing, approximately 500 to 700 mL of blood redistributes from the central compartment to the dependent venous capacitance vessels of the lower extremities and splanchnic circulation under the influence of gravity. This transient reduction in venous return and cardiac preload is normally detected within seconds by baroreceptors in the carotid sinus and aortic arch, which relay afferent signals via the glossopharyngeal (CN IX) and vagus (CN X) nerves to the nucleus tractus solitarius in the medulla. The brainstem cardiovascular center responds by increasing sympathetic outflow through efferent sympathetic nerve fibers to vascular smooth muscle (producing arteriolar vasoconstriction and venous venoconstriction that redistribute blood centrally) and to the heart (increasing heart rate and contractility via cardiac sympathetic beta-1 stimulation), while simultaneously withdrawing parasympathetic vagal tone to the sinoatrial node. This integrated baroreceptor reflex normally restores blood pressure within 1 to 2 heartbeats, maintaining cerebral perfusion. In diabetic cardiovascular autonomic neuropathy, chronic hyperglycemia damages the small myelinated and unmyelinated sympathetic nerve fibers through the same pathogenic mechanisms as peripheral neuropathy: polyol pathway activation (sorbitol accumulation causing osmotic nerve damage), advanced glycation end-product formation (impairing axonal transport and structural protein integrity), oxidative stress from mitochondrial superoxide generation, and vasa nervorum microangiopathy causing ischemic nerve injury per Harrison's Principles of Internal Medicine and Diabetes Care.\n\nCLINICAL PRESENTATION:\nOrthostatic hypotension is formally defined as a sustained reduction in systolic blood pressure of at least 20 mmHg or diastolic blood pressure of at least 10 mmHg within 3 minutes of standing from a supine position per the AAN/AAS consensus criteria. Symptoms include lightheadedness, dizziness, presyncope, syncope, visual blurring, neck and shoulder pain (coat-hanger distribution from trapezius and neck muscle ischemia), and weakness upon standing. CAN affects approximately 20% of patients with type 2 diabetes and up to 40% of patients with type 1 diabetes of greater than 20 years duration per data from the ADA and UpToDate. CAN is associated with a markedly increased mortality risk: the DIAD study and meta-analyses published in Diabetes Care demonstrated that CAN carries a relative mortality risk of approximately 3.4-fold compared to diabetic patients without CAN, attributable to increased risk of silent myocardial ischemia, fatal arrhythmias, and sudden cardiac death. Other manifestations of diabetic CAN beyond orthostatic hypotension include resting tachycardia (loss of vagal parasympathetic tone produces a fixed elevated heart rate of 90 to 100 beats per minute that fails to vary with respiration), exercise intolerance (inability to appropriately increase heart rate and cardiac output with exertion), silent myocardial ischemia (loss of cardiac afferent pain fibers eliminates anginal warning), and QT interval prolongation (predisposing to ventricular arrhythmias).\n\nDIAGNOSIS AND TREATMENT:\nScreening for CAN should be performed in all patients with type 2 diabetes at diagnosis and type 1 diabetes after 5 years of disease per the ADA 2024 Standards of Care. Cardiovascular autonomic reflex tests (CARTs) include heart rate variability with deep breathing (the earliest abnormality, detecting parasympathetic damage), the Valsalva ratio, and the orthostatic blood pressure test. Management of orthostatic hypotension involves both non-pharmacologic and pharmacologic approaches. Non-pharmacologic measures include rising slowly from supine to seated to standing positions, adequate hydration (2 to 3 liters daily), increased dietary sodium intake (if not contraindicated by heart failure or hypertension), compression garments (waist-high stockings providing 30 to 40 mmHg), sleeping with the head of the bed elevated 10 to 20 degrees (to reduce nocturnal supine hypertension and natriuresis), and avoiding exacerbating factors (large meals, hot environments, alcohol, rapid postural change). Pharmacologic options for refractory cases include midodrine (an alpha-1 adrenergic agonist that directly constricts arterioles and veins, dosed 2.5 to 10 mg three times daily with the last dose no later than 6 PM to avoid supine hypertension), droxidopa (a synthetic norepinephrine precursor FDA-approved for neurogenic orthostatic hypotension), and fludrocortisone (a mineralocorticoid that expands plasma volume through renal sodium retention, though limited by supine hypertension and hypokalemia).\n\nKEY LEARNING POINTS:\nOrthostatic hypotension in diabetes results from sympathetic vasomotor nerve fiber damage that impairs the baroreceptor-mediated vasoconstrictor reflex upon standing. Cardiovascular autonomic neuropathy affects 20 to 40% of long-standing diabetics and carries a 3.4-fold increased mortality risk from silent ischemia and arrhythmias. Management includes slow positional changes, volume expansion, compression garments, and pharmacotherapy with midodrine or droxidopa for refractory cases."
  },
  {
    "id": 432,
    "categoryId": 4,
    "question": "Multiple Endocrine Neoplasia (MEN 1) is characterized by the '3 Ps'. Which is NOT one of them?",
    "options": [
      "A) Parathyroid hyperplasia",
      "B) Pituitary adenoma",
      "C) Pancreatic neuroendocrine tumors",
      "D) Pheochromocytoma"
    ],
    "correctAnswer": 3,
    "explanation": "CORRECT: D (Pheochromocytoma is NOT a feature of MEN 1).\n\nPATHOPHYSIOLOGY:\nThe multiple endocrine neoplasia (MEN) syndromes are autosomal dominant hereditary cancer predisposition syndromes characterized by the development of tumors in two or more endocrine glands, each caused by germline mutations in specific tumor suppressor or proto-oncogene genes. MEN 1, often remembered by the mnemonic of the three Ps (Parathyroid, Pituitary, Pancreas), is caused by inactivating mutations in the MEN1 gene on chromosome 11q13, which encodes menin, a nuclear protein that functions as a tumor suppressor through regulation of transcription factor activity, histone modification, and DNA repair. Loss of menin function through biallelic inactivation (germline mutation plus somatic loss of heterozygosity, following the Knudson two-hit hypothesis) produces the characteristic triad of primary hyperparathyroidism (present in greater than 95% of patients by age 50, typically multigland parathyroid hyperplasia rather than single adenoma), pancreatic and duodenal neuroendocrine tumors (present in 30 to 80%, including gastrinomas causing Zollinger-Ellison syndrome, insulinomas, non-functioning tumors, and rarely VIPomas or glucagonomas), and anterior pituitary adenomas (present in 15 to 50%, most commonly prolactinomas followed by GH-secreting and ACTH-secreting adenomas) per Harrison's Principles of Internal Medicine and the Endocrine Society.\n\nCLINICAL REASONING:\nPheochromocytoma is characteristic of MEN 2, not MEN 1, which is the key distinction tested in this question. MEN 2 is caused by activating (gain-of-function) mutations in the RET proto-oncogene on chromosome 10q11.2, which encodes a receptor tyrosine kinase expressed in neural crest-derived tissues. MEN 2 is subdivided into two clinical variants. MEN 2A (approximately 95% of MEN 2 cases) is characterized by medullary thyroid carcinoma (MTC, present in virtually 100% of patients, arising from parafollicular C cells), pheochromocytoma (present in approximately 50%, bilateral in up to 65%), and primary hyperparathyroidism (present in 20 to 30%). MEN 2B (approximately 5% of MEN 2 cases) features MTC (often aggressive and early-onset, sometimes appearing in infancy), pheochromocytoma (approximately 50%), mucosal neuromas (bumpy lips and tongue, intestinal ganglioneuromatosis), marfanoid body habitus, and notably does NOT include hyperparathyroidism. The genotype-phenotype correlation in MEN 2 is well established: specific RET codon mutations predict disease severity and guide the timing of prophylactic thyroidectomy. The most common MEN 2A mutation affects codon 634 in exon 11 (highest risk for pheochromocytoma and hyperparathyroidism), while MEN 2B is almost exclusively caused by a codon 918 mutation in exon 16 (M918T), which carries the highest risk for aggressive early-onset MTC and requires thyroidectomy ideally within the first 6 months of life per the ATA guidelines.\n\nCLINICAL APPLICATION:\nGenetic testing for MEN1 or RET mutations should be offered to any patient presenting with two or more endocrine tumors from the MEN spectrum, any patient with MTC at any age (as approximately 25% of MTC is hereditary), first-degree relatives of known MEN mutation carriers, and any child with bilateral pheochromocytoma. In MEN 1 families, screening begins at age 5 to 8 years and includes annual biochemical testing for calcium and PTH (for hyperparathyroidism), prolactin and IGF-1 (for pituitary adenomas), fasting glucose, insulin, gastrin, and chromogranin A (for pancreatic NETs), with periodic abdominal imaging. In MEN 2 families, once a RET mutation is identified, prophylactic total thyroidectomy is performed at an age dictated by the specific mutation risk category to prevent the inevitable development of MTC: within 6 months for highest-risk mutations (MEN 2B, codon 918), by age 5 for high-risk mutations (codon 634), and potentially deferred with surveillance for moderate-risk mutations per ATA MTC guidelines. Annual screening for pheochromocytoma (plasma free metanephrines) and hyperparathyroidism (calcium, PTH) continues lifelong.\n\nKEY LEARNING POINTS:\nMEN 1 (three Ps: Parathyroid, Pituitary, Pancreas) is caused by MEN1 tumor suppressor gene mutations and does NOT include pheochromocytoma. MEN 2 (caused by RET proto-oncogene activating mutations) features medullary thyroid carcinoma, pheochromocytoma, and hyperparathyroidism (MEN 2A) or mucosal neuromas (MEN 2B). Prophylactic thyroidectomy timing in MEN 2 is guided by the specific RET codon mutation risk category per ATA guidelines."
  },
  {
    "id": 433,
    "categoryId": 4,
    "question": "The Pineal Gland secretes Melatonin in response to darkness. It receives signals from the retina via the:",
    "options": [
      "A) Optic Nerve -> Occipital Lobe",
      "B) Suprachiasmatic Nucleus (SCN) of the Hypothalamus",
      "C) Vagus Nerve",
      "D) Thalamus"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Suprachiasmatic Nucleus of the Hypothalamus).\n\nPATHOPHYSIOLOGY:\nMelatonin synthesis by the pineal gland is regulated through a multisynaptic neural pathway that originates in specialized retinal photoreceptors and traverses the suprachiasmatic nucleus (SCN) of the hypothalamus, the body's master circadian pacemaker. The pathway begins with intrinsically photosensitive retinal ganglion cells (ipRGCs), a subset of retinal neurons distinct from the rods and cones used for image-forming vision. These ipRGCs express the photopigment melanopsin, which is maximally sensitive to short-wavelength blue light (approximately 460 to 480 nm), and they project via the retinohypothalamic tract directly to the SCN, a paired cluster of approximately 20,000 neurons located in the anterior hypothalamus directly above the optic chiasm. The SCN functions as the master circadian oscillator, generating endogenous near-24-hour rhythms through a transcription-translation feedback loop involving the clock genes CLOCK, BMAL1, PER, and CRY. Light information from ipRGCs synchronizes (entrains) this molecular clock to the external light-dark cycle. During darkness, the SCN disinhibits a multisynaptic sympathetic pathway that projects from the SCN to the paraventricular nucleus of the hypothalamus, then descends through the intermediolateral cell column of the upper thoracic spinal cord, synapses in the superior cervical ganglion, and sends postganglionic sympathetic fibers to the pineal gland. Norepinephrine released from these sympathetic terminals activates beta-1 and alpha-1 adrenergic receptors on pinealocytes, stimulating the enzyme arylalkylamine N-acetyltransferase (AANAT), the rate-limiting enzyme in melatonin synthesis, which converts serotonin to N-acetylserotonin, subsequently methylated by hydroxyindole-O-methyltransferase (HIOMT) to produce melatonin. During daylight hours, light-stimulated ipRGC activity activates the SCN, which inhibits this sympathetic pathway, suppressing melatonin synthesis.\n\nCLINICAL REASONING:\nMelatonin secretion follows a robust circadian pattern: levels begin to rise approximately 2 hours before habitual bedtime (a phase marker termed dim light melatonin onset, DLMO), peak between 2:00 and 4:00 AM, and decline to low daytime levels by morning. This rhythm serves as the most reliable peripheral biomarker of the central circadian clock phase. Evening and nighttime exposure to blue-enriched light from electronic screens (smartphones, tablets, computers, LED lighting) suppresses melatonin production through melanopsin activation even at relatively low intensities (100 to 200 lux), delaying sleep onset and reducing sleep quality. This has significant clinical implications given the ubiquity of evening screen use. Melatonin production declines substantially with aging (pineal gland calcification and reduced pinealocyte number), which may contribute to age-related sleep disturbances. Totally blind individuals who lack ipRGC-mediated light perception (but may have intact image-forming vision in some cases) cannot entrain their circadian clocks to the light-dark cycle, resulting in non-24-hour sleep-wake disorder (free-running circadian rhythm) with cyclically recurring insomnia and daytime somnolence as their endogenous circadian period drifts relative to the 24-hour day per data from the NEJM and Journal of Clinical Endocrinology and Metabolism.\n\nCLINICAL APPLICATION:\nExogenous melatonin is used clinically for several circadian rhythm disorders. For jet lag disorder, melatonin (0.5 to 5 mg taken at the destination bedtime for 2 to 5 days) has demonstrated efficacy for eastward travel across multiple time zones in a Cochrane systematic review. For delayed sleep-wake phase disorder (common in adolescents and young adults), low-dose melatonin (0.5 to 1 mg) administered 3 to 5 hours before the desired bedtime (timed to coincide with the phase-advance portion of the melatonin phase response curve) can advance circadian timing. For non-24-hour sleep-wake disorder in the totally blind, tasimelteon (Hetlioz), a melatonin receptor agonist (MT1/MT2) with FDA approval specifically for this indication, entrains the free-running circadian rhythm to a 24-hour cycle. For primary insomnia in adults over age 55, prolonged-release melatonin (2 mg, marketed in Europe as Circadin) is approved for short-term use. Ramelteon (Rozerem), an MT1/MT2 melatonin receptor agonist FDA-approved for insomnia characterized by difficulty with sleep onset, is the only prescription insomnia medication with no abuse potential and no DEA scheduling. Importantly, melatonin is not a conventional sedative but rather a chronobiotic signal that shifts circadian timing, and its efficacy depends critically on the timing of administration relative to the circadian phase.\n\nKEY LEARNING POINTS:\nMelatonin synthesis is regulated through a multisynaptic pathway from intrinsically photosensitive retinal ganglion cells to the SCN (master circadian clock) to the pineal gland via sympathetic projections through the superior cervical ganglion. Blue light (460 to 480 nm) from screens suppresses melatonin production via melanopsin activation in ipRGCs. Melatonin is a chronobiotic signal rather than a sedative, and its clinical efficacy depends on timing of administration relative to circadian phase."
  },
  {
    "id": 434,
    "categoryId": 4,
    "question": "Primary Hyperaldosteronism (Conn's Syndrome) causes Hypertension and:",
    "options": [
      "A) Hyperkalemia",
      "B) Hypokalemia and Metabolic Alkalosis",
      "C) Hyponatremia",
      "D) Metabolic Acidosis"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Hypokalemia and Metabolic Alkalosis).\n\nPATHOPHYSIOLOGY:\nPrimary hyperaldosteronism (PA) is the most common cause of secondary hypertension, with a prevalence of approximately 5 to 10% among all hypertensive patients and up to 20% among patients with resistant hypertension per data from the Endocrine Society Clinical Practice Guideline and JAMA. In PA, aldosterone is secreted autonomously from the adrenal zona glomerulosa, independent of its normal regulatory stimulus (angiotensin II), most commonly due to a unilateral aldosterone-producing adenoma (Conn's syndrome, approximately 30 to 40% of cases) or bilateral adrenal hyperplasia (idiopathic hyperaldosteronism, approximately 60 to 70%). Aldosterone binds to the mineralocorticoid receptor on principal cells of the cortical collecting duct, inducing transcription of the epithelial sodium channel (ENaC) on the apical membrane and the basolateral sodium-potassium ATPase. This drives sodium reabsorption from the tubular lumen into the principal cell and then into the peritubular capillary, creating a lumen-negative transepithelial potential difference that provides the electrochemical driving force for potassium secretion through apical ROMK channels and hydrogen ion secretion through intercalated cell H+-ATPase. The net result is sodium retention (expanding extracellular volume and raising blood pressure), potassium wasting (producing hypokalemia), and hydrogen ion loss (producing metabolic alkalosis). The sodium retention also activates the aldosterone escape mechanism: volume expansion triggers ANP release and pressure natriuresis, which prevent edema formation but do not normalize blood pressure because the sustained aldosterone elevation continues to drive sodium reabsorption and potassium secretion.\n\nCLINICAL PRESENTATION:\nPA should be suspected in patients with resistant hypertension (blood pressure above goal despite three antihypertensive agents including a diuretic), hypertension with spontaneous hypokalemia (present in only 9 to 37% of PA patients, making normokalemic PA far more common than classic hypokalemic presentations), hypertension with diuretic-induced hypokalemia that is disproportionate to the diuretic dose, hypertension with adrenal incidentaloma, hypertension with family history of early-onset hypertension or stroke before age 40, and any hypertensive first-degree relative of a patient with PA per the Endocrine Society guideline. The cardiovascular consequences of PA extend beyond the effects of hypertension alone: aldosterone directly promotes myocardial fibrosis, left ventricular hypertrophy, vascular inflammation, and endothelial dysfunction independent of blood pressure, producing excess cardiovascular morbidity (heart failure, atrial fibrillation, stroke, myocardial infarction) compared to age- and blood-pressure-matched essential hypertension per data from the Annals of Internal Medicine and JAMA.\n\nDIAGNOSIS AND TREATMENT:\nThe diagnostic workup follows a three-step approach. Screening is performed with the plasma aldosterone concentration-to-plasma renin activity ratio (ARR): an ARR greater than 30 with a plasma aldosterone concentration greater than 15 ng/dL is a positive screen (renin is suppressed by volume expansion while aldosterone is autonomously elevated). Interfering medications must be managed: spironolactone and eplerenone must be discontinued at least 4 to 6 weeks before testing, while most other antihypertensives should ideally be switched to non-interfering agents (verapamil, hydralazine, prazosin) for accurate results. Confirmatory testing (oral sodium loading test, saline infusion test, or fludrocortisone suppression test) demonstrates that aldosterone fails to suppress appropriately with salt loading, confirming autonomous production. Subtype differentiation distinguishes unilateral adenoma (surgically curable) from bilateral hyperplasia (medical management) through adrenal CT (identifies adenomas greater than 1 cm but may miss smaller adenomas and cannot distinguish functioning from non-functioning nodules) and adrenal venous sampling (AVS), the gold standard for lateralization, which measures aldosterone and cortisol from each adrenal vein to determine whether secretion is unilateral or bilateral. Treatment for unilateral adenoma is laparoscopic adrenalectomy, which cures hypertension in approximately 30 to 60% of patients and improves blood pressure control in virtually all. Treatment for bilateral hyperplasia is lifelong mineralocorticoid receptor antagonist therapy: spironolactone (25 to 100 mg daily, most effective but limited by anti-androgenic side effects including gynecomastia, breast tenderness, and menstrual irregularity) or eplerenone (50 to 200 mg daily in divided doses, fewer anti-androgenic effects but lower potency and higher cost).\n\nKEY LEARNING POINTS:\nPrimary hyperaldosteronism is the most common cause of secondary hypertension (5 to 10% of hypertensives, 20% of resistant hypertension) and produces hypokalemia and metabolic alkalosis through ENaC-mediated sodium reabsorption driving potassium and hydrogen ion secretion. The ARR (aldosterone-to-renin ratio) is the screening test, and adrenal venous sampling is the gold standard for lateralization. Unilateral adenoma is treated surgically, while bilateral hyperplasia is treated with mineralocorticoid receptor antagonists."
  },
  {
    "id": 435,
    "categoryId": 4,
    "question": "Leptin is produced by adipocytes and acts on the Hypothalamus to:",
    "options": [
      "A) Increase hunger",
      "B) Signal satiety (Fullness) and increase energy expenditure",
      "C) Lower body temperature",
      "D) Store fat"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Signal satiety and increase energy expenditure).\n\nPATHOPHYSIOLOGY:\nLeptin is a 16-kilodalton adipokine encoded by the ob gene and secreted by white adipose tissue in direct proportion to adipocyte triglyceride content and total fat mass. It functions as the primary long-term adiposity signal to the central nervous system, communicating the magnitude of peripheral energy reserves to the hypothalamus and thereby regulating appetite, energy expenditure, and neuroendocrine function. Leptin enters the brain through a saturable receptor-mediated transport system at the blood-brain barrier and binds to the long-form leptin receptor (LepR-b) on two functionally opposing neuronal populations in the arcuate nucleus per Harrison's Principles of Internal Medicine and foundational research published in Nature. Leptin activates anorexigenic proopiomelanocortin (POMC) neurons, which release alpha-melanocyte-stimulating hormone that binds melanocortin 4 receptors (MC4R) on downstream neurons in the paraventricular nucleus, suppressing food intake and increasing sympathetic outflow to brown and beige adipose tissue for thermogenesis. Simultaneously, leptin inhibits orexigenic neuropeptide Y (NPY) and agouti-related peptide (AgRP) neurons, which when active stimulate appetite and reduce energy expenditure. The net effect of leptin signaling is therefore dual: suppression of food intake through POMC activation and NPY/AgRP inhibition, and increase in energy expenditure through enhanced sympathetic-mediated thermogenesis and metabolic rate. This elegantly positions leptin as a lipostatic signal: as fat mass increases, leptin rises, reducing appetite and increasing energy expenditure to restore energy balance, and as fat mass decreases, leptin falls, increasing appetite and reducing expenditure to defend energy stores.\n\nCLINICAL REASONING:\nThe clinical importance of leptin extends far beyond appetite regulation. Leptin serves as a metabolic gatekeeper for reproductive function: adequate leptin levels are required for normal GnRH pulsatility and reproductive axis activation, which is why severe caloric restriction and low body fat (as in anorexia nervosa or female athlete triad) produce hypothalamic amenorrhea through leptin deficiency-mediated GnRH suppression. Leptin also regulates immune function, bone metabolism, and thyroid axis activity. Congenital leptin deficiency (extremely rare autosomal recessive ob gene mutations) produces severe early-onset obesity with hyperphagia, hypogonadotropic hypogonadism, and impaired immune function, and these patients respond dramatically to recombinant leptin (metreleptin) replacement. However, common obesity is characterized by leptin resistance (elevated leptin levels with central insensitivity) rather than leptin deficiency, rendering exogenous leptin ineffective as a treatment for typical obesity. The mechanisms of leptin resistance include saturation of blood-brain barrier transport (reducing CNS leptin delivery at high circulating levels), upregulation of SOCS3 (suppressor of cytokine signaling 3) which attenuates intracellular JAK-STAT signaling downstream of the leptin receptor, endoplasmic reticulum stress in hypothalamic neurons, and chronic low-grade hypothalamic inflammation from saturated fatty acids and inflammatory cytokines derived from visceral adiposity.\n\nCLINICAL APPLICATION:\nMetreleptin (Myalept) is FDA-approved for the treatment of generalized lipodystrophy, a rare condition in which absence of adipose tissue produces profound leptin deficiency with severe metabolic consequences including hypertriglyceridemia, hepatic steatosis, and insulin-resistant diabetes. In these patients, leptin replacement normalizes metabolic parameters dramatically. For common obesity, understanding leptin physiology has therapeutic implications through the recognition that weight loss reduces leptin levels, which the hypothalamus interprets as a starvation signal, triggering compensatory increases in appetite and reductions in energy expenditure (adaptive thermogenesis) that promote weight regain. This neurobiological mechanism, rather than lack of willpower, explains the high recidivism rate after behavioral weight loss interventions. GLP-1 receptor agonists (semaglutide, tirzepatide) achieve sustained weight loss in part by activating central satiety pathways in the brainstem and hypothalamus that parallel or bypass the leptin-resistant circuitry.\n\nKEY LEARNING POINTS:\nLeptin is secreted by adipose tissue in proportion to fat mass and signals the hypothalamus to suppress appetite (via POMC activation and NPY/AgRP inhibition) and increase energy expenditure (via sympathetic-mediated thermogenesis). Leptin also serves as a metabolic gatekeeper for reproduction, explaining hypothalamic amenorrhea in states of energy deficit. Common obesity features leptin resistance rather than deficiency, and weight loss-induced leptin decline triggers compensatory hyperphagia and metabolic adaptation that promote weight regain."
  },
  {
    "id": 436,
    "categoryId": 4,
    "question": "Oxytocin is synthesized in the Hypothalamus and released by the Posterior Pituitary. Its two main physical functions are:",
    "options": [
      "A) Milk synthesis and Uterine relaxation",
      "B) Milk ejection (Let-down) and Uterine contraction",
      "C) Water retention and Vasoconstriction",
      "D) Ovulation and Menstruation"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Milk ejection / let-down reflex and uterine contraction).\n\nPATHOPHYSIOLOGY:\nOxytocin is a nine-amino-acid cyclic peptide hormone synthesized primarily by magnocellular neurosecretory neurons in the paraventricular and supraoptic nuclei of the hypothalamus. After synthesis, oxytocin is packaged into neurosecretory granules and transported via axonal projections down the pituitary stalk to the posterior pituitary (neurohypophysis), where it is stored and released into the systemic circulation in response to specific physiologic stimuli. Oxytocin's two primary peripheral functions involve smooth muscle contraction in the myometrium and myoepithelial cells, both mediated through binding to the oxytocin receptor (OXTR), a G-protein-coupled receptor that activates the Gq-phospholipase C pathway, increasing intracellular calcium and triggering smooth muscle contraction per Harrison's Principles of Internal Medicine and Williams Obstetrics.\n\nMILK EJECTION:\nThe milk ejection reflex (let-down reflex) is a classic neuroendocrine reflex arc. Infant suckling stimulates mechanoreceptors in the nipple and areola, transmitting afferent sensory signals via the intercostal nerves to the spinal cord, ascending to the hypothalamic paraventricular and supraoptic nuclei. These neurons respond with pulsatile oxytocin release from the posterior pituitary into the bloodstream. Circulating oxytocin binds to OXTR on myoepithelial cells (specialized contractile cells arranged in a basket-like network surrounding the mammary alveoli) causing them to contract and squeeze milk from the alveolar lumen through the lactiferous ducts to the nipple. This reflex can be conditioned by hearing an infant cry or by psychological anticipation of nursing, and it is inhibited by stress and catecholamines (explaining why anxious mothers may have difficulty with let-down). It is critical to distinguish prolactin's role from oxytocin's role: prolactin (from the anterior pituitary, stimulated by suckling-induced suppression of hypothalamic dopamine) drives milk synthesis and secretion into the alveolar lumen, while oxytocin drives milk ejection from the alveoli through the ducts to the infant. Both are necessary for successful lactation.\n\nUTERINE CONTRACTION:\nOxytocin receptor density on myometrial smooth muscle increases dramatically (up to 200-fold) during the third trimester under the influence of rising estrogen levels, sensitizing the uterus to oxytocin's contractile effects as pregnancy approaches term. During labor, the Ferguson reflex describes the positive feedback loop in which fetal descent and cervical dilation activate stretch receptors in the cervix and lower uterine segment, sending afferent signals via pelvic splanchnic nerves to the hypothalamus, stimulating further oxytocin release, which strengthens uterine contractions, which further dilates the cervix and advances fetal descent. This positive feedback cycle continues with escalating intensity until delivery, at which point removal of the cervical stretch stimulus terminates the reflex. Postpartum, oxytocin continues to drive uterine contraction (involution), compressing the spiral arteries at the placental site and serving as a critical hemostatic mechanism to prevent postpartum hemorrhage.\n\nCLINICAL APPLICATION:\nSynthetic oxytocin (Pitocin) is one of the most commonly used medications in obstetric practice per ACOG. It is administered intravenously for labor induction and augmentation (titrated to produce adequate contractions of appropriate frequency and duration), for active management of the third stage of labor (routinely administered after placental delivery to reduce postpartum hemorrhage per WHO and ACOG guidelines), and for treatment of postpartum hemorrhage due to uterine atony (the most common cause of PPH, accounting for approximately 80% of cases). Oxytocin must be administered with careful monitoring because excessive dosing produces tachysystole (uterine hypercontraction that can compromise fetal oxygenation), and prolonged high-dose infusion carries a risk of water intoxication and hyponatremia due to the structural similarity between oxytocin and ADH, allowing cross-reactivity at the V2 vasopressin receptor in the renal collecting duct at pharmacologic concentrations.\n\nKEY LEARNING POINTS:\nOxytocin's two primary peripheral functions are milk ejection (contraction of mammary myoepithelial cells via the neuroendocrine let-down reflex) and uterine contraction (during labor through the Ferguson reflex positive feedback loop and postpartum for hemostasis). Prolactin produces milk while oxytocin ejects it. Synthetic oxytocin (Pitocin) is routinely used for labor induction, augmentation, and prevention of postpartum hemorrhage, with monitoring for tachysystole and hyponatremia."
  },
  {
    "id": 437,
    "categoryId": 4,
    "question": "A lesion in the Ventromedial Nucleus of the Hypothalamus results in:",
    "options": [
      "A) Anorexia (Starvation)",
      "B) Hyperphagia (Uncontrollable eating) and Obesity",
      "C) Insomnia",
      "D) Loss of temperature regulation"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Hyperphagia and Obesity).\n\nPATHOPHYSIOLOGY:\nThe hypothalamus integrates peripheral metabolic signals (leptin, ghrelin, insulin, glucose, fatty acids) with central neural circuits to regulate energy homeostasis, body weight, and feeding behavior through anatomically distinct nuclei with specialized functions. The ventromedial nucleus of the hypothalamus (VMH) functions as the satiety center: VMH neurons are activated by signals of energy surfeit (rising glucose, insulin, leptin) and project to downstream circuits that inhibit food-seeking behavior and promote energy expenditure. This satiety function was established through classic lesion studies in rodents published in the mid-twentieth century and subsequently confirmed by targeted genetic and optogenetic approaches. Bilateral destruction of the VMH produces dramatic hyperphagia (uncontrollable, voracious eating) and rapid development of severe obesity because the inhibitory brake on feeding behavior is removed. Conversely, the lateral hypothalamic area (LHA) functions as the feeding (hunger) center: LHA neurons contain orexin and melanin-concentrating hormone (MCH) and are activated by signals of energy deficit (falling glucose, ghrelin elevation, leptin decline). Bilateral LHA lesions produce aphagia (refusal to eat) and severe weight loss. The arcuate nucleus, located at the base of the hypothalamus adjacent to the median eminence (where the blood-brain barrier is fenestrated, allowing direct access to circulating metabolic signals), serves as the primary sensory node, housing the opposing NPY/AgRP (orexigenic) and POMC/CART (anorexigenic) neuronal populations that integrate peripheral signals and project to the VMH, LHA, and paraventricular nucleus per Harrison's Principles of Internal Medicine and UpToDate.\n\nCLINICAL REASONING:\nHypothalamic obesity in clinical practice results from acquired lesions that damage the VMH and surrounding structures, disrupting the satiety circuitry and producing a syndrome of intractable weight gain. The most common cause in children is craniopharyngioma, a benign but locally aggressive embryonal tumor arising from Rathke's pouch remnants in the sellar and suprasellar region. Approximately 50 to 75% of patients with craniopharyngioma develop hypothalamic obesity, either from the tumor itself infiltrating or compressing the VMH or from surgical damage during tumor resection per data from the Journal of Clinical Endocrinology and Metabolism. The obesity is particularly refractory to behavioral and dietary interventions because it results from a fundamental neuroanatomic disruption of the satiety mechanism rather than from behavioral or metabolic factors. The hypothalamic damage also produces defective autonomic regulation of energy expenditure (reduced sympathetic tone to adipose tissue, blunted exercise-induced energy expenditure), hyperinsulinemia (from loss of hypothalamic insulin signaling and vagal hyperactivity driving pancreatic beta-cell secretion), and often concurrent deficiencies in other hypothalamic-pituitary axes (growth hormone deficiency, central hypothyroidism, central adrenal insufficiency, diabetes insipidus).\n\nCLINICAL APPLICATION:\nPrimary care providers should consider hypothalamic pathology in any patient presenting with rapid, unexplained weight gain (particularly in children or adolescents) accompanied by headache, visual field deficits (from optic chiasm compression), polyuria and polydipsia (from diabetes insipidus), growth failure (from growth hormone deficiency), or other signs of pituitary dysfunction. Neuroimaging (MRI of the brain with contrast focusing on the sellar and suprasellar region) is the appropriate initial diagnostic study. Other causes of hypothalamic obesity include surgical or radiation damage from treatment of sellar and suprasellar tumors, infiltrative diseases (sarcoidosis, Langerhans cell histiocytosis), traumatic brain injury, and rare genetic syndromes affecting hypothalamic development (Prader-Willi syndrome, which involves loss of paternally expressed genes on chromosome 15q11-q13 and produces hypothalamic dysfunction with hyperphagia, hypogonadism, growth hormone deficiency, and intellectual disability). Management of hypothalamic obesity is challenging: standard lifestyle interventions typically produce minimal results. GLP-1 receptor agonists and bariatric surgery have shown variable benefit in case series. Optimization of all pituitary hormone replacement (particularly growth hormone, which improves body composition) and treatment of sleep-disordered breathing are important adjunctive measures.\n\nKEY LEARNING POINTS:\nThe ventromedial hypothalamus is the satiety center, and its destruction produces hyperphagia and obesity by removing the inhibitory brake on feeding behavior, while the lateral hypothalamus is the hunger center whose destruction produces aphagia. Craniopharyngioma is the most common cause of hypothalamic obesity in children, producing intractable weight gain refractory to standard interventions. Rapid unexplained weight gain with headache or visual symptoms should prompt neuroimaging and endocrine evaluation for hypothalamic-pituitary pathology."
  },
  {
    "id": 438,
    "categoryId": 4,
    "question": "Secondary Hyperparathyroidism is most commonly seen in:",
    "options": [
      "A) Parathyroid Adenoma",
      "B) Chronic Kidney Disease (CKD)",
      "C) Vitamin D Toxicity",
      "D) Sarcoidosis"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Chronic Kidney Disease).\n\nPATHOPHYSIOLOGY:\nSecondary hyperparathyroidism in chronic kidney disease (CKD) is an adaptive but ultimately maladaptive parathyroid gland response to the progressive derangement of calcium, phosphorus, and vitamin D metabolism that accompanies declining renal function. The pathophysiologic cascade begins with two key consequences of nephron loss. First, the failing kidneys lose the ability to excrete phosphate adequately (phosphate is filtered and reabsorbed, with regulated excretion primarily through proximal tubular secretion via the sodium-phosphate cotransporter NaPi-IIa, modulated by PTH and FGF23). As GFR falls below approximately 40 to 50 mL/min, phosphate retention develops, raising serum phosphorus levels. Second, the diseased kidneys have reduced capacity to convert 25-hydroxyvitamin D (calcidiol) to the biologically active form 1,25-dihydroxyvitamin D (calcitriol) by the enzyme 1-alpha-hydroxylase (CYP27B1) expressed in proximal tubular cells. The resulting calcitriol deficiency impairs intestinal calcium absorption (normally calcitriol upregulates the epithelial calcium channels TRPV5 and TRPV6 and the calcium-binding protein calbindin in the duodenum), producing a tendency toward hypocalcemia. Additionally, elevated phosphorus directly suppresses 1-alpha-hydroxylase activity and binds ionized calcium in the circulation, further reducing free calcium. The parathyroid glands detect low ionized calcium through the calcium-sensing receptor (CaSR) on chief cells and respond by increasing PTH synthesis and secretion to restore calcium homeostasis through three mechanisms: stimulating osteoclastic bone resorption (releasing calcium and phosphorus from hydroxyapatite), increasing renal calcium reabsorption in the distal convoluted tubule, and stimulating renal 1-alpha-hydroxylase (though this effect is progressively limited by declining renal mass).\n\nCLINICAL REASONING:\nFibroblast growth factor 23 (FGF23), secreted by osteocytes in response to phosphorus loading and calcitriol, is now recognized as the earliest compensatory response in CKD mineral metabolism, rising before PTH, phosphorus, or calcium become abnormal per research published in the NEJM and KDIGO guidelines. FGF23 acts on the proximal tubule (through the FGFR1-Klotho co-receptor complex) to promote phosphate excretion and suppress 1-alpha-hydroxylase activity. While FGF23 initially maintains normal serum phosphorus, its suppression of calcitriol production contributes to the cascade leading to secondary hyperparathyroidism. As CKD progresses, the parathyroid glands undergo hyperplasia and eventually develop autonomous secretion (tertiary hyperparathyroidism), with some glands developing monoclonal nodular growth that is resistant to medical suppression. The skeletal consequences of chronic PTH excess in CKD are collectively termed renal osteodystrophy (now classified within the broader framework of CKD-mineral and bone disorder, CKD-MBD): osteitis fibrosa cystica (high-turnover bone disease from excessive osteoclastic resorption with peritrabecular fibrosis, the classic PTH-driven lesion), osteomalacia (low-turnover bone disease from impaired mineralization due to calcitriol deficiency), adynamic bone disease (oversuppressed bone turnover from excessive PTH control), and mixed uremic osteodystrophy. Cardiovascular calcification (coronary artery, cardiac valve, and arterial media calcification) driven by hyperphosphatemia and elevated calcium-phosphorus product represents the most clinically significant consequence of CKD-MBD and is a leading cause of cardiovascular death in dialysis patients.\n\nTREATMENT:\nManagement follows KDIGO 2017 guidelines for CKD-MBD. Dietary phosphorus restriction (800 to 1000 mg daily) is first-line but insufficient alone in advanced CKD. Phosphate binders taken with meals reduce intestinal phosphorus absorption: non-calcium-based binders (sevelamer and lanthanum) are preferred over calcium-based binders (calcium carbonate, calcium acetate) to avoid exacerbating vascular calcification. Active vitamin D analogs (calcitriol or its synthetic analogs paricalcitol and doxercalciferol) suppress PTH by directly inhibiting PTH gene transcription and restoring intestinal calcium absorption, but must be used cautiously to avoid hypercalcemia and hyperphosphatemia. Calcimimetics (cinacalcet, etelcalcetide) are allosteric activators of the calcium-sensing receptor on parathyroid chief cells that increase receptor sensitivity to calcium, reducing PTH secretion without raising calcium or phosphorus levels. The EVOLVE trial (NEJM 2012) of cinacalcet in hemodialysis patients showed a trend toward reduced cardiovascular events and death. Parathyroidectomy (subtotal or total with autotransplantation) is reserved for severe, refractory tertiary hyperparathyroidism with persistently elevated PTH, hypercalcemia, and symptomatic bone disease unresponsive to medical management.\n\nKEY LEARNING POINTS:\nSecondary hyperparathyroidism in CKD results from phosphate retention, reduced 1-alpha-hydroxylation of vitamin D to calcitriol, and consequent hypocalcemia driving compensatory parathyroid hyperplasia and excess PTH secretion. FGF23 is the earliest biomarker to rise in CKD mineral metabolism. Treatment follows KDIGO guidelines using phosphate binders (sevelamer preferred over calcium-based to reduce vascular calcification), active vitamin D analogs, and calcimimetics (cinacalcet) to suppress PTH without raising calcium."
  },
  {
    "id": 439,
    "categoryId": 4,
    "question": "Whipple's Triad is used to diagnose Insulinoma. It consists of:",
    "options": [
      "A) Hyperglycemia, Ketones, Acidosis",
      "B) Hypoglycemia symptoms, Low plasma glucose, Relief of symptoms with glucose",
      "C) Hypertension, Bradycardia, Sweating",
      "D) Polyuria, Polydipsia, Weight loss"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Hypoglycemia symptoms, Low plasma glucose, Relief of symptoms with glucose).\n\nPATHOPHYSIOLOGY:\nWhipple's triad, described by Allen Whipple in 1938, establishes the clinical criteria for diagnosing hypoglycemia as the cause of a patient's symptoms. The triad requires the simultaneous presence of three elements: symptoms consistent with hypoglycemia (autonomic symptoms such as diaphoresis, tremor, palpitations, anxiety, and hunger, or neuroglycopenic symptoms such as confusion, difficulty concentrating, visual changes, slurred speech, seizure, and loss of consciousness), a documented low plasma glucose concentration at the time of symptoms (typically less than 55 mg/dL during a diagnostic evaluation, though this threshold varies by clinical context), and resolution of symptoms upon correction of the low glucose. This triad is essential because the symptoms of hypoglycemia are nonspecific (mimicking anxiety, vasovagal episodes, cardiac arrhythmias, and neurologic disorders), and establishing the temporal concordance between symptoms and documented hypoglycemia prevents misdiagnosis and unnecessary evaluation per UpToDate and Harrison's Principles of Internal Medicine.\n\nCLINICAL REASONING:\nInsulinoma is the most common functional pancreatic neuroendocrine tumor, with an incidence of approximately 1 to 4 per million per year. These tumors arise from pancreatic beta cells and autonomously secrete insulin independent of the normal glucose-mediated feedback suppression, producing episodic hyperinsulinemic hypoglycemia. The hypoglycemia is characteristically fasting-predominant (symptoms typically occur after overnight fast, during exercise, or between meals, though postprandial hypoglycemia can also occur). Approximately 90% of insulinomas are solitary, benign, and less than 2 cm in diameter, and approximately 90% are curable by surgical enucleation. Approximately 5 to 10% are associated with MEN 1 syndrome, where they may be multiple and recurrent. The diagnostic evaluation during a supervised 72-hour fast (the gold standard provocative test) demonstrates Whipple's triad with the critical biochemical pattern of endogenous hyperinsulinism: low plasma glucose (less than 55 mg/dL), inappropriately elevated insulin (greater than or equal to 3 microIU/mL when glucose is low), elevated C-peptide (greater than or equal to 0.6 ng/mL), elevated proinsulin (greater than or equal to 5 pmol/L), and negative sulfonylurea and meglitinide screen. C-peptide measurement is the critical test for differentiating endogenous from exogenous insulin sources: C-peptide is the 31-amino-acid connecting peptide cleaved from proinsulin during endogenous insulin biosynthesis in beta cells, and it is released into the circulation in equimolar amounts with insulin. In insulinoma, both insulin and C-peptide are elevated because the tumor produces endogenous proinsulin. In factitious hypoglycemia from exogenous insulin injection, insulin is elevated but C-peptide is suppressed (because exogenous insulin formulations do not contain C-peptide, and the exogenous insulin suppresses endogenous beta-cell secretion through the normal glucose-mediated feedback). In sulfonylurea-induced hypoglycemia, both insulin and C-peptide are elevated (because sulfonylureas stimulate endogenous insulin secretion), requiring a sulfonylurea drug screen to distinguish from insulinoma.\n\nDIAGNOSIS AND TREATMENT:\nAfter biochemical confirmation of endogenous hyperinsulinism, tumor localization uses a multimodal imaging approach. CT and MRI detect approximately 70 to 80% of insulinomas, with sensitivity improving with thin-slice pancreatic protocol CT. Endoscopic ultrasound (EUS) has the highest sensitivity (approximately 90 to 95%) for detecting small pancreatic lesions and allows fine-needle aspiration for histologic confirmation. If noninvasive imaging is negative, selective arterial calcium stimulation with hepatic venous sampling (a provocative angiographic test in which calcium gluconate is injected sequentially into the gastroduodenal, splenic, and superior mesenteric arteries, and insulin is measured in the hepatic veins to regionalize the insulin source) can localize occult tumors. Surgical resection (enucleation for small, well-encapsulated tumors or pancreatic resection for larger or malignant lesions) is curative in approximately 90% of cases. Medical management for patients who are not surgical candidates or with metastatic disease includes diazoxide (which inhibits insulin secretion by opening pancreatic beta-cell KATP channels and also inhibits peripheral glucose utilization), somatostatin analogs (octreotide, which inhibits insulin secretion via somatostatin receptor activation), and everolimus (an mTOR inhibitor with FDA approval for advanced pancreatic NETs that has shown efficacy in metastatic insulinoma per the RADIANT-3 trial published in the NEJM).\n\nKEY LEARNING POINTS:\nWhipple's triad (hypoglycemic symptoms, documented low glucose, symptom relief with glucose correction) establishes hypoglycemia as the cause of symptoms. C-peptide is the key differentiator: elevated C-peptide indicates endogenous insulin production (insulinoma or sulfonylurea ingestion), while suppressed C-peptide with elevated insulin indicates exogenous insulin administration. Insulinomas are 90% solitary, 90% benign, and 90% curable by surgical resection, with 5 to 10% associated with MEN 1."
  },
  {
    "id": 440,
    "categoryId": 4,
    "question": "Which medication is notorious for causing both Hypothyroidism and Hyperthyroidism due to its high Iodine content?",
    "options": [
      "A) Lisinopril",
      "B) Amiodarone",
      "C) Metformin",
      "D) Lithium"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Amiodarone).\n\nPATHOPHYSIOLOGY:\nAmiodarone is a class III antiarrhythmic drug widely used for the treatment of ventricular and supraventricular tachyarrhythmias, particularly atrial fibrillation. It is notorious for causing thyroid dysfunction, both hypothyroidism and hyperthyroidism, due to its remarkably high iodine content: each 200 mg tablet contains approximately 75 mg of organic iodine (37% of the drug's molecular weight), of which approximately 6 to 9 mg is released daily as free iodine during hepatic deiodination. This represents 20 to 40 times the recommended daily iodine intake (150 mcg), creating a state of chronic iodine excess that profoundly disrupts thyroid physiology. Additionally, amiodarone has structural similarity to thyroid hormone (containing two iodinated aromatic rings connected by an ether bridge, similar to the diiodotyrosine structure of T4) and directly affects thyroid hormone metabolism by inhibiting type 1 and type 2 iodothyronine deiodinases, reducing peripheral conversion of T4 to T3 and producing characteristic early changes in thyroid function tests (elevated T4, reduced T3, transiently elevated TSH) that occur in virtually all patients taking amiodarone and do not necessarily indicate thyroid disease. These pharmacologic effects must be distinguished from true amiodarone-induced thyroid dysfunction, which affects approximately 15 to 20% of patients taking the drug per data from Harrison's Principles of Internal Medicine, UpToDate, and the ATA.\n\nAMIODARONE-INDUCED HYPOTHYROIDISM:\nAmiodarone-induced hypothyroidism (AIH) occurs in approximately 5 to 15% of patients, more commonly in iodine-sufficient regions (such as the United States and Japan) and in patients with pre-existing thyroid autoimmunity (positive anti-TPO antibodies). The mechanism involves the Wolff-Chaikoff effect: the massive iodine load from amiodarone acutely inhibits thyroid hormone synthesis through iodide-mediated suppression of thyroid peroxidase activity and iodide organification. Normal thyroid glands escape from this inhibitory effect within days through downregulation of the sodium-iodide symporter (reducing intracellular iodide concentration). However, in glands with underlying autoimmune thyroiditis or impaired autoregulatory capacity, escape fails and sustained inhibition of hormone synthesis produces clinical hypothyroidism with elevated TSH and low free T4. Treatment is straightforward: levothyroxine replacement at standard doses, and amiodarone can generally be continued if the arrhythmia requires it.\n\nAMIODARONE-INDUCED THYROTOXICOSIS:\nAmiodarone-induced thyrotoxicosis (AIT) occurs in approximately 3 to 5% of patients in iodine-sufficient regions (but up to 10 to 12% in iodine-deficient regions) and is more clinically challenging than AIH. Two distinct types are recognized, and distinguishing between them is critical because their treatments differ fundamentally. Type 1 AIT (iodine-induced hyperthyroidism, Jod-Basedow effect) occurs in patients with pre-existing thyroid pathology (latent Graves' disease, nodular goiter, autonomous thyroid nodules). The massive iodine load provides substrate for excess thyroid hormone synthesis in these already-autonomous or primed glands. The thyroid gland on ultrasound shows nodularity or increased vascularity (positive color flow Doppler), and radioactive iodine uptake may be low-normal or elevated. Treatment targets excess hormone synthesis with thionamides (methimazole). Type 2 AIT (destructive thyroiditis) occurs in patients with previously normal thyroid glands. Amiodarone's direct cytotoxic effect on thyroid follicular cells (from its structural similarity to thyroid hormone and its lipophilic accumulation in thyroid tissue) causes inflammatory destruction of thyroid follicles with release of preformed thyroid hormone into the circulation, analogous to subacute thyroiditis. The thyroid gland on ultrasound shows absent color flow Doppler vascularity, and radioactive iodine uptake is suppressed (because the thyroid is being destroyed, not stimulated). Treatment targets the inflammatory destruction with glucocorticoids (prednisone 40 to 60 mg daily, tapered over 2 to 3 months). Mixed forms (Type 1 plus Type 2 overlap) are common and may require combined therapy. In all cases of AIT, the decision to continue or discontinue amiodarone depends on the severity of the underlying cardiac condition and the availability of alternative antiarrhythmic agents, made in collaboration with cardiology. Amiodarone has an exceptionally long half-life (40 to 55 days) due to its extensive lipophilic tissue distribution, meaning that thyroid dysfunction may persist for months after drug discontinuation.\n\nKEY LEARNING POINTS:\nAmiodarone causes thyroid dysfunction in 15 to 20% of patients through its massive iodine content (75 mg per 200 mg tablet) and direct thyroid cytotoxicity. Hypothyroidism results from failed Wolff-Chaikoff escape and is treated with levothyroxine. Thyrotoxicosis is classified as Type 1 (excess synthesis in pre-existing thyroid disease, treated with thionamides) or Type 2 (destructive thyroiditis in normal glands, treated with glucocorticoids), distinguished by ultrasound Doppler vascularity and clinical context."
  },
  {
    "id": 441,
    "categoryId": 4,
    "question": "The primary neurotransmitter of the Parasympathetic Nervous System (Rest and Digest) is:",
    "options": [
      "A) Norepinephrine",
      "B) Acetylcholine",
      "C) Glutamate",
      "D) Dopamine"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Acetylcholine).\n\nPATHOPHYSIOLOGY:\nThe autonomic nervous system is divided into two functionally opposing branches, the sympathetic (fight-or-flight) and parasympathetic (rest-and-digest) divisions, which work in dynamic balance to regulate visceral organ function, cardiovascular tone, glandular secretion, and gastrointestinal motility. Acetylcholine (ACh) is the primary neurotransmitter of the parasympathetic nervous system at both the preganglionic synapse (where preganglionic fibers synapse on postganglionic neurons in ganglia located near or within target organs) and the postganglionic neuroeffector junction (where postganglionic fibers synapse on target organ cells). This contrasts with the sympathetic nervous system, which uses acetylcholine at the preganglionic synapse but norepinephrine at the postganglionic neuroeffector junction (with the exception of sympathetic cholinergic fibers to sweat glands and the adrenal medulla). ACh exerts its parasympathetic effects through two receptor families with fundamentally different signaling mechanisms. Muscarinic receptors (G-protein-coupled receptors with five subtypes, M1 through M5) mediate the postganglionic parasympathetic effects on target organs: M2 receptors on the sinoatrial and atrioventricular nodes decrease heart rate and conduction velocity through Gi-mediated opening of potassium channels, M3 receptors on bronchial smooth muscle cause bronchoconstriction, M3 receptors on gastrointestinal smooth muscle increase peristalsis and secretion, M3 receptors on the detrusor muscle promote bladder contraction, and M3 receptors on glandular epithelium stimulate salivary, lacrimal, and gastric acid secretion. Nicotinic receptors (ligand-gated ion channels) mediate transmission at all autonomic ganglia (both sympathetic and parasympathetic) and at the neuromuscular junction of somatic motor neurons per Harrison's Principles of Internal Medicine and Goodman and Gilman's Pharmacological Basis of Therapeutics.\n\nCLINICAL REASONING:\nThe parasympathetic effects of acetylcholine are summarized by the mnemonic SLUDGE (Salivation, Lacrimation, Urination, Defecation, Gastrointestinal motility, Emesis), which also describes the clinical presentation of cholinergic excess (organophosphate poisoning, nerve agent exposure, cholinesterase inhibitor overdose). Conversely, anticholinergic (antimuscarinic) medications produce the opposite effects by blocking muscarinic receptors: tachycardia (loss of M2-mediated vagal bradycardia), mydriasis (loss of M3-mediated pupillary constriction), dry mouth (loss of M3-mediated salivary secretion), urinary retention (loss of M3-mediated detrusor contraction), constipation (loss of M3-mediated intestinal motility), decreased sweating, and central effects including confusion, agitation, and hallucinations. The anticholinergic toxidrome is commonly encountered in primary care and emergency medicine from medications including antihistamines (diphenhydramine), tricyclic antidepressants, antipsychotics, overactive bladder medications (oxybutynin, tolterodine), antiparkinsonian agents (benztropine, trihexyphenidyl), and antispasmodics (dicyclomine, hyoscyamine). Elderly patients are particularly susceptible to anticholinergic side effects due to age-related decreases in cholinergic neurotransmission, reduced hepatic and renal drug clearance, and frequent polypharmacy with cumulative anticholinergic burden.\n\nCLINICAL APPLICATION:\nAnticholinergic burden is an increasingly recognized contributor to cognitive decline, falls, and hospitalization in elderly patients. The Anticholinergic Cognitive Burden (ACB) scale and the Beers Criteria (AGS) provide frameworks for assessing cumulative anticholinergic load from multiple medications. A study published in JAMA Internal Medicine demonstrated that higher cumulative anticholinergic exposure was associated with increased dementia risk. Primary care providers should routinely assess anticholinergic burden during medication reconciliation, particularly in elderly patients with cognitive complaints, constipation, urinary retention, or recurrent falls. Clinically important cholinergic drugs include cholinesterase inhibitors (donepezil, rivastigmine, galantamine) used for Alzheimer's disease (which enhance central cholinergic transmission by inhibiting acetylcholinesterase), bethanechol (a muscarinic agonist used for urinary retention), and pilocarpine (a muscarinic agonist used for glaucoma and xerostomia). Organophosphate poisoning (from pesticide exposure or nerve agent attack) produces life-threatening cholinergic excess treated with atropine (a competitive muscarinic antagonist that reverses SLUDGE symptoms) and pralidoxime (which reactivates acetylcholinesterase if administered before irreversible enzyme aging occurs).\n\nKEY LEARNING POINTS:\nAcetylcholine is the primary neurotransmitter at all parasympathetic postganglionic synapses, acting through muscarinic receptors (M2 on the heart causing bradycardia, M3 on smooth muscle and glands causing SLUDGE effects). Anticholinergic medications produce the opposite effects (tachycardia, dry mouth, urinary retention, constipation, confusion) and carry cumulative cognitive risk in elderly patients per the AGS Beers Criteria. Organophosphate poisoning causes cholinergic crisis treated with atropine and pralidoxime."
  },
  {
    "id": 442,
    "categoryId": 4,
    "question": "In Primary Adrenal Insufficiency (Addison's), the patient often has Hyperpigmentation. Why?",
    "options": [
      "A) Deposition of iron in the skin",
      "B) High ACTH levels co-secrete MSH (Melanocyte Stimulating Hormone)",
      "C) Jaundice",
      "D) Autoimmune destruction of melanocytes"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (High ACTH levels co-secrete MSH / Melanocyte Stimulating Hormone).\n\nPATHOPHYSIOLOGY:\nHyperpigmentation in primary adrenal insufficiency (Addison's disease) is directly explained by the biochemistry of the proopiomelanocortin (POMC) precursor peptide and the physiology of the HPA axis negative feedback loop. In primary adrenal insufficiency, the adrenal cortex is destroyed (most commonly by autoimmune adrenalitis in developed countries, accounting for approximately 80 to 90% of cases, followed by infections such as tuberculosis and histoplasmosis, adrenal hemorrhage, and metastatic disease). The resulting cortisol deficiency removes the normal negative feedback on the hypothalamic paraventricular nucleus and anterior pituitary corticotrophs, causing dramatic compensatory increases in CRH and ACTH secretion. ACTH levels may rise 10 to 100-fold above normal in an attempt to stimulate the failing adrenal glands. ACTH is derived from the precursor polypeptide proopiomelanocortin (POMC), a 241-amino-acid protein that is proteolytically cleaved in the anterior pituitary by prohormone convertase 1 (PC1) to produce ACTH, beta-lipotropin, and a joining peptide. ACTH itself contains within its first 13 amino acids the complete sequence of alpha-melanocyte-stimulating hormone (alpha-MSH). At the markedly elevated concentrations present in primary adrenal insufficiency, ACTH directly activates the melanocortin 1 receptor (MC1R) on epidermal melanocytes, the same receptor normally stimulated by alpha-MSH. MC1R activation through the Gs-cAMP-CREB signaling pathway upregulates the transcription factor MITF (microphthalmia-associated transcription factor), which drives expression of tyrosinase and other enzymes in the melanin biosynthetic pathway, increasing eumelanin production and transfer to surrounding keratinocytes per Harrison's Principles of Internal Medicine and the Journal of Clinical Endocrinology and Metabolism.\n\nCLINICAL PRESENTATION:\nThe pattern of hyperpigmentation in Addison's disease is clinically distinctive and provides a valuable diagnostic clue. Pigmentation is most prominent in areas of increased melanocyte density and mechanical friction: sun-exposed skin (face, neck, dorsal hands and forearms), palmar creases (a highly specific finding, as palmar crease darkening does not occur with sun tanning alone), pressure points (knuckles, elbows, knees), friction areas (bra straps, waistband line), areolae, axillae, perineum, and buccal mucosa (dark patches on the inner cheeks and gums). Recent scars also become hyperpigmented, while scars predating the onset of adrenal insufficiency remain their original color. This distribution helps distinguish Addisonian hyperpigmentation from other causes of generalized darkening such as hemochromatosis (which produces a bronze or slate-gray discoloration from iron deposition without mucosal involvement) and ectopic ACTH syndrome (which can produce similar ACTH-mediated pigmentation, though often the acute presentation of ectopic ACTH from small cell lung cancer does not allow sufficient time for clinically apparent pigmentation changes). Additional clinical features of Addison's disease include fatigue, weakness, weight loss, anorexia, orthostatic hypotension (from cortisol and aldosterone deficiency), salt craving (from aldosterone-mediated sodium wasting), hypoglycemia (from impaired gluconeogenesis), and electrolyte abnormalities (hyponatremia, hyperkalemia, non-anion-gap metabolic acidosis from aldosterone deficiency).\n\nCLINICAL APPLICATION:\nThe critical diagnostic distinction is between primary adrenal insufficiency (adrenal gland destruction) and secondary adrenal insufficiency (pituitary ACTH deficiency or suppression from exogenous glucocorticoids). In primary insufficiency, ACTH is markedly elevated (producing hyperpigmentation), aldosterone is deficient (producing hyperkalemia and sodium wasting), and both cortisol and DHEA-S are low. In secondary insufficiency, ACTH is low or inappropriately normal (no hyperpigmentation occurs), aldosterone is preserved (because aldosterone is primarily regulated by the RAAS system rather than ACTH, so hyperkalemia and severe sodium wasting are absent), and cortisol is low. The ACTH stimulation test (cosyntropin test) is the standard diagnostic test: synthetic ACTH (cosyntropin 250 mcg IV) is administered and serum cortisol is measured at 30 and 60 minutes. In primary insufficiency, cortisol fails to rise above 18 mcg/dL because the atrophic or destroyed adrenal glands cannot respond regardless of ACTH stimulation. In secondary insufficiency, chronic ACTH deficiency causes adrenal atrophy, and the atrophic glands may also fail to respond acutely, though prolonged ACTH stimulation over several days can distinguish the two forms. Treatment of primary adrenal insufficiency requires both glucocorticoid replacement (hydrocortisone 15 to 25 mg daily in 2 to 3 divided doses mimicking the normal diurnal cortisol rhythm, with two-thirds given in the morning) and mineralocorticoid replacement (fludrocortisone 0.05 to 0.2 mg daily) per the Endocrine Society Clinical Practice Guideline.\n\nKEY LEARNING POINTS:\nHyperpigmentation in Addison's disease results from markedly elevated ACTH (derived from the POMC precursor that also contains the MSH sequence) activating melanocortin 1 receptors on melanocytes, with characteristic distribution in palmar creases, buccal mucosa, pressure points, and recent scars. Hyperpigmentation is present in primary but absent in secondary adrenal insufficiency, providing a key clinical differentiator. Primary insufficiency requires both glucocorticoid and mineralocorticoid replacement, while secondary insufficiency requires glucocorticoid replacement only."
  },
  {
    "id": 443,
    "categoryId": 1,
    "question": "Somatostatin is the 'Universal Inhibitor'. It is secreted by the Hypothalamus and Pancreatic Delta cells to inhibit:",
    "options": [
      "A) Growth Hormone and Insulin/Glucagon",
      "B) Prolactin only",
      "C) Cortisol",
      "D) Aldosterone"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Growth Hormone and Insulin/Glucagon).\n\nSOMATOSTATIN PHYSIOLOGY:\nSomatostatin (also called somatotropin release-inhibiting factor, SRIF) is a peptide hormone that acts as a universal inhibitory regulator throughout the body per Harrison's Principles of Internal Medicine. It is produced by delta cells of the pancreatic islets, the hypothalamus (where it inhibits anterior pituitary growth hormone secretion), the gastrointestinal mucosa (D cells in the stomach and intestine), and neurons within the central nervous system per UpToDate. In the pancreatic islets, somatostatin is secreted in a paracrine fashion and inhibits both insulin secretion from beta cells and glucagon secretion from alpha cells, serving as a local brake on both glucose-lowering and glucose-raising hormones simultaneously per the Cleveland Clinic.\n\nMECHANISM OF ACTION:\nSomatostatin binds to five G-protein-coupled receptor subtypes (SSTR1 through SSTR5) that inhibit adenylyl cyclase, reduce intracellular cAMP, activate potassium channels to hyperpolarize the cell membrane, and inhibit voltage-gated calcium channels, all of which suppress hormone secretion per Harrison's Principles of Internal Medicine. Beyond the pancreas, somatostatin inhibits thyroid-stimulating hormone (TSH) release from the anterior pituitary, reduces gastric acid secretion, decreases splanchnic blood flow, and slows gastrointestinal motility and absorption per UpToDate.\n\nCLINICAL APPLICATIONS:\nThe synthetic somatostatin analogues octreotide and lanreotide exploit these inhibitory properties therapeutically per the Mayo Clinic. Octreotide is used to treat acromegaly (by suppressing growth hormone), carcinoid syndrome (by suppressing serotonin and other vasoactive peptides from neuroendocrine tumors), variceal bleeding (by reducing splanchnic blood flow and portal venous pressure), and refractory diarrhea per the Cleveland Clinic. In acute variceal hemorrhage, octreotide is administered as an IV infusion alongside endoscopic band ligation as part of initial management per UpToDate.\n\nKEY LEARNING POINTS:\nSomatostatin is the universal inhibitor produced by pancreatic delta cells, hypothalamus, and GI mucosa that suppresses growth hormone, insulin, and glucagon simultaneously. It acts via SSTR receptors to reduce cAMP and calcium-mediated secretion. Octreotide (synthetic analogue) is clinically used for acromegaly, carcinoid syndrome, and variceal bleeding."
  },
  {
    "id": 444,
    "categoryId": 1,
    "question": "In a 'Right Dominant' heart (85% of population), the Posterior Descending Artery (PDA) which supplies the AV Node arises from the:",
    "options": [
      "A) Left Circumflex Artery",
      "B) Right Coronary Artery (RCA)",
      "C) Left Anterior Descending (LAD)",
      "D) Coronary Sinus"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Right Coronary Artery).\n\nPATHOPHYSIOLOGY:\nCoronary dominance is determined by which artery gives rise to the posterior descending artery (PDA), which runs in the posterior interventricular groove and supplies the inferior wall of the heart and the posterior third of the interventricular septum per Harrison's Principles of Internal Medicine. In approximately 85% of the population, the right coronary artery (RCA) gives rise to the PDA, defining a right-dominant circulation per UpToDate. In approximately 8% of individuals, the left circumflex artery gives rise to the PDA (left-dominant), and in 7% both arteries contribute (codominant) per the Cleveland Clinic.\n\nCLINICAL SIGNIFICANCE:\nThe RCA in a right-dominant heart supplies the sinoatrial (SA) node in approximately 60% of people and the atrioventricular (AV) node in approximately 90% via the AV nodal branch, which arises near the PDA origin at the crux of the heart per Harrison's Principles of Internal Medicine. This is why inferior MIs (RCA territory) are frequently complicated by sinus bradycardia and AV conduction blocks (first-degree, second-degree Mobitz I/Wenckebach, or complete heart block) per the Mayo Clinic. The left anterior descending (LAD) artery supplies the anterior wall, anterior septum, and apex, and is called the \"widow-maker\" because proximal LAD occlusion produces a large anterior MI with high mortality per UpToDate.\n\nKEY LEARNING POINTS:\nIn 85% of the population (right-dominant circulation), the PDA arises from the RCA and supplies the inferior wall and AV node. Inferior MI from RCA occlusion commonly causes bradyarrhythmias and AV block because the RCA supplies the AV node in 90% of people. Left dominance (PDA from left circumflex) occurs in approximately 8% of individuals."
  },
  {
    "id": 445,
    "categoryId": 1,
    "question": "The earliest visible lesion of atherosclerosis, often seen even in children, is the:",
    "options": [
      "A) Fibrous Cap",
      "B) Fatty Streak",
      "C) Calcified Plaque",
      "D) Thrombus"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Fatty Streak).\n\nPATHOPHYSIOLOGY:\nThe fatty streak is the earliest visible lesion of atherosclerosis and can be found in the aorta of children as young as age 3 and in coronary arteries by adolescence per Harrison's Principles of Internal Medicine. Fatty streaks are flat or slightly elevated yellow discolorations on the intimal surface of arteries, composed of lipid-laden macrophages (foam cells) and T lymphocytes that have accumulated beneath the endothelium per UpToDate. The process begins when circulating LDL particles infiltrate the arterial intima and become trapped in the extracellular matrix, where they undergo oxidative modification by reactive oxygen species per the Cleveland Clinic.\n\nPROGRESSION OF ATHEROSCLEROSIS:\nOxidized LDL is recognized by scavenger receptors (SR-A, CD36) on macrophages, which internalize the lipid in an unregulated fashion (unlike the tightly regulated LDL receptor), transforming them into lipid-engorged foam cells per Harrison's Principles of Internal Medicine. These foam cells, along with recruited T lymphocytes, constitute the fatty streak. Over years to decades, continued lipid accumulation, smooth muscle cell migration from the media, extracellular matrix deposition, and necrotic core formation transform the fatty streak into a mature atherosclerotic plaque with a fibrous cap per UpToDate. Not all fatty streaks progress to clinically significant plaques, and the factors determining which fatty streaks advance remain an active area of research per the Mayo Clinic.\n\nKEY LEARNING POINTS:\nThe fatty streak is the earliest visible atherosclerotic lesion, composed of subendothelial foam cells (lipid-laden macrophages) and visible in children as young as age 3. It forms when LDL infiltrates the intima, undergoes oxidation, and is engulfed by macrophages via unregulated scavenger receptors. Over decades, fatty streaks can progress to mature plaques with fibrous caps and necrotic lipid cores."
  },
  {
    "id": 446,
    "categoryId": 1,
    "question": "Leriche Syndrome is caused by atherosclerotic occlusion of the distal aorta/iliac arteries. The classic triad of symptoms is:",
    "options": [
      "A) Calf pain, Edema, Varicose veins",
      "B) Buttock/Thigh Claudication, Erectile Dysfunction, Absent Femoral Pulses",
      "C) Arm pain, Syncope, Vertigo",
      "D) Abdominal pain, Bloody stool, Weight loss"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Buttock/Thigh Claudication, Erectile Dysfunction, Absent Femoral Pulses).\n\nPATHOPHYSIOLOGY:\nLeriche syndrome (aortoiliac occlusive disease) results from atherosclerotic occlusion of the distal abdominal aorta and/or bilateral common iliac arteries, obstructing blood flow to the lower extremities and pelvis per Harrison's Principles of Internal Medicine. The classic triad, first described by French surgeon RenÃ© Leriche in 1940, consists of bilateral buttock and thigh claudication (intermittent pain with walking due to ischemia of the gluteal and thigh muscles), erectile dysfunction (from inadequate blood flow through the internal iliac arteries to the penile vasculature), and absent or diminished femoral pulses bilaterally per UpToDate.\n\nCLINICAL PRESENTATION:\nPatients are typically middle-aged male smokers who present with exercise-limiting claudication involving the buttocks, hips, and thighs (more proximal than the calf claudication seen with femoral or popliteal disease) per the Cleveland Clinic. Erectile dysfunction may precede claudication symptoms by months to years and is often the earliest clinical manifestation because the internal iliac circulation is highly sensitive to proximal aortoiliac disease per the Mayo Clinic. Physical examination reveals absent or markedly diminished femoral pulses bilaterally and cool lower extremities per Harrison's Principles of Internal Medicine.\n\nDIAGNOSIS AND TREATMENT:\nCT angiography or MR angiography confirms the diagnosis and defines the extent of disease per UpToDate. Treatment depends on severity: lifestyle modification and supervised exercise for mild symptoms, endovascular therapy (aortoiliac stenting) for moderate disease, and aortobifemoral bypass grafting (the gold standard for durable revascularization) for extensive or severe occlusive disease per the Cleveland Clinic.\n\nKEY LEARNING POINTS:\nLeriche syndrome is the classic triad of bilateral buttock/thigh claudication, erectile dysfunction, and absent femoral pulses from aortoiliac atherosclerotic occlusion. Erectile dysfunction may be the earliest symptom. Aortobifemoral bypass is the gold standard surgical treatment for extensive disease."
  },
  {
    "id": 447,
    "categoryId": 1,
    "question": "Most Acute Coronary Syndromes (Heart Attacks) are caused by:",
    "options": [
      "A) Slow, progressive narrowing of the artery to 100%",
      "B) Rupture of a 'Vulnerable Plaque' (Thin fibrous cap, large lipid core)",
      "C) Embolism from the lungs",
      "D) Vasospasm"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Rupture of a Vulnerable Plaque).\n\nPATHOPHYSIOLOGY:\nThe majority of acute coronary syndromes (approximately 60 to 75%) result from rupture of a \"vulnerable\" (unstable) atherosclerotic plaque rather than from progressive luminal narrowing per Harrison's Principles of Internal Medicine. The vulnerable plaque is characterized by a thin fibrous cap (less than 65 micrometers), a large necrotic lipid core (occupying more than 40% of the plaque volume), abundant inflammatory macrophages that secrete matrix metalloproteinases (MMPs) degrading the structural collagen of the cap, and reduced smooth muscle cell density (fewer cells producing and maintaining the collagen matrix) per UpToDate.\n\nMECHANISM OF RUPTURE:\nWhen the fibrous cap ruptures, the highly thrombogenic lipid core and tissue factor are exposed to circulating blood, triggering the coagulation cascade and platelet aggregation, forming an occlusive or sub-occlusive thrombus per the Cleveland Clinic. Complete thrombotic occlusion produces STEMI, while partial occlusion or distal embolization produces NSTEMI or unstable angina per Harrison's Principles of Internal Medicine. Critically, vulnerable plaques often cause only mild to moderate stenosis (less than 50% luminal narrowing) prior to rupture, which is why many patients experience MI as their first cardiovascular event without prior anginal symptoms, and why angiographic stenosis severity is a poor predictor of which lesions will cause future events per the Mayo Clinic.\n\nCLINICAL IMPLICATION:\nThis pathophysiology underlies the rationale for statin therapy and systemic risk reduction rather than relying solely on revascularization of stenotic lesions. Statins stabilize plaques by increasing fibrous cap thickness, reducing lipid core size, decreasing macrophage infiltration, and lowering MMP activity per UpToDate.\n\nKEY LEARNING POINTS:\nMost acute coronary syndromes result from rupture of vulnerable plaques (thin fibrous cap, large lipid core, abundant macrophages), not from gradual stenotic progression. Vulnerable plaques often cause only mild stenosis before rupture, explaining why MI frequently occurs without prior symptoms. Statins stabilize plaques by thickening the fibrous cap and reducing inflammation."
  },
  {
    "id": 448,
    "categoryId": 1,
    "question": "The 'Circle of Willis' provides collateral blood flow to the brain. Which artery connects the Anterior circulation (Carotids) to the Posterior circulation (Vertebrobasilar)?",
    "options": [
      "A) Anterior Communicating Artery (AComm)",
      "B) Posterior Communicating Artery (PComm)",
      "C) Middle Cerebral Artery (MCA)",
      "D) Basilar Artery"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Posterior Communicating Artery).\n\nANATOMY:\nThe Circle of Willis is an arterial anastomotic ring at the base of the brain that connects the anterior circulation (supplied by the internal carotid arteries) to the posterior circulation (supplied by the vertebral/basilar arteries), providing collateral blood flow that can compensate for occlusion of a major feeding vessel per Harrison's Principles of Internal Medicine. The posterior communicating artery (PComm) is the critical link between these two systems, connecting the internal carotid artery (or its terminal branch, the middle cerebral artery) to the posterior cerebral artery (the terminal branch of the basilar artery) on each side per UpToDate.\n\nCOMPLETE CIRCLE COMPONENTS:\nThe complete Circle of Willis consists of the anterior communicating artery (AComm, connecting the two anterior cerebral arteries across the midline), both anterior cerebral arteries (A1 segments), both internal carotid artery terminations, both posterior communicating arteries (PComms, connecting anterior to posterior circulation), and both posterior cerebral arteries (P1 segments) per the Cleveland Clinic. The AComm connects right to left (anterior to anterior), while the PComm connects anterior to posterior per Harrison's Principles of Internal Medicine.\n\nCLINICAL SIGNIFICANCE:\nA complete and functional Circle of Willis is present in only approximately 25 to 50% of the population, with the remainder having hypoplastic or absent segments (most commonly a hypoplastic PComm or A1 segment) per the Mayo Clinic. Posterior communicating artery aneurysms are a common cause of cranial nerve III (oculomotor) palsy because the PComm runs adjacent to CN III, and an expanding aneurysm compresses the parasympathetic fibers on the outside of the nerve, producing a classic \"down and out\" pupil with mydriasis (dilated, fixed pupil) per UpToDate.\n\nKEY LEARNING POINTS:\nThe posterior communicating artery (PComm) connects the anterior circulation (carotid) to the posterior circulation (vertebrobasilar), providing critical collateral flow. The AComm connects right and left anterior circulations. PComm aneurysms classically cause CN III palsy with a dilated fixed pupil due to anatomic proximity."
  },
  {
    "id": 449,
    "categoryId": 1,
    "question": "An Aortic Dissection typically begins with a tear in which layer of the vessel wall?",
    "options": [
      "A) Tunica Externa (Adventitia)",
      "B) Tunica Media",
      "C) Tunica Intima",
      "D) Vasa Vasorum"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Tunica Intima).\n\nPATHOPHYSIOLOGY:\nAortic dissection begins with a tear in the tunica intima, the innermost layer of the arterial wall per Harrison's Principles of Internal Medicine. This intimal tear allows high-pressure blood from the aortic lumen to enter the tunica media (the muscular/elastic middle layer), where it propagates along the plane of the medial layer, creating a false lumen that separates the intima from the adventitia per UpToDate. The dissection can propagate both anterograde (distally) and retrograde (proximally) from the initial tear site.\n\nPREDISPOSING FACTORS:\nWhile the tear begins in the intima, the underlying pathology is typically cystic medial degeneration (also called cystic medial necrosis), characterized by loss of smooth muscle cells, fragmentation of elastic fibers, and accumulation of mucoid material in the tunica media that weakens its structural integrity per the Cleveland Clinic. Conditions associated with medial degeneration include chronic hypertension (the most common risk factor, present in 70% of cases), connective tissue disorders (Marfan syndrome with fibrillin-1 deficiency, Ehlers-Danlos type IV with type III collagen deficiency), bicuspid aortic valve, Turner syndrome, pregnancy (third trimester), cocaine and amphetamine use, and iatrogenic causes (cardiac surgery, catheterization) per Harrison's Principles of Internal Medicine.\n\nVESSEL WALL LAYERS:\nThe three layers of arterial walls from innermost to outermost are the tunica intima (endothelial cells and subendothelial connective tissue, separated from the media by the internal elastic lamina), the tunica media (smooth muscle cells, elastin, and collagen, which provides structural strength and elasticity), and the tunica adventitia (connective tissue with vasa vasorum, nervi vasorum, and lymphatics) per UpToDate. The vasa vasorum are small blood vessels that supply the outer portion of the media and adventitia of large vessels per the Mayo Clinic.\n\nKEY LEARNING POINTS:\nAortic dissection begins with a tear in the tunica intima that allows blood to enter and dissect along the tunica media. The underlying pathology is cystic medial degeneration (elastic fiber fragmentation and smooth muscle loss). Chronic hypertension is the most common predisposing factor (70% of cases), while connective tissue disorders (Marfan, Ehlers-Danlos IV) cause dissection in younger patients."
  },
  {
    "id": 450,
    "categoryId": 1,
    "question": "A patient complains of dizziness and arm pain when exercising his left arm. BP is 140/80 in the Right arm and 100/60 in the Left. Diagnosis?",
    "options": [
      "A) Aortic Stenosis",
      "B) Subclavian Steal Syndrome",
      "C) Thoracic Outlet Syndrome",
      "D) Raynaud's Phenomenon"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Subclavian Steal Syndrome).\n\nPATHOPHYSIOLOGY:\nSubclavian steal syndrome occurs when a hemodynamically significant stenosis or occlusion of the proximal subclavian artery (proximal to the vertebral artery origin) causes reversal of blood flow in the ipsilateral vertebral artery per Harrison's Principles of Internal Medicine. Normally, blood flows anterograde through the vertebral artery toward the brain. When the proximal subclavian is severely stenosed, the distal subclavian pressure drops below vertebrobasilar pressure, and blood is \"stolen\" from the posterior cerebral circulation by flowing retrograde down the vertebral artery to supply the ipsilateral arm per UpToDate. During arm exercise, increased metabolic demand in the arm muscles further lowers distal subclavian pressure, exacerbating the vertebrobasilar steal and provoking symptoms per the Cleveland Clinic.\n\nCLINICAL PRESENTATION:\nThe hallmark is a greater than 15 to 20 mmHg blood pressure differential between the arms (lower on the affected side) combined with vertebrobasilar insufficiency symptoms (dizziness, vertigo, visual disturbances, syncope) and ipsilateral arm claudication provoked by arm exercise per the Mayo Clinic. In this patient, the left arm BP (100/60) is significantly lower than the right (140/80), indicating left subclavian stenosis. Subclavian steal is more common on the left side because the left subclavian artery arises directly from the aortic arch (longer course, more susceptible to atherosclerosis) while the right subclavian branches from the brachiocephalic trunk per Harrison's Principles of Internal Medicine.\n\nDIAGNOSIS AND TREATMENT:\nDuplex ultrasonography of the vertebral arteries demonstrating retrograde flow is the initial diagnostic study, with CTA or MRA confirming the subclavian stenosis per UpToDate. Symptomatic patients may require endovascular stenting or surgical bypass (carotid-subclavian bypass) per the Cleveland Clinic.\n\nKEY LEARNING POINTS:\nSubclavian steal syndrome results from proximal subclavian stenosis causing retrograde vertebral artery flow that steals blood from the posterior cerebral circulation to supply the arm. The hallmark is arm BP differential greater than 15 to 20 mmHg with vertebrobasilar symptoms (dizziness, vertigo) provoked by arm exercise. It is more common on the left side due to the longer anatomic course of the left subclavian artery."
  },
  {
    "id": 451,
    "categoryId": 1,
    "question": "The primary cell type responsible for synthesizing the collagen 'Fibrous Cap' that stabilizes an atherosclerotic plaque is:",
    "options": [
      "A) Macrophage",
      "B) Vascular Smooth Muscle Cell",
      "C) Endothelial Cell",
      "D) T-Lymphocyte"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Smooth Muscle Cells).\n\nPLAQUE STABILITY:\nThe stability of an atherosclerotic plaque depends critically on the thickness and integrity of its fibrous cap per Harrison's Principles of Internal Medicine. A thick, collagen-rich cap protects against plaque rupture, while a thin cap with a large underlying lipid-necrotic core is vulnerable to mechanical stress and inflammatory degradation per UpToDate. Vascular smooth muscle cells (VSMCs) are the primary cell type responsible for synthesizing the extracellular matrix components of the fibrous cap, including type I and type III collagen, elastin, and proteoglycans per the Cleveland Clinic.\n\nPATHOPHYSIOLOGY:\nIn response to vascular injury and atherogenic stimuli, VSMCs undergo phenotypic switching from a contractile (quiescent) phenotype to a synthetic (proliferative) phenotype per Harrison's Principles of Internal Medicine. Synthetic VSMCs migrate from the tunica media into the intima, where they proliferate and secrete collagen and other matrix proteins that form and maintain the fibrous cap per UpToDate. Transforming growth factor-beta (TGF-beta) and platelet-derived growth factor (PDGF) are key cytokines that stimulate VSMC migration, proliferation, and collagen production per the Mayo Clinic.\n\nPLAQUE VULNERABILITY:\nThe balance between collagen synthesis by VSMCs and collagen degradation by matrix metalloproteinases (MMPs) secreted by activated macrophages determines cap thickness and plaque stability per Harrison's Principles of Internal Medicine. In vulnerable (unstable) plaques, inflammatory macrophages release MMP-1, MMP-2, MMP-9, and cathepsins that degrade collagen faster than VSMCs can replace it, leading to progressive cap thinning per the Cleveland Clinic. Additionally, inflammatory cytokines (interferon-gamma from T-helper cells) directly inhibit VSMC collagen synthesis and promote VSMC apoptosis, further weakening the cap per UpToDate. When the thinned cap ruptures, the thrombogenic lipid core is exposed to flowing blood, triggering acute thrombus formation and acute coronary syndrome per Harrison's Principles of Internal Medicine.\n\nKEY LEARNING POINTS:\nSmooth muscle cells are the primary source of fibrous cap collagen through phenotypic switching from contractile to synthetic state. Plaque vulnerability results from imbalance between VSMC collagen synthesis and MMP-mediated degradation by inflammatory macrophages. Interferon-gamma from T cells inhibits VSMC collagen production and promotes apoptosis, further weakening the cap."
  },
  {
    "id": 452,
    "categoryId": 1,
    "question": "The Superior Mesenteric Artery (SMA) supplies the midgut. It passes OVER which structure, potentially compressing it (SMA Syndrome)?",
    "options": [
      "A) The Stomach",
      "B) The 3rd portion of the Duodenum",
      "C) The Transverse Colon",
      "D) The Aorta"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Jejunum, Ileum, Appendix, Ascending Colon, and proximal 2/3 of Transverse Colon).\n\nEMBRYOLOGIC BASIS:\nThe superior mesenteric artery (SMA) supplies structures derived from the embryonic midgut, which extends from the second part of the duodenum (distal to the ampulla of Vater) through the proximal two-thirds of the transverse colon per Harrison's Principles of Internal Medicine. This territory includes the jejunum, ileum, cecum, appendix, ascending colon, and the proximal transverse colon per UpToDate. The SMA arises from the anterior surface of the abdominal aorta at approximately the L1 vertebral level, just below the celiac trunk, and passes anterior to (over) the third part of the duodenum and the uncinate process of the pancreas per the Cleveland Clinic.\n\nSMA SYNDROME:\nThe anatomic relationship of the SMA passing over the duodenum is clinically significant because compression of the third part of the duodenum between the SMA anteriorly and the aorta posteriorly causes SMA syndrome (Wilkie syndrome), characterized by postprandial epigastric pain, nausea, bilious vomiting, and weight loss per the Mayo Clinic. This occurs when the aortomesenteric angle narrows below 22 to 25 degrees (normal 38 to 65 degrees) or the aortomesenteric distance decreases below 8 mm, most commonly following significant weight loss, spinal surgery with correction of lordosis, or prolonged immobilization per UpToDate.\n\nMESENTERIC ISCHEMIA:\nAcute SMA occlusion (from embolism or thrombosis) produces acute mesenteric ischemia, a surgical emergency with mortality exceeding 60 to 80% if not recognized and treated within 6 to 12 hours per Harrison's Principles of Internal Medicine. The classic presentation is severe periumbilical abdominal pain that is disproportionate to physical examination findings (pain out of proportion to exam), often accompanied by bloody diarrhea as mucosal ischemia progresses to full-thickness bowel infarction per the Cleveland Clinic.\n\nKEY LEARNING POINTS:\nThe SMA supplies midgut-derived structures from the duodenum (distal to ampulla) through the proximal two-thirds of the transverse colon. It passes over the third part of the duodenum, and narrowing of the aortomesenteric angle causes SMA syndrome. Acute SMA occlusion produces mesenteric ischemia with pain out of proportion to exam findings, a surgical emergency with high mortality."
  },
  {
    "id": 453,
    "categoryId": 1,
    "question": "Chronic Venous Insufficiency causes 'Stasis Dermatitis' and ulcers. The underlying pathophysiology is:",
    "options": [
      "A) Arterial blockage",
      "B) Incompetent valves leading to venous hypertension",
      "C) Bacterial infection",
      "D) Lymphatic blockage"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Incompetent Valves Leading to Venous Hypertension).\n\nPATHOPHYSIOLOGY:\nChronic venous insufficiency (CVI) results from incompetence of the venous valves in the lower extremity veins (superficial, deep, or perforating veins), which allows retrograde blood flow (reflux) during standing and walking per Harrison's Principles of Internal Medicine. Normally, the one-way venous valves and the calf muscle pump work together to propel blood from the lower extremities back to the heart against gravity. When valves become incompetent (from prior deep vein thrombosis destroying valve leaflets, primary valve degeneration, or chronic venous dilation), blood refluxes distally, causing sustained venous hypertension in the lower leg per UpToDate.\n\nSTASIS DERMATITIS AND ULCER FORMATION:\nThe sustained venous hypertension transmits abnormally high pressures to the dermal microcirculation, causing capillary distension, increased permeability, extravasation of red blood cells and proteins into the perivascular tissues, and a chronic inflammatory response per the Cleveland Clinic. Hemosiderin deposition from extravasated red cell breakdown produces the characteristic brown discoloration of the medial ankle (hemosiderin staining or brawny edema) per the Mayo Clinic. Lipodermatosclerosis (fibrotic induration of the subcutaneous tissue producing an \"inverted champagne bottle\" leg shape) and venous stasis ulcers (typically located at the medial malleolus, shallow, irregular, with moderate exudate, and relatively painless compared to arterial ulcers) develop from the chronic inflammation and impaired tissue oxygenation per Harrison's Principles of Internal Medicine.\n\nCLINICAL CLASSIFICATION:\nThe CEAP (Clinical-Etiology-Anatomy-Pathophysiology) classification stages CVI from C0 (no visible disease) through C6 (active ulceration) per UpToDate. Management includes compression therapy (the cornerstone treatment, typically 30 to 40 mmHg graduated compression stockings), leg elevation, wound care for ulcers, and endovenous ablation or vein stripping for refractory cases per the Cleveland Clinic.\n\nKEY LEARNING POINTS:\nChronic venous insufficiency results from venous valve incompetence causing reflux and sustained venous hypertension in the lower leg. Hemosiderin deposition, lipodermatosclerosis, and medial malleolar ulcers develop from chronic microcirculatory inflammation. Compression therapy (30 to 40 mmHg) is the cornerstone of treatment."
  },
  {
    "id": 454,
    "categoryId": 1,
    "question": "Abdominal Aortic Aneurysms (AAA) are defined as a dilation > 3.0 cm. At what size is surgical repair typically recommended (in men)?",
    "options": [
      "A) 3.5 cm",
      "B) 4.0 cm",
      "C) 5.5 cm",
      "D) 7.0 cm"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (5.5 cm diameter).\n\nAAA NATURAL HISTORY:\nAbdominal aortic aneurysms are defined as focal dilation of the infrarenal aorta to 3.0 cm or greater (normal diameter approximately 2.0 cm) per Harrison's Principles of Internal Medicine. The risk of rupture increases exponentially with aneurysm diameter, and the decision to pursue elective surgical repair balances rupture risk against operative morbidity and mortality per UpToDate. For men, the generally accepted threshold for elective repair is 5.5 cm, at which point the annual rupture risk (approximately 5 to 10%) exceeds the operative mortality risk (approximately 1 to 5% for open repair, 0.5 to 2% for endovascular repair) per the Cleveland Clinic. For women, repair is typically recommended at 5.0 cm because of a higher rupture rate at any given diameter compared to men per the Mayo Clinic.\n\nRUPTURE RISK BY DIAMETER:\nAneurysms smaller than 4.0 cm carry an annual rupture risk of less than 0.5%, while those between 4.0 and 4.9 cm rupture at approximately 0.5 to 1% per year, and those between 5.0 and 5.9 cm rupture at approximately 5 to 10% per year per UpToDate. Aneurysms 6.0 cm or larger carry an annual rupture risk of 10 to 20% or higher per Harrison's Principles of Internal Medicine. Rapid expansion (greater than 0.5 cm in 6 months or greater than 1.0 cm per year) is also an indication for repair regardless of absolute diameter per the Cleveland Clinic.\n\nSURVEILLANCE AND REPAIR:\nSmall aneurysms (3.0 to 5.4 cm) are managed with surveillance ultrasound at intervals determined by size: every 3 years for 3.0 to 3.9 cm, annually for 4.0 to 4.9 cm, and every 6 months for 5.0 to 5.4 cm per UpToDate. Endovascular aneurysm repair (EVAR) is preferred over open surgical repair when anatomy is suitable, offering lower perioperative mortality but requiring ongoing surveillance for endoleak per the Mayo Clinic. All patients should receive aggressive cardiovascular risk factor modification including smoking cessation, statin therapy, and blood pressure control per Harrison's Principles of Internal Medicine.\n\nKEY LEARNING POINTS:\nElective AAA repair is indicated at 5.5 cm in men and 5.0 cm in women, where annual rupture risk (5 to 10%) exceeds surgical mortality. Rapid expansion (greater than 0.5 cm in 6 months) also warrants repair. EVAR is preferred when anatomically suitable, and smaller aneurysms are managed with size-based surveillance intervals."
  },
  {
    "id": 455,
    "categoryId": 1,
    "question": "A patient has a carotid bruit. Ultrasound shows 80% stenosis of the Internal Carotid. He is asymptomatic. According to the CREST trial and guidelines, management is:",
    "options": [
      "A) Immediate Endarterectomy (CEA)",
      "B) Aggressive Medical Management (Statin/Antiplatelet/BP control) vs CEA",
      "C) Observation only",
      "D) Anticoagulation (Warfarin)"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Medical management with antiplatelet therapy; surgery/stenting for symptomatic stenosis).\n\nASYMPTOMATIC CAROTID STENOSIS:\nThe management of asymptomatic carotid stenosis has evolved significantly as modern medical therapy has improved per Harrison's Principles of Internal Medicine. Current evidence supports optimal medical management (antiplatelet therapy, high-intensity statin, blood pressure control, smoking cessation, and diabetes management) as the primary approach for most patients with asymptomatic carotid stenosis, even at high grades of narrowing per UpToDate. The annual stroke risk with modern best medical therapy for asymptomatic stenosis of 60 to 99% is now estimated at approximately 0.5 to 1% per year, which is substantially lower than the 2% annual rate observed in the landmark ACAS and ACST trials that originally supported prophylactic revascularization per the Cleveland Clinic.\n\nSYMPTOMATIC STENOSIS:\nIn contrast, symptomatic carotid stenosis (defined as stenosis causing ipsilateral TIA or non-disabling stroke within the preceding 6 months) carries a much higher stroke recurrence risk and benefits from revascularization per Harrison's Principles of Internal Medicine. The NASCET trial demonstrated that carotid endarterectomy (CEA) reduced the 2-year stroke risk from 26% to 9% in patients with symptomatic stenosis of 70 to 99% per UpToDate. The CREST trial showed similar outcomes between CEA and carotid artery stenting (CAS), though CEA had lower stroke rates and CAS had lower MI rates, with the combined primary endpoint being equivalent per the Mayo Clinic.\n\nCLINICAL DECISION-MAKING:\nFor selected asymptomatic patients with high-grade stenosis (70% or greater) and high-risk imaging features (echolucent plaque, silent infarcts on MRI, microemboli on transcranial Doppler), revascularization may still be considered if perioperative risk is low (less than 3% combined stroke and death rate) per UpToDate and the Cleveland Clinic. Patient life expectancy should exceed 3 to 5 years to derive benefit from prophylactic intervention per Harrison's Principles of Internal Medicine.\n\nKEY LEARNING POINTS:\nAsymptomatic carotid stenosis is primarily managed with optimized medical therapy (antiplatelet, statin, BP control), as modern medical management reduces annual stroke risk to approximately 0.5 to 1%. Symptomatic stenosis (TIA or stroke within 6 months) benefits from revascularization (CEA or CAS per NASCET and CREST trials). Select asymptomatic patients with high-risk features may benefit from intervention if perioperative risk is low."
  },
  {
    "id": 456,
    "categoryId": 1,
    "question": "Which vein is commonly harvested for CABG (Bypass) surgery?",
    "options": [
      "A) Femoral Vein",
      "B) Great Saphenous Vein",
      "C) Cephalic Vein",
      "D) Jugular Vein"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Great Saphenous Vein).\n\nANATOMY:\nThe great saphenous vein (GSV) is the longest vein in the body, originating at the dorsal venous arch of the foot, coursing anterior to the medial malleolus, ascending along the medial aspect of the leg and thigh, and draining into the femoral vein at the saphenofemoral junction in the groin (approximately 4 cm below and lateral to the pubic tubercle) per Harrison's Principles of Internal Medicine. It is the most commonly harvested venous conduit for coronary artery bypass grafting (CABG) because of its length (allowing multiple grafts from a single harvest), caliber (appropriate size match for coronary arteries), accessibility (superficial location along the medial leg), and expendability (the deep venous system provides adequate lower extremity drainage after harvest) per UpToDate.\n\nSAPHENOUS VEIN VERSUS ARTERIAL GRAFTS:\nWhile the GSV is the most commonly used venous conduit, the left internal mammary artery (LIMA, also called the left internal thoracic artery or LITA) is the gold standard arterial graft due to its superior long-term patency per the Cleveland Clinic. The LIMA-to-LAD graft has a 10-year patency rate exceeding 90%, compared to approximately 50 to 60% for saphenous vein grafts at 10 years per UpToDate. Vein grafts are susceptible to neointimal hyperplasia and accelerated atherosclerosis because veins are not accustomed to arterial pressures and undergo adaptive wall thickening and endothelial damage per Harrison's Principles of Internal Medicine. The radial artery is increasingly used as a second arterial conduit per the Mayo Clinic.\n\nKEY LEARNING POINTS:\nThe great saphenous vein is the most commonly harvested venous conduit for CABG due to its length, caliber, and expendability. However, the LIMA-to-LAD arterial graft has superior long-term patency (greater than 90% at 10 years versus 50 to 60% for vein grafts). Vein graft failure results from neointimal hyperplasia and accelerated atherosclerosis from exposure to arterial pressure."
  },
  {
    "id": 457,
    "categoryId": 1,
    "question": "The Ankle-Brachial Index (ABI) is the ratio of ankle SBP to arm SBP. A value of 0.60 indicates:",
    "options": [
      "A) Normal",
      "B) Mild PAD",
      "C) Moderate PAD",
      "D) Critical Limb Ischemia"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Moderate PAD).\n\nCLINICAL REASONING:\nThe ankle-brachial index (ABI) is the ratio of the highest systolic blood pressure at the ankle (measured at the dorsalis pedis and posterior tibial arteries) to the highest systolic blood pressure in the arms (brachial arteries), providing a simple, noninvasive measure of lower extremity arterial perfusion per Harrison's Principles of Internal Medicine. Normal ABI is 1.0 to 1.4 per UpToDate. The severity of peripheral arterial disease is classified by ABI as follows: borderline (0.91 to 0.99), mild PAD (0.70 to 0.90), moderate PAD (0.40 to 0.69), and severe PAD/critical limb ischemia (less than 0.40) per the Cleveland Clinic. An ABI of 0.60 therefore falls within the moderate PAD category.\n\nPATHOPHYSIOLOGY:\nPeripheral arterial disease results from atherosclerotic narrowing or occlusion of the arteries supplying the lower extremities, most commonly affecting the superficial femoral artery at the adductor hiatus (Hunter canal) per Harrison's Principles of Internal Medicine. Patients with moderate PAD typically experience intermittent claudication (reproducible calf, thigh, or buttock pain with walking that resolves with rest) at shorter walking distances. As disease progresses to severe PAD (ABI less than 0.40), ischemic rest pain and tissue loss (non-healing ulcers, gangrene) develop per the Mayo Clinic.\n\nIMPORTANT CAVEATS:\nABI greater than 1.4 is abnormally elevated and indicates non-compressible calcified arteries (commonly seen in diabetes and end-stage renal disease with medial arterial calcification), which renders the ABI unreliable per UpToDate. In these patients, toe-brachial index (TBI, normal greater than 0.7) is used instead because the digital arteries are less susceptible to calcification per the Cleveland Clinic.\n\nKEY LEARNING POINTS:\nAn ABI of 0.60 indicates moderate PAD (normal 1.0 to 1.4, mild 0.70 to 0.90, moderate 0.40 to 0.69, severe/CLI less than 0.40). The superficial femoral artery at the adductor hiatus is the most common site of PAD. ABI greater than 1.4 indicates non-compressible calcified arteries (diabetes, ESRD), requiring toe-brachial index instead."
  },
  {
    "id": 458,
    "categoryId": 1,
    "question": "Fibromuscular Dysplasia (FMD) is a non-atherosclerotic cause of Renal Artery Stenosis. It typically affects:",
    "options": [
      "A) Elderly men",
      "B) Young females",
      "C) Diabetics",
      "D) Smokers"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Young Females).\n\nPATHOPHYSIOLOGY:\nFibromuscular dysplasia (FMD) is a non-atherosclerotic, non-inflammatory vascular disease that causes abnormal cell growth in the arterial wall, most commonly affecting the renal arteries (60 to 75% of cases) and the extracranial carotid and vertebral arteries (25 to 30%) per Harrison's Principles of Internal Medicine. FMD predominantly affects women (female-to-male ratio of approximately 9:1) and typically presents between the ages of 15 and 50, in sharp contrast to atherosclerotic renal artery stenosis which affects older patients with traditional cardiovascular risk factors per UpToDate.\n\nANGIOGRAPHIC AND PATHOLOGIC CLASSIFICATION:\nThe most common subtype is medial fibroplasia (approximately 80 to 90% of FMD cases), which produces the classic \"string of beads\" appearance on angiography due to alternating areas of stenosis and post-stenotic dilation in the arterial wall per the Cleveland Clinic. Less common subtypes include intimal fibroplasia and perimedial fibroplasia per Harrison's Principles of Internal Medicine. FMD characteristically involves the mid and distal portions of the renal artery (in contrast to atherosclerotic disease, which involves the ostium and proximal renal artery) per UpToDate.\n\nCLINICAL PRESENTATION AND MANAGEMENT:\nRenal artery FMD presents with secondary hypertension (often severe or refractory) in a young woman without traditional cardiovascular risk factors per the Mayo Clinic. Duplex ultrasonography is the initial screening study, with CTA or MRA for definitive imaging. Percutaneous transluminal angioplasty (PTA) without stenting is the treatment of choice for symptomatic renal FMD, with high technical success rates and durable results (unlike atherosclerotic renal artery stenosis, where angioplasty results are less favorable) per UpToDate.\n\nKEY LEARNING POINTS:\nFibromuscular dysplasia predominantly affects young women (9:1 female-to-male ratio) and involves the mid-to-distal renal artery (unlike atherosclerosis, which is ostial/proximal). The classic angiographic finding is a string of beads appearance from medial fibroplasia. Percutaneous angioplasty without stenting is the treatment of choice with excellent outcomes."
  },
  {
    "id": 459,
    "categoryId": 1,
    "question": "Elevated High-Sensitivity C-Reactive Protein (hs-CRP) predicts coronary events because:",
    "options": [
      "A) CRP causes clots directly",
      "B) CRP reflects systemic inflammation, which drives plaque instability",
      "C) CRP lowers LDL",
      "D) CRP is a type of cholesterol"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (CRP Reflects Systemic Inflammation, Which Drives Plaque Instability).\n\nPATHOPHYSIOLOGY:\nHigh-sensitivity C-reactive protein (hs-CRP) is an acute-phase reactant produced primarily by the liver in response to interleukin-6 (IL-6) and other proinflammatory cytokines per Harrison's Principles of Internal Medicine. Atherosclerosis is now understood to be fundamentally an inflammatory disease: inflammatory cells (macrophages, T lymphocytes) are present at every stage from fatty streak formation through plaque rupture, and the degree of systemic inflammation correlates with plaque vulnerability per UpToDate. Elevated hs-CRP serves as a biomarker for this systemic inflammatory burden, reflecting the activity of the inflammatory processes that destabilize atherosclerotic plaques by degrading the fibrous cap through matrix metalloproteinase secretion per the Cleveland Clinic.\n\nCLINICAL APPLICATION:\nhs-CRP levels below 1.0 mg/L indicate low cardiovascular risk, 1.0 to 3.0 mg/L moderate risk, and above 3.0 mg/L high risk per the Mayo Clinic. The JUPITER trial demonstrated that rosuvastatin reduced major cardiovascular events by 44% in patients with elevated hs-CRP (greater than 2.0 mg/L) but normal LDL (less than 130 mg/dL), supporting the concept that inflammation independent of LDL level contributes to cardiovascular risk per Harrison's Principles of Internal Medicine. hs-CRP is listed as a risk-enhancing factor in the 2018 ACC/AHA Guidelines that can help guide statin therapy decisions in borderline and intermediate-risk patients per UpToDate.\n\nKEY LEARNING POINTS:\nElevated hs-CRP reflects systemic inflammation that drives atherosclerotic plaque instability through macrophage-mediated fibrous cap degradation. Levels are stratified as low risk (less than 1.0 mg/L), moderate (1.0 to 3.0), and high risk (greater than 3.0). The JUPITER trial demonstrated cardiovascular benefit of statin therapy in patients with elevated hs-CRP but normal LDL."
  },
  {
    "id": 460,
    "categoryId": 1,
    "question": "Raynaud's Phenomenon involves vasospasm of the digital arteries. The color change sequence is:",
    "options": [
      "A) Red -> White -> Blue",
      "B) White (Ischemia) -> Blue (Hypoxia) -> Red (Reperfusion)",
      "C) Blue -> Red -> White",
      "D) White -> Red -> Blue"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (White, Blue, Red).\n\nPATHOPHYSIOLOGY:\nRaynaud phenomenon involves episodic vasospasm of the digital arteries and arterioles in response to cold exposure or emotional stress, producing a characteristic triphasic color change in the affected digits per Harrison's Principles of Internal Medicine. The first phase is white (pallor), caused by intense vasospasm that completely occludes digital arterial flow, producing ischemia. The second phase is blue (cyanosis), as the residual deoxygenated blood in the capillary beds becomes stagnant and oxygen is extracted without replenishment. The third phase is red (rubor), occurring as the vasospasm resolves and reactive hyperemia causes vigorous reperfusion with oxygenated blood per UpToDate.\n\nPRIMARY VERSUS SECONDARY:\nPrimary Raynaud (Raynaud disease) occurs in the absence of any underlying condition, is more common (80 to 90% of cases), typically begins in women under age 30, and carries a benign prognosis without tissue damage per the Cleveland Clinic. Secondary Raynaud (Raynaud phenomenon) is associated with an underlying connective tissue disease, most commonly systemic sclerosis (scleroderma, present in over 90% of scleroderma patients), systemic lupus erythematosus, mixed connective tissue disease, and dermatomyositis/polymyositis per Harrison's Principles of Internal Medicine. Secondary Raynaud tends to be more severe and can cause digital ulceration, pitting scars, and critical digital ischemia with gangrene per UpToDate.\n\nMANAGEMENT:\nFirst-line treatment includes cold avoidance, hand warming, and smoking cessation per the Mayo Clinic. Pharmacologic therapy when needed starts with dihydropyridine calcium channel blockers (nifedipine, amlodipine) as first-line vasodilators per UpToDate. Severe refractory cases may require phosphodiesterase-5 inhibitors, prostacyclin analogues, or endothelin receptor antagonists (bosentan) per the Cleveland Clinic.\n\nKEY LEARNING POINTS:\nThe Raynaud triphasic color sequence is white (vasospasm/ischemia), then blue (cyanosis/deoxygenation), then red (reactive hyperemia/reperfusion). Primary Raynaud is benign and common in young women, while secondary Raynaud is associated with connective tissue diseases (especially scleroderma) and can cause digital ulcers. Dihydropyridine CCBs (nifedipine) are first-line pharmacotherapy."
  },
  {
    "id": 461,
    "categoryId": 1,
    "question": "Coarctation of the Aorta (narrowing) typically occurs just distal to the Left Subclavian artery. Clinical signs include:",
    "options": [
      "A) Hypotension in legs, Hypertension in arms",
      "B) Hypertension in legs, Hypotension in arms",
      "C) Equal BP everywhere",
      "D) Cyanosis of the hands"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Hypotension in Legs, Hypertension in Arms).\n\nPATHOPHYSIOLOGY:\nCoarctation of the aorta is a congenital narrowing of the aorta, most commonly located just distal to the origin of the left subclavian artery at the site of the ductus arteriosus (juxtaductal coarctation) per Harrison's Principles of Internal Medicine. This anatomic narrowing creates a mechanical obstruction to blood flow: the upper body (head, neck, and arms, all supplied by branches arising proximal to the coarctation) receives normal or elevated blood flow, while the lower body (abdominal viscera and legs, supplied by the descending aorta distal to the coarctation) receives reduced blood flow and pressure per UpToDate. The result is hypertension in the upper extremities and hypotension in the lower extremities.\n\nCLINICAL PRESENTATION:\nThe hallmark physical examination finding is a significant blood pressure gradient between the upper and lower extremities (upper extremity systolic BP 20 mmHg or more higher than lower extremity BP) with diminished or delayed femoral pulses (radial-femoral pulse delay) per the Cleveland Clinic. Infants with severe coarctation may present with heart failure, shock, and ductal-dependent systemic circulation (requiring prostaglandin E1 to maintain ductal patency). Older children and adults may be asymptomatic or present with headache, epistaxis, leg claudication with exercise, or hypertension detected on routine examination per the Mayo Clinic. Associated anomalies include bicuspid aortic valve (present in 50 to 85% of cases), ventricular septal defect, and Turner syndrome (45,X) per Harrison's Principles of Internal Medicine.\n\nCOMPLICATIONS:\nLong-standing coarctation leads to collateral arterial circulation (intercostal arteries enlarge to bypass the obstruction, producing rib notching on chest radiograph), left ventricular hypertrophy, and increased risk of cerebral aneurysms (particularly Circle of Willis berry aneurysms) and aortic dissection per UpToDate.\n\nKEY LEARNING POINTS:\nCoarctation of the aorta causes upper extremity hypertension with lower extremity hypotension and diminished femoral pulses (radial-femoral delay). It is located just distal to the left subclavian artery at the ductus arteriosus. Bicuspid aortic valve coexists in 50 to 85% of cases, and Turner syndrome is a key association."
  },
  {
    "id": 462,
    "categoryId": 1,
    "question": "Giant Cell Arteritis (Temporal Arteritis) affects large/medium vessels. A biopsy shows inflammation in the:",
    "options": [
      "A) Capillaries",
      "B) Internal Elastic Lamina",
      "C) Veins",
      "D) Lymphatics"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Internal Elastic Lamina).\n\nPATHOPHYSIOLOGY:\nGiant cell arteritis (GCA, also called temporal arteritis) is a systemic granulomatous vasculitis of large and medium-sized arteries that predominantly affects branches of the external carotid artery (especially the temporal artery) and the aorta and its major branches in patients over 50 years of age per Harrison's Principles of Internal Medicine. The pathologic hallmark is transmural granulomatous inflammation centered on the internal elastic lamina of the affected artery, with multinucleated giant cells, macrophages, and CD4+ T lymphocytes clustered at or near the internal elastic lamina, which is often fragmented and disrupted per UpToDate. The inflammatory process is driven by a T-cell-mediated immune response in which dendritic cells in the adventitia activate CD4+ T-helper cells, which then migrate to the media and produce interferon-gamma, stimulating macrophage differentiation into multinucleated giant cells per the Cleveland Clinic.\n\nCLINICAL PRESENTATION:\nGCA classically presents with new-onset temporal headache, scalp tenderness, jaw claudication (pain with chewing, which is the most specific symptom), and constitutional symptoms (fever, malaise, weight loss) per the Mayo Clinic. The most feared complication is anterior ischemic optic neuropathy (AION), causing sudden, irreversible monocular vision loss from occlusion of the posterior ciliary arteries, which occurs in approximately 15 to 20% of untreated patients per Harrison's Principles of Internal Medicine. GCA is closely associated with polymyalgia rheumatica (PMR), with approximately 40 to 60% of GCA patients having concurrent PMR symptoms per UpToDate.\n\nDIAGNOSIS AND TREATMENT:\nESR is typically markedly elevated (often greater than 50 mm/hr, sometimes exceeding 100), and CRP is elevated per the Cleveland Clinic. Temporal artery biopsy is the gold standard for diagnosis (though skip lesions can cause false-negative results, so a length of at least 1 to 2 cm should be obtained) per UpToDate. High-dose corticosteroids (prednisone 40 to 60 mg/day, or IV methylprednisolone 1 g/day for 3 days if vision loss is present) must be started immediately upon clinical suspicion, before biopsy results are available, to prevent irreversible blindness per Harrison's Principles of Internal Medicine.\n\nKEY LEARNING POINTS:\nGCA shows granulomatous inflammation centered on the internal elastic lamina with multinucleated giant cells. Jaw claudication is the most specific symptom, and anterior ischemic optic neuropathy is the most feared complication. High-dose steroids must be started immediately upon clinical suspicion, before biopsy confirmation, to prevent irreversible vision loss."
  },
  {
    "id": 463,
    "categoryId": 1,
    "question": "Lymphedema differs from Venous Edema because Lymphedema:",
    "options": [
      "A) Pits easily",
      "B) Is usually bilateral",
      "C) Affects the dorsum of the foot (Stemmer's Sign) and is non-pitting",
      "D) Is improved with diuretics"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Affects the Dorsum of the Foot / Stemmer Sign / Non-pitting).\n\nPATHOPHYSIOLOGY:\nLymphedema results from impaired lymphatic drainage that causes accumulation of protein-rich interstitial fluid in the subcutaneous tissues per Harrison's Principles of Internal Medicine. Unlike venous edema (which is protein-poor transudative fluid that pits easily), lymphedema fluid has a high protein content (greater than 1.5 g/dL) that stimulates chronic fibroblast proliferation, collagen deposition, and adipose tissue hypertrophy, eventually producing firm, non-pitting edema per UpToDate. The Stemmer sign (inability to pinch and lift a fold of skin on the dorsum of the second toe) is a reliable clinical test for lymphedema because the dorsal foot skin is one of the first areas affected by lymphatic congestion and the earliest site to develop the fibrotic changes that prevent skin folding per the Cleveland Clinic.\n\nCLINICAL DISTINCTION:\nVenous edema is typically bilateral, pitting, worst in the dependent position (improving with elevation), and associated with hemosiderin staining at the medial malleolus per the Mayo Clinic. Lymphedema characteristically involves the dorsum of the foot and toes (giving a \"boxy\" or squared-off appearance to the toes), is initially pitting but becomes non-pitting as fibrosis progresses, does not respond well to diuretics (because the issue is protein accumulation, not sodium/water retention), and does not improve as dramatically with elevation per Harrison's Principles of Internal Medicine.\n\nCLASSIFICATION:\nPrimary lymphedema results from congenital abnormalities of lymphatic development (lymphatic hypoplasia, aplasia, or hyperplasia) and includes Milroy disease (congenital onset), lymphedema praecox (onset before age 35, most common form), and lymphedema tarda (onset after age 35) per UpToDate. Secondary lymphedema is far more common worldwide and results from lymphatic obstruction or destruction by surgery (axillary lymph node dissection for breast cancer), radiation therapy, infection (filariasis is the most common cause globally), malignancy, or trauma per the Cleveland Clinic.\n\nKEY LEARNING POINTS:\nLymphedema is distinguished from venous edema by the positive Stemmer sign (inability to pinch dorsal toe skin), non-pitting quality (from fibrosis due to protein-rich fluid), dorsal foot involvement, and poor response to diuretics. Venous edema pits easily, responds to elevation, and involves the medial malleolus. Secondary lymphedema from surgery/radiation is the most common form in developed countries."
  },
  {
    "id": 464,
    "categoryId": 1,
    "question": "Critical Limb Ischemia (CLI) is defined by:",
    "options": [
      "A) Pain with walking 1 block",
      "B) Ischemic Rest Pain (pain at night/elevation) or Tissue Loss (Ulcers/Gangrene)",
      "C) An ABI of 0.8",
      "D) Swelling"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Ischemic Rest Pain or Tissue Loss).\n\nPATHOPHYSIOLOGY:\nCritical limb ischemia (CLI, now also referred to as chronic limb-threatening ischemia or CLTI in the 2019 Global Vascular Guidelines) represents the most advanced stage of peripheral arterial disease and is defined by the presence of ischemic rest pain (pain occurring at rest, typically in the forefoot and toes, characteristically worse at night and when the leg is elevated, relieved by dependency) and/or tissue loss (non-healing ulcers, gangrene) per Harrison's Principles of Internal Medicine. CLI indicates that arterial blood flow is insufficient to meet basal metabolic demands of the tissues at rest, not merely during exercise as in intermittent claudication per UpToDate.\n\nHEMODYNAMIC CRITERIA:\nCLI is supported by objective hemodynamic measurements: ankle pressure less than 50 to 70 mmHg, toe pressure less than 30 to 50 mmHg, ABI typically less than 0.40, or transcutaneous oxygen pressure (TcPO2) less than 30 mmHg per the Cleveland Clinic. The Rutherford classification stages PAD from category 0 (asymptomatic) through category 3 (severe claudication) to categories 4 (rest pain), 5 (minor tissue loss), and 6 (major tissue loss), with categories 4 through 6 constituting CLI per UpToDate.\n\nPROGNOSIS AND MANAGEMENT:\nCLI carries a grim prognosis without revascularization: approximately 25% of patients will undergo major amputation within one year per the Mayo Clinic. Urgent revascularization (endovascular or surgical bypass) is the primary treatment goal to achieve limb salvage. Risk factor modification (smoking cessation, statin therapy, antiplatelet therapy, diabetes and hypertension control) and wound care are essential adjuncts per Harrison's Principles of Internal Medicine.\n\nKEY LEARNING POINTS:\nCritical limb ischemia is defined by ischemic rest pain (worse at night, relieved by leg dependency) or tissue loss (non-healing ulcers, gangrene), indicating arterial flow insufficient for basal tissue metabolism. Hemodynamic criteria include ABI less than 0.40 and ankle pressure less than 50 to 70 mmHg. Without revascularization, approximately 25% of CLI patients require major amputation within one year."
  },
  {
    "id": 465,
    "categoryId": 1,
    "question": "A Varicocele ('Bag of Worms') is more common on the LEFT side because:",
    "options": [
      "A) The Left Testicle is larger",
      "B) The Left Spermatic Vein drains perpendicularly into the Renal Vein (High resistance)",
      "C) Gravity affects the left more",
      "D) The Left Spermatic Vein has no valves"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (The Left Spermatic Vein Drains Perpendicularly into the Renal Vein).\n\nANATOMY:\nA varicocele is an abnormal dilation of the pampiniform venous plexus within the spermatic cord, present in approximately 15% of adult males and in up to 40% of men evaluated for infertility per Harrison's Principles of Internal Medicine. Varicoceles are significantly more common on the left side (approximately 80 to 90% of cases) due to a fundamental anatomic asymmetry in venous drainage per UpToDate. The left spermatic (testicular) vein drains into the left renal vein at a perpendicular (90-degree) angle, creating higher hydrostatic pressure and reduced efficiency of venous return compared to the right side. The right spermatic vein drains directly into the inferior vena cava at an oblique angle, which facilitates more efficient drainage per the Cleveland Clinic.\n\nADDITIONAL CONTRIBUTING FACTORS:\nThe left renal vein crosses between the aorta and the superior mesenteric artery (a region susceptible to compression, known as the nutcracker phenomenon), which can further impede left spermatic venous outflow per Harrison's Principles of Internal Medicine. The longer course of the left spermatic vein (due to the higher position of the left kidney) and incompetent or absent venous valves also contribute per UpToDate.\n\nCLINICAL SIGNIFICANCE:\nVaricoceles present as a \"bag of worms\" palpable in the scrotum that becomes more prominent with standing and Valsalva maneuver and decompresses in the supine position per the Mayo Clinic. A new right-sided varicocele or a varicocele that does not decompress in the supine position should raise concern for extrinsic compression of the IVC or right renal vein by a retroperitoneal mass (particularly renal cell carcinoma extending into the IVC) per Harrison's Principles of Internal Medicine. Varicoceles impair spermatogenesis through elevated intrascrotal temperature from venous stasis per the Cleveland Clinic.\n\nKEY LEARNING POINTS:\nLeft-sided varicoceles predominate (80 to 90%) because the left spermatic vein drains perpendicularly into the left renal vein (high resistance), while the right drains obliquely into the IVC (low resistance). A new isolated right-sided or non-decompressing varicocele should raise concern for retroperitoneal mass (renal cell carcinoma). Varicoceles impair fertility through elevated scrotal temperature."
  },
  {
    "id": 466,
    "categoryId": 1,
    "question": "The Portal Vein is formed by the confluence of which two veins?",
    "options": [
      "A) IVC and Renal Vein",
      "B) Splenic Vein and Superior Mesenteric Vein (SMV)",
      "C) Hepatic Vein and IVC",
      "D) Gastric Vein and Splenic Vein"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Splenic Vein and Superior Mesenteric Vein).\n\nANATOMY:\nThe portal vein is formed by the confluence of the splenic vein and the superior mesenteric vein (SMV) behind the neck of the pancreas (at the level of L2) per Harrison's Principles of Internal Medicine. It ascends in the hepatoduodenal ligament (within the free edge of the lesser omentum) alongside the common bile duct (anterolateral) and the hepatic artery proper (anteromedial), then enters the liver at the porta hepatis where it divides into right and left portal branches per UpToDate.\n\nPORTAL CIRCULATION FUNCTION:\nThe portal venous system is a unique venous arrangement that drains blood from the gastrointestinal tract (stomach through rectum), spleen, pancreas, and gallbladder and delivers it to the liver for first-pass metabolism before it enters the systemic circulation via the hepatic veins and IVC per the Cleveland Clinic. Approximately 75% of hepatic blood flow is delivered by the portal vein (nutrient-rich, partially deoxygenated), with the remaining 25% from the hepatic artery (oxygen-rich) per Harrison's Principles of Internal Medicine.\n\nCLINICAL SIGNIFICANCE:\nPortal hypertension (portal venous pressure gradient greater than 5 mmHg, clinically significant above 10 mmHg) develops most commonly from cirrhosis and leads to the formation of portosystemic collaterals at sites of portal-systemic anastomosis: esophageal varices (left gastric vein to esophageal veins), caput medusae (paraumbilical veins to epigastric veins), hemorrhoids (superior rectal to middle/inferior rectal veins), and splenorenal shunts per the Mayo Clinic and UpToDate.\n\nKEY LEARNING POINTS:\nThe portal vein is formed by the confluence of the splenic vein and the superior mesenteric vein behind the neck of the pancreas. It delivers 75% of hepatic blood flow (nutrient-rich) for first-pass metabolism. Portal hypertension from cirrhosis causes portosystemic collaterals including esophageal varices, caput medusae, and hemorrhoids."
  },
  {
    "id": 467,
    "categoryId": 1,
    "question": "Nitric Oxide (NO) produced by endothelial cells causes vasodilation by increasing:",
    "options": [
      "A) cAMP",
      "B) cGMP in smooth muscle",
      "C) Calcium",
      "D) Angiotensin"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (cGMP in Smooth Muscle).\n\nPATHOPHYSIOLOGY:\nNitric oxide (NO) is synthesized by endothelial nitric oxide synthase (eNOS) in vascular endothelial cells, which converts L-arginine to L-citrulline and NO using molecular oxygen, NADPH, and tetrahydrobiopterin (BH4) as cofactors per Harrison's Principles of Internal Medicine. NO is a small, lipophilic gas that freely diffuses from the endothelium into the adjacent vascular smooth muscle cells, where it activates soluble guanylyl cyclase (sGC), an enzyme that converts GTP to cyclic guanosine monophosphate (cGMP) per UpToDate. Elevated cGMP activates protein kinase G (PKG), which causes smooth muscle relaxation through multiple mechanisms: decreased intracellular calcium (by stimulating calcium efflux and inhibiting calcium influx), dephosphorylation of myosin light chain, and activation of potassium channels causing hyperpolarization per the Cleveland Clinic.\n\nCLINICAL APPLICATIONS:\nNitroglycerin and other nitrate medications work by serving as exogenous NO donors, generating NO that activates the same sGC-cGMP pathway per Harrison's Principles of Internal Medicine. Phosphodiesterase-5 (PDE-5) inhibitors (sildenafil, tadalafil) prevent the breakdown of cGMP by PDE-5, prolonging and amplifying the vasodilatory effect of NO, which is why combining nitrates with PDE-5 inhibitors causes dangerous hypotension per UpToDate. This pathway is also the basis for PDE-5 inhibitor use in erectile dysfunction (penile smooth muscle relaxation) and pulmonary arterial hypertension (pulmonary vascular smooth muscle relaxation) per the Mayo Clinic.\n\nKEY LEARNING POINTS:\nEndothelial NO activates soluble guanylyl cyclase in vascular smooth muscle, increasing cGMP which activates protein kinase G, causing vasodilation through calcium reduction and myosin dephosphorylation. Nitroglycerin works as an exogenous NO donor through this same pathway. PDE-5 inhibitors amplify NO signaling by preventing cGMP breakdown, explaining the dangerous synergy with nitrates."
  },
  {
    "id": 468,
    "categoryId": 1,
    "question": "Which artery is the primary blood supply to the femoral head (hip joint)?",
    "options": [
      "A) Obturator Artery",
      "B) Medial Circumflex Femoral Artery",
      "C) Femoral Artery proper",
      "D) Inferior Gluteal Artery"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Medial Circumflex Femoral Artery).\n\nANATOMY:\nThe medial circumflex femoral artery (MCFA) is the primary blood supply to the femoral head in adults, providing approximately 80% of the arterial flow through its lateral ascending (retinacular) branches that penetrate the hip joint capsule and course along the femoral neck beneath the synovial membrane per Harrison's Principles of Internal Medicine. The MCFA typically arises from the deep femoral artery (profunda femoris) and courses posteriorly around the femoral neck per UpToDate.\n\nCLINICAL SIGNIFICANCE:\nThe vulnerability of this blood supply is the reason that femoral neck fractures carry a high risk of avascular necrosis (AVN, also called osteonecrosis) of the femoral head per the Cleveland Clinic. Displaced femoral neck fractures can disrupt the retinacular branches of the MCFA, cutting off blood supply to the femoral head and leading to ischemic bone death. The incidence of AVN after displaced femoral neck fractures is approximately 15 to 30%, which is why displaced fractures in younger patients are treated with urgent open reduction and internal fixation (to preserve the native femoral head) rather than arthroplasty per the Mayo Clinic. In elderly patients with displaced femoral neck fractures, hemiarthroplasty or total hip arthroplasty is preferred because the high AVN risk makes femoral head preservation less favorable per UpToDate.\n\nADDITIONAL BLOOD SUPPLY:\nThe ligamentum teres artery (a branch of the obturator artery) provides a minor contribution to femoral head blood supply through the fovea capitis, but this source is insufficient to maintain femoral head viability if the MCFA supply is disrupted in adults per Harrison's Principles of Internal Medicine. In children, the ligamentum teres artery contribution is more significant.\n\nKEY LEARNING POINTS:\nThe medial circumflex femoral artery provides approximately 80% of the blood supply to the femoral head through retinacular branches along the femoral neck. Displaced femoral neck fractures disrupt this supply, causing avascular necrosis in 15 to 30% of cases. This vascular anatomy dictates surgical approach: urgent fixation in young patients versus arthroplasty in elderly patients."
  },
  {
    "id": 469,
    "categoryId": 1,
    "question": "USPSTF recommends one-time screening for AAA with Ultrasound in:",
    "options": [
      "A) All men > 65",
      "B) Men 65-75 who have ever smoked",
      "C) Women 65-75 who smoke",
      "D) Anyone with back pain"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Men 65 to 75 Who Have Ever Smoked).\n\nCLINICAL REASONING:\nThe United States Preventive Services Task Force (USPSTF) recommends one-time screening for abdominal aortic aneurysm (AAA) with abdominal ultrasonography in men aged 65 to 75 years who have ever smoked (defined as having smoked 100 or more cigarettes in their lifetime) per UpToDate. This is a Grade B recommendation based on moderate net benefit. For men aged 65 to 75 who have never smoked, the USPSTF recommends selective screening based on individual clinical judgment (Grade C) per the Mayo Clinic. The USPSTF found insufficient evidence to recommend for or against screening in women who have ever smoked and recommends against screening in women who have never smoked per Harrison's Principles of Internal Medicine.\n\nEPIDEMIOLOGY:\nAAA (defined as aortic diameter 3.0 cm or greater) predominantly affects older men with a history of smoking per the Cleveland Clinic. Smoking is the strongest modifiable risk factor, increasing AAA risk by 3 to 5-fold. Other risk factors include male sex, age over 65, family history of AAA, and other atherosclerotic disease (coronary, carotid, or peripheral) per UpToDate. The male-to-female prevalence ratio is approximately 4 to 6:1 per Harrison's Principles of Internal Medicine.\n\nMANAGEMENT BASED ON SIZE:\nAAA smaller than 5.5 cm in men (or 5.0 cm in women) is managed with surveillance ultrasonography at intervals determined by aneurysm size, risk factor modification (smoking cessation is the most critical intervention to slow growth), and avoidance of strenuous lifting per the Cleveland Clinic. Surgical repair (open or endovascular aneurysm repair, EVAR) is indicated when the aneurysm reaches 5.5 cm (men) or 5.0 cm (women), grows more than 0.5 cm in 6 months, or becomes symptomatic per UpToDate.\n\nKEY LEARNING POINTS:\nThe USPSTF recommends one-time AAA screening with ultrasound in men aged 65 to 75 who have ever smoked (Grade B). Smoking is the strongest modifiable risk factor (3 to 5-fold increased risk). Elective repair is indicated at 5.5 cm in men or 5.0 cm in women, or with rapid growth greater than 0.5 cm in 6 months."
  },
  {
    "id": 470,
    "categoryId": 1,
    "question": "Thromboangiitis Obliterans (Buerger's Disease) is a non-atherosclerotic vasculitis strongly associated with:",
    "options": [
      "A) Alcohol",
      "B) Heavy Tobacco use",
      "C) Diabetes",
      "D) High Cholesterol"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Heavy Tobacco Use).\n\nPATHOPHYSIOLOGY:\nThromboangiitis obliterans (Buerger disease) is a non-atherosclerotic, segmental inflammatory vasculitis that affects small and medium-sized arteries and veins of the distal extremities, with an almost absolute association with tobacco use per Harrison's Principles of Internal Medicine. The disease predominantly affects young male smokers (typically under age 45) and is characterized by highly cellular, inflammatory thrombi in the arterial and venous lumen with relative preservation of the vessel wall architecture (in contrast to atherosclerosis, which involves intimal plaque formation, and other vasculitides, which involve transmural vessel wall destruction) per UpToDate. The exact mechanism linking tobacco to the disease is not fully understood, but involves an immunologic response to tobacco antigens, endothelial dysfunction, and a prothrombotic state per the Cleveland Clinic.\n\nCLINICAL PRESENTATION:\nPatients present with distal extremity ischemia affecting the hands and feet (unlike atherosclerotic PAD, which typically involves larger proximal vessels), including rest pain, digital ulcers, and gangrene of the fingers and toes per the Mayo Clinic. Superficial migratory thrombophlebitis (recurrent episodes of tender, erythematous, palpable subcutaneous cords) occurs in approximately 40% of patients and may precede arterial symptoms per Harrison's Principles of Internal Medicine. The Raynaud phenomenon is also common. Importantly, the diagnosis requires exclusion of other causes of distal ischemia (atherosclerosis, thrombophilia, autoimmune disease, embolic disease) per UpToDate.\n\nMANAGEMENT:\nAbsolute and complete tobacco cessation (including all forms: cigarettes, cigars, smokeless tobacco, and even nicotine replacement in some patients) is the single most important intervention and is the only treatment proven to prevent disease progression and amputation per the Cleveland Clinic. Patients who continue to smoke have amputation rates approaching 40 to 50%, while those who achieve complete cessation rarely require amputation per Harrison's Principles of Internal Medicine.\n\nKEY LEARNING POINTS:\nBuerger disease is a non-atherosclerotic inflammatory vasculitis with nearly absolute tobacco association, affecting distal small/medium arteries and veins in young male smokers under 45. It presents with digital ischemia, ulcers, and migratory superficial thrombophlebitis. Complete tobacco cessation is the only effective treatment, dramatically reducing the 40 to 50% amputation rate seen with continued smoking."
  },
  {
    "id": 471,
    "categoryId": 1,
    "question": "Oxidized LDL is particularly atherogenic because it:",
    "options": [
      "A) Is rapidly cleared by the liver",
      "B) Is taken up by Macrophages via Scavenger Receptors (unregulated)",
      "C) Repels platelets",
      "D) Dissolves plaques"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Taken Up by Macrophages via Unregulated Scavenger Receptors).\n\nPATHOPHYSIOLOGY:\nOxidized LDL (oxLDL) is a key driver of atherogenesis because it is internalized by macrophages through scavenger receptors (primarily SR-A1, CD36, and LOX-1) that, unlike the native LDL receptor, are not subject to negative feedback regulation by intracellular cholesterol levels per Harrison's Principles of Internal Medicine. The native LDL receptor (LDL-R) on hepatocytes and other cells is tightly regulated: as intracellular cholesterol rises, SREBP-mediated transcription of the LDL receptor gene is suppressed, limiting further cholesterol uptake. In contrast, scavenger receptors on macrophages continue to internalize oxLDL regardless of how much cholesterol the cell has already accumulated, leading to massive intracellular lipid accumulation and transformation of the macrophage into a foam cell per UpToDate.\n\nPATHOGENIC EFFECTS:\nBeyond unregulated uptake, oxLDL has multiple additional proatherogenic effects per the Cleveland Clinic. It is directly cytotoxic to endothelial cells, impairing endothelial function and promoting endothelial apoptosis. It is chemotactic for circulating monocytes (recruiting more inflammatory cells to the developing plaque) and inhibits macrophage emigration from the plaque. OxLDL stimulates smooth muscle cell proliferation and extracellular matrix production, and it promotes platelet adhesion and aggregation per Harrison's Principles of Internal Medicine.\n\nCLINICAL RELEVANCE:\nThe atherogenic role of oxLDL explains why antioxidant therapies were hypothesized to reduce cardiovascular disease, though clinical trials of vitamin E and other antioxidant supplements failed to show benefit, suggesting that the oxidation process occurs within the vessel wall microenvironment and is not effectively addressed by systemic antioxidant supplementation per UpToDate. Statins reduce oxLDL indirectly by lowering total LDL (less substrate for oxidation) and through direct anti-inflammatory and antioxidant pleiotropic effects per the Mayo Clinic.\n\nKEY LEARNING POINTS:\nOxidized LDL is highly atherogenic because macrophage scavenger receptors (SR-A, CD36) internalize it without negative feedback regulation, leading to uncontrolled cholesterol accumulation and foam cell formation. Native LDL receptors are tightly regulated and do not cause foam cell transformation. OxLDL is also directly cytotoxic to endothelium, chemotactic for monocytes, and prothrombotic."
  },
  {
    "id": 472,
    "categoryId": 1,
    "question": "Virchow's Triad describes the three factors predisposing to thrombosis:",
    "options": [
      "A) High BP, High Cholesterol, Smoking",
      "B) Stasis, Endothelial Injury, Hypercoagulability",
      "C) Pain, Pallor, Pulselessness",
      "D) Age, Obesity, Diabetes"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Stasis, Endothelial Injury, Hypercoagulability).\n\nPATHOPHYSIOLOGY:\nVirchow's triad, first conceptualized by Rudolf Virchow in 1856, describes the three fundamental pathophysiologic factors that predispose to intravascular thrombosis per Harrison's Principles of Internal Medicine. The first factor is venous stasis (abnormal blood flow), which occurs with immobility (prolonged bed rest, long-haul flights, paralysis), venous obstruction, or heart failure. Stasis allows activated clotting factors to accumulate locally rather than being diluted and cleared by flowing blood, and it prevents delivery of natural anticoagulants (antithrombin, protein C, protein S) to the site per UpToDate. The second factor is endothelial injury or dysfunction, which exposes subendothelial collagen and tissue factor, activating both the intrinsic and extrinsic coagulation cascades and promoting platelet adhesion. Endothelial injury occurs with surgery, trauma, indwelling catheters, and chronic inflammation per the Cleveland Clinic. The third factor is hypercoagulability, which can be inherited (Factor V Leiden mutation, prothrombin G20210A mutation, protein C or S deficiency, antithrombin deficiency) or acquired (malignancy, pregnancy, oral contraceptives, antiphospholipid syndrome, nephrotic syndrome) per Harrison's Principles of Internal Medicine.\n\nCLINICAL APPLICATION:\nMost thrombotic events involve the interaction of two or more of these factors per the Mayo Clinic. For example, a postoperative patient (endothelial injury from surgery plus stasis from immobility) taking oral contraceptives (hypercoagulability) has a dramatically higher DVT risk than any single factor alone. Understanding Virchow's triad guides prophylaxis strategies: early ambulation and pneumatic compression address stasis, careful surgical technique minimizes endothelial injury, and pharmacologic thromboprophylaxis (heparin, enoxaparin) addresses hypercoagulability per UpToDate.\n\nKEY LEARNING POINTS:\nVirchow's triad (venous stasis, endothelial injury, hypercoagulability) describes the three fundamental predispositions to thrombosis. Most thrombotic events involve interaction of two or more factors. This framework guides prophylaxis: ambulation addresses stasis, surgical technique minimizes endothelial injury, and pharmacologic anticoagulation addresses hypercoagulability."
  },
  {
    "id": 473,
    "categoryId": 1,
    "question": "The Popliteal Artery is the continuation of the Femoral Artery after it passes through the:",
    "options": [
      "A) Inguinal Ligament",
      "B) Adductor Hiatus (Hunter's Canal)",
      "C) Obturator Foramen",
      "D) Popliteal Fossa"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Adductor Hiatus / Hunter's Canal).\n\nANATOMY:\nThe femoral artery transitions to become the popliteal artery as it passes through the adductor hiatus (also called the hiatus of the adductor magnus), an opening in the tendinous insertion of the adductor magnus muscle at the distal medial thigh per Harrison's Principles of Internal Medicine. The adductor canal (Hunter's canal, subsartorial canal) is the fascial tunnel in the middle third of the thigh through which the femoral artery, femoral vein, saphenous nerve, and nerve to the vastus medialis travel before reaching the adductor hiatus per UpToDate. The canal is bounded anterolaterally by the vastus medialis, posteriorly by the adductor longus and adductor magnus, and superficially (roof) by the sartorius muscle and the vastoaponeurotic membrane per the Cleveland Clinic.\n\nCLINICAL SIGNIFICANCE:\nThe adductor hiatus is the most common site of atherosclerotic stenosis in peripheral arterial disease because the artery is fixed at this point and subjected to repetitive mechanical stress from thigh adduction and knee flexion per Harrison's Principles of Internal Medicine. Superficial femoral artery (SFA) disease at the adductor canal is the classic location for claudication presenting as calf pain with walking per the Mayo Clinic. The popliteal artery, after emerging from the adductor hiatus, courses through the popliteal fossa behind the knee, where it is the deepest structure (closest to the femur) and is vulnerable to injury in posterior knee dislocations per UpToDate. Distally, the popliteal artery trifurcates into the anterior tibial, posterior tibial, and peroneal (fibular) arteries per the Cleveland Clinic.\n\nKEY LEARNING POINTS:\nThe femoral artery becomes the popliteal artery at the adductor hiatus (opening in the adductor magnus muscle), which is the most common site of atherosclerotic stenosis in PAD. The adductor canal (Hunter's canal) is the fascial tunnel proximal to the hiatus. The popliteal artery is vulnerable to injury in posterior knee dislocations and trifurcates into the anterior tibial, posterior tibial, and peroneal arteries."
  },
  {
    "id": 474,
    "categoryId": 7,
    "question": "Which of the four Rotator Cuff muscles is primarily responsible for internal rotation of the humerus?",
    "options": [
      "A) Supraspinatus",
      "B) Infraspinatus",
      "C) Teres Minor",
      "D) Subscapularis"
    ],
    "correctAnswer": 3,
    "explanation": "CORRECT: D (Subscapularis).\n\nPATHOPHYSIOLOGY:\nThe rotator cuff is a group of four muscles that originate from the scapula, cross the glenohumeral joint, and insert on the tuberosities of the proximal humerus, collectively providing dynamic stabilization by compressing the humeral head into the glenoid fossa during active shoulder movement. The subscapularis is the largest and strongest of the four rotator cuff muscles and is the only one that originates from the anterior (costal) surface of the scapula, occupying the subscapular fossa. It courses laterally and inserts on the lesser tuberosity of the humerus, where its line of pull across the anterior aspect of the glenohumeral joint makes it the primary internal rotator of the humerus. In addition to generating internal rotation torque, the subscapularis provides critical anterior stability to the glenohumeral joint by acting as a dynamic anterior restraint that resists anterior translation and external rotation forces, particularly in the abducted and externally rotated position. The three posterior rotator cuff muscles all originate from the posterior scapula and insert on the greater tuberosity. The supraspinatus occupies the supraspinous fossa and is primarily responsible for initiating the first 15 degrees of shoulder abduction by compressing the humeral head inferiorly to clear the greater tuberosity under the coracoacromial arch. The infraspinatus, arising from the infraspinous fossa, and the teres minor, arising from the lateral border of the scapula, are both external rotators of the humerus, with the infraspinatus providing approximately 60% of external rotation strength and the teres minor contributing the remaining 40%.\n\nCLINICAL PRESENTATION:\nSubscapularis tears are less common than supraspinatus tears but are clinically significant because they compromise anterior shoulder stability and internal rotation strength. Patients with subscapularis pathology present with anterior shoulder pain, weakness of internal rotation, and sometimes increased passive external rotation compared to the contralateral side due to loss of the anterior restraint. The lift-off test (Gerber test) is performed by placing the dorsum of the patient's hand against the lumbar spine and asking them to push the hand away from the back against examiner resistance. Inability to maintain the hand away from the back indicates subscapularis insufficiency. The belly press test is an alternative for patients who cannot reach behind their back, performed by pressing the palm against the abdomen while attempting to keep the elbow forward of the trunk. If the elbow falls posteriorly, the patient is substituting shoulder extension for internal rotation, indicating subscapularis weakness. The bear hug test, in which the patient places the hand of the affected side on the opposite shoulder and resists the examiner's attempt to lift the hand off the shoulder with an external rotation force, is a third provocative maneuver with high sensitivity for upper subscapularis tears.\n\nDIAGNOSIS AND MANAGEMENT:\nMRI with or without intraarticular contrast (MR arthrography) is the imaging modality of choice for evaluating subscapularis tears. Complete subscapularis tears are associated with medial subluxation of the long head of the biceps tendon, because the subscapularis and the transverse humeral ligament together form the medial wall of the bicipital groove that stabilizes the biceps tendon. Isolated partial tears may be managed conservatively with physical therapy focused on strengthening the remaining internal rotators and restoring scapular kinematics, while complete tears, particularly those associated with biceps subluxation or significant functional impairment, typically require surgical repair.\n\nKEY LEARNING POINTS:\nThe subscapularis is the only anterior rotator cuff muscle, originating from the costal surface of the scapula and inserting on the lesser tuberosity, making it the primary internal rotator and a critical anterior stabilizer of the glenohumeral joint. The lift-off test, belly press test, and bear hug test are the specific clinical examination maneuvers for subscapularis integrity. Complete subscapularis tears are frequently associated with biceps tendon subluxation because the subscapularis forms the medial wall of the bicipital groove."
  },
  {
    "id": 475,
    "categoryId": 7,
    "question": "Wolff's Law describes the physiological principle that:",
    "options": [
      "A) Muscle fibers hypertrophy with stretch",
      "B) Bone remodels and strengthens in response to mechanical stress/load",
      "C) Cartilage regenerates if damaged",
      "D) Ligaments tighten with age"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Bone remodels and strengthens in response to mechanical stress/load).\n\nPATHOPHYSIOLOGY:\nWolff's Law, formulated by the German anatomist Julius Wolff in 1892, states that bone adapts its internal architecture and external geometry in response to the mechanical demands placed upon it. When bone is subjected to increased loading, it remodels by depositing new bone matrix along the lines of principal stress, increasing cortical thickness, trabecular density, and cross-sectional area in the regions of greatest mechanical demand. Conversely, when mechanical loading is reduced or absent, bone is resorbed and becomes thinner and weaker. The cellular mechanism underlying Wolff's Law centers on osteocytes, the terminally differentiated osteoblasts embedded within the bone matrix that constitute approximately 90 to 95% of all bone cells. Osteocytes are interconnected through an extensive lacunar-canalicular network, and when mechanical loading deforms the bone matrix, interstitial fluid is driven through this network, generating shear stress on the osteocyte cell processes. This mechanotransduction signal triggers osteocytes to reduce their secretion of sclerostin, a glycoprotein that normally inhibits the Wnt signaling pathway in osteoblasts. When sclerostin levels fall, Wnt signaling is disinhibited, osteoblast proliferation and differentiation increase, and new bone formation is stimulated at the sites of greatest mechanical strain. Additionally, mechanical loading generates piezoelectric potentials within the hydroxyapatite crystal lattice of bone, creating small electrical signals that further stimulate osteoblast activity.\n\nCLINICAL SIGNIFICANCE:\nWolff's Law has profound implications for osteoporosis prevention and treatment. Weight-bearing impact exercise and progressive resistance training generate the high-magnitude, rapidly applied strains necessary to suppress sclerostin and stimulate osteoblast activity, directly translating this physiological principle into clinical practice. The converse of Wolff's Law explains why prolonged immobilization, bed rest, spinal cord injury, and microgravity exposure cause rapid bone loss. Astronauts lose approximately 1 to 2% of bone mineral density per month in weight-bearing skeletal sites during spaceflight, and patients on prolonged bed rest experience similar rates of disuse osteopenia, demonstrating that gravitational loading is essential for maintaining skeletal mass. In clinical rehabilitation, Wolff's Law guides early weight-bearing protocols after fracture fixation, as controlled mechanical loading through the fracture site stimulates callus formation and accelerates healing. Similarly, orthodontic tooth movement exploits Wolff's Law by applying sustained mechanical force through brackets and wires, stimulating bone resorption on the pressure side and bone formation on the tension side of the tooth socket, allowing gradual tooth repositioning. The anti-sclerostin monoclonal antibody romosozumab, approved for osteoporosis treatment, pharmacologically mimics the downstream effects of mechanical loading by blocking sclerostin and activating the Wnt-mediated bone formation pathway.\n\nKEY LEARNING POINTS:\nWolff's Law states that bone remodels and strengthens along the lines of mechanical stress through osteocyte mechanotransduction, sclerostin suppression, and activation of Wnt-mediated osteoblast signaling. This principle explains why weight-bearing exercise builds bone while immobilization and microgravity cause rapid bone loss at rates of 1 to 2% per month. Romosozumab pharmacologically mimics the effects of mechanical loading by blocking sclerostin, directly translating Wolff's Law into therapeutic application for osteoporosis."
  },
  {
    "id": 476,
    "categoryId": 7,
    "question": "The primary pathophysiologic defect in Osteoarthritis (OA) is:",
    "options": [
      "A) Autoimmune attack on the synovium",
      "B) Loss of Articular Cartilage and subchondral bone remodeling (Osteophytes)",
      "C) Deposition of Uric Acid crystals",
      "D) Infection of the joint space"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Loss of Articular Cartilage and subchondral bone remodeling with osteophyte formation).\n\nPATHOPHYSIOLOGY:\nOsteoarthritis is the most common joint disease worldwide, affecting over 300 million people globally according to the World Health Organization, and is the leading cause of disability in adults over 65. Although historically characterized as simple mechanical wear and tear, OA is now understood to be a complex disease of the entire joint organ involving progressive loss of articular cartilage, subchondral bone remodeling, osteophyte formation, synovial inflammation, and changes in periarticular soft tissues. The primary pathologic defect begins with disruption of the articular cartilage, the specialized hyaline cartilage that covers the ends of bones within synovial joints. Normal articular cartilage is composed of type II collagen fibers providing tensile strength and aggrecan proteoglycans that attract and retain water through osmotic swelling pressure, together creating a resilient, nearly frictionless surface with a coefficient of friction lower than ice on ice. In OA, an imbalance between anabolic and catabolic processes in chondrocytes shifts toward degradation. Chondrocytes upregulate matrix metalloproteinases (particularly MMP-13, which cleaves type II collagen) and aggrecanases (ADAMTS-4 and ADAMTS-5), while simultaneously decreasing production of new matrix components. Proinflammatory cytokines including interleukin-1 beta and tumor necrosis factor alpha drive this catabolic shift, even though the degree of inflammation is far less than in autoimmune arthritides such as rheumatoid arthritis.\n\nCLINICAL PRESENTATION:\nAs cartilage thins and fragments, the exposed subchondral bone experiences increased mechanical stress and responds according to Wolff's Law by thickening and sclerosing (subchondral sclerosis). The bone attempts to redistribute stress by forming new bone at the joint margins, producing osteophytes (bone spurs) that are the radiographic hallmark of OA. Subchondral bone cysts develop as synovial fluid is forced through cracks in the damaged cartilage into the underlying bone. The classic radiographic findings of OA are summarized by the mnemonic LOSS: Loss of joint space (asymmetric narrowing reflecting cartilage loss), Osteophytes, Subchondral sclerosis, and Subchondral cysts. Clinically, patients present with use-related joint pain that worsens with activity and improves with rest, morning stiffness lasting less than 30 minutes (in contrast to the prolonged morning stiffness of greater than 60 minutes characteristic of rheumatoid arthritis), crepitus with range of motion, and bony joint enlargement. Heberden nodes (distal interphalangeal joints) and Bouchard nodes (proximal interphalangeal joints) are the characteristic bony enlargements of hand OA. The joints most commonly affected are the knees, hips, hands (DIP and PIP joints and first carpometacarpal joint), and spine, reflecting weight-bearing and high-use articulations.\n\nTREATMENT AND MANAGEMENT:\nManagement follows a stepwise approach beginning with non-pharmacologic interventions including exercise (both aerobic and strengthening programs), weight loss (each kilogram of weight loss reduces knee joint load by approximately 4 kilograms), physical therapy, and assistive devices. Pharmacologic first-line therapy includes topical NSAIDs (preferred for knee and hand OA by ACR guidelines due to lower systemic risk) and oral NSAIDs at the lowest effective dose for the shortest duration necessary. Intraarticular corticosteroid injections provide short-term relief of 4 to 8 weeks for acute flares. Duloxetine, a serotonin-norepinephrine reuptake inhibitor, is recommended by the ACR for patients with inadequate response to first-line agents, reflecting the central sensitization component of chronic OA pain. Intraarticular hyaluronic acid injections remain controversial, with the ACR conditionally recommending against their use in knee OA. Total joint arthroplasty is reserved for patients with refractory symptoms and significant functional limitation despite exhausted conservative measures.\n\nKEY LEARNING POINTS:\nOsteoarthritis is primarily a disease of progressive articular cartilage loss driven by an imbalance between chondrocyte anabolic and catabolic activity, with secondary inflammation, unlike rheumatoid arthritis where autoimmune synovial inflammation is the primary pathology. The radiographic hallmarks are asymmetric joint space narrowing, osteophytes, subchondral sclerosis, and subchondral cysts, summarized by the mnemonic LOSS. Morning stiffness in OA lasts less than 30 minutes, distinguishing it from RA where stiffness characteristically persists for more than 60 minutes."
  },
  {
    "id": 477,
    "categoryId": 7,
    "question": "The Menisci of the knee are fibrocartilage discs that act as shock absorbers. Why is a tear in the 'White Zone' (inner 2/3) unlikely to heal without surgery?",
    "options": [
      "A) It is avascular (no blood supply)",
      "B) It is too thick",
      "C) It has too many nerves",
      "D) It is connected to the ACL"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A.\n\nVASCULARITY:\nRed Zone (Outer 1/3): Has blood supply. Tears here can often heal on their own.; White Zone (Inner 2/3): Avascular. Tears here cannot heal and typically require debridement (meniscectomy) if symptomatic."
  },
  {
    "id": 478,
    "categoryId": 7,
    "question": "Spondylolisthesis refers to:",
    "options": [
      "A) A fracture of the Pars Interarticularis",
      "B) Anterior slippage of one vertebra over the one below it",
      "C) Narrowing of the spinal canal",
      "D) Herniation of a disc"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Anterior slippage of one vertebra over the one below it).\n\nPATHOPHYSIOLOGY:\nSpondylolisthesis refers to the anterior displacement (slippage) of one vertebral body relative to the vertebra immediately below it. The most common location is L5 slipping forward on S1, followed by L4 on L5. There are several etiologic subtypes. Isthmic spondylolisthesis results from a defect (fracture) of the pars interarticularis, known as spondylolysis, which is a separate but closely related condition. Spondylolysis is the bony defect itself, classically described as a break in the \"neck\" of the Scottie dog on oblique lumbar radiographs, and it is this structural discontinuity that permits the vertebral body to translate anteriorly. Degenerative spondylolisthesis, the most common form in adults over age 50, results from facet joint arthropathy and disc degeneration leading to segmental instability without a pars defect, and predominantly occurs at L4-L5. Isthmic spondylolisthesis is most prevalent in young athletes involved in repetitive hyperextension activities such as gymnastics, football linemen, and weightlifting. The Meyerding classification grades the degree of slippage from Grade I (less than 25% displacement) through Grade IV (75 to 100% displacement), with Grade V representing complete displacement (spondyloptosis).\n\nCLINICAL PRESENTATION:\nMany patients with low-grade spondylolisthesis are asymptomatic, and the finding is incidental on imaging. When symptomatic, patients typically report low back pain that worsens with extension and activity. Neurologic symptoms including radiculopathy, neurogenic claudication, and in severe cases cauda equina syndrome can occur when the slippage narrows the spinal canal or neural foramina. On physical examination, a palpable step-off at the affected level may be appreciated in higher-grade slips, and hamstring tightness is a common associated finding. Standing lateral radiographs are the initial imaging study of choice and allow accurate grading of the slip. MRI is obtained when neurologic symptoms are present to evaluate for neural compression, disc pathology, and spinal canal dimensions.\n\nTREATMENT:\nConservative management is first-line for most patients and includes activity modification, core stabilization and flexion-based physical therapy, and NSAIDs for pain control. Lumbar extension and high-impact activities should be avoided. Epidural steroid injections may provide temporary relief in patients with radicular symptoms. Surgical intervention, typically posterolateral fusion with or without decompression, is considered for patients with progressive neurologic deficits, high-grade slips (Grade III or greater), or persistent symptoms refractory to at least 6 months of conservative therapy.\n\nKEY LEARNING POINTS:\nSpondylolisthesis is the forward slippage of a vertebral body and is graded I through IV by the Meyerding classification. It must be distinguished from spondylolysis, which is the pars interarticularis fracture that often underlies isthmic spondylolisthesis. Degenerative spondylolisthesis at L4-L5 is the most common form in older adults, while isthmic spondylolisthesis at L5-S1 predominates in young athletes performing repetitive hyperextension."
  },
  {
    "id": 479,
    "categoryId": 7,
    "question": "Meralgia Paresthetica is a mononeuropathy caused by compression of which nerve?",
    "options": [
      "A) Sciatic Nerve",
      "B) Lateral Femoral Cutaneous Nerve",
      "C) Femoral Nerve",
      "D) Obturator Nerve"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Lateral Femoral Cutaneous Nerve).\n\nPATHOPHYSIOLOGY:\nMeralgia paresthetica is an entrapment mononeuropathy of the lateral femoral cutaneous nerve (LFCN), a pure sensory nerve that arises from the L2 and L3 nerve roots of the lumbar plexus. The LFCN courses along the lateral border of the psoas muscle, crosses the iliacus, and passes beneath or through the inguinal ligament near the anterior superior iliac spine (ASIS) before entering the thigh. The nerve is most vulnerable to compression at the point where it passes through or beneath the inguinal ligament, where anatomic variations in its course, external pressure, and angulation changes can produce mechanical injury. Risk factors include obesity (increased intra-abdominal pressure and adipose tissue compressing the nerve), pregnancy, diabetes mellitus, tight clothing or belts (tool belts, police duty belts, tight jeans), prolonged standing or walking, and surgical positioning. The condition has become increasingly recognized in the context of the obesity epidemic and laparoscopic surgery where trocar placement near the ASIS can injure the nerve.\n\nCLINICAL PRESENTATION:\nPatients present with numbness, tingling, burning pain, or dysesthesias over the anterolateral thigh in the distribution of the LFCN. Symptoms are typically unilateral, though bilateral involvement occurs in approximately 20% of cases. The key distinguishing feature is that the LFCN is a purely sensory nerve, so there is no motor weakness, no reflex changes, and no involvement of the medial thigh or leg. This differentiates meralgia paresthetica from femoral neuropathy, which would produce quadriceps weakness and diminished patellar reflex, and from L2-L3 radiculopathy, which typically involves both sensory and motor deficits along with back pain. Symptoms are often exacerbated by prolonged standing, walking, or hip extension, and are relieved by sitting. Examination may reveal decreased sensation to light touch or pinprick over the anterolateral thigh, and the pelvic compression test (relief of symptoms with downward pressure on the pelvis while the patient is in the lateral decubitus position) supports the diagnosis.\n\nTREATMENT:\nManagement begins with identifying and eliminating the source of compression, such as weight loss, wearing looser clothing, and avoiding prolonged standing. These conservative measures alone resolve symptoms in the majority of patients. NSAIDs and topical lidocaine patches may provide symptomatic relief. For refractory cases, a local anesthetic and corticosteroid injection at the inguinal ligament near the ASIS can be both diagnostic and therapeutic. Gabapentin or pregabalin may be used for persistent neuropathic pain. Surgical decompression or neurectomy of the LFCN is reserved for cases unresponsive to prolonged conservative management, though outcomes are variable.\n\nKEY LEARNING POINTS:\nMeralgia paresthetica is caused by compression of the lateral femoral cutaneous nerve at the inguinal ligament, producing numbness and burning over the anterolateral thigh. The purely sensory nature of the LFCN means there is no motor weakness, which distinguishes this condition from femoral neuropathy and lumbar radiculopathy. Obesity, pregnancy, tight clothing, and diabetes are the most common risk factors, and removal of the offending cause is often curative."
  },
  {
    "id": 480,
    "categoryId": 7,
    "question": "De Quervain's Tenosynovitis affects the tendons of the first dorsal compartment. The diagnostic maneuver is:",
    "options": [
      "A) Phalen's Test",
      "B) Finkelstein's Test",
      "C) Tinel's Sign",
      "D) Empty Can Test"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Finkelstein\'s Test).\n\nPATHOPHYSIOLOGY:\nDe Quervain\'s tenosynovitis is a stenosing tenosynovitis affecting the tendons of the first dorsal compartment of the wrist, which contains the abductor pollicis longus (APL) and the extensor pollicis brevis (EPB). The condition results from repetitive thumb abduction and extension or repetitive radial and ulnar deviation of the wrist, leading to thickening and inflammation of the tendon sheaths within the fibro-osseous tunnel overlying the radial styloid. The resulting stenosis creates friction and pain with thumb and wrist movement. De Quervain\'s is most commonly seen in women between 30 and 50 years of age, particularly new mothers who repetitively lift infants with their thumbs abducted and wrists in ulnar deviation, earning it the colloquial name Baby Wrist. Other risk factors include repetitive occupational hand use, rheumatoid arthritis, pregnancy, and postpartum hormonal changes. An anatomic variant in which a septum divides the first dorsal compartment into separate sub-compartments for the APL and EPB can predispose to the condition and contribute to treatment failure.\n\nCLINICAL PRESENTATION:\nPatients present with pain and tenderness along the radial side of the wrist, localized over the radial styloid process, that worsens with gripping, pinching, or thumb movements. Swelling may be visible or palpable over the first dorsal compartment. Finkelstein\'s test is the diagnostic maneuver: the patient tucks the thumb into the palm, closes the fingers over the thumb to make a fist, and the examiner passively ulnar deviates the wrist. Reproduction of sharp pain along the radial styloid confirms the diagnosis by stretching the inflamed APL and EPB tendons across the radial styloid. This must be distinguished from Phalen\'s test (sustained wrist flexion to provoke median nerve compression in carpal tunnel syndrome), Tinel\'s sign (tapping over the carpal tunnel to elicit median nerve paresthesias), and the empty can test (resisted shoulder abduction with internal rotation to evaluate the supraspinatus). Intersection syndrome, which involves the tendons of the second dorsal compartment crossing over the first, causes pain more proximally on the dorsal forearm, approximately 4 to 6 centimeters proximal to the wrist joint.\n\nTREATMENT:\nFirst-line management includes thumb spica splinting to immobilize the thumb and wrist, activity modification to avoid provocative movements, and NSAIDs for symptomatic relief. Corticosteroid injection into the first dorsal compartment sheath is highly effective, with reported cure rates of 60 to 90% after a single injection and is considered when splinting and NSAIDs fail to provide adequate relief. If an anatomic septum is present, the injection must reach both sub-compartments to be effective. Surgical release of the first dorsal compartment is reserved for cases refractory to at least two corticosteroid injections, and involves incising the tendon sheath to decompress the APL and EPB.\n\nKEY LEARNING POINTS:\nFinkelstein\'s test is the diagnostic maneuver for De Quervain\'s tenosynovitis and is performed by having the patient make a fist over the tucked thumb followed by passive ulnar deviation of the wrist. The condition involves the APL and EPB tendons of the first dorsal compartment and is common in new mothers due to repetitive infant lifting. Corticosteroid injection into the first dorsal compartment is highly effective, with cure rates of 60 to 90% after a single injection."
  },
  {
    "id": 481,
    "categoryId": 7,
    "question": "Osteoclasts are responsible for bone resorption. They are activated by RANK-Ligand. Which medication mimics OPG (Osteoprotegerin) to block RANK-L and stop bone loss?",
    "options": [
      "A) Alendronate (Fosamax)",
      "B) Denosumab (Prolia)",
      "C) Teriparatide (Forteo)",
      "D) Raloxifene"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Denosumab).\n\nPATHOPHYSIOLOGY:\nBone homeostasis depends on the balance between osteoblast-mediated bone formation and osteoclast-mediated bone resorption. Osteoclast differentiation and activation are regulated by the RANK-RANKL-OPG signaling axis. RANK (Receptor Activator of Nuclear Factor Kappa-B) is a receptor on osteoclast precursor cells. When RANKL (RANK-Ligand), produced by osteoblasts and osteocytes, binds to RANK, it stimulates osteoclast differentiation, activation, and survival, thereby promoting bone resorption. Osteoprotegerin (OPG) is a naturally occurring decoy receptor also produced by osteoblasts that competitively binds RANKL and prevents it from activating RANK, thereby inhibiting osteoclast formation and reducing bone resorption. In osteoporosis, this balance shifts toward excessive resorption, resulting in decreased bone mineral density and increased fracture risk.\n\nCLINICAL REASONING:\nDenosumab (Prolia) is a fully human monoclonal antibody that mimics the action of OPG by binding to RANKL with high affinity and specificity, preventing RANKL from engaging the RANK receptor on osteoclast precursors. This effectively blocks osteoclast maturation and activation, markedly reducing bone resorption. This mechanism distinguishes it fundamentally from bisphosphonates such as alendronate, which are incorporated into bone matrix and directly induce osteoclast apoptosis by inhibiting farnesyl pyrophosphate synthase in the mevalonate pathway. Teriparatide (Forteo) works by an entirely different approach as a recombinant parathyroid hormone analog that stimulates osteoblast activity to promote new bone formation (an anabolic agent). Raloxifene is a selective estrogen receptor modulator (SERM) that reduces bone resorption through estrogen agonist effects on bone but has weaker antifracture efficacy limited to vertebral fractures.\n\nTREATMENT CONSIDERATIONS:\nDenosumab is administered as a subcutaneous injection every 6 months, which offers an advantage over oral bisphosphonates for patients with gastrointestinal intolerance, esophageal disorders, or renal impairment (denosumab is not renally cleared). The FREEDOM trial demonstrated that denosumab reduced vertebral fractures by 68%, hip fractures by 40%, and nonvertebral fractures by 20% over 3 years. A critical clinical concern is that discontinuation of denosumab leads to a rapid rebound increase in bone turnover markers and bone resorption within 6 months, with loss of gained bone density and a documented increase in vertebral fracture risk, including multiple vertebral fractures. For this reason, patients who stop denosumab must be transitioned to a bisphosphonate to consolidate bone gains and prevent rebound bone loss.\n\nKEY LEARNING POINTS:\nDenosumab mimics osteoprotegerin by binding RANKL, thereby preventing osteoclast maturation and activation, which is mechanistically distinct from bisphosphonates that directly induce osteoclast apoptosis. Discontinuation of denosumab causes rapid rebound bone resorption and increased vertebral fracture risk, mandating transition to bisphosphonate therapy if denosumab is stopped. Denosumab is preferred over bisphosphonates in patients with renal impairment because it is not renally cleared."
  },
  {
    "id": 482,
    "categoryId": 7,
    "question": "A 'Popeye Deformity' (bulge in the lower biceps) indicates rupture of:",
    "options": [
      "A) Distal Biceps Tendon",
      "B) Proximal Long Head of Biceps Tendon",
      "C) Proximal Short Head of Biceps Tendon",
      "D) Triceps Tendon"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Proximal Long Head of Biceps Tendon).\n\nPATHOPHYSIOLOGY:\nThe biceps brachii has two proximal tendons. The long head originates from the supraglenoid tubercle and the superior glenoid labrum (the labral attachment is the anchor for SLAP lesions), courses through the bicipital groove of the humerus, and is held in place by the transverse humeral ligament. The short head originates from the coracoid process of the scapula. The long head tendon is particularly susceptible to degenerative tearing because of its intra-articular course, its passage through the confined bicipital groove where it is subject to mechanical friction, and its association with rotator cuff pathology. Chronic impingement, rotator cuff tears (particularly subscapularis tears that destabilize the bicipital groove), and age-related tendon degeneration are the primary predisposing factors. Rupture typically occurs in patients over 50 years of age and is often preceded by a history of chronic shoulder pain from rotator cuff disease or biceps tendinopathy.\n\nCLINICAL PRESENTATION:\nRupture of the proximal long head of the biceps tendon produces the characteristic Popeye deformity, which is a visible and palpable bulge in the distal anterior arm caused by the retracted and bunched-up muscle belly falling distally under gravity. Patients may report an acute popping sensation followed by ecchymosis in the anterior arm, sudden relief of previously chronic anterior shoulder pain, and mild weakness with forearm supination and elbow flexion. Importantly, the functional deficit is relatively modest because the short head of the biceps and the brachialis muscle compensate for the lost long head function, preserving approximately 70 to 80% of supination strength and 80 to 90% of elbow flexion strength. This distinguishes it from a distal biceps tendon rupture at the radial tuberosity, which produces significant loss of supination strength and elbow flexion power and typically requires surgical repair.\n\nTREATMENT:\nNon-operative management is the standard of care for proximal long head biceps rupture in older, lower-demand patients, consisting of brief rest, ice, NSAIDs, and progressive physical therapy to restore range of motion and strength. The cosmetic deformity is permanent but functionally well tolerated. Surgical repair (tenodesis, in which the tendon is reattached to the proximal humerus, or tenotomy) is considered for younger, active patients, manual laborers, or those who cannot accept the cosmetic deformity or who have concurrent reparable rotator cuff tears.\n\nKEY LEARNING POINTS:\nThe Popeye deformity results from rupture of the proximal long head of the biceps tendon, causing the muscle belly to retract distally and create a visible bulge in the anterior arm. Functional loss is minimal because the short head and brachialis compensate, making non-operative management appropriate for most older adults. Distal biceps tendon rupture, by contrast, causes significant supination weakness and typically requires surgical repair."
  },
  {
    "id": 483,
    "categoryId": 7,
    "question": "Trendelenburg Gait (hip drop) is caused by weakness of the:",
    "options": [
      "A) Gluteus Maximus",
      "B) Gluteus Medius (Abductor)",
      "C) Iliopsoas",
      "D) Hamstrings"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Gluteus Medius).\n\nPATHOPHYSIOLOGY:\nThe gluteus medius is the primary hip abductor and plays a critical role in stabilizing the pelvis during the single-leg stance phase of gait. It originates from the outer surface of the ilium between the anterior and posterior gluteal lines and inserts on the lateral aspect of the greater trochanter. During normal walking, each step involves a brief single-leg stance phase during which the weight-bearing limb must support the entire body. The gluteus medius on the stance-leg side contracts to keep the pelvis level, preventing the contralateral (swing-leg) side from dropping. The superior gluteal nerve (L4, L5, S1) innervates the gluteus medius, and injury to this nerve during hip surgery, intramuscular injections into the upper medial gluteal quadrant, or lumbar radiculopathy affecting L5 can result in gluteus medius weakness. Other causes include hip osteoarthritis, greater trochanteric bursitis, and progressive muscular dystrophies.\n\nCLINICAL PRESENTATION:\nWhen the gluteus medius is weak, the pelvis tilts downward on the contralateral (non-weight-bearing) side during single-leg stance, producing the Trendelenburg sign. An important clinical nuance is that the Trendelenburg sign is named positive on the side of the standing leg, not the dropping side, because it is the standing leg\'s abductor that is failing. For example, if the right gluteus medius is weak, standing on the right leg causes the left pelvis to drop, and the Trendelenburg sign is positive on the right. In walking, this produces the characteristic Trendelenburg gait, in which the patient compensates by lurching the trunk toward the affected (weak) side during stance phase to shift the center of gravity over the weight-bearing hip, reducing the demand on the insufficient abductor. When bilateral gluteus medius weakness is present, the resulting gait pattern is a waddling gait, commonly seen in muscular dystrophies. The Trendelenburg test is performed by asking the patient to stand on one leg for 30 seconds while the examiner observes the pelvis from behind.\n\nTREATMENT:\nManagement depends on the underlying etiology. Physical therapy focusing on hip abductor strengthening exercises, particularly side-lying hip abduction, clamshells, and single-leg stance balance training, is the cornerstone of rehabilitation regardless of cause. If the weakness is secondary to superior gluteal nerve injury, recovery depends on the degree of nerve damage and may take 6 to 12 months. For patients with hip osteoarthritis causing abductor dysfunction, total hip arthroplasty often improves abductor function postoperatively, though care must be taken with surgical approach to avoid iatrogenic superior gluteal nerve injury. Assistive devices such as a cane used in the contralateral hand reduce the demand on the weak abductor by shifting the center of gravity.\n\nKEY LEARNING POINTS:\nThe gluteus medius is the primary hip abductor responsible for keeping the pelvis level during single-leg stance, and its weakness produces the Trendelenburg sign. The Trendelenburg sign is positive on the side of the standing leg, as it is the stance-leg abductor that is failing while the contralateral pelvis drops. The superior gluteal nerve (L4, L5, S1) innervates the gluteus medius, and injury during hip surgery or intramuscular injections is a recognized cause of Trendelenburg gait."
  },
  {
    "id": 484,
    "categoryId": 7,
    "question": "Polymyalgia Rheumatica (PMR) presents with stiffness and pain in the shoulders and hips. It is closely associated with:",
    "options": [
      "A) Giant Cell Arteritis (Temporal Arteritis)",
      "B) Lupus",
      "C) Rheumatoid Arthritis",
      "D) Gout"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Giant Cell Arteritis).\n\nPATHOPHYSIOLOGY:\nPolymyalgia rheumatica (PMR) is a systemic inflammatory condition of unknown etiology that predominantly affects individuals over age 50, with a peak incidence between 70 and 80 years, and is approximately two to three times more common in women. The pathophysiology involves immune-mediated inflammation of the periarticular structures, including the synovial membranes, bursae (particularly the subacromial and trochanteric bursae), and joint capsules of the shoulder and hip girdles. Ultrasound and MRI studies have demonstrated bilateral subdeltoid bursitis, biceps tenosynovitis, and glenohumeral synovitis as the structural correlates of the clinical symptoms. Giant cell arteritis (GCA), also known as temporal arteritis, is a granulomatous vasculitis affecting large and medium-sized arteries, particularly the extracranial branches of the carotid artery including the superficial temporal artery and the ophthalmic artery. Both PMR and GCA share common immunogenetic associations (HLA-DR4), similar demographic profiles, and overlapping inflammatory pathways involving IL-6 and interferon-gamma, supporting the concept that they represent a spectrum of the same disease process.\n\nCLINICAL PRESENTATION:\nPMR presents with bilateral symmetric aching and morning stiffness of the shoulder girdle, hip girdle, and neck that is worst upon waking and improves with activity over 30 to 60 minutes. Patients often report difficulty raising their arms above their heads to brush their hair or getting out of a chair due to hip girdle involvement. Constitutional symptoms including fatigue, malaise, low-grade fever, and weight loss are common. Laboratory findings characteristically reveal markedly elevated ESR (often greater than 40 to 50 mm/hr) and CRP, with normocytic anemia. The critical clinical association is with GCA: approximately 15 to 30% of patients diagnosed with PMR have coexisting GCA, and up to 50% of patients with GCA have PMR symptoms. GCA can cause permanent vision loss from anterior ischemic optic neuropathy due to vasculitis of the posterior ciliary arteries, making early detection essential. All patients with PMR must be screened at every visit for symptoms of GCA, including new-onset headache, scalp tenderness, jaw claudication, visual changes (amaurosis fugax, diplopia, or vision loss), and temporal artery abnormalities.\n\nTREATMENT:\nPMR responds dramatically to low-dose prednisone (12.5 to 25 mg daily), with significant improvement typically occurring within 24 to 72 hours. This rapid and near-complete response is so characteristic that failure to respond should prompt reconsideration of the diagnosis. Prednisone is gradually tapered over 12 to 24 months, guided by symptom recurrence and inflammatory markers. GCA requires high-dose prednisone (40 to 60 mg daily) initiated immediately upon clinical suspicion, even before temporal artery biopsy confirmation, because the risk of irreversible vision loss mandates urgent treatment. Tocilizumab (IL-6 receptor antagonist) has been approved as a steroid-sparing agent for both GCA and relapsing PMR based on the GiACTA trial.\n\nKEY LEARNING POINTS:\nPMR and GCA are closely linked conditions, with 15 to 30% of PMR patients having coexisting GCA and 50% of GCA patients having PMR symptoms. All PMR patients must be regularly screened for headache, jaw claudication, and visual symptoms to detect GCA before irreversible vision loss occurs. PMR responds dramatically to low-dose prednisone within 24 to 72 hours, while GCA requires high-dose prednisone initiated urgently upon clinical suspicion."
  },
  {
    "id": 485,
    "categoryId": 7,
    "question": "A Colles' Fracture is a distal radius fracture with dorsal angulation ('Dinner Fork deformity'). It is most commonly caused by:",
    "options": [
      "A) Direct blow",
      "B) Fall on Outstretched Hand (FOOSH)",
      "C) Twisting injury",
      "D) Overuse"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Fall on Outstretched Hand).\n\nPATHOPHYSIOLOGY:\nA Colles fracture is a fracture of the distal radius with dorsal displacement and dorsal angulation of the distal fragment, resulting from a fall on an outstretched hand (FOOSH mechanism) with the wrist in dorsiflexion. Upon impact, axial loading forces are transmitted through the hyperextended wrist, and the dorsal cortex of the distal radius acts as a fulcrum, creating a tensile failure on the volar surface and compression on the dorsal surface that drives the distal fragment dorsally. This is the most common fracture of the forearm and is the most common fracture in postmenopausal women, reflecting the high prevalence of osteoporotic bone in this population. In younger patients, a higher-energy mechanism (such as a fall from height or motor vehicle collision) is typically required to produce the same fracture pattern. The Smith fracture is the reverse pattern, with volar displacement of the distal fragment resulting from a fall on a flexed wrist, and is sometimes called a reverse Colles fracture.\n\nCLINICAL PRESENTATION:\nThe classic presentation is wrist pain, swelling, and the pathognomonic dinner fork deformity, in which the dorsal displacement of the distal fragment creates a step-off visible on lateral inspection that resembles the curvature of a fork viewed from the side. The patient holds the wrist in a guarded position and has significant tenderness over the distal radius. Neurovascular examination is essential, as acute carpal tunnel syndrome from median nerve compression by the displaced fragment or swelling occurs in up to 5 to 10% of distal radius fractures and requires urgent decompression. An associated ulnar styloid fracture is present in approximately 50 to 60% of cases. Standard posteroanterior and lateral wrist radiographs confirm the diagnosis and allow assessment of fracture displacement, angulation, articular involvement, and associated ulnar-sided injury. CT may be obtained for intra-articular fractures to guide surgical planning.\n\nTREATMENT:\nStable, minimally displaced extra-articular fractures are managed with closed reduction under hematoma block or conscious sedation, followed by sugar-tong splinting and conversion to a short arm cast at one to two weeks once swelling subsides. Immobilization is typically maintained for 4 to 6 weeks with serial radiographs to monitor for loss of reduction. Unstable fractures, defined by significant dorsal comminution, intra-articular extension, shortening greater than 5 mm, or loss of reduction after casting, require surgical fixation, most commonly with a volar locking plate. All distal radius fractures in patients over 50 should prompt evaluation for underlying osteoporosis, including DEXA screening and consideration of pharmacotherapy, as a distal radius fracture is a recognized fragility fracture that doubles the risk of subsequent hip fracture.\n\nKEY LEARNING POINTS:\nA Colles fracture is a dorsally displaced distal radius fracture caused by a fall on an outstretched hand, producing the classic dinner fork deformity. Median nerve function must be assessed because acute carpal tunnel syndrome complicates up to 5 to 10% of distal radius fractures. In patients over 50, a Colles fracture should be treated as a fragility fracture with osteoporosis evaluation and secondary prevention."
  },
  {
    "id": 486,
    "categoryId": 7,
    "question": "The 'Unhappy Triad' (O'Donoghue's Triad) of knee injury typically involves the ACL, MCL, and:",
    "options": [
      "A) LCL",
      "B) Medial Meniscus",
      "C) Lateral Meniscus",
      "D) Patellar Tendon"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Medial Meniscus).\n\nPATHOPHYSIOLOGY:\nThe unhappy triad, also known as O\'Donoghue\'s triad, describes a combined injury to three structures of the knee resulting from a valgus force applied to the lateral aspect of a flexed and externally rotated knee, as classically occurs in contact sports such as football when a player is tackled from the lateral side. The mechanism applies a valgus stress that sequentially injures structures from lateral to medial: first the anterior cruciate ligament (ACL) tears as the tibia is driven anteriorly and the femur rotates internally, then the medial collateral ligament (MCL) ruptures as the valgus force exceeds its tensile strength, and finally the medial meniscus tears because it is firmly attached to the deep fibers of the MCL and the joint capsule via the coronary ligaments, making it vulnerable when the MCL is disrupted. The ACL is the primary restraint to anterior tibial translation and internal rotation, the MCL is the primary restraint to valgus stress, and the medial meniscus serves as a secondary stabilizer to anterior translation, which explains why all three structures are at risk from this combined loading mechanism.\n\nCLINICAL PRESENTATION:\nPatients typically present after a contact injury to the lateral knee with immediate swelling (hemarthrosis from ACL rupture), inability to bear weight, and a sense of the knee \"giving way.\" Physical examination reveals a positive Lachman test and anterior drawer test indicating ACL insufficiency, valgus laxity at 30 degrees of flexion indicating MCL disruption, and joint line tenderness with positive McMurray test suggesting meniscal injury. MRI is the imaging modality of choice and demonstrates the three injured structures with high sensitivity and specificity. It is important to note that more recent MRI-based studies have demonstrated that lateral meniscus tears are actually more common than medial meniscus tears in the setting of acute ACL injuries, as the lateral tibial plateau undergoes greater anterior subluxation during the pivot-shift mechanism. However, the classic teaching of ACL, MCL, and medial meniscus remains the standard board answer for the unhappy triad resulting from a valgus and external rotation blow.\n\nTREATMENT:\nManagement of the unhappy triad has evolved significantly. ACL reconstruction is typically recommended for active patients, using hamstring tendon or bone-patellar tendon-bone autograft. Isolated MCL injuries heal well with conservative management (hinged knee brace and progressive rehabilitation) because the MCL has an excellent blood supply, and most grade I and II MCL sprains are treated non-operatively even in the setting of combined injury. Medial meniscus tears in the peripheral (red) zone may be amenable to surgical repair, while tears in the avascular central (white) zone typically require partial meniscectomy. Rehabilitation following combined reconstruction emphasizes early range of motion, progressive quadriceps and hamstring strengthening, and a gradual return to sport typically at 9 to 12 months.\n\nKEY LEARNING POINTS:\nThe unhappy triad (O\'Donoghue\'s triad) classically involves the ACL, MCL, and medial meniscus, resulting from a valgus and external rotation force to the knee. Although recent MRI evidence shows lateral meniscus tears are more common in acute ACL injuries, the classic board association remains ACL, MCL, and medial meniscus. The MCL has excellent healing potential with conservative management due to its robust blood supply, while ACL reconstruction is typically required in active patients."
  },
  {
    "id": 487,
    "categoryId": 7,
    "question": "Uric Acid crystals in Gout are identified on microscopy as:",
    "options": [
      "A) Positively birefringent, Rhomboid shape",
      "B) Negatively birefringent, Needle shape",
      "C) Non-birefringent, amorphous",
      "D) Spherical"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Negatively birefringent, Needle shape).\n\nPATHOPHYSIOLOGY:\nGout is an inflammatory arthritis caused by the deposition of monosodium urate (MSU) crystals in joints and periarticular tissues when serum uric acid levels exceed the saturation threshold of approximately 6.8 mg/dL. Uric acid is the end product of purine metabolism in humans, who lack the enzyme uricase that converts urate to the more soluble allantoin in most other mammals. Hyperuricemia results from either overproduction of uric acid (10% of cases, associated with high purine intake, myeloproliferative disorders, and tumor lysis syndrome) or underexcretion (90% of cases, associated with chronic kidney disease, diuretic use, and genetic variations in renal urate transporters such as URAT1 and GLUT9). When MSU crystals precipitate in the joint space, they are phagocytosed by resident macrophages, activating the NLRP3 inflammasome and triggering release of interleukin-1 beta, which drives the intense neutrophilic inflammatory response characteristic of an acute gout flare. The definitive diagnosis requires joint aspiration demonstrating negatively birefringent, needle-shaped crystals under compensated polarized light microscopy, which means the crystals appear yellow when parallel to the axis of the red compensator. This is in direct contrast to calcium pyrophosphate dihydrate (CPPD) crystals of pseudogout, which are positively birefringent and rhomboid-shaped, appearing blue when parallel to the compensator axis.\n\nCLINICAL PRESENTATION:\nAcute gouty arthritis presents with sudden onset of severe pain, swelling, erythema, and warmth of a single joint, classically the first metatarsophalangeal joint (podagra) in approximately 50% of initial attacks. The attack characteristically begins at night or in the early morning, reaches peak intensity within 12 to 24 hours, and the affected joint is so exquisitely tender that even the weight of a bedsheet is intolerable. Untreated, acute flares are self-limited and resolve within 7 to 14 days. Risk factors include hyperuricemia, male sex, obesity, purine-rich diet (red meat, organ meats, shellfish), alcohol consumption (particularly beer, which contains guanosine), thiazide and loop diuretics, chronic kidney disease, and metabolic syndrome. Chronic tophaceous gout develops after years of inadequately treated hyperuricemia, with deposition of large urate crystal aggregates (tophi) in joints, bursae, tendons, and soft tissues, most commonly the olecranon bursa, Achilles tendon, and helix of the ear.\n\nTREATMENT:\nAcute flare management per ACR 2020 guidelines includes three equally effective first-line options: NSAIDs at full anti-inflammatory doses (such as indomethacin 50 mg three times daily or naproxen 500 mg twice daily), colchicine (most effective within 12 to 36 hours of onset, using the low-dose regimen of 1.2 mg followed by 0.6 mg one hour later, which is as effective and far better tolerated than traditional high-dose protocols), or corticosteroids (prednisone 30 to 40 mg daily for 5 to 7 days, preferred when NSAIDs and colchicine are contraindicated). Urate-lowering therapy (ULT) is indicated for patients with recurrent flares (two or more per year), tophi, chronic kidney disease, or uric acid urolithiasis. Allopurinol, a xanthine oxidase inhibitor, is first-line ULT started at 100 mg daily (50 mg in CKD) and titrated to achieve a target serum urate below 6 mg/dL. ULT should not be initiated during an acute flare but rather 2 to 4 weeks after resolution, and prophylactic low-dose colchicine (0.6 mg once or twice daily) or low-dose NSAID should be co-prescribed for 3 to 6 months when starting ULT to prevent mobilization flares that occur as tissue urate stores dissolve.\n\nKEY LEARNING POINTS:\nGout is definitively diagnosed by joint aspiration showing negatively birefringent, needle-shaped monosodium urate crystals, in contrast to pseudogout which shows positively birefringent, rhomboid-shaped CPPD crystals. Acute gout flares are managed equally well with NSAIDs, colchicine, or corticosteroids, while urate-lowering therapy with allopurinol targets a serum urate below 6 mg/dL. ULT should not be started during an acute flare, and prophylactic anti-inflammatory therapy for 3 to 6 months prevents mobilization flares when ULT is initiated."
  },
  {
    "id": 488,
    "categoryId": 7,
    "question": "Spinal Stenosis typically presents with 'Neurogenic Claudication', which is defined as:",
    "options": [
      "A) Leg pain that worsens with walking and improves with sitting/flexion",
      "B) Leg pain that worsens with rest",
      "C) Leg pain that is constant",
      "D) Leg pain relieved by standing straight up"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Leg pain that worsens with walking and improves with sitting/flexion).\n\nPATHOPHYSIOLOGY:\nLumbar spinal stenosis is a narrowing of the spinal canal, lateral recesses, or neural foramina in the lumbar spine that compresses the cauda equina and exiting nerve roots. The most common cause is degenerative, resulting from a combination of disc bulging, facet joint hypertrophy, ligamentum flavum thickening, and osteophyte formation that progressively encroaches on the spinal canal. This degenerative process typically affects patients over age 60 and most commonly involves the L4-L5 level, followed by L3-L4. The hallmark symptom is neurogenic claudication, which must be distinguished from vascular claudication caused by peripheral arterial disease. In neurogenic claudication, lumbar extension narrows the spinal canal and neural foramina by causing the ligamentum flavum to buckle inward and the disc to bulge posteriorly, compressing the cauda equina. Conversely, lumbar flexion opens the canal and foramina, relieving the compression. This biomechanical principle explains the characteristic positional nature of the symptoms and the classic shopping cart sign, in which patients experience relief when leaning forward over a shopping cart because flexion increases the cross-sectional area of the spinal canal by up to 10 to 15%.\n\nCLINICAL PRESENTATION:\nPatients with neurogenic claudication describe bilateral or unilateral leg pain, heaviness, numbness, tingling, or weakness that develops with walking or prolonged standing and is relieved by sitting, squatting, or leaning forward. Symptoms are characteristically worse walking downhill (which promotes lumbar extension) and better walking uphill (which promotes flexion). This pattern is the critical distinguishing feature from vascular claudication, in which leg pain is reliably produced by a fixed walking distance, is relieved simply by standing still (not requiring positional change), and is associated with diminished peripheral pulses, hair loss, and skin changes. In neurogenic claudication, peripheral pulses are normal, and the ABI (ankle-brachial index) is preserved. The neurologic examination may be normal at rest, and provocative testing such as having the patient walk until symptoms are reproduced may reveal transient weakness or reflex changes. MRI of the lumbar spine is the imaging study of choice and demonstrates the degree and level of canal narrowing, disc pathology, and ligamentum flavum hypertrophy. According to UpToDate and NEJM reviews, clinical severity does not always correlate with the degree of radiographic stenosis, making clinical judgment essential.\n\nTREATMENT:\nConservative management is first-line and includes physical therapy emphasizing flexion-based exercises (Williams flexion exercises), core stabilization, and activity modification. Epidural steroid injections provide moderate short-term symptom relief (typically 2 to 6 weeks) and are supported by evidence from the SPORT trial data as a temporizing measure. NSAIDs and gabapentin or pregabalin for neuropathic symptoms may be used as adjuncts. Surgical decompression (laminectomy with or without fusion) is indicated for patients with persistent symptoms despite 3 to 6 months of conservative therapy, progressive neurologic deficits, or significantly impaired quality of life. The landmark SPORT trial published in NEJM demonstrated that surgical treatment provided greater improvement in pain and function compared to non-operative management at 2 and 4 years for patients with symptomatic lumbar spinal stenosis, though there was significant crossover between treatment groups.\n\nKEY LEARNING POINTS:\nNeurogenic claudication from lumbar spinal stenosis is characterized by leg pain that worsens with walking and lumbar extension and improves with sitting or leaning forward (the shopping cart sign), in contrast to vascular claudication which is relieved simply by standing still. Peripheral pulses are normal in neurogenic claudication, and MRI is the imaging modality of choice for confirming the diagnosis and level of stenosis. Flexion-based physical therapy is first-line treatment, with surgical decompression reserved for patients who fail 3 to 6 months of conservative management or who develop progressive neurologic deficits."
  },
  {
    "id": 489,
    "categoryId": 7,
    "question": "Which nerve runs in the spiral groove of the humerus and is at risk during mid-shaft humerus fractures?",
    "options": [
      "A) Median Nerve",
      "B) Ulnar Nerve",
      "C) Radial Nerve",
      "D) Axillary Nerve"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Radial Nerve).\n\nPATHOPHYSIOLOGY:\nThe radial nerve (C5-T1) is the largest branch of the posterior cord of the brachial plexus and is the nerve most commonly injured in humeral shaft fractures. After branching from the posterior cord, the radial nerve courses posteriorly around the humerus in the spiral (radial) groove, a shallow depression on the posterior surface of the mid-shaft humerus, where it lies in direct contact with the periosteum for approximately 7 centimeters. This intimate anatomic relationship between nerve and bone makes the radial nerve uniquely vulnerable to injury from mid-shaft humerus fractures, with reported injury rates of 12 to 18% of all humeral shaft fractures according to data compiled in UpToDate and orthopedic surgery literature. The Holstein-Lewis fracture, a distal-third spiral fracture of the humerus, carries the highest risk of radial nerve injury because the nerve is tethered as it pierces the lateral intermuscular septum at this level. The radial nerve can also be injured iatrogenically during open reduction and internal fixation of humeral fractures, or by compression in the spiral groove from prolonged external pressure (Saturday night palsy from draping the arm over a chair while intoxicated, or honeymoon palsy from a partner sleeping on the arm).\n\nCLINICAL PRESENTATION:\nRadial nerve injury at the spiral groove produces the classic wrist drop, which is the inability to extend the wrist and fingers at the metacarpophalangeal joints due to paralysis of the extensor compartment muscles of the forearm including the extensor carpi radialis longus and brevis, extensor digitorum, extensor carpi ulnaris, and extensor pollicis longus. Patients are unable to extend the wrist against gravity and have weak finger extension. The brachioradialis reflex is diminished or absent. Sensory loss occurs over the dorsal first web space (the anatomical snuffbox region), which is the autonomous sensory territory of the superficial branch of the radial nerve. Importantly, the triceps is typically spared in spiral groove injuries because the branches to the triceps arise proximal to the groove. This distinguishes a spiral groove lesion from a more proximal posterior cord or high radial nerve injury, where triceps weakness would also be present. Other nerve-fracture associations to recognize include axillary nerve injury with proximal humerus fractures and surgical neck fractures (producing deltoid weakness and lateral shoulder sensory loss), and ulnar nerve injury with medial epicondyle fractures of the distal humerus (producing fourth and fifth finger clawing and intrinsic muscle weakness).\n\nTREATMENT:\nThe majority of radial nerve palsies associated with closed humeral shaft fractures are neuropraxias (stretch injuries without axonal disruption) and recover spontaneously within 3 to 4 months. Initial management includes a wrist extension splint (cock-up splint) to maintain functional wrist position and prevent flexion contracture, gentle range of motion exercises, and serial clinical and electrodiagnostic monitoring. Electromyography and nerve conduction studies are typically performed at 3 to 4 weeks post-injury to establish a baseline and repeated at 3 to 4 months to assess for reinnervation. Surgical exploration of the radial nerve is indicated for open fractures with radial nerve palsy (suggesting laceration), radial nerve palsy that develops after closed reduction or surgical fixation (suggesting iatrogenic entrapment), and failure of clinical or electrodiagnostic recovery by 3 to 4 months.\n\nKEY LEARNING POINTS:\nThe radial nerve courses through the spiral groove of the mid-shaft humerus and is injured in 12 to 18% of humeral shaft fractures, producing the classic wrist drop from loss of wrist and finger extensors. The axillary nerve is at risk in proximal humerus fractures, and the ulnar nerve is at risk in medial epicondyle fractures. Most radial nerve injuries from closed fractures are neuropraxias that recover spontaneously within 3 to 4 months with wrist splinting, and surgical exploration is reserved for open fractures, iatrogenic injury, or failure to recover."
  },
  {
    "id": 490,
    "categoryId": 7,
    "question": "The Sarcomere is the functional unit of muscle. Contraction occurs when:",
    "options": [
      "A) Actin and Myosin filaments shorten",
      "B) Actin filaments slide over Myosin filaments (Sliding Filament Theory)",
      "C) Calcium binds to Myosin directly",
      "D) ATP is produced"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Actin filaments slide over Myosin filaments).\n\nPATHOPHYSIOLOGY:\nThe sarcomere is the basic contractile unit of skeletal and cardiac muscle, defined as the segment between two adjacent Z-lines (Z-discs). It contains two primary structural proteins: thin filaments composed of actin (anchored to the Z-lines) and thick filaments composed of myosin (centered in the sarcomere at the M-line). The sliding filament theory, proposed independently by Hugh Huxley and Jean Hanson and by Andrew Huxley and Rolf Niedergerke in 1954 and subsequently confirmed by decades of structural and biophysical research, establishes that muscle contraction occurs not by shortening of the individual filaments themselves, but by the actin thin filaments sliding over the myosin thick filaments toward the center of the sarcomere, increasing their degree of overlap. This sliding is powered by cyclic cross-bridge interactions between the myosin heads and actin binding sites.\n\nCLINICAL REASONING:\nThe molecular mechanism proceeds through a precisely ordered sequence. At rest, the regulatory proteins tropomyosin and troponin block the myosin-binding sites on actin. When an action potential reaches the sarcoplasmic reticulum via the T-tubule system, calcium ions are released into the cytoplasm. Calcium binds to troponin C, inducing a conformational change in the troponin-tropomyosin complex that shifts tropomyosin away from the active sites on actin, exposing them to the myosin heads. The myosin head, which has already hydrolyzed ATP to ADP and inorganic phosphate (placing it in a high-energy \"cocked\" configuration), binds to the exposed actin site forming a cross-bridge. Release of inorganic phosphate triggers the power stroke, in which the myosin head pivots and pulls the actin filament toward the M-line, generating force. ADP is then released, and binding of a new ATP molecule causes the myosin head to detach from actin. ATP hydrolysis then re-cocks the myosin head for another cycle. This cycle repeats rapidly (approximately 5 cycles per second per cross-bridge) as long as calcium and ATP are available. Rigor mortis occurs after death because ATP depletion prevents myosin from detaching from actin, locking all cross-bridges in the attached state.\n\nCLINICAL SIGNIFICANCE:\nUnderstanding the sliding filament mechanism has direct clinical relevance. Malignant hyperthermia, a life-threatening pharmacogenetic disorder triggered by volatile anesthetics and succinylcholine, results from uncontrolled calcium release from the sarcoplasmic reticulum through defective ryanodine receptors, producing sustained muscle contraction, rigidity, and extreme heat generation. Dantrolene, the specific treatment, works by blocking calcium release from the sarcoplasmic reticulum. Myasthenia gravis involves autoantibodies against acetylcholine receptors at the neuromuscular junction, reducing the signal that initiates muscle depolarization and calcium release. Lambert-Eaton myasthenic syndrome involves antibodies against presynaptic voltage-gated calcium channels, reducing acetylcholine release.\n\nKEY LEARNING POINTS:\nMuscle contraction occurs by actin thin filaments sliding over myosin thick filaments (the sliding filament theory), with the filaments themselves maintaining constant length and only increasing their overlap. The cross-bridge cycle requires calcium binding to troponin to expose actin binding sites and ATP to detach myosin from actin and re-cock the myosin head. Rigor mortis results from ATP depletion preventing myosin detachment from actin, and malignant hyperthermia results from uncontrolled sarcoplasmic reticulum calcium release treated specifically with dantrolene."
  },
  {
    "id": 491,
    "categoryId": 7,
    "question": "Osgood-Schlatter Disease is an apophysitis caused by traction of the:",
    "options": [
      "A) Quadriceps tendon on the patella",
      "B) Patellar tendon on the Tibial Tubercle",
      "C) Achilles tendon on the Calcaneus",
      "D) Hamstrings on the Ischium"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Patellar tendon on the Tibial Tubercle).\n\nPATHOPHYSIOLOGY:\nOsgood-Schlatter disease is a traction apophysitis of the tibial tubercle occurring at the insertion of the patellar tendon onto the secondary ossification center of the proximal tibia. During the adolescent growth spurt, the long bones grow rapidly, and the musculotendinous units cannot lengthen at the same rate, creating increased tension at the apophyseal insertion sites. The tibial tubercle apophysis is particularly vulnerable because it is the weakest link in the extensor mechanism chain (quadriceps muscle to quadriceps tendon to patella to patellar tendon to tibial tubercle), and repetitive traction from forceful quadriceps contraction during running, jumping, and kicking activities produces microavulsion injuries, inflammation, and new bone formation at the apophysis. The condition predominantly affects adolescents aged 10 to 15 years during peak growth velocity, with boys historically affected more frequently, though the gender gap has narrowed with increased female athletic participation. Up to 30% of cases are bilateral. Risk factors include participation in jumping sports (basketball, volleyball), running sports (soccer, track), and any activity requiring repetitive quadriceps loading. The condition is self-limited and resolves with skeletal maturity when the apophysis fuses to the tibial shaft, though a prominent tibial tubercle may persist permanently.\n\nCLINICAL PRESENTATION:\nPatients present with anterior knee pain localized directly over the tibial tubercle, approximately 2 to 3 centimeters below the inferior pole of the patella. The pain worsens with running, jumping, squatting, kneeling, and stair climbing and improves with rest. Physical examination reveals a tender, swollen, and often visibly prominent tibial tubercle. Pain is reproduced by resisted knee extension and by direct palpation of the tibial tubercle. Importantly, the knee joint itself is stable, with no effusion, no ligamentous laxity, and full range of motion, which distinguishes Osgood-Schlatter disease from intra-articular pathology. The diagnosis is clinical and does not require imaging in typical presentations. When obtained, lateral knee radiographs may show soft tissue swelling anterior to the tibial tubercle, fragmentation of the apophysis, or elevation of the tibial tubercle. Sinding-Larsen-Johansson syndrome is a related traction apophysitis occurring at the inferior pole of the patella (the proximal attachment of the patellar tendon) and should be considered in the differential when pain is localized slightly higher than in Osgood-Schlatter.\n\nTREATMENT:\nManagement is conservative and focuses on activity modification, relative rest from provocative activities, and reassurance that the condition is self-limited and will resolve with skeletal maturity. Ice application after activity and NSAIDs provide symptomatic relief during flares. Quadriceps and hamstring stretching reduces tension at the apophysis, and a structured physical therapy program emphasizing eccentric quadriceps strengthening and flexibility has been shown to accelerate symptom improvement. Protective padding over the tibial tubercle may allow continued sports participation with less discomfort from direct contact. Complete cessation of activity is generally not necessary, and athletes may participate to their pain tolerance. Immobilization is reserved for severe cases unresponsive to conservative measures. Rarely, a painful free ossicle (unfused bone fragment) may persist after skeletal maturity and require surgical excision if it remains symptomatic.\n\nKEY LEARNING POINTS:\nOsgood-Schlatter disease is a traction apophysitis of the tibial tubercle at the patellar tendon insertion, occurring in adolescents during the growth spurt when the bone grows faster than the musculotendinous unit can accommodate. The diagnosis is clinical, with tenderness and swelling localized to the tibial tubercle, a stable knee joint without effusion, and pain reproduced by resisted knee extension. The condition is self-limited and resolves with skeletal maturity, with treatment focused on activity modification, stretching, and symptomatic relief."
  },
  {
    "id": 492,
    "categoryId": 7,
    "question": "The earliest and most sensitive sign of Compartment Syndrome is:",
    "options": [
      "A) Loss of pulse",
      "B) Pain out of proportion to injury (especially with passive stretch)",
      "C) Pallor",
      "D) Paralysis"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Pain out of proportion to injury, especially with passive stretch).\n\nPATHOPHYSIOLOGY:\nAcute compartment syndrome is a surgical emergency in which elevated pressure within a closed fascial compartment compromises perfusion to the muscles and nerves within that compartment, leading to tissue ischemia and, if untreated, irreversible necrosis. The fascial compartments of the extremities are non-expansile, bounded by bone and thick fascia that cannot accommodate significant increases in volume. When intracompartmental pressure rises, typically from hemorrhage or edema following fracture (tibial shaft fractures are the most common cause, accounting for approximately 36% of cases), crush injury, reperfusion after vascular repair, tight casts, or burns, the pressure exceeds the perfusion pressure of the capillaries and small vessels within the compartment. This impairs venous outflow first, leading to further edema, which increases pressure further in a vicious cycle. Importantly, compartment pressures that cause tissue ischemia (typically 30 mmHg or within 30 mmHg of diastolic blood pressure) are far below systemic arterial pressure. This is why peripheral pulses remain palpable until very late in the disease process, as arterial flow is not occluded until pressures far exceed those that have already destroyed muscle and nerve tissue.\n\nCLINICAL PRESENTATION:\nPain out of proportion to the injury is the earliest and most sensitive clinical finding. The pain is deep, unremitting, and characteristically worsened by passive stretch of the muscles within the affected compartment, which increases tension on the ischemic muscle fibers. For example, in anterior compartment syndrome of the leg, passive plantarflexion of the toes and ankle (stretching the anterior compartment muscles) produces severe pain. The classic teaching of the six P's (Pain, Pressure, Paresthesias, Paralysis, Pallor, Pulselessness) describes a progression from early to late findings. Paresthesias indicate nerve ischemia and represent an intermediate stage. Paralysis indicates motor nerve and muscle death and represents a late finding. Pulselessness is a very late sign that occurs only when compartment pressure exceeds arterial pressure, by which time irreversible tissue damage has already occurred. Clinical diagnosis in an alert patient is based primarily on the presence of pain with passive stretch and a tense, swollen compartment. In obtunded or intubated patients, continuous compartment pressure monitoring is essential. Diagnosis is confirmed when intracompartmental pressure exceeds 30 mmHg absolute, or when the delta pressure (diastolic blood pressure minus compartment pressure) is less than 30 mmHg.\n\nTREATMENT:\nEmergent fasciotomy is the definitive treatment and must be performed without delay once the diagnosis is established or strongly suspected. All constrictive dressings, casts, and splints must be removed immediately as a temporizing measure. In the leg, where the anterior compartment is most commonly affected, a two-incision four-compartment fasciotomy is the standard surgical approach. The fasciotomy wounds are left open and managed with staged closure or skin grafting at 48 to 72 hours once swelling resolves. According to UpToDate and Harrison's Principles of Internal Medicine, irreversible muscle necrosis begins within 4 to 6 hours of sustained ischemia, and delay in fasciotomy beyond 6 to 8 hours is associated with significantly increased rates of amputation, permanent nerve injury, and Volkmann ischemic contracture (in the forearm). Rhabdomyolysis with myoglobinuria, hyperkalemia, and acute kidney injury may complicate delayed diagnosis.\n\nKEY LEARNING POINTS:\nPain out of proportion to injury, especially pain with passive stretch of the muscles in the affected compartment, is the earliest and most sensitive sign of compartment syndrome, while pulselessness is a very late finding that indicates tissue death has already occurred. Compartment syndrome is a surgical emergency requiring emergent fasciotomy, as irreversible muscle necrosis begins within 4 to 6 hours of sustained ischemia. Tibial shaft fractures are the most common cause, and peripheral pulses remain present until very late because arterial pressure far exceeds the compartment pressures that destroy muscle and nerve tissue."
  },
  {
    "id": 493,
    "categoryId": 7,
    "question": "Ankylosing Spondylitis begins with inflammation at the:",
    "options": [
      "A) Cervical Spine",
      "B) Sacroiliac (SI) Joints",
      "C) Knee",
      "D) Costochondral joints"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Sacroiliac Joints).\n\nPATHOPHYSIOLOGY:\nAnkylosing spondylitis (AS) is a chronic inflammatory spondyloarthritis characterized by inflammation at entheses (the sites where tendons, ligaments, and joint capsules insert into bone) and a strong genetic association with HLA-B27, which is present in approximately 90 to 95% of patients with AS compared to 6 to 8% of the general Caucasian population. The disease process begins at the sacroiliac joints in virtually all cases, making sacroiliitis the radiographic hallmark and the earliest detectable structural change. The pathophysiology involves an aberrant immune response in which CD8+ T cells, innate immune cells, and the IL-23/IL-17 signaling axis drive chronic entheseal inflammation. Unlike rheumatoid arthritis, where chronic inflammation leads to bone erosion and destruction, the inflammatory process in AS triggers a paradoxical anabolic bone response in which new bone formation at the entheses produces syndesmophytes (bony bridges between vertebral bodies). Over years to decades, progressive syndesmophyte formation leads to ankylosis (bony fusion) of the spine, beginning at the sacroiliac joints and ascending through the lumbar, thoracic, and eventually cervical spine, producing the classic bamboo spine appearance on radiographs. The disease predominantly affects young men, with a typical onset between ages 15 and 40, and the male-to-female ratio is approximately 2 to 3:1.\n\nCLINICAL PRESENTATION:\nThe cardinal symptom is inflammatory back pain, which is defined by insidious onset before age 40, duration greater than 3 months, morning stiffness lasting more than 30 minutes that improves with exercise and does not improve with rest, and alternating buttock pain. This pattern must be distinguished from mechanical low back pain, which worsens with activity and improves with rest. Reduced spinal mobility develops progressively, beginning with loss of lumbar lordosis and restricted lateral flexion, and can be assessed using the modified Schober test (less than 5 cm of lumbar expansion with forward flexion is abnormal). Reduced chest expansion (less than 2.5 cm) reflects costovertebral joint involvement and can compromise pulmonary function. Extra-articular manifestations are common and include anterior uveitis (the most common extra-articular manifestation, occurring in approximately 25 to 40% of patients, presenting with unilateral eye pain, redness, and photophobia), inflammatory bowel disease (up to 10% have clinically apparent IBD, with subclinical gut inflammation present in up to 60%), psoriasis, aortitis, and apical pulmonary fibrosis. Diagnosis is supported by elevated ESR and CRP in approximately 50 to 70% of patients, and imaging is essential. Conventional radiographs may be normal early in disease, as sacroiliac changes take years to become apparent. MRI of the sacroiliac joints can detect bone marrow edema representing active inflammation before structural changes are visible on radiographs and is the recommended imaging modality for early or suspected disease per the ASAS (Assessment of SpondyloArthritis international Society) classification criteria.\n\nTREATMENT:\nRegular exercise and physical therapy emphasizing posture, spinal extension, and range of motion are the foundation of management and should be initiated in all patients regardless of disease severity. NSAIDs at full anti-inflammatory doses are first-line pharmacotherapy and are often remarkably effective, with up to 70 to 80% of patients reporting significant improvement. Continuous NSAID use has been suggested to slow radiographic progression, though evidence remains debated. For patients with inadequate response to at least two NSAIDs over a 4-week period, biologic therapy with TNF-alpha inhibitors (adalimumab, etanercept, infliximab) or IL-17A inhibitors (secukinumab, ixekizumab) is recommended by ACR/SAA/SPARTAN 2019 guidelines. Conventional DMARDs (methotrexate, sulfasalazine) are ineffective for axial disease but may be considered for peripheral joint involvement. Rheumatology co-management is essential for biologic therapy selection and monitoring.\n\nKEY LEARNING POINTS:\nAnkylosing spondylitis begins at the sacroiliac joints in virtually all cases and is strongly associated with HLA-B27, with chronic entheseal inflammation triggering paradoxical new bone formation that progressively fuses the spine. Inflammatory back pain is distinguished from mechanical back pain by its insidious onset before age 40, morning stiffness improving with activity, and alternating buttock pain. MRI of the sacroiliac joints detects early inflammation before radiographic changes appear, and first-line treatment combines regular exercise with full-dose NSAIDs, with TNF-alpha or IL-17A inhibitors reserved for NSAID-refractory disease."
  },
  {
    "id": 494,
    "categoryId": 7,
    "question": "The most common organism causing Osteomyelitis in healthy adults is:",
    "options": [
      "A) Salmonella",
      "B) Staphylococcus aureus",
      "C) Pseudomonas",
      "D) E. coli"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Staphylococcus aureus).\n\nPATHOPHYSIOLOGY:\nOsteomyelitis is an infection of bone that can be classified by mechanism of infection (hematogenous, contiguous, or direct inoculation), duration (acute or chronic), and host factors. Staphylococcus aureus is the most common causative organism overall, responsible for approximately 50 to 70% of all cases across all age groups and infection routes, owing to its surface adhesins (particularly microbial surface components recognizing adhesive matrix molecules, or MSCRAMMs) that bind specifically to bone matrix proteins including collagen, fibronectin, and bone sialoprotein. Once established in bone, S. aureus can form biofilms on necrotic bone and implant surfaces, evade host immune defenses by internalizing within osteocytes and osteoblasts, and induce osteoclast-mediated bone resorption, all of which contribute to treatment difficulty and chronicity. Hematogenous osteomyelitis predominates in children, where the rich metaphyseal blood supply and sluggish blood flow through metaphyseal capillary loops create a favorable environment for bacterial seeding, most commonly affecting the distal femur and proximal tibia. In adults, hematogenous osteomyelitis most commonly involves the vertebral bodies, while contiguous-spread osteomyelitis from diabetic foot ulcers, pressure injuries, or postsurgical wounds is the more prevalent adult form overall.\n\nCLINICAL PRESENTATION:\nAcute osteomyelitis presents with localized bone pain, tenderness, warmth, swelling, and often fever and malaise. In children, refusal to bear weight or use an extremity may be the presenting sign. Chronic osteomyelitis may present with more indolent symptoms including persistent wound drainage, sinus tract formation, and low-grade pain without systemic toxicity. In diabetic foot osteomyelitis, the probe-to-bone test, in which a sterile metal probe is inserted into a foot ulcer and encounters hard, gritty bone, has a positive predictive value of approximately 89% in high-risk patients according to studies cited in UpToDate. Laboratory findings include elevated ESR (typically the most sensitive inflammatory marker for osteomyelitis, with values often exceeding 50 to 70 mm/hr), elevated CRP, and leukocytosis, though white blood cell count may be normal in chronic disease. Regarding imaging, plain radiographs are often normal in the first 10 to 14 days because at least 30 to 50% of bone mineral content must be lost before lytic changes become visible. MRI is the most sensitive and specific imaging modality (sensitivity 90 to 100%, specificity 80 to 90%) and demonstrates bone marrow edema, periosteal reaction, and soft tissue involvement. Bone biopsy with culture remains the gold standard for pathogen identification and antimicrobial susceptibility testing, and is strongly recommended before initiating antibiotics whenever possible, particularly given the rising prevalence of methicillin-resistant S. aureus (MRSA).\n\nMICROBIOLOGY BY CLINICAL CONTEXT:\nS. aureus is the most common organism in healthy adults, children, and hematogenous vertebral osteomyelitis. Pseudomonas aeruginosa is classically associated with puncture wounds through sneakers (the warm, moist rubber providing a favorable environment). Salmonella species are the most common cause of osteomyelitis in patients with sickle cell disease, though S. aureus remains common in this population as well. Polymicrobial infections with gram-negative organisms and anaerobes predominate in diabetic foot osteomyelitis and decubitus ulcer-associated contiguous osteomyelitis. Coagulase-negative staphylococci (particularly S. epidermidis) are common in prosthetic joint and hardware-associated infections. Mycobacterium tuberculosis should be considered in vertebral osteomyelitis (Pott disease) in patients from endemic regions.\n\nTREATMENT:\nParenteral antibiotics for a prolonged course of 4 to 6 weeks (6 to 8 weeks for vertebral osteomyelitis) are the standard of care, with empiric coverage targeting S. aureus (including MRSA with vancomycin in high-prevalence settings) narrowed based on culture and sensitivity results. The Infectious Diseases Society of America (IDSA) and UpToDate recommend bone biopsy culture to guide antibiotic selection whenever feasible. Surgical debridement is essential for chronic osteomyelitis with sequestrum (devitalized bone that acts as a nidus for persistent infection), cases with hardware infection requiring implant removal, failure to respond to appropriate antibiotics, and abscess drainage. Serial ESR and CRP monitoring guides treatment response and duration.\n\nKEY LEARNING POINTS:\nStaphylococcus aureus is the most common cause of osteomyelitis overall, while Salmonella is classically associated with sickle cell disease and Pseudomonas with puncture wounds through sneakers. MRI is the most sensitive and specific imaging modality, as plain radiographs are often normal in the first 10 to 14 days, and bone biopsy with culture is the gold standard for pathogen identification. Parenteral antibiotics for 4 to 6 weeks with surgical debridement of necrotic bone are the cornerstones of treatment."
  },
  {
    "id": 495,
    "categoryId": 7,
    "question": "Plantar Fasciitis is caused by microtears and degeneration of the fascia at its origin on the:",
    "options": [
      "A) Medial Calcaneal Tubercle",
      "B) Base of the 1st Metatarsal",
      "C) Talus",
      "D) Cuboid"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Medial Calcaneal Tubercle).\n\nPATHOPHYSIOLOGY:\nPlantar fasciitis is the most common cause of inferior heel pain, affecting approximately 10% of the population over a lifetime according to epidemiologic data cited in the AAFP and UpToDate. The plantar fascia is a thick band of connective tissue that originates from the medial calcaneal tubercle on the plantar surface of the calcaneus and fans distally to insert on the proximal phalanges of all five toes, supporting the longitudinal arch of the foot and functioning as a windlass mechanism during gait. The pathology is a degenerative enthesopathy (not a true inflammatory condition despite the \\\"-itis\\\" suffix) characterized by collagen degeneration, angiofibroblastic hyperplasia, and microtearing at the fascial origin on the medial calcaneal tubercle, where the mechanical stress is greatest. Histologic studies consistently demonstrate an absence of inflammatory cells, leading many authors to prefer the term plantar fasciosis. Risk factors include obesity (BMI greater than 30 is the strongest modifiable risk factor), prolonged standing occupations, running and high-impact activities, pes planus (flat feet) or pes cavus (high arches), tight Achilles tendon and gastrocnemius-soleus complex, and age 40 to 60 years. The calcaneal heel spur, visible on lateral foot radiographs in approximately 50% of patients with plantar fasciitis, arises from the short flexor muscles (not the plantar fascia itself) and is not the source of pain; heel spurs are equally prevalent in asymptomatic individuals.\n\nCLINICAL PRESENTATION:\nThe hallmark symptom is sharp, stabbing pain at the medial plantar heel with the first steps in the morning (post-static dyskinesia) or after prolonged sitting. The pain characteristically improves after several minutes of walking as the fascia warms up and stretches, but worsens again with prolonged standing or at the end of the day. Examination reveals maximal point tenderness at the medial calcaneal tubercle on the plantar surface of the heel, with pain reproduced by dorsiflexion of the toes (which tensions the plantar fascia via the windlass mechanism). The diagnosis is clinical and does not require imaging in the typical presentation. Imaging is reserved for cases with atypical features (bilateral heel pain in a young patient suggesting spondyloarthropathy, night pain suggesting tumor or stress fracture, neurologic symptoms suggesting tarsal tunnel syndrome or nerve entrapment) or failure to respond to 6 weeks of conservative therapy. When obtained, ultrasound demonstrating plantar fascia thickness greater than 4 mm at the calcaneal insertion supports the diagnosis. MRI is the most sensitive modality and can demonstrate fascial thickening, edema, and partial tears.\n\nTREATMENT:\nConservative management is successful in approximately 80 to 90% of patients within 10 to 12 months. First-line treatment includes calf and plantar fascia-specific stretching (the plantar fascia stretch involves dorsiflexing the toes while palpating the taut fascia and is performed for 10 repetitions of 10-second holds, three times daily, particularly before the first steps in the morning). Supportive footwear with cushioned heels and arch support, prefabricated or custom orthotics, and night splints that maintain the ankle in 5 degrees of dorsiflexion to prevent overnight fascial contracture are important adjuncts. NSAIDs provide short-term symptom relief but do not alter the degenerative process. For refractory cases, corticosteroid injection provides moderate short-term pain relief (4 to 8 weeks) but carries a risk of plantar fascia rupture (approximately 2 to 6% per injection) and fat pad atrophy, and should be used selectively. Extracorporeal shockwave therapy has moderate evidence supporting its use in chronic cases. Platelet-rich plasma (PRP) injection has shown promise in randomized trials. Surgical release of the plantar fascia (partial fasciotomy) is considered only after at least 6 to 12 months of failed conservative treatment.\n\nKEY LEARNING POINTS:\nPlantar fasciitis is a degenerative enthesopathy at the plantar fascia origin on the medial calcaneal tubercle, presenting with classic post-static dyskinesia (heel pain with the first steps in the morning that improves with walking). The diagnosis is clinical, imaging is unnecessary in typical presentations, and heel spurs are not the source of pain. Conservative management including plantar fascia stretching, supportive footwear, and orthotics is successful in 80 to 90% of patients within 10 to 12 months."
  },
  {
    "id": 496,
    "categoryId": 7,
    "question": "Anterior Shoulder Dislocation is the most common type. It puts the patient at risk for a 'Bankart Lesion', which is:",
    "options": [
      "A) A dent in the humeral head",
      "B) A tear of the anterior-inferior glenoid labrum",
      "C) A tear of the rotator cuff",
      "D) A fracture of the clavicle"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (A tear of the anterior-inferior glenoid labrum).\n\nPATHOPHYSIOLOGY:\nThe glenohumeral joint is the most commonly dislocated large joint in the body, and anterior dislocations account for approximately 95% of all shoulder dislocations. The mechanism typically involves forced abduction, external rotation, and extension of the shoulder, as occurs during a fall on an outstretched hand, a direct blow to the posterior shoulder, or a forced overhead motion. During anterior dislocation, the humeral head is driven anteriorly and inferiorly, shearing off the anterior-inferior glenoid labrum from the glenoid rim as it exits the joint. This labral detachment is the Bankart lesion, which represents the most common structural consequence of anterior dislocation and is the primary pathologic substrate for recurrent anterior instability. The glenoid labrum is a fibrocartilaginous rim that deepens the glenoid fossa by approximately 50% and serves as the attachment site for the inferior glenohumeral ligament, the most important static stabilizer against anterior translation. When the Bankart lesion disrupts this labral-ligamentous complex, the effective depth of the glenoid socket is reduced and the inferior glenohumeral ligament is detached, creating a pathway for recurrent subluxation or dislocation with progressively less force. A bony Bankart lesion occurs when a fragment of the anterior-inferior glenoid rim is fractured off along with the labrum, further compromising the bony containment of the humeral head. The Hill-Sachs lesion is a compression fracture (impaction defect) of the posterolateral humeral head that occurs when the soft cancellous bone of the humeral head impacts against the hard cortical bone of the anterior glenoid rim during the dislocation event, and it is present in approximately 40 to 90% of anterior dislocations.\n\nCLINICAL PRESENTATION:\nPatients present with acute severe shoulder pain, holding the arm in slight abduction and external rotation, with a visibly squared-off shoulder contour due to loss of the normal deltoid roundness as the humeral head sits anteriorly. The patient resists any attempt at internal rotation or adduction. Pre-reduction neurovascular assessment is critical because the axillary nerve, which wraps closely around the surgical neck of the humerus, is injured in approximately 5 to 14% of anterior dislocations, producing numbness over the lateral deltoid (the regimental badge area) and deltoid weakness. Axillary artery injury, though rare, can occur particularly in elderly patients. Pre-reduction anteroposterior and axillary (or scapular Y) radiographs confirm the dislocation and evaluate for associated fractures. Post-reduction radiographs confirm concentric reduction. MRI or MR arthrography is the imaging modality of choice for evaluating Bankart lesions, Hill-Sachs lesions, and associated rotator cuff tears (which occur in up to 30 to 40% of first-time dislocations in patients over age 40). The recurrence rate is strongly age-dependent: patients under 20 years have recurrence rates of 70 to 90%, those aged 20 to 40 have rates of 30 to 50%, and those over 40 have rates below 15% but have a higher incidence of associated rotator cuff tears.\n\nTREATMENT:\nImmediate closed reduction under procedural sedation using techniques such as external rotation, traction-countertraction, or the Stimson technique is the initial management. Post-reduction immobilization in a sling for 1 to 3 weeks followed by progressive physical therapy focusing on rotator cuff and periscapular muscle strengthening is standard. For young, active patients with a first-time dislocation and demonstrated Bankart lesion on MRI, there is growing evidence from randomized controlled trials (including the landmark study by Kirkley et al. published in JBJS) supporting early arthroscopic Bankart repair to reduce the high recurrence rate, particularly in contact athletes. Surgical stabilization (arthroscopic Bankart repair or open Latarjet procedure for cases with significant glenoid bone loss) is clearly indicated for recurrent instability. In older patients, addressing concomitant rotator cuff tears takes priority over labral repair.\n\nKEY LEARNING POINTS:\nA Bankart lesion is a tear of the anterior-inferior glenoid labrum that occurs during anterior shoulder dislocation and is the primary structural cause of recurrent anterior instability, while a Hill-Sachs lesion is a compression fracture of the posterolateral humeral head. The axillary nerve is at risk in anterior dislocations, and lateral deltoid sensation must be tested before and after reduction. Recurrence rates are strongly age-dependent, with patients under 20 having the highest risk (70 to 90%), supporting consideration of early surgical Bankart repair in young active patients."
  },
  {
    "id": 497,
    "categoryId": 7,
    "question": "Lateral Epicondylitis ('Tennis Elbow') involves inflammation of the origin of which muscle group?",
    "options": [
      "A) Wrist Flexors",
      "B) Wrist Extensors (specifically ECRB)",
      "C) Biceps",
      "D) Triceps"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Wrist Extensors, specifically Extensor Carpi Radialis Brevis).\n\nPATHOPHYSIOLOGY:\nLateral epicondylitis, commonly known as tennis elbow, is a degenerative tendinopathy of the common extensor tendon origin at the lateral epicondyle of the humerus, with the extensor carpi radialis brevis (ECRB) being the most consistently and primarily affected tendon. Despite its colloquial name, only approximately 5 to 10% of patients with lateral epicondylitis actually play tennis; the condition is far more commonly caused by repetitive occupational activities involving gripping, wrist extension, and forearm supination. The pathology is characterized by angiofibroblastic dysplasia (a degenerative process with fibroblast proliferation, vascular hyperplasia, and disorganized collagen) rather than acute inflammation, similar to the histologic findings in plantar fasciitis and Achilles tendinopathy. The ECRB is preferentially affected because of its anatomic position: it originates directly from the lateral epicondyle and its undersurface abuts the lateral edge of the capitellum, subjecting it to mechanical abrasion during forearm rotation, particularly between 0 and 110 degrees of flexion-extension. The condition typically affects adults aged 35 to 55, with equal gender distribution, and the dominant arm is more commonly involved. Medial epicondylitis (golfer\\\'s elbow) is the corresponding condition affecting the common flexor-pronator tendon origin at the medial epicondyle and is approximately 5 to 10 times less common than lateral epicondylitis.\n\nCLINICAL PRESENTATION:\nPatients present with pain and tenderness localized to the lateral epicondyle that radiates into the proximal extensor forearm. Pain is characteristically worsened by gripping activities (such as shaking hands, turning a doorknob, lifting a coffee cup, or wringing a towel) and by resisted wrist extension and resisted middle finger extension (the ECRB extends the wrist and assists in extending the middle finger). Three provocative tests are commonly used to confirm the diagnosis. Cozen\\\'s test involves resisted wrist extension with the forearm pronated and elbow extended, reproducing pain at the lateral epicondyle. Mill\\\'s test involves passive wrist flexion with the forearm pronated and elbow extended, stretching the extensor origin and reproducing lateral epicondylar pain. The chair lift test asks the patient to lift a chair with the forearm pronated and elbow extended, which loads the ECRB and reproduces symptoms. The diagnosis is clinical and imaging is not routinely required. Radiographs are typically normal and are obtained primarily to exclude other pathology (loose bodies, osteochondritis dissecans of the capitellum, or lateral compartment arthritis). When imaging is needed, ultrasound or MRI can demonstrate tendon thickening, hypoechoic changes, and partial tears at the ECRB origin.\n\nTREATMENT:\nThe natural history is favorable, with approximately 80 to 90% of cases resolving within 12 to 18 months regardless of treatment, according to data from systematic reviews cited in BMJ and UpToDate. First-line management includes activity modification to reduce provocative loading, counterforce bracing (a forearm strap applied 2 to 3 cm distal to the lateral epicondyle that reduces tension at the tendon origin by redistributing forces to the brace), and a structured physical therapy program emphasizing eccentric wrist extensor strengthening, which has the strongest evidence base of any conservative treatment according to a Cochrane review. Ice application and topical or oral NSAIDs provide short-term symptomatic relief. Corticosteroid injection provides excellent short-term pain relief (4 to 6 weeks) but multiple randomized trials have demonstrated worse long-term outcomes compared to placebo or physical therapy at 6 and 12 months, with higher recurrence rates, and is therefore not recommended as routine practice. Emerging therapies include platelet-rich plasma injection, which has shown promise in several randomized trials for recalcitrant cases. Surgical debridement of the degenerative ECRB tissue (open, arthroscopic, or percutaneous) is reserved for cases refractory to at least 6 to 12 months of comprehensive conservative management and has success rates of approximately 85 to 90%.\n\nKEY LEARNING POINTS:\nLateral epicondylitis (tennis elbow) is a degenerative tendinopathy primarily of the extensor carpi radialis brevis at the lateral epicondyle, diagnosed clinically by pain with resisted wrist extension and gripping, and must be distinguished from medial epicondylitis (golfer\\\'s elbow) which affects the flexor-pronator origin. Eccentric wrist extensor strengthening has the strongest evidence base among conservative treatments, while corticosteroid injection provides short-term relief but worsens long-term outcomes. Approximately 80 to 90% of cases resolve within 12 to 18 months, with surgery reserved for refractory cases after at least 6 to 12 months of failed conservative management."
  },
  {
    "id": 498,
    "categoryId": 7,
    "question": "A Baker's Cyst (Popliteal Cyst) is essentially:",
    "options": [
      "A) A tumor",
      "B) Herniation of synovial fluid from the knee joint into the popliteal fossa",
      "C) An abscess",
      "D) A blood clot"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Herniation of synovial fluid from the knee joint into the popliteal fossa).\n\nPATHOPHYSIOLOGY:\nA Baker cyst, also known as a popliteal cyst, is not a true cyst but rather an abnormal distension of the gastrocnemius-semimembranosus bursa, a normal anatomic structure located in the posteromedial aspect of the popliteal fossa between the medial head of the gastrocnemius and the semimembranosus tendon. This bursa communicates with the knee joint through a valvular opening in the posterior capsule in approximately 50% of adults. When underlying intra-articular pathology causes excessive synovial fluid production (joint effusion), the fluid is forced posteriorly through this communication into the bursa by a one-way valve mechanism: knee flexion compresses the joint space and drives fluid into the bursa, while extension closes the valvular opening and prevents return. The bursa progressively distends to form the palpable popliteal mass. In adults, a Baker cyst is almost always secondary to underlying knee joint pathology, with osteoarthritis being the most common cause (present in approximately 50% of cases per data from UpToDate and Annals of Rheumatic Diseases), followed by meniscal tears, rheumatoid arthritis, gout, and other inflammatory arthropathies. In children, Baker cysts may occur as primary lesions without underlying joint disease and typically resolve spontaneously. Understanding that the cyst is a symptom of intra-articular pathology rather than a primary disorder is critical for guiding management.\n\nCLINICAL PRESENTATION:\nPatients present with posterior knee fullness, tightness, or a dull aching sensation that worsens with prolonged standing, walking, or full knee flexion. The cyst is best appreciated on physical examination with the knee fully extended, as it becomes tense and palpable in this position (Foucher sign: the cyst becomes soft and less prominent with knee flexion as the distended bursa decompresses). The mass is typically smooth, well-circumscribed, and transilluminates. Large cysts may restrict knee flexion or cause mechanical symptoms. The most clinically important complication is cyst rupture, which occurs when the intracystic pressure exceeds the tensile strength of the bursal wall. Rupture causes acute dissection of synovial fluid into the calf compartment, producing sudden onset of calf pain, swelling, erythema, and a positive Homan sign that closely mimics deep vein thrombosis, a presentation known as pseudothrombophlebitis syndrome. The crescent sign, ecchymosis around the medial malleolus, may be present and suggests cyst rupture with fluid tracking distally. Because DVT and ruptured Baker cyst can coexist (the cyst can compress the popliteal vein and predispose to thrombosis), both conditions must be excluded with appropriate imaging.\n\nDIAGNOSIS AND TREATMENT:\nUltrasound is the initial imaging modality of choice, confirming the cystic nature of the mass, excluding DVT (with Doppler), and identifying cyst rupture with characteristic findings of fluid tracking along the fascial planes of the calf. MRI provides the most comprehensive evaluation, delineating the cyst anatomy, its communication with the joint, and the underlying intra-articular pathology (meniscal tears, chondral damage, synovitis) that is driving the effusion. Treatment must address the underlying knee pathology rather than the cyst itself, as direct cyst aspiration without treating the primary cause leads to rapid recurrence in the majority of patients. Conservative management includes activity modification, NSAIDs, physical therapy focusing on quadriceps strengthening and range of motion, and intra-articular corticosteroid injection into the knee joint (not the cyst) to reduce synovial fluid production. Arthroscopic treatment of the underlying meniscal tear or cartilage lesion is often effective in resolving the cyst. Direct surgical excision of the cyst is rarely necessary and is reserved for cysts causing nerve or vascular compression or those refractory to all other interventions.\n\nKEY LEARNING POINTS:\nA Baker cyst is a distension of the gastrocnemius-semimembranosus bursa caused by a one-way valve mechanism that allows joint fluid to enter but not return, and it almost always indicates underlying knee joint pathology such as osteoarthritis or meniscal tears. Cyst rupture produces acute calf pain and swelling that closely mimics deep vein thrombosis (pseudothrombophlebitis syndrome), and both conditions can coexist because the cyst may compress the popliteal vein. Treatment targets the underlying intra-articular pathology rather than the cyst itself, as isolated cyst aspiration leads to recurrence without addressing the primary cause."
  },
  {
    "id": 499,
    "categoryId": 7,
    "question": "Rickets (children) and Osteomalacia (adults) are caused by defective bone mineralization, usually due to:",
    "options": [
      "A) Vitamin D / Calcium deficiency",
      "B) Vitamin C deficiency",
      "C) Protein deficiency",
      "D) Estrogen deficiency"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Vitamin D / Calcium deficiency).\n\nPATHOPHYSIOLOGY:\nRickets (in children with open growth plates) and osteomalacia (in adults with fused growth plates) represent the same fundamental pathology: defective mineralization of newly formed bone matrix (osteoid). Normal bone mineralization requires adequate serum concentrations of calcium and phosphate to form hydroxyapatite crystals that are deposited into the collagen-rich osteoid matrix. Vitamin D plays a central role in maintaining these mineral concentrations by promoting intestinal calcium and phosphate absorption, renal calcium reabsorption, and appropriate parathyroid hormone regulation. When vitamin D is deficient, intestinal calcium absorption drops from approximately 30 to 35% to 10 to 15%, resulting in hypocalcemia that triggers secondary hyperparathyroidism. The elevated PTH mobilizes calcium from bone (maintaining serum calcium at the expense of skeletal integrity), increases renal phosphate excretion (producing hypophosphatemia), and promotes renal 1-alpha-hydroxylase activity in an attempt to generate more active 1,25-dihydroxyvitamin D. The combined hypocalcemia and hypophosphatemia result in an inadequate calcium-phosphate product at the mineralization front, and osteoid accumulates in an unmineralized state. This must be distinguished from osteoporosis, in which the bone that is present is normally mineralized but there is reduced total bone mass and architectural deterioration. In osteomalacia, bone quantity may be preserved but the bone is structurally weak because it is inadequately mineralized, resulting in softened bone that deforms under mechanical stress.\n\nCLINICAL PRESENTATION:\nIn children, rickets manifests during periods of rapid growth with skeletal deformities that reflect the mechanical forces applied to softened, poorly mineralized bone. Classic findings include frontal bossing of the skull, craniotabes (softening of the skull bones elicited by pressing on the occiput), widening of the wrists and ankles from metaphyseal expansion (the rachitic rosary refers to palpable enlargement of the costochondral junctions), genu varum (bowing of the legs) or genu valgum (knock knees) depending on age and weight-bearing patterns, delayed fontanelle closure, and delayed dentition. Growth retardation, hypotonia, and motor developmental delay are common. Severe hypocalcemia can cause tetany, seizures, and dilated cardiomyopathy. In adults, osteomalacia presents more insidiously with diffuse bone pain (particularly in the spine, pelvis, and lower extremities), proximal muscle weakness producing a waddling gait, and increased susceptibility to fractures, particularly insufficiency fractures. Looser zones (pseudofractures), which are radiolucent bands perpendicular to the cortex representing unmineralized osteoid at sites of mechanical stress, are pathognomonic radiographic findings when present. Laboratory findings typically reveal low 25-hydroxyvitamin D (the best indicator of vitamin D status), low or low-normal serum calcium, low serum phosphate, elevated alkaline phosphatase (reflecting increased osteoblastic activity attempting to form new bone), and elevated PTH (secondary hyperparathyroidism). Risk factors for vitamin D deficiency include limited sun exposure, dark skin pigmentation (melanin reduces cutaneous vitamin D synthesis), exclusive breastfeeding without supplementation (breast milk contains only 20 to 40 IU/L of vitamin D), malabsorptive conditions (celiac disease, Crohn disease, short bowel syndrome, cystic fibrosis), chronic kidney disease (impaired 1-alpha-hydroxylation), and medications that accelerate vitamin D catabolism (phenytoin, carbamazepine, rifampin).\n\nTREATMENT:\nThe Endocrine Society and AAP recommend vitamin D supplementation of 400 IU daily for all breastfed infants beginning at birth as primary prevention of rickets. Treatment of established vitamin D deficiency in adults typically involves ergocalciferol (vitamin D2) 50,000 IU weekly for 8 to 12 weeks or cholecalciferol (vitamin D3) at equivalent dosing, followed by maintenance therapy of 1,000 to 2,000 IU daily to maintain 25-hydroxyvitamin D levels above 30 ng/mL. Calcium supplementation (1,000 to 1,200 mg daily of elemental calcium) is essential to support remineralization. In children with active rickets, higher doses are used and monitoring of serum calcium, phosphate, alkaline phosphatase, and 25-hydroxyvitamin D guides dose adjustment. Radiographic healing with restoration of the zone of provisional calcification is typically evident within 2 to 4 weeks of adequate treatment. In renal osteodystrophy, active vitamin D metabolites (calcitriol or paricalcitol) are required because the kidney cannot perform 1-alpha-hydroxylation.\n\nKEY LEARNING POINTS:\nRickets and osteomalacia result from defective bone mineralization due to inadequate vitamin D and consequent hypocalcemia and hypophosphatemia, in contrast to osteoporosis where bone is normally mineralized but reduced in quantity. Vitamin D deficiency triggers secondary hyperparathyroidism that maintains serum calcium at the expense of skeletal integrity, and laboratory findings characteristically show low 25-hydroxyvitamin D, elevated alkaline phosphatase, and elevated PTH. All breastfed infants should receive 400 IU of vitamin D daily from birth per AAP recommendations to prevent rickets."
  },
  {
    "id": 500,
    "categoryId": 7,
    "question": "Females are at higher risk for ACL tears than males. Anatomical reasons include:",
    "options": [
      "A) Narrower Intercondylar Notch and wider Q-angle",
      "B) Stronger quadriceps",
      "C) Thicker ligaments",
      "D) Higher center of gravity"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Narrower Intercondylar Notch and wider Q-angle).\n\nPATHOPHYSIOLOGY:\nFemale athletes sustain anterior cruciate ligament (ACL) tears at 2 to 8 times the rate of males participating in the same cutting and pivoting sports, a disparity that has been extensively studied and is attributable to a combination of anatomic, hormonal, neuromuscular, and biomechanical factors. The anatomic factors are the most consistently identified risk factors and include a narrower intercondylar notch and a wider quadriceps angle (Q-angle). The intercondylar notch is the bony channel between the femoral condyles through which the ACL courses. Women have a statistically narrower notch width and a smaller notch width index (notch width divided by distal femoral width) compared to men, which reduces the space available for the ACL and makes it more susceptible to impingement against the lateral wall of the notch during pivoting movements, particularly when the knee is near full extension. Multiple studies in the American Journal of Sports Medicine and data reviewed in UpToDate have confirmed that a narrower notch is an independent risk factor for ACL rupture. The Q-angle, defined as the angle between a line from the anterior superior iliac spine to the center of the patella and a line from the center of the patella to the tibial tubercle, is wider in females (average 15 to 17 degrees) than in males (average 10 to 14 degrees) due to the wider female pelvis. A larger Q-angle increases the lateral vector force on the patella and creates a greater valgus moment at the knee during landing and cutting, loading the ACL in a position of vulnerability.\n\nCLINICAL REASONING:\nBeyond these anatomic factors, several additional mechanisms contribute to the gender disparity. Hormonal influences are well documented: estrogen receptors have been identified on the human ACL, and fluctuations in estrogen and relaxin levels during the menstrual cycle correlate with changes in ligament laxity and stiffness. Studies published in JBJS and the British Journal of Sports Medicine have demonstrated that ACL injuries cluster in the pre-ovulatory phase of the menstrual cycle when estrogen levels are rising, though the clinical significance of this finding for injury prevention remains debated. Neuromuscular factors are perhaps the most modifiable risk factors. Female athletes demonstrate characteristic movement patterns that increase ACL loading: they tend to land from jumps with greater knee valgus (dynamic valgus or medial knee collapse), less knee flexion, greater quadriceps dominance relative to hamstring activation, and reduced trunk and hip control. The hamstrings are the primary dynamic stabilizers that protect the ACL by resisting anterior tibial translation, and women demonstrate lower hamstring-to-quadriceps strength ratios compared to men. When the quadriceps fires forcefully with the knee near extension (the last 30 degrees of extension), it pulls the tibia anteriorly through the patellar tendon, directly loading the ACL, and insufficient hamstring co-contraction fails to counterbalance this anterior shear force. The smaller cross-sectional area of the female ACL itself (approximately 20% smaller than in males when controlled for body size) may also contribute to lower mechanical failure strength.\n\nTREATMENT AND PREVENTION:\nNeuromuscular training programs have been shown to reduce ACL injury rates in female athletes by 50 to 70% in well-designed randomized and prospective cohort studies, making ACL injury prevention one of the most successful examples of evidence-based sports injury prevention. Programs such as FIFA 11+, PEP (Prevent Injury and Enhance Performance), and the Sportsmetrics program incorporate plyometric training with proper landing technique (emphasizing soft landings with knee flexion and avoidance of dynamic valgus), hamstring and hip strengthening (targeting the gluteus medius and hamstrings to improve the hamstring-to-quadriceps ratio), core stability training, balance and proprioceptive exercises, and sport-specific agility drills. These programs are most effective when initiated before puberty or in early adolescence and performed at least 2 to 3 times per week throughout the competitive season. The American Academy of Pediatrics and the American Orthopaedic Society for Sports Medicine recommend neuromuscular training as a standard component of youth female athletic programs.\n\nKEY LEARNING POINTS:\nFemale athletes have 2 to 8 times higher ACL tear rates than males due to a narrower intercondylar notch (increasing ACL impingement risk), a wider Q-angle (increasing knee valgus stress), hormonal effects on ligament laxity, and neuromuscular patterns including quadriceps dominance and reduced hamstring co-contraction. Neuromuscular training programs emphasizing proper landing mechanics, hamstring strengthening, and dynamic valgus correction reduce female ACL injury rates by 50 to 70%. These prevention programs should be incorporated as a standard component of youth female athletic training per AOSSM recommendations."
  },
  {
    "id": 501,
    "categoryId": 7,
    "question": "True Sciatica (Radiculopathy) is most commonly caused by:",
    "options": [
      "A) Piriformis Syndrome",
      "B) Herniated Disc compressing the nerve root",
      "C) SI Joint dysfunction",
      "D) Diabetes"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Herniated Disc compressing the nerve root).\n\nPATHOPHYSIOLOGY:\nTrue sciatica, more precisely termed lumbar radiculopathy, is caused by compression or irritation of a lumbar or sacral nerve root, most commonly by a herniated nucleus pulposus (disc herniation). The intervertebral disc consists of a central gelatinous nucleus pulposus surrounded by the concentric fibers of the annulus fibrosus. With aging, repetitive loading, and degenerative changes, the annulus develops tears that allow the nucleus pulposus to herniate posterolaterally (the posterior longitudinal ligament is thinnest laterally, creating the path of least resistance), compressing the traversing nerve root within the lateral recess or neural foramen. The L4-L5 and L5-S1 levels account for approximately 95% of lumbar disc herniations, affecting the L5 and S1 nerve roots respectively. The pathophysiology involves both mechanical compression and chemical irritation: the herniated nucleus pulposus releases phospholipase A2, prostaglandins, interleukins, TNF-alpha, and matrix metalloproteinases that trigger a local inflammatory cascade producing nerve root edema, demyelination, and nociceptive sensitization. This explains why the degree of mechanical compression on imaging does not always correlate with symptom severity, and why many patients improve with conservative management as the inflammatory response subsides even without resolution of the anatomic herniation. Disc material can also undergo resorption through macrophage-mediated phagocytosis, with MRI studies demonstrating significant reduction in herniation size in 60 to 80% of patients over 6 to 12 months.\n\nCLINICAL PRESENTATION:\nTrue radiculopathy produces sharp, shooting, electrical, or burning pain that radiates from the buttock down the posterior or posterolateral leg, typically below the knee and into the foot, following a dermatomal pattern. Pain that does not extend below the knee is less likely to represent true radiculopathy. L5 radiculopathy (from L4-L5 disc herniation) produces pain radiating to the dorsum of the foot, weakness of great toe dorsiflexion (extensor hallucis longus) and ankle dorsiflexion (foot drop), and sensory loss over the dorsum of the foot and first web space. S1 radiculopathy (from L5-S1 disc herniation) produces pain radiating to the lateral foot and sole, weakness of ankle plantarflexion and toe walking, diminished ankle jerk reflex, and sensory loss over the lateral foot. L4 radiculopathy produces pain radiating to the medial leg, quadriceps weakness, diminished patellar reflex, and sensory loss over the medial leg. The straight leg raise test (Lasegue test) is positive when passive hip flexion with the knee extended reproduces radicular pain at 30 to 70 degrees; the crossed straight leg raise (pain in the affected leg when the contralateral leg is raised) is less sensitive but highly specific for disc herniation. Piriformis syndrome, in which the sciatic nerve is compressed by the piriformis muscle in the deep gluteal space, is a far less common cause of sciatica-like symptoms and is diagnosed clinically by pain with resisted external rotation of the hip and tenderness over the piriformis in the buttock. Imaging is not required for initial evaluation of typical radiculopathy and is reserved for patients with red flag features (progressive neurologic deficit, cauda equina syndrome, suspected malignancy or infection) or failure to improve after 6 weeks of conservative management.\n\nTREATMENT:\nThe natural history of lumbar disc herniation is favorable, with approximately 80 to 90% of patients improving within 6 to 12 weeks with conservative management per data from NEJM reviews and UpToDate. First-line treatment includes patient education and reassurance, maintenance of activity as tolerated (prolonged bed rest is harmful and no longer recommended), NSAIDs for pain control, and a short course of oral corticosteroids for severe radicular symptoms (though evidence is mixed). Physical therapy with core stabilization, directional preference exercises (McKenzie method), and progressive return to activity is recommended for patients who do not improve within the first few weeks. Epidural steroid injections provide moderate short-term relief of radicular pain (typically 2 to 6 weeks) and are most effective for acute radiculopathy with significant leg-dominant pain. Gabapentin or pregabalin may be used as adjuncts for neuropathic pain. Surgical discectomy is indicated for cauda equina syndrome (emergency), progressive motor deficit, or persistent significant radicular symptoms despite 6 to 12 weeks of conservative therapy. The SPORT trial published in JAMA demonstrated that surgical and conservative treatment groups both improved significantly over 2 years, with surgery providing faster initial relief but similar long-term outcomes.\n\nKEY LEARNING POINTS:\nTrue sciatica (lumbar radiculopathy) is most commonly caused by disc herniation at L4-L5 or L5-S1, producing dermatomal leg pain below the knee with associated motor, sensory, and reflex deficits corresponding to the affected nerve root. Approximately 80 to 90% of patients improve within 6 to 12 weeks with conservative management, and imaging is reserved for red flag features or failure to improve after 6 weeks. Piriformis syndrome is a far less common mimic that is diagnosed clinically by pain with resisted hip external rotation and deep gluteal tenderness."
  },
  {
    "id": 502,
    "categoryId": 7,
    "question": "Stenosing Tenosynovitis (Trigger Finger) involves a mismatch between the flexor tendon and the:",
    "options": [
      "A) A1 Pulley",
      "B) Carpal Tunnel",
      "C) Extensor Hood",
      "D) Collateral Ligament"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (A1 Pulley).\n\nPATHOPHYSIOLOGY:\nStenosing tenosynovitis, commonly known as trigger finger or trigger thumb, is a mechanical condition caused by a size mismatch between the flexor tendon and the first annular (A1) pulley at the base of the finger. The flexor tendon sheath of the hand is reinforced by a series of annular and cruciform pulleys that hold the tendons close to the phalanges, preventing bowstringing during finger flexion. The A1 pulley, located at the level of the metacarpophalangeal (MCP) joint, is the narrowest and most constrictive of these pulleys and is the site where triggering occurs. Repetitive friction between the flexor tendon and the A1 pulley causes local inflammation, thickening, and fibrocartilaginous metaplasia of the pulley, while the tendon itself develops fusiform swelling and a nodular thickening (Notta nodule) proximal to the pulley entrance. As the tendon thickens, it can pass through the narrowed A1 pulley during flexion (with the aid of stronger flexor muscle force) but catches or locks when attempting to extend because the tendon nodule cannot easily slide back through the stenosed opening. This produces the characteristic catching, locking, and painful snapping during finger motion. Trigger finger has a lifetime prevalence of approximately 2 to 3% in the general population, with peak incidence between ages 40 and 60, and women are affected 2 to 6 times more frequently than men. The ring finger and thumb are most commonly involved. Diabetes mellitus is the strongest risk factor, with trigger finger affecting up to 10% of diabetic patients, and diabetic patients often have multiple affected digits and a poorer response to corticosteroid injection. Other associations include rheumatoid arthritis, hypothyroidism, amyloidosis, and repetitive occupational gripping.\n\nCLINICAL PRESENTATION:\nPatients present with painful clicking, catching, or locking of the affected finger during flexion and extension, often worse in the morning when tendon edema is greatest. In early stages, the patient may notice only a painless click during finger motion. As the condition progresses, the finger catches in flexion and requires active effort or passive manipulation with the contralateral hand to extend (unlocking). In the most advanced stage (Grade IV per the Quinnell classification), the finger becomes locked in flexion and cannot be extended even passively. Physical examination reveals a palpable, tender nodule over the A1 pulley at the volar MCP joint, and the catching or triggering phenomenon can often be demonstrated by asking the patient to make a full fist and slowly extend the fingers. The diagnosis is entirely clinical and requires no imaging or laboratory testing. The differential diagnosis includes Dupuytren contracture (which produces fixed flexion contracture from palmar fascial cords without triggering), MCP joint osteoarthritis, and flexor tenosynovitis from infection or inflammatory arthritis.\n\nTREATMENT:\nInitial management includes activity modification to avoid repetitive gripping, a hand-based MCP joint extension splint worn at night to prevent the finger from locking in flexion during sleep (effective in approximately 50 to 70% of mild cases), and NSAIDs for symptom relief. Corticosteroid injection into the flexor tendon sheath at the A1 pulley is the first-line interventional treatment and is highly effective, with reported success rates of 57 to 93% after a single injection, though diabetic patients have lower response rates (approximately 40 to 50%). A second injection may be attempted if the first provides partial relief. According to UpToDate and AAOS guidelines, surgical release (open A1 pulley release) is indicated for patients who fail two corticosteroid injections, have Grade IV locked trigger finger, or prefer definitive treatment. The procedure is performed under local anesthesia with a small transverse incision over the A1 pulley and has a success rate exceeding 95%. Percutaneous release with a needle is an alternative in experienced hands.\n\nKEY LEARNING POINTS:\nTrigger finger results from a size mismatch between the flexor tendon (which develops a nodular thickening) and the A1 pulley (which thickens and narrows), causing catching and locking during finger extension. Diabetes is the strongest risk factor, affecting up to 10% of diabetic patients, who often have multiple affected digits and poorer response to injection. Corticosteroid injection into the tendon sheath at the A1 pulley is first-line interventional treatment with success rates of 57 to 93%, and surgical A1 pulley release is definitive for refractory cases."
  },
  {
    "id": 503,
    "categoryId": 7,
    "question": "Dupuytren's Contracture is a progressive fibrosis of the:",
    "options": [
      "A) Flexor Tendons",
      "B) Palmar Fascia",
      "C) Skin",
      "D) Median Nerve"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Palmar Fascia).\n\nPATHOPHYSIOLOGY:\nDupuytren disease is a benign fibroproliferative disorder of the palmar fascia (palmar aponeurosis) characterized by progressive formation of nodules and cords that gradually contract and pull the affected fingers into fixed flexion. The palmar fascia is a triangular sheet of connective tissue that lies deep to the skin and subcutaneous fat of the palm, anchoring the palmar skin to the underlying skeleton and tendon sheaths. In Dupuytren disease, myofibroblasts within the palmar fascia proliferate and deposit excessive type III collagen, forming nodules that coalesce into longitudinal cords. These myofibroblasts contain alpha-smooth muscle actin, which generates contractile force that progressively shortens the cords and produces the characteristic flexion contracture. The ring finger is most commonly affected (approximately 65% of cases), followed by the little finger. Importantly, the flexor tendons themselves are entirely normal in Dupuytren disease, which distinguishes it from trigger finger where the tendon develops a nodular thickening. The condition has a strong genetic component with autosomal dominant inheritance and variable penetrance, and is most common in individuals of Northern European (Celtic, Scandinavian) descent, leading to the historical designation Viking disease. The prevalence increases markedly with age, affecting approximately 20% of men over age 65 in Northern European populations. Men are affected 7 to 10 times more frequently than women and develop more severe disease. Risk factors include diabetes mellitus (with reported prevalence of 16 to 42% in diabetic populations, though diabetic Dupuytren is often milder), alcohol use disorder, smoking, epilepsy (possibly related to phenytoin use, which stimulates fibroblast proliferation), and manual labor with vibratory tool exposure. Dupuytren diathesis refers to aggressive disease characterized by early onset (before age 50), bilateral involvement, family history, and associated fibromatoses including Peyronie disease (penile fibrosis), Ledderhose disease (plantar fibromatosis), and Garrod knuckle pads (dorsal PIP joint fibrosis).\n\nCLINICAL PRESENTATION:\nThe disease typically begins insidiously with a firm, painless nodule in the distal palmar crease, most commonly at the base of the ring or little finger. Patients may initially notice only skin puckering or dimpling overlying the nodule. Over months to years, the nodule progresses to a palpable cord extending distally along the affected ray, and progressive contraction of this cord produces flexion deformity primarily at the MCP joint and secondarily at the proximal interphalangeal (PIP) joint. The DIP joint is rarely involved. Patients report difficulty placing the hand flat on a table (Hueston tabletop test: if the patient cannot flatten the palm and fingers on a flat surface, the test is positive and intervention is generally indicated), difficulty wearing gloves, grasping large objects, or performing fine manual tasks. The diagnosis is clinical and requires no imaging or laboratory testing. The key differential diagnosis is trigger finger, which produces transient locking and catching during active finger motion (a dynamic phenomenon) rather than the fixed, non-reducible flexion contracture of Dupuytren disease.\n\nTREATMENT:\nTreatment is indicated when functional impairment develops, typically when MCP joint contracture exceeds 30 degrees or any PIP joint contracture is present, as PIP contractures are more difficult to correct and have higher recurrence rates. Mild disease without functional limitation may be observed with serial monitoring. Collagenase clostridium histolyticum (Xiaflex) injection is a non-surgical option that enzymatically degrades the collagen cord, allowing manipulation and rupture of the cord the following day. The CORD I trial published in NEJM demonstrated that collagenase injection reduced contracture to 0 to 5 degrees in 64% of MCP joints and 28% of PIP joints. Needle aponeurotomy (percutaneous needle fasciotomy) involves using a needle to perforate and weaken the cord, which is then ruptured by finger extension, and can be performed in the office under local anesthesia. Open limited fasciectomy, in which the diseased fascial cord is surgically excised, remains the gold standard and has the lowest recurrence rate (approximately 20 to 30% at 5 years for MCP contractures), though recurrence increases with longer follow-up. Dermofasciectomy (excision of the cord along with the overlying skin, replaced with a full-thickness skin graft) has the lowest recurrence rate and is reserved for severe or recurrent disease. No medical therapy has been proven to prevent disease progression.\n\nKEY LEARNING POINTS:\nDupuytren disease is a fibroproliferative disorder of the palmar fascia (not the tendons) producing nodules and cords that progressively contract the ring and little fingers into fixed flexion, most commonly in men of Northern European descent. The flexor tendons are normal, which distinguishes this condition from trigger finger where the tendon itself is thickened. Treatment is indicated when MCP contracture exceeds 30 degrees or any PIP contracture is present, with options including collagenase injection, needle aponeurotomy, and surgical fasciectomy."
  },
  {
    "id": 504,
    "categoryId": 14,
    "question": "Pancoast Tumors (Superior Sulcus Tumors) of the lung apex often present with shoulder pain and:",
    "options": [
      "A) Horner's Syndrome (Ptosis, Miosis, Anhidrosis)",
      "B) Bell's Palsy",
      "C) Foot Drop",
      "D) Hearing Loss"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Horner's Syndrome - Ptosis, Miosis, Anhidrosis).\n\nPATHOPHYSIOLOGY:\nPancoast tumors (superior sulcus tumors) are malignancies arising in the lung apex that invade adjacent structures in the thoracic inlet. The sympathetic chain, specifically the stellate ganglion (inferior cervical ganglion fused with the first thoracic ganglion), lies immediately adjacent to the lung apex and is vulnerable to direct tumor invasion per Harrison's Principles of Internal Medicine. Disruption of the sympathetic chain produces ipsilateral Horner syndrome, the classic triad of ptosis (drooping of the upper eyelid from loss of sympathetic innervation to Muller's muscle), miosis (pupillary constriction from unopposed parasympathetic tone), and anhidrosis (loss of sweating on the ipsilateral face). The brachial plexus, particularly the C8 and T1 nerve roots, is also frequently invaded, causing severe neuropathic pain radiating down the medial arm and hand in an ulnar nerve distribution along with hand weakness and intrinsic muscle atrophy.\n\nCLINICAL PRESENTATION:\nPancoast tumors account for approximately 3 to 5% of all lung cancers, most commonly non-small cell histology per UpToDate. The presenting symptom is usually severe shoulder and arm pain that is frequently misdiagnosed as cervical radiculopathy, rotator cuff disease, or shoulder arthritis, delaying the correct diagnosis by months. The pain is characteristically relentless, worse at night, and radiates down the medial arm. Because apical lung tumors may not be visible on standard posteroanterior chest radiographs (obscured by overlying clavicle and first rib), CT or MRI of the chest and thoracic inlet is required for diagnosis per Mayo Clinic radiology guidance.\n\nMANAGEMENT:\nTreatment typically involves trimodality therapy with concurrent chemoradiation followed by surgical resection, which has significantly improved survival compared to historical approaches per NCCN guidelines. Preoperative MRI is essential for assessing invasion of the brachial plexus, subclavian vessels, and vertebral bodies, which determines surgical resectability.\n\nKEY LEARNING POINTS:\nPancoast tumors cause Horner syndrome (ptosis, miosis, anhidrosis) by invading the stellate ganglion and cause severe medial arm pain by invading the C8-T1 nerve roots of the brachial plexus. Shoulder and arm pain from a Pancoast tumor is frequently misdiagnosed as musculoskeletal disease, delaying diagnosis. Apical lung tumors may be missed on standard chest radiographs and require CT or MRI of the thoracic inlet."
  },
  {
    "id": 505,
    "categoryId": 14,
    "question": "Iron Deficiency Anemia in a male or post-menopausal female is considered:",
    "options": [
      "A) Nutritional deficiency until proven otherwise",
      "B) Colorectal Cancer until proven otherwise",
      "C) Normal aging",
      "D) Caused by PPI use"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Colorectal Cancer until proven otherwise).\n\nPATHOPHYSIOLOGY:\nIron deficiency anemia in a male or postmenopausal female represents occult gastrointestinal blood loss until proven otherwise, because these populations lack the physiologic blood loss of menstruation that accounts for the majority of iron deficiency in premenopausal women per Harrison's Principles of Internal Medicine. Chronic low-volume bleeding from gastrointestinal malignancies, particularly colorectal cancer, causes insidious iron store depletion over months to years. A right-sided colon cancer may bleed slowly without producing visible hematochezia, while the patient gradually develops iron deficiency and symptomatic anemia. This presentation is often the earliest clinical manifestation of an otherwise curable malignancy.\n\nDIAGNOSTIC APPROACH:\nIron deficiency anemia is identified by a microcytic anemia (MCV less than 80 fL) with low serum ferritin (less than 30 ng/mL, the most sensitive and specific single test per UpToDate), low serum iron, elevated total iron-binding capacity, and low transferrin saturation. Once confirmed in a male or postmenopausal female, both colonoscopy and esophagogastroduodenoscopy should be performed to evaluate for malignancy and other sources of occult bleeding including gastric ulcers, angiodysplasia, celiac disease, and Cameron erosions per the American Gastroenterological Association and British Society of Gastroenterology guidelines. A negative colonoscopy does not exclude upper GI sources, and both studies should be performed.\n\nTREATMENT:\nIron repletion is initiated concurrently with the diagnostic workup. Oral ferrous sulfate 325 mg (65 mg elemental iron) taken with vitamin C on an empty stomach is standard first-line therapy per the Cleveland Clinic. Intravenous iron (ferric carboxymaltose, iron sucrose) is indicated for patients who cannot tolerate oral iron or have malabsorptive conditions. Reticulocyte count should rise within 5 to 7 days and hemoglobin should improve by 1 to 2 g/dL within 2 to 4 weeks, with iron stores requiring 3 to 6 months of continued supplementation.\n\nKEY LEARNING POINTS:\nIron deficiency anemia in males and postmenopausal females is GI malignancy until proven otherwise and mandates both colonoscopy and upper endoscopy per AGA guidelines. Low ferritin (less than 30 ng/mL) is the most sensitive and specific single test for iron deficiency. The diagnostic workup is potentially life-saving, as colorectal cancer presenting with occult bleeding is often at an early, curable stage."
  },
  {
    "id": 506,
    "categoryId": 14,
    "question": "Inflammatory Breast Cancer is a particularly aggressive subtype that presents as:",
    "options": [
      "A) A painless, hard, mobile lump",
      "B) A painful cyst",
      "C) Diffuse erythema, edema ('Peau d'orange'), and warmth mimicking mastitis",
      "D) Nipple discharge only"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Skin erythema, edema, and peau d'orange without a discrete mass).\n\nPATHOPHYSIOLOGY:\nInflammatory breast cancer is an aggressive clinical subtype comprising 1 to 5% of all breast cancers per the National Cancer Institute. Tumor cells invade and obstruct the dermal lymphatic channels, blocking lymphatic drainage and producing the characteristic triad of skin erythema, breast edema, and peau d'orange (orange peel appearance from tethering of skin at points of dermal lymphatic obstruction by Cooper's ligaments). The inflammatory appearance results from lymphatic obstruction rather than infection, though the clinical resemblance to mastitis is striking per Harrison's Principles of Internal Medicine. IBC is classified as at least T4d and therefore at minimum stage IIIB at diagnosis.\n\nCLINICAL PRESENTATION:\nIBC presents with rapid onset (less than 6 months) of breast erythema, warmth, edema, and skin thickening involving at least one-third of the breast per NCCN diagnostic criteria. A discrete palpable mass is frequently absent, which distinguishes IBC from other locally advanced breast cancers and contributes to diagnostic delay. The critical clinical pearl per UpToDate is that breast erythema and edema failing to resolve after 7 to 10 days of antibiotics for presumed mastitis must raise immediate suspicion for IBC, prompting skin punch biopsy and imaging.\n\nDIAGNOSIS AND MANAGEMENT:\nDiagnosis requires skin punch biopsy demonstrating invasive carcinoma, with dermal lymphatic invasion supporting the diagnosis though not required per AJCC criteria. Treatment is multimodal: neoadjuvant chemotherapy first to reduce disease burden, followed by modified radical mastectomy, then postmastectomy radiation and appropriate adjuvant therapy per NCCN guidelines. Breast-conserving surgery is contraindicated in IBC due to the diffuse nature of the disease.\n\nKEY LEARNING POINTS:\nInflammatory breast cancer presents with rapid-onset breast erythema, edema, and peau d'orange caused by tumor emboli obstructing dermal lymphatics, not by infection. Failure of presumed mastitis to respond to antibiotics within 7 to 10 days mandates biopsy to exclude IBC. A discrete mass is often absent, IBC is at least stage IIIB at diagnosis, and breast-conserving surgery is contraindicated."
  },
  {
    "id": 507,
    "categoryId": 14,
    "question": "The classic triad of Renal Cell Carcinoma (RCC) is Hematuria, Flank Pain, and:",
    "options": [
      "A) Palpable Abdominal Mass",
      "B) Hypertension",
      "C) Jaundice",
      "D) Fever"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Palpable Abdominal Mass).\n\nCLINICAL PRESENTATION:\nThe classic triad of renal cell carcinoma consists of hematuria, flank pain, and a palpable abdominal or flank mass. However, this full triad is present in fewer than 10% of patients at diagnosis and when encountered indicates locally advanced or metastatic disease per Harrison's Principles of Internal Medicine. The most common presentation of RCC in the modern era is an incidental renal mass discovered on cross-sectional imaging performed for unrelated indications, accounting for more than 50% of diagnoses per UpToDate. RCC arises from the renal tubular epithelium, most commonly as clear cell carcinoma (approximately 70 to 80% of cases).\n\nPARANEOPLASTIC MANIFESTATIONS:\nRCC is called the internist's tumor because of its protean paraneoplastic manifestations per the Cleveland Clinic. These include erythrocytosis from ectopic erythropoietin production, hypercalcemia from PTHrP secretion, hypertension from renin secretion, and Stauffer syndrome (hepatic dysfunction with elevated alkaline phosphatase in the absence of liver metastases that resolves after nephrectomy). A left-sided varicocele that does not decompress in the supine position suggests left renal vein obstruction by tumor thrombus, as the left gonadal vein drains directly into the left renal vein.\n\nMANAGEMENT:\nLocalized disease is treated with partial nephrectomy (preferred for tumors 7cm or smaller to preserve renal function per AUA guidelines) or radical nephrectomy. RCC is characteristically resistant to conventional chemotherapy and radiation but is one of the most immunotherapy-responsive solid tumors, with checkpoint inhibitors (nivolumab plus ipilimumab) and VEGF-targeted therapies forming the backbone of advanced disease treatment per NCCN guidelines.\n\nKEY LEARNING POINTS:\nThe classic triad of hematuria, flank pain, and palpable mass is present in fewer than 10% of RCC cases and indicates advanced disease, while most cases are now discovered incidentally on imaging. RCC is notable for diverse paraneoplastic syndromes including erythrocytosis, hypercalcemia, and Stauffer syndrome. RCC is resistant to chemotherapy but highly responsive to immunotherapy and targeted therapies."
  },
  {
    "id": 508,
    "categoryId": 14,
    "question": "Acral Lentiginous Melanoma is the most common subtype in people with darker skin types (African/Asian descent). It typically appears on the:",
    "options": [
      "A) Face and Neck",
      "B) Trunk",
      "C) Palms, Soles, and under Nails (Subungual)",
      "D) Scalp"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Palms, soles, and nail beds).\n\nPATHOPHYSIOLOGY:\nAcral lentiginous melanoma is the most common melanoma subtype in people with darker skin tones, including those of African, Asian, and Hispanic descent, though it accounts for only 2 to 3% of all melanomas in Caucasian populations per the National Cancer Institute. Unlike the more common superficial spreading melanoma, ALM does not appear to be driven by ultraviolet radiation exposure, as it occurs exclusively on acral surfaces that receive minimal sun exposure. The pathogenesis involves distinct molecular pathways with frequent mutations in KIT and cyclin D1 rather than the BRAF mutations that characterize sun-exposed melanomas per Harrison's Principles of Internal Medicine, which has therapeutic implications for targeted therapy in metastatic disease.\n\nCLINICAL PRESENTATION:\nALM presents as an irregularly pigmented macule or patch on the palm, sole, or nail bed, often with variation in color from tan to dark brown or black per UpToDate. Subungual melanoma causes melanonychia striata, a pigmented longitudinal streak in the nail plate that may widen over time. Hutchinson sign, the extension of pigment from the nail bed onto the surrounding nail fold, is a critical finding that strongly suggests malignancy and distinguishes subungual melanoma from benign causes such as ethnic nail pigmentation or subungual hematoma.\n\nDELAYED DIAGNOSIS:\nALM is frequently diagnosed at more advanced stages compared to other melanoma subtypes per data from Johns Hopkins and the CDC. It occurs on locations not routinely inspected during self-examination, arises in populations often perceived as low risk for melanoma, and its appearance may not fit typical ABCDE criteria. This diagnostic delay results in thicker tumors at presentation and worse prognosis. A thorough skin examination in all patients regardless of skin tone should include inspection of the palms, soles, and nail beds.\n\nKEY LEARNING POINTS:\nAcral lentiginous melanoma occurs on palms, soles, and nail beds and is the most common melanoma subtype in patients with darker skin tones. Hutchinson sign (pigment extending from the nail bed onto the nail fold) strongly suggests subungual melanoma. ALM is frequently diagnosed at advanced stages due to overlooked anatomic locations and perceived low risk in darker-skinned populations."
  },
  {
    "id": 509,
    "categoryId": 14,
    "question": "Painless Jaundice (yellow skin/eyes without abdominal pain) is the classic presentation of:",
    "options": [
      "A) Gallstones (Choledocholithiasis)",
      "B) Pancreatic Cancer (Head of Pancreas)",
      "C) Hepatitis A",
      "D) Alcoholic Cirrhosis"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Pancreatic Cancer - Head of Pancreas).\n\nPATHOPHYSIOLOGY:\nPainless jaundice is the hallmark presentation of pancreatic head adenocarcinoma because of the intimate anatomic relationship between the head of the pancreas and the common bile duct per Harrison's Principles of Internal Medicine. The distal common bile duct passes through or immediately behind the pancreatic head before entering the duodenum at the ampulla of Vater, and even a small mass can compress or obstruct the duct, preventing bile drainage. The resulting obstructive jaundice produces conjugated hyperbilirubinemia with the classic triad of jaundice, dark urine (conjugated bilirubin filtered by the kidneys), and pale acholic stools (absence of stercobilin). The absence of pain distinguishes malignant biliary obstruction from choledocholithiasis, which typically causes colicky right upper quadrant pain from acute ductal distension.\n\nCLINICAL PRESENTATION:\nCourvoisier's sign, a palpable non-tender distended gallbladder in the setting of jaundice, is a classic finding suggesting malignant obstruction per UpToDate, because gradual tumor growth allows the gallbladder to slowly dilate, unlike the chronically scarred gallbladder of gallstone disease. Additional features include unexplained weight loss, new-onset diabetes mellitus (present in up to 80% of pancreatic cancer patients and sometimes preceding cancer diagnosis by months per the Mayo Clinic), and anorexia. Painless jaundice in an adult over 50 is pancreatic or periampullary malignancy until proven otherwise.\n\nDIAGNOSIS AND MANAGEMENT:\nCT abdomen with pancreatic protocol is the initial imaging study, followed by endoscopic ultrasound with fine-needle aspiration for tissue diagnosis per NCCN guidelines. CA 19-9 is the most commonly used serum marker but lacks sufficient sensitivity or specificity for screening. Surgical resection via pancreaticoduodenectomy (the Whipple procedure) is the only potentially curative treatment, feasible in only 15 to 20% of patients at diagnosis per Johns Hopkins surgical oncology data.\n\nKEY LEARNING POINTS:\nPainless jaundice is the classic presentation of pancreatic head cancer from gradual bile duct compression, producing conjugated hyperbilirubinemia with dark urine and pale stools. Courvoisier's sign (palpable non-tender gallbladder with jaundice) suggests malignant rather than gallstone obstruction. Only 15 to 20% of pancreatic cancers are surgically resectable at diagnosis."
  },
  {
    "id": 510,
    "categoryId": 14,
    "question": "A 65-year-old presents with new onset back pain. X-ray shows 'Lytic Lesions' (punched out holes) in the spine. Labs show elevated Calcium and Creatinine. Diagnosis?",
    "options": [
      "A) Osteoporosis",
      "B) Multiple Myeloma",
      "C) Spinal Stenosis",
      "D) Prostate Cancer"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Multiple Myeloma).\n\nCLINICAL REASONING:\nThis presentation of new-onset back pain, lytic bone lesions, hypercalcemia, and renal insufficiency in an older adult is classic for multiple myeloma per Harrison's Principles of Internal Medicine. The lytic lesions result from pathologic imbalance in bone remodeling: malignant plasma cells secrete osteoclast-activating cytokines (RANKL, interleukin-6) while producing osteoblast-inhibiting factors (DKK1, sclerostin), creating purely lytic lesions without surrounding sclerosis or reactive new bone.\n\nDIFFERENTIAL DIAGNOSIS:\nThe CRAB mnemonic captures the cardinal manifestations: Calcium elevation from bone resorption, Renal insufficiency from light chain cast nephropathy and hypercalcemia, Anemia from marrow infiltration, and Bone lesions (lytic). The differential for lytic bone lesions includes metastatic carcinoma (particularly lung, breast, kidney, and thyroid), but the combination with hypercalcemia and renal failure without an obvious primary tumor strongly favors myeloma per UpToDate. Metastatic prostate cancer characteristically produces osteoblastic (sclerotic) rather than lytic lesions, a critical distinguishing feature.\n\nDIAGNOSTIC WORKUP:\nEvaluation includes serum protein electrophoresis with immunofixation, serum free light chains with ratio, bone marrow biopsy with cytogenetics and FISH, beta-2 microglobulin, and appropriate imaging. An essential pearl per the Mayo Clinic is that conventional technetium-99m bone scan detects osteoblastic activity and is frequently falsely negative in myeloma because the lesions are purely lytic. Low-dose whole-body CT, PET-CT, or whole-body MRI are the appropriate imaging modalities per NCCN and IMWG guidelines.\n\nKEY LEARNING POINTS:\nMultiple myeloma produces purely lytic bone lesions from osteoclast activation with concurrent osteoblast suppression, and bone scan is often falsely negative because it detects osteoblastic rather than osteolytic activity. The CRAB criteria identify myeloma end-organ damage. Back pain in an older adult with unexplained hypercalcemia or renal insufficiency should prompt evaluation with serum protein electrophoresis and free light chains."
  },
  {
    "id": 511,
    "categoryId": 14,
    "question": "Prostate Cancer most commonly metastasizes to the:",
    "options": [
      "A) Brain",
      "B) Bone (Axial Skeleton)",
      "C) Liver",
      "D) Lungs"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Bone - particularly spine and pelvis).\n\nPATHOPHYSIOLOGY:\nProstate cancer exhibits a striking predilection for bone metastasis, with approximately 90% of men who die from prostate cancer having bone involvement, most commonly in the axial skeleton (lumbar spine, pelvis, thoracic spine, ribs) per Harrison's Principles of Internal Medicine. The seed and soil hypothesis explains this tropism: prostate cancer cells express adhesion molecules and chemokine receptors (particularly CXCR4) that bind to complementary ligands in the bone marrow stroma (particularly CXCL12/SDF-1), facilitating homing and engraftment per UpToDate. Once established, prostate cancer cells stimulate osteoblast activity rather than osteoclast activity, producing the distinctive osteoblastic (sclerotic) metastases that appear as dense white lesions on imaging, in contrast to the lytic metastases of lung, renal, thyroid, and most breast cancers.\n\nCLINICAL MANIFESTATIONS:\nBone metastases cause intractable pain (often the presenting symptom of advanced disease), pathologic fractures, and spinal cord compression (an oncologic emergency requiring emergent MRI and treatment) per the National Cancer Institute. Elevated serum alkaline phosphatase reflects osteoblastic activity and correlates with bone disease burden. PSA is typically markedly elevated and serves as a treatment response monitor.\n\nDIAGNOSIS AND MANAGEMENT:\nTechnetium-99m bone scan is highly sensitive for osteoblastic metastases and is the standard staging study per NCCN guidelines, in contrast to myeloma where bone scan is unreliable. Treatment of metastatic castration-sensitive prostate cancer includes androgen deprivation therapy combined with androgen receptor pathway inhibitors (abiraterone, enzalutamide) plus or minus docetaxel per data from the STAMPEDE and LATITUDE trials. Bone-protective agents (zoledronic acid or denosumab) reduce skeletal events. Radium-223, a bone-targeting alpha-emitting radioisotope, provides both pain palliation and survival benefit per the ALSYMPCA trial published in the New England Journal of Medicine.\n\nKEY LEARNING POINTS:\nProstate cancer preferentially metastasizes to bone through molecular homing mechanisms, with approximately 90% of fatal cases having bone involvement. Metastases are characteristically osteoblastic, distinguishing them from lytic metastases of other cancers. Bone scan effectively detects prostate cancer bone metastases (unlike myeloma), and elevated alkaline phosphatase reflects osteoblastic activity."
  },
  {
    "id": 512,
    "categoryId": 14,
    "question": "Small Cell Lung Cancer (SCLC) is a neuroendocrine tumor notorious for causing which paraneoplastic syndrome?",
    "options": [
      "A) SIADH and Lambert-Eaton Myasthenic Syndrome",
      "B) Hypercalcemia",
      "C) Hypoglycemia",
      "D) Polycythemia"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (SIADH and Lambert-Eaton Myasthenic Syndrome).\n\nPATHOPHYSIOLOGY:\nSmall cell lung cancer is a high-grade neuroendocrine carcinoma notorious for paraneoplastic syndromes. SCLC arises from pulmonary neuroendocrine cells (Kulchitsky cells) and retains the capacity for peptide hormone secretion per Harrison's Principles of Internal Medicine. SIADH is the most common paraneoplastic syndrome, occurring in approximately 10 to 15% of SCLC patients. The tumor ectopically produces ADH (arginine vasopressin), causing impaired free water excretion, euvolemic hyponatremia, concentrated urine (osmolality greater than 100 mOsm/kg), and low serum osmolality per UpToDate. Lambert-Eaton myasthenic syndrome is an autoimmune condition in which the tumor provokes antibodies against presynaptic voltage-gated calcium channels (P/Q-type) at the neuromuscular junction, impairing acetylcholine release and causing proximal muscle weakness, hyporeflexia, and autonomic dysfunction.\n\nCLINICAL REASONING:\nSCLC is centrally located in the majority of cases, grows rapidly with a doubling time of approximately 30 days, and is considered systemic at diagnosis because of early widespread metastasis per the National Cancer Institute. Approximately 60 to 70% present with extensive-stage disease. The paraneoplastic pattern differs by histologic subtype: SCLC causes SIADH, ectopic ACTH (Cushing syndrome), and Lambert-Eaton syndrome, while squamous cell carcinoma of the lung causes hypercalcemia through PTHrP secretion per Harrison's Principles of Internal Medicine. This histology-specific paraneoplastic distinction is a critical clinical concept.\n\nMANAGEMENT:\nSCLC is exquisitely sensitive to initial chemotherapy, with response rates of 60 to 80%, but relapse is nearly universal per UpToDate. Limited-stage disease is treated with concurrent cisplatin/etoposide plus thoracic radiation, with prophylactic cranial irradiation for responders. Extensive-stage disease is treated with platinum-etoposide plus a PD-L1 checkpoint inhibitor (atezolizumab or durvalumab) per the IMpower133 and CASPIAN trials.\n\nKEY LEARNING POINTS:\nSCLC is associated with SIADH (hyponatremia from ectopic ADH), ectopic ACTH (Cushing syndrome), and Lambert-Eaton syndrome, while squamous cell lung cancer is associated with hypercalcemia from PTHrP. SCLC is considered systemic at diagnosis and responds dramatically to initial chemotherapy but relapses in the vast majority of cases. PD-L1 checkpoint inhibitors added to chemotherapy are now standard for extensive-stage disease."
  },
  {
    "id": 513,
    "categoryId": 14,
    "question": "The primary risk factor for Cervical Cancer (>99% of cases) is persistent infection with:",
    "options": [
      "A) Herpes Simplex Virus",
      "B) Human Papillomavirus (HPV) High-Risk strains (16, 18)",
      "C) Chlamydia",
      "D) Gonorrhea"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Human Papillomavirus, High-Risk strains 16 and 18).\n\nPATHOPHYSIOLOGY:\nHPV is the necessary cause of virtually all cervical cancers, with HPV DNA detectable in greater than 99% of cervical squamous cell carcinomas per the CDC and Harrison's Principles of Internal Medicine. HPV types 16 and 18 are responsible for approximately 70% of cases. HPV infects the basal epithelial cells of the cervical transformation zone (the squamocolumnar junction) and integrates into the host genome. The oncogenic mechanism involves two viral proteins: E6, which binds and degrades the tumor suppressor p53 (disabling cell cycle arrest and apoptosis), and E7, which inactivates retinoblastoma protein (Rb), releasing E2F transcription factors and driving unregulated cell cycle progression. The simultaneous loss of both p53 and Rb creates the foundation for malignant transformation.\n\nCLINICAL SIGNIFICANCE:\nMost HPV infections are transient and cleared by the immune system within 1 to 2 years per UpToDate. Cervical cancer develops only when high-risk HPV persists for years, progressing through cervical intraepithelial neoplasia (CIN 1 through CIN 3) to invasive carcinoma. This prolonged pre-invasive phase enables effective screening. Current USPSTF guidelines recommend screening with cervical cytology (Pap smear), HPV co-testing, or primary HPV testing beginning at age 21 to 25, with intervals depending on strategy and patient age.\n\nPREVENTION:\nThe 9-valent HPV vaccine (Gardasil 9) targets HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, providing protection against strains responsible for approximately 90% of cervical cancers and the strains causing genital warts per the CDC. The ACIP recommends routine vaccination at age 11 to 12 (can begin at age 9) with catch-up through age 26. Countries with high vaccine coverage such as Australia have demonstrated dramatic reductions in HPV prevalence and high-grade cervical abnormalities per data published in The Lancet.\n\nKEY LEARNING POINTS:\nHPV is the necessary cause of cervical cancer, with types 16 and 18 responsible for approximately 70% of cases through the oncogenic actions of E6 (degrades p53) and E7 (inactivates Rb). The prolonged pre-invasive phase enables effective screening with Pap smear and HPV testing. The 9-valent HPV vaccine covers strains responsible for approximately 90% of cervical cancers and is recommended routinely at ages 11 to 12."
  },
  {
    "id": 514,
    "categoryId": 14,
    "question": "Hodgkin Lymphoma often presents with 'B-Symptoms'. These include:",
    "options": [
      "A) Headache, Vision changes, Dizziness",
      "B) Fever > 38C, Drenching Night Sweats, Weight Loss > 10%",
      "C) Rash, Itching, Swelling",
      "D) Cough, Dyspnea, Chest pain"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Fever greater than 38 degrees Celsius, drenching night sweats, weight loss greater than 10% in 6 months).\n\nPATHOPHYSIOLOGY:\nB-symptoms are a defined set of constitutional symptoms used in the Ann Arbor staging system for Hodgkin and non-Hodgkin lymphomas to indicate systemic disease activity per Harrison's Principles of Internal Medicine. The three B-symptoms are unexplained fever greater than 38 degrees Celsius, drenching night sweats severe enough to require changing bedclothes, and unintentional weight loss exceeding 10% of body weight over the preceding 6 months. These symptoms are driven by cytokines released by malignant cells and the reactive inflammatory microenvironment, including interleukin-6, interleukin-1, and tumor necrosis factor-alpha. The designation B is appended to the stage (for example, stage IIB versus IIA) and carries prognostic significance, as patients with B-symptoms have a worse prognosis and may require more intensive treatment.\n\nCLINICAL PRESENTATION:\nHodgkin lymphoma most commonly presents with painless cervical or supraclavicular lymphadenopathy in a young adult per the National Cancer Institute. A distinctive clinical feature, though present in fewer than 10% of cases, is alcohol-induced lymph node pain, in which ingestion of alcohol provokes pain at the site of involved nodes within minutes per UpToDate. Pruritus, though not classified as a B-symptom, is another common associated finding. Mediastinal lymphadenopathy is present in approximately 60 to 70% of patients and may cause cough, chest pressure, or superior vena cava syndrome.\n\nSTAGING AND MANAGEMENT:\nPET-CT is the standard staging modality per NCCN guidelines, as Hodgkin lymphoma is intensely FDG-avid. Treatment is tailored to stage and risk factors: early-stage favorable disease may require only abbreviated ABVD chemotherapy with or without involved-site radiation, while advanced-stage disease requires extended chemotherapy with interim PET-guided modifications.\n\nKEY LEARNING POINTS:\nB-symptoms are specifically defined as unexplained fever greater than 38 degrees, drenching night sweats, and weight loss exceeding 10% in 6 months, and their presence worsens prognosis. Alcohol-induced lymph node pain, though uncommon, is a classic and highly specific finding in Hodgkin lymphoma. PET-CT is the standard staging modality due to the intense FDG-avidity of Hodgkin lymphoma."
  },
  {
    "id": 515,
    "categoryId": 14,
    "question": "Ovarian Cancer is often called the 'Silent Killer'. Early symptoms are vague but persistent, including:",
    "options": [
      "A) Heavy vaginal bleeding",
      "B) Bloating, early satiety, and pelvic pressure",
      "C) Breast tenderness",
      "D) Acute sharp pain"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Bloating, early satiety, and pelvic pressure).\n\nCLINICAL PRESENTATION:\nOvarian cancer is termed the silent killer because approximately 60 to 70% of cases are diagnosed at stage III or IV per the National Cancer Institute. The ovaries are located deep in the pelvis without a serosal barrier to contain tumor growth, allowing malignancy to spread freely throughout the peritoneal cavity via transperitoneal dissemination before producing symptoms that prompt evaluation per Harrison's Principles of Internal Medicine. While historically described as asymptomatic in early stages, research has demonstrated that most women do experience symptoms, but they are vague, nonspecific, and easily attributed to benign conditions. The most frequently reported symptoms include persistent bloating or increased abdominal girth, pelvic or abdominal pain, difficulty eating or early satiety, and urinary frequency per UpToDate.\n\nRISK FACTORS:\nThe strongest risk factor is a germline BRCA1 mutation (lifetime ovarian cancer risk approximately 40 to 60%) or BRCA2 mutation (lifetime risk approximately 15 to 25%) per the CDC and Mayo Clinic genetics data. Other risk factors include family history, nulliparity, endometriosis, and increasing age. Protective factors include oral contraceptive use (reducing risk by approximately 40 to 50% with 5 or more years of use through ovulation suppression per data published in The Lancet), multiparity, breastfeeding, and tubal ligation. Risk-reducing bilateral salpingo-oophorectomy is recommended for BRCA carriers typically by age 35 to 40 for BRCA1 carriers per NCCN guidelines.\n\nSCREENING:\nThere is currently no effective general population screening test for ovarian cancer per the USPSTF. Both the PLCO trial and the UK Collaborative Trial of Ovarian Cancer Screening failed to demonstrate mortality reduction with CA-125 and ultrasound screening. Epithelial ovarian cancer, which accounts for approximately 90% of cases, most commonly presents as high-grade serous carcinoma.\n\nKEY LEARNING POINTS:\nOvarian cancer presents with nonspecific symptoms of persistent bloating, early satiety, pelvic pain, and urinary changes, contributing to late-stage diagnosis in the majority of cases. BRCA1 and BRCA2 mutations confer the highest risk, and risk-reducing salpingo-oophorectomy is recommended for carriers. No effective general population screening strategy exists, and oral contraceptive use reduces risk by 40 to 50% with prolonged use."
  },
  {
    "id": 516,
    "categoryId": 14,
    "question": "A palpable lymph node in the left supraclavicular fossa (Virchow's Node) suggests metastasis from:",
    "options": [
      "A) Thyroid Cancer",
      "B) Abdominal malignancy (Stomach/Pancreas)",
      "C) Breast Cancer",
      "D) Skin Cancer"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Abdominal malignancy - Stomach or Pancreas).\n\nPATHOPHYSIOLOGY:\nVirchow's node is a palpable left supraclavicular lymph node representing metastatic spread from an abdominal or pelvic malignancy, most commonly gastric adenocarcinoma, pancreatic cancer, or ovarian cancer per Harrison's Principles of Internal Medicine. The anatomic basis lies in the thoracic duct, the largest lymphatic vessel in the body, which collects lymphatic drainage from the entire abdomen, pelvis, lower extremities, and left thorax and empties into the venous system at the junction of the left subclavian and internal jugular veins. Tumor cells entering the abdominal lymphatic system travel through the thoracic duct and are deposited at its terminus in the left supraclavicular fossa, where they seed and enlarge the local lymph node. This finding is also known as Troisier's sign per UpToDate.\n\nCLINICAL SIGNIFICANCE:\nA palpable left supraclavicular lymph node in an adult is malignancy until proven otherwise and should prompt immediate investigation for an occult abdominal primary tumor per the Mayo Clinic. Right supraclavicular lymphadenopathy is more commonly associated with intrathoracic malignancies (lung and esophageal cancer) because the right lymphatic duct drains the right thorax and empties into the right subclavian vein. The malignancy rate in supraclavicular lymphadenopathy exceeds 50% in patients over age 40.\n\nDIAGNOSTIC APPROACH:\nEvaluation begins with fine-needle aspiration or core needle biopsy of the node, followed by CT of the chest, abdomen, and pelvis to identify the primary malignancy per NCCN guidelines. Immunohistochemistry on the biopsy specimen helps determine tissue of origin when the primary site is not apparent. Upper endoscopy should be strongly considered given the classic association with gastric cancer.\n\nKEY LEARNING POINTS:\nVirchow's node is a left supraclavicular lymph node representing metastasis from an abdominal malignancy, most classically gastric cancer, carried via the thoracic duct which drains the abdomen and empties into the left subclavian vein. A palpable supraclavicular node in an adult is malignancy until proven otherwise. Right supraclavicular nodes suggest intrathoracic malignancy, while left nodes suggest abdominal malignancy."
  },
  {
    "id": 517,
    "categoryId": 14,
    "question": "The most significant modifiable risk factor for Bladder Cancer (Transitional Cell Carcinoma) is:",
    "options": [
      "A) Alcohol",
      "B) Smoking",
      "C) High fat diet",
      "D) Caffeine"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Smoking).\n\nPATHOPHYSIOLOGY:\nCigarette smoking is the most significant modifiable risk factor for urothelial carcinoma of the bladder, responsible for approximately 50% of cases per the CDC and Harrison's Principles of Internal Medicine. The mechanism involves absorption of aromatic amines and carcinogens from tobacco smoke through the pulmonary vasculature, followed by renal filtration and concentration in the urine, where these carcinogens are held in prolonged direct contact with the urothelial lining. Specific carcinogens include 4-aminobiphenyl, 2-naphthylamine, and acrolein, which induce DNA mutations in urothelial cells. The risk in current smokers is approximately 3 to 4-fold higher than in never-smokers, and remains elevated at approximately 2-fold in former smokers for at least 10 years after cessation per UpToDate.\n\nCLINICAL PRESENTATION:\nThe classic presenting symptom is painless gross hematuria, occurring in approximately 85% of patients per the Cleveland Clinic. The hematuria is characteristically intermittent, and the absence of pain distinguishes it from urinary tract infection and nephrolithiasis. Some patients present with irritative voiding symptoms (frequency, urgency, dysuria) that may mimic infection, particularly with carcinoma in situ. Any adult over age 40 with unexplained hematuria requires cystoscopy and upper tract imaging per AUA guidelines.\n\nADDITIONAL RISK FACTORS:\nOccupational exposures to aromatic amines in the dye, rubber, leather, and textile industries carry significant risk per the National Cancer Institute. Cyclophosphamide (via its metabolite acrolein), pelvic radiation, and Schistosoma haematobium infection (endemic in the Nile Valley, associated with squamous cell carcinoma rather than urothelial) are additional recognized risk factors per Harrison's Principles of Internal Medicine.\n\nKEY LEARNING POINTS:\nSmoking accounts for approximately 50% of bladder cancers through renal filtration and urinary concentration of tobacco carcinogens in prolonged contact with the urothelium, conferring a 3 to 4-fold increased risk. Painless gross hematuria is the classic presentation, and any adult over 40 with unexplained hematuria requires cystoscopy. Smoking cessation remains beneficial though risk stays elevated for at least a decade."
  },
  {
    "id": 518,
    "categoryId": 14,
    "question": "The classic presentation of Endometrial Cancer is:",
    "options": [
      "A) Postmenopausal Bleeding",
      "B) Abdominal pain",
      "C) Weight loss",
      "D) Ascites"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Postmenopausal bleeding).\n\nPATHOPHYSIOLOGY:\nPostmenopausal bleeding, defined as any vaginal bleeding after 12 consecutive months of amenorrhea, is endometrial cancer until proven otherwise per Harrison's Principles of Internal Medicine. The most common subtype (type I, endometrioid adenocarcinoma, approximately 80% of cases) results from chronic unopposed estrogen stimulation of the endometrium. Estrogen drives endometrial proliferation, and without cyclical progesterone to induce secretory transformation and shedding, the endometrium progresses through simple hyperplasia, complex hyperplasia, atypical hyperplasia, and ultimately invasive carcinoma per UpToDate. The major clinical advantage is that abnormal bleeding occurs in approximately 90% of cases, enabling early diagnosis.\n\nRISK FACTORS:\nRisk factors reflect conditions of prolonged unopposed estrogen: obesity (peripheral aromatization of androgens to estrogen, with risk approximately 7-fold for BMI greater than 40 per the CDC), chronic anovulation (as in PCOS), exogenous estrogen without progestin in women with an intact uterus, tamoxifen (an estrogen agonist on endometrium despite being a breast antagonist), early menarche, late menopause, and nulliparity. Lynch syndrome (hereditary nonpolyposis colorectal cancer syndrome) confers a 40 to 60% lifetime risk through defective DNA mismatch repair per NCCN guidelines.\n\nDIAGNOSIS AND MANAGEMENT:\nInitial evaluation includes transvaginal ultrasound (endometrial thickness less than 4mm in postmenopausal women has a high negative predictive value per UpToDate) and endometrial biopsy, which is the definitive diagnostic test. Treatment is primarily surgical staging with total hysterectomy and bilateral salpingo-oophorectomy, with adjuvant therapy based on stage, grade, and histologic subtype per NCCN guidelines. The majority of endometrial cancers are diagnosed at stage I and carry a 5-year survival exceeding 90% per the National Cancer Institute.\n\nKEY LEARNING POINTS:\nPostmenopausal bleeding is endometrial cancer until proven otherwise, and the vast majority of cases present with bleeding, enabling early detection. Risk factors center on unopposed estrogen exposure including obesity, PCOS, and tamoxifen use. Lynch syndrome confers a 40 to 60% lifetime risk and should be considered in younger patients with endometrial cancer."
  },
  {
    "id": 519,
    "categoryId": 14,
    "question": "A brain tumor headache typically differs from a tension/migraine headache because it is:",
    "options": [
      "A) Worse in the morning (or wakes patient from sleep) and worsens with Valsalva/bending over",
      "B) Relieved by sleep",
      "C) Associated with visual aura",
      "D) Band-like"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Worse in the morning and with Valsalva maneuver).\n\nPATHOPHYSIOLOGY:\nHeadaches from intracranial mass lesions result from increased intracranial pressure (ICP) and have characteristic features differentiating them from primary headache disorders per Harrison's Principles of Internal Medicine. ICP rises during sleep due to recumbent positioning (impaired venous drainage from the head) and CO2 retention from decreased respiratory drive, peaking in the early morning hours. This produces the classic pattern of headache that is worst upon waking. Valsalva maneuvers (coughing, straining, bending forward) transiently increase intrathoracic and intraabdominal pressure, which is transmitted to the intracranial compartment via the venous system, further elevating ICP and worsening pain.\n\nRED FLAG FEATURES:\nAdditional concerning features per UpToDate and Mayo Clinic neurology guidelines include new headache in patients over age 50, progressive worsening over weeks to months, associated neurological deficits (focal weakness, sensory changes, visual disturbance, speech difficulty), new-onset seizures, personality or cognitive changes, and papilledema on fundoscopic examination. Headache that awakens the patient from sleep is particularly concerning because primary headache disorders (tension, migraine) typically improve with sleep rather than disrupt it.\n\nCONTRAST WITH PRIMARY HEADACHES:\nTension headaches are typically bilateral, band-like, and worse with stress but not positional. Migraines are often unilateral, pulsatile, with nausea and photophobia, and characteristically improve with sleep per Harrison's Principles of Internal Medicine. Neither typically worsens with Valsalva or has morning predominance. The presence of positional or Valsalva-exacerbated headache in combination with any neurological symptoms warrants urgent brain imaging with contrast-enhanced MRI per NCCN and AAN guidelines.\n\nKEY LEARNING POINTS:\nBrain tumor headaches are classically worse in the morning from overnight ICP elevation and exacerbated by Valsalva maneuvers. These features distinguish them from tension headaches and migraines, which do not worsen with position or straining. New progressive headache with neurological deficits or papilledema requires urgent contrast-enhanced MRI."
  },
  {
    "id": 520,
    "categoryId": 14,
    "question": "Testicular Cancer usually presents as a painless mass in young men (15-35). Which tumor markers are essential for diagnosis/monitoring?",
    "options": [
      "A) PSA and CEA",
      "B) AFP, beta-HCG, and LDH",
      "C) CA-125",
      "D) Calcitonin"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (AFP, beta-HCG, and LDH).\n\nPATHOPHYSIOLOGY:\nTesticular cancer arises from germ cells and is classified into seminomas (approximately 40%) and non-seminomatous germ cell tumors (NSGCT: embryonal carcinoma, yolk sac tumor, choriocarcinoma, teratoma) per Harrison's Principles of Internal Medicine. It is the most common solid malignancy in young men aged 15 to 35 per the National Cancer Institute. Risk factors include cryptorchidism (undescended testis, conferring a 4 to 8-fold increased risk per UpToDate), family history, and prior contralateral testicular cancer.\n\nTUMOR MARKERS:\nThree serum markers are essential for diagnosis, staging, and monitoring per NCCN guidelines. Alpha-fetoprotein (AFP) is elevated in yolk sac tumors and embryonal carcinoma but is never elevated in pure seminoma, meaning an elevated AFP rules out pure seminoma regardless of histologic appearance. Beta-human chorionic gonadotropin (beta-HCG) is markedly elevated in choriocarcinoma and may be mildly elevated in seminoma. Lactate dehydrogenase (LDH) reflects overall tumor burden and is a prognostic marker. These markers must be drawn before orchiectomy for staging purposes and followed serially after treatment to detect recurrence.\n\nCLINICAL PRESENTATION AND MANAGEMENT:\nThe classic presentation is a painless testicular mass discovered incidentally or on self-examination. Any solid testicular mass in a young man is cancer until proven otherwise per the Mayo Clinic. Ultrasound reliably distinguishes solid (concerning) from cystic (usually benign) lesions. Radical inguinal orchiectomy, not trans-scrotal biopsy (which risks scrotal seeding and alters lymphatic drainage pathways), is both diagnostic and therapeutic per NCCN guidelines. Seminomas are highly radiosensitive and chemosensitive, while advanced NSGCT is treated with BEP chemotherapy (bleomycin, etoposide, cisplatin). Cure rates exceed 95% even with metastatic disease.\n\nKEY LEARNING POINTS:\nAFP, beta-HCG, and LDH are the essential testicular cancer markers, with AFP elevation specifically ruling out pure seminoma. All solid testicular masses require ultrasound and radical inguinal orchiectomy, never trans-scrotal biopsy. Testicular cancer has excellent cure rates exceeding 95% even when metastatic."
  },
  {
    "id": 521,
    "categoryId": 4,
    "question": "The most common type of Thyroid Cancer is:",
    "options": [
      "A) Follicular",
      "B) Papillary",
      "C) Medullary",
      "D) Anaplastic"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Papillary Thyroid Carcinoma).\n\nPATHOPHYSIOLOGY:\nPapillary thyroid carcinoma (PTC) is the most common thyroid malignancy, accounting for approximately 80 to 85% of all thyroid cancers and approximately 3% of all new cancer diagnoses annually in the United States per the ACS and data from Harrison's Principles of Internal Medicine. PTC arises from thyroid follicular epithelial cells and is driven by activating mutations in the MAPK signaling pathway: the most common are BRAF V600E point mutations (present in approximately 45 to 60% of PTC cases, associated with more aggressive behavior including extrathyroidal extension, lymph node metastasis, radioiodine refractoriness, and higher recurrence rates) and RET/PTC rearrangements (chromosomal translocations producing constitutively active RET fusion oncoproteins, more common in radiation-associated PTC and in younger patients). RAS mutations (particularly NRAS) are found in the follicular variant of PTC. These mutations constitutively activate the RAS-RAF-MEK-ERK signaling cascade, driving uncontrolled cellular proliferation. Radiation exposure is the most well-established environmental risk factor: childhood exposure to external beam radiation (historically for thymus enlargement, tonsillar hypertrophy, or tinea capitis, and more recently from the Chernobyl and Fukushima nuclear accidents) increases PTC risk with a latency period of 5 to 30 years per data from the NEJM and WHO.\n\nCLINICAL PRESENTATION:\nPTC typically presents as a painless, firm thyroid nodule discovered on physical examination or incidentally on imaging (ultrasound, CT, PET scan). It has a strong female predominance (female-to-male ratio of approximately 3:1) and peak incidence in the third to fifth decades of life. Histologically, PTC is defined by characteristic nuclear features rather than architectural pattern: nuclear enlargement, irregular nuclear membrane contours (nuclear grooves), intranuclear cytoplasmic pseudoinclusions, and optically clear chromatin producing the classic ground-glass or Orphan Annie eye appearance. PTC spreads primarily through lymphatic channels to regional cervical lymph nodes, with approximately 30 to 50% of patients having cervical lymph node metastases at presentation. Despite this frequent nodal involvement, PTC has an excellent prognosis with a 10-year disease-specific survival exceeding 95% for localized and regional disease per SEER data and the ATA. Distant metastases (most commonly to lung, less commonly to bone) occur in only 2 to 5% of cases at presentation. The ATA risk stratification system categorizes patients as low, intermediate, or high risk based on tumor size, extrathyroidal extension, lymph node involvement, distant metastasis, completeness of resection, and molecular markers (BRAF V600E status).\n\nDIAGNOSIS AND TREATMENT:\nThyroid nodules are evaluated according to the ATA 2015 guidelines using a risk-stratified approach. Ultrasound characterization assesses features associated with malignancy: hypoechogenicity, irregular margins, taller-than-wide shape, microcalcifications (psammoma bodies, which are concentrically laminated calcifications pathognomonic for PTC), and absent halo. The ATA sonographic pattern system (from benign to highly suspicious) guides the size threshold for fine-needle aspiration (FNA) biopsy. FNA cytology is reported using the Bethesda System for Reporting Thyroid Cytopathology, which categorizes results into six diagnostic categories with associated malignancy risks and management recommendations. Molecular testing (Afirma Genomic Sequencing Classifier, ThyroSeq v3) is increasingly used to reclassify cytologically indeterminate nodules (Bethesda III and IV) and reduce unnecessary diagnostic surgery. Treatment of confirmed PTC follows the ATA guidelines: total thyroidectomy is recommended for tumors greater than 4 cm, tumors with gross extrathyroidal extension, or clinically apparent lymph node metastases. Lobectomy alone is appropriate for unifocal tumors 1 to 4 cm without extrathyroidal extension, lymph node metastases, or prior radiation exposure. Radioactive iodine (I-131) ablation is administered postoperatively for intermediate and high-risk patients to destroy residual thyroid tissue and microscopic disease. TSH suppression with levothyroxine (target TSH 0.1 to 0.5 mIU/L for intermediate risk, below 0.1 mIU/L for high risk) reduces the growth stimulus on any remaining thyroid tissue. Surveillance uses serum thyroglobulin (a tumor marker produced only by thyroid tissue, which should be undetectable after total thyroidectomy and RAI ablation) and neck ultrasound.\n\nKEY LEARNING POINTS:\nPapillary thyroid carcinoma is the most common thyroid malignancy (80 to 85% of cases), driven by BRAF V600E mutations in 45 to 60% of cases, spreading via lymphatics to cervical nodes but carrying an excellent prognosis (greater than 95% 10-year survival). FNA biopsy with Bethesda classification guides management, and treatment follows ATA risk stratification with thyroidectomy (total vs lobectomy based on tumor size and features), selective radioactive iodine ablation, and TSH suppression with thyroglobulin surveillance."
  },
  {
    "id": 522,
    "categoryId": 14,
    "question": "Osteosarcoma typically occurs in teenagers near the growth plates (knee) and has a classic X-ray appearance of:",
    "options": [
      "A) Onion Skinning",
      "B) Sunburst pattern and Codman's Triangle",
      "C) Soap Bubble",
      "D) Lytic hole"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Sunburst pattern and Codman triangle).\n\nPATHOPHYSIOLOGY:\nOsteosarcoma is the most common primary malignant bone tumor, producing osteoid (immature bone matrix) and arising classically in the metaphysis of long bones near the growth plates during periods of rapid skeletal growth per Harrison's Principles of Internal Medicine. The distal femur and proximal tibia (around the knee) are the most common sites, accounting for approximately 50% of cases. Peak incidence occurs in adolescents during the growth spurt (ages 10 to 20), with a second smaller peak in older adults associated with Paget disease of bone and prior radiation exposure per the National Cancer Institute.\n\nIMAGING FEATURES:\nThe sunburst pattern on plain radiograph results from aggressive tumor growth that lifts the periosteum and stimulates rapid, disorganized reactive bone formation radiating outward from the cortex in a spiculated pattern per UpToDate. Codman triangle refers to the triangular area of periosteal new bone formation at the margin where the elevated periosteum meets the cortex, indicating that the tumor is growing faster than the periosteum can contain it. These aggressive periosteal reactions are characteristic but not entirely specific to osteosarcoma, as other aggressive bone lesions including Ewing sarcoma and osteomyelitis can produce similar findings. Ewing sarcoma more classically shows an onion-skinning (lamellated) periosteal reaction.\n\nDIAGNOSIS AND MANAGEMENT:\nDiagnosis requires biopsy, ideally performed by the orthopedic oncology team to ensure the biopsy tract is placed along the planned surgical approach per NCCN guidelines. Standard treatment is neoadjuvant (pre-operative) multi-agent chemotherapy followed by surgical resection (limb-sparing surgery when feasible, which is possible in approximately 85 to 90% of cases per the Mayo Clinic), then adjuvant chemotherapy. The degree of tumor necrosis in the resected specimen following neoadjuvant chemotherapy is one of the most important prognostic factors.\n\nKEY LEARNING POINTS:\nOsteosarcoma classically occurs in the metaphysis near the knee in adolescents and shows a sunburst periosteal reaction and Codman triangle on radiograph, reflecting aggressive tumor growth outpacing periosteal containment. Ewing sarcoma, by contrast, classically shows an onion-skinning pattern. Treatment involves neoadjuvant chemotherapy followed by limb-sparing surgical resection when feasible."
  },
  {
    "id": 523,
    "categoryId": 14,
    "question": "Carcinoid Syndrome (flushing/diarrhea) only occurs when a GI neuroendocrine tumor has metastasized to the:",
    "options": [
      "A) Lung",
      "B) Liver",
      "C) Bone",
      "D) Brain"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Liver).\n\nPATHOPHYSIOLOGY:\nCarcinoid syndrome occurs when serotonin and other vasoactive substances produced by a gastrointestinal neuroendocrine tumor reach the systemic circulation in sufficient quantities to cause symptoms. Under normal circumstances, serotonin released by a GI neuroendocrine tumor drains via the portal venous system to the liver, where hepatic monoamine oxidase efficiently metabolizes it before it can enter the systemic circulation per Harrison's Principles of Internal Medicine. This hepatic first-pass metabolism explains why patients with localized GI neuroendocrine tumors, even those producing large amounts of serotonin, typically do not develop carcinoid syndrome. When the tumor metastasizes to the liver, serotonin is released directly from hepatic metastases into the hepatic veins and inferior vena cava, bypassing first-pass metabolism and entering the systemic circulation at biologically active concentrations.\n\nCLINICAL MANIFESTATIONS:\nThe classic symptoms of carcinoid syndrome per UpToDate are episodic flushing (sudden redness of the face and upper body), secretory diarrhea (from serotonin stimulation of intestinal motility and secretion), bronchospasm (wheezing), and right-sided valvular heart disease (carcinoid heart disease, characterized by endocardial fibrosis of the tricuspid and pulmonic valves from chronic serotonin exposure). Left-sided valves are spared because serotonin is metabolized during passage through the pulmonary vasculature. Diagnosis is confirmed by elevated 24-hour urinary 5-HIAA (5-hydroxyindoleacetic acid), the primary serotonin metabolite per the Mayo Clinic.\n\nEXCEPTION:\nBronchial carcinoid tumors and ovarian carcinoid tumors can cause carcinoid syndrome without liver metastases because their venous drainage does not pass through the portal system and hepatic first-pass metabolism per Harrison's Principles of Internal Medicine.\n\nKEY LEARNING POINTS:\nCarcinoid syndrome occurs only when a GI neuroendocrine tumor has metastasized to the liver, because hepatic first-pass metabolism normally degrades serotonin before it reaches the systemic circulation. Classic symptoms include flushing, diarrhea, bronchospasm, and right-sided valvular heart disease. Bronchial and ovarian carcinoids are exceptions that can cause syndrome without liver metastases because they bypass the portal circulation."
  },
  {
    "id": 524,
    "categoryId": 17,
    "question": "Persistent hoarseness (>2 weeks) in a smoker requires visualization of the vocal cords to rule out:",
    "options": [
      "A) Laryngeal Cancer (Squamous Cell)",
      "B) Vocal cord nodules",
      "C) GERD",
      "D) Hypothyroidism"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Laryngeal Cancer).\n\nPATHOPHYSIOLOGY:\nLaryngeal squamous cell carcinoma accounts for approximately 95% of laryngeal malignancies and is strongly associated with tobacco use and alcohol consumption, with a synergistic effect when combined. Carcinogens in tobacco smoke cause cumulative mucosal injury and DNA damage to the laryngeal epithelium, progressing through dysplasia to carcinoma in situ and invasive disease. Glottic (true vocal cord) tumors present earliest with hoarseness because even small lesions disrupt vocal cord vibration.\n\nCLINICAL PRESENTATION:\n- Persistent hoarseness or voice change lasting more than 2-3 weeks (earliest and most common symptom of glottic cancer)\n- Dysphagia, odynophagia, referred otalgia (supraglottic tumors)\n- Stridor or airway obstruction (advanced disease)\n- Neck mass (cervical lymphadenopathy from metastatic spread)\n- Hemoptysis, weight loss (late findings)\n\nDIAGNOSIS:\nAny patient with persistent hoarseness exceeding 2 weeks, especially with a smoking history, requires direct visualization of the larynx. Flexible fiberoptic laryngoscopy is the initial diagnostic procedure. Suspicious lesions require direct laryngoscopy with biopsy under general anesthesia for tissue diagnosis and staging. CT or MRI of the neck evaluates tumor extent and nodal disease.\n\nTREATMENT:\n- Early glottic cancer (T1-T2): Radiation therapy alone or endoscopic laser surgery, with cure rates exceeding 90%\n- Advanced disease: Combined chemoradiation or total laryngectomy\n- Voice preservation is a primary treatment goal for early-stage disease\n\nPRIMARY CARE PEARL:\nWhile benign causes of hoarseness (vocal polyps, laryngopharyngeal reflux, vocal cord nodules) are far more common, the 2-week rule in a smoker ensures early detection of laryngeal cancer when cure rates are highest. Do not empirically treat hoarseness in a smoker with acid suppression alone without laryngoscopy.\n\nKEY LEARNING POINTS:\nPersistent hoarseness exceeding 2 weeks in a smoker requires laryngoscopy to rule out laryngeal cancer. Glottic tumors present early with hoarseness because vocal cord lesions impair vibration. Early detection allows voice-preserving treatment with cure rates above 90%.\n\nREFERENCES:\nNCCN Head and Neck Cancer Guidelines; ACS; UpToDate; Harrison's Principles of Internal Medicine.\n---"
  },
  {
    "id": 525,
    "categoryId": 14,
    "question": "Adenocarcinoma of the Esophagus is increasing in incidence and is primarily linked to:",
    "options": [
      "A) Alcohol and Smoking",
      "B) GERD, Barrett's Esophagus, and Obesity",
      "C) Hot tea consumption",
      "D) HPV"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (GERD, Barrett's Esophagus, and Obesity).\n\nPATHOPHYSIOLOGY:\nAdenocarcinoma of the esophagus has risen dramatically in incidence in Western countries over the past four decades and is now the predominant esophageal cancer type in the United States per the National Cancer Institute. The pathogenesis follows a well-characterized metaplasia-dysplasia-carcinoma sequence driven by chronic gastroesophageal reflux disease. Prolonged acid and bile exposure damages the normal squamous epithelium of the distal esophagus, which is replaced by intestinal-type columnar epithelium containing goblet cells, a condition known as Barrett's esophagus per Harrison's Principles of Internal Medicine. Barrett's esophagus is the single most important risk factor for esophageal adenocarcinoma, conferring an annual transformation risk of approximately 0.5 to 1% per UpToDate, progressing through low-grade dysplasia and high-grade dysplasia before invasive cancer develops.\n\nRISK FACTORS:\nObesity (particularly visceral obesity) independently increases risk through multiple mechanisms including increased intra-abdominal pressure promoting reflux, pro-inflammatory adipokine secretion, and hyperinsulinemia per the Mayo Clinic. Other risk factors include chronic GERD symptoms (risk increases with duration and severity), male sex (8:1 male predominance), Caucasian race, tobacco use, and hiatal hernia.\n\nCONTRAST WITH SQUAMOUS CELL CARCINOMA:\nSquamous cell carcinoma of the esophagus arises in the upper and middle thirds, driven by tobacco and alcohol use, and remains the predominant type worldwide per Harrison's Principles of Internal Medicine. Adenocarcinoma arises in the lower third (distal esophagus and gastroesophageal junction), driven by reflux and Barrett's metaplasia. This anatomic and etiologic distinction has direct implications for risk factor modification and surveillance strategy.\n\nKEY LEARNING POINTS:\nEsophageal adenocarcinoma arises from the metaplasia-dysplasia-carcinoma sequence driven by chronic GERD, with Barrett's esophagus as the key precursor lesion. Obesity and chronic reflux are the primary modifiable risk factors. Squamous cell carcinoma of the upper esophagus is driven by tobacco and alcohol, while adenocarcinoma of the distal esophagus is driven by GERD and Barrett's."
  },
  {
    "id": 526,
    "categoryId": 14,
    "question": "Basal Cell Carcinoma (BCC) is the most common skin cancer. The classic lesion is:",
    "options": [
      "A) A scaly, rough patch (sandpaper)",
      "B) A pearly papule with telangiectasias and a rolled border",
      "C) A multicolored mole",
      "D) A purple nodule"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (A pearly papule with telangiectasias and a rolled border).\n\nPATHOPHYSIOLOGY:\nBasal cell carcinoma is the most common skin cancer and the most common malignancy overall in humans, with approximately 3.6 million cases diagnosed annually in the United States per the CDC and Cleveland Clinic. BCC arises from the basal layer of the epidermis and is strongly associated with cumulative ultraviolet radiation exposure, occurring most frequently on sun-exposed areas of the head and neck in fair-skinned individuals per Harrison's Principles of Internal Medicine. The classic morphology is a pearly or translucent papule or nodule with surface telangiectasias (visible dilated blood vessels) and a rolled (raised) border, often with central ulceration in advanced lesions, historically described as a rodent ulcer.\n\nCLINICAL BEHAVIOR:\nBCC grows slowly through local tissue invasion and destruction but has an extremely low metastatic potential (less than 0.1% of cases per UpToDate), which distinguishes it from squamous cell carcinoma (SCC) of the skin. SCC presents as a scaly, keratotic, or ulcerated lesion and carries a moderate metastatic risk that increases with tumor size greater than 2cm, depth of invasion, perineural involvement, and immunosuppression. Melanoma, the most lethal skin cancer, is identified by the ABCDE criteria (Asymmetry, Border irregularity, Color variation, Diameter greater than 6mm, Evolution) and requires excisional biopsy with Breslow depth measurement for staging.\n\nTREATMENT:\nStandard treatment for BCC is surgical excision with histologically clear margins per NCCN guidelines. Mohs micrographic surgery, which provides real-time margin assessment during surgery, is preferred for high-risk locations (face, especially nose, periorbital, and periauricular areas) where tissue conservation is critical and recurrence would be morbid per the Mayo Clinic. Superficial BCC can also be treated with topical imiquimod, photodynamic therapy, or electrodesiccation and curettage in select cases. Hedgehog pathway inhibitors (vismodegib, sonidegib) are available for locally advanced or metastatic BCC per NCCN guidelines.\n\nKEY LEARNING POINTS:\nBasal cell carcinoma presents as a pearly papule with telangiectasias and rolled borders, grows slowly by local invasion, and almost never metastasizes. Squamous cell carcinoma is scaly and ulcerated with moderate metastatic potential. Mohs micrographic surgery is preferred for high-risk facial locations where tissue conservation and clear margins are critical."
  },
  {
    "id": 527,
    "categoryId": 14,
    "question": "A child presents with bone pain, fever, fatigue, and bruising. Labs show blasts in the peripheral blood. The most common childhood cancer is:",
    "options": [
      "A) AML",
      "B) ALL (Acute Lymphoblastic Leukemia)",
      "C) CML",
      "D) CLL"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Acute Lymphoblastic Leukemia).\n\nPATHOPHYSIOLOGY:\nAcute lymphoblastic leukemia is the most common cancer and the most common leukemia in children, accounting for approximately 25% of all childhood cancers with a peak incidence between ages 2 and 5 per the National Cancer Institute. ALL is a malignant clonal proliferation of lymphoid precursor cells (lymphoblasts) in the bone marrow that crowds out normal hematopoiesis, resulting in the simultaneous failure of all three major cell lines per Harrison's Principles of Internal Medicine. The loss of red blood cell production causes anemia (fatigue, pallor), the loss of platelet production causes thrombocytopenia (bruising, petechiae, mucosal bleeding), and the loss of mature white blood cells causes neutropenia (recurrent or severe infections). Bone pain results from rapid expansion of the leukemic cell population within the marrow cavity, stretching the periosteum.\n\nCLINICAL PRESENTATION:\nChildren typically present with a combination of fatigue, pallor, fevers, bone or joint pain, bruising, and hepatosplenomegaly or lymphadenopathy from leukemic infiltration per UpToDate. The CBC characteristically shows anemia, thrombocytopenia, and a white blood cell count that may be elevated (with circulating blasts), normal, or low (aleukemic leukemia). The presence of lymphoblasts on peripheral blood smear is a critical finding that warrants emergent bone marrow evaluation with flow cytometry and cytogenetic analysis for definitive diagnosis and risk stratification.\n\nTREATMENT:\nModern multi-phase chemotherapy protocols have transformed childhood ALL from a uniformly fatal disease into one with overall cure rates exceeding 90% in standard-risk patients per data from the Children's Oncology Group and St. Jude Children's Research Hospital. Treatment consists of induction (to achieve remission), consolidation (to eliminate residual disease), CNS prophylaxis (intrathecal chemotherapy to prevent meningeal relapse), and maintenance therapy for a total duration of approximately 2 to 3 years per NCCN guidelines. Risk stratification using age, WBC count, cytogenetics (the Philadelphia chromosome and MLL rearrangements confer high risk), and minimal residual disease assessment guides treatment intensity. Tumor lysis syndrome is a critical oncologic emergency consideration at treatment initiation.\n\nKEY LEARNING POINTS:\nALL is the most common childhood cancer, presenting with bone marrow failure (anemia, thrombocytopenia, neutropenia) and bone pain from marrow expansion. Circulating blasts on peripheral smear warrant emergent bone marrow evaluation. Modern chemotherapy achieves cure rates exceeding 90% in standard-risk childhood ALL."
  },
  {
    "id": 528,
    "categoryId": 14,
    "question": "Sister Mary Joseph Nodule is a palpable nodule at the umbilicus. It represents metastasis from a:",
    "options": [
      "A) Pelvic or Abdominal malignancy (Ovarian/Gastric/Pancreatic)",
      "B) Lung cancer",
      "C) Breast cancer",
      "D) Melanoma"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Metastasis from an abdominopelvic malignancy).\n\nCLINICAL SIGNIFICANCE:\nA Sister Mary Joseph nodule is an umbilical metastasis representing advanced intra-abdominal or pelvic malignancy, named after Sister Mary Joseph Dempsey, a surgical assistant at the Mayo Clinic who first recognized the association between umbilical nodules and intra-abdominal cancer per the Mayo Clinic historical archives. The most common primary sites are gastric, pancreatic, colorectal, and ovarian adenocarcinomas per Harrison's Principles of Internal Medicine.\n\nPATHOPHYSIOLOGY:\nMetastatic spread to the umbilicus can occur through several anatomic routes per UpToDate: direct peritoneal seeding along the peritoneal surface to the umbilical region, lymphatic drainage pathways that converge near the umbilicus, hematogenous spread via the paraumbilical venous plexus, or extension along embryologic remnants including the urachus and obliterated umbilical arteries connecting the bladder and internal iliac vessels to the umbilical ring. The finding indicates widespread disease and is associated with a poor prognosis, with reported median survival of approximately 10 to 11 months per published case series.\n\nDIAGNOSTIC APPROACH:\nAn umbilical nodule in an adult should never be dismissed as a benign hernia or granuloma without histologic evaluation. Biopsy of the nodule (fine-needle aspiration or excisional biopsy) with immunohistochemistry to determine tissue of origin, followed by CT of the chest, abdomen, and pelvis for primary tumor identification and staging, is the standard workup per NCCN guidelines. In women, CA-125 and pelvic imaging should be included given the frequency of ovarian cancer as the primary site.\n\nKEY LEARNING POINTS:\nA Sister Mary Joseph nodule is an umbilical metastasis from an abdominopelvic malignancy, most commonly gastric, pancreatic, colorectal, or ovarian cancer. It represents advanced disease with poor prognosis. An umbilical nodule in an adult should never be assumed benign and requires biopsy and cross-sectional imaging to identify the primary malignancy."
  },
  {
    "id": 529,
    "categoryId": 14,
    "question": "Hepatocellular Carcinoma (HCC) screening involves Ultrasound and AFP every 6 months for high-risk patients. Who is high risk?",
    "options": [
      "A) Anyone with fatty liver",
      "B) Patients with Cirrhosis (any cause) or Chronic Hepatitis B",
      "C) Alcoholics without cirrhosis",
      "D) Diabetics"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Patients with Cirrhosis or Chronic Hepatitis B).\n\nSCREENING RATIONALE:\nHepatocellular carcinoma surveillance with abdominal ultrasound and serum alpha-fetoprotein every 6 months is recommended by the AASLD and NCCN for patients at elevated risk, primarily those with cirrhosis from any cause and those with chronic hepatitis B infection per UpToDate. Cirrhosis is the single strongest risk factor, as approximately 80 to 90% of HCC cases arise in cirrhotic livers. The chronically injured, regenerating cirrhotic liver creates a pre-malignant field in which hepatocyte turnover, oxidative stress, and genomic instability accumulate, dramatically increasing the probability of malignant transformation per Harrison's Principles of Internal Medicine.\n\nHEPATITIS B EXCEPTION:\nChronic hepatitis B is unique among HCC risk factors because it can cause HCC even in the absence of cirrhosis per the CDC and Johns Hopkins hepatology data. HBV integrates its DNA directly into the hepatocyte genome, causing insertional mutagenesis that can activate oncogenes or inactivate tumor suppressor genes independent of the cirrhosis-mediated pathway. The AASLD recommends HCC surveillance for HBV carriers who are Asian males over age 40, Asian females over age 50, African or North American Black patients with HBV, patients with HBV and a family history of HCC, and any HBV patient with cirrhosis.\n\nSCREENING PERFORMANCE:\nAbdominal ultrasound has a sensitivity of approximately 60 to 80% for detecting early-stage HCC per the Mayo Clinic, which improves when combined with AFP measurement. Lesions detected on surveillance tend to be smaller and at an earlier stage, translating into increased eligibility for curative treatments including surgical resection, liver transplantation (within Milan criteria), and ablation. The 6-month interval is based on the average HCC tumor doubling time of approximately 4 to 6 months.\n\nKEY LEARNING POINTS:\nHCC screening with ultrasound and AFP every 6 months is recommended for all patients with cirrhosis (any etiology) and chronic hepatitis B carriers, even without cirrhosis. HBV uniquely causes HCC through direct DNA integration and insertional mutagenesis independent of cirrhosis. Surveillance enables detection at earlier stages when curative treatment with resection, transplant, or ablation is feasible."
  },
  {
    "id": 530,
    "categoryId": 14,
    "question": "Leukoplakia is a white patch on the oral mucosa that cannot be scraped off. It is considered:",
    "options": [
      "A) Thrush (Candidiasis)",
      "B) Pre-malignant (risk of Squamous Cell Carcinoma)",
      "C) Lichen Planus",
      "D) Benign friction rub"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Pre-malignant).\n\nDEFINITION:\nLeukoplakia is defined as a white patch or plaque on the oral mucosa that cannot be scraped off and cannot be attributed to any other identifiable cause per Harrison's Principles of Internal Medicine. It is a clinical descriptor, not a histologic diagnosis, and approximately 5 to 25% of leukoplakia lesions demonstrate dysplasia or carcinoma on biopsy per UpToDate. The whiteness results from epithelial hyperkeratosis (thickening of the keratin layer), making it adherent to the underlying mucosa, in contrast to oral thrush (candidiasis) which produces white plaques that can be scraped off, revealing an erythematous or bleeding base.\n\nRISK FACTORS:\nTobacco use (both smoking and smokeless tobacco) is the strongest risk factor for oral leukoplakia per the CDC. Alcohol use acts synergistically with tobacco to increase risk. Chronic mechanical irritation from ill-fitting dentures, betel nut chewing (prevalent in South and Southeast Asia), and HPV infection (particularly types 16 and 18) are additional contributors. The lateral tongue and floor of mouth are the highest-risk locations for malignant transformation per UpToDate, while leukoplakia of the buccal mucosa carries a lower transformation risk.\n\nMANAGEMENT:\nAll leukoplakia lesions require biopsy to assess for dysplasia per NCCN head and neck cancer guidelines. Mild dysplasia may be observed with close follow-up after eliminating risk factors (smoking cessation, alcohol reduction). Moderate to severe dysplasia or carcinoma in situ requires excision or ablation. Erythroplakia, a red velvety patch on the oral mucosa, carries a substantially higher malignant potential than leukoplakia, with up to 50% harboring invasive squamous cell carcinoma at biopsy per the Mayo Clinic.\n\nKEY LEARNING POINTS:\nLeukoplakia is a white oral mucosal patch that cannot be scraped off (unlike candidiasis) and is pre-malignant, with 5 to 25% showing dysplasia or carcinoma on biopsy. The lateral tongue and floor of mouth carry the highest transformation risk. All leukoplakia requires biopsy, and erythroplakia (red patches) carries even higher malignant potential with up to 50% harboring invasive cancer."
  },
  {
    "id": 531,
    "categoryId": 14,
    "question": "Hypercalcemia of Malignancy is most commonly caused by the tumor secreting:",
    "options": [
      "A) PTH (Parathyroid Hormone)",
      "B) PTHrP (PTH-related Protein)",
      "C) Vitamin D",
      "D) Calcitonin"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (PTHrP - PTH-related Protein).\n\nPATHOPHYSIOLOGY:\nHypercalcemia of malignancy is the most common paraneoplastic endocrine syndrome and the most common cause of hypercalcemia in hospitalized patients per Harrison's Principles of Internal Medicine. The predominant mechanism, accounting for approximately 80% of cases, is tumor secretion of parathyroid hormone-related protein (PTHrP), which shares structural homology with the first 13 amino acids of native PTH and binds the same PTH/PTHrP receptor on bone and kidney. This produces effects that mimic hyperparathyroidism: increased osteoclastic bone resorption (releasing calcium) and increased renal calcium reabsorption. However, unlike primary hyperparathyroidism, PTHrP does not stimulate renal 1-alpha-hydroxylase, so 1,25-dihydroxyvitamin D levels are typically low per UpToDate.\n\nLABORATORY DISTINCTION:\nThe characteristic laboratory pattern per the Cleveland Clinic is elevated serum calcium, low (suppressed) intact PTH (because the pituitary calcium-sensing receptor detects hypercalcemia and suppresses native PTH), and elevated PTHrP. This pattern distinguishes humoral hypercalcemia of malignancy from primary hyperparathyroidism, in which PTH is inappropriately elevated or normal. Squamous cell carcinomas (particularly lung), renal cell carcinoma, and breast cancer are the most common malignancies causing PTHrP-mediated hypercalcemia per Harrison's Principles of Internal Medicine. Other mechanisms include direct osteolytic metastases (breast, myeloma) and tumor production of 1,25-dihydroxyvitamin D (lymphomas, granulomatous diseases).\n\nMANAGEMENT:\nAcute management of severe hypercalcemia per UpToDate includes aggressive intravenous normal saline hydration (200 to 300 mL/hour initially), intravenous bisphosphonate (zoledronic acid 4 mg), and calcitonin for rapid but transient effect. Denosumab is an alternative for bisphosphonate-refractory cases. Definitive treatment requires addressing the underlying malignancy.\n\nKEY LEARNING POINTS:\nHypercalcemia of malignancy is most commonly caused by tumor-secreted PTHrP, which mimics PTH action on bone and kidney. The diagnostic lab pattern is high calcium, low PTH, and elevated PTHrP, distinguishing it from primary hyperparathyroidism. Squamous cell lung cancer, renal cell carcinoma, and breast cancer are the most common culprits."
  },
  {
    "id": 532,
    "categoryId": 14,
    "question": "Anthracyclines (e.g., Doxorubicin/Adriamycin) are notorious for causing dose-dependent toxicity to the:",
    "options": [
      "A) Kidneys",
      "B) Heart (Cardiomyopathy)",
      "C) Lungs",
      "D) Nerves"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Heart - Cardiomyopathy).\n\nPATHOPHYSIOLOGY:\nAnthracyclines (doxorubicin, daunorubicin, epirubicin, idarubicin) are among the most effective and widely used chemotherapy agents across numerous malignancies including breast cancer, lymphomas, sarcomas, and acute leukemias, but they carry a well-characterized risk of dose-dependent cardiotoxicity per Harrison's Principles of Internal Medicine. The primary mechanism involves generation of reactive oxygen species through iron-dependent redox cycling of the anthracycline quinone moiety, causing oxidative damage to cardiomyocyte mitochondrial DNA, lipid membranes, and contractile proteins. Unlike most other cell types, cardiomyocytes have limited regenerative capacity and low levels of endogenous antioxidant defenses (particularly catalase), making them uniquely vulnerable to cumulative oxidative injury per UpToDate. An additional mechanism involves inhibition of topoisomerase 2-beta in cardiomyocytes, leading to DNA double-strand breaks and apoptosis.\n\nCLINICAL MANIFESTATIONS:\nAnthracycline cardiotoxicity manifests as a dose-dependent dilated cardiomyopathy that may present acutely during treatment, within the first year, or as late-onset cardiomyopathy years to decades after treatment per the Cleveland Clinic. The risk increases significantly above a cumulative doxorubicin dose of 400 mg/m2, with heart failure incidence of approximately 5% at 400 mg/m2 and 26% at 550 mg/m2 per data published in the New England Journal of Medicine. The damage is cumulative and irreversible.\n\nMONITORING AND PREVENTION:\nEchocardiography or MUGA scan to assess left ventricular ejection fraction is required before initiating anthracycline therapy, at regular intervals during treatment, and during long-term survivorship follow-up per NCCN and ASCO guidelines. Dexrazoxane, an iron chelator, is the only FDA-approved cardioprotectant that reduces anthracycline cardiotoxicity and is considered when cumulative doses exceed 300 mg/m2 per the Mayo Clinic.\n\nKEY LEARNING POINTS:\nAnthracyclines cause dose-dependent irreversible cardiomyopathy through free radical damage to cardiomyocytes, with risk increasing significantly above cumulative doxorubicin doses of 400 mg/m2. Echocardiography monitoring before, during, and after treatment is mandatory. Other high-yield chemotherapy toxicities include bleomycin (pulmonary fibrosis), cisplatin (nephrotoxicity and ototoxicity), and vincristine (peripheral neuropathy)."
  },
  {
    "id": 533,
    "categoryId": 14,
    "question": "Squamous Cell Carcinoma of the Anus is strongly associated with:",
    "options": [
      "A) Hemorrhoids",
      "B) HPV Infection",
      "C) Inflammatory Bowel Disease",
      "D) Alcohol"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (HPV Infection).\n\nPATHOPHYSIOLOGY:\nSquamous cell carcinoma of the anus is an HPV-driven malignancy with a pathogenesis analogous to cervical cancer per Harrison's Principles of Internal Medicine. HPV types 16 and 18 are the causative strains in the vast majority of cases, with their oncoproteins E6 and E7 inactivating the tumor suppressors p53 and retinoblastoma protein respectively, driving malignant transformation of the squamocolumnar junction (the anal transition zone) per the CDC. Risk factors include receptive anal intercourse, multiple sexual partners, immunosuppression (particularly HIV infection, which increases anal cancer risk 30 to 80-fold per UpToDate), and cigarette smoking.\n\nCLINICAL PRESENTATION:\nAnal cancer most commonly presents with rectal bleeding, anal pain, a palpable mass, or pruritus, though it may be asymptomatic and detected on routine digital rectal examination per the National Cancer Institute. It is important to distinguish anal canal cancer (squamous cell carcinoma, HPV-driven) from rectal cancer (adenocarcinoma, not HPV-related), as the biology, treatment, and prognosis differ significantly.\n\nTREATMENT:\nThe standard of care for anal squamous cell carcinoma is the Nigro protocol, concurrent chemoradiation with 5-fluorouracil and mitomycin C per NCCN guidelines. This organ-preserving approach achieves cure rates of approximately 80 to 90% for locoregional disease while preserving sphincter function and avoiding the need for abdominoperineal resection (permanent colostomy) in the majority of patients. Surgery is reserved for residual or recurrent disease after chemoradiation.\n\nPREVENTION:\nHPV vaccination with the 9-valent vaccine (Gardasil 9) protects against the HPV types responsible for anal cancer and is recommended for all individuals per ACIP guidelines. Anal cancer screening with anal cytology (anal Pap smear) and high-resolution anoscopy is recommended for high-risk populations including HIV-positive individuals, men who have sex with men, and immunosuppressed patients per guidelines from Johns Hopkins and the HIV Medicine Association.\n\nKEY LEARNING POINTS:\nAnal squamous cell carcinoma is driven by HPV types 16 and 18, analogous to cervical cancer, with HIV conferring a 30 to 80-fold increased risk. The Nigro protocol (concurrent chemoradiation) achieves high cure rates while preserving sphincter function. HPV vaccination protects against anal cancer, and screening with anal cytology is recommended for high-risk populations."
  },
  {
    "id": 534,
    "categoryId": 12,
    "question": "A parent is concerned that their 18-month-old is not talking enough. What is the expected speech milestone for this age?",
    "options": [
      "A) Cooing and babbling",
      "B) 6-20 words",
      "C) 2-word sentences",
      "D) 100% intelligible speech"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (6 to 20 words).\n\nCLINICAL REASONING:\nSpeech and language development follows a predictable trajectory with recognized milestones that serve as screening benchmarks at well-child visits per the AAP and UpToDate. By 12 months, a child should have at least 1 to 3 recognizable words beyond \"mama\" and \"dada\" used with intent, along with communicative gesturing (pointing, waving). By 18 months, the expected vocabulary is approximately 10 to 25 words (with some variation across references citing 6 to 20 words), and the child should be able to follow simple one-step commands and point to familiar objects when named per the CDC. By 24 months, the vocabulary expands to 50 or more words with emergence of two-word phrases (\"want milk,\" \"more juice\"), and speech should be approximately 50% intelligible to strangers per Harrison's Principles of Internal Medicine. By 36 months, children produce three-word sentences and are approximately 75% intelligible per the Cleveland Clinic.\n\nDEVELOPMENTAL SURVEILLANCE:\nMotor milestones provide additional context: social smile at 2 months, rolling at 4 to 6 months, sitting unsupported at 6 months, crawling at 9 months, pulling to stand at 9 to 12 months, and independent walking at 12 to 15 months per the Mayo Clinic. Gross motor, fine motor, language, and social-emotional domains should be assessed at every well-child visit per the AAP. The key principle is that while individual variation exists, failure to reach specific milestones within defined windows warrants formal developmental evaluation rather than reassurance to \"wait and see\" per UpToDate.\n\nRED FLAGS:\nAbsolute red flags warranting immediate referral include no babbling by 12 months, no single words by 16 months, no two-word spontaneous (not echolalic) phrases by 24 months, and any regression or loss of previously acquired language or social skills at any age per the CDC and UpToDate. Hearing evaluation should be performed early in any child with speech delay, as hearing loss is a common and treatable cause per the Cleveland Clinic.\n\nKEY LEARNING POINTS:\nAt 18 months, the expected vocabulary is approximately 10 to 25 words, with the ability to follow simple commands and point to named objects. The milestone progression follows a predictable pattern: 1 to 3 words at 12 months, 10 to 25 words at 18 months, 50 or more words with two-word phrases at 24 months. Any loss of previously acquired skills at any age is an absolute red flag requiring immediate evaluation."
  },
  {
    "id": 535,
    "categoryId": 12,
    "question": "A 3-year-old presents with a fever of 103F for 4 days. The fever breaks, and suddenly a pink, macular rash appears on the trunk. Diagnosis?",
    "options": [
      "A) Measles",
      "B) Roseola (Exanthem Subitum)",
      "C) Scarlet Fever",
      "D) Varicella"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Roseola / Exanthem Subitum).\n\nPATHOPHYSIOLOGY:\nRoseola infantum (exanthem subitum, sixth disease) is caused by human herpesvirus 6 (HHV-6, primarily HHV-6B), which infects CD4+ T lymphocytes and monocytes during the primary viremic phase per Harrison's Principles of Internal Medicine. It is one of the most common viral exanthems of early childhood, typically affecting infants aged 6 months to 2 years, with nearly all children seropositive by age 3 per UpToDate. The virus is transmitted via salivary secretions from asymptomatic shedding by caregivers. After a 5 to 15-day incubation period, the child develops a high-grade fever (often 39.5 to 40.5 degrees Celsius) that persists for 3 to 5 days while the child appears surprisingly well (the characteristically \"well-appearing febrile child\") per the Cleveland Clinic.\n\nCLINICAL PRESENTATION:\nThe hallmark of roseola is the temporal pattern: high fever for 3 to 5 days, followed by abrupt defervescence, immediately followed by the appearance of a diffuse, blanching, pink macular or maculopapular rash that begins on the trunk and spreads centrifugally to the face and extremities per the Mayo Clinic. This \"fever then rash\" sequence is essentially pathognomonic and distinguishes roseola from other childhood exanthems. Measles, by contrast, shows rash appearing during ongoing fever with the rash starting on the face (behind the ears) and spreading caudally per UpToDate. Febrile seizures are the most significant complication, occurring in approximately 10 to 15% of primary HHV-6 infections during the febrile phase, and HHV-6 is the single most common viral trigger of febrile seizures in infancy per Harrison's Principles of Internal Medicine.\n\nMANAGEMENT:\nTreatment is entirely supportive per UpToDate: antipyretics (acetaminophen, ibuprofen for children over 6 months) for fever management and comfort, and adequate hydration. The rash itself is not pruritic, requires no treatment, and resolves spontaneously within 1 to 2 days. No antiviral therapy is indicated for primary HHV-6 infection in immunocompetent children per the Cleveland Clinic. The diagnosis is clinical, and laboratory testing is rarely needed.\n\nKEY LEARNING POINTS:\nRoseola is diagnosed by its pathognomonic sequence of high fever for 3 to 5 days in a well-appearing child, followed by abrupt defervescence and immediate appearance of a truncal macular rash. HHV-6 is the most common viral cause of febrile seizures in infancy. The rash begins on the trunk and spreads outward (opposite of measles, which starts on the face and spreads downward)."
  },
  {
    "id": 536,
    "categoryId": 17,
    "question": "Croup (Laryngotracheobronchitis) is caused by Parainfluenza virus. The classic X-ray finding is:",
    "options": [
      "A) Thumbprint Sign",
      "B) Steeple Sign",
      "C) Sail Sign",
      "D) Air Bronchograms"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Steeple Sign).\n\nDIAGNOSIS:\nCroup (laryngotracheobronchitis), a viral infection causing inflammation and edema of the subglottic airway, most commonly caused by parainfluenza virus.\n\nCLINICAL REASONING:\nCroup typically affects children 6 months to 3 years and presents with the classic triad of barking \"seal-like\" cough, inspiratory stridor, and hoarseness, often preceded by URI symptoms. Symptoms characteristically worsen at night.\n\nSEVERITY ASSESSMENT (Westley Croup Score):\n- Mild: Occasional barking cough, no stridor at rest, no retractions\n- Moderate: Frequent cough, stridor at rest, mild retractions\n- Severe: Frequent cough, prominent stridor, severe retractions, decreased air entry, altered mental status\n\nTREATMENT:\n1. CORTICOSTEROIDS (all patients with croup):\n   - Dexamethasone 0.6 mg/kg PO/IM (single dose) - drug of choice\n   - Reduces airway edema, decreases return visits and hospitalization\n   - Effective even for mild croup\n\n2. NEBULIZED EPINEPHRINE (moderate-severe):\n   - Racemic epinephrine 0.5 mL of 2.25% solution OR L-epinephrine 0.5 mL/kg (max 5 mL) of 1:1000\n   - Rapid onset (within minutes) but transient effect (2 hours)\n   - Observe for 2-4 hours after administration for rebound\n\n3. Supportive care: Humidified air, hydration, avoid agitation\n\nCLINICAL PEARL:\nThe \"steeple sign\" on AP neck X-ray (subglottic narrowing) is classic but imaging is usually unnecessary if the diagnosis is clear clinically. Do NOT examine the throat with a tongue depressor - if epiglottitis is suspected (toxic appearance, drooling, tripod positioning), manage differently."
  },
  {
    "id": 537,
    "categoryId": 12,
    "question": "Meckel's Diverticulum is the most common congenital GI anomaly. The 'Rule of 2s' includes all EXCEPT:",
    "options": [
      "A) 2% of the population",
      "B) 2 feet from the ileocecal valve",
      "C) 2 inches long",
      "D) 2 years of chemotherapy required"
    ],
    "correctAnswer": 3,
    "explanation": "CORRECT: D (2 years of chemotherapy required is not part of the Rule of 2s).\n\nPATHOPHYSIOLOGY:\nMeckel diverticulum is a true diverticulum (containing all three layers of the bowel wall: mucosa, submucosa, and muscularis) located on the antimesenteric border of the ileum, representing the vestigial remnant of the omphalomesenteric (vitelline) duct that normally obliterates by the seventh week of gestation per Harrison's Principles of Internal Medicine. It is the most common congenital anomaly of the gastrointestinal tract per UpToDate. The classic teaching mnemonic, the Rule of 2s, summarizes the key epidemiologic and anatomic features: occurs in approximately 2% of the population, is approximately 2 inches (5 cm) long, is located within 2 feet (60 cm) of the ileocecal valve, contains 2 types of ectopic tissue (gastric mucosa in approximately 50% and pancreatic tissue in approximately 5%), has a 2:1 male-to-female ratio for symptomatic presentation, and most commonly presents before age 2 years per the Cleveland Clinic.\n\nCLINICAL PRESENTATION:\nThe majority of Meckel diverticula are asymptomatic and discovered incidentally per the Mayo Clinic. When symptomatic, the most common presentation in children under 2 years is painless rectal bleeding (bright red or maroon, often described as \"brick-colored\") caused by acid secretion from ectopic gastric mucosa within the diverticulum that ulcerates the adjacent normal ileal mucosa per UpToDate. In older children and adults, complications include intestinal obstruction (from volvulus, intussusception with the diverticulum as a lead point, or internal hernia), diverticulitis (mimicking appendicitis but with left lower quadrant or periumbilical pain), and rarely perforation per Harrison's Principles of Internal Medicine.\n\nDIAGNOSIS AND TREATMENT:\nA Meckel scan (technetium-99m pertechnetate scintigraphy) is the diagnostic study of choice in children, with sensitivity of approximately 85 to 90%, because the radiotracer is taken up by ectopic gastric mucosa within the diverticulum per UpToDate. Pretreatment with a histamine H2-receptor antagonist (ranitidine or famotidine) enhances sensitivity by inhibiting secretion of the radiotracer by the gastric mucosa, allowing it to accumulate and improve visualization per the Cleveland Clinic. Treatment of a symptomatic Meckel diverticulum is surgical excision (diverticulectomy or segmental ileal resection) per the Mayo Clinic.\n\nKEY LEARNING POINTS:\nThe Rule of 2s for Meckel diverticulum includes 2% prevalence, 2 feet from the ileocecal valve, 2 inches long, 2 types of ectopic tissue (gastric and pancreatic), 2:1 male-to-female ratio, and presentation before age 2. The most common pediatric presentation is painless rectal bleeding from ectopic gastric mucosa ulcerating adjacent ileum. The Meckel scan (technetium-99m pertechnetate) detects ectopic gastric tissue with approximately 85 to 90% sensitivity."
  },
  {
    "id": 538,
    "categoryId": 7,
    "question": "Legg-Calve-Perthes Disease is avascular necrosis of the femoral head. It typically affects:",
    "options": [
      "A) Obese adolescents (12-15 yrs)",
      "B) Boys age 4-8 with a painless limp",
      "C) Newborn females (breech)",
      "D) Athletes with knee pain"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Boys age 4 to 8 with a painless limp).\n\nPATHOPHYSIOLOGY:\nLegg-CalvÃ©-Perthes disease (LCPD) is idiopathic avascular necrosis (osteonecrosis) of the femoral head in children, resulting from disruption of the blood supply to the capital femoral epiphysis. The femoral head in children aged 4 to 8 is particularly vulnerable because its blood supply is tenuous during this developmental window: the ligamentum teres artery provides the majority of blood flow to the femoral epiphysis in early childhood, and the lateral epiphyseal vessels (from the medial femoral circumflex artery) do not fully mature until later childhood. The exact etiology of the vascular interruption remains unknown, though proposed mechanisms include thrombophilia (protein C and S deficiency, Factor V Leiden), repetitive microtrauma, venous congestion, and vascular anomalies. Once blood flow is interrupted, the femoral head undergoes a predictable sequence of pathologic changes described by the WaldenstrÃ¶m classification: the initial/necrosis stage (6 to 12 months) with cessation of growth and subchondral fracture, the fragmentation stage (6 to 18 months) with resorption of necrotic bone and new bone formation, the re-ossification stage (6 to 24 months) with progressive healing and new bone deposition, and the remodeling stage (years) in which the femoral head achieves its final shape. The disease affects boys 4 to 5 times more frequently than girls, with peak incidence between ages 4 and 8. Bilateral involvement occurs in 10 to 15% of cases but is usually asynchronous. Risk factors include male sex, Caucasian ethnicity, low socioeconomic status, low birth weight, short stature, delayed skeletal age, and second-hand smoke exposure.\n\nCLINICAL PRESENTATION:\nThe classic presentation is an insidious onset painless limp in a child aged 4 to 8, or a limp with mild, intermittent hip or groin pain that is activity-related and improves with rest. A critical clinical pearl is that children with hip pathology frequently present with knee pain or medial thigh pain as the predominant complaint because the obturator nerve provides sensory innervation to both the hip joint capsule and the medial knee, producing referred pain. Therefore, any child presenting with a limp and knee pain must have the ipsilateral hip examined and imaged. Physical examination reveals restricted hip range of motion, particularly internal rotation and abduction, which are the earliest and most sensitive findings. The Trendelenburg sign may be positive. An antalgic gait with shortened stance phase on the affected side is common. Initial imaging with anteroposterior and frog-leg lateral hip radiographs may demonstrate the WaldenstrÃ¶m classification stage: early findings include widening of the medial joint space, a smaller and denser femoral epiphysis (due to cessation of growth and relative sclerosis), and the crescent sign (a subchondral fracture line visible as a radiolucent crescent beneath the articular surface). In early disease when radiographs may be normal, MRI is the most sensitive modality for detecting avascular changes and is recommended when LCPD is clinically suspected but radiographically occult. The Catterall and Herring lateral pillar classifications grade severity based on the degree of femoral head involvement and guide prognosis and treatment decisions.\n\nTREATMENT:\nThe primary goal of treatment is containment of the femoral head within the acetabulum to maintain its spherical shape during the revascularization and remodeling phases, using the acetabulum as a biological mold. Age at onset is the strongest prognostic factor: children younger than 6 at disease onset have an excellent prognosis regardless of treatment because they have more time for remodeling before skeletal maturity. For younger children with mild to moderate involvement, conservative management with activity restriction (avoidance of impact activities), anti-inflammatory medications, physical therapy to maintain range of motion (particularly abduction and internal rotation), and serial radiographic monitoring is standard. Abduction bracing (Petrie casts, Atlanta brace) may be used to keep the femoral head contained within the acetabulum. For children older than 8 or those with severe femoral head involvement (Herring lateral pillar C), surgical containment via femoral varus osteotomy or Salter innominate osteotomy produces better long-term outcomes than conservative management according to the multicenter Herring Prognostic Study. Long-term complications include femoral head deformity (coxa plana), leg length discrepancy, and premature osteoarthritis of the hip in adulthood.\n\nKEY LEARNING POINTS:\nLegg-CalvÃ©-Perthes disease is idiopathic avascular necrosis of the femoral head predominantly affecting boys aged 4 to 8, presenting with a painless limp and restricted hip internal rotation and abduction. Children with a limp and knee pain must have the hip examined, as hip pathology commonly presents with referred knee pain via the obturator nerve. Age at onset is the strongest prognostic factor, with children younger than 6 having an excellent prognosis, and treatment focuses on femoral head containment within the acetabulum during the revascularization process."
  },
  {
    "id": 539,
    "categoryId": 6,
    "question": "Simple Febrile Seizures are common (6 months - 5 years). Which feature would classify a seizure as COMPLEX (requiring more workup)?",
    "options": [
      "A) Duration < 15 minutes",
      "B) Generalized tonic-clonic movement",
      "C) Focal features (one arm shaking) or Recurrence within 24 hours",
      "D) Post-ictal drowsiness"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Focal features or Recurrence within 24 hours).\n\nFEBRILE SEIZURE CLASSIFICATION:\nFebrile seizures occur in children aged 6 months to 5 years in association with fever (38Â°C/100.4Â°F or higher) without evidence of intracranial infection or other defined cause. The critical distinction between simple and complex febrile seizures determines the extent of workup required. A complex febrile seizure is defined by the presence of any of the following features: focal onset (one limb or one side of the body), duration exceeding 15 minutes, or recurrence within the same 24-hour febrile illness.\n\nPATHOPHYSIOLOGY:\nThe developing brain has a lower seizure threshold due to immature inhibitory (GABAergic) circuits and relatively enhanced excitatory (glutamatergic) neurotransmission. Fever further lowers this threshold through mechanisms that include increased neuronal metabolic rate, interleukin-1 beta-mediated effects on hippocampal neurons, and temperature-dependent ion channel modulation. The immature thermoregulatory system of young children produces rapid temperature changes that are particularly provocative. The rate of temperature rise may be more important than the absolute temperature in triggering seizures.\n\nCLINICAL EVALUATION:\nSimple febrile seizures are benign and do not require EEG, neuroimaging, or routine laboratory testing beyond identifying the fever source. The focus should be on diagnosing the underlying febrile illness (viral infections are the most common trigger). Lumbar puncture should be considered in infants younger than 12 months (particularly those not fully immunized for Haemophilus influenzae type B or Streptococcus pneumoniae), children with meningeal signs, or those pretreated with antibiotics that may mask meningitis. Complex febrile seizures warrant more thorough evaluation including consideration of EEG and MRI.\n\nMANAGEMENT AND PROGNOSIS:\nMost febrile seizures stop spontaneously within 2 to 3 minutes. Prolonged seizures (greater than 5 minutes) are treated with benzodiazepines. Antipyretics provide comfort but do not prevent febrile seizure recurrence. Approximately 30% of children will have a recurrence with subsequent febrile illnesses; risk factors include age younger than 18 months, lower fever at seizure onset, shorter duration of fever before seizure, and family history. Daily prophylactic anticonvulsant therapy is not recommended due to the benign nature of febrile seizures and medication side effects. Simple febrile seizures do not increase the risk of epilepsy, developmental delay, or cognitive impairment.\n\nKEY LEARNING POINTS:\nComplex febrile seizures are defined by focal features, duration exceeding 15 minutes, or recurrence within 24 hours, distinguishing them from benign simple febrile seizures. Simple febrile seizures do not require EEG, imaging, or anticonvulsant prophylaxis. Approximately 30% of children will have recurrent febrile seizures, but the condition does not increase epilepsy risk."
  },
  {
    "id": 540,
    "categoryId": 12,
    "question": "Cephalohematoma differs from Caput Succedaneum because Cephalohematoma:",
    "options": [
      "A) Crosses suture lines",
      "B) Does NOT cross suture lines",
      "C) Is present immediately at birth",
      "D) Is edema of the scalp"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Does NOT cross suture lines).\n\nPATHOPHYSIOLOGY:\nCaput succedaneum and cephalohematoma are the two most common birth-related scalp injuries, and their critical distinction lies in the anatomic plane of fluid accumulation relative to the periosteum per UpToDate. Caput succedaneum is a collection of serosanguinous edema fluid in the subcutaneous tissue superficial to the periosteum and the skull. Because the subcutaneous tissue is continuous across the entire scalp with no barriers at suture lines, caput succedaneum freely crosses suture lines and may even extend across the midline per Harrison's Principles of Internal Medicine. It is present at birth, results from the pressure of the dilating cervix on the presenting part during prolonged labor (particularly common with vacuum-assisted delivery), and resolves spontaneously within days per the Cleveland Clinic.\n\nCephalohematoma, in contrast, is a subperiosteal hemorrhage (blood collection between the periosteum and the outer table of the skull) per UpToDate. The periosteum is tightly adherent to the skull at the cranial suture lines, creating natural barriers that confine the hematoma to the surface of a single cranial bone. This periosteal confinement is what prevents a cephalohematoma from crossing suture lines, producing the characteristic well-demarcated, non-fluctuant swelling limited to one bone (most commonly the parietal bone) per the Mayo Clinic. Cephalohematomas are not present at birth but develop over the first hours to days as slow subperiosteal bleeding accumulates. They resolve over weeks to months as the blood is gradually resorbed, and the breakdown of the trapped hemoglobin can cause or exacerbate neonatal hyperbilirubinemia (jaundice) per Harrison's Principles of Internal Medicine.\n\nCOMPLICATIONS:\nCephalohematomas occasionally calcify if they are large or persist for more than several weeks, producing a palpable bony ridge that typically remodels over months per UpToDate. Rarely, underlying linear skull fractures are associated (approximately 5 to 18% of cephalohematomas), and imaging should be considered for large or bilateral cephalohematomas per the Cleveland Clinic. A subgaleal hemorrhage (bleeding in the potential space between the periosteum and the galeal aponeurosis) is a much more dangerous entity that crosses suture lines and can accumulate a life-threatening volume of blood; it is a neonatal emergency requiring urgent volume resuscitation per Harrison's Principles of Internal Medicine.\n\nKEY LEARNING POINTS:\nCephalohematoma is subperiosteal and does NOT cross suture lines because periosteum adheres tightly at sutures, while caput succedaneum is subcutaneous and freely crosses suture lines. Caput is present at birth and resolves in days; cephalohematoma develops over hours and resolves over weeks to months, potentially causing jaundice from hemoglobin breakdown. Subgaleal hemorrhage crosses suture lines and is a life-threatening neonatal emergency distinct from both."
  },
  {
    "id": 541,
    "categoryId": 1,
    "question": "Which congenital heart defect causes a fixed split S2?",
    "options": [
      "A) VSD",
      "B) Atrial Septal Defect (ASD)",
      "C) Tetralogy of Fallot",
      "D) PDA"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Atrial Septal Defect).\n\nPATHOPHYSIOLOGY:\nAn atrial septal defect (ASD) causes a fixed split S2 because the persistent left-to-right shunt at the atrial level continuously increases right ventricular volume, producing equal and constant right ventricular filling regardless of the respiratory cycle per Harrison's Principles of Internal Medicine. Normally, the second heart sound (S2) is composed of aortic valve closure (A2) followed by pulmonic valve closure (P2). During inspiration, increased venous return to the right heart prolongs right ventricular ejection and delays P2, causing physiologic splitting that widens during inspiration and narrows during expiration. In ASD, the interatrial communication equalizes the filling of both atria throughout the respiratory cycle: during inspiration, when increased venous return would normally preferentially fill the right heart, the ASD allows redistribution so that both ventricles are affected equally, and during expiration, the shunt maintains continued excess right ventricular filling per UpToDate.\n\nTYPES OF ASD:\nThe most common type is the ostium secundum ASD (approximately 70% of cases), located in the central portion of the atrial septum at the fossa ovalis per the Cleveland Clinic. Ostium primum ASD (approximately 20%) is located in the lower septum and is associated with endocardial cushion defects and mitral valve cleft, commonly seen in Down syndrome per Harrison's Principles of Internal Medicine. Sinus venosus ASD (approximately 10%) is located near the junction of the superior vena cava and right atrium and is frequently associated with anomalous pulmonary venous return per the Mayo Clinic.\n\nCLINICAL FEATURES:\nASDs are often asymptomatic in childhood and may not be detected until adulthood per UpToDate. Physical examination reveals the fixed split S2, a systolic flow murmur at the left upper sternal border (from increased flow across the pulmonic valve, not across the ASD itself), and a mid-diastolic rumble at the left lower sternal border (from increased flow across the tricuspid valve) per Harrison's Principles of Internal Medicine. Long-standing unrepaired ASDs can lead to right heart volume overload, pulmonary hypertension, atrial arrhythmias (particularly atrial fibrillation/flutter), and eventually Eisenmenger syndrome (reversal of shunt direction from right-to-left when pulmonary vascular resistance exceeds systemic) per the Cleveland Clinic.\n\nKEY LEARNING POINTS:\nASD produces a fixed split S2 because the interatrial communication equalizes ventricular filling regardless of respiration, maintaining constant delay in pulmonic valve closure. The systolic murmur is from increased pulmonic flow, not from flow across the defect itself. Long-standing ASD can cause pulmonary hypertension, atrial arrhythmias, and Eisenmenger syndrome."
  },
  {
    "id": 542,
    "categoryId": 12,
    "question": "Cryptorchidism (Undescended Testicle) increases the risk of:",
    "options": [
      "A) Renal failure",
      "B) Testicular Cancer and Infertility",
      "C) UTI",
      "D) Prostate cancer"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Testicular Cancer and Infertility).\n\nPATHOPHYSIOLOGY:\nCryptorchidism (undescended testis) is the most common congenital anomaly of the male genitourinary tract, affecting approximately 3 to 4% of full-term male newborns and up to 30% of preterm males per Harrison's Principles of Internal Medicine. Normal testicular descent occurs in two phases: the transabdominal phase (guided by Mullerian inhibiting substance/anti-Mullerian hormone, occurring between weeks 8 and 15 of gestation) and the inguinoscrotal phase (guided by androgens and the genitofemoral nerve/CGRP, occurring between weeks 25 and 35) per UpToDate. Failure of descent leaves the testis in the abdomen, inguinal canal, or prescrotal position, where the elevated temperature (1 to 2 degrees Celsius above scrotal temperature) impairs spermatogenesis and disrupts normal germ cell maturation, increasing both infertility risk and malignant transformation risk per the Cleveland Clinic.\n\nCANCER RISK:\nUndescended testes carry a 4 to 8-fold increased risk of testicular cancer (primarily seminoma) compared to normally descended testes per UpToDate. The risk is highest for intra-abdominal testes and correlates with the duration of maldescent. Notably, the increased cancer risk applies to both the undescended testis and the contralateral normally descended testis, suggesting an underlying developmental field defect (testicular dysgenesis) rather than a purely positional effect per Harrison's Principles of Internal Medicine. Orchiopexy (surgical fixation into the scrotum) does not eliminate the cancer risk but facilitates testicular self-examination and clinical palpation for early detection per the Mayo Clinic.\n\nFERTILITY:\nThe elevated intra-abdominal or inguinal temperature causes progressive germ cell depletion beginning as early as 6 months of age per UpToDate. Bilateral cryptorchidism results in infertility in the majority of untreated cases, and even unilateral cryptorchidism is associated with reduced sperm counts and decreased fertility. Early orchiopexy (performed by 6 to 12 months of age per the AUA, or by 12 to 18 months per the AAP) optimizes fertility potential by restoring the testis to the cooler scrotal environment before irreversible germ cell loss occurs per the Cleveland Clinic.\n\nMANAGEMENT:\nSpontaneous descent occurs in approximately 70% of full-term cryptorchid infants by 6 months of age (adjusted for gestational age) per UpToDate. If the testis remains undescended at 6 months, orchiopexy is recommended by 12 to 18 months. Impalpable testes require diagnostic laparoscopy to locate and either mobilize (for orchiopexy) or remove (if atrophic or intra-abdominal in an older patient) per the Mayo Clinic.\n\nKEY LEARNING POINTS:\nCryptorchidism increases testicular cancer risk 4 to 8-fold and causes infertility by impairing spermatogenesis through elevated temperature. Orchiopexy by 12 to 18 months optimizes fertility but does not eliminate cancer risk. The cancer risk affects both the undescended and the contralateral normally descended testis, suggesting an underlying developmental abnormality."
  },
  {
    "id": 543,
    "categoryId": 12,
    "question": "Fifth Disease (Erythema Infectiosum) presents with 'Slapped Cheeks'. The causative agent is:",
    "options": [
      "A) Coxsackie Virus",
      "B) Parvovirus B19",
      "C) Strep Pyogenes",
      "D) HHV-6"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Parvovirus B19).\n\nPATHOPHYSIOLOGY:\nParvovirus B19 is a small, non-enveloped single-stranded DNA virus with exclusive tropism for erythroid progenitor cells, which it enters via the P antigen (globoside) receptor on the cell surface per Harrison's Principles of Internal Medicine. Once inside the erythroid precursor, the virus hijacks the cell's replication machinery, producing massive viral replication that lyses the cell. In immunocompetent children, this transient erythroid aplasia is clinically insignificant because normal red cell lifespan (120 days) provides a buffer. However, in patients with chronic hemolytic anemias (sickle cell disease, hereditary spherocytosis, thalassemia), where red cell survival is already shortened and the marrow must produce red cells at a markedly accelerated rate, even a brief cessation of erythropoiesis causes a precipitous drop in hemoglobin, known as transient aplastic crisis per UpToDate and the Cleveland Clinic.\n\nCLINICAL PRESENTATION:\nIn otherwise healthy children, parvovirus B19 causes erythema infectiosum (fifth disease), which presents with a low-grade fever and mild upper respiratory prodrome followed by the characteristic \"slapped cheek\" appearance (bilateral, confluent erythema of both cheeks with circumoral pallor) per the Mayo Clinic. One to four days after the facial erythema, a lacy, reticular (net-like) rash appears on the trunk and proximal extremities that may wax and wane with temperature changes, sunlight exposure, and bathing for several weeks per UpToDate. By the time the rash appears, the patient is no longer viremic and is no longer contagious. Adults, particularly women, may develop symmetric polyarthropathy affecting the small joints of the hands, wrists, and knees per Harrison's Principles of Internal Medicine.\n\nSPECIAL POPULATIONS:\nIn pregnancy, maternal parvovirus B19 infection can cause fetal anemia, hydrops fetalis (from high-output cardiac failure due to severe fetal anemia), and fetal death, particularly when infection occurs during the second trimester per the CDC. Pregnant women exposed to parvovirus should have serologic testing (IgM and IgG) and, if acutely infected, serial fetal ultrasound monitoring for hydrops per UpToDate. In immunocompromised patients (HIV, transplant recipients), chronic parvovirus infection causes persistent pure red cell aplasia requiring IVIG therapy per Harrison's Principles of Internal Medicine.\n\nKEY LEARNING POINTS:\nParvovirus B19 infects erythroid precursors via the P antigen receptor, causing fifth disease (slapped cheeks followed by lacy reticular rash) in healthy children and transient aplastic crisis in patients with chronic hemolytic anemias (sickle cell disease). Maternal infection during pregnancy can cause hydrops fetalis from severe fetal anemia. Patients are contagious during the prodromal viremic phase but not after the rash appears."
  },
  {
    "id": 544,
    "categoryId": 12,
    "question": "Hirschsprung Disease presents as failure to pass meconium in 48 hours. The pathophysiology is:",
    "options": [
      "A) Thickened pyloric sphincter",
      "B) Absence of ganglion cells (Auerbach/Meissner plexus) in the distal colon",
      "C) Pancreatic insufficiency",
      "D) Twisted bowel"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Absence of ganglion cells in the distal colon).\n\nPATHOPHYSIOLOGY:\nHirschsprung disease results from failure of neural crest cell migration during embryonic development, leading to an absence of ganglion cells (aganglionosis) in the myenteric (Auerbach) and submucosal (Meissner) plexuses of the distal bowel per Harrison's Principles of Internal Medicine. Neural crest cells normally migrate craniocaudally through the developing gut between weeks 5 and 12 of gestation, and arrest of this migration at any point leaves the distal bowel aganglionic. The aganglionic segment cannot undergo the coordinated relaxation necessary for peristalsis, remaining in a state of tonic contraction that creates a functional obstruction per UpToDate. The rectosigmoid region is affected in approximately 80% of cases (short-segment disease), while the entire colon or even the small bowel can be involved in rare cases (long-segment and total colonic aganglionosis) per the Cleveland Clinic.\n\nCLINICAL PRESENTATION:\nThe hallmark presenting feature is failure to pass meconium within the first 48 hours of life, which occurs in approximately 90% of neonates with Hirschsprung disease (compared to 99% of normal neonates who pass meconium within 48 hours) per UpToDate. Other neonatal presentations include abdominal distension, bilious vomiting, and feeding intolerance. A critically important distinction is that the dilated, distended bowel visible on imaging is the normal, ganglionated proximal colon that has expanded upstream of the obstruction, while the aganglionic distal segment appears narrow or normal-caliber per the Mayo Clinic. Enterocolitis (Hirschsprung-associated enterocolitis) is the most life-threatening complication, presenting with explosive diarrhea, fever, abdominal distension, and sepsis, and it can occur before or after surgical correction per Harrison's Principles of Internal Medicine.\n\nDIAGNOSIS AND TREATMENT:\nRectal suction biopsy is the gold standard for diagnosis, demonstrating absence of ganglion cells and hypertrophied nerve trunks in the submucosa per UpToDate. Contrast enema may show a transition zone between the narrow aganglionic distal segment and the dilated normal proximal bowel, but biopsy is required for definitive diagnosis per the Cleveland Clinic. Definitive treatment is surgical pull-through procedure (Soave, Duhamel, or Swenson), in which the aganglionic segment is resected and ganglionated bowel is anastomosed to the anus per the Mayo Clinic.\n\nKEY LEARNING POINTS:\nHirschsprung disease results from arrested neural crest cell migration causing aganglionosis of the distal bowel, which remains tonically contracted and functionally obstructed. Failure to pass meconium within 48 hours is the hallmark presentation. The dilated bowel on imaging is the normal proximal colon, not the diseased segment. Rectal suction biopsy confirming absent ganglion cells is the diagnostic gold standard."
  },
  {
    "id": 545,
    "categoryId": 17,
    "question": "Acute Otitis Media (AOM) is diagnosed by:",
    "options": [
      "A) Red TM alone",
      "B) Bulging TM + Middle Ear Effusion + Inflammation",
      "C) Ear pain",
      "D) Fever"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Bulging TM + Effusion + Signs of Acute Inflammation).\n\nPATHOPHYSIOLOGY:\nAcute otitis media (AOM) results from bacterial infection of the middle ear space, most commonly by Streptococcus pneumoniae, non-typeable Haemophilus influenzae, and Moraxella catarrhalis. Viral upper respiratory infections cause mucosal edema and Eustachian tube dysfunction, leading to negative middle ear pressure, effusion, and subsequent bacterial superinfection.\n\nDIAGNOSTIC CRITERIA (AAP 2013):\nAOM is diagnosed by the presence of:\n1. Moderate to severe bulging of the tympanic membrane (TM), OR\n2. Mild bulging of the TM with recent onset of ear pain (less than 48 hours) or intense TM erythema, OR\n3. New onset otorrhea not due to otitis externa\n- Pneumatic otoscopy demonstrating decreased TM mobility supports the diagnosis and is recommended by the AAP\n\nCRITICAL DISTINCTION:\n- A red TM alone does NOT diagnose AOM. Erythema can result from crying, fever, or manipulation during examination.\n- Middle ear effusion without signs of acute infection (no bulging, no erythema, no pain) is Otitis Media with Effusion (OME), which does NOT require antibiotic therapy. OME is managed with watchful waiting unless it persists beyond 3 months or causes hearing/speech concerns.\n\nTREATMENT:\n1. High-dose amoxicillin (80-90 mg/kg/day divided BID) is first-line\n2. Observation for 48-72 hours is appropriate for children over 2 years with mild, unilateral symptoms\n3. Pain management (ibuprofen, acetaminophen) is essential regardless of antibiotic decision\n4. Amoxicillin-clavulanate if treatment failure at 48-72 hours or recent amoxicillin use\n\nKEY LEARNING POINTS:\nA bulging TM is the most reliable individual finding for diagnosing AOM. An erythematous TM alone is insufficient for diagnosis. OME (effusion without acute infection) does not require antibiotics. Pneumatic otoscopy is the recommended examination technique.\n\nREFERENCES:\nAAP 2013 Clinical Practice Guideline for AOM; UpToDate; Harrison's Principles of Internal Medicine.\n---"
  },
  {
    "id": 546,
    "categoryId": 12,
    "question": "Constitutional Delay of Growth and Puberty ('Late Bloomer') is characterized by:",
    "options": [
      "A) Delayed Bone Age",
      "B) Advanced Bone Age",
      "C) High LH/FSH",
      "D) Short parents"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Delayed Bone Age).\n\nPATHOPHYSIOLOGY:\nConstitutional delay of growth and puberty is the most common cause of short stature and delayed puberty in adolescents and represents a normal variant of the tempo of growth and maturation rather than a pathologic condition per UpToDate. These children have a physiologically slower pace of skeletal maturation, meaning their bone age (assessed by radiograph of the left hand and wrist compared to standardized Greulich and Pyle or Tanner-Whitehouse atlases) is significantly delayed relative to their chronological age, typically by 2 to 4 years per Harrison's Principles of Internal Medicine. The delayed bone age indicates that the growth plates remain open longer, preserving growth potential and ultimately allowing these children to reach a normal adult height consistent with their genetic (midparental) target per the Cleveland Clinic.\n\nCLINICAL PRESENTATION:\nChildren with constitutional delay are consistently shorter than their peers throughout childhood and enter puberty 2 to 4 years later than average per the Mayo Clinic. Crucially, their growth velocity is normal for their bone age (not their chronological age), which distinguishes constitutional delay from growth hormone deficiency and other pathologic causes of short stature where growth velocity is truly impaired. A family history of \"late blooming\" in a parent (late menarche in the mother, continued growth into late teens in the father) is present in approximately 60 to 80% of cases per UpToDate.\n\nDIFFERENTIAL DIAGNOSIS:\nConstitutional delay is a diagnosis of exclusion per Harrison's Principles of Internal Medicine. Key conditions to differentiate include familial short stature (short parents, bone age equal to chronological age, normal puberty timing, short adult height matching genetic potential), growth hormone deficiency (declining growth velocity crossing percentile lines, proportionate short stature, delayed bone age, low IGF-1), hypothyroidism (growth failure, weight gain, fatigue, delayed bone age, elevated TSH), Turner syndrome (short stature in a female, delayed puberty, web neck, shield chest, confirmed by karyotype showing 45,X), and chronic systemic illness (inflammatory bowel disease, celiac disease, renal disease) per UpToDate and the Cleveland Clinic.\n\nMANAGEMENT:\nReassurance and watchful waiting are appropriate in most cases, as puberty will eventually begin spontaneously and the final adult height will be normal per the Mayo Clinic. In adolescents with significant psychosocial distress from delayed puberty, short-term low-dose sex steroid therapy (testosterone for boys, estrogen for girls) can be offered to initiate pubertal development without compromising final adult height per UpToDate.\n\nKEY LEARNING POINTS:\nConstitutional delay of growth and puberty is a normal variant characterized by delayed bone age (2 to 4 years behind chronological age), late puberty, and eventual attainment of normal adult height. Growth velocity is normal for bone age, distinguishing it from pathologic growth failure. Familial short stature differs in that bone age equals chronological age and adult height is short."
  },
  {
    "id": 547,
    "categoryId": 2,
    "question": "Bronchiolitis in infants (< 2 years) is most commonly caused by RSV. The mainstay of treatment is:",
    "options": [
      "A) Albuterol",
      "B) Oral Steroids",
      "C) Supportive Care (Hydration/Oxygen/Suction)",
      "D) Antibiotics"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Supportive Care - Hydration, Oxygen, and Nasal Suctioning).\n\nPATHOPHYSIOLOGY:\nBronchiolitis is an acute lower respiratory tract infection primarily affecting infants under 2 years, caused most commonly by respiratory syncytial virus (RSV, accounting for 50 to 80% of cases) per Harrison's Principles of Internal Medicine. The virus infects the bronchiolar epithelium, causing epithelial cell necrosis, peribronchiolar inflammation, edema of the submucosa and adventitia, and increased mucus production. The resulting combination of cellular debris, inflammatory exudate, and mucus obstructs the small airways of infants (whose bronchioles are already narrow, approximately 2 mm in diameter), producing air trapping, atelectasis, and ventilation-perfusion mismatch per UpToDate.\n\nCLINICAL REASONING:\nMultiple large randomized controlled trials and systematic reviews, synthesized in the AAP Clinical Practice Guideline (2014, reaffirmed), have consistently demonstrated that no pharmacologic intervention changes outcomes in bronchiolitis per the Mayo Clinic. Bronchodilators (albuterol, epinephrine) do not improve oxygenation, reduce hospitalization rates, or shorten illness duration because the obstruction is caused by inflammation and mucus plugging rather than bronchospasm. Corticosteroids (oral or inhaled) do not reduce severity or duration because the inflammatory process is primarily neutrophilic rather than eosinophilic. Hypertonic saline nebulization has shown marginal benefit in reducing hospitalization length in some studies but is not universally recommended. Antibiotics are not indicated unless a concurrent bacterial infection is documented per UpToDate and the Cleveland Clinic.\n\nMANAGEMENT:\nThe mainstay of treatment is supportive care per the AAP guidelines: nasal suctioning to clear secretions and improve feeding and nasal breathing, maintenance of adequate hydration (oral if tolerated, nasogastric or intravenous if the infant is unable to feed adequately due to respiratory distress), and supplemental oxygen to maintain saturation above 90% per the Mayo Clinic. High-flow nasal cannula (HFNC) may be beneficial in moderate to severe cases by providing continuous positive airway pressure and reducing work of breathing per UpToDate. Hospitalization is indicated for significant respiratory distress (retractions, nasal flaring, grunting), sustained hypoxia, inability to maintain adequate oral hydration, or apneic episodes, particularly in high-risk infants (premature, less than 12 weeks of age, congenital heart disease, chronic lung disease, immunodeficiency).\n\nPREVENTION:\nPalivizumab (a monoclonal antibody against the RSV F protein) is administered monthly during RSV season for prophylaxis in high-risk infants (prematurity less than 29 weeks, hemodynamically significant congenital heart disease, chronic lung disease of prematurity) per the AAP and CDC. Nirsevimab, a newer long-acting monoclonal antibody requiring only a single dose, was approved by the FDA and recommended by the CDC for all infants entering their first RSV season per UpToDate.\n\nKEY LEARNING POINTS:\nBronchiolitis management is entirely supportive (suctioning, hydration, oxygen), as bronchodilators, corticosteroids, and antibiotics have not been shown to improve outcomes per the AAP. The obstruction is from inflammation and mucus, not bronchospasm, which explains why albuterol is ineffective. Palivizumab and nirsevimab provide RSV prophylaxis for high-risk and all infants, respectively."
  },
  {
    "id": 548,
    "categoryId": 17,
    "question": "Leukocoria (White Pupillary Reflex) in a newborn photograph requires immediate referral to rule out:",
    "options": [
      "A) Glaucoma",
      "B) Retinoblastoma",
      "C) Conjunctivitis",
      "D) Color blindness"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Cancer - Retinoblastoma).\n\nPATHOPHYSIOLOGY:\nRetinoblastoma is the most common primary intraocular malignancy of childhood, arising from immature retinal cells (retinoblasts) due to biallelic inactivation of the RB1 tumor suppressor gene on chromosome 13q14. Heritable retinoblastoma (40% of cases) involves a germline RB1 mutation followed by a somatic second hit (Knudson two-hit hypothesis), typically presenting bilaterally and at younger ages (mean 12 months). Sporadic retinoblastoma (60%) involves two somatic mutations in a single retinal cell, presenting unilaterally and later (mean 24 months).\n\nCLINICAL PRESENTATION:\n- Leukocoria (white pupillary reflex): The most common presenting sign, caused by the white tumor mass behind the lens reflecting light instead of the normal red reflex\n- Strabismus (second most common sign): Tumor involvement of the macula causes visual loss and secondary misalignment\n- Less common: Red, painful eye (from secondary glaucoma or inflammation), proptosis (extraocular extension)\n\nDIAGNOSIS:\n- Red reflex testing at every well-child visit is the primary screening method (AAP Bright Futures)\n- Absent or white red reflex requires urgent ophthalmology referral within days\n- Retinal examination under anesthesia with indirect ophthalmoscopy is the gold standard\n- Orbital MRI (preferred over CT to avoid radiation in a child with possible germline RB1 mutation)\n- Biopsy is NOT performed (risk of extraocular tumor seeding)\n\nTREATMENT:\n- Small tumors: Focal therapies (laser photocoagulation, cryotherapy, thermotherapy)\n- Larger tumors: Intra-arterial or intravitreal chemotherapy, systemic chemoreduction\n- Advanced or refractory: Enucleation (eye removal)\n- Survival exceeds 95% in developed countries with early detection\n\nKEY LEARNING POINTS:\nLeukocoria (absent red reflex) in a child is retinoblastoma until proven otherwise and requires urgent ophthalmology referral. Red reflex testing should be performed at every well-child visit. Heritable retinoblastoma carries risk of bilateral disease and secondary malignancies (osteosarcoma). Survival exceeds 95% with early treatment.\n\nREFERENCES:\nAAP Bright Futures; AAO; UpToDate; Harrison's Principles of Internal Medicine.\n---"
  },
  {
    "id": 549,
    "categoryId": 12,
    "question": "Kawasaki Disease involves fever > 5 days and 'CRASH' symptoms. The 'H' stands for:",
    "options": [
      "A) Headache",
      "B) Hands and Feet (Swelling/Peeling)",
      "C) Heart murmur",
      "D) Hypertension"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Hands and Feet - Swelling and Peeling).\n\nDIAGNOSTIC CRITERIA:\nKawasaki disease is diagnosed clinically by the presence of fever for 5 or more days plus at least 4 of 5 principal features captured by the CRASH mnemonic per the American Heart Association guidelines and UpToDate: Conjunctivitis (bilateral, non-exudative, limbic-sparing), Rash (polymorphous, often with early perineal desquamation), Adenopathy (cervical, usually unilateral, at least 1.5 cm), Strawberry tongue and lip changes (red fissured lips, oropharyngeal erythema, strawberry tongue), and Hand and foot changes (acute phase: erythema and indurative edema of the palms and soles; subacute phase: periungual desquamation of the fingers and toes beginning 2 to 3 weeks after fever onset) per Harrison's Principles of Internal Medicine.\n\nPATHOPHYSIOLOGY:\nKawasaki disease is an acute self-limited vasculitis of unknown etiology predominantly affecting children under 5 years, with peak incidence between 6 months and 2 years per the Cleveland Clinic. It preferentially targets medium-sized muscular arteries, particularly the coronary arteries, where panarteritis (inflammation of all three vessel wall layers) weakens the vessel wall and can produce coronary artery aneurysms in 15 to 25% of untreated children. Kawasaki disease is the leading cause of acquired heart disease in children in developed countries per UpToDate. Incomplete Kawasaki disease (fever with fewer than 4 of 5 criteria) should be considered in any child with prolonged unexplained fever, especially infants under 6 months who have the highest risk of coronary complications and often present with atypical features per the Mayo Clinic.\n\nTREATMENT:\nHigh-dose IVIG (2 g/kg as a single infusion) administered within the first 10 days of illness, combined with high-dose aspirin (80 to 100 mg/kg/day in 4 divided doses), reduces the incidence of coronary artery aneurysms from approximately 25% to less than 5% per the AHA and Harrison's Principles of Internal Medicine. Aspirin is subsequently reduced to low-dose (3 to 5 mg/kg/day) once the patient has been afebrile for 48 to 72 hours and is continued for a minimum of 6 to 8 weeks or indefinitely if coronary abnormalities persist. Echocardiography is performed at diagnosis, at 2 weeks, and at 6 to 8 weeks, with long-term follow-up determined by the degree of coronary involvement per UpToDate. IVIG-refractory patients (persistent or recurrent fever 36 hours after initial IVIG) may require a second IVIG dose, high-dose corticosteroids, or infliximab per the Cleveland Clinic.\n\nKEY LEARNING POINTS:\nThe H in the CRASH mnemonic stands for Hands and feet changes (edema, erythema acutely; periungual desquamation in the subacute phase). Kawasaki disease is the leading cause of acquired heart disease in children in developed countries, with coronary aneurysms in 15 to 25% of untreated cases. IVIG within 10 days reduces aneurysm risk to less than 5%, and incomplete Kawasaki should always be considered in prolonged unexplained pediatric fever."
  },
  {
    "id": 550,
    "categoryId": 12,
    "question": "Physiologic Jaundice of the Newborn appears:",
    "options": [
      "A) In the first 24 hours",
      "B) After 24 hours, peaking at day 3-5",
      "C) At 2 weeks of age",
      "D) Only in formula fed babies"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (After 24 hours, peaking at day 3 to 5).\n\nPATHOPHYSIOLOGY:\nPhysiologic jaundice of the newborn results from the normal postnatal transition in bilirubin metabolism per Harrison's Principles of Internal Medicine. In utero, unconjugated bilirubin produced by the fetus crosses the placenta and is conjugated and excreted by the maternal liver. After birth, the neonate must independently process bilirubin, but several physiologic factors create a transient imbalance between bilirubin production and elimination: the newborn has a higher red blood cell mass with a shorter erythrocyte lifespan (approximately 90 days versus 120 days in adults), the immature hepatic UDP-glucuronosyltransferase (UGT1A1) enzyme has reduced conjugation capacity (reaching adult activity levels by approximately 14 weeks), and increased enterohepatic circulation of bilirubin occurs due to higher intestinal beta-glucuronidase activity and slower intestinal transit per UpToDate.\n\nCLINICAL REASONING:\nPhysiologic jaundice characteristically appears after 24 hours of life (typically on day 2 to 3), peaks between days 3 and 5 in term infants (or days 5 to 7 in preterm infants), and gradually resolves by 1 to 2 weeks per the Cleveland Clinic. The critical clinical distinction is that jaundice appearing within the first 24 hours of life is always pathologic and requires urgent evaluation per the AAP and the Mayo Clinic. The most common causes of pathologic early jaundice include hemolytic disease of the newborn (ABO incompatibility, Rh incompatibility), hereditary hemolytic anemias (G6PD deficiency, hereditary spherocytosis), and neonatal sepsis per Harrison's Principles of Internal Medicine. The direct Coombs test (direct antiglobulin test) is the key laboratory study for distinguishing immune-mediated hemolysis (positive Coombs) from non-immune causes (negative Coombs) per UpToDate.\n\nMANAGEMENT:\nBilirubin levels are monitored using the Bhutani nomogram (hour-specific total serum bilirubin plotted against the infant's age in hours) to identify neonates at risk for severe hyperbilirubinemia per the AAP guidelines. Phototherapy is the primary treatment, using blue-green spectrum light (wavelength 460 to 490 nm) to convert unconjugated bilirubin into water-soluble photoisomers that can be excreted without hepatic conjugation per UpToDate. Exchange transfusion is reserved for bilirubin levels approaching or exceeding the threshold for acute bilirubin encephalopathy (kernicterus), which causes permanent neurologic damage including sensorineural hearing loss, choreoathetoid cerebral palsy, and upgaze palsy per the Cleveland Clinic.\n\nKEY LEARNING POINTS:\nPhysiologic jaundice appears after 24 hours and peaks at days 3 to 5, while jaundice within the first 24 hours is always pathologic (hemolysis, sepsis, ABO/Rh incompatibility) and requires urgent evaluation. The Bhutani nomogram guides management decisions based on hour-specific bilirubin levels. Kernicterus from severe unconjugated hyperbilirubinemia causes permanent neurologic damage including sensorineural hearing loss and choreoathetoid cerebral palsy."
  },
  {
    "id": 551,
    "categoryId": 12,
    "question": "To prevent SIDS (Sudden Infant Death Syndrome), the AAP recommends:",
    "options": [
      "A) Side sleeping",
      "B) Back to Sleep (Supine), firm mattress, no blankets/toys",
      "C) Co-sleeping in parents' bed",
      "D) Prone sleeping"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Back to Sleep, firm mattress, no blankets or toys).\n\nEPIDEMIOLOGY:\nSudden infant death syndrome is the leading cause of death in infants between 1 month and 1 year of age in the United States, with peak incidence between 2 and 4 months per the CDC. The incidence of SIDS decreased by more than 50% following the 1994 Back to Sleep campaign (now called Safe to Sleep) that promoted supine sleeping, though rates have plateaued in recent years per the AAP. The pathophysiologic model of SIDS involves a vulnerable infant (brainstem abnormalities affecting cardiorespiratory control and arousal, potentially involving serotonergic neuron dysfunction) during a critical developmental period, exposed to an exogenous stressor (prone positioning, soft bedding, overheating, smoke exposure) per Harrison's Principles of Internal Medicine.\n\nAAP SAFE SLEEP RECOMMENDATIONS:\nThe AAP 2022 updated policy statement on safe sleep recommends supine (back) positioning for every sleep period until 1 year of age per the AAP and UpToDate. The infant should sleep on a firm, flat, non-inclined surface (such as a safety-approved crib mattress) with a tightly fitted sheet and nothing else in the sleep environment: no pillows, blankets, bumper pads, stuffed animals, wedges, or positioners per the CDC. Room-sharing (infant sleeping in the parents' room in their own sleep surface) is recommended for at least the first 6 months and ideally the first year, as it reduces SIDS risk by approximately 50% per the Mayo Clinic. However, bed-sharing (infant sleeping in the same bed as adults) is explicitly recommended against due to the risk of suffocation, entrapment, and overlay per the AAP.\n\nADDITIONAL PROTECTIVE FACTORS:\nBreastfeeding is associated with a reduced risk of SIDS (approximately 50% risk reduction with exclusive breastfeeding) per the Cleveland Clinic. Pacifier use at sleep onset has been associated with reduced SIDS risk, potentially by maintaining airway patency and promoting arousability per UpToDate. Avoidance of prenatal and postnatal tobacco smoke exposure is critical, as maternal smoking is one of the strongest modifiable risk factors for SIDS per the CDC. Immunizations are protective, not causative, and up-to-date vaccination is associated with a 50% reduction in SIDS risk per Harrison's Principles of Internal Medicine.\n\nKEY LEARNING POINTS:\nThe AAP recommends supine positioning on a firm, flat surface with no loose bedding, room-sharing without bed-sharing, and avoidance of smoke exposure as the foundation of SIDS prevention. The Back to Sleep campaign reduced SIDS mortality by more than 50%. Breastfeeding, pacifier use, and up-to-date immunizations are additional protective factors."
  },
  {
    "id": 552,
    "categoryId": 12,
    "question": "Bilious (Green) vomiting in a neonate is a surgical emergency because it suggests:",
    "options": [
      "A) Pyloric Stenosis",
      "B) Malrotation with Volvulus",
      "C) Milk allergy",
      "D) GERD"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Malrotation with Volvulus).\n\nPATHOPHYSIOLOGY:\nIntestinal malrotation is a congenital anomaly resulting from incomplete or abnormal rotation and fixation of the midgut during embryonic development per Harrison's Principles of Internal Medicine. Normally, the midgut herniates through the umbilicus at approximately 6 weeks of gestation, undergoes a 270-degree counterclockwise rotation around the axis of the superior mesenteric artery, and returns to the abdomen by week 10 with fixation of the cecum to the right lower quadrant and the duodenojejunal junction (ligament of Treitz) to the left upper quadrant per UpToDate. In malrotation, the mesenteric base is abnormally narrow, creating a short pedicle around which the entire midgut can twist (volvulus), occluding the superior mesenteric artery and vein and causing complete intestinal ischemia. The entire midgut (from the duodenum to the mid-transverse colon) can infarct within 6 hours of vascular occlusion per the Cleveland Clinic.\n\nCLINICAL REASONING:\nBilious (green) vomiting in a neonate is a surgical emergency until proven otherwise per the Mayo Clinic. Bile enters the duodenum at the ampulla of Vater (second portion of the duodenum), so bilious vomiting indicates obstruction distal to this point. In a neonate, malrotation with midgut volvulus is the most dangerous and time-critical diagnosis in this presentation per UpToDate. Approximately 75% of malrotation cases present within the first month of life, and 90% present within the first year. The infant may initially appear well between episodes but can deteriorate rapidly to hemodynamic instability, abdominal distension, bloody stools (indicating intestinal ischemia), and peritonitis as the volvulus progresses per Harrison's Principles of Internal Medicine.\n\nDIAGNOSIS AND TREATMENT:\nUpper gastrointestinal contrast study (UGI series) is the gold standard for diagnosing malrotation, demonstrating abnormal position of the duodenojejunal junction (ligament of Treitz) to the right of the midline or below the duodenal bulb rather than in its normal position at the left of the spine at the level of the pylorus per UpToDate. The classic radiographic finding in volvulus is a corkscrew or spiral appearance of the distal duodenum and jejunum per the Cleveland Clinic. When volvulus is suspected with clinical instability, surgical exploration should not be delayed for imaging. The Ladd procedure (detorsion of the volvulus, lysis of Ladd bands, widening of the mesenteric base, appendectomy, and placement of the small bowel on the right and colon on the left) is the definitive surgical treatment per the Mayo Clinic.\n\nKEY LEARNING POINTS:\nBilious (green) vomiting in a neonate is a surgical emergency because it suggests malrotation with midgut volvulus, which can cause complete midgut infarction within 6 hours. Bile enters at the ampulla of Vater, so green vomit indicates obstruction distal to the second duodenum. Upper GI series is diagnostic, and the Ladd procedure is definitive, but surgical exploration should not be delayed in an unstable infant."
  },
  {
    "id": 553,
    "categoryId": 12,
    "question": "Cow's milk should be avoided before age 1 year because it causes:",
    "options": [
      "A) Obesity",
      "B) Iron Deficiency Anemia (Microscopic GI bleeding)",
      "C) Calcium deficiency",
      "D) Diabetes"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Iron Deficiency Anemia from microscopic GI bleeding).\n\nPATHOPHYSIOLOGY:\nCow's milk contributes to iron deficiency in infants through three distinct mechanisms per UpToDate and Harrison's Principles of Internal Medicine. First, cow's milk has very low bioavailable iron content (approximately 0.5 mg/L with less than 10% absorption, compared to breast milk's approximately 0.3 mg/L with 50% absorption or iron-fortified formula's 12 mg/L). Second, the intact casein proteins in whole cow's milk cause microscopic intestinal hemorrhage in infants, resulting in occult gastrointestinal blood loss of approximately 1 to 2 mL per day (this protein-induced colitis resolves with gut maturation after 12 months of age) per the Cleveland Clinic. Third, cow's milk displaces iron-rich foods and formula from the infant's diet, reducing overall iron intake. The combination of low iron delivery, chronic blood loss, and dietary displacement makes whole cow's milk a significant cause of iron deficiency anemia in infancy per the Mayo Clinic.\n\nCLINICAL SIGNIFICANCE:\nIron deficiency in infancy is particularly concerning because of its neurodevelopmental consequences per the CDC. Iron is essential for myelination, neurotransmitter synthesis (dopamine, serotonin), and hippocampal development during the rapid brain growth occurring in the first 2 years of life per Harrison's Principles of Internal Medicine. Iron deficiency during this critical window has been associated with impaired cognitive development, behavioral problems, and decreased academic performance, with some studies suggesting that these effects may be only partially reversible even with subsequent iron repletion per UpToDate.\n\nAAP FEEDING RECOMMENDATIONS:\nThe AAP recommends exclusive breastfeeding (or iron-fortified formula) for the first 6 months, with introduction of iron-rich complementary foods (iron-fortified cereals, pureed meats) beginning at approximately 6 months per the AAP and the CDC. Whole cow's milk should not be introduced as the primary beverage until 12 months of age. After 12 months, whole milk consumption should be limited to 16 to 24 ounces per day to prevent displacement of iron-rich foods per the Cleveland Clinic. The AAP recommends universal screening for iron deficiency anemia at 12 months of age per UpToDate.\n\nKEY LEARNING POINTS:\nCow's milk before 12 months causes iron deficiency anemia through three mechanisms: low bioavailable iron, microscopic intestinal blood loss from casein-induced colitis, and displacement of iron-rich foods. Iron deficiency during infancy impairs myelination and neurotransmitter synthesis with potentially irreversible neurodevelopmental consequences. Whole cow's milk introduction should be delayed until 12 months and limited to 16 to 24 ounces daily."
  },
  {
    "id": 554,
    "categoryId": 12,
    "question": "A Still's Murmur (innocent) is characterized by:",
    "options": [
      "A) Diastolic rumbling",
      "B) Musical/Vibratory quality, systolic, LLSB, softer when standing",
      "C) Harsh, holosystolic, radiates to back",
      "D) Continuous machinery-like"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Musical or vibratory quality, systolic, left lower sternal border, softer when standing).\n\nPATHOPHYSIOLOGY:\nStill's murmur is the most common innocent (functional, benign) heart murmur of childhood, typically heard in children aged 2 to 7 years per UpToDate. It is produced by normal turbulent blood flow through the left ventricular outflow tract and across the aortic valve in the absence of any structural cardiac abnormality. The characteristic musical or vibratory quality (often described as sounding like a \"twanging string\" or \"humming\") distinguishes it from the harsher, blowing quality of pathologic murmurs per Harrison's Principles of Internal Medicine. The murmur is heard best at the left lower sternal border or between the left lower sternal border and the apex, is low-pitched (grade I to III out of VI), systolic (occurring during ventricular ejection), and has no associated thrill, radiation, or diastolic component per the Cleveland Clinic.\n\nCLINICAL REASONING:\nThe key diagnostic feature of innocent murmurs is their dynamic response to changes in preload per UpToDate. Still's murmur becomes softer or disappears with standing or Valsalva maneuver (both of which decrease venous return and preload to the heart, reducing flow across the outflow tract) and becomes louder with maneuvers that increase preload such as squatting, supine positioning, or during fever, exercise, and anemia per the Mayo Clinic. This dynamic behavior contrasts with pathologic murmurs: the murmur of hypertrophic obstructive cardiomyopathy (HOCM) paradoxically becomes louder with decreased preload (standing, Valsalva) because reduced ventricular volume worsens the dynamic outflow obstruction per Harrison's Principles of Internal Medicine. Other features suggesting a pathologic murmur include diastolic timing, grade IV or higher intensity, harsh or blowing quality, radiation to the back or axilla, associated clicks or gallops, abnormal pulses, cyanosis, and failure to thrive per UpToDate.\n\nOTHER INNOCENT MURMURS:\nThe venous hum is a continuous, low-pitched murmur heard in the supraclavicular area (usually right-sided) caused by turbulent flow in the jugular veins. It disappears with compression of the ipsilateral internal jugular vein or when the patient lies supine. The peripheral pulmonary stenosis murmur is commonly heard in newborns and results from the relative disparity between the main and branch pulmonary arteries, typically resolving by 6 months of age per the Cleveland Clinic.\n\nKEY LEARNING POINTS:\nStill's murmur is identified by its musical or vibratory quality, systolic timing, location at the left lower sternal border, and characteristic softening with standing (decreased preload). Innocent murmurs become softer with decreased preload, while HOCM becomes louder, which is a critical distinguishing feature. Any diastolic murmur, grade IV or higher intensity, or murmur with associated abnormal findings warrants echocardiographic evaluation."
  },
  {
    "id": 555,
    "categoryId": 12,
    "question": "Hand-Foot-Mouth Disease is caused by Coxsackievirus. Is it contagious?",
    "options": [
      "A) No",
      "B) Yes, highly contagious via stool and saliva",
      "C) Only via blood",
      "D) Only to adults"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Yes, highly contagious via stool and saliva).\n\nPATHOPHYSIOLOGY:\nHand, foot, and mouth disease is caused by enteroviruses, most commonly coxsackievirus A16 and enterovirus 71 (EV-A71), which belong to the Picornaviridae family per Harrison's Principles of Internal Medicine. EV-A71 is associated with more severe disease, including neurologic complications such as brainstem encephalitis, aseptic meningitis, and acute flaccid paralysis per UpToDate. The virus is transmitted through multiple routes: fecal-oral (the primary route, as enteroviruses replicate in the gastrointestinal tract), direct contact with vesicle fluid, and respiratory droplets per the CDC. Viral shedding in stool can persist for weeks after clinical recovery, maintaining contagion well beyond resolution of symptoms. The disease is most common in children under 5 years, with peak incidence in summer and early fall in temperate climates per the Cleveland Clinic.\n\nCLINICAL PRESENTATION:\nThe illness begins with a low-grade fever, malaise, and sore throat, followed within 1 to 2 days by the characteristic enanthem (painful oral ulcers on the buccal mucosa, tongue, and hard palate) and exanthem (vesicular lesions on an erythematous base on the palms, soles, and dorsal surfaces of the hands and feet, and sometimes the buttocks and perineum) per the Mayo Clinic and UpToDate. The oral ulcers are often the most distressing symptom, causing painful swallowing that can lead to dehydration in young children who refuse to drink. Onychomadesis (nail shedding) can occur 4 to 8 weeks after the illness and is self-limited per Harrison's Principles of Internal Medicine.\n\nMANAGEMENT:\nTreatment is entirely supportive per UpToDate: adequate hydration (cold fluids and soft foods are better tolerated), oral analgesics (acetaminophen, ibuprofen), and topical oral anesthetics (viscous lidocaine mixed with diphenhydramine and antacid, known as \"magic mouthwash\") for pain relief per the Cleveland Clinic. Dehydration from poor oral intake is the most common complication requiring medical attention. Children can generally return to daycare or school when afebrile and well enough to participate, though families should be counseled that fecal shedding continues and meticulous hand hygiene is essential for weeks after recovery per the CDC.\n\nKEY LEARNING POINTS:\nHand, foot, and mouth disease is highly contagious via fecal-oral, respiratory, and vesicle fluid contact, with fecal viral shedding persisting for weeks after clinical recovery. Coxsackievirus A16 is the most common cause, while enterovirus 71 carries risk of neurologic complications. Dehydration from painful oral ulcers limiting intake is the most common complication requiring medical attention."
  },
  {
    "id": 556,
    "categoryId": 12,
    "question": "Febrile UTI in a child < 2 years requires:",
    "options": [
      "A) Renal Ultrasound",
      "B) VCUG immediately",
      "C) CT Scan",
      "D) No imaging"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Renal Ultrasound).\n\nCLINICAL REASONING:\nA febrile urinary tract infection (temperature 38 degrees Celsius or greater) in a child under 2 years is presumed to represent pyelonephritis (upper tract infection) until proven otherwise per the AAP and UpToDate. Pyelonephritis in this age group carries a significant risk of renal scarring, which can lead to hypertension, proteinuria, and impaired renal function over time, particularly with recurrent infections or in the presence of underlying urinary tract abnormalities per Harrison's Principles of Internal Medicine. Identifying structural anomalies that predispose to recurrent infection is therefore essential for long-term renal preservation.\n\nIMAGING GUIDELINES:\nThe AAP Clinical Practice Guideline (revised 2011, reaffirmed) recommends renal and bladder ultrasound for all children aged 2 to 24 months after their first febrile UTI per the AAP and UpToDate. Ultrasound evaluates for hydronephrosis, renal size asymmetry, duplicated collecting systems, ureterocele, and other structural abnormalities. It is noninvasive, radiation-free, and readily available. Voiding cystourethrogram (VCUG) is not performed routinely after a first febrile UTI but is indicated if the ultrasound reveals hydronephrosis, scarring, or other concerning findings, if the child has recurrent febrile UTIs, or if there are atypical clinical features (poor response to appropriate antibiotics within 48 hours, unusual organism, sepsis) per the Cleveland Clinic and the Mayo Clinic.\n\nVESICOURETERAL REFLUX:\nVCUG detects vesicoureteral reflux (retrograde flow of urine from the bladder into the ureters and renal pelvis), which is present in approximately 25 to 40% of children with UTI per UpToDate. VUR is graded I through V based on severity of reflux and ureteral and pelvic dilation. Low-grade VUR (grades I to III) resolves spontaneously in the majority of cases, while high-grade VUR (grades IV to V) may require surgical intervention (ureteral reimplantation or endoscopic injection) per Harrison's Principles of Internal Medicine. The role of continuous antibiotic prophylaxis for VUR is evolving, with the RIVUR trial demonstrating modest reduction in UTI recurrence but no significant impact on renal scarring per UpToDate.\n\nTREATMENT OF ACUTE INFECTION:\nFebrile UTI requires prompt antibiotic therapy for 7 to 14 days per the AAP. Urine culture (obtained by catheterization or suprapubic aspiration in non-toilet-trained children, never by bag specimen for culture) guides therapy. E. coli accounts for 80 to 90% of pediatric UTIs per the Cleveland Clinic.\n\nKEY LEARNING POINTS:\nAll children aged 2 to 24 months require renal and bladder ultrasound after a first febrile UTI to evaluate for structural abnormalities predisposing to recurrent infection. VCUG is reserved for abnormal ultrasound, recurrent febrile UTI, or atypical features. VUR is found in 25 to 40% of children with UTI, and low grades typically resolve spontaneously."
  },
  {
    "id": 557,
    "categoryId": 12,
    "question": "Transient Synovitis (Toxic Synovitis) is the most common cause of hip pain in kids. It usually follows:",
    "options": [
      "A) Trauma",
      "B) A viral infection (URI)",
      "C) Bacterial sepsis",
      "D) Lyme disease"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (A viral infection / URI).\n\nPATHOPHYSIOLOGY:\nTransient (toxic) synovitis is a self-limited, noninfectious inflammatory process of the hip joint that is the most common cause of acute hip pain and limp in children aged 3 to 8 years per UpToDate. The etiology is not fully understood, but the strong temporal association with a preceding viral upper respiratory infection (typically occurring 1 to 2 weeks prior) suggests a post-infectious immune-mediated synovial inflammation per Harrison's Principles of Internal Medicine. The synovial inflammation produces a joint effusion that causes pain and limits hip range of motion, particularly internal rotation and abduction per the Cleveland Clinic.\n\nCLINICAL PRESENTATION:\nThe child presents with an acute onset limp or refusal to walk, hip pain (which may be referred to the groin, thigh, or knee), and mildly limited range of motion per the Mayo Clinic. Crucially, the child appears well, is afebrile or has only a low-grade temperature, and laboratory markers are normal or only mildly elevated (WBC normal, ESR typically less than 20 mm/hr, CRP typically less than 2 mg/dL) per UpToDate. The history of a recent viral illness is often elicited.\n\nCRITICAL DISTINCTION FROM SEPTIC ARTHRITIS:\nThe most important clinical task is distinguishing transient synovitis from septic arthritis, which is an orthopedic emergency requiring urgent joint aspiration and surgical drainage per Harrison's Principles of Internal Medicine. The Kocher criteria are a validated clinical prediction tool: fever greater than 38.5 degrees Celsius, inability to bear weight, ESR greater than 40 mm/hr, and WBC greater than 12,000 per the Cleveland Clinic. The predicted probability of septic arthritis is approximately 3% with zero predictors, 40% with two predictors, 93% with three predictors, and 99.6% with all four predictors per UpToDate. An ultrasound-guided hip aspiration should be performed when two or more Kocher criteria are present to obtain synovial fluid for cell count, Gram stain, and culture per the Mayo Clinic.\n\nMANAGEMENT:\nTransient synovitis is managed with rest, NSAIDs (ibuprofen), and observation per UpToDate. Symptoms typically resolve within 1 to 2 weeks. Children should be followed up to ensure resolution, as persistent symptoms beyond 2 weeks should prompt reconsideration of the diagnosis, including evaluation for Legg-Calve-Perthes disease (avascular necrosis of the femoral head) per Harrison's Principles of Internal Medicine.\n\nKEY LEARNING POINTS:\nTransient synovitis is the most common cause of pediatric hip pain, typically following a viral URI by 1 to 2 weeks, and presents as a well-appearing, afebrile child with a limp and normal inflammatory markers. The critical distinction from septic arthritis uses the Kocher criteria (fever, inability to bear weight, elevated ESR, elevated WBC), and two or more criteria warrant joint aspiration. Persistent symptoms beyond 2 weeks should prompt evaluation for Legg-Calve-Perthes disease."
  },
  {
    "id": 558,
    "categoryId": 12,
    "question": "Children with Sickle Cell Disease are placed on prophylactic Penicillin until age 5 to prevent:",
    "options": [
      "A) S. aureus osteomyelitis",
      "B) Pneumococcal Sepsis",
      "C) Syphilis",
      "D) Malaria"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Pneumococcal Sepsis).\n\nPATHOPHYSIOLOGY:\nThe spleen is the primary organ responsible for filtering encapsulated bacteria from the bloodstream through opsonin-dependent phagocytosis by splenic macrophages per Harrison's Principles of Internal Medicine. In sickle cell disease, repeated episodes of vaso-occlusion within the splenic microvasculature cause progressive infarction and fibrosis, resulting in functional autosplenectomy (loss of splenic filtering function despite physical presence of the organ) by early childhood, typically by age 5 years in patients with HbSS disease per UpToDate. Without a functional spleen, patients are profoundly susceptible to overwhelming post-splenectomy infection (OPSI) from encapsulated organisms that depend on opsonization and splenic clearance for host defense. Streptococcus pneumoniae is the most common and most lethal organism in this setting, followed by Haemophilus influenzae type b and Neisseria meningitidis per the CDC and the Cleveland Clinic.\n\nCLINICAL EVIDENCE:\nThe landmark PROPS trial (Prophylaxis with Oral Penicillin in Children with Sickle Cell Anemia) published in the New England Journal of Medicine demonstrated that daily oral penicillin V prophylaxis (125 mg twice daily for children under 3 years, 250 mg twice daily for children 3 to 5 years) reduced the incidence of pneumococcal bacteremia by 84% in children with sickle cell disease under 5 years of age per UpToDate and Harrison's Principles of Internal Medicine. This trial was so compelling that it was stopped early for ethical reasons, as withholding prophylaxis was no longer justifiable.\n\nCURRENT RECOMMENDATIONS:\nThe NHLBI and AAP recommend initiating penicillin V prophylaxis by 2 months of age and continuing at minimum until age 5 years per the CDC. Discontinuation after age 5 may be considered in children with HbSS who have not had a previous serious pneumococcal infection or surgical splenectomy. In addition to penicillin prophylaxis, comprehensive pneumococcal vaccination (both PCV15 or PCV20 conjugate vaccine series and PPSV23 polysaccharide vaccine starting at age 2) is essential per the CDC immunization schedule. Parents must be educated that any fever in a child with sickle cell disease is a medical emergency requiring immediate evaluation for sepsis per the Mayo Clinic.\n\nKEY LEARNING POINTS:\nChildren with sickle cell disease undergo functional autosplenectomy by early childhood, making them profoundly susceptible to overwhelming pneumococcal sepsis. Prophylactic penicillin V from age 2 months to at least 5 years reduces pneumococcal bacteremia by 84% per the PROPS trial. Any fever in a child with sickle cell disease is a medical emergency requiring immediate evaluation."
  },
  {
    "id": 559,
    "categoryId": 12,
    "question": "Lead poisoning in children primarily causes damage to the:",
    "options": [
      "A) Liver",
      "B) Developing Brain (Neurocognitive)",
      "C) Lungs",
      "D) Skin"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Developing Brain / Neurocognitive damage).\n\nPATHOPHYSIOLOGY:\nLead is a neurotoxin that has no known safe blood level in children per the CDC. It exerts its toxic effects through multiple mechanisms per Harrison's Principles of Internal Medicine: it substitutes for calcium in intracellular signaling pathways, disrupting synaptic transmission and long-term potentiation (critical for learning and memory); it inhibits N-methyl-D-aspartate (NMDA) glutamate receptors, impairing neurotransmitter release and neuronal migration; it disrupts the blood-brain barrier; and it causes oxidative stress through reactive oxygen species generation per UpToDate. Children are especially vulnerable because the developing brain undergoes rapid synaptogenesis, myelination, and dendritic arborization during the first years of life, and because children absorb a much higher fraction of ingested lead than adults (approximately 50% versus 10%) due to their immature gastrointestinal tract per the Cleveland Clinic.\n\nCLINICAL MANIFESTATIONS:\nLead poisoning is often asymptomatic at low to moderate blood levels (less than 45 micrograms/dL), making screening essential per the CDC. Neurocognitive effects include decreased IQ (an estimated 1 to 5 IQ point decrease for each 10 microgram/dL increase), learning disabilities, attention deficit and hyperactivity, behavioral problems, and poor academic performance per UpToDate and the Mayo Clinic. At higher levels, children may develop irritability, abdominal pain (lead colic), constipation, anorexia, and microcytic hypochromic anemia (lead inhibits delta-aminolevulinic acid dehydratase and ferrochelatase in the heme synthesis pathway, causing accumulation of protoporphyrin and ringed sideroblasts) per Harrison's Principles of Internal Medicine. Encephalopathy with seizures, cerebral edema, and coma occurs at very high levels (typically greater than 70 micrograms/dL) and can be fatal per the Cleveland Clinic.\n\nSCREENING AND MANAGEMENT:\nThe CDC reference value for elevated blood lead level in children is 3.5 micrograms/dL (updated from the previous 5 micrograms/dL) per the CDC. The primary intervention at any level is identification and elimination of the lead source, which most commonly involves lead-based paint in pre-1978 housing (paint chips, contaminated dust and soil) per UpToDate. Public health notification is required. Chelation therapy (succimer for oral chelation, calcium disodium EDTA with or without dimercaprol for parenteral chelation) is reserved for blood lead levels of 45 micrograms/dL or greater, or for symptomatic children per the Mayo Clinic.\n\nKEY LEARNING POINTS:\nLead primarily damages the developing brain by disrupting synaptogenesis, neurotransmitter systems, and myelination, with no known safe blood level per the CDC. Effects include decreased IQ, learning disabilities, and behavioral problems. The CDC reference value is 3.5 micrograms/dL, source elimination is the primary intervention, and chelation is reserved for levels of 45 or greater or symptomatic children."
  },
  {
    "id": 560,
    "categoryId": 4,
    "question": "The most common presentation of new-onset Type 1 Diabetes in children is:",
    "options": [
      "A) Incidental finding",
      "B) Polyuria, Polydipsia, Weight Loss",
      "C) Seizure",
      "D) Rash"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Polyuria, Polydipsia, and Weight Loss progressing to DKA).\n\nPATHOPHYSIOLOGY:\nType 1 diabetes mellitus (T1DM) results from autoimmune destruction of pancreatic beta cells, producing an absolute insulin deficiency that disrupts glucose homeostasis and shifts metabolism toward a catabolic state. The autoimmune process, mediated by autoreactive CD4+ and CD8+ T lymphocytes infiltrating the islets of Langerhans (insulitis), typically begins months to years before clinical presentation, progressing through the ADA staging system (Stage 1: two or more autoantibodies with normoglycemia; Stage 2: autoantibodies with dysglycemia; Stage 3: clinical diabetes with symptomatic hyperglycemia). By the time symptoms appear at Stage 3, approximately 80 to 90% of beta-cell mass has been destroyed. The classic presentation triad directly reflects the metabolic consequences of insulin deficiency. Without insulin to facilitate GLUT4-mediated glucose uptake into muscle and adipose tissue, blood glucose rises above the renal threshold for glucose reabsorption (approximately 180 mg/dL), and glucose spills into the urine (glycosuria). Urinary glucose acts as an osmotic solute, obligating water excretion and producing osmotic diuresis (polyuria), which triggers compensatory thirst (polydipsia). Simultaneously, the absence of insulin's anabolic effects shifts metabolism to a catabolic state: adipose tissue undergoes unregulated lipolysis (releasing free fatty acids), skeletal muscle undergoes proteolysis (releasing amino acids for hepatic gluconeogenesis), and the liver increases glucose output through unrestrained glycogenolysis and gluconeogenesis. The net result is weight loss despite normal or increased caloric intake, as the body cannot utilize glucose for energy and instead catabolizes fat and protein stores per Harrison's Principles of Internal Medicine and the ADA.\n\nCLINICAL PRESENTATION:\nThe symptomatic period before diagnosis is typically brief in children, ranging from days to a few weeks, reflecting the rapid acceleration of beta-cell destruction that characterizes the transition from compensated to decompensated insulin deficiency. Parents often report polyuria (including new-onset nocturnal enuresis in previously toilet-trained children, a particularly important historical clue), excessive thirst, increased hunger with paradoxical weight loss, fatigue, and irritability. If unrecognized, progressive insulin deficiency leads to diabetic ketoacidosis (DKA), which occurs at initial T1DM presentation in approximately 25 to 40% of children in the United States per data from Diabetes Care and the ADA. DKA rates at presentation are highest in children under age 5 (up to 50%, because symptoms are more difficult to recognize in young children and may be attributed to gastroenteritis or urinary tract infection), in families without prior diabetes exposure, and in racial and ethnic minority populations with reduced healthcare access. DKA develops when absolute insulin deficiency drives unregulated lipolysis, releasing free fatty acids that undergo hepatic beta-oxidation to ketone bodies (beta-hydroxybutyrate and acetoacetate). Ketone accumulation produces a high-anion-gap metabolic acidosis (arterial pH less than 7.3, serum bicarbonate less than 18 mEq/L), with clinical manifestations including nausea, vomiting, abdominal pain (mimicking an acute abdomen), Kussmaul respirations (deep, rapid breathing as respiratory compensation for metabolic acidosis), fruity breath odor (from acetone, a volatile ketone), dehydration (often 5 to 10% of body weight), and progressive obtundation. Cerebral edema is the most feared complication of DKA in children, occurring in approximately 0.5 to 1% of pediatric DKA episodes but carrying a mortality rate of 21 to 24% per data from the NEJM and Pediatrics.\n\nDIAGNOSIS AND TREATMENT:\nDiagnosis requires documentation of hyperglycemia meeting ADA criteria (random glucose greater than or equal to 200 mg/dL with symptoms, fasting glucose greater than or equal to 126 mg/dL, or HbA1c greater than or equal to 6.5%) along with evidence of autoimmune etiology: positive islet autoantibodies (GAD65, IA-2, IAA, ZnT8) and low or undetectable C-peptide (confirming absent endogenous insulin production). DKA management follows ISPAD and ADA pediatric guidelines: IV fluid resuscitation with isotonic saline (correcting dehydration gradually over 24 to 48 hours to minimize cerebral edema risk), continuous IV insulin infusion (0.05 to 0.1 units/kg/hour, never given as a bolus in pediatric DKA), potassium replacement (total body potassium is depleted despite potentially normal or elevated serum levels due to acidosis-driven transcellular shift), and careful monitoring of mental status, electrolytes, and glucose every 1 to 2 hours. Subcutaneous insulin transition occurs once DKA has resolved (pH greater than 7.3, bicarbonate greater than 15, anion gap closed, patient tolerating oral intake), with overlap of IV and subcutaneous insulin to prevent rebound ketosis. Long-term management centers on intensive insulin therapy (basal-bolus regimen with multiple daily injections or continuous subcutaneous insulin infusion via pump), carbohydrate counting, and blood glucose monitoring (CGM is now recommended for all youth with T1DM per ADA 2024 Standards of Care).\n\nKEY LEARNING POINTS:\nNew-onset T1DM in children presents with polyuria (including nocturnal enuresis as an early clue), polydipsia, and weight loss, with 25 to 40% presenting in DKA at diagnosis. DKA rates are highest in children under age 5 because symptoms are misattributed to other illnesses. Cerebral edema is the most feared pediatric DKA complication (0.5 to 1% incidence, 21 to 24% mortality), and fluid resuscitation should be gradual over 24 to 48 hours to minimize this risk."
  },
  {
    "id": 561,
    "categoryId": 12,
    "question": "Pyloric Stenosis typically presents in first-born males at 3-6 weeks with:",
    "options": [
      "A) Bilious vomiting",
      "B) Non-bilious, projectile vomiting",
      "C) Diarrhea",
      "D) Fever"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Non-bilious, projectile vomiting).\n\nPATHOPHYSIOLOGY:\nInfantile hypertrophic pyloric stenosis results from progressive hypertrophy and hyperplasia of the circular smooth muscle of the pyloric sphincter, causing gastric outlet obstruction per Harrison's Principles of Internal Medicine. The etiology is multifactorial, involving genetic susceptibility (concordance of approximately 25 to 40% in monozygotic twins, 4-fold increased risk in first-degree relatives), male sex (4 to 5:1 male-to-female ratio with firstborn males at highest risk), and environmental factors per UpToDate. Erythromycin exposure during the first 2 weeks of life significantly increases risk, likely through stimulation of motilin receptors on pyloric smooth muscle causing spasm and subsequent reactive hypertrophy per the Cleveland Clinic.\n\nCLINICAL PRESENTATION:\nSymptoms characteristically begin at 3 to 6 weeks of age (rarely before 2 weeks or after 12 weeks) with progressive, forceful, projectile vomiting occurring immediately after feedings per the Mayo Clinic. The vomitus is always non-bilious (because the pyloric obstruction is proximal to the ampulla of Vater where bile enters the duodenum) and may become blood-tinged from associated gastritis or Mallory-Weiss tear. The infant remains hungry and feeds eagerly despite repeated vomiting (the \"hungry vomiter\"). On physical examination, visible gastric peristaltic waves may be seen traversing the abdomen from left to right, and a firm, mobile, olive-shaped mass (the hypertrophied pylorus) is palpable in the right upper quadrant or epigastrium in approximately 60 to 80% of cases per UpToDate and Harrison's Principles of Internal Medicine.\n\nDIAGNOSIS AND TREATMENT:\nAbdominal ultrasound is the diagnostic study of choice, with pyloric muscle thickness greater than 3 mm and channel length greater than 15 mm considered diagnostic per UpToDate. The characteristic metabolic derangement is hypochloremic, hypokalemic metabolic alkalosis caused by loss of gastric hydrochloric acid through persistent vomiting, with a paradoxical aciduria that develops when the kidneys preferentially reabsorb sodium with bicarbonate (to maintain volume) and excrete hydrogen ions and potassium per the Cleveland Clinic. Treatment requires initial intravenous fluid resuscitation and correction of electrolyte and acid-base abnormalities before proceeding to the definitive surgical treatment: Ramstedt pyloromyotomy (longitudinal incision through the hypertrophied muscle to the submucosa without entering the mucosa), which is curative per the Mayo Clinic.\n\nKEY LEARNING POINTS:\nPyloric stenosis presents at 3 to 6 weeks with projectile non-bilious vomiting in a hungry infant (firstborn male classically), with a palpable olive-shaped mass and visible peristaltic waves. Ultrasound showing pyloric muscle thickness greater than 3 mm is diagnostic. The metabolic derangement is hypochloremic, hypokalemic metabolic alkalosis with paradoxical aciduria, which must be corrected before pyloromyotomy."
  },
  {
    "id": 562,
    "categoryId": 12,
    "question": "Neonatal Acne (onset 2-3 weeks) requires:",
    "options": [
      "A) Topical Retinoids",
      "B) Reassurance (Resolves spontaneously)",
      "C) Oral Antibiotics",
      "D) Diet change"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Reassurance - Resolves spontaneously).\n\nPATHOPHYSIOLOGY:\nNeonatal acne (neonatal cephalic pustulosis) develops in approximately 20% of newborns, typically appearing at 2 to 3 weeks of age per UpToDate. The pathogenesis involves stimulation of the neonatal sebaceous glands by maternal androgens (transferred transplacentally during the third trimester) and by the infant's own adrenal androgens during the postnatal hormonal surge (the \"mini-puberty\" of infancy) per Harrison's Principles of Internal Medicine. The resulting sebum production, combined with colonization of the pilosebaceous unit by Malassezia species (formerly Pityrosporum), produces the characteristic inflammatory papules and pustules on the cheeks, chin, forehead, and occasionally the scalp and upper chest per the Cleveland Clinic.\n\nCLINICAL PRESENTATION:\nNeonatal acne presents as small erythematous papules and pustules on the face, typically without comedones (blackheads or whiteheads), which distinguishes it from true acne vulgaris per UpToDate. The lesions are self-limited and resolve spontaneously within 1 to 3 months as maternal hormone levels decline, requiring no treatment beyond gentle daily cleansing with water per the Mayo Clinic. Parents should be counseled to avoid applying lotions, oils, or over-the-counter acne products, which may irritate the newborn's delicate skin and prolong the condition per the Cleveland Clinic.\n\nDIFFERENTIAL DIAGNOSIS:\nImportantly, neonatal acne (onset at 2 to 3 weeks, self-limited) must be distinguished from infantile acne (onset at 3 to 6 months), which presents with true comedones in addition to papules and pustules and may require treatment with topical retinoids or other acne therapies because it can be more persistent and may cause scarring per UpToDate. Infantile acne should also prompt consideration of an underlying endocrine disorder (congenital adrenal hyperplasia, androgen-secreting tumor) if it is severe, persistent, or accompanied by other signs of androgen excess per Harrison's Principles of Internal Medicine. Other conditions in the neonatal differential include erythema toxicum neonatorum (benign, evanescent erythematous macules and papules in the first 48 hours), milia (tiny white papules from keratin-filled epidermal cysts), and seborrheic dermatitis (greasy, yellowish scales on the scalp and face) per the Mayo Clinic.\n\nKEY LEARNING POINTS:\nNeonatal acne appears at 2 to 3 weeks due to maternal and neonatal androgens stimulating sebaceous glands and requires only reassurance, as it resolves spontaneously within 1 to 3 months. It is distinguished from infantile acne (onset at 3 to 6 months), which has comedones, may require treatment, and should prompt endocrine evaluation if severe. Neonatal acne lacks comedones and should not be treated with topical retinoids or acne medications."
  },
  {
    "id": 563,
    "categoryId": 12,
    "question": "Kernig's Sign involves:",
    "options": [
      "A) Flexing the neck causes hip flexion",
      "B) Pain when extending the knee with the hip flexed",
      "C) Pain with palpation of the tragus",
      "D) Rash that does not blanch"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Pain when extending the knee with the hip flexed).\n\nPATHOPHYSIOLOGY:\nKernig and Brudzinski signs are physical examination maneuvers that detect meningeal irritation, most commonly caused by infection (bacterial or viral meningitis), subarachnoid hemorrhage, or carcinomatous meningitis per Harrison's Principles of Internal Medicine. Inflammation of the meninges sensitizes the spinal nerve roots as they traverse the subarachnoid space, and maneuvers that stretch these inflamed nerve roots elicit pain and reflex protective muscle spasm per UpToDate. The sensitivity of these signs is limited (approximately 5% for Kernig and 5% for Brudzinski in adults per meta-analyses), meaning their absence does not exclude meningitis; however, when present, they are fairly specific and strongly suggest meningeal inflammation per the Cleveland Clinic.\n\nKERNIG SIGN:\nKernig sign is performed with the patient supine by flexing the hip to 90 degrees and then attempting to passively extend the knee per Harrison's Principles of Internal Medicine. The test is positive when extension of the knee beyond 135 degrees produces pain or resistance in the hamstrings and lower back. The mechanism is that knee extension with the hip flexed stretches the sciatic nerve and lumbosacral nerve roots (L4 through S3) that are surrounded by inflamed meninges, eliciting pain and involuntary resistance per UpToDate.\n\nBRUDZINSKI SIGN:\nBrudzinski sign is performed with the patient supine by passively flexing the neck toward the chest per the Mayo Clinic. The test is positive when neck flexion produces involuntary flexion of the hips and knees bilaterally. The mechanism is that cervical flexion stretches the inflamed spinal meninges, and the reflex hip and knee flexion is a protective response to reduce meningeal traction along the spinal cord per Harrison's Principles of Internal Medicine.\n\nCLINICAL APPLICATION:\nIn neonates and young infants, classic meningeal signs including Kernig and Brudzinski signs are unreliable because the immature nervous system may not produce the expected reflex responses per UpToDate. In this population, a bulging fontanelle, irritability, poor feeding, temperature instability, and lethargy are more reliable indicators of meningeal irritation. In older children and adults, the classic meningitis triad of fever, neck stiffness, and altered mental status is present in approximately 44% of cases of bacterial meningitis per the Cleveland Clinic.\n\nKEY LEARNING POINTS:\nKernig sign is pain or resistance with knee extension while the hip is flexed to 90 degrees, caused by stretching inflamed lumbosacral nerve roots. Brudzinski sign is involuntary hip and knee flexion with passive neck flexion, reflecting spinal meningeal irritation. Both signs are specific but have low sensitivity for meningitis, and they are unreliable in neonates where bulging fontanelle and nonspecific signs predominate."
  },
  {
    "id": 564,
    "categoryId": 16,
    "question": "A 42-year-old woman with no family history of breast cancer asks about mammography screening. According to the 2024 USPSTF guidelines, what is the recommended screening approach for average-risk women?",
    "options": [
      "A) Mammogram every year starting at age 40",
      "B) Mammogram every 2 years from age 40-74",
      "C) Mammogram every 2 years starting at age 50",
      "D) Shared decision-making for women 40-49, then every 2 years from 50-74"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Mammogram every 2 years from age 40 to 74).\n\nGUIDELINE UPDATE:\nThe USPSTF 2024 updated recommendation expanded breast cancer screening to begin at age 40 (previously 50 for average-risk women) with biennial (every 2 years) mammography continuing through age 74 per UpToDate and the Mayo Clinic. This Grade B recommendation was driven by increasing breast cancer incidence in women under 50 and modeling studies demonstrating that starting screening at 40 prevents more breast cancer deaths across all racial and ethnic groups per the CDC and Harvard Health.\n\nEVIDENCE BASIS:\nRandomized controlled trials and meta-analyses demonstrate that mammographic screening reduces breast cancer mortality by approximately 15 to 20% in women aged 40 to 49 and 20 to 30% in women aged 50 to 69 per Harrison's Principles of Internal Medicine. The benefit derives from detecting cancers at earlier stages (smaller tumor size, lower likelihood of nodal involvement) when curative treatment is more effective per the Cleveland Clinic. The 2024 USPSTF update particularly emphasized reducing screening disparities for Black women, who have a 40% higher breast cancer mortality rate than White women and are more likely to develop aggressive subtypes (triple-negative breast cancer) at younger ages per UpToDate.\n\nHARMS AND CONSIDERATIONS:\nScreening mammography has an approximately 10% false-positive rate per examination, leading to additional imaging and biopsies that cause anxiety and expense per the Mayo Clinic. Overdiagnosis (detecting cancers that would never have caused symptoms or death) is estimated at approximately 1 to 10% of screen-detected cancers per UpToDate. Dense breast tissue (categories C and D on BI-RADS) reduces mammographic sensitivity, and many states now require supplemental screening notification for women with dense breasts per Harrison's Principles of Internal Medicine. The USPSTF noted insufficient evidence to assess the benefits and harms of supplemental screening with breast MRI or ultrasound in women with dense breasts per Harvard Health.\n\nKEY LEARNING POINTS:\nThe USPSTF 2024 recommendation is biennial mammography for all women aged 40 to 74 (expanded from previous age 50 start). Screening reduces breast cancer mortality by 15 to 30% depending on age group. The update was particularly motivated by reducing disparities in Black women, who have 40% higher breast cancer mortality and more frequent aggressive subtypes at younger ages."
  },
  {
    "id": 565,
    "categoryId": 16,
    "question": "A 32-year-old woman asks about cervical cancer screening. According to current guidelines, what is the PREFERRED screening method for women ages 30-65?",
    "options": [
      "A) Pap smear alone every 3 years",
      "B) HPV test alone every 5 years",
      "C) Co-testing (HPV + Pap) every 5 years",
      "D) HPV test alone every 3 years"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (HPV test alone every 5 years).\n\nGUIDELINE OPTIONS:\nCurrent cervical cancer screening guidelines (USPSTF 2018, ACS 2020) offer multiple evidence-based strategies for women aged 25 to 65: cervical cytology (Pap smear) alone every 3 years, primary HPV testing alone every 5 years (the ACS preferred strategy as of 2020), or co-testing (cytology plus HPV) every 5 years per UpToDate and the Mayo Clinic. The shift toward primary HPV testing reflects the understanding that virtually all cervical cancers are caused by persistent infection with high-risk HPV genotypes (types 16 and 18 account for approximately 70% of cervical cancers) per Harrison's Principles of Internal Medicine.\n\nRATIONALE FOR HPV-BASED SCREENING:\nHPV testing has higher sensitivity (approximately 95%) than cytology alone (approximately 55 to 80%) for detecting CIN3+ (high-grade cervical intraepithelial neoplasia and cancer), though it has somewhat lower specificity per the Cleveland Clinic. Because HPV testing detects the causative agent rather than its cytologic consequences, it identifies precancerous lesions earlier in their natural history, and a negative HPV test provides greater reassurance (lower risk of CIN3+ over the next 5 years) than a negative cytology per UpToDate. This is why the screening interval for HPV testing is 5 years versus 3 years for cytology alone per Harvard Health.\n\nSCREENING BOUNDARIES:\nScreening should begin at age 21 (with cytology) or age 25 (with HPV testing per ACS guidelines) and can be discontinued after age 65 if prior screening has been adequate (three consecutive negative cytologies or two consecutive negative HPV/co-tests within the past 10 years, with the most recent within 5 years) per the CDC and UpToDate. Women who have had a total hysterectomy with removal of the cervix for benign indications and have no history of CIN2+ do not require continued screening per Harrison's Principles of Internal Medicine.\n\nKEY LEARNING POINTS:\nPrimary HPV testing every 5 years is now the ACS preferred cervical cancer screening strategy for women 25 to 65, reflecting HPV's higher sensitivity for CIN3+ compared to cytology alone. Virtually all cervical cancers are caused by persistent high-risk HPV infection (types 16 and 18 account for 70%). Screening can stop after age 65 with adequate prior negative results."
  },
  {
    "id": 566,
    "categoryId": 16,
    "question": "A 55-year-old man with a 25 pack-year smoking history quit smoking 18 years ago. According to the 2023 ACS lung cancer screening guidelines, is he eligible for low-dose CT screening?",
    "options": [
      "A) No, he quit more than 15 years ago",
      "B) Yes, former smokers with â‰¥20 pack-years are eligible regardless of quit time",
      "C) Only if he resumes smoking",
      "D) Only with shared decision-making due to borderline eligibility"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Yes, former smokers with 20 or more pack-years are eligible regardless of quit time).\n\nMAJOR GUIDELINE CHANGE:\nThe American Cancer Society 2023 lung cancer screening guideline made a landmark change by removing the quit-within-15-years requirement that had been part of all previous lung cancer screening criteria per UpToDate and the Cleveland Clinic. Under the updated ACS guideline, annual low-dose CT screening is recommended for individuals aged 50 to 80 with a 20 or more pack-year smoking history, regardless of how long ago they quit per Harvard Health. This patient (25 pack-year history, quit 18 years ago) would have been ineligible under the USPSTF 2021 criteria (which retain the 15-year quit threshold) but is eligible under the ACS 2023 criteria.\n\nRATIONALE:\nThe removal of the quit-time restriction was based on evidence that former smokers retain significant lung cancer risk for decades after cessation per Harrison's Principles of Internal Medicine. Studies from the National Lung Screening Trial and the PLCO cohort demonstrated that approximately 40% of lung cancer deaths in screening-eligible populations occurred in former smokers who had quit more than 15 years ago, meaning the quit-time threshold was systematically excluding a high-risk population from the mortality benefit of screening per the Mayo Clinic and UpToDate.\n\nCOMPARISON OF GUIDELINES:\nThe USPSTF 2021 criteria (age 50 to 80, 20 or more pack-years, current smoker or quit within 15 years) remain more restrictive and are the basis for insurance coverage mandates under the ACA per the CDC. The ACS 2023 criteria are broader and may not yet be universally covered by insurance. Clinicians should be aware of both guidelines and advocate for screening in patients who meet ACS criteria even if they fall outside USPSTF criteria per the Cleveland Clinic.\n\nKEY LEARNING POINTS:\nThe ACS 2023 lung cancer screening guideline removed the quit-within-15-years requirement, making all former smokers with 20 or more pack-years eligible for annual LDCT regardless of quit duration. Approximately 40% of lung cancer deaths in screening-eligible populations occur in long-quit former smokers. The USPSTF 2021 criteria retain the 15-year quit threshold and are the basis for mandatory insurance coverage."
  },
  {
    "id": 567,
    "categoryId": 16,
    "question": "At what age should colorectal cancer screening begin in average-risk adults according to current ACS and USPSTF guidelines?",
    "options": [
      "A) 40 years",
      "B) 45 years",
      "C) 50 years",
      "D) 55 years"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (45 years).\n\nGUIDELINE UPDATE:\nBoth the American Cancer Society (2018) and the USPSTF (2021) lowered the recommended starting age for average-risk colorectal cancer screening from 50 to 45 years per UpToDate and the Cleveland Clinic. This change was driven by a concerning 51% increase in colorectal cancer incidence in adults under 50 between 1994 and 2014, with the steepest rise in adults aged 40 to 49 per Harvard Health and the Mayo Clinic.\n\nSCREENING OPTIONS:\nMultiple modalities are acceptable for average-risk screening per Harrison's Principles of Internal Medicine. Colonoscopy every 10 years is the most comprehensive option, allowing direct visualization, biopsy, and polypectomy in a single procedure. High-sensitivity stool-based tests include annual fecal immunochemical test (FIT, which detects human hemoglobin), FIT-DNA (Cologuard, every 3 years, combining FIT with methylated DNA markers), and annual guaiac-based fecal occult blood test (gFOBT). CT colonography (virtual colonoscopy) every 5 years and flexible sigmoidoscopy every 5 years (or every 10 years combined with annual FIT) are additional options per UpToDate and the CDC. A positive stool-based test must be followed by diagnostic colonoscopy per the Cleveland Clinic.\n\nRISK STRATIFICATION:\nThe age 45 starting point applies to average-risk individuals only per the Mayo Clinic. Higher-risk patients (first-degree relative with CRC before age 60, personal history of inflammatory bowel disease, hereditary syndromes such as Lynch or FAP) require earlier initiation and more frequent surveillance per Harrison's Principles of Internal Medicine. African Americans have the highest CRC incidence and mortality of any racial group in the United States, and some guidelines have historically recommended screening beginning at age 45 for this population specifically per UpToDate.\n\nKEY LEARNING POINTS:\nColorectal cancer screening for average-risk adults now begins at age 45 per both ACS and USPSTF guidelines, driven by rising CRC incidence in adults under 50. Multiple modalities are acceptable including colonoscopy every 10 years, annual FIT, and FIT-DNA every 3 years. Higher-risk patients require earlier initiation based on family history and risk factors."
  },
  {
    "id": 568,
    "categoryId": 16,
    "question": "According to the 2025 CDC immunization schedule, at what age should adults now routinely receive pneumococcal vaccination?",
    "options": [
      "A) 50 years",
      "B) 60 years",
      "C) 65 years",
      "D) 70 years"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Age 50).\n\nUPDATED PNEUMOCOCCAL VACCINATION:\nThe CDC's Advisory Committee on Immunization Practices (ACIP) updated adult pneumococcal vaccination recommendations. All adults should now receive pneumococcal vaccination starting at age 50 (previously 65 for healthy adults), using either PCV20 alone or PCV15 followed by PPSV23.\n\nRATIONALE FOR EARLIER VACCINATION:\nPneumococcal disease causes significant morbidity in adults 50-64, not just those â‰¥65. Earlier vaccination extends protection during a vulnerable decade and simplifies the schedule. Adults with risk factors (diabetes, heart disease, lung disease, smoking) have even higher pneumococcal disease risk.\n\nVACCINE OPTIONS:\nPCV20 (Prevnar 20) can be given as a single dose completing the series. Alternatively, PCV15 followed by PPSV23 at least one year later provides similar coverage. Adults previously vaccinated with PPSV23 alone should receive a PCV (either 15 or 20) at least one year later.\n\nHIGH-RISK POPULATIONS:\nImmunocompromised patients, asplenic patients, cochlear implant recipients, and CSF leak patients should be vaccinated earlier (any age) per specific schedules with both PCV and PPSV23.\n\nKEY LEARNING POINTS:\nUniversal pneumococcal vaccination now starts at age 50, not 65. PCV20 alone or PCV15 + PPSV23 are acceptable regimens. High-risk individuals require vaccination at any age per specific recommendations."
  },
  {
    "id": 569,
    "categoryId": 16,
    "question": "A 58-year-old patient with COPD asks about the RSV vaccine. According to current guidelines, who should receive RSV vaccination?",
    "options": [
      "A) All adults 50 and older",
      "B) Adults 60+ routinely; ages 50-59 with increased risk for severe RSV disease",
      "C) Only adults 75 and older",
      "D) Only immunocompromised adults"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Adults 60 and older routinely; ages 50 to 59 with increased risk for severe RSV disease).\n\nVACCINE BACKGROUND:\nRespiratory syncytial virus (RSV) vaccines (Arexvy by GSK and Abrysvo by Pfizer) were FDA-approved in 2023 for adults aged 60 and older, marking the first RSV vaccines available for the adult population per the CDC and UpToDate. The CDC Advisory Committee on Immunization Practices (ACIP) updated recommendations to include routine RSV vaccination for adults aged 60 and older through shared clinical decision-making, and expanded eligibility in 2024 to include adults aged 50 to 59 with increased risk for severe RSV disease per the Mayo Clinic.\n\nHIGH-RISK CONDITIONS:\nConditions that increase the risk of severe RSV in adults include chronic lung disease (COPD, asthma), chronic heart disease (heart failure, coronary artery disease), moderate to severe immunocompromise, diabetes with end-organ complications, neurologic or neuromuscular conditions that impair airway clearance, chronic kidney or liver disease, and residence in nursing homes or long-term care facilities per the CDC and Harrison's Principles of Internal Medicine. This patient with COPD at age 58 would qualify under the expanded 50 to 59 high-risk criteria per UpToDate.\n\nCLINICAL SIGNIFICANCE:\nRSV causes approximately 60,000 to 160,000 hospitalizations and 6,000 to 10,000 deaths annually among adults aged 65 and older in the United States per the CDC. Clinical trials demonstrated approximately 83% vaccine efficacy against RSV-associated lower respiratory tract disease in adults 60 and older per the Cleveland Clinic. Both vaccines are administered as a single intramuscular dose, and current guidance is for a single lifetime dose (duration of protection and need for revaccination remain under study) per UpToDate and Harvard Health.\n\nKEY LEARNING POINTS:\nRSV vaccination is recommended routinely for adults 60 and older and for adults 50 to 59 with conditions increasing severe RSV risk (COPD, heart failure, immunocompromise, diabetes). RSV causes 60,000 to 160,000 hospitalizations annually in older adults. Both approved vaccines (Arexvy, Abrysvo) are single-dose with approximately 83% efficacy against lower respiratory tract disease."
  },
  {
    "id": 570,
    "categoryId": 16,
    "question": "According to the 2025 CDC schedule, which adults should receive a SECOND dose of the 2024-2025 COVID-19 vaccine?",
    "options": [
      "A) All adults over 50",
      "B) Adults 65+ and those who are moderately/severely immunocompromised",
      "C) Only transplant recipients",
      "D) No one; one dose is sufficient for all adults"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Adults 65 and older and those who are moderately to severely immunocompromised).\n\nRATIONALE:\nThe immune response to COVID-19 vaccination wanes over time, and certain populations maintain lower and less durable antibody and T-cell responses per the CDC and UpToDate. The 2024-2025 updated COVID-19 vaccine (targeting currently circulating variants) is recommended as a single dose for all individuals aged 6 months and older, with a second dose recommended for two specific populations: adults aged 65 and older and individuals who are moderately to severely immunocompromised per Harrison's Principles of Internal Medicine and the Cleveland Clinic.\n\nIMMUNOLOGIC BASIS:\nImmunosenescence (age-related decline in immune function) reduces the magnitude and durability of vaccine-induced immunity in older adults, with lower peak antibody titers and faster waning of neutralizing antibody levels per UpToDate. Moderately to severely immunocompromised individuals (active treatment with high-dose corticosteroids, cancer chemotherapy, solid organ transplant recipients on immunosuppressive therapy, advanced HIV with CD4 less than 200, and B-cell depleting therapy recipients) may fail to mount adequate primary responses to vaccination and benefit from additional antigen exposure per the Mayo Clinic and Harvard Health.\n\nTIMING:\nThe additional dose should be administered at least 6 months after the initial 2024-2025 updated dose for adults 65 and older, and at least 2 months after for immunocompromised individuals (who may receive additional doses beyond two based on clinical judgment and immunologic status) per the CDC. Clinicians should not delay vaccination if the patient has not yet received the current season's formulation, as the updated vaccine provides the best available protection against circulating variants per UpToDate.\n\nKEY LEARNING POINTS:\nAdults 65 and older and moderately to severely immunocompromised individuals should receive a second dose of the 2024-2025 updated COVID-19 vaccine due to immunosenescence and impaired vaccine responses respectively. The additional dose is given at least 6 months after the first for older adults and at least 2 months after for immunocompromised patients. Immunocompromised individuals may receive further doses based on clinical judgment."
  },
  {
    "id": 571,
    "categoryId": 4,
    "question": "According to the 2025 ADA Standards of Care, what is the recommended approach to glucose-lowering therapy in a patient with T2DM and established atherosclerotic cardiovascular disease (ASCVD)?",
    "options": [
      "A) Metformin monotherapy, add sulfonylurea if not at goal",
      "B) GLP-1 RA or SGLT2 inhibitor with proven CV benefit, independent of A1c",
      "C) Start insulin if A1c > 9%",
      "D) DPP-4 inhibitor as first-line after metformin"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (GLP-1 RA or SGLT2 inhibitor with proven CV benefit, independent of A1c).\n\nPATHOPHYSIOLOGY:\nThe paradigm shift in type 2 diabetes management reflected in the ADA Standards of Care represents a fundamental evolution from a glucocentric approach (treating diabetes primarily by lowering HbA1c) to a comorbidity-driven, cardiorenal-metabolic approach (selecting glucose-lowering agents based on their proven benefits for cardiovascular disease, heart failure, and chronic kidney disease, independent of their glycemic effects). This shift was catalyzed by the landmark cardiovascular outcomes trials (CVOTs) mandated by the FDA after 2008, which demonstrated that specific GLP-1 receptor agonists and SGLT2 inhibitors reduce major adverse cardiovascular events (MACE: cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) in patients with established ASCVD. The LEADER trial (NEJM 2016) demonstrated that liraglutide reduced MACE by 13% and cardiovascular death by 22% compared to placebo. The SUSTAIN-6 trial (NEJM 2016) demonstrated that semaglutide reduced MACE by 26%. The REWIND trial (Lancet 2019) demonstrated that dulaglutide reduced MACE by 12% in a broader population including patients with cardiovascular risk factors. Among SGLT2 inhibitors, the EMPA-REG OUTCOME trial (NEJM 2015) demonstrated that empagliflozin reduced MACE by 14% and cardiovascular death by 38%, and the CANVAS Program (NEJM 2017) demonstrated that canagliflozin reduced MACE by 14%. Importantly, these cardiovascular benefits were observed independently of glycemic control, suggesting mechanisms beyond glucose lowering.\n\nCLINICAL REASONING:\nThe ADA 2025 Standards of Care recommends that for patients with T2DM and established ASCVD (defined as prior MI, stroke, TIA, peripheral arterial disease, coronary revascularization, or greater than 50% stenosis of coronary, carotid, or lower extremity arteries), a GLP-1 RA or SGLT2 inhibitor with proven cardiovascular benefit should be included in the treatment regimen independent of HbA1c, independent of whether the patient is already at glycemic target, and independent of current metformin use. This represents a departure from the traditional stepwise approach of starting with metformin and adding agents sequentially based on A1c. For patients with T2DM and heart failure (HFrEF or HFpEF), SGLT2 inhibitors carry a specific Class I recommendation based on the DAPA-HF (NEJM 2019) and EMPEROR-Reduced (NEJM 2020) trials for HFrEF, and the EMPEROR-Preserved (NEJM 2021) and DELIVER (NEJM 2022) trials for HFpEF. For patients with T2DM and CKD (eGFR 20 to 60 mL/min or UACR greater than 200 mg/g), SGLT2 inhibitors are recommended based on the CREDENCE (NEJM 2019) and DAPA-CKD (NEJM 2020) trials, which demonstrated 30 to 39% reductions in the composite kidney endpoint. GLP-1 RAs also demonstrate kidney benefits and are recommended when SGLT2 inhibitors are not tolerated.\n\nCLINICAL APPLICATION:\nThe practical implementation of this comorbidity-driven framework requires primary care providers to assess every patient with T2DM for the presence of ASCVD, heart failure, and CKD at diagnosis and at each visit, as these comorbidities should drive medication selection rather than HbA1c alone. For the patient in this question with established ASCVD, a GLP-1 RA with proven cardiovascular benefit (semaglutide, liraglutide, or dulaglutide) or an SGLT2 inhibitor with proven cardiovascular benefit (empagliflozin, dapagliflozin, or canagliflozin) should be initiated regardless of baseline A1c. If additional glycemic control is needed, metformin remains a reasonable component of the regimen for its low cost, tolerability, weight neutrality, and extensive safety record. The 2025 guidelines also emphasize expanding CGM access to T2DM patients not on insulin, recognizing GLP-1 RA benefits for weight management and cardiorenal protection beyond glycemic control, and incorporating tirzepatide (a dual GIP/GLP-1 receptor agonist) which demonstrated 15 to 20% weight loss in the SURMOUNT trials and cardiovascular benefit in the SURPASS-CVOT trial.\n\nKEY LEARNING POINTS:\nThe ADA 2025 Standards of Care recommends GLP-1 RAs or SGLT2 inhibitors with proven cardiovascular benefit for all patients with T2DM and established ASCVD, independent of A1c level. This comorbidity-driven approach prioritizes cardiorenal protection over glucocentric management. SGLT2 inhibitors are specifically recommended for T2DM with heart failure (HFrEF and HFpEF) and CKD based on landmark trials demonstrating benefits independent of glycemic control."
  },
  {
    "id": 572,
    "categoryId": 4,
    "question": "A patient has a fasting glucose of 118 mg/dL and HbA1c of 6.3%. According to ADA criteria, what is this patient's diagnosis?",
    "options": [
      "A) Normal",
      "B) Prediabetes",
      "C) Diabetes mellitus",
      "D) Impaired fasting glucose only"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Prediabetes).\n\nPATHOPHYSIOLOGY:\nPrediabetes represents an intermediate metabolic state between normal glucose homeostasis and overt diabetes mellitus, characterized by glucose levels above normal but below the diagnostic threshold for diabetes. Prediabetes reflects progressive beta-cell dysfunction and worsening insulin resistance that have exceeded the capacity for full metabolic compensation but have not yet reached the degree of derangement that produces frank diabetes. Approximately 38% of US adults (98 million people) have prediabetes per CDC data, and without intervention, approximately 5 to 10% of individuals with prediabetes progress to type 2 diabetes annually, with up to 70% eventually developing diabetes over their lifetime. The pathophysiologic continuum from normal to prediabetes to diabetes involves the progressive failure of pancreatic beta cells to maintain compensatory hyperinsulinemia in the face of worsening peripheral insulin resistance (driven by visceral adiposity, physical inactivity, and genetic predisposition). Each of the three diagnostic tests (fasting plasma glucose, oral glucose tolerance test, and HbA1c) captures a different aspect of dysglycemia: fasting glucose primarily reflects hepatic insulin resistance and basal hepatic glucose output, the 2-hour OGTT value reflects peripheral insulin resistance and impaired muscle glucose uptake, and HbA1c reflects average glycemia over the preceding 2 to 3 months per Harrison's Principles of Internal Medicine and the ADA.\n\nCLINICAL REASONING:\nThe ADA diagnostic criteria define clear numeric thresholds for prediabetes and diabetes. For this patient with fasting glucose of 118 mg/dL and HbA1c of 6.3%, both values fall within the prediabetes range: fasting glucose of 100 to 125 mg/dL defines impaired fasting glucose (IFG), and HbA1c of 5.7 to 6.4% defines the prediabetes HbA1c range. Diabetes is diagnosed when fasting glucose is 126 mg/dL or greater, 2-hour OGTT glucose is 200 mg/dL or greater, HbA1c is 6.5% or greater, or random glucose is 200 mg/dL or greater with classic hyperglycemic symptoms. The ADA recommends that an abnormal result on any single test should be confirmed by repeat testing (either the same test or a different test) on a separate day, unless the clinical presentation is unambiguous (such as symptomatic hyperglycemia with random glucose greater than 200 mg/dL). Important caveats apply to HbA1c interpretation: conditions that alter red blood cell lifespan can produce falsely elevated values (iron deficiency anemia, vitamin B12 deficiency, asplenia) or falsely reduced values (hemolytic anemias, recent transfusion, erythropoietin therapy, chronic liver disease). Hemoglobin variants (HbS, HbC, HbE) may interfere with certain HbA1c assay methods, and alternative monitoring with fructosamine or glycated albumin should be considered in these populations per ADA Standards of Care.\n\nCLINICAL APPLICATION:\nThe diagnosis of prediabetes should trigger a structured prevention strategy centered on lifestyle intervention and appropriate screening. The Diabetes Prevention Program (DPP), a landmark NIH-funded randomized controlled trial published in the NEJM (2001), demonstrated that structured lifestyle intervention (targeting 7% weight loss through a reduced-calorie, low-fat diet and 150 minutes of moderate-intensity physical activity weekly) reduced progression from prediabetes to type 2 diabetes by 58% compared to placebo, outperforming metformin (which reduced progression by 31%). The benefit was sustained at 10-year and 15-year follow-up (Diabetes Prevention Program Outcomes Study). Based on this evidence, the ADA recommends referral to a CDC-recognized Diabetes Prevention Program (DPP) for all patients with prediabetes. Metformin may be considered for diabetes prevention in patients at highest risk: those with BMI 35 or greater, age less than 60, women with prior gestational diabetes, and those with rising HbA1c despite lifestyle intervention. Screening for prediabetes and type 2 diabetes is recommended by the ADA for all adults aged 35 and older (updated from age 45 in previous editions), regardless of weight, and for adults of any age with BMI 25 or greater (23 or greater in Asian Americans) with one or more additional risk factors (physical inactivity, first-degree relative with diabetes, high-risk ethnicity, history of gestational diabetes, hypertension, HDL less than 35 or triglycerides greater than 250, polycystic ovary syndrome, HbA1c 5.7% or greater, or history of cardiovascular disease).\n\nKEY LEARNING POINTS:\nPrediabetes is diagnosed by fasting glucose 100 to 125 mg/dL (impaired fasting glucose), 2-hour OGTT 140 to 199 mg/dL (impaired glucose tolerance), or HbA1c 5.7 to 6.4%, and affects 38% of US adults. The Diabetes Prevention Program demonstrated that structured lifestyle intervention reduces progression to diabetes by 58%, outperforming metformin (31% reduction). All patients with prediabetes should be referred to a CDC-recognized Diabetes Prevention Program for structured behavioral intervention."
  },
  {
    "id": 573,
    "categoryId": 1,
    "question": "According to the 2022 AHA/ACC/HFSA Heart Failure Guidelines (updated 2024), which medication class is now recommended for ALL patients with HFrEF regardless of diabetes status?",
    "options": [
      "A) DPP-4 inhibitors",
      "B) SGLT2 inhibitors",
      "C) GLP-1 receptor agonists",
      "D) Thiazolidinediones"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (SGLT2 Inhibitors).\n\nCLINICAL REASONING:\nThe 2022 AHA/ACC/HFSA Heart Failure Guidelines (with 2024 focused update) recommend SGLT2 inhibitors (dapagliflozin and empagliflozin) as one of the four pillars of guideline-directed medical therapy (GDMT) for all patients with heart failure with reduced ejection fraction (HFrEF, EF 40% or less), regardless of diabetes status per Harrison's Principles of Internal Medicine. This represents a paradigm shift: SGLT2 inhibitors were originally developed as glucose-lowering agents for type 2 diabetes, but the cardiovascular outcome trials (DAPA-HF for dapagliflozin and EMPEROR-Reduced for empagliflozin) demonstrated significant reductions in the composite of cardiovascular death and heart failure hospitalization in HFrEF patients with and without diabetes per UpToDate.\n\nTHE FOUR PILLARS OF HFrEF GDMT:\nThe 2022 guidelines establish four foundational medication classes for HFrEF per the Cleveland Clinic: an ARNI (sacubitril/valsartan, or ACEi/ARB if ARNI is not tolerated), an evidence-based beta-blocker (carvedilol, metoprolol succinate, or bisoprolol), a mineralocorticoid receptor antagonist (spironolactone or eplerenone), and an SGLT2 inhibitor (dapagliflozin or empagliflozin). The guidelines emphasize early initiation of all four classes (even before full dose uptitration of each) and rapid sequencing rather than the previous stepwise approach per Harrison's Principles of Internal Medicine.\n\nEXPANDED INDICATIONS:\nSGLT2 inhibitors are now recommended across the entire ejection fraction spectrum of heart failure: HFrEF (EF 40% or less), HFmrEF (EF 41 to 49%), and HFpEF (EF 50% or greater) based on the DELIVER and EMPEROR-Preserved trials per UpToDate. The mechanism of benefit in heart failure involves natriuresis and osmotic diuresis (reducing congestion), improved myocardial energetics, reduced interstitial fibrosis, and decreased inflammation, all independent of glucose-lowering effects per the Mayo Clinic.\n\nKEY LEARNING POINTS:\nSGLT2 inhibitors (dapagliflozin, empagliflozin) are now recommended for ALL HFrEF patients regardless of diabetes, as one of the four GDMT pillars alongside ARNI, evidence-based beta-blocker, and MRA. The benefit is independent of glucose lowering and extends across the entire HF ejection fraction spectrum. Guidelines now emphasize early initiation of all four drug classes simultaneously."
  },
  {
    "id": 574,
    "categoryId": 1,
    "question": "According to the 2025 AHA/ACC Hypertension Guidelines, what is the blood pressure threshold for initiating pharmacotherapy in a patient with 10-year ASCVD risk â‰¥10%?",
    "options": [
      "A) â‰¥120/80 mmHg",
      "B) â‰¥130/80 mmHg",
      "C) â‰¥140/90 mmHg",
      "D) â‰¥150/90 mmHg"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (130/80 mmHg or greater).\n\nGUIDELINE EVOLUTION:\nThe 2017 ACC/AHA Hypertension Clinical Practice Guidelines lowered the diagnostic threshold for hypertension from the previous JNC 7 standard of 140/90 mmHg to 130/80 mmHg, reclassifying approximately 31 million additional Americans as hypertensive per Harrison's Principles of Internal Medicine and UpToDate. The revised classification defines normal BP as less than 120/80, elevated BP as systolic 120 to 129 with diastolic less than 80, Stage 1 hypertension as 130 to 139 systolic or 80 to 89 diastolic, and Stage 2 hypertension as 140 or greater systolic or 90 or greater diastolic per the Cleveland Clinic.\n\nEVIDENCE BASIS:\nThe decision to lower the threshold was driven primarily by the SPRINT trial (Systolic Blood Pressure Intervention Trial), which demonstrated that targeting a systolic BP below 120 mmHg (intensive treatment) reduced major cardiovascular events by 25% and all-cause mortality by 27% compared to standard treatment targeting below 140 mmHg in high-risk patients without diabetes per UpToDate. Meta-analyses of over 60 clinical trials confirmed continuous cardiovascular risk reduction with lower BP targets, with no clear threshold below which benefit ceased per Harrison's Principles of Internal Medicine.\n\nTREATMENT THRESHOLDS:\nThe guideline distinguishes between diagnosis and pharmacologic treatment initiation per the Mayo Clinic. For Stage 1 hypertension (130 to 139/80 to 89), lifestyle modification alone is recommended unless the patient has established ASCVD or a 10-year ASCVD risk of 10% or greater, in which case antihypertensive medication is also indicated per UpToDate. For Stage 2 hypertension (140/90 or greater), both lifestyle modification and pharmacotherapy are recommended for all patients regardless of ASCVD risk per the Cleveland Clinic. First-line medication classes include thiazide diuretics, ACE inhibitors, ARBs, and calcium channel blockers per Harrison's Principles of Internal Medicine.\n\nKEY LEARNING POINTS:\nThe 2017 ACC/AHA guidelines define hypertension at 130/80 mmHg or greater, down from the previous 140/90 threshold, based on SPRINT trial evidence showing 25% cardiovascular event reduction with intensive targets. Stage 1 hypertension (130 to 139/80 to 89) requires pharmacotherapy only with established ASCVD or 10-year risk of 10% or greater. Stage 2 (140/90 or greater) warrants medication for all patients."
  },
  {
    "id": 575,
    "categoryId": 1,
    "question": "A patient has uncontrolled BP despite adherence to maximum doses of amlodipine, lisinopril, and chlorthalidone. According to current guidelines, what is the preferred fourth-line agent for resistant hypertension?",
    "options": [
      "A) Hydralazine",
      "B) Clonidine",
      "C) Spironolactone",
      "D) Doxazosin"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Spironolactone).\n\nDEFINITION OF RESISTANT HYPERTENSION:\nResistant hypertension is blood pressure that remains above goal despite concurrent use of three antihypertensive medications from different classes at maximally tolerated doses, one of which must be a diuretic, or blood pressure controlled on four or more medications per Harrison's Principles of Internal Medicine. Before diagnosing true resistant hypertension, clinicians must exclude pseudo-resistance: medication non-adherence (the most common cause), white coat hypertension (confirmed by ambulatory monitoring), improper BP measurement technique, and secondary causes of hypertension per UpToDate.\n\nPATHWAY-2 TRIAL:\nThe landmark PATHWAY-2 trial (Prevention and Treatment of Hypertension with Algorithm-based therapY-2) demonstrated that spironolactone was significantly more effective as fourth-line add-on therapy than bisoprolol, doxazosin, or placebo in patients with confirmed resistant hypertension per UpToDate and the Cleveland Clinic. Spironolactone reduced systolic BP by an average of 8.7 mmHg more than placebo, compared to 4.5 mmHg for bisoprolol (beta-blocker) and 4.0 mmHg for doxazosin (alpha-blocker) per Harrison's Principles of Internal Medicine.\n\nPATHOPHYSIOLOGY:\nThe superiority of spironolactone reflects the role of aldosterone excess (termed aldosterone breakthrough) as a major driver of treatment-resistant hypertension per the Mayo Clinic. Even in patients already taking ACE inhibitors or ARBs, aldosterone levels may escape suppression over time through angiotensin-independent pathways (potassium-mediated secretion, ACTH stimulation, and autonomous adrenal production), contributing to sodium retention, volume expansion, and direct vascular stiffening per UpToDate. By directly blocking the mineralocorticoid receptor in both the kidney and vasculature, spironolactone addresses this pathophysiology. Eplerenone is an alternative with fewer anti-androgenic side effects (gynecomastia, breast tenderness) for patients who cannot tolerate spironolactone per the Cleveland Clinic.\n\nKEY LEARNING POINTS:\nSpironolactone is the most effective fourth-line agent for resistant hypertension per the PATHWAY-2 trial, reducing systolic BP 8.7 mmHg more than placebo, outperforming both bisoprolol and doxazosin. Its superiority reflects aldosterone breakthrough as a key driver of resistant hypertension. Pseudo-resistance (non-adherence, white coat effect) must be excluded before diagnosing true resistant hypertension."
  },
  {
    "id": 576,
    "categoryId": 2,
    "question": "According to GOLD 2024 guidelines, a COPD patient on LAMA+LABA with frequent exacerbations has an eosinophil count of 400 cells/Î¼L. What is the next step?",
    "options": [
      "A) Add theophylline",
      "B) Add inhaled corticosteroid (ICS) to form triple therapy",
      "C) Start roflumilast",
      "D) Add azithromycin prophylaxis"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Add inhaled corticosteroid to form triple therapy).\n\nCLINICAL REASONING:\nThis patient has COPD with frequent exacerbations despite LAMA plus LABA dual bronchodilator therapy, and a blood eosinophil count of 400 cells per microliter. The GOLD 2024 guidelines use blood eosinophil count as a biomarker to guide the decision to add ICS per UpToDate. With eosinophils of 400 (well above the 300 threshold), the recommended escalation is to add ICS to form LAMA/LABA/ICS triple therapy. The IMPACT trial (published in the New England Journal of Medicine) demonstrated that fluticasone furoate/umeclidinium/vilanterol triple therapy reduced moderate and severe exacerbations by 15% and all-cause mortality by 42% compared to LAMA/LABA alone in patients with elevated eosinophils. The ETHOS trial confirmed these findings with a budesonide-containing triple inhaler per Harrison's Principles of Internal Medicine.\n\nEOSINOPHIL-GUIDED ICS THERAPY:\nThe rationale for eosinophil-guided therapy is that eosinophilic airway inflammation in COPD identifies a subset of patients whose exacerbations are driven by a steroid-responsive inflammatory phenotype, analogous to asthma per the Cleveland Clinic. Eosinophils 300 or greater strongly support ICS addition with clear evidence of benefit. Eosinophils 100 to 300 provide moderate support, particularly with 2 or more exacerbations per year. Eosinophils less than 100 predict minimal ICS benefit with increased pneumonia risk, and ICS should be avoided or withdrawn in these patients per GOLD 2024 and UpToDate.\n\nSTEPWISE ESCALATION:\nThe GOLD 2024 escalation pathway for persistent exacerbations follows a stepwise approach per the Mayo Clinic: LAMA monotherapy is escalated to LAMA/LABA, then to LAMA/LABA/ICS if eosinophils are 300 or greater. If exacerbations persist despite triple therapy, roflumilast (a phosphodiesterase-4 inhibitor, specifically for patients with FEV1 less than 50% predicted and chronic bronchitis phenotype) or chronic azithromycin (for former smokers, with QTc monitoring) is added per GOLD 2024 guidelines. Theophylline has fallen out of favor due to its narrow therapeutic window and significant toxicity.\n\nKEY LEARNING POINTS:\nBlood eosinophils 300 or greater in a COPD patient with persistent exacerbations on LAMA/LABA is the key indication for adding ICS to form triple therapy per GOLD 2024. The IMPACT and ETHOS trials demonstrated both exacerbation reduction and mortality benefit with triple therapy in eosinophilic COPD. Roflumilast and azithromycin are reserved for patients who continue to exacerbate despite optimized triple therapy."
  },
  {
    "id": 577,
    "categoryId": 2,
    "question": "According to GINA 2024 guidelines, what is the preferred reliever medication for adults with mild asthma (Track 1)?",
    "options": [
      "A) Short-acting beta-agonist (SABA) alone as needed",
      "B) As-needed low-dose ICS-formoterol",
      "C) Daily low-dose ICS plus SABA as needed",
      "D) Oral corticosteroids for exacerbations only"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (As-needed low-dose ICS-formoterol).\n\nCLINICAL REASONING:\nThe Global Initiative for Asthma (GINA) 2024 guidelines represent a paradigm shift in asthma management by recommending against SABA-only treatment for any severity of asthma, including mild intermittent disease per UpToDate. This change reflects accumulating evidence that patients treated with SABA alone have increased risk of severe exacerbations and asthma-related death because SABA addresses only bronchospasm without treating the underlying eosinophilic airway inflammation that is present even in mild disease per Harrison's Principles of Internal Medicine. The GINA 2024 preferred approach (Track 1) uses low-dose ICS-formoterol (budesonide-formoterol) as the sole reliever medication for Steps 1 and 2, ensuring that every rescue dose delivers both a rapid-onset bronchodilator (formoterol, which has an onset of action within 1 to 3 minutes comparable to albuterol) and an anti-inflammatory corticosteroid per the Cleveland Clinic.\n\nTRACK 1 VS TRACK 2:\nTrack 1 (preferred) uses as-needed ICS-formoterol at Steps 1 and 2, progressing to ICS-formoterol as both maintenance and reliever therapy (MART) at Steps 3 through 5, with the same inhaler used for both scheduled and rescue dosing per GINA 2024. Track 2 (alternative) retains SABA as the reliever but requires that an ICS be taken with every SABA dose, which presents significant adherence challenges. The SYGMA 1 and SYGMA 2 trials (published in the New England Journal of Medicine) demonstrated that as-needed budesonide-formoterol reduced severe exacerbations by 60 to 70% compared to SABA alone and was noninferior to daily ICS plus as-needed SABA for exacerbation prevention in mild asthma per UpToDate.\n\nSTEPWISE THERAPY:\nGINA 2024 Steps per the Mayo Clinic are: Steps 1 to 2 use as-needed low-dose ICS-formoterol (Track 1) for symptom relief and anti-inflammatory coverage. Step 3 adds low-dose ICS-formoterol as daily maintenance plus as-needed reliever (MART). Step 4 escalates to medium-dose ICS-formoterol maintenance plus as-needed reliever. Step 5 involves high-dose ICS-formoterol, add-on LAMA (tiotropium), and consideration of biologic therapies guided by phenotype (anti-IgE omalizumab, anti-IL5 mepolizumab or benralizumab, anti-IL4/IL13 dupilumab, anti-TSLP tezepelumab) per UpToDate.\n\nKEY LEARNING POINTS:\nGINA 2024 recommends against SABA-only treatment for any asthma severity, favoring as-needed low-dose ICS-formoterol as the preferred reliever (Track 1) to ensure anti-inflammatory therapy with every rescue dose. The SYGMA trials demonstrated that PRN ICS-formoterol reduces severe exacerbations by 60 to 70% compared to SABA alone. The MART approach (maintenance and reliever therapy with a single ICS-formoterol inhaler) simplifies management at Steps 3 and above."
  },
  {
    "id": 578,
    "categoryId": 11,
    "question": "According to the 2024 ACP guidelines for major depressive disorder, what is recommended as first-line treatment for adults in the acute phase?",
    "options": [
      "A) Second-generation antidepressant monotherapy only",
      "B) CBT monotherapy only",
      "C) Either CBT or a second-generation antidepressant as monotherapy",
      "D) Combination therapy with antidepressant plus CBT for all patients"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Either CBT or a second-generation antidepressant as monotherapy).\n\nGUIDELINE BASIS:\nThe 2024 American College of Physicians (ACP) clinical practice guideline for acute-phase treatment of major depressive disorder (MDD) in adults recommends either cognitive behavioral therapy (CBT) or a second-generation antidepressant (SGA) as equivalent first-line monotherapy options per UpToDate and the Mayo Clinic. This recommendation reflects moderate-certainty evidence that CBT and SGAs produce comparable response and remission rates in acute MDD, with the choice depending on patient preference, access, cost, and side effect concerns per Harrison's Principles of Internal Medicine.\n\nSECOND-GENERATION ANTIDEPRESSANTS:\nThe ACP guideline encompasses SSRIs (sertraline, escitalopram, fluoxetine, citalopram, paroxetine), SNRIs (venlafaxine, duloxetine, desvenlafaxine), bupropion, and mirtazapine as the second-generation antidepressant options per UpToDate. The guideline does not recommend one SGA over another as initial therapy because head-to-head trials show comparable efficacy, though side effect profiles differ and should guide selection (for example, bupropion for patients concerned about weight gain or sexual dysfunction, mirtazapine for patients with prominent insomnia and appetite loss) per the Cleveland Clinic.\n\nCOMBINATION THERAPY:\nThe ACP guideline does not recommend initial combination therapy (CBT plus antidepressant) for all patients, reserving this approach for patients who do not achieve adequate response with monotherapy per Harvard Health. For patients with moderate to severe MDD who fail an initial adequate trial (6 to 8 weeks at therapeutic dose), augmentation strategies (adding an atypical antipsychotic such as aripiprazole, adding lithium, or combining CBT with pharmacotherapy) or switching medication class are recommended per UpToDate and Harrison's Principles of Internal Medicine.\n\nTREATMENT DURATION:\nThe ACP recommends continuing antidepressant therapy for a minimum of 4 to 9 months after achieving remission to reduce relapse risk, with longer continuation (1 to 3 years or indefinitely) for patients with recurrent episodes, severe initial presentation, or residual symptoms per the Mayo Clinic.\n\nKEY LEARNING POINTS:\nThe 2024 ACP guideline recommends CBT or a second-generation antidepressant as equivalent first-line monotherapy for acute MDD, with choice guided by patient preference and side effect profile. Combination therapy is reserved for monotherapy non-responders. Antidepressants should be continued 4 to 9 months after remission to prevent relapse."
  },
  {
    "id": 579,
    "categoryId": 11,
    "question": "The PHQ-9 is used for depression screening. A score of 15 indicates:",
    "options": [
      "A) Minimal depression",
      "B) Mild depression",
      "C) Moderately severe depression",
      "D) Severe depression"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Moderately severe depression).\n\nSCREENING TOOL:\nThe Patient Health Questionnaire-9 (PHQ-9) is a validated, self-administered depression screening and severity assessment instrument derived from the nine DSM-5 criteria for major depressive disorder per UpToDate and the Mayo Clinic. Each item is scored from 0 (not at all) to 3 (nearly every day) over the past 2 weeks, yielding a total score of 0 to 27 per Harrison's Principles of Internal Medicine. The USPSTF recommends screening all adults for depression in primary care using validated instruments such as the PHQ-9 (Grade B recommendation) per the CDC and Harvard Health.\n\nSCORE INTERPRETATION:\nPHQ-9 severity thresholds are: 0 to 4 (minimal or no depression), 5 to 9 (mild depression), 10 to 14 (moderate depression), 15 to 19 (moderately severe depression), and 20 to 27 (severe depression) per UpToDate and the Cleveland Clinic. A score of 10 or greater has a sensitivity of 88% and specificity of 88% for major depressive disorder, making it an effective screening threshold per Harvard Health. A score of 15, as in this case, indicates moderately severe depression warranting active treatment (pharmacotherapy, psychotherapy, or combination) per Harrison's Principles of Internal Medicine.\n\nCLINICAL APPLICATION:\nBeyond initial screening, the PHQ-9 is valuable for monitoring treatment response over time per the Mayo Clinic. A decrease of 5 or more points is considered a clinically meaningful response, and a score below 5 represents remission per UpToDate. The PHQ-9 should be administered at each visit during active treatment (every 2 to 4 weeks initially, then at follow-up intervals) to guide treatment adjustments per the Cleveland Clinic. Question 9 specifically asks about suicidal ideation (\"thoughts that you would be better off dead or of hurting yourself\") and any positive response requires immediate safety assessment regardless of total score per Harrison's Principles of Internal Medicine.\n\nKEY LEARNING POINTS:\nPHQ-9 severity thresholds are: 0 to 4 minimal, 5 to 9 mild, 10 to 14 moderate, 15 to 19 moderately severe, 20 to 27 severe. A score of 10 or greater has 88% sensitivity and specificity for MDD. The PHQ-9 should be used for both screening and longitudinal treatment monitoring, with a 5-point decrease indicating clinically meaningful response and question 9 requiring immediate safety assessment if positive."
  },
  {
    "id": 580,
    "categoryId": 7,
    "question": "According to the 2024 USPSTF recommendation, which women should be screened for osteoporosis?",
    "options": [
      "A) All women over 50",
      "B) Women 65+ and postmenopausal women <65 at increased fracture risk",
      "C) Only women with prior fractures",
      "D) All postmenopausal women regardless of age"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Women 65+ and postmenopausal women under 65 at increased fracture risk).\n\nPATHOPHYSIOLOGY:\nOsteoporosis is a systemic skeletal disorder characterized by low bone mass and microarchitectural deterioration of bone tissue, leading to increased bone fragility and susceptibility to fracture. Peak bone mass is achieved by approximately age 30 and is determined by genetic factors (accounting for 60 to 80% of variance), nutrition, physical activity, and hormonal status. After peak bone mass, a gradual age-related decline in bone mineral density (BMD) occurs in both sexes at approximately 0.5 to 1% per year. In women, estrogen withdrawal at menopause accelerates bone loss to 2 to 5% per year for the first 5 to 7 postmenopausal years by removing estrogen\\\'s inhibitory effects on osteoclast activity and lifespan, shifting bone remodeling toward net resorption. This estrogen-dependent accelerated phase is the primary reason women develop osteoporosis earlier and more frequently than men. By age 80, women have lost approximately 40% of their peak bone mass compared to 25% for men. Osteoporotic fractures, particularly hip fractures, carry devastating consequences: hip fracture in elderly women carries a one-year mortality rate of approximately 20 to 30% per data from JAMA and Harrison\\\'s Principles of Internal Medicine, and up to 50% of hip fracture survivors never regain their pre-fracture functional status.\n\nCLINICAL REASONING:\nThe 2024 USPSTF recommendation (Grade B) specifies two populations for osteoporosis screening: all women aged 65 years and older, and postmenopausal women younger than 65 who are at increased risk of osteoporosis as determined by a clinical risk assessment tool. This recommendation is based on evidence that screening with central DXA (dual-energy X-ray absorptiometry) of the hip and lumbar spine can identify women with low BMD, and that treatment of screen-detected osteoporosis reduces fracture risk. The 2024 update specifically refines the recommendation by specifying central DXA as the screening modality, rather than the broader term \\\"bone measurement testing\\\" used in the 2018 recommendation. For postmenopausal women younger than 65, risk assessment tools including the FRAX (Fracture Risk Assessment Tool developed by WHO), the Osteoporosis Self-Assessment Tool (OST), and the ORAI (Osteoporosis Risk Assessment Instrument) can identify those who should undergo DXA screening. The USPSTF issued an I statement (insufficient evidence) regarding screening men, as there are no randomized trials demonstrating that screening reduces fracture risk in men. Risk factors for osteoporotic fracture include advanced age, low body weight (less than 127 pounds or BMI less than 20), personal history of fragility fracture after age 50, parental history of hip fracture, current smoking, excessive alcohol intake (3 or more drinks daily), glucocorticoid use (5 mg or more of prednisone daily for 3 or more months), rheumatoid arthritis, and secondary causes of osteoporosis (hyperparathyroidism, hyperthyroidism, celiac disease, chronic kidney disease).\n\nDIAGNOSIS AND CLASSIFICATION:\nOsteoporosis is diagnosed by central DXA, with results reported as T-scores (the number of standard deviations the patient\\\'s BMD falls below the mean for a healthy 30-year-old reference population). The WHO classification defines normal bone density as a T-score of -1.0 or above, osteopenia (low bone mass) as a T-score between -1.0 and -2.5, and osteoporosis as a T-score of -2.5 or below at the lumbar spine, femoral neck, or total hip. Osteoporosis can also be diagnosed clinically by the occurrence of a low-trauma (fragility) fracture of the hip, vertebral body, or other characteristic site regardless of BMD. The FRAX tool, available at the WHO Collaborating Centre for Metabolic Bone Diseases website, calculates the 10-year probability of major osteoporotic fracture (hip, spine, forearm, humerus) and hip fracture specifically, incorporating clinical risk factors with or without BMD. Treatment thresholds endorsed by the National Osteoporosis Foundation (now Bone Health and Osteoporosis Foundation) include a 10-year hip fracture probability of 3% or greater or a major osteoporotic fracture probability of 20% or greater.\n\nTREATMENT:\nNon-pharmacologic interventions for all patients include adequate calcium intake (1,000 to 1,200 mg daily from diet and supplements per the Endocrine Society and National Osteoporosis Foundation), vitamin D supplementation (800 to 1,000 IU daily to maintain serum 25-hydroxyvitamin D above 30 ng/mL), weight-bearing and resistance exercise, fall prevention measures, smoking cessation, and limiting alcohol. First-line pharmacotherapy includes oral bisphosphonates (alendronate 70 mg weekly or risedronate 35 mg weekly), which inhibit osteoclast-mediated bone resorption and reduce vertebral fractures by 40 to 70% and hip fractures by 40 to 50% in the FIT and VERT trials. Denosumab (60 mg subcutaneously every 6 months) is a RANKL inhibitor appropriate for patients intolerant of or non-responsive to bisphosphonates, or with renal impairment. Anabolic agents including teriparatide and romosozumab are reserved for patients with very high fracture risk (T-score below -3.0, multiple vertebral fractures, or fracture while on anti-resorptive therapy). The duration of bisphosphonate therapy is typically 3 to 5 years for moderate risk patients, with reassessment (drug holiday consideration) after this period based on updated fracture risk assessment, as recommended by the ACP and Endocrine Society guidelines.\n\nKEY LEARNING POINTS:\nThe 2024 USPSTF recommends screening all women 65 and older and postmenopausal women under 65 at increased risk using central DXA (Grade B), while evidence for screening men remains insufficient. Osteoporosis is defined by a T-score of -2.5 or below at the lumbar spine, femoral neck, or total hip, and can also be diagnosed clinically by a fragility fracture. First-line pharmacotherapy with oral bisphosphonates reduces vertebral fractures by 40 to 70% and hip fractures by 40 to 50%, with treatment duration of 3 to 5 years followed by reassessment for drug holiday consideration."
  },
  {
    "id": 581,
    "categoryId": 4,
    "question": "According to current guidelines, what is the first-line treatment for obesity (BMI â‰¥30)?",
    "options": [
      "A) GLP-1 receptor agonist medication",
      "B) Comprehensive lifestyle intervention (diet, physical activity, behavioral therapy)",
      "C) Bariatric surgery referral",
      "D) Low-carbohydrate diet alone"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Comprehensive lifestyle intervention: diet, physical activity, behavioral therapy).\n\nPATHOPHYSIOLOGY:\nObesity is a chronic, relapsing, multifactorial disease characterized by excess adiposity that impairs health, driven by a complex interplay of genetic susceptibility (heritability of BMI is approximately 40 to 70% based on twin studies), neurohormonal dysregulation (alterations in leptin sensitivity, ghrelin signaling, melanocortin pathways, and hypothalamic energy homeostasis circuits), environmental factors (calorie-dense food availability, sedentary occupations, sleep deprivation, psychosocial stress), and epigenetic modifications per the Endocrine Society, AMA, and WHO, all of which recognize obesity as a disease rather than a behavioral choice. Visceral adipose tissue is metabolically active, secreting proinflammatory adipokines (TNF-alpha, IL-6, resistin, MCP-1) and reducing production of the anti-inflammatory and insulin-sensitizing adipokine adiponectin. This creates a chronic low-grade inflammatory state that drives insulin resistance (through serine phosphorylation of insulin receptor substrate-1 impairing PI3K-Akt signaling), endothelial dysfunction (reducing nitric oxide bioavailability), atherogenesis, and prothrombotic state. Ectopic lipid deposition in the liver (nonalcoholic fatty liver disease affecting approximately 75% of patients with obesity), skeletal muscle (intramyocellular lipids impairing GLUT4 translocation), and pancreas (lipotoxicity accelerating beta-cell apoptosis) further compounds metabolic dysfunction. Clinically meaningful weight loss of 5 to 10% produces significant improvements in glycemia (HbA1c reduction of 0.6 to 1.0%), blood pressure (reduction of 5 mmHg systolic), triglycerides (reduction of 40 mg/dL), HDL cholesterol (increase of 5 mg/dL), sleep apnea severity, and osteoarthritis symptoms per data from the NEJM and the AHA/ACC/TOS 2013 obesity guidelines.\n\nCLINICAL REASONING:\nComprehensive lifestyle intervention is designated as first-line treatment for obesity by the AHA/ACC/TOS guidelines, the Endocrine Society Clinical Practice Guideline, and the USPSTF, which gives a B recommendation for clinicians to offer or refer adults with BMI 30 or greater to intensive, multicomponent behavioral interventions. The three essential components are dietary modification (creating a sustained caloric deficit of 500 to 750 kcal/day through reduced portion sizes and energy-dense food choices, with multiple dietary patterns showing equivalent efficacy when adherence is maintained, including Mediterranean, DASH, low-carbohydrate, low-fat, and plant-based approaches per the DIETFITS trial published in JAMA), increased physical activity (the AHA recommends at least 150 minutes per week of moderate-intensity aerobic activity for health benefits, with 200 to 300 minutes per week recommended for weight loss maintenance), and behavioral strategies (self-monitoring through food diaries and regular weigh-ins, stimulus control, goal setting, problem solving, cognitive restructuring of negative thought patterns, and stress management). High-intensity programs providing 14 or more contact sessions in 6 months consistently produce the best outcomes (average weight loss of 5 to 8% of body weight), as demonstrated in the DPP and the Look AHEAD trial.\n\nTREATMENT ESCALATION:\nWhen lifestyle intervention alone is insufficient after 3 to 6 months, pharmacotherapy should be offered for patients with BMI 30 or greater, or BMI 27 or greater with weight-related comorbidities, as part of a comprehensive approach that continues lifestyle modification. The treatment landscape has been transformed by GLP-1 receptor agonists and dual incretin agonists. Semaglutide 2.4 mg weekly (Wegovy) produced 14.9% mean weight loss at 68 weeks in the STEP 1 trial (NEJM 2021), and the SELECT trial (NEJM 2023) demonstrated a 20% reduction in MACE in patients with obesity and established cardiovascular disease without diabetes. Tirzepatide (a dual GIP/GLP-1 receptor agonist, Zepbound) produced up to 22.5% mean weight loss at 72 weeks in the SURMOUNT-1 trial (NEJM 2022). These results approach the efficacy of bariatric surgery for moderate obesity. Older medications (orlistat, phentermine-topiramate, naltrexone-bupropion) remain available but produce more modest weight loss (5 to 10%). Bariatric surgery (Roux-en-Y gastric bypass, sleeve gastrectomy) is indicated for BMI 40 or greater, BMI 35 or greater with weight-related comorbidities, or BMI 30 or greater with poorly controlled T2DM per the ASMBS/IFSO 2022 updated guidelines, producing durable weight loss of 20 to 35% and diabetes remission rates of 30 to 60% at 5 years.\n\nKEY LEARNING POINTS:\nComprehensive lifestyle intervention (diet, physical activity, and behavioral therapy) is first-line treatment for obesity per AHA/ACC/TOS and USPSTF guidelines, with high-intensity programs (14 or more sessions in 6 months) producing 5 to 8% weight loss. Pharmacotherapy with GLP-1 RAs should be added after 3 to 6 months if lifestyle alone is insufficient, with semaglutide and tirzepatide producing 15 to 22.5% weight loss. Weight management medications require long-term continuation, as discontinuation typically results in weight regain due to neurohormonal counter-regulatory mechanisms."
  },
  {
    "id": 582,
    "categoryId": 17,
    "question": "According to AAP guidelines, vision screening using instrument-based screening should begin at what age?",
    "options": [
      "A) 6 months",
      "B) 12 months",
      "C) 3 years",
      "D) 5 years"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (12 months).\n\nSCREENING RATIONALE:\nEarly detection of amblyopia and its risk factors (refractive errors, strabismus, media opacities) during the critical period of visual development is essential. The visual system undergoes rapid maturation from birth through approximately age 7-8 years, and untreated amblyopia beyond this window becomes increasingly resistant to correction.\n\nVISION SCREENING BY AGE (AAP Bright Futures / AAPOS):\n\n1. NEWBORN TO 12 MONTHS:\n   - Red reflex testing at every well-child visit (detects cataracts, retinoblastoma, large refractive errors)\n   - External inspection of eyes and lids\n   - Pupil examination (size, reactivity, symmetry)\n   - Assess for fixation and following behavior\n   - Instrument-based screening (photoscreening, autorefractors) can begin at 12 months\n\n2. AGES 1-3 YEARS:\n   - Instrument-based screening (photoscreening or autorefraction) at every well-child visit\n   - Assess for strabismus (corneal light reflex, cover-uncover test)\n   - Continue red reflex testing\n\n3. AGES 3-5 YEARS:\n   - Visual acuity testing when the child can cooperate (Lea symbols, HOTV charts)\n   - Instrument-based screening as alternative if acuity testing is not feasible\n   - Critical period for amblyopia detection and treatment\n\n4. SCHOOL AGE AND BEYOND:\n   - Visual acuity screening at periodic well-child visits\n   - Refer if screening fails\n\nRED FLAGS AT ANY AGE:\n- Leukocoria (white pupillary reflex) - urgent referral\n- Persistent strabismus beyond 4 months of age\n- Nystagmus\n- Ptosis obscuring the visual axis\n\nKEY LEARNING POINTS:\nInstrument-based vision screening should begin at 12 months per AAP/AAPOS guidelines. Red reflex testing is performed at every well-child visit from birth. Amblyopia treatment is most effective when initiated during the critical period (before age 7). Photoscreening devices allow objective screening in preverbal children.\n\nREFERENCES:\nAAP Bright Futures; AAPOS Vision Screening Guidelines; USPSTF Amblyopia Screening Recommendation; UpToDate.\n---"
  },
  {
    "id": 583,
    "categoryId": 4,
    "question": "According to CDC Medical Eligibility Criteria (MEC), which contraceptive method is Category 4 (unacceptable health risk) for a 38-year-old woman who smokes 20 cigarettes/day?",
    "options": [
      "A) Copper IUD",
      "B) Progestin-only pill",
      "C) Combined oral contraceptive",
      "D) Depot medroxyprogesterone acetate"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Combined oral contraceptive).\n\nPATHOPHYSIOLOGY:\nThe contraindication to combined hormonal contraceptives (CHCs) in women aged 35 and older who smoke reflects the synergistic interaction between exogenous estrogen and cigarette smoking on arterial thrombotic risk. Ethinyl estradiol, the synthetic estrogen component of most combined oral contraceptives (COCs), patches, and vaginal rings, increases hepatic synthesis of procoagulant factors (factors II, VII, VIII, X, and fibrinogen) while reducing the natural anticoagulants antithrombin III, protein S, and tissue factor pathway inhibitor. This shifts the hemostatic balance toward a prothrombotic state, increasing the risk of both venous thromboembolism (deep vein thrombosis and pulmonary embolism) and arterial thrombotic events (myocardial infarction and ischemic stroke). Smoking independently promotes arterial thrombosis through multiple mechanisms: cigarette smoke components damage vascular endothelium (reducing nitric oxide production and promoting endothelial dysfunction), activate platelets (increasing aggregation and thromboxane A2 production), elevate fibrinogen, increase blood viscosity, promote atherosclerotic plaque formation and instability, and induce coronary vasospasm. When estrogen and smoking are combined, the effects on arterial thrombosis are synergistic rather than merely additive: epidemiologic data demonstrate that women older than 35 who smoke and use COCs have approximately 10 to 20-fold increased risk of myocardial infarction compared to non-smoking non-users per data from the WHO Collaborative Study and Lancet meta-analyses reviewed in UpToDate and ACOG.\n\nCLINICAL REASONING:\nThe US Medical Eligibility Criteria for Contraceptive Use (US MEC), published by the CDC and endorsed by ACOG, uses a four-category classification system to rate the safety of contraceptive methods for specific medical conditions. Category 1 indicates no restriction (the method can be used in any circumstance). Category 2 indicates that the advantages generally outweigh the theoretical or proven risks. Category 3 indicates that the theoretical or proven risks usually outweigh the advantages (the method is generally not recommended unless other more appropriate methods are not available or acceptable). Category 4 indicates an unacceptable health risk (the method should not be used). For combined hormonal contraceptives, the CDC US MEC assigns Category 4 (absolute contraindication) for women aged 35 and older who smoke 15 or more cigarettes per day, and Category 3 (relative contraindication) for women aged 35 and older who smoke fewer than 15 cigarettes per day. In practice, many clinicians treat any smoking in women 35 and older as a contraindication to CHCs given the difficulty of accurately quantifying cigarette consumption and the availability of safe, highly effective alternatives. Other Category 4 conditions for CHCs include current or history of VTE, known thrombogenic mutations (Factor V Leiden, prothrombin G20210A), current or history of ischemic heart disease or stroke, valvular heart disease with complications, migraine with aura at any age, breast cancer (current), and severe decompensated cirrhosis.\n\nCLINICAL APPLICATION:\nThe critical clinical teaching point is that progestin-only methods are safe alternatives for women who smoke, regardless of age, because progestins do not significantly affect hepatic coagulation factor synthesis or arterial thrombotic risk. All of the following are Category 1 or 2 for smokers of any age: progestin-only pills (Category 1), depot medroxyprogesterone acetate (DMPA, Category 1), levonorgestrel or etonogestrel subdermal implant (Category 1), levonorgestrel IUD (Category 1), and the copper IUD (Category 1, non-hormonal). Long-acting reversible contraceptives (LARCs: IUDs and implants) are particularly appropriate as they combine the highest typical-use effectiveness (greater than 99%) with an excellent safety profile. When counseling this 38-year-old patient who smokes 20 cigarettes daily, the provider should clearly explain that CHCs pose an unacceptable cardiovascular risk, offer progestin-only or non-hormonal alternatives, discuss smoking cessation (which would remove the CHC contraindication and provide enormous independent health benefits), and provide appropriate screening for cardiovascular risk factors (blood pressure, lipids, glucose). Emergency contraception considerations are also relevant: levonorgestrel emergency contraception and the copper IUD are appropriate for smokers, while ulipristal acetate (a selective progesterone receptor modulator) is also Category 1.\n\nKEY LEARNING POINTS:\nCombined hormonal contraceptives are Category 4 (absolute contraindication) per CDC US MEC for women aged 35 and older who smoke 15 or more cigarettes per day, due to synergistic arterial thrombotic risk from estrogen and smoking producing a 10 to 20-fold increased MI risk. All progestin-only methods (pills, DMPA, implant, LNG-IUD) and the copper IUD are Category 1 (safe) for smokers of any age. Smoking cessation removes the CHC contraindication and should be actively promoted."
  },
  {
    "id": 584,
    "categoryId": 16,
    "question": "According to CDC guidelines, which sexually active populations should receive routine screening for chlamydia?",
    "options": [
      "A) All sexually active women under 25",
      "B) Only women with multiple partners",
      "C) Only pregnant women",
      "D) All sexually active adults annually"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (All sexually active women under 25).\n\nGUIDELINE BASIS:\nThe CDC, USPSTF, and American College of Obstetricians and Gynecologists (ACOG) recommend annual chlamydia screening for all sexually active women under age 25, regardless of symptoms or perceived risk factors per the CDC and UpToDate. This is a Grade A USPSTF recommendation (high certainty of substantial net benefit). For women aged 25 and older, screening is recommended only with risk factors such as a new sexual partner, multiple partners, a partner with an STI, or inconsistent condom use per Harrison's Principles of Internal Medicine.\n\nEPIDEMIOLOGY:\nChlamydia trachomatis is the most commonly reported bacterial STI in the United States, with approximately 1.8 million cases reported annually (and an estimated 2.9 million actual infections given significant underdiagnosis) per the CDC. The highest prevalence is in sexually active women aged 15 to 24, affecting approximately 1 in 20 in this age group per the Cleveland Clinic. Approximately 70 to 80% of chlamydia infections in women are asymptomatic, meaning screening is the only way to detect most cases per the Mayo Clinic.\n\nCOMPLICATIONS OF UNTREATED INFECTION:\nUntreated chlamydia can ascend from the cervix to cause pelvic inflammatory disease (PID) in 10 to 15% of infected women, leading to tubal scarring, chronic pelvic pain, ectopic pregnancy, and tubal factor infertility per Harrison's Principles of Internal Medicine. Chlamydia during pregnancy increases risk of preterm delivery and neonatal conjunctivitis and pneumonia per UpToDate. Screening and treatment with single-dose azithromycin (1g) or doxycycline (100mg twice daily for 7 days, now preferred by CDC 2021 guidelines for superior efficacy) prevents these complications per the CDC and the Cleveland Clinic.\n\nKEY LEARNING POINTS:\nAnnual chlamydia screening is recommended for all sexually active women under 25 (USPSTF Grade A) because 70 to 80% of infections are asymptomatic and prevalence peaks in this age group. Untreated chlamydia causes PID in 10 to 15%, leading to infertility and ectopic pregnancy. Doxycycline 100mg BID for 7 days is now the CDC-preferred treatment over single-dose azithromycin."
  },
  {
    "id": 585,
    "categoryId": 16,
    "question": "According to the Beers Criteria, which medication class should generally be AVOIDED in older adults due to anticholinergic effects and fall risk?",
    "options": [
      "A) ACE inhibitors",
      "B) First-generation antihistamines (diphenhydramine)",
      "C) Calcium channel blockers",
      "D) Thiazide diuretics"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (First-generation antihistamines such as diphenhydramine).\n\nBEERS CRITERIA:\nThe American Geriatrics Society (AGS) Beers Criteria is the most widely referenced list of potentially inappropriate medications (PIMs) for older adults aged 65 and older per UpToDate and Harrison's Principles of Internal Medicine. First-generation antihistamines (diphenhydramine, hydroxyzine, chlorpheniramine, promethazine) are among the most strongly recommended medications to avoid because of their potent anticholinergic properties per the Cleveland Clinic.\n\nANTICHOLINERGIC BURDEN:\nFirst-generation antihistamines cross the blood-brain barrier readily and block central muscarinic acetylcholine receptors, producing cognitive impairment, confusion, delirium, sedation, falls, urinary retention, constipation, dry mouth, blurred vision, and tachycardia per the Mayo Clinic. Older adults are particularly vulnerable to these effects because of age-related reductions in hepatic metabolism (decreased CYP enzyme activity), renal clearance, and cholinergic neurotransmitter reserves (baseline acetylcholine levels decline with aging) per Harrison's Principles of Internal Medicine. Cumulative anticholinergic exposure has been associated with increased risk of dementia in large prospective studies per Harvard Health and UpToDate.\n\nCOMMON CLINICAL PITFALLS:\nDiphenhydramine (Benadryl) is frequently used as an over-the-counter sleep aid (marketed as Unisom, ZzzQuil, and Tylenol PM) by older adults, making it one of the most commonly used Beers-listed medications per the Cleveland Clinic. Clinicians should specifically ask about OTC sleep aids and allergy medications during medication reconciliation. Safer alternatives for insomnia include cognitive behavioral therapy for insomnia (CBT-I, first-line per AASM guidelines), melatonin, and if needed, low-dose trazodone or suvorexant per UpToDate. Safer alternatives for allergies include second-generation antihistamines (cetirizine, loratadine, fexofenadine) that have minimal blood-brain barrier penetration per the Mayo Clinic.\n\nKEY LEARNING POINTS:\nThe Beers Criteria strongly recommend avoiding first-generation antihistamines (diphenhydramine, hydroxyzine) in older adults due to potent central anticholinergic effects causing confusion, falls, delirium, and cumulative dementia risk. Diphenhydramine is commonly hidden in OTC sleep aids (ZzzQuil, Tylenol PM). Safer alternatives include second-generation antihistamines for allergies and CBT-I for insomnia."
  },
  {
    "id": 586,
    "categoryId": 5,
    "question": "A patient with T2DM and CKD Stage 3 (eGFR 45) has persistent albuminuria (UACR 350 mg/g) despite maximum dose ACE inhibitor. According to KDIGO 2024 guidelines, which medication should be added?",
    "options": [
      "A) Add ARB to ACE inhibitor",
      "B) Add SGLT2 inhibitor",
      "C) Switch to calcium channel blocker",
      "D) Add aldosterone antagonist only"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Add SGLT2 inhibitor).\n\nGUIDELINE BASIS:\nThe KDIGO 2024 guidelines recommend SGLT2 inhibitors (dapagliflozin, empagliflozin) as first-line add-on therapy for patients with CKD and persistent albuminuria (UACR greater than 200 mg/g) despite maximum-dose RAAS blockade, regardless of diabetes status per UpToDate and Harrison's Principles of Internal Medicine. This recommendation represents a paradigm shift in nephroprotection based on landmark trials per the Cleveland Clinic.\n\nEVIDENCE:\nThe DAPA-CKD trial demonstrated that dapagliflozin reduced the composite endpoint of sustained GFR decline, end-stage kidney disease, or renal/cardiovascular death by 39% compared to placebo in CKD patients (with or without diabetes), leading to early trial termination due to overwhelming benefit per UpToDate. The CREDENCE trial showed that canagliflozin reduced the risk of kidney failure by 30% in patients with type 2 diabetes and CKD per Harvard Health. The EMPA-KIDNEY trial confirmed these findings with empagliflozin across a broader CKD population per the Mayo Clinic.\n\nMECHANISM:\nSGLT2 inhibitors reduce proximal tubular sodium and glucose reabsorption, increasing sodium delivery to the macula densa per Harrison's Principles of Internal Medicine. This activates tubuloglomerular feedback, constricting the afferent arteriole and reducing intraglomerular pressure (the same protective hemodynamic effect as RAAS blockade, but through a complementary mechanism) per UpToDate. Additional renoprotective mechanisms include reduced tubular workload and oxygen consumption, decreased inflammation, reduced fibrosis, and improved tubular energy metabolism through ketone utilization per the Cleveland Clinic.\n\nFOUR PILLARS OF CKD CARE:\nThe KDIGO guidelines now describe the \"four pillars\" of evidence-based CKD management per UpToDate: RAAS blockade (ACE inhibitor or ARB, maximally tolerated dose), SGLT2 inhibitor (added for persistent albuminuria), finerenone (a nonsteroidal mineralocorticoid receptor antagonist for diabetic kidney disease with persistent albuminuria on RAAS blockade plus SGLT2i), and GLP-1 receptor agonist (for diabetic CKD patients needing additional glycemic and cardiovascular benefit) per Harrison's Principles of Internal Medicine.\n\nKEY LEARNING POINTS:\nSGLT2 inhibitors (dapagliflozin, empagliflozin) are KDIGO-recommended as first add-on therapy for CKD with persistent albuminuria on maximum RAAS blockade, reducing kidney failure by 30 to 39% via tubuloglomerular feedback-mediated afferent arteriolar constriction. The four pillars of CKD care are RAAS blockade, SGLT2 inhibitor, finerenone, and GLP-1 agonist."
  },
  {
    "id": 587,
    "categoryId": 3,
    "question": "A 55-year-old man with chronic GERD asks about long-term PPI use. According to current evidence, which is a documented risk of prolonged PPI therapy?",
    "options": [
      "A) Increased risk of C. difficile infection",
      "B) Hepatotoxicity",
      "C) QT prolongation",
      "D) Pancreatitis"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Increased risk of C. difficile infection).\n\nPATHOPHYSIOLOGY:\nProton pump inhibitors raise intragastric pH from its normal range of 1-2 to above 4, effectively neutralizing the gastric acid barrier that normally serves as a first-line defense against ingested pathogens. Clostridioides difficile spores are acid-resistant, but the vegetative (active, toxin-producing) form is susceptible to gastric acid. By raising gastric pH, PPIs allow greater survival and passage of both vegetative C. difficile organisms and other enteric pathogens into the lower gastrointestinal tract. Multiple meta-analyses have demonstrated a 1.5 to 2.7-fold increased risk of C. difficile infection with PPI use.\n\nOTHER DOCUMENTED PPI RISKS:\nAdditional risks supported by moderate evidence include community-acquired pneumonia (due to bacterial overgrowth in the achlorhydric stomach with subsequent micro-aspiration), hypomagnesemia (which can be refractory to supplementation and cause cardiac arrhythmias), vitamin B12 deficiency (from impaired cleavage of protein-bound B12), calcium malabsorption with increased fracture risk (particularly hip fractures in postmenopausal women after more than one year of use), and increased risk of chronic kidney disease with long-term use. An association with dementia and gastric cancer has been suggested in observational studies but remains controversial and unconfirmed.\n\nCLINICAL IMPLICATIONS:\nThe FDA has issued safety communications regarding several of these risks. Current guidelines recommend prescribing PPIs at the lowest effective dose for the shortest duration necessary. Patients requiring long-term PPI therapy (Barrett's esophagus, severe erosive esophagitis, Zollinger-Ellison syndrome) should have their indication periodically reassessed, magnesium levels monitored, and bone density evaluated when additional osteoporosis risk factors are present. Step-down to H2 receptor antagonists should be attempted when appropriate.\n\nKEY LEARNING POINTS:\nPPI use increases C. difficile infection risk 1.5 to 2.7-fold by raising gastric pH and eliminating the acid barrier to ingested pathogens. Other documented risks include pneumonia, hypomagnesemia, B12 deficiency, calcium malabsorption with fractures, and chronic kidney disease. PPIs should be prescribed at the lowest effective dose for the shortest duration. Long-term users require periodic reassessment and monitoring."
  },
  {
    "id": 588,
    "categoryId": 13,
    "question": "A patient with gout has a serum uric acid of 8.5 mg/dL and 3 flares in the past year. According to ACR guidelines, what is the target serum uric acid for urate-lowering therapy?",
    "options": [
      "A) < 8.0 mg/dL",
      "B) < 7.0 mg/dL",
      "C) < 6.0 mg/dL",
      "D) < 5.0 mg/dL"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (< 6.0 mg/dL).\n\nPATHOPHYSIOLOGY:\nGout results from deposition of monosodium urate crystals when serum uric acid exceeds its saturation point, approximately 6.8 mg/dL at physiologic temperature and pH. Crystal deposition triggers intense inflammation mediated by IL-1Î². The goal of urate-lowering therapy (ULT) is to reduce serum uric acid below its saturation point, allowing dissolution of existing crystal deposits and preventing new deposition and flares.\n\nTARGET URIC ACID LEVEL:\nCurrent guidelines recommend targeting serum uric acid below 6.0 mg/dL for all patients on urate-lowering therapy. This threshold provides a margin below the saturation point (6.8 mg/dL), accounting for variations in temperature, pH, and measurement. For patients with tophi or severe disease, a more aggressive target of <5.0 mg/dL may be appropriate to accelerate tophus resolution. The target should be maintained indefinitely, as discontinuing ULT leads to uric acid rebound and recurrent flares.\n\nACHIEVING TARGET:\nAllopurinol is first-line ULT. Start low (100mg daily, 50mg in CKD) and titrate by 100mg increments every 2-4 weeks until target uric acid is achieved. Many patients require 300-800mg daily; do not stop titrating at arbitrary dose limits if target is not met. Febuxostat is an alternative for allopurinol-intolerant patients. Probenecid (uricosuric) is an option for patients who are uric acid underexcreters with normal renal function.\n\nKEY LEARNING POINTS:\nTarget serum uric acid is <6.0 mg/dL (or <5.0 mg/dL if tophi present). This target is below the saturation point of 6.8 mg/dL, promoting crystal dissolution. Titrate allopurinol to achieve target, not to a fixed dose."
  },
  {
    "id": 589,
    "categoryId": 8,
    "question": "A 35-year-old returning from Southeast Asia presents with 2 weeks of fever, dry cough, and night sweats. Chest X-ray shows upper lobe infiltrates with cavitation. PPD is 18mm. What is the most appropriate initial step?",
    "options": [
      "A) Start 4-drug RIPE therapy immediately",
      "B) Obtain 3 sputum samples for AFB smear and culture",
      "C) Start Isoniazid monotherapy",
      "D) Obtain CT chest with contrast"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Obtain 3 sputum samples for AFB smear and culture).\n\nPATHOPHYSIOLOGY:\nMycobacterium tuberculosis is an aerobic, acid-fast bacillus transmitted via airborne droplet nuclei. Following inhalation, the organism is phagocytosed by alveolar macrophages but resists intracellular killing due to its mycolic acid-rich cell wall. In immunocompetent hosts, T-cell-mediated granuloma formation typically contains the infection (latent TB). Active pulmonary TB develops when host immunity is overwhelmed, particularly in the upper lobes where higher oxygen tension favors mycobacterial growth. Cavitary disease, as seen in this patient, indicates high mycobacterial burden and increased infectivity.\n\nCLINICAL PRESENTATION:\nThis patientâ€™s presentation is classic for pulmonary tuberculosis: prolonged fever, night sweats, dry cough, travel to a TB-endemic region (Southeast Asia), upper lobe infiltrates with cavitation on chest X-ray, and a strongly positive PPD (â‰¥10mm is positive for individuals from endemic areas). The differential diagnosis for cavitary lung lesions includes lung abscess, malignancy, and endemic fungal infections, but the clinical picture strongly favors TB.\n\nDIAGNOSIS:\nObtaining microbiologic confirmation before starting treatment is critical. Three sputum samples collected on separate occasions maximize diagnostic sensitivity (single-sample sensitivity for AFB smear is only 50-60%). AFB smear results, available within 24 hours, guide infection control decisions. Importantly, culture enables drug susceptibility testing, which is essential given rising global rates of multidrug-resistant TB. Nucleic acid amplification testing (e.g., GeneXpert MTB/RIF) provides rapid confirmation and simultaneous rifampin resistance detection.\n\nTREATMENT:\nEmpiric 4-drug RIPE therapy (Rifampin, Isoniazid, Pyrazinamide, Ethambutol) should be initiated after sputum collection when clinical suspicion is high. The intensive phase lasts 2 months, followed by a continuation phase of isoniazid and rifampin for 4 months. Patients must be placed in airborne isolation (negative pressure room with N95 respirators for healthcare workers) until three consecutive negative AFB smears or clinical improvement on therapy.\n\nKEY LEARNING POINTS:\nAlways obtain 3 sputum samples for AFB smear and culture before initiating TB treatment. Culture enables drug susceptibility testing, which is essential for directing therapy. Empiric RIPE therapy starts after sputum collection in high-suspicion cases. Airborne isolation is mandatory until infectivity is excluded.\n\nREFERENCES:\nCDC TB Guidelines; WHO TB Treatment Guidance; UpToDate; Harrison's Principles of Internal Medicine.\n---"
  },
  {
    "id": 590,
    "categoryId": 8,
    "question": "A healthy 28-year-old woman presents with 1 day of dysuria and urinary frequency. She is afebrile with no flank pain. Urinalysis shows pyuria and bacteriuria. Per IDSA guidelines, what is the preferred empiric treatment?",
    "options": [
      "A) Ciprofloxacin 500mg BID x 3 days",
      "B) Nitrofurantoin 100mg BID x 5 days",
      "C) Amoxicillin-clavulanate 875mg BID x 7 days",
      "D) TMP-SMX DS BID x 3 days"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Nitrofurantoin 100mg BID x 5 days).\n\nPATHOPHYSIOLOGY:\nUncomplicated cystitis is a lower urinary tract infection occurring in non-pregnant, premenopausal women without urologic abnormalities. Escherichia coli accounts for approximately 75-95% of cases, with Staphylococcus saprophyticus, Klebsiella, and Proteus comprising most of the remainder. Uropathogens from the fecal flora colonize the periurethral area and ascend via the urethra. The short female urethra and proximity to the anus explain the much higher incidence in women compared to men.\n\nCLINICAL PRESENTATION:\nDysuria, urinary frequency, and urgency in a young, healthy, afebrile woman without vaginal symptoms have a positive predictive value exceeding 90% for cystitis. Urine culture is not required for diagnosis of uncomplicated cystitis but should be obtained when the presentation is atypical, when pyelonephritis is suspected (fever, flank pain, CVA tenderness), or in cases of recurrent infection.\n\nTREATMENT:\nThe IDSA 2010 guidelines recommend the following first-line agents for uncomplicated cystitis: nitrofurantoin monohydrate/macrocrystals 100mg BID for 5 days, trimethoprim-sulfamethoxazole (TMP-SMX) 160/800mg BID for 3 days (if local E. coli resistance is below 20%), or fosfomycin 3g as a single dose. Fluoroquinolones should be avoided for uncomplicated cystitis due to FDA black box warnings for serious adverse effects (tendinopathy, aortic dissection, neuropathy) and the need to preserve this antibiotic class for more serious infections. Nitrofurantoin achieves therapeutic concentrations only in urine, making it effective for cystitis but inappropriate for pyelonephritis or systemic infections.\n\nKEY LEARNING POINTS:\nNitrofurantoin and TMP-SMX are first-line for uncomplicated cystitis. Fluoroquinolones should be reserved for complicated UTIs due to FDA safety concerns. Nitrofurantoin is effective only in the lower urinary tract and cannot treat pyelonephritis.\n\nREFERENCES:\nIDSA 2010 Uncomplicated UTI Guidelines; FDA Drug Safety Communications; UpToDate; Harrison's Principles of Internal Medicine.\n---"
  },
  {
    "id": 591,
    "categoryId": 8,
    "question": "A 45-year-old male with HIV (CD4 count 85) presents with headache, fever, and confusion over 2 weeks. CSF shows elevated opening pressure, lymphocytic pleocytosis, low glucose, and positive India ink stain. What is the treatment of choice?",
    "options": [
      "A) Fluconazole 400mg daily",
      "B) Amphotericin B + Flucytosine induction, then Fluconazole",
      "C) Voriconazole",
      "D) Caspofungin"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Amphotericin B + Flucytosine induction, then Fluconazole).\n\nPATHOPHYSIOLOGY:\nCryptococcus neoformans is an encapsulated yeast found in soil contaminated with bird (especially pigeon) droppings. Inhalation leads to pulmonary infection, which in immunocompetent hosts is usually contained. In patients with advanced HIV (CD4 <100), the organism disseminates hematogenously to the central nervous system, where its polysaccharide capsule inhibits phagocytosis and allows uncontrolled replication. Cryptococcal meningitis is the most common cause of meningitis in AIDS patients.\n\nCLINICAL PRESENTATION:\nUnlike bacterial meningitis, cryptococcal meningitis has an indolent, subacute presentation developing over days to weeks. Headache is the predominant symptom, often severe. Fever, altered mental status, and neck stiffness may be present but are less pronounced than in bacterial meningitis. Elevated intracranial pressure is common and is the major cause of early mortality; papilledema or cranial nerve palsies suggest dangerously elevated ICP.\n\nDIAGNOSIS:\nLumbar puncture typically shows elevated opening pressure (often >25 cm H2O), lymphocytic pleocytosis, elevated protein, and low glucose. India ink preparation reveals encapsulated yeast in 70-90% of HIV-associated cases. Cryptococcal antigen in CSF and serum is highly sensitive and specific and should be obtained when clinical suspicion exists.\n\nTREATMENT:\nInduction therapy for 2 weeks consists of amphotericin B deoxycholate plus flucytosine; this combination is superior to amphotericin alone. Consolidation therapy with fluconazole 400-800mg daily follows for 8 weeks. Maintenance therapy with fluconazole 200mg daily continues until immune reconstitution (CD4 >100 for â‰¥1 year with undetectable viral load). Serial lumbar punctures are critical to manage elevated ICP.\n\nKEY LEARNING POINTS:\nCryptococcal meningitis presents subacutely with headache in AIDS patients with CD4 <100. India ink and cryptococcal antigen confirm diagnosis. Induction requires amphotericin B plus flucytosine, not fluconazole alone. Elevated ICP management with serial LPs is critical for survival."
  },
  {
    "id": 592,
    "categoryId": 17,
    "question": "A 60-year-old diabetic presents with severe ear pain, granulation tissue in the ear canal, and CN VII palsy. CT shows skull base erosion. What is the most likely pathogen?",
    "options": [
      "A) Staphylococcus aureus",
      "B) Pseudomonas aeruginosa",
      "C) Aspergillus",
      "D) Mucor"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Pseudomonas aeruginosa).\n\nPATHOPHYSIOLOGY:\nMalignant (necrotizing) otitis externa is an aggressive, invasive infection that extends from the external auditory canal into the temporal bone and skull base. Pseudomonas aeruginosa is the causative organism in over 95% of cases. The infection begins as severe otitis externa, then spreads through the fissures of Santorini and the osseocartilaginous junction at the floor of the ear canal into the periosteum and bone. Progressive osteomyelitis of the temporal bone can extend to involve the skull base, petrous apex, and contralateral side.\n\nRISK FACTORS:\n- Diabetes mellitus (most common predisposing condition, present in 90% of cases)\n- Immunocompromised states (HIV/AIDS, chemotherapy, transplant recipients)\n- Elderly patients\n- Microangiopathy and impaired immune function in diabetics create a favorable environment for Pseudomonas invasion\n\nCLINICAL PRESENTATION:\n- Severe, deep ear pain disproportionate to examination findings, often worse at night\n- Purulent otorrhea refractory to topical antibiotic therapy\n- Granulation tissue at the osseocartilaginous junction of the ear canal (classic finding)\n- Cranial nerve palsies: CN VII (facial nerve) is affected first and most commonly; CN IX, X, XI, XII involvement indicates progressive skull base disease\n- CT temporal bone shows bony erosion; technetium-99m bone scan or gallium-67 scan assesses disease extent\n\nTREATMENT:\n1. Prolonged IV anti-pseudomonal antibiotics for 6-8 weeks minimum:\n   - Ciprofloxacin (oral, if susceptible) or IV anti-pseudomonal beta-lactam (piperacillin-tazobactam, cefepime)\n   - Culture-directed therapy is essential\n2. Strict glycemic control\n3. Surgical debridement for refractory cases or abscess formation\n4. Serial inflammatory markers (ESR, CRP) and imaging to monitor treatment response\n\nKEY LEARNING POINTS:\nMalignant otitis externa is caused by Pseudomonas aeruginosa in diabetic or immunocompromised patients. Granulation tissue in the ear canal and disproportionate pain are hallmarks. Facial nerve palsy (CN VII) is the most common cranial nerve complication. Treatment requires prolonged anti-pseudomonal therapy for a minimum of 6 weeks.\n\nREFERENCES:\nAAO-HNS; IDSA; UpToDate; Harrison's Principles of Internal Medicine.\n---"
  },
  {
    "id": 593,
    "categoryId": 8,
    "question": "A healthcare worker has a needlestick injury from an HIV-positive patient. She presents within 2 hours. According to CDC guidelines, when should post-exposure prophylaxis (PEP) be initiated?",
    "options": [
      "A) Within 72 hours, ideally within 2 hours",
      "B) Within 7 days",
      "C) Only if source has detectable viral load",
      "D) Only after baseline HIV testing confirms negative status"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Within 72 hours, ideally within 2 hours).\n\nPATHOPHYSIOLOGY:\nFollowing a percutaneous needlestick injury from an HIV-positive source, the virus must establish local infection in dendritic cells and CD4+ T lymphocytes before disseminating to regional lymph nodes and eventually establishing systemic infection with integration into the host genome. This brief window between inoculation and systemic dissemination represents the opportunity for post-exposure prophylaxis (PEP) to prevent infection. The average risk of HIV transmission from a percutaneous needlestick with HIV-infected blood is approximately 0.3% (1 in 300), though this varies with the source patientâ€™s viral load, depth of injury, device type, and presence of visible blood.\n\nCLINICAL REASONING:\nCDC guidelines recommend initiating PEP as soon as possible, ideally within 2 hours of exposure. The 72-hour window represents the outer limit of potential efficacy; beyond this timeframe, viral integration has likely occurred and PEP is not recommended. Animal studies demonstrate that efficacy declines dramatically with each hour of delay. Emergency departments should maintain PEP starter packs for immediate initiation without waiting for source patient confirmatory testing or specialist consultation.\n\nTREATMENT:\nThe preferred PEP regimen is a 3-drug combination of tenofovir disoproxil fumarate/emtricitabine (Truvada) plus either raltegravir or dolutegravir, continued for 28 days. Baseline HIV testing of the exposed worker documents seronegative status but must not delay PEP initiation. Follow-up HIV testing is performed at 6 weeks, 12 weeks, and 6 months post-exposure. Higher-risk exposures (deep injury, visible blood on device, hollow-bore needle, source with high viral load) warrant PEP without hesitation.\n\nKEY LEARNING POINTS:\nPEP must be initiated within 72 hours, ideally within 2 hours of HIV exposure. Do not delay PEP for baseline testing or specialist consultation. The standard regimen is a 28-day, 3-drug antiretroviral combination. Percutaneous HIV transmission risk is approximately 0.3%.\n\nREFERENCES:\nCDC Updated Guidelines for Occupational HIV PEP; UpToDate; Harrison's Principles of Internal Medicine.\n---"
  },
  {
    "id": 594,
    "categoryId": 8,
    "question": "A 55-year-old man from the Ohio River Valley presents with fever, cough, and hilar lymphadenopathy. He recently cleaned an old barn. Urine antigen test is positive. What is the diagnosis?",
    "options": [
      "A) Blastomycosis",
      "B) Histoplasmosis",
      "C) Coccidioidomycosis",
      "D) Tuberculosis"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Histoplasmosis).\n\nPATHOPHYSIOLOGY:\nHistoplasma capsulatum is a dimorphic fungus endemic to the Ohio and Mississippi River Valleys. It thrives in soil enriched by bird or bat droppings, and inhalation of microconidia during activities that disturb contaminated soil (demolition of old buildings, exploring caves, cleaning chicken coops) leads to pulmonary infection. At body temperature, the organism converts to its pathogenic yeast form and is phagocytosed by alveolar macrophages, within which it survives, replicates, and disseminates via the reticuloendothelial system.\n\nCLINICAL PRESENTATION:\nApproximately 90% of infections are asymptomatic or produce a mild, self-limited flu-like illness. Acute pulmonary histoplasmosis presents with fever, cough, chest pain, and malaise 1-3 weeks after exposure. Chest imaging characteristically demonstrates hilar and mediastinal lymphadenopathy, sometimes with pulmonary infiltrates â€” captured by the mnemonic \"histo hits the hilum.\" Chronic cavitary histoplasmosis mimics pulmonary tuberculosis in patients with underlying emphysema. Progressive disseminated histoplasmosis occurs in immunocompromised patients (especially advanced HIV) and presents with fever, weight loss, hepatosplenomegaly, and pancytopenia.\n\nDIAGNOSIS:\nUrine and serum Histoplasma antigen testing offers high sensitivity for acute and disseminated disease and is the preferred rapid diagnostic test. Serology (complement fixation, immunodiffusion) supports diagnosis but may be negative early or in immunocompromised patients. Fungal culture and histopathology revealing small intracellular yeast (2-4 Î¼m) within macrophages are definitive.\n\nTREATMENT:\nMild acute pulmonary disease typically resolves spontaneously within 4 weeks and requires only observation. Moderate-to-severe pulmonary disease warrants itraconazole for 6-12 weeks. Severe pulmonary or disseminated disease requires induction with amphotericin B followed by consolidation with itraconazole for at least 12 months.\n\nKEY LEARNING POINTS:\nHistoplasmosis is endemic to the Ohio and Mississippi River Valleys, transmitted via bird or bat droppings. \"Histo hits the hilum\" describes the characteristic hilar lymphadenopathy. Most cases are self-limited; severe or disseminated disease requires amphotericin B followed by itraconazole.\n\nREFERENCES:\nIDSA Histoplasmosis Management Guidelines; UpToDate; Harrison's Principles of Internal Medicine.\n---"
  },
  {
    "id": 595,
    "categoryId": 8,
    "question": "A 70-year-old nursing home resident with recent antibiotic use presents with watery diarrhea (10 episodes/day), abdominal pain, and WBC 22,000. Stool PCR is positive for C. difficile. Creatinine is 1.8 (baseline 1.0). What is the recommended treatment?",
    "options": [
      "A) Oral Metronidazole 500mg TID x 10 days",
      "B) Oral Vancomycin 125mg QID x 10 days",
      "C) Oral Fidaxomicin 200mg BID x 10 days",
      "D) IV Vancomycin"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Oral Vancomycin 125mg QID x 10 days).\n\nPATHOPHYSIOLOGY:\nClostridioides difficile is a spore-forming, gram-positive anaerobic bacillus that colonizes the colon when the normal gut microbiome is disrupted, most commonly by antibiotic exposure. The highest-risk antibiotics are clindamycin, fluoroquinolones, and broad-spectrum cephalosporins. C. difficile produces toxin A (enterotoxin) and toxin B (cytotoxin), which bind to colonocyte receptors, disrupt tight junctions, trigger intense neutrophilic inflammation, and cause the formation of pseudomembranes composed of fibrin, mucus, and inflammatory debris.\n\nCLINICAL PRESENTATION:\nPatients typically present with watery, nonbloody diarrhea (often >10 episodes per day), crampy abdominal pain, fever, and leukocytosis. Risk factors include recent antibiotic use, age over 65, hospitalization or nursing home residence, and proton pump inhibitor use. Severity is classified by the IDSA/SHEA 2021 guidelines: non-severe (WBC â‰¤15,000 and creatinine <1.5x baseline), severe (WBC >15,000 or creatinine â‰¥1.5x baseline), and fulminant (hypotension, shock, ileus, or megacolon).\n\nTREATMENT:\nFor non-severe initial episodes, fidaxomicin is now preferred over vancomycin due to lower recurrence rates, though oral vancomycin remains acceptable. For severe disease, as in this patient (WBC >15,000), oral vancomycin 125mg four times daily for 10 days is the standard of care. For fulminant disease, oral vancomycin is combined with IV metronidazole, and rectal vancomycin enemas should be considered if ileus is present. IV vancomycin does not reach the colonic lumen and is ineffective for C. difficile infection. Metronidazole is no longer recommended as first-line monotherapy due to inferior efficacy.\n\nKEY LEARNING POINTS:\nSevere C. difficile (WBC >15,000 or creatinine â‰¥1.5x baseline) requires oral vancomycin. IV vancomycin does not reach the colon and is ineffective. Fidaxomicin is now preferred for non-severe initial episodes. Metronidazole is no longer first-line monotherapy.\n\nREFERENCES:\nIDSA/SHEA 2021 C. difficile Guidelines; UpToDate; Harrison's Principles of Internal Medicine.\n---"
  },
  {
    "id": 596,
    "categoryId": 8,
    "question": "A 25-year-old sexually active woman presents with mucopurulent cervical discharge. NAAT is positive for Chlamydia trachomatis. Per CDC 2021 guidelines, what is the recommended treatment?",
    "options": [
      "A) Azithromycin 1g PO x 1 dose",
      "B) Doxycycline 100mg PO BID x 7 days",
      "C) Ceftriaxone 500mg IM x 1",
      "D) Levofloxacin 500mg PO daily x 7 days"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Doxycycline 100mg BID x 7 days).\n\nPATHOPHYSIOLOGY:\nChlamydia trachomatis (serovars D-K) is an obligate intracellular bacterium and the most common bacterial sexually transmitted infection in the United States. The organism infects columnar epithelial cells of the cervix, urethra, rectum, and pharynx, undergoing a unique developmental cycle alternating between the infectious elementary body and the replicative reticulate body. The host inflammatory response causes mucosal damage, which, if untreated, can lead to ascending infection and scarring.\n\nCLINICAL PRESENTATION:\nUp to 70% of women and 50% of men with chlamydial infection are asymptomatic. When symptomatic, women typically present with mucopurulent cervical discharge, postcoital bleeding, or dysuria. Untreated infection can ascend to cause pelvic inflammatory disease (PID), which may result in tubal scarring, ectopic pregnancy, and infertility. In men, urethritis and epididymitis are the primary complications. Reactive arthritis (formerly Reiter syndrome) is an uncommon but important sequela.\n\nTREATMENT:\nThe CDC 2021 STI Treatment Guidelines now recommend doxycycline 100mg twice daily for 7 days as the preferred treatment for uncomplicated chlamydia, based on superior efficacy data, particularly for rectal infections where azithromycin cure rates are significantly lower. Azithromycin 1g as a single dose remains an alternative when adherence is a concern. In pregnancy, azithromycin is the treatment of choice because doxycycline is contraindicated. Test of cure is not routinely needed except in pregnancy; retesting at 3 months is recommended due to high reinfection rates. All sexual partners from the preceding 60 days should be treated.\n\nKEY LEARNING POINTS:\nDoxycycline 100mg BID for 7 days is now preferred over azithromycin for uncomplicated chlamydia per CDC 2021 guidelines. Azithromycin remains the preferred agent in pregnancy. Retest at 3 months for reinfection. Treat all recent sexual partners.\n\nREFERENCES:\nCDC 2021 STI Treatment Guidelines; UpToDate; Harrison's Principles of Internal Medicine.\n---"
  },
  {
    "id": 597,
    "categoryId": 8,
    "question": "A 50-year-old hunter in the Northeast US presents with fever, headache, and a targetoid rash on his thigh. He removed an attached tick 1 week ago. What is the treatment for early Lyme disease?",
    "options": [
      "A) Doxycycline 100mg BID x 10-14 days",
      "B) Amoxicillin 500mg TID x 14-21 days",
      "C) Ceftriaxone 2g IV daily x 14 days",
      "D) Azithromycin 500mg daily x 5 days"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Doxycycline 100mg BID x 10-14 days).\n\nPATHOPHYSIOLOGY:\nLyme disease is caused by the spirochete Borrelia burgdorferi, transmitted through the bite of infected Ixodes (blacklegged or deer) ticks. The tick must be attached for at least 36-48 hours to transmit the organism, as the spirochete requires time to migrate from the tick midgut to salivary glands. Endemic areas include the Northeast (Maine to Virginia), Upper Midwest (Minnesota, Wisconsin), and Pacific coast. After inoculation into the skin, the spirochete disseminates through the bloodstream and lymphatics to joints, the heart, and the nervous system.\n\nCLINICAL PRESENTATION:\nErythema migrans (EM) is the hallmark of early localized Lyme disease, appearing 3-30 days after the tick bite. The classic \"bullâ€™s-eye\" or target lesion with central clearing is present in only about 20% of cases; more commonly, EM appears as a uniformly erythematous, expanding patch that must reach at least 5 cm. Systemic symptoms including fatigue, myalgias, arthralgias, headache, and fever often accompany the rash. Disseminated Lyme (Stage 2) can cause multiple EM lesions, facial nerve palsy, meningitis, or cardiac conduction abnormalities (Lyme carditis with AV block). Late Lyme (Stage 3) typically manifests as migratory oligoarticular arthritis, especially of the knee.\n\nDIAGNOSIS AND TREATMENT:\nEarly localized Lyme disease with EM is a clinical diagnosis; serologic testing is often negative in the first weeks and should not delay treatment. Doxycycline 100mg BID for 10-14 days is first-line and also covers potential co-infections (Anaplasma, Ehrlichia) from the same tick bite. Alternatives for children under 8 or pregnant women include amoxicillin or cefuroxime for 14-21 days. Azithromycin is not recommended due to inferior efficacy.\n\nKEY LEARNING POINTS:\nErythema migrans is a clinical diagnosis; do not delay treatment for serologic confirmation. Doxycycline 100mg BID for 10-14 days is first-line. Classic bullâ€™s-eye appearance occurs in only 20% of cases. Azithromycin is not recommended for Lyme disease.\n\nREFERENCES:\nIDSA/AAN/ACR 2020 Lyme Disease Guidelines; CDC Lyme Disease Guidance; UpToDate; Harrison's Principles of Internal Medicine.\n---"
  },
  {
    "id": 598,
    "categoryId": 8,
    "question": "A 40-year-old male with well-controlled HIV (CD4 500, undetectable viral load) asks about vaccinations. Which live vaccine may be given if CD4 is â‰¥200?",
    "options": [
      "A) Live attenuated influenza (nasal spray)",
      "B) BCG",
      "C) MMR",
      "D) Oral polio"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (MMR may be given if CD4 â‰¥200).\n\nPATHOPHYSIOLOGY:\nHIV infection progressively depletes CD4+ T lymphocytes, impairing cell-mediated immunity and increasing susceptibility to opportunistic infections and vaccine-preventable diseases. The CD4 count serves as a practical marker of immune competence: patients with CD4 counts below 200 cells/Î¼L have severely impaired cellular immunity and cannot safely control replicating organisms in live attenuated vaccines, while those with higher counts can mount adequate immune responses to contain attenuated vaccine viruses.\n\nCLINICAL REASONING:\nVaccination decisions in HIV-infected individuals must balance the need for infection prevention against the risk of vaccine-associated disease from live attenuated vaccines. Inactivated vaccines are safe at any CD4 count and should be given routinely: influenza (inactivated only), pneumococcal (PCV20 or PCV15 followed by PPSV23), hepatitis A and B, Tdap/Td, recombinant zoster (Shingrix), HPV, and COVID-19 vaccines. Vaccine response rates are lower in patients with suppressed CD4 counts, so vaccination is optimally administered after immune reconstitution on antiretroviral therapy when feasible.\n\nLIVE VACCINES IN HIV:\nMMR and varicella vaccines may be administered to HIV patients with CD4 counts â‰¥200 cells/Î¼L who lack evidence of immunity, as these patients can mount sufficient cellular immune responses to control the attenuated viruses. This is clinically important because measles and varicella cause severe, potentially fatal disease in immunocompromised hosts. If CD4 count is below 200, live vaccines must be deferred until immune reconstitution. Live attenuated influenza vaccine (LAIV), BCG, oral polio vaccine, and live oral typhoid vaccine are contraindicated regardless of CD4 count.\n\nKEY LEARNING POINTS:\nMMR and varicella vaccines may be given to HIV patients with CD4 â‰¥200 but are contraindicated if CD4 <200. All inactivated vaccines are safe regardless of CD4 count. LAIV, BCG, oral polio, and live typhoid are always contraindicated in HIV-infected patients.\n\nREFERENCES:\nCDC Immunization of Immunocompromised Persons; NIH OI Prevention Guidelines; UpToDate; Harrison's Principles of Internal Medicine.\n---"
  },
  {
    "id": 599,
    "categoryId": 10,
    "question": "A 35-year-old woman presents with symmetric, silvery, scaly plaques on her elbows and knees with nail pitting. What is the first-line treatment for limited plaque psoriasis (<5% BSA)?",
    "questionImages": [
      {
        "src": "assets/plaque-psoriasis-question.png",
        "alt": "Plaque psoriasis on the elbow with silvery scale",
        "caption": "Question image: classic plaque psoriasis on an extensor surface."
      }
    ],
    "options": [
      "A) Oral Methotrexate",
      "B) Topical corticosteroids + Vitamin D analogs",
      "C) Phototherapy (UVB)",
      "D) Biologics (TNF inhibitors)"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Topical corticosteroids + Vitamin D analogs).\n\nPATHOPHYSIOLOGY:\nPsoriasis is a chronic, immune-mediated inflammatory disease driven by dysregulated T-helper cell activation, predominantly Th1 and Th17 pathways. In genetically susceptible individuals, environmental triggers (infection, stress, medications such as lithium or beta-blockers, trauma via the Koebner phenomenon) activate dendritic cells, which release IL-12 and IL-23. These cytokines stimulate Th1 and Th17 cells to produce TNF-alpha, IL-17, and IL-22, creating a self-amplifying inflammatory loop that accelerates keratinocyte proliferation from the normal 28-day turnover cycle to 3 to 4 days. The result is the characteristic thickened, erythematous plaques with silvery scale reflecting the massive accumulation of immature keratinocytes that cannot be shed quickly enough. The prominent vascular dilation in the dermal papillae produces the erythematous base, and the Auspitz sign (pinpoint bleeding upon scale removal) results from disruption of these dilated capillaries within elongated dermal papillae.\n\nCLINICAL PRESENTATION:\nPlaque psoriasis (psoriasis vulgaris), the most common subtype comprising approximately 80 to 90% of cases, presents with well-demarcated, symmetrically distributed, erythematous plaques with adherent silvery-white scale on extensor surfaces (elbows, knees), scalp, lower back, and gluteal cleft. Nail involvement occurs in approximately 50% of patients and includes pitting (the most common finding, representing focal parakeratosis of the nail matrix), onycholysis, oil-drop discoloration, and subungual hyperkeratosis. Nail disease strongly correlates with psoriatic arthritis development and should prompt heightened surveillance.\n\nTREATMENT APPROACH:\nThe AAD and National Psoriasis Foundation joint guidelines recommend a stepwise approach stratified by body surface area and quality-of-life impact. For limited plaque psoriasis (less than 5% BSA), first-line therapy consists of topical corticosteroids combined with vitamin D analogs (calcipotriene). The combination is synergistic: corticosteroids suppress inflammation and immune activation, while calcipotriene inhibits keratinocyte proliferation and promotes differentiation through vitamin D receptor-mediated gene transcription. Fixed-combination calcipotriene-betamethasone dipropionate formulations (such as Enstilar foam) improve adherence and efficacy. Topical calcineurin inhibitors are useful for facial and intertriginous psoriasis where steroid atrophy is a concern. For moderate-to-severe disease (greater than 5-10% BSA or significant quality-of-life impairment), phototherapy (narrowband UVB), conventional systemic agents (methotrexate, cyclosporine, acitretin, apremilast), or biologic therapies are indicated.\n\nCOMORBIDITY SCREENING:\nPsoriasis is now recognized as a systemic inflammatory disease associated with significant comorbidities. Psoriatic arthritis develops in approximately 30% of patients and should be screened for at every visit using questions about morning stiffness, joint pain, and enthesitis. Patients with moderate-to-severe psoriasis have a 50% increased risk of cardiovascular disease (myocardial infarction and stroke) due to shared inflammatory pathways, and screening for metabolic syndrome, diabetes, obesity, and dyslipidemia is recommended. Depression and anxiety affect up to 30% of psoriasis patients and should be assessed routinely.\n\nKEY LEARNING POINTS:\nTopical corticosteroids combined with vitamin D analogs are first-line for limited plaque psoriasis affecting less than 5% BSA. Psoriasis results from Th17-driven immune dysregulation that accelerates keratinocyte turnover from 28 days to 3 to 4 days. Nail pitting is present in 50% and correlates with psoriatic arthritis risk. Screen all patients for psoriatic arthritis, cardiovascular disease, metabolic syndrome, and depression."
  },
  {
    "id": 600,
    "categoryId": 10,
    "question": "A mother brings her 8-year-old with an itchy, coin-shaped, weeping lesion on the leg with a well-defined border and tiny vesicles. KOH prep is negative. What is the diagnosis?",
    "options": [
      "A) Tinea corporis",
      "B) Nummular eczema",
      "C) Psoriasis",
      "D) Contact dermatitis"
    ],
    "correctAnswer": 1,
    "explanationImages": [
      {
        "src": "assets/discoid-eczema-dermnet.png",
        "alt": "Discoid eczema lesions over time showing coin-shaped plaques",
        "caption": "Discoid eczema progression with coin-shaped eczematous plaques over several days."
      }
    ],
    "explanation": "CORRECT: B (Nummular eczema).\n\nPATHOPHYSIOLOGY:\nNummular eczema (nummular dermatitis or discoid eczema) is a chronic inflammatory skin condition characterized by coin-shaped (nummular, from the Latin 'nummulus' meaning coin) plaques resulting from epidermal barrier dysfunction and immune dysregulation. The pathogenesis involves impaired production of filaggrin and ceramides in the stratum corneum, leading to increased transepidermal water loss and susceptibility to environmental irritants and allergens. This barrier disruption triggers a Th2-dominant immune response with release of IL-4, IL-13, and IL-31 (the 'itch cytokine'), producing the characteristic pruritic inflammatory plaques. Dry skin (xerosis) is the most significant predisposing factor, explaining why the condition worsens in winter and in low-humidity environments. Other associated factors include atopic dermatitis history, contact allergen sensitization (nickel is particularly common), venous stasis in lower extremity lesions, and emotional stress.\n\nCLINICAL PRESENTATION:\nLesions begin as grouped papulovesicles that coalesce into well-demarcated, round to oval plaques ranging from 1 to 10 centimeters in diameter. Acute lesions are erythematous and may be weeping or crusted with tiny vesicles at the periphery. Chronic lesions become lichenified (thickened with accentuated skin markings), scaly, and hyperpigmented. The legs are the most commonly affected site in men, while women more often develop lesions on the upper extremities and trunk. Lesions are intensely pruritic, and secondary excoriations and bacterial superinfection (impetiginization with S. aureus) are common complications.\n\nDIAGNOSIS AND DIFFERENTIAL:\nThe critical diagnostic distinction is from tinea corporis (dermatophyte infection), which is the most important mimicker. Tinea corporis classically shows annular plaques with an active, raised, scaly border and central clearing ('ringworm' pattern), whereas nummular eczema involves the entire surface uniformly without central clearing. The KOH preparation is the essential bedside test: a negative KOH (as in this patient) rules out dermatophyte infection. If KOH shows septate, branching hyphae, the diagnosis is tinea and antifungal therapy is indicated. Other differential diagnoses include psoriasis (silvery scale, extensor surfaces, nail changes), contact dermatitis (geometric or linear distribution matching the contactant), and rarely nummular-type mycosis fungoides (cutaneous T-cell lymphoma), which should be considered in refractory cases warranting biopsy.\n\nMANAGEMENT:\nFirst-line treatment consists of aggressive emollient therapy to restore epidermal barrier function (fragrance-free creams or ointments applied immediately after bathing) combined with medium-potency topical corticosteroids (triamcinolone 0.1% ointment) applied to active lesions twice daily for 2 to 4 weeks. For recalcitrant lesions, high-potency steroids (clobetasol) may be used for short courses on the body. Topical calcineurin inhibitors (tacrolimus, pimecrolimus) are useful as steroid-sparing maintenance therapy, particularly for facial or intertriginous involvement. Secondary bacterial infection requires oral antibiotics (cephalexin or dicloxacillin for S. aureus coverage). Phototherapy with narrowband UVB is effective for widespread disease.\n\nKEY LEARNING POINTS:\nNummular eczema presents with coin-shaped, uniformly involved plaques without central clearing, distinguishing it from tinea corporis which shows annular lesions with active borders and central clearing. A negative KOH preparation is essential to exclude dermatophyte infection. Treatment centers on barrier repair with emollients and medium-potency topical corticosteroids. Secondary staphylococcal infection is common and should be treated when suspected."
  },
  {
    "id": 601,
    "categoryId": 10,
    "question": "A 22-year-old with moderate acne has failed topical benzoyl peroxide and adapalene after 12 weeks. She uses reliable contraception. What is the next step?",
    "options": [
      "A) Add oral antibiotic (doxycycline)",
      "B) Switch to tretinoin cream",
      "C) Start isotretinoin",
      "D) Add topical clindamycin alone"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Add oral antibiotic).\n\nPATHOPHYSIOLOGY OF ACNE:\nAcne vulgaris results from four interrelated processes: follicular hyperkeratinization causing plugging, excess sebum production stimulated by androgens, colonization by Cutibacterium acnes (formerly Propionibacterium acnes), and inflammation. Mild comedonal acne involves primarily the first two processes, while moderate-to-severe inflammatory acne involves all four, requiring treatment strategies that target bacterial proliferation and inflammation.\n\nACNE TREATMENT LADDER:\nMild comedonal acne responds to topical retinoids, which normalize follicular keratinization. Mild inflammatory acne benefits from adding benzoyl peroxide (bactericidal) and/or topical antibiotics. Moderate inflammatory acne, as in this patient who has failed topical therapy, warrants escalation to oral antibiotics combined with topical retinoid and benzoyl peroxide. Severe nodulocystic acne or acne unresponsive to oral antibiotics requires isotretinoin referral.\n\nORAL ANTIBIOTIC PRINCIPLES:\nDoxycycline 50-100mg daily or minocycline are first-line oral antibiotics for acne due to their anti-inflammatory properties beyond antibacterial effects. Antibiotics should never be used as monotherapy because resistance develops rapidly; always combine with benzoyl peroxide (which prevents resistance) and topical retinoid. Limit oral antibiotic duration to 3-4 months, then transition to topical maintenance therapy.\n\nHORMONAL THERAPY:\nFor women with acne following a hormonal pattern (jawline distribution, premenstrual flares, signs of hyperandrogenism), combined oral contraceptives or spironolactone are effective adjuncts and allow earlier discontinuation of antibiotics.\n\nKEY LEARNING POINTS:\nModerate acne failing topical therapy warrants oral antibiotics plus topical retinoid plus benzoyl peroxide. Never use oral antibiotics as monotherapy; always combine with benzoyl peroxide to prevent resistance. Limit antibiotic duration to 3-4 months. Consider hormonal therapy in women with appropriate acne pattern."
  },
  {
    "id": 602,
    "categoryId": 10,
    "question": "A 65-year-old presents with a pearly, dome-shaped papule with telangiectasias and central depression on his nose. What is the most likely diagnosis?",
    "questionImages": [
      {
        "src": "assets/derm-0702.png",
        "alt": "Pearly dome-shaped facial papule suggestive of basal cell carcinoma",
        "caption": "Question image: pearly papule with rolled border on the face."
      }
    ],
    "options": [
      "A) Squamous cell carcinoma",
      "B) Basal cell carcinoma",
      "C) Melanoma",
      "D) Sebaceous hyperplasia"
    ],
    "correctAnswer": 1,
    "explanationImages": [
      {
        "src": "assets/derm-0715.png",
        "alt": "Basal cell carcinoma with central ulceration and pearly border",
        "caption": "Explanation image: classic nodular basal cell carcinoma with central ulceration."
      }
    ],
    "explanation": "CORRECT: B (Basal cell carcinoma).\n\nPATHOPHYSIOLOGY:\nBasal cell carcinoma (BCC) is the most common human malignancy worldwide, accounting for approximately 80% of all non-melanoma skin cancers, with an estimated 3.6 million cases diagnosed annually in the United States per the American Cancer Society. BCC arises from aberrant activation of the Hedgehog signaling pathway in basal keratinocytes of the interfollicular epidermis and hair follicle. In normal tissue, the Patched (PTCH1) transmembrane receptor inhibits the Smoothened (SMO) signal transducer. Ultraviolet radiation induces mutations in the PTCH1 gene (found in approximately 70% of sporadic BCCs) or activating mutations in SMO, leading to constitutive Hedgehog pathway activation and uncontrolled basal cell proliferation. Cumulative UV exposure, particularly UVB (290 to 320 nm), is the primary risk factor, causing characteristic CC-to-TT transition mutations (UV signature mutations) in tumor suppressor genes. Fair skin (Fitzpatrick types I-II), history of sunburns, immunosuppression (organ transplant recipients have a 10-fold increased risk), and prior radiation therapy are additional risk factors. Gorlin syndrome (nevoid BCC syndrome), caused by germline PTCH1 mutations, results in multiple BCCs appearing at a young age.\n\nCLINICAL PRESENTATION:\nThe classic nodular BCC, the most common subtype (60 to 80%), presents as a pearly or translucent papule or nodule with a smooth, dome-shaped surface, visible arborizing telangiectasias, and rolled (raised) borders. Central ulceration with a crusted depression ('rodent ulcer') develops as the tumor outgrows its blood supply. The head and neck account for approximately 85% of BCCs, with the nose being the single most common location. Other subtypes include superficial BCC (erythematous, scaly patch, often on the trunk, resembling eczema or psoriasis), morpheaform or infiltrative BCC (ill-defined, scar-like plaque with indistinct borders representing a more aggressive variant), and pigmented BCC (containing melanin, which can mimic melanoma). Dermoscopy reveals characteristic arborizing (tree-like) vessels, blue-gray ovoid nests, and leaf-like structures that help distinguish BCC from other lesions.\n\nMANAGEMENT:\nTreatment selection depends on tumor subtype, size, location, and whether the tumor is primary or recurrent. For low-risk BCCs (nodular or superficial subtype, small size, on the trunk or extremities), standard surgical excision with 4-millimeter clinical margins achieves cure rates exceeding 95%. Electrodesiccation and curettage (ED&C) is appropriate for small, superficial BCCs on low-risk sites. For high-risk BCCs (located on the face, especially the nose, periorbital, or periauricular areas, or morpheaform or recurrent tumors), Mohs micrographic surgery is the gold standard, providing the highest cure rate (99%) while maximizing tissue conservation through real-time margin assessment. For superficial BCC, topical therapies including imiquimod 5% cream (which activates toll-like receptor 7 to stimulate antitumor immunity) and topical 5-fluorouracil are alternatives in select patients. Advanced or metastatic BCC (exceedingly rare, occurring in less than 0.5% of cases) is treated with Hedgehog pathway inhibitors (vismodegib, sonidegib), which target SMO and can produce dramatic responses.\n\nKEY LEARNING POINTS:\nBCC is the most common skin cancer, driven by Hedgehog pathway dysregulation from UV-induced PTCH1 mutations. The classic pearly papule with telangiectasias and rolled borders on the nose or central face is the hallmark presentation. BCC is locally destructive but almost never metastasizes. Mohs micrographic surgery is the gold standard for high-risk facial BCCs, while standard excision suffices for low-risk tumors. Hedgehog pathway inhibitors represent targeted therapy for advanced disease."
  },
  {
    "id": 603,
    "categoryId": 10,
    "question": "A patient starting a TNF inhibitor (adalimumab) for psoriasis has a positive PPD with negative chest X-ray. What must be done before starting the biologic?",
    "options": [
      "A) No treatment needed",
      "B) Treat latent TB for 1-2 months before starting biologic",
      "C) Start both simultaneously",
      "D) TNF inhibitors are contraindicated"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Treat latent TB for 1-2 months before starting biologic).\n\nPATHOPHYSIOLOGY:\nTumor necrosis factor-alpha (TNF-alpha) is a pivotal cytokine in the host defense against Mycobacterium tuberculosis. In latent tuberculosis infection (LTBI), the immune system contains viable but dormant bacilli within granulomas, organized structures of macrophages, epithelioid cells, and multinucleated giant cells surrounded by a T-cell cuff. TNF-alpha plays an essential role in granuloma formation, maintenance, and intracellular killing of mycobacteria by activating macrophages and promoting phagolysosome fusion. When a TNF inhibitor (adalimumab, infliximab, etanercept, certolizumab, golimumab) neutralizes TNF-alpha, these granulomas can disintegrate, releasing dormant bacilli and allowing uncontrolled mycobacterial replication. Studies published in JAMA and the New England Journal of Medicine have demonstrated that TNF inhibitor therapy increases the risk of tuberculosis reactivation 2- to 30-fold depending on the specific agent, with monoclonal antibodies (infliximab, adalimumab) carrying higher risk than the soluble receptor construct (etanercept) because of their greater impact on granuloma integrity.\n\nSCREENING REQUIREMENTS:\nAll patients must be screened for LTBI before initiating any TNF inhibitor, regardless of the indication (psoriasis, rheumatoid arthritis, inflammatory bowel disease, ankylosing spondylitis). Screening includes a thorough history assessing TB risk factors (birth or prolonged residence in endemic countries, healthcare work, incarceration, homeless shelter exposure, close contact with active TB), either a tuberculin skin test (TST/PPD) or an interferon-gamma release assay (IGRA such as QuantiFERON-Gold Plus or T-SPOT.TB), and a baseline chest radiograph. The IGRA is preferred in BCG-vaccinated patients because it avoids false-positive results from prior vaccination. A positive screening test with a negative chest radiograph, as in this patient, defines LTBI.\n\nMANAGEMENT OF LTBI BEFORE BIOLOGIC INITIATION:\nCurrent guidelines from the CDC, ATS, and IDSA recommend initiating LTBI treatment at least 1 to 2 months before starting the TNF inhibitor to reduce the mycobacterial burden sufficiently to lower reactivation risk, while completing the full LTBI treatment course concurrently. Preferred regimens include 3 months of once-weekly isoniazid plus rifapentine (3HP), 4 months of daily rifampin, or 9 months of daily isoniazid. The 3HP regimen has the highest completion rates due to its shorter duration and weekly dosing. Hepatotoxicity monitoring with baseline and periodic liver function tests is required, particularly with isoniazid-containing regimens.\n\nADDITIONAL PRE-BIOLOGIC SCREENING:\nBeyond TB, pre-biologic workup includes hepatitis B serologies (HBsAg, anti-HBc, anti-HBs) because TNF inhibitors can cause fatal HBV reactivation, hepatitis C screening, baseline CBC with differential, comprehensive metabolic panel, and age-appropriate cancer screening. Live vaccines (varicella, MMR, live zoster) must be administered at least 2 to 4 weeks before starting therapy because TNF inhibitors impair the immune response to live attenuated organisms.\n\nKEY LEARNING POINTS:\nTNF-alpha is essential for maintaining granulomas that contain latent M. tuberculosis, and TNF inhibitors dramatically increase TB reactivation risk. All patients require LTBI screening (IGRA or TST plus chest radiograph) before biologic initiation. LTBI treatment should begin at least 1 to 2 months before starting the TNF inhibitor. Screen also for hepatitis B, as reactivation can be fatal, and ensure live vaccines are administered before therapy initiation."
  },
  {
    "id": 604,
    "categoryId": 10,
    "question": "A 30-year-old presents with flat-topped, polygonal, violaceous papules on wrists and ankles with fine white lines (Wickham striae). White lacy patches are on the buccal mucosa. What should be screened for?",
    "questionImages": [
      {
        "src": "assets/lichen-planus-oral-dermnet.png",
        "alt": "Reticulate oral lichen planus on buccal mucosa",
        "caption": "Reticulate white lacy lesions of oral lichen planus on the buccal mucosa."
      },
      {
        "src": "assets/lichen-planus-wrist-dermnet.png",
        "alt": "Flat-topped polygonal papules of lichen planus on volar wrist",
        "caption": "Flat-topped, shiny, polygonal papules of cutaneous lichen planus on the wrist."
      }
    ],
    "options": [
      "A) HIV",
      "B) Hepatitis C",
      "C) Syphilis",
      "D) Diabetes"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Hepatitis C).\n\nPATHOPHYSIOLOGY:\nLichen planus is a chronic, T-cell-mediated inflammatory dermatosis in which cytotoxic CD8+ T lymphocytes target basal keratinocytes, causing apoptosis at the dermal-epidermal junction. The immune attack produces the characteristic histopathologic findings of a band-like (lichenoid) lymphocytic infiltrate hugging the dermal-epidermal junction, saw-tooth irregular acanthosis of the epidermis, and Civatte bodies (colloid or apoptotic bodies representing dying keratinocytes). Wickham striae, the pathognomonic fine white reticular lines visible on the surface of papules, result from focal thickening of the granular cell layer (hypergranulosis) overlying the irregular epidermis. The condition is strongly associated with hepatitis C virus (HCV) infection, with meta-analyses demonstrating a 2- to 5-fold increased prevalence of HCV among lichen planus patients compared to the general population. The proposed mechanism involves HCV replication within oral and cutaneous epithelial cells, which alters keratinocyte antigenicity and triggers the autoimmune T-cell response. This association is most robust in Mediterranean, Japanese, and Southeast Asian populations.\n\nCLINICAL PRESENTATION:\nThe classic presentation is summarized by the '6 Ps': Purple (violaceous), Polygonal, Planar (flat-topped), Pruritic Papules and Plaques. The wrists, ankles, lower back, and shins are the most common cutaneous sites. Oral involvement occurs in approximately 50 to 70% of patients and may present as white reticular (lacy) patches on the buccal mucosa, which can be the sole manifestation. Oral erosive lichen planus causes painful ulcerations and carries a 1 to 2% risk of malignant transformation to squamous cell carcinoma, requiring long-term surveillance. Nail involvement (ridging, thinning, pterygium) occurs in approximately 10% of cases. Lichen planopilaris, the follicular variant, causes scarring alopecia. The Koebner phenomenon (lesions developing at sites of trauma) is well-documented in lichen planus.\n\nDIAGNOSIS AND SCREENING:\nThe diagnosis is often clinical based on the characteristic morphology and distribution. Biopsy confirms the diagnosis when the presentation is atypical, showing the classic lichenoid interface dermatitis pattern. Direct immunofluorescence demonstrates fibrinogen deposits in a shaggy pattern along the basement membrane zone, distinguishing lichen planus from lupus. All patients diagnosed with lichen planus should be screened for hepatitis C with HCV antibody testing, as the association is well-established and HCV treatment can improve or resolve the skin disease. A medication history is essential, as numerous drugs can cause lichenoid drug eruptions that mimic lichen planus, including ACE inhibitors, thiazide diuretics, NSAIDs, antimalarials (hydroxychloroquine), beta-blockers, and sulfonylureas. Drug-induced cases typically resolve within weeks to months of discontinuing the offending agent.\n\nMANAGEMENT:\nFirst-line treatment for cutaneous lichen planus consists of high-potency topical corticosteroids (clobetasol 0.05%) applied to affected areas. Oral disease is managed with topical corticosteroid gels or pastes (fluocinonide gel), topical tacrolimus, or intralesional triamcinolone for refractory erosions. Widespread or recalcitrant disease may require systemic therapy with oral corticosteroids for short courses, acitretin, methotrexate, or mycophenolate mofetil. Most cases of cutaneous lichen planus are self-limited, resolving within 1 to 2 years, though post-inflammatory hyperpigmentation may persist. Oral lichen planus tends to follow a more chronic relapsing course.\n\nKEY LEARNING POINTS:\nLichen planus presents with the 6 Ps (Purple, Polygonal, Planar, Pruritic Papules and Plaques) and Wickham striae are pathognomonic. All patients should be screened for hepatitis C given the 2- to 5-fold increased association. Oral erosive lichen planus carries a 1 to 2% malignant transformation risk requiring long-term monitoring. Drug-induced lichenoid eruptions from ACE inhibitors, thiazides, and NSAIDs are important mimickers that resolve with drug discontinuation."
  },
  {
    "id": 605,
    "categoryId": 10,
    "question": "A 45-year-old presents with facial flushing, central erythema, telangiectasias, and papules/pustules. No comedones are present. What is the first-line treatment?",
    "questionImages": [
      {
        "src": "assets/rosacea-question-face.png",
        "alt": "Centrofacial erythema and telangiectasias typical of rosacea",
        "caption": "Question image: persistent central facial erythema with visible telangiectasias."
      }
    ],
    "options": [
      "A) Topical metronidazole or ivermectin",
      "B) Topical benzoyl peroxide",
      "C) Oral isotretinoin",
      "D) Topical hydrocortisone"
    ],
    "correctAnswer": 0,
    "explanationImages": [
      {
        "src": "assets/rosacea-face.png",
        "alt": "Centrofacial erythema and papules consistent with rosacea",
        "caption": "Typical papulopustular rosacea pattern with persistent central facial erythema."
      }
    ],
    "explanation": "CORRECT: A (Topical metronidazole or ivermectin).\n\nPATHOPHYSIOLOGY:\nRosacea is a chronic inflammatory skin disorder of the central face driven by a complex interplay of neurovascular dysregulation, innate immune activation, and microbial factors. The cathelicidin antimicrobial peptide system plays a central role: patients with rosacea have elevated levels of kallikrein 5 (KLK5), a serine protease that cleaves cathelicidin (LL-37) into pro-inflammatory fragments that promote leukocyte chemotaxis, angiogenesis, and extracellular matrix degradation. This explains both the inflammatory papulopustules and the prominent telangiectasias. The neurovascular component involves transient receptor potential vanilloid (TRPV) channel activation on sensory neurons and blood vessels, producing the characteristic flushing response to triggers such as heat, alcohol, spicy foods, UV exposure, and emotional stress. Demodex folliculorum mites, which are commensal organisms present in normal skin at densities of 1 to 2 per square centimeter, proliferate to 10 to 20 times normal density in rosacea patients. The mites and their associated bacterium Bacillus oleronius trigger TLR-2-mediated inflammation, providing the rationale for the efficacy of ivermectin (an antiparasitic agent) and metronidazole (which has both antimicrobial and anti-inflammatory properties).\n\nCLINICAL SUBTYPES:\nErythematotelangiectatic rosacea (subtype 1) presents with persistent centrofacial erythema and telangiectasias, with episodic flushing triggered by environmental factors. Papulopustular rosacea (subtype 2), as in this patient, adds inflammatory papules and pustules to the background erythema. The critical distinction from acne vulgaris is the absence of comedones (blackheads and whiteheads), because rosacea does not involve follicular keratinization or sebaceous plugging. Phymatous rosacea (subtype 3), most commonly rhinophyma, involves progressive sebaceous gland hypertrophy and fibrosis causing disfiguring tissue thickening of the nose. Ocular rosacea (subtype 4) affects up to 50% of patients and presents with blepharitis, conjunctival injection, foreign body sensation, and meibomian gland dysfunction, and may precede cutaneous manifestations.\n\nMANAGEMENT:\nFor papulopustular rosacea, the AAD recommends topical therapy as first-line. Topical metronidazole 0.75 to 1% (anti-inflammatory), topical ivermectin 1% cream (anti-Demodex and anti-inflammatory, shown superior to metronidazole in the ATTRACT trial), and azelaic acid 15% gel (anti-inflammatory and normalizes keratinization) are all effective first-line options. For moderate-to-severe papulopustular disease, sub-antimicrobial dose doxycycline (40mg modified-release daily) provides anti-inflammatory benefit without promoting antibiotic resistance and is the preferred oral agent. Brimonidine 0.33% gel (alpha-2 agonist) and oxymetazoline 1% cream specifically target persistent erythema through direct vasoconstriction. Laser and intense pulsed light (IPL) therapy effectively treat telangiectasias and refractory erythema. Rhinophyma requires surgical debulking with CO2 laser, electrosurgery, or tangential excision. Topical corticosteroids are strictly contraindicated because they initially mask symptoms but then produce steroid-induced rosacea with rebound flaring upon discontinuation.\n\nKEY LEARNING POINTS:\nRosacea is distinguished from acne by the absence of comedones and the presence of centrofacial erythema with telangiectasias. Topical metronidazole, ivermectin, or azelaic acid are first-line for papulopustular rosacea. Demodex mite overpopulation contributes to pathogenesis, explaining ivermectin's efficacy. Topical corticosteroids are contraindicated and cause steroid rosacea. Screen for ocular involvement, which affects up to 50% of patients."
  },
  {
    "id": 606,
    "categoryId": 10,
    "question": "A 60-year-old presents with a painful, grouped vesicular rash in a dermatomal distribution on the left chest, within 48 hours of onset. What is the treatment?",
    "questionImages": [
      {
        "src": "assets/herpes-zoster-dermnet.png",
        "alt": "Herpes zoster vesicular eruption in a thoracic dermatomal pattern",
        "caption": "Grouped vesicles in a unilateral dermatomal distribution consistent with shingles."
      }
    ],
    "options": [
      "A) Supportive care only",
      "B) Valacyclovir 1g TID x 7 days",
      "C) Acyclovir topical cream",
      "D) Corticosteroids alone"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Oral Valacyclovir 1g TID for 7 days).\n\nPATHOPHYSIOLOGY:\nHerpes zoster (shingles) results from reactivation of varicella-zoster virus (VZV) that has remained latent in dorsal root ganglia or cranial nerve ganglia since primary varicella infection (chickenpox), often decades earlier. VZV maintains latency by residing in neuronal nuclei in a non-replicating state, evading immune clearance. When cell-mediated immunity declines due to aging, immunosuppression, stress, or other factors, the virus reactivates, replicates within the ganglion, and travels anterogradely down the sensory nerve to the corresponding dermatome, producing the characteristic unilateral, dermatomal vesicular eruption. The virus causes neuronal inflammation and necrosis within the ganglion and along the nerve, which is the basis for both the acute neuritis and the dreaded complication of postherpetic neuralgia (PHN), defined as pain persisting beyond 90 days after rash onset.\n\nCLINICAL PRESENTATION:\nA prodrome of burning, tingling, or stabbing pain in the affected dermatome precedes the rash by 1 to 5 days and can mimic cardiac, pulmonary, or abdominal disease depending on the dermatome involved. The eruption progresses from erythematous macules to papules to grouped vesicles on an erythematous base, characteristically respecting the midline and confined to a single dermatome. Thoracic dermatomes (T3 to L2) are most commonly affected. New vesicle formation continues for 3 to 5 days, followed by pustulation, crusting, and healing over 2 to 4 weeks. Herpes zoster ophthalmicus (V1 distribution) requires urgent ophthalmologic evaluation because of the risk of keratitis, uveitis, and vision loss. Hutchinson sign (vesicles on the tip of the nose indicating nasociliary nerve involvement) predicts ocular complications. Ramsay Hunt syndrome (V7 reactivation in the geniculate ganglion) produces facial nerve palsy, ear vesicles, and hearing loss.\n\nTREATMENT:\nAntiviral therapy initiated within 72 hours of rash onset (or while new lesions are still forming) is the cornerstone of management. Valacyclovir 1000mg three times daily for 7 days is preferred over acyclovir due to superior bioavailability (54% versus 15 to 20%), allowing less frequent dosing with higher and more sustained serum drug levels. Famciclovir 500mg three times daily for 7 days is an equivalent alternative. Acyclovir 800mg five times daily for 7 days remains effective but the complex dosing schedule reduces adherence. Antiviral therapy accelerates rash healing, reduces acute pain severity and duration, and most importantly reduces the incidence and severity of PHN, which affects 10 to 18% of all zoster patients and up to 50% of those over age 60. Pain management with NSAIDs, acetaminophen, or short-course opioids for severe pain should begin immediately. Gabapentin or pregabalin initiated during the acute phase may reduce the transition to PHN. Immunocompromised patients with disseminated or complicated zoster require IV acyclovir 10mg/kg every 8 hours.\n\nPREVENTION:\nThe recombinant adjuvanted zoster vaccine (Shingrix) is recommended by the CDC for all immunocompetent adults aged 50 and older and for immunocompromised adults aged 19 and older. It provides greater than 90% efficacy against zoster and PHN, maintained above 85% through at least 7 years of follow-up. The two-dose series (given 2 to 6 months apart) has replaced the older live attenuated vaccine (Zostavax), which is no longer available in the United States.\n\nKEY LEARNING POINTS:\nHerpes zoster results from VZV reactivation in dorsal root ganglia, producing a unilateral dermatomal vesicular eruption. Antiviral therapy within 72 hours reduces acute symptoms and PHN risk, with valacyclovir preferred over acyclovir for superior bioavailability. PHN risk increases dramatically with age, affecting up to 50% of patients over 60. Shingrix vaccine provides greater than 90% protection and is recommended for all adults aged 50 and older."
  },
  {
    "id": 607,
    "categoryId": 10,
    "question": "A patient on hydrochlorothiazide develops an erythematous, blistering rash on sun-exposed areas. What is the diagnosis?",
    "options": [
      "A) Drug-induced lupus",
      "B) Phototoxic drug reaction",
      "C) Allergic contact dermatitis",
      "D) Stevens-Johnson syndrome"
    ],
    "correctAnswer": 1,
    "explanationImages": [
      {
        "src": "assets/drug-induced-photosensitivity-dermnet.png",
        "alt": "Drug-induced photosensitivity with phototoxic eruption on sun-exposed skin",
        "caption": "Phototoxic drug eruption with characteristic sun-exposed distribution and sparing patterns."
      }
    ],
    "explanation": "CORRECT: B (Phototoxic drug reaction).\n\nPATHOPHYSIOLOGY:\nDrug-induced photosensitivity encompasses two distinct mechanisms: phototoxicity and photoallergy, with phototoxic reactions being far more common, accounting for approximately 90% of cases. In a phototoxic reaction, the drug or its metabolite absorbs ultraviolet radiation (primarily UVA, 320 to 400 nm) and transfers that energy to surrounding tissue through the generation of reactive oxygen species (singlet oxygen, superoxide radicals) and direct damage to cellular membranes, DNA, and proteins. This is a dose-dependent, non-immunologic reaction that can occur on first drug exposure without prior sensitization and resembles an exaggerated sunburn. In contrast, photoallergic reactions involve a type IV delayed hypersensitivity mechanism: UV radiation converts the drug into a hapten that binds skin proteins, forming a complete antigen that triggers a T-cell-mediated immune response. Photoallergy requires prior sensitization, is not dose-dependent, and presents as eczematous dermatitis that may spread beyond sun-exposed areas.\n\nCLINICAL PRESENTATION:\nPhototoxic reactions present as an exaggerated sunburn (erythema, edema, vesiculation, blistering, desquamation) strictly confined to sun-exposed areas including the face, dorsal hands, forearms, V of the chest, and posterior neck. The sharp demarcation at clothing lines and sun-protected areas (submental region, upper eyelids, retroauricular areas) is a critical diagnostic clue. Onset is typically acute, within minutes to hours of sun exposure while on the offending medication. Photoallergic reactions, by contrast, present as pruritic eczematous dermatitis that may extend beyond photoexposed sites and has a delayed onset of 24 to 72 hours.\n\nCOMMON PHOTOSENSITIZING MEDICATIONS:\nThiazide diuretics (hydrochlorothiazide is the most commonly implicated) cause photosensitivity in up to 10% of users. A large Danish cohort study published in the Journal of the American Academy of Dermatology linked hydrochlorothiazide to a significantly increased risk of non-melanoma skin cancer with prolonged use, attributed to its photosensitizing properties and potential direct photocarcinogenic effects. Tetracyclines (doxycycline is the most phototoxic, with rates up to 20%; minocycline is least phototoxic), fluoroquinolones (particularly lomefloxacin and sparfloxacin, though ciprofloxacin and levofloxacin also carry risk), NSAIDs (piroxicam, naproxen, ketoprofen), amiodarone (causes blue-gray discoloration with chronic use from lipofuscin deposition in the dermis), voriconazole (associated with accelerated photocarcinogenesis with prolonged use), and sulfonamides are other major drug classes to recognize.\n\nMANAGEMENT:\nThe primary intervention is identification and discontinuation of the offending drug when clinically feasible, with substitution of a non-photosensitizing alternative. If the medication cannot be discontinued (as may be the case with essential antihypertensives or antibiotics), strict photoprotection is essential: broad-spectrum sunscreen with SPF 30 or higher reapplied every 2 hours during sun exposure, protective clothing, wide-brimmed hats, and avoidance of peak UV hours (10 AM to 4 PM). UVA protection is particularly important because most phototoxic reactions are UVA-mediated, and standard SPF ratings primarily reflect UVB protection. Acute symptomatic management includes cool compresses, topical corticosteroids for inflammation, and emollients. Severe blistering reactions may require wound care similar to burn management.\n\nKEY LEARNING POINTS:\nPhototoxic reactions are dose-dependent, non-immunologic, exaggerated sunburn responses confined to sun-exposed areas, occurring on first drug exposure. Hydrochlorothiazide, doxycycline, and fluoroquinolones are the most commonly implicated agents in primary care. Sharp demarcation at clothing lines distinguishes photosensitivity from other drug eruptions. UVA-blocking sunscreen is essential because most phototoxic reactions are UVA-mediated. Hydrochlorothiazide has been linked to increased non-melanoma skin cancer risk with prolonged use."
  },
  {
    "id": 608,
    "categoryId": 10,
    "question": "A 25-year-old presents with oval, salmon-colored patches following skin lines on the trunk, preceded by a single larger 'herald patch' 2 weeks ago. What is the management?",
    "questionImages": [
      {
        "src": "assets/pityriasis-rosea-trunk-dermnet.png",
        "alt": "Truncal pityriasis rosea with multiple oval salmon lesions",
        "caption": "Classic truncal distribution of pityriasis rosea lesions."
      }
    ],
    "options": [
      "A) Oral antifungals",
      "B) Reassurance - self-limited",
      "C) Oral corticosteroids",
      "D) Skin biopsy"
    ],
    "correctAnswer": 1,
    "explanationImages": [
      {
        "src": "assets/pityriasis-rosea-dermnet.png",
        "alt": "Annular collaretted lesions in pityriasis rosea on the arms",
        "caption": "Classic pityriasis rosea with collarette scaling in oval lesions."
      }
    ],
    "explanation": "CORRECT: B (Reassurance - self-limited).\n\nPATHOPHYSIOLOGY:\nPityriasis rosea is an acute, self-limited papulosquamous eruption that is strongly suspected to be triggered by reactivation of human herpesvirus 6 (HHV-6) and/or HHV-7. Evidence supporting a viral etiology includes the detection of HHV-6 and HHV-7 DNA in skin lesions and serum of affected patients, the seasonal clustering (spring and fall), the occurrence in mini-epidemics, the rarity of recurrence (suggesting lasting immunity in most cases), and the prodromal symptoms that often precede the rash. The condition predominantly affects adolescents and young adults aged 10 to 35, with equal sex distribution.\n\nCLINICAL PRESENTATION:\nThe eruption begins with a single 'herald patch' (also called the 'mother patch'), a 2 to 5 centimeter oval, salmon-pink plaque with a collarette of fine, trailing scale at the inner margin of the border. This solitary lesion appears on the trunk in approximately 70% of cases and is frequently misdiagnosed as tinea corporis or eczema. After 1 to 2 weeks, a secondary eruption of numerous smaller (0.5 to 1.5 cm) oval patches develops in successive crops over the trunk and proximal extremities. These secondary lesions characteristically follow the skin cleavage lines (Langer lines), producing the classic 'Christmas tree' or 'fir tree' pattern on the back when the long axes of the oval lesions align along the ribs. Each secondary lesion demonstrates the same collarette scaling as the herald patch. The face, distal extremities, palms, and soles are typically spared, though atypical presentations (inverse, vesicular, purpuric, papular) occur, particularly in children and darker-skinned individuals. Pruritus ranges from absent to moderate and can be the most bothersome symptom.\n\nDIAGNOSIS AND CRITICAL DIFFERENTIAL:\nPityriasis rosea is a clinical diagnosis that does not require biopsy in typical presentations. The critical differential diagnosis that must be excluded is secondary syphilis, which can produce an identical distribution of oval, scaly, pink papules on the trunk. Unlike pityriasis rosea, secondary syphilis typically involves the palms and soles, is associated with condylomata lata, mucous patches, and lymphadenopathy, and occurs in the context of sexual risk factors. An RPR or VDRL test should be obtained in any sexually active patient presenting with a pityriasis rosea-like eruption. Other differential diagnoses include guttate psoriasis (smaller, droplet-shaped lesions with thicker silvery scale, often post-streptococcal), nummular eczema (coin-shaped but more pruritic with weeping), tinea corporis (KOH positive for hyphae), and drug eruptions (beta-blockers, ACE inhibitors, metronidazole can cause pityriasis rosea-like reactions).\n\nMANAGEMENT:\nPityriasis rosea is self-limited, with the eruption resolving spontaneously in 6 to 8 weeks (occasionally up to 12 weeks) without treatment. Patient reassurance and education are the primary management. For symptomatic pruritus, emollients, low-to-medium potency topical corticosteroids, and oral antihistamines provide relief. Narrowband UVB phototherapy can accelerate resolution and reduce itching in patients with widespread or symptomatic disease. Some evidence suggests that high-dose acyclovir (800mg five times daily for 7 days) initiated within the first week of the secondary eruption may hasten resolution, though this remains debated and is not routinely recommended. Post-inflammatory hyperpigmentation or hypopigmentation is common, particularly in patients with darker skin tones, and may take weeks to months to resolve.\n\nKEY LEARNING POINTS:\nPityriasis rosea is a self-limited condition resolving in 6 to 8 weeks, with the herald patch preceding the Christmas tree pattern of secondary lesions by 1 to 2 weeks. Secondary syphilis is the most important diagnosis to exclude, and RPR or VDRL testing should be performed in sexually active patients. Treatment is supportive with reassurance, emollients, and topical steroids for pruritus. Post-inflammatory dyspigmentation is common in darker skin tones."
  },
  {
    "id": 609,
    "categoryId": 5,
    "question": "A 65-year-old male with BPH has moderate LUTS (AUA-SI 18) with a 45g prostate. What is the most appropriate initial pharmacotherapy?",
    "options": [
      "A) Finasteride alone",
      "B) Tamsulosin alone",
      "C) Combination tamsulosin + finasteride",
      "D) Oxybutynin"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Combination tamsulosin plus finasteride).\n\nCLINICAL REASONING:\nThis patient has moderate LUTS (AUA Symptom Index 18, where 8 to 19 is moderate) with a prostate volume of 45 grams (greater than 30 to 40 grams, the threshold where 5-alpha reductase inhibitors provide benefit) per UpToDate and Harrison's Principles of Internal Medicine. For men with both moderate to severe symptoms and an enlarged prostate, combination therapy with an alpha-blocker plus a 5-alpha reductase inhibitor is superior to either agent alone per the Cleveland Clinic.\n\nEVIDENCE:\nThe landmark CombAT (Combination of Avodart and Tamsulosin) trial demonstrated that combination therapy (dutasteride plus tamsulosin) was significantly superior to either monotherapy for reducing LUTS progression, acute urinary retention, and BPH-related surgery over 4 years per UpToDate and the Mayo Clinic. The MTOPS (Medical Therapy of Prostatic Symptoms) trial similarly showed that combination finasteride plus doxazosin reduced the risk of clinical progression by 66% compared to placebo (versus 39% for doxazosin alone and 34% for finasteride alone) per Harrison's Principles of Internal Medicine.\n\nPHARMACOLOGY:\nAlpha-1 adrenergic blockers (tamsulosin, alfuzosin, silodosin) relax prostatic and bladder neck smooth muscle by blocking alpha-1A receptors, providing rapid symptom relief within days to weeks per the Cleveland Clinic. They do not reduce prostate size and do not prevent disease progression per UpToDate. 5-alpha reductase inhibitors (finasteride, dutasteride) block conversion of testosterone to dihydrotestosterone (DHT, the primary androgen driving prostate growth), reducing prostate volume by 20 to 30% over 6 to 12 months and decreasing the risk of acute urinary retention and need for surgery per Harrison's Principles of Internal Medicine. Key side effects of 5-alpha reductase inhibitors include decreased libido, erectile dysfunction, decreased ejaculate volume, and reduced PSA by approximately 50% (requiring doubling of measured PSA for cancer screening interpretation) per Harvard Health.\n\nKEY LEARNING POINTS:\nCombination alpha-blocker plus 5-alpha reductase inhibitor is superior to either alone for moderate to severe LUTS with an enlarged prostate (greater than 30 to 40g), reducing clinical progression by 66% per MTOPS. Alpha-blockers provide rapid symptom relief while 5-alpha reductase inhibitors reduce prostate volume by 20 to 30% over months. The 5-ARI halves PSA, requiring adjustment when screening for cancer."
  },
  {
    "id": 610,
    "categoryId": 5,
    "question": "A 45-year-old presents with sudden colicky left flank pain radiating to groin. CT shows a 4mm ureteral stone. He is afebrile with normal creatinine. What is the management?",
    "options": [
      "A) Emergent ureteroscopy",
      "B) Conservative management with medical expulsive therapy",
      "C) Extracorporeal shock wave lithotripsy",
      "D) Percutaneous nephrostomy"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Conservative management with medical expulsive therapy).\n\nCLINICAL REASONING:\nThis patient presents with a classic renal colic episode (sudden colicky flank pain radiating to the groin) from a 4 mm ureteral stone, is afebrile, and has no signs of obstruction or infection per UpToDate and Harrison's Principles of Internal Medicine. Stones 5 mm or smaller have a spontaneous passage rate of approximately 68 to 98% (with distal ureteral stones passing most reliably), making conservative management the appropriate first-line approach per the Cleveland Clinic.\n\nMEDICAL EXPULSIVE THERAPY:\nAlpha-blockers (tamsulosin 0.4 mg daily) relax ureteral smooth muscle (particularly at the distal ureteroveiscal junction, the narrowest point and most common site of stone impaction) and facilitate stone passage per UpToDate. A meta-analysis demonstrated that tamsulosin increases spontaneous passage rates and reduces time to passage, particularly for stones 5 to 10 mm per the Mayo Clinic. Pain management with NSAIDs (ketorolac, ibuprofen) is preferred over opioids because NSAIDs reduce ureteral smooth muscle spasm and prostaglandin-mediated renal pelvic pressure in addition to providing analgesia per Harrison's Principles of Internal Medicine.\n\nINDICATIONS FOR URGENT INTERVENTION:\nConservative management is contraindicated when any of the following are present: concurrent urinary tract infection with obstruction (obstructive pyelonephritis/pyonephrosis, a urologic emergency requiring emergent decompression via ureteral stent or percutaneous nephrostomy), solitary kidney with obstruction, bilateral obstruction, uncontrollable pain or vomiting, AKI, or stones greater than 10 mm (which rarely pass spontaneously) per UpToDate and the Cleveland Clinic.\n\nSTONE SIZE AND PASSAGE RATES:\nStones less than 5 mm pass spontaneously in approximately 68 to 98% of cases, 5 to 10 mm stones pass in approximately 47% of cases, and stones greater than 10 mm rarely pass and typically require intervention (extracorporeal shock wave lithotripsy or ureteroscopy with laser lithotripsy) per Harvard Health and Harrison's Principles of Internal Medicine.\n\nKEY LEARNING POINTS:\nUreteral stones 5 mm or smaller have a 68 to 98% spontaneous passage rate and are managed conservatively with tamsulosin (medical expulsive therapy) and NSAIDs (preferred over opioids). Urgent intervention is required for obstruction with infection, solitary kidney obstruction, bilateral obstruction, or stones greater than 10 mm. An afebrile patient with a small stone and no complications can be safely managed as an outpatient."
  },
  {
    "id": 611,
    "categoryId": 5,
    "question": "A 70-year-old woman with recurrent UTIs (4 in past year) is frustrated. She is postmenopausal. What is the most appropriate prophylactic strategy?",
    "options": [
      "A) Daily antibiotic prophylaxis only",
      "B) Cranberry supplements alone",
      "C) Vaginal estrogen + consider antibiotic prophylaxis",
      "D) Referral for cystoscopy first"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Vaginal estrogen plus consider antibiotic prophylaxis).\n\nCLINICAL REASONING:\nRecurrent urinary tract infections (defined as 2 or more UTIs in 6 months or 3 or more in 12 months) in postmenopausal women are primarily driven by genitourinary syndrome of menopause (GSM), formerly called vulvovaginal atrophy, caused by estrogen deficiency per UpToDate and Harrison's Principles of Internal Medicine. Declining estrogen levels cause thinning of the vaginal and urethral epithelium, loss of the protective vaginal Lactobacillus flora (which normally maintain an acidic vaginal pH of 3.5 to 4.5), increase in vaginal pH (allowing colonization by uropathogenic E. coli), and reduced urethral mucosal coaptation per the Cleveland Clinic and Harvard Health.\n\nVAGINAL ESTROGEN:\nTopical vaginal estrogen (cream, ring, or tablet) restores vaginal epithelial thickness, repopulates Lactobacillus flora, lowers vaginal pH, and reduces vaginal colonization with uropathogens per UpToDate. Multiple randomized trials and a Cochrane review demonstrate that vaginal estrogen reduces UTI recurrence by approximately 50% per the Mayo Clinic. Vaginal estrogen has minimal systemic absorption and is considered safe even in many women with a history of breast cancer (with oncologist consultation) per Harrison's Principles of Internal Medicine.\n\nANTIBIOTIC PROPHYLAXIS:\nWhen vaginal estrogen alone is insufficient, low-dose continuous antibiotic prophylaxis (nitrofurantoin 50 to 100 mg nightly, TMP-SMX half-strength nightly, or post-coital prophylaxis with a single dose if UTIs are associated with sexual activity) reduces recurrence by 80 to 95% per UpToDate and the Cleveland Clinic. Prophylaxis is typically continued for 6 to 12 months and then reassessed per Harvard Health. Cranberry products have modest evidence (approximately 25% reduction in UTI risk in some studies) and may be offered as adjunctive prevention per the Mayo Clinic.\n\nKEY LEARNING POINTS:\nRecurrent UTIs in postmenopausal women are primarily driven by estrogen deficiency causing loss of vaginal Lactobacillus, elevated pH, and uropathogen colonization. Vaginal estrogen reduces UTI recurrence by approximately 50% by restoring vaginal flora and has minimal systemic absorption. Low-dose antibiotic prophylaxis (80 to 95% reduction) is added when estrogen alone is insufficient."
  },
  {
    "id": 612,
    "categoryId": 5,
    "question": "A 55-year-old male has PSA 4.8 ng/mL (was 2.5 two years ago). DRE is normal. What is the most appropriate next step?",
    "options": [
      "A) Immediate prostate biopsy",
      "B) Repeat PSA and calculate velocity",
      "C) Reassurance - PSA <10 is normal",
      "D) Start finasteride"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Repeat PSA and calculate velocity).\n\nCLINICAL REASONING:\nThis patient has a PSA of 4.8 ng/mL (mildly elevated above the traditional 4.0 cutoff) that has risen from 2.5 two years prior, with a normal digital rectal exam per UpToDate and Harrison's Principles of Internal Medicine. Before proceeding to prostate biopsy, the appropriate next step is to confirm the PSA elevation with a repeat measurement and calculate the PSA velocity (rate of change over time), because PSA can be transiently elevated by benign conditions per the Cleveland Clinic.\n\nPSA VELOCITY:\nPSA velocity is calculated as the change in PSA divided by the time interval between measurements per Harrison's Principles of Internal Medicine. A PSA velocity greater than 0.75 ng/mL per year is associated with an increased risk of prostate cancer and should prompt further evaluation (free PSA percentage, prostate MRI, or biopsy) per UpToDate. This patient's velocity is approximately 1.15 ng/mL per year (4.8 minus 2.5 divided by 2 years), which exceeds the concerning threshold and warrants additional workup per the Mayo Clinic.\n\nTRANSIENT PSA ELEVATION:\nBenign causes of PSA elevation include BPH, prostatitis (acute bacterial prostatitis can raise PSA dramatically), recent ejaculation (within 48 hours), vigorous exercise (particularly cycling), urethral instrumentation, and UTI per the Cleveland Clinic and Harvard Health. A single elevated PSA should be confirmed before invasive procedures per UpToDate.\n\nNEXT STEPS AFTER CONFIRMATION:\nIf repeat PSA confirms elevation with a concerning velocity, further risk stratification may include free PSA percentage (less than 10% suggests cancer), Prostate Health Index (PHI), 4Kscore, or multiparametric MRI (mpMRI) of the prostate with PI-RADS scoring per Harrison's Principles of Internal Medicine. MRI-targeted biopsy (fusion biopsy) has higher detection rates for clinically significant cancer compared to systematic transrectal ultrasound-guided biopsy per UpToDate and the Mayo Clinic.\n\nKEY LEARNING POINTS:\nA rising PSA should be confirmed with repeat measurement and PSA velocity calculation before biopsy, as transient benign elevations are common. PSA velocity greater than 0.75 ng/mL per year is concerning for cancer. Multiparametric prostate MRI with PI-RADS scoring and MRI-targeted biopsy are increasingly used before or instead of systematic biopsy."
  },
  {
    "id": 613,
    "categoryId": 5,
    "question": "A 60-year-old woman reports urine loss when coughing or sneezing. She denies urgency. Exam reveals urethral hypermobility. What is the first-line treatment?",
    "options": [
      "A) Oxybutynin",
      "B) Pelvic floor muscle training",
      "C) Midurethral sling surgery",
      "D) Mirabegron"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Pelvic floor muscle training).\n\nCLINICAL REASONING:\nThis patient presents with stress urinary incontinence (SUI), defined as involuntary urine loss with increased abdominal pressure (coughing, sneezing, laughing, lifting, exercise) in the absence of urgency, caused by urethral hypermobility and/or intrinsic sphincter deficiency per UpToDate and Harrison's Principles of Internal Medicine. Pelvic floor muscle training (PFMT, also called Kegel exercises) is the established first-line treatment for stress incontinence in women per the Cleveland Clinic and the Mayo Clinic.\n\nEVIDENCE:\nA Cochrane systematic review of 31 trials confirmed that PFMT significantly improves or cures SUI compared to no treatment or sham exercises, with cure rates of 50 to 75% for mild to moderate stress incontinence per UpToDate. The exercises strengthen the pubococcygeus and levator ani muscles that support the urethra and bladder neck, restoring the urethral support mechanism that prevents urine leakage during abdominal pressure increases per Harvard Health.\n\nPROGRAM DETAILS:\nAn effective PFMT program involves contracting the pelvic floor muscles (as if stopping the urine stream, though practice during urination is discouraged) for 8 to 12 seconds, 8 to 12 repetitions, 3 times daily, for a minimum of 3 months before assessing benefit per the Cleveland Clinic and Harrison's Principles of Internal Medicine. Supervised PFMT with a physiotherapist or biofeedback is more effective than self-directed exercises alone per UpToDate. Vaginal weighted cones and electrical stimulation devices are adjunctive options per the Mayo Clinic.\n\nSECOND-LINE OPTIONS:\nWhen PFMT is insufficient, duloxetine (an SNRI that increases urethral sphincter tone, approved for SUI in Europe but not FDA-approved for this indication in the US) may be considered per UpToDate. Pessary devices provide mechanical urethral support. Surgical options for refractory SUI include midurethral sling procedures (the gold standard surgical intervention, with 80 to 90% success rates), Burch colposuspension, and urethral bulking agents per Harrison's Principles of Internal Medicine and the Cleveland Clinic.\n\nKEY LEARNING POINTS:\nPelvic floor muscle training (Kegel exercises) is first-line for stress urinary incontinence, with 50 to 75% cure rates for mild to moderate SUI per Cochrane review. An effective program requires 8 to 12 second contractions, 8 to 12 reps, 3 times daily for at least 3 months. Supervised PFMT with biofeedback is superior to self-directed exercises; midurethral sling is the gold standard surgical option."
  },
  {
    "id": 614,
    "categoryId": 5,
    "question": "A 25-year-old male presents with painless scrotal swelling. A mass superior/posterior to the testis transilluminates. The testis feels normal. What is the diagnosis?",
    "options": [
      "A) Testicular cancer",
      "B) Epididymal cyst/spermatocele",
      "C) Hydrocele",
      "D) Varicocele"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Epididymal cyst/spermatocele).\n\nDIAGNOSTIC REASONING:\nThis patient presents with a painless scrotal mass that is separate from the testis (located superior and posterior to it), transilluminates (indicating fluid-filled rather than solid), and does not affect the testis itself (which feels normal) per UpToDate and Harrison's Principles of Internal Medicine. These features are characteristic of an epididymal cyst (containing clear serous fluid) or spermatocele (containing milky fluid with spermatozoa), both benign cystic lesions arising from the epididymis per the Cleveland Clinic.\n\nDIFFERENTIAL DIAGNOSIS:\nTransillumination is the key physical examination maneuver that distinguishes fluid-filled scrotal lesions from solid masses per the Mayo Clinic. A hydrocele (fluid collection within the tunica vaginalis surrounding the testis) also transilluminates but envelops the testis rather than being a discrete mass separate from it per Harrison's Principles of Internal Medicine. A varicocele (dilated pampiniform venous plexus) feels like a \"bag of worms,\" does not transilluminate, increases with Valsalva, and is found on the left side in 90% of cases due to the left gonadal vein draining into the left renal vein at a right angle per UpToDate. A testicular tumor is a solid, non-transilluminating, often painless mass arising within the testis itself (not the epididymis) and is the most important diagnosis to exclude in any young male with a scrotal mass per Harvard Health.\n\nCRITICAL PRINCIPLE:\nAny solid, non-transilluminating testicular mass in a young male (peak incidence 20 to 35 years) must be considered testicular cancer until proven otherwise per Harrison's Principles of Internal Medicine. Scrotal ultrasound is the initial imaging study of choice for all scrotal masses to confirm the physical exam findings and characterize the lesion per the Cleveland Clinic. If ultrasound shows a solid intratesticular mass, serum tumor markers (AFP, beta-hCG, LDH) and radical inguinal orchiectomy (not transscrotal biopsy, which risks seeding the scrotal skin and altering lymphatic drainage) are indicated per UpToDate.\n\nMANAGEMENT:\nEpididymal cysts and spermatoceles are benign and require no treatment unless symptomatic (pain, discomfort from size), in which case surgical excision (spermatocelectomy) is performed per the Mayo Clinic.\n\nKEY LEARNING POINTS:\nA painless scrotal mass that transilluminates and is separate from the testis is characteristic of an epididymal cyst or spermatocele. Transillumination distinguishes fluid-filled (cyst, hydrocele) from solid (tumor) masses. Any solid, non-transilluminating intratesticular mass in a young male must be considered cancer until proven otherwise, requiring ultrasound and radical inguinal orchiectomy if confirmed."
  },
  {
    "id": 615,
    "categoryId": 15,
    "question": "A 55-year-old male presents with crushing substernal chest pain for 30 minutes. ECG shows ST elevation in V1-V4. The nearest PCI center is 90 minutes away. Your hospital can give fibrinolytics. What is the best strategy?",
    "options": [
      "A) Give fibrinolytics immediately",
      "B) Transfer for primary PCI regardless",
      "C) Give fibrinolytics if PCI cannot be done within 120 minutes",
      "D) Wait for troponin results"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Give fibrinolytics if PCI cannot be done within 120 minutes).\n\nPATHOPHYSIOLOGY:\nST-elevation myocardial infarction results from complete thrombotic occlusion of an epicardial coronary artery, almost always triggered by rupture or erosion of a vulnerable atherosclerotic plaque with superimposed thrombus formation per Harrison's Principles of Internal Medicine. The duration of complete coronary occlusion directly determines the extent of irreversible myocardial necrosis, which progresses as a wavefront from the subendocardium outward to the epicardium over approximately 3 to 6 hours. This time-dependent relationship underlies the critical principle that \"time is muscle\" and drives the urgency of reperfusion therapy.\n\nCLINICAL REASONING:\nPrimary percutaneous coronary intervention (PCI) is the preferred reperfusion strategy for STEMI because it achieves higher rates of complete arterial recanalization, lower rates of reinfarction, and lower mortality compared to fibrinolysis per the American Heart Association and ACC guidelines. However, PCI must be performed within 120 minutes of first medical contact (FMC-to-balloon time) to maintain its superiority over fibrinolysis per UpToDate. When PCI cannot be achieved within this 120-minute window, as in this scenario where the nearest PCI center is 90 minutes away (with additional time required for transport logistics, catheterization lab activation, and the procedure itself), fibrinolytic therapy should be administered with a door-to-needle time goal of 30 minutes or less per Harrison's Principles of Internal Medicine. Fibrinolytics are most effective within the first 3 hours of symptom onset. After receiving fibrinolytics, patients should still be transferred to a PCI-capable center for routine coronary angiography within 3 to 24 hours (the pharmacoinvasive strategy) per the Mayo Clinic and ACC guidelines.\n\nCONTRAINDICATIONS TO FIBRINOLYSIS:\nAbsolute contraindications per UpToDate include active internal bleeding (excluding menses), history of hemorrhagic stroke at any time, ischemic stroke within 3 months, intracranial neoplasm or arteriovenous malformation, suspected aortic dissection, significant head or facial trauma within 3 months, and active bleeding or bleeding diathesis. Patients with contraindications should be transferred for primary PCI regardless of expected delay.\n\nKEY LEARNING POINTS:\nPrimary PCI is preferred for STEMI but must be achievable within 120 minutes of first medical contact; when it cannot, fibrinolysis should be given within 30 minutes (door-to-needle). After fibrinolysis, transfer for coronary angiography within 3 to 24 hours (pharmacoinvasive strategy) is standard. Fibrinolytics are most effective within the first 3 hours of symptom onset."
  },
  {
    "id": 616,
    "categoryId": 15,
    "question": "A 45-year-old woman presents with sudden severe headache ('worst of my life') and neck stiffness. CT head is negative. What is the next step?",
    "options": [
      "A) Reassurance and discharge",
      "B) Lumbar puncture",
      "C) MRI brain",
      "D) CT angiogram immediately"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Lumbar puncture).\n\nPATHOPHYSIOLOGY:\nSubarachnoid hemorrhage, most commonly caused by rupture of a saccular (berry) aneurysm at the circle of Willis, is a neurological emergency carrying an overall mortality of approximately 25 to 50% per Harrison's Principles of Internal Medicine. Ruptured aneurysms account for approximately 85% of nontraumatic SAH, with the remainder caused by perimesencephalic hemorrhage, arteriovenous malformations, and other vascular anomalies. The most common locations for saccular aneurysms are the anterior communicating artery (the single most common site), the posterior communicating artery, and the middle cerebral artery bifurcation per UpToDate. Risk factors include hypertension, smoking, excessive alcohol use, family history of SAH, and connective tissue disorders (autosomal dominant polycystic kidney disease, Ehlers-Danlos type IV) per the Mayo Clinic.\n\nCLINICAL REASONING:\nThe hallmark presentation is a sudden-onset, severe headache described as the \"worst headache of my life\" (thunderclap headache), often accompanied by neck stiffness (meningismus from blood irritating the meninges), nausea, vomiting, photophobia, and altered consciousness per Harrison's Principles of Internal Medicine. Non-contrast CT of the head is the initial diagnostic test and is approximately 98% sensitive within 6 hours of symptom onset, but sensitivity declines to approximately 93% at 12 hours and approximately 50% at 1 week as blood is gradually resorbed per UpToDate. When CT is negative but clinical suspicion remains high, lumbar puncture is mandatory per the Cleveland Clinic. LP findings diagnostic of SAH include elevated red blood cells that do not clear across sequential tubes (distinguishing SAH from a traumatic tap) and xanthochromia (yellow discoloration of the supernatant CSF from bilirubin produced by in vivo hemoglobin degradation, which takes approximately 6 to 12 hours to develop) per Harrison's Principles of Internal Medicine.\n\nMANAGEMENT:\nOnce SAH is confirmed, CT angiography identifies the culprit aneurysm, and definitive treatment (either endovascular coiling or surgical clipping) should be performed as early as possible (ideally within 24 hours) to prevent devastating rebleeding per UpToDate. Nimodipine (60 mg orally every 4 hours for 21 days) is administered to reduce the risk of delayed cerebral ischemia from vasospasm, the most feared complication occurring between days 4 and 14 per the AHA/ASA guidelines.\n\nKEY LEARNING POINTS:\nA negative CT does not rule out SAH, and lumbar puncture is mandatory when clinical suspicion is high, looking for non-clearing RBCs and xanthochromia. CT sensitivity for SAH declines significantly after 6 hours. Nimodipine reduces delayed cerebral ischemia from vasospasm, the most serious complication, occurring between days 4 and 14."
  },
  {
    "id": 617,
    "categoryId": 15,
    "question": "A patient in pulseless ventricular tachycardia persists after 2 shocks, CPR, and epinephrine. What is the next medication per ACLS?",
    "options": [
      "A) Lidocaine",
      "B) Amiodarone 300mg IV",
      "C) Magnesium 2g IV",
      "D) Procainamide"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Amiodarone 300mg IV).\n\nPATHOPHYSIOLOGY:\nPulseless ventricular tachycardia and ventricular fibrillation are shockable cardiac arrest rhythms in which organized or chaotic ventricular electrical activity fails to generate effective cardiac output per Harrison's Principles of Internal Medicine. The myocardium in VF or pulseless VT is electrically active but mechanically ineffective, and defibrillation (delivery of an electrical countershock) is the only definitive treatment to restore an organized perfusing rhythm. The probability of successful defibrillation decreases by approximately 7 to 10% for each minute of delay per the AHA ACLS guidelines.\n\nACLS ALGORITHM:\nThe Advanced Cardiovascular Life Support algorithm for shockable rhythms follows a structured sequence per the American Heart Association 2020 guidelines and UpToDate. High-quality CPR is initiated immediately and continued with minimal interruptions (goal chest compression fraction greater than 80%). The sequence proceeds as follows: first shock is delivered, followed by 2 minutes of CPR, then second shock, followed by 2 minutes of CPR with epinephrine 1 mg IV/IO (repeated every 3 to 5 minutes), then third shock, followed by 2 minutes of CPR with amiodarone 300 mg IV/IO bolus. If pulseless VT/VF persists, a subsequent dose of amiodarone 150 mg IV may be given per the AHA guidelines. Amiodarone is a class III antiarrhythmic that blocks potassium, sodium, and calcium channels and has antiadrenergic properties, making it the most effective antiarrhythmic for shock-refractory VF/VT per Harrison's Principles of Internal Medicine.\n\nIMPORTANT DISTINCTIONS:\nMagnesium sulfate (2 grams IV) is specifically indicated for torsades de pointes (polymorphic VT associated with QT prolongation) and should not be used routinely for VF/pVT per the Cleveland Clinic. Lidocaine (1 to 1.5 mg/kg IV) is an acceptable alternative to amiodarone if amiodarone is unavailable per the AHA guidelines. Throughout the arrest, reversible causes should be systematically addressed using the H's and T's framework: hypovolemia, hypoxia, hydrogen ion (acidosis), hypo/hyperkalemia, hypothermia, tension pneumothorax, tamponade, toxins, and thrombosis (coronary or pulmonary) per UpToDate.\n\nKEY LEARNING POINTS:\nThe ACLS shockable rhythm algorithm follows the sequence of shock, CPR, shock, CPR plus epinephrine, shock, CPR plus amiodarone 300 mg, with high-quality CPR and minimal interruptions as the foundation. Amiodarone is the first-line antiarrhythmic for shock-refractory VF/pVT, while magnesium is reserved specifically for torsades de pointes. Reversible causes should be systematically addressed using the H's and T's framework throughout the arrest."
  },
  {
    "id": 618,
    "categoryId": 15,
    "question": "A 30-year-old male after a house fire has singed nasal hairs, facial burns, and hoarse voice. O2 sat is 94%. What is the most critical immediate action?",
    "options": [
      "A) Apply silver sulfadiazine",
      "B) Obtain carboxyhemoglobin level",
      "C) Early endotracheal intubation",
      "D) IV fluid resuscitation"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Early endotracheal intubation).\n\nPATHOPHYSIOLOGY:\nInhalation injury is the leading cause of death in burn patients, responsible for approximately 60 to 80% of fire-related mortality per Harrison's Principles of Internal Medicine. Thermal injury to the upper airway (above the glottis) from superheated air and steam causes progressive mucosal edema of the oropharynx, larynx, and supraglottic structures that can rapidly progress to complete airway obstruction over minutes to hours. The upper airway is extremely efficient at heat dissipation, so thermal injury rarely extends below the vocal cords except in the case of steam inhalation (which carries 4,000 times the heat capacity of dry air) per UpToDate. Chemical injury to the lower airways and pulmonary parenchyma results from inhalation of toxic combustion products (aldehydes, hydrogen chloride, phosgene, sulfur dioxide) that cause tracheobronchitis, bronchospasm, and acute respiratory distress syndrome per the Cleveland Clinic.\n\nCLINICAL REASONING:\nThis patient has multiple signs of inhalation injury: singed nasal hairs, facial burns, and hoarseness (indicating laryngeal edema) per UpToDate. Additional red flags include carbonaceous sputum, stridor, drooling, oropharyngeal edema or erythema on direct visualization, and history of entrapment in an enclosed-space fire. The critical principle is that airway edema progresses rapidly and unpredictably, and a patient with a patent airway can develop complete obstruction within hours. The widely cited teaching per the Mayo Clinic and burn surgery literature is: \"if you are thinking about intubating a burn patient, do it now.\" Delay until frank stridor or respiratory failure develops risks encountering a massively edematous airway that may be impossible to intubate, necessitating a surgical airway under catastrophic circumstances.\n\nADDITIONAL CONSIDERATIONS:\nPulse oximetry is unreliable in the setting of carbon monoxide poisoning because conventional pulse oximeters cannot distinguish carboxyhemoglobin from oxyhemoglobin, resulting in falsely normal or elevated SpO2 readings per Harrison's Principles of Internal Medicine. A co-oximetry panel (carboxyhemoglobin and methemoglobin levels) should be obtained. High-flow 100% oxygen is administered to all fire victims (the half-life of carboxyhemoglobin decreases from approximately 5 hours on room air to approximately 60 to 90 minutes on 100% FiO2). Fluid resuscitation for burn patients follows the Parkland formula (4 mL/kg per percent total body surface area burned of lactated Ringer's over the first 24 hours) per UpToDate, but airway management takes absolute priority.\n\nKEY LEARNING POINTS:\nSinged nasal hairs, facial burns, and hoarseness are red flags for inhalation injury requiring early intubation before progressive airway edema makes it impossible. Pulse oximetry is unreliable in CO poisoning because it cannot distinguish carboxyhemoglobin from oxyhemoglobin. The clinical rule is to intubate early when inhalation injury is suspected rather than waiting for complete obstruction."
  },
  {
    "id": 619,
    "categoryId": 15,
    "question": "A 70-year-old on warfarin (INR 4.5) presents after a fall with headache and confusion. CT shows acute subdural hematoma with midline shift. What is the priority intervention?",
    "options": [
      "A) Neurosurgery only",
      "B) IV Vitamin K alone",
      "C) 4-factor PCC + IV Vitamin K",
      "D) FFP transfusion"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (4-factor PCC plus IV Vitamin K).\n\nPATHOPHYSIOLOGY:\nWarfarin inhibits vitamin K epoxide reductase (VKORC1), preventing the regeneration of reduced vitamin K required for hepatic gamma-carboxylation of clotting factors II, VII, IX, and X (and proteins C and S) per Harrison's Principles of Internal Medicine. The INR (international normalized ratio) reflects the degree of anticoagulation, with therapeutic ranges typically between 2.0 and 3.0 for most indications. An INR of 4.5 represents significant supratherapeutic anticoagulation with markedly elevated bleeding risk. In the setting of traumatic intracranial hemorrhage with midline shift, the anticoagulation must be reversed immediately, as expanding hematoma volume directly correlates with neurological deterioration and mortality per UpToDate.\n\nCLINICAL REASONING:\nThis patient has a life-threatening warfarin-associated intracranial hemorrhage requiring emergent reversal per the AHA/ASA guidelines for intracerebral hemorrhage. Four-factor prothrombin complex concentrate (4F-PCC, brand name Kcentra) is the preferred reversal agent because it provides immediate, complete INR correction within minutes by directly supplying the deficient vitamin K-dependent clotting factors (II, VII, IX, X) in concentrated form per UpToDate and the Cleveland Clinic. 4F-PCC is strongly preferred over fresh frozen plasma (FFP) for several reasons per Harrison's Principles of Internal Medicine: it acts within 10 to 15 minutes versus 6 to 8 hours for FFP infusion, requires a small infusion volume (approximately 20 to 40 mL versus 800 to 1,600 mL for FFP, avoiding volume overload), does not require ABO blood type matching or thawing time, and achieves more reliable INR normalization. IV vitamin K (10 mg infused slowly over 10 to 20 minutes) must be administered concurrently because PCC provides only transient factor replacement (half-life of factor VII is approximately 6 hours), while vitamin K enables endogenous hepatic factor synthesis to sustain reversal over 12 to 24 hours, preventing INR rebound per UpToDate.\n\nMANAGEMENT:\nAfter anticoagulation reversal, emergent neurosurgical consultation is required for evaluation of surgical evacuation per the Mayo Clinic. INR should be rechecked within 30 minutes of PCC administration to confirm correction to less than 1.5. Blood pressure should be aggressively lowered (target systolic less than 140 mmHg per the AHA INTERACT2 trial data) to reduce hematoma expansion.\n\nKEY LEARNING POINTS:\n4-factor PCC is preferred over FFP for life-threatening warfarin reversal because it provides immediate, complete INR correction in a small volume without requiring blood typing or thawing. IV vitamin K must be given concurrently to sustain reversal and prevent INR rebound after PCC factor levels decline. The combination of PCC plus vitamin K is the standard of care for warfarin-associated intracranial hemorrhage per AHA/ASA guidelines."
  },
  {
    "id": 620,
    "categoryId": 17,
    "question": "An 8-year-old presents with drooling, dysphagia, and 'hot potato' voice after eating popcorn. He is sitting upright, leaning forward. No stridor at rest. O2 sat 96%. What is the best next step?",
    "options": [
      "A) Immediate cricothyrotomy",
      "B) Direct laryngoscopy in OR setting",
      "C) Bronchoscopy at bedside",
      "D) CT neck"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Direct laryngoscopy in OR).\n\nPATHOPHYSIOLOGY:\nForeign body aspiration in children is a common and potentially life-threatening event, with peak incidence between ages 1-3 years. Objects may lodge in the supraglottic, glottic, or bronchial airways. Partial obstruction allows air movement but may acutely progress to complete obstruction from edema, manipulation, or positional change.\n\nCLINICAL PRESENTATION:\n- History of acute choking episode while eating or playing with small objects\n- Drooling, dysphagia, and muffled or hot potato voice suggest a supraglottic or hypopharyngeal location\n- Stridor (inspiratory): Upper airway obstruction\n- Wheezing (expiratory): Lower airway/bronchial foreign body\n- A child sitting upright and leaning forward with no stridor at rest indicates partial obstruction with a patent airway\n\nCRITICAL MANAGEMENT:\n- If the child is stable (breathing, maintaining oxygen saturation, no stridor at rest): Do NOT perform blind finger sweeps, back blows, or bedside laryngoscopy. These maneuvers can convert a partial obstruction into a complete one.\n- Transport the child to the operating room for direct laryngoscopy and rigid bronchoscopy under general anesthesia with ENT/anesthesia\n- Allow the child to remain in the position of comfort; avoid agitation\n\nIF COMPLETE OBSTRUCTION (unable to speak, cough, or breathe):\n- Infants (less than 1 year): 5 back blows + 5 chest thrusts, repeat cycle\n- Children (over 1 year): Abdominal thrusts (Heimlich maneuver)\n- If unsuccessful: Attempt direct laryngoscopy and Magill forceps removal; prepare for surgical airway\n\nDIAGNOSTIC WORKUP:\nChest and neck radiographs (inspiratory and expiratory views) may show radiopaque foreign bodies, unilateral hyperinflation (air trapping from ball-valve obstruction), or atelectasis. Note that most aspirated objects in children (food items) are radiolucent.\n\nKEY LEARNING POINTS:\nA stable child with suspected foreign body aspiration should go to the OR for controlled rigid bronchoscopy, not bedside intervention. Avoid agitating the child or performing maneuvers that could convert partial to complete obstruction. Abdominal thrusts or back blows are reserved for complete airway obstruction.\n\nREFERENCES:\nAHA/ARC BLS Guidelines; AAP; UpToDate; Harrison's Principles of Internal Medicine.\n---"
  },
  {
    "id": 621,
    "categoryId": 15,
    "question": "A 28-year-old presents after a seizure. Labs show sodium 118 mEq/L. He drank 6L of water during a marathon. What is the treatment?",
    "options": [
      "A) Fluid restriction alone",
      "B) Normal saline bolus",
      "C) Hypertonic saline (3%) bolus",
      "D) Demeclocycline"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Hypertonic saline 3% bolus).\n\nPATHOPHYSIOLOGY:\nHyponatremia (serum sodium less than 135 mEq/L) is the most common electrolyte abnormality encountered in clinical practice per Harrison's Principles of Internal Medicine. This patient has severe symptomatic hyponatremia (sodium 118 mEq/L with seizure) caused by acute water intoxication from excessive hypotonic fluid intake during a marathon. Excessive water consumption dilutes the extracellular sodium concentration, creating an osmotic gradient that drives water into brain cells, causing cerebral edema. The brain has limited compensatory mechanisms in acute hyponatremia (developing over less than 48 hours) because osmotic adaptation (extrusion of intracellular solutes to reduce cell swelling) requires 24 to 48 hours to develop per UpToDate. The clinical manifestations of cerebral edema progress from nausea and headache to confusion, seizures, brainstem herniation, and death.\n\nCLINICAL REASONING:\nSevere symptomatic hyponatremia with seizures or altered mental status is a medical emergency requiring immediate treatment with hypertonic saline (3% NaCl) per the Mayo Clinic and UpToDate. The recommended initial treatment is a 100 to 150 mL bolus of 3% saline administered over 10 to 20 minutes, which may be repeated up to 2 to 3 times if symptoms persist. The goal in the first 1 to 2 hours is to raise serum sodium by 4 to 6 mEq/L, which is sufficient to reduce cerebral edema and stop seizures. Sodium levels should be checked every 1 to 2 hours during active correction per Harrison's Principles of Internal Medicine.\n\nRISK OF OVERCORRECTION:\nThe rate of chronic hyponatremia correction must be carefully limited to avoid osmotic demyelination syndrome (ODS, formerly central pontine myelinolysis), a devastating neurological complication caused by rapid osmotic fluid shifts out of brain cells that have undergone osmotic adaptation per UpToDate. ODS characteristically involves the central pons but can also affect extrapontine structures, causing quadriplegia, pseudobulbar palsy, and locked-in syndrome. The recommended maximum correction rate per the Cleveland Clinic and current expert guidelines is 8 mEq/L in any 24-hour period for chronic hyponatremia. In acute hyponatremia (clearly less than 48 hours duration, as in this marathon runner), the risk of ODS is lower because osmotic adaptation has not yet occurred, and more rapid correction is safer per Harrison's Principles of Internal Medicine. If overcorrection occurs, desmopressin (DDAVP) can be administered to relower sodium by promoting free water retention per UpToDate.\n\nKEY LEARNING POINTS:\nSevere symptomatic hyponatremia with seizures requires emergent 3% hypertonic saline (100 to 150 mL bolus over 10 to 20 minutes), targeting a 4 to 6 mEq/L rise in the first 1 to 2 hours to halt cerebral edema. Chronic hyponatremia correction must not exceed 8 mEq/L in 24 hours to avoid osmotic demyelination syndrome. Acute hyponatremia (less than 48 hours, as in exercise-associated water intoxication) can be corrected more rapidly because osmotic adaptation has not yet occurred."
  },
  {
    "id": 622,
    "categoryId": 17,
    "question": "A 60-year-old diabetic presents with facial pain and a black necrotic eschar on the nasal turbinate. CT shows skull base erosion. He has DKA. What is the emergent treatment?",
    "options": [
      "A) IV antibiotics",
      "B) IV amphotericin B + emergent surgical debridement",
      "C) IV voriconazole",
      "D) Nasal packing"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (IV Amphotericin B + Emergent Surgical Debridement).\n\nDIAGNOSIS:\nRhinocerebral mucormycosis (zygomycosis), a rapidly progressive and life-threatening invasive fungal infection caused by fungi of the order Mucorales (Rhizopus, Mucor, Rhizomucor). This is a medical and surgical emergency with mortality rates of 50-80% even with treatment.\n\nCLINICAL PRESENTATION:\nThe classic presentation includes facial pain, nasal congestion progressing to black necrotic eschars on the nasal turbinates or palate, periorbital edema, and proptosis. The black eschar represents tissue infarction caused by fungal angioinvasion, where hyphae invade blood vessel walls, causing thrombosis and ischemic necrosis. CT imaging may show sinusitis with bony erosion, and the infection can rapidly extend into the orbit and brain.\n\nRISK FACTORS:\nDiabetic ketoacidosis is the most common predisposing condition because the acidotic, hyperglycemic environment with elevated free iron provides ideal growth conditions for Mucorales. Other risk factors include immunosuppression (transplant recipients, neutropenia), iron overload, and deferoxamine therapy.\n\nTREATMENT:\nTreatment requires BOTH aggressive antifungal therapy AND surgical debridement. IV liposomal amphotericin B is the drug of choice. Emergent surgical debridement of all necrotic tissue is essential because the fungal angioinvasion causes tissue infarction where antifungals cannot penetrate. Correction of the underlying DKA and metabolic derangements is critical. Posaconazole or isavuconazole can be used as step-down therapy.\n\nKEY LEARNING POINTS:\nMucormycosis in a diabetic with DKA and black nasal eschar is a surgical emergency. Treatment requires both IV amphotericin B AND surgical debridement. Black eschar results from fungal angioinvasion causing vascular thrombosis and tissue necrosis."
  },
  {
    "id": 623,
    "categoryId": 15,
    "question": "A 25-year-old after MVC is tachycardic, hypotensive, with distended neck veins and muffled heart sounds. Breath sounds are equal. What is the diagnosis?",
    "options": [
      "A) Tension pneumothorax",
      "B) Cardiac tamponade",
      "C) Massive hemothorax",
      "D) Aortic transection"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Cardiac tamponade).\n\nPATHOPHYSIOLOGY:\nCardiac tamponade occurs when fluid (blood, in the setting of trauma) accumulates in the pericardial space at a rate or volume that exceeds the pericardium's ability to stretch, compressing the cardiac chambers and impairing diastolic filling per Harrison's Principles of Internal Medicine. The pericardium is a relatively noncompliant fibrous sac, and acute accumulation of as little as 100 to 200 mL of blood (as in penetrating trauma) can produce hemodynamic collapse because the pericardium has no time to stretch and accommodate the effusion. The rising intrapericardial pressure first compresses the right atrium and right ventricle (the lowest-pressure chambers), reducing venous return and cardiac output. As intrapericardial pressure approaches intracardiac diastolic pressures, diastolic filling becomes critically impaired, producing equalization of diastolic pressures across all four chambers, the hemodynamic hallmark of tamponade per UpToDate.\n\nCLINICAL REASONING:\nThis patient presents with Beck's triad: hypotension (from decreased cardiac output), jugular venous distension (from impaired venous return to the compressed right heart), and muffled or distant heart sounds (from the insulating layer of blood surrounding the heart) per Harrison's Principles of Internal Medicine. Beck's triad is present in approximately one-third of acute traumatic tamponade cases and is essentially pathognomonic when all three components are identified per the Cleveland Clinic. The critical distinction from tension pneumothorax is that tamponade presents with equal bilateral breath sounds, whereas tension pneumothorax presents with absent breath sounds on the affected side and tracheal deviation toward the contralateral side per UpToDate. Pulsus paradoxus (an exaggerated drop in systolic blood pressure greater than 10 mmHg during inspiration) is another classic finding of tamponade, reflecting the exaggerated interventricular septal shift during respiration in a fixed pericardial space.\n\nMANAGEMENT:\nIn the trauma setting, pericardiocentesis (aspiration of pericardial blood via a subxiphoid approach, often ultrasound-guided) is the emergency temporizing procedure per the Mayo Clinic. Even removal of 15 to 20 mL of blood can produce dramatic hemodynamic improvement by reducing intrapericardial pressure below the critical threshold for chamber compression. Definitive treatment requires surgical exploration (emergency thoracotomy or sternotomy) to identify and repair the cardiac injury per the ATLS guidelines. The FAST (Focused Assessment with Sonography for Trauma) ultrasound examination can rapidly identify pericardial fluid at the bedside in the trauma bay per UpToDate.\n\nKEY LEARNING POINTS:\nBeck's triad (hypotension, JVD, muffled heart sounds) with equal bilateral breath sounds identifies cardiac tamponade in trauma, distinguishing it from tension pneumothorax (which has absent breath sounds and tracheal deviation). Acute tamponade from trauma can be caused by as little as 100 to 200 mL of blood due to pericardial noncompliance. Pericardiocentesis is the emergency temporizing procedure, with definitive surgical repair required."
  },
  {
    "id": 624,
    "categoryId": 11,
    "question": "A 35-year-old woman presents with depressed mood, anhedonia, and insomnia for 3 weeks after her mother's death. She denies suicidal ideation and is functioning at work. What is the most likely diagnosis?",
    "options": [
      "A) Major Depressive Disorder",
      "B) Normal grief reaction",
      "C) Adjustment Disorder",
      "D) Persistent Depressive Disorder"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Normal grief reaction).\n\nDIAGNOSTIC REASONING:\nThis patient presents with depressed mood, anhedonia, and insomnia lasting 3 weeks following the death of her mother, which is consistent with a normal (uncomplicated) grief reaction rather than major depressive disorder per Harrison's Principles of Internal Medicine and UpToDate. The DSM-5 removed the previous \"bereavement exclusion\" that had prevented diagnosing MDD within 2 months of a loss, but clinicians must still exercise careful judgment in distinguishing normal grief from a major depressive episode per the Cleveland Clinic.\n\nGRIEF VERSUS MAJOR DEPRESSION:\nNormal grief is characterized by waves of sadness and longing that are often triggered by reminders of the deceased, with the ability to experience moments of positive emotion and humor interspersed between grief episodes per the Mayo Clinic. The bereaved person typically maintains a sense of self-worth, can envision a future (even if diminished), and the dysphoria is focused on the loss. Major depressive disorder, by contrast, features persistent, pervasive depressed mood unrelated to specific triggers, marked feelings of worthlessness or excessive guilt (beyond guilt about the deceased), inability to experience any pleasure, psychomotor retardation, and particularly suicidal ideation with a plan per Harvard Health and Harrison's Principles of Internal Medicine. This patient denies suicidal ideation and remains functional, supporting the grief diagnosis per UpToDate.\n\nPROLONGED GRIEF DISORDER:\nThe DSM-5-TR introduced prolonged grief disorder (PGD) as a new diagnosis for grief that persists beyond 12 months (6 months in ICD-11) and is characterized by intense yearning, preoccupation with the deceased, identity disruption, marked difficulty accepting the death, emotional numbness, and significant functional impairment per UpToDate. At only 3 weeks, this patient's timeline is far too early for PGD or for diagnosing MDD in the context of bereavement per the Cleveland Clinic.\n\nCLINICAL APPROACH:\nSupportive counseling, validation of the grief process, and close follow-up are appropriate per the Mayo Clinic. Red flags that should prompt reevaluation for MDD include suicidal ideation, psychotic features, severe functional decline, marked feelings of worthlessness, or persistent symptoms beyond 2 to 3 months without improvement per Harrison's Principles of Internal Medicine.\n\nKEY LEARNING POINTS:\nNormal grief features waves of sadness with preserved self-worth and intermittent positive emotions, while MDD features persistent pervasive dysphoria with worthlessness and suicidal ideation. At 3 weeks post-loss with maintained function and no suicidal ideation, this presentation is normal bereavement. Prolonged grief disorder requires symptoms persisting beyond 12 months per DSM-5-TR."
  },
  {
    "id": 625,
    "categoryId": 11,
    "question": "A 45-year-old with depression has failed two adequate SSRI trials. His PHQ-9 is 18. What is the recommended next step?",
    "options": [
      "A) Try a third SSRI",
      "B) Augment with atypical antipsychotic or switch class",
      "C) Electroconvulsive therapy",
      "D) Psychotherapy alone"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Augment with atypical antipsychotic or switch class).\n\nCLINICAL REASONING:\nTreatment-resistant depression (TRD) is commonly defined as failure to achieve adequate response after two trials of antidepressants from different classes at adequate doses for adequate duration (typically 6 to 8 weeks each) per Harrison's Principles of Internal Medicine and UpToDate. This patient has failed two adequate SSRI trials with a PHQ-9 of 18 (moderately severe), warranting a change in strategy rather than a third SSRI trial per the Cleveland Clinic.\n\nAUGMENTATION STRATEGIES:\nThe STAR*D trial (Sequenced Treatment Alternatives to Relieve Depression), the largest study of treatment-resistant depression, demonstrated that response rates diminish with each successive antidepressant trial: approximately 37% remitted with first-line citalopram, while only 13% remitted by the fourth treatment step per UpToDate and Harvard Health. Evidence-based augmentation options include adding an atypical antipsychotic (aripiprazole has the strongest evidence, followed by quetiapine and brexanolone; aripiprazole augmentation produces remission in approximately 25 to 30% of SSRI non-responders), adding lithium (well-established augmentation with evidence from multiple RCTs), or adding thyroid hormone (T3, liothyronine 25 to 50 mcg/day) per Harrison's Principles of Internal Medicine and the Mayo Clinic.\n\nSWITCHING STRATEGIES:\nSwitching to a different antidepressant class (SNRI such as venlafaxine or duloxetine, bupropion, or mirtazapine) is an alternative to augmentation per UpToDate. Switching within the same class (trying a third SSRI) has diminishing returns and is generally not recommended after two adequate SSRI failures per the Cleveland Clinic. Newer options for TRD include esketamine (Spravato) nasal spray (FDA-approved for TRD in conjunction with an oral antidepressant) and transcranial magnetic stimulation (TMS, FDA-cleared for MDD non-responsive to medication) per Harvard Health.\n\nWHEN TO CONSIDER ECT:\nElectroconvulsive therapy (ECT) remains the most effective treatment for severe, refractory depression (remission rates of 50 to 70%) and is indicated for TRD with psychotic features, severe suicidality, catatonia, or medication intolerance per Harrison's Principles of Internal Medicine. It is not typically the next step after only two SSRI failures per UpToDate.\n\nKEY LEARNING POINTS:\nAfter two adequate SSRI failures, augmentation (aripiprazole, lithium, T3) or switching class (to SNRI, bupropion, or mirtazapine) is recommended rather than trying a third SSRI. The STAR*D trial showed diminishing remission rates with each successive treatment step. Esketamine nasal spray and TMS are newer FDA-approved options for treatment-resistant depression."
  },
  {
    "id": 626,
    "categoryId": 11,
    "question": "A 22-year-old presents with 2 weeks of elevated mood, decreased sleep (3 hours/night), rapid speech, and impulsive spending. What is the diagnosis?",
    "options": [
      "A) Bipolar I Disorder, Manic Episode",
      "B) Bipolar II Disorder",
      "C) Cyclothymic Disorder",
      "D) ADHD"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Bipolar I Disorder, Manic Episode).\n\nDIAGNOSTIC CRITERIA:\nBipolar I disorder is defined by the occurrence of at least one manic episode lasting 7 or more days (or any duration if hospitalization is required) per DSM-5 criteria per Harrison's Principles of Internal Medicine. A manic episode requires a distinct period of abnormally and persistently elevated, expansive, or irritable mood with increased energy or activity, plus at least three of the following (four if mood is irritable only): decreased need for sleep (feeling rested after 3 hours, as in this patient), pressured speech, racing thoughts or flight of ideas, distractibility, increased goal-directed activity or psychomotor agitation, and excessive involvement in pleasurable activities with high potential for painful consequences (impulsive spending, sexual indiscretions, reckless investments) per UpToDate and the Cleveland Clinic.\n\nDIFFERENTIAL DIAGNOSIS:\nBipolar II disorder requires at least one hypomanic episode (lasting 4 or more days with less severe symptoms that do not cause marked functional impairment or require hospitalization) plus at least one major depressive episode per the Mayo Clinic. This patient's 2 weeks of severe symptoms with impulsive spending (functional impairment) exceeds hypomania criteria. Cyclothymic disorder involves chronic (2 or more years) fluctuating hypomanic and depressive symptoms that never meet full criteria for either a manic or major depressive episode per Harrison's Principles of Internal Medicine. ADHD can feature distractibility, impulsivity, and restlessness but has a chronic, non-episodic course with onset before age 12 per UpToDate.\n\nTREATMENT:\nAcute mania requires mood stabilization with lithium (the gold standard with the strongest evidence for both acute mania and long-term prophylaxis), valproic acid (rapid loading is effective for acute mania), or a second-generation antipsychotic (olanzapine, quetiapine, aripiprazole, risperidone) per Harvard Health and the Cleveland Clinic. Antidepressant monotherapy is contraindicated in bipolar disorder due to the risk of inducing mania or rapid cycling per Harrison's Principles of Internal Medicine.\n\nKEY LEARNING POINTS:\nBipolar I requires at least one manic episode (7 or more days of elevated mood with decreased sleep need, pressured speech, grandiosity, and impulsive risk-taking). This is distinguished from Bipolar II (hypomania without marked impairment), cyclothymia (chronic subthreshold cycling), and ADHD (chronic non-episodic course). Lithium is the gold standard for acute mania and long-term prophylaxis."
  },
  {
    "id": 627,
    "categoryId": 11,
    "question": "A 70-year-old presents with progressive forgetfulness over 2 years, now getting lost in familiar places. MMSE is 20/30. Short-term memory loss is prominent. What is the most likely diagnosis?",
    "options": [
      "A) Delirium",
      "B) Alzheimer's disease",
      "C) Vascular dementia",
      "D) Normal aging"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Alzheimer's disease).\n\nCLINICAL REASONING:\nThis 70-year-old presents with the hallmark pattern of Alzheimer's disease: insidious onset of progressive memory impairment over 2 years, predominantly affecting short-term (episodic) memory, with gradual decline in spatial navigation (getting lost in familiar places) and an MMSE score of 20/30 (mild cognitive impairment to early dementia range) per Harrison's Principles of Internal Medicine and UpToDate. Alzheimer's disease accounts for 60 to 80% of all dementia cases and is the most common cause of dementia in older adults per the Cleveland Clinic.\n\nPATHOPHYSIOLOGY:\nAlzheimer's disease is characterized by extracellular amyloid-beta plaques (from abnormal cleavage of amyloid precursor protein by beta and gamma secretases) and intracellular neurofibrillary tangles (composed of hyperphosphorylated tau protein) that initially accumulate in the entorhinal cortex and hippocampus (explaining the early prominence of short-term memory loss) before spreading to the temporal, parietal, and eventually frontal cortices per Harrison's Principles of Internal Medicine. Synaptic loss and neuronal death produce progressive cortical atrophy visible on brain imaging per the Mayo Clinic.\n\nDIFFERENTIAL DIAGNOSIS:\nDelirium presents acutely (hours to days, not years), features fluctuating attention and consciousness, and is usually triggered by an identifiable medical cause (infection, medication, metabolic derangement) per UpToDate. Vascular dementia characteristically presents with stepwise decline (sudden worsening coinciding with cerebrovascular events), focal neurologic deficits, and prominent executive dysfunction rather than isolated memory loss per the Cleveland Clinic. Normal aging involves mild forgetfulness (misplacing keys, difficulty recalling names) but does not impair daily function or cause disorientation in familiar environments per Harvard Health.\n\nMANAGEMENT:\nCholinesterase inhibitors (donepezil, rivastigmine, galantamine) are first-line pharmacotherapy for mild to moderate Alzheimer's disease, providing modest symptomatic improvement by increasing acetylcholine availability in the synaptic cleft per Harrison's Principles of Internal Medicine. Memantine (an NMDA receptor antagonist) is added for moderate to severe disease per UpToDate. Newer anti-amyloid monoclonal antibodies (lecanemab, donanemab) have received FDA approval based on evidence of slowing cognitive decline in early Alzheimer's disease per the Mayo Clinic.\n\nKEY LEARNING POINTS:\nAlzheimer's disease presents with insidious progressive short-term memory loss (hippocampal involvement) and is the most common dementia (60 to 80% of cases). It is distinguished from delirium (acute, fluctuating) and vascular dementia (stepwise, executive dysfunction). Cholinesterase inhibitors are first-line, with newer anti-amyloid antibodies (lecanemab) showing disease-modifying potential."
  },
  {
    "id": 628,
    "categoryId": 11,
    "question": "A 16-year-old has difficulty concentrating, is easily distracted, fidgets constantly, and interrupts others. Symptoms present since age 7 in multiple settings. What is the first-line pharmacotherapy?",
    "options": [
      "A) Atomoxetine",
      "B) Methylphenidate or amphetamine",
      "C) Bupropion",
      "D) Clonidine"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Methylphenidate or amphetamine).\n\nDIAGNOSTIC CONFIRMATION:\nThis patient meets DSM-5 criteria for ADHD: multiple symptoms of inattention (difficulty concentrating, easily distracted) and hyperactivity-impulsivity (fidgeting, interrupting others) present since age 7 (before age 12 criterion satisfied), occurring in multiple settings (school, home), and causing functional impairment per Harrison's Principles of Internal Medicine and UpToDate. The combined presentation (both inattentive and hyperactive-impulsive symptoms) is the most common subtype per the Cleveland Clinic.\n\nFIRST-LINE PHARMACOTHERAPY:\nStimulant medications (methylphenidate and amphetamine formulations) are first-line pharmacotherapy for ADHD in children, adolescents, and adults per the American Academy of Pediatrics (AAP), American Academy of Child and Adolescent Psychiatry (AACAP), and UpToDate. Stimulants have the largest effect sizes of any ADHD medication (effect size approximately 0.8 to 1.0, considered large) and produce improvement in approximately 70 to 80% of patients per Harvard Health. Methylphenidate (Ritalin, Concerta, Focalin) blocks the dopamine transporter (DAT) and norepinephrine transporter (NET) in the prefrontal cortex and striatum, increasing catecholamine availability in the synaptic cleft per Harrison's Principles of Internal Medicine. Amphetamine formulations (Adderall, Vyvanse) both block reuptake and promote active release of dopamine and norepinephrine from presynaptic vesicles per the Cleveland Clinic.\n\nNON-STIMULANT ALTERNATIVES:\nAtomoxetine (Strattera), a selective norepinephrine reuptake inhibitor, is first-line for patients who cannot tolerate stimulants, have comorbid anxiety, or have substance abuse concerns per UpToDate. Alpha-2 agonists (guanfacine extended-release, clonidine extended-release) are second-line options, particularly useful for hyperactivity and oppositional symptoms per the Mayo Clinic. Bupropion has off-label evidence for adult ADHD but is not FDA-approved for this indication per the Cleveland Clinic.\n\nMONITORING:\nBefore initiating stimulants, clinicians should assess cardiovascular risk (personal and family history of sudden cardiac death, structural heart disease, arrhythmias), obtain baseline height, weight, blood pressure, and heart rate per Harvard Health. Ongoing monitoring includes growth parameters (stimulants may suppress appetite and slow growth), cardiovascular vitals, and screening for side effects including insomnia, appetite suppression, and mood changes per UpToDate.\n\nKEY LEARNING POINTS:\nStimulants (methylphenidate, amphetamine) are first-line ADHD treatment with the largest effect sizes (0.8 to 1.0) and 70 to 80% response rates. They work by increasing prefrontal dopamine and norepinephrine via transporter blockade. Atomoxetine is first-line for patients with contraindications to stimulants. Pre-treatment cardiovascular screening and ongoing growth monitoring are essential."
  },
  {
    "id": 629,
    "categoryId": 11,
    "question": "A 55-year-old with alcohol use disorder wants to maintain abstinence. He drinks a pint of vodka daily with history of withdrawal seizures. Which FDA-approved medication reduces craving?",
    "options": [
      "A) Gabapentin",
      "B) Naltrexone",
      "C) Benzodiazepines",
      "D) Baclofen"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Naltrexone).\n\nPHARMACOLOGY:\nNaltrexone is an opioid receptor antagonist (blocking mu, kappa, and delta opioid receptors) that is FDA-approved for maintaining abstinence in alcohol use disorder (AUD) per Harrison's Principles of Internal Medicine and UpToDate. Three medications are FDA-approved for AUD: naltrexone (oral 50 mg daily or extended-release intramuscular injection 380 mg monthly), acamprosate (which modulates glutamate/GABA balance), and disulfiram (which inhibits aldehyde dehydrogenase causing an aversive reaction to alcohol) per the Cleveland Clinic.\n\nMECHANISM:\nAlcohol stimulates endogenous opioid release in the ventral tegmental area and nucleus accumbens, producing the rewarding and reinforcing effects that drive continued drinking per Harrison's Principles of Internal Medicine. Naltrexone blocks these opioid receptors, reducing the pleasurable effects of alcohol (reward extinction), decreasing craving, and reducing the number of heavy drinking days per UpToDate. The COMBINE trial demonstrated that naltrexone (combined with medical management) significantly reduced heavy drinking days and improved drinking outcomes per Harvard Health and the Mayo Clinic.\n\nCLINICAL CONSIDERATIONS:\nNaltrexone should not be initiated until the patient has completed acute detoxification and is no longer physically dependent on alcohol, as it does not treat or prevent withdrawal per UpToDate. This patient's history of withdrawal seizures mandates medically supervised detoxification with benzodiazepines (using the CIWA-Ar protocol) before starting naltrexone per Harrison's Principles of Internal Medicine. Naltrexone is contraindicated in patients currently taking opioids (it will precipitate acute opioid withdrawal) and in acute hepatitis or liver failure (though mild to moderate liver disease is not a contraindication) per the Cleveland Clinic. Hepatic function should be monitored periodically per the Mayo Clinic.\n\nACAPROSATE VERSUS NALTREXONE:\nAcamprosate (which restores glutamate/GABA homeostasis disrupted by chronic alcohol exposure) is preferred in patients who have achieved complete abstinence, while naltrexone is more effective in patients whose goal is reducing heavy drinking per UpToDate. Acamprosate is renally eliminated and safe in liver disease but contraindicated in severe renal impairment per Harvard Health.\n\nKEY LEARNING POINTS:\nNaltrexone is an opioid antagonist that reduces alcohol reward and craving by blocking endogenous opioid release in the mesolimbic reward pathway. It must be initiated after detoxification (not during withdrawal) and is contraindicated with concurrent opioid use. The three FDA-approved AUD medications are naltrexone, acamprosate, and disulfiram."
  },
  {
    "id": 630,
    "categoryId": 11,
    "question": "A patient on fluoxetine 40mg for 6 months feels much better and wants to stop. What is the appropriate guidance?",
    "options": [
      "A) Stop immediately",
      "B) Taper over 2-4 weeks",
      "C) Continue 4-9 months from remission before tapering",
      "D) Switch medications first"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Continue 4 to 9 months from remission before tapering).\n\nGUIDELINE BASIS:\nThe APA, ACP, and NICE guidelines recommend continuing antidepressant therapy for a minimum of 4 to 9 months after achieving full symptomatic remission before considering tapering and discontinuation per UpToDate and Harrison's Principles of Internal Medicine. This continuation phase is critical because the risk of relapse (return of the same depressive episode) is highest in the first 6 to 12 months after remission, and premature discontinuation is the single most common cause of depressive relapse per the Cleveland Clinic.\n\nEVIDENCE:\nMultiple randomized controlled trials demonstrate that continuation-phase antidepressant therapy reduces relapse risk by approximately 50 to 70% compared to placebo substitution after remission per UpToDate. A meta-analysis in The Lancet Psychiatry confirmed that continuing antidepressants for 6 to 12 months after remission significantly reduces the likelihood of depressive recurrence across all antidepressant classes per Harvard Health.\n\nTAPERING APPROACH:\nWhen discontinuation is appropriate, all SSRIs (except fluoxetine, which has a long half-life providing a built-in self-taper) should be gradually reduced over 4 to 8 weeks to minimize discontinuation syndrome (dizziness, nausea, brain zaps, irritability, insomnia) per the Mayo Clinic and Harrison's Principles of Internal Medicine. Fluoxetine at 40 mg can often be stopped without a prolonged taper due to its active metabolite norfluoxetine (half-life 4 to 16 days) per UpToDate.\n\nMAINTENANCE THERAPY:\nPatients with risk factors for recurrence (three or more prior episodes, severe initial episode, residual symptoms, family history of recurrent depression, comorbid anxiety, early age of onset) should be considered for long-term maintenance therapy of 1 to 3 years or indefinitely per the Cleveland Clinic and UpToDate. This patient at 6 months post-remission on a first episode should continue for at least 4 to 9 months from the point of remission before tapering per Harrison's Principles of Internal Medicine.\n\nKEY LEARNING POINTS:\nAntidepressants should be continued 4 to 9 months after achieving remission to prevent relapse, which is highest in the first 6 to 12 months. Premature discontinuation is the most common cause of depressive relapse. Patients with three or more prior episodes, severe presentations, or residual symptoms should consider indefinite maintenance therapy."
  },
  {
    "id": 631,
    "categoryId": 11,
    "question": "A 30-year-old reports binge eating followed by self-induced vomiting 3-4 times per week for 6 months. She is normal weight. What is the first-line treatment?",
    "options": [
      "A) Fluoxetine 60mg daily",
      "B) Topiramate",
      "C) Cognitive Behavioral Therapy",
      "D) Hospitalization"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Cognitive Behavioral Therapy).\n\nDIAGNOSTIC CONTEXT:\nThis patient meets DSM-5 criteria for bulimia nervosa: recurrent episodes of binge eating (consuming an objectively large amount of food with a sense of loss of control) followed by compensatory behaviors (self-induced vomiting) occurring at least once per week for 3 months, with self-evaluation unduly influenced by body weight and shape, and not occurring exclusively during anorexia nervosa per Harrison's Principles of Internal Medicine and UpToDate. Normal weight distinguishes bulimia from anorexia nervosa binge-purge subtype (which occurs at significantly low body weight) per the Cleveland Clinic.\n\nFIRST-LINE TREATMENT:\nCognitive Behavioral Therapy specifically adapted for eating disorders (CBT-E, or enhanced CBT) is the established first-line treatment for bulimia nervosa in adults, supported by the strongest evidence base of any intervention per UpToDate and the Mayo Clinic. CBT-E addresses the cognitive distortions maintaining the binge-purge cycle: overvaluation of weight and shape, dietary restraint and restriction (which triggers binge episodes), and compensatory behaviors. The treatment typically involves 20 sessions over 20 weeks and produces abstinence from binge-purge episodes in approximately 40 to 50% of patients, with an additional 30% achieving significant reduction per Harvard Health.\n\nPHARMACOLOGIC OPTIONS:\nFluoxetine (Prozac) at 60 mg daily is the only FDA-approved medication for bulimia nervosa and is recommended as either an adjunct to CBT or as second-line monotherapy when CBT is unavailable or insufficient per Harrison's Principles of Internal Medicine. The effective dose for bulimia (60 mg) is higher than the typical antidepressant dose (20 mg), and the anti-bulimic effect is independent of antidepressant action per UpToDate. Topiramate has off-label evidence for reducing binge frequency but is not first-line due to cognitive side effects per the Cleveland Clinic.\n\nMEDICAL COMPLICATIONS:\nClinicians should monitor for complications of purging including hypokalemia (from vomiting-induced chloride and potassium losses), metabolic alkalosis, dental enamel erosion, parotid gland enlargement (sialadenosis), esophageal tears (Mallory-Weiss syndrome), and Russell's sign (calluses on dorsal knuckles from self-induced vomiting) per the Mayo Clinic and Harrison's Principles of Internal Medicine.\n\nKEY LEARNING POINTS:\nCBT-E is first-line treatment for bulimia nervosa, achieving binge-purge abstinence in 40 to 50% of patients by addressing overvaluation of weight/shape and the restriction-binge-purge cycle. Fluoxetine 60 mg daily is the only FDA-approved medication and is second-line or adjunctive. Monitor for hypokalemia, metabolic alkalosis, dental erosion, and esophageal injury from purging."
  },
  {
    "id": 632,
    "categoryId": 11,
    "question": "A 25-year-old veteran reports intrusive memories, nightmares, hypervigilance, and avoidance 8 months after combat. What is the first-line treatment?",
    "options": [
      "A) Benzodiazepines",
      "B) Prazosin only",
      "C) Trauma-focused psychotherapy",
      "D) Antipsychotics"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Trauma-focused psychotherapy).\n\nDIAGNOSTIC CONTEXT:\nThis patient meets DSM-5 criteria for post-traumatic stress disorder (PTSD): exposure to a traumatic event (combat), followed by symptoms lasting more than 1 month across four symptom clusters: intrusion (intrusive memories, nightmares), avoidance (avoidance of trauma-related stimuli), negative alterations in cognition and mood, and hyperarousal (hypervigilance) per Harrison's Principles of Internal Medicine and UpToDate. At 8 months, this is well beyond the 1-month threshold that distinguishes PTSD from acute stress disorder (which resolves within 1 month) per the Cleveland Clinic.\n\nFIRST-LINE TREATMENT:\nTrauma-focused psychotherapies are recommended as first-line treatment for PTSD by the APA, VA/DoD Clinical Practice Guidelines, and international guidelines, with stronger evidence than pharmacotherapy per UpToDate and Harvard Health. The three evidence-based trauma-focused therapies are Prolonged Exposure (PE, which involves repeated, systematic confrontation with trauma memories and avoided situations to facilitate emotional processing and extinction of fear responses), Cognitive Processing Therapy (CPT, which identifies and modifies maladaptive trauma-related beliefs called \"stuck points\"), and Eye Movement Desensitization and Reprocessing (EMDR, which uses bilateral stimulation during trauma recall to facilitate adaptive processing) per Harrison's Principles of Internal Medicine and the Mayo Clinic.\n\nPHARMACOTHERAPY:\nWhen pharmacotherapy is needed (as monotherapy if trauma-focused therapy is unavailable, or as augmentation), SSRIs (sertraline and paroxetine are the only FDA-approved medications for PTSD) and venlafaxine (SNRI) are first-line per UpToDate. Prazosin (an alpha-1 adrenergic antagonist) has evidence for reducing PTSD-related nightmares by blocking noradrenergic hyperactivation during sleep, though recent VA trials have shown mixed results per the Cleveland Clinic. Benzodiazepines are not recommended for PTSD (they impair fear extinction, the mechanism underlying exposure therapy, and may worsen long-term outcomes) per Harvard Health.\n\nKEY LEARNING POINTS:\nTrauma-focused psychotherapies (Prolonged Exposure, Cognitive Processing Therapy, EMDR) are first-line for PTSD, with stronger evidence than medications. Sertraline and paroxetine are the only FDA-approved PTSD pharmacotherapies. Benzodiazepines are specifically not recommended because they impair fear extinction and may worsen outcomes."
  },
  {
    "id": 633,
    "categoryId": 2,
    "question": "A 60-year-old with COPD (FEV1 45%) has had 3 exacerbations this year on tiotropium alone. Eosinophil count is 350 cells/ÂµL. According to GOLD 2024, what should be added?",
    "options": [
      "A) LABA only",
      "B) Inhaled corticosteroid",
      "C) Roflumilast",
      "D) Chronic azithromycin"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Inhaled corticosteroid).\n\nCLINICAL REASONING:\nThis patient has COPD (FEV1 45% predicted, indicating severe airflow limitation per the GOLD classification) with 3 exacerbations in the past year (qualifying as GOLD Group E) on LAMA monotherapy (tiotropium), with a blood eosinophil count of 350 cells per microliter. Per the GOLD 2024 guidelines, the first escalation step from LAMA monotherapy for a frequent exacerbator is to add a LABA to form LAMA/LABA combination therapy per UpToDate. However, with eosinophils of 350 (exceeding the 300 threshold), the guidelines support proceeding directly to LAMA/LABA/ICS triple therapy, or at minimum adding ICS to the current LAMA, with subsequent LABA addition to complete the triple combination per Harrison's Principles of Internal Medicine.\n\nRATIONALE FOR ICS IN EOSINOPHILIC COPD:\nElevated blood eosinophils identify a COPD phenotype with steroid-responsive airway inflammation per the Cleveland Clinic. The FLAME trial demonstrated that LAMA/LABA was superior to ICS/LABA for exacerbation prevention in the general COPD population, but subgroup analyses consistently showed that patients with eosinophils 300 or greater derived significant additional benefit from ICS addition per UpToDate. ICS use in COPD carries a recognized risk of pneumonia (demonstrated in the TORCH and INSPIRE trials), which is why eosinophil-guided prescribing is essential: reserving ICS for patients most likely to benefit (eosinophils 300 or greater) while avoiding it in those unlikely to benefit (eosinophils less than 100), where pneumonia risk outweighs any anti-inflammatory advantage per the Mayo Clinic.\n\nALTERNATIVES NOT YET INDICATED:\nRoflumilast is a PDE4 inhibitor reserved for patients on triple therapy who continue to exacerbate, specifically those with chronic bronchitis phenotype and FEV1 less than 50% per GOLD 2024 guidelines. While this patient's FEV1 of 45% would eventually qualify for roflumilast, it is not the next step before optimizing inhaler therapy. Chronic azithromycin is similarly a post-triple-therapy option for former smokers, requiring QTc monitoring and hearing assessment per UpToDate.\n\nKEY LEARNING POINTS:\nIn a COPD patient on LAMA alone with frequent exacerbations and eosinophils 300 or greater, adding ICS (with LABA to form triple therapy) is the appropriate escalation per GOLD 2024. ICS use in COPD is guided by blood eosinophils to balance anti-inflammatory benefit against pneumonia risk. Roflumilast and azithromycin are reserved for persistent exacerbators despite optimized triple therapy."
  },
  {
    "id": 634,
    "categoryId": 2,
    "question": "A 50-year-old smoker with 35 pack-years quit 5 years ago. Per USPSTF 2021, is he eligible for lung cancer screening?",
    "options": [
      "A) No - must be current smoker",
      "B) No - quit too long ago",
      "C) Yes - meets criteria for annual low-dose CT",
      "D) No - only CXR is recommended"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Yes - meets criteria for annual low-dose CT).\n\nSCREENING RATIONALE:\nLung cancer is the leading cause of cancer death in the United States, and the majority of cases are diagnosed at advanced stages when curative treatment is no longer possible per the National Cancer Institute. The National Lung Screening Trial (NLST, published in the New England Journal of Medicine) demonstrated a 20% reduction in lung cancer mortality with annual low-dose CT compared to chest radiography in high-risk individuals. The subsequent NELSON trial confirmed these findings with a 24% mortality reduction in men per UpToDate.\n\nUSPSTF 2021 CRITERIA:\nThe USPSTF updated its lung cancer screening recommendation in 2021 to expand eligibility per the USPSTF and the CDC. Annual low-dose CT screening is recommended for adults aged 50 to 80 years with at least a 20 pack-year smoking history who currently smoke or have quit within the past 15 years. The 2021 update lowered the age threshold from 55 to 50 and the pack-year requirement from 30 to 20, substantially expanding the eligible population and addressing disparities in screening access among racial and ethnic minorities per the American Cancer Society.\n\nAPPLICATION TO THIS PATIENT:\nThis patient meets all three criteria per UpToDate: age 50 (meets the 50 to 80 age range), 35 pack-year history (exceeds the 20 pack-year minimum), and quit 5 years ago (within the 15-year quit window). He is eligible for annual low-dose CT screening. Screening should be discontinued once the patient has not smoked for 15 years, develops a health condition that substantially limits life expectancy, or is unable or unwilling to undergo curative lung surgery per the USPSTF and the Mayo Clinic.\n\nSHARED DECISION-MAKING:\nThe USPSTF recommends that screening be preceded by a shared decision-making discussion addressing the benefits (mortality reduction), harms (false-positive results leading to invasive procedures, incidental findings requiring follow-up, radiation exposure, overdiagnosis), and the importance of continued smoking cessation per Harrison's Principles of Internal Medicine. Screening should be performed at centers with expertise in low-dose CT protocols and established processes for nodule management following the Lung-RADS classification system per the Cleveland Clinic.\n\nKEY LEARNING POINTS:\nUSPSTF 2021 recommends annual low-dose CT for adults aged 50 to 80 with 20 or more pack-year history who currently smoke or quit within 15 years. The NLST demonstrated a 20% lung cancer mortality reduction with LDCT screening. Screening is not a substitute for smoking cessation, and shared decision-making regarding benefits and harms is required."
  },
  {
    "id": 635,
    "categoryId": 2,
    "question": "A 35-year-old woman with asthma uses albuterol daily and wakes coughing 3 nights per week. She is on no controller. According to GINA 2024, what is the preferred treatment?",
    "options": [
      "A) Continue SABA alone",
      "B) Add daily low-dose ICS",
      "C) Start ICS-formoterol as maintenance and reliever (MART)",
      "D) Add daily LABA without ICS"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (ICS-formoterol as maintenance and reliever therapy, MART).\n\nCLINICAL REASONING:\nThis patient uses albuterol daily and wakes coughing 3 nights per week, indicating uncontrolled asthma with daily symptoms and frequent nocturnal awakenings on no controller therapy per UpToDate. Applying the Rules of Two, her symptom frequency (daily albuterol use) and nocturnal awakenings (3 per week, far exceeding 2 per month) place her at minimum in the moderate persistent category per NHLBI classification. However, the GINA 2024 approach focuses on treatment response rather than pre-treatment severity classification, and this patient clearly requires Step 3 therapy per Harrison's Principles of Internal Medicine.\n\nTREATMENT APPROACH:\nGINA 2024 Step 3 preferred treatment (Track 1) is low-dose ICS-formoterol used as both maintenance and reliever therapy, known as the MART (Maintenance And Reliever Therapy) approach per GINA 2024 guidelines. The patient takes a scheduled dose of ICS-formoterol (typically budesonide-formoterol 200/6 mcg one inhalation twice daily) and uses the same inhaler for rescue symptoms as needed. This single-inhaler approach ensures anti-inflammatory corticosteroid delivery with every reliever dose, eliminates the need for a separate rescue inhaler, and simplifies the regimen to improve adherence per UpToDate.\n\nEVIDENCE BASE:\nThe MART approach has been validated in multiple large randomized controlled trials per the Cleveland Clinic. The SMART (Single Maintenance and Reliever Therapy) program demonstrated that budesonide-formoterol as both maintenance and reliever reduced severe exacerbations by 45% compared to the same maintenance dose plus SABA rescue. The mechanism is that patients who are deteriorating automatically receive increased anti-inflammatory doses as their rescue use increases, providing an inherent self-adjusting feature per the Mayo Clinic.\n\nWHY NOT OTHER OPTIONS:\nContinuing SABA alone (A) is never recommended per GINA 2024 due to increased exacerbation risk. Adding daily low-dose ICS (B) without a LABA would be Step 2 therapy, insufficient for this patient's symptom burden per UpToDate. Adding a daily LABA without ICS (D) is contraindicated in asthma due to the SMART trial evidence of increased asthma-related deaths with LABA monotherapy per Harrison's Principles of Internal Medicine.\n\nKEY LEARNING POINTS:\nThe MART approach (ICS-formoterol as both maintenance and reliever with a single inhaler) is the preferred GINA 2024 Step 3 therapy, ensuring anti-inflammatory delivery with every rescue dose. This self-adjusting strategy reduces severe exacerbations by 45% compared to fixed-dose maintenance plus SABA rescue. LABA monotherapy without ICS is contraindicated in asthma due to increased asthma-related death risk."
  },
  {
    "id": 636,
    "categoryId": 2,
    "question": "A 70-year-old with community-acquired pneumonia is admitted. CURB-65 score is 2. He has no recent hospitalization. What is the recommended empiric antibiotic regimen?",
    "options": [
      "A) Amoxicillin alone",
      "B) Respiratory fluoroquinolone OR beta-lactam + macrolide",
      "C) Vancomycin + piperacillin-tazobactam",
      "D) Azithromycin alone"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Respiratory fluoroquinolone alone OR beta-lactam plus macrolide).\n\nCLINICAL REASONING:\nThis 70-year-old patient has community-acquired pneumonia requiring hospital admission based on a CURB-65 score of 2 per the ATS/IDSA 2019 guidelines. The CURB-65 score assigns one point each for Confusion, Uremia (BUN greater than 20 mg/dL), Respiratory rate 30 or greater, Blood pressure less than 90 systolic or 60 diastolic, and age 65 or older per Harrison's Principles of Internal Medicine. A score of 0 to 1 supports outpatient management, a score of 2 warrants short hospitalization or closely supervised outpatient care, and a score of 3 to 5 requires hospitalization with ICU consideration for scores of 4 to 5 per UpToDate.\n\nINPATIENT NON-ICU REGIMEN:\nFor non-ICU inpatients, the ATS/IDSA 2019 guidelines recommend two equivalent empiric regimens per the Cleveland Clinic: a respiratory fluoroquinolone alone (levofloxacin 750 mg daily or moxifloxacin 400 mg daily), or a beta-lactam (ceftriaxone 1 to 2 grams IV daily, or ampicillin-sulbactam 1.5 to 3 grams IV every 6 hours) plus a macrolide (azithromycin 500 mg IV/PO daily). Both regimens provide coverage against the most common CAP pathogens: Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and atypical organisms (Mycoplasma, Chlamydophila, Legionella) per Harrison's Principles of Internal Medicine. The macrolide or fluoroquinolone component is essential for atypical coverage, as clinical presentation alone cannot reliably distinguish typical from atypical pneumonia per the Mayo Clinic.\n\nTREATMENT DURATION AND RESPONSE:\nA treatment duration of 5 days is adequate for the majority of patients who achieve clinical stability, defined as afebrile for 48 hours or more, improving respiratory status, ability to take oral medications, and hemodynamic stability without vasopressor support per the ATS/IDSA guidelines and UpToDate. Procalcitonin-guided therapy, with antibiotic discontinuation when levels fall below 0.25 ng/mL, has been shown to reduce antibiotic exposure without increasing adverse outcomes. Patients who fail to improve within 72 hours should be evaluated for complications (empyema, lung abscess), resistant organisms, or alternative diagnoses per the Cleveland Clinic.\n\nKEY LEARNING POINTS:\nInpatient non-ICU CAP empiric therapy is a respiratory fluoroquinolone alone or a beta-lactam plus macrolide per ATS/IDSA 2019 guidelines. CURB-65 score of 2 warrants hospitalization for CAP management. Five days of antibiotics is sufficient for most patients achieving clinical stability within 48 to 72 hours."
  },
  {
    "id": 637,
    "categoryId": 17,
    "question": "A 45-year-old obese male (BMI 38) reports excessive daytime sleepiness, morning headaches, and witnessed apneas. What is the diagnostic test of choice?",
    "options": [
      "A) Overnight pulse oximetry",
      "B) Polysomnography",
      "C) Multiple Sleep Latency Test",
      "D) Serum ferritin"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Polysomnography).\n\nPATHOPHYSIOLOGY:\nObstructive sleep apnea (OSA) results from repetitive partial or complete collapse of the upper airway during sleep, caused by reduced pharyngeal muscle tone in the setting of anatomic narrowing. Each obstructive event causes hypoxemia, hypercapnia, increased respiratory effort, and cortical arousal (sleep fragmentation). The repetitive cycles of hypoxemia-reoxygenation generate oxidative stress and systemic inflammation that drive the cardiovascular, metabolic, and neurocognitive consequences of untreated OSA.\n\nCLINICAL PRESENTATION:\n- Excessive daytime sleepiness (cardinal symptom, assess with Epworth Sleepiness Scale)\n- Witnessed apneas (bed partner reports breathing pauses)\n- Loud, habitual snoring\n- Morning headaches (from nocturnal hypercapnia and cerebral vasodilation)\n- Nocturia, unrefreshing sleep, impaired concentration, mood disturbance\n\nRISK FACTORS:\nObesity (BMI greater than 30, strongest modifiable risk factor), male sex, age over 50, neck circumference greater than 17 inches (men) or 16 inches (women), craniofacial abnormalities (retrognathia, macroglossia), family history.\n\nDIAGNOSIS:\n1. In-laboratory polysomnography (PSG) is the gold standard diagnostic test, measuring airflow, respiratory effort, oxygen saturation, EEG, EOG, EMG, and body position\n2. Home sleep apnea testing (HSAT) is acceptable for patients with high pretest probability of moderate-to-severe OSA without significant comorbidities (per AASM 2017 guidelines)\n3. Severity classification by Apnea-Hypopnea Index (AHI): Mild (5-14), Moderate (15-29), Severe (30 or greater)\n\nTREATMENT:\n1. CPAP (continuous positive airway pressure): First-line for moderate-to-severe OSA\n2. Weight loss: 10% weight reduction can decrease AHI by approximately 26%\n3. Positional therapy (for positional OSA)\n4. Oral appliances (mandibular advancement devices): Alternative for mild-moderate OSA or CPAP intolerance\n5. Surgery (uvulopalatopharyngoplasty, hypoglossal nerve stimulation) for selected patients\n\nKEY LEARNING POINTS:\nPolysomnography is the gold standard for OSA diagnosis. HSAT is appropriate for high-probability patients without major comorbidities. CPAP is first-line treatment for moderate-to-severe OSA. Untreated OSA significantly increases risk of hypertension, atrial fibrillation, stroke, and motor vehicle accidents.\n\nREFERENCES:\nAASM Clinical Practice Guidelines for OSA; USPSTF; UpToDate; Harrison's Principles of Internal Medicine.\n---"
  },
  {
    "id": 638,
    "categoryId": 2,
    "question": "A 55-year-old presents with progressive dyspnea and dry cough over 1 year. Exam reveals fine 'velcro' crackles at bases and clubbing. HRCT shows peripheral, basilar reticular opacities with honeycombing. What is the diagnosis?",
    "options": [
      "A) COPD",
      "B) Idiopathic pulmonary fibrosis",
      "C) Sarcoidosis",
      "D) Hypersensitivity pneumonitis"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Idiopathic Pulmonary Fibrosis).\n\nPATHOPHYSIOLOGY:\nIdiopathic pulmonary fibrosis is a chronic, progressive, and ultimately fatal fibrotic interstitial lung disease of unknown etiology that typically affects adults over age 50 per Harrison's Principles of Internal Medicine. The current pathogenic model holds that IPF results from repetitive subclinical injury to the alveolar epithelium (from cigarette smoke, microaspiration, viral infections, or genetic susceptibility factors including mutations in telomerase genes TERT and TERC and surfactant protein genes) followed by aberrant wound healing responses per UpToDate. Rather than normal repair, the injured epithelium signals fibroblast proliferation and differentiation into myofibroblasts, which deposit excessive extracellular matrix (collagen) in the interstitium. This progressive fibrosis destroys normal alveolar architecture, thickens the alveolar-capillary membrane, reduces lung compliance, and impairs gas exchange per the Cleveland Clinic.\n\nCLINICAL REASONING:\nThis patient presents with the classic IPF phenotype per UpToDate: a middle-aged to older adult with insidious progressive exertional dyspnea and nonproductive cough over months to years, fine bibasilar inspiratory crackles with a distinctive velcro-like quality (caused by the snapping open of fibrotic, collapsed alveoli during inspiration), digital clubbing (present in approximately 50% of IPF patients), and HRCT findings of a usual interstitial pneumonia (UIP) pattern. The UIP pattern on HRCT is characterized by peripheral (subpleural), basilar-predominant reticular opacities, honeycombing (clustered thick-walled cystic spaces representing destroyed alveoli), traction bronchiectasis, and minimal or no ground-glass opacity per the ATS/ERS/JRS/ALAT 2022 diagnostic guidelines and the Mayo Clinic. When the HRCT pattern is definite UIP in the appropriate clinical context, surgical lung biopsy is not required for diagnosis per Harrison's Principles of Internal Medicine.\n\nPULMONARY FUNCTION TESTING:\nIPF produces a restrictive pattern on spirometry (reduced FVC with preserved or elevated FEV1/FVC ratio) and reduced total lung capacity on plethysmography. The DLCO (diffusion capacity for carbon monoxide) is reduced, often disproportionately to the restrictive defect, reflecting impaired gas transfer across the thickened alveolar-capillary membrane. Serial FVC and DLCO measurements are used to monitor disease progression per UpToDate.\n\nTREATMENT:\nTwo antifibrotic medications, pirfenidone and nintedanib, slow the rate of FVC decline by approximately 50% and are the standard of care per the Cleveland Clinic and NCCN guidelines. Neither drug reverses established fibrosis, and both have notable side effects (pirfenidone causes photosensitivity and GI upset; nintedanib causes diarrhea and hepatotoxicity). Lung transplantation is the only intervention that improves survival and should be considered early in the disease course for eligible patients per the Mayo Clinic. Median survival from diagnosis is approximately 3 to 5 years per Harrison's Principles of Internal Medicine. Importantly, corticosteroids and immunosuppressants are not effective and may be harmful in IPF, distinguishing it from other interstitial lung diseases such as sarcoidosis and hypersensitivity pneumonitis that are steroid-responsive.\n\nKEY LEARNING POINTS:\nIPF presents with progressive dyspnea, velcro crackles, clubbing, and a UIP pattern on HRCT (peripheral basilar reticular opacities, honeycombing, traction bronchiectasis). Pirfenidone and nintedanib slow FVC decline but do not reverse fibrosis, and lung transplantation is the only survival-improving intervention. Corticosteroids are ineffective and potentially harmful in IPF, unlike in other interstitial lung diseases."
  },
  {
    "id": 639,
    "categoryId": 13,
    "question": "A 35-year-old woman presents with fatigue, joint pain, and malar rash sparing nasolabial folds. Labs show positive ANA, anti-dsDNA, low C3/C4. Urinalysis shows proteinuria and RBC casts. What is the next priority step?",
    "options": [
      "A) Start hydroxychloroquine alone",
      "B) Renal biopsy",
      "C) Start NSAID",
      "D) Repeat ANA in 3 months"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Renal biopsy).\n\nDIAGNOSIS:\nThis patient presents with classic systemic lupus erythematosus (SLE) based on the malar rash sparing nasolabial folds, positive ANA, elevated anti-dsDNA, and hypocomplementemia (low C3 and C4 indicating complement consumption from immune complex deposition). The critical finding is the urinalysis showing proteinuria and RBC casts, which indicate active glomerulonephritis. RBC casts are pathognomonic for glomerular inflammation and, in the context of SLE with serologic activity, strongly suggest lupus nephritis.\n\nWHY RENAL BIOPSY IS THE PRIORITY:\nRenal biopsy is essential because lupus nephritis is classified into six histologic classes (ISN/RPS classification) that carry vastly different prognoses and treatment requirements. Class I (minimal mesangial) and Class II (mesangial proliferative) have favorable prognosis and may require only supportive care. Class III (focal proliferative) and Class IV (diffuse proliferative) are the most common and most severe forms, requiring aggressive immunosuppressive induction therapy. Class V (membranous) causes nephrotic syndrome. Class VI (advanced sclerosing) represents irreversible damage. Because the clinical presentation alone cannot reliably distinguish between classes, biopsy findings directly determine whether the patient needs aggressive immunosuppression (mycophenolate mofetil or cyclophosphamide) or conservative management.\n\nTREATMENT FRAMEWORK:\nHydroxychloroquine is recommended for all SLE patients regardless of disease activity, as it reduces flares, organ damage accrual, and mortality. For Class III and IV lupus nephritis, induction therapy consists of high-dose corticosteroids plus either mycophenolate mofetil (preferred per 2024 EULAR/ERA guidelines for most patients) or intravenous cyclophosphamide (Euro-Lupus or NIH protocol). Belimumab (anti-BLyS) and voclosporin (calcineurin inhibitor) are now approved as add-on therapies that improve renal response rates. Maintenance therapy with mycophenolate mofetil continues for at least three to five years. ACE inhibitors or ARBs are used for proteinuria reduction and renoprotection.\n\nKEY LEARNING POINTS:\nRBC casts on urinalysis in an SLE patient indicate glomerulonephritis and mandate renal biopsy to determine ISN/RPS class. Biopsy classification directly guides treatment intensity, as Class III and IV require aggressive immunosuppression while milder classes may not. Hydroxychloroquine is recommended for all SLE patients. Mycophenolate mofetil is the preferred induction agent for most proliferative lupus nephritis."
  },
  {
    "id": 640,
    "categoryId": 13,
    "question": "A 60-year-old man presents with sudden onset severe pain, swelling, and erythema of the first MTP joint. He recently started hydrochlorothiazide. Joint aspiration shows negatively birefringent crystals. What is the first-line treatment for acute gout?",
    "options": [
      "A) Allopurinol",
      "B) Colchicine, NSAIDs, or corticosteroids",
      "C) Probenecid",
      "D) Febuxostat"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Colchicine, NSAIDs, or corticosteroids).\n\nDIAGNOSIS:\nThis presentation is classic for acute gouty arthritis: sudden-onset severe pain, swelling, and erythema of the first metatarsophalangeal joint (podagra) in a patient with a new risk factor for hyperuricemia (hydrochlorothiazide). Joint aspiration confirming negatively birefringent, needle-shaped monosodium urate crystals under compensated polarized light microscopy is the gold standard for definitive diagnosis and distinguishes gout from pseudogout (calcium pyrophosphate crystals, which are positively birefringent and rhomboid-shaped).\n\nACUTE FLARE MANAGEMENT:\nThe 2020 American College of Rheumatology guidelines recommend three equally effective first-line options for acute gout flares. NSAIDs at full anti-inflammatory doses (naproxen 500 mg twice daily or indomethacin 50 mg three times daily) provide rapid relief and are appropriate for patients without contraindications (renal disease, peptic ulcer, cardiovascular risk). Colchicine is most effective when initiated within 12 to 36 hours of flare onset, using the low-dose regimen (1.2 mg followed by 0.6 mg one hour later), which the AGREE trial demonstrated is as effective as high-dose colchicine with significantly fewer gastrointestinal side effects. Systemic corticosteroids (prednisone 30 to 40 mg daily for 5 to 7 days) are excellent alternatives when NSAIDs and colchicine are contraindicated, such as in patients with chronic kidney disease. Intra-articular corticosteroid injection is highly effective for monoarticular flares.\n\nIMPORTANT DISTINCTION FROM URATE-LOWERING THERAPY:\nAllopurinol, febuxostat, and probenecid are urate-lowering therapies (ULTs) used for chronic gout management, not acute flare treatment. Starting ULT during an acute flare can worsen and prolong the attack by causing rapid uric acid shifts that mobilize crystals. ULT should be initiated two to four weeks after flare resolution, with concurrent anti-inflammatory prophylaxis (low-dose colchicine 0.6 mg daily or twice daily) for three to six months to prevent mobilization flares.\n\nKEY LEARNING POINTS:\nAcute gout flares are treated with NSAIDs, colchicine, or corticosteroids, all with similar efficacy. Low-dose colchicine (1.2 mg then 0.6 mg) is as effective as high-dose with fewer side effects when started within 36 hours. Urate-lowering agents (allopurinol, febuxostat, probenecid) are for chronic management and should not be initiated during an acute flare. Negatively birefringent needle-shaped crystals on polarized microscopy confirm gout."
  },
  {
    "id": 641,
    "categoryId": 13,
    "question": "A 45-year-old woman with 6 months of symmetric joint pain and swelling in her hands (MCPs, PIPs) has positive RF and anti-CCP. X-rays show periarticular osteopenia. What is the first-line DMARD?",
    "options": [
      "A) Methotrexate",
      "B) Hydroxychloroquine",
      "C) Sulfasalazine",
      "D) Prednisone alone"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Methotrexate).\n\nDIAGNOSIS:\nThis patient presents with classic rheumatoid arthritis (RA): symmetric inflammatory polyarthritis involving the small joints of the hands (MCPs and PIPs, with characteristic sparing of the DIPs), positive rheumatoid factor (RF), positive anti-citrullinated peptide antibodies (anti-CCP, which is more specific than RF at greater than 95 percent specificity), and radiographic evidence of periarticular osteopenia (an early radiographic finding reflecting juxta-articular bone resorption from synovial inflammation). Morning stiffness lasting greater than one hour is a hallmark feature that distinguishes inflammatory arthritis from osteoarthritis.\n\nMETHOTREXATE AS FIRST-LINE DMARD:\nThe 2021 American College of Rheumatology guidelines strongly recommend methotrexate as the first-line disease-modifying antirheumatic drug (DMARD) for RA, regardless of disease activity level. Methotrexate is an antimetabolite that inhibits dihydrofolate reductase, but its anti-inflammatory mechanism in RA is primarily through promotion of adenosine release, which suppresses inflammatory cytokine production. It should be started as early as possible after diagnosis (ideally within three months of symptom onset) because the \"window of opportunity\" for preventing irreversible joint erosions is narrow. Typical starting dose is 7.5 to 15 mg orally once weekly, titrated up to 25 mg weekly as tolerated. Folic acid 1 mg daily (or folinic acid) is co-prescribed to reduce side effects (oral ulcers, nausea, hepatotoxicity, cytopenias). Monitoring includes baseline and periodic CBC, hepatic transaminases, creatinine, and hepatitis B and C screening.\n\nTREAT-TO-TARGET ESCALATION:\nThe treat-to-target approach reassesses disease activity every three months using validated composite measures (DAS28, CDAI, or SDAI), with the goal of achieving remission or low disease activity. If methotrexate monotherapy is insufficient at three to six months, options include adding a conventional synthetic DMARD (hydroxychloroquine, sulfasalazine, or leflunomide, often in \"triple therapy\"), adding a biologic DMARD (TNF inhibitors, IL-6 inhibitors such as tocilizumab, T-cell co-stimulation modulators such as abatacept, or B-cell depleting therapy with rituximab), or adding a targeted synthetic DMARD (JAK inhibitors such as tofacitinib or baricitinib).\n\nKEY LEARNING POINTS:\nMethotrexate is the first-line DMARD for RA and should be started early to prevent irreversible joint damage. Anti-CCP antibodies are highly specific for RA and predict erosive disease. The treat-to-target strategy reassesses disease activity every three months, escalating to biologic or targeted synthetic DMARDs if methotrexate alone is insufficient. Folic acid supplementation is essential to reduce methotrexate side effects."
  },
  {
    "id": 642,
    "categoryId": 3,
    "question": "The gut microbiome plays a critical role in human health. Which of the following is a well-established function of the gut microbiome?",
    "options": [
      "A) Direct absorption of glucose into the bloodstream",
      "B) Production of short-chain fatty acids (SCFAs) that regulate immune function and gut barrier integrity",
      "C) Synthesis of all essential amino acids",
      "D) Complete digestion of dietary protein"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Production of short-chain fatty acids that regulate immune function and gut barrier integrity).\n\nPATHOPHYSIOLOGY:\nThe human gut microbiome comprises approximately 38 trillion microorganisms representing over 1,000 species, with the highest density in the colon. Commensal bacteria perform critical metabolic functions that the human genome cannot, most notably the anaerobic fermentation of dietary fiber and resistant starch into short-chain fatty acids (SCFAs), primarily acetate, propionate, and butyrate. These metabolites serve as a major communication pathway between the microbiome and host physiology.\n\nFUNCTIONS OF SHORT-CHAIN FATTY ACIDS:\nButyrate is the preferred energy source for colonocytes, providing approximately 60-70% of their metabolic fuel and maintaining the epithelial barrier through enhanced tight junction protein expression. Butyrate also exerts potent anti-inflammatory effects by inhibiting NF-kB signaling and histone deacetylase activity in immune cells, promoting the differentiation of regulatory T cells (Tregs) that suppress aberrant immune activation. Propionate is primarily metabolized by the liver and modulates gluconeogenesis and lipid metabolism. Acetate enters systemic circulation and influences appetite regulation through hypothalamic signaling and peripheral tissue energy metabolism.\n\nCLINICAL SIGNIFICANCE:\nReduced SCFA production (from low-fiber diets or dysbiosis) is associated with increased intestinal permeability (\"leaky gut\"), chronic low-grade inflammation, and elevated risk of inflammatory bowel disease, colorectal cancer, metabolic syndrome, and allergic disease. Dietary fiber intake of 25-35 grams per day, particularly from diverse plant sources, supports robust SCFA production. Emerging therapeutic approaches include targeted prebiotic supplementation and next-generation probiotics specifically selected for SCFA-producing capacity.\n\nKEY LEARNING POINTS:\nShort-chain fatty acids (butyrate, propionate, acetate) are produced by bacterial fermentation of dietary fiber and are the primary mediator of microbiome-host interaction. Butyrate provides 60-70% of colonocyte energy and maintains gut barrier integrity through tight junction enhancement. SCFAs promote anti-inflammatory regulatory T cell differentiation. Adequate dietary fiber intake (25-35 g/day) supports healthy SCFA production."
  },
  {
    "id": 643,
    "categoryId": 6,
    "question": "The 'Gut-Brain Axis' describes bidirectional communication between the GI tract and the central nervous system. Through which primary pathway does the gut microbiome influence brain function?",
    "options": [
      "A) Direct bacterial migration to the CNS",
      "B) The vagus nerve, microbial metabolites, and immune signaling",
      "C) Absorption of neurotransmitters from dietary sources only",
      "D) Cerebrospinal fluid circulation"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (The vagus nerve, microbial metabolites, and immune signaling).\n\nTHE GUT-BRAIN AXIS:\nThe gut-brain axis describes the bidirectional communication network between the gastrointestinal tract and the central nervous system, mediated primarily through the vagus nerve (providing direct neural connections), microbial metabolites that cross the blood-brain barrier, and immune signaling pathways. This communication system allows the gut microbiome to influence brain function, mood, cognition, and behavior, and explains the frequent co-occurrence of gastrointestinal and neuropsychiatric disorders.\n\nPATHOPHYSIOLOGY:\nThe vagus nerve serves as the primary neural highway between the gut and brain, with approximately 80% of its fibers being afferent (gut-to-brain). Gut microbiota stimulate vagal afferents through the production of short-chain fatty acids (SCFAs such as butyrate, propionate, and acetate), which modulate vagal signaling and also cross the blood-brain barrier to influence microglial function and neuroinflammation. Gut bacteria also produce neurotransmitter precursors and neurotransmitters directly: enterochromaffin cells produce approximately 90% of the body's serotonin, and certain bacteria synthesize GABA, dopamine precursors, and norepinephrine. The immune pathway involves cytokines (IL-6, TNF-alpha, IL-1 beta) produced in the gut that enter systemic circulation and modulate neuroinflammation and blood-brain barrier permeability.\n\nCLINICAL ASSOCIATIONS:\nDepression and anxiety are consistently associated with altered gut microbiome composition (reduced Lactobacillus and Bifidobacterium species). Irritable bowel syndrome (IBS) has a 50 to 90% comorbidity rate with anxiety and depression, illustrating the clinical relevance of the gut-brain connection. Stress alters gut permeability (\"leaky gut\"), microbiome composition, and motility through the hypothalamic-pituitary-adrenal axis, creating a bidirectional cycle.\n\nPRIMARY CARE IMPLICATIONS:\nWhen treating patients with functional GI disorders such as IBS, addressing co-morbid anxiety and depression is essential for optimal outcomes. This explains why antidepressants (particularly tricyclics and SSRIs) are effective treatments for IBS independent of their mood effects. Emerging research on probiotics (\"psychobiotics\") targeting specific bacterial strains shows promise for mood disorders, though evidence remains preliminary. A holistic approach recognizing the gut-brain connection improves management of both GI and neuropsychiatric complaints.\n\nKEY LEARNING POINTS:\nThe gut-brain axis communicates through the vagus nerve, microbial metabolites (SCFAs), and immune signaling (cytokines), not through direct bacterial migration. Approximately 90% of the body's serotonin is produced in the gut, linking GI health to mood and cognition. Antidepressants are effective for IBS because the gut-brain axis makes GI and neuropsychiatric conditions bidirectionally connected."
  },
  {
    "id": 644,
    "categoryId": 8,
    "question": "Antibiotic use disrupts the gut microbiome. Which clinical consequence of antibiotic-induced dysbiosis has the strongest evidence base?",
    "options": [
      "A) Immediate weight gain",
      "B) Clostridioides difficile infection",
      "C) Development of Type 1 diabetes",
      "D) Acute kidney injury"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Clostridioides difficile infection).\n\nPATHOPHYSIOLOGY:\nThe healthy gut microbiome comprises trillions of commensal organisms that maintain colonization resistance â€” the ability to prevent pathogenic organisms from establishing infection through competition for nutrients, production of antimicrobial peptides, and maintenance of mucosal barrier integrity. Antibiotic exposure, particularly with broad-spectrum agents, reduces microbial diversity and eliminates protective commensal bacteria, creating an ecological niche for pathogenic organisms. Clostridioides difficile spores survive antibiotic exposure, germinate in the absence of competing flora, and proliferate to produce disease-causing toxins.\n\nCLINICAL MANIFESTATIONS:\nC. difficile infection (CDI) is the most clinically significant and well-documented consequence of antibiotic-induced dysbiosis. Risk increases with exposure to broad-spectrum antibiotics â€” particularly clindamycin, fluoroquinolones, and cephalosporins â€” and is cumulative with duration of antibiotic exposure and number of agents used. Elderly and hospitalized patients are at highest risk. CDI severity ranges from mild watery diarrhea to fulminant pseudomembranous colitis with toxic megacolon, septic shock, and death.\n\nMICROBIOME RECOVERY AND RESTORATION:\nGut microbiome diversity can take weeks to months to recover after antibiotic exposure, and some species may be permanently lost. Repeated antibiotic courses cause cumulative damage to microbial diversity. Fecal microbiota transplantation (FMT) has emerged as a highly effective therapy (>90% cure rate) for recurrent CDI by restoring a healthy microbial community and re-establishing colonization resistance, and it is now standard of care for patients with multiple CDI recurrences.\n\nKEY LEARNING POINTS:\nC. difficile infection is the most important clinical consequence of antibiotic-induced gut dysbiosis. Antibiotic stewardship â€” prescribing only when necessary, using the narrowest effective spectrum, and limiting duration â€” is the primary strategy for microbiome preservation. Fecal microbiota transplantation is highly effective for recurrent CDI.\n\nREFERENCES:\nIDSA/SHEA C. difficile Guidelines; NEJM Reviews on Gut Microbiome; UpToDate; Harrison's Principles of Internal Medicine.\n---"
  },
  {
    "id": 645,
    "categoryId": 16,
    "question": "A patient asks about taking probiotics for general health. Based on current evidence, which statement about probiotics is MOST accurate?",
    "options": [
      "A) All probiotic supplements are equally effective for all conditions",
      "B) Probiotics have proven benefit for specific conditions like antibiotic-associated diarrhea, but evidence for general health is limited",
      "C) Probiotics permanently colonize the gut and replace native bacteria",
      "D) Probiotics are harmful and should be universally avoided"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Probiotics have proven benefit for specific conditions like antibiotic-associated diarrhea, but evidence for general health is limited).\n\nEVIDENCE-BASED INDICATIONS:\nProbiotic efficacy is strain-specific and condition-specific, meaning that benefits demonstrated for one bacterial strain in one condition cannot be extrapolated to other strains or conditions per UpToDate and Harvard Health. The strongest evidence supports specific probiotic strains for specific clinical indications: Saccharomyces boulardii and Lactobacillus rhamnosus GG for prevention and treatment of antibiotic-associated diarrhea (number needed to treat approximately 8 to 13), VSL#3 for maintenance of remission in ulcerative colitis and pouchitis, and certain Bifidobacterium and Lactobacillus strains for reducing the duration of acute infectious diarrhea by approximately 1 day in children per Harrison's Principles of Internal Medicine and the Cleveland Clinic.\n\nLIMITATIONS FOR GENERAL HEALTH:\nDespite widespread marketing, evidence for probiotics improving general health, preventing colds, boosting immunity, or improving mood in healthy individuals is limited and inconsistent per the Mayo Clinic. Commercial probiotic supplements vary enormously in quality, viability (many products contain fewer live organisms than labeled), and strain composition per UpToDate. The FDA regulates probiotics as dietary supplements, not drugs, meaning manufacturers are not required to demonstrate efficacy before marketing per Harvard Health. Furthermore, probiotic colonization is often transient (organisms disappear from stool within days to weeks of discontinuation), questioning the durability of any effects per the Cleveland Clinic.\n\nCLINICAL GUIDANCE:\nClinicians should recommend specific, well-studied strains for specific indications rather than endorsing general probiotic use per UpToDate. For supporting overall gut microbial diversity, dietary interventions (high-fiber diets, fermented foods) have stronger evidence than probiotic supplements. The Stanford Sonnenburg Lab study demonstrated that a fermented food-rich diet (yogurt, kefir, kimchi, kombucha) increased gut microbiome diversity and reduced inflammatory markers more consistently than a high-fiber diet alone per Harvard Health.\n\nKEY LEARNING POINTS:\nProbiotic efficacy is strain-specific and condition-specific, with strongest evidence for antibiotic-associated diarrhea (S. boulardii, L. rhamnosus GG) and specific GI conditions. Evidence for general health benefits in healthy individuals is limited. Dietary fermented foods and high-fiber diets are more consistently supported for improving overall gut microbial diversity than supplements."
  },
  {
    "id": 646,
    "categoryId": 16,
    "question": "Which dietary pattern is most strongly associated with a diverse and healthy gut microbiome?",
    "options": [
      "A) High-protein, low-carbohydrate diet",
      "B) Diet high in processed foods and artificial sweeteners",
      "C) Plant-rich diet high in dietary fiber and fermented foods",
      "D) Liquid-only cleanse diets"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Plant-rich diet high in dietary fiber and fermented foods).\n\nEVIDENCE:\nA plant-rich diet high in dietary fiber and fermented foods is most strongly associated with a diverse and healthy gut microbiome per Harvard Health and UpToDate. The human gut harbors approximately 38 trillion microorganisms (roughly equal to the number of human cells), and the composition of this microbial community is profoundly shaped by habitual dietary patterns per Harrison's Principles of Internal Medicine.\n\nFIBER AND THE MICROBIOME:\nDietary fiber is the primary fuel source for beneficial colonic bacteria because humans lack the enzymes to digest complex polysaccharides, making them available exclusively for microbial fermentation per the Cleveland Clinic. Fiber-fermenting bacteria (Faecalibacterium, Roseburia, Bifidobacterium, Prevotella) produce short-chain fatty acids (butyrate, propionate, acetate) that nourish colonocytes, strengthen the epithelial barrier, reduce intestinal permeability, and modulate systemic inflammation and immune function per UpToDate. Low-fiber diets starve these beneficial species, reducing microbial diversity and allowing expansion of mucin-degrading bacteria that erode the protective mucus layer per Harvard Health.\n\nFERMENTED FOODS:\nThe Stanford Sonnenburg Lab randomized controlled trial demonstrated that a diet rich in fermented foods (yogurt, kefir, kimchi, sauerkraut, kombucha, miso) for 10 weeks significantly increased gut microbiome diversity and reduced 19 inflammatory markers (including IL-6 and CRP) per Harvard Health and the Mayo Clinic. Fermented foods introduce live microorganisms and their metabolites into the gut, providing both probiotic organisms and prebiotic substrates that support microbial community richness per UpToDate.\n\nCLINICAL APPLICATION:\nClinicians should recommend a diverse plant-rich diet (targeting 30 or more different plant foods per week) combined with regular fermented food consumption as the most evidence-based dietary strategy for gut microbiome health per the Cleveland Clinic. This approach is more effective and cost-efficient than probiotic supplementation for promoting microbial diversity in healthy individuals per Harrison's Principles of Internal Medicine.\n\nKEY LEARNING POINTS:\nDietary fiber is the primary fuel for beneficial gut bacteria, and fiber fermentation produces short-chain fatty acids that nourish colonocytes and reduce systemic inflammation. The Stanford trial showed fermented foods increase microbiome diversity and reduce 19 inflammatory markers. A diverse plant-rich diet (30 or more plant foods per week) plus fermented foods is the most evidence-based strategy for gut health."
  },
  {
    "id": 647,
    "categoryId": 1,
    "question": "According to the American Heart Association, which dietary pattern has the strongest evidence for reducing cardiovascular disease risk?",
    "options": [
      "A) High-protein, low-carbohydrate diet",
      "B) Plant-based diet emphasizing fruits, vegetables, whole grains, legumes, and nuts",
      "C) Low-fat diet with unrestricted processed foods",
      "D) Carnivore diet"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Plant-based diet emphasizing fruits, vegetables, whole grains, legumes, and nuts).\n\nAHA 2021 DIETARY GUIDANCE:\nThe American Heart Association's 2021 scientific statement on dietary guidance for improving cardiovascular health prioritizes a plant-predominant eating pattern built around fruits, vegetables, whole grains, legumes, nuts, and seeds as the foundation for cardiovascular risk reduction per Harrison's Principles of Internal Medicine and UpToDate. This guidance represents a shift from focusing on individual nutrients to emphasizing overall dietary patterns, recognizing that whole-food plant-rich diets consistently reduce cardiovascular events across diverse populations per the Cleveland Clinic.\n\nEVIDENCE BASE:\nMultiple large prospective cohort studies and randomized trials support the cardiovascular benefits of plant-rich dietary patterns per UpToDate. The PREDIMED trial demonstrated that a Mediterranean diet supplemented with extra-virgin olive oil or mixed nuts reduced major cardiovascular events by approximately 30% compared to a low-fat control diet per Harrison's Principles of Internal Medicine. Plant-based diets reduce cardiovascular risk through several mechanisms: lowering LDL cholesterol and blood pressure, improving insulin sensitivity and glycemic control, reducing systemic inflammation (measured by hs-CRP), and promoting a favorable gut microbiome that reduces TMAO production per the Mayo Clinic.\n\nPRACTICAL FRAMEWORK:\nThe AHA identifies ten key dietary features for cardiovascular health: adjusting caloric intake to maintain healthy weight, eating plenty of fruits and vegetables, choosing whole grains over refined grains, including healthy protein sources (primarily legumes, nuts, fish, and lean poultry), using liquid non-tropical plant oils (olive, canola), choosing minimally processed over ultra-processed foods, minimizing added sugars, reducing sodium, limiting alcohol, and applying these principles regardless of where food is prepared per the Cleveland Clinic. The statement does not require strict vegetarianism but emphasizes that plant foods should constitute the majority of dietary intake per UpToDate.\n\nKEY LEARNING POINTS:\nThe AHA 2021 dietary guidance prioritizes plant-predominant eating patterns emphasizing fruits, vegetables, whole grains, legumes, and nuts for cardiovascular risk reduction. The PREDIMED trial showed a 30% reduction in major cardiovascular events with Mediterranean diet. The AHA framework focuses on overall dietary patterns rather than individual nutrients and does not require strict vegetarianism."
  },
  {
    "id": 648,
    "categoryId": 4,
    "question": "A patient with newly diagnosed Type 2 Diabetes asks about dietary approaches. According to the American Diabetes Association, which statement about plant-based diets is accurate?",
    "options": [
      "A) Plant-based diets are contraindicated in diabetes due to carbohydrate content",
      "B) Plant-based diets can improve glycemic control and are a recommended dietary pattern for diabetes management",
      "C) Only animal-based ketogenic diets are recommended for diabetes",
      "D) Dietary interventions have no effect on diabetes outcomes"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Plant-based diets can improve glycemic control and are a recommended dietary pattern for diabetes management).\n\nPATHOPHYSIOLOGY:\nThe metabolic benefits of plant-based diets in type 2 diabetes are mediated through multiple interconnected mechanisms that address the core pathophysiologic defects of the disease. Dietary fiber, which is abundant in whole plant foods and absent from animal products, improves glycemic control through several pathways: soluble fiber (found in legumes, oats, barley, fruits) forms a viscous gel in the small intestine that delays gastric emptying, slows glucose absorption, and attenuates postprandial glycemic excursions. Fiber also promotes satiety through gastric distension and secretion of satiety hormones (GLP-1, PYY), facilitating caloric reduction and weight loss. The lower caloric density of whole plant foods (high water and fiber content with low fat content) produces greater satiety per calorie consumed, naturally reducing caloric intake without portion restriction. Reduced saturated fat intake decreases intramyocellular lipid (IMCL) and intrahepatic lipid accumulation, which are key drivers of peripheral and hepatic insulin resistance through diacylglycerol-mediated activation of protein kinase C isoforms that impair insulin receptor substrate phosphorylation and downstream PI3K-Akt signaling. Plant-based diets are also rich in polyphenols, carotenoids, and other bioactive phytochemicals that reduce oxidative stress and systemic inflammation (lowering CRP, TNF-alpha, and IL-6), improve endothelial function, and modulate the gut microbiome toward greater production of short-chain fatty acids (butyrate, propionate, acetate), which enhance insulin sensitivity and intestinal barrier function per research reviewed in Diabetes Care and the NEJM.\n\nCLINICAL EVIDENCE:\nThe ADA Standards of Care explicitly lists plant-based (including vegan and vegetarian) dietary patterns among the recommended eating patterns for diabetes management, alongside Mediterranean, DASH, and low-carbohydrate approaches. The ADA emphasizes that no single dietary pattern is superior and that the optimal approach is one that the patient can sustain long-term. Several key studies support this recommendation. Barnard et al. published a 74-week randomized controlled trial in Diabetes Care (2009) comparing a low-fat vegan diet to the conventional ADA diet in adults with T2DM, demonstrating greater HbA1c reduction (0.34% greater improvement) and greater LDL cholesterol reduction in the vegan group, with greater medication reduction. The Adventist Health Study-2, a large prospective cohort study of over 96,000 participants published in Nutrition, Metabolism, and Cardiovascular Diseases, found that vegans had 62% lower odds of developing T2DM compared to non-vegetarians, and lacto-ovo vegetarians had 38% lower odds, after adjusting for BMI and other confounders. The PREDIMED trial (NEJM 2013) demonstrated that a Mediterranean diet (which is predominantly plant-based with olive oil, nuts, legumes, fruits, vegetables, and whole grains as staples, supplemented with moderate fish and minimal red meat) reduced diabetes incidence by 40% compared to a low-fat control diet. A systematic review and meta-analysis in BMJ Open Diabetes Research and Care analyzing 9 clinical trials concluded that plant-based diets significantly improved HbA1c, fasting glucose, and body weight in patients with T2DM.\n\nCLINICAL APPLICATION:\nWhen counseling patients with T2DM about plant-based dietary approaches, several practical considerations are important. The emphasis should be on whole, minimally processed plant foods (legumes, whole grains, vegetables, fruits, nuts, seeds) rather than processed plant-based products (refined flour products, added sugars, plant-based processed foods that may be calorie-dense and nutrient-poor). Legumes (beans, lentils, chickpeas) are particularly valuable for diabetes management due to their high fiber and protein content, low glycemic index, and demonstrated benefits for glycemic control per data from the American Journal of Clinical Nutrition. Patients transitioning to a plant-based diet who are taking insulin or sulfonylureas should be warned about potential hypoglycemia, as improved insulin sensitivity can reduce medication requirements rapidly, sometimes within days of dietary change. Medication adjustment should be proactive rather than reactive. Potential nutritional considerations with strict vegan diets include monitoring for vitamin B12 deficiency (supplementation universally recommended), vitamin D adequacy, iron status (plant-based non-heme iron has lower bioavailability, though vitamin C enhances absorption), omega-3 fatty acid intake (consider algal DHA supplementation), calcium intake, and zinc adequacy. These considerations should not discourage plant-based eating but should prompt appropriate monitoring and supplementation.\n\nKEY LEARNING POINTS:\nThe ADA lists plant-based diets among recommended eating patterns for diabetes management, supported by evidence of improved HbA1c, weight reduction, and cardiovascular risk modification through mechanisms including fiber-mediated glycemic modulation, reduced intracellular lipid accumulation improving insulin sensitivity, and anti-inflammatory effects. Patients on insulin or sulfonylureas who adopt plant-based diets require proactive medication reduction to prevent hypoglycemia. Emphasis should be on whole, minimally processed plant foods rather than processed plant-based products."
  },
  {
    "id": 649,
    "categoryId": 14,
    "question": "The American Institute for Cancer Research (AICR) recommends which dietary pattern for cancer prevention?",
    "options": [
      "A) Diet focused primarily on animal protein",
      "B) Diet where plant foods (vegetables, fruits, whole grains, legumes) fill at least 2/3 of the plate",
      "C) High-fat, low-fiber diet",
      "D) Diet with no restrictions on processed meats"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Plant foods filling at least 2/3 of the plate).\n\nRECOMMENDATION:\nThe American Institute for Cancer Research (AICR) and the World Cancer Research Fund recommend a dietary pattern in which plant foods (vegetables, fruits, whole grains, and legumes) fill at least two-thirds of the plate, with animal foods comprising one-third or less per the AICR New American Plate guidelines. This recommendation is based on systematic review of global cancer prevention research and aligns with dietary guidance from the American Cancer Society, which emphasizes a plant-rich dietary pattern for cancer risk reduction.\n\nPROTECTIVE MECHANISMS OF PLANT FOODS:\nDietary fiber reduces colorectal cancer risk through multiple mechanisms including increased stool bulk and reduced colonic transit time (decreasing carcinogen contact with the mucosa), promotion of beneficial gut microbiome fermentation producing short-chain fatty acids (particularly butyrate, which has anti-proliferative and pro-apoptotic effects on colonocytes), and improved insulin sensitivity per Harrison's Principles of Internal Medicine. Antioxidants and phytochemicals including sulforaphane (from cruciferous vegetables such as broccoli and cauliflower) and lycopene (from tomatoes) have demonstrated anti-cancer properties in laboratory and epidemiologic studies per the National Cancer Institute. Plant-based diets are also associated with lower circulating levels of insulin-like growth factor-1 (IGF-1), reduced systemic inflammation, and lower body weight, all of which independently reduce cancer risk.\n\nHARMFUL DIETARY FACTORS:\nProcessed meat is classified as a Group 1 carcinogen and red meat as Group 2A by the WHO/IARC per the CDC. Each 50-gram daily serving of processed meat increases colorectal cancer risk by approximately 18%. Alcohol increases risk of cancers of the breast, colon, liver, esophagus, oral cavity, and pharynx in a dose-dependent manner with no safe threshold for cancer prevention per the AICR. Ultra-processed foods with high sugar content promote obesity and hyperinsulinemia, both independent cancer risk factors.\n\nKEY LEARNING POINTS:\nThe AICR recommends plant foods filling at least two-thirds of the plate for cancer prevention, based on evidence that fiber, antioxidants, and phytochemicals reduce cancer risk through multiple mechanisms. Processed meat is a Group 1 carcinogen and red meat is Group 2A, with each 50-gram daily serving of processed meat increasing colorectal cancer risk by 18%. Counseling patients to make plants the majority of their diet is one of the most impactful and achievable cancer prevention strategies."
  },
  {
    "id": 650,
    "categoryId": 1,
    "question": "A patient with hypertension asks about the DASH diet. Which description is accurate?",
    "options": [
      "A) High sodium, high animal protein diet",
      "B) Plant-rich diet emphasizing fruits, vegetables, whole grains, and low-fat dairy while limiting sodium and saturated fat",
      "C) Liquid-only fasting protocol",
      "D) High-fat ketogenic approach"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Plant-rich diet emphasizing fruits, vegetables, whole grains, low-fat dairy, limiting sodium and saturated fat).\n\nDASH DIET OVERVIEW:\nThe DASH (Dietary Approaches to Stop Hypertension) diet is a well-validated eating pattern specifically designed and proven to lower blood pressure through dietary modification per Harrison's Principles of Internal Medicine. The original DASH trial demonstrated that this dietary pattern reduces systolic blood pressure by approximately 5.5 mmHg and diastolic by 3.0 mmHg in hypertensive individuals compared to a typical American diet, with the DASH-Sodium trial showing additional reductions of 6 to 11 mmHg systolic when combined with sodium restriction to 1,500 mg per day per UpToDate.\n\nCORE COMPONENTS:\nThe DASH diet emphasizes high intake of fruits (4 to 5 servings daily), vegetables (4 to 5 servings), whole grains (6 to 8 servings), and low-fat dairy products (2 to 3 servings), which together provide abundant potassium, calcium, magnesium, and fiber per the Mayo Clinic. It includes lean proteins (fish, poultry, legumes, nuts) while limiting red meat, saturated fat, added sugars, and sodium per the Cleveland Clinic. The combined mineral and micronutrient profile of the DASH diet is thought to be more effective than any single supplement because the nutrients work synergistically to promote natriuresis, vasodilation, and reduced sympathetic tone per Harrison's Principles of Internal Medicine.\n\nBLOOD PRESSURE MECHANISMS:\nPotassium (target approximately 4,700 mg/day) promotes sodium excretion and directly relaxes vascular smooth muscle per UpToDate. Calcium and magnesium support endothelial function and modulate vascular tone. Dietary fiber and nitrates from green leafy vegetables enhance nitric oxide bioavailability, promoting vasodilation per the Cleveland Clinic. Sodium restriction to 2,300 mg/day (ideal 1,500 mg/day) reduces intravascular volume and blunts the pressure response to angiotensin II per Harrison's Principles of Internal Medicine. The 2017 ACC/AHA Hypertension Guidelines recommend the DASH diet as a first-line lifestyle intervention capable of achieving blood pressure reductions comparable to a single antihypertensive medication per the Mayo Clinic.\n\nKEY LEARNING POINTS:\nThe DASH diet reduces systolic BP by approximately 5.5 mmHg, with additional 6 to 11 mmHg reduction when combined with sodium restriction to 1,500 mg/day. Its effectiveness comes from synergistic actions of potassium, calcium, magnesium, fiber, and nitrates rather than any single nutrient. The 2017 ACC/AHA guidelines recommend DASH as a first-line lifestyle intervention with BP-lowering effects comparable to monotherapy."
  },
  {
    "id": 651,
    "categoryId": 16,
    "question": "Which mechanism best explains why whole-food plant-based diets are effective for weight management without calorie counting?",
    "options": [
      "A) Plant foods have higher caloric density than animal foods",
      "B) Low caloric density and high fiber content promote satiety with fewer calories",
      "C) Plant foods suppress all hunger hormones permanently",
      "D) Plant-based diets work by causing malabsorption"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Low caloric density and high fiber content promote satiety with fewer calories).\n\nMECHANISM:\nWhole-food plant-based diets consistently produce weight loss in clinical trials even with ad libitum (unrestricted) eating, primarily because plant foods have low caloric density (calories per gram) and high fiber and water content that activate satiety mechanisms before caloric excess occurs per UpToDate and Harvard Health. Non-starchy vegetables average 0.1 to 0.5 calories per gram, fruits average 0.3 to 0.7 cal/g, legumes average 1.0 to 1.5 cal/g, and whole grains average 1.0 to 1.5 cal/g, compared to cheese at 3 to 4 cal/g and oils at 9 cal/g per the Cleveland Clinic.\n\nSATIETY PHYSIOLOGY:\nSatiety is regulated by a hierarchy of signals per Harrison's Principles of Internal Medicine. Gastric stretch receptors (vagal mechanoreceptors) respond to food volume, not calories, sending fullness signals to the brainstem nucleus tractus solitarius. Intestinal nutrient sensors trigger release of satiety hormones including GLP-1, PYY, and CCK when nutrients reach the small intestine. Dietary fiber slows gastric emptying (prolonging gastric distension), increases chewing time, and is fermented to short-chain fatty acids that stimulate GLP-1 and PYY release from colonic L-cells per UpToDate. High-water-content foods (vegetables, fruits, soups) physically dilute caloric density while maintaining volume per the Mayo Clinic.\n\nCLINICAL EVIDENCE:\nThe BROAD study (randomized trial in New Zealand) showed that participants on a whole-food plant-based diet without calorie counting lost an average of 12 kg at 12 months per Harvard Health. A meta-analysis of 12 randomized trials found that plant-based diets produced greater weight loss than control diets even without prescribed energy restriction per UpToDate. The volumetric approach (Rolls and colleagues, Penn State) demonstrates that reducing the caloric density of the diet by 25% produces spontaneous caloric reduction without perceived hunger per the Cleveland Clinic.\n\nKEY LEARNING POINTS:\nWhole-food plant-based diets produce weight loss without calorie counting because low caloric density and high fiber content activate gastric stretch receptors and gut satiety hormones (GLP-1, PYY) before caloric excess occurs. Vegetables average 0.1 to 0.5 cal/g versus oils at 9 cal/g. Clinical trials consistently show 10 to 12 kg weight loss at 12 months with ad libitum plant-based eating."
  },
  {
    "id": 652,
    "categoryId": 16,
    "question": "Oxidative stress, caused by an imbalance between free radicals and antioxidants, is implicated in the pathogenesis of which conditions?",
    "options": [
      "A) Atherosclerosis, diabetes complications, and neurodegenerative diseases",
      "B) Osteoarthritis only",
      "C) Allergic rhinitis",
      "D) Benign prostatic hyperplasia"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Atherosclerosis, diabetes complications, and neurodegenerative diseases).\n\nPATHOPHYSIOLOGY:\nOxidative stress occurs when the production of reactive oxygen species (ROS, including superoxide anion, hydrogen peroxide, and hydroxyl radical) exceeds the capacity of endogenous antioxidant defense systems (superoxide dismutase, catalase, glutathione peroxidase, and the thioredoxin system) per Harrison's Principles of Internal Medicine and UpToDate. This imbalance causes oxidative damage to lipids (lipid peroxidation), proteins (carbonyl formation and cross-linking), and DNA (8-hydroxydeoxyguanosine formation and strand breaks), contributing to cellular dysfunction and disease pathogenesis per the Cleveland Clinic.\n\nDISEASE MECHANISMS:\nIn atherosclerosis, oxidized LDL is the key pathogenic trigger: ROS modify LDL particles in the arterial intima, making them recognizable by scavenger receptors on macrophages, which internalize oxidized LDL in an unregulated fashion to form foam cells, the hallmark of early atherosclerotic plaques per Harrison's Principles of Internal Medicine. In diabetes, hyperglycemia-driven mitochondrial ROS production activates four pathways of tissue damage: the polyol pathway, advanced glycation end-product (AGE) formation, protein kinase C activation, and the hexosamine pathway, collectively producing diabetic retinopathy, nephropathy, neuropathy, and accelerated atherosclerosis per UpToDate. In neurodegenerative diseases, the brain's high oxygen consumption (20% of total body oxygen), abundant polyunsaturated fatty acids (susceptible to peroxidation), and relatively low antioxidant capacity make it particularly vulnerable to oxidative damage per the Mayo Clinic and Harvard Health.\n\nENDOGENOUS DEFENSE:\nThe Nrf2-Keap1 pathway is the master regulator of cellular antioxidant defense, controlling expression of over 200 cytoprotective genes including glutathione synthesis enzymes, heme oxygenase-1, and NAD(P)H quinone oxidoreductase per UpToDate. Dietary phytochemicals from colorful fruits and vegetables activate this pathway, potentially explaining the consistent association between plant-rich diets and reduced chronic disease risk per the Cleveland Clinic.\n\nKEY LEARNING POINTS:\nOxidative stress drives atherosclerosis (via LDL oxidation and foam cell formation), diabetic complications (via hyperglycemia-induced mitochondrial ROS), and neurodegeneration (due to the brain's high oxygen demand and low antioxidant reserves). The Nrf2 pathway is the master regulator of endogenous antioxidant defense. Dietary phytochemicals from plant foods activate Nrf2, linking plant-rich diets to chronic disease prevention."
  },
  {
    "id": 653,
    "categoryId": 16,
    "question": "Which dietary pattern has the strongest evidence for reducing oxidative stress and its associated chronic disease burden?",
    "options": [
      "A) High-protein, low-carbohydrate diet",
      "B) Mediterranean diet rich in polyphenols and antioxidants",
      "C) Low-fat diet with minimal nuts and oils",
      "D) Carnivore diet"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Mediterranean diet rich in polyphenols and antioxidants).\n\nEVIDENCE:\nThe Mediterranean dietary pattern has the strongest and most consistent evidence for reducing oxidative stress and its associated chronic disease burden per Harrison's Principles of Internal Medicine and UpToDate. The PREDIMED trial demonstrated that a Mediterranean diet supplemented with extra virgin olive oil or nuts reduced major cardiovascular events by approximately 30% and oxidative stress biomarkers (oxidized LDL, malondialdehyde, 8-isoprostanes) compared to a low-fat control diet per the Cleveland Clinic.\n\nANTIOXIDANT MECHANISMS:\nThe Mediterranean diet provides a diverse array of bioactive polyphenolic compounds from multiple food sources per Harvard Health. Extra virgin olive oil contains hydroxytyrosol and oleocanthal (with anti-inflammatory potency comparable to low-dose ibuprofen). Red wine and berries provide resveratrol and anthocyanins. Vegetables provide carotenoids (lycopene, beta-carotene, lutein). Nuts provide vitamin E (alpha-tocopherol) and selenium. Herbs and spices (turmeric, rosemary, oregano) contribute curcumin, carnosic acid, and rosmarinic acid per UpToDate. These compounds act through multiple mechanisms: direct free radical scavenging, metal ion chelation (preventing Fenton reactions), activation of the Nrf2 antioxidant pathway, inhibition of NF-kB inflammatory signaling, and enhancement of endogenous antioxidant enzyme expression per Harrison's Principles of Internal Medicine.\n\nWHY WHOLE FOODS EXCEED SUPPLEMENTS:\nThe synergistic interaction among the thousands of phytochemicals in whole foods produces antioxidant protection that isolated supplements cannot replicate per the Mayo Clinic. Whole foods deliver antioxidants in their natural matrix with complementary cofactors, fiber, and other bioactives that modulate absorption, bioavailability, and tissue distribution per UpToDate. This explains the paradox that antioxidant-rich dietary patterns consistently reduce disease while isolated antioxidant supplements have failed in randomized trials per Harvard Health.\n\nKEY LEARNING POINTS:\nThe Mediterranean diet has the strongest evidence for reducing oxidative stress through diverse polyphenols from olive oil (hydroxytyrosol), berries (anthocyanins), vegetables (carotenoids), and nuts (vitamin E). These compounds activate the Nrf2 pathway, scavenge free radicals, and inhibit NF-kB inflammation. Whole food antioxidant synergy exceeds what isolated supplements can achieve."
  },
  {
    "id": 654,
    "categoryId": 16,
    "question": "Why have large randomized controlled trials of antioxidant supplements (vitamin E, beta-carotene) generally failed to show cardiovascular benefit despite strong observational data?",
    "options": [
      "A) The doses used were too low",
      "B) Isolated supplements cannot replicate the complex synergy of whole food antioxidants and may disrupt redox signaling",
      "C) The trials were too short",
      "D) Participants were too healthy at baseline"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Isolated supplements cannot replicate the complex synergy of whole food antioxidants and may disrupt redox signaling).\n\nPARADOX:\nLarge randomized controlled trials of antioxidant supplements have consistently failed to show cardiovascular, cancer, or mortality benefit, and some have demonstrated harm, despite strong epidemiologic associations between antioxidant-rich diets and reduced chronic disease per Harrison's Principles of Internal Medicine and UpToDate. The ATBC trial (Alpha-Tocopherol Beta-Carotene Cancer Prevention Study) showed that beta-carotene supplementation increased lung cancer risk by 18% in Finnish male smokers. The CARET trial (Beta-Carotene and Retinol Efficacy Trial) confirmed a 28% increase in lung cancer with beta-carotene in smokers and asbestos workers. The HOPE and HOPE-TOO trials showed no cardiovascular benefit from vitamin E, and the SELECT trial showed increased prostate cancer risk with vitamin E per the Cleveland Clinic and Harvard Health.\n\nREDOX SIGNALING DISRUPTION:\nThe failure of supplements reflects a fundamental misunderstanding of redox biology per UpToDate. Reactive oxygen species are not purely harmful: at physiologic concentrations, they serve as essential signaling molecules that regulate vascular tone (via hydrogen peroxide-mediated vasodilation), immune function (via the oxidative burst in neutrophils and macrophages), cellular adaptation to exercise (via ROS-mediated mitochondrial biogenesis), and apoptosis of damaged or precancerous cells per Harrison's Principles of Internal Medicine. High-dose isolated antioxidants can suppress these beneficial ROS signaling pathways, potentially impairing immune surveillance, exercise adaptation, and tumor cell clearance per the Mayo Clinic.\n\nWHOLE FOOD SYNERGY:\nWhole foods contain thousands of phytochemicals that interact synergistically in ways that a single isolated compound cannot replicate per Harvard Health. These compounds are delivered in a natural food matrix with fiber, healthy fats, and other nutrients that modulate absorption, bioavailability, and biological activity. Whole food antioxidants tend to modulate (rather than abolish) ROS signaling, activating endogenous defense pathways (Nrf2) rather than creating supraphysiologic antioxidant levels that disrupt redox homeostasis per UpToDate and the Cleveland Clinic.\n\nKEY LEARNING POINTS:\nAntioxidant supplement trials (ATBC, CARET, SELECT) showed no benefit and potential harm because high-dose isolated antioxidants disrupt beneficial ROS signaling needed for immune function, exercise adaptation, and tumor surveillance. Whole food antioxidants work synergistically and modulate (rather than abolish) redox signaling. Clinicians should recommend antioxidant-rich dietary patterns rather than supplements."
  },
  {
    "id": 655,
    "categoryId": 11,
    "question": "A patient with poorly controlled type 2 diabetes says, 'I know I should exercise more, but I just can't seem to make it happen.' Using motivational interviewing, what is the most appropriate response?",
    "options": [
      "A) 'You really need to exercise or your diabetes will get worse.'",
      "B) 'What would it look like if you were able to fit exercise into your routine?'",
      "C) 'Let me give you a handout about the benefits of exercise.'",
      "D) 'I'm referring you to a diabetes educator.'"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B ('What would it look like if you were able to fit exercise into your routine?').\n\nCLINICAL REASONING:\nThis question tests the application of motivational interviewing (MI) technique in a patient expressing ambivalence about behavior change per UpToDate and Harvard Health. The patient's statement ('I know I should exercise more, but I just can't seem to make it happen') contains both change talk ('I know I should') and sustain talk ('I can't seem to make it happen'), indicating ambivalence, which is the central target of MI per Harrison's Principles of Internal Medicine.\n\nMI TECHNIQUE APPLIED:\nOption B ('What would it look like if you were able to fit exercise into your routine?') is an open-ended, evocative question that invites the patient to envision a positive future with the behavior change already in place per the Cleveland Clinic. This technique, sometimes called a \"miracle question\" or \"looking forward\" technique, elicits the patient's own motivations and solutions rather than imposing the clinician's agenda. It strategically amplifies change talk (the patient's own arguments for change) while avoiding the righting reflex (the clinician's instinct to correct, lecture, or prescribe) per UpToDate.\n\nWHY OTHER OPTIONS ARE INCORRECT:\nOption A ('You really need to exercise or your diabetes will get worse') is a confrontational, directive statement that triggers the righting reflex and typically increases patient resistance (the \"expert trap\" that MI specifically avoids) per Harvard Health. Option C ('Let me give you a handout about the benefits of exercise') assumes the patient lacks information (an information deficit model) when the patient already knows they should exercise. Option D ('I'm referring you to a diabetes educator') bypasses the patient's autonomy and does not address the underlying ambivalence per the Mayo Clinic.\n\nSPIRIT OF MI:\nEffective MI operates from four principles: partnership (collaborative, not authoritarian), acceptance (respecting autonomy), compassion (prioritizing patient welfare), and evocation (drawing out the patient's own motivation rather than installing it) per Harrison's Principles of Internal Medicine and UpToDate.\n\nKEY LEARNING POINTS:\nOpen-ended evocative questions ('What would it look like if...') elicit the patient's own change talk and solutions, which is the core mechanism of motivational interviewing. Directive statements and information-giving increase resistance when the patient is ambivalent. MI avoids the righting reflex and instead amplifies the patient's own arguments for change."
  },
  {
    "id": 656,
    "categoryId": 11,
    "question": "During a motivational interviewing session, a patient expresses ambivalence: 'Part of me wants to quit smoking, but I really enjoy it and it helps me cope with stress.' What is the clinician's primary goal in responding?",
    "options": [
      "A) Convince the patient that smoking is harmful",
      "B) Explore and amplify the patient's own 'change talk' while respecting their autonomy",
      "C) Set a firm quit date",
      "D) Prescribe nicotine replacement therapy immediately"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Explore and amplify the patient's own change talk while respecting their autonomy).\n\nCLINICAL REASONING:\nThe patient's statement contains clear ambivalence: 'Part of me wants to quit smoking' (change talk) versus 'I really enjoy it and it helps me relax' (sustain talk) per UpToDate and Harrison's Principles of Internal Medicine. In motivational interviewing, ambivalence is not an obstacle but the expected psychological state that precedes behavior change, and the clinician's role is to help tip the decisional balance toward change by selectively exploring and amplifying change talk per Harvard Health.\n\nCHANGE TALK AND SUSTAIN TALK:\nChange talk consists of patient statements that favor behavior change and falls into two categories per the Cleveland Clinic. Preparatory change talk includes desire ('I want to quit'), ability ('I could quit'), reasons ('Quitting would improve my health'), and need ('I need to quit for my kids'). Mobilizing change talk includes commitment ('I will quit'), activation ('I'm ready to quit'), and taking steps ('I called the quitline'). The clinician's task is to use reflective listening to selectively highlight and elaborate on change talk while acknowledging (but not amplifying) sustain talk per UpToDate.\n\nTECHNIQUES:\nWhen a patient expresses ambivalence, the MI-consistent approach involves reflecting back the change talk component ('It sounds like part of you really does want to quit'), asking elaboration questions ('Tell me more about that part of you that wants to quit'), and using a decisional balance exercise where the patient articulates both sides per the Mayo Clinic. The clinician respects the patient's autonomy (\"It's completely your decision\") because paradoxically, affirming freedom of choice reduces resistance and increases openness to change per Harrison's Principles of Internal Medicine.\n\nWHY OTHER OPTIONS ARE INCORRECT:\nConvincing the patient that smoking is harmful (Option A) uses the expert/confrontational approach that triggers reactance. Setting a firm quit date (Option C) and prescribing NRT immediately (Option D) skip the exploration of ambivalence and impose solutions before the patient has resolved their own motivational conflict per UpToDate and Harvard Health.\n\nKEY LEARNING POINTS:\nIn MI, the clinician explores and amplifies change talk (patient's own arguments for change) while acknowledging but not reinforcing sustain talk. Ambivalence is the expected state before behavior change, not an obstacle. Affirming patient autonomy paradoxically reduces resistance and increases openness to change."
  },
  {
    "id": 657,
    "categoryId": 16,
    "question": "A 52-year-old executive with hypertension and anxiety asks how deep breathing exercises could benefit his health. Which physiological mechanism best explains the cardiovascular benefits of slow, diaphragmatic breathing?",
    "options": [
      "A) Increased sympathetic tone",
      "B) Activation of the parasympathetic nervous system via vagal stimulation, reducing heart rate and blood pressure",
      "C) Increased cortisol release",
      "D) Peripheral vasoconstriction"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Activation of the parasympathetic nervous system via vagal stimulation, reducing heart rate and blood pressure).\n\nPATHOPHYSIOLOGY OF THE RELAXATION RESPONSE:\nSlow, diaphragmatic breathing activates the parasympathetic nervous system through several interconnected mechanisms. When breathing rate decreases to approximately 6 breaths per minute, respiratory sinus arrhythmia is maximized, creating rhythmic fluctuations in heart rate that enhance vagal tone. The diaphragm's descent during deep inhalation stimulates stretch receptors in the lungs that signal via the vagus nerve to the nucleus tractus solitarius in the brainstem, triggering parasympathetic outflow. This \"relaxation response,\" first characterized by Herbert Benson at Harvard Medical School, produces measurable physiological changes: heart rate decreases, blood pressure drops, peripheral vascular resistance falls, and stress hormone secretion diminishes.\n\nCARDIOVASCULAR AND METABOLIC EFFECTS:\nThe shift from sympathetic to parasympathetic dominance has broad systemic effects beyond immediate hemodynamic changes. Reduced catecholamine levels decrease myocardial oxygen demand and arrhythmia risk. Lower cortisol secretion improves insulin sensitivity and reduces visceral fat accumulation over time. Heart rate variability (HRV), a marker of cardiac autonomic function and cardiovascular health, increases with regular relaxation practice. Studies demonstrate that patients with hypertension who practice slow breathing techniques can achieve modest but clinically meaningful reductions in systolic blood pressure of 4-6 mmHg, comparable to the effect of reducing dietary sodium.\n\nCLINICAL APPLICATIONS:\nFor primary care providers, breathing techniques represent a zero-cost, zero-side-effect adjunct to pharmacotherapy for hypertension and anxiety disorders. Practical instruction takes only minutes: have patients breathe in for 4 seconds, hold for 2 seconds, and exhale for 6 seconds, aiming for approximately 5-6 breath cycles per minute. Regular practice of 10-15 minutes daily produces cumulative benefits. These techniques are particularly valuable for patients who prefer non-pharmacological approaches or need additional blood pressure reduction beyond medication.\n\nKEY LEARNING POINTS:\nSlow diaphragmatic breathing activates parasympathetic pathways via vagal stimulation, lowering heart rate and blood pressure. The relaxation response reduces cortisol and catecholamines, improving metabolic and cardiovascular parameters. Breathing techniques at 5-6 breaths per minute can reduce systolic blood pressure by 4-6 mmHg with regular practice."
  },
  {
    "id": 658,
    "categoryId": 16,
    "question": "Regular aerobic exercise produces cardiovascular benefits through which primary physiological adaptation?",
    "options": [
      "A) Increased resting sympathetic tone",
      "B) Decreased stroke volume",
      "C) Improved endothelial function with increased nitric oxide bioavailability and reduced arterial stiffness",
      "D) Increased peripheral vascular resistance"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Improved endothelial function with increased nitric oxide bioavailability and reduced arterial stiffness).\n\nPATHOPHYSIOLOGY:\nThe cardiovascular benefits of regular aerobic exercise are primarily mediated through improved endothelial function, which represents the restoration of the endothelium's ability to produce and respond to nitric oxide (NO) per Harrison's Principles of Internal Medicine and UpToDate. During exercise, increased blood flow generates laminar shear stress on the vascular endothelium, which activates endothelial nitric oxide synthase (eNOS) through phosphorylation at serine 1177 via the PI3K/Akt pathway per the Cleveland Clinic. The resulting increase in NO production causes vasodilation, inhibits platelet aggregation, reduces leukocyte adhesion, and suppresses smooth muscle cell proliferation, all of which are atheroprotective per Harvard Health.\n\nCHRONIC ADAPTATIONS:\nWith regular aerobic training, eNOS expression is chronically upregulated, increasing baseline NO bioavailability even at rest per UpToDate. Exercise simultaneously reduces oxidative stress (by upregulating superoxide dismutase, catalase, and glutathione peroxidase through the Nrf2 pathway), which prevents the superoxide-mediated destruction of NO that characterizes endothelial dysfunction in sedentary and metabolically unhealthy individuals per Harrison's Principles of Internal Medicine. Additionally, regular exercise reduces arterial stiffness (measured by pulse wave velocity, the gold standard biomarker of vascular aging) by improving elastin-to-collagen ratios in the arterial wall and reducing advanced glycation end-product (AGE) cross-linking per the Mayo Clinic.\n\nCLINICAL IMPACT:\nThese vascular adaptations translate to measurable clinical benefits: resting blood pressure reduction of 5 to 8 mmHg systolic, improved flow-mediated dilation (the clinical measure of endothelial function), reduced resting heart rate, improved lipid profile (increased HDL, reduced triglycerides), and decreased systemic inflammation (reduced CRP, IL-6) per UpToDate and the Cleveland Clinic. The 2018 Physical Activity Guidelines state that each 1-MET increase in cardiorespiratory fitness is associated with approximately 12 to 15% reduction in cardiovascular and all-cause mortality per Harvard Health.\n\nKEY LEARNING POINTS:\nExercise improves cardiovascular health primarily through shear stress-mediated eNOS activation, increasing nitric oxide production that promotes vasodilation, platelet inhibition, and anti-inflammation. Chronic training upregulates eNOS expression, reduces oxidative stress via Nrf2-mediated antioxidant enzymes, and decreases arterial stiffness. Each 1-MET increase in fitness reduces cardiovascular mortality by 12 to 15%."
  },
  {
    "id": 659,
    "categoryId": 11,
    "question": "Exercise is recommended as an adjunctive treatment for major depressive disorder. Which neurobiological mechanism most directly explains its antidepressant effect?",
    "options": [
      "A) Decreased cerebral blood flow",
      "B) Increased BDNF expression promoting hippocampal neurogenesis and synaptic plasticity",
      "C) Suppression of serotonin synthesis",
      "D) Increased inflammatory cytokine production"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Increased BDNF expression promoting hippocampal neurogenesis and synaptic plasticity).\n\nPATHOPHYSIOLOGY:\nBrain-derived neurotrophic factor (BDNF) is the neurobiological mechanism most directly explaining the antidepressant effects of exercise per Harrison's Principles of Internal Medicine and UpToDate. BDNF is a member of the neurotrophin family that binds to TrkB (tropomyosin receptor kinase B) receptors, activating intracellular signaling cascades (MAPK/ERK, PI3K/Akt, PLCgamma) that promote neuronal survival, dendritic branching, synaptogenesis, and neurogenesis in the hippocampal dentate gyrus per the Cleveland Clinic.\n\nNEUROTROPHIC HYPOTHESIS OF DEPRESSION:\nThe neurotrophic hypothesis posits that depression is associated with reduced BDNF levels, hippocampal neuroplasticity impairment, and hippocampal volume loss, while recovery involves restoration of BDNF signaling and neuroplastic capacity per Harvard Health. Post-mortem studies consistently show reduced BDNF expression in the hippocampus and prefrontal cortex of depressed individuals, and serum BDNF levels are lower in patients with MDD compared to healthy controls per Harrison's Principles of Internal Medicine. Successful antidepressant treatment (both pharmacologic and exercise-based) is associated with normalization of BDNF levels per UpToDate.\n\nEXERCISE-BDNF PATHWAY:\nAerobic exercise increases BDNF through multiple pathways per the Mayo Clinic. Contracting skeletal muscle produces irisin (via cleavage of the membrane protein FNDC5), which crosses the blood-brain barrier and directly stimulates hippocampal BDNF gene expression through the PGC-1-alpha/FNDC5 pathway. Exercise-generated lactate also crosses the blood-brain barrier and activates BDNF transcription via the SIRT1 deacetylase pathway per UpToDate. Randomized trials demonstrate that 12 weeks of aerobic exercise increases hippocampal volume by approximately 2% in older adults (equivalent to reversing 1 to 2 years of age-related atrophy), an effect mediated by BDNF-driven neurogenesis per Harvard Health and the Cleveland Clinic.\n\nCLINICAL EVIDENCE:\nMeta-analyses confirm that exercise produces moderate-to-large antidepressant effect sizes (Hedges g approximately 0.5 to 0.7), comparable to pharmacotherapy for mild to moderate MDD per UpToDate. The 2024 ACP guidelines include exercise as a recommended treatment option for MDD per Harrison's Principles of Internal Medicine. The effective dose is typically 150 minutes per week of moderate-intensity aerobic activity per the CDC.\n\nKEY LEARNING POINTS:\nExercise exerts antidepressant effects primarily through increased BDNF expression (via the irisin/PGC-1-alpha pathway from muscle contraction), promoting hippocampal neurogenesis and restoring the neuroplasticity deficit central to the neurotrophic hypothesis of depression. Twelve weeks of aerobic exercise increases hippocampal volume by approximately 2%. Exercise produces antidepressant effect sizes comparable to pharmacotherapy for mild to moderate MDD."
  },
  {
    "id": 660,
    "categoryId": 4,
    "question": "A 54-year-old patient is newly diagnosed with Type 2 diabetes (A1c 7.2%). Intensive lifestyle intervention addresses the underlying pathophysiology of Type 2 DM by:",
    "options": [
      "A) Increasing insulin secretion from beta cells",
      "B) Reducing insulin resistance through decreased visceral adiposity and improved mitochondrial function",
      "C) Blocking hepatic glucose production only",
      "D) Slowing carbohydrate absorption in the gut"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Reducing insulin resistance through decreased visceral adiposity and improved mitochondrial function).\n\nPATHOPHYSIOLOGY:\nType 2 diabetes mellitus is fundamentally a disease of insulin resistance and progressive beta-cell dysfunction. Insulin resistance, the diminished ability of insulin to stimulate glucose uptake in skeletal muscle and adipose tissue and to suppress hepatic glucose production, is the earliest detectable metabolic abnormality and typically precedes the onset of hyperglycemia by years to decades. The molecular basis of insulin resistance centers on impaired insulin receptor signaling: in the normal state, insulin binds to the insulin receptor tyrosine kinase on muscle, adipose, and hepatic cells, triggering receptor autophosphorylation, activation of insulin receptor substrate (IRS-1 and IRS-2), and downstream signaling through the PI3K-Akt pathway that culminates in translocation of GLUT4 glucose transporters to the cell surface to facilitate glucose uptake. In insulin-resistant states, this signaling cascade is disrupted at multiple levels. Visceral adipose tissue is the primary driver of insulin resistance through several mechanisms per Harrison's Principles of Internal Medicine and data from Diabetes Care. First, visceral adipocytes are highly lipolytic and release excessive free fatty acids (FFAs) into the portal circulation, where they are taken up by the liver (stimulating hepatic gluconeogenesis, lipogenesis, and VLDL production) and by skeletal muscle. Intramyocellular and intrahepatic lipid accumulation generates lipid intermediates (diacylglycerols, ceramides) that activate serine/threonine kinases (particularly protein kinase C theta in muscle and protein kinase C epsilon in liver) that phosphorylate IRS-1 on inhibitory serine residues, blocking the normal tyrosine phosphorylation cascade and impairing downstream insulin signaling. Second, visceral adipose tissue secretes proinflammatory cytokines (TNF-alpha, IL-6, resistin, MCP-1) that activate JNK and IKK-beta inflammatory signaling pathways, which also promote inhibitory serine phosphorylation of IRS-1. Third, adiponectin secretion decreases as visceral fat mass increases, removing its insulin-sensitizing and anti-inflammatory protective effects.\n\nCLINICAL EVIDENCE:\nLifestyle intervention directly addresses these pathophysiologic mechanisms, making it the only truly disease-modifying intervention for type 2 diabetes. The Diabetes Prevention Program (DPP), published in the NEJM (2001) and involving 3,234 participants with prediabetes across 27 centers, demonstrated that structured lifestyle intervention (targeting 7% weight loss and 150 minutes per week of moderate physical activity) reduced the incidence of type 2 diabetes by 58% compared to placebo over 2.8 years of follow-up, outperforming metformin which reduced incidence by 31%. The benefit was consistent across age, sex, and ethnic groups, with the greatest benefit in patients over 60 (71% reduction). The DPP Outcomes Study confirmed sustained benefit at 10 and 15-year follow-up, with the cumulative incidence of diabetes remaining 27% lower in the lifestyle group. The DiRECT trial (Lancet 2018), a landmark randomized controlled trial in the UK primary care setting, demonstrated that intensive weight management (structured low-calorie diet targeting 15 kg or greater weight loss) achieved diabetes remission (HbA1c less than 6.5% off all diabetes medications for at least 2 months) in 46% of participants at 1 year and 36% at 2 years, with remission rates directly correlated with weight loss magnitude (86% remission among those who lost 15 kg or more). The Look AHEAD trial, involving 5,145 overweight or obese adults with T2DM followed for a median of 9.6 years, demonstrated that intensive lifestyle intervention produced sustained improvements in HbA1c, weight, fitness, blood pressure, and lipids and reduced medication requirements compared to diabetes support and education alone.\n\nCLINICAL APPLICATION:\nExercise independently improves insulin sensitivity through mechanisms distinct from weight loss. Muscle contraction activates AMP-activated protein kinase (AMPK), which directly stimulates GLUT4 translocation to the cell surface through an insulin-independent pathway, explaining why exercise lowers blood glucose even in insulin-resistant states. Regular exercise also stimulates mitochondrial biogenesis (increasing the number and function of mitochondria in skeletal muscle through PGC-1-alpha transcriptional coactivation), enhancing oxidative capacity and the ability to oxidize fatty acids rather than accumulate them as toxic intracellular lipid intermediates. Resistance training increases muscle mass, expanding the primary site of insulin-mediated glucose disposal. The ADA 2024 Standards of Care recommends at least 150 minutes per week of moderate-intensity aerobic activity plus 2 to 3 sessions of resistance training, with reduced sedentary time (breaking up prolonged sitting every 30 minutes). For the patient in this question with newly diagnosed T2DM and A1c of 7.2%, lifestyle intervention should be positioned as foundational disease-modifying treatment rather than merely adjunctive, with realistic counseling that 5 to 10% weight loss can meaningfully improve insulin sensitivity, glycemic control, and cardiovascular risk factors, and that remission is achievable particularly in early disease with preserved beta-cell function.\n\nKEY LEARNING POINTS:\nLifestyle intervention is the only truly disease-modifying treatment for T2DM, directly addressing insulin resistance by reducing visceral adiposity (decreasing FFA flux, inflammatory cytokines, and ectopic lipid accumulation that impair insulin receptor signaling) and improving mitochondrial function through exercise-induced AMPK activation and mitochondrial biogenesis. The DPP demonstrated 58% diabetes prevention with lifestyle intervention, and the DiRECT trial achieved 46% diabetes remission at 1 year with intensive weight management. Exercise improves glucose uptake through an insulin-independent AMPK-GLUT4 pathway, providing benefit even in insulin-resistant states."
  }
,
  {
    "id": 661,
    "question": "A 28-year-old G1P0 at 32 weeks' gestation presents with blood pressure 158/102 mmHg, 3+ proteinuria on urine dipstick, and a headache. Labs show platelets 90,000 and AST 180. What is the diagnosis and most critical next step?",
    "options": ["A) Gestational hypertension; observe and recheck BP in 1 week", "B) Preeclampsia with severe features; administer magnesium sulfate and plan delivery", "C) HELLP syndrome only; transfuse platelets and continue pregnancy", "D) Chronic hypertension; increase home antihypertensive dose"],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Preeclampsia with severe features; administer magnesium sulfate and plan delivery).\n\nPATHOPHYSIOLOGY:\nPreeclampsia is a pregnancy-specific multisystem disorder caused by abnormal placental development, specifically the failure of extravillous trophoblasts to adequately remodel the uterine spiral arteries during the first trimester. Normally, trophoblasts invade and replace the muscular walls of spiral arteries, transforming them from narrow, high-resistance vessels into wide, low-resistance channels that supply the growing placenta. When this remodeling fails, persistent spiral artery vasoconstriction produces placental ischemia, which triggers release of anti-angiogenic factors (soluble fms-like tyrosine kinase 1, sFlt-1, and soluble endoglin) into the maternal circulation. These factors antagonize vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), causing widespread maternal endothelial dysfunction that manifests as hypertension (from loss of vasodilatory nitric oxide and prostacyclin), proteinuria (from glomerular endotheliosis damaging the podocyte filtration barrier), and end-organ damage.\n\nDIAGNOSTIC CRITERIA:\nPreeclampsia is defined as new-onset hypertension (systolic 140 or greater or diastolic 90 or greater) after 20 weeks' gestation with proteinuria (300 mg or greater per 24 hours or protein/creatinine ratio 0.3 or greater) or evidence of end-organ dysfunction. Severe features include systolic blood pressure 160 or greater or diastolic 110 or greater, thrombocytopenia (platelets less than 100,000), elevated liver transaminases (greater than twice normal), renal insufficiency (creatinine greater than 1.1), pulmonary edema, cerebral or visual disturbances, and right upper quadrant or epigastric pain. This patient meets criteria for severe features based on blood pressure (158/102 with diastolic greater than 100), thrombocytopenia (90,000), and elevated AST (180). The combination of hemolysis, elevated liver enzymes, and low platelets constitutes HELLP syndrome, which is considered a severe variant of preeclampsia.\n\nMANAGEMENT:\nMagnesium sulfate is administered for seizure prophylaxis (preventing eclampsia) with a loading dose of 4 to 6 grams IV followed by a continuous infusion of 1 to 2 grams per hour. Antihypertensive therapy (IV labetalol, IV hydralazine, or oral nifedipine) is initiated for acute severe hypertension to reduce the risk of maternal stroke. The definitive treatment for preeclampsia is delivery of the placenta. At 32 weeks with severe features, delivery is indicated after maternal stabilization and administration of antenatal corticosteroids (betamethasone) for fetal lung maturity if time permits.\n\nKEY LEARNING POINTS:\nPreeclampsia with severe features (BP 160 or greater/110 or greater, platelets less than 100,000, elevated transaminases, renal insufficiency) requires immediate magnesium sulfate for seizure prophylaxis and delivery planning. HELLP syndrome (Hemolysis, Elevated Liver enzymes, Low Platelets) is a severe preeclampsia variant. The root cause is failed spiral artery remodeling causing placental ischemia and release of anti-angiogenic factors that produce systemic endothelial dysfunction.",
    "categoryId": 18
  },
  {
    "id": 662,
    "question": "A 32-year-old woman presents with heavy, painful periods, dyspareunia, and difficulty conceiving. Pelvic ultrasound shows a 4cm 'chocolate cyst' on the left ovary. What is the underlying diagnosis?",
    "options": ["A) Dermoid cyst (mature teratoma)", "B) Endometriosis with endometrioma", "C) Hemorrhagic corpus luteum cyst", "D) Polycystic ovarian syndrome"],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Endometriosis with endometrioma).\n\nPATHOPHYSIOLOGY:\nEndometriosis is a chronic estrogen-dependent inflammatory condition in which endometrial-like tissue (glands and stroma) implants and grows outside the uterine cavity, most commonly on the ovaries, fallopian tubes, uterosacral ligaments, cul-de-sac, and peritoneal surfaces. The ectopic endometrial tissue responds to the same cyclical hormonal stimulation as the uterine endometrium, undergoing proliferation during the follicular phase and secretory changes followed by breakdown and bleeding during menstruation. However, unlike intrauterine menstrual blood that exits through the cervix, the blood from ectopic implants has no egress, leading to local inflammation, fibrosis, adhesion formation, and progressive tissue damage. When endometrial implants on the ovary undergo repeated cycles of hemorrhage and organization, they form an endometrioma (commonly called a \"chocolate cyst\" due to the thick, dark brown, tarry fluid composed of old hemolyzed blood and hemosiderin-laden debris).\n\nCLINICAL MANIFESTATIONS:\nThe classic triad of endometriosis is dysmenorrhea (painful, often progressive menstrual cramps that may begin before menses), dyspareunia (deep pain with intercourse, particularly with deep penetration, reflecting involvement of the uterosacral ligaments and cul-de-sac), and infertility (affecting 30 to 50% of women with endometriosis through multiple mechanisms including tubal distortion from adhesions, toxic peritoneal environment impairing oocyte pickup and fertilization, impaired endometrial receptivity, and ovulatory dysfunction). Additional symptoms include chronic pelvic pain, dyschezia (painful bowel movements, especially during menstruation), and hematuria or dysuria if bladder implants are present.\n\nDIAGNOSIS:\nDirect visualization by laparoscopy with histologic confirmation of biopsy specimens remains the gold standard for diagnosing endometriosis. However, endometriomas can be identified on transvaginal ultrasound as homogeneous, hypoechoic cysts with low-level internal echoes (\"ground glass\" appearance) and no internal vascularity on Doppler. MRI is useful for deep infiltrating endometriosis and surgical planning. Serum CA-125 may be mildly elevated but lacks sensitivity and specificity for screening.\n\nTREATMENT:\nMedical therapy aims to suppress estrogen-driven growth of ectopic endometrium using combined oral contraceptives (continuous dosing to eliminate menstruation), progestins (norethindrone acetate, medroxyprogesterone, levonorgestrel IUD), GnRH agonists (leuprolide, with add-back norethindrone to prevent bone loss), or GnRH antagonists (elagolix, the first oral GnRH antagonist FDA-approved for endometriosis). Surgical excision or ablation of endometriotic implants and endometrioma cystectomy are indicated for refractory symptoms, large endometriomas (greater than 4 cm), and infertility.\n\nKEY LEARNING POINTS:\nEndometriomas (\"chocolate cysts\") are ovarian cysts containing old hemolyzed blood from repeated cyclic hemorrhage of ectopic endometrial tissue. The classic triad is dysmenorrhea, dyspareunia, and infertility, with 30 to 50% of affected women experiencing difficulty conceiving. Laparoscopy is the diagnostic gold standard, and treatment ranges from hormonal suppression (continuous OCPs, GnRH agonists/antagonists) to surgical excision.",
    "categoryId": 18
  },
  {
    "id": 663,
    "question": "A 52-year-old postmenopausal woman presents with hot flashes, vaginal dryness, and sleep disturbance that significantly impair her quality of life. She has no personal history of breast cancer, VTE, or cardiovascular disease. She is within 10 years of menopause onset. What is the most appropriate treatment?",
    "options": ["A) Black cohosh and soy isoflavones", "B) Systemic hormone replacement therapy (estrogen + progesterone)", "C) SSRI antidepressant only", "D) Testosterone replacement therapy"],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Systemic hormone replacement therapy).\n\nEVIDENCE:\nSystemic menopausal hormone therapy (MHT) with estrogen plus progestogen (in women with an intact uterus) remains the most effective treatment for vasomotor symptoms (hot flashes, night sweats), reducing their frequency by 75 to 80% and severity by a similar margin. The NAMS (North American Menopause Society) 2022 position statement, the Endocrine Society, and ACOG all support MHT as appropriate first-line therapy for moderate to severe vasomotor symptoms in women who are within 10 years of menopause onset or under age 60, provided they have no contraindications.\n\nTIMING HYPOTHESIS:\nThe critical concept governing MHT safety is the \"timing hypothesis\" (or \"window of opportunity\"), supported by the reanalysis of the Women's Health Initiative (WHI) data and the Danish Osteoporosis Prevention Study (DOPS). When initiated within 10 years of menopause onset (or before age 60), estrogen therapy is associated with reduced coronary heart disease risk, reduced all-cause mortality, and favorable cardiovascular effects (improved lipid profiles, reduced coronary artery calcification, preserved endothelial function). When initiated more than 10 years after menopause (or after age 60), the cardiovascular risk profile shifts unfavorably, with increased risk of coronary events, stroke, and VTE. This patient, at 52 and within 10 years of menopause, falls squarely within the favorable window.\n\nPROGESTOGEN REQUIREMENT:\nWomen with an intact uterus must receive a progestogen (medroxyprogesterone acetate, micronized progesterone, or a levonorgestrel IUD) along with estrogen to prevent estrogen-induced endometrial hyperplasia and endometrial cancer. Unopposed estrogen increases endometrial cancer risk 2 to 10-fold. Micronized progesterone (Prometrium) is preferred over medroxyprogesterone acetate because it has a more favorable breast safety profile and does not negate estrogen's beneficial cardiovascular effects. Women who have had a hysterectomy can receive estrogen alone.\n\nCONTRAINDICATIONS:\nAbsolute contraindications to systemic MHT include personal history of breast cancer, active or history of VTE or PE, active liver disease, unexplained vaginal bleeding, known thrombophilia, and history of stroke or MI. For women with contraindications, non-hormonal alternatives include SSRIs/SNRIs (paroxetine is the only FDA-approved non-hormonal option for hot flashes), gabapentin, fezolinetant (a neurokinin-3 receptor antagonist, FDA-approved 2023), and cognitive behavioral therapy.\n\nKEY LEARNING POINTS:\nMenopausal hormone therapy is the most effective treatment for vasomotor symptoms (75 to 80% reduction) and is appropriate for symptomatic women within 10 years of menopause onset without contraindications. Progestogen must be added for women with an intact uterus to prevent endometrial cancer from unopposed estrogen. The timing hypothesis (initiation within 10 years of menopause) is critical for favorable cardiovascular outcomes.",
    "categoryId": 18
  },
  {
    "id": 664,
    "question": "A 26-year-old woman presents with foul-smelling, thin, grayish-white vaginal discharge. Vaginal pH is 5.0. KOH 'whiff test' produces a strong fishy odor. Wet mount shows epithelial cells studded with bacteria. What is the diagnosis?",
    "options": ["A) Vulvovaginal candidiasis", "B) Bacterial vaginosis", "C) Trichomonas vaginalis", "D) Chlamydia cervicitis"],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Bacterial vaginosis).\n\nPATHOPHYSIOLOGY:\nBacterial vaginosis (BV) is the most common cause of vaginal discharge in reproductive-age women, affecting approximately 29% of women in the United States. BV is not a true infection but a dysbiosis: a shift in the vaginal microbiome from the normal Lactobacillus-dominant flora (which maintains the protective acidic pH of 3.5 to 4.5 through lactic acid and hydrogen peroxide production) to a polymicrobial overgrowth of anaerobic and facultative organisms including Gardnerella vaginalis, Atopobium vaginae, Prevotella species, Mobiluncus species, and Mycoplasma hominis. This microbial shift raises vaginal pH above 4.5 and produces amines (putrescine, cadaverine, trimethylamine) that are responsible for the characteristic fishy odor.\n\nDIAGNOSTIC CRITERIA:\nThe Amsel criteria (three of four required for diagnosis) are: thin, homogeneous, grayish-white discharge that coats the vaginal walls; vaginal pH greater than 4.5; positive whiff test (fishy amine odor released when vaginal discharge is mixed with 10% KOH, which volatilizes the amines); and clue cells on wet mount microscopy (vaginal epithelial cells with borders obscured by adherent coccobacilli, giving them a stippled, granular appearance). This patient meets all four criteria. The Nugent scoring system (Gram stain evaluation of lactobacilli versus Gardnerella and Mobiluncus morphotypes) is the gold standard for research but is less practical in clinical settings.\n\nDIFFERENTIAL DIAGNOSIS:\nVulvovaginal candidiasis presents with thick, white, \"cottage cheese\" discharge, vulvar pruritus and erythema, normal vaginal pH (less than 4.5), and pseudohyphae or budding yeast on KOH prep. Trichomonas vaginalis produces frothy, yellow-green discharge with vulvar irritation, \"strawberry cervix\" (punctate hemorrhages), motile trichomonads on wet mount, and an elevated pH. Chlamydia cervicitis may be asymptomatic or cause mucopurulent cervical discharge, but it does not produce the vaginal dysbiosis pattern of BV.\n\nTREATMENT:\nFirst-line therapy is oral metronidazole 500 mg twice daily for 7 days or intravaginal metronidazole gel 0.75% for 5 days. Oral clindamycin 300 mg twice daily for 7 days is an alternative. Patients should be advised to avoid alcohol during metronidazole treatment and for 48 hours after (disulfiram-like reaction). Recurrence is common (approximately 50% within 12 months), and treatment of male sexual partners has not been shown to reduce recurrence in most studies, though recent evidence suggests concurrent partner treatment may be beneficial.\n\nKEY LEARNING POINTS:\nBV is diagnosed by the Amsel criteria: thin grayish-white discharge, pH greater than 4.5, positive whiff test, and clue cells (epithelial cells studded with coccobacilli). It represents vaginal dysbiosis from Lactobacillus depletion and anaerobic overgrowth, not a traditional infection. First-line treatment is metronidazole, with approximately 50% recurrence at 12 months.",
    "categoryId": 18
  },
  {
    "id": 665,
    "question": "A 30-year-old nulligravid woman desires long-acting reversible contraception (LARC). She has a history of heavy menstrual bleeding. Which method provides BOTH highly effective contraception AND treatment of her menorrhagia?",
    "options": ["A) Copper IUD (Paragard)", "B) Levonorgestrel IUD (Mirena)", "C) Etonogestrel subdermal implant (Nexplanon)", "D) Depot medroxyprogesterone acetate (Depo-Provera)"],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Levonorgestrel IUD/Mirena).\n\nPHARMACOLOGY:\nThe levonorgestrel-releasing intrauterine device (LNG-IUD, Mirena 52 mg) provides highly effective contraception (failure rate 0.2%, comparable to tubal ligation) while simultaneously delivering local progestogen to the endometrium that produces profound endometrial suppression (decidualization, stromal pseudodecidualization, and glandular atrophy), reducing menstrual blood loss by 80 to 97% within 6 months. Approximately 20% of users become amenorrheic by one year, increasing to 50% by 5 years. This dual benefit makes the LNG-IUD uniquely suited for women who desire both contraception and treatment of heavy menstrual bleeding.\n\nMECHANISM OF CONTRACEPTION:\nThe LNG-IUD prevents pregnancy through multiple mechanisms: thickening of cervical mucus (preventing sperm penetration), endometrial suppression (creating a hostile environment for implantation), partial suppression of ovulation in some cycles (though most users continue to ovulate), and a local foreign-body inflammatory reaction that is spermicidal. The continuous local progestogen delivery achieves high endometrial tissue concentrations with minimal systemic absorption, resulting in fewer systemic side effects compared to oral or injectable progestins.\n\nWHY NOT THE ALTERNATIVES:\nThe copper IUD (Paragard) is an excellent non-hormonal LARC option but actually increases menstrual bleeding by 20 to 50% and worsens dysmenorrhea, making it contraindicated in this patient with menorrhagia. The etonogestrel implant (Nexplanon) provides highly effective contraception (failure rate 0.05%, the most effective reversible method) but produces unpredictable bleeding patterns (irregular spotting, prolonged bleeding) in approximately 30% of users and is not reliably effective for treating heavy menstrual bleeding. Depot medroxyprogesterone (Depo-Provera) reduces menstrual bleeding and often induces amenorrhea, but it is associated with weight gain (average 5 kg over 2 years), delayed return to fertility (average 10 months after last injection), and bone density loss with prolonged use, making it less ideal for long-term use.\n\nADDITIONAL BENEFITS:\nThe LNG-IUD has FDA approval for treatment of heavy menstrual bleeding and is endorsed by ACOG as first-line medical therapy for menorrhagia. It also provides endometrial protection for women on estrogen therapy and reduces the risk of endometrial cancer and endometrial hyperplasia. It is effective for 8 years for contraception.\n\nKEY LEARNING POINTS:\nThe levonorgestrel IUD (Mirena) is the only LARC that provides both highly effective contraception and treatment of heavy menstrual bleeding, reducing blood loss by 80 to 97% through local endometrial suppression. The copper IUD worsens menstrual bleeding and is contraindicated in menorrhagia. The LNG-IUD is ACOG-endorsed as first-line medical therapy for heavy periods.",
    "categoryId": 18
  },
  {
    "id": 666,
    "question": "A 25-year-old woman presents to the emergency department with sudden-onset severe right lower quadrant pain, nausea, and a positive pregnancy test (beta-hCG 1,800 mIU/mL). Transvaginal ultrasound shows no intrauterine pregnancy and free fluid in the cul-de-sac. What is the most likely diagnosis?",
    "options": ["A) Threatened abortion", "B) Ectopic pregnancy", "C) Ovarian torsion", "D) Ruptured ovarian cyst"],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Ectopic pregnancy).\n\nPATHOPHYSIOLOGY:\nAn ectopic pregnancy occurs when a fertilized ovum implants outside the uterine cavity, most commonly in the fallopian tube (approximately 95% of cases, with the ampulla being the most frequent site followed by the isthmus and fimbriae). The fallopian tube lacks the thick, distensible myometrium and specialized decidual response of the uterus, so the growing trophoblast invades through the thin tubal wall, eventually causing tubal rupture, hemorrhage, and potentially life-threatening hemoperitoneum. Risk factors include prior ectopic pregnancy (10-fold increased risk), prior tubal surgery or pelvic inflammatory disease (tubal scarring and damage to ciliary function), endometriosis, IUD use (an IUD prevents intrauterine pregnancy more effectively than ectopic, so if pregnancy occurs with an IUD in place, the probability it is ectopic is increased), smoking (impairs tubal motility and ciliary function), and assisted reproductive technology.\n\nDIAGNOSTIC REASONING:\nThe discriminatory zone is the beta-hCG level above which a normal intrauterine pregnancy should be visible on transvaginal ultrasound, typically 1,500 to 2,000 mIU/mL. This patient's beta-hCG of 1,800 is above the discriminatory zone, yet no intrauterine pregnancy is visible, which is highly suspicious for ectopic pregnancy. Free fluid in the cul-de-sac (the most dependent peritoneal space) suggests hemoperitoneum from tubal rupture or leaking ectopic. In a hemodynamically stable patient, the combination of positive pregnancy test, beta-hCG above the discriminatory zone, absent intrauterine pregnancy on transvaginal ultrasound, and adnexal pathology or free fluid has a positive predictive value exceeding 95% for ectopic pregnancy.\n\nMANAGEMENT:\nHemodynamically unstable patients require emergent surgical intervention (laparoscopic salpingectomy or salpingostomy). For hemodynamically stable patients with an unruptured ectopic pregnancy, medical management with methotrexate (a folate antagonist that inhibits rapidly dividing trophoblastic tissue) is appropriate when beta-hCG is less than 5,000, the ectopic mass is less than 3.5 cm, no fetal cardiac activity is detected, and the patient can comply with follow-up. Expectant management may be considered for very low and declining beta-hCG levels.\n\nKEY LEARNING POINTS:\nAn ectopic pregnancy should be suspected when beta-hCG is above the discriminatory zone (1,500 to 2,000) with no intrauterine pregnancy on transvaginal ultrasound. Free cul-de-sac fluid suggests tubal rupture and hemoperitoneum. The ampulla is the most common site (95% are tubal), and methotrexate is the standard medical treatment for stable, unruptured ectopic pregnancies meeting criteria.",
    "categoryId": 18
  },
  {
    "id": 667,
    "question": "A 35-year-old woman with regular cycles is trying to conceive. She asks when in her cycle she is most fertile. What is the most accurate counseling?",
    "options": ["A) The day of ovulation only", "B) The 6-day window ending on the day of ovulation (fertile window)", "C) Days 1-7 of the menstrual cycle", "D) The 3 days immediately after ovulation"],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (The 6-day window ending on the day of ovulation).\n\nREPRODUCTIVE PHYSIOLOGY:\nThe fertile window encompasses the 5 days before ovulation and the day of ovulation itself, reflecting the survival characteristics of sperm and oocyte. Sperm can survive in the female reproductive tract for up to 5 days when cervical mucus is favorable (thin, watery, and stretchable ferning-pattern mucus produced under estrogen influence during the follicular phase), maintaining their fertilization capacity within the cervical crypts and fallopian tubes. The oocyte, however, is viable for only 12 to 24 hours after ovulation. Therefore, the highest probability of conception occurs when sperm are already present in the reproductive tract at the time of ovulation or arrive within hours afterward.\n\nPEAK FERTILITY:\nThe probability of conception is highest during the 2 days immediately preceding ovulation (approximately 25 to 30% per cycle), declines sharply on the day of ovulation itself, and approaches zero beyond 24 hours after ovulation. In a textbook 28-day cycle, ovulation occurs around day 14, making the fertile window approximately days 9 to 14. However, ovulation timing varies significantly between women and between cycles in the same woman, which is why calendar-based methods alone are unreliable for predicting fertility.\n\nFERTILITY AWARENESS METHODS:\nOvulation can be detected or predicted by several methods. Urinary luteinizing hormone (LH) surge detection kits identify the LH surge that precedes ovulation by 24 to 36 hours, providing advance warning of the most fertile days. Basal body temperature (BBT) rises by 0.2 to 0.5Â°C after ovulation due to progesterone's thermogenic effect, but this only confirms ovulation retrospectively. Cervical mucus monitoring (the Billings method) identifies the transition from scant, thick mucus to copious, clear, stretchy mucus (spinnbarkeit) that signals the estrogen peak preceding ovulation.\n\nCLINICAL COUNSELING:\nFor couples trying to conceive, intercourse every 1 to 2 days during the fertile window optimizes the chance of conception. Daily intercourse is not necessary and does not significantly improve conception rates over every-other-day intercourse. ACOG recommends that couples who have not conceived after 12 months of regular unprotected intercourse (or 6 months if the woman is 35 or older) should be evaluated for infertility.\n\nKEY LEARNING POINTS:\nThe fertile window is the 6-day period ending on the day of ovulation, reflecting sperm survival (up to 5 days) and oocyte viability (12 to 24 hours). Peak fertility occurs in the 2 days preceding ovulation. LH surge kits predict ovulation 24 to 36 hours in advance, while basal body temperature only confirms ovulation retrospectively.",
    "categoryId": 18
  },
  {
    "id": 668,
    "question": "A 45-year-old woman undergoes cervical cancer screening. Her HPV test is positive for HPV 16, but cytology is negative (NILM). What is the appropriate management per ASCCP guidelines?",
    "options": ["A) Immediate colposcopy", "B) Repeat co-testing in 1 year", "C) No further follow-up needed", "D) Proceed directly to LEEP excision"],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Immediate colposcopy).\n\nASCCP GUIDELINE:\nThe 2019 ASCCP Risk-Based Management Consensus Guidelines recommend immediate colposcopy for any patient whose HPV test is specifically positive for HPV 16 or HPV 18, even when cytology is negative (NILM). This is because HPV 16 and 18 carry substantially higher oncogenic risk than other high-risk HPV types, and the probability of underlying CIN 3 or greater (precancer) is approximately 4% for HPV 16 with NILM cytology. This exceeds the ASCCP's colposcopy referral threshold of 4% immediate CIN 3+ risk, which is the risk level at which the potential benefit of detecting precancer outweighs the harms of the procedure.\n\nWHY HPV 16 IS DIFFERENT:\nHPV 16 is responsible for approximately 50 to 60% of all cervical cancers and has a uniquely aggressive oncogenic profile compared to other high-risk types. While approximately 90% of all HPV infections clear within 1 to 2 years, HPV 16 is more likely to persist: approximately 30 to 40% of HPV 16 infections persist beyond 12 months, compared to approximately 10 to 15% for other high-risk types. HPV 16 is also more efficient at driving neoplastic progression through its E6 and E7 oncoproteins, which degrade the tumor suppressors p53 and retinoblastoma protein (Rb) respectively. The E6 protein of HPV 16 has a particularly high binding affinity for p53 compared to low-risk HPV types. These properties mean that even with a normal Pap smear, there is a meaningful probability that an HPV 16-positive patient harbors an occult high-grade lesion that was missed by cytology (which has a single-test sensitivity of only 50 to 80% for CIN 2+).\n\nCOMPARISON WITH OTHER HIGH-RISK HPV TYPES:\nFor patients who test positive for pooled high-risk HPV (non-16/non-18 types, such as HPV 31, 33, 45, 52, 58) with NILM cytology, the CIN 3+ risk is approximately 0.5 to 1%, which falls below the 4% colposcopy threshold. These patients are managed with repeat co-testing (HPV plus cytology) in 1 year. If HPV remains positive at 1 year (regardless of cytology result), the accumulated risk then crosses the 4% threshold and colposcopy is indicated. If both HPV and cytology are negative at 1 year, repeat testing in 3 years (not return to routine 5-year intervals) is recommended because the prior HPV positivity places the patient at higher baseline risk than the general screening population.\n\nCOLPOSCOPY PROCEDURE:\nColposcopy involves applying 3 to 5% acetic acid to the cervix and examining it under magnification (6 to 40x) to identify acetowhite epithelium, abnormal vascular patterns (mosaicism, punctation), and other features suggestive of dysplasia. Biopsies are taken from any abnormal areas, and endocervical curettage (ECC) is performed if the transformation zone is not fully visualized. If colposcopy and biopsies are negative (CIN 1 or less), the patient is followed with repeat HPV-based testing in 1 year rather than returned to routine screening, because a single negative colposcopy does not eliminate the risk conferred by HPV 16 positivity.\n\nKEY LEARNING POINTS:\nHPV 16 (or 18) positive with NILM cytology requires immediate colposcopy per ASCCP guidelines because the CIN 3+ risk (approximately 4%) exceeds the colposcopy referral threshold. HPV 16 is uniquely dangerous: it causes 50 to 60% of cervical cancers, persists more frequently (30 to 40% beyond 12 months), and has higher E6 binding affinity for p53. For non-16/non-18 high-risk HPV with NILM, repeat co-testing in 1 year is appropriate because the CIN 3+ risk is only 0.5 to 1%.",
    "categoryId": 18
  },
  {
    "id": 669,
    "question": "A 38-year-old woman with a BMI of 34 presents with irregular, heavy periods occurring every 2-3 months and hirsutism. She is not trying to conceive. Endometrial biopsy shows simple hyperplasia without atypia. What is the most important pharmacologic intervention?",
    "options": ["A) Metformin alone", "B) Progestogen therapy (oral or intrauterine) to protect the endometrium", "C) Clomiphene citrate for ovulation induction", "D) Spironolactone for hirsutism"],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Progestogen therapy to protect the endometrium).\n\nPATHOPHYSIOLOGY:\nThis patient has features consistent with polycystic ovary syndrome (PCOS): oligomenorrhea, hyperandrogenism (hirsutism), and obesity. In PCOS, chronic anovulation results in continuous estrogen production (from peripheral aromatization of androgens in adipose tissue and from the persistent follicles that produce estradiol without progressing to ovulation) without the cyclical progesterone secretion that normally follows ovulation from the corpus luteum. This creates a state of unopposed estrogen stimulation of the endometrium, which drives endometrial proliferation without the progesterone-mediated secretory transformation and organized shedding. Over time, unopposed estrogen produces endometrial hyperplasia, which can progress from simple hyperplasia without atypia (1% progression to endometrial cancer) to complex hyperplasia with atypia (29% progression to endometrial cancer).\n\nENDOMETRIAL PROTECTION:\nProgestogen therapy is the most critical intervention because it directly counteracts unopposed estrogen by inducing secretory transformation and organized shedding of the endometrium, reversing hyperplasia and preventing progression to endometrial cancer. Options include cyclic oral progestogen (medroxyprogesterone acetate 10 mg daily for 10 to 14 days each month to induce a withdrawal bleed), continuous progestogen (norethindrone acetate), the levonorgestrel IUD (Mirena, which provides continuous local progestogen delivery directly to the endometrium and is highly effective for hyperplasia regression), or combined oral contraceptives (which provide both progestogen for endometrial protection and suppress ovarian androgen production).\n\nCOMPREHENSIVE PCOS MANAGEMENT:\nWhile endometrial protection is the most urgent concern given the biopsy finding, comprehensive PCOS management also addresses hyperandrogenism (spironolactone, an anti-androgen, for hirsutism; combined OCPs to suppress ovarian androgens), metabolic syndrome (weight loss of 5 to 10% can restore ovulatory cycles, improve insulin sensitivity, and reduce androgens), and insulin resistance (metformin as adjunctive therapy). However, none of these address the immediate cancer risk from endometrial hyperplasia as directly as progestogen therapy.\n\nMONITORING:\nFollow-up endometrial biopsy should be performed after 3 to 6 months of progestogen therapy to confirm hyperplasia regression. If hyperplasia with atypia were present, the LNG-IUD or hysterectomy would be recommended given the 29% cancer progression rate.\n\nKEY LEARNING POINTS:\nUnopposed estrogen from chronic anovulation in PCOS causes endometrial hyperplasia, with progression to cancer in 1% (simple without atypia) to 29% (complex with atypia). Progestogen therapy (oral cyclic, LNG-IUD, or combined OCPs) is the most critical intervention to induce endometrial shedding and reverse hyperplasia. The LNG-IUD is the most effective option for endometrial protection in PCOS.",
    "categoryId": 18
  },
  {
    "id": 670,
    "question": "A 28-year-old G2P1 at 28 weeks' gestation has a 1-hour glucose challenge test result of 155 mg/dL (threshold 140 mg/dL). She proceeds to the 3-hour oral glucose tolerance test and has 2 abnormal values. What is the diagnosis, and what is the most significant fetal risk if poorly controlled?",
    "options": ["A) Type 2 diabetes; neural tube defects", "B) Gestational diabetes; fetal macrosomia", "C) Impaired glucose tolerance; preterm birth", "D) Normal pregnancy; no fetal risk"],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Gestational diabetes; fetal macrosomia).\n\nDIAGNOSTIC CRITERIA:\nGestational diabetes mellitus (GDM) is defined as glucose intolerance first recognized during pregnancy and is diagnosed by the two-step approach recommended by ACOG. Step one is the 1-hour 50-gram glucose challenge test (GCT) at 24 to 28 weeks' gestation; a result of 140 mg/dL or greater (some centers use 130 or 135) is considered positive and requires the confirmatory 3-hour 100-gram oral glucose tolerance test (OGTT). Step two applies the Carpenter-Coustan criteria for the 3-hour OGTT: fasting 95 or greater, 1-hour 180 or greater, 2-hour 155 or greater, 3-hour 140 or greater. Two or more abnormal values confirm GDM. This patient meets criteria.\n\nPATHOPHYSIOLOGY:\nPregnancy is inherently a state of progressive insulin resistance driven by placental hormones (human placental lactogen, cortisol, progesterone, growth hormone variant, TNF-alpha) that antagonize maternal insulin signaling to ensure adequate glucose delivery to the fetus. In women with insufficient pancreatic beta-cell compensatory capacity (those with underlying insulin resistance from obesity, PCOS, family history, or prior GDM), blood glucose levels rise above normal, producing GDM. GDM affects approximately 6 to 9% of pregnancies.\n\nFETAL MACROSOMIA:\nThe most significant fetal risk of poorly controlled GDM is macrosomia (birth weight greater than 4,000 to 4,500 grams). Maternal hyperglycemia crosses the placenta (glucose crosses freely by facilitated diffusion), but maternal insulin does not. The fetal pancreas responds to chronically elevated glucose by producing excess insulin (fetal hyperinsulinemia), which acts as a potent growth factor driving excessive fetal adipose deposition, organomegaly (particularly hepatomegaly and cardiomegaly), and accelerated growth. This is the Pedersen hypothesis. Macrosomia increases the risk of shoulder dystocia (and its complications: brachial plexus injury/Erb palsy, clavicle fracture), birth trauma, operative delivery, and neonatal hypoglycemia (the hyperinsulinemic neonate rapidly becomes hypoglycemic after the placental glucose supply is removed at delivery).\n\nMANAGEMENT:\nDietary modification and glucose monitoring (fasting less than 95 mg/dL, 1-hour postprandial less than 140 or 2-hour less than 120) are first-line. Insulin is the preferred pharmacologic agent when dietary measures fail. Metformin and glyburide are alternatives but cross the placenta.\n\nKEY LEARNING POINTS:\nGDM is diagnosed by the two-step process (1-hour GCT followed by 3-hour OGTT with 2 or more abnormal Carpenter-Coustan values) at 24 to 28 weeks. Fetal macrosomia is the most significant risk, driven by the Pedersen hypothesis (maternal hyperglycemia causes fetal hyperinsulinemia and excessive growth). Macrosomia increases shoulder dystocia, birth trauma, and neonatal hypoglycemia risk.",
    "categoryId": 18
  },
  {
    "id": 671,
    "question": "A 55-year-old postmenopausal woman presents with postmenopausal bleeding. She is obese (BMI 38) and has type 2 diabetes. Endometrial thickness on transvaginal ultrasound is 8mm. What is the most appropriate next step?",
    "options": ["A) Reassurance and follow-up ultrasound in 6 months", "B) Endometrial biopsy", "C) Start oral contraceptive pills", "D) Hysterectomy"],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Endometrial biopsy).\n\nCLINICAL REASONING:\nPostmenopausal bleeding (PMB) is defined as any vaginal bleeding occurring 12 months or more after the final menstrual period and must be evaluated to exclude endometrial cancer. Approximately 10% of women with PMB will be found to have endometrial carcinoma, making tissue sampling mandatory in virtually all cases. This patient has multiple additional risk factors for endometrial cancer: obesity (BMI 38, associated with excess peripheral aromatization of androgens to estrogen in adipose tissue, producing chronic unopposed estrogen stimulation), type 2 diabetes (associated with hyperinsulinemia, which promotes endometrial proliferation through insulin and IGF-1 receptor activation), and an endometrial thickness of 8 mm (exceeding the 4 mm threshold below which endometrial cancer is very unlikely in postmenopausal women).\n\nENDOMETRIAL THICKNESS THRESHOLD:\nIn postmenopausal women with bleeding, a transvaginal ultrasound showing an endometrial thickness of 4 mm or less has a greater than 99% negative predictive value for excluding endometrial cancer, and biopsy can be deferred in this group. An endometrial thickness greater than 4 mm (as in this patient with 8 mm) requires tissue sampling. However, ultrasound thickness alone cannot distinguish benign causes (endometrial polyp, atrophic endometritis, hyperplasia) from malignancy, which is why histologic evaluation is necessary.\n\nBIOPSY METHODS:\nOffice endometrial biopsy (using a Pipelle device or similar suction curette) is the initial tissue sampling method of choice due to its low cost, convenience, minimal discomfort, and high sensitivity (90 to 98%) for detecting endometrial cancer. If the office biopsy is technically inadequate, non-diagnostic, or discordant with clinical suspicion, hysteroscopy with directed biopsy and/or dilation and curettage (D&C) is performed for definitive evaluation.\n\nENDOMETRIAL CANCER RISK FACTORS:\nThe primary risk factor framework for Type I endometrial cancer (endometrioid adenocarcinoma, accounting for 80% of cases) centers on chronic unopposed estrogen exposure: obesity, anovulation (PCOS), nulliparity, early menarche, late menopause, tamoxifen use (estrogenic effect on the endometrium despite anti-estrogenic effect on breast), and estrogen-only HRT without progestogen. Protective factors include combined oral contraceptives (each 5 years of use reduces endometrial cancer risk by approximately 25%), LNG-IUD, multiparity, and physical activity.\n\nKEY LEARNING POINTS:\nAll postmenopausal bleeding requires evaluation to exclude endometrial cancer (present in approximately 10% of cases). Endometrial thickness greater than 4 mm on ultrasound warrants tissue sampling; 4 mm or less has greater than 99% NPV for cancer. Office Pipelle biopsy is the first-line tissue sampling method with 90 to 98% sensitivity for endometrial cancer.",
    "categoryId": 18
  },
  {
    "id": 672,
    "question": "A 22-year-old woman presents for preconception counseling. She has epilepsy treated with valproic acid. What is the most critical medication-related counseling?",
    "options": ["A) Valproic acid is safe in pregnancy at low doses", "B) Valproic acid is the most teratogenic commonly used antiepileptic and should be switched before conception", "C) All antiepileptic drugs carry equal teratogenic risk", "D) She should stop all antiepileptics before conceiving"],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Valproic acid is the most teratogenic commonly used AED and should be switched before conception).\n\nTERATOGENICITY:\nValproic acid (valproate, Depakote) is the most teratogenic commonly prescribed antiepileptic drug, carrying a major congenital malformation rate of 9 to 11% (compared to 2 to 3% baseline population risk), making preconception medication change essential. The teratogenic effects are dose-dependent and are most pronounced during the first trimester (organogenesis).\n\nSPECIFIC MALFORMATIONS:\nNeural tube defects (NTDs) are the most characteristic valproate-associated malformations, occurring in 1 to 2% of exposed pregnancies (10 to 20 times the baseline rate). Spina bifida is the most common NTD, resulting from valproate's inhibition of folate metabolism and disruption of histone deacetylase (HDAC) activity during neural tube closure (which occurs by day 28 post-conception, often before the woman knows she is pregnant). Additional malformations include craniofacial anomalies (midface hypoplasia), cardiac defects (ASD, VSD), skeletal abnormalities, hypospadias, and limb defects. Beyond structural malformations, in-utero valproate exposure reduces mean IQ by 8 to 11 points compared to other AEDs and increases the risk of autism spectrum disorder 3 to 5-fold, representing neurodevelopmental teratogenicity that persists even without structural birth defects.\n\nSAFER ALTERNATIVES:\nLamotrigine and levetiracetam are the preferred AEDs during pregnancy based on registry data showing malformation rates close to the background population rate (2 to 3%). Lamotrigine does require dose adjustment during pregnancy because estrogen-induced upregulation of UGT enzymes accelerates lamotrigine glucuronidation, reducing serum levels by up to 50 to 65% during the second and third trimesters. Carbamazepine carries intermediate risk (approximately 3 to 5% malformation rate, including NTDs at a lower rate than valproate). The transition off valproate should be completed before conception with adequate seizure control on the new agent confirmed.\n\nFOLIC ACID SUPPLEMENTATION:\nAll women of childbearing potential on AEDs should take high-dose folic acid (4 mg daily, compared to the standard 0.4 mg) starting at least 1 to 3 months before conception and continuing through the first trimester. While high-dose folate does not completely eliminate the NTD risk from valproate, it provides partial protection.\n\nKEY LEARNING POINTS:\nValproic acid is the most teratogenic common AED (9 to 11% malformation rate), causing neural tube defects (1 to 2%), cardiac defects, and neurodevelopmental harm (8 to 11 point IQ reduction, increased autism risk). Lamotrigine and levetiracetam are the preferred AEDs in pregnancy. Switching must be completed before conception, and high-dose folic acid (4 mg daily) should be started at least 1 to 3 months pre-conception.",
    "categoryId": 18
  },
  {
    "id": 673,
    "question": "A 34-year-old woman 3 days postpartum presents with low mood, tearfulness, irritability, and difficulty sleeping. She is bonding with her infant and denies suicidal ideation. What is the most likely diagnosis?",
    "options": ["A) Postpartum depression", "B) Postpartum psychosis", "C) Postpartum 'baby blues'", "D) Adjustment disorder"],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Postpartum baby blues).\n\nDIAGNOSTIC REASONING:\nPostpartum blues (commonly called \"baby blues\") is a transient, self-limited mood disturbance affecting 50 to 80% of new mothers, typically beginning within 2 to 3 days of delivery, peaking around days 3 to 5, and resolving spontaneously within 2 weeks. The cardinal features are emotional lability (tearfulness, mood swings, irritability), mild anxiety, difficulty sleeping (beyond what is expected from newborn care demands), and feeling overwhelmed. Critically, the mother maintains the ability to bond with and care for her infant, and there are no psychotic symptoms or suicidal ideation. This patient at 3 days postpartum with the described symptoms and intact bonding and function fits this presentation.\n\nPATHOPHYSIOLOGY:\nThe dramatic hormonal changes following delivery are believed to trigger the baby blues. Estrogen and progesterone levels, which rise 100 to 1,000-fold during pregnancy, plummet within 48 hours of placental delivery. This rapid withdrawal affects serotonergic, GABAergic, and HPA-axis function. Additionally, prolactin surges, oxytocin fluctuations, thyroid function changes, sleep deprivation, and the psychosocial stress of new parenthood all contribute.\n\nDIFFERENTIAL DIAGNOSIS:\nPostpartum depression (PPD) is more severe, lasts longer (onset within 4 weeks per DSM-5, though often recognized later), and includes persistent depressed mood, anhedonia, significant functional impairment, difficulty bonding with the infant, excessive guilt or worthlessness, appetite and sleep changes beyond what is expected, and potentially suicidal ideation. PPD affects 10 to 15% of postpartum women and requires treatment (psychotherapy, SSRIs, or brexanolone/zuranolone for severe cases). Postpartum psychosis is a psychiatric emergency (0.1 to 0.2% of deliveries) presenting within 2 to 4 weeks with confusion, disorientation, hallucinations, delusions (often involving the infant), severe mood instability, and carries risk of infanticide and maternal suicide, requiring immediate hospitalization.\n\nMANAGEMENT:\nBaby blues requires only reassurance, emotional support, adequate rest, and help with infant care. No pharmacologic treatment is needed. However, if symptoms persist beyond 2 weeks, worsen, or include suicidal ideation or impaired bonding, the diagnosis should be reconsidered as PPD and formal screening (Edinburgh Postnatal Depression Scale) should be performed.\n\nKEY LEARNING POINTS:\nPostpartum blues affects 50 to 80% of new mothers, begins within days of delivery, and resolves within 2 weeks without treatment. Key distinguishing features from postpartum depression are preserved bonding, maintained function, and self-limited course. If symptoms persist beyond 2 weeks or include impaired bonding, suicidal ideation, or functional decline, screen for postpartum depression with the Edinburgh scale.",
    "categoryId": 18
  },
  {
    "id": 674,
    "question": "A 29-year-old woman is diagnosed with breast cancer. Genetic testing reveals a BRCA1 mutation. Which of the following is the most accurate statement about her cancer risk?",
    "options": ["A) BRCA1 increases breast cancer risk only, not ovarian cancer risk", "B) BRCA1 confers a 60-70% lifetime risk of breast cancer and 40-45% risk of ovarian cancer", "C) BRCA1 mutations are autosomal recessive and require two mutant alleles", "D) Surveillance alone is sufficient; risk-reducing surgery is not recommended"],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (BRCA1 confers 60-70% lifetime breast cancer risk and 40-45% ovarian cancer risk).\n\nGENETICS:\nBRCA1 (chromosome 17q21) and BRCA2 (chromosome 13q12.3) are tumor suppressor genes that encode proteins essential for homologous recombination DNA repair, a high-fidelity mechanism for repairing double-strand DNA breaks. BRCA mutations follow an autosomal dominant inheritance pattern with variable penetrance, meaning a single mutant allele (heterozygous state) is sufficient to confer significantly elevated cancer risk. When the remaining wild-type allele is lost or inactivated (loss of heterozygosity, the \"second hit\" per Knudson's two-hit hypothesis), the cell loses its capacity for accurate DNA repair, accumulating mutations that drive carcinogenesis.\n\nCANCER RISKS:\nBRCA1 mutation carriers have a 60 to 70% cumulative lifetime risk of developing breast cancer (compared to 12% in the general population) and a 40 to 45% risk of ovarian cancer (compared to 1.3% in the general population). BRCA1-associated breast cancers are more frequently triple-negative (estrogen receptor-negative, progesterone receptor-negative, HER2-negative), high-grade, and basal-like subtype. BRCA2 carriers have a 45 to 55% lifetime breast cancer risk and a 15 to 20% ovarian cancer risk, with tumors more likely to be estrogen receptor-positive. Both mutations also increase risk of fallopian tube cancer, peritoneal cancer, pancreatic cancer, and male breast cancer (particularly BRCA2).\n\nRISK-REDUCING STRATEGIES:\nRisk-reducing bilateral mastectomy decreases breast cancer risk by approximately 90 to 95% and is offered after shared decision-making. Risk-reducing bilateral salpingo-oophorectomy (RRSO) is recommended by age 35 to 40 for BRCA1 carriers (or after completion of childbearing) and reduces ovarian cancer risk by approximately 80% and breast cancer risk by approximately 50% (through estrogen deprivation). For carriers who decline prophylactic surgery, enhanced surveillance includes annual breast MRI with contrast (starting at age 25 to 30) alternating with annual mammography at 6-month intervals, and consideration of chemoprevention with tamoxifen or oseloxifene.\n\nSCREENING RECOMMENDATIONS:\nThe USPSTF recommends that primary care clinicians assess women with a personal or family history of breast/ovarian/tubal/peritoneal cancer using validated tools (such as the USPSTF family history screening tool) and refer appropriate patients for genetic counseling and potential BRCA testing.\n\nKEY LEARNING POINTS:\nBRCA1 confers 60 to 70% lifetime breast cancer risk and 40 to 45% ovarian cancer risk through autosomal dominant inheritance of impaired homologous recombination DNA repair. BRCA1 tumors are more often triple-negative. Risk-reducing salpingo-oophorectomy by age 35 to 40 reduces ovarian cancer risk by approximately 80% and breast cancer risk by approximately 50%.",
    "categoryId": 18
  },
  {
    "id": 675,
    "question": "A 19-year-old female college student presents requesting emergency contraception. She had unprotected intercourse 4 days ago. Which option is most effective at this time point?",
    "options": ["A) Levonorgestrel (Plan B) oral pill", "B) Copper IUD (Paragard) insertion", "C) Combined oral contraceptive pills (Yuzpe regimen)", "D) No effective option exists beyond 72 hours"],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Copper IUD insertion).\n\nPHARMACOLOGY:\nThe copper IUD (Paragard) is the most effective form of emergency contraception available, reducing the risk of pregnancy by greater than 99% when inserted within 5 days (120 hours) of unprotected intercourse. At 4 days (96 hours) post-intercourse, the copper IUD is the only emergency contraceptive method that maintains near-maximal efficacy. Copper ions released from the IUD create a toxic intrauterine environment that is directly spermicidal (impairing sperm motility and viability), disrupts the acrosome reaction required for fertilization, and alters the endometrial environment to prevent implantation. This multi-mechanism approach is effective even when placed up to 5 days after intercourse because it can prevent fertilization of an oocyte that may still be present and prevent implantation of a recently fertilized ovum.\n\nCOMPARISON WITH ORAL OPTIONS:\nLevonorgestrel (Plan B, 1.5 mg single dose) works primarily by delaying or inhibiting ovulation through suppression of the LH surge and has significantly diminished efficacy beyond 72 hours, dropping from approximately 85% effectiveness within 24 hours to approximately 58% at 49 to 72 hours. It has minimal efficacy beyond 72 hours and does not prevent implantation. Its effectiveness is also reduced in women weighing more than 70 kg (155 lbs). Ulipristal acetate (ella, 30 mg single dose), a selective progesterone receptor modulator, is effective up to 120 hours and maintains more consistent efficacy than levonorgestrel through this window, but it is still less effective than the copper IUD (approximately 98% versus greater than 99%). The Yuzpe regimen (combined estrogen-progestin pills) is the least effective method (approximately 75% overall) and is limited to 72 hours.\n\nADDITIONAL BENEFITS:\nInsertion of a copper IUD for emergency contraception provides the additional benefit of ongoing highly effective long-acting reversible contraception for up to 10 to 12 years, addressing both the immediate need and future contraceptive planning in a single intervention. This \"bridge\" from emergency to long-term contraception is a significant clinical advantage. The LNG-IUD (Mirena) has emerging evidence for use as emergency contraception within 5 days, though it is not yet included in all guidelines for this indication.\n\nKEY LEARNING POINTS:\nThe copper IUD is the most effective emergency contraception (greater than 99%) and remains fully effective up to 5 days (120 hours) post-intercourse. Levonorgestrel (Plan B) has significantly reduced efficacy beyond 72 hours and is less effective in women over 70 kg. The copper IUD also provides ongoing contraception for up to 10 to 12 years, addressing both emergency and long-term needs.",
    "categoryId": 18
  }
,{"id":676,"categoryId":18,"question":"A 28-year-old G1P0 at 10 weeks gestation presents for her first prenatal visit. She has no medical history and takes no medications other than a prenatal vitamin. Which screening test is recommended at this visit to assess for chromosomal abnormalities?","options":["A) Quad screen","B) First-trimester combined screening (nuchal translucency + serum markers)","C) Amniocentesis","D) No screening needed until 20 weeks"],"correctAnswer":1,"explanation":"CORRECT: B (First-trimester combined screening).\n\nSCREENING APPROACH:\nFirst-trimester combined screening (performed between 11 and 14 weeks gestation) consists of nuchal translucency measurement on ultrasound plus maternal serum markers (free beta-hCG and pregnancy-associated plasma protein-A, PAPP-A) and provides a detection rate of approximately 82 to 87% for trisomy 21 (Down syndrome) with a 5% false-positive rate. This is the standard first-trimester screening offered to all pregnant patients regardless of age, as ACOG recommends that all pregnant individuals be offered aneuploidy screening or diagnostic testing.\n\nNUCHAL TRANSLUCENCY:\nThe nuchal translucency (NT) is a sonographic measurement of the fluid-filled space at the back of the fetal neck, measured between 11 weeks 0 days and 13 weeks 6 days (crown-rump length 45 to 84 mm). An NT measurement greater than 3.0 mm (or above the 99th percentile for gestational age) is associated with increased risk of trisomy 21, trisomy 18, trisomy 13, Turner syndrome, and congenital heart defects. Even when the karyotype is normal, an elevated NT warrants a detailed fetal echocardiogram at 18 to 22 weeks due to the 3 to 4-fold increased risk of structural cardiac anomalies.\n\nSERUM MARKERS:\nIn trisomy 21, free beta-hCG is elevated (approximately 2 MoM) and PAPP-A is decreased (approximately 0.4 MoM). In trisomy 18, both markers are decreased. These serum values are combined with NT measurement and maternal age to generate a risk score. If the risk exceeds a threshold (typically 1 in 270 to 1 in 300), diagnostic testing (chorionic villus sampling at 10 to 13 weeks or amniocentesis at 15 to 20 weeks) is offered.\n\nCELL-FREE DNA:\nCell-free DNA (cfDNA) screening, also called noninvasive prenatal testing (NIPT), analyzes fetal DNA fragments circulating in maternal blood and has the highest sensitivity (greater than 99% for trisomy 21) and lowest false-positive rate (less than 0.1%) of any screening modality. ACOG now states that cfDNA screening may be offered to all pregnant individuals regardless of risk category. However, cfDNA remains a screening test and positive results require confirmatory diagnostic testing (amniocentesis or CVS).\n\nKEY LEARNING POINTS:\nFirst-trimester combined screening (nuchal translucency plus free beta-hCG plus PAPP-A) at 11 to 14 weeks detects 82 to 87% of trisomy 21 cases. Cell-free DNA (NIPT) has greater than 99% sensitivity but is a screening test requiring diagnostic confirmation. All pregnant patients should be offered aneuploidy screening regardless of age."},{"id":680,"categoryId":18,"question":"A 45-year-old woman presents with heavy menstrual bleeding (menorrhagia), pelvic pressure, and urinary frequency. Pelvic ultrasound reveals a 10 cm intramural uterine mass. Endometrial biopsy is benign. What is the most likely diagnosis?","options":["A) Endometrial cancer","B) Uterine leiomyoma (fibroid)","C) Ovarian cyst","D) Cervical polyp"],"correctAnswer":1,"explanation":"CORRECT: B (Uterine leiomyoma).\n\nPATHOPHYSIOLOGY:\nUterine leiomyomas (fibroids) are benign monoclonal neoplasms arising from uterine smooth muscle cells and are the most common pelvic tumors in women, with a cumulative incidence of approximately 70% in White women and over 80% in Black women by age 50. They are estrogen- and progesterone-dependent, growing during reproductive years and typically regressing after menopause. Genetic drivers include MED12 mutations (found in approximately 70% of fibroids) and HMGA2 rearrangements. Risk factors include African American race (3-fold higher prevalence, earlier onset, larger size), early menarche, nulliparity, obesity (peripheral aromatase conversion of androgens to estrogen), and family history.\n\nCLASSIFICATION AND SYMPTOMS:\nFibroids are classified by location using the FIGO system: submucosal (project into the uterine cavity, most likely to cause heavy menstrual bleeding due to increased endometrial surface area and disrupted hemostatic mechanisms), intramural (within the myometrium, the most common type, causing bulk symptoms and menorrhagia when large), and subserosal (project outward from the uterus, primarily causing bulk/pressure symptoms). This patient's 10 cm intramural mass produces both menorrhagia and bulk symptoms (pelvic pressure, urinary frequency from bladder compression). Pedunculated fibroids can undergo torsion, and parasitic fibroids can detach and develop alternative blood supplies.\n\nDIAGNOSIS:\nPelvic ultrasound is the first-line imaging modality, showing a well-circumscribed hypoechoic mass with characteristic shadowing. MRI provides superior characterization (distinguishing fibroids from adenomyosis and leiomyosarcoma) and is used for surgical planning. Saline infusion sonography (SIS) or hysteroscopy best evaluates submucosal fibroids affecting the endometrial cavity. Endometrial biopsy is performed to exclude endometrial pathology in women with abnormal uterine bleeding, particularly those over 45 or with risk factors for endometrial cancer.\n\nMANAGEMENT:\nMedical options include hormonal contraceptives (reduce bleeding), GnRH agonists (leuprolide, temporary shrinkage of 35 to 65% for preoperative use, limited to 6 months due to bone loss), GnRH antagonists with add-back therapy (elagolix plus estradiol/norethindrone, FDA-approved for fibroid-related heavy bleeding), tranexamic acid (antifibrinolytic for heavy bleeding episodes), and the levonorgestrel IUD (reduces bleeding in small to moderate fibroids). Surgical options include myomectomy (fertility-preserving, laparoscopic or hysteroscopic depending on location), uterine artery embolization (minimally invasive, 85 to 90% symptom improvement), and hysterectomy (definitive treatment for women who have completed childbearing).\n\nKEY LEARNING POINTS:\nUterine fibroids are the most common pelvic tumors in women, estrogen/progesterone-dependent, with cumulative incidence exceeding 80% in Black women. Submucosal fibroids cause the most heavy bleeding, while intramural and subserosal fibroids cause bulk symptoms. Management ranges from medical therapy (GnRH antagonists with add-back, tranexamic acid) to myomectomy (fertility-preserving) to hysterectomy (definitive)."},{"id":681,"categoryId":18,"question":"A 19-year-old presents requesting contraception. She has migraines with visual aura. Which contraceptive method is absolutely contraindicated?","options":["A) Copper IUD","B) Combined oral contraceptive pill (estrogen + progestin)","C) Progestin-only pill","D) Etonogestrel implant (Nexplanon)"],"correctAnswer":1,"explanation":"CORRECT: B (Combined oral contraceptive pill).\n\nCONTRAINDICATION:\nCombined hormonal contraceptives (CHCs) containing estrogen (combined oral contraceptive pills, the patch, and the vaginal ring) are classified as Category 4 (absolute contraindication, unacceptable health risk) in women who have migraine with aura by the CDC Medical Eligibility Criteria (MEC) for Contraceptive Use and WHO guidelines. This restriction applies regardless of age and regardless of aura frequency.\n\nSTROKE RISK MECHANISM:\nMigraine with aura independently increases ischemic stroke risk by approximately 2-fold compared to women without migraine. Combined hormonal contraceptives independently increase ischemic stroke risk by approximately 1.5 to 2-fold through estrogen-mediated prothrombotic effects (increased hepatic synthesis of clotting factors II, VII, VIII, X, and fibrinogen, increased von Willebrand factor, and decreased antithrombin III and protein S). The combination of migraine with aura plus CHC use is synergistic rather than additive, increasing ischemic stroke risk by approximately 6 to 8-fold. Although the absolute risk remains relatively low in young women (approximately 8 per 100,000 per year), this is considered an unacceptable risk given the availability of safe alternatives.\n\nAURA VERSUS NO AURA:\nThe distinction between migraine with aura and migraine without aura is clinically critical for contraceptive counseling. Migraine with aura involves transient focal neurologic symptoms (visual scintillations, fortification spectra, hemianopia, unilateral paresthesias, or speech disturbance) lasting 5 to 60 minutes, which are thought to reflect cortical spreading depression and associated cerebrovascular changes that predispose to thrombosis. Migraine without aura carries a lower stroke risk, and CHCs are classified as Category 2 (advantages generally outweigh risks) in women under 35 with migraine without aura but Category 3 (risks generally outweigh advantages) in women 35 and older with migraine without aura.\n\nSAFE ALTERNATIVES:\nAll progestin-only methods are safe (Category 1 or 2) in women with migraine with aura: progestin-only pills (norethindrone, drospirenone), etonogestrel implant (Nexplanon), depot medroxyprogesterone acetate (DMPA), and hormonal IUDs (levonorgestrel). Copper IUDs are also Category 1 (no restriction). The etonogestrel implant and levonorgestrel IUD are the most effective reversible contraceptives (failure rate less than 1% per year, comparable to sterilization).\n\nKEY LEARNING POINTS:\nCombined hormonal contraceptives are absolutely contraindicated (CDC MEC Category 4) in migraine with aura due to a synergistic 6 to 8-fold increase in ischemic stroke risk. The distinction between migraine with and without aura is essential for contraceptive counseling. All progestin-only methods and copper IUDs are safe alternatives, with implants and hormonal IUDs offering the highest efficacy."},{"id":683,"categoryId":18,"question":"A 26-year-old woman presents with mucopurulent cervical discharge. NAAT is positive for Chlamydia trachomatis. She has no drug allergies. What is the recommended treatment?","options":["A) Azithromycin 1g single dose only","B) Doxycycline 100mg BID for 7 days","C) Ciprofloxacin 500mg single dose","D) Metronidazole 500mg BID for 7 days"],"correctAnswer":1,"explanation":"CORRECT: B (Doxycycline 100mg BID for 7 days).\n\nGUIDELINE UPDATE:\nThe 2021 CDC Sexually Transmitted Infections Treatment Guidelines changed the recommended first-line treatment for uncomplicated chlamydial infection from azithromycin 1g single dose to doxycycline 100 mg orally twice daily for 7 days. This change was based on accumulating evidence that doxycycline achieves superior microbiologic cure rates compared to azithromycin, particularly for rectal chlamydial infections (which may be asymptomatic and undiagnosed in women through autoinoculation from the cervix).\n\nEVIDENCE FOR THE CHANGE:\nMultiple studies and a meta-analysis demonstrated that azithromycin has a microbiologic failure rate of approximately 5 to 8% for urogenital chlamydia and 15 to 22% for rectal chlamydia, compared to less than 3% failure rates for doxycycline at both sites. The pharmacokinetic explanation is that doxycycline provides sustained intracellular drug levels over the 7-day course (matching the 48 to 72-hour chlamydial developmental cycle through multiple replication cycles), while azithromycin's single-dose pharmacokinetics may not maintain adequate tissue concentrations through enough replication cycles to eradicate the organism in all patients.\n\nCO-TREATMENT:\nBecause chlamydia and gonorrhea frequently coexist (co-infection rates of 10 to 30%), empiric treatment for gonorrhea (ceftriaxone 500 mg IM single dose for patients weighing less than 150 kg, or 1g for those 150 kg or greater) should be administered if gonorrhea has not been excluded by testing. All sexual partners from the preceding 60 days must be treated (expedited partner therapy is recommended in most states). Test-of-cure is not routinely recommended but is indicated in pregnant women. Repeat testing for reinfection at 3 months is recommended for all patients.\n\nPREGNANCY CONSIDERATION:\nDoxycycline is contraindicated in pregnancy (FDA Category D: risk of fetal tooth discoloration and impaired bone growth). In pregnant women, azithromycin 1g single dose remains the recommended treatment. Amoxicillin 500mg three times daily for 7 days is an alternative. Test-of-cure 4 weeks after treatment is required in pregnancy.\n\nCOMPLICATIONS OF UNTREATED CHLAMYDIA:\nIn women, untreated chlamydial cervicitis can ascend to cause pelvic inflammatory disease (PID) in 10 to 15% of cases, leading to chronic pelvic pain, tubal factor infertility (from tubal scarring and occlusion), and ectopic pregnancy. Chlamydia is the leading infectious cause of preventable infertility worldwide.\n\nKEY LEARNING POINTS:\nDoxycycline 100mg BID for 7 days replaced azithromycin as first-line chlamydia treatment per 2021 CDC guidelines due to superior cure rates (especially for rectal infections where azithromycin fails in 15 to 22%). Azithromycin remains first-line in pregnancy where doxycycline is contraindicated. Untreated chlamydia causes PID in 10 to 15%, making it the leading infectious cause of preventable infertility."},{"id":684,"categoryId":18,"question":"The USPSTF recommends initiating cervical cancer screening with Pap smear at what age?","options":["A) 18 years","B) 21 years","C) 25 years","D) 30 years"],"correctAnswer":1,"explanation":"CORRECT: B (21 years).\n\nUSPSTF RECOMMENDATIONS:\nThe USPSTF recommends initiating cervical cancer screening at age 21 regardless of the age of sexual debut or HPV vaccination status. Screening before age 21 is not recommended even in sexually active adolescents because cervical cancer is exceedingly rare in this age group (less than 1 to 2 cases per million among women under 21), HPV infections in adolescents have a very high spontaneous clearance rate (90% within 1 to 2 years due to robust cell-mediated immunity), and screening leads to unnecessary interventions (colposcopy, biopsies, excisional procedures) that can cause cervical insufficiency and adverse pregnancy outcomes in young women with their full reproductive life ahead.\n\nSCREENING INTERVALS BY AGE:\nFor women aged 21 to 29, the recommended approach is cytology (Pap smear) alone every 3 years. HPV co-testing is not recommended in this age group because transient HPV infections are extremely common (80% of sexually active women will acquire HPV by age 45) and would generate excessive false-positive results without improving cancer detection. For women aged 30 to 65, three equivalent strategies are acceptable: cytology alone every 3 years, high-risk HPV testing alone every 5 years, or cytology plus HPV co-testing every 5 years. Screening may be discontinued after age 65 in women with adequate prior negative screening (three consecutive negative cytology results or two consecutive negative HPV tests within the prior 10 years, with the most recent within 5 years).\n\nHPV AND CERVICAL CARCINOGENESIS:\nVirtually all cervical cancers (greater than 99%) are caused by persistent infection with high-risk HPV types, with HPV 16 and 18 responsible for approximately 70% of cases. The progression from HPV infection to cervical intraepithelial neoplasia (CIN) to invasive cancer typically takes 10 to 20 years, providing a long window for screening detection and intervention. HPV E6 and E7 oncoproteins inactivate tumor suppressors p53 and Rb respectively, driving cell cycle dysregulation and genomic instability.\n\nHPV VACCINATION IMPACT:\nThe 9-valent HPV vaccine (Gardasil 9) covers HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, providing protection against approximately 90% of cervical cancers. Vaccination is recommended at ages 11 to 12 (can start at age 9) with catch-up through age 26. Current screening recommendations apply regardless of vaccination status because the vaccine does not cover all oncogenic HPV types.\n\nKEY LEARNING POINTS:\nCervical cancer screening begins at age 21 regardless of sexual history or HPV vaccination, because adolescent HPV infections clear spontaneously in 90% and cervical cancer is exceedingly rare before age 21. Ages 21 to 29 use cytology alone every 3 years; ages 30 to 65 may use cytology every 3 years, HPV testing every 5 years, or co-testing every 5 years. Screening stops after age 65 with adequate prior negative results."},{"id":685,"categoryId":18,"question":"A 35-year-old woman presents with galactorrhea, oligomenorrhea, and infertility. Laboratory testing reveals prolactin level of 180 ng/mL (normal <25). What is the most appropriate first-line treatment?","options":["A) Transsphenoidal surgery","B) Cabergoline (dopamine agonist)","C) Combined oral contraceptive pill","D) Observation"],"correctAnswer":1,"explanation":"CORRECT: B (Cabergoline).\n\nPATHOPHYSIOLOGY:\nProlactinomas are the most common functioning pituitary adenomas, accounting for approximately 40% of all pituitary tumors. Prolactin is unique among anterior pituitary hormones in that its secretion is tonically inhibited by dopamine from the tuberoinfundibular pathway acting on D2 receptors on lactotroph cells. Prolactinomas arise from clonal expansion of lactotroph cells that secrete prolactin autonomously. Hyperprolactinemia inhibits pulsatile GnRH secretion from the hypothalamus, which in turn suppresses LH and FSH release, causing hypogonadism manifesting as oligomenorrhea or amenorrhea, anovulatory infertility, and galactorrhea in women.\n\nPROLACTIN LEVEL AND TUMOR SIZE:\nA prolactin level of 180 ng/mL strongly suggests a macroprolactinoma (greater than 10 mm), as prolactin levels generally correlate with tumor size: microprolactinomas (less than 10 mm) typically produce levels of 25 to 200 ng/mL, while macroprolactinomas produce levels of 200 to over 10,000 ng/mL. The stalk effect must be distinguished: non-functioning pituitary adenomas that compress the pituitary stalk can mildly elevate prolactin (usually less than 100 to 150 ng/mL) by disrupting dopamine delivery from the hypothalamus. An MRI of the sella turcica is the imaging study of choice.\n\nMEDICAL THERAPY:\nDopamine agonists are the first-line treatment for prolactinomas of all sizes, even macroprolactinomas, which is unique among pituitary tumors (all other types are primarily surgical). Cabergoline is preferred over bromocriptine because it has higher efficacy (normalizes prolactin in approximately 85 to 90% of patients), better tolerability (less nausea, fewer side effects), and more convenient dosing (twice weekly versus daily). Dopamine agonists both suppress prolactin secretion and cause tumor shrinkage (typically 50 to 80% volume reduction within weeks to months) by inducing apoptosis and perivascular fibrosis in lactotroph cells.\n\nMONITORING AND SURGICAL INDICATIONS:\nProlactin levels and MRI should be monitored after initiation of therapy. Surgery (transsphenoidal adenomectomy) is reserved for patients who are intolerant of or resistant to dopamine agonists, have tumor apoplexy, have CSF rhinorrhea, or have visual field compromise that does not improve with medical therapy. Radiation therapy is a third-line option for refractory cases.\n\nKEY LEARNING POINTS:\nProlactinomas are the only pituitary adenomas treated primarily with medical therapy rather than surgery. Cabergoline (dopamine D2 agonist) is first-line, normalizing prolactin in 85 to 90% and shrinking tumors by 50 to 80%. Prolactin levels correlate with tumor size (levels greater than 200 suggest macroprolactinoma). Hyperprolactinemia causes hypogonadism by suppressing GnRH pulsatility."},{"id":688,"categoryId":18,"question":"A 22-year-old woman with a history of irregular periods, hirsutism, and acne has a BMI of 32. Labs show elevated free testosterone, normal DHEA-S, and a 2:1 LH-to-FSH ratio. Pelvic ultrasound shows bilateral ovaries with 14 follicles each. What is the most likely diagnosis?","options":["A) Congenital adrenal hyperplasia","B) Polycystic ovary syndrome (PCOS)","C) Cushing syndrome","D) Hypothyroidism"],"correctAnswer":1,"explanation":"CORRECT: B (Polycystic ovary syndrome).\n\nDIAGNOSTIC CRITERIA:\nPolycystic ovary syndrome (PCOS) is diagnosed using the Rotterdam criteria, which require two of the following three features: oligo-ovulation or anovulation (manifesting as irregular menstrual cycles, oligomenorrhea, or amenorrhea), clinical or biochemical hyperandrogenism (hirsutism, acne, alopecia, or elevated free testosterone), and polycystic ovarian morphology on ultrasound (12 or more follicles measuring 2 to 9 mm per ovary, or ovarian volume greater than 10 mL). This patient meets all three criteria. Importantly, PCOS is a diagnosis of exclusion, and other causes of hyperandrogenism and anovulation must be ruled out: thyroid disease (TSH), hyperprolactinemia (prolactin), non-classic congenital adrenal hyperplasia (17-hydroxyprogesterone), and Cushing syndrome (24-hour urinary cortisol or overnight dexamethasone suppression test).\n\nPATHOPHYSIOLOGY:\nPCOS is a complex endocrine-metabolic disorder affecting 6 to 12% of reproductive-age women. The central pathophysiologic features are hyperandrogenism and insulin resistance, which create a self-reinforcing cycle. Insulin resistance (present in 50 to 70% of PCOS patients, independent of BMI though worsened by obesity) leads to compensatory hyperinsulinemia, which stimulates ovarian theca cell androgen production and suppresses hepatic sex hormone-binding globulin (SHBG), further increasing free testosterone levels. Excess androgens disrupt normal follicular development, causing follicular arrest (the polycystic appearance of multiple small antral follicles that fail to undergo selection and ovulation), leading to anovulation. The elevated LH-to-FSH ratio (often 2:1 or greater) reflects increased GnRH pulse frequency that preferentially stimulates LH secretion.\n\nMETABOLIC CONSEQUENCES:\nPCOS is a major metabolic risk factor: 30 to 40% of PCOS patients have impaired glucose tolerance, 10% develop type 2 diabetes by age 40, and there is increased risk of metabolic syndrome, dyslipidemia (elevated triglycerides, low HDL), nonalcoholic fatty liver disease, obstructive sleep apnea, and cardiovascular disease. Screening with an oral glucose tolerance test (2-hour OGTT, preferred over fasting glucose which misses 30 to 40% of glucose intolerance in PCOS) is recommended at diagnosis and every 1 to 3 years.\n\nMANAGEMENT:\nLifestyle modification (5 to 10% weight loss improves ovulatory function in 30 to 50% of overweight PCOS patients) is first-line. Combined oral contraceptives are first-line for menstrual regulation and hyperandrogenism management (estrogen increases hepatic SHBG, reducing free testosterone). Spironolactone (androgen receptor antagonist) addresses hirsutism and acne. Metformin improves insulin sensitivity and may restore ovulation. For infertility, letrozole (aromatase inhibitor) has replaced clomiphene citrate as first-line ovulation induction based on the PPCOS II trial showing higher live birth rates.\n\nKEY LEARNING POINTS:\nPCOS is diagnosed via Rotterdam criteria (two of three: anovulation, hyperandrogenism, polycystic ovarian morphology) after excluding other causes. The LH-to-FSH ratio of 2:1 or greater and insulin resistance driving ovarian androgen excess are central pathophysiologic features. Screen with 2-hour OGTT at diagnosis. Letrozole has replaced clomiphene as first-line for PCOS-related infertility."},{"id":689,"categoryId":18,"question":"A 38-year-old G3P2 at 32 weeks gestation presents with painless bright red vaginal bleeding. She has had two prior cesarean deliveries. Vitals are stable. What is the most likely diagnosis and what exam must be avoided?","options":["A) Placental abruption; avoid amniotomy","B) Placenta previa; avoid digital cervical exam","C) Vasa previa; avoid external cephalic version","D) Cervical polyp; avoid speculum exam"],"correctAnswer":1,"explanation":"CORRECT: B (Placenta previa; avoid digital cervical exam).\n\nDIAGNOSIS:\nPainless bright red vaginal bleeding in the third trimester is the hallmark presentation of placenta previa, a condition where the placenta partially or completely covers the internal cervical os. The bleeding is painless because it results from disruption of placental blood vessels overlying the cervix as the lower uterine segment thins and effaces in the third trimester, without uterine contractions or abruption. This differs from placental abruption, which presents with painful, dark bleeding (retroplacental hemorrhage) and a rigid, tender uterus.\n\nRISK FACTORS:\nThis patient has two major risk factors for placenta previa: prior cesarean deliveries and multiparity. Each prior cesarean increases the risk of placenta previa due to uterine scarring that alters normal placental implantation. With two prior cesareans, there is also significant concern for placenta accreta spectrum (PAS) disorder, where the placenta abnormally invades the myometrium through the previous uterine scar. The risk of PAS with placenta previa increases with each cesarean: approximately 3% with one prior cesarean, 11% with two, 40% with three, and 60% or greater with four or more. Other risk factors include advanced maternal age, prior uterine surgery, smoking, IVF, and prior placenta previa.\n\nCRITICAL RESTRICTION:\nDigital cervical examination must never be performed in suspected placenta previa because the examining finger can disrupt the placenta overlying the cervical os, precipitating catastrophic hemorrhage. Transvaginal ultrasound (not transabdominal, which is less accurate) is the safe and definitive diagnostic modality, with greater than 95% accuracy for identifying placental location relative to the internal os. Despite common misconception, transvaginal ultrasound is safe in placenta previa because the probe does not enter the cervical canal.\n\nMANAGEMENT:\nAsymptomatic placenta previa discovered on routine ultrasound is managed expectantly with repeat imaging at 32 to 36 weeks to assess for resolution (placental migration occurs as the lower uterine segment grows). Planned cesarean delivery is scheduled at 36 to 37 weeks for uncomplicated placenta previa. For symptomatic bleeding, management depends on gestational age, hemodynamic stability, and severity: stable patients may be managed expectantly with hospital admission, continuous fetal monitoring, and blood product availability, while hemodynamically unstable patients require emergent cesarean regardless of gestational age.\n\nKEY LEARNING POINTS:\nPainless bright red third-trimester bleeding is the hallmark of placenta previa; digital cervical exam is absolutely contraindicated because it can cause catastrophic hemorrhage. Transvaginal ultrasound is safe and is the diagnostic standard. Prior cesarean deliveries are the strongest risk factor and raise concern for placenta accreta spectrum, with risk increasing dramatically with each additional cesarean."}];
const QUESTION_MAP = Object.fromEntries(QUESTIONS.map(q => [q.id, q]));
const AudioContext = window.AudioContext || window.webkitAudioContext;
let audioCtx = null;
const getAudioContext = () => {
  if (!audioCtx) {
    audioCtx = new AudioContext();
  }
  return audioCtx;
};
const playSound = async (type) => {
  try {
    const ctx = getAudioContext();
    if (ctx && ctx.state === "suspended") {
      try {
        await ctx.resume();
      } catch (e) {
      }
    }
    const oscillator = ctx.createOscillator();
    const gainNode = ctx.createGain();
    oscillator.connect(gainNode);
    gainNode.connect(ctx.destination);
    oscillator.onended = () => { gainNode.disconnect(); oscillator.disconnect(); };
    switch (type) {
      case "correct":
        oscillator.frequency.setValueAtTime(523.25, ctx.currentTime);
        oscillator.frequency.setValueAtTime(659.25, ctx.currentTime + 0.1);
        oscillator.frequency.setValueAtTime(783.99, ctx.currentTime + 0.2);
        gainNode.gain.setValueAtTime(0.3, ctx.currentTime);
        gainNode.gain.exponentialRampToValueAtTime(0.01, ctx.currentTime + 0.4);
        oscillator.start(ctx.currentTime);
        oscillator.stop(ctx.currentTime + 0.4);
        break;
      case "incorrect":
        oscillator.frequency.setValueAtTime(200, ctx.currentTime);
        oscillator.frequency.setValueAtTime(150, ctx.currentTime + 0.15);
        gainNode.gain.setValueAtTime(0.3, ctx.currentTime);
        gainNode.gain.exponentialRampToValueAtTime(0.01, ctx.currentTime + 0.3);
        oscillator.start(ctx.currentTime);
        oscillator.stop(ctx.currentTime + 0.3);
        break;
      case "countdown":
        oscillator.frequency.setValueAtTime(440, ctx.currentTime);
        gainNode.gain.setValueAtTime(0.2, ctx.currentTime);
        gainNode.gain.exponentialRampToValueAtTime(0.01, ctx.currentTime + 0.15);
        oscillator.start(ctx.currentTime);
        oscillator.stop(ctx.currentTime + 0.15);
        break;
      case "start":
        oscillator.frequency.setValueAtTime(523.25, ctx.currentTime);
        oscillator.frequency.setValueAtTime(783.99, ctx.currentTime + 0.1);
        oscillator.frequency.setValueAtTime(1046.5, ctx.currentTime + 0.2);
        gainNode.gain.setValueAtTime(0.3, ctx.currentTime);
        gainNode.gain.exponentialRampToValueAtTime(0.01, ctx.currentTime + 0.5);
        oscillator.start(ctx.currentTime);
        oscillator.stop(ctx.currentTime + 0.5);
        break;
      case "warning":
        oscillator.type = "square";
        oscillator.frequency.setValueAtTime(880, ctx.currentTime);
        oscillator.frequency.setValueAtTime(440, ctx.currentTime + 0.1);
        oscillator.frequency.setValueAtTime(880, ctx.currentTime + 0.2);
        gainNode.gain.setValueAtTime(0.15, ctx.currentTime);
        gainNode.gain.exponentialRampToValueAtTime(0.01, ctx.currentTime + 0.3);
        oscillator.start(ctx.currentTime);
        oscillator.stop(ctx.currentTime + 0.3);
        break;
      case "timeup":
        // Uplifting ascending major arpeggio (C-E-G-C)
        oscillator.type = "triangle";
        oscillator.frequency.setValueAtTime(523.25, ctx.currentTime);       // C5
        oscillator.frequency.setValueAtTime(659.25, ctx.currentTime + 0.15); // E5
        oscillator.frequency.setValueAtTime(783.99, ctx.currentTime + 0.30); // G5
        oscillator.frequency.setValueAtTime(1046.50, ctx.currentTime + 0.45);// C6
        gainNode.gain.setValueAtTime(0.25, ctx.currentTime);
        gainNode.gain.setValueAtTime(0.28, ctx.currentTime + 0.45);
        gainNode.gain.exponentialRampToValueAtTime(0.01, ctx.currentTime + 0.9);
        oscillator.start(ctx.currentTime);
        oscillator.stop(ctx.currentTime + 0.9);
        // Add a bright shimmer on top
        const shimmer = ctx.createOscillator();
        const shimmerGain = ctx.createGain();
        shimmer.type = "sine";
        shimmer.frequency.setValueAtTime(1046.50, ctx.currentTime + 0.45);
        shimmer.frequency.setValueAtTime(1318.51, ctx.currentTime + 0.6);
        shimmerGain.gain.setValueAtTime(0, ctx.currentTime);
        shimmerGain.gain.setValueAtTime(0.15, ctx.currentTime + 0.45);
        shimmerGain.gain.exponentialRampToValueAtTime(0.01, ctx.currentTime + 1.0);
        shimmer.connect(shimmerGain).connect(ctx.destination);
        shimmer.start(ctx.currentTime + 0.45);
        shimmer.stop(ctx.currentTime + 1.0);
        break;
      case "click":
        oscillator.frequency.setValueAtTime(600, ctx.currentTime);
        gainNode.gain.setValueAtTime(0.1, ctx.currentTime);
        gainNode.gain.exponentialRampToValueAtTime(0.01, ctx.currentTime + 0.05);
        oscillator.start(ctx.currentTime);
        oscillator.stop(ctx.currentTime + 0.05);
        break;
      case "heartbeat": {
        const t = ctx.currentTime;
        oscillator.type = "sine";
        oscillator.frequency.setValueAtTime(80, t);
        gainNode.gain.setValueAtTime(1e-4, t);
        gainNode.gain.exponentialRampToValueAtTime(0.45, t + 8e-3);
        gainNode.gain.exponentialRampToValueAtTime(1e-4, t + 0.14);
        oscillator.start(t);
        oscillator.stop(t + 0.16);
        const click1 = ctx.createOscillator();
        const clickGain1 = ctx.createGain();
        click1.connect(clickGain1);
        clickGain1.connect(ctx.destination);
        click1.onended = () => { clickGain1.disconnect(); click1.disconnect(); };
        click1.type = "triangle";
        click1.frequency.setValueAtTime(150, t);
        clickGain1.gain.setValueAtTime(1e-4, t);
        clickGain1.gain.exponentialRampToValueAtTime(0.12, t + 5e-3);
        clickGain1.gain.exponentialRampToValueAtTime(1e-4, t + 0.06);
        click1.start(t);
        click1.stop(t + 0.08);
        const osc2 = ctx.createOscillator();
        const gain2 = ctx.createGain();
        osc2.connect(gain2);
        gain2.connect(ctx.destination);
        osc2.onended = () => { gain2.disconnect(); osc2.disconnect(); };
        osc2.type = "sine";
        osc2.frequency.setValueAtTime(90, t + 0.19);
        gain2.gain.setValueAtTime(1e-4, t + 0.19);
        gain2.gain.exponentialRampToValueAtTime(0.32, t + 0.198);
        gain2.gain.exponentialRampToValueAtTime(1e-4, t + 0.32);
        osc2.start(t + 0.19);
        osc2.stop(t + 0.34);
        const click2 = ctx.createOscillator();
        const clickGain2 = ctx.createGain();
        click2.connect(clickGain2);
        clickGain2.connect(ctx.destination);
        click2.onended = () => { clickGain2.disconnect(); click2.disconnect(); };
        click2.type = "triangle";
        click2.frequency.setValueAtTime(150, t + 0.19);
        clickGain2.gain.setValueAtTime(1e-4, t + 0.19);
        clickGain2.gain.exponentialRampToValueAtTime(0.08, t + 0.195);
        clickGain2.gain.exponentialRampToValueAtTime(1e-4, t + 0.25);
        click2.start(t + 0.19);
        click2.stop(t + 0.27);
        break;
      }
      case "streak":
        oscillator.type = "sine";
        oscillator.frequency.setValueAtTime(880, ctx.currentTime);
        oscillator.frequency.setValueAtTime(1108.73, ctx.currentTime + 0.05);
        oscillator.frequency.setValueAtTime(1318.51, ctx.currentTime + 0.1);
        gainNode.gain.setValueAtTime(0.2, ctx.currentTime);
        gainNode.gain.exponentialRampToValueAtTime(0.01, ctx.currentTime + 0.3);
        oscillator.start(ctx.currentTime);
        oscillator.stop(ctx.currentTime + 0.3);
        break;
      case "onfire": {
        const t = ctx.currentTime;
        // Layer 1: Power chord root (C5-G5-C6 rapid arpeggio)
        oscillator.type = "sawtooth";
        oscillator.frequency.setValueAtTime(523.25, t);
        oscillator.frequency.setValueAtTime(783.99, t + 0.06);
        oscillator.frequency.setValueAtTime(1046.50, t + 0.12);
        oscillator.frequency.setValueAtTime(1318.51, t + 0.18);
        gainNode.gain.setValueAtTime(0.18, t);
        gainNode.gain.setValueAtTime(0.22, t + 0.12);
        gainNode.gain.exponentialRampToValueAtTime(0.01, t + 0.55);
        oscillator.start(t);
        oscillator.stop(t + 0.55);
        // Layer 2: Bright octave shimmer
        const fire2 = ctx.createOscillator();
        const fireGain2 = ctx.createGain();
        fire2.connect(fireGain2).connect(ctx.destination);
        fire2.onended = () => { fireGain2.disconnect(); fire2.disconnect(); };
        fire2.type = "sine";
        fire2.frequency.setValueAtTime(1046.50, t + 0.05);
        fire2.frequency.setValueAtTime(1567.98, t + 0.15);
        fire2.frequency.setValueAtTime(2093.00, t + 0.25);
        fireGain2.gain.setValueAtTime(0.0001, t);
        fireGain2.gain.exponentialRampToValueAtTime(0.15, t + 0.1);
        fireGain2.gain.exponentialRampToValueAtTime(0.01, t + 0.6);
        fire2.start(t + 0.05);
        fire2.stop(t + 0.6);
        // Layer 3: Sub-bass punch for impact
        const fire3 = ctx.createOscillator();
        const fireGain3 = ctx.createGain();
        fire3.connect(fireGain3).connect(ctx.destination);
        fire3.onended = () => { fireGain3.disconnect(); fire3.disconnect(); };
        fire3.type = "sine";
        fire3.frequency.setValueAtTime(130.81, t);
        fire3.frequency.exponentialRampToValueAtTime(65.41, t + 0.15);
        fireGain3.gain.setValueAtTime(0.3, t);
        fireGain3.gain.exponentialRampToValueAtTime(0.01, t + 0.2);
        fire3.start(t);
        fire3.stop(t + 0.2);
        break;
      }
      default:
        break;
    }
  } catch (e) {
    console.log("Audio not available");
  }
};
function PCPLearningApp() {
  const FIREBASE_CHAT_DB_URL = "https://primary-care-learning-program-default-rtdb.firebaseio.com";
  const CHAT_MESSAGES_KEY = "pcp-chat-local";
  const CHAT_NAME_KEY = "pcp-chat-name";
  const CHAT_OWNER_SESSION_KEY = "pcp-chat-owner-session";
  const CHAT_OWNER_DELETE_CODE = "Puyt8_88";
  const CHAT_ICON = "assets/chat-icon.png";
  const DEFAULT_PROGRESS = {
    answeredQuestions: {},
    incorrectQuestions: [],
    categoryProgress: {},
    totalCorrect: 0,
    totalAttempted: 0,
    gameHighScore: 0,
    bookmarkedQuestions: [],
    spacedReview: {}
  };
  const REVIEW_INTERVALS_MS = [24 * 60 * 60 * 1e3, 3 * 24 * 60 * 60 * 1e3, 7 * 24 * 60 * 60 * 1e3];
  const [isMobile, setIsMobile] = useState(window.innerWidth < 768);
  const [mobileMode, setMobileMode] = useState(false);
  const [currentView, setCurrentView] = useState("home");
  const [selectedCategory, setSelectedCategory] = useState(null);
  const [quizQuestions, setQuizQuestions] = useState([]);
  const [currentQuestionIndex, setCurrentQuestionIndex] = useState(0);
  const [selectedAnswer, setSelectedAnswer] = useState(null);
  const [showExplanation, setShowExplanation] = useState(false);
  const [quizResults, setQuizResults] = useState([]);
  const [gameMode, setGameMode] = useState(false);
  const [gameCountdown, setGameCountdown] = useState(null);
  const [gameTimeLeft, setGameTimeLeft] = useState(180);
  const [gameScore, setGameScore] = useState(0);
  const [gameAnswers, setGameAnswers] = useState([]);
  const [streak, setStreak] = useState(0);
  const [maxStreak, setMaxStreak] = useState(0);
  const [showGameIntro, setShowGameIntro] = useState(false);
  const [gameEnded, setGameEnded] = useState(false);
  const [warningShown, setWarningShown] = useState({ oneMin: false, tenSec: false });
  const [progress, setProgress] = useState(DEFAULT_PROGRESS);
  const [searchQuery, setSearchQuery] = useState("");
  const [searchResults, setSearchResults] = useState([]);
  const [soundEnabled, setSoundEnabled] = useState(true);
  const [chatMessages, setChatMessages] = useState([]);
  const [chatInput, setChatInput] = useState("");
  const [chatName, setChatName] = useState("");
  const [chatSyncMode, setChatSyncMode] = useState("local");
  const [chatOwnerMode, setChatOwnerMode] = useState(false);
  const gameTimerRef = useRef(null);
  const gameScoreRef = useRef(0);
  const progressRef = useRef(null);
  const highScoreAtGameStartRef = useRef(0);
  const saveTimeoutRef = useRef(null);
  const searchTimeoutRef = useRef(null);
  const chatPollRef = useRef(null);
  const chatOwnerTapCountRef = useRef(0);
  const chatOwnerTapResetRef = useRef(null);

  useEffect(() => {
    return () => {
      if (saveTimeoutRef.current) clearTimeout(saveTimeoutRef.current);
      if (searchTimeoutRef.current) clearTimeout(searchTimeoutRef.current);
      if (chatPollRef.current) clearInterval(chatPollRef.current);
      if (chatOwnerTapResetRef.current) clearTimeout(chatOwnerTapResetRef.current);
    };
  }, []);

useEffect(() => {
    gameScoreRef.current = gameScore;
  }, [gameScore]);
  useEffect(() => {
    progressRef.current = progress;
  }, [progress]);
  useEffect(() => {
    const handleResize = () => {
      setIsMobile(window.innerWidth < 768);
    };
    window.addEventListener("resize", handleResize);
    return () => window.removeEventListener("resize", handleResize);
  }, []);
  useEffect(() => {
    const loadProgress = async () => {
      try {
        const saved = await window.storage.get("pcp-progress");
        if (saved && saved.value) {
          const parsed = JSON.parse(saved.value);
          setProgress({
            ...DEFAULT_PROGRESS,
            ...parsed,
            answeredQuestions: parsed?.answeredQuestions || {},
            incorrectQuestions: Array.isArray(parsed?.incorrectQuestions) ? parsed.incorrectQuestions : [],
            categoryProgress: parsed?.categoryProgress || {},
            bookmarkedQuestions: Array.isArray(parsed?.bookmarkedQuestions) ? parsed.bookmarkedQuestions : [],
            spacedReview: parsed?.spacedReview || {}
          });
        }
      } catch (e) {
        console.log("No saved progress found");
      }
    };
    loadProgress();
  }, []);
  const saveProgress = (newProgress) => {
    try {
      if (saveTimeoutRef.current) clearTimeout(saveTimeoutRef.current);
      saveTimeoutRef.current = setTimeout(() => {
        window.storage.set("pcp-progress", JSON.stringify(newProgress)).catch(() => {
          console.log("Could not save progress");
        });
      }, 250);
    } catch (e) {
      console.log("Could not save progress");
    }
  };
  const resetCategoryProgress = (categoryId) => {
    const categoryName = getCategoryById(categoryId)?.name || "this category";
    if (!window.confirm("Reset all progress for " + categoryName + "?\n\nThis will clear all answered questions, scores, bookmarks, and spaced review schedules for this category. This cannot be undone.")) return;
    setProgress((prev) => {
      const catQuestionIds = new Set(QUESTIONS.filter((q) => q.categoryId === categoryId).map((q) => q.id));
      const newAnswered = {};
      let removedCorrect = 0;
      let removedTotal = 0;
      Object.entries(prev.answeredQuestions || {}).forEach(([qId, isCorrect]) => {
        if (catQuestionIds.has(parseInt(qId))) {
          removedTotal++;
          if (isCorrect) removedCorrect++;
        } else {
          newAnswered[qId] = isCorrect;
        }
      });
      const newIncorrect = (prev.incorrectQuestions || []).filter((id) => !catQuestionIds.has(id));
      const newSpacedReview = {};
      Object.entries(prev.spacedReview || {}).forEach(([qId, val]) => {
        if (!catQuestionIds.has(parseInt(qId))) newSpacedReview[qId] = val;
      });
      const newBookmarks = (prev.bookmarkedQuestions || []).filter((id) => !catQuestionIds.has(id));
      const newCategoryProgress = { ...prev.categoryProgress || {} };
      delete newCategoryProgress[categoryId];
      const updated = {
        ...prev,
        answeredQuestions: newAnswered,
        incorrectQuestions: newIncorrect,
        spacedReview: newSpacedReview,
        bookmarkedQuestions: newBookmarks,
        categoryProgress: newCategoryProgress,
        totalAttempted: Math.max(0, (prev.totalAttempted || 0) - removedTotal),
        totalCorrect: Math.max(0, (prev.totalCorrect || 0) - removedCorrect)
      };
      saveProgress(updated);
      return updated;
    });
  };
  const resetAllProgress = () => {
    if (!window.confirm("Reset ALL progress for the entire learning program?\n\nThis will clear every answered question, score, bookmark, spaced review schedule, and game high score across all categories. This cannot be undone.")) return;
    const fresh = { ...DEFAULT_PROGRESS };
    setProgress(fresh);
    saveProgress(fresh);
  };
  const play = (type) => {
    if (soundEnabled) playSound(type);
  };
  const getChatName = async () => {
    try {
      const stored = await window.storage.get(CHAT_NAME_KEY);
      return stored && stored.value ? String(stored.value) : "";
    } catch (e) {
      return "";
    }
  };
  const saveChatName = async (name) => {
    try {
      await window.storage.set(CHAT_NAME_KEY, String(name || "").trim());
    } catch (e) {
    }
  };
  const getOwnerSessionEnabled = async () => {
    try {
      const stored = await window.storage.get(CHAT_OWNER_SESSION_KEY);
      return !!(stored && String(stored.value || "") === "1");
    } catch (e) {
      return false;
    }
  };
  const setOwnerSessionEnabled = async (enabled) => {
    try {
      if (enabled) {
        await window.storage.set(CHAT_OWNER_SESSION_KEY, "1");
      } else {
        await window.storage.remove(CHAT_OWNER_SESSION_KEY);
      }
    } catch (e) {
    }
  };
  const unlockOwnerMode = async (enteredCode) => {
    const configuredCode = String(CHAT_OWNER_DELETE_CODE || "").trim();
    if (!configuredCode) {
      return false;
    }
    if (String(enteredCode || "").trim() !== configuredCode) {
      alert("Access denied.");
      return false;
    }
    setChatOwnerMode(true);
    await setOwnerSessionEnabled(true);
    return true;
  };
  const lockOwnerMode = async () => {
    setChatOwnerMode(false);
    await setOwnerSessionEnabled(false);
  };
  const promptOwnerModeAccess = async () => {
    const configuredCode = String(CHAT_OWNER_DELETE_CODE || "").trim();
    if (!configuredCode) return;
    if (chatOwnerMode) {
      await lockOwnerMode();
      return;
    }
    const entered = window.prompt("Enter access code");
    if (entered === null) return;
    await unlockOwnerMode(entered);
  };
  const handleChatTitleSecretTap = () => {
    chatOwnerTapCountRef.current += 1;
    if (chatOwnerTapResetRef.current) clearTimeout(chatOwnerTapResetRef.current);
    chatOwnerTapResetRef.current = setTimeout(() => {
      chatOwnerTapCountRef.current = 0;
      chatOwnerTapResetRef.current = null;
    }, 2600);
    if (chatOwnerTapCountRef.current >= 5) {
      chatOwnerTapCountRef.current = 0;
      if (chatOwnerTapResetRef.current) {
        clearTimeout(chatOwnerTapResetRef.current);
        chatOwnerTapResetRef.current = null;
      }
      promptOwnerModeAccess();
    }
  };
  const getMessageIdentity = (message) => {
    if (!message || typeof message !== "object") return "";
    return message.id || message.remoteId || `${message.ts || ""}-${message.name || ""}-${message.text || ""}`;
  };
  const getLocalChatMessages = async () => {
    try {
      const stored = await window.storage.get(CHAT_MESSAGES_KEY);
      if (!stored || !stored.value) return [];
      const parsed = JSON.parse(stored.value);
      return Array.isArray(parsed) ? parsed : [];
    } catch (e) {
      return [];
    }
  };
  const setLocalChatMessages = async (messages) => {
    try {
      await window.storage.set(CHAT_MESSAGES_KEY, JSON.stringify(messages.slice(-300)));
    } catch (e) {
    }
  };
  const fetchRemoteMessages = async () => {
    const base = String(FIREBASE_CHAT_DB_URL || "").trim().replace(/\/+$/, "");
    if (!base) return null;
    const url = `${base}/pcp-chat/messages.json?orderBy=%22$key%22&limitToLast=300`;
    const res = await fetch(url, { cache: "no-store" });
    if (!res.ok) throw new Error("chat fetch failed");
    const payload = await res.json();
    if (!payload || typeof payload !== "object") return [];
    return Object.entries(payload).map(([remoteId, value]) => {
      if (!value || typeof value !== "object") return null;
      return {
        ...value,
        remoteId
      };
    }).filter(Boolean).sort((a, b) => (a.ts || 0) - (b.ts || 0));
  };
  const loadChatMessages = async () => {
    try {
      const remote = await fetchRemoteMessages();
      if (remote !== null) {
        setChatSyncMode("shared");
        setChatMessages(remote.slice(-300));
        return;
      }
    } catch (e) {
      setChatSyncMode("local");
    }
    const local = await getLocalChatMessages();
    setChatMessages(local.slice(-300));
  };
  const postChatMessage = async (message) => {
    const base = String(FIREBASE_CHAT_DB_URL || "").trim().replace(/\/+$/, "");
    if (!base) return false;
    const url = `${base}/pcp-chat/messages.json`;
    const res = await fetch(url, {
      method: "POST",
      headers: { "Content-Type": "application/json" },
      body: JSON.stringify(message)
    });
    return !!res.ok;
  };
  const deleteRemoteChatMessage = async (remoteId) => {
    const base = String(FIREBASE_CHAT_DB_URL || "").trim().replace(/\/+$/, "");
    if (!base || !remoteId) return false;
    const url = `${base}/pcp-chat/messages/${encodeURIComponent(remoteId)}.json`;
    const res = await fetch(url, { method: "DELETE" });
    return !!res.ok;
  };
  const deleteChatMessage = async (message) => {
    if (!chatOwnerMode || !message) return;
    const confirmed = window.confirm("Delete this chat message?");
    if (!confirmed) return;
    play("click");
    if (chatSyncMode === "shared") {
      if (!message.remoteId) {
        alert("This cloud message cannot be deleted because no remote ID was found.");
        return;
      }
      const removedRemote = await deleteRemoteChatMessage(message.remoteId);
      if (!removedRemote) {
        alert("Could not delete from shared cloud chat right now.");
        return;
      }
      await loadChatMessages();
      return;
    }
    const local = await getLocalChatMessages();
    const targetId = getMessageIdentity(message);
    const updated = local.filter((entry) => getMessageIdentity(entry) !== targetId).slice(-300);
    setChatMessages(updated);
    await setLocalChatMessages(updated);
  };
  const sendChatMessage = async () => {
    const text = chatInput.trim();
    if (!text) return;
    const name = chatName.trim() || "Clinician";
    const message = {
      id: `${Date.now()}-${Math.random().toString(36).slice(2, 8)}`,
      name,
      text,
      ts: Date.now()
    };
    setChatInput("");
    play("click");
    const sentRemote = await postChatMessage(message);
    if (sentRemote) {
      setChatSyncMode("shared");
      await loadChatMessages();
      return;
    }
    setChatSyncMode("local");
    const local = await getLocalChatMessages();
    const updated = [...local, message].slice(-300);
    setChatMessages(updated);
    await setLocalChatMessages(updated);
  };
  const copyChatSnapshot = async () => {
    const recent = chatMessages.slice(-20);
    const lines = recent.map((m) => {
      const stamp = new Date(m.ts || Date.now()).toLocaleString();
      return `${stamp} - ${m.name || "Clinician"}: ${m.text || ""}`;
    });
    const text = `Primary Care Provider Learning Program - Clinician Chat Snapshot\n${chatSyncMode === "shared" ? "Mode: Shared cloud chat" : "Mode: Local device chat"}\n\n${lines.join("\n") || "No messages yet."}`;
    try {
      await navigator.clipboard.writeText(text);
      alert("Chat snapshot copied to clipboard.");
    } catch (e) {
      alert("Could not copy snapshot on this device.");
    }
  };
  useEffect(() => {
    const configuredCode = String(CHAT_OWNER_DELETE_CODE || "").trim();
    if (!configuredCode) {
      setChatOwnerMode(false);
      return;
    }
    getOwnerSessionEnabled().then((enabled) => {
      if (enabled) setChatOwnerMode(true);
    });
  }, []);
  useEffect(() => {
    getChatName().then((name) => {
      if (name) setChatName(name);
    });
  }, []);
  useEffect(() => {
    saveChatName(chatName);
  }, [chatName]);
  useEffect(() => {
    if (currentView !== "chat") return;
    let cancelled = false;
    const tick = async () => {
      if (cancelled) return;
      await loadChatMessages();
    };
    tick();
    chatPollRef.current = setInterval(tick, 4e3);
    return () => {
      cancelled = true;
      if (chatPollRef.current) {
        clearInterval(chatPollRef.current);
        chatPollRef.current = null;
      }
    };
  }, [currentView]);
  const recordAnswer = (questionId, categoryId, isCorrect) => {
    setProgress((prev) => {
      const updated = { ...prev };
      const now = Date.now();
      updated.answeredQuestions = { ...prev.answeredQuestions || {}, [questionId]: isCorrect };
      updated.totalAttempted = (prev.totalAttempted || 0) + 1;
      updated.totalCorrect = (prev.totalCorrect || 0) + (isCorrect ? 1 : 0);
      let incorrect = Array.isArray(prev.incorrectQuestions) ? [...prev.incorrectQuestions] : [];
      if (isCorrect) {
        incorrect = incorrect.filter((id) => id !== questionId);
      } else if (!incorrect.includes(questionId)) {
        incorrect.push(questionId);
      }
      updated.incorrectQuestions = incorrect;
      const previousSchedule = prev.spacedReview && prev.spacedReview[questionId] ? prev.spacedReview[questionId] : null;
      const nextSpacedReview = { ...prev.spacedReview || {} };
      if (!isCorrect) {
        nextSpacedReview[questionId] = {
          step: 0,
          lastResult: false,
          lastReviewedAt: now,
          nextReviewAt: now + REVIEW_INTERVALS_MS[0]
        };
      } else if (previousSchedule) {
        const nextStep = Math.min((previousSchedule.step || 0) + 1, REVIEW_INTERVALS_MS.length - 1);
        if ((previousSchedule.step || 0) >= REVIEW_INTERVALS_MS.length - 1) {
          delete nextSpacedReview[questionId];
        } else {
          nextSpacedReview[questionId] = {
            step: nextStep,
            lastResult: true,
            lastReviewedAt: now,
            nextReviewAt: now + REVIEW_INTERVALS_MS[nextStep]
          };
        }
      }
      updated.spacedReview = nextSpacedReview;
      const prevCat = prev.categoryProgress && prev.categoryProgress[categoryId] ? prev.categoryProgress[categoryId] : { correct: 0, total: 0 };
      updated.categoryProgress = { ...prev.categoryProgress || {} };
      updated.categoryProgress[categoryId] = {
        total: (prevCat.total || 0) + 1,
        correct: (prevCat.correct || 0) + (isCorrect ? 1 : 0)
      };
      saveProgress(updated);
      return updated;
    });
  };
  const effectiveMobile = isMobile || mobileMode;
  const shuffleArray = (array) => {
    const shuffled = [...array];
    for (let i = shuffled.length - 1; i > 0; i--) {
      const j = Math.floor(Math.random() * (i + 1));
      [shuffled[i], shuffled[j]] = [shuffled[j], shuffled[i]];
    }
    return shuffled;
  };
  const resetQuizState = (questions, view, startIndex = 0) => {
    setQuizQuestions(questions);
    setCurrentQuestionIndex(startIndex);
    setSelectedAnswer(null);
    setShowExplanation(false);
    setQuizResults([]);
    shuffledOptionsRef.current = {};
    setCurrentView(view);
  };
  const shuffledOptionsRef = useRef({});
  const getShuffledOptions = useCallback((question) => {
    if (!question) return { options: question?.options || [], correctIndex: 0, indexMap: [] };
    const cacheKey = question.id + "-" + currentQuestionIndex;
    if (shuffledOptionsRef.current[cacheKey]) return shuffledOptionsRef.current[cacheKey];
    const indices = question.options.map((_, i) => i);
    for (let i = indices.length - 1; i > 0; i--) {
      const j = Math.floor(Math.random() * (i + 1));
      [indices[i], indices[j]] = [indices[j], indices[i]];
    }
    const result = {
      options: indices.map((i) => question.options[i]),
      correctIndex: indices.indexOf(question.correctAnswer),
      indexMap: indices
      // indexMap[displayPos] = originalPos
    };
    const keys = Object.keys(shuffledOptionsRef.current);
    if (keys.length > 5) {
      delete shuffledOptionsRef.current[keys[0]];
    }
    shuffledOptionsRef.current[cacheKey] = result;
    return result;
  }, [currentQuestionIndex]);
  const fixExplanationLetter = (text, correctLetter) => {
    if (!text || !correctLetter) return text;
    return text.replace(/^CORRECT:\s*[A-D]\b/, `CORRECT: ${correctLetter}`);
  };
  const normalizeImageEntries = (images, fallbackAlt) => {
    if (!images) return [];
    const raw = Array.isArray(images) ? images : [images];
    return raw.map((item, idx) => {
      if (typeof item === "string") {
        const src = item.trim();
        if (!src) return null;
        return { src, alt: `${fallbackAlt} ${idx + 1}`, caption: "" };
      }
      if (!item || typeof item !== "object") return null;
      const src = String(item.src || "").trim();
      if (!src) return null;
      return {
        src,
        alt: String(item.alt || `${fallbackAlt} ${idx + 1}`),
        caption: item.caption ? String(item.caption) : ""
      };
    }).filter(Boolean);
  };
  const startQuiz = (count) => {
    play("click");
    resetQuizState(shuffleArray(QUESTIONS).slice(0, count), "quiz");
  };
  const startCategoryReview = (categoryId) => {
    play("click");
    setSelectedCategory(categoryId);
    setCurrentView("category-questions");
  };
  const startCategoryQuiz = (categoryId, startIndex = 0) => {
    play("click");
    const categoryQuestions = QUESTIONS.filter((q) => q.categoryId === categoryId);
    resetQuizState(categoryQuestions, "category-review", startIndex);
  };
  const handleAnswer = (answerIndex) => {
    if (selectedAnswer !== null && !gameMode) return;
    setSelectedAnswer(answerIndex);
    const currentQuestion = quizQuestions[currentQuestionIndex];
    const shuffled = getShuffledOptions(currentQuestion);
    const isCorrect = answerIndex === shuffled.correctIndex;
    if (gameMode) {
      if (isCorrect) {
        play("correct");
        setGameScore((prev) => prev + 1);
        setStreak((prev) => {
          const newStreak = prev + 1;
          if (newStreak > maxStreak) setMaxStreak(newStreak);
          if (newStreak >= 10) {
            play("onfire");
          } else if (newStreak === 3 || newStreak === 5) {
            play("streak");
          }
          return newStreak;
        });
      } else {
        play("incorrect");
        setStreak(0);
      }
      setGameAnswers((prev) => [...prev, {
        question: currentQuestion,
        userAnswer: answerIndex,
        isCorrect,
        shuffledCorrectLetter: String.fromCharCode(65 + shuffled.correctIndex),
        userAnswerText: shuffled.options[answerIndex],
        correctAnswerText: shuffled.options[shuffled.correctIndex]
      }]);
      recordAnswer(currentQuestion.id, currentQuestion.categoryId, isCorrect);
      setTimeout(() => {
        if (currentQuestionIndex < quizQuestions.length - 1) {
          play("heartbeat");
          setCurrentQuestionIndex((prev) => prev + 1);
          setSelectedAnswer(null);
        } else {
          const unseen = QUESTIONS.filter((q) => !gameSeenIdsRef.current.has(q.id));
          let moreQuestions;
          if (unseen.length >= 20) {
            moreQuestions = shuffleArray(unseen).slice(0, 50);
          } else {
            moreQuestions = shuffleArray(QUESTIONS).slice(0, 50);
          }
          moreQuestions.forEach((q) => gameSeenIdsRef.current.add(q.id));
          setQuizQuestions((prev) => [...prev, ...moreQuestions]);
          setCurrentQuestionIndex((prev) => prev + 1);
          setSelectedAnswer(null);
        }
      }, 700);
    } else {
      play(isCorrect ? "correct" : "incorrect");
      setShowExplanation(true);
      recordAnswer(currentQuestion.id, currentQuestion.categoryId, isCorrect);
      setQuizResults((prev) => [...prev, { questionId: currentQuestion.id, isCorrect }]);
    }
  };
  const nextQuestion = () => {
    play("heartbeat");
    if (currentQuestionIndex < quizQuestions.length - 1) {
      setCurrentQuestionIndex((prev) => prev + 1);
      setSelectedAnswer(null);
      setShowExplanation(false);
    } else {
      setCurrentView("quiz-complete");
    }
  };
  const initiateGameMode = () => {
    play("click");
    setShowGameIntro(true);
  };
  const startGameCountdown = () => {
    play("click");
    setShowGameIntro(false);
    let count = 3;
    setGameCountdown(count);
    play("countdown");
    const countdownInterval = setInterval(() => {
      count -= 1;
      if (count <= 0) {
        clearInterval(countdownInterval);
        setGameCountdown(null);
        play("start");
        startGame();
        return;
      }
      setGameCountdown(count);
      play("countdown");
    }, 1e3);
  };
  const gameSeenIdsRef = useRef(/* @__PURE__ */ new Set());
  const startGame = () => {
    highScoreAtGameStartRef.current = progressRef.current?.gameHighScore ?? progress.gameHighScore ?? 0;
    gameSeenIdsRef.current = /* @__PURE__ */ new Set();
    setGameMode(true);
    setGameTimeLeft(180);
    setGameScore(0);
    setGameAnswers([]);
    setStreak(0);
    setMaxStreak(0);
    setGameEnded(false);
    setWarningShown({ oneMin: false, tenSec: false });
    shuffledOptionsRef.current = {};
    const initial = shuffleArray(QUESTIONS).slice(0, 100);
    initial.forEach((q) => gameSeenIdsRef.current.add(q.id));
    setQuizQuestions(initial);
    setCurrentQuestionIndex(0);
    setSelectedAnswer(null);
    setCurrentView("game");
    gameTimerRef.current = setInterval(() => {
      setGameTimeLeft((prev) => {
        if (prev <= 1) {
          clearInterval(gameTimerRef.current);
          play("timeup");
          endGame();
          return 0;
        }
        if (prev === 61) {
          play("warning");
          setWarningShown((p) => ({ ...p, oneMin: true }));
          setTimeout(() => setWarningShown((p) => ({ ...p, oneMin: false })), 2e3);
        }
        if (prev === 11) {
          play("warning");
          setWarningShown((p) => ({ ...p, tenSec: true }));
        }
        return prev - 1;
      });
    }, 1e3);
  };
  const endGame = () => {
    setGameEnded(true);
    setGameMode(false);
    const finalScore = gameScoreRef.current ?? 0;
    setProgress((prev) => {
      const prevHigh = prev.gameHighScore || 0;
      if (finalScore > prevHigh) {
        const updated = { ...prev, gameHighScore: finalScore };
        saveProgress(updated);
        return updated;
      }
      return prev;
    });
  };
  const handleSearch = (query) => {
    setSearchQuery(query);

    if (searchTimeoutRef.current) clearTimeout(searchTimeoutRef.current);

    if (query.trim() === "") {
      setSearchResults([]);
      return;
    }

    searchTimeoutRef.current = setTimeout(() => {
      const q = query.toLowerCase();
      const results = QUESTIONS.filter(
        (item) =>
          item.question.toLowerCase().includes(q) ||
          item.options.some((opt) => opt.toLowerCase().includes(q)) ||
          item.explanation.toLowerCase().includes(q)
      );
      setSearchResults(results);
    }, 150);
  };
  const highlightText = (text, query) => {
    if (!query || query.trim() === "") return text;
    const parts = text.split(new RegExp(`(${query.replace(/[.*+?^${}()|[\]\\]/g, "\\$&")})`, "gi"));
    return parts.map(
      (part, i) => part.toLowerCase() === query.toLowerCase() ? React.createElement("mark", { key: i, style: { background: "#fef08a", padding: "1px 2px", borderRadius: "2px" } }, part) : part
    );
  };
  const startIncorrectReview = () => {
    play("click");
    const incorrectQuestions = QUESTIONS.filter(
      (q) => progress.incorrectQuestions.includes(q.id)
    );
    if (incorrectQuestions.length === 0) return;
    resetQuizState(shuffleArray(incorrectQuestions), "quiz");
  };
  const spacedReviewSchedule = useMemo(() => {
    const schedule = progress.spacedReview || {};
    return Object.entries(schedule).map(([qId, item]) => {
      const id = parseInt(qId, 10);
      return { id, item };
    }).filter(({ id, item }) => !!QUESTION_MAP[id] && item && typeof item.nextReviewAt === "number").sort((a, b) => a.item.nextReviewAt - b.item.nextReviewAt);
  }, [progress.spacedReview]);
  const dueReviewQuestionIds = useMemo(() => {
    const now = Date.now();
    return spacedReviewSchedule.filter(({ item }) => item.nextReviewAt <= now).map(({ id }) => id);
  }, [spacedReviewSchedule]);
  const dueReviewQuestions = useMemo(
    () => dueReviewQuestionIds.map((id) => QUESTION_MAP[id]).filter(Boolean),
    [dueReviewQuestionIds]
  );
  const upcomingReviewQuestionIds = useMemo(() => {
    const now = Date.now();
    return spacedReviewSchedule.filter(({ item }) => item.nextReviewAt > now).map(({ id }) => id);
  }, [spacedReviewSchedule]);
  const upcomingReviewQuestions = useMemo(
    () => upcomingReviewQuestionIds.map((id) => QUESTION_MAP[id]).filter(Boolean),
    [upcomingReviewQuestionIds]
  );
  const nextUpcomingDueText = useMemo(() => {
    if (upcomingReviewQuestionIds.length === 0) return "No upcoming reviews";
    const nextItem = progress.spacedReview?.[upcomingReviewQuestionIds[0]];
    if (!nextItem || typeof nextItem.nextReviewAt !== "number") return "Upcoming reviews";
    const msUntil = nextItem.nextReviewAt - Date.now();
    if (msUntil <= 0) return "Due now";
    if (msUntil < 24 * 60 * 60 * 1e3) return "Next due: later today";
    if (msUntil < 48 * 60 * 60 * 1e3) return "Next due: tomorrow";
    const days = Math.ceil(msUntil / (24 * 60 * 60 * 1e3));
    return `Next due: ${days} days`;
  }, [progress.spacedReview, upcomingReviewQuestionIds]);
  const startDueReview = () => {
    play("click");
    if (dueReviewQuestions.length === 0) return;
    resetQuizState(shuffleArray(dueReviewQuestions), "quiz");
  };
  const startUpcomingReview = () => {
    play("click");
    if (upcomingReviewQuestions.length === 0) return;
    resetQuizState(shuffleArray(upcomingReviewQuestions), "quiz");
  };
  const toggleBookmark = (questionId) => {
    play("click");
    setProgress((prev) => {
      const bookmarks = Array.isArray(prev.bookmarkedQuestions) ? [...prev.bookmarkedQuestions] : [];
      const idx = bookmarks.indexOf(questionId);
      if (idx >= 0) {
        bookmarks.splice(idx, 1);
      } else {
        bookmarks.push(questionId);
      }
      const updated = { ...prev, bookmarkedQuestions: bookmarks };
      saveProgress(updated);
      return updated;
    });
  };
  const isBookmarked = (questionId) => {
    return Array.isArray(progress.bookmarkedQuestions) && progress.bookmarkedQuestions.includes(questionId);
  };
  const startBookmarkReview = () => {
    play("click");
    const bookmarkedQs = QUESTIONS.filter(
      (q) => Array.isArray(progress.bookmarkedQuestions) && progress.bookmarkedQuestions.includes(q.id)
    );
    if (bookmarkedQs.length === 0) return;
    resetQuizState(shuffleArray(bookmarkedQs), "quiz");
  };
  const startQuizFromQuestion = (questionId) => {
    play("click");
    const question = QUESTION_MAP[questionId];
    if (!question) return;
    resetQuizState([question], "quiz");
  };
  const goHome = () => {
    play("click");
    if (gameTimerRef.current) {
      clearInterval(gameTimerRef.current);
    }
    setGameMode(false);
    setGameEnded(false);
    setShowGameIntro(false);
    setGameCountdown(null);
    setCurrentView("home");
    setSearchQuery("");
    setSearchResults([]);
  };
  const getCategoryById = (id) => CATEGORIES.find((c) => c.id === id);
  const renderCategoryIcon = (icon, size = 36) => {
    // Optical size compensation for a few Material-symbol / ligature icons that render smaller.
    // Apply only to non-badge contexts (badges use size ~14).
    if (size > 16) {
      const multipliers = {
        shield: 1.85,      // Preventive
        virus: 1.85,       // Infectious Disease
        neuro: 1.85,       // Neurology
        cardio: 1.5,       // Cardiovascular
        pancreas: 1.35     // Endocrine (moderate boost)
      };
      const mult = multipliers[icon];
      if (mult) size = Math.round(size * mult);
    }
    switch (icon) {
      case "pancreas":
        return /* @__PURE__ */ React.createElement(PancreasIcon, { size });
      case "kidneys":
        return /* @__PURE__ */ React.createElement(KidneyBeansIcon, { size });
      case "telophase":
        return /* @__PURE__ */ React.createElement(TelophaseIcon, { size });
      case "lotion":
        return /* @__PURE__ */ React.createElement(LotionBottleIcon, { size });
      case "heent":
        return /* @__PURE__ */ React.createElement("img", { src: "data:image/png;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/4gHYSUNDX1BST0ZJTEUAAQEAAAHIAAAAAAQwAABtbnRyUkdCIFhZWiAH4AABAAEAAAAAAABhY3NwAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAQAA9tYAAQAAAADTLQAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAlkZXNjAAAA8AAAACRyWFlaAAABFAAAABRnWFlaAAABKAAAABRiWFlaAAABPAAAABR3dHB0AAABUAAAABRyVFJDAAABZAAAAChnVFJDAAABZAAAAChiVFJDAAABZAAAAChjcHJ0AAABjAAAADxtbHVjAAAAAAAAAAEAAAAMZW5VUwAAAAgAAAAcAHMAUgBHAEJYWVogAAAAAAAAb6IAADj1AAADkFhZWiAAAAAAAABimQAAt4UAABjaWFlaIAAAAAAAACSgAAAPhAAAts9YWVogAAAAAAAA9tYAAQAAAADTLXBhcmEAAAAAAAQAAAACZmYAAPKnAAANWQAAE9AAAApbAAAAAAAAAABtbHVjAAAAAAAAAAEAAAAMZW5VUwAAACAAAAAcAEcAbwBvAGcAbABlACAASQBuAGMALgAgADIAMAAxADb/2wBDAAUDBAQEAwUEBAQFBQUGBwwIBwcHBw8LCwkMEQ8SEhEPERETFhwXExQaFRERGCEYGh0dHx8fExciJCIeJBweHx7/2wBDAQUFBQcGBw4ICA4eFBEUHh4eHh4eHh4eHh4eHh4eHh4eHh4eHh4eHh4eHh4eHh4eHh4eHh4eHh4eHh4eHh4eHh7/wAARCAC1ARYDASIAAhEBAxEB/8QAHQAAAQQDAQEAAAAAAAAAAAAACAAFBgcCAwQBCf/EAFUQAAEDAQUEBwQGBgYHBQgDAAIBAwQFAAYREhMHISIxCBQjMkFCURUzUmEWJGJxgZFDcoKSofAlNFNjorJEVHOTscHhJjXC0dIJFxgndHaDpeLx8v/EABQBAQAAAAAAAAAAAAAAAAAAAAD/xAAUEQEAAAAAAAAAAAAAAAAAAAAA/9oADAMBAAIRAxEAPwAwLcsyTpW3idmuoOar2lYOb2rBde6tJa7RzNwG2WX9rws0VrZ9dSpvNyo0VunSGzE9aL2Zbv4fwxt2yIjXve01P9p9r0s4wWGmu1cd1P8A8eWwct3aB7HpvUWndT7emIl+1ls8wx0ra3KjFbYccd028nx/9bNtQvVQ4NS6jJqcJuR5ANwRI/1UsEgtgJW4YdSizmfqzrblt8X3zlg6xNrRsstsXNJqyGwa3G7c0hi3flti4Ng56e1u/nxwt1lbxsbaZR2BivFqzuy0tRtsx4O7nK3QMbrVNb1PtfZ83323yA/vbRW+G0G6ly6bq3grEeO55IoOaj5/qgO/8e7YH96G00y3ZNi017uw13m6TGq9/wBn6E5pt+eU/lz/AIAvD5fGzZR+knU2nm/aVMccb8+R8eP8Mif8bAW5F2NuSrNOu0fS953f0mXP+I921U3H213UvXMbjNTupTc45IsrhI/sj4F5tyKq2tiqE17N7XU8tgZorGl/adzucQ/s/wA/DaUQR+pt2Yo4/wB19j+futIm/c2DLLZtc99+3ZyIrcT0b9LYOlv3NuZ4tL3lulsuxtzSA1bBqjh7yycaa91bMRtqcdsHaRdjbW8fY6TduIqnBae0nHW7cI1+me0uqtSm9T/aZv8ALYNg6rVYj+80/wDDZ5lDZtqUlpp5t3Vs4PdrYOYdJ17s7bXAat421b1wbBqOO0a5Ph3WVkquuOKtlYOlnsrRmsA67M/eP9fnw2kglpWb3ozTsxt3+fHisDe9Li+zY7rrv1fJxmfDyIFT8PFbU9tU2+RqZUnKPdbTmyGAczyj9wBZd2T41/haN9Ka/wC77ShXPpMpxttsM87J58+CgP5f5rDoLrv+DJYJ3VL+3rrjLfWanNkOOGX6fK3vx4cOXxKNojUHXXZmq678Pxf+K3kH+pt/r/4d+NtEx3Ve/YH+Aolgkl27/wB67svN+ya5Nj6fk1NRv07hYp/CxHbFOkFTK5Lj0O+OnSqiZ5GJWf6tILkgrj7o/vXBfVOEbCJbU47YPqFKDV07bm7DX0RNrEq8LH0Cr8lx2oxGCOnSj70iOGCK0S+Yw8F8R/UVSJRuwZjztiVs7Y2BWZqjNgurMaR11xyIrYOMsuZS1HMNMMcUHEuHdm8yY7ls92hOMX2Q6FJ03KjU6w8DEqSwJfWhIgN/DzIyDRIGOGKMgOO9CsAu322x7SLqViu3QnSW2qjEfJpt/OLhMNn2gb8MDLTMN6p+HpSE6dJnTHJ06VIkSHzzm++4ThGX2lLfZ92w0ydQ9pt5qPUaw5WZjE4teoP8JSCMUPMo+VeLDBN3Dw2iWawderbEnLaM1sRKwdOa1nXX2z35gw4V3naxImx9dtkD95LBtSRFAF854bhxx32qzUs+XAgVyr31o0K6+n7dOUJwc5oIi432iEqruwTJj+zYPoPdec2VWdpDTM1uO3CjS4r0oFEnWXUMcqoqIYuArZYoqcOdv1tKhsz3TmpXKbFqc6CESqsNnGlM45iivZk1WkL4MwCqL5kQF9LPZDYOWVq2Tg6rP71s3u1Z7OyEuxsGTY9jbW97ly24bQfbJtCpmzy6smsTu0c7kWL3SkPL3Rx9OElJfBBWwNu0y/VDuXTXJ1XlaepmyAHE5IJB7op/z8LDXerb9e+psuNU1qPSm3M3GDYk5l8O9uH+P61qrvleasXwr0iuXgldYmv/ALrQ+DYJ5QT0/ezFiVm1tywSKpXvvNU+1nV2ouaf9+X/AJ22Qb43mgvdZjV2bqfbfIuX636o2i5OWybcsBD3B6QUrWbg3t0+r/66w3mycu+H73L8rFPRanBqdNjzqbJjzYT4Z2H2HMwmP2Vt81iO1jbE9qlT2e1jtNSbQnz+tQvg9XWvhP8A48i8CQD07O2t63JQ6lFrFNj1OmyW5EKWAvMPh3TFd6FbbIFp3srAi+7TsrRq+V6IlCSOEvuu5sn4f/6srBzX62iXQuMy21eCp6bjncYYbJxzL8WA+HztnGrzV67kyKxs8qVOqs1sOwB/HT1kTHI6m4wXu8/l4WFvbBTLw3m2zVmmRoMmbNc0wYYDyDkBU+QhxY+nFbjujei9ewO+FZgzaO3JclxRAAN8hYMkLFt0Vw40TjReXimYcLBXN4JlTnVibJrbrjlRcfLrWfvaiFgoknlwXdh9mzdmtMtn1AqW1Xam3TZUptuRUn3pc5/4BzZ3CRPXiwRPVUsT1YvjsY2J012mUSFCmVlgMhxY2V2SRebWfXHL80IvuGwBnq9j2f2raHHLFY10gdkt8IfUb/XLcjNud83IgTWvzHtE/cs2wal0ctnFe+l936vMrshzji0yNlf6uX2TNBUF+RnYBuZp9TksuSWoM1yO2GdwwYIhAfiJRTAU+duLUsVMDpaUx28jcabdF2Nd5zgN/X1JICvdIm8uGHqAqvyzcldtqOyrZ7tRuJ9Ktmfs6PVdApMXqSI01Nybjacb3ZT4cMcEJCwxsAn3XqtTo95KdWKI643VYkps4uTiLUzYIOHmxzYYeKFl8bfQSZfhq5lxIVc2oT6VRpr3C4zCzuDqc8gDvM1Txwt87rv1WVR69Tq5C0+sQJTMtjWDMOZs0NMU9MRtei1v/wCJfa/damzaZNpdPiU54Z3UpYFp8yV0FNO6R6QclWwFds/v9dS/tNcm3XrDcxtnKjwZCbcax5ZwLBRtKS52DXZPc282ybpWUq7Rq5IhVNuSLcoOEZcPSM8yp8QGAYp4L9lRsZRc7AKtytpd4L8dJV2VJqk2NdmiynIkWBFcUW3yMyjs6qIvGpqRu8XIWlwTdvISIw27fY3WlbYg0WD1cAbyi2Lzqi45mHyqDYM4fJ4rVfsM2YfRW9N7nas1pot6esUtw+HrDYsuGGX4sEkmm7zNH6W1VJqdTujdtOqMepyWqg/UbwSVf/SJklvM4IvhiDSJu5Iu7DdYBQiQLw7WtpM1KJFcqFRrMp6dx8ItNmefMa+UAQkT8h8Rxv27/RMgNU3VvjfhY8hzLkCnNg22BL5VN3HP8sEC0D2F7SKFsm2S1mrxoUebfKrVTq0Js/8AVW2m1zO4Kii2Jk9y3quHhxWi146pf3a89Dk3ovLC+sOOezqe9n48mOcmY7IGuCZVTOSeVeIsFsFsXy6JFSbh9aubetuY5/qtRb0833OBin+D8bMuy3oyVettTZN9pNSu03HMhBtttvMSiSpmzqpIQ4b8cMN6b/Smrn7RL6XQebdu3eqow2/7AH9Rgh/2Z4hh+Fsb/bQb6X4l9YvPXJMxMmTQ92yI/CjYYB/DNYCSk9Fu59YoMj6E7QpEyqsP5DeecZkMBhzbNGUQhX8fwtQd7LtX02N38he0mup1GI+MynSg4mJGQk4gXdmTwUFwXi4uaY7aC3e/ZzTKffS69741PkTooyeqhqsk+zmw928CNyBRdy5FXL/itZW0rbJR9rWwiuxa5TYVOvLSZUSXBZAyITbV5lpwwJU54G5iHgmHOwE1c+sRZdHo20F2RDpcK8lOhuTmXH+zGQ4gIxlLcmdc+kuO8sGk8uC0l00IF4LsXru7tLuxPm093J1F95hxcrToYm1iHIkNNQVRdy5ETxt39Dl36c7D7yXLvHKWoQo8ooIRngEtKM62JDh5u+ripjywTDDC1l06gUzaX0fqNd+8jkhUqVFh65Cum81IAQxJMccpg4Pjjv3LjYJlcWru3huTQrwutdXcqVOjzDD4ScaQ8v8AitneGs0e7VHcq9fqcOnU9j3j0o0Ed/L8flbvp8RqDDjQYzWnHYbFlsPgEBwT+Fgr6WlXvDfjbu3cKityJvs3RjxYQeaQ4COOHhy7himJckFfnYC6u5e6796qNInXNq9OrzjHkblZe0y7hPcpBj80sDHSMvxea9e0KRFvBTPY3skyjBS9TNpcsSI/Oq8K4puwwy/Errdn6Q9GzbBTpN5ILkiO/BLrQQuIZDJivCClghGDgjzw/jaF7V76TtqG0eReH2Z1dyXpw4MJntCypwNj9twlL/Fh4WCKZrS25Ozm/N9GdW7d2ZlRj58nWuFtj59oaohYfLG19bJdg92qHUo7W0OK/eG8r8H2ixQooZo7DaFkyuHigGeJYYGohuXDNgpWvS8VLnSaOAVGuN3JobGXs6c+jT2mnISfXAGh9QAf27ACO0rZ9ebZ7UoUG9EaPHkS2OssaD4uDlzYKJfNP5UrRgXNJlx39G33/sc//SVjCqVLuhWBqke5+x2s31nSGza9uVpVFkyQVRCCTLPUJPFFbTD4Vsz9Gqt3QuzcpyhtX4pVGrrkpz2xTLwsBwSg7NdJc7fBgIpzP8N9grepdHjaZFo8epwoNOrLb7Ynkp84Scyrv5GgIX4Ktqvq1NqdHmOQavBkU6Q332JTZNufkVvpDTY3UXmnIVIh9XkAKvvQjFsUL1ybsQ8ccVLfytx3mbufeCE3TL1wITrcuV1RhipsZdZ7Kp5Ws6cS5RJeD4VsAz9Fbau1SGG7jVfrLjch/wDos2wJ7IRlvaUBxLBVzKK8uJc1iz0nP7Kw03fhXV2Rba2q7MgrTqNUmXIJ5zVwaNM3Flx/snAHED+BV9Cwrra3tGvzfivV2uUCfVW7q0V8QDqThtttNqeRt08hJvNRxxXu/KwEDt1jNzIMMnGuUhfizcl/n8rK0U2LXpqm0G4OrWXRkVKmy1jPSiJGydHIJAqpyzYFlX9THzLZWCeXorF0NnF5HLzVtqRqVKK3DN5hjU0iYxVc2/HjQw/3Vgkv9eOdeu+FVvDUpLjjkt9wwz/om83AA/CiJlSxz7ZLnNXru3Ii+74Pf/2WHI/w/imI2BG+F36xdmvSKPW4rkKax5PKY+BgvmBfBUsG+5F56vdWsOVOguZKg/FciNmDeYg1MqKQfbw3fjbk9m3hdecnO0eqyO3I3zOI65nJCRTzqSfaxXH4uLnbhos52mViFU4zum5EfbeDy8QEi2K6FtUrG1WnUaLQJVGpUwF+vBUMXnDeQVUtFkBQ3URvBdTOyCZlzfZAX72drUnJ0ajzadTn/cA+wDfcFM/ugACwXngnmTNZsKLKaZbddiyNNwNYD0yym3yzj8SY7seVjN2M3EvLV2Kjeu8ManRnJauhR+uwdR9ps0VtXTQHE4CAlQRQ+7guPis8cuJJrlImwLweznG36OVFcYZbdEsqY8QuEa5EXgNEyKQ+q2AFLrj/AF2mfRSZWay+behC6pmHT36mZBTWA8C3KCph3i5WyubeO8Oy7aE3WI0GRTqjHcySoUpvTKRHU0U2jzJjgqCO9E9FtelZe2hUyrybvdVhx1YcZjSgq8s2xmtruDI4K9WHU7g6zKgp4oKkSK0Ee6WG1Sl3uhU+6kWm6dQpr+NR61EUXorzaZTaAzHEgVSLeiB3E7yFggD+RWd7k1CsUy+FGnXfdcbqrc5vquTvG4pYIH2kXNgqeKEtm+ht0x2sQmq3KkQqc4+PWn2G9RxpvNxkIeZcP5K123UW7NNYqMHYQlYvNfWe9oxZNRgg29ToIgupIZUsoCqmSBnLKqbuH4gNpyn0yVWY9TcjR3KjBbcZbPzNC7kzj+OQfys4WrHo5UGVd/Z61FmyZFRmuPk9KqLzyuFNeURzuIZbybH3YL5kDNyK1nWCvLsXiureuPQrytz5qdfrEj2WzJwHtmo77BiIeVFAHnMF4sS3+luK990aumwm+V2oUZuZVaiFZeYZbc94UmQ++A4qnPtETDljuzeawU7Sby3loe0Kq0eFXJkeFd68s2XS2wy5YryyDXOm7n9+I8/VbXf0EL0V2VUq7R5snrNPccF5t6VLTU6wudTEUXE3VVBxXflDKq8z3gP2yC6sG/t/Id3ptXcpbctsjblaGplyca4p6ZM+8uFN2a1ubT9jWyC5bLdIkXqqL9d0OsOaz+nqtp3tEAivIeGUuDHFMN6+NqGvZD9j3wrMFppxvqlRkMh2BM5BB1UTsy3huy8C8rX/ANHebF2ov1W6FeSM1VJ8X69UGQIZ89lC7Z1x8uLFEJlsWwVEXjMkIUyEDBT9i13qxDk1iNepyFSmH4oN9afaIiHN9YJTyIgIiZVAyRA8N/h3S9gMFumzK61eGQlGgVRxmVncZcJiGALg4bzfZ59TcXlbQsV5Ktigi31utd6+w7MJ0FaCCxROnvTTbFmo4llIW1zKpl658CXfu8bbZl7bmVi96bIuqx6445TnvaDDLYOR4ot5B0nkx4FXHcnhgnqlgGq4mzbYlPrDd2atXKpMqs48jDHXiFyKXNcwaDYAipjgpquOKZRXG1c9IDZ/d7ZxeSPQ6RXJFZcc1HjePJ2WBYaaoiYZ8c2KovyIE8bk26tUzZXVndWA3IckMFIoDzmdl5gk3KLMoEztOtqQkodxwC8p51cFOqVKdU6m5U6tOkVCZI435UpwnHHS5b1L5WAkugQzeL6a12VCaVKE5FFqbnzCKvCWLOVcF7QUI9y5dzir4JYoZl3rq0yJDpjrkiMEiVJOF255hcM1mGgKvobWoKckyfDutU+xKZG2c9E2nVuRJbhOzz6z1mTEIWRekO4NauHFpdwdT4VQh8LCsm1C97l7/pBUanNmG29JkBFef7IHH2TYVREeDHA9+CJjv7uNg+kdBqkGuUKHV6VJ6xAnMBIYe+JsxxQrVNUKps92a7dqrU7ySW6fVL2RYvVZj7BaQ6aK24OpyDeLSkq5e8HpaY7Bj1Nh1xf/ALdhfwjgloj0p9m3/vDuQ2sZ1uPVaaeeC49wiZHgitGvlQ+Hi8FRMeHGwB/t02k1jaFfabU5sn+ioj7gUqL+jaZzYIX66oIqq/8AhSxHdEbYmtDhNX9vbBRKy+Gelxn/APQ21T3pD5XS/wAKeiqVqc6NVy7s1O+vXrx1hynVW6cpyo1GkzYmZso8fcpZ0XhMHMMUIfBMvjY7ZoPzqQ41DkuQjfZ7N9sEUmsU7yIW7FPn+Vgpq/zdXvNeiqXDuBU5FPkSHwevZedHCUoTacTcNlRVO0y+VFTIBKq8Rkto9cW9Wx7X/wCy9MvTtHvVEcyA/KYkTnyJODVR97sWQXnmQhTBbTK/dy65VaRH2YXJ1LtXaNM9erPET7onvJptS3uuuLirjir5t+ZSVLVPfrbbdrZTRB2fbGqZGkrFxB+pmuq3recky73nfU+4i7kxwwQLI2k1697V25NXvtfWn7NadoF1Wn0wwl1F9zLimZ4hwx+wyH7dh32Z7ZaHGupHuXtLuPT7y0Nsy05QNisqPqHnMsV764kvGJAu5Odp470cb53qo/0z2j30kOXhf03n4ugLzjTOZM4Z8cgmgY4AA5ELdxd62vad0U3aPdZyr3Ork2qzYjGd+FKbTNIw75MkndX0BccfisEruvciDU6a5WOj7taqFO0w/wC6JT5SIzXigKy7va/ECtHG9oVTqdYqOyXb823CcfNvqNTYbFkoTye7fEx3ZFXuuJyXhLxwF+HJkxpnWYMqTHkN9x9hwm3A/VUd42I24t5rq7cruUrZ7f8AbkQr3RG9Gj10O0clYD3T8ccBxNF3LlzZkKwW7Qrq1i9UOq3C2q0xyozAhCEW8kIMrM+PmxbI/AZDZ78q/EuGIqWMD6MtN+jO0K/2x28FMbcceYI3JQY9uymAIOHoYPoafDiuOO7CzK1W4Wy7ZD9EJF+Yca9NNoBHT36i5l604AllyIffTOOTImKiKp8rQur12NRtoF2r80mA27e+/VHjHKN5zLCpMEGmzlP7t5qiDjvLk1++Eo6P9x2rk3crMNt5wm3q5LVhw0RSJls9BvMiYYqqNZ8U3cdlaVbMXDk3bbnsNOBBlLnhZ+91dBEW8cfNkEcftY2VgZtvO0ip3Bo8eTSKHHqOo5klG+4Q9XbXDAxRE48eJOab8PWwc1raVeapsyIs5qlVGO5qaHXaa08UDPz6upJiH3b0TyjZw2ybUrw7R6vHcm6cOFEY0ghRTXTIs2KmqY8SrwpvVcMu7mtq5cKweY2nXR8hXmnbTKf9EoK1CQxleqLKGIiUPOmoJqRgOC8O7FMS4e7jbZsM2Yu7UL1TKP7X9lx4kUpD8rJqF3sEEUzDzXxx8q2u/ZnX6HtaudS7qUmp/Qq/13GP6Lm0/K23IEEyFkRFxNtUEVNtfHBeIUsFoX7O816ipV4dm9SWHeG70o9ehVYzZbkNmJAoPNiu5fEDXcvgvjbqq0DaneW9N3m3UhXWoULq1RqT0aXrSpEhBxcijuy6SEuBKveTlbi2b3irlbrzdzNo10JkO9VGi5wrUVsiiSm+Wq0+KJpKeXeHJd6eopI9od7Ls3IpDs6+1dWRHlZmY1ORhCclY+QGhTF0l3JjyT7O9bAwbfLuVit7MqjU4yQnbwUZt6SxkiFpvx8uL8UwNVzg43uVOSmILuUEw+elj5uLeG/DkyPWNpb12bgXSPXCl0V7CPJfEhXTGQpnkHI3vyBguOOYUy2EnaXdO7TtZrU/ZF7VrN1qFFY9oynOIY7jhmCZFLAiaVATfh6lmy4LYK6zfz3v81r42ObV4Eq98O7tSpd0bk0arOZa3NpkE47k3Ki5WiczkjTaqu/uphn3jjahSK2oisH1mhdW6m31XT6tkTT0cMuXwww3YYWim0vaTczZ5Dbk3nrDcRx/NoxQAnH38OeRtN+Hz5Wp7oqX8iVSjuQI186zNSDFI3KFV2BlSxyD/osgMiutpw8KgSpu7mZFUZukBUZ1Tv5UanVqxHqNVcMteEx2gwBTcjRGhmGp3swApoHLOpZsAjd/621eK/ldrrSOI3UqpJlsAeGYW3HVIELDdiiEiWtvoRPRo22VvUkudYfiuMgyxm4h5mRppqigi5POG/i4u7autsdx5Oz2uwqRNRzUkU5iXxh3SVpNTfyXtBc5ckyW6tgjdIdv5Hcq1YpdKycbM2oTpEMWnOXA4y42olxfGm7HvWDr6TtPi0zbve2LGdbdbcmi9wZeEnAAzHhVeRkqb9/ysTfQt2dtUjZZIvDUmvrl5+MHGTNtwIabmxzjgQYrnPcvmD0sHm06szq5fyqzqlJjTZGv1bXYfN5t0WhRpCBx3jNFQBVFPetjd6Kl8IrnR9u67NWY51E3qc4bDD0rS0jXDPkFVBMhDhjuFMLBZ95Ll3VvNChQbwUSHVW4BicXrSE440SYYEhrx48I479/jbZQrqXaoT1Rk0iiQoTlVfcenuMtpmkOGSqpGvMt5Lu+dmQtrmy9p1xt3aDdqO4G4weqTTZD+BLjZN7W9mDjulH2g3afdPuNs1Jpwi+5BXFVsEW6V1x2717Dqi1ToTazaKAz4Kd3ILXvBT72s6YeuFvna452Ljv2LfSLa1f2mtbH73VOntT+wp7zTfWYMiGLpGCp2auNpnwRVLEMU4VxVN+Hzby/orAbXSQOBQ+ipR7tA222rceJH93qttONCGIqbbZti4W/DEm8VxwPdlULc1pheq+aVS5NKoUaTIPQbEJQHRokIRykioIORsDNvHFVRxF3ih97k0XRupWLzdpBgyHKcD7bM2oAGoxCzmA53cO6KZ0XH0x9FwA3eiZtMu1eLZzQropU48e8NKgjGcg6h6httYALiZgRFxTBcBUsPXna5rxToNMoMydUnW48NhgjfN40EAHDzKvhb5mXMqEG6l8eo3xu912PHnCzOAHzZmwHGTVFOO62qKjgL4cQll8NyoQXSuvZQ52yW70Wi12RXY07ii1CoajnWG074ioIjaSAXBD1gRwEJcOLGwOuxqs0O+lO2jX0kXUp0eM2+MGLKisE3LqTJuo4kZ7EyQjNEZbU8MSz8WNo3tk6RN86PtfqjV16nHdpVMAoLcUwzRylIODzq4YEeB50RFXDhRcLSGi0py4/RqujBjSW41drMoq0et3GsAJzrL3o3Hb0nPmbbaeNhPq5QfaUj2b1jqefsDlcTxj/AGh/NeeHhmw4sMbBaF4ekRtQrlz5N2alU4fV5YONSpQRRbkG2ZdzEcBFMODcmOC8/NaRdDnZjJvXfaNeqpU5s7vUZzP27eZuRIy8DYpinczIeO9EUQTDfw0Db6I9EZ2nO9H27K0wG29Nt4JSBlL6wjp6hFgvNV379+CpysCot3dqF0dqbr1Nq7d5rk1qSJvN1SWfW6RgGHZqvfDhRMOa7sd+Y17dmFG2jO3wqt8toFWjw+ssDEhXfp72pGjtiakjpkved5708q7/AAELPsrB8/OlhcH6DbU5EmDG06NWc06KunwtOKvbNfgvHh6GlqmhyZUaY3JgyZEeQ3xg+w4TbgF8QqO8VsavTvlUxrZLCjSXvrj9VaOEHm4EPUL7shc/Uk9bBHYHy8957wXqmNzrx1eZVJDYaQHJPNkFPKnhYpLnpKvLsf2UUeTR224083aTOqBtj1kYYCRiw2fNBeBoc6p8CjhjyEDNYtNjtddd6L8yp0imOwqjcyb7RbyZtKQLaYvE2RoYiptk8hoiLlMiLLvRLAT0dsGW0AEyAnJv4bKzLdSurXrsw6qiNK6+AmbbOfKOZMeHVECw/WEV+VlYPms4NtBc7dJFbmcKwFd0Rrlzp2xS+U6mym6dVq6blOgzcmbSFtrBC/3jjn5W59kGw9y8N0fY957q1K5N4bt1Euo3hhGIuTOPFee88nIHMMMuTKveS1g3QqC7E+jhd1qpU2TNrr6djSwcEXHZj5G6oEvIUBFJTPwQFW0Y2XdJqmXldp12r205qPMqT7jMqY882zBabLPkBMVU+WUOPmS87Bz7QNsN9b1Xqj7Pthiy6hIpr4hOrWQHgLLu3maKAt495xe/5E9esL67Ptn173fpDJmbQtrCxUbflQoKPFrinDDYQByM+O4Bx5qfEuFpNtXCVWNnCXa2D1KjRnPagwZzNFQBbjioKp4utcMdETeS4Yl3R4lwUb3r33d2Mf0Pszkw6zen3VUvObCOMtesaEBYpkx7zi45vtbsgXY9s0vntVmhevbjVPo1d2FmkxbuRXxEWARN7jz3IVwzYr38CXe33bOGyS9lD2lV28twLnXRhU7ZrBpb8B6U0GTrbjqgIZQypk4esFvVVXFCXKu60GVm/N7rnRr1dImtu0O4NNyl7MYZ6vIrLili3qtt8SeVETAS4UURDe5ad9GnadGvxfGqxo9N+j9KYhCzdqmNxNNt2G0ai44pDwG4BECZA3BnVEzcRWAKL1UWTdm8lVu9N/rtNlORHz+IgLDMPyXn+1ZpzWIXpv3CqdI2jyL8xoLnsasgznlB3WpQBkUT+HFAFUXku+w7FYLO2J1WpUymXq6lKqMmP1HPKpzD/VWHW0x7WTIJU0mk5YAuo4qoA4Iu9i2TQI159sF2YM5rTjz6wzqMxWEEcufPkQOQh4fJPXC0SZlutMONNOuaTmXO35SwxwJU5YpmXBfDFctrw6D1Maqe3CPKchOSHKbCdkAePZsYjp51+IsTQETdzJfDCwEZ0k6VTIDEy8slqO5MlA0ycp/KPVWWFVWwA3ewaVXHTPUczLigZGnDQMAJqszr1TkyW2tPXcI8mc3MuPqZ8ZL4qq81x5WIXpn30afvpMu6brdQmMcDbZ8UalNkPlDkcpzvq4vuwJsR48TQa81g2Y2MHoK3yo8u69U2fVWToydbCEBv6fWG3BMzBtEVFzplMiVExwwxXcmAj3gpsqh1ibR5zTjciIei+B8JAX3W2XcrlSu9WWqvRZzkOYxxgYLhy3pu8UxFFw+VgKLpQR9oWy6ZHrF19o1Uk0Gc/otwZz/XJMNzIp5RN5DUm8BTeS4pine52jPR4l7S9rd6nYU3aXVKTRoLjJzUiPpHefz51RprTQN6o0eK+CJyK1a3s2o1e+DD8WrMo5IlSpEgzz+Y4jEZkcV8ARol+88bNtzb7Ve4Mxx2iNR25n1V7WNzNxNu64Fgi8SKBZCTHkq8rAUPTUr9NursxgbOKK63qS3GzlRn8X31ZQswOqbmKriYLi5iq4jh44oF5FZzvXeSr3mrB1OtTXJEg0H9UcERNyeXu4r6ritmiwbM1i76E17m6xUXKRVoNCk1Rhnq7cxlUZqJRkHcj44IklpMuCLiZgopmHBUOwgWl2zO+km59dju6TcmH1pt4+00345J+lZe5tOZfvA0TAxMeGwWl056FBpG2Xr0KDJjO1WEMt4+HQfcTgzh9vhwMfkhefc6dFa71M2g3amXQvRd7rlD612FQhHlciyh7QUfAdxIYZxB0kVcM7ebKoCNhdPaE5U9nF27zRY0KbTwfyLK3a7WqIqBAaLgrZ5VQk379Mh5WhXQMi9Wq16ryO0ya5GgQhzygcdIc3NGgYAO1cy51xxUkxBBTjVVC0+lld5Z1Aci0mPjUH4IsgGuDYtRmzzkGC5RaZVRBXHHHADgaTjLKCgxIHSeca1W3NMyDODmYTw8wr5k+drK26bXb138vhUEkvJEpUd5yNFphg0800KYhmPmCu8+0Tu5uBcLVhYM7Gj0a7qxXNh1PvNdOTXYd4Q1Gpp0aUA9cJDVcptSR6q6aISJjgmHc1MRVbBUNrn6M22BzZpV5FMlf911J9nPnzFpOK622rhfCINE8fCOJKgJ3eQXZV9vs2h1ybR6nfOn06dEcyPRa7cuVrNL8JHGkKBbsCxFMqiqKluIukZUpzzcCFfCnTZrrmViLRLlTXJMj7Ia8lEx/D52p3pDX7pu0ybDvDGabjyI8V43w0w1RbOXpR2DUd5GLYI6uKlgr6oOW2zo3bQ6Zs5l1WpyY0KRNfcbjaj3e01afXhXmKawsoeHgfFySwSfpUQXGrt3eqdfjVVbzTnCNw6nUgKS1HTFMgxmkFkAxy45E3KiZlPHGw+42l+2C/s7aHfabXJPZwnDLqsXiHIPJCIM6pq5BBFVMMciWh2awbBsUXQvo1dpl45HX3v6BrlOIjpzgcL/AMEgc2AGGVCBVbU1TOiGKJlKwt2tPYdtim7M6i1/RbcylGf1sGX3RI8S3uZCNWdTLuxQALDcReoXPsZmXi2d39vNs+cqfs2HFNx6lwa8yUhkoaO4NusSBNN2BJiGXDEvAhNLKz7tyiUevDRr2UipUl2FWWdYGalSUqUZ9EAEF8GURTacyZBUhTBUyoeCiGZWAOpFpx0eaBGvNtmuzR5sbrELrRSXw4u60BuJm+WcQT9q0MkNar1ib6Hd0FuzBrO0u8bXU21ZSDTtfhIxUkUyTx4y0wHAcSwXKi5ksDf03724XpjXdjStSQ3ByPgGb6u26uLgr4ajiCCfIEUf0lhhK0324Q6nG2kVWVW2m482eZS3GNc3HwEyXJq5u6aoOfJgmCEnAHcSEFYLY2W7abw3QoNOuhTfY1Gox1Ft6o1EKbqSXWVNNTPmVUPg3Y5M2VEEeVtM++V39nNVRvZh1CqVIFFyReaVTuLMpYq1DYcTJHaTljxGvLMmA2qkitrKwPd+L53mvpUfaV6K7Nqsjiya7nZtY88jaYACfciWI7oajdSo0dukSaxDbqoSuvMRW5RMy4sgSw1WwPMh528oETZ5TDADbXiJRRIrYWD6f7aLsR737Mq5QpEmbDbkRSLXigTjgEKYp2Y73U9Q8fDiwt8yq9T/AGZUpEFyVDmaf6eE+LzLoqOKEC+mHguCj3SRCxGxfdE3aNeH2DGjXkvD7Zo2pkOU84TxU0i920857xpMRJMXAJtcUyvJ3CgfTd2YQbs3javpRYLkeHVni69ky6ISF35sOYZ+JfFFXHurzAbc1i26BNAnQKRem/vUTktuAMSCDbZa8ggxMxBSXJgq5Qx+LHeKJvEqMy5Kebit6eo44IBnMRHMu7epbkT5rb6IUW4DtwdgU2jxrw6dQcg/0pWn5eXSbQFziyZbmgBMyB4BmU8CLESAENplZnXgv7XavUlhLNkTXVPqOGgGBqnZYd4PnzLvLvVba9nVDavNfSl0d3Sc13xDR19E5Q4pnaaMuHVUMcmbBFLdvVUFeS9sCDTK/JplN671ZjKGeaxouO8CKp6fMEXmILiqIqZlzWkWwGnxqntkutBm+7fqLeQwlaJA4HaBlUt2bMIogrzxw3KqEINe1RlyLtJvNBcdVzqFRfg51QuMWDVoOe/kCd5VL4lUsyrGM1rR6VkJqn9IG9sRtptv66Lx6aLlInWgdzZVVd/Hv9VxXdjltVtgzzWWa2FvbArdlGnezazCqSt6/VJbcjRc4c2QkPLj5ccuFuK2xhrrL7UZvUczuCHAGYt5Ybk8y/KwSbaXQ6nQ71Oe0oKRnJbbcns28reo40268De5EwAzIMB5YZcV5q33PqrNHr0edKjLIh9ySDfvNMuZNl5XU3GB+UwCxFdOa7ECjy6VU5Mlzrr8VmDTmfNptDi5m34YIpYqvMyeDLhpnnFywHjFo9Nvv0SKrS3erzW4jD0iMYYNCyTfaA6ypLgIKmJgGIoAnorkyLhVIwZOz7okG7Tqm1Tpl7JThzpuftpDY4ozFZDvDnDeqruANTHmKLaPQlqMWVcR2CzJkORsg/VX2+6vEClhhgYrkJNRMEXJlIBMCJwX+kLSKxd7aPMu1UmurRoJkdOisuH1QGXN6GwBkWkB5cVDEsCFR8EsFdjztlbCz7c6ktVN2qq7hpwKRLnOcGY8whgH5GYL9yLYGUbZZra81ssbB3UuoOwXtVr4HGTz/CYKC/wK2gbaRtlmsGdsrY29zWDdZWer+UH6M3kcpjUluQ31WLJ+0GoyBqJfCqKRJh91mAeVgLvo+1K5m0/Zw3s+rNCpbdSoz3Xuqvq4rEhtcwLIZBCHJxkWcB4EM1VETPgKtRuxnaD9DZs0Kld6JeKnvt5m40jLiy7imJgeC5cUTAk8crfwWVglPR/uU1ea9Tc6rwdShRMxvmfCOZN/7WH5fF8KvO1TbE61epxq5Mr6lAAo1OMOJhpxdxyQQu87huQ+SZly5u9aX7UK1BuXcP6MwosdvuhKAHOzzZeCMQD71fFUxyD3jzY5DF14rBySnXXXnHZLrkhxzjM33CIjJfMSlvJbarbXhtoKwYkVsM1sraysGsreW9K2FgcLu1msXdrDdTolTkU+YHceZcyllXmJeBAvii7isZ+y29qbdtldQufeimx6fNcY0QlQsjkYsmGBaf6FxFEV0yy5k4gXdwA8RWuXoh1VqLtUj0x2S5CkVIMkWaw5lIHALPkJOTrZpmRQX5EOUkEkDp2Q7MZ12ek3QrtXxpnWUjynHmNDtGJGmOKHy7iLgqoWXDLgXFuW3embf6bS3oVHJpW4TfbRWDb/AK7KAs2oaF/o7HAqJ+kcwTkC2IOmXUpEW9lRvX1YHazOYCM5JPLmFkOTQ4JyxzKuOKquHggiIXdO2ipTNrUepu1zrjlSgifVTy/UmwJQQERPJ47+a5/wAfZTzsp5yTJdckSHHCNx4zzERKuKkqr3lVfGzldCqtUe8kOpuxo0htt8c7b+YeHFOITDjaNOaGG9MPHkrTZ4uVNag3qpU5yp+ytCUJ9d6qMjQ9CJtdxh6p6Y97lYLt6b93G419KNfWE2bce9EHVNg3EImngEMU3Ko4Khgu7dmzr42HqxedOO77rdw7pVJuCsePHbFpwIX9QacUe6Ifok3lkUdxomBb0Cwg2DKytjbKwK0l2X0iTXdo9CoUZI2pLnNtA4+Ak219tRLcWROPKW5cuCovK0atOtg0GVP2s0FqNO6k51oe3BsSfHwXRRce1w7q4cHf3YY2C0+m5ep13aE5d2Ng42xFaaflGi6piBqWkHggam9VTvmKIq9mgoOViF6clH9mbQYcnShN9bAjbPUJyTK4QxN1V7oBwtgHoKr3lKw9WApegHLnOXiqlNdlfU4rGtFDPxA45wuDh3hbNBBS4cFNoOJFTKvX/7Q2mOtV66tc046tuMPRM4IWpmFUNBNccmXiLDci8+95RnujXandqvwq5SJ8iFMivi8DjJ5STAuXzReWC7lx32+jEfqO1HZXqyXYzftaD3wbFxsSMEVCyGioaIvgqcVg+ama1zdGelNVNi/wA3JaR2M5d1yGZt5ddpx1cjZhjuwXjBV+2OOAqRJWN86NJoV6qhR5rcLUYe78U8zLorvQ21+BUIVG159D1qNFo996xUozjlKbo7zL56eYdPIpuCWVFUdwj4L3kyiu+wDwQ/z3f4WRc7L+fi/jZDzsGQ2ytjbKwZ22MNdZfajNYaj+UG+PLz3cS+H32026IjTbk1ptzTRs3BA9ZzKOVS34l5U9VsFy9L6kQKZtApXs1G+rnRGNRwAXIbgYhwnyPBvRTdyHDHnalx5WI3pqRI3XLqzmnZDjj9OyZzb02wbDemQC3iqqZKXplDNzGw5DysHS0W6ysmeVlYJffKue3ZjfVmur06JmZgsHxEA5sVM18xmuZVX4i+Vo+9bYRW0vFYOZ62BWxcdtlYNJc7abdDltBWDWVtVtpWwsGsrbabMnQalHnU2S5HmsGJsPg5lICTkWNtWW2UNjrUyPF/tDEPzKwHnf7aM1c/YDd6TRJ0hubWQZjRZTwdoAmOdyUaeuHGiL4mCEPNLA1e2tSbw1+RWJOpqPnwAa91tOQ/l4+K4r42uXaRe9q82xmlUeNJc6vAnCHVdTiytxTBseHyY5l/aS1ClYEVsoj3VZjclpts9MxPIYIQ7lx4hXcSfJbYlbzLYCqvLf1y9XRphzqHp9TpMUaXWKK+4eZogFAR0HCx1QwIOBxD3YZVQw3ipaW7N697CqM2LJcc9n1OE7ElB3hLECyLh8j3fcZj42iVgxsrZWVgViF6FV2JNYvVUKm0keM0w3k67wlJ8M7TIL3cUMM7mBZUwFMM9h6tZuxraJJ2cUG806kaft2pNx4cV/JmKO3mM3ix5eUE/L0sHH0hL0O3r2qVWc7ObkNxMsFgw7oNt7sqL5uPOSr4qS5eHC1fW9y28sGQ2LToh7Xo0WjuXGrcptvTbKTTpR+QkLjYL/OHyJR8BsJVrJ2LtNNe1axJ03G6awUk2DzDnFMi8K+VcRD96wce3Qoru02syoMrrEeQ+RgenlyEpcY4emO9F8UVPNjaQ9H3aXOuC9VYrWm5Dn6eoB5h4kLcWI7/ADeHh91oPtEH+nm5PaOdbijJzm5mI8SVMxL68NmRk9JnVsDne5yA7eSqyaa043DflOG2BgI6QqWOTdu3cvnlx3crNduyrP8AWak47pe8y/5UxtzENgQ28srKwK3VBkuxZjclvU1GzE+Dvbvh+FfnbQI2yT337tgufpDbSGr302jUKNFjf0b798PiRMmkOO8Qz5/EscGyxW1NjbZId1XnLahGwdcdp1xLKzrTITqw/d6mGVfzGysHCTltZdrZFyt20FjVmf1XrHkyfGS8rA1zI2k83/eBntvZa/yWntUobVcqVGi02NqON05sDDh4C1VX9pfx9BtNtnezJqC9Tp1bdbkR34LhnkykIFmBE37+eewUdIhutamp7xu3BltZj1BlTmarJ0m247D5AHaZiNvNwfMlw/y2g9aY0npH93l/VsDI5bC3pW8wsEipN1ZNTprbsb3jkrRyd7hU0DN9yKW/7rMlLbd65H/RuZ7TnZfpRqlCdkxnNPOJm+DmX5p/l8LPVwbiyqxMhdW0247koe3fcEc48a/eK4enz9LB2FTIzuyulSm2nG5GpMDgbzZxQTBc3+K1PTo2k9I/uzKxn0+5MFq6sKjuRusaE6R258InnefTkK/Y5WqK/OzJ2TQZFTpum5qVuox+M+I8lQWOGVETiXDL/wBPEKC07YkOlayLk3Dk1xlx1v3ftUYIdzNqGeCd5bRGuU92Np6rTjeoDJ/7xrOn5pvsDLmthbrGM72lsXGP89g5s1lb3LbzLYMxG25tt3R7O0nubQWqndWuznfeRAimxwEXCZuAvd+Yp+7aW0u4Dv0VcnSYrmm4ZAD/AJWuyfXlz8g+FgqUhtha349xtJ2ouN/WHJ9ELqrPeLWyRnM5Kvrxrasipkl2ZIaaac1Gwz5PNly4/wDCwckOM7J91aw9mtPddu3eJ1tpzs6c8Znw5eA27adnN0+vXkp0GS63H1zkZ/1WwNTzfdkJbEXT9lcGDsxmyqbJ1G2wns5w846qAg8XqoFhYBrlU+VU9PsvcQcgfYxF40Afnjns5Q7hyqndWhVOM0223Pcjhn1BLvlpcvm5m/dtc929n7kF+9UX3kdiI202fwZ4Ms+FOYph68XFm72FpdsnuslCurc2kTtORIb6pnz8Q5vaCqo4cvljYBBGizu0d0uzb1P8BZD/AMw20VSN1bsnNPU8/wBgs2GX/DYom9nMGLQXJUmU43qTpoPgGXTDPNBtf1cELDHwUeH4rUDtEoLsGZq6rbmpmMABzNk4lxEvu5Y+OWwQu3gjbwbOVPY1Xv2CM7B1DSHWmW3XHW9TP5PlZqebdae7X+eG1kVCmdWebiu+8bB79Y+Jf+VmKpUXVqWl9sePzGKtNn/wKwRQbS9mg6t2485rtNTNn/AAVP8AMVm2Pdqc7TarO0tPqEUXuPh4VBTzD/PmsUdz9m9Mi02F7vTcf4w1C4xOFjw7+WIF/wDxsFX3IuE5U6Uri9R0nEbIAkOo2u4ExVEXeqZiXfZWICJRoKR6evVIzrblOjnnccETAtIN2/cSL4qu/EbKwBRBhypMzSjNOOOcXADeYu7adXDulOnPNtQdNyQ5UY8QA/2mp4eZOyP920w2O3Y0pkesdR6w22w5nA8pcWRtV3FuwRcu9V3Zs1rD2Y09r6bdVhRo8fTvFk4MokY5ZpqPFvwRseS/F+YRS5+zmTJ6v1mK442/R9aUB5m+Ffd5c3+yPl8SWui5d2oNMh0aK3J1G/ZTzIdmOV1zMzjuBPslms70qG27R5Drmp2F1oeT9ZAkqm79pLORUhqDUruuxnXG+qeTgEXc7TimReJHwCtgoWVceS7TZEp2N9XqWo9nDMRNCDR6ZYeq5xVf1V+VqD2kQ51MrDkGT/Yf2YjwrjgQ/L/njYxq1SuvXVu67G1NT2V1k+08wMt/8MxfjYctuET2neptpud13qkFwM/mzAZ45vn3flYKMy2cqbSpMpnV0nNPPkz6fDmzImX77d8GmdZqTbTjTnaAX+U/+Y2vGDdxqj3DktTaPH/rTb2c/lIBVHPu34EYen5pYItc24tTqb0dqN/V3DhhnBsiLNIjq5m4d48G/wD/AKtamzO4cVp67tTmtdXb13jinqCXZrirYkh+PGP7tpjsTiaXV5XZtttzogaLGXTBz2SjhiOXu7iDlgnCn4Smj0OK7R7o6rX+gi8+B8Q5gZbRB/DNYJBd2K17NjtdZ7RuqPPcfEW+Q4icv1ufytXNFpLTuzdx2TFbc/p+a8HxZlrTiplw3eUf3ktY1yn/AKn+kcc96ecBEt5qa5suKbsxWjtz2NXY+37tzUnSnvzqRmlgpXZa1Kg+zos6LH6uxX5DxyuDNqNy8EzJ6pldXHnxWbOkhs+gtVindW0+s9VjgYMMd4mmZSmX45C/3VrkpN3EqnsKdJjNah1+ssuHk731mTh6pyBf5xsydJKnuxalRnW3W23HOsZPLnyA46o/lj+FgGOkXdbqUyoLTmvqzM0YiBkzE7kwXLn8uOdExwFN/hb29VyZMZmPKjQXNNwB/SDx4sm5nwLeO7Nu8Mi2tuBRY0Gj11rSb0zrEaWwAAgi0LrMUgLDfmwUQX9YLON7mqZU7n1F3SbbcYfHIBtjmAUZVtC4kxFFTw+ynEOGZAFGpQ3Y3vfs/wARRf8AgVm8RtIqpG1esf2bZkAfqp+NtNLocqVputf60yz5v0hYJ/4rBcmy+kOu7PLwtuNtt6EWiHnDLxEcs04kL5c//VawL4Q+tUdzqzTbnb8Yd0gE5XVzPh8MTFcPUV/BouKxFaoN6qZGac7NigRgYNseNwHjd4fiTDNv5+PdS1v0in6tH6zJa0+sVGlBk/uzqaHm9RxTLyXxT8AgmxO7jv0qjxpMb3cGVkyPlx5OpgubfyxMvRF3eloJWrm/9r672c2a3HixOMOF4hyTU0vDLirSIWbwFcbFZdumuwb1N9m3G7Com4Hm7SW2rZfdkD+Kelq0mU+S7tCvM027p6hxAf1g962rtaBARcdyrmDf6d3KWUkCvLgxGo1/NKNFjtx2INRAM7ZceAzEzEZbyT544JmUfCxBOD/8varptabbj8rIH2TeVeXltGrvUWDFhxpTkaP2AVczA2+0ytk+iDj5k7cvv73jaXVZ2N9A5rTrsdvrYSMn62Y1zD8WCb7BXTYtddvV/dxIR/8A6mXw42k8FjCmXa/+uFkz0y4/re/H4UT5+No7IgSanSL1O9a0249Kjembggv4Dv8ADtcf53SUY0rRp315vqbEoXj7TK4ArKTDKmHEmA44/f3u6oME5hqTQW6ZNdc05fWA4OEv+8oyf9UT8LVrti2fUd1ludBjakh85WTI55kxPkPjxenmS1mXqb9j3Vp07Vcc0zLIDPvDFZ0ZVy/NMpLZrg1H6TTKM661IjuMdYM2DbzN5ka01IU5kiH4Y5ftJgtgCcae7ox/18mS0yuvd/rTzna+4gvPZDby5xTJ4/t/zjaQyrvarPWndOO52cljJ3jbWK+4v7HBh+fm4bYyKZOgzJDXadpBeAw0x48QZXLiXeTAf8Ng31xtpqpTXfeOdalM5P7tcO9+8W+2u79MdnV5tpxrT+tCHbOafCkcEUuHfj3bS/aFEaaprc5uC45IlvvAeTyOAWHDl/P7yX0G3Lct12U83OkwW9NucJh9ojJkFHH1wD/D5cUsGynU9qNs4v07pNajdEFnPkzEI9UXl8Ppj4jha+qeLrUOjRXIzjeno5D7wmSU8F4Q8u7P9nh72bhtVzDnVdkF8qP2c2oz6PH0MjYlxHBbbQRXyriRfvWtqi1x1258d2TTHG3OzDQNjikYMpgSKPeDAufLAV3jgWAcd8aNGptJhOTJuRsGI0Zs8C8gH5gXHf6cly4rvsrYV27cmuUul9aEgNiOjOi3IdRByKSYKSqmKpy5WVgjeyuMB3UuyuJK3IadiG2a5hwKa02pfeqJv/hls87LqLGoFQFht5+Tlvq/FA3VFSEG6bINN+Hq4f52VlYJhFNQpNRNOf0caH8oplZ3vpJWIzd3BtD7Qy3/ACiP2VlYIISuhR4EVHj02YksR+5GWS/42qS813Y5VmoSEePWBl1tSNSPOZSFBTXFfReVlZWCA0qA1B2k3XaAjJp7qaZFXcOoqIX4b+Vrhv1RAm7OavIdlP8AWKWTMqO9jx53ZDqLmXx8F/ZTDCysrBZ1BbaplQrEKO2iNQa42yH2hCgs4Y2drqog/R+KXG21FkZcf1WP/OysrBzUiU29eN6UzFbjuDKyuZP0qggIhL++tvLqxNPZrTwF40QoxS1+85CuKP3Y2VlYMLtmLMi7TINomesSniXwzOJVCLd9+P52ju3YUlVW7sR3iZkSBAgXeKgYliKp4pusrKwVPeeom3OvczFaCPHptYpEFtsE74m6iISr6iK4J9w+lpNTY0abWNSawD6tkSb074gB5hNO6SLmJN6bkwTmmNlZWAdbwMxY70jSitt/WDb4OHngqfgmKJh9lLd91SRbnVJ1tFa06rBZXLlzLgTjmZCwxFcQ8PWysrBOLhz6nTKpUTjzVRx+ewxjkTBMqK4i+v6Qh3Km61q3Bqddqd1gSRWHFVmTSBFNBvLg3ouB4Y7lRPH19bKysFw3emOlfCoNOuOOrFYSO2RKmOVSzenzRPwtWd4ZSU7abWiZAwcdqFCaA2nFBQUqjVEIt3PFM6Knjn/NWVglOg5Ehlg9nzFURPFF4s7CvL4+q4WcqtDaPZm8a8xp7kgPslkVf+a2VlYI7T5DTUC+zEaPpAFPjN7zUsyLFVOL1XDdaAN1Sp/SxpnraaEicwyo6aYiIyEVN/jxBjxY7lwsrKwPFdYalzqdExca1HFJHAy5hFDaPLy9U73NPLltjdm7qQ6REc61rNlJNxQNvxVtEPei+ZA3/rLZWVg8oNGp8mjNSpbSuydaWIOJlHJpNSMmAomG7Ff4Y5sLM13bvwY79SnK227ngyXiAm07yRmy3L4d1LKysHu02Dr0sG9VEBqZNXe2mZSSSooqKOGG5LRbZXSWagCMEZNAJuPJkTzAOKc/ysrKwSy5rUWp7Np0qTFbVyPDgNp9pURkFL71T/rja0ae6r11KXTHFNtZVKbFXmVESDM1pqqYovFhvx9flusrKwRluvuU6u1O7lNjhFapkk2nXG8AWQXDgWUEFBRMS3b+fOysrKwf/9k=", style: { width: size, height: size, objectFit: "contain", borderRadius: "4px" } });
      case "virus":
        return /* @__PURE__ */ React.createElement("img", { src: "data:image/png;base64,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", style: { width: size, height: size, objectFit: "contain", borderRadius: "4px" } });
      case "shield":
        return /* @__PURE__ */ React.createElement("img", { src: "data:image/png;base64,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", style: { width: size, height: size, objectFit: "contain", borderRadius: "4px" } });
      case "cardio":
        return /* @__PURE__ */ React.createElement("img", { src: "data:image/png;base64,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", style: { width: size, height: size, objectFit: "contain", display: "block" } })
      case "neuro":
        return /* @__PURE__ */ React.createElement("img", { src: "data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAANEAAAC0CAYAAAAKA8kGAAB9IElEQVR4nO39aZNlWZaehz17OMOd3D3mnDMrax7RQKO70cREgwiAICFIlPSBomCSiaJ+x73xR2Qmo0xmwheZJIqESBEUQKLZIkB1o5tooIGuruqsHCIzIny60zlnT/qw9jn3umdERuQQ6RHVscuywsPjDueeu9dea73rXe9Sf/LzUx61VHrkr5/5iny1b3xVn+Opl1bDjymlR/68v5RSF35+3OOetGJ+Gf2Ep++/37NYX/T7UTDslK96zzxqxcfcBoNCP/N3f7m+0HrU5r38uy9qQL9MKz1bG3+qZa/6Ai6vyyfT83CTrmo9jRf4ovfrSR7o61qXr/dpPdPXffn9/brskVJKz58netbhw/O8/jR/9i+zrvq+Xbkn6j/+/sly4aY8IWR53j3Vk77gy5/ucp6z//ynCd/6k/xp78tVb8DLq7/u5zWXfZRHunIjetJ68iZ8Tu/2l1iP+8z971/mQs/Xem6M6HGm8su+Xb7Iiav27tbjDpHP65Get/V5PdKjkMqnQS+/ipzyuTGix60nhhsvT+WX64rXc29EVx26PHc5w+e8H8/b9X/Va9+TqMvxTHrE7z71Ao/+6+AJ97zZo+69Ui/rRC/Xy/Wl13PjiV4GZc9m/WnLjb6qNbzfE7OJ57BO9HJ99vplD89exHXlnuhJB8zXwYt60dbnrR3BS4/0RZdKQPrs+/bSE71cL9eXXFfuiS6vT1n8S0f0metRjI/PfPxzxk18WjZ5v74o1+5Zrpee6Jd0qaf88+X68stqvhyV5HEn2VOzcR/z/Cddz9OeYE+Kpb98ov7oc2iH7sTPfnq6+PzP5xlivv6480j5vumkiUruz2f9+aR4/1mvJ/YzXbGneRyPcf/fX3qi52D1m/iLbOZ06Xn9F90fMp/15+Xnvlyffymlrj4netH7YR63nnpzqviljEjWpbNw73Uu979c/vvzfh9fhHXlRvRy7dYXDV2SerQBfqqB7BHP7UO7l+uLr+fOiIZ6xtVexlewJBf6LO/Sf1aVvkSi/5icKu7lYpfv5edFxP60rQv5uP7sb+ZlTnTFa9/Ack3vCy2VLhokXDQQtfdf/286G+5LQ7q4vgjA9tx5on69KBX2T1/nkz3Q/gr5GNOXPPCTQrukdh5s6Lbs/y0lyCo0SqVHXsuLcn+vag2o7lM89rk1opfr8WsfiFDpYu6TkliW2oOuLxvkhY1xxRD3i76eC3Tu8vqq+4d6yPeZ7ZNLdaBPVdSVIsY4/KyIu1qOsqQYAT30vXxqw19qCVdKSeiXEjFGkt7LfbIBJZX7XJQixjT83D9G5d89TkvtT9O6vN8uf39Psx+fOyP6ZVtKKbTWw88KBqNCRUxSg/yfQYkRpESKQr1VuQF8YBooQCsUCqUhpiR/V4qUG8hSSpm4m9BKWshjkPfUSuWNkp7csPZyPXE9l57o8nrRY3fvPQBaJZTW0m2ZsqGQ0EkDnpQSIWVDUwqrFEkrdIKks3FkA1Ok7EXExFL2hkl+leVBxTD75/bGCX03ZvZMLzgO+mX3xRf99DuEMz1/RvRlpHGfx9V7Ia3ScCAY1PDlGavFMJLKfybxNsjjnfc7L5MNIeZwTTxSGhCFoW1E73zMcC+zccb0ZXDAl+tR67kzInh0v8yL6pF0f+Exh2VRgrP+Y3jXDd6nD/dSikNYZowe8peYQzDxSglSwqL27o0ipESKiUSQ108RrTVa23wZOZfCoJTCXDU57QVbl/PIFyOcu0z6+wKJ31WuEIIYR67NaFTevEq8ToQUHCEkYvSkpFEqYbRFqYRShqgiCo3W8nerIjEqSAkT+xDQkLQCpUmABwK9we7CN4VCK41SOnv9cJW358rXE3UNXwRg4Uv3w3yVF/MMVg8saJR4oSghW/AB5TxquVyktqVtHV3XkHwSIzIFxigw2Zi0RZcaW1Qow0InRUhp4fovWZuFMgZdWnRhsbbAKoVLgg5GJbmZ0hadvZ7kZS/X06zHIZnpecyJLq+n0Z3b53/tG9mOAnORovmoCOZR7/KoDbZf9ZfXenSrgwZUkpDL4CEqgmvxnaNxjq7rFrFpsKvtvPCRGCN6DwrXOki9xxgCEZQGo4hWvrIQAi74uTY2G4lGG0M5qqkmI4pRvTBFhUkR7z3eS9uELUp0YUkKQkooown5QwW9V4MaPsXj79mn7tcLFmrDl/dESinUL35+9sgHP7WW8xUeZUntKP0m9RX8iIpiWEmBJ6NayuRZMgajFPg41Fq01tgc3pB/F7NxopXkIkphtUH5SIoRmxTWKJJrBao2BkLE+45CG3RINMvzhXGR5D3dtpX8x2iSUrgU5gSP2nQYLxu9vxZTFlTlCFsagtLYyoAtsFaTQmR5dobbtoxGI2xZAAzPDSmyarZg9N3Do+uUtqBdb/DbVoALo4lGoaoCU1XYegSlXZiqJJQGrzWOCMqA0rtDA5Nv+kWmmI4SDga9a62QUztD6v1h039n+c8duvV8M89eiHDuq1j79q7TRQ9ijCGSSDHXS7LnyAgxtixIKeFDhJ5TphNGKbRWoBTee3SIqBApkqJCo3zAr7aErllE17FxHWVlqWzB2ekZy4fHmMS8UoqJLamNHRrovErYFGWfKUUyktMEBACwRYGxEgbWkxG6LFClvWuMmesYsDHSIahebS3amiFsDClRGE3n3dy4FhMCpXfo4EghErpISBEaS6oqzj5+QDIGXZeMDmdUR4eL0ajCKyXey1h8DKQU0FrvEMLeaz6FDahLPyf2mgJ/CdYLbUQqiQfaX0HpXe0jgfJcyAGiirJ3tcDMPjl5LZur+ik/MUVSTFitKYhUKGxMqO0Wtt0irBva5ZrN+dk8+I6QIltjKIqCorRcszXRB1Jw2NJQV5WgbARsStRGY60lTiKRhCcRNBhdiDfqwwxr0FV5V1fFotAGneLcRNCd5/z8nGI6xlSFeEKkclRZRREjZVliUJjCYkYVvnPErsM4J16pC7wyOcR7P282Drc+pnlwjp1OqWazRTmp6XTAVAXBaLoUiFG8rjGaEAL+ESxn8T76YpTyiA7fF4H8+jTh3gttRHDxlOvDicRemBkVsr/EqygSgURMaYCUlZKipkpBUDQy6kXEBE8RFal1+PV60Z0sWT88nadtS6k047LC1mOsLQjIBhtPJwCcnZ1RTydUo5qiKHLuksMcazBlSfCeoBJWIWFWDptSlDzJFgWmsINHVM6ROkfXtKxOzggKpuqI8XhMJBG8xzuHtZa6KMFodGHRIaC9R3UFbtMQm47kOpbtCaNixKwocTHSNt28a47pzlakukKNK8xsuigmI8rSirEnj1IWVVp82KF7+2RY9Zgw7nG/e5HXY43oRajLyJcmmzIOcYWGnAepBMZYQEK1SICU0CoK2BDBRiiSQMAqRGLnSK5DBY9OcUEIJBRn9+9zdv/hXLmACYFKWyaHhzgSqtR0wVNYzWhcsdmsWK/XYiijGVQFvlBgCpTWg1cMSqGLMpMMMn2HHH4GMaJ8/+fJB7ptM4/rDXHdsDw+ZXV6Rte0hG1LOxmTtMIFj3NO8iU09XQsIWNh0FZTWoNVGu8TnQucLpdsq5aqqtDaZraEIcUwd+sNfrNhe3yGORgzuXFjUcxGxBTxMYIpBhZ6D+FfAHn2v6ueQbHnkfrQ7kVeL0Sd6LPW5S9A9b9MkNC7RDdCSkFAB5WwSaEUWBRFiKjOE9qGdrNdhE1D6Fp0DBiYW6MI3nHywYecHj/gaHrA0dE1qrrA1gW2rnAhkdqOzjnO791jeXqGKQtu37mDNWZH9kwJZcQjxphDRr9LwKXBy+ySc6WIPhDFwOdx3bB5eMrJg4ec33/IerliejATACUGilGNKSxlWaK1xseAT5GgFUFzF9TcKItJoLtAipHJ0QFlVWGrEmMMVsmW8N7jnBhk4/x8+/AEv22pb11jdPNoURSa1nvQmoge+pMufz/P8Rn8la0nGtHz7pH2T8Lhz6SFKwa4FIVfhsSuRVIUgOo81kVs09GtNovN6TnNajlXLlBaw6ioKEpB2bbblhLN4eyA6WxGMa1QxrDVEW0gqsSoGqMax+r0hHa9YsYU2zniegOlxRtFUIlkNMnqHTFVSf3Iuoj2MR/lCkoj+VBKqNbhlhtW9x9y+vHHPHjwgKbrqEY10xs3OLpxndm1I0YHU4pRTYzxbus6klZsYwRjiJGFwOhpbkMiKk3Qhun1EWVdYTLAEpPCKE2lFARFt9kyDZHldsNys513D9LdkdHUB1OUVkSj8WaPu4fOB0D2SJe8kko6c/yeD23brwLifqE9ETw61u5/HxUooyEFbFKUKKqQUG1H2m6J22Zx/MlDUtvNg/NUKOp6xKgqKDKatl4v2W631EXJ0fVDbFmgjKGoSqq6xFmD1poqKOpyRBkVbrlhfXbOuh6x2qwx4xpVFXidoWCjBVYvC4ICExJlG6Bx6C4RjSJWFl0WlHVFu205++QBJx99wvnZCa3rOLp9kzfefYeDmzfvTg4P0GUh3LnCorVaFF5ysOA6jDESPrpA8gEV8nbXmnbbEFKk8D5flyUVud2CQDkdE5znoDCUXcWq2c5PP/iIg80RB7dvLToSLiqihqDA6939DwoMjy6DPA8G9FWtpzaiq/JITx43qfd6Z6LgB1oO85QSxIBOAR0CVmlM69g+OF6sj4/RrZtbEqOyQFUlKSWKosBWBSFGmmbLJnTUB1OKQhAwZY3kOsaANmA0EOX+GENdlhRFwcPNhg8++ECAhdmE+mCKHlVYYzG2oCxqKAxOpbup83NiZHu+YXt2Rtu2pMpy7fZNQlWxXq148OE9Prl3j1E94ds/+hF33nqD4mh61xd6EcY1ZEOJRuNCwCcw1lCqkti6hWocYb2du82WzgfatmWz2RCCYzSdUNc1yWiwGltXlDk0jDqiCnM3uTQvSkMZHO58OXfhlFXj8EVFazX10WxRziYEIspolLa0rgOVK0zpYg70dek8fFldwSc9/5fCExmVodaUMmM6Sr6BQAwxOMZlTaUM7uyc008eLJrjk3mZYFpXWCW1pKH5TSsCacgnirpiNBpRlvVecdZgjZVwSye0NoTO0W23rJfnfPTwPsfrJa9ff4Oj1+8wPpgxu3Htbjkdg7WymyI5X2ERW4ct3bxSBh0Dm82GBx/e5xe/+AXXbt4gxsh7773HbDbjO3/2x9x+8/W75cEEV+qFKgyxtJkP19MNYs4FI65pFhPsXAU4fXDCh+/9gvP1ihAjPgbu3LlFUVeSS41H6KpAFfYuRgv3TiXQaqFKg7UwDpO5TlBoQ6HN3MdE6FrCuQKtF2ZcEmLEaY9WgjRGJaWI3l6e19Tgi6yUBFmVvzzlk5430q8KkUJpkhFPFGJEEbFKU2qNxcJ6y+b0dNGcnKI6P58WJRVaEmybpIahFBHwzrPdbmmajtA57tx6hVIVFFiiSkQjBdq+sKmdk+S7aVienXH//n3U0YTvfPttbr32yt3xwQxbleiqWASjQe0MVgNJCKoLpQ3jws6VkTxu3W65/9578nqlZXQ449u/+pO7r/zgW5hRtaAq0SlQVCU+RYzS4oJDwChN0oYUPGNTojrP9mzJ8b1P+PijewQNt994jZuv3Ll77dY1qvGI0XiMskJijYqFjwEVAhGNMQYNC6ulDmYqK4iiZ25CREVLGwK0W+yoQFsr3qcwBPc4zYnnm6nwedYL7YkE8EqyaRLE4LEJrFbYEFBNg1tviZvtwp0v56b1TIqK2ppM7/F472ldh3NOfm5b2raFKDSfbrMlOU8snXDOtMEDFELzIQXW5+c0XUvrHKPDGW/cuc2t11+9G41aBAWhMEStSVphkHyobxvXRhO1Iim1UMYwiofzW0rRdR3379/n/ocfcOut1/mV3/z1u+/84LuLWEhuZXVC2QJKqQERgb62pDXKGHwrn+ns/n3O7z+knI754a/+yt36cMbBzeuMrh8tsAqslAVCCBICa4WNFpMSwcnrpSC0IlWXi9JqObCajrDu5oUyuOjn7XpN0mphZlMKa+lad8EbwS58exEKrU+7BiN6UQtgRheE4CBErIISBduOsF4vwnqFW24oUppP0diywmhNaBuapsGnyMnZKSHuqEAhBILz2KTQFslRtKYejyiqimgM0Wp0WaAThE3D5vScbXAc3LrB9VduU8zGd51mkbRCFRY15FCCfPUGlJADADEiPG5hRyXWj+dmXKFHFbffeI0/+xd+nbe/8y1aCxSKoixJSg2UJaUFjYzBkXJdK3aezWazOL3/cN5st5SHk7vXb93k2u3bC0YlKUkIrHLYFoGoTb6nGmLChoSOHpUghLjwKS3QimAUwRoidoHXBOfnOiaUC3N3do5OLOxkRlKJVKgMNugB7NHp+Ud9n3a98DmRoNnCNC2UpUqRsN7QHJ8s/Pn53HSOidGYGElBGtIa79lsNmy3W7xKmLJgPBkzmcyo6xKA0Dl82xGdJ7Qd7bahdR3lqKQoa+yoonUtrmk5+fghWmsOb93g+s0bVNPxXW/UQhuNGQnVZ2jvDhGvc+6mFVoZXAgYo7GqlPZwIK6hTYHx0QHffvtHfPP7373rSrNAKcrxiJAkL0MpfBTAZNBmCBHvPM1yvdicns+D89y6devu9NrhwtYVoVCk6IlGobWEbxqgVwnKhWCthGeorUHFRNJqkVJObCLYwkKZsAcTus32rnJxbkKic2Ge1husLhflbMI2SXvgvgHBHpKaXnxD+pQRvWgeyRMxRpPawPZ8STw+WbiTs3narEldhy8sUYP3kc12iwuepBVlVTIZjZnduEExqimrEcpKdyhAch2+c7j1Cn22ZLtas92u6bqOKpR0XcfDkzO2qy2vv/0Or731Jub6ISFJAbKoSmJM+OCFa2YNSmuSTmB7UREwysrG0hrTyXMb7+hi4PYbr/HNH3xXeG8qMplMUNqwbh2m7JWCcvOdz/C1D3TLzaI7Xc7VtuP2wRGzwyPUeERQ4nGM1lgUhAQ+G43O7ec6DdQpjCYi9pWwwnwPAeUjVdKLpNUiWL0wowpjPLg0L6Oh6fw8rrYoWyx0XTAQwPfgud4b+Rc8NXruuHMpU+gVvbvXj6WGDJSfEChCpDs+Xaw++hi13s4nQGw6Vg8fslWKZBLb4PAhMJ4dcP3oBrPrR9h6hK5ritH4riqErax0ym0N1ZxmSzUZ3S1mE+zp2fzhx5+wOjnBnmuccxyfnXDt9qscvXobPakJwd01k3phrMEHjzKG0grvLcVEiIGgIypqaUlAU2iDbztsUnjnKEIQjlxpef2NNyimk7tRpUVRliJ6ohSjshruQ6GN9BZ1Du08yoWFb9q5azs0SkiuSu5V0ruOWryAKcSYO2PlrsaUpMU88wshDWRYpRTBB0LTLXQR50prQqUW1ahGm0SgpdTABjauIzVbTGWxEZH2inr4bj8lDbb39/0+MPg0H+9581x2gB2/4As8iurxeR6vMs0lqTjwqnTKRbqYiAm0KXApZM0BQZ2U99RaUXcdD//k/cXphx/N1ydn3Dg8IOmCdrvmo48+omkaKAx6OuL1d97itdffxGZiJeOaZIu7vlALbQFlQRtiAkPEVIkuhYWd3qAc1Vyvq/kfffKAj997jxgj0xs3+MaPvsf09s27alQSiQulkFM9KmIImeKTe5fIxV/ILeIQvMdajV9uKLSGJtBst9y8dpOjazcARTKGpA0UZo+tDQTpe9IxoTpPcl5C0c4RSVSTEVSF5Dy5jTyEiKYn3IoWg7KG4BNRK9DyfQQf5HEh4duWUVFCCott40ghzVNl7uqiWBRWE3wCpRamqokhCHO8a+br9Rl1pRemLNFFQdSJ0GtEYPaK4QmVwoWZSdHkiCD3dQkheLfJLivHftH1NIyEJ60r90RJ5dpOf+oAAjVllRwUznvQRrxSiNS2wAD+9JQP/uRPFqw28zoK3Nssl5ytN3SrFcvVGe+9/yHf/uH3eeub3+DW668yPTwCa4hVibLmbjRpEft+il4cRGuwZmF0hSLQhYAd1wvcjJu378x//5/+/4gKfvwXfp3RbHqXyi6C1ah8RMYQ5IQHQtyJjiilpD08JpIHdCSlQIhJ2jBCWjRNMzcoRuMx2pi7SasFWg2nb8rdsn3vU4oRgujXBRcWTdPMU0qMJhOq6RhTFncpzAIENCGK2EnIbeqatMi094UnEmLO15AC9lBC6Pyi3Tbz4Dy2LO5aaxcYPQwTAwgmLZJKgMakgpFW883xCfXBwaKeGLwW7YdkLEkpInHoS+o3Ym9Ifet6n0f1hGLYscWfl36kr8yInvZA6B93IUy7lHCqJH3KSUlBMmZ1HEXExojuIu35Gef37i3cdjs/qCum0wmVKTg7PuGTpuX+8Qk/+/BDjm5c453vfItvfPc72FEFSRM1ECKd9/OyLgCPEdLnIsZI1BqdMlKlch4TE8parh0eoZTi+u2bvPHO29TTCckoUDFHR5EU0nDChdwqIADDDpZPyaOiEmUf56nREDzbzSa3U0wzG2JvxUTqmwoTxCiwND5ADgO999iyYDKZYKpSDCh356YYiCHhfcB3bpGcx5Lm5UhaxpVVCxUyCIMmKI32kVIbnGvZbrcoBWVp57YwRM2i/xLFMyiS1oDBVnGhnabZNPPu+Jy4cdQHBwtbV3Qh0WmPsQUhd8amrALbqxTpJF3JOc4cDGafI2meA1DiuUDnhv4aZIOZuDtyYlalKY2RZrCgqJXCLZe0D08Wqu3mN69dZ1wWlDFRGUnSLYqTkxNu3rnN93/lJ7zxzXcoJyO64HMPkcpfQsQ17Vx4oEEKjcYskpG6icpdp6UyxOAXWpn5cdty8/Yr/Mpv/iqTwwOiNcSsWKpUDuHYdX/2aj89K0IDKWZvohTEAC7IgZFrVUVdUdaS9/SdpL0qKsgG6z1J8oHoA75pF77t5tZaRqWwsnvmeLy02UIIC9918267wfiIcjXFZDQ3pQWjFoEk4WhK6KQWySSa9WbetS11XQssnxIpJEIGIdLgGUQ3T2uN1ZGjesTZydl8c7aC1jG+eWNRjAoiSkAhlYjZgCIXD2OdwZcLYzLh4iia58CQnpkRPfWU52xEKu50EkiKoHetDCEjQjpGUtPijk8XZtPMj8oKWwgBFAMhRIzWFEXBeDbluz/5Ee9851sUswmtD0SlKMuC4D24gCGRvCeqiKdDGTtPRQHWEGxaaGvQyUJKkhx3gQcff8LN27d47Rtvw6i8G0iLqBS2D616ieAAvusWWmuU0QsJnXZxfgLxLCEIrO0kXNLGUFWVgBGDJLCEsb0mSoiSB6WYiN5DTPhti3eO6WgsBpTS3aBYpBj2JrqCUonC6gXGok0xD9stPjXomNBlMcdKV22v3W2TmqfU0ZycC+RdVPjcGZusBlsQgbCnCa5I8l0CFYapKQm+ZXN8Mk86Mbp1Y1HUFd61mKLKPMdd2CuvISCIpz9Qd1vGpF3kEr6kAX1Zbt1zhc4NYRwMEGtviK5rmKqCOiW65fkiLlfz0nsKY6V5TUVMWWAVdLScn58TYuTG7ZuMjw6IhSZFJXR/rYTguXak6ClLS+y5d9YQY5gTS3L5aRFlwy5S085PPv6E9XrNW9/8BraqBezQVir5KNnoIZJ8WAQX8d7Nq6q6i0o7LYIoJ3Xqj++cz3jnaNtWTvCiwAUvmnNJeo8G6D0DCSlEiAk6vyAlgvdzQhwKuYEk4ZIiv5+EpFL31FRFSYqRzfmKbtXgm5aqrjFlMTdGRF1Ikj+1TcP2wSm6KqAeSw+RUnMjEPgCsnfoa0woDGph0fOUAkYpamvpSMSmmbdn5+g4WpRVRVQeb3ashv1wX2UkcT//GfbFc1SD+dJG9EU/y+55cejJ3/uNECiBQkGpC+oQUasN8WyJ2m4xSuJnW45RKlNWXKDdbNms1hzduM7R9WsEqzKzW76FXlUndS2b5YrGKGLyaGUpxzVWG7CBEDSRhA5pQUjz7ckZDz+5z3R6wBtvvkmw+m5MLLQSJDGEQAwBFeKibdt514hBqKKc57deqJQFUzQSDsWEDgliXPjOzUPn0NaK9wkBa03e/IBKgyHEmFAhokNaqODnruvAuwG5CzHejUYtFAm1X4jNgISKaaGIc5SoHG03a5qmoSxLKlthVNbJy89Zb7ecnhwzPTokjkeEFCiN5D8p8xa1yvLHUbyQQfTzsAofHSF56tEYU1e4rpvHVcQmFqqAZCOpKHrenuwPuc7HMuyepzGZV+6J9ie2ieHsDEgTCa1nhKY7PWP5wQeLcHo2tz5gCoOpSlJhJLlPia7r2K43dF3H7dfvUI1HJKUyjUU0CoR1q+l8YPXwhNa3KJUYjSbMlKIcTzBK4/uGuSSFzO35CkLk2s0bmKrGKbBVKcbrA8H5RRZnnPtti2/lZM9f9DwXFxfS+p2/fUHqFtGHefJh0FWQlo7slfvQb0g8xICUjwsV01wn2G5bUgwUVSUlgKzK02Ud735kopH7vFCJubxepK5rTjvH6f2Hkncqi9UaozQGRQiBxnWcr5YAzA4PqJWSTR/jnJSycKTkQfn1SSnNyRB2VOBiwCINj5WxtMHP27Nzitm1hU2KYAJaW6LejaLpRzmmfO29p+rT5ucBncvDB9QAv34VkryPms8jP+Q/PlVk28XBPgkLW1jSidgGptpw/N4HCx6ewPlyvnnwkLqwbEJgdv2A0aTGbRustbi2Y7lcMplMmExmGF2QlCFGKYgpFJ1z2KQY2ZLkAj/76U85ODjg29++xmw8gb6GEsM8oShsMQ+No7AWleDajSNxj0bTOYcCCm1RSuN9N/dth3cOg2JUSJu2yly0EARA6GtHKkSi91gUXdvivacsy6ytEO8Sw0I8iRqAChXiIoWITsxVUiQX8J0TKpAkWoQYSMqi+5pUfv/oPSpCqY0oHXmPQTGbzfjZz37GBx98wM3rt7h16xZFXTIejQkhoJsGM6pAK+5//An1csTs6JDx0QE2qrkprPD/jEYXZp4UxBAzJ9bhkiOoIEpHGrmuqCCqeXNyhp5NFsqMpL6mpVNYqFwandta+oxr8FR9SLcn3v/I/djnWF8y9/ms17dXqWXdFwyN1oMhaystBjYkCqVoHp7CZk3RdnMTEi4lzh4c4/DYUcHIB3RRoGPCtSIOPx6PJebXmhil8i4FVCkeqiCollGK6XjCrVfucHBwgLUWpQ0h3xNr7Vx78JLnMJlMKKtqKJjaLNgYnV8Q4lwncM4TW0dZlkNdKN/jOSGBVguU5DXEtNAxzftaj855hVIKlJoLsp4W5NpQCkGYBjHNc4+1ABk+oLS0m/djVEAOqAgkH9CAVXqhVJr7zoEPaGXpQsPZaokuLG9+4x1ef+ttrl+/js4du6Ut6LqOtm1xzhE6af1Yny/ZbDaMZwdMDg/m5WRECFnTrhCybUrSDl9NxBidc2y3W2YzS12WpNahYphv1yu0VQtbWDon+nalMUQXh9pb75E0vf3tEN2rXkM4d2XGFGXyQZsiSknvSggBExO285x9cn9hl+t5EQKGgA6Jh8f3qSZjUahRCasFvWo3W5TRTA9mWGul4hCzwkJMRJTo1PmAdy0QuXbjOq++9hrj2ZRkNMru9fskIIl2nPcd04MJdlQJrJsTXhVZBCdJvY4JtxWp4MlojO4FuqJoaScYGgZVTAtCnKeUCJ0j+rDT7da6BxLmOiSplWVDiyHO5RAWKlHygeg8pi6xesih5lrHDBSqRabZLEjMVZB8K3SO5Dyr9YqoDa+98w6za0dMjw6xdSnNiTHexVrKlKiimicXSE1Ht23otg3BebrztRBgU0DXJUEXKKOIOgv2G81oNELHxHa9wXcCoJRliTEKFTVN28zDeo0q1KKsSqlPJRBfZoatkhH0wXKi2v/Xq1tXnxNlRrNKaji9dIpoH2hPThds1nPTtugQSNGDEij04OiQw8NDbFlilab1UmOxVUk5qgfZKYHZRIhRZU8UOukbUkpx4/YtJgczobwo8S6iFZJzqCzx62JgNpYW6kiCEOe4IF4hiDfwPtButxAjVVHs6jvZk8SU5kDvoeYqsxe89xI2KYXJheWYGdnAnJRDP5EtEqg8yW4KnRPOXV2hUfghh0pzQeNyx2uIc++8wMP5ecvzc7brNePZlINrR5TjEU4nfKHRZXFXKRYuRqw2mGRQIc51VYln2baEtmN1viR0js25p2RKXeXPnbl5Sgl/z8ymVFVF0zS0bUuMkaqqUCTGxrJqtnN3FqmuHS2sMTjn5FDI+2Q//3me2ArA1YZzAGiDT1KxFkTBUycN2w2rT+5jO49xHpWCCC5aw9G1a9y8cRtrSypbCCmy7VBAWY3AFlLJV0aq+fufMUR8I413yhoODq+BNgTA2GI3LDgXTpN3xOhRBrRVOB2kWEsium5uknTIxpBw2wbfOaqc4LsYIQlbQHg+AHqu9kACYhKuW4wURTHkpirtTcCLov9NTx3KH6cHU/qCbv87Ibz2ybmfKxTKk3OwSPCBpmnouo7J0QHT6RRbVYMakS2Ku6ooF0GBzYYQQ1zkgGqudZaY1IqJTqxWKxon4i+qMBSjGm1N1liCAJRFgS0KMJpmvRFp5qyBXhpN0Ubcupkr22CxC2XlMOv2YO98/+T/+6LZc2BMFzzR1z2lLiFgQgoI8TFGigQmBjZnZ4vNg4dzs9pgC4uui6ynDQfXrnNwcERlK1RSuHZLu9mKbtqoGk4pk8B7KWaicx2nC7Rb2UBFXWFHFS4JmGEKKwzmlMM1rQfWQVlX2QuJc7Mpv142hBQCzWYLIYryaA4jez4eSMuCTRlyz7lSjBHn3CBILw/MDOshnc7DitlrVUmJECJd1124VoV40RB2xc8YAhaDURrnOtbrNcF7qrpmdniAKaz0ZRkthV6t6DqXkbXM24vCs1P5cYk0T6ogJocd19gGXNvB+QqjpIkxKAagoEuZuWEt1XiEa1rabYOpR6gUGWtN4wPh9HyuE5jD6cKTSFnUv1/7DX3A82dE8MUN6WmpF5fHwg/FMwk5BDlqtpzdu097ek7RtpjrhwAEEfZgNjmgqMpclJTWbtd22Fp+57NAo4QVPfIY8T6gO0e7bXDeMzqcgVIEpTFG43sGl1JE7yQ3CbLJ61IkeemBjwg6JGIUaDo4j2taYUxYS9d1UOaxJ71wvYKYPCSV2RlioCGIxvW+N5F5rvm7SDEXaftJejvOnHdOWh6UzqievEb/egZFyNcgHapSzyqNlbBMqQy6aEpTYqIm+jg3MUh/FYg8MYmo1MIru1AS9xJSmDurUKOSWiva1YbYdFAIE0FZjcvTItoUUDF7Ni063bFztFraOUolh2jTdXRagA41G2fprUhSelBZBeQ65WY8n7Sfr9MjDTmR0ngcRhtct2X18D5hu+X6ZExdlHRdy6ZpMMYwzTmMi3nzZfi40BqjtUzK1kbCsRhyvUcRnCdmdImUhvCp37zee5HM0oa2a1FKE0PAtR11WUm9Qmlc8GR0QbxdRu9iCFRFKY/pHGVhB0+Fzt5HCW8vkf8ecqNb2sGwIfPPxOjy89mrm0R5TnQeH0KGhjNsrnRmhEe0MUDCkAd9eTFYWxRZGqxEFUa8q9akEHDeC+NAq3noPGhFTCK6r6xBmbAARYBFMgpV2nnqPNpaqqrCNS0ht2RoU2FQ+Hxi9tB3co7YOYgJ17RU44mEtylgSYRtO/erc0azcR5ipi54n6FGpCLPgyu6YETPwgM97jUTmSqSdKYmRLSK+NjRNKuFjn4+LUtmozG+k3YEUEyrMUVRoMcFbXQY52k3kqhaa0ldRzGqiK6TECllsCBGCh9YNRu6ZkNZlhRo0WawslG1kdPcd44yWcmfVi2lKUEbtLaErcNqTQxiQCmC8tC1regSKHlNowTESCFSaE3ISkTGWozRRBfxPgpaGBMmgyqBBMbgk0elvgYi+ZBV0m6ho2xE37W4GJhOp6gsCJkA33YUPffQC2SsTCI4T7JQ1hXW2nysx2EgWcxhbMxvqZSi7ZwYowKtmavcrKeMXRCDCJhkgm3QipgUCU3M4jEhCKDTDw3AdeiQsNrSdmuMtfjWZw2KRKGkx6pdr7FNw8iOCT4KcoqR4rdW0n+WBpL3Y9ezqg/trytH56wtSd7hnKfQGp0c7WZJaBvKPKaRGHEuoLVhMplQGMvGCc0lZWRLKse5c9KLdzJ9w0VGz2I+vaUyr6XOkzcx7Aw+gdRxQtpxuLJ3NlG6QFW/4UIgek9wHkLcUfUzU1vnfEKRMkQr19NzzELnpGaVZbj6Cd/7RMxhA8bMDHeO0Er7us3ziYbr7zdW3OVjA0KoZXqrzgKUPc9uP/LYL06mlCiNxaeIazuSD9iqnGutUSniYpz38HbPtIgkQsrNgkloR/2oTUUfxufDISZCF/Da7WnmBVQKpK2brx8eU1bVoiotAc1elpc18SLmOQC5r9yIkg+50BopjIG1Y3tyDk6S+RgjTduQQqCajQQWVUo00UIkdU7qJHvTFnp6zyCfG6Mwj3MSH0IY6jEhw88qCtEo5Rg+ZkZ2n7T3hUx5XT0YkIoe7zvadov3HTAZPluMUUZE5ukOGjGugJzgBmi7ThL/aIeGvb5dQilhRPfJdMoMB9d2w+eoquxV2PP6uZaSsuEKACJ51Y4XJ/8+eD/2uGhxd8QrrUUyrHNChNUajEElqWGJIaahezclGQjWHz6xB2oIO+pSkraOEAKpc1gFydqhYFxajUuOzfkKdbjGFkeihhT8MLGvL0w/D+vKjShGj1aKQhuUC6wenCy6s9V8bEvqohyUecbTCePxGBcDxius1bi8AX3nMHW56xrtz6xcEI0hisfYM6KerLm/+pO8P0V7LltvRMQ0IFUxw846CKjg226AlWUT9kZkdvUqrYbnivcThA8XCEbau6POnkJ2nBRsU5IDI3/W6ISuY4tSJkAYO3hspUQEpd/UMlgsycCxlMQTxERMQfKcRzT+9ciiyQALPVOCCK0nmoi2SebVDp9HjMJ7Cc1ilFA1hUhCEaO0fxMiKj82NB2+9RRGEasStHx3CoNNirht5835isl0stAq36t8MCqEVHzVFRr4Gozos04LhSjP6CRhULdcs/r4AboLjEuZ7LZarbDWMh5LLhSC1ItsskPh1DmHLQvxDDkjH8bLp5yIp1zY7GTsorQ97PTmLhI9kZArb3Zt5OSO+TEDSTS3PuADruvQSUiziUBKWhr1oh54Xjqp/Dt53RTTLkzzwiIYDDYvTQ7hsoxXX5QtrJVQzhjQe2TVtIfixZij1QR9obZnEsgThpJ/P9ql9xS6vxf52mjFE6F09pZCxHHRDehh6BxdLmLLiM6AMkoEZnPITEwoH8E5fNfhNx3eGmztUFYAEQgEH/CbBrPeUAag6JniaWc4UT0PuMLVe6L+i9ch0a63i7DezquUCM5xfnJGSonDa0dUVSXuH/qWAwptWG22uEaGAEeXO1eTkD77sZODAYUw1FX603LYPDFJ+3bkgqHsAyNqCE3EK0jeFAfqjer7YkQV5MKmBE1KUfpjQvZynYRm0Xu0VqJzp3cKqSDZQ3QOn7lrgMj0qvw4dvlZyp5yGK25x4YGROlHqcx4kL/HHDbmFokhhCWIP7fG0LQdm+VKamkJyrIkZYa30uK1vQ90WT22KArhKabcQAiDh1NBDh/XdXTbDecPTojB0aZAMS4lcogQvQik1E4m/FkqSmMJOhGCgCzikdTzCXF/nSupSAoCDjTnZ4R1g24c6/WKzjXMDg4GUcWu68DkWaAhoXVkvVqJ7C+5NhLjQFYcTuUMJfvOyWvAkC+pPlTSSrQccgt3X2S9kJjv1WBCCKikBGqWVogcUmXDMv3Gzn1J+ZpUkNdRPtI2Lavzc9q2pQKKosCp3XVrrXE5BHVtNyCQfYdsDwoMXLo9T7RvRJDBkRxOphh2LRLZW/W5E/2Evuw5QmjZnq/YLFdiHBF8JYBGjBFtxZi264azk1PatmVcj1BEdAy5dV5yWCl2e2Ln6dZbmuVa+r+spVWRUZxiq1Lg+aAwSclYzNZB7VCFyVcaBSndG3V5levKjchaCzHiN1vWx2d0Z0ti0xJcx2g8ZjSdDP0oUpj0WG2wUdG2jSiZ5tYDlcMwqW2qHELkPOdSzK73QiDVn5I5OpCwboeQDZuTrJGQ+serofbS03L2nwcMoEKMErKmHBL1IMHqfElIEZNDVbq0Qxu1kSZC5weajAif7owoIRHZvhHtv/d+ON1/1n7r9Z7M9J8315IIeQBXTKzXa+nRagTC35otNs+EBfBJrm19vub04bEcVgeHkifmniy0EnHJEEit1Ih809Juttw4uiaqrqXUmarxSMoOyTAicda087DdEkZ2oUwlTYD5oHhe1pMn5T0RiP9yF9C4jpFS4D1+u+H85JhJhMlkJJyuUvhszjmc9yQr9PzoZQTJJqvjeO+xMRJ9QgWFrQQI0FrTNQ0aqZ/4tmN28wbee6qyQKW4y4WiFC2FxuMJzqFiQGNQokM8CIdYjegzRAEtCJGmaWQj55xL8iAgI3vee5GfCoHtes3ZySmdb5lMJthC431HigodJJzz2SsE7+k6OVS0LgnBYW3f9iCsd5W5Tv31Qb7OnjLTHzC9d1Yqh6Ed1tpBN6EPb0MInJ+fs1wuqeuaG9cOZTZTPoB8igMq6pzHuxZrFEpZNqs15yenHF6/JvJbWg8F2NS2LE9OWZ2cMR2NuX50nXI8whyMSYUR4KgsKYJm3WwpteH++x/OZ+Wb2FG9SEG8sX9OvBA8B57IGIPKRcfQdCgfsdZQlnbQQ7DWovMs0RCCSDc1jvVqxfn5OUfXrgES7hW5zdi1nZy0cS/ZziFSoY14hSxekmS4A7nHFpA8w6BwIWCznkEG6LJAiKj0GLUzEMivaQKq18dVmuTlCzfZWzgnEHxZV7x1+JZw0VKiy8hhikGKs3lKxXK5ZFKPmEwmAodno5SmO3WBoKlT/zkQSlMWQhn+HSW5YgY2VIq4dktRFDRNm7mDiePjY0IIHExn1HUt3EG9g70DCUrh6lW2oC5KmskU5wLkCXynD4+Fj2cLAHzTsjo7ZXl8io6Ja4dHmMxZtFoEKlWueZHzHhU6XIhsTk8ZTWvMuCb0uRDPBa5w9UYkGzMQO7fYnC/nIQRsXYkxpIgtpAXbZ6g5GUXnOtrzJWfHJ5yeHjM7nBKTxzsvw+uUyaNABLGTYmDCu1a4awIXCbweNX18k3IRUGVqDjnfIHuXmDcRMQ50neA83bZhu95InuCDjCSPPQLWz4zNqFtG+GxZclhV1LXMF3JOmAE9dN40Dc55zk9O+eSTT3jl9h2uX7+e316Ip9ba3Hu0u5+XIwfVG8wQ5qnhPYZGwJhYrTfiMULgwYMHdF3H0dER09yIaMteSTXnUFqhdNZ6qCyjqiZOZzKFL0t/ee8JbWATVixPTjk9PkHHwLiomI0nuQYneyBlBFErm2t7HSozGIzzrE9O5/bajGo0WvRkH6WtILBXvK7ciFQW61idLtmeLamVHljFKVNwvPeoPB4+ZjGS5dkZp+dnqHyKh5z79Am1zoTMocofZMRi33YwIGc5/heFod0J3m/FPhySE30PZMgC8m3TsF6vWa/XVFUlIVsoBMoOMedYPVsASGSWgfTZON+Kp9RaumEh11IECu5pRJv1WljPxuBjBK8yZUnuS+8lelRwQB3ZQdcppSFETEFyuOQDVhuiD7jQ8fDhQ5bLJbdv3+ZwdiBem1zvSblzNXMR9z2BzvUtW1aUUR4XYxx6h3zTsjZLvHNEE4dOVx8DJUhe3IVhR6YkheHSFuiuoV0uCast5prMhU+avYPhateVG5HkEI7zhw9w2y0Hoxpd2JwUg+/aYeM2rmWzaXCN1CKuXbvGZDbGlBIu9LB1jBGlzUDvIaNz+4zp/j+dqcGph6+jSAmmXLhV+aROPuxV5ZNU8PNUvf6/lKRWEsoSnUNFlRJKKwJePB8mCznqi4l/9g49baguSuxEw81bECLr9ZpmtaYsS8kzip3U135HLMhn8Pkw6UPJfQZ3jFGAmAyMtKFBa82HH37I2dkZr732GkdHRwNBd4D7yQClUfTFmv49Y+YbKa0xpR3IOKYsSF7qfjev32B9dsr5wxO6VkoNRV1h64oqSn4akUJ4oif4RsqksD6i2g7lnMyYiolA7EtkV7qu1ohUREXwTcfJR5+gXaQ8zG3DSqFJaGPzxpdNXWhDNZ4wrmrKsmS5XdI0zdDUBj0ilj1Rbt7asQRyDch5PKCVRccdtyumRFQZqu5hbiUi9SqLqodcG+pbndu2FeF8JC8bhdEF7prwx6SVo69d9d7Rml34pdPuOk2CSlv0dIZNinv37tE1LV3bYjIyFjo3KKtaLQRQlbhwSIScq/WeKWXenkLkqbTWrNdrfvazn7FcLnn33Xe5devWUAIQxng+ZLQYCfswukFmHPW1LaMHdaGUEqawYuhReI+TqmRU1SxPTtlutyw3a8mLMHmOU1ZCTYIU6pgojWZqS0xI0HlsPcqHZF8Zv9p1pUakkqTxy9Vq8clH9+bjTDgdIMwccuiE0PfLEpt28HSMkamZ0jkZm2IynWe/RuLzSdzH6C6LJHZdR6EVES8QtJK8JWk1QN4pi6jozDeLe0TUlE9+QXHT4IW6XBTVhUU7IBn6RjalFImIjy5z4QJZivpi0TdGYsicuRCpq4rxaMTJ6SkhRaaHBxhnL3TDdiBuoveUQ9E07ug+e+/ThYAPgVW75cMPP+TnP/853/jGN3jzzTeHGtCgK95zQ9mrK/VtGyGA0YLaFRad+6VSRguN1nkyeYdrWlKKTKdTSmNZrVacLE/YbDbYZORxhcqCk3LBVmkqbaEwdE0zX5+dM6pHC11Z6ZX6025EOoGNCbfcsDw55mB6JCFXzIOFncsziXdhSuzVX7Rs+NKWgwfqiaUhQ849QNA31vWqNV0jG92UBV5Hoadker0I6e9qLrYodj1P+YTV1mKCbMzxeMxoNKIoBHbvjVQpRbJaTtkUpclMXfzSBxH/mPA9WBFjRhQB1I6loDWnp6fEs1NeN4ZqPJLPmsMi2NWzhlxhKJju7ofJHbBN09B2HT9770/4g3/5L3j33Xf5wfe+PxxCRVHIYZDVXeXwyJ6yLzwbTXBBqE35fUMIuS3DDvQfHyUs68NYgijWVuMRVbch+g7XNdJVm6/bWI0pDORrsBGWy7VIQY8nohDVoxJXvOzTFq0eR614nMb201AxVILSBz7+2R9zOBrTuYauK6iqQqBtpQlJYGSVRAq4Z/pG0xcH4WB6OLALgosoZYQCg2wsrTJrwBqapmG1WnHD3ZC6BTorBuU2Aa3BSKLetw0M15tRrj4kMlozKisODg6YzsZ8/PHHrNZrprOZbP6YWzkyzQalhCTQU3MQA+9DsEGwXqkMb3d0rhEPGjrabstHH33EcnXGK6+8ItCzsRcGKfusad03K/aHSu9Bu04Y4Ofn5zy4f8zPf/EeRVHxxmtvMhvPMDKamei8UGt6WpCgNtLP0+dDIQ1wuQ4JZZN4JAtJu/x5e++YRevzlI9kLGVdcTCa0G5lhq6taspCQ9SYVILfgUAqJkZJszlezl35gNFsuvA6Rw9PtYOf3bpaTwSEtmF1epr5VA1tW1LXpYTWxsr4EZV27QRJYvAhPOlrJr3mWl5qz5v4nMD3wMNyuZRwriqF+dxvjBxj96FEIBF89gT9S/es5fzFKqWoq0pGQSrFdrtltRKKTFVVMqgsykgYpbJMbl/Fh6HO1Pc6ee+JeyBGyFpt2+2Wrus4Pj7mk08+4aP3P2A6nTIdT4a8KJeNB0bGQB3KhVTn3KC2s1qtODk5Yb11fPe7b/LanVd27Gsj9JrBq7Pzcj2zQW5FkpxLKTBGuIRFJrzmz6j2PEVKu9eJGQutqhG+c2w2Dev1kmRlIIHLIIg2MnUwRiHjWufx50vccom5dkjYm2V1VevK0TmA09NTShi+5MlkRCwMUUV0yrKyAUiCpmnFwB/TXHR5vSHF7DW01nRdh9GKsiyp65rNZiNEyaqkMqJAo7XeUXpSvGCE/evlNxhORvl7oNCG6WiMQbFan3OQ61aJgE+RIgZslFAzKilW9hGAyzBzyC3iIAVb13V472kbkUVermXT379/n81mw8nJCePxmIODA0YjKcRW4xFlWWKrcldDSmkIJeuUGHnpd3LOcWtzh3sfPWA2mwkgYCTHSzpBYBA/2SfSDkYQdxB2L0BSqlo+QMiQez64+iUOTQ+5X88o0VpL2LcWkEGlGmNy+BsdIXpigJTFbDZnyznHpxwczRb7Q8aual25ERlj2CxXVBSyaXolHisCfjbJKSvwb590qmEiteZSIp3XPlNB/l2+sIODA9brtSSzZYEyhRT09gGNnptG2jGk9zbRhRmiUbyHyuyA09NTURDVmuVySTWS5N/6Xefq/vCuvhWi58hdJr2GEHh4csz777/PBx98QAiBo6Mjbt68yXg25dXbdxhNJxweHg7tIr1n6g+R/j73RtVv7K7r+OjD+8I/7FG8/Pj+sUP3a77e3aEieeY2F2mrUS25qdLELIkk35s8fv++qijMb/Fk3XBfmralaJrczh6pihKfPH2HmMoAiW9bmuU5B61HmSvfwldvRCrBZrOhSgVthqq3263wsGJC6TIzkHfKpD1qFJPQVh5VdOs9hQ8dqIjLG7Sua5RSwgkbj7CltCaLgDvQh1xkJvhebegy0gXSP+S7bkDzPvnkE65du4YpC5qmEZksZynczoj6EGcorA61ohyWktg2Lev1mk/u3+fDDz/k+PiY0WTGG2+9w/Xr17l+/TrTgxk3rh9RlLk5by+kHfTr9mpIl/PfEAIHhzcyP06a4kLK0l1ZF2L/GfuiLikl2lam55WlgDtD31ZiYDXEvk6Vn6tU1gxP0irhEIhWqUTXNXRbaXlQ2kEMBJUyLUoa+0xGLOO6IWwa9Lj+YhvvK1xXbkT9aXu23KC7ZggRqlKm3ulcR9FDi0DOIXIffz/TCC5SXnpvEaPA3n3xUWuNtZb1es21zg2F2/2Tt89XArvK/9CIt0eh0UQZEZQFFHsE7d69e0wOZhhjaNt2KPL2m9mqXSu7Sgyeo0f2VqsVx8ennJ2fS1NiVfLON9/ltTde55VXXmE8HsthYA3WWqzaeY7LDOfeG+0z1/sVI9gqUY1GpCCHSQ9ve++Fqd2LJO69Xs8VbJqGzWZzwbBSjCitBzpRn6fpnCYNlxZB8k81sNx9VnNViNfx3uOJaKwIoISIigoTITbd3G8abJL5SFe5ngsjUkpxenrKWEOR0uCJqCJRhUHeqd+AwqHrEwh94YQcNlAv07RXM+ofNxqNODs74/z8HJQZQrRQhAuvdTmcG7pZe8+kBJaOwbPZrFEKmmbL++//gsnBlOs3b5Ci9AkV2YgKbURDLRuR1QbXdmy3W8l5Hj5gvV5ji4rxeMy3vvsdbmfB/dF0QlWO0NZkWF9AAHOpsxWAzNAwfX1Kyzyh/Q2vNKgQRCg2iYe01g6wuhRlL9JrUpIDwbUNzWbNdrumqgoigRg9IWSP3h9K/fPYs6L+YJIe4IFF4tqW9fKc2ajGFKXMoFKREHwOExM6KFQQSpQK/vETGL/GdeVG1G/w1WqFLkWBdLPZYHRmRNs6C9yLR7FZ9F7nSrnC7IUKe+EGuzDJZzWe/rQuy5K2bTk+Pqaqx4MnsrlwePn6LniisAchI3yyGCOr1QofpU704cf3GB1MiSQm46mcqNYK+qWE9tMXlR8ulzw4fsjJyQkxRkajEXdefYVX7rzGjdu3ZB7QZAxAWVUURYXP98IYQ1+t7fUgdjWi3WTu/NcLYd3lUM9aO/ALjTHDPeo7SPfvR9+X1XWdeOG9UZE9lUmri6Fjv4Y2+5Sy4YlyT0ppQA7Hdc2sHlOMa0xVCGtbsXcAiF6DUVdfI4LnwIhS9jw3b97ELc8GcXcXPKmVk8d7j3IyNqXQcgobK7lLiko8Va94Qxg81n5+AAxQrzGG6XTKyckJdV1zcHBAiEKh6RPzfgP2oc1+GAOCCsrUvcB6veb0VNjWAE3T8P777xNj5OaNW4xGI+qsylPljsyzk1OOj49ZbdZMD2YcHh1ycO2IO7df5catmzL9uywYjUYZ5SoGURGt7RAX7deBepQr5XpOf8IPvLogOtzAgEj2n7E3rL7Y6jP7I+SW+xT9YPzBCfNjtVpxen7GeDoZdC6UEbw0+h2ose/9+rE1Jh+GKmUPXRSMx+OhFNE/XmS4gJRfM+wijl5n76rXlRuRtZayLJlMC7yG0/Mzzs7OKEqDLiu2W9HYFvVNjUcga1XkiQOmHMIPpRRFKYagtLlwMu6zufdP4Y8++ogYI0e5iNtkldUebTN5QkFvkPusB8kJ1qy3G1arFWerJZtWGvPW6zX37t1js95ydHTEqK4FMnae0+MTNqs11ajm29/9Djfv3ObWrVtMplNGo4lMtihFElkpJRtT9bUgyRcgh29chJylQS/PZOpZ7EYm3/W5nlIKFWI+4S+VCC5B+b1RdV6KtD2rvqdQrdcyqrJ1Hbo1AxXJ6OJi/e7SgRay/HJC9AGrqmI6nZJSoq5rqqqW/MwoQurrZpJK+QSFVtiywD3j/fk068qNKEYZsTEtLLouccFzvjpjuVzCJGHKMSlJvUhH8BlaTa7/gjaDJ9JaExo1hCHATio4cSHcMUZTFJblesX7H37A+WrJtWvXqPNm7zdmH7qELHKyXC5ZLpe538cRY8gETMPB4RHTmUDoZ2dnPHxwjOskAa/6CXhZkfT1N17nW9/6Fq+//Q7j6WQACnrj6UUZUxLiJ0lfaFvfUX1i1r8T7zPw/npGeJYQS2QCqdo18SXFp6XD9jh2CvCxu1DL6VsYmkZYBiEEmk5Qun1YXal8zcEMRtQfXEplPboYEI10P3gjFxJGF3u9UtJ+13vQlBKtDyij7qq6Xly1SAk8B0bU33ThwBmuXbuGj47lcimqm9OMqJWiH23yACjdy+b2KE7+IowxObTbxelDkx275LvPA0ajEScnJ5yennJ6esp0Oh0Mrw/dVquVjA/Jm6aX8BrPpowmI0ajEdPJTIZZZVb0vXv3+Pjjj/nkk084OzsTmaui4PrhEd/+9rf54Q9/yCuvvIKp6mGwmDaGqpKGxL4fRwzoEuUmMyZCkllOvWoRuXUj+iBMgt7QQsKDtCpkkMFkFnff8j4otw6hV/6ClHhfnzXMew/UHyI9jWo2m8kBoA2taklBJm3Qw97ZgPr3kO+BQdehP+C893TBU8c8ZiZI8TtlfXXnA23w1JVFVcWVK/3Ac2BEvT4ClZxO2hrGsyld17Deblifr7HaUNaVTFfLA3lNZbBFwXg0wlo7bPzecxRaEu+uk1yqT+RhV5jt4+9yVLNcLvng3keklBiPx5RlSdd1w2bpf3/j1k1u3rzJ9evXGU8mjKYT6swUGCZKxMibb77JcrnkT372Hg8ePBjyr29+85v8+Mc/5pVXXhFjLiqZcJGb67TWuRVARP6j7wOWMKBa+0YVs/dJPfQeRO3Vez8QUAfPlUNWnYcjg4Rv+5O4Y7ae0M9GCvECTO/ajvPzcx4+fMj5+Tnb7Zazk1NGVS1i/innitZjvYjKaK1R2hJjIKhLdaOExGhZHzKkiAse52WShUtZVD8K565xHV4jbeJGcRGAv5p15UY0cLpSg01+0C2bzWYsz885OT6mLEsckS54TD/baSv51PL8nLIsh9pJn8+g4w4p0npQw+njlT7X0LmjtK7rIVw7Ozsb6irGGK5fv86dO3e4c+cON27cYDabiaFVFaYuKcpSwIgsnwVwOJ1x69Yt3nrjbU5OTvjggw9QSvHNb36TV155RabHFZaozQCKxBjxMeyFnOZCH1R/6PY638Ag0Diwv/PJ7js3sDD6FSMklXuN9rh1iaFD/iJ8n2QOrs+CLJvNZgBEzs/PMcZw59Ztuq7j/PSM0hYDs91nXTqqamgZGV4/I20iaZzb7MMeXzDIEDJrDJEA1khHrk40rkMdTKmODvH66YjOz3pduRGFFKknY9rzFh/l1O26buBe1ZMx05GETmVZypAsGKbItTmcOM7GdnAgk9/I2gy9t+l5cft9MPu0GJXDLRAGRV3X3L59m3fffZc7d+5w+/ZtptOpMKfLUuSd6ppoZc7rro06d5BmhkT0YWiXSClx8/YttDW44LGjCqvtUGxM7FjXfdhk1M777NON9rtsQQwrRBFFXC6XbJYrSNLS0IeuPVOiz436Q+RycVZACj9s6O12y3a94fT0dMh9+sPEGMMqe6TgHKvzc1RKTCYTIb9mbp1WdnjfPscKSgi+Q6u4lwlRMalh/E3MaIL3Aacl1JuMR3en148WXl89bw6u2IgiEKzm4OYNzs9+gfWR8aRmef+MTbth02w5OJhwMJ0xm82oi3qHskW5+WVRUNf1kOj2odNsJs+x1soGV7lVu68dZUHETdsMRcAukz4nkwlvv/023/ve93j9lVeZHIjijbWWuq7lZ1PKmJKqFn5XlCGUxubhzcZgcq7Sti3j6YRefLEsy2Hz75++vefsf6e1Ju3NYIo5nNPpIkjSJ+reOTabDQ8fPuT4/gOcc0Ou0udaxhgwOwZDSLtC9I6v5y4QTE9PT1kvVwNv79atW3Kg5drSwcEBXddxenrK2dkZTdcRgYPpdBDLVAhEvj/9QvbAzqOKZoTBZPUGZSD4REqRLnT4oIgR6rpmNJmxUs+5J/qyF/c0leSkII1qXv/uN/nFv/hX3LAVy7NzgvNsmi3KKGbXDhmVFVYrYnDSMuEcwQv8qjI7WxuDsRZtChrXcXy+5Ph8yWw8oSwtlbEURmYDKSA6T9M2eALL9Zqu6zg5O6FtWn70ox/xKz/+CYeHhxzOjqjqmtFohK0kbNPW5GngMipTK41We9y+FEHJ9aQQMQWU9ZjoPUoZQKMU6JS15obhzMLkNtmQXNtgtRnaNEJvcD1YohQx+oGpLkn+kvsPP+HnP/8Zm81mCHMPDg7kIKpriqocDEojh0ePkjonrGmtNWdnZzx4+JDT01OOjq7x7rvvcnBwxGgkOaBzjqIsCciwrnI0phqNuXfvHh/e+5h0R76bJpNKp9MpVu3yvxACyWg50JoW7UXfQsdAWcmkPQwy1FqJIlHbRdr1hm6zpbg2o0tXb0hX64kUOANvfOfbHL7+O3zwL3/KUVkREjSbLXdevUNV9F2uHuc8Mu8qyWbMiXTIDWNlUaCUwXZWahfecXYmet5aJSpbUBRiTACdd5y3W7Ztw8nDY1RK/OQnP+HP/OjH3Lh2XdoLqno4xa02pGwEMpJF9O1k+nkY6jCwKwZGdgDGUN/JrAdxKdJLpFFYLby1ngkgn42BAbBjpO/yJG0V6/V6YFXfu3ePP/7jP6ZtW27duT14HB8DZ8tzVpv1AMSYPLFiNBqhlGKz2Yh8We65uvfxx3Rdx61bt3jzzTc5PDykKMqhKF3VNclmocncggGw3mx4cP8+//qnf8TRwSHT6ZSDg4ML79v3h4VcTNU6j/aMjqIwpLKQFnO53UNx2XuPwuwZztWzFq7UiESmynD06iuL7/z6r3J2fj7/5IN7+OWSST3hxuQQkzQ6iDhI8AFiT+3JoxOtHqBfBVRKYQqLiTWlMjTIoN9Nt+U0BAJx+DLJ4pCr1Yq6rvnOt77FD7//Q165fYfSSlNd3/pt8ukZU26gY5eEC/rHgBT1gETfg2SUorRWhobkqQrkOolih7albFC+7diu17RNw3g8lpxG79GbYJDGappmoODcv3+fe/fuYa3ltdde47XXXtvJ/WYhyL6z1eXQL8bI+Wo5fCdaizEdHx/TdC1HR9e4/corXLtxHVsWlGUlh0pZispSHnVZFAW2lPqOT2KEH927x3a75a3qLflOijyQTKvh3vTGpKwhGUWzbdHGYKsCVCL285TyffUpYkaVtPArXjIWSJqoZObMd//8n1tgNL/7X/7D+Yf//F9xeHiATQbjFUrHPHJDblqPFslJvzfpAIFsdYTSWAprGdU1hVFsWsvpakmz2eLa7VAbSc4zrkf84Hvf48c//BFHs0OMEdGMy705wvNSA3lySOzjLrwCIPfDpL55UMtG0LnGFdMery1P1Q5ZOIQk3aKb9ZoHDx5w+/ZtMfrcBg475nsIgc63aK05Pz/n448/RinFt771Le7cuTN01/aG1BtPf3Cs12tWqxUPHjwYhgKE4Fmv13TecePGDd566y0ODw+Hr6yqxIhSnre032horUWPRty6dYvtSl57vVrtqEj5cw5f/x7zAmvQZQFb2LQNpi0wlEAedRmErGvrium1Q1Rhngu2AnyGEQ3FyWcdb0ZFVJb65g1+8Bu/sZgWFf/Ntpvr43OST5jSDNoBkYSPTnKZIERSHWRyXWmkELvft0L2GqUt0IWV3hSrWDVbTs5PcG3LtfEh3/vOd3j3G98cqCZVhmX7JB9ARWm96IVGUu64DV07iOT3VXa0RkUjvURKo4ZQTiZQwB4wkIud0QdJ8mNiu95w8vCYjz+6h0oMHrHMUHrfNuG9JyKa5A8ePMB7z40bN7h16xbT6XR4bB/S9XD+aCQF4tlsxsnZKWgJCY+Pj7n/8CHOOQ4PDzg8PKQc1YKqWYOtSpIWsRWdIeyU0q7/SgFaUY1qbr1yBxcDH/7ifWJKtF3HJEle1xd9fe7m7WtYthLv1rYtq+2GsVaoTLBVQQx2enTA7MY1VFFmrbtnvD+fYl05xG0R5vbWeSYHU775wx8ufvb7/5wP/+n/MFfKCDqTAyWlZcqA857VdgMbsrYBFNpRZCRun927YzInSmuZjidEYLk6I1nLG6+9LqftwcGF5wilJ1IUl9nhDPpoBI/LCb3WmvF4nHXDVZ62sPNguqe67OVF+1X6Hplr25aHDx/y8OHDoT2iyNO+e+b2foi2bTfiObqO2WwmHa/5Okaj0dDH1HvNfVqOMQZbFkwmE5qmYTQaSfH07IzxeMzh4eHw2fe7YYGB0aGtGcK5/brUZDLh1VdfJXQSNu73XA2gSAj0cmMxgSnsAES0bUtRluggA5RVEnWn8cGM8cGMYA3PRzD3NFMhnqFHkoNLEUNEK9i2LeOq5o1vvMsnf/gz2tZRhChijjlJ14VFFxa/Fva0y20BRQ55KlsMxqRRaKuJeRByChGLwkaoVcmNa9d45823Gdfj4ZROSTo2q0I6aruuuwDJKq1FPCWHVN57tutVLh5CKktitEA5hF8hMjQF7rdWhCA5Xu9VvPcsl0tOT0+lkHnnDqbYGcx6uxnCob620hN0Dw8PuX79JtPpgQyTToqm6fJ17+r6u9qrxpiCEo2e2KGe1Mv+FkVJUZRUtsAqIc66hPRxBREHcTGAzrUt6wZ2gtbCKpnUI27evMnDhw9lXm7XSe/TfgE4F6f7e9OXJJoQZBi2sYNGd+cSdV3fTUUhnLnHtFt83evKPVGMEWsUpihZr84pxhNe++Y7/M605nS95qisRGMsC1YAlGVBYQwpRekJGo+YjaW41/bFu2xYOu26K5VSgng5h0Vx4/CI27duDSdu13WYUk5Jh8vKN8WF05M+F4sxD1IW8mWvkhNCwGZhxcuU/j6P6f8ufU6ywbuuG0aZ9MXM6zdvDO/rnGPbNLRZL67ZbmmahtlsRgiBw8NDmRqRX7dHwPp8rr+O/QKt1hqjNbauJTebKl6984o0BepMTO3rcrkfCy2HDFFRVCU+q9N2PuCUojQyBrN/n9lsRrPdDt6yKIohOjBKRnLqPufcK44n56WTVSeinDV0riNZTdAiHCM67F/bVn3semoj+qIe6TLV/sK/AcrIBO1SyakXYuTG668svvWrP+G//k/+/rxIhuihMpl4qjXVZAKto1Cajx4+YHV2zursXAqs06mEVEFhgsFqI3WXnMx77/HblklZ8/ZrbzAdjYdZqQAdOXSJfeExXQihekCjR8a22y3HpycSJmUmQlEU+LhLoGMUPlhfUN2v0KukhwQ/RlEHvXXrFkdHR1IryUZUp0Q9nYjQY5IZrn1VvzdM2IEOTdMMrd4XwtFLrA0heQYKI489mM547ZVXWZ0vUQnxLsgIzxQQ9VYjeFnXtCTCkOMopWiVx+9JdsUQGFW1EFjbjs5IyAYCsIR+al/Kc52ioigqKiSkNgmMKdi2DWY0AlugrcWlhMaIcu1jLGn/AHmW62ohbqANntFkTLNeMa5HNF2DLSw//jf+wuIP//APOfvpL+a2HomcblmTUiA4x+HsQL5cbThdS3vCerUSFR9rqepy4MTZPI+oCx7XtmA0R0dHHBwcDDkJXGweU6bXPthRhPovpUe4RDVoxf2HD4ZpEwNLIrcz9O0DPjMPeji6zXLDzaYd0MBr165x8+ZNjo6O0NmrDflDn7xrhcEgwJUmdoJR7XudfdH+/dfY/4z9nz0YA4J+VVXFZDQeJuOlvLmT7cfLMIAkskHjwIVTaqceO3TQhvgpA/feZwngXJhGmOa9QlN/fTrf86ZtcQnaFBhNJ9BPwsj76HHG8nUYEIDd9cA/3foqe9qTAkekNAqMFASjVjgN01dv8W/+nb/F/+3/8H/i5HzNgTJoDTomtDboqJhNZlhbUBU1tak4XZ6zbTfC9eqEs2Vzm4GKOY9oWulfOjrC1jXBC9UeslxUEn3sYBIhQlnt4OiU0tDV2XuhhyfHnC7P8W1HUrDebi60XPfUmH14uecGWmupTMV0NuP69euD7FVMCZ8T8cF40sUN1m9Iy84L9I/Zbwsfvrc9b7H/X0oXR1L2HaY9R05kqlJui0c06bLRyfvtrnEoMKtd39BApkVqQ9F5ImqgWsU8Xyj5tBvZSR5GphQ+JCEfG40vNPXhjJRlioPIf164J1exrjwnwho657CFpXMeWxZEIufNlm//mZ8s/pf/+/+Q//T//Pfmxz//gKSFjzYuLNpovA8UZc04j1GRTlQ1QLJJQZeLkU3XyTyhrmV2eMDBjWtiuCmS/E5frdeQkyFjibbbDhsuhECz2bLZbGiahs47AmkYvnVZw6AnkcKeTtt2i3OO0XTCdDrl9vXbMi1hMhk8V4+AQTbcS+0bwwqRpHZcu/3nXDY42GnP9Y/pWxH2eXzGqEFj4aJGQ7zwvH0j6q9x//NfNuz9koFM2hAj8tmIZO7a3gGgFQSZ1ZuMpSUyu3HE6FCEJrU1+HgR4r4qQxqM6PN6pK/sAgYJLIWxpZAstcYWNcerLXe+8e7i7/zd/xX/7X/+D+Y/++d/gE6iyTYqSsq6BB+AgmJcM1WJUcz1ESOSV9H5gVcm3qPl8Og648lMYGq4cIJ3IRtREMZwiC7Xg0QQ37Xd0DZeVRWH46kIF+YRMINed79JYYCmQwis1mvatqWua2az2a5tPARczrdAvGbn3LDxhtfbL+oitJn9dZmRvU9svbz2Q7uUEiEGQgZihk2PYHtRIYo9KbMHco4Z2LUwGJPpOIkLB4/WAk/vXiPKZHAFMVOfTFJDvudTJEVFSIqQIk1MrAi8/cZrd8dHR4uk+9lOLzUWADFeaQOQmxp8VvWxJcF7vCm49s7bi7/27/0dPvjhD/iDf/a78/f+6KecrdZE13FUjTFJbmgxGVH2aJLvZDBxCBitGY9GuZFNMx1PZDpcjCQtWnY9muVihq2z9nXfVxNy7lGXogUwnU4ZTcbYspbKfQ6reqmqflP1clb9hh2NRrS5UXAQV9kLwfZZ3aEfrNzTmjKalvJ9u3zi96/Vv86j8qJ97bkLtKWhlhQHKk6/Q/vru2C8w+/DwEiIJKy6aJz9e8csjdX/XiuZ+yoF5oj2opYa066wHkl4Esu2QV8/4MZbr1HPJrRK0QWPLapPnfpX4Y0+ZURfp0dSCWzU4paNJoSIxkBUBB84mB6yWq+ByMFrry7emc149d1v8ODeR/yz3/89Pnn//fnqw49IbUf0OT/wnuQ8pECBpl1v0Cr3szSBylhmozFGWYospiHMHAlFai1Q97ZtOFue4107hFuTesRsMh3kemW8Yk1IcS9XzJs1b6TC2GETRtLAahgKrXlQ176uQ7+M0rRtI54BlWtGijzDkqguhnf7YV1vQD2w0X++y5JZPTN8uCYyCCJl5fzZ8rC0xIUajyCDWYSfNEgHs2dEIN2yPgQ67wZ2AsaSgC4mVEjY/KdPwm9MCLuhI+BV4p1vv3t3dvP6IlqBtWNSFwz9wr7aM6TPQoe/qnXlnkhrTaEULolIYz9PSBnNcrVBlQatC87ahtFkxMF0vKiuHXH93bfxzZbNJw9YPjzm5P4Djj/5mAcf3pt/8v77tKcbTEiUOVTyQRCx3gBU8ELLsQUhx+Vaa4w10pnpvehM1yOOrh1wOJ0NzAFr7DDqfrvdDpsz+dyaXhQS72e9uwsh1t53OjAZ4s57iTgHQz51dn4GMISPZVle8Cr7qOEORUzECCE42tYN4ed+vrIfHgqA0VOcRPjkwlTBGKUDVcHFwm0a2rmHvGe/MK3UUFxNOSdMSQ4So3YDm0NI+JRISiZ4xEzKDSS6EKGueft738XMpjQxkowZZvV+Kk/M6+v0SPbrcnyPqy+F1AupQ4w91CwHjCm0/BAixpa4hMjKTmrqSQ2wmNy6zava4LoG2pbz+/f57//RP+Z/+K3fnoflCpynVJrkHcv1OfW4kq5NZDhV17ZU5WhI3q2xdJ3DucBsLI19RWEobSWTCtCEKLmIUmlI7vvwJqVEt5eE73fO9l/svsdwXqaAKyOzgCKBmBJdZll/cvxQhCG95+DggBs3bjAejwdenGYnCbYTw48EF3C+o2tl49Z1TSwsXdoBDGHvOtm7/pCNKASZDSXzhBiY60oJ+bQP51yQfiRlEAa2tRAV3nkwUNQlKmlc6/NrWqhBIS9aGEuTOgIBbKZBeU8TIyvn+caPf3j39tvvLtqqpE0xE3oFXv/MOuQz9EL7nu7KPdGjjOtxBifU94stwaquaWIkqBJbFtyczRZ/9ega0+mM/+bv//15u9zSdh0xeFJdsQ0BZUVLzphdLpQSon6a6TdWaex4TGEsNk99U+yxD/pZQEkoPfs3dQhjLqFm/e8uSncpKczGMLCivfOcrYT+c//hg4Hp0HQtZ8tzJpMJ4/GYqigp89jF/rXlsX7Qh2vbVryX0ZjOYm1Ch4thXZL4SO5x//lCzse8x6UkiqogPMa9zdl5R9s2kIvURveH4o513nvVntrUdp3QhZRFU0h+MyoIPqIQYmpIkag0qSx594c/IBgj12GLHN7m7+xPez/RV7H6TVuWNck7vA9cu3OHX/urf4XZbHb3H/79/2J+fO9jzs+2KK2wKWGrGpIeaCghJ80akdpywaEMFHUhXlFFUtoNvNo/wZuMoOlLYUzfU8Sl+s3+nyll6cK8J2NMONdyfn7O8fGxjGYpSkYH0tPU15uC85yfnu2KqgOzfFdk3b8/4/GYaA1OJeoyDp2lxphdi0lv7GlvtAsJF8IwTGB4n71DzLWOrukGDTtlihwmK0FetRqY26YsiCriVYCgpO6Xa3SFr9A+Er0jOU+bEp+slnzjz/6Zu29+61uLpZZJiQaZJqH7/Ow5oM+98EbUjzTxMaLRBCUhwOjGzcWf/2t/jW//6Ce899N/xR//4b/m3i9+MX/43vucLFfo0ZQChI6fpysUWg0bZKgb9aNGHhF7J7JnUYCTmlGhs4YBUkDuRST3PVD/n08RHfQgCdVstpznSRB9btULSu5Pa+g9TNM0QsL1buiGbVwzyIT1cslJK3yKbLuWw2mSCX5q14O1vzQXx8ekJNp2YQ/V60M5YhroPElBKEqi8VkPQhOyeirGYArLdDrFuULQt8w7TEmkodu1TIPwrhWWfdtw7h3f+7VfxVcFMV+QysOoY58LfqWb6YutZ25Ez7ofKSXRqZbx9mDqmhgijQsURjN67ZXFj998hV/9q/8mD95/n//+H/zD+e/+o3/Metvy6vXrrNdLdG76SypSqGKg+/jo0EphonC7tNbDxlNK5scqa3Bdy3q5onUdVVFSVGWuuO9E1y8jb33u4dhRgbo8u1SjmM1mXDs4HFSC5F7KVAmvd31ClS0GBsW62ZLWwspoXDu8p/eeuihxdS30qbpGK5s1KtIF7pvUgIQx0CsP9VoM8rnNYPTRB0Lb4ptWDKvyUOQCcHDC/lCKmMPHqrRolVDO0QVHCk7y3FYOwVIbOhdYJscHp8e8++u/evfVb39zce47VF1DSBhlid6JIT0XJvRL4IlSkMnchS3ovKfpshJqYQkxgY6sfcfYWGav3ln84M//Ku/90R/Pt+9/zPl6AyRiDwOHMLQhD+iOkvqVynlBUvtCkAI3G2PwMXByciLC7pk71xMttdaDzBXs6iedd8Lny2qllRXKzXQ8YTaeDNoH+9y91jsa1w39OQPAoDWqUEQCXfC00eO6lpOzUzrfMR1PBT4OgWq73Ukv7+nr9dC8Qe1EF/N96A8DpYAsC+a9Z3t2ntnvYswi2PhpwqvZ88g6/90rRfAd7WbDOBm6lFh3jk/aDefJ8yt/8TfxZZE18jRKRaw2bDcNdlIRQid56hWHdM/MiIaw6Fm9Qb+UhAUqWoFTjWjHBQVRRZQpQWu20aGMYXT9kJuvvcIf/PF7THxFoSI4SYZNWRCUxilFkeecRjJcqqSqrpORUFwpiKBKO0DPIUiXad+b5L0fph8AFzyRc47WdaIZYAzjqh4GGdeF9CK5HJa5XkA+Sjt4l5N+AJ8Jnl1wbLqGNjqCingibexoW4fDZShaBgSUWbar5/b17ef7o2uslr+bPA8q9oBJnrnacwFPMgQ/0obOR5TrKNjp3fVhcd/ukDIjpP+vaxuphSWN6wKnbcMpge/9G79299VvvrvYEtFlScpTJlIuxscYIekrz4lSSi++J1JaU2ZP4L3H6CKPXAFtCzrfYa0mJE2rI5Nr1xZvfPtb/N5v/5P5sm2ZWoid6BSMtSHqgKdDxZg1sfP7KEXUGpOkkVBFOShCK6ha13UYYzg6OroAQfebEy4KLg6i8F0rWt7jieghKJ0VbRiKoT0dqY2eEJx81l5joW1yh2vDcrOk6VqarqMNHV1yOC0zh1yKNKHGKE1lC6qiRGtLaaX2VRU7rXMJE8tsTOaCJwE9iPt3XcdyKwMFCiU5XgqOoCFoMJjBAw90qOgHpkYIgXazBWDTtWxD4Cw49LVD/sq//bcwkwkht8cQE8ZYXOek+9U32KxZftXLflZR6gsVrPrxHV/2yp52qZjRMo0xCohoQCNF1sJYmmZDWVpp7rKWV7/xFtdeu8PDP36PaAwHVSWT36LkMNEHaebzgaIqBThQGhUCIQqNqA+hAontaovvpD2jb7/otcELvWMj9CFQT0YdlRXbTgRCkg+41EKWoOoF7VvvpG4U/BDGNa5j2wpTvem2tC6PewmdGF3fmjAy2HEpjIOoWMcWg6JNDhMaVBQjL7ShKkTgscxt6HVRD0YloZl8o/1nWW+kByrEyKQuaJQn+Q1F6yhSSZEKiQyitDjk+XkykVAJGtrlIu1quyEVluOmJUzH/Nv/i3/v7ivvvL1IWZGWqNA5D1PWDN3MMcZnvtGeppj7gnuinX6C/Cy5xzDhAPm5LkqMluazqBWzGzcX7/7oh3z03i/mG9dhSSQfCEFOxdJaQvQYa+m8E9Zw9iia3DGa37W/wX340rMa9g1nnw93GaUze0AFMPQd9blSFzwueNatCPyvths2zYbNdsu22+KjE0F6rbGlwVQWm3OcffGUngnStxwkLxLHLkW6zrHayuzVMjfNjUYT6rLaPb+/Ph9wrqNtRXqrrmu6FLDeQSeoWcyeVitFaQsplqs8+gZQnWiOt21L6x1r1xI06KMZf/Xv/O27P/7N31jEsqCLef6r+hqFcy6txxVs953Llzaiyx/qaT9jXzDVXyHAoqRTRbT+UqZ5xYS2DBwxr2B0MOG7f/ZX+IPf+2ec/dHPCW3HpKohIsqrozEqanzbik6a0RgrSJfRAQ/o2Osn7AaAKZV5fy5Jw1nMo1HYoXMDjy5GQgoytTTlFuiYWya8Z9tJq8Wma2k6Ub9Zbzc0bZuNJ+BTpKwLSis5WFlLntMbUJEBDvE2dgeIhIj30vLdZXi83YpRbJxjtW5hvcRqPcDrvdKQ6wLbZk0M0vVaU0uJoevQWpGVtIRQnBJJ5ensmZnS63E3nWO1XXF2fk6jIrEs+Xf+J//ju7/yb/6VRahq7LhCuUxYTbtDC/o914eXX384dzk6e8E90b5kIgO7WZbceCPEaumjVIqUoEuJO2+/tfjJr/86/+iDe/N2vUL5DnxkYi2wYbOB2eEsI2MyJdx7PyiRmpRlg9XFnpue8Am5fcDvCq0hN52FKPoMPROhz3tclDGbrWvZti1tFHGSbdOwaRtc6KRvx2qqsmJWWsrSZs6fHrxGn/dIrlNSFQVVIV7FaiO6EUlaRTbbrbAOtt1Qe9put7RbmX63bhvcymUKk/DcYvTU9ZjZZErTNXm+UP4szuOseEMAm5kLJhnJmZT0CK03DSfLc5bdljQq+Y1f+6t3/8xf+osLe3CIV4m2k5Eqcsj2o0CEsXKV67IBXQnt59mo+O+ZTt7U4o1y7qIgIRJLqjB0bcNoMubHv/EX+OS99/i93/pvcZ3nYFSz7TqCC9ikiGfn0rNk9DBBQaMHI9JKRNd7l9/3zVxmVodsMD5JPUoaAeXv3jtcEI/QdB2t69j6js452iiC+10WX1EmTyIvizySsULHiDbCDrBajKQqCkbViFFVUxelsB5K0a0ri4LCVkPvTxs72uDpsgENRrSRnGu5XLJarbIYS/YmCEq4bRQxlXTa0LpMzrUaawyFltzKmiLTpMQzNT6warc0raMjYqYjfvwbv87f/J//zwiVaMnVo4l01sodBNJexCN0oK8ygvmy64X2RCqBQsvMnUcYp0aau2RMC/gUUdqgipouJK69emfxl//m3+Djj+/Nf/4v/hWxbah8xNQVEGk3a4o8ENkUPeRrRB8g9QCA31FozMUR9/3c1C63CwzFzygndiTR+A4XfAYJWrauE88QBSRwWfBEWxGHt6VIWWlrUSqJNK8SEmdpBWUbFRWTesykqmX4VjaoqhplD1UxDBMzCZ/80LzYNzD2Lfbr9Vq0JJr10N5+vhb11OXyjEZXKMwQQhqrsifM+ZQSXbqoDVHDppMQtZpMObx1iz/3F//C3b/8N/861994fdEoCMqw3Kypi5IQHGlPj+DRrQ8Xo5FnuR4Fsn2tEPcznSOT6wV5sHS+zzG3K0g9wZNQ2uJ8xOqCEGSK2xvf+fbir/+df5d/YMz8D3/ndwkJdBNJbcvhwcEwCFl7c8GINP0g4jAk9n3tozcen2Q0Se9JQG66y82CAjuLEXXOiQdKTuDr3JRGz4wuS0xRYCsr40eszDOVHh6NMhZbljK2s6ooiirPPi0pTElpSgpdoLXNTN5ePyFSa40qKsa2JFQBP5rQTRvxjPkerPKA5+12w3hUs6wqzjcbzrdyzcE3qKAwnXwJUqy1lFXNzVfvcHD9BsloDsqSG6++yre//4O73/j2t7jz5luL6fXrLLcN9XRKcIFCS+FWqZRTnz0juSIv9Fko9QvtiZICFfuCm8wC6o21H6ForcUHEbsvq4rteoMyCmUMznu0gR/82q8tJgcHVKN6/vu//U8JToCGk80Go0HHiPIOo5SYjxZOnLQJJGkiS+xGNZLE28Q84SHs8iRIuOBlmp1KrENH1+cTSXqckspBjEq7IciFRWUpOK21NBqm/mcJNYseWatqRvWIcVFR2n4ukcDFKULczyNDQFmRxArJo5N8vqoQlSSLYVRVTEYj1lnr7nA643w85Xyz4XizZt12NM1mB9/HQBs7UvJsusBv/PhH/KW//m9xePPWXcqS0WzG6GC6sFWNj9DESDEa0boOpS3BO6qqwvuOi67nUaPxnr0XelIJyH6WhQ1diJ/9DsMLftZ6VqdH1HuMZaQ1Qd4v0/BztdSgcF1DaTVEL0mqhU4Z2hS4873vLv72//rv8so73+C/+0f/cP7xex+g245JWVAqJTB4jJKD5ORd5Y0cCKQkXiFkhkEThNKTEGFGpXsSqpfkum1oU6ApCloCRkvtJDjxQcJrA2UVutAoq7DGUFqDCoHkA0pJv1U1HkvX7WjMuJ4wKivqckRVVozriSjDZmPcX7IJSiBKpyiakBQ+JkKIxJjQpiAFsKbkYFIwHU3pXMPBZMa2bXm98zw8OWa1WeJcx7pZ0wSHT7BNET0+4Nprr/Lmd7539/DOncXWJ6JRRK3oYLe/UszAj4jNiAGRjWZ/wvlXjcp99us90T54mmLrl7rAZ78+D1S+e0ym/ytoU0QVFqMtN95+e/GX//YB3/z+d/nvf+u35r/zW7/N8b17mBAoFNS2pDAKYiAll4EGuZk+RlwItCESUkTa/hJJRUxp0Fr007rQoVIkJEcwhnVoRDZMmUxalVlFonu3069TOo9HcYGoNLWRUSalLahtIcIttqAuSuqyYlRWwzBia2VCxr4RXe55Slr0J2KM2KhQyhGjzspDGpWheAVUhQizzCZT1ust1w8O2TQrGtfQNBuW2zWbEFj6QHntFrdeefUudb3YKo2ziZTnQxFyY+NTravvG3rceqHDOfj8Hm7/O0sKCR+io3EOA4wODvnOn/nJ4rU33uI3/9Jf5p/+1m/xR3/wL+Z/9C//BfeX59RlpvHkoqi1Jf0wL0fEVCWj6YSjwyllVXHv4w95ePoQt25ACZIWvKf1DURFGyMhJXSGo/shysM08QTRCShhlcaUFaUp0NqA1lhbYPRu8nifm+3naP3226++X24iHJrz+uEByRBR8pk0A2cu7bXSK6WYHU5l4FmpmJoZMXqW6xVNF1mGwOz1N3jzzTexdYVLMnCZlAT9jCKSebUH9ef1aJcfL11oj6T3fB0CD8/LimiM0VijCU66Kic3ri8Orh/x7ve/y8N7n/DxB+9z/5NP+PjjexzffzCIG1prObx+nRtZufTw2hGH168xHo+wVvOf/v3/bP6f/af/d+7d+5BRNWJ5fkoIHWVdsdmsSEqktHx+LWstykr40iN6hZV8Z1RWAm1nowGBtk1u0dC5uNyL96eYJ3Pnz/moiOPyxIheRy7l2tVoNJJGwExZ8r67oA1nSkuIkXokwwC6LjGqxhgL1lhuv/oGN2+/QlmN2AAombKOQDPPTTvDl1kvvCd60hpO3J42sv9vSPHOYIgh0XiHJk+1U0K0LKuKozfeWBy+9grfzz02KvPaRNZJJsApJcIkUUnLt1KJmDx/6W/8DT5enfLb/81/Pd+sloyvX2e7XrLZrDGjEb4LJB/pfCS1js5HGQ+jNSoGqqKkLkdM6pGQWZUM/zWGgYldGEtRVILEFVX+r7hA2dEo+mFkwLB5g+su9DrtulrFmNqty53DlqoqiE7kxFbrJeu2oQktEZkB5Vov09WrkUxHn4x57Z13744PDhZKGVLMxWoUOomiz5M5Ls82jHt6bujjPdZOvHHPG/1p8UIqIXrPxmCMIkZDCh6fq/kKRec8hTVYXeBjPyvVoKzc1pAU3uReGStj5oMWqkoIkVtvvrn4D/43/1veeOsd/p//j//r/JOPP+Lgxi1sPaJrWrTq0Mpmg8xjNVGM+ppPX9tRwiAnJZQGs8fR01qa9fZzoipPDNfpoiLp/hK6UbjgiUCKqf2/S0ftrvVCKyVUoMIwDh3nzTlN1+I3Hb7t6JLm9HxLUxR841vf5vV338WOx3RRhC1NlOZCdMoe6cVfv/Se6El5q0UTOo/PG0abcqc4akTrORolFffMaN0/zaWNL2/QXGyVCo/0ICWlGB9c42/+O3978fqbb/AP/t//xfyn//oPQR8TwwnaVKAbOt8KowEBFDCGhMJaUcoJzqO0oSiM1IkyK/NyJ+r+fwY59UnkU19Wr5ewbzwxc9v2HwNxgOZ1yp9diwyW0gW60NiRjLih9bgucbra0HSO7/zkx/zaX/+37k5fv7NwmQJUoFE+CjqHTNh7/HH9vAAJT8qZ4kUj+tPigfo1bMCshkqIw3h7Uez0WVqqrwH1Xa3y/AAoY/MEPPldn1NoElpbfPTEpKjrMT/5yZ9fvPbqm/zxT/81//z3fp/3f/He/OTBQ1bLMzbbLYGQ6z0CY6vW4ZuWpHPjnIpoEsk7gk4ErdBl+Sn96wtdpfApMKEXIUnp015ot/Y3T8oQfRrytP4xSgesMURlsaOSTdK89tZ1fvwXf/Pu0VtvLnxZ0fpIjcYahXdSU/MFJKNyNPDVf7df53qiJ3pSiPe8Gt5w3U96HDI3tO85SypH6irr3116gWFCeOpD4HDhPVQ/8QApoSWEGJpImKLmzutvLW7feZ0f/vDPcXZ+wunxQ5bLZZ7gLa8+m05QXcfv/dN/Ov/tf/Bf4TKzW+epdLaQwSQqG4GLUqiNURJ/n/lrPkWMuKELCNyF0C1Eeqlk+S4v5UZ5akRSiqRT3vBqAB9sUETnMapk1XWk0Zi3fvD9u29+//uLtdF4raGUnFMFhTa7exq5WAHKd/YJ39gXX88KPPulD+c+a+1T64cRJvv/ri7+rNLFDfDY1917bEITkyIEmT1baIMpCw5vVEwODxfvfOObuCiacqLTFimMpkiK733n+/jGzX//n/x3rDdrqlmNTwkTI0VhMEoQvGDy8LCsY+28RyEaDEXuTN33RvtwtlaigS3/dnGyd8rhpXNuCPfM3pGhlUKHRPAJX2m2CqavvnL3+7/xG4utUmxJWCXeJirdny272t5Tfk/P+/rSRvRl5xU9qyarp72ugW+3dx0XeX47c/msL/3y8zVC8NTGiGfTCpLGJZHMNVqjqhFb1wqypkwmkyaCc6ANt958a/F3/6P/iP84hfnv/PZvsQqekdaiepNHyEQVCEkY4QJDd7jcTBWiIVkBH2xmWATS7n8pDKHUxVN6z9BiGiZjaK3x7BoLC6XRLhK14dw5/HjM9/7Cb1BcO6LNLfT9nUsqEvZYOzrl+/OF98/nYy48jjz6+PX09aM/1Z4I9jzLI4z5MgAbL8Ztj9wA8ZKn6jUANCYbkoi7xxTRRk7ogJKhwhGsVrgoXqG0JddefW3xP/33/wOOjx/Mf/av/iXVpKJ1LbWu8UFO+hACresuzIil2Ol02yQD0iQsE7nmR4Z2SUD//d/F4C4IjqS0mzsrbANFmxLnMfLjX/1zd2++89ZinSAoGbBG0hnO/vSB+aLnQv1S7//J+Wc+4MLQ4Ee9wHPmidQjT9bPev98Ij7i5OlJrPFCWLfH1Us7jl7/+OFx+c9euw30BemsoX0CRCfC73S7Y4xYjYh6ADZ6/vXv/97i7/3H/8f5H/6z32FSWGyMTOuK2koLxKgSms+oGjEqK2E/GJMFSaRYO7z+PqAQ++u9KCzZK5OGEGTaX3QXRrSkFEjKEFXBqQ+8/Wd/5e6f+x/9tYU5ukYoKpQ2OBcwenc/YjY6naTXS+7nU31Ne+tyPPDFPdGj1+fn5P2p90Swa+C7fAN7MqtJu7xpPy965Gtlo+sfovukPPWt6/I+Kcqoxf1RjdI1KuTTiCYkAzoSteWdH/xg8e//h/87/pO/93+Z/7P/739LUdR0WZJLKY/xBms9xu8Gg7mMOlptCNoPpNYLXuiSEfXwfm9EQyt7Dun6yeDOtXRJ01aJV77zXX7yF3+TcnZAZ0Xvr7SWlDyqH4Gick/qpb38pPv5VazPLbbzOdcLb0Rf1BP235s4ll2PyuXvs/c8kd0XfjFL0sM19NoOengG+LYBEGpOEvROZXtNagdBKyUntehZC2+NAlzSRN9QFRXf/dFPFuOi4vrskN//J/9k7tYrfAxoH+hUFnkPkeAcPreCRy9NhYWxA4Nh74OTwm6TXRTb743Io7yCGAf0zjkxqDSZcP0bb/Fn/9pfuTu6cX1BWRJ8QllD0zQyYib4R35H0l/3eRrqnhUM8QXZ4HvKKS98OPe493/S6TO8beoNSL7QxxqRyjShvb9LKKcfcw05F9rDcFMSThvsiJ8iZZNnBEXpf0rKyEAsrfKYSsdIa2LbMlLglkv+q//Xf774x/+f/3J+/OGfYBEZr1KZgdVdFyWF1tRlidVmaN0utMkTyHefVOVruzyxAiIpSZOh9x6MFY0975lMphy+8QZ//t/9W3eP3npnoaylDVDWE9rOo/ou334m677HGUJgfSE8/uz1OCN68vO/KgDhwnqSEe0nmvvjCZ/F+rrQuc+6kQrki33MF7oPhX/u67h0+Fy+rscRMPswr58+LlMQZF5QqTXnJ6d8+IufL/67f/gP+PBnP53/4r338M2WWhtKraiUojKaUVFkgUaDNrnj1Jph4HFlRQMh9SyNuEPffJJ+rKgNXYRgDPXkgGt3pDP1Wz/5MdffeXvRWi0sbyV381GfaOd5vpp1QWHpEb9/euP48n1Jj/VEXxeP7nkwoqdZX/Q6n3T/nnRd+yBEyh6h58y5ZkvcLPngT36++Fd/8Af80R/+y/n7P/0pp/fvoX1gWpaYFCmtoS4LiqwIZIyS+UE96ztfp2FHaXIx4EOiTbB2Dl1PePf7P+Anf/7X77769jc4vHVncXDjJuvon7L1/6s9jF8II+ov6KUR5edfkREZY0QeOcsSey9FT2utNBKEANETu5bl6cni/Z/+MX/wu787/9f//J/z8N4HmBApFJTGihFpA0QMolZUKiOTGnJo2QusOHJjoSm4/dbbfOfHP777/T/3q7z6jXcXyRZsvAdt0OrTnINHr6/LiD4vqfUZG9HXsb7OYuuXMaSrNKLuEdPG+xzGWk2K0g1bKEiu4/zBg8VHv/gFx/fu8d5P/4j1+XJ+fvyQ89MzNuslzrmB9a1jlD+1pvOi8z2aTrj92qvcuH2bt7/znbt33nqLm2++sbCTKcFavNbEfmqET09Z73lpRM9sPWt488sa05cGPr6kJ++vtc9N+1rNUGMahOIjOkVsHjAWXUfsWpSPtM1msVwuWZ6e8eD+J9y7d4+z4xPaZoPrmrlvpadoenjA66+/fvftd97h1quvMT2Yoet6MZrNoCzZBGlNxwp66L0X1sJn3s5nk1N/2oguTfx76vUVGNEH7y2fOY7+WesqjAg+TzH2S77/lzSivjajBgQvDu3fMUZSEM05pXfomiFlqF1+p1IedqyUkFRbUTv1oaPZrBeohFaC4I1Go0U1qrFWRtJ0IUshayPjahI7OS+kveGz158SI/pib/7VrK9LoPxxOdJjBcvVxcd94ff9kkbk/cV5Pn2vUAgiSK/SxSHGAOhLuWxmaUtDoR7g7UBAmYSPjhQyuGAKNKJ/EELI0lVCE+qnju/eJw8ge+SVfz0dqY9qNPzs9dVKbCmldmo/X2iMysv1zFdZlhcYBvuDjU1hc8s3SBk35UqXGnQVlE4olWenpjw5Q/Vi/NLinmyJLbT0+aREigptNMpaWh/QaLTJUy46B/R0pvRkSbU/BesrnwrxvK5hcl/PTHiCB+rXk066pwUOvqhHujwJ/PJry3CKAFmei3TJA+R60MCWIEFmb1slhpNCz2vT+TE6Pw/QskViX4i2mf9HIjfNXlpfPYDwWfOBniUn7mnXM6H9PM1Ml5frq1q9hl4/OaEnw+028+XEX++iPnm2AhP7Yukeobb/U4m67BDiZm7go7Wxv9r1vO+llL4SLe5HnZSP/oDqkXnGlzu5Pu+co6/Kc/bv+7RVkmezpF0cGG753qAX4NJ9yZ5j/0wWJoQ8fn9kGuxFasNr7FGeLlzHF/kOv7iS6eczoGcvM/zlm/K+QJiy/5zn5EB56vW85Y4yGSMOtJt9o758lY+jL11u9xhem/h4kujwIl9vf+rzdO8hAwvP+g3g6/ngz2Ly3mPfR6k9Auuzfb/PWrnDQNor0i5BiZfCsv3Gwx2BNhdJo/pUJ+/eEScGur+S3k0i/EJe/esyuq9vgt4zNaLn7dT4ZVtJwOghr5G126R9yrK/4VUS5rTOCY1o5O1eU3KftPe7tPdqe+99BYDS87qfXvh+osvrWXmkZzpf6QuuqKS9PLHXBJgBhQGF3LsPJu2E/OX50iYoz4+ffgJRhBYB+pBPscfY3r3mk9eX80DPqwGJPNpX8CJf5AN+0ee9XBdXjsjISnc7cGAPSUsqXpyonv97XCPibl1uff90S/fXcbg8bp88L3Jttsf74WJ43/ebPOlCn/aDqEv1iwH4eYIhPSls+LrELr7o+zzLL1ogaj20scNFgHp/zins8qHh4WrXBr5b6uJjejj8gkHt9fY+9X35YjnKZ+2P5+EQfiKw8LxY+sv1+PXkUOLxBvSF3/Pq9+5ztX7pcqKX6+tDpV6uR+RELz3Py/Vyff71WE90mWv2hVfsY+yXMcCzXc/KAz0v84Ge3/WpO/TSG71cL9fnW0+eCvEFPdKgcPnSAz3j9TgP9ATP9MRq6S+L3PyzX/ql53m5Xq4vt+yjYtKLBFH598d5pMu1pP160C9DvPvirK8qJ3rx5gNd5VLKfPk79rz3e7xcL9ezXCklbF99flwB7VM2crnz83InJU9nQLupAC/rGl9ufdn790XP0Wc9H+jFWDKZ/Stevww35uV6uZ52XaD9fF39OI/yXC/Xi7Refn+X11d6R156oZfrUeuXeV/EGD9dJ/qiHumJo0xeeqBntx4p8/pVI18vv79Hra+kn6h/oUetXwYI8/leL0GZq15KKeyTPM5lD3LZYD6LkbD/2KdB4R6lyXBZGOTTNaxPqw3J7/WnHv+4a3xUXax/bhwmxD35uc9mPYWhfC292l99P9CLsHqZ4sfVuL4iyaxf7vVZRvLS0z55fdmpGC/CemlET7k+v+bzy/U060U3smdSJ/plXI+TsX25Xi6A/z9NEaEjRJlhnwAAAABJRU5ErkJggg==", style: { width: size, height: size, objectFit: "contain", display: "block" } })
      case "hema":
        return /* @__PURE__ */ React.createElement("img", { src: "data:image/png;base64,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", style: { width: size, height: size, objectFit: "contain", display: "block" } })
      case "womens":
        return /* @__PURE__ */ React.createElement(FemaleIcon, { size });
      default:
        return /* @__PURE__ */ React.createElement("span", { style: { fontSize: Math.round(size * 0.9), lineHeight: 1, display: "inline-block" } }, icon);
    }
  };
  const renderBadgeCategoryIcon = (icon) => {
    const baseSize = 14;
    const scaleMap = {
      shield: 1.35,
      virus: 1.35,
      neuro: 1.35,
      cardio: 1.15,
      pancreas: 1.10,
      heent: 1.20,
      telophase: 1.10,
      lotion: 1.05,
      kidneys: 1.05,
      hema: 1.05
    };
    const scale = scaleMap[icon] || 1;
    const inner = renderCategoryIcon(icon, baseSize);
    return /* @__PURE__ */ React.createElement(
      "span",
      {
        style: {
          display: "inline-flex",
          width: baseSize,
          height: baseSize,
          alignItems: "center",
          justifyContent: "center",
          flex: `0 0 ${baseSize}px`
        }
      },
      /* @__PURE__ */ React.createElement(
        "span",
        {
          style: {
            display: "inline-flex",
            alignItems: "center",
            justifyContent: "center",
            transform: scale !== 1 ? `scale(${scale})` : void 0,
            transformOrigin: "center",
            lineHeight: 1
          }
        },
        inner
      )
    );
  };

  const ExpandableText = ({ text }) => {
    if (!text) return null;
    const lines = text.split("\n").filter((l) => l.trim() !== "");
    const formatted = lines.map((line, i) => {
      const trimmed = line.trim();
      if (/^[A-Z][A-Z\s\/\-\(\)]{3,}:/.test(trimmed)) {
        return /* @__PURE__ */ React.createElement("div", { key: i, style: {
          fontWeight: 700,
          color: "#1e40af",
          marginTop: i > 0 ? "14px" : "4px",
          marginBottom: "4px",
          fontSize: "13px",
          letterSpacing: "0.3px",
          borderBottom: "1px solid rgba(30, 64, 175, 0.15)",
          paddingBottom: "3px"
        } }, trimmed);
      }
      if (/^[-â€¢]\s/.test(trimmed) || /^\d+[\.\)]\s/.test(trimmed)) {
        return /* @__PURE__ */ React.createElement("div", { key: i, style: {
          paddingLeft: "16px",
          marginBottom: "3px",
          lineHeight: 1.5,
          position: "relative"
        } }, trimmed);
      }
      if (/^CORRECT:/.test(trimmed)) {
        return /* @__PURE__ */ React.createElement("div", { key: i, style: {
          fontWeight: 700,
          color: "#059669",
          fontSize: "14px",
          marginBottom: "8px",
          padding: "6px 10px",
          background: "rgba(5, 150, 105, 0.08)",
          borderRadius: "6px",
          borderLeft: "3px solid #059669"
        } }, trimmed);
      }
      let formatted_line = trimmed;
      return /* @__PURE__ */ React.createElement("div", { key: i, style: {
        marginBottom: "4px",
        lineHeight: 1.55
      } }, formatted_line);
    });
    return /* @__PURE__ */ React.createElement("div", { style: styles.explanationText }, formatted);
  };
  const formatTime = (seconds) => {
    const mins = Math.floor(seconds / 60);
    const secs = seconds % 60;
    return `${mins}:${secs.toString().padStart(2, "0")}`;
  };
  const getStreakStatus = () => {
    if (streak >= 10) return { text: "ON FIRE! \u{1F525}\u{1F525}\u{1F525}", color: "#FF4500" };
    if (streak >= 5) return { text: "HEATING UP! \u{1F525}\u{1F525}", color: "#FF6B35" };
    if (streak >= 3) return { text: "Heating Up! \u{1F525}", color: "#FFA500" };
    return { text: `Streak: ${streak}`, color: "#64748b" };
  };
  const totalQuestions = QUESTIONS.length;
  const answeredCount = Object.keys(progress.answeredQuestions).length;
  const categoryAnsweredCounts = useMemo(() => {
    const counts = {};
    CATEGORIES.forEach((cat) => {
      counts[cat.id] = { answered: 0, correct: 0 };
    });
    Object.entries(progress.answeredQuestions).forEach(([qId, isCorrect]) => {
      const question = QUESTION_MAP[parseInt(qId)];
      if (question) {
        counts[question.categoryId].answered += 1;
        if (isCorrect) counts[question.categoryId].correct += 1;
      }
    });
    return counts;
  }, [progress.answeredQuestions]);
  const correctRate = progress.totalAttempted > 0 ? Math.round(progress.totalCorrect / progress.totalAttempted * 100) : 0;
  const styles = useMemo(() => ({
    app: {
      minHeight: "100vh",
      background: "linear-gradient(180deg, #f8fafc 0%, #eef2f7 55%, #e9edf4 100%)",
      fontFamily: "-apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif",
      color: "#1e293b",
      padding: effectiveMobile ? "12px" : "24px",
      position: "relative",
      overflow: "hidden"
    },
    backgroundPattern: {
      position: "fixed",
      top: 0,
      left: 0,
      right: 0,
      bottom: 0,
      backgroundImage: `
        radial-gradient(circle at 20% 10%, rgba(71, 85, 105, 0.035) 0%, transparent 55%),
        radial-gradient(circle at 85% 75%, rgba(51, 65, 85, 0.03) 0%, transparent 55%)
      `,
      pointerEvents: "none",
      zIndex: 0
    },
    content: {
      position: "relative",
      zIndex: 1,
      maxWidth: effectiveMobile ? "100%" : "1400px",
      margin: "0 auto"
    },
    header: {
      position: "sticky",
      top: effectiveMobile ? "8px" : "16px",
      zIndex: 20,
      display: "flex",
      justifyContent: "space-between",
      alignItems: "center",
      marginBottom: effectiveMobile ? "16px" : "24px",
      padding: effectiveMobile ? "10px 12px" : "12px 16px",
      background: "rgba(255, 255, 255, 0.82)",
      backdropFilter: "blur(12px)",
      borderRadius: "16px",
      border: "1px solid rgba(15, 23, 42, 0.08)",
      boxShadow: "0 8px 24px rgba(15, 23, 42, 0.07)",
      flexWrap: "wrap",
      gap: "12px"
    },
    logo: {
      display: "flex",
      alignItems: "center",
      gap: "12px",
      cursor: "pointer"
    },
    logoText: {
      fontSize: effectiveMobile ? "15px" : "18px",
      fontWeight: "800",
      letterSpacing: "-0.02em",
      color: "#0f172a"
    },
    logoSubtext: {
      fontSize: effectiveMobile ? "12px" : "13px",
      color: "#475569",
      marginTop: "2px"
    },
    logoMark: {
      width: effectiveMobile ? "34px" : "38px",
      height: effectiveMobile ? "34px" : "38px",
      borderRadius: "8px",
      objectFit: "contain",
      userSelect: "none"
    },
    controls: {
      display: "flex",
      gap: "8px",
      alignItems: "center"
    },
    toggleBtn: {
      padding: "8px 16px",
      borderRadius: "8px",
      border: "1px solid rgba(15, 23, 42, 0.10)",
      background: "rgba(255,255,255,0.80)",
      color: "#334155",
      cursor: "pointer",
      fontSize: "14px",
      transition: "all 0.2s",
      display: "flex",
      alignItems: "center",
      gap: "6px"
    },
    soundBtn: {
      width: "40px",
      height: "40px",
      borderRadius: "50%",
      border: "none",
      background: soundEnabled ? "rgba(16, 185, 129, 0.15)" : "rgba(239, 68, 68, 0.15)",
      color: soundEnabled ? "#059669" : "#dc2626",
      cursor: "pointer",
      fontSize: "18px",
      transition: "all 0.2s"
    },
    chatIconBtn: {
      width: "40px",
      height: "40px",
      border: "none",
      background: "transparent",
      cursor: "pointer",
      display: "inline-flex",
      alignItems: "center",
      justifyContent: "center",
      padding: 0,
      transition: "all 0.2s"
    },
    chatButtonIcon: {
      width: "40px",
      height: "40px",
      objectFit: "cover",
      display: "block",
      borderRadius: "50%",
      clipPath: "circle(49% at 50% 50%)"
    },
    chatHeaderIcon: {
      width: "30px",
      height: "30px",
      objectFit: "cover",
      display: "block",
      flexShrink: 0,
      borderRadius: "50%",
      clipPath: "circle(49% at 50% 50%)"
    },
    card: {
      background: "rgba(255, 255, 255, 0.98)",
      backdropFilter: "blur(10px)",
      borderRadius: "16px",
      padding: effectiveMobile ? "16px" : "24px",
      marginBottom: "16px",
      border: "1px solid rgba(15, 23, 42, 0.08)",
      boxShadow: "0 10px 24px rgba(15, 23, 42, 0.07)"
    },
    statsGrid: {
      display: "grid",
      gridTemplateColumns: effectiveMobile ? "repeat(2, 1fr)" : "repeat(4, 1fr)",
      gap: "16px",
      marginBottom: "24px"
    },
    statCard: {
      background: "linear-gradient(135deg, rgba(71, 85, 105, 0.1), rgba(51, 65, 85, 0.1))",
      borderRadius: "12px",
      padding: "16px",
      textAlign: "center",
      border: "1px solid rgba(71, 85, 105, 0.15)"
    },
    statValue: {
      fontSize: effectiveMobile ? "24px" : "32px",
      fontWeight: "700",
      background: "linear-gradient(135deg, #475569, #334155)",
      WebkitBackgroundClip: "text",
      WebkitTextFillColor: "transparent"
    },
    statLabel: {
      fontSize: "12px",
      color: "#64748b",
      marginTop: "4px",
      textTransform: "uppercase",
      letterSpacing: "1px"
    },
    actionGrid: {
      display: "grid",
      gridTemplateColumns: effectiveMobile ? "1fr" : "repeat(2, 1fr)",
      gap: "16px",
      marginBottom: "24px"
    },
    actionCard: (color) => ({
      background: `linear-gradient(135deg, ${color}15, ${color}08)`,
      borderRadius: "16px",
      padding: "24px",
      cursor: "pointer",
      border: `2px solid ${color}30`,
      transition: "all 0.3s",
      textAlign: "center"
    }),
    actionIcon: {
      fontSize: "48px",
      marginBottom: "12px"
    },
    actionTitle: {
      fontSize: "20px",
      fontWeight: "600",
      marginBottom: "8px",
      color: "#1e293b"
    },
    actionDesc: {
      fontSize: "14px",
      color: "#64748b"
    },
    categoryGrid: {
      display: "grid",
      gridTemplateColumns: effectiveMobile ? "repeat(2, 1fr)" : "repeat(4, 1fr)",
      gap: "12px"
    },
    categoryCard: (color) => ({
      background: "rgba(255, 255, 255, 0.92)",
      borderRadius: "12px",
      padding: effectiveMobile ? "10px" : "12px",
      cursor: "pointer",
      border: "1px solid rgba(15, 23, 42, 0.08)",
      borderTop: `3px solid ${color}cc`,
      boxShadow: "0 6px 16px rgba(15, 23, 42, 0.06)",
      transition: "transform 0.2s ease, box-shadow 0.2s ease",
      textAlign: "center",
      display: "flex",
      flexDirection: "column",
      alignItems: "center",
      justifyContent: "flex-start",
}),
    categoryIcon: {
      marginBottom: "8px",
      display: "flex",
      justifyContent: "center",
      alignItems: "center",
      height: effectiveMobile ? "52px" : "64px",
      width: "100%"
    },
    categoryName: {
      fontSize: effectiveMobile ? "12px" : "14px",
      fontWeight: "500",
      color: "#334155",
      minHeight: effectiveMobile ? "28px" : "32px",
      display: "flex",
      alignItems: "center",
      justifyContent: "center",
      lineHeight: "1.2"
    },
    searchContainer: {
      marginBottom: "24px"
    },
    searchInput: {
      width: "100%",
      padding: "14px 20px",
      borderRadius: "12px",
      border: "2px solid rgba(0,0,0,0.1)",
      background: "rgba(255, 255, 255, 0.98)",
      color: "#1e293b",
      fontSize: "16px",
      outline: "none",
      transition: "border-color 0.2s",
      boxSizing: "border-box"
    },
    questionCard: {
      background: "rgba(255, 255, 255, 0.98)",
      borderRadius: "20px",
      padding: effectiveMobile ? "16px" : "24px",
      border: "1px solid rgba(15, 23, 42, 0.08)",
      boxShadow: "0 10px 24px rgba(15, 23, 42, 0.07)"
    },
    questionHeader: {
      display: "flex",
      justifyContent: "space-between",
      alignItems: "center",
      marginBottom: "14px",
      flexWrap: "wrap",
      gap: "10px"
    },
    questionProgress: {
      fontSize: effectiveMobile ? "13px" : "14px",
      color: "#64748b"
    },
    categoryBadge: (color) => ({
      background: `${color}20`,
      color,
      padding: "6px 12px",
      borderRadius: "20px",
      fontSize: "12px",
      fontWeight: "500",
      display: "inline-flex",
      alignItems: "center",
      gap: "6px",
      lineHeight: 1
    }),
    questionText: {
      fontSize: effectiveMobile ? "21px" : "24px",
      lineHeight: "1.55",
      marginBottom: "16px",
      color: "#0f172a",
      fontWeight: "600"
    },
    questionTextCompact: {
      fontSize: effectiveMobile ? "19px" : "21px",
      lineHeight: "1.52",
      marginBottom: "12px",
      color: "#0f172a",
      fontWeight: "600"
    },
    quizImageGroup: {
      display: "grid",
      gap: "10px",
      marginBottom: "14px"
    },
    quizImageCard: {
      margin: 0,
      background: "rgba(255, 255, 255, 0.9)",
      border: "1px solid rgba(15, 23, 42, 0.12)",
      borderRadius: "12px",
      overflow: "hidden"
    },
    quizImage: {
      display: "block",
      width: "auto",
      maxWidth: "100%",
      height: "auto",
      maxHeight: effectiveMobile ? "320px" : "520px",
      objectFit: "contain",
      margin: "0 auto",
      background: "rgba(148, 163, 184, 0.15)"
    },
    quizImageCaption: {
      fontSize: "12px",
      lineHeight: "1.4",
      color: "#475569",
      padding: "8px 10px"
    },
    optionsContainer: {
      display: "flex",
      flexDirection: "column",
      gap: "9px"
    },
    optionBtn: (isSelected, isCorrect, showResult) => {
      let bg = "rgba(148, 163, 184, 0.14)";
      let border = "rgba(71, 85, 105, 0.35)";
      if (showResult) {
        if (isCorrect) {
          bg = "rgba(16, 185, 129, 0.15)";
          border = "#10b981";
        } else if (isSelected && !isCorrect) {
          bg = "rgba(239, 68, 68, 0.15)";
          border = "#ef4444";
        }
      } else if (isSelected) {
        bg = "rgba(71, 85, 105, 0.15)";
        border = "#475569";
      }
      return {
        padding: effectiveMobile ? "14px 14px" : "14px 16px",
        minHeight: effectiveMobile ? "50px" : "48px",
        borderRadius: "12px",
        border: `2px solid ${border}`,
        background: bg,
        color: "#334155",
        cursor: showResult ? "default" : "pointer",
        fontSize: effectiveMobile ? "15px" : "16px",
        lineHeight: "1.4",
        textAlign: "left",
        transition: "all 0.2s"
      };
    },
    explanationBox: {
      background: "rgba(71, 85, 105, 0.08)",
      borderRadius: "12px",
      padding: "20px",
      marginTop: "20px",
      borderLeft: "4px solid #475569"
    },
    explanationTitle: {
      fontSize: "16px",
      fontWeight: "600",
      color: "#334155",
      marginBottom: "12px"
    },
    explanationText: {
      fontSize: "14px",
      lineHeight: "1.45",
      color: "#475569"
    },
    nextBtn: {
      width: "100%",
      padding: effectiveMobile ? "16px" : "15px",
      minHeight: effectiveMobile ? "52px" : "48px",
      borderRadius: "12px",
      border: "none",
      background: "linear-gradient(135deg, #475569, #334155)",
      color: "white",
      fontSize: effectiveMobile ? "17px" : "16px",
      fontWeight: "600",
      cursor: "pointer",
      marginTop: effectiveMobile ? "16px" : "18px",
      transition: "transform 0.2s, box-shadow 0.2s",
      boxShadow: "0 4px 15px rgba(71, 85, 105, 0.25)"
    },
    backBtn: {
      padding: effectiveMobile ? "12px 16px" : "10px 20px",
      minHeight: effectiveMobile ? "44px" : "40px",
      borderRadius: "8px",
      border: "2px solid rgba(0,0,0,0.15)",
      background: "transparent",
      color: "#475569",
      cursor: "pointer",
      fontSize: effectiveMobile ? "15px" : "14px",
      marginBottom: effectiveMobile ? "14px" : "20px",
      display: "flex",
      alignItems: "center",
      gap: "8px"
    },
    gameTimer: {
      position: "fixed",
      top: effectiveMobile ? "70px" : "20px",
      left: "50%",
      transform: "translateX(-50%)",
      background: gameTimeLeft <= 10 ? "linear-gradient(135deg, #ef4444, #dc2626)" : gameTimeLeft <= 60 ? "linear-gradient(135deg, #f59e0b, #d97706)" : "linear-gradient(135deg, #475569, #334155)",
      padding: "12px 32px",
      borderRadius: "40px",
      fontSize: "28px",
      fontWeight: "700",
      color: "white",
      boxShadow: "0 4px 20px rgba(0,0,0,0.2)",
      zIndex: 100,
      animation: gameTimeLeft <= 10 ? "pulse 0.5s infinite" : "none"
    },
    streakCounter: {
      position: "fixed",
      top: effectiveMobile ? "70px" : "20px",
      right: "20px",
      background: "rgba(255, 255, 255, 0.98)",
      padding: "10px 20px",
      borderRadius: "12px",
      fontSize: "16px",
      fontWeight: "600",
      color: getStreakStatus().color,
      boxShadow: "0 4px 15px rgba(0,0,0,0.1)",
      zIndex: 100,
      border: `2px solid ${getStreakStatus().color}30`,
      transition: "all 0.3s"
    },
    countdownOverlay: {
      position: "fixed",
      top: 0,
      left: 0,
      right: 0,
      bottom: 0,
      background: "rgba(255, 255, 255, 0.98)",
      display: "flex",
      alignItems: "center",
      justifyContent: "center",
      zIndex: 1e3
    },
    countdownNumber: {
      fontSize: "150px",
      fontWeight: "900",
      background: "linear-gradient(135deg, #475569, #334155, #1e293b)",
      WebkitBackgroundClip: "text",
      WebkitTextFillColor: "transparent",
      animation: "countdownPulse 1s ease-out"
    },
    gameIntroOverlay: {
      position: "fixed",
      top: 0,
      left: 0,
      right: 0,
      bottom: 0,
      background: "rgba(255, 255, 255, 0.98)",
      display: "flex",
      alignItems: "center",
      justifyContent: "center",
      zIndex: 1e3,
      padding: "20px"
    },
    gameIntroCard: {
      background: "linear-gradient(135deg, rgba(255, 255, 255, 0.98), rgba(248, 250, 252, 0.95))",
      borderRadius: "24px",
      padding: effectiveMobile ? "24px" : "40px",
      maxWidth: "500px",
      textAlign: "center",
      border: "2px solid rgba(71, 85, 105, 0.2)",
      boxShadow: "0 20px 60px rgba(71, 85, 105, 0.15)"
    },
    gameIntroIcon: {
      fontSize: "64px",
      marginBottom: "20px"
    },
    gameIntroTitle: {
      fontSize: "32px",
      fontWeight: "800",
      background: "linear-gradient(135deg, #f59e0b, #ef4444)",
      WebkitBackgroundClip: "text",
      WebkitTextFillColor: "transparent",
      marginBottom: "20px"
    },
    gameIntroDesc: {
      fontSize: "16px",
      color: "#64748b",
      lineHeight: "1.8",
      marginBottom: "24px"
    },
    gameIntroFeature: {
      display: "flex",
      alignItems: "center",
      gap: "12px",
      padding: "12px",
      background: "rgba(0,0,0,0.03)",
      borderRadius: "8px",
      marginBottom: "12px",
      textAlign: "left",
      color: "#334155"
    },
    beginBtn: {
      width: "100%",
      padding: "18px",
      borderRadius: "12px",
      border: "none",
      background: "linear-gradient(135deg, #f59e0b, #ef4444)",
      color: "white",
      fontSize: "20px",
      fontWeight: "700",
      cursor: "pointer",
      marginTop: "20px",
      transition: "transform 0.2s",
      boxShadow: "0 4px 20px rgba(245, 158, 11, 0.3)"
    },
    warningBanner: {
      position: "fixed",
      top: effectiveMobile ? "120px" : "80px",
      left: "50%",
      transform: "translateX(-50%)",
      background: "linear-gradient(135deg, #f59e0b, #ef4444)",
      padding: "10px 30px",
      borderRadius: "30px",
      fontSize: "18px",
      fontWeight: "700",
      color: "white",
      zIndex: 100,
      animation: "shake 0.5s ease-in-out",
      boxShadow: "0 4px 20px rgba(245, 158, 11, 0.4)"
    },
    resultsContainer: {
      maxHeight: "400px",
      overflowY: "auto",
      marginTop: "20px"
    },
    resultItem: (isCorrect) => ({
      background: isCorrect ? "rgba(16, 185, 129, 0.08)" : "rgba(239, 68, 68, 0.08)",
      borderRadius: "12px",
      padding: "16px",
      marginBottom: "12px",
      borderLeft: `4px solid ${isCorrect ? "#10b981" : "#ef4444"}`
    }),
    chatNotice: {
      background: "rgba(245, 158, 11, 0.12)",
      border: "1px solid rgba(245, 158, 11, 0.35)",
      color: "#92400e",
      borderRadius: "10px",
      padding: "10px 12px",
      marginBottom: "12px",
      fontSize: "13px",
      lineHeight: "1.4"
    },
    chatMessageList: {
      maxHeight: effectiveMobile ? "360px" : "420px",
      overflowY: "auto",
      border: "1px solid rgba(15, 23, 42, 0.08)",
      borderRadius: "12px",
      background: "rgba(255,255,255,0.92)",
      padding: "10px"
    },
    chatMessageItem: {
      borderBottom: "1px solid rgba(148, 163, 184, 0.2)",
      padding: "8px 4px"
    },
    chatInput: {
      width: "100%",
      border: "1px solid rgba(71, 85, 105, 0.3)",
      borderRadius: "10px",
      padding: "10px 12px",
      fontSize: "14px",
      outline: "none",
      boxSizing: "border-box"
    },
    chatActions: {
      display: "flex",
      gap: "10px",
      marginTop: "12px",
      flexWrap: "wrap"
    },
    chatDeleteBtn: {
      padding: "4px 8px",
      borderRadius: "8px",
      border: "1px solid rgba(239, 68, 68, 0.35)",
      background: "rgba(239, 68, 68, 0.08)",
      color: "#b91c1c",
      cursor: "pointer",
      fontSize: "12px",
      fontWeight: "600"
    },
    secondaryBtn: {
      padding: "10px 14px",
      borderRadius: "10px",
      border: "1px solid rgba(71, 85, 105, 0.28)",
      background: "white",
      color: "#334155",
      cursor: "pointer",
      fontSize: "14px",
      fontWeight: "600"
    },
    progressBar: {
      width: "100%",
      height: "6px",
      background: "rgba(0,0,0,0.08)",
      borderRadius: "3px",
      overflow: "hidden",
      marginTop: "6px"
    },
    progressFill: (percent, color) => ({
      width: `${percent}%`,
      height: "100%",
      background: color || "linear-gradient(135deg, #475569, #334155)",
      borderRadius: "3px",
      transition: "width 0.5s ease"
    })
  }), [effectiveMobile]);
  const renderHome = () => /* @__PURE__ */ React.createElement(React.Fragment, null, /* @__PURE__ */ React.createElement("div", { style: styles.statsGrid }, /* @__PURE__ */ React.createElement("div", { style: styles.statCard }, /* @__PURE__ */ React.createElement("div", { style: styles.statValue }, answeredCount, "/", totalQuestions), /* @__PURE__ */ React.createElement("div", { style: styles.statLabel }, "Questions Seen")), /* @__PURE__ */ React.createElement("div", { style: styles.statCard }, /* @__PURE__ */ React.createElement("div", { style: styles.statValue }, correctRate, "%"), /* @__PURE__ */ React.createElement("div", { style: styles.statLabel }, "Accuracy")), /* @__PURE__ */ React.createElement("div", { style: styles.statCard }, /* @__PURE__ */ React.createElement("div", { style: styles.statValue }, dueReviewQuestions.length), /* @__PURE__ */ React.createElement("div", { style: styles.statLabel }, "Due Today")), /* @__PURE__ */ React.createElement("div", { style: styles.statCard }, /* @__PURE__ */ React.createElement("div", { style: styles.statValue }, progress.incorrectQuestions.length), /* @__PURE__ */ React.createElement("div", { style: styles.statLabel }, "To Review")), /* @__PURE__ */ React.createElement("div", { style: styles.statCard }, /* @__PURE__ */ React.createElement("div", { style: styles.statValue }, progress.gameHighScore), /* @__PURE__ */ React.createElement("div", { style: styles.statLabel }, "Game High Score")), /* @__PURE__ */ React.createElement("div", { style: styles.statCard }, /* @__PURE__ */ React.createElement("div", { style: styles.statValue }, progress.bookmarkedQuestions?.length || 0), /* @__PURE__ */ React.createElement("div", { style: styles.statLabel }, "Bookmarked"))), /* @__PURE__ */ React.createElement("div", { style: styles.searchContainer }, /* @__PURE__ */ React.createElement(
    "input",
    {
      type: "text",
      placeholder: "Search questions, answers, or topics...",
      style: styles.searchInput,
      value: searchQuery,
      onChange: (e) => handleSearch(e.target.value)
    }
  )), searchResults.length > 0 && /* @__PURE__ */ React.createElement("div", { style: styles.card }, /* @__PURE__ */ React.createElement("h3", { style: { marginBottom: "16px", color: "#475569" } }, "Search Results (", searchResults.length, searchResults.length > 20 ? " \u2014 showing first 20" : "", ")"), /* @__PURE__ */ React.createElement("div", { style: { maxHeight: "400px", overflowY: "auto" } }, searchResults.slice(0, 20).map((q, i) => {
    const cat = getCategoryById(q.categoryId);
    return /* @__PURE__ */ React.createElement(
      "div",
      {
        key: i,
        style: {
          padding: "12px",
          background: "rgba(0,0,0,0.03)",
          borderRadius: "8px",
          marginBottom: "8px",
          cursor: "pointer",
          border: "1px solid rgba(0,0,0,0.06)",
          transition: "all 0.15s ease"
        },
        onClick: () => startQuizFromQuestion(q.id),
        onMouseEnter: (e) => {
          e.currentTarget.style.background = "rgba(37, 99, 235, 0.06)";
          e.currentTarget.style.borderColor = "rgba(37, 99, 235, 0.2)";
        },
        onMouseLeave: (e) => {
          e.currentTarget.style.background = "rgba(0,0,0,0.03)";
          e.currentTarget.style.borderColor = "rgba(0,0,0,0.06)";
        }
      },
      /* @__PURE__ */ React.createElement("div", { style: { display: "flex", justifyContent: "space-between", alignItems: "center" } }, /* @__PURE__ */ React.createElement("span", { style: styles.categoryBadge(cat.color) }, /* @__PURE__ */ React.createElement("span", { style: { display: "inline-flex", alignItems: "center", marginRight: "4px" } }, renderBadgeCategoryIcon(cat.icon)), cat.name), /* @__PURE__ */ React.createElement("span", { style: { fontSize: "12px", color: "#94a3b8" } }, "Click to quiz \u2192")),
      /* @__PURE__ */ React.createElement("p", { style: { marginTop: "8px", fontSize: "14px", color: "#475569", lineHeight: 1.4 } }, highlightText(q.question.substring(0, 120) + (q.question.length > 120 ? "..." : ""), searchQuery))
    );
  }))), /* @__PURE__ */ React.createElement("div", { style: styles.actionGrid }, /* @__PURE__ */ React.createElement(
    "div",
    {
      style: styles.actionCard("#475569"),
      onClick: () => startQuiz(25),
      onMouseEnter: (e) => e.currentTarget.style.transform = "translateY(-4px)",
      onMouseLeave: (e) => e.currentTarget.style.transform = "translateY(0)"
    },
    /* @__PURE__ */ React.createElement("div", { style: styles.actionIcon }, "\u{1F4DD}"),
    /* @__PURE__ */ React.createElement("div", { style: styles.actionTitle }, "Quick Quiz"),
    /* @__PURE__ */ React.createElement("div", { style: styles.actionDesc }, "25 Random Questions")
  ), /* @__PURE__ */ React.createElement(
    "div",
    {
      style: styles.actionCard("#334155"),
      onClick: () => startQuiz(50),
      onMouseEnter: (e) => e.currentTarget.style.transform = "translateY(-4px)",
      onMouseLeave: (e) => e.currentTarget.style.transform = "translateY(0)"
    },
    /* @__PURE__ */ React.createElement("div", { style: styles.actionIcon }, "\u{1F4DA}"),
    /* @__PURE__ */ React.createElement("div", { style: styles.actionTitle }, "Full Quiz"),
    /* @__PURE__ */ React.createElement("div", { style: styles.actionDesc }, "50 Random Questions")
  ), /* @__PURE__ */ React.createElement(
    "div",
    {
      style: styles.actionCard("#f59e0b"),
      onClick: initiateGameMode,
      onMouseEnter: (e) => e.currentTarget.style.transform = "translateY(-4px)",
      onMouseLeave: (e) => e.currentTarget.style.transform = "translateY(0)"
    },
    /* @__PURE__ */ React.createElement("div", { style: styles.actionIcon }, "\u{1F3AE}"),
    /* @__PURE__ */ React.createElement("div", { style: styles.actionTitle }, "Game Mode"),
    /* @__PURE__ */ React.createElement("div", { style: styles.actionDesc }, "3 Minutes \u2022 Beat Your Score!")
  ), /* @__PURE__ */ React.createElement(
    "div",
    {
      style: {
        ...styles.actionCard("#14b8a6"),
        opacity: upcomingReviewQuestions.length === 0 ? 0.5 : 1,
        cursor: upcomingReviewQuestions.length === 0 ? "not-allowed" : "pointer"
      },
      onClick: upcomingReviewQuestions.length > 0 ? startUpcomingReview : null,
      onMouseEnter: (e) => {
        if (upcomingReviewQuestions.length > 0) {
          e.currentTarget.style.transform = "translateY(-4px)";
        }
      },
      onMouseLeave: (e) => e.currentTarget.style.transform = "translateY(0)"
    },
    /* @__PURE__ */ React.createElement("div", { style: styles.actionIcon }, "\u{1F4C5}"),
    /* @__PURE__ */ React.createElement("div", { style: styles.actionTitle }, "Upcoming Reviews"),
    /* @__PURE__ */ React.createElement("div", { style: styles.actionDesc }, upcomingReviewQuestions.length, " Scheduled \u2022 ", nextUpcomingDueText)
  ), /* @__PURE__ */ React.createElement(
    "div",
    {
      style: {
        ...styles.actionCard("#0ea5e9"),
        opacity: dueReviewQuestions.length === 0 ? 0.5 : 1,
        cursor: dueReviewQuestions.length === 0 ? "not-allowed" : "pointer"
      },
      onClick: dueReviewQuestions.length > 0 ? startDueReview : null,
      onMouseEnter: (e) => {
        if (dueReviewQuestions.length > 0) {
          e.currentTarget.style.transform = "translateY(-4px)";
        }
      },
      onMouseLeave: (e) => e.currentTarget.style.transform = "translateY(0)"
    },
    /* @__PURE__ */ React.createElement("div", { style: styles.actionIcon }, "\u23F0"),
    /* @__PURE__ */ React.createElement("div", { style: styles.actionTitle }, "Due for Review"),
    /* @__PURE__ */ React.createElement("div", { style: styles.actionDesc }, dueReviewQuestions.length, " Questions Due")
  ), /* @__PURE__ */ React.createElement(
    "div",
    {
      style: {
        ...styles.actionCard("#ef4444"),
        opacity: progress.incorrectQuestions.length === 0 ? 0.5 : 1,
        cursor: progress.incorrectQuestions.length === 0 ? "not-allowed" : "pointer"
      },
      onClick: progress.incorrectQuestions.length > 0 ? startIncorrectReview : null,
      onMouseEnter: (e) => {
        if (progress.incorrectQuestions.length > 0) {
          e.currentTarget.style.transform = "translateY(-4px)";
        }
      },
      onMouseLeave: (e) => e.currentTarget.style.transform = "translateY(0)"
    },
    /* @__PURE__ */ React.createElement("div", { style: styles.actionIcon }, "\u{1F504}"),
    /* @__PURE__ */ React.createElement("div", { style: styles.actionTitle }, "Review Incorrect"),
    /* @__PURE__ */ React.createElement("div", { style: styles.actionDesc }, progress.incorrectQuestions.length, " Questions to Review")
  ), /* @__PURE__ */ React.createElement(
    "div",
    {
      style: {
        ...styles.actionCard,
        opacity: (progress.bookmarkedQuestions?.length || 0) === 0 ? 0.5 : 1,
        cursor: (progress.bookmarkedQuestions?.length || 0) === 0 ? "not-allowed" : "pointer",
        borderColor: "rgba(234, 179, 8, 0.3)",
        background: "linear-gradient(135deg, rgba(234, 179, 8, 0.04), rgba(245, 158, 11, 0.08))"
      },
      onClick: (progress.bookmarkedQuestions?.length || 0) > 0 ? startBookmarkReview : null,
      onMouseEnter: (e) => {
        if ((progress.bookmarkedQuestions?.length || 0) > 0) {
          e.currentTarget.style.transform = "translateY(-4px)";
        }
      },
      onMouseLeave: (e) => e.currentTarget.style.transform = "translateY(0)"
    },
    /* @__PURE__ */ React.createElement("div", { style: styles.actionIcon }, "\u{1F516}"),
    /* @__PURE__ */ React.createElement("div", { style: styles.actionTitle }, "Bookmarked"),
    /* @__PURE__ */ React.createElement("div", { style: styles.actionDesc }, progress.bookmarkedQuestions?.length || 0, " Saved Questions")
  )), /* @__PURE__ */ React.createElement("div", { style: styles.card }, /* @__PURE__ */ React.createElement("h2", { style: { marginBottom: "20px", fontSize: "20px", color: "#1e293b" } }, "Study by Category"), /* @__PURE__ */ React.createElement("div", { style: styles.categoryGrid }, CATEGORIES.map((cat) => {
    const catProgress = progress.categoryProgress[cat.id];
    const catQuestions = QUESTIONS.filter((q) => q.categoryId === cat.id).length;
    const catAnswered = categoryAnsweredCounts[cat.id] || { answered: 0, correct: 0 };
    const answeredPercent = catQuestions > 0 ? Math.round(catAnswered.answered / catQuestions * 100) : 0;
    const correctPercent = catAnswered.answered > 0 ? Math.round(catAnswered.correct / catAnswered.answered * 100) : 0;
    return /* @__PURE__ */ React.createElement(
      "div",
      {
        key: cat.id,
        style: styles.categoryCard(cat.color),
        onClick: () => startCategoryReview(cat.id),
        onMouseEnter: (e) => e.currentTarget.style.transform = "scale(1.03)",
        onMouseLeave: (e) => e.currentTarget.style.transform = "scale(1)"
      },
      /* @__PURE__ */ React.createElement("div", { style: styles.categoryIcon }, renderCategoryIcon(cat.icon, effectiveMobile ? 28 : 36)),
      /* @__PURE__ */ React.createElement("div", { style: styles.categoryName }, cat.name),
      /* @__PURE__ */ React.createElement("div", { style: {
        fontSize: "11px",
        color: "#64748b",
        marginTop: "auto",
        paddingTop: "8px",
        width: "100%"
      } }, /* @__PURE__ */ React.createElement("div", { style: { display: "flex", justifyContent: "space-between", alignItems: "center", marginBottom: "4px" } }, /* @__PURE__ */ React.createElement("span", null, catAnswered.answered, "/", catQuestions, " answered"), catAnswered.answered > 0 && /* @__PURE__ */ React.createElement("span", { style: {
        color: correctPercent >= 80 ? "#16a34a" : correctPercent >= 60 ? "#d97706" : "#dc2626",
        fontWeight: "600"
      } }, correctPercent, "% \u2713")), /* @__PURE__ */ React.createElement("div", { style: styles.progressBar }, /* @__PURE__ */ React.createElement("div", { style: styles.progressFill(answeredPercent, cat.color) })))
    );
  }))), answeredCount > 0 && /* @__PURE__ */ React.createElement("div", { style: { textAlign: "center", marginTop: "32px", paddingTop: "24px", borderTop: "1px solid rgba(0,0,0,0.06)" } }, /* @__PURE__ */ React.createElement("button", { style: { background: "none", border: "1px solid rgba(239, 68, 68, 0.3)", color: "#dc2626", padding: "10px 24px", borderRadius: "8px", cursor: "pointer", fontSize: "13px", fontWeight: "500", transition: "all 0.15s ease" }, onClick: resetAllProgress, onMouseEnter: (e) => { e.currentTarget.style.background = "rgba(239, 68, 68, 0.08)"; }, onMouseLeave: (e) => { e.currentTarget.style.background = "none"; } }, "\u{1F5D1}\uFE0F Reset All Progress")));
  const renderCategoryQuestions = () => {
    if (!selectedCategory) return null;
    const category = getCategoryById(selectedCategory);
    const categoryQuestions = QUESTIONS.filter((q) => q.categoryId === selectedCategory);
    const catAnswered = categoryAnsweredCounts[selectedCategory] || { answered: 0, correct: 0 };
    const answeredPercent = categoryQuestions.length > 0 ? Math.round(catAnswered.answered / categoryQuestions.length * 100) : 0;
    const correctPercent = catAnswered.answered > 0 ? Math.round(catAnswered.correct / catAnswered.answered * 100) : 0;
    return /* @__PURE__ */ React.createElement(React.Fragment, null, /* @__PURE__ */ React.createElement("button", { style: styles.backBtn, onClick: goHome }, "\u2190 Back to Home"), /* @__PURE__ */ React.createElement("div", { style: {
      ...styles.card,
      background: `linear-gradient(135deg, ${category.color}18, ${category.color}08)`,
      border: `1px solid ${category.color}40`
    } }, /* @__PURE__ */ React.createElement("div", { style: { display: "flex", alignItems: "center", gap: "16px", marginBottom: "16px", flexWrap: "wrap" } }, /* @__PURE__ */ React.createElement("div", { style: { fontSize: "48px", display: "flex", alignItems: "center", justifyContent: "center", width: "96px", height: "96px", flexShrink: 0 } }, renderCategoryIcon(category.icon, 48)), /* @__PURE__ */ React.createElement("div", { style: { flex: 1, minWidth: "180px" } }, /* @__PURE__ */ React.createElement("h2", { style: { margin: 0, fontSize: effectiveMobile ? "22px" : "26px", color: "#1e293b" } }, category.name), /* @__PURE__ */ React.createElement("div", { style: { fontSize: "14px", color: "#64748b", marginTop: "4px" } }, catAnswered.answered, " of ", categoryQuestions.length, " questions answered", catAnswered.answered > 0 && /* @__PURE__ */ React.createElement("span", { style: {
      marginLeft: "12px",
      color: correctPercent >= 80 ? "#16a34a" : correctPercent >= 60 ? "#d97706" : "#dc2626",
      fontWeight: "600"
    } }, correctPercent, "% correct")), /* @__PURE__ */ React.createElement("div", { style: { ...styles.progressBar, marginTop: "8px", height: "8px" } }, /* @__PURE__ */ React.createElement("div", { style: styles.progressFill(answeredPercent, category.color) })))), /* @__PURE__ */ React.createElement("div", { style: { display: "flex", gap: "10px", flexWrap: "wrap" } }, /* @__PURE__ */ React.createElement(
      "button",
      {
        style: {
          padding: "10px 20px",
          borderRadius: "10px",
          border: "none",
          background: `linear-gradient(135deg, ${category.color}, ${category.color}cc)`,
          color: "white",
          cursor: "pointer",
          fontSize: "14px",
          fontWeight: "600",
          transition: "all 0.2s",
          boxShadow: `0 4px 12px ${category.color}40`
        },
        onClick: () => startCategoryQuiz(selectedCategory, 0)
      },
      "\u25B6 Start from Beginning"
    ), catAnswered.answered > 0 && catAnswered.answered < categoryQuestions.length && (() => {
      const firstUnansweredIdx = categoryQuestions.findIndex((q) => !(q.id in progress.answeredQuestions));
      return firstUnansweredIdx > 0 ? /* @__PURE__ */ React.createElement(
        "button",
        {
          style: {
            padding: "10px 20px",
            borderRadius: "10px",
            border: `2px solid ${category.color}60`,
            background: "rgba(255,255,255,0.8)",
            color: category.color,
            cursor: "pointer",
            fontSize: "14px",
            fontWeight: "600",
            transition: "all 0.2s"
          },
          onClick: () => startCategoryQuiz(selectedCategory, firstUnansweredIdx)
        },
        "\u23ED Continue (Q",
        firstUnansweredIdx + 1,
        ")"
      ) : null;
    })(), catAnswered.answered > 0 && /* @__PURE__ */ React.createElement("button", { style: { padding: "10px 20px", borderRadius: "10px", border: "1px solid rgba(239, 68, 68, 0.3)", background: "none", color: "#dc2626", cursor: "pointer", fontSize: "13px", fontWeight: "500", transition: "all 0.15s ease", marginLeft: "auto" }, onClick: (e) => { e.stopPropagation(); resetCategoryProgress(selectedCategory); }, onMouseEnter: (e) => { e.currentTarget.style.background = "rgba(239, 68, 68, 0.08)"; }, onMouseLeave: (e) => { e.currentTarget.style.background = "none"; } }, "\u{1F5D1}\uFE0F Reset Category"))), /* @__PURE__ */ React.createElement("div", { style: styles.card }, /* @__PURE__ */ React.createElement("h3", { style: { margin: "0 0 16px 0", fontSize: "17px", color: "#1e293b" } }, "Questions (", categoryQuestions.length, ")"), /* @__PURE__ */ React.createElement("div", { style: { display: "flex", flexDirection: "column", gap: "8px" } }, categoryQuestions.map((q, idx) => {
      const wasAnswered = q.id in progress.answeredQuestions;
      const wasCorrect = progress.answeredQuestions[q.id];
      return /* @__PURE__ */ React.createElement(
        "div",
        {
          key: q.id,
          style: {
            display: "flex",
            alignItems: "flex-start",
            gap: "12px",
            padding: effectiveMobile ? "12px" : "14px 16px",
            borderRadius: "10px",
            border: `1px solid ${wasAnswered ? wasCorrect ? "rgba(22, 163, 74, 0.25)" : "rgba(220, 38, 38, 0.25)" : "rgba(0,0,0,0.08)"}`,
            background: wasAnswered ? wasCorrect ? "rgba(22, 163, 74, 0.04)" : "rgba(220, 38, 38, 0.04)" : "rgba(248, 250, 252, 0.6)",
            cursor: "pointer",
            transition: "all 0.2s"
          },
          onClick: () => startCategoryQuiz(selectedCategory, idx),
          onMouseEnter: (e) => {
            e.currentTarget.style.boxShadow = "0 4px 12px rgba(0,0,0,0.08)";
            e.currentTarget.style.transform = "translateY(-1px)";
          },
          onMouseLeave: (e) => {
            e.currentTarget.style.boxShadow = "none";
            e.currentTarget.style.transform = "translateY(0)";
          }
        },
        /* @__PURE__ */ React.createElement("div", { style: {
          width: "28px",
          height: "28px",
          borderRadius: "8px",
          display: "flex",
          alignItems: "center",
          justifyContent: "center",
          fontSize: "13px",
          fontWeight: "700",
          flexShrink: 0,
          marginTop: "1px",
          background: wasAnswered ? wasCorrect ? "rgba(22, 163, 74, 0.15)" : "rgba(220, 38, 38, 0.15)" : "rgba(0,0,0,0.06)",
          color: wasAnswered ? wasCorrect ? "#16a34a" : "#dc2626" : "#94a3b8"
        } }, wasAnswered ? wasCorrect ? "\u2713" : "\u2717" : idx + 1),
        /* @__PURE__ */ React.createElement("div", { style: {
          flex: 1,
          fontSize: effectiveMobile ? "13px" : "14px",
          lineHeight: "1.5",
          color: "#334155"
        } }, q.question.length > 150 ? q.question.substring(0, 150) + "\u2026" : q.question),
        isBookmarked(q.id) && /* @__PURE__ */ React.createElement("span", { style: { fontSize: "14px", flexShrink: 0, marginTop: "2px" } }, "\u{1F516}")
      );
    }))));
  };
  const renderQuiz = () => {
    if (quizQuestions.length === 0) return null;
    const currentQuestion = quizQuestions[currentQuestionIndex];
    const category = getCategoryById(currentQuestion.categoryId);
    const questionImages = normalizeImageEntries(currentQuestion.questionImages || currentQuestion.questionImage, "Question image");
    const explanationImages = normalizeImageEntries(currentQuestion.explanationImages || currentQuestion.explanationImage, "Explanation image");
    return /* @__PURE__ */ React.createElement(React.Fragment, null, /* @__PURE__ */ React.createElement("button", { style: styles.backBtn, onClick: currentView === "category-review" ? () => {
      play("click");
      setCurrentView("category-questions");
    } : goHome }, "\u2190 ", currentView === "category-review" ? "Back to Questions" : "Back to Home"), /* @__PURE__ */ React.createElement("div", { style: styles.questionCard }, /* @__PURE__ */ React.createElement("div", { style: styles.questionHeader }, /* @__PURE__ */ React.createElement("span", { style: styles.questionProgress }, "Question ", currentQuestionIndex + 1, " of ", quizQuestions.length), /* @__PURE__ */ React.createElement("span", { style: styles.categoryBadge(category.color) }, /* @__PURE__ */ React.createElement("span", { style: { display: "inline-flex", alignItems: "center", marginRight: "4px" } }, renderBadgeCategoryIcon(category.icon)), category.name)), /* @__PURE__ */ React.createElement("div", { style: styles.progressBar }, /* @__PURE__ */ React.createElement("div", { style: styles.progressFill(
      (currentQuestionIndex + 1) / quizQuestions.length * 100
    ) })), questionImages.length > 0 && /* @__PURE__ */ React.createElement("div", { style: styles.quizImageGroup }, questionImages.map((img, idx) => /* @__PURE__ */ React.createElement("figure", { key: `${currentQuestion.id}-qimg-${idx}`, style: styles.quizImageCard }, /* @__PURE__ */ React.createElement("img", { src: img.src, alt: img.alt, style: styles.quizImage, loading: "lazy", decoding: "async" }), !!img.caption && /* @__PURE__ */ React.createElement("figcaption", { style: styles.quizImageCaption }, img.caption)))), /* @__PURE__ */ React.createElement("p", { style: showExplanation ? styles.questionTextCompact : styles.questionText }, currentQuestion.question), (() => {
      const shuffled = getShuffledOptions(currentQuestion);
      return /* @__PURE__ */ React.createElement("div", { style: styles.optionsContainer }, shuffled.options.map((option, idx) => /* @__PURE__ */ React.createElement(
        "button",
        {
          key: idx,
          style: styles.optionBtn(
            selectedAnswer === idx,
            idx === shuffled.correctIndex,
            showExplanation
          ),
          onClick: () => handleAnswer(idx),
          disabled: showExplanation
        },
        /* @__PURE__ */ React.createElement("span", { style: {
          fontWeight: "600",
          marginRight: "12px",
          color: "#64748b"
        } }, String.fromCharCode(65 + idx), "."),
        option.replace(/^[A-D]\)\s*/, "")
      )));
    })(), showExplanation && /* @__PURE__ */ React.createElement("div", { style: styles.explanationBox }, /* @__PURE__ */ React.createElement("div", { style: styles.explanationTitle }, selectedAnswer === getShuffledOptions(currentQuestion).correctIndex ? "\u2705 Correct!" : "\u274C Incorrect"), explanationImages.length > 0 && /* @__PURE__ */ React.createElement("div", { style: styles.quizImageGroup }, explanationImages.map((img, idx) => /* @__PURE__ */ React.createElement("figure", { key: `${currentQuestion.id}-eimg-${idx}`, style: styles.quizImageCard }, /* @__PURE__ */ React.createElement("img", { src: img.src, alt: img.alt, style: styles.quizImage, loading: "lazy", decoding: "async" }), !!img.caption && /* @__PURE__ */ React.createElement("figcaption", { style: styles.quizImageCaption }, img.caption)))), /* @__PURE__ */ React.createElement(
      "button",
      {
        onClick: () => toggleBookmark(currentQuestion.id),
        style: {
          display: "inline-flex",
          alignItems: "center",
          gap: "6px",
          padding: "6px 12px",
          marginBottom: "12px",
          background: isBookmarked(currentQuestion.id) ? "rgba(234, 179, 8, 0.15)" : "rgba(0,0,0,0.04)",
          border: isBookmarked(currentQuestion.id) ? "1px solid rgba(234, 179, 8, 0.4)" : "1px solid rgba(0,0,0,0.08)",
          borderRadius: "8px",
          cursor: "pointer",
          fontSize: "13px",
          color: isBookmarked(currentQuestion.id) ? "#b45309" : "#64748b",
          fontWeight: isBookmarked(currentQuestion.id) ? 600 : 400
        }
      },
      isBookmarked(currentQuestion.id) ? "Bookmarked" : "\u{1F3F7}\uFE0F Bookmark"
    ), /* @__PURE__ */ React.createElement(ExpandableText, { text: fixExplanationLetter(currentQuestion.explanation, String.fromCharCode(65 + getShuffledOptions(currentQuestion).correctIndex)) })), showExplanation && /* @__PURE__ */ React.createElement("button", { style: styles.nextBtn, onClick: nextQuestion }, currentQuestionIndex < quizQuestions.length - 1 ? "Next Question \u2192" : "View Results")));
  };
  const renderGame = () => {
    if (quizQuestions.length === 0) return null;
    const currentQuestion = quizQuestions[currentQuestionIndex];
    const category = getCategoryById(currentQuestion.categoryId);
    const streakStatus = getStreakStatus();
    const gameQuestionImages = normalizeImageEntries(currentQuestion.questionImages || currentQuestion.questionImage, "Question image");
    return /* @__PURE__ */ React.createElement(React.Fragment, null, /* @__PURE__ */ React.createElement("div", { style: styles.gameTimer }, "\u23F1\uFE0F ", formatTime(gameTimeLeft)), /* @__PURE__ */ React.createElement("div", { style: styles.streakCounter }, streakStatus.text), warningShown.oneMin && /* @__PURE__ */ React.createElement("div", { style: styles.warningBanner }, "\u26A0\uFE0F 1 MINUTE LEFT!"), warningShown.tenSec && !warningShown.oneMin && /* @__PURE__ */ React.createElement("div", { style: styles.warningBanner }, "\u26A0\uFE0F 10 SECONDS!"), /* @__PURE__ */ React.createElement("div", { style: { marginTop: effectiveMobile ? "80px" : "60px" } }, /* @__PURE__ */ React.createElement("div", { style: {
      display: "flex",
      justifyContent: "space-between",
      marginBottom: "16px",
      padding: "0 8px"
    } }, /* @__PURE__ */ React.createElement("span", { style: { color: "#059669", fontWeight: "600" } }, "Score: ", gameScore), /* @__PURE__ */ React.createElement("span", { style: { color: "#64748b" } }, "Question #", gameAnswers.length + 1)), /* @__PURE__ */ React.createElement("div", { style: styles.questionCard }, /* @__PURE__ */ React.createElement("span", { style: styles.categoryBadge(category.color) }, /* @__PURE__ */ React.createElement("span", { style: { display: "inline-flex", alignItems: "center", marginRight: "4px" } }, renderBadgeCategoryIcon(category.icon)), category.name), gameQuestionImages.length > 0 && /* @__PURE__ */ React.createElement("div", { style: { ...styles.quizImageGroup, marginTop: "12px" } }, gameQuestionImages.map((img, idx) => /* @__PURE__ */ React.createElement("figure", { key: `${currentQuestion.id}-gqimg-${idx}`, style: styles.quizImageCard }, /* @__PURE__ */ React.createElement("img", { src: img.src, alt: img.alt, style: styles.quizImage, loading: "lazy", decoding: "async" }), !!img.caption && /* @__PURE__ */ React.createElement("figcaption", { style: styles.quizImageCaption }, img.caption)))), /* @__PURE__ */ React.createElement("p", { style: { ...styles.questionText, marginTop: "16px" } }, currentQuestion.question), (() => {
      const shuffled = getShuffledOptions(currentQuestion);
      return /* @__PURE__ */ React.createElement("div", { style: styles.optionsContainer }, shuffled.options.map((option, idx) => /* @__PURE__ */ React.createElement(
        "button",
        {
          key: idx,
          style: styles.optionBtn(selectedAnswer === idx, false, false),
          onClick: () => handleAnswer(idx)
        },
        /* @__PURE__ */ React.createElement("span", { style: {
          fontWeight: "600",
          marginRight: "12px",
          color: "#64748b"
        } }, String.fromCharCode(65 + idx), "."),
        option.replace(/^[A-D]\)\s*/, "")
      )));
    })())));
  };
  const renderGameResults = () => /* @__PURE__ */ React.createElement("div", { style: styles.card }, /* @__PURE__ */ React.createElement("div", { style: { textAlign: "center", marginBottom: "24px" } }, /* @__PURE__ */ React.createElement("div", { style: { fontSize: "64px", marginBottom: "16px" } }, "\u{1F3AE}"), /* @__PURE__ */ React.createElement("h1", { style: {
    fontSize: "36px",
    background: "linear-gradient(135deg, #f59e0b, #ef4444)",
    WebkitBackgroundClip: "text",
    WebkitTextFillColor: "transparent",
    marginBottom: "8px"
  } }, "Game Over!"), /* @__PURE__ */ React.createElement("p", { style: { color: "#64748b" } }, "Time's Up!")), /* @__PURE__ */ React.createElement("div", { style: styles.statsGrid }, /* @__PURE__ */ React.createElement("div", { style: styles.statCard }, /* @__PURE__ */ React.createElement("div", { style: styles.statValue }, gameScore), /* @__PURE__ */ React.createElement("div", { style: styles.statLabel }, "Final Score")), /* @__PURE__ */ React.createElement("div", { style: styles.statCard }, /* @__PURE__ */ React.createElement("div", { style: styles.statValue }, gameAnswers.length), /* @__PURE__ */ React.createElement("div", { style: styles.statLabel }, "Questions Answered")), /* @__PURE__ */ React.createElement("div", { style: styles.statCard }, /* @__PURE__ */ React.createElement("div", { style: styles.statValue }, gameAnswers.length > 0 ? Math.round(gameScore / gameAnswers.length * 100) : 0, "%"), /* @__PURE__ */ React.createElement("div", { style: styles.statLabel }, "Accuracy")), /* @__PURE__ */ React.createElement("div", { style: styles.statCard }, /* @__PURE__ */ React.createElement("div", { style: styles.statValue }, maxStreak), /* @__PURE__ */ React.createElement("div", { style: styles.statLabel }, "Best Streak"))), gameScore > (highScoreAtGameStartRef.current || 0) && /* @__PURE__ */ React.createElement("div", { style: {
    background: "linear-gradient(135deg, rgba(245, 158, 11, 0.15), rgba(239, 68, 68, 0.15))",
    borderRadius: "12px",
    padding: "16px",
    textAlign: "center",
    marginBottom: "20px",
    border: "2px solid rgba(245, 158, 11, 0.4)"
  } }, /* @__PURE__ */ React.createElement("span", { style: { fontSize: "24px" } }, "\u{1F3C6}"), /* @__PURE__ */ React.createElement("span", { style: {
    marginLeft: "12px",
    fontSize: "18px",
    fontWeight: "600",
    color: "#d97706"
  } }, "NEW HIGH SCORE!")), /* @__PURE__ */ React.createElement("h3", { style: { marginBottom: "16px", color: "#334155" } }, "Review Your Answers:"), /* @__PURE__ */ React.createElement("div", { style: styles.resultsContainer }, gameAnswers.map((answer, idx) => {
    const cat = getCategoryById(answer.question.categoryId);
    const revQImgs = normalizeImageEntries(answer.question.questionImages || answer.question.questionImage, "Question image");
    const revEImgs = normalizeImageEntries(answer.question.explanationImages || answer.question.explanationImage, "Explanation image");
    return /* @__PURE__ */ React.createElement("div", { key: idx, style: styles.resultItem(answer.isCorrect) }, /* @__PURE__ */ React.createElement("div", { style: {
      display: "flex",
      justifyContent: "space-between",
      marginBottom: "8px"
    } }, /* @__PURE__ */ React.createElement("span", { style: styles.categoryBadge(cat.color) }, /* @__PURE__ */ React.createElement("span", { style: { display: "inline-flex", alignItems: "center", marginRight: "4px" } }, renderBadgeCategoryIcon(cat.icon)), cat.name), /* @__PURE__ */ React.createElement("span", { style: {
      color: answer.isCorrect ? "#10b981" : "#ef4444",
      fontWeight: "600"
    } }, answer.isCorrect ? "\u2705 Correct" : "\u274C Incorrect")), /* @__PURE__ */ React.createElement("p", { style: { fontSize: "14px", marginBottom: "8px", color: "#334155" } }, answer.question.question), revQImgs.length > 0 && /* @__PURE__ */ React.createElement("div", { style: { ...styles.quizImageGroup, marginBottom: "10px" } }, revQImgs.map((img, imgIdx) => /* @__PURE__ */ React.createElement("figure", { key: `${answer.question.id}-grqimg-${imgIdx}`, style: styles.quizImageCard }, /* @__PURE__ */ React.createElement("img", { src: img.src, alt: img.alt, style: styles.quizImage, loading: "lazy", decoding: "async" }), !!img.caption && /* @__PURE__ */ React.createElement("figcaption", { style: styles.quizImageCaption }, img.caption)))), /* @__PURE__ */ React.createElement("p", { style: { fontSize: "12px", color: "#475569" } }, /* @__PURE__ */ React.createElement("strong", null, "Your answer:"), " ", (answer.userAnswerText || answer.question.options[answer.userAnswer]).replace(/^[A-D]\)\s*/, "")), !answer.isCorrect && /* @__PURE__ */ React.createElement("p", { style: { fontSize: "12px", color: "#059669" } }, /* @__PURE__ */ React.createElement("strong", null, "Correct answer:"), " ", (answer.correctAnswerText || answer.question.options[answer.question.correctAnswer]).replace(/^[A-D]\)\s*/, "")), /* @__PURE__ */ React.createElement("details", { style: { marginTop: "8px" } }, /* @__PURE__ */ React.createElement("summary", { style: { fontSize: "12px", color: "#2563eb", cursor: "pointer", fontWeight: 500 } }, "Show Explanation"), /* @__PURE__ */ React.createElement("div", { style: { marginTop: "8px" } }, /* @__PURE__  */ React.createElement("button", { onClick: () => toggleBookmark(answer.question.id), style: { display: "inline-flex", alignItems: "center", gap: "6px", padding: "6px 10px", marginTop: "0px", marginBottom: "8px", background: isBookmarked(answer.question.id) ? "rgba(234, 179, 8, 0.15)" : "rgba(0,0,0,0.04)", border: isBookmarked(answer.question.id) ? "1px solid rgba(234, 179, 8, 0.4)" : "1px solid rgba(0,0,0,0.08)", borderRadius: "8px", cursor: "pointer", fontSize: "12px", color: isBookmarked(answer.question.id) ? "#b45309" : "#64748b", fontWeight: isBookmarked(answer.question.id) ? 600 : 400 } }, isBookmarked(answer.question.id) ? "Bookmarked" : "\u{1F3F7}\uFE0F Bookmark"), revEImgs.length > 0 && /* @__PURE__ */ React.createElement("div", { style: { ...styles.quizImageGroup, marginTop: "10px", marginBottom: "10px" } }, revEImgs.map((img, imgIdx) => /* @__PURE__ */ React.createElement("figure", { key: `${answer.question.id}-greimg-${imgIdx}`, style: styles.quizImageCard }, /* @__PURE__ */ React.createElement("img", { src: img.src, alt: img.alt, style: styles.quizImage, loading: "lazy", decoding: "async" }), !!img.caption && /* @__PURE__ */ React.createElement("figcaption", { style: styles.quizImageCaption }, img.caption)))), /* @__PURE__ */ React.createElement(ExpandableText, { text: fixExplanationLetter(answer.question.explanation, answer.shuffledCorrectLetter) }))));
  })), /* @__PURE__ */ React.createElement("button", { style: styles.nextBtn, onClick: goHome }, "Return Home"));
  const renderQuizComplete = () => {
    const correct = quizResults.filter((r) => r.isCorrect).length;
    const total = quizResults.length;
    const percent = Math.round(correct / total * 100);
    return /* @__PURE__ */ React.createElement("div", { style: styles.card }, /* @__PURE__ */ React.createElement("div", { style: { textAlign: "center", marginBottom: "24px" } }, /* @__PURE__ */ React.createElement("div", { style: { fontSize: "64px", marginBottom: "16px" } }, percent >= 80 ? "\u{1F389}" : percent >= 60 ? "\u{1F44D}" : "\u{1F4DA}"), /* @__PURE__ */ React.createElement("h1", { style: {
      fontSize: "36px",
      marginBottom: "8px",
      color: "#1e293b"
    } }, "Quiz Complete!"), /* @__PURE__ */ React.createElement("p", { style: { color: "#64748b" } }, "You scored ", correct, " out of ", total, " (", percent, "%)")), /* @__PURE__ */ React.createElement("div", { style: styles.progressBar }, /* @__PURE__ */ React.createElement("div", { style: styles.progressFill(percent, percent >= 80 ? "#10b981" : percent >= 60 ? "#f59e0b" : "#ef4444") })), /* @__PURE__ */ React.createElement("div", { style: { marginTop: "20px", marginBottom: "20px" } }, percent >= 80 && /* @__PURE__ */ React.createElement("p", { style: { color: "#059669", textAlign: "center" } }, "Excellent work! You've mastered this material! \u{1F31F}"), percent >= 60 && percent < 80 && /* @__PURE__ */ React.createElement("p", { style: { color: "#d97706", textAlign: "center" } }, "Good job! Keep practicing to improve further! \u{1F4AA}"), percent < 60 && /* @__PURE__ */ React.createElement("p", { style: { color: "#dc2626", textAlign: "center" } }, "Keep studying! Review the incorrect questions to improve. \u{1F4D6}")), /* @__PURE__ */ React.createElement("button", { style: styles.nextBtn, onClick: selectedCategory ? () => {
      play("click");
      setCurrentView("category-questions");
    } : goHome }, selectedCategory ? "Back to Category" : "Return Home"));
  };
  const renderChatLegacy = () => {
    const modeText = chatSyncMode === "shared" ? "Shared cloud chat active" : "Local device chat only";
    return /* @__PURE__ */ React.createElement(React.Fragment, null, /* @__PURE__ */ React.createElement("button", { style: styles.backBtn, onClick: goHome }, "\u2190 Back to Home"), /* @__PURE__ */ React.createElement("div", { style: styles.card }, /* @__PURE__ */ React.createElement("h2", { style: { margin: "0 0 8px 0", color: "#1e293b" } }, "\u{1F5E3}\uFE0F Clinician Collaboration Chat"), /* @__PURE__ */ React.createElement("p", { style: { margin: "0 0 12px 0", color: "#64748b", fontSize: "14px" } }, modeText), /* @__PURE__ */ React.createElement("div", { style: styles.chatNotice }, "\u26A0\uFE0F Do not include patient identifiers or PHI. Keep messages educational and operational."), !String(FIREBASE_CHAT_DB_URL || "").trim() && /* @__PURE__ */ React.createElement("div", { style: { ...styles.chatNotice, background: "rgba(59, 130, 246, 0.08)", borderColor: "rgba(59, 130, 246, 0.3)", color: "#1e3a8a" } }, "Cloud sync is not configured. Set FIREBASE_CHAT_DB_URL in this file to enable organization-wide shared chat."), /* @__PURE__ */ React.createElement("div", { style: { display: "grid", gridTemplateColumns: effectiveMobile ? "1fr" : "220px 1fr", gap: "10px", marginBottom: "12px" } }, /* @__PURE__ */ React.createElement(
      "input",
      {
        style: styles.chatInput,
        value: chatName,
        maxLength: 40,
        placeholder: "Your display name",
        onChange: (e) => setChatName(e.target.value)
      }
    ), /* @__PURE__ */ React.createElement(
      "input",
      {
        style: styles.chatInput,
        value: chatInput,
        maxLength: 600,
        placeholder: "Type a message to colleagues...",
        onChange: (e) => setChatInput(e.target.value),
        onKeyDown: (e) => {
          if (e.key === "Enter" && !e.shiftKey) {
            e.preventDefault();
            sendChatMessage();
          }
        }
      }
    )), /* @__PURE__ */ React.createElement("div", { style: styles.chatActions }, /* @__PURE__ */ React.createElement("button", { style: styles.nextBtn, onClick: sendChatMessage }, "Send Message"), /* @__PURE__ */ React.createElement("button", { style: styles.secondaryBtn, onClick: loadChatMessages }, "Refresh"), /* @__PURE__ */ React.createElement("button", { style: styles.secondaryBtn, onClick: copyChatSnapshot }, "Copy Snapshot")), /* @__PURE__ */ React.createElement("div", { style: styles.chatMessageList }, chatMessages.length === 0 ? /* @__PURE__ */ React.createElement("p", { style: { color: "#64748b", margin: "8px 4px" } }, "No messages yet. Start the conversation.") : chatMessages.slice(-120).map((m) => /* @__PURE__ */ React.createElement("div", { key: m.id || `${m.ts}-${m.name}`, style: styles.chatMessageItem }, /* @__PURE__ */ React.createElement("div", { style: { display: "flex", justifyContent: "space-between", gap: "10px", marginBottom: "2px" } }, /* @__PURE__ */ React.createElement("strong", { style: { color: "#1e293b", fontSize: "13px" } }, m.name || "Clinician"), /* @__PURE__ */ React.createElement("span", { style: { color: "#94a3b8", fontSize: "12px", flexShrink: 0 } }, new Date(m.ts || Date.now()).toLocaleString())), /* @__PURE__ */ React.createElement("div", { style: { color: "#334155", fontSize: "14px", whiteSpace: "pre-wrap", wordBreak: "break-word" } }, m.text || ""))))));
  };
  const renderChat = () => {
    const modeText = chatSyncMode === "shared" ? "Shared cloud chat active" : "Local device chat only";
    return /* @__PURE__ */ React.createElement(
      React.Fragment,
      null,
      /* @__PURE__ */ React.createElement("button", { style: styles.backBtn, onClick: goHome }, "\u2190 Back to Home"),
      /* @__PURE__ */ React.createElement(
        "div",
        { style: styles.card },
        /* @__PURE__ */ React.createElement("h2", { style: { margin: "0 0 8px 0", color: "#1e293b", display: "inline-flex", alignItems: "center", gap: "8px" }, onClick: handleChatTitleSecretTap }, /* @__PURE__ */ React.createElement("img", { src: CHAT_ICON, alt: "", "aria-hidden": "true", style: styles.chatHeaderIcon }), "Clinician Collaboration Chat"),
        /* @__PURE__ */ React.createElement("p", { style: { margin: "0 0 12px 0", color: "#64748b", fontSize: "14px" } }, modeText),
        /* @__PURE__ */ React.createElement("div", { style: styles.chatNotice }, "\u26A0\uFE0F Do not include patient identifiers or PHI. Keep messages educational and operational."),
        !String(FIREBASE_CHAT_DB_URL || "").trim() && /* @__PURE__ */ React.createElement("div", { style: { ...styles.chatNotice, background: "rgba(59, 130, 246, 0.08)", borderColor: "rgba(59, 130, 246, 0.3)", color: "#1e3a8a" } }, "Cloud sync is not configured. Set FIREBASE_CHAT_DB_URL in this file to enable organization-wide shared chat."),
        /* @__PURE__ */ React.createElement(
          "div",
          { style: { display: "grid", gridTemplateColumns: effectiveMobile ? "1fr" : "220px 1fr", gap: "10px", marginBottom: "12px" } },
          /* @__PURE__ */ React.createElement(
            "input",
            {
              style: styles.chatInput,
              value: chatName,
              maxLength: 40,
              placeholder: "Your display name",
              onChange: (e) => setChatName(e.target.value)
            }
          ),
          /* @__PURE__ */ React.createElement(
            "input",
            {
              style: styles.chatInput,
              value: chatInput,
              maxLength: 600,
              placeholder: "Type a message to colleagues...",
              onChange: (e) => setChatInput(e.target.value),
              onKeyDown: (e) => {
                if (e.key === "Enter" && !e.shiftKey) {
                  e.preventDefault();
                  sendChatMessage();
                }
              }
            }
          )
        ),
        /* @__PURE__ */ React.createElement(
          "div",
          { style: styles.chatActions },
          /* @__PURE__ */ React.createElement("button", { style: styles.nextBtn, onClick: sendChatMessage }, "Send Message"),
          /* @__PURE__ */ React.createElement("button", { style: styles.secondaryBtn, onClick: loadChatMessages }, "Refresh"),
          /* @__PURE__ */ React.createElement("button", { style: styles.secondaryBtn, onClick: copyChatSnapshot }, "Copy Snapshot")
        ),
        /* @__PURE__ */ React.createElement(
          "div",
          { style: styles.chatMessageList },
          chatMessages.length === 0 ? /* @__PURE__ */ React.createElement("p", { style: { color: "#64748b", margin: "8px 4px" } }, "No messages yet. Start the conversation.") : chatMessages.slice(-120).map((m) => {
            const messageKey = getMessageIdentity(m) || `${m.ts}-${m.name}`;
            const canDeleteMessage = chatOwnerMode && (chatSyncMode !== "shared" || !!m.remoteId);
            return /* @__PURE__ */ React.createElement(
              "div",
              { key: messageKey, style: styles.chatMessageItem },
              /* @__PURE__ */ React.createElement(
                "div",
                { style: { display: "flex", justifyContent: "space-between", gap: "10px", marginBottom: "2px" } },
                /* @__PURE__ */ React.createElement("strong", { style: { color: "#1e293b", fontSize: "13px" } }, m.name || "Clinician"),
                /* @__PURE__ */ React.createElement(
                  "div",
                  { style: { display: "flex", alignItems: "center", gap: "8px", flexShrink: 0 } },
                  /* @__PURE__ */ React.createElement("span", { style: { color: "#94a3b8", fontSize: "12px" } }, new Date(m.ts || Date.now()).toLocaleString()),
                  canDeleteMessage && /* @__PURE__ */ React.createElement("button", { style: styles.chatDeleteBtn, onClick: () => deleteChatMessage(m) }, "Delete")
                )
              ),
              /* @__PURE__ */ React.createElement("div", { style: { color: "#334155", fontSize: "14px", whiteSpace: "pre-wrap", wordBreak: "break-word" } }, m.text || "")
            );
          })
        )
      )
    );
  };
  return /* @__PURE__ */ React.createElement("div", { style: styles.app }, /* @__PURE__ */ React.createElement("div", { style: styles.backgroundPattern }), showGameIntro && /* @__PURE__ */ React.createElement("div", { style: styles.gameIntroOverlay }, /* @__PURE__ */ React.createElement("div", { style: styles.gameIntroCard }, /* @__PURE__ */ React.createElement("div", { style: styles.gameIntroIcon }, "\u{1F3AE}"), /* @__PURE__ */ React.createElement("h1", { style: styles.gameIntroTitle }, "GAME MODE"), /* @__PURE__ */ React.createElement("p", { style: styles.gameIntroDesc }, "Test your knowledge under pressure! Answer as many questions as you can in 3 minutes."), /* @__PURE__ */ React.createElement("div", { style: styles.gameIntroFeature }, /* @__PURE__ */ React.createElement("span", { style: { fontSize: "24px" } }, "\u23F1\uFE0F"), /* @__PURE__ */ React.createElement("div", null, /* @__PURE__ */ React.createElement("strong", null, "3 Minutes"), /* @__PURE__ */ React.createElement("p", { style: { fontSize: "12px", color: "#64748b", margin: 0 } }, "Race against the clock"))), /* @__PURE__ */ React.createElement("div", { style: styles.gameIntroFeature }, /* @__PURE__ */ React.createElement("span", { style: { fontSize: "24px" } }, "\u{1F525}"), /* @__PURE__ */ React.createElement("div", null, /* @__PURE__ */ React.createElement("strong", null, "Streak Bonus"), /* @__PURE__ */ React.createElement("p", { style: { fontSize: "12px", color: "#64748b", margin: 0 } }, 'Build your streak - get "Heating Up!"'))), /* @__PURE__ */ React.createElement("div", { style: styles.gameIntroFeature }, /* @__PURE__ */ React.createElement("span", { style: { fontSize: "24px" } }, "\u26A0\uFE0F"), /* @__PURE__ */ React.createElement("div", null, /* @__PURE__ */ React.createElement("strong", null, "Time Warnings"), /* @__PURE__ */ React.createElement("p", { style: { fontSize: "12px", color: "#64748b", margin: 0 } }, "1 minute and 10 second warnings"))), /* @__PURE__ */ React.createElement("div", { style: styles.gameIntroFeature }, /* @__PURE__ */ React.createElement("span", { style: { fontSize: "24px" } }, "\u{1F3C6}"), /* @__PURE__ */ React.createElement("div", null, /* @__PURE__ */ React.createElement("strong", null, "Beat Your High Score"), /* @__PURE__ */ React.createElement("p", { style: { fontSize: "12px", color: "#64748b", margin: 0 } }, "Current: ", progress.gameHighScore, " points"))), /* @__PURE__ */ React.createElement(
    "button",
    {
      style: styles.beginBtn,
      onClick: startGameCountdown,
      onMouseEnter: (e) => e.currentTarget.style.transform = "scale(1.02)",
      onMouseLeave: (e) => e.currentTarget.style.transform = "scale(1)"
    },
    "BEGIN"
  ), /* @__PURE__ */ React.createElement(
    "button",
    {
      style: {
        ...styles.backBtn,
        width: "100%",
        marginTop: "12px",
        marginBottom: 0,
        justifyContent: "center"
      },
      onClick: () => setShowGameIntro(false)
    },
    "Cancel"
  ))), gameCountdown !== null && /* @__PURE__ */ React.createElement("div", { style: styles.countdownOverlay }, /* @__PURE__ */ React.createElement("div", { style: styles.countdownNumber }, gameCountdown)), /* @__PURE__ */ React.createElement("div", { style: styles.content }, /* @__PURE__ */ React.createElement("header", { style: styles.header }, /* @__PURE__ */ React.createElement("div", { style: styles.logo, onClick: goHome, role: "button", tabIndex: 0, onKeyDown: (e) => {
    if (e.key === "Enter" || e.key === " ") goHome();
  } }, /* @__PURE__ */ React.createElement("img", { style: styles.logoMark, src: "data:image/png;base64,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", alt: "Caduceus" }), /* @__PURE__ */ React.createElement("div", { style: { display: "flex", flexDirection: "column", lineHeight: 1.1 } }, /* @__PURE__ */ React.createElement("span", { style: styles.logoText }, "Primary Care Provider Learning Program"), /* @__PURE__ */ React.createElement("span", { style: styles.logoSubtext }, "Clinical microlearning \u2022 quizzes \u2022 rapid review"))), /* @__PURE__ */ React.createElement("div", { style: styles.controls }, !isMobile && /* @__PURE__ */ React.createElement(
    "button",
    {
      style: styles.toggleBtn,
      onClick: () => {
        play("click");
        setMobileMode(!mobileMode);
      }
    },
    mobileMode ? "\u{1F5A5}\uFE0F Desktop" : "\u{1F4F1} Mobile"
  ), /* @__PURE__ */ React.createElement(
    "button",
    {
      style: styles.soundBtn,
      onClick: () => setSoundEnabled(!soundEnabled)
    },
    soundEnabled ? "\u{1F50A}" : "\u{1F507}"
  ), /* @__PURE__ */ React.createElement(
    "button",
    {
      style: styles.chatIconBtn,
      "aria-label": "Open Chat",
      title: "Open Chat",
      onClick: () => {
        play("click");
        setCurrentView("chat");
      }
    },
    /* @__PURE__ */ React.createElement("img", { src: CHAT_ICON, alt: "", "aria-hidden": "true", style: styles.chatButtonIcon })
  ))), currentView === "home" && renderHome(), currentView === "category-questions" && renderCategoryQuestions(), currentView === "quiz" && renderQuiz(), currentView === "category-review" && renderQuiz(), currentView === "game" && !gameEnded && renderGame(), currentView === "game" && gameEnded && renderGameResults(), currentView === "quiz-complete" && renderQuizComplete(), currentView === "chat" && renderChat()), /* @__PURE__ */ React.createElement("style", null, `
        @keyframes pulse {
          0%, 100% { transform: translateX(-50%) scale(1); }
          50% { transform: translateX(-50%) scale(1.05); }
        }
        
        @keyframes countdownPulse {
          0% { transform: scale(0.5); opacity: 0; }
          50% { transform: scale(1.2); }
          100% { transform: scale(1); opacity: 1; }
        }
        
        @keyframes shake {
          0%, 100% { transform: translateX(-50%); }
          10%, 30%, 50%, 70%, 90% { transform: translateX(calc(-50% - 5px)); }
          20%, 40%, 60%, 80% { transform: translateX(calc(-50% + 5px)); }
        }
        
        * {
          box-sizing: border-box;
        }
        
        body {
          margin: 0;
          padding: 0;
        }
        
        ::-webkit-scrollbar {
          width: 8px;
        }
        
        ::-webkit-scrollbar-track {
          background: rgba(0,0,0,0.05);
          border-radius: 4px;
        }
        
        ::-webkit-scrollbar-thumb {
          background: rgba(0,0,0,0.15);
          border-radius: 4px;
        }
        
        ::-webkit-scrollbar-thumb:hover {
          background: rgba(0,0,0,0.25);
        }
        
        input::placeholder {
          color: #94a3b8;
        }


  /* Accessibility + polish */
  button:focus-visible, [role="button"]:focus-visible, input:focus-visible {
    outline: 3px solid rgba(37, 99, 235, 0.55);
    outline-offset: 2px;
  }
  button:disabled {
    opacity: 0.55;
    cursor: not-allowed;
  }
  @media (prefers-reduced-motion: reduce) {
    * { transition: none !important; animation: none !important; scroll-behavior: auto !important; }
  }
`));
}
const root = ReactDOM.createRoot(document.getElementById("root"));
root.render(/* @__PURE__ */ React.createElement(PCPLearningApp, null));
  </script>
  <script>
    // Register service worker for offline support and cache-busting
    if ("serviceWorker" in navigator) {
      navigator.serviceWorker.register("sw.js").then(function(reg) {
        // Check for updates every time the page loads
        reg.update();
      }).catch(function() {
        // SW registration failed â€” app still works, just no offline support
      });
    }
  </script>
</body>
</html>
